diff --git "a/tokenizer.json" "b/tokenizer.json" --- "a/tokenizer.json" +++ "b/tokenizer.json" @@ -138,93254 +138,63800 @@ "": 0, "": 1, "": 2, - "<0x00>": 3, - "<0x01>": 4, - "<0x02>": 5, - "<0x03>": 6, - "<0x04>": 7, - "<0x05>": 8, - "<0x06>": 9, - "<0x07>": 10, - "<0x08>": 11, - "<0x09>": 12, - "<0x0A>": 13, - "<0x0B>": 14, - "<0x0C>": 15, - "<0x0D>": 16, - "<0x0E>": 17, - "<0x0F>": 18, - "<0x10>": 19, - "<0x11>": 20, - "<0x12>": 21, - "<0x13>": 22, - "<0x14>": 23, - "<0x15>": 24, - "<0x16>": 25, - "<0x17>": 26, - "<0x18>": 27, - "<0x19>": 28, - "<0x1A>": 29, - "<0x1B>": 30, - "<0x1C>": 31, - "<0x1D>": 32, - "<0x1E>": 33, - "<0x1F>": 34, - "<0x20>": 35, - "<0x21>": 36, - "<0x22>": 37, - "<0x23>": 38, - "<0x24>": 39, - "<0x25>": 40, - "<0x26>": 41, - "<0x27>": 42, - "<0x28>": 43, - "<0x29>": 44, - "<0x2A>": 45, - "<0x2B>": 46, - "<0x2C>": 47, - "<0x2D>": 48, - "<0x2E>": 49, - "<0x2F>": 50, - "<0x30>": 51, - "<0x31>": 52, - "<0x32>": 53, - "<0x33>": 54, - "<0x34>": 55, - "<0x35>": 56, - "<0x36>": 57, - "<0x37>": 58, - "<0x38>": 59, - "<0x39>": 60, - "<0x3A>": 61, - "<0x3B>": 62, - "<0x3C>": 63, - "<0x3D>": 64, - "<0x3E>": 65, - "<0x3F>": 66, - "<0x40>": 67, - "<0x41>": 68, - "<0x42>": 69, - "<0x43>": 70, - "<0x44>": 71, - "<0x45>": 72, - "<0x46>": 73, - "<0x47>": 74, - "<0x48>": 75, - "<0x49>": 76, - "<0x4A>": 77, - "<0x4B>": 78, - "<0x4C>": 79, - "<0x4D>": 80, - "<0x4E>": 81, - "<0x4F>": 82, - "<0x50>": 83, - "<0x51>": 84, - "<0x52>": 85, - "<0x53>": 86, - "<0x54>": 87, - "<0x55>": 88, - "<0x56>": 89, - "<0x57>": 90, - "<0x58>": 91, - "<0x59>": 92, - "<0x5A>": 93, - "<0x5B>": 94, - "<0x5C>": 95, - "<0x5D>": 96, - "<0x5E>": 97, - "<0x5F>": 98, - "<0x60>": 99, - "<0x61>": 100, - "<0x62>": 101, - "<0x63>": 102, - "<0x64>": 103, - "<0x65>": 104, - "<0x66>": 105, - "<0x67>": 106, - "<0x68>": 107, - "<0x69>": 108, - "<0x6A>": 109, - "<0x6B>": 110, - "<0x6C>": 111, - "<0x6D>": 112, - "<0x6E>": 113, - "<0x6F>": 114, - "<0x70>": 115, - "<0x71>": 116, - "<0x72>": 117, - "<0x73>": 118, - "<0x74>": 119, - "<0x75>": 120, - "<0x76>": 121, - "<0x77>": 122, - "<0x78>": 123, - "<0x79>": 124, - "<0x7A>": 125, - "<0x7B>": 126, - "<0x7C>": 127, - "<0x7D>": 128, - "<0x7E>": 129, - "<0x7F>": 130, - "<0x80>": 131, - "<0x81>": 132, - "<0x82>": 133, - "<0x83>": 134, - "<0x84>": 135, - "<0x85>": 136, - "<0x86>": 137, - "<0x87>": 138, - "<0x88>": 139, - "<0x89>": 140, - "<0x8A>": 141, - "<0x8B>": 142, - "<0x8C>": 143, - "<0x8D>": 144, - "<0x8E>": 145, - "<0x8F>": 146, - "<0x90>": 147, - "<0x91>": 148, - "<0x92>": 149, - "<0x93>": 150, - "<0x94>": 151, - "<0x95>": 152, - "<0x96>": 153, - "<0x97>": 154, - "<0x98>": 155, - "<0x99>": 156, - "<0x9A>": 157, - "<0x9B>": 158, - "<0x9C>": 159, - "<0x9D>": 160, - "<0x9E>": 161, - "<0x9F>": 162, - "<0xA0>": 163, - "<0xA1>": 164, - "<0xA2>": 165, - "<0xA3>": 166, - "<0xA4>": 167, - "<0xA5>": 168, - "<0xA6>": 169, - "<0xA7>": 170, - "<0xA8>": 171, - "<0xA9>": 172, - "<0xAA>": 173, - "<0xAB>": 174, - "<0xAC>": 175, - "<0xAD>": 176, - "<0xAE>": 177, - "<0xAF>": 178, - "<0xB0>": 179, - "<0xB1>": 180, - "<0xB2>": 181, - "<0xB3>": 182, - "<0xB4>": 183, - "<0xB5>": 184, - "<0xB6>": 185, - "<0xB7>": 186, - "<0xB8>": 187, - "<0xB9>": 188, - "<0xBA>": 189, - "<0xBB>": 190, - "<0xBC>": 191, - "<0xBD>": 192, - "<0xBE>": 193, - "<0xBF>": 194, - "<0xC0>": 195, - "<0xC1>": 196, - "<0xC2>": 197, - "<0xC3>": 198, - "<0xC4>": 199, - "<0xC5>": 200, - "<0xC6>": 201, - "<0xC7>": 202, - "<0xC8>": 203, - "<0xC9>": 204, - "<0xCA>": 205, - "<0xCB>": 206, - "<0xCC>": 207, - "<0xCD>": 208, - "<0xCE>": 209, - "<0xCF>": 210, - "<0xD0>": 211, - "<0xD1>": 212, - "<0xD2>": 213, - "<0xD3>": 214, - "<0xD4>": 215, - "<0xD5>": 216, - "<0xD6>": 217, - "<0xD7>": 218, - "<0xD8>": 219, - "<0xD9>": 220, - "<0xDA>": 221, - "<0xDB>": 222, - "<0xDC>": 223, - "<0xDD>": 224, - "<0xDE>": 225, - "<0xDF>": 226, - "<0xE0>": 227, - "<0xE1>": 228, - "<0xE2>": 229, - "<0xE3>": 230, - "<0xE4>": 231, - "<0xE5>": 232, - "<0xE6>": 233, - "<0xE7>": 234, - "<0xE8>": 235, - "<0xE9>": 236, - "<0xEA>": 237, - "<0xEB>": 238, - "<0xEC>": 239, - "<0xED>": 240, - "<0xEE>": 241, - "<0xEF>": 242, - "<0xF0>": 243, - "<0xF1>": 244, - "<0xF2>": 245, - "<0xF3>": 246, - "<0xF4>": 247, - "<0xF5>": 248, - "<0xF6>": 249, - "<0xF7>": 250, - "<0xF8>": 251, - "<0xF9>": 252, - "<0xFA>": 253, - "<0xFB>": 254, - "<0xFC>": 255, - "<0xFD>": 256, - "<0xFE>": 257, - "<0xFF>": 258, - "▁▁": 259, - "▁t": 260, - "er": 261, - "in": 262, - "▁a": 263, - "en": 264, - "on": 265, - "▁th": 266, - "es": 267, - "▁▁▁▁": 268, - "▁s": 269, - "▁d": 270, - "at": 271, - "or": 272, - "an": 273, - "▁c": 274, - "is": 275, - "re": 276, - "it": 277, - "▁the": 278, - "ar": 279, - "le": 280, - "▁w": 281, - "▁p": 282, - "ou": 283, - "al": 284, - "▁f": 285, - "▁m": 286, - "ed": 287, - "▁o": 288, - "▁b": 289, - "om": 290, - "ion": 291, - "ing": 292, - "ic": 293, - "as": 294, - "el": 295, - "ent": 296, - "▁in": 297, - "▁h": 298, - "nd": 299, - "et": 300, - "▁l": 301, - "▁n": 302, - "st": 303, - "▁to": 304, - "ch": 305, - "▁I": 306, - "ro": 307, - "▁▁▁▁▁▁▁▁": 308, - "il": 309, - "▁of": 310, - "de": 311, - "ct": 312, - "▁(": 313, - "am": 314, - "▁C": 315, - "▁de": 316, - "▁S": 317, - "▁u": 318, - "▁A": 319, - "▁\\": 320, - "▁e": 321, - "▁and": 322, - "▁T": 323, - "ol": 324, - "▁v": 325, - "im": 326, - "ot": 327, - "ad": 328, - "ut": 329, - "▁g": 330, - "em": 331, - "ur": 332, - "id": 333, - "▁*": 334, - "ig": 335, - "ra": 336, - "▁re": 337, - "▁is": 338, - "qu": 339, - "ow": 340, - "▁M": 341, - "est": 342, - "▁y": 343, - "se": 344, - "ve": 345, - "ce": 346, - "ie": 347, - "un": 348, - "▁P": 349, - "▁B": 350, - "ag": 351, - "ul": 352, - "▁=": 353, - "he": 354, - "end": 355, - "ode": 356, - "ter": 357, - "ment": 358, - "os": 359, - "▁D": 360, - "if": 361, - "ation": 362, - "▁for": 363, - "▁r": 364, - "▁L": 365, - "▁you": 366, - "▁be": 367, - "ly": 368, - "ver": 369, - "ab": 370, - "te": 371, - "▁it": 372, - "▁on": 373, - "ri": 374, - "us": 375, - "▁\"": 376, - "▁wh": 377, - "▁con": 378, - "▁H": 379, - "▁st": 380, - "ir": 381, - "▁E": 382, - "▁F": 383, - "ck": 384, - "▁an": 385, - "th": 386, - "eg": 387, - "ay": 388, - "ith": 389, - "▁R": 390, - "ist": 391, - "and": 392, - "▁that": 393, - "▁al": 394, - "▁$": 395, - "▁#": 396, - "od": 397, - "um": 398, - "▁W": 399, - "ht": 400, - "code": 401, - "▁G": 402, - "ate": 403, - "ess": 404, - "▁N": 405, - "ere": 406, - "pp": 407, - "▁as": 408, - "▁se": 409, - "▁pro": 410, - "▁with": 411, - "pe": 412, - "▁k": 413, - "ers": 414, - "pt": 415, - ");": 416, - "lo": 417, - "▁▁▁▁▁": 418, - "▁com": 419, - "ame": 420, - "▁`": 421, - "▁Com": 422, - "ia": 423, - "ant": 424, - "▁la": 425, - "▁{": 426, - "▁en": 427, - "ction": 428, - "▁ex": 429, - "ld": 430, - "ub": 431, - "▁j": 432, - "la": 433, - "ue": 434, - "▁J": 435, - "ich": 436, - "▁do": 437, - "▁O": 438, - "▁qu": 439, - "iv": 440, - "ort": 441, - "art": 442, - "▁un": 443, - "▁##": 444, - "▁this": 445, - "ke": 446, - "▁ha": 447, - "▁-": 448, - "out": 449, - "▁The": 450, - "▁not": 451, - "▁ne": 452, - "ill": 453, - "▁le": 454, - "ci": 455, - "rom": 456, - "ine": 457, - "//": 458, - "op": 459, - "egin": 460, - "▁Comment": 461, - "▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁": 462, - "begin": 463, - "ст": 464, - "ass": 465, - "iz": 466, - ").": 467, - "og": 468, - "▁п": 469, - "▁or": 470, - "▁was": 471, - "▁at": 472, - "our": 473, - "▁i": 474, - "ain": 475, - "▁K": 476, - "на": 477, - "▁V": 478, - "ge": 479, - "▁su": 480, - "ap": 481, - "age": 482, - "ould": 483, - "ne": 484, - "av": 485, - "xt": 486, - "ore": 487, - "ile": 488, - "--": 489, - "▁в": 490, - "▁by": 491, - "li": 492, - "ath": 493, - "ра": 494, - "ber": 495, - "ach": 496, - "all": 497, - "▁Th": 498, - "ult": 499, - "▁}": 500, - "▁U": 501, - "▁us": 502, - "▁z": 503, - "ust": 504, - "▁have": 505, - "lic": 506, - "ни": 507, - "▁can": 508, - "tr": 509, - "com": 510, - "),": 511, - "▁In": 512, - "ind": 513, - "ell": 514, - "▁from": 515, - "ов": 516, - "to": 517, - "▁[": 518, - "able": 519, - "ost": 520, - "▁ch": 521, - "ect": 522, - "ight": 523, - "int": 524, - "▁'": 525, - "▁are": 526, - "▁im": 527, - "▁sh": 528, - "▁<": 529, - "▁An": 530, - "▁с": 531, - "ata": 532, - "ire": 533, - "▁tr": 534, - "con": 535, - "ord": 536, - "ity": 537, - "ard": 538, - "▁▁▁▁▁▁": 539, - "▁he": 540, - "▁but": 541, - "oc": 542, - "=\"": 543, - "▁pr": 544, - "ure": 545, - "per": 546, - "ack": 547, - "ork": 548, - "ong": 549, - "ans": 550, - "ко": 551, - "ple": 552, - "▁des": 553, - "ok": 554, - "orm": 555, - "wer": 556, - "ak": 557, - "pr": 558, - "ase": 559, - "▁el": 560, - "ph": 561, - "ac": 562, - "▁und": 563, - "▁ar": 564, - "▁if": 565, - "ud": 566, - "ps": 567, - "ite": 568, - "ble": 569, - "но": 570, - "fer": 571, - "pl": 572, - "ive": 573, - "ang": 574, - "ens": 575, - "ро": 576, - "▁so": 577, - "so": 578, - "ast": 579, - "()": 580, - "swer": 581, - "ru": 582, - "ies": 583, - "▁:": 584, - "au": 585, - "ov": 586, - "ре": 587, - "го": 588, - "▁der": 589, - "▁my": 590, - "▁we": 591, - "▁me": 592, - "nt": 593, - "▁ad": 594, - "urn": 595, - "▁your": 596, - "://": 597, - "are": 598, - "▁all": 599, - "ff": 600, - "io": 601, - "estion": 602, - "ime": 603, - "▁er": 604, - "lass": 605, - "▁и": 606, - "▁which": 607, - "ome": 608, - "ont": 609, - "▁par": 610, - "▁ma": 611, - "▁Y": 612, - "\",": 613, - "▁о": 614, - "ft": 615, - "ial": 616, - "cc": 617, - "ound": 618, - "▁li": 619, - "▁res": 620, - "eth": 621, - "ject": 622, - "▁app": 623, - "▁St": 624, - "ice": 625, - "▁am": 626, - "act": 627, - "▁del": 628, - "gr": 629, - "ated": 630, - "ier": 631, - "▁▁▁▁▁▁▁▁▁▁▁▁": 632, - "▁ab": 633, - "▁et": 634, - "ally": 635, - "..": 636, - "port": 637, - "ik": 638, - "▁per": 639, - "▁cont": 640, - "ри": 641, - "ка": 642, - "ser": 643, - "ли": 644, - "ll": 645, - "iew": 646, - "ign": 647, - "_{": 648, - "put": 649, - "one": 650, - "unction": 651, - "▁di": 652, - "ary": 653, - "ition": 654, - "ma": 655, - "ен": 656, - "get": 657, - "▁lo": 658, - "▁val": 659, - "▁Q": 660, - "ran": 661, - "▁д": 662, - "ence": 663, - "▁work": 664, - "▁на": 665, - "ip": 666, - "item": 667, - "ype": 668, - "▁&": 669, - "▁his": 670, - "▁use": 671, - "der": 672, - "▁Answer": 673, - "▁will": 674, - "ize": 675, - "та": 676, - "low": 677, - "▁Ch": 678, - "▁get": 679, - "ide": 680, - "ous": 681, - "ink": 682, - "ption": 683, - "ла": 684, - "turn": 685, - "ung": 686, - "ec": 687, - "ug": 688, - "form": 689, - "res": 690, - "htt": 691, - "oug": 692, - "ль": 693, - "▁no": 694, - "cl": 695, - "▁ro": 696, - "▁one": 697, - "tt": 698, - "cri": 699, - "du": 700, - "▁up": 701, - "то": 702, - "(\"": 703, - "▁ob": 704, - "we": 705, - "ory": 706, - "▁est": 707, - "ery": 708, - "iel": 709, - "str": 710, - "ob": 711, - "▁que": 712, - "ian": 713, - "▁out": 714, - "▁pl": 715, - "▁new": 716, - "ки": 717, - "▁+": 718, - "ry": 719, - "oth": 720, - "ther": 721, - "▁var": 722, - "▁would": 723, - "▁ser": 724, - "tern": 725, - "text": 726, - "▁there": 727, - "ish": 728, - "ror": 729, - "те": 730, - "▁set": 731, - "▁@": 732, - "▁по": 733, - "▁te": 734, - "ex": 735, - "▁return": 736, - "ail": 737, - "▁any": 738, - "▁It": 739, - "▁function": 740, - "{\\": 741, - "',": 742, - "és": 743, - "ale": 744, - "ан": 745, - "▁when": 746, - "ib": 747, - "▁go": 748, - "ance": 749, - "▁had": 750, - "▁Qu": 751, - "▁comp": 752, - "ле": 753, - "▁з": 754, - "math": 755, - "▁has": 756, - "▁м": 757, - "▁pre": 758, - "ener": 759, - "▁part": 760, - "elf": 761, - "▁die": 762, - "▁like": 763, - "ray": 764, - "irst": 765, - "▁dis": 766, - "▁man": 767, - "rit": 768, - "▁then": 769, - "▁class": 770, - "pro": 771, - "▁po": 772, - "▁using": 773, - "eb": 774, - "▁code": 775, - "own": 776, - "▁some": 777, - "ces": 778, - "▁$\\": 779, - "ер": 780, - "lect": 781, - "▁au": 782, - "isch": 783, - "▁col": 784, - "▁–": 785, - "up": 786, - "ons": 787, - "▁add": 788, - "ild": 789, - "iss": 790, - "val": 791, - "ount": 792, - "les": 793, - "vent": 794, - "▁▁▁▁▁▁▁▁▁▁▁▁▁": 795, - "▁Z": 796, - "In": 797, - "row": 798, - "ear": 799, - "ations": 800, - "ah": 801, - "que": 802, - "ublic": 803, - "ank": 804, - "▁sp": 805, - "▁Wh": 806, - "----": 807, - "sk": 808, - "ew": 809, - "ags": 810, - "ти": 811, - "ann": 812, - "▁—": 813, - "ert": 814, - "ace": 815, - "sch": 816, - "▁need": 817, - "▁à": 818, - "ien": 819, - "ough": 820, - "не": 821, - "▁def": 822, - "ij": 823, - "ern": 824, - "▁what": 825, - "▁Ar": 826, - "wo": 827, - "ml": 828, - "": 976, - "▁fil": 977, - "name": 978, - "inal": 979, - "▁il": 980, - "ample": 981, - "▁way": 982, - "ica": 983, - "во": 984, - "cess": 985, - "itt": 986, - "uch": 987, - "▁where": 988, - "ми": 989, - "org": 990, - "https": 991, - "▁vo": 992, - "ient": 993, - "ove": 994, - "▁value": 995, - "eng": 996, - "▁La": 997, - "^{": 998, - "ref": 999, - "ied": 1000, - "ER": 1001, - "▁stat": 1002, - "fig": 1003, - "me": 1004, - "▁von": 1005, - "▁inter": 1006, - "roid": 1007, - "ater": 1008, - "▁their": 1009, - "▁bet": 1010, - "▁ein": 1011, - "}\\": 1012, - "\">": 1013, - "▁sub": 1014, - "▁op": 1015, - "▁don": 1016, - "ty": 1017, - "▁try": 1018, - "▁Pro": 1019, - "▁tra": 1020, - "▁same": 1021, - "ep": 1022, - "▁two": 1023, - "▁name": 1024, - "old": 1025, - "let": 1026, - "▁sim": 1027, - "sp": 1028, - "▁av": 1029, - "bre": 1030, - "blem": 1031, - "ey": 1032, - "▁could": 1033, - "▁cor": 1034, - "▁acc": 1035, - "ays": 1036, - "cre": 1037, - "urr": 1038, - "si": 1039, - "▁const": 1040, - "ues": 1041, - "}$": 1042, - "View": 1043, - "▁act": 1044, - "▁bo": 1045, - "▁ко": 1046, - "▁som": 1047, - "▁about": 1048, - "land": 1049, - "mer": 1050, - "▁list": 1051, - "cal": 1052, - "▁import": 1053, - "col": 1054, - "▁na": 1055, - "na": 1056, - "::": 1057, - "▁who": 1058, - "▁error": 1059, - "▁X": 1060, - "ator": 1061, - "ext": 1062, - "▁been": 1063, - "ér": 1064, - "▁run": 1065, - "pos": 1066, - "▁cl": 1067, - "**": 1068, - "▁К": 1069, - "ular": 1070, - "ause": 1071, - "▁reg": 1072, - "▁know": 1073, - "▁see": 1074, - "▁him": 1075, - "ning": 1076, - "▁за": 1077, - "ates": 1078, - "fore": 1079, - "ions": 1080, - "▁hel": 1081, - "ute": 1082, - "▁rem": 1083, - "▁го": 1084, - "▁Mar": 1085, - "ру": 1086, - "vice": 1087, - "irect": 1088, - "ner": 1089, - "▁under": 1090, - "rib": 1091, - "hr": 1092, - "че": 1093, - "▁As": 1094, - "▁end": 1095, - "ember": 1096, - "▁а": 1097, - "▁att": 1098, - "ina": 1099, - "son": 1100, - "▁follow": 1101, - "▁Sch": 1102, - "pect": 1103, - "▁rel": 1104, - "▁So": 1105, - "▁look": 1106, - "abel": 1107, - "▁problem": 1108, - "▁van": 1109, - "strong": 1110, - "co": 1111, - "pon": 1112, - "ca": 1113, - "ada": 1114, - "\":": 1115, - "cond": 1116, - "amb": 1117, - "},": 1118, - "quest": 1119, - "▁aut": 1120, - "▁result": 1121, - "▁may": 1122, - "Re": 1123, - "http": 1124, - "):": 1125, - "▁And": 1126, - "red": 1127, - "▁How": 1128, - "po": 1129, - "ско": 1130, - "att": 1131, - "oup": 1132, - "ced": 1133, - "▁type": 1134, - "▁than": 1135, - "▁cons": 1136, - "uf": 1137, - "ци": 1138, - "▁question": 1139, - "raph": 1140, - "igh": 1141, - "▁М": 1142, - "▁htt": 1143, - "ins": 1144, - "den": 1145, - "▁da": 1146, - "▁ver": 1147, - "oh": 1148, - "▁=>": 1149, - "riv": 1150, - "ude": 1151, - "▁For": 1152, - "▁ra": 1153, - "frac": 1154, - "ма": 1155, - "▁after": 1156, - "}{": 1157, - "▁method": 1158, - "\")": 1159, - "amp": 1160, - "ash": 1161, - "▁rec": 1162, - "▁differ": 1163, - "ON": 1164, - "ax": 1165, - "ament": 1166, - "ource": 1167, - "Con": 1168, - "its": 1169, - "Name": 1170, - "man": 1171, - "▁bec": 1172, - "che": 1173, - "▁En": 1174, - "aj": 1175, - "▁gener": 1176, - "IN": 1177, - "▁id": 1178, - "ages": 1179, - "▁loc": 1180, - "fo": 1181, - "br": 1182, - "▁she": 1183, - "Pro": 1184, - "▁una": 1185, - "▁к": 1186, - "eta": 1187, - "log": 1188, - "olog": 1189, - "▁sur": 1190, - "arg": 1191, - "▁--": 1192, - "kt": 1193, - "(\\": 1194, - "min": 1195, - "▁line": 1196, - "▁vari": 1197, - "ся": 1198, - "ics": 1199, - "ня": 1200, - "very": 1201, - "add": 1202, - "▁object": 1203, - "Id": 1204, - "▁But": 1205, - "▁case": 1206, - "▁make": 1207, - "▁cal": 1208, - "▁pass": 1209, - "сь": 1210, - "ession": 1211, - "net": 1212, - ".\"": 1213, - "▁г": 1214, - "är": 1215, - "де": 1216, - "no": 1217, - "ating": 1218, - "ato": 1219, - "line": 1220, - "ви": 1221, - "▁Ex": 1222, - "▁ass": 1223, - "▁vers": 1224, - "ля": 1225, - "▁ed": 1226, - "umn": 1227, - "other": 1228, - "ста": 1229, - "ative": 1230, - "String": 1231, - "▁los": 1232, - "wn": 1233, - "▁answer": 1234, - "▁let": 1235, - "▁pe": 1236, - "ents": 1237, - "▁fe": 1238, - "ince": 1239, - "ni": 1240, - "ider": 1241, - "ows": 1242, - "▁test": 1243, - "▁here": 1244, - "roll": 1245, - "▁call": 1246, - "ruct": 1247, - "▁pol": 1248, - "ait": 1249, - "▁back": 1250, - "ho": 1251, - "Ex": 1252, - "ress": 1253, - "ST": 1254, - "ried": 1255, - "date": 1256, - "ет": 1257, - "▁did": 1258, - "ting": 1259, - "▁El": 1260, - "▁dem": 1261, - ")$": 1262, - "ова": 1263, - "urrent": 1264, - "lace": 1265, - "right": 1266, - "ren": 1267, - "по": 1268, - "▁each": 1269, - "cy": 1270, - "block": 1271, - "data": 1272, - "▁%": 1273, - "▁ac": 1274, - "▁==": 1275, - "ür": 1276, - "▁por": 1277, - "ask": 1278, - "arch": 1279, - "ames": 1280, - "▁Con": 1281, - "ча": 1282, - "▁off": 1283, - "▁find": 1284, - "cont": 1285, - "▁now": 1286, - "work": 1287, - "ational": 1288, - "dd": 1289, - "ción": 1290, - "▁А": 1291, - "ault": 1292, - "List": 1293, - "▁ext": 1294, - "urs": 1295, - "ake": 1296, - "ule": 1297, - "▁point": 1298, - "AT": 1299, - "aut": 1300, - "▁trans": 1301, - "▁co": 1302, - "▁read": 1303, - "▁used": 1304, - "ски": 1305, - "ari": 1306, - "LE": 1307, - "eter": 1308, - "oun": 1309, - "ever": 1310, - "self": 1311, - "ined": 1312, - "idth": 1313, - "ux": 1314, - "js": 1315, - "▁such": 1316, - "▁Is": 1317, - "ée": 1318, - "ful": 1319, - "▁dist": 1320, - "▁bu": 1321, - "itemize": 1322, - "Cont": 1323, - "je": 1324, - "си": 1325, - "▁prov": 1326, - "bb": 1327, - "ward": 1328, - "esent": 1329, - "erson": 1330, - "anks": 1331, - "wh": 1332, - "not": 1333, - "▁We": 1334, - "ka": 1335, - "rop": 1336, - "atur": 1337, - "als": 1338, - "▁bel": 1339, - "ör": 1340, - "fr": 1341, - "▁example": 1342, - "▁incl": 1343, - "amil": 1344, - "▁ра": 1345, - "▁“": 1346, - "▁string": 1347, - "▁think": 1348, - "Th": 1349, - "▁tem": 1350, - "ave": 1351, - "▁Fran": 1352, - "▁number": 1353, - "▁si": 1354, - "imes": 1355, - "tem": 1356, - "my": 1357, - "ler": 1358, - "load": 1359, - "==": 1360, - "▁hand": 1361, - "za": 1362, - "▁because": 1363, - "▁sch": 1364, - "vo": 1365, - "this": 1366, - "ID": 1367, - "ão": 1368, - "▁start": 1369, - "▁war": 1370, - "▁help": 1371, - "ts": 1372, - "▁char": 1373, - "▁ph": 1374, - "▁min": 1375, - "til": 1376, - "rite": 1377, - "--------": 1378, - "els": 1379, - "▁mit": 1380, - "edia": 1381, - "ку": 1382, - "▁Sh": 1383, - "any": 1384, - "];": 1385, - "▁Б": 1386, - "ique": 1387, - "da": 1388, - "ef": 1389, - "dex": 1390, - "▁produ": 1391, - "▁Н": 1392, - "gram": 1393, - "▁Or": 1394, - "▁gre": 1395, - "quote": 1396, - "leg": 1397, - "orn": 1398, - "▁ind": 1399, - "▁post": 1400, - "▁dep": 1401, - "],": 1402, - "vi": 1403, - "▁user": 1404, - "▁>": 1405, - "lick": 1406, - "▁very": 1407, - "ething": 1408, - "▁array": 1409, - "▁gu": 1410, - "▁dur": 1411, - "`.": 1412, - "ть": 1413, - "lication": 1414, - "сти": 1415, - "ek": 1416, - "ico": 1417, - "▁dat": 1418, - "ор": 1419, - "html": 1420, - "ione": 1421, - "▁different": 1422, - "▁check": 1423, - "▁fr": 1424, - "▁Er": 1425, - "▁text": 1426, - "ні": 1427, - "icht": 1428, - "stack": 1429, - "EN": 1430, - "rag": 1431, - "▁every": 1432, - "Ar": 1433, - "▁before": 1434, - "alse": 1435, - "▁fin": 1436, - "▁dé": 1437, - "▁these": 1438, - "▁det": 1439, - "Val": 1440, - "ception": 1441, - "▁android": 1442, - "blockquote": 1443, - "▁je": 1444, - "file": 1445, - "ats": 1446, - "▁до": 1447, - "essage": 1448, - "▁again": 1449, - "aw": 1450, - "Ch": 1451, - "ween": 1452, - "▁Д": 1453, - "for": 1454, - "cial": 1455, - "play": 1456, - "pre": 1457, - "ida": 1458, - "▁Par": 1459, - "ny": 1460, - "ract": 1461, - "▁supp": 1462, - "ased": 1463, - "lection": 1464, - "▁dans": 1465, - "air": 1466, - "rol": 1467, - "▁thr": 1468, - "Data": 1469, - "lich": 1470, - "▁про": 1471, - "▁long": 1472, - "▁second": 1473, - "ually": 1474, - "ines": 1475, - "▁found": 1476, - "ength": 1477, - "yp": 1478, - "ead": 1479, - "▁log": 1480, - "ui": 1481, - "new": 1482, - "▁Р": 1483, - "go": 1484, - "aus": 1485, - "ody": 1486, - "▁son": 1487, - "ме": 1488, - "ero": 1489, - "ved": 1490, - "sub": 1491, - "▁right": 1492, - "view": 1493, - "▁following": 1494, - "')": 1495, - "\");": 1496, - "▁said": 1497, - "же": 1498, - "чи": 1499, - "ту": 1500, - "ott": 1501, - "се": 1502, - "ars": 1503, - "$.": 1504, - "gg": 1505, - "▁br": 1506, - "ool": 1507, - "yle": 1508, - "use": 1509, - "▁show": 1510, - "lease": 1511, - "cia": 1512, - "▁direct": 1513, - "doc": 1514, - "ар": 1515, - "ms": 1516, - "▁giv": 1517, - "▁exp": 1518, - "ql": 1519, - "ду": 1520, - "ве": 1521, - "▁Be": 1522, - "Com": 1523, - "iter": 1524, - "RE": 1525, - "mp": 1526, - "men": 1527, - "▁Ro": 1528, - "MA": 1529, - "▁Col": 1530, - "ister": 1531, - "▁well": 1532, - "▁": 1599, - "ene": 1600, - "▁mon": 1601, - "▁dec": 1602, - "▁still": 1603, - "▁об": 1604, - "▁Tr": 1605, - "▁ф": 1606, - "ife": 1607, - "ism": 1608, - "by": 1609, - "raw": 1610, - "ior": 1611, - "▁med": 1612, - "orld": 1613, - "▁comple": 1614, - "ww": 1615, - "▁art": 1616, - "ron": 1617, - "▁Г": 1618, - "▁My": 1619, - "▁als": 1620, - "rect": 1621, - "▁auf": 1622, - "▁down": 1623, - "ather": 1624, - "Col": 1625, - "Text": 1626, - "back": 1627, - "$,": 1628, - "▁year": 1629, - "мо": 1630, - "pi": 1631, - "▁Gr": 1632, - "ream": 1633, - "▁rep": 1634, - "bf": 1635, - "www": 1636, - "▁wur": 1637, - "▁org": 1638, - "inter": 1639, - "▁Die": 1640, - "▁being": 1641, - "\".": 1642, - "label": 1643, - "▁cent": 1644, - "java": 1645, - "bar": 1646, - "ante": 1647, - "ana": 1648, - "__": 1649, - "▁solution": 1650, - "▁О": 1651, - "▁fl": 1652, - "▁create": 1653, - "ici": 1654, - "ste": 1655, - "ython": 1656, - "unt": 1657, - "ason": 1658, - "ference": 1659, - "SE": 1660, - "▁non": 1661, - "ane": 1662, - "▁ins": 1663, - "ader": 1664, - "_{\\": 1665, - "Res": 1666, - "▁main": 1667, - "пи": 1668, - "▁▁▁▁▁▁▁▁▁▁▁▁▁▁": 1669, - "▁There": 1670, - "▁pour": 1671, - "RO": 1672, - "`,": 1673, - "lish": 1674, - "bject": 1675, - "ccess": 1676, - "▁orig": 1677, - "▁▁▁": 1678, - "ischen": 1679, - "ower": 1680, - "▁het": 1681, - "uc": 1682, - "▁else": 1683, - "».": 1684, - "▁от": 1685, - "equ": 1686, - "sible": 1687, - "test": 1688, - "stand": 1689, - "én": 1690, - "ets": 1691, - "GE": 1692, - "ident": 1693, - "▁е": 1694, - "▁при": 1695, - ".,": 1696, - "▁das": 1697, - "ock": 1698, - ",\"": 1699, - "▁vol": 1700, - "▁fo": 1701, - "▁para": 1702, - "▁Т": 1703, - "▁Car": 1704, - "ral": 1705, - "▁Sp": 1706, - "var": 1707, - "▁play": 1708, - "ouse": 1709, - "▁та": 1710, - "ically": 1711, - "▁contain": 1712, - "ponse": 1713, - "▁String": 1714, - "án": 1715, - "▁both": 1716, - "ken": 1717, - "AR": 1718, - "ере": 1719, - "▁Il": 1720, - "▁iss": 1721, - "▁open": 1722, - "▁)": 1723, - "▁What": 1724, - "fe": 1725, - "rivate": 1726, - "reg": 1727, - "▁without": 1728, - "▁zu": 1729, - "vis": 1730, - "flow": 1731, - "▁http": 1732, - "abase": 1733, - "▁word": 1734, - "▁change": 1735, - "▁works": 1736, - "▁ge": 1737, - "▁!": 1738, - "▁een": 1739, - "itle": 1740, - "▁event": 1741, - "word": 1742, - "ando": 1743, - "SB": 1744, - "rem": 1745, - "▁field": 1746, - "ving": 1747, - "Ser": 1748, - "▁our": 1749, - "▁qui": 1750, - "▁oper": 1751, - "▁ist": 1752, - "def": 1753, - "▁made": 1754, - "ние": 1755, - "px": 1756, - "▁men": 1757, - "rm": 1758, - "ais": 1759, - "cent": 1760, - "list": 1761, - "To": 1762, - "▁To": 1763, - "ja": 1764, - "vert": 1765, - "▁mar": 1766, - "value": 1767, - "▁„": 1768, - "\";": 1769, - "▁aus": 1770, - "▁Br": 1771, - "ole": 1772, - "▁mult": 1773, - "ought": 1774, - "▁mat": 1775, - "▁view": 1776, - "fil": 1777, - "▁со": 1778, - "га": 1779, - "▁void": 1780, - "▁good": 1781, - "бо": 1782, - "CT": 1783, - "▁many": 1784, - "ben": 1785, - "▁во": 1786, - "▁ка": 1787, - "▁system": 1788, - "ino": 1789, - "▁another": 1790, - "▁rest": 1791, - "user": 1792, - "ility": 1793, - "ai": 1794, - "▁might": 1795, - "ustom": 1796, - "▁order": 1797, - "▁Ver": 1798, - "SS": 1799, - "})": 1800, - "▁eff": 1801, - "до": 1802, - "ett": 1803, - "▁sign": 1804, - "му": 1805, - "IT": 1806, - "string": 1807, - "elle": 1808, - "▁sing": 1809, - "cul": 1810, - "▁trying": 1811, - "▁beg": 1812, - "▁page": 1813, - "хо": 1814, - "▁Can": 1815, - "▁Ser": 1816, - "++": 1817, - "▁must": 1818, - "▁values": 1819, - "▁key": 1820, - "ible": 1821, - "].": 1822, - "ird": 1823, - "▁program": 1824, - "roller": 1825, - "▁conne": 1826, - "▁say": 1827, - "▁param": 1828, - "ache": 1829, - "velop": 1830, - "▁select": 1831, - "▁famil": 1832, - "▁last": 1833, - "▁Thanks": 1834, - "▁pop": 1835, - "}.": 1836, - "eq": 1837, - "▁doesn": 1838, - "['": 1839, - "▁term": 1840, - "▁ré": 1841, - "▁document": 1842, - "па": 1843, - "лу": 1844, - "ateg": 1845, - ".)": 1846, - "ling": 1847, - "ional": 1848, - "ables": 1849, - "▁tak": 1850, - "utton": 1851, - "▁arg": 1852, - "type": 1853, - "▁sure": 1854, - "▁real": 1855, - "▁web": 1856, - "▁current": 1857, - "▁Pl": 1858, - "cho": 1859, - "ments": 1860, - "▁Joh": 1861, - "ots": 1862, - "▁exist": 1863, - "ну": 1864, - "▁für": 1865, - "▁из": 1866, - "do": 1867, - "ного": 1868, - "▁las": 1869, - "▁null": 1870, - "▁inform": 1871, - "▁Л": 1872, - "▁version": 1873, - "▁chang": 1874, - "ager": 1875, - "▁Comm": 1876, - "лі": 1877, - "ush": 1878, - "▁Ge": 1879, - "▁high": 1880, - "▁input": 1881, - "ogle": 1882, - "ros": 1883, - "box": 1884, - "gen": 1885, - "▁ste": 1886, - "▁local": 1887, - "Im": 1888, - "▁process": 1889, - "ternal": 1890, - "ized": 1891, - "ги": 1892, - "ét": 1893, - "▁Ind": 1894, - "▁och": 1895, - "lt": 1896, - "▁column": 1897, - "▁tried": 1898, - "▁command": 1899, - "▁best": 1900, - "aster": 1901, - "за": 1902, - "▁prim": 1903, - "▁model": 1904, - "▁і": 1905, - "▁those": 1906, - "ities": 1907, - "ère": 1908, - "▁ре": 1909, - "је": 1910, - "ши": 1911, - "ques": 1912, - "▁Am": 1913, - "▁own": 1914, - "lin": 1915, - "зи": 1916, - "Value": 1917, - "thing": 1918, - "▁,": 1919, - "▁Te": 1920, - "▁stud": 1921, - "▁um": 1922, - "▁server": 1923, - "ille": 1924, - "▁put": 1925, - "ativ": 1926, - "gy": 1927, - "ови": 1928, - "raf": 1929, - "ово": 1930, - "▁wurde": 1931, - "▁When": 1932, - "▁div": 1933, - "ants": 1934, - "▁ter": 1935, - "▁partic": 1936, - "▁т": 1937, - "▁Do": 1938, - "▁No": 1939, - "sert": 1940, - "ido": 1941, - "mathcal": 1942, - "ade": 1943, - "▁II": 1944, - "lear": 1945, - "ograph": 1946, - "ense": 1947, - "▁row": 1948, - "num": 1949, - "▁possible": 1950, - "▁since": 1951, - "▁Bo": 1952, - "ctions": 1953, - "▁Im": 1954, - "OR": 1955, - "ці": 1956, - "▁ide": 1957, - "map": 1958, - "▁correct": 1959, - "ves": 1960, - "php": 1961, - "▁output": 1962, - "▁Ph": 1963, - "AL": 1964, - "ared": 1965, - "\\\\": 1966, - "▁image": 1967, - "esch": 1968, - "жи": 1969, - "▁conf": 1970, - "por": 1971, - "query": 1972, - "ures": 1973, - "ium": 1974, - "ends": 1975, - "▁Ab": 1976, - "SBN": 1977, - "ід": 1978, - "ether": 1979, - "ptions": 1980, - "itu": 1981, - "lib": 1982, - "ns": 1983, - "ki": 1984, - "▁working": 1985, - "▁como": 1986, - "▁Then": 1987, - "ML": 1988, - "key": 1989, - "class": 1990, - "ople": 1991, - "ittle": 1992, - "▁match": 1993, - "ways": 1994, - "mathbb": 1995, - "▁require": 1996, - "alt": 1997, - "▁vis": 1998, - "▁bl": 1999, - "▁called": 2000, - "Item": 2001, - "ura": 2002, - "vec": 2003, - "eme": 2004, - "▁della": 2005, - "embre": 2006, - "urg": 2007, - "Se": 2008, - "▁request": 2009, - "ische": 2010, - "▁port": 2011, - "▁instead": 2012, - "=\\": 2013, - "▁У": 2014, - "hor": 2015, - "ente": 2016, - "ume": 2017, - "erd": 2018, - "са": 2019, - "▁why": 2020, - "rist": 2021, - "▁person": 2022, - "▁...": 2023, - "▁private": 2024, - "▁tot": 2025, - "pha": 2026, - "ift": 2027, - "ita": 2028, - "loc": 2029, - "▁old": 2030, - "он": 2031, - "▁nel": 2032, - "']": 2033, - "ti": 2034, - "iet": 2035, - "cite": 2036, - "plement": 2037, - "▁above": 2038, - "ks": 2039, - "ready": 2040, - "▁come": 2041, - "section": 2042, - "▁Pol": 2043, - "▁writ": 2044, - "▁https": 2045, - "▁$$": 2046, - "▁»": 2047, - "▁build": 2048, - "ito": 2049, - "▁consider": 2050, - "aft": 2051, - "App": 2052, - ",\\": 2053, - "indows": 2054, - "comm": 2055, - "▁;": 2056, - "ground": 2057, - "▁place": 2058, - "By": 2059, - "▁project": 2060, - "Object": 2061, - "▁repr": 2062, - "ences": 2063, - "indow": 2064, - "zt": 2065, - "▁files": 2066, - "cz": 2067, - "ivity": 2068, - "▁init": 2069, - "▁prob": 2070, - "▁sk": 2071, - "orth": 2072, - "iment": 2073, - "ouble": 2074, - "atal": 2075, - "irc": 2076, - "▁è": 2077, - "▁bre": 2078, - "ista": 2079, - "input": 2080, - "▁И": 2081, - "ной": 2082, - "sum": 2083, - "path": 2084, - "▁cour": 2085, - "▁too": 2086, - "▁Ad": 2087, - "▁Gu": 2088, - "▁false": 2089, - "▁fun": 2090, - "▁ст": 2091, - "ood": 2092, - "ès": 2093, - "▁enc": 2094, - "bol": 2095, - "rl": 2096, - "arget": 2097, - "order": 2098, - "▁mean": 2099, - "пе": 2100, - "igen": 2101, - "▁пре": 2102, - "width": 2103, - ";\r": 2104, - "itor": 2105, - "▁state": 2106, - "▁great": 2107, - "enn": 2108, - "bin": 2109, - "Er": 2110, - "Mod": 2111, - "oz": 2112, - "▁won": 2113, - "▁fact": 2114, - "▁java": 2115, - "▁Univers": 2116, - "▁cap": 2117, - "istor": 2118, - "}(": 2119, - "ku": 2120, - "ither": 2121, - "ales": 2122, - "▁ou": 2123, - "ross": 2124, - "▁take": 2125, - "rix": 2126, - "lob": 2127, - "▁eine": 2128, - "ases": 2129, - "▁access": 2130, - "ité": 2131, - "istr": 2132, - "ization": 2133, - "▁appro": 2134, - "ball": 2135, - "▁mak": 2136, - "}^": 2137, - "▁Cons": 2138, - "press": 2139, - "serv": 2140, - "().": 2141, - "af": 2142, - "▁ref": 2143, - ")\\": 2144, - "▁contin": 2145, - "su": 2146, - "iver": 2147, - "▁cond": 2148, - "▁expect": 2149, - "▁charact": 2150, - "bert": 2151, - "elt": 2152, - "ters": 2153, - "script": 2154, - "▁Ed": 2155, - "apt": 2156, - "');": 2157, - "print": 2158, - "▁size": 2159, - "▁sich": 2160, - "face": 2161, - "enden": 2162, - "▁Amer": 2163, - "ified": 2164, - "ów": 2165, - "▁Su": 2166, - "tes": 2167, - "med": 2168, - "▁Reg": 2169, - "sole": 2170, - "▁includ": 2171, - "ini": 2172, - "inci": 2173, - "▁pla": 2174, - "▁left": 2175, - "df": 2176, - "Par": 2177, - "▁All": 2178, - "▁occ": 2179, - "▁At": 2180, - "▁cr": 2181, - "Qu": 2182, - "▁given": 2183, - "▁System": 2184, - "ican": 2185, - "▁final": 2186, - "itions": 2187, - "▁бы": 2188, - "▁perform": 2189, - "AN": 2190, - "▁Me": 2191, - "uro": 2192, - "▁That": 2193, - "гра": 2194, - "▁По": 2195, - "▁ви": 2196, - "ably": 2197, - "▁present": 2198, - "duct": 2199, - "ric": 2200, - "▁Eng": 2201, - "try": 2202, - "▁lar": 2203, - "bl": 2204, - "idd": 2205, - "▁är": 2206, - "ora": 2207, - "LL": 2208, - "oss": 2209, - "▁ISBN": 2210, - "▁three": 2211, - "jo": 2212, - "ní": 2213, - "rc": 2214, - "▁far": 2215, - "▁Not": 2216, - "▁little": 2217, - "dis": 2218, - "ati": 2219, - "function": 2220, - "▁able": 2221, - "less": 2222, - "со": 2223, - "▁path": 2224, - "▁pres": 2225, - "lose": 2226, - "PI": 2227, - "▁issue": 2228, - "ackage": 2229, - "time": 2230, - "ige": 2231, - "ams": 2232, - "▁Cl": 2233, - "ails": 2234, - "alk": 2235, - "ii": 2236, - "ше": 2237, - "pen": 2238, - "QL": 2239, - "▁eas": 2240, - "RL": 2241, - "cel": 2242, - "▁sl": 2243, - "▁ask": 2244, - "▁nom": 2245, - "▁top": 2246, - "ides": 2247, - "index": 2248, - "ém": 2249, - "▁happ": 2250, - "ox": 2251, - "cd": 2252, - "▁better": 2253, - "▁load": 2254, - "ados": 2255, - "zen": 2256, - "▁ce": 2257, - "▁fa": 2258, - "▁John": 2259, - "IMA": 2260, - "▁Bar": 2261, - "overflow": 2262, - "▁де": 2263, - "ness": 2264, - "cer": 2265, - "▁Here": 2266, - "ret": 2267, - "▁sz": 2268, - "ambda": 2269, - "opy": 2270, - "url": 2271, - "py": 2272, - "rt": 2273, - "▁understand": 2274, - "ał": 2275, - "her": 2276, - "##": 2277, - "▁child": 2278, - "▁exec": 2279, - "▁application": 2280, - "▁struct": 2281, - "▁я": 2282, - "File": 2283, - "▁cert": 2284, - "ison": 2285, - "▁variable": 2286, - "DE": 2287, - "rs": 2288, - "▁really": 2289, - "Port": 2290, - "ba": 2291, - "▁Ber": 2292, - "▁inte": 2293, - "▁static": 2294, - "▁config": 2295, - "▁She": 2296, - "estions": 2297, - "▁plus": 2298, - "▁hab": 2299, - "ope": 2300, - "▁mus": 2301, - "▁count": 2302, - "ME": 2303, - "▁support": 2304, - "▁people": 2305, - "▁beh": 2306, - "▁already": 2307, - "Tr": 2308, - "▁done": 2309, - "dem": 2310, - "size": 2311, - "alpha": 2312, - "▁disc": 2313, - "])": 2314, - "▁Man": 2315, - "▁mil": 2316, - "▁stand": 2317, - "▁group": 2318, - "▁small": 2319, - "▁mag": 2320, - "сть": 2321, - "▁default": 2322, - "▁single": 2323, - "link": 2324, - "clude": 2325, - "▁ear": 2326, - "ilar": 2327, - "****": 2328, - "▁fix": 2329, - "ley": 2330, - "▁pas": 2331, - "ний": 2332, - "ission": 2333, - "▁implement": 2334, - "itch": 2335, - "▁года": 2336, - "▁always": 2337, - "▁Jah": 2338, - "pring": 2339, - "ção": 2340, - "plate": 2341, - "▁descri": 2342, - "▁head": 2343, - "init": 2344, - "ograf": 2345, - "▁query": 2346, - "ived": 2347, - "▁ing": 2348, - "pty": 2349, - "ha": 2350, - "▁mov": 2351, - "▁э": 2352, - "ette": 2353, - "ily": 2354, - "▁got": 2355, - "iled": 2356, - "icro": 2357, - "▁wr": 2358, - "ря": 2359, - "▁never": 2360, - "ores": 2361, - "▁bas": 2362, - "ios": 2363, - "lack": 2364, - "aint": 2365, - "vious": 2366, - "▁give": 2367, - "idad": 2368, - "En": 2369, - "ный": 2370, - "table": 2371, - "▁На": 2372, - "▁pat": 2373, - "тор": 2374, - "angu": 2375, - "loy": 2376, - "▁seg": 2377, - "array": 2378, - "▁Fl": 2379, - "▁index": 2380, - "▁sw": 2381, - "IMAGE": 2382, - "▁km": 2383, - "би": 2384, - "Class": 2385, - "ena": 2386, - "мен": 2387, - "comp": 2388, - "atus": 2389, - "rap": 2390, - "▁List": 2391, - "Error": 2392, - "▁typ": 2393, - "▁ма": 2394, - "cs": 2395, - "':": 2396, - "ji": 2397, - "▁However": 2398, - "▁те": 2399, - "▁below": 2400, - "▁App": 2401, - "ще": 2402, - "}_": 2403, - "bum": 2404, - "vir": 2405, - "ées": 2406, - "▁record": 2407, - "tain": 2408, - "lem": 2409, - "ital": 2410, - "▁imp": 2411, - "ego": 2412, - "▁od": 2413, - "▁rece": 2414, - "mit": 2415, - "ffic": 2416, - "stackoverflow": 2417, - "ieve": 2418, - "▁З": 2419, - "▁nov": 2420, - "це": 2421, - "▁Intern": 2422, - "bu": 2423, - "▁sugg": 2424, - "▁loop": 2425, - "ride": 2426, - "▁$(": 2427, - "▁super": 2428, - "rid": 2429, - "ных": 2430, - "▁Per": 2431, - "▁dom": 2432, - "='": 2433, - "utsch": 2434, - "len": 2435, - "▁write": 2436, - "▁inv": 2437, - "outh": 2438, - "▁Her": 2439, - "▁years": 2440, - "▁original": 2441, - "ega": 2442, - "▁Ste": 2443, - "▁seems": 2444, - "ég": 2445, - "▁next": 2446, - "eder": 2447, - "▁Ne": 2448, - "avas": 2449, - "ification": 2450, - "Exception": 2451, - "▁Der": 2452, - "▁ve": 2453, - "atic": 2454, - "hat": 2455, - "brary": 2456, - "return": 2457, - "urch": 2458, - "ision": 2459, - "mi": 2460, - "oint": 2461, - "▁day": 2462, - "iction": 2463, - "ál": 2464, - "▁és": 2465, - "▁though": 2466, - "action": 2467, - "ít": 2468, - "ungen": 2469, - "ours": 2470, - "▁script": 2471, - "▁information": 2472, - "▁multi": 2473, - "▁\\\\": 2474, - "ster": 2475, - "ке": 2476, - "AC": 2477, - "cies": 2478, - "▁display": 2479, - "oman": 2480, - "Time": 2481, - "ius": 2482, - "));": 2483, - "tre": 2484, - "▁lim": 2485, - "ately": 2486, - "éd": 2487, - "iste": 2488, - "▁са": 2489, - "post": 2490, - "uel": 2491, - "img": 2492, - "▁ч": 2493, - "ска": 2494, - "eld": 2495, - "pper": 2496, - "ula": 2497, - "▁general": 2498, - "Al": 2499, - "Form": 2500, - "▁upon": 2501, - "zo": 2502, - "amente": 2503, - "▁prom": 2504, - "▁ü": 2505, - "lex": 2506, - "▁turn": 2507, - "▁ме": 2508, - "ention": 2509, - "лен": 2510, - "▁af": 2511, - "icle": 2512, - "ств": 2513, - "▁Fil": 2514, - "▁Ф": 2515, - "avascript": 2516, - "Man": 2517, - "ara": 2518, - "ware": 2519, - "align": 2520, - "angle": 2521, - "▁Sc": 2522, - "unic": 2523, - "▁fran": 2524, - "Un": 2525, - "zi": 2526, - "met": 2527, - "Add": 2528, - "▁pub": 2529, - "ков": 2530, - "▁gen": 2531, - "▁pod": 2532, - "▁sum": 2533, - "▁having": 2534, - "▁avec": 2535, - "sl": 2536, - "▁fig": 2537, - "▁Res": 2538, - "Date": 2539, - "ules": 2540, - "with": 2541, - "ский": 2542, - "gu": 2543, - "ET": 2544, - "▁bro": 2545, - "rie": 2546, - "aps": 2547, - "ending": 2548, - "mail": 2549, - "ook": 2550, - "▁success": 2551, - "berg": 2552, - "▁deb": 2553, - "elta": 2554, - "()`": 2555, - "ential": 2556, - "frame": 2557, - "Key": 2558, - "inn": 2559, - "▁simple": 2560, - "ival": 2561, - "▁care": 2562, - "▁Web": 2563, - "\").": 2564, - ">": 2900, - "ko": 2901, - "▁exper": 2902, - "▁separ": 2903, - "yl": 2904, - "ourn": 2905, - "▁dev": 2906, - "▁auch": 2907, - "▁block": 2908, - "book": 2909, - "▁map": 2910, - "illa": 2911, - "▁comput": 2912, - "▁space": 2913, - "result": 2914, - ")}": 2915, - "▁echo": 2916, - "config": 2917, - "hi": 2918, - "▁large": 2919, - "▁width": 2920, - "▁Go": 2921, - "mat": 2922, - "▁diff": 2923, - "▁kind": 2924, - "ances": 2925, - "ynam": 2926, - "▁color": 2927, - "Int": 2928, - "sol": 2929, - "▁pi": 2930, - "▁character": 2931, - "oment": 2932, - "▁response": 2933, - "igma": 2934, - "wards": 2935, - "arrow": 2936, - "су": 2937, - "ties": 2938, - "▁über": 2939, - "Image": 2940, - "yd": 2941, - "▁пере": 2942, - "▁node": 2943, - "▁item": 2944, - "achine": 2945, - "ima": 2946, - "▁va": 2947, - "▁approach": 2948, - "▁wer": 2949, - "▁че": 2950, - "On": 2951, - "ollow": 2952, - "она": 2953, - "cted": 2954, - "ured": 2955, - "Controller": 2956, - "lied": 2957, - "▁jo": 2958, - "▁dal": 2959, - "unk": 2960, - "▁î": 2961, - "start": 2962, - "ola": 2963, - "▁compon": 2964, - "IC": 2965, - "bit": 2966, - "▁base": 2967, - "пу": 2968, - "▁idea": 2969, - "▁dire": 2970, - "▁rad": 2971, - "group": 2972, - "▁With": 2973, - "server": 2974, - "side": 2975, - "sing": 2976, - "▁dies": 2977, - "▁near": 2978, - "▁voor": 2979, - "▁argument": 2980, - "▁},": 2981, - "▁land": 2982, - "▁names": 2983, - "▁option": 2984, - "ithub": 2985, - "pped": 2986, - "aug": 2987, - "▁links": 2988, - "▁full": 2989, - "▁situ": 2990, - "▁console": 2991, - "▁etc": 2992, - "aux": 2993, - "▁Cor": 2994, - "icrosoft": 2995, - "▁came": 2996, - "local": 2997, - "▁known": 2998, - "▁multiple": 2999, - "anguage": 3000, - "▁total": 3001, - "ology": 3002, - "ät": 3003, - "▁Х": 3004, - "▁fre": 3005, - "▁ten": 3006, - "ideo": 3007, - "▁bes": 3008, - "true": 3009, - "Query": 3010, - "omm": 3011, - "▁Art": 3012, - "▁keep": 3013, - "▁University": 3014, - "reate": 3015, - "pport": 3016, - "▁python": 3017, - "tra": 3018, - "ector": 3019, - "рі": 3020, - "oph": 3021, - "▁conc": 3022, - "▁four": 3023, - "viron": 3024, - "▁via": 3025, - "?\"": 3026, - "image": 3027, - "oll": 3028, - "ные": 3029, - "▁context": 3030, - "▁sem": 3031, - "._": 3032, - "▁eng": 3033, - "mar": 3034, - "AD": 3035, - "▁mor": 3036, - "▁Cal": 3037, - "▁cell": 3038, - "imal": 3039, - "ATE": 3040, - "▁inf": 3041, - "ön": 3042, - "uffer": 3043, - "sq": 3044, - "....": 3045, - "▁zur": 3046, - "With": 3047, - "ран": 3048, - "chn": 3049, - "▁door": 3050, - "content": 3051, - "▁miss": 3052, - "▁simp": 3053, - "ár": 3054, - "ira": 3055, - "▁hat": 3056, - "Test": 3057, - "▁certain": 3058, - "NS": 3059, - "▁cho": 3060, - "▁adv": 3061, - "where": 3062, - "▁looking": 3063, - "▁times": 3064, - "них": 3065, - "uto": 3066, - "▁É": 3067, - "can": 3068, - "host": 3069, - "▁(*": 3070, - "loat": 3071, - "▁nicht": 3072, - "Field": 3073, - "burg": 3074, - "const": 3075, - "ades": 3076, - "▁Mus": 3077, - "▁nothing": 3078, - "▁incre": 3079, - "▁Min": 3080, - "▁power": 3081, - "▁American": 3082, - "ln": 3083, - "valid": 3084, - "ungs": 3085, - "▁National": 3086, - "▁San": 3087, - "▁York": 3088, - "Request": 3089, - "char": 3090, - "▁Ze": 3091, - "button": 3092, - "▁alg": 3093, - "SON": 3094, - "▁ap": 3095, - "uff": 3096, - "ability": 3097, - "ем": 3098, - "▁anything": 3099, - "ela": 3100, - "())": 3101, - "ба": 3102, - "ampion": 3103, - "▁pot": 3104, - "▁fut": 3105, - "ailable": 3106, - "▁prop": 3107, - "\"]": 3108, - "▁less": 3109, - "lag": 3110, - "▁August": 3111, - "It": 3112, - "▁please": 3113, - "▁style": 3114, - "▁Also": 3115, - "bt": 3116, - "▁probably": 3117, - "▁One": 3118, - "▁poss": 3119, - "UI": 3120, - "uit": 3121, - "▁West": 3122, - "hn": 3123, - "+\\": 3124, - "Button": 3125, - "json": 3126, - "err": 3127, - "rame": 3128, - "dom": 3129, - "ilon": 3130, - "alf": 3131, - "▁client": 3132, - "▁continu": 3133, - "xml": 3134, - "pec": 3135, - "ador": 3136, - "ls": 3137, - "▁however": 3138, - "▁Any": 3139, - "änd": 3140, - "mathrm": 3141, - "▁url": 3142, - "▁book": 3143, - "▁gl": 3144, - "ives": 3145, - "gi": 3146, - "▁tro": 3147, - "▁US": 3148, - "point": 3149, - "open": 3150, - "▁cur": 3151, - "▁era": 3152, - "▁particular": 3153, - "▁HT": 3154, - "oot": 3155, - "ello": 3156, - "lobal": 3157, - "▁action": 3158, - "▁Int": 3159, - "▁include": 3160, - "▁elements": 3161, - "ная": 3162, - "ards": 3163, - "▁Bl": 3164, - "▁hum": 3165, - "from": 3166, - "change": 3167, - "▁functions": 3168, - "hen": 3169, - "Service": 3170, - "▁height": 3171, - "▁Land": 3172, - "ias": 3173, - "gs": 3174, - "ión": 3175, - "лов": 3176, - "node": 3177, - ".”": 3178, - "hand": 3179, - "▁бу": 3180, - "▁amb": 3181, - "▁Lu": 3182, - "▁throw": 3183, - "▁mot": 3184, - "▁Act": 3185, - "▁world": 3186, - "_\\": 3187, - "base": 3188, - "▁Co": 3189, - "▁arch": 3190, - "▁####": 3191, - "ged": 3192, - "pril": 3193, - "older": 3194, - "Model": 3195, - "▁several": 3196, - "lie": 3197, - "check": 3198, - "]{": 3199, - "cons": 3200, - "▁Tra": 3201, - "heck": 3202, - "▁least": 3203, - "down": 3204, - "ebru": 3205, - "Def": 3206, - "param": 3207, - "ischer": 3208, - "▁cas": 3209, - "CH": 3210, - "▁address": 3211, - "▁раз": 3212, - "ufen": 3213, - "urope": 3214, - "ей": 3215, - "▁bound": 3216, - "CO": 3217, - "▁Ang": 3218, - "▁Ma": 3219, - "Index": 3220, - "core": 3221, - "ouch": 3222, - "atabase": 3223, - "ribution": 3224, - "document": 3225, - "Le": 3226, - "}_{": 3227, - "vern": 3228, - "▁statement": 3229, - "▁Brit": 3230, - "ono": 3231, - "psilon": 3232, - "▁level": 3233, - "▁product": 3234, - "IS": 3235, - "▁course": 3236, - "▁Mr": 3237, - ">\r": 3238, - "▁background": 3239, - "▁ret": 3240, - "ering": 3241, - "most": 3242, - "сько": 3243, - "▁thread": 3244, - "itional": 3245, - "ites": 3246, - "Pl": 3247, - "▁dos": 3248, - "ga": 3249, - "day": 3250, - "▁Gener": 3251, - "▁tw": 3252, - "Ad": 3253, - "\"><": 3254, - "▁($": 3255, - "▁moment": 3256, - "title": 3257, - "create": 3258, - "version": 3259, - "Manager": 3260, - "▁fur": 3261, - "pping": 3262, - "ijn": 3263, - "ос": 3264, - "▁rather": 3265, - "ptember": 3266, - "OS": 3267, - "▁site": 3268, - "▁caus": 3269, - "ani": 3270, - "▁home": 3271, - "мі": 3272, - "▁short": 3273, - "pa": 3274, - "▁lead": 3275, - "ished": 3276, - "cing": 3277, - "ording": 3278, - "▁prote": 3279, - "сле": 3280, - "LECT": 3281, - "▁didn": 3282, - "position": 3283, - "\",\"": 3284, - "(),": 3285, - "trans": 3286, - "▁lot": 3287, - "▁од": 3288, - "AS": 3289, - "▁sat": 3290, - "▁points": 3291, - "github": 3292, - "style": 3293, - "▁году": 3294, - "▁Dis": 3295, - "ponent": 3296, - "omet": 3297, - "zer": 3298, - "ULL": 3299, - "▁pa": 3300, - "AP": 3301, - "aces": 3302, - "▁United": 3303, - "ama": 3304, - "ety": 3305, - "Color": 3306, - "▁enough": 3307, - "US": 3308, - "▁length": 3309, - "());": 3310, - "^{\\": 3311, - "fty": 3312, - "Box": 3313, - "apter": 3314, - "▁complet": 3315, - "ник": 3316, - "max": 3317, - "object": 3318, - "({": 3319, - "imgur": 3320, - "itive": 3321, - "unch": 3322, - "▁Sub": 3323, - "ende": 3324, - "гу": 3325, - "ategory": 3326, - "ты": 3327, - "iano": 3328, - "▁upd": 3329, - "▁Aust": 3330, - "}{\\": 3331, - "top": 3332, - "las": 3333, - "pis": 3334, - "iness": 3335, - "▁{\r": 3336, - "▁Е": 3337, - "Gr": 3338, - "▁AS": 3339, - "▁ве": 3340, - "thers": 3341, - "▁defined": 3342, - "azione": 3343, - "▁offic": 3344, - "▁autom": 3345, - "ün": 3346, - "▁brow": 3347, - "▁serv": 3348, - "▁remove": 3349, - "iro": 3350, - "▁Bibli": 3351, - "ED": 3352, - "▁whole": 3353, - "▁ш": 3354, - "▁Java": 3355, - "▁zum": 3356, - "ua": 3357, - "pm": 3358, - "dev": 3359, - "кра": 3360, - "olds": 3361, - "▁War": 3362, - "än": 3363, - "pass": 3364, - "uz": 3365, - "[\"": 3366, - "▁tri": 3367, - "ised": 3368, - "ха": 3369, - "▁memory": 3370, - "▁Port": 3371, - "oper": 3372, - "Up": 3373, - "▁Thank": 3374, - "▁Mich": 3375, - "ych": 3376, - "board": 3377, - "бу": 3378, - "Inst": 3379, - "▁begin": 3380, - "ination": 3381, - "▁Mod": 3382, - "_,": 3383, - "▁Den": 3384, - "option": 3385, - "▁construct": 3386, - "▁Just": 3387, - "Map": 3388, - "run": 3389, - "▁respect": 3390, - "ham": 3391, - "ман": 3392, - "imedia": 3393, - "▁apply": 3394, - "cription": 3395, - "main": 3396, - "▁Ка": 3397, - "oid": 3398, - "Code": 3399, - "};": 3400, - "Info": 3401, - "▁format": 3402, - "Log": 3403, - "▁су": 3404, - "▁lat": 3405, - "utor": 3406, - "▁reference": 3407, - "▁calcul": 3408, - "onn": 3409, - "Lo": 3410, - "infty": 3411, - "▁along": 3412, - "▁č": 3413, - "▁task": 3414, - "▁ev": 3415, - "theta": 3416, - "ras": 3417, - "jor": 3418, - "▁бо": 3419, - "▁princip": 3420, - "My": 3421, - "▁einer": 3422, - "▁Es": 3423, - "omb": 3424, - "quad": 3425, - "^{-": 3426, - "ump": 3427, - "▁till": 3428, - "ді": 3429, - "▁looks": 3430, - "▁ok": 3431, - "ца": 3432, - "nu": 3433, - "Fil": 3434, - "▁sont": 3435, - "▁Med": 3436, - "ague": 3437, - "▁cost": 3438, - "▁Sim": 3439, - "▁comment": 3440, - "▁(\\": 3441, - "egen": 3442, - "▁parameter": 3443, - "▁France": 3444, - "rep": 3445, - "▁TH": 3446, - "▁yet": 3447, - "▁away": 3448, - "▁circ": 3449, - "▁API": 3450, - "emp": 3451, - "ві": 3452, - "Layout": 3453, - "▁lines": 3454, - "▁Part": 3455, - "empt": 3456, - "▁Bi": 3457, - "▁mind": 3458, - "ky": 3459, - "ging": 3460, - "▁report": 3461, - "▁Add": 3462, - "род": 3463, - "▁range": 3464, - "cias": 3465, - "lip": 3466, - "▁Kar": 3467, - "▁Commons": 3468, - "gerufen": 3469, - "aff": 3470, - "sec": 3471, - "▁html": 3472, - "lig": 3473, - "▁window": 3474, - "inition": 3475, - "cis": 3476, - "▁ut": 3477, - "eln": 3478, - "▁aux": 3479, - "▁neg": 3480, - "Hand": 3481, - "▁);": 3482, - "▁anal": 3483, - "▁fri": 3484, - "▁си": 3485, - "etch": 3486, - "md": 3487, - "page": 3488, - "▁library": 3489, - "▁:=": 3490, - "ROM": 3491, - "You": 3492, - "space": 3493, - "▁durch": 3494, - "▁host": 3495, - "aven": 3496, - "▁File": 3497, - "alle": 3498, - "тив": 3499, - "▁pap": 3500, - "ство": 3501, - "mark": 3502, - "▁mais": 3503, - "erman": 3504, - "Size": 3505, - "ек": 3506, - "▁Ма": 3507, - "▁isn": 3508, - "▁copy": 3509, - "sten": 3510, - "river": 3511, - "▁went": 3512, - "▁javascript": 3513, - "▁sam": 3514, - "▁frame": 3515, - "▁vi": 3516, - "▁previous": 3517, - "rodu": 3518, - "▁methods": 3519, - "▁necess": 3520, - "NA": 3521, - "cket": 3522, - "▁opt": 3523, - "Loc": 3524, - "how": 3525, - "▁în": 3526, - "ship": 3527, - "▁itself": 3528, - "▁Please": 3529, - "iene": 3530, - "вер": 3531, - "▁<<": 3532, - "▁mill": 3533, - "▁trad": 3534, - "pace": 3535, - "▁Har": 3536, - "iten": 3537, - "wise": 3538, - "write": 3539, - "ции": 3540, - "ры": 3541, - "Line": 3542, - "olo": 3543, - "▁accept": 3544, - "height": 3545, - "▁elect": 3546, - "ella": 3547, - "▁på": 3548, - "Select": 3549, - "▁ли": 3550, - "▁\\<": 3551, - "((": 3552, - "▁ID": 3553, - "ops": 3554, - "ван": 3555, - "ió": 3556, - "TP": 3557, - "»,": 3558, - "nection": 3559, - "parent": 3560, - "▁Mag": 3561, - "Table": 3562, - "Over": 3563, - "▁network": 3564, - "спо": 3565, - "▁assign": 3566, - "igger": 3567, - "irm": 3568, - ")`": 3569, - "ottom": 3570, - "beta": 3571, - "▁dell": 3572, - "▁body": 3573, - "▁да": 3574, - "▁Your": 3575, - "▁fue": 3576, - "▁package": 3577, - "▁light": 3578, - "▁**": 3579, - "MP": 3580, - "▁cou": 3581, - "yes": 3582, - ":\\": 3583, - "▁Ч": 3584, - "▁mention": 3585, - "ensch": 3586, - "▁deg": 3587, - "▁convert": 3588, - "▁Dav": 3589, - "adt": 3590, - "Result": 3591, - "though": 3592, - "▁bus": 3593, - "xy": 3594, - "▁seen": 3595, - "All": 3596, - "public": 3597, - "ively": 3598, - "▁Rec": 3599, - "▁His": 3600, - "sim": 3601, - "▁för": 3602, - "▁histor": 3603, - "▁sett": 3604, - "rat": 3605, - "abled": 3606, - "▁»,": 3607, - "google": 3608, - "Web": 3609, - "él": 3610, - "▁title": 3611, - "▁Janu": 3612, - "ја": 3613, - "▁took": 3614, - "iden": 3615, - "sz": 3616, - "▁Get": 3617, - "▁objects": 3618, - "▁common": 3619, - "▁changes": 3620, - "▁Lond": 3621, - "▁extern": 3622, - "▁ju": 3623, - "Is": 3624, - "▁available": 3625, - "tri": 3626, - "▁más": 3627, - "osa": 3628, - "Be": 3629, - "▁Data": 3630, - "ural": 3631, - "▁hom": 3632, - "▁account": 3633, - "oo": 3634, - "▁perm": 3635, - "respond": 3636, - "yt": 3637, - "▁send": 3638, - "▁returns": 3639, - "ivid": 3640, - "▁expla": 3641, - "ín": 3642, - "▁nor": 3643, - "If": 3644, - "▁From": 3645, - "▁target": 3646, - "fect": 3647, - "ент": 3648, - "▁uit": 3649, - "▁Jo": 3650, - "▁variables": 3651, - "▁series": 3652, - "▁func": 3653, - "▁himself": 3654, - "▁ча": 3655, - "anti": 3656, - "▁ach": 3657, - "ialog": 3658, - "▁std": 3659, - "ae": 3660, - "▁foot": 3661, - "▁unter": 3662, - "gress": 3663, - "Not": 3664, - "rad": 3665, - "fér": 3666, - "▁util": 3667, - "orem": 3668, - "▁sou": 3669, - "opt": 3670, - "▁og": 3671, - "▁uma": 3672, - "itar": 3673, - "▁Ok": 3674, - "ück": 3675, - "sqrt": 3676, - "▁ant": 3677, - "▁werden": 3678, - "år": 3679, - "});": 3680, - "▁Paris": 3681, - "▁exception": 3682, - "▁determ": 3683, - "▁Vol": 3684, - "▁Sam": 3685, - "▁ess": 3686, - "lies": 3687, - "ioni": 3688, - "oding": 3689, - "idget": 3690, - "▁pri": 3691, - "▁whether": 3692, - "▁под": 3693, - "▁numbers": 3694, - "▁~": 3695, - "event": 3696, - "▁shows": 3697, - "atures": 3698, - "▁house": 3699, - "▁face": 3700, - "▁się": 3701, - "vironment": 3702, - "van": 3703, - "▁including": 3704, - "▁<-": 3705, - "times": 3706, - "now": 3707, - "▁pur": 3708, - "ifier": 3709, - "▁emp": 3710, - "▁cla": 3711, - "mon": 3712, - "▁Das": 3713, - "ady": 3714, - "▁від": 3715, - "▁ц": 3716, - "abor": 3717, - "OST": 3718, - "▁band": 3719, - "▁ú": 3720, - "▁exactly": 3721, - "iert": 3722, - "avig": 3723, - "▁redu": 3724, - "▁SE": 3725, - "lished": 3726, - "Bu": 3727, - "Message": 3728, - "cell": 3729, - "fully": 3730, - "▁sv": 3731, - "▁makes": 3732, - "pol": 3733, - "▁required": 3734, - "ferrer": 3735, - "▁pers": 3736, - "▁mi": 3737, - "FI": 3738, - "▁Paul": 3739, - "▁UI": 3740, - "▁Bel": 3741, - "inc": 3742, - "▁contains": 3743, - "Out": 3744, - "asure": 3745, - "pu": 3746, - "oto": 3747, - "▁game": 3748, - "zn": 3749, - "▁Why": 3750, - "orith": 3751, - "big": 3752, - "кий": 3753, - "sigma": 3754, - "▁quite": 3755, - "▁jed": 3756, - "rec": 3757, - "▁SQL": 3758, - "бе": 3759, - "▁Mart": 3760, - "ya": 3761, - "▁school": 3762, - "▁simply": 3763, - "▁vor": 3764, - "▁double": 3765, - "рав": 3766, - "▁Str": 3767, - "iem": 3768, - "▁album": 3769, - "▁resol": 3770, - "▁dei": 3771, - "▁Wik": 3772, - "▁aw": 3773, - "umb": 3774, - "ols": 3775, - "▁*/": 3776, - "▁ze": 3777, - "▁anim": 3778, - "/>": 3779, - "ris": 3780, - "resh": 3781, - "No": 3782, - "iques": 3783, - "current": 3784, - "▁period": 3785, - "▁April": 3786, - "▁store": 3787, - "','": 3788, - "▁Set": 3789, - "={": 3790, - "ached": 3791, - "▁Mal": 3792, - "▁Pal": 3793, - "antes": 3794, - "aterial": 3795, - "▁worked": 3796, - "leq": 3797, - "oreferrer": 3798, - "▁happen": 3799, - "▁box": 3800, - "ney": 3801, - "▁close": 3802, - "▁gran": 3803, - "▁lie": 3804, - "▁ir": 3805, - "▁expected": 3806, - "▁для": 3807, - "click": 3808, - "și": 3809, - "▁parte": 3810, - "ogn": 3811, - "▁Form": 3812, - "▁memb": 3813, - "▁plan": 3814, - "▁team": 3815, - "][": 3816, - "▁commun": 3817, - "orry": 3818, - "ency": 3819, - "gl": 3820, - "inary": 3821, - "cdot": 3822, - "^\\": 3823, - "▁First": 3824, - "ander": 3825, - "▁Dec": 3826, - "request": 3827, - "ства": 3828, - "▁structure": 3829, - "▁||": 3830, - "▁Comp": 3831, - "actory": 3832, - "▁Mil": 3833, - "▁Some": 3834, - "Stream": 3835, - "▁assum": 3836, - "uen": 3837, - "▁words": 3838, - "▁September": 3839, - "▁Ко": 3840, - "▁days": 3841, - "ories": 3842, - "став": 3843, - "sm": 3844, - "vin": 3845, - "partial": 3846, - "▁parent": 3847, - "oj": 3848, - "нии": 3849, - "!\"": 3850, - "ugin": 3851, - "▁Windows": 3852, - "Ed": 3853, - ":}": 3854, - "▁q": 3855, - "▁ben": 3856, - "iana": 3857, - "▁label": 3858, - "state": 3859, - "uted": 3860, - "▁()": 3861, - "▁сво": 3862, - "▁edit": 3863, - "uring": 3864, - "▁NS": 3865, - "▁Jahr": 3866, - "▁provide": 3867, - "He": 3868, - "▁Yes": 3869, - "anel": 3870, - "ename": 3871, - "▁Don": 3872, - "isk": 3873, - "gra": 3874, - "elij": 3875, - "▁root": 3876, - "*/": 3877, - "▁Fre": 3878, - "▁Mor": 3879, - "used": 3880, - "range": 3881, - "▁tamb": 3882, - "▁module": 3883, - "▁directory": 3884, - "ounds": 3885, - "Activity": 3886, - "▁mu": 3887, - "info": 3888, - "▁free": 3889, - "orge": 3890, - "tab": 3891, - ")=": 3892, - "lang": 3893, - "▁ос": 3894, - "▁FROM": 3895, - "▁enter": 3896, - "▁became": 3897, - "idae": 3898, - "хи": 3899, - "▁States": 3900, - "verse": 3901, - "▁expl": 3902, - "ynt": 3903, - "UN": 3904, - "ee": 3905, - "endent": 3906, - "▁making": 3907, - "▁\"$": 3908, - "uni": 3909, - "quence": 3910, - "▁lui": 3911, - "HT": 3912, - "▁uses": 3913, - "zie": 3914, - "nia": 3915, - "Content": 3916, - "▁Count": 3917, - "▁standard": 3918, - "ENT": 3919, - "▁кон": 3920, - "fort": 3921, - "adas": 3922, - "зу": 3923, - "System": 3924, - "▁Sw": 3925, - "▁ever": 3926, - "LO": 3927, - "▁correspond": 3928, - "▁Po": 3929, - "argin": 3930, - "кт": 3931, - "ій": 3932, - "▁remain": 3933, - "cio": 3934, - "▁actual": 3935, - "сту": 3936, - "▁sind": 3937, - "▁Pe": 3938, - "▁changed": 3939, - "▁Note": 3940, - "skie": 3941, - "▁family": 3942, - "ità": 3943, - "cos": 3944, - "txt": 3945, - "ker": 3946, - "ceed": 3947, - "▁arr": 3948, - "▁cam": 3949, - "izer": 3950, - "▁Dan": 3951, - "hel": 3952, - "icult": 3953, - "HP": 3954, - "iler": 3955, - "▁Sal": 3956, - "▁connection": 3957, - "usion": 3958, - "kn": 3959, - "RI": 3960, - "▁vom": 3961, - "Listener": 3962, - "▁ö": 3963, - "▁dim": 3964, - "▁press": 3965, - "▁esc": 3966, - "▁Try": 3967, - "atalog": 3968, - "▁thanks": 3969, - "DO": 3970, - "▁written": 3971, - "dir": 3972, - "rew": 3973, - "▁fire": 3974, - "▁Nach": 3975, - "▁á": 3976, - "enc": 3977, - "▁origin": 3978, - "▁November": 3979, - "▁};": 3980, - "Count": 3981, - "▁За": 3982, - "▁graph": 3983, - "▁mis": 3984, - "▁External": 3985, - "▁▁▁▁▁▁▁▁▁": 3986, - "▁options": 3987, - "▁URL": 3988, - "▁php": 3989, - "▁integr": 3990, - "Config": 3991, - "▁Text": 3992, - "inner": 3993, - "▁crit": 3994, - ",”": 3995, - "▁tog": 3996, - "$$": 3997, - "nof": 3998, - "▁ses": 3999, - "ühr": 4000, - "▁Since": 4001, - "Des": 4002, - "ube": 4003, - "▁section": 4004, - "▁gi": 4005, - "ford": 4006, - "▁Ass": 4007, - "ainer": 4008, - "ttp": 4009, - "▁behav": 4010, - "ports": 4011, - "draw": 4012, - "This": 4013, - "ranch": 4014, - "inding": 4015, - "▁estab": 4016, - "▁obtain": 4017, - "rich": 4018, - "licit": 4019, - "ев": 4020, - "▁qual": 4021, - "▁za": 4022, - "▁har": 4023, - "▁fac": 4024, - "aar": 4025, - "jet": 4026, - "icles": 4027, - "▁Aus": 4028, - "▁hor": 4029, - "▁remov": 4030, - "▁wie": 4031, - "Client": 4032, - "▁natur": 4033, - "hip": 4034, - "Sub": 4035, - "▁random": 4036, - "DF": 4037, - "▁area": 4038, - "tag": 4039, - "Pr": 4040, - "▁Ital": 4041, - "▁roku": 4042, - "nofollow": 4043, - "*}": 4044, - "▁others": 4045, - "▁limit": 4046, - "▁sil": 4047, - "▁sav": 4048, - "▁often": 4049, - "▁render": 4050, - "DB": 4051, - "▁Mc": 4052, - "▁zijn": 4053, - "жен": 4054, - "▁tag": 4055, - "ming": 4056, - "lichen": 4057, - "pack": 4058, - "▁Ag": 4059, - "▁sense": 4060, - "pg": 4061, - "Method": 4062, - "aged": 4063, - "ág": 4064, - "ła": 4065, - "▁interest": 4066, - "▁associ": 4067, - "volution": 4068, - "▁empty": 4069, - "iche": 4070, - "▁gro": 4071, - "▁types": 4072, - "▁Sie": 4073, - "Inter": 4074, - "▁noreferrer": 4075, - "▁gives": 4076, - "hal": 4077, - "▁save": 4078, - "▁font": 4079, - "ruction": 4080, - "Script": 4081, - "▁alla": 4082, - "▁says": 4083, - "▁fu": 4084, - "ape": 4085, - "▁language": 4086, - "iger": 4087, - "▁King": 4088, - "bor": 4089, - "uv": 4090, - "▁shall": 4091, - "▁Europe": 4092, - "▁einem": 4093, - "▁water": 4094, - "▁govern": 4095, - "anz": 4096, - "ators": 4097, - "▁month": 4098, - "ye": 4099, - "▁important": 4100, - "atz": 4101, - "first": 4102, - "▁Trans": 4103, - "▁Mad": 4104, - "▁bra": 4105, - "ika": 4106, - "▁Saint": 4107, - "oria": 4108, - "kre": 4109, - "ements": 4110, - "▁Ben": 4111, - "lav": 4112, - "▁admin": 4113, - "▁Hen": 4114, - "ril": 4115, - "▁Sm": 4116, - "cat": 4117, - "▁Refer": 4118, - "▁Ш": 4119, - "▁pract": 4120, - "▁Pat": 4121, - "▁Gre": 4122, - "▁young": 4123, - "▁Inter": 4124, - "oma": 4125, - "teger": 4126, - "ibility": 4127, - "▁parameters": 4128, - "▁everything": 4129, - "dat": 4130, - "urop": 4131, - "olean": 4132, - "▁returned": 4133, - "▁Class": 4134, - "acy": 4135, - "####": 4136, - "▁př": 4137, - "▁folder": 4138, - "▁kon": 4139, - "▁guess": 4140, - "gt": 4141, - "jen": 4142, - "annel": 4143, - "icon": 4144, - "▁comb": 4145, - "rict": 4146, - "▁hij": 4147, - "▁author": 4148, - "see": 4149, - "here": 4150, - "stra": 4151, - "▁entire": 4152, - "▁directly": 4153, - "raft": 4154, - "heet": 4155, - "ester": 4156, - "▁ми": 4157, - "▁mass": 4158, - "untu": 4159, - "▁users": 4160, - "chi": 4161, - "PE": 4162, - "▁component": 4163, - "Click": 4164, - "Att": 4165, - "▁sobre": 4166, - "ands": 4167, - "▁Hol": 4168, - "▁Sant": 4169, - "ori": 4170, - "▁sua": 4171, - "std": 4172, - "entic": 4173, - "CC": 4174, - "▁filter": 4175, - "SQL": 4176, - "▁God": 4177, - "At": 4178, - "▁му": 4179, - "▁performance": 4180, - "delta": 4181, - "ande": 4182, - "amer": 4183, - "ды": 4184, - "▁cult": 4185, - "▁Nor": 4186, - "but": 4187, - "▁lik": 4188, - "********": 4189, - "ствен": 4190, - "▁comme": 4191, - "▁dr": 4192, - "imer": 4193, - "ordin": 4194, - "▁condition": 4195, - "este": 4196, - "([": 4197, - "FF": 4198, - "ться": 4199, - "imo": 4200, - "rab": 4201, - "іль": 4202, - "▁half": 4203, - "each": 4204, - "Dis": 4205, - "▁rows": 4206, - "▁hon": 4207, - "▁together": 4208, - "▁și": 4209, - "medi": 4210, - "agn": 4211, - "alled": 4212, - "▁vill": 4213, - "ING": 4214, - "idden": 4215, - "▁draw": 4216, - "yntax": 4217, - "▁attempt": 4218, - "URL": 4219, - "pose": 4220, - "▁indic": 4221, - "ника": 4222, - "▁English": 4223, - "▁déc": 4224, - "▁needs": 4225, - "▁normal": 4226, - "urt": 4227, - "▁но": 4228, - "}}\\": 4229, - "last": 4230, - "▁Fin": 4231, - "▁Febru": 4232, - "ila": 4233, - "▁country": 4234, - "▁fields": 4235, - "▁max": 4236, - "lés": 4237, - "owie": 4238, - "▁deux": 4239, - "▁built": 4240, - "▁Main": 4241, - "▁camp": 4242, - "ivo": 4243, - "iva": 4244, - "icy": 4245, - "zione": 4246, - "Node": 4247, - "▁:)": 4248, - "▁among": 4249, - "▁Ob": 4250, - "▁cases": 4251, - "haps": 4252, - "sers": 4253, - "arter": 4254, - "ści": 4255, - "▁iter": 4256, - "▁named": 4257, - "exec": 4258, - "▁season": 4259, - "tot": 4260, - "=>": 4261, - "graph": 4262, - "▁nil": 4263, - "acional": 4264, - "▁NULL": 4265, - "▁special": 4266, - "сте": 4267, - "css": 4268, - "▁\\(": 4269, - "vs": 4270, - "ael": 4271, - "▁city": 4272, - "ova": 4273, - "▁article": 4274, - "▁South": 4275, - "Action": 4276, - "ça": 4277, - "spring": 4278, - "itude": 4279, - "▁complex": 4280, - "▁что": 4281, - "build": 4282, - "gamma": 4283, - "▁Ent": 4284, - "iers": 4285, - "'.": 4286, - "car": 4287, - "apache": 4288, - "ingen": 4289, - "Input": 4290, - ": ": 4291, - "▁dynam": 4292, - "alls": 4293, - "show": 4294, - "|\\": 4295, - "▁wird": 4296, - "Bar": 4297, - "alth": 4298, - "model": 4299, - "Trans": 4300, - "Row": 4301, - "abe": 4302, - "▁lib": 4303, - "null": 4304, - "ragment": 4305, - "▁State": 4306, - "▁law": 4307, - "Frame": 4308, - "▁Lo": 4309, - "geb": 4310, - "}$.": 4311, - "▁needed": 4312, - "▁contr": 4313, - "aries": 4314, - "▁screen": 4315, - "yr": 4316, - "mm": 4317, - "▁shown": 4318, - "▁bad": 4319, - "▁cast": 4320, - "▁Test": 4321, - "▁Auf": 4322, - "▁quant": 4323, - "iga": 4324, - "▁ren": 4325, - "▁Mac": 4326, - "▁transform": 4327, - "▁difference": 4328, - "▁tit": 4329, - "TE": 4330, - "▁step": 4331, - "▁capt": 4332, - "▁collection": 4333, - "ictionary": 4334, - "▁Tom": 4335, - "rier": 4336, - "▁move": 4337, - "cope": 4338, - "ords": 4339, - "▁further": 4340, - "▁columns": 4341, - "▁Lin": 4342, - "▁fixed": 4343, - "▁children": 4344, - "MS": 4345, - "mo": 4346, - "una": 4347, - "▁individ": 4348, - "tty": 4349, - "aste": 4350, - "src": 4351, - "match": 4352, - "wi": 4353, - "▁х": 4354, - "▁ди": 4355, - "▁ord": 4356, - "iving": 4357, - "▁Bro": 4358, - "▁almost": 4359, - "▁Pres": 4360, - "reci": 4361, - "aring": 4362, - "▁///": 4363, - "ется": 4364, - "▁sig": 4365, - "light": 4366, - "▁Red": 4367, - "▁suggest": 4368, - "olf": 4369, - "▁été": 4370, - "isation": 4371, - "зна": 4372, - "New": 4373, - "стан": 4374, - "LA": 4375, - "unicip": 4376, - "▁figure": 4377, - "mt": 4378, - "iale": 4379, - "▁catch": 4380, - "default": 4381, - "▁tele": 4382, - "▁matter": 4383, - "cast": 4384, - "▁Rich": 4385, - "▁handle": 4386, - "valu": 4387, - "$-": 4388, - "об": 4389, - "▁json": 4390, - "Create": 4391, - "▁exam": 4392, - "аль": 4393, - "ют": 4394, - "ored": 4395, - "idos": 4396, - "append": 4397, - "▁Array": 4398, - "кс": 4399, - "}[": 4400, - "rive": 4401, - "▁club": 4402, - "mann": 4403, - "▁este": 4404, - "esta": 4405, - "▁Gi": 4406, - "▁Jap": 4407, - "▁Name": 4408, - "Column": 4409, - "oups": 4410, - "ismo": 4411, - "▁City": 4412, - "▁classes": 4413, - "▁infl": 4414, - "hl": 4415, - "ром": 4416, - "▁adding": 4417, - "▁fail": 4418, - "xx": 4419, - "ões": 4420, - "Sc": 4421, - "util": 4422, - "▁location": 4423, - "lege": 4424, - "ago": 4425, - "▁properties": 4426, - "abil": 4427, - "vas": 4428, - "}$,": 4429, - "itted": 4430, - "ód": 4431, - "▁Dem": 4432, - "▁asked": 4433, - "▁tab": 4434, - "Source": 4435, - "▁errors": 4436, - "ographie": 4437, - "▁жи": 4438, - "▁mal": 4439, - "stract": 4440, - "▁dro": 4441, - "rak": 4442, - "▁note": 4443, - "▁setting": 4444, - "▁fem": 4445, - "▁saw": 4446, - "iar": 4447, - "HER": 4448, - "ес": 4449, - "▁pred": 4450, - "▁Out": 4451, - "▁items": 4452, - "лан": 4453, - "▁werd": 4454, - "ersion": 4455, - "lia": 4456, - "▁sin": 4457, - "ichte": 4458, - "▁feel": 4459, - "▁пра": 4460, - "▁oder": 4461, - "UE": 4462, - "ocument": 4463, - "▁mode": 4464, - "▁Na": 4465, - "ден": 4466, - "mes": 4467, - "framework": 4468, - "▁auto": 4469, - "ным": 4470, - "uby": 4471, - "▁template": 4472, - "▁mess": 4473, - "ieder": 4474, - "▁related": 4475, - "oken": 4476, - "▁follows": 4477, - "search": 4478, - "ami": 4479, - "▁wait": 4480, - "igr": 4481, - "▁low": 4482, - "ских": 4483, - "ская": 4484, - "▁Mark": 4485, - "▁ill": 4486, - "amento": 4487, - "\\<": 4488, - "▁df": 4489, - "osition": 4490, - "▁Ви": 4491, - "isf": 4492, - "▁Deutsch": 4493, - "ahl": 4494, - "war": 4495, - "itect": 4496, - "▁sal": 4497, - "elen": 4498, - "ById": 4499, - "▁gru": 4500, - "sv": 4501, - "▁passed": 4502, - "▁añ": 4503, - "Sch": 4504, - "▁solve": 4505, - "weise": 4506, - "atos": 4507, - "▁meg": 4508, - "▁member": 4509, - "ername": 4510, - "▁connect": 4511, - "ips": 4512, - "▁round": 4513, - "▁]": 4514, - "nes": 4515, - "▁dir": 4516, - "▁London": 4517, - "dy": 4518, - "FA": 4519, - "▁received": 4520, - "reet": 4521, - "▁Log": 4522, - "▁School": 4523, - "ango": 4524, - "▁These": 4525, - "▁Mont": 4526, - "▁ener": 4527, - "lad": 4528, - "▁define": 4529, - "sign": 4530, - "▁cle": 4531, - "figure": 4532, - "▁View": 4533, - "textbf": 4534, - "$\\": 4535, - "зы": 4536, - "number": 4537, - "▁din": 4538, - "eller": 4539, - "orithm": 4540, - "false": 4541, - "fol": 4542, - "fficient": 4543, - "▁HTML": 4544, - "liche": 4545, - "▁Mo": 4546, - "▁introdu": 4547, - "exp": 4548, - "▁strong": 4549, - "▁thus": 4550, - "/)": 4551, - "▁ele": 4552, - "▁так": 4553, - "▁па": 4554, - "▁dont": 4555, - "▁cause": 4556, - "Number": 4557, - "▁images": 4558, - "▁sample": 4559, - "▁sci": 4560, - "like": 4561, - "▁Lou": 4562, - "div": 4563, - "anc": 4564, - "▁front": 4565, - "nen": 4566, - "▁missing": 4567, - "aria": 4568, - "pres": 4569, - "▁пред": 4570, - "DI": 4571, - "filter": 4572, - "▁Mit": 4573, - "UR": 4574, - "▁opp": 4575, - "▁sql": 4576, - "▁року": 4577, - "eren": 4578, - "emat": 4579, - "ís": 4580, - "▁Jean": 4581, - "éc": 4582, - "▁ci": 4583, - "enne": 4584, - "atform": 4585, - "▁taken": 4586, - "▁Of": 4587, - "▁насе": 4588, - "▁err": 4589, - "OP": 4590, - "From": 4591, - "Default": 4592, - "▁General": 4593, - "wiki": 4594, - "▁grand": 4595, - "▁einen": 4596, - "Reg": 4597, - "Handler": 4598, - "conom": 4599, - "anger": 4600, - "▁был": 4601, - "▁Los": 4602, - "▁expression": 4603, - "ша": 4604, - "yal": 4605, - "▁$('": 4606, - "▁switch": 4607, - "▁vector": 4608, - "▁Thom": 4609, - "▁virt": 4610, - "leased": 4611, - "▁cover": 4612, - "▁resp": 4613, - "ako": 4614, - "rench": 4615, - "ota": 4616, - "Cell": 4617, - "anged": 4618, - "▁+=": 4619, - "lac": 4620, - "ska": 4621, - "next": 4622, - "▁International": 4623, - "▁Wil": 4624, - "▁ont": 4625, - "ibr": 4626, - "ustr": 4627, - "▁black": 4628, - "▁selected": 4629, - "cher": 4630, - "▁liter": 4631, - "root": 4632, - "лся": 4633, - "▁Life": 4634, - "▁insert": 4635, - "▁matrix": 4636, - "ises": 4637, - ")]": 4638, - "▁pel": 4639, - "Override": 4640, - "rypt": 4641, - "▁former": 4642, - "▁Film": 4643, - "▁North": 4644, - "client": 4645, - "▁night": 4646, - "ходи": 4647, - "▁Austral": 4648, - "▁Ret": 4649, - "rho": 4650, - "▁пер": 4651, - "ipedia": 4652, - "▁express": 4653, - "▁third": 4654, - "▁major": 4655, - "▁grad": 4656, - "owe": 4657, - "▁believe": 4658, - "ournal": 4659, - "▁status": 4660, - "unc": 4661, - "▁dou": 4662, - "▁JSON": 4663, - "uis": 4664, - "▁population": 4665, - "enz": 4666, - "▁William": 4667, - "sf": 4668, - "▁Object": 4669, - "▁cin": 4670, - "▁Di": 4671, - "curity": 4672, - "▁Open": 4673, - "▁ле": 4674, - "lar": 4675, - "adding": 4676, - "▁kom": 4677, - "}(\\": 4678, - "▁kil": 4679, - "umer": 4680, - "\"/>": 4681, - "▁feature": 4682, - "▁Are": 4683, - "cks": 4684, - "▁Internet": 4685, - "▁ih": 4686, - "▁started": 4687, - "▁early": 4688, - "▁began": 4689, - "TH": 4690, - "python": 4691, - "asp": 4692, - "▁Fr": 4693, - "▁clos": 4694, - "istic": 4695, - "▁music": 4696, - "▁dig": 4697, - "▁ital": 4698, - "▁David": 4699, - "▁website": 4700, - "▁controller": 4701, - "▁Mer": 4702, - "context": 4703, - "product": 4704, - "osp": 4705, - "▁▁▁▁▁▁▁": 4706, - "▁jun": 4707, - "rown": 4708, - "▁Az": 4709, - "\":\"": 4710, - "▁aan": 4711, - "▁Date": 4712, - "mult": 4713, - "▁browser": 4714, - "ред": 4715, - "which": 4716, - "RA": 4717, - "quare": 4718, - "▁Russ": 4719, - "▁soon": 4720, - "▁Pre": 4721, - "tau": 4722, - "▁week": 4723, - "▁ба": 4724, - "▁oct": 4725, - "▁town": 4726, - "roy": 4727, - "▁els": 4728, - "blic": 4729, - "undle": 4730, - "▁Histor": 4731, - "▁foi": 4732, - "▁models": 4733, - "зо": 4734, - "onym": 4735, - "Param": 4736, - "▁Met": 4737, - "gener": 4738, - "ją": 4739, - "▁espe": 4740, - "CE": 4741, - "▁device": 4742, - "ellow": 4743, - "▁debug": 4744, - "érie": 4745, - "using": 4746, - "анг": 4747, - "▁*)": 4748, - "udi": 4749, - "▁Miss": 4750, - "ком": 4751, - "posed": 4752, - "▁zwe": 4753, - "ін": 4754, - "▁Robert": 4755, - "▁Oct": 4756, - "lop": 4757, - "jar": 4758, - "▁aver": 4759, - "▁habit": 4760, - "▁::": 4761, - "äng": 4762, - "Start": 4763, - "▁pow": 4764, - "▁src": 4765, - "▁pattern": 4766, - "▁Э": 4767, - "▁bi": 4768, - "otes": 4769, - "▁__": 4770, - "▁sens": 4771, - "▁avoid": 4772, - "example": 4773, - "utt": 4774, - "Label": 4775, - "tex": 4776, - "boot": 4777, - "esto": 4778, - "▁March": 4779, - "▁easy": 4780, - "icture": 4781, - "Group": 4782, - "▁father": 4783, - "▁updated": 4784, - "▁Vo": 4785, - "▁III": 4786, - "omega": 4787, - "▁alle": 4788, - "Rec": 4789, - "yg": 4790, - "зе": 4791, - "▁Dim": 4792, - "nect": 4793, - "▁Tor": 4794, - "▁deutsch": 4795, - "▁white": 4796, - "▁national": 4797, - "ppe": 4798, - "▁air": 4799, - "▁password": 4800, - "det": 4801, - "▁big": 4802, - "▁Use": 4803, - "call": 4804, - "▁extra": 4805, - "We": 4806, - "ania": 4807, - "▁hold": 4808, - "Control": 4809, - "▁CO": 4810, - "▁мі": 4811, - "iti": 4812, - "▁Ke": 4813, - "enu": 4814, - "▁Park": 4815, - "том": 4816, - "▁auth": 4817, - "▁center": 4818, - "Ph": 4819, - "тов": 4820, - "iding": 4821, - "▁across": 4822, - "▁song": 4823, - "▁phys": 4824, - "▁numer": 4825, - "ща": 4826, - "▁Alex": 4827, - "▁problems": 4828, - "▁Error": 4829, - "format": 4830, - "▁Acc": 4831, - "▁six": 4832, - "▁db": 4833, - "▁Cast": 4834, - "oms": 4835, - "project": 4836, - "▁vert": 4837, - "cret": 4838, - "▁header": 4839, - "▁stream": 4840, - "ids": 4841, - "▁tor": 4842, - "▁sept": 4843, - "▁estim": 4844, - "▁decl": 4845, - "▁gave": 4846, - "▁player": 4847, - "ysis": 4848, - "▁дру": 4849, - "amm": 4850, - "що": 4851, - "▁(\"": 4852, - "▁ax": 4853, - "Property": 4854, - "usr": 4855, - "▁someone": 4856, - "▁impro": 4857, - "aden": 4858, - "rote": 4859, - "▁Ми": 4860, - "ih": 4861, - "++)": 4862, - "▁video": 4863, - "▁exists": 4864, - "кла": 4865, - "▁complete": 4866, - "▁session": 4867, - "▁constant": 4868, - "icos": 4869, - "▁pack": 4870, - "rome": 4871, - "egr": 4872, - "Application": 4873, - "▁yes": 4874, - "▁elle": 4875, - "▁email": 4876, - "orf": 4877, - "case": 4878, - "▁pointer": 4879, - "▁regard": 4880, - "sen": 4881, - "status": 4882, - "▁mes": 4883, - "▁delle": 4884, - "ington": 4885, - "▁Bas": 4886, - ")^": 4887, - "develop": 4888, - "▁force": 4889, - "▁characters": 4890, - "▁cross": 4891, - "▁death": 4892, - "▁takes": 4893, - "éri": 4894, - "igne": 4895, - "чен": 4896, - "UP": 4897, - ".:": 4898, - "Thread": 4899, - "ju": 4900, - "iny": 4901, - "▁details": 4902, - "▁xml": 4903, - "tait": 4904, - "output": 4905, - "message": 4906, - "''": 4907, - "▁British": 4908, - "ville": 4909, - "▁Div": 4910, - "▁User": 4911, - "cm": 4912, - "чно": 4913, - "column": 4914, - "eqref": 4915, - "ór": 4916, - "onom": 4917, - "▁Post": 4918, - "ellen": 4919, - "Ab": 4920, - "ulté": 4921, - "▁perfect": 4922, - "(){": 4923, - "vision": 4924, - "active": 4925, - "lier": 4926, - "rij": 4927, - "sd": 4928, - "▁kö": 4929, - "▁nie": 4930, - "▁relig": 4931, - "▁ot": 4932, - "▁machine": 4933, - "▁held": 4934, - ")$.": 4935, - "========": 4936, - "cker": 4937, - "вы": 4938, - "born": 4939, - "▁past": 4940, - "рия": 4941, - "▁Dr": 4942, - "▁regular": 4943, - "▁provided": 4944, - "TER": 4945, - "▁univers": 4946, - "▁gets": 4947, - "▁nu": 4948, - "▁/*": 4949, - "ober": 4950, - "fin": 4951, - "▁nella": 4952, - "▁become": 4953, - "▁``": 4954, - "▁history": 4955, - "▁Sol": 4956, - "▁Rad": 4957, - "▁terms": 4958, - "▁events": 4959, - "lymp": 4960, - ")))": 4961, - "рова": 4962, - "▁absol": 4963, - "▁soft": 4964, - "links": 4965, - "▁hope": 4966, - "▁subject": 4967, - "\"),": 4968, - "▁creating": 4969, - "▁}\r": 4970, - "▁Sk": 4971, - "▁flow": 4972, - "▁Ра": 4973, - "▁assert": 4974, - "zet": 4975, - "▁Frank": 4976, - "sa": 4977, - "▁distribution": 4978, - "cu": 4979, - "band": 4980, - "izz": 4981, - "▁job": 4982, - "iner": 4983, - "struct": 4984, - "ák": 4985, - "TO": 4986, - "auf": 4987, - "▁extends": 4988, - "▁Gra": 4989, - "display": 4990, - "▁signific": 4991, - "oney": 4992, - "source": 4993, - "microsoft": 4994, - "inder": 4995, - "▁quick": 4996, - "▁wonder": 4997, - "Instance": 4998, - "elles": 4999, - "ème": 5000, - "▁company": 5001, - "uß": 5002, - ".}": 5003, - "▁separate": 5004, - "UM": 5005, - "HERE": 5006, - "▁writing": 5007, - "itution": 5008, - "▁Gesch": 5009, - "мя": 5010, - "▁James": 5011, - "▁DE": 5012, - "▁Spe": 5013, - "process": 5014, - "Str": 5015, - "▁sym": 5016, - "▁ao": 5017, - "▁wy": 5018, - "▁anyone": 5019, - "▁Up": 5020, - "useum": 5021, - "aron": 5022, - "▁definition": 5023, - "▁`$": 5024, - "▁fav": 5025, - "ributes": 5026, - "▁Ré": 5027, - "ografia": 5028, - "element": 5029, - "cap": 5030, - "pat": 5031, - "▁Bra": 5032, - ")(": 5033, - "▁according": 5034, - "ге": 5035, - "▁pie": 5036, - "eli": 5037, - "}\"": 5038, - "▁activ": 5039, - "▁stop": 5040, - "patch": 5041, - "ті": 5042, - "▁Jose": 5043, - "End": 5044, - "▁prze": 5045, - "▁age": 5046, - "itory": 5047, - "▁PHP": 5048, - "agement": 5049, - "▁`.": 5050, - "▁pretty": 5051, - "▁recomm": 5052, - "▁sud": 5053, - "▁requ": 5054, - "▁обла": 5055, - "atives": 5056, - "▁High": 5057, - "áz": 5058, - "oul": 5059, - "rest": 5060, - "▁Ter": 5061, - "under": 5062, - "thern": 5063, - "center": 5064, - "▁ur": 5065, - "lat": 5066, - "▁interface": 5067, - "▁ин": 5068, - "▁whose": 5069, - "icas": 5070, - "amen": 5071, - "Filter": 5072, - "▁station": 5073, - "Page": 5074, - "▁arm": 5075, - "▁eyes": 5076, - "▁рай": 5077, - "▁seu": 5078, - "oli": 5079, - "win": 5080, - "lik": 5081, - "gex": 5082, - "chan": 5083, - "idence": 5084, - "args": 5085, - "aking": 5086, - "▁Google": 5087, - "▁Stud": 5088, - "▁ho": 5089, - "торы": 5090, - "Su": 5091, - "▁automat": 5092, - "ême": 5093, - "▁cy": 5094, - "lor": 5095, - "▁stack": 5096, - "▁SELECT": 5097, - "AF": 5098, - "▁>>": 5099, - "▁compet": 5100, - "▁pair": 5101, - "▁inglés": 5102, - "Response": 5103, - "▁Fig": 5104, - "grad": 5105, - "▁documentation": 5106, - "▁cant": 5107, - "▁appreci": 5108, - "ån": 5109, - "▁learn": 5110, - "▁indep": 5111, - "▁pal": 5112, - "package": 5113, - "ares": 5114, - "▁Berlin": 5115, - "бли": 5116, - "reich": 5117, - "ён": 5118, - "▁satisf": 5119, - "▁region": 5120, - "▁friend": 5121, - "▁George": 5122, - "▁Во": 5123, - "▁\"\"": 5124, - "▁desde": 5125, - "Factory": 5126, - "▁County": 5127, - "ouv": 5128, - "▁‘": 5129, - "▁installed": 5130, - "▁wanted": 5131, - "▁Python": 5132, - "▁interpre": 5133, - "▁included": 5134, - "▁((": 5135, - "▁altern": 5136, - "isto": 5137, - "gn": 5138, - "▁border": 5139, - "pdf": 5140, - "▁dup": 5141, - "▁download": 5142, - "just": 5143, - "▁members": 5144, - "child": 5145, - "▁pay": 5146, - "▁cer": 5147, - "▁looked": 5148, - "▁correctly": 5149, - "auth": 5150, - "▁стан": 5151, - "▁esp": 5152, - "▁desc": 5153, - "eben": 5154, - "▁questions": 5155, - "mal": 5156, - "▁abgerufen": 5157, - "▁Band": 5158, - "▁[]": 5159, - "Base": 5160, - "▁ris": 5161, - "▁fort": 5162, - "▁Id": 5163, - "▁various": 5164, - "▁League": 5165, - "▁Hand": 5166, - "▁Type": 5167, - "irl": 5168, - "▁Fe": 5169, - "ién": 5170, - "itter": 5171, - "▁fast": 5172, - "sta": 5173, - "▁except": 5174, - "icz": 5175, - "▁French": 5176, - "▁environment": 5177, - "▁conse": 5178, - "ур": 5179, - "ого": 5180, - "▁necessary": 5181, - "target": 5182, - "▁reading": 5183, - "home": 5184, - "zeich": 5185, - "▁equal": 5186, - "▁più": 5187, - "▁prem": 5188, - "▁difficult": 5189, - "▁unit": 5190, - "▁replace": 5191, - "▁heart": 5192, - "▁talk": 5193, - "AM": 5194, - "▁RE": 5195, - "▁Person": 5196, - "endency": 5197, - "▁imm": 5198, - "▁human": 5199, - "dn": 5200, - "▁Kir": 5201, - "▁Aut": 5202, - "known": 5203, - "▁frequ": 5204, - "system": 5205, - "лав": 5206, - "▁Sz": 5207, - "▁Gal": 5208, - "ное": 5209, - "selves": 5210, - "rightarrow": 5211, - "▁Са": 5212, - "=\"@": 5213, - "▁building": 5214, - "import": 5215, - "▁fam": 5216, - "▁delete": 5217, - "aire": 5218, - "mary": 5219, - "▁fund": 5220, - "▁particip": 5221, - "▁syn": 5222, - "sin": 5223, - "▁lower": 5224, - "▁zero": 5225, - "▁sec": 5226, - "▁fra": 5227, - "Point": 5228, - "▁failed": 5229, - "iento": 5230, - "cup": 5231, - "▁slow": 5232, - "▁nation": 5233, - "ähr": 5234, - "▁info": 5235, - "▁Public": 5236, - "▁decla": 5237, - "▁Та": 5238, - "▁sold": 5239, - "▁Rem": 5240, - "▁Phil": 5241, - "стра": 5242, - "▁mehr": 5243, - "▁Work": 5244, - "▁Nord": 5245, - "▁fait": 5246, - "▁gew": 5247, - "println": 5248, - "obile": 5249, - "▁Kon": 5250, - "▁assume": 5251, - "lands": 5252, - "▁amount": 5253, - "▁Press": 5254, - "ých": 5255, - "▁maxim": 5256, - "▁Champion": 5257, - "library": 5258, - "añ": 5259, - "▁Wal": 5260, - "Comm": 5261, - "]]": 5262, - "▁zw": 5263, - "▁social": 5264, - "LI": 5265, - "▁Unter": 5266, - "vor": 5267, - "Delta": 5268, - "email": 5269, - "raint": 5270, - "oni": 5271, - "▁alt": 5272, - "▁né": 5273, - "ция": 5274, - "ography": 5275, - "▁mentioned": 5276, - "▁<=": 5277, - "▁cette": 5278, - "▁currently": 5279, - "vare": 5280, - "izing": 5281, - "▁Def": 5282, - "icol": 5283, - "ünd": 5284, - "▁configuration": 5285, - "estig": 5286, - "III": 5287, - "lam": 5288, - "ière": 5289, - "▁Ear": 5290, - "▁tu": 5291, - "Ent": 5292, - "▁Using": 5293, - "▁ком": 5294, - "cie": 5295, - "▁proof": 5296, - "▁invol": 5297, - "▁History": 5298, - "><": 5299, - "▁AND": 5300, - "avy": 5301, - "▁relations": 5302, - "${": 5303, - "▁comes": 5304, - "▁direction": 5305, - "▁June": 5306, - "▁Way": 5307, - "Component": 5308, - "ech": 5309, - "▁Peter": 5310, - "sg": 5311, - "▁stra": 5312, - "uct": 5313, - "▁implementation": 5314, - "attle": 5315, - "▁cz": 5316, - "plot": 5317, - "▁played": 5318, - "\">(": 5961, - "▁ground": 5962, - "unn": 5963, - "rod": 5964, - "spe": 5965, - "ursor": 5966, - "▁leave": 5967, - "erk": 5968, - "▁tal": 5969, - "▁bottom": 5970, - "IO": 5971, - "▁popular": 5972, - "igo": 5973, - "▁Time": 5974, - "values": 5975, - "▁Loc": 5976, - "▁Club": 5977, - "▁anche": 5978, - "iał": 5979, - "ії": 5980, - "Omega": 5981, - "▁located": 5982, - "Url": 5983, - "▁Esp": 5984, - "лы": 5985, - "ць": 5986, - "ulate": 5987, - "▁join": 5988, - "aves": 5989, - "vet": 5990, - "lio": 5991, - "remove": 5992, - "▁token": 5993, - "▁optim": 5994, - "▁claim": 5995, - "ological": 5996, - "▁css": 5997, - "▁although": 5998, - "▁priv": 5999, - "▁Ba": 6000, - "ül": 6001, - "entication": 6002, - "▁ven": 6003, - "Server": 6004, - "▁Cong": 6005, - "NET": 6006, - "CON": 6007, - "dt": 6008, - "perties": 6009, - "▁epis": 6010, - "wikipedia": 6011, - "▁engine": 6012, - "▁fer": 6013, - "getElement": 6014, - "▁Cla": 6015, - "ří": 6016, - "▁rom": 6017, - "varepsilon": 6018, - "▁prime": 6019, - "istry": 6020, - "pected": 6021, - "orage": 6022, - "▁touch": 6023, - "▁['": 6024, - "▁dan": 6025, - "Em": 6026, - "aciones": 6027, - "Can": 6028, - "▁whom": 6029, - "▁behavior": 6030, - "▁strings": 6031, - "▁Europ": 6032, - "▁Rom": 6033, - "circ": 6034, - "▁pun": 6035, - "▁register": 6036, - "buntu": 6037, - "rain": 6038, - "Ob": 6039, - "TA": 6040, - "▁sometimes": 6041, - "▁ment": 6042, - "▁integer": 6043, - "▁Jac": 6044, - "legate": 6045, - "othing": 6046, - "▁sound": 6047, - "laces": 6048, - "▁Ба": 6049, - "rb": 6050, - "di": 6051, - "ления": 6052, - "▁themselves": 6053, - "▁Black": 6054, - "▁settings": 6055, - "▁norm": 6056, - "▁runs": 6057, - "▁NOT": 6058, - "KE": 6059, - "▁perhaps": 6060, - "▁Я": 6061, - "▁mol": 6062, - "▁ans": 6063, - "atre": 6064, - "▁Dies": 6065, - "Token": 6066, - "anie": 6067, - "▁allowed": 6068, - "Range": 6069, - "▁Gro": 6070, - "via": 6071, - "utorial": 6072, - "ensor": 6073, - "estival": 6074, - ");\r": 6075, - "краї": 6076, - "▁turned": 6077, - "scope": 6078, - "▁bien": 6079, - "=$": 6080, - "▁extension": 6081, - "atore": 6082, - "▁Ро": 6083, - "▁specify": 6084, - "edu": 6085, - "Datos": 6086, - "▁stored": 6087, - "▁parse": 6088, - "▁answers": 6089, - "ills": 6090, - "▁heard": 6091, - "lu": 6092, - "▁THE": 6093, - "▁gén": 6094, - "▁ful": 6095, - "ez": 6096, - "▁Prem": 6097, - "then": 6098, - "dp": 6099, - "ського": 6100, - "▁Si": 6101, - "ço": 6102, - "Edit": 6103, - "ків": 6104, - "▁Ли": 6105, - "▁Sing": 6106, - "▁categ": 6107, - "Equ": 6108, - "▁guer": 6109, - "Width": 6110, - "▁Christian": 6111, - "stat": 6112, - "Write": 6113, - "▁woman": 6114, - "wood": 6115, - "Vis": 6116, - "раз": 6117, - "▁$$\\": 6118, - "oder": 6119, - "▁bool": 6120, - "▁international": 6121, - "ность": 6122, - "▁Richard": 6123, - "▁addition": 6124, - "▁Music": 6125, - "▁aber": 6126, - "tó": 6127, - "▁hier": 6128, - "ugh": 6129, - "▁pob": 6130, - "▁tables": 6131, - "Do": 6132, - "▁higher": 6133, - "psi": 6134, - "rá": 6135, - "▁active": 6136, - "▁Table": 6137, - "ње": 6138, - "▁description": 6139, - "▁seemed": 6140, - "íst": 6141, - "▁myself": 6142, - "▁menu": 6143, - "del": 6144, - "▁ž": 6145, - "ele": 6146, - "Aut": 6147, - "▁гру": 6148, - "mut": 6149, - "oon": 6150, - "asc": 6151, - "bug": 6152, - "▁moved": 6153, - "CL": 6154, - "▁datas": 6155, - "SO": 6156, - "оло": 6157, - "▁Georg": 6158, - "▁reach": 6159, - ":\"": 6160, - "▁evalu": 6161, - "▁Hel": 6162, - "▁River": 6163, - "▁Ар": 6164, - "////": 6165, - "▁sets": 6166, - "▁Olymp": 6167, - "Adapter": 6168, - ".'": 6169, - "overn": 6170, - "▁Lord": 6171, - "!--": 6172, - "jpg": 6173, - "imento": 6174, - "▁Prof": 6175, - "▁achieve": 6176, - "}:": 6177, - "▁incor": 6178, - "▁onder": 6179, - "engl": 6180, - "ABLE": 6181, - "▁Mary": 6182, - "▁waren": 6183, - "lage": 6184, - "Dec": 6185, - "англ": 6186, - "encias": 6187, - "лей": 6188, - "▁Machine": 6189, - "▁Ан": 6190, - "uda": 6191, - "▁ś": 6192, - "▁XX": 6193, - "only": 6194, - "ление": 6195, - "▁también": 6196, - "nej": 6197, - "▁relative": 6198, - "▁hours": 6199, - "▁indeed": 6200, - "undo": 6201, - "ingu": 6202, - "area": 6203, - "▁Create": 6204, - "beit": 6205, - "▁removed": 6206, - "master": 6207, - "haus": 6208, - "▁Bern": 6209, - "▁speed": 6210, - "▁Bay": 6211, - "▁Att": 6212, - "▁None": 6213, - "application": 6214, - "üd": 6215, - "▁fit": 6216, - "▁Maria": 6217, - "▁nord": 6218, - "▁split": 6219, - "▁stru": 6220, - "▁official": 6221, - "▁execute": 6222, - "ouve": 6223, - "{{": 6224, - "▁Ap": 6225, - "▁ку": 6226, - "IL": 6227, - "▁^": 6228, - "dim": 6229, - "▁setup": 6230, - "ск": 6231, - "▁share": 6232, - "▁minutes": 6233, - "gle": 6234, - "oco": 6235, - "stell": 6236, - "▁Coun": 6237, - "▁temper": 6238, - "keit": 6239, - "ський": 6240, - "ao": 6241, - "▁Long": 6242, - "(&": 6243, - "кан": 6244, - "▁dens": 6245, - "But": 6246, - "XX": 6247, - "DATE": 6248, - "gan": 6249, - ".).": 6250, - "▁entry": 6251, - "install": 6252, - "▁зна": 6253, - "▁Som": 6254, - "Command": 6255, - "ßen": 6256, - "▁starting": 6257, - "▁sto": 6258, - "IG": 6259, - "▁minim": 6260, - "▁explicit": 6261, - "▁bytes": 6262, - "▁party": 6263, - "tober": 6264, - "▁Grand": 6265, - "▁Vor": 6266, - "▁leur": 6267, - "Document": 6268, - "erc": 6269, - "ensive": 6270, - "CP": 6271, - "env": 6272, - "▁arguments": 6273, - "▁Gran": 6274, - "arily": 6275, - "▁lin": 6276, - "tn": 6277, - "(-": 6278, - "geq": 6279, - "▁Famil": 6280, - "▁Бо": 6281, - "▁tour": 6282, - "▁nav": 6283, - "▁properly": 6284, - "▁Mrs": 6285, - "▁Mel": 6286, - "▁scale": 6287, - "astic": 6288, - "ds": 6289, - "▁Sir": 6290, - "▁Church": 6291, - "}^{\\": 6292, - "you": 6293, - "/.": 6294, - "So": 6295, - "▁brought": 6296, - "▁role": 6297, - "▁Sur": 6298, - "▁fond": 6299, - "▁ges": 6300, - "że": 6301, - "eten": 6302, - "▁était": 6303, - "SER": 6304, - "▁которы": 6305, - "▁equation": 6306, - "aspx": 6307, - "▁Afr": 6308, - "▁dit": 6309, - "empty": 6310, - "alement": 6311, - "wrap": 6312, - "▁Bet": 6313, - "▁collect": 6314, - "▁git": 6315, - "▁vie": 6316, - "▁..": 6317, - "рой": 6318, - "▁": 6580, - "▁Ва": 6581, - "nost": 6582, - "▁nem": 6583, - "▁pen": 6584, - "Open": 6585, - "▁church": 6586, - "кон": 6587, - "▁average": 6588, - "▁comments": 6589, - "▁corresponding": 6590, - "levant": 6591, - "▁bed": 6592, - "▁meaning": 6593, - "Version": 6594, - "Link": 6595, - "bel": 6596, - "▁extract": 6597, - "ść": 6598, - "▁IV": 6599, - "▁Ir": 6600, - "▁computer": 6601, - "▁affect": 6602, - "▁Ста": 6603, - "AX": 6604, - "sort": 6605, - "▁species": 6606, - "▁Oper": 6607, - "▁hash": 6608, - "ches": 6609, - "▁Einzeln": 6610, - "▁keys": 6611, - "▁marzo": 6612, - "▁interpret": 6613, - "hood": 6614, - "▁coordin": 6615, - "ös": 6616, - "rage": 6617, - "etz": 6618, - "iza": 6619, - "дер": 6620, - "üt": 6621, - "^*": 6622, - "▁modify": 6623, - "▁termin": 6624, - "▁cred": 6625, - "zon": 6626, - "ную": 6627, - "▁mie": 6628, - "▁''": 6629, - "▁Mos": 6630, - "▁connected": 6631, - "NO": 6632, - "▁compile": 6633, - "▁\"\\": 6634, - "▁cat": 6635, - "fiddle": 6636, - "uta": 6637, - "Access": 6638, - "▁Sto": 6639, - "▁Bur": 6640, - "▁north": 6641, - "Gamma": 6642, - "▁alloc": 6643, - "Init": 6644, - "▁Link": 6645, - "ialize": 6646, - "Impl": 6647, - "oupe": 6648, - "ropri": 6649, - "▁Gold": 6650, - "▁solo": 6651, - "▁Dist": 6652, - ",-": 6653, - "nav": 6654, - "▁alert": 6655, - "esis": 6656, - "▁Os": 6657, - "///": 6658, - "▁feb": 6659, - "▁-->": 6660, - "foot": 6661, - "▁Fried": 6662, - "▁Einzelnach": 6663, - "▁rev": 6664, - "zeit": 6665, - "▁Stat": 6666, - "▁Seg": 6667, - "▁blo": 6668, - "wick": 6669, - "EL": 6670, - "caption": 6671, - "header": 6672, - "▁president": 6673, - "▁multip": 6674, - "▁Einzelnachweise": 6675, - "▁seine": 6676, - "?”": 6677, - "Function": 6678, - "▁Stand": 6679, - "▁Function": 6680, - "▁?>": 6681, - "▁Bill": 6682, - "▁spect": 6683, - "▁redirect": 6684, - "rupt": 6685, - "▁walk": 6686, - "вши": 6687, - "springframework": 6688, - "place": 6689, - "ého": 6690, - "Entity": 6691, - "▁Service": 6692, - "inte": 6693, - "▁training": 6694, - "▁(`": 6695, - "фор": 6696, - "▁кра": 6697, - "aur": 6698, - "▁fetch": 6699, - "▁†": 6700, - "▁même": 6701, - "▁('": 6702, - "atively": 6703, - "▁execut": 6704, - "äch": 6705, - "▁Catalogue": 6706, - "based": 6707, - "Attribute": 6708, - "▁spring": 6709, - "phone": 6710, - "тра": 6711, - "▁пи": 6712, - "тера": 6713, - "▁`\\": 6714, - "▁Od": 6715, - "One": 6716, - "send": 6717, - "bon": 6718, - "▁°": 6719, - "MO": 6720, - "▁asking": 6721, - "▁où": 6722, - "▁ingår": 6723, - "▁testing": 6724, - "▁фа": 6725, - "▁Book": 6726, - "imm": 6727, - "▁progress": 6728, - "bro": 6729, - "First": 6730, - "▁phot": 6731, - "▁ON": 6732, - "Template": 6733, - "developer": 6734, - "annot": 6735, - "▁>=": 6736, - "mission": 6737, - "▁któ": 6738, - "pc": 6739, - "bach": 6740, - "zent": 6741, - "ued": 6742, - "▁ones": 6743, - "ји": 6744, - "▁rout": 6745, - "▁Ки": 6746, - "Post": 6747, - "ції": 6748, - "▁Vir": 6749, - "nek": 6750, - "aging": 6751, - "▁ок": 6752, - "izont": 6753, - "▁agosto": 6754, - "▁choose": 6755, - "▁\r": 6756, - "▁systems": 6757, - "loss": 6758, - "iente": 6759, - "▁Cre": 6760, - "▁contra": 6761, - "ums": 6762, - "▁beginning": 6763, - "emy": 6764, - "istics": 6765, - "▁served": 6766, - "Down": 6767, - "options": 6768, - "▁Govern": 6769, - "▁BY": 6770, - "▁jest": 6771, - "té": 6772, - "▁continue": 6773, - "pers": 6774, - "▁easier": 6775, - "▁cos": 6776, - "esso": 6777, - ">>": 6778, - "Net": 6779, - "▁Bor": 6780, - "▁Cr": 6781, - "▁transfer": 6782, - "▁CSS": 6783, - "▁finns": 6784, - "▁хо": 6785, - "username": 6786, - "▁constru": 6787, - "▁pain": 6788, - "▁Tem": 6789, - "▁specified": 6790, - "▁brit": 6791, - "ские": 6792, - "irk": 6793, - "rapper": 6794, - "▁counter": 6795, - "▁[\"": 6796, - "oded": 6797, - "дан": 6798, - "property": 6799, - "hard": 6800, - "istrict": 6801, - ")/": 6802, - "▁Pour": 6803, - "▁Where": 6804, - "▁===": 6805, - "▁sowie": 6806, - "▁Про": 6807, - "▁dess": 6808, - "▁tras": 6809, - "▁уча": 6810, - "▁Over": 6811, - "note": 6812, - "▁America": 6813, - "cp": 6814, - "▁grande": 6815, - "Me": 6816, - ")-": 6817, - "Mode": 6818, - "▁passing": 6819, - "▁giving": 6820, - "Cl": 6821, - "}/": 6822, - "Menu": 6823, - "!!": 6824, - "angular": 6825, - "▁launch": 6826, - "varphi": 6827, - "▁Johann": 6828, - "▁foreach": 6829, - "ró": 6830, - "sequ": 6831, - "ifi": 6832, - "Am": 6833, - "arp": 6834, - "▁buffer": 6835, - "▁ni": 6836, - "▁mix": 6837, - "▁Museum": 6838, - "▁meant": 6839, - "asi": 6840, - "▁kan": 6841, - "прав": 6842, - "Comp": 6843, - "istoire": 6844, - "iful": 6845, - "jer": 6846, - "issions": 6847, - "Resource": 6848, - "▁воз": 6849, - "▁ST": 6850, - "▁solutions": 6851, - "▁belong": 6852, - "▁Associ": 6853, - "cf": 6854, - "▁Mär": 6855, - "▁grid": 6856, - "Mult": 6857, - "▁requires": 6858, - "kk": 6859, - "▁teach": 6860, - "emeinde": 6861, - "▁square": 6862, - "▁коман": 6863, - "▁Event": 6864, - "▁rules": 6865, - "▁bur": 6866, - "▁eing": 6867, - "▁Mai": 6868, - "▁nam": 6869, - "▁slä": 6870, - "hör": 6871, - "▁tip": 6872, - "▁Literatur": 6873, - "▁scope": 6874, - "overline": 6875, - "▁exit": 6876, - ")?": 6877, - "bet": 6878, - "▁vict": 6879, - "Off": 6880, - "▁approxim": 6881, - "▁Geb": 6882, - "ktop": 6883, - "heit": 6884, - "▁Ю": 6885, - "template": 6886, - "рон": 6887, - "▁uno": 6888, - "Serv": 6889, - "▁framework": 6890, - "operator": 6891, - "▁generally": 6892, - "▁hundred": 6893, - "▁divers": 6894, - "ovi": 6895, - "▁rés": 6896, - "abs": 6897, - "▁gal": 6898, - "çais": 6899, - "▁feet": 6900, - "▁virtual": 6901, - "czy": 6902, - "ску": 6903, - "./": 6904, - "hu": 6905, - "ancy": 6906, - "▁recommend": 6907, - "▁під": 6908, - "▁money": 6909, - "▁versions": 6910, - "▁helps": 6911, - "▁Hor": 6912, - "Items": 6913, - "look": 6914, - "connect": 6915, - "anges": 6916, - "ViewController": 6917, - "elijk": 6918, - "▁occup": 6919, - "▁editor": 6920, - "auto": 6921, - "ög": 6922, - "▁seconds": 6923, - "▁obvious": 6924, - "vm": 6925, - "akes": 6926, - "▁gegen": 6927, - "▁til": 6928, - "jection": 6929, - "лення": 6930, - "▁operations": 6931, - "▁East": 6932, - "ogy": 6933, - "▁Polit": 6934, - "uten": 6935, - "▁Joseph": 6936, - "\"`": 6937, - "▁Company": 6938, - "▁callback": 6939, - "▁sen": 6940, - "cción": 6941, - "▁associated": 6942, - "▁containing": 6943, - "▁practice": 6944, - "elijke": 6945, - "oke": 6946, - "éra": 6947, - "uns": 6948, - "anta": 6949, - "vey": 6950, - "zu": 6951, - "▁Bes": 6952, - "▁Flor": 6953, - "mem": 6954, - "ycz": 6955, - "▁architect": 6956, - "▁anni": 6957, - "▁contact": 6958, - "YPE": 6959, - "▁Cas": 6960, - "▁полу": 6961, - "ovo": 6962, - "▁bring": 6963, - "▁concept": 6964, - "▁js": 6965, - "▁Referencias": 6966, - "emble": 6967, - "▁н": 6968, - "▁supported": 6969, - "Big": 6970, - "▁Hans": 6971, - "erv": 6972, - "▁Maj": 6973, - "▁arriv": 6974, - "▁Have": 6975, - "▁probability": 6976, - "▁Pop": 6977, - "▁Pass": 6978, - "token": 6979, - "Provider": 6980, - "▁Ra": 6981, - "Reader": 6982, - "ooth": 6983, - "lap": 6984, - "▁assist": 6985, - "adow": 6986, - "▁tests": 6987, - "сси": 6988, - "▁king": 6989, - "langle": 6990, - "▁Sum": 6991, - "OIN": 6992, - "▁security": 6993, - "nis": 6994, - "../": 6995, - "▁basic": 6996, - "unity": 6997, - "`:": 6998, - "▁кото": 6999, - "kow": 7000, - "▁Bibliothèque": 7001, - "asion": 7002, - "alo": 7003, - "ifest": 7004, - "▁novembre": 7005, - "▁peu": 7006, - "▁Ж": 7007, - "enschaft": 7008, - "clus": 7009, - "ју": 7010, - "Height": 7011, - "ún": 7012, - "▁tur": 7013, - "▁ideas": 7014, - "▁ces": 7015, - "frak": 7016, - "▁premier": 7017, - "itation": 7018, - "▁sé": 7019, - "HTML": 7020, - "▁Royal": 7021, - "ської": 7022, - "▁byte": 7023, - "PS": 7024, - "▁segu": 7025, - "inen": 7026, - "▁Great": 7027, - "▁Ку": 7028, - "▁external": 7029, - "Title": 7030, - "Top": 7031, - "Process": 7032, - "ität": 7033, - "▁`/": 7034, - "▁secret": 7035, - "pository": 7036, - "▁potential": 7037, - "▁Bud": 7038, - "names": 7039, - "asons": 7040, - "stackexchange": 7041, - "background": 7042, - "пер": 7043, - "сов": 7044, - "after": 7045, - "▁pero": 7046, - "▁software": 7047, - "▁sed": 7048, - "▁arrays": 7049, - "tmp": 7050, - "▁asp": 7051, - "scale": 7052, - "▁Lat": 7053, - "anal": 7054, - "▁gem": 7055, - "PU": 7056, - "▁Altri": 7057, - "That": 7058, - "▁Ни": 7059, - "ifact": 7060, - "Address": 7061, - "▁south": 7062, - "▁formula": 7063, - "▁Colleg": 7064, - "▁ін": 7065, - "ktion": 7066, - "▁sac": 7067, - "SH": 7068, - "ajo": 7069, - "etc": 7070, - "vc": 7071, - "`](": 7072, - "▁Dur": 7073, - "▁Ме": 7074, - "▁Smith": 7075, - "items": 7076, - "CK": 7077, - "elo": 7078, - "▁plugin": 7079, - "▁serie": 7080, - "ienne": 7081, - "▁или": 7082, - "Mar": 7083, - "▁Image": 7084, - "got": 7085, - "andas": 7086, - "▁matches": 7087, - "▁worth": 7088, - "▁Deb": 7089, - "▁cache": 7090, - "▁felt": 7091, - "ersch": 7092, - "izes": 7093, - "Oper": 7094, - "▁Jahre": 7095, - "▁commune": 7096, - "thread": 7097, - "▁ny": 7098, - "dec": 7099, - "ouw": 7100, - "▁surface": 7101, - "▁Por": 7102, - "▁Street": 7103, - "при": 7104, - "▁candid": 7105, - "▁Return": 7106, - "▁Kom": 7107, - "gru": 7108, - "▁ти": 7109, - "[\\": 7110, - "▁depends": 7111, - "▁influ": 7112, - "▁towards": 7113, - "ained": 7114, - "▁rank": 7115, - "▁Januar": 7116, - "▁components": 7117, - "gest": 7118, - "getElementById": 7119, - "▁checked": 7120, - "airs": 7121, - "join": 7122, - "▁dead": 7123, - "▁hit": 7124, - "ény": 7125, - "▁equivalent": 7126, - "▁Пре": 7127, - "▁appropri": 7128, - "Pass": 7129, - "▁primer": 7130, - "englisch": 7131, - "▁appar": 7132, - "▁During": 7133, - "▁knowledge": 7134, - "▁trigger": 7135, - "▁core": 7136, - "▁Ol": 7137, - "▁Produ": 7138, - "▁Fern": 7139, - "▁нача": 7140, - "Te": 7141, - "▁Mot": 7142, - "erve": 7143, - "тво": 7144, - "▁mid": 7145, - "▁finally": 7146, - "aires": 7147, - "▁especially": 7148, - "▁tut": 7149, - "▁receive": 7150, - "adre": 7151, - "▁neigh": 7152, - "ktet": 7153, - "ilde": 7154, - "▁radio": 7155, - "▁driver": 7156, - "лись": 7157, - "endencies": 7158, - "▁IE": 7159, - "▁saved": 7160, - "ffect": 7161, - "▁Wayback": 7162, - "iat": 7163, - "▁padding": 7164, - "window": 7165, - "тиче": 7166, - "▁mur": 7167, - "actor": 7168, - "▁Han": 7169, - "ональ": 7170, - "▁gar": 7171, - "▁familjen": 7172, - "ós": 7173, - "▁nationale": 7174, - "▁pré": 7175, - "ded": 7176, - "onal": 7177, - "▁President": 7178, - "▁\\,": 7179, - "▁placed": 7180, - "erni": 7181, - "▁signal": 7182, - "nab": 7183, - "hm": 7184, - "Mon": 7185, - "▁vs": 7186, - "SC": 7187, - "▁progetti": 7188, - "▁Ü": 7189, - "▁forms": 7190, - "▁messages": 7191, - "inf": 7192, - "users": 7193, - "GET": 7194, - "▁dels": 7195, - "Collection": 7196, - "▁Good": 7197, - "▁Maybe": 7198, - "▁compr": 7199, - "▁larger": 7200, - "gres": 7201, - "aper": 7202, - "▁При": 7203, - "undes": 7204, - "▁sea": 7205, - "▁Spring": 7206, - "ulo": 7207, - "▁mechan": 7208, - "▁sans": 7209, - "GB": 7210, - "Valid": 7211, - "▁communic": 7212, - "▁pra": 7213, - "vier": 7214, - "▁Се": 7215, - "▁ain": 7216, - "тура": 7217, - "kom": 7218, - "skiego": 7219, - "ково": 7220, - "adata": 7221, - "▁Ре": 7222, - "▁boolean": 7223, - "sets": 7224, - "▁effort": 7225, - ".[": 7226, - "▁został": 7227, - "PA": 7228, - "▁Vict": 7229, - "SD": 7230, - "ował": 7231, - "▁emb": 7232, - "▁prima": 7233, - "▁hour": 7234, - "subsection": 7235, - "▁Fort": 7236, - "mathfrak": 7237, - "igin": 7238, - "GL": 7239, - ")+": 7240, - "fi": 7241, - "▁anci": 7242, - "▁pan": 7243, - "\\)": 7244, - "▁lug": 7245, - "▁deploy": 7246, - "domain": 7247, - "▁slight": 7248, - "JSON": 7249, - "▁morning": 7250, - "▁hi": 7251, - "▁compare": 7252, - "ije": 7253, - "▁blue": 7254, - "▁Ac": 7255, - "▁middle": 7256, - "anden": 7257, - "▁shared": 7258, - "▁Camp": 7259, - "▁Á": 7260, - "ounded": 7261, - "uw": 7262, - "ierung": 7263, - "Stack": 7264, - "▁eines": 7265, - "▁Da": 7266, - "lij": 7267, - "enti": 7268, - "▁й": 7269, - "Util": 7270, - "▁experience": 7271, - "▁await": 7272, - "uls": 7273, - "▁requests": 7274, - "▁impos": 7275, - "▁constraint": 7276, - "Change": 7277, - "emph": 7278, - "бер": 7279, - "▁Another": 7280, - "Custom": 7281, - "▁significant": 7282, - "cr": 7283, - "▁million": 7284, - "reek": 7285, - "▁dalla": 7286, - "▁Germ": 7287, - "otal": 7288, - "ateur": 7289, - "btn": 7290, - "▁thinking": 7291, - "▁interval": 7292, - "onne": 7293, - "▁liv": 7294, - "():": 7295, - "▁Ве": 7296, - "oe": 7297, - "▁Ev": 7298, - "meta": 7299, - "▁broad": 7300, - "Rem": 7301, - "apply": 7302, - "▁couple": 7303, - "▁techni": 7304, - "idades": 7305, - "▁goal": 7306, - "▁CD": 7307, - "hab": 7308, - "▁explan": 7309, - "anner": 7310, - "▁Because": 7311, - "blog": 7312, - "includegraphics": 7313, - "▁voice": 7314, - "▁Map": 7315, - "vention": 7316, - "Session": 7317, - "▁Liens": 7318, - "▁sor": 7319, - "category": 7320, - "ashington": 7321, - "▁März": 7322, - "pop": 7323, - "illet": 7324, - "▁zwei": 7325, - "▁Lie": 7326, - "Null": 7327, - "address": 7328, - "▁factor": 7329, - "▁ligne": 7330, - "▁HTTP": 7331, - "▁suf": 7332, - "▁personal": 7333, - "cip": 7334, - "▁Dar": 7335, - "▁adm": 7336, - "кой": 7337, - "▁Ext": 7338, - "▁god": 7339, - "aa": 7340, - "Right": 7341, - "été": 7342, - "▁dynamic": 7343, - "▁maintain": 7344, - "tor": 7345, - "########": 7346, - "▁Fra": 7347, - "▁choice": 7348, - "▁сто": 7349, - "СР": 7350, - "▁Feder": 7351, - "ston": 7352, - "▁flag": 7353, - "kit": 7354, - "Module": 7355, - "▁спо": 7356, - "▁Stra": 7357, - "icks": 7358, - "▁haven": 7359, - "▁Mass": 7360, - "▁Emp": 7361, - "▁Pi": 7362, - "▁Pen": 7363, - "Rect": 7364, - "▁Kr": 7365, - "itat": 7366, - "eler": 7367, - "ября": 7368, - "itet": 7369, - "▁Start": 7370, - "▁produced": 7371, - "▁пол": 7372, - "(_": 7373, - "▁delet": 7374, - "▁hot": 7375, - "▁Geschichte": 7376, - "~~": 7377, - "▁months": 7378, - "▁tod": 7379, - "▁ни": 7380, - "ús": 7381, - "temp": 7382, - "▁Dez": 7383, - "ypes": 7384, - "▁cui": 7385, - "ommun": 7386, - "actions": 7387, - "▁eigen": 7388, - "▁immediately": 7389, - "PL": 7390, - "▁Го": 7391, - "▁Bal": 7392, - "ље": 7393, - "ului": 7394, - "▁online": 7395, - "▁años": 7396, - "▁namespace": 7397, - "▁mond": 7398, - "▁Base": 7399, - "▁Canada": 7400, - "etzt": 7401, - "}-": 7402, - "▁defin": 7403, - "▁doubt": 7404, - "▁investig": 7405, - "views": 7406, - "▁Line": 7407, - "▁stage": 7408, - "ettings": 7409, - "ubre": 7410, - "float": 7411, - "▁Play": 7412, - "▁Las": 7413, - "ptr": 7414, - "▁becomes": 7415, - "estamp": 7416, - "▁independent": 7417, - "▁analysis": 7418, - "▁Look": 7419, - "lain": 7420, - "▁рас": 7421, - "Reference": 7422, - "▁sorry": 7423, - "▁supposed": 7424, - "ût": 7425, - "▁degree": 7426, - "utz": 7427, - "MM": 7428, - "▁desired": 7429, - "ły": 7430, - "▁len": 7431, - "▁alone": 7432, - "signed": 7433, - "▁Sta": 7434, - "Person": 7435, - "▁applied": 7436, - "▁Back": 7437, - "▁mars": 7438, - "Part": 7439, - "▁Did": 7440, - "▁externes": 7441, - "▁np": 7442, - "ongo": 7443, - "▁esta": 7444, - "Block": 7445, - "▁pou": 7446, - "adores": 7447, - "▁Studio": 7448, - ".$": 7449, - "▁reached": 7450, - "bot": 7451, - "▁Juni": 7452, - "tons": 7453, - "itel": 7454, - "▁Gar": 7455, - "▁articles": 7456, - "▁District": 7457, - "▁trouble": 7458, - "lide": 7459, - "▁Found": 7460, - "ád": 7461, - "▁equip": 7462, - "▁internal": 7463, - "'],": 7464, - "▁async": 7465, - "UB": 7466, - "gel": 7467, - "▁ai": 7468, - "ensure": 7469, - "▁appeared": 7470, - "▁$_": 7471, - "▁maximum": 7472, - "▁Си": 7473, - "рь": 7474, - "▁announ": 7475, - "лась": 7476, - "▁cm": 7477, - "ган": 7478, - "aupt": 7479, - "▁latter": 7480, - "▁platform": 7481, - "▁dra": 7482, - "▁capital": 7483, - "▁solved": 7484, - "riz": 7485, - "edic": 7486, - "▁Mur": 7487, - "▁Top": 7488, - "тся": 7489, - "Panel": 7490, - "rule": 7491, - "etic": 7492, - "▁Ren": 7493, - "▁Wikimedia": 7494, - "▁TO": 7495, - "second": 7496, - "isl": 7497, - "▁hy": 7498, - "▁niet": 7499, - "▁loaded": 7500, - "dig": 7501, - "▁mayo": 7502, - "[:": 7503, - "Acc": 7504, - "▁bek": 7505, - "нию": 7506, - "login": 7507, - "tx": 7508, - "▁Fur": 7509, - "▁Santa": 7510, - "azz": 7511, - "▁conduct": 7512, - "▁India": 7513, - "Order": 7514, - "irth": 7515, - "tw": 7516, - "}+": 7517, - "▁wieder": 7518, - "▁Edu": 7519, - "AV": 7520, - "▁```": 7521, - "▁manually": 7522, - "▁Read": 7523, - "fortunately": 7524, - "▁Run": 7525, - "▁Award": 7526, - "▁Foot": 7527, - "*)": 7528, - "params": 7529, - "пі": 7530, - "▁native": 7531, - "rift": 7532, - "▁ä": 7533, - "ATH": 7534, - "▁yourself": 7535, - "▁prior": 7536, - "▁cit": 7537, - "äh": 7538, - "▁treat": 7539, - "▁meas": 7540, - "ributed": 7541, - "▁clar": 7542, - "card": 7543, - "ROR": 7544, - "illes": 7545, - "▁layer": 7546, - "auer": 7547, - "▁rat": 7548, - "bernate": 7549, - "▁stato": 7550, - "▁China": 7551, - "▁$('#": 7552, - "▁naar": 7553, - "zip": 7554, - "▁${\\": 7555, - "▁appreciated": 7556, - "▁име": 7557, - "ży": 7558, - "▁przez": 7559, - "▁Indian": 7560, - "▁Tod": 7561, - "▁Source": 7562, - "▁други": 7563, - "internal": 7564, - "ionale": 7565, - "Product": 7566, - "▁Men": 7567, - "▁upper": 7568, - "▁Every": 7569, - "},\\": 7570, - "▁printf": 7571, - "▁continued": 7572, - "▁nodes": 7573, - "лки": 7574, - "▁nice": 7575, - "modules": 7576, - "eign": 7577, - "▁Mex": 7578, - "▁According": 7579, - "▁undefined": 7580, - "▁binary": 7581, - "cut": 7582, - "Current": 7583, - "edy": 7584, - "}}{": 7585, - "bles": 7586, - "▁вой": 7587, - "scri": 7588, - "eqn": 7589, - "Changed": 7590, - "▁köz": 7591, - "▁remote": 7592, - "вля": 7593, - "▁quel": 7594, - "▁align": 7595, - "▁пар": 7596, - "SV": 7597, - "yer": 7598, - "▁Californ": 7599, - "▁places": 7600, - "▁primary": 7601, - "▁conv": 7602, - "▁Juli": 7603, - "▁visual": 7604, - "▁Select": 7605, - "atory": 7606, - "=(": 7607, - "iser": 7608, - "▁intent": 7609, - "sur": 7610, - "container": 7611, - "iced": 7612, - "▁board": 7613, - "astr": 7614, - "omial": 7615, - "вет": 7616, - "зва": 7617, - "▁cru": 7618, - "▁Oktober": 7619, - "save": 7620, - "▁greater": 7621, - "▁inn": 7622, - "▁picture": 7623, - "▁То": 7624, - "▁obtained": 7625, - "Wikimedia": 7626, - "úblic": 7627, - "▁lors": 7628, - "▁mont": 7629, - "obre": 7630, - "▁civil": 7631, - "▁construction": 7632, - "▁Welt": 7633, - "▁Under": 7634, - "undert": 7635, - "▁edge": 7636, - "▁Liste": 7637, - "csv": 7638, - "▁experiment": 7639, - "localhost": 7640, - "▁Edit": 7641, - "greg": 7642, - "ová": 7643, - "ља": 7644, - "msg": 7645, - "▁Green": 7646, - "Dialog": 7647, - "Ident": 7648, - "▁JS": 7649, - "^{(": 7650, - "▁släktet": 7651, - "____": 7652, - "Project": 7653, - "▁beskre": 7654, - "▁ber": 7655, - "▁wouldn": 7656, - "▁react": 7657, - "Hel": 7658, - "zw": 7659, - "▁Washington": 7660, - "orie": 7661, - "task": 7662, - "▁category": 7663, - "▁artist": 7664, - "anno": 7665, - "▁ook": 7666, - "ammen": 7667, - "▁Minister": 7668, - "▁declar": 7669, - "▁Key": 7670, - ",.": 7671, - "▁mach": 7672, - "▁ww": 7673, - "isen": 7674, - "Fran": 7675, - "▁Росси": 7676, - "бор": 7677, - "три": 7678, - "▁rock": 7679, - "quis": 7680, - "mos": 7681, - "пера": 7682, - "▁esterni": 7683, - "▁gold": 7684, - "Windows": 7685, - "%%": 7686, - "▁partial": 7687, - "▁weight": 7688, - "▁spr": 7689, - "}).": 7690, - "▁français": 7691, - "fun": 7692, - "▁thous": 7693, - "holder": 7694, - "▁gone": 7695, - "▁Č": 7696, - "▁rend": 7697, - "DA": 7698, - "▁answered": 7699, - "▁False": 7700, - "Buffer": 7701, - "▁daugh": 7702, - ".--": 7703, - "▁Show": 7704, - "▁rect": 7705, - "▁Kre": 7706, - "dr": 7707, - "osoph": 7708, - "▁yield": 7709, - "urity": 7710, - "toString": 7711, - "aval": 7712, - "Pol": 7713, - "▁lock": 7714, - "imation": 7715, - "antic": 7716, - "Local": 7717, - "▁beskrevs": 7718, - "ités": 7719, - "grid": 7720, - "ут": 7721, - "▁_{": 7722, - "сі": 7723, - "FILE": 7724, - "▁км": 7725, - "▁speak": 7726, - "summary": 7727, - "prop": 7728, - "javascript": 7729, - "zk": 7730, - "izontal": 7731, - "▁trois": 7732, - "▁Rod": 7733, - "prise": 7734, - "рово": 7735, - "▁odd": 7736, - "▁gest": 7737, - "▁produce": 7738, - "▁waar": 7739, - "▁Av": 7740, - "ribu": 7741, - "вання": 7742, - "▁finished": 7743, - "▁adapt": 7744, - "▁Sar": 7745, - "textit": 7746, - "▁Ce": 7747, - "▁Fa": 7748, - "osen": 7749, - "▁deriv": 7750, - "▁ship": 7751, - "▁opin": 7752, - "▁Even": 7753, - "gesch": 7754, - "▁suppose": 7755, - "▁Fer": 7756, - "ское": 7757, - "▁worden": 7758, - "sey": 7759, - "hline": 7760, - "▁Union": 7761, - "▁/**": 7762, - "▁vez": 7763, - "▁Collegamenti": 7764, - "▁Society": 7765, - "▁econom": 7766, - "ší": 7767, - "oi": 7768, - "▁orient": 7769, - "▁Teil": 7770, - "rent": 7771, - "лекс": 7772, - "▁solid": 7773, - "▁cart": 7774, - "****************": 7775, - "▁cab": 7776, - "▁Message": 7777, - "dots": 7778, - "▁ég": 7779, - "▁twe": 7780, - "aga": 7781, - "▁naz": 7782, - "▁Microsoft": 7783, - "▁underarter": 7784, - "ppen": 7785, - "▁recent": 7786, - "▁net": 7787, - "▁resources": 7788, - "Ste": 7789, - ".\\": 7790, - "▁SO": 7791, - "лом": 7792, - "▁cele": 7793, - "▁lic": 7794, - "▁benef": 7795, - "ldots": 7796, - "▁serial": 7797, - "Integer": 7798, - "cles": 7799, - "▁miles": 7800, - "▁Ale": 7801, - "▁entered": 7802, - "▁Two": 7803, - "wie": 7804, - "▁includes": 7805, - "▁Each": 7806, - "elling": 7807, - "quer": 7808, - "▁Dom": 7809, - "pf": 7810, - "WS": 7811, - "▁straight": 7812, - "▁Stan": 7813, - "▁nos": 7814, - "ícul": 7815, - "atro": 7816, - "▁Center": 7817, - "FT": 7818, - "▁Inga": 7819, - "ilo": 7820, - "▁www": 7821, - "jsfiddle": 7822, - "nic": 7823, - "▁European": 7824, - "▁commer": 7825, - "▁girl": 7826, - "total": 7827, - "▁Star": 7828, - "▁suggested": 7829, - "pal": 7830, - "▁zwischen": 7831, - "писа": 7832, - "IM": 7833, - "▁handler": 7834, - "▁Program": 7835, - "xsl": 7836, - "ály": 7837, - "BU": 7838, - ",--": 7839, - "▁vid": 7840, - "▁established": 7841, - "▁Spiel": 7842, - "ometry": 7843, - "unes": 7844, - "▁sit": 7845, - "▁inher": 7846, - "▁puis": 7847, - "▁être": 7848, - "▁Most": 7849, - "Header": 7850, - "insert": 7851, - "▁sist": 7852, - "▁favor": 7853, - "dest": 7854, - "▁entity": 7855, - "Cal": 7856, - "▁Therefore": 7857, - "DD": 7858, - ";;": 7859, - "▁Dezember": 7860, - "▁Rh": 7861, - "iments": 7862, - "▁returning": 7863, - "sto": 7864, - "▁Value": 7865, - "▁liber": 7866, - "▁Result": 7867, - "▁bind": 7868, - "voir": 7869, - "▁Tim": 7870, - "▁Movie": 7871, - "weg": 7872, - "ket": 7873, - "▁исто": 7874, - "▁friends": 7875, - "▁fn": 7876, - "▁él": 7877, - "▁&=": 7878, - "arden": 7879, - "fficial": 7880, - "▁community": 7881, - "▁api": 7882, - "Args": 7883, - "ieren": 7884, - "▁dann": 7885, - "omorph": 7886, - "adr": 7887, - "loop": 7888, - "uman": 7889, - "▁vous": 7890, - "bst": 7891, - "submit": 7892, - "\\|": 7893, - "тин": 7894, - "Container": 7895, - "asket": 7896, - "?)": 7897, - "Sec": 7898, - "▁drive": 7899, - "Ass": 7900, - "▁swe": 7901, - "▁amer": 7902, - "▁mine": 7903, - "▁Ham": 7904, - "▁avait": 7905, - "▁Hon": 7906, - "▁après": 7907, - "▁Mann": 7908, - "ська": 7909, - "▁increase": 7910, - "▁ty": 7911, - "sky": 7912, - "▁accur": 7913, - "article": 7914, - "weight": 7915, - "▁sex": 7916, - "▁listade": 7917, - "/**": 7918, - "▁está": 7919, - "}}$": 7920, - "argo": 7921, - "define": 7922, - "▁состав": 7923, - "session": 7924, - "ads": 7925, - "стви": 7926, - "▁Law": 7927, - "▁dialog": 7928, - "▁duplicate": 7929, - "▁ép": 7930, - "▁voc": 7931, - "fri": 7932, - "▁green": 7933, - "▁hidden": 7934, - "▁Island": 7935, - "▁diag": 7936, - "owej": 7937, - "mysql": 7938, - "teil": 7939, - "rä": 7940, - "ikan": 7941, - "▁José": 7942, - "aled": 7943, - "Runtime": 7944, - "▁train": 7945, - "▁Division": 7946, - "ниц": 7947, - "▁Span": 7948, - "нима": 7949, - ")=\\": 7950, - "тан": 7951, - "▁stay": 7952, - "▁foo": 7953, - "▁accom": 7954, - "▁hers": 7955, - "▁нау": 7956, - "▁Mün": 7957, - "ideos": 7958, - "static": 7959, - "▁ready": 7960, - "]`": 7961, - "▁visible": 7962, - "▁Hope": 7963, - "ulated": 7964, - "▁Cult": 7965, - "стро": 7966, - "Co": 7967, - "▁smaller": 7968, - "atura": 7969, - "▁perfectly": 7970, - "req": 7971, - "▁proposed": 7972, - "▁degli": 7973, - "Search": 7974, - "▁ich": 7975, - "Max": 7976, - "▁volume": 7977, - "execute": 7978, - "gre": 7979, - "▁sport": 7980, - "udad": 7981, - "PT": 7982, - "▁Records": 7983, - "▁cook": 7984, - "▁expand": 7985, - "бі": 7986, - "▁altri": 7987, - "ppet": 7988, - "arse": 7989, - "▁wet": 7990, - "▁Bob": 7991, - "▁FC": 7992, - "▁Association": 7993, - "uje": 7994, - "▁fel": 7995, - "▁слу": 7996, - "▁Big": 7997, - "/\\": 7998, - "Ge": 7999, - "while": 8000, - "{(": 8001, - "▁sufficient": 8002, - "Position": 8003, - "▁understanding": 8004, - "▁nue": 8005, - "▁raz": 8006, - "▁ye": 8007, - "hem": 8008, - "Num": 8009, - "▁Project": 8010, - "▁Its": 8011, - "▁hasta": 8012, - "enso": 8013, - "▁wire": 8014, - "Ret": 8015, - "uj": 8016, - "proof": 8017, - "▁relevant": 8018, - "▁partir": 8019, - "▁ago": 8020, - "ificate": 8021, - "▁domin": 8022, - "▁boy": 8023, - "▁plant": 8024, - "▁encoding": 8025, - "▁throws": 8026, - "▁Rock": 8027, - "zone": 8028, - "gang": 8029, - "widget": 8030, - "▁interesting": 8031, - "DER": 8032, - "▁demon": 8033, - "▁office": 8034, - "amt": 8035, - "äter": 8036, - "▁White": 8037, - "▁versch": 8038, - "▁dieser": 8039, - "▁Mount": 8040, - "▁students": 8041, - "▁Pub": 8042, - "▁Де": 8043, - "ija": 8044, - "▁Cy": 8045, - "▁California": 8046, - "▁abril": 8047, - "äll": 8048, - "▁чем": 8049, - "TV": 8050, - "▁més": 8051, - "▁declared": 8052, - "▁ю": 8053, - "ől": 8054, - "appa": 8055, - "▁Бе": 8056, - "echo": 8057, - "numer": 8058, - "▁posted": 8059, - "▁вер": 8060, - "▁године": 8061, - "▁weak": 8062, - "▁Republic": 8063, - "▁champion": 8064, - "ensuremath": 8065, - "your": 8066, - "▁Ober": 8067, - "▁Central": 8068, - "isa": 8069, - "анд": 8070, - "yy": 8071, - "▁fully": 8072, - "▁SD": 8073, - "▁Linux": 8074, - "▁Scott": 8075, - "partment": 8076, - "kon": 8077, - "▁contract": 8078, - "▁OF": 8079, - "▁ale": 8080, - "▁Ann": 8081, - "▁над": 8082, - "lah": 8083, - "▁Next": 8084, - "oren": 8085, - "▁disk": 8086, - "▁eg": 8087, - "atu": 8088, - "логи": 8089, - "▁games": 8090, - "Left": 8091, - "▁lu": 8092, - "▁finite": 8093, - "▁ки": 8094, - "▁crash": 8095, - "pher": 8096, - "exe": 8097, - "ATION": 8098, - "▁brother": 8099, - "Eng": 8100, - "tat": 8101, - "▁Integer": 8102, - "ному": 8103, - "▁colon": 8104, - "iqu": 8105, - ")).": 8106, - "ivi": 8107, - "▁Method": 8108, - "arten": 8109, - "Uni": 8110, - "vector": 8111, - "▁wood": 8112, - "рт": 8113, - "▁Ле": 8114, - "▁siècle": 8115, - "▁gent": 8116, - "}\r": 8117, - "▁contents": 8118, - "▁compan": 8119, - "Go": 8120, - "▁jou": 8121, - "uent": 8122, - "Async": 8123, - "printf": 8124, - "▁Model": 8125, - "▁kept": 8126, - "ASE": 8127, - "▁provides": 8128, - "▁Abgerufen": 8129, - "▁Gall": 8130, - "▁Alf": 8131, - "SA": 8132, - "▁Mem": 8133, - "▁kter": 8134, - "▁Bru": 8135, - "Android": 8136, - "(:": 8137, - "▁Украї": 8138, - "Ne": 8139, - "Min": 8140, - "atr": 8141, - "▁Hal": 8142, - "delete": 8143, - "odo": 8144, - "▁não": 8145, - "ène": 8146, - "▁calculate": 8147, - "Json": 8148, - "keys": 8149, - "ней": 8150, - "▁hence": 8151, - "▁ow": 8152, - "▁Lib": 8153, - "eno": 8154, - "▁Love": 8155, - "osi": 8156, - "wide": 8157, - "▁score": 8158, - "full": 8159, - "вод": 8160, - "▁determine": 8161, - "▁spaces": 8162, - "лова": 8163, - "▁peut": 8164, - "éral": 8165, - "ół": 8166, - "▁appoint": 8167, - "▁Tw": 8168, - "();": 8295, - "▁pure": 8296, - "▁embed": 8297, - "ação": 8298, - "controller": 8299, - "▁married": 8300, - "▁Fol": 8301, - "famil": 8302, - "▁prec": 8303, - "▁recurs": 8304, - "pad": 8305, - "istration": 8306, - "▁respectively": 8307, - "[$": 8308, - "autor": 8309, - "▁grav": 8310, - "iera": 8311, - "azioni": 8312, - "▁Bul": 8313, - "▁Australia": 8314, - "mond": 8315, - "▁Tro": 8316, - "▁Ele": 8317, - "packages": 8318, - "msdn": 8319, - "▁Als": 8320, - "▁przy": 8321, - "ART": 8322, - "▁charge": 8323, - "▁applications": 8324, - "Unit": 8325, - "aren": 8326, - "▁sudden": 8327, - "ometer": 8328, - "▁dot": 8329, - "acji": 8330, - "ктор": 8331, - "imin": 8332, - "ening": 8333, - "▁donde": 8334, - "▁Ho": 8335, - "tree": 8336, - "mb": 8337, - "▁drag": 8338, - "aje": 8339, - "▁invalid": 8340, - "▁finish": 8341, - "laim": 8342, - "▁feed": 8343, - "▁Nap": 8344, - "room": 8345, - "images": 8346, - "▁сай": 8347, - "▁succ": 8348, - "iffer": 8349, - "▁año": 8350, - "▁cual": 8351, - "мери": 8352, - "DR": 8353, - "▁Bilder": 8354, - "бра": 8355, - "rait": 8356, - "pan": 8357, - "ень": 8358, - "▁distinct": 8359, - "▁Kn": 8360, - "önig": 8361, - "anced": 8362, - "▁loading": 8363, - "▁Techn": 8364, - "▁Sel": 8365, - "mus": 8366, - "▁rail": 8367, - "▁student": 8368, - "▁notice": 8369, - "▁sla": 8370, - "▁Да": 8371, - "▁guard": 8372, - "▁Day": 8373, - "вали": 8374, - "Option": 8375, - "aison": 8376, - "ipp": 8377, - "▁Jun": 8378, - "▁fell": 8379, - "▁absolute": 8380, - "ове": 8381, - "debug": 8382, - "▁Sud": 8383, - "пы": 8384, - "ugins": 8385, - "▁views": 8386, - "lay": 8387, - "▁surr": 8388, - "▁stood": 8389, - "▁ві": 8390, - "selected": 8391, - "гі": 8392, - "▁attributes": 8393, - "final": 8394, - "enda": 8395, - "▁Bon": 8396, - "ners": 8397, - "▁Wer": 8398, - "bur": 8399, - "ittel": 8400, - "▁moving": 8401, - "▁Plan": 8402, - "isches": 8403, - "Java": 8404, - "▁basis": 8405, - "▁Bus": 8406, - "▁Au": 8407, - "▁Ill": 8408, - "▁время": 8409, - "▁цент": 8410, - "handle": 8411, - "ступ": 8412, - "▁Far": 8413, - "▁oraz": 8414, - "ocr": 8415, - "▁seit": 8416, - "onder": 8417, - "дом": 8418, - ":/": 8419, - "chor": 8420, - "▁Town": 8421, - "▁definit": 8422, - "react": 8423, - "▁piece": 8424, - "▁Karl": 8425, - "CI": 8426, - "▁Application": 8427, - "unter": 8428, - "▁formed": 8429, - "▁пу": 8430, - "Bo": 8431, - "▁Daniel": 8432, - "▁пла": 8433, - "Body": 8434, - "})$": 8435, - "▁были": 8436, - "▁earth": 8437, - "гла": 8438, - "There": 8439, - "▁стра": 8440, - "▁ville": 8441, - "▁centre": 8442, - ")\r": 8443, - "▁helpful": 8444, - "▁++": 8445, - "▁CG": 8446, - "izione": 8447, - "▁Game": 8448, - "▁Which": 8449, - "▁pip": 8450, - "▁Portug": 8451, - "DS": 8452, - "▁describe": 8453, - "▁checking": 8454, - "▁manager": 8455, - "BO": 8456, - "▁Bundes": 8457, - "buch": 8458, - "▁decided": 8459, - "▁Jahrhundert": 8460, - "▁fif": 8461, - "efficient": 8462, - "anci": 8463, - "braries": 8464, - "▁fails": 8465, - "▁kernel": 8466, - "▁Gl": 8467, - "▁Nacional": 8468, - "▁proceed": 8469, - "▁fuer": 8470, - "▁living": 8471, - "▁successfully": 8472, - "▁faster": 8473, - "▁contre": 8474, - "▁prison": 8475, - "ORT": 8476, - "help": 8477, - "▁autor": 8478, - "ław": 8479, - "ają": 8480, - "▁Arm": 8481, - "▁provin": 8482, - "▁naam": 8483, - "/#": 8484, - "sed": 8485, - "▁gesch": 8486, - "▁мар": 8487, - "esk": 8488, - "term": 8489, - "▁Tex": 8490, - "iring": 8491, - "▁tools": 8492, - "PDF": 8493, - "▁ult": 8494, - "issenschaft": 8495, - "▁couldn": 8496, - "ding": 8497, - "Dep": 8498, - "{-": 8499, - "▁predict": 8500, - "antage": 8501, - "▁Like": 8502, - "▁Би": 8503, - "tools": 8504, - "estra": 8505, - "▁ki": 8506, - "▁Jim": 8507, - "star": 8508, - "▁remark": 8509, - "óg": 8510, - "nabla": 8511, - "▁Although": 8512, - "mode": 8513, - "Host": 8514, - "▁strange": 8515, - "None": 8516, - "black": 8517, - "▁Festival": 8518, - "▁IS": 8519, - "anza": 8520, - "▁(-": 8521, - "icket": 8522, - "кола": 8523, - "▁Jes": 8524, - "▁flex": 8525, - "▁À": 8526, - "▁Network": 8527, - "▁EX": 8528, - "▁enero": 8529, - "!”": 8530, - "▁Ort": 8531, - "▁alors": 8532, - "▁Original": 8533, - "▁zo": 8534, - "ными": 8535, - "▁spl": 8536, - "Draw": 8537, - "yond": 8538, - "──": 8539, - "▁Ot": 8540, - "▁dram": 8541, - "▁division": 8542, - "▁efficient": 8543, - "▁Га": 8544, - "▁vier": 8545, - "nak": 8546, - "LS": 8547, - "▁spirit": 8548, - "zeichnet": 8549, - "▁dici": 8550, - "clear": 8551, - "copy": 8552, - "yar": 8553, - "▁році": 8554, - "usqu": 8555, - "▁nous": 8556, - "▁blev": 8557, - "жде": 8558, - "Arg": 8559, - "▁performed": 8560, - "▁Make": 8561, - "▁Carol": 8562, - "etto": 8563, - "▁Sand": 8564, - "▁Disc": 8565, - "Enc": 8566, - "rero": 8567, - "hash": 8568, - "▁focus": 8569, - "▁attention": 8570, - "▁agre": 8571, - "▁divis": 8572, - "▁было": 8573, - "▁ej": 8574, - "▁march": 8575, - "▁phase": 8576, - "ías": 8577, - "▁phil": 8578, - "▁Pap": 8579, - "▁river": 8580, - "▁caused": 8581, - "plugin": 8582, - "▁Team": 8583, - "uler": 8584, - "▁$(\"#": 8585, - "iej": 8586, - "ISBN": 8587, - "nam": 8588, - "▁fight": 8589, - "vid": 8590, - "▁Lud": 8591, - "Selected": 8592, - ":@\"": 8593, - "▁Pod": 8594, - "▁années": 8595, - "arios": 8596, - "▁deutscher": 8597, - "▁NA": 8598, - "▁ию": 8599, - "▁dictionary": 8600, - "▁Ла": 8601, - "▁Tri": 8602, - "èn": 8603, - "▁political": 8604, - "ridge": 8605, - "atten": 8606, - "▁circle": 8607, - "▁transport": 8608, - "emas": 8609, - "FC": 8610, - "▁replaced": 8611, - "▁Aud": 8612, - "iska": 8613, - "Configuration": 8614, - "▁soort": 8615, - "▁Не": 8616, - "▁sequ": 8617, - "PRO": 8618, - "▁bud": 8619, - "▁{{": 8620, - "ließ": 8621, - "▁Mas": 8622, - "ders": 8623, - "usammen": 8624, - "esa": 8625, - "▁Ly": 8626, - "вро": 8627, - "mac": 8628, - "▁испо": 8629, - "▁suc": 8630, - "uy": 8631, - "▁illustr": 8632, - "▁primera": 8633, - "ilation": 8634, - "▁storage": 8635, - "▁params": 8636, - "kaz": 8637, - "▁terminal": 8638, - "раль": 8639, - "▁holds": 8640, - "лось": 8641, - "▁nad": 8642, - "”.": 8643, - "▁octubre": 8644, - "bul": 8645, - "▁hus": 8646, - "ULT": 8647, - "▁également": 8648, - "▁Mill": 8649, - "ład": 8650, - "▁contiene": 8651, - "\"?": 8652, - "▁>>>": 8653, - "Que": 8654, - "  ": 8655, - "▁plain": 8656, - "ativa": 8657, - "ocker": 8658, - "Names": 8659, - "▁Jud": 8660, - "▁agree": 8661, - "▁Gemeinde": 8662, - "lare": 8663, - "каза": 8664, - "▁starts": 8665, - "▁price": 8666, - "Target": 8667, - "cus": 8668, - "▁Instead": 8669, - ".;": 8670, - "▁alternative": 8671, - "▁вла": 8672, - "IE": 8673, - "▁organiz": 8674, - "inu": 8675, - "▁completed": 8676, - "▁carry": 8677, - "atom": 8678, - "▁depending": 8679, - "▁Our": 8680, - "▁insp": 8681, - "▁&\\": 8682, - "aily": 8683, - "irection": 8684, - "фа": 8685, - "▁defe": 8686, - "TAC": 8687, - "▁designed": 8688, - "▁voir": 8689, - "break": 8690, - "▁partie": 8691, - "▁Jahren": 8692, - "▁studio": 8693, - "▁jour": 8694, - "▁Notes": 8695, - "fire": 8696, - "house": 8697, - "success": 8698, - "▁Juan": 8699, - "JS": 8700, - "▁Custom": 8701, - "▁besch": 8702, - "▁stated": 8703, - "bootstrap": 8704, - "ött": 8705, - "ozzá": 8706, - "▁CON": 8707, - "hav": 8708, - "▁sleep": 8709, - "eda": 8710, - "hot": 8711, - "ánd": 8712, - "▁Sy": 8713, - "▁temps": 8714, - "amar": 8715, - "▁scal": 8716, - "▁ast": 8717, - "▁opening": 8718, - "clipse": 8719, - "▁programming": 8720, - "▁letters": 8721, - "▁profile": 8722, - "nah": 8723, - "▁beyond": 8724, - "▁Further": 8725, - "faces": 8726, - "▁chart": 8727, - "зда": 8728, - "aign": 8729, - "ній": 8730, - "▁Rol": 8731, - "овано": 8732, - "terior": 8733, - "wed": 8734, - "▁herself": 8735, - "▁ng": 8736, - "anguages": 8737, - "}=\\": 8738, - "ynamic": 8739, - "▁jug": 8740, - "▁Example": 8741, - "▁(†": 8742, - "▁playing": 8743, - "▁usage": 8744, - "▁managed": 8745, - "▁Natur": 8746, - "тери": 8747, - "▁Et": 8748, - "eria": 8749, - "▁daughter": 8750, - "нием": 8751, - "Fragment": 8752, - "▁hol": 8753, - "Fl": 8754, - "ографи": 8755, - "▁ihn": 8756, - "üh": 8757, - "instance": 8758, - "▁comun": 8759, - "▁truth": 8760, - "▁само": 8761, - "▁implemented": 8762, - "▁anyway": 8763, - "▁Cro": 8764, - "фе": 8765, - "GC": 8766, - "ubuntu": 8767, - "types": 8768, - "ês": 8769, - ".~\\": 8770, - "fold": 8771, - "▁joined": 8772, - "??": 8773, - "▁mé": 8774, - "▁wild": 8775, - "клю": 8776, - "rowser": 8777, - "▁Home": 8778, - "skiej": 8779, - "▁JOIN": 8780, - "▁juin": 8781, - "hof": 8782, - "▁dataset": 8783, - "жду": 8784, - "'))": 8785, - "▁miejs": 8786, - "API": 8787, - "▁edited": 8788, - "ools": 8789, - "▁seeing": 8790, - "ijd": 8791, - "▁procedure": 8792, - "▁Bras": 8793, - "▁signed": 8794, - "▁externos": 8795, - "▁disapp": 8796, - "▁Direct": 8797, - "cyc": 8798, - "▁consult": 8799, - "örd": 8800, - "Widget": 8801, - "cious": 8802, - "sect": 8803, - "▁Ди": 8804, - "▁wind": 8805, - "▁Archivado": 8806, - "aml": 8807, - "сс": 8808, - "Wh": 8809, - "kbd": 8810, - "▁Army": 8811, - "▁suffer": 8812, - "artifact": 8813, - "▁resolve": 8814, - "▁Sport": 8815, - "▁це": 8816, - "idas": 8817, - "▁tax": 8818, - "idi": 8819, - "▁actions": 8820, - "пра": 8821, - "pués": 8822, - "▁naj": 8823, - "False": 8824, - "▁chance": 8825, - "▁тако": 8826, - "äd": 8827, - "▁dol": 8828, - "▁env": 8829, - "▁basically": 8830, - "▁Council": 8831, - "zte": 8832, - "▁displayed": 8833, - "nil": 8834, - "complete": 8835, - "▁Lem": 8836, - "iance": 8837, - "▁основ": 8838, - "▁depend": 8839, - "plom": 8840, - "ensus": 8841, - "uts": 8842, - "▁Hot": 8843, - "bitr": 8844, - "▁validation": 8845, - "abb": 8846, - "▁тре": 8847, - "km": 8848, - "zd": 8849, - "öff": 8850, - "WE": 8851, - "▁interested": 8852, - "▁{\"": 8853, - "aro": 8854, - "▁correl": 8855, - "▁dedic": 8856, - "▁lists": 8857, - "▁Bibliografia": 8858, - "▁earlier": 8859, - "program": 8860, - "▁première": 8861, - "front": 8862, - "Tab": 8863, - "ству": 8864, - "drop": 8865, - "▁fear": 8866, - "▁Enlaces": 8867, - "▁Capt": 8868, - "▁realiz": 8869, - "▁hal": 8870, - "▁instances": 8871, - "▁susp": 8872, - "illing": 8873, - "%;": 8874, - "{}": 8875, - "||": 8876, - "▁partition": 8877, - "▁Build": 8878, - "▁wo": 8879, - "▁Пер": 8880, - "▁director": 8881, - "▁Sin": 8882, - "тия": 8883, - "rsg": 8884, - "ouver": 8885, - "▁nearly": 8886, - "oda": 8887, - "ктив": 8888, - "▁sir": 8889, - "IME": 8890, - "▁janvier": 8891, - "▁Win": 8892, - "Build": 8893, - "ieurs": 8894, - "INE": 8895, - "double": 8896, - "Last": 8897, - "▁policy": 8898, - "store": 8899, - "▁observed": 8900, - "▁familie": 8901, - "nica": 8902, - "rey": 8903, - "зь": 8904, - "▁Year": 8905, - "▁developed": 8906, - "▁Institute": 8907, - "▁reply": 8908, - "Comple": 8909, - "ician": 8910, - "▁Guer": 8911, - "▁dall": 8912, - "▁desp": 8913, - "▁Football": 8914, - "Empty": 8915, - "cken": 8916, - "unda": 8917, - "▁Ur": 8918, - "▁ig": 8919, - "▁Atl": 8920, - "author": 8921, - "▁Bol": 8922, - "zig": 8923, - "nat": 8924, - "št": 8925, - "security": 8926, - "onic": 8927, - "▁pes": 8928, - "itan": 8929, - "▁Extern": 8930, - "jan": 8931, - "VAL": 8932, - "▁им": 8933, - "bold": 8934, - "▁ва": 8935, - "▁Мо": 8936, - "▁disput": 8937, - "▁trick": 8938, - "▁ped": 8939, - ")^{": 8940, - "into": 8941, - "Sim": 8942, - "▁parallel": 8943, - "fox": 8944, - "normal": 8945, - "inent": 8946, - "педи": 8947, - "hold": 8948, - "OK": 8949, - "▁chem": 8950, - "▁twice": 8951, - "▁username": 8952, - "ič": 8953, - "▁representation": 8954, - "▁journal": 8955, - "▁:-": 8956, - "▁batt": 8957, - "\\%": 8958, - "▁certainly": 8959, - "▁Exception": 8960, - "eps": 8961, - "shot": 8962, - "ategy": 8963, - "Show": 8964, - "▁Carl": 8965, - "rig": 8966, - "▁reported": 8967, - "bottom": 8968, - "TF": 8969, - "▁Francisco": 8970, - "nap": 8971, - "▁Championship": 8972, - "▁court": 8973, - "▁sources": 8974, - "iour": 8975, - "▁conserv": 8976, - "dict": 8977, - "▁Ру": 8978, - "IB": 8979, - "▁Ve": 8980, - "▁№": 8981, - "▁ER": 8982, - "\"));": 8983, - "▁Point": 8984, - "azine": 8985, - "▁internet": 8986, - "дна": 8987, - "▁carried": 8988, - "▁Field": 8989, - "axis": 8990, - "▁Sun": 8991, - "▁ave": 8992, - "пис": 8993, - "ян": 8994, - "asy": 8995, - "▁julio": 8996, - "▁depuis": 8997, - "▁suggestion": 8998, - "[[": 8999, - "▁Archive": 9000, - "ęp": 9001, - "▁Pra": 9002, - "reh": 9003, - "▁demonstr": 9004, - "фі": 9005, - "cmd": 9006, - "▁wasn": 9007, - "▁phone": 9008, - "upload": 9009, - "aya": 9010, - "тора": 9011, - "lines": 9012, - "▁indu": 9013, - "▁vot": 9014, - "▁espa": 9015, - "▁bin": 9016, - "▁после": 9017, - "plan": 9018, - "▁junio": 9019, - "orial": 9020, - "free": 9021, - "sterreich": 9022, - "▁ду": 9023, - "▁linked": 9024, - "▁enable": 9025, - "PC": 9026, - "▁density": 9027, - "▁Egy": 9028, - "yo": 9029, - "endre": 9030, - "▁съ": 9031, - "▁italiano": 9032, - "▁AR": 9033, - "▁Pers": 9034, - "férés": 9035, - "▁скла": 9036, - "Var": 9037, - "▁Once": 9038, - "Red": 9039, - "buffer": 9040, - "▁Enter": 9041, - "▁Š": 9042, - "imiento": 9043, - "Store": 9044, - "▁health": 9045, - "vat": 9046, - "IST": 9047, - "Oh": 9048, - "▁kw": 9049, - "▁riv": 9050, - "▁somewhere": 9051, - "ografie": 9052, - "private": 9053, - "кти": 9054, - "▁delay": 9055, - "▁Http": 9056, - "job": 9057, - "rael": 9058, - "empor": 9059, - "▁diciembre": 9060, - "ête": 9061, - "цу": 9062, - "▁commit": 9063, - "oso": 9064, - "Values": 9065, - "▁headers": 9066, - "transform": 9067, - "▁processing": 9068, - "rå": 9069, - "▁Ah": 9070, - "▁Node": 9071, - "------------": 9072, - "▁faire": 9073, - "▁hun": 9074, - "Player": 9075, - "▁review": 9076, - "гда": 9077, - "▁limited": 9078, - "▁Property": 9079, - "▁serve": 9080, - "riage": 9081, - "▁Master": 9082, - "▁kann": 9083, - "crete": 9084, - "phere": 9085, - "ёр": 9086, - "▁chief": 9087, - "▁scene": 9088, - "kin": 9089, - "▁uniform": 9090, - "▁febrero": 9091, - "\"}": 9092, - "illo": 9093, - "ITE": 9094, - "ouvel": 9095, - "usepackage": 9096, - "enth": 9097, - "▁quickly": 9098, - "Lambda": 9099, - "xes": 9100, - "▁cells": 9101, - "rog": 9102, - "amin": 9103, - "▁Мар": 9104, - "▁mayor": 9105, - "player": 9106, - "++;": 9107, - "▁Насе": 9108, - "▁safe": 9109, - "▁veloc": 9110, - "▁обра": 9111, - "Database": 9112, - "neh": 9113, - "Vert": 9114, - "▁fle": 9115, - "▁фор": 9116, - "▁foreign": 9117, - "Abstract": 9118, - "▁magn": 9119, - "▁modified": 9120, - "▁military": 9121, - "▁monde": 9122, - "▁Action": 9123, - "▁bank": 9124, - "Serial": 9125, - "▁continuous": 9126, - "▁gel": 9127, - "▁physical": 9128, - "▁introduced": 9129, - "uture": 9130, - "rick": 9131, - "▁presented": 9132, - "▁Prov": 9133, - "▁Both": 9134, - "Pos": 9135, - "super": 9136, - "&#": 9137, - "▁finding": 9138, - "nel": 9139, - "unde": 9140, - "▁från": 9141, - "skim": 9142, - "▁Hill": 9143, - "fn": 9144, - "▁Canad": 9145, - "▁intended": 9146, - "ozzáférés": 9147, - "▁juillet": 9148, - "▁Wars": 9149, - "▁successful": 9150, - "▁charg": 9151, - "iele": 9152, - "omething": 9153, - "oku": 9154, - "fetch": 9155, - "▁}}": 9156, - "bank": 9157, - "operatorname": 9158, - "▁Color": 9159, - "▁Card": 9160, - "tu": 9161, - "▁\",": 9162, - "wid": 9163, - "▁gep": 9164, - "XML": 9165, - "================": 9166, - "▁Virgin": 9167, - "ährend": 9168, - "licated": 9169, - "Dir": 9170, - "zero": 9171, - "▁Kal": 9172, - "▁Party": 9173, - "▁å": 9174, - "price": 9175, - "don": 9176, - "▁warning": 9177, - "▁Bad": 9178, - "▁Supp": 9179, - "▁Liga": 9180, - "▁Pierre": 9181, - "Record": 9182, - "ulator": 9183, - "▁Rome": 9184, - "▁theorem": 9185, - "▁entirely": 9186, - "ским": 9187, - "het": 9188, - "▁dopo": 9189, - "Next": 9190, - "mlung": 9191, - "wig": 9192, - "▁Ath": 9193, - "▁Sou": 9194, - "licher": 9195, - "▁sudo": 9196, - "ests": 9197, - "хів": 9198, - "▁septiembre": 9199, - "▁micro": 9200, - "▁trop": 9201, - "fit": 9202, - "Core": 9203, - "▁Radio": 9204, - "▁Organ": 9205, - "▁Power": 9206, - "CF": 9207, - "▁Last": 9208, - "▁oppos": 9209, - "▁offset": 9210, - "▁regia": 9211, - "▁minimum": 9212, - "▁helped": 9213, - "andon": 9214, - "ifying": 9215, - "ruit": 9216, - "enschapp": 9217, - "▁bere": 9218, - "VM": 9219, - "▁Awards": 9220, - "▁agr": 9221, - "ynomial": 9222, - "enced": 9223, - "▁devices": 9224, - "▁bot": 9225, - "▁firm": 9226, - "▁writer": 9227, - "▁ring": 9228, - ".-": 9229, - "istes": 9230, - "lä": 9231, - "▁mel": 9232, - "entation": 9233, - "▁Schw": 9234, - "▁nome": 9235, - "▁pobla": 9236, - "▁woj": 9237, - "▁ul": 9238, - "ento": 9239, - "ых": 9240, - "▁resist": 9241, - "▁remains": 9242, - "▁Ca": 9243, - "aña": 9244, - "▁Court": 9245, - "utable": 9246, - "entially": 9247, - "▁trat": 9248, - "▁Visual": 9249, - "▁restrict": 9250, - "▁previously": 9251, - "cation": 9252, - "▁осо": 9253, - "▁MySQL": 9254, - "för": 9255, - "cala": 9256, - "▁culture": 9257, - "live": 9258, - "▁accepted": 9259, - "Did": 9260, - "▁hous": 9261, - "▁selection": 9262, - "▁decre": 9263, - "margin": 9264, - "urb": 9265, - "▁Inc": 9266, - "▁Many": 9267, - "ibt": 9268, - "▁succeed": 9269, - "Binding": 9270, - "cí": 9271, - "▁Rog": 9272, - "▁shouldn": 9273, - "cloud": 9274, - "▁dz": 9275, - "вав": 9276, - "▁pix": 9277, - "small": 9278, - "▁projects": 9279, - "▁OK": 9280, - "▁latest": 9281, - "▁references": 9282, - "Program": 9283, - "▁erst": 9284, - "▁як": 9285, - "▁kam": 9286, - "▁Camb": 9287, - "ellt": 9288, - "öd": 9289, - "none": 9290, - "▁jusqu": 9291, - "king": 9292, - "▁Ped": 9293, - "assert": 9294, - "CS": 9295, - "rito": 9296, - "essa": 9297, - "лько": 9298, - "▁Von": 9299, - "▁Edward": 9300, - "▁impossible": 9301, - "np": 9302, - "words": 9303, - "ielt": 9304, - "▁Page": 9305, - "lers": 9306, - "▁pier": 9307, - "▁области": 9308, - "ittee": 9309, - "▁([": 9310, - "▁trust": 9311, - "NG": 9312, - "redu": 9313, - "<<": 9314, - "rial": 9315, - "▁products": 9316, - "▁Ern": 9317, - "rière": 9318, - "гов": 9319, - "▁Reich": 9320, - "▁Road": 9321, - "▁nested": 9322, - "Display": 9323, - "▁strength": 9324, - "ografía": 9325, - "▁announced": 9326, - "▁Science": 9327, - "▁райо": 9328, - "Parameter": 9329, - "▁Task": 9330, - "uments": 9331, - "▁adopt": 9332, - "▁Only": 9333, - "ють": 9334, - "▁cli": 9335, - "▁lem": 9336, - "stood": 9337, - "▁FI": 9338, - "ências": 9339, - "ponents": 9340, - "]$": 9341, - "comment": 9342, - "▁ya": 9343, - "should": 9344, - "ike": 9345, - "tim": 9346, - "ellig": 9347, - "▁sending": 9348, - "▁ajax": 9349, - "▁noviembre": 9350, - "umes": 9351, - "▁weiter": 9352, - "▁Dans": 9353, - "opp": 9354, - "▁septembre": 9355, - "otimes": 9356, - "ző": 9357, - "▁ep": 9358, - "vere": 9359, - "▁oh": 9360, - ":=": 9361, - "▁Song": 9362, - "”,": 9363, - "▁viv": 9364, - "▁queries": 9365, - "▁vá": 9366, - "▁décembre": 9367, - "▁unable": 9368, - "▁erh": 9369, - "▁`-": 9370, - "▁Lee": 9371, - "▁ersten": 9372, - "ôt": 9373, - "стве": 9374, - "TS": 9375, - "▁fragment": 9376, - "▁wide": 9377, - "▁suff": 9378, - "▁dut": 9379, - "▁Vere": 9380, - "іс": 9381, - "ading": 9382, - "iego": 9383, - "icago": 9384, - "▁Argent": 9385, - "orer": 9386, - "ennes": 9387, - "▁Leb": 9388, - "linux": 9389, - "acing": 9390, - "▁broken": 9391, - "tp": 9392, - "ío": 9393, - "abeth": 9394, - "istas": 9395, - "gew": 9396, - "ième": 9397, - "cas": 9398, - "▁preced": 9399, - "▁Dal": 9400, - "▁compared": 9401, - "equiv": 9402, - "illy": 9403, - "teen": 9404, - "▁Console": 9405, - "▁strict": 9406, - "itaire": 9407, - "▁ED": 9408, - "entials": 9409, - "▁perman": 9410, - "▁tous": 9411, - "▁geme": 9412, - "▁extrem": 9413, - "▁окру": 9414, - "kg": 9415, - "▁heavy": 9416, - "▁avril": 9417, - "▁anti": 9418, - "▁octobre": 9419, - "utf": 9420, - "helm": 9421, - "amples": 9422, - "▁(_": 9423, - "aken": 9424, - "▁dear": 9425, - "▁opinion": 9426, - "▁fish": 9427, - "▁Alexander": 9428, - "iw": 9429, - "им": 9430, - "cadem": 9431, - "▁reflect": 9432, - "▁др": 9433, - "▁trib": 9434, - "common": 9435, - "▁clearly": 9436, - "▁saf": 9437, - "=\"@+": 9438, - "▁Мос": 9439, - "сите": 9440, - "eqnarray": 9441, - "nung": 9442, - "▁relationship": 9443, - "▁Sem": 9444, - "▁killed": 9445, - "ted": 9446, - "uno": 9447, - "▁лі": 9448, - "▁wid": 9449, - "anning": 9450, - "▁panel": 9451, - "▁Leben": 9452, - "▁ruby": 9453, - "ansion": 9454, - "▁aren": 9455, - "tabular": 9456, - "alet": 9457, - "}$$": 9458, - "▁Lake": 9459, - "▁suite": 9460, - "▁minor": 9461, - "Hozzáférés": 9462, - "▁xmlns": 9463, - "DIR": 9464, - "driver": 9465, - "ints": 9466, - "▁vic": 9467, - "AND": 9468, - "prim": 9469, - "сылки": 9470, - "▁Ox": 9471, - "TC": 9472, - "rivial": 9473, - "atie": 9474, - "▁eight": 9475, - "▁conflic": 9476, - "angel": 9477, - "▁Begr": 9478, - "▁explicitly": 9479, - "ются": 9480, - "▁Dev": 9481, - "render": 9482, - "▁reprodu": 9483, - "▁cré": 9484, - "Gu": 9485, - "MB": 9486, - "▁kön": 9487, - "▁remained": 9488, - "▁kl": 9489, - "хов": 9490, - "▁byl": 9491, - "Phi": 9492, - "▁detail": 9493, - "jav": 9494, - "▁mouse": 9495, - "Bas": 9496, - "ię": 9497, - "asser": 9498, - "hs": 9499, - "▁shift": 9500, - "▁últ": 9501, - "rand": 9502, - "▁btn": 9503, - "raz": 9504, - "▁pul": 9505, - "▁statements": 9506, - "filename": 9507, - "▁prompt": 9508, - "élé": 9509, - "ikz": 9510, - "▁Sus": 9511, - "▁debut": 9512, - "Stat": 9513, - "forms": 9514, - "▁Hein": 9515, - "stadt": 9516, - "ennis": 9517, - "пол": 9518, - "arante": 9519, - "цій": 9520, - "▁queue": 9521, - "▁reci": 9522, - "▁sta": 9523, - "ynchron": 9524, - "centering": 9525, - "Some": 9526, - "Graph": 9527, - "▁tested": 9528, - "▁Kunst": 9529, - "ом": 9530, - "▁Nothing": 9531, - "ieu": 9532, - "“.": 9533, - "Bundle": 9534, - "▁oficial": 9535, - "allow": 9536, - "▁React": 9537, - "▁Library": 9538, - "blue": 9539, - "▁verw": 9540, - "▁pare": 9541, - "▁Friedrich": 9542, - "▁aware": 9543, - "Exp": 9544, - "▁effects": 9545, - "▁горо": 9546, - "lopedia": 9547, - "▁Ven": 9548, - "rale": 9549, - "▁Final": 9550, - "▁propos": 9551, - "lacement": 9552, - "kten": 9553, - "▁novel": 9554, - "orter": 9555, - "▁Germany": 9556, - "▁django": 9557, - "▁transition": 9558, - "▁happened": 9559, - "▁beautiful": 9560, - "▁neither": 9561, - "▁libraries": 9562, - "▁hide": 9563, - "alg": 9564, - "▁aspect": 9565, - "▁forget": 9566, - "cademy": 9567, - "onte": 9568, - "refix": 9569, - "▁cloud": 9570, - "ned": 9571, - "cdots": 9572, - "register": 9573, - "nym": 9574, - ".):": 9575, - "▁Jew": 9576, - "▁très": 9577, - "ниче": 9578, - "▁Dor": 9579, - "▁proc": 9580, - "▁gan": 9581, - "▁є": 9582, - "▁Sav": 9583, - "ví": 9584, - "Settings": 9585, - "▁Vari": 9586, - "▁cours": 9587, - "Ro": 9588, - "▁conj": 9589, - "▁reasons": 9590, - "▁reader": 9591, - "лександ": 9592, - "icate": 9593, - "}),": 9594, - "▁tasks": 9595, - "▁Ray": 9596, - "▁ric": 9597, - "Ke": 9598, - "onie": 9599, - "rf": 9600, - ")[": 9601, - "▁subsequ": 9602, - "▁Turn": 9603, - "▁VIAF": 9604, - "mathsf": 9605, - "HE": 9606, - "▁declare": 9607, - "▁protocol": 9608, - "▁PC": 9609, - "цион": 9610, - "ViewById": 9611, - "▁animation": 9612, - "▁confused": 9613, - "вич": 9614, - "▁enabled": 9615, - "owo": 9616, - "ást": 9617, - "öt": 9618, - "▁mand": 9619, - "▁Rail": 9620, - "fields": 9621, - "▁Kap": 9622, - "▁algebra": 9623, - "▁Су": 9624, - "férence": 9625, - "▁Current": 9626, - "сно": 9627, - "▁Lim": 9628, - "Params": 9629, - "▁Antonio": 9630, - "▁tv": 9631, - "late": 9632, - "ifer": 9633, - "Entry": 9634, - "▁Serv": 9635, - "▁musical": 9636, - "▁trace": 9637, - "▁scient": 9638, - "fic": 9639, - "▁forgot": 9640, - "video": 9641, - "▁older": 9642, - "Tree": 9643, - "▁uns": 9644, - "ники": 9645, - "▁Europa": 9646, - "▁Zwe": 9647, - "▁бе": 9648, - "▁vec": 9649, - "жу": 9650, - "▁▁▁▁▁▁▁▁▁▁▁": 9651, - "Match": 9652, - "span": 9653, - "▁blank": 9654, - "▁später": 9655, - "▁Ty": 9656, - "▁dict": 9657, - "ña": 9658, - "▁confirm": 9659, - "▁vý": 9660, - "зан": 9661, - "Rel": 9662, - "film": 9663, - "▁Rot": 9664, - "▁Hy": 9665, - "ках": 9666, - "▁demand": 9667, - "▁minist": 9668, - "▁Madrid": 9669, - "▁usual": 9670, - "spiel": 9671, - "eros": 9672, - "▁tutorial": 9673, - "▁Ссылки": 9674, - "sys": 9675, - "циаль": 9676, - "▁spread": 9677, - "▁convers": 9678, - "▁roll": 9679, - "artifactId": 9680, - "▁Number": 9681, - "▁symmet": 9682, - "▁Mult": 9683, - "expected": 9684, - "▁axis": 9685, - "▁matching": 9686, - "▁food": 9687, - "groupId": 9688, - "Mapp": 9689, - "▁свя": 9690, - "▁vend": 9691, - "Found": 9692, - "otto": 9693, - "Cat": 9694, - "crit": 9695, - "istent": 9696, - "▁drei": 9697, - "▁ended": 9698, - "▁Tele": 9699, - "component": 9700, - "▁involved": 9701, - "▁Estados": 9702, - "▁danger": 9703, - "▁chain": 9704, - "▁Prom": 9705, - "hom": 9706, - "▁polít": 9707, - "cop": 9708, - "▁nap": 9709, - "rif": 9710, - "plements": 9711, - "▁vent": 9712, - "anna": 9713, - "anted": 9714, - "dated": 9715, - "anth": 9716, - "▁threads": 9717, - "зова": 9718, - "▁станов": 9719, - "▁eerst": 9720, - "buf": 9721, - "heid": 9722, - "▁Ru": 9723, - "▁Prim": 9724, - "▁migr": 9725, - "▁Unidos": 9726, - "▁arbitr": 9727, - "▁roman": 9728, - "ountry": 9729, - "ultur": 9730, - "▁König": 9731, - "▁annot": 9732, - "aching": 9733, - "▁Haupt": 9734, - "umin": 9735, - "▁hem": 9736, - "ckets": 9737, - "bau": 9738, - "ection": 9739, - "eft": 9740, - "▁packages": 9741, - "▁Kur": 9742, - "thur": 9743, - "▁pays": 9744, - "liament": 9745, - "▁Бу": 9746, - "▁cada": 9747, - "points": 9748, - "ocket": 9749, - "▁verb": 9750, - "лее": 9751, - "▁submit": 9752, - "▁san": 9753, - "ruby": 9754, - "▁east": 9755, - "kov": 9756, - "▁Verlag": 9757, - "▁spot": 9758, - "ppo": 9759, - "Each": 9760, - "jekt": 9761, - "▁Biographie": 9762, - "▁news": 9763, - "▁país": 9764, - "ufact": 9765, - "▁dia": 9766, - "кова": 9767, - "▁accompl": 9768, - "▁Ét": 9769, - "ilities": 9770, - "▁ihm": 9771, - "invoke": 9772, - "▁append": 9773, - ".),": 9774, - "▁lab": 9775, - "anging": 9776, - "istan": 9777, - "resol": 9778, - "▁Section": 9779, - "Parent": 9780, - "moz": 9781, - "Mat": 9782, - "styles": 9783, - "unden": 9784, - "“,": 9785, - "irtschaft": 9786, - "ким": 9787, - "▁Finally": 9788, - "phen": 9789, - "▁Pac": 9790, - "▁ArrayList": 9791, - "▁recover": 9792, - "▁education": 9793, - "models": 9794, - "ped": 9795, - "▁happy": 9796, - "чу": 9797, - "▁guerra": 9798, - "media": 9799, - "OF": 9800, - "▁ensure": 9801, - "Mark": 9802, - "database": 9803, - "oggle": 9804, - "▁publish": 9805, - "OW": 9806, - "▁Bau": 9807, - "?.": 9808, - "▁части": 9809, - "▁repository": 9810, - "▁Matt": 9811, - "high": 9812, - "oven": 9813, - "▁ger": 9814, - "▁unknown": 9815, - "Amer": 9816, - "▁Brown": 9817, - "ALL": 9818, - "▁resulting": 9819, - "▁bor": 9820, - "▁poet": 9821, - "ними": 9822, - "Email": 9823, - "Font": 9824, - "▁hist": 9825, - "▁today": 9826, - "▁Berg": 9827, - "▁buttons": 9828, - "тал": 9829, - "▁sni": 9830, - "▁челов": 9831, - "Cre": 9832, - "▁union": 9833, - "▁zich": 9834, - "ishop": 9835, - "▁quando": 9836, - "Po": 9837, - "CTION": 9838, - "▁Cost": 9839, - "судар": 9840, - "erved": 9841, - "Note": 9842, - "Equal": 9843, - "лия": 9844, - "бур": 9845, - "▁abstract": 9846, - "stop": 9847, - "▁advice": 9848, - "▁icon": 9849, - "▁travel": 9850, - "BS": 9851, - "vens": 9852, - "▁batch": 9853, - "lique": 9854, - "sheet": 9855, - "▁ihre": 9856, - "emon": 9857, - "berto": 9858, - "▁assigned": 9859, - "ью": 9860, - "Phone": 9861, - "▁award": 9862, - "▁functionality": 9863, - "alla": 9864, - "▁Dam": 9865, - "▁ciudad": 9866, - "▁cluster": 9867, - "Description": 9868, - "▁sheet": 9869, - "▁Australian": 9870, - "▁».": 9871, - "▁\"<": 9872, - "▁wondering": 9873, - "aine": 9874, - "▁represented": 9875, - "kappa": 9876, - "nb": 9877, - "▁sy": 9878, - "▁Kö": 9879, - "=\"#": 9880, - "▁seven": 9881, - "Directory": 9882, - "▁sister": 9883, - "plates": 9884, - "▁luck": 9885, - "▁remaining": 9886, - "▁Vill": 9887, - "werk": 9888, - "anni": 9889, - "etti": 9890, - "func": 9891, - "▁ban": 9892, - "ims": 9893, - "miss": 9894, - "agraph": 9895, - "екси": 9896, - "▁Ref": 9897, - "nitt": 9898, - "▁Gab": 9899, - "▁andere": 9900, - "▁jedoch": 9901, - "results": 9902, - "!\\": 9903, - "▁listed": 9904, - "▁loro": 9905, - "▁knows": 9906, - "жно": 9907, - "Rad": 9908, - "▁socket": 9909, - "multi": 9910, - "▁рі": 9911, - "rails": 9912, - "▁tar": 9913, - "▁gentle": 9914, - "sett": 9915, - "services": 9916, - "bound": 9917, - "igkeit": 9918, - "aja": 9919, - "▁cmd": 9920, - "agger": 9921, - "▁ba": 9922, - "▁Belg": 9923, - "▁Kle": 9924, - "▁wordt": 9925, - "▁fost": 9926, - "▁dimension": 9927, - "Ang": 9928, - "uming": 9929, - "Obj": 9930, - "нен": 9931, - "▁Marie": 9932, - "exists": 9933, - "тро": 9934, - "▁боль": 9935, - "emente": 9936, - "▁Jon": 9937, - "SERT": 9938, - "▁highest": 9939, - "aki": 9940, - "▁tres": 9941, - "▁circum": 9942, - "▁Down": 9943, - "ommen": 9944, - "urer": 9945, - "▁causes": 9946, - "venue": 9947, - "issance": 9948, - "▁influence": 9949, - "▁fat": 9950, - "реди": 9951, - "}\\\\": 9952, - "▁entr": 9953, - "▁Sign": 9954, - "▁кла": 9955, - "▁binding": 9956, - "essen": 9957, - "▁Фран": 9958, - "▁Local": 9959, - "▁явля": 9960, - "appro": 9961, - "▁dependencies": 9962, - "▁talking": 9963, - "▁zurück": 9964, - "connection": 9965, - "Active": 9966, - "bbe": 9967, - "irls": 9968, - "▁Inf": 9969, - "wd": 9970, - "▁ис": 9971, - "road": 9972, - "▁conven": 9973, - "ět": 9974, - "вез": 9975, - "▁entries": 9976, - "esc": 9977, - "▁bits": 9978, - "asso": 9979, - "WR": 9980, - "ships": 9981, - "▁dés": 9982, - "esp": 9983, - "Make": 9984, - "▁familiar": 9985, - "Art": 9986, - "▁army": 9987, - "ctr": 9988, - "éric": 9989, - "queue": 9990, - "▁\\{": 9991, - "uela": 9992, - "amiento": 9993, - "ших": 9994, - "▁\"\"\"": 9995, - "contr": 9996, - "лле": 9997, - "FS": 9998, - "▁market": 9999, - "ång": 10000, - "citep": 10001, - "Ill": 10002, - "rank": 10003, - "▁sender": 10004, - "▁beim": 10005, - "рак": 10006, - "▁compat": 10007, - "▁occurs": 10008, - "▁diese": 10009, - "ститу": 10010, - "awa": 10011, - "▁iOS": 10012, - "▁Chinese": 10013, - "▁TR": 10014, - "▁Ken": 10015, - "▁Une": 10016, - "▁creates": 10017, - "▁showed": 10018, - "▁év": 10019, - "ologia": 10020, - "▁protest": 10021, - "▁Pf": 10022, - "▁squad": 10023, - "++,": 10024, - "áv": 10025, - "▁essere": 10026, - "зя": 10027, - "kol": 10028, - "▁slightly": 10029, - "addr": 10030, - "ân": 10031, - "▁reduce": 10032, - "▁\\(\\": 10033, - "▁Dep": 10034, - "▁generic": 10035, - "Loader": 10036, - "ți": 10037, - "▁пос": 10038, - "▁occasion": 10039, - "▁Lady": 10040, - "entity": 10041, - "▁avant": 10042, - "▁Pas": 10043, - "aggio": 10044, - "\\{": 10045, - "пад": 10046, - "atholic": 10047, - "Password": 10048, - "▁respond": 10049, - "▁Non": 10050, - "AG": 10051, - "neg": 10052, - "▁ус": 10053, - "blob": 10054, - "cke": 10055, - "▁Consider": 10056, - "▁Care": 10057, - "iki": 10058, - "▁Chicago": 10059, - "inden": 10060, - "▁Cop": 10061, - "]+": 10062, - "öm": 10063, - "évrier": 10064, - "кло": 10065, - "alen": 10066, - "▁maj": 10067, - "racy": 10068, - "orte": 10069, - "ients": 10070, - "ells": 10071, - "activity": 10072, - "▁runtime": 10073, - "NULL": 10074, - "▁possibly": 10075, - "▁stri": 10076, - "izi": 10077, - "▁mir": 10078, - "▁Version": 10079, - "prime": 10080, - "▁twenty": 10081, - "▁Mah": 10082, - "▁sounds": 10083, - "шен": 10084, - "clusion": 10085, - "acz": 10086, - "▁determined": 10087, - "▁Rep": 10088, - "▁Landes": 10089, - "▁wall": 10090, - "igi": 10091, - "▁reset": 10092, - "шо": 10093, - "yan": 10094, - "Met": 10095, - "ei": 10096, - "▁appearance": 10097, - "▁fois": 10098, - "▁nell": 10099, - "esi": 10100, - "ёт": 10101, - "loor": 10102, - "▁Ul": 10103, - "▁resolution": 10104, - "▁fot": 10105, - "▁throughout": 10106, - "▁ri": 10107, - "Level": 10108, - "pool": 10109, - "▁identity": 10110, - "▁janu": 10111, - "▁imper": 10112, - "▁över": 10113, - "}`": 10114, - "▁infer": 10115, - "▁dates": 10116, - "▁Standard": 10117, - "force": 10118, - "ockey": 10119, - "tera": 10120, - "▁distingu": 10121, - "▁presence": 10122, - "lica": 10123, - "▁leaving": 10124, - "itung": 10125, - "éb": 10126, - "▁establish": 10127, - "▁maar": 10128, - "adi": 10129, - "▁News": 10130, - "azon": 10131, - "folg": 10132, - "▁Hence": 10133, - "▁Ye": 10134, - "▁fab": 10135, - "▁führ": 10136, - "itmap": 10137, - "▁Vers": 10138, - "rov": 10139, - "Sign": 10140, - "device": 10141, - "Sigma": 10142, - "▁wetenschapp": 10143, - "▁Ps": 10144, - "PATH": 10145, - "▁torn": 10146, - "vest": 10147, - "стов": 10148, - "account": 10149, - "▁largest": 10150, - "▁percent": 10151, - "▁Women": 10152, - "▁img": 10153, - "tool": 10154, - "▁roce": 10155, - "▁ay": 10156, - "inet": 10157, - "▁août": 10158, - "▁polynomial": 10159, - "▁integral": 10160, - "▁areas": 10161, - "}'": 10162, - "▁hyp": 10163, - "loyee": 10164, - "таль": 10165, - "▁proxy": 10166, - "▁Wy": 10167, - "▁Мекси": 10168, - "▁escape": 10169, - "olar": 10170, - "▁mistake": 10171, - ")}{": 10172, - "▁Pot": 10173, - "▁processes": 10174, - "\">\r": 10175, - "halten": 10176, - "zza": 10177, - "amo": 10178, - "кре": 10179, - "▁Wood": 10180, - "ør": 10181, - "▁сер": 10182, - "ocia": 10183, - "two": 10184, - "profile": 10185, - "▁Ast": 10186, - "embro": 10187, - "▁arms": 10188, - "inas": 10189, - "innen": 10190, - "▁msg": 10191, - "INT": 10192, - "▁batter": 10193, - "ignment": 10194, - "▁vy": 10195, - "Hrsg": 10196, - "▁Grund": 10197, - "roc": 10198, - "seg": 10199, - "▁decor": 10200, - "▁eventually": 10201, - ">,": 10202, - "▁pag": 10203, - "anten": 10204, - "▁strugg": 10205, - "}^\\": 10206, - "daten": 10207, - "▁rela": 10208, - "пов": 10209, - "▁коро": 10210, - "▁Bos": 10211, - "▁labor": 10212, - "▁Secret": 10213, - "ugen": 10214, - "▁jap": 10215, - "▁husband": 10216, - "▁Album": 10217, - "▁etwa": 10218, - "▁произ": 10219, - "richt": 10220, - "rach": 10221, - "bat": 10222, - "▁prepar": 10223, - "▁Stock": 10224, - "▁lack": 10225, - "хід": 10226, - "▁hogy": 10227, - "▁Chrome": 10228, - "▁Admin": 10229, - "▁comparison": 10230, - "▁increasing": 10231, - "нг": 10232, - "imi": 10233, - "Db": 10234, - "▁gef": 10235, - "ucht": 10236, - "ése": 10237, - "gence": 10238, - "▁Core": 10239, - "▁incorrect": 10240, - "▁assuming": 10241, - "ourse": 10242, - "ieron": 10243, - "▁Theorem": 10244, - "▁casa": 10245, - "jes": 10246, - "▁дере": 10247, - "▁`\"": 10248, - "LD": 10249, - "äß": 10250, - "Deb": 10251, - "▁suiv": 10252, - "▁Bank": 10253, - "libs": 10254, - "▁Leon": 10255, - "▁quart": 10256, - "▁professional": 10257, - "▁tiene": 10258, - "▁accomp": 10259, - "стер": 10260, - "▁UK": 10261, - "NN": 10262, - "▁lí": 10263, - "ця": 10264, - "kel": 10265, - "▁•": 10266, - "▁dise": 10267, - "onto": 10268, - "▁má": 10269, - "ifs": 10270, - "bild": 10271, - "▁compute": 10272, - "▁éd": 10273, - "ję": 10274, - "▁Mé": 10275, - "▁languages": 10276, - "▁Times": 10277, - "cen": 10278, - "▁авто": 10279, - "ým": 10280, - "enez": 10281, - "▁upp": 10282, - "▁méd": 10283, - "▁cuando": 10284, - "од": 10285, - "Intent": 10286, - "eerd": 10287, - "▁Tal": 10288, - "offset": 10289, - "▁haben": 10290, - "reme": 10291, - "▁Stack": 10292, - "▁dri": 10293, - "▁seinem": 10294, - "▁février": 10295, - "▁combination": 10296, - "▁soll": 10297, - "▁movement": 10298, - "Spec": 10299, - "кры": 10300, - "retch": 10301, - "Offset": 10302, - "Root": 10303, - "Ар": 10304, - "wart": 10305, - "▁Follow": 10306, - "▁Social": 10307, - "ников": 10308, - "▁→": 10309, - "Don": 10310, - "▁harm": 10311, - "agr": 10312, - "nego": 10313, - "resource": 10314, - "▁Luc": 10315, - "▁seinen": 10316, - "▁Department": 10317, - "▁Update": 10318, - "▁Texas": 10319, - "▁reve": 10320, - "▁Pos": 10321, - "▁shot": 10322, - "othe": 10323, - "▁repeated": 10324, - "▁recently": 10325, - "ában": 10326, - "aks": 10327, - "пан": 10328, - "▁cha": 10329, - "ohl": 10330, - "▁tend": 10331, - "▁дво": 10332, - "chts": 10333, - "çaise": 10334, - "pling": 10335, - "album": 10336, - "ej": 10337, - "▁`[": 10338, - "maps": 10339, - "▁units": 10340, - "▁": 15110, - "▁pří": 15111, - "pandas": 15112, - "▁Plus": 15113, - "yll": 15114, - "▁terror": 15115, - "▁crim": 15116, - "▁zak": 15117, - "issue": 15118, - "panel": 15119, - "svg": 15120, - "▁reb": 15121, - "Customer": 15122, - "switch": 15123, - "обра": 15124, - "▁Championships": 15125, - "clo": 15126, - "atte": 15127, - "▁anymore": 15128, - "▁excellent": 15129, - "▁opportunity": 15130, - "▁Bahn": 15131, - "чин": 15132, - "eting": 15133, - "▁incident": 15134, - "tom": 15135, - "Pers": 15136, - "bben": 15137, - "ственной": 15138, - "их": 15139, - "router": 15140, - "▁newly": 15141, - "▁silence": 15142, - "▁GNU": 15143, - "▁Rails": 15144, - "▁Amb": 15145, - "▁Qual": 15146, - "▁Schaus": 15147, - "▁Sohn": 15148, - "▁ALL": 15149, - "▁royal": 15150, - "▁£": 15151, - "wię": 15152, - "▁entfer": 15153, - "▁Remove": 15154, - "▁hardly": 15155, - "Using": 15156, - "лог": 15157, - "▁Ich": 15158, - "▁derni": 15159, - "▁Connection": 15160, - "fish": 15161, - "▁Inform": 15162, - "▁Ener": 15163, - "roit": 15164, - "Bbb": 15165, - "ViewModel": 15166, - "Video": 15167, - "iley": 15168, - "▁много": 15169, - "▁Gem": 15170, - "▁compreh": 15171, - "enumerate": 15172, - "ulas": 15173, - "▁Bah": 15174, - "▁Yet": 15175, - "BR": 15176, - "хра": 15177, - "▁county": 15178, - "▁Hist": 15179, - "▁Гу": 15180, - "▁Ј": 15181, - "▁mari": 15182, - "▁Clar": 15183, - "Bitmap": 15184, - "▁Cz": 15185, - "▁mån": 15186, - "▁mere": 15187, - "▁musique": 15188, - "also": 15189, - "dates": 15190, - "▁DVD": 15191, - "▁gol": 15192, - "fony": 15193, - "▁Castle": 15194, - "▁фами": 15195, - "▁arrang": 15196, - "▁Business": 15197, - "▁Kaz": 15198, - "▁osc": 15199, - "▁secolo": 15200, - "▁affected": 15201, - "▁Health": 15202, - "reb": 15203, - "editor": 15204, - "▁owned": 15205, - "tl": 15206, - "▁ví": 15207, - "чних": 15208, - "кви": 15209, - "▁devient": 15210, - "Mutable": 15211, - "▁tegen": 15212, - "Register": 15213, - "єю": 15214, - "▁caracter": 15215, - "лли": 15216, - "▁nouvelle": 15217, - "oko": 15218, - "ichtet": 15219, - "▁evol": 15220, - "▁Hab": 15221, - "▁militar": 15222, - "▁puts": 15223, - "endif": 15224, - "▁Davis": 15225, - "▁Scotland": 15226, - "regular": 15227, - "▁Context": 15228, - "ispiel": 15229, - "▁Gallery": 15230, - "\",\r": 15231, - "▁arc": 15232, - "▁INFO": 15233, - "▁cod": 15234, - "дів": 15235, - "▁varchar": 15236, - "▁toujours": 15237, - "atial": 15238, - "▁hanno": 15239, - "▁профес": 15240, - "▁launched": 15241, - "▁населення": 15242, - "▁ton": 15243, - "aused": 15244, - "▁із": 15245, - "▁tö": 15246, - "▁Pur": 15247, - "▁olymp": 15248, - "ARN": 15249, - "óm": 15250, - "▁august": 15251, - "▁furn": 15252, - "▁Colomb": 15253, - "▁Staats": 15254, - "hora": 15255, - "▁мор": 15256, - "canvas": 15257, - "▁grave": 15258, - "▁composition": 15259, - "acja": 15260, - "▁которые": 15261, - "▁чо": 15262, - "General": 15263, - "ані": 15264, - "▁Johannes": 15265, - "кар": 15266, - "▁част": 15267, - "▁Васи": 15268, - "ssh": 15269, - "▁replacing": 15270, - "▁<>": 15271, - "ців": 15272, - "laus": 15273, - "eny": 15274, - "ähl": 15275, - "▁marg": 15276, - "cience": 15277, - "▁instruction": 15278, - "▁који": 15279, - "Editor": 15280, - "▁fundamental": 15281, - "mund": 15282, - "▁exceptions": 15283, - "▁plate": 15284, - "▁Lis": 15285, - "▁deren": 15286, - "prep": 15287, - "▁januari": 15288, - "Scope": 15289, - "ynast": 15290, - "rv": 15291, - "orsz": 15292, - "▁Tony": 15293, - "▁ді": 15294, - "▁одна": 15295, - "▁sab": 15296, - "oti": 15297, - "jel": 15298, - "▁generator": 15299, - "▁'.": 15300, - "▁sharp": 15301, - "▁только": 15302, - "▁accounts": 15303, - "▁že": 15304, - "▁foram": 15305, - "▁gouvern": 15306, - "TIME": 15307, - "▁Soviet": 15308, - "▁Gé": 15309, - "▁exped": 15310, - "▁ordinary": 15311, - "▁Conserv": 15312, - "▁compla": 15313, - "tei": 15314, - "▁captain": 15315, - "▁Samuel": 15316, - "▁Dark": 15317, - "▁він": 15318, - "▁delight": 15319, - "recht": 15320, - "dia": 15321, - "esses": 15322, - "ulp": 15323, - "шки": 15324, - "bez": 15325, - "▁detection": 15326, - "▁cookie": 15327, - "antry": 15328, - "Multi": 15329, - "oba": 15330, - "▁joy": 15331, - "▁safety": 15332, - "|^": 15333, - "pod": 15334, - "adém": 15335, - "▁Chron": 15336, - "▁Django": 15337, - "▁ehemal": 15338, - "kh": 15339, - "èle": 15340, - "▁poc": 15341, - "Bottom": 15342, - "launch": 15343, - "nem": 15344, - "▁GROUP": 15345, - "ního": 15346, - "▁Gib": 15347, - "sdk": 15348, - "BE": 15349, - "▁Gene": 15350, - "▁Staff": 15351, - "▁subsequent": 15352, - "icion": 15353, - "▁victory": 15354, - "▁canon": 15355, - "izar": 15356, - "izia": 15357, - "▁mate": 15358, - "▁layers": 15359, - "sudo": 15360, - "schule": 15361, - "periment": 15362, - "ület": 15363, - "ARCHAR": 15364, - "▁террито": 15365, - "▁measures": 15366, - "▁zou": 15367, - "opsis": 15368, - "нами": 15369, - "tbody": 15370, - "▁ese": 15371, - "sterdam": 15372, - "▁photo": 15373, - "ynchronous": 15374, - "setminus": 15375, - "▁loads": 15376, - "▁pleasure": 15377, - "▁meille": 15378, - "}\\,": 15379, - "qual": 15380, - "▁favour": 15381, - "▁rod": 15382, - "Der": 15383, - "рабо": 15384, - "▁pressed": 15385, - "rę": 15386, - "ieving": 15387, - "material": 15388, - "virt": 15389, - "▁capable": 15390, - "сло": 15391, - "ushed": 15392, - "▁побе": 15393, - "usetts": 15394, - "unsigned": 15395, - "ków": 15396, - "▁ov": 15397, - "egeben": 15398, - "▁applying": 15399, - "▁galax": 15400, - "▁Oracle": 15401, - "▁Stuttgart": 15402, - "Infl": 15403, - "achusetts": 15404, - "▁deel": 15405, - "lire": 15406, - "▁statunit": 15407, - "▁Politiker": 15408, - "▁beauty": 15409, - ")>": 15410, - "▁Columbia": 15411, - "▁zewnętrzne": 15412, - "▁програ": 15413, - "▁dx": 15414, - "cknow": 15415, - "▁dub": 15416, - "unächst": 15417, - "findViewById": 15418, - "▁Mand": 15419, - "áll": 15420, - "naire": 15421, - "▁destin": 15422, - "isting": 15423, - "aggi": 15424, - "chart": 15425, - "▁justice": 15426, - "Simple": 15427, - "▁unfortunately": 15428, - "ір": 15429, - "▁questa": 15430, - "▁Governor": 15431, - "яв": 15432, - "▁música": 15433, - "▁equipo": 15434, - "▁Dest": 15435, - "elect": 15436, - "StackTrace": 15437, - "зом": 15438, - "proc": 15439, - "entin": 15440, - "adora": 15441, - "▁Лю": 15442, - "▁registered": 15443, - "HL": 15444, - "facebook": 15445, - "▁storing": 15446, - "▁Currently": 15447, - "▁quadr": 15448, - "Standard": 15449, - "trim": 15450, - "ears": 15451, - "sender": 15452, - "▁Vas": 15453, - "▁edific": 15454, - "▁Bür": 15455, - "▁Country": 15456, - "tha": 15457, - ";\"": 15458, - "nor": 15459, - "▁Doctor": 15460, - "rument": 15461, - "Gen": 15462, - "▁Buen": 15463, - "rade": 15464, - "▁kun": 15465, - "navigation": 15466, - "Pay": 15467, - "▁captured": 15468, - "▁struck": 15469, - "venir": 15470, - "ément": 15471, - "▁Tree": 15472, - "▁xx": 15473, - "▁narr": 15474, - "льного": 15475, - "▁installing": 15476, - "▁association": 15477, - "▁inserted": 15478, - "erner": 15479, - "validate": 15480, - "▁lut": 15481, - "▁glo": 15482, - "▁technology": 15483, - "▁Place": 15484, - "$?": 15485, - "▁zv": 15486, - "слі": 15487, - "EP": 15488, - "▁atmos": 15489, - "ugo": 15490, - "ért": 15491, - "▁Werk": 15492, - "▁%}": 15493, - "tele": 15494, - "Span": 15495, - "▁Raj": 15496, - "▁Personen": 15497, - "▁Cant": 15498, - "▁combat": 15499, - "▁observation": 15500, - "parameter": 15501, - "▁agreed": 15502, - "pur": 15503, - "▁shadow": 15504, - "▁gł": 15505, - "Keys": 15506, - "Cred": 15507, - "ouri": 15508, - "▁pale": 15509, - "ické": 15510, - "▁Week": 15511, - "▁Prime": 15512, - ">.": 15513, - "Initial": 15514, - "▁один": 15515, - "▁'',": 15516, - "▁учи": 15517, - "▁Inv": 15518, - "cola": 15519, - "cible": 15520, - "▁Theatre": 15521, - "▁bem": 15522, - "▁satisfy": 15523, - "xl": 15524, - "▁разви": 15525, - "▁pixel": 15526, - "lán": 15527, - "▁twee": 15528, - "çon": 15529, - "нения": 15530, - "▁AT": 15531, - "ège": 15532, - "▁Mort": 15533, - "▁mysq": 15534, - "ften": 15535, - "▁пес": 15536, - "éma": 15537, - "▁Services": 15538, - "customer": 15539, - "▁AWS": 15540, - "ът": 15541, - "▁Ach": 15542, - "%.": 15543, - "▁clarify": 15544, - "▁университе": 15545, - "xture": 15546, - "umi": 15547, - "▁så": 15548, - "▁Pel": 15549, - "serial": 15550, - "URI": 15551, - "▁rg": 15552, - "▁соста": 15553, - "chestra": 15554, - "].[": 15555, - "wen": 15556, - "▁Londres": 15557, - "▁anys": 15558, - "DataSource": 15559, - "▁районе": 15560, - "▁rein": 15561, - "▁metadata": 15562, - "umble": 15563, - "arbeit": 15564, - "hner": 15565, - "cient": 15566, - "▁norte": 15567, - "▁она": 15568, - "▁scored": 15569, - "▁ray": 15570, - "▁февра": 15571, - "▁protagon": 15572, - "▁Sac": 15573, - "▁commonly": 15574, - "LinearLayout": 15575, - "▁applic": 15576, - "▁мая": 15577, - "За": 15578, - "▁accessible": 15579, - "iewer": 15580, - "flag": 15581, - "▁Rück": 15582, - "äu": 15583, - "▁erano": 15584, - "▁authentic": 15585, - "▁Ry": 15586, - "▁неско": 15587, - "▁embargo": 15588, - "▁dry": 15589, - "▁reasonable": 15590, - "▁Module": 15591, - "▁acceler": 15592, - "▁interview": 15593, - "▁Creek": 15594, - "▁alpha": 15595, - "serie": 15596, - "They": 15597, - "ючи": 15598, - "▁Hof": 15599, - "▁CR": 15600, - "modal": 15601, - "▁sequences": 15602, - "closed": 15603, - ")}$": 15604, - "▁Чер": 15605, - "▁ORDER": 15606, - "Rightarrow": 15607, - "hausen": 15608, - "}}_": 15609, - "▁també": 15610, - "▁magnetic": 15611, - "▁McC": 15612, - "▁winning": 15613, - "underline": 15614, - "▁Billboard": 15615, - "naio": 15616, - "▁liqu": 15617, - "displaystyle": 15618, - "timeout": 15619, - "▁considerable": 15620, - "▁eben": 15621, - "ifferent": 15622, - "anu": 15623, - "▁Сов": 15624, - "[(": 15625, - "▁:-)": 15626, - "leitung": 15627, - "formed": 15628, - "▁Manager": 15629, - "▁onclick": 15630, - "TY": 15631, - "тах": 15632, - "CV": 15633, - "runtime": 15634, - "poque": 15635, - "▁Ло": 15636, - "Temp": 15637, - "loaded": 15638, - "▁!==": 15639, - "▁singer": 15640, - "far": 15641, - "▁Comple": 15642, - "▁Österreich": 15643, - "Policy": 15644, - "▁worker": 15645, - "Wrapper": 15646, - "obi": 15647, - "▁discussed": 15648, - "▁buy": 15649, - "▁января": 15650, - "▁Din": 15651, - "▁ged": 15652, - "ској": 15653, - "Europe": 15654, - "▁tall": 15655, - "hos": 15656, - "лаго": 15657, - "▁Block": 15658, - "▁identified": 15659, - "ListView": 15660, - "▁attempting": 15661, - "▁typical": 15662, - "psum": 15663, - "oster": 15664, - "▁журна": 15665, - "Pe": 15666, - "merce": 15667, - "▁unexpected": 15668, - "hui": 15669, - "letter": 15670, - "▁nuevo": 15671, - "▁або": 15672, - "▁VALUES": 15673, - "▁Iz": 15674, - "Flags": 15675, - "▁TRUE": 15676, - "ización": 15677, - "▁growing": 15678, - "estre": 15679, - "▁poly": 15680, - "▁Stone": 15681, - "▁VIII": 15682, - "▁localhost": 15683, - "ählt": 15684, - "▁embedded": 15685, - "jdbc": 15686, - "▁convention": 15687, - "▁scala": 15688, - "сок": 15689, - "▁analog": 15690, - "▁\"+": 15691, - "цю": 15692, - "occ": 15693, - "▁litt": 15694, - "PN": 15695, - "▁актив": 15696, - "attributes": 15697, - "▁Ferd": 15698, - "▁azure": 15699, - "ști": 15700, - "ños": 15701, - "ping": 15702, - "▁teacher": 15703, - "}&": 15704, - "ipe": 15705, - "▁Nob": 15706, - "▁има": 15707, - "Bind": 15708, - "▁magic": 15709, - "▁Transport": 15710, - "ixel": 15711, - "▁computed": 15712, - "agna": 15713, - "erst": 15714, - "HA": 15715, - "Wait": 15716, - "▁authors": 15717, - "▁;)": 15718, - "clam": 15719, - "▁Pennsylvan": 15720, - "▁drug": 15721, - "▁vain": 15722, - "▁employed": 15723, - "▁individuals": 15724, - "▁ange": 15725, - "utat": 15726, - "▁$-": 15727, - "correct": 15728, - "▁experiments": 15729, - "Argument": 15730, - "▁IB": 15731, - "▁père": 15732, - "▁Brian": 15733, - "berger": 15734, - "Mac": 15735, - "iast": 15736, - "Perm": 15737, - "Cast": 15738, - "▁{};": 15739, - "▁Student": 15740, - "▁statt": 15741, - "algebra": 15742, - "▁equals": 15743, - "▁projet": 15744, - "▁président": 15745, - "ActivityThread": 15746, - "▁einz": 15747, - "enia": 15748, - "rez": 15749, - "essional": 15750, - "▁августа": 15751, - "override": 15752, - "news": 15753, - "▁planet": 15754, - "nn": 15755, - "▁Wis": 15756, - "твер": 15757, - "▁Valid": 15758, - "▁Gef": 15759, - "град": 15760, - "▁eig": 15761, - "antom": 15762, - "▁Meister": 15763, - "flags": 15764, - "fficiale": 15765, - "шая": 15766, - "-,": 15767, - "ationen": 15768, - "mouse": 15769, - "standard": 15770, - "Single": 15771, - "▁bol": 15772, - "isis": 15773, - "▁fruit": 15774, - "course": 15775, - "itants": 15776, - "▁étaient": 15777, - "TextField": 15778, - "▁фон": 15779, - "▁aircraft": 15780, - "▁ISSN": 15781, - "▁western": 15782, - "▁representing": 15783, - "Esp": 15784, - "▁Else": 15785, - "▁sizes": 15786, - "▁satisfied": 15787, - "otos": 15788, - "UD": 15789, - "Final": 15790, - "ój": 15791, - "ève": 15792, - "▁Roy": 15793, - "ffen": 15794, - "▁salt": 15795, - "▁Label": 15796, - "Sk": 15797, - "▁кре": 15798, - "▁Литература": 15799, - "▁см": 15800, - "Attributes": 15801, - "aye": 15802, - "ськ": 15803, - "▁высо": 15804, - "-)": 15805, - "oses": 15806, - "calcul": 15807, - "▁Cannot": 15808, - "Generic": 15809, - "emo": 15810, - "▁Autor": 15811, - "лён": 15812, - "лага": 15813, - "vote": 15814, - "licates": 15815, - "rus": 15816, - "éli": 15817, - "opf": 15818, - "atique": 15819, - "scala": 15820, - "▁Ohio": 15821, - "▁Britann": 15822, - "▁bef": 15823, - "▁Евро": 15824, - "▁Career": 15825, - "isée": 15826, - "ót": 15827, - "bose": 15828, - "▁Бер": 15829, - "▁Controller": 15830, - "pole": 15831, - "▁allen": 15832, - "▁hack": 15833, - "▁extent": 15834, - "▁calci": 15835, - "Mer": 15836, - "▁summary": 15837, - "Mart": 15838, - "▁historical": 15839, - "imat": 15840, - "bud": 15841, - "▁FOR": 15842, - "export": 15843, - "edi": 15844, - "Mapping": 15845, - "▁Ay": 15846, - "▁Ruby": 15847, - "▁definitions": 15848, - "▁{$": 15849, - "▁yours": 15850, - "rias": 15851, - "Touch": 15852, - "▁Gaz": 15853, - "▁Autom": 15854, - "▁истори": 15855, - "▁delen": 15856, - "▁Kinder": 15857, - "}}%": 15858, - "��performing": 15859, - "FR": 15860, - "▁Sig": 15861, - "▁Brad": 15862, - "bras": 15863, - "▁Jar": 15864, - "pkg": 15865, - "wr": 15866, - "▁Pays": 15867, - "NC": 15868, - "▁opposed": 15869, - "Try": 15870, - "▁везе": 15871, - "▁Bog": 15872, - "▁writes": 15873, - "▁stories": 15874, - "▁mater": 15875, - "▁stagione": 15876, - "▁sty": 15877, - "▁compatible": 15878, - "heast": 15879, - "▁Guy": 15880, - "egründ": 15881, - "▁identifier": 15882, - "▁heads": 15883, - "пози": 15884, - "▁stup": 15885, - "▁tf": 15886, - "▁још": 15887, - "▁Hugh": 15888, - "▁cards": 15889, - "ovy": 15890, - "▁Toast": 15891, - "allas": 15892, - "▁públic": 15893, - "▁assumes": 15894, - "▁чемпиона": 15895, - "ycler": 15896, - "▁Junior": 15897, - "▁Fich": 15898, - "▁estimated": 15899, - "zerw": 15900, - "dialog": 15901, - "шин": 15902, - "shell": 15903, - "▁них": 15904, - "▁pitch": 15905, - "дол": 15906, - "outube": 15907, - "▁Santi": 15908, - "OnClickListener": 15909, - "▁Magyar": 15910, - "▁vue": 15911, - "ião": 15912, - "▁`#": 15913, - "collect": 15914, - "▁Rou": 15915, - "analysis": 15916, - "istrzost": 15917, - "▁Digital": 15918, - "▁crist": 15919, - "riere": 15920, - "▁campo": 15921, - "Us": 15922, - "▁circa": 15923, - "▁Component": 15924, - "▁NSString": 15925, - "pd": 15926, - "▁prince": 15927, - "▁invoke": 15928, - "▁Marine": 15929, - "Allow": 15930, - "estic": 15931, - "ристи": 15932, - "bone": 15933, - "туры": 15934, - "▁passion": 15935, - "áció": 15936, - "▁orn": 15937, - "вед": 15938, - "▁invari": 15939, - "▁ні": 15940, - "Remove": 15941, - "encies": 15942, - "ilib": 15943, - "▁Director": 15944, - "\"\"": 15945, - "▁Conse": 15946, - "googleapis": 15947, - "ók": 15948, - "▁Укра": 15949, - "▁Having": 15950, - "Domain": 15951, - "ierz": 15952, - "нологи": 15953, - "Cho": 15954, - "undefined": 15955, - "alloc": 15956, - "▁pied": 15957, - "▁fraction": 15958, - "bia": 15959, - "▁поло": 15960, - "ugno": 15961, - "minister": 15962, - "▁principale": 15963, - "▁refused": 15964, - "browser": 15965, - "*,": 15966, - "▁Hospital": 15967, - "▁universal": 15968, - "▁Ernst": 15969, - "who": 15970, - "▁Gard": 15971, - "'_": 15972, - "conde": 15973, - "▁[{": 15974, - "sob": 15975, - "▁Crit": 15976, - "▁декабря": 15977, - "▁punto": 15978, - "▁eingesetzt": 15979, - "▁tör": 15980, - "▁Ni": 15981, - "▁worry": 15982, - "▁legend": 15983, - "▁були": 15984, - "▁komm": 15985, - "rijk": 15986, - "effect": 15987, - "Ori": 15988, - "RES": 15989, - "▁Peters": 15990, - "▁Baron": 15991, - "▁Got": 15992, - "▁honest": 15993, - "äre": 15994, - "ász": 15995, - "▁noble": 15996, - "▁conclusion": 15997, - "▁formatting": 15998, - "▁otto": 15999, - "▁deleg": 16000, - "мб": 16001, - "ptop": 16002, - "▁sends": 16003, - "urname": 16004, - "▁festival": 16005, - ",‎": 16006, - "рус": 16007, - "▁doch": 16008, - "subject": 16009, - "▁careful": 16010, - "quent": 16011, - "▁Load": 16012, - "temperaturen": 16013, - "▁rue": 16014, - "Memory": 16015, - "ța": 16016, - "iona": 16017, - "▁dentro": 16018, - "▁begann": 16019, - "▁Aqu": 16020, - "▁scientific": 16021, - "kań": 16022, - "лок": 16023, - "elde": 16024, - "▁Those": 16025, - "quier": 16026, - "actér": 16027, - "▁Auflage": 16028, - ")'": 16029, - "▁gradient": 16030, - "integer": 16031, - "▁Import": 16032, - "SK": 16033, - "▁Status": 16034, - "▁explo": 16035, - "AE": 16036, - "Shell": 16037, - "▁Paulo": 16038, - ".»": 16039, - "}'": 16299, - "havior": 16300, - "lei": 16301, - "ulf": 16302, - "▁geometry": 16303, - "prev": 16304, - "empl": 16305, - "▁Lé": 16306, - "anson": 16307, - "▁Alice": 16308, - "prototype": 16309, - "READ": 16310, - "icular": 16311, - "▁бі": 16312, - "▁deutsche": 16313, - "▁Represent": 16314, - "sites": 16315, - "▁Mean": 16316, - "▁diss": 16317, - "▁Zur": 16318, - "▁през": 16319, - "PAR": 16320, - "▁'#": 16321, - "▁Dra": 16322, - "сон": 16323, - "▁steht": 16324, - "markt": 16325, - "▁ease": 16326, - "Drawing": 16327, - "=%": 16328, - "Stop": 16329, - "▁serving": 16330, - "▁także": 16331, - "▁DNS": 16332, - "▁literal": 16333, - "Die": 16334, - "▁вос": 16335, - "▁senior": 16336, - "acion": 16337, - "▁ubuntu": 16338, - "▁Frankfurt": 16339, - "▁Sunday": 16340, - "áb": 16341, - "▁journey": 16342, - "issa": 16343, - "berry": 16344, - "▁sep": 16345, - "▁ion": 16346, - "wert": 16347, - "ország": 16348, - "serve": 16349, - "▁Milano": 16350, - "▁века": 16351, - "рах": 16352, - "▁июля": 16353, - "▁manera": 16354, - "▁stations": 16355, - "▁adopted": 16356, - "▁anybody": 16357, - "VERSION": 16358, - "FE": 16359, - "dorf": 16360, - "...,": 16361, - "▁образова": 16362, - "Logger": 16363, - "фициаль": 16364, - "WRITE": 16365, - "▁ham": 16366, - "▁Future": 16367, - "oten": 16368, - "▁AG": 16369, - "▁trained": 16370, - "▁Nich": 16371, - "▁university": 16372, - "▁Olympics": 16373, - "▁doit": 16374, - "▁cultural": 16375, - "Conf": 16376, - "▁Conference": 16377, - "orno": 16378, - "▁MP": 16379, - "▁bou": 16380, - "cin": 16381, - "High": 16382, - "annte": 16383, - "▁displaying": 16384, - "▁chapter": 16385, - "▁Frauen": 16386, - "▁realized": 16387, - "▁attempted": 16388, - "▁preferred": 16389, - "Dat": 16390, - "▁trouve": 16391, - "▁intention": 16392, - "▁Notice": 16393, - "timestamp": 16394, - "*(": 16395, - "▁Ша": 16396, - "anas": 16397, - "cla": 16398, - "isz": 16399, - "tbl": 16400, - "Arr": 16401, - "▁inverse": 16402, - "▁terrible": 16403, - "▁occupied": 16404, - "JAX": 16405, - "<-": 16406, - "▁Philosoph": 16407, - "▁Corps": 16408, - "builder": 16409, - "▁begins": 16410, - "▁census": 16411, - ".’": 16412, - "▁proven": 16413, - "metric": 16414, - "▁increases": 16415, - "wich": 16416, - "▁ABC": 16417, - "projects": 16418, - "▁Thor": 16419, - "▁confidence": 16420, - "▁ufficiale": 16421, - "elm": 16422, - "▁garden": 16423, - "▁robust": 16424, - "▁così": 16425, - "iedz": 16426, - "▁Islam": 16427, - "▁Address": 16428, - "▁divide": 16429, - "▁Eu": 16430, - "catal": 16431, - "detail": 16432, - "ependant": 16433, - "fg": 16434, - "▁bew": 16435, - "▁fis": 16436, - "▁BO": 16437, - "▁wsp": 16438, - "▁pipeline": 16439, - "hd": 16440, - "▁Session": 16441, - "länd": 16442, - "iveau": 16443, - "estr": 16444, - "▁particle": 16445, - "▁laravel": 16446, - "pic": 16447, - "▁nau": 16448, - "▁fins": 16449, - "▁Vil": 16450, - "▁fus": 16451, - "▁quasi": 16452, - "operation": 16453, - "▁aller": 16454, - "▁analy": 16455, - "▁Он": 16456, - "▁Mes": 16457, - "▁опера": 16458, - "▁handled": 16459, - "▁deprec": 16460, - "tto": 16461, - "▁Ek": 16462, - "▁stran": 16463, - "▁anglais": 16464, - "jure": 16465, - "▁Silver": 16466, - "▁closely": 16467, - "enkins": 16468, - "anos": 16469, - "sted": 16470, - "▁сентября": 16471, - "brand": 16472, - "ньо": 16473, - "▁présent": 16474, - "rok": 16475, - "mount": 16476, - "▁Anthony": 16477, - "▁Furthermore": 16478, - "inha": 16479, - "▁архи": 16480, - "▁разли": 16481, - "▁октября": 16482, - "▁pint": 16483, - "ný": 16484, - "pts": 16485, - "▁italien": 16486, - "▁реги": 16487, - "лез": 16488, - "дина": 16489, - "atherine": 16490, - "Internal": 16491, - "Question": 16492, - "▁settlement": 16493, - "▁Все": 16494, - "▁folders": 16495, - "дри": 16496, - "▁valor": 16497, - "▁Miller": 16498, - "▁Assert": 16499, - "▁patient": 16500, - "▁Nieder": 16501, - "▁EP": 16502, - "▁Agr": 16503, - "▁onde": 16504, - "▁scop": 16505, - "sequence": 16506, - "▁PL": 16507, - "▁seek": 16508, - "javase": 16509, - "▁Vector": 16510, - "▁ná": 16511, - "▁categoría": 16512, - "clone": 16513, - "NR": 16514, - "available": 16515, - "▁Besch": 16516, - "▁eclipse": 16517, - "wicklung": 16518, - "deploy": 16519, - "enie": 16520, - "▁\")": 16521, - "äst": 16522, - "▁sync": 16523, - "CODE": 16524, - "▁Че": 16525, - "▁floating": 16526, - "/`": 16527, - "▁retired": 16528, - "deb": 16529, - "▁particul": 16530, - "▁collected": 16531, - "▁downloaded": 16532, - "nice": 16533, - "▁Buffer": 16534, - "▁Account": 16535, - "▁maggio": 16536, - "▁реда": 16537, - "▁sales": 16538, - "▁statunitense": 16539, - "▁Ki": 16540, - "▁Ferr": 16541, - "Lock": 16542, - "▁Isabel": 16543, - "clar": 16544, - "▁pov": 16545, - "atra": 16546, - "▁Frau": 16547, - "▁sorting": 16548, - "▁phrase": 16549, - "▁апреля": 16550, - "▁деятель": 16551, - "▁André": 16552, - "definition": 16553, - "writing": 16554, - "éré": 16555, - "щу": 16556, - "▁Ord": 16557, - "▁rum": 16558, - "▁Turk": 16559, - "▁Ivan": 16560, - "theless": 16561, - "▁ги": 16562, - "▁sake": 16563, - "▁Based": 16564, - "deck": 16565, - "orus": 16566, - "▁tutti": 16567, - "▁blan": 16568, - "▁Пу": 16569, - "Detail": 16570, - "▁Но": 16571, - "▁Sky": 16572, - "▁près": 16573, - "мой": 16574, - "coln": 16575, - "ческой": 16576, - "eti": 16577, - "▁arrow": 16578, - "▁Cha": 16579, - "chmark": 16580, - "œur": 16581, - "fab": 16582, - "куль": 16583, - "GridView": 16584, - "▁Background": 16585, - "sn": 16586, - "▁seguito": 16587, - "▁nic": 16588, - "cou": 16589, - "тів": 16590, - "▁bzw": 16591, - "addEventListener": 16592, - "sync": 16593, - "azzo": 16594, - "abstract": 16595, - "assets": 16596, - "▁Dru": 16597, - "зд": 16598, - "ordnet": 16599, - "▁bigger": 16600, - "▁initialized": 16601, - "каз": 16602, - "ogene": 16603, - "viously": 16604, - "▁guid": 16605, - "scheidung": 16606, - "▁Zent": 16607, - "▁frames": 16608, - "rieben": 16609, - "▁issued": 16610, - "▁dow": 16611, - "▁describes": 16612, - "ilst": 16613, - "▁criteria": 16614, - "▁gentleman": 16615, - "Basic": 16616, - "nez": 16617, - "Dev": 16618, - "Move": 16619, - "▁estaba": 16620, - "▁settembre": 16621, - "circle": 16622, - "▁fais": 16623, - "▁myst": 16624, - "▁archiv": 16625, - "dynamic": 16626, - "jà": 16627, - "itas": 16628, - "▁який": 16629, - "▁dor": 16630, - "▁Amazon": 16631, - "▁neces": 16632, - "▁Marcel": 16633, - "▁ella": 16634, - "рок": 16635, - "▁Pennsylvania": 16636, - "cular": 16637, - "Pack": 16638, - "itage": 16639, - "▁Burn": 16640, - "▁RO": 16641, - "▁они": 16642, - "~$": 16643, - "TeX": 16644, - "assign": 16645, - "▁beat": 16646, - "idense": 16647, - "acent": 16648, - "Alert": 16649, - "▁strateg": 16650, - "▁månaden": 16651, - "LOC": 16652, - "▁catalog": 16653, - "printStackTrace": 16654, - "()).": 16655, - "usted": 16656, - "▁Framework": 16657, - "ECK": 16658, - "▁até": 16659, - "Framework": 16660, - "▁attacks": 16661, - "▁Bert": 16662, - "▁тран": 16663, - ":%": 16664, - "arsi": 16665, - "notation": 16666, - "▁logical": 16667, - "weet": 16668, - "▁visited": 16669, - "bru": 16670, - "▁surprise": 16671, - "^^": 16672, - "inale": 16673, - "remote": 16674, - "'},": 16675, - "Syntax": 16676, - "iane": 16677, - "onnen": 16678, - "▁breaking": 16679, - "parser": 16680, - "apk": 16681, - "▁Miguel": 16682, - "▁§": 16683, - "▁acting": 16684, - "▁gebru": 16685, - "AtIndex": 16686, - "ються": 16687, - "▁offers": 16688, - "▁prac": 16689, - "▁grant": 16690, - "ternoon": 16691, - "▁acquired": 16692, - "▁Ny": 16693, - "▁comma": 16694, - "ník": 16695, - "▁Step": 16696, - "inners": 16697, - "▁SA": 16698, - "▁wat": 16699, - "days": 16700, - "▁rectangle": 16701, - "dar": 16702, - "▁trac": 16703, - "▁Indones": 16704, - "▁feedback": 16705, - "▁breaks": 16706, - "partition": 16707, - "icans": 16708, - "▁Notices": 16709, - "▁improved": 16710, - "phan": 16711, - "▁differential": 16712, - "scripts": 16713, - "▁XIII": 16714, - "▁Labor": 16715, - "▁precision": 16716, - "▁seed": 16717, - "bundle": 16718, - "idents": 16719, - "hre": 16720, - "▁Douglas": 16721, - "uld": 16722, - "▁secondary": 16723, - "▁brig": 16724, - "▁confirmed": 16725, - "▁claims": 16726, - "Role": 16727, - "▁Jewish": 16728, - "▁před": 16729, - "▁hotel": 16730, - "▁compte": 16731, - "▁recursive": 16732, - "](#)": 16733, - "▁rotate": 16734, - "▁chrome": 16735, - "inea": 16736, - "%;\r": 16737, - "▁Environment": 16738, - "platz": 16739, - "▁Single": 16740, - "▁sevent": 16741, - "▁posting": 16742, - "▁dealing": 16743, - "parameters": 16744, - "граф": 16745, - "Authentication": 16746, - "touch": 16747, - "Az": 16748, - "▁gray": 16749, - "encing": 16750, - "boldmath": 16751, - "▁сайте": 16752, - "▁Za": 16753, - "anje": 16754, - "▁polar": 16755, - "▁ули": 16756, - "kil": 16757, - "▁hover": 16758, - "▁REST": 16759, - "▁Come": 16760, - "jb": 16761, - "▁Georgia": 16762, - "▁Estado": 16763, - "OutputStream": 16764, - "ћи": 16765, - "▁dump": 16766, - "▁Age": 16767, - "▁swo": 16768, - "mobile": 16769, - "occup": 16770, - "шего": 16771, - "▁constitution": 16772, - "good": 16773, - "aku": 16774, - "▁анг": 16775, - "ieck": 16776, - "▁Psych": 16777, - "▁roots": 16778, - "▁vest": 16779, - "▁годах": 16780, - "▁República": 16781, - "▁pian": 16782, - "igration": 16783, - "▁préc": 16784, - "▁generates": 16785, - "LY": 16786, - "(`": 16787, - "▁=~": 16788, - "шения": 16789, - "▁Rah": 16790, - "▁connecting": 16791, - "ží": 16792, - "▁fő": 16793, - "▁appel": 16794, - "▁Railway": 16795, - "гли": 16796, - "▁développ": 16797, - "▁apo": 16798, - "fran": 16799, - "▁immediate": 16800, - "вого": 16801, - "Runner": 16802, - "äg": 16803, - "Something": 16804, - "▁généra": 16805, - "EventArgs": 16806, - "inction": 16807, - "gly": 16808, - "▁Due": 16809, - "▁prost": 16810, - "▁referring": 16811, - "▁jog": 16812, - "▁executable": 16813, - "▁Dream": 16814, - "acs": 16815, - "▁Cole": 16816, - "ampf": 16817, - "▁Bis": 16818, - "▁июня": 16819, - "lieder": 16820, - "тек": 16821, - "▁vb": 16822, - "▁mom": 16823, - "▁:(": 16824, - "▁dernier": 16825, - "'=>": 16826, - "▁этого": 16827, - "▁neue": 16828, - "▁Ча": 16829, - "▁weitere": 16830, - "▁alleg": 16831, - "▁reality": 16832, - "▁judge": 16833, - "▁Balt": 16834, - "▁thin": 16835, - "▁Ged": 16836, - "ieval": 16837, - "mx": 16838, - "ціональ": 16839, - "▁выпу": 16840, - "▁IX": 16841, - "▁blind": 16842, - "▁Motor": 16843, - "▁ша": 16844, - "▁approximation": 16845, - "dam": 16846, - "▁fog": 16847, - "кор": 16848, - "▁Writ": 16849, - "▁ling": 16850, - "▁писа": 16851, - "▁Mars": 16852, - "otti": 16853, - "Enum": 16854, - "▁Trib": 16855, - "▁merc": 16856, - "zung": 16857, - "vanced": 16858, - "cfg": 16859, - "нах": 16860, - "schen": 16861, - "\"].": 16862, - "bek": 16863, - "▁ster": 16864, - "jp": 16865, - "▁Rap": 16866, - "▁recording": 16867, - "▁peint": 16868, - "▁lets": 16869, - "änge": 16870, - ">\";": 16871, - "▁місце": 16872, - "▁caval": 16873, - "▁CSV": 16874, - "▁entstand": 16875, - "▁helper": 16876, - "endet": 16877, - "▁Gram": 16878, - "▁Diego": 16879, - "▁Bishop": 16880, - "TAG": 16881, - "▁ecc": 16882, - "▁Een": 16883, - "▁AV": 16884, - "City": 16885, - "▁Guide": 16886, - "hind": 16887, - "rical": 16888, - "▁Основ": 16889, - "Bus": 16890, - "▁zunächst": 16891, - "▁tick": 16892, - "▁Colonel": 16893, - "Thanks": 16894, - "▁ferm": 16895, - "▁granted": 16896, - "▁threshold": 16897, - "omorphic": 16898, - "▁Hun": 16899, - "enis": 16900, - "▁прав": 16901, - "▁які": 16902, - "PG": 16903, - "▁ws": 16904, - "▁technical": 16905, - "estro": 16906, - "klär": 16907, - "vars": 16908, - "ocrat": 16909, - "▁општи": 16910, - "onso": 16911, - "iba": 16912, - "▁Save": 16913, - "▁programa": 16914, - "▁въ": 16915, - "▁invån": 16916, - ">()": 16917, - "▁mejor": 16918, - "▁слова": 16919, - "▁replacement": 16920, - "▁impr": 16921, - "▁Francesco": 16922, - "▁Hotel": 16923, - "▁UPDATE": 16924, - "▁музы": 16925, - "ugs": 16926, - "vard": 16927, - "▁faz": 16928, - "inton": 16929, - "▁arts": 16930, - "▁Ky": 16931, - "▁Ils": 16932, - "▁sera": 16933, - "▁Volume": 16934, - "▁giugno": 16935, - "▁asym": 16936, - "▁Pir": 16937, - "▁NAS": 16938, - "▁Tam": 16939, - "ěl": 16940, - "Sequ": 16941, - "kmal": 16942, - "▁Eins": 16943, - "▁компа": 16944, - "obe": 16945, - "oor": 16946, - "▁heap": 16947, - "ctl": 16948, - "▁separately": 16949, - "reader": 16950, - "▁significantly": 16951, - "▁Lag": 16952, - "notes": 16953, - "▁sele": 16954, - "▁dedicated": 16955, - "▁Host": 16956, - "choice": 16957, - "wing": 16958, - "▁Titel": 16959, - "▁befindet": 16960, - "large": 16961, - "▁conten": 16962, - "JavaScript": 16963, - "▁deser": 16964, - "▁Gordon": 16965, - "спе": 16966, - "▁patri": 16967, - "▁Random": 16968, - "▁Returns": 16969, - "ым": 16970, - "рома": 16971, - "▁Studies": 16972, - "Sl": 16973, - "▁frü": 16974, - "TEXT": 16975, - "inate": 16976, - "▁Tol": 16977, - "▁everywhere": 16978, - "arta": 16979, - "▁orbit": 16980, - "▁Aires": 16981, - "▁Iss": 16982, - "▁też": 16983, - "▁diverse": 16984, - "▁numeric": 16985, - "maz": 16986, - "▁mise": 16987, - "▁battery": 16988, - "▁Akadem": 16989, - "нение": 16990, - "▁simultane": 16991, - "▁Dead": 16992, - "▁clust": 16993, - "▁otro": 16994, - "▁cerca": 16995, - "()`,": 16996, - "roz": 16997, - "ăt": 16998, - "▁MO": 16999, - "riften": 17000, - "important": 17001, - "▁jeho": 17002, - "▁findViewById": 17003, - "▁consequence": 17004, - "▁measured": 17005, - "ishes": 17006, - "▁sze": 17007, - "iendo": 17008, - "▁Wahl": 17009, - "strip": 17010, - "ARD": 17011, - "▁opacity": 17012, - "WORD": 17013, - "▁Ві": 17014, - "▁Location": 17015, - "rai": 17016, - "пен": 17017, - "▁rif": 17018, - "aussian": 17019, - "FileName": 17020, - "▁disco": 17021, - "ilen": 17022, - "▁vagy": 17023, - "licity": 17024, - "Border": 17025, - "▁Track": 17026, - "бом": 17027, - "fact": 17028, - "oka": 17029, - "▁gior": 17030, - "▁XVII": 17031, - "▁där": 17032, - "Site": 17033, - "ało": 17034, - "ská": 17035, - "▁pixels": 17036, - "vity": 17037, - "jQuery": 17038, - "▁sculpt": 17039, - "▁cargo": 17040, - "▁directive": 17041, - "▁wal": 17042, - "▁conna": 17043, - "▁Through": 17044, - "▁этом": 17045, - "Static": 17046, - "omsnitt": 17047, - "▁rund": 17048, - "▁claimed": 17049, - "зня": 17050, - "sha": 17051, - "▁rag": 17052, - "crement": 17053, - "▁fünf": 17054, - "▁rival": 17055, - "rin": 17056, - "slash": 17057, - "▁thirty": 17058, - "sleep": 17059, - "ологи": 17060, - "SM": 17061, - "gate": 17062, - "izations": 17063, - "vik": 17064, - "▁bless": 17065, - "▁Illinois": 17066, - "▁TE": 17067, - "uting": 17068, - "▁solving": 17069, - "GER": 17070, - "▁XIV": 17071, - "▁Indians": 17072, - "express": 17073, - "▁Heil": 17074, - "▁mujer": 17075, - "▁invånare": 17076, - "']);": 17077, - "▁aur": 17078, - "boost": 17079, - "GO": 17080, - "▁nin": 17081, - "tok": 17082, - "god": 17083, - "oter": 17084, - ")$$": 17085, - "▁descend": 17086, - "рю": 17087, - "▁Language": 17088, - "▁diver": 17089, - "▁Assuming": 17090, - "▁frequent": 17091, - "чні": 17092, - "▁Biography": 17093, - ",[": 17094, - "urm": 17095, - "▁walked": 17096, - "▁federal": 17097, - "▁Michigan": 17098, - "▁facts": 17099, - "▁Integr": 17100, - "LES": 17101, - "▁Alan": 17102, - "▁coup": 17103, - "Ber": 17104, - "▁particles": 17105, - "ће": 17106, - "Inflater": 17107, - "+(": 17108, - "Bound": 17109, - "▁Sü": 17110, - "Audio": 17111, - "citet": 17112, - "yect": 17113, - "▁nr": 17114, - "xe": 17115, - "▁Brun": 17116, - "▁_,": 17117, - "avor": 17118, - "▁discipl": 17119, - "alm": 17120, - "▁ноября": 17121, - "▁SSL": 17122, - "▁Kaiser": 17123, - "▁recher": 17124, - "ygon": 17125, - "▁regardless": 17126, - "▁configur": 17127, - "▁unnecess": 17128, - "▁Clark": 17129, - "PHP": 17130, - "▁FALSE": 17131, - "▁pad": 17132, - "$}": 17133, - "▁valu": 17134, - "▁disease": 17135, - "▁maior": 17136, - "▁hommes": 17137, - "▁Edition": 17138, - "slant": 17139, - "▁ending": 17140, - "▁settled": 17141, - "urus": 17142, - "hed": 17143, - "Pattern": 17144, - "▁година": 17145, - "▁Philadel": 17146, - "tikzpicture": 17147, - "▁coal": 17148, - "▁sede": 17149, - "▁satisfies": 17150, - "▁trim": 17151, - "▁bat": 17152, - "▁américain": 17153, - "▁luglio": 17154, - "▁поча": 17155, - "ffff": 17156, - "▁Target": 17157, - "generate": 17158, - "▁Zie": 17159, - "ția": 17160, - "▁gard": 17161, - "▁workers": 17162, - "▁Job": 17163, - "▁urban": 17164, - "ahlen": 17165, - "▁Building": 17166, - "▁neu": 17167, - "▁chron": 17168, - "▁Earl": 17169, - "gro": 17170, - "USE": 17171, - "▁XII": 17172, - "▁wealth": 17173, - "inae": 17174, - "▁Бра": 17175, - "▁libert": 17176, - "iros": 17177, - ":$": 17178, - "lee": 17179, - "ieves": 17180, - "▁Justice": 17181, - "▁oil": 17182, - "▁Athlet": 17183, - "▁clo": 17184, - "Scale": 17185, - "▁lips": 17186, - "▁april": 17187, - "▁impression": 17188, - "▁perce": 17189, - "▁участи": 17190, - "vil": 17191, - "éch": 17192, - "▁equality": 17193, - "▁мет": 17194, - "▁annotation": 17195, - "ernal": 17196, - "▁Mach": 17197, - "▁intitul": 17198, - "problem": 17199, - "ющих": 17200, - "oplus": 17201, - "▁thousands": 17202, - "▁calculations": 17203, - "umps": 17204, - "▁triangle": 17205, - "phal": 17206, - "▁Dorf": 17207, - "▁dollars": 17208, - "▁denen": 17209, - "lès": 17210, - "olid": 17211, - "▁Results": 17212, - "▁Stadium": 17213, - "▁Desp": 17214, - "▁Eisen": 17215, - "imir": 17216, - "▁sotto": 17217, - "▁či": 17218, - "atable": 17219, - "orum": 17220, - "▁convergence": 17221, - "▁jeune": 17222, - "oking": 17223, - "▁живо": 17224, - "aining": 17225, - "pointer": 17226, - "culo": 17227, - "▁jsou": 17228, - "▁grab": 17229, - "akte": 17230, - "▁hoping": 17231, - "▁Mak": 17232, - "▁sag": 17233, - "origine": 17234, - "▁послед": 17235, - "▁Veg": 17236, - "▁theoret": 17237, - "▁Tru": 17238, - "nement": 17239, - "▁faces": 17240, - "Hor": 17241, - "Join": 17242, - "arel": 17243, - "▁около": 17244, - "However": 17245, - "▁catal": 17246, - "bourg": 17247, - "▁mysqli": 17248, - "acions": 17249, - "▁Initial": 17250, - "▁rain": 17251, - "iture": 17252, - "▁Sciences": 17253, - "▁Kreis": 17254, - ".__": 17255, - "▁cinq": 17256, - "▁Auß": 17257, - "ithmet": 17258, - "itors": 17259, - "amazon": 17260, - "▁gap": 17261, - "▁ignored": 17262, - "adv": 17263, - "кої": 17264, - "▁часть": 17265, - "▁corpor": 17266, - "цер": 17267, - "▁crime": 17268, - "uous": 17269, - "▁налази": 17270, - "DataFrame": 17271, - "води": 17272, - "Ign": 17273, - "▁Lincoln": 17274, - "▁menos": 17275, - "▁Luft": 17276, - "▁Lind": 17277, - "▁Cook": 17278, - "▁materials": 17279, - "apped": 17280, - "ignore": 17281, - "▁откры": 17282, - "fried": 17283, - "▁gouvernement": 17284, - "▁fired": 17285, - "▁screenshot": 17286, - "сен": 17287, - "▁[(": 17288, - "▁организа": 17289, - "Graphics": 17290, - "▁проти": 17291, - "▁phen": 17292, - "craft": 17293, - "▁brain": 17294, - "▁Como": 17295, - "▁Everything": 17296, - "anes": 17297, - "IGN": 17298, - "▁nederbörd": 17299, - "▁Forest": 17300, - "zahl": 17301, - "▁Among": 17302, - "Qt": 17303, - "▁togg": 17304, - "▁variant": 17305, - "▁hill": 17306, - "писи": 17307, - "colon": 17308, - "▁dicembre": 17309, - "гор": 17310, - "▁Wind": 17311, - "ünstler": 17312, - "▁=\\": 17313, - "saved": 17314, - "▁nej": 17315, - "unte": 17316, - "utto": 17317, - "▁recens": 17318, - "▁sick": 17319, - "▁desen": 17320, - "UST": 17321, - "▁worst": 17322, - "▁Angel": 17323, - "odox": 17324, - "▁Province": 17325, - "▁Maz": 17326, - "▁agreement": 17327, - "▁Bass": 17328, - "▁segunda": 17329, - "onces": 17330, - "▁Linki": 17331, - "▁CL": 17332, - "▁já": 17333, - "itement": 17334, - "▁área": 17335, - "▁scalar": 17336, - "▁Рес": 17337, - "awt": 17338, - "sieme": 17339, - "▁juni": 17340, - "▁худож": 17341, - "ikus": 17342, - "▁lid": 17343, - "ppel": 17344, - "avi": 17345, - "▁balance": 17346, - "ipping": 17347, - "cussion": 17348, - "ческих": 17349, - "(\".": 17350, - "Also": 17351, - "▁whis": 17352, - "HOME": 17353, - "▁brown": 17354, - "▁día": 17355, - "▁può": 17356, - "plotlib": 17357, - "▁Jahrhunderts": 17358, - "DK": 17359, - "▁anchor": 17360, - "...]": 17361, - "▁Austria": 17362, - "▁marca": 17363, - "▁gez": 17364, - "iously": 17365, - "▁lazy": 17366, - "xa": 17367, - "▁Channel": 17368, - "▁neuen": 17369, - "das": 17370, - "▁searched": 17371, - "▁staat": 17372, - "▁Так": 17373, - "▁Josef": 17374, - "▁Sher": 17375, - "pois": 17376, - "▁enem": 17377, - "▁accessing": 17378, - "▁неко": 17379, - "▁furono": 17380, - "▁pseudo": 17381, - "?>": 17382, - "▁estadoun": 17383, - "▁Види": 17384, - "▁motiv": 17385, - "▁recall": 17386, - "isson": 17387, - "ób": 17388, - ")--": 17389, - "▁Erz": 17390, - "▁савез": 17391, - "Direct": 17392, - "соб": 17393, - "▁sho": 17394, - "völker": 17395, - "Ap": 17396, - "gens": 17397, - "ништво": 17398, - "▁Amsterdam": 17399, - "usk": 17400, - "пло": 17401, - "▁simulation": 17402, - "▁BC": 17403, - "▁Woj": 17404, - "autom": 17405, - "Alex": 17406, - "▁economic": 17407, - "гом": 17408, - "ikai": 17409, - "▁altre": 17410, - "▁'-": 17411, - "▁Weg": 17412, - "NotFound": 17413, - "йской": 17414, - "▁converting": 17415, - "phabet": 17416, - "atrice": 17417, - "bourne": 17418, - "alom": 17419, - "▁comparing": 17420, - "▁Zo": 17421, - "▁fla": 17422, - "вая": 17423, - "▁entra": 17424, - "▁charset": 17425, - "developers": 17426, - "ística": 17427, - "}>": 17428, - "▁Jazz": 17429, - "▁Howard": 17430, - "шта": 17431, - "▁clone": 17432, - "door": 17433, - "▁Pin": 17434, - "***": 17435, - "▁silent": 17436, - "ecycle": 17437, - "isce": 17438, - "▁mud": 17439, - "▁Display": 17440, - "▁lip": 17441, - "▁использова": 17442, - "▁characteristic": 17443, - "▁sb": 17444, - "firebase": 17445, - "▁Bew": 17446, - "Calendar": 17447, - "▁uso": 17448, - "èse": 17449, - "▁Rat": 17450, - "▁esper": 17451, - "▁throwing": 17452, - "▁rodz": 17453, - "▁yards": 17454, - "▁grass": 17455, - "▁marker": 17456, - "▁Kos": 17457, - "Theta": 17458, - "▁organis": 17459, - "kernel": 17460, - "▁personas": 17461, - "keep": 17462, - "▁exclaimed": 17463, - "oslav": 17464, - "▁Entertain": 17465, - "нер": 17466, - "▁inwon": 17467, - "▁Rand": 17468, - "reduce": 17469, - "fac": 17470, - "expression": 17471, - "yj": 17472, - "▁differenti": 17473, - "aglia": 17474, - "▁templates": 17475, - "▁mű": 17476, - "▁prv": 17477, - "▁mois": 17478, - "▁gewann": 17479, - "▁була": 17480, - "bibli": 17481, - "demo": 17482, - "▁Anderson": 17483, - "▁ред": 17484, - "▁porque": 17485, - "▁Pologne": 17486, - "▁trip": 17487, - "▁exemple": 17488, - "▁Internacional": 17489, - "▁као": 17490, - "Insert": 17491, - "general": 17492, - "SESSION": 17493, - "berga": 17494, - "hält": 17495, - "unas": 17496, - "мира": 17497, - "▁yields": 17498, - "mapsto": 17499, - "spot": 17500, - "▁+\\": 17501, - "лла": 17502, - "▁precisely": 17503, - "▁член": 17504, - "shadow": 17505, - "Are": 17506, - "unal": 17507, - "▁dispar": 17508, - "▁título": 17509, - "nest": 17510, - "▁Low": 17511, - "▁prot": 17512, - "▁Costa": 17513, - "named": 17514, - "▁gained": 17515, - "lesia": 17516, - "▁administration": 17517, - "Import": 17518, - "branch": 17519, - "▁sympath": 17520, - "voj": 17521, - "▁EC": 17522, - "▁municipio": 17523, - "▁animated": 17524, - "▁directories": 17525, - "▁roof": 17526, - "ząd": 17527, - "imet": 17528, - "proto": 17529, - "bla": 17530, - ":]": 17531, - "have": 17532, - "atem": 17533, - "▁ns": 17534, - "▁sector": 17535, - "three": 17536, - "owane": 17537, - "wers": 17538, - "ових": 17539, - "rence": 17540, - "▁extr": 17541, - "igten": 17542, - "▁occident": 17543, - "ță": 17544, - "▁eat": 17545, - "▁hydro": 17546, - "ubernetes": 17547, - "[@": 17548, - "▁Moon": 17549, - "▁Sho": 17550, - "▁elsewhere": 17551, - "üller": 17552, - "Upload": 17553, - "ланд": 17554, - "▁För": 17555, - "wissenschaft": 17556, - "KS": 17557, - "▁physics": 17558, - "tz": 17559, - "▁серед": 17560, - "▁Arbeit": 17561, - "▁мест": 17562, - "▁Gebiet": 17563, - "▁insect": 17564, - "Ah": 17565, - "izado": 17566, - "▁temple": 17567, - "▁annual": 17568, - "stad": 17569, - "▁habitat": 17570, - "▁AB": 17571, - "wort": 17572, - "▁repos": 17573, - "▁Neu": 17574, - "▁$(\".": 17575, - "Vorlage": 17576, - "▁reprezent": 17577, - "estanden": 17578, - "Intern": 17579, - ".`": 17580, - "▁failing": 17581, - "▁Material": 17582, - "▁effectively": 17583, - "телем": 17584, - "▁гла": 17585, - "▁nahm": 17586, - "▁differently": 17587, - "extension": 17588, - "▁Verm": 17589, - "enabled": 17590, - "configure": 17591, - "nio": 17592, - "ciones": 17593, - "▁Beach": 17594, - "сона": 17595, - "▁copying": 17596, - "▁україн": 17597, - "▁призна": 17598, - "zh": 17599, - "Desktop": 17600, - "▁sost": 17601, - "▁subsequently": 17602, - "▁Lehr": 17603, - "▁ó": 17604, - "lär": 17605, - "odor": 17606, - "phon": 17607, - "nc": 17608, - "iterator": 17609, - "▁эти": 17610, - "▁europé": 17611, - "▁Toronto": 17612, - "ódigo": 17613, - "▁posto": 17614, - "ffe": 17615, - "▁crew": 17616, - "▁Schwar": 17617, - "Sa": 17618, - "square": 17619, - "▁beside": 17620, - "▁Мі": 17621, - "▁ath": 17622, - "▁advent": 17623, - "cji": 17624, - "written": 17625, - "▁russ": 17626, - "rost": 17627, - "HI": 17628, - "▁dice": 17629, - "cca": 17630, - "▁dép": 17631, - "ply": 17632, - "bigg": 17633, - "ział": 17634, - "ütt": 17635, - "▁одно": 17636, - "JECT": 17637, - "ському": 17638, - "nos": 17639, - "mock": 17640, - "Launch": 17641, - "same": 17642, - "▁jobs": 17643, - "▁widely": 17644, - "▁defines": 17645, - "▁Pse": 17646, - "▁neighbour": 17647, - "ющие": 17648, - "▁closer": 17649, - "▁располо": 17650, - "▁clubs": 17651, - "fly": 17652, - "шим": 17653, - "▁suffered": 17654, - "▁nar": 17655, - "▁lavor": 17656, - "Extension": 17657, - "itionally": 17658, - "▁grace": 17659, - "▁Campeonato": 17660, - "▁Christmas": 17661, - "middle": 17662, - "othek": 17663, - "elements": 17664, - "▁sondern": 17665, - "▁tarde": 17666, - "▁permanent": 17667, - "▁conclude": 17668, - "Seg": 17669, - "▁акаде": 17670, - "}\",": 17671, - "▁февраля": 17672, - "řed": 17673, - "▁IL": 17674, - "jud": 17675, - "▁USS": 17676, - "▁Nature": 17677, - "ifference": 17678, - "Serializer": 17679, - "▁twelve": 17680, - "tid": 17681, - "мия": 17682, - "ческого": 17683, - "▁calendar": 17684, - "concat": 17685, - "▁intersection": 17686, - "▁PA": 17687, - "azure": 17688, - "▁située": 17689, - "▁kinds": 17690, - "▁ausge": 17691, - "▁rural": 17692, - "Theme": 17693, - "▁tale": 17694, - "noindent": 17695, - "going": 17696, - "rx": 17697, - "agi": 17698, - "wrapper": 17699, - "▁Coast": 17700, - "mbH": 17701, - "▁перед": 17702, - "spre": 17703, - "▁}\\": 17704, - "▁LI": 17705, - "znam": 17706, - "itled": 17707, - "Sample": 17708, - "uliar": 17709, - "*\\": 17710, - "▁resistance": 17711, - "stock": 17712, - "ked": 17713, - "▁HE": 17714, - "▁possession": 17715, - "▁Ring": 17716, - "▁magyar": 17717, - "outs": 17718, - "▁Secretary": 17719, - "nde": 17720, - "▁Wald": 17721, - "-(": 17722, - "▁ISO": 17723, - "▁afternoon": 17724, - "ionen": 17725, - "▁stops": 17726, - "▁constants": 17727, - "guard": 17728, - "bow": 17729, - "▁ers": 17730, - "▁Firebase": 17731, - "▁Clear": 17732, - "▁Holy": 17733, - "Win": 17734, - "▁titles": 17735, - "▁трав": 17736, - "▁contrib": 17737, - "häng": 17738, - "▁photograph": 17739, - "▁Distribution": 17740, - "ifts": 17741, - "▁aunque": 17742, - "comb": 17743, - "ADD": 17744, - "▁publication": 17745, - "▁служ": 17746, - "▁кня": 17747, - "▁ayant": 17748, - "▁restore": 17749, - "▁belief": 17750, - "▁vég": 17751, - "▁extensions": 17752, - "▁decom": 17753, - "вший": 17754, - "WT": 17755, - "▁parti": 17756, - "▁gioc": 17757, - "▁мира": 17758, - "▁issu": 17759, - "pipe": 17760, - "▁props": 17761, - "▁willing": 17762, - "▁nest": 17763, - "aso": 17764, - "pot": 17765, - "▁handles": 17766, - "▁фо": 17767, - "▁moder": 17768, - "▁ebenfalls": 17769, - "▁fighting": 17770, - "umbn": 17771, - "▁transparent": 17772, - "▁Krist": 17773, - "▁homes": 17774, - "▁voyage": 17775, - "Failed": 17776, - "▁Bird": 17777, - "▁Heart": 17778, - "Counter": 17779, - "▁Scottish": 17780, - "ática": 17781, - "▁arbeit": 17782, - "^{-\\": 17783, - "▁Sor": 17784, - "▁engaged": 17785, - "▁aside": 17786, - "▁Fou": 17787, - "▁wiel": 17788, - "▁reconst": 17789, - "ousin": 17790, - "▁hosted": 17791, - "▁classe": 17792, - "▁contest": 17793, - "...\"": 17794, - "мом": 17795, - "▁bean": 17796, - "gem": 17797, - "▁consultato": 17798, - "▁bio": 17799, - "▁subjects": 17800, - "boBox": 17801, - "▁Schrift": 17802, - "▁dinner": 17803, - "ăr": 17804, - "▁równ": 17805, - "▁%%": 17806, - "bage": 17807, - "▁veröff": 17808, - "▁detected": 17809, - "ienn": 17810, - "rose": 17811, - "▁Ton": 17812, - "Complete": 17813, - "▁proto": 17814, - "ichts": 17815, - "STAT": 17816, - "Checked": 17817, - "▁inten": 17818, - "▁smile": 17819, - "▁strip": 17820, - "neut": 17821, - "');\r": 17822, - "four": 17823, - "▁todas": 17824, - "Controls": 17825, - "▁thorough": 17826, - "rup": 17827, - "▁држави": 17828, - "ită": 17829, - "Protocol": 17830, - "Ка": 17831, - "▁expanded": 17832, - "extra": 17833, - "oport": 17834, - "▁Станов": 17835, - "leases": 17836, - "▁notion": 17837, - "▁guest": 17838, - "▁Islands": 17839, - "icked": 17840, - "▁Dave": 17841, - "▁reflection": 17842, - "liv": 17843, - "ální": 17844, - "▁revealed": 17845, - "▁sog": 17846, - "▁Tax": 17847, - "▁periodo": 17848, - "▁Weltkrie": 17849, - "catalina": 17850, - "qué": 17851, - "▁Father": 17852, - "▁Bir": 17853, - "expect": 17854, - "▁regression": 17855, - "iné": 17856, - "▁dabei": 17857, - "perm": 17858, - "мене": 17859, - "▁Abd": 17860, - "▁CF": 17861, - "arks": 17862, - "resolve": 17863, - "wedge": 17864, - "▁initialization": 17865, - "▁Véase": 17866, - "▁приня": 17867, - "stmt": 17868, - "▁income": 17869, - "MY": 17870, - "▁odkazy": 17871, - "▁Siehe": 17872, - "▁bodies": 17873, - "▁soc": 17874, - "Random": 17875, - "▁senza": 17876, - "ablo": 17877, - "▁regarded": 17878, - "onCreate": 17879, - "▁Magazine": 17880, - "▁Raf": 17881, - "▁Buenos": 17882, - "ил": 17883, - ")));": 17884, - "capt": 17885, - "redirect": 17886, - "▁petit": 17887, - "▁farm": 17888, - "▁rôle": 17889, - "▁статьи": 17890, - "    ": 17891, - "subfigure": 17892, - "èces": 17893, - "ziel": 17894, - "▁окон": 17895, - "EE": 17896, - "mee": 17897, - "▁perten": 17898, - "▁représent": 17899, - "▁LA": 17900, - "?'": 17901, - "▁тру": 17902, - "▁rational": 17903, - "osof": 17904, - "▁kne": 17905, - "▁artists": 17906, - "Flow": 17907, - "▁Аль": 17908, - "izard": 17909, - "▁numero": 17910, - "actic": 17911, - "▁destruct": 17912, - "▁Пра": 17913, - "onsieur": 17914, - "qt": 17915, - "abestanden": 17916, - "ność": 17917, - "Connect": 17918, - "▁oracle": 17919, - "▁Stockholm": 17920, - "sizeof": 17921, - "▁gemäß": 17922, - "ACT": 17923, - "▁expert": 17924, - "utions": 17925, - "▁hacia": 17926, - "▁logger": 17927, - "▁fool": 17928, - "rypto": 17929, - "ær": 17930, - "▁cidade": 17931, - "▁составе": 17932, - "oker": 17933, - "▁Transfer": 17934, - "▁denied": 17935, - "Track": 17936, - "▁radi": 17937, - "zec": 17938, - "▁Historic": 17939, - "▁Einwohner": 17940, - "кою": 17941, - "▁хра": 17942, - "▁Category": 17943, - "▁Disney": 17944, - "▁swap": 17945, - "Begin": 17946, - "▁mientras": 17947, - "▁dance": 17948, - "▁tête": 17949, - "▁droit": 17950, - "erta": 17951, - "▁birds": 17952, - "▁convin": 17953, - "parator": 17954, - "дра": 17955, - "▁ES": 17956, - "▁Ressources": 17957, - "EGIN": 17958, - "ücke": 17959, - "▁Cruz": 17960, - "abling": 17961, - "▁\"@": 17962, - "▁metres": 17963, - "▁Beg": 17964, - "▁Gründ": 17965, - "▁Boh": 17966, - "▁mile": 17967, - "▁Technology": 17968, - "\"+": 17969, - "acco": 17970, - "▁ss": 17971, - "▁Fed": 17972, - "▁Hend": 17973, - "usch": 17974, - "itä": 17975, - "folk": 17976, - "▁absor": 17977, - "antal": 17978, - "odge": 17979, - "▁WHEN": 17980, - "▁Externí": 17981, - "▁Regiment": 17982, - "▁evaluation": 17983, - "▁Tai": 17984, - "▁vocals": 17985, - "▁experimental": 17986, - "embed": 17987, - "▁Minn": 17988, - "▁вме": 17989, - "prec": 17990, - "every": 17991, - "▁hoof": 17992, - "▁Fernando": 17993, - "▁Bibliographie": 17994, - "▁nag": 17995, - "amerikanischer": 17996, - "▁marks": 17997, - "▁UTC": 17998, - "▁uncertain": 17999, - "дия": 18000, - "olia": 18001, - "▁cup": 18002, - "▁fille": 18003, - "▁dok": 18004, - "useppe": 18005, - "esterd": 18006, - "▁Brand": 18007, - "▁Third": 18008, - "PP": 18009, - "nodes": 18010, - "▁Pad": 18011, - "▁loved": 18012, - "swing": 18013, - "▁surprised": 18014, - "ardi": 18015, - "▁GR": 18016, - "]\"": 18017, - "▁equally": 18018, - "ihe": 18019, - "care": 18020, - "писок": 18021, - "lijk": 18022, - "rinn": 18023, - "▁\\[\\": 18024, - "▁sons": 18025, - "▁tät": 18026, - "icamente": 18027, - "▁listing": 18028, - "iellement": 18029, - "▁nyelven": 18030, - "▁ds": 18031, - "▁agricult": 18032, - "▁Hermann": 18033, - "▁besides": 18034, - "progress": 18035, - "▁peculiar": 18036, - "focus": 18037, - "cn": 18038, - "-$": 18039, - "ственный": 18040, - "ourg": 18041, - "▁wyn": 18042, - "▁conducted": 18043, - "▁Становништво": 18044, - "connected": 18045, - "▁bott": 18046, - "▁смер": 18047, - "▁Poz": 18048, - "unct": 18049, - "conda": 18050, - "▁савезној": 18051, - "▁havet": 18052, - "ligt": 18053, - "orted": 18054, - "▁entering": 18055, - "multip": 18056, - "▁Temple": 18057, - "▁Plant": 18058, - "typeof": 18059, - "▁Vlad": 18060, - "▁qued": 18061, - "▁reste": 18062, - "▁май": 18063, - "▁Very": 18064, - "ambiguation": 18065, - "▁challeng": 18066, - "▁respective": 18067, - "▁тор": 18068, - "Ctrl": 18069, - "▁absence": 18070, - "aru": 18071, - "вое": 18072, - "▁först": 18073, - "▁sq": 18074, - "▁Emperor": 18075, - "▁Ign": 18076, - "▁това": 18077, - ":`": 18078, - "adoop": 18079, - "▁Madame": 18080, - "▁gruppo": 18081, - "stud": 18082, - "▁externas": 18083, - "▁Александр": 18084, - "▁dign": 18085, - "▁живе": 18086, - "Amount": 18087, - "▁correlate": 18088, - "▁Fant": 18089, - "▁rails": 18090, - "fp": 18091, - "министратив": 18092, - "▁bought": 18093, - "▁filters": 18094, - "▁ancora": 18095, - "▁partner": 18096, - "▁quand": 18097, - "symbol": 18098, - "ulating": 18099, - "▁zd": 18100, - "awn": 18101, - "▁Grant": 18102, - "because": 18103, - "rable": 18104, - "\\}": 18105, - "ísticas": 18106, - "▁уче": 18107, - "▁période": 18108, - "▁ske": 18109, - "▁Anyway": 18110, - "▁indexes": 18111, - "▁directions": 18112, - "▁RAM": 18113, - "chrome": 18114, - "▁apost": 18115, - "▁warnings": 18116, - "▁Airport": 18117, - "VI": 18118, - "abile": 18119, - "▁lord": 18120, - "provider": 18121, - "▁Ji": 18122, - "ostream": 18123, - "▁gemeente": 18124, - "tableView": 18125, - "Extra": 18126, - "cursor": 18127, - "eground": 18128, - "▁Moz": 18129, - "▁rib": 18130, - "▁morph": 18131, - "loads": 18132, - "elsk": 18133, - "▁MAX": 18134, - "▁Santiago": 18135, - "▁Him": 18136, - "codes": 18137, - "▁lanz": 18138, - "▁counts": 18139, - "rinningsområ": 18140, - "щё": 18141, - "▁spé": 18142, - "▁pierws": 18143, - "▁Sver": 18144, - "▁acknow": 18145, - "Boolean": 18146, - "▁фамили": 18147, - "▁Senate": 18148, - "шов": 18149, - "agers": 18150, - "▁Nueva": 18151, - "bil": 18152, - "kiem": 18153, - "▁Mey": 18154, - "wij": 18155, - "▁GmbH": 18156, - "validation": 18157, - "▁ensuite": 18158, - "inking": 18159, - "▁campion": 18160, - "▁financial": 18161, - "izon": 18162, - "Headers": 18163, - "▁deprecated": 18164, - "▁fonction": 18165, - "REG": 18166, - "▁volumes": 18167, - "▁Chi": 18168, - "▁encountered": 18169, - "lak": 18170, - "рая": 18171, - "▁continues": 18172, - "▁~[": 18173, - "uerte": 18174, - "▁\\;": 18175, - "▁Dok": 18176, - "▁weights": 18177, - "▁rh": 18178, - "▁Napole": 18179, - "▁naturally": 18180, - "sku": 18181, - "pas": 18182, - "▁gegründ": 18183, - "etr": 18184, - "▁Ku": 18185, - "icted": 18186, - "▁fabric": 18187, - "▁ASC": 18188, - "▁Entertainment": 18189, - "▁energ": 18190, - "клад": 18191, - "omon": 18192, - "theme": 18193, - "▁харак": 18194, - "▁draft": 18195, - "▁channels": 18196, - "▁desert": 18197, - "▁través": 18198, - "▁Lock": 18199, - "▁siendo": 18200, - "фек": 18201, - "même": 18202, - "▁packet": 18203, - "▁Mountain": 18204, - "▁Fahr": 18205, - "braio": 18206, - "пере": 18207, - "▁genannt": 18208, - "▁deployment": 18209, - "Pal": 18210, - "ног": 18211, - "стру": 18212, - "Prim": 18213, - "für": 18214, - "▁dangerous": 18215, - "▁szám": 18216, - "reck": 18217, - "▁popup": 18218, - "icky": 18219, - "inar": 18220, - "cowo": 18221, - "нцикло": 18222, - "ítás": 18223, - "▁plugins": 18224, - "▁driven": 18225, - "лев": 18226, - "▁\"(": 18227, - "tta": 18228, - "▁Ú": 18229, - "▁eb": 18230, - "▁'';": 18231, - "▁knock": 18232, - "▁основа": 18233, - "▁maison": 18234, - "гля": 18235, - "▁Honor": 18236, - "tail": 18237, - "ritz": 18238, - "▁guys": 18239, - "▁combinations": 18240, - "ondere": 18241, - "▁Ald": 18242, - "▁fiddle": 18243, - "дав": 18244, - "urd": 18245, - "▁projection": 18246, - "▁También": 18247, - "verb": 18248, - "▁terre": 18249, - "rugu": 18250, - "▁september": 18251, - "▁=": 18572, - "▁Beat": 18573, - "▁Sax": 18574, - "vertical": 18575, - "кто": 18576, - "▁plants": 18577, - "▁Références": 18578, - "▁ogni": 18579, - "▁curs": 18580, - "▁SK": 18581, - "они": 18582, - "▁destac": 18583, - "\");\r": 18584, - "▁Sure": 18585, - "▁partido": 18586, - "▁Folge": 18587, - "▁Moore": 18588, - "▁wz": 18589, - "скус": 18590, - "ltre": 18591, - "ondo": 18592, - "▁pose": 18593, - "imos": 18594, - "бой": 18595, - "ципа": 18596, - "jus": 18597, - ".....": 18598, - "▁época": 18599, - "▁quanto": 18600, - "▁Support": 18601, - "geschichte": 18602, - "SERVER": 18603, - "▁Georges": 18604, - "enum": 18605, - "▁herm": 18606, - "▁nebo": 18607, - "▁Chr": 18608, - "character": 18609, - "▁***": 18610, - "▁Forsch": 18611, - "iami": 18612, - "▁¿": 18613, - "cych": 18614, - "▁fifth": 18615, - "sent": 18616, - "▁anderem": 18617, - "▁proportion": 18618, - "▁prest": 18619, - "▁Girl": 18620, - "▁drama": 18621, - "wand": 18622, - "▁Mail": 18623, - "▁Lux": 18624, - "▁který": 18625, - "▁Gesellschaft": 18626, - "▁Hinweis": 18627, - "nisse": 18628, - "▁mondo": 18629, - "Eq": 18630, - "▁perí": 18631, - "▁eastern": 18632, - "▁UEFA": 18633, - "uale": 18634, - "▁convex": 18635, - "▁поль": 18636, - "▁Hey": 18637, - "zenie": 18638, - "initely": 18639, - "▁Zusammen": 18640, - "SSL": 18641, - "ocal": 18642, - "▁canal": 18643, - "voy": 18644, - "▁Кри": 18645, - "▁között": 18646, - "▁cars": 18647, - "▁versión": 18648, - "Environment": 18649, - "Her": 18650, - "▁señ": 18651, - "▁spatial": 18652, - "ymi": 18653, - "Fire": 18654, - "▁veget": 18655, - "▁Wie": 18656, - "▁znaj": 18657, - "▁damage": 18658, - "▁endl": 18659, - "gif": 18660, - "▁quali": 18661, - "▁которых": 18662, - "ellan": 18663, - "▁mens": 18664, - "▁plug": 18665, - "▁abund": 18666, - "FIG": 18667, - "▁sf": 18668, - "▁confl": 18669, - "▁населения": 18670, - "▁principles": 18671, - "▁Gabriel": 18672, - "ibe": 18673, - "▁{%": 18674, - "▁població": 18675, - "ніципа": 18676, - "▁extreme": 18677, - "▁asse": 18678, - "▁vu": 18679, - "Mock": 18680, - "▁spielte": 18681, - "▁Aer": 18682, - "▁datos": 18683, - "endes": 18684, - "▁Gel": 18685, - "▁Gor": 18686, - "Christ": 18687, - "chos": 18688, - "Processor": 18689, - "▁instruct": 18690, - "▁picked": 18691, - "nahme": 18692, - "fahr": 18693, - "▁indicated": 18694, - "▁%.": 18695, - "▁ts": 18696, - "▁notable": 18697, - "▁qualified": 18698, - "▁Ал": 18699, - "Black": 18700, - "▁council": 18701, - "▁overhead": 18702, - "aci": 18703, - "année": 18704, - "▁initWith": 18705, - "bió": 18706, - "▁introduction": 18707, - "▁companion": 18708, - "▁expon": 18709, - "▁kör": 18710, - "oby": 18711, - "burn": 18712, - "gnu": 18713, - "virtual": 18714, - "▁intellect": 18715, - "▁держа": 18716, - "'+": 18717, - "бле": 18718, - "▁strictly": 18719, - "▁recognize": 18720, - "hour": 18721, - "▁Wrest": 18722, - "ennen": 18723, - "$).": 18724, - "fff": 18725, - "▁Centro": 18726, - "▁Pitt": 18727, - "▁dział": 18728, - "▁cela": 18729, - "▁francese": 18730, - "рами": 18731, - "special": 18732, - "▁Dup": 18733, - "toire": 18734, - "каль": 18735, - "COUNT": 18736, - "▁Brook": 18737, - "▁руково": 18738, - "publique": 18739, - "▁seconda": 18740, - "▁compt": 18741, - "▁bland": 18742, - "Before": 18743, - "▁Pack": 18744, - "alty": 18745, - "öder": 18746, - "▁intervals": 18747, - "▁Datenbank": 18748, - "Movie": 18749, - "▁transm": 18750, - "▁tap": 18751, - "▁поч": 18752, - "fon": 18753, - "iai": 18754, - "▁fib": 18755, - "▁wyd": 18756, - "▁hung": 18757, - "▁alive": 18758, - "Clear": 18759, - "▁pushed": 18760, - "▁tuple": 18761, - "achen": 18762, - "гово": 18763, - "▁revers": 18764, - "▁augment": 18765, - "▁challenge": 18766, - "lost": 18767, - "▁deuxième": 18768, - "structor": 18769, - "▁mehrerer": 18770, - "atural": 18771, - "Split": 18772, - "стем": 18773, - "шла": 18774, - ")\\\\": 18775, - "▁Dog": 18776, - "▁developers": 18777, - "▁nod": 18778, - "▁сторо": 18779, - "▁NaN": 18780, - "▁priest": 18781, - "▁exha": 18782, - "UND": 18783, - "pair": 18784, - "alone": 18785, - "▁moon": 18786, - "▁#!/": 18787, - "▁guns": 18788, - "rola": 18789, - "чита": 18790, - "▁Encyclopedia": 18791, - "atis": 18792, - "▁'\"": 18793, - "zych": 18794, - "▁superfic": 18795, - "▁эк": 18796, - "едера": 18797, - "feed": 18798, - "LAY": 18799, - "Fi": 18800, - "unks": 18801, - "isecond": 18802, - "▁'@": 18803, - "▁Adding": 18804, - "рое": 18805, - "▁tang": 18806, - "цо": 18807, - "hung": 18808, - "bis": 18809, - "ského": 18810, - "▁advert": 18811, - "▁занима": 18812, - "uzz": 18813, - "ágina": 18814, - "▁Tel": 18815, - "sig": 18816, - "▁Ez": 18817, - "▁guarantee": 18818, - "▁teaching": 18819, - "oty": 18820, - "termin": 18821, - "▁distributions": 18822, - "FLA": 18823, - "▁Giuseppe": 18824, - "querySelector": 18825, - "▁/\\": 18826, - "▁Squad": 18827, - "gz": 18828, - "delay": 18829, - "▁surrounding": 18830, - "▁manus": 18831, - "▁Hou": 18832, - "²,": 18833, - "▁cultiv": 18834, - "▁troubles": 18835, - "▁raison": 18836, - "expand": 18837, - "▁cov": 18838, - "nungen": 18839, - ")){": 18840, - "▁geen": 18841, - "▁außer": 18842, - "▁Лі": 18843, - "ři": 18844, - "▁situations": 18845, - "▁telep": 18846, - "▁Jed": 18847, - "▁travail": 18848, - "lias": 18849, - "bullet": 18850, - "▁selecting": 18851, - "avier": 18852, - "▁essential": 18853, - "(/": 18854, - "yyyy": 18855, - "ště": 18856, - "ulty": 18857, - "▁kra": 18858, - "▁tabs": 18859, - "▁experienced": 18860, - "azi": 18861, - "▁Directory": 18862, - "▁cron": 18863, - "▁spend": 18864, - "▁RA": 18865, - "▁selenium": 18866, - "▁Thé": 18867, - "Elements": 18868, - "cii": 18869, - "▁plat": 18870, - "▁archive": 18871, - "▁assistance": 18872, - "▁neck": 18873, - "▁Avenue": 18874, - "▁wheel": 18875, - "▁hade": 18876, - "Common": 18877, - "▁Dialog": 18878, - "▁forg": 18879, - "▁surely": 18880, - "▁hockey": 18881, - "któ": 18882, - "▁tk": 18883, - "▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁": 18884, - "▁Bruce": 18885, - "▁enorm": 18886, - ",’": 18887, - "▁Christopher": 18888, - "jev": 18889, - "▁quad": 18890, - "▁AJAX": 18891, - "���relief": 18892, - "▁modes": 18893, - "sklär": 18894, - "▁Vid": 18895, - "▁Serial": 18896, - "▁tokens": 18897, - "▁Poland": 18898, - "\\]": 18899, - "▁vide": 18900, - "rooms": 18901, - "omas": 18902, - "▁Bureau": 18903, - "cx": 18904, - "ностью": 18905, - "▁signs": 18906, - "шение": 18907, - "lossen": 18908, - "▁Queens": 18909, - "▁membre": 18910, - "▁mez": 18911, - "▁Bool": 18912, - "▁Naj": 18913, - "▁Memory": 18914, - "▁Khan": 18915, - "▁là": 18916, - "▁Hud": 18917, - "▁dismiss": 18918, - "ighth": 18919, - "▁fs": 18920, - "prevent": 18921, - "▁меда": 18922, - "▁Police": 18923, - "▁ско": 18924, - "finite": 18925, - "▁ami": 18926, - "▁Much": 18927, - "owania": 18928, - "ORY": 18929, - "iors": 18930, - "▁Premio": 18931, - "▁textbox": 18932, - "dm": 18933, - "▁afin": 18934, - "▁Donald": 18935, - "▁Priv": 18936, - "▁decid": 18937, - "▁Maurice": 18938, - "agan": 18939, - "▁Britannica": 18940, - "▁oft": 18941, - "▁consecutive": 18942, - "\"?>": 18943, - "овий": 18944, - "student": 18945, - "▁peque": 18946, - "▁dieses": 18947, - "▁retour": 18948, - "étr": 18949, - "▁сез": 18950, - "▁kre": 18951, - "▁votes": 18952, - "ruption": 18953, - "izada": 18954, - "▁Wiel": 18955, - "▁Gray": 18956, - "▁Leop": 18957, - "teilung": 18958, - "(['": 18959, - "▁whites": 18960, - "frica": 18961, - "animation": 18962, - "curl": 18963, - "lings": 18964, - "=\"$": 18965, - "loyd": 18966, - "textsc": 18967, - "ору": 18968, - "▁села": 18969, - "esian": 18970, - "▁Mission": 18971, - "▁неза": 18972, - "▁ultimately": 18973, - "бов": 18974, - "olen": 18975, - "скому": 18976, - "nete": 18977, - "▁Dit": 18978, - "▁costru": 18979, - "dependent": 18980, - "▁Resource": 18981, - "▁hosts": 18982, - "▁rear": 18983, - "Duration": 18984, - "ників": 18985, - "Ма": 18986, - "▁planning": 18987, - "▁prediction": 18988, - "▁Lyn": 18989, - "▁kir": 18990, - "▁Legisl": 18991, - "мат": 18992, - "▁Soccer": 18993, - "▁survey": 18994, - "▁estadounidense": 18995, - "orgen": 18996, - "jourd": 18997, - "▁aprile": 18998, - "▁ids": 18999, - "ське": 19000, - "▁employee": 19001, - "▁Schauspieler": 19002, - "ръ": 19003, - "▁multimedia": 19004, - "▁свою": 19005, - "▁wine": 19006, - "▁EU": 19007, - "ică": 19008, - "▁Rhein": 19009, - "▁Palmar": 19010, - "oteca": 19011, - "▁prepare": 19012, - "▁Tot": 19013, - "▁Null": 19014, - "▁kin": 19015, - "inals": 19016, - "▁Newton": 19017, - "▁tbl": 19018, - "▁Sold": 19019, - "▁verf": 19020, - "aturing": 19021, - "▁laptop": 19022, - "▁Совет": 19023, - "secret": 19024, - "▁Olympic": 19025, - "▁footballer": 19026, - "▁Rudolf": 19027, - "▁conhe": 19028, - "zysk": 19029, - "▁evaluated": 19030, - "»)": 19031, - "shop": 19032, - "repository": 19033, - "▁zach": 19034, - "▁losing": 19035, - "etter": 19036, - "▁Wirtschaft": 19037, - "так": 19038, - "▁unnecessary": 19039, - "▁Phot": 19040, - "anska": 19041, - "▁Native": 19042, - "CCE": 19043, - "▁fifty": 19044, - "▁erw": 19045, - "rh": 19046, - "issent": 19047, - "}{(": 19048, - "▁lanç": 19049, - "▁Xcode": 19050, - "город": 19051, - "cir": 19052, - "▁película": 19053, - "▁Oscar": 19054, - "▁shore": 19055, - "▁supplied": 19056, - "examples": 19057, - "Mess": 19058, - "VICE": 19059, - "▁exclude": 19060, - "▁hen": 19061, - "▁губер": 19062, - "▁Fragment": 19063, - "▁Bitte": 19064, - "▁Besides": 19065, - "▁hes": 19066, - "▁ihrem": 19067, - "▁Serge": 19068, - "▁artific": 19069, - "=\"${": 19070, - "лово": 19071, - "uteur": 19072, - "taire": 19073, - "пас": 19074, - "▁easiest": 19075, - "▁famiglia": 19076, - "Normal": 19077, - "▁dalle": 19078, - "▁nations": 19079, - "rp": 19080, - "thead": 19081, - "▁області": 19082, - "▁Democratic": 19083, - "▁челове": 19084, - "мож": 19085, - "▁гер": 19086, - "▁smallest": 19087, - "▁Publishing": 19088, - "▁Ts": 19089, - "▁laughed": 19090, - "lle": 19091, - "▁Amt": 19092, - "▁IIS": 19093, - "FORM": 19094, - "Mag": 19095, - "дон": 19096, - "▁storia": 19097, - "▁organized": 19098, - "ční": 19099, - "▁ox": 19100, - "lingen": 19101, - "▁luego": 19102, - "cció": 19103, - "▁rely": 19104, - "▁tussen": 19105, - "erten": 19106, - "▁honour": 19107, - "▁Claude": 19108, - "▁Korea": 19109, - "▁Metropol": 19110, - "Super": 19111, - "rien": 19112, - "érature": 19113, - "attro": 19114, - "▁біль": 19115, - "▁Herbert": 19116, - "▁auteurs": 19117, - "▁darauf": 19118, - "▁mental": 19119, - "▁rang": 19120, - "▁són": 19121, - "▁Soph": 19122, - ")\",": 19123, - "Descriptor": 19124, - "prepare": 19125, - "▁Landkreis": 19126, - "HC": 19127, - "cross": 19128, - "лиза": 19129, - "▁Login": 19130, - "onen": 19131, - "Feature": 19132, - "▁museum": 19133, - "vek": 19134, - "▁Nelson": 19135, - "▁rejo": 19136, - "▁команди": 19137, - "▁summar": 19138, - "▁следу": 19139, - "ämp": 19140, - "▁Gas": 19141, - "вом": 19142, - "VALUE": 19143, - "inge": 19144, - "period": 19145, - "lassen": 19146, - "ával": 19147, - "▁altogether": 19148, - "umph": 19149, - "istro": 19150, - "ąż": 19151, - "▁Keep": 19152, - "▁Marco": 19153, - "▁étant": 19154, - "▁Dre": 19155, - "geometry": 19156, - "▁Kas": 19157, - "messages": 19158, - "Cook": 19159, - "▁Side": 19160, - "▁коми": 19161, - "стри": 19162, - "▁excess": 19163, - "▁Biografia": 19164, - "XXXX": 19165, - "▁Nie": 19166, - "vendor": 19167, - "xsd": 19168, - "Mill": 19169, - "processing": 19170, - "▁Missouri": 19171, - "▁permett": 19172, - "▁apar": 19173, - "▁crowd": 19174, - "fert": 19175, - "▁Dou": 19176, - "rí": 19177, - "▁CC": 19178, - "▁payment": 19179, - "▁Hollywood": 19180, - "▁Virtual": 19181, - "▁spoken": 19182, - "▁tram": 19183, - "▁Community": 19184, - "▁administrative": 19185, - "▁воло": 19186, - "gior": 19187, - "visor": 19188, - "▁Украи": 19189, - "stage": 19190, - "▁Format": 19191, - "▁convenient": 19192, - "На": 19193, - "▁median": 19194, - "▁вра": 19195, - "▁Према": 19196, - "enig": 19197, - "▁Opera": 19198, - "rés": 19199, - "▁fmt": 19200, - "▁efficiency": 19201, - "male": 19202, - "Master": 19203, - "Series": 19204, - "▁syd": 19205, - "generic": 19206, - "interval": 19207, - "▁efect": 19208, - "▁inwoners": 19209, - "лимпи": 19210, - "irement": 19211, - "Err": 19212, - "öh": 19213, - "▁lying": 19214, - "▁Settings": 19215, - "!=": 19216, - "ematic": 19217, - "argv": 19218, - "▁Basic": 19219, - "▁consideration": 19220, - "▁habe": 19221, - "-%": 19222, - "▁mountains": 19223, - "▁peak": 19224, - "▁fallen": 19225, - "eded": 19226, - "logic": 19227, - "▁matched": 19228, - "▁typing": 19229, - ")},": 19230, - "▁fancy": 19231, - "▁elegant": 19232, - "ال": 19233, - "▁участ": 19234, - "▁Sarah": 19235, - "▁Verd": 19236, - "▁tego": 19237, - "rules": 19238, - "▁mounted": 19239, - "▁ім": 19240, - "еру": 19241, - "stoff": 19242, - "fahren": 19243, - "distance": 19244, - "▁License": 19245, - "▁LEFT": 19246, - "▁wp": 19247, - "/{": 19248, - "▁amazon": 19249, - ">&": 19250, - "▁első": 19251, - "quarters": 19252, - "▁shock": 19253, - "nick": 19254, - "▁Archite": 19255, - "▁Square": 19256, - "▁rates": 19257, - "iore": 19258, - "▁Nat": 19259, - "▁Charlot": 19260, - "reichen": 19261, - "▁variation": 19262, - "osis": 19263, - "life": 19264, - "slide": 19265, - "abi": 19266, - "uki": 19267, - "mysq": 19268, - "▁primitive": 19269, - "▁universitaire": 19270, - "LENG": 19271, - "ależ": 19272, - "ebook": 19273, - "syn": 19274, - "▁Gegen": 19275, - "▁Kü": 19276, - "▁але": 19277, - "▁Lub": 19278, - "concurrent": 19279, - "izzato": 19280, - "▁stub": 19281, - "▁ie": 19282, - "▁'./": 19283, - "cod": 19284, - "▁internacional": 19285, - "▁Glas": 19286, - "▁mare": 19287, - "▁Neb": 19288, - "▁GB": 19289, - "kwargs": 19290, - "▁aument": 19291, - "WID": 19292, - "▁род": 19293, - "punkt": 19294, - "▁Grad": 19295, - "SN": 19296, - "AMP": 19297, - "▁Born": 19298, - "▁Guerre": 19299, - "готов": 19300, - "▁medio": 19301, - "Med": 19302, - "supp": 19303, - "actual": 19304, - "dropdown": 19305, - "▁oktober": 19306, - "▁ř": 19307, - "▁circular": 19308, - "▁skin": 19309, - "▁emphas": 19310, - "▁голов": 19311, - "▁pue": 19312, - "▁informations": 19313, - "▁Wolfgang": 19314, - "▁useless": 19315, - "ит": 19316, - "▁Joan": 19317, - "▁бор": 19318, - "▁Glad": 19319, - "▁Know": 19320, - "ként": 19321, - "speed": 19322, - "▁Kevin": 19323, - "unft": 19324, - "▁arqu": 19325, - "▁Casa": 19326, - "(...": 19327, - "▁rapidly": 19328, - "▁proble": 19329, - "▁Википеди": 19330, - "žen": 19331, - "▁Neben": 19332, - "▁Meter": 19333, - "Children": 19334, - "cem": 19335, - "igos": 19336, - "aju": 19337, - "▁Retrie": 19338, - "▁Hell": 19339, - "▁gig": 19340, - "▁controvers": 19341, - "▁zoom": 19342, - "▁cens": 19343, - "▁alcuni": 19344, - "▁Header": 19345, - "Meta": 19346, - "Required": 19347, - "▁институ": 19348, - "▁skup": 19349, - "▁ingles": 19350, - "égl": 19351, - "bij": 19352, - "▁tér": 19353, - "▁compag": 19354, - "▁committed": 19355, - "▁processed": 19356, - "Lower": 19357, - "▁Foreign": 19358, - "▁seq": 19359, - "sheets": 19360, - "▁Fem": 19361, - "hoz": 19362, - "inks": 19363, - "▁kall": 19364, - "variant": 19365, - "▁libro": 19366, - "▁clicks": 19367, - "▁gobierno": 19368, - "iegel": 19369, - "мого": 19370, - "geme": 19371, - "▁tower": 19372, - "▁parish": 19373, - "▁TCP": 19374, - "▁ls": 19375, - "▁nginx": 19376, - "NaN": 19377, - "▁Dir": 19378, - "▁Begriffe": 19379, - "arie": 19380, - "ímp": 19381, - "icios": 19382, - "▁sharing": 19383, - "▁cinéma": 19384, - "bec": 19385, - "RED": 19386, - "▁Kra": 19387, - "abol": 19388, - "▁flux": 19389, - "▁expensive": 19390, - "▁суще": 19391, - "▁`_": 19392, - "ocz": 19393, - "лист": 19394, - "▁acquaint": 19395, - "▁wise": 19396, - "▁pouvoir": 19397, - "▁devant": 19398, - "▁momentum": 19399, - "immer": 19400, - "▁Coupe": 19401, - "indexOf": 19402, - "▁doesnt": 19403, - "▁зав": 19404, - "▁license": 19405, - "▁â": 19406, - "CSS": 19407, - "▁rice": 19408, - "Team": 19409, - "▁ano": 19410, - "lit": 19411, - "▁merged": 19412, - "▁Cell": 19413, - "лл": 19414, - "boy": 19415, - "asts": 19416, - "▁sell": 19417, - "▁große": 19418, - "▁virtuel": 19419, - "Cancel": 19420, - "▁sj": 19421, - "gment": 19422, - ".<": 19423, - "чай": 19424, - "ië": 19425, - "akh": 19426, - "izers": 19427, - "prit": 19428, - "▁Tib": 19429, - "▁elaborate": 19430, - "▁fé": 19431, - "▁меди": 19432, - "LENGTH": 19433, - "▁primarily": 19434, - "▁scores": 19435, - "▁carrying": 19436, - "▁lake": 19437, - "compose": 19438, - "▁Township": 19439, - "unge": 19440, - "▁alberga": 19441, - "anych": 19442, - "quelle": 19443, - "▁Ark": 19444, - "▁pris": 19445, - "▁voll": 19446, - "шли": 19447, - "Validation": 19448, - "▁ceux": 19449, - "▁populate": 19450, - "\"\r": 19451, - "▁femmes": 19452, - "ANG": 19453, - "▁Despite": 19454, - "вые": 19455, - "iske": 19456, - "zug": 19457, - "нача": 19458, - "▁hatten": 19459, - "INSERT": 19460, - "Employee": 19461, - "▁moments": 19462, - "▁última": 19463, - "▁holder": 19464, - "blank": 19465, - "Collections": 19466, - "athers": 19467, - "▁grade": 19468, - "▁affairs": 19469, - ".$$": 19470, - "▁delta": 19471, - "▁Jugend": 19472, - "▁español": 19473, - "▁OUT": 19474, - "▁mathematical": 19475, - "▁mongo": 19476, - "▁Фе": 19477, - "uling": 19478, - "▁revolution": 19479, - "▁coin": 19480, - "▁subclass": 19481, - "\"=>": 19482, - "äche": 19483, - "▁pyg": 19484, - "щая": 19485, - "illery": 19486, - "▁comenz": 19487, - "depth": 19488, - "▁cél": 19489, - "▁resize": 19490, - "▁Same": 19491, - "▁strik": 19492, - "▁tir": 19493, - "▁scarc": 19494, - "▁Member": 19495, - "subscribe": 19496, - "óż": 19497, - "útbol": 19498, - "except": 19499, - "▁driving": 19500, - "kie": 19501, - "zony": 19502, - "èmes": 19503, - "David": 19504, - "issant": 19505, - "▁ты": 19506, - "▁élect": 19507, - "▁rename": 19508, - "▁Running": 19509, - "▁interfaces": 19510, - "////////////////": 19511, - "▁Walker": 19512, - "▁société": 19513, - "▁asks": 19514, - "brid": 19515, - "▁jewe": 19516, - "▁seines": 19517, - "▁agents": 19518, - "▁MY": 19519, - "▁Lawrence": 19520, - "dess": 19521, - "iesen": 19522, - "▁людях": 19523, - "прави": 19524, - "▁ancest": 19525, - "▁welche": 19526, - "raum": 19527, - "▁orb": 19528, - "scal": 19529, - "▁Lear": 19530, - "▁wear": 19531, - "▁slave": 19532, - "▁renamed": 19533, - "čen": 19534, - "maste": 19535, - "angles": 19536, - "▁América": 19537, - "▁ti": 19538, - "▁demsel": 19539, - "▁beneath": 19540, - "binary": 19541, - "▁edición": 19542, - "▁kilomet": 19543, - "uits": 19544, - "▁cuatro": 19545, - "▁entrance": 19546, - "ondissement": 19547, - "▁bag": 19548, - "▁Armen": 19549, - "ijo": 19550, - "▁Lors": 19551, - "▁demselben": 19552, - "êm": 19553, - "▁discrete": 19554, - "▁prominent": 19555, - "▁Jay": 19556, - "decor": 19557, - "DL": 19558, - "▁dí": 19559, - "Struct": 19560, - "▁Production": 19561, - "they": 19562, - "arius": 19563, - "schnitt": 19564, - "▁Cou": 19565, - "▁lex": 19566, - "youtube": 19567, - "▁работа": 19568, - "station": 19569, - "sep": 19570, - "▁mirror": 19571, - "▁hits": 19572, - "▁Beck": 19573, - "atically": 19574, - "▁Laz": 19575, - "▁winner": 19576, - "DEX": 19577, - "▁INT": 19578, - "}^{-": 19579, - "▁wegen": 19580, - "mad": 19581, - "Angle": 19582, - "zing": 19583, - "▁Bayern": 19584, - "sal": 19585, - "äger": 19586, - "▁busy": 19587, - "▁stör": 19588, - "▁folk": 19589, - "▁prix": 19590, - "▁allocated": 19591, - "▁pt": 19592, - "affen": 19593, - "cluster": 19594, - "▁complement": 19595, - "árs": 19596, - "▁Amerika": 19597, - "рій": 19598, - "▁valley": 19599, - "▁rooms": 19600, - "▁moi": 19601, - ".\",": 19602, - ";;;;": 19603, - "▁lowest": 19604, - "nog": 19605, - "▁landet": 19606, - "▁programme": 19607, - "chio": 19608, - "▁Während": 19609, - "ández": 19610, - "▁долж": 19611, - "▁ouv": 19612, - "omány": 19613, - "▁Википедии": 19614, - "▁só": 19615, - "▁elektr": 19616, - "Desc": 19617, - "▁Beaut": 19618, - "нар": 19619, - "▁може": 19620, - "Pierre": 19621, - "esota": 19622, - "▁operated": 19623, - "▁forte": 19624, - "рис": 19625, - "▁opposition": 19626, - "alia": 19627, - "▁Syl": 19628, - "getName": 19629, - "вели": 19630, - "fik": 19631, - "▁comprom": 19632, - "▁TextView": 19633, - "Spring": 19634, - "metadata": 19635, - "engu": 19636, - "/,": 19637, - "▁carri": 19638, - "istol": 19639, - "▁diagonal": 19640, - "lista": 19641, - "izen": 19642, - "▁rende": 19643, - "gcc": 19644, - "beck": 19645, - "lius": 19646, - "iral": 19647, - "Resolver": 19648, - "▁percentage": 19649, - "▁attra": 19650, - "strings": 19651, - "wiąz": 19652, - "ods": 19653, - "волю": 19654, - "ęż": 19655, - "▁newspaper": 19656, - "imiter": 19657, - "ABC": 19658, - "▁Manchester": 19659, - "[{": 19660, - "Agent": 19661, - "▁Wor": 19662, - "▁Kath": 19663, - "▁пові": 19664, - "▁entonces": 19665, - "▁niveau": 19666, - "atted": 19667, - "learn": 19668, - "atiques": 19669, - "▁уби": 19670, - "▁quindi": 19671, - "binding": 19672, - "▁imported": 19673, - "▁Horn": 19674, - "emberg": 19675, - "complex": 19676, - "▁neural": 19677, - "information": 19678, - "▁recognition": 19679, - "ingt": 19680, - "▁inhabitants": 19681, - "vue": 19682, - "▁Bevölker": 19683, - "▁curves": 19684, - "▁leb": 19685, - "дій": 19686, - "▁sow": 19687, - "▁sentiment": 19688, - "PH": 19689, - "rache": 19690, - "▁-(": 19691, - "▁estable": 19692, - "▁Ferdinand": 19693, - "▁écrit": 19694, - "▁primeiro": 19695, - "▁tex": 19696, - "▁intermediate": 19697, - "verage": 19698, - "ibus": 19699, - "▁serves": 19700, - "ivas": 19701, - "▁bru": 19702, - "▁lum": 19703, - "attice": 19704, - "чный": 19705, - "▁Dres": 19706, - "▁videos": 19707, - "duration": 19708, - "▁abit": 19709, - "▁egg": 19710, - "ographical": 19711, - "alph": 19712, - "STATE": 19713, - "▁пара": 19714, - "reading": 19715, - "▁vehicle": 19716, - "▁fortune": 19717, - "ultats": 19718, - "▁Storia": 19719, - "midt": 19720, - "łącz": 19721, - "▁Memorial": 19722, - "▁vas": 19723, - "▁зан": 19724, - "▁utility": 19725, - "▁obsc": 19726, - "▁relacion": 19727, - "▁runat": 19728, - "Release": 19729, - "take": 19730, - "▁Oliver": 19731, - "▁Sid": 19732, - "ulos": 19733, - "▁Garc": 19734, - "▁розта": 19735, - "▁Sak": 19736, - "Py": 19737, - "führt": 19738, - "▁trabal": 19739, - "*{": 19740, - "▁zes": 19741, - "▁szere": 19742, - "▁varios": 19743, - "▁otra": 19744, - "▁eval": 19745, - "▁situé": 19746, - "▁wounded": 19747, - "▁Vincent": 19748, - "▁викори": 19749, - "▁encode": 19750, - "Modal": 19751, - "▁forb": 19752, - "▁dynamics": 19753, - "▁depos": 19754, - "arde": 19755, - "▁streets": 19756, - "▁Komm": 19757, - "=$(": 19758, - "▁повер": 19759, - "▁dois": 19760, - "▁vitt": 19761, - "▁automatisch": 19762, - "▁reload": 19763, - "▁Verwalt": 19764, - "bero": 19765, - "▁hub": 19766, - "▁mos": 19767, - "▁tutto": 19768, - "▁Frederick": 19769, - "łow": 19770, - "antages": 19771, - "aque": 19772, - "paper": 19773, - "▁einige": 19774, - "`),": 19775, - "dj": 19776, - "▁Ple": 19777, - "▁%,": 19778, - "▁Bitmap": 19779, - "▁friendly": 19780, - "▁truly": 19781, - "▁stroke": 19782, - "roph": 19783, - "▁engl": 19784, - "▁coff": 19785, - "▁dust": 19786, - "▁Jahres": 19787, - "ppi": 19788, - "▁wys": 19789, - "factor": 19790, - "schluss": 19791, - "▁деревня": 19792, - "▁Past": 19793, - "▁дома": 19794, - "COM": 19795, - "▁pueden": 19796, - "▁gift": 19797, - "▁Gla": 19798, - "▁triggered": 19799, - "ély": 19800, - "ülés": 19801, - "▁Oliv": 19802, - "▁verso": 19803, - "▁lle": 19804, - "▁Gli": 19805, - "▁Ltd": 19806, - "oa": 19807, - "▁territorio": 19808, - "ordre": 19809, - "▁deck": 19810, - "dra": 19811, - "aszt": 19812, - "▁concerning": 19813, - "▁Additionally": 19814, - "▁které": 19815, - "▁grund": 19816, - "▁Gest": 19817, - "▁misunder": 19818, - "pret": 19819, - "────": 19820, - "▁reputation": 19821, - "zia": 19822, - "▁успе": 19823, - "▁escaped": 19824, - "▁Prag": 19825, - "perform": 19826, - "▁austral": 19827, - "▁Vater": 19828, - "час": 19829, - "▁races": 19830, - "▁Byte": 19831, - "Mask": 19832, - "▁Territ": 19833, - "стю": 19834, - "▁Voci": 19835, - "▁Fichier": 19836, - "▁Населення": 19837, - "▁Unterscheidung": 19838, - "teenth": 19839, - "▁pilot": 19840, - "▁ji": 19841, - "▁двух": 19842, - "▁orientation": 19843, - "indre": 19844, - "▁Dort": 19845, - "ças": 19846, - "пли": 19847, - "▁reaction": 19848, - "▁consisting": 19849, - "▁ferro": 19850, - "тисти": 19851, - "yard": 19852, - "▁сві": 19853, - "▁interpretation": 19854, - "ią": 19855, - "rah": 19856, - "▁fand": 19857, - "Public": 19858, - "▁universe": 19859, - "▁retir": 19860, - "▁conscious": 19861, - "arqu": 19862, - "▁waste": 19863, - "▁Bib": 19864, - "yclerView": 19865, - "▁listening": 19866, - "gleich": 19867, - "niejs": 19868, - "▁correlation": 19869, - "▁receiver": 19870, - "▁уда": 19871, - "▁courage": 19872, - "uchs": 19873, - "fass": 19874, - "▁chunk": 19875, - "▁Anfang": 19876, - "▁großen": 19877, - "continue": 19878, - "▁Warszawa": 19879, - "hé": 19880, - "iy": 19881, - "ivement": 19882, - "▁α": 19883, - "▁exposed": 19884, - "▁zahl": 19885, - "▁sacr": 19886, - "▁Looks": 19887, - "▁eager": 19888, - "enten": 19889, - "Cursor": 19890, - "/_": 19891, - "ixa": 19892, - "рела": 19893, - "знача": 19894, - "▁фамилией": 19895, - "▁argent": 19896, - "▁Anders": 19897, - "œuvre": 19898, - "▁Isa": 19899, - "мента": 19900, - "▁advers": 19901, - "riction": 19902, - "GP": 19903, - "▁після": 19904, - "▁preserve": 19905, - "▁Garden": 19906, - "Rate": 19907, - "après": 19908, - "▁readable": 19909, - "indu": 19910, - "▁skill": 19911, - "▁helping": 19912, - "ographique": 19913, - "cling": 19914, - "ologist": 19915, - "▁Filter": 19916, - "▁finger": 19917, - "▁Vall": 19918, - "▁Polish": 19919, - "lg": 19920, - "▁Familien": 19921, - "▁waters": 19922, - "▁pseud": 19923, - "aza": 19924, - "_)": 19925, - "ARY": 19926, - "▁среди": 19927, - "▁Must": 19928, - "▁Bod": 19929, - "anon": 19930, - "▁lado": 19931, - "▁tight": 19932, - "imen": 19933, - "appen": 19934, - "frames": 19935, - "ingers": 19936, - "▁COVID": 19937, - "▁зі": 19938, - "▁све": 19939, - "▁ць": 19940, - "▁Left": 19941, - "]];": 19942, - "чь": 19943, - "фика": 19944, - "▁сло": 19945, - "▁пі": 19946, - "▁existe": 19947, - "▁Atlantic": 19948, - "▁maintained": 19949, - "▁irre": 19950, - "▁année": 19951, - "▁commented": 19952, - "веро": 19953, - "berta": 19954, - "▁Lad": 19955, - "▁Upon": 19956, - "▁pause": 19957, - "mill": 19958, - "opter": 19959, - "UK": 19960, - "рес": 19961, - "нциклопеди": 19962, - "▁alongside": 19963, - "▁robot": 19964, - "▁fert": 19965, - "▁moy": 19966, - "▁ade": 19967, - "Mapper": 19968, - ")->": 19969, - "igua": 19970, - "étique": 19971, - "тка": 19972, - "alias": 19973, - "▁ори": 19974, - "▁Magn": 19975, - "▁gehörte": 19976, - "imb": 19977, - ")}{\\": 19978, - "▁Wikipédia": 19979, - "▁urs": 19980, - "▁ende": 19981, - "leb": 19982, - "▁GC": 19983, - "Hol": 19984, - "ancing": 19985, - "Union": 19986, - "▁tenía": 19987, - "TT": 19988, - "▁estate": 19989, - "há": 19990, - "▁полі": 19991, - "ultan": 19992, - "▁Hockey": 19993, - "ulse": 19994, - "▁choices": 19995, - "scher": 19996, - "▁[],": 19997, - "▁potentially": 19998, - "▁Übers": 19999, - "▁admit": 20000, - "Comment": 20001, - "стя": 20002, - "▁Vien": 20003, - "▁ці": 20004, - "▁permut": 20005, - "cgi": 20006, - "▁crít": 20007, - "Console": 20008, - "ctic": 20009, - "▁okres": 20010, - "awk": 20011, - "football": 20012, - "ouest": 20013, - "CTYPE": 20014, - "ologique": 20015, - "▁constit": 20016, - "▁interests": 20017, - "▁Progress": 20018, - "▁Menu": 20019, - "▁také": 20020, - "▁Asian": 20021, - "▁защи": 20022, - "▁younger": 20023, - "▁wished": 20024, - "▁Sort": 20025, - "▁audience": 20026, - "amba": 20027, - "▁gehört": 20028, - "▁Kansas": 20029, - "yaume": 20030, - "▁Professional": 20031, - "âce": 20032, - "▁fatto": 20033, - "tod": 20034, - "▁datasets": 20035, - "▁fare": 20036, - "▁waves": 20037, - "~/": 20038, - "▁measurement": 20039, - "▁wol": 20040, - "indust": 20041, - "▁struggling": 20042, - "▁pulled": 20043, - "▁caratter": 20044, - "▁Externe": 20045, - "▁действи": 20046, - "cnt": 20047, - "liches": 20048, - "▁Possible": 20049, - "▁faced": 20050, - "▁hypothesis": 20051, - "▁kilom": 20052, - "▁när": 20053, - "boolean": 20054, - "PY": 20055, - "ampa": 20056, - "▁kiss": 20057, - "▁astero": 20058, - "▁negli": 20059, - "aments": 20060, - "▁Stu": 20061, - "ató": 20062, - "▁Constitution": 20063, - "▁interpol": 20064, - "▁Unable": 20065, - "▁pis": 20066, - "▁parc": 20067, - "\"])": 20068, - "pler": 20069, - "▁autory": 20070, - "▁algunos": 20071, - "ywna": 20072, - "}))": 20073, - "▁falls": 20074, - "▁équip": 20075, - "▁emit": 20076, - "▁profil": 20077, - "gets": 20078, - "фо": 20079, - "▁Military": 20080, - "▁nombreux": 20081, - "oct": 20082, - "Replace": 20083, - "▁seasons": 20084, - "▁château": 20085, - "▁typeof": 20086, - "polit": 20087, - "▁rand": 20088, - "▁quar": 20089, - "▁erstmals": 20090, - "сини": 20091, - "▁payload": 20092, - "По": 20093, - "кін": 20094, - "repo": 20095, - "▁Pav": 20096, - "Score": 20097, - "erves": 20098, - "▁sollte": 20099, - "▁між": 20100, - "ébec": 20101, - "▁clip": 20102, - "▁Nice": 20103, - "▁neben": 20104, - "▁assass": 20105, - "itories": 20106, - "▁unity": 20107, - "▁ен": 20108, - "▁Institut": 20109, - "▁internationale": 20110, - "▁наук": 20111, - "▁comand": 20112, - "▁kleine": 20113, - "▁adjacent": 20114, - "▁delivered": 20115, - "▁ше": 20116, - "зем": 20117, - "▁cot": 20118, - "visual": 20119, - "вает": 20120, - "▁Census": 20121, - "\\_": 20122, - "▁territory": 20123, - "чил": 20124, - "чные": 20125, - "flutter": 20126, - "DidLoad": 20127, - "Documents": 20128, - "▁dob": 20129, - "Bre": 20130, - "animate": 20131, - "▁biz": 20132, - "▁bata": 20133, - "▁SU": 20134, - "eso": 20135, - "▁priority": 20136, - "ván": 20137, - "iras": 20138, - "▁charged": 20139, - "▁Micro": 20140, - "atoire": 20141, - "чер": 20142, - "abad": 20143, - "uru": 20144, - "▁vš": 20145, - "dire": 20146, - "▁Twitter": 20147, - "▁мето": 20148, - ")..": 20149, - "▁Цент": 20150, - "▁entwick": 20151, - "▁Mind": 20152, - "▁функ": 20153, - "Future": 20154, - "lst": 20155, - "łoż": 20156, - "fli": 20157, - "tensor": 20158, - "▁topology": 20159, - "▁arte": 20160, - "ERT": 20161, - "▁variance": 20162, - "Images": 20163, - "▁(@": 20164, - "ArrayList": 20165, - "OC": 20166, - "▁Демо": 20167, - "aucoup": 20168, - "▁denotes": 20169, - "imon": 20170, - "њи": 20171, - "▁Przyp": 20172, - "▁Zag": 20173, - "▁дире": 20174, - "▁Similarly": 20175, - "бро": 20176, - "▁militaire": 20177, - "▁тому": 20178, - "▁Johnny": 20179, - "▁Мексику": 20180, - "ћа": 20181, - "Supp": 20182, - "▁junior": 20183, - "oltre": 20184, - "▁Моск": 20185, - "▁admitted": 20186, - "▁religios": 20187, - "зяй": 20188, - "его": 20189, - "▁tears": 20190, - "ingo": 20191, - "odu": 20192, - "iveness": 20193, - "▁logo": 20194, - "▁último": 20195, - "▁aliment": 20196, - "▁UITableView": 20197, - ")!": 20198, - "▁nj": 20199, - "lette": 20200, - "▁resident": 20201, - "▁termine": 20202, - "▁уже": 20203, - "▁Сте": 20204, - "office": 20205, - "▁carte": 20206, - "▁livre": 20207, - "▁Москов": 20208, - "▁elections": 20209, - "зиден": 20210, - "Trigger": 20211, - "▁Benjamin": 20212, - "addClass": 20213, - "ског": 20214, - "▁Observable": 20215, - "Cla": 20216, - "gemein": 20217, - "▁consent": 20218, - "ври": 20219, - "▁unfold": 20220, - "▁governor": 20221, - "нал": 20222, - "▁toda": 20223, - "Remote": 20224, - "arias": 20225, - "▁instal": 20226, - "fixed": 20227, - "▁decay": 20228, - "▁дерев": 20229, - "xyz": 20230, - "▁DATE": 20231, - "imar": 20232, - "ntil": 20233, - "▁startup": 20234, - "alion": 20235, - "▁kolej": 20236, - "cios": 20237, - "▁ranges": 20238, - "▁stupid": 20239, - "▁implementations": 20240, - "▁rm": 20241, - "ének": 20242, - "▁gcc": 20243, - "▁scène": 20244, - "Navigation": 20245, - "▁ ": 20246, - "▁кан": 20247, - "▁towns": 20248, - "Username": 20249, - "▁фе": 20250, - "▁leaders": 20251, - "oit": 20252, - "wär": 20253, - "▁dummy": 20254, - "▁assistant": 20255, - "{$\\": 20256, - "бір": 20257, - "▁roy": 20258, - "▁Layout": 20259, - "▁Jung": 20260, - "Lines": 20261, - "▁Holland": 20262, - "пор": 20263, - "▁Гри": 20264, - "▁Bened": 20265, - "▁Под": 20266, - "xls": 20267, - "▁Gol": 20268, - "▁Aleks": 20269, - "▁ejemplo": 20270, - "▁sezon": 20271, - "arding": 20272, - "footnote": 20273, - "▁Congrès": 20274, - "refer": 20275, - "ската": 20276, - "Iterator": 20277, - "▁ourselves": 20278, - "▁Mic": 20279, - "▁código": 20280, - "▁площа": 20281, - "▁\\$": 20282, - "▁Charlie": 20283, - "Nodes": 20284, - "▁puzz": 20285, - "▁Identifier": 20286, - "▁flutter": 20287, - "▁prü": 20288, - "▁ort": 20289, - "▁Cort": 20290, - "asticsearch": 20291, - "▁Свя": 20292, - "▁Bull": 20293, - "udem": 20294, - "▁apparent": 20295, - ":--": 20296, - "▁Хар": 20297, - "▁Lap": 20298, - "▁comport": 20299, - "matically": 20300, - "▁curios": 20301, - "▁может": 20302, - "▁Bh": 20303, - "apping": 20304, - "▁basketball": 20305, - "zetek": 20306, - "▁runt": 20307, - "▁Milan": 20308, - "fection": 20309, - "ría": 20310, - "▁Kin": 20311, - "▁slower": 20312, - "both": 20313, - "▁Instituto": 20314, - "▁Historical": 20315, - "▁również": 20316, - "matches": 20317, - "yci": 20318, - "▁espèce": 20319, - "▁Schweizer": 20320, - "NT": 20321, - "SF": 20322, - "acia": 20323, - "forge": 20324, - "Points": 20325, - "numbers": 20326, - "▁falling": 20327, - "▁inheritance": 20328, - "▁Erst": 20329, - "▁customers": 20330, - "▁actu": 20331, - "▁migration": 20332, - "\\'": 20333, - "Plan": 20334, - "Mr": 20335, - "othy": 20336, - "▁upgrad": 20337, - "бира": 20338, - "▁Offic": 20339, - "▁Wait": 20340, - "▁toler": 20341, - "ardon": 20342, - "▁slide": 20343, - ")_": 20344, - "▁став": 20345, - "▁nuclear": 20346, - "▁Bil": 20347, - "owner": 20348, - "▁Harris": 20349, - "Information": 20350, - "▁pó": 20351, - "▁включа": 20352, - "▁nuovo": 20353, - "▁Cav": 20354, - "▁Descri": 20355, - "▁ак": 20356, - "ództ": 20357, - "▁reactjs": 20358, - "▁Adams": 20359, - "▁Alternatively": 20360, - "струк": 20361, - ")`,": 20362, - "substring": 20363, - "▁massive": 20364, - "▁heavily": 20365, - "▁сезо": 20366, - "▁Ana": 20367, - "▁vale": 20368, - "Pad": 20369, - "▁Either": 20370, - "▁rs": 20371, - "anche": 20372, - "▁uploaded": 20373, - "▁(/": 20374, - "▁спор": 20375, - "▁reduction": 20376, - "▁Tokyo": 20377, - "gren": 20378, - "▁migli": 20379, - "▁iterator": 20380, - "stav": 20381, - "▁supporting": 20382, - "▁österreich": 20383, - "▁NSLog": 20384, - "istiques": 20385, - "rimin": 20386, - "MODE": 20387, - "}}}\\": 20388, - "▁explos": 20389, - "оте": 20390, - "▁(„": 20391, - "Sal": 20392, - "▁simplest": 20393, - "▁già": 20394, - "▁тан": 20395, - "▁cyl": 20396, - "bir": 20397, - "▁measurements": 20398, - "Created": 20399, - "erek": 20400, - "lookup": 20401, - "wirtschaft": 20402, - "▁Воло": 20403, - "timer": 20404, - "derr": 20405, - "▁стала": 20406, - "▁scenes": 20407, - "▁persu": 20408, - "liest": 20409, - "▁schedule": 20410, - "tal": 20411, - "лено": 20412, - "▁painting": 20413, - "▁improvement": 20414, - "software": 20415, - "▁governo": 20416, - "▁Hir": 20417, - "Execution": 20418, - "▁Okay": 20419, - "Prop": 20420, - "loster": 20421, - "ніципалі": 20422, - "▁peuvent": 20423, - "olu": 20424, - "▁Фа": 20425, - "rollo": 20426, - "▁коло": 20427, - "▁carrière": 20428, - "▁toggle": 20429, - "▁($\\": 20430, - "▁aggregate": 20431, - "▁Бі": 20432, - "textarea": 20433, - "Ok": 20434, - "itto": 20435, - "▁stim": 20436, - "▁recursion": 20437, - "▁Federation": 20438, - ")_{": 20439, - "ategor": 20440, - "▁distribu": 20441, - "Cloud": 20442, - "▁madre": 20443, - "▁iv": 20444, - "▁Lieutenant": 20445, - "▁substant": 20446, - "▁leaf": 20447, - "▁Kontrola": 20448, - "VA": 20449, - "▁tomb": 20450, - "эн": 20451, - "atoes": 20452, - "▁godine": 20453, - "▁#>": 20454, - "Cert": 20455, - "▁empresa": 20456, - "Props": 20457, - "▁planned": 20458, - "▁randomly": 20459, - "jähr": 20460, - "elem": 20461, - "▁Operation": 20462, - "*`": 20463, - "protocol": 20464, - "()));": 20465, - "wel": 20466, - "▁praw": 20467, - "▁сим": 20468, - "▁wob": 20469, - "▁hace": 20470, - "▁nearest": 20471, - "disable": 20472, - "▁Commun": 20473, - "▁revel": 20474, - "Free": 20475, - "▁brackets": 20476, - "IOException": 20477, - "▁alto": 20478, - "▁marry": 20479, - "▁auc": 20480, - "),\\": 20481, - "▁typo": 20482, - "edad": 20483, - "ará": 20484, - "icator": 20485, - "tatywna": 20486, - "▁buff": 20487, - "orders": 20488, - "▁asynchronous": 20489, - "▁econ": 20490, - "▁feu": 20491, - "▁Iron": 20492, - "▁rising": 20493, - "Radius": 20494, - "clk": 20495, - "▁zweiten": 20496, - "`'": 20497, - "▁uniqu": 20498, - "▁FM": 20499, - "▁Bran": 20500, - "▁flu": 20501, - "▁sensitive": 20502, - "urre": 20503, - "▁Iter": 20504, - "▁Sein": 20505, - "▁diferentes": 20506, - "▁него": 20507, - "chia": 20508, - "▁Anleitung": 20509, - "aturday": 20510, - "▁shorter": 20511, - "▁translated": 20512, - "▁Rés": 20513, - "▁rode": 20514, - "drag": 20515, - "▁lange": 20516, - "Bi": 20517, - "üb": 20518, - "leur": 20519, - "▁ordering": 20520, - "alous": 20521, - "▁Кор": 20522, - "archar": 20523, - "destroy": 20524, - "ervation": 20525, - "]],": 20526, - "AccessorImpl": 20527, - "▁autorytatywna": 20528, - "Sequence": 20529, - "▁proyect": 20530, - "▁bran": 20531, - "▁(+": 20532, - "▁Kab": 20533, - "▁zem": 20534, - "▁Calcul": 20535, - "▁seul": 20536, - "▁Niger": 20537, - "▁chiam": 20538, - "throw": 20539, - "▁Planet": 20540, - "bildung": 20541, - "▁zones": 20542, - "transition": 20543, - "лений": 20544, - "▁mapped": 20545, - "onaut": 20546, - "Pair": 20547, - "ilian": 20548, - "▁Morgan": 20549, - "▁unto": 20550, - "jou": 20551, - "▁hid": 20552, - "▁Meta": 20553, - "▁elles": 20554, - "Lou": 20555, - "rama": 20556, - "geordnet": 20557, - "▁scarcely": 20558, - "▁mint": 20559, - "Focus": 20560, - "▁Alter": 20561, - "▁dio": 20562, - "▁ampl": 20563, - "ièrement": 20564, - "▁исследова": 20565, - "LED": 20566, - "algorithm": 20567, - "▁сайті": 20568, - "▁\"\")": 20569, - "History": 20570, - "pk": 20571, - "▁Whit": 20572, - "▁систем": 20573, - "▁Kirchen": 20574, - "rà": 20575, - "APP": 20576, - "▁<%": 20577, - "antine": 20578, - "▁Disk": 20579, - "conv": 20580, - "welt": 20581, - "▁Fut": 20582, - "▁Nom": 20583, - "ordo": 20584, - "ellij": 20585, - "▁receives": 20586, - "cow": 20587, - "ytu": 20588, - "▁obras": 20589, - "▁purchase": 20590, - "▁earned": 20591, - "▁accessed": 20592, - "axi": 20593, - "▁Mans": 20594, - "ivan": 20595, - "▁tuvo": 20596, - "▁Trace": 20597, - "rimonio": 20598, - "▁desenvol": 20599, - "érique": 20600, - "▁resulted": 20601, - "▁computing": 20602, - "▁inspired": 20603, - "▁Prize": 20604, - "*\"": 20605, - "Comput": 20606, - "▁extensive": 20607, - "èg": 20608, - "▁Portály": 20609, - "▁castle": 20610, - "▁*.": 20611, - "▁photos": 20612, - "▁voet": 20613, - "ONG": 20614, - "▁Alle": 20615, - "▁threaten": 20616, - "stüt": 20617, - "▁albums": 20618, - "▁dense": 20619, - "flat": 20620, - "continu": 20621, - "Subject": 20622, - "▁readonly": 20623, - "Opt": 20624, - "писко": 20625, - "▁Aber": 20626, - "▁Position": 20627, - "▁Today": 20628, - "▁mini": 20629, - "▁Bef": 20630, - "listen": 20631, - "ственного": 20632, - "SUB": 20633, - "ossa": 20634, - "▁Pope": 20635, - "▁Jimmy": 20636, - "▁Дру": 20637, - "ungsseite": 20638, - "▁tren": 20639, - "optim": 20640, - "itsch": 20641, - "▁samt": 20642, - "▁испол": 20643, - "&=": 20644, - "▁Przypisy": 20645, - "▁продол": 20646, - "Cr": 20647, - "ermann": 20648, - "▁матери": 20649, - "▁Hugo": 20650, - "▁Deze": 20651, - "TRUE": 20652, - "▁defeat": 20653, - "▁watched": 20654, - "▁Gent": 20655, - "AUT": 20656, - "orous": 20657, - "▁опреде": 20658, - "orientation": 20659, - "▁distinguished": 20660, - "▁mesmo": 20661, - "▁sli": 20662, - "мена": 20663, - "mittel": 20664, - "gericht": 20665, - "eton": 20666, - "->{": 20667, - "▁wont": 20668, - "▁weg": 20669, - "▁classific": 20670, - "ilus": 20671, - "▁MD": 20672, - "tasks": 20673, - "▁chim": 20674, - "await": 20675, - "▁gang": 20676, - "▁wię": 20677, - "through": 20678, - "▁Russell": 20679, - "▁guessing": 20680, - "▁акт": 20681, - "блі": 20682, - "categories": 20683, - "сут": 20684, - "▁Fen": 20685, - "▁муж": 20686, - "▁newer": 20687, - "▁Async": 20688, - "▁terme": 20689, - ">/": 20690, - "пара": 20691, - "▁Trust": 20692, - "▁Opt": 20693, - "▁dah": 20694, - "▁wonderful": 20695, - "adratkil": 20696, - "▁Гра": 20697, - "mapping": 20698, - "▁discovery": 20699, - "▁BE": 20700, - "Enable": 20701, - "▁Friend": 20702, - "сня": 20703, - "▁controlled": 20704, - "чної": 20705, - "▁contributions": 20706, - "jší": 20707, - "▁Lev": 20708, - "▁francés": 20709, - "▁mic": 20710, - "zik": 20711, - "▁alem": 20712, - "cancel": 20713, - "!'": 20714, - "▁grat": 20715, - "▁Begriffsklär": 20716, - "Camera": 20717, - "ificación": 20718, - "ród": 20719, - "▁Arnold": 20720, - "▁bezeichneter": 20721, - "▁fought": 20722, - "▁deput": 20723, - "▁Drop": 20724, - "tax": 20725, - "dg": 20726, - "▁Hop": 20727, - "GN": 20728, - "▁Kirch": 20729, - "▁Бар": 20730, - "Invoke": 20731, - "▁erhalten": 20732, - "▁veel": 20733, - "▁wordpress": 20734, - "▁INNER": 20735, - "transaction": 20736, - "▁déjà": 20737, - "Fact": 20738, - "▁надмор": 20739, - "▁angularjs": 20740, - "▁át": 20741, - "▁alap": 20742, - "▁Price": 20743, - "▁effet": 20744, - "▁sphere": 20745, - "ClassLoader": 20746, - "▁rugby": 20747, - "▁kingdom": 20748, - "▁Mut": 20749, - "▁кино": 20750, - "▁reward": 20751, - "cit": 20752, - "▁presente": 20753, - "Sto": 20754, - "Character": 20755, - "logs": 20756, - "▁centrale": 20757, - "▁mouv": 20758, - "▁okay": 20759, - "▁aplic": 20760, - "More": 20761, - "ények": 20762, - "▁Köln": 20763, - "nett": 20764, - "▁истории": 20765, - "▁describing": 20766, - "▁soldier": 20767, - "▁Need": 20768, - "Light": 20769, - "▁\"\\<": 20770, - "▁hav": 20771, - "ermo": 20772, - "▁inferior": 20773, - "lea": 20774, - "▁gg": 20775, - "▁конце": 20776, - "fragment": 20777, - "sb": 20778, - "Country": 20779, - "▁vě": 20780, - "▁Beng": 20781, - "▁Это": 20782, - "▁водо": 20783, - "мар": 20784, - "STRING": 20785, - "▁új": 20786, - "multiple": 20787, - "statement": 20788, - "▁involves": 20789, - "▁tecn": 20790, - "Student": 20791, - "gré": 20792, - "▁lean": 20793, - "▁bringing": 20794, - "▁Medical": 20795, - "▁програм": 20796, - "▁Vog": 20797, - "▁жов": 20798, - "▁Spirit": 20799, - "nth": 20800, - "▁standards": 20801, - "▁Profile": 20802, - "▁ez": 20803, - "▁территории": 20804, - "▁stem": 20805, - "uil": 20806, - "▁Og": 20807, - "Btn": 20808, - "nal": 20809, - "▁nearby": 20810, - "▁producing": 20811, - "criv": 20812, - "▁assumptions": 20813, - "▁Spark": 20814, - "▁Lot": 20815, - "itudes": 20816, - "afka": 20817, - "five": 20818, - "atio": 20819, - "▁distinguish": 20820, - "rock": 20821, - "église": 20822, - "▁rappres": 20823, - ">\\<": 20824, - "лій": 20825, - "▁мини": 20826, - "▁intitulé": 20827, - "}}(\\": 20828, - "▁Rout": 20829, - "▁Border": 20830, - "▁overrid": 20831, - "HOST": 20832, - "ritten": 20833, - "say": 20834, - "▁Чи": 20835, - "ichtung": 20836, - "▁straightforward": 20837, - "obb": 20838, - "▁Terra": 20839, - "▁[:": 20840, - "Ben": 20841, - "▁composite": 20842, - ")+\\": 20843, - "▁crown": 20844, - "direction": 20845, - "▁несколько": 20846, - "▁avail": 20847, - "▁purchased": 20848, - "hook": 20849, - "eties": 20850, - "▁fase": 20851, - "▁Rum": 20852, - "▁genom": 20853, - "▁dét": 20854, - "ową": 20855, - "mpeg": 20856, - "▁Ін": 20857, - "desktop": 20858, - "▁injection": 20859, - "agle": 20860, - "▁Edd": 20861, - "_{(": 20862, - "▁Hem": 20863, - "utos": 20864, - "proj": 20865, - "▁superficie": 20866, - "Plot": 20867, - "▁Docker": 20868, - "ätz": 20869, - "kreich": 20870, - "▁unclear": 20871, - "▁Unity": 20872, - "▁streams": 20873, - "вид": 20874, - "▁simplified": 20875, - "Fill": 20876, - "▁sant": 20877, - "▁Kommun": 20878, - "▁duc": 20879, - "▁две": 20880, - "▁obs": 20881, - "žit": 20882, - "▁Janeiro": 20883, - "бя": 20884, - "▁presso": 20885, - "▁Ministry": 20886, - "▁burst": 20887, - "▁reaching": 20888, - "liter": 20889, - "▁responses": 20890, - "▁Eug": 20891, - "▁sod": 20892, - "▁Cord": 20893, - "▁Perm": 20894, - "parts": 20895, - "цима": 20896, - "variables": 20897, - "▁forgotten": 20898, - "Fern": 20899, - "ostęp": 20900, - "vl": 20901, - "▁См": 20902, - "kim": 20903, - "ając": 20904, - "наль": 20905, - "гле": 20906, - "helper": 20907, - "dup": 20908, - "euw": 20909, - "fra": 20910, - "ellite": 20911, - "anya": 20912, - "▁reign": 20913, - "gesamt": 20914, - "седа": 20915, - "▁Ryan": 20916, - "▁formatted": 20917, - "▁Borg": 20918, - "walk": 20919, - "▁ал": 20920, - "agnostics": 20921, - "▁Cape": 20922, - "▁Franco": 20923, - "▁fug": 20924, - ":)": 20925, - "юз": 20926, - "Fetch": 20927, - "▁roughly": 20928, - "▁Mis": 20929, - "uetooth": 20930, - "▁Venezuela": 20931, - "▁astronom": 20932, - "\")`": 20933, - "ombres": 20934, - "▁которой": 20935, - "óp": 20936, - "owed": 20937, - "HR": 20938, - "▁Camer": 20939, - "кие": 20940, - "parison": 20941, - "▁Bij": 20942, - "templates": 20943, - "environment": 20944, - "ização": 20945, - "▁ér": 20946, - "▁plenty": 20947, - "▁TypeError": 20948, - "▁forty": 20949, - "коном": 20950, - "▁Sed": 20951, - "▁thats": 20952, - "▁gravity": 20953, - "▁spiritual": 20954, - "▁duplicates": 20955, - "▁encryption": 20956, - "▁reven": 20957, - "getInstance": 20958, - "ällor": 20959, - "disk": 20960, - "▁thro": 20961, - "▁Nak": 20962, - "▁poł": 20963, - "▁heraus": 20964, - "invalid": 20965, - "sBy": 20966, - "Boot": 20967, - "▁bucket": 20968, - "▁Parse": 20969, - "hex": 20970, - "Conne": 20971, - "▁Computer": 20972, - "zyk": 20973, - "▁induced": 20974, - "▁Bruno": 20975, - "▁addressed": 20976, - "mania": 20977, - "▁inclus": 20978, - "ounced": 20979, - "scriptsize": 20980, - "▁Epis": 20981, - "▁vocal": 20982, - "▁Jonathan": 20983, - "ум": 20984, - "staden": 20985, - "▁Children": 20986, - "пей": 20987, - "Italia": 20988, - "reibung": 20989, - "▁nost": 20990, - "▁ещё": 20991, - "▁Werke": 20992, - "▁actress": 20993, - "▁Minnesota": 20994, - "rike": 20995, - "▁tek": 20996, - "▁primeira": 20997, - "▁frat": 20998, - "▁Configuration": 20999, - "▁bid": 21000, - "trigger": 21001, - "Contents": 21002, - "▁constantly": 21003, - "!!!": 21004, - "▁dread": 21005, - "▁hundreds": 21006, - "istische": 21007, - "▁cardinal": 21008, - "TABLE": 21009, - "▁estos": 21010, - "assoc": 21011, - "gray": 21012, - "▁Schloss": 21013, - "▁sche": 21014, - "cong": 21015, - "▁koji": 21016, - "ètes": 21017, - "▁Era": 21018, - "omi": 21019, - "▁SR": 21020, - "▁wrapped": 21021, - "▁trunc": 21022, - "▁ah": 21023, - "egos": 21024, - "oki": 21025, - "mouth": 21026, - "logging": 21027, - "▁fasc": 21028, - "▁Sample": 21029, - "▁conte": 21030, - "▁villa": 21031, - "comments": 21032, - "▁batal": 21033, - "▁García": 21034, - "▁Norte": 21035, - "▁wechsel": 21036, - "▁Museo": 21037, - "▁enfants": 21038, - "▁whisper": 21039, - "nake": 21040, - "▁jednak": 21041, - "lês": 21042, - "enders": 21043, - "▁äl": 21044, - "▁VB": 21045, - "▁cookies": 21046, - "zeti": 21047, - "atum": 21048, - "▁dedu": 21049, - "▁arranged": 21050, - "laz": 21051, - "▁cuenta": 21052, - "yml": 21053, - "▁flav": 21054, - "MR": 21055, - "emet": 21056, - "біль": 21057, - "cmp": 21058, - "ituto": 21059, - "zett": 21060, - "▁envi": 21061, - "▁kot": 21062, - "$:": 21063, - "upper": 21064, - "▁Alberto": 21065, - "kb": 21066, - "Anal": 21067, - "ört": 21068, - "▁[-": 21069, - "▁führte": 21070, - "iah": 21071, - "▁Tun": 21072, - "▁искус": 21073, - "uwe": 21074, - "ispecies": 21075, - "Pub": 21076, - "Sync": 21077, - "▁Colombia": 21078, - "akers": 21079, - "▁Imperial": 21080, - "oving": 21081, - "▁intelligence": 21082, - "▁equipment": 21083, - "ein": 21084, - "dagger": 21085, - "▁Edge": 21086, - "▁Республи": 21087, - "adratkilometer": 21088, - "▁Anto": 21089, - "▁charges": 21090, - "▁Ocean": 21091, - "▁simplify": 21092, - "▁miesz": 21093, - "running": 21094, - "▁Lac": 21095, - "genommen": 21096, - "▁representative": 21097, - "=.": 21098, - "▁Pred": 21099, - "▁spite": 21100, - "ciale": 21101, - "▁nave": 21102, - "▁extens": 21103, - "▁neutral": 21104, - "▁которая": 21105, - ".::": 21347, - "шёл": 21348, - "▁principales": 21349, - "▁цар": 21350, - "▁tied": 21351, - "▁alta": 21352, - "▁Cit": 21353, - "lined": 21354, - "major": 21355, - "▁punk": 21356, - "▁cinco": 21357, - "ický": 21358, - "▁raggi": 21359, - "typen": 21360, - "тельство": 21361, - "▁conference": 21362, - "▁сіль": 21363, - "▁heut": 21364, - "iš": 21365, - "ета": 21366, - "velope": 21367, - "hbox": 21368, - "nown": 21369, - "▁zar": 21370, - "ktiv": 21371, - "ieß": 21372, - "▁стре": 21373, - "▁EventArgs": 21374, - "▁Ira": 21375, - "▁VBA": 21376, - "▁Santo": 21377, - "▁Fach": 21378, - "▁FF": 21379, - "▁Raymond": 21380, - "мец": 21381, - "implementation": 21382, - "▁brothers": 21383, - "▁côté": 21384, - "▁controllers": 21385, - "▁Cle": 21386, - "▁cable": 21387, - "▁confer": 21388, - "▁{-": 21389, - "▁czł": 21390, - "▁Filip": 21391, - "atorio": 21392, - "▁wicht": 21393, - "▁beaucoup": 21394, - "▁Lit": 21395, - "▁sessions": 21396, - "▁Success": 21397, - "▁routing": 21398, - "niu": 21399, - "▁Vice": 21400, - "▁krit": 21401, - "updated": 21402, - "▁Invalid": 21403, - "▁Mannschaft": 21404, - "▁aos": 21405, - "▁tudi": 21406, - "▁després": 21407, - "qua": 21408, - "Contains": 21409, - "Company": 21410, - "▁persona": 21411, - "adapter": 21412, - "сни": 21413, - "▁voj": 21414, - "▁escri": 21415, - "agt": 21416, - "▁ство": 21417, - "▁distrito": 21418, - "apan": 21419, - "▁aspects": 21420, - "▁zal": 21421, - ")^{\\": 21422, - "▁système": 21423, - "▁ана": 21424, - "iums": 21425, - "▁premiers": 21426, - "▁поэ": 21427, - "▁mère": 21428, - "▁Gun": 21429, - "aping": 21430, - "▁Rain": 21431, - "▁igual": 21432, - "▁processor": 21433, - "')`": 21434, - "bling": 21435, - "▁mism": 21436, - "bráz": 21437, - "▁closest": 21438, - "▁Reading": 21439, - "▁попу": 21440, - "cono": 21441, - "▁kult": 21442, - "▁!!": 21443, - "▁Expression": 21444, - "▁induction": 21445, - "ahren": 21446, - "▁cp": 21447, - "▁violence": 21448, - "ientí": 21449, - "cente": 21450, - "▁Dob": 21451, - "jack": 21452, - "song": 21453, - "bucket": 21454, - "▁deport": 21455, - "кими": 21456, - "lm": 21457, - "▁innoc": 21458, - "Changes": 21459, - "▁prohib": 21460, - "angol": 21461, - "iseconds": 21462, - "▁пор": 21463, - "▁hip": 21464, - "▁pů": 21465, - "endorf": 21466, - "▁scheduled": 21467, - "▁Flug": 21468, - "acyj": 21469, - "▁Films": 21470, - "athedral": 21471, - "Power": 21472, - "ardin": 21473, - "kap": 21474, - "icken": 21475, - "resize": 21476, - "eus": 21477, - "rr": 21478, - "лян": 21479, - "▁Hav": 21480, - "▁ora": 21481, - "FROM": 21482, - "лося": 21483, - "▁terug": 21484, - "▁Width": 21485, - "▁accepts": 21486, - "бен": 21487, - "▁mich": 21488, - "▁Czech": 21489, - "▁Bedeut": 21490, - "▁вид": 21491, - "ôme": 21492, - "▁Loop": 21493, - "spect": 21494, - "ük": 21495, - "eston": 21496, - "▁slot": 21497, - "▁została": 21498, - "▁Charlotte": 21499, - "▁составляет": 21500, - "▁Promise": 21501, - "▁epo": 21502, - "▁diction": 21503, - "▁Franklin": 21504, - "▁Riv": 21505, - "руг": 21506, - "cida": 21507, - "▁Explorer": 21508, - "cookie": 21509, - "▁formerly": 21510, - "▁municipality": 21511, - "▁Stefan": 21512, - "lists": 21513, - "COMP": 21514, - "Len": 21515, - "▁Staat": 21516, - "▁NBA": 21517, - "dens": 21518, - "▁oscill": 21519, - "!.": 21520, - "▁PO": 21521, - "ône": 21522, - "eses": 21523, - "▁националь": 21524, - "voor": 21525, - "▁копи": 21526, - "▁пози": 21527, - "ulu": 21528, - "Constraint": 21529, - "▁своей": 21530, - "▁algebraic": 21531, - "чня": 21532, - "Dict": 21533, - "▁appearing": 21534, - "▁prav": 21535, - "▁Universal": 21536, - "Browser": 21537, - "▁Singap": 21538, - "ennessee": 21539, - "]_": 21540, - "▁Sof": 21541, - "▁Cad": 21542, - "ounce": 21543, - "▁costs": 21544, - "]{\\": 21545, - "../../": 21546, - "ській": 21547, - "ühl": 21548, - "iety": 21549, - "пр": 21550, - "▁interpreted": 21551, - "ajn": 21552, - "colog": 21553, - "YS": 21554, - "mans": 21555, - "▁metrics": 21556, - "▁registr": 21557, - "istance": 21558, - "▁Поль": 21559, - "▁anonymous": 21560, - "▁institutions": 21561, - "▁zdob": 21562, - "prüng": 21563, - "▁арти": 21564, - "▁estat": 21565, - "acci": 21566, - "▁academic": 21567, - "▁chiesa": 21568, - "▁Gian": 21569, - "contrib": 21570, - "umed": 21571, - "▁Gir": 21572, - "▁baseball": 21573, - "numeric": 21574, - "Generator": 21575, - "GM": 21576, - "▁tiny": 21577, - "▁distinction": 21578, - "гер": 21579, - "▁rust": 21580, - "▁FIFA": 21581, - "▁Properties": 21582, - "^-": 21583, - "▁экс": 21584, - "▁Stanis": 21585, - "▁Ajax": 21586, - "escape": 21587, - "▁consp": 21588, - "▁Chen": 21589, - "▁Naval": 21590, - "Bit": 21591, - "▁bât": 21592, - "скими": 21593, - "drive": 21594, - "▁Round": 21595, - "photo": 21596, - "▁Level": 21597, - "▁geg": 21598, - "Tom": 21599, - "▁Mobile": 21600, - "▁Trop": 21601, - "Direction": 21602, - "isan": 21603, - ")^{-": 21604, - "▁Setting": 21605, - "▁Probably": 21606, - "лья": 21607, - "▁assets": 21608, - "▁atte": 21609, - "▁bulk": 21610, - "ést": 21611, - "▁wing": 21612, - "nius": 21613, - "▁wins": 21614, - "▁lud": 21615, - "ushing": 21616, - "▁deven": 21617, - "ограф": 21618, - "burger": 21619, - "▁embar": 21620, - "FilterChain": 21621, - "▁tum": 21622, - "▁öss": 21623, - "▁nommé": 21624, - "▁pir": 21625, - "▁luc": 21626, - "dbo": 21627, - "agues": 21628, - "▁alcan": 21629, - "ouwen": 21630, - "▁Stanley": 21631, - "циали": 21632, - "▁grown": 21633, - "▁preserved": 21634, - "▁solar": 21635, - "▁Население": 21636, - "▁performances": 21637, - "▁Cow": 21638, - "▁engineering": 21639, - "▁scaling": 21640, - "atomic": 21641, - "endance": 21642, - "▁ace": 21643, - "ängen": 21644, - "Anim": 21645, - "phase": 21646, - "zburg": 21647, - "Old": 21648, - "▁servant": 21649, - "▁gemeins": 21650, - "▁Observ": 21651, - "translate": 21652, - "▁covering": 21653, - "▁están": 21654, - "▁problema": 21655, - "▁установ": 21656, - "▁llev": 21657, - "▁czerw": 21658, - "éal": 21659, - "mez": 21660, - "REE": 21661, - "ERR": 21662, - "тури": 21663, - "segu": 21664, - "▁profit": 21665, - "▁multiplication": 21666, - "kommen": 21667, - "▁faut": 21668, - "▁candidates": 21669, - "▁Uri": 21670, - "▁Laura": 21671, - "▁sap": 21672, - "▁висини": 21673, - "▁Between": 21674, - "fade": 21675, - "▁reserved": 21676, - "▁involving": 21677, - "▁Mare": 21678, - "▁Container": 21679, - "▁назна": 21680, - "▁DEBUG": 21681, - "▁hurt": 21682, - "▁Polski": 21683, - "▁lux": 21684, - "CB": 21685, - "wach": 21686, - "▁период": 21687, - "▁Catherine": 21688, - "▁ganz": 21689, - "uchte": 21690, - "▁consumer": 21691, - "▁crossed": 21692, - "ordered": 21693, - "away": 21694, - "techn": 21695, - "▁subscri": 21696, - "▁shortcut": 21697, - "▁производ": 21698, - "▁simultaneously": 21699, - "▁rating": 21700, - "▁Kings": 21701, - "▁relationships": 21702, - "▁Sex": 21703, - "▁Tool": 21704, - "agh": 21705, - "acters": 21706, - "logger": 21707, - "homme": 21708, - "engers": 21709, - "▁Ri": 21710, - "earance": 21711, - "▁appearances": 21712, - "Real": 21713, - "▁passe": 21714, - "iclopedia": 21715, - "чко": 21716, - "terre": 21717, - "▁Ontario": 21718, - "▁переда": 21719, - "footer": 21720, - "archivi": 21721, - "ifiz": 21722, - "▁Protest": 21723, - "▁LIN": 21724, - "unnable": 21725, - "▁centuries": 21726, - "▁Bayer": 21727, - "цію": 21728, - "овин": 21729, - "▁Andrea": 21730, - "selection": 21731, - "▁calm": 21732, - "▁modification": 21733, - "▁shortly": 21734, - "inaire": 21735, - "▁fusion": 21736, - "▁feelings": 21737, - "PK": 21738, - "▁Roberto": 21739, - "гне": 21740, - "Shared": 21741, - "▁mehrere": 21742, - "▁Niem": 21743, - "omp": 21744, - "Env": 21745, - "▁Article": 21746, - "▁Pok": 21747, - "▁VARCHAR": 21748, - "▁dil": 21749, - "▁afford": 21750, - "▁confront": 21751, - "owanie": 21752, - "▁ministre": 21753, - "adesh": 21754, - "▁Poly": 21755, - "▁Распо": 21756, - "▁Gruppe": 21757, - "▁Helen": 21758, - "▁cc": 21759, - "▁portrait": 21760, - "bew": 21761, - "▁beta": 21762, - "▁Wir": 21763, - "▁Audio": 21764, - "▁(\\<": 21765, - "riority": 21766, - "▁nit": 21767, - "▁представи": 21768, - "▁Vie": 21769, - "▁wür": 21770, - "▁Hold": 21771, - "▁Sad": 21772, - "▁Tochter": 21773, - "▁oltre": 21774, - "▁Activ": 21775, - "▁Jason": 21776, - "▁wieku": 21777, - "▁regards": 21778, - "▁taste": 21779, - "agnostic": 21780, - "лася": 21781, - "▁Self": 21782, - "▁apr": 21783, - "▁Deep": 21784, - "scop": 21785, - "Activ": 21786, - "▁typedef": 21787, - "ContentView": 21788, - "compiler": 21789, - "▁Roth": 21790, - "xc": 21791, - "зик": 21792, - "▁largo": 21793, - "▁Rena": 21794, - "heiten": 21795, - "▁platforms": 21796, - "ulla": 21797, - "▁glance": 21798, - "▁mascul": 21799, - "▁mex": 21800, - "▁Jorge": 21801, - "▁funcion": 21802, - "choose": 21803, - "▁reviews": 21804, - "▁Alban": 21805, - "▁Glo": 21806, - "▁Species": 21807, - "▁Fame": 21808, - "▁Roll": 21809, - "▁Puerto": 21810, - "▁\\)": 21811, - "ymnas": 21812, - "environ": 21813, - "▁iphone": 21814, - "▁Wrestling": 21815, - "ały": 21816, - "▁Indiana": 21817, - "Radio": 21818, - "VS": 21819, - "▁independence": 21820, - "тай": 21821, - "▁decode": 21822, - "White": 21823, - "▁journ": 21824, - "ículo": 21825, - "▁Barb": 21826, - "▁Evangel": 21827, - "▁Andy": 21828, - "▁Welcome": 21829, - "▁Device": 21830, - "gef": 21831, - "▁remembered": 21832, - "▁variations": 21833, - "▁Adolf": 21834, - "itaine": 21835, - "▁надморској": 21836, - "▁steam": 21837, - "▁concerns": 21838, - "▁`|": 21839, - "▁био": 21840, - "тельства": 21841, - "▁quattro": 21842, - "extend": 21843, - "▁trabajo": 21844, - "enberg": 21845, - "▁scenarios": 21846, - "ânt": 21847, - "▁kommt": 21848, - "▁domestic": 21849, - "▁Basketball": 21850, - "▁Cooper": 21851, - "sock": 21852, - "держа": 21853, - "={\\": 21854, - "▁inici": 21855, - "▁Phill": 21856, - "▁генерал": 21857, - "archiviato": 21858, - "ън": 21859, - "Rob": 21860, - "▁tong": 21861, - "▁characteristics": 21862, - "▁amaz": 21863, - "▁Mode": 21864, - "▁inaugur": 21865, - "wehr": 21866, - "rant": 21867, - "ionali": 21868, - "▁Mother": 21869, - "Ma": 21870, - "équ": 21871, - "▁Kelly": 21872, - "cile": 21873, - "▁besteht": 21874, - "▁estimates": 21875, - "ruguay": 21876, - "▁Ans": 21877, - "Mad": 21878, - "▁нав": 21879, - "▁données": 21880, - "▁tropical": 21881, - "▁Several": 21882, - "elter": 21883, - "▁Pho": 21884, - "kem": 21885, - "▁Customer": 21886, - "▁складі": 21887, - "▁courses": 21888, - "Platform": 21889, - "navbar": 21890, - "learning": 21891, - "▁Swedish": 21892, - "▁zast": 21893, - "▁Lig": 21894, - "management": 21895, - "▁lod": 21896, - "uffle": 21897, - "Texture": 21898, - "arga": 21899, - "átum": 21900, - "▁DDR": 21901, - "нії": 21902, - "▁Société": 21903, - "▁domains": 21904, - "▁permitted": 21905, - "▁externe": 21906, - "▁quelque": 21907, - "vt": 21908, - "yman": 21909, - "▁Ward": 21910, - "▁agli": 21911, - "▁andra": 21912, - "Snapshot": 21913, - "▁må": 21914, - "▁yeah": 21915, - "дена": 21916, - "ępu": 21917, - "askell": 21918, - "▁République": 21919, - "inject": 21920, - "▁';": 21921, - "änn": 21922, - "▁zelf": 21923, - "▁Entwicklung": 21924, - "ária": 21925, - "onomy": 21926, - "▁svil": 21927, - "iese": 21928, - "▁conser": 21929, - "▁nim": 21930, - "▁rész": 21931, - "▁Итали": 21932, - "▁partici": 21933, - "▁Lion": 21934, - "sr": 21935, - "always": 21936, - "▁Владимир": 21937, - "ческие": 21938, - "[,": 21939, - "▁Definition": 21940, - "nant": 21941, - "oem": 21942, - "Ids": 21943, - "▁вне": 21944, - "▁[...]": 21945, - "▁направ": 21946, - "▁GO": 21947, - "▁års": 21948, - "▁után": 21949, - "▁outros": 21950, - "▁región": 21951, - "▁Mong": 21952, - "▁filme": 21953, - "▁triple": 21954, - "▁spons": 21955, - "Develop": 21956, - "▁outcome": 21957, - "▁Bible": 21958, - "▁имени": 21959, - "Canvas": 21960, - "пута": 21961, - "curr": 21962, - "ások": 21963, - "){\\": 21964, - "ningar": 21965, - "`;": 21966, - "▁Flash": 21967, - ":#": 21968, - "must": 21969, - "cpu": 21970, - "▁formats": 21971, - "Har": 21972, - "▁episodio": 21973, - "▁Rosa": 21974, - "▁dès": 21975, - "emit": 21976, - "riteria": 21977, - "Annotation": 21978, - "Flag": 21979, - "gmail": 21980, - "▁Normal": 21981, - "ollary": 21982, - "▁foss": 21983, - "▁concurrent": 21984, - "▁crashes": 21985, - "▁виде": 21986, - "▁Minor": 21987, - "▁Sit": 21988, - "▁SN": 21989, - "▁scar": 21990, - "▁femin": 21991, - "▁specification": 21992, - "soap": 21993, - "▁operate": 21994, - "▁principalmente": 21995, - "▁aust": 21996, - "ibile": 21997, - "itime": 21998, - "лежа": 21999, - "iframe": 22000, - "▁concepts": 22001, - "▁tack": 22002, - "▁viss": 22003, - "▁carbon": 22004, - "tery": 22005, - "▁naming": 22006, - "▁Orts": 22007, - "idente": 22008, - "▁Capit": 22009, - "▁expr": 22010, - "▁насељу": 22011, - "▁Selected": 22012, - "▁hinter": 22013, - "▁iframe": 22014, - "▁zb": 22015, - "indexPath": 22016, - "coll": 22017, - "▁wrześ": 22018, - "▁acht": 22019, - "▁gradually": 22020, - "▁чу": 22021, - "зей": 22022, - "haft": 22023, - "▁tran": 22024, - "▁laquelle": 22025, - "ytics": 22026, - "IDE": 22027, - "▁pygame": 22028, - "▁Package": 22029, - "▁className": 22030, - "Bal": 22031, - "perl": 22032, - "тина": 22033, - "Occ": 22034, - "▁infrastr": 22035, - "▁Champions": 22036, - "▁classic": 22037, - "▁Raw": 22038, - "▁partially": 22039, - "▁Ted": 22040, - "▁stolet": 22041, - "rained": 22042, - "WHERE": 22043, - "▁vall": 22044, - "▁Julia": 22045, - "zat": 22046, - "▁surrounded": 22047, - "SEE": 22048, - "▁walking": 22049, - "Bad": 22050, - "FOR": 22051, - "contre": 22052, - "▁Palest": 22053, - "ático": 22054, - "▁engineer": 22055, - "▁partners": 22056, - "▁Jews": 22057, - "ilers": 22058, - "▁cerem": 22059, - "▁interactions": 22060, - "acu": 22061, - "sty": 22062, - "▁Princess": 22063, - "sharp": 22064, - "▁Singles": 22065, - "▁їх": 22066, - "chez": 22067, - "Receiver": 22068, - "▁patients": 22069, - "stringify": 22070, - "▁competed": 22071, - "bey": 22072, - "$;": 22073, - "▁Bd": 22074, - "hadoop": 22075, - "▁División": 22076, - "öld": 22077, - "▁restricted": 22078, - "▁commander": 22079, - "▁Highway": 22080, - "▁Česk": 22081, - "▁myth": 22082, - "чан": 22083, - "raham": 22084, - "▁enqu": 22085, - "▁pog": 22086, - "▁comuna": 22087, - "▁println": 22088, - "▁круп": 22089, - "▁depois": 22090, - "▁seats": 22091, - "▁neighb": 22092, - "циона": 22093, - "agine": 22094, - "▁clothes": 22095, - "▁Prior": 22096, - "Brain": 22097, - "FFFF": 22098, - "':'": 22099, - "features": 22100, - "▁filesystem": 22101, - "▁singles": 22102, - "▁Melbourne": 22103, - "▁destruction": 22104, - "▁Lyon": 22105, - "▁Insel": 22106, - "Nav": 22107, - "▁Replace": 22108, - "▁lé": 22109, - "Who": 22110, - "▁Estad": 22111, - "▁dimensional": 22112, - "▁öff": 22113, - "▁grands": 22114, - "джа": 22115, - "plane": 22116, - "ності": 22117, - "▁Origin": 22118, - "WI": 22119, - "änner": 22120, - "▁Cry": 22121, - "ITION": 22122, - "▁född": 22123, - "▁cultura": 22124, - "▁Rank": 22125, - "▁vuel": 22126, - "▁zag": 22127, - "▁Maxim": 22128, - "ону": 22129, - "()))": 22130, - "Raw": 22131, - "kirche": 22132, - "▁además": 22133, - "▁tie": 22134, - "▁Style": 22135, - "сков": 22136, - "istant": 22137, - "olph": 22138, - "▁Zür": 22139, - "▁Info": 22140, - "DOM": 22141, - "usc": 22142, - "nahm": 22143, - "▁Федера": 22144, - "▁Fot": 22145, - "▁specifying": 22146, - "▁titolo": 22147, - "▁Boys": 22148, - "iech": 22149, - "Place": 22150, - "▁Hoff": 22151, - "▁cached": 22152, - "валь": 22153, - "isher": 22154, - "rolling": 22155, - "opens": 22156, - "▁hr": 22157, - "------": 22158, - "▁maggior": 22159, - "▁transactions": 22160, - "▁criminal": 22161, - "▁retre": 22162, - "▁Campbell": 22163, - ")):": 22164, - "▁ned": 22165, - "Pager": 22166, - "▁Hero": 22167, - "(__": 22168, - "▁uncle": 22169, - "▁reaches": 22170, - "arto": 22171, - "▁hello": 22172, - "Preferences": 22173, - "▁затем": 22174, - "Named": 22175, - "▁readers": 22176, - "хі": 22177, - "kern": 22178, - "▁упо": 22179, - "кин": 22180, - "▁lav": 22181, - "▁nob": 22182, - "▁secre": 22183, - "▁ListView": 22184, - "вания": 22185, - "▁Mayor": 22186, - "borough": 22187, - "▁filosof": 22188, - "нення": 22189, - "фри": 22190, - "▁patr": 22191, - "FM": 22192, - "▁acid": 22193, - "▁Salvador": 22194, - "▁abb": 22195, - "▁Graham": 22196, - "policy": 22197, - "negative": 22198, - "ńskiego": 22199, - "▁Heimat": 22200, - "▁dazu": 22201, - "▁mely": 22202, - "▁ride": 22203, - "▁duties": 22204, - "overy": 22205, - "▁Proposition": 22206, - "▁Paolo": 22207, - "/'": 22208, - "▁Mau": 22209, - "imenti": 22210, - "Saint": 22211, - "father": 22212, - "▁equilib": 22213, - "phony": 22214, - "▁clas": 22215, - "▁отли": 22216, - "▁Buffered": 22217, - "rek": 22218, - "▁mitt": 22219, - "▁Hur": 22220, - "▁Harvard": 22221, - "▁demonstrate": 22222, - "uario": 22223, - "▁dolor": 22224, - "▁rejected": 22225, - "▁Müller": 22226, - "▁nac": 22227, - "▁Belle": 22228, - "▁gathered": 22229, - "nr": 22230, - "frika": 22231, - "öll": 22232, - "▁chemical": 22233, - "nig": 22234, - "▁calc": 22235, - "▁DEFAULT": 22236, - "▁philosophy": 22237, - "▁Laravel": 22238, - "▁alignment": 22239, - "EV": 22240, - "eor": 22241, - "▁dzie": 22242, - "▁mest": 22243, - "▁Io": 22244, - "CRE": 22245, - "зви": 22246, - "▁Medic": 22247, - "▁nä": 22248, - "▁zab": 22249, - "▁Slov": 22250, - "utlich": 22251, - "▁amplit": 22252, - "▁Frankreich": 22253, - "▁кіль": 22254, - "IND": 22255, - "execution": 22256, - "▁Karriere": 22257, - "dostęp": 22258, - "▁réal": 22259, - "engo": 22260, - "▁severe": 22261, - "зма": 22262, - "▁турни": 22263, - "▁Carter": 22264, - "▁Robinson": 22265, - "getElementsBy": 22266, - "▁prototype": 22267, - "▁japon": 22268, - "führung": 22269, - "▁consegu": 22270, - "▁studi": 22271, - "▁lire": 22272, - "▁schließ": 22273, - "▁Buff": 22274, - "▁redund": 22275, - "▁ern": 22276, - "▁myster": 22277, - "▁proprio": 22278, - "ateful": 22279, - "▁Parent": 22280, - "▁ladies": 22281, - "rack": 22282, - "тика": 22283, - "enburg": 22284, - "▁качестве": 22285, - "▁EF": 22286, - "▁stam": 22287, - "▁nueva": 22288, - "▁filtered": 22289, - "reten": 22290, - "▁Ian": 22291, - "▁Matthew": 22292, - "kih": 22293, - "▁ő": 22294, - "▁компози": 22295, - "▁forever": 22296, - "oires": 22297, - ":\\\\": 22298, - "▁études": 22299, - "▁soup": 22300, - "▁pleased": 22301, - ")}(": 22302, - "▁Stop": 22303, - "Setter": 22304, - "▁Help": 22305, - "▁bars": 22306, - "▁ERR": 22307, - "▁(?": 22308, - "▁poetry": 22309, - "▁Util": 22310, - "AK": 22311, - "▁fick": 22312, - "▁IM": 22313, - "▁proud": 22314, - "носи": 22315, - "▁muerte": 22316, - "▁Palmarès": 22317, - "▁Nas": 22318, - "щих": 22319, - "▁quer": 22320, - "▁apenas": 22321, - "]['": 22322, - "▁Konst": 22323, - "пон": 22324, - "▁Schiff": 22325, - "▁mp": 22326, - "▁благо": 22327, - "fram": 22328, - "▁household": 22329, - "▁tract": 22330, - "encoding": 22331, - "▁undert": 22332, - "▁Aug": 22333, - "ован": 22334, - "▁Arten": 22335, - "▁invoked": 22336, - "▁dynast": 22337, - "▁fleet": 22338, - "чество": 22339, - "▁Murray": 22340, - "▁gut": 22341, - "elihood": 22342, - "▁SSH": 22343, - "ответ": 22344, - "▁personally": 22345, - "прия": 22346, - "▁financi": 22347, - "▁Thompson": 22348, - "alu": 22349, - "identity": 22350, - "▁Grab": 22351, - "addle": 22352, - "Ét": 22353, - "▁Tob": 22354, - "▁verlor": 22355, - "▁Sainte": 22356, - "▁dop": 22357, - "▁вере": 22358, - "___": 22359, - "▁promotion": 22360, - "▁-=": 22361, - "▁отде": 22362, - "▁ambigu": 22363, - "ORDER": 22364, - "▁Communic": 22365, - "▁imply": 22366, - "oned": 22367, - "cluding": 22368, - "▁collision": 22369, - "▁fragments": 22370, - "scription": 22371, - "▁'{": 22372, - "лях": 22373, - "▁hans": 22374, - "ус": 22375, - "wire": 22376, - "namespace": 22377, - "▁sword": 22378, - "refresh": 22379, - "▁kwam": 22380, - "zs": 22381, - "commons": 22382, - "▁cosa": 22383, - "▁regime": 22384, - "grep": 22385, - "▁dioc": 22386, - "▁Contact": 22387, - "▁estas": 22388, - "▁Stewart": 22389, - "▁viele": 22390, - "това": 22391, - "▁Ran": 22392, - "annes": 22393, - "iday": 22394, - "▁snapshot": 22395, - "orrow": 22396, - "▁zač": 22397, - "▁участие": 22398, - "▁promised": 22399, - "Assembly": 22400, - "▁championship": 22401, - "▁Define": 22402, - "▁eren": 22403, - "▁ново": 22404, - "▁thinks": 22405, - "Age": 22406, - "▁gev": 22407, - "varchar": 22408, - "ività": 22409, - "compos": 22410, - "▁Mutter": 22411, - "CONT": 22412, - "armée": 22413, - "agnet": 22414, - "▁Brow": 22415, - ".—": 22416, - "▁Television": 22417, - "▁Для": 22418, - "▁vm": 22419, - "▁ordin": 22420, - "▁Михай": 22421, - "▁aproxim": 22422, - "')->": 22423, - "▁zoo": 22424, - "ippi": 22425, - "▁sino": 22426, - "▁Québec": 22427, - "rages": 22428, - "äck": 22429, - "eing": 22430, - "arlo": 22431, - "pios": 22432, - "▁Chan": 22433, - "▁elli": 22434, - "▁incons": 22435, - "gestellt": 22436, - "ppers": 22437, - "Jean": 22438, - "anstalt": 22439, - "▁Dance": 22440, - "▁toen": 22441, - "▁decis": 22442, - "▁Резу": 22443, - "▁officially": 22444, - "ätze": 22445, - "▁доро": 22446, - "▁enumer": 22447, - "▁troisième": 22448, - "typ": 22449, - "offs": 22450, - "боль": 22451, - "odn": 22452, - "▁Zar": 22453, - "▁друго": 22454, - "quia": 22455, - "▁Nicolas": 22456, - "пису": 22457, - "▁mob": 22458, - "paces": 22459, - "нього": 22460, - "Alg": 22461, - "éroï": 22462, - "Errors": 22463, - "▁гре": 22464, - "▁женщи": 22465, - "inch": 22466, - "▁Korean": 22467, - "▁Apost": 22468, - "▁Liver": 22469, - "▁elementary": 22470, - "▁DI": 22471, - "виси": 22472, - "▁soil": 22473, - "▁DLL": 22474, - "▁risp": 22475, - "▁Shakespe": 22476, - "▁Gaussian": 22477, - "▁Kurt": 22478, - "Vertex": 22479, - "ebol": 22480, - "organisation": 22481, - "ären": 22482, - "▁YES": 22483, - "CUR": 22484, - "▁началь": 22485, - "▁постро": 22486, - "▁Luigi": 22487, - "▁caching": 22488, - "preventDefault": 22489, - "amd": 22490, - "▁Vit": 22491, - "subst": 22492, - "▁строи": 22493, - "▁Campion": 22494, - "chr": 22495, - "фере": 22496, - "▁Список": 22497, - "NF": 22498, - "▁cím": 22499, - "▁hé": 22500, - "rebbe": 22501, - "ocy": 22502, - "below": 22503, - "▁bylo": 22504, - "▁Уи": 22505, - "▁\\({\\": 22506, - "▁`:": 22507, - "giore": 22508, - "San": 22509, - "▁Gate": 22510, - "▁вс": 22511, - "▁olimp": 22512, - "▁Matrix": 22513, - "▁hearing": 22514, - "rii": 22515, - "tfrac": 22516, - "▁allemand": 22517, - "▁Vue": 22518, - "лн": 22519, - "▁compiling": 22520, - "▁Ens": 22521, - "▁investigation": 22522, - "▁Ax": 22523, - "▁chars": 22524, - "▁targets": 22525, - "▁loud": 22526, - "usement": 22527, - "▁Nether": 22528, - "commerce": 22529, - "IGHT": 22530, - "ocoa": 22531, - "ifecycle": 22532, - "▁Leo": 22533, - "priv": 22534, - "▁goods": 22535, - "adamente": 22536, - "Austral": 22537, - "▁reboot": 22538, - "Gest": 22539, - "▁representations": 22540, - "ceu": 22541, - "▁doctrine": 22542, - "cers": 22543, - "▁Krak": 22544, - "▁advoc": 22545, - "▁squadra": 22546, - "▁arbeitete": 22547, - "üst": 22548, - "▁pill": 22549, - "Answer": 22550, - "▁квіт": 22551, - "▁Wa": 22552, - "umann": 22553, - "▁Dynam": 22554, - "Famil": 22555, - "▁tennis": 22556, - "▁Engineering": 22557, - "▁circles": 22558, - "▁Maryland": 22559, - "▁besta": 22560, - "▁bases": 22561, - "▁znajdu": 22562, - "ктора": 22563, - "▁arrest": 22564, - "лер": 22565, - "▁Gia": 22566, - "▁remarkable": 22567, - "▁могу": 22568, - "▁Supreme": 22569, - "▁`%": 22570, - "dor": 22571, - "▁aujourd": 22572, - "▁wis": 22573, - "WIDTH": 22574, - "▁misma": 22575, - "▁fluid": 22576, - "▁petite": 22577, - "▁Tow": 22578, - "Registry": 22579, - "emed": 22580, - "▁Wisconsin": 22581, - "▁Racing": 22582, - "▁registration": 22583, - "/%": 22584, - "third": 22585, - "▁monuments": 22586, - "чей": 22587, - "▁jet": 22588, - "▁Urban": 22589, - "álva": 22590, - "▁milieu": 22591, - "▁possess": 22592, - "▁germ": 22593, - "dependencies": 22594, - "▁enemies": 22595, - "▁samen": 22596, - "▁Werner": 22597, - "▁hizo": 22598, - "▁td": 22599, - "▁yesterday": 22600, - "▁Ад": 22601, - "▁hasn": 22602, - "cellation": 22603, - "ování": 22604, - "lika": 22605, - "Week": 22606, - "▁Ing": 22607, - "▁Email": 22608, - "▁mètres": 22609, - "▁OCLC": 22610, - "▁amongst": 22611, - "▁splend": 22612, - "fur": 22613, - "antics": 22614, - "▁XXX": 22615, - "▁группы": 22616, - "lach": 22617, - "▁cousin": 22618, - "▁invariant": 22619, - "ђу": 22620, - "▁Beispiel": 22621, - "▁harder": 22622, - "▁bell": 22623, - "▁orch": 22624, - "tb": 22625, - "Footnote": 22626, - "regon": 22627, - "Martin": 22628, - "▁incon": 22629, - "▁attacked": 22630, - "_{-": 22631, - "▁Tras": 22632, - "party": 22633, - "iteit": 22634, - "▁saint": 22635, - "rások": 22636, - "▁containers": 22637, - "Mo": 22638, - "▁Sn": 22639, - "quantity": 22640, - "▁ras": 22641, - "▁Canal": 22642, - "ccion": 22643, - "uvo": 22644, - "▁idx": 22645, - "typename": 22646, - "▁Rugby": 22647, - "▁Seems": 22648, - "▁transmit": 22649, - "▁Präsident": 22650, - "зне": 22651, - "▁Baker": 22652, - "inth": 22653, - "▁több": 22654, - "verein": 22655, - "▁especie": 22656, - ",(": 22657, - "▁téc": 22658, - "▁WITH": 22659, - "▁unos": 22660, - "▁politics": 22661, - "createElement": 22662, - "▁stats": 22663, - "▁Tennessee": 22664, - "▁Bedeutung": 22665, - "▁Screen": 22666, - "▁Straße": 22667, - "anze": 22668, - "▁partly": 22669, - "manuel": 22670, - "olation": 22671, - "horizontal": 22672, - "érieure": 22673, - "ampio": 22674, - "▁струк": 22675, - "Weight": 22676, - "Land": 22677, - "poly": 22678, - "▁Dak": 22679, - "▁Assume": 22680, - "\".$": 22681, - "▁casi": 22682, - "▁gross": 22683, - "▁entertain": 22684, - "▁década": 22685, - "'.$": 22686, - "encer": 22687, - "▁guaranteed": 22688, - "]$.": 22689, - "лися": 22690, - "▁acceptable": 22691, - "raise": 22692, - "irus": 22693, - "weit": 22694, - "▁Ана": 22695, - "▁hills": 22696, - "ipage": 22697, - "BIT": 22698, - "▁nucle": 22699, - "▁utilis": 22700, - "CAA": 22701, - "ènes": 22702, - "▁Schweiz": 22703, - "▁AA": 22704, - "ninger": 22705, - "▁bands": 22706, - "▁tender": 22707, - "som": 22708, - "Warning": 22709, - "▁Bischof": 22710, - "▁Arc": 22711, - "▁Woman": 22712, - "▁transmission": 22713, - "чни": 22714, - "istre": 22715, - "BY": 22716, - "▁SI": 22717, - "▁Пар": 22718, - "▁}).": 22719, - "▁presenta": 22720, - "▁René": 22721, - "▁happiness": 22722, - "▁Punk": 22723, - "cols": 22724, - "▁Desde": 22725, - "рёх": 22726, - "▁мона": 22727, - "▁scratch": 22728, - "▁tcp": 22729, - "êtes": 22730, - "itated": 22731, - "▁diferen": 22732, - "geh": 22733, - "nahmen": 22734, - "Пе": 22735, - "cki": 22736, - "▁Teatro": 22737, - "▁Remember": 22738, - "▁fright": 22739, - "▁Yam": 22740, - "western": 22741, - "leted": 22742, - "▁встре": 22743, - "▁település": 22744, - "зин": 22745, - "▁Quant": 22746, - "▁supre": 22747, - "ája": 22748, - "дія": 22749, - "▁carrera": 22750, - "kret": 22751, - "para": 22752, - "▁SUM": 22753, - "▁pit": 22754, - "źdz": 22755, - "éo": 22756, - "рення": 22757, - "▁Chor": 22758, - "▁voix": 22759, - "▁executive": 22760, - "▁allerdings": 22761, - "Maybe": 22762, - "▁день": 22763, - "▁flying": 22764, - "▁parliament": 22765, - "ждан": 22766, - "▁fram": 22767, - "▁жовт": 22768, - "▁ugly": 22769, - "▁буду": 22770, - "igny": 22771, - "\\|_{": 22772, - "▁bitter": 22773, - "sce": 22774, - "▁pole": 22775, - "Verlag": 22776, - "▁totalité": 22777, - "▁foundation": 22778, - "jt": 22779, - "▁slice": 22780, - "ifique": 22781, - "▁integrate": 22782, - "strij": 22783, - "▁asympt": 22784, - "▁ему": 22785, - "▁perturb": 22786, - "▁Flow": 22787, - "jboss": 22788, - "RIG": 22789, - "▁Aless": 22790, - "XXX": 22791, - "▁summ": 22792, - "sqlite": 22793, - "▁cheer": 22794, - "prob": 22795, - "▁GPU": 22796, - "ził": 22797, - "(*)": 22798, - "▁induct": 22799, - "RAY": 22800, - "blatt": 22801, - "questa": 22802, - "oru": 22803, - "▁Inside": 22804, - "▁McG": 22805, - "▁Nep": 22806, - "мп": 22807, - "▁inve": 22808, - "▁Animal": 22809, - "▁sob": 22810, - "ított": 22811, - "loyment": 22812, - "▁bund": 22813, - "Station": 22814, - "▁BEGIN": 22815, - "▁partiellement": 22816, - "igg": 22817, - "estore": 22818, - "▁coinc": 22819, - "▁Sommer": 22820, - "▁md": 22821, - "▁locked": 22822, - "mathchar": 22823, - "arma": 22824, - "pent": 22825, - "arium": 22826, - "▁ears": 22827, - "▁Songs": 22828, - "▁similarly": 22829, - "▁literally": 22830, - "▁inches": 22831, - "▁affection": 22832, - "lp": 22833, - "▁concluded": 22834, - "▁муніципалі": 22835, - "▁памя": 22836, - "estaur": 22837, - "▁Josh": 22838, - "▁Fritz": 22839, - "DBC": 22840, - "дён": 22841, - "posa": 22842, - "▁golden": 22843, - "▁pc": 22844, - "▁comte": 22845, - "▁Ziel": 22846, - "▁présente": 22847, - "marks": 22848, - "igneur": 22849, - "▁Drive": 22850, - "▁neglect": 22851, - "▁rozp": 22852, - "▁Five": 22853, - "spaces": 22854, - "▁Medi": 22855, - "▁existed": 22856, - "▁była": 22857, - "джи": 22858, - "▁frente": 22859, - "тник": 22860, - "odd": 22861, - "▁answering": 22862, - "bian": 22863, - "▁Eugen": 22864, - "▁Publications": 22865, - "▁Dia": 22866, - "lá": 22867, - "▁'_": 22868, - "▁recuper": 22869, - "ому": 22870, - "▁Append": 22871, - "obar": 22872, - "▁employees": 22873, - "▁compens": 22874, - "emetery": 22875, - "▁элект": 22876, - "MON": 22877, - "olin": 22878, - "▁historic": 22879, - "his": 22880, - "ąd": 22881, - "nm": 22882, - "▁Goth": 22883, - "▁stress": 22884, - "▁partecip": 22885, - "▁Aw": 22886, - "▁sar": 22887, - "▁hu": 22888, - "▁matplotlib": 22889, - "▁Myst": 22890, - "();`": 22891, - "schein": 22892, - "Longrightarrow": 22893, - "▁ря": 22894, - "▁Isra": 22895, - "[^": 22896, - "nou": 22897, - "▁synd": 22898, - "working": 22899, - "▁Nation": 22900, - "▁Pent": 22901, - "▁klass": 22902, - "▁applicable": 22903, - "▁Diam": 22904, - "▁brasile": 22905, - "▁pac": 22906, - "▁Height": 22907, - "Put": 22908, - "▁intro": 22909, - "▁unusual": 22910, - "nas": 22911, - "▁Gebäude": 22912, - "▁beam": 22913, - "▁Rect": 22914, - "▁Primera": 22915, - "▁haut": 22916, - "▁trait": 22917, - "prüft": 22918, - "inación": 22919, - "▁configurations": 22920, - "▁gilt": 22921, - "▁territoire": 22922, - "hez": 22923, - "▁alte": 22924, - "relative": 22925, - "Excel": 22926, - "▁Wright": 22927, - "GV": 22928, - "поли": 22929, - "Quant": 22930, - "▁gauge": 22931, - "▁multiply": 22932, - "ASS": 22933, - "ственно": 22934, - "ану": 22935, - "▁jeden": 22936, - "▁literary": 22937, - "▁Dro": 22938, - "▁advise": 22939, - "itzen": 22940, - "▁disag": 22941, - "website": 22942, - "▁дія": 22943, - "▁observer": 22944, - "▁január": 22945, - "vě": 22946, - "kup": 22947, - "▁Ses": 22948, - "▁wojew": 22949, - "▁stages": 22950, - "▁времени": 22951, - "łuż": 22952, - "нос": 22953, - "Download": 22954, - "ipo": 22955, - "▁graf": 22956, - "▁робо": 22957, - "▁Nikol": 22958, - "▁fic": 22959, - "▁joining": 22960, - "▁diversos": 22961, - "▁LIKE": 22962, - "▁Fitz": 22963, - "▁dimin": 22964, - "▁distrib": 22965, - "Sam": 22966, - "koz": 22967, - "▁alphabet": 22968, - "oser": 22969, - "OUR": 22970, - "uka": 22971, - "кая": 22972, - "▁steel": 22973, - "▁`--": 22974, - "▁tener": 22975, - "marker": 22976, - "▁Heaven": 22977, - "newcommand": 22978, - "▁prisoners": 22979, - "▁Knight": 22980, - "▁presents": 22981, - "▁questi": 22982, - "▁trains": 22983, - "opera": 22984, - "▁Linear": 22985, - "▁ME": 22986, - "▁Buc": 22987, - "Leg": 22988, - "▁agua": 22989, - "▁Griff": 22990, - "olg": 22991, - "dst": 22992, - ".\r": 22993, - "▁persones": 22994, - "Mal": 22995, - "бере": 22996, - "folge": 22997, - "▁acab": 22998, - "ctu": 22999, - "ptic": 23000, - "▁Navigation": 23001, - "Russ": 23002, - "галь": 23003, - "▁Ful": 23004, - "▁має": 23005, - "чная": 23006, - "wner": 23007, - "contra": 23008, - "▁joueur": 23009, - "▁Jess": 23010, - "▁renew": 23011, - "▁lap": 23012, - "▁casting": 23013, - "gal": 23014, - "▁tématu": 23015, - "▁называ": 23016, - "зах": 23017, - "чне": 23018, - ")-\\": 23019, - "▁часто": 23020, - "}$-": 23021, - "▁licz": 23022, - "▁emot": 23023, - "harm": 23024, - "▁occasionally": 23025, - "▁horror": 23026, - "east": 23027, - "▁printer": 23028, - "aran": 23029, - "▁Mississ": 23030, - "follow": 23031, - "▁Barry": 23032, - "▁investigate": 23033, - "gow": 23034, - "▁Americans": 23035, - "Since": 23036, - "▁відо": 23037, - "▁reun": 23038, - "osci": 23039, - "▁Chapter": 23040, - "▁bay": 23041, - "роме": 23042, - "ethe": 23043, - "édie": 23044, - "comot": 23045, - "▁miejscowo": 23046, - "▁studierte": 23047, - "ouvert": 23048, - "▁кур": 23049, - "▁DESC": 23050, - "▁touched": 23051, - "▁Jerry": 23052, - "uese": 23053, - "лище": 23054, - "authentication": 23055, - "▁colle": 23056, - "heart": 23057, - "▁regiment": 23058, - "cribed": 23059, - "▁Боль": 23060, - "▁проис": 23061, - "ceae": 23062, - "▁masses": 23063, - "▁scrolling": 23064, - "usto": 23065, - "SW": 23066, - "ovat": 23067, - "▁grâce": 23068, - "▁Архив": 23069, - "▁Север": 23070, - "avait": 23071, - "▁Marshall": 23072, - "▁HashMap": 23073, - "acon": 23074, - "ücken": 23075, - "[])": 23076, - "▁evangel": 23077, - "etzung": 23078, - "ttemberg": 23079, - "sters": 23080, - "TM": 23081, - "▁литера": 23082, - "quot": 23083, - "Pred": 23084, - "▁werk": 23085, - "▁haber": 23086, - "lava": 23087, - "vous": 23088, - "▁Late": 23089, - "cycle": 23090, - "тирова": 23091, - "▁проду": 23092, - "▁populations": 23093, - "▁Yan": 23094, - "Prefix": 23095, - "actéristiques": 23096, - "+'": 23097, - "()`](": 23098, - "▁Ль": 23099, - "филь": 23100, - "▁жизни": 23101, - "ftp": 23102, - "▁всех": 23103, - "▁gdzie": 23104, - "▁videa": 23105, - "oauth": 23106, - "▁pid": 23107, - "ům": 23108, - "▁pesso": 23109, - "▁tracking": 23110, - "izin": 23111, - "▁Morris": 23112, - "щий": 23113, - "▁Provinz": 23114, - "▁Mitte": 23115, - "▁artificial": 23116, - "brázky": 23117, - "▁дости": 23118, - "▁restored": 23119, - "▁communicate": 23120, - "agit": 23121, - "Recogn": 23122, - "▁lon": 23123, - "▁заня": 23124, - "▁Argument": 23125, - "flush": 23126, - "мана": 23127, - "seconds": 23128, - "UC": 23129, - "▁Ruth": 23130, - "▁tub": 23131, - "▁Bret": 23132, - "▁Pere": 23133, - "▁responsibility": 23134, - "ńczy": 23135, - "▁environments": 23136, - "kee": 23137, - "▁groot": 23138, - "▁painted": 23139, - "▁Éditions": 23140, - "cpy": 23141, - "árt": 23142, - "lichkeit": 23143, - "arda": 23144, - "Batch": 23145, - "▁Leopold": 23146, - "reason": 23147, - "noreferrer": 23148, - "sens": 23149, - "▁rocks": 23150, - "▁Hitler": 23151, - "лат": 23152, - "▁quoted": 23153, - "▁колле": 23154, - "▁уров": 23155, - "bag": 23156, - ".\")": 23157, - "▁ML": 23158, - "▁komt": 23159, - "▁[_": 23160, - "▁spectral": 23161, - "edo": 23162, - "▁insieme": 23163, - "▁suffering": 23164, - "slider": 23165, - "▁Kennedy": 23166, - "olate": 23167, - "▁Patri": 23168, - "зии": 23169, - "OH": 23170, - "▁теа": 23171, - "▁права": 23172, - "мах": 23173, - "rewrite": 23174, - "▁Einsatz": 23175, - "external": 23176, - "holds": 23177, - "▁Places": 23178, - "atype": 23179, - "▁vulner": 23180, - "▁abandoned": 23181, - "Origin": 23182, - "▁maximal": 23183, - "AAAA": 23184, - "▁Baseball": 23185, - "▁Close": 23186, - "▁painter": 23187, - "▁assigning": 23188, - "NB": 23189, - "blast": 23190, - "▁Künstler": 23191, - ")](": 23192, - "fach": 23193, - "▁Constantin": 23194, - "okes": 23195, - "▁nobody": 23196, - "▁subtract": 23197, - "▁fosse": 23198, - "▁certific": 23199, - "▁muse": 23200, - "/),": 23201, - "▁Profil": 23202, - "▁proxim": 23203, - "▁Jerusalem": 23204, - "▁simplicity": 23205, - "▁wsz": 23206, - "NUMBER": 23207, - "uttavia": 23208, - "UITableView": 23209, - "ichter": 23210, - "жан": 23211, - "▁Lav": 23212, - "itchen": 23213, - "▁Чем": 23214, - "Tu": 23215, - "▁geom": 23216, - "▁zvuky": 23217, - "▁Survey": 23218, - "ANCE": 23219, - "▁encrypted": 23220, - "prof": 23221, - "▁dare": 23222, - "▁Loren": 23223, - "тв": 23224, - "▁Алек": 23225, - "▁computers": 23226, - "▁expectation": 23227, - "▁substantial": 23228, - "▁Дми": 23229, - "▁`{": 23230, - "▁дра": 23231, - "ubble": 23232, - "▁performs": 23233, - "▁Krieg": 23234, - "▁incoming": 23235, - "▁Classification": 23236, - "WebView": 23237, - "▁episodes": 23238, - "apper": 23239, - "äufig": 23240, - "▁giov": 23241, - "▁Depart": 23242, - "бора": 23243, - "edly": 23244, - "ospod": 23245, - "▁ptr": 23246, - "▁dátum": 23247, - "▁estimation": 23248, - "icole": 23249, - "▁----": 23250, - "▁princes": 23251, - "HEAD": 23252, - "▁diffusion": 23253, - "▁drie": 23254, - "▁Ada": 23255, - "нице": 23256, - "nginx": 23257, - "shal": 23258, - "▁februari": 23259, - "▁Tat": 23260, - "looking": 23261, - "kund": 23262, - "▁Dean": 23263, - "mongodb": 23264, - "вших": 23265, - "▁Aur": 23266, - "▁Flora": 23267, - "▁Studios": 23268, - "ције": 23269, - "eil": 23270, - "Install": 23271, - "▁franch": 23272, - "▁HMS": 23273, - "▁practices": 23274, - "lej": 23275, - "dale": 23276, - "▁poste": 23277, - "▁Hels": 23278, - "▁reliable": 23279, - "ździer": 23280, - "▁verse": 23281, - "ermeister": 23282, - "▁quit": 23283, - "ético": 23284, - "ilis": 23285, - "edor": 23286, - "▁Cultural": 23287, - "дже": 23288, - "▁liked": 23289, - "▁mongodb": 23290, - "▁Broadway": 23291, - "▁IR": 23292, - "eszt": 23293, - "hov": 23294, - "▁míst": 23295, - "reiche": 23296, - "▁kB": 23297, - "стом": 23298, - "▁SQLite": 23299, - "▁torneo": 23300, - "\\.": 23301, - "Ord": 23302, - "▁Administration": 23303, - "▁зда": 23304, - "▁Hinter": 23305, - "▁Via": 23306, - "Decimal": 23307, - "orious": 23308, - "▁nécessaire": 23309, - "wx": 23310, - "▁tej": 23311, - "▁tema": 23312, - "Obrázky": 23313, - "рите": 23314, - "▁builds": 23315, - "▁laten": 23316, - "▁гг": 23317, - "Visibility": 23318, - "läu": 23319, - "▁sechs": 23320, - "▁луч": 23321, - "cera": 23322, - "Could": 23323, - "▁traject": 23324, - "}}^{": 23325, - "▁Japon": 23326, - "another": 23327, - "IK": 23328, - "▁belonging": 23329, - "▁facilities": 23330, - "▁Daily": 23331, - "▁dece": 23332, - "intro": 23333, - "▁случа": 23334, - "Namespace": 23335, - "▁Bak": 23336, - "locale": 23337, - "UG": 23338, - "=${": 23339, - "▁compañ": 23340, - "jąc": 23341, - "▁arithmetic": 23342, - "forum": 23343, - "▁porta": 23344, - "onk": 23345, - "▁gender": 23346, - "▁expects": 23347, - "бка": 23348, - "▁nak": 23349, - "▁Grace": 23350, - "▁stro": 23351, - "ividual": 23352, - "▁COM": 23353, - "▁Farm": 23354, - "▁canton": 23355, - "тому": 23356, - "javax": 23357, - "сей": 23358, - "▁briefly": 23359, - "Face": 23360, - "rotate": 23361, - "constant": 23362, - "▁gallery": 23363, - "astro": 23364, - "allery": 23365, - "▁DJ": 23366, - "charge": 23367, - "ходить": 23368, - "Cent": 23369, - "\\\",": 23370, - "▁donna": 23371, - "arca": 23372, - "lade": 23373, - "zin": 23374, - "▁Ned": 23375, - "▁hosting": 23376, - "idor": 23377, - "itative": 23378, - "igs": 23379, - "▁пря": 23380, - "▁ticket": 23381, - "▁studying": 23382, - "▁designer": 23383, - "lapsed": 23384, - "▁laat": 23385, - "▁dix": 23386, - "▁integrated": 23387, - "▁informed": 23388, - "▁behave": 23389, - "▁labour": 23390, - "estellt": 23391, - "calendar": 23392, - "▁killing": 23393, - "▁twitter": 23394, - "iae": 23395, - "▁historique": 23396, - "DEFAULT": 23397, - "iała": 23398, - "▁theoretical": 23399, - "▁unders": 23400, - "ляет": 23401, - "atan": 23402, - "▁surname": 23403, - "▁intercept": 23404, - "гласно": 23405, - "▁општини": 23406, - "▁tired": 23407, - "▁Beth": 23408, - "▁административ": 23409, - "Li": 23410, - "▁Тур": 23411, - "▁Scanner": 23412, - "▁Stern": 23413, - "▁вместе": 23414, - "▁reporting": 23415, - "▁sull": 23416, - "цией": 23417, - "berts": 23418, - "ogonal": 23419, - "ők": 23420, - "▁ipsum": 23421, - "▁seulement": 23422, - "▁Seiten": 23423, - "wordpress": 23424, - "▁featuring": 23425, - "istischen": 23426, - "jub": 23427, - "▁étr": 23428, - "▁tea": 23429, - "▁adapted": 23430, - "▁scales": 23431, - "▁nan": 23432, - "getValue": 23433, - "▁Blues": 23434, - "acles": 23435, - "▁stati": 23436, - "▁entitled": 23437, - "▁Ralph": 23438, - "gravity": 23439, - "▁entrepr": 23440, - "któber": 23441, - "limat": 23442, - "lis": 23443, - "Demo": 23444, - "relation": 23445, - "▁nep": 23446, - "prowad": 23447, - "itis": 23448, - "▁pup": 23449, - "nehmer": 23450, - "▁disappoint": 23451, - "▁etwas": 23452, - "annon": 23453, - "▁approved": 23454, - "▁clever": 23455, - "Loading": 23456, - "▁verz": 23457, - "resse": 23458, - "▁inspir": 23459, - "▁sampling": 23460, - "▁Bek": 23461, - "})$.": 23462, - "▁грома": 23463, - "▁specie": 23464, - "▁repub": 23465, - "▁loader": 23466, - "▁erf": 23467, - "▁shoulder": 23468, - "rais": 23469, - "▁мате": 23470, - "▁Month": 23471, - "Scene": 23472, - "▁blocking": 23473, - "▁ocean": 23474, - "geben": 23475, - "▁Kilometer": 23476, - "▁bedeut": 23477, - "▁Mix": 23478, - "fmt": 23479, - "▁Norweg": 23480, - "▁IDs": 23481, - "parallel": 23482, - "▁anticip": 23483, - "▁revis": 23484, - "хан": 23485, - "▁свет": 23486, - "CASE": 23487, - "▁führt": 23488, - "▁atomic": 23489, - "▁darkness": 23490, - "▁Fußballspieler": 23491, - "▁Жи": 23492, - "quisition": 23493, - "▁Sieg": 23494, - "Circ": 23495, - "▁cientí": 23496, - "nelle": 23497, - "SHA": 23498, - "▁urb": 23499, - "▁ksi": 23500, - "leqslant": 23501, - "▁фрон": 23502, - "▁defect": 23503, - "▁rá": 23504, - "▁stronger": 23505, - "▁pł": 23506, - "▁communities": 23507, - "нина": 23508, - "enas": 23509, - "iennent": 23510, - "▁safely": 23511, - "▁тя": 23512, - "▁benchmark": 23513, - "▁Braun": 23514, - "methods": 23515, - "argument": 23516, - "vos": 23517, - "obox": 23518, - "рови": 23519, - "▁recherche": 23520, - "mn": 23521, - "▁brings": 23522, - "machine": 23523, - "CESS": 23524, - "hosts": 23525, - "▁NY": 23526, - "Autow": 23527, - "▁современ": 23528, - "▁Gary": 23529, - "▁sensor": 23530, - "▁documented": 23531, - "▁prendre": 23532, - "▁peer": 23533, - "enix": 23534, - "hai": 23535, - "arbe": 23536, - "цент": 23537, - "_(": 23538, - "▁URI": 23539, - "ева": 23540, - "▁Regie": 23541, - "▁Monument": 23542, - "▁onderwerp": 23543, - "Bag": 23544, - "tit": 23545, - "▁stir": 23546, - "▁nerv": 23547, - "сторія": 23548, - "▁sov": 23549, - "▁writers": 23550, - "▁sorts": 23551, - "absolute": 23552, - "▁difficulties": 23553, - "▁parlament": 23554, - "▁IEnumerable": 23555, - "▁dissol": 23556, - "▁CHECK": 23557, - "arina": 23558, - "inburgh": 23559, - "DM": 23560, - "▁eind": 23561, - "▁budget": 23562, - "▁certains": 23563, - "▁första": 23564, - "anja": 23565, - "▁годов": 23566, - "▁тек": 23567, - "▁Duch": 23568, - "gui": 23569, - "▁Teams": 23570, - "▁многи": 23571, - "Marie": 23572, - "Integr": 23573, - "ThreadPool": 23574, - "rust": 23575, - "ík": 23576, - "%\"": 23577, - "enf": 23578, - "spl": 23579, - "▁begun": 23580, - "lou": 23581, - "▁RewriteRule": 23582, - "tuple": 23583, - "aneous": 23584, - "▁marine": 23585, - "attan": 23586, - "ikal": 23587, - "▁graduated": 23588, - "illé": 23589, - "▁прове": 23590, - "▁Роз": 23591, - "',\r": 23592, - "▁Pfarr": 23593, - "▁nivel": 23594, - "▁працю": 23595, - "music": 23596, - "▁setTimeout": 23597, - "ERS": 23598, - "▁Erik": 23599, - "pit": 23600, - "▁Хро": 23601, - "▁pił": 23602, - "▁peri": 23603, - "док": 23604, - "uszt": 23605, - "▁Bear": 23606, - "ClassName": 23607, - "▁Parlament": 23608, - "▁aix": 23609, - "▁invited": 23610, - "▁PATH": 23611, - "xter": 23612, - "▁Race": 23613, - "▁hecho": 23614, - "▁Tower": 23615, - "▁utf": 23616, - "actly": 23617, - "▁буде": 23618, - "▁angles": 23619, - "няя": 23620, - "ouvelles": 23621, - "▁climate": 23622, - "▁singing": 23623, - "▁navigate": 23624, - ">';": 23625, - "adows": 23626, - "▁leta": 23627, - "▁Sitz": 23628, - "▁partitions": 23629, - "▁dock": 23630, - "▁ży": 23631, - "▁allocate": 23632, - "▁benefits": 23633, - "▁nieder": 23634, - "xpath": 23635, - "meck": 23636, - "älle": 23637, - "▁coupling": 23638, - "жил": 23639, - "ForKey": 23640, - "argent": 23641, - "clou": 23642, - "▁instruments": 23643, - "▁enthus": 23644, - "▁még": 23645, - "▁Пав": 23646, - "▁Rach": 23647, - "-----": 23648, - "▁APIs": 23649, - "▁Vier": 23650, - "Cmd": 23651, - "itore": 23652, - "▁Cuba": 23653, - "▁dátummal": 23654, - "▁embedding": 23655, - "stdio": 23656, - "▁Gilbert": 23657, - "▁geprüft": 23658, - "▁stating": 23659, - "▁triggers": 23660, - "+=": 23661, - "▁spécial": 23662, - "▁deliber": 23663, - "мин": 23664, - "Produ": 23665, - "▁Stati": 23666, - "▁zus": 23667, - "ktionen": 23668, - "Dispatcher": 23669, - "idal": 23670, - "▁LP": 23671, - "optera": 23672, - "▁estar": 23673, - "▁значи": 23674, - "смо": 23675, - "ouses": 23676, - "engono": 23677, - "▁WPF": 23678, - "publish": 23679, - "▁teor": 23680, - "elif": 23681, - "▁erg": 23682, - "▁separation": 23683, - "Pan": 23684, - "▁Orchestra": 23685, - "Peter": 23686, - "bounds": 23687, - "▁Shakespeare": 23688, - "▁cantante": 23689, - "▁demi": 23690, - "▁Popular": 23691, - "фр": 23692, - "arring": 23693, - "цин": 23694, - "▁Ис": 23695, - "von": 23696, - "▁substitution": 23697, - "▁línea": 23698, - "\\}$.": 23699, - "como": 23700, - "▁важ": 23701, - "wagen": 23702, - "▁rarely": 23703, - "▁periods": 23704, - "glob": 23705, - "▁Frid": 23706, - "▁Terr": 23707, - "▁Release": 23708, - "Brainz": 23709, - "▁граф": 23710, - "DIS": 23711, - "compatible": 23712, - "▁poč": 23713, - "LIN": 23714, - "▁Källor": 23715, - "▁Arizona": 23716, - "ppy": 23717, - "Seq": 23718, - "▁Ain": 23719, - "▁Tourn": 23720, - "brow": 23721, - "▁Kör": 23722, - "▁ash": 23723, - "ogeneous": 23724, - "▁dialect": 23725, - "▁насеља": 23726, - "mysqli": 23727, - "цов": 23728, - "▁flor": 23729, - "▁фло": 23730, - "IAB": 23731, - "▁Within": 23732, - "^(": 23733, - "▁bois": 23734, - "▁tank": 23735, - "▁affili": 23736, - "▁hijo": 23737, - "▁Kate": 23738, - "▁Verl": 23739, - "▁Miami": 23740, - "▁typescript": 23741, - "њу": 23742, - "▁Vern": 23743, - "▁висо": 23744, - "iemann": 23745, - "▁coverage": 23746, - "brie": 23747, - "▁Starting": 23748, - "numpy": 23749, - "▁Jenkins": 23750, - "▁két": 23751, - "▁grup": 23752, - "▁Scient": 23753, - "▁interrupt": 23754, - "▁blob": 23755, - "ugel": 23756, - "▁Orth": 23757, - "abama": 23758, - "▁Bapt": 23759, - "ownik": 23760, - "▁быть": 23761, - "▁Julius": 23762, - "▁През": 23763, - "▁substitute": 23764, - "supported": 23765, - "chy": 23766, - "egyzetek": 23767, - "▁Performance": 23768, - "lessly": 23769, - "Constructor": 23770, - "▁extending": 23771, - "▁Muslim": 23772, - "Overflow": 23773, - "▁Jenn": 23774, - "▁produz": 23775, - "мії": 23776, - "▁países": 23777, - "▁eux": 23778, - "▁fate": 23779, - "ologe": 23780, - "ук": 23781, - "▁wobei": 23782, - "▁Sachsen": 23783, - "▁сайт": 23784, - "Models": 23785, - "▁Fast": 23786, - "besondere": 23787, - "▁FR": 23788, - "▁acon": 23789, - "▁Denkmal": 23790, - "▁anch": 23791, - "▁público": 23792, - "▁Tas": 23793, - "▁cand": 23794, - "▁paździer": 23795, - "▁Мон": 23796, - "▁versus": 23797, - "rut": 23798, - "GT": 23799, - "▁inserting": 23800, - "▁canad": 23801, - "єм": 23802, - "▁Metro": 23803, - "▁Herzog": 23804, - "Ignore": 23805, - "▁decrease": 23806, - "▁пун": 23807, - "▁Fischer": 23808, - "▁Mall": 23809, - "▁nörd": 23810, - "iostream": 23811, - "▁Luxemb": 23812, - "payload": 23813, - "▁Zeitung": 23814, - "▁modifying": 23815, - "▁Cher": 23816, - "▁Luci": 23817, - "nx": 23818, - "▁loose": 23819, - "▁topics": 23820, - "▁varied": 23821, - "▁pg": 23822, - "ajes": 23823, - "umm": 23824, - "Views": 23825, - "▁Beau": 23826, - "MAP": 23827, - "ipeline": 23828, - "▁Interest": 23829, - "arith": 23830, - "▁según": 23831, - "▁Gemeins": 23832, - "▁Attribute": 23833, - "community": 23834, - "▁центр": 23835, - "▁kilometer": 23836, - "▁économ": 23837, - "laration": 23838, - "▁къ": 23839, - "▁carriage": 23840, - "▁Lane": 23841, - "▁необ": 23842, - "kur": 23843, - "▁AF": 23844, - "INTER": 23845, - "))$": 23846, - "▁beide": 23847, - "destination": 23848, - "▁fonts": 23849, - "appendChild": 23850, - "▁MAR": 23851, - "▁gay": 23852, - "mil": 23853, - "lesh": 23854, - "èt": 23855, - "▁Wang": 23856, - "▁Years": 23857, - "▁Symbol": 23858, - "Live": 23859, - "quency": 23860, - "▁Users": 23861, - "▁Unicode": 23862, - "▁Sau": 23863, - "▁tons": 23864, - "▁Ні": 23865, - "▁краї": 23866, - "AXI": 23867, - "▁Pick": 23868, - "AI": 23869, - "▁hath": 23870, - "▁ainda": 23871, - "▁papa": 23872, - "▁Censo": 23873, - "▁Bald": 23874, - "▁Насеље": 23875, - "▁simulations": 23876, - "▁jaren": 23877, - "▁inherited": 23878, - "▁той": 23879, - "▁feels": 23880, - "ression": 23881, - "▁október": 23882, - "bid": 23883, - "ási": 23884, - "▁muss": 23885, - "ventory": 23886, - "▁meist": 23887, - "▁bore": 23888, - "▁slider": 23889, - "дели": 23890, - "\\;": 23891, - "▁extracted": 23892, - "кур": 23893, - "Edge": 23894, - "▁perf": 23895, - "▁Brigade": 23896, - "▁град": 23897, - "ienie": 23898, - "▁Norden": 23899, - "▁cancer": 23900, - "\"/": 23901, - "Cur": 23902, - "▁Сере": 23903, - "▁liquid": 23904, - "structure": 23905, - "▁choosing": 23906, - "▁Perl": 23907, - "Side": 23908, - "üs": 23909, - "ритор": 23910, - "▁kost": 23911, - "▁packets": 23912, - "▁которого": 23913, - "▁Comun": 23914, - "▁fingers": 23915, - "ográfica": 23916, - ">:": 23917, - "▁championnat": 23918, - "▁blieb": 23919, - "▁Situ": 23920, - "▁suic": 23921, - "andis": 23922, - "Fre": 23923, - "▁Conc": 23924, - "▁republic": 23925, - "▁armed": 23926, - "▁hell": 23927, - "▁hög": 23928, - "ragma": 23929, - "▁ense": 23930, - "▁acres": 23931, - "▁Від": 23932, - "▁Reform": 23933, - "MainActivity": 23934, - "keeper": 23935, - "erb": 23936, - "▁monaster": 23937, - "subsubsection": 23938, - "▁Див": 23939, - "▁creature": 23940, - "▁indicating": 23941, - "▁urls": 23942, - "▁kein": 23943, - "образ": 23944, - "pick": 23945, - "▁Admir": 23946, - "▁oldest": 23947, - "▁muz": 23948, - "▁contradiction": 23949, - "▁probabil": 23950, - "illiant": 23951, - "▁pav": 23952, - "▁papel": 23953, - "ubs": 23954, - "▁жена": 23955, - "AML": 23956, - "▁recip": 23957, - "▁COL": 23958, - "added": 23959, - "▁clue": 23960, - "▁Ukraine": 23961, - "▁jelent": 23962, - "чень": 23963, - "▁mathematics": 23964, - "Accept": 23965, - "▁сот": 23966, - "▁север": 23967, - "▁isolated": 23968, - "▁поя": 23969, - "wür": 23970, - "Router": 23971, - "CAT": 23972, - "rgb": 23973, - "▁Lov": 23974, - "mutable": 23975, - "▁Wes": 23976, - "▁Italien": 23977, - "Drag": 23978, - "enium": 23979, - "atting": 23980, - "tcp": 23981, - "▁erfolgte": 23982, - "▁Beit": 23983, - "гато": 23984, - "▁Systems": 23985, - "▁reserve": 23986, - "eree": 23987, - "▁Пари": 23988, - "▁зали": 23989, - "▁rent": 23990, - "▁sunt": 23991, - "▁Girls": 23992, - "▁Ernest": 23993, - "▁fits": 23994, - "▁oppon": 23995, - "▁живело": 23996, - "▁avaient": 23997, - "▁Florence": 23998, - "▁числе": 23999, - "▁engines": 24000, - "Dynamic": 24001, - "▁stycznia": 24002, - "▁bias": 24003, - "▁Exchange": 24004, - "дий": 24005, - "▁historiques": 24006, - "▁Hä": 24007, - "hod": 24008, - "▁wł": 24009, - "schap": 24010, - "▁lac": 24011, - "▁Foi": 24012, - "▁dwell": 24013, - "▁Unternehmen": 24014, - "URN": 24015, - "▁kilometres": 24016, - "▁Однако": 24017, - "кли": 24018, - "▁Sri": 24019, - "Groups": 24020, - "mind": 24021, - "oslov": 24022, - "fern": 24023, - "egu": 24024, - "abeled": 24025, - "Fiddle": 24026, - "▁Century": 24027, - "/-": 24028, - "▁Jegyzetek": 24029, - "Hen": 24030, - "ensemble": 24031, - "▁Gut": 24032, - "_{{\\": 24033, - "▁ranking": 24034, - "+$": 24035, - "ала": 24036, - "▁#{": 24037, - "imientos": 24038, - "achim": 24039, - "rides": 24040, - "▁Klaus": 24041, - "▁intend": 24042, - "▁Kentucky": 24043, - "cipe": 24044, - "▁Dienst": 24045, - "▁situated": 24046, - "▁póź": 24047, - "▁scrit": 24048, - "clip": 24049, - "нет": 24050, - "tables": 24051, - "▁Nied": 24052, - "▁McK": 24053, - "▁powst": 24054, - "▁kunnen": 24055, - "▁Evans": 24056, - "жды": 24057, - "вать": 24058, - "uchar": 24059, - "▁residents": 24060, - "iak": 24061, - "▁Resol": 24062, - "▁veces": 24063, - "▁satisfying": 24064, - "INF": 24065, - "▁син": 24066, - "▁crossing": 24067, - "iben": 24068, - "▁широ": 24069, - "pto": 24070, - "ILL": 24071, - "▁роль": 24072, - "▁aktiv": 24073, - "▁обращения": 24074, - "Wikispecies": 24075, - "▁Höhe": 24076, - "cro": 24077, - "════": 24078, - "altra": 24079, - "▁FILE": 24080, - "▁ups": 24081, - "▁allocation": 24082, - "Michael": 24083, - "▁acknowled": 24084, - "Linux": 24085, - "▁metros": 24086, - "tte": 24087, - "afen": 24088, - "▁xcode": 24089, - "▁тради": 24090, - "species": 24091, - "▁injury": 24092, - "▁самы": 24093, - "▁lattice": 24094, - "Material": 24095, - "andenburg": 24096, - "▁huvudstaden": 24097, - "story": 24098, - "▁varying": 24099, - "▁követ": 24100, - "▁Российской": 24101, - "irse": 24102, - "▁drum": 24103, - "Pressed": 24104, - "Lar": 24105, - "▁Agu": 24106, - "▁weil": 24107, - "▁commence": 24108, - "▁Según": 24109, - "Gesture": 24110, - "Shape": 24111, - "▁Vors": 24112, - "▁succès": 24113, - "▁corrected": 24114, - "Kar": 24115, - "▁cruel": 24116, - "▁politico": 24117, - "▁Schriftsteller": 24118, - "▁risult": 24119, - "etu": 24120, - "archiv": 24121, - "▁género": 24122, - "▁Lü": 24123, - "▁triumph": 24124, - "ORS": 24125, - "Lu": 24126, - "▁personnel": 24127, - "▁Hills": 24128, - "asset": 24129, - "domin": 24130, - "Receive": 24131, - "▁Oak": 24132, - "▁Kno": 24133, - "▁Theory": 24134, - "irie": 24135, - "owan": 24136, - "▁estava": 24137, - "▁executes": 24138, - "йт": 24139, - "ópez": 24140, - "поло": 24141, - "ética": 24142, - "▁название": 24143, - "▁converges": 24144, - "▁notre": 24145, - "▁populated": 24146, - "▁movements": 24147, - "▁statistical": 24148, - "▁Zweiten": 24149, - "quin": 24150, - "▁importantes": 24151, - "▁klein": 24152, - "▁Segunda": 24153, - "schließend": 24154, - "Failure": 24155, - "nar": 24156, - "dag": 24157, - "▁ruolo": 24158, - "▁fiction": 24159, - "▁использу": 24160, - "▁crisis": 24161, - "▁Getting": 24162, - ",%": 24163, - "▁армии": 24164, - "▁campus": 24165, - "▁footer": 24166, - "▁días": 24167, - "бан": 24168, - "▁liberty": 24169, - "▁gh": 24170, - "▁chamber": 24171, - "▁districts": 24172, - "▁excited": 24173, - "▁canción": 24174, - "tero": 24175, - "▁Working": 24176, - "▁części": 24177, - "льный": 24178, - "▁forum": 24179, - "▁Ehe": 24180, - "▁ката": 24181, - "itations": 24182, - "Tools": 24183, - "achiv": 24184, - "▁cres": 24185, - "asto": 24186, - "▁rever": 24187, - "▁nazionale": 24188, - "▁doors": 24189, - "▁Nancy": 24190, - "▁islands": 24191, - "Imp": 24192, - "▁Chair": 24193, - "▁vorm": 24194, - "sein": 24195, - "▁доку": 24196, - "erset": 24197, - "▁tätig": 24198, - "▁Krit": 24199, - "▁пя": 24200, - "▁conservation": 24201, - "▁Partido": 24202, - "minipage": 24203, - "Validator": 24204, - "▁recovery": 24205, - "▁NASA": 24206, - "▁breast": 24207, - "ilty": 24208, - "analy": 24209, - "elines": 24210, - "▁Saturday": 24211, - "emark": 24212, - "cej": 24213, - "Zero": 24214, - "▁Turner": 24215, - "secure": 24216, - "Exists": 24217, - "▁Rick": 24218, - "evalu": 24219, - "ctrl": 24220, - "▁compression": 24221, - "▁CURL": 24222, - "textcolor": 24223, - ")\\,": 24224, - "longrightarrow": 24225, - "▁Fernseh": 24226, - "icha": 24227, - "▁loi": 24228, - "▁Оте": 24229, - "▁cave": 24230, - "▁dozen": 24231, - "▁explaining": 24232, - "▁innov": 24233, - "▁Nicholas": 24234, - "▁diameter": 24235, - "▁Marian": 24236, - "▁fires": 24237, - "▁artifact": 24238, - "▁Parker": 24239, - "▁Bund": 24240, - "▁verte": 24241, - "▁talent": 24242, - "▁Lucas": 24243, - "reverse": 24244, - "▁folgenden": 24245, - "▁Sah": 24246, - "jections": 24247, - "▁invece": 24248, - "▁costitu": 24249, - "▁ssl": 24250, - "}}^": 24251, - "▁violent": 24252, - "▁spos": 24253, - "Rout": 24254, - "jdk": 24255, - "▁заме": 24256, - "▁furent": 24257, - "andal": 24258, - "Hom": 24259, - "▁Senior": 24260, - "▁pounds": 24261, - "▁Discogs": 24262, - "▁зе": 24263, - "'}[": 24264, - "▁Napoleon": 24265, - "ordinates": 24266, - "àn": 24267, - "▁kurz": 24268, - "▁vere": 24269, - "▁reuse": 24270, - "▁Ген": 24271, - "▁Syst": 24272, - "▁disappeared": 24273, - "▁Watch": 24274, - "bibliothek": 24275, - "▁корпу": 24276, - "▁Cs": 24277, - "▁}`": 24278, - "▁rör": 24279, - "▁дела": 24280, - "VB": 24281, - "▁calculus": 24282, - "рода": 24283, - "▁judgment": 24284, - "atile": 24285, - "▁longue": 24286, - "▁Hus": 24287, - "Jac": 24288, - "}})": 24289, - "RIPT": 24290, - "IABot": 24291, - "▁após": 24292, - "▁aston": 24293, - "Webachiv": 24294, - "▁URLs": 24295, - "▁coat": 24296, - "▁эконо": 24297, - "▁lear": 24298, - "extensions": 24299, - "▁Classic": 24300, - "TI": 24301, - "▁Tage": 24302, - "▁lá": 24303, - "▁semb": 24304, - "▁développement": 24305, - "ISTS": 24306, - "▁solves": 24307, - ",\\,": 24308, - "▁чемпі": 24309, - "ordinary": 24310, - "▁Bav": 24311, - "▁muchos": 24312, - "Self": 24313, - "▁Май": 24314, - "▁Diet": 24315, - "▁necessity": 24316, - "від": 24317, - "▁mano": 24318, - "▁Ср": 24319, - "▁carre": 24320, - "▁Camera": 24321, - "▁Narod": 24322, - "▁Phone": 24323, - "▁polym": 24324, - "imore": 24325, - "isEmpty": 24326, - "▁Houston": 24327, - "▁Rece": 24328, - "▁presentation": 24329, - "ниципа": 24330, - "▁Db": 24331, - "▁confident": 24332, - "▁}{": 24333, - "▁bullet": 24334, - "▁{},": 24335, - "ANGE": 24336, - "▁Notre": 24337, - "chin": 24338, - "▁Dragon": 24339, - "erca": 24340, - "iali": 24341, - "▁asset": 24342, - "▁muito": 24343, - "▁deeply": 24344, - "▁restriction": 24345, - "▁commerce": 24346, - "▁Bomb": 24347, - "caught": 24348, - "qq": 24349, - "▁Arag": 24350, - "▁немец": 24351, - "▁Analysis": 24352, - "▁článku": 24353, - "▁baby": 24354, - "▁echter": 24355, - "▁одного": 24356, - "жена": 24357, - "▁whitespace": 24358, - "çu": 24359, - "LIST": 24360, - "frique": 24361, - "▁varias": 24362, - "▁Wit": 24363, - "▁Licencia": 24364, - "Exit": 24365, - "▁sierp": 24366, - "▁assemb": 24367, - "▁splitting": 24368, - "▁palace": 24369, - "▁blocked": 24370, - "▁boundaries": 24371, - "▁iterations": 24372, - "▁Rotten": 24373, - "▁Verkehr": 24374, - "▁weer": 24375, - "Tests": 24376, - "ifting": 24377, - "▁regul": 24378, - "▁persist": 24379, - "▁Solution": 24380, - "pb": 24381, - "▁collapse": 24382, - "▁arrested": 24383, - "▁predicate": 24384, - "▁Zone": 24385, - "▁ingen": 24386, - "zález": 24387, - "▁banks": 24388, - "plant": 24389, - "▁Nella": 24390, - "▁бан": 24391, - "▁Snow": 24392, - "▁Kreuz": 24393, - "ício": 24394, - "▁enters": 24395, - "▁expose": 24396, - "či": 24397, - "шие": 24398, - "Qual": 24399, - "▁landscape": 24400, - "▁подацима": 24401, - "mai": 24402, - "stag": 24403, - "ований": 24404, - "DEF": 24405, - "[]{": 24406, - "▁dernière": 24407, - "icut": 24408, - "▁Xml": 24409, - "▁subgroup": 24410, - "▁Polsce": 24411, - "▁Warning": 24412, - "▁vehicles": 24413, - "iot": 24414, - "▁dll": 24415, - "ront": 24416, - "▁Louise": 24417, - "▁ara": 24418, - "▁Scala": 24419, - "▁canonical": 24420, - "▁placing": 24421, - "ERY": 24422, - "▁Jag": 24423, - "▁virus": 24424, - "emu": 24425, - "▁});\r": 24426, - "▁мм": 24427, - "▁Trying": 24428, - "▁Lexikon": 24429, - "abord": 24430, - "▁expedition": 24431, - "▁demanded": 24432, - "Zyg": 24433, - "lein": 24434, - "▁verwendet": 24435, - "рина": 24436, - "wol": 24437, - "▁pivot": 24438, - "▁однако": 24439, - "▁propriet": 24440, - "▁awards": 24441, - "tout": 24442, - "▁assim": 24443, - "▁Storm": 24444, - "Limit": 24445, - "elin": 24446, - "wealth": 24447, - "uez": 24448, - "▁rappresent": 24449, - "▁resta": 24450, - "▁gegründet": 24451, - "▁journalist": 24452, - "isie": 24453, - "▁facility": 24454, - "illed": 24455, - "ulk": 24456, - "▁PK": 24457, - "Anchor": 24458, - "▁_)": 24459, - "VF": 24460, - "LAB": 24461, - "▁nå": 24462, - "odos": 24463, - "▁billion": 24464, - "virti": 24465, - "▁Jeux": 24466, - "юза": 24467, - "tomcat": 24468, - "▁charts": 24469, - "▁Bundle": 24470, - "▁lst": 24471, - "▁exer": 24472, - "▁females": 24473, - "▁obliged": 24474, - "▁aby": 24475, - "rolled": 24476, - "dri": 24477, - "▁Sche": 24478, - "▁vessels": 24479, - "IMARY": 24480, - "▁reasoning": 24481, - "▁проте": 24482, - "FILES": 24483, - "verk": 24484, - "osos": 24485, - "▁комму": 24486, - "дії": 24487, - "▁dd": 24488, - "▁соответ": 24489, - "▁IOException": 24490, - "ských": 24491, - "▁CLI": 24492, - "▁ње": 24493, - "CM": 24494, - "TD": 24495, - "▁possibilities": 24496, - "▁Compos": 24497, - "half": 24498, - "▁webpage": 24499, - "▁swing": 24500, - "▁zas": 24501, - "���cycl": 24502, - "leid": 24503, - "istica": 24504, - "▁Insert": 24505, - "▁Sweden": 24506, - "▁wanting": 24507, - "▁ال": 24508, - "▁eeuw": 24509, - "▁Administr": 24510, - "▁Warren": 24511, - "▁bs": 24512, - "▁pam": 24513, - "anus": 24514, - "Dra": 24515, - "expl": 24516, - "▁Kant": 24517, - "▁Austin": 24518, - "▁csak": 24519, - "▁theatre": 24520, - "▁compatibility": 24521, - "матиче": 24522, - "setState": 24523, - "бю": 24524, - "}{|": 24525, - "▁Dy": 24526, - "▁Zwischen": 24527, - "Alt": 24528, - "CLARE": 24529, - "steps": 24530, - "▁Lage": 24531, - "▁Mitt": 24532, - "▁Dublin": 24533, - "▁работы": 24534, - "deep": 24535, - "▁flows": 24536, - "▁Palace": 24537, - "unix": 24538, - "refs": 24539, - "umar": 24540, - "aset": 24541, - "cov": 24542, - "▁ping": 24543, - "▁Safari": 24544, - "flug": 24545, - "creens": 24546, - "{#": 24547, - "▁реа": 24548, - "adors": 24549, - "▁amor": 24550, - "uce": 24551, - "demic": 24552, - "▁Netherlands": 24553, - "▁clusters": 24554, - "▁enfor": 24555, - "marine": 24556, - "▁bugs": 24557, - "izzata": 24558, - "▁scra": 24559, - "Les": 24560, - "quick": 24561, - "▁turno": 24562, - "_*": 24563, - "ера": 24564, - "Generated": 24565, - ">[": 24566, - "▁estre": 24567, - "orde": 24568, - "▁verg": 24569, - "роз": 24570, - "▁pau": 24571, - "includes": 24572, - "assa": 24573, - "aders": 24574, - "▁Герма": 24575, - "▁estaven": 24576, - "▁earliest": 24577, - "▁resultado": 24578, - "mun": 24579, - "▁plots": 24580, - "din": 24581, - "sorted": 24582, - "▁preference": 24583, - "rió": 24584, - "туре": 24585, - "▁Ligue": 24586, - "▁завер": 24587, - "phr": 24588, - "▁pocket": 24589, - "▁parl": 24590, - "▁lak": 24591, - "▁powie": 24592, - "▁altres": 24593, - "$};": 24594, - "plain": 24595, - "▁Cred": 24596, - "itza": 24597, - "perp": 24598, - "Green": 24599, - "▁devoted": 24600, - "production": 24601, - "worker": 24602, - "elsen": 24603, - "▁vern": 24604, - "▁március": 24605, - "▁Confeder": 24606, - "▁Liverpool": 24607, - "▁музи": 24608, - "▁emails": 24609, - "▁distances": 24610, - "▁segments": 24611, - "▁anth": 24612, - "▁wrest": 24613, - "▁hoog": 24614, - "▁cinema": 24615, - "rror": 24616, - "▁geboren": 24617, - "▁éc": 24618, - "Marker": 24619, - "▁Compet": 24620, - "▁листо": 24621, - "allowed": 24622, - "volume": 24623, - "Espagne": 24624, - "Ze": 24625, - "▁fixes": 24626, - "▁rond": 24627, - "▁arrangement": 24628, - "/~": 24629, - ".](": 24630, - "▁Források": 24631, - "▁weiteren": 24632, - "excel": 24633, - "▁змі": 24634, - "▁moderne": 24635, - "English": 24636, - "▁Transfermarkt": 24637, - "▁bearing": 24638, - "▁cleared": 24639, - "▁сам": 24640, - "▁divs": 24641, - "ći": 24642, - "▁этой": 24643, - "▁Геор": 24644, - "scene": 24645, - "▁ages": 24646, - "GEN": 24647, - "rän": 24648, - "▁Toul": 24649, - "▁Abs": 24650, - "ját": 24651, - "▁mediante": 24652, - "▁empres": 24653, - "▁Employee": 24654, - "▁polynomials": 24655, - "▁optimize": 24656, - "▁выступа": 24657, - "fare": 24658, - "вей": 24659, - "xf": 24660, - "quez": 24661, - "▁botan": 24662, - "▁defend": 24663, - "▁Quart": 24664, - "Mont": 24665, - "vb": 24666, - "tick": 24667, - "WD": 24668, - "mine": 24669, - "▁modific": 24670, - "notification": 24671, - "▁denn": 24672, - "▁algo": 24673, - "▁Spo": 24674, - "▁mistrzost": 24675, - "/:": 24676, - "▁apresent": 24677, - "▁прод": 24678, - "Volume": 24679, - "ską": 24680, - "protected": 24681, - "▁Turkish": 24682, - "azy": 24683, - "▁pouv": 24684, - "▁período": 24685, - "skog": 24686, - "▁entropy": 24687, - "zed": 24688, - "тори": 24689, - "▁lij": 24690, - "boards": 24691, - "▁стату": 24692, - "Bool": 24693, - "▁polity": 24694, - "@\",": 24695, - "▁рік": 24696, - "née": 24697, - "▁Zug": 24698, - "▁Uniti": 24699, - "émet": 24700, - "atience": 24701, - "dimen": 24702, - "▁Steven": 24703, - "Ha": 24704, - "ACTION": 24705, - "▁wand": 24706, - "▁Navar": 24707, - "▁січня": 24708, - "Watch": 24709, - "▁Stuart": 24710, - "▁zde": 24711, - "▁контро": 24712, - "dataset": 24713, - "yó": 24714, - "▁Bush": 24715, - "▁себя": 24716, - "▁worthy": 24717, - "▁Ble": 24718, - "▁propor": 24719, - "▁Village": 24720, - "▁ry": 24721, - "▁voit": 24722, - "▁копия": 24723, - "▁zp": 24724, - "▁cura": 24725, - "▁Html": 24726, - "▁Dieser": 24727, - "▁Days": 24728, - "onnes": 24729, - "▁antigu": 24730, - "▁Staaten": 24731, - "▁faint": 24732, - "ongs": 24733, - "▁öst": 24734, - "Redirect": 24735, - "ель": 24736, - "atorial": 24737, - "▁bother": 24738, - "EditText": 24739, - "▁Giul": 24740, - "▁заво": 24741, - "▁pueblo": 24742, - "▁Mississippi": 24743, - "jak": 24744, - "▁wings": 24745, - "onc": 24746, - "ível": 24747, - "iencia": 24748, - "entlicht": 24749, - "▁BTW": 24750, - "ornal": 24751, - "▁Коро": 24752, - "▁одним": 24753, - "▁salv": 24754, - "▁finden": 24755, - "geo": 24756, - "▁авиа": 24757, - "attung": 24758, - "viv": 24759, - "▁Luther": 24760, - "▁общи": 24761, - "▁Rolle": 24762, - "▁Abraham": 24763, - "▁centered": 24764, - "▁slash": 24765, - "isat": 24766, - "emann": 24767, - "Os": 24768, - "парта": 24769, - "▁Pablo": 24770, - "▁collaboration": 24771, - "paths": 24772, - "édition": 24773, - "▁viewed": 24774, - "▁consisted": 24775, - "▁recovered": 24776, - "▁Mexican": 24777, - "▁Fix": 24778, - "▁spell": 24779, - "Special": 24780, - "▁Ст": 24781, - "esseur": 24782, - "▁Украины": 24783, - "former": 24784, - "▁św": 24785, - "▁zeros": 24786, - "▁Straßen": 24787, - "▁organisation": 24788, - "üssen": 24789, - "▁Sierra": 24790, - "▁Season": 24791, - "▁volont": 24792, - "BeanFactory": 24793, - "▁помощ": 24794, - "▁pressing": 24795, - "▁equivalence": 24796, - "▁catt": 24797, - "icity": 24798, - "▁accomplished": 24799, - "▁yo": 24800, - "▁sic": 24801, - "▁imports": 24802, - "▁accommod": 24803, - "▁Porto": 24804, - "▁яка": 24805, - "▁loan": 24806, - "тики": 24807, - "▁checkout": 24808, - "▁assess": 24809, - "▁Population": 24810, - "urent": 24811, - "clojure": 24812, - "▁Santos": 24813, - "▁információ": 24814, - "POS": 24815, - "▁gare": 24816, - "▁kick": 24817, - "▁radical": 24818, - "▁Peace": 24819, - "▁streaming": 24820, - "camp": 24821, - "ząt": 24822, - "говор": 24823, - "▁Regierung": 24824, - "▁proceeded": 24825, - "fm": 24826, - "лены": 24827, - "▁earnest": 24828, - "▁Parad": 24829, - "requests": 24830, - "▁Raum": 24831, - "šč": 24832, - "▁policies": 24833, - "▁Tig": 24834, - "▁sitt": 24835, - "▁Energy": 24836, - "▁purely": 24837, - "▁Haut": 24838, - "▁Speed": 24839, - "bio": 24840, - "▁orange": 24841, - "▁biggest": 24842, - "▁britannique": 24843, - "▁Notable": 24844, - "vu": 24845, - "лении": 24846, - "бин": 24847, - "▁Nash": 24848, - "щение": 24849, - "▁ciel": 24850, - "adémie": 24851, - "▁грудня": 24852, - "▁joue": 24853, - "▁voted": 24854, - "rico": 24855, - "▁гор": 24856, - "▁команду": 24857, - "itivity": 24858, - "▁ще": 24859, - "▁definite": 24860, - "uropa": 24861, - "!\");": 24862, - "Defaults": 24863, - "▁некоторы": 24864, - "édération": 24865, - "▁silly": 24866, - "▁talked": 24867, - "reu": 24868, - "▁Lomb": 24869, - "▁statue": 24870, - "кта": 24871, - "юр": 24872, - "umably": 24873, - "▁городе": 24874, - "▁Runtime": 24875, - "▁diagn": 24876, - "▁retro": 24877, - "▁Sverige": 24878, - "▁inicial": 24879, - "ienza": 24880, - "▁figlio": 24881, - "▁zog": 24882, - "▁rey": 24883, - "▁Rund": 24884, - "тный": 24885, - "▁ceased": 24886, - "erno": 24887, - "▁esa": 24888, - "▁trouv": 24889, - "▁Gemeinden": 24890, - "▁comercial": 24891, - "skap": 24892, - "enario": 24893, - "▁juris": 24894, - "TB": 24895, - "нала": 24896, - "▁vij": 24897, - "VO": 24898, - "▁clin": 24899, - "jör": 24900, - "сан": 24901, - "owała": 24902, - "ribución": 24903, - "▁ursprüng": 24904, - "▁condem": 24905, - "▁Stage": 24906, - "▁mixing": 24907, - "▁різ": 24908, - "▁fans": 24909, - "ház": 24910, - "social": 24911, - "zan": 24912, - "▁свой": 24913, - "Cookie": 24914, - "▁Roland": 24915, - "azionale": 24916, - "▁Sloven": 24917, - "▁Fiche": 24918, - "▁Sé": 24919, - "hä": 24920, - "▁officials": 24921, - "▁înt": 24922, - "Interceptor": 24923, - "Tables": 24924, - "▁davon": 24925, - "initialize": 24926, - "]=\"": 24927, - "▁Body": 24928, - "▁Upper": 24929, - "▁Collect": 24930, - "▁Zürich": 24931, - "Horizontal": 24932, - "Typ": 24933, - "▁político": 24934, - "▁RewriteCond": 24935, - "▁hoped": 24936, - "▁anxious": 24937, - "Liter": 24938, - "jahr": 24939, - "▁assemble": 24940, - "▁crypt": 24941, - "lahoma": 24942, - "ASH": 24943, - "▁Бри": 24944, - "▁Cic": 24945, - "twitter": 24946, - "hyper": 24947, - "▁Tell": 24948, - "ільки": 24949, - "вобо": 24950, - "▁bazie": 24951, - "▁contemporary": 24952, - "▁Parameter": 24953, - "stwa": 24954, - "▁bekend": 24955, - "cock": 24956, - "previous": 24957, - "enska": 24958, - "▁caller": 24959, - "]])": 24960, - "▁Raz": 24961, - "▁Selon": 24962, - "▁proposal": 24963, - "▁bý": 24964, - "▁Sied": 24965, - "▁Arbeits": 24966, - "▁pride": 24967, - "▁slope": 24968, - "idé": 24969, - "gradient": 24970, - "▁Джерела": 24971, - "▁SH": 24972, - "▁разрабо": 24973, - "iversity": 24974, - "сподар": 24975, - "\\{\\": 24976, - "▁стали": 24977, - "▁Einzel": 24978, - "▁rgba": 24979, - "▁Anim": 24980, - "▁alles": 24981, - "бар": 24982, - "erte": 24983, - "▁réalisé": 24984, - "Institut": 24985, - "▁markup": 24986, - "▁vars": 24987, - "▁gam": 24988, - "▁Василь": 24989, - "izza": 24990, - "▁Cob": 24991, - "▁Metal": 24992, - "▁leak": 24993, - "▁Lanc": 24994, - "Switch": 24995, - "Delay": 24996, - "atuur": 24997, - "▁четы": 24998, - "▁англий": 24999, - "▁legacy": 25000, - "▁desarroll": 25001, - "▁topological": 25002, - "▁jeweils": 25003, - "▁Nederlandse": 25004, - "▁atmosphere": 25005, - "urban": 25006, - "▁slov": 25007, - "▁lawyer": 25008, - "pecially": 25009, - "▁alternate": 25010, - "▁paramet": 25011, - "▁establishment": 25012, - "▁woods": 25013, - "PD": 25014, - "▁наи": 25015, - "▁mang": 25016, - "▁wechselte": 25017, - "ську": 25018, - ".=": 25019, - "▁fifteen": 25020, - "SUM": 25021, - "▁Fro": 25022, - "▁LED": 25023, - "owano": 25024, - "ствие": 25025, - "▁Données": 25026, - "tol": 25027, - "żyn": 25028, - "cref": 25029, - "ствии": 25030, - "horn": 25031, - "▁сооб": 25032, - "▁оборо": 25033, - "▁Complete": 25034, - "“)": 25035, - "▁kindly": 25036, - "▁Chamber": 25037, - "ség": 25038, - "WH": 25039, - "▁ambient": 25040, - "кро": 25041, - "▁cheval": 25042, - "▁написа": 25043, - "flu": 25044, - "▁Offiz": 25045, - "mate": 25046, - "natural": 25047, - "separ": 25048, - "empre": 25049, - "ViewHolder": 25050, - "fw": 25051, - "▁letech": 25052, - "▁trailing": 25053, - "atri": 25054, - "▁Gó": 25055, - "▁Bonn": 25056, - "▁unlikely": 25057, - "RAM": 25058, - "enst": 25059, - "Stats": 25060, - "▁политиче": 25061, - ")--(": 25062, - "▁trom": 25063, - "!...": 25064, - "▁Meanwhile": 25065, - "стана": 25066, - "▁Reino": 25067, - "▁Arist": 25068, - "$}}%": 25069, - "▁solem": 25070, - "closure": 25071, - "ignation": 25072, - "łod": 25073, - "▁divor": 25074, - "▁международ": 25075, - "=\"": 25230, - "Orientation": 25231, - "cid": 25232, - "Cart": 25233, - "▁murm": 25234, - "▁assez": 25235, - "▁linking": 25236, - "building": 25237, - "▁reconna": 25238, - "▁shook": 25239, - "managed": 25240, - "landa": 25241, - "▁León": 25242, - "▁création": 25243, - "дой": 25244, - "ocity": 25245, - "▁wij": 25246, - "▁wieś": 25247, - "xtart": 25248, - "▁Move": 25249, - "lungen": 25250, - "ствует": 25251, - "orney": 25252, - "optional": 25253, - "macro": 25254, - "Condition": 25255, - "▁squares": 25256, - "▁mistaken": 25257, - "ánt": 25258, - "▁Ris": 25259, - "▁sentences": 25260, - "erea": 25261, - "▁mij": 25262, - "Und": 25263, - "▁nombr": 25264, - "zA": 25265, - "▁Independent": 25266, - "▁preview": 25267, - "imas": 25268, - "▁males": 25269, - "inental": 25270, - "Thank": 25271, - "▁popol": 25272, - "▁pover": 25273, - "▁grasp": 25274, - "▁imped": 25275, - "▁campionato": 25276, - "▁Wei": 25277, - "▁titled": 25278, - "▁Además": 25279, - "▁Password": 25280, - "▁Pam": 25281, - "UILD": 25282, - "▁липня": 25283, - "werb": 25284, - "................": 25285, - "▁Río": 25286, - "▁teeth": 25287, - "bp": 25288, - "▁SW": 25289, - "ulaire": 25290, - "▁seized": 25291, - "▁Stef": 25292, - "úl": 25293, - "▁viz": 25294, - "iony": 25295, - "▁junt": 25296, - "▁která": 25297, - "▁września": 25298, - "<>": 25299, - "▁surg": 25300, - "▁tutte": 25301, - "▁Hob": 25302, - "повід": 25303, - "▁wohl": 25304, - "▁trag": 25305, - "▁Crown": 25306, - "▁trova": 25307, - "стову": 25308, - "▁Vienna": 25309, - "esehen": 25310, - "▁metropol": 25311, - "▁reflected": 25312, - "тета": 25313, - "▁traduc": 25314, - "▁Bast": 25315, - "▁erschien": 25316, - "woord": 25317, - "()\"": 25318, - "talet": 25319, - "▁roads": 25320, - "ведения": 25321, - "ührung": 25322, - "▁cogn": 25323, - "▁Valle": 25324, - "▁landing": 25325, - "▁Regex": 25326, - "▁Iowa": 25327, - "dział": 25328, - "▁erreichte": 25329, - "aum": 25330, - "▁founder": 25331, - "apolis": 25332, - "Compiler": 25333, - "▁kop": 25334, - "▁marc": 25335, - "▁територ": 25336, - "))`": 25337, - "▁lei": 25338, - "geon": 25339, - "▁weapons": 25340, - "▁horn": 25341, - "▁elif": 25342, - "▁Capital": 25343, - "će": 25344, - "▁forall": 25345, - "▁эта": 25346, - "preview": 25347, - "▁DNA": 25348, - "▁sid": 25349, - "orch": 25350, - "▁Ras": 25351, - "▁arab": 25352, - "Best": 25353, - "▁счита": 25354, - "▁López": 25355, - "ança": 25356, - "▁funkc": 25357, - "▁tienen": 25358, - ";&": 25359, - "museum": 25360, - "▁Err": 25361, - "▁resort": 25362, - "Nov": 25363, - "▁kal": 25364, - "MW": 25365, - "шь": 25366, - "anchor": 25367, - "▁роман": 25368, - "leading": 25369, - "▁manten": 25370, - "▁Silva": 25371, - "dade": 25372, - "▁designated": 25373, - "▁revista": 25374, - "Oct": 25375, - "percent": 25376, - "▁уні": 25377, - "identifier": 25378, - "mass": 25379, - "@@": 25380, - "ulsion": 25381, - "germeister": 25382, - "▁predicted": 25383, - "▁сви": 25384, - "жной": 25385, - "▁Ergeb": 25386, - "▁cust": 25387, - "▁removes": 25388, - "charg": 25389, - "пример": 25390, - "▁forming": 25391, - "asma": 25392, - "stdout": 25393, - "Fun": 25394, - "yme": 25395, - "tered": 25396, - "ursive": 25397, - "ighed": 25398, - "▁след": 25399, - "verband": 25400, - "▁LOG": 25401, - "rams": 25402, - "éon": 25403, - "endra": 25404, - "▁Bereich": 25405, - "▁temporal": 25406, - "▁langue": 25407, - "▁Inn": 25408, - "▁moreover": 25409, - "▁tutorials": 25410, - "Middle": 25411, - "▁советский": 25412, - "▁maintenance": 25413, - "asures": 25414, - "▁válto": 25415, - "BASE": 25416, - "▁disappear": 25417, - "ския": 25418, - "▁conocido": 25419, - "▁Нау": 25420, - "▁Libert": 25421, - "▁Harold": 25422, - "▁lifetime": 25423, - "▁Tür": 25424, - "▁zawod": 25425, - "omic": 25426, - "▁Retrieved": 25427, - "architecture": 25428, - "čka": 25429, - "iformes": 25430, - "development": 25431, - "ordnung": 25432, - "Inf": 25433, - "leben": 25434, - "▁Stars": 25435, - "signal": 25436, - "▁grammar": 25437, - "▁corso": 25438, - "▁Wagner": 25439, - "▁geht": 25440, - "▁royale": 25441, - "warn": 25442, - "umbled": 25443, - "▁instit": 25444, - "▁Ши": 25445, - "hh": 25446, - "▁refuge": 25447, - "▁favorite": 25448, - "ierto": 25449, - "▁condado": 25450, - "▁Ther": 25451, - "▁человека": 25452, - "▁Food": 25453, - "▁seizo": 25454, - "▁Initialize": 25455, - "▁connu": 25456, - "▁overlap": 25457, - "▁Emil": 25458, - "▁Martí": 25459, - "▁жовтня": 25460, - "erva": 25461, - "▁boats": 25462, - "ações": 25463, - "▁derrot": 25464, - "▁malloc": 25465, - "▁conject": 25466, - "jk": 25467, - "▁sare": 25468, - "лемен": 25469, - "▁sums": 25470, - "Authorization": 25471, - "▁Kun": 25472, - "]$,": 25473, - "gemeinde": 25474, - "odot": 25475, - "defin": 25476, - "▁emission": 25477, - "▁Крас": 25478, - "▁appart": 25479, - "▁stopping": 25480, - "▁Сред": 25481, - "▁conjug": 25482, - "▁insight": 25483, - "▁Broadcast": 25484, - "▁PMID": 25485, - "▁advantages": 25486, - "enes": 25487, - "▁residence": 25488, - "ljen": 25489, - "isseur": 25490, - "▁pubblicato": 25491, - "▁GitHub": 25492, - "▁Peru": 25493, - "▁galaxies": 25494, - "▁annotations": 25495, - "gas": 25496, - "▁répond": 25497, - "Js": 25498, - "▁independently": 25499, - "NP": 25500, - "▁inqu": 25501, - "▁grounds": 25502, - "Components": 25503, - "▁anten": 25504, - "▁вз": 25505, - "▁hos": 25506, - "▁sint": 25507, - "▁hiding": 25508, - "▁województ": 25509, - "Messages": 25510, - "▁показа": 25511, - "===": 25512, - "▁Abstract": 25513, - "▁läng": 25514, - "▁Formula": 25515, - "dawn": 25516, - "▁designs": 25517, - "Img": 25518, - "▁Portuguese": 25519, - "▁incluy": 25520, - "avigator": 25521, - "▁Brothers": 25522, - "▁continent": 25523, - "▁evidently": 25524, - "race": 25525, - "цького": 25526, - "▁reck": 25527, - "▁серпня": 25528, - "▁Grey": 25529, - "▁appeal": 25530, - "▁unlike": 25531, - "▁powershell": 25532, - "▁racc": 25533, - "fers": 25534, - "▁burning": 25535, - "fasst": 25536, - "installed": 25537, - "▁Give": 25538, - "▁colonial": 25539, - "▁€": 25540, - "▁Rö": 25541, - "▁christ": 25542, - "nehm": 25543, - "там": 25544, - "▁corpo": 25545, - "▁convirti": 25546, - "yter": 25547, - "Sym": 25548, - "▁Greece": 25549, - "▁moth": 25550, - "▁Johan": 25551, - "▁monarch": 25552, - "▁Download": 25553, - "▁craft": 25554, - "už": 25555, - "▁Luke": 25556, - "▁suffix": 25557, - "\\/": 25558, - "Have": 25559, - "▁карь": 25560, - "▁comfortable": 25561, - "▁tips": 25562, - "▁Після": 25563, - "▁броја": 25564, - "▁информа": 25565, - "MQ": 25566, - "бран": 25567, - "▁tx": 25568, - "▁slaves": 25569, - "▁firewall": 25570, - "▁Forces": 25571, - "atif": 25572, - "▁Quellen": 25573, - "▁théâtre": 25574, - "льных": 25575, - "▁расположен": 25576, - "▁Details": 25577, - "ką": 25578, - "▁longitud": 25579, - "INST": 25580, - "▁naval": 25581, - "Fernseh": 25582, - "essel": 25583, - "Grad": 25584, - "▁belang": 25585, - "▁aggi": 25586, - "ZygoteInit": 25587, - "łów": 25588, - "▁Sug": 25589, - "sil": 25590, - "▁exterior": 25591, - "щі": 25592, - "ORD": 25593, - "enser": 25594, - "▁rapide": 25595, - "▁темпера": 25596, - "incie": 25597, - "Si": 25598, - "avam": 25599, - "arded": 25600, - "▁Added": 25601, - "Endpoint": 25602, - "hardt": 25603, - "стран": 25604, - "▁estilo": 25605, - "▁Haz": 25606, - "▁musste": 25607, - "uo": 25608, - "iii": 25609, - "▁ří": 25610, - "anzen": 25611, - "жений": 25612, - "aha": 25613, - "ARNING": 25614, - "▁renov": 25615, - "▁divine": 25616, - "▁convinced": 25617, - "▁humans": 25618, - "▁departure": 25619, - "▁Mediter": 25620, - "qa": 25621, - "▁possessed": 25622, - "▁церкви": 25623, - "giv": 25624, - "▁свої": 25625, - "▁Ortste": 25626, - "Rich": 25627, - "puis": 25628, - "increment": 25629, - "▁Hannover": 25630, - "▁ucz": 25631, - "Done": 25632, - "▁alguns": 25633, - "FIX": 25634, - "▁Heritage": 25635, - "removeClass": 25636, - "фер": 25637, - "▁abc": 25638, - "Dr": 25639, - "▁семей": 25640, - "{:": 25641, - "▁seule": 25642, - "zeichnungen": 25643, - "addy": 25644, - "▁París": 25645, - "üsseld": 25646, - "▁reception": 25647, - "folio": 25648, - "tiny": 25649, - "▁recensement": 25650, - "▁Nur": 25651, - "▁kier": 25652, - "▁gmina": 25653, - "staat": 25654, - "ándose": 25655, - "ческая": 25656, - "▁speaker": 25657, - "▁exponential": 25658, - "▁Dieu": 25659, - "▁приз": 25660, - "▁Rafael": 25661, - "▁ggplot": 25662, - "▁Template": 25663, - "oure": 25664, - "▁Inner": 25665, - "ogne": 25666, - "igare": 25667, - "▁Arte": 25668, - "▁Cov": 25669, - "▁aufgrund": 25670, - "▁Бы": 25671, - "▁ceremony": 25672, - "▁Spart": 25673, - "jective": 25674, - "yi": 25675, - "▁inizi": 25676, - "▁latin": 25677, - "▁Nevertheless": 25678, - "▁Done": 25679, - "тря": 25680, - "▁Arr": 25681, - "season": 25682, - "▁складу": 25683, - "▁podczas": 25684, - "▁Beautiful": 25685, - "▁Weltkrieg": 25686, - "▁зо": 25687, - "▁overcome": 25688, - "▁Praha": 25689, - "▁району": 25690, - "▁subscription": 25691, - "igent": 25692, - "▁пока": 25693, - "latex": 25694, - "▁beach": 25695, - "▁роках": 25696, - "geg": 25697, - "▁probl": 25698, - "arguments": 25699, - "▁organizations": 25700, - "▁Nan": 25701, - "▁stones": 25702, - "▁Hunter": 25703, - "▁regularly": 25704, - "шого": 25705, - "▁flexible": 25706, - "opts": 25707, - "ář": 25708, - "witz": 25709, - "▁')": 25710, - "PASS": 25711, - "▁kraj": 25712, - "▁fake": 25713, - "heits": 25714, - "osph": 25715, - "parseInt": 25716, - "FALSE": 25717, - "▁profess": 25718, - "people": 25719, - "▁precip": 25720, - "dirname": 25721, - "▁perpet": 25722, - "▁Updated": 25723, - "rayed": 25724, - "▁provoc": 25725, - "▁травня": 25726, - "▁categorie": 25727, - "▁тео": 25728, - "сну": 25729, - "otr": 25730, - "▁Верхов": 25731, - "▁compét": 25732, - "Cost": 25733, - "▁wider": 25734, - "▁Obviously": 25735, - "писан": 25736, - "▁настоя": 25737, - "▁seeking": 25738, - "()),": 25739, - "▁équipe": 25740, - "▁commits": 25741, - "▁Svens": 25742, - "ябре": 25743, - "atern": 25744, - "▁heter": 25745, - "▁Bootstrap": 25746, - "éné": 25747, - "▁derivatives": 25748, - "▁Detroit": 25749, - "▁provincial": 25750, - "onomie": 25751, - "EB": 25752, - "▁cuer": 25753, - "▁относи": 25754, - "▁ней": 25755, - ")».": 25756, - "▁Ciudad": 25757, - "IAL": 25758, - "zyst": 25759, - ")\")": 25760, - "▁Alc": 25761, - "blogs": 25762, - "▁parmi": 25763, - "▁Albums": 25764, - "▁Boliv": 25765, - "▁clés": 25766, - "Products": 25767, - "uerdo": 25768, - "▁gelang": 25769, - "znik": 25770, - "hagen": 25771, - "anonymous": 25772, - "▁svg": 25773, - "▁Conseil": 25774, - "▁Ari": 25775, - "coli": 25776, - "▁czy": 25777, - "▁CV": 25778, - "▁ford": 25779, - "▁Außer": 25780, - "▁CI": 25781, - "▁tempt": 25782, - "▁Organisation": 25783, - "áš": 25784, - "▁cycles": 25785, - "▁geslacht": 25786, - "▁людей": 25787, - "ými": 25788, - "▁Spieler": 25789, - "efe": 25790, - "▁Marvel": 25791, - "▁portal": 25792, - "▁Серг": 25793, - "▁grado": 25794, - "▁handlers": 25795, - "▁Interface": 25796, - "AME": 25797, - "▁seriously": 25798, - "▁Binding": 25799, - "▁Rang": 25800, - "▁nada": 25801, - "oce": 25802, - "▁integra": 25803, - "ocracy": 25804, - "▁альбо": 25805, - "▁stability": 25806, - "Uns": 25807, - "▁veter": 25808, - "------+": 25809, - "▁serait": 25810, - "▁omitted": 25811, - "▁uncertainty": 25812, - "onian": 25813, - "▁resto": 25814, - "▁желез": 25815, - "▁одной": 25816, - "▁Bevölkerung": 25817, - "▁Kraft": 25818, - "стр": 25819, - "▁Moscow": 25820, - "lane": 25821, - "arab": 25822, - "▁spole": 25823, - "▁своего": 25824, - "?:": 25825, - "START": 25826, - "▁интер": 25827, - "▁sympt": 25828, - "▁Lorenzo": 25829, - "▁ejec": 25830, - "▁prosper": 25831, - "DAT": 25832, - "лимпий": 25833, - "▁shapes": 25834, - "valueOf": 25835, - "▁associate": 25836, - "▁Medien": 25837, - "ENV": 25838, - "▁сре": 25839, - "▁државе": 25840, - "▁theories": 25841, - "heb": 25842, - "▁Wayne": 25843, - "▁StringBuilder": 25844, - "iwers": 25845, - "▁Maps": 25846, - "Phys": 25847, - "\\}\\": 25848, - "▁Parte": 25849, - "▁Hudson": 25850, - "лон": 25851, - "Lng": 25852, - "▁ры": 25853, - "стей": 25854, - "lau": 25855, - "ancer": 25856, - "▁Coppa": 25857, - "▁війсь": 25858, - "▁ucc": 25859, - "▁Pattern": 25860, - "▁garbage": 25861, - "▁González": 25862, - "▁Encyclop": 25863, - "etten": 25864, - "External": 25865, - "REF": 25866, - ">;": 25867, - "lijke": 25868, - "▁intersect": 25869, - "▁Unless": 25870, - "▁deeper": 25871, - "▁жі": 25872, - "dent": 25873, - "lef": 25874, - "▁chanson": 25875, - "▁diffus": 25876, - "▁primi": 25877, - "▁Wieder": 25878, - "▁aws": 25879, - "owana": 25880, - "▁sociale": 25881, - "ikk": 25882, - "льной": 25883, - "▁divisions": 25884, - "лосо": 25885, - "▁Claud": 25886, - "▁Ya": 25887, - "▁voce": 25888, - "▁Branch": 25889, - "▁fitted": 25890, - "orr": 25891, - "ôtel": 25892, - "stroke": 25893, - "listener": 25894, - "iman": 25895, - "восто": 25896, - "▁Shah": 25897, - "Introduction": 25898, - "▁newline": 25899, - "▁tile": 25900, - "']))": 25901, - "▁travaux": 25902, - "CONFIG": 25903, - "▁quadratic": 25904, - "onneur": 25905, - "▁Giorg": 25906, - "▁identific": 25907, - "éricaine": 25908, - "▁UIView": 25909, - "▁Liberal": 25910, - "▁Koch": 25911, - "▁Berliner": 25912, - "▁notifications": 25913, - "▁Susan": 25914, - "▁cadre": 25915, - "▁Kloster": 25916, - "▁examine": 25917, - "▁един": 25918, - "▁UNION": 25919, - "▁alten": 25920, - "▁finit": 25921, - "▁pedig": 25922, - "cyk": 25923, - "▁mouvement": 25924, - "IOS": 25925, - "▁британ": 25926, - "▁bout": 25927, - "▁автор": 25928, - "ництво": 25929, - "ето": 25930, - "lera": 25931, - "cls": 25932, - "▁Ley": 25933, - "amy": 25934, - "agens": 25935, - "ashed": 25936, - "▁okrę": 25937, - "гро": 25938, - "ellett": 25939, - "▁Fellow": 25940, - "▁manifold": 25941, - "$),": 25942, - "lder": 25943, - "▁voz": 25944, - "▁begg": 25945, - "▁baron": 25946, - "▁fid": 25947, - "▁firing": 25948, - "ilda": 25949, - "dek": 25950, - "AU": 25951, - "itare": 25952, - "▁Ara": 25953, - "▁Exit": 25954, - "▁cinemat": 25955, - "▁intros": 25956, - "▁contacts": 25957, - "пени": 25958, - "▁möglich": 25959, - "▁Singapore": 25960, - "ström": 25961, - "▁Hern": 25962, - "▁sixth": 25963, - "▁publications": 25964, - "vie": 25965, - "▁Hat": 25966, - "▁accepting": 25967, - "ác": 25968, - "stwo": 25969, - "▁quietly": 25970, - "Photo": 25971, - "▁basket": 25972, - "▁eigenvalues": 25973, - "▁médec": 25974, - "▁Olimp": 25975, - "▁церков": 25976, - "alin": 25977, - "consum": 25978, - "▁lassen": 25979, - "▁анти": 25980, - "▁Seq": 25981, - "\";\r": 25982, - "rare": 25983, - "▁$|\\": 25984, - "▁nick": 25985, - "dflare": 25986, - "Vec": 25987, - "bindung": 25988, - "▁bg": 25989, - "changes": 25990, - "Days": 25991, - "▁Mouse": 25992, - "▁waited": 25993, - "▁Tomatoes": 25994, - "▁fas": 25995, - "verte": 25996, - "▁succession": 25997, - "сор": 25998, - "▁sols": 25999, - "▁Render": 26000, - "▁leadership": 26001, - "▁significance": 26002, - "▁gauche": 26003, - "cano": 26004, - "▁Pie": 26005, - "ensoort": 26006, - "▁cambio": 26007, - "▁уз": 26008, - "▁endeav": 26009, - "Completed": 26010, - "▁Архивная": 26011, - "jd": 26012, - "órico": 26013, - "▁churches": 26014, - "▁animate": 26015, - "SG": 26016, - "compute": 26017, - "▁uniformly": 26018, - "INIT": 26019, - "lles": 26020, - "HttpRequest": 26021, - "Ко": 26022, - "Diff": 26023, - "▁sah": 26024, - "airo": 26025, - "maybe": 26026, - "UTE": 26027, - "▁Dow": 26028, - "human": 26029, - "▁aurait": 26030, - "dark": 26031, - "▁repair": 26032, - "▁ner": 26033, - "▁Dabei": 26034, - "▁Botan": 26035, - "Original": 26036, - "ază": 26037, - "▁NAT": 26038, - "imper": 26039, - "▁Youth": 26040, - "thes": 26041, - "▁округа": 26042, - "▁Flo": 26043, - "▁breakfast": 26044, - "urls": 26045, - "▁übernahm": 26046, - "ários": 26047, - "▁Orange": 26048, - "▁Affairs": 26049, - "ske": 26050, - "▁notify": 26051, - "imoine": 26052, - "▁Arena": 26053, - "▁liberal": 26054, - "▁obec": 26055, - "ifa": 26056, - "guez": 26057, - "iono": 26058, - "ператор": 26059, - "▁retained": 26060, - "failed": 26061, - "bine": 26062, - "тных": 26063, - "▁CGRect": 26064, - "camera": 26065, - "idenote": 26066, - "KB": 26067, - "▁lights": 26068, - "▁Pictures": 26069, - "▁Squadron": 26070, - "▁Volk": 26071, - "▁burg": 26072, - ",]": 26073, - "Gi": 26074, - "êque": 26075, - "makeText": 26076, - "▁everybody": 26077, - "▁Hyper": 26078, - "▁Deux": 26079, - "▁glory": 26080, - "presentation": 26081, - "onica": 26082, - "▁frère": 26083, - "aget": 26084, - "▁hints": 26085, - "▁tunnel": 26086, - "▁Ej": 26087, - "ális": 26088, - "▁Viv": 26089, - "ственных": 26090, - "▁caps": 26091, - "PART": 26092, - "oci": 26093, - "▁prices": 26094, - "currency": 26095, - "▁achter": 26096, - "romagnet": 26097, - "gender": 26098, - "▁suis": 26099, - "versions": 26100, - "▁Training": 26101, - "inside": 26102, - "ege": 26103, - "▁totale": 26104, - "▁Daar": 26105, - "▁grudnia": 26106, - "▁Ier": 26107, - "▁occasions": 26108, - "▁kde": 26109, - "▁tensorflow": 26110, - "▁ór": 26111, - "Methods": 26112, - "▁looping": 26113, - "▁directeur": 26114, - "kę": 26115, - "▁isomorphism": 26116, - "▁João": 26117, - "▁aligned": 26118, - "онов": 26119, - "urger": 26120, - "▁nova": 26121, - "morrow": 26122, - "altern": 26123, - "HD": 26124, - "▁marqu": 26125, - "ativas": 26126, - "ggreg": 26127, - "▁ancien": 26128, - "nit": 26129, - "▁secured": 26130, - "mier": 26131, - "▁Ole": 26132, - "▁инте": 26133, - "▁minus": 26134, - "▁clearer": 26135, - "▁nello": 26136, - "▁információk": 26137, - "▁propre": 26138, - "{.": 26139, - "ilog": 26140, - "▁Quick": 26141, - "▁accus": 26142, - "employee": 26143, - "▁зу": 26144, - "цький": 26145, - "фіцій": 26146, - "▁публи": 26147, - "▁bent": 26148, - "▁позво": 26149, - "▁Пор": 26150, - "ází": 26151, - "ánico": 26152, - "emptyset": 26153, - "▁surtout": 26154, - "reno": 26155, - "unya": 26156, - "▁уез": 26157, - "▁Millionen": 26158, - "▁listopada": 26159, - "▁Maine": 26160, - "▁grupos": 26161, - "▁Storage": 26162, - "▁apple": 26163, - "▁Lö": 26164, - "oused": 26165, - "дро": 26166, - "sci": 26167, - "▁hibernate": 26168, - "dog": 26169, - "▁восто": 26170, - "▁intensity": 26171, - "legend": 26172, - "▁Wille": 26173, - "▁szerint": 26174, - "gesellschaft": 26175, - "▁Living": 26176, - "allo": 26177, - "▁Split": 26178, - "dru": 26179, - "need": 26180, - "▁Джон": 26181, - "▁Swiss": 26182, - "▁spraw": 26183, - "▁beho": 26184, - "▁fotograf": 26185, - "▁rencontre": 26186, - "▁kis": 26187, - "▁signing": 26188, - "akult": 26189, - "▁indexing": 26190, - "apor": 26191, - "▁conception": 26192, - "aggreg": 26193, - "▁Савез": 26194, - "▁affair": 26195, - "ění": 26196, - "August": 26197, - "▁секре": 26198, - "▁mieszkań": 26199, - "UIImage": 26200, - "▁bishop": 26201, - "▁servants": 26202, - "▁trail": 26203, - "digit": 26204, - "▁joins": 26205, - "▁Near": 26206, - "öffentlich": 26207, - ">{": 26208, - "▁skład": 26209, - "geführt": 26210, - "▁Holz": 26211, - "▁Militär": 26212, - "achi": 26213, - "Upper": 26214, - "pine": 26215, - "utzt": 26216, - "▁nuova": 26217, - "ibration": 26218, - "▁Bien": 26219, - "▁первый": 26220, - "▁Creating": 26221, - "Once": 26222, - "▁einmal": 26223, - "▁geometric": 26224, - "stvo": 26225, - "▁kW": 26226, - "▁decomposition": 26227, - "▁comedy": 26228, - "▁activation": 26229, - "▁angry": 26230, - "illeurs": 26231, - "▁instantly": 26232, - "▁suggesting": 26233, - "▁Clay": 26234, - "cot": 26235, - "▁Gén": 26236, - "($(": 26237, - "unwrap": 26238, - "▁lifted": 26239, - "▁Kit": 26240, - "▁linea": 26241, - "ок": 26242, - "hart": 26243, - "->_": 26244, - "▁nuit": 26245, - "▁Issue": 26246, - "лии": 26247, - "▁röm": 26248, - "Tasks": 26249, - "▁Sr": 26250, - "▁seis": 26251, - "asia": 26252, - "}}$.": 26253, - ":{": 26254, - "controls": 26255, - "▁Stim": 26256, - "▁Recht": 26257, - "ociación": 26258, - "▁Natal": 26259, - "▁Philippines": 26260, - "ulen": 26261, - "Fixed": 26262, - "▁switched": 26263, - "Zip": 26264, - "ospel": 26265, - "▁начале": 26266, - "▁Blan": 26267, - "urst": 26268, - "▁autour": 26269, - "Ca": 26270, - "▁latitude": 26271, - "▁Frei": 26272, - "▁Musée": 26273, - "▁Kurz": 26274, - "▁região": 26275, - "swap": 26276, - "▁hate": 26277, - "▁modifications": 26278, - "▁Ком": 26279, - "▁Antoine": 26280, - "uga": 26281, - "RECT": 26282, - "éter": 26283, - "GROUP": 26284, - "▁sacrific": 26285, - "▁Whe": 26286, - "▁Stevens": 26287, - "ologische": 26288, - "Summary": 26289, - "obs": 26290, - "hnen": 26291, - "<%=": 26292, - "dienst": 26293, - "remark": 26294, - "▁veröffentlicht": 26295, - "ел": 26296, - "▁Mock": 26297, - "▁Льв": 26298, - "▁três": 26299, - "gb": 26300, - "▁celebrated": 26301, - "▁Eb": 26302, - "▁costa": 26303, - "▁Geographic": 26304, - "▁attachment": 26305, - "mannschaft": 26306, - "▁dependence": 26307, - "��": 26308, - "▁attitude": 26309, - "etal": 26310, - "vic": 26311, - "baut": 26312, - "▁дов": 26313, - "▁interven": 26314, - "▁Gü": 26315, - "ónica": 26316, - "▁Pon": 26317, - "▁disponible": 26318, - "▁Feb": 26319, - "▁worship": 26320, - "▁Specifically": 26321, - "Hy": 26322, - "iju": 26323, - "▁cb": 26324, - "▁spac": 26325, - "leveland": 26326, - "▁localidad": 26327, - "▁preceding": 26328, - "▁Hessen": 26329, - "xp": 26330, - "▁Wein": 26331, - "▁Româ": 26332, - "▁giorno": 26333, - "▁квітня": 26334, - "llaços": 26335, - "▁Academia": 26336, - "▁kül": 26337, - "▁Års": 26338, - "▁нај": 26339, - "uclide": 26340, - "Internet": 26341, - "orton": 26342, - "▁corn": 26343, - "ями": 26344, - "▁\"*": 26345, - "▁Felix": 26346, - "apat": 26347, - "▁свои": 26348, - "MIT": 26349, - "made": 26350, - "▁locomot": 26351, - "хода": 26352, - "FP": 26353, - "▁pm": 26354, - ".*;": 26355, - "▁Hamm": 26356, - "`}": 26357, - "LayoutInflater": 26358, - "==\"": 26359, - "▁Eur": 26360, - "▁dogs": 26361, - "жении": 26362, - "▁azon": 26363, - "▁emulator": 26364, - "▁ricon": 26365, - "beeld": 26366, - "▁ну": 26367, - "▁approximate": 26368, - "LM": 26369, - "▁Bond": 26370, - "▁enh": 26371, - "ędz": 26372, - "▁solit": 26373, - "RelativeLayout": 26374, - "eteor": 26375, - "amentos": 26376, - "▁indirect": 26377, - "iből": 26378, - "▁gros": 26379, - "▁Originals": 26380, - "commands": 26381, - "Export": 26382, - "▁Avec": 26383, - "▁solemn": 26384, - "▁correction": 26385, - "▁проводи": 26386, - "▁Mosk": 26387, - "▁подо": 26388, - "▁gebied": 26389, - "▁następ": 26390, - "▁Driver": 26391, - "▁Ook": 26392, - "▁Vec": 26393, - "▁lungo": 26394, - "ficos": 26395, - "▁svol": 26396, - "▁kid": 26397, - "nja": 26398, - "▁Hr": 26399, - "▁поддер": 26400, - "▁visibility": 26401, - "▁Méd": 26402, - "▁cpu": 26403, - "discussion": 26404, - "Asset": 26405, - "▁defense": 26406, - "▁Anyone": 26407, - "▁Justin": 26408, - "iszt": 26409, - "▁Collins": 26410, - "▁Valent": 26411, - "▁Pale": 26412, - "▁fuel": 26413, - "▁nose": 26414, - "ríguez": 26415, - "▁Schles": 26416, - "▁Malays": 26417, - "▁commut": 26418, - "dro": 26419, - "uing": 26420, - "▁Rico": 26421, - "▁Emma": 26422, - "orp": 26423, - "▁Kirk": 26424, - "▁Quando": 26425, - "▁Neue": 26426, - "▁demande": 26427, - "▁Cover": 26428, - "▁rescue": 26429, - "▁gewählt": 26430, - "▁Calendar": 26431, - "▁Madonna": 26432, - "WP": 26433, - "oshi": 26434, - "▁Maven": 26435, - "▁belle": 26436, - "▁wx": 26437, - "▁sugar": 26438, - "▁Betrieb": 26439, - "▁equilibrium": 26440, - "EAR": 26441, - "▁texts": 26442, - "слов": 26443, - "▁czerwca": 26444, - "▁Düsseld": 26445, - "▁ELSE": 26446, - "▁amery": 26447, - "▁ani": 26448, - "▁obey": 26449, - "▁Nell": 26450, - "▁inne": 26451, - "▁тро": 26452, - "FD": 26453, - "cco": 26454, - "▁Zob": 26455, - "alette": 26456, - "▁május": 26457, - "ected": 26458, - "▁Turkey": 26459, - "▁Whether": 26460, - "qi": 26461, - "▁што": 26462, - "▁headquarters": 26463, - "endi": 26464, - "arus": 26465, - "opus": 26466, - "▁золо": 26467, - "▁destru": 26468, - "▁Lok": 26469, - "▁satisfaction": 26470, - "()\r": 26471, - "▁Тер": 26472, - "Jose": 26473, - "▁conquer": 26474, - "▁Effect": 26475, - "LayoutParams": 26476, - "iez": 26477, - "▁externs": 26478, - "▁gegenüber": 26479, - "▁ESP": 26480, - "olta": 26481, - "processor": 26482, - "▁Kult": 26483, - "▁Atlanta": 26484, - "▁tier": 26485, - "Operator": 26486, - "▁диа": 26487, - "▁пись": 26488, - "▁groß": 26489, - "▁hearts": 26490, - "▁millimeter": 26491, - "although": 26492, - "alles": 26493, - "▁Magic": 26494, - "training": 26495, - "oline": 26496, - "▁органі": 26497, - ">\\<^": 26498, - "ціаль": 26499, - "exports": 26500, - "Workbook": 26501, - "▁вересня": 26502, - "▁teles": 26503, - "▁economy": 26504, - "▁trap": 26505, - "▁refuse": 26506, - "▁stranger": 26507, - "▁instinct": 26508, - "пода": 26509, - "olan": 26510, - "▁ning": 26511, - "inflate": 26512, - "itatea": 26513, - "acks": 26514, - "▁Joy": 26515, - "FLAG": 26516, - "ailand": 26517, - "▁sorti": 26518, - "▁впер": 26519, - "▁pén": 26520, - "Nothing": 26521, - "▁száz": 26522, - "▁Áng": 26523, - "▁AUT": 26524, - "Actions": 26525, - "Every": 26526, - "▁червня": 26527, - "▁автомо": 26528, - "▁routine": 26529, - "▁estruct": 26530, - "▁Gang": 26531, - "▁holes": 26532, - "thesis": 26533, - "▁concl": 26534, - "▁pé": 26535, - "riers": 26536, - "ровой": 26537, - "adic": 26538, - "Speed": 26539, - "▁commanded": 26540, - "▁Nazionale": 26541, - "Managed": 26542, - "▁DECLARE": 26543, - "▁sedan": 26544, - "Strings": 26545, - "▁sacred": 26546, - "tersuch": 26547, - "▁abitanti": 26548, - "brit": 26549, - "▁NCAA": 26550, - "▁СП": 26551, - "▁aged": 26552, - "▁Chiesa": 26553, - "▁revision": 26554, - "opro": 26555, - "▁overwrite": 26556, - "embros": 26557, - "▁sortie": 26558, - "▁otten": 26559, - "xiv": 26560, - "▁deli": 26561, - "▁Asp": 26562, - "▁balls": 26563, - "kaf": 26564, - "▁brave": 26565, - "▁всего": 26566, - "egn": 26567, - "jpeg": 26568, - "▁Osten": 26569, - "Constants": 26570, - "▁Infantry": 26571, - "▁Nev": 26572, - "▁яких": 26573, - "▁муниципа": 26574, - "cija": 26575, - "▁poem": 26576, - "▁negro": 26577, - "хар": 26578, - "▁Ask": 26579, - "▁avo": 26580, - "▁Meyer": 26581, - "▁Westen": 26582, - "▁oko": 26583, - "agin": 26584, - "▁Süden": 26585, - "entries": 26586, - "▁Republik": 26587, - "CollectionView": 26588, - "-------": 26589, - "▁firefox": 26590, - "▁alcune": 26591, - "▁фото": 26592, - "▁отрима": 26593, - "~~~~~~~~": 26594, - "▁Раз": 26595, - "▁Complex": 26596, - "▁pia": 26597, - "▁publicada": 26598, - "wei": 26599, - "cedure": 26600, - "occupation": 26601, - "▁medicine": 26602, - "▁drove": 26603, - "Problem": 26604, - "▁beginner": 26605, - "▁thoroughly": 26606, - "uria": 26607, - "avant": 26608, - "ucha": 26609, - "▁lever": 26610, - "▁teatro": 26611, - "AVA": 26612, - "squ": 26613, - "trat": 26614, - "ivatal": 26615, - "▁dirty": 26616, - "▁seconde": 26617, - "▁gravit": 26618, - "▁proposition": 26619, - "hbar": 26620, - "omini": 26621, - "▁”": 26622, - "▁Camil": 26623, - "▁queen": 26624, - "modifier": 26625, - "Jan": 26626, - "▁lyr": 26627, - "ComboBox": 26628, - "ionic": 26629, - "▁holy": 26630, - "▁Sebastian": 26631, - "|_{": 26632, - "▁{@": 26633, - "▁можно": 26634, - "▁Creative": 26635, - "▁interess": 26636, - "▁CT": 26637, - "ições": 26638, - "▁chant": 26639, - "▁współ": 26640, - "▁Мексика": 26641, - "▁ranked": 26642, - "▁października": 26643, - "▁brut": 26644, - "▁farther": 26645, - "▁Verb": 26646, - "▁Seven": 26647, - "lbl": 26648, - "▁mentions": 26649, - "▁Fight": 26650, - "ifen": 26651, - "▁bog": 26652, - "▁regres": 26653, - "▁scoring": 26654, - "icane": 26655, - "▁Elli": 26656, - "▁pierw": 26657, - "measure": 26658, - "ńskiej": 26659, - "#{": 26660, - "▁деся": 26661, - "▁varmaste": 26662, - "▁Unix": 26663, - "IZ": 26664, - "itié": 26665, - "Primary": 26666, - "▁Springer": 26667, - "üng": 26668, - "▁anv": 26669, - "▁versione": 26670, - "▁shoulders": 26671, - "▁брига": 26672, - "▁jav": 26673, - "ltal": 26674, - "▁kallaste": 26675, - "▁Mitchell": 26676, - "▁wireless": 26677, - "▁Ál": 26678, - "respons": 26679, - "could": 26680, - "▁relax": 26681, - "Lond": 26682, - "ńcz": 26683, - "ствовал": 26684, - "▁polski": 26685, - "enç": 26686, - "zar": 26687, - "▁dtype": 26688, - "owned": 26689, - "unknown": 26690, - "▁mutable": 26691, - "▁siempre": 26692, - "▁Montreal": 26693, - "▁locate": 26694, - "▁traces": 26695, - "▁insgesamt": 26696, - "▁Nil": 26697, - "▁прода": 26698, - "▁Warner": 26699, - "▁Nau": 26700, - "triangle": 26701, - "▁concentration": 26702, - "▁gentlemen": 26703, - "ächt": 26704, - "filters": 26705, - "incipal": 26706, - "VALID": 26707, - "▁депута": 26708, - "adó": 26709, - "▁konst": 26710, - "gså": 26711, - "agas": 26712, - "▁meilleur": 26713, - "▁данным": 26714, - "єдна": 26715, - "encoded": 26716, - "<'": 26717, - "▁sheets": 26718, - "cuador": 26719, - "▁використову": 26720, - "▁Deput": 26721, - "▁manière": 26722, - "ąg": 26723, - "csol": 26724, - ")$-": 26725, - "UIView": 26726, - "▁millones": 26727, - "▁Ehren": 26728, - "Sil": 26729, - "▁atac": 26730, - "▁Cold": 26731, - "\"\\": 26732, - "▁approached": 26733, - "▁Årsmed": 26734, - "WM": 26735, - "▁Deport": 26736, - "mis": 26737, - "andbox": 26738, - "observ": 26739, - "setting": 26740, - "ható": 26741, - "▁strat": 26742, - "▁spre": 26743, - "▁personne": 26744, - "▁dirige": 26745, - "pull": 26746, - "dating": 26747, - "▁Fact": 26748, - "▁manipulate": 26749, - "▁MAC": 26750, - "▁dej": 26751, - "ultimo": 26752, - "FX": 26753, - "Life": 26754, - "▁crack": 26755, - "▁mí": 26756, - "▁пове": 26757, - "▁wore": 26758, - "université": 26759, - "▁formulas": 26760, - "▁Elisabeth": 26761, - "plots": 26762, - "mile": 26763, - "▁menor": 26764, - "тил": 26765, - "keyword": 26766, - "▁Baltimore": 26767, - "hrer": 26768, - "▁Clement": 26769, - "vim": 26770, - "rass": 26771, - "Take": 26772, - "▁című": 26773, - "▁Convention": 26774, - "atge": 26775, - "seed": 26776, - "▁Dí": 26777, - "▁Spider": 26778, - "ahoo": 26779, - "▁имеет": 26780, - "ührt": 26781, - "▁пописа": 26782, - "▁Cot": 26783, - "▁nobles": 26784, - "RESS": 26785, - "▁chemin": 26786, - "▁główn": 26787, - "GG": 26788, - "▁Germania": 26789, - "▁Alexandre": 26790, - "hens": 26791, - "swift": 26792, - "oop": 26793, - "Subview": 26794, - "▁requiring": 26795, - "ędzy": 26796, - "▁fict": 26797, - "▁Констан": 26798, - "▁déput": 26799, - "▁surprising": 26800, - "▁deix": 26801, - "▁unterschied": 26802, - "inson": 26803, - "▁Character": 26804, - "▁gestion": 26805, - "chus": 26806, - "comes": 26807, - "▁neur": 26808, - "▁yeux": 26809, - "ollar": 26810, - "▁parad": 26811, - "▁maggiore": 26812, - "TRAN": 26813, - "▁votre": 26814, - "▁descent": 26815, - "▁Icon": 26816, - "▁Judge": 26817, - "▁occupation": 26818, - "eping": 26819, - "▁tongue": 26820, - "▁Enllaços": 26821, - "ruf": 26822, - "▁protein": 26823, - "▁visitors": 26824, - "axy": 26825, - "esten": 26826, - "blica": 26827, - "hw": 26828, - "▁spirits": 26829, - "▁reduces": 26830, - "▁мен": 26831, - "▁Lamb": 26832, - "▁Mine": 26833, - "▁verified": 26834, - "▁Baby": 26835, - "▁prize": 26836, - "вър": 26837, - "▁ratings": 26838, - "▁fore": 26839, - "asha": 26840, - "urrence": 26841, - "▁intér": 26842, - "▁Olímp": 26843, - "cra": 26844, - "▁computational": 26845, - "irche": 26846, - ".: ": 26847, - "▁illustrated": 26848, - "▁Share": 26849, - "▁households": 26850, - "▁convolution": 26851, - "oemd": 26852, - "▁zdoby": 26853, - "ccc": 26854, - "▁quantities": 26855, - "Che": 26856, - "Should": 26857, - "▁genius": 26858, - "adj": 26859, - "хва": 26860, - "Петер": 26861, - "EMA": 26862, - "▁Rights": 26863, - "▁Eli": 26864, - "VAR": 26865, - "шло": 26866, - "▁збір": 26867, - "iftung": 26868, - "▁contributed": 26869, - "zef": 26870, - "▁CHAR": 26871, - "▁Sib": 26872, - "▁Mant": 26873, - "▁связи": 26874, - "▁javafx": 26875, - "▁cependant": 26876, - "▁intu": 26877, - "▁твор": 26878, - "▁Ó": 26879, - "guer": 26880, - "rado": 26881, - "▁Revol": 26882, - "▁fémin": 26883, - "▁Orleans": 26884, - "▁poj": 26885, - "▁prez": 26886, - "Tex": 26887, - "ouwd": 26888, - "?(": 26889, - "▁LIM": 26890, - "istique": 26891, - "esar": 26892, - "▁heures": 26893, - "icki": 26894, - "▁dbo": 26895, - "skih": 26896, - "confirm": 26897, - "▁világ": 26898, - "▁ciutat": 26899, - "▁DR": 26900, - "▁Hawai": 26901, - "ched": 26902, - "▁spher": 26903, - "▁Artikel": 26904, - "▁Multiple": 26905, - "ciu": 26906, - "▁мы": 26907, - "▁lipca": 26908, - "](/": 26909, - "Strategy": 26910, - "▁Alabama": 26911, - "SDK": 26912, - "UTC": 26913, - "__.": 26914, - "Arguments": 26915, - "▁setContentView": 26916, - "île": 26917, - "ByVal": 26918, - "▁JVM": 26919, - "ющего": 26920, - "▁Leonard": 26921, - "▁justify": 26922, - "цем": 26923, - "▁nab": 26924, - "CCESS": 26925, - "▁hopes": 26926, - ")&": 26927, - "sero": 26928, - "▁зай": 26929, - "слід": 26930, - "▁Rég": 26931, - "▁Sang": 26932, - "▁fung": 26933, - "baar": 26934, - "▁coffee": 26935, - "assembly": 26936, - "▁Він": 26937, - "эй": 26938, - "▁comprend": 26939, - "filled": 26940, - "рд": 26941, - "odia": 26942, - "▁gens": 26943, - "fluss": 26944, - "Drawable": 26945, - "▁surve": 26946, - "Setup": 26947, - "▁należ": 26948, - "▁conjunto": 26949, - "▁Его": 26950, - "▁oldal": 26951, - "▁verbose": 26952, - "▁Electric": 26953, - "▁Harrison": 26954, - "engen": 26955, - "paragraph": 26956, - "▁nouvelles": 26957, - "▁време": 26958, - "▁memor": 26959, - "▁mayoría": 26960, - "сад": 26961, - "▁bataille": 26962, - "▁thermal": 26963, - "▁Хронологи": 26964, - "▁Better": 26965, - "bye": 26966, - "▁театра": 26967, - "roe": 26968, - "▁segle": 26969, - "rott": 26970, - "▁opinions": 26971, - ")})": 26972, - "ühle": 26973, - "▁Gün": 26974, - "▁Щ": 26975, - "ból": 26976, - "▁Larry": 26977, - "▁solic": 26978, - "▁zwar": 26979, - "▁Caroline": 26980, - "▁Reichs": 26981, - "Extensions": 26982, - "migr": 26983, - ":@": 26984, - "▁enumerate": 26985, - "▁eigenen": 26986, - "▁explore": 26987, - "ému": 26988, - "▁gat": 26989, - "▁imperial": 26990, - "▁Usually": 26991, - "▁tud": 26992, - "▁укра": 26993, - "him": 26994, - "▁corners": 26995, - "▁SER": 26996, - "▁interpreter": 26997, - "▁Ice": 26998, - "▁amounts": 26999, - "▁Pala": 27000, - "▁tinha": 27001, - "vole": 27002, - "▁gle": 27003, - "ucci": 27004, - "▁siehe": 27005, - "Jack": 27006, - "▁woll": 27007, - "▁elder": 27008, - "▁кораб": 27009, - "▁engag": 27010, - "▁Laurent": 27011, - "▁achiev": 27012, - "istik": 27013, - "arct": 27014, - "тного": 27015, - "▁gir": 27016, - "▁Singh": 27017, - "mathop": 27018, - "USA": 27019, - "▁Projekt": 27020, - "▁debe": 27021, - "richtung": 27022, - "▁Tsch": 27023, - "uminate": 27024, - "▁szó": 27025, - "lyph": 27026, - "зидент": 27027, - "▁limitations": 27028, - "ющей": 27029, - "▁bila": 27030, - "Push": 27031, - "▁offering": 27032, - "iennes": 27033, - "Fri": 27034, - "▁postgresql": 27035, - "▁Tommy": 27036, - "▁particolare": 27037, - "▁století": 27038, - "▁arrib": 27039, - "▁Eva": 27040, - "school": 27041, - "▁vendor": 27042, - "▁Dallas": 27043, - "▁prolong": 27044, - "CREATE": 27045, - "▁suivante": 27046, - "STATUS": 27047, - "là": 27048, - "kv": 27049, - "▁häufig": 27050, - "▁Agricult": 27051, - "▁huit": 27052, - "▁inoltre": 27053, - "▁Lloyd": 27054, - "▁француз": 27055, - "▁выпол": 27056, - "▁faithful": 27057, - "▁Вар": 27058, - "▁verl": 27059, - "▁juego": 27060, - "▁Резултати": 27061, - ",...,": 27062, - "▁implicitly": 27063, - "irks": 27064, - "Calcul": 27065, - "▁meses": 27066, - "omed": 27067, - "▁pak": 27068, - "herit": 27069, - "▁optical": 27070, - "▁Історія": 27071, - "veis": 27072, - "▁capitale": 27073, - "placeholder": 27074, - "intrag": 27075, - "▁Atlas": 27076, - ")];": 27077, - "icons": 27078, - "▁Bent": 27079, - "▁Widget": 27080, - "▁volunt": 27081, - "avo": 27082, - "égr": 27083, - "lige": 27084, - "▁NAME": 27085, - "▁abstra": 27086, - "▁fís": 27087, - "▁Browser": 27088, - "▁bush": 27089, - "hall": 27090, - "▁clouds": 27091, - "▁SUB": 27092, - "▁tandis": 27093, - "▁Commonwealth": 27094, - "тая": 27095, - "▁exhaust": 27096, - "________________": 27097, - "▁Statistics": 27098, - "▁Religion": 27099, - "▁Muham": 27100, - "uals": 27101, - "goto": 27102, - "Digital": 27103, - "Family": 27104, - "▁Bun": 27105, - "letin": 27106, - "Management": 27107, - "▁capabilities": 27108, - "annten": 27109, - "▁себе": 27110, - "▁stays": 27111, - "kter": 27112, - "▁dost": 27113, - "▁Тре": 27114, - "лович": 27115, - "▁dying": 27116, - "sections": 27117, - "ános": 27118, - "▁apparten": 27119, - "▁zoals": 27120, - "▁dressed": 27121, - "▁compress": 27122, - "ńska": 27123, - "▁sierpnia": 27124, - "▁титу": 27125, - "dictionary": 27126, - "▁rabb": 27127, - "▁vérit": 27128, - "Во": 27129, - "▁singleton": 27130, - "▁vital": 27131, - "Refresh": 27132, - "мель": 27133, - "▁Zh": 27134, - "▁Afghan": 27135, - "inkel": 27136, - "aaaa": 27137, - "▁participants": 27138, - "arin": 27139, - "▁Mold": 27140, - "▁primeros": 27141, - "▁ран": 27142, - "▁Амери": 27143, - "▁restaurant": 27144, - "ével": 27145, - "▁SL": 27146, - "▁Rey": 27147, - "chas": 27148, - "▁electrons": 27149, - "▁Pitts": 27150, - "▁Jules": 27151, - "май": 27152, - "enant": 27153, - "-}": 27154, - "лад": 27155, - "▁Москва": 27156, - "gom": 27157, - "▁Fernández": 27158, - "fund": 27159, - "interno": 27160, - "▁Mari": 27161, - "▁rius": 27162, - "▁Prozent": 27163, - "стрі": 27164, - "▁внут": 27165, - "anterie": 27166, - "▁прис": 27167, - "▁обы": 27168, - "▁Marina": 27169, - "▁occurrence": 27170, - "rikt": 27171, - "▁физи": 27172, - "▁schwer": 27173, - "▁Гре": 27174, - "Reset": 27175, - "▁mucho": 27176, - "andr": 27177, - "▁Wies": 27178, - "▁Keith": 27179, - "▁Julian": 27180, - "▁cole": 27181, - "ciendo": 27182, - "▁Contempor": 27183, - "etry": 27184, - "elian": 27185, - "гии": 27186, - "▁голо": 27187, - "▁dél": 27188, - "▁decent": 27189, - "РСР": 27190, - "▁szeptember": 27191, - "мест": 27192, - "castle": 27193, - "▁держав": 27194, - "}\")": 27195, - "▁ASCII": 27196, - "▁Glen": 27197, - "itzerland": 27198, - "Toggle": 27199, - "▁tradicional": 27200, - "▁Plat": 27201, - "vee": 27202, - "abgerufen": 27203, - "(|": 27204, - "CLI": 27205, - "}}$,": 27206, - "▁Bowl": 27207, - "▁Male": 27208, - "▁Bres": 27209, - "▁пси": 27210, - "▁Challenge": 27211, - "zó": 27212, - "▁projekt": 27213, - "▁negoti": 27214, - "above": 27215, - "▁перио": 27216, - "▁longest": 27217, - "authentic": 27218, - "▁tradu": 27219, - "▁mujeres": 27220, - "▁Andre": 27221, - "▁hadn": 27222, - "▁Schule": 27223, - "odel": 27224, - "bled": 27225, - "▁Trade": 27226, - "▁mobil": 27227, - "▁algunas": 27228, - "▁Lak": 27229, - "▁Connecticut": 27230, - "▁alco": 27231, - "▁Selbst": 27232, - "ił": 27233, - "▁alb": 27234, - "ouverneur": 27235, - "▁sr": 27236, - "▁vba": 27237, - "loped": 27238, - "▁Partei": 27239, - "uate": 27240, - "▁Authentication": 27241, - "bei": 27242, - "}}.": 27243, - "▁konnten": 27244, - "▁допо": 27245, - "▁hyd": 27246, - "Office": 27247, - "données": 27248, - "▁Cleveland": 27249, - "rita": 27250, - "íos": 27251, - "▁выше": 27252, - "▁Roberts": 27253, - "▁élections": 27254, - "▁'')": 27255, - "▁publishing": 27256, - "▁bapt": 27257, - "<>();": 27258, - "missing": 27259, - "ровано": 27260, - "▁housing": 27261, - "▁inference": 27262, - "▁Renaissance": 27263, - "▁règ": 27264, - "▁Steph": 27265, - "CES": 27266, - "ERE": 27267, - "кет": 27268, - "OU": 27269, - "▁grouping": 27270, - "verkehr": 27271, - "jih": 27272, - "agli": 27273, - "▁milk": 27274, - "lait": 27275, - "Stage": 27276, - "▁byly": 27277, - "▁wooden": 27278, - "keley": 27279, - "etra": 27280, - "▁Peg": 27281, - "▁donné": 27282, - "adal": 27283, - "sequently": 27284, - "▁insbesondere": 27285, - "ELD": 27286, - "▁Mam": 27287, - "▁volte": 27288, - "▁prospect": 27289, - "нове": 27290, - "▁denoted": 27291, - "▁overlay": 27292, - "Permission": 27293, - "een": 27294, - "▁EM": 27295, - "▁uz": 27296, - "Mc": 27297, - "olit": 27298, - "▁servi": 27299, - "▁Heidel": 27300, - "▁Wiener": 27301, - "▁illegal": 27302, - "▁predictions": 27303, - "▁goog": 27304, - "hon": 27305, - "▁Cinema": 27306, - "▁револю": 27307, - "▁Rule": 27308, - "wod": 27309, - "▁radiation": 27310, - "oł": 27311, - "ової": 27312, - "▁Perform": 27313, - "▁prisoner": 27314, - "▁amet": 27315, - "▁figura": 27316, - "▁Commander": 27317, - "▁официаль": 27318, - "▁trov": 27319, - "▁acted": 27320, - "▁workflow": 27321, - "▁Республики": 27322, - "▁guidance": 27323, - "▁мене": 27324, - "National": 27325, - "▁Kel": 27326, - "webpack": 27327, - "простра": 27328, - "▁llamado": 27329, - "alog": 27330, - "terra": 27331, - "ixen": 27332, - "legraph": 27333, - "äischen": 27334, - "▁teachers": 27335, - "uden": 27336, - "▁også": 27337, - "possible": 27338, - "▁Soul": 27339, - "▁Geography": 27340, - "▁зада": 27341, - "hit": 27342, - "▁anger": 27343, - "▁remporte": 27344, - "Pod": 27345, - "чке": 27346, - "▁aria": 27347, - "▁Astronom": 27348, - "chapter": 27349, - "▁fork": 27350, - "▁Cuando": 27351, - "mense": 27352, - "▁Christians": 27353, - "gc": 27354, - "▁#(": 27355, - "Organ": 27356, - "▁steady": 27357, - "pse": 27358, - "жить": 27359, - "ignes": 27360, - "aterra": 27361, - "movie": 27362, - "posta": 27363, - "raste": 27364, - "▁Ressource": 27365, - "▁País": 27366, - "▁();": 27367, - "▁penalty": 27368, - "тт": 27369, - "▁trasfer": 27370, - "century": 27371, - "▁cleaner": 27372, - "selenium": 27373, - "ortheast": 27374, - "xic": 27375, - "лії": 27376, - "▁inglese": 27377, - "▁Tang": 27378, - "▁gods": 27379, - "frent": 27380, - "ciente": 27381, - "starts": 27382, - "▁musica": 27383, - "ymnasium": 27384, - "----+": 27385, - "▁terrest": 27386, - "▁retrieved": 27387, - "iare": 27388, - "unning": 27389, - "▁Marcus": 27390, - "▁promote": 27391, - "warning": 27392, - "тый": 27393, - "})$,": 27394, - "Transport": 27395, - "▁reson": 27396, - "▁Clo": 27397, - "▁erm": 27398, - "▁eliminate": 27399, - "heimer": 27400, - "▁saves": 27401, - "▁prayer": 27402, - "Classes": 27403, - "Express": 27404, - "▁Akademie": 27405, - "Else": 27406, - "Turn": 27407, - "▁ikke": 27408, - "▁rei": 27409, - "▁dirett": 27410, - "▁Rost": 27411, - "▁Papa": 27412, - "▁jsf": 27413, - "лением": 27414, - "▁Tul": 27415, - "▁Zak": 27416, - "▁niemieck": 27417, - "Tw": 27418, - "amour": 27419, - "nested": 27420, - "ppets": 27421, - "шп": 27422, - "dit": 27423, - "зен": 27424, - "zyma": 27425, - "hrte": 27426, - "Constraints": 27427, - "▁ownership": 27428, - "Arm": 27429, - "▁consumption": 27430, - "▁fet": 27431, - "ivari": 27432, - "chrom": 27433, - "setAttribute": 27434, - "▁compose": 27435, - "▁backing": 27436, - "▁Paz": 27437, - "▁scri": 27438, - "▁Mechan": 27439, - "▁Norway": 27440, - "▁Jup": 27441, - "▁mér": 27442, - "▁administrator": 27443, - "▁cabe": 27444, - "ivalent": 27445, - "▁throne": 27446, - "▁dues": 27447, - "▁humor": 27448, - "▁Adri": 27449, - "▁abort": 27450, - "ñas": 27451, - "▁Київ": 27452, - "jící": 27453, - "▁zweite": 27454, - "▁doub": 27455, - "ershell": 27456, - "шой": 27457, - "▁Fam": 27458, - "åk": 27459, - "▁tweede": 27460, - "▁Rib": 27461, - "▁før": 27462, - "pción": 27463, - "inned": 27464, - "rvm": 27465, - "▁Appar": 27466, - "▁Dj": 27467, - "▁Shang": 27468, - "Distance": 27469, - "▁dawn": 27470, - "▁Matth": 27471, - "▁errichtet": 27472, - "phantom": 27473, - "▁releases": 27474, - "Recognizer": 27475, - "▁Kop": 27476, - "▁Pul": 27477, - "ué": 27478, - "nats": 27479, - "relax": 27480, - "▁fled": 27481, - "▁experiences": 27482, - "щее": 27483, - "меня": 27484, - "▁персона": 27485, - "▁Identity": 27486, - "rets": 27487, - "kunft": 27488, - "larg": 27489, - "ListItem": 27490, - "vd": 27491, - "runner": 27492, - "lant": 27493, - "ipart": 27494, - "bay": 27495, - "iei": 27496, - "▁lengths": 27497, - "▁cattle": 27498, - "jets": 27499, - "▁sehen": 27500, - "Jul": 27501, - "fatt": 27502, - "▁surrender": 27503, - "▁Trump": 27504, - "дного": 27505, - "▁Fourier": 27506, - "ieben": 27507, - "_\"": 27508, - "▁früher": 27509, - "▁garant": 27510, - "uclidean": 27511, - "ägt": 27512, - "▁півден": 27513, - "Pages": 27514, - "▁rivers": 27515, - "▁donner": 27516, - "svn": 27517, - "▁ł": 27518, - "ově": 27519, - "▁Leist": 27520, - "arial": 27521, - "ových": 27522, - "▁filling": 27523, - "▁musicale": 27524, - "maxim": 27525, - "▁dashed": 27526, - "▁Нов": 27527, - "Drawer": 27528, - "▁Medicine": 27529, - "▁dokument": 27530, - "owel": 27531, - "vić": 27532, - "hely": 27533, - "▁elet": 27534, - "Seconds": 27535, - "▁Gonz": 27536, - "rou": 27537, - "▁finales": 27538, - "rn": 27539, - "fø": 27540, - "▁indexed": 27541, - "className": 27542, - "▁ober": 27543, - "▁duas": 27544, - "▁optimized": 27545, - "▁kdy": 27546, - "versary": 27547, - "energy": 27548, - "▁центра": 27549, - "▁currency": 27550, - "zyż": 27551, - "Like": 27552, - "▁Ги": 27553, - "sono": 27554, - "▁palab": 27555, - "▁pushing": 27556, - "ublik": 27557, - "▁Hass": 27558, - "}\\,\\": 27559, - "unker": 27560, - "▁Factory": 27561, - "▁Resources": 27562, - "datei": 27563, - "▁Tools": 27564, - "▁stehen": 27565, - "sime": 27566, - "▁Ху": 27567, - "▁hoch": 27568, - "▁Rodríguez": 27569, - "zeitig": 27570, - "▁Terry": 27571, - "▁обу": 27572, - "Usage": 27573, - "urchase": 27574, - "lö": 27575, - "▁Introduction": 27576, - "▁participation": 27577, - "ος": 27578, - "ogli": 27579, - "apy": 27580, - "▁hopefully": 27581, - "ponder": 27582, - "▁Yang": 27583, - "▁promises": 27584, - "▁верну": 27585, - "▁остров": 27586, - "^{+": 27587, - "▁mostra": 27588, - "▁CURLOPT": 27589, - "HH": 27590, - "▁stdout": 27591, - "▁brilliant": 27592, - "▁manuscript": 27593, - "▁decir": 27594, - "▁Bolog": 27595, - "▁места": 27596, - "▁invisible": 27597, - "▁Chal": 27598, - "▁analyze": 27599, - "prilis": 27600, - "attend": 27601, - "Mvc": 27602, - "than": 27603, - "cko": 27604, - "▁Quebec": 27605, - "▁planta": 27606, - "▁télévis": 27607, - "▁uninstall": 27608, - "ències": 27609, - "▁gminie": 27610, - "▁Pref": 27611, - "▁lequel": 27612, - "Invocation": 27613, - "▁Í": 27614, - "▁transformed": 27615, - "MAN": 27616, - "gebaut": 27617, - "▁сохра": 27618, - "▁второй": 27619, - "▁Lith": 27620, - "wendung": 27621, - "▁Politik": 27622, - "▁Senator": 27623, - "▁LL": 27624, - "ждение": 27625, - "ште": 27626, - "▁Cés": 27627, - "▁bande": 27628, - "▁historian": 27629, - "▁passwords": 27630, - "malloc": 27631, - "▁semif": 27632, - "▁rå": 27633, - "unicí": 27634, - "Available": 27635, - "Optional": 27636, - "▁Twe": 27637, - "▁kró": 27638, - "▁subsets": 27639, - "▁DAT": 27640, - "▁doubles": 27641, - "никами": 27642, - "▁зв": 27643, - "gegeben": 27644, - "▁Попис": 27645, - "▁július": 27646, - "▁meteor": 27647, - "Mount": 27648, - "ivent": 27649, - "▁Nathan": 27650, - "▁Schutz": 27651, - "egov": 27652, - "▁död": 27653, - "▁meat": 27654, - "▁пункт": 27655, - "▁minds": 27656, - "elivery": 27657, - "▁TLS": 27658, - "рем": 27659, - "ckså": 27660, - "▁stayed": 27661, - "▁Bin": 27662, - "▁Pia": 27663, - "▁имен": 27664, - "▁Bobby": 27665, - "▁produit": 27666, - "empio": 27667, - "▁reducing": 27668, - "▁Yu": 27669, - "▁Geschäft": 27670, - "▁perché": 27671, - "▁cors": 27672, - "▁icons": 27673, - "AppData": 27674, - "▁Hog": 27675, - "▁рів": 27676, - "▁Sans": 27677, - "▁siège": 27678, - "stellen": 27679, - "Brush": 27680, - "OFF": 27681, - "▁visitor": 27682, - "▁bath": 27683, - "▁fee": 27684, - "atisf": 27685, - "▁curv": 27686, - "▁folgender": 27687, - "▁conscience": 27688, - "▁Seattle": 27689, - "▁medieval": 27690, - "distribution": 27691, - "▁DM": 27692, - "▁мя": 27693, - "▁RUN": 27694, - "akov": 27695, - "ceil": 27696, - "▁letting": 27697, - "▁dov": 27698, - "▁оби": 27699, - "kiej": 27700, - "▁direkt": 27701, - "▁tm": 27702, - "colors": 27703, - "▁altro": 27704, - "▁tijdens": 27705, - "]{'": 27706, - "▁Bom": 27707, - "▁kunst": 27708, - "▁shelter": 27709, - "▁rav": 27710, - "predict": 27711, - "▁comenzó": 27712, - "▁świat": 27713, - "▁Durant": 27714, - "▁schemes": 27715, - "▁mesh": 27716, - "▁indicator": 27717, - "▁Emer": 27718, - "▁guilty": 27719, - "нец": 27720, - "▁consequences": 27721, - "cludes": 27722, - "▁Lower": 27723, - "▁поме": 27724, - "▁pace": 27725, - "даго": 27726, - "▁ambos": 27727, - "lb": 27728, - "▁educated": 27729, - "urale": 27730, - "anh": 27731, - "esség": 27732, - "▁associations": 27733, - "town": 27734, - "▁trif": 27735, - "samples": 27736, - "bos": 27737, - "▁Spect": 27738, - "▁Це": 27739, - "altung": 27740, - "▁Lob": 27741, - "▁curiosity": 27742, - "▁Weiter": 27743, - "estone": 27744, - "▁demol": 27745, - "▁apolog": 27746, - "▁Dynamic": 27747, - "Inner": 27748, - "esper": 27749, - "ecz": 27750, - "uellement": 27751, - "▁Hamiltonian": 27752, - "Atlas": 27753, - "▁argue": 27754, - "Foreign": 27755, - "collapse": 27756, - "▁términ": 27757, - "▁electronic": 27758, - "▁NR": 27759, - "▁corr": 27760, - "temps": 27761, - "IndexPath": 27762, - "яз": 27763, - "▁talál": 27764, - "today": 27765, - "wave": 27766, - "▁sib": 27767, - "▁спи": 27768, - "▁convey": 27769, - "▁Géographie": 27770, - "▁Нью": 27771, - "▁Hibernate": 27772, - "▁tin": 27773, - "dic": 27774, - "ppings": 27775, - "sweise": 27776, - "▁rolling": 27777, - "▁selects": 27778, - ")\\)": 27779, - "▁poeta": 27780, - "▁степени": 27781, - "▁Abr": 27782, - "▁höch": 27783, - "▁stern": 27784, - "▁fjär": 27785, - "▁installer": 27786, - "decl": 27787, - "▁miser": 27788, - "groupby": 27789, - "substr": 27790, - "▁phenomen": 27791, - "▁Wing": 27792, - "▁fills": 27793, - "▁único": 27794, - "Running": 27795, - "Come": 27796, - "irable": 27797, - "simeq": 27798, - "▁remp": 27799, - "kele": 27800, - "liers": 27801, - "▁kwietnia": 27802, - "▁interrupted": 27803, - "▁Jet": 27804, - "=\\{": 27805, - "ído": 27806, - "▁Taiwan": 27807, - "▁возра": 27808, - "▁alternatives": 27809, - "▁Tir": 27810, - "▁Reserve": 27811, - "▁Кур": 27812, - "▁Nobel": 27813, - "▁работал": 27814, - "▁axes": 27815, - "▁Cependant": 27816, - "ká": 27817, - "▁erneut": 27818, - "▁Demo": 27819, - "communic": 27820, - "constructor": 27821, - "▁Monday": 27822, - "Nil": 27823, - "HashMap": 27824, - "payment": 27825, - "▁fixing": 27826, - "▁ADD": 27827, - "review": 27828, - "▁possibil": 27829, - "▁grote": 27830, - "▁grouped": 27831, - "▁Lima": 27832, - "▁Augen": 27833, - "▁också": 27834, - "onas": 27835, - "▁debate": 27836, - "▁Ingl": 27837, - "Da": 27838, - "SOUR": 27839, - "ettbe": 27840, - "▁Battalion": 27841, - "▁Float": 27842, - "▁cone": 27843, - "readsheet": 27844, - "court": 27845, - "ligen": 27846, - "▁Beginn": 27847, - "▁LIMIT": 27848, - "▁enjoyed": 27849, - "▁Jakob": 27850, - "▁telt": 27851, - "backend": 27852, - "▁Gemeinsame": 27853, - "lint": 27854, - "alling": 27855, - "▁bör": 27856, - "grand": 27857, - "▁diverses": 27858, - "▁związ": 27859, - "▁Kompon": 27860, - "▁innerhalb": 27861, - "▁desarrollo": 27862, - "▁Masters": 27863, - "ioso": 27864, - "]`.": 27865, - "▁francesa": 27866, - "Aff": 27867, - "inek": 27868, - "▁dessin": 27869, - "`.`": 27870, - "▁ranks": 27871, - "берг": 27872, - "▁skal": 27873, - "▁Sultan": 27874, - "АН": 27875, - "▁способ": 27876, - "▁contradict": 27877, - "▁recom": 27878, - "▁Oklahoma": 27879, - "▁Vladimir": 27880, - "▁meters": 27881, - "transport": 27882, - "▁consulté": 27883, - "▁ATP": 27884, - "ebb": 27885, - "▁volunte": 27886, - "▁outline": 27887, - "LIC": 27888, - "▁euro": 27889, - "CharField": 27890, - "medium": 27891, - "▁Belgique": 27892, - "Proc": 27893, - "routes": 27894, - "▁contribu": 27895, - "!}": 27896, - "ším": 27897, - "▁Less": 27898, - "▁Kost": 27899, - "▁eredetiből": 27900, - "reven": 27901, - "verify": 27902, - "▁Salt": 27903, - "▁shooting": 27904, - "▁dispose": 27905, - "ují": 27906, - "▁tierra": 27907, - "▁poison": 27908, - "sak": 27909, - "perimental": 27910, - "▁Né": 27911, - "▁Kid": 27912, - "agyar": 27913, - "▁archiválva": 27914, - "bereich": 27915, - "íz": 27916, - "▁Ritter": 27917, - "▁Хронологија": 27918, - "zeum": 27919, - "дах": 27920, - "▁gründ": 27921, - "▁programmer": 27922, - "▁conseil": 27923, - "▁encrypt": 27924, - "integration": 27925, - "Culture": 27926, - "▁Circle": 27927, - "Observable": 27928, - "▁genomsnitt": 27929, - "▁Selection": 27930, - "▁irregular": 27931, - "Autres": 27932, - "Percent": 27933, - "fault": 27934, - "▁virtue": 27935, - "ąpi": 27936, - "▁sess": 27937, - "▁Также": 27938, - "Timestamp": 27939, - "▁littérature": 27940, - "▁moż": 27941, - "▁borrow": 27942, - "▁conced": 27943, - "чник": 27944, - "▁Lund": 27945, - "IONS": 27946, - "ynie": 27947, - "▁Shin": 27948, - "▁osob": 27949, - "bě": 27950, - "▁intuit": 27951, - "▁нап": 27952, - "▁proph": 27953, - "▁pitt": 27954, - "▁IBM": 27955, - "▁Till": 27956, - "▁hina": 27957, - "ittest": 27958, - "generator": 27959, - "▁Nin": 27960, - "▁Kot": 27961, - "▁passer": 27962, - "▁disposition": 27963, - "uning": 27964, - "▁fame": 27965, - "▁tenia": 27966, - "ancement": 27967, - "▁Suisse": 27968, - "`-": 27969, - "▁hombres": 27970, - "▁infinity": 27971, - "▁оконча": 27972, - "▁cosm": 27973, - "▁Dennis": 27974, - "baz": 27975, - "haupt": 27976, - "▁mighty": 27977, - "▁prede": 27978, - "usable": 27979, - "▁wszyst": 27980, - "▁lb": 27981, - "ABASE": 27982, - "jna": 27983, - "нев": 27984, - "▁ases": 27985, - "▁finalmente": 27986, - "йм": 27987, - "pection": 27988, - "▁Studien": 27989, - "▁Norwegian": 27990, - "cego": 27991, - "INDEX": 27992, - "orten": 27993, - "▁friendship": 27994, - "metro": 27995, - "thick": 27996, - "▁Zel": 27997, - "LOW": 27998, - "▁thereby": 27999, - "unted": 28000, - "▁surfaces": 28001, - "ющим": 28002, - "%).": 28003, - "▁Wonder": 28004, - "▁redundant": 28005, - "▁Gros": 28006, - "▁websites": 28007, - "▁vio": 28008, - "▁ocas": 28009, - "vés": 28010, - "▁Gam": 28011, - "dw": 28012, - "Indicator": 28013, - "▁Kob": 28014, - "▁jack": 28015, - "Hint": 28016, - "▁Apol": 28017, - "▁другие": 28018, - "▁NUM": 28019, - "▁ofic": 28020, - "ystycz": 28021, - "▁wereld": 28022, - "мости": 28023, - "LEFT": 28024, - "▁Types": 28025, - "seen": 28026, - "uncia": 28027, - "▁narod": 28028, - "▁этот": 28029, - "Sidenote": 28030, - "ueil": 28031, - "▁отме": 28032, - "▁courts": 28033, - "fir": 28034, - "urz": 28035, - "ченко": 28036, - "Credentials": 28037, - "▁imagination": 28038, - "itats": 28039, - "buff": 28040, - "flash": 28041, - "▁badly": 28042, - "▁worn": 28043, - "▁округу": 28044, - "catalog": 28045, - "lime": 28046, - "▁Gill": 28047, - "▁Sent": 28048, - "iella": 28049, - "▁Craig": 28050, - "▁Sele": 28051, - "▁Independ": 28052, - "▁provincie": 28053, - "ossen": 28054, - "▁запад": 28055, - "▁infant": 28056, - "▁prevents": 28057, - "▁provinces": 28058, - "afé": 28059, - "beg": 28060, - "▁colours": 28061, - "BF": 28062, - "ën": 28063, - "▁Между": 28064, - "în": 28065, - "Observer": 28066, - "forsch": 28067, - "ígen": 28068, - "umption": 28069, - "▁Illustr": 28070, - "рист": 28071, - "▁полови": 28072, - "▁`&": 28073, - "▁ore": 28074, - "▁supplies": 28075, - "▁parenthes": 28076, - "Foundation": 28077, - "▁vou": 28078, - "▁Tout": 28079, - "Donald": 28080, - "▁RET": 28081, - "weig": 28082, - "▁producción": 28083, - "mix": 28084, - "▁utwor": 28085, - "▁föl": 28086, - "▁então": 28087, - "▁Sister": 28088, - "Tags": 28089, - "▁Савезне": 28090, - "▁privileges": 28091, - "▁nazw": 28092, - "▁Rav": 28093, - "▁repro": 28094, - "▁Mason": 28095, - "▁Platform": 28096, - "▁пробле": 28097, - "▁Pérez": 28098, - "▁blanc": 28099, - "Behavior": 28100, - "фици": 28101, - "eken": 28102, - "▁meets": 28103, - "(.*": 28104, - "▁få": 28105, - "epen": 28106, - "maker": 28107, - "▁loyal": 28108, - "members": 28109, - "meisterschaft": 28110, - "goal": 28111, - "шлен": 28112, - "▁северо": 28113, - "iende": 28114, - "дні": 28115, - "Proof": 28116, - "▁explic": 28117, - "▁electro": 28118, - "iels": 28119, - "reload": 28120, - "▁eleven": 28121, - "▁partidos": 28122, - "îne": 28123, - "▁Regin": 28124, - "▁éx": 28125, - "▁Bulg": 28126, - "▁networking": 28127, - "▁separator": 28128, - "UserName": 28129, - "▁edificio": 28130, - "▁Mie": 28131, - "▁idle": 28132, - "yed": 28133, - "▁passengers": 28134, - "+)": 28135, - "meno": 28136, - "eggi": 28137, - "▁nicely": 28138, - "endencia": 28139, - "чий": 28140, - "étés": 28141, - "ightarrow": 28142, - "▁orthogonal": 28143, - "▁Half": 28144, - "▁fewer": 28145, - "▁propi": 28146, - "▁primit": 28147, - "icale": 28148, - "▁flower": 28149, - "merk": 28150, - "▁Отече": 28151, - "▁persistent": 28152, - "▁Ville": 28153, - "Men": 28154, - "gaben": 28155, - "▁Isaac": 28156, - "ativity": 28157, - "▁północ": 28158, - "▁rok": 28159, - "cards": 28160, - "дения": 28161, - "▁юго": 28162, - "▁extraordinary": 28163, - "▁kyr": 28164, - "(\",": 28165, - "))]": 28166, - "▁unix": 28167, - "кол": 28168, - "▁sink": 28169, - "apsed": 28170, - "▁kommen": 28171, - "▁forcing": 28172, - "About": 28173, - "▁Halle": 28174, - "▁Majesty": 28175, - "▁Switch": 28176, - "▁abroad": 28177, - "▁acceleration": 28178, - "urbed": 28179, - "▁остан": 28180, - "Ready": 28181, - "▁півні": 28182, - "Bra": 28183, - "▁цього": 28184, - "▁plut": 28185, - "▁Train": 28186, - "▁április": 28187, - "▁puesto": 28188, - "▁toss": 28189, - "▁irrelevant": 28190, - "▁dip": 28191, - "segment": 28192, - "opacity": 28193, - "▁lorsque": 28194, - "▁verschill": 28195, - "ена": 28196, - "▁Doc": 28197, - "%%%%%%%%": 28198, - "▁borders": 28199, - "gebras": 28200, - "▁ries": 28201, - "▁Olympedia": 28202, - "▁Generation": 28203, - "metros": 28204, - "▁horizon": 28205, - "▁adaptation": 28206, - "▁Zahl": 28207, - "▁nahe": 28208, - "▁Bug": 28209, - "Picture": 28210, - "љи": 28211, - "RGB": 28212, - "Owner": 28213, - "adin": 28214, - "▁Catalunya": 28215, - "ných": 28216, - "▁cualquier": 28217, - "▁Institution": 28218, - "insen": 28219, - "▁Brasile": 28220, - "▁fitting": 28221, - "Deleg": 28222, - "ictwo": 28223, - "▁Exper": 28224, - "ochastic": 28225, - "▁dus": 28226, - "▁пора": 28227, - "▁substring": 28228, - "ссии": 28229, - "oin": 28230, - "▁школа": 28231, - "▁cx": 28232, - "▁%)": 28233, - "▁Buddh": 28234, - "▁pending": 28235, - "▁Entry": 28236, - "▁Berl": 28237, - "▁cler": 28238, - "▁Soc": 28239, - "▁rounded": 28240, - "▁mv": 28241, - "ített": 28242, - "▁Diplom": 28243, - "▁französischen": 28244, - "▁Gan": 28245, - "▁Investig": 28246, - "▁indexPath": 28247, - "▁molti": 28248, - "persistence": 28249, - "▁XIXe": 28250, - "▁Electron": 28251, - "bü": 28252, - "gele": 28253, - "▁Maler": 28254, - "▁proyecto": 28255, - "▁Bath": 28256, - "ellers": 28257, - "▁GP": 28258, - "oning": 28259, - "cloudflare": 28260, - "▁při": 28261, - "▁ded": 28262, - "▁Odkazy": 28263, - "▁Msg": 28264, - "▁Being": 28265, - "▁Depuis": 28266, - "▁Primary": 28267, - "▁Appro": 28268, - "▁formally": 28269, - "ступил": 28270, - "▁fuera": 28271, - "▁Root": 28272, - "▁autonom": 28273, - "▁secretary": 28274, - "▁osób": 28275, - "▁cuales": 28276, - "▁Depending": 28277, - "▁asi": 28278, - "vera": 28279, - "▁russe": 28280, - "▁proves": 28281, - "▁presiden": 28282, - "RU": 28283, - "▁Watson": 28284, - "▁webpack": 28285, - "elligence": 28286, - "кам": 28287, - "▁Officer": 28288, - "▁delivery": 28289, - "ждён": 28290, - "▁импе": 28291, - "▁wil": 28292, - "▁vesc": 28293, - "usztus": 28294, - "▁Geoff": 28295, - "()}": 28296, - "▁Fore": 28297, - "▁wenig": 28298, - "▁Airl": 28299, - "▁Efter": 28300, - "▁Break": 28301, - "▁Städ": 28302, - "ismiss": 28303, - "íp": 28304, - "▁avoided": 28305, - "▁assertion": 28306, - "DN": 28307, - "▁teat": 28308, - "ína": 28309, - "▁mechanical": 28310, - "isu": 28311, - "@{": 28312, - "▁nou": 28313, - "Italie": 28314, - "sourceforge": 28315, - "▁svo": 28316, - "▁király": 28317, - "▁References": 28318, - "six": 28319, - "▁Archives": 28320, - "▁finishing": 28321, - "acje": 28322, - "état": 28323, - "iffs": 28324, - "▁stead": 28325, - "▁feas": 28326, - "aware": 28327, - "lande": 28328, - "Inject": 28329, - "▁Agent": 28330, - "▁Normdatei": 28331, - "▁amen": 28332, - "▁Architecture": 28333, - "aze": 28334, - "ște": 28335, - "▁usar": 28336, - "▁cores": 28337, - "лін": 28338, - "▁Castro": 28339, - "▁væ": 28340, - ">\",": 28341, - "omena": 28342, - "▁gesam": 28343, - "▁Martín": 28344, - "egung": 28345, - "▁společ": 28346, - "▁amplitude": 28347, - "▁importing": 28348, - "▁listview": 28349, - "THE": 28350, - "ziale": 28351, - "cedes": 28352, - "▁particulier": 28353, - "▁Расподела": 28354, - "▁край": 28355, - "▁divent": 28356, - "▁ké": 28357, - "quit": 28358, - "тором": 28359, - "CheckBox": 28360, - "▁Zobacz": 28361, - "phe": 28362, - "pta": 28363, - "▁sjö": 28364, - "▁розташ": 28365, - "▁tedesco": 28366, - "▁stal": 28367, - "▁Beruf": 28368, - "овая": 28369, - "▁svě": 28370, - "▁flush": 28371, - "▁відбу": 28372, - "▁radial": 28373, - "▁différentes": 28374, - "анта": 28375, - "▁Perry": 28376, - "Coll": 28377, - "liqu": 28378, - "▁Optional": 28379, - "▁Санкт": 28380, - "▁LINQ": 28381, - "▁Franc": 28382, - "cije": 28383, - "▁Guillaume": 28384, - "know": 28385, - "▁Units": 28386, - "olk": 28387, - "▁Système": 28388, - "▁Sales": 28389, - "▁ehemaligen": 28390, - "мирова": 28391, - "xhtml": 28392, - "setopt": 28393, - "▁mellan": 28394, - "▁zie": 28395, - "▁giant": 28396, - "Board": 28397, - "▁Caval": 28398, - "▁defence": 28399, - "----------": 28400, - "pshire": 28401, - "mart": 28402, - "▁Dioc": 28403, - "iskt": 28404, - "▁inse": 28405, - "▁épisode": 28406, - "чик": 28407, - "bars": 28408, - "Sito": 28409, - "▁integrity": 28410, - "auff": 28411, - "▁vär": 28412, - "Azure": 28413, - "▁starb": 28414, - "▁контра": 28415, - "▁Мексичка": 28416, - "▁запа": 28417, - "▁Mountains": 28418, - "}}=": 28419, - "▁pulling": 28420, - "▁satellite": 28421, - "▁atoms": 28422, - "▁profesor": 28423, - "▁repeatedly": 28424, - "▁invasion": 28425, - "programming": 28426, - "├──": 28427, - "▁Lip": 28428, - "вшие": 28429, - "▁keen": 28430, - "▁critics": 28431, - "▁Nicola": 28432, - "▁Cand": 28433, - "▁distint": 28434, - "▁heading": 28435, - "pragma": 28436, - "{|": 28437, - "ymen": 28438, - "▁terrain": 28439, - "iedenis": 28440, - "▁besonders": 28441, - "▁nominated": 28442, - "BOOL": 28443, - "▁Kay": 28444, - "cian": 28445, - "stelle": 28446, - "▁dispute": 28447, - "▁щ": 28448, - "DataSet": 28449, - "nothing": 28450, - "Autom": 28451, - "hören": 28452, - "▁shed": 28453, - "▁paused": 28454, - "san": 28455, - "▁nunca": 28456, - "!(\"": 28457, - "▁położ": 28458, - "Secret": 28459, - "▁Domain": 28460, - "▁возмож": 28461, - "XV": 28462, - "lv": 28463, - "ikh": 28464, - "▁Sony": 28465, - "mq": 28466, - "otrop": 28467, - "▁Logger": 28468, - "▁threat": 28469, - "asted": 28470, - "зько": 28471, - "▁freely": 28472, - "▁improvements": 28473, - "istema": 28474, - "▁illustrate": 28475, - "▁tact": 28476, - "▁figur": 28477, - "ués": 28478, - "riminal": 28479, - "odon": 28480, - "intendo": 28481, - "▁influenced": 28482, - "FFER": 28483, - "▁Ghost": 28484, - "▁совер": 28485, - "nad": 28486, - "ioned": 28487, - "▁Events": 28488, - "▁wrapping": 28489, - "---------+": 28490, - "fif": 28491, - "▁(**": 28492, - "={{": 28493, - "маль": 28494, - "▁losses": 28495, - "▁Galerie": 28496, - "tel": 28497, - "▁лютого": 28498, - "▁Kru": 28499, - "▁Polen": 28500, - "нім": 28501, - "near": 28502, - "▁shame": 28503, - "▁moyenne": 28504, - "▁CP": 28505, - "preis": 28506, - "▁passenger": 28507, - "lek": 28508, - "ionales": 28509, - "kafka": 28510, - "▁participe": 28511, - "▁membership": 28512, - "[_": 28513, - "lando": 28514, - "stelling": 28515, - "Sem": 28516, - "gon": 28517, - "▁Correct": 28518, - "▁valle": 28519, - "▁readily": 28520, - "▁Dokument": 28521, - "honneur": 28522, - "▁testim": 28523, - "ulative": 28524, - "doFilter": 28525, - "▁dominant": 28526, - "ammer": 28527, - "▁која": 28528, - "▁Monsieur": 28529, - "zeg": 28530, - "▁війни": 28531, - "▁Fo": 28532, - "▁Amy": 28533, - "▁¡": 28534, - "▁február": 28535, - "▁downloading": 28536, - "▁leng": 28537, - "\\}$,": 28538, - "▁neat": 28539, - "▁Cache": 28540, - "ICATION": 28541, - "▁deve": 28542, - "▁sorrow": 28543, - "slow": 28544, - "▁hinaus": 28545, - "▁reconoc": 28546, - "▁Linked": 28547, - "▁Shaw": 28548, - "market": 28549, - "▁Dic": 28550, - "▁Ski": 28551, - "▁delimiter": 28552, - "▁MainActivity": 28553, - "▁Musical": 28554, - "▁Reyn": 28555, - "ScrollView": 28556, - "▁conventional": 28557, - "ença": 28558, - "▁refactor": 28559, - "'-": 28560, - "▁Hed": 28561, - "sprech": 28562, - "▁athlet": 28563, - "▁especies": 28564, - "▁Schön": 28565, - "▁kleinen": 28566, - "шко": 28567, - "▁Йо": 28568, - "▁Happy": 28569, - "multirow": 28570, - "▁augusti": 28571, - "▁Gand": 28572, - "▁appointment": 28573, - "▁Mediabestanden": 28574, - "Three": 28575, - "▁Kenneth": 28576, - "NEW": 28577, - "▁Notification": 28578, - "▁Marx": 28579, - "▁insc": 28580, - "Mor": 28581, - "вый": 28582, - "väst": 28583, - "vidia": 28584, - "▁demonstrated": 28585, - "fonts": 28586, - "▁kamen": 28587, - "▁Ster": 28588, - "▁mieszkańców": 28589, - "▁Koh": 28590, - "~$\\": 28591, - "»).": 28592, - "rene": 28593, - "insic": 28594, - "ická": 28595, - "xygen": 28596, - "▁mn": 28597, - "▁sched": 28598, - "ASC": 28599, - "Ig": 28600, - "▁Constant": 28601, - "▁opportun": 28602, - "▁MyClass": 28603, - "sef": 28604, - "oped": 28605, - "▁injured": 28606, - "VIS": 28607, - "▁Pero": 28608, - "▁Until": 28609, - "▁flesh": 28610, - "orphism": 28611, - "▁Portal": 28612, - "▁gminy": 28613, - "▁власти": 28614, - "▁Nä": 28615, - "ктиче": 28616, - "▁hrab": 28617, - "▁Cub": 28618, - "avoir": 28619, - "▁Lars": 28620, - "▁Бело": 28621, - "▁seizoen": 28622, - "▁Genomsnitt": 28623, - "▁Lil": 28624, - "▁Pool": 28625, - "▁Dios": 28626, - "TX": 28627, - "aes": 28628, - "autore": 28629, - "Alpha": 28630, - "states": 28631, - "Lab": 28632, - "nederbörd": 28633, - "erton": 28634, - "▁brid": 28635, - "▁richt": 28636, - "▁Ela": 28637, - "▁сла": 28638, - "▁weapon": 28639, - "▁combatt": 28640, - "agar": 28641, - "▁regnig": 28642, - "▁utilisé": 28643, - "▁servir": 28644, - "▁brick": 28645, - "▁gateway": 28646, - "▁torraste": 28647, - "▁procedures": 28648, - "▁årsnederbörd": 28649, - "▁Genomsnittlig": 28650, - "чёт": 28651, - "▁områ": 28652, - "▁regnigaste": 28653, - "▁честь": 28654, - "▁amid": 28655, - "▁grateful": 28656, - "▁DIS": 28657, - "DAY": 28658, - "▁ору": 28659, - "▁rivière": 28660, - "heure": 28661, - "▁Richmond": 28662, - "▁Compar": 28663, - "▁Нор": 28664, - "DOC": 28665, - "esia": 28666, - "calc": 28667, - "▁IU": 28668, - "▁vorg": 28669, - "▁habían": 28670, - "çoit": 28671, - "▁arist": 28672, - "▁кли": 28673, - "▁Sue": 28674, - "▁Touch": 28675, - "▁Writing": 28676, - "ifiable": 28677, - "▁wc": 28678, - "▁withdraw": 28679, - "зар": 28680, - "▁presently": 28681, - "▁FK": 28682, - "▁prakt": 28683, - "▁colored": 28684, - "usb": 28685, - "▁Perú": 28686, - "▁plata": 28687, - "▁wishes": 28688, - "▁кам": 28689, - "azar": 28690, - "ável": 28691, - "▁lamp": 28692, - "bishop": 28693, - "▁inclusion": 28694, - "jq": 28695, - "arth": 28696, - "▁Flag": 28697, - "▁нор": 28698, - "ædia": 28699, - "UNCTION": 28700, - "▁Bahnhof": 28701, - "▁approaching": 28702, - "▁Gött": 28703, - "▁cube": 28704, - "▁argued": 28705, - "▁Things": 28706, - "Gui": 28707, - "дови": 28708, - "▁recre": 28709, - "▁réseau": 28710, - "▁significa": 28711, - "Git": 28712, - "gebracht": 28713, - "▁liga": 28714, - "▁assured": 28715, - "alus": 28716, - "рит": 28717, - "▁энциклопеди": 28718, - "▁%).": 28719, - "▁Première": 28720, - "▁declarations": 28721, - "▁tricky": 28722, - "▁profiles": 28723, - "▁Fon": 28724, - "▁Jas": 28725, - "âr": 28726, - "babel": 28727, - "▁Friday": 28728, - "▁június": 28729, - "▁cols": 28730, - "▁EXISTS": 28731, - "▁Italiana": 28732, - "▁authorization": 28733, - "▁sulle": 28734, - "▁Emb": 28735, - "▁Variable": 28736, - "trees": 28737, - "▁Fly": 28738, - "riors": 28739, - "▁damals": 28740, - "▁findet": 28741, - "▁Sept": 28742, - "▁mundial": 28743, - "▁removal": 28744, - "▁longitude": 28745, - "clic": 28746, - "▁fade": 28747, - "▁gradle": 28748, - "▁zák": 28749, - "▁timing": 28750, - "trightarrow": 28751, - "atia": 28752, - "-.": 28753, - "uche": 28754, - "▁serialize": 28755, - "▁Hmm": 28756, - "▁Representatives": 28757, - "bah": 28758, - "rend": 28759, - "assador": 28760, - "▁shield": 28761, - "ucion": 28762, - "▁américaine": 28763, - "zę": 28764, - "villa": 28765, - "▁hombre": 28766, - "áss": 28767, - "▁SF": 28768, - "▁repeating": 28769, - "▁criter": 28770, - "▁Struct": 28771, - "???": 28772, - "▁cheap": 28773, - "▁rings": 28774, - "abhäng": 28775, - "▁corte": 28776, - "▁administ": 28777, - "ixon": 28778, - "gypt": 28779, - "▁puntos": 28780, - "▁mezi": 28781, - "▁pochod": 28782, - "isko": 28783, - "nię": 28784, - "▁осу": 28785, - "▁ár": 28786, - "тельной": 28787, - "▁Metropolitan": 28788, - "jin": 28789, - "zess": 28790, - "▁віці": 28791, - "▁conflicts": 28792, - "ijst": 28793, - "▁Market": 28794, - "стров": 28795, - "▁\",\"": 28796, - "▁Scroll": 28797, - "gun": 28798, - "тара": 28799, - "▁amateur": 28800, - "▁róż": 28801, - "poss": 28802, - "▁generalized": 28803, - "▁Harm": 28804, - "cita": 28805, - "▁Switzerland": 28806, - "icola": 28807, - "▁muit": 28808, - "located": 28809, - "▁có": 28810, - "▁arose": 28811, - "▁communauté": 28812, - "})^": 28813, - "visibility": 28814, - "ída": 28815, - "▁FB": 28816, - "▁Freund": 28817, - "gat": 28818, - "\":{\"": 28819, - "intellij": 28820, - "ifie": 28821, - "hmen": 28822, - "▁édition": 28823, - "▁које": 28824, - "▁інших": 28825, - "oming": 28826, - "▁arquitect": 28827, - "▁Presidente": 28828, - "▁Під": 28829, - "▁cabin": 28830, - "Theorem": 28831, - "▁Gay": 28832, - "ifice": 28833, - "▁hect": 28834, - "lą": 28835, - "irmingham": 28836, - "▁semantic": 28837, - "▁Louisiana": 28838, - "▁sacrifice": 28839, - "▁Christoph": 28840, - "▁Executive": 28841, - "_+": 28842, - "ják": 28843, - "▁seria": 28844, - "▁Overflow": 28845, - "▁Lucy": 28846, - "▁melhor": 28847, - "▁voices": 28848, - "cza": 28849, - "▁капи": 28850, - "▁университета": 28851, - "INCT": 28852, - "▁coloc": 28853, - "▁prue": 28854, - "▁geomet": 28855, - "▁diretto": 28856, - "reso": 28857, - "▁Akt": 28858, - "▁unh": 28859, - "▁сери": 28860, - "▁Alert": 28861, - "Wel": 28862, - "audi": 28863, - "äler": 28864, - "▁guests": 28865, - "▁иде": 28866, - "Studio": 28867, - "▁кате": 28868, - "▁exponent": 28869, - "rze": 28870, - "pmod": 28871, - "rolle": 28872, - "▁Limited": 28873, - "Allemagne": 28874, - "▁pity": 28875, - "▁lä": 28876, - "▁runner": 28877, - "kende": 28878, - "EQ": 28879, - "▁MM": 28880, - "szág": 28881, - "поді": 28882, - "▁regret": 28883, - "▁publié": 28884, - "▁departamento": 28885, - "▁accused": 28886, - "hp": 28887, - "▁Pfl": 28888, - "▁Sint": 28889, - "▁ekonom": 28890, - "ractor": 28891, - "▁Пів": 28892, - "▁awful": 28893, - "ować": 28894, - "]->": 28895, - "▁Fine": 28896, - "Са": 28897, - "tis": 28898, - "éta": 28899, - "▁Роди": 28900, - "▁Düsseldorf": 28901, - "LOB": 28902, - "osas": 28903, - "werke": 28904, - "▁lance": 28905, - "▁листопада": 28906, - "▁incomplete": 28907, - "▁Picture": 28908, - "('\\": 28909, - "esters": 28910, - "▁belonged": 28911, - "▁Sank": 28912, - "ammed": 28913, - "▁repositories": 28914, - "▁addr": 28915, - "Collect": 28916, - "Hot": 28917, - "▁tyl": 28918, - "▁instanceof": 28919, - "▁bonus": 28920, - "ový": 28921, - "▁моря": 28922, - "▁interactive": 28923, - "▁Mys": 28924, - "▁Edmund": 28925, - "fileName": 28926, - "emor": 28927, - "▁Три": 28928, - "▁Rosen": 28929, - "▁Prima": 28930, - "▁voting": 28931, - "▁XP": 28932, - "▁Zero": 28933, - "▁Led": 28934, - "amsung": 28935, - "▁enables": 28936, - "▁redirects": 28937, - "AST": 28938, - "Paint": 28939, - "acker": 28940, - "lecht": 28941, - "▁chairman": 28942, - "▁Aven": 28943, - "▁Sach": 28944, - "(\"<": 28945, - "кер": 28946, - "▁mistakes": 28947, - "▁Weit": 28948, - "▁prowad": 28949, - "▁didnt": 28950, - "énario": 28951, - "unless": 28952, - "▁backwards": 28953, - "boa": 28954, - "duino": 28955, - "```": 28956, - "stor": 28957, - "Completion": 28958, - "puesta": 28959, - "▁dinast": 28960, - "últ": 28961, - "▁SY": 28962, - "ifolia": 28963, - "œuvres": 28964, - "▁racing": 28965, - "▁cabinet": 28966, - "▁cutting": 28967, - "▁thumb": 28968, - "▁Кара": 28969, - "highlight": 28970, - "куп": 28971, - "▁sd": 28972, - "▁національ": 28973, - "▁campagne": 28974, - "▁registers": 28975, - "▁educational": 28976, - "▁pesar": 28977, - "üge": 28978, - "▁oro": 28979, - "burgo": 28980, - "▁Athletics": 28981, - "▁MTV": 28982, - "getMessage": 28983, - "▁Hyp": 28984, - "▁victim": 28985, - "))\\": 28986, - "▁drums": 28987, - "hostname": 28988, - "tał": 28989, - "making": 28990, - "▁powiat": 28991, - "őd": 28992, - "threads": 28993, - "▁absolv": 28994, - "▁люди": 28995, - "▁stepped": 28996, - "exist": 28997, - "▁NK": 28998, - "▁ves": 28999, - "istiche": 29000, - "%'": 29001, - "ativos": 29002, - "▁такой": 29003, - "▁MongoDB": 29004, - "▁Ung": 29005, - "▁Рус": 29006, - "▁elim": 29007, - "▁Fif": 29008, - "icación": 29009, - "▁Tennis": 29010, - "▁Jefferson": 29011, - "ján": 29012, - "fog": 29013, - "anha": 29014, - "zor": 29015, - "▁університе": 29016, - "ahu": 29017, - "iada": 29018, - "Sdk": 29019, - "Setting": 29020, - "▁Kill": 29021, - "▁Wend": 29022, - "▁bald": 29023, - "▁Kub": 29024, - "▁visto": 29025, - "▁jeunes": 29026, - "collections": 29027, - "ací": 29028, - "вропей": 29029, - "▁arise": 29030, - "оні": 29031, - "MAIN": 29032, - "доступ": 29033, - "▁berg": 29034, - "▁criticism": 29035, - "▁Torre": 29036, - "▁descript": 29037, - "ières": 29038, - "▁estudio": 29039, - "▁ili": 29040, - "▁militare": 29041, - "▁Clara": 29042, - "▁Ellen": 29043, - "limited": 29044, - "лм": 29045, - "▁Españ": 29046, - "▁infinitely": 29047, - "America": 29048, - "ouc": 29049, - "glass": 29050, - "▁rud": 29051, - "▁zat": 29052, - "▁rin": 29053, - "▁Bibliografía": 29054, - "▁merchant": 29055, - "tensorflow": 29056, - "▁dér": 29057, - "▁ActiveRecord": 29058, - "IES": 29059, - "▁linker": 29060, - "▁estudios": 29061, - "cdnjs": 29062, - "▁Государ": 29063, - "ánchez": 29064, - "appe": 29065, - "club": 29066, - "▁další": 29067, - "▁Algorithm": 29068, - "dfs": 29069, - "▁Bac": 29070, - "▁кафе": 29071, - "▁&=\\": 29072, - "▁ат": 29073, - "▁Глав": 29074, - "▁Mou": 29075, - "Machine": 29076, - "(...)": 29077, - "▁compart": 29078, - "▁augusztus": 29079, - "avan": 29080, - "▁rolled": 29081, - "▁еди": 29082, - "Scan": 29083, - "▁регі": 29084, - "▁świata": 29085, - "▁mines": 29086, - "},{": 29087, - "▁Tier": 29088, - "Cannot": 29089, - "мін": 29090, - "▁NEW": 29091, - "▁Вол": 29092, - "▁Manh": 29093, - "▁Gregory": 29094, - "▁principe": 29095, - "ISO": 29096, - "prog": 29097, - "▁Fail": 29098, - "▁aa": 29099, - "▁fecha": 29100, - "▁WCF": 29101, - "▁magistr": 29102, - "▁Zach": 29103, - "▁unicode": 29104, - "▁converter": 29105, - "▁dispers": 29106, - "ksam": 29107, - "▁Uncle": 29108, - "PropertyChanged": 29109, - "▁lider": 29110, - "▁opts": 29111, - "▁там": 29112, - "locked": 29113, - "zak": 29114, - "▁counted": 29115, - "▁persone": 29116, - "▁hurried": 29117, - "ätter": 29118, - "▁outras": 29119, - "▁genu": 29120, - "BD": 29121, - "veg": 29122, - "due": 29123, - "▁Pract": 29124, - "▁posible": 29125, - "▁contribute": 29126, - "UMN": 29127, - "▁Bürger": 29128, - "▁wars": 29129, - "▁exhibition": 29130, - "hill": 29131, - "▁astr": 29132, - "▁музе": 29133, - "▁CASE": 29134, - "manifest": 29135, - "yellow": 29136, - "Fn": 29137, - "▁RC": 29138, - "▁sott": 29139, - "▁sujet": 29140, - "▁Socket": 29141, - "▁Chine": 29142, - "▁frameworks": 29143, - "Hold": 29144, - "êts": 29145, - "▁філь": 29146, - "Loaded": 29147, - "ophe": 29148, - "texte": 29149, - "▁expres": 29150, - "▁consume": 29151, - "▁Richtung": 29152, - "ografi": 29153, - "▁magnific": 29154, - "àt": 29155, - "▁indul": 29156, - "ryty": 29157, - "▁offici": 29158, - "▁assault": 29159, - "rund": 29160, - "▁variants": 29161, - "▁сельсов": 29162, - "▁excitement": 29163, - "Times": 29164, - "kotlin": 29165, - "▁gering": 29166, - "▁Engel": 29167, - "▁Timer": 29168, - "²).": 29169, - "▁Ng": 29170, - "ässt": 29171, - "schau": 29172, - "SError": 29173, - "▁Edwards": 29174, - "▁Terminal": 29175, - "lict": 29176, - "Under": 29177, - "▁spawn": 29178, - "ürgen": 29179, - "▁Außerdem": 29180, - "▁kitchen": 29181, - "fahrt": 29182, - "▁Colors": 29183, - "▁система": 29184, - "▁terminated": 29185, - "▁LaTeX": 29186, - "igkeiten": 29187, - "▁mesure": 29188, - "▁Amts": 29189, - "▁empir": 29190, - "▁striking": 29191, - "▁exclusive": 29192, - "тех": 29193, - "▁rez": 29194, - "▁quan": 29195, - "▁Glasgow": 29196, - "▁lecture": 29197, - "▁Testament": 29198, - "▁funds": 29199, - "▁stessa": 29200, - "▁tribes": 29201, - "▁parfois": 29202, - "▁treball": 29203, - "nitz": 29204, - "bove": 29205, - "▁заслу": 29206, - "▁absent": 29207, - "▁Lauf": 29208, - "Smith": 29209, - "▁Николай": 29210, - "▁européenne": 29211, - "lr": 29212, - "▁programma": 29213, - "▁midst": 29214, - "▁daughters": 29215, - "Syn": 29216, - "oben": 29217, - "ână": 29218, - "idan": 29219, - "▁ther": 29220, - "odore": 29221, - "sdl": 29222, - "▁Quint": 29223, - "▁casos": 29224, - "▁Zam": 29225, - "▁страны": 29226, - "▁sprite": 29227, - "кал": 29228, - "▁nasc": 29229, - "▁сотруд": 29230, - "▁trava": 29231, - "▁хозяй": 29232, - "▁Uruguay": 29233, - "▁sparse": 29234, - "▁поле": 29235, - "▁mystery": 29236, - "▁Mang": 29237, - "registr": 29238, - "▁CGFloat": 29239, - "▁submission": 29240, - "вана": 29241, - "▁\":": 29242, - "▁Traceback": 29243, - "▁Pit": 29244, - "▁Ehr": 29245, - "▁сра": 29246, - "▁Graphics": 29247, - "Updated": 29248, - "▁svensk": 29249, - "▁spacing": 29250, - "tritt": 29251, - "▁Guinea": 29252, - "▁França": 29253, - "Associ": 29254, - "▁Tová": 29255, - "stab": 29256, - "▁Learning": 29257, - "▁Bright": 29258, - "śc": 29259, - "▁idő": 29260, - "}}_{\\": 29261, - "▁droite": 29262, - "▁raising": 29263, - "getting": 29264, - "ythm": 29265, - "onyme": 29266, - "żs": 29267, - "▁blah": 29268, - "TagName": 29269, - "Vertical": 29270, - "▁aper": 29271, - "postgresql": 29272, - "▁Handle": 29273, - "zew": 29274, - "▁skulle": 29275, - "▁opere": 29276, - "layers": 29277, - "▁possono": 29278, - "▁relate": 29279, - "ąc": 29280, - "▁Mih": 29281, - "âge": 29282, - "▁Świ": 29283, - "isses": 29284, - "▁servlet": 29285, - "Los": 29286, - "▁Advanced": 29287, - "atica": 29288, - "▁ced": 29289, - "▁elementos": 29290, - "рона": 29291, - "iks": 29292, - "arf": 29293, - "ariat": 29294, - "Mobile": 29295, - "agua": 29296, - "▁timp": 29297, - "▁Comité": 29298, - "▁combining": 29299, - "wohl": 29300, - "▁Study": 29301, - "coordinate": 29302, - "▁recommendation": 29303, - "▁transformations": 29304, - "until": 29305, - "bounded": 29306, - "▁изу": 29307, - "hanced": 29308, - "▁вопро": 29309, - "▁Prés": 29310, - "▁coord": 29311, - "xty": 29312, - "▁$,": 29313, - "▁champions": 29314, - "Den": 29315, - "Mil": 29316, - "(',": 29317, - "▁Preis": 29318, - "▁eigh": 29319, - "▁markers": 29320, - "▁gewesen": 29321, - "ätten": 29322, - "▁pione": 29323, - "mv": 29324, - "▁ју": 29325, - "zeichnis": 29326, - "hoff": 29327, - "News": 29328, - "▁Stanisław": 29329, - "▁Brandenburg": 29330, - "▁Feuer": 29331, - "=&": 29332, - "жет": 29333, - "▁Neil": 29334, - "▁wirk": 29335, - "▁società": 29336, - "▁spare": 29337, - "▁civile": 29338, - "sprach": 29339, - "▁disse": 29340, - "▁gates": 29341, - "▁anom": 29342, - "▁Федерации": 29343, - "▁tib": 29344, - "▁fútbol": 29345, - "▁Wikiped": 29346, - "iate": 29347, - "Front": 29348, - "▁craw": 29349, - "▁Rak": 29350, - "▁зву": 29351, - "street": 29352, - "▁Agency": 29353, - "вало": 29354, - "▁Рас": 29355, - "▁mkdir": 29356, - "ację": 29357, - "▁shares": 29358, - "Story": 29359, - "▁remarks": 29360, - "▁keywords": 29361, - "Bob": 29362, - "▁toe": 29363, - "▁Vitt": 29364, - "▁rhs": 29365, - "ROP": 29366, - "oris": 29367, - "/@": 29368, - "сии": 29369, - "▁traverse": 29370, - "▁referencing": 29371, - "präsident": 29372, - "rong": 29373, - "'):": 29374, - "aties": 29375, - "AW": 29376, - "Outlet": 29377, - "▁évol": 29378, - "ikes": 29379, - "▁environmental": 29380, - "icum": 29381, - "▁Lied": 29382, - "▁warn": 29383, - "▁Butler": 29384, - "▁%),": 29385, - "▁Zeitschrift": 29386, - "▁Montr": 29387, - "важа": 29388, - "▁Mercur": 29389, - "jekte": 29390, - "meter": 29391, - "ducation": 29392, - "▁attributed": 29393, - "*$": 29394, - "▁unf": 29395, - "▁Vertrag": 29396, - "zien": 29397, - "▁Роб": 29398, - "lices": 29399, - "pply": 29400, - "ansen": 29401, - "▁zeit": 29402, - "▁immense": 29403, - "▁lutego": 29404, - "▁Bulgar": 29405, - "▁miembros": 29406, - "▁Националь": 29407, - "▁Allow": 29408, - "▁anglès": 29409, - "дви": 29410, - "▁Toy": 29411, - "туа": 29412, - "▁yard": 29413, - "(%": 29414, - "isser": 29415, - "▁golf": 29416, - "▁Ukrain": 29417, - "▁hosp": 29418, - "Include": 29419, - "▁Lisa": 29420, - "▁csal": 29421, - "▁Mira": 29422, - "recogn": 29423, - "▁Ке": 29424, - "▁hitting": 29425, - "кономі": 29426, - "▁Tournament": 29427, - "LOAD": 29428, - "▁Guardian": 29429, - "▁daher": 29430, - "▁timezone": 29431, - "▁tomcat": 29432, - "▁successor": 29433, - "▁Void": 29434, - "▁começ": 29435, - "▁converts": 29436, - "ächs": 29437, - "osex": 29438, - "xelles": 29439, - "aser": 29440, - "▁És": 29441, - "▁mou": 29442, - "▁ung": 29443, - "▁origen": 29444, - "▁Crow": 29445, - "▁Erd": 29446, - "▁sieben": 29447, - "lua": 29448, - "▁BB": 29449, - "RENT": 29450, - "▁piłkar": 29451, - "▁marque": 29452, - "▁Labour": 29453, - "viders": 29454, - "▁exempl": 29455, - "Sound": 29456, - "▁Wass": 29457, - "arrison": 29458, - "▁течение": 29459, - "▁Oficina": 29460, - "▁Daw": 29461, - "▁Kauf": 29462, - "ént": 29463, - "éső": 29464, - "▁=\"": 29465, - "▁kat": 29466, - "diction": 29467, - "▁Voll": 29468, - "▁highway": 29469, - "James": 29470, - "zeuge": 29471, - "▁modelo": 29472, - "Throw": 29473, - "▁Forum": 29474, - "(\"@": 29475, - "▁enfer": 29476, - "▁специаль": 29477, - "Numbers": 29478, - "▁Binary": 29479, - "▁Martínez": 29480, - "▁Stato": 29481, - "▁festiv": 29482, - "▁katol": 29483, - "▁Аб": 29484, - "▁limitation": 29485, - "▁STR": 29486, - "▁Официаль": 29487, - "ipes": 29488, - "▁Isn": 29489, - "▁ruled": 29490, - "▁cí": 29491, - "geber": 29492, - "▁lavoro": 29493, - "▁parentheses": 29494, - "оз": 29495, - "▁équipes": 29496, - "▁efficiently": 29497, - "▁Period": 29498, - "▁Regarding": 29499, - "leaf": 29500, - "▁similarity": 29501, - "▁gesture": 29502, - "datab": 29503, - "▁terminate": 29504, - "▁semantics": 29505, - "▁Alo": 29506, - "▁cig": 29507, - "▁OpenGL": 29508, - "▁heutigen": 29509, - "xaml": 29510, - "▁frequencies": 29511, - ")}.": 29512, - "▁threatened": 29513, - "тик": 29514, - "▁calcio": 29515, - "▁Riemann": 29516, - "slug": 29517, - "▁Finale": 29518, - "LR": 29519, - "▁Derby": 29520, - "▁още": 29521, - "▁deviation": 29522, - "ächen": 29523, - "▁Cris": 29524, - "ново": 29525, - "▁столі": 29526, - "▁relev": 29527, - "▁splendid": 29528, - "▁учё": 29529, - "erving": 29530, - "gable": 29531, - "▁générale": 29532, - "pom": 29533, - "▁Cheers": 29534, - "▁imprison": 29535, - "▁indent": 29536, - "▁analyz": 29537, - "▁revert": 29538, - "érer": 29539, - "▁phases": 29540, - "FirstName": 29541, - "▁mig": 29542, - "▁disturb": 29543, - "▁mixture": 29544, - "▁){": 29545, - "inture": 29546, - "▁Tried": 29547, - "▁sooner": 29548, - "▁pels": 29549, - "▁établ": 29550, - "etro": 29551, - "itie": 29552, - "▁quartier": 29553, - "▁гово": 29554, - "▁város": 29555, - "ufe": 29556, - "heten": 29557, - "хом": 29558, - "▁soap": 29559, - "utors": 29560, - "▁duch": 29561, - "syntax": 29562, - "▁tribe": 29563, - "▁chante": 29564, - "Tri": 29565, - "▁Mate": 29566, - "quality": 29567, - "uola": 29568, - "=\".": 29569, - "chk": 29570, - "▁всі": 29571, - "▁przeci": 29572, - "▁Meteor": 29573, - "▁scattered": 29574, - "Plus": 29575, - "trad": 29576, - "▁stackoverflow": 29577, - "▁retra": 29578, - "▁éditions": 29579, - "▁sain": 29580, - "cribe": 29581, - "ignon": 29582, - "ucker": 29583, - "▁мало": 29584, - "▁tenir": 29585, - "▁exports": 29586, - "▁auxili": 29587, - "▁]]": 29588, - "▁CBS": 29589, - "uniform": 29590, - "▁periodic": 29591, - "agrant": 29592, - "▁emple": 29593, - "Wil": 29594, - "▁fres": 29595, - "▁strutt": 29596, - "▁світ": 29597, - "▁betre": 29598, - "▁объек": 29599, - "тися": 29600, - "▁bisher": 29601, - "baum": 29602, - "ishi": 29603, - "▁Gazette": 29604, - "backgroundColor": 29605, - "jl": 29606, - "▁fiel": 29607, - "▁према": 29608, - "▁protagonista": 29609, - "▁Muhammad": 29610, - "▁simulate": 29611, - "▁Hook": 29612, - "fest": 29613, - "▁своих": 29614, - "Sender": 29615, - "▁listened": 29616, - "жі": 29617, - "jest": 29618, - "kord": 29619, - "Choice": 29620, - "▁hoofd": 29621, - "reducible": 29622, - "hpp": 29623, - "▁Wu": 29624, - "ši": 29625, - "▁Marse": 29626, - "▁soir": 29627, - "westen": 29628, - "emos": 29629, - "▁Duc": 29630, - "▁amerik": 29631, - "|}{": 29632, - "▁Gul": 29633, - "▁Sprache": 29634, - "▁mismatch": 29635, - "Scal": 29636, - "Pixel": 29637, - "EF": 29638, - "▁Sep": 29639, - "▁powiecie": 29640, - "urk": 29641, - "▁Napoli": 29642, - "▁neighbourhood": 29643, - "стоян": 29644, - "▁searches": 29645, - "yrus": 29646, - "пет": 29647, - "Help": 29648, - "pont": 29649, - "▁Orient": 29650, - "▁Alfonso": 29651, - "▁monitoring": 29652, - "iao": 29653, - "édé": 29654, - "▁César": 29655, - "шее": 29656, - "Shift": 29657, - "suit": 29658, - "coded": 29659, - "ното": 29660, - "▁Parti": 29661, - "▁lasci": 29662, - "▁awesome": 29663, - "usta": 29664, - "▁Сове": 29665, - "▁Fland": 29666, - "oom": 29667, - "▁devi": 29668, - "engelsk": 29669, - "endum": 29670, - "▁Pascal": 29671, - "▁Bind": 29672, - "▁siguientes": 29673, - "JB": 29674, - "▁Petersburg": 29675, - "▁incorrectly": 29676, - "▁Bash": 29677, - "▁pelos": 29678, - "▁zespo": 29679, - "NSURL": 29680, - "▁přek": 29681, - "▁Crime": 29682, - "nach": 29683, - "▁thrust": 29684, - "▁Cultura": 29685, - "WF": 29686, - "▁Solo": 29687, - "▁invas": 29688, - "▁individually": 29689, - "ibm": 29690, - "▁etapa": 29691, - "▁handed": 29692, - "▁wherever": 29693, - "▁interpolation": 29694, - "▁musée": 29695, - "▁CNN": 29696, - "idia": 29697, - "ństw": 29698, - "▁przew": 29699, - "ughing": 29700, - "▁actors": 29701, - "▁Oriental": 29702, - "▁convenience": 29703, - "▁miasta": 29704, - "brains": 29705, - "▁меся": 29706, - "▁infatti": 29707, - "▁AllMovie": 29708, - "▁critique": 29709, - "▁successo": 29710, - "ancouver": 29711, - "▁fá": 29712, - "ългар": 29713, - "▁wisdom": 29714, - "▁Phoenix": 29715, - "hole": 29716, - "▁información": 29717, - "▁Airlines": 29718, - ".«": 29719, - "mort": 29720, - "userId": 29721, - "▁*/\r": 29722, - "▁Congo": 29723, - "▁\"`": 29724, - "corr": 29725, - "▁problemas": 29726, - "▁bib": 29727, - "▁później": 29728, - "▁fileName": 29729, - "zott": 29730, - "macht": 29731, - "▁Ulrich": 29732, - "Cy": 29733, - "endpoint": 29734, - "▁sheep": 29735, - "▁ibn": 29736, - "Feed": 29737, - "▁sympathy": 29738, - "▁Ib": 29739, - "▁territorial": 29740, - "rating": 29741, - "дами": 29742, - "▁dst": 29743, - "ую": 29744, - "aho": 29745, - "▁sug": 29746, - "emia": 29747, - "▁ted": 29748, - "▁Api": 29749, - "▁Rica": 29750, - "▁MR": 29751, - "ńskim": 29752, - "▁Voor": 29753, - "▁devil": 29754, - "▁Фо": 29755, - "▁När": 29756, - "▁...)": 29757, - "▁vois": 29758, - "▁abbre": 29759, - "▁Männer": 29760, - "ximo": 29761, - "▁intellectual": 29762, - "▁tales": 29763, - "similar": 29764, - "neum": 29765, - "▁Orig": 29766, - "▁postal": 29767, - "▁hvor": 29768, - "▁identification": 29769, - "▁Од": 29770, - "uesto": 29771, - "▁../": 29772, - "▁bir": 29773, - "▁Лон": 29774, - "▁esempio": 29775, - "▁Eing": 29776, - "Expand": 29777, - "▁PRIMARY": 29778, - "▁Jin": 29779, - "▁však": 29780, - "ourses": 29781, - "▁Betty": 29782, - "▁WM": 29783, - "▁flask": 29784, - "hlen": 29785, - "▁Adel": 29786, - "laravel": 29787, - "▁дет": 29788, - "ською": 29789, - "▁Mundo": 29790, - "iczn": 29791, - "ifié": 29792, - "▁Мор": 29793, - "▁древ": 29794, - "DateFormat": 29795, - "ським": 29796, - "▁dated": 29797, - "коли": 29798, - "▁результате": 29799, - "\\).": 29800, - "▁delayed": 29801, - "sound": 29802, - "▁Мак": 29803, - "▁\"...": 29804, - "▁binnen": 29805, - "▁факуль": 29806, - "▁polygon": 29807, - "▁eggs": 29808, - "AtIndexPath": 29809, - "менталь": 29810, - "▁incred": 29811, - "chunk": 29812, - "webdriver": 29813, - "▁свобо": 29814, - "▁między": 29815, - "Received": 29816, - "▁Monde": 29817, - "▁JQuery": 29818, - "Butt": 29819, - "▁PDO": 29820, - "▁forec": 29821, - "▁discipline": 29822, - "chev": 29823, - "нат": 29824, - "▁redis": 29825, - "▁hunting": 29826, - "▁alk": 29827, - "▁proofs": 29828, - "PRI": 29829, - "▁chip": 29830, - "ésie": 29831, - "▁HO": 29832, - "▁rug": 29833, - "zos": 29834, - "▁sorte": 29835, - "▁zeigt": 29836, - "▁Physics": 29837, - "legte": 29838, - "▁proportional": 29839, - "▁toolbar": 29840, - "vement": 29841, - "notin": 29842, - "▁první": 29843, - "blah": 29844, - "▁présence": 29845, - "▁lloc": 29846, - "▁líder": 29847, - "▁Accept": 29848, - "▁Always": 29849, - "▁\"{": 29850, - "▁diversi": 29851, - "ikor": 29852, - "Period": 29853, - "жён": 29854, - "▁Alliance": 29855, - "▁relay": 29856, - "Bro": 29857, - "jön": 29858, - "▁Baud": 29859, - "▁Bian": 29860, - "')[": 29861, - "чив": 29862, - "▁Poss": 29863, - "▁Mitglieder": 29864, - "▁nev": 29865, - "Daniel": 29866, - "▁tends": 29867, - "▁compagnie": 29868, - "���livres": 29869, - "lub": 29870, - "▁": 29871, - "e": 29872, - "t": 29873, - "a": 29874, - "i": 29875, - "n": 29876, - "o": 29877, - "r": 29878, - "s": 29879, - "l": 29880, - "d": 29881, - "h": 29882, - "c": 29883, - "u": 29884, - "m": 29885, - "p": 29886, - "g": 29887, - "f": 29888, - ".": 29889, - "b": 29890, - "y": 29891, - ",": 29892, - "w": 29893, - "v": 29894, - "k": 29895, - "1": 29896, - ")": 29897, - "(": 29898, - "-": 29899, - "0": 29900, - ":": 29901, - "I": 29902, - "S": 29903, - "о": 29904, - "\\": 29905, - "2": 29906, - "C": 29907, - "\"": 29908, - "A": 29909, - "а": 29910, - "T": 29911, - "{": 29912, - "}": 29913, - "/": 29914, - "'": 29915, - "x": 29916, - "и": 29917, - "_": 29918, - "е": 29919, - "z": 29920, - "н": 29921, - "=": 29922, - "E": 29923, - "M": 29924, - "P": 29925, - "j": 29926, - "р": 29927, - "D": 29928, - "9": 29929, - "*": 29930, - "L": 29931, - "т": 29932, - "B": 29933, - "R": 29934, - "с": 29935, - ";": 29936, - "#": 29937, - "$": 29938, - "q": 29939, - "N": 29940, - "3": 29941, - "в": 29942, - "F": 29943, - "л": 29944, - "5": 29945, - "4": 29946, - "8": 29947, - "é": 29948, - "O": 29949, - "H": 29950, - "к": 29951, - "`": 29952, - "6": 29953, - "G": 29954, - "7": 29955, - "W": 29956, - "д": 29957, - ">": 29958, - "м": 29959, - "у": 29960, - "[": 29961, - "]": 29962, - "V": 29963, - "п": 29964, - "U": 29965, - "<": 29966, - "J": 29967, - "K": 29968, - "г": 29969, - "я": 29970, - "і": 29971, - "з": 29972, - "?": 29973, - "+": 29974, - "б": 29975, - "á": 29976, - "й": 29977, - "ь": 29978, - "Y": 29979, - "ó": 29980, - "ч": 29981, - "ы": 29982, - "í": 29983, - "Q": 29984, - "^": 29985, - "ä": 29986, - "&": 29987, - "х": 29988, - "|": 29989, - "X": 29990, - "!": 29991, - "@": 29992, - "ü": 29993, - "–": 29994, - "%": 29995, - "ц": 29996, - "ö": 29997, - "ж": 29998, - "Z": 29999, - "è": 30000, - "à": 30001, - "ш": 30002, - "—": 30003, - "\r": 30004, - "ю": 30005, - "ł": 30006, - "»": 30007, - "С": 30008, - "«": 30009, - "’": 30010, - "ф": 30011, - "В": 30012, - "П": 30013, - "К": 30014, - "“": 30015, - "ј": 30016, - "М": 30017, - "А": 30018, - "ç": 30019, - "å": 30020, - "щ": 30021, - "~": 30022, - "ę": 30023, - "”": 30024, - "ą": 30025, - "č": 30026, - "Р": 30027, - "ї": 30028, - "Н": 30029, - "ú": 30030, - "Б": 30031, - "Д": 30032, - "ã": 30033, - "ß": 30034, - "ă": 30035, - "ě": 30036, - "ê": 30037, - "О": 30038, - "š": 30039, - "Г": 30040, - "Т": 30041, - "ż": 30042, - "ё": 30043, - "ž": 30044, - "ś": 30045, - "ñ": 30046, - "ř": 30047, - "ő": 30048, - "„": 30049, - "Л": 30050, - "э": 30051, - "ý": 30052, - "У": 30053, - "И": 30054, - "ъ": 30055, - "є": 30056, - "â": 30057, - "î": 30058, - "ò": 30059, - "З": 30060, - "Ф": 30061, - "É": 30062, - "ć": 30063, - "·": 30064, - "ș": 30065, - "ń": 30066, - "ț": 30067, - "Х": 30068, - "ô": 30069, - "Е": 30070, - "ù": 30071, - "ů": 30072, - "°": 30073, - "Ш": 30074, - "љ": 30075, - "Ч": 30076, - "ø": 30077, - "æ": 30078, - "њ": 30079, - " ": 30080, - " ": 30081, - "Э": 30082, - "ë": 30083, - "õ": 30084, - "ï": 30085, - "‘": 30086, - "†": 30087, - "²": 30088, - "ű": 30089, - "І": 30090, - "─": 30091, - "Ц": 30092, - "ћ": 30093, - "Ö": 30094, - "û": 30095, - "Я": 30096, - "ì": 30097, - "…": 30098, - "ō": 30099, - "Ж": 30100, - "Ю": 30101, - "Á": 30102, - "́": 30103, - "Ü": 30104, - "º": 30105, - "œ": 30106, - "ā": 30107, - "Č": 30108, - "ź": 30109, - "α": 30110, - "│": 30111, - "ا": 30112, - "À": 30113, - "═": 30114, - "Š": 30115, - "ђ": 30116, - "№": 30117, - " ": 30118, - "•": 30119, - "−": 30120, - "→": 30121, - "×": 30122, - "ο": 30123, - "₂": 30124, - "Ä": 30125, - "Î": 30126, - "Ś": 30127, - "đ": 30128, - "Å": 30129, - "ı": 30130, - "‎": 30131, - "ū": 30132, - "ν": 30133, - "Й": 30134, - "ª": 30135, - "ι": 30136, - "τ": 30137, - "ل": 30138, - "′": 30139, - "�": 30140, - "È": 30141, - "λ": 30142, - "": 30143, - "Ž": 30144, - "ς": 30145, - "ň": 30146, - "ρ": 30147, - "₁": 30148, - "Є": 30149, - "ī": 30150, - "ε": 30151, - "§": 30152, - "Ł": 30153, - "Ј": 30154, - "£": 30155, - "ر": 30156, - "Ż": 30157, - "¿": 30158, - "م": 30159, - "″": 30160, - "Ú": 30161, - "ن": 30162, - "ي": 30163, - "σ": 30164, - "´": 30165, - "​": 30166, - "μ": 30167, - "³": 30168, - "ş": 30169, - "π": 30170, - "و": 30171, - "د": 30172, - "κ": 30173, - "₃": 30174, - "Í": 30175, - "ˈ": 30176, - "ب": 30177, - "Ó": 30178, - "Ã": 30179, - "¡": 30180, - "€": 30181, - "ť": 30182, - "η": 30183, - "ə": 30184, - "ー": 30185, - "Щ": 30186, - "β": 30187, - "├": 30188, - "ð": 30189, - "ґ": 30190, - "­": 30191, - "υ": 30192, - "¹": 30193, - "₄": 30194, - "ت": 30195, - "י": 30196, - "γ": 30197, - "س": 30198, - "の": 30199, - "ğ": 30200, - "δ": 30201, - "ی": 30202, - "ン": 30203, - "ه": 30204, - "ו": 30205, - "ω": 30206, - "ί": 30207, - "█": 30208, - "θ": 30209, - "的": 30210, - "©": 30211, - "Â": 30212, - "↑": 30213, - "，": 30214, - "ː": 30215, - "ά": 30216, - "―": 30217, - "ع": 30218, - "Ç": 30219, - "₀": 30220, - "±": 30221, - "Ø": 30222, - "ď": 30223, - "Ř": 30224, - "Œ": 30225, - "½": 30226, - "└": 30227, - "ό": 30228, - "‚": 30229, - "ē": 30230, - "₅": 30231, - "Æ": 30232, - "Ș": 30233, - "ɛ": 30234, - "ה": 30235, - "ר": 30236, - "φ": 30237, - "₆": 30238, - "ė": 30239, - "ح": 30240, - "ف": 30241, - "ة": 30242, - "İ": 30243, - " ": 30244, - "←": 30245, - "║": 30246, - "ɔ": 30247, - "≤": 30248, - "ל": 30249, - "Đ": 30250, - "ա": 30251, - "Ō": 30252, - "א": 30253, - "്": 30254, - "ス": 30255, - "ش": 30256, - "大": 30257, - "ル": 30258, - "џ": 30259, - "イ": 30260, - "⟩": 30261, - " ": 30262, - "µ": 30263, - "∈": 30264, - "ق": 30265, - "⟨": 30266, - "。": 30267, - "Ґ": 30268, - "ा": 30269, - "ج": 30270, - "ʿ": 30271, - "ა": 30272, - "έ": 30273, - "χ": 30274, - "中": 30275, - "ב": 30276, - "ი": 30277, - "₈": 30278, - "ト": 30279, - "ή": 30280, - "ラ": 30281, - "Џ": 30282, - "ك": 30283, - "₇": 30284, - "מ": 30285, - "ת": 30286, - "一": 30287, - "Π": 30288, - "า": 30289, - "・": 30290, - "Σ": 30291, - "Α": 30292, - "Δ": 30293, - "ש": 30294, - "ز": 30295, - "्": 30296, - "ร": 30297, - "い": 30298, - "ʻ": 30299, - "Њ": 30300, - "₉": 30301, - "ʼ": 30302, - "リ": 30303, - "‐": 30304, - "ク": 30305, - "∞": 30306, - "⁄": 30307, - "ύ": 30308, - "Ş": 30309, - "ア": 30310, - "Ε": 30311, - "ɪ": 30312, - "人": 30313, - "Κ": 30314, - "∀": 30315, - "र": 30316, - "ッ": 30317, - "►": 30318, - "子": 30319, - "¬": 30320, - "خ": 30321, - "◄": 30322, - "َ": 30323, - "ע": 30324, - "日": 30325, - "し": 30326, - "ḥ": 30327, - "נ": 30328, - "山": 30329, - "、": 30330, - "Ї": 30331, - "る": 30332, - "文": 30333, - "Ñ": 30334, - "ド": 30335, - "ד": 30336, - "ն": 30337, - "Ђ": 30338, - "Γ": 30339, - "þ": 30340, - "’": 30341, - "®": 30342, - "ک": 30343, - "“": 30344, - "⚭": 30345, - "本": 30346, - "ℕ": 30347, - "น": 30348, - "ѝ": 30349, - "̶": 30350, - "อ": 30351, - "ў": 30352, - "に": 30353, - "数": 30354, - "ე": 30355, - "国": 30356, - "Ω": 30357, - "　": 30358, - "ǎ": 30359, - "ص": 30360, - "”": 30361, - "Μ": 30362, - " ": 30363, - "と": 30364, - "⁠": 30365, - "た": 30366, - "ط": 30367, - "ր": 30368, - "タ": 30369, - "ÿ": 30370, - "な": 30371, - "أ": 30372, - "シ": 30373, - "新": 30374, - "﹕": 30375, - "ʃ": 30376, - "ľ": 30377, - "ロ": 30378, - "⁴": 30379, - "்": 30380, - "⇒": 30381, - "ţ": 30382, - "：": 30383, - "Ț": 30384, - "ക": 30385, - "≥": 30386, - "ി": 30387, - "マ": 30388, - "ん": 30389, - "ṣ": 30390, - "ジ": 30391, - "是": 30392, - "이": 30393, - "⋅": 30394, - "田": 30395, - "を": 30396, - "道": 30397, - "ง": 30398, - "¨": 30399, - "ـ": 30400, - "เ": 30401, - "村": 30402, - "Ê": 30403, - "ם": 30404, - "›": 30405, - "用": 30406, - "ώ": 30407, - "天": 30408, - "）": 30409, - "་": 30410, - "镇": 30411, - "か": 30412, - "不": 30413, - "Τ": 30414, - "学": 30415, - "ư": 30416, - "有": 30417, - "ո": 30418, - "（": 30419, - "レ": 30420, - "گ": 30421, - "‏": 30422, - "フ": 30423, - "न": 30424, - "ก": 30425, - "ɑ": 30426, - "す": 30427, - "ח": 30428, - "上": 30429, - "‌": 30430, - "∧": 30431, - "ṭ": 30432, - "ק": 30433, - "ξ": 30434, - "¤": 30435, - "ि": 30436, - "会": 30437, - "ന": 30438, - "カ": 30439, - "ų": 30440, - "ま": 30441, - "ു": 30442, - "͡": 30443, - "क": 30444, - "া": 30445, - "小": 30446, - "ן": 30447, - "行": 30448, - "は": 30449, - "ʁ": 30450, - "Ő": 30451, - "Þ": 30452, - "り": 30453, - "キ": 30454, - "Λ": 30455, - "რ": 30456, - "三": 30457, - "が": 30458, - "コ": 30459, - "ζ": 30460, - "市": 30461, - "王": 30462, - "ℝ": 30463, - "Ź": 30464, - "う": 30465, - "て": 30466, - "区": 30467, - "ാ": 30468, - "‚": 30469, - "年": 30470, - "פ": 30471, - "ի": 30472, - "ſ": 30473, - "‹": 30474, - "त": 30475, - "ŏ": 30476, - "‑": 30477, - "̃": 30478, - "Ć": 30479, - "ى": 30480, - "「": 30481, - "」": 30482, - "ს": 30483, - "Ā": 30484, - "म": 30485, - "生": 30486, - "≠": 30487, - "Љ": 30488, - "स": 30489, - "↔": 30490, - "Ο": 30491, - "ว": 30492, - "ლ": 30493, - "成": 30494, - "定": 30495, - "ล": 30496, - "¶": 30497, - "כ": 30498, - "で": 30499, - "ּ": 30500, - "ม": 30501, - "个": 30502, - "和": 30503, - "ס": 30504, - "在": 30505, - "Β": 30506, - "ิ": 30507, - "Ι": 30508, - "⁵": 30509, - "ั": 30510, - "ɡ": 30511, - "━": 30512, - "ら": 30513, - "オ": 30514, - "¼": 30515, - "ե": 30516, - "バ": 30517, - "ָ": 30518, - "ŋ": 30519, - "ŭ": 30520, - "グ": 30521, - "⁶": 30522, - "Ь": 30523, - "⁰": 30524, - "方": 30525, - "บ": 30526, - "—": 30527, - "高": 30528, - "ệ": 30529, - "Ν": 30530, - "ѣ": 30531, - "ィ": 30532, - "地": 30533, - "月": 30534, - "Ô": 30535, - "™": 30536, - "ウ": 30537, - "き": 30538, - "公": 30539, - "ạ": 30540, - "ო": 30541, - "ɾ": 30542, - "่": 30543, - "出": 30544, - "法": 30545, - "Θ": 30546, - "ส": 30547, - "名": 30548, - "ย": 30549, - "ത": 30550, - "Φ": 30551, - "↓": 30552, - "れ": 30553, - "ג": 30554, - "Ё": 30555, - "ơ": 30556, - "下": 30557, - "ә": 30558, - "ψ": 30559, - "┼": 30560, - "ャ": 30561, - "√": 30562, - "¥": 30563, - "社": 30564, - "ṇ": 30565, - "さ": 30566, - "ِ": 30567, - "く": 30568, - "े": 30569, - "Ы": 30570, - "ἐ": 30571, - "テ": 30572, - "为": 30573, - "乡": 30574, - "川": 30575, - "ナ": 30576, - "之": 30577, - "字": 30578, - "ム": 30579, - "ी": 30580, - "海": 30581, - "ブ": 30582, - "≈": 30583, - "！": 30584, - "پ": 30585, - "¯": 30586, - "ἀ": 30587, - "ƒ": 30588, - "こ": 30589, - "ְ": 30590, - "東": 30591, - "明": 30592, - "ὶ": 30593, - "时": 30594, - "ท": 30595, - "ɨ": 30596, - "デ": 30597, - "️": 30598, - "ʊ": 30599, - "エ": 30600, - "南": 30601, - "西": 30602, - "ल": 30603, - "メ": 30604, - "プ": 30605, - "平": 30606, - "式": 30607, - "ῖ": 30608, - "қ": 30609, - "व": 30610, - "غ": 30611, - "Ò": 30612, - "家": 30613, - "ʒ": 30614, - "サ": 30615, - "≡": 30616, - "ダ": 30617, - "ต": 30618, - "∃": 30619, - "₹": 30620, - "प": 30621, - "第": 30622, - "ര": 30623, - "ض": 30624, - "▄": 30625, - "城": 30626, - "ミ": 30627, - "ɐ": 30628, - "¦": 30629, - "美": 30630, - "件": 30631, - "ნ": 30632, - "Ð": 30633, - "ַ": 30634, - "ニ": 30635, - "部": 30636, - "ņ": 30637, - "ǐ": 30638, - "ט": 30639, - "य": 30640, - "あ": 30641, - "¾": 30642, - "ả": 30643, - "ち": 30644, - "ュ": 30645, - "÷": 30646, - "女": 30647, - "神": 30648, - "♦": 30649, - "¢": 30650, - "以": 30651, - "้": 30652, - "র": 30653, - "太": 30654, - "্": 30655, - "チ": 30656, - "յ": 30657, - "前": 30658, - "金": 30659, - "ւ": 30660, - "野": 30661, - "北": 30662, - "ห": 30663, - "‰": 30664, - "っ": 30665, - "加": 30666, - "原": 30667, - "ʲ": 30668, - "置": 30669, - "安": 30670, - "ガ": 30671, - "我": 30672, - "Ḥ": 30673, - "യ": 30674, - "京": 30675, - "▀": 30676, - "მ": 30677, - "ვ": 30678, - "ʾ": 30679, - "∨": 30680, - "ִ": 30681, - "可": 30682, - "取": 30683, - "县": 30684, - "二": 30685, - "▒": 30686, - "理": 30687, - "自": 30688, - "信": 30689, - "代": 30690, - "ี": 30691, - "צ": 30692, - "်": 30693, - "द": 30694, - "⁸": 30695, - "̯": 30696, - "お": 30697, - "要": 30698, - "ῦ": 30699, - "க": 30700, - "ễ": 30701, - "ु": 30702, - "ƒ": 30703, - "ʰ": 30704, - "化": 30705, - "✓": 30706, - "പ": 30707, - "의": 30708, - "다": 30709, - "木": 30710, - "ُ": 30711, - "̀": 30712, - "ˌ": 30713, - "ह": 30714, - "パ": 30715, - "水": 30716, - "ế": 30717, - "ด": 30718, - "ズ": 30719, - "⁹": 30720, - "島": 30721, - "‍": 30722, - "も": 30723, - "正": 30724, - "■": 30725, - "آ": 30726, - "พ": 30727, - "内": 30728, - "Ì": 30729, - "ǔ": 30730, - "┬": 30731, - "作": 30732, - "合": 30733, - "ὸ": 30734, - "み": 30735, - "▼": 30736, - "ῶ": 30737, - "⊙": 30738, - "～": 30739, - "ị": 30740, - "ْ": 30741, - "回": 30742, - "了": 30743, - "所": 30744, - "事": 30745, - "表": 30746, - "ำ": 30747, - "分": 30748, - "⁷": 30749, - "ү": 30750, - "€": 30751, - "入": 30752, - "全": 30753, - "إ": 30754, - "里": 30755, - "Χ": 30756, - "ं": 30757, - "ハ": 30758, - "ค": 30759, - "⁻": 30760, - "モ": 30761, - "郎": 30762, - "据": 30763, - "●": 30764, - "州": 30765, - "∩": 30766, - "者": 30767, - "通": 30768, - "都": 30769, - "ℤ": 30770, - "♭": 30771, - "╌": 30772, - "つ": 30773, - "ḍ": 30774, - "江": 30775, - "ז": 30776, - "Ý": 30777, - "ө": 30778, - "์": 30779, - "到": 30780, - "ி": 30781, - "ʂ": 30782, - "对": 30783, - "스": 30784, - "使": 30785, - "ি": 30786, - "よ": 30787, - "Ἀ": 30788, - "Ï": 30789, - "∘": 30790, - "사": 30791, - "ন": 30792, - "世": 30793, - "ɕ": 30794, - "կ": 30795, - "უ": 30796, - "ട": 30797, - "ბ": 30798, - "ो": 30799, - "വ": 30800, - "果": 30801, - "十": 30802, - "ุ": 30803, - "藤": 30804, - "来": 30805, - "面": 30806, - "け": 30807, - "ĕ": 30808, - "ビ": 30809, - "这": 30810, - "지": 30811, - "ം": 30812, - "街": 30813, - "石": 30814, - "能": 30815, - "空": 30816, - "տ": 30817, - "ئ": 30818, - "武": 30819, - "ʹ": 30820, - "ϕ": 30821, - "后": 30822, - "ะ": 30823, - "元": 30824, - "ʔ": 30825, - "리": 30826, - "기": 30827, - "河": 30828, - "町": 30829, - "花": 30830, - "ὐ": 30831, - "类": 30832, - "░": 30833, - "物": 30834, - "Η": 30835, - "¸": 30836, - "ு": 30837, - "თ": 30838, - "ث": 30839, - "െ": 30840, - "╠": 30841, - "⊆": 30842, - "》": 30843, - "ツ": 30844, - "版": 30845, - "动": 30846, - "如": 30847, - "真": 30848, - "ɲ": 30849, - "号": 30850, - "ذ": 30851, - "정": 30852, - "林": 30853, - "書": 30854, - "民": 30855, - "口": 30856, - "ّ": 30857, - "示": 30858, - "മ": 30859, - "아": 30860, - "图": 30861, - "∪": 30862, - "戦": 30863, - "李": 30864, - "ല": 30865, - "《": 30866, - "光": 30867, - "白": 30868, - "心": 30869, - "த": 30870, - "ज": 30871, - "设": 30872, - "���": 30873, - "路": 30874, - "ग": 30875, - "∥": 30876, - "한": 30877, - "最": 30878, - "Ћ": 30879, - "手": 30880, - "ս": 30881, - "？": 30882, - "型": 30883, - "ầ": 30884, - "セ": 30885, - "建": 30886, - "ェ": 30887, - "主": 30888, - "시": 30889, - "대": 30890, - "ῆ": 30891, - "‡": 30892, - "集": 30893, - "დ": 30894, - "目": 30895, - "Ρ": 30896, - "ァ": 30897, - "度": 30898, - "長": 30899, - "星": 30900, - "ノ": 30901, - "ộ": 30902, - "가": 30903, - "五": 30904, - "چ": 30905, - "로": 30906, - "ョ": 30907, - "重": 30908, - "于": 30909, - "发": 30910, - "史": 30911, - "ظ": 30912, - "ช": 30913, - "え": 30914, - "國": 30915, - "ĭ": 30916, - "ப": 30917, - "인": 30918, - "你": 30919, - "駅": 30920, - "‒": 30921, - "♥": 30922, - "多": 30923, - "ħ": 30924, - "Қ": 30925, - "ồ": 30926, - "士": 30927, - "四": 30928, - "┴": 30929, - "ம": 30930, - "司": 30931, - "ে": 30932, - "ὰ": 30933, - "∂": 30934, - "╬": 30935, - "次": 30936, - "Ľ": 30937, - "⟶": 30938, - "立": 30939, - "点": 30940, - "音": 30941, - "⠀": 30942, - "器": 30943, - "하": 30944, - "井": 30945, - "存": 30946, - "ֹ": 30947, - "当": 30948, - "Ë": 30949, - "★": 30950, - "寺": 30951, - "性": 30952, - "也": 30953, - "め": 30954, - "だ": 30955, - "位": 30956, - "ങ": 30957, - "ہ": 30958, - "值": 30959, - "古": 30960, - "გ": 30961, - "ব": 30962, - "院": 30963, - "േ": 30964, - "▶": 30965, - "ர": 30966, - "界": 30967, - "語": 30968, - "സ": 30969, - "수": 30970, - "ǒ": 30971, - "愛": 30972, - "✔": 30973, - "時": 30974, - "ọ": 30975, - "റ": 30976, - "մ": 30977, - "ケ": 30978, - "东": 30979, - "同": 30980, - "주": 30981, - "保": 30982, - "Õ": 30983, - "ố": 30984, - "ἰ": 30985, - "青": 30986, - "ゴ": 30987, - "体": 30988, - "清": 30989, - "相": 30990, - "จ": 30991, - "ء": 30992, - "情": 30993, - "𝕜": 30994, - "ক": 30995, - "ḫ": 30996, - "ờ": 30997, - "将": 30998, - "族": 30999, - "동": 31000, - "Υ": 31001, - "┌": 31002, - "ボ": 31003, - "宮": 31004, - "』": 31005, - "ম": 31006, - "『": 31007, - "ļ": 31008, - "श": 31009, - "ป": 31010, - "Ա": 31011, - "ब": 31012, - "자": 31013, - "政": 31014, - "ா": 31015, - "间": 31016, - "fi": 31017, - "松": 31018, - "ṃ": 31019, - "始": 31020, - "息": 31021, - "少": 31022, - "教": 31023, - "获": 31024, - "列": 31025, - "开": 31026, - "ტ": 31027, - "ワ": 31028, - "კ": 31029, - "科": 31030, - "春": 31031, - "治": 31032, - "吉": 31033, - "ས": 31034, - "ศ": 31035, - "ɒ": 31036, - "台": 31037, - "ネ": 31038, - "း": 31039, - "ĩ": 31040, - "工": 31041, - "ά": 31042, - "知": 31043, - "八": 31044, - "場": 31045, - "画": 31046, - "百": 31047, - "☆": 31048, - "記": 31049, - "得": 31050, - "ソ": 31051, - "氏": 31052, - "ာ": 31053, - "에": 31054, - "ল": 31055, - "ṛ": 31056, - "关": 31057, - "ġ": 31058, - "έ": 31059, - "∑": 31060, - "ベ": 31061, - "标": 31062, - "니": 31063, - "ὴ": 31064, - "ֵ": 31065, - "外": 31066, - "♠": 31067, - "わ": 31068, - "間": 31069, - "ภ": 31070, - "校": 31071, - "制": 31072, - "แ": 31073, - "力": 31074, - "門": 31075, - "好": 31076, - "ғ": 31077, - "Ù": 31078, - "ℓ": 31079, - "ֶ": 31080, - "는": 31081, - "┐": 31082, - "∗": 31083, - "指": 31084, - "色": 31085, - "返": 31086, - "馬": 31087, - "请": 31088, - "≫": 31089, - "風": 31090, - "ό": 31091, - "接": 31092, - "서": 31093, - "↳": 31094, - "せ": 31095, - "志": 31096, - "̲": 31097, - "魔": 31098, - "ң": 31099, - "更": 31100, - "程": 31101, - "김": 31102, - "郡": 31103, - "ོ": 31104, - "ũ": 31105, - "ച": 31106, - "利": 31107, - "県": 31108, - "周": 31109, - "そ": 31110, - "や": 31111, - "谷": 31112, - "香": 31113, - "♯": 31114, - "じ": 31115, - "،": 31116, - "期": 31117, - "∅": 31118, - "┘": 31119, - "初": 31120, - "福": 31121, - "片": 31122, - "ザ": 31123, - "動": 31124, - "参": 31125, - "성": 31126, - "Ə": 31127, - "╦": 31128, - "어": 31129, - "ხ": 31130, - "義": 31131, - "च": 31132, - "象": 31133, - "功": 31134, - "♂": 31135, - "도": 31136, - "고": 31137, - "过": 31138, - "վ": 31139, - "皇": 31140, - "特": 31141, - "ậ": 31142, - "长": 31143, - "英": 31144, - "ấ": 31145, - "ണ": 31146, - "Ъ": 31147, - "স": 31148, - "其": 31149, - "ত": 31150, - "流": 31151, - "除": 31152, - "일": 31153, - "ু": 31154, - "្": 31155, - "永": 31156, - "直": 31157, - "상": 31158, - "千": 31159, - "ắ": 31160, - "館": 31161, - "Ť": 31162, - "朝": 31163, - "ட": 31164, - "ɣ": 31165, - "单": 31166, - "ʀ": 31167, - "格": 31168, - "德": 31169, - "전": 31170, - "☺": 31171, - "ピ": 31172, - "歌": 31173, - "进": 31174, - "限": 31175, - "夫": 31176, - "트": 31177, - "⊢": 31178, - "園": 31179, - "量": 31180, - "土": 31181, - "放": 31182, - "码": 31183, - "等": 31184, - "系": 31185, - "∼": 31186, - "華": 31187, - "↵": 31188, - "소": 31189, - "常": 31190, - "否": 31191, - "見": 31192, - "源": 31193, - "ׁ": 31194, - "实": 31195, - "博": 31196, - "라": 31197, - "원": 31198, - "보": 31199, - "⊕": 31200, - "解": 31201, - "〜": 31202, - "男": 31203, - "দ": 31204, - "ポ": 31205, - "ろ": 31206, - "나": 31207, - "ག": 31208, - "無": 31209, - "Û": 31210, - "̥": 31211, - "ұ": 31212, - "查": 31213, - "̣": 31214, - "╗": 31215, - "╩": 31216, - "条": 31217, - "য": 31218, - "ὁ": 31219, - "後": 31220, - "他": 31221, - "网": 31222, - "ல": 31223, - "≃": 31224, - "화": 31225, - "ە": 31226, - "阿": 31227, - "ေ": 31228, - "户": 31229, - "∫": 31230, - "구": 31231, - "ར": 31232, - "မ": 31233, - "▸": 31234, - "լ": 31235, - "○": 31236, - "命": 31237, - "就": 31238, - "龍": 31239, - "君": 31240, - "夏": 31241, - "": 31242, - "言": 31243, - "先": 31244, - "➜": 31245, - "შ": 31246, - "ძ": 31247, - "ਾ": 31248, - "வ": 31249, - "ど": 31250, - "ヒ": 31251, - "ไ": 31252, - "ன": 31253, - "ば": 31254, - "ギ": 31255, - "գ": 31256, - "ἄ": 31257, - "ヤ": 31258, - "典": 31259, - "府": 31260, - "̄": 31261, - "신": 31262, - "组": 31263, - "改": 31264, - "ὲ": 31265, - "华": 31266, - "与": 31267, - "调": 31268, - "╝": 31269, - "ヴ": 31270, - "ქ": 31271, - "由": 31272, - "修": 31273, - "學": 31274, - "♣": 31275, - "消": 31276, - "符": 31277, - "ʌ": 31278, - "부": 31279, - "ớ": 31280, - "‾": 31281, - "▲": 31282, - "录": 31283, - "ള": 31284, - "연": 31285, - "을": 31286, - "ひ": 31287, - "영": 31288, - "┤": 31289, - "已": 31290, - "陽": 31291, - "င": 31292, - "국": 31293, - "容": 31294, - "未": 31295, - "宗": 31296, - "ᴇ": 31297, - "び": 31298, - "장": 31299, - "龙": 31300, - "්": 31301, - "提": 31302, - "ĝ": 31303, - "六": 31304, - "形": 31305, - "제": 31306, - "Հ": 31307, - "伊": 31308, - "ϵ": 31309, - "ข": 31310, - "Ű": 31311, - "ゃ": 31312, - "火": 31313, - "Ṣ": 31314, - "佐": 31315, - "⊥": 31316, - "̪": 31317, - "ứ": 31318, - "□": 31319, - "结": 31320, - "九": 31321, - "雄": 31322, - "թ": 31323, - "ា": 31324, - "而": 31325, - "བ": 31326, - "우": 31327, - "张": 31328, - "ट": 31329, - "ष": 31330, - "向": 31331, - "ῥ": 31332, - "选": 31333, - "공": 31334, - "ゲ": 31335, - "ʐ": 31336, - "仁": 31337, - "堂": 31338, - "ך": 31339, - "ု": 31340, - "ἔ": 31341, - "അ": 31342, - "ề": 31343, - "ད": 31344, - "선": 31345, - "오": 31346, - "久": 31347, - "œ": 31348, - "义": 31349, - "अ": 31350, - "╔": 31351, - "无": 31352, - "
": 31353, - "은": 31354, - "ʷ": 31355, - "那": 31356, - "線": 31357, - "务": 31358, - "基": 31359, - "属": 31360, - "配": 31361, - "미": 31362, - "軍": 31363, - "โ": 31364, - "津": 31365, - "完": 31366, - "研": 31367, - "注": 31368, - "失": 31369, - "应": 31370, - "က": 31371, - "╚": 31372, - "友": 31373, - "章": 31374, - "Ψ": 31375, - "求": 31376, - "ण": 31377, - "경": 31378, - "‬": 31379, - "भ": 31380, - "们": 31381, - "模": 31382, - "需": 31383, - "ச": 31384, - "電": 31385, - "প": 31386, - "դ": 31387, - "へ": 31388, - "此": 31389, - "夜": 31390, - "或": 31391, - "橋": 31392, - "根": 31393, - "Ī": 31394, - "玉": 31395, - "ู": 31396, - "ṅ": 31397, - "交": 31398, - "品": 31399, - "良": 31400, - "ང": 31401, - "ォ": 31402, - "则": 31403, - "開": 31404, - "Ζ": 31405, - "문": 31406, - "被": 31407, - "조": 31408, - "株": 31409, - "记": 31410, - "會": 31411, - "经": 31412, - "ू": 31413, - "ょ": 31414, - "转": 31415, - "崎": 31416, - "마": 31417, - "⌘": 31418, - "比": 31419, - "造": 31420, - "ܐ": 31421, - "ื": 31422, - "没": 31423, - "现": 31424, - "七": 31425, - "Ά": 31426, - "商": 31427, - "ை": 31428, - "机": 31429, - "阳": 31430, - "ĉ": 31431, - "角": 31432, - "站": 31433, - "բ": 31434, - "해": 31435, - "及": 31436, - "ध": 31437, - "術": 31438, - "认": 31439, - "‘": 31440, - "创": 31441, - "編": 31442, - "ղ": 31443, - "ḩ": 31444, - "伝": 31445, - "岡": 31446, - "ड": 31447, - "ホ": 31448, - "港": 31449, - "任": 31450, - "登": 31451, - "ི": 31452, - "็": 31453, - "布": 31454, - "究": 31455, - "帝": 31456, - "여": 31457, - "산": 31458, - "န": 31459, - "◦": 31460, - "密": 31461, - "变": 31462, - "序": 31463, - "♀": 31464, - "∣": 31465, - "计": 31466, - "曲": 31467, - "Ă": 31468, - "ύ": 31469, - "ʋ": 31470, - "传": 31471, - "】": 31472, - "包": 31473, - "意": 31474, - "去": 31475, - "沙": 31476, - "⸮": 31477, - "【": 31478, - "写": 31479, - "超": 31480, - "ய": 31481, - "今": 31482, - "┈": 31483, - "森": 31484, - "ි": 31485, - "⊗": 31486, - "비": 31487, - "հ": 31488, - "Ḩ": 31489, - "ǫ": 31490, - "黄": 31491, - "∙": 31492, - "드": 31493, - "🌍": 31494, - "景": 31495, - "湖": 31496, - "ք": 31497, - "ိ": 31498, - "ⁿ": 31499, - "̂": 31500, - "ペ": 31501, - "何": 31502, - "宇": 31503, - "張": 31504, - "语": 31505, - "老": 31506, - "例": 31507, - "Ṭ": 31508, - "鉄": 31509, - "克": 31510, - "☉": 31511, - "™": 31512, - "ɹ": 31513, - "ἱ": 31514, - "ⴰ": 31515, - "然": 31516, - "를": 31517, - "ǧ": 31518, - "報": 31519, - "服": 31520, - "Ď": 31521, - "想": 31522, - "‖": 31523, - "ユ": 31524, - "実": 31525, - "载": 31526, - "요": 31527, - "ℚ": 31528, - "波": 31529, - "马": 31530, - "状": 31531, - "线": 31532, - "유": 31533, - "洋": 31534, - "万": 31535, - "진": 31536, - "জ": 31537, - "添": 31538, - "球": 31539, - "機": 31540, - "支": 31541, - "显": 31542, - "拉": 31543, - "ὑ": 31544, - "送": 31545, - "隊": 31546, - "ธ": 31547, - "处": 31548, - "師": 31549, - "⊂": 31550, - "像": 31551, - "়": 31552, - "黒": 31553, - "ց": 31554, - "": 31555, - "ủ": 31556, - "只": 31557, - "起": 31558, - "段": 31559, - "တ": 31560, - "區": 31561, - "選": 31562, - "천": 31563, - "業": 31564, - "算": 31565, - "广": 31566, - "រ": 31567, - "视": 31568, - "秋": 31569, - "因": 31570, - "년": 31571, - "ے": 31572, - "输": 31573, - "̱": 31574, - "Մ": 31575, - "∆": 31576, - "康": 31577, - "세": 31578, - "思": 31579, - "死": 31580, - "聖": 31581, - "민": 31582, - "－": 31583, - "头": 31584, - "ർ": 31585, - "∉": 31586, - "車": 31587, - "┃": 31588, - "▇": 31589, - "按": 31590, - "⍵": 31591, - "夢": 31592, - "汉": 31593, - "从": 31594, - "ী": 31595, - "题": 31596, - "ˆ": 31597, - "ἡ": 31598, - "展": 31599, - "省": 31600, - "ུ": 31601, - "葉": 31602, - "호": 31603, - "ਰ": 31604, - "素": 31605, - "関": 31606, - "그": 31607, - "；": 31608, - "න": 31609, - "页": 31610, - "共": 31611, - "宿": 31612, - "态": 31613, - "ན": 31614, - "技": 31615, - "乐": 31616, - "控": 31617, - "移": 31618, - "影": 31619, - "ụ": 31620, - "ゆ": 31621, - "ご": 31622, - "್": 31623, - "管": 31624, - "ൾ": 31625, - "╣": 31626, - "戸": 31627, - "⇔": 31628, - "函": 31629, - "ẓ": 31630, - "尾": 31631, - "场": 31632, - "介": 31633, - "": 31634, - "育": 31635, - "ර": 31636, - "泉": 31637, - "ൽ": 31638, - "说": 31639, - "换": 31640, - "必": 31641, - "紀": 31642, - "མ": 31643, - "ེ": 31644, - "ợ": 31645, - "ൻ": 31646, - "宝": 31647, - "気": 31648, - "门": 31649, - "令": 31650, - "左": 31651, - "漢": 31652, - "若": 31653, - "屋": 31654, - "局": 31655, - "打": 31656, - "発": 31657, - "问": 31658, - "恋": 31659, - "兵": 31660, - "別": 31661, - "ા": 31662, - "Ս": 31663, - "߬": 31664, - "গ": 31665, - "并": 31666, - "ख": 31667, - "ή": 31668, - "节": 31669, - "ʑ": 31670, - "ץ": 31671, - "Ḫ": 31672, - "ℂ": 31673, - "引": 31674, - "统": 31675, - "智": 31676, - "̩": 31677, - "ै": 31678, - "电": 31679, - "현": 31680, - "✅": 31681, - "赤": 31682, - "断": 31683, - "ね": 31684, - "称": 31685, - "শ": 31686, - "身": 31687, - "首": 31688, - "付": 31689, - "⅓": 31690, - "ਸ": 31691, - "連": 31692, - "ზ": 31693, - "官": 31694, - "持": 31695, - "奈": 31696, - "御": 31697, - "親": 31698, - "군": 31699, - "库": 31700, - "秀": 31701, - "址": 31702, - "守": 31703, - "活": 31704, - "ལ": 31705, - "ふ": 31706, - "藏": 31707, - "ស": 31708, - "竹": 31709, - "草": 31710, - "結": 31711, - "ා": 31712, - "昌": 31713, - "樹": 31714, - "ள": 31715, - "무": 31716, - "হ": 31717, - "ゼ": 31718, - "̈": 31719, - "շ": 31720, - "勝": 31721, - "足": 31722, - "ရ": 31723, - "위": 31724, - "į": 31725, - "Ἰ": 31726, - "航": 31727, - "陳": 31728, - "业": 31729, - "富": 31730, - "雪": 31731, - "आ": 31732, - "再": 31733, - "안": 31734, - "默": 31735, - "박": 31736, - "용": 31737, - "✿": 31738, - "楽": 31739, - "沢": 31740, - "羅": 31741, - "Ė": 31742, - "ʎ": 31743, - "忠": 31744, - "错": 31745, - "단": 31746, - "면": 31747, - "ķ": 31748, - "桥": 31749, - "雲": 31750, - "该": 31751, - "ṯ": 31752, - "岩": 31753, - "남": 31754, - "ỹ": 31755, - "专": 31756, - "切": 31757, - "店": 31758, - "朱": 31759, - "ף": 31760, - "ず": 31761, - "幸": 31762, - "母": 31763, - "ɫ": 31764, - "々": 31765, - "∷": 31766, - "串": 31767, - "击": 31768, - "Ἐ": 31769, - "設": 31770, - "⊤": 31771, - "ₗ": 31772, - "經": 31773, - "강": 31774, - "ပ": 31775, - "।": 31776, - "ѐ": 31777, - "ᾶ": 31778, - "➖": 31779, - "座": 31780, - "씨": 31781, - "ぶ": 31782, - "Ţ": 31783, - "云": 31784, - "告": 31785, - "変": 31786, - "试": 31787, - "隆": 31788, - "개": 31789, - "պ": 31790, - "判": 31791, - "劉": 31792, - "˜": 31793, - "ˠ": 31794, - "编": 31795, - "ณ": 31796, - "ữ": 31797, - "达": 31798, - "Ě": 31799, - "ܝ": 31800, - "ြ": 31801, - "ḷ": 31802, - "右": 31803, - "들": 31804, - "ŝ": 31805, - "ӏ": 31806, - "్": 31807, - "എ": 31808, - "ற": 31809, - "复": 31810, - "看": 31811, - "話": 31812, - "坂": 31813, - "尔": 31814, - "衛": 31815, - "զ": 31816, - "차": 31817, - "丸": 31818, - "样": 31819, - "鬼": 31820, - "़": 31821, - "학": 31822, - "喜": 31823, - "斯": 31824, - "銀": 31825, - "만": 31826, - "Ξ": 31827, - "ც": 31828, - "群": 31829, - "近": 31830, - "塔": 31831, - "ϊ": 31832, - "ந": 31833, - "む": 31834, - "确": 31835, - "索": 31836, - "∇": 31837, - "非": 31838, - "望": 31839, - "❯": 31840, - "希": 31841, - "ỳ": 31842, - "甲": 31843, - "越": 31844, - "鳥": 31845, - "麻": 31846, - "雅": 31847, - "拳": 31848, - "ក": 31849, - "溪": 31850, - "测": 31851, - "话": 31852, - "池": 31853, - "菜": 31854, - "食": 31855, - "터": 31856, - "ਿ": 31857, - "渡": 31858, - "速": 31859, - "ھ": 31860, - "ರ": 31861, - "陈": 31862, - "健": 31863, - "ো": 31864, - "ක": 31865, - "ὺ": 31866, - "军": 31867, - "庄": 31868, - "红": 31869, - "Ħ": 31870, - "論": 31871, - "Ÿ": 31872, - "Έ": 31873, - "ự": 31874, - "孝": 31875, - "頭": 31876, - "飛": 31877, - "˚": 31878, - "▓": 31879, - "ً": 31880, - "‭": 31881, - "么": 31882, - "達": 31883, - "ѫ": 31884, - "巴": 31885, - "洞": 31886, - "貴": 31887, - "项": 31888, - "ദ": 31889, - "ɵ": 31890, - "̍": 31891, - "ҡ": 31892, - "种": 31893, - "运": 31894, - "식": 31895, - "ྱ": 31896, - "ḳ": 31897, - "彦": 31898, - "⥤": 31899, - "书": 31900, - "构": 31901, - "米": 31902, - "连": 31903, - "操": 31904, - "装": 31905, - "과": 31906, - "ぐ": 31907, - "反": 31908, - "̌": 31909, - "仮": 31910, - "员": 31911, - "昭": 31912, - "ശ": 31913, - "兴": 31914, - "客": 31915, - "删": 31916, - "ම": 31917, - "ව": 31918, - "პ": 31919, - "ċ": 31920, - "ഷ": 31921, - "သ": 31922, - "ᵉ": 31923, - "居": 31924, - "타": 31925, - "𝓝": 31926, - "थ": 31927, - "現": 31928, - "ˇ": 31929, - "종": 31930, - "助": 31931, - "唐": 31932, - "瀬": 31933, - "ន": 31934, - "微": 31935, - "１": 31936, - "Ġ": 31937, - "ほ": 31938, - "舞": 31939, - "내": 31940, - "중": 31941, - "Ē": 31942, - "导": 31943, - "效": 31944, - "방": 31945, - "ḏ": 31946, - "深": 31947, - "梅": 31948, - "料": 31949, - "월": 31950, - "每": 31951, - "洲": 31952, - "회": 31953, - "茶": 31954, - "败": 31955, - "ഞ": 31956, - "ể": 31957, - "ヨ": 31958, - "些": 31959, - "双": 31960, - "嘉": 31961, - "모": 31962, - "바": 31963, - "ษ": 31964, - "進": 31965, - "음": 31966, - "ญ": 31967, - "丁": 31968, - "故": 31969, - "計": 31970, - "遠": 31971, - "교": 31972, - "재": 31973, - "候": 31974, - "房": 31975, - "명": 31976, - "两": 31977, - "ფ": 31978, - "才": 31979, - "합": 31980, - "止": 31981, - "番": 31982, - "ɯ": 31983, - "奇": 31984, - "怪": 31985, - "联": 31986, - "역": 31987, - "泰": 31988, - "백": 31989, - "ὀ": 31990, - "げ": 31991, - "べ": 31992, - "边": 31993, - "还": 31994, - "黃": 31995, - "왕": 31996, - "收": 31997, - "弘": 31998, - "给": 31999 + "\n": 3, + "!": 4, + "\"": 5, + "#": 6, + "$": 7, + "%": 8, + "&": 9, + "'": 10, + "(": 11, + ")": 12, + "*": 13, + "+": 14, + ",": 15, + "-": 16, + ".": 17, + "/": 18, + "0": 19, + "1": 20, + "2": 21, + "3": 22, + "4": 23, + "5": 24, + "6": 25, + "7": 26, + "8": 27, + "9": 28, + ":": 29, + ";": 30, + "<": 31, + "=": 32, + ">": 33, + "?": 34, + "@": 35, + "A": 36, + "B": 37, + "C": 38, + "D": 39, + "E": 40, + "F": 41, + "G": 42, + "H": 43, + "I": 44, + "J": 45, + "K": 46, + "L": 47, + "M": 48, + "N": 49, + "O": 50, + "P": 51, + "Q": 52, + "R": 53, + "S": 54, + "T": 55, + "U": 56, + "V": 57, + "W": 58, + "X": 59, + "Y": 60, + "Z": 61, + "[": 62, + "\\": 63, + "]": 64, + "_": 65, + "`": 66, + "a": 67, + "b": 68, + "c": 69, + "d": 70, + "e": 71, + "f": 72, + "g": 73, + "h": 74, + "i": 75, + "j": 76, + "k": 77, + "l": 78, + "m": 79, + "n": 80, + "o": 81, + "p": 82, + "q": 83, + "r": 84, + "s": 85, + "t": 86, + "u": 87, + "v": 88, + "w": 89, + "x": 90, + "y": 91, + "z": 92, + "{": 93, + "}": 94, + "~": 95, + "§": 96, + "©": 97, + "®": 98, + "°": 99, + "±": 100, + "²": 101, + "³": 102, + "´": 103, + "µ": 104, + "·": 105, + "º": 106, + "½": 107, + "¾": 108, + "Í": 109, + "Ò": 110, + "Ö": 111, + "×": 112, + "Ü": 113, + "ß": 114, + "á": 115, + "â": 116, + "ä": 117, + "è": 118, + "é": 119, + "ê": 120, + "ë": 121, + "í": 122, + "ï": 123, + "ñ": 124, + "ó": 125, + "ö": 126, + "ü": 127, + "ų": 128, + "ž": 129, + "Δ": 130, + "Φ": 131, + "Ψ": 132, + "α": 133, + "β": 134, + "γ": 135, + "θ": 136, + "λ": 137, + "μ": 138, + "ρ": 139, + "χ": 140, + "–": 141, + "—": 142, + "‘": 143, + "’": 144, + "“": 145, + "”": 146, + "†": 147, + "‡": 148, + "•": 149, + "…": 150, + "": 151, + "™": 152, + "⅓": 153, + "⅔": 154, + "↑": 155, + "→": 156, + "↓": 157, + "−": 158, + "∞": 159, + "∼": 160, + "≠": 161, + "≤": 162, + "≥": 163, + "▁": 164, + "○": 165, + "◦": 166, + "♦": 167, + "": 168, + "": 169, + "": 170, + "": 171, + "": 172, + "": 173, + "": 174, + "": 175, + "": 176, + "": 177, + "": 178, + "": 179, + "": 180, + "": 181, + "": 182, + "": 183, + "": 184, + "": 185, + "": 186, + "": 187, + "": 188, + "": 189, + "": 190, + "": 191, + "": 192, + "": 193, + "": 194, + "": 195, + "": 196, + "": 197, + "": 198, + "": 199, + "": 200, + "": 201, + "": 202, + "": 203, + "": 204, + "..": 205, + "e▁": 206, + "....": 207, + "in": 208, + "▁t": 209, + "at": 210, + "on": 211, + "\n\n": 212, + "▁a": 213, + "en": 214, + "er": 215, + "or": 216, + "........": 217, + "s▁": 218, + "d▁": 219, + "re": 220, + "▁th": 221, + "al": 222, + "st": 223, + "y▁": 224, + "ion": 225, + "ent": 226, + "it": 227, + "▁the▁": 228, + "of": 229, + "an": 230, + ",▁": 231, + "ro": 232, + "ed▁": 233, + "▁an": 234, + "ic": 235, + "................": 236, + ".▁": 237, + "ct": 238, + "ll": 239, + "ar": 240, + "ed": 241, + "▁p": 242, + "▁c": 243, + "ing": 244, + "▁b": 245, + "es": 246, + "for": 247, + "et": 248, + "ation": 249, + "▁to": 250, + "is": 251, + "▁s": 252, + "as": 253, + "▁of": 254, + "um": 255, + "ou": 256, + "▁d": 257, + "th": 258, + "▁w": 259, + "▁m": 260, + "▁and▁": 261, + "om": 262, + "ud": 263, + "ect": 264, + ".\n\n": 265, + "ment": 266, + "ill": 267, + "al▁": 268, + "el": 269, + "ol": 270, + "ab": 271, + "is▁": 272, + "▁A": 273, + "▁be▁": 274, + "iv": 275, + "▁in": 276, + "im": 277, + "................................": 278, + "ur": 279, + "ev": 280, + "res": 281, + "ith": 282, + "ig": 283, + "00": 284, + "id": 285, + "oc": 286, + "pl": 287, + "▁1": 288, + "▁C": 289, + "stud": 290, + "os": 291, + "ac": 292, + "est": 293, + "es▁": 294, + "▁P": 295, + "pro": 296, + "ati": 297, + "il": 298, + "▁(": 299, + "em": 300, + "▁2": 301, + "Th": 302, + "reat": 303, + "us": 304, + "ul": 305, + "con": 306, + "ra": 307, + "ill▁be▁": 308, + "anc": 309, + "if": 310, + "atient": 311, + "▁S": 312, + "ub": 313, + "▁I": 314, + "▁re": 315, + "ot": 316, + "ag": 317, + "ow": 318, + "un": 319, + "▁D": 320, + "cl": 321, + "ri": 322, + "▁h": 323, + "with": 324, + "▁l": 325, + "e▁of": 326, + "ap": 327, + "reatment": 328, + "▁E": 329, + "▁f": 330, + "am": 331, + "ver": 332, + "ch": 333, + "ject": 334, + "▁or": 335, + "e▁t": 336, + "ir": 337, + "ut": 338, + "ys": 339, + "form": 340, + "ther": 341, + "ter": 342, + "The▁": 343, + "\n\nP": 344, + "iz": 345, + "ex": 346, + "qu": 347, + "ec": 348, + "end": 349, + "▁n": 350, + "ator": 351, + "ist": 352, + "per": 353, + "ons": 354, + "od": 355, + "\n\nA": 356, + "ate▁": 357, + "study▁": 358, + "lin": 359, + "oll": 360, + "▁and": 361, + "abl": 362, + "▁O": 363, + "▁as": 364, + "sion": 365, + "▁pro": 366, + "ubject": 367, + "all": 368, + "▁T": 369, + "up": 370, + "▁ad": 371, + "eas": 372, + "▁N": 373, + "du": 374, + "ess": 375, + "ep": 376, + "vest": 377, + "vestig": 378, + "op": 379, + "toc": 380, + "ef": 381, + "ay▁": 382, + "tocol": 383, + "will▁be▁": 384, + "ast": 385, + "com": 386, + "▁ar": 387, + "other": 388, + "▁for": 389, + "and": 390, + "��R": 391, + "ib": 392, + "e\n\n": 393, + "rom": 394, + "ed▁in": 395, + "▁treatment": 396, + "enc": 397, + "ain": 398, + "ical▁": 399, + "study": 400, + "ed▁to": 401, + "ive▁": 402, + ".1": 403, + "alys": 404, + "ort": 405, + "og": 406, + ".2": 407, + "av": 408, + "▁with": 409, + "e▁to": 410, + "ed▁b": 411, + "min": 412, + "s▁of": 413, + "ber": 414, + "In": 415, + "our": 416, + "be▁": 417, + "atients▁": 418, + "duct": 419, + "ad": 420, + "ign": 421, + "ant": 422, + "age▁": 423, + "oul": 424, + "ug": 425, + "\n\nS": 426, + "ancer": 427, + "▁that": 428, + "▁200": 429, + "pons": 430, + "umab": 431, + "▁is▁": 432, + "▁of▁": 433, + "ollow": 434, + "▁al": 435, + "................................................................": 436, + "▁will▁be▁": 437, + "e▁s": 438, + "eri": 439, + "art": 440, + "ould▁": 441, + "e▁th": 442, + "▁M": 443, + "▁r": 444, + "▁0": 445, + "▁3": 446, + "ppro": 447, + "▁con": 448, + "act": 449, + "rotocol": 450, + "cor": 451, + "event": 452, + "▁of▁the▁": 453, + "wh": 454, + "ust": 455, + "cont": 456, + "e,▁": 457, + "vers": 458, + "ph": 459, + "▁o": 460, + "▁com": 461, + "ear": 462, + "▁F": 463, + ".▁A": 464, + ".▁The▁": 465, + "ity▁": 466, + "vestigator": 467, + "▁as▁": 468, + "▁g": 469, + "port": 470, + "not": 471, + "as▁": 472, + "hould▁": 473, + "01": 474, + "200": 475, + "sess": 476, + "▁the▁s": 477, + "▁are▁": 478, + "▁on": 479, + ",▁and▁": 480, + "ection": 481, + "rad": 482, + "ated▁": 483, + "ee": 484, + "ition": 485, + "▁v": 486, + "ine▁": 487, + "▁L": 488, + "ly▁": 489, + "able▁": 490, + "iseas": 491, + ".3": 492, + "ave▁": 493, + "int": 494, + "ever": 495, + "▁B": 496, + "inu": 497, + "umber": 498, + "ific": 499, + "ression": 500, + "▁this▁": 501, + "s,▁": 502, + "eek": 503, + "af": 504, + "ata": 505, + "e:": 506, + "▁y": 507, + "▁all": 508, + "ary▁": 509, + "clud": 510, + "tud": 511, + "verse▁": 512, + "ical": 513, + "▁res": 514, + "ure": 515, + "12": 516, + "ip": 517, + "out": 518, + "andom": 519, + "ce": 520, + "ose▁": 521, + "▁ther": 522, + "▁analys": 523, + "▁st": 524, + "ial": 525, + "ach": 526, + "\n\nC": 527, + "▁ch": 528, + "cid": 529, + "▁will": 530, + "rug": 531, + "e▁in": 532, + "apy▁": 533, + "follow": 534, + "een": 535, + "umor": 536, + "ing▁the▁": 537, + "alu": 538, + "cord": 539, + "olog": 540, + "▁5": 541, + "eff": 542, + "bo": 543, + "ity": 544, + "will": 545, + "▁6": 546, + "from": 547, + "ult": 548, + "▁H": 549, + "and▁": 550, + "tudy▁": 551, + "cur": 552, + "▁subject": 553, + "▁patients▁": 554, + "▁4": 555, + "sessment": 556, + "ew": 557, + "▁the▁p": 558, + ")\n\n": 559, + "minist": 560, + "linical▁": 561, + "od▁": 562, + "gression": 563, + "plat": 564, + "__": 565, + "dition": 566, + "▁at": 567, + "ay": 568, + "ampl": 569, + "andomiz": 570, + "ail": 571, + "itum": 572, + "\n\nPage▁": 573, + "itumumab": 574, + "s▁(": 575, + "▁the▁in": 576, + "▁ac": 577, + "one▁": 578, + "evel": 579, + "anitumumab": 580, + "eg": 581, + ".4": 582, + "▁study▁": 583, + "continu": 584, + "\n\n1": 585, + "pprov": 586, + "platin": 587, + "ident": 588, + "ase▁": 589, + "lo": 590, + "hould▁be▁": 591, + "vi": 592, + "▁mg": 593, + "po": 594, + "s▁in": 595, + "xim": 596, + "mend": 597, + "▁cancer": 598, + "gen": 599, + "isease▁": 600, + ".5": 601, + "s.▁": 602, + "apy": 603, + "▁af": 604, + "▁week": 605, + "ire": 606, + "ens": 607, + "rel": 608, + "cons": 609, + "usion": 610, + "rit": 611, + "▁any▁": 612, + "▁V": 613, + "▁ex": 614, + "▁the▁t": 615, + "fir": 616, + "afet": 617, + "reg": 618, + "ell": 619, + "ance▁": 620, + "onth": 621, + "ak": 622, + "▁wh": 623, + "\n\nD": 624, + "med": 625, + "ed▁by": 626, + "formed▁": 627, + "ept": 628, + "fer": 629, + "rior": 630, + "urv": 631, + "���after": 632, + "eth": 633, + "cre": 634, + "xic": 635, + "emother": 636, + "ycl": 637, + "ation▁of": 638, + "ally▁": 639, + "verse▁event": 640, + "ed▁for": 641, + "s▁and▁": 642, + "ed▁on": 643, + "19": 644, + "e▁d": 645, + "\n\nX": 646, + "esion": 647, + "ath": 648, + "cid:": 649, + "ication": 650, + "ly": 651, + "EC": 652, + ".▁S": 653, + ".0": 654, + "Protocol": 655, + "ob": 656, + "▁patient": 657, + "10": 658, + "▁the▁d": 659, + "urviv": 660, + "TI": 661, + "ang": 662, + "plet": 663, + "s▁will▁be▁": 664, + "▁have▁": 665, + "ies▁": 666, + "▁G": 667, + "▁un": 668, + "report": 669, + "ous": 670, + "ard": 671, + "▁U": 672, + "▁e": 673, + "tain": 674, + "ely▁": 675, + "MC": 676, + "▁J": 677, + "e▁the▁": 678, + "▁Number": 679, + "▁pl": 680, + "If": 681, + "ov": 682, + "▁tim": 683, + "pt": 684, + "ies": 685, + "AE": 686, + ".▁P": 687, + "▁of▁1": 688, + "\n\nE": 689, + "der": 690, + "rial": 691, + "igh": 692, + "orm": 693, + "GF": 694, + "ponse▁": 695, + "us▁": 696, + "asel": 697, + "▁In": 698, + "se": 699, + "oun": 700, + "),▁": 701, + "▁ant": 702, + "▁from": 703, + "requ": 704, + "ure▁": 705, + "s\n\n": 706, + "ed▁by▁": 707, + "pos": 708, + "ax": 709, + "vent": 710, + "evalu": 711, + "▁is": 712, + "▁Protocol": 713, + "rim": 714, + "iscontinu": 715, + ".▁Th": 716, + "▁not": 717, + "on-": 718, + "ument": 719, + "et▁al": 720, + "orator": 721, + "▁tumor": 722, + "EN": 723, + "ON": 724, + "ration": 725, + "ia": 726, + "ced": 727, + "▁may▁": 728, + "eter": 729, + "s▁for": 730, + "ial▁": 731, + "ement": 732, + "icac": 733, + "ust▁be▁": 734, + "vestigation": 735, + "▁7": 736, + "su": 737, + "▁month": 738, + "ous▁": 739, + "rade▁": 740, + "▁dos": 741, + "ction": 742, + "ich": 743, + "roduct": 744, + "revi": 745, + "ost": 746, + "ere▁": 747, + "been": 748, + "formation": 749, + "effect": 750, + "pres": 751, + "ocument": 752, + "clin": 753, + "CT": 754, + "es▁of": 755, + ",▁the▁": 756, + "(cid:": 757, + "▁study": 758, + "isit": 759, + "bin": 760, + "e-": 761, + "may▁": 762, + "fusion": 763, + "▁adverse▁event": 764, + "artic": 765, + "amin": 766, + "roup": 767, + "mon": 768, + "etast": 769, + "vid": 770, + "▁per": 771, + "▁ass": 772, + "e▁v": 773, + "pect": 774, + "includ": 775, + "ate:": 776, + "pec": 777, + "str": 778, + "s)": 779, + "afety▁": 780, + "▁10": 781, + "pp": 782, + "cept": 783, + "ibl": 784, + ".6": 785, + "ser": 786, + "▁to▁the▁": 787, + "▁analysis▁": 788, + "cent": 789, + "ix": 790, + "50": 791, + "lood▁": 792, + "can": 793, + ".▁In": 794, + "II": 795, + "so": 796, + "▁appro": 797, + "fident": 798, + ".▁E": 799, + "▁assessment": 800, + "▁ag": 801, + "▁test": 802, + "18": 803, + "arg": 804, + "are": 805, + "▁mg/": 806, + "ated": 807, + "▁ph": 808, + "record": 809, + "efin": 810, + "over": 811, + "s.\n\n": 812, + "RA": 813, + ",▁and": 814, + "aus": 815, + ".▁C": 816, + "atic": 817, + "eria": 818, + "11": 819, + "efor": 820, + "▁sign": 821, + "riteria": 822, + "occur": 823, + "point": 824, + "ider": 825, + "RI": 826, + "▁Date:": 827, + "ution": 828, + "▁cont": 829, + "til": 830, + "AL": 831, + "who": 832, + "▁ab": 833, + "ately▁": 834, + "ifi": 835, + "te": 836, + ".▁T": 837, + "ceiv": 838, + "ed▁with": 839, + "aborator": 840, + "40": 841, + "peri": 842, + "par": 843, + "▁Number:": 844, + "’s▁": 845, + "▁x": 846, + "-up": 847, + "▁med": 848, + "▁administ": 849, + "20": 850, + "drug": 851, + ",▁or": 852, + "▁the": 853, + "progression": 854, + "CR": 855, + "ed▁at": 856, + "▁in▁the▁": 857, + "ong": 858, + "ract": 859, + "ym": 860, + "roduct:": 861, + "radi": 862, + "FI": 863, + "▁Number:▁200": 864, + "e.\n\n": 865, + "ary": 866, + "OL": 867, + "▁le": 868, + "▁Protocol▁Number:▁200": 869, + "patient": 870, + "25": 871, + "▁disease���": 872, + "):": 873, + "ace": 874, + "ian": 875, + "kin": 876, + "investigator": 877, + "yp": 878, + "▁9": 879, + "emet": 880, + "\n\nX\n\nX": 881, + ".,▁": 882, + "have▁": 883, + "▁8": 884, + "EGF": 885, + "e▁(": 886, + "▁0▁0": 887, + "first": 888, + "ersion": 889, + "MG": 890, + "rib": 891, + "articip": 892, + "s▁s": 893, + "▁us": 894, + "mit": 895, + "▁o▁r": 896, + "alysis▁": 897, + "ight": 898, + "\n\nProduct:": 899, + "\n\nN": 900, + "following": 901, + "rior▁to": 902, + "15": 903, + "cal": 904, + "e▁for": 905, + "▁each": 906, + "he": 907, + "pre": 908, + "ran": 909, + "al▁pro": 910, + "30": 911, + "mgen": 912, + "ppend": 913, + "s▁with": 914, + "andomization": 915, + "▁p▁p": 916, + "▁data": 917, + "every▁": 918, + "▁trial": 919, + "▁o▁r▁p▁p": 920, + "d▁e▁v": 921, + "ulation": 922, + "▁16": 923, + "▁o▁r▁p▁p▁A": 924, + "d▁e▁v▁o▁r▁p▁p▁A": 925, + "▁X": 926, + "FS": 927, + ").\n\n": 928, + ".▁If": 929, + "................................................................................": 930, + "mendment": 931, + ".7": 932, + "arm": 933, + "fidential": 934, + "ppendix": 935, + "\n\n2": 936, + "imen": 937, + "eath": 938, + "▁form": 939, + "y▁of": 940, + "arget": 941, + "rex": 942, + "bas": 943, + "▁should▁be▁": 944, + "ative▁": 945, + "roll": 946, + "ark": 947, + "____": 948, + "earch": 949, + "ard▁": 950, + "acebo": 951, + "▁other": 952, + "......": 953, + "ari": 954, + "ne": 955, + "▁lesion": 956, + "▁the▁investigator": 957, + "\n\nR": 958, + "ular": 959, + "emetrex": 960, + "17": 961, + "subject": 962, + "▁your": 963, + "▁T▁I": 964, + "Study▁": 965, + "axel": 966, + "ten": 967, + "itor": 968, + "etermin": 969, + "ind": 970, + "inib": 971, + "etic": 972, + "NC": 973, + "▁-": 974, + "emotherapy▁": 975, + "MC-": 976, + "▁to▁be▁": 977, + "▁Ad": 978, + "to": 979, + "▁the\n\n": 980, + "▁pre": 981, + "ed▁as▁": 982, + "24": 983, + "evac": 984, + "ity▁of": 985, + "▁has▁": 986, + "izumab": 987, + "urvival": 988, + "evacizumab": 989, + "▁Study▁": 990, + "▁also": 991, + "▁you": 992, + "the▁": 993, + "ass": 994, + "ence▁": 995, + "des": 996, + "ual": 997, + "easure": 998, + "ff": 999, + "▁a▁s": 1000, + "▁the▁study": 1001, + "\n\nF": 1002, + "▁cycl": 1003, + "present": 1004, + "ount": 1005, + "14": 1006, + "\n\nT": 1007, + "e,": 1008, + "rial▁": 1009, + "▁E▁L": 1010, + "................................................................................................": 1011, + "\n\n3": 1012, + "000": 1013, + "▁im": 1014, + "54": 1015, + "ci": 1016, + "aseline▁": 1017, + "consent": 1018, + "ence▁of": 1019, + "protocol": 1020, + "serv": 1021, + "actor": 1022, + "On": 1023, + "sh": 1024, + "ating": 1025, + "dur": 1026, + "ron": 1027, + "ese▁": 1028, + "▁the▁patient": 1029, + "ched": 1030, + "ed,▁": 1031, + "chedul": 1032, + "ximately▁": 1033, + "dra": 1034, + "respons": 1035, + "ER": 1036, + "\n\nY": 1037, + "▁addition": 1038, + "ening": 1039, + "▁The▁": 1040, + "own": 1041, + "▁follow": 1042, + "ification": 1043, + ".▁D": 1044, + "▁the▁l": 1045, + "\n\nS▁I": 1046, + "ST": 1047, + "no": 1048, + "s▁are▁": 1049, + "▁dose▁": 1050, + "▁inter": 1051, + "d▁of": 1052, + "▁least": 1053, + "oci": 1054, + "▁reg": 1055, + "y,▁": 1056, + "complet": 1057, + "▁W": 1058, + "coll": 1059, + "ed▁as": 1060, + "etastatic": 1061, + "RAS": 1062, + "KRAS": 1063, + "▁than": 1064, + "rimary▁": 1065, + "pr": 1066, + ".\n\nA": 1067, + "e)": 1068, + "▁ob": 1069, + "efficac": 1070, + "\n\nThe▁": 1071, + "▁toxic": 1072, + "ed▁in▁the▁": 1073, + "\n\n4": 1074, + ".▁F": 1075, + "▁day": 1076, + "le": 1077, + "▁cons": 1078, + "onfidential": 1079, + "ically▁": 1080, + "id▁": 1081, + "uc": 1082, + "data": 1083, + "I-": 1084, + "abil": 1085, + ".\n\nP": 1086, + "e▁b": 1087, + "5-": 1088, + "require": 1089, + "s▁to": 1090, + "unit": 1091, + "▁therapy": 1092, + "s▁that": 1093, + "al▁product": 1094, + "13": 1095, + "23": 1096, + "\n\nI": 1097, + "rent": 1098, + "inal": 1099, + "pri": 1100, + "▁arm": 1101, + "▁mg/m": 1102, + "draw": 1103, + ",▁S": 1104, + "i-": 1105, + "▁panitumumab": 1106, + "▁2007": 1107, + "hy": 1108, + "▁clin": 1109, + "▁visit": 1110, + "defin": 1111, + "isk": 1112, + "yst": 1113, + "olor": 1114, + "lind": 1115, + "LC": 1116, + "iven": 1117, + "pproved": 1118, + "arker": 1119, + "unitinib": 1120, + "oth": 1121, + "▁patients▁with": 1122, + "quest": 1123, + "s▁or": 1124, + "80": 1125, + "ympt": 1126, + "son": 1127, + "▁it": 1128, + "ymptom": 1129, + "vestigational▁product": 1130, + "bination": 1131, + "car": 1132, + "raph": 1133, + "pare": 1134, + "stit": 1135, + "\n\nAd": 1136, + "action": 1137, + "▁therapy▁": 1138, + "ays": 1139, + "▁accord": 1140, + "es,▁": 1141, + "armac": 1142, + "evelop": 1143, + "/or": 1144, + "▁car": 1145, + "▁was▁": 1146, + "result": 1147, + "▁Clinical▁": 1148, + "fl": 1149, + "isplatin": 1150, + "▁act": 1151, + "performed▁": 1152, + "administ": 1153, + "▁Version": 1154, + "which": 1155, + "Clinical▁": 1156, + "ugh": 1157, + "in▁the▁": 1158, + "ing▁to": 1159, + "▁min": 1160, + "emotherapy": 1161, + "ung": 1162, + "equ": 1163, + "rm": 1164, + "▁death": 1165, + "ember": 1166, + ".\n\nS": 1167, + "ated▁to": 1168, + ")▁": 1169, + "creas": 1170, + "alth": 1171, + "level": 1172, + "main": 1173, + "including": 1174, + "e▁treatment": 1175, + "Event": 1176, + "5%": 1177, + "ures": 1178, + "must▁be▁": 1179, + "▁Th": 1180, + "cond": 1181, + "uppl": 1182, + "boplatin": 1183, + "199": 1184, + "▁30": 1185, + "uid": 1186, + "etw": 1187, + "rans": 1188, + "dos": 1189, + "ally": 1190, + "patients▁": 1191, + "d▁e▁v▁o▁r▁p▁p▁A\n\nProduct:": 1192, + "An": 1193, + "SC": 1194, + "▁progression": 1195, + "▁evalu": 1196, + "e▁and▁": 1197, + "provid": 1198, + "prior▁to": 1199, + "rop": 1200, + "sign": 1201, + "using": 1202, + "urvival▁": 1203, + "rough": 1204, + "ponsor": 1205, + "ed▁and▁": 1206, + "ack": 1207, + "olorect": 1208, + "▁di": 1209, + "▁An": 1210, + "ystem": 1211, + "201": 1212, + "▁the▁study▁": 1213, + "▁includ": 1214, + "ral▁": 1215, + "may▁be▁": 1216, + "▁peri": 1217, + "ificant": 1218, + "▁must▁be▁": 1219, + "007": 1220, + "s:": 1221, + "▁over": 1222, + "etween": 1223, + "etu": 1224, + "iffer": 1225, + "▁sampl": 1226, + "▁factor": 1227, + "ximab": 1228, + "pecific": 1229, + "etuximab": 1230, + "ate▁of": 1231, + "▁Amendment": 1232, + "ru": 1233, + "▁infusion": 1234, + "E-": 1235, + "tion": 1236, + "ox": 1237, + "enter": 1238, + "ceive▁": 1239, + "row": 1240, + "ology▁": 1241, + "▁13": 1242, + "ativ": 1243, + "perform": 1244, + "firm": 1245, + "issu": 1246, + ".▁R": 1247, + "SA": 1248, + "ND": 1249, + "itamin": 1250, + "olv": 1251, + "endpoint": 1252, + "efore▁": 1253, + "ely": 1254, + ",▁a": 1255, + "you": 1256, + "until": 1257, + "receiv": 1258, + "formed▁consent": 1259, + "▁162": 1260, + "MG▁162": 1261, + "▁mg/m2": 1262, + "ann": 1263, + ".▁200": 1264, + "ed▁from": 1265, + "▁sit": 1266, + "enroll": 1267, + "▁cell": 1268, + "consider": 1269, + "question": 1270, + "\n\n0": 1271, + "epend": 1272, + "▁subjects▁": 1273, + "pon": 1274, + "▁year": 1275, + "ide▁": 1276, + "ay▁1": 1277, + "▁the▁subject": 1278, + "Investigator": 1279, + "verse▁Event": 1280, + "▁dose▁of": 1281, + "inter": 1282, + "▁complet": 1283, + "JM": 1284, + "\n\nH": 1285, + "agn": 1286, + "▁group": 1287, + "▁this▁study": 1288, + "NA": 1289, + "discontinu": 1290, + "▁ap": 1291, + "ital": 1292, + "▁Com": 1293, + "▁approximately▁": 1294, + "aging": 1295, + "▁of▁12": 1296, + "▁particip": 1297, + "▁AB": 1298, + "appro": 1299, + "ed.\n\n": 1300, + "▁discontinu": 1301, + "hem": 1302, + ",▁P": 1303, + "ES": 1304, + "randomiz": 1305, + "▁treat": 1306, + "aselin": 1307, + "St": 1308, + "valu": 1309, + "\n\n\n\n": 1310, + "document": 1311, + "stat": 1312, + "▁sub": 1313, + "outcom": 1314, + "inc": 1315, + "cancer": 1316, + "crib": 1317, + "Cl": 1318, + "kn": 1319, + "y▁and▁": 1320, + "ZD": 1321, + "▁CT": 1322, + "▁their": 1323, + "▁et▁al": 1324, + "OR": 1325, + "▁ind": 1326, + "reas": 1327, + "duc": 1328, + "plic": 1329, + "▁tak": 1330, + "ither": 1331, + "ild": 1332, + "▁if": 1333, + "e▁that": 1334, + "36": 1335, + "disease▁": 1336, + "▁mod": 1337, + "es▁will▁be▁": 1338, + "hase▁": 1339, + "ed\n\n": 1340, + ".▁B": 1341, + ",\n\n": 1342, + "ess▁": 1343, + "ish": 1344, + "response▁": 1345, + "otent": 1346, + "eb": 1347, + "rint": 1348, + "▁do": 1349, + "ENTI": 1350, + "enos": 1351, + "▁analysis": 1352, + "number": 1353, + "olorectal": 1354, + "▁and/or": 1355, + "▁continu": 1356, + "▁Panitumumab": 1357, + "enosumab": 1358, + "-0": 1359, + ".8": 1360, + "\\A": 1361, + "wo": 1362, + "es▁in": 1363, + "ed▁s": 1364, + "▁receive▁": 1365, + "collect": 1366, + "\n\nx": 1367, + "▁=": 1368, + "iom": 1369, + "rol": 1370, + "val": 1371, + "▁occur": 1372, + "fficac": 1373, + "\n\n6": 1374, + "I-007": 1375, + "▁days": 1376, + "ssessment": 1377, + "▁scan": 1378, + "▁report": 1379, + "dis": 1380, + "erum": 1381, + ".▁M": 1382, + "▁provid": 1383, + "▁response▁": 1384, + "IT": 1385, + "dose▁": 1386, + "▁Cancer": 1387, + "▁the▁tim": 1388, + ")▁and▁": 1389, + "aboratory▁": 1390, + "▁event": 1391, + "▁Page▁": 1392, + "cess": 1393, + "................................................": 1394, + "▁disease▁progression": 1395, + "16": 1396, + "▁should▁": 1397, + "vanc": 1398, + "e▁S": 1399, + ",▁s": 1400, + "sequ": 1401, + "easurement": 1402, + "loc": 1403, + "▁these▁": 1404, + "ros": 1405, + "ization": 1406, + "mod": 1407, + "atist": 1408, + "-t": 1409, + "s▁b": 1410, + ",▁M": 1411, + "erious": 1412, + "\n\n7": 1413, + "ress": 1414, + "ali": 1415, + "ed:": 1416, + "33": 1417, + "rowth": 1418, + "GE": 1419, + "mended▁": 1420, + "ociated▁": 1421, + "▁dis": 1422, + "▁requ": 1423, + ",▁200": 1424, + "▁sh": 1425, + "elect": 1426, + "▁may▁be▁": 1427, + "sequent": 1428, + "ealth": 1429, + "ha": 1430, + "any▁": 1431, + "umm": 1432, + "120": 1433, + "RO": 1434, + ".▁H": 1435, + "abel": 1436, + "arr": 1437, + "▁mor": 1438, + "▁combination": 1439, + ".2.1": 1440, + "-rel": 1441, + "▁clinical": 1442, + "mall": 1443, + "▁drug": 1444, + "▁up": 1445, + "s▁will": 1446, + "itant": 1447, + "cedure": 1448, + "week": 1449, + "cin": 1450, + "▁dur": 1451, + "elin": 1452, + "comitant": 1453, + "▁non-": 1454, + "▁study▁treatment": 1455, + "unction": 1456, + "▁through": 1457, + "▁survival": 1458, + "easur": 1459, + "X-": 1460, + "▁must": 1461, + "ibod": 1462, + "current": 1463, + ",▁C": 1464, + "▁hour": 1465, + "▁loc": 1466, + "3E-": 1467, + "medication": 1468, + "observ": 1469, + "▁rel": 1470, + "1-": 1471, + "▁(A": 1472, + "regn": 1473, + "administer": 1474, + "sub": 1475, + "▁level": 1476, + "e▁of▁the▁": 1477, + "1)": 1478, + "Trial▁": 1479, + "▁metastatic": 1480, + ".9": 1481, + "▁Res": 1482, + "▁blood▁": 1483, + "creening": 1484, + "TION": 1485, + "aliplatin": 1486, + "▁result": 1487, + "non-": 1488, + "efit": 1489, + "▁H▁T": 1490, + "emetrexed▁": 1491, + "ed▁on▁the▁": 1492, + "rade▁3": 1493, + "sampl": 1494, + "ation▁of▁": 1495, + "yt": 1496, + "urg": 1497, + "man": 1498, + "econd": 1499, + ".▁An": 1500, + "arget▁lesion": 1501, + "norm": 1502, + "ocet": 1503, + "review": 1504, + "\n\nIn": 1505, + ",▁b": 1506, + "es▁for": 1507, + "ower": 1508, + "▁stat": 1509, + "ocetaxel": 1510, + "s,": 1511, + "▁19": 1512, + "IN": 1513, + "IST": 1514, + "cul": 1515, + "e.": 1516, + ".▁N": 1517, + "col": 1518, + "ext": 1519, + "duction": 1520, + "Wh": 1521, + "ulator": 1522, + "▁and▁the▁": 1523, + "ronic": 1524, + "▁activ": 1525, + "ibil": 1526, + "▁gen": 1527, + "........................................................................................": 1528, + "RB": 1529, + "vail": 1530, + "Ad": 1531, + "risk": 1532, + "itab": 1533, + "e▁m": 1534, + "\n\nB": 1535, + "ethod": 1536, + "mer": 1537, + "thor": 1538, + "oma": 1539, + "▁follow-up": 1540, + "▁by▁": 1541, + "acil": 1542, + "tein": 1543, + "▁–": 1544, + "es▁(": 1545, + "jectiv": 1546, + "▁On": 1547, + "▁chemotherapy▁": 1548, + "d▁to": 1549, + "\n\nM": 1550, + "▁can": 1551, + "able▁to": 1552, + "▁administer": 1553, + "AB": 1554, + "conduct": 1555, + "▁which": 1556, + "▁information": 1557, + "CRF": 1558, + "ric": 1559, + "set": 1560, + "▁respons": 1561, + "s▁after": 1562, + "ograph": 1563, + "enefit": 1564, + "ologic": 1565, + "▁number": 1566, + "▁randomization": 1567, + ".▁This▁": 1568, + "cedures": 1569, + "owever": 1570, + "itamin▁D": 1571, + "▁receiv": 1572, + "nd": 1573, + "▁[": 1574, + "end▁of": 1575, + "▁to▁": 1576, + "mitt": 1577, + "given": 1578, + "uor": 1579, + "0%": 1580, + "part": 1581, + "clinical": 1582, + "etastas": 1583, + "priate▁": 1584, + "ull": 1585, + "Trial▁Protocol": 1586, + "▁baseline▁": 1587, + "▁S▁A": 1588, + "clinical▁": 1589, + "ependent": 1590, + "uthor": 1591, + "reast": 1592, + "ENTIAL": 1593, + "hib": 1594, + "rati": 1595, + "▁placebo": 1596, + "e▁or": 1597, + "urther": 1598, + "otec": 1599, + "▁until": 1600, + "▁E▁L▁P": 1601, + "▁S▁A▁E▁L▁P": 1602, + "bl": 1603, + "pression": 1604, + "ogen": 1605, + "ether": 1606, + "uidelin": 1607, + "otecan": 1608, + "▁tissu": 1609, + "ivid": 1610, + "chang": 1611, + "▁administration": 1612, + "iomarker": 1613, + "▁any": 1614, + "IV": 1615, + "▁C▁O": 1616, + "▁N▁E": 1617, + "opulation": 1618, + "ry▁": 1619, + "inotecan": 1620, + "▁this": 1621, + "plac": 1622, + "OX": 1623, + "RE": 1624, + "▁M▁U": 1625, + "when": 1626, + "rimary": 1627, + ".▁T▁N▁E": 1628, + "▁C▁O▁D": 1629, + "▁M▁U▁C▁O▁D": 1630, + ".▁T▁N▁E▁M▁U▁C▁O▁D": 1631, + "▁N▁I": 1632, + "▁F▁E": 1633, + "olorectal▁cancer": 1634, + "▁R▁O": 1635, + "your": 1636, + "▁E▁T": 1637, + "OS": 1638, + "▁PFS": 1639, + "▁Section": 1640, + "▁ID": 1641, + "▁R▁P": 1642, + "cell": 1643, + "▁F▁E▁B": 1644, + "▁R▁O▁F▁E▁B": 1645, + "CAE": 1646, + "were▁": 1647, + "III": 1648, + "▁N▁I▁R▁P": 1649, + "▁E▁T▁N▁I▁R▁P": 1650, + "▁S▁U": 1651, + "▁there▁": 1652, + "ities": 1653, + "FU": 1654, + "▁document": 1655, + "▁P▁O": 1656, + ".▁E▁S▁U": 1657, + ".\n\nThe▁": 1658, + "▁L▁A": 1659, + "▁P▁O▁C": 1660, + "With": 1661, + "▁I▁L▁A": 1662, + "▁D▁I▁L▁A": 1663, + "▁T▁I▁D▁I▁L▁A": 1664, + "▁T▁I▁D▁I▁L▁A▁V": 1665, + "-s": 1666, + "imit": 1667, + "ile▁": 1668, + "▁advanc": 1669, + "inal▁": 1670, + ",▁A": 1671, + "▁des": 1672, + "▁C▁E": 1673, + "K▁C▁E": 1674, + "ed▁a": 1675, + "▁Arm": 1676, + "▁H▁C": 1677, + "▁not▁be▁": 1678, + "K▁C▁E▁H▁C": 1679, + "lit": 1680, + "na": 1681, + "▁12": 1682, + ")(cid:": 1683, + "was▁": 1684, + "▁the▁treatment": 1685, + "obtain": 1686, + "ing▁of": 1687, + "elig": 1688, + "pli": 1689, + "irst": 1690, + "pproved▁by": 1691, + "▁AMG▁162": 1692, + "eport": 1693, + "ONFI": 1694, + "-lin": 1695, + "eight": 1696, + "▁determin": 1697, + "▁17": 1698, + "ode▁": 1699, + "DENTIAL": 1700, + "blind": 1701, + "lesion": 1702, + "ONFIDENTIAL": 1703, + "06": 1704, + "22": 1705, + "sibl": 1706, + "▁\\": 1707, + "estim": 1708, + "▁Clin": 1709, + "ium": 1710, + ",▁H": 1711, + "elet": 1712, + "studies▁": 1713, + "reatin": 1714, + "▁then": 1715, + ".000": 1716, + "Print": 1717, + "OG": 1718, + "uman": 1719, + "by▁": 1720, + "rat": 1721, + ".\n\nC": 1722, + "osp": 1723, + "▁chang": 1724, + "ma": 1725, + "▁combination▁with": 1726, + "-200": 1727, + "▁ter": 1728, + "\n\nDate▁": 1729, + "-5": 1730, + "ean": 1731, + "each": 1732, + "oxic": 1733, + "yl": 1734, + "▁radi": 1735, + "state▁": 1736, + ".▁J": 1737, + "clusion": 1738, + "stitution": 1739, + "aclit": 1740, + "▁2006": 1741, + "follow-up": 1742, + "aclitaxel": 1743, + "overall": 1744, + "ech": 1745, + "\n\n8": 1746, + "▁Amgen": 1747, + "olution": 1748, + "di": 1749, + "▁ne": 1750, + "▁effect": 1751, + "........................................................................": 1752, + "OLF": 1753, + "ed▁or": 1754, + "▁both": 1755, + "under": 1756, + "panitumumab": 1757, + "well": 1758, + "▁det": 1759, + "▁the▁last": 1760, + "gress": 1761, + "information": 1762, + "▁CR": 1763, + "aboratory": 1764, + "▁criteria": 1765, + "▁int": 1766, + "4054": 1767, + "ship": 1768, + "urn": 1769, + "▁N▁O": 1770, + "andard▁": 1771, + "group": 1772, + "must": 1773, + "ceptor": 1774, + "X-EGF": 1775, + "▁T▁C": 1776, + ".▁For": 1777, + "Clinical▁Study▁": 1778, + "ociated▁with": 1779, + "3E-MC-": 1780, + "L▁Version": 1781, + "−201": 1782, + "▁I▁N▁O": 1783, + "▁R▁T▁C": 1784, + "▁E▁L▁E": 1785, + "GEL▁Version": 1786, + "▁ID:": 1787, + ".000−": 1788, + "Printed:": 1789, + "\n\nDate▁Printed:": 1790, + "▁I▁N▁O▁R▁T▁C": 1791, + "GEL▁Version▁ID:": 1792, + "▁I▁N▁O▁R▁T▁C▁E▁L▁E": 1793, + "\n\nAn": 1794, + "3E-MC-JM": 1795, + "pproved\n\nDate▁Printed:": 1796, + "ZD4054": 1797, + "onitor": 1798, + ",▁B": 1799, + "77": 1800, + "by": 1801, + "should▁be▁": 1802, + "ed▁by▁the▁": 1803, + "ype▁": 1804, + "fficacy▁": 1805, + "▁OS": 1806, + "▁dec": 1807, + "s▁of▁the▁": 1808, + "ork": 1809, + "tern": 1810, + "OLFOX": 1811, + "view": 1812, + "▁agent": 1813, + "ities▁": 1814, + "perienc": 1815, + "________": 1816, + "27": 1817, + "▁•": 1818, + "▁diseas": 1819, + "PFS": 1820, + "s▁from": 1821, + "▁time▁": 1822, + "have▁been": 1823, + "38": 1824, + "48": 1825, + "▁approv": 1826, + "▁avail": 1827, + "ational▁": 1828, + "▁2008": 1829, + "▁plus▁": 1830, + "\n\nS▁I▁H▁T": 1831, + "known": 1832, + "28": 1833, + "▁a▁c": 1834, + "es▁and▁": 1835, + "Cons": 1836, + "mun": 1837, + "li": 1838, + "tension": 1839, + "▁K": 1840, + ".▁All": 1841, + "▁study▁drug": 1842, + "▁antibod": 1843, + "ariabl": 1844, + "efficacy▁": 1845, + "SCLC": 1846, + "▁tot": 1847, + "qual": 1848, + "pril": 1849, + "▁su": 1850, + "pared▁": 1851, + "▁Y": 1852, + ".▁I": 1853, + "\n\nConfidential": 1854, + "(s)": 1855, + "assessment": 1856, + "itiv": 1857, + "ram": 1858, + "\n\nApproved\n\nDate▁Printed:": 1859, + "▁medication": 1860, + "erious▁adverse▁event": 1861, + "eing": 1862, + "ite▁": 1863, + "s▁should▁be▁": 1864, + "▁differ": 1865, + "▁within": 1866, + "ardi": 1867, + "vention": 1868, + "represent": 1869, + "▁Pro": 1870, + "▁Sub": 1871, + "eck": 1872, + "stru": 1873, + ".▁Patients▁": 1874, + "03": 1875, + "FA": 1876, + "fre": 1877, + "start": 1878, + "▁bevacizumab": 1879, + "▁new": 1880, + "/L": 1881, + "▁April": 1882, + "▁increas": 1883, + "▁Drug": 1884, + "▁Date:▁0": 1885, + "go": 1886, + "just": 1887, + "▁this▁study▁": 1888, + "medi": 1889, + "▁Panitumumab▁Protocol▁Number:▁200": 1890, + ",▁G": 1891, + "ENT": 1892, + "s▁on": 1893, + "jective▁": 1894, + "irinotecan": 1895, + "aff": 1896, + "ician": 1897, + "▁Edition": 1898, + "eet": 1899, + "\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:": 1900, + "(cid:120": 1901, + "ible▁for": 1902, + "mis": 1903, + "▁investigational▁product": 1904, + "ECIST": 1905, + "▁about": 1906, + "visit": 1907, + "▁AE": 1908, + "versus▁": 1909, + "ption": 1910, + "▁has▁been": 1911, + "▁lung": 1912, + "cri": 1913, + "\n\nL": 1914, + ",▁et▁al": 1915, + "cinoma": 1916, + "▁count": 1917, + "design": 1918, + "\n\nF▁O": 1919, + "ed▁c": 1920, + "▁chemotherapy": 1921, + "▁Feb": 1922, + "▁x▁x": 1923, + "treatment": 1924, + "ing▁a": 1925, + "iver": 1926, + "▁assess": 1927, + "has▁": 1928, + "io": 1929, + "s▁and": 1930, + "\n\n(": 1931, + "research": 1932, + "▁who": 1933, + "▁minut": 1934, + "▁baselin": 1935, + "oph": 1936, + "▁anti-": 1937, + "are▁": 1938, + "▁allow": 1939, + "open": 1940, + ".1.1": 1941, + "during▁the▁": 1942, + "ea": 1943, + "omen": 1944, + "▁St": 1945, + "-m": 1946, + "not▁be▁": 1947, + "▁also▁be▁": 1948, + ",▁D": 1949, + "used▁to": 1950, + "ouracil": 1951, + "istor": 1952, + "Clinical▁Study▁Protocol": 1953, + "determin": 1954, + "▁trans": 1955, + "▁previ": 1956, + "▁applic": 1957, + "uorouracil": 1958, + "▁review": 1959, + "such": 1960, + "regnanc": 1961, + "s▁at": 1962, + "▁part": 1963, + "▁by": 1964, + "long": 1965, + "mCl": 1966, + "irect": 1967, + "easurable▁": 1968, + "▁every▁": 1969, + ".2.2": 1970, + "within": 1971, + "identifi": 1972, + "\n\nY▁P▁O▁C": 1973, + "▁according▁to": 1974, + "Com": 1975, + "orin": 1976, + "ingl": 1977, + "\n\n5": 1978, + "▁a▁m": 1979, + "describ": 1980, + "Con": 1981, + "Jul": 1982, + "mad": 1983, + "ecess": 1984, + "45": 1985, + "count": 1986, + "▁compar": 1987, + "47": 1988, + "▁protocol": 1989, + "ection:": 1990, + "\n\nX\n\nX\n\nX\n\nX": 1991, + "\n\nG": 1992, + "\n\ns": 1993, + "▁14": 1994, + "▁no": 1995, + "▁perform": 1996, + "day▁": 1997, + "erg": 1998, + "commend": 1999, + ")\n\nGEL▁Version▁ID:": 2000, + "▁at▁least": 2001, + "MD": 2002, + "ler": 2003, + "▁mL": 2004, + "▁Appendix": 2005, + "placebo": 2006, + "emat": 2007, + "▁Day▁1": 2008, + "▁first": 2009, + "Res": 2010, + "prov": 2011, + "ucov": 2012, + "-M": 2013, + "▁ver": 2014, + "▁randomiz": 2015, + "▁Form": 2016, + "ucovorin": 2017, + "Un": 2018, + "cer": 2019, + "dend": 2020, + "anib": 2021, + "afety": 2022, + "alysis▁S": 2023, + "dendum": 2024, + "43": 2025, + "volv": 2026, + ",▁L": 2027, + "▁develop": 2028, + "iranib": 2029, + "cular": 2030, + "randomization": 2031, + "studies": 2032, + "\n\nAppendix": 2033, + "ummar": 2034, + "s,▁and▁": 2035, + "▁the▁first": 2036, + "▁be\n\n": 2037, + "▁the▁sam": 2038, + "related▁to": 2039, + "analysis▁": 2040, + "emia": 2041, + "ameter": 2042, + "s▁prior▁to": 2043, + ",▁p": 2044, + "▁cetuximab": 2045, + "▁hy": 2046, + "IC": 2047, + "fract": 2048, + "▁period": 2049, + "\n\nK▁C▁E▁H▁C": 2050, + "▁cal": 2051, + "evi": 2052, + "reatinine▁": 2053, + "Cancer": 2054, + "dic": 2055, + "e▁will": 2056, + "▁24": 2057, + "ify": 2058, + "ubl": 2059, + "econdary▁": 2060, + "Y23": 2061, + "▁sever": 2062, + "▁under": 2063, + "1514": 2064, + "based▁on": 2065, + "indic": 2066, + "Y231514": 2067, + "growth": 2068, + "ash": 2069, + "upplement": 2070, + "21": 2071, + "84": 2072, + "Code▁": 2073, + "▁coll": 2074, + "▁Dec": 2075, + "▁Edition▁Number": 2076, + "diseas": 2077, + "▁+": 2078, + "▁colorectal▁cancer": 2079, + "ractic": 2080, + "PA": 2081, + "UM": 2082, + "-3": 2083, + "▁201": 2084, + "▁associated▁with": 2085, + "▁phas": 2086, + "label": 2087, + "regimen": 2088, + "itabine▁": 2089, + "ividual": 2090, + "IRB": 2091, + "vis": 2092, + "▁the▁event": 2093, + "ized▁": 2094, + "oh": 2095, + "e▁a": 2096, + "cisplatin": 2097, + "fic": 2098, + "▁p.▁": 2099, + "assess": 2100, + "ence▁in": 2101, + "-related▁": 2102, + "▁IV": 2103, + "ously▁": 2104, + "mClone▁": 2105, + "alysis▁Set": 2106, + "caus": 2107, + "olic": 2108, + "▁toxicity▁": 2109, + "particip": 2110, + "▁Q": 2111, + "▁two": 2112, + "evid": 2113, + "ance▁with": 2114, + "CT-": 2115, + "▁assign": 2116, + "significant": 2117, + "ing▁and▁": 2118, + "mitte": 2119, + "▁for▁the▁": 2120, + "DMC": 2121, + "▁pos": 2122, + "hea": 2123, + "required▁": 2124, + ")▁(": 2125, + ".▁O": 2126, + "ed▁that": 2127, + "emon": 2128, + "▁Oncol": 2129, + "ubjects▁": 2130, + "receiving": 2131, + "normal": 2132, + "BC": 2133, + "kg": 2134, + "ven": 2135, + "erv": 2136, + "aly": 2137, + "stra": 2138, + "ospital": 2139, + "112": 2140, + "ysician": 2141, + "▁KRAS": 2142, + "ate": 2143, + "▁clinical▁": 2144, + "upport": 2145, + "carboplatin": 2146, + ")▁will▁be▁": 2147, + "618": 2148, + "yn": 2149, + "\n\nO": 2150, + "▁between": 2151, + "▁IMC-": 2152, + "after": 2153, + "questionna": 2154, + "bra": 2155, + "s.▁The▁": 2156, + "▁Ch": 2157, + "\n\nE▁R▁O▁F▁E▁B": 2158, + "▁pain": 2159, + "ation▁of▁the▁": 2160, + "FIRI": 2161, + "OLFIRI": 2162, + "US": 2163, + "ate▁the▁": 2164, + "▁analysis▁of": 2165, + "▁17:": 2166, + "expect": 2167, + "):▁p.▁": 2168, + "▁require": 2169, + "/m": 2170, + "osph": 2171, + "ycle▁": 2172, + "e▁Section": 2173, + "TA": 2174, + "ient": 2175, + "\n\n9": 2176, + "study▁treatment": 2177, + "ary▁200": 2178, + "▁Subst": 2179, + "ing▁s": 2180, + "ability": 2181, + "▁lung▁cancer": 2182, + "-S": 2183, + "s.": 2184, + "tt": 2185, + "xaliplatin": 2186, + "▁A\n\nF▁O": 2187, + "chemotherapy▁": 2188, + "▁receptor": 2189, + "▁Adverse▁Event": 2190, + "emonstr": 2191, + "y▁or": 2192, + "▁SAE": 2193, + "ratio": 2194, + "Version": 2195, + "▁mm": 2196, + "is▁not": 2197, + "eca": 2198, + ")▁Clinical▁": 2199, + "▁bone▁": 2200, + "ober": 2201, + "ual▁": 2202, + "▁research": 2203, + "Zen": 2204, + "▁of▁a": 2205, + "umour": 2206, + ".\n\nT": 2207, + "▁15": 2208, + "▁confirm": 2209, + "\n\nD▁E▁T▁N▁I▁R▁P": 2210, + "▁Drug▁Subst": 2211, + "straZen": 2212, + "straZeneca": 2213, + "SAE": 2214, + "oug": 2215, + "▁withdraw": 2216, + "\n\nS▁T▁I": 2217, + "pecifi": 2218, + "▁the▁b": 2219, + ",▁in": 2220, + "▁health": 2221, + "centration": 2222, + ")▁Clinical▁Protocol": 2223, + "at▁least": 2224, + "▁cl": 2225, + "▁survival▁": 2226, + "▁OF": 2227, + "\n\nClinical▁": 2228, + "amination": 2229, + "▁Study▁Code▁": 2230, + "either": 2231, + "▁agre": 2232, + "new": 2233, + "ctober": 2234, + "plan": 2235, + "person": 2236, + "\n\nStudy▁": 2237, + "andomis": 2238, + "(cid:120)": 2239, + "F8": 2240, + "ding": 2241, + "iqu": 2242, + "thes": 2243, + "▁Ph": 2244, + "pproved▁": 2245, + "ritten": 2246, + "86": 2247, + "▁bas": 2248, + "elow": 2249, + "▁A618": 2250, + "terim": 2251, + "1,▁": 2252, + "IG": 2253, + "ral": 2254, + "urop": 2255, + "▁<": 2256, + "▁the▁c": 2257, + "ascular": 2258, + "eg,▁": 2259, + "fi": 2260, + "ess▁of": 2261, + "rof": 2262, + "ediranib": 2263, + "imaging": 2264, + "▁hav": 2265, + "pectiv": 2266, + "ry": 2267, + "ism": 2268, + "▁Treatment": 2269, + "\n\nY▁T▁I▁D▁I▁L▁A▁V": 2270, + "▁measurement": 2271, + "35": 2272, + "att": 2273, + "▁the▁end▁of": 2274, + "es▁not": 2275, + "11F8": 2276, + "state▁cancer": 2277, + "▁author": 2278, + "▁18": 2279, + "chemotherapy": 2280, + "alyz": 2281, + "HR": 2282, + "ad▁": 2283, + "stor": 2284, + "▁in▁combination▁with": 2285, + "acter": 2286, + "\n\nAdd▁": 2287, + "zard▁": 2288, + "ates": 2289, + "\n\nthe▁": 2290, + "▁and▁s": 2291, + "▁October": 2292, + "riteria▁for": 2293, + "rate▁": 2294, + "aracter": 2295, + "ome▁": 2296, + "\n\nC▁I▁N▁O▁R▁T▁C▁E▁L▁E": 2297, + "ximum": 2298, + "901": 2299, + "pens": 2300, + "eral▁": 2301, + "only▁": 2302, + "using▁the▁": 2303, + "confirm": 2304, + "▁long": 2305, + "\n\nE▁S▁A▁E▁L▁P": 2306, + "kinetic": 2307, + "▁observ": 2308, + "arrhea": 2309, + ")▁or": 2310, + "cium": 2311, + "armaco": 2312, + "turn": 2313, + ",▁R": 2314, + "▁sp": 2315, + "▁safety▁": 2316, + "▁were▁": 2317, + "plorator": 2318, + "ology": 2319, + "99": 2320, + "LLC": 2321, + "e18": 2322, + "▁20": 2323, + "except": 2324, + "due▁to": 2325, + "On:": 2326, + "pproved\\A": 2327, + "fluorouracil": 2328, + "▁overall": 2329, + "▁ABI-007": 2330, + "\\Approved\\A": 2331, + "77e18": 2332, + "ough": 2333, + "pproved▁On:": 2334, + "90177e18": 2335, + "\\Approved\\Approved▁On:": 2336, + "81": 2337, + "age:": 2338, + "otherapy▁": 2339, + "▁phase▁": 2340, + "meric": 2341, + "most": 2342, + "▁cas": 2343, + "erious▁": 2344, + "▁5-": 2345, + "▁acid▁": 2346, + "armacokinetic": 2347, + "al▁of": 2348, + "eph": 2349, + "▁subjects▁with": 2350, + "▁significant": 2351, + ".,▁et���al": 2352, + "▁regimen": 2353, + "refer": 2354, + "ugust": 2355, + "▁is▁not": 2356, + "HO": 2357, + "pert": 2358, + "median": 2359, + "blood▁": 2360, + "eral": 2361, + "y▁s": 2362, + "analys": 2363, + "▁cor": 2364, + "▁symptom": 2365, + "\n\nProtocol": 2366, + "during": 2367, + "mClone▁LLC": 2368, + ",▁as▁": 2369, + "Treatment": 2370, + "reast▁cancer": 2371, + "urpos": 2372, + "ysical▁": 2373, + "press": 2374, + "EGFR": 2375, + "Onc": 2376, + "........................................................": 2377, + "▁docetaxel": 2378, + "▁AND": 2379, + "ensitiv": 2380, + "ECOG": 2381, + "incip": 2382, + "growth▁factor": 2383, + "100": 2384, + "last": 2385, + "▁thes": 2386, + "objectiv": 2387, + "........................................................................................................": 2388, + "▁advanced▁": 2389, + "Clinical▁Study▁Protocol▁Drug▁Subst": 2390, + "fection": 2391, + "ics▁": 2392, + "olon": 2393, + "study▁drug": 2394, + "responsible▁for": 2395, + "▁Study▁Code▁D": 2396, + ");": 2397, + "less": 2398, + "itive▁": 2399, + "calcul": 2400, + "otential": 2401, + "\n\nx\n\nx": 2402, + "Ex": 2403, + ",▁W": 2404, + "util": 2405, + "isting": 2406, + "contact": 2407, + "\n\n13": 2408, + "▁when": 2409, + ",▁which": 2410, + "▁prior▁to": 2411, + "▁toler": 2412, + "ate▁th": 2413, + "e.▁": 2414, + "ration▁of": 2415, + "es▁to": 2416, + "▁serum": 2417, + "▁August": 2418, + "opp": 2419, + "ed▁to▁be▁": 2420, + "▁medical▁": 2421, + "struction": 2422, + "clear": 2423, + "▁mg/kg": 2424, + "efinition": 2425, + "-bas": 2426, + ":\n\n": 2427, + "ateri": 2428, + ".\n\n6": 2429, + "▁EGF": 2430, + "5-FU": 2431, + "RECIST": 2432, + "▁without": 2433, + "\n\n10": 2434, + "gressive▁": 2435, + "primary▁": 2436, + "iti": 2437, + "\n\nSection:": 2438, + "\n\nS▁I\n\nS▁I▁H▁T": 2439, + "ild-t": 2440, + "dependent": 2441, + "pe": 2442, + "e▁from": 2443, + "uring": 2444, + "▁contain": 2445, + "▁Clin▁Oncol": 2446, + "26": 2447, + "▁CA": 2448, + ".▁Ad": 2449, + "pothes": 2450, + "stitut": 2451, + "Consent": 2452, + "2)": 2453, + "C00": 2454, + "Pro": 2455, + "SI": 2456, + "prior": 2457, + "▁the▁following": 2458, + "▁pemetrex": 2459, + "respon": 2460, + "▁PD": 2461, + "used▁for": 2462, + "ance▁of": 2463, + "70": 2464, + ",▁if": 2465, + "contain": 2466, + "lood": 2467, + "enia": 2468, + "reduction": 2469, + "▁an▁": 2470, + "ing▁": 2471, + "ature": 2472, + ".▁L": 2473, + "arb": 2474, + "▁prior": 2475, + "▁or▁": 2476, + "▁condition": 2477, + "bov": 2478, + "defined▁as": 2479, + "ndpoint": 2480, + ".,▁et▁al.,▁": 2481, + "▁pres": 2482, + "▁system": 2483, + "▁Con": 2484, + "izer": 2485, + "▁ONC": 2486, + "e▁to▁be▁": 2487, + "▁time▁to": 2488, + "▁ONC.000−": 2489, + "red": 2490, + "▁sunitinib": 2491, + "e▁subject": 2492, + "▁Grade▁": 2493, + "report▁form": 2494, + "▁consent": 2495, + "▁period▁": 2496, + "▁term": 2497, + "withdraw": 2498, + "evaluation": 2499, + "▁model": 2500, + "29": 2501, + "\n\nt": 2502, + "ctor": 2503, + "\n\nAmended▁": 2504, + ".3.1": 2505, + "▁weeks▁": 2506, + "e/": 2507, + "eplac": 2508, + "er▁than": 2509, + "ason": 2510, + "▁they▁": 2511, + "her": 2512, + "▁1▁1": 2513, + "es▁or": 2514, + "ecaus": 2515, + "relation": 2516, + "agnos": 2517, + "501": 2518, + "PD": 2519, + "summar": 2520, + "itial": 2521, + "▁patients▁who": 2522, + "post": 2523, + "cretion": 2524, + "▁Ther": 2525, + "▁ABX-EGF": 2526, + "RP": 2527, + "mor": 2528, + "recommend": 2529, + "y▁(": 2530, + ",▁T": 2531, + "use▁of": 2532, + "▁accept": 2533, + "▁the▁date▁of": 2534, + "hyd": 2535, + "-5D": 2536, + "2-": 2537, + "5)": 2538, + "off": 2539, + "ed▁(": 2540, + "▁par": 2541, + "▁Patients▁": 2542, + "ourc": 2543, + "brax": 2544, + "Q-5D": 2545, + "ed▁treatment": 2546, + "▁benefit": 2547, + "▁11": 2548, + "ould": 2549, + "central▁": 2550, + "▁appropriate▁": 2551, + "urger": 2552, + "AN": 2553, + "Sci": 2554, + "fizer": 2555, + "▁acid": 2556, + "▁caus": 2557, + "▁CP": 2558, + "ilar": 2559, + "▁21": 2560, + "\n\n090177e18": 2561, + "46": 2562, + "aw": 2563, + "iev": 2564, + "\n\nth": 2565, + "emb": 2566, + "▁27": 2567, + "utrop": 2568, + "phosph": 2569, + "ound": 2570, + "echn": 2571, + "\n\n.▁T▁N▁E▁M▁U▁C▁O▁D": 2572, + ",▁K": 2573, + "imum": 2574, + "▁human": 2575, + "e▁than": 2576, + "▁either": 2577, + "monitor": 2578, + "reason": 2579, + "-C": 2580, + "bevacizumab": 2581, + "do": 2582, + "e▁f": 2583, + "urrent": 2584, + "clos": 2585, + "▁start": 2586, + "lock": 2587, + "onitoring": 2588, + "You": 2589, + "ier": 2590, + "measure": 2591, + "ational": 2592, + "▁record": 2593, + "jection": 2594, + "ated▁in": 2595, + "elay": 2596, + "fficacy▁An": 2597, + "▁April▁2008": 2598, + "401": 2599, + "ED": 2600, + "hav": 2601, + "emc": 2602, + "pared▁to": 2603, + "▁dat": 2604, + ".\n\nE": 2605, + "▁fail": 2606, + "avail": 2607, + "fidential▁": 2608, + "▁August▁2007": 2609, + "laboratory": 2610, + ",▁199": 2611, + "cond▁": 2612, + "▁No": 2613, + "▁3▁D": 2614, + "Trial▁Protocol:": 2615, + "▁Edition▁Number▁3▁D": 2616, + "Clinical▁Study▁Protocol▁Drug▁Substance▁": 2617, + "-fre": 2618, + "oint": 2619, + "−Jul": 2620, + "▁:": 2621, + "▁those▁": 2622, + "is▁a": 2623, + "−2014": 2624, + "▁Panitumumab▁Protocol▁Number:▁20050": 2625, + "▁Febru": 2626, + "−Jul−2014": 2627, + "oid": 2628, + "ised▁": 2629, + "regard": 2630, + "regulator": 2631, + "formed▁Consent": 2632, + "▁antic": 2633, + "▁its▁": 2634, + "enrollment": 2635, + "ATION": 2636, + "\n\nin": 2637, + "▁metastas": 2638, + "cidence▁of": 2639, + "ensor": 2640, + "vestigational▁": 2641, + "ability▁": 2642, + "cycl": 2643, + "−6": 2644, + ".▁1": 2645, + "incipal▁": 2646, + ").": 2647, + "e.▁The▁": 2648, + "ness": 2649, + "weight": 2650, + "\n\nm": 2651, + "This▁": 2652, + "cover": 2653, + "limit": 2654, + ",▁d": 2655, + ".\n\n5": 2656, + "imilar": 2657, + "▁further": 2658, + "\n\nAll": 2659, + "▁X▁X": 2660, + "Amgen": 2661, + "being": 2662, + "▁am": 2663, + "▁high": 2664, + "verall": 2665, + "▁norm": 2666, + "▁Med": 2667, + "ioSci": 2668, + "MENT": 2669, + "laboratory▁": 2670, + "vant": 2671, + ".▁G": 2672, + "agement": 2673, + "ize▁": 2674, + "Assessment": 2675, + "LY231514": 2676, + "UC": 2677, + "▁meet": 2678, + "▁Assessment": 2679, + "▁100": 2680, + "apec": 2681, + "▁procedure": 2682, + "aken": 2683, + "▁toxicity": 2684, + "▁of▁126": 2685, + "wer": 2686, + "ase▁report▁form": 2687, + "▁patients": 2688, + "occurr": 2689, + "hemat": 2690, + "▁days▁after": 2691, + "eplace:": 2692, + "alate▁": 2693, + "ett": 2694, + "ops": 2695, + "s▁in▁the▁": 2696, + "▁treated▁with": 2697, + "▁biomarker": 2698, + ".\n\nD": 2699, + "▁during▁the▁": 2700, + "oled": 2701, + "▁reaction": 2702, + "▁as▁a": 2703, + "ulti": 2704, + "egin": 2705, + "▁have▁been": 2706, + "MCL": 2707, + "possibl": 2708, + "ffic": 2709, + "▁total": 2710, + "representativ": 2711, + "ploratory▁": 2712, + "b)": 2713, + "rac": 2714, + "ature▁": 2715, + "anu": 2716, + "product": 2717, + "▁last": 2718, + "ate▁in": 2719, + "ostic": 2720, + "FACT-": 2721, + "RS": 2722, + ",▁F": 2723, + "etin": 2724, + "evant": 2725, + "ed▁in▁Section": 2726, + "ide▁effect": 2727, + "42": 2728, + "PR": 2729, + "▁amendment": 2730, + "elf": 2731, + "▁concentration": 2732, + "portant": 2733, + "aterial": 2734, + "e▁with": 2735, + "\n\na": 2736, + "raven": 2737, + "number▁of": 2738, + "▁2010": 2739, + "LN": 2740, + "\n\n.▁E▁S▁U": 2741, + "▁would▁": 2742, + "▁treatment▁group": 2743, + "ed▁to▁the▁": 2744, + "pared▁with": 2745, + "C0001": 2746, + "lif": 2747, + "orig": 2748, + "s▁must▁be▁": 2749, + ".\n\nIn": 2750, + "▁IMCL": 2751, + "hibitor": 2752, + "(f": 2753, + "For": 2754, + "ey": 2755, + "▁Phase▁": 2756, + "ological": 2757, + "CRC": 2758, + "small": 2759, + "ue▁to": 2760, + "ation,▁": 2761, + "▁(se": 2762, + "-label": 2763, + "symptom": 2764, + "▁ens": 2765, + "▁denosumab": 2766, + "adverse▁event": 2767, + "ance▁stat": 2768, + "vestigational": 2769, + "▁obtain": 2770, + "▁subsequent": 2771, + "comitant▁medication": 2772, + "cus": 2773, + "por": 2774, + "olum": 2775, + "ificance▁": 2776, + "serum": 2777, + "▁carcinoma": 2778, + "▁the▁time▁of": 2779, + "ype▁KRAS": 2780, + "zard▁ratio": 2781, + "▁IMCL▁CP": 2782, + "▁e▁": 2783, + "reaction": 2784, + "align": 2785, + "▁with▁the▁": 2786, + "merican": 2787, + "utropenia": 2788, + "ask": 2789, + "▁28": 2790, + "▁compl": 2791, + "▁dose▁level": 2792, + ".▁However": 2793, + "oledronic": 2794, + "3)": 2795, + "ss": 2796, + "rem": 2797, + "ing,▁": 2798, + "▁are▁not": 2799, + "ethod▁": 2800, + "▁have▁a": 2801, + "▁evaluation": 2802, + "e;": 2803, + "less▁": 2804, + "▁Criteria": 2805, + "▁(C": 2806, + "ire▁": 2807, + "quam": 2808, + "gan": 2809, + "gest": 2810, + "nel": 2811, + "▁er": 2812, + "▁Report": 2813, + ".▁In▁addition": 2814, + "ee▁": 2815, + "gl": 2816, + "necess": 2817, + "only": 2818, + "ison": 2819, + "ision": 2820, + "agent": 2821, + "pers": 2822, + "▁and\n\n": 2823, + ".2.3": 2824, + "49": 2825, + "between": 2826, + "▁scor": 2827, + "ime▁to": 2828, + "▁CONFIDENTIAL": 2829, + "▁reason": 2830, + "▁Nov": 2831, + "▁vari": 2832, + ".......▁": 2833, + "52": 2834, + "▁Approved▁by": 2835, + "▁investigator": 2836, + "plann": 2837, + "collection": 2838, + "▁design": 2839, + "mission": 2840, + "such▁as▁": 2841, + "%▁of": 2842, + "Endpoint": 2843, + "▁are": 2844, + "ed▁m": 2845, + ".▁199": 2846, + "istent": 2847, + ".4.1": 2848, + "\n\nImClone▁LLC": 2849, + "▁available▁": 2850, + "▁target▁lesion": 2851, + "standard▁": 2852, + "rogen": 2853, + "olid": 2854, + "whether": 2855, + "▁only": 2856, + "▁valu": 2857, + "▁expression": 2858, + "▁is▁a": 2859, + "has▁been": 2860, + "▁IMC-11F8": 2861, + "oper": 2862, + "\n\nPro": 2863, + "ency▁": 2864, + "ours": 2865, + "phase▁": 2866, + "▁0▁0▁2": 2867, + "▁additional": 2868, + "e.g": 2869, + "3\n\nA": 2870, + "gn": 2871, + "▁≥": 2872, + "▁tel": 2873, + "one▁s": 2874, + "▁a▁patient": 2875, + "▁population": 2876, + ".\n\n3": 2877, + "respectiv": 2878, + "\n\nSunitinib": 2879, + "▁the▁sponsor": 2880, + "pan": 2881, + "ors": 2882, + "ify▁": 2883, + "▁of▁each": 2884, + "▁throughout": 2885, + "dendum▁13": 2886, + "dict": 2887, + "ospitalization": 2888, + "pir": 2889, + "arch": 2890, + "▁breast▁cancer": 2891, + "▁1▁0": 2892, + "utant": 2893, + "examination": 2894, + "ital▁sign": 2895, + "▁CTCAE": 2896, + "069": 2897, + "evidence▁of": 2898, + "entral▁": 2899, + "itis▁": 2900, + "▁Arm▁A": 2901, + "braxis▁": 2902, + "e▁P": 2903, + "fort": 2904, + "▁Denosumab": 2905, + "app": 2906, + "ed▁into": 2907, + "strati": 2908, + "ibility": 2909, + "ographic": 2910, + "8480": 2911, + "(f)▁Clinical▁Protocol": 2912, + "%)": 2913, + "but": 2914, + "develop": 2915, + "ren": 2916, + "▁studies▁": 2917, + "▁.▁1": 2918, + "▁tem": 2919, + "▁treatment▁arm": 2920, + "ribut": 2921, + "requirement": 2922, + "regnancy": 2923, + "ET": 2924, + "▁d▁e▁v▁o▁r▁p▁p▁A": 2925, + "▁cisplatin": 2926, + "▁Subject": 2927, + "epar": 2928, + "▁the▁primary▁": 2929, + "65": 2930, + "eding": 2931, + "uring▁the▁": 2932, + "e▁tumor": 2933, + "▁2000": 2934, + "▁2005": 2935, + ".0▁Approved▁by": 2936, + "258": 2937, + "▁.▁1▁\\": 2938, + "3-": 2939, + "▁All": 2940, + "ultipl": 2941, + "ju": 2942, + "ates▁": 2943, + "ately": 2944, + "▁1▁6": 2945, + "▁Confidential": 2946, + "condition": 2947, + "▁has": 2948, + "▁interim": 2949, + "e,▁and▁": 2950, + "▁versus▁": 2951, + ".\n\n7": 2952, + "opt": 2953, + "▁conduct": 2954, + "▁50": 2955, + "aily▁": 2956, + "medical▁": 2957, + "▁person": 2958, + "▁April▁2008\n\nPage▁": 2959, + "60": 2960, + "Ph": 2961, + "s;": 2962, + "\n\nV": 2963, + "statist": 2964, + "▁the▁f": 2965, + "ed▁Version": 2966, + "esign": 2967, + "appropriate▁": 2968, + "-line▁treatment": 2969, + "▁\\▁d▁e▁v▁o▁r▁p▁p▁A": 2970, + "▁0▁0▁2▁-": 2971, + "AT": 2972, + "▁trial▁": 2973, + "ion▁of▁the▁": 2974, + "ited▁": 2975, + "▁practic": 2976, + "▁bi": 2977, + "olec": 2978, + "▁If": 2979, + "▁0▁1▁0": 2980, + "▁therap": 2981, + "CTCAE": 2982, + "▁0▁0▁0▁0": 2983, + "otential▁": 2984, + "Adverse▁Event": 2985, + ")\n\nGEL▁Version▁ID:▁ONC.000−": 2986, + "▁0▁0▁0▁0▁0▁1▁0": 2987, + "i.": 2988, + "▁app": 2989, + "edact": 2990, + "▁power": 2991, + "▁schedul": 2992, + "ocyt": 2993, + "used▁in": 2994, + "opy▁of": 2995, + "▁consider": 2996, + "edacted▁Version": 2997, + "32": 2998, + "6258": 2999, + "cas": 3000, + "ord": 3001, + "........................................": 3002, + "protein": 3003, + "▁En": 3004, + "▁product": 3005, + "▁MRI": 3006, + "MGEN": 3007, + "▁randomized▁": 3008, + "▁Edition▁Number▁3▁Date▁": 3009, + "/d": 3010, + "UN": 3011, + "sit": 3012, + "year": 3013, + "▁tumour": 3014, + "ing▁on": 3015, + "une▁": 3016, + ".▁It": 3017, + "ood▁": 3018, + "atch": 3019, + "ed,": 3020, + "▁colon": 3021, + "▁skin": 3022, + "oubl": 3023, + "▁conf": 3024, + "ound▁": 3025, + "▁can▁be▁": 3026, + "▁A\n\nF▁O\n\nY▁P▁O▁C": 3027, + "Pl": 3028, + "jor": 3029, + ",▁m": 3030, + ",▁you": 3031, + "ing▁to▁the▁": 3032, + "▁Ex": 3033, + "therapy▁": 3034, + "▁FOLFOX": 3035, + "RP6258": 3036, + "34": 3037, + "inf": 3038, + "\n\n\\": 3039, + "▁informed▁consent": 3040, + "up▁to": 3041, + "▁risk": 3042, + "prof": 3043, + "efficacy": 3044, + "oxaliplatin": 3045, + "open-label": 3046, + "▁\\▁d▁e▁v▁o▁r▁p▁p▁A\n\n\\": 3047, + "ern": 3048, + ",▁N": 3049, + "ing▁of▁the▁": 3050, + "asod": 3051, + "▁was": 3052, + "▁Efficacy▁An": 3053, + "adi": 3054, + ".3.2": 3055, + "teb": 3056, + "inding": 3057, + "▁accordance▁with": 3058, + "MR": 3059, + "non": 3060, + "▁lif": 3061, + "other▁than": 3062, + "e▁sampl": 3063, + ".0▁Approved▁by\n\nApproved\n\nDate▁Printed:": 3064, + ")▁in": 3065, + "H3E-MC-JM": 3066, + "ZER": 3067, + "ey▁": 3068, + "fa": 3069, + "variabl": 3070, + "▁": 3071, + "on▁the▁": 3072, + "of▁the▁": 3073, + "oler": 3074, + "▁25": 3075, + "▁only▁": 3076, + "▁the▁data": 3077, + "▁appropri": 3078, + "FIZER": 3079, + "leucovorin": 3080, + "discontinuation": 3081, + "▁CONFIDENTIAL▁Page▁": 3082, + "FIZER▁CONFIDENTIAL▁Page▁": 3083, + "IEC": 3084, + "pain": 3085, + "roun": 3086, + "etail": 3087, + "▁CV": 3088, + "▁PRO": 3089, + "experienc": 3090, + "epo": 3091, + "ausea": 3092, + "\n\nH3E-MC-JM": 3093, + "asodex": 3094, + "vitamin▁D": 3095, + "atur": 3096, + "ival": 3097, + "▁PR": 3098, + "▁indic": 3099, + "▁doctor": 3100, + "eview": 3101, + "ificance▁level": 3102, + ",▁with": 3103, + "▁the▁trial": 3104, + "▁medical": 3105, + "1B": 3106, + "rin": 3107, + "▁marker": 3108, + "ourn": 3109, + "▁Grade▁3": 3110, + "RIO": 3111, + "▁November": 3112, + "2▁(": 3113, + ":5": 3114, + "▁ident": 3115, + "it▁is▁": 3116, + "▁3.0": 3117, + "With:": 3118, + "▁performance▁stat": 3119, + "epoetin": 3120, + "87": 3121, + "HD": 3122, + "rang": 3123, + "s,▁and": 3124, + "e▁will▁be▁": 3125, + "in-": 3126, + "s▁were▁": 3127, + "arboplatin": 3128, + "▁but": 3129, + "ecom": 3130, + "opy▁": 3131, + "controll": 3132, + "ITT": 3133, + "▁clinical▁trial": 3134, + ".▁J▁Clin▁Oncol": 3135, + "lik": 3136, + "\n\n090177e18069": 3137, + "juvant": 3138, + "target▁lesion": 3139, + "\n\nd": 3140, + "ed▁using": 3141, + "▁cut": 3142, + "▁Safety▁": 3143, + "▁2004": 3144, + "▁May▁": 3145, + "▁vitamin▁D": 3146, + "▁prostate▁cancer": 3147, + "mong": 3148, + ").▁The▁": 3149, + "-D": 3150, + "-day▁": 3151, + "37": 3152, + "BI-007": 3153, + "UD": 3154, + "zoledronic": 3155, + "for▁the▁": 3156, + ".\n\nB": 3157, + "emist": 3158, + "used▁": 3159, + "combin": 3160, + "achment": 3161, + ",▁but": 3162, + "-month": 3163, + "▁Denosumab▁Protocol▁Number:▁200": 3164, + "AR": 3165, + "▁a▁p": 3166, + "omit": 3167, + "00▁mg/m2": 3168, + "▁alfa": 3169, + "Appendix": 3170, + "CC": 3171, + "e,▁the▁": 3172, + "ok": 3173, + "s▁may▁be▁": 3174, + "analyz": 3175, + "ministration": 3176, + "▁Janu": 3177, + "▁such": 3178, + "ttachment": 3179, + "217": 3180, + "met": 3181, + "previ": 3182, + "▁man": 3183, + "chest": 3184, + "▁protein": 3185, + "andard": 3186, + "▁Protocol▁Number:▁200401": 3187, + "NCI": 3188, + "▁improv": 3189, + "▁AMG▁162▁Protocol▁Number:▁200401": 3190, + "cription": 3191, + "130": 3192, + "FOLFOX": 3193, + "T-": 3194, + "censor": 3195, + "eut": 3196, + "jud": 3197, + "ror": 3198, + "...▁": 3199, + "▁(S": 3200, + "▁(or": 3201, + "▁26": 3202, + "\n\nAMGEN": 3203, + "opos": 3204, + "▁treatment▁with": 3205, + ".1.2": 3206, + ".0\n\nApproved\n\nDate▁Printed:": 3207, + "radiation": 3208, + "considered▁": 3209, + "upportive▁": 3210, + "arbepoetin": 3211, + "Grade▁": 3212, + "high": 3213, + "ie,▁": 3214, + "population": 3215, + "▁typ": 3216, + "ate\n\n": 3217, + "▁due▁to": 3218, + "▁order": 3219, + "astin": 3220, + "▁carboplatin": 3221, + "▁include▁": 3222, + "performed": 3223, + "▁detail": 3224, + "▁previous▁": 3225, + ")▁(cid:": 3226, + "1121B": 3227, + "treat": 3228, + "ing▁p": 3229, + "▁mic": 3230, + "accept": 3231, + "Ther": 3232, + "▁alon": 3233, + "▁compli": 3234, + "▁given": 3235, + "iderm": 3236, + "ified▁": 3237, + "▁subjects▁who": 3238, + "▁local": 3239, + "ibility▁": 3240, + ",▁all": 3241, + "red▁": 3242, + "alg": 3243, + "ion▁of": 3244, + ".\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:": 3245, + "compar": 3246, + "aintain": 3247, + "genetic": 3248, + "clinically▁": 3249, + "▁Response▁": 3250, + "relationship": 3251, + "fficient": 3252, + "o-": 3253, + "▁>": 3254, + "▁a▁l": 3255, + ",▁E": 3256, + "igu": 3257, + "▁oxaliplatin": 3258, + "▁the▁dis": 3259, + "baseline▁": 3260, + "guidelin": 3261, + "skin": 3262, + "remain": 3263, + "▁supplement": 3264, + "maintain": 3265, + "▁collect": 3266, + "ficial▁": 3267, + "(b)": 3268, + "98": 3269, + "increas": 3270, + "is▁of": 3271, + "resolv": 3272, + "▁Cycle▁": 3273, + "e▁should▁be▁": 3274, + "pharmac": 3275, + "s▁includ": 3276, + "▁aff": 3277, + "▁whether": 3278, + "\n\n2\n\n3": 3279, + "▁minutes": 3280, + "▁applicabl": 3281, + "-based▁": 3282, + "Oak": 3283, + "aplan": 3284, + "cru": 3285, + "eier": 3286, + "ner": 3287, + "rup": 3288, + "repe": 3289, + "immedi": 3290, + "ure▁that": 3291, + "▁PSA": 3292, + "where▁": 3293, + "ethyl": 3294, + "ousand▁": 3295, + "ribution": 3296, + "17:": 3297, + "▁objective▁": 3298, + "indicated": 3299, + "at▁the▁": 3300, + "linded▁": 3301, + "▁does▁not": 3302, + "▁October▁2006": 3303, + "Aug": 3304, + "Follow": 3305, + ".▁W": 3306, + ".\n\n2": 3307, + "procedures": 3308, + "▁fl": 3309, + "imension": 3310, + "ZD217": 3311, + "▁more▁than": 3312, + "oxicity▁": 3313, + "arbepoetin▁alfa": 3314, + "8\n\nPage▁": 3315, + "Product": 3316, + "put": 3317, + "wis": 3318, + "infusion": 3319, + "its▁": 3320, + "ing▁in": 3321, + "es▁will": 3322, + "▁Sep": 3323, + "▁Dose▁": 3324, + "▁one▁": 3325, + "▁abnormal": 3326, + "eligibl": 3327, + "UDY": 3328, + "2:": 3329, + "94": 3330, + "Sponsor": 3331, + "function": 3332, + "safety▁": 3333, + "asma": 3334, + "▁day▁": 3335, + "▁limit": 3336, + "option": 3337, + "alysis": 3338, + "012": 3339, + "▁experienc": 3340, + "ousand▁Oak": 3341, + ",▁an": 3342, + "air": 3343, + "dec": 3344, + "ead": 3345, + "ermin": 3346, + "staff": 3347, + "▁before▁": 3348, + "addition": 3349, + "adjust": 3350, + "need": 3351, + "agnes": 3352, + "▁individual": 3353, + "▁taken": 3354, + "▁local▁": 3355, + "/T": 3356, + "31": 3357, + ",▁c": 3358, + "roch": 3359, + "▁bod": 3360, + "second": 3361, + "272": 3362, + "ysical▁examination": 3363, + "idermal▁": 3364, + "-ra": 3365, + "Evalu": 3366, + "Med": 3367, + "metastas": 3368, + "measurable▁": 3369, + "es▁that": 3370, + "es▁from": 3371, + "istic": 3372, + "▁of▁6": 3373, + "DA": 3374, + "Group": 3375, + "−Aug": 3376, + "▁“": 3377, + "▁function": 3378, + "odium": 3379, + "erior": 3380, + "curr": 3381, + "▁2007▁17:": 3382, + "▁13−Aug": 3383, + "36.4": 3384, + "cess▁to": 3385, + "model": 3386, + "▁different": 3387, + "\n\n13▁Sep": 3388, + "−636.4": 3389, + "17:03": 3390, + "272−636.4": 3391, + "▁2007▁17:17:03": 3392, + "▁13−Aug−201": 3393, + "\n\n13▁Sep▁2007▁17:17:03": 3394, + "90": 3395, + "95%": 3396, + "direct": 3397, + "hel": 3398, + "roph": 3399, + "▁cediranib": 3400, + "▁been": 3401, + "▁screening": 3402, + "plus▁": 3403, + "emerg": 3404, + "agraph": 3405, + "▁physician": 3406, + "................................................................................................................": 3407, + "▁take▁": 3408, + "\n\nConfidential\n\nAMGEN": 3409, + "apecitabine▁": 3410, + "▁May▁200": 3411, + "fter": 3412, + "sol": 3413, + "▁target": 3414, + ",▁J": 3415, + "▁To": 3416, + "▁grade▁": 3417, + "ological▁": 3418, + "▁June▁": 3419, + "▁days▁": 3420, + "Stat": 3421, + "▁et▁al.▁200": 3422, + "electronic": 3423, + "▁teleph": 3424, + "▁January▁200": 3425, + "EQ-5D": 3426, + "itis": 3427, + "rout": 3428, + "ations▁": 3429, + "▁demonstr": 3430, + "ock": 3431, + "ula": 3432, + "▁Table▁": 3433, + "otherapy": 3434, + "oglo": 3435, + "e▁the▁s": 3436, + "▁any▁other": 3437, + "CTG": 3438, + "▁detect": 3439, + "personnel": 3440, + "quamous▁": 3441, + "IM": 3442, + "cum": 3443, + "de": 3444, + "lor": 3445, + "list": 3446, + "primary": 3447, + "s▁a": 3448, + "ed.▁The▁": 3449, + "even": 3450, + "rain": 3451, + "otic": 3452, + "\n\nNo": 3453, + "health": 3454, + "249": 3455, + "▁up▁to": 3456, + "lat": 3457, + "s/": 3458, + "▁known": 3459, + "ed)": 3460, + "ation▁in": 3461, + "old": 3462, + "urin": 3463, + "\n\nAmgen": 3464, + "allow": 3465, + "▁are▁s": 3466, + "▁For": 3467, + "tudy": 3468, + "▁4▁week": 3469, + "ed▁by▁the▁investigator": 3470, + "▁again": 3471, + "ein": 3472, + ".\n\nN": 3473, + "ment▁of": 3474, + "evised▁": 3475, + "uggest": 3476, + "▁the▁safety▁": 3477, + "▁onc": 3478, + "▁chest": 3479, + "▁6▁month": 3480, + "equate▁": 3481, + "▁December": 3482, + "HA": 3483, + "low": 3484, + "▁u": 3485, + "▁en": 3486, + "read": 3487, + "reduc": 3488, + "▁my▁": 3489, + "▁Patient": 3490, + "ily▁": 3491, + "age": 3492, + "▁NC": 3493, + "▁days▁prior▁to": 3494, + "care▁": 3495, + "interim": 3496, + "normal▁": 3497, + "stitutional▁": 3498, + "\n\nD▁E▁T▁N▁I▁R▁P\n\nA": 3499, + "echniqu": 3500, + "101": 3501, + "lig": 3502, + "sk": 3503, + "▁paclitaxel": 3504, + "reported▁": 3505, + "evaluated▁": 3506, + "▁109": 3507, + "\n\nTable▁": 3508, + "ability▁of": 3509, + "▁minimum": 3510, + "4320": 3511, + "summariz": 3512, + "vestigational▁Product": 3513, + "one▁scan": 3514, + "▁temper": 3515, + "▁Efficacy▁Analysis▁Set": 3516, + "ivalent": 3517, + "onal": 3518, + "▁(P": 3519, + "▁reduc": 3520, + "▁NSCLC": 3521, + "control": 3522, + ".▁At": 3523, + "relevant": 3524, + "▁diameter": 3525, + "▁the▁treatment▁of": 3526, + "ourse▁of": 3527, + "Ob": 3528, + "Report": 3529, + "Tumor": 3530, + "rincipal▁": 3531, + "uro": 3532, + ",▁h": 3533, + "▁and▁D": 3534, + "▁(m": 3535, + "▁alone▁": 3536, + "requir": 3537, + "▁analysis▁will▁be▁": 3538, + "efore▁the▁": 3539, + "blem": 3540, + "\n\nS▁T▁I\n\nK▁C▁E▁H▁C": 3541, + "emcitabine▁": 3542, + "oglobin": 3543, + "d:": 3544, + "scal": 3545, + "ually▁": 3546, + "vastin": 3547, + "ate,▁": 3548, + "ed▁until": 3549, + ".▁5": 3550, + "\n\nCom": 3551, + "s▁should▁": 3552, + "▁discontinuation": 3553, + "EF": 3554, + "sent": 3555, + ".▁Wh": 3556, + "▁DNA": 3557, + "40249": 3558, + "▁more▁": 3559, + "▁termin": 3560, + "ild-type▁KRAS": 3561, + "NSCLC": 3562, + "aximum": 3563, + "ires": 3564, + "should▁": 3565, + "es▁are▁": 3566, + "idence▁in": 3567, + "reatening": 3568, + "terval": 3569, + "▁randomis": 3570, + "ity▁to": 3571, + "ultic": 3572, + "▁from▁the▁": 3573, + "period": 3574, + "▁immedi": 3575, + "emetrexed▁H3E-MC-JM": 3576, + "3\n\nApproved▁by": 3577, + "▁13−Aug−2013\n\nApproved▁by": 3578, + "),": 3579, + ".▁On": 3580, + "▁procedures": 3581, + "early▁": 3582, + "▁FOLFIRI": 3583, + "0147": 3584, + "ega": 3585, + "-free▁s": 3586, + "(S": 3587, + "criteria": 3588, + "ning": 3589, + "es▁the▁": 3590, + "important": 3591, + "(cid:13": 3592, + "can▁be▁": 3593, + "lead": 3594, + "▁Thousand▁Oak": 3595, + "▁cell▁lung▁cancer": 3596, + "▁decreas": 3597, + "histor": 3598, + "sing": 3599, + "order": 3600, + ".▁V": 3601, + "ed▁according▁to": 3602, + "▁mon": 3603, + "▁method": 3604, + "medical": 3605, + "▁additional▁": 3606, + "erious▁Adverse▁Event": 3607, + "metastatic": 3608, + "return": 3609, + "efer": 3610, + "▁of▁0": 3611, + "activ": 3612, + "▁guidelin": 3613, + "▁standard▁": 3614, + "ifferent": 3615, + "▁provide▁": 3616, + "ublication": 3617, + "utant▁KRAS": 3618, + "8480C0001": 3619, + "▁13−Aug−2013\n\nApproved▁by\n\n13▁Sep▁2007▁17:17:03": 3620, + "),▁and▁": 3621, + "▁k": 3622, + "\n\nW": 3623, + "ased▁on": 3624, + "without": 3625, + "common": 3626, + "▁60": 3627, + "Protocol▁A618": 3628, + "▁participate▁in": 3629, + "▁determine▁": 3630, + "\n\nProtocol▁Amendment": 3631, + ")▁for": 3632, + "-study▁": 3633, + "/IRB": 3634, + "BioSci": 3635, + "ik": 3636, + "s.▁A": 3637, + "schedul": 3638, + "▁studies": 3639, + "▁post": 3640, + "▁current": 3641, + "▁women": 3642, + "▁and▁d": 3643, + "cedure▁": 3644, + "subjects▁": 3645, + "▁30−Jul−2014": 3646, + "▁applicable▁": 3647, + "measured▁": 3648, + "braxis▁BioSci": 3649, + "▁CV.000−": 3650, + "alges": 3651, + "(b)▁Confidential": 3652, + ",000": 3653, + "Schedul": 3654, + "Up": 3655, + "▁questionna": 3656, + "\n\nb": 3657, + "\n\n(cid:120)": 3658, + "▁Co": 3659, + "▁Per": 3660, + "exam": 3661, + "▁ULN": 3662, + "▁XRP6258": 3663, + "risk▁of": 3664, + "▁CRF": 3665, + "▁possibl": 3666, + "272−636.4.0\n\nApproved\n\nDate▁Printed:": 3667, + "89": 3668, + ",▁O": 3669, + ".\n\nR": 3670, + "▁involv": 3671, + "▁Casodex": 3672, + "ection▁of": 3673, + "both": 3674, + "▁expos": 3675, + "hemist": 3676, + "itabin": 3677, + "-2007": 3678, + "ZD4054▁Study▁Code▁D": 3679, + "Clinical▁Study▁Protocol▁Drug▁Substance▁ZD4054▁Study▁Code▁D": 3680, + "gnostic": 3681, + "tebral▁": 3682, + "eutic": 3683, + "evised▁Clinical▁Study▁Protocol▁Drug▁Substance▁ZD4054▁Study▁Code▁D": 3684, + "▁Thousand▁Oaks": 3685, + "evised▁Clinical▁Study▁Protocol▁Drug▁Substance▁ZD4054▁Study▁Code▁D4320": 3686, + "EP": 3687, + "ently▁": 3688, + "▁creatinine▁": 3689, + "ing▁or": 3690, + "▁and▁in": 3691, + "establ": 3692, + "▁cycle▁": 3693, + "formed▁consent▁form": 3694, + "▁the▁subject’s▁": 3695, + "calculated▁": 3696, + "-2": 3697, + "LD": 3698, + "Mod": 3699, + "rect": 3700, + "urine▁": 3701, + "osis": 3702, + "▁remain": 3703, + "▁leg": 3704, + "extension": 3705, + "e,▁or": 3706, + "▁will▁not▁be▁": 3707, + "e▁data": 3708, + "▁equ": 3709, + "▁954": 3710, + "MG▁954": 3711, + "regnant": 3712, + "8480C00013": 3713, + "establish": 3714, + "7▁August▁2007": 3715, + ".\n\n9": 3716, + ".\n\nIf": 3717, + "utcom": 3718, + "therapy": 3719, + "pertension": 3720, + "\n\nSt": 3721, + "▁exampl": 3722, + "ECG": 3723, + "▁median": 3724, + "203": 3725, + "\n\nReplace:": 3726, + "cript": 3727, + ")\n\nGEL▁Version▁ID:▁CV.000−": 3728, + "▁assignment": 3729, + "▁longer": 3730, + "cut": 3731, + "g/m": 3732, + "work": 3733, + "written": 3734, + "\n\nIf": 3735, + "etter": 3736, + "est▁diameter": 3737, + "andl": 3738, + "\n\n1\n\n2\n\n3": 3739, + "▁of▁10": 3740, + "CT▁scan": 3741, + "articular": 3742, + "▁status": 3743, + "▁against": 3744, + "ulticenter": 3745, + "bum": 3746, + "econd▁": 3747, + "log": 3748, + "▁date▁": 3749, + ".\n\n8": 3750, + "otal▁": 3751, + "▁EC": 3752, + "▁31": 3753, + ".▁These▁": 3754, + "pective▁": 3755, + "▁abd": 3756, + "perience▁": 3757, + "assign": 3758, + "hazard▁ratio": 3759, + "CP": 3760, + "best": 3761, + "val▁": 3762, + "▁a▁subject": 3763, + "▁throm": 3764, + "▁the▁protocol": 3765, + "exclud": 3766, + "▁Malate▁": 3767, + "▁growth": 3768, + "▁Lesion": 3769, + "xicity▁": 3770, + "▁JM": 3771, + "clinic": 3772, + ".▁Con": 3773, + "▁significance▁level": 3774, + "rank": 3775, + "▁Study▁D": 3776, + "▁according▁to▁the▁": 3777, + "▁(AMG▁954": 3778, + "▁approval": 3779, + "▁availabl": 3780, + "\n\nE▁R▁O▁F▁E▁B\n\nY▁T▁I▁D▁I▁L▁A▁V": 3781, + "growth▁factor▁receptor": 3782, + "▁the▁discretion": 3783, + "272−636.4.0\n\nApproved\n\nDate▁Printed:▁13−Aug−2013\n\nApproved▁by\n\n13▁Sep▁2007▁17:17:03": 3784, + "Review": 3785, + "test": 3786, + "orl": 3787, + ",▁patients▁": 3788, + "thics▁": 3789, + ".\n\n10": 3790, + "▁PAN": 3791, + "ema": 3792, + "\n\nABI-007": 3793, + "ence,▁": 3794, + "▁with▁a": 3795, + "▁the▁investigational▁product": 3796, + "s.▁In": 3797, + "ously": 3798, + "ERS": 3799, + "ransfer": 3800, + "approximately▁": 3801, + "ITUM": 3802, + "AB▁(AMG▁954": 3803, + "UMAB▁(AMG▁954": 3804, + "50181": 3805, + "▁PANITUM": 3806, + ")▁Protocol▁Number:▁200": 3807, + ",▁w": 3808, + "▁prof": 3809, + "otal": 3810, + "\n\nSubject": 3811, + "▁the▁primary": 3812, + "▁Date:▁07▁August▁2007": 3813, + "▁January▁2009": 3814, + "40249▁Date:▁07▁August▁2007": 3815, + "▁30−Jul−2014\n\nS": 3816, + "UMAB▁(AMG▁954)▁Protocol▁Number:▁200": 3817, + "▁PANITUMUMAB▁(AMG▁954)▁Protocol▁Number:▁200": 3818, + "▁PANITUMUMAB▁(AMG▁954)▁Protocol▁Number:▁20040249▁Date:▁07▁August▁2007": 3819, + "-in": 3820, + "6▁month": 3821, + "LIN": 3822, + "OT": 3823, + "eafter": 3824, + "less▁of": 3825, + "specific": 3826, + "▁solution": 3827, + "ubin": 3828, + "▁full": 3829, + "ponent": 3830, + "▁metastatic▁colorectal▁cancer": 3831, + "▁the▁last▁dose▁of": 3832, + "▁the▁same▁": 3833, + "▁irinotecan": 3834, + "alt": 3835, + "is▁to": 3836, + "istribution": 3837, + "s,▁or": 3838, + "outlin": 3839, + "ase▁(": 3840, + "▁Inc": 3841, + "▁assess▁": 3842, + "persensitiv": 3843, + "respectively": 3844, + "stratifi": 3845, + "ially▁": 3846, + "▁tabl": 3847, + "ed▁if": 3848, + "▁official▁": 3849, + "▁SD": 3850, + "▁Lill": 3851, + "▁character": 3852, + "ology,▁": 3853, + "e▁document": 3854, + ".▁Patient": 3855, + "see▁": 3856, + "▁control": 3857, + ".▁No": 3858, + "rict": 3859, + "EX": 3860, + "MRI": 3861, + "mean": 3862, + "tic": 3863, + "▁ZD4054": 3864, + ".....▁": 3865, + "es:": 3866, + "▁in▁patients▁with": 3867, + "ubsequent": 3868, + "▁or▁4": 3869, + "existing": 3870, + ".▁To": 3871, + "▁taking": 3872, + "ummary▁": 3873, + "▁blood▁sampl": 3874, + "▁Date:▁04": 3875, + "▁Panitumumab▁Protocol▁Number:▁20050181": 3876, + "AC": 3877, + "XOL": 3878, + "frequ": 3879, + "nd▁of": 3880, + "neck": 3881, + "ing▁for": 3882, + "▁section": 3883, + "emor": 3884, + "ulmon": 3885, + "astro": 3886, + "2004": 3887, + "▁the▁sampl": 3888, + "▁plat": 3889, + "submitt": 3890, + "\n\nC▁I▁N▁O▁R▁T▁C▁E▁L▁E\n\nN": 3891, + "▁Therapy▁": 3892, + "original": 3893, + "▁appear": 3894, + ",▁the▁investigator": 3895, + "4▁week": 3896, + "IMC-": 3897, + "s▁as▁": 3898, + "stopp": 3899, + "ane": 3900, + "ed.": 3901, + "\n\nPh": 3902, + "▁adverse▁": 3903, + "▁Rec": 3904, + "while▁": 3905, + "e▁blood▁": 3906, + "▁February▁200": 3907, + "▁normal": 3908, + "\n\nConfidential\n\nAMGEN\n\nProduct:": 3909, + "culation": 3910, + "gram": 3911, + "lid": 3912, + "mph": 3913, + "taken": 3914, + "us▁(": 3915, + "▁qual": 3916, + "▁an▁in": 3917, + "▁pemetrexed▁": 3918, + "▁wors": 3919, + "old▁": 3920, + "▁compared▁to": 3921, + "▁on▁the▁": 3922, + "▁6▁0▁0▁0▁0���0▁1▁0": 3923, + "platelet": 3924, + ".4.2": 3925, + "via": 3926, + "▁Date:▁21": 3927, + "▁complete▁": 3928, + "ogenic": 3929, + "▁any▁tim": 3930, + "IVRS": 3931, + "ed▁abov": 3932, + "________________": 3933, + "ed▁copy▁": 3934, + "is▁not▁official▁": 3935, + "▁Panitumumab▁Protocol▁Number:▁20050203": 3936, + "▁Date:▁21▁January▁2009": 3937, + "ed▁copy▁is▁not▁official▁": 3938, + "▁Panitumumab▁Protocol▁Number:▁20050203▁Date:▁21▁January▁2009": 3939, + "ed▁copy▁is▁not▁official▁record": 3940, + "L/": 3941, + "▁........................................................................................": 3942, + "▁path": 3943, + "▁CI": 3944, + "▁(cid:": 3945, + "ed▁in▁a": 3946, + "ardiov": 3947, + "▁based▁on": 3948, + "braxis▁BioScience▁": 3949, + "pany▁": 3950, + "sp": 3951, + "▁end": 3952, + "▁thir": 3953, + "procedure": 3954, + "▁(R": 3955, + "▁non": 3956, + "▁the▁sit": 3957, + "objective▁": 3958, + "▁plann": 3959, + "request": 3960, + "▁pre-": 3961, + "regnancy▁test": 3962, + ".0▁Approved▁by\n\nApproved\n\nDate▁Printed:▁30−Jul−2014\n\nS": 3963, + "judg": 3964, + "▁telephone▁": 3965, + "algesic": 3966, + "75": 3967, + "Phase▁": 3968, + "benefit": 3969, + "great": 3970, + "rh": 3971, + "s▁the▁": 3972, + "▁≤": 3973, + "▁among": 3974, + "eriv": 3975, + "re-": 3976, + "stim": 3977, + ".▁You": 3978, + "▁AstraZeneca": 3979, + "▁necess": 3980, + "▁add": 3981, + "ovari": 3982, + "results▁of": 3983, + "▁diagnos": 3984, + "randomized▁to": 3985, + "modification": 3986, + "-sid": 3987, + "solut": 3988, + "IS": 3989, + "ood": 3990, + "s▁ar": 3991, + ",▁including": 3992, + ".▁(": 3993, + "▁represent": 3994, + "with▁the▁": 3995, + "aps": 3996, + "▁or▁MRI": 3997, + "term": 3998, + "atory▁": 3999, + "▁and▁a": 4000, + "▁March": 4001, + "\n\nCONFIDENTIAL": 4002, + "ays▁": 4003, + "▁Investigator": 4004, + ".▁Ex": 4005, + ".▁Cancer": 4006, + "urvival▁(": 4007, + "▁acceptable▁": 4008, + "▁PANITUMUMAB▁(AMG▁954)▁Protocol▁Number:▁20040249▁Date:▁07▁August▁2007\n\nPage▁": 4009, + "SF": 4010, + "leas": 4011, + "rCl": 4012, + "▁efficacy▁": 4013, + "▁men": 4014, + "▁may": 4015, + "impl": 4016, + "▁nod": 4017, + "gener": 4018, + "\n\nEx": 4019, + "atistical▁": 4020, + "going": 4021, + "ingle▁": 4022, + ",▁then": 4023, + "grad": 4024, + "ww": 4025, + "ert": 4026, + "ality": 4027, + "ed▁the▁": 4028, + "▁(T": 4029, + "▁reduction": 4030, + "▁of▁your": 4031, + "▁of▁the▁study": 4032, + "▁Follow": 4033, + ".▁The▁investigator": 4034, + "xicity": 4035, + ",▁and▁the▁": 4036, + "perior": 4037, + "required": 4038, + "▁clinically▁": 4039, + "▁Clinical▁Trial▁Protocol:": 4040, + "▁Research": 4041, + "▁version": 4042, + "PAND": 4043, + "\n\nSunitinib▁Malate▁": 4044, + "▁confidence▁in": 4045, + "rophil": 4046, + "▁Clinical▁Trial▁Protocol:▁CA": 4047, + ":▁1": 4048, + "UR": 4049, + "e.▁If": 4050, + "los": 4051, + "next": 4052, + "oy": 4053, + "atas": 4054, + "eng": 4055, + "ation▁or": 4056, + "▁met": 4057, + ".\n\nWh": 4058, + "▁will▁be▁administer": 4059, + "▁vs▁": 4060, + "ensive▁": 4061, + "▁using": 4062, + "▁the▁patient’s▁": 4063, + "hypothes": 4064, + "othel": 4065, + "-line▁": 4066, + "available▁": 4067, + "-week": 4068, + "2▁week": 4069, + "44": 4070, + "TUDY": 4071, + "dn": 4072, + "delay": 4073, + "fat": 4074, + "right": 4075, + "\n\nto": 4076, + "▁another": 4077, + "▁malign": 4078, + "▁and▁other": 4079, + "imin": 4080, + "▁IN": 4081, + "upon": 4082, + "e▁siz": 4083, + "lob": 4084, + "related▁": 4085, + "lymph": 4086, + "▁contact": 4087, + "▁regard": 4088, + "Oncology▁": 4089, + "containing": 4090, + "omiting": 4091, + "72": 4092, + "88": 4093, + "91": 4094, + "CH": 4095, + "PRO": 4096, + "lot": 4097, + "nausea": 4098, + "site▁": 4099, + "vial": 4100, + "\n\nU": 4101, + "aline▁": 4102, + "al▁or": 4103, + "▁Data": 4104, + "expos": 4105, + "Inc": 4106, + "▁analyses": 4107, + ".5.1": 4108, + "▁ext": 4109, + "▁assessment▁of": 4110, + "heart": 4111, + "\n\nTo": 4112, + "▁participant": 4113, + "▁Date:▁04▁April▁2008\n\nPage▁": 4114, + "▁Panitumumab▁Protocol▁Number:▁20050203▁Date:▁21▁January▁2009\n\nPage▁": 4115, + "-1": 4116, + "Data": 4117, + "XPAND": 4118, + "cetuximab": 4119, + "oag": 4120, + "sid": 4121, + "s),▁": 4122, + "was": 4123, + "stanc": 4124, + "▁surger": 4125, + ".\n\nY": 4126, + "uly▁": 4127, + "confidential▁": 4128, + "\n\nAbraxis▁BioScience▁": 4129, + "dose▁of": 4130, + "▁of▁127": 4131, + "disease▁progression": 4132, + "maximum": 4133, + "(b)▁Confidential\n\nProtocol▁Amendment": 4134, + "74": 4135, + "JEC": 4136, + "opl": 4137, + "sence▁of": 4138, + "is/": 4139, + "▁written": 4140, + "▁2.0": 4141, + "used": 4142, + "▁ha": 4143, + "vert": 4144, + "▁vs.▁": 4145, + ".▁Subject": 4146, + "106": 4147, + "▁regulator": 4148, + "equire": 4149, + "-Meier": 4150, + "aplan-Meier": 4151, + "ardiovascular": 4152, + "1.5": 4153, + "uch": 4154, + "▁question": 4155, + "s▁may▁": 4156, + "ed▁tumor": 4157, + "▁infection": 4158, + "ilir": 4159, + "chiev": 4160, + "▁common": 4161, + "▁Final▁": 4162, + "followed▁for": 4163, + "▁dosing": 4164, + "▁radiation": 4165, + "ardiac": 4166, + "olecular": 4167, + "▁order▁to": 4168, + "▁affect": 4169, + "▁109/L": 4170, + "▁6▁0▁0▁0▁0▁0▁1▁0\n\nSunitinib▁Malate▁": 4171, + "ilirubin": 4172, + "'s▁": 4173, + "care": 4174, + "further": 4175, + "s)\n\n": 4176, + "ice▁": 4177, + "▁Ac": 4178, + "emal": 4179, + "age▁of": 4180, + "\n\nPage:": 4181, + ".10": 4182, + "aking": 4183, + "▁of▁133": 4184, + "calcium": 4185, + "▁you▁are▁": 4186, + "onfidential\n\nPage▁": 4187, + "▁5-FU": 4188, + "asked▁to": 4189, + "profil": 4190, + "thics▁Com": 4191, + "7)": 4192, + "BJEC": 4193, + "sever": 4194, + "s,▁the▁": 4195, + "▁endpoint": 4196, + "s▁have▁": 4197, + "etc": 4198, + "▁serious▁adverse▁event": 4199, + "omega": 4200, + "▁1,▁": 4201, + "▁laboratory": 4202, + "uture▁": 4203, + "istant": 4204, + "percent": 4205, + "epidermal▁": 4206, + "▁statist": 4207, + "\n\nFor": 4208, + "5-fluorouracil": 4209, + "rinted▁copy▁is▁not▁official▁record": 4210, + "▁requir": 4211, + "▁status▁": 4212, + "Response▁": 4213, + "\n\nABI-007▁Clinical▁Trial▁Protocol:▁CA": 4214, + ".00": 4215, + "NP": 4216, + "eal": 4217, + "▁specific": 4218, + "ol/L": 4219, + "uspect": 4220, + "ott": 4221, + "▁Dos": 4222, + "amm": 4223, + "\n\nPatients▁": 4224, + "▁that▁is▁": 4225, + "▁50%": 4226, + "408": 4227, + "▁administration▁of": 4228, + "\n\nRevised▁Clinical▁Study▁Protocol▁Drug▁Substance▁ZD4054▁Study▁Code▁D4320": 4229, + "performed▁at": 4230, + "▁during": 4231, + "ingle-": 4232, + "analysis▁of": 4233, + "(d": 4234, + "ajor": 4235, + "®\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:": 4236, + "och": 4237, + "plain": 4238, + "▁return": 4239, + "▁less": 4240, + "very▁": 4241, + "portion": 4242, + "▁this▁protocol": 4243, + "s.▁S": 4244, + "ed▁by▁a": 4245, + "▁use▁": 4246, + "▁Arm▁B": 4247, + "clusion▁Criteria": 4248, + "ternational▁": 4249, + "fracture▁": 4250, + "gressive▁disease▁": 4251, + "▁systemic": 4252, + "small▁cell▁lung▁cancer": 4253, + "-rank": 4254, + "Grade▁3": 4255, + "case▁report▁form": 4256, + "human": 4257, + ",▁un": 4258, + "ick": 4259, + "etopos": 4260, + "outh": 4261, + "▁Peri": 4262, + "utam": 4263, + "expression": 4264, + "combination": 4265, + "12-0": 4266, + "▁will▁also▁be▁": 4267, + "regulation": 4268, + "11-0": 4269, + "20408": 4270, + "patients▁with": 4271, + "know": 4272, + "\n\nConfidential\n\nPage▁": 4273, + "uropath": 4274, + "regardless▁of": 4275, + "LT": 4276, + "fication": 4277, + "▁estim": 4278, + "e▁is▁": 4279, + "rok": 4280, + "umb": 4281, + ".\n\nLY231514": 4282, + "is▁or": 4283, + "▁hospitalization": 4284, + "active▁": 4285, + "122": 4286, + "▁child": 4287, + "▁account": 4288, + "ed▁as▁a": 4289, + "▁activity▁": 4290, + "ogenes": 4291, + "echan": 4292, + "perty▁of": 4293, + "lotinib": 4294, + "BP": 4295, + "hour": 4296, + "e▁C": 4297, + "▁techniqu": 4298, + "\n\nof": 4299, + "also": 4300, + "icin": 4301, + "ations": 4302, + "▁work": 4303, + ".\n\n4": 4304, + "opin": 4305, + "▁compared▁with": 4306, + ".3.3": 4307, + "\n\nCon": 4308, + "e▁in▁the▁": 4309, + ".▁Thes": 4310, + "sert": 4311, + "neut": 4312, + "..................................................................................................": 4313, + "subsequent": 4314, + "▁time▁point": 4315, + "made▁": 4316, + "ubjects▁who": 4317, + "▁Study▁Code▁D8480C00013": 4318, + "necessary": 4319, + "Lill": 4320, + "hip": 4321, + "measurement": 4322, + "sponsor": 4323, + "us▁of": 4324, + "y▁to": 4325, + "in▁patients▁with": 4326, + "\n\n12": 4327, + "eroid": 4328, + "s▁A": 4329, + "ank": 4330, + "arcinoma": 4331, + "▁in▁a": 4332, + "▁SC": 4333, + "▁lin": 4334, + "apan": 4335, + "▁adjuvant": 4336, + "▁0▁.▁1▁\\": 4337, + "▁great": 4338, + "▁this▁research": 4339, + "▁strati": 4340, + "es▁of▁the▁": 4341, + "▁testing": 4342, + "ed▁within": 4343, + "period▁": 4344, + "30-day▁": 4345, + "ity▁of▁lif": 4346, + "-052": 4347, + "s▁before▁": 4348, + "48-052": 4349, + "regulatory▁": 4350, + "appear": 4351, + "▁the▁discretion▁of▁the▁": 4352, + "(1": 4353, + "-6": 4354, + "biomarker": 4355, + "▁................................................................................": 4356, + "e▁and": 4357, + "▁or▁placebo": 4358, + "e▁test": 4359, + "▁chemist": 4360, + "▁assum": 4361, + "▁they": 4362, + "every▁3": 4363, + "ucos": 4364, + "Clinical▁Trial▁Protocol": 4365, + "using▁a": 4366, + "▁CT▁scan": 4367, + "response▁(": 4368, + "▁genetic": 4369, + "ethods▁of": 4370, + "Consider": 4371, + "▁equivalent": 4372, + "▁Final▁Protocol": 4373, + "39": 4374, + "Outcom": 4375, + "before▁": 4376, + "e.▁A": 4377, + "eCRF": 4378, + "ward": 4379, + "itumor": 4380, + "esoph": 4381, + "▁defin": 4382, + "▁Tumor": 4383, + "▁is▁responsible▁for": 4384, + "s,▁including": 4385, + "consistent": 4386, + ".▁Ther": 4387, + "▁Committe": 4388, + "▁do▁not": 4389, + "ohort": 4390, + "▁200048-052": 4391, + "▁colon▁cancer": 4392, + "MR▁200048-052": 4393, + "IEC/IRB": 4394, + "56": 4395, + "date▁": 4396, + "ynd": 4397, + "\n\nbe▁": 4398, + "▁laboratory▁": 4399, + "follows:": 4400, + "▁6.0": 4401, + "ies▁of": 4402, + "mon▁T": 4403, + "▁With": 4404, + "▁antibodies": 4405, + "regnancy▁": 4406, + "▁EGFr": 4407, + "\n\n1\n\n2\n\n3\n\n4": 4408, + ")▁is▁": 4409, + "606": 4410, + "SRE": 4411, + "ful": 4412, + "grade▁": 4413, + "▁enroll": 4414, + "▁evidence▁of": 4415, + "e▁on": 4416, + "s▁is▁": 4417, + ",▁V": 4418, + "▁being": 4419, + "es)": 4420, + "propos": 4421, + "▁vial": 4422, + "e▁dos": 4423, + ".▁Pro": 4424, + "pecimen": 4425, + "▁analysis▁set": 4426, + "alysis▁of": 4427, + "▁interval": 4428, + "struct": 4429, + ".▁Addition": 4430, + "elf-": 4431, + "(b)▁Confidential\n\nProtocol▁Amendment\n\nPage▁": 4432, + "yndrom": 4433, + "**": 4434, + "-012": 4435, + "/I": 4436, + "FOLFIRI": 4437, + "MS": 4438, + "No": 4439, + "e)\n\n": 4440, + "final": 4441, + "▁well": 4442, + "ubset": 4443, + "▁los": 4444, + "irumab": 4445, + "▁at▁the▁": 4446, + "TIV": 4447, + "ucirumab": 4448, + "-related▁to": 4449, + "ethod▁of": 4450, + "operative▁": 4451, + "RIO-012": 4452, + "/TRIO-012": 4453, + "12-0606": 4454, + "79": 4455, + ":38": 4456, + "Safety▁": 4457, + "brevi": 4458, + "▁/": 4459, + "stable▁": 4460, + "▁and▁C": 4461, + ".\n\nM": 4462, + "▁AD": 4463, + "corpor": 4464, + "▁the▁interim": 4465, + "tenance▁": 4466, + "▁you▁have▁": 4467, + "Research": 4468, + "▁agree▁to": 4469, + "atty": 4470, + "▁present": 4471, + "ouble-": 4472, + "RT": 4473, + "demonstr": 4474, + "paclitaxel": 4475, + "\n\n−": 4476, + "▁del": 4477, + "▁into": 4478, + "igure▁": 4479, + "▁Pain": 4480, + "▁fre": 4481, + "▁for▁a": 4482, + "▁x▁ULN": 4483, + "▁active▁": 4484, + "▁of▁121": 4485, + "▁discus": 4486, + "▁April▁2005": 4487, + "cern": 4488, + "urpose▁of": 4489, + "▁IMCL▁CP12-0606": 4490, + "▁\\▁d▁e▁v▁o▁r▁p▁p▁A\n\n\\▁0▁.▁1▁\\": 4491, + "echanism": 4492, + ":1": 4493, + "dat": 4494, + "full": 4495, + "uest": 4496, + "ateg": 4497, + "\n\ni": 4498, + "enoc": 4499, + "▁blood": 4500, + "▁Ram": 4501, + "ed▁below": 4502, + "age▁III": 4503, + "pha": 4504, + "▁strict": 4505, + "▁accur": 4506, + "afety▁and▁": 4507, + "e-th": 4508, + "recorded▁on▁the▁": 4509, + "▁Amendment▁4": 4510, + "by▁the▁": 4511, + "participation": 4512, + "hematologic": 4513, + "Objectiv": 4514, + "-rank▁test": 4515, + "11-080": 4516, + "AS": 4517, + "DNA": 4518, + "JV": 4519, + "Page▁": 4520, + "RNA": 4521, + "eir": 4522, + "lung": 4523, + "pregnant": 4524, + "improv": 4525, + "atio": 4526, + "▁request": 4527, + "unblind": 4528, + "▁orig": 4529, + "irth": 4530, + "intest": 4531, + "▁anti": 4532, + "▁adverse▁events▁": 4533, + "leeding": 4534, + "▁samples": 4535, + "eligibility▁": 4536, + "\n\nE▁S▁A▁E▁L▁P\n\n.▁T▁N▁E▁M▁U▁C▁O▁D": 4537, + "▁EGFR": 4538, + "Modification": 4539, + "-off": 4540, + "4T-": 4541, + "5▁mg/m2": 4542, + "PT": 4543, + "cr": 4544, + "groun": 4545, + "may": 4546, + "........................": 4547, + "▁multipl": 4548, + "eptember": 4549, + "▁is▁the▁": 4550, + "▁days▁of": 4551, + "\n\nAddendum▁13": 4552, + "diarrhea": 4553, + "▁minutes▁": 4554, + "made▁to": 4555, + "cruit": 4556, + "(3": 4557, + "4)": 4558, + "76": 4559, + "HC": 4560, + "IE-": 4561, + "cemia": 4562, + "eel": 4563, + "hist": 4564, + "\n\nand▁": 4565, + "anof": 4566, + "escal": 4567, + "▁maintain": 4568, + "▁histor": 4569, + "▁Reg": 4570, + "into": 4571, + "▁Bo": 4572, + "followed▁by▁": 4573, + "poss": 4574, + "251": 4575, + "▁data▁will▁be▁": 4576, + "▁predict": 4577, + "▁intraven": 4578, + "responding": 4579, + "ource▁document": 4580, + "zoledronic▁acid▁": 4581, + "e-threatening": 4582, + "JVBC": 4583, + "4T-IE-": 4584, + "4T-IE-JVBC": 4585, + "41": 4586, + "Not": 4587, + "Sign": 4588, + "’s": 4589, + "▁outcom": 4590, + "▁........................................................................": 4591, + "s▁must": 4592, + "▁thre": 4593, + "stract": 4594, + "▁direct": 4595, + "▁member": 4596, + "ulating": 4597, + "▁horm": 4598, + "▁EMR▁200048-052": 4599, + "e▁tim": 4600, + "▁BMD": 4601, + "▁at▁a": 4602, + "▁of▁119": 4603, + "▁of▁124": 4604, + "▁months▁": 4605, + "▁pers": 4606, + "ociation": 4607, + "▁Amendment▁2": 4608, + "▁appl": 4609, + "valid": 4610, + "clinical▁trial": 4611, + "United▁": 4612, + "▁calcium": 4613, + "\n\nClinical▁Trial▁Protocol:": 4614, + "▁its▁design": 4615, + "eparate▁": 4616, + "HD(f)▁Clinical▁Protocol": 4617, + ".\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁Panitumumab▁Protocol▁Number:▁20050203▁Date:▁21▁January▁2009\n\nPage▁": 4618, + "20408▁Amendment▁4": 4619, + "/I4T-IE-JVBC": 4620, + "/TRIO-012▁Ram": 4621, + "▁IMCL▁CP12-0606/I4T-IE-JVBC": 4622, + "11-0806": 4623, + "anofi-": 4624, + "/TRIO-012▁Ramucirumab": 4625, + "▁IMCL▁CP12-0606/I4T-IE-JVBC/TRIO-012▁Ramucirumab": 4626, + "58": 4627, + "C000": 4628, + "Test": 4629, + "fil": 4630, + "kelet": 4631, + "would▁": 4632, + "ated▁by▁": 4633, + "s▁have▁been": 4634, + "ed▁trial": 4635, + "▁investig": 4636, + "immun": 4637, + "estro": 4638, + "▁label": 4639, + "permitt": 4640, + "▁Other": 4641, + "▁ask": 4642, + "▁rash": 4643, + ".▁The▁patient": 4644, + "will▁not▁be▁": 4645, + "▁approach": 4646, + ".▁Treatment": 4647, + "based▁on▁the▁": 4648, + "\n\nAdd:": 4649, + "\n\nx▁x▁x": 4650, + "hibit": 4651, + "ogenetic": 4652, + "▁anticancer": 4653, + "▁IMCL▁CP11-0806": 4654, + "ulmonary▁": 4655, + "\n\nClinical▁Trial▁Protocol:▁IMCL▁CP12-0606/I4T-IE-JVBC/TRIO-012▁Ramucirumab": 4656, + "/122": 4657, + "death": 4658, + "dividual": 4659, + "itial▁": 4660, + "▁Avastin": 4661, + "▁25-": 4662, + "▁2▁year": 4663, + "ecut": 4664, + "\n\nAb": 4665, + "e▁sh": 4666, + "▁Monitoring": 4667, + "▁on-study▁": 4668, + "region": 4669, + "1786": 4670, + "244": 4671, + "▁dose▁reduction": 4672, + "ackgroun": 4673, + "▁of▁128": 4674, + "▁assess▁the▁": 4675, + "MD▁27": 4676, + "prior▁to▁the▁": 4677, + "▁Cycle▁1": 4678, + "agnesium": 4679, + "MD▁271786": 4680, + ")▁and": 4681, + "6▁week": 4682, + "az": 4683, + "course▁of": 4684, + "at▁a": 4685, + "though": 4686, + "▁Attachment": 4687, + "▁injection": 4688, + "▁Pre": 4689, + "class": 4690, + "version": 4691, + "\n\nEXPAND": 4692, + "revious▁": 4693, + "\n\nTreatment": 4694, + "▁Version▁6.0": 4695, + "received▁": 4696, + "had▁": 4697, + "▁there▁is▁": 4698, + ".\n\nTo": 4699, + "regulatory": 4700, + "▁(see▁Section": 4701, + "remov": 4702, + "e.g.,▁": 4703, + "censored▁at": 4704, + "▁of▁124\n\nPage▁": 4705, + "MD▁271786▁EMR▁200048-052": 4706, + ")▁to": 4707, + "-9": 4708, + ":▁A": 4709, + "bone▁": 4710, + "\n\nThis▁": 4711, + "receptor": 4712, + "ed▁and": 4713, + "▁had▁": 4714, + "apt": 4715, + ".2.4": 4716, + "▁rate▁": 4717, + "axol": 4718, + "▁Date:▁19": 4719, + "\n\nProduct:▁AMG▁162▁Protocol▁Number:▁200401": 4720, + "▁prevent": 4721, + "▁imaging": 4722, + "▁evaluate▁the▁": 4723, + "ology▁C": 4724, + "▁independent": 4725, + "ergic": 4726, + "▁error": 4727, + "secondary▁": 4728, + "URES": 4729, + "ID": 4730, + "PP": 4731, + "gre": 4732, + "suppl": 4733, + "ste": 4734, + "ation▁and▁": 4735, + "▁inform": 4736, + "▁fract": 4737, + "utr": 4738, + "astern": 4739, + "▁as▁well": 4740, + "▁study▁of": 4741, + "\n\nEMD▁271786▁EMR▁200048-052": 4742, + "periment": 4743, + "\n\nNot": 4744, + "▁Administration": 4745, + "completion": 4746, + "▁therapy▁(": 4747, + "▁receiving": 4748, + "38▁Date:▁19": 4749, + "is/her": 4750, + "▁IMCL▁CP11-0806▁IMC-11F8": 4751, + "38▁Date:▁19▁February▁200": 4752, + "-L": 4753, + "-T": 4754, + "TS": 4755, + "ft": 4756, + "s▁to▁be▁": 4757, + "inum": 4758, + "▁be": 4759, + "▁block": 4760, + "abov": 4761, + "emoglobin": 4762, + "▁recent": 4763, + "▁fil": 4764, + "▁or▁s": 4765, + "▁10▁October▁2006": 4766, + "▁Date:▁10▁October▁2006": 4767, + "▁immun": 4768, + "ed▁as▁an": 4769, + ".\n\nAll": 4770, + "efficacy▁of": 4771, + "olorectal▁": 4772, + ".▁Any▁": 4773, + "-specific": 4774, + "ECOG▁performance▁stat": 4775, + "SION": 4776, + "▁Panitumumab▁Protocol▁Number:▁20050251": 4777, + "\n\nH3E-MC-JMHD(f)▁Clinical▁Protocol": 4778, + "omega-3": 4779, + "estroy": 4780, + "▁Panitumumab▁Protocol▁Number:▁20050251▁Date:▁10▁October▁2006": 4781, + "docetaxel": 4782, + "potential": 4783, + "\n\nc": 4784, + "▁achiev": 4785, + "ention": 4786, + "itt": 4787, + "▁cyt": 4788, + "▁small": 4789, + "ass▁": 4790, + "▁I▁H▁T": 4791, + "compli": 4792, + "berg": 4793, + "▁Lung": 4794, + "▁thereafter": 4795, + "effusion": 4796, + "firmed": 4797, + "ference▁": 4798, + "see▁Section": 4799, + ".▁There▁": 4800, + "50244": 4801, + ".▁If▁the▁": 4802, + "▁T▁I\n\nK▁C▁E▁H▁C": 4803, + "▁diarrhea": 4804, + "2011": 4805, + "▁site▁": 4806, + ".▁Patients▁who": 4807, + "\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX": 4808, + "▁collection": 4809, + "ATIONS": 4810, + "occurring": 4811, + ")\n\nGEL▁Version▁ID:▁ONC.000−272−636.4.0\n\nApproved\n\nDate▁Printed:▁13−Aug−2013\n\nApproved▁by\n\n13▁Sep▁2007▁17:17:03": 4812, + "repeated▁": 4813, + "umbar": 4814, + "3;": 4815, + "LE": 4816, + "randomis": 4817, + "e▁M": 4818, + "ret": 4819, + "ality▁": 4820, + "arter": 4821, + "▁center": 4822, + "▁and▁B": 4823, + "ure▁of": 4824, + "ocl": 4825, + "▁Sampl": 4826, + "▁nam": 4827, + "▁ratio": 4828, + "TIC": 4829, + "TIN": 4830, + "▁Institut": 4831, + "▁95%": 4832, + "defined▁as▁": 4833, + "flamm": 4834, + "▁Respons": 4835, + "colon": 4836, + "oxicity": 4837, + "▁decid": 4838, + "IRB/": 4839, + "▁5-fluorouracil": 4840, + "▁of▁126\n\nClinical▁Trial▁Protocol:▁IMCL▁CP12-0606/I4T-IE-JVBC/TRIO-012▁Ramucirumab": 4841, + "\n\nImClone▁LLC▁Version▁6.0": 4842, + "lorid": 4843, + "exameth": 4844, + "▁of▁108": 4845, + "astrointest": 4846, + "\n\nProduct:▁AMG▁162▁Protocol▁Number:▁20040138▁Date:▁19▁February▁200": 4847, + ")▁will": 4848, + "MUN": 4849, + "OC": 4850, + "RC": 4851, + "oid▁": 4852, + "swer": 4853, + "volum": 4854, + "y▁with": 4855, + ",▁f": 4856, + "▁side▁effect": 4857, + "udit": 4858, + "rag": 4859, + "ally,▁": 4860, + "opy": 4861, + "ologist": 4862, + "egative▁": 4863, + "▁VER": 4864, + ".▁St": 4865, + "▁have▁not": 4866, + "effects▁of": 4867, + "consent▁form": 4868, + "▁Ant": 4869, + "▁previously▁": 4870, + "▁development": 4871, + "\n\nClinical▁Trial▁Protocol": 4872, + "▁February▁": 4873, + "ZD2171)": 4874, + "routine▁": 4875, + "uestion": 4876, + "-cell": 4877, + "Arm": 4878, + "To": 4879, + "ee▁Section": 4880, + "s\n\nA": 4881, + "y-": 4882, + "d▁for": 4883, + ".▁U": 4884, + "es▁a": 4885, + "ation▁to": 4886, + "▁de": 4887, + "empl": 4888, + "\n\nPanitumumab": 4889, + "istration": 4890, + "ency": 4891, + "▁that▁the▁": 4892, + ".▁This": 4893, + "50▁mg": 4894, + "efore,▁": 4895, + "complete▁": 4896, + "▁toxicities▁": 4897, + "\n\n4\n\n4": 4898, + "administration": 4899, + "▁total▁": 4900, + "▁Panitumumab▁Protocol▁Number:▁20050181▁Date:▁04▁April▁2008\n\nPage▁": 4901, + "ategor": 4902, + "▁strictly▁": 4903, + "\n\nClinical▁Trial▁Protocol▁IMCL▁CP11-0806▁IMC-11F8": 4904, + "5▁May▁200": 4905, + "Ch": 4906, + "bi": 4907, + "kaline▁": 4908, + "light": 4909, + "select": 4910, + "yel": 4911, + "\n\nl": 4912, + ",▁v": 4913, + "▁cent": 4914, + "▁to▁detect": 4915, + "isphosph": 4916, + "▁daily▁": 4917, + "ominal": 4918, + "imal": 4919, + "▁(1": 4920, + "▁regression": 4921, + "ircum": 4922, + "ending": 4923, + "▁as▁the▁": 4924, + "▁TA": 4925, + "compared▁": 4926, + "compared▁with": 4927, + "avent": 4928, + "wher": 4929, + "ologically▁": 4930, + "s.▁B": 4931, + "▁July▁": 4932, + "head": 4933, + "response▁to": 4934, + ".\n\nAd": 4935, + "2010": 4936, + "▁show": 4937, + "3E-US": 4938, + "▁increase▁in": 4939, + ".▁Other": 4940, + "erminology▁C": 4941, + "Evaluation": 4942, + "requiring": 4943, + "-sided▁": 4944, + "breviation": 4945, + "anofi-avent": 4946, + "▁of▁126\n\nClinical▁Trial▁Protocol:▁IMCL▁CP12-0606/I4T-IE-JVBC/TRIO-012▁Ramucirumab\n\nImClone▁LLC": 4947, + "isphosphon": 4948, + "53": 4949, + "57": 4950, + "▁enrollment": 4951, + "ed▁after": 4952, + "▁of▁any▁": 4953, + "▁mak": 4954, + "▁mCRC": 4955, + "▁1.5": 4956, + "▁September": 4957, + "compared▁to": 4958, + "comfort": 4959, + "ogram": 4960, + "pheral▁": 4961, + "▁resolv": 4962, + "▁analyses▁will▁be▁": 4963, + "193": 4964, + "e▁the▁patient": 4965, + "articl": 4966, + "ible▁": 4967, + "▁mg/d": 4968, + "prefer": 4969, + "▁the▁investigator’s▁": 4970, + "ative▁to": 4971, + "▁et▁al,▁200": 4972, + "ENTIN": 4973, + "▁administered▁": 4974, + "▁received▁": 4975, + "▁to▁ens": 4976, + "▁by▁the▁": 4977, + "IG(f)▁Clinical▁Protocol": 4978, + "pressure": 4979, + "▁terms▁of": 4980, + "hydration": 4981, + "ruption": 4982, + "▁abdomen": 4983, + "rinted▁copy▁is▁not▁official▁record.\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁Panitumumab▁Protocol▁Number:▁20050203▁Date:▁21▁January▁2009\n\nPage▁": 4984, + "®\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁Panitumumab▁Protocol▁Number:▁20050251▁Date:▁10▁October▁2006": 4985, + "enocarcinoma": 4986, + "/122\n\nEMD▁271786▁EMR▁200048-052": 4987, + "▁VERSION": 4988, + "2,▁": 4989, + "WB": 4990, + "cod": 4991, + "dent": 4992, + "has": 4993, + "tumor": 4994, + "zard": 4995, + "ed▁prior▁to": 4996, + "▁darbepoetin▁alfa": 4997, + "al▁from": 4998, + "▁CON": 4999, + "▁23": 5000, + "otherwis": 5001, + "earli": 5002, + "ECENTIN": 5003, + "▁of▁103": 5004, + "▁pharmac": 5005, + "EGFr": 5006, + "s▁that▁are▁": 5007, + "epending▁on": 5008, + "intervention": 5009, + "-03": 5010, + "follow-up▁visit": 5011, + "ematologic": 5012, + "-S130": 5013, + "▁(RECENTIN": 5014, + "urvival▁(PFS": 5015, + "epidermal▁growth▁factor▁receptor": 5016, + "mon▁Terminology▁C": 5017, + "3E-US-S130": 5018, + "6.7": 5019, + ":▁The▁": 5020, + "C6": 5021, + "MI": 5022, + "be▁t": 5023, + "cc": 5024, + "fin": 5025, + "gi": 5026, + "men": 5027, + "mmun": 5028, + "trial": 5029, + "\n\nTh": 5030, + "reak": 5031, + "▁bon": 5032, + "▁siz": 5033, + "▁suppl": 5034, + "igen": 5035, + "es▁with": 5036, + "▁recommend": 5037, + "e▁section": 5038, + "physician": 5039, + "ipt": 5040, + "▁will▁not": 5041, + "▁4.6": 5042, + ".05": 5043, + "▁sites▁of": 5044, + "ORR": 5045, + "\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁PANITUMUMAB▁(AMG▁954)▁Protocol▁Number:▁20040249▁Date:▁07▁August▁2007\n\nPage▁": 5046, + "ttp": 5047, + "ediranib▁(RECENTIN": 5048, + "withdrawn": 5049, + "postdiscontinuation": 5050, + "i.e": 5051, + "MUNEX": 5052, + "-term": 5053, + "3a": 5054, + "97": 5055, + "=0": 5056, + "Broch": 5057, + "co": 5058, + "rig": 5059, + "orph": 5060, + "recon": 5061, + "ed▁an": 5062, + "ase\n\n": 5063, + ".\n\nF": 5064, + "election": 5065, + "▁Overall": 5066, + "▁Require": 5067, + "early": 5068, + "▁the▁pres": 5069, + "reporting": 5070, + "deriv": 5071, + "s▁for▁the▁": 5072, + "▁Date:▁26": 5073, + "▁Addendum▁13": 5074, + "▁cycles▁of": 5075, + "▁2007;": 5076, + "▁participating": 5077, + "▁continue▁": 5078, + "-treat": 5079, + "observed▁in": 5080, + "1-Jul": 5081, + "hibition": 5082, + "changes▁in": 5083, + ",▁AZD2171)": 5084, + "estimated▁": 5085, + "▁ABX-EGF▁Protocol▁Number:▁200": 5086, + "formed▁Consent▁Form": 5087, + "▁area": 5088, + "▁Engl": 5089, + "anofi-aventis▁": 5090, + "C6193": 5091, + ").▁A": 5092, + "Ga": 5093, + "Health": 5094, + "VEGF": 5095, + "eam": 5096, + "nam": 5097, + "s’": 5098, + "system": 5099, + "yth": 5100, + "▁................................................................": 5101, + "initi": 5102, + "ater": 5103, + "\n\nsubject": 5104, + "ectom": 5105, + "▁As": 5106, + "▁inhibitor": 5107, + "character": 5108, + "▁n°": 5109, + "▁will▁be▁used▁to": 5110, + "e▁infusion": 5111, + "e▁dis": 5112, + "second▁": 5113, + "▁Protocol▁Amendment": 5114, + "e▁variabl": 5115, + "ALT": 5116, + "....................................................................................................": 5117, + "local▁": 5118, + "-2008": 5119, + "▁Date:▁05▁May▁200": 5120, + "▁24▁hour": 5121, + "participating": 5122, + "▁November▁2006": 5123, + "▁Denosumab▁Protocol▁Number:▁20050244": 5124, + "▁less▁than": 5125, + "▁of▁121\n\nClinical▁Trial▁Protocol▁IMCL▁CP11-0806▁IMC-11F8": 5126, + "i.e.,▁": 5127, + "▁Denosumab▁Protocol▁Number:▁20050244▁Date:▁05▁May▁200": 5128, + "-to": 5129, + "-PR": 5130, + "//": 5131, + "02▁(": 5132, + "59": 5133, + "6)": 5134, + "BMD": 5135, + "D-03": 5136, + "EL": 5137, + "Qual": 5138, + "RR": 5139, + "W-C": 5140, + "°C": 5141, + "▁of▁s": 5142, + "idin": 5143, + "ocal": 5144, + "accord": 5145, + "prot": 5146, + "unless": 5147, + "\n\nPatient": 5148, + "▁adjust": 5149, + "pproximately▁": 5150, + "pharmacokinetic": 5151, + "19-D": 5152, + "EC-200": 5153, + "▁Un": 5154, + "▁in▁the▁study": 5155, + "\n\nRedacted▁Version": 5156, + "▁-▁1": 5157, + "▁consist": 5158, + "007-S": 5159, + "▁this▁trial": 5160, + "reatinin": 5161, + "▁differenc": 5162, + "Confidential▁": 5163, + "eviation": 5164, + "immediately▁": 5165, + "LIN-PR": 5166, + "▁third▁": 5167, + "▁VERSION▁n°": 5168, + "3E-US-S130(d": 5169, + "1-Jul-2008": 5170, + "02▁(19-D": 5171, + "D-03▁VERSION▁n°": 5172, + "W-CLIN-PR": 5173, + "007-SD-03▁VERSION▁n°": 5174, + "02▁(19-DEC-200": 5175, + "W-CLIN-PR007-SD-03▁VERSION▁n°": 5176, + "W-CLIN-PR007-SD-03▁VERSION▁n°02▁(19-DEC-200": 5177, + "/EF": 5178, + "Bri": 5179, + "Gen": 5180, + "WW-CLIN-PR007-SD-03▁VERSION▁n°02▁(19-DEC-200": 5181, + "XA": 5182, + "eur": 5183, + "fact": 5184, + "wor": 5185, + "▁enter": 5186, + "▁co": 5187, + "▁some▁": 5188, + "▁and▁E": 5189, + "omic": 5190, + "▁Al": 5191, + "process": 5192, + "▁(electronic": 5193, + "check": 5194, + "utation": 5195, + "astric": 5196, + "▁Randomiz": 5197, + "e▁to▁receive▁": 5198, + "▁the▁sanofi-aventis▁": 5199, + "followed▁": 5200, + "▁5▁XRP6258": 5201, + "),▁or": 5202, + "strument": 5203, + "▁-▁strictly▁": 5204, + "▁Version▁number": 5205, + "anner": 5206, + "response▁rate▁": 5207, + "ABX-EGF": 5208, + "group▁-▁strictly▁": 5209, + "▁survival▁(": 5210, + "RECIST▁criteria": 5211, + "▁of▁each▁cycl": 5212, + "\n\nD▁E▁T▁N▁I▁R▁P\n\nA\n\nS▁I\n\nS▁I▁H▁T": 5213, + ":▁1▁(electronic": 5214, + "confidential▁WW-CLIN-PR007-SD-03▁VERSION▁n°02▁(19-DEC-200": 5215, + "perty▁of▁the▁sanofi-aventis▁": 5216, + "regulatory▁requirement": 5217, + "Clinical▁Trial▁Protocol▁5▁XRP6258": 5218, + "20408▁Amendment▁4▁Date:▁26": 5219, + "ircumstanc": 5220, + "ediranib▁(RECENTIN,▁AZD2171)": 5221, + "▁ABX-EGF▁Protocol▁Number:▁20020408▁Amendment▁4▁Date:▁26": 5222, + "1-Jul-2008▁Version▁number": 5223, + "/EFC6193": 5224, + "group▁-▁strictly▁confidential▁WW-CLIN-PR007-SD-03▁VERSION▁n°02▁(19-DEC-200": 5225, + ":▁1▁(electronic▁2.0": 5226, + "perty▁of▁the▁sanofi-aventis▁group▁-▁strictly▁confidential▁WW-CLIN-PR007-SD-03▁VERSION▁n°02▁(19-DEC-200": 5227, + "Clinical▁Trial▁Protocol▁5▁XRP6258/EFC6193": 5228, + "▁ABX-EGF▁Protocol▁Number:▁20020408▁Amendment▁4▁Date:▁26▁April▁2005": 5229, + "1-Jul-2008▁Version▁number:▁1▁(electronic▁2.0": 5230, + "(106": 5231, + "66": 5232, + "://": 5233, + "Cediranib▁(RECENTIN,▁AZD2171)": 5234, + "iet": 5235, + "uk": 5236, + "ed▁using▁the▁": 5237, + "osen": 5238, + "raft": 5239, + "otyp": 5240, + "unt": 5241, + "▁4.7": 5242, + "e▁dose▁": 5243, + "paration": 5244, + "54I": 5245, + "ically▁significant": 5246, + "SCO": 5247, + "ackage▁": 5248, + "ational▁Cancer": 5249, + "▁calcul": 5250, + "\n\nAmended▁Clinical▁Trial▁Protocol▁5▁XRP6258/EFC6193": 5251, + "50136": 5252, + "▁Cooperative▁": 5253, + "bumin": 5254, + "oclonal": 5255, + "ttp://": 5256, + "Cediranib▁(RECENTIN,▁AZD2171)▁Study▁Code▁D8480C00013": 5257, + ",▁to": 5258, + ",▁al": 5259, + "-F": 5260, + "07": 5261, + "1▁and▁": 5262, + "NT": 5263, + "way": 5264, + "insert": 5265, + "alf": 5266, + ",▁it": 5267, + ",▁25": 5268, + "▁point": 5269, + "▁dated▁": 5270, + "omet": 5271, + "absence▁of": 5272, + "▁Coll": 5273, + "quant": 5274, + "▁problem": 5275, + "▁Non-": 5276, + "effort": 5277, + "2009": 5278, + "cidence▁": 5279, + "▁att": 5280, + "▁any▁of": 5281, + ".▁Each": 5282, + "▁use▁of": 5283, + ".▁Res": 5284, + "▁shown": 5285, + "▁neutropenia": 5286, + "efficacy▁endpoint": 5287, + "longest▁diameter": 5288, + "referenc": 5289, + "analysis": 5290, + "Clinical▁Study▁Protocol▁Drug▁Substance▁Cediranib▁(RECENTIN,▁AZD2171)▁Study▁Code▁D8480C00013": 5291, + "olidation": 5292, + "Plan": 5293, + "-2007▁0": 5294, + "▁thromb": 5295, + "▁endothel": 5296, + "▁Attachment▁JM": 5297, + "mon▁Terminology▁Criteria▁for": 5298, + "Dose▁": 5299, + "Drug": 5300, + "SS": 5301, + "e\n\nA": 5302, + "e.▁In": 5303, + "jur": 5304, + "section": 5305, + "ating▁the▁": 5306, + "\n\no": 5307, + "▁a▁b": 5308, + "still": 5309, + "ential": 5310, + "▁becom": 5311, + "ising": 5312, + "isone▁": 5313, + "▁supportive▁": 5314, + "▁material": 5315, + ".\n\nH": 5316, + "olism": 5317, + "confidential": 5318, + "concomitant▁medication": 5319, + "▁fatty": 5320, + "\n\nPFIZER▁CONFIDENTIAL▁Page▁": 5321, + "▁respect": 5322, + "▁patients▁(": 5323, + "stric": 5324, + "▁Date:▁14": 5325, + "▁x▁109/L": 5326, + "ed▁at▁the▁": 5327, + "ronch": 5328, + "ociet": 5329, + "▁Company▁": 5330, + "▁determine▁the▁": 5331, + "overall▁survival": 5332, + "▁antibody▁": 5333, + "▁parameter": 5334, + "etting": 5335, + "▁appropriat": 5336, + "previously▁": 5337, + "stitutional▁Review": 5338, + "/122\n\nEMD▁271786▁EMR▁200048-052\n\nEXPAND": 5339, + "3E-US-S130(d)▁Clinical▁Protocol": 5340, + "▁Date:▁14▁November▁2006": 5341, + "1;": 5342, + "55": 5343, + "ACT-": 5344, + "how": 5345, + "oL": 5346, + "specifi": 5347, + "e▁c": 5348, + "institution": 5349, + "▁a▁f": 5350, + "ory▁": 5351, + ".▁K": 5352, + "ed.▁If": 5353, + "ous▁in": 5354, + "ure▁to": 5355, + "empt": 5356, + "▁Sign": 5357, + "▁will▁be▁provid": 5358, + "▁commer": 5359, + "\n\nCT": 5360, + "s.▁Th": 5361, + "ardial▁": 5362, + "▁Date:▁30": 5363, + "ed▁at▁least": 5364, + "ymph": 5365, + "▁cycles": 5366, + "id▁not": 5367, + "▁including": 5368, + "discontinued▁from": 5369, + "starting": 5370, + "ublish": 5371, + "▁medical▁record": 5372, + "▁Denosumab▁Protocol▁Number:▁20050136": 5373, + "neutrophil": 5374, + "greement": 5375, + "-cell▁lung▁cancer": 5376, + "▁ABX-EGF▁Protocol▁Number:▁20020408▁Amendment▁4▁Date:▁26▁April▁2005\n\nPage▁": 5377, + "ational▁Cancer▁Institut": 5378, + "▁Denosumab▁Protocol▁Number:▁20050136▁Date:▁30": 5379, + ".[": 5380, + "2▁Amendment": 5381, + "FL": 5382, + "eart": 5383, + "lab": 5384, + "e▁at": 5385, + "onc": 5386, + "or▁other": 5387, + "rection": 5388, + "edd": 5389, + "▁At": 5390, + "▁1▁week": 5391, + "osis▁": 5392, + "▁(N": 5393, + "▁2▁week": 5394, + "raction": 5395, + "▁his/her": 5396, + "▁RECIST": 5397, + "▁B12": 5398, + "▁5▁0": 5399, + "▁Group": 5400, + "position": 5401, + "heet": 5402, + "▁Addendum": 5403, + "administration▁of": 5404, + "Investigator’s▁": 5405, + "administered▁": 5406, + "mittee": 5407, + "openia": 5408, + "▁bone▁metastas": 5409, + "▁management": 5410, + "▁ECOG": 5411, + "▁31−Jul−2014": 5412, + "kaline▁phosph": 5413, + "▁TAXOL": 5414, + "▁of▁121\n\nClinical▁Trial▁Protocol▁IMCL▁CP11-0806▁IMC-11F8\n\nImClone▁LLC▁Version▁6.0": 5415, + "09": 5416, + "All": 5417, + "Amended▁": 5418, + "AstraZeneca": 5419, + "CED": 5420, + "Form": 5421, + "a\\Approved\\Approved▁On:": 5422, + "a3a": 5423, + "done▁": 5424, + "e),▁": 5425, + "vascular": 5426, + "erm": 5427, + "stage▁": 5428, + "ed.▁A": 5429, + "▁primary▁": 5430, + "▁mean": 5431, + "▁monitor": 5432, + "▁monitoring": 5433, + "▁and▁m": 5434, + "▁initial": 5435, + "▁Pl": 5436, + "▁Pfizer": 5437, + "\n\nPrimary▁": 5438, + "▁prot": 5439, + "ep-2007▁0": 5440, + "▁strat": 5441, + "\n\n15": 5442, + "▁of▁101": 5443, + "lood▁sampl": 5444, + "▁abl": 5445, + "▁therapy,▁": 5446, + "▁carry▁": 5447, + "\n\nH3E-US-S130(d)▁Clinical▁Protocol": 5448, + "▁–▁Company▁": 5449, + "28▁August▁2007": 5450, + "reatinine▁clear": 5451, + "1122▁Amendment": 5452, + "ynops": 5453, + "-Sep-2007▁0": 5454, + "▁27-Sep-2007▁0": 5455, + "2:42": 5456, + "Protocol▁A6181122▁Amendment": 5457, + "▁legally": 5458, + ".\n\nWhat": 5459, + "▁1,▁28▁August▁2007": 5460, + "\n\nProduct:▁AMG▁162▁Protocol▁Number:▁20040138▁Date:▁19▁February▁2008\n\nPage▁": 5461, + "®\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁Panitumumab▁Protocol▁Number:▁20050251▁Date:▁10▁October▁2006\n\nPage▁": 5462, + "Confidential▁Page▁": 5463, + "Amended▁Protocol▁A6181122▁Amendment": 5464, + "a\\Approved\\Approved▁On:▁27-Sep-2007▁0": 5465, + "a3aa\\Approved\\Approved▁On:▁27-Sep-2007▁0": 5466, + "▁–▁Company▁Confidential▁Page▁": 5467, + "Amended▁Protocol▁A6181122▁Amendment▁1,▁28▁August▁2007": 5468, + "a3aa\\Approved\\Approved▁On:▁27-Sep-2007▁02:42": 5469, + "(m": 5470, + ":45": 5471, + "kept": 5472, + "lic": 5473, + "pact": 5474, + "safety": 5475, + "investig": 5476, + "es,▁and▁": 5477, + "▁safety": 5478, + "▁and▁p": 5479, + "▁and▁for": 5480, + "▁AUC": 5481, + "▁had": 5482, + "▁Man": 5483, + "▁Factor": 5484, + "▁Health": 5485, + "▁patients▁receiving": 5486, + "▁Gen": 5487, + "▁plasma": 5488, + ".▁Phase▁": 5489, + "neutropenia": 5490, + "▁it▁is▁": 5491, + "▁therapy▁for": 5492, + "..........................................................................................": 5493, + "ABI-007": 5494, + "eligibility": 5495, + "▁sufficient": 5496, + "▁partial▁": 5497, + "embedd": 5498, + "▁normal▁": 5499, + "racept": 5500, + "/dL": 5501, + "variables": 5502, + "\n\nH3E-MC-JMIG(f)▁Clinical▁Protocol": 5503, + "genetic▁research": 5504, + "orld": 5505, + "solute▁": 5506, + "Oncology▁Group": 5507, + "olorectal▁Cancer": 5508, + "stitutional▁Review▁Bo": 5509, + "1st": 5510, + "69": 5511, + "Non-": 5512, + "Rel": 5513, + "U01": 5514, + "e.▁S": 5515, + "spect": 5516, + "ton": 5517, + "ucl": 5518, + "vir": 5519, + "y\n\n": 5520, + "investigational▁product": 5521, + "▁tub": 5522, + "ed▁dos": 5523, + "▁primary": 5524, + "▁bilirubin": 5525, + "▁of▁an": 5526, + "▁measurable▁": 5527, + "illness": 5528, + "pleas": 5529, + "▁(B": 5530, + "age,▁": 5531, + "▁Evalu": 5532, + "upper": 5533, + "ortic": 5534, + "▁patients▁in": 5535, + "e▁during▁the▁": 5536, + "s\n\nThe▁": 5537, + "included▁in": 5538, + "aryn": 5539, + "emetic": 5540, + "first-line▁treatment": 5541, + "pret": 5542, + "independent": 5543, + "▁reported▁": 5544, + ",▁2008": 5545, + "hazard": 5546, + "............................................................................................": 5547, + "▁2011": 5548, + "▁IMC-1121B": 5549, + "10145": 5550, + "uroQ": 5551, + "emetrexed▁H3E-MC-JMHO": 5552, + "▁confidence▁interval": 5553, + "thics▁Committe": 5554, + "/placebo": 5555, + "522": 5556, + "Nov": 5557, + "baselin": 5558, + "begin": 5559, + "e,▁and": 5560, + "ias": 5561, + "serious▁adverse▁event": 5562, + "receive▁": 5563, + "▁date▁of": 5564, + ".\n\nFor": 5565, + "imens": 5566, + "▁1▁.▁1▁\\": 5567, + "unless▁": 5568, + "ries▁": 5569, + "▁frequ": 5570, + "▁Med▁": 5571, + "▁grade▁3": 5572, + "▁respon": 5573, + "e▁inhibitor": 5574, + "▁6▁8": 5575, + "crease▁": 5576, + "ed▁for▁each": 5577, + "▁months▁after": 5578, + "including▁the▁": 5579, + "▁analysis▁will": 5580, + "▁toxicities": 5581, + "required▁to": 5582, + "▁item": 5583, + "itamin▁B12": 5584, + "approv": 5585, + "ince▁": 5586, + "▁describ": 5587, + "\n\n8▁2": 5588, + "representative▁": 5589, + "▁hypothes": 5590, + "▁calculation": 5591, + "evidenc": 5592, + "ate▁that": 5593, + "▁higher": 5594, + "persensitivity▁": 5595, + "▁platinum": 5596, + "ecutive▁": 5597, + "umbar▁sp": 5598, + "▁February▁2011": 5599, + "▁-▁1▁3": 5600, + "5:": 5601, + "MP": 5602, + "▁A▁-▁1▁3": 5603, + "ilut": 5604, + "▁(if": 5605, + "ance\n\n": 5606, + ".1.3": 5607, + "▁rul": 5608, + "▁g▁u": 5609, + "▁analyses▁": 5610, + "box": 5611, + "▁4▁:": 5612, + "▁the▁informed▁consent": 5613, + "s.▁If": 5614, + "▁7▁0▁0▁2▁-": 5615, + "neuropath": 5616, + "▁interaction": 5617, + "flu": 5618, + "▁This▁": 5619, + "currently▁": 5620, + "fracture": 5621, + "▁undergo": 5622, + "ohn": 5623, + "▁requirement": 5624, + "respond": 5625, + "ationale▁for": 5626, + "▁throughout▁the▁study": 5627, + "▁1▁6▁6▁8": 5628, + "▁March▁2007": 5629, + "employ": 5630, + "▁5▁0▁7▁0▁0▁2▁-": 5631, + "▁1▁.▁1▁\\\n\n8▁2": 5632, + "▁g▁u▁A▁-▁1▁3": 5633, + "▁4▁:▁5▁0▁7▁0▁0▁2▁-": 5634, + "▁1▁.▁1▁\\\n\n8▁2▁1▁6▁6▁8": 5635, + "▁4▁:▁5▁0▁7▁0▁0▁2▁-▁g▁u▁A▁-▁1▁3": 5636, + "2;": 5637, + "Trial": 5638, + "pen": 5639, + "pne": 5640, + "zym": 5641, + "one-": 5642, + "\n\nWh": 5643, + "s▁[": 5644, + "al▁s": 5645, + "▁analyz": 5646, + "▁set": 5647, + "▁of▁all": 5648, + ".\n\nI": 5649, + "prostate▁cancer": 5650, + "▁(eg,▁": 5651, + "▁her": 5652, + "study▁will": 5653, + "▁component": 5654, + "▁Baseline▁": 5655, + "▁BioSci": 5656, + "▁stor": 5657, + "▁will▁receive▁": 5658, + "follow▁up": 5659, + ".▁Study▁": 5660, + "▁clinic": 5661, + "▁evaluate▁": 5662, + "▁non-target▁lesion": 5663, + "uropean": 5664, + "utility▁": 5665, + "▁Patients▁with": 5666, + "emcitabin": 5667, + "merican▁BioSci": 5668, + "measurable▁lesion": 5669, + "MUNEX\n\nConfidential\n\nAMGEN\n\nProduct:": 5670, + "\n\nAmended▁Clinical▁Trial▁Protocol▁5▁XRP6258/EFC6193\n\n2": 5671, + "CEDURES": 5672, + "/min": 5673, + "TC": 5674, + "date▁of": 5675, + "factor": 5676, + "tinu": 5677, + "▁i": 5678, + "▁abov": 5679, + "alid": 5680, + "anad": 5681, + "▁analgesic": 5682, + "ed▁according▁to▁the▁": 5683, + "▁colorectal": 5684, + "▁below": 5685, + "ession": 5686, + "for▁exampl": 5687, + "▁major": 5688, + "▁incidence▁of": 5689, + "��Cycl": 5690, + "▁STUDY": 5691, + "amil": 5692, + "alli": 5693, + "e▁their": 5694, + "correct": 5695, + "▁resolution": 5696, + "xicities": 5697, + "oste": 5698, + "▁XIV": 5699, + ".\n\nPage:": 5700, + ",▁St": 5701, + "randomized,▁": 5702, + "s▁by▁": 5703, + "observed▁": 5704, + "extent": 5705, + "\n\nAmended▁Clinical▁Study▁Protocol▁Drug▁Substance▁Cediranib▁(RECENTIN,▁AZD2171)▁Study▁Code▁D8480C00013": 5706, + "▁would▁be▁": 5707, + "necessary▁": 5708, + "clinically▁indicated": 5709, + "ence,▁Inc": 5710, + "perty▁of▁the▁sanofi-aventis▁group▁-▁strictly▁confidential▁WW-CLIN-PR007-SD-03▁VERSION▁n°02▁(19-DEC-2005)": 5711, + "mon▁Terminology▁Criteria▁for▁Adverse▁Event": 5712, + "\n\nAmended▁Clinical▁Trial▁Protocol▁5▁XRP6258/EFC6193\n\n21-Jul-2008▁Version▁number:▁1▁(electronic▁2.0": 5713, + "(2": 5714, + "3,▁": 5715, + "5;": 5716, + ";▁•": 5717, + "Your": 5718, + "had": 5719, + "rash": 5720, + "−30": 5721, + "▁s▁": 5722, + "▁d▁": 5723, + "▁tw": 5724, + "s▁during▁the▁": 5725, + "ed▁Outcom": 5726, + "▁Societ": 5727, + "▁or▁without": 5728, + "▁MA": 5729, + "▁3▁week": 5730, + "▁oil": 5731, + "▁grad": 5732, + "▁variabl": 5733, + "▁volum": 5734, + "▁study▁medication": 5735, + "GFR": 5736, + "▁doses▁of": 5737, + "15▁February▁2011": 5738, + "\n\n21": 5739, + "e,▁a": 5740, + "▁moder": 5741, + "▁Procedure": 5742, + "▁Feb▁2011": 5743, + "▁phase▁of": 5744, + "▁18▁Feb▁2011": 5745, + "▁11:38": 5746, + "do▁not": 5747, + "▁failure": 5748, + "▁failure▁": 5749, + "▁ensure▁that": 5750, + ":55": 5751, + "rincipal▁investigator": 5752, + "appearance▁of": 5753, + "C00033": 5754, + "▁Denosumab▁Protocol▁Number:▁20050244▁Date:▁05▁May▁2008\n\nPage▁": 5755, + "522−30": 5756, + "▁4▁:▁5▁0▁7▁0▁0▁2▁-▁g▁u▁A▁-▁1▁3▁\\▁d▁e▁v▁o▁r▁p▁p▁A\n\n\\": 5757, + "merican▁BioScience,▁Inc": 5758, + "▁18▁Feb▁2011▁11:38": 5759, + "522−306.7": 5760, + "▁18▁Feb▁2011▁11:38:55": 5761, + "64": 5762, + "Mutant▁KRAS": 5763, + "Rec": 5764, + "del": 5765, + "lower": 5766, + "▁ent": 5767, + "oft": 5768, + "ed▁M": 5769, + "▁copy▁of": 5770, + "es▁and": 5771, + "ation▁(": 5772, + "▁surg": 5773, + "▁of▁Cancer": 5774, + "omin": 5775, + "▁1.0": 5776, + "▁Primary▁": 5777, + "▁hel": 5778, + "▁organ": 5779, + "formance▁": 5780, + "efic": 5781, + "▁analyses▁of": 5782, + "▁stopp": 5783, + "▁study▁visit": 5784, + "▁70": 5785, + ".6.2": 5786, + "ated▁that": 5787, + "efficacy▁and▁": 5788, + "▁Analys": 5789, + "......................................................": 5790, + "quality▁of▁lif": 5791, + "does▁not": 5792, + "▁anticip": 5793, + "▁Edition▁Number▁3▁Date▁15▁February▁2011": 5794, + "ournal▁of": 5795, + "\n\n090177e18069a3aa\\Approved\\Approved▁On:▁27-Sep-2007▁02:42": 5796, + "▁cut-off": 5797, + "Follow-up": 5798, + "(106)\n\nGEL▁Version▁ID:▁ONC.000−272−636.4.0\n\nApproved\n\nDate▁Printed:▁13−Aug−2013\n\nApproved▁by\n\n13▁Sep▁2007▁17:17:03": 5799, + "C00033▁Edition▁Number▁3▁Date▁15▁February▁2011": 5800, + "▁4▁:▁5▁0▁7▁0▁0▁2▁-▁g▁u▁A▁-▁1▁3▁\\▁d▁e▁v▁o▁r▁p▁p▁A\n\n\\▁1▁.▁1▁\\\n\n8▁2▁1▁6▁6▁8": 5801, + "%▁(": 5802, + "(C": 5803, + "62": 5804, + "AMG▁162": 5805, + "Laboratory▁": 5806, + "TT": 5807, + "bear": 5808, + "▁q": 5809, + "▁them": 5810, + "um▁of▁the▁": 5811, + "▁mis": 5812, + "plor": 5813, + "▁Study": 5814, + "otransfer": 5815, + "▁low": 5816, + "▁feel": 5817, + "duced": 5818, + "▁of▁98": 5819, + "e▁sit": 5820, + "▁confidential": 5821, + "1248": 5822, + "\n\nCR": 5823, + "\n\nCh": 5824, + "e▁includ": 5825, + "ella": 5826, + "reported▁to": 5827, + ".▁Ph": 5828, + "▁tumor▁tissu": 5829, + "effective▁": 5830, + "predict": 5831, + "▁X-ra": 5832, + "arget▁Lesion": 5833, + "▁Week": 5834, + ".\n\nAn": 5835, + "Analysis▁": 5836, + "outcome▁variabl": 5837, + "▁CRC": 5838, + "▁authorized▁": 5839, + "fizer▁–▁Company▁Confidential▁Page▁": 5840, + "likely": 5841, + "▁improvement": 5842, + "94)\n\nGEL▁Version▁ID:▁CV.000−": 5843, + "▁Lung▁Cancer": 5844, + "perty▁of▁the▁sanofi-aventis▁group▁-▁strictly▁confidential▁WW-CLIN-PR007-SD-03▁VERSION▁n°02▁(19-DEC-2005)\n\nPage▁": 5845, + "94)\n\nGEL▁Version▁ID:▁CV.000−522−306.7": 5846, + ").▁In": 5847, + "TH": 5848, + "different": 5849, + "found▁": 5850, + "mpt": 5851, + "▁t▁c": 5852, + ",▁will▁be▁": 5853, + ".▁19": 5854, + "ing▁from": 5855, + "▁of▁panitumumab": 5856, + "00▁mg": 5857, + "▁IU": 5858, + "study▁medication": 5859, + "▁adequate▁": 5860, + "avor": 5861, + "phen": 5862, + "▁this▁document": 5863, + "icalutam": 5864, + "minister": 5865, + "▁the▁inter": 5866, + "riter": 5867, + "▁tumor▁assessment": 5868, + "174": 5869, + "NCCTG": 5870, + "▁interest": 5871, + ".▁2000": 5872, + "ed▁from▁the▁": 5873, + "agnostic": 5874, + "▁discontinuation▁of": 5875, + "▁treated▁": 5876, + ".9%": 5877, + "▁response▁to": 5878, + "▁decision": 5879, + "\n\nGrade▁": 5880, + "▁reasonable▁": 5881, + "ordin": 5882, + "\n\nAmgen▁Thousand▁Oaks": 5883, + "hemistry▁": 5884, + "▁the▁discretion▁of▁the▁investigator": 5885, + "U011248": 5886, + "MUNEX\n\nConfidential\n\nAMGEN\n\nProduct:▁ABX-EGF▁Protocol▁Number:▁20020408▁Amendment▁4▁Date:▁26▁April▁2005\n\nPage▁": 5887, + "H)": 5888, + "PC": 5889, + "Reg": 5890, + "Table▁": 5891, + "ca": 5892, + "eucovorin": 5893, + "ring": 5894, + "e▁an": 5895, + "e▁as": 5896, + "involv": 5897, + "▁Ass": 5898, + "▁(80": 5899, + "▁Serum": 5900, + "▁Serious▁Adverse▁Event": 5901, + "▁refer": 5902, + "study▁will▁be▁": 5903, + "▁process": 5904, + "e\n\nC": 5905, + "add": 5906, + "▁as▁describ": 5907, + "▁standard": 5908, + "▁will▁be\n\n": 5909, + "▁antitumor": 5910, + "positive▁": 5911, + "ified▁as▁": 5912, + "progression-free▁s": 5913, + ".▁Data": 5914, + "principal▁": 5915, + "patients▁who": 5916, + "unctional▁": 5917, + "clusion▁criteria": 5918, + "▁intak": 5919, + "▁a▁copy▁of": 5920, + "▁positive▁": 5921, + "▁overall▁survival": 5922, + "gressive▁diseas": 5923, + "eyon": 5924, + "olid▁tumor": 5925, + "acceptable▁to": 5926, + "ummary▁of": 5927, + "spection": 5928, + "▁July▁2004": 5929, + "▁of▁101\n\n090177e18069a3aa\\Approved\\Approved▁On:▁27-Sep-2007▁02:42": 5930, + "▁able▁to": 5931, + "▁help": 5932, + "riterion": 5933, + ",6": 5934, + "-Up": 5935, + "225": 5936, + "68": 5937, + "FDA": 5938, + "Salt": 5939, + "YP": 5940, + "a)": 5941, + "hes": 5942, + "rinotecan": 5943, + "▁........................................................................................................": 5944, + "\n\np": 5945, + "\n\ntreatment": 5946, + "rest": 5947, + "room": 5948, + "arily▁": 5949, + "▁PK": 5950, + "▁however": 5951, + "ysical": 5952, + "able▁of": 5953, + "minimum": 5954, + "antic": 5955, + "▁will▁be▁collect": 5956, + "▁as▁possibl": 5957, + "▁one▁of▁the▁": 5958, + "ification▁of": 5959, + "▁check": 5960, + "▁experience▁": 5961, + "▁the▁two": 5962, + "creen": 5963, + "▁each▁patient": 5964, + "cient": 5965, + "completed": 5966, + "▁response▁rate▁": 5967, + "▁Onc": 5968, + "▁agreement": 5969, + "35▁Date:▁14▁November▁2006": 5970, + "▁therapeutic": 5971, + "▁December▁2010": 5972, + "▁temperature▁": 5973, + "▁Cooperative▁Oncology▁Group": 5974, + ")\n\nS": 5975, + "OP": 5976, + "Other": 5977, + "rid": 5978, + "▁know": 5979, + "in▁a": 5980, + "standard": 5981, + "▁wer": 5982, + "elvis": 5983, + "oly": 5984, + "▁22": 5985, + "▁future▁": 5986, + "ender": 5987, + "▁and▁all": 5988, + "▁program": 5989, + "e\n\nS": 5990, + "▁08": 5991, + "▁3.3": 5992, + "127": 5993, + "s.▁P": 5994, + "▁while▁": 5995, + ".6.1": 5996, + "▁assessments▁": 5997, + ".▁Ch": 5998, + "ongo": 5999, + "chedule▁of": 6000, + "▁Analysis": 6001, + "status": 6002, + "▁should▁not": 6003, + "econdary": 6004, + "ING": 6005, + "▁activity": 6006, + "▁the▁criteria▁for": 6007, + "ecause▁of": 6008, + "suppli": 6009, + "principal▁investigator": 6010, + "6;": 6011, + "DS": 6012, + "New": 6013, + "Oct": 6014, + "TE": 6015, + "call": 6016, + "rative▁": 6017, + "\n\npanitumumab": 6018, + "stand": 6019, + ",▁I": 6020, + "▁blinded▁": 6021, + "is▁(": 6022, + "uria": 6023, + "otass": 6024, + "owel": 6025, + "▁hr": 6026, + "▁liver": 6027, + "▁or▁other": 6028, + "ay▁of": 6029, + "▁Radi": 6030, + "▁will▁be▁performed▁": 6031, + "▁36": 6032, + "▁on▁Day▁1": 6033, + "▁Information": 6034, + "first▁dose▁of": 6035, + "evelopment": 6036, + "▁Any▁": 6037, + "randomized▁": 6038, + "discus": 6039, + "▁gener": 6040, + "required▁for": 6041, + "\n\nx\n\nx\n\nx\n\nx": 6042, + "▁Medication": 6043, + "ournal": 6044, + "▁June▁2009": 6045, + "▁NCCTG": 6046, + "IMC-1121B": 6047, + "▁6▁0▁0▁0▁0▁0▁1▁0\n\nSunitinib▁Malate▁Amended▁Protocol▁A6181122▁Amendment▁1,▁28▁August▁2007": 6048, + "uestionna": 6049, + "otassium": 6050, + ")▁at": 6051, + "1/": 6052, + "EA": 6053, + "Practic": 6054, + "be\n\n": 6055, + "fail": 6056, + "iol": 6057, + "lect": 6058, + "scor": 6059, + "vari": 6060, + "▁early▁": 6061, + "eril": 6062, + ",▁for": 6063, + "▁bo": 6064, + "▁to▁a": 6065, + "▁dep": 6066, + ".\n\n.▁E▁S▁U": 6067, + "olid▁": 6068, + "respir": 6069, + "rast": 6070, + "▁EV": 6071, + "aintenance▁": 6072, + "eriou": 6073, + "every": 6074, + "▁the▁purpose▁of": 6075, + ".▁The\n\n": 6076, + "sufficient": 6077, + "ed▁with▁the▁": 6078, + "▁Wh": 6079, + "drawn": 6080, + ",▁Ch": 6081, + "▁(Arm": 6082, + "vailable▁": 6083, + "change▁in": 6084, + "\n\nAny▁": 6085, + "▁difference▁in": 6086, + "affin-": 6087, + "▁case▁of": 6088, + "▁patients▁treated▁with": 6089, + "▁designe": 6090, + ".0▁Approved▁by\n\nApproved\n\nDate▁Printed:▁30−Jul−2014\n\nS▁18▁Feb▁2011▁11:38:55": 6091, + "▁they▁are▁": 6092, + "astern▁Cooperative▁Oncology▁Group": 6093, + "formance▁Stat": 6094, + ",9": 6095, + "1120": 6096, + "4;": 6097, + "eopl": 6098, + "leg": 6099, + "law": 6100, + "m▁J": 6101, + "▁identifi": 6102, + "e▁G": 6103, + "edg": 6104, + "ing▁any▁": 6105, + "▁scal": 6106, + "▁day▁1": 6107, + "that": 6108, + "▁in▁this▁study": 6109, + "urance▁": 6110, + "▁(2": 6111, + "▁(94)\n\nGEL▁Version▁ID:▁CV.000−522−306.7": 6112, + "▁IC": 6113, + "▁lymph": 6114, + "▁or▁not": 6115, + "ize▁the▁": 6116, + "▁prolong": 6117, + "compan": 6118, + "andid": 6119, + "▁Re": 6120, + "▁0.8": 6121, + "▁combin": 6122, + "able▁for": 6123, + "outsid": 6124, + "▁will▁continu": 6125, + "s▁(including": 6126, + "\n\n1▁4▁:▁5▁0▁7▁0▁0▁2▁-▁g▁u▁A▁-▁1▁3▁\\▁d▁e▁v▁o▁r▁p▁p▁A\n\n\\▁1▁.▁1▁\\\n\n8▁2▁1▁6▁6▁8": 6127, + "▁any▁caus": 6128, + "ed▁for▁all": 6129, + "▁72": 6130, + "▁months▁for": 6131, + ".▁Com": 6132, + "▁lead": 6133, + "▁16▁July▁2004": 6134, + "\n\nRes": 6135, + "▁sample▁": 6136, + "▁samples▁": 6137, + "ince▁th": 6138, + "plicable▁": 6139, + "ish▁oil": 6140, + "weekly▁": 6141, + "TIONS": 6142, + "031": 6143, + "\n\nLY231514": 6144, + "▁every▁3": 6145, + "▁comparison": 6146, + "/mm": 6147, + "▁have▁s": 6148, + "▁Grade▁4": 6149, + "-CSF": 6150, + "▁PROCEDURES": 6151, + "▁AMG▁162▁Protocol▁Number:▁20040135▁Date:▁14▁November▁2006": 6152, + "even▁if": 6153, + "ready▁": 6154, + "cutane": 6155, + "log-rank▁test": 6156, + "▁Study▁Design": 6157, + "-8": 6158, + "433": 6159, + "61": 6160, + "67": 6161, + "96": 6162, + "Disease▁": 6163, + "HE": 6164, + "PSA": 6165, + "ai": 6166, + "cit": 6167, + "finding": 6168, + "s▁to▁the▁": 6169, + "screening": 6170, + "s▁about": 6171, + "vas": 6172, + "e▁as▁": 6173, + "▁tr": 6174, + "atigu": 6175, + "ite▁blood▁": 6176, + "rox": 6177, + "ed-": 6178, + "▁of▁patients▁with": 6179, + ".\n\n12": 6180, + "▁initi": 6181, + "studi": 6182, + "estru": 6183, + "▁fever": 6184, + "vertebral▁": 6185, + "e▁trial": 6186, + "izing": 6187, + "▁O\n\nY▁P▁O▁C": 6188, + "▁go": 6189, + "▁L-M": 6190, + "from▁the▁": 6191, + ".5.2": 6192, + "ensity▁": 6193, + "related": 6194, + "angu": 6195, + "▁Date:▁16▁July▁2004": 6196, + "▁leucovorin": 6197, + "▁Protocol▁Number:▁20010145": 6198, + "ORD": 6199, + "▁general": 6200, + "▁chemotherapy▁regimen": 6201, + "▁there▁are▁": 6202, + "major": 6203, + "▁a▁maximum": 6204, + "DMC▁will": 6205, + "▁required": 6206, + "▁safety▁data": 6207, + "y▁system": 6208, + "\n\nComplet": 6209, + "▁profil": 6210, + "▁stratifi": 6211, + "s▁before▁randomization": 6212, + "▁September▁2007": 6213, + "▁Protocol▁Amendment▁6": 6214, + "▁Denosumab▁Protocol▁Number:▁20050136▁Date:▁30▁April▁2008\n\nPage▁": 6215, + "estruction": 6216, + "-2010": 6217, + "fac": 6218, + "method": 6219, + "ually": 6220, + "war": 6221, + "\n\nfor": 6222, + "retain": 6223, + "ital▁": 6224, + "▁an▁ex": 6225, + "▁cm": 6226, + "▁cod": 6227, + "▁capecitabine▁": 6228, + "▁best": 6229, + "▁to▁have▁": 6230, + "▁weight": 6231, + "el:": 6232, + "access▁to": 6233, + "▁(including": 6234, + "▁2▁1": 6235, + "ush": 6236, + "▁hist": 6237, + "apeutic": 6238, + "▁or\n\n": 6239, + "▁progress": 6240, + "▁adenocarcinoma": 6241, + "e▁to▁the▁": 6242, + "ed▁before▁": 6243, + "▁of▁81": 6244, + "▁37": 6245, + "▁concomitant": 6246, + "ology▁and▁": 6247, + "aily": 6248, + "s.▁J": 6249, + "ensity": 6250, + "▁Guidelin": 6251, + "s.\n\nS": 6252, + "▁has▁not": 6253, + "ymptomatic": 6254, + "▁must▁be▁obtain": 6255, + "rospective▁": 6256, + "-2006": 6257, + "related▁to▁the▁": 6258, + "ify▁the▁": 6259, + "▁October▁2010": 6260, + "▁paragraph": 6261, + "imilar▁to": 6262, + "C00015": 6263, + "▁Reporting": 6264, + "statistical": 6265, + "▁power▁to▁detect": 6266, + "apsul": 6267, + "▁regulatory": 6268, + "▁discussion": 6269, + "withdrawn▁from": 6270, + "cientific": 6271, + "Wild-type▁KRAS": 6272, + "a-": 6273, + "lational▁": 6274, + "rate▁of": 6275, + "vital▁sign": 6276, + "yoc": 6277, + "s▁who": 6278, + ",▁con": 6279, + "ed;": 6280, + "ed,▁and▁": 6281, + "▁of▁C": 6282, + "▁might": 6283, + "▁and▁bevacizumab": 6284, + "ure▁in": 6285, + "▁(E": 6286, + "▁IRB": 6287, + "unable▁to": 6288, + "▁Or": 6289, + "easure▁": 6290, + "▁treatment▁for": 6291, + "▁via": 6292, + "following▁the▁": 6293, + "▁any▁reason": 6294, + "\n\nDose▁": 6295, + "s▁and▁symptom": 6296, + "▁Japan": 6297, + "END": 6298, + "aminotransfer": 6299, + "1865": 6300, + "40.5": 6301, + "associated▁with": 6302, + "\n\nYou": 6303, + "ORTC": 6304, + "▁days)": 6305, + "▁related▁to": 6306, + "ividual▁": 6307, + "▁PFS▁event": 6308, + "▁documented▁": 6309, + ".\n\nConfidential\n\nPage▁": 6310, + "▁17:07": 6311, + "▁A6181120": 6312, + "roft": 6313, + "\\Approved\\Approved▁On:▁25-": 6314, + "laboratory▁test": 6315, + "alate▁Salt": 6316, + "▁comply▁with": 6317, + "currence▁": 6318, + "returned▁to": 6319, + "▁worsening": 6320, + "▁hazard▁ratio": 6321, + "esophag": 6322, + "corporating": 6323, + "ouble-blind": 6324, + "giogenes": 6325, + ",▁25▁October▁2010": 6326, + "1741865": 6327, + "Oct-2010": 6328, + "affin-embedd": 6329, + "▁L-Malate▁Salt": 6330, + "▁Protocol▁Amendment▁6,▁25▁October▁2010": 6331, + "▁A6181120▁Protocol▁Amendment▁6,▁25▁October▁2010": 6332, + "\\Approved\\Approved▁On:▁25-Oct-2010": 6333, + "1741865\\Approved\\Approved▁On:▁25-Oct-2010": 6334, + "1741865\\Approved\\Approved▁On:▁25-Oct-2010▁17:07": 6335, + "63": 6336, + "bstract": 6337, + "cop": 6338, + "mail": 6339, + "meet": 6340, + "oor": 6341, + "sunitinib": 6342, + "s▁and▁the▁": 6343, + "s▁associated▁with": 6344, + "one": 6345, + "▁a▁2": 6346, + "error": 6347, + "▁thos": 6348, + "▁potential": 6349, + "▁care": 6350, + "▁bone▁scan": 6351, + "ation▁for": 6352, + "▁of▁treatment": 6353, + "▁and▁S": 6354, + ".\n\n13": 6355, + "emographic": 6356, + "▁Secondary▁": 6357, + "amily▁": 6358, + "ody▁": 6359, + "ate▁a": 6360, + "▁prognostic": 6361, + "opport": 6362, + "superior": 6363, + "50%": 6364, + "area": 6365, + "s.\n\nThe▁": 6366, + "..................................................................................": 6367, + "pared": 6368, + "whichever": 6369, + "▁situ": 6370, + "collected▁": 6371, + "ross": 6372, + "statistic": 6373, + "▁cutoff": 6374, + "ski": 6375, + "emetrexed▁H3E-MC-JMHR": 6376, + "leading▁to": 6377, + "ength": 6378, + "▁(94)\n\nGEL▁Version▁ID:▁CV.000−522−306.7.0▁Approved▁by\n\nApproved\n\nDate▁Printed:▁30−Jul−2014\n\nS▁18▁Feb▁2011▁11:38:55": 6379, + ".V": 6380, + "1\n\n7": 6381, + "7▁December▁2010": 6382, + "destroy": 6383, + "iarrhea": 6384, + "maging": 6385, + "pair": 6386, + "replac": 6387, + "aling": 6388, + "▁central▁": 6389, + "asm": 6390, + "▁dimension": 6391, + "▁and▁f": 6392, + "▁and▁will": 6393, + "▁in▁S": 6394, + "▁investigational": 6395, + "ocal▁": 6396, + "ochem": 6397, + "▁Cell": 6398, + "ili": 6399, + "▁(d": 6400, + "otoxic": 6401, + "▁list": 6402, + "easures": 6403, + "adir": 6404, + "e▁size▁": 6405, + "▁06": 6406, + "phyl": 6407, + "\n\n11": 6408, + ".▁Sampl": 6409, + "s▁will▁be▁performed▁": 6410, + "▁pleur": 6411, + "▁performed▁": 6412, + "pecial": 6413, + "▁10:": 6414, + "ception": 6415, + "center": 6416, + "e.\n\nThe▁": 6417, + "pre-": 6418, + "▁The▁investigator": 6419, + "▁mg/mL": 6420, + "evelopment▁of": 6421, + "Clinical▁Practic": 6422, + "▁There▁": 6423, + "non-target▁lesion": 6424, + "ulatory▁": 6425, + "06:45": 6426, + "▁antibody": 6427, + "ardiogram": 6428, + "▁severe▁": 6429, + "▁Dec▁2010": 6430, + "▁17:06:45": 6431, + "confirmed▁": 6432, + "most▁common": 6433, + "▁Therapy": 6434, + "−640.5": 6435, + "controlled▁": 6436, + "puter": 6437, + "▁days▁prior▁to▁randomization": 6438, + "criptive▁": 6439, + "emorrh": 6440, + "▁malignanc": 6441, + "▁mg/dL": 6442, + "ous▁infusion": 6443, + "09▁June▁2009": 6444, + "ucle": 6445, + "(106)\n\nGEL▁Version▁ID:▁ONC.000−272−636.4.0\n\nApproved\n\nDate▁Printed:▁13−Aug−2013\n\nApproved▁by\n\n13▁Sep▁2007▁17:17:03\n\nAmended▁Clinical▁Study▁Protocol▁Drug▁Substance▁Cediranib▁(RECENTIN,▁AZD2171)▁Study▁Code▁D8480C00013": 6446, + "icalutamide▁": 6447, + "U011248▁L-Malate▁Salt": 6448, + "▁08▁Dec▁2010": 6449, + "433−640.5": 6450, + "ite▁blood▁cell": 6451, + "▁Date:▁16▁July▁2004\n\nPage▁": 6452, + "▁08▁Dec▁2010▁17:06:45": 6453, + ")▁with": 6454, + "-Nov": 6455, + ":14": 6456, + "Man": 6457, + "mov": 6458, + "material": 6459, + "s?": 6460, + "\n\nWith:": 6461, + "item": 6462, + ",▁ch": 6463, + ",▁19": 6464, + "▁to\n\n": 6465, + "▁and▁PFS": 6466, + ".\n\nL": 6467, + "uration▁of": 6468, + "plication": 6469, + "▁1.2": 6470, + "▁(ie,▁": 6471, + "▁http://": 6472, + "▁procedure▁": 6473, + "opaus": 6474, + "▁are▁the▁": 6475, + "e\n\nD": 6476, + "ed▁in▁accordance▁with": 6477, + ".22": 6478, + "▁of▁5": 6479, + "corresponding": 6480, + "ceipt": 6481, + "▁stable▁": 6482, + "▁40": 6483, + "▁45": 6484, + "▁what": 6485, + "1099": 6486, + "▁unblind": 6487, + "▁Protocol▁A618": 6488, + "▁tumor▁cell": 6489, + "ement▁of": 6490, + "centr": 6491, + "soon": 6492, + "s.\n\nP": 6493, + "every▁6▁week": 6494, + "▁imag": 6495, + "▁the▁patient▁is▁": 6496, + "no▁longer": 6497, + "completed▁": 6498, + "▁the▁study▁drug": 6499, + "▁Combination": 6500, + "discretion": 6501, + "▁should": 6502, + "clinical▁study▁": 6503, + "▁starting": 6504, + "▁Edition▁Number▁3▁Date▁7▁December▁2010": 6505, + "decreas": 6506, + "adjusted▁": 6507, + "▁body▁": 6508, + "quamous▁cell": 6509, + "rincipal▁Investigator": 6510, + "greater▁than": 6511, + "\n\nABI-007▁Clinical▁Trial▁Protocol:▁CA031": 6512, + "▁original": 6513, + "▁Monitoring▁Committe": 6514, + "▁survival▁(OS": 6515, + "bearing▁p": 6516, + "C00015▁Edition▁Number▁3▁Date▁7▁December▁2010": 6517, + "opportun": 6518, + "IB": 6519, + "liver": 6520, + "s\n\nS": 6521, + "ina": 6522, + ",▁1": 6523, + "icro": 6524, + "▁most": 6525, + "▁mutation": 6526, + ".\n\n.▁T▁N▁E▁M▁U▁C▁O▁D": 6527, + "elv": 6528, + "eliev": 6529, + "plasma": 6530, + "if▁the▁": 6531, + "opor": 6532, + "ed▁in▁Appendix": 6533, + "adequate▁": 6534, + "▁along": 6535, + "▁will▁be▁assess": 6536, + "▁3▁:": 6537, + "▁vit": 6538, + "▁stop": 6539, + "▁weekly▁": 6540, + "ed▁for▁the▁": 6541, + "paragraph": 6542, + ",▁or▁other": 6543, + ".▁If▁you": 6544, + "....................................................................................": 6545, + ".\n\nPFIZER▁CONFIDENTIAL▁Page▁": 6546, + "▁years▁of": 6547, + "▁disease▁progression▁or": 6548, + "▁disorder": 6549, + "▁Amgen▁Inc": 6550, + "diagnos": 6551, + "▁withdrawal": 6552, + "▁class": 6553, + "▁advanced▁non-": 6554, + "opsy▁": 6555, + ".▁It▁is▁": 6556, + "zoledronic▁acid": 6557, + "▁temperature": 6558, + "persensitivity▁reaction": 6559, + "▁06▁October▁2006": 6560, + "▁3▁:▁2▁1": 6561, + "(34": 6562, + "51": 6563, + "AST": 6564, + "Dis": 6565, + "cial": 6566, + "eep": 6567, + "ledg": 6568, + "nual▁": 6569, + "potential▁": 6570, + "e▁all": 6571, + "\n\n[": 6572, + "stant": 6573, + ",▁st": 6574, + ",▁in▁the▁": 6575, + "▁port": 6576, + "umption": 6577, + "▁date:": 6578, + "al▁relationship": 6579, + "abase▁": 6580, + "progress": 6581, + "rap": 6582, + "ancreat": 6583, + "express": 6584, + "\n\nAt": 6585, + "▁Tim": 6586, + "▁advers": 6587, + "▁treatment▁assignment": 6588, + "aint": 6589, + "▁is▁defined▁as": 6590, + "e▁the▁subject": 6591, + "▁of▁the▁study▁": 6592, + "2007": 6593, + "ated▁for": 6594, + "relimin": 6595, + "\n\nX▁X▁X": 6596, + "ENC": 6597, + "▁associated▁": 6598, + "18cc": 6599, + "▁16-Nov": 6600, + ").\n\nThe▁": 6601, + "▁formula": 6602, + ".\n\nPro": 6603, + "▁reporting": 6604, + "vanced▁": 6605, + "comitant▁Medication": 6606, + "▁cannot▁be▁": 6607, + "-specifi": 6608, + "shipp": 6609, + "ENTS": 6610, + "(cid:120)\n\n": 6611, + "▁x▁x▁x▁x": 6612, + "▁baseline▁to": 6613, + "ophil": 6614, + "▁severity": 6615, + "\n\nOverall": 6616, + "▁18:5": 6617, + "\\Approved\\Approved▁On:▁16-Nov": 6618, + "ild-typ": 6619, + "MENTS": 6620, + "▁(see▁": 6621, + "\n\nSunitinib▁A6181120▁Protocol▁Amendment▁6,▁25▁October▁2010": 6622, + "olecul": 6623, + "ood▁Clinical▁Practic": 6624, + "ature▁of": 6625, + "▁previous▁dos": 6626, + "▁once▁": 6627, + ")\n\nGEL▁Version▁ID:▁CV.000−433−640.5": 6628, + "stimulating": 6629, + "earlier": 6630, + "▁endothelial▁": 6631, + "-2006▁18:5": 6632, + "1741865\\Approved\\Approved▁On:▁25-Oct-2010▁17:07\n\nSunitinib▁A6181120▁Protocol▁Amendment▁6,▁25▁October▁2010": 6633, + "U011248▁L-Malate▁Salt▁Protocol▁A618": 6634, + "18cc\\Approved\\Approved▁On:▁16-Nov": 6635, + "U011248▁L-Malate▁Salt▁Protocol▁A6181099": 6636, + "18cc\\Approved\\Approved▁On:▁16-Nov-2006▁18:5": 6637, + "CA": 6638, + "Efficacy▁": 6639, + "Method": 6640, + "PE": 6641, + "e\n\nP": 6642, + "handl": 6643, + "nd▁": 6644, + "ness▁of": 6645, + "path": 6646, + "atis": 6647, + "s▁other▁than": 6648, + "red▁to": 6649, + "stip": 6650, + ",▁12": 6651, + "arction": 6652, + "▁bleeding": 6653, + "▁in▁this▁": 6654, + "resect": 6655, + "idine▁": 6656, + "produc": 6657, + "unknown": 6658, + "withhel": 6659, + "apac": 6660, + "amid": 6661, + "chemist": 6662, + "▁treatment▁effect": 6663, + "\n\nSafety▁": 6664, + "▁of▁outcome▁variabl": 6665, + "....................................................................": 6666, + "▁oste": 6667, + "▁compens": 6668, + "▁the▁previous▁": 6669, + "▁the▁infusion": 6670, + "▁the▁tumor": 6671, + "▁the▁drug": 6672, + "reported▁as▁": 6673, + "ed▁at▁baselin": 6674, + "......................................................................................": 6675, + "▁your▁doctor": 6676, + "▁region": 6677, + ".\n\nPage▁": 6678, + "provided▁to": 6679, + "number▁of▁": 6680, + "▁result▁in": 6681, + "▁Progression": 6682, + "s▁on▁the▁": 6683, + "\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁AMG▁162▁Protocol▁Number:▁20040135▁Date:▁14▁November▁2006": 6684, + "\n\nOther": 6685, + "▁preserv": 6686, + "more▁": 6687, + "apecitabin": 6688, + "Therapy▁": 6689, + "deem": 6690, + "▁decrease▁in": 6691, + "platelet▁count": 6692, + "oagulation": 6693, + "\n\nAbraxis▁BioScience▁09▁June▁2009": 6694, + "\n\nRevised▁Clinical▁Study▁Protocol▁Drug▁Substance▁ZD4054▁Study▁Code▁D4320C00033▁Edition▁Number▁3▁Date▁15▁February▁2011": 6695, + "etoposid": 6696, + "\n\nAbbreviation": 6697, + "opyrim": 6698, + "▁Engl▁J": 6699, + "according▁to": 6700, + "▁of▁101\n\n090177e18069a3aa\\Approved\\Approved▁On:▁27-Sep-2007▁02:42\n\n1▁4▁:▁5▁0▁7▁0▁0▁2▁-▁g▁u▁A▁-▁1▁3▁\\▁d▁e▁v▁o▁r▁p▁p▁A\n\n\\▁1▁.▁1▁\\\n\n8▁2▁1▁6▁6▁8": 6701, + "discuss": 6702, + ").▁S": 6703, + ",▁this▁": 6704, + "-of": 6705, + "-hour": 6706, + ":\n\n1": 6707, + "Ass": 6708, + "BX-EGF": 6709, + "PI": 6710, + "UL": 6711, + "UBJEC": 6712, + "dated▁": 6713, + "fe": 6714, + "ness▁": 6715, + "yros": 6716, + "▁efficacy": 6717, + "▁eligibility▁": 6718, + "incidence▁of": 6719, + "\n\nor": 6720, + "erc": 6721, + "y▁in": 6722, + ",▁will": 6723, + ",▁subject": 6724, + ",▁it▁is▁": 6725, + ".▁With": 6726, + "ctiv": 6727, + "▁particular": 6728, + "▁could▁": 6729, + "escription": 6730, + "▁to▁re": 6731, + "▁select": 6732, + "▁delay": 6733, + "▁and▁neck": 6734, + "▁1:1": 6735, + "▁CO": 6736, + "▁(1)": 6737, + "▁SRE": 6738, + "▁rest": 6739, + "▁Dis": 6740, + "▁hyp": 6741, + "terval▁": 6742, + "examin": 6743, + "endar": 6744, + "perman": 6745, + "\n\nA▁": 6746, + "ate▁(": 6747, + "▁aspect": 6748, + "▁Taxol": 6749, + "▁Nutr": 6750, + "ogn": 6751, + "\n\nSD": 6752, + "▁2003": 6753, + "▁Methods▁of": 6754, + "▁LD": 6755, + "▁Har": 6756, + "s▁(eg,▁": 6757, + "▁study▁ent": 6758, + "s.▁H": 6759, + "axan": 6760, + ".▁Clin": 6761, + "occurred▁": 6762, + "parameter": 6763, + "▁data▁from": 6764, + "\n\n3▁4": 6765, + "shown": 6766, + "▁following": 6767, + "▁followed▁by▁": 6768, + "agnetic": 6769, + "▁continuous▁": 6770, + "▁should▁not▁be▁": 6771, + "▁activities": 6772, + "▁number▁of": 6773, + "given▁to": 6774, + "REAT": 6775, + "▁there▁is▁a": 6776, + "............................................................................": 6777, + "▁transfusion": 6778, + "▁required▁": 6779, + "▁these▁s": 6780, + "small-cell▁lung▁cancer": 6781, + "s▁including": 6782, + "▁day▁of": 6783, + "Gault": 6784, + "ackage▁insert": 6785, + "▁respect▁to": 6786, + "umbar▁spine▁": 6787, + "olid▁Tumor": 6788, + "78": 6789, + "MA": 6790, + "horm": 6791, + "lack": 6792, + "ry,▁": 6793, + "s\n\nP": 6794, + "y/": 6795, + "yes": 6796, + "ych": 6797, + "▁qu": 6798, + "investigation": 6799, + "▁a▁M": 6800, + "ic▁acid▁": 6801, + "▁pregnancy▁test": 6802, + "▁curv": 6803, + "▁sequ": 6804, + "abas": 6805, + "ance": 6806, + "ance:": 6807, + "ager": 6808, + "▁Disease▁": 6809, + "able\n\n": 6810, + "▁O▁-": 6811, + "▁adher": 6812, + "ibi": 6813, + "e\n\nThe▁": 6814, + "ed▁based▁on": 6815, + "e▁system": 6816, + ".▁Al": 6817, + "▁gl": 6818, + "▁at▁baseline▁": 6819, + "▁access▁to": 6820, + "▁Investigational▁Product": 6821, + "▁is\n\n": 6822, + "▁tumor▁response▁": 6823, + "▁pharmacokinetic": 6824, + ".\n\nAmgen": 6825, + "inalization": 6826, + "▁evaluate▁th": 6827, + "\n\n6▁0▁0▁2▁-": 6828, + "▁the▁time▁": 6829, + "-related": 6830, + "uoropyrim": 6831, + "▁E▁T▁N▁I▁R▁P\n\nA": 6832, + "ematology▁": 6833, + "participant": 6834, + "▁OF▁T": 6835, + "▁the▁final": 6836, + "lease▁": 6837, + "▁Final▁Protocol▁06▁October▁2006": 6838, + "consistent▁with": 6839, + "▁Requirement": 6840, + "▁t▁c▁O▁-": 6841, + "▁of▁81\n\nABI-007▁Clinical▁Trial▁Protocol:▁CA031": 6842, + "1\n\n7▁3▁:▁2▁1": 6843, + "U011248▁L-Malate▁Salt▁Protocol▁A6181099▁Final▁Protocol▁06▁October▁2006": 6844, + "18cc\\Approved\\Approved▁On:▁16-Nov-2006▁18:51\n\n7▁3▁:▁2▁1": 6845, + "yrosine▁": 6846, + "\n\n6▁0▁0▁2▁-▁t▁c▁O▁-": 6847, + "\n\n6▁0▁0▁2▁-▁t▁c▁O▁-▁1▁1": 6848, + "046": 6849, + "95": 6850, + "BL": 6851, + "Kaplan-Meier": 6852, + "VEGFR": 6853, + "▁el": 6854, + "\n\n®\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁Panitumumab▁Protocol▁Number:▁20050251▁Date:▁10▁October▁2006\n\nPage▁": 6855, + "▁action": 6856, + "ery▁": 6857, + "s▁such▁as▁": 6858, + "al\n\n": 6859, + "itl": 6860, + "▁the▁m": 6861, + ",▁etc": 6862, + "edu": 6863, + "ed▁through": 6864, + "▁case▁report▁form": 6865, + "▁bisphosphon": 6866, + "▁slid": 6867, + "asone▁": 6868, + "▁and▁c": 6869, + "▁Cisplatin": 6870, + "problem": 6871, + "reath": 6872, + "▁recover": 6873, + "▁line▁": 6874, + "ecome▁": 6875, + "onset": 6876, + "▁and▁to": 6877, + "opath": 6878, + "ed▁in▁this▁study": 6879, + "ency▁of": 6880, + "Incorporating": 6881, + "▁2001,▁": 6882, + "▁of▁91": 6883, + "▁altern": 6884, + "▁alpha": 6885, + "▁will▁be▁perform": 6886, + "▁3▁–": 6887, + "▁valid": 6888, + "▁6▁1▁1": 6889, + "ditional▁": 6890, + "▁the▁information": 6891, + "consist": 6892, + "▁VEGF": 6893, + "\n\nDiscontinu": 6894, + "19▁2001,▁": 6895, + "▁doses▁": 6896, + "monotherapy▁": 6897, + "included▁in▁the▁": 6898, + "occurred": 6899, + "radiograph": 6900, + "\n\nN▁A": 6901, + "predn": 6902, + ").\n\nS": 6903, + "▁cycles▁": 6904, + "e▁by": 6905, + "roughout": 6906, + "fficacy": 6907, + "▁shall": 6908, + ".▁N▁Engl▁J": 6909, + "▁tissue▁": 6910, + ".\n\nC▁I▁N▁O▁R▁T▁C▁E▁L▁E": 6911, + ".▁Patients▁with": 6912, + "▁increased▁": 6913, + "▁Stat": 6914, + "ohist": 6915, + "▁Chang": 6916, + "▁the▁end▁of▁the▁": 6917, + ",▁as▁well": 6918, + "............................................................": 6919, + ".\n\nE▁S▁A▁E▁L▁P": 6920, + "▁1▁6▁0▁0▁0▁0▁0▁1▁0": 6921, + "inferior": 6922, + "▁compliance▁with": 6923, + "emergent": 6924, + "▁June▁19▁2001,▁": 6925, + "sent▁to": 6926, + "efer▁to": 6927, + "\n\nC▁I▁N▁O▁R▁T▁C▁E▁L▁E\n\nN▁A\n\nF▁O\n\nY▁P▁O▁C": 6928, + "implement": 6929, + "fication▁factor": 6930, + "30-day▁postdiscontinuation": 6931, + "examethasone▁": 6932, + "▁dated▁23": 6933, + "uroQol": 6934, + "▁(80)\n\nGEL▁Version▁ID:▁CV.000−433−640.5": 6935, + "unctional▁Assessment": 6936, + "yocardial▁": 6937, + "▁date:▁June▁19▁2001,▁": 6938, + "\n\n3▁4▁6▁1▁1": 6939, + "inalization▁date:▁June▁19▁2001,▁": 6940, + "▁3▁–▁dated▁23": 6941, + "\n\n3▁4▁6▁1▁1▁1▁6▁0▁0▁0▁0▁0▁1▁0": 6942, + "inalization▁date:▁June▁19▁2001,▁Incorporating": 6943, + "-dose▁": 6944, + "4W": 6945, + "82": 6946, + "Agreement": 6947, + "den": 6948, + "survival": 6949, + "e▁J": 6950, + "onist": 6951, + ",▁Y": 6952, + ",▁at": 6953, + "▁so": 6954, + "▁sodium": 6955, + ".\n\nTh": 6956, + "olym": 6957, + "accur": 6958, + "▁PA": 6959, + "▁Pemetrexed▁": 6960, + "confirmed": 6961, + "▁recon": 6962, + "▁recruit": 6963, + "▁log": 6964, + "▁or▁n": 6965, + "yspne": 6966, + "▁pros": 6967, + "Investigational▁Product": 6968, + "▁staff": 6969, + "followed▁until": 6970, + "▁5%": 6971, + "▁patients▁will▁be▁": 6972, + "▁the▁investigational": 6973, + "▁expect": 6974, + "▁US": 6975, + "strong": 6976, + "\n\nNon-": 6977, + "s▁are▁not": 6978, + "\n\nx▁x": 6979, + "management": 6980, + "ibility▁of": 6981, + "part▁of▁the▁": 6982, + "state▁Cancer": 6983, + "..............................................................................": 6984, + "ype▁I": 6985, + "ifying": 6986, + "ecause▁": 6987, + "e▁fil": 6988, + "phase▁II": 6989, + "▁November▁2008": 6990, + "Grade▁4": 6991, + "▁NCI": 6992, + "g/mL": 6993, + "▁telephone▁contact": 6994, + "www": 6995, + "ingle-agent": 6996, + "▁greater": 6997, + "crual": 6998, + "▁Methods▁of▁assessment": 6999, + "\n\n6▁0▁0▁2▁-▁t▁c▁O▁-▁1▁1▁\\▁d▁e▁v▁o▁r▁p▁p▁A\n\n\\▁0▁.▁1▁\\": 7000, + "yspnea": 7001, + "8▁week": 7002, + "Design": 7003, + "E▁EV": 7004, + "Guid": 7005, + "VD": 7006, + "blood": 7007, + "croft": 7008, + "found": 7009, + "gemcitabine▁": 7010, + "larg": 7011, + "mograph": 7012, + "t▁is▁": 7013, + "traven": 7014, + "yro": 7015, + "▁µ": 7016, + "enog": 7017, + "s▁per": 7018, + "▁the▁2": 7019, + "anop": 7020, + "ropo": 7021, + "▁publication": 7022, + "▁deriv": 7023, + "▁measur": 7024, + "omat": 7025, + "omagnes": 7026, + "▁Cox": 7027, + "▁Colorectal▁Cancer": 7028, + "raw": 7029, + "▁I\n\nS▁I▁H▁T": 7030, + "▁finding": 7031, + "amic": 7032, + "▁or▁2": 7033, + "\n\nPD": 7034, + "percal": 7035, + "▁as▁an": 7036, + "eft": 7037, + "astic": 7038, + "age▁and▁": 7039, + "notification": 7040, + "▁subjects▁will▁be▁": 7041, + "s▁(±": 7042, + "\n\n14": 7043, + "lost": 7044, + "e▁during": 7045, + "▁is▁to▁be▁": 7046, + "▁-▁5": 7047, + "cipl": 7048, + "appropri": 7049, + "documented▁": 7050, + "▁modification": 7051, + "▁any▁time▁": 7052, + "▁disease": 7053, + "econdary▁endpoint": 7054, + "..............................................................": 7055, + "7054I": 7056, + "es▁or▁No": 7057, + "▁meeting": 7058, + "phase▁III": 7059, + "ibility▁that": 7060, + "ZD2171": 7061, + "optional": 7062, + "95%▁CI": 7063, + "ockcroft": 7064, + "excluding": 7065, + "oagul": 7066, + "opinion": 7067, + "emetrexed▁H3E-MC-JMHO(b)▁Confidential\n\nProtocol▁Amendment\n\nPage▁": 7068, + "ongoing": 7069, + "ancreatic": 7070, + "enograft": 7071, + "anoparticl": 7072, + ",5": 7073, + ",▁a▁s": 7074, + "-4": 7075, + ".01": 7076, + "7)▁(cid:": 7077, + "85": 7078, + "A4": 7079, + "Criteria": 7080, + "Cisplatin": 7081, + "Carboplatin": 7082, + "Day▁1": 7083, + "IHC": 7084, + "KL": 7085, + "QoL": 7086, + "card": 7087, + "eh": 7088, + "hould": 7089, + "run": 7090, + "serious": 7091, + "s▁thereafter": 7092, + "▁d▁e▁v▁o▁r▁p▁p▁A\n\nProduct:": 7093, + "▁urine▁": 7094, + "▁amended▁": 7095, + "recom": 7096, + ",▁respectively": 7097, + "ed▁when": 7098, + "▁blind": 7099, + "ationship": 7100, + "ase▁of": 7101, + "al▁CT▁scan": 7102, + "elan": 7103, + "▁Am": 7104, + "▁Aim": 7105, + "evic": 7106, + "idem": 7107, + "▁(H": 7108, + "▁(L": 7109, + "usual": 7110, + "▁Oxaliplatin": 7111, + "ence▁to": 7112, + "e▁scor": 7113, + "▁of▁the▁t": 7114, + "▁as▁referenc": 7115, + "▁all▁other": 7116, + "12▁November▁2008": 7117, + "ulti-": 7118, + "___": 7119, + "▁approxim": 7120, + "articipant": 7121, + "carri": 7122, + "Analys": 7123, + "outcomes": 7124, + "ITY": 7125, + "observation": 7126, + "▁related▁": 7127, + ".\n\nThe▁investigator": 7128, + "▁compare▁": 7129, + "▁mL/min": 7130, + "▁Dec▁2004": 7131, + "expected▁to": 7132, + "▁spir": 7133, + "ensitivity": 7134, + "utility": 7135, + "▁serum▁creatinine▁": 7136, + "▁containing": 7137, + "monitoring": 7138, + "▁therapies": 7139, + "rupt": 7140, + "▁of▁69": 7141, + "▁December▁2004": 7142, + "▁participate▁in▁this▁study": 7143, + "▁tablet": 7144, + "▁necessary": 7145, + "right▁to": 7146, + "is▁or▁her": 7147, + "Evaluation▁Criteria": 7148, + "▁fatty▁acid": 7149, + "kaline▁phosphatas": 7150, + "▁legally▁acceptable▁": 7151, + "\n\n21▁Dec▁2004": 7152, + "efici": 7153, + "127−": 7154, + "reliminary▁": 7155, + "www.": 7156, + "\n\n21▁Dec▁2004▁10:": 7157, + "),▁the▁": 7158, + ",▁the▁patient": 7159, + ",▁abdomen": 7160, + "71": 7161, + "AUC": 7162, + "det": 7163, + "lem": 7164, + "seen": 7165, + "▁own": 7166, + "▁routine▁": 7167, + "erb": 7168, + "ed▁out": 7169, + "ickn": 7170, + "▁cardiac": 7171, + "▁and▁3": 7172, + "▁and▁OS": 7173, + ".\n\n[": 7174, + ".\n\nWith:": 7175, + "resistant": 7176, + "ulation▁of": 7177, + "▁Europ": 7178, + "exploratory▁": 7179, + "▁treatment▁is▁": 7180, + ".12": 7181, + "ortality": 7182, + "anti-": 7183, + "\n\nSection": 7184, + "▁that▁may▁": 7185, + "▁of▁74": 7186, + "what": 7187, + "▁the▁sign": 7188, + "boemb": 7189, + "▁6.4": 7190, + "▁study▁(": 7191, + "▁the▁dos": 7192, + "▁plan": 7193, + "CTC": 7194, + "▁study▁therapy": 7195, + "preh": 7196, + "to-": 7197, + "......................................................................................................": 7198, + "▁care▁": 7199, + "collected▁for": 7200, + "▁locally": 7201, + "▁relevant": 7202, + "manu": 7203, + "\n\nMed": 7204, + "eligible▁for": 7205, + "▁study▁drug▁administration": 7206, + "▁partner": 7207, + "▁Chemotherapy▁": 7208, + "recommended���that": 7209, + "Pharmac": 7210, + "▁therapies▁": 7211, + "▁Grade▁3▁or▁4": 7212, + "▁Dose▁Modification": 7213, + "▁limit▁of": 7214, + "decision": 7215, + "currenc": 7216, + "Report▁Form": 7217, + "Protocol▁A61810": 7218, + ".0▁Approved▁by\n\nApproved\n\nDate▁Printed:▁30−Jul−2014\n\nS▁08▁Dec▁2010▁17:06:45": 7219, + "▁malignant": 7220, + "lymph▁nod": 7221, + "site▁personnel": 7222, + "\n\nAbraxis▁BioScience▁12▁November▁2008": 7223, + "▁XIV▁Page▁": 7224, + "\n\nAmended▁Clinical▁Trial▁Protocol▁5▁XRP6258/EFC6193\n\n21-Jul-2008▁Version▁number:▁1▁(electronic▁2.0)\n\n": 7225, + "\n\n6▁0▁0▁2▁-▁t▁c▁O▁-▁1▁1▁\\▁d▁e▁v▁o▁r▁p▁p▁A\n\n\\▁0▁.▁1▁\\\n\n3▁4▁6▁1▁1▁1▁6▁0▁0▁0▁0▁0▁1▁0": 7226, + "percalcemia": 7227, + "▁of▁69▁Addendum▁13": 7228, + ")▁of": 7229, + "/00": 7230, + "/carboplatin": 7231, + ">>": 7232, + "PCR": 7233, + "dex": 7234, + "dilut": 7235, + "rd▁": 7236, + "sam": 7237, + "\n\nn": 7238, + "orac": 7239, + ",▁Z": 7240, + "roc": 7241, + ".▁Onc": 7242, + "ed)\n\n": 7243, + "▁capsul": 7244, + "es,": 7245, + "ation▁is▁": 7246, + "ased▁on▁the▁": 7247, + "▁distribution": 7248, + "▁did▁not": 7249, + "▁match": 7250, + "imag": 7251, + "▁(eg": 7252, + "use▁": 7253, + "concern": 7254, + "iffic": 7255, + "▁light": 7256, + "epat": 7257, + "\n\nSU011248▁L-Malate▁Salt▁Protocol▁A6181099▁Final▁Protocol▁06▁October▁2006": 7258, + "▁ren": 7259, + ".▁Am▁J": 7260, + "▁one▁or": 7261, + "▁Bicalutamide▁": 7262, + "s,▁which": 7263, + "12▁week": 7264, + "▁the▁pre": 7265, + "▁exploratory▁": 7266, + "\n\nX▁X": 7267, + "▁time▁of": 7268, + "effect▁of▁": 7269, + "NCI-": 7270, + "▁important": 7271, + "▁consecutive▁": 7272, + "e▁by▁": 7273, + "▁visit▁or": 7274, + "80%": 7275, + "response▁rat": 7276, + "-treatment": 7277, + "..........................................................................": 7278, + "\n\nAny": 7279, + "certain": 7280, + "▁hypertension": 7281, + "▁confirmed▁": 7282, + "ysical▁Ex": 7283, + "withdrawal": 7284, + "▁the▁date▁of▁randomization": 7285, + "closure▁": 7286, + "regarding": 7287, + ")\n\nGEL▁Version▁ID:▁ONC.000−127−": 7288, + "guidelines": 7289, + "▁supplementation": 7290, + "▁immediately▁": 7291, + "ACK": 7292, + "ovariates": 7293, + "▁Account": 7294, + "BJECTIV": 7295, + ".\n\nLY231514\n\nPage▁": 7296, + "Lilly▁": 7297, + "▁history▁of": 7298, + "e▁shown": 7299, + "Brien": 7300, + "worst": 7301, + "reatinine▁clearance▁": 7302, + "(34)\n\nGEL▁Version▁ID:▁ONC.000−127−": 7303, + "\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁AMG▁162▁Protocol▁Number:▁20040135▁Date:▁14▁November▁2006\n\nPage▁": 7304, + "ibiotic": 7305, + "ifficult": 7306, + "▁Bicalutamide▁Study▁": 7307, + "BJECTIVES": 7308, + "3▁F": 7309, + "MT": 7310, + "d▁and▁": 7311, + "ho": 7312, + "iel": 7313, + "purpos": 7314, + "surger": 7315, + "ti-": 7316, + "topos": 7317, + "vomiting": 7318, + "wit": 7319, + "▁": 7320, + "e▁B": 7321, + "at▁the▁end▁of": 7322, + "onance▁": 7323, + "revers": 7324, + "▁and▁N": 7325, + "urfac": 7326, + "prob": 7327, + "procedure▁": 7328, + "concomitant": 7329, + "▁Sunitinib": 7330, + "▁DIS": 7331, + "▁lik": 7332, + "▁E▁S▁A▁E▁L▁P": 7333, + "chem": 7334, + "line▁": 7335, + "epatic": 7336, + "..................................................................": 7337, + "e▁the▁in": 7338, + "cord▁": 7339, + ".▁After": 7340, + "▁46": 7341, + "▁exce": 7342, + "reported▁in": 7343, + "▁predn": 7344, + "show": 7345, + "duration▁of▁": 7346, + "▁regular": 7347, + ".▁Follow": 7348, + "\n\nI▁am": 7349, + ",▁Sh": 7350, + "hypertension": 7351, + "oxy": 7352, + "▁apopt": 7353, + "▁participate▁": 7354, + "modified▁": 7355, + "s▁between": 7356, + "\n\n75%": 7357, + "arris▁": 7358, + "1-day▁": 7359, + "▁activity▁of": 7360, + "Administration": 7361, + "▁–▁Amendment▁2": 7362, + "during▁the▁study": 7363, + "Conference▁": 7364, + "chemotherapy▁regimen": 7365, + "y▁or▁its▁design": 7366, + "▁AND▁D": 7367, + "ATIONAL": 7368, + "e.g.▁": 7369, + "ocytopenia": 7370, + ",▁however": 7371, + "keletal▁": 7372, + "▁decide▁to": 7373, + "▁the▁presence▁of": 7374, + "yrosine▁kin": 7375, + "unctional▁Assessment▁of▁Cancer": 7376, + "(eg,▁": 7377, + "/leucovorin": 7378, + "8;": 7379, + "ATA": 7380, + "EFI": 7381, + "FR": 7382, + "GCP": 7383, + "IL": 7384, + "Qu": 7385, + "UG": 7386, + "cogn": 7387, + "s,\n\n": 7388, + "▁Z": 7389, + "▁iv": 7390, + "▁........................................": 7391, + "initial": 7392, + "ate▁to": 7393, + "ont": 7394, + "s▁occurring": 7395, + "alin": 7396, + "alog": 7397, + "ically": 7398, + "▁sponsor": 7399, + "▁support": 7400, + "▁of▁these▁": 7401, + "ourag": 7402, + ".\n\nW": 7403, + "olus▁": 7404, + "▁Synops": 7405, + "▁Definition": 7406, + "▁Deriv": 7407, + "aper": 7408, + "▁Ep": 7409, + "amp": 7410, + "e▁trans": 7411, + "\n\nPR": 7412, + "▁Ob": 7413, + "comp": 7414, + "▁treatment▁phas": 7415, + "......................................................................": 7416, + "▁0.5": 7417, + "▁3.4": 7418, + "▁of▁the▁following": 7419, + "▁Laboratory▁": 7420, + "▁at▁any▁tim": 7421, + "\n\n1▁8": 7422, + "s▁involv": 7423, + "▁of▁16": 7424, + "▁Informed▁Consent": 7425, + "ventor": 7426, + "▁is▁to": 7427, + "▁months,▁": 7428, + "▁aged▁": 7429, + "aceut": 7430, + "armaceut": 7431, + "▁cycle▁of": 7432, + "should": 7433, + "▁addition▁to": 7434, + ".▁Dose▁": 7435, + "▁includes": 7436, + "▁discontinue▁": 7437, + "hase▁III": 7438, + "dose▁reduction": 7439, + "▁new▁lesion": 7440, + "▁previously": 7441, + "▁protocol▁amendment": 7442, + "questionnaire": 7443, + "▁AND▁R": 7444, + "less▁than": 7445, + "▁pemetrexed▁and▁": 7446, + "▁Cont": 7447, + "life-threatening": 7448, + "▁variable▁": 7449, + "infarction": 7450, + "▁micro": 7451, + "latelet": 7452, + "▁monoclonal": 7453, + "▁Performance▁Stat": 7454, + "ation▁or▁calculation": 7455, + "\n\nRevised▁Clinical▁Study▁Protocol▁Drug▁Substance▁ZD4054▁Study▁Code▁D4320C00015▁Edition▁Number▁3▁Date▁7▁December▁2010": 7456, + "TICAL": 7457, + "pheral▁neuropath": 7458, + "solute▁neutrophil": 7459, + "▁of▁101\n\n090177e18069a3aa\\Approved\\Approved▁On:▁27-Sep-2007▁02:42\n\n1▁4▁:▁5▁0▁7▁0▁0▁2▁-▁g▁u▁A▁-▁1▁3▁\\▁d▁e▁v▁o▁r▁p▁p▁A\n\n\\▁1▁.▁1▁\\\n\n8▁2▁1▁6▁6▁8▁6▁0▁0▁0▁0▁0▁1▁0\n\nSunitinib▁Malate▁Amended▁Protocol▁A6181122▁Amendment▁1,▁28▁August▁2007": 7460, + "▁of▁81\n\nABI-007▁Clinical▁Trial▁Protocol:▁CA031\n\nAbraxis▁BioScience▁09▁June▁2009": 7461, + "18cc\\Approved\\Approved▁On:▁16-Nov-2006▁18:51\n\n7▁3▁:▁2▁1\n\n6▁0▁0▁2▁-▁t▁c▁O▁-▁1▁1▁\\▁d▁e▁v▁o▁r▁p▁p▁A\n\n\\▁0▁.▁1▁\\\n\n3▁4▁6▁1▁1▁1▁6▁0▁0▁0▁0▁0▁1▁0": 7462, + "Conference▁on": 7463, + "▁Derivation▁or▁calculation": 7464, + "(6": 7465, + "Cod": 7466, + "Hy": 7467, + "LQ": 7468, + "NI": 7469, + "Y▁T▁I▁D▁I▁L▁A▁V": 7470, + "gent": 7471, + "gether": 7472, + "i▁S": 7473, + "mark": 7474, + "rd": 7475, + "▁end▁of": 7476, + "orth": 7477, + "al▁cell": 7478, + "ed▁upon": 7479, + "▁pulmonary▁": 7480, + "▁box": 7481, + "▁to▁receive▁": 7482, + "▁to▁follow-up": 7483, + "isition": 7484, + "▁som": 7485, + "▁of▁subject": 7486, + "play": 7487, + "▁Cetuximab": 7488, + "▁SA": 7489, + "▁his▁or▁her": 7490, + "ences": 7491, + ".11": 7492, + ".2.5": 7493, + "International▁": 7494, + "▁is▁in": 7495, + "▁alter": 7496, + "▁concomitant▁medication": 7497, + "▁guid": 7498, + "▁B:": 7499, + "▁allergic": 7500, + "tudies▁": 7501, + "▁Hy": 7502, + ")\n\n(cid:": 7503, + "\n\n100": 7504, + "▁patients,▁": 7505, + "▁have▁no": 7506, + "▁uniqu": 7507, + "ated▁and▁": 7508, + "ed▁at▁a": 7509, + "ranul": 7510, + ".7.1": 7511, + "basis▁of": 7512, + "ffect": 7513, + "\n\n3\n\n3": 7514, + "cially": 7515, + "\n\nAdverse▁Event": 7516, + "▁30▁days▁after": 7517, + "oxant": 7518, + "▁participation▁in": 7519, + "s▁will▁also▁be▁": 7520, + "s▁after▁the▁last▁dose▁of": 7521, + "GEL▁Version▁ID:▁ONC.000−": 7522, + "▁antibodies▁": 7523, + "▁Appendix▁D": 7524, + "merica": 7525, + "\n\nSection:▁10": 7526, + "e▁from▁baseline▁": 7527, + "\n\n090177e181741865\\Approved\\Approved▁On:▁25-Oct-2010▁17:07\n\nSunitinib▁A6181120▁Protocol▁Amendment▁6,▁25▁October▁2010": 7528, + "alignanc": 7529, + "ify▁for": 7530, + "▁appropriate": 7531, + "previous▁": 7532, + "▁monotherapy▁": 7533, + ",▁we▁will": 7534, + "while▁on": 7535, + "▁planned▁": 7536, + "▁or▁MRI▁scan": 7537, + "e▁dose▁of": 7538, + "▁darbepoetin▁alfa▁Protocol▁Number:▁20010145": 7539, + "otherwise▁": 7540, + "urvival▁(PFS)": 7541, + "orticost": 7542, + "alliative▁": 7543, + "▁Harmon": 7544, + "olymorph": 7545, + "▁darbepoetin▁alfa▁Protocol▁Number:▁20010145▁–▁Amendment▁2": 7546, + "WBC": 7547, + "])": 7548, + "laborator": 7549, + "l/00": 7550, + "rile▁": 7551, + "▁±": 7552, + "e▁A": 7553, + "ink": 7554, + "ers▁": 7555, + "ar-2007": 7556, + "▁begin": 7557, + "▁bronch": 7558, + "for▁each": 7559, + "▁writ": 7560, + "omer": 7561, + ".\n\n1": 7562, + "olin": 7563, + "▁ANC": 7564, + "▁inhibition": 7565, + "▁120": 7566, + "ray▁": 7567, + "▁Schedul": 7568, + "▁ref": 7569, + "▁recurrent": 7570, + "▁Event": 7571, + "chosen": 7572, + "▁oral": 7573, + "\n\nArm": 7574, + "▁Toxicity▁": 7575, + "▁will▁be▁asked▁to": 7576, + "▁will▁be▁censored▁at": 7577, + "e▁should▁": 7578, + "whil": 7579, + "▁wher": 7580, + "e▁detail": 7581, + "▁is▁an": 7582, + "▁75%": 7583, + "▁abnormal▁": 7584, + "▁objectiv": 7585, + "defined▁in▁Section": 7586, + "▁therapy▁or": 7587, + "rue▁": 7588, + "performed▁as▁": 7589, + "▁completion": 7590, + "▁Compli": 7591, + "▁approximately▁30": 7592, + "hemoglobin": 7593, + "▁their▁last": 7594, + "ild-T": 7595, + "s▁will▁not▁be▁": 7596, + "▁related": 7597, + "review▁bo": 7598, + "ynamic": 7599, + "▁observed▁in": 7600, + "▁Reported▁Outcom": 7601, + "▁only▁be▁": 7602, + "▁take▁part": 7603, + "evaluated▁for": 7604, + "\n\nABI-007▁Clinical▁Trial▁Protocol:▁CA046": 7605, + "portional▁": 7606, + "etoposide▁": 7607, + "opinion▁of▁the▁": 7608, + "▁deliver": 7609, + "▁(80)\n\nGEL▁Version▁ID:▁CV.000−433−640.5.0▁Approved▁by\n\nApproved\n\nDate▁Printed:▁30−Jul−2014\n\nS▁08▁Dec▁2010▁17:06:45": 7610, + "yocardial▁infarction": 7611, + "7054Il/00": 7612, + "-being": 7613, + ";▁": 7614, + "Day▁": 7615, + "E▁S▁A▁E▁L▁P": 7616, + "Replace:": 7617, + "VES": 7618, + "VERS": 7619, + "detail": 7620, + "null": 7621, + "oz": 7622, + "\n\nd▁e▁v▁o▁r▁p▁p▁A": 7623, + "▁a▁minimum": 7624, + "ers": 7625, + ",▁randomized,▁": 7626, + "ed▁visit": 7627, + "ed,▁the▁": 7628, + "▁breast": 7629, + "ess▁or": 7630, + "▁setting": 7631, + "▁of▁2": 7632, + "▁and▁will▁be▁": 7633, + "▁(0": 7634, + "▁2.3": 7635, + "concurrent": 7636, + "ance▁to": 7637, + "▁Soc": 7638, + "▁lower": 7639, + "apable▁of": 7640, + "experience▁": 7641, + "experiment": 7642, + "able,▁": 7643, + "▁will▁be▁record": 7644, + "events▁": 7645, + "▁comp": 7646, + "2000": 7647, + "intraven": 7648, + "intoler": 7649, + "e▁indic": 7650, + "platinum": 7651, + "general": 7652, + "ensiv": 7653, + "▁Visit": 7654, + "regular": 7655, + "e▁daily▁": 7656, + "TIG": 7657, + "▁unit": 7658, + "▁from▁study▁treatment": 7659, + "▁months▁(": 7660, + "e-to-": 7661, + ",▁and/or": 7662, + "▁lead▁": 7663, + "Statistical▁": 7664, + "▁the▁time▁of▁the▁": 7665, + "s▁befor": 7666, + "arrho": 7667, + ".2.1.1": 7668, + "▁metastatic▁breast▁cancer": 7669, + ".▁New": 7670, + "▁chemotherapy▁(": 7671, + "▁change▁in": 7672, + "ophor": 7673, + "\n\nGen": 7674, + "▁vertebral▁": 7675, + "▁in▁combination▁with▁docetaxel": 7676, + "\n\nAdd▁3": 7677, + "utiliz": 7678, + ",▁whichever": 7679, + "-based": 7680, + "doctor": 7681, + "racycl": 7682, + "\n\n.▁E▁S▁U\n\nE▁R▁O▁F▁E▁B\n\nY▁T▁I▁D▁I▁L▁A▁V": 7683, + "▁complaint": 7684, + "standard▁of": 7685, + "▁practice▁": 7686, + ".0▁Approved▁by\n\nApproved\n\nDate▁Printed:▁31−Jul−2014": 7687, + "combination▁of": 7688, + "▁of▁63▁F": 7689, + "▁randomisation": 7690, + "▁adverse▁effect": 7691, + "▁three▁": 7692, + "▁on-study▁SRE": 7693, + "▁regression▁model": 7694, + "menopaus": 7695, + "▁Procedures▁for": 7696, + "YP3": 7697, + "▁in▁Solid▁Tumor": 7698, + "oagulant": 7699, + "manufact": 7700, + "VESTIG": 7701, + "▁of▁63▁Finalization▁date:▁June▁19▁2001,▁Incorporating": 7702, + ").▁": 7703, + "2f": 7704, + "6-": 7705, + "73": 7706, + "92": 7707, + "STICAL": 7708, + "mol/L": 7709, + "oice▁": 7710, + "ped": 7711, + "publish": 7712, + "vs.▁": 7713, + "way▁": 7714, + "’Brien": 7715, + "informed▁consent": 7716, + "infection": 7717, + "on▁a": 7718, + "one▁in": 7719, + "▁a\n\n": 7720, + "alyt": 7721, + "ic▁acid": 7722, + "educ": 7723, + "iss": 7724, + "umon": 7725, + "thracycl": 7726, + "▁wild-type▁KRAS": 7727, + ".\n\nST": 7728, + "iller": 7729, + "▁America": 7730, + "ithm": 7731, + "▁Cons": 7732, + "esthes": 7733, + "es▁should▁be▁": 7734, + "progressive▁disease▁": 7735, + "▁2▁:": 7736, + "▁Suppl": 7737, + "▁hemoglobin": 7738, + "▁ED": 7739, + "▁or▁PR": 7740, + "▁and▁an": 7741, + "antibod": 7742, + "▁of▁the▁protocol": 7743, + "▁ongoing": 7744, + "▁at▁the▁time▁of": 7745, + ".5▁mg": 7746, + ".▁Safety▁": 7747, + ".▁Sunitinib": 7748, + "TISTICAL": 7749, + "▁Up": 7750, + "e▁the▁following": 7751, + ".▁Pre": 7752, + "recorded▁as": 7753, + "radiotherapy▁": 7754, + "25%": 7755, + "▁16:14": 7756, + "▁a▁single▁": 7757, + "\n\nFollow": 7758, + "ERENC": 7759, + "ackag": 7760, + "\n\n0\n\n1\n\n2\n\n3\n\n4": 7761, + "▁19-M": 7762, + ".\n\nCONFIDENTIAL": 7763, + "designed▁to": 7764, + "▁14▁March▁2007": 7765, + "Respons": 7766, + "▁under▁the▁": 7767, + ".\n\nTable▁": 7768, + "86\\Approved\\Approved▁On:": 7769, + "\n\nAdd▁6": 7770, + "blood▁sampl": 7771, + "dependent▁E": 7772, + "recommendation": 7773, + ".\n\nE▁R▁O▁F▁E▁B": 7774, + "original▁": 7775, + "Placebo": 7776, + "87▁Final▁Protocol": 7777, + "acceptable▁": 7778, + "012-0": 7779, + "emergency▁": 7780, + "▁immediate▁": 7781, + "orld▁": 7782, + "judgment": 7783, + "▁version▁3.0": 7784, + ".\n\nY▁T▁I▁D▁I▁L▁A▁V": 7785, + "▁50%▁of": 7786, + "▁Period": 7787, + "▁childbearing▁p": 7788, + "▁working": 7789, + "PPEND": 7790, + "above▁": 7791, + "\n\nH3E-MC-JMHD(f)▁Clinical▁Protocol\n\nPage▁": 7792, + "▁95%▁CI": 7793, + "volume▁of": 7794, + "▁Assign": 7795, + "emetrexed▁H3E-MC-JMHR(b)▁Confidential\n\nProtocol▁Amendment\n\nPage▁": 7796, + "leming": 7797, + "Protocol▁A6181087▁Final▁Protocol": 7798, + "▁Derivation▁or▁calculation▁of▁outcome▁variabl": 7799, + "▁darbepoetin▁alfa▁Protocol▁Number:▁20010145▁–▁Amendment▁2▁Date:▁16▁July▁2004\n\nPage▁": 7800, + "ar-2007▁16:14": 7801, + "VERSE▁EV": 7802, + "2f86\\Approved\\Approved▁On:": 7803, + "▁2▁:▁1▁1": 7804, + "▁19-Mar-2007▁16:14": 7805, + "Protocol▁A6181087▁Final▁Protocol▁14▁March▁2007": 7806, + "2f86\\Approved\\Approved▁On:▁19-Mar-2007▁16:14": 7807, + "-\n\n": 7808, + "American": 7809, + "DR": 7810, + "EG": 7811, + "Peri": 7812, + "fill": 7813, + "menc": 7814, + "pur": 7815, + "pemetrexed▁": 7816, + "rine▁": 7817, + "s\n\nAll": 7818, + "wid": 7819, + "informed▁consent▁form": 7820, + "erlotinib": 7821, + "recent": 7822, + "recover": 7823, + "▁though": 7824, + "ed/": 7825, + "▁birth": 7826, + "▁methyl": 7827, + "older": 7828, + "iving": 7829, + "oward▁": 7830, + "▁final": 7831, + "endor": 7832, + "ollection": 7833, + "will▁be▁assess": 7834, + "▁arch": 7835, + "physical▁examination": 7836, + "▁FACT-": 7837, + "▁alloc": 7838, + "▁6▁week": 7839, + "▁at▁each": 7840, + "▁whom": 7841, + "eptor": 7842, + "▁have▁an": 7843, + "include▁": 7844, + "▁analysis▁for": 7845, + "ed▁with▁a": 7846, + "▁x-ra": 7847, + "▁disease▁(": 7848, + "▁90": 7849, + "▁80%": 7850, + "etermination▁of": 7851, + "\n\nTime▁to": 7852, + "▁follow▁up": 7853, + "▁interfer": 7854, + ".\n\nPatients▁": 7855, + "dosing": 7856, + "outcomes▁": 7857, + "���modified▁": 7858, + "▁relationship": 7859, + "IST▁OF": 7860, + "▁response▁of": 7861, + "▁need▁to": 7862, + "such▁as": 7863, + "▁clos": 7864, + "▁phase▁III": 7865, + "primary▁endpoint": 7866, + "central▁imaging": 7867, + "i.e.▁": 7868, + "remaining": 7869, + "later": 7870, + "▁determine▁if": 7871, + "▁possible▁": 7872, + "bumin-": 7873, + "▁characteristic": 7874, + "IMC-11F8": 7875, + "fatigu": 7876, + "apture": 7877, + "astrointestinal▁": 7878, + "▁stratum": 7879, + "for▁example,▁": 7880, + "anticip": 7881, + "ORDERS": 7882, + "30-day▁postdiscontinuation▁follow-up": 7883, + "▁DISORDERS": 7884, + "Conference▁on▁Harmon": 7885, + "orticosteroid": 7886, + "YP3A4": 7887, + "-B": 7888, + "-valu": 7889, + ".g": 7890, + "8)": 7891, + "9)": 7892, + "SU": 7893, + "System": 7894, + "below": 7895, + "e(s)": 7896, + "hold▁": 7897, + "ih": 7898, + "▁↓": 7899, + "atl": 7900, + "\n\nwill▁be▁": 7901, + "end▁": 7902, + "eryth": 7903, + "alvert": 7904, + "ently": 7905, + "▁the▁use▁of": 7906, + ",▁except": 7907, + "ing▁of▁": 7908, + "ing▁information": 7909, + "▁brain": 7910, + "▁to▁1": 7911, + "▁soft": 7912, + "▁molecul": 7913, + ".\n\n11": 7914, + "al▁CT": 7915, + "olunt": 7916, + "about": 7917, + "prognostic": 7918, + "▁2.5": 7919, + "▁IEC": 7920, + "▁Days▁": 7921, + "▁four": 7922, + "ate▁and▁": 7923, + "▁prostat": 7924, + "▁for▁each": 7925, + "ed▁informed▁consent▁form": 7926, + "▁treatment▁cycl": 7927, + "s▁of▁a": 7928, + "▁r▁a▁M": 7929, + "▁3▁1▁6": 7930, + "▁convention": 7931, + "▁the▁second▁": 7932, + "will▁receive▁": 7933, + "▁48": 7934, + "▁acut": 7935, + "one▁or": 7936, + "s.▁This▁": 7937, + "▁plac": 7938, + ".▁Panitumumab": 7939, + "may▁occur": 7940, + "▁adverse▁events▁(": 7941, + "▁perfor": 7942, + ".▁In▁the▁event": 7943, + "RIAL": 7944, + "▁9.1": 7945, + "prevention": 7946, + ").\n\nP": 7947, + "ification▁number": 7948, + "definition": 7949, + "ackaging": 7950, + "▁Analysis▁": 7951, + "pecific▁Aim": 7952, + "▁et▁al,▁199": 7953, + "\n\n7▁0▁0▁2▁-": 7954, + "▁ship": 7955, + "▁gene▁": 7956, + "s▁from▁the▁": 7957, + "longer": 7958, + "described▁in▁the▁": 7959, + "described▁in▁Section": 7960, + "▁first-line▁treatment": 7961, + "▁Grade▁1": 7962, + "▁period▁of": 7963, + "having": 7964, + "▁date.\n\n": 7965, + "▁complication": 7966, + "▁determine▁whether": 7967, + "▁may▁also": 7968, + "▁statistical": 7969, + "TIVE": 7970, + "United▁St": 7971, + "-term▁follow-up": 7972, + "-to-treat": 7973, + "strict": 7974, + "▁protect": 7975, + "viron": 7976, + "▁endothelial▁growth▁factor": 7977, + "▁-▁5▁1": 7978, + "\n\n1▁8▁3▁1▁6": 7979, + "solute▁neutrophil▁count": 7980, + "18cc\\Approved\\Approved▁On:▁16-Nov-2006▁18:51\n\n7▁3▁:▁2▁1\n\n6▁0▁0▁2▁-▁t▁c▁O▁-▁1▁1▁\\▁d▁e▁v▁o▁r▁p▁p▁A\n\n\\▁0▁.▁1▁\\\n\n3▁4▁6▁1▁1▁1▁6▁0▁0▁0▁0▁0▁1▁0\n\nSU011248▁L-Malate▁Salt▁Protocol▁A6181099▁Final▁Protocol▁06▁October▁2006": 7981, + "▁2▁:▁1▁1\n\n7▁0▁0▁2▁-": 7982, + "▁r▁a▁M▁-▁5▁1": 7983, + "\n\n1▁8▁3▁1▁6▁4": 7984, + "▁2▁:▁1▁1\n\n7▁0▁0▁2▁-▁r▁a▁M▁-▁5▁1": 7985, + "(5": 7986, + "3:": 7987, + "90%": 7988, + ":▁a": 7989, + ":\n\n\n\n": 7990, + ";▁(": 7991, + "DE": 7992, + "breast": 7993, + "could▁": 7994, + "day": 7995, + "marker": 7996, + "power": 7997, + "rb": 7998, + "vs▁": 7999, + "ential▁": 8000, + "▁answer": 8001, + "▁call": 8002, + "▁def": 8003, + "▁ml": 8004, + "▁and▁P": 8005, + ".\n\n15": 8006, + "▁Carboplatin": 8007, + "es▁may▁be▁": 8008, + "concentration": 8009, + "untreat": 8010, + "clar": 8011, + "amount": 8012, + "onsquamous▁": 8013, + "▁Randomization": 8014, + "ed▁in▁Table▁": 8015, + "▁treatment▁and▁": 8016, + "ence\n\n": 8017, + "Int": 8018, + "▁that▁are▁": 8019, + "▁albumin": 8020, + "▁will▁be▁summariz": 8021, + "▁38": 8022, + "▁gemcitabine▁": 8023, + ".3.4": 8024, + "▁Blood▁": 8025, + "▁6.1": 8026, + "ase▁Report▁Form": 8027, + "eptid": 8028, + "cediranib": 8029, + "▁WC": 8030, + "▁days▁before▁randomization": 8031, + "entered▁into": 8032, + "JMIG": 8033, + "hemor": 8034, + "local": 8035, + "▁require▁": 8036, + "e▁must": 8037, + "well▁toler": 8038, + "▁You": 8039, + "▁anti-cancer": 8040, + "▁CA012-0": 8041, + "hydrox": 8042, + "reason▁for": 8043, + "aintain▁dose▁level": 8044, + "adjustment": 8045, + "sky▁": 8046, + ".▁When": 8047, + "▁termination": 8048, + "▁questionnaire": 8049, + "hemistry": 8050, + "▁taking▁as▁referenc": 8051, + "▁Pain▁In": 8052, + "course▁of▁the▁study": 8053, + "classified▁as▁": 8054, + "▁Randomized,▁": 8055, + "ohnson": 8056, + "▁reasonable▁poss": 8057, + "opportunity▁to": 8058, + "agnetic▁res": 8059, + ".\n\nAmgen▁Thousand▁Oaks": 8060, + "prehensive▁": 8061, + "onance▁imaging": 8062, + "olymorphism": 8063, + "2f86\\Approved\\Approved▁On:▁19-Mar-2007▁16:14\n\n0": 8064, + ".S": 8065, + "1]": 8066, + "5,▁": 8067, + "DC": 8068, + "Document": 8069, + "European": 8070, + "MIN": 8071, + "bod": 8072, + "before▁the▁": 8073, + "hyp": 8074, + "iagnos": 8075, + "mouth": 8076, + "pemetrex": 8077, + "td": 8078, + "us▁will▁be▁": 8079, + "we▁": 8080, + "▁ep": 8081, + "▁our": 8082, + "▁.▁T▁N▁E▁M▁U▁C▁O▁D": 8083, + "▁team": 8084, + "at▁the▁time▁of": 8085, + "\n\ng": 8086, + "\n\nan": 8087, + "\n\nGEL▁Version▁ID:▁ONC.000−": 8088, + "s▁when": 8089, + "reach": 8090, + "alcul": 8091, + "stain": 8092, + ".▁Your": 8093, + "ing▁that": 8094, + "es.": 8095, + "es.▁The▁": 8096, + "▁to▁determine▁the▁": 8097, + "ase-": 8098, + "ely,▁": 8099, + "urr": 8100, + "▁retain": 8101, + "▁remov": 8102, + "▁or▁e": 8103, + "ircul": 8104, + "atory": 8105, + "▁Trial": 8106, + "aster": 8107, + "and▁the▁": 8108, + "romatas": 8109, + "▁treatment▁of": 8110, + "encourag": 8111, + "Informed▁Consent▁Form": 8112, + "e▁sum": 8113, + "e▁thickn": 8114, + ".▁Available▁": 8115, + "▁will▁provid": 8116, + "s▁(or": 8117, + "▁any▁un": 8118, + "s▁and▁other": 8119, + ".▁Subjects▁": 8120, + "angi": 8121, + "▁GCP": 8122, + "▁unable▁to": 8123, + "▁is▁administer": 8124, + "▁adverse▁events,▁": 8125, + "50▁mg/m2": 8126, + "teer": 8127, + "▁99": 8128, + "every▁2▁week": 8129, + "ard▁(": 8130, + "indow": 8131, + "▁a▁separate▁": 8132, + "▁minim": 8133, + "1999": 8134, + ".▁Rec": 8135, + "▁complete▁the▁": 8136, + "otentially▁": 8137, + "dispens": 8138, + "e▁Size▁": 8139, + "blinded▁": 8140, + "goal": 8141, + "PARC": 8142, + "Version▁3.0": 8143, + "▁mmol/L": 8144, + "▁phase▁II": 8145, + "▁symptomatic": 8146, + "..........................................................................................................": 8147, + "central▁laboratory": 8148, + "ness▁to": 8149, + "▁ensure▁": 8150, + "%▁of▁previous▁dos": 8151, + "ributed▁to": 8152, + "▁complianc": 8153, + "-based▁chemotherapy": 8154, + "▁objective▁progression": 8155, + "IMP": 8156, + "(SD": 8157, + "▁the▁primary▁analysis▁": 8158, + "▁qualify▁for": 8159, + "▁6▁0▁0▁0▁0▁0▁1▁0\n\nSunitinib▁Malate▁Protocol▁A6181087▁Final▁Protocol▁14▁March▁2007": 8160, + "▁directly▁": 8161, + "headach": 8162, + "▁any▁of▁the▁following": 8163, + "lice▁thickn": 8164, + "Related▁": 8165, + "▁Organ": 8166, + "e▁filter": 8167, + "arrhoea": 8168, + "ERENCES": 8169, + "▁Assignment": 8170, + "vironment": 8171, + "\n\n1▁8▁3▁1▁6▁4▁6▁0▁0▁0▁0▁0▁1▁0\n\nSunitinib▁Malate▁Protocol▁A6181087▁Final▁Protocol▁14▁March▁2007": 8172, + "▁2▁:▁1▁1\n\n7▁0▁0▁2▁-▁r▁a▁M▁-▁5▁1▁\\▁d▁e▁v▁o▁r▁p▁p▁A\n\n\\▁0▁.▁1▁\\": 8173, + "agnetic▁resonance▁imaging": 8174, + "-lif": 8175, + "Ne": 8176, + "S130": 8177, + "ULN": 8178, + "bal": 8179, + "differ": 8180, + "day▁1": 8181, + "hold": 8182, + "half": 8183, + "pa": 8184, + "riv": 8185, + "inor": 8186, + "at▁any▁tim": 8187, + "ertain": 8188, + "orithm": 8189, + "s▁if": 8190, + "refract": 8191, + "arly▁": 8192, + "ing▁an": 8193, + "omain": 8194, + ".\n\nK▁C▁E▁H▁C": 8195, + "is▁in": 8196, + "is▁defined▁as": 8197, + "00▁IU": 8198, + "used▁as▁": 8199, + "▁Subjects▁": 8200, + "▁repe": 8201, + "with▁a": 8202, + "▁Each": 8203, + "▁facil": 8204, + "chema": 8205, + "▁or▁1": 8206, + "\n\nPrinted▁copy▁is▁not▁official▁record.\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁Panitumumab▁Protocol▁Number:▁20050203▁Date:▁21▁January▁2009\n\nPage▁": 8207, + "study▁is▁": 8208, + "▁and▁toler": 8209, + "▁Toxicity": 8210, + "▁for▁all": 8211, + "ibly▁": 8212, + "adverse▁": 8213, + "▁g/dL": 8214, + "curv": 8215, + "▁the▁prior": 8216, + ")\n\n4": 8217, + "▁study▁completion": 8218, + "\n\n1\n\n1": 8219, + "lying": 8220, + "▁the▁dose▁": 8221, + "\n\nEnd▁of": 8222, + ".▁The▁t": 8223, + ".▁Clinical▁": 8224, + "ed▁without": 8225, + "have▁a": 8226, + "al▁protein": 8227, + "s▁within": 8228, + "\n\n2\n\n2": 8229, + "▁should▁be▁performed▁": 8230, + "individual": 8231, + "▁a▁serious▁adverse▁event": 8232, + "duration▁of": 8233, + "data▁from": 8234, + ".\n\nSection:": 8235, + ".\n\nS▁I▁H▁T": 8236, + ".\n\nS▁T▁I\n\nK▁C▁E▁H▁C": 8237, + "e▁treatment▁effect": 8238, + "approval": 8239, + "fficacy▁of": 8240, + "display": 8241, + "▁dispens": 8242, + "your▁doctor": 8243, + "▁2006;": 8244, + "▁deterior": 8245, + "▁a▁central▁": 8246, + "justment": 8247, + "▁baseline,▁": 8248, + "ematology": 8249, + "vision": 8250, + "▁IV▁infusion": 8251, + "▁Qual": 8252, + "▁Adverse▁Events▁": 8253, + "refer▁to": 8254, + "..........................................................": 8255, + "▁Medical▁": 8256, + "▁End▁of": 8257, + "▁worsen": 8258, + "Lilly": 8259, + "▁greater▁than": 8260, + "▁chemistry▁": 8261, + "regulatory▁author": 8262, + "▁as▁well▁as▁": 8263, + "ECOG▁performance▁status": 8264, + "TING": 8265, + "▁commercial": 8266, + "\n\nH3E-US-S130(d)▁Clinical▁Protocol\n\nPage▁": 8267, + "▁surgical": 8268, + "mptly▁": 8269, + "stimulating▁factor": 8270, + "found▁to▁be▁": 8271, + "recommended▁": 8272, + "hemorrh": 8273, + "irculating": 8274, + "(4": 8275, + ",10": 8276, + "1:": 8277, + ":▁0": 8278, + ":▁http://": 8279, + "Principal▁Investigator": 8280, + "SD": 8281, + "SH": 8282, + "ez": 8283, + "letter": 8284, + "publication": 8285, + "rul": 8286, + "s▁as": 8287, + "tm": 8288, + "we": 8289, + "▁studi": 8290, + "\n\n(cid:13": 8291, + "orn": 8292, + "alp": 8293, + "itative▁": 8294, + ",▁no": 8295, + "▁an▁un": 8296, + "▁peopl": 8297, + "▁cohort": 8298, + "ing▁this▁": 8299, + "▁of▁thes": 8300, + "▁of▁denosumab": 8301, + "▁definition": 8302, + ".\n\nb": 8303, + "illett": 8304, + "abul": 8305, + "▁institution": 8306, + "▁instruction": 8307, + "es▁in▁the▁": 8308, + "uscular": 8309, + "▁hom": 8310, + "▁larg": 8311, + "\n\nPre": 8312, + "ate▁you": 8313, + "linical": 8314, + "able": 8315, + "ably▁": 8316, + "able▁s": 8317, + "▁progressive▁disease▁": 8318, + "ed▁information": 8319, + "▁of▁study▁drug": 8320, + "e▁sub": 8321, + "artment": 8322, + "contracept": 8323, + "▁the▁sub": 8324, + "ayo": 8325, + "egre": 8326, + "▁examin": 8327, + "▁after▁the▁": 8328, + "10▁September▁2007": 8329, + "reported": 8330, + "▁may▁have▁been": 8331, + "▁75▁mg/m2": 8332, + "ost-": 8333, + "▁assay": 8334, + "▁10.6": 8335, + "cannot▁be▁": 8336, + "▁assessments▁will▁be▁": 8337, + "ed▁at▁baseline▁": 8338, + "▁using▁the▁": 8339, + "24-month": 8340, + "▁intern": 8341, + ")▁•": 8342, + "rowth▁Factor": 8343, + "mall▁Cell": 8344, + ".▁Analysis▁of": 8345, + "conducted▁in": 8346, + "clinical▁study": 8347, + "ospasm": 8348, + "disease,▁": 8349, + "▁of▁action": 8350, + "new▁lesion": 8351, + "\n\nAmended▁Clinical▁Study▁Protocol": 8352, + "central▁laboratory▁": 8353, + "▁procedures▁": 8354, + "\n\n.▁E▁S▁U\n\nE▁R▁O▁F▁E▁B": 8355, + "▁Phase▁3": 8356, + "▁reasons▁other▁than": 8357, + "e▁Paclitaxel": 8358, + "▁Edition▁Number▁3▁Date▁10▁September▁2007": 8359, + "metab": 8360, + "▁growth▁factor": 8361, + "\n\nCONFIDENTIAL\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁PANITUMUMAB▁(AMG▁954)▁Protocol▁Number:▁20040249▁Date:▁07▁August▁2007\n\nPage▁": 8362, + "▁requiring": 8363, + "BPI-": 8364, + "▁this▁research▁study": 8365, + "astrointestinal": 8366, + "preferred": 8367, + "pressure,▁": 8368, + "Brochure▁": 8369, + "aminotransferase▁(": 8370, + "▁adverse\n\n": 8371, + "eduction": 8372, + "anoparticle▁Paclitaxel": 8373, + "Evaluation▁Criteria▁in▁Solid▁Tumor": 8374, + "\n\nABI-007▁Clinical▁Trial▁Protocol:▁CA046\n\nAbraxis▁BioScience▁12▁November▁2008": 8375, + ".)": 8376, + "3.0": 8377, + "93": 8378, + "AP": 8379, + "Dos": 8380, + "LAN": 8381, + "MB": 8382, + "Sampl": 8383, + "color": 8384, + "denosumab": 8385, + "hospital": 8386, + "iform": 8387, + "lacebo": 8388, + "methyl": 8389, + "nerv": 8390, + "s,▁a": 8391, + "tr": 8392, + "we▁will": 8393, + "’s\n\n": 8394, + "▁#": 8395, + "e▁patient": 8396, + "attern": 8397, + "on▁Day▁1": 8398, + "▁a▁t": 8399, + "recruit": 8400, + "alcium": 8401, + "itu": 8402, + "ed▁patient": 8403, + "ing▁with": 8404, + "▁breath": 8405, + "etric": 8406, + "▁to▁s": 8407, + "▁to▁obtain": 8408, + "▁to▁prevent": 8409, + "▁date": 8410, + "▁measure": 8411, + "▁and▁M": 8412, + "▁and▁T": 8413, + "impact": 8414, + "urer": 8415, + "uration": 8416, + "plement": 8417, + "ilat": 8418, + "▁(I": 8419, + "▁25%": 8420, + "oter": 8421, + "▁Discontinu": 8422, + "▁lo": 8423, + "e▁two": 8424, + "\n\nAMG▁162": 8425, + "▁proc": 8426, + "committe": 8427, + "▁treatment▁regimen": 8428, + "▁is▁given": 8429, + "▁will▁be▁stratifi": 8430, + "e▁survival": 8431, + "e▁the▁d": 8432, + "▁MJ": 8433, + "▁rang": 8434, + "▁rate▁of": 8435, + "▁concern": 8436, + "intent": 8437, + "▁Bevacizumab": 8438, + "tudies": 8439, + "will▁be\n\n": 8440, + "▁6.2": 8441, + "▁HR": 8442, + "s.▁C": 8443, + "releas": 8444, + "afety,▁": 8445, + "xicities▁": 8446, + "10▁mg": 8447, + "▁time▁and▁": 8448, + ".,▁L": 8449, + "\n\nN▁A\n\nF▁O\n\nY▁P▁O▁C": 8450, + "▁consult": 8451, + "flect": 8452, + "▁death▁or": 8453, + "▁samples▁will▁be▁": 8454, + "▁discontinuation▁of▁": 8455, + "ince▁the▁": 8456, + "e▁or▁sh": 8457, + "ICH": 8458, + "TAXOL": 8459, + "▁mm▁with": 8460, + "▁Pharmac": 8461, + "▁observation": 8462, + "ploratory": 8463, + "\n\nProtocol▁Attachment▁JM": 8464, + "objectives": 8465, + "▁weeks▁until": 8466, + "post-": 8467, + "available▁to": 8468, + "▁total▁of▁": 8469, + "FACT-P": 8470, + "▁type▁of": 8471, + "additional": 8472, + "plus▁carboplatin": 8473, + "▁post-": 8474, + "extension▁lead▁": 8475, + "greater": 8476, + "United▁Stat": 8477, + "riger": 8478, + "caution": 8479, + "▁ICON": 8480, + "/mm3": 8481, + "omagnesemia": 8482, + "ild-Type▁KRAS": 8483, + "2f86\\Approved\\Approved▁On:▁19-Mar-2007▁16:14\n\n0▁2▁:▁1▁1\n\n7▁0▁0▁2▁-▁r▁a▁M▁-▁5▁1▁\\▁d▁e▁v▁o▁r▁p▁p▁A\n\n\\▁0▁.▁1▁\\": 8484, + ")\n\nA": 8485, + ".D": 8486, + "/MRI": 8487, + "4-": 8488, + ";▁or": 8489, + "Ab": 8490, + "DRA": 8491, + "PK": 8492, + "birth": 8493, + "ccess": 8494, + "htm": 8495, + "junction": 8496, + "month": 8497, + "pregnancy▁test": 8498, + "target": 8499, + "yvitamin▁D": 8500, + "instruct": 8501, + "at▁each": 8502, + "▁a▁significant": 8503, + "s▁due▁to": 8504, + "stick": 8505, + "ed▁over": 8506, + "▁an▁adverse▁event": 8507, + "▁anthracycl": 8508, + "ed,▁or": 8509, + "▁purpos": 8510, + "inger": 8511, + "▁before▁the▁": 8512, + "is▁that": 8513, + "▁specifi": 8514, + "▁source▁document": 8515, + "▁wish": 8516, + "▁maximum": 8517, + "▁AN": 8518, + "▁in▁Combination": 8519, + "idne": 8520, + "▁(n": 8521, + "uls": 8522, + "▁re-": 8523, + "▁receipt": 8524, + "▁fat": 8525, + "▁negative▁": 8526, + "odynamic": 8527, + "ate▁for": 8528, + "Information": 8529, + "physical": 8530, + "▁FOR": 8531, + "▁Baselin": 8532, + "achiev": 8533, + "▁5.5": 8534, + "▁patients▁enroll": 8535, + "▁42": 8536, + "▁access": 8537, + "▁accru": 8538, + "poon": 8539, + "▁explor": 8540, + "ed▁only▁": 8541, + "▁the▁development▁of": 8542, + "▁antigen": 8543, + "▁antibiotic": 8544, + "▁Protocol▁CA012-0": 8545, + "▁75": 8546, + ",▁the▁following": 8547, + "▁assay▁": 8548, + "radiotherapy": 8549, + "every▁6▁month": 8550, + "▁trial▁of": 8551, + "▁Adverse▁event": 8552, + ",▁Sch": 8553, + "result▁in": 8554, + "e▁treatment▁start": 8555, + "provided": 8556, + "▁subscal": 8557, + "36-month": 8558, + "role▁of": 8559, + "▁occurs▁": 8560, + "▁Cancer▁In": 8561, + "▁events▁": 8562, + "▁(ANC": 8563, + "urgical▁": 8564, + "Adjustment": 8565, + "▁there▁is": 8566, + "▁need": 8567, + "\n\nAnalysis▁Set": 8568, + "open▁label": 8569, + "Cont": 8570, + "▁clinical▁studies▁": 8571, + "ation▁of▁the▁study": 8572, + "expected▁": 8573, + "pressure▁": 8574, + "▁pemetrexed": 8575, + "more▁than": 8576, + ".▁Gen": 8577, + "remophor": 8578, + "\n\nProgression": 8579, + "▁the▁primary▁endpoint": 8580, + "experiencing": 8581, + "▁abnormalities▁": 8582, + "▁limited▁to": 8583, + "▁Lilly▁or▁its▁design": 8584, + "Brochure": 8585, + "▁(Nanoparticle▁Paclitaxel": 8586, + "▁carry▁out": 8587, + "cutaneous▁": 8588, + "vasive▁": 8589, + "▁(94)\n\nGEL▁Version▁ID:▁CV.000−522−306.7.0▁Approved▁by\n\nApproved\n\nDate▁Printed:▁30−Jul−2014\n\nS▁18▁Feb▁2011▁11:38:55\n\nRevised▁Clinical▁Study▁Protocol▁Drug▁Substance▁ZD4054▁Study▁Code▁D4320C00033▁Edition▁Number▁3▁Date▁15▁February▁2011": 8590, + "s.▁However": 8591, + "uoropyrimidin": 8592, + "ysical▁Examination": 8593, + "EFINI": 8594, + "null▁hypothes": 8595, + "C▁I▁N▁O▁R▁T▁C▁E▁L▁E": 8596, + "Reduction": 8597, + "UND": 8598, + "fax": 8599, + "mat": 8600, + "yes▁": 8601, + "▁eth": 8602, + "e▁n": 8603, + "inanc": 8604, + "investigational": 8605, + "▁audit": 8606, + "orption": 8607, + "d▁or": 8608, + "ream": 8609, + "▁the▁IVRS": 8610, + ",▁24": 8611, + "ed▁about": 8612, + "▁of▁the\n\n": 8613, + "▁mad": 8614, + ".\n\nG": 8615, + "▁A\n\nS▁I\n\nS▁I▁H▁T": 8616, + "▁investigation": 8617, + "▁inclusion": 8618, + "▁Central▁": 8619, + "es▁on": 8620, + "▁PC": 8621, + "usually▁": 8622, + "▁ret": 8623, + "applicable▁": 8624, + "▁progressive▁diseas": 8625, + "▁Natl": 8626, + "▁arter": 8627, + "and/or": 8628, + "adjuvant": 8629, + "▁will▁be▁present": 8630, + "artil": 8631, + "actic": 8632, + "content": 8633, + "ity▁in": 8634, + "ated▁with": 8635, + "▁vis": 8636, + "▁Backgroun": 8637, + "▁all▁randomized▁": 8638, + "ipstick": 8639, + "e▁information": 8640, + "▁400▁mg/m2": 8641, + "▁the▁principal▁investigator": 8642, + "▁accrual": 8643, + "▁study▁in": 8644, + "▁any▁s": 8645, + "ed▁by▁an": 8646, + "▁may▁continu": 8647, + "▁10%": 8648, + "ixed▁": 8649, + ".▁Cetuximab": 8650, + "\n\nX\n\nX\n\nX": 8651, + "▁the▁lesion": 8652, + "▁intervention": 8653, + ".▁Further": 8654, + "data▁will▁be▁": 8655, + ")▁≤": 8656, + "levels▁of": 8657, + "▁Common▁Terminology▁Criteria▁for▁Adverse▁Event": 8658, + "▁reported▁in": 8659, + "▁clinical▁progression": 8660, + "observed": 8661, + "▁relative▁to": 8662, + "▁status▁of": 8663, + "..............................................................................................": 8664, + "RBC": 8665, + "▁approved▁": 8666, + "▁York": 8667, + "ed▁colorectal▁cancer": 8668, + "-mg": 8669, + "analysis▁will▁be▁": 8670, + "▁Questionna": 8671, + "questionnair": 8672, + "storage▁": 8673, + "▁contains▁": 8674, + "▁prior▁to▁the▁": 8675, + "▁ensuring": 8676, + ".▁However,▁": 8677, + "95%▁confidence▁interval": 8678, + "uroto": 8679, + "Phase▁3": 8680, + "▁representative▁": 8681, + "Considerations▁": 8682, + "-related▁toxicities": 8683, + "▁Regimen": 8684, + "▁at▁a▁dose▁of": 8685, + "▁total▁hip": 8686, + "yeloma": 8687, + "confidentiality▁of": 8688, + "▁recruitment": 8689, + "armaceutical": 8690, + "ranulocyt": 8691, + "▁reasonable▁possibility▁that": 8692, + ")\n\nCONFIDENTIAL": 8693, + ":50": 8694, + ";▁and▁": 8695, + "BSC": 8696, + "DH": 8697, + "En": 8698, + "LES": 8699, + "ME": 8700, + "National▁Cancer▁Institut": 8701, + "femal": 8702, + "hospitalization": 8703, + "le▁": 8704, + "s▁and/or": 8705, + "void▁": 8706, + "\n\nInvestigator": 8707, + "s▁•": 8708, + "s▁not": 8709, + "rease▁": 8710, + "anine▁": 8711, + "ctive▁": 8712, + "ara": 8713, + "▁cur": 8714, + "ess▁s": 8715, + "▁to▁Amgen": 8716, + "▁syndrom": 8717, + "▁deviation": 8718, + ".\n\nO": 8719, + "▁American": 8720, + "▁in▁terms▁of": 8721, + "resection": 8722, + "resolution": 8723, + "▁Cl": 8724, + "▁PLAN": 8725, + "▁(F": 8726, + "▁SNP": 8727, + "▁hospital": 8728, + "▁E▁R▁O▁F▁E▁B": 8729, + "explain": 8730, + "study▁for": 8731, + "study▁sit": 8732, + "▁and▁the▁investigator": 8733, + "▁Time▁to": 8734, + "ef▁Pain▁In": 8735, + "comment": 8736, + "\n\nSerum": 8737, + "▁will▁be▁the▁": 8738, + "▁will▁be▁given": 8739, + "e▁sign": 8740, + "e▁sever": 8741, + "▁rat": 8742, + "▁3.1": 8743, + "correction": 8744, + "2008": 8745, + "▁vascular": 8746, + "▁vital▁sign": 8747, + "▁chart": 8748, + "▁chronic": 8749, + "e▁inter": 8750, + ".4.3": 8751, + "genital": 8752, + "103": 8753, + "▁the▁definition": 8754, + "evaluation▁of": 8755, + "▁months▁of": 8756, + "reviously▁": 8757, + "▁permit": 8758, + "▁10.2.2": 8759, + "▁physical▁examination": 8760, + "s.\n\nA": 8761, + "roduct:▁Denosumab▁Protocol▁Number:▁20050136▁Date:▁30▁April▁2008\n\nPage▁": 8762, + "radiographic": 8763, + "e.\n\nS": 8764, + "▁using▁a": 8765, + "premedication": 8766, + "▁should▁be▁made▁to": 8767, + "rollment": 8768, + "indication": 8769, + "onfidential\n\nProduct:▁AMG▁162▁Protocol▁Number:▁20040138▁Date:▁19▁February▁2008\n\nPage▁": 8770, + "▁carcin": 8771, + "ranslational▁": 8772, + "▁sites▁": 8773, + "interfer": 8774, + "▁the▁time▁from": 8775, + "ross▁": 8776, + "s▁by": 8777, + "▁Clin▁Nutr": 8778, + "▁intoler": 8779, + "▁this▁study▁will▁be▁": 8780, + "miss": 8781, + "▁who▁is▁": 8782, + "▁anti-tumor": 8783, + "▁at▁least▁on": 8784, + "▁clear": 8785, + "Progression": 8786, + "▁time▁to▁progression": 8787, + "redn": 8788, + "phosphor": 8789, + "▁metastases": 8790, + "therapy▁for": 8791, + "ART": 8792, + "comparison": 8793, + "▁body": 8794, + "LDH": 8795, + "▁Lilly▁": 8796, + "s▁are▁to▁be▁": 8797, + "▁clinically▁indicated": 8798, + "▁confidence▁interval▁": 8799, + "lobal▁": 8800, + "esophage": 8801, + "(3):": 8802, + "▁fracture▁": 8803, + "▁Response\n\n": 8804, + "▁twic": 8805, + "ordinating": 8806, + "▁every▁3▁week": 8807, + "soon▁as▁possibl": 8808, + "UBJECT": 8809, + "idemi": 8810, + "rocardiogram": 8811, + "▁participate▁in▁the▁": 8812, + "romatase▁inhibitor": 8813, + "2f86\\Approved\\Approved▁On:▁19-Mar-2007▁16:14\n\n0▁2▁:▁1▁1\n\n7▁0▁0▁2▁-▁r▁a▁M▁-▁5▁1▁\\▁d▁e▁v▁o▁r▁p▁p▁A\n\n\\▁0▁.▁1▁\\\n\n1▁8▁3▁1▁6▁4▁6▁0▁0▁0▁0▁0▁1▁0\n\nSunitinib▁Malate▁Protocol▁A6181087▁Final▁Protocol▁14▁March▁2007": 8814, + "(O": 8815, + "(eg": 8816, + "-containing": 8817, + "/4": 8818, + "2▁or": 8819, + "4/": 8820, + "4:": 8821, + "9-": 8822, + ";▁however": 8823, + "ANC": 8824, + "Bone▁": 8825, + "End▁of": 8826, + "GRO": 8827, + "HS": 8828, + "QOL": 8829, + "Radi": 8830, + "Sub": 8831, + "gorithm": 8832, + "hanc": 8833, + "s▁treated▁with": 8834, + "incid": 8835, + "onin": 8836, + ",▁2": 8837, + ".▁6": 8838, + "ing\n\n": 8839, + "ing▁physician": 8840, + "▁become▁": 8841, + "eturn": 8842, + "▁suggest": 8843, + "▁off": 8844, + "▁dist": 8845, + "▁and▁pro": 8846, + "ectal▁": 8847, + "abd": 8848, + "▁(G": 8849, + "emper": 8850, + "ulative▁": 8851, + "▁Screening": 8852, + "▁Supplement": 8853, + "age\n\n": 8854, + "▁head": 8855, + "uppression": 8856, + "▁Not": 8857, + "ed▁to▁a": 8858, + "ed▁to▁b": 8859, + "minut": 8860, + "\n\nSecondary▁": 8861, + "▁33": 8862, + "pheral": 8863, + "▁the▁screening": 8864, + "▁the▁subset": 8865, + "▁Lif": 8866, + "▁5▁year": 8867, + "▁subject▁is▁": 8868, + "▁subjects\n\n": 8869, + "▁explain": 8870, + ".025": 8871, + "reported▁as": 8872, + "evaluated": 8873, + "e.\n\nP": 8874, + "height": 8875, + ".75": 8876, + "associated▁": 8877, + "\n\nTumor": 8878, + "▁dose▁modification": 8879, + "\n\n4.6": 8880, + "data▁cut-off": 8881, + "e▁but": 8882, + "▁therapy▁and▁": 8883, + "▁was▁not": 8884, + "▁Clinical▁Onc": 8885, + "Analysis▁Set": 8886, + "▁samples▁for": 8887, + "SAP": 8888, + "\n\n\n\n\n\n\n\n": 8889, + "rolog": 8890, + "\n\n6.1": 8891, + "ITAL": 8892, + "▁(Appendix": 8893, + "e▁of▁the▁following": 8894, + "▁statement": 8895, + "es▁(PRO": 8896, + "▁responsible▁for": 8897, + "partial▁": 8898, + "-line▁filter": 8899, + "rates▁": 8900, + "▁super": 8901, + "▁clinical▁studies": 8902, + "▁<<": 8903, + "\n\nAdd▁2": 8904, + "..............................................................................................................": 8905, + ".▁Adverse▁Event": 8906, + "SIS": 8907, + "arbon": 8908, + "-C30": 8909, + "▁date,▁": 8910, + "LY231514\n\nPage▁": 8911, + "▁total▁bilirubin": 8912, + "stratification▁factor": 8913, + "ATOR": 8914, + "tebral": 8915, + "▁4▁weeks▁after": 8916, + "extension▁period": 8917, + "\n\nC▁I▁N▁O▁R▁T▁C▁E▁L▁E\n\nN▁A": 8918, + "L/N": 8919, + "▁..........................................................................................": 8920, + "▁pre-existing": 8921, + "▁representativ": 8922, + "▁Follow-up": 8923, + "▁Period▁": 8924, + "▁genetic▁research": 8925, + ")▁is▁defined▁as": 8926, + "▁persistent": 8927, + "▁Antibod": 8928, + "Arm▁B": 8929, + "istration/": 8930, + "▁to▁ensure▁that": 8931, + "▁thrombocytopenia": 8932, + "Mutant▁KRAS▁Efficacy▁Analysis▁Set": 8933, + "▁1:1▁ratio": 8934, + "ohistoc": 8935, + "▁3▁–▁dated▁23▁May▁200": 8936, + "ropoi": 8937, + "7)▁(cid:13": 8938, + "ACKGRO": 8939, + "1-day▁cycl": 8940, + "LQ-C30": 8941, + "▁defect": 8942, + "mall▁Cell▁Lung▁Cancer": 8943, + "▁(Nanoparticle▁Paclitaxel)\n\nCONFIDENTIAL": 8944, + "ACKGROUND": 8945, + "(9": 8946, + "-year": 8947, + "Ac": 8948, + "DHA": 8949, + "DXA": 8950, + "FOR": 8951, + "Hg": 8952, + "criteria▁for": 8953, + "e?": 8954, + "e).\n\n": 8955, + "length": 8956, + "member": 8957, + "malignanc": 8958, + "re▁": 8959, + "▁................................................................................................................": 8960, + "one:": 8961, + "s▁provid": 8962, + ",▁U": 8963, + ",▁n": 8964, + "▁angiogenes": 8965, + "arc": 8966, + "arrow": 8967, + "ed,▁and": 8968, + "ing▁(": 8969, + "▁bound": 8970, + "▁satis": 8971, + "▁of\n\n": 8972, + "▁domain": 8973, + "▁mucos": 8974, + "is▁for": 8975, + "▁Author": 8976, + "▁injur": 8977, + "oss": 8978, + "▁(s": 8979, + "▁Survival": 8980, + "▁Sodium": 8981, + "ries": 8982, + "▁or▁IV": 8983, + "▁or▁more▁": 8984, + "ecia": 8985, + "▁and▁then": 8986, + "▁OR": 8987, + "opecia": 8988, + "▁for\n\n": 8989, + "▁for▁this▁study": 8990, + "▁within▁the▁": 8991, + "▁will▁be▁compared▁": 8992, + "▁35": 8993, + "versus": 8994, + "▁get": 8995, + "▁the▁schedul": 8996, + "▁the▁site▁": 8997, + "▁str": 8998, + "▁step": 8999, + "▁chlorid": 9000, + "\n\n16": 9001, + "s.▁D": 9002, + "▁any▁new": 9003, + "reported▁on▁the▁": 9004, + "ovel": 9005, + "▁antag": 9006, + "ostdiscontinuation": 9007, + "e-specific": 9008, + "▁percent": 9009, + "▁signific": 9010, + "▁content": 9011, + "▁80": 9012, + "▁8.2": 9013, + "\n\nN0147": 9014, + "\n\nThe▁following": 9015, + "ley▁": 9016, + "▁Version▁3.0": 9017, + ".\n\nSubject": 9018, + "patients▁will▁be▁": 9019, + "▁evaluable▁": 9020, + "▁include:": 9021, + "▁include▁a": 9022, + "interval": 9023, + "randomized▁treatment": 9024, + "dose▁level": 9025, + "e▁Siz": 9026, + "INT": 9027, + "▁tissue▁sampl": 9028, + "▁radiograph": 9029, + "▁radiotherapy▁": 9030, + "▁Y▁T▁I▁D▁I▁L▁A▁V": 9031, + "▁transfer": 9032, + "▁transient": 9033, + "▁compare▁the▁": 9034, + "▁understand": 9035, + "▁the▁case▁of": 9036, + "attempt": 9037, + "refer▁to▁the▁": 9038, + "clearly▁": 9039, + "▁benefit▁from": 9040, + "▁amount": 9041, + "▁100▁mg/m2": 9042, + "3\n\nAmerican▁BioScience,▁Inc": 9043, + "▁personnel": 9044, + "open-label▁Casodex": 9045, + "▁indicated": 9046, + "\n\n090177e1806918cc\\Approved\\Approved▁On:▁16-Nov-2006▁18:51\n\n7▁3▁:▁2▁1\n\n6▁0▁0▁2▁-▁t▁c▁O▁-▁1▁1▁\\▁d▁e▁v▁o▁r▁p▁p▁A\n\n\\▁0▁.▁1▁\\\n\n3▁4▁6▁1▁1▁1▁6▁0▁0▁0▁0▁0▁1▁0\n\nSU011248▁L-Malate▁Salt▁Protocol▁A6181099▁Final▁Protocol▁06▁October▁2006": 9047, + "higher": 9048, + "▁include▁all": 9049, + "▁guidelines": 9050, + "▁questionnair": 9051, + "g/m2": 9052, + "▁Investigator’s▁": 9053, + "percentage▁of": 9054, + "elf-care": 9055, + "▁loss▁of": 9056, + "▁the▁investigator’s▁discretion": 9057, + "▁sites▁of▁disease▁": 9058, + "astric▁cancer": 9059, + "stitutional▁Review▁Board": 9060, + "▁spiral▁CT▁scan": 9061, + "boembolic": 9062, + ".▁Available▁at": 9063, + "▁Protocol▁CA012-0▁ABI-007": 9064, + "(8": 9065, + "(or": 9066, + "(PD": 9067, + "(see▁Section": 9068, + "/In": 9069, + "/FA": 9070, + "4PFS": 9071, + "Cycl": 9072, + "Fl": 9073, + "IDMC": 9074, + "Monitor": 9075, + "National▁": 9076, + "Pfizer": 9077, + "Redacted▁Version": 9078, + "TOC": 9079, + "au": 9080, + "fib": 9081, + "grade▁3": 9082, + "land▁": 9083, + "mok": 9084, + "o▁not": 9085, + "sen": 9086, + "women": 9087, + "yto": 9088, + "▁ill": 9089, + "\n\nassessment": 9090, + "revis": 9091, + "itoxant": 9092, + ",▁panitumumab": 9093, + "ed▁per": 9094, + "ed▁under": 9095, + ".▁8": 9096, + ".▁9": 9097, + "arin": 9098, + "edema": 9099, + "▁cardiovascular": 9100, + "▁criterion": 9101, + "is\n\n": 9102, + "▁solid▁tumor": 9103, + "▁mov": 9104, + "▁molecular": 9105, + "▁and▁b": 9106, + "al▁neck": 9107, + "al▁effusion": 9108, + "olate▁": 9109, + "▁inf": 9110, + "▁1.1": 9111, + "▁150": 9112, + "promis": 9113, + "▁(NSCLC": 9114, + "emov": 9115, + "▁Survival▁": 9116, + "rier": 9117, + "▁how": 9118, + "▁fish▁oil": 9119, + "▁or▁d": 9120, + "▁or▁death": 9121, + "\n\nAmendment": 9122, + "▁and▁that": 9123, + "▁ascit": 9124, + "▁Non": 9125, + "▁N0147": 9126, + "opies▁of": 9127, + "compression": 9128, + "and\n\n": 9129, + "ed▁tomograph": 9130, + ".25": 9131, + "\n\nScreening": 9132, + "▁Month": 9133, + "▁Metastatic": 9134, + "▁FDA": 9135, + "radical": 9136, + ".3.1.1": 9137, + "▁this▁genetic▁research": 9138, + "▁cho": 9139, + "▁chair": 9140, + "▁subject’s▁": 9141, + "s.▁For": 9142, + "▁the▁test": 9143, + "▁the▁day▁of": 9144, + "▁JR": 9145, + "▁notification": 9146, + "▁7.1": 9147, + "▁months)": 9148, + "▁10.3": 9149, + "RAN": 9150, + "▁xenograft": 9151, + "OLL": 9152, + "▁prefer": 9153, + "ed▁in▁the▁Study▁": 9154, + "\n\nIM": 9155, + "inal▁cor": 9156, + "▁its": 9157, + "▁Analysis▁Set": 9158, + "ystemic": 9159, + "atively▁": 9160, + "JMHD": 9161, + "NAGE": 9162, + "▁participation": 9163, + "ed.\n\nThe▁": 9164, + "documented▁in▁the▁": 9165, + "▁submit": 9166, + "outcome▁of": 9167, + ".▁Bevacizumab": 9168, + "ISTRA": 9169, + "▁until▁disease▁progression": 9170, + "▁radiographic": 9171, + "▁disease,▁": 9172, + "▁by▁the▁investigator": 9173, + "▁calendar": 9174, + "▁positiv": 9175, + "only▁if": 9176, + "-free▁": 9177, + "Endpoints": 9178, + "itis▁or": 9179, + "▁biological": 9180, + "CCE": 9181, + "pharmacogenetic": 9182, + "immediately": 9183, + "Follow-Up": 9184, + "▁the▁safety▁of": 9185, + "▁applicable▁regulatory▁requirement": 9186, + "▁exposure▁": 9187, + "▁abdominal": 9188, + "emoral▁neck": 9189, + "fatal": 9190, + "e▁size▁of": 9191, + "lobal": 9192, + "\n\nUE": 9193, + "fully▁": 9194, + "would▁be▁": 9195, + "IRB/IEC": 9196, + "ocalcemia": 9197, + "▁differences▁in": 9198, + "▁General▁": 9199, + "aryng": 9200, + "anada": 9201, + "▁Society▁of": 9202, + "▁missing": 9203, + "REATMENT": 9204, + "yroid▁": 9205, + "oracic": 9206, + "▁one▁or▁more▁": 9207, + ".gov": 9208, + "MINISTRA": 9209, + "▁Cancer▁Inst": 9210, + "▁Protocol▁CA012-0▁ABI-007▁(Nanoparticle▁Paclitaxel)\n\nCONFIDENTIAL": 9211, + "TOCOL": 9212, + "NAGEMENT": 9213, + ",▁treatment": 9214, + ",▁ther": 9215, + ".htm": 9216, + "2.5": 9217, + "Blood▁": 9218, + "Japan": 9219, + "PEC": 9220, + "Population": 9221, + "Target▁Lesion": 9222, + "WS": 9223, + "XR": 9224, + "bulator": 9225, + "cyt": 9226, + "double-blind": 9227, + "e.▁For": 9228, + "mic": 9229, + "mut": 9230, + "mix": 9231, + "sych": 9232, + "us▁in": 9233, + "wallow": 9234, + "yo": 9235, + "±▁1▁week": 9236, + "▁out": 9237, + "▁urin": 9238, + "▁zoledronic▁acid▁": 9239, + "e▁et▁al": 9240, + "inform": 9241, + "▁tra": 9242, + "ated▁b": 9243, + "one\n\n": 9244, + "\n\nstudy▁": 9245, + "▁a▁": 9246, + "orb": 9247, + "al▁well": 9248, + ",▁An": 9249, + ",▁such▁as▁": 9250, + ",▁regardless▁of": 9251, + ",▁pleas": 9252, + "▁circumstanc": 9253, + "▁to▁in": 9254, + "isation": 9255, + "▁and▁its▁": 9256, + "oman": 9257, + "ivo": 9258, + "▁incidence▁": 9259, + "▁1▁hour": 9260, + "▁Criteria▁for": 9261, + "▁CrCl": 9262, + "estrogen": 9263, + "▁(FOLFOX": 9264, + "ulcer": 9265, + "▁ICH": 9266, + "amend": 9267, + "cho": 9268, + "istics▁": 9269, + "▁Trial▁": 9270, + "▁are▁to": 9271, + "ortality▁": 9272, + "s▁of▁treatment": 9273, + "▁that▁you": 9274, + "▁will▁be▁conduct": 9275, + "e▁solution": 9276, + "▁congenital": 9277, + "ustral": 9278, + "▁on▁study▁": 9279, + "▁will▁also": 9280, + "▁the▁point": 9281, + "ired▁": 9282, + "\n\nDrug": 9283, + "▁the▁disease▁": 9284, + "▁J▁Cancer": 9285, + "▁Inter": 9286, + "▁from▁any▁caus": 9287, + "positiv": 9288, + "s)▁and▁": 9289, + "▁age▁": 9290, + "e▁(DMC": 9291, + "▁your▁cancer": 9292, + ".\n\nA\n\nS▁I\n\nS▁I▁H▁T": 9293, + ")▁[": 9294, + "interruption": 9295, + "documentation": 9296, + "status▁of": 9297, + "ebrile▁": 9298, + ",▁2004": 9299, + "mallest": 9300, + "▁non-small▁cell▁lung▁cancer": 9301, + "▁1999": 9302, + "▁information▁on": 9303, + "Withdraw": 9304, + "▁advanced▁colorectal▁cancer": 9305, + "▁changes▁in": 9306, + "▁need▁to▁be▁": 9307, + "▁disease\n\n": 9308, + "▁AEs▁": 9309, + "has▁not": 9310, + ",▁potassium": 9311, + "21:": 9312, + "olic▁acid▁": 9313, + "▁mmHg": 9314, + "▁Phase\n\n": 9315, + "fiel": 9316, + "▁start▁of": 9317, + "medical▁occurr": 9318, + "▁Exploratory▁": 9319, + "rincipl": 9320, + "▁abnormalities": 9321, + "Medical▁": 9322, + "Medication": 9323, + "help": 9324, + "loride▁": 9325, + "\n\nS▁T▁I\n\nK▁C▁E▁H▁C\n\nE▁S▁A▁E▁L▁P\n\n.▁T▁N▁E▁M▁U▁C▁O▁D": 9326, + "lead▁to": 9327, + "▁of▁0.05": 9328, + "L/min": 9329, + "▁surgery": 9330, + "aking▁hour": 9331, + "▁children": 9332, + "ankyo": 9333, + ".▁Additional": 9334, + "echanism▁of▁action": 9335, + "▁accurate▁": 9336, + "▁anticancer▁therapy": 9337, + "be▁taken": 9338, + "\n\nH3E-MC-JMIG(f)▁Clinical▁Protocol\n\nPage▁": 9339, + "eyond▁": 9340, + "aiich": 9341, + "apacity": 9342, + "UGA": 9343, + "opinion▁of▁the▁investigator": 9344, + "▁adverse\n\nevent": 9345, + ".,▁Ltd": 9346, + "▁reasonable▁possibility▁that▁the▁event": 9347, + "%▁and▁": 9348, + ",▁after": 9349, + "1,": 9350, + "7-": 9351, + "7;": 9352, + "Ha": 9353, + "Level": 9354, + "UCT": 9355, + "XRP6258": 9356, + "Y▁P▁O▁C": 9357, + "],▁": 9358, + "befor": 9359, + "dist": 9360, + "eat": 9361, + "hort": 9362, + "i▁A": 9363, + "iemetic": 9364, + "mith": 9365, + "s▁taken": 9366, + "’s▁in": 9367, + "onucle": 9368, + "\n\ns▁": 9369, + "\n\nal": 9370, + "org": 9371, + "rea": 9372, + "▁the▁Investigator": 9373, + ",▁patient": 9374, + "▁anx": 9375, + "▁categor": 9376, + "▁specimen": 9377, + ".\n\nStudy▁": 9378, + "al▁for": 9379, + "▁CBC": 9380, + "es▁were▁": 9381, + "es▁only": 9382, + "ilution": 9383, + "▁29": 9384, + "ance,▁": 9385, + "▁lumbar▁spine▁": 9386, + "▁EL": 9387, + "▁next": 9388, + "\n\nApproved▁by": 9389, + "commer": 9390, + "avir": 9391, + "\n\nSampl": 9392, + "▁Measurement": 9393, + "▁committe": 9394, + "portion▁of": 9395, + "▁the��sum▁of▁the▁": 9396, + "intend": 9397, + "s,▁s": 9398, + "▁all▁subjects▁": 9399, + "▁will▁have▁": 9400, + "▁HA": 9401, + "▁subjects▁(": 9402, + "▁patients▁on": 9403, + "▁study▁is▁": 9404, + "▁plot": 9405, + "over▁the▁": 9406, + "▁signs▁and▁symptom": 9407, + "▁contrast": 9408, + ".▁Tumor": 9409, + "first-line▁": 9410, + "e▁for▁the▁": 9411, + ".7.2": 9412, + "\n\nRec": 9413, + "▁prepar": 9414, + "▁premedication": 9415, + "ity▁of▁the▁": 9416, + "e,▁then": 9417, + "▁regulation": 9418, + ".\n\nPhase▁III": 9419, + "\n\nIV": 9420, + "equiv": 9421, + "▁30%": 9422, + "▁progression-free▁s": 9423, + "▁cells": 9424, + "ssessment▁of": 9425, + "disclos": 9426, + "▁response▁will▁be▁": 9427, + ".▁Ann": 9428, + "ABLES": 9429, + "▁PFS▁in▁the▁": 9430, + "urnover": 9431, + "\n\nConfidential\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁AMG▁162▁Protocol▁Number:▁20040135▁Date:▁14▁November▁2006\n\nPage▁": 9432, + "eeting": 9433, + "missing": 9434, + "▁countries▁": 9435, + "treatment▁phas": 9436, + "olic▁acid": 9437, + "▁in▁combination▁with▁FOLFOX": 9438, + "confirmed▁by▁": 9439, + "blood▁cell": 9440, + "last▁dose▁of": 9441, + "objective▁tumor": 9442, + ",▁Willett": 9443, + "Procedures": 9444, + "▁ensur": 9445, + "▁erlotinib": 9446, + "▁eryth": 9447, + "round": 9448, + "\n\n090177e180692f86\\Approved\\Approved▁On:▁19-Mar-2007▁16:14\n\n0▁2▁:▁1▁1\n\n7▁0▁0▁2▁-▁r▁a▁M▁-▁5▁1▁\\▁d▁e▁v▁o▁r▁p▁p▁A\n\n\\▁0▁.▁1▁\\\n\n1▁8▁3▁1▁6▁4▁6▁0▁0▁0▁0▁0▁1▁0\n\nSunitinib▁Malate▁Protocol▁A6181087▁Final▁Protocol▁14▁March▁2007": 9449, + "NCI▁CTCAE": 9450, + "▁fluorouracil": 9451, + "allowed▁to": 9452, + "▁creatinine▁clear": 9453, + "▁ECG": 9454, + "▁address": 9455, + "every▁3▁week": 9456, + "response▁(CR": 9457, + "Consideration": 9458, + "▁there▁is▁no": 9459, + "reconstruction": 9460, + "reconstitut": 9461, + "▁becomes▁": 9462, + "(mg": 9463, + "▁MANAGEMENT": 9464, + "ominant": 9465, + "▁vitro": 9466, + "permanently▁": 9467, + "portional▁hazard": 9468, + "▁antagonist": 9469, + "(ORR": 9470, + "/f": 9471, + "150": 9472, + "1)▁": 9473, + "2]": 9474, + "4]": 9475, + "5]": 9476, + "6]": 9477, + ":▁(": 9478, + "DUCT": 9479, + "HER": 9480, + "NS": 9481, + "Oral▁": 9482, + "OX-": 9483, + "Per": 9484, + "Rectal▁": 9485, + "Visit": 9486, + "brid": 9487, + "distribution": 9488, + "gency▁": 9489, + "manner": 9490, + "oot": 9491, + "rath": 9492, + "ry▁and▁": 9493, + "supplement": 9494, + "tra": 9495, + "urolog": 9496, + "wors": 9497, + "▁establish": 9498, + "s▁m": 9499, + "recurrent": 9500, + "iter": 9501, + "▁anemia": 9502, + "icarbon": 9503, + ".▁Un": 9504, + "▁po": 9505, + "▁potential▁": 9506, + "▁code▁": 9507, + "es\n\n": 9508, + "▁to▁confirm": 9509, + "is▁allow": 9510, + "▁seen": 9511, + "▁second▁": 9512, + "▁waking▁hour": 9513, + "▁1000": 9514, + "▁PJ": 9515, + "▁Pemetrex": 9516, + "ily": 9517, + "▁(ECOG": 9518, + "▁2-sided▁": 9519, + "und": 9520, + "▁DR": 9521, + "▁DMC": 9522, + "▁or▁a": 9523, + "▁or▁mor": 9524, + "▁or▁its▁design": 9525, + "there▁": 9526, + "upd": 9527, + "ed▁in▁an": 9528, + "ed▁in▁combination▁with": 9529, + "encies▁": 9530, + "e▁these▁": 9531, + "▁0.00": 9532, + "▁0.01": 9533, + "earn": 9534, + "▁give▁": 9535, + ".33": 9536, + "▁all▁s": 9537, + "urea": 9538, + "▁analyses▁for": 9539, + "▁4.3": 9540, + "s▁(S": 9541, + "\n\n1.1": 9542, + "▁the▁trial▁": 9543, + "▁where▁": 9544, + "ly,▁": 9545, + "\n\nEach": 9546, + "see▁section": 9547, + "▁from▁the▁study": 9548, + "s\n\n(": 9549, + "▁tumor▁progression": 9550, + "▁dose-": 9551, + "oster": 9552, + "effect▁of": 9553, + "binding": 9554, + "▁perman": 9555, + "recorded▁in": 9556, + "recorded▁on": 9557, + ".▁Two": 9558, + "arket": 9559, + "▁your▁last": 9560, + "▁the\n\ninvestigator": 9561, + "▁a▁subsequent": 9562, + "hydra": 9563, + "results▁in": 9564, + "performed▁within": 9565, + "equivalent": 9566, + "▁subjects▁receiving": 9567, + "interaction": 9568, + "▁completion▁of▁the▁": 9569, + "▁submission": 9570, + "hase▁3": 9571, + ".8.1": 9572, + "▁should▁contact": 9573, + "1)(cid:": 9574, + "partate▁": 9575, + ",▁AST": 9576, + "lesions▁": 9577, + "▁radiotherapy": 9578, + "by▁the▁investigator": 9579, + "▁Procedures": 9580, + "cribe▁": 9581, + "described▁in": 9582, + "ICAL": 9583, + "ynth": 9584, + "USP": 9585, + "only▁be▁": 9586, + "reference▁": 9587, + "pertensive▁": 9588, + "▁correspond": 9589, + "▁No▁No": 9590, + "eginning": 9591, + "panel:": 9592, + "▁conducted": 9593, + "▁life-threatening": 9594, + "▁micron": 9595, + "relationship▁between": 9596, + ".▁Vitamin▁D": 9597, + "subjects▁who": 9598, + "Schedule▁(": 9599, + "clinic▁visit▁or": 9600, + "\n\nPhysical▁examination": 9601, + "▁men▁with": 9602, + ".\n\nY▁P▁O▁C": 9603, + ".▁Therefore,▁": 9604, + "flammatory▁": 9605, + "▁(1),▁": 9606, + "▁analyses▁will▁be▁conduct": 9607, + "▁Management": 9608, + "arynx": 9609, + "likely▁to": 9610, + "▁72▁hour": 9611, + "imilar▁to▁that": 9612, + "\n\nC▁I▁N▁O▁R▁T▁C▁E▁L▁E\n\nN▁A\n\nF▁O\n\nY▁P▁O▁C\n\nD▁E▁T▁N▁I▁R▁P\n\nA\n\nS▁I\n\nS▁I▁H▁T": 9613, + "lost▁to▁follow-up": 9614, + "▁amended▁protocol": 9615, + "arris▁WS": 9616, + "Code:": 9617, + "VERSE▁EVENT": 9618, + "inorel": 9619, + "▁in▁Combination▁with": 9620, + "&N": 9621, + ",▁they▁": 9622, + "/-": 9623, + ":risk": 9624, + "Al": 9625, + "LS": 9626, + "MO": 9627, + "Patient": 9628, + "TP": 9629, + "Wild-Type▁KRAS": 9630, + "daily▁": 9631, + "depending▁on": 9632, + "final▁": 9633, + "however": 9634, + "nic": 9635, + "negative▁": 9636, + "surance▁": 9637, + "▁.▁E▁S▁U": 9638, + "▁..................................................................................................": 9639, + "\n\nKRAS": 9640, + "\n\nproduct": 9641, + "er▁R": 9642, + "organ": 9643, + "d▁(": 9644, + "al▁p": 9645, + "y▁Guid": 9646, + "entire▁": 9647, + "anel": 9648, + "arian": 9649, + "ed▁against": 9650, + "espec": 9651, + "es▁to▁the▁": 9652, + "▁to▁the▁patient": 9653, + "▁serv": 9654, + "▁drop": 9655, + "thical▁": 9656, + "▁and▁F": 9657, + "▁and▁10": 9658, + "▁ASCO": 9659, + "ime▁": 9660, + "imal▁": 9661, + "resum": 9662, + "ray": 9663, + "▁I.V": 9664, + "▁hematologic": 9665, + "▁lig": 9666, + "apies": 9667, + "verage▁": 9668, + "▁or▁in": 9669, + "▁or▁designe": 9670, + "e▁turnover": 9671, + "ister": 9672, + "▁Tissu": 9673, + "essential": 9674, + "epartment": 9675, + "study-specific": 9676, + "ed▁between": 9677, + "▁will▁be▁analyz": 9678, + "▁will▁be▁test": 9679, + "e▁this▁": 9680, + "▁Mod": 9681, + "▁of▁the▁patient": 9682, + "▁are▁met": 9683, + "▁one▁of": 9684, + "▁Biomarker": 9685, + "ceeding": 9686, + "▁the▁individual": 9687, + "s▁in▁case▁of": 9688, + "gene▁": 9689, + "\n\nDos": 9690, + "oblig": 9691, + "▁patients.▁": 9692, + "▁Good▁Clinical▁Practic": 9693, + "▁unless▁": 9694, + "AEs▁": 9695, + "▁from▁baseline▁to": 9696, + "preserv": 9697, + "▁permitt": 9698, + "ared": 9699, + ",▁and▁all": 9700, + "have▁not": 9701, + "▁8.1": 9702, + "\n\nThe▁investigator": 9703, + "lead▁": 9704, + "maintenance▁": 9705, + "▁diet": 9706, + "Clear": 9707, + "reasons": 9708, + ".▁Med": 9709, + "elective▁": 9710, + "▁upon": 9711, + "\n\nInformed▁Consent": 9712, + "▁number▁of▁": 9713, + ".▁Journal▁of": 9714, + "ed▁or▁chair": 9715, + "ternal": 9716, + "ternal▁": 9717, + "ternative▁": 9718, + "▁within▁30": 9719, + "▁the▁same▁d": 9720, + "ICES": 9721, + "reatinine▁Clear": 9722, + "▁24-hour": 9723, + "olicy": 9724, + "terim▁Analysis": 9725, + "▁have▁the▁": 9726, + "exception▁of": 9727, + "objective▁of": 9728, + "▁Concomitant▁medication": 9729, + "limiting": 9730, + "possible▁": 9731, + "symptomatic": 9732, + "▁denosumab▁is▁": 9733, + "ultiple▁": 9734, + "▁considered▁": 9735, + "▁risk▁of": 9736, + "▁medical▁condition": 9737, + "judic": 9738, + "routin": 9739, + "IMMUNEX\n\nConfidential\n\nAMGEN\n\nProduct:▁ABX-EGF▁Protocol▁Number:▁20020408▁Amendment▁4▁Date:▁26▁April▁2005\n\nPage▁": 9740, + "▁immediately": 9741, + "s.▁In▁addition": 9742, + "see▁Appendix": 9743, + "▁Data▁Monitoring▁Committe": 9744, + "▁regulatory▁": 9745, + "afety▁and▁efficacy▁": 9746, + "▁multiple▁": 9747, + "head▁and▁neck": 9748, + "otyping": 9749, + "▁phase▁of▁the▁study": 9750, + "▁entry▁": 9751, + "phenhydra": 9752, + "ital▁Sign": 9753, + "▁cutoff▁date▁": 9754, + "ochemical": 9755, + "detect": 9756, + "effect▁of▁ZD4054": 9757, + "▁exceed▁": 9758, + "alogu": 9759, + "i▁Sankyo": 9760, + "International▁Conference▁on▁Harmon": 9761, + "review▁board": 9762, + "pedited▁": 9763, + "PPENDICES": 9764, + "hydroxyvitamin▁D": 9765, + "▁may▁have▁been▁caus": 9766, + "instructed▁to": 9767, + "▁wish▁to": 9768, + "ustralia": 9769, + "aiichi▁Sankyo": 9770, + "phenhydramin": 9771, + ").▁This▁": 9772, + "+DHA": 9773, + ",▁as": 9774, + "-emergent": 9775, + "500": 9776, + "8-": 9777, + "9]": 9778, + "BUN": 9779, + "Confidential\n\nPage▁": 9780, + "Efficacy▁of": 9781, + "Histor": 9782, + "PS": 9783, + "Randomization": 9784, + "Us": 9785, + "VI": 9786, + "aEC": 9787, + "cip": 9788, + "e.▁D": 9789, + "ehydration": 9790, + "gu": 9791, + "gres": 9792, + "graph": 9793, + "ham": 9794, + "ior": 9795, + "particular": 9796, + "pending": 9797, + "▁tyrosine▁kin": 9798, + "\n\nK": 9799, + "\n\nwith": 9800, + "\n\n(cid:": 9801, + "steril": 9802, + "roly": 9803, + "ed▁not": 9804, + ".▁2": 9805, + "ed.▁In": 9806, + "▁pregnancy▁": 9807, + "ations▁of": 9808, + "is▁an": 9809, + "ission": 9810, + "omas": 9811, + ".\n\nRE": 9812, + ".\n\nYou": 9813, + "al▁expos": 9814, + "ive\n\n": 9815, + "resorption": 9816, + "oclast": 9817, + "▁150▁mg": 9818, + "ester": 9819, + "rare": 9820, + "▁Immun": 9821, + "▁recurrence▁": 9822, + "▁lab": 9823, + "▁EQ-5D": 9824, + "▁femal": 9825, + "e▁tumour": 9826, + "\n\nPfizer▁–▁Company▁Confidential▁Page▁": 9827, + "study-related▁": 9828, + "ed▁but": 9829, + "age▁IV": 9830, + "▁is▁s": 9831, + "▁of▁study▁": 9832, + "▁will▁be▁consider": 9833, + "▁0.7": 9834, + "▁of▁the▁event": 9835, + "▁commun": 9836, + "notifi": 9837, + "▁Bone▁": 9838, + "▁analyses▁will": 9839, + "▁the▁initial▁": 9840, + "ly▁to": 9841, + "Protocol▁Attachment▁JM": 9842, + "▁unless": 9843, + "s▁for▁each": 9844, + "prescrib": 9845, + "▁study▁arm": 9846, + "▁tests▁": 9847, + "ared▁": 9848, + "prepared▁": 9849, + "subjects▁with": 9850, + "▁-▁-": 9851, + "▁the\n\nsubject": 9852, + "▁Study▁of": 9853, + ".......................................................................................................▁": 9854, + "▁implement": 9855, + "s▁that▁you": 9856, + "hyth": 9857, + "▁therapy▁with": 9858, + "results▁will▁be▁": 9859, + "performed▁for": 9860, + "you▁are▁": 9861, + "enrolled▁in": 9862, + "▁apart": 9863, + "duced▁": 9864, + "▁should▁continu": 9865, + "▁requires": 9866, + "When": 9867, + "clinical▁data": 9868, + "▁change\n\n": 9869, + "underlying": 9870, + "must▁have▁": 9871, + "▁OS▁event": 9872, + "▁OS▁and▁PFS": 9873, + "start▁of": 9874, + "▁randomized▁trial": 9875, + "indicated▁": 9876, + "PA+DHA": 9877, + "significantly▁": 9878, + "▁Pharmacokinetic": 9879, + "▁basis": 9880, + "stored▁at": 9881, + "▁observed▁": 9882, + "most▁recent": 9883, + "al▁of▁consent": 9884, + "objectives▁": 9885, + "opping": 9886, + "ild-type▁": 9887, + "▁Edition▁Number▁3▁Date\n\n": 9888, + "▁carcinoma▁of▁the▁": 9889, + "planned▁": 9890, + "▁schedule▁": 9891, + ".▁It▁is": 9892, + "▁PRODUCT": 9893, + "like▁": 9894, + ",▁creatinin": 9895, + "▁enzym": 9896, + "\n\nS▁T▁I\n\nK▁C▁E▁H▁C\n\nE▁S▁A▁E▁L▁P": 9897, + "should▁not▁be▁": 9898, + "▁Co.,▁Ltd": 9899, + "us▁(0": 9900, + "▁among▁subjects▁with": 9901, + "generally▁": 9902, + "thics▁Committee": 9903, + "▁statistically▁significant": 9904, + "(1):▁p.▁": 9905, + "participation▁in▁the▁": 9906, + "▁hormone▁": 9907, + "▁application": 9908, + "omega-3▁fatty▁acid": 9909, + "loride,▁": 9910, + "examethason": 9911, + "yelos": 9912, + "effort▁should▁be▁made▁to": 9913, + "▁improvement▁in": 9914, + "avorable▁": 9915, + ".▁2000;": 9916, + "phylax": 9917, + "oporosis": 9918, + "ness▁of▁breath": 9919, + "▁compensate▁you": 9920, + "▁aspects▁of": 9921, + "▁study▁entry": 9922, + "BLIG": 9923, + "▁limit▁of▁normal▁": 9924, + "urface▁": 9925, + "▁Soc▁Clin▁Oncol": 9926, + "▁perforation": 9927, + "idney▁": 9928, + "▁Natl▁Cancer▁Inst": 9929, + "eturn▁of": 9930, + ",▁potassium,▁ch": 9931, + ",▁Willett▁WC": 9932, + "rolyt": 9933, + ")▁that": 9934, + ")▁should▁be▁": 9935, + "),▁a": 9936, + ",▁t": 9937, + "/Placebo": 9938, + "75%": 9939, + ";\n\n": 9940, + "Cox": 9941, + "E▁R▁O▁F▁E▁B": 9942, + "Figure▁": 9943, + "Overall": 9944, + "]▁and▁": 9945, + "gender": 9946, + "henia": 9947, + "much": 9948, + "nature▁of": 9949, + "pose▁": 9950, + "transfer": 9951, + "▁‘": 9952, + "▁eligibl": 9953, + "atent": 9954, + "▁aim": 9955, + "s▁regarding": 9956, + "ree▁": 9957, + "itrogen": 9958, + "ed▁f": 9959, + "ed▁due▁to": 9960, + "ed▁during": 9961, + "▁pregnancy": 9962, + "▁to▁moder": 9963, + "▁summar": 9964, + "▁of▁blood▁": 9965, + "▁measure▁": 9966, + "elt": 9967, + "▁in▁this▁study▁": 9968, + "urs": 9969, + "osin": 9970, + "estern": 9971, + "▁(p": 9972, + "emin": 9973, + "▁ImClone▁LLC": 9974, + "ages▁": 9975, + "▁Development": 9976, + "aphy": 9977, + "▁Efficacy▁": 9978, + "▁Efficacy": 9979, + "amine▁": 9980, + "▁or▁m": 9981, + "e▁treat": 9982, + "exist": 9983, + "quisition": 9984, + "lind▁": 9985, + "linear": 9986, + "▁advant": 9987, + "▁New": 9988, + "essel": 9989, + "commun": 9990, + "ive▁heart": 9991, + ".2\n\nR": 9992, + "e▁toxicity▁": 9993, + "▁alw": 9994, + "▁already▁": 9995, + "▁will▁be▁obtain": 9996, + "▁will▁be▁responsible▁for": 9997, + "▁concurrent": 9998, + "▁of▁the▁subject": 9999, + "ity▁(": 10000, + "▁as▁defin": 10001, + "2006": 10002, + "evere▁": 10003, + "▁Bi": 10004, + "▁yet": 10005, + "▁will▁have▁a": 10006, + "▁55": 10007, + "▁5.2": 10008, + "▁5.3": 10009, + "will▁not": 10010, + "ultiv": 10011, + ")\n\nD": 10012, + "s▁(RECIST": 10013, + "egr": 10014, + "reli": 10015, + "▁the▁treat": 10016, + "▁the▁total▁": 10017, + "regimens": 10018, + "Protocol:": 10019, + "107": 10020, + "evaluating": 10021, + "▁tumor▁measurement": 10022, + "e▁visit": 10023, + ".▁Investigator": 10024, + "recorded": 10025, + "▁controll": 10026, + "Study▁T": 10027, + "▁Advanced▁": 10028, + "doses▁of": 10029, + "▁includes▁": 10030, + ".▁2005": 10031, + "intern": 10032, + "▁Complet": 10033, + ",▁2000": 10034, + "▁must▁not▁be▁": 10035, + "TION▁OF": 10036, + "IV▁infusion": 10037, + "▁documentation▁of": 10038, + "▁description": 10039, + "blinded▁treatment": 10040, + "▁approval▁of": 10041, + "▁within▁1": 10042, + "\n\nF▁O\n\nY▁P▁O▁C": 10043, + "▁who▁conducted": 10044, + "ublic": 10045, + "ashion": 10046, + "imaging▁techniqu": 10047, + "▁medical▁event": 10048, + "▁or▁“": 10049, + "summaris": 10050, + "▁patients▁who▁have▁": 10051, + "\n\ninvestigational▁product": 10052, + "▁Phase▁2": 10053, + "ssum": 10054, + "ET▁scan": 10055, + "ording▁of": 10056, + "▁CVD": 10057, + "addition▁of": 10058, + "directly▁": 10059, + "history▁of": 10060, + ",▁we▁": 10061, + "persensitivity": 10062, + "▁Receptor": 10063, + "\n\nConfidential\n\nAMGEN\n\nProduct:▁darbepoetin▁alfa▁Protocol▁Number:▁20010145▁–▁Amendment▁2▁Date:▁16▁July▁2004\n\nPage▁": 10064, + "\n\nExploratory▁": 10065, + "▁assumption": 10066, + "Objectives": 10067, + "e▁time▁": 10068, + "ittl": 10069, + "▁CONT": 10070, + "▁carry▁on": 10071, + "essional": 10072, + "appearance▁of▁all": 10073, + ".▁Pharmac": 10074, + "▁a▁copy▁of▁the▁": 10075, + "s.▁Patients▁": 10076, + "▁Reaction": 10077, + "ince▁the▁treatment▁start": 10078, + "Wild-type▁KRAS▁Efficacy▁Analysis▁Set": 10079, + "ulatory▁A": 10080, + "▁body▁weight": 10081, + "▁along▁with": 10082, + ".▁N▁Engl▁J▁Med▁": 10083, + "efer▁to▁Section": 10084, + "▁or▁nail": 10085, + "▁approximately": 10086, + "carried▁out": 10087, + ".▁Am▁J▁Clin▁Nutr": 10088, + "menopausal": 10089, + "oward▁medical▁occurr": 10090, + ":▁http://www.": 10091, + "extension▁lead▁period": 10092, + "(OH)": 10093, + "\n\nIMMUNEX\n\nConfidential\n\nAMGEN\n\nProduct:▁ABX-EGF▁Protocol▁Number:▁20020408▁Amendment▁4▁Date:▁26▁April▁2005\n\nPage▁": 10094, + "ebrile▁neutropenia": 10095, + ".\n\nPhase▁III▁Protocol▁CA012-0▁ABI-007▁(Nanoparticle▁Paclitaxel)\n\nCONFIDENTIAL": 10096, + "Oral▁Rectal▁": 10097, + ",3": 10098, + "-SCLC": 10099, + "500▁mg/m2": 10100, + "745": 10101, + "Fatigu": 10102, + "Scal": 10103, + "colorectal▁cancer": 10104, + "dr": 10105, + "langu": 10106, + "mutant▁KRAS": 10107, + "multicenter": 10108, + "random": 10109, + "suggest": 10110, + "”▁or▁“": 10111, + "▁&": 10112, + "e▁D": 10113, + "\n\n30": 10114, + "orter": 10115, + "or▁cyt": 10116, + "s▁model": 10117, + "alk": 10118, + "alpha": 10119, + ",▁placebo": 10120, + "ed▁log-rank▁test": 10121, + "es▁an": 10122, + "ese▁sit": 10123, + "isol": 10124, + "▁dam": 10125, + "▁woman": 10126, + "▁mortality": 10127, + "▁and▁must": 10128, + "▁and▁carboplatin": 10129, + "▁and▁Treatment": 10130, + "is▁no": 10131, + "▁Ab": 10132, + "▁Aci": 10133, + "▁in▁writ": 10134, + "ocrit": 10135, + "▁Cor": 10136, + "▁Prior": 10137, + "▁Path": 10138, + "prolong": 10139, + "▁2.1": 10140, + "▁SU": 10141, + "otograph": 10142, + "age▁to": 10143, + "▁heart": 10144, + "▁or▁the▁": 10145, + "e▁techniqu": 10146, + "utom": 10147, + "\n\nPRO": 10148, + "▁nec": 10149, + "▁novel": 10150, + "\n\nAttachment": 10151, + "ate▁s": 10152, + "study▁of": 10153, + "▁OBLIG": 10154, + "component": 10155, + "commenc": 10156, + "▁arth": 10157, + "androgen": 10158, + "▁REP": 10159, + "age▁(": 10160, + "▁of▁M": 10161, + "▁will▁be▁calculated▁": 10162, + "▁0.0": 10163, + "▁as▁per": 10164, + "▁on▁day▁1": 10165, + "▁vendor": 10166, + "▁BSA": 10167, + "▁reserv": 10168, + "▁steril": 10169, + "▁500": 10170, + "▁express": 10171, + "\n\nData": 10172, + "s▁and▁in": 10173, + "▁patients▁to": 10174, + "▁from▁a": 10175, + "ed▁by▁Lilly": 10176, + "▁study-related▁": 10177, + "▁to▁the▁first": 10178, + ".▁Carboplatin": 10179, + "▁signaling": 10180, + "▁contribut": 10181, + "▁9.3": 10182, + "▁use▁in": 10183, + "al▁procedures": 10184, + "▁other▁than": 10185, + "ERB": 10186, + ".▁During▁the▁": 10187, + "▁interval▁": 10188, + "othelin": 10189, + "flow": 10190, + "performed▁on": 10191, + ".▁Randomiz": 10192, + "until▁the▁": 10193, + ".▁2004": 10194, + "▁completed▁": 10195, + "ESS": 10196, + "randomized": 10197, + "status▁": 10198, + "discover": 10199, + "....................................................": 10200, + ",▁2007": 10201, + "▁duration▁of": 10202, + "subset": 10203, + "▁levels▁of": 10204, + "manag": 10205, + "▁activities▁": 10206, + "s▁after▁the▁": 10207, + "reast▁Cancer": 10208, + "▁Section:": 10209, + "▁then▁be▁": 10210, + "▁Kaplan-Meier": 10211, + "\n\nLIST▁OF": 10212, + "ivers": 10213, + "are▁no": 10214, + "▁no▁longer": 10215, + "▁Day▁1▁of": 10216, + "▁IVRS": 10217, + "\n\nOb": 10218, + "expected": 10219, + "▁the▁best": 10220, + "▁the▁baseline▁": 10221, + "\n\nClinical▁Study▁": 10222, + "ralizing": 10223, + "▁measurements▁and▁": 10224, + "exception": 10225, + "▁period▁(": 10226, + "summarized▁": 10227, + "embolism": 10228, + "e▁frequ": 10229, + "lifer": 10230, + ".▁However,▁if": 10231, + "▁evaluation▁period": 10232, + "▁are\n\n": 10233, + "▁only)": 10234, + "ETHO": 10235, + "▁50▁mg": 10236, + "▁identify": 10237, + "rochure": 10238, + "plus▁cisplatin": 10239, + ",▁Johnson": 10240, + "▁up▁to▁2▁year": 10241, + "▁the▁safety▁follow▁up": 10242, + "ogenicity": 10243, + "L/00": 10244, + "▁regarding": 10245, + "roken": 10246, + ".▁Proc": 10247, + "▁fracture": 10248, + "characteriz": 10249, + "followed▁up": 10250, + "striction": 10251, + "▁had▁a": 10252, + "orldwid": 10253, + "▁primary▁tumor": 10254, + "eyond": 10255, + "acceptable▁toxicity": 10256, + "▁years▁of▁ag": 10257, + "erck": 10258, + "▁prospective▁": 10259, + "▁legally▁acceptable▁representative▁": 10260, + "e▁transamin": 10261, + "gether▁with": 10262, + ".\n\nSTUDY": 10263, + "▁prostatectom": 10264, + "DERA": 10265, + "comment]": 10266, + "radical▁prostatectom": 10267, + "%▁power▁to▁detect": 10268, + ")▁and▁the▁": 10269, + ",▁that": 10270, + "-lead▁": 10271, + ".A": 10272, + "3]": 10273, + "3.1": 10274, + "450": 10275, + ";▁3": 10276, + "Baseline▁": 10277, + "CI": 10278, + "CrCl": 10279, + "Ethics▁Committe": 10280, + "GI": 10281, + "Re": 10282, + "Study": 10283, + "Week": 10284, + "bon": 10285, + "cardiovascular": 10286, + "cohort": 10287, + "e.▁M": 10288, + "guid": 10289, + "mg": 10290, + "nown": 10291, + "oprot": 10292, + "pite▁": 10293, + "rone▁": 10294, + "vitamin": 10295, + "▁em": 10296, + "▁every": 10297, + "e▁L": 10298, + "iness": 10299, + "ree▁S": 10300, + "stability▁": 10301, + "stein": 10302, + "▁the▁result": 10303, + "▁believ": 10304, + "▁to▁6": 10305, + "ise▁": 10306, + "▁and▁H": 10307, + "al▁function": 10308, + "el-": 10309, + "eline▁": 10310, + "▁CL": 10311, + "es▁B": 10312, + "▁(D": 10313, + "▁(for": 10314, + "▁(e.g.,▁": 10315, + "us,▁": 10316, + "uscl": 10317, + "ulin": 10318, + "if▁they▁": 10319, + "▁S▁T▁I\n\nK▁C▁E▁H▁C": 10320, + "▁IFL": 10321, + "▁read": 10322, + "otion": 10323, + "▁Day▁": 10324, + "▁fraction": 10325, + "▁futility▁": 10326, + "▁family▁": 10327, + "formulation": 10328, + "ecreas": 10329, + "▁nausea": 10330, + "▁and▁are▁": 10331, + "and-": 10332, + "▁treatment▁phase▁": 10333, + "study,▁": 10334, + "ortness▁of▁breath": 10335, + "▁200▁mg/m2": 10336, + "▁is▁required▁": 10337, + "▁of▁33": 10338, + "artial▁": 10339, + "e▁the\n\n": 10340, + "▁concent": 10341, + "▁confirmed": 10342, + "achin": 10343, + "▁will▁provide▁": 10344, + "▁Hematologic": 10345, + "▁at▁all": 10346, + "▁at▁the▁sit": 10347, + "▁the▁initial": 10348, + "continuing": 10349, + "ritical▁": 10350, + "▁experiment": 10351, + "\n\nDescription": 10352, + ".▁Specific": 10353, + "10%": 10354, + "▁antif": 10355, + "▁may▁not▁be▁": 10356, + "▁7▁days▁of": 10357, + ".▁Efficacy▁": 10358, + "▁test▁result": 10359, + "▁contracept": 10360, + "▁absence▁of": 10361, + "20%": 10362, + "▁8.3": 10363, + "▁used▁to": 10364, + "s▁without": 10365, + "\n\n24": 10366, + "▁your▁medical▁record": 10367, + "ity▁of▁Lif": 10368, + "▁a▁singl": 10369, + "\n\nFigure▁": 10370, + "e,\n\n": 10371, + ".▁Detail": 10372, + "abiliz": 10373, + ".\n\nPrinted▁copy▁is▁not▁official▁record.\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁Panitumumab▁Protocol▁Number:▁20050203▁Date:▁21▁January▁2009\n\nPage▁": 10374, + "e▁block": 10375, + "roponin": 10376, + "▁diagnostic": 10377, + "▁Amendment▁3▁–▁dated▁23▁May▁200": 10378, + "performed▁to": 10379, + ".▁Randomization": 10380, + "▁provide▁a": 10381, + "▁response▁rat": 10382, + ",▁Mc": 10383, + ",▁2005": 10384, + "cedures▁in▁case▁of": 10385, + "easurabl": 10386, + "▁hours▁": 10387, + "non-small▁cell▁lung▁cancer": 10388, + "▁199": 10389, + "s▁after▁the▁last": 10390, + "▁PFS▁and▁OS": 10391, + "follow-up▁period": 10392, + "liott": 10393, + "ramuscular": 10394, + "▁has▁been▁shown": 10395, + ",▁et▁al.▁Phase▁": 10396, + "ivertic": 10397, + "▁assessed▁by▁": 10398, + "▁anti-panitumumab": 10399, + "ead▁": 10400, + "▁transl": 10401, + "ICON": 10402, + "▁Chemotherapy": 10403, + "pectively▁": 10404, + "calculated": 10405, + "▁or▁irinotecan": 10406, + "▁prescrib": 10407, + "▁the▁date▁of▁death": 10408, + "▁metastasis": 10409, + "occurrence▁of": 10410, + "aterials▁and▁": 10411, + ".▁In▁addition,": 10412, + ".▁In▁addition,▁": 10413, + "▁score▁": 10414, + ".▁1999": 10415, + "▁interim▁analysis": 10416, + "▁biopsy▁": 10417, + "variables▁": 10418, + "rink": 10419, + "range▁of": 10420, + "Tumor▁Response▁": 10421, + "▁women▁with": 10422, + ".\n\nRedacted▁Version": 10423, + "▁exposure▁to": 10424, + "▁fully▁": 10425, + "submitted▁to▁the▁": 10426, + ",▁the▁investigator▁must": 10427, + "▁Rece": 10428, + "procedures▁for": 10429, + "▁reduction▁in": 10430, + "Response▁(": 10431, + "recorded▁on▁the▁CRF": 10432, + "▁hormone-": 10433, + "▁persist": 10434, + "\n\n4\n\n4\n\n4\n\n4": 10435, + "deliver": 10436, + "▁Oncology▁": 10437, + "that▁is": 10438, + "▁sample▁collection": 10439, + "▁37.5▁mg": 10440, + "▁regulatory▁author": 10441, + "criptive▁statistic": 10442, + "▁Am▁Soc▁Clin▁Oncol": 10443, + "unctional▁Assessment▁of▁Cancer▁Therapy▁": 10444, + "▁Performance▁Status▁": 10445, + "▁of▁63▁Finalization▁date:▁June▁19▁2001,▁Incorporating▁Amendment▁3▁–▁dated▁23▁May▁200": 10446, + "▁50%▁of▁waking▁hour": 10447, + "\n\nGEL▁Version▁ID:▁ONC.000−272−636.4.0\n\nApproved\n\nDate▁Printed:▁13−Aug−2013\n\nApproved▁by\n\n13▁Sep▁2007▁17:17:03": 10448, + "ayo▁Clin": 10449, + "armaceutical▁product": 10450, + "3\n\nAmerican▁BioScience,▁Inc.\n\nPhase▁III▁Protocol▁CA012-0▁ABI-007▁(Nanoparticle▁Paclitaxel)\n\nCONFIDENTIAL": 10451, + ".gov/": 10452, + "▁(ECOG)": 10453, + "especially▁": 10454, + "aiichi▁Sankyo▁Co.,▁Ltd": 10455, + "▁OBLIGATIONS": 10456, + "liotti": 10457, + ")▁are▁": 10458, + ")▁must▁be▁": 10459, + "0\n\n1\n\n2\n\n3\n\n4": 10460, + "5)(cid:": 10461, + "83": 10462, + ":54": 10463, + "Lesion": 10464, + "Pre": 10465, + "Small▁Cell▁Lung▁Cancer": 10466, + "Toxicity▁": 10467, + "UE": 10468, + "XP": 10469, + "a▁S": 10470, + "cag": 10471, + "divid": 10472, + "e.▁P": 10473, + "famil": 10474, + "left": 10475, + "mg/m2": 10476, + "nod": 10477, + "purpose▁of": 10478, + "rif": 10479, + "tabul": 10480, + "ycin": 10481, + "±▁3": 10482, + "▁option": 10483, + "▁electronic": 10484, + "▁even": 10485, + "inent": 10486, + "▁type▁I": 10487, + "at▁baselin": 10488, + "\n\nf": 10489, + "\n\nWith": 10490, + "oral": 10491, + "s▁can▁be▁": 10492, + "al▁practic": 10493, + "steroid": 10494, + "entral": 10495, + "of▁of": 10496, + "▁case▁": 10497, + "▁candid": 10498, + "▁bind": 10499, + "▁to▁2": 10500, + "▁sheet": 10501, + "▁of▁patients▁": 10502, + "ump": 10503, + "▁down": 10504, + "▁and▁may▁": 10505, + "▁Approv": 10506, + "ulate▁": 10507, + "▁I▁be▁": 10508, + "otop": 10509, + "▁DXA": 10510, + "irrespectiv": 10511, + "ysesthes": 10512, + "\n\nPFS": 10513, + "exclusion▁criteria": 10514, + "▁nor": 10515, + "▁with▁or▁without": 10516, + "▁rate": 10517, + "phas": 10518, + "▁comes▁": 10519, + "▁Fax": 10520, + ".▁Amgen": 10521, + "▁vein": 10522, + "▁vomiting": 10523, + "▁viol": 10524, + "▁this▁information": 10525, + "▁all▁patients▁": 10526, + "ical▁and▁": 10527, + "cident": 10528, + "e▁increas": 10529, + "▁57": 10530, + "▁Histor": 10531, + ")\n\nThe▁": 10532, + "▁weekly": 10533, + "ensitive▁": 10534, + "▁white▁blood▁cell": 10535, + "\n\nDisease▁": 10536, + "19-9": 10537, + "s▁will▁be▁provid": 10538, + "reported▁as▁an": 10539, + "▁JA": 10540, + "ound▁to": 10541, + "evaluable▁": 10542, + "▁7.5": 10543, + "▁7.7": 10544, + "▁association": 10545, + "▁10▁mm": 10546, + "▁analysis▁is▁": 10547, + "▁analysis▁plan": 10548, + "▁administrative▁": 10549, + "FIC": 10550, + "e.\n\nA": 10551, + "patient▁reported▁": 10552, + "▁8▁week": 10553, + "\n\n28": 10554, + "▁other▁lesion": 10555, + ".▁During": 10556, + ")▁=": 10557, + "\n\nHy": 10558, + "y▁and▁Com": 10559, + "ild▁to▁moder": 10560, + "collected": 10561, + "rolment": 10562, + ".▁Most": 10563, + "moder": 10564, + "▁discomfort": 10565, + "arrant": 10566, + ",▁blood▁": 10567, + "▁this▁trial▁": 10568, + ",▁Amgen": 10569, + "▁effect▁on": 10570, + "▁both▁the▁": 10571, + "▁time▁will▁be▁": 10572, + "▁total▁protein": 10573, + "▁superior": 10574, + "during▁the▁study▁": 10575, + "▁at▁least▁1": 10576, + "▁at▁least▁one▁": 10577, + "\n\nAppendix▁I": 10578, + "fractures": 10579, + "-related▁reaction": 10580, + "▁QLQ-C30": 10581, + "questionnaire▁": 10582, + "ing▁schedul": 10583, + "▁the▁baselin": 10584, + "\n\nStudy▁Design": 10585, + "▁the▁end▁of▁the▁study": 10586, + "▁authoriz": 10587, + "except▁for": 10588, + "▁cases▁of": 10589, + "objectives▁of": 10590, + "Experienc": 10591, + "▁Grade▁2": 10592, + "▁anticoagulant": 10593, + "▁during▁the▁study▁": 10594, + "▁28▁days▁after": 10595, + "chest,▁abdomen": 10596, + "clinically▁significant": 10597, + "maintained": 10598, + "▁demonstrate▁": 10599, + "▁alone▁as▁": 10600, + "▁profile▁": 10601, + "▁platelet": 10602, + "▁diagnosis": 10603, + "▁diagnosis▁of": 10604, + "ottl": 10605, + "▁is▁responsible▁for▁ensuring": 10606, + "proposed▁": 10607, + "▁and▁CVD": 10608, + "▁origin": 10609, + "▁achieve▁": 10610, + ".\n\nAdd▁": 10611, + "protect": 10612, + "▁third▁part": 10613, + "▁bone▁metastases": 10614, + "▁strateg": 10615, + "Analysis▁Plan": 10616, + "progression-free▁survival▁(PFS)": 10617, + "▁combined▁with": 10618, + "-of-": 10619, + "▁adherence▁to": 10620, + "toposid": 10621, + "▁delivery▁system": 10622, + "▁(80)\n\nGEL▁Version▁ID:▁CV.000−433−640.5.0▁Approved▁by\n\nApproved\n\nDate▁Printed:▁30−Jul−2014\n\nS▁08▁Dec▁2010▁17:06:45\n\nRevised▁Clinical▁Study▁Protocol▁Drug▁Substance▁ZD4054▁Study▁Code▁D4320C00015▁Edition▁Number▁3▁Date▁7▁December▁2010": 10623, + "▁or▁equal": 10624, + "aphyl": 10625, + "▁REPOR": 10626, + "cagliotti": 10627, + ")▁is": 10628, + ",7": 10629, + "-20": 10630, + ".M": 10631, + "2.▁": 10632, + "Growth▁Factor": 10633, + "HN": 10634, + "Monitoring": 10635, + "URE": 10636, + "ah": 10637, + "bicarbon": 10638, + "c)": 10639, + "categor": 10640, + "creatinine▁clearance▁": 10641, + "dication": 10642, + "hol": 10643, + "ken": 10644, + "mm": 10645, + "tx": 10646, + "▁epidermal▁growth▁factor▁receptor": 10647, + "▁evidenc": 10648, + "atell": 10649, + "ated▁by▁the▁": 10650, + "\n\nOn": 10651, + "\n\n(cid:120)\n\n": 10652, + "erile▁": 10653, + "or▁in": 10654, + "s▁wer": 10655, + "ston": 10656, + "y▁will▁be▁": 10657, + "its": 10658, + "▁package▁insert": 10659, + "▁principl": 10660, + "▁binding": 10661, + "▁better": 10662, + "▁bolus▁": 10663, + "es/": 10664, + "▁to▁4": 10665, + "▁doubl": 10666, + "▁mal": 10667, + "▁magnesium": 10668, + "▁and▁is▁": 10669, + "▁and▁placebo": 10670, + "▁and▁leucovorin": 10671, + "is▁s": 10672, + "▁instrument": 10673, + "imer": 10674, + "▁1.3": 10675, + "ossibl": 10676, + "▁(3": 10677, + "▁(W": 10678, + "▁(a": 10679, + "ancet": 10680, + "▁Scan": 10681, + "▁System": 10682, + "▁It": 10683, + "▁Diarrhea": 10684, + "▁hemorrh": 10685, + "▁futility": 10686, + "izz": 10687, + "▁as\n\n": 10688, + "▁adult": 10689, + ".32": 10690, + "▁state▁": 10691, + "ial▁cell": 10692, + "will▁also▁be▁": 10693, + "▁subjects▁in": 10694, + "▁44": 10695, + ")\n\n(cid:120)": 10696, + "ed▁by▁the▁sponsor": 10697, + "▁the▁dur": 10698, + "▁the▁differ": 10699, + "▁Infusion": 10700, + "ONS": 10701, + "central": 10702, + ",▁and\n\n": 10703, + "who▁are▁": 10704, + "radiology▁": 10705, + "▁disease▁or": 10706, + "ribonucle": 10707, + "▁use▁the▁": 10708, + "s▁with▁a": 10709, + "every▁8▁week": 10710, + "neopl": 10711, + "▁the▁study▁and▁": 10712, + "d▁of▁the▁": 10713, + "ed▁in▁the▁study▁": 10714, + "\n\nAdverse▁event": 10715, + "Clinical▁Trial": 10716, + "▁progression▁of": 10717, + "▁over▁2": 10718, + ".▁Report": 10719, + "considered▁to▁be▁": 10720, + "▁Compar": 10721, + "▁subgroup": 10722, + "▁CTC": 10723, + "ducer": 10724, + "dose▁modification": 10725, + "▁upper": 10726, + "▁non-metastatic": 10727, + "non-inferior": 10728, + "ed▁on▁the▁basis▁of": 10729, + "ibilities▁": 10730, + "sett": 10731, + "undergo": 10732, + "ed▁by▁the▁randomization": 10733, + "affin": 10734, + "\n\nGP": 10735, + "▁several▁": 10736, + "▁poss": 10737, + "brain": 10738, + "▁significantly▁": 10739, + "analyses▁of": 10740, + "............................................................................................................": 10741, + "structions▁for": 10742, + "responder": 10743, + "▁metastasis▁": 10744, + "▁metastases▁": 10745, + "▁as▁a▁result": 10746, + "\n\na.\n\nWhat": 10747, + ".▁However,": 10748, + "optimal": 10749, + "medical▁record": 10750, + "CCHN": 10751, + "▁protein▁expression": 10752, + "▁(Section": 10753, + "puted▁tomograph": 10754, + "eligible▁to": 10755, + "interim▁analysis": 10756, + "▁randomised▁": 10757, + "ifferential": 10758, + "▁kit": 10759, + "▁median▁OS": 10760, + "▁assess▁whether": 10761, + "▁third": 10762, + "loss": 10763, + "loss▁of": 10764, + "s▁have▁occurred": 10765, + "▁link": 10766, + "▁antibodies▁against": 10767, + "▁into▁the▁": 10768, + "▁antiemetic": 10769, + "derived▁": 10770, + "▁Collection": 10771, + "▁ECOG▁performance▁stat": 10772, + "▁partial▁response▁": 10773, + "emcitabine-": 10774, + "▁colorectal▁carcinoma": 10775, + "(2):": 10776, + "▁stopping": 10777, + "▁Analyses": 10778, + "\n\nChang": 10779, + "▁lymph▁nod": 10780, + "majority▁of": 10781, + "\n\nComplete▁": 10782, + "ORTC▁QLQ-C30": 10783, + "Efficacy▁Endpoint": 10784, + "deemed▁": 10785, + "prednisone▁": 10786, + "▁µg": 10787, + "▁exploratory▁biomarker": 10788, + "cially▁available▁": 10789, + "e-to-event": 10790, + ",▁whichever▁is▁": 10791, + "United▁States": 10792, + "inancial▁": 10793, + ",▁potassium,▁chloride,▁": 10794, + "-lead▁ECG": 10795, + "(ie,▁": 10796, + "-12": 10797, + "-reported▁": 10798, + ".80": 10799, + "E:": 10800, + "GOT": 10801, + "JCC": 10802, + "Journal": 10803, + "LY": 10804, + "Panitumumab": 10805, + "Tc": 10806, + "a▁T": 10807, + "cycle▁": 10808, + "co-": 10809, + "circumstanc": 10810, + "capable▁of": 10811, + "capture": 10812, + "down": 10813, + "dividual▁": 10814, + "dominant": 10815, + "iat": 10816, + "now": 10817, + "pG": 10818, + "pit": 10819, + "panc": 10820, + "pidermal▁": 10821, + "ris": 10822, + "tration": 10823, + "ate▁t": 10824, + "enic": 10825, + "eness▁of": 10826, + "enzym": 10827, + "s▁related▁to": 10828, + "offer": 10829, + ",▁calcium": 10830, + "rod": 10831, + "ed▁of": 10832, + ".▁•": 10833, + "aries▁": 10834, + "▁cours": 10835, + "▁break": 10836, + "▁squamous▁cell": 10837, + "▁of▁this▁": 10838, + "omol": 10839, + "omere▁": 10840, + "eleph": 10841, + "▁induction": 10842, + "▁in▁human": 10843, + "imb": 10844, + "▁1st": 10845, + "▁C225": 10846, + "est▁dimension": 10847, + "▁Paclitaxel": 10848, + "pros": 10849, + "prostat": 10850, + "program": 10851, + "▁(M": 10852, + "▁SY": 10853, + "rient": 10854, + "▁Elect": 10855, + "utrient": 10856, + "\n\nPer": 10857, + "\n\nPrimary": 10858, + "explor": 10859, + "study▁report": 10860, + "▁OBJECTIVES": 10861, + "epoint": 10862, + "compos": 10863, + "▁are▁to▁be▁": 10864, + "ed▁interim": 10865, + "ed▁in▁section": 10866, + "ence": 10867, + "▁of▁at▁least": 10868, + "▁will▁be▁us": 10869, + "e▁subjects▁": 10870, + "correspond": 10871, + "contract": 10872, + "▁good▁": 10873, + "▁the▁skin": 10874, + "intak": 10875, + "▁BP": 10876, + "▁will▁contain": 10877, + "▁the▁patients▁": 10878, + ")\n\n(cid:13": 10879, + "▁the▁independent": 10880, + "▁cancer▁and▁CVD": 10881, + "s.▁I": 10882, + "relative▁": 10883, + "▁the▁target": 10884, + "\n\nDefinition": 10885, + "ed▁onc": 10886, + "s▁will▁be▁used▁to": 10887, + "ouse▁": 10888, + ".▁Pemetrexed▁": 10889, + "ounter": 10890, + "),▁which": 10891, + "ed▁by▁Amgen": 10892, + "▁may▁occur": 10893, + "suit": 10894, + "▁pharmaceutical▁product": 10895, + "recorded▁in▁the▁": 10896, + ".▁Current": 10897, + "116)": 10898, + "▁medicin": 10899, + "radiological▁": 10900, + "▁data▁are▁": 10901, + ".▁If▁a▁patient": 10902, + "neumon": 10903, + "assay": 10904, + "asse▁et▁al": 10905, + "▁a▁small": 10906, + "response▁of": 10907, + ".\n\nAppendix": 10908, + "\n\nThe▁primary▁": 10909, + "s▁that▁can▁be▁": 10910, + "▁mg/m²": 10911, + "defined▁": 10912, + ".\n\nSUBJECT": 10913, + ")▁≥": 10914, + "▁Analysis▁of": 10915, + ".▁Refer": 10916, + ".▁2007": 10917, + "interpret": 10918, + "▁Committee": 10919, + ",▁PR": 10920, + "Stor": 10921, + "collected▁and▁": 10922, + "▁occurred▁": 10923, + "▁response▁and▁": 10924, + "rosatell": 10925, + "▁clinical▁benefit": 10926, + "s▁will▁be\n\n": 10927, + "▁duration": 10928, + "▁results▁in": 10929, + ".▁Ant": 10930, + "\n\nInter": 10931, + "▁status▁(": 10932, + "e▁myeloma": 10933, + "▁received": 10934, + "whenever": 10935, + "▁12.3": 10936, + "▁criteria▁for": 10937, + "▁plus▁docetaxel": 10938, + "\n\nGrade▁3": 10939, + ",▁pain": 10940, + "PACCE": 10941, + "▁the▁event▁that": 10942, + "▁assigned▁to": 10943, + "▁Phas": 10944, + "▁longest▁diameter": 10945, + "▁cases▁": 10946, + "▁tolerated▁": 10947, + "itiation▁of": 10948, + "\n\nSection:▁2.3": 10949, + "C0000": 10950, + ",▁if▁applicabl": 10951, + "▁time▁to▁first": 10952, + "▁the▁date▁of▁the▁last": 10953, + "braxis": 10954, + "Assessments": 10955, + ".\n\nDose▁": 10956, + "representative▁of": 10957, + "FACT-G": 10958, + "gestive▁heart": 10959, + "▁tempor": 10960, + "i.e.": 10961, + "..............................................": 10962, + "radiation▁therapy": 10963, + "▁compliance▁": 10964, + "repeat": 10965, + "▁grade▁4": 10966, + "\n\nD▁E▁T▁N▁I▁R▁P\n\nA\n\nS▁I": 10967, + "see▁comment]": 10968, + "________________________________": 10969, + "▁nonhematologic": 10970, + "stimated▁": 10971, + "\n\nPatients▁will▁be▁": 10972, + "response▁(PR": 10973, + "▁laboratory▁valu": 10974, + "regulatory▁ag": 10975, + "▁adjustment": 10976, + "▁some▁cas": 10977, + "ometa": 10978, + "baseline▁sum": 10979, + "Laboratory▁Test": 10980, + "\n\nGrade▁4": 10981, + "▁knowledg": 10982, + "respiration": 10983, + "\n\nResponse▁": 10984, + "▁there▁are▁no": 10985, + "▁Japanese▁sit": 10986, + "(106)\n\nGEL▁Version▁ID:▁ONC.000−272−636.4.0\n\nApproved\n\nDate▁Printed:▁13−Aug−2013\n\nApproved▁by\n\n13▁Sep▁2007▁17:17:03\n\nAmended▁Clinical▁Study▁Protocol▁Drug▁Substance▁Cediranib▁(RECENTIN,▁AZD2171)▁Study▁Code▁D8480C00013▁Edition▁Number▁3▁Date▁10▁September▁2007": 10987, + "(106)\n\nGEL▁Version▁ID:▁ONC.000−272−636.4.0\n\nApproved\n\nDate▁Printed:▁13−Aug−2013\n\nApproved▁by\n\n13▁Sep▁2007▁17:17:03\n\nAmended▁Clinical▁Study▁Protocol▁Drug▁Substance▁Cediranib▁(RECENTIN,▁AZD2171)▁Study▁Code▁D8480C00013▁Edition▁Number▁3▁Date\n\n": 10988, + "▁portion▁of▁the▁": 10989, + ".\n\nProperty▁of▁the▁sanofi-aventis▁group▁-▁strictly▁confidential▁WW-CLIN-PR007-SD-03▁VERSION▁n°02▁(19-DEC-2005)\n\nPage▁": 10990, + "feeding": 10991, + "▁the▁time▁point": 10992, + "strongly▁": 10993, + "ancreatic▁cancer": 10994, + "▁Accountability▁": 10995, + ".▁Following": 10996, + "al▁cell▁carcinoma": 10997, + "▁Schedule▁": 10998, + "experimental": 10999, + "▁in▁combination▁with▁docetaxel▁on": 11000, + "▁wild-type▁KRAS▁tumor": 11001, + "▁childbearing▁potential": 11002, + "▁conventional": 11003, + "alculated▁": 11004, + "%▁of▁previous▁dose\n\n": 11005, + "urface▁area": 11006, + "L/0024": 11007, + "(A": 11008, + ",[": 11009, + "-Gault": 11010, + "1%": 11011, + "1.▁": 11012, + "110": 11013, + ":\n\nA": 11014, + "?\n\nYou": 11015, + "Each": 11016, + "EOS": 11017, + "FET": 11018, + "IP": 11019, + "Is": 11020, + "NM": 11021, + "case▁": 11022, + "capecitabine▁": 11023, + "eys": 11024, + "e.▁This▁": 11025, + "fric": 11026, + "ge": 11027, + "iate▁": 11028, + "iary▁": 11029, + "mand": 11030, + "s\n\nC": 11031, + "yring": 11032, + "ºC": 11033, + "▁efficacy▁and▁": 11034, + "in▁combination▁with": 11035, + "ates▁for": 11036, + "onary▁": 11037, + "\n\nnot": 11038, + "\n\ndocument": 11039, + "\n\nchemotherapy": 11040, + "enn": 11041, + "s▁during": 11042, + "s▁hav": 11043, + "recur": 11044, + ",▁other": 11045, + ",▁Inc": 11046, + "▁anom": 11047, + "arn": 11048, + "▁cess": 11049, + "▁befor": 11050, + "▁to▁treat": 11051, + "▁to▁allow": 11052, + "▁se": 11053, + "▁syn": 11054, + "▁sensitiv": 11055, + "▁size▁": 11056, + "▁separate▁": 11057, + "▁of▁target▁lesion": 11058, + "▁many▁": 11059, + "▁myocardial▁infarction": 11060, + "▁and▁L": 11061, + "▁and▁should▁be▁": 11062, + "▁and▁vitamin▁D": 11063, + "▁and▁Gault": 11064, + ".\n\nK": 11065, + "election▁of": 11066, + "elimin": 11067, + "▁PM": 11068, + "ild▁": 11069, + "▁(4": 11070, + "uscript": 11071, + "ra-": 11072, + "▁Safety": 11073, + "▁rect": 11074, + "▁DS": 11075, + "▁Diseas": 11076, + "▁D▁E▁T▁N▁I▁R▁P": 11077, + "▁During": 11078, + "▁Dimension": 11079, + "▁hemat": 11080, + "▁half": 11081, + "▁EA": 11082, + "▁or▁significant": 11083, + "e▁target▁lesion": 11084, + "expert": 11085, + "▁progn": 11086, + "will▁be▁no": 11087, + "astration": 11088, + "▁RT": 11089, + "▁Review": 11090, + "▁Roch": 11091, + "romb": 11092, + "romos": 11093, + "ed▁informed▁consent": 11094, + "ence▁(": 11095, + ".20": 11096, + "\n\nStudy": 11097, + "▁is▁being": 11098, + "▁of▁31": 11099, + "▁MS": 11100, + "▁rate,▁": 11101, + "▁0.6": 11102, + "▁3▁month": 11103, + "e,▁if": 11104, + "▁computer": 11105, + "ity▁Ass": 11106, + "▁on▁a": 11107, + "ured": 11108, + "▁stage▁III": 11109, + "▁52": 11110, + "▁Hemat": 11111, + "▁Head": 11112, + "▁Heart": 11113, + "▁4.1": 11114, + "▁the▁incidence▁of": 11115, + "consolidation": 11116, + "▁Vital▁sign": 11117, + "\n\nDate:": 11118, + "e▁disease▁": 11119, + ".▁Schedule▁of": 11120, + "▁the▁day": 11121, + "s▁will▁be▁analyz": 11122, + "▁UE": 11123, + "▁of▁14": 11124, + "s\n\n4": 11125, + "▁tumor▁respons": 11126, + "▁7.4": 11127, + "▁study,▁": 11128, + "e-bas": 11129, + "may▁continu": 11130, + "includes▁": 11131, + "centre": 11132, + "▁tests▁and▁": 11133, + "▁signature▁": 11134, + "ed▁at▁each": 11135, + "\n\nX\n\nX▁X": 11136, + "▁data▁collection": 11137, + "index": 11138, + "▁preparation": 11139, + "associ": 11140, + "\n\n3.4": 11141, + "▁consolidation": 11142, + "s▁that▁are▁s": 11143, + "carcinoma": 11144, + ".\n\nSt": 11145, + "atively": 11146, + "ed▁from▁the▁sampl": 11147, + "interrupt": 11148, + ",▁Phase▁3": 11149, + "modifi": 11150, + ",▁Man": 11151, + "hair": 11152, + "hazard▁": 11153, + "▁chemotherapy▁in": 11154, + "ABLE": 11155, + "clinical▁investigation": 11156, + "estimated▁to": 11157, + "overall▁survival▁(OS": 11158, + "\n\n8.1": 11159, + "underst": 11160, + "▁time▁from": 11161, + ".▁Patients▁will▁be▁": 11162, + "\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁Panitumumab▁Protocol▁Number:▁20050181▁Date:▁04▁April▁2008\n\nPage▁": 11163, + "\n\nLaboratory▁": 11164, + "▁Stor": 11165, + "▁applicable▁to": 11166, + "s▁at▁the▁": 11167, + "s▁prior▁to▁randomization": 11168, + "ed▁that▁the▁": 11169, + "▁the▁benefit": 11170, + "ryth": 11171, + "y▁surface▁area": 11172, + "▁advanced▁NSCLC": 11173, + ".▁Adverse▁event": 11174, + "ecause▁of▁the▁": 11175, + "▁failure▁of": 11176, + ",▁1997": 11177, + "limited▁to": 11178, + "laboratory▁valu": 11179, + "▁meets": 11180, + "▁biomarker▁development": 11181, + "origin": 11182, + "phase▁3": 11183, + "▁has▁a": 11184, + "............................................": 11185, + "controlled,▁": 11186, + "ITT)": 11187, + ".▁J▁Clin▁Oncol.▁200": 11188, + "iguous▁": 11189, + "resolved▁or": 11190, + "▁more▁than▁50%▁of▁waking▁hour": 11191, + ".\n\nN0147": 11192, + "EFERENCES": 11193, + "▁additional▁information": 11194, + "commonly▁": 11195, + "▁Percent": 11196, + "EPC": 11197, + "▁thromboembolic": 11198, + "frequency▁of": 11199, + "submitted▁to": 11200, + "▁(cid:120": 11201, + "▁SCLC": 11202, + ".▁Therefor": 11203, + "demonstrated": 11204, + "▁accurately▁": 11205, + "(3):▁p.▁": 11206, + "▁intravenous▁": 11207, + "▁investigate▁the▁": 11208, + "removed▁from": 11209, + "utrition": 11210, + "-Label": 11211, + "▁cytotoxic": 11212, + "▁previously▁untreat": 11213, + "▁deem": 11214, + "fined▁to▁b": 11215, + ".\n\nF▁O\n\nY▁P▁O▁C": 11216, + "▁4.7.1.1": 11217, + "▁supportive▁car": 11218, + "▁ruler": 11219, + "pen-Label": 11220, + "anadian": 11221, + "found▁in": 11222, + ".\n\n.▁E▁S▁U\n\nE▁R▁O▁F▁E▁B": 11223, + "astern▁Cooperative▁Oncology▁Group▁(ECOG)": 11224, + "▁IRB/": 11225, + "replacement": 11226, + ",▁strok": 11227, + "cardia": 11228, + "elanoma": 11229, + "ield": 11230, + "▁and▁Neck": 11231, + "oxygen": 11232, + "modified▁RECIST▁criteria": 11233, + "BPI-SF": 11234, + "ranslational▁Research": 11235, + ".▁Randomized▁": 11236, + "iverticul": 11237, + "FETY": 11238, + "8,▁": 11239, + "AZD2171": 11240, + "CS": 11241, + "During": 11242, + "EERS": 11243, + "Met": 11244, + "N0147": 11245, + "Q4W": 11246, + "bleeding": 11247, + "cess▁": 11248, + "deviation": 11249, + "ii": 11250, + "je": 11251, + "max": 11252, + "rant": 11253, + "scan": 11254, + "tak": 11255, + "x-ra": 11256, + "ycardia": 11257, + "▁eligibility": 11258, + "▁employ": 11259, + "": 11260, + "one,▁": 11261, + "\n\niv": 11262, + "environment": 11263, + "orpt": 11264, + "s▁P": 11265, + "s▁occur": 11266, + "s▁which": 11267, + "s▁identifi": 11268, + "s▁using▁a": 11269, + "s▁do▁not": 11270, + "al/": 11271, + "already▁": 11272, + "stop": 11273, + ",▁data": 11274, + "▁an▁event": 11275, + "arrier": 11276, + "ed▁tissu": 11277, + "ess▁in": 11278, + "forward": 11279, + "is▁to▁be▁": 11280, + "▁serious▁": 11281, + "▁single▁": 11282, + "▁special": 11283, + "th▁December▁2004": 11284, + "▁wor": 11285, + "▁and▁oxaliplatin": 11286, + "▁and▁valid": 11287, + ".\n\n14": 11288, + "abnormal": 11289, + "ive▁of": 11290, + "▁in▁Section": 11291, + "▁in▁accordance▁with": 11292, + "▁in▁order▁to": 11293, + "imm": 11294, + "imulating": 11295, + "uric▁acid": 11296, + "ocial": 11297, + "proportion": 11298, + "▁(5": 11299, + "▁(J": 11300, + "▁(and▁": 11301, + "▁(i.e.,▁": 11302, + "▁SW": 11303, + "▁III": 11304, + "▁IND": 11305, + "▁repair": 11306, + "clus": 11307, + "rist": 11308, + "▁handl": 11309, + "e▁typ": 11310, + "irradi": 11311, + "\n\nAstraZeneca": 11312, + "link": 11313, + "▁Test": 11314, + "▁Toxic": 11315, + "▁adequ": 11316, + "compr": 11317, + "ed▁infusion": 11318, + "Injection": 11319, + "adequ": 11320, + "▁of▁study▁treatment": 11321, + "▁of▁32": 11322, + "e▁threatening": 11323, + "▁METHO": 11324, + "▁right": 11325, + "▁0.9": 11326, + "physical▁": 11327, + "▁one▁dose▁of": 11328, + "▁vivo": 11329, + "▁LB": 11330, + "able▁and▁": 11331, + "s,▁such▁as▁": 11332, + "▁therefore▁": 11333, + "▁charter": 11334, + "▁5▁mm": 11335, + "▁5▁20": 11336, + "willing▁to": 11337, + ")\n\nX": 11338, + "s▁(≤": 11339, + "egativ": 11340, + "continuous▁": 11341, + "▁any▁of▁the▁": 11342, + "formed▁of": 11343, + "▁G-CSF": 11344, + "▁Informed▁Consent▁Form": 11345, + "on-study▁": 11346, + "▁tumor▁growth": 11347, + "ous▁system": 11348, + "▁assist": 11349, + ".▁End▁of": 11350, + "▁assessment▁of▁": 11351, + "e.\n\n8": 11352, + "▁used": 11353, + "prepar": 11354, + "preparation": 11355, + "▁impact": 11356, + "▁following▁the▁": 11357, + ".▁Drug": 11358, + "▁the▁local▁": 11359, + "▁interruption": 11360, + "complete▁or": 11361, + "ed▁as▁the▁": 11362, + "ed▁in▁the▁protocol": 11363, + "▁days▁befor": 11364, + "▁consequ": 11365, + "hypersensitivity▁reaction": 11366, + "hypercalcemia": 11367, + "▁therapy▁will▁be▁": 11368, + "es,▁including": 11369, + "▁actual": 11370, + "▁the▁study▁is▁": 11371, + "▁approximately▁1": 11372, + "▁approximately▁2": 11373, + "number▁and▁": 11374, + "▁disclos": 11375, + "substudy": 11376, + "▁metastatic▁disease▁": 11377, + "▁Result": 11378, + "samples▁will▁be▁": 11379, + "ricular": 11380, + "▁baseline▁and▁": 11381, + "▁this\n\n": 11382, + "▁change▁of": 11383, + "▁neut": 11384, + "▁plus▁FOLFIRI": 11385, + "assessment▁of": 11386, + "▁Staging": 11387, + "▁part▁of▁the▁": 11388, + "easurable▁lesion": 11389, + "▁severity▁": 11390, + "-related▁quality▁of▁lif": 11391, + "▁Q4W": 11392, + "required▁by": 11393, + "▁analysis▁of▁the▁": 11394, + "▁required▁for": 11395, + "▁bone▁lesion": 11396, + "▁withdrawal▁from": 11397, + "median▁survival": 11398, + "▁correlation": 11399, + "aterial▁": 11400, + ".▁Lancet": 11401, + "ecause▁the▁": 11402, + "ource▁": 11403, + "\n\nmonth": 11404, + "▁e▁n": 11405, + "▁identify▁": 11406, + "T-11": 11407, + "▁a▁larg": 11408, + "..................................................................................................................": 11409, + ".\n\nN▁A\n\nF▁O\n\nY▁P▁O▁C": 11410, + "▁applicable▁law": 11411, + "▁tables": 11412, + "▁metab": 11413, + "followed▁for▁survival▁": 11414, + ",▁unless▁": 11415, + "(1):": 11416, + "stable▁disease▁": 11417, + "ologically▁or▁cyt": 11418, + "untoward▁medical▁occurr": 11419, + ",▁alkaline▁phosphatas": 11420, + "▁When": 11421, + "whichever▁is▁": 11422, + "▁pleural▁effusion": 11423, + "▁sodium▁chlorid": 11424, + "ockcroft▁and▁Gault": 11425, + "reversibl": 11426, + "▁Synopsis": 11427, + "(6):": 11428, + "olinic▁acid▁": 11429, + "▁vertebral▁fracture▁": 11430, + "VESTIGATIONAL": 11431, + "angiogenic": 11432, + "ohistochemistry▁": 11433, + "clinic▁visit▁or▁telephone▁contact": 11434, + "(OH)D": 11435, + "▁REPORTING": 11436, + "fined▁to▁bed▁or▁chair": 11437, + ").▁If": 11438, + ",11": 11439, + "/N": 11440, + "/t": 11441, + "/day▁": 11442, + "0.00": 11443, + "3rd": 11444, + "60%": 11445, + "7]": 11446, + ":▁": 11447, + ":\n\nC": 11448, + "CD": 11449, + "Nam": 11450, + "Number": 11451, + "Target": 11452, + "cint": 11453, + "doubl": 11454, + "eu": 11455, + "e.▁T": 11456, + "i▁R": 11457, + "ias▁": 11458, + "keep": 11459, + "nadir": 11460, + "ois": 11461, + "practic": 11462, + "rch": 11463, + "sia": 11464, + "similar": 11465, + "side▁effect": 11466, + "supportive▁": 11467, + "total": 11468, + "y▁and": 11469, + "zen": 11470, + "▁μ": 11471, + "▁": 11472, + "▁................................................": 11473, + "▁etoposid": 11474, + "e▁any▁": 11475, + "ated▁by": 11476, + "atern": 11477, + "\n\n≤": 11478, + "\n\nlesion": 11479, + "\n\nrandomization": 11480, + "s▁-": 11481, + "s▁B": 11482, + "s▁based▁on": 11483, + "s▁used▁in": 11484, + "stabl": 11485, + ",▁hemat": 11486, + "ed▁will▁be▁": 11487, + "ed▁dose▁": 11488, + "aries": 11489, + "▁paper": 11490, + "▁certain": 11491, + "es;": 11492, + "ford▁": 11493, + "etit": 11494, + "isen": 11495, + "is▁the▁": 11496, + "▁secondary▁": 11497, + "▁don": 11498, + "▁dig": 11499, + "▁daily": 11500, + "thir": 11501, + "▁wk": 11502, + "▁maintenance▁": 11503, + "▁and▁4": 11504, + "▁and▁5-FU": 11505, + ".\n\nProtocol": 11506, + "els": 11507, + "▁Ap": 11508, + "▁inspect": 11509, + "igraph": 11510, + "▁1▁and▁": 11511, + "▁1.4": 11512, + "▁1▁dose▁level": 11513, + "es▁[": 11514, + "empor": 11515, + "▁20%": 11516, + "▁S▁I▁H▁T": 11517, + "▁I▁am": 11518, + "▁five▁": 11519, + "▁or▁D": 11520, + "▁or▁IEC": 11521, + "e▁taken": 11522, + "▁for▁the▁treatment▁of": 11523, + "▁Res▁": 11524, + "▁Replace:": 11525, + ".27": 11526, + "ed▁befor": 11527, + "▁of▁VEGF": 11528, + "▁will▁be▁performed": 11529, + "e▁skin": 11530, + "▁05": 11531, + "▁3▁year": 11532, + "▁3rd▁": 11533, + "actual": 11534, + "cord▁of": 11535, + "whol": 11536, + "whose▁": 11537, + "contribut": 11538, + "2003": 11539, + "2005": 11540, + "200.3": 11541, + "▁the▁safety": 11542, + ",▁and▁p": 11543, + "▁5.0": 11544, + "ity,▁": 11545, + "▁6.9": 11546, + "s▁in▁patients▁with": 11547, + "▁VA": 11548, + "ellular": 11549, + "e▁drug": 11550, + "▁patient▁is▁": 11551, + "▁the▁dat": 11552, + "▁the▁design": 11553, + "▁Grad": 11554, + "▁time▁(": 11555, + "▁from▁the▁study▁": 11556, + "▁dose\n\n": 11557, + "e▁valu": 11558, + "includes": 11559, + "over▁30": 11560, + "ALY": 11561, + "▁abil": 11562, + "ed▁at▁the▁time▁of": 11563, + ".......................................................................................▁": 11564, + "ative▁sit": 11565, + "▁pretreatment": 11566, + "ence▁and▁": 11567, + "▁a▁sec": 11568, + "▁the▁level": 11569, + "▁the▁long": 11570, + "199.3": 11571, + "Analysis": 11572, + "SA)": 11573, + "▁subjects▁have▁": 11574, + "cribed▁": 11575, + "36:54": 11576, + "ummary": 11577, + "risks▁of": 11578, + "▁which▁the▁": 11579, + "partner": 11580, + "elete:": 11581, + ".\n\nConfidential\n\nProduct:▁AMG▁162▁Protocol▁Number:▁20040138▁Date:▁19▁February▁2008\n\nPage▁": 11582, + "by-": 11583, + "▁disease.\n\n": 11584, + "▁Prostate▁Cancer": 11585, + "start▁of▁the▁": 11586, + "s▁and▁treatment": 11587, + "▁every▁4▁week": 11588, + "▁verification": 11589, + "▁the▁same▁dose▁": 11590, + "▁clinical▁outcom": 11591, + "▁between▁the▁2": 11592, + "▁analysis▁of▁PFS": 11593, + "▁15▁minutes": 11594, + "▁confirmation▁of▁": 11595, + "\n\nY▁T▁I▁D▁I▁L▁A▁V\n\nS▁T▁I": 11596, + "\n\nAdd▁5": 11597, + "▁20th▁December▁2004": 11598, + "100%": 11599, + "eginn": 11600, + "number▁of▁patients▁": 11601, + "▁Phase▁III": 11602, + "alignant": 11603, + "▁variation": 11604, + ",▁without": 11605, + "Grade▁1": 11606, + "........................................................................................................................": 11607, + "▁chest▁CT": 11608, + "extension▁period▁": 11609, + "written▁informed▁consent": 11610, + ".▁Concomitant": 11611, + "▁solution▁for": 11612, + "▁clinically▁significant": 11613, + "profile▁of": 11614, + "▁accountability▁": 11615, + "PTV": 11616, + "ackground▁": 11617, + ".▁Upon": 11618, + "\n\nl\n\na": 11619, + "▁recommendation": 11620, + "early▁termination": 11621, + "characteristic": 11622, + "▁attack": 11623, + "\n\nCTCAE": 11624, + "▁the▁informed▁consent▁discussion": 11625, + "ominated▁": 11626, + ".\n\nAny▁": 11627, + "room▁temperature▁": 11628, + "erious,▁": 11629, + "▁(Arm▁A": 11630, + "\n\nLY231514\n\nPage▁": 11631, + "▁has▁not▁been": 11632, + "\n\nAbbreviations:": 11633, + ",▁as▁well▁as▁": 11634, + "Analyses": 11635, + "\n\n21▁Dec▁2004▁10:21:": 11636, + "\n\n21▁Dec▁2004▁10:36:54": 11637, + "▁allergic▁reaction": 11638, + "e▁from▁baseline▁in": 11639, + "Period": 11640, + "▁archiv": 11641, + "▁shipment": 11642, + "refractory▁": 11643, + "ropoietin": 11644, + "fibros": 11645, + "emoval▁of": 11646, + "inal▁cord▁": 11647, + "blinded▁treatment▁phas": 11648, + ",▁placebo-": 11649, + "cintigraph": 11650, + "\n\n21▁Dec▁2004▁10:21:22": 11651, + "%),▁": 11652, + "(7": 11653, + "(D": 11654, + ")▁on": 11655, + ",12": 11656, + "-R": 11657, + "-associated▁": 11658, + "-▁or▁nail": 11659, + "/A": 11660, + "214": 11661, + "6th": 11662, + "8▁weeks▁": 11663, + ":▁the▁": 11664, + "Attachment": 11665, + "CN": 11666, + "Cycle▁": 11667, + "FF": 11668, + "GPT": 11669, + "M)": 11670, + "Questionna": 11671, + "V)": 11672, + "VF": 11673, + "Zometa": 11674, + "ait": 11675, + "author": 11676, + "bone▁scan": 11677, + "four": 11678, + "hn": 11679, + "key": 11680, + "lu": 11681, + "som": 11682, + "saf": 11683, + "solution": 11684, + "typ": 11685, + "vessel": 11686, + "window": 11687, + "zel": 11688, + "▁onset": 11689, + "▁teas": 11690, + "▁taxan": 11691, + "atal": 11692, + "\n\nGF": 11693, + "\n\nanalysis▁": 11694, + "or▁to": 11695, + "s▁R": 11696, + "s▁S": 11697, + "s▁containing": 11698, + "s▁may": 11699, + "aliv": 11700, + "itz": 11701, + "anin": 11702, + ",▁investigator": 11703, + "ed▁via": 11704, + "▁an▁AE": 11705, + "icular": 11706, + "icron": 11707, + "▁poly": 11708, + "▁poor": 11709, + "ing▁placebo": 11710, + "ingness▁to": 11711, + "▁bal": 11712, + "es,▁and": 11713, + "es▁to▁": 11714, + "▁second": 11715, + "▁depend": 11716, + "▁method▁": 11717, + "▁mechanism": 11718, + "omach": 11719, + ".\n\n16": 11720, + ".\n\n0\n\n1\n\n2\n\n3\n\n4": 11721, + "al▁D": 11722, + "elay▁": 11723, + "▁increase▁": 11724, + "es▁must▁be▁": 11725, + "es▁have▁been": 11726, + "▁Pres": 11727, + "▁(5-FU": 11728, + "▁(IVRS": 11729, + "▁21-day▁cycl": 11730, + "used▁on": 11731, + "▁record▁": 11732, + "owski": 11733, + "▁During▁the▁": 11734, + "▁END": 11735, + "▁or▁l": 11736, + "▁orally▁": 11737, + "▁or▁his/her": 11738, + "\n\nPrior": 11739, + "quartil": 11740, + "oda": 11741, + "\n\nABX-EGF": 11742, + "▁and▁any▁": 11743, + "▁Over": 11744, + "▁produc": 11745, + "▁Nam": 11746, + "▁RES": 11747, + "ed▁intraven": 11748, + "▁treatment▁in": 11749, + ".23": 11750, + "▁is▁discontinu": 11751, + "▁algorithm": 11752, + "▁alopecia": 11753, + "e▁specific": 11754, + "▁run": 11755, + "▁090177e18": 11756, + "▁3.2": 11757, + "▁conjunction": 11758, + ".▁Access": 11759, + "▁the▁survival▁": 11760, + "ave▁you": 11761, + "outpatient": 11762, + "▁steroid": 11763, + "ing▁the▁study": 11764, + "▁62": 11765, + "▁6.3": 11766, + "▁4.0": 11767, + "▁the▁panitumumab": 11768, + "ditional": 11769, + "s▁(CTCAE": 11770, + ".49": 11771, + "emotherapeutic": 11772, + "ly▁available▁": 11773, + "104": 11774, + "▁times": 11775, + "▁time▁for": 11776, + "ies▁to": 11777, + "▁may▁request": 11778, + "effectiv": 11779, + "so▁that": 11780, + "s.\n\n6": 11781, + "▁Date:▁20th▁December▁2004": 11782, + "aboratories▁": 11783, + "▁Number:▁05": 11784, + "CRO": 11785, + "25▁Edition▁Number": 11786, + "first▁met": 11787, + "\n\nN▁A\n\nF▁O": 11788, + "heal": 11789, + "prevent": 11790, + "every▁2": 11791, + "\n\n2.1": 11792, + "\n\nRest": 11793, + "assumption": 11794, + "\n\nFACT-": 11795, + "\n\n3.3": 11796, + "duration": 11797, + "responsibility▁of": 11798, + "no▁less▁than": 11799, + "▁dose▁(": 11800, + "ed▁as▁target▁lesion": 11801, + "\n\n4.1": 11802, + "data▁for": 11803, + "\n\nI▁have▁": 11804, + "resulting▁in": 11805, + "▁minor": 11806, + "performed▁in": 11807, + "▁sites": 11808, + "considered": 11809, + "consideration": 11810, + "▁if▁you": 11811, + "▁modifi": 11812, + "ed\n\nto": 11813, + "ed▁sampl": 11814, + "valence▁of": 11815, + "fficacy▁and▁": 11816, + "▁Cancer▁Societ": 11817, + ",▁2003": 11818, + "▁clinical▁trial▁": 11819, + "▁must▁not": 11820, + "review▁of": 11821, + ".▁Not": 11822, + "▁chemotherapy▁is▁": 11823, + "▁12.2": 11824, + "▁both▁arm": 11825, + "▁KGa": 11826, + "▁this▁study▁is▁to": 11827, + "▁Edition▁Number:▁05": 11828, + "\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁Denosumab▁Protocol▁Number:▁20050244▁Date:▁05▁May▁2008\n\nPage▁": 11829, + "▁Stage▁III": 11830, + "▁by▁an": 11831, + "▁every▁2▁week": 11832, + "Complet": 11833, + "▁a▁multicenter": 11834, + "▁first-line▁": 11835, + "▁hyper": 11836, + "▁hypersensitivity▁reaction": 11837, + "Code▁7054Il/00": 11838, + "fice▁": 11839, + "olicy▁": 11840, + ".▁Of": 11841, + "ynomol": 11842, + "stored▁for": 11843, + "most▁frequ": 11844, + "median▁PFS": 11845, + "Clinical▁Study▁Protocol▁Drug▁Substance:": 11846, + ");▁•": 11847, + "▁medical▁histor": 11848, + "SIDERA": 11849, + "▁Concomitant": 11850, + "▁patients▁who▁are▁": 11851, + "hydrogen": 11852, + "2-week": 11853, + "▁paraffin-embedd": 11854, + "\n\nthe▁in": 11855, + "availabl": 11856, + "▁further▁detail": 11857, + "s▁in▁the▁ITT": 11858, + "anufact": 11859, + ".\n\nIn▁addition": 11860, + "ee▁Appendix": 11861, + "planned": 11862, + "whether▁or▁not": 11863, + "one▁scintigraph": 11864, + "▁Subjects▁with": 11865, + "▁2005;": 11866, + "▁vitamin▁D3": 11867, + ".\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁Panitumumab▁Protocol▁Number:▁20050181▁Date:▁04▁April▁2008\n\nPage▁": 11868, + "▁fluoropyrimidin": 11869, + "▁(mCRC": 11870, + "▁exposure": 11871, + "excluded▁from": 11872, + "OTENTIAL": 11873, + "altz": 11874, + "▁adverse▁drug": 11875, + "▁............................................................................................": 11876, + "▁pathologic": 11877, + "Phase▁III": 11878, + "randomized▁to▁receive▁": 11879, + "ochran": 11880, + "-related▁toxicities▁": 11881, + "possibly▁": 11882, + "Note:": 11883, + "azol": 11884, + "y-stimulating▁factor": 11885, + "▁CONSIDERA": 11886, + "▁bone\n\n": 11887, + "▁supplies": 11888, + "▁Randomized▁": 11889, + "54IL/0024": 11890, + ".▁Result": 11891, + ".\n\nHow": 11892, + "▁fatty▁acid▁": 11893, + "▁analgesic▁us": 11894, + "▁7054IL/0024": 11895, + "▁adenocarcinoma▁of▁the▁": 11896, + "(34)\n\nGEL▁Version▁ID:▁ONC.000−127−200.3": 11897, + "(34)\n\nGEL▁Version▁ID:▁ONC.000−127−199.3": 11898, + "▁Bicalutamide▁Study▁Code:": 11899, + "▁Bicalutamide▁Study▁Code▁7054Il/00": 11900, + "▁AND▁DEFINI": 11901, + "▁bronchospasm": 11902, + "manufacturer": 11903, + "▁ED-SCLC": 11904, + "TISTICAL▁METHO": 11905, + "▁Derivation▁or▁calculation▁of▁outcome▁variable": 11906, + "▁thought": 11907, + "▁Organization": 11908, + "▁repeat": 11909, + "▁occurs▁first": 11910, + "RANKL": 11911, + "▁reasonable▁possibility▁that▁the▁event▁may▁have▁been▁caus": 11912, + "equivoc": 11913, + "yelosuppression": 11914, + "utomatic": 11915, + "erck▁KGa": 11916, + "inancial▁Dis": 11917, + "▁or▁significant▁dis": 11918, + "▁5▁20▁December▁2004": 11919, + "25▁Edition▁Number▁5▁20▁December▁2004": 11920, + "▁Edition▁Number:▁05▁Date:▁20th▁December▁2004": 11921, + "ynomolg": 11922, + "Clinical▁Study▁Protocol▁Drug▁Substance:▁Bicalutamide▁Study▁Code:": 11923, + "▁7054IL/0024▁Edition▁Number:▁05▁Date:▁20th▁December▁2004": 11924, + "▁Bicalutamide▁Study▁Code▁7054Il/0025▁Edition▁Number▁5▁20▁December▁2004": 11925, + "TISTICAL▁METHODS": 11926, + "erck▁KGaA": 11927, + "Clinical▁Study▁Protocol▁Drug▁Substance:▁Bicalutamide▁Study▁Code:▁7054IL/0024▁Edition▁Number:▁05▁Date:▁20th▁December▁2004": 11928, + "(10": 11929, + ")▁was▁": 11930, + "2▁Feb": 11931, + "600": 11932, + "Australia": 11933, + "D1": 11934, + "Immun": 11935, + "Oxaliplatin": 11936, + "PO": 11937, + "Treat": 11938, + "aution": 11939, + "dimension": 11940, + "gastric▁cancer": 11941, + "i▁M": 11942, + "ious▁": 11943, + "ker": 11944, + "marrow": 11945, + "pic": 11946, + "prim": 11947, + "poly": 11948, + "uper": 11949, + "▁y▁": 11950, + "▁....................................................................................................": 11951, + "\n\nfrom": 11952, + "\n\nrecord": 11953, + "\n\n20": 11954, + "\n\n25": 11955, + "\n\ninformation": 11956, + "▁amend": 11957, + "ero": 11958, + "s▁until": 11959, + "reet": 11960, + "restart": 11961, + "▁thoracic": 11962, + "itch": 11963, + "▁the▁appropriate▁": 11964, + ",▁di": 11965, + ",▁phosphor": 11966, + "ed▁during▁the▁": 11967, + "▁animal": 11968, + ".▁3": 11969, + "ing,▁and▁": 11970, + "ation▁with▁the▁": 11971, + "▁to▁continu": 11972, + "▁to▁participate▁in": 11973, + "is▁and▁": 11974, + "is▁an▁": 11975, + "umer": 11976, + "▁devic": 11977, + "▁and▁7": 11978, + "▁in▁the▁s": 11979, + "▁inhibit": 11980, + "urit": 11981, + "▁1:": 11982, + "▁1▁(": 11983, + "proper": 11984, + "▁(SAE": 11985, + "used▁at": 11986, + "ubmitt": 11987, + "amide▁": 11988, + "forming": 11989, + "therapeutic": 11990, + "tero": 11991, + "\n\nPRI": 11992, + "▁ng/mL": 11993, + "\n\nAl": 11994, + "▁TO": 11995, + "▁THE": 11996, + "▁advis": 11997, + "▁admission": 11998, + "▁RS": 11999, + "▁RAN": 12000, + "▁treatment.": 12001, + ".13": 12002, + "minor": 12003, + "▁200401": 12004, + "▁will▁be▁ask": 12005, + "▁will▁be▁assign": 12006, + "e▁symptom": 12007, + "e▁side▁effect": 12008, + "▁39": 12009, + "▁compan": 12010, + ".▁A▁copy▁of": 12011, + "ity▁for": 12012, + "▁as▁need": 12013, + "as▁follows:": 12014, + "▁the▁subsequent": 12015, + "ly▁s": 12016, + "s,▁with": 12017, + "▁stain": 12018, + "will▁have▁": 12019, + "▁49": 12020, + "▁the▁purpos": 12021, + "▁acne": 12022, + "\n\n17": 12023, + ".5.3": 12024, + "medic": 12025, + "s▁and▁SAE": 12026, + "▁patients▁and▁": 12027, + "109": 12028, + "▁the▁day▁": 12029, + "▁GI": 12030, + "▁Us": 12031, + "\n\nEGF": 12032, + "require▁": 12033, + "s\n\n7": 12034, + "roduction": 12035, + "CTSU": 12036, + "▁10▁mg": 12037, + ".▁In▁the▁": 12038, + "s.\n\n8": 12039, + "paraffin-embedd": 12040, + "progression▁of": 12041, + "▁in▁the▁absence▁of": 12042, + "s▁suggest": 12043, + "heum": 12044, + ").\n\nA": 12045, + ".▁If▁a": 12046, + "▁Administer": 12047, + "▁pre-specifi": 12048, + "▁Study▁Treatment": 12049, + "▁a▁second▁": 12050, + "▁the▁lung": 12051, + "▁dose▁escal": 12052, + "▁regimens": 12053, + "e▁bevacizumab": 12054, + "▁Clinical▁Oncology▁": 12055, + ".\n\nS▁I\n\nS▁I▁H▁T": 12056, + "oxid": 12057, + "considered▁as▁": 12058, + "discontinue▁": 12059, + "Stimulating": 12060, + "▁do▁so": 12061, + "▁occurs,▁": 12062, + "discomfort": 12063, + "ytic": 12064, + ".▁Non-": 12065, + "extract": 12066, + "▁received▁at▁least": 12067, + "clinical▁trial▁": 12068, + "▁the▁treatment▁group": 12069, + "rate,▁": 12070, + "undergoing": 12071, + ".▁For▁exampl": 12072, + "▁decide▁": 12073, + "▁2008;": 12074, + "▁a▁clinical▁": 12075, + ",▁et▁al.▁A": 12076, + "identifier": 12077, + "▁compare▁treatment": 12078, + "▁Appendix▁Edition▁Number": 12079, + "▁hyd": 12080, + "21▁days": 12081, + "▁Character": 12082, + "\n\n9.1": 12083, + "▁Drug▁Substance▁": 12084, + "at▁least▁1": 12085, + ".............................................................▁": 12086, + ":\n\n(cid:120)": 12087, + "\n\nthe▁s": 12088, + "echnical▁": 12089, + "fficacy▁Analysis▁Set": 12090, + ".\n\nD▁E▁T▁N▁I▁R▁P": 12091, + "▁during▁the▁study": 12092, + "panel": 12093, + "\n\nVisit": 12094, + "▁skin▁cancer": 12095, + ",▁No": 12096, + "ecommend": 12097, + "ITT▁population": 12098, + "▁such▁as▁": 12099, + "FOLFOX6": 12100, + "censored▁on": 12101, + "Grade▁2": 12102, + ".▁We▁": 12103, + "ligibility▁": 12104, + ".▁What": 12105, + "(cid:131)▁": 12106, + "measured▁by▁": 12107, + "Schedule▁of": 12108, + "▁Panitumumab▁Protocol▁Number:▁20050181▁Amendment▁2": 12109, + "frequency▁": 12110, + "\n\nC▁I▁N▁O▁R▁T▁C▁E▁L▁E\n\nN▁A\n\nF▁O": 12111, + "\n\nPharmacokinetic": 12112, + "▁..............................................................................................": 12113, + "ed▁in▁a▁1:1▁ratio": 12114, + "▁telephone▁number": 12115, + "Phase▁2": 12116, + "leason": 12117, + "available▁for": 12118, + "plaint": 12119, + "active▁v": 12120, + "measurements▁and▁": 12121, + "Considerations": 12122, + "▁Withdraw": 12123, + "▁intravenous": 12124, + "\n\nx▁x▁x▁x": 12125, + "IRB/aEC": 12126, + "▁centre": 12127, + "▁to▁ensure▁": 12128, + "ermat": 12129, + "▁protection": 12130, + "▁should▁notify▁the▁": 12131, + "▁Radiation": 12132, + "phylactic": 12133, + "▁advanced▁non-small▁cell▁lung▁cancer": 12134, + "red▁to▁as▁": 12135, + "withheld▁": 12136, + "seen▁in": 12137, + "▁Europe,▁": 12138, + "\n\nMedical▁": 12139, + "NCI-CTCAE": 12140, + "▁prednisone▁": 12141, + "s▁involved▁in": 12142, + "▁Contact": 12143, + "▁Appendix▁Date▁": 12144, + "▁under▁the▁curv": 12145, + "one▁or▁mor": 12146, + "encouraged▁to": 12147, + "▁anthracyclin": 12148, + "▁Lilly▁or▁its▁designee▁": 12149, + "▁retrospective▁": 12150, + "ordinating▁investigator": 12151, + "▁Antibodies": 12152, + ".▁Available▁at:▁http://www.": 12153, + "Fluorouracil": 12154, + "itoxantrone▁": 12155, + "▁lumbar▁spine▁BMD": 12156, + "rarely▁": 12157, + "osinophil": 12158, + "▁CONTENTS": 12159, + "▁Day▁1▁of▁Cycle▁1": 12160, + "irrespective▁of": 12161, + "▁is▁responsible▁for▁ensuring▁that": 12162, + ".\n\nAppendix▁XIV▁Page▁": 12163, + "▁CONSIDERATIONS": 12164, + "▁Panitumumab▁Protocol▁Number:▁20050181▁Amendment▁2▁Date:▁04▁April▁2008\n\nPage▁": 12165, + ",▁there▁": 12166, + "-15": 12167, + "-derived▁": 12168, + ".org": 12169, + "/S": 12170, + "1),▁": 12171, + "2)▁and▁": 12172, + ":▁In": 12173, + ";▁p": 12174, + "Bi": 12175, + "Best": 12176, + "Cell": 12177, + "DUC": 12178, + "EMENT": 12179, + "F)": 12180, + "N▁A\n\nF▁O\n\nY▁P▁O▁C": 12181, + "Subject": 12182, + "Tim": 12183, + "block": 12184, + "ek": 12185, + "fashion": 12186, + "mak": 12187, + "method▁": 12188, + "mega": 12189, + "ness▁or": 12190, + "uish": 12191, + "vit": 12192, + "wild-type▁KRAS": 12193, + "wild-typ": 12194, + "y)": 12195, + "y,▁or": 12196, + "−77": 12197, + "▁................................": 12198, + "▁": 12199, + "\n\nh": 12200, + "\n\nUn": 12201, + "▁a▁re": 12202, + "ension": 12203, + "s▁was▁": 12204, + "recogn": 12205, + "step": 12206, + "stea": 12207, + "y▁S": 12208, + "y▁for": 12209, + ",▁on": 12210, + ",▁who": 12211, + ",▁until": 12212, + ",▁weight": 12213, + ",▁oxaliplatin": 12214, + ",▁where▁": 12215, + ",▁nausea": 12216, + "rozen": 12217, + "▁an▁increase▁in": 12218, + ".▁16": 12219, + ".▁Up": 12220, + "arcin": 12221, + "ed▁therapy": 12222, + "es,▁or": 12223, + "es,\n\n": 12224, + "ess▁of▁the▁": 12225, + "ety▁of": 12226, + "▁serious": 12227, + "▁suspect": 12228, + "ase▁inhibitor": 12229, + "▁wid": 12230, + "▁and▁if": 12231, + "omening": 12232, + "al▁in": 12233, + "el▁J": 12234, + "▁initial▁": 12235, + "▁1%": 12236, + "▁CEA": 12237, + "▁CYP3A4": 12238, + "▁PT": 12239, + "▁Part": 12240, + "proportion▁of": 12241, + "▁(K": 12242, + "▁(2)": 12243, + "▁(32": 12244, + "conf": 12245, + "ife▁": 12246, + "▁Skin": 12247, + "▁SCCHN": 12248, + "▁red▁": 12249, + "otype▁": 12250, + "otension": 12251, + "unexpect": 12252, + "▁Dr": 12253, + "cl-2": 12254, + "▁or▁SAE": 12255, + "\n\nPemetrexed▁H3E-MC-JMHO(b)▁Confidential\n\nProtocol▁Amendment\n\nPage▁": 12256, + "per▁local": 12257, + "ate▁or": 12258, + "▁and▁about": 12259, + "▁as▁to": 12260, + "ep.": 12261, + "eful": 12262, + "▁forth": 12263, + "▁treatment▁failure▁": 12264, + "s▁of▁your": 12265, + "\n\nSTUDY": 12266, + "▁of▁5%": 12267, + "e▁setting": 12268, + "correlation": 12269, + "▁as▁follows:": 12270, + "▁this▁h": 12271, + "clude▁": 12272, + "▁will▁occur": 12273, + "▁5▁x▁ULN": 12274, + "▁65": 12275, + "from▁the▁date▁of▁randomization": 12276, + "▁subjects▁to": 12277, + "▁patients▁have▁": 12278, + ")\n\nIf": 12279, + "eger": 12280, + "continued)\n\n": 12281, + "\n\n18": 12282, + "eptomening": 12283, + "fer▁MJ": 12284, + "ation▁of▁Addendum": 12285, + "e▁daily": 12286, + "atheter": 12287, + "obil": 12288, + "▁patients\n\n": 12289, + "▁patients)": 12290, + "102": 12291, + "▁time\n\n": 12292, + "▁timepoint": 12293, + "▁In▁addition": 12294, + "▁from▁all": 12295, + "ventory▁": 12296, + "▁is▁any▁": 12297, + "(cid:14": 12298, + "▁10.1": 12299, + "▁10▁minutes": 12300, + "tebra": 12301, + "▁x▁109": 12302, + "CRPC": 12303, + "▁used▁in": 12304, + "▁used▁for": 12305, + "▁usually▁": 12306, + "\n\nProduct:▁Denosumab▁Protocol▁Number:▁20050136▁Date:▁30▁April▁2008\n\nPage▁": 12307, + "al▁progression": 12308, + "every▁4▁week": 12309, + "▁trials▁": 12310, + "e,▁the▁investigator": 12311, + "shortness▁of▁breath": 12312, + "▁days▁(": 12313, + "ically▁documented▁": 12314, + "e▁before▁": 12315, + "fluor": 12316, + "▁actual▁": 12317, + "in▁the▁absence▁of": 12318, + "significance▁level": 12319, + "▁sample▁siz": 12320, + ".▁Re": 12321, + "anna": 12322, + "anned▁M": 12323, + ".▁2006": 12324, + "\n\nHa": 12325, + "Stage▁III": 12326, + "Stopping": 12327, + "▁sub-": 12328, + "▁individual▁": 12329, + "\n\n6.3": 12330, + "▁provides": 12331, + "▁response▁assessment": 12332, + "RODUC": 12333, + "efitinib": 12334, + "urgical": 12335, + "extend": 12336, + "\n\nBevacizumab": 12337, + "▁follow-up▁visit": 12338, + "▁to▁estim": 12339, + "ry▁skin": 12340, + "▁documentation▁of▁": 12341, + ".▁E▁S▁U\n\nE▁R▁O▁F▁E▁B": 12342, + "▁Clinical": 12343, + "▁changes": 12344, + "▁2006▁15": 12345, + "▁suit": 12346, + "FACT": 12347, + "▁increasing": 12348, + "designe": 12349, + "▁minutes,▁": 12350, + ",▁pelvis": 12351, + "▁several": 12352, + ".▁Overall": 12353, + "▁requires▁": 12354, + "\n\n9.2": 12355, + "▁agrees▁to": 12356, + "▁based▁on▁the▁": 12357, + "▁the▁course▁of": 12358, + "\n\nAdd▁9": 12359, + "▁correct": 12360, + "▁symptoms▁of": 12361, + "100)": 12362, + "istinguish": 12363, + "used▁for▁the▁": 12364, + ".\n\nD▁E▁T▁N▁I▁R▁P\n\nA": 12365, + "▁(see▁section": 12366, + "collection▁of": 12367, + "▁are:": 12368, + "\n\nProcedures▁in▁case▁of": 12369, + "8480C0000": 12370, + "-line▁treatment▁of": 12371, + "case▁of": 12372, + "other▁than▁the▁": 12373, + ",▁with▁the▁": 12374, + ".0\n\nApproved\n\nDate▁Printed:▁31−Jul−2014": 12375, + "comparator": 12376, + ".▁We▁will": 12377, + "ermination": 12378, + "es▁from▁the▁": 12379, + "control▁arm": 12380, + "▁procedures▁are▁": 12381, + "▁questionnaire▁": 12382, + "▁questionnaires": 12383, + "▁legal▁": 12384, + ",▁patients▁will▁be▁": 12385, + "▁Lilly▁and▁Com": 12386, + "ovariates▁": 12387, + "generic": 12388, + "exposed▁to": 12389, + "▁compared▁with▁placebo": 12390, + "▁Study▁Code▁D8480C00013▁Appendix▁Edition▁Number": 12391, + "period▁of": 12392, + ":38:50": 12393, + "databas": 12394, + "keletal": 12395, + "▁of▁128\n\n": 12396, + "▁behalf": 12397, + "▁Sample▁Size▁": 12398, + "where▁the▁": 12399, + "participating▁in▁the▁": 12400, + "pharmacokinetics▁of": 12401, + "SSESS": 12402, + "▁supportive▁care▁": 12403, + "osis▁in": 12404, + "kaline▁phosphat": 12405, + "fluenc": 12406, + "▁q21": 12407, + "ella▁D": 12408, + "outside▁the▁": 12409, + "▁initiation▁of": 12410, + "icroRNA": 12411, + "▁sponsor-": 12412, + "ampfer▁MJ": 12413, + "▁refriger": 12414, + "ensive-": 12415, + ".0▁Approved▁by\n\nApproved\n\nDate▁Printed:▁31−Jul−2014\n\n21▁Dec▁2004▁10:36:54": 12416, + "▁Consent": 12417, + "dependent▁Ethics▁Committe": 12418, + "bumin-adjusted▁": 12419, + "▁albumin,": 12420, + "(4):▁p.▁": 12421, + "contraception": 12422, + "egree▁of": 12423, + "▁this▁research▁study?": 12424, + "▁ANALY": 12425, + "ef▁Pain▁Inventor": 12426, + "▁become▁pregnant": 12427, + "MINISTRATIVE": 12428, + "▁congenital▁anom": 12429, + "\n\nApproved▁by\n\n21▁Dec▁2004▁10:21:22": 12430, + "permanently▁discontinu": 12431, + "hythm": 12432, + "▁who▁conducted▁the▁informed▁consent▁discussion": 12433, + "▁comes▁first": 12434, + ",▁potassium,▁chloride,▁bicarbon": 12435, + "AZD2171▁Study▁Code▁D8480C00013▁Appendix▁Edition▁Number": 12436, + "inal▁cord▁compression": 12437, + "214−77": 12438, + "2▁Feb▁2006▁15": 12439, + "▁Drug▁Substance▁AZD2171▁Study▁Code▁D8480C00013▁Appendix▁Edition▁Number": 12440, + "anned▁Methods▁of": 12441, + "214−771.5": 12442, + "2▁Feb▁2006▁15:38:50": 12443, + "%▁in": 12444, + "%▁in▁the▁": 12445, + "(s)\n\n": 12446, + "),▁and": 12447, + ",▁are▁": 12448, + ",13": 12449, + ",▁these▁": 12450, + ".L": 12451, + "0.0": 12452, + "1▁(": 12453, + ":3": 12454, + "Calvert": 12455, + "F▁O\n\nY▁P▁O▁C": 12456, + "Hugh": 12457, + "J,▁B": 12458, + "Offic": 12459, + "TO": 12460, + "Vitamin▁D": 12461, + "Wild-typ": 12462, + "],[": 12463, + "creatinine▁": 12464, + "few": 12465, + "greg": 12466, + "i▁C": 12467, + "rlotinib": 12468, + "s▁treat": 12469, + "tane": 12470, + "uclear": 12471, + "volunt": 12472, + "y,▁and▁": 12473, + "▁": 12474, + "▁........................": 12475, + "▁versus": 12476, + "ine,▁": 12477, + "in▁which": 12478, + "ates▁and▁": 12479, + "one▁of": 12480, + "\n\nGE": 12481, + "ref": 12482, + "al▁power": 12483, + "ster": 12484, + ",▁6": 12485, + ",▁9": 12486, + ",▁15": 12487, + ",▁5-FU": 12488, + ",▁USP": 12489, + "ed▁graph": 12490, + ".▁b": 12491, + "ctep.": 12492, + "aragraph": 12493, + "▁pattern": 12494, + "ing,▁s": 12495, + "▁bag": 12496, + "is▁also": 12497, + "▁similar": 12498, + "▁single-agent": 12499, + "▁salin": 12500, + "▁slice▁thickn": 12501, + "▁of▁A": 12502, + "▁dail": 12503, + "▁dilution": 12504, + "▁and▁vomiting": 12505, + "ome-": 12506, + "ively▁": 12507, + "▁in▁subjects▁with": 12508, + "▁PS": 12509, + "▁Participant": 12510, + "▁Previously▁": 12511, + "progressive▁diseas": 12512, + "There▁": 12513, + "used▁and▁": 12514, + "ift": 12515, + "▁Sponsor": 12516, + "▁Irinotecan": 12517, + "unused▁": 12518, + "▁Di": 12519, + "▁littl": 12520, + "▁Endpoint": 12521, + "ame▁": 12522, + "vertebral": 12523, + "▁or▁p": 12524, + "▁or▁at": 12525, + "quarter": 12526, + "▁prolifer": 12527, + "alleng": 12528, + "▁TRIO": 12529, + "opard": 12530, + "will▁be▁collect": 12531, + "will▁be▁used▁to": 12532, + "andler": 12533, + "▁Rev": 12534, + "▁Rational": 12535, + "▁treatment▁(": 12536, + "▁treatment▁period": 12537, + "ed▁to▁have▁": 12538, + "ed▁to▁receive▁": 12539, + ".29": 12540, + "s▁of▁all": 12541, + "▁that▁occur": 12542, + "e▁the▁infusion": 12543, + "▁MF": 12544, + "▁0.05": 12545, + "▁comprehensive▁": 12546, + "▁First": 12547, + ".▁The▁sponsor": 12548, + "not▁to": 12549, + "intil": 12550, + "ing▁the▁study▁": 12551, + "▁5.1": 12552, + "book": 12553, + "ity▁and▁": 12554, + "▁6.5": 12555, + ")\n\nR": 12556, + "amples▁of": 12557, + "s▁(SAE": 12558, + "▁study▁doctor": 12559, + "▁cancer▁treatment": 12560, + "ired": 12561, + "▁the▁toxicity▁": 12562, + "ellect": 12563, + "eptic": 12564, + "▁after▁failure▁of": 12565, + "crepanc": 12566, + "ly\n\n": 12567, + ".▁Prior": 12568, + "\n\nEQ-5D": 12569, + "▁Int": 12570, + ".▁They▁": 12571, + "et▁al.▁200": 12572, + "▁tumor▁typ": 12573, + "cedur": 12574, + "▁may▁have▁": 12575, + "bind": 12576, + "e-fre": 12577, + "▁analysis▁(": 12578, + ".▁In▁this▁": 12579, + "180": 12580, + "▁physical": 12581, + "records▁": 12582, + "▁contiguous▁": 12583, + "▁medi": 12584, + "radiologist": 12585, + "▁leuk": 12586, + "▁9.2": 12587, + "▁8.2.1": 12588, + "al▁protocol": 12589, + "30▁days▁": 12590, + "\n\nRandomization": 12591, + "Study▁D": 12592, + "▁Add:": 12593, + "association": 12594, + "▁the▁study▁treatment": 12595, + "servation": 12596, + "response\n\n": 12597, + ".▁Des": 12598, + "no▁more▁than": 12599, + "▁dose▁is▁": 12600, + "▁interstit": 12601, + ".\n\nA\n\nS▁I": 12602, + ".\n\nProduct:▁Denosumab▁Protocol▁Number:▁20050136▁Date:▁30▁April▁2008\n\nPage▁": 12603, + "23▁Edition▁Number": 12604, + "hypertensive▁": 12605, + "in▁the▁event": 12606, + ")▁versus▁": 12607, + "creased▁": 12608, + "main▁study": 12609, + "▁These▁": 12610, + "dose-": 12611, + "e▁and▁other": 12612, + "▁diphenhydramin": 12613, + "▁peripheral▁neuropath": 12614, + "considered▁s": 12615, + "questions▁about": 12616, + "pontane": 12617, + "▁completing": 12618, + "▁discontinue▁from": 12619, + "documented▁in": 12620, + "iometric": 12621, + "disabl": 12622, + "locally": 12623, + "▁disposition": 12624, + "▁more▁detail": 12625, + "▁reli": 12626, + "urgent": 12627, + "\n\nInvestigational▁Product": 12628, + ".▁Neither": 12629, + ".........................................................................................▁": 12630, + "\n\nBlood▁": 12631, + "clinical▁research": 12632, + "your▁last": 12633, + "ospital▁": 12634, + "\n\n8.3": 12635, + "▁CR▁or▁PR": 12636, + "li▁Lilly▁and▁Com": 12637, + "▁within▁24▁hour": 12638, + "▁Proc": 12639, + "▁count,▁": 12640, + "▁chemotherapy▁alon": 12641, + "ophag": 12642, + "▁Street": 12643, + "determined▁by▁": 12644, + "▁review▁of": 12645, + "▁every▁6▁month": 12646, + "\n\nGS": 12647, + "▁very▁": 12648, + "cert": 12649, + ".▁Ob": 12650, + "attribut": 12651, + "▁were▁not": 12652, + "99.9": 12653, + "▁these▁data": 12654, + "Extension": 12655, + "\n\nSection:▁Appendix": 12656, + "container": 12657, + "ed▁treatment▁with": 12658, + "EDTA": 12659, + "possible▁that": 12660, + "FACT-L/N": 12661, + "s▁must▁be▁complet": 12662, + "▁e▁r": 12663, + "▁designee▁": 12664, + "\n\nVery▁": 12665, + "▁scheduled▁": 12666, + "▁randomized▁subject": 12667, + "open-label▁treatment▁phas": 12668, + "▁identification": 12669, + "eutrophil": 12670, + "▁>99.9": 12671, + "▁applicable)": 12672, + "eligible▁": 12673, + "itis/": 12674, + "medical▁condition": 12675, + "▁median▁PFS": 12676, + "frequently▁": 12677, + "▁efficacy▁endpoint": 12678, + "▁Follow-Up": 12679, + "▁of▁133\n\n": 12680, + ",▁unless": 12681, + "expression▁of": 12682, + "knowledg": 12683, + "▁......................................................................................": 12684, + "▁free▁survival": 12685, + "▁apply": 12686, + "IRB/EC": 12687, + "Arm▁A": 12688, + "WBDC": 12689, + "be▁treat": 12690, + "mend▁": 12691, + "stitutional▁Review▁Board▁(": 12692, + "ince▁your▁last": 12693, + "▁twice▁": 12694, + "▁authorized▁representativ": 12695, + "▁the▁interpret": 12696, + "▁while▁on": 12697, + "TERI": 12698, + "erious▁and▁": 12699, + "e▁Guidelin": 12700, + "company": 12701, + "unable▁to▁toler": 12702, + "returned▁to▁baselin": 12703, + "clinical▁study▁report": 12704, + "▁(see▁Appendix": 12705, + "stipation": 12706, + "amidron": 12707, + "chemistry▁": 12708, + "\n\nA▁®": 12709, + ".▁Although": 12710, + "▁Requirements": 12711, + "▁urine▁collection": 12712, + "eficiency▁": 12713, + "epatitis▁": 12714, + "ATIONALE": 12715, + "purpose▁": 12716, + "prevention▁of": 12717, + "▁and▁tolerability▁of": 12718, + "adverse▁effect": 12719, + "alpable▁": 12720, + "\n\nAmended▁Clinical▁Study▁Protocol▁Bicalutamide▁Study▁Code▁7054Il/0025▁Edition▁Number▁5▁20▁December▁2004": 12721, + "birth▁defect": 12722, + "ART▁B:": 12723, + "FORM": 12724, + "moking": 12725, + "▁preferred": 12726, + "mallest▁s": 12727, + "\n\nClinical▁Study▁Protocol:": 12728, + "omere▁length": 12729, + ".▁Schedule▁of▁Assessment": 12730, + "jeopard": 12731, + "(34)\n\nGEL▁Version▁ID:▁ONC.000−127−200.3.0\n\nApproved\n\nDate▁Printed:▁31−Jul−2014": 12732, + "(34)\n\nGEL▁Version▁ID:▁ONC.000−127−199.3.0▁Approved▁by\n\nApproved\n\nDate▁Printed:▁31−Jul−2014\n\n21▁Dec▁2004▁10:36:54": 12733, + "heumat": 12734, + "214−771.5.0▁Approved▁by\n\nApproved\n\nDate▁Printed:▁31−Jul−2014": 12735, + "23▁Edition▁Number▁7": 12736, + "(M": 12737, + "(11": 12738, + ")▁scan": 12739, + ",▁the\n\n": 12740, + ",▁total▁bilirubin": 12741, + "-Report": 12742, + ".J": 12743, + "/birth▁defect": 12744, + "3.": 12745, + "4)(cid:": 12746, + "6:": 12747, + ":▁W": 12748, + ";▁and": 12749, + "AX": 12750, + "Appro": 12751, + "DI": 12752, + "EU": 12753, + "ML": 12754, + "PG": 12755, + "Studies": 12756, + "TRIO": 12757, + "UT": 12758, + "Vital▁sign": 12759, + "VEF": 12760, + "a▁A": 12761, + "bine▁": 12762, + "born": 12763, + "dom": 12764, + "did▁not": 12765, + "e’": 12766, + "e’s▁": 12767, + "e.▁At": 12768, + "fever": 12769, + "found▁to": 12770, + "gel": 12771, + "i▁P": 12772, + "land": 12773, + "nrollment": 12774, + "oi": 12775, + "py": 12776, + "packag": 12777, + "son-": 12778, + "serious▁": 12779, + "s▁are▁s": 12780, + "tim": 12781, + "–▁Arm▁A": 12782, + "▁illness": 12783, + "e▁must▁be▁": 12784, + "e▁after": 12785, + "▁ten": 12786, + "▁tract": 12787, + "onazol": 12788, + "\n\nchemotherapy▁": 12789, + "\n\n5-FU": 12790, + "▁a▁n": 12791, + "s▁D": 12792, + "regression": 12793, + "recurrenc": 12794, + "al▁partner": 12795, + "alternative▁": 12796, + "stability": 12797, + "entricular": 12798, + "▁the▁results▁of": 12799, + "answer": 12800, + ",▁4": 12801, + ",▁7": 12802, + "aria": 12803, + "ed▁assessment": 12804, + "ed.▁This▁": 12805, + "▁pag": 12806, + "▁publish": 12807, + "▁palliative▁": 12808, + "▁capecitabin": 12809, + "▁corticosteroid": 12810, + "eta-": 12811, + "▁to▁this▁": 12812, + "the▁s": 12813, + "▁and▁of": 12814, + "▁and▁EQ-5D": 12815, + ".\n\n19": 12816, + ".\n\nOther": 12817, + "illary▁": 12818, + "al▁visit": 12819, + "elop": 12820, + "▁in▁Table▁": 12821, + "▁in▁situ": 12822, + "uration▁of▁": 12823, + "resid": 12824, + "ocock": 12825, + "ilt": 12826, + "▁(as▁": 12827, + "ance▁in": 12828, + "▁Sever": 12829, + "▁Scal": 12830, + "▁recom": 12831, + "▁reach": 12832, + "agre": 12833, + "applic": 12834, + "▁final▁": 12835, + "▁famil": 12836, + "▁folic▁acid▁": 12837, + "\n\nPemetrexed▁H3E-MC-JMHR(b)▁Confidential\n\nProtocol▁Amendment\n\nPage▁": 12838, + "\n\nA\n\n®\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁Panitumumab▁Protocol▁Number:▁20050251▁Date:▁10▁October▁2006\n\nPage▁": 12839, + "ate▁with": 12840, + "study▁design": 12841, + "▁androgen": 12842, + "easibl": 12843, + "▁N▁A\n\nF▁O\n\nY▁P▁O▁C": 12844, + "▁for▁D": 12845, + "▁Revised▁Clinical▁Study▁Protocol▁Drug▁Substance▁ZD4054▁Study▁Code▁D4320": 12846, + ".21": 12847, + "age▁Adjustment": 12848, + "e▁suggest": 12849, + "▁of▁the▁original": 12850, + "e,▁m": 12851, + "▁as▁soon▁as▁possibl": 12852, + "▁are▁being": 12853, + "ated▁at": 12854, + "▁ven": 12855, + "▁Based▁on": 12856, + "▁53": 12857, + "▁6-month": 12858, + "▁patients▁per": 12859, + "▁patients▁have▁been": 12860, + "ministrative▁": 12861, + "s▁(eg": 12862, + "▁accum": 12863, + ".48": 12864, + "\n\n19": 12865, + "relative▁to": 12866, + "▁extension": 12867, + "\n\nDenosumab": 12868, + "ed▁by▁treatment▁group": 12869, + "ation▁of▁a": 12870, + "ECTION": 12871, + ".▁Subjects▁who": 12872, + "s▁will▁be▁present": 12873, + "s▁will▁be▁randomiz": 12874, + "▁Utero": 12875, + "▁timely▁": 12876, + "▁times▁the▁": 12877, + "s\n\nIn": 12878, + "ed▁by▁M": 12879, + "▁issu": 12880, + "▁is▁also": 12881, + "▁is▁associated▁with": 12882, + "▁may▁not": 12883, + "▁may▁develop": 12884, + "▁may▁experienc": 12885, + "▁77": 12886, + "▁7.3": 12887, + ",▁the▁Investigator": 12888, + "▁assess▁s": 12889, + "pecial▁": 12890, + ".67": 12891, + "▁to▁the▁clinic": 12892, + "▁phen": 12893, + ".▁Cons": 12894, + "patient▁population": 12895, + "e▁(GCP": 12896, + "s▁schedul": 12897, + "\n\nNumber": 12898, + ").\n\n2": 12899, + "\n\n23": 12900, + "▁Add▁": 12901, + "ity▁of▁investigational▁product": 12902, + "▁also▁been": 12903, + "description": 12904, + "▁a▁safety▁": 12905, + "response▁system": 12906, + ".▁DATA": 12907, + ".▁Do▁not": 12908, + "id▁in": 12909, + "\n\nIMC-": 12910, + "hypo": 12911, + ".\n\nS▁T▁I": 12912, + "ack▁of": 12913, + "▁the▁study▁(": 12914, + "▁infusion▁of": 12915, + "▁13.4": 12916, + "\n\n02▁Feb▁2006▁15:38:50": 12917, + "▁subjects▁will": 12918, + "▁CT▁or▁MRI▁scan": 12919, + "plicate▁": 12920, + ".▁Based▁on": 12921, + "▁analysis.▁The▁": 12922, + ".8.2": 12923, + "ed▁solution": 12924, + "role▁in": 12925, + "▁occurring": 12926, + "▁should▁have▁": 12927, + "roscribed▁": 12928, + "▁short": 12929, + "▁clinical▁data": 12930, + "▁relaps": 12931, + "sample▁size▁": 12932, + "es▁for▁the▁": 12933, + "▁status▁will▁be▁": 12934, + "▁chemotherapy▁for": 12935, + "▁placebo▁(": 12936, + "changes▁": 12937, + "▁any\n\n": 12938, + ".▁E▁S▁U\n\nE▁R▁O▁F▁E▁B\n\nY▁T▁I▁D▁I▁L▁A▁V": 12939, + "▁12▁month": 12940, + "▁determining": 12941, + "rates▁of": 12942, + ".\n\nCom": 12943, + "▁changes▁": 12944, + "▁criteria▁are▁met": 12945, + "quality": 12946, + "▁Your": 12947, + "▁Yes▁or▁No": 12948, + "▁difference▁": 12949, + "are▁first▁met": 12950, + "▁comparing": 12951, + "ate1": 12952, + "▁analysis▁of▁OS": 12953, + "▁the▁beginn": 12954, + "▁health▁state▁": 12955, + "▁Study▁Code▁7054Il/00": 12956, + "▁Physician": 12957, + "▁based▁": 12958, + "▁and▁should▁": 12959, + "confirmation": 12960, + "▁correl": 12961, + "▁AND▁L": 12962, + "utilization": 12963, + "▁container": 12964, + "Prostate▁Cancer": 12965, + "▁or▁urine▁": 12966, + ".3.1.2": 12967, + "▁causal▁relationship": 12968, + "utropenic": 12969, + "closure": 12970, + "▁Medic": 12971, + "▁e▁e▁": 12972, + "archiv": 12973, + "▁Arm▁A▁and▁": 12974, + ")\n\nGEL▁Version▁ID:▁ONC.000−214−771.5.0▁Approved▁by\n\nApproved\n\nDate▁Printed:▁31−Jul−2014": 12975, + "proteinuria": 12976, + "▁skin▁rash": 12977, + "▁indicate▁that": 12978, + "▁doctor▁will": 12979, + "▁a▁particular": 12980, + "▁types▁of": 12981, + "increased▁": 12982, + "pharmacodynamic": 12983, + "▁affili": 12984, + "directed▁against": 12985, + "▁telephon": 12986, + "sent▁to▁the▁": 12987, + "▁approval▁of▁the▁protocol": 12988, + "ticaria": 12989, + "procedures▁": 12990, + "▁noncompli": 12991, + ".▁The▁investigator▁must": 12992, + "hypothesiz": 12993, + "lymphocyt": 12994, + "dose▁of▁panitumumab": 12995, + "ed▁tumor▁tissu": 12996, + "Grade▁3▁or▁4": 12997, + "▁hospitalization▁or": 12998, + "▁activity▁in": 12999, + "▁chemistry": 13000, + "▁you▁have▁any▁": 13001, + "▁investigate▁": 13002, + "▁25-hydroxyvitamin▁D": 13003, + "ECOG▁performance▁status▁(0": 13004, + "\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX": 13005, + "2,▁3": 13006, + "ALT,▁AST": 13007, + "1▁and▁2": 13008, + "▁Plus▁": 13009, + ",▁2008;": 13010, + "▁months▁after▁the▁first": 13011, + "osteoclast": 13012, + "▁tumor▁tissue▁sampl": 13013, + "▁lead▁to": 13014, + "▁have▁some▁": 13015, + "▁goal": 13016, + "▁might▁be▁": 13017, + "ody▁weight": 13018, + "▁along▁with▁the▁": 13019, + "paragraph\n\nReplace:": 13020, + "resectable▁": 13021, + "▁hypocalcemia": 13022, + "VEGFR-2": 13023, + ".▁N▁Engl▁J▁Med": 13024, + ".\n\nE▁S▁A▁E▁L▁P\n\n.▁T▁N▁E▁M▁U▁C▁O▁D": 13025, + "▁PATI": 13026, + "\n\nNon-PD": 13027, + "resistant▁prostate▁cancer": 13028, + "▁Accountability": 13029, + "▁Objective▁": 13030, + "▁aged▁≥": 13031, + "▁microRNA": 13032, + "’Brien-F": 13033, + "▁taking▁as▁reference▁the▁": 13034, + "teering": 13035, + "nervous▁system": 13036, + "▁will▁be▁stratified▁by▁": 13037, + "▁discontinuation▁of▁study▁treatment": 13038, + "▁vascular▁endothelial▁growth▁factor": 13039, + "abdomen": 13040, + "▁persistent▁or▁significant▁dis": 13041, + "emoral▁neck▁BMD": 13042, + "PECI": 13043, + "▁disease\n\nprogression": 13044, + "▁Efficacy\n\nAnalysis▁Set": 13045, + "▁or▁equal▁to": 13046, + "▁Heart▁Ass": 13047, + "▁thromboembolic▁event": 13048, + "VESTIGATIONAL▁PRODUCT": 13049, + "▁RANKL": 13050, + "RODUCTION": 13051, + "-Reported▁Outcom": 13052, + "▁Study▁Code▁7054Il/0023▁Edition▁Number▁7": 13053, + "(s),▁": 13054, + ")▁in▁the▁": 13055, + "-minut": 13056, + "/sh": 13057, + "3)(cid:": 13058, + "3)▁(cid:": 13059, + "4)▁(cid:": 13060, + "5W": 13061, + "8:": 13062, + ":\n\nS": 13063, + ":▁B": 13064, + "Central▁": 13065, + "Fract": 13066, + "First": 13067, + "H&N": 13068, + "NR": 13069, + "P)": 13070, + "PONS": 13071, + "Return▁of": 13072, + "XX": 13073, + "df": 13074, + "dys": 13075, + "delet": 13076, + "difficult": 13077, + "ei": 13078, + "e”": 13079, + "eMet": 13080, + "gone▁": 13081, + "gastrointestinal▁": 13082, + "kit": 13083, + "measures": 13084, + "moter": 13085, + "negativ": 13086, + "pdf": 13087, + "support": 13088, + "s▁as▁a": 13089, + "uperior": 13090, + "vul": 13091, + "vitamin▁B12": 13092, + "▁ir": 13093, + "▁kin": 13094, + "e▁form": 13095, + "e▁Com": 13096, + "inspect": 13097, + "ate.\n\n": 13098, + "ated▁in▁the▁": 13099, + "ates,▁": 13100, + "\n\nQ": 13101, + "\n\nun": 13102, + "\n\nform": 13103, + "\n\n50": 13104, + "or▁equivalent": 13105, + "orrection": 13106, + "s▁C": 13107, + "s▁................................................................................": 13108, + "s▁defin": 13109, + "▁think": 13110, + "stream": 13111, + ",▁per": 13112, + ",▁diarrhea": 13113, + "▁ann": 13114, + "icardial▁": 13115, + "▁cost": 13116, + "ing▁at": 13117, + "▁back": 13118, + "▁bowel": 13119, + "es),▁": 13120, + "▁to▁the\n\n": 13121, + "isod": 13122, + "▁sus": 13123, + "▁singl": 13124, + "▁sourc": 13125, + "ous▁(": 13126, + "▁dys": 13127, + "▁wall": 13128, + "▁mass": 13129, + "▁m▁u": 13130, + "▁making": 13131, + "▁and▁n": 13132, + ".\n\n17": 13133, + "olun": 13134, + "olys": 13135, + "abor": 13136, + "is▁is▁": 13137, + "▁A\n\nS▁I": 13138, + "urden": 13139, + "acerb": 13140, + "es▁may▁": 13141, + "es▁containing": 13142, + "▁(MRI": 13143, + "▁2.2": 13144, + "conclud": 13145, + "conclusion": 13146, + "rays": 13147, + "▁SPARC": 13148, + "▁restriction": 13149, + "unning": 13150, + "▁Darbepoetin▁alfa": 13151, + "apies▁": 13152, + "apular": 13153, + "appli": 13154, + "charg": 13155, + "▁or▁after": 13156, + "▁n▁o": 13157, + "▁nadir": 13158, + "\n\nAE": 13159, + "\n\nA\n\nS▁I": 13160, + "▁Option": 13161, + "▁TRT": 13162, + "▁advert": 13163, + "epression": 13164, + "will▁be▁summariz": 13165, + "will▁be▁censored▁at": 13166, + "▁for▁patients▁with": 13167, + "▁for▁detail": 13168, + "▁forward": 13169, + "▁RA": 13170, + "▁Redacted▁Version": 13171, + "▁treatment-emergent": 13172, + ".1%": 13173, + ".14": 13174, + "Inter": 13175, + "ading": 13176, + "adem": 13177, + "antel-": 13178, + "▁is▁required": 13179, + "▁of▁4": 13180, + "▁of▁irinotecan": 13181, + "▁will▁be▁based▁on": 13182, + "▁will▁be▁suppli": 13183, + "▁MSI": 13184, + "▁rath": 13185, + ",▁and▁in": 13186, + "integr": 13187, + "▁all▁of▁the▁following": 13188, + "ary▁n": 13189, + "▁resid": 13190, + "▁analyses,▁": 13191, + "acher": 13192, + "▁66": 13193, + "▁Horm": 13194, + "▁subjects,▁": 13195, + "▁the▁past": 13196, + "▁the▁potential▁": 13197, + "▁study▁enrollment": 13198, + "identification▁number": 13199, + "s▁indic": 13200, + "enszel": 13201, + "▁any▁fracture▁": 13202, + "▁VITAL": 13203, + "▁examination": 13204, + "\n\nDate1": 13205, + "ethical▁": 13206, + ".▁Secondary▁": 13207, + ".▁Serious▁Adverse▁Event": 13208, + "s▁will▁be▁summariz": 13209, + "ies▁will▁be▁": 13210, + "reported▁s": 13211, + "AEs▁will▁be▁": 13212, + ".▁Primary▁": 13213, + "▁of▁19": 13214, + "\n\nElect": 13215, + "ed▁by▁clinic▁visit▁or▁telephone▁contact": 13216, + "posure▁in": 13217, + "▁7.6": 13218, + "mont": 13219, + "▁per▁year": 13220, + ".▁Interim": 13221, + ".▁Effect": 13222, + "▁phys": 13223, + "recorded▁as▁": 13224, + "s.\n\n2": 13225, + ",▁and▁any▁": 13226, + "▁signal": 13227, + "▁abort": 13228, + "e.\n\nIf": 13229, + "▁90%": 13230, + "▁each▁of▁the▁": 13231, + "healing": 13232, + "preced": 13233, + "need▁for": 13234, + "\n\nRationale▁for": 13235, + "▁you▁decide▁to": 13236, + "▁a▁subset": 13237, + "e,▁albumin,": 13238, + "\n\n3.1": 13239, + "▁The▁primary▁": 13240, + "▁dose▁will▁be▁": 13241, + "▁Weight": 13242, + "▁Work": 13243, + "I-H": 13244, + ".\n\nPfizer▁–▁Company▁Confidential▁Page▁": 13245, + "s▁that▁do▁not": 13246, + "\n\nAdd": 13247, + "resulting▁from": 13248, + "performed▁using": 13249, + ")▁if": 13250, + "Events▁": 13251, + "d▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁Panitumumab▁Protocol▁Number:▁20050181▁Date:▁04▁April▁2008\n\nPage▁": 13252, + "signed▁and▁": 13253, + "▁diarrhoea": 13254, + "performance▁stat": 13255, + "▁dose▁of▁panitumumab": 13256, + "▁dose▁of▁study▁drug": 13257, + "▁index": 13258, + ".▁Br": 13259, + "response▁assessment": 13260, + "▁Panitumumab▁Clinical▁": 13261, + "▁occurr": 13262, + "\n\n6.4": 13263, + ".▁Mor": 13264, + "location": 13265, + "atistic": 13266, + "s▁will▁occur": 13267, + "weeks▁": 13268, + "▁blood▁pressure▁": 13269, + "▁results▁from": 13270, + "sample▁": 13271, + "ation▁of▁existing": 13272, + "e▁method": 13273, + "▁administered": 13274, + "▁to▁ver": 13275, + "▁to▁zoledronic▁acid▁": 13276, + "clinical▁practic": 13277, + "▁advanced▁or": 13278, + ",▁Al": 13279, + "-5▁Dimension": 13280, + "▁radiological": 13281, + "overall▁survival▁": 13282, + "▁effects▁of": 13283, + ",▁Bon": 13284, + "quality▁of": 13285, + "good▁": 13286, + "▁who▁have▁": 13287, + "-mail": 13288, + "-micron": 13289, + "determined▁to▁be▁": 13290, + "longest▁dimension": 13291, + "Result": 13292, + "▁assigned▁": 13293, + "s.▁The▁investigator": 13294, + "ation▁of▁the▁study▁": 13295, + "▁bone▁los": 13296, + "▁clas": 13297, + "▁OF▁S": 13298, + "▁OF▁CONTENTS": 13299, + "▁the▁case▁report▁form": 13300, + "▁have▁their": 13301, + "rate▁for": 13302, + "dependent▁children": 13303, + "▁an▁estimated▁": 13304, + "▁Concurrent": 13305, + "▁sunitinib/placebo": 13306, + "\n\ntest": 13307, + "\n\ntumor": 13308, + "\n\nAmended▁Clinical▁Study▁Protocol▁Drug▁Substance:▁Bicalutamide▁Study▁Code:▁7054IL/0024▁Edition▁Number:▁05▁Date:▁20th▁December▁2004": 13309, + "embran": 13310, + "ensory▁": 13311, + "▁high-": 13312, + "▁100%": 13313, + "▁during▁the▁course▁of▁the▁study": 13314, + "▁variety▁of": 13315, + "renal": 13316, + "▁but▁not": 13317, + "combined▁with": 13318, + "previously": 13319, + "▁(or▁equivalent": 13320, + "comparing": 13321, + "guidelines▁": 13322, + "▁PSA▁progression": 13323, + "▁flu": 13324, + "▁abnormality": 13325, + "needed▁to": 13326, + "▁local▁regulation": 13327, + "95%▁confidence▁interval▁": 13328, + "ed▁by▁the▁investigator▁or": 13329, + "ed▁by▁the▁investigator▁to▁be▁": 13330, + "▁chest▁X-ra": 13331, + "\n\nTable▁1": 13332, + "Objective▁": 13333, + "▁and▁Drug": 13334, + "scale▁scor": 13335, + "measured▁in": 13336, + "hazard▁ratio▁for": 13337, + "▁available,▁": 13338, + "OTE:": 13339, + "▁characteriz": 13340, + ".▁Cancer▁Research": 13341, + "▁regard▁to": 13342, + "▁surgery▁": 13343, + "ogenesis": 13344, + "s▁A▁and▁D": 13345, + "▁....................................................................................": 13346, + "every▁3▁month": 13347, + "improvement": 13348, + "followed▁by▁5-FU": 13349, + "▁Premedication": 13350, + "▁95%▁confidence▁interval": 13351, + "flammation": 13352, + "▁side▁effects▁of": 13353, + "▁have▁not▁progress": 13354, + "administration▁of▁the▁": 13355, + "▁pharmacogenetic": 13356, + "▁2007;▁8": 13357, + "-treated▁": 13358, + "Quality▁of▁Lif": 13359, + "-Free▁S": 13360, + ".▁Response▁": 13361, + "discontinued▁from▁study▁treatment": 13362, + ".[see▁comment]": 13363, + "labell": 13364, + "▁At▁least": 13365, + "\n\nWhen": 13366, + "▁storage▁": 13367, + "▁Analyses▁": 13368, + ".9%▁Sodium": 13369, + "▁referenc": 13370, + "progression-free▁survival": 13371, + "▁depress": 13372, + "▁regulatory▁ag": 13373, + "▁vita": 13374, + "▁classification": 13375, + "▁advanced▁non-small-cell▁lung▁cancer": 13376, + "\n\nX▁X▁X▁X▁X": 13377, + "▁osteoporosis": 13378, + "hormone▁": 13379, + "▁OF▁THE": 13380, + "management▁of": 13381, + "ockcroft-Gault": 13382, + "▁the▁dose▁of": 13383, + "▁AND▁RATIONALE": 13384, + "Hypothes": 13385, + "▁pulmonary▁fibros": 13386, + "▁30▁days▁after▁the▁last▁dose▁of": 13387, + "▁Compliance▁": 13388, + "▁methylation": 13389, + "Evaluation▁Criteria▁in▁Solid▁Tumors▁(RECIST": 13390, + "intent-to-treat": 13391, + "▁curative▁": 13392, + "field▁": 13393, + "▁progression-free▁survival": 13394, + "▁cells/L": 13395, + "▁permanent": 13396, + "thics▁Committee/In": 13397, + "▁always▁": 13398, + "▁necitumumab": 13399, + "ate▁synth": 13400, + "rosatellit": 13401, + "▁Japanese▁sites▁only": 13402, + "▁conventional▁techniqu": 13403, + "ABLE▁OF▁CONTENTS": 13404, + "understood": 13405, + "physical▁exam": 13406, + "ologically▁or▁cytologically▁": 13407, + "aternal▁expos": 13408, + "▁conjunction▁with": 13409, + "▁Derivation▁or▁calculation▁of▁outcome▁variable......................................................": 13410, + "ynomolgus▁": 13411, + "▁the▁purposes▁of": 13412, + "▁(32)\n\nGEL▁Version▁ID:▁ONC.000−214−771.5.0▁Approved▁by\n\nApproved\n\nDate▁Printed:▁31−Jul−2014": 13413, + "intiles▁": 13414, + ",▁2008;▁Page▁": 13415, + "unningham": 13416, + "e,▁albumin,▁total▁protein": 13417, + "&E": 13418, + "(G": 13419, + ")-": 13420, + ").▁All": 13421, + ",▁any▁": 13422, + "0;": 13423, + "0.22": 13424, + "2nd▁": 13425, + "400": 13426, + ":▁P": 13427, + "A*": 13428, + "AFETY": 13429, + "Blind": 13430, + "EAS": 13431, + "OW": 13432, + "PLS": 13433, + "SE": 13434, + "Section": 13435, + "URA": 13436, + "a▁M": 13437, + "a▁H": 13438, + "blind▁": 13439, + "broken": 13440, + "eak": 13441, + "eutropenia": 13442, + "food▁": 13443, + "ie,": 13444, + "mal": 13445, + "mas": 13446, + "ping": 13447, + "sec": 13448, + "s.▁An": 13449, + "xy": 13450, + "▁op": 13451, + "▁zoledronic▁acid": 13452, + "▁......................................................................................................": 13453, + "ind▁": 13454, + "in▁subjects▁with": 13455, + "atin": 13456, + "ateness▁of": 13457, + "enu": 13458, + "enz": 13459, + "err": 13460, + "or▁un": 13461, + "s▁3": 13462, + "s▁J": 13463, + "record▁": 13464, + "restrict": 13465, + "alian": 13466, + "▁the▁C": 13467, + "▁the▁appearance▁of": 13468, + "icient": 13469, + "▁pill": 13470, + "▁cover": 13471, + "ingful": 13472, + "▁bottl": 13473, + "▁to▁d": 13474, + "▁to▁8": 13475, + "isch": 13476, + "▁sor": 13477, + "▁surviv": 13478, + "▁mut": 13479, + "▁manner": 13480, + "▁and▁6": 13481, + "▁and▁patient": 13482, + "omas▁": 13483, + "al▁event": 13484, + "al▁5-FU": 13485, + "ela": 13486, + "eleg": 13487, + "olit": 13488, + "▁AST": 13489, + "▁Amended▁": 13490, + "ively": 13491, + "▁in▁your": 13492, + "▁inspection": 13493, + "ure▁d": 13494, + "ocardiogram": 13495, + "access": 13496, + "account": 13497, + "▁Page:": 13498, + "▁Platelet": 13499, + "▁(V": 13500, + "▁(per": 13501, + "▁(AE": 13502, + "▁(HR": 13503, + "▁(ITT)": 13504, + "used,▁": 13505, + "ramont": 13506, + "▁SJ": 13507, + "▁Scor": 13508, + "▁S▁T▁I": 13509, + "▁Schema": 13510, + "▁Days": 13511, + "with▁placebo": 13512, + "▁or▁your": 13513, + "▁or▁discomfort": 13514, + "e▁target": 13515, + "uture": 13516, + "endel": 13517, + "▁node▁": 13518, + "per▁protocol": 13519, + "ollection▁of": 13520, + "▁aspir": 13521, + "▁proportional▁hazard": 13522, + "▁addendum": 13523, + "eason": 13524, + "▁North": 13525, + "will▁be▁administer": 13526, + "compared": 13527, + "▁RE": 13528, + "▁treatment\n\n": 13529, + "study\n\n": 13530, + ".19": 13531, + "avoid": 13532, + "▁2009": 13533, + "▁is▁provid": 13534, + "▁of▁un": 13535, + "▁of▁every▁": 13536, + "▁will▁be▁defined▁as": 13537, + "e▁scan": 13538, + "e▁through": 13539, + "▁M0": 13540, + "contra": 13541, + "e,▁which": 13542, + ".▁As▁": 13543, + ".▁Approximately▁": 13544, + "▁the▁specific": 13545, + "▁the▁second": 13546, + "ly▁for": 13547, + ".31": 13548, + "▁BID": 13549, + "▁all▁subsequent": 13550, + "ary▁for": 13551, + "▁stage▁": 13552, + "▁sterile▁": 13553, + "▁will\n\n": 13554, + "▁will▁sign": 13555, + "▁will▁compensate▁you": 13556, + "ing▁the▁following": 13557, + "▁4.2": 13558, + ")\n\n\n\n": 13559, + "continue▁to": 13560, + "identify▁": 13561, + "irection": 13562, + "ensit": 13563, + "consecutive▁": 13564, + "▁existing": 13565, + "▁examine▁": 13566, + "▁whol": 13567, + "medically▁": 13568, + "e▁dimension": 13569, + ".▁Subsequent": 13570, + ".▁See▁Section": 13571, + "oblast": 13572, + "105": 13573, + "▁the▁date▁": 13574, + "angina": 13575, + "▁have▁access▁to": 13576, + "AEs)": 13577, + ".▁Please▁": 13578, + "\n\nEvalu": 13579, + "▁Independent": 13580, + "▁Inclusion▁Criteria": 13581, + "evaluated▁in": 13582, + "▁is▁available▁": 13583, + ",▁the▁study▁": 13584, + "▁adverse▁events▁and▁": 13585, + "s)▁with": 13586, + "▁10.2": 13587, + "▁10.2.1": 13588, + "▁to▁the▁study": 13589, + ".▁Elig": 13590, + "▁assessment▁of▁the▁": 13591, + "▁photograph": 13592, + "RAF": 13593, + "RIABLES": 13594, + "▁absolut": 13595, + "patient’s▁": 13596, + "s▁sh": 13597, + "calculation": 13598, + ").\n\n6": 13599, + "▁lesions,▁": 13600, + "assum": 13601, + "descript": 13602, + "▁the▁study.▁The▁": 13603, + "▁cycle▁(": 13604, + "e,▁as▁": 13605, + "...................................................................................................▁": 13606, + "shall": 13607, + "\n\nYes": 13608, + ".▁Dis": 13609, + ".▁Discontinu": 13610, + "completely▁": 13611, + "\n\nThe▁subject": 13612, + "\n\n4.7": 13613, + "▁consistent": 13614, + "ucci": 13615, + ".\n\nPemetrexed▁H3E-MC-JMHO(b)▁Confidential\n\nProtocol▁Amendment\n\nPage▁": 13616, + "s▁that▁occur": 13617, + "s▁that▁are▁not": 13618, + "results▁": 13619, + "▁Clinical▁Trial": 13620, + "flush": 13621, + "equal": 13622, + "level▁of": 13623, + "using▁an": 13624, + "▁the▁study▁sit": 13625, + "▁overdose▁": 13626, + "SAID": 13627, + "until▁toxicity▁": 13628, + ".▁2001;": 13629, + "enrolled▁into": 13630, + "ed.\n\n7": 13631, + ",▁Ph": 13632, + "▁submitt": 13633, + "▁CT/MRI": 13634, + "▁if▁I": 13635, + ".▁Blinded▁": 13636, + "ed▁since▁the▁treatment▁start": 13637, + "▁provided▁": 13638, + "▁response▁are▁first▁met": 13639, + "▁the▁time▁to": 13640, + "atistical": 13641, + "s▁before▁the▁": 13642, + ",▁Mor": 13643, + "▁discover": 13644, + "▁shrink": 13645, + ".▁Health": 13646, + "▁study▁treatment▁or": 13647, + "▁study▁treatment▁visit": 13648, + "▁study▁treatment▁administration": 13649, + "▁must▁have▁a": 13650, + "ed▁on▁the▁CRF": 13651, + "extrem": 13652, + "clinical▁outcom": 13653, + ".\n\nThe▁following": 13654, + "obtained▁from": 13655, + "▁neuroto": 13656, + "▁effective▁": 13657, + "ed▁by▁the▁Investigator": 13658, + "▁total▁of": 13659, + "▁this▁study▁is▁": 13660, + "Committe": 13661, + "\n\n5\n\n6": 13662, + "▁no▁more▁than": 13663, + "\n\nAppendix▁A": 13664, + "▁the▁same▁techniqu": 13665, + "ICS": 13666, + "\n\nK▁C▁E▁H▁C\n\nE▁S▁A▁E▁L▁P": 13667, + "Cancer▁Research": 13668, + "growth▁of": 13669, + "▁collection▁of": 13670, + "ficial": 13671, + "▁two▁week": 13672, + "questionnaires": 13673, + "ability/": 13674, + "ability,▁": 13675, + "▁bone▁resorption": 13676, + "at▁least▁one▁": 13677, + "▁clar": 13678, + "1,▁2": 13679, + "▁having": 13680, + "pectively": 13681, + "▁and▁survival": 13682, + "▁phase▁2": 13683, + "▁corresponding": 13684, + "▁the▁following:": 13685, + "awson-": 13686, + "\n\nthat": 13687, + "monitored▁": 13688, + "e▁facil": 13689, + "▁database▁": 13690, + ",▁1999": 13691, + "▁those▁who": 13692, + "ability▁for": 13693, + "ee▁J": 13694, + "▁value▁": 13695, + "\n\nProperty▁of▁the▁sanofi-aventis▁group▁-▁strictly▁confidential▁WW-CLIN-PR007-SD-03▁VERSION▁n°02▁(19-DEC-2005)\n\nPage▁": 13696, + "e.g.": 13697, + "appen": 13698, + "8480C000": 13699, + "Pharmacokinetic": 13700, + "▁appetit": 13701, + "▁confid": 13702, + "▁25(OH)D": 13703, + "▁identification▁number": 13704, + "s▁were▁not": 13705, + "ecommended▁": 13706, + "ARY": 13707, + "▁proteinuria": 13708, + "performed▁after": 13709, + "treated▁": 13710, + "▁experienced▁": 13711, + "addition▁of▁panitumumab": 13712, + "needl": 13713, + "▁differential": 13714, + "▁differential▁": 13715, + "dehydrogen": 13716, + "▁once▁daily▁": 13717, + ".▁Only▁": 13718, + "▁guidelines▁(": 13719, + "▁involvement": 13720, + "\n\nStatistical▁": 13721, + ".▁Continu": 13722, + "-induced▁": 13723, + "outlined▁in▁Section": 13724, + "▁SD▁PD": 13725, + "▁quality▁of▁lif": 13726, + "benefits▁of": 13727, + "▁necessarily▁": 13728, + "ood▁and▁Drug": 13729, + "▁version▁of▁the▁": 13730, + "confidential▁information": 13731, + "▁ADT": 13732, + "▁presentation": 13733, + "▁delay▁": 13734, + "▁predictor": 13735, + "▁asked▁to": 13736, + "agnesium,▁creatinin": 13737, + "removed▁from▁the▁": 13738, + "ergic▁reaction": 13739, + "▁errors▁(": 13740, + "retrospective▁": 13741, + "ominal▁significance▁level": 13742, + "initiation": 13743, + "e▁disorder": 13744, + "local▁regulation": 13745, + "e▁to▁receive▁the▁": 13746, + "response▁rate▁(ORR": 13747, + "kept▁in": 13748, + "▁partial▁respons": 13749, + ",▁Stampfer▁MJ": 13750, + "Record": 13751, + "um▁of▁the▁longest▁diameter": 13752, + "▁as▁described▁in▁Section": 13753, + "▁programm": 13754, + "respiratory▁": 13755, + "\n\nResult": 13756, + "ochemical▁": 13757, + "Manager": 13758, + "▁stable▁disease▁": 13759, + "\n\nA▁®\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:": 13760, + "itle:": 13761, + "uroQol-5▁Dimension": 13762, + "travenous▁": 13763, + "▁legally▁acceptable▁representativ": 13764, + ",▁however,▁": 13765, + "▁monoclonal▁antibody▁": 13766, + "\n\n100%": 13767, + "standard▁of▁car": 13768, + ".\n\nCONFIDENTIAL\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁PANITUMUMAB▁(AMG▁954)▁Protocol▁Number:▁20040249▁Date:▁07▁August▁2007\n\nPage▁": 13769, + "Documentation": 13770, + "displayed▁graph": 13771, + "▁range▁of": 13772, + ",▁24,▁": 13773, + "anine▁aminotransferase▁(": 13774, + "▁the▁subset▁of▁subject": 13775, + "ATORY": 13776, + "▁abdominal▁pain": 13777, + "wallowing": 13778, + "amendment": 13779, + "Haenszel": 13780, + "partate▁aminotransferase▁(": 13781, + "inorelbine▁": 13782, + "e▁turnover▁marker": 13783, + "ultivari": 13784, + "flow▁chart": 13785, + "▁the▁duration▁of▁the▁study": 13786, + "neoplastic": 13787, + "asse▁et▁al.▁2000": 13788, + "\n\nPRINT": 13789, + "(cid:131)▁You": 13790, + "eptomeningeal": 13791, + "ically▁documented▁PD": 13792, + "▁ANALYSIS": 13793, + "▁congenital▁anomaly": 13794, + "WBDC▁system": 13795, + "(34)\n\nGEL▁Version▁ID:▁ONC.000−127−200.3.0\n\nApproved\n\nDate▁Printed:▁31−Jul−2014\n\nApproved▁by\n\n21▁Dec▁2004▁10:21:22": 13796, + "’Brien-Fleming": 13797, + "▁Heart▁Association": 13798, + "icardial▁effusion": 13799, + "olunteer": 13800, + "antel-Haenszel": 13801, + "\n\nDate1\n\nPRINT": 13802, + "awson-Hugh": 13803, + "addition▁of▁panitumumab▁to": 13804, + ",▁the▁subject": 13805, + "-17": 13806, + ".C": 13807, + "1.2": 13808, + "2/": 13809, + "6)▁(cid:": 13810, + "70%": 13811, + "8]": 13812, + "Clinical": 13813, + "GT": 13814, + "Gloss": 13815, + "I)": 13816, + "Risk": 13817, + "U.S": 13818, + "Voice▁": 13819, + "Zoledronic": 13820, + "breast▁cancer": 13821, + "cost": 13822, + "density": 13823, + "e.▁E": 13824, + "euk": 13825, + "eosinophil": 13826, + "farin": 13827, + "gly": 13828, + "iov": 13829, + "night": 13830, + "nominated▁": 13831, + "oes▁not": 13832, + "past": 13833, + "rhythm": 13834, + "sun": 13835, + "s.▁All": 13836, + "some▁": 13837, + "sheet": 13838, + "uer": 13839, + "ways": 13840, + "▁": 13841, + "▁ed": 13842, + "▁etoposide▁": 13843, + "e▁versus▁": 13844, + "e▁pain": 13845, + "inct": 13846, + "inclusion": 13847, + "ates▁of": 13848, + "atures": 13849, + "at▁the▁discretion▁of▁the▁investigator": 13850, + "\n\nECOG": 13851, + "▁a▁r": 13852, + "orex": 13853, + "s▁L": 13854, + "s▁receiv": 13855, + "s▁develop": 13856, + "sthenia": 13857, + "y▁K": 13858, + ",▁g": 13859, + ",▁of": 13860, + ",▁when": 13861, + ",▁platelet▁count": 13862, + "ed▁while▁on": 13863, + ".▁18": 13864, + "ed,▁a": 13865, + "▁pen": 13866, + "▁pancreatic▁cancer": 13867, + "▁circulating": 13868, + "▁castration": 13869, + "ing▁all": 13870, + "▁sent": 13871, + "▁self-": 13872, + "▁of▁D": 13873, + "umulative▁": 13874, + "▁done▁": 13875, + "▁we▁": 13876, + "▁magnetic▁resonance▁imaging": 13877, + "▁market": 13878, + "▁and▁cisplatin": 13879, + "▁and▁secondary▁": 13880, + "omission": 13881, + ".\n\n23": 13882, + "al▁A": 13883, + "abet": 13884, + "▁American▁BioScience,▁Inc": 13885, + "▁institutional▁": 13886, + "▁in▁Patients▁with": 13887, + "import": 13888, + "ur▁J▁Cancer": 13889, + "occas": 13890, + "▁CRI": 13891, + "▁(the▁": 13892, + "useful": 13893, + "▁SG": 13894, + "▁reflect": 13895, + "unding": 13896, + "unequivoc": 13897, + "▁DH": 13898, + "▁DM": 13899, + "▁Document": 13900, + "▁D5W": 13901, + "clot": 13902, + "rief": 13903, + "▁height": 13904, + "▁lat": 13905, + "▁less▁": 13906, + "e▁of▁administration": 13907, + "▁EPA+DHA": 13908, + "▁fe": 13909, + "chain": 13910, + "▁or▁carboplatin": 13911, + "\n\nPl": 13912, + "\n\nPain": 13913, + "odd": 13914, + "\n\nAfter": 13915, + "▁and▁their": 13916, + "▁progressive▁": 13917, + "▁prophylax": 13918, + "▁for▁their": 13919, + "▁treatment▁or": 13920, + "▁treatment-related▁": 13921, + "encies": 13922, + ".24": 13923, + "avis▁": 13924, + "adic": 13925, + "▁of▁vitamin▁D": 13926, + "▁r▁": 13927, + "▁rac": 13928, + "▁rating": 13929, + "▁32": 13930, + "▁34": 13931, + "▁3.4.1": 13932, + "▁of▁the▁data": 13933, + "e,▁with": 13934, + ".▁The▁first": 13935, + ".▁The▁subject": 13936, + ".▁The▁median": 13937, + "▁one-": 13938, + ",▁and▁3": 13939, + "eez": 13940, + "▁vir": 13941, + "ly▁with": 13942, + ".36": 13943, + "▁Blinded▁": 13944, + "▁resist": 13945, + "▁resection": 13946, + "▁will▁allow": 13947, + "e▁in▁patients▁with": 13948, + "e▁individual": 13949, + "ology▁of": 13950, + "▁56": 13951, + "▁5.6": 13952, + "▁6.6": 13953, + "▁60%": 13954, + "and▁cisplatin": 13955, + "▁41": 13956, + "▁47": 13957, + "▁4.4": 13958, + "▁the▁potential": 13959, + "s▁(e.g.,▁": 13960, + "▁the▁investig": 13961, + ".45": 13962, + "▁study▁procedures": 13963, + "▁study▁participant": 13964, + ".52": 13965, + "▁exact": 13966, + "▁the▁true▁": 13967, + "\n\nDay▁1": 13968, + "ethical": 13969, + "ethnic": 13970, + "e▁definition": 13971, + ".▁Sit": 13972, + "obstruction": 13973, + "10)": 13974, + "ies▁must▁be▁": 13975, + "▁G4PFS": 13976, + "ely▁disabl": 13977, + "▁JE": 13978, + "s\n\n(cid:120)": 13979, + "▁7.2": 13980, + "▁dose,▁": 13981, + "e-related▁": 13982, + "▁assays": 13983, + "afety▁data": 13984, + ".6.6": 13985, + "s.\n\n9": 13986, + "s.\n\nIn": 13987, + "s.\n\nWith:": 13988, + ",▁and▁a": 13989, + "▁abs": 13990, + ".▁TRIAL": 13991, + "e.\n\n9": 13992, + "patient▁is▁": 13993, + ".,▁S": 13994, + "\n\nNam": 13995, + "precaution": 13996, + "30%": 13997, + "▁XP": 13998, + "\n\nRadi": 13999, + "NCE": 14000, + "▁Additional▁": 14001, + "▁prem": 14002, + "ence▁or": 14003, + "▁a▁similar": 14004, + "ating▁to": 14005, + "ifications▁for": 14006, + ".\n\nA\n\n®\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁Panitumumab▁Protocol▁Number:▁20050251▁Date:▁10▁October▁2006\n\nPage▁": 14007, + "\n\n4.2": 14008, + "\n\n4.2.1": 14009, + "leep": 14010, + "\n\nIt": 14011, + ")▁": 14012, + "▁infusion▁reaction": 14013, + "firmation": 14014, + ".▁Radi": 14015, + "you▁have▁": 14016, + "received": 14017, + "annucci": 14018, + ".▁2008": 14019, + "JMHR": 14020, + "\n\nHealth": 14021, + "▁discontinues▁": 14022, + ",▁Per": 14023, + "randomized▁trial": 14024, + "Standard": 14025, + "statement": 14026, + "▁subset": 14027, + "outcomes▁(PRO": 14028, + "cancer.gov/": 14029, + "ild-": 14030, + ",\n\nand▁": 14031, + ".85": 14032, + "collected▁from": 14033, + "16)(cid:": 14034, + "s▁but": 14035, + "electrolyt": 14036, + "▁drug▁delivery▁system": 14037, + "▁through▁the▁": 14038, + "▁must▁have▁": 14039, + ",▁CA": 14040, + "▁relation▁to": 14041, + "▁blood▁collection": 14042, + "▁result▁from": 14043, + ",▁bevacizumab": 14044, + "INR": 14045, + "extros": 14046, + "▁active,": 14047, + "risk▁factor": 14048, + "▁chemotherapy▁cycl": 14049, + "\n\nMonth": 14050, + "▁can▁occur": 14051, + "▁response\n\n": 14052, + "▁randomization▁to": 14053, + "clinical▁studies▁": 14054, + "your▁own": 14055, + "▁Arm▁D": 14056, + "▁12.1": 14057, + "undertaken": 14058, + "▁CR,▁PR": 14059, + "▁increase▁of": 14060, + "affect": 14061, + "▁anti-EGFr": 14062, + "▁Statistical▁": 14063, + "▁translational▁": 14064, + "easurable▁Lesion": 14065, + "▁every▁12▁week": 14066, + "identified▁as▁": 14067, + "placebo▁group": 14068, + "ICD": 14069, + "disease\n\n": 14070, + "assessed▁by▁": 14071, + "▁two-": 14072, + ")▁will▁be▁used▁to": 14073, + "ing▁scal": 14074, + "ates▁that": 14075, + "▁tolerated": 14076, + "▁tolerability": 14077, + "gressive▁Disease▁": 14078, + "▁pemetrexed,▁": 14079, + "▁Patients▁who": 14080, + "embry": 14081, + "▁databas": 14082, + "regarding▁the▁": 14083, + "▁Assessment▁of": 14084, + "▁concentrations▁of": 14085, + "life▁threatening": 14086, + "quamation": 14087, + "▁CTCAE▁=": 14088, + "evidence▁of▁disease▁progression": 14089, + "▁the▁primary▁prevention▁of": 14090, + "conditional▁": 14091, + "▁biops": 14092, + "CTCAE▁version▁3.0": 14093, + ",▁you▁will": 14094, + "profile▁": 14095, + "round▁": 14096, + ",▁but▁not": 14097, + "highest": 14098, + "guidelines▁for": 14099, + "▁Cycle▁2": 14100, + "▁fluid": 14101, + "safety▁of": 14102, + "▁local▁requirement": 14103, + "measurable▁disease▁": 14104, + "istic▁regression▁model": 14105, + "currence▁of": 14106, + "listed▁abov": 14107, + "urinalysis▁": 14108, + "idence▁interval": 14109, + "▁metastatic▁colorectal▁cancer▁(mCRC": 14110, + "▁adverse▁reaction": 14111, + "e▁blood▁count": 14112, + "▁nodul": 14113, + "▁laboratory▁abnormalities▁": 14114, + "epidermal▁growth▁factor": 14115, + "\n\nConcomitant": 14116, + "subsequently▁": 14117, + "hipment": 14118, + ".▁Additional▁": 14119, + "Signific": 14120, + ".▁The▁patient▁has▁": 14121, + "regional": 14122, + "▁filter": 14123, + "▁immunod": 14124, + "retention": 14125, + "ragm": 14126, + ".▁Us": 14127, + "ible▁person": 14128, + "▁received▁panitumumab": 14129, + "\n\nThere▁": 14130, + "▁size▁(": 14131, + "▁sites▁of▁diseas": 14132, + "systemic": 14133, + "Brief▁Pain▁Inventor": 14134, + "▁means▁that": 14135, + "▁and▁pelvis": 14136, + "first-line▁treatment▁of": 14137, + "▁responding": 14138, + "▁clinic▁visit": 14139, + "▁clinically": 14140, + "▁incidence▁of▁new": 14141, + "effective▁in": 14142, + "THICS": 14143, + "found▁in▁the▁": 14144, + "▁..........................................................................................................": 14145, + "\n\nx\n\nx\n\nx\n\nx\n\nx\n\nx\n\nx\n\nx": 14146, + "e▁Gramont": 14147, + "▁Guidelines": 14148, + "▁performed▁at": 14149, + "nual▁M": 14150, + "stantial": 14151, + "ULATORY": 14152, + "▁could▁be▁": 14153, + "hormonal": 14154, + "▁queri": 14155, + "▁Methods▁of▁assessment▁..........................................................................................": 14156, + "run-in": 14157, + "same▁m": 14158, + "MTD": 14159, + "toposide▁": 14160, + "witch": 14161, + ".\n\nWill": 14162, + "▁inhibition▁of": 14163, + "▁120▁mg": 14164, + "Statistical▁Analysis▁Plan": 14165, + "▁a▁single▁agent": 14166, + "emergency▁room": 14167, + "EGAL": 14168, + "preferred▁term": 14169, + "Brochure▁for": 14170, + "ilateral▁": 14171, + "esophageal": 14172, + "▁head▁and▁neck": 14173, + "malignancy▁": 14174, + "▁movement": 14175, + ".html": 14176, + "hort▁Form": 14177, + ":risk▁profile▁": 14178, + "▁among▁subjects▁with▁wild-type▁KRAS▁tumor": 14179, + "▁no▁longer▁be▁": 14180, + ".▁Proc▁Am▁Soc▁Clin▁Oncol": 14181, + "oproteger": 14182, + "▁Performance▁Status▁Scal": 14183, + "▁type▁I▁error": 14184, + "▁platelet▁count": 14185, + "Growth▁Factor▁Receptor": 14186, + "radiology▁review": 14187, + "emcitabine-cisplatin": 14188, + "▁Schedule▁4/": 14189, + "▁applicable▁to▁amended▁protocol": 14190, + "▁(cid:120)": 14191, + "▁tablespoon": 14192, + "8▁weeks▁±▁1▁week": 14193, + "ed▁intravenously▁": 14194, + "TERIA": 14195, + ".9%▁Sodium▁Ch": 14196, + "▁(32)\n\nGEL▁Version▁ID:▁ONC.000−214−771.5.0▁Approved▁by\n\nApproved\n\nDate▁Printed:▁31−Jul−2014\n\n02▁Feb▁2006▁15:38:50": 14197, + "ood▁and▁Drug▁Administration": 14198, + "iovannucci": 14199, + "orexia": 14200, + "▁CRITERIA": 14201, + "%▁to": 14202, + ")▁of▁the▁": 14203, + ").▁For": 14204, + ",▁administer": 14205, + "-▁and▁": 14206, + "-▁up": 14207, + ".”": 14208, + "/G": 14209, + "/M": 14210, + "/withdraw": 14211, + "0.5": 14212, + "1000": 14213, + "2.▁C": 14214, + "800": 14215, + ":▁S": 14216, + "<0.00": 14217, + "AMA": 14218, + "Biomarker": 14219, + "IFL": 14220, + "Primary▁": 14221, + "Scan": 14222, + "VAL": 14223, + "VAS": 14224, + "aemia": 14225, + "bound": 14226, + "bowel": 14227, + "e):": 14228, + "ffer": 14229, + "ger": 14230, + "hom": 14231, + "ially": 14232, + "lip": 14233, + "might": 14234, + "measur": 14235, + "mechanism": 14236, + "n=": 14237, + "ool": 14238, + "patent": 14239, + "survival▁": 14240, + "xia": 14241, + "▁........................................................": 14242, + "▁older": 14243, + "e▁R": 14244, + "e▁may▁be▁": 14245, + "in▁accordance▁with": 14246, + "▁tend": 14247, + "▁tell": 14248, + "ate)": 14249, + "ately,▁": 14250, + "\n\nmedication": 14251, + "\n\nadministration": 14252, + "eno": 14253, + "enhanc": 14254, + "er▁B": 14255, + "erson": 14256, + "s▁&": 14257, + "s▁................................................": 14258, + "s▁Ad": 14259, + "s▁using▁the▁": 14260, + "remit": 14261, + "reduced": 14262, + "reflect": 14263, + "▁thus▁": 14264, + "alopath": 14265, + "strok": 14266, + "▁the▁opportunity▁to": 14267, + "anol": 14268, + ",▁is▁": 14269, + ",▁18": 14270, + ",▁median": 14271, + "ed▁protocol": 14272, + "ed▁data": 14273, + "ed▁placebo": 14274, + ".▁7": 14275, + "ed.▁C": 14276, + "▁py": 14277, + "▁page▁": 14278, + "▁pregnant": 14279, + "for▁all": 14280, + "eting": 14281, + "etab": 14282, + "▁to▁provide▁": 14283, + "▁send": 14284, + "▁sensitivity": 14285, + "uma": 14286, + "▁difficult": 14287, + "th▁paragraph": 14288, + "▁wash": 14289, + "▁water": 14290, + "▁and▁document": 14291, + "▁and▁non-": 14292, + "▁and▁48": 14293, + "▁and▁without": 14294, + ".\n\nV": 14295, + ".\n\n20": 14296, + "illion": 14297, + "ills,▁": 14298, + "illness▁": 14299, + "elaps": 14300, + "is▁N": 14301, + "▁Activ": 14302, + "▁in▁an": 14303, + "urticaria": 14304, + "ithel": 14305, + "idi": 14306, + "idyl": 14307, + "acet": 14308, + "property▁of": 14309, + "promptly▁": 14310, + "▁(v": 14311, + "▁250": 14312, + "used▁in▁the▁": 14313, + "ulse": 14314, + "ulated": 14315, + "convention": 14316, + "if▁you": 14317, + "▁recogn": 14318, + "otide▁": 14319, + "▁DI": 14320, + "▁Delay": 14321, + "e▁of▁your": 14322, + "e▁of▁death": 14323, + "verag": 14324, + "chronic": 14325, + "▁or▁CR": 14326, + "termin": 14327, + "\n\nPSA": 14328, + "\n\nPlatelet": 14329, + "▁nmol/L": 14330, + "▁nitrogen": 14331, + "ist▁of": 14332, + "▁and▁any▁other": 14333, + "able)": 14334, + "▁ON": 14335, + "essential▁": 14336, + "epeat": 14337, + "computer": 14338, + "▁are▁th": 14339, + "enceph": 14340, + ".26": 14341, + "e▁to▁withdraw": 14342, + "ed▁blood▁": 14343, + "s▁of▁disease▁progression": 14344, + "Informed▁Consent": 14345, + "ourse": 14346, + "advert": 14347, + "\n\nSubjects▁": 14348, + "▁although": 14349, + "e▁seen": 14350, + "e▁throughout": 14351, + "▁rare▁": 14352, + "▁3▁hour": 14353, + "▁of▁the▁investigator": 14354, + "contrast": 14355, + "e,▁in": 14356, + "▁o▁n": 14357, + "▁compared": 14358, + "▁the▁sever": 14359, + "▁v3.0": 14360, + "▁BSC": 14361, + "▁this▁event": 14362, + "▁resum": 14363, + "ured▁": 14364, + "achycardia": 14365, + "\n\nCisplatin": 14366, + "\n\nCarboplatin": 14367, + "▁will▁take▁": 14368, + "▁will▁only▁be▁": 14369, + "▁Human": 14370, + "▁43": 14371, + "ministration▁of": 14372, + "▁the▁institution": 14373, + "▁the▁initiation▁of": 14374, + "one▁(": 14375, + "egold▁": 14376, + "pproval": 14377, + "general▁": 14378, + "▁the▁total": 14379, + "ed▁by▁the▁subject": 14380, + "▁after▁start▁of": 14381, + "e▁discontinu": 14382, + ".▁Such": 14383, + "ies▁(": 14384, + "▁Guid": 14385, + "ous,▁and▁": 14386, + "▁Jr": 14387, + "▁Journal▁of": 14388, + "▁times▁": 14389, + "requires": 14390, + ".▁Thus": 14391, + "▁may▁experience▁": 14392, + "monoclonal": 14393, + "s.\n\n10": 14394, + "▁abus": 14395, + "ymidyl": 14396, + "e.\n\n6": 14397, + "25-": 14398, + "s▁show": 14399, + "▁each▁arm": 14400, + ").\n\nIn": 14401, + ".70": 14402, + "▁formal": 14403, + "based▁upon": 14404, + "▁should▁be▁not": 14405, + "\n\nRefer": 14406, + "etermination": 14407, + "▁to▁be▁performed▁": 14408, + "▁prejudic": 14409, + "desir": 14410, + "▁a▁sampl": 14411, + "\n\nFull": 14412, + "e,▁all": 14413, + ".▁Dos": 14414, + "completion▁of▁the▁": 14415, + "ed▁as▁a▁c": 14416, + "KRAS▁status▁": 14417, + "▁days▁from": 14418, + "s▁that▁may▁": 14419, + "▁therapy▁of": 14420, + "ruct": 14421, + "performed▁by▁": 14422, + ".▁REFERENCES": 14423, + "SATION": 14424, + "formed▁consent▁document": 14425, + "▁years▁": 14426, + "▁approximately▁3": 14427, + "randomized▁into": 14428, + "\n\n6.2": 14429, + "▁should▁be\n\n": 14430, + "\n\n7.1": 14431, + "\n\n7.6": 14432, + "s▁will▁receive▁": 14433, + "administered▁at": 14434, + "sample▁siz": 14435, + "risk▁for": 14436, + "risks▁and▁": 14437, + "▁chemotherapy▁or": 14438, + "\n\nMaintain▁dose▁level": 14439, + "conducted▁at": 14440, + "▁information▁about": 14441, + "ullet": 14442, + "REVI": 14443, + "-scor": 14444, + "▁12.5": 14445, + "\n\n8.4": 14446, + "under▁the▁": 14447, + "Clinical▁Study▁Agreement": 14448, + "▁plus▁placebo": 14449, + "▁plus▁cisplatin": 14450, + ".▁Irinotecan": 14451, + "free▁": 14452, + "▁increase▁to": 14453, + "▁investigational▁product▁is▁": 14454, + "opharynx": 14455, + "▁anti-denosumab": 14456, + "are▁not": 14457, + "\n\n5.1": 14458, + "\n\nschedul": 14459, + "\n\nserious▁adverse▁event": 14460, + "-Mantel-Haenszel": 14461, + "▁randomized,▁": 14462, + "▁Formula": 14463, + "▁developing": 14464, + "econdary▁Endpoint": 14465, + "▁severe▁d": 14466, + "IRB)": 14467, + "▁the▁event▁is▁": 14468, + "required▁by▁": 14469, + "ing▁screening": 14470, + "s.[": 14471, + "▁researcher": 14472, + "▁health▁status▁": 14473, + "▁clearly▁": 14474, + "▁Physical▁examination": 14475, + "▁Phone:": 14476, + "stored▁in": 14477, + "▁20▁mm": 14478, + ",▁which▁is▁": 14479, + "▁mg/kg▁given": 14480, + "▁CA19-9": 14481, + ".,▁et▁al.,▁A": 14482, + "▁systematic": 14483, + "e/cisplatin": 14484, + "▁patients▁who▁receive▁": 14485, + "▁Patients▁will▁be▁": 14486, + "possible▁to": 14487, + "▁total▁cancer": 14488, + "product▁complaint": 14489, + "e▁with▁the▁": 14490, + "life▁": 14491, + "▁various▁": 14492, + ".▁1995;": 14493, + "▁values": 14494, + "ed▁into▁the▁": 14495, + "▁studies▁of": 14496, + "medical▁histor": 14497, + "▁indicate▁": 14498, + "considered▁related▁to": 14499, + "Therapy": 14500, + "relationship▁to": 14501, + ",▁Eisen": 14502, + "skin▁rash": 14503, + "▁applicable\n\n": 14504, + "repeated": 14505, + "immediate▁": 14506, + ",▁cetuximab": 14507, + "Medicin": 14508, + "ological▁imaging": 14509, + "\n\nNo\n\nUE": 14510, + "urinary▁": 14511, + "▁the▁safety▁follow-up▁visit": 14512, + "▁chest▁CT▁scan": 14513, + "▁(mL/min": 14514, + "▁alone▁(": 14515, + "s▁should▁not▁be▁": 14516, + "activity▁": 14517, + "▁postmenopausal": 14518, + "subjects▁have▁": 14519, + "ticancer": 14520, + "▁(TTP": 14521, + "▁you▁are▁a": 14522, + "▁laboratory▁test": 14523, + "▁accountability": 14524, + "e▁Collection": 14525, + "neutralizing": 14526, + "every▁3▁months▁": 14527, + "proposed▁m": 14528, + "▁accurac": 14529, + "recorded▁on▁the▁appropriate▁": 14530, + "▁Preclinical▁": 14531, + "classifi": 14532, + "Chang": 14533, + "▁make▁": 14534, + "▁1.5▁x▁109/L": 14535, + "=0.00": 14536, + "NTX": 14537, + "NTx": 14538, + "▁Collection▁of": 14539, + "▁shown▁to": 14540, + "institutional▁practic": 14541, + "s.▁Thes": 14542, + "▁Placebo": 14543, + "lood▁samples▁for": 14544, + "▁grade▁3▁or▁4": 14545, + "▁responder": 14546, + "pen-label": 14547, + "▁variables": 14548, + "▁confidentiality▁": 14549, + "▁22▁March▁2007": 14550, + "various▁": 14551, + "/mm3)": 14552, + "Management": 14553, + "every▁6▁weeks▁(±": 14554, + "expressing": 14555, + "▁alternative▁": 14556, + "▁shall▁be▁": 14557, + "▁sodium,▁potassium,▁chloride,▁bicarbon": 14558, + "▁reconstitut": 14559, + "\n\nPD\n\nAny": 14560, + "▁of▁the▁total▁": 14561, + "NCI-CTC": 14562, + "▁likely": 14563, + "▁decide▁to▁withdraw": 14564, + "ILITY": 14565, + "\n\nGenetic": 14566, + "oice▁response▁system": 14567, + "▁hemoglobin▁concentration": 14568, + "well▁tolerated": 14569, + "headache,▁": 14570, + "open▁label▁ZD4054": 14571, + "▁arterial": 14572, + "storage▁condition": 14573, + "rednisone▁": 14574, + "emperature▁": 14575, + "▁Clinical▁Oncology,▁": 14576, + "ACKGROUND▁AND▁RATIONALE": 14577, + "▁strata": 14578, + "▁(NSCLC)": 14579, + "aryngeal": 14580, + "▁ICH▁GCP": 14581, + "panel:▁sodium,▁potassium,▁chloride,▁bicarbon": 14582, + "▁serve▁as": 14583, + "▁is▁suspect": 14584, + "Protocol▁Attachment▁JMHO": 14585, + "▁Fax:": 14586, + "iatric": 14587, + "composite▁": 14588, + "▁the▁day▁after": 14589, + "▁VARIABLES": 14590, + "ochran-Mantel-Haenszel": 14591, + "utomatically▁": 14592, + "active▁voice▁response▁system": 14593, + "▁x▁109▁cells/L": 14594, + "alpable▁lymph▁nod": 14595, + "(34)\n\nGEL▁Version▁ID:▁ONC.000−127−199.3.0▁Approved▁by\n\nApproved\n\nDate▁Printed:▁31−Jul−2014\n\n21▁Dec▁2004▁10:36:54\n\nAmended▁Clinical▁Study▁Protocol▁Drug▁Substance:▁Bicalutamide▁Study▁Code:▁7054IL/0024▁Edition▁Number:▁05▁Date:▁20th▁December▁2004": 14596, + "posure▁in▁Utero": 14597, + "ynomolgus▁mon": 14598, + "e,▁albumin,▁total▁protein,▁total▁bilirubin": 14599, + "awson-Hughes▁B": 14600, + "occasion": 14601, + "encephalopath": 14602, + "ymidylate▁synth": 14603, + "(X": 14604, + "(16": 14605, + "-G": 14606, + "-f": 14607, + "-▁or": 14608, + ".R": 14609, + ".▁and▁": 14610, + "/ND": 14611, + "1.0": 14612, + "5)▁(cid:": 14613, + "7)\n\n(cid:13": 14614, + ":▁All": 14615, + "AA": 14616, + "BREVI": 14617, + "Center": 14618, + "Case▁Report▁Form": 14619, + "Hels": 14620, + "IND": 14621, + "IRC": 14622, + "IDMC▁will": 14623, + "Rest": 14624, + "TOR": 14625, + "Toxicity": 14626, + "believ": 14627, + "cardiac": 14628, + "creatinin": 14629, + "fit": 14630, + "gain": 14631, + "hand": 14632, + "lide▁": 14633, + "ltr": 14634, + "multipl": 14635, + "melanoma": 14636, + "s▁an": 14637, + "safety▁and▁": 14638, + "veal": 14639, + "water": 14640, + "zem": 14641, + "▁%": 14642, + "iness▁": 14643, + "in▁order▁to": 14644, + "incidence▁": 14645, + "▁techn": 14646, + "atter": 14647, + "at▁any▁": 14648, + "onych": 14649, + "▁a▁drug": 14650, + "▁a▁30%": 14651, + "ertebral▁": 14652, + "or▁non-": 14653, + "s▁un": 14654, + "reen": 14655, + "receipt": 14656, + "reproduc": 14657, + "▁the▁overall": 14658, + "▁the▁modified▁RECIST▁criteria": 14659, + "any": 14660, + ",▁3": 14661, + ",▁Q": 14662, + ",▁Th": 14663, + ",▁201": 14664, + ",▁carboplatin": 14665, + ",▁leucovorin": 14666, + ",▁both": 14667, + "rog": 14668, + "ed▁study▁": 14669, + "▁annual▁": 14670, + ".▁4": 14671, + "▁cross": 14672, + "ington": 14673, + "▁bit": 14674, + "▁to▁10": 14675, + "is,▁": 14676, + "▁saline▁": 14677, + "▁single-": 14678, + "▁secondary▁endpoint": 14679, + "as▁a": 14680, + "▁of▁N": 14681, + "▁of▁bevacizumab": 14682, + "▁distant": 14683, + "▁mail": 14684, + "▁and▁at": 14685, + "ominal▁": 14686, + "udden": 14687, + "ector": 14688, + ".\n\nJ": 14689, + ".\n\nThis▁": 14690, + "illy▁or": 14691, + "▁AL": 14692, + "▁AS": 14693, + "▁Abraxis▁": 14694, + "▁Approximately▁": 14695, + "▁Active▁": 14696, + "▁ins": 14697, + "▁in-line▁filter": 14698, + "resh": 14699, + "▁1)": 14700, + "▁Cut": 14701, + "▁Count": 14702, + "osc": 14703, + "est▁response▁of": 14704, + "▁Sheet": 14705, + "▁Specific▁Aim": 14706, + "▁II": 14707, + "▁learn": 14708, + "▁EXPAND": 14709, + "▁favor": 14710, + "chart": 14711, + "▁nonsquamous▁": 14712, + "istula": 14713, + "▁Treat": 14714, + "▁National▁Cancer▁Institut": 14715, + "compl": 14716, + "compens": 14717, + "▁RR": 14718, + "ed▁in▁this▁": 14719, + "▁treatment▁failure": 14720, + "ences▁of▁the▁": 14721, + "ed▁to▁occur": 14722, + "ed▁breast▁cancer": 14723, + "ed▁based▁on▁the▁": 14724, + "minim": 14725, + "s▁of▁Addendum": 14726, + "ignificant": 14727, + "\n\nSerious▁Adverse▁Event": 14728, + "\n\nSubjects▁who": 14729, + "▁that▁the▁investigator": 14730, + "e▁the▁treatment▁effect": 14731, + "actual▁": 14732, + "white▁blood▁cell": 14733, + "e,▁will▁be▁": 14734, + "e,▁but": 14735, + "earing": 14736, + "▁Figure▁": 14737, + ".▁AD": 14738, + ".▁Abstract": 14739, + ".▁The▁primary": 14740, + "ity▁or": 14741, + "▁as▁clinically▁indicated": 14742, + "▁the▁secondary▁endpoint": 14743, + "able▁Disease▁": 14744, + "intention": 14745, + "intensity": 14746, + "▁allerg": 14747, + "▁respir": 14748, + "12-lead▁ECG": 14749, + "outine▁": 14750, + "\n\nCons": 14751, + "from▁a": 14752, + "▁H3E-MC-JM": 14753, + "▁Handl": 14754, + "▁subjects▁that": 14755, + "▁patients▁were▁": 14756, + ")\n\nE": 14757, + "▁at▁which": 14758, + "s▁(as▁": 14759, + ".40": 14760, + "s▁in▁this▁": 14761, + ".56": 14762, + ".57": 14763, + "▁weeks▁of": 14764, + "▁exception": 14765, + "▁whos": 14766, + "\n\nDay▁": 14767, + "\n\nDuring▁the▁": 14768, + "ed▁for▁the▁study": 14769, + ".▁Sever": 14770, + ".▁Similar": 14771, + ".▁Should": 14772, + "▁patient’s▁": 14773, + "▁patient▁has▁": 14774, + "s▁will▁be▁assess": 14775, + "s▁will▁be▁calcul": 14776, + "▁eCRF": 14777, + "\n\nEth": 14778, + "\n\nEvery▁": 14779, + "dermat": 14780, + "s\n\n9": 14781, + "axoter": 14782, + "rational": 14783, + "▁may▁hav": 14784, + "▁associ": 14785, + "include:": 14786, + ".62": 14787, + "507)": 14788, + "187": 14789, + "▁mg/day▁": 14790, + "records▁of": 14791, + "s.\n\nIf": 14792, + ".▁Cl": 14793, + "▁absolute▁neutrophil▁count": 14794, + ",▁or▁until": 14795, + "▁in▁the▁study▁": 14796, + "FISH": 14797, + "▁disease▁will▁be▁": 14798, + "\n\nNew": 14799, + "▁each▁visit": 14800, + "▁data▁on": 14801, + "▁otherwis": 14802, + "need▁to": 14803, + "NCCN": 14804, + "▁the\n\ntreatment": 14805, + "▁the▁patient▁to": 14806, + "ed,▁but": 14807, + "ERMS": 14808, + "\n\nYear": 14809, + ".▁Due▁to": 14810, + "princip": 14811, + "uck": 14812, + "iveness": 14813, + "s▁or▁other": 14814, + "\n\nAdminister": 14815, + "▁according": 14816, + "ally▁acceptable▁": 14817, + "provided▁that": 14818, + "ative\n\n": 14819, + "considered▁a": 14820, + "\n\n0\n\n1": 14821, + "▁appli": 14822, + "▁ABBREVI": 14823, + ",▁Pfizer": 14824, + "documented": 14825, + "360": 14826, + "▁continuing": 14827, + "▁continue▁to": 14828, + "▁continue▁to▁be▁": 14829, + "collected▁at": 14830, + "▁providing": 14831, + "dose▁and▁": 14832, + "16)": 14833, + ",▁skin": 14834, + "haemorrh": 14835, + "▁upd": 14836, + "administered▁as▁": 14837, + "▁blood▁pressure": 14838, + "ytotoxic": 14839, + "▁chemotherapy▁regimens": 14840, + "▁administered▁to": 14841, + "conducted▁to": 14842, + "▁receive\n\n": 14843, + "▁describe▁": 14844, + "estimated": 14845, + ".▁JAMA": 14846, + "\n\n8.2": 14847, + "ed▁orally▁": 14848, + "information▁on": 14849, + "▁criteria:": 14850, + "\n\nAnalysis▁of": 14851, + "▁agents▁": 14852, + "____________": 14853, + "liqu": 14854, + "▁Key▁": 14855, + "▁Yes": 14856, + "▁within▁7": 14857, + "▁Subsequent": 14858, + "/LV": 14859, + "▁allow▁for": 14860, + "▁part▁of▁the▁study": 14861, + "irect▁access▁to": 14862, + "▁protocol▁deviation": 14863, + "\n\nAppendix▁D": 14864, + "▁hybrid": 14865, + "▁clinical▁study▁report": 14866, + "chemotherapy▁for": 14867, + "pecified▁": 14868, + "▁health▁stat": 14869, + "IGN": 14870, + "▁cases": 14871, + "blood▁pressure": 14872, + ",▁as▁follow": 14873, + "▁advanced▁cancer": 14874, + "ics▁committe": 14875, + "ature,▁": 14876, + "▁Concomitant▁Medication": 14877, + "▁11.1": 14878, + "awa": 14879, + "awar": 14880, + "▁date▁to": 14881, + "laboratory▁result": 14882, + ".▁Grade▁3": 14883, + "hematology▁": 14884, + "productive▁": 14885, + "e▁without": 14886, + "▁Phase▁II": 14887, + "▁Reporting▁of": 14888, + "ed▁metastatic": 14889, + ".▁1998;": 14890, + "phase▁2": 14891, + "▁throughout▁the▁": 14892, + "eparately": 14893, + "▁versus▁placebo": 14894, + "optys": 14895, + "▁personally▁": 14896, + "open-label,▁": 14897, + "▁only▁limit": 14898, + "ranging▁from": 14899, + "ed▁using▁a": 14900, + "combinant": 14901, + "omitt": 14902, + "chest▁X-ra": 14903, + "ing▁path": 14904, + "-based▁chemotherapy▁regimen": 14905, + "functional▁well": 14906, + "additional▁": 14907, + "MedDRA": 14908, + "▁screening▁procedure": 14909, + "▁6▁months▁": 14910, + "▁6▁months▁after": 14911, + "normal▁rang": 14912, + "▁analysis▁will▁be▁performed▁": 14913, + ".▁Where▁": 14914, + "▁monotherapy": 14915, + "activity▁of": 14916, + "▁women▁of": 14917, + "Schedule▁": 14918, + "▁the▁primary▁analysis": 14919, + "LING": 14920, + "stratified▁by▁": 14921, + "▁characterize▁the▁": 14922, + "existing▁condition": 14923, + "▁appear▁to▁be▁": 14924, + "▁pathway▁": 14925, + "▁pre-randomization": 14926, + "▁(Table▁": 14927, + "active▁Voice▁": 14928, + "\n\nContinu": 14929, + "made▁available▁to": 14930, + "▁SC▁injection": 14931, + ".▁Additionally,▁": 14932, + "-related▁toxicity▁": 14933, + "demonstrated▁that": 14934, + "▁multiple▁myeloma": 14935, + "▁............................................................................": 14936, + "regional▁": 14937, + "▁small▁cell▁lung▁cancer": 14938, + "▁and▁Bevacizumab": 14939, + "colony-stimulating▁factor": 14940, + "▁have▁not▁been": 14941, + "compared▁between": 14942, + ".▁Otherwis": 14943, + "▁mg/day": 14944, + "derived▁from": 14945, + "▁..................................................................": 14946, + "participating▁in▁this▁study": 14947, + "\n\nRedacted▁Version\n\n": 14948, + "▁calculated▁": 14949, + "▁Signature": 14950, + "age,▁Administration": 14951, + "necessary▁for": 14952, + "(2):▁p.▁": 14953, + "had▁a": 14954, + "▁variables▁": 14955, + "oftw": 14956, + ".9%▁sodium▁chlorid": 14957, + "legal▁": 14958, + "▁prolongation▁of▁existing": 14959, + "compani": 14960, + "▁will▁continue▁to": 14961, + "▁a▁20%": 14962, + "▁imagin": 14963, + "rapid": 14964, + "rapid▁": 14965, + "Methods:": 14966, + "pathway": 14967, + "▁preservativ": 14968, + "Therapy▁During": 14969, + "▁eligibility▁criteria": 14970, + "▁elimin": 14971, + ",▁etc.": 14972, + ",▁as▁well▁as": 14973, + "▁NCI▁CTCAE": 14974, + "t▁is▁important": 14975, + "usual▁activities": 14976, + "witz": 14977, + "unctional▁Assessment▁of▁Cancer▁Therapy": 14978, + "▁Content": 14979, + "▁unique▁": 14980, + "▁compound": 14981, + "▁EDTA": 14982, + "dependent▁Ethics▁Committee/In": 14983, + "Period▁": 14984, + "central▁imaging▁vendor": 14985, + "rbitu": 14986, + "▁the▁primary▁analysis▁data▁cut-off": 14987, + "rivation": 14988, + "▁deterioration": 14989, + "\n\nAmended▁Clinical▁Study▁Protocol▁Study▁Code▁7054Il/0023▁Edition▁Number▁7": 14990, + "▁post-baseline▁": 14991, + "▁accrual▁": 14992, + "7)▁(cid:137)▁(cid:13": 14993, + "▁satisf": 14994, + "ley▁J": 14995, + "(PD):": 14996, + "▁Nonhematologic": 14997, + "rather▁than": 14998, + "▁or▁designee▁will": 14999, + "▁limit▁of▁normal▁(": 15000, + "ild▁to▁moderate▁": 15001, + "setting": 15002, + "capable▁of▁all▁s": 15003, + "romosom": 15004, + "▁Head▁and▁Neck": 15005, + "▁the▁database▁": 15006, + "▁ability▁to": 15007, + "▁the▁same▁dose▁level": 15008, + "▁ENDPO": 15009, + ",▁phosphorous,▁and▁": 15010, + "▁q21d": 15011, + "Calvert▁formula": 15012, + "gregate▁": 15013, + "\n\nClinical▁Study▁Protocol:▁Appendix": 15014, + "▁tract▁infection": 15015, + "▁for▁Destruction": 15016, + "vulsion": 15017, + "▁advanced▁or▁metastatic": 15018, + "▁fluid▁": 15019, + "intiles▁L": 15020, + "ability/inc": 15021, + "quamation*": 15022, + "Helsink": 15023, + "ltras": 15024, + "▁ABBREVIATIONS": 15025, + "rbitux": 15026, + "(including": 15027, + "-7": 15028, + "-A": 15029, + "/omega-3": 15030, + "1b": 15031, + "2),▁": 15032, + "7.5": 15033, + ":▁(1)": 15034, + "?\n\n1\n\n2\n\n3": 15035, + "AM": 15036, + "Abraxis▁": 15037, + "CF": 15038, + "CG": 15039, + "Dx": 15040, + "Definition": 15041, + "EM": 15042, + "Ed": 15043, + "FT": 15044, + "Prior": 15045, + "Path": 15046, + "T3": 15047, + "UATION": 15048, + "Wild-type▁": 15049, + "aim": 15050, + "back": 15051, + "cm": 15052, + "cess▁of": 15053, + "cili": 15054, + "eine▁": 15055, + "eclar": 15056, + "fol": 15057, + "gG": 15058, + "k▁MF": 15059, + "mac": 15060, + "mence▁": 15061, + "match": 15062, + "nor": 15063, + "o▁G": 15064, + "pulmonary▁": 15065, + "ranc": 15066, + "sum": 15067, + "sur": 15068, + "trial▁": 15069, + "uation": 15070, + "vary▁": 15071, + "xiet": 15072, + "β-": 15073, + "▁j": 15074, + "▁": 15075, + "▁omega-3▁fatty▁acid": 15076, + "e▁[": 15077, + "e▁r": 15078, + "ineopl": 15079, + "▁table▁": 15080, + "▁tru": 15081, + "ate-": 15082, + "\n\ny▁": 15083, + "\n\nshould▁be▁": 15084, + "▁a▁new": 15085, + "▁aromatase▁inhibitor": 15086, + "ened": 15087, + "or▁b": 15088, + "or▁depress": 15089, + "s▁contain": 15090, + "s▁list": 15091, + "re-s": 15092, + "recurrence▁": 15093, + "entir": 15094, + "▁the▁number▁of": 15095, + "ofsky▁": 15096, + "ano": 15097, + ",▁“": 15098, + ",▁defined▁as": 15099, + "▁an▁overall": 15100, + "▁an▁SRE": 15101, + "ic▁lesion": 15102, + "iction": 15103, + ".▁0": 15104, + ".▁13": 15105, + ".▁Qual": 15106, + "edent": 15107, + "▁pur": 15108, + "▁polymorphism": 15109, + "▁pneumon": 15110, + "▁ble": 15111, + "▁batch": 15112, + "es▁and/or": 15113, + "▁to▁Pfizer": 15114, + "▁sol": 15115, + "▁of▁patient": 15116, + "▁of▁this": 15117, + "▁of▁AMG▁162": 15118, + "▁du": 15119, + "▁diverticul": 15120, + "throm": 15121, + "▁mutant": 15122, + "▁and▁non": 15123, + "▁and▁will▁not▁be▁": 15124, + "elev": 15125, + "eloda": 15126, + "▁Approved\n\nDate▁Printed:": 15127, + "▁AZD2171": 15128, + "▁invasive▁": 15129, + "▁Center": 15130, + "▁CFR": 15131, + "acent": 15132, + "es▁A": 15133, + "▁Par": 15134, + "procedur": 15135, + "▁(IMC-1121B": 15136, + "rav": 15137, + "ifen": 15138, + "▁Imaging": 15139, + "▁red": 15140, + "▁recurrenc": 15141, + "agen": 15142, + "uns": 15143, + "uniqu": 15144, + "▁EOS": 15145, + "▁ful": 15146, + "▁food▁": 15147, + "chocardiogram": 15148, + "▁or▁for": 15149, + "e▁tissu": 15150, + "utopsy▁": 15151, + "therton": 15152, + "exerc": 15153, + "endothel": 15154, + "\n\nANC": 15155, + "▁and▁the▁study▁": 15156, + "ablet": 15157, + "▁Target▁Lesion": 15158, + "▁TREATMENT": 15159, + "▁NO": 15160, + "opoi": 15161, + "toch": 15162, + "will▁be▁taken": 15163, + "complication": 15164, + "▁treatment,▁": 15165, + ".28": 15166, + "antitative▁": 15167, + "▁that▁would▁": 15168, + "▁of▁3": 15169, + "▁will▁be▁analys": 15170, + "▁will▁be▁used▁in": 15171, + "e▁survival▁": 15172, + "▁May": 15173, + "▁random": 15174, + "▁3.5": 15175, + "▁3▁weeks▁": 15176, + "correl": 15177, + "▁comment": 15178, + "▁FU": 15179, + ".▁AstraZeneca": 15180, + ".▁Assum": 15181, + ".▁The▁s": 15182, + ".▁The▁study▁": 15183, + "▁gain": 15184, + "▁the▁source▁document": 15185, + "▁vial▁": 15186, + "▁vitamin": 15187, + ".30": 15188, + ".38": 15189, + "cluding": 15190, + "▁therefore,▁": 15191, + "ach/": 15192, + "▁will▁continue▁": 15193, + "e▁initi": 15194, + "followed▁as▁": 15195, + "▁patients▁from": 15196, + "▁4.8": 15197, + "ework": 15198, + ".4%": 15199, + ".43": 15200, + "▁study▁design": 15201, + "▁study▁participation": 15202, + "continue▁to▁be▁": 15203, + "\n\n1st": 15204, + "poor": 15205, + "s▁in▁a": 15206, + ".54": 15207, + "s.▁Ther": 15208, + "s.▁To": 15209, + "ance▁for": 15210, + "\n\nDis": 15211, + "ed▁for▁this▁study": 15212, + "s▁and▁will▁be▁": 15213, + "▁the▁diagnos": 15214, + "s▁will▁be▁complet": 15215, + "s▁will▁be▁made▁to": 15216, + "ies▁in": 15217, + "▁JL": 15218, + "▁plus": 15219, + "ovarian": 15220, + "▁Intravenous▁": 15221, + "ceding": 15222, + "super": 15223, + "▁doses": 15224, + ".▁Eur▁J▁Cancer": 15225, + "▁assessment▁(": 15226, + "▁test▁for": 15227, + "RIN": 15228, + "▁9.1.2": 15229, + "\n\nX\n\nX▁X▁X": 15230, + "\n\nNO": 15231, + "▁each▁treatment▁arm": 15232, + "he/sh": 15233, + "s▁with▁respect▁to": 15234, + "▁data▁protection": 15235, + ").\n\n4": 15236, + "need▁to▁be▁": 15237, + "\n\nReduc": 15238, + "▁the\n\nstudy": 15239, + "24▁hour": 15240, + "▁you▁to": 15241, + "▁a▁sub": 15242, + "▁cycle,▁": 15243, + "response,▁": 15244, + "etastatic▁Colorectal▁Cancer": 15245, + "\n\nThe▁principal▁investigator": 15246, + "ically▁steril": 15247, + "data▁cutoff▁date▁": 15248, + "5-Fluorouracil": 15249, + "defined▁in": 15250, + "s▁or▁symptom": 15251, + "ung▁Cancer": 15252, + "▁death▁(": 15253, + ".\n\nSubjects▁who": 15254, + "patients▁(": 15255, + "▁Any": 15256, + "▁peripheral": 15257, + "oxifen": 15258, + ".▁Rationale▁for": 15259, + "until▁disease▁progression": 15260, + ".▁2002": 15261, + "\n\n0\n\n0": 15262, + "ed.\n\n6": 15263, + "ed.\n\n10": 15264, + "▁discontinued▁": 15265, + "\n\n\n\nIn": 15266, + "es▁involv": 15267, + "\n\n60": 15268, + "\n\n7.2": 15269, + "\n\n7.3": 15270, + "\n\n7.4": 15271, + ",▁2006": 15272, + "electrocardiogram": 15273, + "abeling": 15274, + "▁non-small-cell▁lung▁cancer": 15275, + "1-2": 15276, + "1-year": 15277, + "▁levels▁": 15278, + "▁level▁of": 15279, + "▁blood▁pressure,▁": 15280, + "TIONAL": 15281, + "ation▁of▁Helsink": 15282, + "ytim": 15283, + ".▁Analys": 15284, + "s,▁are▁": 15285, + "e▁measurement": 15286, + "▁One▁": 15287, + "\n\nM0": 15288, + "\n\nMethod▁of": 15289, + "ologically": 15290, + "▁receives▁": 15291, + "place▁": 15292, + "pproved▁by▁the▁": 15293, + "▁change▁from▁baseline▁in": 15294, + "understand": 15295, + "welling": 15296, + "▁intramuscular": 15297, + "▁disease,": 15298, + "quality▁": 15299, + "\n\nConfidential\n\nProduct:▁AMG▁162▁Protocol▁Number:▁20040138▁Date:▁19▁February▁2008\n\nPage▁": 15300, + "assessment▁date.\n\n": 15301, + "s▁and\n\n": 15302, + "\n\n(X": 15303, + ".1.1.1": 15304, + "▁transamin": 15305, + "▁review▁and▁": 15306, + "identified▁by▁": 15307, + "▁according▁to▁RECIST": 15308, + "Conduct": 15309, + "Continu": 15310, + "▁performing": 15311, + "▁at▁least▁2": 15312, + "ematology▁and▁": 15313, + "\n\nAppendix▁F": 15314, + "olick▁MF": 15315, + "▁pain▁progression": 15316, + "expected▁to▁be▁": 15317, + "ability▁to": 15318, + ".\n\nTreatment": 15319, + ",▁in▁accordance▁with": 15320, + "▁health▁status": 15321, + "imaging▁mod": 15322, + "▁Treatment▁Assignment": 15323, + "attributed▁to": 15324, + "\n\nSection:▁Protocol": 15325, + ".▁Leucovorin": 15326, + "▁consent▁of": 15327, + "▁period▁or": 15328, + ",▁Table▁": 15329, + "monitoring▁of": 15330, + "closely▁": 15331, + ",▁1996": 15332, + ",▁differential": 15333, + "ed▁to▁the▁extent": 15334, + "▁Phase▁I": 15335, + "glish": 15336, + "▁designee": 15337, + "piral▁CT": 15338, + "▁the▁primary▁PFS": 15339, + "conditional▁power": 15340, + "▁has▁already▁": 15341, + "optimal▁": 15342, + "▁personal": 15343, + "Physician": 15344, + "\n\nVital▁sign": 15345, + "▁appar": 15346, + "▁power▁for": 15347, + "▁FOLFOX4": 15348, + "▁informed▁consent▁form": 15349, + "up▁to▁a▁maximum": 15350, + "olerability▁of": 15351, + "experienced▁": 15352, + "rinalysis": 15353, + "considered▁non-": 15354, + "treated▁with": 15355, + "o-)": 15356, + "e▁should▁be▁used▁to": 15357, + "pharmacist": 15358, + "▁affin": 15359, + "Sponsor▁will": 15360, + "decid": 15361, + "▁before▁any▁": 15362, + "▁demonstrated▁": 15363, + "cumulative▁": 15364, + "s▁a▁result": 15365, + "health▁stat": 15366, + "▁keep": 15367, + "▁involved▁in": 15368, + "best▁overall": 15369, + "▁the▁protocol,▁": 15370, + "▁Lesions\n\n": 15371, + ".▁To▁date,▁": 15372, + "▁taking▁part": 15373, + "s▁as▁well": 15374, + "▁pemetrexed▁plus▁carboplatin": 15375, + "▁diagnosis▁": 15376, + "-sided": 15377, + "▁may▁also▁be▁": 15378, + "hypothesis": 15379, + "related▁event": 15380, + "PRO▁assessment": 15381, + "heart▁rate,▁": 15382, + ".\n\nYour": 15383, + "▁commonly▁": 15384, + "omega-6": 15385, + "ochberg": 15386, + "▁return▁to▁the▁clinic": 15387, + "very▁effort▁should▁be▁made▁to": 15388, + "s▁A▁and▁B": 15389, + "▁stratification": 15390, + "demonstrated▁": 15391, + "▁freez": 15392, + "▁antihist": 15393, + "histology▁": 15394, + "▁Regulatory▁A": 15395, + "▁members▁": 15396, + "▁hormonal": 15397, + "▁persons": 15398, + "validation": 15399, + "prior▁to▁the▁start": 15400, + "at▁a▁significance▁level": 15401, + "bone▁metastas": 15402, + "compliance▁with": 15403, + ".▁Patients▁who▁have▁not": 15404, + "▁declin": 15405, + "Chemotherapy▁": 15406, + "▁to▁ensur": 15407, + "according▁to▁the▁": 15408, + "▁Union": 15409, + "ABX-EGF▁infusion": 15410, + "ometric": 15411, + "▁Non-PD": 15412, + "▁appropriate▁to": 15413, + "▁a▁few": 15414, + "▁IMC-1121B▁or▁placebo": 15415, + "▁volume▁of": 15416, + "▁surgical▁": 15417, + "▁anticipated": 15418, + "▁able▁to▁carry▁out": 15419, + "able▁of▁Content": 15420, + "▁the▁two▁treatment▁arm": 15421, + "▁the▁criteria▁for▁response▁are▁first▁met": 15422, + "▁36\n\nSection:▁2.3": 15423, + "▁generally▁": 15424, + "1/2": 15425, + "▁Recon": 15426, + "vertebral▁fracture": 15427, + "▁of▁Center": 15428, + "▁prognostic▁factor": 15429, + "pairment": 15430, + "centre▁": 15431, + "▁starting▁study▁treatment": 15432, + "plasma▁and▁": 15433, + "stipation,▁": 15434, + "▁Disposition": 15435, + "▁hypomagnesemia": 15436, + "accurately▁": 15437, + "\n\nx▁x\n\nx▁x": 15438, + "omatitis": 15439, + "▁the▁signed▁": 15440, + "e▁shown▁that": 15441, + "ti-Panitumumab": 15442, + "▁Synopsis▁": 15443, + "compati": 15444, + "▁Performance▁Status": 15445, + "▁have▁no▁problem": 15446, + "\n\n3\n\n3\n\n3\n\n3": 15447, + "laboratories": 15448, + "▁objective▁tumor": 15449, + "TISTICAL▁CONSIDERATIONS": 15450, + "▁childbearing▁potential▁": 15451, + "central▁imaging▁center": 15452, + "eptide▁(": 15453, + "(SD):": 15454, + "▁IV▁infusion▁in": 15455, + "▁to▁prevent▁one▁of▁the▁": 15456, + "ilateral": 15457, + "36-month▁evaluation▁period": 15458, + "Control": 15459, + "▁Questionnaire": 15460, + "English": 15461, + "esophageal▁": 15462, + "arcotic": 15463, + "▁strong": 15464, + "▁significance▁of": 15465, + "e▁Size▁and▁": 15466, + "documented▁in▁the▁CRF": 15467, + "▁Society▁of▁Clinical▁Oncology▁": 15468, + "▁one▁or▁more▁new▁lesion": 15469, + "sychiatric": 15470, + "▁anxious▁": 15471, + "urologic": 15472, + "urea▁nitrogen": 15473, + "▁ligand": 15474, + ".▁Median": 15475, + "cipient": 15476, + "▁within▁1▁working": 15477, + "▁damage▁": 15478, + "▁sterile,▁": 15479, + "Response▁(CR": 15480, + "▁of▁63▁Finalization▁date:▁June▁19▁2001,▁Incorporating▁Amendment▁3▁–▁dated▁23▁May▁2003\n\nAmerican▁BioScience,▁Inc.\n\nPhase▁III▁Protocol▁CA012-0▁ABI-007▁(Nanoparticle▁Paclitaxel)\n\nCONFIDENTIAL": 15481, + "ayo▁Clinic": 15482, + "holding": 15483, + "izziness": 15484, + "offered▁": 15485, + "suitable▁for": 15486, + "arnofsky▁": 15487, + "▁meets▁the▁criteria▁for": 15488, + ",▁stroke,▁": 15489, + ",▁hematocrit": 15490, + "▁the▁longest▁diameter": 15491, + "emoval▁of▁Subject": 15492, + "▁090177e18069": 15493, + "possibly▁related▁to": 15494, + "is▁an▁open-label": 15495, + "oxidant": 15496, + "mega-3": 15497, + "▁red▁blood▁cell": 15498, + "ctep.cancer.gov/": 15499, + "iometrics▁": 15500, + "eficiency▁vir": 15501, + "Approach/": 15502, + "▁have▁some▁problem": 15503, + "\n\n5\n\n6\n\n7": 15504, + "\n\nA▁®\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁PANITUMUMAB▁(AMG▁954)▁Protocol▁Number:▁20040249▁Date:▁07▁August▁2007\n\nPage▁": 15505, + "anine▁aminotransferase▁(ALT": 15506, + "partate▁aminotransferase▁(AST": 15507, + "▁congenital▁anomaly/birth▁defect": 15508, + "Glossary": 15509, + "\n\nMonth\n\nYear": 15510, + "oprotegerin": 15511, + "▁prejudice▁to": 15512, + "proposed▁mechanism▁of▁action": 15513, + ",▁as▁follows▁(≤": 15514, + "eclaration▁of▁Helsink": 15515, + "ineoplastic": 15516, + "opoietic": 15517, + "▁anxious▁or▁depress": 15518, + ").▁Subject": 15519, + ",▁the▁s": 15520, + "-d": 15521, + "-▁": 15522, + "-10": 15523, + "-50": 15524, + "-feeding": 15525, + "1.": 15526, + "1▁error": 15527, + "3rd▁": 15528, + "7)(cid:": 15529, + "<<": 15530, + "AGE": 15531, + "Avastin": 15532, + "Bevacizumab": 15533, + "Canada": 15534, + "Diseas": 15535, + "Grad": 15536, + "Month": 15537, + "NOP": 15538, + "Specific": 15539, + "Studies▁": 15540, + "Taxol": 15541, + "ZE": 15542, + "]▁H": 15543, + "audit": 15544, + "cir": 15545, + "ceas": 15546, + "fatty": 15547, + "future": 15548, + "ge▁": 15549, + "gia": 15550, + "han": 15551, + "hragm": 15552, + "multi-": 15553, + "oam": 15554, + "pet": 15555, + "pulmon": 15556, + "polymorphism": 15557, + "ras": 15558, + "s▁taking": 15559, + "selection": 15560, + "ward▁": 15561, + "y▁active,": 15562, + "≥▁3": 15563, + "▁)": 15564, + "▁e\n\n": 15565, + "▁just": 15566, + "e▁if": 15567, + "at▁any▁time▁": 15568, + "one)": 15569, + "\n\n200": 15570, + "\n\n\n\nD": 15571, + "\n\nendpoint": 15572, + "\n\napproximately▁": 15573, + "\n\ndisease▁progression": 15574, + "▁a▁person": 15575, + "▁a▁previous▁": 15576, + "▁a▁median": 15577, + "eness": 15578, + "en▁J": 15579, + "or▁serum": 15580, + "s▁........................................................................": 15581, + "sthes": 15582, + "itol": 15583, + "▁the▁adverse▁event": 15584, + "annot": 15585, + "anagement": 15586, + "an-D": 15587, + ",▁10": 15588, + ",▁either": 15589, + ",▁NCI": 15590, + ",▁while▁": 15591, + "rob": 15592, + "rovascular": 15593, + "ed▁ABI-007": 15594, + "▁an▁investigator": 15595, + "▁analogu": 15596, + "ict": 15597, + "arily": 15598, + "ed▁adverse▁event": 15599, + "ed▁therapy▁": 15600, + "ederal▁": 15601, + "▁pack": 15602, + "▁potent": 15603, + "▁principal▁investigator": 15604, + "▁cyto": 15605, + "esc": 15606, + "ation▁with": 15607, + "▁to▁the▁subject": 15608, + "▁to▁evaluate▁th": 15609, + "▁safety▁and▁": 15610, + "▁of▁23": 15611, + "▁want": 15612, + "▁we▁will": 15613, + "▁mes": 15614, + "▁mutant▁KRAS": 15615, + "▁million": 15616, + "▁and▁5": 15617, + "▁and▁MRI": 15618, + "▁and▁women": 15619, + ".\n\n(": 15620, + "elih": 15621, + "olytic": 15622, + "▁A:": 15623, + "▁Abraxis": 15624, + "▁in▁which": 15625, + "urt": 15626, + "ursing": 15627, + "urrog": 15628, + "resent": 15629, + "respect": 15630, + "▁1▁year": 15631, + "▁CH": 15632, + "▁Cremophor": 15633, + "acut": 15634, + "▁Pregnancy▁": 15635, + "▁PET▁scan": 15636, + "prostate▁": 15637, + "▁(with": 15638, + "▁(a)": 15639, + "usually": 15640, + "if▁applicabl": 15641, + "▁Supportive▁": 15642, + "ubicin": 15643, + "▁ImClone▁": 15644, + "▁reference▁": 15645, + "age.\n\n": 15646, + "owder": 15647, + "▁DES": 15648, + "▁DHA": 15649, + "▁he/": 15650, + "▁he▁or▁sh": 15651, + "▁laborator": 15652, + "aphragm": 15653, + "▁ENR": 15654, + "▁fax": 15655, + "e▁total": 15656, + "\n\nPlacebo": 15657, + "external": 15658, + "ex▁Cor": 15659, + "\n\nAm": 15660, + "\n\nA\n\nS▁I\n\nS▁I▁H▁T": 15661, + "\n\nALT": 15662, + "\n\nA▁Randomized,▁": 15663, + "▁Outcom": 15664, + "▁propos": 15665, + "▁TR": 15666, + "uppress": 15667, + "▁N▁A": 15668, + "eps": 15669, + "▁for▁treatment": 15670, + "▁Rationale▁for": 15671, + "e\n\nE": 15672, + "ed▁infection": 15673, + "▁treatment▁until": 15674, + "ed▁to▁Amgen": 15675, + "ed▁to▁have▁a": 15676, + "orton": 15677, + "og-rank▁test": 15678, + "anti": 15679, + "\n\nSAE": 15680, + "▁that▁your": 15681, + "▁is▁defined▁as▁": 15682, + "▁of▁other": 15683, + "e▁safety▁": 15684, + "e▁such": 15685, + "▁Mon": 15686, + "▁of▁the▁trial": 15687, + "e,▁ALT,▁AST": 15688, + "▁Fail": 15689, + ".▁Appro": 15690, + ".▁The▁hazard▁ratio": 15691, + "▁the▁secondary▁": 15692, + "ated▁(": 15693, + "intens": 15694, + "▁Both": 15695, + "▁Breast▁Cancer": 15696, + "▁all▁of▁the▁": 15697, + "ipment": 15698, + "▁will▁include▁": 15699, + "efficient": 15700, + "will▁remain": 15701, + "▁69": 15702, + "▁HER": 15703, + "▁400▁IU": 15704, + "▁the▁informed▁consent▁form": 15705, + "▁across": 15706, + "continued)": 15707, + "identify": 15708, + "vial▁": 15709, + "s.▁E": 15710, + "s.▁M": 15711, + "s.▁W": 15712, + "consult": 15713, + "medicin": 15714, + "ally▁con": 15715, + "e▁des": 15716, + "▁patient▁will▁be▁": 15717, + "▁patients▁are▁": 15718, + "108": 15719, + "s▁will▁be▁performed▁at": 15720, + "ies▁of▁the▁": 15721, + "reported▁in▁the▁": 15722, + "▁Joint": 15723, + "GF-": 15724, + "▁International▁": 15725, + "ed▁by▁C": 15726, + "▁may▁lead▁to": 15727, + "▁months▁for▁the▁": 15728, + "presence▁of": 15729, + "CT▁or▁MRI": 15730, + "(cid:12": 15731, + "(cid:100)": 15732, + "▁adverse▁events\n\n": 15733, + "▁permission": 15734, + "e▁vial": 15735, + "included▁": 15736, + "▁10.4": 15737, + "sohn": 15738, + "argin": 15739, + "records,▁": 15740, + "over▁tim": 15741, + "▁contribution": 15742, + "▁abstract": 15743, + "20▁mg": 15744, + "investigator▁should▁": 15745, + "▁8.5": 15746, + "▁8▁hour": 15747, + "ppendic": 15748, + "every▁6": 15749, + ".▁If▁a▁subject": 15750, + "\n\n2.2": 15751, + "▁forms▁will▁be▁": 15752, + "▁lesions▁": 15753, + "\n\nRational": 15754, + "▁Study▁Endpoint": 15755, + "presented▁in": 15756, + "present▁at": 15757, + "\n\nTABLE▁OF▁CONTENTS": 15758, + "Only▁": 15759, + "▁the▁patient▁has▁": 15760, + "ERC": 15761, + "\n\nYour": 15762, + "\n\nYES": 15763, + "KRAS▁Efficacy▁Analysis▁Set": 15764, + ".\n\nAt": 15765, + "e)▁and▁": 15766, + ".▁FOLFIRI": 15767, + "▁days▁(±": 15768, + "least": 15769, + ".\n\nPanitumumab": 15770, + "e▁break": 15771, + "hyper": 15772, + "▁therapy▁in": 15773, + "including▁a": 15774, + "e▁treatment▁with": 15775, + "1998": 15776, + "etwork": 15777, + "Anti-": 15778, + "▁evaluated▁in": 15779, + "provided▁in▁the▁": 15780, + "ack▁of▁": 15781, + "▁the▁study▁is▁to": 15782, + "▁sample▁for": 15783, + "▁sample▁will▁be▁": 15784, + "▁the▁subject▁or": 15785, + "▁dose▁of▁investigational▁product": 15786, + "approach": 15787, + "ed.\n\nD": 15788, + "ed.\n\nIn": 15789, + "▁et▁al▁19": 15790, + "▁if▁the▁": 15791, + "▁if▁it": 15792, + "▁if▁this▁h": 15793, + ".▁Break": 15794, + "ebrovascular": 15795, + "diss": 15796, + ",▁suppl": 15797, + "hauer": 15798, + "s▁will▁includ": 15799, + "weekly": 15800, + "▁survival▁and▁": 15801, + "▁hours▁after": 15802, + "administered": 15803, + "subgroup": 15804, + "\n\nInclusion▁Criteria": 15805, + "▁active▁treatment": 15806, + "\n\nBaselin": 15807, + "conduct▁of": 15808, + "partial": 15809, + "uthorship": 15810, + "▁until▁PD": 15811, + "OSE": 15812, + "▁there▁a": 15813, + "▁documentation": 15814, + "22:": 15815, + "estimate▁of": 15816, + "estimated▁that": 15817, + "follow-up▁information": 15818, + "undergone▁": 15819, + ",▁Bl": 15820, + "▁decrease▁": 15821, + "▁approval▁from": 15822, + "▁antibody▁(": 15823, + ".▁Imaging": 15824, + "s▁should▁be▁performed▁": 15825, + "▁bevacizumab▁and▁": 15826, + "▁chemotherapy▁and▁": 15827, + "research▁study▁": 15828, + "ophosph": 15829, + "▁Stage▁IV": 15830, + "istory▁of": 15831, + "determination▁of": 15832, + "▁transcription": 15833, + "▁part▁of": 15834, + "described▁abov": 15835, + "\n\nsymptom": 15836, + "▁Day▁1▁of▁each▁cycl": 15837, + "ceral": 15838, + "\n\nAppendix▁C": 15839, + "s,▁and▁other": 15840, + "▁Qu": 15841, + "ervic": 15842, + "expectanc": 15843, + "ycle▁1": 15844, + "\n\n9.3": 15845, + "▁15▁mg/kg": 15846, + "fied▁with": 15847, + "▁measurements▁": 15848, + "chemotherapy▁and▁bevacizumab": 15849, + "HRQoL": 15850, + "Exploratory▁": 15851, + ".,▁et▁al.,▁M": 15852, + "evaluation▁or": 15853, + "\n\ntime▁to": 15854, + "recommended▁for": 15855, + "ource:": 15856, + "central▁review": 15857, + "central▁radiology▁review": 15858, + "462": 15859, + "measured": 15860, + ".\n\nEX": 15861, + "MENTAL": 15862, + "Assessments▁": 15863, + "▁100▁x▁109/L": 15864, + "FACT-Fatigu": 15865, + "poration": 15866, + "olume▁of": 15867, + "▁value▁of": 15868, + "▁telomere▁length": 15869, + "eparately▁": 15870, + "▁2000;": 15871, + "optotic": 15872, + "medical▁institution": 15873, + "statistically▁significant": 15874, + "▁biologic": 15875, + "Pleas": 15876, + "▁Extension": 15877, + "▁was\n\n": 15878, + "▁Efficacy▁Analysis": 15879, + ")▁in▁patients▁with": 15880, + "▁PROTOCOL": 15881, + "▁indicator": 15882, + "ITT▁Efficacy▁Analysis▁Set": 15883, + "▁2004;": 15884, + "meta-": 15885, + "chest▁CT▁scan": 15886, + "▁due▁to▁any▁caus": 15887, + "▁alone.\n\n": 15888, + ".\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁Denosumab▁Protocol▁Number:▁20050244▁Date:▁05▁May▁2008\n\nPage▁": 15889, + "▁et▁al.▁2005)": 15890, + "▁demonstrating": 15891, + "▁demonstrate▁a": 15892, + "▁4▁weeks▁of": 15893, + ".\n\nNot": 15894, + ".\n\nN▁A\n\nF▁O": 15895, + "▁enhanc": 15896, + "▁alone▁as": 15897, + "risk▁of▁death": 15898, + "▁Study▁Drug": 15899, + "▁available)": 15900, + "ricted▁in": 15901, + "▁Therapy▁for": 15902, + "stopped▁": 15903, + "▁compared▁to▁placebo": 15904, + "▁pathway": 15905, + "▁addres": 15906, + ".▁(for": 15907, + ".\n\nWho": 15908, + "exposure▁to": 15909, + "▁extent": 15910, + "Data▁Collection": 15911, + "▁hazard▁": 15912, + "severity": 15913, + "etc.": 15914, + "Response▁System": 15915, + "▁returned▁to": 15916, + "▁systemic▁anticancer▁therapy": 15917, + "measurement▁of": 15918, + "us▁of▁0": 15919, + "▁this▁research▁study▁": 15920, + "▁they▁are▁s": 15921, + ",▁Van": 15922, + "ethod▁of▁assessment": 15923, + "▁the▁interim▁analysis": 15924, + "RTK": 15925, + "dates▁of": 15926, + "participation▁in▁the▁study": 15927, + "cras": 15928, + "▁intravenous▁infusion": 15929, + "filter": 15930, + "▁as▁well▁as": 15931, + "▁receiving▁panitumumab": 15932, + "-Line▁": 15933, + "▁small-cell▁lung▁cancer": 15934, + "lightly▁": 15935, + ",▁vomiting": 15936, + "▁centr": 15937, + "▁1.5▁x▁ULN": 15938, + "▁pharmacist": 15939, + "financ": 15940, + "eam▁Physician": 15941, + "▁will▁be▁used▁to▁compare▁treatment": 15942, + "▁calculate▁the▁": 15943, + ",▁although": 15944, + "ometim": 15945, + "quantitative▁": 15946, + "▁commercially▁available▁": 15947, + "Investigator’s▁Brochure": 15948, + "Formulation": 15949, + "▁AUC▁6": 15950, + "▁sufficient▁shrink": 15951, + "▁Evaluation": 15952, + "approved▁": 15953, + "▁platinum-based▁": 15954, + "MPLE": 15955, + "▁Cycles▁": 15956, + "efficacy▁and▁safety": 15957, + "▁the▁interaction": 15958, + "\n\nAmgen▁Thousand▁Oaks\n\nConfidential\n\nAMGEN\n\nProduct:▁darbepoetin▁alfa▁Protocol▁Number:▁20010145▁–▁Amendment▁2▁Date:▁16▁July▁2004\n\nPage▁": 15959, + "acceptable▁toxicity▁": 15960, + "▁should▁notify▁": 15961, + "▁blinded▁study▁medication": 15962, + "▁(Arm▁B": 15963, + ",9,10": 15964, + "▁will▁continue▁to▁be▁": 15965, + ".▁Compar": 15966, + "▁profile▁of": 15967, + "el:▁+": 15968, + "s▁and▁the▁proposed▁mechanism▁of▁action": 15969, + "▁x▁x▁x▁x▁x▁x▁x▁x": 15970, + "discussed▁with": 15971, + "UBJECTS": 15972, + ".▁Clin▁Cancer": 15973, + "▁will▁be▁performed▁to": 15974, + "followed▁until▁resolution": 15975, + "▁Dose▁Modifications▁for": 15976, + "d▁and▁Signific": 15977, + "s▁occurring▁at▁the▁sit": 15978, + "▁Epidemi": 15979, + "E▁S▁A▁E▁L▁P\n\n.▁T▁N▁E▁M▁U▁C▁O▁D": 15980, + "apable▁of▁only▁limit": 15981, + "intravenous▁infusion": 15982, + "e▁indicate▁": 15983, + ".▁New▁York": 15984, + "VESTIGATOR": 15985, + "recommendations▁for": 15986, + ".\n\nE▁R▁O▁F▁E▁B\n\nY▁T▁I▁D▁I▁L▁A▁V": 15987, + "orld▁Health": 15988, + "▁x-ray▁": 15989, + "▁interfere▁with": 15990, + "▁acute▁": 15991, + "balanc": 15992, + "▁large▁": 15993, + "▁look": 15994, + "▁mm▁with▁spiral▁CT▁scan": 15995, + "every▁6▁months▁for": 15996, + ".▁Furthermor": 15997, + "▁total▁hip▁BMD": 15998, + "ranulocyte▁": 15999, + "▁Clinical▁Oncology": 16000, + "▁missing▁data": 16001, + ",▁Anti-Panitumumab": 16002, + "choos": 16003, + ".▁Ann▁Oncol": 16004, + "▁creatinine▁clearanc": 16005, + "gene▁expression": 16006, + "▁dietary▁": 16007, + ".▁Journal▁of▁Clinical▁Oncology,▁": 16008, + "objective▁of▁this▁study▁is▁to": 16009, + "effect▁of▁ZD4054▁in▁combination▁with▁docetaxel▁on": 16010, + "History": 16011, + "particularly▁": 16012, + "idney▁ston": 16013, + "▁the▁treating▁physician": 16014, + "\n\nPROTOCOL": 16015, + "▁arthrit": 16016, + "mg/m2▁IV": 16017, + "±▁3▁days": 16018, + "captured▁": 16019, + "pG▁is": 16020, + "▁medicinal▁product": 16021, + "gestive▁heart▁failure": 16022, + "stimated▁Study▁D": 16023, + "▁sensitivity▁to": 16024, + "ity▁Assurance▁": 16025, + "e-based▁": 16026, + "original▁protocol": 16027, + "oisotop": 16028, + "▁teaspoon": 16029, + "▁taxane▁": 16030, + "primarily▁": 16031, + "Stimulating▁Factor": 16032, + "ecommendation": 16033, + ".▁Up▁and▁about": 16034, + "confidence▁interval": 16035, + "SSESSMENTS": 16036, + "▁sponsor-nominated▁": 16037, + "refriger": 16038, + "jeopardiz": 16039, + "▁causal▁relationship▁with": 16040, + "▁e▁e▁k": 16041, + "▁Arm▁A▁and▁Arm▁B": 16042, + "▁PATIENTS": 16043, + "3)▁(cid:4)▁(cid:": 16044, + "dyscras": 16045, + "▁physically▁": 16046, + "▁to▁zoledronic▁acid▁with": 16047, + "rosatellite▁in": 16048, + "EASURE": 16049, + "endelsohn": 16050, + "(34)\n\nGEL▁Version▁ID:▁ONC.000−127−200.3.0\n\nApproved\n\nDate▁Printed:▁31−Jul−2014\n\nApproved▁by\n\n21▁Dec▁2004▁10:21:22\n\nAmended▁Clinical▁Study▁Protocol▁Bicalutamide▁Study▁Code▁7054Il/0025▁Edition▁Number▁5▁20▁December▁2004": 16051, + "▁later▁than": 16052, + ".6.6,▁Anti-Panitumumab": 16053, + "desirable▁": 16054, + "5)▁(cid:6)▁(cid:": 16055, + "melanoma▁skin▁cancer": 16056, + "axotere": 16057, + "▁limit▁of▁normal▁(ULN": 16058, + "intiles▁Laboratories▁": 16059, + "thrombin": 16060, + "▁36\n\nSection:▁2.3.6.6,▁Anti-Panitumumab": 16061, + "eclaration▁of▁Helsinki": 16062, + "NOPSIS": 16063, + "▁DESIGN": 16064, + "▁ENROLL": 16065, + "apable▁of▁only▁limited▁s": 16066, + "stimated▁Study▁Duration": 16067, + "▁36\n\nSection:▁2.3.6.6,▁Anti-Panitumumab▁Antibodies": 16068, + "%▁of▁the▁": 16069, + "%,▁respectively": 16070, + "(B": 16071, + "(12": 16072, + ")▁may▁be▁": 16073, + "+/-": 16074, + "-lik": 16075, + "140": 16076, + "6,▁12": 16077, + ":15": 16078, + "AZ": 16079, + "BSA": 16080, + "CONFIDENTIAL": 16081, + "Creatinine▁Clear": 16082, + "Double-": 16083, + "ETIC": 16084, + "Gemcitabine▁": 16085, + "Gleason": 16086, + "J,▁G": 16087, + "J,▁K": 16088, + "LA": 16089, + "Master": 16090, + "Over": 16091, + "OST": 16092, + "PT-11": 16093, + "Serious▁Adverse▁Event": 16094, + "Time▁to": 16095, + "VC": 16096, + "VER": 16097, + "W,▁S": 16098, + "Yes▁or▁No": 16099, + "a▁D": 16100, + "a▁bit": 16101, + "be": 16102, + "bu": 16103, + "covariates": 16104, + "eous▁": 16105, + "foc": 16106, + "fall": 16107, + "fix": 16108, + "facil": 16109, + "future▁": 16110, + "funding": 16111, + "ga": 16112, + "hin": 16113, + "jacent": 16114, + "keys": 16115, + "lev": 16116, + "potentially▁": 16117, + "race": 16118, + "rare▁": 16119, + "sa": 16120, + "squ": 16121, + "s▁through": 16122, + "time▁to": 16123, + "ytoch": 16124, + "▁−": 16125, + "▁eas": 16126, + "▁ever": 16127, + "▁outlin": 16128, + "▁esophag": 16129, + "e▁p": 16130, + "inavir": 16131, + "▁tast": 16132, + "ates▁(": 16133, + "at▁screening": 16134, + "ate▁transamin": 16135, + "onic": 16136, + "one▁of▁the▁": 16137, + "\n\nand": 16138, + "\n\nOS": 16139, + "\n\nanalysis": 16140, + "▁a▁1": 16141, + "▁a▁non-": 16142, + "▁avoid▁": 16143, + "or\n\n": 16144, + "ord▁": 16145, + "s▁–": 16146, + "s▁using": 16147, + "ree-": 16148, + "▁thor": 16149, + "▁thus": 16150, + "▁thyroid▁": 16151, + "stage▁III": 16152, + "itate▁": 16153, + "ital▁or": 16154, + "▁the▁other": 16155, + "▁the▁right▁to": 16156, + "of▁Consent": 16157, + "analyt": 16158, + ",▁follow-up": 16159, + ",▁based▁on": 16160, + "road": 16161, + "ed▁up": 16162, + ".▁Protocol": 16163, + "arine▁": 16164, + "▁potentially▁": 16165, + "▁cav": 16166, + "▁course": 16167, + "▁black": 16168, + "es▁as▁": 16169, + "es,▁a": 16170, + "ation,▁or": 16171, + "▁to▁evaluate▁the▁": 16172, + "▁tomograph": 16173, + "asons": 16174, + "▁of▁approximately▁": 16175, + "▁of▁paclitaxel": 16176, + "▁of▁cycles▁": 16177, + "um▁LD": 16178, + "▁dipstick": 16179, + "▁wound▁": 16180, + "▁and▁not": 16181, + "▁and▁your": 16182, + "▁and▁weight": 16183, + "▁and▁post-": 16184, + "ectib": 16185, + ".\n\nd▁e▁v▁o▁r▁p▁p▁A": 16186, + "is▁F": 16187, + "▁Acid": 16188, + "▁ALT": 16189, + "▁in▁10": 16190, + "▁in▁the\n\n": 16191, + "....................................": 16192, + "......................................": 16193, + "urwitz": 16194, + "evident": 16195, + "ocrin": 16196, + "plant": 16197, + "▁C1": 16198, + "▁Carcinoma": 16199, + "es▁it": 16200, + "▁Policy": 16201, + "▁PART▁B:": 16202, + "progn": 16203, + "▁(±": 16204, + "▁(not": 16205, + "▁(to": 16206, + "▁(LD": 16207, + "▁(longest▁diameter": 16208, + "▁(Version▁3.0": 16209, + "▁Sci": 16210, + "▁Summary▁of": 16211, + "▁S▁I\n\nS▁I▁H▁T": 16212, + "▁reproductive▁": 16213, + "▁reasons": 16214, + "otally▁con": 16215, + "unn": 16216, + "▁DFS": 16217, + "▁Death": 16218, + "close▁": 16219, + "appe": 16220, + "▁EB": 16221, + "▁End": 16222, + "▁fib": 16223, + "▁or▁T": 16224, + "▁or▁greater": 16225, + "e▁tub": 16226, + "▁nail": 16227, + "oday": 16228, + "\n\nAST": 16229, + "▁Target": 16230, + "▁adding": 16231, + "▁NOT": 16232, + "opoul": 16233, + "will▁be▁analyz": 16234, + "▁arrest": 16235, + "▁for▁genetic▁research": 16236, + "▁RPLS": 16237, + "encod": 16238, + "ed▁to▁your": 16239, + ".16": 16240, + ".17": 16241, + ".1.4": 16242, + ".2\n\nStudy▁": 16243, + "▁withhold": 16244, + "▁with▁zoledronic▁acid▁": 16245, + "ed▁both": 16246, + "s▁of▁blood▁": 16247, + "s▁of▁22▁March▁2007": 16248, + "▁that▁tim": 16249, + "▁that▁may▁be▁": 16250, + "▁2003;": 16251, + "▁will▁be▁used▁for": 16252, + "▁MC": 16253, + "▁3-week": 16254, + "▁constitut": 16255, + "correlated▁": 16256, + "event▁that": 16257, + "▁of▁the▁first": 16258, + "▁o▁t": 16259, + ".▁The▁Investigator": 16260, + "▁as▁direct": 16261, + "▁as▁specifi": 16262, + "▁giv": 16263, + "▁on▁all": 16264, + ",▁and▁1": 16265, + ",▁and▁at": 16266, + ",▁and▁bevacizumab": 16267, + "ine▁needl": 16268, + "▁LY231514": 16269, + "▁this▁is▁": 16270, + "s,▁bas": 16271, + "s,▁CA": 16272, + "▁allel": 16273, + "▁all▁pre-": 16274, + "\n\nCetuximab": 16275, + "▁charg": 16276, + "ing▁the▁protocol": 16277, + "▁54": 16278, + "▁6▁mg/kg": 16279, + ")\n\nM": 16280, + "▁the▁investigational▁": 16281, + ".41": 16282, + ".42": 16283, + ".46": 16284, + "continue▁": 16285, + "continuous": 16286, + "identification": 16287, + ".5%": 16288, + "s.▁Ex": 16289, + "▁any▁in": 16290, + "▁any▁subject": 16291, + "▁Vitamin▁B12": 16292, + "▁the▁target▁lesion": 16293, + "\n\nDelete:": 16294, + ".▁Serum": 16295, + "▁the▁death": 16296, + "▁GA": 16297, + ".▁PFS": 16298, + ".▁Pleas": 16299, + "▁is▁allow": 16300, + "ial▁lung": 16301, + "monocyt": 16302, + "strenu": 16303, + "s)▁will▁be▁": 16304, + ".6.3": 16305, + "▁to▁the▁efficacy▁of": 16306, + "▁assessments▁(": 16307, + "▁agonist": 16308, + "▁phosph": 16309, + "recording": 16310, + "s.\n\n3": 16311, + "teomic": 16312, + ".▁Totally▁con": 16313, + ",▁or▁death": 16314, + ".,▁M": 16315, + "▁88": 16316, + "e▁(IEC": 16317, + "1500": 16318, + "every▁4": 16319, + ".72": 16320, + "▁form▁used": 16321, + "ular▁fil": 16322, + "Study▁Medication": 16323, + "▁has▁returned▁to▁baselin": 16324, + "▁a▁schedul": 16325, + "▁cycle\n\n": 16326, + "e,▁the▁patient": 16327, + "during▁screening": 16328, + "ERMI": 16329, + "▁the▁low": 16330, + "▁interpret": 16331, + "▁registration/": 16332, + ".\n\nAD": 16333, + "▁days▁or": 16334, + "▁days▁before▁": 16335, + "ucoc": 16336, + "data▁on": 16337, + "e▁between": 16338, + "priateness▁of": 16339, + "▁panitumumab▁in▁combination▁with": 16340, + "s▁or▁to": 16341, + "▁Clinical▁Research": 16342, + "▁death,▁": 16343, + "d▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁Denosumab▁Protocol▁Number:▁20050244▁Date:▁05▁May▁2008\n\nPage▁": 16344, + "▁evaluating": 16345, + "enteral": 16346, + "ed▁from▁Amgen": 16347, + "▁cell▁lin": 16348, + "JMHO": 16349, + "approval▁": 16350, + ",▁Pa": 16351, + "randomized▁in▁a▁1:1▁ratio": 16352, + "y▁and▁capable▁of▁all▁s": 16353, + "▁CT▁or▁MRI": 16354, + "e▁that▁is▁": 16355, + ".▁Bi": 16356, + ".▁By▁": 16357, + "response▁and▁": 16358, + "number,▁": 16359, + "ed▁slid": 16360, + "▁Page▁1": 16361, + "...................................................▁": 16362, + "▁disease▁progression▁is▁": 16363, + "rosome▁": 16364, + "-telop": 16365, + "▁discretion": 16366, + "▁discrepanc": 16367, + "▁drugs▁": 16368, + "▁duration▁of▁": 16369, + "▁during▁or": 16370, + "▁location": 16371, + "administered▁in": 16372, + "manual": 16373, + "manuscript": 16374, + ".▁Any": 16375, + "\n\nInternational▁": 16376, + "▁responsible▁person": 16377, + "part▁of": 16378, + "▁until▁the▁": 16379, + "ogenous▁": 16380, + "REG": 16381, + ")(cid:10": 16382, + "obtained▁": 16383, + "\n\n8\n\n9": 16384, + "▁Amgen’s▁": 16385, + "by▁a": 16386, + "s▁should▁be▁select": 16387, + ".▁Patients▁will": 16388, + "▁increase▁the▁": 16389, + "▁countri": 16390, + "\n\n(continued)\n\n": 16391, + "▁who▁are▁": 16392, + "▁baseline▁of": 16393, + "determined▁": 16394, + "▁a▁mean": 16395, + "Concomitant▁Medication": 16396, + "▁protocol▁procedure": 16397, + "▁mL▁of": 16398, + "▁developed▁": 16399, + "▁the▁first▁day▁of": 16400, + "▁the▁same▁tim": 16401, + "▁+/-": 16402, + "▁phase,▁": 16403, + "participation▁in": 16404, + "▁QTc": 16405, + ".\n\nTumor": 16406, + "▁1572": 16407, + "▁confirmation▁of": 16408, + "▁withdrawn": 16409, + "▁withdrawal▁of▁consent": 16410, + "andomisation": 16411, + "ralgia": 16412, + "▁have\n\n": 16413, + "▁18▁years▁of▁ag": 16414, + "pensation": 16415, + "▁long-term": 16416, + "▁safety▁concern": 16417, + "median▁OS": 16418, + "analyses": 16419, + "Treatment▁of▁": 16420, + "study▁drug▁administration": 16421, + ",▁Wang": 16422, + "ate▁that▁the▁": 16423, + "\n\n10.1": 16424, + "reduction▁in": 16425, + "▁time▁to▁clinical▁progression": 16426, + "▁period▁for": 16427, + "▁acceptable▁to": 16428, + "▁acceptable\n\n": 16429, + "2-hour": 16430, + "▁causality": 16431, + "\n\nthe▁subject": 16432, + "▁its▁representativ": 16433, + "\n\ninfusion": 16434, + "▁ambulator": 16435, + "▁meet▁the▁": 16436, + "▁days▁after▁the▁last": 16437, + "racellular": 16438, + "▁amendments,▁": 16439, + "▁amendment▁3▁–▁dated▁23": 16440, + "glucos": 16441, + "ison▁of": 16442, + "▁various": 16443, + "▁values▁": 16444, + "respectively▁": 16445, + "eparin": 16446, + "▁conduct▁of▁the▁": 16447, + "statistical▁": 16448, + "▁consideration": 16449, + "▁Exclusion▁Criteria": 16450, + "\n\ndeath": 16451, + "omiting,▁": 16452, + "▁treatment▁with▁panitumumab": 16453, + "ing▁puls": 16454, + "▁>▁2": 16455, + "remains▁": 16456, + "▁whether▁or▁not": 16457, + "staff▁will": 16458, + "Statement": 16459, + "e▁the▁safety▁": 16460, + "\n\nAmgen▁Inc": 16461, + "▁chest,▁abdomen": 16462, + "▁Patient▁Reported▁Outcom": 16463, + "stitutional▁review▁board": 16464, + "\n\nTable▁3": 16465, + "▁the▁treatment▁of▁patients▁with": 16466, + "should▁not": 16467, + "measured▁from▁the▁date▁of▁randomization": 16468, + "\n\nStop": 16469, + "LINICAL": 16470, + ".▁Patient▁has▁": 16471, + "▁blood▁sample▁will▁be▁": 16472, + "emoradi": 16473, + "▁appears▁to▁be▁": 16474, + "▁(cid:13": 16475, + "▁added▁to": 16476, + "▁of▁your▁cancer": 16477, + "required▁to▁be▁": 16478, + "lymph▁node▁": 16479, + "▁regarding▁the▁": 16480, + "▁written▁informed▁consent": 16481, + "severity▁of": 16482, + "▁Dosage,▁Administration": 16483, + "▁administration▁of▁investigational▁product": 16484, + "▁estimate▁the▁": 16485, + ".▁These▁data": 16486, + "▁line▁treatment": 16487, + "▁stratification▁factor": 16488, + "▁the▁discretion▁of▁the▁Investigator": 16489, + "▁..................................................................................": 16490, + "e▁testing": 16491, + "fulfill": 16492, + "grade▁4": 16493, + ".▁Proceeding": 16494, + "stable▁angina": 16495, + "▁ADVERSE▁EVENT": 16496, + "Modifications▁for": 16497, + "Notification": 16498, + "’s▁treatment▁assignment": 16499, + "▁..............................................................................": 16500, + "▁on-study▁chemotherapy": 16501, + "version▁of▁the▁": 16502, + "IDMS": 16503, + "\n\nNot▁applicable▁to▁amended▁protocol": 16504, + "▁or▁sedent": 16505, + "ass▁vial": 16506, + "▁Response": 16507, + "▁central": 16508, + "participating▁in": 16509, + "-to-": 16510, + "quantity▁of": 16511, + "▁attempt": 16512, + "▁appropriate.\n\n": 16513, + "neutrophils,▁": 16514, + "once▁": 16515, + "▁Manual": 16516, + ".▁Phase▁III": 16517, + "▁measurable▁lesion": 16518, + "▁respond": 16519, + "▁months▁after▁the▁last": 16520, + "evidence▁that": 16521, + "pneumon": 16522, + "al▁surv": 16523, + "\n\nAmended▁Clinical▁Trial▁Protocol▁5▁XRP6258/EFC6193\n\n21-Jul-2008▁Version▁number:▁1▁(electronic▁2.0)": 16524, + "▁anticipated▁that": 16525, + "reported▁to▁Amgen": 16526, + "▁discontinuation▁of▁treatment": 16527, + ".▁Chemotherapy▁": 16528, + "weekly▁for": 16529, + "▁trend": 16530, + "ware▁of": 16531, + "whichever▁occurs▁first": 16532, + "▁There▁is▁a": 16533, + "▁starting▁dose▁of": 16534, + ",▁in▁the▁opinion▁of▁the▁investigator": 16535, + "y/illness": 16536, + "▁glutam": 16537, + "▁at▁baseline▁and▁": 16538, + "▁OF▁TERMS": 16539, + "▁reconstitution": 16540, + "erbst": 16541, + "▁limit▁of▁normal": 16542, + "diluted▁solution": 16543, + "▁light▁or▁sedent": 16544, + "at▁the▁end▁of▁treatment": 16545, + "▁prednison": 16546, + "▁apoptotic": 16547, + "▁discontinue▁study▁treatment": 16548, + "▁of▁101\n\n090177e18069a3aa\\Approved\\Approved▁On:▁27-Sep-2007▁02:42\n\n1▁4▁:▁5▁0▁7▁0▁0▁2▁-▁g▁u▁A▁-▁1▁3▁\\▁d▁e▁v▁o▁r▁p▁p▁A\n\n\\▁1▁.▁1▁\\\n\n8▁2▁1▁6▁6▁8▁6▁0▁0▁0▁0▁0▁1▁0\n\nSunitinib▁Malate▁Amended▁Protocol▁A6181122▁Amendment▁1,▁28▁August▁2007\n\nPfizer▁–▁Company▁Confidential▁Page▁": 16549, + "ed▁at▁a▁dose▁of": 16550, + "▁will▁be▁censored▁at▁the▁date▁of▁the▁last": 16551, + "▁practice▁guidelines": 16552, + "▁of▁63▁Finalization▁date:▁June▁19▁2001,▁Incorporating▁amendment▁3▁–▁dated▁23": 16553, + "▁relationship▁to": 16554, + "fatigue,▁": 16555, + "▁DISORDERS▁-": 16556, + "▁IEC/IRB": 16557, + "refractor": 16558, + "arly▁Stopping": 16559, + "▁commercial▁pharmaceutical▁product": 16560, + "impact▁of": 16561, + "ICH▁GCP": 16562, + "▁mm▁with▁conventional▁techniqu": 16563, + "\n\nProgression-free▁s": 16564, + "matter": 16565, + "End▁of▁Study▁": 16566, + "▁<>": 16629, + "ular▁filtration": 16630, + "ERMINA": 16631, + "▁ambulatory▁and": 16632, + "ing▁pulse,▁": 16633, + "▁of▁63▁Finalization▁date:▁June▁19▁2001,▁Incorporating▁amendment▁3▁–▁dated▁23▁May": 16634, + "▁<>": 16635, + "eosinophils,▁basophil": 16636, + "ely▁disabled.▁Cannot": 16637, + "ricted▁in▁physically▁strenuous": 16638, + "%▁versus▁": 16639, + "'s▁s": 16640, + "-E": 16641, + "-28": 16642, + "-Related▁": 16643, + "1▁level": 16644, + "1:1": 16645, + "216": 16646, + ":▁T": 16647, + ":▁M": 16648, + ";▁it": 16649, + "CM": 16650, + "Department": 16651, + "FERENCES": 16652, + "Guidelin": 16653, + "Imaging": 16654, + "J,▁M": 16655, + "L)": 16656, + "LAC": 16657, + "NF": 16658, + "Post": 16659, + "QU": 16660, + "Rad": 16661, + "Suppl": 16662, + "TM": 16663, + "VA": 16664, + "WHO": 16665, + "XAL": 16666, + "[plasma▁and▁": 16667, + "],▁and▁": 16668, + "].▁In": 16669, + "axim": 16670, + "average▁": 16671, + "bag": 16672, + "corticosteroid": 16673, + "don": 16674, + "dre": 16675, + "dipstick": 16676, + "eer": 16677, + "e.▁All": 16678, + "give▁": 16679, + "harm": 16680, + "http://": 16681, + "ij": 16682, + "iation": 16683, + "jun": 16684, + "never": 16685, + "nell": 16686, + "nonsquamous▁": 16687, + "oal": 16688, + "ook": 16689, + "sem": 16690, + "surg": 16691, + "single▁": 16692, + "wide▁": 16693, + "warrant": 16694, + "yalg": 16695, + "°F": 16696, + "±▁15▁minutes": 16697, + "▁00": 16698, + "▁effort": 16699, + "e▁1": 16700, + "e▁has▁been": 16701, + "inic": 16702, + "increase▁": 16703, + "informed▁of": 16704, + "▁trough": 16705, + "▁troponin": 16706, + "atinib": 16707, + "atzem": 16708, + "\n\nac": 16709, + "\n\nevent": 16710, + "\n\nVersion": 16711, + "\n\nQu": 16712, + "▁approved": 16713, + "enal▁": 16714, + "enrolment": 16715, + "s▁report": 16716, + "s▁consent": 16717, + "s▁relevant": 16718, + "y▁A": 16719, + "y▁b": 16720, + "y▁stimulating▁factor": 16721, + "entan": 16722, + "iting": 16723, + "▁the▁AE": 16724, + ",▁sign": 16725, + ",▁non-": 16726, + "▁an▁SAE": 16727, + "▁an▁objective▁": 16728, + "▁an▁ongoing": 16729, + "ic▁attack": 16730, + ".▁10": 16731, + ".▁11": 16732, + "▁cerv": 16733, + "ing▁about": 16734, + "for▁at▁least": 16735, + "et]": 16736, + "etary▁": 16737, + "etention": 16738, + "▁to▁assess": 16739, + "issing": 16740, + "▁often": 16741, + "umatic": 16742, + "▁der": 16743, + "▁devi": 16744, + "▁dexamethasone▁": 16745, + "▁draw": 16746, + "▁walk": 16747, + "▁wait": 16748, + "▁mix": 16749, + "▁mouth": 16750, + "▁material▁": 16751, + "▁and▁1": 16752, + ".\n\nU": 16753, + ".\n\nd": 16754, + ".\n\nInvestigator": 16755, + ".\n\n33": 16756, + "olus": 16757, + "abstract": 16758, + "▁in\n\n": 16759, + "▁incid": 16760, + "imon": 16761, + "imet": 16762, + "imult": 16763, + "..................................": 16764, + "plus": 16765, + "pleur": 16766, + "▁1/": 16767, + "es▁is▁": 16768, + "▁PFIZER▁CONFIDENTIAL▁Page▁": 16769, + "▁Previous▁": 16770, + "project": 16771, + "▁(within": 16772, + "▁(EGFR": 16773, + "▁(serum": 16774, + "▁2.4": 16775, + "▁Stud": 16776, + "otid": 16777, + "otrex": 16778, + "▁letter": 16779, + "▁few": 16780, + "▁felt": 16781, + "▁febrile▁neutropenia": 16782, + "e▁total▁": 16783, + "▁now": 16784, + "▁natur": 16785, + "\n\nApproved": 16786, + "\n\nAssessment▁of": 16787, + "▁ORR": 16788, + "▁OXAL": 16789, + "▁prob": 16790, + "▁adapt": 16791, + "▁arrang": 16792, + "other▁treatment": 16793, + "▁for▁this▁": 16794, + "▁for▁colorectal▁cancer": 16795, + "▁for▁metastatic▁colorectal▁cancer": 16796, + "anders▁": 16797, + "e\n\n(": 16798, + "ences▁of": 16799, + "ency,▁": 16800, + "s▁off": 16801, + "advanced▁": 16802, + "\n\nSurvival▁": 16803, + "\n\nSafety": 16804, + "▁that▁of": 16805, + "▁of▁existing": 16806, + "▁will▁be▁estimated▁": 16807, + "e▁select": 16808, + "▁Maintain▁dose▁level": 16809, + "▁31,▁": 16810, + "▁3▁x▁ULN": 16811, + "▁of▁the▁investigational▁product": 16812, + "wheez": 16813, + ".▁The▁overall": 16814, + ".▁The▁incidence▁of": 16815, + "ity▁Form": 16816, + "▁the▁serum": 16817, + "▁on▁study": 16818, + "ated▁lung": 16819, + "ated▁fatty": 16820, + "ine▁and▁": 16821, + "intensity▁": 16822, + "s,▁S": 16823, + "s,▁respectively": 16824, + "123": 16825, + "ips": 16826, + "▁still": 16827, + "▁stabiliz": 16828, + "▁chemotherapeutic": 16829, + "▁will▁include▁a": 16830, + "e▁involv": 16831, + "▁500▁mg/m2": 16832, + "▁5▁years▁of": 16833, + "▁6▁1": 16834, + "▁6.3.1": 16835, + "curric": 16836, + "▁subjects▁treated▁with": 16837, + "▁4%": 16838, + "▁the▁pemetrex": 16839, + "▁accident": 16840, + "ego": 16841, + "ege▁of": 16842, + ".44": 16843, + "continued▁until": 16844, + ".51": 16845, + ".58": 16846, + "s.▁You": 16847, + "▁weeks)": 16848, + "ritical": 16849, + "▁any▁purpose▁": 16850, + "▁exclud": 16851, + "ellow": 16852, + "ellet]": 16853, + "ance▁and▁": 16854, + "▁whil": 16855, + "ed▁by▁the▁patient": 16856, + "ethotrex": 16857, + "ally▁related▁to": 16858, + "ed▁for▁a": 16859, + "s▁and▁Study▁T": 16860, + "e▁dail": 16861, + "▁patients,": 16862, + "angitis▁": 16863, + "▁G▁M": 16864, + "▁unused▁": 16865, + "ousework": 16866, + "▁UPCR": 16867, + "e▁the▁right▁to": 16868, + "pts)▁with": 16869, + ".▁Power": 16870, + "s\n\nFor": 16871, + "ed▁by▁each": 16872, + "evaluating▁the▁": 16873, + "▁tumor▁lesion": 16874, + "▁tumor▁imaging": 16875, + "effect▁on": 16876, + "▁study\n\n": 16877, + "▁study▁therapy▁": 16878, + "articulate▁": 16879, + "s).": 16880, + "ppear": 16881, + "recorded▁and▁": 16882, + "recording▁of": 16883, + "s.\n\n5": 16884, + "s.\n\nD": 16885, + ",▁and▁that": 16886, + "▁sign▁this▁": 16887, + "RIMENTAL": 16888, + ".▁Table▁": 16889, + ",▁or▁if": 16890, + "▁9.1.1": 16891, + "pretreatment": 16892, + ").\n\n5": 16893, + "\n\n22": 16894, + "y▁of▁the▁following": 16895, + "▁should▁be▁discontinu": 16896, + "▁AdEERS": 16897, + "▁Study▁Manager": 16898, + "asse▁P": 16899, + "\n\nFirst": 16900, + "▁the▁patient's▁": 16901, + "response": 16902, + "responsibility▁": 16903, + "▁The▁Investigator": 16904, + "s▁are▁responsible▁for": 16905, + "▁WT": 16906, + "KRAS▁testing": 16907, + "KRAS▁mutation": 16908, + "▁oblig": 16909, + "▁days▁of▁the▁": 16910, + "\n\nI▁feel": 16911, + "i-squ": 16912, + "▁panitumumab▁administration": 16913, + "▁therapy▁is▁": 16914, + "results▁of▁the▁": 16915, + "dosage▁": 16916, + "▁progression▁event": 16917, + "▁peripheral▁": 16918, + "▁over▁30": 16919, + "received▁treatment▁with": 16920, + "considered▁in": 16921, + "considered▁for": 16922, + "▁subjects▁randomized▁to": 16923, + "▁approximately▁every▁6▁months▁for": 16924, + "▁their▁sp": 16925, + "▁et▁al.▁199": 16926, + "disease▁or": 16927, + "es▁will▁be▁test": 16928, + "isher": 16929, + "iomet": 16930, + "▁provides▁": 16931, + "▁response▁is▁": 16932, + "dose▁until▁toxicity▁": 16933, + "▁the▁time▁that": 16934, + "▁these▁studies▁": 16935, + "s▁below": 16936, + ",▁Mur": 16937, + "\n\n7.5": 16938, + ",▁2009": 16939, + "elected▁": 16940, + "s▁will▁only▁be▁": 16941, + "▁non-measurable▁lesion": 16942, + "▁must▁be\n\n": 16943, + "subinvestigator": 16944, + "▁level▁is▁": 16945, + "▁metastatic▁sit": 16946, + "▁blood▁[plasma▁and▁": 16947, + "▁results▁of": 16948, + "arget▁lesions▁should▁be▁select": 16949, + "INTS": 16950, + "INVESTIGATIONAL▁PRODUCT": 16951, + ".▁Non": 16952, + "\n\nBaseline▁": 16953, + "\n\nBiomarker": 16954, + "given▁at": 16955, + "partate▁transamin": 16956, + "uthorization": 16957, + "ratification": 16958, + "▁tissue▁block": 16959, + "changes": 16960, + "changes▁to": 16961, + "ry▁(": 16962, + ")(cid:3)(cid:": 16963, + ",▁Hean": 16964, + ".▁Journal": 16965, + "dient": 16966, + "▁neuropath": 16967, + "ed▁organ": 16968, + "▁both▁treatment▁arm": 16969, + "▁intens": 16970, + "▁intellect": 16971, + "ed▁by▁the▁following": 16972, + "▁approved▁informed▁consent▁form": 16973, + "known▁as▁": 16974, + "▁a▁cor": 16975, + "ed▁cycl": 16976, + ",▁Day▁1": 16977, + "▁previous": 16978, + "▁every▁21▁days": 16979, + "Under": 16980, + ",▁Lang": 16981, + "▁development▁of": 16982, + "\n\nAppendix▁B": 16983, + ",▁power": 16984, + "▁cetuximab▁infusion": 16985, + "▁periodic": 16986, + "causal▁relationship": 16987, + "▁two-sided▁": 16988, + "▁KRAS▁status▁": 16989, + "study▁treatment▁period▁or": 16990, + "chemotherapy▁(": 16991, + "▁research▁study": 16992, + "▁of▁a▁light▁or▁sedent": 16993, + "▁healthy▁": 16994, + "▁healthcare▁": 16995, + "▁health▁care▁": 16996, + "▁health-related▁quality▁of▁lif": 16997, + "IGIB": 16998, + "▁authorization": 16999, + "▁and▁scientific": 17000, + "▁20▁mg": 17001, + "erious▁or": 17002, + "epher": 17003, + "during▁follow-up": 17004, + ",▁Wol": 17005, + "▁prior▁to▁randomization": 17006, + "e.▁W": 17007, + "respond▁to": 17008, + "used▁for▁any▁purpose▁": 17009, + "eplacement▁of": 17010, + "er▁than▁the▁": 17011, + "▁11.2": 17012, + "\n\nthis▁": 17013, + ",▁dyspnea": 17014, + "ize▁each": 17015, + "▁patients▁treat": 17016, + "hematology": 17017, + "▁28▁days": 17018, + "▁28▁days▁": 17019, + "quamous": 17020, + "%▁of▁patients▁": 17021, + "stratification": 17022, + "developed▁": 17023, + "▁bias": 17024, + ".........................................▁": 17025, + "▁risk▁factor": 17026, + "professional": 17027, + "open-label▁denosumab": 17028, + "▁25▁mg": 17029, + "aturated▁fatty": 17030, + "▁PR▁PR": 17031, + "-Day▁": 17032, + "combined▁": 17033, + "ARM": 17034, + "▁manage▁": 17035, + "▁detailed▁": 17036, + "ing▁purpos": 17037, + "▁alone,▁": 17038, + "▁alone)": 17039, + "comparative▁": 17040, + "▁oxaliplatin▁dose▁level": 17041, + "resolved▁": 17042, + "s▁include▁": 17043, + "where▁appropri": 17044, + "▁individuals▁": 17045, + "rochure▁": 17046, + "▁body▁system": 17047, + "es▁from▁baseline▁": 17048, + ",▁hyp": 17049, + "▁analysis▁will▁be▁conduct": 17050, + ".▁While▁": 17051, + "periodically▁": 17052, + ".▁Oncol": 17053, + "▁currently▁available▁": 17054, + "▁involved▁organ": 17055, + "\n\nStor": 17056, + "CT▁scan▁or▁MRI": 17057, + "assigned▁a": 17058, + ".▁Concomitant▁Medication": 17059, + "▁professional": 17060, + "otal▁bilirubin": 17061, + "stratified▁log-rank▁test": 17062, + "stopped▁for": 17063, + "▁Record": 17064, + "ogenicity▁": 17065, + ".▁The▁investigator▁should▁notify▁the▁": 17066, + "delayed▁for": 17067, + "▁INFORM": 17068, + "▁extraction": 17069, + "\n\nPage:▁36\n\nSection:▁2.3.6.6,▁Anti-Panitumumab▁Antibodies": 17070, + "▁statistic": 17071, + "▁specifically▁": 17072, + "▁Dosage▁Adjustment": 17073, + "\n\nPatients▁who": 17074, + "▁this▁research.▁Neither▁Amgen": 17075, + "▁chemistry,▁": 17076, + "▁EGFr▁expression": 17077, + "e▁on▁a": 17078, + "▁well-being": 17079, + "recorded▁on▁the▁case▁report▁form": 17080, + "▁predictive▁": 17081, + "s▁must▁not▁be▁": 17082, + "▁assess▁the▁effects▁of": 17083, + "prior▁to▁the▁first": 17084, + "version▁3.0": 17085, + "▁rate▁(": 17086, + "\n\nNote:": 17087, + ".▁Patients▁who▁are▁": 17088, + "▁5-fluorouracil/": 17089, + "igenetic": 17090, + "=0.0": 17091, + "hibition▁of": 17092, + "e▁discomfort": 17093, + "ELL": 17094, + "▁consists▁of": 17095, + "▁and▁Early▁Stopping": 17096, + "▁calculate▁": 17097, + "▁thrombosis": 17098, + "starting▁dose▁of": 17099, + "lood▁samples▁will▁be▁": 17100, + "licens": 17101, + "▁plasma▁concentration": 17102, + ".▁Phase▁II": 17103, + "▁sufficient▁increase▁to": 17104, + "box▁number": 17105, + "fluid▁": 17106, + "\n\nWhat": 17107, + "▁grading": 17108, + "▁miss": 17109, + "e▁aspir": 17110, + "▁experience▁any▁": 17111, + "▁3.3.4": 17112, + "failure": 17113, + "▁fever▁or": 17114, + "▁stratified▁by▁the▁randomization": 17115, + "ed▁before▁any▁": 17116, + "statistical▁analysis▁plan": 17117, + "▁investigational\n\nproduct": 17118, + "ed▁in▁accordance▁with▁the▁": 17119, + "adjusted▁HR": 17120, + ".▁It▁is▁recommended▁that": 17121, + "PERIMENTAL": 17122, + "withheld▁for": 17123, + "▁selected▁": 17124, + "▁activities.▁Up▁and▁about": 17125, + "▁Investigational▁Product▁for▁Destruction": 17126, + "▁and▁cardiovascular": 17127, + ".\n\nThere▁": 17128, + "s▁per▁organ": 17129, + "omatitis▁": 17130, + ",5,6": 17131, + "▁renal▁cell▁carcinoma": 17132, + "▁apoptosis": 17133, + "▁aged▁>": 17134, + "should▁also▁be▁": 17135, + "▁previously▁treat": 17136, + "▁previously▁treated▁": 17137, + "(6):▁p.▁": 17138, + "omerular▁filtration": 17139, + "performed▁as▁clinically▁indicated": 17140, + "recently▁": 17141, + "▁archival": 17142, + "hold▁dose▁until▁toxicity▁": 17143, + "United▁States▁": 17144, + "(5):▁p.▁": 17145, + "▁ml/min": 17146, + "amount▁of": 17147, + "entered▁into▁the▁study": 17148, + "European▁Union": 17149, + "▁unable▁to▁carry▁out": 17150, + "blinded▁study▁medication": 17151, + "goal▁of▁the▁": 17152, + "▁qualify▁for▁PD": 17153, + "paid▁": 17154, + "▁the▁prior▁written": 17155, + "weak": 17156, + "▁Discontinuation▁of": 17157, + "▁proces": 17158, + "▁Lilly▁or▁its▁designe": 17159, + "▁all▁randomized▁subject": 17160, + "reported▁as▁adverse▁event": 17161, + "Academ": 17162, + "▁radiographically▁documented▁PD": 17163, + "▁Metastatic▁Colorectal▁Cancer": 17164, + "double-blind,▁placebo-": 17165, + "▁trail": 17166, + ",▁please▁": 17167, + "▁1999;": 17168, + "has▁not▁been": 17169, + "loride▁Injection": 17170, + "\n\nS▁T▁I\n\nK▁C▁E▁H▁C\n\nE▁S▁A▁E▁L▁P\n\n.▁T▁N▁E▁M▁U▁C▁O▁D\n\nC▁I▁N▁O▁R▁T▁C▁E▁L▁E\n\nN▁A\n\nF▁O\n\nY▁P▁O▁C\n\nD▁E▁T▁N▁I▁R▁P\n\nA\n\nS▁I\n\nS▁I▁H▁T": 17171, + "▁ELIGIB": 17172, + "reconstruction▁interval▁": 17173, + "thical▁Review": 17174, + "▁24-hour▁urine▁collection": 17175, + "terim▁Analysis▁and▁Early▁Stopping": 17176, + ".\n\nREFERENCES": 17177, + "ed▁but▁not": 17178, + "▁controlled▁": 17179, + "▁and▁Treatment▁Schema": 17180, + "age▁to▁qualify▁for": 17181, + "▁prescribing▁information": 17182, + ".▁1999;": 17183, + "▁fully▁human": 17184, + "moderate▁": 17185, + "objectives▁of▁the▁study": 17186, + "categoriz": 17187, + "ossible▁": 17188, + "▁the▁difference▁in": 17189, + "ed▁once▁": 17190, + "PACCE▁protocol": 17191, + "▁compliance▁is▁": 17192, + "respiration▁rate": 17193, + "▁prognosis": 17194, + "▁Rochester": 17195, + "s▁-▁Other": 17196, + "▁digit": 17197, + "third▁": 17198, + "▁3rd▁quarter": 17199, + "▁a▁secure▁": 17200, + "▁between▁the▁2▁treatment▁arm": 17201, + "▁run-in": 17202, + "fice▁work": 17203, + "most▁frequently▁": 17204, + "▁adverse▁drug▁reaction": 17205, + "inancial▁Disclosure▁": 17206, + "red▁to▁as▁“": 17207, + "one▁or▁more▁of▁the▁following": 17208, + "Wild-type▁and▁": 17209, + "ome-▁what": 17210, + "▁little▁b": 17211, + "▁diphenhydramine▁": 17212, + ".▁Objectiv": 17213, + "attributable▁to": 17214, + "the▁sam": 17215, + "▁persistent▁or▁significant▁disability/inc": 17216, + "ethical▁review▁board": 17217, + "▁abortion": 17218, + "ensory▁neuropath": 17219, + "with▁placebo▁in▁terms▁of": 17220, + "ability▁for▁accurate▁": 17221, + "▁result▁from▁this▁research.▁Neither▁Amgen": 17222, + "\n\nFully▁active,": 17223, + "risks▁and▁benefits▁of": 17224, + "Medicine,▁": 17225, + "active▁Voice▁Response▁System": 17226, + "▁SC▁injection▁of▁denosumab": 17227, + "Therapy▁During▁Study▁": 17228, + "unsaturated▁fatty": 17229, + "▁apparent": 17230, + "at▁a▁significance▁level▁of▁5%": 17231, + "or▁serum▁pregnancy▁test": 17232, + "ometimes▁": 17233, + "▁sufficient▁shrinkage▁to▁qualify▁for": 17234, + "d▁and▁Significance:": 17235, + "3)▁(cid:4)▁(cid:5)▁(cid:6)▁(cid:": 17236, + "ine▁needle▁aspir": 17237, + "▁all▁pre-disease▁": 17238, + "▁registration/randomization": 17239, + "priateness▁of▁Measurement": 17240, + "representative▁of▁all▁involved▁organ": 17241, + "elegation▁of▁Author": 17242, + "atzemeier": 17243, + "imultane": 17244, + "s▁and▁Study▁Termination": 17245, + "▁their▁spous": 17246, + "▁blood▁[plasma▁and▁cell": 17247, + ",▁Heaney▁": 17248, + "▁of▁a▁light▁or▁sedentary▁n": 17249, + "▁assess▁the▁effects▁of▁ZD4054": 17250, + "PERIMENTAL▁PLAN": 17251, + "hold▁dose▁until▁toxicity▁is▁": 17252, + "▁ELIGIBILITY": 17253, + "%,▁": 17254, + "(if": 17255, + "(neutrophils,▁": 17256, + ")\n\nC": 17257, + ").▁P": 17258, + ",▁third▁": 17259, + "-P": 17260, + "-18": 17261, + "-23": 17262, + "-paclitaxel": 17263, + "-and-": 17264, + "/in": 17265, + "/benefit": 17266, + "0)": 17267, + "1.3": 17268, + "8.0": 17269, + ":4": 17270, + ":6": 17271, + ":\n\nThe▁": 17272, + ":26": 17273, + ":29": 17274, + ":▁If": 17275, + "CVD": 17276, + "DG": 17277, + "EING": 17278, + "Handl": 17279, + "IX": 17280, + "I.V": 17281, + "KS": 17282, + "Multicenter": 17283, + "NO": 17284, + "N▁A": 17285, + "OD": 17286, + "Scor": 17287, + "Weight": 17288, + "because▁of": 17289, + "because▁": 17290, + "cu": 17291, + "cial▁": 17292, + "coh": 17293, + "critical▁": 17294, + "ee▁the▁": 17295, + "feet": 17296, + "feel": 17297, + "iro": 17298, + "let": 17299, + "lact": 17300, + "mab": 17301, + "methods▁of": 17302, + "method▁of": 17303, + "measure▁": 17304, + "nucle": 17305, + "o.": 17306, + "powder": 17307, + "rich": 17308, + "sch": 17309, + "trans": 17310, + "vein": 17311, + "–▁S": 17312, + "”▁and▁": 17313, + "≤1": 17314, + "▁kg": 17315, + "▁emergent": 17316, + "▁radical▁prostatectom": 17317, + "e▁In": 17318, + "in,▁": 17319, + "institut": 17320, + "inflammatory▁": 17321, + "influenc": 17322, + "▁turn": 17323, + "▁train": 17324, + "▁tired": 17325, + "on▁P": 17326, + "\n\n": 17327, + "\n\nis▁": 17328, + "\n\n40": 17329, + "\n\nadverse▁event": 17330, + "\n\n50%": 17331, + "▁ax": 17332, + "▁a▁study▁": 17333, + "er▁A": 17334, + "s▁6": 17335, + "s▁can": 17336, + "al▁cancer": 17337, + "stead": 17338, + "y▁M": 17339, + "entries▁": 17340, + "itron": 17341, + "▁the▁DMC": 17342, + ",▁8": 17343, + ",▁must▁be▁": 17344, + ",▁week": 17345, + ",▁Wh": 17346, + ",▁lung": 17347, + ",▁even▁if": 17348, + "rov": 17349, + "roat": 17350, + "rook": 17351, + "ed▁health": 17352, + "▁an▁interim": 17353, + "▁anytim": 17354, + "icl": 17355, + "ic▁or": 17356, + "icens": 17357, + ".▁or": 17358, + ".▁15": 17359, + "are▁m": 17360, + "ed▁and/or": 17361, + "ed.▁For": 17362, + "▁pregnanc": 17363, + "▁cardi": 17364, + "ing▁in▁the▁": 17365, + "ing▁this▁document": 17366, + "▁bl": 17367, + "for▁a": 17368, + "for▁any▁reason": 17369, + "eta": 17370, + "etoc": 17371, + "▁top": 17372, + "▁to▁an": 17373, + "▁to▁maintain": 17374, + "isation▁(": 17375, + "▁spec": 17376, + "▁of▁original": 17377, + "▁demographic": 17378, + "▁mM": 17379, + "▁mult": 17380, + "▁multicenter": 17381, + "▁and▁15": 17382, + "▁and▁fluorouracil": 17383, + "▁and▁Amgen": 17384, + "▁and▁platelet": 17385, + "▁and▁5-fluorouracil": 17386, + ".\n\n25": 17387, + ".\n\n24": 17388, + ".\n\n27": 17389, + ".\n\n(cid:120)": 17390, + ".\n\nIMMUNEX\n\nConfidential\n\nAMGEN\n\nProduct:▁ABX-EGF▁Protocol▁Number:▁20020408▁Amendment▁4▁Date:▁26▁April▁2005\n\nPage▁": 17391, + "mental": 17392, + "al▁outcom": 17393, + "olubl": 17394, + "is▁will▁be▁": 17395, + "▁Agent": 17396, + "▁induc": 17397, + "▁incorpor": 17398, + "urb": 17399, + "igm": 17400, + "▁Current": 17401, + "▁Calculated▁": 17402, + "es▁between": 17403, + "▁Product": 17404, + "▁Practic": 17405, + "▁Pre-": 17406, + "ilogram": 17407, + "▁(O": 17408, + "▁(Z": 17409, + "▁(c": 17410, + "▁(CRF": 17411, + "▁(CRC": 17412, + "▁(WBC": 17413, + "▁(that▁is": 17414, + "▁2▁cm": 17415, + "ifest": 17416, + "▁SI": 17417, + "▁Sh": 17418, + "▁Skeletal▁": 17419, + "▁Studies": 17420, + "ages": 17421, + "▁Date\n\n": 17422, + "▁hand": 17423, + "within▁the▁": 17424, + "▁l-L": 17425, + "appens": 17426, + "▁Ethics▁Committe": 17427, + "▁Eligibility▁": 17428, + "▁fill": 17429, + "▁found": 17430, + "▁find▁": 17431, + "ametric": 17432, + "amisol": 17433, + "irculation": 17434, + "uter": 17435, + "formula": 17436, + "therapies": 17437, + "\n\nPre-": 17438, + "exact": 17439, + "exclusion": 17440, + "expens": 17441, + "exploratory": 17442, + "pericardial▁effusion": 17443, + "\n\nAssessment": 17444, + "\n\nA▁little▁b": 17445, + "▁and▁tumor": 17446, + "▁and▁the▁same▁techniqu": 17447, + "▁as▁a▁single▁agent": 17448, + "▁project": 17449, + "▁promptly▁": 17450, + "▁T2": 17451, + "▁TNM": 17452, + "updated▁": 17453, + "▁for▁the▁purpose▁of": 17454, + "and▁a": 17455, + "e\n\n4": 17456, + "e\n\n6": 17457, + "romol/L": 17458, + ".2.6": 17459, + "avour": 17460, + "advanc": 17461, + "advis": 17462, + "antitumor": 17463, + "\n\nSome-▁what": 17464, + "▁that▁has▁": 17465, + "▁2002": 17466, + "▁is▁oblig": 17467, + "▁of▁9": 17468, + "▁of▁W": 17469, + "▁of▁zoledronic▁acid▁": 17470, + "▁of▁XRP6258": 17471, + "▁alkaline▁phosphat": 17472, + "e▁scal": 17473, + "e▁serum": 17474, + "e▁similar": 17475, + "e▁subjects▁who": 17476, + "e▁them": 17477, + "▁MED": 17478, + "▁rank": 17479, + "▁35%": 17480, + "▁of▁the▁sampl": 17481, + "e,▁s": 17482, + "e,▁including": 17483, + "▁compromis": 17484, + ".▁The▁following": 17485, + "▁as▁long": 17486, + "▁as▁part▁of▁the▁": 17487, + "200401": 17488, + "▁the▁shipment": 17489, + "▁are▁also": 17490, + ",▁and▁d": 17491, + ",▁and▁other": 17492, + "itioner": 17493, + "▁LS": 17494, + ".34": 17495, + ".37": 17496, + "▁BNP": 17497, + "▁BPI": 17498, + "▁this▁section": 17499, + "▁all▁study▁": 17500, + "uretic": 17501, + "ipp": 17502, + "▁staging": 17503, + "▁willing▁to": 17504, + "▁will▁remain": 17505, + "▁will\n\nbe▁": 17506, + "ing▁the▁first▁dose▁of": 17507, + "ity-of": 17508, + "▁63": 17509, + "▁6.2.1": 17510, + "▁Hyp": 17511, + "▁40%": 17512, + "▁the▁poss": 17513, + "amplification": 17514, + "\n\nPage▁1": 17515, + "s▁(a": 17516, + "▁the▁injection": 17517, + "▁acc": 17518, + "▁across▁": 17519, + "one▁number": 17520, + "egion": 17521, + "egally▁acceptable▁": 17522, + ".47": 17523, + ".4.4": 17524, + "▁study▁screening": 17525, + "s▁in▁this▁study": 17526, + "s▁in▁human": 17527, + "▁weeks,▁": 17528, + "▁any▁study▁": 17529, + "▁excess": 17530, + "register": 17531, + "▁whose▁": 17532, + "s▁and▁Definition": 17533, + "ed▁on▁Day▁1": 17534, + "e▁death": 17535, + "athyroid▁": 17536, + ".▁Sub": 17537, + ".▁STUDY": 17538, + "s▁will▁be▁maintain": 17539, + "▁Global▁": 17540, + "derly▁": 17541, + "ormal": 17542, + "),▁with": 17543, + "),▁including": 17544, + "s\n\nM": 17545, + "rimidine▁": 17546, + "▁notify▁": 17547, + "eterson": 17548, + "▁74": 17549, + "▁7▁days": 17550, + "▁adverse▁event▁report": 17551, + ".60": 17552, + ".63": 17553, + ".▁International▁": 17554, + "overn": 17555, + "s.\n\n4": 17556, + "s.\n\nAll": 17557, + ".▁Copies▁of": 17558, + ".▁Circulation": 17559, + "ALITY": 17560, + "parent": 17561, + ",▁or\n\n": 17562, + "CR▁or▁PR": 17563, + "ractitioner": 17564, + "radiological": 17565, + "patient▁hospitalization▁or": 17566, + "▁disease▁and▁": 17567, + "s▁should": 17568, + "s▁submitt": 17569, + "▁usual": 17570, + "▁each▁subject": 17571, + "pread": 17572, + "30▁mg": 17573, + "▁data▁collect": 17574, + "▁data▁monitoring": 17575, + "▁your▁body": 17576, + "▁your▁study▁doctor": 17577, + "▁to▁be▁us": 17578, + "▁a▁specific": 17579, + "▁cycles▁(": 17580, + "\n\nToxicity▁": 17581, + ".▁Determination▁of": 17582, + "▁the▁local": 17583, + "▁registration": 17584, + "completed.\n\n": 17585, + "▁WELL": 17586, + "e).": 17587, + "\n\nThe▁secondary▁": 17588, + "\n\n4.3": 17589, + "e▁blood": 17590, + "e▁barrier": 17591, + "\n\nIEC": 17592, + "\n\nIRB": 17593, + "▁visit▁the▁": 17594, + "defined▁by▁": 17595, + "ystic▁lesion": 17596, + "s▁or▁worsen": 17597, + "▁was▁removed▁from▁the▁": 17598, + "results▁from": 17599, + "fluoropyrimidin": 17600, + "equence▁": 17601, + "condom": 17602, + "doses▁": 17603, + "Ant": 17604, + "provided▁in▁Appendix": 17605, + "prior▁to▁each": 17606, + "ed▁and▁document": 17607, + "ed▁and▁dated▁": 17608, + "▁overdos": 17609, + "▁13.1": 17610, + "performance▁of": 17611, + ".▁2004;": 17612, + "considered▁an": 17613, + "▁complete▁a": 17614, + "discontinuation▁of": 17615, + "▁approximately▁12": 17616, + ",▁PAX": 17617, + "▁subtyp": 17618, + "▁their▁size▁(": 17619, + "▁indication": 17620, + "ed\n\nin": 17621, + "▁occurred": 17622, + "▁response▁(": 17623, + ",▁should▁be▁": 17624, + ",▁sunitinib": 17625, + "arrativ": 17626, + "▁drug▁product": 17627, + "▁during▁a": 17628, + "▁non-mut": 17629, + ",▁Cold": 17630, + "▁local▁procedures": 17631, + "observed▁to": 17632, + "1-6": 17633, + "▁(AMG▁162": 17634, + "1)▁(cid:": 17635, + "s,▁an": 17636, + "e▁month": 17637, + "\n\nBy▁": 17638, + "\n\nBefore▁": 17639, + "mergency▁": 17640, + "▁information▁sheet": 17641, + "▁receive▁treatment": 17642, + "end▁of▁study": 17643, + "▁to▁establish": 17644, + "IV)": 17645, + "▁this▁test": 17646, + ".\n\nThe▁patient": 17647, + ",▁Arb": 17648, + "was▁not": 17649, + "▁the▁treatment▁of▁": 17650, + "▁the▁treatment▁arm": 17651, + "▁the▁treatment▁assignment": 17652, + "obtained▁prior▁to": 17653, + "▁determination▁of": 17654, + "22)(cid:": 17655, + ",▁Hu": 17656, + ",▁Harris▁WS": 17657, + "rates": 17658, + "ospital▁or": 17659, + "▁radiologic": 17660, + "dihyd": 17661, + "diagnostic": 17662, + "information▁about": 17663, + "shipment": 17664, + "\n\nAn▁adverse▁event": 17665, + "▁available▁to": 17666, + "▁plus▁BSC": 17667, + "ite▁a▁bit": 17668, + "▁within▁3": 17669, + "ed▁caus": 17670, + "▁assessing": 17671, + "ophen": 17672, + ",▁Dawson-Hughes▁B": 17673, + "used▁to▁assess▁": 17674, + "s▁at▁any▁time▁": 17675, + "▁by▁a": 17676, + "▁every▁other": 17677, + ".2.2.2": 17678, + "\n\nX\n\nX\n\nX\n\nX\n\nX": 17679, + "▁randomized▁to": 17680, + "alysis▁Subset": 17681, + "\n\nAppendix▁X": 17682, + "analysis▁of▁the▁": 17683, + "▁hypo": 17684, + "▁hypercalcemia": 17685, + "fractur": 17686, + "diction": 17687, + "indicator": 17688, + "▁+1": 17689, + "ing▁and▁Data▁Collection": 17690, + "DMC▁member": 17691, + ".▁Oxaliplatin": 17692, + "ing▁system": 17693, + "▁the▁blood": 17694, + "▁Physical▁Examination": 17695, + "rofil": 17696, + "▁and▁safety▁": 17697, + ",▁Ros": 17698, + "▁overall▁survival▁(OS": 17699, + "▁docetaxel-based▁chemotherapy▁regimen": 17700, + "\n\n13.1": 17701, + "▁prior▁to▁disease▁progression": 17702, + "Proof▁of": 17703, + ".,▁et▁al.,▁C": 17704, + "▁they▁have▁": 17705, + "ecause▁th": 17706, + "PDGFR": 17707, + "RPC": 17708, + "more▁frequ": 17709, + "measured▁and▁": 17710, + "▁MedDRA": 17711, + "were▁d": 17712, + "▁days▁after▁the▁last▁dose▁of": 17713, + "ultiplic": 17714, + "representatives▁from": 17715, + "FACT-B": 17716, + "serum▁calcium": 17717, + "▁are▁not▁limited▁to": 17718, + "persons": 17719, + "ed▁method": 17720, + "e▁Panitumumab": 17721, + "▁cisplatin▁plus▁": 17722, + "ATE": 17723, + "atchful": 17724, + "▁confin": 17725, + "▁risk▁reduction": 17726, + ",▁New": 17727, + "▁▁": 17728, + "on▁the▁CRF": 17729, + "▁markers▁of": 17730, + "▁performance▁status▁": 17731, + "▁manual": 17732, + "censored▁using▁the▁": 17733, + "▁carboplatin▁infusion": 17734, + "▁subjects▁who▁have▁": 17735, + "resolved▁to": 17736, + "pharmacy▁": 17737, + "▁applicable▁sit": 17738, + ".\n\n2.3": 17739, + "procedures▁and▁": 17740, + "procedures▁are▁": 17741, + "optional▁": 17742, + "secondary": 17743, + "Evaluations": 17744, + "272−636.4.0": 17745, + "held▁for": 17746, + "▁To▁be▁": 17747, + "▁any▁other▁reason": 17748, + "▁reduced▁": 17749, + "▁alone▁or": 17750, + "ate,▁BUN": 17751, + "▁discontinuation▁from▁study▁treatment": 17752, + "▁terminate▁the▁": 17753, + "ed▁according▁to▁treatment": 17754, + "\n\nWBC": 17755, + "schedule▁of": 17756, + "▁Perform": 17757, + ",▁O'": 17758, + "EPLAC": 17759, + "rectum": 17760, + "work▁activities.▁Up▁and▁about": 17761, + "assignment": 17762, + "see▁Table▁": 17763, + "▁pemetrexed▁plus▁cisplatin": 17764, + "objective▁progression": 17765, + "judged▁to▁be▁": 17766, + "▁March▁2006": 17767, + ".▁Exclusion▁Criteria": 17768, + "▁Followed▁by▁M": 17769, + "delayed▁until": 17770, + "▁contact▁with": 17771, + "used▁throughout▁the▁study": 17772, + "▁Access": 17773, + "▁you▁are▁pregnant": 17774, + "▁use▁an": 17775, + "▁work▁of▁a▁light▁or▁sedentary▁n": 17776, + "▁Tumor▁Response▁": 17777, + "▁Committee▁on": 17778, + "mon▁Toxicity▁": 17779, + "▁antibodies▁to": 17780, + "▁evidence▁of▁disease▁progression": 17781, + "PTH": 17782, + "histology": 17783, + "keletal▁surv": 17784, + "e▁should": 17785, + "at▁a▁minimum": 17786, + "received▁prior": 17787, + "omega-3▁fatty▁acid▁": 17788, + "▁diarrhea▁(": 17789, + "randomisation": 17790, + "▁Sampling": 17791, + "biops": 17792, + "biological": 17793, + "light▁h": 17794, + "selected▁": 17795, + ".\n\nAdverse▁event": 17796, + "▁make▁s": 17797, + "▁administered▁over": 17798, + "▁will▁not▁be\n\n": 17799, + "▁Overall▁Response▁": 17800, + "▁participating▁in": 17801, + "second▁interim": 17802, + "General": 17803, + "▁coincid": 17804, + "ABX-EGF▁arm": 17805, + "ietary▁": 17806, + "▁attribut": 17807, + ".▁Each▁vial": 17808, + ".▁Respon": 17809, + "▁endothelial▁cell": 17810, + ".▁Kaplan-Meier": 17811, + "vascularization": 17812, + "Non-Small▁Cell▁Lung▁Cancer": 17813, + "▁measurable▁lesions▁": 17814, + "▁the▁informed▁consent▁document": 17815, + "al▁sourc": 17816, + ".\n\nIt": 17817, + "▁d▁o": 17818, + "▁Procedures▁": 17819, + "lower▁than": 17820, + "ed▁March": 17821, + "▁organ▁clas": 17822, + "▁confidentiality": 17823, + "e▁include▁": 17824, + "ella▁F": 17825, + ".▁Pharmacokinetic": 17826, + "hemistry▁panel:▁sodium,▁potassium,▁chloride,▁bicarbon": 17827, + "▁positive▁benefit": 17828, + "▁one▁of▁the▁following": 17829, + "OPG": 17830, + ".\n\n.▁E▁S▁U\n\nE▁R▁O▁F▁E▁B\n\nY▁T▁I▁D▁I▁L▁A▁V": 17831, + "▁0.85": 17832, + "ince▁this▁": 17833, + "withdrawn▁from▁the▁study▁": 17834, + "superior▁to": 17835, + "▁stable▁diseas": 17836, + "▁tumor▁cells▁and▁the▁proposed▁mechanism▁of▁action": 17837, + "2007;": 17838, + "number▁of▁event": 17839, + "uoropyrimidine▁": 17840, + "ematology▁panel:": 17841, + "▁log-rank▁test": 17842, + "yroid": 17843, + "▁Cox▁model": 17844, + "▁Cox▁regression▁model": 17845, + "▁locally▁advanced▁": 17846, + "probabl": 17847, + "duration▁of▁response▁(": 17848, + "▁Definitions": 17849, + "▁AND▁REPLAC": 17850, + "▁SAMPLE": 17851, + ",▁we▁will▁have▁": 17852, + "▁take▁part▁in": 17853, + "\n\nFollow-up": 17854, + "(5):": 17855, + "Neutropenia": 17856, + "▁and▁tolerability▁": 17857, + "▁a▁central▁laboratory": 17858, + "▁End▁of▁Study▁": 17859, + "able▁safety▁": 17860, + "▁reasons▁other▁than▁PD": 17861, + "▁and▁Tim": 17862, + "\n\nProtocol▁Attachment▁JMHO": 17863, + "▁(ANC▁<": 17864, + "ed▁about▁the▁": 17865, + "ef▁Pain▁Inventory▁": 17866, + "▁superficial": 17867, + "(9):": 17868, + "▁boundary▁": 17869, + "Monitoring▁and▁Data▁Collection": 17870, + "distribut": 17871, + "▁HAHA": 17872, + "\n\nIVRS": 17873, + "▁corresponds▁to": 17874, + "MOVAL": 17875, + "▁exceed▁10": 17876, + "pedited▁reporting": 17877, + "▁tyrosine▁kinase▁inhibitor": 17878, + "communic": 17879, + "Study▁Team▁Physician": 17880, + "randomly": 17881, + "cardiovascular▁mortality": 17882, + "▁concentration▁of": 17883, + "▁contraception": 17884, + "\n\nFigure▁1": 17885, + "reported▁as▁an▁AE": 17886, + "▁association▁with": 17887, + "\n\nStudy▁Design\n\nThis▁": 17888, + "▁hemorrhage▁": 17889, + "loss▁of▁appetit": 17890, + "▁synerg": 17891, + "▁half-lif": 17892, + "▁deemed▁": 17893, + "pen-Label▁Treatment": 17894, + "▁in▁Section▁4.7.1.1": 17895, + "imm▁EB": 17896, + "irradiated▁": 17897, + "compris": 17898, + "itz▁GA": 17899, + "anine▁transamin": 17900, + "quartiles,▁and▁": 17901, + "\n\nRestricted▁in▁physically▁strenuous": 17902, + "\n\nthe▁investigator": 17903, + "▁reasonable▁possibility▁that▁the▁event▁may▁have▁been▁caused▁by": 17904, + "▁staining": 17905, + "EMENT▁OF▁S": 17906, + "stead▁of": 17907, + "participating▁in▁the▁PACCE▁protocol": 17908, + "MINISTRATIVE▁AND▁L": 17909, + "▁proliferation": 17910, + "▁Rationale▁": 17911, + "▁interstitial▁lung": 17912, + "li▁Lilly▁and▁Company▁": 17913, + "certification": 17914, + "\n\nVery▁much": 17915, + "heumatoid": 17916, + "(11):": 17917, + "▁a▁safety▁follow-up▁visit": 17918, + "PONSOR": 17919, + "▁dysfunction": 17920, + "▁Worksheet": 17921, + "▁to▁verify": 17922, + "embrane▁": 17923, + "-Free▁Survival": 17924, + "▁always▁be▁": 17925, + "ultivariate▁": 17926, + "addition▁of▁panitumumab▁to▁chemotherapy▁(": 17927, + "rhythmia": 17928, + "gressive▁Disease▁(PD):": 17929, + "EGAL▁OBLIGATIONS": 17930, + ".9%▁Sodium▁Chloride▁Injection": 17931, + "idiarr": 17932, + "essential▁for": 17933, + "onychia": 17934, + ".▁Qualifications▁for": 17935, + "RING": 17936, + "accurately▁measured▁in": 17937, + "robust": 17938, + "▁he/sh": 17939, + "EASUREMENTS": 17940, + "correlated▁with": 17941, + "Notification▁Worksheet": 17942, + "\n\nComplete▁Response▁(CR):": 17943, + "rate▁for▁solution▁for▁infusion": 17944, + "ERMINATION▁OF": 17945, + "▁of▁63▁Finalization▁date:▁June▁19▁2001,▁Incorporating▁amendment▁3▁–▁dated▁23▁May,▁200": 17946, + "\n\nQuite▁a▁bit": 17947, + "articulate▁matter": 17948, + "arget▁lesions▁should▁be▁selected▁on▁the▁basis▁of": 17949, + "epherd▁": 17950, + "elegation▁of▁Authority▁Form": 17951, + "etoconazol": 17952, + "\n\nA▁little▁bit": 17953, + "▁the▁possibility▁of": 17954, + "▁was▁removed▁from▁the▁regimen": 17955, + ",▁Colditz▁GA": 17956, + ",▁Arbuck": 17957, + "Proof▁of▁Receipt": 17958, + "atchful▁wait": 17959, + "censored▁using▁the▁last": 17960, + "▁Followed▁by▁Maintenance▁": 17961, + "▁measurable▁lesions▁up▁to▁a▁maximum": 17962, + "▁AND▁REPLACEMENT▁OF▁S": 17963, + "MOVAL▁AND▁REPLACEMENT▁OF▁S": 17964, + "MINISTRATIVE▁AND▁LEGAL▁OBLIGATIONS": 17965, + "MOVAL▁AND▁REPLACEMENT▁OF▁SUBJECTS": 17966, + "%\n\n0": 17967, + "(except": 17968, + ")▁after": 17969, + "),\n\n": 17970, + ")▁within": 17971, + "),▁and▁the▁": 17972, + ",4": 17973, + ",8": 17974, + ",▁any": 17975, + "-16": 17976, + "-65": 17977, + "/kg": 17978, + "2-sided▁": 17979, + "3▁d": 17980, + "4.": 17981, + "4.0": 17982, + "6▁cycles▁of": 17983, + "7.1": 17984, + ":▁•": 17985, + ";▁": 17986, + ";▁if": 17987, + "ACR": 17988, + "Agent": 17989, + "C225": 17990, + "Cockcroft▁and▁Gault": 17991, + "DB": 17992, + "DM": 17993, + "EK": 17994, + "E,▁S": 17995, + "ERIO": 17996, + "Eastern▁Cooperative▁Oncology▁Group": 17997, + "EORTC▁QLQ-C30": 17998, + "Functional▁Assessment▁of▁Cancer▁Therapy▁": 17999, + "Functional▁Assessment▁of▁Cancer▁Therapy": 18000, + "Gill": 18001, + "HNC": 18002, + "ImClone▁": 18003, + "I▁am": 18004, + "KM": 18005, + "Long": 18006, + "N▁A\n\nF▁O": 18007, + "Power": 18008, + "TR": 18009, + "VITAL": 18010, + "YY": 18011, + "auc": 18012, + "bronch": 18013, + "code▁": 18014, + "covari": 18015, + "capecitabin": 18016, + "counter": 18017, + "dated▁in": 18018, + "darbepoetin▁alfa": 18019, + "days▁": 18020, + "eav": 18021, + "fast": 18022, + "favorable▁": 18023, + "get": 18024, + "mount": 18025, + "ny▁": 18026, + "natur": 18027, + "ooxygen": 18028, + "palliative▁": 18029, + "pase-": 18030, + "public": 18031, + "rurit": 18032, + "specimen": 18033, + "uit": 18034, + "ufficient": 18035, + "void": 18036, + "wt": 18037, + "wy": 18038, + "web": 18039, + "wash": 18040, + "would": 18041, + "y;": 18042, + "yg": 18043, + "y▁are▁": 18044, + "“other": 18045, + "▁................": 18046, + "▁et": 18047, + "▁e▁v": 18048, + "▁®\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁Panitumumab▁Protocol▁Number:▁20050251▁Date:▁10▁October▁2006\n\nPage▁": 18049, + "▁outsid": 18050, + "e▁cell": 18051, + "inski": 18052, + "▁type▁": 18053, + "ated▁based▁on": 18054, + "\n\ncancer": 18055, + "\n\nreview": 18056, + "\n\nanalys": 18057, + "\n\nsubjects▁": 18058, + "enberg": 18059, + "erated▁lung": 18060, + "or▁leg": 18061, + "oradic": 18062, + "s▁5": 18063, + "s▁is": 18064, + "s▁you": 18065, + "reed": 18066, + "y▁with▁the▁": 18067, + "ionucl": 18068, + "it▁is": 18069, + "itating": 18070, + "▁the▁Sponsor": 18071, + "▁the▁original": 18072, + "▁the▁IEC/IRB": 18073, + "an-": 18074, + ",▁first": 18075, + ",▁provid": 18076, + ",▁may▁be▁": 18077, + ",▁Ad": 18078, + ",▁standard▁": 18079, + ",▁platelet": 18080, + "▁an▁individual": 18081, + "▁an▁abnormal▁": 18082, + ".▁Y": 18083, + ".▁14": 18084, + ".▁ECOG": 18085, + "ar-": 18086, + "ed▁tumour": 18087, + "▁prim": 18088, + "▁panel": 18089, + "▁pump": 18090, + "▁pellet]": 18091, + "▁cop": 18092, + "▁cert": 18093, + "▁cynomolgus▁mon": 18094, + "▁be:": 18095, + "esid": 18096, + "escent": 18097, + "eton": 18098, + "et▁forth": 18099, + "▁to▁another": 18100, + "▁together▁with": 18101, + "is▁a▁m": 18102, + "isolon": 18103, + "▁sex": 18104, + "▁secondary": 18105, + "▁scientific": 18106, + "▁safety,▁": 18107, + "ased▁": 18108, + "asian": 18109, + "▁offic": 18110, + "▁of▁two": 18111, + "▁of▁previous▁dos": 18112, + "ouill": 18113, + "▁warrant": 18114, + "▁mand": 18115, + "▁mild": 18116, + "▁mCRPC": 18117, + "▁and▁A": 18118, + "▁and▁clinical▁": 18119, + "▁and▁has▁been": 18120, + "▁and▁final": 18121, + "ected▁": 18122, + ".\n\n18": 18123, + ".\n\n28": 18124, + "illi": 18125, + "is▁responsible▁for": 18126, + "▁AT": 18127, + "ive,▁": 18128, + "ocrine▁": 18129, + "▁1▁month": 18130, + "▁Cal": 18131, + "▁Colon": 18132, + "oscl": 18133, + "osis▁or": 18134, + "est▁X-ra": 18135, + "es▁must": 18136, + "▁Publication": 18137, + "proxim": 18138, + "progres": 18139, + "▁(7": 18140, + "▁(excluding": 18141, + "eman": 18142, + "▁2nd▁": 18143, + "iff": 18144, + "▁IHC": 18145, + "oto": 18146, + "agu": 18147, + "agic": 18148, + "▁DJ": 18149, + "▁DATA": 18150, + "▁lot": 18151, + "▁lost": 18152, + "▁loper": 18153, + "▁ER": 18154, + "▁fall": 18155, + "▁field": 18156, + "ampt": 18157, + "among": 18158, + "verifi": 18159, + "challeng": 18160, + "▁or▁breast": 18161, + "▁or▁rect": 18162, + "▁or▁drug▁delivery▁system": 18163, + "e▁termin": 18164, + "yself": 18165, + "formation▁of": 18166, + "\n\nPrinted▁copy▁is▁not▁official▁record": 18167, + "ized▁s": 18168, + "external▁": 18169, + "ecret": 18170, + "istribut": 18171, + "per-": 18172, + "▁and▁abdomen": 18173, + "▁ascertain": 18174, + "▁as▁appropriate": 18175, + "▁progres": 18176, + "alling": 18177, + "▁Translational▁Research": 18178, + "▁adv": 18179, + "▁aris": 18180, + "▁Rel": 18181, + "▁RNA": 18182, + "▁Refer": 18183, + "ed▁in▁this▁document": 18184, + "mineral": 18185, + "Ind": 18186, + "Independent": 18187, + "\n\nSelection": 18188, + "▁that▁particular": 18189, + "▁alcoh": 18190, + "e▁safety": 18191, + "e▁see▁Section": 18192, + "e▁the▁sampl": 18193, + "▁0.2": 18194, + "▁3▁days)": 18195, + "▁conven": 18196, + "▁of▁the▁drug": 18197, + "context": 18198, + "▁FWB": 18199, + ".▁Ac": 18200, + ".▁As": 18201, + ".▁A▁subject": 18202, + ".▁The▁purpose▁of": 18203, + "▁as▁it": 18204, + "▁gu": 18205, + "▁global": 18206, + "hould▁not": 18207, + "2005;": 18208, + "▁on▁Days▁": 18209, + "▁ventricular": 18210, + "▁volunteer": 18211, + "▁Lead▁": 18212, + ".35": 18213, + "s,▁but": 18214, + "▁therefor": 18215, + "▁stabil": 18216, + "▁chosen": 18217, + "▁chemoradi": 18218, + "▁willingness▁to": 18219, + "followed▁by▁a": 18220, + "ing▁the▁t": 18221, + "▁59": 18222, + "▁5.7": 18223, + "will▁occur": 18224, + "from▁the▁study▁": 18225, + "▁HNC": 18226, + "▁H&E": 18227, + "and▁m": 18228, + "▁subject▁with": 18229, + "▁the▁post": 18230, + "▁the▁paclitaxel": 18231, + "▁the▁pregnancy▁": 18232, + "▁the▁package▁insert": 18233, + ")\n\n2": 18234, + ")\n\n[": 18235, + "▁at\n\n": 18236, + "▁at▁the▁tim": 18237, + "▁at▁the▁first": 18238, + "▁at▁the▁time▁of▁the▁": 18239, + "s▁(longest▁diameter": 18240, + "▁study▁will▁be▁": 18241, + "identical": 18242, + "s▁inter": 18243, + "s.▁F": 18244, + "s.▁R": 18245, + "s.▁T": 18246, + "▁weeks▁and▁": 18247, + "consisting": 18248, + "elling": 18249, + "ation▁of▁data": 18250, + "▁patients▁that": 18251, + "▁the▁det": 18252, + "reported▁by▁": 18253, + "reporting▁of": 18254, + "e▁the▁Efficacy▁of": 18255, + ".▁Postdiscontinuation": 18256, + "\n\nEfficacy▁Analysis▁Set": 18257, + "▁Interim": 18258, + "▁Individual▁": 18259, + "s\n\nH": 18260, + "s\n\nof": 18261, + ".▁The▁tim": 18262, + "on-study": 18263, + "▁may▁requir": 18264, + "▁dose.\n\n": 18265, + "press▁": 18266, + "(cid:11": 18267, + "may▁not": 18268, + "e▁vitamin▁D": 18269, + "sertion": 18270, + "▁analysis▁data▁cut-off": 18271, + ".▁In▁the▁case▁of": 18272, + ".▁Estim": 18273, + ".▁Erlotinib": 18274, + "recorded.\n\n": 18275, + ",▁and▁to": 18276, + "113": 18277, + "ALU": 18278, + ".▁Tissu": 18279, + "ed▁within▁the▁": 18280, + "’s▁b": 18281, + "▁x▁upper": 18282, + "205-": 18283, + ",▁or▁m": 18284, + "▁disease▁assessment": 18285, + "investigator▁will": 18286, + "▁92": 18287, + "▁9.4.1": 18288, + "▁85": 18289, + "▁85▁mg/m2": 18290, + "e▁(or": 18291, + "first-lin": 18292, + "\n\nProduct:▁darbepoetin▁alfa▁Protocol▁Number:▁20010145▁–▁Amendment▁2▁Date:▁16▁July▁2004\n\nPage▁": 18293, + "\n\nNA*": 18294, + "premedic": 18295, + "every▁12▁week": 18296, + ").\n\n10": 18297, + "...................................................................................▁": 18298, + "▁formulation": 18299, + "basis▁for": 18300, + "▁the\n\nIEC/IRB": 18301, + "▁predominantly▁s": 18302, + "ed▁as▁follows:": 18303, + "assification": 18304, + "despite▁": 18305, + "▁a▁screening": 18306, + "14-": 18307, + "\n\nTable▁of▁Content": 18308, + "▁the▁patient▁must▁be▁": 18309, + "responses▁": 18310, + "responsibilities▁": 18311, + ".▁Disease▁": 18312, + "completed▁at": 18313, + "▁WIT": 18314, + "\n\n4.9": 18315, + ".▁Form": 18316, + "▁consumption": 18317, + "data,▁": 18318, + "I-L": 18319, + ".\n\nPlease▁": 18320, + "e▁becom": 18321, + "13]": 18322, + "\n\nImmun": 18323, + ",▁Safety▁": 18324, + "▁panitumumab▁or": 18325, + "ystolic": 18326, + "linding": 18327, + "LCSS": 18328, + "s▁or▁s": 18329, + "performed▁using▁the▁": 18330, + "equential": 18331, + "▁deaths▁": 18332, + "ures,▁": 18333, + "▁30▁mg": 18334, + "▁evaluation▁of": 18335, + "▁sample,▁": 18336, + "ative▁treatment": 18337, + ".▁Reg": 18338, + ".▁Refer▁to▁Section": 18339, + "you▁will▁be▁asked▁to": 18340, + "▁cells▁in": 18341, + "▁completion▁of": 18342, + "\n\nHemoglobin": 18343, + "NA**": 18344, + "ed.\n\n5": 18345, + "ed.\n\n9": 18346, + ",▁Pat": 18347, + "Standard▁": 18348, + "\n\n\n\nIf": 18349, + "▁CTX": 18350, + "disease▁(": 18351, + "▁modul": 18352, + "ed\n\nfor": 18353, + "▁analysis▁and▁": 18354, + "▁continuous▁infusion": 18355, + "▁occurs▁prior▁to": 18356, + "disposition": 18357, + "..................................................": 18358, + "169": 18359, + ".▁Hy": 18360, + ".▁Har": 18361, + ".2.1.2": 18362, + "▁must▁ensure▁that": 18363, + "observed▁at": 18364, + "▁releas": 18365, + "1-3": 18366, + "▁(AUC": 18367, + "\n\nInt": 18368, + ",▁breast": 18369, + "risks▁associated▁with": 18370, + "\n\nBone▁": 18371, + "\n\nBefor": 18372, + "▁this▁tim": 18373, + "when▁the▁": 18374, + "▁advanced,▁": 18375, + "▁advanced▁s": 18376, + "▁advanced▁breast▁cancer": 18377, + "blinding": 18378, + "▁change▁": 18379, + ".▁J▁Natl▁Cancer▁Inst": 18380, + "▁effect▁of": 18381, + "...............................................................................▁": 18382, + "well-being": 18383, + "▁intensity▁": 18384, + "must▁sign": 18385, + "▁a▁caus": 18386, + "▁K:": 18387, + ".▁Im": 18388, + "ramp": 18389, + "start▁of▁treatment": 18390, + "▁investigational▁product▁will▁be▁": 18391, + "▁has▁been▁reported▁in": 18392, + "\n\nLong": 18393, + "\n\nLaboratory": 18394, + ",▁et▁al.▁Cetuximab": 18395, + "eau": 18396, + "determined▁from": 18397, + "determined▁that": 18398, + "▁transport": 18399, + "s▁at▁least": 18400, + "mClone": 18401, + "identified▁as▁target▁lesion": 18402, + "Compli": 18403, + "\n\n5.3": 18404, + "country": 18405, + "\n\nsurvival": 18406, + "▁14▁days▁prior▁to▁randomization": 18407, + "proven": 18408, + "▁verify": 18409, + "431": 18410, + ",▁Lee▁J": 18411, + "\n\nAppendix▁E": 18412, + "\n\nAppendix▁G": 18413, + "\n\nAppendix▁XIV▁Page▁": 18414, + "▁undergoing": 18415, + "▁the▁event▁of": 18416, + "causality": 18417, + "▁QoL": 18418, + "▁assigned▁treatment": 18419, + "▁KRAS▁mutation": 18420, + "\n\nOxaliplatin": 18421, + "▁between▁1▁and▁": 18422, + "▁pain▁control": 18423, + "TA▁visit": 18424, + "▁Adverse▁Events": 18425, + "▁Treatment▁Group": 18426, + "attach": 18427, + "▁long-term▁follow-up": 18428, + "▁observed": 18429, + "▁sporadic": 18430, + "ECOG▁PS": 18431, + "▁advanced▁gastric▁cancer": 18432, + "▁when▁the▁": 18433, + "▁pemetrexed▁infusion": 18434, + "70▁and▁": 18435, + ".▁Laboratory▁": 18436, + "withdraw▁from": 18437, + "more▁sever": 18438, + "recommended": 18439, + "▁acceptabl": 18440, + "ed▁(eg,▁": 18441, + "urgery▁": 18442, + "awel▁J": 18443, + "monitored▁for": 18444, + ",▁1998": 18445, + "▁No.▁": 18446, + "▁meeting▁the▁": 18447, + "▁of▁126\n\n": 18448, + "▁during▁the▁treatment▁phas": 18449, + "▁subsequently▁": 18450, + "serum▁creatinine▁": 18451, + "mission▁Form": 18452, + "ed▁measurable▁": 18453, + ".▁1997;": 18454, + "has▁been▁observed▁in": 18455, + "operable▁": 18456, + "%)▁patient": 18457, + "▁Subject▁incidence▁of": 18458, + "e▁tumor▁assessment": 18459, + "optim": 18460, + "▁personal▁": 18461, + "\n\nVEGF": 18462, + "▁the▁full": 18463, + "cases▁": 18464, + "..........................................": 18465, + "protein▁expression": 18466, + "▁Enrollment": 18467, + "ed,▁all": 18468, + "infus": 18469, + "olerated▁": 18470, + "▁only▁if": 18471, + "▁January▁": 18472, + "▁typically▁": 18473, + "red▁blood▁cell": 18474, + "compare▁": 18475, + "remainder": 18476, + "▁objective▁response▁rat": 18477, + "▁does▁not▁meet": 18478, + "▁individual▁patient": 18479, + "▁cediranib▁in▁combination▁with▁FOLFOX": 18480, + "e▁the▁sam": 18481, + "dehydration": 18482, + "latter": 18483, + "▁4▁weeks,▁": 18484, + "▁environment": 18485, + "▁NCI-": 18486, + "reported▁lesion": 18487, + "control▁group": 18488, + "requiring▁": 18489, + "ually▁for": 18490, + "ed▁according▁to▁local": 18491, + "▁provide▁an": 18492, + "▁key▁": 18493, + "measured▁by▁the▁": 18494, + "▁the▁subject’s▁clinical▁": 18495, + "calculated▁from": 18496, + "LD▁of▁target▁lesion": 18497, + "g/ml": 18498, + "▁the▁primary▁analysis▁of": 18499, + "s,▁or▁other": 18500, + "outlined▁in": 18501, + "meaningful": 18502, + "▁qualify": 18503, + "ertiary▁": 18504, + "▁Following": 18505, + ".▁Subjects▁with": 18506, + "▁serious▁adverse▁event▁information": 18507, + "ed▁by▁aerated▁lung": 18508, + "combination▁with": 18509, + ".▁Thereafter": 18510, + "yndrome▁(": 18511, + "▁discuss": 18512, + "\n\ni\n\n": 18513, + "............................": 18514, + "▁minutes▁on▁Day▁1": 18515, + "escalated▁to": 18516, + "’s▁assessment": 18517, + "▁of▁119\n\n": 18518, + "validated▁": 18519, + "Testing": 18520, + "▁investigative▁sit": 18521, + "▁ask▁question": 18522, + "\n\nx▁x▁x\n\nx▁x▁x": 18523, + "▁Monitoring▁Committee": 18524, + "ackground": 18525, + "compliant": 18526, + "randomised▁to": 18527, + "volume▁": 18528, + ",▁von▁P": 18529, + "dentification": 18530, + "earliest": 18531, + "▁bone▁turnover▁marker": 18532, + "coordinating▁investigator": 18533, + "▁......................................................................": 18534, + "General▁": 18535, + "astric▁Cancer": 18536, + "e▁dose▁by▁": 18537, + "▁patients▁(pts)▁with": 18538, + "s.▁These▁": 18539, + "▁Denosumab▁Protocol▁Number:▁20050136▁Date:▁30▁April▁2008": 18540, + "Investigator’s▁Agreement": 18541, + "vascular▁endothelial▁growth▁factor": 18542, + "▁Planned▁Methods▁of": 18543, + "\n\nPrimary▁Objectiv": 18544, + "▁Healthcare▁": 18545, + "▁normal▁limit": 18546, + "stitutional▁Review▁Board▁": 18547, + "e▁during▁the▁study": 18548, + "s.▁If▁the▁": 18549, + "ohn’s▁": 18550, + "▁of▁98\n\n": 18551, + "likely▁to▁be▁": 18552, + "▁the▁intervention": 18553, + "ordinator": 18554, + "\n\nAmgen▁Thousand▁Oaks\n\nConfidential\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁AMG▁162▁Protocol▁Number:▁20040135▁Date:▁14▁November▁2006\n\nPage▁": 18555, + "▁liver▁metastases▁": 18556, + "variable▁": 18557, + "▁to▁avoid▁": 18558, + "sufficiently▁": 18559, + "drawn▁from": 18560, + "▁lymphocyt": 18561, + "\n\nCompletely▁disabled.▁Cannot": 18562, + "▁(depending▁on": 18563, + "▁malignancy▁": 18564, + "Manual": 18565, + ",▁chills,▁": 18566, + "▁Monitoring▁Committee▁(DMC": 18567, + "icroar": 18568, + "elvic": 18569, + "elvis▁": 18570, + "resectable,▁": 18571, + "▁decrease▁in▁the▁sum▁of▁the▁": 18572, + "Association": 18573, + ".▁Within": 18574, + "▁continuous▁daily▁": 18575, + "▁these▁side▁effect": 18576, + "▁the▁information▁provid": 18577, + "\n\nDiscontinuation▁of": 18578, + "▁expected▁to": 18579, + "elani": 18580, + "Analyses▁": 18581, + "boembolism": 18582, + "▁regular▁interval": 18583, + "\n\n75%\n\n75%": 18584, + "▁microar": 18585, + "▁refus": 18586, + "standard▁of▁care": 18587, + "▁three▁week": 18588, + "▁Procedures▁for▁All": 18589, + "▁95%▁CI:▁0": 18590, + "▁birth▁control": 18591, + "▁x-ray": 18592, + "anticipated▁": 18593, + "end▁date▁": 18594, + "oluntary▁": 18595, + "▁2.5▁mg/kg": 18596, + "ackaging▁and▁": 18597, + ";▁(3)": 18598, + "could▁be▁": 18599, + "body▁system": 18600, + "s▁(or▁sites▁of▁diseas": 18601, + "▁minimize▁the▁": 18602, + "\n\n2\n\n2\n\n2\n\n2": 18603, + "\n\n(cid:131)": 18604, + "e▁subscale▁scor": 18605, + "contraceptive▁": 18606, + "▁internal": 18607, + "coloration": 18608, + "▁explore▁": 18609, + "▁explore▁the▁": 18610, + ".▁General▁": 18611, + "▁Background▁and▁Significance:": 18612, + "ixed▁effect": 18613, + "e▁significant": 18614, + "e▁intervention": 18615, + "emperature": 18616, + "ossella▁F": 18617, + "▁choic": 18618, + "ated▁benefit": 18619, + "],▁[": 18620, + "▁CBC,▁differential": 18621, + "intended▁to": 18622, + "over▁the▁36-month▁evaluation▁period": 18623, + "\n\nRecording▁of": 18624, + "rounded▁by▁aerated▁lung": 18625, + "▁2-sided▁95%▁confidence▁interval": 18626, + "Schedule▁(Attachment": 18627, + "▁Biomarker▁Development": 18628, + "▁communication": 18629, + "▁carry▁on▁any▁s": 18630, + "Oral▁Rectal▁Oral▁Rectal▁": 18631, + "▁Acid▁": 18632, + "▁expressing": 18633, + "ed▁by▁Lilly:": 18634, + "▁experimental": 18635, + ".▁Specifically,▁": 18636, + "▁contraceptive▁": 18637, + ",▁et▁al.▁Phase▁II": 18638, + "▁hormone-resistant▁prostate▁cancer": 18639, + "left▁to": 18640, + ",▁blood▁pressure,▁": 18641, + "▁the▁baseline▁sum": 18642, + "▁(Western": 18643, + "Journal▁of▁": 18644, + "▁SYNOPSIS": 18645, + "s▁that▁can▁be▁accurately▁measured▁in": 18646, + ".\n\nSUBJECT▁ENROLLMENT": 18647, + "strongly▁encouraged▁to": 18648, + "e▁disease▁assessment": 18649, + ",▁Manegold▁C": 18650, + "▁time▁from▁randomization": 18651, + "▁ruler▁to▁estim": 18652, + "scann": 18653, + "▁adequately": 18654, + "complete▁or▁partial▁response▁": 18655, + "▁actual▁body▁weight": 18656, + "followed▁for▁survival▁for": 18657, + "doublet": 18658, + "▁μg": 18659, + "emporary▁": 18660, + "▁every▁4▁weeks▁schedul": 18661, + "no▁less▁than▁4▁weeks▁after": 18662, + "▁Stage▁IIIB": 18663, + "altz▁LB": 18664, + "uperficial▁": 18665, + "\n\nEGFr": 18666, + "measurements▁and▁variables": 18667, + "▁Lilly▁or▁its▁designee▁via": 18668, + ",▁who▁will": 18669, + "obility": 18670, + "other▁than▁the▁evaluation▁or": 18671, + "▁Previously▁Un": 18672, + "EDTA▁blood▁[plasma▁and▁cell": 18673, + "▁>99.9▁>99.9": 18674, + "stitutional▁Review▁Board▁(IRB)": 18675, + "▁patients▁per▁arm": 18676, + "orrections▁to": 18677, + "▁source▁data": 18678, + "▁Darbepoetin▁alfa▁Protocol▁Number:▁20010145": 18679, + "▁advertising": 18680, + "▁residual": 18681, + "▁curative▁intent": 18682, + "unningham▁D": 18683, + "▁proportional▁hazards▁model": 18684, + "\n\nResults▁in": 18685, + "▁SG,▁Eisenhauer": 18686, + "▁prematur": 18687, + "embryonic": 18688, + "▁120▁mg▁SC": 18689, + "▁head▁and▁neck▁cancer": 18690, + "s▁Administer": 18691, + "▁you▁are▁a▁woman": 18692, + "able▁Disease▁(SD):": 18693, + "▁hybridization": 18694, + "▁imaginable▁": 18695, + "re-screen": 18696, + "▁Reconciliation": 18697, + "\n\n5\n\n6\n\n7\n\n8\n\n9": 18698, + "e,▁ALT,▁AST,▁calcium": 18699, + "including▁a▁ruler▁to▁estim": 18700, + ".\n\nEXPERIMENTAL▁PLAN": 18701, + "financial": 18702, + "▁has▁returned▁to▁baseline,▁then": 18703, + "▁conduct▁of▁the▁clinical▁investigation": 18704, + "▁mm▁with▁conventional▁techniques▁or": 18705, + "▁will▁compensate▁you▁if▁this▁happens": 18706, + "▁ambulatory▁and▁able▁to▁carry▁out": 18707, + "▁6▁1▁G▁M": 18708, + "asse▁P,▁Arbuck": 18709, + "▁INFORMATION": 18710, + "atzemeier▁U": 18711, + "-and-subsequent": 18712, + "▁and▁the▁same▁technique▁should▁be▁used▁to": 18713, + ",▁PAXgen": 18714, + "▁work▁of▁a▁light▁or▁sedentary▁nature,▁": 18715, + "heumatoid▁arthrit": 18716, + "censored��using▁the▁last▁available▁": 18717, + "aucasian": 18718, + "or▁legal▁partner": 18719, + ",▁von▁Pawel▁J": 18720, + "▁SG,▁Eisenhauer▁EA": 18721, + "including▁a▁ruler▁to▁estimate▁th": 18722, + "▁6▁1▁G▁M▁A": 18723, + "asse▁P,▁Arbuck▁SG,▁Eisenhauer▁EA": 18724, + "(as▁": 18725, + "(IHC": 18726, + ")/": 18727, + ")▁In": 18728, + ")▁-": 18729, + ")▁was": 18730, + ",▁the▁sponsor": 18731, + ",▁treatment▁with": 18732, + "-re": 18733, + "-99": 18734, + "-by-": 18735, + ".E": 18736, + "/0": 18737, + "/PR": 18738, + "/vomiting": 18739, + "/exclusion▁criteria": 18740, + "0.9": 18741, + "1▁year": 18742, + "300": 18743, + "85-": 18744, + "85%": 18745, + "82)": 18746, + ":▁An": 18747, + ";▁s": 18748, + ">2": 18749, + "Amendment": 18750, + "Co": 18751, + "Chemistry▁": 18752, + "Collection": 18753, + "Discontinu": 18754, + "EI": 18755, + "ETA": 18756, + "Epidermal▁": 18757, + "Hochberg": 18758, + "HARM": 18759, + "Im": 18760, + "L,▁C": 18761, + "M,▁C": 18762, + "N-": 18763, + "Obl": 18764, + "Rational": 18765, + "TX": 18766, + "aud": 18767, + "bound▁": 18768, + "better": 18769, + "devi": 18770, + "e\n\nAn": 18771, + "eagu": 18772, + "fram": 18773, + "foot": 18774, + "gulin": 18775, + "iou": 18776, + "ioc": 18777, + "ieth": 18778, + "k▁r": 18779, + "lthough": 18780, + "living": 18781, + "learn": 18782, + "ml": 18783, + "my▁": 18784, + "nes": 18785, + "nect": 18786, + "n▁=": 18787, + "peptid": 18788, + "s”": 18789, + "s▁according▁to": 18790, + "screen": 18791, + "surgical▁": 18792, + "sophag": 18793, + "uz": 18794, + "vinc": 18795, + "vendor": 18796, + "wk": 18797, + "worldwid": 18798, + "ying": 18799, + "”▁(": 18800, + "▁\"": 18801, + "▁×": 18802, + "▁formation": 18803, + "▁open-label▁Casodex": 18804, + "e▁you": 18805, + "e▁into": 18806, + "e▁would▁": 18807, + "ine,": 18808, + "▁t▁s▁": 18809, + "ond": 18810, + "onal▁": 18811, + "on▁D": 18812, + "\n\n>": 18813, + "\n\nat": 18814, + "\n\nas": 18815, + "\n\nblood▁": 18816, + "\n\nbevacizumab": 18817, + "\n\nyes▁": 18818, + "▁a▁trial": 18819, + "era": 18820, + "er▁S": 18821, + "orst": 18822, + "orubicin": 18823, + "s▁/": 18824, + "s▁following": 18825, + "s▁versus▁": 18826, + "s▁such": 18827, + "s▁resulting▁from": 18828, + "revascularization": 18829, + "alive▁": 18830, + "entr": 18831, + "ite\n\n": 18832, + ",▁may▁": 18833, + ",▁dos": 18834, + ",▁only▁": 18835, + ",▁followed▁by▁": 18836, + ",▁including▁the▁": 18837, + "ed▁“": 18838, + "ed▁following": 18839, + "▁an▁appropriate▁": 18840, + "▁an▁additional": 18841, + ".▁[": 18842, + ".▁c": 18843, + ".▁12": 18844, + ".▁25": 18845, + ".▁30": 18846, + ".▁22": 18847, + "ed?": 18848, + "ed,\n\n": 18849, + "ed▁appropriate▁": 18850, + "▁past": 18851, + "▁policy▁": 18852, + "▁co-": 18853, + "▁capt": 18854, + "▁capture": 18855, + "ing▁treatment": 18856, + "es.▁C": 18857, + "ford": 18858, + "▁to▁collect": 18859, + "▁to▁participate▁in▁the▁": 18860, + "is,▁and▁": 18861, + "is▁associated▁with": 18862, + "▁of▁cycle▁": 18863, + "▁destroy": 18864, + "▁web": 18865, + "▁would": 18866, + "▁manufact": 18867, + "▁and▁h": 18868, + "▁and▁study▁": 18869, + "▁and▁irinotecan": 18870, + "▁and▁last": 18871, + "▁and▁results▁of": 18872, + "▁and▁check": 18873, + "▁and▁platelet▁count": 18874, + ".\n\nc": 18875, + ".\n\n(cid:": 18876, + ".\n\nUn": 18877, + ".\n\n26": 18878, + "al▁(": 18879, + "al▁S": 18880, + "al▁f": 18881, + "al▁vitamin▁D": 18882, + "al▁5-fluorouracil": 18883, + "eland▁": 18884, + "elson": 18885, + "▁AG": 18886, + "▁AMGEN": 18887, + "▁After": 18888, + "imput": 18889, + "igment": 18890, + "idd": 18891, + "idimension": 18892, + "▁15-": 18893, + "▁180": 18894, + "▁1▁or▁2": 18895, + "▁CK": 18896, + "▁Cur": 18897, + "▁Criterion": 18898, + "acetic": 18899, + "prompt": 18900, + "proportional▁hazard": 18901, + "▁(<": 18902, + "▁(JM": 18903, + "▁(EGFr": 18904, + "▁(VEGF": 18905, + "▁(Visit": 18906, + "���(includes": 18907, + "▁(wt": 18908, + "emotion": 18909, + "usiness▁": 18910, + "ulated▁": 18911, + "conven": 18912, + "conomic": 18913, + "constant": 18914, + "▁STA": 18915, + "▁S130": 18916, + "▁Steering": 18917, + "▁I▁have▁": 18918, + "▁recombinant": 18919, + "again": 18920, + "▁Date▁of": 18921, + "▁Duration▁of": 18922, + "▁D▁E▁T▁N▁I▁R▁P\n\nA": 18923, + "▁Delegation▁of▁Authority▁Form": 18924, + "cl-": 18925, + "rix": 18926, + "▁his▁": 18927, + "▁heparin": 18928, + "▁Eastern▁Cooperative▁Oncology▁Group▁(ECOG)": 18929, + "ject▁the▁": 18930, + "▁or▁SD": 18931, + "▁or▁less": 18932, + "e▁today": 18933, + "\n\nPost": 18934, + "\n\nPAGE": 18935, + "ecision": 18936, + "\n\nApproximately▁": 18937, + "study▁duration": 18938, + "▁proce": 18939, + "▁propert": 18940, + "▁adjacent": 18941, + "astinal": 18942, + "▁for▁other": 18943, + "▁for▁Arm▁A": 18944, + "▁for▁injection": 18945, + "▁R,▁B": 18946, + "e\n\nof": 18947, + "romet": 18948, + "▁treatment▁should▁be▁": 18949, + "encounter": 18950, + ".15": 18951, + ".18": 18952, + "▁with▁treatment▁group": 18953, + "▁withholding": 18954, + "ed▁bone▁": 18955, + "s▁of▁the▁data": 18956, + "Inf": 18957, + "▁that▁it": 18958, + "▁20020408▁Amendment▁4": 18959, + "▁is▁obtain": 18960, + "▁of▁study-related▁": 18961, + "▁alert": 18962, + "e▁selection": 18963, + "▁MD": 18964, + "▁MI": 18965, + "▁Master": 18966, + "▁0.25": 18967, + "event-": 18968, + "event▁analysis": 18969, + "▁of▁the▁treatment": 18970, + "whos": 18971, + "▁commenc": 18972, + "▁FA": 18973, + "▁FF": 18974, + ".▁Ab": 18975, + "▁as▁≥": 18976, + "▁gastrointestinal": 18977, + "▁gefitinib": 18978, + "▁onward": 18979, + ",▁and▁S": 18980, + "radionucl": 18981, + "▁Letter": 18982, + "ly▁diagnos": 18983, + ".39": 18984, + "▁this▁substudy": 18985, + "▁stay▁": 18986, + "\n\nCapable▁of▁only▁limited▁s": 18987, + "▁will▁help": 18988, + "e▁interim": 18989, + "e▁infection": 18990, + "e▁interval": 18991, + "▁58": 18992, + "▁525": 18993, + "▁5.5.1": 18994, + "will▁also": 18995, + "willing▁or": 18996, + "▁6-week": 18997, + "▁HRPC": 18998, + "▁patients▁in▁the▁": 18999, + ")\n\nand▁": 19000, + "▁at▁any▁": 19001, + "▁at▁the▁end▁of": 19002, + "s▁(such▁as▁": 19003, + "▁the▁instruction": 19004, + "▁accom": 19005, + "▁accompany": 19006, + "▁study▁conduct": 19007, + "\n\n1.2": 19008, + "▁mg▁AMG▁162": 19009, + "iregulin": 19010, + "ensure▁that": 19011, + "▁the▁typ": 19012, + "▁after▁2": 19013, + "ed▁on▁a": 19014, + "1989": 19015, + "ECORD": 19016, + ".▁Sh": 19017, + ".▁Some▁": 19018, + ".0▁mL": 19019, + ".0▁g/dL": 19020, + "▁patient▁population": 19021, + "▁unstain": 19022, + "▁equal": 19023, + "▁Journal": 19024, + "▁time-to-event": 19025, + "▁from▁baseline▁": 19026, + "▁from▁the▁treatment": 19027, + "s\n\nmust▁be▁": 19028, + "ed▁by▁subject": 19029, + "axis": 19030, + "▁Protocol▁Number": 19031, + ".▁The": 19032, + "et▁al,▁200": 19033, + "▁tumor▁for": 19034, + "ONE": 19035, + "▁dosage▁": 19036, + "roduction▁of": 19037, + "oston": 19038, + "CT/MRI": 19039, + "es▁of▁America": 19040, + "may▁have▁": 19041, + "▁adverse▁events▁will▁be▁": 19042, + "monotherapy": 19043, + "pectromet": 19044, + "▁10.5": 19045, + ".68": 19046, + ".▁Int": 19047, + "▁assessment▁and▁": 19048, + "▁assessment▁is▁": 19049, + "▁significance▁": 19050, + "▁signs▁the▁": 19051, + "peripheral": 19052, + "20]": 19053, + ",▁or▁an": 19054, + "progression▁fre": 19055, + "patients▁are▁": 19056, + "▁98": 19057, + "▁9.4": 19058, + "e▁(NCI": 19059, + "s▁select": 19060, + "s▁specifi": 19061, + "▁each▁treatment▁group": 19062, + "prepared": 19063, + "every▁effort▁should▁be▁made▁to": 19064, + "every▁8▁weeks▁±▁1▁week": 19065, + ".77": 19066, + "\n\n26th": 19067, + "y▁of▁the▁": 19068, + "▁should▁be▁follow": 19069, + "▁should▁be▁exerc": 19070, + "rolled▁": 19071, + "▁the▁investigator(s)": 19072, + "▁the▁investigator's▁": 19073, + "▁the\n\nprimary▁": 19074, + "ed▁as▁part▁of▁the▁": 19075, + "easures▁": 19076, + "protocol-specifi": 19077, + "ating▁that": 19078, + "ronically▁": 19079, + "ed,▁with": 19080, + "responsibility": 19081, + "responsible▁": 19082, + "\n\nYes▁or▁No": 19083, + "▁addition▁to▁the▁": 19084, + "▁The▁following": 19085, + "▁the▁lower": 19086, + "▁dose▁and▁": 19087, + "▁dose▁adjustment": 19088, + "colleagu": 19089, + "KRAS▁status": 19090, + ".\n\nPemetrexed▁H3E-MC-JMHR(b)▁Confidential\n\nProtocol▁Amendment\n\nPage▁": 19091, + ".\n\nPOTENTIAL": 19092, + "e▁benefit": 19093, + "s▁to▁follow-up": 19094, + "13)(cid:": 19095, + "▁panitumumab▁in": 19096, + "othenberg": 19097, + "s▁or▁term": 19098, + "▁was▁observed▁in": 19099, + "▁Clinical▁Study▁": 19100, + "▁Version▁4.0": 19101, + "ungal": 19102, + "▁deaths▁have▁occurred": 19103, + "▁30-day▁": 19104, + "▁evaluate▁t": 19105, + "provider": 19106, + "provided▁with": 19107, + "signing▁this▁": 19108, + "using▁the▁same▁": 19109, + "▁sampling": 19110, + "oxorubicin": 19111, + "until▁disease▁progression▁or": 19112, + "▁mg/m2/day▁": 19113, + "▁the▁subject’s\n\n": 19114, + "interest": 19115, + "▁completely▁": 19116, + "▁approximately▁10": 19117, + "▁approximately▁745": 19118, + "▁participate": 19119, + "▁discontinuation▁of▁the▁": 19120, + ",▁PFS": 19121, + ",▁Placebo": 19122, + "values▁": 19123, + "\n\n\n\n\n\n": 19124, + "▁et▁al▁200": 19125, + "▁et▁al▁2007": 19126, + "▁et▁al.▁19": 19127, + "▁analysis,▁": 19128, + "▁continue▁in": 19129, + "▁continue▁to▁receive▁": 19130, + "ed▁survival": 19131, + "collected▁to": 19132, + "▁=▁area": 19133, + "▁response▁rate▁of": 19134, + "dose▁(": 19135, + "160": 19136, + "▁should▁only▁be▁": 19137, + "▁these▁studies": 19138, + "▁these▁agent": 19139, + ",▁Mat": 19140, + ",▁Moor": 19141, + "ROQOL": 19142, + ".▁Harris▁WS": 19143, + "▁must▁submit": 19144, + ",▁CD": 19145, + "observed▁in▁the▁": 19146, + "▁(ABI-007": 19147, + "▁resulted▁in": 19148, + "ation▁of▁study▁drug": 19149, + "manager": 19150, + "review▁of▁the▁": 19151, + "s,▁as▁": 19152, + "s,▁tumor▁cells▁and▁the▁proposed▁mechanism▁of▁action": 19153, + "▁1976": 19154, + "e▁measure": 19155, + "▁chemotherapy▁with": 19156, + "able▁to▁Evalu": 19157, + ".▁This▁will▁be▁": 19158, + "clinical▁benefit": 19159, + "uller": 19160, + "hibits▁": 19161, + "ratios": 19162, + "▁this▁amended▁protocol": 19163, + "▁PFS▁in": 19164, + "ed▁among": 19165, + "▁Arm▁G": 19166, + "▁12▁week": 19167, + "studies▁have▁": 19168, + "ratum": 19169, + ".\n\nCh": 19170, + "clusion▁Criterion": 19171, + "echt": 19172, + "OLFOX-": 19173, + "must▁not▁be▁": 19174, + ".▁For▁the▁": 19175, + "Clinical▁Study▁Report": 19176, + "▁agents,▁": 19177, + "▁agent(s)": 19178, + "▁•▁S": 19179, + "FAS": 19180, + "▁increased▁in": 19181, + "▁this▁study▁protocol": 19182, + "s▁only": 19183, + "▁AEs▁and▁SAE": 19184, + ",▁et▁al:": 19185, + ",▁et▁al.▁S": 19186, + "io▁n": 19187, + "s▁and▁their": 19188, + "▁anti-AMG▁162": 19189, + "\n\n5.\n\nSUBJECT▁ENROLLMENT": 19190, + "Concomitant▁medication": 19191, + "▁vertebra": 19192, + "cerning": 19193, + "▁the▁same▁m": 19194, + "ICH)": 19195, + "indicate▁that": 19196, + "21]": 19197, + "▁Decreas": 19198, + "IRB▁or▁IEC": 19199, + "▁toxicity▁grade▁": 19200, + "evidence▁": 19201, + "▁for▁the▁following": 19202, + "\n\n9.4": 19203, + "▁of▁a▁new": 19204, + ",▁in▁which": 19205, + "▁agree▁that": 19206, + "personally▁": 19207, + "only▁for": 19208, + "▁overall▁survival▁": 19209, + "Treatment▁of": 19210, + "EGFR-": 19211, + "100▁mg/m2": 19212, + "▁medical▁emerg": 19213, + "▁an▁option": 19214, + ".▁Long": 19215, + "e/Cisplatin": 19216, + "herein": 19217, + "y▁(CT": 19218, + "2-7": 19219, + "\n\nthroughout": 19220, + "▁recorded▁": 19221, + "-free▁disease▁assessment": 19222, + ",▁depending▁on": 19223, + "▁Medicin": 19224, + "▁100)": 19225, + "▁procedures▁for": 19226, + "▁have▁been▁report": 19227, + "FACT-L": 19228, + "vestigational▁drug": 19229, + "▁are▁not▁confirmed": 19230, + "persed": 19231, + "▁designed▁to": 19232, + "▁≥2": 19233, + ".\n\n3.1": 19234, + "e▁P450": 19235, + "renal▁function": 19236, + "3-year": 19237, + "Pharm": 19238, + "▁If▁you": 19239, + "used▁investigational▁product": 19240, + "cases,▁": 19241, + "/day": 19242, + "▁skin▁reaction": 19243, + "▁Ext": 19244, + "none)": 19245, + "▁appropriate,▁": 19246, + "▁PR▁or▁CR": 19247, + "▁the▁trial▁are▁": 19248, + "ournal▁": 19249, + "▁identical": 19250, + "it▁is▁estimated▁that": 19251, + "controlled▁trial": 19252, + "likely▁": 19253, + "\n\ndenosumab": 19254, + ".\n\nBevacizumab": 19255, + "chest▁CT": 19256, + "FOLFOX4": 19257, + "▁(SGOT": 19258, + "▁alone": 19259, + ",▁all▁subjects▁": 19260, + "▁a▁legally▁acceptable▁": 19261, + "increase▁the▁": 19262, + "linded▁Treatment": 19263, + "▁experiences▁a": 19264, + "▁before▁study▁": 19265, + "▁before▁randomization": 19266, + "▁local▁institutional▁practic": 19267, + "measurable▁diseas": 19268, + "es▁that▁are▁": 19269, + "▁grade▁2": 19270, + "▁days▁following": 19271, + "s▁among": 19272, + "\n\nNo\n\nPR": 19273, + "health▁status": 19274, + "▁known▁to▁have▁": 19275, + "oldberg": 19276, + "▁For▁all": 19277, + "▁(PSA)": 19278, + ".▁58": 19279, + ".▁5.7": 19280, + "medical▁car": 19281, + "▁of▁0.025": 19282, + "\n\nWeek": 19283, + "established▁tumor": 19284, + ".\n\n8.2": 19285, + ".\n\n8.3": 19286, + "assigned▁to": 19287, + "▁available.\n\n": 19288, + "-induced": 19289, + "▁full▁consent": 19290, + "persensitivity▁to": 19291, + "ummary▁statistic": 19292, + "astroenter": 19293, + "▁(cid:116)": 19294, + "with▁the▁exception▁of": 19295, + "atory▁Obl": 19296, + ".▁Expos": 19297, + "delayed▁": 19298, + "exposure▁": 19299, + "was▁also": 19300, + "▁of▁127\n\n": 19301, + "1.5▁x▁ULN": 19302, + "s▁may▁occur": 19303, + "▁use▁adequate▁": 19304, + "LT▁<": 19305, + "▁activity▁but": 19306, + "e▁Casodex": 19307, + "▁compared▁with▁docetaxel": 19308, + "\n\nCont": 19309, + "before▁each": 19310, + "consistent▁with▁the▁": 19311, + "▁do▁not▁have▁": 19312, + ".▁Additionally": 19313, + "▁loss,▁": 19314, + "-related▁toxicity": 19315, + "Safety▁Follow-Up": 19316, + "▁agree▁to▁ensure▁that": 19317, + "Objectives:": 19318, + "▁antiandrogen": 19319, + "may▁also▁be▁": 19320, + "▁minutes▁prior▁to": 19321, + "escalation": 19322, + "▁anticancer▁therapy▁": 19323, + "▁2▁years▁after": 19324, + "prior▁to▁the▁first▁dose▁of": 19325, + "▁fractures": 19326, + "\n\nNot▁at▁all": 19327, + "▁or▁sponsor": 19328, + "▁small▁lesion": 19329, + "▁centers:": 19330, + "TINAL": 19331, + "colony▁stimulating▁factor": 19332, + "colon▁or▁rect": 19333, + "▁5-fluorouracil/leucovorin": 19334, + ".▁Stat": 19335, + "▁Anti-": 19336, + "complete▁respons": 19337, + "complete▁response▁": 19338, + "Character": 19339, + "s.▁Biometrics▁": 19340, + "dentity▁of▁investigational▁product": 19341, + "▁participating▁in▁the▁study": 19342, + "▁England▁": 19343, + "initially▁": 19344, + "local▁regulatory▁requirement": 19345, + "°C▁(": 19346, + "▁Non-metastatic": 19347, + "▁a▁best▁response▁of": 19348, + "how▁good▁": 19349, + "▁Signature▁": 19350, + "▁Signatory▁Obl": 19351, + "Investigator’s▁Brochure▁": 19352, + "\n\nPrimary▁Endpoint": 19353, + "▁measurable▁disease▁": 19354, + "beginning": 19355, + "al▁sequence▁": 19356, + "▁components▁of": 19357, + "▁above▁": 19358, + "▁major▁body▁system": 19359, + "ed▁Metastatic▁Colorectal▁Cancer": 19360, + "▁Primary▁Endpoint": 19361, + "▁Study▁to": 19362, + "predictive▁": 19363, + "Regulatory▁A": 19364, + "▁Serious▁Adverse▁Event▁Reporting": 19365, + "e\n\nConfidential\n\nPage▁": 19366, + "▁able▁to▁carry▁on": 19367, + "legibl": 19368, + "▁truly▁": 19369, + "vertebral▁fracture▁": 19370, + "anguage": 19371, + ",▁confined▁to▁bed▁or▁chair": 19372, + "following▁the▁last▁dose▁of": 19373, + "▁documented▁disease▁progression": 19374, + "▁mg/dL;": 19375, + "every▁6▁weeks,▁": 19376, + "▁original▁source▁document": 19377, + "▁treatment▁effect▁on": 19378, + "examining": 19379, + "ate▁(or": 19380, + "occurred▁in": 19381, + "▁curves▁will▁be▁": 19382, + "▁sequential": 19383, + "▁bisphosphonates": 19384, + "▁alpha▁level": 19385, + "prednison": 19386, + "uroQol▁Group": 19387, + "▁reconstruction": 19388, + "▁prospectively▁": 19389, + "▁derivative▁": 19390, + ",500": 19391, + "idemiol": 19392, + "decision▁to": 19393, + "▁matching▁placebo": 19394, + "use▁only": 19395, + "▁important▁medical▁event": 19396, + "purposes": 19397, + "keletal▁related▁event": 19398, + "▁Epidemiol": 19399, + "▁pemetrexed▁and▁cisplatin": 19400, + "▁objectives▁and▁": 19401, + "▁relatedness▁to": 19402, + "ersus▁": 19403, + "▁unit▁errors▁(": 19404, + ".2.1.1.6": 19405, + "utilized▁for": 19406, + ".\n\nSTA": 19407, + "iller▁J": 19408, + "▁Consider": 19409, + "antibodies": 19410, + ".\n\nY▁T▁I▁D▁I▁L▁A▁V\n\nS▁T▁I": 19411, + "30-day▁postdiscontinuation▁follow-up▁visit": 19412, + "erythema": 19413, + "may▁occur▁between▁1▁and▁": 19414, + "described▁in▁the▁protocol": 19415, + ";▁(2)": 19416, + "vs▁no": 19417, + "-based▁chemotherapy▁and▁bevacizumab": 19418, + "▁objective▁progression-free▁disease▁assessment": 19419, + "Neuropath": 19420, + "differenc": 19421, + ".\n\nS▁T▁I\n\nK▁C▁E▁H▁C\n\nE▁S▁A▁E▁L▁P": 19422, + "▁dispensing": 19423, + "▁chemistry▁panel": 19424, + "regulatory▁authorities": 19425, + "hemorrhage▁": 19426, + "publication▁or": 19427, + "▁people▁": 19428, + "▁the▁subgroup": 19429, + "ost-Study▁": 19430, + "▁10.6.2.1": 19431, + "metabol": 19432, + "color▁photograph": 19433, + "▁consultation▁with▁the▁": 19434, + "\n\nProtocol▁Attachment▁JMHD": 19435, + "United▁States▁of▁America": 19436, + "▁anthracycline▁": 19437, + "Reductions▁for": 19438, + "▁visual": 19439, + "▁Background▁": 19440, + "▁York▁Heart▁Association": 19441, + "▁carcinomas": 19442, + "▁at▁least▁one▁dimension": 19443, + "▁headach": 19444, + "height▁(": 19445, + "▁mucositis": 19446, + "▁Investigator’s▁Brochure": 19447, + "(8):▁p.▁": 19448, + "ed▁in▁the▁Study▁Plan": 19449, + "▁participation▁in▁the▁study": 19450, + "e▁size▁of▁the▁lesion": 19451, + "▁circumstances▁": 19452, + "commercial": 19453, + "(mg/dL": 19454, + "updates": 19455, + ".\n\nY▁P▁O▁C\n\nD▁E▁T▁N▁I▁R▁P": 19456, + "inorelbin": 19457, + "▁150▁mg▁once▁daily▁": 19458, + "▁carcinoma▁of▁the▁head▁and▁neck": 19459, + "participation▁in▁the▁clinical▁study": 19460, + "Figure▁S130": 19461, + "appearance▁of▁all▁target▁lesion": 19462, + "language▁": 19463, + "othelin▁receptor": 19464, + "▁measurements▁and▁variables": 19465, + "stability▁limit": 19466, + "▁Oncology▁Group": 19467, + "▁violation": 19468, + "▁other▁lesions▁(or▁sites▁of▁diseas": 19469, + "Experience": 19470, + "cagliotti▁G": 19471, + ".\n\nSUBJECT▁ELIGIBILITY": 19472, + ".▁References": 19473, + "▁temporal▁sequence▁": 19474, + "▁signature▁p": 19475, + "index▁scor": 19476, + "▁previously▁untreated▁": 19477, + "anadian▁Cancer▁Societ": 19478, + "▁a▁large▁": 19479, + "▁inspecting▁the▁": 19480, + "-▁or▁nail-related▁toxicities": 19481, + "▁thought▁to▁be▁": 19482, + "▁20040135": 19483, + "s▁suggestive▁of": 19484, + "▁Characteristic": 19485, + "echnical▁Standard": 19486, + "▁is▁any▁untoward▁medical▁occurr": 19487, + "ensive-stage▁": 19488, + "dependent▁Ethics▁Committee▁(IEC": 19489, + "s▁treated▁at▁the▁": 19490, + "unable▁to▁tolerate▁": 19491, + "epatitis▁B": 19492, + "▁timely▁manner": 19493, + "▁phenotyp": 19494, + "\n\nNumber▁of": 19495, + "Fracture▁": 19496, + "ed▁by▁clinic▁visit▁or▁telephone▁contact▁approximately▁every▁6▁months▁for": 19497, + ".▁Effects▁of": 19498, + ",▁Bonom": 19499, + "aternal▁exposure": 19500, + "▁to▁distinguish": 19501, + "▁survival▁pro": 19502, + "▁(AE)": 19503, + "▁or▁your▁legally▁acceptable▁representative▁": 19504, + "▁must▁have▁a▁negative▁": 19505, + "▁differential▁(neutrophils,▁": 19506, + "▁g": 19507, + "ence▁or▁absence▁of": 19508, + "▁translational▁research": 19509, + "▁metastatic▁colorectal▁cancer▁(mCRC)": 19510, + "ULATORY▁OBLIGATIONS": 19511, + "hort▁Form▁(": 19512, + "remities": 19513, + "ological▁imaging▁of▁the▁": 19514, + "▁postmenopausal▁women": 19515, + "s▁will▁be▁calculated▁and▁": 19516, + "▁health▁state▁today": 19517, + "oftware": 19518, + "▁prolongation▁of▁existing▁hospitalization": 19519, + "▁a▁20%▁increase▁in": 19520, + "▁satisfaction": 19521, + "▁ENDPOINTS": 19522, + "s▁with▁respect▁to▁both": 19523, + "▁transaminas": 19524, + "▁has▁already▁been": 19525, + "compatibl": 19526, + "▁mutant▁KRAS▁tumor": 19527, + "▁Supportive▁C": 19528, + "\n\nAmbulatory▁and▁capable▁of▁all▁s": 19529, + "▁contributions▁to": 19530, + "ebrovascular▁accident": 19531, + ".▁(for▁Japanese▁sites▁only": 19532, + "rosatellite▁instability": 19533, + "Double-Blind": 19534, + "Gleason▁scor": 19535, + "▁thorough": 19536, + "▁(longest▁diameter▁to▁be▁": 19537, + ".▁Totally▁confined▁to▁bed▁or▁chair": 19538, + "lymph▁node▁is▁N": 19539, + "▁Dosage,▁Administration,▁and▁": 19540, + ".▁Proceedings▁of▁the▁": 19541, + "at▁the▁end▁of▁treatment/withdrawal▁visit": 19542, + "ytochrome▁P450": 19543, + "drew": 19544, + "▁of▁existing▁non-target▁lesion": 19545, + "s,▁Subset": 19546, + "▁stratified▁by▁the▁randomization▁factor": 19547, + "▁and▁cardiovascular▁disease▁": 19548, + "▁unable▁to▁carry▁out▁any▁": 19549, + "▁persistent▁or▁significant▁disability/incapacity": 19550, + "”▁and▁“": 19551, + "▁SIZE": 19552, + "▁BPI▁scor": 19553, + "▁Committee▁on▁Cancer": 19554, + "▁and▁Timing▁of": 19555, + "ef▁Pain▁Inventory▁–▁S": 19556, + "arget▁lesions▁should▁be▁selected▁on▁the▁basis▁of▁their▁size▁(": 19557, + "Proof▁of▁Receipt▁Form": 19558, + "▁alcohol": 19559, + "ALUATIONS": 19560, + "▁time▁from▁randomization▁date▁to": 19561, + "other▁than▁the▁evaluation▁or▁conduct▁of▁the▁clinical▁investigation": 19562, + "▁Darbepoetin▁alfa▁Protocol▁Number:▁20010145▁Date:▁16▁July▁2004\n\nPage▁": 19563, + "including▁a▁ruler▁to▁estimate▁the▁size▁of▁the▁lesion": 19564, + "HARMAC": 19565, + "willing▁or▁unable▁to": 19566, + "\n\n26th▁April▁2005": 19567, + "clusion▁Criterion▁[": 19568, + "colon▁or▁rectum": 19569, + "how▁good▁or▁b": 19570, + "▁Signatory▁Oblig": 19571, + "may▁occur▁between▁1▁and▁9": 19572, + "▁temporal▁sequence▁from": 19573, + "(18": 19574, + "(2)": 19575, + ")▁as▁": 19576, + ")▁and/or": 19577, + ")▁plus▁": 19578, + ")▁have▁been": 19579, + ",▁temperature": 19580, + "-th": 19581, + "-drug": 19582, + "-25": 19583, + "-na": 19584, + "-approv": 19585, + "/no": 19586, + "/100": 19587, + "/infusion": 19588, + "0-": 19589, + "1a": 19590, + "150▁mg": 19591, + "2.": 19592, + "2▁and▁": 19593, + "3)\n\n": 19594, + "7▁September▁2007": 19595, + ":13": 19596, + ";▁in": 19597, + "AD": 19598, + "Ap": 19599, + "Chemistry": 19600, + "Confidential\n\nProduct:▁AMG▁162▁Protocol▁Number:▁20040138▁Date:▁19▁February▁2008\n\nPage▁": 19601, + "EuroQ": 19602, + "H▁agonist": 19603, + "ImClone▁LLC": 19604, + "King": 19605, + "K,▁L": 19606, + "Kaplan": 19607, + "Lab": 19608, + "Last": 19609, + "Lan-D": 19610, + "MARY": 19611, + "Ntx": 19612, + "PY": 19613, + "Toxic": 19614, + "Tumour": 19615, + "Women": 19616, + "[RNA": 19617, + "a,▁": 19618, + "ault": 19619, + "aeno": 19620, + "becom": 19621, + "bisphosphon": 19622, + "cision": 19623, + "cross": 19624, + "circulating": 19625, + "dep": 19626, + "dail": 19627, + "devic": 19628, + "defici": 19629, + "fel": 19630, + "ffusion": 19631, + "hospital▁or": 19632, + "i)": 19633, + "iec": 19634, + "iary": 19635, + "key▁": 19636, + "lcer": 19637, + "listing": 19638, + "mL": 19639, + "many▁": 19640, + "molecular": 19641, + "mechanism▁of▁action": 19642, + "nia": 19643, + "ning▁of▁the▁": 19644, + "oy▁": 19645, + "o▁S": 19646, + "o▁R": 19647, + "oencephalopath": 19648, + "oembryonic": 19649, + "pend": 19650, + "rising": 19651, + "s\n\nD": 19652, + "scientific": 19653, + "special": 19654, + "s▁approximately▁30": 19655, + "tinent": 19656, + "vin": 19657, + "went": 19658, + "y.": 19659, + "yrimidine▁": 19660, + "≤▁5▁x▁ULN": 19661, + "▁................................................................................................": 19662, + "▁util": 19663, + "▁opinion": 19664, + "▁judgment": 19665, + "▁room▁temperature▁": 19666, + "inh": 19667, + "inhibitor": 19668, + "▁text": 19669, + "▁true▁": 19670, + "ato": 19671, + "ates▁in": 19672, + "at▁baseline▁": 19673, + "at▁Week": 19674, + "on▁subject": 19675, + "on▁day▁1": 19676, + "\n\n<": 19677, + "\n\ninvestigator": 19678, + "\n\nwas▁": 19679, + "\n\nvisit": 19680, + "\n\nwithout": 19681, + "enough": 19682, + "erlin": 19683, + "ercent": 19684, + "s▁it": 19685, + "s▁................................................................": 19686, + "read▁": 19687, + "redient": 19688, + "alic": 19689, + "alter": 19690, + "stage▁of": 19691, + "stabiliz": 19692, + "stomach": 19693, + "y▁[": 19694, + "entry": 19695, + "itud": 19696, + "▁the▁physician": 19697, + ",▁us": 19698, + ",▁not": 19699, + ",▁so": 19700, + ",▁14": 19701, + ",▁cer": 19702, + ",▁based▁on▁the▁": 19703, + ",▁changes▁in": 19704, + "ed▁drug": 19705, + "ed▁product": 19706, + "▁an▁additional▁": 19707, + ".▁": 19708, + ".▁35": 19709, + "ed▁the▁study": 19710, + "ed▁throughout": 19711, + "▁p-valu": 19712, + "▁pamidron": 19713, + "▁particulate▁matter": 19714, + "▁cap": 19715, + "▁course▁of": 19716, + "▁covari": 19717, + "ing▁Group": 19718, + "ingredient": 19719, + "▁burden": 19720, + "▁bullet": 19721, + "esk": 19722, + "es,▁the▁": 19723, + "es▁to▁be▁": 19724, + "es.▁B": 19725, + "ations,▁": 19726, + "▁to▁other": 19727, + "▁to▁be\n\n": 19728, + "▁to▁the▁date▁of": 19729, + "▁to▁assess▁the▁": 19730, + "▁to▁the▁date▁of▁death": 19731, + "isul": 19732, + "▁squamous▁": 19733, + "▁simpl": 19734, + "▁summary▁of": 19735, + "▁safety▁and▁efficacy▁": 19736, + "▁switch": 19737, + "▁of▁previous▁": 19738, + "▁degree▁of": 19739, + "▁war": 19740, + "▁world": 19741, + "▁mit": 19742, + "▁main": 19743, + "▁mamm": 19744, + "▁measures": 19745, + "▁mortality▁": 19746, + "▁mitoxantrone▁": 19747, + "▁msec": 19748, + "▁and▁g": 19749, + "▁and▁subject": 19750, + "▁and▁must▁be▁": 19751, + "▁and▁may▁be▁": 19752, + "▁and▁dis": 19753, + "▁and▁design": 19754, + "▁and▁blood▁sampl": 19755, + "▁and▁vitamin▁B12": 19756, + ".\n\n21": 19757, + ".\n\n(cid:131)▁You": 19758, + "mention": 19759, + "absolut": 19760, + "▁Abstract": 19761, + "▁Afric": 19762, + "▁in▁study▁": 19763, + "▁inducer": 19764, + "resist": 19765, + "igand▁": 19766, + "▁CIMP": 19767, + "▁Canada": 19768, + "▁CXR": 19769, + "acular": 19770, + "accru": 19771, + "es▁P": 19772, + "es▁contain": 19773, + "▁PCR": 19774, + "produced": 19775, + "▁(in": 19776, + "▁(17": 19777, + "embl": 19778, + "▁2:": 19779, + "▁284": 19780, + "use▁vial": 19781, + "ulum": 19782, + "ulsky▁": 19783, + "ifies": 19784, + "▁Symptom": 19785, + "▁Studies▁": 19786, + "▁recur": 19787, + "▁replac": 19788, + "▁refract": 19789, + "▁revis": 19790, + "unlikely▁to": 19791, + "▁Docetaxel": 19792, + "▁Demographic": 19793, + "riev": 19794, + "▁hepatic": 19795, + "▁EM": 19796, + "▁Eastern▁Cooperative▁Oncology▁Group": 19797, + "▁food": 19798, + "▁fatigu": 19799, + "▁folic▁acid": 19800, + "verifying": 19801, + "chanc": 19802, + "▁or▁non-": 19803, + "e▁trial▁": 19804, + "e▁time▁to": 19805, + "irreversibl": 19806, + "quire▁": 19807, + "ecros": 19808, + "end-of-": 19809, + "▁ng/ml": 19810, + "\n\nAs▁of▁22▁March▁2007": 19811, + "study▁protocol": 19812, + "▁and▁treatment": 19813, + "▁and▁these▁": 19814, + "▁Oc": 19815, + "▁Oper": 19816, + "▁as▁they▁": 19817, + "▁aseptic": 19818, + "uption": 19819, + "▁Ne": 19820, + "efram": 19821, + "will▁be▁based▁on": 19822, + "committee": 19823, + "▁for▁vitamin▁D": 19824, + "andara": 19825, + "▁RH": 19826, + "▁Ret": 19827, + "e\n\nM": 19828, + "e\n\nrandomization": 19829, + "romycin": 19830, + "ed▁investigational▁product": 19831, + "ed▁in▁your▁medical▁record": 19832, + "ency▁and▁": 19833, + "ency▁s": 19834, + "ed▁bas": 19835, + "ed▁block": 19836, + "Interim": 19837, + "Institut": 19838, + "\n\nSecondary": 19839, + "▁that▁will▁be▁": 19840, + "▁is▁unable▁to": 19841, + "▁is▁no▁longer": 19842, + "▁will▁be▁extract": 19843, + "e▁som": 19844, + "arto": 19845, + "arton": 19846, + "arting": 19847, + "▁Miss": 19848, + "▁rates▁": 19849, + "▁300": 19850, + "▁36▁month": 19851, + "▁3-year": 19852, + "▁of▁the▁National▁Cancer▁Institut": 19853, + "▁o▁B": 19854, + "▁Federal▁": 19855, + ".▁The▁maximum": 19856, + "▁as▁first-line▁treatment": 19857, + "▁as▁first-line▁": 19858, + "200▁mg": 19859, + "2003;": 19860, + "▁the▁symptom": 19861, + ",▁and▁oxaliplatin": 19862, + "ection▁of▁the▁": 19863, + "▁Blood": 19864, + "▁this▁clinical▁study": 19865, + "verse▁Drug": 19866, + "▁will▁record": 19867, + "▁will▁include▁all": 19868, + "follow-▁up": 19869, + "▁5.4": 19870, + "▁6.8": 19871, + "▁6.1.1": 19872, + "▁subjects": 19873, + "▁480": 19874, + "ail▁b": 19875, + "s▁(B": 19876, + "s▁(the▁": 19877, + "s▁(either": 19878, + "s▁(ie,▁": 19879, + ".4▁month": 19880, + "▁study▁or": 19881, + "▁study▁personnel": 19882, + "▁study▁specific": 19883, + "▁study▁day▁1": 19884, + "continuation": 19885, + "s▁in-": 19886, + ".53": 19887, + ".5▁month": 19888, + "s.▁Pro": 19889, + "consequ": 19890, + "▁any▁AE": 19891, + "▁except": 19892, + "registration": 19893, + "\n\nDead": 19894, + "ferential": 19895, + "ally▁measurable▁lesion": 19896, + ".▁Screening": 19897, + ".▁Safety": 19898, + "▁patients.▁The▁": 19899, + "reported\n\n": 19900, + "ardt": 19901, + "ardian": 19902, + "▁U/L": 19903, + "▁JD": 19904, + "▁J,▁S": 19905, + "▁J,▁H": 19906, + "▁timing▁of": 19907, + "\n\nEfficacy▁": 19908, + "aselga": 19909, + "▁Instruction": 19910, + "▁Index": 19911, + "ounc": 19912, + "s\n\n3": 19913, + "s\n\n6": 19914, + "s\n\nand▁": 19915, + "s\n\nReplace:": 19916, + "evaluable▁for": 19917, + "▁tumor▁or": 19918, + "▁tumors,▁": 19919, + "ONTIN": 19920, + "▁months": 19921, + "effect▁of▁treatment": 19922, + "(cid:116)": 19923, + "may▁includ": 19924, + "▁adverse▁events▁of": 19925, + "aminophen": 19926, + "▁pertinent": 19927, + "pecify": 19928, + "pecimens": 19929, + "s),": 19930, + "▁10.2.3": 19931, + ".61": 19932, + "▁to▁the▁Efficacy▁of": 19933, + "▁analysis▁in": 19934, + ".▁Initial": 19935, + ".▁Informed▁Consent": 19936, + ".▁Evalu": 19937, + ".▁EQ-5D": 19938, + "▁tests,▁": 19939, + "▁testoster": 19940, + "18]": 19941, + "aresthes": 19942, + ",▁and▁all▁other": 19943, + "111": 19944, + "▁signs": 19945, + "▁signature": 19946, + "40%": 19947, + "parametric": 19948, + ",▁or▁a": 19949, + "▁in▁the▁D": 19950, + "radio": 19951, + "e.\n\n3": 19952, + "e.\n\n10": 19953, + "patient-reported▁": 19954, + "25▁mg/m2": 19955, + "▁9.2.1": 19956, + "e▁(1)": 19957, + "s▁set▁forth": 19958, + "▁use▁a": 19959, + "\n\nNC": 19960, + "▁data▁cut-off": 19961, + "▁trial▁supplies": 19962, + "y▁of▁Sci": 19963, + "basis": 19964, + "▁should▁be▁administer": 19965, + "▁should▁be▁retain": 19966, + "▁lesions▁per▁organ": 19967, + "\n\nReport": 19968, + "179": 19969, + "NCY": 19970, + "▁the\n\nfollowing": 19971, + "▁preval": 19972, + "\n\nFOLFIRI": 19973, + "Only": 19974, + ".▁Document": 19975, + "s▁are▁identifi": 19976, + "▁dose▁in": 19977, + "completed▁in": 19978, + ".\n\nAMG▁162": 19979, + "e);": 19980, + "efficacy,▁": 19981, + "▁toxic▁factor": 19982, + "\n\n4.4": 19983, + "leuk": 19984, + "e▁below": 19985, + "5-9": 19986, + "▁mg/m▁2": 19987, + ",▁Stein": 19988, + "isks▁of▁a": 19989, + "▁patients▁with▁a": 19990, + "results▁will▁not▁be▁": 19991, + "equential▁": 19992, + "equipment": 19993, + ".\n\nSecondary▁": 19994, + ".\n\nSAFETY": 19995, + "crease▁in": 19996, + "e▁treatment▁in": 19997, + "SCONTIN": 19998, + "▁evaluat": 19999, + "ed▁and▁reported▁lesion": 20000, + "▁Analgesic": 20001, + "▁included▁in▁the▁": 20002, + "▁over▁120": 20003, + "ifferenc": 20004, + "▁factorial": 20005, + "performed:": 20006, + "performance▁with": 20007, + "until▁death": 20008, + "until▁resolution": 20009, + "received▁at▁least": 20010, + "formed▁consent▁must▁be▁obtain": 20011, + "▁cell▁death": 20012, + "considered▁to": 20013, + "▁the▁subject▁has▁": 20014, + "▁this▁study▁are▁": 20015, + "NANCY": 20016, + "discontinued▁for": 20017, + "▁treating": 20018, + "▁et▁al.,▁": 20019, + "▁if▁a": 20020, + "▁if▁they▁": 20021, + ".8%": 20022, + "ioma": 20023, + "\n\n6.5": 20024, + "\n\n6.6": 20025, + ".▁Mayo▁Clin": 20026, + "▁provide▁the▁": 20027, + "▁response▁or": 20028, + "▁disease▁progression▁should▁be▁": 20029, + ",▁surger": 20030, + "modality▁": 20031, + "▁dispos": 20032, + ".▁Have▁you": 20033, + "▁drug?": 20034, + "s▁will▁include▁": 20035, + "current▁version▁of▁the▁": 20036, + ",▁Car": 20037, + "sub-": 20038, + "submission": 20039, + "▁levels▁will▁be▁": 20040, + "▁level▁in▁the▁": 20041, + "▁metastatic▁CRC": 20042, + "\n\nIn▁addition": 20043, + ",▁by": 20044, + "s,▁the▁investigator": 20045, + "cold": 20046, + "▁activation": 20047, + "Add▁": 20048, + "e▁material": 20049, + "\n\nBest": 20050, + "▁cannot": 20051, + "▁administered▁a": 20052, + "▁response": 20053, + ".▁This▁number": 20054, + ".▁This▁information": 20055, + "clinical▁progression": 20056, + "hibited▁": 20057, + "▁this▁treatment": 20058, + "▁this▁time▁point": 20059, + ".▁T▁N▁E▁M▁U▁C▁O▁D\n\nC▁I▁N▁O▁R▁T▁C▁E▁L▁E": 20060, + ",▁Ar": 20061, + "▁descriptive▁": 20062, + "K▁C▁E▁H▁C\n\nE▁S▁A▁E▁L▁P": 20063, + "▁12.4": 20064, + ")(cid:5": 20065, + ")(cid:4)(cid:": 20066, + "estimation": 20067, + "each▁patient": 20068, + "▁Amgen▁for": 20069, + "▁both▁agent": 20070, + "▁availability": 20071, + "▁plus▁sunitinib": 20072, + "known▁to▁be▁": 20073, + ".▁Patients▁should▁be▁": 20074, + "▁bevacizumab▁until": 20075, + "ed▁cardiac": 20076, + "treatment▁phase▁": 20077, + "▁baseline\n\n": 20078, + "▁allowed": 20079, + "long-term▁follow-up": 20080, + "▁every▁6": 20081, + "within▁7": 20082, + "Comprehensive▁": 20083, + "▁a▁member": 20084, + "45▁mL/min": 20085, + "▁Appendix▁XIV▁Page▁": 20086, + "▁Day▁1▁of▁the▁": 20087, + "▁randomized▁treatment": 20088, + "\n\nAppendix▁1": 20089, + "related▁to▁study▁drug": 20090, + "▁hypersensitivity": 20091, + "▁24▁week": 20092, + "indicated▁for": 20093, + "ohen": 20094, + "assessed": 20095, + "assessed▁for": 20096, + "causing": 20097, + "cause▁a": 20098, + "cause▁of▁death": 20099, + "DMC▁charter": 20100, + "head▁of▁the▁": 20101, + "receiving▁panitumumab": 20102, + "ynthes": 20103, + "US)": 20104, + "chemotherapy▁or": 20105, + "▁of▁a▁pre-existing": 20106, + "planation": 20107, + "personal": 20108, + "person▁who▁conducted▁the▁informed▁consent▁discussion": 20109, + "1,▁8": 20110, + "IGNA": 20111, + "▁the▁cas": 20112, + "confirmed▁by": 20113, + "▁spending": 20114, + "▁spinal▁cord▁compression": 20115, + "▁ABI-007▁and▁": 20116, + "▁phase▁I": 20117, + "▁cases,▁": 20118, + "y▁supplement": 20119, + "▁coronary▁": 20120, + "▁symptoms▁": 20121, + "contact▁nam": 20122, + "▁medical▁intervention": 20123, + "\n\n10.6": 20124, + "\n\ntim": 20125, + "es▁or▁no": 20126, + "y▁(BP": 20127, + "▁causes▁": 20128, + "echnology▁": 20129, + ".\n\n5.5": 20130, + "▁further▁treatment": 20131, + "▁Assessments": 20132, + "ature▁and▁": 20133, + "ide▁effects▁of": 20134, + "▁e▁d▁": 20135, + ".▁However,▁the▁": 20136, + ".▁However,▁in": 20137, + "▁eruption": 20138, + ".▁In▁addition,▁the▁": 20139, + "only▁to": 20140, + "▁investigators▁and▁": 20141, + "▁available▁for": 20142, + "▁target▁lesions▁will▁be▁calculated▁and▁": 20143, + "standard▁error": 20144, + "rogen-free▁": 20145, + "▁a▁patient’s▁": 20146, + ".\n\n3.3": 20147, + "respectively,▁": 20148, + "orsening": 20149, + "development▁of": 20150, + "▁Subject▁Information": 20151, + "3-8": 20152, + "▁has▁taken": 20153, + "▁conduct▁of▁the▁study": 20154, + "▁person▁who": 20155, + "s;▁and▁": 20156, + "s;▁however": 20157, + "▁bias▁": 20158, + "▁randomized▁patient": 20159, + "/docetaxel": 20160, + "▁informed▁consent▁document": 20161, + "open-label,▁Phase▁3": 20162, + "e▁samples▁will▁be▁": 20163, + "pain▁severity": 20164, + "pain▁interfer": 20165, + "vitamin▁D▁supplement": 20166, + "▁PR▁nor": 20167, + "rinalysis▁": 20168, + "▁markers▁": 20169, + "s,▁and▁the▁": 20170, + "s,▁and/or": 20171, + "▁clinical▁trials,▁": 20172, + "\n\ndemonstr": 20173, + "▁subjects▁who▁develop": 20174, + "skin▁toxicity": 20175, + "pharmacological": 20176, + "s▁included▁": 20177, + "▁minutes▁apart": 20178, + "es▁will▁not▁be▁": 20179, + "eligible▁subject": 20180, + "▁experiences▁": 20181, + "directly": 20182, + "▁grade▁1": 20183, + "▁et▁al.▁2008": 20184, + "ula▁vita": 20185, + "IMS": 20186, + "listed▁in▁Section": 20187, + "s/SAE": 20188, + ".\n\nNo": 20189, + "▁oncology▁": 20190, + "▁days▁prior▁to▁C1": 20191, + "care▁physician": 20192, + "ligand": 20193, + "▁(multiple▁": 20194, + "▁procedures▁and▁": 20195, + "es▁the▁risk▁of": 20196, + "▁standard▁of": 20197, + "▁remains▁": 20198, + ".\n\nIf▁you": 20199, + "g/m2)": 20200, + "▁JMIG": 20201, + "▁available": 20202, + "▁full-dose▁": 20203, + "▁the▁last▁dose▁of▁study▁treatment": 20204, + "▁characterize▁each": 20205, + "mean▁QTc": 20206, + "frequently": 20207, + "astroesophageal▁": 20208, + "\n\nPharmac": 20209, + "\n\nPhysical▁Examination": 20210, + "▁quality": 20211, + "▁based▁on▁assessment▁of": 20212, + ".▁(or▁equivalent": 20213, + "with▁the▁exception": 20214, + ".▁Expression": 20215, + "generated": 20216, + "\n\nExclusion▁Criteria": 20217, + "▁clinically▁relevant": 20218, + ".\n\nWhen": 20219, + "PRO▁endpoint": 20220, + "▁extensive▁": 20221, + "▁surgery,▁": 20222, + "▁radiation▁therapy": 20223, + "emale▁": 20224, + "s.▁Subject": 20225, + "outh▁America": 20226, + "ogenesis▁": 20227, + "also▁been": 20228, + "\n\n12.1": 20229, + "▁chemistry▁and▁": 20230, + "proposed": 20231, + "796": 20232, + "▁ADMINISTRA": 20233, + "ouble-blind▁": 20234, + "▁discuss▁with": 20235, + "Objectives▁": 20236, + "into▁the▁study": 20237, + "▁intravenously▁": 20238, + "▁..........................................................................": 20239, + "▁...............................................................................▁": 20240, + "s▁have▁been▁observ": 20241, + "▁2▁years▁after▁the▁last▁dose▁of": 20242, + "secondary▁endpoint": 20243, + "▁immune▁": 20244, + "ECOG▁performance▁status▁": 20245, + ".▁There▁are▁no": 20246, + "randomised▁": 20247, + "flammation▁of▁the▁": 20248, + ")▁will▁review": 20249, + "OCBP": 20250, + "consent▁form,▁you": 20251, + "▁dehydration": 20252, + ".\n\nAdditional▁": 20253, + "breviations:": 20254, + "▁by▁the▁Investigator": 20255, + ":▁The▁addition▁of▁panitumumab▁to▁chemotherapy▁(": 20256, + "▁....................................................................": 20257, + "ELOX": 20258, + "▁consisting▁of": 20259, + "1▁and▁8": 20260, + "SSURA": 20261, + "previously▁untreat": 20262, + "ynopsis": 20263, + "▁AUC▁=▁area": 20264, + "begins▁on": 20265, + "pension": 20266, + "▁above▁or": 20267, + "▁3▁weeks▁after▁the▁last▁dose▁of": 20268, + "▁future▁research": 20269, + "▁3.3.5": 20270, + "▁while▁receiving": 20271, + ".▁Chang": 20272, + "▁early▁stopp": 20273, + "company,▁": 20274, + "▁leading▁to": 20275, + "▁goal▁": 20276, + "▁histology▁": 20277, + "statistical▁analysis▁of": 20278, + "▁IRB▁or▁IEC": 20279, + "s.\n\nThe▁investigator": 20280, + "▁days▁prior▁to▁randomization):": 20281, + "▁of▁5▁lesions▁per▁organ": 20282, + "centrally▁": 20283, + ".\n\n.▁T▁N▁E▁M▁U▁C▁O▁D\n\nC▁I▁N▁O▁R▁T▁C▁E▁L▁E": 20284, + "▁disorder▁that": 20285, + "expressed▁in": 20286, + "\n\nAt▁least": 20287, + "shipping": 20288, + "resected▁": 20289, + "▁compensation": 20290, + "\n\nAbbreviations▁and▁Definition": 20291, + "permanent": 20292, + "ate▁(UE": 20293, + "▁continuous▁regimen": 20294, + "▁sequela": 20295, + "-related▁activities": 20296, + "consisting▁of": 20297, + "included▁in▁the▁analysis▁of": 20298, + "▁Status": 20299, + "▁Status▁": 20300, + "▁expected▁": 20301, + "ropoies": 20302, + "▁derived▁from": 20303, + "omatous▁": 20304, + "▁participate▁in▁this▁study,▁you": 20305, + "▁the▁significance▁level": 20306, + "same▁": 20307, + "worst▁pain": 20308, + "chemic▁attack": 20309, + "▁apoptosis▁in": 20310, + "▁includes▁all": 20311, + "▁pemetrexed▁and▁carboplatin": 20312, + "pheral▁neuropathy": 20313, + "Hyd": 20314, + "▁end▁of▁study▁treatment▁visit": 20315, + "orth▁America": 20316, + "WBC▁differential▁(neutrophils,▁": 20317, + "\n\nArm▁A": 20318, + "▁their▁last▁evaluable▁": 20319, + "▁Reported▁Outcomes▁": 20320, + "▁competing": 20321, + ".▁New▁guidelin": 20322, + "▁vertebral▁fracture": 20323, + "-based▁therapy": 20324, + "one▁in▁Patients▁with": 20325, + "issure": 20326, + "e▁the▁following:": 20327, + "recorded▁as▁adverse▁event": 20328, + "▁immediate▁risk▁of▁death": 20329, + "PPENDIX": 20330, + "▁allocation": 20331, + "▁relationship▁between": 20332, + "-BEING": 20333, + "▁gene▁expression": 20334, + "es▁may▁be▁collected▁": 20335, + "concentration▁in": 20336, + ".\n\nAmgen▁Thousand▁Oaks\n\nConfidential\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁AMG▁162▁Protocol▁Number:▁20040135▁Date:▁14▁November▁2006\n\nPage▁": 20337, + "s▁when▁the▁": 20338, + "1999;": 20339, + "half-lif": 20340, + "refer▁to▁Section": 20341, + "metabolism": 20342, + "▁process▁": 20343, + "\n\nProtocol▁Attachment▁JMHR": 20344, + "▁Baseline:": 20345, + "▁ethics▁committe": 20346, + "▁may▁continue▁to▁receive▁": 20347, + "ranulocyte-": 20348, + "▁time▁to▁progression▁(TTP": 20349, + "ordinating▁Investigator": 20350, + "INTRODUCTION": 20351, + "National▁Academ": 20352, + "▁molecular▁biomarker": 20353, + "▁infused▁": 20354, + "▁xenograft▁model": 20355, + "itis▁or▁pulmonary▁fibros": 20356, + "▁General▁Approach/": 20357, + "▁Society▁of▁Clinical▁Oncology": 20358, + "▁incidence▁rates▁of": 20359, + "disclosed▁to": 20360, + "▁creatinine▁clearance▁": 20361, + "VERSE▁EVENT▁REPORTING": 20362, + "organ▁function": 20363, + "al▁policy": 20364, + "thical▁Conduct": 20365, + "AEs▁leading▁to": 20366, + "▁denosumab▁is▁determin": 20367, + "ission▁tomograph": 20368, + "participation▁in▁the▁clinical▁trial": 20369, + "▁will▁be▁responsible▁for▁obtain": 20370, + "international▁": 20371, + "driven": 20372, + "▁in▁writing": 20373, + "\n\nLIST▁OF▁ABBREVIATIONS▁AND▁DEFINI": 20374, + ".\n\nSTUDY▁PROCEDURES": 20375, + "▁emission▁tomograph": 20376, + "tabulated": 20377, + "ysesthesias": 20378, + "chest,▁abdomen,▁and▁p": 20379, + "▁Compare▁the▁Efficacy▁of": 20380, + ",▁whichever▁is▁earlier": 20381, + "prospective▁": 20382, + ".▁Antiemetic": 20383, + "baseline▁sum▁LD": 20384, + "▁knowledge▁of": 20385, + "EOS▁visit": 20386, + "▁MSI-H": 20387, + ".▁Therefore,": 20388, + ".▁Randomized▁phase▁III": 20389, + "al/pericardial▁effusion": 20390, + "ocial/f": 20391, + "▁(June▁": 20392, + "clusive▁": 20393, + "adequately▁": 20394, + "▁approximately▁2▁minutes▁apart": 20395, + "▁neutrophil": 20396, + ",▁alkaline▁phosphatase,": 20397, + "rchiv": 20398, + "▁Applicable▁": 20399, + ".▁Note▁that": 20400, + "Completion": 20401, + "▁Concomitant▁Therapy▁": 20402, + "▁acneiform": 20403, + "▁intravenous;": 20404, + "▁Europe,▁Australia": 20405, + "recogniz": 20406, + "e▁daily;": 20407, + "(cid:149)": 20408, + "bumin-adjusted▁serum▁calcium": 20409, + "▁slice▁thickness": 20410, + "clinical▁research▁physician": 20411, + "▁count,▁hemoglobin": 20412, + "Extension▁Period▁": 20413, + "knowledge▁of": 20414, + "▁recommend▁": 20415, + "▁Revised▁Clinical▁Study▁Protocol▁Drug▁Substance▁ZD4054▁Study▁Code▁D4320C00033▁Edition▁Number▁3▁Date▁15▁February▁2011": 20416, + "▁venous": 20417, + "\n\nIMC-11F8": 20418, + "▁Medicine▁": 20419, + "directed▁against▁the▁": 20420, + "olysorb": 20421, + "▁2007;▁85:": 20422, + "0.22-micron": 20423, + "easons▁for": 20424, + "equal▁to": 20425, + ",▁platelet▁count,▁and▁": 20426, + "▁racem": 20427, + "electrolyte▁": 20428, + "▁CR,▁PR,▁or": 20429, + "▁DISCONTIN": 20430, + "▁Journal▁of▁Cancer": 20431, + "composite▁endpoint": 20432, + "posure▁in▁Utero▁Form": 20433, + "ences▁of▁the▁United▁States▁of▁America": 20434, + "\n\nEthical": 20435, + "rationale▁for": 20436, + "▁Key▁Study▁": 20437, + ".9%▁sodium▁chloride▁solution": 20438, + ",▁in▁accordance▁with▁local▁procedures": 20439, + "]▁Have▁": 20440, + "circl": 20441, + "e▁describ": 20442, + "▁Joint▁Committee▁on▁Cancer": 20443, + "expectancy▁": 20444, + "s▁occurring▁at▁the▁site▁and▁other": 20445, + "desirable▁medical▁condition": 20446, + "axotere®": 20447, + "Master▁Informed▁Consent▁Form": 20448, + "▁reproductive▁potential": 20449, + "REGNANCY": 20450, + "Treatment▁of▁Bone▁": 20451, + "e▁the▁safety▁of": 20452, + "ectibix®": 20453, + "inicrop": 20454, + "▁cervical": 20455, + "▁derive▁": 20456, + "ppearance▁of": 20457, + ",▁power▁would▁be▁": 20458, + "▁sufficient▁increase▁to▁qualify▁for▁PD": 20459, + "▁the▁prior▁written▁consent▁of": 20460, + "▁sufficient▁shrinkage▁to▁qualify▁for▁PR▁nor": 20461, + "▁all▁pre-disease▁performance▁with": 20462, + ",▁Heaney▁RP": 20463, + "itron▁emission▁tomograph": 20464, + "uterine▁": 20465, + "▁is▁obligated▁to": 20466, + "▁of▁World": 20467, + "▁WELL-BEING": 20468, + "judged▁to▁be▁due▁to": 20469, + "mon▁Toxicity▁Criteria": 20470, + "▁SAMPLE▁SIZE": 20471, + "\n\nRestricted▁in▁physically▁strenuous▁activity▁but": 20472, + "▁of▁63▁Finalization▁date:▁June▁19▁2001,▁Incorporating▁amendment▁3▁–▁dated▁23▁May,▁2003\n\nAmerican▁BioScience,▁Inc.\n\nPhase▁III▁Protocol▁CA012-0▁ABI-007▁(Nanoparticle▁Paclitaxel)\n\nCONFIDENTIAL": 20473, + "▁pellet],▁PAXgen": 20474, + "illiam": 20475, + "mineral▁d": 20476, + "ackaging▁and▁Formulation": 20477, + "▁accommod": 20478, + "\n\nYes▁or▁No\n\nPD\n\nAny": 20479, + "able▁to▁Evaluate▁(UE": 20480, + "personally▁dat": 20481, + ",▁confined▁to▁bed▁or▁chair▁more▁than▁50%▁of▁waking▁hour": 20482, + "▁unable▁to▁carry▁out▁any▁work▁activities.▁Up▁and▁about": 20483, + "Kingdom": 20484, + "aenoic▁acid▁": 20485, + "alicyl": 20486, + "verse▁Drug▁Reaction": 20487, + "y▁of▁Sciences▁of▁the▁United▁States▁of▁America": 20488, + ".▁Mayo▁Clin▁Proc": 20489, + "rogen-free▁0": 20490, + "pain▁interferenc": 20491, + "▁ADMINISTRATION": 20492, + "National▁Academy▁of▁Sciences▁of▁the▁United▁States▁of▁America": 20493, + "thical▁Conduct▁of▁the▁": 20494, + "▁DISCONTINUATION": 20495, + "▁all▁pre-disease▁performance▁without": 20496, + "(NA": 20497, + "(FACT-G": 20498, + "(Arm▁A": 20499, + ")]": 20500, + ")▁from": 20501, + ")▁x": 20502, + ")▁prior▁to": 20503, + ")▁of▁0": 20504, + ",▁there▁is▁": 20505, + "-30": 20506, + "-43": 20507, + "-21": 20508, + "-associ": 20509, + ".)\n\n": 20510, + "/bevacizumab": 20511, + "/INR": 20512, + "0.8": 20513, + "350": 20514, + "7:": 20515, + ":18": 20516, + ":▁result": 20517, + ">▁6▁month": 20518, + "?”": 20519, + "Coll": 20520, + "CIMP": 20521, + "DOR": 20522, + "Double-blind": 20523, + "EE": 20524, + "EORTC": 20525, + "Efficacy": 20526, + "IF": 20527, + "Measures": 20528, + "OM": 20529, + "R▁form": 20530, + "R,▁G": 20531, + "S):": 20532, + "Safety": 20533, + "TF": 20534, + "TW": 20535, + "Util": 20536, + "WRS": 20537, + "bid": 20538, + "bone▁scintigraph": 20539, + "bacher": 20540, + "eover": 20541, + "e>>": 20542, + "family▁": 20543, + "felt": 20544, + "g/dL": 20545, + "h▁P": 20546, + "ie▁": 20547, + "ien": 20548, + "iologic": 20549, + "iagnostic": 20550, + "lav": 20551, + "lumbar▁spine▁": 20552, + "ne-": 20553, + "nominal▁significance▁level": 20554, + "os▁": 20555, + "pand": 20556, + "p-valu": 20557, + "rar": 20558, + "rum": 20559, + "ris▁": 20560, + "sf": 20561, + "s▁than": 20562, + "s\n\n13": 20563, + "slid": 20564, + "s▁throughout▁the▁study": 20565, + "s▁apart": 20566, + "two": 20567, + "uent": 20568, + "wart": 20569, + "y:": 20570, + "yet": 20571, + "≥2": 20572, + "▁@": 20573, + "▁ic": 20574, + "▁rout": 20575, + "▁etc": 20576, + "▁early": 20577, + "▁embedd": 20578, + "▁room": 20579, + "▁..............................................................": 20580, + "in▁L": 20581, + "inally,▁": 20582, + "instrument": 20583, + "incipl": 20584, + "invasive▁": 20585, + "▁tri": 20586, + "▁tap": 20587, + "▁tachycardia": 20588, + "▁t-scor": 20589, + "ate▁treatment": 20590, + "on▁first": 20591, + "\n\ndose▁": 20592, + "\n\nobtain": 20593, + "\n\nare▁": 20594, + "\n\nfactor": 20595, + "\n\n________________________________": 20596, + "▁approved▁by▁the▁": 20597, + "er▁H": 20598, + "..........": 20599, + "s▁≥": 20600, + "s▁such▁as": 20601, + "d▁=": 20602, + "al▁anti-": 20603, + "albumin": 20604, + "stance▁": 20605, + "stated": 20606, + "y▁J": 20607, + "▁the▁maximum": 20608, + ",▁11": 20609, + ",▁using": 20610, + ",▁Cl": 20611, + ",▁your": 20612, + ",▁chest": 20613, + ",▁intoler": 20614, + ",▁functional▁well": 20615, + "ed▁directly▁": 20616, + "▁anaphyl": 20617, + ".▁CT": 20618, + ".▁OS": 20619, + "arameter": 20620, + "arsen": 20621, + "ed▁the▁study▁": 20622, + "ed▁the▁data": 20623, + "▁practitioner": 20624, + "▁ceas": 20625, + "▁censor": 20626, + "ing▁agent": 20627, + "▁because▁of": 20628, + "▁beyond▁": 20629, + "es▁and▁the▁": 20630, + "ations▁in": 20631, + "▁to▁which": 20632, + "▁to▁determin": 20633, + "▁to▁improv": 20634, + "▁to▁60": 20635, + "▁to▁the▁investigational▁product": 20636, + "▁to▁take▁part": 20637, + "▁sun": 20638, + "▁six": 20639, + "▁sEGFR": 20640, + "▁selection": 20641, + "asc": 20642, + "asia": 20643, + "▁of▁rest": 20644, + "▁dyspnea": 20645, + "the▁d": 20646, + "▁and▁by": 20647, + "▁and▁at▁the▁": 20648, + "▁and▁paclitaxel": 20649, + "▁and▁followed▁by▁": 20650, + ".\n\n29": 20651, + ".\n\nTher": 20652, + "mental▁": 20653, + "elays": 20654, + "ole▁of": 20655, + "▁APPENDICES": 20656, + "ive▁treatment": 20657, + "▁in▁cancer": 20658, + "▁1-": 20659, + "▁CD": 20660, + "▁CNS": 20661, + "acul": 20662, + "es▁including": 20663, + "es▁such▁as▁": 20664, + "es▁with▁the▁": 20665, + "▁PO": 20666, + "▁Prior▁to": 20667, + "▁PPI": 20668, + "▁(un": 20669, + "▁(12": 20670, + "▁(no": 20671, + "▁(week": 20672, + "▁(1-": 20673, + "▁(kg": 20674, + "emoptys": 20675, + "▁2▁Appendix▁Date▁": 20676, + "used▁at▁baselin": 20677, + "if▁clinically▁indicated": 20678, + "▁SLD": 20679, + "▁Servic": 20680, + "ubrod": 20681, + "▁re-s": 20682, + "▁record▁of": 20683, + "unct": 20684, + "clough": 20685, + "rik": 20686, + "riend": 20687, + "with▁an": 20688, + "apoptotic": 20689, + "▁European": 20690, + "▁EORTC": 20691, + "▁Etoposid": 20692, + "▁E-mail": 20693, + "▁femoral▁neck▁BMD": 20694, + "amma": 20695, + "▁or▁an": 20696, + "▁or▁H": 20697, + "▁or▁un": 20698, + "▁or▁TAXOL": 20699, + "▁or▁intoler": 20700, + "▁or▁vomiting": 20701, + "irrit": 20702, + "utein": 20703, + "theroscl": 20704, + "The▁primary▁": 20705, + "\n\nPK": 20706, + "\n\nPhase▁": 20707, + "\n\nPemetrexed▁H3E-MC-JMHO": 20708, + "endron": 20709, + "▁nature": 20710, + "▁narcotic": 20711, + "istence▁of": 20712, + "\n\nAc": 20713, + "ate▁dehydrogen": 20714, + "▁TSH": 20715, + "▁N▁A\n\nF▁O": 20716, + "oppos": 20717, + "opulation▁of": 20718, + "tocoll": 20719, + "will▁be▁a": 20720, + "asthenia": 20721, + "▁arrhythmia": 20722, + "▁for▁which": 20723, + "▁for▁at▁least": 20724, + "▁for▁the▁first": 20725, + "▁for▁any▁reason": 20726, + "▁RM": 20727, + "e\n\nTo": 20728, + "ed▁in▁the▁study": 20729, + "▁treatment▁discontinuation": 20730, + "ence▁that": 20731, + "ency▁or": 20732, + "ive▁patients▁with": 20733, + "avar": 20734, + "e▁toxic": 20735, + "ed▁before▁the▁": 20736, + "s▁of▁vitamin▁D": 20737, + "ignature": 20738, + "\n\nSkin": 20739, + "\n\nSponsor": 20740, + "\n\nSerious▁adverse▁event": 20741, + "▁is▁suppli": 20742, + "▁is▁required▁for": 20743, + "▁of▁B": 20744, + "▁alkaline▁phosphatas": 20745, + "▁will▁be▁identifi": 20746, + "e▁specifi": 20747, + "e▁the▁dose▁by▁": 20748, + "▁Method": 20749, + "▁conception": 20750, + "coronary▁": 20751, + "ustain": 20752, + "contigu": 20753, + "▁compr": 20754, + "▁Food▁": 20755, + "▁F▁O\n\nY▁P▁O▁C": 20756, + "▁F▁Drug▁Substance▁AZD2171▁Study▁Code▁D8480C00013▁Appendix▁Edition▁Number": 20757, + ".▁As▁a▁result": 20758, + ".▁The▁DMC▁will": 20759, + ".▁The▁most▁common": 20760, + "ity▁is▁": 20761, + "▁as▁compared▁to": 20762, + "▁as▁monotherapy▁": 20763, + "▁as▁defined▁in▁Section": 20764, + "2006;": 20765, + "▁the▁sunitinib": 20766, + "▁the▁schedule▁of": 20767, + "▁are▁currently▁": 20768, + "▁on▁an": 20769, + "ated▁or": 20770, + "ated▁KRAS": 20771, + "ine▁is▁": 20772, + "▁Level": 20773, + "▁L,▁B": 20774, + "▁Leucovorin": 20775, + "eversibl": 20776, + "▁BC": 20777, + "▁this▁form": 20778, + "s,▁low": 20779, + "▁stead": 20780, + "▁strok": 20781, + "ologies▁": 20782, + "▁51": 20783, + "▁61": 20784, + "▁6.4.1": 20785, + "▁6.3.2": 20786, + "from▁normal": 20787, + "ultin": 20788, + "▁patients▁had▁": 20789, + "▁patients▁experiencing": 20790, + "▁400": 20791, + "▁4▁mg": 20792, + "▁the▁path": 20793, + "▁at▁screening": 20794, + "amples▁": 20795, + "s▁(EQ-5D": 20796, + "▁the▁inclusion": 20797, + "▁study▁closure": 20798, + "continued▁": 20799, + "\n\n1.\n\nTo": 20800, + "pool": 20801, + "s▁in▁walk": 20802, + "ximately": 20803, + "genomic": 20804, + ".59": 20805, + "s.▁N": 20806, + "ritish": 20807, + "▁exclusion": 20808, + "▁exacerb": 20809, + "aki": 20810, + "urve": 20811, + "▁after▁the▁last▁dose▁of": 20812, + "cret": 20813, + "s▁and▁regulation": 20814, + "s▁and▁mutant▁KRAS": 20815, + "s▁and▁feet": 20816, + "19]": 20817, + "e▁develop": 20818, + "▁patient▁reported▁": 20819, + "▁the▁docetaxel": 20820, + "▁the▁development": 20821, + "s▁will▁be▁given": 20822, + "s▁will▁be▁based▁on▁the▁": 20823, + "s▁will▁be▁evaluated▁for": 20824, + "ies▁with": 20825, + "▁unresectable▁": 20826, + "▁play": 20827, + "▁time▁that": 20828, + "ies,▁except": 20829, + "orman": 20830, + "evaluate▁": 20831, + ".▁Thre": 20832, + "et▁al,▁199": 20833, + "▁tumor\n\n": 20834, + "iaz": 20835, + "▁73": 20836, + "▁doses▁and▁": 20837, + "effect▁modification": 20838, + ",▁the▁F": 20839, + "may▁patent": 20840, + "pected▁": 20841, + ".64": 20842, + ".66": 20843, + "▁to▁the▁study▁": 20844, + ".▁In▁a": 20845, + ".▁Inter": 20846, + ".▁EuroQol": 20847, + "▁assessments▁at": 20848, + "▁age,▁": 20849, + "▁tested▁": 20850, + "▁testing▁of": 20851, + "s.\n\n7": 20852, + "s.\n\n13": 20853, + "RATOR": 20854, + "114": 20855, + "116": 20856, + "▁medically▁": 20857, + "▁medically": 20858, + ",▁or▁2": 20859, + "radiologic": 20860, + "▁93": 20861, + "▁83:": 20862, + "mitoxant": 20863, + "\n\nNe": 20864, + "\n\nNational▁Cancer▁Institut": 20865, + "prem": 20866, + "s▁with▁performing": 20867, + ").\n\n3": 20868, + ".74": 20869, + ".76": 20870, + "▁should▁be▁given": 20871, + "▁other▁sites▁of▁disease▁": 20872, + "▁your▁willingness▁to": 20873, + "tend▁": 20874, + "▁prevention": 20875, + "ed▁as▁per": 20876, + "▁Study▁Group": 20877, + "\n\nForm": 20878, + "\n\nFOLFOX": 20879, + "▁cycle.\n\n": 20880, + "\n\nTest": 20881, + "\n\n36": 20882, + "\n\n3.5": 20883, + "shorter": 20884, + ".▁Direct": 20885, + "no”": 20886, + "completed▁and▁": 20887, + "completion▁of": 20888, + "▁WJ": 20889, + "principl": 20890, + "e)▁KRAS": 20891, + ".\n\nPatient": 20892, + "5-7": 20893, + "s▁that▁have▁been": 20894, + "\n\nICH": 20895, + "i-dimension": 20896, + "iveness▁of": 20897, + "resulted▁in": 20898, + ".\n\nSafety▁": 20899, + "ated▁to▁be▁": 20900, + ")▁": 20901, + "patients▁in": 20902, + "Analyt": 20903, + "signs▁and▁symptom": 20904, + "▁Annual▁Meeting": 20905, + "▁over▁1▁hour": 20906, + "ruising": 20907, + "▁13.2": 20908, + "▁13.3": 20909, + "performed,▁": 20910, + "performed▁and▁": 20911, + ",▁asthenia": 20912, + ".▁2002;": 20913, + ".▁2005;": 20914, + "▁years,▁": 20915, + "▁the▁subjects’": 20916, + "Investigator's▁": 20917, + "▁group▁A": 20918, + "▁approximately▁every▁": 20919, + "▁ABC": 20920, + "ed.\n\n4": 20921, + "▁discontinue▁the▁": 20922, + "\n\n\n\nis▁": 20923, + "documentation▁of": 20924, + "▁their▁review": 20925, + "▁their▁physician": 20926, + ".▁Baseline▁": 20927, + "▁analysis.": 20928, + "▁and/or▁the▁": 20929, + "ed▁survival▁": 20930, + "collected▁prior▁to": 20931, + "▁occurs▁at": 20932, + "\n\n6.7": 20933, + "▁days.▁The▁": 20934, + "disodium": 20935, + "disorder": 20936, + "ITD": 20937, + "dose▁adjustment": 20938, + "▁disease▁progression▁on": 20939, + "▁should▁receive▁": 20940, + ",▁sever": 20941, + ",▁swell": 20942, + ",▁subsequent": 20943, + "▁these▁event": 20944, + "▁these▁patients▁": 20945, + "roscop": 20946, + ",▁M.D": 20947, + "▁shorter": 20948, + "▁clinical▁practic": 20949, + "X-ray": 20950, + "▁must▁personally▁": 20951, + "▁hours,▁": 20952, + "1-5": 20953, + "1-7": 20954, + "1-Day▁": 20955, + "administered▁to": 20956, + "substitut": 20957, + "▁metastatic▁diseas": 20958, + ".90": 20959, + ".9.1": 20960, + "\n\nInformed▁consent": 20961, + "\n\nInterim": 20962, + "s,▁then": 20963, + "▁1998": 20964, + "▁by▁imaging▁techniqu": 20965, + "▁–▁ag": 20966, + "ABG": 20967, + "ABI": 20968, + "conducted▁": 20969, + "▁information▁should▁be▁": 20970, + "riction": 20971, + "▁to▁identify▁": 20972, + "part▁of▁": 20973, + "▁administration▁of▁study▁drug": 20974, + "▁any▁adverse▁event": 20975, + "were▁no": 20976, + "▁documents▁to": 20977, + "▁document▁their▁review": 20978, + "inal▁Investigational▁Product": 20979, + "▁desquamation*": 20980, + "was▁no": 20981, + "blinded▁to": 20982, + ",▁Hart": 20983, + ",▁Holick▁MF": 20984, + "studies▁of": 20985, + ".\n\nCon": 20986, + "▁change▁to": 20987, + "▁radiological▁": 20988, + "ed▁or▁volunteer": 20989, + "▁OS▁in▁the▁": 20990, + "▁time▁fram": 20991, + "38-": 20992, + "▁plus▁carboplatin": 20993, + "ardiologist": 20994, + "▁Property▁of▁the▁sanofi-aventis▁group▁-▁strictly▁confidential▁WW-CLIN-PR007-SD-03▁VERSION▁n°02▁(19-DEC-2005)\n\nPage▁": 20995, + "▁Proceeding": 20996, + ".▁Patients▁must▁have▁": 20997, + "▁this▁study▁will": 20998, + ",▁Gar": 20999, + ",▁Gray▁": 21000, + "▁AEs,▁": 21001, + "▁Febrile▁": 21002, + "▁who▁will": 21003, + "▁anti-angiogenic": 21004, + "▁Standard▁": 21005, + "determined▁by": 21006, + "s▁at▁the▁time▁of": 21007, + "within▁72▁hour": 21008, + "Common": 21009, + "described▁": 21010, + "describes▁the▁": 21011, + "made▁by": 21012, + "country▁": 21013, + "▁compare▁the▁treatment▁effect": 21014, + "day▁of": 21015, + "▁first▁dos": 21016, + ",▁LDH": 21017, + "\n\nAppendix▁H": 21018, + "ummariz": 21019, + "analysis▁data▁cutoff▁date▁": 21020, + "ify▁the▁investigator": 21021, + "ubling": 21022, + "ashington": 21023, + "disease.\n\n": 21024, + "visual": 21025, + "▁two▁consecutive▁": 21026, + ".▁Oste": 21027, + "11248": 21028, + "▁clinical▁fracture▁": 21029, + "expected▁s": 21030, + ".\n\nTREATMENT": 21031, + "▁15▁minutes▁": 21032, + "ougier": 21033, + "▁class▁": 21034, + "▁OF▁STUDY": 21035, + "ritten▁informed▁consent": 21036, + "▁measurement▁and▁": 21037, + "▁measurements\n\n": 21038, + "▁authorship": 21039, + "\n\nAdd▁10": 21040, + "\n\nthe▁study▁": 21041, + ",▁Rubin": 21042, + ",▁Rimm▁EB": 21043, + "exception▁of▁the▁": 21044, + "except▁Japan": 21045, + "due▁to▁a": 21046, + "▁correction": 21047, + "during▁treatment": 21048, + ",▁as▁follows:": 21049, + "\n\nx\n\nx▁x": 21050, + ".\n\n6.2": 21051, + ".▁Lung▁Cancer": 21052, + "▁condition▁that": 21053, + ".,▁et▁al.,▁The▁": 21054, + "▁period▁is▁": 21055, + "▁Therasse▁et▁al.▁2000": 21056, + "recommended▁but▁not": 21057, + "▁21▁CFR": 21058, + "\n\n.▁T▁N▁E▁M▁U▁C▁O▁D\n\nC▁I▁N▁O▁R▁T▁C▁E▁L▁E": 21059, + "e▁further": 21060, + "▁recording": 21061, + ",▁1995": 21062, + "\n\nmeasurement": 21063, + "Amgen▁Delegation▁of▁Authority▁Form": 21064, + "laboratory▁parameter": 21065, + "LY231514\n\nH3E-MC-JMHD(f)▁Clinical▁Protocol\n\nPage▁": 21066, + "were\n\n": 21067, + "race,▁": 21068, + "FACT-H&N": 21069, + ",▁Fish": 21070, + ".\n\nInt": 21071, + "adverse▁event.▁If": 21072, + "▁e▁p": 21073, + "▁28▁days▁of": 21074, + "▁28▁days▁prior▁to▁randomization": 21075, + "▁comply▁with▁the▁": 21076, + "▁(CPT-11": 21077, + "49▁weeks▁and▁": 21078, + "▁variation▁in": 21079, + "%▁of▁patients▁treated▁with": 21080, + ".▁1996;": 21081, + "operating": 21082, + ".\n\n3.2": 21083, + "▁of▁each▁laboratory▁": 21084, + "ographic▁region": 21085, + "development": 21086, + "renew": 21087, + "renbacher": 21088, + "▁has▁to▁be▁": 21089, + "\n\nVital▁Sign": 21090, + "\n\nVolume▁of": 21091, + "statistician": 21092, + "▁trial▁(": 21093, + "otential▁Risk": 21094, + "▁product▁is▁": 21095, + "▁confoun": 21096, + ",▁magnesium,▁creatinine,▁albumin,▁total▁protein,▁total▁bilirubin": 21097, + "therapy▁in▁patients▁with": 21098, + "▁was▁also": 21099, + "▁was▁administer": 21100, + "▁was▁administered▁": 21101, + "MRT": 21102, + "nontarget▁lesion": 21103, + "▁appropriately▁": 21104, + "▁indicated▁": 21105, + "▁medical▁problem": 21106, + "▁markers": 21107, + "▁identity▁": 21108, + "▁identifying": 21109, + "opy▁number": 21110, + "-day▁period▁": 21111, + "37-": 21112, + "s▁may▁be▁performed▁as▁clinically▁indicated": 21113, + "▁such▁a": 21114, + "T-1": 21115, + "▁micromol/L": 21116, + "▁alone▁in": 21117, + "baseline▁valu": 21118, + "maintaining": 21119, + "▁does▁not▁wish▁to": 21120, + ".\n\n2.2": 21121, + "ing▁in▁a": 21122, + "es▁will▁be\n\n": 21123, + "▁Dose▁Level": 21124, + "safety▁data": 21125, + "ousand▁Oaks,▁CA": 21126, + ",▁analyz": 21127, + "airclough": 21128, + "▁local▁laboratory": 21129, + ",▁capecitabine▁": 21130, + "▁body▁surface▁area": 21131, + "es▁that▁are▁not▁confirmed": 21132, + "held▁": 21133, + "▁physician▁may▁": 21134, + "▁Table▁JMIG": 21135, + "e▁the▁smallest▁s": 21136, + "allowed": 21137, + "▁enrolment": 21138, + "reduced▁to": 21139, + "▁days▁prior▁to▁Day▁1▁of▁Cycle▁1": 21140, + "interim▁analysis▁": 21141, + "evaluated▁leading▁to": 21142, + "\n\nTable▁6": 21143, + "scale▁": 21144, + ".▁Whil": 21145, + "),▁time▁to▁progression▁(TTP": 21146, + "(cid:133)": 21147, + "▁guidelines▁": 21148, + "▁and▁distribut": 21149, + "▁exposed▁to": 21150, + "▁and▁institution": 21151, + "established▁": 21152, + "therapy,▁": 21153, + "best▁supportive▁car": 21154, + ",▁patients▁with": 21155, + "▁assess▁disease▁": 21156, + "ed▁if▁the▁": 21157, + "▁pathology▁": 21158, + ".▁You▁will": 21159, + "s▁arising": 21160, + "graded▁according▁to▁the▁": 21161, + "▁Following▁the▁": 21162, + "oyal▁": 21163, + "▁will▁be▁administered▁": 21164, + "othelioma": 21165, + "▁regardless▁of": 21166, + "\n\nUpon": 21167, + "▁participants▁in": 21168, + "▁surgery▁or": 21169, + "equired▁": 21170, + "▁Access▁to": 21171, + "calcium▁and▁vitamin▁D": 21172, + "Response▁R": 21173, + "performed▁at▁screening": 21174, + "regardless▁of▁whether": 21175, + "e▁and/or": 21176, + "every▁3▁months▁for": 21177, + "▁defined▁as": 21178, + "▁evidence▁of▁progression": 21179, + "▁the▁interim▁analysis▁": 21180, + "database▁": 21181, + "fully": 21182, + "enocarcin": 21183, + "improves▁": 21184, + "improved▁to": 21185, + "..........................": 21186, + "▁Registration": 21187, + "▁calcium▁and▁vitamin▁D": 21188, + "immunotherapy": 21189, + "immunogenicity": 21190, + ".▁Treatment▁Compliance▁": 21191, + "\n\nx▁x▁x▁x▁x▁x▁x": 21192, + "bone▁marrow": 21193, + "▁evaluate▁the▁response▁to": 21194, + "secondary▁efficacy▁endpoint": 21195, + "▁as▁well▁as▁the▁": 21196, + "▁small▁molecul": 21197, + "▁site▁personnel": 21198, + "▁decides▁": 21199, + "\n\nProduct:▁AMG▁162▁Protocol▁Number:▁20040138▁Date:▁19▁February▁2008": 21200, + "▁Overall▁Survival": 21201, + "▁the▁present": 21202, + "e▁discover": 21203, + "▁of▁six": 21204, + "▁coum": 21205, + "followed▁every▁": 21206, + "Drug▁Administration": 21207, + ".▁Kris": 21208, + ".\n\nWhat▁are▁the▁": 21209, + "▁had▁any▁": 21210, + "▁Evaluate▁": 21211, + "▁date▁of▁death": 21212, + "unless▁otherwise▁": 21213, + "▁frequency▁": 21214, + "ed▁for▁each▁treatment▁group": 21215, + "employed▁to": 21216, + "▁evaluate▁whether": 21217, + "for▁example,": 21218, + "correct▁CRF": 21219, + "extent▁of▁your": 21220, + "▁d▁n": 21221, + "Recor": 21222, + "▁1.0▁Appendix▁Date▁": 21223, + "efficacy▁and▁safety▁of": 21224, + "(CrCl": 21225, + "\n\nCR\n\nCR": 21226, + "differenti": 21227, + "▁treated▁subject": 21228, + "\n\nGrade▁2": 21229, + "▁intake▁of": 21230, + "resting▁pulse,▁": 21231, + "▁depend▁": 21232, + ",▁Chen": 21233, + "▁identified▁and▁reported▁lesion": 21234, + "▁Study▁Design▁..............................................................................................": 21235, + "ed-RECIST": 21236, + ".\n\n12.2": 21237, + "▁stratified▁log-rank▁test": 21238, + "s.▁J▁Natl▁Cancer▁Inst": 21239, + "▁paragraph\n\nReplace:": 21240, + "Wild-type▁KRAS▁Efficacy\n\nAnalysis▁Set": 21241, + ",▁constipation,▁": 21242, + "returned▁to▁Amgen": 21243, + "▁worsening▁of▁": 21244, + "superior▁to▁zoledronic▁acid▁with": 21245, + "▁situations▁": 21246, + "▁central▁nervous▁system": 21247, + "most▁commonly▁": 21248, + "▁malignancy": 21249, + "e▁the▁subject’s▁": 21250, + ",▁it▁is▁recommended▁that": 21251, + "▁Taxol/carboplatin": 21252, + "REATMENTS": 21253, + "▁Disease▁Progression": 21254, + "Kaplan-Meier▁method": 21255, + "▁action▁taken": 21256, + "ed▁through▁the▁IVRS": 21257, + "consists▁of": 21258, + "omagnesaemia": 21259, + "ehrenbacher": 21260, + "▁Oxaliplatin/": 21261, + "ulti-center": 21262, + "▁serum▁creatinine▁concentration▁in": 21263, + ",▁the▁patient▁will▁be▁": 21264, + "▁locally▁advanced▁or▁metastatic": 21265, + "site▁personnel▁must": 21266, + "▁matched▁placebo": 21267, + "BJECTIVES▁........................................................................................................": 21268, + "reversible▁": 21269, + "probability▁of": 21270, + "duration▁of▁respons": 21271, + "▁regularly▁": 21272, + "▁box▁number": 21273, + "while▁on▁study": 21274, + "▁ANC▁<": 21275, + "▁where▁the▁": 21276, + "portional▁hazard▁": 21277, + "▁a▁minimum▁of▁": 21278, + ",▁randomized,▁multicenter": 21279, + "progressive▁disease▁will▁be▁": 21280, + ".▁Prevalence▁of": 21281, + "VERSE▁EVENTS": 21282, + "▁6▁weeks▁after": 21283, + "▁modified▁RECIST": 21284, + "▁phase▁III▁trial": 21285, + "▁characteristics▁of": 21286, + "Systems▁": 21287, + "iagnosis▁of": 21288, + ".\n\nK▁C▁E▁H▁C\n\nE▁S▁A▁E▁L▁P": 21289, + ".\n\nK▁C▁E▁H▁C\n\nE▁S▁A▁E▁L▁P\n\n.▁T▁N▁E▁M▁U▁C▁O▁D": 21290, + "study▁is▁designed▁to": 21291, + "adverse▁effects▁of": 21292, + ".▁The▁total": 21293, + "have▁a▁causal▁relationship▁with": 21294, + "▁deterioration▁of": 21295, + "alpit": 21296, + "▁of▁denosumab▁with▁zoledronic▁acid▁": 21297, + "BPI-sf": 21298, + "▁measured▁": 21299, + "objectives▁are▁to": 21300, + "▁specified▁": 21301, + "ulse▁": 21302, + "ed▁only▁if": 21303, + "▁Central▁Tumor▁Response▁": 21304, + "applicable▁law": 21305, + "analysis▁will▁be▁censored▁using▁the▁last▁available▁": 21306, + "e▁signature": 21307, + "comparison▁of": 21308, + "Subcutaneous▁": 21309, + "▁responsible▁for▁the▁": 21310, + ")▁is▁defined▁as▁the▁time▁from": 21311, + "ropoietic": 21312, + "(9):▁p.▁": 21313, + "members▁of": 21314, + "▁satisfied▁with": 21315, + "▁transient▁is": 21316, + "▁how▁to": 21317, + "Target▁Lesions▁": 21318, + "▁trauma": 21319, + "status▁of▁that▁particular": 21320, + "▁anxiet": 21321, + "▁becomes▁pregnant": 21322, + "worsening": 21323, + "▁or▁its▁designe": 21324, + "effect▁of▁AMG▁162": 21325, + "▁I.V.▁(or▁equivalent": 21326, + "preservative▁": 21327, + "effect▁of▁ZD4054▁on": 21328, + "International▁Conference▁on▁Harmonization": 21329, + "Use▁of": 21330, + "most▁recent▁chemotherapy���regimen": 21331, + "examethasone,▁": 21332, + "]▁and▁dependent▁children": 21333, + "appearance▁of▁all▁non-target▁lesion": 21334, + "▁on▁day▁1▁of▁cycles▁": 21335, + "discoveries": 21336, + ".A.,▁et▁al.,▁": 21337, + "Study▁to": 21338, + "eline▁on": 21339, + "ramuscular▁Intravenous▁": 21340, + "aterials▁and▁Methods:": 21341, + "▁authorized▁to": 21342, + ".▁Reporting": 21343, + "▁possibility▁that": 21344, + "elephone:": 21345, + "\n\nPercent": 21346, + "▁some▁cases,▁": 21347, + "Is▁there▁a": 21348, + "rombocytopenia": 21349, + "estimated▁to▁be▁": 21350, + "": 21351, + "forwarded▁to": 21352, + "▁Toxicities▁": 21353, + "ohistochemistry▁(IHC": 21354, + "▁the▁level▁of": 21355, + "\n\nAdd▁5,6": 21356, + "\n\nl\n\na▁c": 21357, + "FFPE": 21358, + "s▁(CTCAE)": 21359, + "one▁scintigraphy▁": 21360, + "▁2008;▁83:": 21361, + "ermatology": 21362, + "/Skin": 21363, + "correlation▁between": 21364, + "ation▁of▁Addendum▁9": 21365, + "▁suitability▁for▁accurate▁": 21366, + "▁supportive▁care▁al": 21367, + "ella▁DF": 21368, + "▁Drug▁Substance▁AZD2171▁Study▁Code▁D8480C00013▁Appendix▁Edition▁Number▁1.0▁Appendix▁Date▁": 21369, + "unused▁portion": 21370, + "ince▁your▁last▁visit": 21371, + "gel▁capsul": 21372, + "residual▁": 21373, + ".\n\nCommon": 21374, + "▁difference▁between": 21375, + "▁taking▁as▁reference▁the▁nadir": 21376, + "-minute▁infusion": 21377, + "▁masses▁that▁are▁not▁confirmed": 21378, + "▁the▁potential▁for": 21379, + "signed▁and▁personally▁dat": 21380, + "▁assigned▁study▁treatment": 21381, + "\n\nEvaluation▁of": 21382, + "respiratory▁rat": 21383, + "displayed▁graphically▁": 21384, + "odds▁": 21385, + "e▁definition▁in▁Section▁4.7.1.1": 21386, + "▁performed▁at▁this▁time▁point": 21387, + "▁Activities": 21388, + "▁(mL/min)\n\n": 21389, + "▁Head▁and▁Neck▁Cancer": 21390, + "/omega-3▁ratio": 21391, + "macor": 21392, + "utopsy▁report": 21393, + "therton▁PM": 21394, + "omega-6/omega-3▁ratio": 21395, + "▁to▁prevent▁one▁of▁the▁outcomes▁": 21396, + "offered▁open-label▁denosumab": 21397, + "elihood": 21398, + "▁laboratory▁and▁": 21399, + "▁demonstrating▁a▁significant": 21400, + "▁demonstrate▁a▁statistically▁significant": 21401, + ".▁Comparison▁of": 21402, + "orld▁Health▁Organization": 21403, + "pG▁island▁": 21404, + "CONFIDENTIAL\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁PANITUMUMAB▁(AMG▁954)▁Protocol▁Number:▁20040249▁Date:▁07▁August▁2007\n\nPage▁": 21405, + "▁and▁post-study▁treatment": 21406, + "\n\n(continued)\n\nH3E-MC-JM": 21407, + "▁will▁be▁censored▁at▁the▁date▁of▁the▁last▁objective▁progression-free▁disease▁assessment": 21408, + "-Etherton▁PM": 21409, + "junctiv": 21410, + "▁31,▁2010": 21411, + ",▁Wolf": 21412, + "eplacement▁of▁Subject": 21413, + ".▁The▁investigator▁should▁notify▁the▁IEC/IRB": 21414, + "s▁-▁Other▁(": 21415, + "\n\nFully▁active,▁able▁to▁carry▁on": 21416, + "active▁Voice▁Response▁System▁(IVRS": 21417, + "▁Practice▁Guidelin": 21418, + "▁(Zubrod": 21419, + "▁MEDIC": 21420, + "▁rank▁test": 21421, + "▁adverse▁event▁reports▁receiv": 21422, + "▁applicable▁sites▁of": 21423, + "▁Accessed▁March": 21424, + "randomly▁assigned▁to": 21425, + "ERIOUS": 21426, + "▁lost▁to▁follow-up": 21427, + ".▁Harv": 21428, + "\n\nCompletely▁disabled.▁Cannot▁carry▁on▁any▁s": 21429, + "▁ambulatory▁and▁able▁to▁carry▁out▁work▁of▁a▁light▁or▁sedentary▁nature,▁": 21430, + "▁and▁lasts▁approximately▁30": 21431, + "▁20020408▁Amendment▁4\n\nPage▁": 21432, + "▁FFPE": 21433, + "▁signs▁the▁consent": 21434, + "▁evaluate▁time▁to": 21435, + "ROQOL▁EQ-5D": 21436, + "▁local▁institutional▁practice),▁": 21437, + "▁survival▁prob": 21438, + "IGNAT": 21439, + "▁person▁who▁signs▁the▁consent": 21440, + "▁of▁5▁lesions▁per▁organ▁and▁10": 21441, + "chest,▁abdomen,▁and▁pelvis": 21442, + "▁Applicable▁(NA": 21443, + "olysorbate▁": 21444, + "▁unable▁to▁carry▁out▁any▁work▁activities.▁Up▁and▁about▁more▁than▁50%▁of▁waking▁hour": 21445, + ".▁Mayo▁Clin▁Proc▁2008;▁83:": 21446, + "▁2▁Appendix▁Date▁7▁September▁2007": 21447, + "e▁the▁dose▁by▁1▁level": 21448, + "▁F▁Drug▁Substance▁AZD2171▁Study▁Code▁D8480C00013▁Appendix▁Edition▁Number▁2▁Appendix▁Date▁7▁September▁2007": 21449, + "s▁in▁walking▁about": 21450, + "RATORY": 21451, + "s▁with▁performing▁my▁": 21452, + "▁must▁personally▁enter": 21453, + "▁by▁imaging▁techniques▁or": 21454, + "▁document▁their▁review▁of▁each▁laboratory▁": 21455, + "▁compare▁the▁treatment▁effect▁of▁denosumab▁with▁zoledronic▁acid▁": 21456, + ".▁Kris-Etherton▁PM": 21457, + "status▁of▁that▁particular▁tumor▁for": 21458, + "▁masses▁that▁are▁not▁confirmed▁and▁followed▁by▁": 21459, + "▁document▁their▁review▁of▁each▁laboratory▁report": 21460, + "▁compare▁the▁treatment▁effect▁of▁denosumab▁with▁zoledronic▁acid▁on": 21461, + "(T": 21462, + ").▁This": 21463, + ",▁to▁the▁": 21464, + ",▁approximately▁": 21465, + ",▁through": 21466, + ",▁according▁to": 21467, + ",▁time▁to": 21468, + ",▁the▁data": 21469, + ",▁assum": 21470, + ",▁thrombocytopenia": 21471, + "-resistant": 21472, + ".B": 21473, + "/U": 21474, + "/week": 21475, + "0.05": 21476, + "118": 21477, + "1)\n\nIf": 21478, + "31)": 21479, + ":▁E": 21480, + ":▁H": 21481, + ":19": 21482, + ":23": 21483, + ":▁Th": 21484, + ";▁the▁": 21485, + "Abraxis": 21486, + "BAP": 21487, + "Cochran-Mantel-Haenszel": 21488, + "Determination": 21489, + "Early▁": 21490, + "G4PFS": 21491, + "Journal▁of": 21492, + "Measurement": 21493, + "Mutant": 21494, + "M-CSF": 21495, + "Non": 21496, + "Oc": 21497, + "ORING": 21498, + "Q2-week": 21499, + "RL": 21500, + "Serum": 21501, + "Selection": 21502, + "Subling": 21503, + "TD": 21504, + "Total▁": 21505, + "V-": 21506, + "])▁and▁": 21507, + "a▁N": 21508, + "a▁R": 21509, + "bad": 21510, + "bilirubin": 21511, + "become▁": 21512, + "cis": 21513, + "cast": 21514, + "cough": 21515, + "candid": 21516, + "dam": 21517, + "eal▁": 21518, + "fing": 21519, + "fraction": 21520, + "glob": 21521, + "gemcitabin": 21522, + "hCG": 21523, + "joint": 21524, + "leptomeningeal": 21525, + "mCRC": 21526, + "mutant": 21527, + "oon": 21528, + "oeb": 21529, + "pplicable▁": 21530, + "package▁insert": 21531, + "paper": 21532, + "pattern": 21533, + "rill": 21534, + "rincip": 21535, + "sper": 21536, + "s▁also": 21537, + "s▁act": 21538, + "side▁": 21539, + "s............................................................................": 21540, + "s▁are\n\n": 21541, + "ui": 21542, + "ual▁pro": 21543, + "uNTx": 21544, + "wound▁": 21545, + "world": 21546, + "zak": 21547, + "α=0": 21548, + "”,▁“": 21549, + "≥▁2": 21550, + "▁earli": 21551, + "▁even▁if": 21552, + "▁............................................................": 21553, + "instruction": 21554, + "▁t▁i": 21555, + "at▁weeks▁": 21556, + "\n\nJ": 21557, + "\n\n\n\nS": 21558, + "\n\ndata": 21559, + "\n\neach": 21560, + "\n\nmanagement": 21561, + "▁average▁": 21562, + "▁avoid": 21563, + "enlarg": 21564, + "erop": 21565, + "or▁p": 21566, + "or▁for": 21567, + "s▁1,▁": 21568, + "s▁cannot▁be▁": 21569, + "reject": 21570, + "recalculated▁": 21571, + "▁throat": 21572, + "als": 21573, + "al▁and▁": 21574, + "strom": 21575, + "stated▁": 21576, + "static": 21577, + "ites▁": 21578, + "itarget": 21579, + "▁the▁E": 21580, + "▁the▁assessment": 21581, + "an▁K": 21582, + ",▁>": 21583, + ",▁X": 21584, + ",▁discontinu": 21585, + ",▁cisplatin": 21586, + ",▁using▁the▁": 21587, + ",▁EGFR": 21588, + ",▁reduc": 21589, + ",▁second▁": 21590, + ",▁±▁3▁days": 21591, + "road▁": 21592, + "ed▁log": 21593, + "ed▁vial": 21594, + "ed▁Dos": 21595, + "edit": 21596, + "edical▁": 21597, + "ed.▁F": 21598, + "ed▁and▁the▁": 21599, + "ed▁assessments▁will▁be▁": 21600, + "▁capacity": 21601, + "▁cumulative▁": 21602, + "ing▁m": 21603, + "ing▁investigator": 21604, + "es▁the▁s": 21605, + "for▁any▁": 21606, + "▁to▁3": 21607, + "▁to▁perform": 21608, + "▁to▁bone▁": 21609, + "▁to▁help": 21610, + "▁to▁check": 21611, + "▁to▁whom": 21612, + "▁sid": 21613, + "▁sec": 21614, + "▁satur": 21615, + "▁skeletal": 21616, + "▁of▁Casodex": 21617, + "those▁": 21618, + "▁murine▁": 21619, + "▁and▁11": 21620, + "▁and▁enter": 21621, + "▁and▁cancer": 21622, + "▁and▁follow-up": 21623, + "▁and▁calcium": 21624, + ".\n\nWith": 21625, + ".\n\n22": 21626, + "elz": 21627, + "absolute▁neutrophil▁count": 21628, + "▁Appro": 21629, + "▁AUT": 21630, + "▁ASSESSMENTS": 21631, + "▁be▁evaluated▁leading▁to": 21632, + "ives,▁": 21633, + "▁in▁NSCLC": 21634, + "▁in▁the▁treatment▁of": 21635, + "▁instanc": 21636, + "impa": 21637, + "ide▁by": 21638, + "▁CJ": 21639, + "accrual": 21640, + "accompani": 21641, + "es▁at": 21642, + "es▁without": 21643, + "▁Post": 21644, + "▁Product:": 21645, + "▁Population": 21646, + "▁Proscribed▁": 21647, + "ilk": 21648, + "▁(an": 21649, + "▁(11": 21650, + "▁(SC": 21651, + "▁(by▁": 21652, + "▁(panitumumab": 21653, + "▁(except": 21654, + "▁(weight": 21655, + "▁(other▁than": 21656, + "▁(e.g.▁": 21657, + "▁(i.e.▁": 21658, + "▁2+": 21659, + "ulated▁in": 21660, + "ulin-": 21661, + "concent": 21662, + "rauterine▁": 21663, + "▁SP": 21664, + "▁SS": 21665, + "▁Subjects▁who": 21666, + "▁restart": 21667, + "▁reveal": 21668, + "ote▁": 21669, + "age/": 21670, + "▁DE": 21671, + "▁Done▁(": 21672, + "cline▁": 21673, + "rief▁Pain▁Inventory▁–▁S": 21674, + "▁hepat": 21675, + "▁happen": 21676, + "▁listing": 21677, + "▁later": 21678, + "▁liter": 21679, + "e▁of▁the▁patient": 21680, + "▁Effect": 21681, + "▁fet": 21682, + "▁fast": 21683, + "▁feasibl": 21684, + "chi": 21685, + "▁or▁PD": 21686, + "▁or▁the▁sponsor": 21687, + "ire▁(": 21688, + "irregular": 21689, + "ysp": 21690, + "formal▁": 21691, + "\n\nPemetrexed▁": 21692, + "\n\nPartial▁": 21693, + "▁nutrient": 21694, + "per▁treatment▁arm": 21695, + "study▁visit": 21696, + "▁and▁approximately▁": 21697, + "ables": 21698, + "▁Offic": 21699, + "▁O’Brien-Fleming": 21700, + "▁prom": 21701, + "▁proper": 21702, + "▁promis": 21703, + "allel": 21704, + "▁Tri": 21705, + "ep▁vein": 21706, + "will▁be▁present": 21707, + "will▁be▁responsible▁for": 21708, + "will▁be▁followed▁for": 21709, + "compart": 21710, + "▁for▁you": 21711, + "▁for▁women": 21712, + "▁for▁Lung▁Cancer": 21713, + "▁for▁femal": 21714, + "▁for▁evaluating": 21715, + "▁RBC": 21716, + "e\n\nth": 21717, + "e\n\nIn": 21718, + "ed▁independent": 21719, + "▁treatment▁by▁": 21720, + "aindra": 21721, + "study▁therapy": 21722, + "▁with\n\n": 21723, + "▁with▁placebo": 21724, + "▁with▁modification": 21725, + "e▁to▁the▁individual": 21726, + "ed▁brain": 21727, + "adin": 21728, + "adenocarcinoma": 21729, + "▁that▁has▁been": 21730, + "▁that▁is▁not": 21731, + "▁is▁permitt": 21732, + "▁is▁preferred": 21733, + "▁alive▁": 21734, + "▁alanine▁transamin": 21735, + "▁will▁be▁performed▁at": 21736, + "eries▁of": 21737, + "▁ML": 21738, + "▁Member": 21739, + "▁M,▁P": 21740, + "▁Monitor": 21741, + "▁Mucos": 21742, + "▁MUGA": 21743, + "▁conclusion": 21744, + "▁of▁the▁adverse▁event": 21745, + "▁of▁the▁diluted▁solution": 21746, + "e,▁pleas": 21747, + "▁oper": 21748, + ".▁The▁study▁will": 21749, + "▁gemcitabin": 21750, + "▁gastric▁cancer": 21751, + "notify▁": 21752, + "▁the▁survival": 21753, + "▁on-": 21754, + ",▁and▁(": 21755, + ",▁and▁by▁": 21756, + "▁vitamin▁B12": 21757, + "▁LA": 21758, + "▁Limit": 21759, + "▁LIST▁OF": 21760, + "▁BA": 21761, + "▁BE": 21762, + "▁Biom": 21763, + "s,▁in": 21764, + "▁all▁SAE": 21765, + "ures▁": 21766, + "▁analyses▁(": 21767, + "▁analyses▁and▁": 21768, + "\n\nCycl": 21769, + "\n\nCycle▁": 21770, + "\n\nCediranib": 21771, + "\n\nClinical": 21772, + "▁5.4.1": 21773, + "▁6.4.2": 21774, + "ultras": 21775, + "▁Hg": 21776, + "▁Hist": 21777, + "▁Hemoglobin": 21778, + "▁patients▁will": 21779, + "▁the▁pemetrexed▁": 21780, + "▁the▁pre-": 21781, + ")\n\n7": 21782, + "▁at▁his▁or▁her": 21783, + "aylor": 21784, + "ay\n\nMonth\n\nYear": 21785, + "s▁(t": 21786, + "▁study▁sit": 21787, + "continue▁to▁receive▁the▁": 21788, + "genotyp": 21789, + "genotyping": 21790, + "genotype▁": 21791, + "s.▁L": 21792, + "s.▁St": 21793, + "relev": 21794, + "▁any▁SAE": 21795, + "▁any▁symptom": 21796, + "▁any▁problem": 21797, + "▁any▁study-related▁": 21798, + "▁VEGFR": 21799, + "▁Vital▁Sign": 21800, + "▁external": 21801, + "▁external▁": 21802, + "onthly▁": 21803, + "\n\nDuration▁of": 21804, + "s▁and▁report": 21805, + "s▁and▁risks▁of": 21806, + "19)(cid:": 21807, + "e▁different": 21808, + "ly▁associated▁with": 21809, + "obes": 21810, + "▁patients.\n\n": 21811, + "10]": 21812, + "▁the▁discontinu": 21813, + "▁the▁destruction": 21814, + "▁the▁duration▁of": 21815, + "▁the▁determination▁of": 21816, + "▁the▁date▁for": 21817, + "TIES": 21818, + "s▁will▁be▁used▁for": 21819, + "▁Goal": 21820, + "reported▁for": 21821, + "▁Urine▁": 21822, + "▁eight": 21823, + "▁times▁to": 21824, + "ies▁and▁": 21825, + ".▁Pregnancy▁": 21826, + "\n\nEthics▁": 21827, + "▁Intern": 21828, + "▁Injection": 21829, + "),▁d": 21830, + "ed▁by▁AstraZeneca": 21831, + "ed▁by▁Pfizer": 21832, + "evaluated▁by▁": 21833, + "▁is▁assum": 21834, + "▁not▁to": 21835, + "ONIT": 21836, + "▁may▁caus": 21837, + "▁76": 21838, + "▁7.8": 21839, + "▁7▁days▁after": 21840, + "suant": 21841, + "▁monthly▁": 21842, + "▁months▁and▁": 21843, + "▁dosing,▁": 21844, + "clinician": 21845, + "may▁be\n\n": 21846, + "s)▁or": 21847, + "▁10▁mL": 21848, + "▁10.6.2": 21849, + ".65": 21850, + ".6%)": 21851, + "▁analysis▁may▁be▁": 21852, + ".▁In▁order▁to": 21853, + ".▁End": 21854, + "▁assessments▁are▁": 21855, + "▁test▁the▁": 21856, + "▁tests▁or": 21857, + "recorded▁at▁baselin": 21858, + "RAD": 21859, + "RAY": 21860, + ",▁and▁the\n\n": 21861, + ".▁CA": 21862, + "▁contra": 21863, + ".▁Time▁to": 21864, + "ed▁with▁other": 21865, + "paraffin": 21866, + ",▁or▁the▁": 21867, + "▁in▁the▁United▁States": 21868, + "e.\n\n5": 21869, + "e.\n\nB": 21870, + "OLOG": 21871, + "▁94": 21872, + "▁96": 21873, + "EGF▁receptor": 21874, + "e▁(IDMC": 21875, + "first▁patient": 21876, + "s▁support": 21877, + "▁each▁group": 21878, + "pre-specifi": 21879, + "preexisting▁condition": 21880, + "s▁with▁the▁": 21881, + "▁data▁for": 21882, + "▁data▁from▁the▁": 21883, + "▁data▁cutoff": 21884, + ").\n\n8": 21885, + ".▁If▁any▁": 21886, + "▁formal▁": 21887, + "basis▁": 21888, + "neither": 21889, + "neurolog": 21890, + "▁the▁investigator▁believ": 21891, + "\n\nReg": 21892, + "▁your▁treatment": 21893, + "Study▁200": 21894, + "▁to▁be▁obtain": 21895, + "▁has▁no": 21896, + "assAR": 21897, + "▁a▁serum": 21898, + "▁the▁study.": 21899, + "▁the▁study.\n\nThe▁": 21900, + "\n\n31": 21901, + "▁the▁patient▁population": 21902, + ".▁Docetaxel": 21903, + ".▁Definition": 21904, + "▁WBC": 21905, + ".\n\nAb": 21906, + "\n\nThe▁overall": 21907, + "▁toxicology▁": 21908, + "\n\n4.2.2": 21909, + ".▁Future▁": 21910, + "leeland▁": 21911, + "ically▁for": 21912, + "uccess": 21913, + "s▁that▁the▁": 21914, + "s▁that▁have▁": 21915, + "23]": 21916, + "\n\nIN": 21917, + "hypersensitivity": 21918, + "▁visits▁": 21919, + "ystal": 21920, + "carcin": 21921, + "care▁but": 21922, + "▁was▁unable▁to": 21923, + "results▁to": 21924, + "flict": 21925, + "performed▁if": 21926, + "in▁the▁form": 21927, + ".\n\nSerum": 21928, + ")▁": 21929, + "main▁study▁": 21930, + "mainten": 21931, + "patients▁may▁": 21932, + "e▁and▁Events▁": 21933, + "provide▁": 21934, + "urvival▁Follow-up": 21935, + "▁Analysis▁Subset": 21936, + "▁the▁study▁protocol": 21937, + "▁must▁be▁completed": 21938, + "s:\n\n1": 21939, + "rown": 21940, + ".▁RECIST": 21941, + "you▁with": 21942, + ".▁2001": 21943, + ".▁2003;": 21944, + "questions▁regarding": 21945, + "▁the▁subject▁is▁": 21946, + "▁the▁subject’s": 21947, + "Investigator▁B": 21948, + "▁completing▁the▁": 21949, + "▁complete▁blood▁count": 21950, + "▁completeness": 21951, + "▁this▁study.": 21952, + "▁this▁study▁and▁": 21953, + "▁approximately▁462": 21954, + ",▁PSA": 21955, + "randomized▁(": 21956, + "▁treating▁physician": 21957, + "document▁contains▁": 21958, + "status▁will▁be▁": 21959, + "▁their▁own": 21960, + "▁et▁al▁2004": 21961, + "▁individ": 21962, + "es▁will▁be▁used▁to": 21963, + "ed\n\non": 21964, + ".▁Both": 21965, + ".▁Bone▁scan": 21966, + "response▁will▁be▁": 21967, + "▁Panitumumab▁in▁Combination▁with": 21968, + "▁receive▁panitumumab": 21969, + "▁=▁creatinine▁clearanc": 21970, + "▁=▁intravenous;": 21971, + "\n\n6.4.1": 21972, + "dispos": 21973, + "discard": 21974, + ".▁Mod": 21975, + ".▁Molecular": 21976, + "▁Cancer▁J": 21977, + "▁events▁are▁": 21978, + ",▁self-care": 21979, + "locally▁": 21980, + ",▁2001": 21981, + ",▁2001.▁": 21982, + "▁may▁be▁given": 21983, + "▁may▁be▁asked▁to": 21984, + "any▁other": 21985, + ".▁High": 21986, + "▁more▁frequ": 21987, + ".2.10": 21988, + "▁non-melanoma▁skin▁cancer": 21989, + "▁survival▁data": 21990, + "▁hours▁of": 21991, + "▁lock": 21992, + "▁relative▁": 21993, + "▁metastatic▁colorectal▁carcinoma": 21994, + "▁results▁are▁": 21995, + ",▁blinded▁": 21996, + ".▁Nature▁": 21997, + "extensive▁": 21998, + "What": 21999, + "▁general▁": 22000, + "▁gene▁c": 22001, + "risk▁of▁": 22002, + "e▁metastas": 22003, + "▁follow-up▁for": 22004, + "▁Only▁": 22005, + "▁Only": 22006, + "\n\nMonitoring": 22007, + "▁administered▁with": 22008, + "conduct▁of▁the▁study": 22009, + "▁responses": 22010, + "▁responsibility▁": 22011, + ".▁This▁is▁": 22012, + "▁to▁irinotecan": 22013, + "▁to▁elimin": 22014, + "▁baseline▁assessment": 22015, + "uthorities": 22016, + "▁placebo▁relative▁to": 22017, + "▁until▁disease▁progression▁or": 22018, + "ogene": 22019, + "change▁in▁the▁": 22020, + "change▁from▁baseline▁": 22021, + "ry▁mouth": 22022, + "▁this▁time▁": 22023, + "placed▁on": 22024, + "▁document▁the▁": 22025, + "▁the▁treatment▁effect": 22026, + "obtained": 22027, + "lesions,▁": 22028, + "▁Clinic": 22029, + "by▁which": 22030, + "diarrhoea": 22031, + "▁neither": 22032, + "▁neutropenic": 22033, + "▁effect▁in": 22034, + ".▁For▁each": 22035, + "ZD4054/placebo": 22036, + "ed▁by▁the▁Sponsor": 22037, + "ype▁1▁error": 22038, + "▁approved▁for": 22039, + "▁plus▁bevacizumab": 22040, + "Consolidation": 22041, + ".▁I▁am": 22042, + "(s)▁or": 22043, + "▁within▁4▁week": 22044, + "▁Subset": 22045, + "freez": 22046, + "start▁of▁the▁study": 22047, + "/Lilly▁or": 22048, + "▁this▁study▁may▁be▁": 22049, + ",▁Gatzemeier▁U": 22050, + "\n\nLesion": 22051, + "\n\nLDH": 22052, + ",▁et▁al.▁The▁": 22053, + "ioid": 22054, + "researcher": 22055, + "▁allows▁for": 22056, + "▁transforming▁growth▁factor": 22057, + "▁every▁6▁week": 22058, + "Common▁Terminology▁Criteria▁for▁Adverse▁Event": 22059, + "described▁below": 22060, + "▁compare▁Casodex": 22061, + "\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX": 22062, + "\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX": 22063, + "\n\nspecific": 22064, + "▁at▁least▁25%": 22065, + "▁mL▁of▁0": 22066, + "Unevaluable▁": 22067, + ",▁Li": 22068, + "▁the▁same\n\n": 22069, + "e▁will▁not▁be▁": 22070, + "▁24▁month": 22071, + "▁24▁and▁48": 22072, + "indicated▁in": 22073, + "▁IV▁antibiotic": 22074, + "▁toxicity▁attributed▁to": 22075, + "▁QU": 22076, + "▁Question": 22077, + "▁two-t": 22078, + "DMC▁will▁be▁": 22079, + "required▁for▁the▁": 22080, + "\n\nOmit": 22081, + "ate▁the▁patient": 22082, + "ability▁to▁determine▁the▁": 22083, + "is▁not▁a": 22084, + "ual▁Int": 22085, + "▁confirmation": 22086, + "▁withdraws▁consent": 22087, + "▁the▁blood▁sampl": 22088, + "at▁least▁one▁dose▁of": 22089, + "\n\nStudy▁Glossary": 22090, + "ralat": 22091, + "ismatch": 22092, + ",▁Ram": 22093, + "▁spine▁": 22094, + "▁cases▁and▁": 22095, + "ephro": 22096, + "HORI": 22097, + "median▁will▁be▁provid": 22098, + "analyses▁will▁be▁": 22099, + "▁symptoms,▁": 22100, + "▁symptoms▁or": 22101, + "100▁mg": 22102, + "100,000": 22103, + "▁prior▁to▁each": 22104, + "▁serum▁concentration": 22105, + "Procedure": 22106, + "▁an▁emergency▁room": 22107, + "▁presence▁of": 22108, + "▁prescription": 22109, + "▁Concentration": 22110, + "▁time▁to▁event": 22111, + "e/SD": 22112, + "postmenopausal": 22113, + "use▁of▁a": 22114, + "hydroch": 22115, + "reasonably▁": 22116, + "fficacy▁Analys": 22117, + "is▁amended▁": 22118, + "cycle▁of": 22119, + ",▁death": 22120, + "▁further▁information": 22121, + "▁X▁X▁X▁X": 22122, + "Amgen▁Thousand▁Oaks": 22123, + "▁ampl": 22124, + "▁highly▁": 22125, + "▁procedures▁should▁be▁": 22126, + "▁days▁after▁receiving": 22127, + "representatives▁of": 22128, + "anuary▁": 22129, + "product▁or▁for": 22130, + "▁last▁dose▁of": 22131, + ",▁Fossella▁F": 22132, + "ey▁are▁": 22133, + "▁Phase▁1": 22134, + "adverse▁event▁CRF": 22135, + "cussion": 22136, + "▁carcinoma▁in▁situ": 22137, + "▁complex": 22138, + "ing,▁stor": 22139, + "ethod▁with": 22140, + "e;▁•": 22141, + "▁Report▁Form": 22142, + "glutam": 22143, + "▁score,▁": 22144, + "▁reasons▁for": 22145, + "planned▁for": 22146, + "olid▁tumour": 22147, + "▁throughout▁the▁study▁": 22148, + "▁throughout▁the▁treatment": 22149, + "▁CTCAE▁Grade▁3": 22150, + "developing": 22151, + "3-9": 22152, + "▁Confidentiality▁": 22153, + "▁interim▁analyses": 22154, + "▁versus▁yes": 22155, + "s;▁•": 22156, + "▁the▁final▁": 22157, + "ited▁data": 22158, + "▁colonic": 22159, + ",▁you▁should▁": 22160, + "therapy▁(": 22161, + "profit": 22162, + "open-label▁treatment▁phase▁": 22163, + "ing▁of▁the▁study": 22164, + "olerability": 22165, + "range▁": 22166, + "ITT▁Analysis▁Set": 22167, + "37.5▁mg": 22168, + "▁a▁potential": 22169, + "▁manifest": 22170, + "▁proteins▁involved▁in": 22171, + "▁improved▁": 22172, + "▁(SGPT": 22173, + "▁localized▁": 22174, + ",▁all▁effort": 22175, + "▁Response▁Evaluation▁Criteria▁in▁Solid▁Tumors▁(RECIST": 22176, + ",▁Europ": 22177, + "guidelines▁in": 22178, + "guidelines▁and▁": 22179, + "pharmacy,▁": 22180, + "functional": 22181, + "staff▁member": 22182, + "Evaluable▁": 22183, + "▁demonstrated": 22184, + "primary▁analyses▁of": 22185, + "raining▁of▁": 22186, + "\n\nNo\n\nSD": 22187, + "▁known▁as▁": 22188, + "HA)": 22189, + "▁enough": 22190, + "reader": 22191, + "reading": 22192, + "▁my▁famil": 22193, + "reported▁if": 22194, + "\n\nTable▁JMIG": 22195, + ".▁At▁the▁time▁of": 22196, + "▁and▁DNA": 22197, + "iresorptive▁": 22198, + "(cid:131)": 22199, + "s.▁After": 22200, + "(b)▁Confidential\n\nPage▁": 22201, + "Schedule,▁": 22202, + ".\n\nRisks▁of▁a": 22203, + "-220": 22204, + "▁remaining": 22205, + ".\n\n9.1": 22206, + "▁example,▁": 22207, + "▁median▁survival": 22208, + "cutoff": 22209, + "cutis/": 22210, + "\n\nIf▁a▁patient": 22211, + "best▁response▁": 22212, + "▁a▁subject▁(or": 22213, + "▁approval▁of▁the▁": 22214, + "▁approval▁must▁be▁": 22215, + "EXT": 22216, + "▁blood▁samples▁for": 22217, + ",▁the▁investigator▁or▁designee▁will": 22218, + "stopping": 22219, + "e▁blood▁[RNA": 22220, + "▁complete▁respons": 22221, + "▁complete▁response▁": 22222, + "▁telephone▁or": 22223, + "Phase▁II": 22224, + "benefit▁from": 22225, + ".▁You▁will▁also▁be▁": 22226, + "▁necessary▁": 22227, + "▁necessarily": 22228, + "\n\nExplanation": 22229, + "▁reduction▁of": 22230, + ".▁The▁investigator▁will": 22231, + "ation▁or▁special": 22232, + "available▁at": 22233, + "2▁weeks▁off": 22234, + "lymphangitis▁": 22235, + "▁extrem": 22236, + "Data▁Monitoring▁Committee▁(DMC": 22237, + "was▁a": 22238, + "was▁associated▁with": 22239, + "▁written▁information": 22240, + "▁written▁agreement": 22241, + "1.5▁x▁109/L": 22242, + "followed▁for▁survival": 22243, + "\n\nPage:▁1": 22244, + "asked▁to▁sign": 22245, + "percentag": 22246, + "▁return▁for": 22247, + "▁systemic▁anti-tumor": 22248, + "Grade▁3/4": 22249, + ".\n\nLY231514\n\nH3E-MC-JMHD(f)▁Clinical▁Protocol\n\nPage▁": 22250, + "ed▁as▁a▁sterile,▁": 22251, + ".▁These▁includ": 22252, + ".▁These▁signature": 22253, + "necessary,▁": 22254, + "hipping": 22255, + "measurements▁(either": 22256, + "▁the▁discretion▁of▁the▁treat": 22257, + ".▁Therapy▁": 22258, + "MSS": 22259, + "Safety▁follow-up": 22260, + "breviation▁or▁special": 22261, + "▁ADVERSE▁EVENTS": 22262, + "\n\ni▁l": 22263, + "\n\ni\n\ns▁": 22264, + "▁request▁or": 22265, + "▁antioxidant": 22266, + "▁EGFR-": 22267, + "..............................": 22268, + "▁is▁the▁responsibility▁of": 22269, + "s▁must▁document▁their▁review▁of▁each▁laboratory▁report": 22270, + "▁direct▁access▁to": 22271, + "▁apply▁to": 22272, + ".▁The▁patient▁has": 22273, + "▁anticancer▁treatment": 22274, + "e▁short": 22275, + "region▁(Western": 22276, + ")▁and▁their": 22277, + "classification": 22278, + "▁independent▁review": 22279, + "\n\nNot▁applicable\n\n": 22280, + "-Term": 22281, + "▁immunogenicity": 22282, + "ed▁as▁an▁AE": 22283, + "colon▁cancer": 22284, + ".▁Statistical▁": 22285, + "▁Antigen": 22286, + "▁Antiemetic": 22287, + "s\n\nAssessment▁of": 22288, + "es▁aware▁of": 22289, + ",▁vomiting,▁": 22290, + "▁make▁a": 22291, + "▁et▁al,▁2003)": 22292, + "has▁a▁p": 22293, + "▁English": 22294, + "ectomy": 22295, + "▁Assess": 22296, + "e▁infusion▁reaction": 22297, + "▁Denosumab▁Protocol▁Number:▁20050244▁Date:▁05▁May▁2008": 22298, + "Quality▁Assurance▁": 22299, + "▁cooper": 22300, + "▁Cooperative▁Group": 22301, + "Dose▁Level": 22302, + "previously▁received▁treatment▁with": 22303, + "empty▁": 22304, + "▁Significant": 22305, + "s.▁There▁": 22306, + "e▁at▁the▁same▁dose▁level": 22307, + "▁2▁weeks▁of": 22308, + "▁his/her▁signature": 22309, + "ynopsis▁": 22310, + "▁General": 22311, + "▁partial▁response▁(PR": 22312, + "upper▁limit▁of▁normal": 22313, + "s\n\nThe▁investigator": 22314, + "ias/d": 22315, + "▁(if▁liver▁metastases▁": 22316, + "▁will▁receive▁a": 22317, + "s▁during▁the▁study▁treatment▁period▁or": 22318, + "deleg": 22319, + "▁entitl": 22320, + "▁Primary▁.......................................................................................................▁": 22321, + "▁anticipated▁": 22322, + "Registration/": 22323, + "▁Serious▁Adverse▁Events▁": 22324, + "▁refers▁to": 22325, + "▁as▁described▁below": 22326, + "▁antitumor▁efficacy▁": 22327, + "positive▁for": 22328, + "patients▁who▁are▁": 22329, + "▁............................................................................................................": 22330, + "▁response▁rate▁(": 22331, + "▁response▁rate▁(ORR": 22332, + "DSMB": 22333, + "New▁England▁": 22334, + "IMC-1121B▁or▁placebo": 22335, + "failure▁": 22336, + "ensity▁(": 22337, + "access▁to▁commercially▁available▁": 22338, + "▁histology": 22339, + "▁histologically▁or▁cytologically▁": 22340, + "▁Guidelines▁": 22341, + "▁Reporting▁Requirements": 22342, + "withdrawn▁from▁study▁treatment": 22343, + "▁of▁CYP3A4": 22344, + "▁(Erbitux": 22345, + "\n\nDose▁Level": 22346, + "▁Secondary▁..................................................................................................": 22347, + "▁unblinding▁the▁study": 22348, + "s.\n\nPage:": 22349, + "paragraph\n\nAdd:": 22350, + "▁withdrawal▁criteria▁are▁met": 22351, + "\n\nOverall▁survival": 22352, + "pathologic": 22353, + "▁in▁this▁substudy": 22354, + "chemistry,▁": 22355, + "number▁of▁vial": 22356, + "▁preserve▁the▁": 22357, + ".▁Clin.▁Oncol": 22358, + "▁glass▁vial": 22359, + "▁the▁final▁analysis": 22360, + "▁elev": 22361, + "\n\nDiscontinue▁bevacizumab": 22362, + ").\n\nSubject": 22363, + "▁increased▁risk▁of": 22364, + "▁Statement": 22365, + ".\n\nThes": 22366, + "▁Pemetrexed▁plus▁": 22367, + "▁5%▁significance▁level": 22368, + "s▁are▁not▁required": 22369, + "rawford▁": 22370, + "eft▁ventricular": 22371, + "▁d▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁Panitumumab▁Protocol▁Number:▁20050203▁Date:▁21▁January▁2009\n\nPage▁": 22372, + "monitoring▁visit": 22373, + ".▁Once▁": 22374, + ".▁Once▁the▁": 22375, + "▁the▁preceding": 22376, + "withdrawal,▁or��death": 22377, + "▁supplementation▁reduc": 22378, + "e▁the▁incidence▁of": 22379, + "s▁involving": 22380, + "▁of▁16\n\nVersion": 22381, + "▁previously▁treated▁with": 22382, + "\n\nAdverse▁Events": 22383, + "laboratory▁and▁": 22384, + "▁Event▁Goal": 22385, + "▁approximately▁30▁minutes": 22386, + "▁(0)": 22387, + "intravenous▁": 22388, + "generalized▁": 22389, + "▁units▁or▁term": 22390, + "utilized▁to": 22391, + "▁Procedures▁for▁discontinuation": 22392, + "published,▁": 22393, + "▁Update▁": 22394, + "radiotherapy▁for": 22395, + "pemetrexed▁500▁mg/m2": 22396, + "recovered▁from": 22397, + "▁modified▁RECIST▁criteria": 22398, + "▁closely▁": 22399, + "30-day▁postdiscontinuation▁follow-up▁period": 22400, + "erythropoietin": 22401, + "▁prostate-specific▁antigen": 22402, + ".▁In▁the▁event▁of": 22403, + "▁statistical▁analysis": 22404, + "90%▁power▁to▁detect": 22405, + "power▁to▁detect": 22406, + "Intent": 22407, + "▁anti-cancer▁therapy": 22408, + "▁Randomized,▁Multicenter": 22409, + "▁episod": 22410, + "urrence▁of": 22411, + ".▁Record": 22412, + "▁repeated▁": 22413, + "(4):": 22414, + "24-month▁treatment▁phas": 22415, + "astrointestinal▁perforation": 22416, + "\n\nN▁A\n\nF▁O\n\nY▁P▁O▁C\n\nD▁E▁T▁N▁I▁R▁P\n\nA\n\nS▁I\n\nS▁I▁H▁T": 22417, + "▁purposes": 22418, + "yes▁vs▁no": 22419, + "investigational▁drug": 22420, + "reamlin": 22421, + "applicable▁regulatory▁requirement": 22422, + "▁Background": 22423, + "urotoxicity▁": 22424, + "BSC▁arm": 22425, + "▁and▁the▁investigator▁agree▁to": 22426, + "▁will▁be▁the▁primary▁": 22427, + "interfere▁with": 22428, + "therapy▁for▁metastatic▁colorectal▁cancer": 22429, + "▁fracture▁(": 22430, + "▁suggest▁that": 22431, + "arcoid": 22432, + "reported▁on▁the▁CRF": 22433, + ",▁panitumumab▁was▁removed▁from▁the▁regimen": 22434, + "▁or▁devic": 22435, + "▁FDA▁1572": 22436, + "RANK": 22437, + "▁itself": 22438, + "-free▁rates▁": 22439, + "▁biological▁samples": 22440, + "\n\nUE/ND": 22441, + ",▁therefore,▁": 22442, + "Japan▁only": 22443, + "▁(FOLFOX)": 22444, + "ortality▁in": 22445, + "▁abnormalities,▁and▁": 22446, + "commercially": 22447, + "▁plots▁of": 22448, + "▁ensure▁the▁": 22449, + "▁erythropoietin": 22450, + "(mg)▁=": 22451, + "worsen": 22452, + "imilar▁to▁that▁of▁the▁": 22453, + "Wild-Type▁KRAS▁Efficacy▁Analysis▁Set": 22454, + "▁within▁30▁days▁of": 22455, + "▁regulatory▁report": 22456, + "International▁Conference▁on▁Harmonisation▁(": 22457, + "pending▁function": 22458, + "clinical▁data▁management": 22459, + "▁change\n\nNo": 22460, + "Cox▁model": 22461, + "▁advantage▁": 22462, + "communication": 22463, + "ultivitamin": 22464, + "\n\nObjectiv": 22465, + "\n\nObjective▁": 22466, + ",▁Johnson▁DH": 22467, + "▁primary▁tumor▁is▁": 22468, + "e.▁Measurement": 22469, + "stein▁L": 22470, + "▁concentrate▁for▁solution▁for▁infusion": 22471, + "▁antifolate▁": 22472, + "▁antifungal": 22473, + "easurable:": 22474, + "Response▁(PR": 22475, + "delivered▁over": 22476, + "steroidal▁anti-": 22477, + "▁candidates▁for": 22478, + "itself": 22479, + "imeric": 22480, + "ribonucleic▁acid": 22481, + "▁non-metastatic▁prostate▁cancer": 22482, + "▁as▁a▁result▁of": 22483, + "down▁of▁this": 22484, + "▁SYST": 22485, + "▁Electronic": 22486, + "ed▁by▁Amgen▁Inc": 22487, + "▁time▁to▁first▁on-study▁SRE": 22488, + "experimental▁arm": 22489, + "Each▁person▁who▁signs▁the▁consent": 22490, + "▁seem": 22491, + "▁synthes": 22492, + "▁Review▁of": 22493, + "rythema": 22494, + "s▁identified▁at▁baselin": 22495, + "proportions▁of": 22496, + "▁change▁of▁lumbar▁spine▁BMD": 22497, + "contribute▁to": 22498, + "100%▁dose▁level": 22499, + "\n\nanalysis▁set": 22500, + "s▁may▁also▁be▁": 22501, + "▁or▁less▁in": 22502, + "▁or▁his/her▁designee▁": 22503, + "(10):▁p.▁": 22504, + "▁1▁(baselin": 22505, + "▁hydration": 22506, + ".org/": 22507, + ".▁In▁this▁cas": 22508, + "▁authorized▁representatives▁of": 22509, + "\n\nA▁®\n\nProduct:▁AMG▁162▁Protocol▁Number:▁20040138▁Date:▁19▁February▁2008\n\nPage▁": 22510, + "serious▁AE": 22511, + ".▁DATA▁ANALYSIS": 22512, + "▁the▁beginning▁of": 22513, + "ECOG▁performance▁status▁(0▁or▁1": 22514, + "PECIAL": 22515, + "PECIFIC": 22516, + "-Reported▁Outcomes▁(PRO": 22517, + "healing▁complication": 22518, + ".▁Br▁J": 22519, + "restricted▁to": 22520, + "▁Independent▁Data▁Monitoring▁Committe": 22521, + ".▁Eligibl": 22522, + "▁neurotoxicity": 22523, + "ability,▁withdrawal,▁or▁death": 22524, + "▁the▁subset▁of▁subjects▁in▁the▁ITT": 22525, + "abetes,▁": 22526, + "unequivocal▁progression": 22527, + "▁virus": 22528, + "identified▁as▁non-target▁lesion": 22529, + "Brief▁Pain▁Inventory▁(BP": 22530, + "same▁method▁of▁assessment": 22531, + ".\n\nWill▁I": 22532, + "▁are▁those▁": 22533, + "Rest▁of▁World": 22534, + "▁post-baseline▁PRO▁assessment": 22535, + "▁redact": 22536, + "▁review▁and▁meta-": 22537, + "\n\nSection:▁Protocol▁Synopsis": 22538, + "decide▁to": 22539, + "▁antihistamin": 22540, + "pulmonis": 22541, + "▁mesothelioma": 22542, + "undergone▁a": 22543, + "Please▁": 22544, + "▁should▁notify▁your▁doctor": 22545, + "▁Epidemiology,▁": 22546, + "e▁indicate▁how": 22547, + "funding▁this▁clinical▁study": 22548, + "▁ever▁comes▁first": 22549, + "y/illness▁that▁is▁": 22550, + "erbst▁RS": 22551, + "▁ascites,▁pleur": 22552, + "single▁agent": 22553, + "i-squar": 22554, + "used▁for▁any▁purpose▁other▁than▁the▁evaluation▁or▁conduct▁of▁the▁clinical▁investigation": 22555, + "\n\nPage:▁36\n\nSection:▁2.3.6.6,▁Anti-Panitumumab▁Antibodies,▁third▁": 22556, + "terim▁Analysis▁and▁Early▁Stopping▁Guidelines": 22557, + "one▁or▁more▁of▁the▁following:": 22558, + "hold▁dose▁until▁toxicity▁is▁grade▁": 22559, + ",▁week▁13": 22560, + "▁l-LV)": 22561, + "patient▁hospitalization▁or▁prolongation▁of▁existing▁hospitalization": 22562, + "▁data▁monitoring▁committe": 22563, + "fracture▁during▁the▁": 22564, + "▁synergistic": 22565, + "epherd▁FA": 22566, + "▁measurable▁lesions▁up▁to▁a▁maximum▁of▁5▁lesions▁per▁organ▁and▁10": 22567, + "pase-3": 22568, + "reedman": 22569, + "▁cynomolgus▁monkeys": 22570, + "amptoth": 22571, + "per-protocol": 22572, + "consisting▁of▁": 22573, + "▁Individual▁Subject": 22574, + "205-216": 22575, + "▁WITH": 22576, + "mClone/Lilly▁or": 22577, + "dentification▁Number": 22578, + "obility,▁self-care": 22579, + "EDTA▁blood▁[plasma▁and▁cell▁pellet],▁PAXgen": 22580, + "▁source▁data▁verification": 22581, + "▁premature▁discontinu": 22582, + "▁imaginable▁health▁stat": 22583, + "\n\n5\n\n6\n\n7\n\n8\n\n9\n\n10": 22584, + ".▁Stat▁Med▁": 22585, + "▁150▁mg▁once▁daily▁with▁placebo▁in▁terms▁of": 22586, + "▁other▁lesions▁(or▁sites▁of▁disease)": 22587, + "▁20040135\n\nPage▁": 22588, + "lymph▁node▁is▁N0": 22589, + ".▁Proceedings▁of▁the▁National▁Academy▁of▁Sciences▁of▁the▁United▁States▁of▁America": 22590, + "/infusion-related▁reaction": 22591, + "iecew": 22592, + "oembryonic▁antigen": 22593, + "▁Subject▁Information▁Sheet": 22594, + "▁(multiple▁event▁analysis": 22595, + "▁racemate▁(or": 22596, + "▁Key▁Study▁Endpoints": 22597, + "▁sufficient▁shrinkage▁to▁qualify▁for▁PR▁nor▁sufficient▁increase▁to▁qualify▁for▁PD": 22598, + "wartz": 22599, + ",▁intolerability,▁withdrawal,▁or▁death": 22600, + "s▁and▁mutant▁KRAS▁tumor": 22601, + "1-Day▁Cycl": 22602, + "inal▁Investigational▁Product▁Reconciliation": 22603, + ".\n\nTREATMENT▁PROCEDURES": 22604, + "recommended▁but▁not▁required": 22605, + "ehrenbacher▁L": 22606, + "portional▁hazard▁model": 22607, + "ermatology/Skin": 22608, + "macor®": 22609, + "▁(Zubrod)": 22610, + "▁must▁personally▁enter▁the▁date▁for": 22611, + "▁by▁imaging▁techniques▁or▁clinically": 22612, + "▁masses▁that▁are▁not▁confirmed▁and▁followed▁by▁imaging▁techniqu": 22613, + "oebel": 22614, + "eropol": 22615, + "es▁the▁smallest▁s": 22616, + "▁AUTHORI": 22617, + "▁Done▁(ND": 22618, + "aindrault": 22619, + "ONITORING": 22620, + "assARRAY": 22621, + "▁compare▁Casodex▁150▁mg▁once▁daily▁with▁placebo▁in▁terms▁of": 22622, + "ual▁Intramuscular▁Intravenous▁": 22623, + "product▁or▁for▁up▁to▁2▁year": 22624, + ",▁all▁efforts▁will▁be▁made▁to": 22625, + "raining▁of▁staff": 22626, + "cutis/pulmonis": 22627, + "breviation▁or▁special▁term": 22628, + "New▁England▁Journal▁of▁": 22629, + "access▁to▁commercially▁available▁product▁or▁for▁up▁to▁2▁year": 22630, + "▁of▁16\n\nVersion▁Date:▁14▁November▁2006": 22631, + "down▁of▁this▁analysis▁set": 22632, + "obility,▁self-care,▁": 22633, + "▁must▁personally▁enter▁the▁date▁for▁his/her▁signature": 22634, + ")▁as": 22635, + ")▁which": 22636, + ")▁is▁a": 22637, + ").▁If▁the▁": 22638, + ",▁to▁be▁": 22639, + "-point": 22640, + "-24": 22641, + "-33": 22642, + "-27": 22643, + "/renew": 22644, + "0.025": 22645, + "1).\n\n": 22646, + "1▁vs▁": 22647, + "2_": 22648, + "354": 22649, + "380": 22650, + "4▁mg": 22651, + "7▁days": 22652, + "8.3": 22653, + ":10": 22654, + ":▁p.▁": 22655, + ":▁Patients▁": 22656, + ":▁To": 22657, + ";▁serum": 22658, + "@may": 22659, + "American▁BioScience,▁Inc": 22660, + "BI": 22661, + "BU": 22662, + "Colon": 22663, + "Diction": 22664, + "EPA": 22665, + "EAR": 22666, + "Effect": 22667, + "FWB": 22668, + "G-CSF": 22669, + "GENC": 22670, + "HIV": 22671, + "H,▁L": 22672, + "Head": 22673, + "J,▁C": 22674, + "Los": 22675, + "LEX": 22676, + "Measurable▁Lesion": 22677, + "NOT": 22678, + "N-telop": 22679, + "PIN": 22680, + "PET": 22681, + "R)": 22682, + "SLD": 22683, + "SNP": 22684, + "Title:": 22685, + "UBL": 22686, + "WH": 22687, + "Work": 22688, + "a▁t": 22689, + "aortic": 22690, + "broad": 22691, + "cillary▁": 22692, + "depend": 22693, + "daily": 22694, + "demographic": 22695, + "dyspnea": 22696, + "done▁in": 22697, + "e\n\nAny": 22698, + "e(s)\n\n": 22699, + "fect": 22700, + "feasibl": 22701, + "friend": 22702, + "gina": 22703, + "gemcitabine-cisplatin": 22704, + "iul": 22705, + "iew": 22706, + "kull": 22707, + "ketoconazol": 22708, + "metic": 22709, + "material▁": 22710, + "o▁A": 22711, + "oedema": 22712, + "pound": 22713, + "palli": 22714, + "palpable▁lymph▁nod": 22715, + "rand": 22716, + "r▁o": 22717, + "r▁e▁": 22718, + "s▁the▁patient": 22719, + "s\n\nSt": 22720, + "s....................................................................................": 22721, + "schema": 22722, + "ta": 22723, + "taking": 22724, + "u▁m▁u": 22725, + "vad": 22726, + "varian": 22727, + "vinorelbine▁": 22728, + "x2": 22729, + "x▁109/L": 22730, + "xenograft": 22731, + "……": 22732, + "▁z": 22733, + "▁utility▁": 22734, + "▁emergency▁": 22735, + "▁elective▁": 22736, + "▁early▁termination": 22737, + "▁occasion": 22738, + "▁β-": 22739, + "e▁N": 22740, + "e▁•": 22741, + "e▁level": 22742, + "ini": 22743, + "in▁2": 22744, + "inary▁": 22745, + "informed▁": 22746, + "ineph": 22747, + "inner": 22748, + "in▁terms▁of": 22749, + "insurance▁": 22750, + "atom": 22751, + "ate,": 22752, + "on▁study": 22753, + "onym": 22754, + "one▁that": 22755, + "one▁of▁the▁following": 22756, + "\n\n:": 22757, + "\n\n": 22758, + "\n\nall": 22759, + "\n\nother": 22760, + "\n\nprogression": 22761, + "\n\nany▁": 22762, + "\n\nchang": 22763, + "\n\nUp": 22764, + "\n\nECG": 22765, + "▁a▁D": 22766, + "▁a▁dose▁of": 22767, + "▁a▁total": 22768, + "▁a▁difference▁in": 22769, + "▁a▁number▁of": 22770, + "▁a▁protocol▁amendment": 22771, + "enabl": 22772, + "enne": 22773, + "energ": 22774, + "oral▁": 22775, + "oregion": 22776, + "............": 22777, + "s▁under": 22778, + "s▁where▁": 22779, + "s▁upon": 22780, + "s▁..................................................................................................": 22781, + "s▁consistent▁with": 22782, + "s▁..............................................................................": 22783, + "s▁regarding▁the▁": 22784, + "reparation": 22785, + "alm": 22786, + "al▁of▁the▁": 22787, + "altern": 22788, + "staging": 22789, + "entry▁": 22790, + "entries": 22791, + "ita": 22792, + "itely▁": 22793, + "it▁should▁be▁": 22794, + "▁the▁D": 22795, + "▁the▁evaluation▁of": 22796, + "animal": 22797, + ",▁50": 22798, + ",▁17": 22799, + ",▁13": 22800, + ",▁16": 22801, + ",▁each": 22802, + ",▁ORR": 22803, + ",▁prostat": 22804, + ",▁whether▁or▁not": 22805, + "ed▁immediately": 22806, + "ed▁chemotherapy▁and▁bevacizumab": 22807, + "▁analog": 22808, + "▁an▁observed▁": 22809, + ".▁28": 22810, + "arcom": 22811, + "ed▁tim": 22812, + "eding,▁": 22813, + "▁press": 22814, + "▁copies▁of": 22815, + "▁caution": 22816, + "ing▁it": 22817, + "ing▁•": 22818, + "ing▁informed▁consent": 22819, + "ing▁whether": 22820, + "▁b)": 22821, + "▁bio": 22822, + "▁border": 22823, + "▁broken": 22824, + "▁business▁": 22825, + "for▁whom": 22826, + "▁to▁us": 22827, + "▁to▁report": 22828, + "▁to▁consent": 22829, + "▁to▁include▁": 22830, + "▁to▁measur": 22831, + "ised": 22832, + "is▁acceptable▁": 22833, + "▁suppression": 22834, + "▁sum▁of▁the▁longest▁diameter": 22835, + "ase:": 22836, + "▁of▁adverse▁event": 22837, + "uming": 22838, + "outer": 22839, + "▁den": 22840, + "▁draft": 22841, + "▁way": 22842, + "▁w▁±": 22843, + "▁window": 22844, + "▁worldwid": 22845, + "▁m▁a▁b": 22846, + "▁myelosuppression": 22847, + "▁and▁24": 22848, + "▁and▁no": 22849, + "▁and▁baseline▁": 22850, + "▁and▁GCP": 22851, + "ometer": 22852, + "udra": 22853, + ".\n\n36": 22854, + ".\n\n38": 22855, + ".\n\nFollow": 22856, + "eliver": 22857, + "▁AC": 22858, + "▁in▁on": 22859, + "▁in▁one▁": 22860, + "▁in▁vitro": 22861, + "▁informed▁of": 22862, + "imulation": 22863, + "respective▁": 22864, + "igand": 22865, + "plit": 22866, + "▁15%": 22867, + "▁Covariates": 22868, + "osmetic": 22869, + "acqu": 22870, + "acy▁of": 22871, + "es▁•": 22872, + "es▁combin": 22873, + "▁Potential": 22874, + "▁Policy▁": 22875, + "▁(f": 22876, + "▁(from": 22877, + "▁(19": 22878, + "▁(20": 22879, + "▁(SAP": 22880, + "▁(507)": 22881, + "▁2%": 22882, + "▁2▁consecutive▁": 22883, + "▁22-hour": 22884, + "used▁with": 22885, + "constitut": 22886, + "▁SEL": 22887, + "▁ITT": 22888, + "▁I▁have▁an": 22889, + "▁reject": 22890, + "otom": 22891, + "otal▁protein": 22892, + "unrelated▁to": 22893, + "▁D8480C00013": 22894, + "with▁other": 22895, + "with▁or▁without": 22896, + "▁li": 22897, + "▁lack▁of▁": 22898, + "e▁of▁0": 22899, + "apter": 22900, + "▁fix": 22901, + "charter": 22902, + "▁or▁c": 22903, + "▁or▁until": 22904, + "▁or▁worsen": 22905, + "e▁taking": 22906, + "formed\n\n": 22907, + "formulated": 22908, + "\n\nParagraph": 22909, + "ized": 22910, + "ized▁for": 22911, + "explan": 22912, + "expir": 22913, + "ecin": 22914, + "▁never": 22915, + "ody": 22916, + "\n\nAvastin": 22917, + "study▁enrollment": 22918, + "study▁personnel": 22919, + "study▁specific": 22920, + "▁Omega-3": 22921, + "▁aspartate▁transamin": 22922, + "▁promoter": 22923, + "▁TRIAL": 22924, + "▁Taxotere®": 22925, + "▁adenocarcin": 22926, + "episod": 22927, + "epresent": 22928, + "opic": 22929, + "opiate▁": 22930, + "will▁be▁used▁for": 22931, + "astolic": 22932, + "computed▁tomograph": 22933, + "▁for▁information": 22934, + "▁for▁men": 22935, + "▁for▁submission": 22936, + "▁for▁more▁detail": 22937, + "andbook": 22938, + "▁Rest": 22939, + "▁Recommendation": 22940, + "ed▁in▁this▁protocol": 22941, + "▁treatment▁of▁": 22942, + "▁treatment▁emergent": 22943, + "study▁therapy▁": 22944, + "▁with▁all": 22945, + "s▁of▁disease▁": 22946, + "Insert": 22947, + "anton": 22948, + "ant▁to": 22949, + "▁2002;": 22950, + "▁is▁of": 22951, + "▁is▁us": 22952, + "▁is▁observ": 22953, + "▁is▁recommend": 22954, + "▁is▁considered▁": 22955, + "▁of▁radiation": 22956, + "▁will▁be▁includ": 22957, + "▁will▁be▁followed▁for": 22958, + "▁will▁be▁based▁on▁the▁": 22959, + "e▁set": 22960, + "erial": 22961, + "e▁this": 22962, + "▁0.1": 22963, + "▁0.33": 22964, + "▁350": 22965, + "▁3▁days": 22966, + "▁3.10": 22967, + "events▁are▁": 22968, + "e,▁F": 22969, + "▁computed▁tomograph": 22970, + "▁Fil": 22971, + "▁Folic": 22972, + "▁Fatt": 22973, + ".▁The▁New▁England▁Journal▁of▁": 22974, + "▁grow": 22975, + "notified▁": 22976, + "2002;": 22977, + "▁the▁sum": 22978, + "▁the▁serious▁adverse▁event": 22979, + "▁on▁placebo": 22980, + "▁ongo": 22981, + ",▁and▁s": 22982, + "▁Long": 22983, + "able▁disease▁": 22984, + "▁BH": 22985, + "▁Best": 22986, + "▁this▁endpoint": 22987, + "s,▁ECG": 22988, + "s,▁2004": 22989, + "s,▁regulation": 22990, + "▁all▁the▁": 22991, + "▁rescu": 22992, + "12]": 22993, + "12▁month": 22994, + "▁stim": 22995, + "\n\nCalcium": 22996, + "▁chem": 22997, + "▁chromosom": 22998, + "▁will▁review": 22999, + "▁will▁consist": 23000, + "▁will▁undergo": 23001, + "e▁index": 23002, + "ing▁the▁investigator": 23003, + "▁5▁mg/kg": 23004, + "▁600▁mg/m2": 23005, + "ultim": 23006, + "▁HIV": 23007, + "and▁who": 23008, + "▁patients▁randomized▁to": 23009, + "▁4.5": 23010, + "▁4▁weeks▁": 23011, + "▁4-week": 23012, + "▁4.10": 23013, + "▁the▁pain": 23014, + ")\n\n1": 23015, + "▁at▁this▁": 23016, + "amples▁will▁be▁": 23017, + "andomized,▁": 23018, + "s▁(P": 23019, + "s▁(Appendix": 23020, + "s▁(i.e.,▁": 23021, + "▁the▁investigation": 23022, + "▁acet": 23023, + "▁acros": 23024, + "egment": 23025, + "egrad": 23026, + "▁study▁closure▁": 23027, + "continuing▁on": 23028, + "\n\n1.\n\n": 23029, + "\n\n1Each▁person▁who▁signs▁the▁consent": 23030, + "vix": 23031, + "poons": 23032, + ".50": 23033, + "ense▁": 23034, + "▁exist": 23035, + "▁exhibit": 23036, + "▁the▁tumour": 23037, + "\n\nDate\n\n": 23038, + "▁after▁a": 23039, + "▁after▁the▁last": 23040, + "▁after▁the▁first": 23041, + "ation▁of▁major▁body▁system": 23042, + "ed▁for▁response▁assessment": 23043, + "s▁and▁In": 23044, + "s▁and▁Amgen": 23045, + "e▁defin": 23046, + ".▁Som": 23047, + ".▁Sign": 23048, + ".▁Spiral▁CT": 23049, + "▁the▁date▁th": 23050, + "▁the▁detail": 23051, + "▁the▁distribution": 23052, + "▁Gl": 23053, + "▁GMT": 23054, + "▁unknown": 23055, + "report▁the▁": 23056, + "report▁accurately▁": 23057, + "▁Upon": 23058, + "▁Using": 23059, + "▁JF": 23060, + "▁J,▁K": 23061, + "▁Number▁of": 23062, + "▁Number▁of▁Center": 23063, + "▁time": 23064, + "▁time,▁": 23065, + "▁time:": 23066, + "▁time-": 23067, + ".▁Pain": 23068, + ".▁Pemetrex": 23069, + "▁In▁the▁": 23070, + "▁from▁your": 23071, + "▁is▁this▁document": 23072, + "▁may▁be\n\n": 23073, + "▁71": 23074, + "▁70%": 23075, + "▁months▁and": 23076, + "▁dosing▁and▁": 23077, + "▁dose▁should▁be▁": 23078, + "ction▁taken": 23079, + "osterior": 23080, + "CTEP": 23081, + "▁adverse▁events,▁including": 23082, + "▁adverse▁events▁(including": 23083, + "▁per▁local": 23084, + "strateg": 23085, + "▁10.3.1": 23086, + "ible▁to": 23087, + ".6▁month": 23088, + "▁to▁the▁last": 23089, + ".▁Informed▁Consent▁Form": 23090, + ".▁In▁general": 23091, + "sover": 23092, + ".▁En": 23093, + ".▁Every▁effort▁should▁be▁made▁to": 23094, + "▁aggregate▁": 23095, + "▁testing▁for": 23096, + "ated▁as▁": 23097, + "recorded,": 23098, + "recorded)": 23099, + "recorded▁since▁the▁treatment▁start": 23100, + "s.\n\nConfidential\n\nPage▁": 23101, + ",▁and▁agree▁to": 23102, + ".▁Caus": 23103, + ".▁Cisplatin": 23104, + ".▁Calcul": 23105, + "115": 23106, + "11]": 23107, + ".▁Test": 23108, + ".▁Tabl": 23109, + "paronychia": 23110, + "’s▁effect": 23111, + "drug▁accountability▁": 23112, + "▁in▁the▁following": 23113, + "e.\n\n2": 23114, + "e.\n\n4": 23115, + "ary▁and▁": 23116, + "▁91": 23117, + "▁95": 23118, + ".,▁C": 23119, + "MGMT": 23120, + "articipating": 23121, + ").\n\nD": 23122, + ".▁If▁this▁": 23123, + ".▁If▁you▁are▁": 23124, + ".71": 23125, + "\n\n2.": 23126, + "\n\n2.\n\n3": 23127, + "▁should▁be▁contact": 23128, + "▁should▁be▁provided▁to": 23129, + "ario": 23130, + "▁lesions▁in": 23131, + "▁the▁investigator▁to": 23132, + "▁the▁investigator’s▁assessment": 23133, + "\n\nRemoval▁of▁Subject": 23134, + "▁your▁DNA": 23135, + "▁Administration▁of": 23136, + "▁precaution": 23137, + "ed▁as▁well": 23138, + "▁Study▁JM": 23139, + "▁you▁receive▁": 23140, + "▁cycles)": 23141, + "\n\nTrial▁": 23142, + "\n\nTraining▁of▁staff": 23143, + "e,▁the▁day▁of": 23144, + "\n\n37": 23145, + "\n\n3.7": 23146, + "shop": 23147, + "▁the▁patient▁has▁been": 23148, + "▁The▁patient": 23149, + ".▁Death": 23150, + ".▁Did▁": 23151, + "s▁are▁being": 23152, + "▁dose▁or": 23153, + "▁dose▁for": 23154, + "▁Will": 23155, + "▁World▁": 23156, + "e)▁for": 23157, + "\n\nThe▁patient": 23158, + "I-GI": 23159, + ".\n\nPh": 23160, + "e▁bone▁": 23161, + "▁therapy.": 23162, + "133": 23163, + ",▁SD": 23164, + "▁visit▁for": 23165, + "defined▁by▁the▁": 23166, + "▁itu▁m▁u": 23167, + "▁therapy▁should▁be▁": 23168, + "es,▁which": 23169, + "results▁are▁": 23170, + "▁actually▁": 23171, + "performed▁when": 23172, + "administrative▁": 23173, + "ing▁to▁a": 23174, + ")▁>": 23175, + "1996": 23176, + "dosing▁schedul": 23177, + "e▁and▁overall": 23178, + "provided▁by": 23179, + "ropyrimidine▁": 23180, + "ack▁pain": 23181, + "▁diary▁": 23182, + "▁the▁study▁in": 23183, + "▁includes▁a": 23184, + "▁must▁be▁report": 23185, + "▁over▁60": 23186, + "▁samples▁and▁": 23187, + "▁infusions▁may▁be▁": 23188, + "▁infusion▁pump": 23189, + ".▁Repeat": 23190, + "NDLING": 23191, + ",▁a\n\n": 23192, + "you▁can": 23193, + "receiving▁the▁": 23194, + "▁site▁of": 23195, + "enrolled▁in▁the▁": 23196, + "▁cellular": 23197, + "considered▁measurable▁": 23198, + "▁subjects▁have▁been": 23199, + "▁years▁from": 23200, + "▁years▁after▁the▁": 23201, + "▁the▁subject▁agrees▁to": 23202, + "▁completed": 23203, + "▁complete▁and▁": 23204, + "agnitud": 23205, + "▁this▁study?": 23206, + "ESTINAL": 23207, + "\n\n\n\nif": 23208, + "outcome▁": 23209, + "▁modest": 23210, + ".▁Bone▁": 23211, + ".▁Because▁the▁": 23212, + ",\n\nor": 23213, + "response▁criteria": 23214, + "ed▁sub": 23215, + "valid▁": 23216, + "▁occur▁when": 23217, + "▁reports▁of": 23218, + "dose▁reduc": 23219, + ",▁symptom": 23220, + ",▁symptomatic": 23221, + "▁these▁other▁treatment": 23222, + "rossover": 23223, + "-time▁": 23224, + "ROINT": 23225, + "s▁will▁have▁": 23226, + "▁non-inferior": 23227, + "unctional": 23228, + "easure▁of": 23229, + ",▁Cox": 23230, + "▁hours▁prior▁to": 23231, + "observed▁with": 23232, + "1-9": 23233, + "1-D": 23234, + "administered\n\n": 23235, + "subcutaneous▁": 23236, + "▁levels▁in": 23237, + "e▁of▁the▁person▁who▁conducted▁the▁informed▁consent▁discussion": 23238, + "1).": 23239, + ".9▁mmol/L": 23240, + "▁blood▁cell": 23241, + "▁blood▁vessel": 23242, + "TION▁OF▁TERMS": 23243, + "non-small-cell▁lung▁cancer": 23244, + "reviewed▁for": 23245, + "\n\nIndependent": 23246, + ",▁by▁": 23247, + ",▁body▁weight": 23248, + "s,▁as▁well▁as▁": 23249, + "▁genotyping": 23250, + "e▁mor": 23251, + "teinuria": 23252, + "\n\nMod": 23253, + "▁administered▁intravenously▁": 23254, + "conduct▁of▁the▁": 23255, + "▁response,▁": 23256, + "▁received\n\n": 23257, + "▁to▁zoledronic▁acid": 23258, + "▁to▁keep": 23259, + "mitted▁to": 23260, + "party▁": 23261, + "clinical▁examination": 23262, + "blank": 23263, + "ogenomic": 23264, + "▁anyone▁": 23265, + "when▁they▁are▁s": 23266, + "your▁identity▁": 23267, + "▁documents,▁": 23268, + ",▁AND": 23269, + "▁despit": 23270, + "▁Arm▁1": 23271, + "▁12▁months▁of": 23272, + ")(cid:32": 23273, + "22]": 23274, + ",▁Holl": 23275, + "Printed▁copy▁is▁not▁official▁record": 23276, + "-57": 23277, + "eanu": 23278, + "yltransfer": 23279, + "...........................................................................▁": 23280, + "under▁applicable▁law": 23281, + "panitumumab▁infusion": 23282, + "must▁have▁been": 23283, + "s▁of▁the▁protocol": 23284, + "ities▁of": 23285, + "▁disease-fre": 23286, + "▁approved▁in": 23287, + "qualified▁": 23288, + "ite▁staff": 23289, + "ite▁personnel": 23290, + "s▁should▁be▁performed▁as▁": 23291, + "▁Program": 23292, + "free▁of": 23293, + "▁bevacizumab▁plus▁": 23294, + "▁bevacizumab▁in▁combination▁with▁FOLFOX": 23295, + "/Leucovorin": 23296, + "▁Drug▁Safety▁": 23297, + "(cid:120)▁": 23298, + "▁AEs▁and▁": 23299, + "▁country": 23300, + "▁chemotherapy▁are▁": 23301, + "s▁and▁then": 23302, + "▁who▁is▁not": 23303, + "▁who▁received▁": 23304, + "within▁a": 23305, + "▁according▁to▁local▁": 23306, + "▁according▁to▁standard▁": 23307, + "described▁in▁Appendix": 23308, + "▁first▁subject": 23309, + "provision": 23310, + "▁vertebral": 23311, + "▁develop▁a": 23312, + "▁develops▁": 23313, + "analysis▁set": 23314, + ",▁prior": 23315, + "▁hypertensive▁": 23316, + "▁hypersensitivity▁to": 23317, + "e▁will▁also": 23318, + "e▁will▁undergo": 23319, + "▁+▁5-FU": 23320, + "UMB": 23321, + "visual▁": 23322, + "assessed▁": 23323, + "▁toxicity▁recur": 23324, + "▁QD": 23325, + "▁assigning": 23326, + "normalized▁": 23327, + "▁KRAS▁WT": 23328, + "▁clinical▁research": 23329, + "▁ChRT": 23330, + "/metastatic": 23331, + "study▁treatment▁period": 23332, + "ing▁skin": 23333, + "ing▁serum": 23334, + "▁Adverse▁Events▁(": 23335, + "▁bone▁density": 23336, + "▁1500": 23337, + "▁confirm▁the▁": 23338, + "▁confirm▁that": 23339, + "SAER▁form": 23340, + "▁withdraw▁from▁the▁study": 23341, + "▁the▁beginning": 23342, + "at▁least▁5": 23343, + "andomised,▁": 23344, + "iquantitative▁": 23345, + "1,▁22": 23346, + "rofolate▁": 23347, + "▁Treatment▁Arm": 23348, + "▁Treatment▁Arm▁B": 23349, + "▁measurements▁of": 23350, + "▁the▁end▁of▁study": 23351, + "chemotherapy▁and▁": 23352, + "stored▁in▁the▁": 23353, + "\n\nAdd▁12": 23354, + "▁20▁mg/mL": 23355, + "▁phase▁1": 23356, + "most\n\n": 23357, + "most▁severe▁": 23358, + "▁is▁not▁consider": 23359, + "y▁scan": 23360, + "...........................................................▁": 23361, + "▁AND▁S": 23362, + "▁AND▁PROCEDURES": 23363, + "▁these▁two": 23364, + "▁advanced▁HNC": 23365, + ");▁and▁": 23366, + "Experience▁": 23367, + "Exclusion▁Criteria": 23368, + "▁mg/kg▁to": 23369, + ".\n\n6.3": 23370, + ".\n\n6.4": 23371, + "dependent▁on": 23372, + "▁contains": 23373, + "▁CASE": 23374, + ".▁Administration": 23375, + "pothesis": 23376, + "Project": 23377, + "▁PD▁PD": 23378, + "ance▁of▁approval▁must▁be▁": 23379, + "▁an▁optional": 23380, + "▁an▁outpatient": 23381, + "▁prior▁bevacizumab": 23382, + "▁Continu": 23383, + "▁sunitinib▁administer": 23384, + "▁Grade▁≤": 23385, + "withdrawal▁of▁consent": 23386, + "e/carboplatin": 23387, + "morning": 23388, + "y▁(or": 23389, + "2-year": 23390, + "off-F": 23391, + "central▁lab": 23392, + "▁cause▁of": 23393, + "▁causality▁": 23394, + "▁human▁tumor": 23395, + "▁human▁immunodeficiency▁vir": 23396, + "reasonable▁": 23397, + "reasons▁for": 23398, + "reason(s)": 23399, + "closure▁of": 23400, + "▁recorded▁since▁the▁treatment▁start": 23401, + "ated▁into": 23402, + "have▁to": 23403, + "have▁to▁be▁": 23404, + "▁date.": 23405, + ".\n\nEach": 23406, + ",▁1990": 23407, + "ised▁of": 23408, + "▁anticoagulation": 23409, + "vestigational▁Plan": 23410, + "vestigational▁New": 23411, + "\n\nmetastatic": 23412, + ",▁decreas": 23413, + "laboratory▁finding": 23414, + "Assessments:": 23415, + "▁Assessments\n\n": 23416, + "racer": 23417, + "FACT-C": 23418, + ",▁Fehrenbacher▁L": 23419, + "▁concentration▁of▁the▁diluted▁solution": 23420, + "life-": 23421, + "ation,▁it▁is▁": 23422, + "3).▁The▁": 23423, + "▁(Cella": 23424, + "glomerular▁filtration": 23425, + "only▁the▁": 23426, + "▁scores▁": 23427, + "▁Nov▁2009": 23428, + "▁designated▁": 23429, + "Endpoints▁": 23430, + "ed▁method▁of": 23431, + "standard▁practic": 23432, + "dictive▁": 23433, + "▁CTCAE▁Grade▁3▁or▁4": 23434, + "e▁Point": 23435, + "appa": 23436, + "developed▁a": 23437, + "▁treatment▁arms:": 23438, + "ETERMINATION▁OF": 23439, + "▁the▁primary▁efficacy▁endpoint": 23440, + "▁has▁also▁been": 23441, + "▁conducted▁": 23442, + "medical▁information": 23443, + "appropriate▁section": 23444, + "▁If▁a▁patient": 23445, + "▁power▁to": 23446, + "▁randomized▁patients▁": 23447, + "▁randomized▁clinical▁trial": 23448, + ",▁mean": 23449, + "up▁to▁2": 23450, + "ing▁of▁the▁study▁for": 23451, + "▁was▁amend": 23452, + "▁the▁data▁from": 23453, + "▁medical\n\n": 23454, + "▁November▁2005": 23455, + "▁identity": 23456, + "▁clinical▁trials▁of": 23457, + "▁clinical▁trials▁in": 23458, + "▁Safety▁Analysis▁Set": 23459, + "37.5": 23460, + "e,▁the▁report▁accurately▁": 23461, + "acceptabl": 23462, + "▁oxaliplatin▁or▁irinotecan": 23463, + "▁the▁dispens": 23464, + "procedures▁and": 23465, + "needed": 23466, + "second-line▁": 23467, + "es▁that▁I": 23468, + "▁“yes": 23469, + "▁function,▁as▁follows▁(≤": 23470, + "directly▁to": 23471, + "held": 23472, + "....................................................................................................................": 23473, + "\n\nConfidential\n\nAMGEN\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁AMG▁162▁Protocol▁Number:▁20040135▁Date:▁14▁November▁2006\n\nPage▁": 23474, + "▁et▁al.▁2006": 23475, + "health▁status▁": 23476, + "▁known▁to▁be▁": 23477, + "urinary": 23478, + "▁6▁months▁prior▁to": 23479, + "▁minimum▁of▁": 23480, + "▁(PRO": 23481, + ".▁53": 23482, + ".▁One▁": 23483, + ".▁Only": 23484, + "important▁for": 23485, + "important▁to▁the▁": 23486, + "important▁medical▁event": 23487, + "history": 23488, + "metastatic▁disease▁": 23489, + "metastatic▁colorectal▁cancer": 23490, + "activities": 23491, + "▁guidelines▁for": 23492, + "▁kept": 23493, + "common▁(": 23494, + "s.▁Abstract": 23495, + "schedule▁": 23496, + "scheduled▁visit": 23497, + "▁postdiscontinuation": 23498, + "Schedule": 23499, + "\n\nbone▁": 23500, + "89;": 23501, + ",▁O’": 23502, + "▁involves▁": 23503, + "▁Casodex▁150▁mg": 23504, + ".\n\n9.2": 23505, + "cut-off": 23506, + "working": 23507, + "best▁interest": 23508, + "best▁currently▁available▁": 23509, + "▁significance▁level▁of▁0.05": 23510, + "▁approval/renew": 23511, + "specifically▁": 23512, + "outlined▁in▁section": 23513, + "▁characteristics▁": 23514, + "frequent": 23515, + "▁the▁sample▁siz": 23516, + "original▁sign": 23517, + ",▁the▁investigator▁will": 23518, + "▁adverse▁effects▁of": 23519, + "▁Recurrent": 23520, + "\n\nConfidential\n\nAMGEN\n\nProduct:▁Darbepoetin▁alfa▁Protocol▁Number:▁20010145▁Date:▁16▁July▁2004\n\nPage▁": 23521, + "▁pemetrexed▁500▁mg/m2": 23522, + "▁pathways": 23523, + "objective▁response▁rat": 23524, + "judgement": 23525, + "s▁are▁th": 23526, + ".▁Examples▁of": 23527, + "urvival▁(OS": 23528, + "implication": 23529, + "graded▁according▁to": 23530, + "▁reduction▁in▁the▁": 23531, + "▁Research▁B": 23532, + "next▁cycle▁": 23533, + "hypothesis▁": 23534, + "hypothesis▁that": 23535, + "▁INVESTIGATOR": 23536, + "upon▁request": 23537, + "▁contact▁the▁": 23538, + "▁extract": 23539, + "▁participants▁who": 23540, + "▁vs.▁3.1": 23541, + "▁dosing▁decision": 23542, + "▁affect▁the▁": 23543, + "percentage▁": 23544, + "▁requiring▁s": 23545, + "▁Dose\n\n": 23546, + "▁this▁protocol,▁the▁": 23547, + ",▁unacceptable▁toxicity": 23548, + "▁accounting▁for": 23549, + "ed▁as▁a▁SAE": 23550, + "\n\nConcurrent": 23551, + "necessary▁to": 23552, + "necessary▁to▁elimin": 23553, + "▁CT▁scan▁or▁MRI": 23554, + "date▁and▁": 23555, + "▁EGFr▁signaling": 23556, + "▁into▁the▁study": 23557, + "▁blood▁and": 23558, + "lung▁cancer": 23559, + "▁adverse▁events▁occurring": 23560, + "eligibility▁criteria": 23561, + "▁EGFR▁expression": 23562, + "into▁the▁": 23563, + "▁directly": 23564, + "▁months▁versus▁": 23565, + "permitted▁": 23566, + "\n\nx▁x▁x\n\nx\n\nx": 23567, + "ulmonary▁embolism": 23568, + "had▁been": 23569, + "▁had▁been": 23570, + "TS\n\na.\n\nWhat": 23571, + "▁blockad": 23572, + "potential▁biomarker▁development": 23573, + "itting": 23574, + "complianc": 23575, + "defined▁as▁4▁week": 23576, + "y-Stimulating▁Factor": 23577, + "compared▁with▁docetaxel": 23578, + "▁showed▁": 23579, + "preferabl": 23580, + "▁et▁al,▁2004": 23581, + "▁supply": 23582, + "reporting/": 23583, + "▁2007;▁99": 23584, + "e▁disappearance▁of": 23585, + "unless▁the▁": 23586, + "▁United▁": 23587, + "▁some▁circumstanc": 23588, + "▁and▁EPA+DHA": 23589, + "▁Algorithm": 23590, + "response▁rate▁was▁": 23591, + "▁Collaborator": 23592, + "▁supportive▁care": 23593, + "▁commercial▁": 23594, + "\n\nCT▁scan": 23595, + "▁legally▁acceptable\n\n": 23596, + "▁and▁for▁6▁month": 23597, + "Non-Target▁Lesion": 23598, + "▁of▁an▁over": 23599, + "▁of▁an▁Adverse▁Event": 23600, + "orticoid": 23601, + "\n\nWhere▁": 23602, + "▁set-up": 23603, + "osteopor": 23604, + "extent▁of": 23605, + "▁doses▁of▁panitumumab": 23606, + "▁Analyses▁of": 23607, + "TTPD": 23608, + "\n\nCRF": 23609, + "\n\nCR\n\nNo": 23610, + "\n\nChemotherapy▁": 23611, + "▁authorized▁under▁applicable▁law": 23612, + "THICAL": 23613, + "Regimen": 23614, + "▁Assoc": 23615, + "▁Associ": 23616, + "additive▁": 23617, + "▁as▁described▁abov": 23618, + "progression-free▁survival▁(PFS": 23619, + "patients▁who▁have▁": 23620, + "anticoagulation": 23621, + "▁temperature▁recording": 23622, + "▁liver▁metastases": 23623, + "1/3": 23624, + "▁EVALUATIONS": 23625, + "formance▁Status": 23626, + "ing▁any▁record": 23627, + "▁ICD": 23628, + "outside▁of▁the▁": 23629, + "TIONS▁OF": 23630, + "▁initially▁": 23631, + "methods▁": 23632, + "retained▁at": 23633, + "▁an▁extension": 23634, + "▁cm3": 23635, + "ure▁information": 23636, + "e.\n\nThe▁investigator": 23637, + "▁There▁is▁no": 23638, + "▁classified▁as▁": 23639, + "ASTROINT": 23640, + "▁endothelial▁growth▁factor▁receptor": 23641, + "amide,▁": 23642, + "ctivities▁": 23643, + ".▁Clinical": 23644, + "given▁to▁you": 23645, + "▁transfusions,▁": 23646, + "y/illness▁": 23647, + "▁quarter": 23648, + "▁OF▁TRIAL": 23649, + "▁elderly▁": 23650, + ",▁etc.)": 23651, + "▁recovery": 23652, + ".\n\nC▁I▁N▁O▁R▁T▁C▁E▁L▁E\n\nN▁A": 23653, + "▁or▁near": 23654, + "Investigational▁Product▁Accountability▁": 23655, + "▁USP": 23656, + "▁µg/mL": 23657, + "Carboplatin▁and▁Bevacizumab": 23658, + "serious”": 23659, + "▁Europe▁versus▁": 23660, + "▁malignant▁pleur": 23661, + "ysical▁Exam": 23662, + "Lilly▁clinical▁research▁physician": 23663, + "ield▁": 23664, + "procedure▁for": 23665, + "▁AND▁DETERMINATION▁OF": 23666, + "Quintiles▁Laboratories▁": 23667, + "▁Epidermal▁": 23668, + "▁Observation": 23669, + "▁months,▁respectively": 23670, + ".▁Dose▁reduction": 23671, + "▁variable▁and▁": 23672, + "▁writing": 23673, + "▁75%▁of▁previous▁": 23674, + "hemoglobin▁concentration": 23675, + "▁lower▁level": 23676, + "2000;": 23677, + "\n\n.▁E▁S▁U\n\nE▁R▁O▁F▁E▁B\n\nY▁T▁I▁D▁I▁L▁A▁V\n\nS▁T▁I\n\nK▁C▁E▁H▁C\n\nE▁S▁A▁E▁L▁P\n\n.▁T▁N▁E▁M▁U▁C▁O▁D\n\nC▁I▁N▁O▁R▁T▁C▁E▁L▁E\n\nN▁A\n\nF▁O\n\nY▁P▁O▁C\n\nD▁E▁T▁N▁I▁R▁P\n\nA\n\nS▁I\n\nS▁I▁H▁T": 23678, + "vs.▁>▁6▁month": 23679, + "progressive▁disease▁or": 23680, + "▁and▁an▁IV▁infusion": 23681, + "recorded▁as▁adverse▁events▁": 23682, + "▁immediate▁hazard": 23683, + "recovery▁": 23684, + ".\n\nPatients▁who": 23685, + "▁close▁to": 23686, + "30-day▁postdiscontinuation▁follow-up▁period▁": 23687, + "below▁the▁": 23688, + "solute▁neutrophil▁count▁(ANC": 23689, + "▁taking▁as▁references▁the▁smallest▁s": 23690, + ".\n\nAmgen▁Thousand▁Oaks\n\nConfidential\n\nAMGEN\n\nProduct:▁darbepoetin▁alfa▁Protocol▁Number:▁20010145▁–▁Amendment▁2▁Date:▁16▁July▁2004\n\nPage▁": 23691, + "hypomagnesemia": 23692, + "▁epithel": 23693, + "\n\nany": 23694, + "atory▁tract▁infection": 23695, + "▁Trial▁of": 23696, + "goals▁for": 23697, + "▁symptomatic▁progression": 23698, + "▁directly▁or▁to": 23699, + "lice▁thickness": 23700, + "used▁as▁referenc": 23701, + "found▁to▁be▁abnormal": 23702, + "▁studied▁in": 23703, + "ed▁information▁about": 23704, + "e▁submission": 23705, + "▁examine▁the▁": 23706, + "▁Pharmacogenetic": 23707, + "▁ANY": 23708, + "▁(n=": 23709, + "▁Adverse▁event▁evaluation": 23710, + "EFINITION▁OF": 23711, + "inancial": 23712, + "▁all▁randomized▁subjects▁have▁": 23713, + "▁400▁mg/m2▁IV": 23714, + "RBC▁count,▁hemoglobin": 23715, + "confidentiality▁of▁your▁medical▁record": 23716, + "▁Clar": 23717, + "▁PLAN▁AND▁PROCEDURES": 23718, + "e▁interaction": 23719, + "rednison": 23720, + "abdominal": 23721, + "▁the▁subset▁of": 23722, + "▁subject▁is▁randomiz": 23723, + "e▁but▁are▁not▁limited▁to": 23724, + "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n": 23725, + "▁<1": 25568, + "Abstract": 25569, + "BW": 25570, + "Baselin": 25571, + "Breast▁Cancer": 25572, + "CE": 25573, + "CL": 25574, + "Ct": 25575, + "Criteria▁for": 25576, + "C,▁W": 25577, + "Cremophor": 25578, + "CXR": 25579, + "DCR": 25580, + "Dock": 25581, + "D8480C0000": 25582, + "DOSE": 25583, + "Every▁": 25584, + "EMR▁6220": 25585, + "G,▁S": 25586, + "Heart": 25587, + "Hepatic": 25588, + "IH": 25589, + "I▁have▁no▁problem": 25590, + "I▁have▁some▁problem": 25591, + "ITIES": 25592, + "Journal▁": 25593, + "LO": 25594, + "MMR": 25595, + "N▁55": 25596, + "OAE": 25597, + "OMI": 25598, + "PM": 25599, + "Park": 25600, + "Paclitaxel": 25601, + "PET▁scan": 25602, + "PLEX": 25603, + "RY": 25604, + "Randomisation": 25605, + "T1": 25606, + "Term": 25607, + "Technical▁Standard": 25608, + "USA": 25609, + "UTC": 25610, + "Valu": 25611, + "W,▁G": 25612, + "[3": 25613, + "aro": 25614, + "aros": 25615, + "aad▁": 25616, + "aju": 25617, + "aesthes": 25618, + "b,": 25619, + "ben": 25620, + "b▁no": 25621, + "ck": 25622, + "cen": 25623, + "coagulation": 25624, + "densit": 25625, + "e\n\nAd": 25626, + "flo": 25627, + "finger": 25628, + "febrile▁neutropenia": 25629, + "hl": 25630, + "h▁C": 25631, + "iar": 25632, + "iPLEX": 25633, + "joy": 25634, + "larynx": 25635, + "mig": 25636, + "microRNA": 25637, + "membrane▁": 25638, + "mild▁to▁moderate▁in": 25639, + "potent": 25640, + "psych": 25641, + "pinal▁cord▁compression": 25642, + "s]": 25643, + "sel": 25644, + "salt": 25645, + "satis": 25646, + "sensitive▁": 25647, + "slide▁": 25648, + "ty▁": 25649, + "uard": 25650, + "van": 25651, + "wic": 25652, + "yes,▁": 25653, + "zar": 25654, + "zol": 25655, + "°▁to": 25656, + "’s▁of": 25657, + "“audit▁trail": 25658, + "≥3": 25659, + "▁rol": 25660, + "▁encourag": 25661, + "▁ulcer": 25662, + "e▁patients▁with": 25663, + "ineligibl": 25664, + "at▁baseline,▁": 25665, + "onary": 25666, + "onatal": 25667, + "\n\ny": 25668, + "\n\ncontinu": 25669, + "\n\nno": 25670, + "\n\nweek": 25671, + "\n\nmust": 25672, + "\n\n5-fluorouracil": 25673, + "\n\nchemotherapy▁regimen": 25674, + "\n\nECOG▁performance▁status": 25675, + "▁a▁P": 25676, + "▁a▁pre": 25677, + "▁a▁history▁of": 25678, + "▁a▁change▁in": 25679, + "enopaus": 25680, + "eric": 25681, + "or▁g": 25682, + "s▁G": 25683, + "s▁T": 25684, + "s▁used▁to": 25685, + "s▁CH": 25686, + "al,▁": 25687, + "al▁con": 25688, + "al,▁or": 25689, + "alarm": 25690, + "al▁mesothelioma": 25691, + "stag": 25692, + "stomatitis▁": 25693, + "y▁D": 25694, + "y▁signing▁this▁consent▁form,▁you": 25695, + "it▁is▁not": 25696, + "▁the▁complet": 25697, + "▁the▁condition": 25698, + "▁the▁option": 25699, + "▁the▁attach": 25700, + "anter": 25701, + "an▁N": 25702, + ",▁pro": 25703, + ",▁over": 25704, + ",▁OS": 25705, + ",▁compared▁with": 25706, + ",▁whil": 25707, + ",▁hypo": 25708, + "roduc": 25709, + "ed▁death": 25710, + "ed▁I▁am": 25711, + "▁an▁investigational▁product": 25712, + "icos": 25713, + ".▁24": 25714, + ".▁(S": 25715, + "aric": 25716, + "ed.\n\nP": 25717, + "ed)▁and▁": 25718, + "ed.▁An": 25719, + "ed.▁All": 25720, + "▁pay▁": 25721, + "▁p53": 25722, + "▁particl": 25723, + "▁palpable▁lymph▁nod": 25724, + "▁cou": 25725, + "▁cold": 25726, + "▁c▁/": 25727, + "▁carton": 25728, + "ings▁": 25729, + "ing▁and": 25730, + "ing▁the▁subject": 25731, + "ing▁for▁the▁": 25732, + "▁bother": 25733, + "esch": 25734, + "es▁all": 25735, + "es▁the▁subject": 25736, + "for▁the▁treatment▁of": 25737, + "etime▁": 25738, + "etable▁and▁": 25739, + "et▁No.▁": 25740, + "▁to▁the▁investigator": 25741, + "▁to▁you": 25742, + "▁to▁either": 25743, + "▁to▁FOLFOX": 25744, + "▁to▁determine▁if": 25745, + "▁to▁Informed▁Consent▁Form": 25746, + "is▁approximately▁": 25747, + "▁schem": 25748, + "▁sensitive▁": 25749, + "▁serious,▁": 25750, + "▁sensory▁neuropath": 25751, + "▁success": 25752, + "asp": 25753, + "▁offer": 25754, + "▁of▁Panitumumab": 25755, + "▁of▁cetuximab": 25756, + "▁of▁tumor▁cell": 25757, + "▁dark": 25758, + "▁dry▁": 25759, + "▁dilut": 25760, + "▁defici": 25761, + "▁double-blind▁": 25762, + "than": 25763, + "this▁": 25764, + "three-": 25765, + "▁warm": 25766, + "▁ment": 25767, + "▁multiplic": 25768, + "▁mismatch▁repair": 25769, + "▁and▁I": 25770, + "▁and▁≤": 25771, + "▁and▁be▁": 25772, + "▁and▁blood▁": 25773, + "▁and▁Consent": 25774, + "▁and▁serum": 25775, + "▁and▁genetic": 25776, + "▁and▁metastas": 25777, + "▁and▁overall▁survival": 25778, + "▁and▁physical▁examination": 25779, + "▁and▁FACT-P": 25780, + "▁and▁Vitamin▁D": 25781, + "▁and▁expression▁of": 25782, + "▁and▁flow▁chart": 25783, + "▁and▁Control": 25784, + "omograph": 25785, + ".\n\nQ": 25786, + ".\n\nResponse▁": 25787, + "illa": 25788, + "illing": 25789, + "al▁is▁": 25790, + "ole▁": 25791, + "ol▁M": 25792, + "olescent": 25793, + "abolic": 25794, + "is▁no▁longer": 25795, + "is▁BW": 25796, + "▁A,▁T": 25797, + "▁in▁any▁": 25798, + "▁input": 25799, + "▁in▁advanced▁colorectal▁cancer": 25800, + "▁in▁some▁cas": 25801, + "▁invit": 25802, + "▁in▁making": 25803, + "reshold▁": 25804, + "ocinski": 25805, + "▁101": 25806, + "▁115": 25807, + "▁1▁day▁": 25808, + "▁CG": 25809, + "▁Case▁Report▁Form": 25810, + "oscop": 25811, + "estra": 25812, + "es▁3": 25813, + "es▁by▁": 25814, + "▁Pregnancy": 25815, + "protocoll": 25816, + "▁(study▁": 25817, + "▁(In": 25818, + "▁(irinotecan": 25819, + "▁(b)": 25820, + "▁(NCI": 25821, + "▁(ECG": 25822, + "▁(FDA": 25823, + "▁(i.e.": 25824, + "▁(measured▁by▁": 25825, + "▁2.2.1": 25826, + "usual▁": 25827, + "if▁there▁are▁": 25828, + "▁South": 25829, + "▁It▁is▁": 25830, + "▁restrict": 25831, + "otoxicity▁": 25832, + "owell": 25833, + "unc": 25834, + "unter": 25835, + "uncommon": 25836, + "uniform": 25837, + "unused▁investigational▁product": 25838, + "▁DC": 25839, + "▁Dur": 25840, + "▁Diet": 25841, + "clared▁": 25842, + "▁heter": 25843, + "▁hold": 25844, + "with▁ABI-007": 25845, + "e▁of▁these▁": 25846, + "apent": 25847, + "apparent": 25848, + "▁Estimated▁Study▁Duration": 25849, + "▁ET-1": 25850, + "▁fact": 25851, + "▁fixed▁": 25852, + "▁folinic▁acid▁": 25853, + "▁favour": 25854, + "vertebra": 25855, + "cholesterol": 25856, + "▁or▁to": 25857, + "▁or▁as▁": 25858, + "▁or▁in▁the▁": 25859, + "▁or▁prior": 25860, + "▁or▁local": 25861, + "▁or▁FOLFIRI": 25862, + "▁or▁equivalent": 25863, + "thereafter": 25864, + "there▁is▁": 25865, + "\n\nPrior▁to": 25866, + "\n\nPostdiscontinuation": 25867, + "\n\nProscribed▁": 25868, + "izes▁": 25869, + "excretion": 25870, + "exacerb": 25871, + "explicit": 25872, + "▁nons": 25873, + "▁nerv": 25874, + "▁n▁d▁": 25875, + "▁nominal▁significance▁level": 25876, + "istinct": 25877, + "istrar": 25878, + "odilator": 25879, + "\n\nAUC": 25880, + "\n\nAss": 25881, + "study▁may▁be▁": 25882, + "▁and▁after": 25883, + "▁and▁administer": 25884, + "▁O’Brien": 25885, + "▁OUTC": 25886, + "▁as▁a▁s": 25887, + "▁asymptomatic": 25888, + "▁as▁a▁serious▁adverse▁event": 25889, + "▁proced": 25890, + "allpoint": 25891, + "all▁Street": 25892, + "▁Tumour": 25893, + "▁Total▁": 25894, + "▁Tel:": 25895, + "▁Title:": 25896, + "▁TREATMENTS": 25897, + "epist": 25898, + "epidemi": 25899, + "epigenetic": 25900, + "opies▁of▁the▁": 25901, + "efract": 25902, + "com/": 25903, + "commence▁": 25904, + "▁for▁PFS": 25905, + "▁for▁both": 25906, + "▁for▁review": 25907, + "▁Rul": 25908, + "▁Risk": 25909, + "▁REG": 25910, + "▁Royal▁": 25911, + "ibb": 25912, + "e\n\n1": 25913, + "e\n\nsubject": 25914, + "e\n\ntreatment": 25915, + "romboembolic": 25916, + "ed▁individual": 25917, + "▁treatment▁and": 25918, + "▁treatment▁on": 25919, + "▁treatment▁option": 25920, + "▁treatment▁of▁your▁cancer": 25921, + "ences▁": 25922, + "ical▁Plan": 25923, + "ed▁to▁allow": 25924, + "ed▁toxicity": 25925, + ".2%": 25926, + "▁with▁panitumumab": 25927, + "▁with▁95%▁CI": 25928, + "▁withdrew": 25929, + "e▁to▁protect": 25930, + "e▁toxicities▁": 25931, + "ed▁bi": 25932, + "ed▁back": 25933, + "s▁of▁interest": 25934, + "s▁of▁safety▁data": 25935, + "berrant": 25936, + "Instruction": 25937, + "Inflammatory▁": 25938, + "ourth": 25939, + "admission": 25940, + "adigm": 25941, + "\n\nSC": 25942, + "▁that▁all": 25943, + "▁that▁patient": 25944, + "▁is▁used▁to": 25945, + "▁is▁identifi": 25946, + "▁is▁further": 25947, + "▁is▁necessary": 25948, + "▁is▁required▁to": 25949, + "▁is▁positiv": 25950, + "▁is▁essential▁for": 25951, + "▁of▁MI": 25952, + "▁of▁established▁tumor": 25953, + "▁aliqu": 25954, + "▁alanine▁aminotransferase▁(ALT": 25955, + "▁will▁be▁approximately▁": 25956, + "▁will▁be▁made▁to": 25957, + "▁will▁be▁followed▁until": 25958, + "▁will▁be▁dilut": 25959, + "▁will▁be▁manufact": 25960, + "▁will▁be▁event-": 25961, + "▁MO": 25962, + "▁Mal": 25963, + "▁M,▁H": 25964, + "▁Meier": 25965, + "▁rates": 25966, + "▁rate\n\n": 25967, + "▁0.22": 25968, + "▁3▁days▁": 25969, + "▁3.4.2": 25970, + "▁constant": 25971, + "act▁of": 25972, + "core▁": 25973, + "events": 25974, + "e,▁M": 25975, + "e,▁R": 25976, + "e,▁irinotecan": 25977, + "verse\n\n": 25978, + "▁company▁": 25979, + "▁Financial▁Disclosure▁": 25980, + ".▁ASCO": 25981, + ".▁Agreement": 25982, + "▁g/": 25983, + "▁grant": 25984, + "▁gemcitabine-cisplatin": 25985, + "▁are▁un": 25986, + "▁are▁cons": 25987, + "▁are▁responsible▁for": 25988, + "▁are▁plann": 25989, + "▁are▁available▁": 25990, + "▁are▁clearly▁": 25991, + ",▁and▁5": 25992, + ",▁and▁15": 25993, + ",▁and▁institution": 25994, + ",▁and▁reproduc": 25995, + "ly▁interval": 25996, + ".3).\n\n": 25997, + ".3\n\nSampl": 25998, + "ever▁possibl": 25999, + "▁BY": 26000, + "▁BEN": 26001, + "▁Bio": 26002, + "▁this▁regimen": 26003, + "s,▁even▁if": 26004, + "s,▁1999": 26005, + "aflet": 26006, + "▁all▁study▁medication": 26007, + "126": 26008, + "129": 26009, + "out▁Panitumumab": 26010, + "▁analyses▁are▁": 26011, + "▁still▁be▁": 26012, + "▁state▁you": 26013, + "ial▁pneumon": 26014, + "achine▁": 26015, + "\n\nCollection": 26016, + "\n\nCase▁Report▁Form": 26017, + "\n\nCollection▁of": 26018, + "\n\nChemistry▁panel:▁sodium,▁potassium,▁chloride,▁bicarbon": 26019, + "▁will▁monitor": 26020, + "▁will▁go": 26021, + "ing▁the▁patient": 26022, + "ity,▁an": 26023, + "▁64": 26024, + "▁600": 26025, + "▁6▁weeks▁": 26026, + "▁6.10": 26027, + "▁HL": 26028, + "▁However": 26029, + "▁Hematology▁": 26030, + "and▁subject": 26031, + "▁patients▁enter": 26032, + "▁patients▁only": 26033, + "▁4.2.1": 26034, + ")\n\nL": 26035, + "▁at▁any▁time▁": 26036, + "s▁(s": 26037, + "s▁(see▁Appendix": 26038, + "▁the▁increas": 26039, + "▁the▁individual▁": 26040, + "egal▁": 26041, + "eguard": 26042, + "▁study▁data": 26043, + "▁study▁staff": 26044, + "▁study▁withdrawal": 26045, + "continuously": 26046, + "\n\n1.\n\nO": 26047, + "loper": 26048, + "vious▁": 26049, + "s▁index": 26050, + "▁cancer-related▁": 26051, + "genes▁": 26052, + ".5▁mg/kg": 26053, + "s.▁U": 26054, + "s.▁Data": 26055, + "▁week▁8": 26056, + "relatively▁": 26057, + "conserv": 26058, + "regulation▁of": 26059, + "ed▁by▁the▁l": 26060, + "▁after▁all": 26061, + "▁after▁each": 26062, + "▁after▁discussion": 26063, + "ally▁for": 26064, + "ally▁Ad": 26065, + "s▁and▁subjects▁with": 26066, + "ed▁on▁the▁l": 26067, + "e▁diarrhea": 26068, + "e▁direct▁access▁to": 26069, + ".▁Studies▁": 26070, + ".▁Simopoul": 26071, + "▁the▁diet": 26072, + "ang▁et▁al,▁199": 26073, + "s▁will▁be▁considered▁": 26074, + "s▁will▁be▁performed": 26075, + "s▁will▁be▁mail": 26076, + "s▁will▁be▁sent▁to": 26077, + "s▁will▁be▁collected▁and▁": 26078, + "▁Gemcitabine▁": 26079, + "▁USA": 26080, + "▁JS": 26081, + "▁plastic": 26082, + "▁timetable▁and▁": 26083, + "ies▁that": 26084, + "ies.▁All": 26085, + "AEs),▁": 26086, + ".▁PSA": 26087, + ".▁Paclitaxel": 26088, + ".▁Preliminary▁": 26089, + "\n\nEstimated▁": 26090, + "ormonal": 26091, + "GFα": 26092, + "▁Incomplete▁response/SD": 26093, + "see▁below": 26094, + "),▁until": 26095, + "▁antineoplastic": 26096, + "▁from▁Amgen": 26097, + "requency▁of": 26098, + "s\n\nwill▁be▁": 26099, + "positron▁emission▁tomograph": 26100, + "evaluation▁of▁": 26101, + "▁is▁that": 26102, + "▁is▁toler": 26103, + "▁Protocol▁Amendment▁2": 26104, + ".▁Thus,▁": 26105, + "▁notification▁of": 26106, + "▁tumor▁biomarker": 26107, + "▁may▁feel": 26108, + "▁78": 26109, + "suffic": 26110, + "▁dose,▁the▁": 26111, + "effects▁on": 26112, + "prescription": 26113, + "prescribe▁": 26114, + ",▁the▁DMC": 26115, + "▁study▁therapy,▁": 26116, + "may▁begin": 26117, + "▁adverse▁events▁that": 26118, + "▁per▁arm": 26119, + "▁per▁day▁": 26120, + "▁per▁lin": 26121, + "e▁vari": 26122, + "pectrum": 26123, + "include▁the▁": 26124, + "include▁all": 26125, + "strength": 26126, + "s),▁and▁": 26127, + "s)▁should▁be▁": 26128, + "s)▁until": 26129, + "▁to▁the▁next": 26130, + "▁analysis▁on": 26131, + ".▁In▁this▁study": 26132, + ".▁In▁case▁of": 26133, + "▁assessments▁and": 26134, + "▁tests▁(": 26135, + "18▁year": 26136, + "ated▁and▁destroy": 26137, + "recorded▁": 26138, + "over▁time▁": 26139, + "s.\n\n.▁T▁N▁E▁M▁U▁C▁O▁D": 26140, + "s.\n\nPro": 26141, + ",▁and▁treatment": 26142, + ",▁and▁the▁day▁after": 26143, + "AL▁PRODUCT": 26144, + "▁absent": 26145, + "▁abide▁by▁all": 26146, + "peripheral▁": 26147, + "’s▁“audit▁trail": 26148, + "▁x▁ic": 26149, + "20)(cid:": 26150, + "ed▁at▁screening": 26151, + "▁in▁the▁model": 26152, + "▁in▁the▁first-line▁treatment": 26153, + "▁in▁the▁opinion▁of▁the▁investigator": 26154, + "▁in▁the▁Treatment▁of▁Bone▁": 26155, + "e.\n\n7": 26156, + "e.\n\nC": 26157, + "e.\n\nAll": 26158, + "patient▁who": 26159, + "):5": 26160, + "▁8.9": 26161, + "▁800▁IU": 26162, + "e▁(eg,▁": 26163, + "▁use▁during▁the▁": 26164, + "mitage▁": 26165, + "\n\nProduct:▁Denosumab▁Protocol▁Number:▁20050136▁Date:▁30▁April▁2008": 26166, + "\n\nN▁H": 26167, + "\n\nNSCLC": 26168, + "▁each▁assessment": 26169, + "▁each▁dose▁of": 26170, + "▁each▁radiological": 26171, + "▁X▁D": 26172, + "▁Xeloda": 26173, + ").\n\n9": 26174, + ").\n\nIf": 26175, + ".▁If▁the▁true▁": 26176, + ".78": 26177, + "\n\n27": 26178, + "\n\n29": 26179, + "\n\n2.\n\nTo": 26180, + "▁format": 26181, + "basaju": 26182, + "▁should▁be▁destroy": 26183, + "arked▁": 26184, + "▁your▁partner": 26185, + "individual▁": 26186, + "▁Adverse▁Drug▁Reaction": 26187, + "▁the\n\nstudy▁": 26188, + "▁preclinical▁data": 26189, + "ed▁as▁soon▁as▁possibl": 26190, + "▁Study▁S": 26191, + "▁the▁study▁team": 26192, + "▁cyclooxygen": 26193, + "\n\nTim": 26194, + "e,▁an": 26195, + "rial▁fib": 26196, + "\n\n39": 26197, + "000▁g": 26198, + "shine▁": 26199, + "▁the▁patient▁was▁": 26200, + "▁the▁patient▁and▁the▁investigator▁agree▁to": 26201, + "draft": 26202, + "▁additionally▁": 26203, + ".▁Do": 26204, + "no▁additional": 26205, + "s▁are▁administer": 26206, + "▁dose▁interruption": 26207, + "▁We▁": 26208, + "▁Wil": 26209, + "▁than▁in": 26210, + "prurit": 26211, + "e)▁is▁": 26212, + "ed▁in▁the▁course▁of": 26213, + "\n\n4.5": 26214, + "leb": 26215, + "data,▁and▁": 26216, + "data.▁Direct": 26217, + "▁mg/ml": 26218, + ",▁Sz": 26219, + ",▁S.,▁et▁al.,▁": 26220, + ",▁Somer": 26221, + "▁visits,▁": 26222, + "defined▁and▁": 26223, + "linding▁and▁": 26224, + "s▁or▁addition": 26225, + "▁was▁reported▁in": 26226, + "in▁the▁range▁of": 26227, + ")▁–": 26228, + "mainly▁": 26229, + "e▁treatment▁arm": 26230, + "▁progression▁free▁survival": 26231, + "▁evaluated▁": 26232, + "e▁and▁disclosure▁of": 26233, + "signed▁by▁the▁investigator▁or": 26234, + "sign,▁symptom": 26235, + "urvival▁follow-up": 26236, + "ed▁and▁un": 26237, + "ed▁and▁dated▁in": 26238, + "▁diary": 26239, + "▁the▁study▁must▁be▁": 26240, + "▁the▁study▁records▁to": 26241, + "may▁be▁used▁for": 26242, + "s:\n\n\n\n": 26243, + "▁samples▁from": 26244, + "▁infusion-related▁reaction": 26245, + "rowley▁J": 26246, + "▁13.5": 26247, + "▁135:": 26248, + ".▁Rational": 26249, + "SABP": 26250, + "NDOMI": 26251, + ",▁a▁regulatory▁author": 26252, + "ed▁from▁a": 26253, + "▁site▁will▁be▁": 26254, + "▁sites▁will": 26255, + "▁cell▁lung": 26256, + "▁subjects▁per": 26257, + "▁subjects▁enroll": 26258, + "▁subjects▁were▁": 26259, + "Investigators▁": 26260, + "Investigator▁should▁": 26261, + "\n\nHR": 26262, + "\n\nH&N": 26263, + "discontinued▁": 26264, + "discontinued▁if": 26265, + "▁Compensation": 26266, + "▁approximately▁100": 26267, + "ed.\n\nIf": 26268, + "▁discontinue▁b": 26269, + "Struct": 26270, + "value▁": 26271, + "values▁may▁be▁collected▁": 26272, + "\n\n\n\nis▁a": 26273, + "documented▁in▁a": 26274, + "▁CT▁Scan": 26275, + "▁et▁al▁2003": 26276, + ",\n\nrespectively": 26277, + "ebb": 26278, + "eby▁": 26279, + "▁and/or▁AstraZeneca": 26280, + "▁continuation": 26281, + "▁Panitumumab▁Preclinical▁": 26282, + "es▁in▁relation▁to": 26283, + "ed▁separately": 26284, + "▁receive▁any▁": 26285, + "collected▁using": 26286, + "▁occurs:": 26287, + "▁occurs▁after": 26288, + ")▁and▁cisplatin": 26289, + "▁Page▁15": 26290, + "▁disease▁progression▁is▁suspect": 26291, + "16]": 26292, + ",▁som": 26293, + "▁these▁analys": 26294, + "modified▁as▁": 26295, + "atistical▁and▁": 26296, + "s▁being": 26297, + ",▁M.,▁et▁al.,▁": 26298, + ",▁Mendelsohn": 26299, + "\n\n70": 26300, + "▁disc": 26301, + "electronically▁": 26302, + "haematology▁and▁": 26303, + "any▁caus": 26304, + ".▁Hospitalization": 26305, + "arrhyth": 26306, + "-related▁injur": 26307, + "mall▁cell▁lung▁cancer": 26308, + "▁drug▁exposure▁": 26309, + "▁drug▁abus": 26310, + "s▁will▁remain": 26311, + "▁through▁a": 26312, + "easurability▁of": 26313, + "▁must▁have▁been": 26314, + "▁location,▁": 26315, + "1-14": 26316, + "▁(AJCC": 26317, + "administered▁with": 26318, + "submit": 26319, + "1).▁The▁": 26320, + "▁metastatic▁prostate▁cancer": 26321, + ".99": 26322, + "ation▁of▁“": 26323, + "normally▁": 26324, + "\n\nInformation": 26325, + "\n\nInvestigational▁product": 26326, + "▁status▁in": 26327, + "INAL▁PRODUCT": 26328, + "▁genes": 26329, + "Adjuvant": 26330, + "e▁microar": 26331, + "▁by▁mouth": 26332, + "▁–▁Arm▁B": 26333, + "▁–▁general": 26334, + "\n\nMonitor": 26335, + "▁can▁imag": 26336, + "▁administering": 26337, + "▁administered▁for": 26338, + "conducted▁as▁": 26339, + "▁information▁and▁": 26340, + "▁number▁per▁lin": 26341, + "given▁over▁2▁to▁4": 26342, + "clinical▁studies": 26343, + "clinical▁judgment": 26344, + "▁tissues": 26345, + "▁tissue▁section": 26346, + "▁administration,▁": 26347, + "OS▁and▁PFS": 26348, + "▁IDMC": 26349, + "were▁conduct": 26350, + "▁there▁ar": 26351, + "▁there▁have▁been": 26352, + "ities;": 26353, + ".\n\nThe▁principal▁investigator": 26354, + "▁desired▁": 26355, + "K▁C▁E▁H▁C\n\nE▁S▁A▁E▁L▁P\n\n.▁T▁N▁E▁M▁U▁C▁O▁D": 26356, + "obtained▁for": 26357, + "obtain▁approval▁from": 26358, + "ing▁of▁biological▁samples": 26359, + "▁17.1": 26360, + "lesions▁will▁only▁be▁": 26361, + "studies▁in": 26362, + "by▁Amgen": 26363, + "-58": 26364, + "each▁statement": 26365, + "▁radiologist": 26366, + ".▁J.▁Clin.▁Oncol": 26367, + ".▁J▁Urol": 26368, + "panitumumab▁administration": 26369, + "information,▁": 26370, + "▁CR▁PR": 26371, + "urnbull": 26372, + "must▁not": 26373, + ".▁For▁patients▁who": 26374, + "\n\nAnt": 26375, + "ed▁by▁the▁central▁laboratory": 26376, + "▁•▁D": 26377, + "▁plus▁prednisone▁": 26378, + "es▁and▁monocyt": 26379, + "es▁and▁Technical▁Standard": 26380, + "▁K,▁S": 26381, + ".▁All▁data": 26382, + ".▁All▁other": 26383, + "▁Yes▁or▁no": 26384, + ".▁IMC-": 26385, + "\n\nConfidentiality▁": 26386, + "▁new▁treatment": 26387, + "▁new▁protocol▁amendment": 26388, + ",▁Gre": 26389, + ",▁Grif": 26390, + ",▁Giovannucci": 26391, + "▁investigational▁product▁administration": 26392, + "▁about▁your": 26393, + "▁has▁been▁for▁you": 26394, + "ed▁cohort": 26395, + "ing▁a▁comprehensive▁": 26396, + "s▁and▁a": 26397, + "▁allows▁": 26398, + "during▁the▁first": 26399, + "▁Start": 26400, + "-malate▁": 26401, + "▁transmission": 26402, + "▁review▁the▁subject’s▁": 26403, + "▁review▁of▁the▁data": 26404, + "s▁at▁baselin": 26405, + "s▁at▁Baseline:": 26406, + "▁party▁or": 26407, + "▁every▁4": 26408, + "within▁30": 26409, + "within▁the▁previous▁": 26410, + "Connell": 26411, + "mado": 26412, + "made▁by▁": 26413, + "▁protocol▁violation": 26414, + "\n\nGl": 26415, + "\n\nGCP": 26416, + "\n\nshould▁": 26417, + "\n\nscreening": 26418, + "▁14▁days▁before▁randomization": 26419, + "▁perform▁a": 26420, + "MDAS": 26421, + "▁Appendix▁A": 26422, + "▁verify▁the▁": 26423, + "Uniform": 26424, + "cervix": 26425, + ",▁Leucovorin": 26426, + ",▁Litin": 26427, + "randomization▁factor": 26428, + "studies▁to": 26429, + "▁the▁first▁PSA": 26430, + "related▁to▁the▁study": 26431, + ",▁pemetrex": 26432, + "▁cetuximab▁therapy▁": 26433, + "upplementation": 26434, + "2100": 26435, + "disease,": 26436, + "disease)": 26437, + "▁+44": 26438, + "labeled▁per": 26439, + "e▁a▁t": 26440, + "ence▁in▁a▁patient": 26441, + "▁IV▁contrast": 26442, + "▁IV▁infused▁": 26443, + "causal": 26444, + "▁QOL": 26445, + "▁assign▁the▁study▁records▁to": 26446, + "venous▁": 26447, + "▁KRAS▁status": 26448, + "▁clinical▁study": 26449, + "61810": 26450, + "ation▁of▁the▁trial": 26451, + "expected▁that": 26452, + "osphor": 26453, + "▁the▁bevacizumab": 26454, + ",▁increas": 26455, + "▁health▁benefit": 26456, + "▁health▁rating": 26457, + "at▁least▁400▁IU": 26458, + "▁OF▁EMERGENCY": 26459, + "▁agrees▁with▁the▁": 26460, + "new▁responsible▁person": 26461, + "\n\nStudy▁Treatment": 26462, + "\n\nStudy▁flow▁chart": 26463, + "86G": 26464, + "1,▁8,▁": 26465, + "IGH": 26466, + "▁have▁to": 26467, + "▁Treatment▁Arm▁A": 26468, + "▁1895": 26469, + "HRQOL": 26470, + "\n\nthe▁event": 26471, + "▁and▁send": 26472, + "▁October▁2003": 26473, + "▁longer▁than": 26474, + "▁safety▁review": 26475, + "▁safety▁follow-up": 26476, + "▁safety▁information": 26477, + "ology/": 26478, + "▁ABI-007/carboplatin": 26479, + "▁phase▁3": 26480, + "▁subjects▁without": 26481, + "referred▁to▁as▁“": 26482, + "▁AND▁QU": 26483, + "100▁x▁109/L": 26484, + ");▁": 26485, + "▁serum▁PSA": 26486, + ".\n\n6.1": 26487, + "RECIST▁Criteria": 26488, + "▁without▁objective▁": 26489, + "primary▁care▁physician": 26490, + ",▁if▁b": 26491, + "contained▁in▁the▁": 26492, + "ing▁evidence▁of": 26493, + ".▁Lill": 26494, + "▁or▁early▁termination": 26495, + "▁conditional▁": 26496, + "bove▁": 26497, + "▁Conf": 26498, + "redness": 26499, + "evaluation▁–▁general": 26500, + "\n\ntissu": 26501, + "2-19": 26502, + "▁paraffin": 26503, + "▁Patients▁With": 26504, + "awless": 26505, + ",▁Kim": 26506, + "ierarch": 26507, + "measures▁of": 26508, + "have▁shown▁that": 26509, + "availability▁of": 26510, + "ised▁Registration/": 26511, + "cycle,▁": 26512, + "\n\nm▁c▁/": 26513, + ".\n\n5.1": 26514, + ".\n\n5.2": 26515, + "Amgen\n\n": 26516, + "▁Medical": 26517, + ".▁Given": 26518, + ".▁Grup": 26519, + "occurrence▁and▁nature▁of": 26520, + "elf▁care": 26521, + "▁would▁indicate▁that": 26522, + ".\n\nIn▁the▁": 26523, + "eyel": 26524, + "▁(see▁definition▁in▁Section▁4.7.1.1": 26525, + "▁e▁c": 26526, + "▁28,▁2008": 26527, + "▁28▁days▁before▁randomization": 26528, + "agents▁inter": 26529, + "persistent": 26530, + "▁score▁(": 26531, + "▁investigator▁assessment": 26532, + "planned▁treatment": 26533, + "ed▁method▁": 26534, + "ed▁manner": 26535, + ".▁1994;": 26536, + "▁only),▁": 26537, + "\n\nProgressive▁Disease▁(PD):": 26538, + "▁≥▁100▁x▁109/L": 26539, + "▁CTCAE▁grad": 26540, + "▁CTCAE▁Grade▁4": 26541, + "▁Arm▁A▁(": 26542, + "%)▁had▁": 26543, + "renal▁": 26544, + "rench": 26545, + "requirements▁for": 26546, + "▁the▁primary▁OS": 26547, + "3-4": 26548, + "ates▁into": 26549, + ".\n\n7.1": 26550, + "▁person▁responsible▁for▁the▁": 26551, + "esign▁and▁Control": 26552, + "ATED": 26553, + "▁scheduled▁visit": 26554, + "ocytes": 26555, + "cases▁of": 26556, + "▁MRI▁scan": 26557, + "site▁of": 26558, + "ing▁one▁(1)": 26559, + "atch▁number": 26560, + "atching▁placebo": 26561, + "ed,▁the▁investigator": 26562, + ",▁mic": 26563, + "▁Exclusion": 26564, + ")▁in▁patients▁(pts)▁with": 26565, + "olerability▁": 26566, + "▁25▁mg/m2": 26567, + "▁25,▁2008": 26568, + "▁the▁trial.▁The▁": 26569, + "▁medical▁practitioner": 26570, + "▁Grade▁3-4": 26571, + "s,▁and▁agrees▁with▁the▁": 26572, + "▁button": 26573, + ".▁J▁Clin▁Oncol▁23": 26574, + ".▁J▁Clin▁Oncol▁22": 26575, + "▁Safety▁Follow-Up": 26576, + "▁Safety▁Officer": 26577, + ".\n\nBefore▁": 26578, + "CC1": 26579, + "e,▁the▁end▁of▁study▁is▁": 26580, + "analyzed▁": 26581, + "chest▁wall": 26582, + "NCI]": 26583, + "▁improve▁": 26584, + "▁(or▁other": 26585, + ".1.2▁Rec": 26586, + "highly▁": 26587, + "high-dose▁": 26588, + "▁microsatellite▁instability": 26589, + "▁microscop": 26590, + "Therasse▁et▁al.▁2000": 26591, + "clinically▁relevant": 26592, + "o-gastric▁cancer": 26593, + "▁a▁log-rank▁test": 26594, + ",▁El": 26595, + "baseline▁BMD": 26596, + "skin▁toxicity▁": 26597, + "▁supplemental▁sourc": 26598, + "resolved?": 26599, + "▁fluoropyrimidine▁": 26600, + "infusion▁reaction": 26601, + "▁Dose▁Reduction": 26602, + "Sponsor▁Contact": 26603, + "safety▁information": 26604, + "safety▁follow-up▁visit": 26605, + "▁experiences": 26606, + "▁experiences▁an": 26607, + "es▁that▁have▁their": 26608, + "▁functional▁": 26609, + "▁function▁test": 26610, + "plus▁prednisone▁": 26611, + "......................................................................................................................": 26612, + "▁target▁volum": 26613, + ",▁Jud": 26614, + ",▁Jack": 26615, + "▁To▁evaluate▁": 26616, + "▁Table▁1": 26617, + "declared▁": 26618, + "listed▁in": 26619, + "ed▁by▁the▁investigator▁as▁": 26620, + ".\n\nN▁A": 26621, + "▁oncology": 26622, + "▁chest▁wall": 26623, + "HASE": 26624, + "read▁the▁attach": 26625, + "skelet": 26626, + "▁paclitaxel▁and▁carboplatin": 26627, + "evaluated▁at▁each": 26628, + "\n\nTable▁JMHD": 26629, + "ability▁of▁all": 26630, + ".▁At▁the▁": 26631, + "▁and▁Dis": 26632, + "▁and▁Day▁": 26633, + ".▁59": 26634, + "\n\nCommon": 26635, + ".▁Wher": 26636, + "▁randomisation▁to": 26637, + "(Suppl": 26638, + ".▁Vial": 26639, + "activated▁": 26640, + "\n\nWeight": 26641, + "▁60▁mL/min": 26642, + "\n\nProtocol▁Amendment\n\nPage▁": 26643, + "s.▁Amgen": 26644, + "scheduled▁": 26645, + "▁and▁demographic": 26646, + ",000/mm3)": 26647, + "\n\n(cid:120)▁Percent": 26648, + "▁Person": 26649, + "▁possible▁to": 26650, + ",▁OVER": 26651, + "EPO": 26652, + "▁and▁initial": 26653, + "e,▁or▁spinal▁cord▁compression": 26654, + "cute▁": 26655, + "▁of▁10▁mM": 26656, + "▁date▁for": 26657, + "▁thromboembolism": 26658, + ".▁Confirm": 26659, + ".▁Concurrent": 26660, + "▁significance▁level▁of▁0.025": 26661, + ",▁patients▁who": 26662, + ".\n\n10.5": 26663, + "▁with▁a▁black": 26664, + "▁the▁primary▁tumor▁or": 26665, + "stratified▁by▁the▁randomization": 26666, + ".▁No▁significant": 26667, + "▁ZD4054▁or▁placebo": 26668, + "▁blood▁sample▁for": 26669, + "▁blood▁sampling▁and▁handl": 26670, + "▁Date:▁04▁April▁2008": 26671, + "▁Panitumumab▁Protocol▁Number:▁20050181▁Date:▁04▁April▁2008": 26672, + "▁the▁sample▁size▁": 26673, + "4▁weeks▁prior▁to": 26674, + "▁normal▁saline▁": 26675, + "▁quality▁": 26676, + "▁an▁inability▁to▁determine▁the▁status▁of▁that▁particular▁tumor▁for": 26677, + "▁pathologist": 26678, + "procedures▁or": 26679, + "objective▁response▁rate▁": 26680, + "objective▁response▁rate▁(ORR": 26681, + "▁planned▁interim": 26682, + "requested▁to": 26683, + "▁additive▁": 26684, + "ISH": 26685, + "s▁aris": 26686, + "s▁are▁the▁": 26687, + ".▁Exception": 26688, + "▁men▁and▁women": 26689, + "generated▁": 26690, + "▁(TO": 26691, + "▁Research▁Addendum": 26692, + "▁Research▁and▁Treatment": 26693, + "hypotheses": 26694, + "▁INR": 26695, + "▁IN-T": 26696, + "▁IN▁CASE": 26697, + "▁regards▁to": 26698, + "888)": 26699, + "nausea▁or▁vomiting": 26700, + "\n\nULN": 26701, + "\n\nUrine▁": 26702, + "disease▁progression▁or": 26703, + "maximum▁tolerated▁": 26704, + "▁written▁statement": 26705, + "▁vs.▁8": 26706, + "care\n\n": 26707, + "carefully▁": 26708, + "▁Acet": 26709, + "▁5-FU/FA": 26710, + "severity▁": 26711, + "severe▁(": 26712, + "▁endpoints▁": 26713, + "▁statistician": 26714, + "5-fluorouracil▁dose▁level": 26715, + "uspected▁": 26716, + "▁50%▁of▁the▁": 26717, + ",▁unstable▁angina": 26718, + ".▁These\n\n": 26719, + "made▁available▁for": 26720, + "made▁only▁with": 26721, + "necessary▁to▁provide▁": 26722, + "\n\n12.4": 26723, + "es▁of▁the▁company,▁": 26724, + "period▁from": 26725, + "(1),▁": 26726, + "▁definitiv": 26727, + "▁Tumor▁Tissu": 26728, + "▁is▁responsible▁for▁forward": 26729, + "s,▁including▁small▁lesion": 26730, + "▁laboratory▁certification": 26731, + "▁Within": 26732, + "es).▁In": 26733, + ".▁Progression": 26734, + "▁well-t": 26735, + ".\n\nMEASUREMENTS": 26736, + "▁the▁interim▁and▁final": 26737, + "▁you▁have▁an": 26738, + "▁delays": 26739, + "▁for▁a▁duration▁of": 26740, + "fully▁in": 26741, + "\n\ni\n\nl\n\na": 26742, + "recorded▁on▁the▁eCRF": 26743, + "hematologic▁toxicities": 26744, + "improved": 26745, + "▁antiangiogenic": 26746, + "\n\nE▁S▁A▁E▁L▁P\n\n.▁T▁N▁E▁M▁U▁C▁O▁D\n\nC▁I▁N▁O▁R▁T▁C▁E▁L▁E\n\nN▁A\n\nF▁O\n\nY▁P▁O▁C\n\nD▁E▁T▁N▁I▁R▁P\n\nA\n\nS▁I\n\nS▁I▁H▁T": 26747, + "crystal": 26748, + "may▁also": 26749, + "▁is▁the▁most▁common": 26750, + "▁minutes▁at": 26751, + "HCG": 26752, + "histologic": 26753, + "▁history": 26754, + "▁...........................................................................▁": 26755, + "s▁must▁also▁be▁": 26756, + "▁asks▁about": 26757, + "\n\nAdd:▁PART▁B:": 26758, + "ecutiv": 26759, + ")▁and▁then": 26760, + "at▁a▁starting▁dose▁of": 26761, + "censored▁at▁the▁last": 26762, + "\n\nThis▁is▁a": 26763, + "\n\nThis▁study▁will▁be▁": 26764, + "▁rate▁and▁": 26765, + "▁informing▁the▁": 26766, + "-Treat": 26767, + "▁recently▁": 26768, + "▁named▁": 26769, + "consent▁form▁should▁be▁provided▁to": 26770, + ".▁Using": 26771, + "s.▁Br": 26772, + "compared▁to▁docetaxel": 26773, + "▁resolve▁": 26774, + "▁resolve▁any▁": 26775, + "epidermal▁growth▁factor▁receptor▁(EGFR": 26776, + "be▁termin": 26777, + "\n\nThese▁": 26778, + "orphine▁": 26779, + "▁Required▁": 26780, + "▁cycles▁of▁treatment": 26781, + "▁2007;▁9": 26782, + "changes▁in▁laboratory▁valu": 26783, + "▁.......................................................................▁": 26784, + "initiated": 26785, + "\n\nsubjects▁with": 26786, + "characteristics▁": 26787, + "▁Protocol▁Amendments▁and▁Study▁Termination": 26788, + "▁less▁than▁1": 26789, + "\n\nPatient▁Reported▁Outcom": 26790, + "▁adjusting▁for": 26791, + "immediately▁life-threatening": 26792, + "▁third▁dose▁reduction": 26793, + "wording": 26794, + "▁some▁patients▁": 26795, + "perty▁of▁the▁sanofi-aventis▁group▁-▁strictly▁confidential▁WW-CLIN-PR007-SD-03▁VERSION▁n°02▁(19-DEC-2005": 26796, + "ackage▁Insert": 26797, + ",▁it▁is": 26798, + "▁Non-Small▁Cell▁Lung▁Cancer": 26799, + "cidence▁and▁": 26800, + "▁thrombosis▁": 26801, + "e.▁Investigator": 26802, + "ating▁the▁confidentiality▁of": 26803, + "overall▁survival▁tend": 26804, + ".▁KM": 26805, + "starting▁at": 26806, + "once▁daily▁": 26807, + "▁1▁week▁or▁mor": 26808, + "administration▁of▁panitumumab": 26809, + "done▁at": 26810, + "▁primary▁endpoint": 26811, + "▁Manuscript": 26812, + "▁Health▁Study": 26813, + "▁Genetic": 26814, + ".▁Phase▁I": 26815, + "spector": 26816, + "ed▁dose,▁": 26817, + "please▁": 26818, + "serious▁adverse▁events▁": 26819, + "▁frequency": 26820, + "approved▁by▁the▁": 26821, + "fluence▁": 26822, + "▁stored▁at": 26823, + "▁non-target▁lesions▁identified▁at▁baselin": 26824, + "▁above▁the▁": 26825, + "▁analgesics,▁": 26826, + "essional▁": 26827, + "▁STUDY▁P": 26828, + "▁STUDY▁PROCEDURES": 26829, + "observed▁RR": 26830, + "Recording▁of": 26831, + "▁entry": 26832, + "▁study▁visit?": 26833, + "AMG▁162▁in▁the▁Treatment▁of▁Bone▁": 26834, + "bearing": 26835, + "e▁including": 26836, + "\n\nGrade▁1": 26837, + "Regulatory▁": 26838, + "address": 26839, + ".▁Data▁Qual": 26840, + "rest▁of": 26841, + "minimum▁lesion": 26842, + "minimum,▁and▁maximum": 26843, + "▁as▁possible▁": 26844, + "▁response▁rate▁and▁": 26845, + "OPUL": 26846, + "in▁a▁continuous▁regimen": 26847, + "▁were\n\n": 26848, + "▁and▁all▁other▁sites▁of▁disease▁": 26849, + ".6.1▁General▁Approach/": 26850, + "supplied▁in": 26851, + "▁hr▁after▁start▁of": 26852, + "▁on▁Day▁1▁of▁each▁cycl": 26853, + "▁Information▁and▁Consent": 26854, + "▁generating": 26855, + "▁NCCTG▁Addendum": 26856, + "EA▁level": 26857, + "▁identifier": 26858, + "▁ICF": 26859, + "▁prolonged▁": 26860, + "▁combined▁": 26861, + ".▁Complet": 26862, + "▁leads▁to": 26863, + "▁track": 26864, + "wareness▁of▁the▁": 26865, + "▁best▁supportive▁car": 26866, + "▁concomitantly▁with": 26867, + "▁must▁be▁obtained▁for▁all": 26868, + "▁might▁affect": 26869, + "▁documented▁PD": 26870, + "copies▁of": 26871, + "▁those▁that": 26872, + "area▁under▁the▁curv": 26873, + "whichever▁comes▁first": 26874, + "▁investigational▁agent": 26875, + "confirmed▁no▁less▁than▁4▁weeks▁after": 26876, + "controlled▁Study▁to": 26877, + "ed▁in▁accordance▁with▁institutional▁policy": 26878, + "▁should▁also▁be▁": 26879, + "greater▁than▁or▁equal▁to": 26880, + "opportunity▁for": 26881, + ",▁1,▁or▁2": 26882, + "▁stop▁the▁": 26883, + "diagnosis": 26884, + ",▁in▁the▁case▁of": 26885, + "▁portion▁of": 26886, + "▁of▁the▁study▁staff": 26887, + "handling": 26888, + "▁of▁outcome▁variables▁in▁relation▁to": 26889, + "▁osteoclast": 26890, + "▁COM": 26891, + "▁COX-": 26892, + "▁study▁entry▁": 26893, + "yes/no": 26894, + "opathological▁": 26895, + "▁validation": 26896, + "▁validated": 26897, + "▁VEGF▁inhibitor": 26898, + "ohistochemical▁": 26899, + "▁logistic▁regression▁model": 26900, + "▁staff)": 26901, + "▁the▁investigational▁sit": 26902, + "s▁per▁day": 26903, + "▁derivativ": 26904, + "notifications,▁and▁agrees▁with▁the▁": 26905, + "▁d▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁PANITUMUMAB▁(AMG▁954)▁Protocol▁Number:▁20040249▁Date:▁07▁August▁2007\n\nPage▁": 26906, + "▁d▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁Panitumumab▁Protocol▁Number:▁20050181▁Date:▁04▁April▁2008\n\nPage▁": 26907, + "usual▁activities▁": 26908, + "Pharmacy▁Guid": 26909, + "images▁": 26910, + "▁(eg,▁a": 26911, + "▁the▁prepar": 26912, + "80%▁dose▁level": 26913, + "purpose▁of▁the▁": 26914, + "▁Sunitinib▁Malate▁": 26915, + "showed▁that": 26916, + "\n\nI▁am▁able▁to": 26917, + "ATA▁MANAGEMENT": 26918, + "▁..............................................": 26919, + "ontarget▁Lesion": 26920, + "▁to▁receive▁either": 26921, + "▁is▁inadvert": 26922, + "▁guidance▁": 26923, + "\n\nSection:▁10.5": 26924, + "▁recurrent▁or": 26925, + "\n\nArm▁B": 26926, + "▁a▁minimum▁of▁two": 26927, + "regularly▁": 26928, + "▁complaint▁form": 26929, + "manufacturing": 26930, + "▁Suppl):": 26931, + "\n\nAdd▁6\n\nAdd▁6": 26932, + "recovered▁to": 26933, + "▁FACT-L/N": 26934, + ".\n\nPatients▁will▁be▁": 26935, + "dosing▁regimen": 26936, + "▁determine▁if▁denosumab▁is▁": 26937, + "bumin-bound▁": 26938, + "30-day▁postdiscontinuation▁follow-up▁period▁(": 26939, + "-Based▁": 26940, + "9)Toxicity▁": 26941, + "hold▁panitumumab": 26942, + "▁↓▁One▁": 26943, + "▁brain▁metastases": 26944, + "▁softw": 26945, + "prognostic▁factor": 26946, + "▁Days▁1-14": 26947, + ".▁In▁the▁event▁that": 26948, + "definitions▁of": 26949, + "breast-feeding": 26950, + "clarification": 26951, + "▁treatment▁and▁follow-up": 26952, + "▁WC,▁H": 26953, + "we▁have▁": 26954, + ".▁Your▁doctor▁will": 26955, + "▁objective▁progression▁of": 26956, + "at▁any▁time▁and▁": 26957, + ")\n\n4.2.1": 26958, + "▁should▁be▁performed▁with": 26959, + "your▁doctor▁will": 26960, + "▁2006;▁8": 26961, + "▁Quality▁of▁Lif": 26962, + "▁Medical▁Journal▁": 26963, + "weating": 26964, + "\n\nPretreatment": 26965, + "▁the▁subdistribution": 26966, + "▁internal▁": 26967, + "▁international": 26968, + "▁reasons▁other▁than▁disease▁progression": 26969, + "ituation": 26970, + "▁and▁Meier": 26971, + "▁rate▁of▁5%": 26972, + "▁HRQoL": 26973, + "▁consult▁with": 26974, + "▁samples▁will▁be▁destroy": 26975, + "▁observation▁mad": 26976, + "extension▁lead▁period▁": 26977, + ".D.,▁": 26978, + "at▁each▁visit": 26979, + "▁needl": 26980, + "▁the▁primary▁endpoint▁of": 26981, + "null▁hypothesis": 26982, + "ity▁in▁accordance▁with": 26983, + "▁any▁side▁effect": 26984, + "ed▁by▁an▁independent": 26985, + "▁Questionnaires": 26986, + "questionnaire▁and▁": 26987, + "▁contains▁no": 26988, + "▁curatively": 26989, + "▁deviations▁from": 26990, + "▁Classification": 26991, + "▁rates▁of": 26992, + "indication▁to": 26993, + "▁confidence▁interval▁for▁the▁": 26994, + "▁fracture▁or": 26995, + "Radiotherapy▁": 26996, + "▁Supplement),▁": 26997, + "e.\n\nPatients▁": 26998, + "partial▁respons": 26999, + "partial▁response▁(PR": 27000, + "\n\nAdd▁2,3": 27001, + "▁angiogenesis▁": 27002, + "▁mucosa": 27003, + "▁will▁be▁compared▁at▁a▁significance▁level▁of▁5%": 27004, + "refer▁to▁the▁current": 27005, + "▁questionnaire▁that": 27006, + "/Independent▁Ethics▁Committee▁(IEC": 27007, + "▁move▁them": 27008, + "▁Survival▁Follow-up": 27009, + "▁ascites▁or": 27010, + "▁abdominal▁masses▁that▁are▁not▁confirmed▁and▁followed▁by▁imaging▁techniqu": 27011, + "information▁of": 27012, + "▁to▁increase▁": 27013, + "estrogen▁receptor": 27014, + "▁age▁group": 27015, + "s▁taken▁in▁combination▁with": 27016, + "▁all▁subjects▁have▁": 27017, + "▁will▁have▁access▁to": 27018, + "▁signs▁and▁symptoms▁of": 27019, + ".▁Annal": 27020, + "▁address▁and": 27021, + ".▁Under": 27022, + "▁Pemetrexed▁in": 27023, + "undred▁": 27024, + "▁or▁its▁designated▁": 27025, + "arketing": 27026, + "▁subjects▁receiving▁AMG▁162": 27027, + ".▁Vitamin▁D▁intak": 27028, + "Code:▁D8480C00013": 27029, + "final▁PFS": 27030, + "▁drop▁in": 27031, + "▁ASCO▁Annual▁Meeting▁Proceeding": 27032, + "symptomatic▁deterioration": 27033, + "International▁Conference▁on▁Harmonisation": 27034, + "▁of▁study▁population": 27035, + "notified▁to": 27036, + "prescribed▁dos": 27037, + "ared▁Res": 27038, + "enrolled▁in▁the▁study": 27039, + "objectives▁–": 27040, + "E▁R▁O▁F▁E▁B\n\nY▁T▁I▁D▁I▁L▁A▁V": 27041, + "egrated▁": 27042, + "▁Advanced▁Non-Small▁Cell▁Lung▁Cancer": 27043, + "▁Completed▁": 27044, + "▁description▁of▁the▁": 27045, + ",▁we▁have▁": 27046, + "Oral▁Rectal▁Subcutaneous▁": 27047, + "▁SU11248": 27048, + "▁reserves▁the▁": 27049, + "▁study-related▁record": 27050, + "▁interval▁is▁": 27051, + "▁measurements▁and▁co-": 27052, + "▁the▁safety▁follow▁up▁phas": 27053, + ".\n\nSTUDY▁MANAGEMENT": 27054, + "oprotection": 27055, + "vitamin▁E": 27056, + "▁Day▁8": 27057, + "achine▁typ": 27058, + "▁7▁days▁of▁each▁radiological": 27059, + "▁1993;": 27060, + "▁anti-panitumumab▁antibody": 27061, + "procedures▁for▁unblinding▁the▁study": 27062, + "▁regulatory▁authorities": 27063, + "▁regulatory▁authorities▁": 27064, + "nodul": 27065, + "▁Approved▁by▁Lilly:": 27066, + "ysesthesia": 27067, + "▁Fax:▁(": 27068, + "patient▁reported▁outcomes▁(PRO": 27069, + "▁superiority▁of": 27070, + "\n\nAppendix▁I▁Page▁": 27071, + "\n\nStudy▁Design▁and▁Treatment▁Schema": 27072, + "chest,▁abdomen,▁pelvis": 27073, + "▁origin▁in▁the▁D": 27074, + "kens▁CH": 27075, + "▁principles▁that▁have▁their": 27076, + "▁bolus▁given▁over▁2▁to▁4": 27077, + "▁Italian": 27078, + "▁possibly▁": 27079, + "▁antibodies▁against▁panitumumab": 27080, + "▁antibodies▁against▁IMC-11F8": 27081, + "▁ECOG▁performance▁status": 27082, + "\n\nChanges▁to▁the▁protocol": 27083, + "▁exploratory▁biomarker▁development": 27084, + ",▁whichever▁is▁later": 27085, + "captured": 27086, + "imburg": 27087, + "\n\nPerform": 27088, + "▁a▁small▁molecul": 27089, + ".▁Refer▁to▁the▁": 27090, + "▁occurred▁in": 27091, + "gestive▁heart▁failure▁": 27092, + "regulatory▁agency▁": 27093, + "regulatory▁agency": 27094, + "geographic▁region": 27095, + "s▁during▁treatment": 27096, + "▁Disease": 27097, + "▁RTK": 27098, + "romosome▁": 27099, + "\n\nStudy▁agreement": 27100, + "association▁of": 27101, + "carcinoma▁of▁the▁": 27102, + "hazard▁ratios": 27103, + "▁the▁benefit:risk▁profile▁": 27104, + ",▁stroke,▁and▁": 27105, + "▁handling": 27106, + "comprised▁of": 27107, + "▁LB,▁Willett▁WC": 27108, + "▁consequences": 27109, + "▁change▁of▁femoral▁neck▁BMD": 27110, + "ockcroft▁and▁Gault▁1976": 27111, + "▁etoposide/cisplatin": 27112, + "▁subjects▁have▁access▁to▁commercially▁available▁product▁or▁for▁up▁to▁2▁year": 27113, + "ummary▁tabl": 27114, + "▁confirmation▁of▁eligibility": 27115, + ":▁the▁effects▁of": 27116, + "▁balance▁of": 27117, + "▁second-line▁": 27118, + "▁Overview": 27119, + "▁modified-RECIST": 27120, + "fficacy▁and▁pharmacodynamic": 27121, + ".▁Of▁the▁": 27122, + "stored▁for▁up▁to": 27123, + "median▁PFS▁for": 27124, + "▁AND▁DEFINITIONS▁OF": 27125, + "inancial▁Disclosure": 27126, + "▁companies▁": 27127, + "▁pre-specified▁": 27128, + "\n\nVisit\n\nVisit": 27129, + "Schedule▁of▁Assessment": 27130, + "measurements▁and▁variables▁": 27131, + "▁Radiation▁Therapy▁": 27132, + "stead▁of▁the▁": 27133, + "▁CYP3A4▁inhibitor": 27134, + "10223": 27135, + "▁from▁all▁supplemental▁sourc": 27136, + "anna▁N": 27137, + "▁sub-population": 27138, + ".▁Overall▁survival": 27139, + "TOI": 27140, + "▁slice▁thickness▁": 27141, + "▁or▁at▁hom": 27142, + "▁First▁Street": 27143, + "not▁to▁participate▁in▁this▁study": 27144, + "binding▁of": 27145, + "▁leukopenia": 27146, + "▁peripheral▁neuropathy▁": 27147, + "▁discontinue▁from▁study▁treatment": 27148, + "documented▁in▁the▁subject’s▁": 27149, + "ince▁your▁last▁study▁visit?": 27150, + "▁twice▁per": 27151, + "▁the▁interpretation▁of▁the▁study▁": 27152, + "chemistry▁profil": 27153, + "epatitis▁C": 27154, + "uration▁of▁response▁(": 27155, + "ocock▁SJ": 27156, + "ance▁in▁Investigational▁Product": 27157, + "▁androgen▁dep": 27158, + "▁health▁state▁index▁scor": 27159, + "▁telephone,▁and": 27160, + "\n\nNon-PD/NA**": 27161, + "inspector": 27162, + "▁back▁to": 27163, + "es),▁surgery▁to": 27164, + "▁rather▁than": 27165, + "▁a▁subset▁of": 27166, + "95%▁confidence▁interval▁for▁the▁": 27167, + "improvement▁in": 27168, + "▁At▁least▁a▁20%▁increase▁in": 27169, + "▁regulatory▁agencies▁": 27170, + ",▁2008;▁Page▁D": 27171, + "mass▁index": 27172, + "▁the▁appearance▁of▁one▁or▁more▁new▁lesion": 27173, + "▁Amended▁Clinical▁Study▁Protocol": 27174, + "▁or▁discomfort▁I▁have▁": 27175, + "e▁through▁the▁": 27176, + "▁BID▁=": 27177, + "▁the▁date▁when": 27178, + ".▁Discussion": 27179, + "▁CT/MRI▁scan": 27180, + ",▁Mori": 27181, + "▁discovery▁or": 27182, + "at▁least▁one▁on-study▁SRE": 27183, + "\n\nStatistical▁evaluation▁–▁general": 27184, + ",▁Stampfer▁MJ,▁Colditz▁GA": 27185, + ",▁24,▁36": 27186, + "ed▁while▁on▁or▁after": 27187, + "▁of▁Design▁and▁Control": 27188, + "useful▁in": 27189, + "avis▁CD": 27190, + "▁abscess": 27191, + "▁pemetrexed,▁carboplatin": 27192, + "lipid": 27193, + "ersonal▁": 27194, + "▁sensitivity▁analyses▁of": 27195, + "▁washout": 27196, + "▁compared▁to▁the▁": 27197, + "▁investigational▁product▁is▁re": 27198, + "▁Formula▁for": 27199, + "▁make▁entries▁and/or": 27200, + "▁reconstituted▁ABI-007": 27201, + "▁VARIABLES▁AND▁DEFINITIONS▁OF": 27202, + "7)\n\n(cid:137)\n\n(cid:13": 27203, + "7)\n\n(cid:137)▁(cid:137)▁(cid:13": 27204, + "at▁any▁dos": 27205, + "complish": 27206, + "▁Figure▁1": 27207, + "▁H3E-MC-JMIG": 27208, + "▁throughout▁the▁entir": 27209, + "▁(Table▁1)": 27210, + "regional▁lymph▁node▁is▁N0": 27211, + "ltrasound▁": 27212, + "DxS": 27213, + "Pathology▁": 27214, + "surrounded▁by▁aerated▁lung": 27215, + "enediamin": 27216, + "▁an▁SRE▁by▁": 27217, + "endothelial▁cell": 27218, + "s.▁Thereafter": 27219, + "he/she▁must": 27220, + "\n\nM0▁M0": 27221, + "\n\nMethod▁of▁assigning": 27222, + "▁intramuscular▁injection": 27223, + "▁Non-PD▁Non-PD": 27224, + "▁IV▁infusion▁in▁500▁mL": 27225, + "arnofsky▁Scor": 27226, + "▁anxious▁or▁depressed▁I▁am": 27227, + "▁we▁will▁have▁": 27228, + "uppressive▁": 27229, + "medicinal▁product": 27230, + "FACT-Fatigue▁subscale▁scor": 27231, + "▁alone▁as\n\n": 27232, + "▁will▁be▁used▁to▁compare▁treatments▁with▁respect▁to▁both": 27233, + "J,▁Kaplan": 27234, + "Overdose▁": 27235, + "facilities": 27236, + "▁esophagitis▁": 27237, + "▁taste▁in": 27238, + "unn▁PA": 27239, + "ed▁both▁individ": 27240, + "▁the▁investigational▁study▁sit": 27241, + "rosome▁amplification": 27242, + ")(cid:10)(cid:": 27243, + "▁+/-▁C225": 27244, + "reported▁to▁Amgen▁within▁1▁working▁day▁of": 27245, + "▁glutamic": 27246, + "\n\nProgression-free▁survival▁(PFS": 27247, + "\n\nDescription▁of▁analysis▁set": 27248, + "informed▁of▁all": 27249, + "e▁involvement": 27250, + "▁intellectual": 27251, + "Undergoing": 27252, + "where▁appropriate": 27253, + "delayed▁for▁up▁to": 27254, + "e▁on▁a▁variable▁": 27255, + "▁fever▁or▁infection": 27256, + "▁archival▁tumour": 27257, + "Therapy▁During▁Study▁Period": 27258, + "▁apparent▁discrepanc": 27259, + "inflammatory▁drug": 27260, + "▁tiredness": 27261, + "▁cardioprotection": 27262, + "urbanc": 27263, + "▁Calculated▁Creatinine▁Clear": 27264, + "▁Product▁Characteristic": 27265, + "▁Shared▁Res": 27266, + "▁TNM▁Staging▁System▁for▁Lung▁Cancer": 27267, + "advised▁to": 27268, + "athyroid▁hormone▁": 27269, + ".▁Determination▁of▁Sample▁Size▁": 27270, + "▁non-mutated▁(": 27271, + "more▁frequent": 27272, + "▁risk▁reduction.▁For": 27273, + "procedures▁and▁data.▁Direct": 27274, + "keletal▁surveys": 27275, + "light▁housework": 27276, + ".▁Respondent": 27277, + "ematology▁panel:▁CBC": 27278, + "duration▁of▁response▁(DOR": 27279, + "▁corresponds▁to▁ECOG": 27280, + "▁reasonable▁possibility▁that▁the▁event▁may▁have▁been▁caused▁by\n\ninvestigational▁product": 27281, + "▁always▁be▁ask": 27282, + "idiarrheal": 27283, + "DMSC": 27284, + "covariate▁": 27285, + "▁loperamide▁": 27286, + "’s▁brochure": 27287, + ".▁Disease▁progression": 27288, + ".▁Regulatory▁": 27289, + "▁occurs▁prior▁to▁disease▁progression": 27290, + "70▁and▁older": 27291, + "▁NCI-CTCAE": 27292, + "▁qualifying▁for": 27293, + "▁Planned▁Methods▁of▁Analysis▁": 27294, + "drawn▁from▁each▁patient": 27295, + "emperature,▁blood▁pressure,▁": 27296, + "▁adequately▁treat": 27297, + "▁Previously▁Untreated▁Metastatic▁Colorectal▁Cancer": 27298, + "orrections▁to▁electronic": 27299, + "/0,": 27300, + "surgical▁resection": 27301, + "▁manufacturer": 27302, + "against": 27303, + "▁must▁submit▁and": 27304, + "echt▁JR": 27305, + "▁an▁option▁to": 27306, + "hereinafter": 27307, + "increase▁the▁risk▁of": 27308, + "▁before▁study▁initiation": 27309, + "▁known▁to▁have���di": 27310, + "every▁6▁weeks,▁±▁1▁week": 27311, + "examining,▁analyz": 27312, + "publication▁or▁presentation": 27313, + "ed▁in▁the▁Study▁Plan,▁Table▁": 27314, + "hort▁Form▁(BPI-SF": 27315, + "oftware’s▁“audit▁trail": 27316, + "▁time▁from▁randomization▁date▁to▁date▁of": 27317, + "how▁good▁or▁bad▁": 27318, + "daily▁supplement": 27319, + "mechanism▁of▁action▁of▁necitumumab": 27320, + "▁true▁each▁statement": 27321, + "▁safety▁and▁efficacy▁data": 27322, + "ulum▁vita": 27323, + "▁should▁be▁retained▁in▁accordance▁with▁institutional▁policy": 27324, + "▁disease▁progression▁should▁be▁evaluated▁for": 27325, + "▁level▁in▁the▁blood;": 27326, + ",▁Armitage▁": 27327, + "▁coronary▁heart": 27328, + "pain▁severity▁and▁": 27329, + "vitamin▁D▁supplements,▁": 27330, + "▁days▁prior▁to▁C1D1": 27331, + "\n\nEthical▁conduct▁of▁the▁study": 27332, + "circling▁one▁(1)": 27333, + "▁cervical▁cancer": 27334, + ",▁Heaney▁RP,▁Holick▁MF": 27335, + "▁is▁obligated▁to▁inform": 27336, + "\n\nRestricted▁in▁physically▁strenuous▁activity▁but▁ambulatory▁and▁able▁to▁carry▁out▁work▁of▁a▁light▁or▁sedentary▁nature,▁": 27337, + "aenoic▁acid▁[": 27338, + "opposed▁to": 27339, + "▁Methods▁for": 27340, + "ine▁is▁marked▁": 27341, + "ultinational": 27342, + "\n\nTest▁result": 27343, + "i-dimensionally▁measurable▁lesion": 27344, + "Analytical▁Plan": 27345, + "▁occurs▁at▁or▁near": 27346, + "substituted▁for": 27347, + ",▁Garland▁": 27348, + "▁Febrile▁Neutropenia": 27349, + "describes▁the▁conduct▁and▁results▁of": 27350, + "▁OF▁STUDY▁VARIABLES▁AND▁DEFINITIONS▁OF": 27351, + ".\n\nIntroduction": 27352, + "\n\nVolume▁of▁blood▁sampling▁and▁handl": 27353, + "▁medical▁problems▁s": 27354, + "▁and▁institution▁permit": 27355, + "best▁supportive▁care▁(": 27356, + "▁Evaluate▁AMG▁162▁in▁the▁Treatment▁of▁Bone▁": 27357, + "analysis▁will▁be▁censored▁using▁the▁last▁available▁assessment▁date.\n\n": 27358, + "▁transient▁ischemic▁attack": 27359, + "residual▁lesion": 27360, + "pG▁island▁methyl": 27361, + "▁Practice▁Guidelines▁and▁Technical▁Standard": 27362, + "▁MEDICINAL▁PRODUCT": 27363, + "▁evaluate▁time▁to▁response▁and▁": 27364, + "s▁with▁performing▁my▁usual▁activities▁": 27365, + "▁earlier▁than": 27366, + "elzack": 27367, + "rauterine▁devic": 27368, + "e,▁please▁indicate▁how": 27369, + "leeland▁CS": 27370, + "▁gene▁copy▁number": 27371, + "▁at▁least▁25%▁for▁a▁duration▁of": 27372, + "▁mL▁of▁0.9%▁Sodium▁Chloride▁Injection": 27373, + "Evaluable▁Analysis▁Set": 27374, + ".▁These▁signatures▁will": 27375, + "▁fracture▁(vertebral▁": 27376, + "Response▁(PR):": 27377, + "▁SYSTEM": 27378, + "▁Epidemiology,▁Biomarker": 27379, + "▁ever▁comes▁first.▁If": 27380, + "antonio": 27381, + "▁600▁mg/m2▁IV▁infusion▁in▁500▁mL": 27382, + "ultimately▁": 27383, + ",▁Hollis▁BW": 27384, + "Printed▁copy▁is▁not▁official▁record.\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁Panitumumab▁Protocol▁Number:▁20050203▁Date:▁21▁January▁2009\n\nPage▁": 27385, + "ing▁any▁records▁and▁report": 27386, + "▁and▁an▁IV▁infusion▁of▁zoledronic▁acid▁": 27387, + "goals▁for▁the▁target": 27388, + "▁400▁mg/m2▁IV▁bolus▁given▁over▁2▁to▁4": 27389, + "/favorable▁opinion": 27390, + "Committee▁of▁Medical▁Journal▁": 27391, + "▁blood▁pressure,▁resting▁pulse,▁respiration▁rate,▁and": 27392, + "recorded▁and▁measured▁at▁baselin": 27393, + "s,▁Subsets,▁and▁C": 27394, + "istence▁of▁one▁or▁more▁non-target▁lesion": 27395, + "▁Biomedical▁Journal": 27396, + "▁w▁±3▁d▁after▁Day▁1": 27397, + "OME▁VARIABLES": 27398, + "os▁AP": 27399, + "islation": 27400, + "▁witness": 27401, + "▁1.▁OBJECTIVES▁........................................................................................................": 27402, + "agazin": 27403, + "\n\nAudits▁and▁inspection": 27404, + "▁NUMBER": 27405, + "▁confidential▁information": 27406, + "eventh▁Edition": 27407, + "▁on▁which▁they▁are▁": 27408, + "\n\nDetermination▁of▁sample▁siz": 27409, + "equisition▁Form": 27410, + "ABORATORY": 27411, + ",▁Hennekens▁CH": 27412, + "▁radioisotopes),▁surgery▁to": 27413, + "s▁of▁the▁question:": 27414, + "289],▁1997": 27415, + ",▁Gordon▁D": 27416, + "▁during▁the▁past▁7▁days": 27417, + "best▁of▁his▁or▁her▁knowledge,▁the▁report▁accurately▁": 27418, + "used.▁Corrections▁to▁electronic": 27419, + "▁child-bearing▁p": 27420, + "otherwise▁indicated": 27421, + "▁item▁of▁the▁Brief▁Pain▁Inventory▁(BP": 27422, + ".▁Sample▁Size▁and▁Statistical▁Method": 27423, + "▁OR▁PREGNANCY": 27424, + "▁and▁Human▁Servic": 27425, + "▁and▁MRI▁are▁the▁best▁currently▁available▁and▁": 27426, + "▁global▁deterioration▁of▁health▁status▁requiring": 27427, + "\n\nNot▁at▁all\n\nA▁little▁bit\n\nSome-▁what\n\nQuite▁a▁bit\n\nVery▁much": 27428, + "ensive▁treatment▁in▁an▁emergency▁room▁or▁at▁hom": 27429, + "(serum▁sample,▁": 27430, + "Docket▁No.▁": 27431, + "DOSE▁OR▁PREGNANCY": 27432, + "Randomisation▁C": 27433, + "onatal▁death": 27434, + "▁to▁Informed▁Consent▁Form▁for": 27435, + "estramust": 27436, + "▁OUTCOME▁VARIABLES": 27437, + "all▁Street▁Journal": 27438, + "efractory▁": 27439, + "▁are▁consuming": 27440, + ",▁and▁reproducing▁any▁records▁and▁report": 27441, + "▁BENEFI": 27442, + "▁state▁you▁can▁imag": 27443, + ".▁Simopoulos▁AP": 27444, + "▁timetable▁and▁end▁of▁study": 27445, + "suffici": 27446, + "rial▁fibrill": 27447, + "defined▁and▁surrounded▁by▁aerated▁lung": 27448, + "linding▁and▁procedures▁for▁unblinding▁the▁study": 27449, + "atistical▁and▁Analytical▁Plan": 27450, + "arrhythmic": 27451, + "▁number▁per▁line,▁please▁indicate▁how": 27452, + "lesions▁will▁only▁be▁considered▁measurable▁when▁they▁are▁superficial▁": 27453, + "▁new▁protocol▁amendment▁would▁be▁": 27454, + "▁has▁been▁for▁you▁during▁the▁past▁7▁days": 27455, + "-malate▁salt": 27456, + "▁review▁the▁subject’s▁original": 27457, + "▁party▁or▁move▁them": 27458, + "MDASI-GI": 27459, + "Uniform▁Requirement": 27460, + ",▁Litin▁LB,▁Willett▁WC": 27461, + "▁OF▁EMERGENCY,▁OVER": 27462, + "▁1895▁525": 27463, + "▁without▁objective▁evidence▁of▁disease▁progression": 27464, + "▁or▁early▁termination▁and▁send": 27465, + "ised▁Registration/Randomisation▁C": 27466, + "\n\nm▁c▁/▁g": 27467, + ".▁Gruppo": 27468, + "agents▁interact": 27469, + "e,▁the▁end▁of▁study▁is▁defined▁as▁4▁week": 27470, + ".1.2▁Recording▁of": 27471, + "baseline▁BMD▁valu": 27472, + "read▁the▁attached▁protocol": 27473, + "▁Research▁Addendum▁to▁Informed▁Consent▁Form▁for": 27474, + "▁Research▁and▁Treatment▁of▁Cancer": 27475, + "▁IN-TEXT": 27476, + "▁IN▁CASE▁OF▁EMERGENCY,▁OVER": 27477, + ".\n\nMEASUREMENTS▁OF▁STUDY▁VARIABLES▁AND▁DEFINITIONS▁OF": 27478, + "▁asks▁about▁your": 27479, + "ating▁the▁confidentiality▁of▁the▁subject": 27480, + ".▁Data▁Quality▁Assur": 27481, + "▁of▁outcome▁variables▁in▁relation▁to▁objectives▁and▁": 27482, + "notifications,▁and▁agrees▁with▁the▁content": 27483, + "9)Toxicity▁resolved?": 27484, + "▁↓▁One▁5-fluorouracil▁dose▁level": 27485, + "▁observation▁made▁on▁a▁variable▁": 27486, + "▁origin▁in▁the▁Declaration▁of▁Helsinki": 27487, + "▁principles▁that▁have▁their▁origin▁in▁the▁Declaration▁of▁Helsinki": 27488, + "▁from▁all▁supplemental▁sources▁combin": 27489, + "▁the▁interpretation▁of▁the▁study▁result": 27490, + ".▁Discussion▁of▁Design▁and▁Control": 27491, + "\n\nStatistical▁evaluation▁–▁general▁aspect": 27492, + "oftware’s▁“audit▁trail”": 27493, + "▁true▁each▁statement▁has▁been▁for▁you▁during▁the▁past▁7▁days": 27494, + "circling▁one▁(1)▁number▁per▁line,▁please▁indicate▁how": 27495, + "▁occurs▁at▁or▁near▁the▁end▁of▁the▁": 27496, + "\n\nVolume▁of▁blood▁sampling▁and▁handling▁of▁biological▁samples": 27497, + "▁Evaluate▁AMG▁162▁in▁the▁Treatment▁of▁Bone▁Loss▁in": 27498, + "▁at▁least▁25%▁for▁a▁duration▁of▁1▁week▁or▁mor": 27499, + "Committee▁of▁Medical▁Journal▁Editor": 27500, + "Docket▁No.▁86G": 27501, + "▁state▁you▁can▁imagine▁is▁marked▁": 27502, + "▁IN▁CASE▁OF▁EMERGENCY,▁OVERDOSE▁OR▁PREGNANCY": 27503, + ".\n\nMEASUREMENTS▁OF▁STUDY▁VARIABLES▁AND▁DEFINITIONS▁OF▁OUTCOME▁VARIABLES": 27504, + "circling▁one▁(1)▁number▁per▁line,▁please▁indicate▁how▁true▁each▁statement▁has▁been▁for▁you▁during▁the▁past▁7▁days": 27505, + "%)\n\n": 27506, + "(20": 27507, + "(24": 27508, + "(28": 27509, + "(including▁the▁": 27510, + "(a)": 27511, + ")\n\nP": 27512, + ")▁N": 27513, + ").▁E": 27514, + ").▁C": 27515, + ")▁visit": 27516, + ")▁until": 27517, + ")▁document": 27518, + ").▁Patients▁": 27519, + ")▁for▁the▁": 27520, + ")▁were▁": 27521, + ")▁is▁not": 27522, + ",▁ag": 27523, + ",▁the▁subject’s▁": 27524, + "--": 27525, + "-J": 27526, + "-54": 27527, + "-13": 27528, + "-80": 27529, + "-70": 27530, + "-Ntx": 27531, + "-profit": 27532, + ".G": 27533, + ".pdf": 27534, + "/5": 27535, + "/Ph": 27536, + "/paclitaxel": 27537, + "/vital▁sign": 27538, + "/discomfort": 27539, + "/ethnic": 27540, + "/independent▁ethics▁committe": 27541, + "0.": 27542, + "0.1": 27543, + "119": 27544, + "21-Day▁Cycl": 27545, + "35%": 27546, + "3▁days)": 27547, + "5▁mg": 27548, + "6-month": 27549, + "6▁plann": 27550, + "92:": 27551, + "900▁mg": 27552, + "9▁weeks▁until": 27553, + ":▁R": 27554, + ":12": 27555, + ":▁J": 27556, + ":28": 27557, + ":\n\n(": 27558, + ":▁a▁m": 27559, + ";▁S": 27560, + ";▁M": 27561, + ";▁L": 27562, + ";▁NCI": 27563, + "=▁0": 27564, + ">▁1": 27565, + "B▁receptor": 27566, + "Based▁on": 27567, + "Cor": 27568, + "COG": 27569, + "CSI": 27570, + "DLT": 27571, + "D8480C000": 27572, + "Escal": 27573, + "Etoposid": 27574, + "EuroQol▁Group": 27575, + "Fig": 27576, + "Fax": 27577, + "Food▁and▁Drug▁Administration": 27578, + "Hu": 27579, + "High": 27580, + "IA": 27581, + "IgG": 27582, + "L,▁L": 27583, + "Min": 27584, + "Measures▁": 27585, + "Or": 27586, + "OUS": 27587, + "OMP": 27588, + "O’Brien": 27589, + "O’Brien-Fleming": 27590, + "P3": 27591, + "QLQ-C30": 27592, + "Rang": 27593, + "Refer": 27594, + "Ratio": 27595, + "Retention": 27596, + "S/": 27597, + "SR": 27598, + "Sh": 27599, + "SPARC": 27600, + "Tissu": 27601, + "T▁cell": 27602, + "Taken": 27603, + "ULE": 27604, + "V5": 27605, + "ZED": 27606, + "]▁or": 27607, + "]),▁": 27608, + "aum": 27609, + "aqu": 27610, + "automatically▁": 27611, + "aive▁patients▁with": 27612, + "ble": 27613, + "copy▁of": 27614, + "covariates▁": 27615, + "cosmetic": 27616, + "dres": 27617, + "dominal": 27618, + "e.▁Th": 27619, + "e.▁In▁addition": 27620, + "favor": 27621, + "fish▁oil": 27622, + "futility": 27623, + "g/": 27624, + "gastric": 27625, + "giving": 27626, + "hang": 27627, + "holid": 27628, + "his/her": 27629, + "hospital▁": 27630, + "iR": 27631, + "iere▁": 27632, + "ie▁C": 27633, + "jaw": 27634, + "kidney▁": 27635, + "kilogram": 27636, + "led▁to": 27637, + "luorouracil": 27638, + "less▁s": 27639, + "less▁of▁the▁": 27640, + "me": 27641, + "ms": 27642, + "magnesium": 27643, + "malignant": 27644, + "margin": 27645, + "oil": 27646, + "pin": 27647, + "pag": 27648, + "preliminary▁": 27649, + "rw": 27650, + "rend": 27651, + "s'": 27652, + "seek": 27653, + "six": 27654, + "spr": 27655, + "s▁abnormal": 27656, + "solid▁tumor": 27657, + "spontane": 27658, + "s▁available▁to": 27659, + "summary▁statistic": 27660, + "teen": 27661, + "try▁": 27662, + "ud▁": 27663, + "uite▁": 27664, + "vast": 27665, + "west": 27666, + "wish": 27667, + "watchful▁wait": 27668, + "ïv": 27669, + "’t": 27670, + "’s▁a": 27671, + "”▁on": 27672, + "≥1/": 27673, + "▁escal": 27674, + "▁effusion": 27675, + "▁optional": 27676, + "▁..........................................................": 27677, + "▁estrogen": 27678, + "▁routin": 27679, + "▁.▁0": 27680, + "e▁collection": 27681, + "e▁cetuximab": 27682, + "inear": 27683, + "in▁other": 27684, + "injection": 27685, + "ineer": 27686, + "▁t▁n": 27687, + "▁trastuzumab": 27688, + "atim": 27689, + "atomic": 27690, + "ona": 27691, + "onad": 27692, + "\n\n“": 27693, + "\n\nim": 27694, + "\n\nstudy": 27695, + "\n\nas▁": 27696, + "\n\nreport": 27697, + "\n\n54": 27698, + "\n\n80": 27699, + "\n\nmay▁be▁": 27700, + "\n\ninter": 27701, + "\n\ngroup": 27702, + "\n\nhave▁been": 27703, + "\n\nUS": 27704, + "\n\ncontact": 27705, + "\n\ninterval": 27706, + "▁a▁clinical": 27707, + "▁a▁local": 27708, + "▁automatically▁": 27709, + "▁a▁docetaxel-based▁chemotherapy▁regimen": 27710, + "en▁S": 27711, + "en▁E": 27712, + "erl": 27713, + "er▁C": 27714, + "er▁J": 27715, + "erman": 27716, + "ercul": 27717, + "or▁S": 27718, + "or▁may▁not": 27719, + "..............": 27720, + "s▁=": 27721, + "s▁10": 27722, + "s▁observed▁in": 27723, + "s▁......................................................................................................": 27724, + "s▁Sub": 27725, + "s▁would▁be▁": 27726, + "reduct": 27727, + "restriction": 27728, + "alo": 27729, + "alone▁": 27730, + "alities": 27731, + "stand▁": 27732, + "ion▁of▁": 27733, + "ental▁": 27734, + "ite": 27735, + "itation": 27736, + "itone": 27737, + "itidine▁": 27738, + "▁the▁n": 27739, + "▁the▁‘": 27740, + "▁the▁consent": 27741, + "▁the▁effects▁of": 27742, + "an▁American": 27743, + ",▁5": 27744, + ",▁Study▁": 27745, + ",▁chemotherapy▁": 27746, + ",▁has▁been": 27747, + ",▁ie,▁": 27748, + ",▁5-fluorouracil": 27749, + ",▁56": 27750, + ",▁see▁Section": 27751, + ",▁consent▁form": 27752, + ",▁on▁a": 27753, + ",▁headache,▁": 27754, + ",▁laboratories": 27755, + "rovers": 27756, + "roubl": 27757, + "ed▁during▁the▁study": 27758, + "ed▁visually▁for": 27759, + "▁ang": 27760, + "▁angi": 27761, + "▁analyt": 27762, + "▁an▁IVRS": 27763, + "icc": 27764, + "icz": 27765, + ".▁21": 27766, + ".▁29": 27767, + ".▁39": 27768, + "llum": 27769, + "arp": 27770, + "arin-": 27771, + "ed▁all": 27772, + "eding▁and▁": 27773, + "ed▁time▁point": 27774, + "▁packaging": 27775, + "▁pages▁": 27776, + "▁pmab": 27777, + "▁pigment": 27778, + "▁piecew": 27779, + "▁crit": 27780, + "▁cred": 27781, + "▁coagulation": 27782, + "▁catheter": 27783, + "▁bu": 27784, + "▁beg": 27785, + "▁because▁": 27786, + "▁brief": 27787, + "esis": 27788, + "es.▁All": 27789, + "es▁associated▁with": 27790, + "es▁as▁an": 27791, + "for▁the▁difference▁in": 27792, + "eto": 27793, + "etect": 27794, + "etium": 27795, + "ation▁in▁the▁": 27796, + "▁tool": 27797, + "▁to▁com": 27798, + "▁to▁disease▁progression": 27799, + "▁to▁review": 27800, + "▁together": 27801, + "▁to▁indicate▁": 27802, + "▁to▁Lilly▁or▁its▁designee▁via": 27803, + "ispan": 27804, + "▁saf": 27805, + "▁sett": 27806, + "▁self": 27807, + "▁separ": 27808, + "▁since▁": 27809, + "▁sleep": 27810, + "ase,▁": 27811, + "ass▁s": 27812, + "ase;": 27813, + "▁of▁E": 27814, + "▁of▁their": 27815, + "▁of▁Ch": 27816, + "▁of▁cediranib": 27817, + "▁of▁chest": 27818, + "▁of▁DNA": 27819, + "▁of▁childbearing▁potential▁": 27820, + "ouch": 27821, + "▁date▁in": 27822, + "▁depending▁on": 27823, + "through": 27824, + "▁wild-typ": 27825, + "▁method▁of": 27826, + "▁mouse▁": 27827, + "▁mild▁": 27828, + "▁maxim": 27829, + "▁and▁one▁": 27830, + "▁and▁30": 27831, + "▁and▁including": 27832, + "▁and▁III": 27833, + "▁and▁chemotherapy▁": 27834, + "▁and▁stor": 27835, + "▁and▁49": 27836, + "▁and▁maximum": 27837, + "▁and▁does▁not": 27838, + "▁and▁evaluate▁": 27839, + ".\n\ng": 27840, + ".\n\n30": 27841, + ".\n\n35": 27842, + ".\n\nGrade▁4": 27843, + "al▁lymph▁nod": 27844, + "al▁Anti-": 27845, + "eli": 27846, + "elic": 27847, + "abs": 27848, + "absent": 27849, + "▁AM": 27850, + "▁AP": 27851, + "▁Agreement": 27852, + "▁Are▁": 27853, + "▁ASSURA": 27854, + "ivotal▁": 27855, + "▁in-": 27856, + "▁in▁Cancer": 27857, + "▁in▁both": 27858, + "▁in▁bone▁": 27859, + "▁in▁men▁with": 27860, + "▁influenc": 27861, + "...................................▁": 27862, + "ura": 27863, + "urse": 27864, + "uration▁for": 27865, + "evening": 27866, + "evice▁": 27867, + "iguration": 27868, + "00000": 27869, + "occ": 27870, + "plastin": 27871, + "▁1▁to": 27872, + "▁1.2.3": 27873, + "▁COLL": 27874, + "acy": 27875, + "ace▁": 27876, + "acquisition▁of": 27877, + "es▁specifi": 27878, + "es▁should▁not▁be▁": 27879, + "▁PI": 27880, + "▁PET": 27881, + "prohibit": 27882, + "prolifer": 27883, + "▁(8": 27884, + "▁(X": 27885, + "▁(as": 27886, + "▁(radi": 27887, + "▁(14": 27888, + "▁(SCLC": 27889, + "▁(such▁as▁": 27890, + "▁(defined▁as▁": 27891, + "▁(VEGFR": 27892, + "▁(CTC": 27893, + "▁(e.g.": 27894, + "▁(OPG": 27895, + "▁(x▁109/L": 27896, + "emzar": 27897, + "▁2)": 27898, + "▁225": 27899, + "▁2.2.5": 27900, + "ul▁S": 27901, + "ulates": 27902, + "raine▁": 27903, + "if▁necessary": 27904, + "if▁appropriate": 27905, + "▁Squamous▁": 27906, + "▁Summary▁": 27907, + "▁Symptomatic": 27908, + "▁Solid▁Tumor": 27909, + "▁Sequential▁": 27910, + "▁IRC": 27911, + "▁reproduc": 27912, + "aggregate▁": 27913, + "uncontroll": 27914, + "unacceptable▁toxicity": 27915, + "▁D1": 27916, + "▁Detail": 27917, + "▁DLT": 27918, + "▁Dextros": 27919, + "class▁": 27920, + "▁hospital▁": 27921, + "▁heav": 27922, + "e▁often": 27923, + "e▁of▁Administration": 27924, + "▁Ed": 27925, + "▁E,▁B": 27926, + "▁Economic": 27927, + "amol": 27928, + "amoxifen": 27929, + "chn": 27930, + "chron": 27931, + "chair": 27932, + "chemotherapeutic": 27933, + "▁or▁v": 27934, + "▁orally": 27935, + "▁or▁lung": 27936, + "▁or▁FOLFOX": 27937, + "▁or▁EC": 27938, + "▁or▁CT▁scan": 27939, + "▁or▁pharmacist": 27940, + "e▁taxan": 27941, + "ird▁": 27942, + "utophag": 27943, + "uties.▁All": 27944, + "format": 27945, + "formed": 27946, + "formed▁to": 27947, + "forms/": 27948, + "\n\nPublication": 27949, + "\n\nPlease▁": 27950, + "ization▁of": 27951, + "ize▁discover": 27952, + "exual▁": 27953, + "query▁": 27954, + "▁nM": 27955, + "▁nor▁other": 27956, + "▁numer": 27957, + "ody▁surface▁area": 27958, + "ate▁and": 27959, + "ate▁with▁the▁": 27960, + "study▁subject": 27961, + "study▁data": 27962, + "study▁population": 27963, + "study▁participation": 27964, + "line▁or": 27965, + "▁and▁time▁to": 27966, + "▁and▁as▁needed": 27967, + "able,": 27968, + "▁proxim": 27969, + "▁prostate▁": 27970, + "▁proportion": 27971, + "▁prompt": 27972, + "▁T1": 27973, + "▁T3": 27974, + "▁TH": 27975, + "▁TS": 27976, + "▁Two": 27977, + "▁Type▁": 27978, + "▁TIS": 27979, + "▁TABLES": 27980, + "▁Telephone:": 27981, + "▁aden": 27982, + "▁adolescent": 27983, + "▁Neither": 27984, + "▁artic": 27985, + "▁for▁additional": 27986, + "▁for▁use▁in": 27987, + "▁for▁collection▁of": 27988, + "▁for▁Injection": 27989, + "▁for▁Research▁and▁Treatment▁of▁Cancer": 27990, + "▁for-profit": 27991, + "▁Rep": 27992, + "▁RIS": 27993, + "e\n\n3": 27994, + "e\n\nF": 27995, + "e\n\nIf": 27996, + "e\n\nStudy▁": 27997, + "e\n\nKRAS": 27998, + "romat": 27999, + "▁treatment▁due▁to": 28000, + "avies▁": 28001, + "▁with▁no": 28002, + "▁with▁either": 28003, + "▁with▁non-mutated▁(": 28004, + "e▁to▁perform": 28005, + "e▁to▁determine▁if": 28006, + "ed▁best": 28007, + "s▁of▁s": 28008, + "s▁of▁the▁study▁": 28009, + "In▁addition": 28010, + "be▁maintained": 28011, + "ade▁J": 28012, + "antigen": 28013, + "\n\nSchedul": 28014, + "\n\nSevere▁": 28015, + "▁that▁time▁point": 28016, + "▁that▁you▁have▁": 28017, + "▁that▁provides": 28018, + "▁is▁complet": 28019, + "▁is▁delay": 28020, + "▁is▁less▁than": 28021, + "▁of▁oxaliplatin": 28022, + ".....................................................................▁": 28023, + "▁will▁be▁repeated▁": 28024, + "▁will▁be▁done▁": 28025, + "▁will▁be▁included▁in": 28026, + "▁will▁be▁sent▁to": 28027, + "▁will▁be▁summaris": 28028, + "e▁schedul": 28029, + "▁ME": 28030, + "▁M,▁C": 28031, + "▁M,▁G": 28032, + "▁M,▁D": 28033, + "▁Method▁of": 28034, + "▁r▁o": 28035, + "▁0▁to": 28036, + "▁0\n\n1": 28037, + "▁3▁4": 28038, + "▁375": 28039, + "▁construct": 28040, + "▁constipation": 28041, + "▁convulsion": 28042, + "▁congestive���heart▁failure": 28043, + "event-free▁rates▁": 28044, + "▁of▁the▁correction": 28045, + "e,▁S": 28046, + "▁o▁i": 28047, + "▁compos": 28048, + "▁Fact": 28049, + "▁Fever": 28050, + "▁Fatigu": 28051, + "▁FOLLOW": 28052, + ".▁A▁hazard▁ratio": 28053, + ".▁ABX-EGF": 28054, + ".▁APPENDICES": 28055, + ".▁The▁number▁of": 28056, + "ity▁will▁be▁": 28057, + "ity▁Assessment": 28058, + "▁graph": 28059, + "▁gram": 28060, + "not▁related▁to": 28061, + "▁the▁solution": 28062, + "▁the▁safety▁and▁": 28063, + ",▁and▁subject": 28064, + ",▁and▁24": 28065, + ",▁and▁vital▁sign": 28066, + "ated▁plac": 28067, + "▁veh": 28068, + "▁v4.0": 28069, + "▁Low": 28070, + "isease": 28071, + "▁BL": 28072, + "▁Before▁": 28073, + "▁Bone▁scan": 28074, + "▁this▁with": 28075, + "s,▁C": 28076, + "s,▁it": 28077, + "s,▁will▁be▁": 28078, + "s,▁should▁be▁": 28079, + "s,▁laboratory": 28080, + "s,▁MRI": 28081, + "s,▁etc": 28082, + "s,▁so▁that": 28083, + "▁all▁patient": 28084, + "▁all▁patients": 28085, + "cludes▁": 28086, + "clude▁the▁s": 28087, + "12.3": 28088, + "ipunct": 28089, + "\n\nCentral▁": 28090, + "\n\nCoagulation": 28091, + "▁will▁include:": 28092, + "▁will▁serve▁as": 28093, + "▁will▁the▁confidentiality▁of": 28094, + "e▁investigator": 28095, + "e▁in▁combination▁with": 28096, + "e▁instruction": 28097, + "e▁initial": 28098, + "ing▁the▁articl": 28099, + "▁5FU": 28100, + "▁5▁dimension": 28101, + "boplastin": 28102, + "ity▁and": 28103, + "will\n\nbe▁": 28104, + "will▁be": 28105, + "▁67": 28106, + "▁68": 28107, + "▁6:": 28108, + "from▁randomisation": 28109, + "▁Have▁you": 28110, + "and▁survival": 28111, + "▁subject\n\n": 28112, + "▁subjects,": 28113, + "▁subjects’": 28114, + "▁patients▁should▁be▁": 28115, + "▁4.9": 28116, + ")\n\n(": 28117, + ")\n\nIn": 28118, + ")\n\nUn": 28119, + ")\n\nFor": 28120, + "gression▁models▁and▁": 28121, + "▁attain": 28122, + "▁at▁start▁of": 28123, + "ailed▁": 28124, + "s▁(for": 28125, + "s▁(CRF": 28126, + "s▁(e.g.▁": 28127, + "s▁(see▁section": 28128, + "egen": 28129, + "▁study▁guid": 28130, + "▁study▁initiation": 28131, + "\n\n1.": 28132, + "\n\n1.3": 28133, + "\n\n1.0": 28134, + "\n\n1.\n\nB": 28135, + "\n\n1.\n\n2": 28136, + "ase▁2": 28137, + "viously▁": 28138, + "genes": 28139, + "s.▁V": 28140, + "s.▁Cancer": 28141, + "s.▁Disease▁": 28142, + "▁weeks▁(": 28143, + "▁weeks▁for": 28144, + "enson": 28145, + "relating▁to": 28146, + "▁any▁form": 28147, + "▁any▁subsequent": 28148, + "▁Valu": 28149, + "▁Ventricular": 28150, + "▁Versus▁": 28151, + "▁excess▁of": 28152, + "▁expedited▁reporting": 28153, + "eller": 28154, + "ake▁": 28155, + "\n\nDMC": 28156, + "\n\nDuring": 28157, + "\n\nDay\n\nMonth\n\nYear": 28158, + "formed▁decision": 28159, + "urvey▁": 28160, + "▁after▁the▁end▁of": 28161, + "▁after▁paclitaxel": 28162, + "▁after▁your▁last": 28163, + "ethic": 28164, + "ed▁for▁this▁": 28165, + "s▁and▁preferred▁term": 28166, + "s▁and▁p-valu": 28167, + "s▁and▁investigative▁": 28168, + "athologic": 28169, + "ly▁as▁possible▁": 28170, + ".▁Sci": 28171, + ".▁Summary▁of": 28172, + ".▁SUBJECT": 28173, + "▁patients.▁In": 28174, + "▁the▁denosumab": 28175, + "s▁will▁be▁includ": 28176, + "s▁will▁be▁the▁": 28177, + "s▁will▁be▁determin": 28178, + "s▁will▁be▁taken": 28179, + "ies▁or▁in": 28180, + "▁GD": 28181, + "▁Gy▁": 28182, + "▁Gy▁in": 28183, + "▁Gastrointestinal▁": 28184, + "▁unscheduled▁visit": 28185, + "reported▁according▁to▁the▁": 28186, + "▁e.g": 28187, + "▁JJ": 28188, + "e▁the▁error": 28189, + "▁time▁in": 28190, + ".▁Prospective▁": 28191, + "\n\nEvent": 28192, + "\n\nEnd": 28193, + "\n\nEndpoint": 28194, + "\n\nEGFR": 28195, + "\n\nEnrollment": 28196, + "▁Initial": 28197, + "),▁radiation▁therapy▁to▁bone▁": 28198, + "▁antidiarrheal": 28199, + "s\n\n2": 28200, + "s\n\n5": 28201, + "s\n\nY▁T▁I▁D▁I▁L▁A▁V": 28202, + "ed▁by▁Consolidation": 28203, + "▁is▁a▁c": 28204, + "▁is▁a▁m": 28205, + "▁is▁abnormal": 28206, + "▁is▁able▁to": 28207, + "▁is▁the▁purpose▁of": 28208, + ".▁The▁trial": 28209, + "▁notic": 28210, + "▁notation": 28211, + "▁not▁be\n\n": 28212, + "▁not▁associated▁with": 28213, + "ENSATION": 28214, + "▁may▁result▁in": 28215, + "s▁for▁the▁first": 28216, + "ial▁TE": 28217, + "▁7.2.1": 28218, + "▁7▁days▁before▁randomization": 28219, + "▁months.\n\n": 28220, + "▁dose": 28221, + "▁dose.▁If": 28222, + "ichotom": 28223, + "effects▁(": 28224, + "effect▁was▁": 28225, + "ocumentation▁and▁": 28226, + "CT▁of▁the▁": 28227, + "▁study▁assessments▁": 28228, + "▁per▁the▁modified▁RECIST▁criteria": 28229, + "stront": 28230, + "s).▁For": 28231, + ".69": 28232, + "50,000": 28233, + ".▁El": 28234, + "▁assessments": 28235, + "▁assessments,▁": 28236, + "▁assessment▁must▁be▁": 28237, + "▁age▁and▁": 28238, + "▁tests▁of": 28239, + "▁testing▁and▁": 28240, + "areas": 28241, + "ated▁according▁to": 28242, + "ated▁tablet": 28243, + "▁phone▁": 28244, + "s.\n\nPage▁": 28245, + ",▁and▁then": 28246, + ",▁and▁applicable▁": 28247, + "▁signed▁": 28248, + "▁signed▁and▁dated▁": 28249, + "RIOR": 28250, + "▁Date:▁<>": 28251, + "who▁in": 28252, + "▁abst": 28253, + "techn": 28254, + ".▁Tel:▁+": 28255, + "ed▁with▁the▁study": 28256, + "’s▁discretion": 28257, + "20▁mm▁with▁conventional▁techniques▁or": 28258, + "ed▁at▁the▁discretion▁of▁the▁investigator": 28259, + "radiation,▁": 28260, + "25▁mg": 28261, + "iano": 28262, + "kine-": 28263, + "kind▁of": 28264, + "▁9.5": 28265, + "▁9.7": 28266, + "▁913": 28267, + "emetics▁": 28268, + "▁82": 28269, + "s▁specific": 28270, + "▁use▁in▁the▁": 28271, + "ightCycl": 28272, + "\n\nN0": 28273, + "\n\nNCI": 28274, + "cale▁(": 28275, + "calcit": 28276, + "premix": 28277, + "▁data▁will▁not▁be▁": 28278, + "every▁14": 28279, + "every▁effort": 28280, + "▁trials▁of": 28281, + ").\n\n[": 28282, + "▁should▁be▁report": 28283, + "▁should▁be▁performed▁in": 28284, + "_______": 28285, + "▁other▁studies▁": 28286, + "neo": 28287, + "neutropenic": 28288, + "\n\nRECIST": 28289, + "\n\nReview": 28290, + "17]": 28291, + "subject’s▁": 28292, + "▁your▁future▁": 28293, + "▁your▁rights▁as▁a": 28294, + "▁-2": 28295, + "ed▁as▁“": 28296, + "24▁and▁": 28297, + "24-3": 28298, + "▁Study▁Monitoring▁and▁Data▁Collection": 28299, + "▁Study▁Code:▁D8480C00013": 28300, + "▁you▁will": 28301, + "▁you▁directly▁or▁to▁alter": 28302, + "▁a▁slight": 28303, + "▁the▁study\n\ns": 28304, + "\n\nFDA": 28305, + "▁cycles,▁": 28306, + "presenting▁with": 28307, + "presentations,▁": 28308, + "\n\nT2": 28309, + "\n\nTumour": 28310, + "\n\nTotal": 28311, + "\n\n34": 28312, + "\n\n3.6": 28313, + "\n\n3.8": 28314, + "000▁mg/m2": 28315, + "▁import": 28316, + "▁im▁=": 28317, + "One▁": 28318, + "shared": 28319, + "▁the▁patients’": 28320, + "ed,▁label": 28321, + "drain": 28322, + "▁The▁first": 28323, + "▁the▁lat": 28324, + "no▁further": 28325, + "▁dose▁group": 28326, + "▁interactive▁voice▁response▁system": 28327, + "▁than▁on▁placebo": 28328, + ".\n\nAPPENDICES": 28329, + "\n\n44": 28330, + "\n\n4.8": 28331, + ".▁From": 28332, + ".▁Finally,▁": 28333, + "▁days▁for": 28334, + "leav": 28335, + ".\n\nPrior▁to": 28336, + "e▁beginning": 28337, + "s▁to▁detect": 28338, + "s▁to▁measur": 28339, + "s▁to▁determine▁whether": 28340, + "s▁that▁were▁": 28341, + "s▁that▁result▁from▁this▁research.▁Neither▁Amgen": 28342, + "\n\nINT": 28343, + "\n\nIt▁is▁": 28344, + "▁panitumumab\n\n": 28345, + "▁panitumumab-related▁": 28346, + "▁panitumumab▁monotherapy▁": 28347, + "hypert": 28348, + "defined▁to▁be▁": 28349, + "ysteine▁": 28350, + "▁patients▁with▁ED-SCLC": 28351, + "carbam": 28352, + "/oral": 28353, + "▁was▁shown": 28354, + "flak": 28355, + "fluid": 28356, + "▁Version▁No:": 28357, + "▁Version▁Date:▁<>": 28358, + "▁minimal": 28359, + "▁min▁after▁start▁of": 28360, + "▁death▁due▁to": 28361, + ")▁/": 28362, + "main▁bronch": 28363, + "main▁study▁is▁": 28364, + "must▁be▁reported▁to": 28365, + "▁Thorac": 28366, + "upply▁and▁": 28367, + "1994;": 28368, + "▁30▁days▁": 28369, + "Ann": 28370, + "SC▁injection": 28371, + "▁progression▁is▁": 28372, + "▁progression▁or▁death": 28373, + "▁evaluable▁for": 28374, + "e▁and▁cisplatin": 28375, + "provided▁": 28376, + "prior▁to▁dosing": 28377, + "signature": 28378, + "▁dihyd": 28379, + "▁the▁study▁or": 28380, + "▁the▁study▁design": 28381, + "▁included▁": 28382, + "▁must▁be▁submitted▁to▁the▁": 28383, + "▁sample▁d": 28384, + "ruv": 28385, + "ruit": 28386, + "▁infusion▁(": 28387, + "oxin": 28388, + "performed.\n\n": 28389, + "ely:": 28390, + ",▁a▁commercial▁pharmaceutical▁product": 28391, + ",▁applicable▁": 28392, + "you▁will": 28393, + "until▁study▁completion": 28394, + "received▁s": 28395, + "annock": 28396, + "annitol": 28397, + "ed▁from▁light": 28398, + "▁cells▁": 28399, + "considering▁the▁": 28400, + "\n\nHepatic": 28401, + "discontinuing": 28402, + "discontinued▁due▁to": 28403, + "ed.\n\nFor": 28404, + "▁treated▁for": 28405, + "▁treat▁based▁on": 28406, + "Stage▁": 28407, + "▁subcutane": 28408, + "▁subcutaneous▁": 28409, + "▁et▁al▁2005": 28410, + "ORE": 28411, + "ducci": 28412, + "▁modify": 28413, + "es▁will▁be▁assign": 28414, + ".▁Before▁": 28415, + "ebrid": 28416, + "▁analysis\n\n": 28417, + "▁and/or▁panitumumab": 28418, + "▁and/or▁recurrent": 28419, + "▁Panitumumab▁Investigator’s▁Brochure▁for▁further▁detail": 28420, + "ed▁since▁the▁": 28421, + "ed▁should▁not": 28422, + "collected▁in▁the▁": 28423, + "▁=▁moder": 28424, + "▁=▁mild": 28425, + "\n\n6.": 28426, + "▁reporting▁s": 28427, + "▁provides▁the▁": 28428, + "▁should▁includ": 28429, + "▁should▁call": 28430, + ",▁should▁": 28431, + ",▁safety▁": 28432, + ",▁survival": 28433, + "▁these▁patient": 28434, + "▁these▁result": 28435, + "▁these▁cas": 28436, + "▁these▁monitoring▁visit": 28437, + "atistician": 28438, + "s▁beyond▁": 28439, + ",▁Month": 28440, + ",▁MRI": 28441, + "\n\n7.\n\nSTUDY▁MANAGEMENT": 28442, + "▁may▁be▁develop": 28443, + ".▁History▁of": 28444, + "▁more▁f": 28445, + ".2.1.3": 28446, + ".2.1▁Methods▁of▁assessment": 28447, + "▁clinical\n\n": 28448, + "▁drug-related▁": 28449, + "▁drug▁depend": 28450, + "week▁9": 28451, + "▁during▁and▁": 28452, + "▁survival▁benefit": 28453, + "▁must▁remain": 28454, + ",▁Cont": 28455, + ",▁Crawford▁": 28456, + "observed▁for": 28457, + "▁blood▁or": 28458, + "▁blood▁draw": 28459, + "▁blood▁product": 28460, + "▁results▁": 28461, + "non-measurable▁lesion": 28462, + "ation▁of▁study▁treatment": 28463, + "\n\nIn▁the▁": 28464, + "\n\nInduction": 28465, + ",▁baseline▁": 28466, + "▁1987": 28467, + "▁1990": 28468, + "▁actively▁": 28469, + "▁genes▁in": 28470, + "...........................................................................................▁": 28471, + "Addendum": 28472, + "e▁may": 28473, + "e▁marker": 28474, + "\n\nBNP": 28475, + "thorax": 28476, + "es▁(ie,▁": 28477, + "\n\nMor": 28478, + "\n\nMetastatic": 28479, + "\n\nMaximum": 28480, + "able▁to▁receive▁": 28481, + "▁administered▁once▁": 28482, + "▁information▁for": 28483, + "set▁at": 28484, + "set▁forth": 28485, + "▁receives": 28486, + "▁receiving▁the▁": 28487, + "▁receiving▁": 28488, + "▁[1]": 28489, + "end▁of▁trial": 28490, + "▁to▁enter": 28491, + "part▁of▁your": 28492, + "ullick": 28493, + "uthorized▁s": 28494, + "e▁or▁h": 28495, + "e▁or▁all▁of▁the▁": 28496, + "e▁or▁revis": 28497, + "urthermor": 28498, + "▁until▁subjects▁have▁access▁to▁commercially▁available▁product▁or▁for▁up▁to▁2▁year": 28499, + "▁any▁amendment": 28500, + "IV▁investigational▁product": 28501, + "OXAL": 28502, + "▁documenting": 28503, + "▁Arms▁A▁and▁D": 28504, + "was▁observed▁in": 28505, + "was▁chosen": 28506, + "obtain▁the▁consent": 28507, + "▁AMG▁162▁in": 28508, + "▁AMG▁162▁level": 28509, + "▁175▁mg/m2": 28510, + ",▁Hol": 28511, + ",▁Hung": 28512, + "▁then▁treat▁based▁on": 28513, + "OG-Ntx": 28514, + "by▁either": 28515, + "▁change▁the▁": 28516, + "-55": 28517, + "stitution,▁who▁will": 28518, + "overall▁progression▁of": 28519, + "under▁medical": 28520, + "▁criteria:\n\n": 28521, + "▁intra-": 28522, + "shipment▁of": 28523, + "must▁also": 28524, + ".▁For▁this▁": 28525, + "\n\nAn▁observation▁made▁on▁a▁variable▁": 28526, + "by▁the▁treating▁physician": 28527, + "▁OS,▁the▁": 28528, + "s▁of▁the▁abdomen": 28529, + "▁disease▁in": 28530, + "▁disease;": 28531, + "▁approved▁by▁": 28532, + "▁approved▁in▁the▁": 28533, + "known▁to": 28534, + "▁a▁cardiologist": 28535, + "▁Kit": 28536, + "efficacy▁variabl": 28537, + "▁Y▁P▁O▁C": 28538, + "(s)▁must": 28539, + "(s),▁and▁the▁": 28540, + "assessments▁": 28541, + "s▁should▁be▁representative▁of": 28542, + "ventional▁CT": 28543, + "ventions▁that▁result▁from▁this▁research.▁Neither▁Amgen": 28544, + "representing": 28545, + "▁new▁cases▁of": 28546, + ",▁Grade▁": 28547, + "s▁on▁Day▁1": 28548, + "versus▁placebo": 28549, + ",▁et▁al.▁In": 28550, + ",▁et▁al.▁M": 28551, + ",▁et▁al.▁Irinotecan": 28552, + "▁countries": 28553, + "ed▁care": 28554, + "▁chemotherapy▁administration": 28555, + "▁chemotherapy-na": 28556, + "▁x▁x▁x": 28557, + "ing▁a▁subject": 28558, + "ing▁a▁high": 28559, + "ing▁aromatase▁inhibitor": 28560, + "s▁and▁are▁": 28561, + "s▁and▁those▁": 28562, + "s▁and▁amendments▁to": 28563, + "research▁using": 28564, + "-mL": 28565, + ",▁Day▁": 28566, + "▁partially▁": 28567, + "▁by\n\nthe▁investigator": 28568, + "▁every▁2": 28569, + "within▁the▁past": 28570, + "identifiable▁": 28571, + "\n\n56": 28572, + "\n\n57": 28573, + "▁a▁molecular": 28574, + "▁comparator": 28575, + "▁14▁days": 28576, + "▁mL▁vial": 28577, + "▁Appendix▁C": 28578, + "▁first▁line▁": 28579, + "-Melzack": 28580, + "\n\nAppendix▁J": 28581, + "▁the▁first▁documentation▁of▁": 28582, + ",▁paclitaxel": 28583, + "ICF": 28584, + "▁under▁a": 28585, + "indicate▁": 28586, + "indicating": 28587, + "21▁November▁2005": 28588, + "▁+▁FOLFIRI": 28589, + "PART": 28590, + "ized▁fil": 28591, + "▁IV▁bisphosphon": 28592, + "olicit": 28593, + "▁for▁the▁final": 28594, + "▁position": 28595, + ")▁(X": 28596, + "▁Oncol▁2": 28597, + "normality": 28598, + "ate/": 28599, + "▁clinical▁import": 28600, + "\n\nOc": 28601, + "▁between▁the▁": 28602, + "/month": 28603, + "\n\n95%": 28604, + "\n\n9.3.1": 28605, + "chemotherapy▁in": 28606, + "▁SAEs▁and▁those▁": 28607, + "is▁not▁positiv": 28608, + "▁research▁companies▁": 28609, + "▁of▁a▁treatment": 28610, + "▁of▁a▁21-day▁cycl": 28611, + "▁confirmatory▁": 28612, + "▁withdrawal▁of": 28613, + "pecified▁that": 28614, + ",▁infection": 28615, + ",▁informed▁consent▁form": 28616, + "▁clot": 28617, + "▁survival▁rate▁": 28618, + "new▁version": 28619, + "new▁location": 28620, + "person▁who▁conducted": 28621, + "ascular▁endothelial▁growth▁factor": 28622, + "rofich": 28623, + "▁have▁shown▁that": 28624, + "▁have▁the▁sampl": 28625, + "▁Treatment▁of": 28626, + "attention": 28627, + "▁the▁end▁of▁study▁": 28628, + "▁the▁end▁of▁study▁treatment": 28629, + "▁18:": 28630, + "▁and▁skin": 28631, + "▁and▁sunitinib": 28632, + "▁and▁support": 28633, + "pensation▁for": 28634, + "▁observed▁or▁volunteer": 28635, + ",▁Re": 28636, + ",▁Rob": 28637, + "▁were▁recorded,": 28638, + "except▁where▁": 28639, + "due▁to▁un": 28640, + "▁overall▁survival▁(": 28641, + "▁significant▁difference▁in": 28642, + "▁is▁not▁yet": 28643, + "median▁time▁to▁progression": 28644, + "blood▁pressure,▁": 28645, + "y▁should▁": 28646, + "analyses▁": 28647, + "▁corpor": 28648, + "\n\nProtocol▁Synopsis▁": 28649, + "Treatment▁Arm▁A": 28650, + "Treatment▁Cycl": 28651, + "ensitivity▁": 28652, + "ECOG▁45": 28653, + "▁these▁drug": 28654, + ".............................................................................................................▁": 28655, + "���advanced▁esophag": 28656, + "calculated▁to": 28657, + "calculated▁based▁on": 28658, + "Expression": 28659, + "utilizing": 28660, + "es▁to▁have▁access▁to": 28661, + "▁serum▁or▁urine▁pregnancy▁test": 28662, + "▁medical▁emergency▁": 28663, + "▁EGF▁receptor": 28664, + "RECIST▁Criteria▁for": 28665, + "\n\nSection:▁14": 28666, + "260": 28667, + "26]": 28668, + "Protein": 28669, + "▁PD▁=▁progressive▁diseas": 28670, + "▁an▁enrollment": 28671, + "▁an▁electronic": 28672, + ".▁Lesion": 28673, + "▁prior▁chemotherapy▁regimen": 28674, + "▁conditions▁": 28675, + "▁consent▁to▁the▁": 28676, + "▁patients▁who▁received▁": 28677, + "posterior": 28678, + ",▁Tulsky▁": 28679, + "use▁of▁radioisotopes),▁surgery▁to": 28680, + "▁the▁date▁of▁withdrawal": 28681, + "2-9": 28682, + "urgery": 28683, + "▁acids▁and▁": 28684, + "echnetium": 28685, + ",▁Kaplan-Meier": 28686, + "▁either▁occur": 28687, + "▁either▁“": 28688, + "▁records▁will▁be▁": 28689, + "have▁shown": 28690, + ".\n\nETHICS": 28691, + "▁those▁with": 28692, + "▁those▁patients▁": 28693, + "\n\nincreas": 28694, + "ensory": 28695, + "cycle\n\n": 28696, + "cycle)": 28697, + "weight▁and▁": 28698, + "\n\nmetastas": 28699, + "covering": 28700, + ".\n\n5.7": 28701, + "Amgen▁Center": 28702, + "Assessments\n\n": 28703, + "LY231514\n\nH3E-US-S130(d)▁Clinical▁Protocol\n\nPage▁": 28704, + "▁procedures▁will▁be▁": 28705, + "▁toxicity▁that": 28706, + "were▁treat": 28707, + "hematological": 28708, + "ett▁CL": 28709, + ".\n\nDenosumab": 28710, + "possible,▁": 28711, + "representatives▁to▁have▁access▁to": 28712, + "products▁develop": 28713, + "▁lasting": 28714, + "\n\na\n\nb": 28715, + "▁would▁otherwise▁": 28716, + ".\n\nIn▁some▁circumstanc": 28717, + ".\n\nIn▁signing▁this▁document": 28718, + "eyes,▁": 28719, + "ation,▁etc.": 28720, + "▁denosumab▁concentration": 28721, + "adverse▁event▁case▁report▁form": 28722, + "▁evaluation▁by▁": 28723, + "▁(Cycle▁": 28724, + "▁(C225": 28725, + "▁(CEA": 28726, + ".▁In▁addition▁to": 28727, + "planned▁to": 28728, + "Endpoints:": 28729, + "▁are:\n\n": 28730, + ".4.1.2": 28731, + "▁is▁a▁requirement": 28732, + ".\n\n32": 28733, + "▁the▁sponsor’s▁": 28734, + "▁CTCAE▁version▁3.0": 28735, + "▁CTCAE▁v3.0": 28736, + "itis▁(": 28737, + "append": 28738, + "▁studies▁with": 28739, + "3-week": 28740, + "▁All▁other▁lesion": 28741, + "condition▁of▁the▁drug": 28742, + ".\n\n7.3": 28743, + "▁50▁ml/min": 28744, + "Phosph": 28745, + "▁schedule▁(": 28746, + "▁considered": 28747, + "▁Enroll": 28748, + "/depression": 28749, + "▁tumour▁sampl": 28750, + "▁tumour▁siz": 28751, + "ed,▁then": 28752, + "▁colon▁carcinoma": 28753, + ",▁multicenter": 28754, + "infused▁": 28755, + ",▁Nak": 28756, + "▁accordance▁with▁ICH▁GCP": 28757, + "nonmeasurable▁lesion": 28758, + "nonlinear": 28759, + "other▁than▁SAEs▁and▁those▁": 28760, + "e▁samples": 28761, + "▁the▁data▁cutoff": 28762, + "▁appropriately": 28763, + "leucovorin,▁": 28764, + "experienced▁an": 28765, + "range▁from": 28766, + "controlled▁by▁": 28767, + "▁Safety▁Analysis": 28768, + "▁vitamin▁D▁and▁": 28769, + ").▁The▁original▁sign": 28770, + ".\n\nBoth": 28771, + "combined": 28772, + ",▁but▁must": 28773, + "ARD": 28774, + "Appendix▁B": 28775, + "radiation▁treatment": 28776, + "higher▁than": 28777, + "▁details▁of": 28778, + "treated▁as▁": 28779, + "Therapies": 28780, + "▁localised▁": 28781, + ",▁all▁subsequent": 28782, + "▁a▁log": 28783, + "▁a▁list▁of": 28784, + ",▁Einh": 28785, + "skin▁reaction": 28786, + "maintain▁a▁list▁of": 28787, + "increased": 28788, + "▁PSA▁valu": 28789, + "ethylen": 28790, + "▁objective▁disease▁progression": 28791, + "▁objective▁response▁rate▁": 28792, + "Follow▁Up": 28793, + ".\n\n2.4": 28794, + "▁more▁than▁on": 28795, + "▁Dose▁reduction": 28796, + "▁one▁year": 28797, + "adjusted▁for": 28798, + "▁local▁lab": 28799, + ",▁cardiac": 28800, + ",▁colorless": 28801, + "Evaluation▁of": 28802, + "Evaluations▁": 28803, + "Medic": 28804, + "Median": 28805, + "▁functional": 28806, + "905": 28807, + "▁physician,▁or▁other": 28808, + "▁take▁plac": 28809, + "▁take▁appropriate▁": 28810, + "solvent": 28811, + "▁grade▁2▁or": 28812, + "▁et▁al.▁2004": 28813, + "▁et▁al.▁2002)": 28814, + "primary▁tumor": 28815, + "primary▁analysis▁of": 28816, + "raining": 28817, + "\n\nNo▁change\n\n": 28818, + "\n\nAmgen▁Protocol▁Number": 28819, + "▁end▁": 28820, + "▁enable▁": 28821, + "ready": 28822, + "readily": 28823, + "reduced▁": 28824, + "▁my▁illness": 28825, + "▁my▁records▁": 28826, + "reported▁SAE": 28827, + "reported▁immediately": 28828, + "evaluated▁using": 28829, + "▁(PIN": 28830, + ".▁At▁each": 28831, + "ate,▁5%": 28832, + ".▁57": 28833, + "s▁should▁be▁taken": 28834, + "▁DNA▁extraction": 28835, + "periodic": 28836, + "▁FOLFIRI▁plus▁placebo": 28837, + "metastatic▁breast▁cancer": 28838, + "activity▁in": 28839, + "▁standard▁chemotherapy": 28840, + "▁60▁mg": 28841, + "▁studies,▁the▁": 28842, + "▁current▁practic": 28843, + ",000▁women": 28844, + "\n\nbefore▁": 28845, + "\n\nbaselin": 28846, + "▁possible,": 28847, + ",▁Oz": 28848, + ".\n\nRandomization": 28849, + "▁exposure▁of": 28850, + "urine▁protein": 28851, + "ECGs▁may▁be▁performed▁as▁clinically▁indicated": 28852, + "best▁possible▁": 28853, + "▁a▁subject▁has▁": 28854, + ".▁Concomitant▁medication": 28855, + ".▁Confirmation": 28856, + "▁Study▁Documentation▁and▁": 28857, + "▁the▁discretion▁of▁the\n\n": 28858, + ",▁would▁": 28859, + "▁the▁primary▁and▁secondary▁": 28860, + "s,▁or▁research▁companies▁": 28861, + "outlined▁below": 28862, + "outlined▁in▁Appendix": 28863, + "ase▁(AST": 28864, + "ology,▁blood▁": 28865, + "tic▁syndrom": 28866, + "▁the▁sample▁to▁be▁": 28867, + "submitted▁for": 28868, + "4▁weeks▁on": 28869, + "aneous▁": 28870, + "e▁blood▁sampl": 28871, + "▁normalization": 28872, + "us▁(ECOG": 28873, + "IVRS▁vendor": 28874, + "▁(cid:14": 28875, + "spection▁of": 28876, + "▁the▁situation": 28877, + "▁planning": 28878, + "▁pre-medication": 28879, + "judgment▁of": 28880, + "▁necessary▁for": 28881, + "results▁of▁a": 28882, + "modifications▁for": 28883, + "ISS": 28884, + "term▁“": 28885, + "\n\nCONFIDENTIAL\n\nA▁®\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁PANITUMUMAB▁(AMG▁954)▁Protocol▁Number:▁20040249▁Date:▁07▁August▁2007\n\nPage▁": 28886, + ".▁Exploratory▁": 28887, + "\n\nExploratory": 28888, + ",▁then▁the▁": 28889, + "ertiary": 28890, + "loss▁to▁follow-up": 28891, + "engineer": 28892, + "▁the▁patient’s▁underlying": 28893, + "\n\nto▁the▁": 28894, + "▁and▁other▁researcher": 28895, + "▁extend": 28896, + "sided▁": 28897, + "▁surgery▁(": 28898, + "confidential▁information▁of": 28899, + "▁written▁approval": 28900, + "▁question▁is▁": 28901, + "s▁may▁us": 28902, + "s▁may▁prescribe▁": 28903, + "s)\n\n\n\n": 28904, + "s.▁Sever": 28905, + "▁systemic▁therapy▁": 28906, + "▁estimate▁th": 28907, + ".\n\n4.2": 28908, + "\n\nConcomitant▁medication": 28909, + "▁linear": 28910, + "▁this▁research▁will▁compensate▁you▁if▁this▁happens": 28911, + "es▁of▁the▁medical": 28912, + "▁.....................................................................................▁": 28913, + "before▁any▁": 28914, + "e.▁Amgen": 28915, + "▁defined▁": 28916, + "▁Tumor▁Lesion": 28917, + "▁With:": 28918, + ")▁is▁defined▁as▁": 28919, + "FOLFIRI▁arm": 28920, + "final▁analysis▁for": 28921, + "stable▁for": 28922, + "▁ADMINISTRATIVE": 28923, + "▁active▁agent": 28924, + "▁active▁infection": 28925, + "▁blood▁test": 28926, + "▁blood▁and/or": 28927, + "improved▁": 28928, + "unblinding▁in": 28929, + "▁EGFR▁inhibitor": 28930, + "cris": 28931, + "possib": 28932, + "Not▁Done▁(ND": 28933, + "Significant": 28934, + "▁outcomes▁": 28935, + "▁outcomes▁of": 28936, + "▁.............................................................................▁": 28937, + "s▁must▁be\n\n": 28938, + "▁applies": 28939, + "permitted": 28940, + ".▁The▁patient▁has▁a": 28941, + ".▁Treatments▁Administer": 28942, + "▁dose▁reductions▁and▁": 28943, + "▁assess▁the▁effect▁of▁ZD4054▁in▁combination▁with▁docetaxel▁on": 28944, + "azep": 28945, + "\n\nTreatment▁compli": 28946, + ".\n\nTo▁investigate▁the▁": 28947, + "removed▁for": 28948, + "▁preventing": 28949, + "▁imaging▁test": 28950, + "completion▁or▁early▁termination▁and▁send": 28951, + "▁or▁sell": 28952, + "▁or▁suspect": 28953, + "\n\ncopy▁of": 28954, + "▁achieve▁the▁": 28955, + "▁cytologic": 28956, + ".▁There▁is▁": 28957, + "retriev": 28958, + "▁names▁for": 28959, + "▁decline▁": 28960, + ".▁This\n\n": 28961, + "kaline▁Phosph": 28962, + "where▁the▁in": 28963, + "▁mCRC▁among▁subjects▁with": 28964, + "▁the▁investigator’s▁report": 28965, + "▁et▁al,▁2004)": 28966, + "code▁break": 28967, + "otherwise▁specifi": 28968, + "▁size;": 28969, + "▁4.6.1.1": 28970, + "▁sites▁of▁disease": 28971, + "MUNEX\n\nConfidential\n\nAMGEN": 28972, + "coprotein": 28973, + "rigger": 28974, + "▁Required": 28975, + "▁participating▁countries▁": 28976, + "estimated▁using▁the▁": 28977, + "system▁organ▁clas": 28978, + "ectomy,▁": 28979, + "ectomy/": 28980, + "▁will▁be▁used▁to▁identify": 28981, + "local▁laboratory▁": 28982, + "local▁lab": 28983, + "ELIS": 28984, + "Quality": 28985, + "RR=": 28986, + "▁of▁single-agent": 28987, + "▁enter▁the▁": 28988, + "▁co/": 28989, + "▁coefficient": 28990, + "(106)\n\nGEL▁Version▁ID:▁ONC.000−": 28991, + "ically▁significant▁adverse▁events▁": 28992, + "▁College▁of": 28993, + "quantities▁of": 28994, + "▁shown▁to▁be▁": 28995, + "▁thrombotic": 28996, + "jury▁": 28997, + ".\n\nHowever": 28998, + "concomitant▁medications▁will▁be▁": 28999, + "ous▁injection": 29000, + "▁2▁weeks▁prior▁to": 29001, + "administered▁over": 29002, + "\n\nPrimary▁variabl": 29003, + "(mL/min": 29004, + "investigated▁in": 29005, + "▁and▁packag": 29006, + "please▁see▁Section": 29007, + "▁(BUN": 29008, + "included▁in▁the▁shipment": 29009, + "beginning▁of▁the▁": 29010, + "▁grade▁3/4": 29011, + "▁respond▁to": 29012, + "▁respondent": 29013, + "▁analysis▁will▁not": 29014, + "▁described▁abov": 29015, + "representative▁and▁": 29016, + "▁(if▁applicable)": 29017, + "▁undergo▁an▁": 29018, + ".▁Study▁Population": 29019, + "CEDURES▁IN▁CASE▁OF▁EMERGENCY,▁OVERDOSE▁OR▁PREGNANCY": 29020, + "▁resolution▁to": 29021, + "3,▁6": 29022, + "had▁the▁opportunity▁to": 29023, + "▁copy▁of▁the▁": 29024, + "▁stopping▁the▁": 29025, + "Follow-up▁Visit": 29026, + "effective▁contraception": 29027, + "Analysis▁Data": 29028, + ".▁1982": 29029, + "▁of▁panitumumab▁plus▁FOLFIRI": 29030, + "icalutamid": 29031, + "▁interest▁in▁the▁": 29032, + "e▁an▁objective▁": 29033, + "involvement": 29034, + "▁as▁described▁in▁Appendix": 29035, + "▁standardized▁": 29036, + "acceptable▁toxicities": 29037, + "FDA▁form": 29038, + "anticoagulant": 29039, + "▁experience▁a": 29040, + "▁the▁two▁treatment▁group": 29041, + "▁know▁which": 29042, + "▁and▁all▁amendment": 29043, + "▁while▁you▁are▁": 29044, + "scored▁as▁": 29045, + "▁board": 29046, + "▁department": 29047, + "every▁three▁week": 29048, + "▁(Arm▁1": 29049, + "▁patients▁treated▁with▁bevacizumab": 29050, + "▁prolongation▁of": 29051, + "\n\nLY231514\n\nH3E-US-S130(d)▁Clinical▁Protocol\n\nPage▁": 29052, + "▁comparison▁of": 29053, + "PSA▁values": 29054, + "s▁to▁the▁appropriate▁": 29055, + "from▁the▁IEC/IRB": 29056, + "relatedness▁of": 29057, + "▁a▁maximum▁of▁": 29058, + "▁progressed▁after": 29059, + "ology▁and▁Pharmacokinetic": 29060, + "ed;▁however": 29061, + "▁any▁reason,▁": 29062, + "aminotransferase\n\n": 29063, + "▁related▁to▁that": 29064, + "cope▁of": 29065, + "meeting": 29066, + "▁those▁subject": 29067, + "ody▁S": 29068, + "iliary▁": 29069, + "▁(darbepoetin▁alfa": 29070, + ".▁Samples▁will▁be▁": 29071, + "puterized▁": 29072, + ",▁1982)": 29073, + "▁procedure▁(": 29074, + "▁unblinding▁information": 29075, + "s.\n\nPartial▁": 29076, + "▁original▁dose\n\n": 29077, + "diagnosed▁with": 29078, + "shipped▁to": 29079, + "withheld": 29080, + "▁compensated▁for": 29081, + "▁result▁in▁hospitalization": 29082, + "▁particular▁clinical▁import": 29083, + "escription▁of": 29084, + "▁delays▁in": 29085, + "▁COMP": 29086, + "permanently": 29087, + "▁aspects▁of▁the▁": 29088, + "shown▁in▁Table▁": 29089, + "▁there▁is▁a▁reasonable▁": 29090, + ".▁Altern": 29091, + "reathing": 29092, + "▁alternative▁to": 29093, + "▁alternative▁treatment": 29094, + "radiographically▁": 29095, + "roughout▁the▁study": 29096, + "e▁JA": 29097, + "accurate▁": 29098, + "▁5%▁Dextros": 29099, + "▁telephone▁contact▁with": 29100, + "▁µmol/L": 29101, + "▁measuring": 29102, + "notification▁to▁Pfizer": 29103, + "▁subjects▁will▁be▁followed▁for▁survival▁for": 29104, + "\n\n14.▁REFERENCES": 29105, + "hould▁a▁subject▁(or": 29106, + "s▁thereafter▁until": 29107, + "▁urine▁protein": 29108, + "▁(Lawless": 29109, + ".\n\nThe▁investigator▁will▁be▁responsible▁for▁obtaining▁an": 29110, + "rupt▁until": 29111, + "▁cardiac▁failure▁": 29112, + "anti-tumor": 29113, + "▁Chemotherapy▁Al": 29114, + "▁Dose▁Modification▁Algorithm": 29115, + "decision▁by▁the▁investigator▁or": 29116, + "▁of▁69▁Addendum▁13\n\n": 29117, + ".▁Oncogen": 29118, + "▁renal": 29119, + ".▁Am▁J▁Clin▁Oncol": 29120, + "\n\nX▁X\n\nX▁X": 29121, + "\n\nAny\n\nYes": 29122, + "▁confirmed▁CR▁or▁PR": 29123, + "▁immediately▁if": 29124, + "e▁Blood▁": 29125, + "line▁strok": 29126, + "\n\nI▁am▁satisfied▁with": 29127, + "▁at▁any▁time▁by▁": 29128, + "▁protocol▁amendments▁and▁": 29129, + "▁is▁in▁effect": 29130, + "▁Hyper": 29131, + "▁Hypo": 29132, + "\n\n100%▁of▁previous▁dose\n\n": 29133, + "▁oral▁bisphosphon": 29134, + "▁will▁be▁censored▁at▁the▁last": 29135, + "▁their▁last▁observation": 29136, + "ozn": 29137, + "▁will▁be▁recorded": 29138, + "intravenous": 29139, + "\n\nGeneral": 29140, + "\n\nAdd▁3,5,6": 29141, + "standard▁of▁care▁": 29142, + "pedit": 29143, + "\n\nFollowing▁the▁": 29144, + "acceptable▁adverse▁event": 29145, + "▁allocation▁of": 29146, + "▁allocated▁to": 29147, + "▁at▁each▁centr": 29148, + "▁90▁": 29149, + "SUE": 29150, + "▁the▁use▁of▁your": 29151, + "▁soft▁tissu": 29152, + "▁2.5▁x▁ULN": 29153, + "▁the▁second▁interim▁analysis": 29154, + "may▁occur▁in▁10": 29155, + ").\n\nPage:": 29156, + "▁Analysis▁Population": 29157, + ";▁(4)": 29158, + "local▁practic": 29159, + "well▁tolerated▁in": 29160, + "▁epidemi": 29161, + "\n\nGEL▁Version▁ID:▁ONC.000−272−636.4.0": 29162, + ".▁Your▁doctor": 29163, + "▁will▁provide▁the▁": 29164, + "s▁(or▁equivalent": 29165, + "▁any▁unexpected▁s": 29166, + ".▁Recent": 29167, + "▁mmol/L▁mmol/L": 29168, + "Related▁Event": 29169, + "balance▁": 29170, + "hold▁and▁check": 29171, + "▁facilit": 29172, + "data▁from▁a": 29173, + "metabolic": 29174, + "recruited▁into": 29175, + "recruitment▁of": 29176, + "▁(IFL": 29177, + "s.▁Clin": 29178, + "▁death▁or▁hospitalization": 29179, + "▁Pharmacy▁Guid": 29180, + "target\n\nlesion": 29181, + "physical▁well▁being": 29182, + "▁the▁development▁of▁commercial▁pharmaceutical▁product": 29183, + "▁trial▁of▁pemetrexed▁": 29184, + "Contact": 29185, + "investigational\n\nproduct": 29186, + "▁inclusion▁cutoff▁date▁": 29187, + "contents▁of": 29188, + "▁visceral": 29189, + "storage▁period": 29190, + "▁will▁be▁the▁primary": 29191, + "correction▁fluid,▁or": 29192, + "▁the▁definition▁of▁a": 29193, + "ranslational▁research": 29194, + "s▁by▁the▁": 29195, + "phosphoryl": 29196, + "ART▁B": 29197, + "▁body▁authorized▁under▁applicable▁law▁to▁consent": 29198, + "▁twice▁daily;": 29199, + "2▁or▁has▁returned▁to▁baseline,▁then": 29200, + "incidence,▁": 29201, + "▁and▁propri": 29202, + "▁and▁promptly▁": 29203, + "partial▁response▁": 29204, + "re▁T": 29205, + ",▁USA": 29206, + "ed,▁and▁accurately▁": 29207, + "▁boundaries": 29208, + "▁Sodium▁Acet": 29209, + "▁will▁be▁compared▁between": 29210, + "▁805": 29211, + "▁understanding▁of▁the▁": 29212, + "clearly▁defined▁and▁surrounded▁by▁aerated▁lung": 29213, + "elf-care.▁Totally▁confined▁to▁bed▁or▁chair": 29214, + "/FACT": 29215, + "▁illness▁or": 29216, + "revised▁to": 29217, + "▁molecular▁weight": 29218, + "\n\nScreening▁and▁demographic": 29219, + "cytotoxic": 29220, + "micid": 29221, + "▁urinary▁": 29222, + "orbitol": 29223, + "▁the▁point▁at▁which": 29224, + "▁your▁cancer▁has▁": 29225, + "documentation▁related▁to▁that": 29226, + "▁non-small▁cell▁lung▁cancer▁(NSCLC)": 29227, + "▁Exploratory▁................................................................................................": 29228, + "\n\nS▁T▁I\n\nK▁C▁E▁H▁C\n\nE▁S▁A▁E▁L▁P\n\n.▁T▁N▁E▁M▁U▁C▁O▁D\n\nC▁I▁N▁O▁R▁T▁C▁E▁L▁E": 29229, + "’s▁institution,▁who▁will": 29230, + "ance,▁other▁than▁SAEs▁and▁those▁": 29231, + "NS)": 29232, + "s▁might": 29233, + "▁second▁line▁": 29234, + "recorded▁on▁a▁Serious▁Adverse▁Event": 29235, + "▁No▁No▁No▁No": 29236, + ",▁they▁must": 29237, + "negative▁or": 29238, + "▁I.V.▁": 29239, + "▁will▁be▁analyzed▁using": 29240, + "▁Model": 29241, + "▁Good▁Clinical▁Practice▁and": 29242, + "s.▁In▁addition,▁the▁": 29243, + "pedited▁report": 29244, + "instructed▁to▁contact": 29245, + "▁wish▁to▁assign▁the▁study▁records▁to": 29246, + "▁tyrosine▁kinas": 29247, + "▁will▁be▁considered▁a": 29248, + "s▁for▁each▁endpoint": 29249, + "▁-▁-▁-▁-": 29250, + "▁the\n\nsubject▁or": 29251, + "▁OS▁events▁are▁": 29252, + ",▁creatinine,▁": 29253, + "▁summariz": 29254, + ".2\n\nRandomization": 29255, + "prolonged▁(": 29256, + "▁SUPP": 29257, + "▁heartbeat": 29258, + ".▁During▁the▁extension▁period": 29259, + "othelin-1": 29260, + "▁activities▁of": 29261, + "summarized▁descript": 29262, + "▁email": 29263, + "▁every▁two▁week": 29264, + "▁Hematologic▁Toxicity▁": 29265, + "\n\nDescription▁of▁outcome▁variables▁in▁relation▁to▁objectives▁and▁": 29266, + "▁antifol": 29267, + "\n\n4\n\n4\n\n4\n\n4\n\n4\n\n4": 29268, + "unctional▁Assessment▁of▁Cancer▁Therapy▁–": 29269, + "▁of▁63▁Finalization▁date:▁June▁19▁2001,▁Incorporating▁Amendment▁3▁–▁dated▁23▁May▁2003": 29270, + "familiar": 29271, + "ysesthesias▁": 29272, + "▁nor▁the▁principal▁investigator": 29273, + "▁History": 29274, + "▁History▁of": 29275, + "▁weekly▁then▁treat▁based▁on": 29276, + "\n\nDisease▁progression": 29277, + ".▁During▁this▁": 29278, + "▁superiority": 29279, + ".\n\nAdd▁6": 29280, + "protective▁": 29281, + "cagliotti▁et▁al.▁200": 29282, + "creatinine▁clearance▁(CrCl": 29283, + "▁evidence▁that": 29284, + "▁and▁placebo▁group": 29285, + "▁Comparison": 29286, + "▁third-": 29287, + "▁ECOG▁performance▁status▁": 29288, + "▁stopping▁boundary▁": 29289, + "aries▁for": 29290, + "▁squamous▁cell▁carcinoma▁of▁the▁head▁and▁neck": 29291, + "▁of▁at▁least▁2": 29292, + "▁the▁event▁that▁bone▁scan": 29293, + "▁nonhematologic▁toxicities": 29294, + "regulatory▁agencies": 29295, + "(106)\n\nGEL▁Version▁ID:▁ONC.000−272−636.4.0\n\nApproved\n\nDate▁Printed:▁13−Aug−2013\n\nApproved▁by\n\n13▁Sep▁2007▁17:17:03\n\nAmended▁Clinical▁Study▁Protocol▁Drug▁Substance▁Cediranib▁(RECENTIN,▁AZD2171)▁Study▁Code▁D8480C00013▁Edition▁Number▁3▁Date\n\n.▁E▁S▁U": 29296, + "▁the▁time▁points▁": 29297, + "▁efficacy▁and▁safety": 29298, + "ennett▁CL": 29299, + ",▁other▁researcher": 29300, + "▁cessation▁of▁": 29301, + "▁rectal▁cancer": 29302, + "▁hematological": 29303, + "\n\nStudy▁timetable▁and▁end▁of▁study": 29304, + "ured▁and▁packag": 29305, + "▁stage▁III▁colon▁cancer": 29306, + "▁data▁collection▁for": 29307, + "▁Storage▁": 29308, + "resolved▁or▁stabiliz": 29309, + ".▁Therefore,▁the▁": 29310, + "▁ruler▁or▁c": 29311, + "▁withdrawal▁from▁study▁treatment": 29312, + "▁metabolism": 29313, + "whichever▁is▁later": 29314, + "Number:": 29315, + "double▁barrier": 29316, + "s▁used▁in▁this▁protocol,▁the▁": 29317, + "▁paper▁forms▁will▁be▁": 29318, + "▁the▁designated▁": 29319, + "over▁30▁minutes▁": 29320, + ".▁Concomitant▁Therapy▁": 29321, + "PTV▁receives▁": 29322, + "▁archived▁tumor▁tissu": 29323, + "(7):▁p.▁": 29324, + "anine-": 29325, + "▁balanc": 29326, + "▁balance▁": 29327, + "randomized▁to▁receive▁panitumumab": 29328, + ".\n\nHow▁will▁the▁confidentiality▁of": 29329, + "▁Organization▁for▁Research▁and▁Treatment▁of▁Cancer": 29330, + "▁reasonable▁possibility▁that▁the▁event▁may▁have▁been▁caused▁by▁": 29331, + "(10):": 29332, + "polyglutam": 29333, + "properly": 29334, + "amide▁ribonucle": 29335, + "▁RS,▁Rubin": 29336, + "▁dose▁escalate▁to": 29337, + "\n\nx▁x▁x▁x\n\nx▁x▁x▁x": 29338, + "wild-type)▁KRAS": 29339, + ",▁on▁behalf▁of▁a": 29340, + "▁PTV": 29341, + "▁Drive▁": 29342, + "per▁local▁practic": 29343, + ".▁Regression▁models▁and▁": 29344, + "▁behalf▁of": 29345, + "▁patterns▁of": 29346, + "andler▁A": 29347, + "▁after▁failure▁of▁a▁docetaxel-based▁chemotherapy▁regimen": 29348, + "▁physical▁activity": 29349, + "pontaneously▁": 29350, + "▁relief": 29351, + "▁count,▁RBC▁count,▁hemoglobin": 29352, + "▁these▁data▁into▁the▁": 29353, + "\n\nSection:▁Appendix▁K:▁Informed▁Consent": 29354, + "FACT-L/Ntx": 29355, + "DITIONS": 29356, + "TRIO▁Safety▁Officer": 29357, + "born▁bab": 29358, + "▁family,▁": 29359, + "▁are▁being▁asked▁to": 29360, + "▁may▁experience▁include▁": 29361, + "▁CT▁or▁MRI▁scan▁of▁your": 29362, + "▁correlate▁with": 29363, + "▁Plus▁D": 29364, + "Fracture": 29365, + "First-line▁": 29366, + "eira": 29367, + "uperiority▁of": 29368, + "▁irrit": 29369, + "inspected▁visually▁for": 29370, + "s▁.....................................................................................▁": 29371, + "▁suspension": 29372, + "▁single▁dose▁": 29373, + "charge▁s": 29374, + "integrity▁of": 29375, + "\n\nRationale▁for▁Chang": 29376, + "▁Panitumumab▁Clinical▁Efficacy▁": 29377, + ".▁Moreover": 29378, + "hazard▁ratio▁for▁placebo▁relative▁to": 29379, + "Hypothesis": 29380, + "field▁MR": 29381, + "accountability▁of▁all": 29382, + "▁Platelet▁count": 29383, + "study\n\ndrug": 29384, + "▁will▁sign▁the▁final": 29385, + "consecutive▁12-lead▁ECG": 29386, + "▁overdose▁with": 29387, + "▁SD▁PD▁Any▁": 29388, + "▁legally▁acceptable▁representative)": 29389, + "unequivocally▁": 29390, + "ies▁must▁be▁made▁available▁for": 29391, + "▁G4PFS▁and▁PFS": 29392, + "▁discontinues▁dos": 29393, + "risk▁factors▁for": 29394, + "systemic▁steroid": 29395, + "▁Schedule▁4/2▁(": 29396, + "/GOG-Ntx": 29397, + "home▁and▁": 29398, + "▁and▁documents▁to▁determine▁whether": 29399, + "acetamol": 29400, + "conventional": 29401, + "\n\nRefer▁to▁the▁": 29402, + "every▁3▁months▁±": 29403, + "▁accuracy": 29404, + "▁the▁day▁after▁the▁patient▁and▁the▁investigator▁agree▁to": 29405, + "▁a▁drug▁or▁drug▁delivery▁system": 29406, + ",▁2017": 29407, + "▁single-use▁vial": 29408, + "▁ALL": 29409, + "oscopy": 29410, + "\n\nSerious▁Adverse▁Event▁Reporting": 29411, + "white▁blood▁cell▁count": 29412, + "▁respiratory▁tract▁infection": 29413, + "dermatitis": 29414, + "s\n\n9.1.1": 29415, + "\n\nAdminister▁panitumumab▁@": 29416, + "▁administered▁to▁the▁subject": 29417, + "_____________": 29418, + "awa▁Y": 29419, + "made▁available▁to▁member": 29420, + "colony-stimulating▁factor▁(G": 29421, + "ranch": 29422, + "unique▁to▁the▁individual": 29423, + "▁fulfill": 29424, + "ovarian▁cancer": 29425, + "▁cycle,▁hold▁and▁check": 29426, + "▁change▁from▁baseline▁in▁lumbar▁spine▁BMD": 29427, + "▁disease,▁ascites,▁pleur": 29428, + "quality▁control": 29429, + "closely▁monitor": 29430, + "ed▁to▁the▁extent▁of▁the▁": 29431, + "▁persons▁authorized▁to": 29432, + "ayo▁Clinic▁Rochester": 29433, + "is▁an▁open-label,▁randomized,▁multicenter": 29434, + "Month▁24": 29435, + "petitive▁": 29436, + "▁CHF": 29437, + "▁Pregnancy▁Test": 29438, + "▁PET▁scans▁or▁s": 29439, + "investigator▁should▁maintain▁a▁list▁of": 29440, + "ERCOR": 29441, + "▁active▁treatment▁than▁on▁placebo": 29442, + "jeopardize▁the▁subject": 29443, + "LASA": 29444, + "▁(not▁necessarily": 29445, + "\n\nAST▁(SGOT": 29446, + "JMHO.1": 29447, + "▁Page▁1▁of▁1": 29448, + "\n\nInternational▁Conference▁on▁Harmon": 29449, + "▁its▁representatives": 29450, + "refractory": 29451, + "refractory▁to": 29452, + "reliable▁data": 29453, + "▁Kaplan-Meier▁methods▁and▁": 29454, + "▁<>▁Version▁Date:▁<>": 29455, + "http://www.": 29456, + "surgically▁steril": 29457, + "entanyl": 29458, + "anders▁J,▁Kaplan": 29459, + "ipsilateral▁": 29460, + "curriculum▁vita": 29461, + "e▁daily▁(": 29462, + "iometrik": 29463, + ",▁Murray▁": 29464, + ".▁Journal▁of▁the▁National▁Cancer▁Institut": 29465, + "▁and▁scientific▁judgment": 29466, + "comparative▁analysis▁of": 29467, + "rochure▁for": 29468, + "▁rate▁(GFR": 29469, + "paid▁for": 29470, + "▁controlled▁room▁temperature▁": 29471, + "Wild-type▁and▁Mutant▁KRAS": 29472, + "▁assess▁the▁effects▁of▁ZD4054▁in▁combination▁with▁docetaxel▁on": 29473, + "icensee": 29474, + ".▁or▁sponsor-nominated▁CRO": 29475, + "ed▁and/or▁compensated▁for": 29476, + "▁topical": 29477, + "▁(WBC▁count,▁RBC▁count,▁hemoglobin": 29478, + "antitumor▁activity▁of": 29479, + "▁alkaline▁phosphatase▁": 29480, + "ALITY▁ASSURA": 29481, + "▁(AMG▁162▁or▁placebo": 29482, + "▁he/she▁": 29483, + "bronchospasm": 29484, + ",▁standard▁deviation,▁": 29485, + "eside▁the▁error": 29486, + "▁to▁another▁location,▁": 29487, + "▁officer": 29488, + "ouillard▁": 29489, + "agic▁event": 29490, + "▁lot▁number": 29491, + "ecreted▁": 29492, + "▁on▁Days▁1▁and▁8": 29493, + "▁Lead▁Period": 29494, + ")\n\n21-Jul-2008▁Version▁number:▁1▁(electronic▁2.0": 29495, + "▁the▁deterior": 29496, + "▁may▁require▁intervention": 29497, + "sertion▁of▁the▁correction": 29498, + ",▁Safety▁Evaluation": 29499, + ",▁Patel": 29500, + "▁minutes▁on▁Day▁1▁of▁each▁cycl": 29501, + "General▁(FACT-G": 29502, + "contraceptive▁precaution": 29503, + "▁the▁baseline▁sum▁longest▁diameter": 29504, + "85%▁power": 29505, + "Epidermal▁Growth▁Factor▁Receptor": 29506, + "vincrist": 29507, + "ed▁appropriate▁by▁the▁investigator": 29508, + "▁Steering▁Committee": 29509, + "whose▁tumor": 29510, + "▁from▁the▁treatment▁portion▁of▁the▁trial": 29511, + "OLFOX-4": 29512, + "EGFR-pathway": 29513, + ",▁all▁subjects▁currently▁undergoing": 29514, + "▁a▁legally▁acceptable▁representative)": 29515, + "Safety▁Follow-Up▁visit": 29516, + "▁minutes▁prior▁to▁paclitaxel": 29517, + "▁Non-metastatic▁Prostate▁Cancer": 29518, + "30-day▁postdiscontinuation▁follow-up▁visit▁occurs▁at▁or▁near▁the▁end▁of▁the▁": 29519, + "differences▁in": 29520, + "cagliotti▁GV": 29521, + ",▁Bonomi▁P": 29522, + "▁Supportive▁Care▁": 29523, + "willing▁or▁unable▁to▁comply▁with": 29524, + "Kaplan▁and▁Meier": 29525, + "Toxicology▁and▁Pharmacokinetic": 29526, + "Women’s▁": 29527, + "▁particulate▁matter▁and▁dis": 29528, + "resistance▁to": 29529, + "verifying,▁and▁reproducing▁any▁records▁and▁report": 29530, + "end-of-study": 29531, + "s\n\n3\n\nCapable▁of▁only▁limited▁s": 29532, + ".▁Initial▁serious▁adverse▁event▁information": 29533, + "aresthesias/d": 29534, + "results▁will▁not▁be▁plac": 29535, + "▁response▁or▁stable▁disease▁": 29536, + "modality▁should▁be▁": 29537, + "▁disposal": 29538, + "▁administered▁a▁pharmaceutical▁product": 29539, + "▁a▁member▁of▁the▁study▁staff": 29540, + "▁ABI-007▁and▁TAXOL": 29541, + "g/m2)▁100": 29542, + "\n\nPharmacogenetic": 29543, + "▁chemistry▁and▁hematology▁": 29544, + "▁2▁years▁after▁the▁last▁dose▁of▁blinded▁IP": 29545, + "begins▁on▁the▁day▁after▁the▁patient▁and▁the▁investigator▁agree▁to": 29546, + "statistical▁analysis▁of▁the▁study▁is▁to": 29547, + "-related▁activities▁and▁documents▁to▁determine▁whether": 29548, + "disclosed▁to▁anyone▁": 29549, + "organ▁function▁as▁defin": 29550, + "AEs▁leading▁to▁discontinuation▁of▁the▁": 29551, + "able▁to▁Evaluate▁(UE):": 29552, + "-associated": 29553, + "▁room▁temperature": 29554, + "on▁first▁demonstrating▁a▁significant": 29555, + "▁(week▁5": 29556, + "ency▁or▁drug▁abus": 29557, + "ritish▁Journal▁of▁Cancer": 29558, + "may▁patent▁or▁sell": 29559, + "▁days.▁The▁30-day▁postdiscontinuation▁follow-up▁visit▁occurs▁at▁or▁near▁the▁end▁of▁the▁": 29560, + ",▁magnesium,▁creatinine,▁albumin,▁total▁protein,▁total▁bilirubin,▁alkaline▁phosphatas": 29561, + "▁participants▁in▁this▁research▁will▁compensate▁you▁if▁this▁happens": 29562, + "▁identified▁and▁reported▁lesion▁at▁baseline▁and▁": 29563, + "▁Oxaliplatin/▁5-fluorouracil/▁leucovorin": 29564, + "one▁scintigraphy▁is▁not": 29565, + "▁taking▁as▁reference▁the▁nadir▁SLD": 29566, + "▁demonstrate▁a▁statistically▁significant▁effect▁in": 29567, + "\n\n(continued)\n\nH3E-MC-JMIG(f)▁Clinical▁Protocol": 29568, + "ERIOUS▁ADVERSE▁EVENT": 29569, + "▁and▁lasts▁approximately▁30▁days.▁The▁30-day▁postdiscontinuation▁follow-up▁visit▁occurs▁at▁or▁near▁the▁end▁of▁the▁": 29570, + "▁survival▁probability▁": 29571, + "IGNATURES": 29572, + "at▁weeks▁8,▁12": 29573, + "▁and▁enter▁these▁data▁into▁the▁": 29574, + "chiectom": 29575, + "▁promising": 29576, + "s▁(temperature,▁blood▁pressure,▁": 29577, + "▁Intern▁Med▁": 29578, + "▁your▁treatment▁course": 29579, + "care▁but▁unable▁to▁carry▁out▁any▁work▁activities.▁Up▁and▁about▁more▁than▁50%▁of▁waking▁hour": 29580, + "maintenanc": 29581, + "document▁contains▁confidential▁information▁of": 29582, + "▁Cancer▁J▁Clin": 29583, + "▁IV▁antibiotic▁or▁IV▁antifungal": 29584, + "ephrotic▁syndrom": 29585, + ".▁You▁will▁also▁be▁ask": 29586, + "lymphangitis▁cutis/pulmonis": 29587, + ")▁and▁their▁suitability▁for▁accurate▁": 29588, + "s▁during▁the▁study▁treatment▁period▁or▁during▁the▁": 29589, + "▁prostate-specific▁antigen▁(PSA)": 29590, + "▁will▁be▁the▁primary▁population": 29591, + "-Reported▁Outcomes▁(PROs)": 29592, + ".▁Eligible▁subject": 29593, + "identified▁as▁non-target▁lesions▁and▁": 29594, + "▁measurable▁lesions▁up▁to▁a▁maximum▁of▁5▁lesions▁per▁organ▁and▁10▁lesions▁in": 29595, + "EDTA▁blood▁[plasma▁and▁cell▁pellet],▁PAXgene▁blood▁[RNA": 29596, + "eropol▁N": 29597, + "UBLIC": 29598, + "x2▁factorial": 29599, + "inephrin": 29600, + "ing▁it▁crit": 29601, + "▁business▁day": 29602, + "▁rejecting▁the▁": 29603, + "▁lieu": 29604, + "▁the▁sum▁of▁": 29605, + "s,▁ECG▁and▁physical▁examination": 29606, + "▁acetaminophen": 29607, + ".\n\nPharmacokinetic": 29608, + "▁must▁be▁reported▁in▁accordance▁with▁the▁": 29609, + "▁years▁after▁the▁main▁study▁is▁": 29610, + "mitted▁to▁Biomedical▁Journal": 29611, + "normalized▁ratio": 29612, + "andomised,▁Double-blind": 29613, + "rofolate▁reduct": 29614, + "vestigational▁New▁Drug": 29615, + "implications▁for": 29616, + "▁requiring▁systemic": 29617, + "Investigational▁Product▁Accountability▁Record": 29618, + "30-day▁postdiscontinuation▁follow-up▁period▁begins▁on▁the▁day▁after▁the▁patient▁and▁the▁investigator▁agree▁to": 29619, + "▁all▁randomized▁subjects▁have▁completed▁their": 29620, + "▁expected▁to▁benefit▁you▁directly▁or▁to▁alter": 29621, + "▁Study▁to▁Compare▁the▁Efficacy▁of▁Panitumumab▁in▁Combination▁with": 29622, + "Sublingual▁Intramuscular▁Intravenous▁Oral▁Rectal▁Subcutaneous▁": 29623, + "▁was▁unable▁to▁be▁evaluated▁leading▁to▁an▁inability▁to▁determine▁the▁status▁of▁that▁particular▁tumor▁for": 29624, + "▁Electronic▁Data▁Record": 29625, + "cGill-Melzack": 29626, + "kalemia": 29627, + "▁of▁Health▁and▁Human▁Servic": 29628, + "e▁see▁the▁current▁version▁of▁the▁": 29629, + ".▁STATISTICAL▁CONSIDERATIONS": 29630, + "▁death,▁whichever▁occurs▁first": 29631, + "e.▁When▁the▁evaluation▁of": 29632, + "▁my▁medical▁information▁if▁I": 29633, + "re-started▁at▁the▁": 29634, + "CHEDULE": 29635, + ",▁Verwe": 29636, + "DNA▁methyltransfer": 29637, + "▁modified▁version▁of▁the▁RECIST▁criteria": 29638, + "irradiated▁area": 29639, + "▁(KM)▁time▁to▁event": 29640, + "Return▁of▁Investigational▁Product▁for▁Destruction▁Form": 29641, + "aborative▁Group": 29642, + "▁the▁duration▁of▁the▁study.▁Copies▁of▁the▁investigator’s▁report": 29643, + "mg/m2▁IV▁over▁2▁hr": 29644, + "▁3▁x▁ULN▁(if▁liver▁metastases▁≤▁5▁x▁ULN": 29645, + "Comprehensive▁Cancer▁Network": 29646, + "preservative▁free▁liquid▁in": 29647, + "discoveries,▁or▁derivative▁material": 29648, + "▁Staging▁Manual,▁Seventh▁Edition": 29649, + "Handbook▁for▁Investigator": 29650, + "abbinavar▁F": 29651, + "neo-)adjuvant▁(radi": 29652, + "have▁been▁answered▁to▁your▁satisfaction.\n\nIn▁signing▁this▁document": 29653, + "▁“on-study”▁death": 29654, + "cenario": 29655, + "iPLEX▁G": 29656, + "icosapent": 29657, + "allpoint▁pen": 29658, + "Inflammatory▁Drug": 29659, + "▁will▁be▁manufactured▁and▁packag": 29660, + "▁x▁ic▁": 29661, + ",▁Somerfield▁MR": 29662, + ",▁Griffin": 29663, + "labeled▁per▁site▁": 29664, + "▁AND▁QUALITY▁ASSURA": 29665, + "s.▁Amgen▁and▁other▁researcher": 29666, + "▁of▁10▁mM▁Sodium▁Acet": 29667, + "made▁only▁with▁the▁prior": 29668, + "▁named▁representatives▁to▁have▁access▁to": 29669, + "consent▁form▁should▁be▁provided▁to▁the▁subject▁or": 29670, + "perty▁of▁the▁sanofi-aventis▁group▁-▁strictly▁confidential▁WW-CLIN-PR007-SD-03▁VERSION▁n°02▁(19-DEC-2005)\n\n21-Jul-2008▁Version▁number:▁1▁(electronic▁2.0": 29671, + "▁Manuscripts▁Sub": 29672, + "▁is▁inadvertently▁": 29673, + "refer▁to▁the▁current▁Panitumumab▁Investigator’s▁Brochure▁for▁further▁detail": 29674, + "▁will▁have▁access▁to▁my▁medical▁information▁if▁I": 29675, + "▁study-related▁records▁without": 29676, + "▁interval▁is▁prolonged▁(": 29677, + "regulatory▁agency▁inspector": 29678, + "regulatory▁agency(s),▁and▁the▁": 29679, + "▁the▁benefit:risk▁profile▁is▁not▁positiv": 29680, + "▁First▁Street▁SW": 29681, + "epatitis▁C▁virus": 29682, + "ance▁in▁Investigational▁Product▁Administration": 29683, + "ed▁while▁on▁or▁after▁prior": 29684, + "▁make▁entries▁and/or▁correction": 29685, + "he/she▁must▁notify▁": 29686, + "unn▁PA▁Jr": 29687, + "▁intellectual▁content": 29688, + "▁must▁submit▁and,▁where▁": 29689, + "residual▁lesion▁be▁investig": 29690, + ".▁These▁signatures▁will▁indicate▁that": 29691, + "▁ever▁comes▁first.▁If▁the▁benefit:risk▁profile▁is▁not▁positiv": 29692, + "ensive▁treatment▁in▁an▁emergency▁room▁or▁at▁home▁for": 29693, + "▁party▁or▁move▁them▁to▁another▁location,▁": 29694, + "read▁the▁attached▁protocol▁entitl": 29695, + "6▁planned▁cycl": 29696, + "HuEPO": 29697, + "kilograms)": 29698, + "al▁Anti-Inflammatory▁Drug": 29699, + "uration▁for▁Participant": 29700, + "▁COLLECTION": 29701, + "acquisition▁of▁informed▁consent": 29702, + "▁or▁ECHO": 29703, + "uties.▁All▁persons▁authorized▁to": 29704, + "ize▁discoveries▁or▁in": 29705, + "▁nor▁other▁participants▁in▁this▁research▁will▁compensate▁you▁if▁this▁happens": 29706, + "▁and▁as▁needed▁thereafter": 29707, + "▁TISSUE": 29708, + "▁RISKS▁AND▁DISCOMFOR": 29709, + "event-free▁rates▁at": 29710, + "clude▁the▁selection▁of": 29711, + "ing▁the▁article▁or▁revis": 29712, + "▁at▁start▁of▁cycle,▁hold▁and▁check": 29713, + "▁study▁initiation▁and▁as▁needed▁thereafter": 29714, + "s▁and▁p-values": 29715, + "s▁and▁investigative▁staff": 29716, + "ly▁as▁possible▁up▁to": 29717, + "reported▁according▁to▁the▁protocol": 29718, + "strontium": 29719, + "▁91320": 29720, + "ightCycler": 29721, + "▁Study▁Code:▁D8480C00013▁Version▁No:": 29722, + "▁im▁=▁intramuscular": 29723, + ",▁a▁commercial▁pharmaceutical▁product▁may▁be▁develop": 29724, + "es▁will▁be▁assigned▁for▁each": 29725, + "ebridement": 29726, + "▁drug▁dependency▁or▁drug▁abus": 29727, + "▁until▁subjects▁have▁access▁to▁commercially▁available▁product▁or▁for▁up▁to▁2▁years,▁which": 29728, + "obtain▁the▁consent▁of▁the▁subject": 29729, + "ventions▁that▁result▁from▁this▁research.▁Neither▁Amgen▁nor▁other▁participants▁in▁this▁research▁will▁compensate▁you▁if▁this▁happens": 29730, + "pensation▁for▁Injur": 29731, + "Treatment▁Cycle-": 29732, + "ECOG▁4599": 29733, + "▁advanced▁esophago-gastric▁cancer": 29734, + "▁PD▁=▁progressive▁disease;": 29735, + ",▁Tulsky▁DS": 29736, + "echnetium▁99": 29737, + "Amgen▁Center▁Drive▁": 29738, + "products▁developed▁from▁the▁sampl": 29739, + "condition▁of▁the▁drug▁and▁enter▁these▁data▁into▁the▁": 29740, + ",▁Einhorn": 29741, + "▁my▁records▁be▁maintained": 29742, + "s,▁or▁research▁companies▁may▁patent▁or▁sell": 29743, + "included▁in▁the▁shipment▁of▁used▁and▁": 29744, + "▁of▁panitumumab▁plus▁FOLFIRI▁on": 29745, + "▁as▁described▁in▁Appendix▁1": 29746, + "▁unblinding▁information.▁This▁": 29747, + "▁particular▁clinical▁importance,▁other▁than▁SAEs▁and▁those▁": 29748, + "▁Dose▁Modification▁Algorithm▁for": 29749, + "\n\nAny\n\nYes\n\nPD": 29750, + "▁the▁development▁of▁commercial▁pharmaceutical▁products.▁Amgen▁and▁other▁researcher": 29751, + "ed,▁and▁accurately▁reported▁according▁to▁the▁protocol": 29752, + "’s▁institution,▁who▁will▁check": 29753, + "▁weekly▁then▁treat▁based▁on▁interval": 29754, + ",▁other▁researchers,▁or▁research▁companies▁may▁patent▁or▁sell": 29755, + "▁ruler▁or▁cali": 29756, + "▁paper▁forms▁will▁be▁made▁by": 29757, + ".\n\nHow▁will▁the▁confidentiality▁of▁my▁records▁be▁maintained": 29758, + "▁RS,▁Rubinstein▁L": 29759, + "accountability▁of▁all▁us": 29760, + "ies▁must▁be▁made▁available▁for▁inspection": 29761, + "▁PET▁scans▁or▁skeletal▁surveys": 29762, + "anders▁J,▁Kaplan▁RS,▁Rubinstein▁L": 29763, + "sertion▁of▁the▁correction▁above▁or": 29764, + "aresthesias/dysesthesias": 29765, + "document▁contains▁confidential▁information▁of▁Amgen▁Inc": 29766, + "ing▁it▁critically▁for": 29767, + "▁expected▁to▁benefit▁you▁directly▁or▁to▁alter▁your▁treatment▁course": 29768, + "▁will▁be▁manufactured▁and▁packaged▁by▁Amgen▁Inc": 29769, + "▁AND▁QUALITY▁ASSURANCE": 29770, + "▁of▁10▁mM▁Sodium▁Acetate,▁5%": 29771, + "▁Manuscripts▁Submitted▁to▁Biomedical▁Journal": 29772, + "ize▁discoveries▁or▁inventions▁that▁result▁from▁this▁research.▁Neither▁Amgen▁nor▁other▁participants▁in▁this▁research▁will▁compensate▁you▁if▁this▁happens": 29773, + "ing▁the▁article▁or▁revising▁it▁critically▁for": 29774, + "▁at▁start▁of▁cycle,▁hold▁and▁check▁weekly▁then▁treat▁based▁on▁interval": 29775, + "▁Study▁Code:▁D8480C00013▁Version▁No:▁<>▁Version▁Date:▁<>": 29776, + "▁particular▁clinical▁importance,▁other▁than▁SAEs▁and▁those▁AEs▁leading▁to▁discontinuation▁of▁the▁": 29777, + "▁the▁development▁of▁commercial▁pharmaceutical▁products.▁Amgen▁and▁other▁researchers▁may▁us": 29778, + "\"▁of▁the▁study": 29779, + "\"sponsor": 29780, + "%,▁and▁": 29781, + "'Inf": 29782, + "(25": 29783, + "(to": 29784, + "(14": 29785, + "(13": 29786, + "(i.e.,▁": 29787, + "(essential": 29788, + "(EOS": 29789, + ")▁of▁": 29790, + ")▁M": 29791, + "),▁as▁": 29792, + ").▁No": 29793, + ")\n\nAny▁": 29794, + ")▁is▁an": 29795, + "),▁and▁all": 29796, + ")▁provided▁that": 29797, + ",▁ac": 29798, + ",▁adverse▁event": 29799, + ",16": 29800, + ",▁an▁": 29801, + ",▁the▁prior": 29802, + "-k": 29803, + "-11": 29804, + "-arm": 29805, + "-36": 29806, + "-75": 29807, + "-91": 29808, + "-enhanc": 29809, + ".H": 29810, + ".P": 29811, + ".,▁and▁": 29812, + "/D": 29813, + "/s": 29814, + "/d▁": 29815, + "/fl": 29816, + "/III": 29817, + "/5-FU": 29818, + "/ALT": 29819, + "/SD": 29820, + "/Discomfort": 29821, + "0.01": 29822, + "0.75": 29823, + "1▁tablespoon": 29824, + "1▁oxaliplatin▁dose▁level": 29825, + "215": 29826, + "2-0": 29827, + "21-day▁": 29828, + "3).\n\n": 29829, + "6▁mg/kg": 29830, + "6-methylgu": 29831, + "790": 29832, + "7▁days▁prior▁to": 29833, + "900": 29834, + "9-5": 29835, + ":▁C": 29836, + ":▁2": 29837, + ":17": 29838, + ":\n\nH": 29839, + ":▁intervention": 29840, + ":▁N0147": 29841, + ":▁Result": 29842, + ":▁Proc": 29843, + ";35": 29844, + "?\n\nA": 29845, + "?▁J": 29846, + "?\n\nThis▁": 29847, + "Approv": 29848, + "AVF2107": 29849, + "Bax": 29850, + "Brain": 29851, + "Bilirubin": 29852, + "BNP": 29853, + "Cent": 29854, + "CRA": 29855, + "Cetuximab": 29856, + "Candid": 29857, + "Calcium": 29858, + "DP": 29859, + "Da": 29860, + "Eur": 29861, + "EMENTS": 29862, + "Efficacy▁Analys": 29863, + "From": 29864, + "FFIC": 29865, + "Fah": 29866, + "FDG": 29867, + "GB": 29868, + "G,▁G": 29869, + "HL": 29870, + "H▁test": 29871, + "Hospitalization": 29872, + "Hematology": 29873, + "Hanna": 29874, + "Identification▁Number": 29875, + "LL": 29876, + "Lung": 29877, + "LLN": 29878, + "May▁": 29879, + "Metastas": 29880, + "MAT": 29881, + "NL": 29882, + "OU": 29883, + "Oste": 29884, + "O▁NOT": 29885, + "Open-Label,▁Phase▁3▁Study▁of": 29886, + "Profile▁": 29887, + "Question": 29888, + "Rev": 29889, + "Roch": 29890, + "Squ": 29891, + "Type▁I": 29892, + "ULT": 29893, + "Urea": 29894, + "Vitamin▁B12": 29895, + "WOG": 29896, + "WHS": 29897, + "[1]": 29898, + "]▁+": 29899, + "aj": 29900, + "a▁l": 29901, + "a▁K": 29902, + "a▁subject’s▁": 29903, + "bain": 29904, + "bone": 29905, + "bolus▁": 29906, + "bittl": 29907, + "cat": 29908, + "capp": 29909, + "copy▁": 29910, + "capacity": 29911, + "cise▁": 29912, + "cLe": 29913, + "d-": 29914, + "drogen": 29915, + "destruction": 29916, + "dizziness": 29917, + "eem": 29918, + "eign": 29919, + "e.▁Patients▁": 29920, + "e.▁These▁": 29921, + "ewhat": 29922, + "eoxy": 29923, + "five▁": 29924, + "fixed▁": 29925, + "frozen": 29926, + "fistula": 29927, + "fine▁needle▁aspir": 29928, + "gast": 29929, + "grant": 29930, + "gastroesophageal▁junction": 29931, + "hu": 29932, + "h▁t": 29933, + "hal": 29934, + "hov": 29935, + "hepatic": 29936, + "he▁or▁sh": 29937, + "hives,▁": 29938, + "iaries": 29939, + "iak▁A": 29940, + "iantonio": 29941, + "kine▁": 29942, + "k-1": 29943, + "kdr": 29944, + "m-": 29945, + "mild": 29946, + "mometer": 29947, + "nR": 29948, + "nas": 29949, + "nutrient": 29950, + "o▁per": 29951, + "o▁Y": 29952, + "octor": 29953, + "pine▁": 29954, + "puscular": 29955, + "pulse": 29956, + "p=0.00": 29957, + "rur": 29958, + "rive▁": 29959, + "rinc": 29960, + "siz": 29961, + "s\n\nSubject": 29962, + "source▁document": 29963, + "s..................................................................................": 29964, + "serious,▁": 29965, + "s▁the▁specific": 29966, + "specimens": 29967, + "t)": 29968, + "ves": 29969, + "viven": 29970, + "vital": 29971, + "v3.": 29972, + "writ": 29973, + "yi": 29974, + "yers▁": 29975, + "yellow": 29976, + "za▁n": 29977, + "’▁button": 29978, + "“chronic": 29979, + "“symptomatic▁deterioration": 29980, + "”)": 29981, + "”▁if": 29982, + "▁—": 29983, + "▁ra": 29984, + "▁elect": 29985, + "▁e▁m": 29986, + "▁________": 29987, + "▁eg,▁": 29988, + "▁**": 29989, + "▁optimal": 29990, + "▁role▁in": 29991, + "▁routinely▁": 29992, + "e▁F": 29993, + "e▁d▁": 29994, + "e▁one▁": 29995, + "e▁are▁": 29996, + "e▁model": 29997, + "inus": 29998, + "inhibit": 29999, + "inflamm": 30000, + "in▁our": 30001, + "in-line▁filter": 30002, + "invit": 30003, + "in▁nature": 30004, + "at▁the\n\n": 30005, + "at▁the▁tim": 30006, + "atabas": 30007, + "at▁anytim": 30008, + "atal▁outcom": 30009, + "at▁the▁discretion▁of▁the▁treat": 30010, + "onto": 30011, + "on▁baseline▁": 30012, + "onavir": 30013, + "\n\npo": 30014, + "\n\ndrug": 30015, + "\n\narm": 30016, + "\n\nlevel": 30017, + "\n\nreaction": 30018, + "\n\n________________": 30019, + "\n\noverall▁survival": 30020, + "\n\n___": 30021, + "▁a▁different": 30022, + "▁a▁statistically▁significant": 30023, + "enal": 30024, + "enable▁": 30025, + "eron": 30026, + "ori": 30027, + "ors▁of": 30028, + "or▁through": 30029, + "or▁follow-up": 30030, + "or▁within": 30031, + "or▁preclinical▁data": 30032, + "s▁9": 30033, + "s▁11": 30034, + "s▁is▁not": 30035, + "s▁..........................................................................................": 30036, + "s▁....................................................": 30037, + "s▁deemed▁": 30038, + "s▁gain": 30039, + "s▁vary▁": 30040, + "rell": 30041, + "reas▁": 30042, + "reech": 30043, + "record▁of": 30044, + "reveal": 30045, + "▁threatening": 30046, + "▁thymidylate▁synth": 30047, + "alang": 30048, + "along": 30049, + "stay▁": 30050, + "stable": 30051, + "itre": 30052, + "ite▁for": 30053, + "▁the▁current": 30054, + "▁the▁follow-up": 30055, + "▁the▁randomization": 30056, + "▁the▁original▁": 30057, + "▁the▁blinded▁treatment▁phas": 30058, + "ane▁": 30059, + "an▁D": 30060, + "an▁G": 30061, + "any▁of": 30062, + "analogu": 30063, + "an▁immediate▁hazard": 30064, + "analgesia": 30065, + ",▁study▁": 30066, + ",▁In": 30067, + ",▁40": 30068, + ",▁drug": 30069, + ",▁NC": 30070, + ",▁under": 30071, + ",▁study▁treatment": 30072, + ",▁due▁to": 30073, + ",▁high": 30074, + ",▁wher": 30075, + ",▁what": 30076, + ",▁erlotinib": 30077, + ",▁such▁as": 30078, + ",▁especially▁": 30079, + ",▁glucos": 30080, + ",▁fatigue,▁": 30081, + ",▁representative▁of▁all▁involved▁organ": 30082, + ",▁2▁weeks▁off": 30083, + "ed▁no": 30084, + "ed▁disease▁": 30085, + "▁an▁assessment▁of": 30086, + "▁an▁important": 30087, + "▁animal▁": 30088, + "ico": 30089, + "....................": 30090, + ".▁p": 30091, + ".▁d▁": 30092, + ".▁INTRODUCTION": 30093, + "ed-up": 30094, + "ed.\n\nS": 30095, + "ed,▁as▁": 30096, + "ed.▁Patients▁with": 30097, + "▁page": 30098, + "▁palli": 30099, + "▁push": 30100, + "▁packag": 30101, + "▁cit": 30102, + "▁covariates": 30103, + "ing▁M": 30104, + "ing▁hormone▁": 30105, + "ing▁cause▁of": 30106, + "▁bid": 30107, + "▁bi-": 30108, + "▁bicalutamide▁": 30109, + "▁barrier": 30110, + "▁bolus": 30111, + "▁beside▁the▁error": 30112, + "es.▁If": 30113, + "es\n\nThe▁": 30114, + "ese▁data": 30115, + "es\n\nof": 30116, + "ation▁from": 30117, + "▁to▁placebo": 30118, + "▁to▁compar": 30119, + "▁to▁withdraw": 30120, + "▁to▁Treatment": 30121, + "▁to▁the▁sponsor": 30122, + "▁to▁conduct": 30123, + "▁to▁50": 30124, + "▁to▁take▁": 30125, + "▁to▁reduc": 30126, + "▁to▁determine▁": 30127, + "▁to▁creatinine▁": 30128, + "▁to▁control": 30129, + "▁to▁evaluate▁": 30130, + "▁to▁follow▁up": 30131, + "▁to▁determine▁whether": 30132, + "▁to▁measure▁": 30133, + "▁to▁provide▁a": 30134, + "▁to▁0.9": 30135, + "▁to▁characterize▁the▁objective▁tumor▁respons": 30136, + "▁to▁attest▁that": 30137, + "is-": 30138, + "is▁assum": 30139, + "▁sens": 30140, + "▁slow": 30141, + "▁since▁the▁treatment▁start": 30142, + "▁sera": 30143, + "ases▁of": 30144, + "ased▁upon": 30145, + "▁of▁ABX-EGF": 30146, + "▁of▁protein": 30147, + "▁of▁malignanc": 30148, + "▁of▁chest,▁abdomen": 30149, + "▁dress": 30150, + "▁della": 30151, + "▁diction": 30152, + "▁degrad": 30153, + "th▁subject": 30154, + "they▁": 30155, + "▁much": 30156, + "▁margin": 30157, + "▁mioc": 30158, + "▁and▁2": 30159, + "▁and▁9": 30160, + "▁and▁12": 30161, + "▁and▁report": 30162, + "▁and▁36": 30163, + "▁and▁Appendix": 30164, + "▁and▁maintain": 30165, + "▁and▁zoledronic▁acid▁": 30166, + "▁and▁fatigu": 30167, + "▁and▁ANC": 30168, + "▁and▁KRAS▁mutation": 30169, + "▁and▁colleagu": 30170, + "▁and▁0.22-micron": 30171, + ".\n\nZ": 30172, + ".\n\nf": 30173, + ".\n\nh": 30174, + ".\n\nClinical▁": 30175, + ".\n\nWithdrawal▁of": 30176, + "illip": 30177, + "al▁infection": 30178, + "al▁Therapy": 30179, + "el▁L": 30180, + "olar": 30181, + "olac": 30182, + "abnormal▁": 30183, + "absolute▁": 30184, + "is▁with": 30185, + "is▁performed": 30186, + "is▁restricted▁to": 30187, + "ive▁t": 30188, + "ive▁to": 30189, + "ive-": 30190, + "ivari": 30191, + "ivotal": 30192, + "▁in▁W": 30193, + "▁in▁clinical▁trial": 30194, + "▁in▁any▁other": 30195, + "▁in▁patients▁receiving": 30196, + "▁inventor": 30197, + "▁insurance▁": 30198, + "imeter": 30199, + "imbalanc": 30200, + "imonthly▁": 30201, + "evolv": 30202, + "ress▁s": 30203, + "igin": 30204, + "igrad": 30205, + "009": 30206, + "idence▁": 30207, + "ocabul": 30208, + "ocally▁Ad": 30209, + "▁1,": 30210, + "▁112": 30211, + "▁1-year": 30212, + "▁C).\n\n": 30213, + "▁Cardi": 30214, + "▁Cediranib": 30215, + "▁Calcium": 30216, + "▁CLINICAL": 30217, + "oss▁of": 30218, + "es▁C": 30219, + "es▁during": 30220, + "▁Pleas": 30221, + "▁Prednisone▁": 30222, + "▁Post-Study▁": 30223, + "proc": 30224, + "prop": 30225, + "iluent": 30226, + "▁(“": 30227, + "▁(200": 30228, + "▁(16": 30229, + "▁(plac": 30230, + "▁(US": 30231, + "▁(3)": 30232, + "▁(CTCAE": 30233, + "▁(test": 30234, + "▁(Grade▁3": 30235, + "▁(FOLFIRI": 30236, + "▁(include▁": 30237, + "▁(femal": 30238, + "▁(limited▁to": 30239, + "▁(ie,": 30240, + "emic": 30241, + "emur": 30242, + "emal▁A": 30243, + "▁2.2.2": 30244, + "▁2▁x▁ULN": 30245, + "▁250▁mg/m2": 30246, + "used▁or": 30247, + "ulman": 30248, + "convert": 30249, + "construct": 30250, + "connect": 30251, + "ance▁that": 30252, + "ifer": 30253, + "if▁not": 30254, + "▁SL": 30255, + "▁Sop": 30256, + "▁Specific": 30257, + "▁SOC": 30258, + "▁See▁Section": 30259, + "▁IP": 30260, + "▁IgG": 30261, + "▁retest": 30262, + "▁reappear": 30263, + "otor": 30264, + "otny▁": 30265, + "uncontrolled▁": 30266, + "unadjusted▁HR": 30267, + "unborn▁bab": 30268, + "▁D,▁B": 30269, + "▁hold▁": 30270, + "▁lev": 30271, + "▁liqu": 30272, + "▁length": 30273, + "e▁of▁the▁s": 30274, + "e▁of▁principal▁investigator": 30275, + "▁Eth": 30276, + "▁Elig": 30277, + "▁Effusion": 30278, + "▁file▁": 30279, + "▁fresh": 30280, + "very▁s": 30281, + "cher": 30282, + "chill": 30283, + "▁or▁G": 30284, + "▁or▁may▁": 30285, + "▁or▁consent": 30286, + "▁or▁commercial": 30287, + "▁or▁NO": 30288, + "▁or▁matching▁placebo": 30289, + "e▁tell": 30290, + "e▁tempor": 30291, + "irradiation": 30292, + "utero": 30293, + "utaneous▁": 30294, + "ysphagia": 30295, + "formyltransfer": 30296, + "\n\nPeri": 30297, + "\n\nPregnancy▁": 30298, + "\n\nPemetrexed▁H3E-MC-JMHR": 30299, + "ized,▁": 30300, + "ized▁c": 30301, + "ized▁tomograph": 30302, + "exhibit": 30303, + "excipient": 30304, + "express▁": 30305, + "quiv": 30306, + "ecitumumab": 30307, + "▁nutritional▁": 30308, + "▁narratives▁of": 30309, + "per▁the▁": 30310, + "\n\nAs": 30311, + "\n\nA▁copy▁of": 30312, + "\n\nA▁X▁D": 30313, + "ate▁if": 30314, + "study▁site▁": 30315, + "▁and▁also": 30316, + "▁and▁administration▁of": 30317, + "▁O▁N": 30318, + "▁OME": 30319, + "▁as▁the▁independent": 30320, + "▁proven": 30321, + "▁prophylactic": 30322, + "allic": 30323, + "allel-": 30324, + "▁T4": 30325, + "▁Technetium▁99": 30326, + "upset": 30327, + "▁N1": 30328, + "▁NA": 30329, + "▁N/A": 30330, + "▁NSAID": 30331, + "vestigation▁of": 30332, + "opapular": 30333, + "will▁be▁performed▁at": 30334, + "will▁be▁kept": 30335, + "astiere▁": 30336, + "▁for▁patient": 30337, + "▁for▁subjects▁with": 30338, + "▁for▁specific": 30339, + "▁for▁further▁detail": 30340, + "▁for▁any▁other▁reason": 30341, + "and▁after": 30342, + "and▁then": 30343, + "▁RD": 30344, + "▁Rash": 30345, + "▁Requisition▁Form": 30346, + "e\n\n2": 30347, + "▁treatment▁given": 30348, + "▁treatment▁rest": 30349, + "▁treatment▁regimens": 30350, + "▁treatment-by-": 30351, + "▁treatment▁administered▁for": 30352, + "study,▁a": 30353, + "ed▁toxicity▁": 30354, + "ed▁to▁ensure▁that": 30355, + ".1.\n\nStudy▁": 30356, + "ogastric": 30357, + ".2.7": 30358, + "▁with▁other": 30359, + "▁with▁respect▁to": 30360, + "▁with▁the▁longest▁diameter": 30361, + "ed▁because▁of": 30362, + "minotransfer": 30363, + "s▁of▁tumor": 30364, + "s▁of▁CYP3A4": 30365, + "s▁of▁the▁target▁lesion": 30366, + "s▁of▁the▁dispens": 30367, + "be▁readily": 30368, + "anta": 30369, + "ants▁of": 30370, + "\n\nSet": 30371, + "\n\nSurvival": 30372, + "\n\nSummary▁of": 30373, + "▁that▁persist": 30374, + "▁2005)": 30375, + "▁is▁conduct": 30376, + "▁is▁stopp": 30377, + "▁is▁expos": 30378, + "▁is▁found▁to": 30379, + "▁is▁hypothesiz": 30380, + "▁is▁strongly▁encouraged▁to": 30381, + "▁is▁unique▁to▁the▁individual": 30382, + "▁will▁be▁considered▁": 30383, + "▁will▁be▁allow": 30384, + "▁will▁be▁used": 30385, + "▁will▁be▁mail": 30386, + "▁will▁be▁included▁in▁the▁": 30387, + "▁will▁be▁censored▁on": 30388, + "▁will▁be▁left▁to": 30389, + "e▁sunitinib": 30390, + "e▁sequ": 30391, + "e▁subsequent": 30392, + "erious▁infusion": 30393, + "artin": 30394, + "e▁then": 30395, + "e▁the▁treatment": 30396, + "▁Men": 30397, + "▁Metastas": 30398, + "▁MMR": 30399, + "▁MSS": 30400, + "▁rhin": 30401, + "▁0.4": 30402, + "▁3.3.2": 30403, + "▁32:": 30404, + "▁3.3.3": 30405, + "▁concerning": 30406, + "usthov": 30407, + "e,▁it": 30408, + "e,▁patients▁": 30409, + "e,▁platelet": 30410, + "e,▁i.e.,▁": 30411, + "e,▁incidence,▁": 30412, + "▁oxy": 30413, + "▁o▁x▁ic▁": 30414, + "▁FIG": 30415, + "▁Femal": 30416, + "▁Fleming": 30417, + ".▁A▁recent": 30418, + ".▁A▁second▁": 30419, + ".▁The▁result": 30420, + ".▁The▁analysis▁": 30421, + ".▁The▁DMC": 30422, + ".▁The▁use▁of": 30423, + ".▁The▁monitor": 30424, + ".▁The▁IEC/IRB": 30425, + "▁as▁required": 30426, + "▁gender": 30427, + "▁global▁": 30428, + "not▁consent": 30429, + "not▁experienc": 30430, + "not▁been": 30431, + "not▁meeting": 30432, + "as▁defined▁in▁Section": 30433, + "01)": 30434, + "▁the▁scan": 30435, + "▁the▁software’s▁“audit▁trail”": 30436, + "▁are▁protein": 30437, + "▁are▁described▁in▁Section": 30438, + "▁on▁the▁s": 30439, + "▁on▁active▁treatment▁than▁on▁placebo": 30440, + ",▁and▁Amgen": 30441, + "radycardia": 30442, + "ated▁study▁": 30443, + "ated▁from": 30444, + "ated▁with▁the▁": 30445, + "ition▁of▁the▁": 30446, + "▁Lett": 30447, + "▁Biol": 30448, + "▁Based▁on▁the▁": 30449, + "▁BAP": 30450, + "ificance▁of": 30451, + "▁this▁question": 30452, + "▁this▁confidential▁information": 30453, + "s,▁200": 30454, + "s,▁other▁than": 30455, + "s,▁including▁the▁": 30456, + "s,▁method": 30457, + "s,▁lymphocyt": 30458, + "s,▁laboratory▁and▁": 30459, + "▁yes▁": 30460, + "▁yellow": 30461, + "▁all▁data": 30462, + "▁all▁study▁drug": 30463, + "▁all▁patients▁who": 30464, + "▁all▁samples▁": 30465, + "▁all▁sites▁of▁disease▁": 30466, + "ary▁lesion": 30467, + "12-month": 30468, + "▁analyses▁in": 30469, + "▁struct": 30470, + "\n\nCLINICAL": 30471, + "▁chemon": 30472, + "▁chimeric": 30473, + "▁will▁follow": 30474, + "▁will▁comply▁with": 30475, + "▁will▁employ": 30476, + "▁will▁correct": 30477, + "e▁in▁a": 30478, + "e▁injection": 30479, + "e▁instrument": 30480, + "▁5.2.1": 30481, + "▁5.1.1": 30482, + "▁5.2.2": 30483, + "▁6▁to": 30484, + "▁6.1.3": 30485, + "from▁other": 30486, + "▁HM": 30487, + "▁High": 30488, + "▁Hospitalization": 30489, + "▁subject▁confidentiality▁": 30490, + "▁patients▁for": 30491, + "▁447": 30492, + "▁4.3.2": 30493, + "ewart": 30494, + ")\n\n3": 30495, + ")\n\nT": 30496, + ")\n\nWith": 30497, + ")\n\n(X": 30498, + "▁at▁your": 30499, + "▁at▁the▁investigator’s▁discretion": 30500, + "▁at▁immediate▁risk▁of▁death": 30501, + "aybittl": 30502, + "ample▁Siz": 30503, + "s▁(2": 30504, + "s▁(C": 30505, + "s▁(G": 30506, + "▁acknowledg": 30507, + "▁accompani": 30508, + "▁acne-": 30509, + "eg,▁p": 30510, + "▁study▁document": 30511, + "▁study▁requirement": 30512, + "▁study▁observation": 30513, + "continued": 30514, + "continue▁on": 30515, + "identity▁of▁investigational▁product": 30516, + "loia": 30517, + "s▁in▁addition▁to": 30518, + "s▁in▁women▁with": 30519, + ".55": 30520, + "s.▁(": 30521, + "▁week▁of▁rest": 30522, + "ensure▁": 30523, + "ense▁or": 30524, + "ritonavir": 30525, + "▁any▁clinical": 30526, + "▁any▁remaining": 30527, + "▁any▁component": 30528, + "▁Very▁": 30529, + "▁the▁transfer": 30530, + "▁the▁tablet": 30531, + "ell'Inf": 30532, + "▁white▁": 30533, + "\n\nDocetaxel": 30534, + "ed▁by\n\n": 30535, + "ed▁by▁the\n\n": 30536, + "ed▁by▁treatment▁arm": 30537, + "urvey": 30538, + "▁after▁pemetrex": 30539, + "▁after▁carboplatin": 30540, + "▁after▁discontinuation▁of▁treatment": 30541, + "ed▁for▁consist": 30542, + "ed▁on▁an": 30543, + "198": 30544, + "e▁determin": 30545, + "e▁date▁of": 30546, + "e▁depend": 30547, + "e▁design": 30548, + "e▁description": 30549, + "e▁do▁not": 30550, + "e▁does▁not": 30551, + ".▁Sch": 30552, + ".▁Survival": 30553, + ".▁Single-": 30554, + ".0▁month": 30555, + "obvious▁": 30556, + "▁patients.▁S": 30557, + "s▁will▁be▁collect": 30558, + "s▁will▁be▁administer": 30559, + "s▁will▁be▁conduct": 30560, + "▁have▁caus": 30561, + "▁have▁access": 30562, + "▁Gemcitabin": 30563, + "▁undesirable▁medical▁condition": 30564, + "▁unwilling▁or▁unable▁to▁comply▁with": 30565, + "ardico": 30566, + "▁ejection": 30567, + "▁e-mail": 30568, + "▁J,▁L": 30569, + "ovind": 30570, + "▁timing,▁s": 30571, + "AEs,▁": 30572, + ".▁Poly": 30573, + ".▁Participant": 30574, + ".▁Placebo": 30575, + "\n\nEastern▁Cooperative▁Oncology▁Group": 30576, + "\n\nEstimated▁Study▁Duration": 30577, + "\n\nEfficacy▁and▁pharmacodynamic": 30578, + "),▁will▁be▁": 30579, + "▁antim": 30580, + "▁from▁study▁": 30581, + "s\n\nR": 30582, + "s\n\nT": 30583, + "s\n\n[": 30584, + "s\n\n.▁T▁N▁E▁M▁U▁C▁O▁D": 30585, + "s\n\nNew": 30586, + "s\n\nY▁P▁O▁C": 30587, + "evaluation▁of▁the▁study": 30588, + "▁is▁a▁s": 30589, + "▁is▁appropriate▁": 30590, + "▁not▁indicated": 30591, + "▁tumor▁model": 30592, + "▁may▁withdraw": 30593, + "s▁for▁verification": 30594, + "ements▁should▁": 30595, + "▁7)": 30596, + "▁7.9": 30597, + "▁7▁days▁": 30598, + "supersed": 30599, + "▁months▁from": 30600, + "▁months▁in▁the▁": 30601, + "▁dose,": 30602, + "▁doses▁(": 30603, + "▁doses▁are▁": 30604, + "▁doses,": 30605, + "ction▁to▁be▁": 30606, + "effect▁is▁": 30607, + "CTD": 30608, + ",▁the▁use▁of": 30609, + "e-adjusted▁": 30610, + "▁adverse▁events": 30611, + "▁adverse▁events▁were▁": 30612, + "vidence▁": 30613, + "▁per▁mL": 30614, + "e▁valid": 30615, + "e▁vocabul": 30616, + "strat": 30617, + "▁10.5.1": 30618, + "▁10.5.2": 30619, + "▁10.▁STATISTICAL▁CONSIDERATIONS": 30620, + "ible▁method": 30621, + ".6.4": 30622, + "cans▁were▁not▁performed▁at▁this▁time▁point": 30623, + ".▁Individual": 30624, + ".▁ETHICS": 30625, + ".▁Ethical▁Review": 30626, + "▁assessments▁for": 30627, + "recorded▁from": 30628, + "records▁from": 30629, + "s.\n\nB": 30630, + "s.\n\n11": 30631, + "s.\n\nC▁I▁N▁O▁R▁T▁C▁E▁L▁E": 30632, + "RANCE": 30633, + ",▁and▁their": 30634, + ",▁and▁any▁other": 30635, + ".▁Cell": 30636, + ".▁Calcium": 30637, + ".▁Creatinine▁Clear": 30638, + "117": 30639, + "▁sign▁of": 30640, + "▁signalling": 30641, + "ALP": 30642, + "40▁–▁ag": 30643, + "peripheral▁neuropath": 30644, + "pars": 30645, + "drug?": 30646, + "drug▁administration": 30647, + "drug▁storage▁": 30648, + "drug▁accountability": 30649, + "drugs▁taken▁in▁combination▁with": 30650, + ",▁or▁both": 30651, + ",▁or▁if▁you": 30652, + "CR\n\n": 30653, + "ed▁at▁the▁end▁of": 30654, + "▁in▁the▁event": 30655, + "▁in▁the▁eCRF": 30656, + "ympos": 30657, + "ymmet": 30658, + "radioisotop": 30659, + "e.\n\n11": 30660, + "▁disease▁fre": 30661, + "):▁a": 30662, + "yped▁or": 30663, + "▁9.0": 30664, + "\n\nX\n\nX\n\nX▁X": 30665, + ".,▁K": 30666, + ".,▁W": 30667, + "▁8.5.1": 30668, + "▁8.12": 30669, + "e▁(S": 30670, + "e▁(including": 30671, + "first▁day▁of": 30672, + "▁used▁": 30673, + "▁used▁in▁this▁study": 30674, + "▁used▁in▁combination▁with": 30675, + "▁use▁vocabul": 30676, + "\n\nProduct:▁ABX-EGF▁Protocol▁Number:▁20020408▁Amendment▁4▁Date:▁26▁April▁2005\n\nPage▁": 30677, + "\n\nN1": 30678, + "e▁for▁completion": 30679, + "heit": 30680, + "ranial▁": 30681, + "30▁and▁M": 30682, + "▁data▁record": 30683, + "▁data▁received▁at": 30684, + "▁data)▁provided▁that": 30685, + "every▁other": 30686, + "every▁week": 30687, + "every▁32": 30688, + "every▁21▁days": 30689, + "▁trials▁in": 30690, + "▁trial▁compar": 30691, + "▁trial▁material": 30692, + "▁trial▁comparing": 30693, + ".79": 30694, + "armDx": 30695, + "\n\n2\n\nAmbulatory▁and▁capable▁of▁all▁s": 30696, + "▁should▁be▁withheld▁": 30697, + "▁should▁be▁signed▁and▁personally▁dat": 30698, + "▁should▁be▁prepared▁in": 30699, + "earch▁for": 30700, + "▁others?": 30701, + "nequiv": 30702, + "▁the▁investigator▁will": 30703, + "▁the▁investigator▁wish▁to▁assign▁the▁study▁records▁to": 30704, + "subjects▁will▁be▁": 30705, + "subject▁who": 30706, + "subjects”": 30707, + "▁your▁current": 30708, + "Study▁Plan": 30709, + "indler": 30710, + "NCIC": 30711, + "▁-20°C": 30712, + "▁to▁be▁used▁at": 30713, + "▁preclinical": 30714, + "▁precision": 30715, + "ed▁as▁having": 30716, + "2400": 30717, + "24▁week": 30718, + "24-hour": 30719, + "▁has▁demonstrated": 30720, + "▁Study▁Endpoints": 30721, + "▁Study▁Candid": 30722, + "despit": 30723, + "▁a▁second": 30724, + "▁a▁special": 30725, + "▁a▁solit": 30726, + "\n\nFax": 30727, + "▁cycle.▁": 30728, + "present▁at▁the▁": 30729, + "present▁and▁no": 30730, + "14▁days": 30731, + "\n\nT1": 30732, + "\n\nTarget": 30733, + "e,▁their▁spous": 30734, + "\n\n33": 30735, + "\n\n35": 30736, + "\n\n3.\n\nEXPERIMENTAL▁PLAN": 30737, + "000▁µg": 30738, + "▁implication": 30739, + "▁impartial": 30740, + "protocol▁signature▁p": 30741, + "▁the▁patient’s": 30742, + "ed,▁double-blind": 30743, + "▁The▁primary": 30744, + "▁follow▁a": 30745, + "▁following▁": 30746, + "ification▁of▁the▁": 30747, + ".▁Depending▁on": 30748, + ".▁Duration▁of": 30749, + "▁the▁larg": 30750, + "▁the▁laboratory": 30751, + "▁the▁liver": 30752, + "▁the▁lumbar▁spine▁": 30753, + "▁the▁log-rank▁test": 30754, + "STS/": 30755, + "no▁prior": 30756, + "s▁are▁original": 30757, + "s▁are▁no▁longer": 30758, + "▁dose▁(mg)▁=": 30759, + "▁register": 30760, + "y,▁is▁": 30761, + "y,▁including▁a▁ruler▁to▁estimate▁the▁size▁of▁the▁lesion": 30762, + "complete,▁and▁": 30763, + "completed▁within": 30764, + "priv": 30765, + ".\n\nAc": 30766, + ".\n\nA▁subject": 30767, + "▁obes": 30768, + "▁obviously▁": 30769, + "efficaci": 30770, + "\n\nThe▁first": 30771, + "\n\nThe▁study▁will": 30772, + "▁toxicity▁of": 30773, + "\n\n4.7.1": 30774, + ".▁Fever": 30775, + "ically▁Significant": 30776, + "data▁will▁not▁be▁": 30777, + "data▁collection": 30778, + "e▁bowel": 30779, + "e▁body▁": 30780, + "5-10": 30781, + "requires▁in-": 30782, + "unit▁errors▁(": 30783, + "s▁that▁may▁be▁": 30784, + "23▁2": 30785, + "23.5": 30786, + "23-3": 30787, + "\n\nI▁worry": 30788, + ",▁Sug": 30789, + ",▁Simon": 30790, + ",▁Sien": 30791, + "▁panitumumab▁infusion": 30792, + "defined▁in▁the▁": 30793, + "s▁or▁inspection": 30794, + "s▁or▁retest": 30795, + "ymptoms▁of": 30796, + "care▁of▁the▁patient": 30797, + "es,▁if": 30798, + "es,▁it▁is▁": 30799, + "▁carri": 30800, + "▁carbon": 30801, + "▁was▁10": 30802, + "▁was▁given": 30803, + "▁was▁freely▁": 30804, + "▁Clinical▁Trial▁": 30805, + "in▁the▁CRF": 30806, + "in▁the▁case▁report▁form": 30807, + "▁deaths▁occurring": 30808, + ".\n\nSIGNATURES": 30809, + ")▁×": 30810, + "e▁treatment▁at": 30811, + "5%▁significance▁level": 30812, + "must▁be▁complet": 30813, + "must▁be▁taken": 30814, + "must▁be▁done▁": 30815, + "1990;": 30816, + "dose": 30817, + "dose,▁": 30818, + "patients▁must▁be▁": 30819, + "SCCHN": 30820, + "e▁and▁blood▁": 30821, + "provides▁": 30822, + "provided\n\n": 30823, + "urvival▁in": 30824, + "rought": 30825, + "ed▁and▁be▁readily": 30826, + "▁diastolic": 30827, + "▁An▁independent": 30828, + "▁Androgen": 30829, + "▁the▁study▁will▁be▁": 30830, + "▁the▁study▁will": 30831, + "▁the▁study▁investigator": 30832, + "▁the▁study▁may▁be▁": 30833, + "▁the▁study▁site▁personnel": 30834, + "▁including▁the▁": 30835, + "may▁be▁judged▁to▁be▁due▁to": 30836, + "may▁be▁asked▁to▁sign": 30837, + "▁must▁be▁confirm": 30838, + "▁must▁be▁reported▁to": 30839, + "s:▁": 30840, + "▁infusional▁5-fluorouracil": 30841, + "▁infusion▁set-up": 30842, + "ox▁model": 30843, + "entered": 30844, + "entered▁in": 30845, + ".▁Risk": 30846, + ".▁REG": 30847, + "▁sites▁(": 30848, + "▁site▁facil": 30849, + "▁site▁initi": 30850, + "enrolled▁to": 30851, + "considered▁by▁the▁investigator▁to▁be▁": 30852, + "\n\n0.8": 30853, + "\n\n0\n\nFully▁active,▁able▁to▁carry▁on": 30854, + "▁yearly▁": 30855, + "▁years▁after▁the▁last": 30856, + "▁the▁subject▁signs": 30857, + "▁the▁subject▁does▁not▁wish▁to": 30858, + "Investigator▁must": 30859, + "▁complete\n\n": 30860, + "▁complete▁description": 30861, + "\n\nHuman": 30862, + "▁group▁sequential": 30863, + "▁this▁study▁and▁for": 30864, + "discontinuing▁the▁": 30865, + "▁Commission": 30866, + "▁approximately▁7": 30867, + "▁approximately▁16": 30868, + "▁participate,▁": 30869, + "▁discontinues": 30870, + "ESP": 30871, + "ES▁or▁NO": 30872, + "randomized\n\n": 30873, + "randomized▁to▁the▁": 30874, + "Statistical": 30875, + "Stratification": 30876, + "value▁in": 30877, + "documented▁as▁": 30878, + "ince▁treatment▁start": 30879, + "cribing": 30880, + "▁indwelling": 30881, + "duced▁by▁": 30882, + "ed\n\nfrom": 30883, + "ed\n\nby": 30884, + ".▁Blood": 30885, + "ished▁": 30886, + "response▁rate▁of": 30887, + "▁and/or▁to": 30888, + "▁and/or▁written▁statement": 30889, + ".8.▁Treatment▁Compliance▁": 30890, + "ed▁should▁be▁": 30891, + "\n\nx\n\nPage▁": 30892, + "▁=▁sever": 30893, + "▁=▁No": 30894, + "▁=▁absolute▁neutrophil▁count": 30895, + "\n\n61": 30896, + "\n\n65": 30897, + ".▁Method▁of": 30898, + ".▁Miller": 30899, + "▁provided▁by▁": 30900, + ")▁and▁its▁": 30901, + ")▁and▁progression-free▁survival▁(PFS)▁compared▁to": 30902, + "▁events▁(": 30903, + "▁events:": 30904, + "cessive▁": 30905, + "▁disease▁progression;": 30906, + "▁disease▁progression▁(per": 30907, + "▁should▁be▁taken": 30908, + ",▁safety,▁": 30909, + ",▁severe▁": 30910, + ",▁specify": 30911, + "located▁and▁destroy": 30912, + "▁these▁assessment": 30913, + "s▁beyond": 30914, + ",▁MN▁55": 30915, + ",▁2002": 30916, + "▁shock": 30917, + "electas": 30918, + "▁may▁be▁a": 30919, + "▁may▁be▁found▁in▁the▁": 30920, + ".▁How": 30921, + "▁morbid": 30922, + "s▁will▁include▁a": 30923, + "cinamide▁ribonucle": 30924, + "▁must▁also▁be▁": 30925, + "▁must▁agree▁to": 30926, + "▁locally▁": 30927, + "medication▁for": 30928, + "observed,": 30929, + "▁relev": 30930, + "▁(Al": 30931, + "administered▁s": 30932, + "substantial": 30933, + "▁levels▁and▁": 30934, + "▁metastatic▁disease": 30935, + "▁metastatic▁and/or▁recurrent": 30936, + "▁blood▁count": 30937, + "▁blood▁drawn": 30938, + "▁resulting▁from": 30939, + "ed▁on▁the▁eCRF": 30940, + "ation▁of▁overall": 30941, + ".▁Antic": 30942, + "reviewed": 30943, + "review.▁The▁": 30944, + "review▁of▁all": 30945, + "review,▁subject": 30946, + "review▁of▁study-related▁": 30947, + "\n\nIn▁addition▁to": 30948, + "\n\nIndependent▁Ethics▁Committee/In": 30949, + ",▁bone▁": 30950, + ",▁because▁": 30951, + "es▁for▁Standard▁": 30952, + "▁states:": 30953, + "s,▁anticip": 30954, + "s,▁abstract": 30955, + "s,▁this▁study▁may▁be▁": 30956, + "▁1997": 30957, + "▁1996": 30958, + "▁1995": 30959, + ".▁Nature": 30960, + "extraction": 30961, + "risk▁and▁": 30962, + "e▁measurable▁lesion": 30963, + "\n\nBlood▁samples▁for": 30964, + "\n\nBlinded▁Treatment": 30965, + "\n\nBlinding▁and▁procedures▁for▁unblinding▁the▁study": 30966, + "▁by▁representatives▁from": 30967, + "▁by▁color▁photograph": 30968, + "▁–▁S": 30969, + "es▁(e.g": 30970, + "es▁(leg": 30971, + "able▁to▁continu": 30972, + "▁response,": 30973, + "▁responsibilities▁": 30974, + "ographical▁": 30975, + "▁randomization▁in▁the▁study": 30976, + "▁[11": 30977, + "end▁of▁study▁visit": 30978, + "ully▁": 30979, + "▁baseline▁valu": 30980, + "▁baseline▁weight": 30981, + "▁baseline▁PSA": 30982, + "e▁or▁the▁condition": 30983, + "urther▁management": 30984, + "change▁": 30985, + "change▁must▁be▁": 30986, + "REIM": 30987, + "when▁clinically▁indicated": 30988, + "when▁this▁event": 30989, + "▁ID▁number": 30990, + "CAEPR": 30991, + "were▁not": 30992, + "▁documents▁submitt": 30993, + "ed▁approv": 30994, + "ed▁as▁of▁the▁data": 30995, + "▁12▁months▁(": 30996, + "▁12-lead▁ECG": 30997, + "was▁based▁on": 30998, + "▁the▁treatment▁period": 30999, + "▁the▁treatment▁phase▁of": 31000, + "eporting": 31001, + "▁1700": 31002, + "▁17.0": 31003, + "blinding▁at": 31004, + "▁Clinically▁significant": 31005, + ",▁Harris▁": 31006, + ".0005": 31007, + "▁change▁from": 31008, + "each▁year": 31009, + "\n\n8.7": 31010, + "▁Amgen's▁": 31011, + "▁Amgen▁and▁the▁investigator": 31012, + "diphenhydramin": 31013, + "diaries": 31014, + "dietary▁": 31015, + "▁need▁for": 31016, + "▁neurologic": 31017, + "ed▁or▁reviewed▁the▁data": 31018, + "well▁as▁": 31019, + "▁CR/PR": 31020, + "▁intend": 31021, + "▁intention": 31022, + "\n\nAn▁Investigational▁Product": 31023, + "▁OS▁and/or": 31024, + "▁agents▁that": 31025, + "▁disease.▁": 31026, + "▁disease,▁or": 31027, + "s▁from▁the▁previous▁": 31028, + "▁time▁is▁": 31029, + "have▁been▁conduct": 31030, + "▁approved▁method▁of": 31031, + "▁plus▁irinotecan": 31032, + "▁plus▁cetuximab": 31033, + "▁plus▁Carboplatin▁and▁Bevacizumab▁Followed▁by▁Maintenance▁": 31034, + "▁KD": 31035, + "▁Known": 31036, + "▁Karnofsky▁Scor": 31037, + "▁study▁drug▁or": 31038, + "efficacy▁evaluation": 31039, + "▁YES▁or▁NO": 31040, + ".▁Immun": 31041, + "assessment▁of▁": 31042, + "\n\nApproved\n\nDate▁Printed:▁13−Aug−2013": 31043, + "▁medication▁you▁are▁": 31044, + "s▁should▁be▁follow": 31045, + "▁within▁42": 31046, + "▁Project": 31047, + "▁Procedure▁": 31048, + ".▁Patients▁should▁": 31049, + ".▁Patients▁experiencing": 31050, + "▁newly▁diagnos": 31051, + "justifi": 31052, + "▁this▁study▁with": 31053, + "▁this▁study▁must▁be▁": 31054, + "mediated": 31055, + ",▁Gold": 31056, + ",▁Good▁Clinical▁Practice▁(GCP": 31057, + "s▁only▁": 31058, + "s▁on▁study": 31059, + "visiting▁the▁investigator": 31060, + "versus▁no": 31061, + "▁has▁been\n\n": 31062, + "▁has▁been▁report": 31063, + ",▁et▁al.▁C": 31064, + "designee▁": 31065, + "ioedema": 31066, + "io▁della": 31067, + "▁who\n\n": 31068, + "▁anti-EGFR": 31069, + "▁anti-hypertensive▁": 31070, + "▁allows": 31071, + "▁allow▁the▁": 31072, + "opened▁vial": 31073, + ",▁Desch": 31074, + "determined▁on▁the▁": 31075, + "determined▁by▁the▁": 31076, + "determined▁to▁have▁": 31077, + "▁transformation": 31078, + "▁review▁process": 31079, + "▁review▁will▁be▁performed▁": 31080, + "regnancy▁(": 31081, + "within▁24▁hour": 31082, + "within▁4▁weeks▁of": 31083, + "\n\nY▁P▁O▁C\n\nD▁E▁T▁N▁I▁R▁P": 31084, + "Compensation▁for▁Injur": 31085, + "\n\n53": 31086, + "\n\n5.2.1": 31087, + "countability": 31088, + "470": 31089, + "▁protocol▁devi": 31090, + "\n\nGood▁Clinical▁Practic": 31091, + "▁performing▁any▁": 31092, + "▁at▁least▁28▁days▁after": 31093, + "▁first▁study▁drug▁administration": 31094, + "Univers": 31095, + ",▁Lim": 31096, + ",▁Lilly▁or": 31097, + "\n\nAppendix▁2": 31098, + "\n\nAppendix▁K": 31099, + "ummaris": 31100, + "s,▁and▁will▁be▁": 31101, + "▁the▁first▁infusion": 31102, + "▁the▁first▁analysis": 31103, + "▁the▁first▁on-study▁": 31104, + "analysis▁may": 31105, + ",▁particular": 31106, + "▁cetuximab▁treatment": 31107, + "▁cetuximab▁in▁combination▁with": 31108, + "Cancer▁Treatment▁Group": 31109, + "ifying▁": 31110, + "▁severity▁to": 31111, + "based▁on▁PFS": 31112, + "▁+▁FOLFOX": 31113, + "-3rd": 31114, + "▁associated▁with▁the▁use▁of": 31115, + "viscer": 31116, + "vised▁informed▁consent": 31117, + "visceral": 31118, + "assessed▁using": 31119, + "ence▁in▁situ": 31120, + "▁IV▁over": 31121, + "cause▁": 31122, + "▁toxicity▁or": 31123, + "▁toxicity▁should▁": 31124, + "▁toxicity▁criteria": 31125, + "▁toxicity▁grad": 31126, + "▁toxicity▁(G": 31127, + "ing▁and▁visiting▁the▁investigator": 31128, + "required▁in": 31129, + "required▁study": 31130, + ".▁Over": 31131, + "▁clinical▁or▁preclinical▁data": 31132, + "carboplatin-paclitaxel": 31133, + ")▁will▁be▁summariz": 31134, + "\n\nOutcom": 31135, + "\n\nOste": 31136, + "▁between▁the▁treatment▁arm": 31137, + "after▁the▁last": 31138, + "▁pain▁from": 31139, + "▁pain▁severity": 31140, + "▁pain▁severity▁": 31141, + "▁Adverse▁Events\n\nAll": 31142, + "y▁or▁radiotherapy": 31143, + "▁SAEs▁will▁be▁": 31144, + "▁mm▁Hg": 31145, + "▁bone▁pain": 31146, + "▁withdraws▁from": 31147, + ",▁infusion": 31148, + ",▁inspect": 31149, + ",▁in▁the▁investigator’s▁opinion": 31150, + "at▁least▁a": 31151, + "▁survival▁follow-up": 31152, + "▁agree▁to▁be▁": 31153, + "new▁year": 31154, + "personal▁": 31155, + "\n\nStudy▁Schedule,▁Protocol": 31156, + "▁the▁circumstanc": 31157, + "▁Treatment:": 31158, + "▁the▁end▁of▁the▁trial": 31159, + "▁18.0": 31160, + "ates▁a▁significant": 31161, + "▁and▁sponsor": 31162, + "confirmation▁of": 31163, + "confirming▁that": 31164, + "▁safety▁(": 31165, + "▁safety▁evaluation": 31166, + "▁overall▁5%▁significance▁level": 31167, + "▁phase▁will▁be▁": 31168, + "▁5-year": 31169, + "▁acid▁(": 31170, + "▁significant▁medical▁": 31171, + "referred▁": 31172, + "▁is▁not▁required▁for": 31173, + "blood▁collection": 31174, + "y▁skin": 31175, + "analyses▁for": 31176, + "\n\nProtocol▁amendment": 31177, + "EGFR▁expression": 31178, + "EGFR▁gene▁copy▁number": 31179, + "ensitivity▁of": 31180, + "▁these▁d": 31181, + "ics▁committee": 31182, + "study▁drug▁or": 31183, + "responsible▁for▁the▁": 31184, + ",▁Week": 31185, + ",▁Wanders▁J,▁Kaplan▁RS,▁Rubinstein▁L": 31186, + ",▁which▁is": 31187, + "▁prior▁to▁administration": 31188, + "▁prior▁to▁starting": 31189, + "es▁to▁a": 31190, + ":\n\no": 31191, + ":\n\n…": 31192, + ":\n\nIf": 31193, + ":\n\n▁": 31194, + "▁without▁interruption": 31195, + "\n\n10.5": 31196, + "26)(cid:": 31197, + "Program": 31198, + "SIB": 31199, + "▁the▁following:\n\n\n\n": 31200, + "▁the▁following▁exception": 31201, + "used▁for▁sensitivity▁analyses▁of": 31202, + ",▁if▁applicable▁": 31203, + "▁an▁opportunity▁to": 31204, + "ing▁entries▁": 31205, + ".▁Local▁": 31206, + "▁prior▁written▁agreement": 31207, + "▁or▁enter": 31208, + "▁or▁erythema": 31209, + "bove▁the▁": 31210, + "e▁subjects▁in": 31211, + "▁Grade▁0": 31212, + "▁Grade▁≥2": 31213, + "▁consent▁for": 31214, + "29]": 31215, + "29▁(week▁5": 31216, + "▁they▁develop": 31217, + "summaries▁": 31218, + "post-treatment": 31219, + "y▁(including": 31220, + "▁parenteral": 31221, + "▁paradigm": 31222, + "\n\nthan": 31223, + ",▁Kaplan": 31224, + "monitor▁to▁ensure▁that": 31225, + "bevacizumab▁(": 31226, + "close▁to▁the▁": 31227, + "▁start▁of▁other": 31228, + "▁dates▁of": 31229, + "availability": 31230, + ",▁1994": 31231, + "ised▁representatives▁of": 31232, + "\n\ninfection": 31233, + "▁metastases,▁": 31234, + "ability▁or▁in": 31235, + "cycles▁": 31236, + "cycles▁of": 31237, + "cycle▁(": 31238, + "e.▁The▁investigator": 31239, + "\n\nmg": 31240, + "This▁study▁will▁be▁": 31241, + ",▁docetaxel": 31242, + "being▁studi": 31243, + "laboratory▁for": 31244, + "▁meet▁the▁criteria▁for": 31245, + "▁100▁mg": 31246, + "▁patients▁achiev": 31247, + "hematological▁": 31248, + "▁treated▁with▁no": 31249, + "▁biomarkers▁of": 31250, + "▁total,▁representative▁of▁all▁involved▁organ": 31251, + "RSEMENTS": 31252, + ",▁Fleming▁TR": 31253, + "▁amendment▁3▁–▁dated▁23▁May▁200": 31254, + "elfcare": 31255, + "\n\na)": 31256, + "eyer": 31257, + "ation,▁suitable▁for": 31258, + "▁obtaining": 31259, + "serum▁glutamic": 31260, + "▁with▁the▁Sponsor": 31261, + "▁with▁the▁corresponding": 31262, + "▁with▁the▁exception▁of▁the▁": 31263, + "▁28▁days▁befor": 31264, + "ing,▁verifying,▁and▁reproducing▁any▁records▁and▁report": 31265, + "▁are▁not▁known": 31266, + "▁are▁not▁eligibl": 31267, + "e;\n\nDrug": 31268, + "▁(CNS)": 31269, + "▁Report▁form": 31270, + "agent▁is▁": 31271, + "planned▁interim": 31272, + "▁areas▁": 31273, + "ed▁my▁": 31274, + "ed▁mean": 31275, + "standard▁operating": 31276, + "whether▁the▁": 31277, + "phase▁1": 31278, + "▁≥1": 31279, + "e▁Personal▁": 31280, + "reng": 31281, + "renheit": 31282, + "▁Subject’s▁": 31283, + "▁Subjects\n\nP": 31284, + "▁Subject▁Confidentiality▁": 31285, + "e▁tumor▁lesion": 31286, + ".0▁Approved▁by\n\nApproved": 31287, + "3-7": 31288, + "3-only▁": 31289, + ".\n\n7.4": 31290, + "60▁mg/m2": 31291, + "60-minute▁infusion": 31292, + "▁the▁fac": 31293, + "▁the▁further▁management": 31294, + "appropriate▁care▁of▁the▁patient": 31295, + "▁trial▁is▁": 31296, + "CTCAEv3.": 31297, + "▁considered▁to▁be▁": 31298, + "UNI": 31299, + "sites,▁a": 31300, + "yearly▁": 31301, + "▁tumour▁growth": 31302, + ".▁It▁has": 31303, + "▁skin▁lesion": 31304, + "▁skin-related▁toxicities▁": 31305, + "▁can▁be▁assess": 31306, + ",▁you▁should▁notify▁your▁doctor": 31307, + "therapy▁in": 31308, + "up▁to▁4": 31309, + "efficacy▁analyses": 31310, + "efficacy▁analyses▁will▁be▁": 31311, + "ing▁of▁the▁wor": 31312, + "variables▁(": 31313, + "on▁the▁basis▁of": 31314, + "on▁the▁adverse▁event▁case▁report▁form": 31315, + "▁only▁one▁": 31316, + "▁the▁data▁analysis▁": 31317, + "▁the▁data;▁and": 31318, + "experienced": 31319, + "experiencing▁on": 31320, + "ature▁of▁the▁": 31321, + "ournigand▁": 31322, + "▁Grade▁3/4": 31323, + "87;": 31324, + "range)": 31325, + "s,▁and▁their▁spous": 31326, + "s▁were▁observ": 31327, + "▁but▁is▁": 31328, + "ITT▁principl": 31329, + "\n\nday": 31330, + "▁Safety▁Monitoring": 31331, + ".\n\nBACKGROUND▁AND▁RATIONALE": 31332, + "used▁consistent": 31333, + "ARTIC": 31334, + "ARFT": 31335, + "▁a▁potent": 31336, + "▁a▁p-valu": 31337, + "00▁mg/m2/day▁": 31338, + "okes▁": 31339, + "▁such▁a▁c": 31340, + "▁manag": 31341, + "FOLFOX)▁will": 31342, + "censoring": 31343, + "highlight": 31344, + "Therasse▁et▁al": 31345, + "▁subjects▁who▁are▁": 31346, + "▁subjects▁who▁have▁a": 31347, + ",▁all▁original▁source▁document": 31348, + "▁Response▁(": 31349, + ",▁Ethical▁Review": 31350, + "▁supplemental▁vitamin▁D": 31351, + "maintained▁and▁be▁readily": 31352, + "increase▁of": 31353, + "ing▁into": 31354, + "▁Dose▁Selection": 31355, + ",▁another": 31356, + "decrease▁": 31357, + "staff▁are▁responsible▁for": 31358, + "▁before▁progression": 31359, + "needed▁for▁the▁": 31360, + "▁individual▁box": 31361, + "▁local▁laboratory▁": 31362, + "Medical": 31363, + "es▁that▁may▁be▁": 31364, + "currence,▁": 31365, + "▁differentiation": 31366, + "directed▁in▁the▁Laboratory▁": 31367, + "plus▁bevacizumab": 31368, + "emergency▁s": 31369, + "solubl": 31370, + "▁target▁or▁non-": 31371, + "▁To▁investigate▁potential▁biomarker▁development": 31372, + "▁demonstrated▁in": 31373, + "ockroft": 31374, + "e▁the▁safety": 31375, + "▁any▁other▁systemic▁anti-tumor": 31376, + "listed.\n\n": 31377, + "listed▁below": 31378, + "health▁care▁": 31379, + "health-related▁quality▁of▁lif": 31380, + "▁up▁to▁3": 31381, + "▁known▁response▁to": 31382, + "urinalysis": 31383, + "▁the▁safety▁follow-up": 31384, + "▁chest▁x-ray▁": 31385, + "▁my▁friend": 31386, + "stitutional▁review▁board▁(": 31387, + "ska": 31388, + "\n\nTable▁S130": 31389, + "▁temperatures": 31390, + "▁(PLT▁<": 31391, + "▁reducing": 31392, + "▁reduce▁the▁dose▁by▁1▁level": 31393, + ".▁At▁least": 31394, + "Observation": 31395, + ",▁he▁or▁sh": 31396, + "▁alone▁cannot▁be▁": 31397, + "ate,▁complete,▁and▁": 31398, + "\n\nCompensation": 31399, + "s▁should▁be▁t": 31400, + "▁discontinuation▁from▁the▁study▁": 31401, + "▁more▁about": 31402, + "▁terminology": 31403, + "▁randomised,▁double-blind": 31404, + "period▁and▁for": 31405, + "leader": 31406, + "ed▁according▁to▁RECIST": 31407, + "▁kappa": 31408, + "▁current▁and▁should▁": 31409, + "subjects▁may▁": 31410, + "▁applicable▁regulatory": 31411, + ",000▁men": 31412, + "\n\n(cid:120)▁Subject▁incidence▁of": 31413, + ",▁Os": 31414, + ",▁Obasaju": 31415, + "EPIC": 31416, + "rectom": 31417, + "▁remain▁on": 31418, + "e▁data▁are▁": 31419, + "ECGs▁should▁be▁": 31420, + "work▁at▁hom": 31421, + "written▁approval": 31422, + "written▁approval▁of▁the▁protocol": 31423, + "\n\nIf▁you": 31424, + "▁a▁subject▁is▁": 31425, + "▁thromboplastin": 31426, + "▁Lesions▁": 31427, + "▁Lesions▁that▁can▁be▁accurately▁measured▁in": 31428, + "xicity▁profil": 31429, + ".▁Cont": 31430, + "\n\nE▁R▁O▁F▁E▁B\n\nY▁T▁I▁D▁I▁L▁A▁V\n\nS▁T▁I": 31431, + "▁the▁discretion▁of▁your": 31432, + "ase▁(G": 31433, + "ase▁(ALT": 31434, + "ase▁(LDH": 31435, + "▁assess▁your": 31436, + ".▁Patient▁has": 31437, + "▁control▁for": 31438, + ".▁No▁eras": 31439, + "meaning▁of▁the▁wor": 31440, + "▁ZD4054▁studies": 31441, + "▁in▁patients▁with▁cancer": 31442, + "▁blood▁sample▁(": 31443, + "ACS": 31444, + "ACY": 31445, + "frequency": 31446, + "submitted,▁": 31447, + "▁appear▁to": 31448, + ",▁the▁investigator,▁or": 31449, + ",▁the▁investigator▁is▁responsible▁for": 31450, + "▁February▁2006": 31451, + "▁on▁the▁CRF": 31452, + "▁complete▁6▁cycles▁of": 31453, + "ogenic▁process": 31454, + "ardiovasc": 31455, + "▁based▁on▁clinical▁or▁preclinical▁data": 31456, + "spelling": 31457, + "▁the▁site": 31458, + "▁the▁site▁to": 31459, + "objective▁is▁to": 31460, + "▁among▁wild-type▁KRAS": 31461, + ".▁You▁will▁be▁": 31462, + ".▁You▁may▁": 31463, + "▁AstraZeneca▁or": 31464, + "oodman": 31465, + "s▁are▁taken": 31466, + ".▁Cancer▁Res": 31467, + ".▁Cancer▁Epidemiology,▁Biomarker": 31468, + "\n\nExtension": 31469, + "graded▁using": 31470, + "ertip": 31471, + ".▁The▁investigator▁is▁obligated▁to▁inform": 31472, + "ataset": 31473, + "rights▁to": 31474, + "right▁now": 31475, + "al▁or▁per": 31476, + "al▁or▁life-threatening": 31477, + "▁extremities": 31478, + "heart▁rate": 31479, + "▁participants▁will": 31480, + "sidiaries": 31481, + "was\n\n": 31482, + "maximum▁concentration▁of▁the▁diluted▁solution": 31483, + "▁written▁subject": 31484, + "▁5-FU/leucovorin": 31485, + "▁serious▁adverse▁events,▁": 31486, + "▁laboratory▁test▁result": 31487, + "percent▁change▁from▁baseline▁in▁lumbar▁spine▁BMD": 31488, + "\n\nFor▁the▁": 31489, + "▁require▁that": 31490, + "ottom": 31491, + "▁Dosing": 31492, + "\n\nPatients▁with": 31493, + "ochond": 31494, + "gressive▁disease▁(PD": 31495, + "case▁report▁form▁(CRF": 31496, + "▁Peripheral▁neuropathy": 31497, + "▁Peripheral▁Neuropath": 31498, + "regulations/": 31499, + "regardless▁of▁causality": 31500, + "roke▁": 31501, + "ed▁as▁a▁minimum": 31502, + ".\n\n41": 31503, + ".3.3.3": 31504, + "\n\nConfirm": 31505, + "sponsor▁will": 31506, + "(140▁–▁ag": 31507, + "▁they▁are▁not": 31508, + "before▁randomization": 31509, + "e.▁After": 31510, + "▁definitely▁": 31511, + "▁Tumor▁Assessment": 31512, + "▁is▁responsible▁for▁informing▁the▁": 31513, + "▁Committee▁(": 31514, + "MR▁200048-052▁Master▁Subject▁Information▁Sheet▁and▁Informed▁Consent▁Form▁Version▁4.0▁/▁20▁Nov▁2009": 31515, + "▁enrolled▁": 31516, + "proposed▁informed▁consent▁form": 31517, + "e▁doses▁of": 31518, + "struct▁patient": 31519, + "FOLFIRI)▁will": 31520, + "▁at▁the▁next": 31521, + "corporates▁": 31522, + "paclitaxel▁and▁carboplatin": 31523, + "▁active▁in": 31524, + "unblinding▁any▁": 31525, + "unblinded▁when": 31526, + "unblinded▁interim": 31527, + "▁adverse▁events▁leading▁to": 31528, + "...............................▁": 31529, + "▁is▁the▁\"sponsor": 31530, + "▁days▁of▁the▁last": 31531, + "▁maintaining": 31532, + "▁maintaining▁a▁comprehensive▁": 31533, + "▁predict▁disease▁progression": 31534, + "ource▁documents▁are▁original": 31535, + "Signature": 31536, + "▁applies▁to": 31537, + "United▁Kingdom": 31538, + "files▁contain": 31539, + "immunohistochemistry▁": 31540, + "▁labels▁with▁a": 31541, + "permitted▁to": 31542, + "azdur": 31543, + "▁Prevention": 31544, + ".\n\nTo▁collect": 31545, + "removal▁from": 31546, + "▁had▁previously▁": 31547, + "▁evaluate▁the▁benefit": 31548, + "-Lung": 31549, + "▁files▁containing": 31550, + "efficacy▁of▁the▁": 31551, + "▁site▁staff": 31552, + "▁site▁notification": 31553, + "\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX": 31554, + "repeated▁every▁3▁week": 31555, + "umbar▁vertebra": 31556, + "e▁Measures": 31557, + "e▁Management": 31558, + "TINIB": 31559, + "▁decides▁that": 31560, + "▁deciding▁whether": 31561, + "udit▁plan": 31562, + "ragment": 31563, + ".▁This▁approach": 31564, + "biochemical▁": 31565, + "selected\n\nfor": 31566, + ",▁van": 31567, + ",▁vitamin▁B12": 31568, + "▁daily▁living": 31569, + "compared▁with▁placebo": 31570, + "whereas": 31571, + "-sided▁log-rank▁test": 31572, + "▁resolved▁or": 31573, + "e▁the▁patient▁has▁": 31574, + "▁the▁investigator’s▁clinical▁judgment": 31575, + "▁et▁al,▁2003": 31576, + "▁by▁the▁Sponsor": 31577, + "codone▁": 31578, + "dental▁pro": 31579, + "intervention▁indicated▁": 31580, + "▁size▁to": 31581, + "▁will▁not▁compensate▁you": 31582, + "rigor": 31583, + "ed▁an▁adverse▁event": 31584, + "election▁and▁Timing▁of": 31585, + "early▁as▁": 31586, + "▁the▁presence▁or▁absence▁of": 31587, + "deriving": 31588, + "▁continue▁until": 31589, + "▁continue▁receiving": 31590, + "▁continue▁participation▁in▁the▁study": 31591, + "ater▁for▁Injection": 31592, + "▁less▁than▁or▁equal▁to": 31593, + "ELOX-": 31594, + "idine,▁": 31595, + "ocalca": 31596, + "▁differences▁between": 31597, + "immediately▁notify▁": 31598, + "▁and▁End▁of": 31599, + "processing": 31600, + "checked▁for▁consist": 31601, + "ed▁using▁the▁log-rank▁test": 31602, + ",▁along": 31603, + "insert▁nam": 31604, + "▁use▁of▁at▁least▁25%▁for▁a▁duration▁of▁1▁week▁or▁mor": 31605, + "Dose▁Modification": 31606, + "e.▁In▁the▁": 31607, + "still▁on": 31608, + "▁becomes": 31609, + "▁materials▁": 31610, + "▁material▁must▁be▁submitted▁to▁the▁": 31611, + "confidentiality▁is▁": 31612, + "▁respect▁to▁the▁first": 31613, + "▁parameters▁": 31614, + "▁a▁fever": 31615, + "▁Group▁B": 31616, + "▁primary▁solid▁tumor": 31617, + "▁and▁member": 31618, + "\n\n15.\n\nAPPENDICES": 31619, + "reatinine▁clearance\n\n": 31620, + "kept▁current▁and▁should▁": 31621, + "▁Manager": 31622, + "▁Health▁Status▁": 31623, + "ABI-007/carboplatin": 31624, + "solute▁Neutrophil": 31625, + "Related▁to": 31626, + "e.▁Specific": 31627, + "ton▁D": 31628, + "▁tubercul": 31629, + "ed▁dose)": 31630, + "▁(BMI": 31631, + "▁(BSA)": 31632, + "▁(Background▁": 31633, + "e▁during▁the▁study▁": 31634, + "▁analysis▁will▁occur▁when": 31635, + "evidenced▁by▁": 31636, + "umbar▁spine,▁total▁hip": 31637, + "s.▁If▁results▁of▁the▁trial▁are▁published,▁your▁identity▁will▁remain▁confidential": 31638, + "currently▁with": 31639, + "currently▁no": 31640, + "s▁[CTCAE": 31641, + "▁of▁all▁study-related▁": 31642, + "▁Baseline▁and▁": 31643, + "utility▁bound": 31644, + "▁major▁CVD": 31645, + "▁Cycles": 31646, + "osteoporosis": 31647, + "osteoblast": 31648, + "observed▁during▁the▁study▁": 31649, + "▁3▁weeks▁after": 31650, + "▁volume▁infusion": 31651, + "▁volume,▁platelet": 31652, + "do▁not▁have▁": 31653, + "TTP": 31654, + "▁low▁molecular▁weight": 31655, + "▁feeling": 31656, + "▁improvements▁in": 31657, + ").▁In▁the▁event": 31658, + "THER": 31659, + "▁treated▁patient": 31660, + "PCI": 31661, + "involving": 31662, + "involved▁with": 31663, + "e\n\nCONFIDENTIAL": 31664, + "▁antitumor▁activity▁": 31665, + "▁antitumor▁activity▁of": 31666, + ",6,7": 31667, + "YP2": 31668, + "arily▁withdraw▁from": 31669, + "▁Oncology": 31670, + "▁Oncology,▁": 31671, + "▁temperature▁alarm": 31672, + "in▁a▁timely▁manner": 31673, + "▁future▁medical▁car": 31674, + "▁and▁all▁co/": 31675, + "s.▁Panitumumab": 31676, + ".▁Chest": 31677, + ",▁Ish": 31678, + "▁liver▁metastas": 31679, + "required▁for▁a▁best▁response▁of": 31680, + "failed▁": 31681, + ",▁for▁a": 31682, + "▁Whol": 31683, + "change▁in▁hemoglobin": 31684, + "▁designee▁will": 31685, + "that▁are▁clearly▁": 31686, + "▁(21-day▁cycl": 31687, + "s▁(including,▁if▁applicabl": 31688, + "ed▁for▁all▁randomized▁patients▁": 31689, + "\n\nLY231514\n\nH3E-MC-JMIG(f)▁Clinical▁Protocol\n\nPage▁": 31690, + "e▁trials▁": 31691, + "\n\nCompletion▁of": 31692, + "▁best▁interest": 31693, + "ushing": 31694, + "s.▁J▁Clin▁Oncol": 31695, + "s.▁J▁Nutr": 31696, + "▁Reporting▁Procedures▁for▁All": 31697, + "▁discussion▁(not▁necessarily": 31698, + "ed,▁and▁stor": 31699, + "▁of▁Certain": 31700, + "▁(EuroQol-5▁Dimension": 31701, + "▁IRB▁approval▁of": 31702, + "▁via▁the▁": 31703, + "▁PFS▁events▁have▁occurred": 31704, + "▁worsening▁of▁a▁pre-existing": 31705, + "esophagectomy/": 31706, + "▁a▁25%": 31707, + "errors▁that▁occur": 31708, + "▁those▁subjects▁who": 31709, + "▁potential▁side▁effect": 31710, + "pre-medication": 31711, + "pre-existing": 31712, + "▁antibody▁assay": 31713, + "▁procedure▁for": 31714, + "▁of▁5.2": 31715, + "▁45▁mL/min": 31716, + "▁unblinded▁": 31717, + "▁the▁patient▁is▁lost▁to▁follow-up": 31718, + "▁should\n\nbe▁": 31719, + "elve▁": 31720, + "nual▁IEC/IRB": 31721, + "stantially▁": 31722, + ",▁stabilization": 31723, + "progressing": 31724, + "▁adversely": 31725, + "ated▁for▁2": 31726, + "▁associated▁95%▁confidence▁interval": 31727, + "▁osteopor": 31728, + "▁the▁previous▁dose▁level": 31729, + "reported▁as▁such": 31730, + "▁preserve▁": 31731, + "▁of▁101\n\n090177e18069a3aa\\Approved\\Approved▁On:▁27-Sep-2007▁02:42\n\n1▁4▁:▁5▁0▁7▁0▁0▁2▁-▁g▁u▁A▁-▁1▁3▁\\▁d▁e▁v▁o▁r▁p▁p▁A\n\n\\▁1▁.▁1▁\\\n\n8▁2▁1▁6▁6▁8▁6▁0▁0▁0▁0▁0▁1▁0": 31732, + ",▁this▁information": 31733, + "▁COSTS/": 31734, + "endar▁Days": 31735, + "▁20030194": 31736, + "▁study▁entry▁and▁": 31737, + ".▁Also": 31738, + "▁evaluate▁the▁treatment▁effect": 31739, + "▁the▁final▁analysis▁of": 31740, + "▁recovered▁to": 31741, + "▁doses▁ranging▁from": 31742, + "▁the▁end▁of▁the▁blinded▁treatment▁phas": 31743, + "▁the▁end▁of▁the▁storage▁period": 31744, + "30-day▁postdiscontinuation▁visit": 31745, + "inalization▁date:▁June▁19▁2001,▁Incorporating▁amendment▁3▁–▁dated▁23▁May▁200": 31746, + "accurate,▁complete,▁and▁": 31747, + "▁PACCE": 31748, + "▁the▁investigational▁drug": 31749, + "large▁cell": 31750, + "age▁and▁mode▁of▁administration": 31751, + "notification▁to▁Amgen": 31752, + "appropriate\n\n": 31753, + ",▁a▁serum": 31754, + "Day▁1▁of": 31755, + "▁urine▁or▁serum▁pregnancy▁test": 31756, + "▁blinded▁investigational▁product": 31757, + "▁approximation": 31758, + "right▁to▁discontinu": 31759, + "▁own▁health▁state▁today": 31760, + "ed▁out▁with▁a▁black": 31761, + "▁treatment▁is▁discontinu": 31762, + "▁relevant▁clinical": 31763, + "\n\nMedian": 31764, + "eligible▁for▁the▁study": 31765, + "Pharmacology▁": 31766, + "rocort": 31767, + "ation▁is▁measured▁from▁the▁date▁of▁randomization": 31768, + "▁(eg,▁s": 31769, + "▁important▁intellectual▁content": 31770, + "e▁by▁contact": 31771, + "withdrawal▁criteria": 31772, + "withdrawals▁due▁to": 31773, + "BJECTIVES\n\n1.1": 31774, + "surgery,▁": 31775, + "urface▁A": 31776, + "▁exceed": 31777, + "▁regular▁basis": 31778, + "initialed▁and▁": 31779, + "compound": 31780, + ".▁Dose▁escalation": 31781, + "▁monoclonal▁antibod": 31782, + "▁monoclonal▁antibody": 31783, + "LQI": 31784, + "▁his▁or▁her▁sit": 31785, + "International▁Committee▁of▁Medical▁Journal▁Editor": 31786, + "▁allergic▁bronchospasm": 31787, + "▁Hypertension": 31788, + "▁unique▁Personal▁": 31789, + "▁participation▁in▁a": 31790, + "previous▁SRE▁(": 31791, + "laboratory,▁": 31792, + "omerase▁": 31793, + "olinic▁acid": 31794, + "▁ANC▁≥": 31795, + "\n\nArm▁1:": 31796, + "e▁should▁be\n\n": 31797, + "▁Compliance": 31798, + "▁approximately▁30▁days▁after": 31799, + "combination▁of▁cetuximab": 31800, + "▁Suppl▁1:": 31801, + ".▁Sunitinib/Placebo": 31802, + ".▁Premedication": 31803, + ".▁Preparation": 31804, + "radiotherapy▁or": 31805, + "▁a▁single▁line▁strok": 31806, + "\n\nFollowing": 31807, + ".\n\nCONFIDENTIALITY": 31808, + "\n\nAdd▁6,7": 31809, + ".\n\nY▁T▁I▁D▁I▁L▁A▁V\n\nS▁T▁I\n\nK▁C▁E▁H▁C": 31810, + "volume▁of▁distribution": 31811, + "informed▁consent▁form?": 31812, + "ed▁with▁a▁unique▁Personal▁": 31813, + "primary▁endpoint▁of": 31814, + "fatigue▁(": 31815, + "▁↓▁1": 31816, + "▁fourth": 31817, + "▁the▁second▁infusion": 31818, + "▁48▁hours▁after": 31819, + "▁placement": 31820, + "▁called▁": 31821, + "European▁Commission": 31822, + "body▁surface▁area": 31823, + "pemetrexed▁and▁": 31824, + "\n\nan▁investigator": 31825, + "▁will▁provide▁the▁sponsor": 31826, + ".▁Subjects▁not▁meeting": 31827, + "▁minimiz": 31828, + "▁minimize▁": 31829, + ".▁Receptor": 31830, + "e▁Size▁Determination": 31831, + "▁ensure▁adequate▁": 31832, + "▁Assignment▁to▁Treatment": 31833, + "00▁IU/": 31834, + "▁Subjects▁Undergoing": 31835, + "▁facilities▁": 31836, + "▁for▁all▁target▁lesions▁will▁be▁calculated▁and▁": 31837, + "\n\n1\n\n1\n\n1\n\n1": 31838, + "\n\n1\n\n1\n\n2\n\n2\n\n3": 31839, + "\n\nEnd▁of▁Study": 31840, + "ed▁without▁prior▁written▁agreement": 31841, + "▁greater▁than▁1": 31842, + "regulatory▁authority": 31843, + "regulatory▁authority▁in": 31844, + "ruled▁out": 31845, + "▁international▁": 31846, + "metabolit": 31847, + "▁a▁taxan": 31848, + "recruitment": 31849, + "▁lo▁Stud": 31850, + "committee▁(": 31851, + "10▁mg▁orally▁": 31852, + "▁time▁and▁initial": 31853, + "birth▁control": 31854, + "▁fatal": 31855, + "▁access▁the▁IVRS": 31856, + "radiotherapy,▁or": 31857, + "faxed▁to": 31858, + "▁audit▁by▁representatives▁from": 31859, + "▁Central▁Cancer▁Treatment▁Group": 31860, + "▁will▁be▁presented▁as▁a▁sterile,▁": 31861, + "ated▁within▁the▁": 31862, + "urotoxicity": 31863, + "▁representative▁and▁": 31864, + "▁at▁a▁dose▁of▁6▁mg/kg": 31865, + "▁chronic▁diseas": 31866, + "radiographic▁studies": 31867, + "▁at▁least▁one▁dose▁of": 31868, + "▁clearance▁": 31869, + "▁twice▁daily▁": 31870, + "(eg,▁a": 31871, + "▁distinct": 31872, + "▁distal▁radi": 31873, + "▁Supplementation": 31874, + "▁Note:": 31875, + "▁Notification▁of": 31876, + "▁subjects\n\nwith": 31877, + "▁superficial▁": 31878, + "▁supervision": 31879, + "istration/Randomization": 31880, + ",▁UK": 31881, + "▁injury▁": 31882, + "▁and▁then▁every▁": 31883, + "▁the▁scheduled▁": 31884, + "elf-care,▁confined▁to▁bed▁or▁chair▁more▁than▁50%▁of▁waking▁hour": 31885, + "auer": 31886, + "promising": 31887, + "\n\nAmendment▁2": 31888, + "▁10.3▁Sample▁Size▁": 31889, + "atively▁resected▁": 31890, + "▁participation▁in▁the▁": 31891, + "▁radiographic▁scan": 31892, + "itis▁or▁fib": 31893, + "Blood▁Cell": 31894, + "mixed▁with": 31895, + "al▁well-being": 31896, + ",▁And": 31897, + "choic": 31898, + "\n\nDrug▁Subst": 31899, + "documentation▁(see▁Section": 31900, + "documentation▁by▁color▁photograph": 31901, + "mith▁T": 31902, + "▁erythema": 31903, + "allowed▁to▁receive▁": 31904, + "reconstituted▁ABI-007": 31905, + "▁becomes▁stabl": 31906, + "150/100": 31907, + ":▁(may▁occur▁between▁1▁and▁9": 31908, + "rather": 31909, + ".▁Unblinding▁at": 31910, + "▁PJ,▁M": 31911, + "▁DRUG": 31912, + "▁or▁its▁designee▁": 31913, + "updates▁": 31914, + "ed▁in▁combination▁with▁cisplatin": 31915, + "▁0.01103": 31916, + "▁analyses▁for▁the▁": 31917, + "▁dose-related": 31918, + "recorded▁on▁each": 31919, + "▁submission▁to▁the▁": 31920, + "d▁(excluding": 31921, + "▁drop-in": 31922, + "▁hematologic▁toxicities": 31923, + ",▁and▁all▁drug-related▁": 31924, + "head▁and▁neck▁cancer": 31925, + ").▁This▁will": 31926, + "History▁": 31927, + "cipitating": 31928, + ".\n\nREG": 31929, + "▁recurrence▁or": 31930, + "▁community": 31931, + "notified": 31932, + "prescribing▁information": 31933, + "▁tests▁needed▁for▁the▁": 31934, + "▁implementation▁of▁Addendum▁9": 31935, + "▁carcinoma▁of▁the▁colon▁or▁rectum": 31936, + ",▁tachycardia": 31937, + "ed▁frozen": 31938, + "▁of▁the▁subject.▁Unblinding▁at": 31939, + "▁as▁defined▁by▁the▁": 31940, + ")\n\nDiscontinu": 31941, + "▁description▁of▁the▁event": 31942, + "Objectives\n\nReplace:": 31943, + ".▁Pharmacogenetic": 31944, + "extension▁lead▁period▁and▁": 31945, + "mutant▁KRAS▁stratum": 31946, + "commencement▁of": 31947, + ",▁2007.▁": 31948, + "▁the▁safety▁follow▁up▁phase▁of▁the▁study": 31949, + "followed▁up▁for": 31950, + "gether▁with▁its": 31951, + "uscle▁pain": 31952, + "▁experimental▁": 31953, + ".▁Randomization▁will▁be▁stratifi": 31954, + "▁has▁been▁shown▁to": 31955, + "▁has▁been▁shown▁to▁be▁": 31956, + ",▁et▁al.▁Phase▁I": 31957, + "calculated▁as": 31958, + "▁even▁after▁discontinuation▁of▁treatment": 31959, + "steroidal▁Anti-Inflammatory▁Drug": 31960, + "of▁of▁receipt": 31961, + "▁violating▁the▁confidentiality▁of▁the▁subject": 31962, + "reported▁as▁an▁SAE": 31963, + "▁association▁between": 31964, + "FICATION": 31965, + "\n\nHypertension": 31966, + "▁during▁the▁study▁period▁and▁for": 31967, + "maintained▁temperature▁alarm": 31968, + "protected▁from▁light": 31969, + "▁third▁parties,▁except": 31970, + ".M.,▁et▁al.,▁": 31971, + "▁evidence▁suggest": 31972, + "▁magnesium▁level": 31973, + "ribonucleic▁acid▁": 31974, + "non-inferiority": 31975, + "▁breaking▁the▁": 31976, + "▁squamous▁cell▁carcinoma": 31977, + "▁induction▁therapy": 31978, + "explored.\n\n": 31979, + "▁will▁be▁used▁as": 31980, + "e▁subjects▁may▁be▁": 31981, + "correspondence\n\n": 31982, + "recorded▁in▁the▁CRF": 31983, + "radiological▁review": 31984, + "radiological▁imag": 31985, + "▁data▁are▁obtained": 31986, + "interpretation▁of▁data": 31987, + "▁received▁any▁": 31988, + "▁Phase": 31989, + "▁cases▁where▁": 31990, + "▁nonhematologic▁toxicities▁": 31991, + "baseline▁sum▁longest▁diameter": 31992, + "▁Accountability▁Recor": 31993, + "mandator": 31994, + ",▁other▁written▁subject": 31995, + "▁and▁Leukemia": 31996, + "▁DSMB": 31997, + "s\n\n4\n\nCompletely▁disabled.▁Cannot▁carry▁on▁any▁s": 31998, + "hair▁los": 31999 }, "merges": [ - "▁ t", - "e r", + ". .", + "e ▁", + ".. ..", "i n", + "▁ t", + "a t", + "o n", + "\n \n", "▁ a", "e n", - "o n", - "▁t h", - "▁ th", - "e s", - "▁ s", - "▁ d", - "a t", + "e r", "o r", - "a n", - "▁ c", - "i s", + ".... ....", + "s ▁", + "d ▁", "r e", + "▁t h", + "a l", + "s t", + "y ▁", + "i on", + "en t", "i t", - "▁t he", - "▁th e", - "▁ the", + "▁th e▁", + "o f", + "a n", + ", ▁", + "r o", + "e d▁", + "▁a n", + "i c", + "........ ........", + ". ▁", + "c t", + "l l", "a r", - "l e", - "▁ w", - "▁ p", - "o u", - "a l", - "▁ f", - "▁ m", "e d", - "▁ o", - "▁ b", - "o m", - "io n", - "i on", + "▁ p", + "▁ c", "in g", - "i ng", - "i c", - "a s", - "e l", - "en t", - "e nt", - "▁i n", - "▁ in", - "▁ h", - "n d", + "▁ b", + "e s", + "f or", "e t", - "▁ l", - "▁ n", - "s t", + "at ion", "▁t o", - "▁ to", - "c h", - "▁ I", - "r o", - "i l", - "▁o f", + "i s", + "▁ s", + "a s", "▁ of", - "d e", - "c t", - "▁ (", - "a m", - "▁ C", - "▁d e", - "▁ de", - "▁ S", - "▁ u", - "▁ A", - "▁ \\", - "▁ e", - "▁a nd", - "▁an d", - "▁ and", - "▁ T", + "u m", + "o u", + "▁ d", + "t h", + "▁ w", + "▁ m", + "▁an d▁", + "o m", + "u d", + "e ct", + ". \n\n", + "m ent", + "i ll", + "al ▁", + "e l", "o l", - "▁ v", + "a b", + "i s▁", + "▁ A", + "▁b e▁", + "i v", + "▁ in", "i m", - "o t", - "a d", - "u t", - "▁ g", - "e m", + "................ ................", "u r", - "i d", - "▁ *", + "e v", + "re s", + "it h", "i g", + "0 0", + "i d", + "o c", + "p l", + "▁ 1", + "▁ C", + "st ud", + "o s", + "a c", + "e st", + "e s▁", + "▁ P", + "p ro", + "at i", + "i l", + "▁ (", + "e m", + "▁ 2", + "T h", + "re at", + "u s", + "u l", + "c on", "r a", - "▁r e", + "ill ▁be▁", + "an c", + "i f", + "ati ent", + "▁ S", + "u b", + "▁ I", "▁ re", - "▁i s", - "▁ is", - "q u", + "o t", + "a g", "o w", - "▁ M", - "es t", - "e st", - "▁ y", - "s e", - "v e", - "c e", - "i e", "u n", - "▁ P", - "▁ B", - "a g", - "u l", - "▁ =", - "h e", - "en d", - "e nd", - "od e", - "o de", - "te r", - "t er", - "me nt", - "men t", - "m ent", - "o s", "▁ D", - "i f", - "at ion", - "ati on", - "atio n", - "a tion", - "▁f or", - "▁fo r", - "▁ for", - "▁ r", - "▁ L", - "▁y ou", - "▁yo u", - "▁ you", - "▁b e", - "▁ be", - "l y", - "ve r", - "v er", - "a b", - "t e", - "▁i t", - "▁ it", - "▁o n", - "▁ on", + "c l", "r i", - "u s", - "▁ \"", - "▁w h", - "▁ wh", - "▁c on", - "▁co n", - "▁ con", - "▁ H", - "▁s t", - "▁ st", - "i r", + "▁ h", + "w ith", + "▁ l", + "e▁ of", + "a p", + "reat ment", "▁ E", - "▁ F", - "c k", - "▁a n", - "▁ an", - "t h", - "e g", - "a y", - "it h", - "i th", - "▁ R", - "is t", + "▁ f", + "a m", + "v er", + "c h", + "j ect", + "▁ or", + "e▁ t", + "i r", + "u t", + "y s", + "for m", + "th er", + "t er", + "Th e▁", + "\n\n P", + "i z", + "e x", + "q u", + "e c", + "en d", + "▁ n", + "at or", "i st", - "an d", - "a nd", - "▁t hat", - "▁th at", - "▁ that", - "▁a l", - "▁ al", - "▁ $", - "▁ #", + "p er", + "on s", "o d", - "u m", - "▁ W", - "h t", - "co de", - "cod e", - "c ode", - "▁ G", - "at e", - "a te", - "es s", - "e ss", - "▁ N", - "er e", - "e re", - "p p", + "\n\n A", + "at e▁", + "stud y▁", + "l in", + "o ll", + "▁an d", + "ab l", + "▁ O", "▁a s", - "▁ as", - "▁s e", - "▁ se", + "s ion", "▁p ro", - "▁pr o", - "▁ pro", + "ub ject", + "al l", + "▁ T", + "u p", + "▁a d", + "e as", + "▁ N", + "d u", + "es s", + "e p", + "v est", + "vest ig", + "o p", + "t oc", + "e f", + "a y▁", + "toc ol", + "w ill▁be▁", + "a st", + "c om", + "▁a r", + "o ther", + "▁ for", + "an d", + "▁ R", + "i b", + "e \n\n", + "ro m", + "ed▁ in", + "▁t reatment", + "en c", + "a in", + "ic al▁", + "stud y", + "ed ▁to", + "iv e▁", + ". 1", + "al ys", + "or t", + "o g", + ". 2", + "a v", "▁w ith", - "▁wit h", - "▁ with", - "p e", - "▁ k", - "er s", - "e rs", - "p t", - ") ;", - "l o", - "▁c om", - "▁co m", - "▁ com", - "am e", - "a me", - "▁ `", - "▁C om", - "▁Co m", - "▁ Com", - "i a", - "an t", - "a nt", - "▁l a", - "▁ la", - "▁ {", - "▁e n", - "▁ en", - "ct ion", - "c tion", - "▁e x", - "▁ ex", - "l d", - "u b", - "▁ j", - "l a", - "u e", - "▁ J", - "ic h", - "i ch", - "▁d o", - "▁ do", - "▁ O", - "▁q u", - "▁ qu", - "i v", - "or t", - "o rt", - "ar t", - "a rt", - "▁u n", - "▁ un", - "▁# #", - "▁ ##", - "▁t his", - "▁th is", - "▁ this", - "k e", - "▁h a", - "▁ ha", - "▁ -", - "ou t", - "o ut", - "▁T he", - "▁Th e", - "▁ The", - "▁n ot", - "▁no t", - "▁ not", - "▁n e", - "▁ ne", - "il l", - "i ll", - "▁l e", - "▁ le", - "c i", - "ro m", - "r om", - "in e", - "i ne", - "/ /", - "o p", - "eg in", - "e gin", - "▁Com ment", - "▁Comm ent", - "▁ Comment", - "be gin", - "beg in", - "b egin", - "с т", - "as s", - "a ss", - "i z", - ") .", - "o g", - "▁ п", - "▁o r", - "▁ or", - "▁w as", - "▁wa s", - "▁ was", - "▁a t", - "▁ at", - "ou r", - "o ur", - "▁ i", - "ai n", - "a in", - "▁ K", - "н а", - "▁ V", - "g e", - "▁s u", - "▁ su", - "a p", - "ag e", - "a ge", - "ou ld", - "oul d", - "o uld", - "n e", - "a v", - "x t", - "or e", - "o re", - "il e", - "i le", - "- -", - "▁ в", - "▁b y", - "▁ by", - "l i", - "at h", - "a th", - "р а", - "be r", + "e▁t o", + "ed▁ b", + "m in", + "s▁ of", "b er", - "ac h", - "a ch", - "al l", - "a ll", - "▁T h", - "▁ Th", - "ul t", - "u lt", - "▁ }", - "▁ U", - "▁u s", - "▁ us", - "▁ z", - "us t", + "I n", + "ou r", + "b e▁", + "atient s▁", + "du ct", + "a d", + "ig n", + "an t", + "ag e▁", + "ou l", + "u g", + "\n\n S", + "anc er", + "▁th at", + "▁2 00", + "p ons", + "um ab", + "▁ is▁", + "▁of ▁", + "oll ow", + "▁a l", + "................................ ................................", + "▁w ill▁be▁", + "e▁ s", + "er i", + "ar t", + "oul d▁", + "e▁ th", + "▁ M", + "▁ r", + "▁ 0", + "▁ 3", + "p pro", + "▁c on", + "a ct", + "ro tocol", + "c or", + "ev ent", + "▁of ▁the▁", + "w h", "u st", - "▁h ave", - "▁ha ve", - "▁hav e", - "▁ have", - "li c", - "l ic", - "н и", - "▁c an", - "▁ca n", - "▁ can", - "t r", - "co m", - "c om", - ") ,", - "▁I n", - "▁ In", - "in d", - "i nd", - "el l", - "e ll", - "▁f rom", - "▁fr om", - "▁fro m", - "▁ from", - "о в", - "t o", - "▁ [", - "ab le", - "abl e", - "a ble", - "os t", - "o st", - "▁c h", - "▁ ch", - "ec t", - "e ct", - "ig ht", - "igh t", + "con t", + "e ,▁", + "ver s", + "p h", + "▁ o", + "▁c om", + "e ar", + "▁ F", + ".▁ A", + ".▁ The▁", + "it y▁", + "vestig ator", + "▁a s▁", + "▁ g", + "p ort", + "n ot", + "a s▁", + "h ould▁", + "0 1", + "2 00", + "s ess", + "▁the▁ s", + "▁ar e▁", + "▁ on", + ", ▁and▁", + "ect ion", + "ra d", + "at ed▁", + "e e", + "it ion", + "▁ v", + "in e▁", + "▁ L", + "l y▁", + "abl e▁", + "is eas", + ". 3", + "av e▁", "in t", - "i nt", - "▁ '", - "▁a re", - "▁ar e", - "▁ are", - "▁i m", - "▁ im", - "▁s h", - "▁ sh", - "▁ <", - "▁A n", - "▁ An", - "▁ с", + "ev er", + "▁ B", + "in u", + "um ber", + "if ic", + "res sion", + "▁th is▁", + "s ,▁", + "ee k", + "a f", "at a", - "a ta", - "ir e", - "i re", - "▁t r", - "▁ tr", - "co n", - "c on", - "or d", - "o rd", - "it y", - "i ty", - "ar d", - "a rd", - "▁h e", - "▁ he", - "▁b ut", - "▁bu t", - "▁ but", - "o c", - "= \"", - "▁p r", - "▁ pr", - "ur e", + "e :", + "▁ y", + "▁a ll", + "ar y▁", + "cl ud", + "t ud", + "vers e▁", + "ic al", + "▁ res", "u re", - "pe r", - "p er", - "ac k", - "a ck", - "or k", - "on g", - "o ng", - "an s", - "a ns", - "к о", - "pl e", - "p le", - "▁d es", - "▁de s", - "▁ des", - "o k", - "or m", - "o rm", - "we r", - "w er", + "1 2", + "i p", + "ou t", + "and om", + "c e", + "os e▁", + "▁th er", + "▁an alys", + "▁ st", + "i al", + "ac h", + "\n\n C", + "▁c h", + "c id", + "▁w ill", + "r ug", + "e▁ in", + "ap y▁", + "f ollow", + "e en", + "um or", + "ing ▁the▁", + "al u", + "cor d", + "ol og", + "▁ 5", + "ef f", + "b o", + "it y", + "w ill", + "▁ 6", + "f rom", + "ul t", + "▁ H", + "an d▁", + "tud y▁", + "c ur", + "▁s ubject", + "▁p atients▁", + "▁ 4", + "sess ment", + "e w", + "▁the▁ p", + ") \n\n", + "min ist", + "lin ical▁", + "o d▁", + "g ression", + "pl at", + "_ _", + "d ition", + "▁ at", + "a y", + "am pl", + "andom iz", + "a il", + "it um", + "\n\nP age▁", + "itum umab", + "s▁ (", + "▁the▁ in", + "▁a c", + "on e▁", + "ev el", + "an itumumab", + "e g", + ". 4", + "▁ study▁", + "cont inu", + "\n\n 1", + "ppro v", + "plat in", + "id ent", + "as e▁", + "l o", + "hould▁ be▁", + "v i", + "▁m g", + "p o", + "s▁ in", + "x im", + "m end", + "▁c ancer", + "g en", + "iseas e▁", + ". 5", + "s .▁", + "ap y", + "▁a f", + "▁w eek", + "i re", + "en s", + "re l", + "con s", + "us ion", + "r it", + "▁an y▁", + "▁ V", + "▁ ex", + "▁the▁ t", + "f ir", + "af et", + "re g", + "e ll", + "anc e▁", + "on th", "a k", - "p r", - "as e", - "a se", - "▁e l", - "▁ el", - "p h", - "a c", - "▁u nd", - "▁un d", - "▁ und", - "▁a r", - "▁ ar", - "▁i f", - "▁ if", - "u d", - "p s", - "it e", - "i te", - "bl e", - "b le", - "н о", - "fe r", + "▁w h", + "\n\n D", + "m ed", + "ed▁b y", + "form ed▁", + "ep t", "f er", - "p l", - "iv e", - "i ve", + "ri or", + "ur v", + "▁af ter", + "et h", + "c re", + "x ic", + "em other", + "y cl", + "ation ▁of", + "all y▁", + "verse▁ event", + "ed▁ for", + "s ▁and▁", + "ed▁ on", + "1 9", + "e▁ d", + "\n\n X", + "es ion", + "at h", + "cid :", + "ic ation", + "l y", + "E C", + ".▁ S", + ". 0", + "P rotocol", + "o b", + "▁p atient", + "1 0", + "▁the▁ d", + "urv iv", + "T I", "an g", - "a ng", - "en s", - "e ns", - "р о", - "▁s o", - "▁ so", - "s o", - "as t", - "a st", - "( )", - "sw er", - "s wer", - "r u", - "ie s", - "i es", - "▁ :", - "a u", + "pl et", + "s▁ will▁be▁", + "▁h ave▁", + "i es▁", + "▁ G", + "▁ un", + "re port", + "ou s", + "ar d", + "▁ U", + "▁ e", + "t ain", + "el y▁", + "M C", + "▁ J", + "e▁th e▁", + "▁N umber", + "▁p l", + "I f", "o v", - "р е", - "г о", - "▁d er", - "▁de r", - "▁ der", - "▁m y", - "▁ my", - "▁w e", - "▁ we", - "▁m e", - "▁ me", - "n t", - "▁a d", - "▁ ad", - "ur n", - "u rn", - "▁y our", - "▁you r", - "▁yo ur", - "▁ your", - ":/ /", - ": //", - "ar e", - "a re", - "▁a ll", - "▁al l", - "▁ all", - "f f", - "i o", - "es tion", - "est ion", - "esti on", - "im e", - "i me", - "▁e r", - "▁ er", - "la ss", - "las s", - "l ass", - "▁ и", - "▁wh ich", - "▁ which", - "om e", - "o me", - "on t", - "o nt", - "▁p ar", - "▁pa r", - "▁ par", - "▁m a", - "▁ ma", - "▁ Y", - "\" ,", - "▁ о", - "f t", - "ia l", - "i al", - "c c", - "ou nd", - "oun d", - "o und", - "▁l i", - "▁ li", - "▁re s", - "▁r es", - "▁ res", - "et h", - "e th", - "je ct", - "j ect", - "▁a pp", - "▁ap p", - "▁ app", - "▁S t", - "▁ St", - "ic e", - "i ce", - "▁a m", - "▁ am", - "ac t", - "a ct", - "▁d el", - "▁de l", - "▁ del", - "g r", - "at ed", - "ate d", - "a ted", - "ie r", - "i er", - "▁a b", - "▁ ab", - "▁e t", - "▁ et", - "al ly", - "all y", - ". .", - "po rt", - "por t", - "p ort", - "i k", + "▁t im", + "p t", + "i es", + "A E", + ".▁ P", + "▁of ▁1", + "\n\n E", + "d er", + "ri al", + "ig h", + "or m", + "G F", + "pons e▁", + "u s▁", + "as el", + "▁I n", + "s e", + "ou n", + ") ,▁", + "▁an t", + "▁f rom", + "re qu", + "ur e▁", + "s \n\n", + "ed▁b y▁", + "p os", + "a x", + "v ent", + "ev alu", + "▁ is", + "▁P rotocol", + "r im", + "is continu", + ".▁ Th", + "▁n ot", + "on -", + "um ent", + "et ▁al", + "or ator", + "▁t umor", + "E N", + "O N", + "r ation", + "i a", + "c ed", + "▁m ay▁", + "et er", + "s▁ for", + "i al▁", + "e ment", + "ic ac", + "ust ▁be▁", + "vestig ation", + "▁ 7", + "s u", + "▁m onth", + "ou s▁", + "rad e▁", + "▁d os", + "ct ion", + "ic h", + "ro duct", + "re vi", + "o st", + "er e▁", + "b een", + "form ation", + "eff ect", + "p res", + "oc ument", + "cl in", + "C T", + "es▁ of", + ", ▁the▁", + "( cid:", + "▁ study", + "is it", + "b in", + "e -", + "m ay▁", + "f usion", + "▁ad verse▁event", + "art ic", + "am in", + "ro up", + "m on", + "et ast", + "v id", "▁p er", - "▁pe r", - "▁ per", - "▁c ont", - "▁con t", - "▁co nt", - "▁ cont", - "р и", - "к а", - "se r", + "▁as s", + "e▁ v", + "p ect", + "in clud", + "at e:", + "p ec", + "st r", + "s )", + "afet y▁", + "▁1 0", + "p p", + "c ept", + "ib l", + ". 6", "s er", - "л и", - "l l", - "ie w", - "i ew", - "ig n", - "i gn", - "_ {", - "pu t", - "p ut", - "on e", - "o ne", - "un ction", - "unc tion", - "unct ion", - "▁d i", - "▁ di", + "▁to ▁the▁", + "▁analys is▁", + "c ent", + "i x", + "5 0", + "lo od▁", + "c an", + ".▁ In", + "I I", + "s o", + "▁a ppro", + "f ident", + ".▁ E", + "▁as sessment", + "▁a g", + "▁t est", + "1 8", + "ar g", + "a re", + "▁mg /", + "at ed", + "▁p h", + "re cord", + "ef in", + "o ver", + "s .\n\n", + "R A", + ", ▁and", + "a us", + ".▁ C", + "at ic", + "eri a", + "1 1", + "e for", + "▁s ign", + "rit eria", + "oc cur", + "po int", + "id er", + "R I", + "▁D ate:", + "ut ion", + "▁con t", + "t il", + "A L", + "wh o", + "▁a b", + "at ely▁", + "if i", + "t e", + ".▁ T", + "ce iv", + "ed▁ with", + "ab orator", + "4 0", + "per i", + "p ar", + "▁Number :", + "’ s▁", + "▁ x", + "- up", + "▁m ed", + "▁ad minist", + "2 0", + "d rug", + ",▁ or", + "▁th e", + "pro gression", + "C R", + "ed▁ at", + "▁in ▁the▁", + "on g", + "ra ct", + "y m", + "roduct :", + "rad i", + "F I", + "▁Number: ▁200", + "e .\n\n", "ar y", - "a ry", - "it ion", - "iti on", - "i tion", - "m a", - "е н", - "ge t", - "g et", - "▁l o", - "▁ lo", - "▁v al", - "▁va l", - "▁ val", - "▁ Q", - "ra n", - "r an", - "▁ д", - "en ce", - "enc e", - "▁w ork", - "▁wor k", - "▁ work", - "▁н а", - "▁ на", - "i p", - "it em", - "ite m", - "i tem", - "yp e", - "y pe", - "▁ &", - "▁h is", - "▁hi s", - "▁ his", - "▁u se", - "▁us e", - "▁ use", - "de r", - "d er", - "▁An swer", - "▁Ans wer", - "▁ Answer", - "▁w ill", - "▁wil l", - "▁ will", - "iz e", - "i ze", - "т а", - "lo w", - "l ow", - "▁C h", - "▁ Ch", - "▁g et", - "▁ge t", - "▁ get", - "id e", - "i de", - "ou s", - "o us", - "in k", - "pt ion", - "p tion", - "л а", - "tu rn", - "t urn", - "un g", - "u ng", - "e c", - "u g", - "fo rm", - "for m", - "f orm", - "re s", - "r es", - "ht t", - "h tt", - "ou g", - "o ug", - "л ь", - "▁n o", - "▁ no", - "c l", - "▁r o", - "▁ ro", - "▁o ne", - "▁on e", - "▁ one", - "t t", - "cr i", - "c ri", - "d u", - "▁u p", - "▁ up", - "т о", - "( \"", - "▁o b", - "▁ ob", - "w e", - "or y", - "o ry", - "▁e st", - "▁es t", - "▁ est", - "er y", - "e ry", - "ie l", - "i el", - "st r", - "s tr", - "o b", - "▁qu e", - "▁q ue", - "▁ que", - "ia n", + "O L", + "▁l e", + "▁Protocol ▁Number:▁200", + "p atient", + "2 5", + "▁d isease▁", + ") :", + "ac e", "i an", - "▁o ut", - "▁ou t", - "▁ out", - "▁p l", - "▁ pl", - "▁n ew", - "▁ne w", - "▁ new", - "к и", - "▁ +", - "r y", - "ot h", - "o th", - "th er", - "the r", - "t her", - "▁v ar", - "▁va r", - "▁ var", - "▁w ould", - "▁wo uld", - "▁s er", - "▁se r", - "▁ ser", - "ter n", - "te rn", - "t ern", - "te xt", - "tex t", - "t ext", - "▁t here", - "▁th ere", - "▁the re", - "▁ther e", - "▁ there", - "is h", - "i sh", - "ro r", - "r or", - "т е", - "▁s et", - "▁se t", - "▁ set", - "▁ @", - "▁п о", - "▁ по", - "▁t e", - "▁ te", - "e x", - "▁re turn", - "▁ret urn", - "▁ return", - "ai l", - "a il", - "▁a ny", - "▁an y", - "▁ any", - "▁I t", - "▁ It", - "▁f unction", - "▁fun ction", - "▁func tion", - "▁ function", - "{ \\", - "' ,", - "é s", - "al e", - "a le", - "а н", - "▁w hen", - "▁wh en", - "▁whe n", - "▁ when", - "i b", - "▁g o", - "▁ go", - "an ce", - "anc e", - "▁h ad", - "▁ha d", - "▁ had", - "▁Q u", - "▁ Qu", - "▁c omp", - "▁com p", - "▁co mp", - "▁ comp", - "л е", - "▁ з", - "ma th", - "mat h", - "m ath", - "▁h as", - "▁ha s", - "▁ has", - "▁ м", + "k in", + "in vestigator", + "y p", + "▁ 9", + "em et", + "\n\nX \n\nX", + ". ,▁", + "h ave▁", + "▁ 8", + "E GF", + "e▁ (", + "▁0 ▁0", + "fir st", + "er sion", + "M G", + "ri b", + "artic ip", + "s▁ s", + "▁ us", + "m it", + "▁o ▁r", + "alys is▁", + "igh t", + "\n\nP roduct:", + "\n\n N", + "follow ing", + "rior ▁to", + "1 5", + "c al", + "e▁ for", + "▁e ach", + "h e", + "p re", + "r an", + "al ▁pro", + "3 0", + "m gen", + "pp end", + "s▁ with", + "andomiz ation", + "▁p ▁p", + "▁d ata", + "ever y▁", + "▁t rial", + "▁o▁r ▁p▁p", + "d▁ e▁v", + "ul ation", + "▁1 6", + "▁o▁r▁p▁p ▁A", + "d▁e▁v ▁o▁r▁p▁p▁A", + "▁ X", + "F S", + ") .\n\n", + ".▁ If", + "................................................................ ................", + "mend ment", + ". 7", + "ar m", + "fident ial", + "ppend ix", + "\n\n 2", + "im en", + "e ath", + "▁ form", + "y▁ of", + "arg et", + "re x", + "b as", + "▁s hould▁be▁", + "at ive▁", + "ro ll", + "ar k", + "__ __", + "ear ch", + "ar d▁", + "ace bo", + "▁ other", + ".... ..", + "ar i", + "n e", + "▁l esion", + "▁the▁in vestigator", + "\n\n R", + "ul ar", + "emet rex", + "1 7", + "s ubject", + "▁y our", + "▁T ▁I", + "S tudy▁", + "ax el", + "t en", + "it or", + "eter min", + "in d", + "in ib", + "et ic", + "N C", + "▁ -", + "emother apy▁", + "MC -", + "▁to ▁be▁", + "▁A d", + "t o", + "▁th e\n\n", "▁p re", - "▁pr e", - "▁ pre", - "en er", - "ene r", - "e ner", - "▁p art", - "▁par t", - "▁pa rt", - "▁ part", - "el f", - "▁d ie", - "▁di e", - "▁ die", - "▁l ike", - "▁li ke", - "▁lik e", - "▁ like", - "ra y", - "r ay", - "ir st", - "irs t", - "▁d is", - "▁di s", - "▁ dis", - "▁m an", - "▁ma n", - "▁ man", - "ri t", - "r it", - "▁t hen", - "▁th en", - "▁the n", - "▁ then", - "▁c lass", - "▁cl ass", - "▁cla ss", - "▁clas s", - "▁ class", - "pr o", - "p ro", - "▁p o", - "▁ po", - "▁u sing", - "▁us ing", - "▁ using", - "e b", - "▁c ode", - "▁co de", - "▁cod e", - "▁ code", - "ow n", - "o wn", - "▁s ome", - "▁so me", - "▁som e", - "▁ some", - "ce s", - "c es", - "▁$ \\", - "▁ $\\", - "е р", - "le ct", - "l ect", - "▁a u", - "▁ au", - "is ch", - "isc h", - "i sch", - "▁c ol", - "▁co l", - "▁ col", - "▁ –", - "u p", - "on s", - "o ns", - "▁a dd", - "▁ad d", - "▁ add", - "il d", - "i ld", - "is s", - "i ss", - "va l", - "v al", - "ou nt", + "ed ▁as▁", + "2 4", + "ev ac", + "ity▁ of", + "▁h as▁", + "iz umab", + "urviv al", + "evac izumab", + "▁S tudy▁", + "▁al so", + "▁y ou", + "th e▁", + "as s", + "enc e▁", + "d es", + "u al", + "eas ure", + "f f", + "▁a ▁s", + "▁the▁ study", + "\n\n F", + "▁c ycl", + "pres ent", "oun t", - "o unt", - "le s", - "l es", - "ve nt", - "ven t", - "v ent", - "▁ Z", - "I n", - "ro w", - "r ow", - "ea r", - "e ar", - "at ions", - "ation s", - "ati ons", - "atio ns", - "a h", - "qu e", - "q ue", - "ub lic", - "u blic", - "an k", - "▁s p", - "▁ sp", - "▁W h", - "▁ Wh", - "-- --", - "--- -", - "- ---", - "s k", - "e w", - "ag s", - "a gs", - "т и", - "an n", - "a nn", - "▁ —", - "er t", - "e rt", - "ac e", - "a ce", - "sc h", - "s ch", - "▁n eed", - "▁ne ed", - "▁ need", - "▁ à", - "ie n", - "i en", - "ou gh", - "oug h", - "o ugh", - "н е", - "▁d ef", - "▁de f", - "▁ def", - "i j", - "er n", - "e rn", - "▁w hat", - "▁wh at", - "▁ what", - "▁A r", - "▁ Ar", - "w o", - "m l", - "< /", - "▁R e", - "▁ Re", - "▁e s", - "▁ es", - "▁in st", - "▁ins t", - "▁ inst", - "b o", - "a z", - "▁# ##", - "▁## #", - "▁ б", - "er m", - "e rm", - "▁A l", - "▁ Al", - "le d", - "l ed", - "д а", - "te n", - "t en", - "se t", - "s et", - "л о", - "▁c omm", - "▁com m", - "▁co mm", - "▁ comm", + "1 4", + "\n\n T", + "e ,", + "ri al▁", + "▁E ▁L", + "................................................................ ................................", + "\n\n 3", + "00 0", + "▁ im", + "5 4", + "c i", + "asel ine▁", + "cons ent", + "enc e▁of", + "pro tocol", + "ser v", + "act or", + "O n", "s h", - "в а", - "▁ /", - "▁d ata", - "▁da ta", - "▁dat a", - "▁ data", - "▁/ /", - "▁ //", - "] (", - "▁s tr", - "▁st r", - "▁ str", - "os e", - "o se", - "▁U n", - "▁ Un", - "ve n", - "v en", - "S t", - ".. .", - ". ..", - "▁ С", - "ys t", - "y st", - "▁ «", - "ic k", - "i ck", - "i x", - "pa r", - "p ar", - "▁ у", - "▁w ant", - "▁wa nt", - "n g", - "ot e", - "o te", - "▁g r", - "▁ gr", - "▁d u", - "▁ du", - "▁ .", - "un d", - "u nd", - "▁on ly", - "▁ only", - "▁s a", - "▁ sa", - "el y", - "e ly", - "ve rs", - "ver s", - "v ers", - "▁e nt", - "▁en t", - "▁ ent", - ") )", - "( '", - "▁m od", - "▁mo d", - "▁ mod", - "av a", - "a va", - "to n", - "t on", - "▁sh ould", - "▁sho uld", - "▁ should", - "em ent", - "eme nt", - "emen t", - "e ment", - "▁f orm", - "▁for m", - "▁fo rm", - "▁ form", - "▁al so", - "▁als o", - "▁ also", - "▁s c", - "▁ sc", - "in gs", - "ing s", - "▁Y ou", - "▁ You", - "ó n", - "▁k n", - "▁ kn", - "() ;", - "( );", - "▁ |", - "▁w ere", - "▁we re", - "▁wer e", - "s s", - "▁Qu estion", - "▁ Question", - "is e", - "i se", - "▁th ey", - "▁the y", - "▁ they", - "▁D e", - "▁ De", - "on d", - "o nd", - "▁s ol", - "▁so l", - "▁ sol", - "▁f ol", - "▁fo l", - "▁ fol", - "▁m ore", - "▁mo re", - "▁mor e", - "▁ more", - "▁h er", - "▁he r", - "▁ her", - "▁ _", - "▁ é", - "at ch", - "ft er", - "fte r", - "f ter", - "▁c re", - "▁cr e", - "▁ cre", - "lo ck", - "loc k", - "l ock", - "tr ing", - "tri ng", - "t ring", - "▁T his", - "▁Th is", - "▁ This", - "z e", - "ad o", - "a do", - "ul l", - "u ll", - "ge r", - "g er", - "b e", - "▁o ther", - "▁ot her", - "▁ other", - "▁T ags", - "▁Tag s", - "▁Ta gs", - "▁ Tags", - "ut ion", - "uti on", - "u tion", - "ic t", - "i ct", - "▁h ow", - "▁ho w", - "▁ how", - "▁ x", - "▁S e", - "▁ Se", - "▁c he", - "▁ch e", - "▁ che", - "cri pt", - "cr ipt", - "▁j ust", - "▁ju st", - "▁ just", - "▁p os", - "▁po s", - "▁ pos", - "an ge", - "ang e", - "if ic", - "ifi c", - "i fic", - "re e", - "r ee", - "} }", - "▁t ime", - "▁tim e", - "▁ti me", - "▁ time", - "ap p", - "a pp", - "н ы", - "▁f ile", - "▁fil e", - "▁fi le", - "▁ file", - "ar k", - "ic al", - "ica l", - "i cal", - "▁f irst", - "▁fir st", - "▁ first", - "▁in t", - "▁i nt", - "▁ int", - "▁ В", - "▁H e", - "▁ He", - "t a", - "um ent", - "ume nt", - "umen t", - "u ment", - "or s", - "o rs", - "le ment", - "lem ent", - "l ement", - "ra c", - "r ac", - "▁a g", - "▁ ag", - "▁do es", - "▁ does", - "y n", - "re ad", - "rea d", - "r ead", - "ua l", - "u al", - "▁L e", - "▁ Le", - "y s", - "▁e m", - "▁ em", - "▁n um", - "▁nu m", - "▁ num", - "ve l", - "v el", - "д и", - "ov er", - "ove r", - "o ver", - "▁d if", - "▁di f", - "et hod", - "eth od", - "▁I f", - "▁ If", - "▁s pe", - "▁sp e", - "▁ spe", - "y m", - "▁t hem", - "▁th em", - "▁the m", - "▁in to", - "▁int o", - "▁ into", - "▁l es", - "▁le s", - "▁ les", - "▁it s", - "▁i ts", - "▁ its", - "es e", - "e se", - "ie ld", - "iel d", - "i eld", - "▁p ublic", - "▁pub lic", - "▁pu blic", - "▁publi c", - "▁ public", - "▁ П", - "▁d en", - "▁de n", - "▁ den", - "yst em", - "ys tem", - "o f", - "▁o ver", - "▁ov er", - "▁ over", - "- >", - "▁f il", - "▁fi l", - "▁ fil", - "na me", - "nam e", - "n ame", - "in al", - "ina l", - "i nal", - "▁i l", - "▁ il", - "am ple", - "amp le", - "▁w ay", - "▁wa y", - "▁ way", - "ic a", - "i ca", - "в о", - "ce ss", - "ces s", - "c ess", - "it t", - "i tt", - "uc h", - "u ch", - "▁w here", - "▁wh ere", - "▁whe re", - "▁ where", - "м и", - "or g", - "o rg", - "htt ps", - "http s", - "▁v o", - "▁ vo", - "ie nt", - "ien t", - "i ent", - "ov e", - "o ve", - "▁val ue", - "▁valu e", - "▁ value", - "en g", - "e ng", - "▁L a", - "▁ La", - "^ {", - "re f", - "r ef", - "ie d", - "i ed", + "at ing", + "d ur", + "r on", + "es e▁", + "▁the▁p atient", + "ch ed", + "ed ,▁", + "ched ul", + "xim ately▁", + "d ra", + "res pons", "E R", - "▁s tat", - "▁st at", - "▁sta t", - "▁ stat", - "fi g", - "f ig", - "m e", - "▁v on", - "▁vo n", - "▁ von", + "\n\n Y", + "▁ad dition", + "en ing", + "▁ The▁", + "ow n", + "▁f ollow", + "ific ation", + ".▁ D", + "▁the▁ l", + "\n\nS ▁I", + "S T", + "n o", + "s ▁are▁", + "▁d ose▁", "▁in ter", - "▁int er", - "▁inte r", - "▁ inter", - "ro id", - "r oid", - "at er", - "ate r", - "a ter", - "▁the ir", - "▁b et", - "▁be t", - "▁ bet", - "▁e in", - "▁ ein", - "} \\", - "\" >", - "▁s ub", - "▁su b", - "▁ sub", - "▁o p", - "▁ op", - "▁d on", - "▁do n", - "▁ don", - "t y", - "▁t ry", - "▁tr y", - "▁ try", - "▁P ro", - "▁Pr o", - "▁ Pro", - "▁t ra", - "▁tr a", - "▁ tra", - "▁s ame", - "▁sa me", - "▁sam e", - "▁ same", - "e p", - "▁t wo", - "▁tw o", - "▁ two", - "▁n ame", - "▁na me", - "▁nam e", - "▁ name", - "ol d", - "o ld", - "le t", - "l et", - "▁s im", - "▁si m", - "▁ sim", - "s p", - "▁a v", - "▁ av", - "br e", - "b re", - "ble m", - "bl em", - "b lem", - "e y", - "▁c ould", - "▁co uld", - "▁cou ld", - "▁ could", - "▁c or", - "▁co r", - "▁ cor", - "▁a cc", - "▁ac c", - "▁ acc", - "ay s", - "a ys", - "cr e", - "c re", - "ur r", - "u rr", - "s i", - "▁con st", - "▁cons t", - "▁ const", - "ue s", - "u es", - "} $", - "V iew", - "▁a ct", - "▁ac t", - "▁ act", - "▁b o", - "▁ bo", - "▁к о", - "▁ ко", - "▁s om", - "▁so m", - "▁ som", - "▁ab out", - "▁ about", - "la nd", - "lan d", - "l and", - "me r", - "m er", - "▁l ist", - "▁li st", - "▁ list", - "ca l", - "c al", - "▁im port", - "▁imp ort", - "▁ import", - "co l", - "c ol", - "▁n a", - "▁ na", - "n a", - ": :", - "▁w ho", - "▁wh o", - "▁ who", - "▁e rror", - "▁er ror", - "▁err or", - "▁ error", - "▁ X", - "at or", - "ato r", - "a tor", - "ex t", - "e xt", - "▁b een", - "▁be en", - "é r", - "▁r un", - "▁ru n", - "▁ run", - "po s", - "p os", - "▁c l", - "▁ cl", - "* *", - "▁ К", - "ul ar", - "ula r", - "u lar", - "au se", - "aus e", - "a use", + "d▁ of", + "▁le ast", + "oc i", "▁re g", - "▁r eg", - "▁ reg", - "▁k now", - "▁kn ow", - "▁ know", - "▁s ee", - "▁se e", - "▁ see", - "▁h im", - "▁hi m", - "▁ him", - "ni ng", - "n ing", - "▁з а", - "▁ за", - "at es", - "ate s", - "a tes", - "fo re", - "for e", - "f ore", - "ion s", - "io ns", - "i ons", - "▁h el", - "▁he l", - "▁ hel", - "ut e", - "u te", - "▁re m", - "▁r em", - "▁ rem", - "▁г о", - "▁ го", - "▁M ar", - "▁Ma r", - "▁ Mar", - "р у", - "vi ce", - "vic e", - "v ice", - "ir ect", - "ire ct", - "i rect", - "ne r", - "n er", - "▁u nder", - "▁un der", - "▁und er", - "▁ under", - "ri b", - "r ib", - "h r", - "ч е", - "▁A s", - "▁ As", - "▁e nd", - "▁en d", - "▁ end", - "em ber", - "emb er", - "▁ а", - "▁a tt", - "▁at t", - "▁ att", - "in a", - "i na", - "so n", - "s on", - "▁f ollow", - "▁fol low", - "▁ follow", - "▁S ch", - "▁Sc h", - "▁ Sch", - "pe ct", - "pec t", - "p ect", - "▁re l", - "▁r el", - "▁ rel", - "▁S o", - "▁ So", - "▁l ook", - "▁lo ok", - "▁ look", - "ab el", - "abe l", - "a bel", - "▁pro blem", - "▁prob lem", - "▁proble m", - "▁probl em", - "▁ problem", - "▁v an", - "▁va n", - "▁ van", - "st rong", - "str ong", - "c o", - "po n", - "p on", - "c a", - "ad a", - "a da", - "\" :", - "con d", - "co nd", - "c ond", - "am b", - "a mb", - "} ,", - "qu est", - "que st", - "ques t", - "q uest", - "▁a ut", - "▁au t", - "▁ aut", - "▁res ult", - "▁ result", - "▁m ay", - "▁ma y", - "▁ may", - "R e", - "ht tp", - "htt p", - "h ttp", - ") :", - "▁A nd", - "▁An d", - "▁ And", - "re d", - "r ed", - "▁H ow", - "▁Ho w", - "▁ How", - "p o", - "ск о", - "с ко", - "at t", - "a tt", - "ou p", - "o up", - "ce d", - "c ed", - "▁t ype", - "▁typ e", - "▁ty pe", - "▁ type", - "▁t han", + "y ,▁", + "com plet", + "▁ W", + "c oll", + "ed ▁as", + "etast atic", + "RA S", + "K RAS", "▁th an", - "▁ than", + "rim ary▁", + "p r", + ".\n\n A", + "e )", + "▁o b", + "eff icac", + "\n\n The▁", + "▁to xic", + "ed▁in ▁the▁", + "\n\n 4", + ".▁ F", + "▁d ay", + "l e", "▁c ons", - "▁con s", - "▁co ns", - "▁ cons", - "u f", - "ц и", - "▁qu estion", - "▁quest ion", - "▁questi on", - "▁ question", + "on fidential", + "ic ally▁", + "i d▁", + "u c", + "d ata", + "I -", + "ab il", + ".\n\n P", + "e▁ b", + "5 -", + "requ ire", + "s ▁to", + "un it", + "▁ther apy", + "s ▁that", + "al▁pro duct", + "1 3", + "2 3", + "\n\n I", + "r ent", + "in al", + "p ri", + "▁ar m", + "▁mg/ m", + "dra w", + ",▁ S", + "i -", + "▁p anitumumab", + "▁200 7", + "h y", + "▁c lin", + "▁v isit", + "d efin", + "is k", + "y st", + "ol or", + "lin d", + "L C", + "iv en", + "pprov ed", + "ark er", + "unit inib", + "o th", + "▁patients▁ with", + "qu est", + "s▁ or", + "8 0", + "ym pt", + "s on", + "▁ it", + "ympt om", + "vestigation al▁product", + "bin ation", + "c ar", "ra ph", - "rap h", - "r aph", - "ig h", - "i gh", - "▁ М", - "▁h tt", - "▁ htt", - "in s", - "i ns", - "de n", - "d en", - "▁d a", - "▁ da", - "▁v er", - "▁ve r", - "▁ ver", - "o h", - "▁= >", - "▁ =>", - "ri v", - "r iv", - "ud e", - "u de", - "▁F or", - "▁Fo r", - "▁ For", - "▁r a", - "▁ ra", - "fr ac", - "fra c", - "f rac", - "м а", - "▁a fter", - "▁af ter", - "▁ after", - "} {", - "▁m ethod", - "▁met hod", - "▁ method", - "\" )", - "am p", - "a mp", - "as h", - "a sh", - "▁re c", - "▁r ec", - "▁ rec", - "▁d iffer", - "▁dif fer", - "▁diff er", - "O N", - "a x", - "am ent", - "ame nt", - "amen t", - "a ment", - "our ce", - "Co n", - "C on", - "it s", - "i ts", - "Na me", - "N ame", - "ma n", - "m an", - "▁b ec", - "▁be c", - "▁ bec", - "ch e", - "c he", - "▁E n", - "▁ En", - "a j", - "▁g ener", - "▁ge ner", - "▁gen er", - "▁gene r", - "▁ gener", - "I N", - "▁i d", - "▁ id", - "ag es", - "age s", - "a ges", - "▁l oc", - "▁lo c", - "▁ loc", - "f o", - "b r", - "▁s he", - "▁sh e", - "▁ she", - "Pr o", - "P ro", - "▁u na", - "▁un a", - "▁ una", - "▁ к", - "et a", - "e ta", - "lo g", - "l og", - "ol og", - "olo g", - "o log", - "▁s ur", - "▁su r", - "▁ sur", - "ar g", - "a rg", - "▁- -", - "▁ --", - "k t", - "( \\", - "mi n", - "m in", - "▁l ine", - "▁li ne", - "▁lin e", - "▁ line", - "▁v ari", - "▁var i", - "▁va ri", - "▁ vari", - "с я", - "ic s", - "i cs", - "н я", - "ve ry", - "ver y", - "v ery", - "ad d", - "a dd", - "▁o bject", - "▁ob ject", - "▁obj ect", - "▁ object", - "I d", - "▁B ut", - "▁Bu t", - "▁ But", - "▁c ase", - "▁cas e", - "▁ca se", - "▁ case", - "▁m ake", - "▁ma ke", - "▁mak e", - "▁ make", - "▁c al", - "▁ca l", - "▁ cal", - "▁p ass", - "▁pas s", - "▁pa ss", - "▁ pass", - "с ь", - "ess ion", - "ne t", - "n et", - ". \"", - "▁ г", - "ä r", - "д е", - "n o", - "at ing", - "ati ng", - "atin g", - "a ting", - "at o", - "a to", - "li ne", - "lin e", - "l ine", - "в и", - "▁E x", - "▁ Ex", - "▁a ss", - "▁as s", - "▁ ass", - "▁v ers", - "▁ver s", - "▁ve rs", - "▁ vers", - "л я", - "▁e d", - "▁ ed", - "um n", - "u mn", - "ot her", - "oth er", - "othe r", - "o ther", - "ст а", - "с та", - "at ive", - "ativ e", - "ati ve", - "St ring", - "Str ing", - "S tring", - "▁l os", - "▁lo s", - "▁ los", - "w n", - "▁an swer", - "▁ans wer", - "▁ answer", - "▁l et", - "▁le t", - "▁ let", - "▁p e", - "▁ pe", - "en ts", - "ent s", - "▁f e", - "▁ fe", - "in ce", - "inc e", - "n i", - "id er", - "ide r", - "i der", - "ow s", - "o ws", - "▁t est", - "▁te st", - "▁ test", - "▁h ere", - "▁he re", - "▁her e", - "▁ here", - "ro ll", - "rol l", - "r oll", - "▁c all", - "▁cal l", - "▁ca ll", - "▁ call", - "ru ct", - "r uct", - "▁p ol", - "▁po l", - "▁ pol", - "ai t", - "a it", - "▁b ack", - "▁ba ck", - "▁ back", - "h o", - "E x", - "re ss", - "res s", - "r ess", - "S T", - "ri ed", - "rie d", - "r ied", - "da te", - "dat e", - "d ate", - "е т", - "▁d id", - "▁di d", - "▁ did", - "ti ng", - "t ing", - "▁E l", - "▁ El", - "▁d em", - "▁de m", - "▁ dem", - ") $", - "ов а", - "о ва", - "ur rent", - "urr ent", - "urre nt", - "la ce", - "lac e", - "l ace", - "rig ht", - "r ight", - "re n", - "r en", - "п о", - "▁e ach", - "▁ each", - "c y", - "bl ock", - "blo ck", - "b lock", - "da ta", - "dat a", - "d ata", - "▁ %", - "▁a c", - "▁ ac", - "▁= =", - "▁ ==", - "ü r", - "▁p or", - "▁po r", - "▁ por", - "as k", - "a sk", - "ar ch", - "arc h", - "am es", - "ame s", - "a mes", - "▁C on", - "▁Co n", - "▁ Con", - "ч а", - "▁o ff", - "▁of f", - "▁ off", - "▁f ind", - "▁fin d", - "▁fi nd", - "▁ find", - "con t", - "co nt", - "c ont", - "▁n ow", - "▁no w", - "▁ now", - "wor k", - "w ork", - "at ional", - "ation al", - "ati onal", - "atio nal", - "d d", - "ci ón", - "ció n", - "c ión", - "▁ А", - "au lt", - "a ult", - "Li st", - "L ist", - "▁e xt", - "▁ex t", - "▁ ext", - "ur s", - "u rs", - "ak e", - "a ke", - "ul e", - "u le", - "▁p oint", - "▁po int", - "▁poi nt", - "▁ point", - "A T", - "au t", - "a ut", - "▁tr ans", - "▁tra ns", - "▁tran s", - "▁ trans", - "▁c o", - "▁ co", - "▁re ad", - "▁r ead", - "▁ read", - "▁u sed", - "▁us ed", - "▁use d", - "▁ used", - "ск и", - "с ки", - "ar i", - "a ri", - "L E", - "et er", - "ete r", - "e ter", - "ou n", - "o un", - "ev er", - "e ver", - "sel f", - "s elf", - "in ed", - "ine d", - "i ned", - "id th", - "u x", - "j s", - "▁s uch", - "▁su ch", - "▁suc h", - "▁ such", - "▁I s", - "▁ Is", - "é e", - "fu l", - "f ul", - "▁d ist", - "▁di st", - "▁dis t", - "▁ dist", - "▁b u", - "▁ bu", - "item ize", - "Con t", - "Co nt", - "C ont", - "j e", - "с и", - "▁p rov", - "▁pro v", - "▁pr ov", - "▁ prov", - "b b", - "wa rd", - "war d", - "w ard", - "es ent", - "ese nt", - "esen t", - "e sent", - "er son", - "ers on", - "an ks", - "ank s", - "w h", - "no t", - "n ot", - "▁W e", - "▁ We", - "k a", - "ro p", - "r op", - "at ur", - "atu r", - "al s", - "a ls", - "▁b el", - "▁be l", - "▁ bel", - "ö r", - "f r", - "▁ex ample", - "▁exam ple", - "▁ example", - "▁in cl", - "▁inc l", - "am il", - "ami l", - "a mil", - "▁р а", - "▁ ра", - "▁ “", - "▁s tring", - "▁st ring", - "▁str ing", - "▁stri ng", - "▁ string", - "▁th ink", - "▁thin k", - "T h", - "▁t em", - "▁te m", - "▁ tem", - "av e", - "a ve", - "▁F ran", - "▁Fr an", - "▁Fra n", - "▁ Fran", - "▁n umber", - "▁num ber", - "▁ number", - "▁s i", - "▁ si", - "im es", - "ime s", - "i mes", - "te m", - "t em", - "m y", - "le r", - "l er", - "lo ad", - "= =", - "▁h and", - "▁ha nd", - "▁han d", - "▁ hand", - "z a", - "▁b ecause", - "▁bec ause", - "▁ because", - "▁s ch", - "▁sc h", - "▁ sch", - "v o", - "th is", - "t his", - "I D", - "ã o", - "▁st art", - "▁star t", - "▁sta rt", - "▁ start", - "▁w ar", - "▁wa r", - "▁ war", - "▁he lp", - "▁hel p", - "▁ help", - "t s", - "▁c har", - "▁ch ar", - "▁cha r", - "▁ char", - "▁p h", - "▁ ph", - "▁m in", - "▁mi n", - "▁ min", - "ti l", - "t il", - "ri te", - "rit e", - "r ite", - "-- ------", - "---- ----", - "--- -----", - "------ --", - "----- ---", - "------- -", - "- -------", - "el s", - "e ls", - "▁m it", - "▁mi t", - "▁ mit", - "ed ia", - "edi a", - "e dia", - "к у", - "▁S h", - "▁ Sh", - "an y", - "a ny", - "] ;", - "▁ Б", - "iqu e", - "i que", - "d a", - "e f", - "de x", - "d ex", - "▁p rodu", - "▁pro du", - "▁pr odu", - "▁prod u", - "▁ produ", - "▁ Н", - "gr am", - "gra m", - "g ram", - "▁O r", - "▁ Or", - "▁g re", - "▁gr e", - "▁ gre", - "qu ote", - "quot e", - "le g", - "l eg", - "or n", - "o rn", - "▁in d", - "▁i nd", - "▁ ind", - "▁p ost", - "▁po st", - "▁pos t", - "▁ post", - "▁d ep", - "▁de p", - "▁ dep", - "] ,", - "v i", - "▁u ser", - "▁us er", - "▁use r", - "▁ user", - "▁ >", - "li ck", - "lic k", - "l ick", - "▁v ery", - "▁ver y", - "▁ve ry", - "▁ very", - "et hing", - "eth ing", - "e thing", - "▁ar ray", - "▁arr ay", - "▁ array", - "▁g u", - "▁ gu", - "▁d ur", - "▁du r", - "` .", - "т ь", - "li cation", - "lic ation", - "lica tion", - "ст и", - "с ти", - "e k", - "ic o", - "i co", - "▁d at", - "▁da t", - "▁ dat", - "о р", - "ht ml", - "htm l", - "h tml", - "ion e", - "io ne", - "i one", - "▁d ifferent", - "▁differ ent", - "▁c heck", - "▁che ck", - "▁ check", - "▁f r", - "▁ fr", - "▁E r", - "▁ Er", - "▁t ext", - "▁te xt", - "▁tex t", - "▁ text", - "н і", - "ic ht", - "ich t", - "i cht", - "st ack", - "sta ck", - "E N", - "ra g", - "r ag", - "▁e very", - "▁ev ery", - "▁ever y", - "▁ every", - "A r", - "▁be fore", - "▁bef ore", - "▁ before", - "al se", - "als e", - "▁f in", - "▁fi n", - "▁ fin", - "▁d é", - "▁th ese", - "▁the se", - "▁d et", - "▁de t", - "▁ det", - "V al", - "ce ption", - "cept ion", - "cep tion", - "▁and roid", - "▁ android", - "block quote", - "▁j e", - "▁ je", - "fil e", - "fi le", - "f ile", - "at s", - "a ts", - "▁д о", - "▁ до", - "ess age", - "essa ge", - "▁ag ain", - "a w", - "C h", - "we en", - "w een", - "▁ Д", - "fo r", - "f or", - "ci al", - "cia l", - "c ial", - "pl ay", - "pla y", - "p lay", - "pr e", - "p re", - "id a", - "i da", - "▁P ar", - "▁Pa r", - "▁ Par", - "n y", - "ra ct", - "rac t", - "r act", - "▁s upp", - "▁su pp", - "▁sup p", - "▁ supp", - "as ed", - "ase d", - "a sed", - "le ction", - "lect ion", - "l ection", - "▁d ans", - "▁da ns", - "▁dan s", - "ai r", - "a ir", - "ro l", - "r ol", - "▁t hr", - "▁th r", - "Dat a", - "Da ta", - "D ata", - "li ch", - "lic h", - "l ich", - "▁п ро", - "▁пр о", - "▁ про", - "▁l ong", - "▁lo ng", - "▁lon g", - "▁ long", - "▁se cond", - "▁sec ond", - "▁ second", - "ual ly", - "u ally", - "in es", - "ine s", - "i nes", - "▁f ound", - "▁fo und", - "▁fou nd", - "▁ found", - "eng th", - "y p", - "ea d", - "e ad", - "▁l og", - "▁lo g", - "▁ log", - "u i", - "ne w", - "n ew", - "▁ Р", - "g o", - "au s", - "a us", - "od y", - "o dy", - "▁s on", - "▁so n", - "▁ son", - "м е", - "er o", - "e ro", - "ve d", - "v ed", - "su b", - "s ub", - "▁r ight", - "▁rig ht", - "▁ right", - "vi ew", - "vie w", - "v iew", - "▁follow ing", - "' )", - "\") ;", - "\" );", - "▁sa id", - "ж е", - "ч и", - "т у", - "ot t", - "o tt", - "с е", - "ar s", - "a rs", - "$ .", - "g g", - "▁b r", - "▁ br", - "oo l", - "o ol", - "yl e", - "y le", - "us e", - "u se", - "▁s how", - "▁sh ow", - "▁sho w", - "▁ show", - "le ase", - "lea se", - "ci a", - "c ia", - "▁d irect", - "▁di rect", - "▁dire ct", - "▁dir ect", - "▁ direct", - "do c", - "d oc", - "а р", - "m s", - "▁g iv", - "▁gi v", - "▁ giv", - "▁e xp", - "▁ex p", - "▁ exp", - "q l", - "д у", - "в е", - "▁B e", - "▁ Be", - "Co m", - "C om", - "it er", - "ite r", - "i ter", - "R E", - "m p", - "me n", - "m en", - "▁R o", - "▁ Ro", - "M A", - "▁C ol", - "▁Co l", - "▁ Col", - "is ter", - "ist er", - "iste r", - "i ster", - "▁w ell", - "▁we ll", - "▁wel l", - "▁ well", - "▁< /", - "▁ ", - "▁ ->", - "en e", - "e ne", - "▁m on", - "▁mo n", - "▁ mon", - "▁d ec", - "▁de c", - "▁ dec", - "▁st ill", - "▁о б", - "▁ об", - "▁T r", - "▁ Tr", - "▁ ф", - "if e", - "i fe", - "is m", - "i sm", - "b y", - "ra w", - "r aw", - "io r", - "i or", - "▁m ed", - "▁me d", - "▁ med", - "or ld", - "▁com ple", - "▁comp le", - "▁compl e", - "▁ comple", - "w w", - "▁a rt", - "▁ar t", - "▁ art", - "ro n", - "r on", - "▁ Г", - "▁M y", - "▁ My", - "▁a ls", - "▁al s", - "▁ als", - "re ct", - "rec t", - "r ect", - "▁a uf", - "▁au f", - "▁ auf", - "▁d own", - "▁do wn", - "▁dow n", - "▁ down", - "at her", - "ath er", - "a ther", - "Co l", - "C ol", - "Te xt", - "Tex t", - "T ext", - "ba ck", - "b ack", - "$ ,", - "▁y ear", - "▁ye ar", - "▁ year", - "м о", - "p i", - "▁G r", - "▁ Gr", - "re am", - "rea m", - "▁re p", - "▁r ep", - "▁ rep", - "b f", - "ww w", - "w ww", - "▁w ur", - "▁o rg", - "▁or g", - "▁ org", - "in ter", - "int er", - "inte r", - "▁D ie", - "▁Di e", - "▁ Die", - "▁b eing", - "▁be ing", - "▁bei ng", - "\" .", - "la bel", - "lab el", - "l abel", - "▁c ent", - "▁ce nt", - "▁ cent", - "ja va", - "jav a", - "j ava", - "ba r", - "b ar", - "an te", - "ant e", - "an a", - "a na", - "_ _", - "▁sol ution", - "▁ О", - "▁f l", - "▁ fl", - "▁c reate", - "▁cre ate", - "▁ create", - "ic i", - "i ci", - "st e", - "s te", - "yth on", - "yt hon", - "un t", - "u nt", - "as on", - "aso n", - "a son", - "fer ence", - "fe rence", - "S E", - "▁n on", - "▁no n", - "▁ non", - "an e", - "a ne", - "▁in s", - "▁i ns", - "▁ ins", - "ad er", - "ade r", - "a der", - "_{ \\", - "_ {\\", - "Re s", - "R es", - "▁m ain", - "▁ma in", - "▁mai n", - "▁ main", - "п и", - "▁T here", - "▁The re", - "▁Th ere", - "▁Ther e", - "▁ There", - "▁p our", - "▁po ur", - "▁pou r", - "R O", - "` ,", - "li sh", - "lis h", - "l ish", - "b ject", - "cc ess", - "c cess", - "▁o rig", - "▁or ig", - "▁ orig", - "is chen", - "isch en", - "ische n", - "isc hen", - "i schen", - "ow er", - "owe r", - "o wer", - "▁h et", - "▁he t", - "▁ het", - "u c", - "▁el se", - "▁els e", - "▁ else", - "» .", - "▁о т", - "▁ от", - "eq u", + "is platin", + "▁a ct", + "per formed▁", + "ad minist", + "▁V ersion", + "wh ich", + "C linical▁", + "ug h", + "in ▁the▁", + "ing ▁to", + "▁m in", + "emother apy", + "un g", "e qu", - "si ble", - "s ible", - "te st", - "tes t", - "t est", - "st and", - "sta nd", - "stan d", - "é n", - "et s", - "e ts", - "G E", - "id ent", - "ide nt", - "iden t", - "i dent", - "▁ е", - "▁п ри", - "▁пр и", - "▁ при", - ". ,", - "▁d as", - "▁da s", - "▁ das", - "oc k", - "o ck", - ", \"", - "▁v ol", - "▁vo l", - "▁ vol", - "▁f o", - "▁ fo", - "▁p ara", - "▁par a", - "▁pa ra", - "▁ para", - "▁ Т", - "▁C ar", - "▁Ca r", - "▁ Car", - "ra l", - "r al", - "▁S p", - "▁ Sp", - "va r", - "v ar", - "▁p lay", - "▁pl ay", - "▁pla y", - "▁ play", - "ou se", - "ous e", - "o use", - "▁т а", - "▁ та", - "ic ally", - "ical ly", - "▁con tain", - "▁cont ain", - "pon se", - "▁S tring", - "▁St ring", - "▁Str ing", - "▁ String", - "á n", - "▁b oth", - "▁bo th", - "▁bot h", - "▁ both", - "ke n", - "k en", - "A R", - "ер е", - "е ре", - "▁I l", - "▁ Il", - "▁is s", - "▁i ss", - "▁ iss", - "▁o pen", - "▁op en", - "▁ open", - "▁ )", - "▁W hat", - "▁Wh at", - "▁ What", - "f e", - "riv ate", - "re g", - "r eg", - "▁with out", - "▁ without", - "▁z u", - "▁ zu", - "vi s", - "v is", - "fl ow", - "f low", - "▁h ttp", - "▁htt p", - "▁ http", - "ab ase", - "aba se", - "a base", - "▁w ord", - "▁wor d", - "▁wo rd", - "▁ word", - "▁ch ange", - "▁chang e", - "▁ change", - "▁work s", - "▁wor ks", - "▁ works", - "▁g e", - "▁ ge", - "▁ !", - "▁e en", - "▁ een", - "it le", - "▁e vent", - "▁even t", - "▁ev ent", - "▁ event", - "wo rd", - "wor d", - "w ord", - "an do", - "and o", - "S B", - "re m", - "r em", - "▁f ield", - "▁fi eld", - "▁fiel d", - "▁ field", - "vi ng", - "vin g", - "v ing", - "Se r", - "S er", - "▁o ur", - "▁ou r", - "▁ our", - "▁qu i", - "▁q ui", - "▁ qui", - "▁o per", - "▁op er", - "▁ oper", - "▁is t", - "▁i st", - "▁ ist", - "de f", - "d ef", - "▁m ade", - "▁ma de", - "▁mad e", - "▁ made", - "ни е", - "p x", - "▁m en", - "▁me n", - "▁ men", "r m", - "ai s", - "a is", - "ce nt", - "cen t", - "c ent", - "li st", - "lis t", - "l ist", - "T o", - "▁T o", - "▁ To", - "j a", - "ve rt", - "ver t", - "v ert", - "▁m ar", - "▁ma r", - "▁ mar", - "val ue", - "valu e", - "▁ „", - "\" ;", - "▁a us", - "▁au s", - "▁ aus", - "▁B r", - "▁ Br", - "ol e", - "o le", - "▁m ult", - "▁mu lt", - "▁mul t", - "▁ mult", - "oug ht", - "ough t", - "▁m at", - "▁ma t", - "▁ mat", - "▁v iew", - "▁vi ew", - "▁vie w", - "▁ view", - "fi l", - "f il", - "▁с о", - "▁ со", - "г а", - "▁v oid", - "▁vo id", - "▁ void", - "▁g ood", - "▁go od", - "▁ good", - "б о", - "C T", - "▁m any", - "▁ma ny", - "▁man y", - "▁ many", - "be n", - "b en", - "▁в о", - "▁ во", - "▁к а", - "▁ ка", - "▁s ystem", - "▁sys tem", - "▁syst em", - "▁ system", - "in o", - "i no", - "▁an other", - "▁ano ther", - "▁ another", - "▁re st", - "▁r est", - "▁res t", - "▁ rest", - "us er", - "use r", - "u ser", - "il ity", - "ili ty", - "a i", - "▁m ight", - "▁mig ht", - "us tom", - "ust om", - "usto m", - "▁or der", - "▁ord er", - "▁ order", - "▁V er", - "▁Ve r", - "▁ Ver", - "S S", - "} )", - "▁e ff", - "▁ eff", - "д о", - "et t", - "e tt", - "▁s ign", - "▁si gn", - "▁sig n", - "▁ sign", - "м у", + "▁d eath", + "em ber", + ".\n\n S", + "at ed▁to", + ") ▁", + "cre as", + "al th", + "l evel", + "m ain", + "includ ing", + "e▁t reatment", + "E vent", + "5 %", + "u res", + "m ust▁be▁", + "▁ Th", + "con d", + "up pl", + "bo platin", + "19 9", + "▁3 0", + "u id", + "et w", + "ran s", + "d os", + "all y", + "p atients▁", + "d▁e▁v▁o▁r▁p▁p▁A \n\nProduct:", + "A n", + "S C", + "▁pro gression", + "▁ evalu", + "e▁ and▁", + "pro vid", + "p rior▁to", + "ro p", + "s ign", + "us ing", + "urviv al▁", + "ro ugh", + "pons or", + "ed ▁and▁", + "ac k", + "olor ect", + "▁d i", + "▁A n", + "yst em", + "2 01", + "▁the▁ study▁", + "▁in clud", + "r al▁", + "may▁ be▁", + "▁p eri", + "ific ant", + "▁m ust▁be▁", + "00 7", + "s :", + "▁o ver", + "etw een", + "et u", + "if fer", + "▁s ampl", + "▁f actor", + "xim ab", + "pec ific", + "etu ximab", + "at e▁of", + "▁A mendment", + "r u", + "▁in fusion", + "E -", + "t ion", + "o x", + "ent er", + "ce ive▁", + "ro w", + "olog y▁", + "▁1 3", + "at iv", + "per form", + "fir m", + "is su", + ".▁ R", + "S A", + "N D", + "it amin", + "ol v", + "end point", + "efor e▁", + "el y", + ", ▁a", + "y ou", + "un til", + "re ceiv", + "formed▁ consent", + "▁16 2", + "MG ▁162", + "▁mg/m 2", + "an n", + ".▁ 200", + "ed▁ from", + "▁s it", + "en roll", + "▁c ell", + "cons ider", + "quest ion", + "\n\n 0", + "ep end", + "▁subject s▁", + "p on", + "▁y ear", + "id e▁", + "ay▁ 1", + "▁the▁s ubject", + "In vestigator", + "verse▁ Event", + "▁dos e▁of", + "in ter", + "▁com plet", + "J M", + "\n\n H", + "ag n", + "▁g roup", + "▁this▁ study", + "N A", + "d iscontinu", + "▁a p", + "it al", + "▁C om", + "▁appro ximately▁", + "ag ing", + "▁of▁1 2", + "▁p articip", + "▁A B", + "ap pro", + "ed .\n\n", + "▁d iscontinu", + "h em", + ",▁ P", + "E S", + "r andomiz", + "▁t reat", + "asel in", + "S t", + "v alu", + "\n\n \n\n", + "d ocument", + "st at", + "▁s ub", + "out com", + "in c", + "c ancer", + "c rib", + "C l", + "k n", + "y ▁and▁", + "Z D", + "▁C T", + "▁the ir", + "▁ et▁al", + "O R", + "▁in d", + "re as", + "du c", + "pl ic", + "▁t ak", + "ith er", + "il d", + "▁ if", + "e▁th at", + "3 6", + "d isease▁", + "▁m od", + "es▁ will▁be▁", + "h ase▁", + "ed \n\n", + ".▁ B", + ", \n\n", + "es s▁", + "is h", + "res ponse▁", + "ot ent", + "e b", + "r int", + "▁d o", + "EN TI", + "en os", + "▁analys is", + "n umber", + "olorect al", + "▁and /or", + "▁cont inu", + "▁P anitumumab", + "enos umab", + "- 0", + ". 8", + "\\ A", + "w o", + "es▁ in", + "ed▁ s", + "▁re ceive▁", + "coll ect", + "\n\n x", + "▁ =", + "i om", + "ro l", + "v al", + "▁ occur", + "ff icac", + "\n\n 6", + "I- 007", + "▁d ays", + "s sessment", + "▁s can", + "▁re port", + "d is", + "er um", + ".▁ M", + "▁pro vid", + "▁res ponse▁", "I T", - "st ring", - "str ing", - "s tring", - "el le", - "ell e", - "e lle", - "▁s ing", - "▁si ng", - "▁sin g", - "▁ sing", - "cu l", - "c ul", - "▁tr ying", - "▁try ing", - "▁b eg", - "▁be g", - "▁ beg", - "▁p age", - "▁pa ge", - "▁pag e", - "▁ page", - "х о", - "▁C an", - "▁Ca n", - "▁ Can", - "▁S er", - "▁Se r", - "▁ Ser", - "+ +", + "d ose▁", + "▁C ancer", + "▁the▁t im", + ") ▁and▁", + "aborator y▁", + "▁ event", + "▁P age▁", + "c ess", + "................................ ................", + "▁disease▁ progression", + "1 6", + "▁s hould▁", + "v anc", + "e▁ S", + ",▁ s", + "se qu", + "easure ment", + "l oc", + "▁th ese▁", + "ro s", + "iz ation", + "m od", + "ati st", + "- t", + "s▁ b", + ",▁ M", + "eri ous", + "\n\n 7", + "res s", + "al i", + "ed :", + "3 3", + "row th", + "G E", + "mend ed▁", + "oci ated▁", + "▁d is", + "▁re qu", + ",▁ 200", + "▁s h", + "el ect", + "▁may▁ be▁", + "sequ ent", + "e alth", + "h a", + "an y▁", + "um m", + "12 0", + "R O", + ".▁ H", + "ab el", + "ar r", + "▁m or", + "▁com bination", + ".2 .1", + "- rel", + "▁clin ical", + "m all", + "▁d rug", + "▁ up", + "s▁ will", + "it ant", + "ced ure", + "w eek", + "c in", + "▁d ur", + "el in", + "com itant", + "▁n on-", + "▁study ▁treatment", + "un ction", + "▁th rough", + "▁s urvival", + "eas ur", + "X -", "▁m ust", - "▁mus t", - "▁mu st", - "▁ must", - "▁val ues", - "▁value s", - "▁valu es", - "▁ values", - "▁k ey", - "▁ke y", - "▁ key", - "ib le", - "i ble", - "] .", - "ir d", - "i rd", - "▁pro gram", - "▁pr ogram", - "▁ program", - "roll er", - "rol ler", - "rolle r", - "▁c onne", - "▁con ne", - "▁conn e", - "▁ conne", - "▁s ay", - "▁sa y", - "▁ say", - "▁p aram", - "▁par am", - "▁para m", - "▁pa ram", - "▁ param", - "ach e", - "ac he", - "a che", - "ve lop", - "vel op", - "▁s elect", - "▁se lect", - "▁sel ect", - "▁sele ct", - "▁ select", - "▁f amil", - "▁fa mil", - "▁fam il", - "▁ famil", - "▁l ast", - "▁la st", - "▁las t", - "▁ last", - "▁Th anks", - "▁Thank s", - "▁ Thanks", - "▁p op", - "▁po p", - "▁ pop", - "} .", - "e q", - "▁does n", - "[ '", - "▁t erm", - "▁te rm", - "▁ter m", - "▁ term", - "▁r é", - "▁ ré", + "ib od", + "cur rent", + ",▁ C", + "▁h our", + "▁l oc", + "3 E-", + "med ication", + "ob serv", + "▁re l", + "1 -", + "▁( A", + "reg n", + "administ er", + "s ub", + "▁l evel", + "e▁of ▁the▁", + "1 )", + "T rial▁", + "▁m etastatic", + ". 9", + "▁R es", + "▁b lood▁", + "cre ening", + "TI ON", + "ali platin", + "▁res ult", + "n on-", + "ef it", + "▁H ▁T", + "emetrex ed▁", + "ed▁on ▁the▁", + "rade▁ 3", + "s ampl", + "ation ▁of▁", + "y t", + "ur g", + "m an", + "e cond", + ".▁A n", + "arget ▁lesion", + "n orm", + "oc et", + "revi ew", + "\n\n In", + ",▁ b", + "es▁ for", + "ow er", + "▁st at", + "ocet axel", + "s ,", + "▁1 9", + "I N", + "I ST", + "c ul", + "e .", + ".▁ N", + "c ol", + "ex t", + "duct ion", + "W h", + "ul ator", + "▁and ▁the▁", + "ron ic", + "▁act iv", + "ib il", + "▁g en", + "................................................................................ ........", + "R B", + "v ail", + "A d", + "r isk", + "it ab", + "e▁ m", + "\n\n B", + "eth od", + "m er", + "th or", + "om a", + "▁follow -up", + "▁b y▁", + "ac il", + "te in", + "▁ –", + "es▁ (", + "ject iv", + "▁O n", + "▁ch emotherapy▁", + "d ▁to", + "\n\n M", + "▁c an", + "abl e▁to", + "▁administ er", + "A B", + "con duct", + "▁wh ich", + "▁in formation", + "CR F", + "r ic", + "s et", + "▁res pons", + "s ▁after", + "og raph", + "en efit", + "olog ic", + "▁n umber", + "▁r andomization", + ".▁Th is▁", + "ced ures", + "ow ever", + "itamin ▁D", + "▁re ceiv", + "n d", + "▁ [", + "en d▁of", + "▁to ▁", + "mit t", + "g iven", + "u or", + "0 %", + "p art", + "clin ical", + "etast as", + "pri ate▁", + "u ll", + "Trial▁ Protocol", + "▁b aseline▁", + "▁S ▁A", + "clin ical▁", + "epend ent", + "u thor", + "re ast", + "ENTI AL", + "h ib", + "r ati", + "▁pl acebo", + "e▁ or", + "ur ther", + "ot ec", + "▁un til", + "▁E▁L ▁P", + "▁S▁A ▁E▁L▁P", + "b l", + "p ression", + "og en", + "eth er", + "uid elin", + "otec an", + "▁t issu", + "iv id", + "ch ang", + "▁administ ration", + "iom arker", + "▁an y", + "I V", + "▁C ▁O", + "▁N ▁E", + "op ulation", + "r y▁", + "in otecan", + "▁th is", + "pl ac", + "O X", + "R E", + "▁M ▁U", + "wh en", + "rim ary", + ".▁T ▁N▁E", + "▁C▁O ▁D", + "▁M▁U ▁C▁O▁D", + ".▁T▁N▁E ▁M▁U▁C▁O▁D", + "▁N ▁I", + "▁F ▁E", + "olorectal ▁cancer", + "▁R ▁O", + "y our", + "▁E ▁T", + "O S", + "▁P FS", + "▁S ection", + "▁I D", + "▁R ▁P", + "ce ll", + "▁F▁E ▁B", + "▁R▁O ▁F▁E▁B", + "C AE", + "w ere▁", + "II I", + "▁N▁I ▁R▁P", + "▁E▁T ▁N▁I▁R▁P", + "▁S ▁U", + "▁ther e▁", + "it ies", + "F U", "▁d ocument", - "▁doc ument", - "▁ document", - "п а", - "л у", - "at eg", - "ate g", - ". )", - "li ng", - "lin g", - "l ing", - "ion al", - "io nal", - "iona l", - "i onal", - "ab les", - "able s", - "abl es", - "a bles", - "▁t ak", - "▁ta k", - "ut ton", - "utt on", - "utto n", - "▁a rg", - "▁ar g", - "▁ arg", - "ty pe", - "typ e", - "t ype", - "▁s ure", - "▁su re", - "▁sur e", - "▁re al", - "▁ real", - "▁w eb", - "▁we b", - "▁ web", - "▁c urrent", - "▁cur rent", - "▁curr ent", - "▁ current", - "▁P l", - "▁ Pl", - "ch o", - "c ho", - "ment s", - "men ts", - "m ents", - "▁J oh", - "▁Jo h", - "ot s", - "o ts", - "▁ex ist", - "▁ exist", - "н у", - "▁f ür", - "▁ für", - "▁и з", - "▁ из", - "d o", - "но го", - "ног о", - "н ого", - "▁l as", - "▁la s", - "▁ las", - "▁n ull", - "▁nu ll", - "▁ null", - "▁in form", - "▁inf orm", - "▁info rm", - "▁ Л", - "▁v ersion", - "▁vers ion", - "▁ version", - "▁c hang", + "▁P ▁O", + ".▁E ▁S▁U", + ".\n\n The▁", + "▁L ▁A", + "▁P▁O ▁C", + "W ith", + "▁I ▁L▁A", + "▁D ▁I▁L▁A", + "▁T▁I ▁D▁I▁L▁A", + "▁T▁I▁D▁I▁L▁A ▁V", + "- s", + "im it", + "il e▁", + "▁ad vanc", + "in al▁", + ",▁ A", + "▁d es", + "▁C ▁E", + "K ▁C▁E", + "ed ▁a", + "▁A rm", + "▁H ▁C", + "▁not ▁be▁", + "K▁C▁E ▁H▁C", + "l it", + "n a", + "▁1 2", + ") (cid:", + "w as▁", + "▁the▁t reatment", + "ob tain", + "ing ▁of", + "el ig", + "pl i", + "ir st", + "pprov ed▁by", + "▁A MG▁162", + "ep ort", + "ON FI", + "- lin", + "e ight", + "▁d etermin", + "▁1 7", + "od e▁", + "D ENTIAL", + "b lind", + "l esion", + "ONFI DENTIAL", + "0 6", + "2 2", + "s ibl", + "▁ \\", + "est im", + "▁C lin", + "i um", + ",▁ H", + "el et", + "stud ies▁", + "reat in", + "▁th en", + ". 000", + "P rint", + "O G", + "um an", + "b y▁", + "r at", + ".\n\n C", + "os p", "▁ch ang", - "▁cha ng", - "ag er", - "age r", - "a ger", - "▁C omm", - "▁Com m", - "▁Co mm", - "▁ Comm", - "л і", - "us h", - "u sh", - "▁G e", - "▁ Ge", - "▁h igh", - "▁hi gh", - "▁ high", - "▁in put", - "▁ input", - "og le", - "o gle", - "ro s", - "r os", - "bo x", - "b ox", - "ge n", - "g en", - "▁s te", - "▁st e", - "▁ ste", - "▁l ocal", - "▁lo cal", - "▁loc al", - "▁ local", - "I m", - "▁pro cess", - "▁proc ess", - "▁proces s", - "▁ process", - "ter nal", - "tern al", - "t ernal", - "iz ed", - "ize d", - "i zed", - "г и", - "é t", - "▁I nd", - "▁In d", - "▁ Ind", - "▁o ch", - "▁oc h", - "▁ och", - "l t", - "▁col umn", - "▁ column", - "▁t ried", - "▁tr ied", - "▁tri ed", - "▁comm and", - "▁comma nd", - "▁ command", - "▁b est", - "▁be st", - "▁bes t", - "▁ best", - "as ter", - "ast er", - "aste r", - "a ster", - "з а", - "▁p rim", - "▁pr im", - "▁pri m", - "▁ prim", - "▁m odel", - "▁mod el", - "▁mo del", - "▁mode l", - "▁ model", - "▁ і", - "▁th ose", - "it ies", - "iti es", - "itie s", - "i ties", - "è re", - "▁р е", - "▁ ре", - "ј е", - "ш и", - "qu es", - "que s", - "q ues", - "▁A m", - "▁ Am", - "▁o wn", - "▁ow n", - "▁ own", - "li n", - "l in", - "з и", - "Val ue", - "th ing", - "t hing", - "▁ ,", - "▁T e", - "▁ Te", - "▁st ud", - "▁ stud", - "▁u m", - "▁ um", - "▁ser ver", - "▁serv er", - "▁serve r", - "▁ server", - "il le", - "ill e", - "i lle", - "▁p ut", - "▁pu t", - "▁ put", - "at iv", - "ati v", - "g y", - "ов и", - "о ви", - "ra f", - "r af", - "ов о", - "о во", - "▁wur de", - "▁W hen", - "▁Wh en", - "▁Whe n", - "▁ When", - "▁d iv", - "▁di v", - "▁ div", - "an ts", - "ant s", + "m a", + "▁combination ▁with", + "- 200", "▁t er", - "▁te r", - "▁ ter", - "▁part ic", - "▁parti c", - "▁ т", - "▁D o", - "▁ Do", - "▁N o", - "▁ No", - "se rt", - "ser t", - "s ert", - "id o", - "i do", - "math cal", - "ad e", - "a de", - "▁I I", - "▁ II", - "le ar", - "lea r", - "l ear", - "og raph", - "o graph", - "en se", - "ens e", - "▁r ow", - "▁ro w", - "▁ row", - "nu m", - "n um", - "▁pos sible", - "▁poss ible", - "▁possib le", - "▁ possible", - "▁s ince", - "▁sin ce", - "▁ since", - "▁B o", - "▁ Bo", - "ct ions", - "ction s", - "▁I m", - "▁ Im", - "O R", - "ц і", - "▁i de", - "▁id e", - "▁ ide", - "ma p", - "m ap", - "▁cor rect", - "▁corre ct", - "▁corr ect", - "▁ correct", - "ve s", - "v es", - "ph p", - "p hp", - "▁out put", - "▁ output", - "▁P h", - "▁ Ph", - "A L", - "ar ed", - "are d", - "a red", - "\\ \\", - "▁im age", - "▁imag e", - "▁ image", - "es ch", - "esc h", - "e sch", - "ж и", - "▁con f", - "▁ conf", - "po r", - "p or", - "qu ery", - "que ry", - "quer y", - "ur es", - "ure s", - "u res", - "iu m", - "i um", - "en ds", - "end s", - "▁A b", - "▁ Ab", - "SB N", - "і д", - "et her", - "eth er", - "ethe r", - "e ther", - "pt ions", - "ption s", - "it u", - "i tu", - "li b", - "l ib", - "n s", - "k i", - "▁work ing", - "▁wor king", - "▁ working", - "▁c omo", - "▁com o", - "▁co mo", - "▁ como", - "▁T hen", - "▁The n", - "▁Th en", - "▁ Then", - "M L", - "ke y", - "k ey", - "cl ass", - "cla ss", - "c lass", - "op le", - "o ple", - "itt le", - "▁m atch", - "▁mat ch", - "▁ match", - "way s", - "wa ys", - "w ays", - "math bb", - "▁re quire", - "▁requ ire", - "▁ require", - "al t", - "a lt", - "▁v is", - "▁vi s", - "▁ vis", - "▁b l", - "▁ bl", - "▁c alled", - "▁cal led", - "▁call ed", - "▁ called", - "It em", - "I tem", - "ur a", - "u ra", - "ve c", - "v ec", - "em e", - "e me", - "▁d ella", - "▁de lla", - "▁del la", - "▁dell a", - "em bre", - "emb re", - "ur g", - "u rg", - "S e", - "▁re quest", - "▁requ est", - "▁req uest", - "▁ request", - "is che", - "isch e", - "isc he", - "i sche", - "▁p ort", - "▁po rt", - "▁por t", - "▁ port", - "▁inst ead", - "= \\", - "▁ У", - "ho r", - "h or", - "en te", - "ent e", - "um e", - "u me", - "er d", - "e rd", - "с а", - "▁w hy", - "▁wh y", - "▁ why", - "ri st", - "ris t", - "r ist", - "▁p erson", - "▁per son", - "▁pers on", - "▁ person", - "▁. ..", - "▁.. .", - "▁ ...", - "▁p rivate", - "▁priv ate", - "▁ private", - "▁t ot", + "\n\nD ate▁", + "- 5", + "e an", + "e ach", + "o xic", + "y l", + "▁ radi", + "st ate▁", + ".▁ J", + "cl usion", + "stit ution", + "ac lit", + "▁200 6", + "follow -up", + "aclit axel", + "over all", + "e ch", + "\n\n 8", + "▁A mgen", + "ol ution", + "d i", + "▁n e", + "▁ effect", + "................................................................ ........", + "OL F", + "ed▁ or", + "▁b oth", + "un der", + "p anitumumab", + "w ell", + "▁d et", + "▁the▁l ast", + "g ress", + "in formation", + "▁C R", + "aborator y", + "▁c riteria", + "▁in t", + "40 54", + "sh ip", + "ur n", + "▁N ▁O", + "and ard▁", + "g roup", + "m ust", + "cept or", + "X- EGF", + "▁T ▁C", + ".▁F or", + "Clinical▁ Study▁", + "ociated▁ with", + "3E- MC-", + "L ▁Version", + "− 201", + "▁I ▁N▁O", + "▁R ▁T▁C", + "▁E▁L ▁E", + "GE L▁Version", + "▁ID :", + ".000 −", + "Print ed:", + "\n\nDate▁ Printed:", + "▁I▁N▁O ▁R▁T▁C", + "GEL▁Version ▁ID:", + "▁I▁N▁O▁R▁T▁C ▁E▁L▁E", + "\n\nA n", + "3E-MC- JM", + "pproved \n\nDate▁Printed:", + "ZD 4054", + "on itor", + ",▁ B", + "7 7", + "b y", + "s hould▁be▁", + "ed▁by ▁the▁", + "yp e▁", + "fficac y▁", + "▁O S", + "▁d ec", + "s▁of ▁the▁", + "or k", + "ter n", + "OLF OX", + "vi ew", + "▁ag ent", + "it ies▁", + "peri enc", + "____ ____", + "2 7", + "▁ •", + "▁d iseas", + "P FS", + "s▁ from", + "▁tim e▁", + "have▁ been", + "3 8", + "4 8", + "▁a pprov", + "▁a vail", + "ation al▁", + "▁200 8", + "▁pl us▁", + "\n\nS▁I ▁H▁T", + "kn own", + "2 8", + "▁a ▁c", + "es ▁and▁", + "C ons", + "m un", + "l i", + "ten sion", + "▁ K", + ".▁A ll", + "▁study▁ drug", + "▁ant ibod", + "ari abl", + "efficac y▁", + "SC LC", "▁to t", - "▁ tot", - "ph a", - "p ha", - "if t", - "i ft", - "it a", - "i ta", - "lo c", - "l oc", - "▁o ld", - "▁ol d", - "▁ old", - "о н", - "▁n el", - "▁ne l", - "▁ nel", - "' ]", - "t i", - "ie t", - "i et", - "ci te", - "cit e", - "c ite", - "ple ment", - "pl ement", - "p lement", - "▁a bove", - "▁ab ove", - "▁ above", - "k s", - "re ady", - "read y", - "rea dy", - "▁c ome", - "▁com e", - "▁co me", - "▁ come", - "se ction", - "sec tion", - "sect ion", - "s ection", - "▁P ol", - "▁Po l", - "▁ Pol", - "▁w rit", - "▁wr it", - "▁ writ", - "▁htt ps", - "▁http s", - "▁ https", - "▁$ $", - "▁ $$", - "▁ »", - "▁bu ild", - "▁ build", - "it o", - "i to", - "▁cons ider", - "▁consid er", - "af t", - "a ft", - "Ap p", - "A pp", - ", \\", - "ind ows", - "indow s", - "indo ws", - "com m", - "co mm", - "c omm", - "▁ ;", - "gr ound", - "gro und", - "g round", - "▁p lace", - "▁pl ace", - "▁pla ce", - "▁ place", - "B y", - "▁pro ject", - "▁ project", - "Ob ject", - "Obj ect", - "O bject", - "▁re pr", - "▁rep r", - "en ces", - "ence s", - "enc es", - "ind ow", - "indo w", - "z t", - "▁f iles", - "▁file s", - "▁fil es", - "▁fi les", - "▁ files", - "c z", - "iv ity", - "ivi ty", - "i vity", - "▁in it", - "▁i nit", - "▁ init", - "▁p rob", - "▁pro b", - "▁pr ob", - "▁ prob", - "▁s k", - "▁ sk", - "or th", - "ort h", - "im ent", - "ime nt", - "imen t", - "i ment", - "ou ble", - "at al", - "ata l", - "a tal", - "ir c", - "i rc", - "▁ è", - "▁b re", - "▁br e", - "▁ bre", - "is ta", - "ist a", - "i sta", - "in put", - "▁ И", - "но й", - "su m", - "s um", - "pa th", - "pat h", - "p ath", - "▁c our", - "▁co ur", - "▁cou r", - "▁t oo", - "▁to o", - "▁A d", - "▁ Ad", - "▁G u", - "▁ Gu", - "▁f alse", - "▁fal se", - "▁ false", - "▁f un", - "▁fu n", - "▁ fun", - "▁с т", - "▁ ст", - "oo d", - "o od", - "è s", - "▁e nc", - "▁en c", - "▁ enc", - "bo l", - "b ol", - "r l", - "ar get", - "arg et", - "or der", - "ord er", - "orde r", - "▁me an", - "▁ mean", - "п е", - "ig en", - "ige n", - "i gen", - "▁п ре", - "▁пр е", - "▁ пре", - "wid th", - "w idth", - "; \r", - "it or", - "ito r", - "i tor", - "▁st ate", - "▁stat e", - "▁sta te", - "▁ state", - "▁gre at", - "en n", - "e nn", - "bi n", - "b in", - "E r", - "Mo d", - "M od", - "o z", - "▁w on", - "▁wo n", - "▁ won", - "▁f act", - "▁fa ct", - "▁fac t", - "▁ fact", - "▁j ava", - "▁ja va", - "▁jav a", - "▁ java", - "▁Un ivers", - "▁ Univers", - "▁c ap", - "▁ca p", - "▁ cap", - "is tor", - "ist or", - "isto r", - "i stor", - "} (", - "k u", - "it her", - "ith er", - "i ther", - "al es", - "ale s", - "a les", - "▁o u", - "▁ ou", - "ro ss", - "ros s", - "r oss", - "▁t ake", - "▁tak e", - "▁ta ke", - "▁ take", - "ri x", - "r ix", - "lo b", - "l ob", - "▁e ine", - "▁ein e", - "as es", - "ase s", - "▁a ccess", - "▁acc ess", - "▁ac cess", - "▁ access", - "it é", - "i té", - "is tr", - "ist r", - "i str", - "iz ation", - "iza tion", - "▁app ro", - "▁ap pro", - "▁ appro", - "ba ll", - "bal l", - "b all", - "▁m ak", - "▁ma k", - "} ^", - "▁C ons", - "▁Con s", - "▁Co ns", - "▁ Cons", - "pr ess", - "pre ss", - "pres s", - "p ress", - "se rv", - "ser v", - "s erv", - "() .", - "( ).", - "a f", - "▁re f", - "▁r ef", - "▁ ref", - ") \\", - "▁cont in", - "s u", + "qu al", + "pr il", + "▁s u", + "pare d▁", + "▁ Y", + ".▁ I", + "\n\nC onfidential", + "( s)", + "as sessment", + "it iv", + "ra m", + "\n\nA pproved\n\nDate▁Printed:", + "▁med ication", + "erious ▁adverse▁event", + "e ing", + "it e▁", + "s▁s hould▁be▁", + "▁d iffer", + "▁with in", + "ard i", + "vent ion", + "re present", + "▁P ro", + "▁S ub", + "ec k", + "str u", + ".▁P atients▁", + "0 3", + "F A", + "f re", + "st art", + "▁b evacizumab", + "▁n ew", + "/ L", + "▁A pril", + "▁in creas", + "▁D rug", + "▁Date: ▁0", + "g o", + "j ust", + "▁this▁ study▁", + "med i", + "▁Panitumumab ▁Protocol▁Number:▁200", + ",▁ G", + "EN T", + "s▁ on", + "ject ive▁", + "ir inotecan", + "af f", + "ic ian", + "▁E dition", + "e et", + "\n\n d▁e▁v▁o▁r▁p▁p▁A\n\nProduct:", + "(cid: 120", + "ibl e▁for", + "m is", + "▁in vestigational▁product", + "EC IST", + "▁ab out", + "v isit", + "▁A E", + "vers us▁", + "pt ion", + "▁has▁ been", + "▁l ung", + "c ri", + "\n\n L", + ",▁ et▁al", + "cin oma", + "▁c ount", + "des ign", + "\n\nF ▁O", + "ed▁ c", + "▁ch emotherapy", + "▁F eb", + "▁x ▁x", + "t reatment", + "ing ▁a", "iv er", - "ive r", - "i ver", - "▁c ond", - "▁con d", - "▁co nd", - "▁ cond", - "▁ex pect", - "▁exp ect", - "▁ expect", - "▁char act", - "▁cha ract", - "ber t", - "be rt", - "b ert", - "el t", - "e lt", - "ter s", - "te rs", - "t ers", - "scri pt", - "scr ipt", - "s cript", - "▁E d", - "▁ Ed", - "ap t", - "a pt", - "') ;", - "' );", - "pr int", - "▁s ize", - "▁si ze", - "▁ size", - "▁s ich", - "▁si ch", - "▁sic h", - "fa ce", - "fac e", - "f ace", - "en den", - "end en", - "ende n", - "▁A mer", - "▁Am er", - "▁ Amer", - "if ied", - "ifi ed", - "ifie d", - "ó w", - "▁S u", - "▁ Su", - "te s", - "t es", - "me d", - "m ed", - "▁R eg", - "▁Re g", - "▁ Reg", - "so le", - "sol e", - "s ole", - "▁in clud", - "▁incl ud", - "▁inclu d", - "▁ includ", - "in i", - "i ni", - "in ci", - "inc i", - "▁p la", - "▁pl a", - "▁ pla", - "▁l eft", - "▁le ft", - "▁ left", - "d f", - "Pa r", - "P ar", - "▁A ll", - "▁Al l", - "▁ All", - "▁o cc", - "▁oc c", - "▁ occ", - "▁A t", - "▁ At", - "▁c r", - "▁ cr", - "Q u", - "▁g iven", - "▁giv en", - "▁give n", - "▁gi ven", - "▁S ystem", - "▁Syst em", - "▁ System", - "ic an", - "ica n", - "i can", - "▁f inal", - "▁fin al", - "▁fi nal", - "▁ final", - "it ions", - "ition s", - "iti ons", - "▁б ы", - "▁ бы", + "▁as sess", + "h as▁", + "i o", + "s ▁and", + "\n\n (", + "res earch", + "▁wh o", + "▁min ut", + "▁b aselin", + "op h", + "▁ant i-", + "ar e▁", + "▁all ow", + "op en", + ".1 .1", + "dur ing▁the▁", + "e a", + "om en", + "▁S t", + "- m", + "not ▁be▁", + "▁also ▁be▁", + ",▁ D", + "us ed▁to", + "our acil", + "ist or", + "Clinical▁Study▁ Protocol", + "d etermin", + "▁t rans", + "▁p revi", + "▁ap plic", + "uor ouracil", + "▁re view", + "su ch", + "regn anc", + "s▁ at", + "▁p art", + "▁b y", + "l ong", + "m Cl", + "ire ct", + "easur able▁", + "▁ every▁", + ".2 .2", + "with in", + "ident ifi", + "\n\nY ▁P▁O▁C", + "▁accord ing▁to", + "C om", + "or in", + "ing l", + "\n\n 5", + "▁a ▁m", + "des crib", + "C on", + "J ul", + "m ad", + "ec ess", + "4 5", + "c ount", + "▁com par", + "4 7", + "▁pro tocol", + "ection :", + "\n\nX\n\nX \n\nX\n\nX", + "\n\n G", + "\n\n s", + "▁1 4", + "▁n o", "▁per form", - "▁perf orm", - "▁ perform", - "A N", - "▁M e", - "▁ Me", - "ur o", - "u ro", - "▁T hat", - "▁Th at", - "▁ That", - "г ра", - "▁П о", - "▁ По", - "▁в и", - "▁ ви", - "ab ly", - "abl y", - "▁pr esent", - "▁pre sent", - "▁pres ent", - "▁ present", - "du ct", - "d uct", - "ri c", - "r ic", - "▁E ng", - "▁En g", - "▁ Eng", - "tr y", - "t ry", - "▁l ar", - "▁la r", - "▁ lar", - "b l", - "id d", - "i dd", - "▁ä r", - "▁ är", - "or a", - "o ra", - "L L", - "os s", - "o ss", - "▁I SBN", - "▁ ISBN", - "▁th ree", - "▁thr ee", - "▁thre e", - "▁ three", - "j o", - "n í", - "r c", - "▁f ar", - "▁fa r", - "▁ far", - "▁N ot", - "▁No t", - "▁ Not", - "▁l ittle", - "▁litt le", - "di s", - "d is", - "at i", - "a ti", - "fun ction", - "func tion", - "f unction", - "▁a ble", - "▁ab le", - "▁ able", - "le ss", - "les s", - "l ess", - "с о", - "▁p ath", - "▁pat h", - "▁pa th", - "▁ path", - "▁p res", - "▁pr es", - "▁pre s", - "▁ pres", - "lo se", - "los e", - "l ose", - "P I", - "▁iss ue", - "▁issu e", - "▁ issue", - "ack age", - "ti me", - "tim e", - "t ime", - "ig e", - "i ge", - "am s", - "a ms", - "▁C l", - "▁ Cl", - "ail s", - "ai ls", - "a ils", - "al k", - "i i", - "ш е", - "pe n", - "p en", - "Q L", - "▁e as", - "R L", - "ce l", - "c el", - "▁s l", - "▁ sl", - "▁a sk", - "▁as k", - "▁ ask", - "▁n om", - "▁no m", - "▁ nom", - "▁t op", - "▁to p", - "▁ top", - "id es", - "ide s", - "i des", - "in dex", - "ind ex", - "inde x", - "é m", - "▁h app", - "▁ha pp", - "o x", - "c d", - "▁b etter", - "▁bet ter", - "▁lo ad", - "▁ load", - "ad os", - "ado s", - "ze n", - "z en", - "▁c e", - "▁ ce", - "▁f a", - "▁ fa", - "▁J ohn", - "▁Joh n", - "▁Jo hn", - "▁ John", - "IM A", - "I MA", - "▁B ar", - "▁Ba r", - "▁ Bar", - "over flow", - "▁д е", - "▁ де", - "ne ss", - "nes s", - "n ess", - "ce r", + "d ay▁", + "er g", + "com mend", + ")\n\n GEL▁Version▁ID:", + "▁at ▁least", + "M D", + "l er", + "▁m L", + "▁A ppendix", + "pl acebo", + "em at", + "▁D ay▁1", + "▁f irst", + "R es", + "pro v", + "uc ov", + "- M", + "▁ ver", + "▁r andomiz", + "▁F orm", + "ucov orin", + "U n", "c er", - "▁H ere", - "▁He re", - "▁Her e", - "▁ Here", - "re t", - "r et", - "▁s z", - "▁ sz", - "amb da", - "op y", - "o py", - "ur l", - "u rl", - "p y", - "r t", - "▁under stand", - "a ł", - "he r", - "h er", - "# #", - "▁ch ild", - "▁chi ld", - "��� child", - "▁ex ec", - "▁ exec", - "▁app lication", - "▁applic ation", - "▁ application", - "▁st ruct", - "▁str uct", - "▁stru ct", - "▁ struct", - "▁ я", - "Fil e", - "Fi le", - "F ile", - "▁c ert", - "▁ce rt", - "▁cer t", - "▁ cert", - "is on", - "iso n", - "i son", - "▁vari able", - "▁ variable", - "D E", - "r s", - "▁re ally", - "▁real ly", - "Po rt", - "P ort", - "b a", - "▁B er", - "▁Be r", - "▁ Ber", - "▁in te", - "▁int e", - "▁ inte", - "▁st atic", - "▁stat ic", - "▁stati c", - "▁ static", - "▁con fig", - "▁conf ig", - "▁ config", - "▁S he", - "▁Sh e", - "▁ She", - "est ions", - "estion s", - "esti ons", - "▁p lus", - "▁pl us", - "▁ plus", - "▁h ab", - "▁ha b", - "▁ hab", - "op e", - "o pe", - "▁m us", - "▁mu s", - "▁ mus", - "▁c ount", - "▁co unt", - "▁coun t", - "▁cou nt", - "▁ count", - "M E", - "▁su pport", - "▁supp ort", - "▁sup port", - "▁ support", - "▁pe ople", - "▁ people", - "▁b eh", - "▁be h", - "▁al ready", - "T r", - "▁d one", - "▁do ne", - "▁don e", - "▁ done", - "de m", - "d em", - "si ze", - "s ize", - "al pha", - "alph a", - "▁d isc", - "▁di sc", - "▁dis c", - "] )", - "▁M an", - "▁Ma n", - "▁ Man", - "▁m il", - "▁mi l", - "▁ mil", - "▁st and", - "▁sta nd", - "▁stan d", - "▁ stand", - "▁gr oup", - "▁gro up", - "▁ group", - "▁sm all", - "▁ small", - "▁m ag", - "▁ma g", - "▁ mag", - "ст ь", - "с ть", - "▁de fault", - "▁def ault", - "▁ default", - "▁sing le", - "▁sin gle", - "▁ single", - "lin k", - "l ink", - "cl ude", - "clud e", - "▁e ar", - "▁ ear", - "il ar", - "ila r", - "i lar", - "** **", - "*** *", - "* ***", - "▁f ix", - "▁fi x", - "▁ fix", - "le y", - "l ey", - "▁p as", - "▁pa s", - "▁ pas", - "ни й", - "iss ion", - "▁im plement", - "▁imp lement", - "▁impl ement", - "it ch", - "▁го да", - "▁год а", - "▁al ways", - "▁ always", - "▁J ah", - "▁Ja h", - "pr ing", - "p ring", - "ç ão", - "pl ate", - "pla te", - "p late", - "▁de scri", - "▁des cri", - "▁desc ri", - "▁h ead", - "▁he ad", - "▁ head", - "in it", - "ini t", - "i nit", - "og raf", - "▁qu ery", - "▁que ry", - "▁quer y", - "▁ query", - "iv ed", - "ive d", - "i ved", - "▁in g", - "▁i ng", - "▁ ing", - "pt y", - "p ty", - "h a", - "▁m ov", - "▁mo v", - "▁ mov", - "▁ э", - "et te", - "ett e", - "e tte", - "il y", - "i ly", - "▁g ot", - "▁go t", - "▁ got", - "il ed", - "ile d", - "i led", - "ic ro", - "i cro", - "▁w r", - "▁ wr", - "р я", - "▁n ever", - "▁ne ver", - "▁nev er", - "or es", - "ore s", - "o res", - "▁b as", - "▁ba s", - "▁ bas", - "io s", - "i os", - "la ck", - "lac k", - "l ack", - "ain t", - "ai nt", - "a int", - "vi ous", - "v ious", - "▁g ive", - "▁giv e", - "▁gi ve", - "id ad", - "ida d", - "E n", - "ны й", - "н ый", - "ta ble", - "tab le", - "t able", - "▁Н а", - "▁ На", - "▁p at", - "▁pa t", - "▁ pat", - "то р", - "т ор", - "an gu", - "ang u", - "lo y", - "l oy", - "▁s eg", - "▁se g", - "▁ seg", - "ar ray", - "arr ay", - "▁F l", - "▁ Fl", - "▁in dex", - "▁ind ex", - "▁inde x", - "▁ index", - "▁s w", - "▁ sw", - "IMA GE", - "IM AGE", - "▁k m", - "▁ km", - "б и", - "Cl ass", - "Cla ss", - "C lass", - "en a", - "e na", - "ме н", - "м ен", - "com p", - "co mp", - "c omp", - "at us", - "atu s", - "ra p", - "r ap", - "▁L ist", - "▁Li st", - "▁Lis t", - "▁ List", - "Er ror", - "Err or", - "E rror", - "▁t yp", - "▁ty p", - "▁ typ", - "▁м а", - "▁ ма", - "c s", - "' :", - "j i", - "▁How ever", - "▁ However", - "▁т е", - "▁ те", - "▁be low", - "▁bel ow", - "▁ below", - "▁A pp", - "▁Ap p", - "▁ App", - "щ е", - "} _", - "bu m", - "b um", - "vi r", - "v ir", - "ée s", - "é es", + "d end", + "an ib", + "afet y", + "alysis▁ S", + "dend um", + "4 3", + "v olv", + ",▁ L", + "▁d evelop", + "ir anib", + "c ular", + "r andomization", + "stud ies", + "\n\nA ppendix", + "umm ar", + "s ,▁and▁", + "▁the▁ first", + "▁b e\n\n", + "▁the▁s am", + "rel ated▁to", + "an alysis▁", + "em ia", + "am eter", + "s▁ prior▁to", + ",▁ p", + "▁c etuximab", + "▁h y", + "I C", + "f ract", + "▁peri od", + "\n\n K▁C▁E▁H▁C", + "▁c al", + "ev i", + "reatin ine▁", + "C ancer", + "d ic", + "e▁ will", + "▁2 4", + "if y", + "ub l", + "econd ary▁", + "Y 23", + "▁s ever", + "▁un der", + "15 14", + "bas ed▁on", + "ind ic", + "Y23 1514", + "g rowth", + "as h", + "uppl ement", + "2 1", + "8 4", + "C ode▁", + "▁c oll", + "▁D ec", + "▁Edition ▁Number", + "d iseas", + "▁ +", + "▁c olorectal▁cancer", + "ract ic", + "P A", + "U M", + "- 3", + "▁2 01", + "▁ass ociated▁with", + "▁ph as", + "l abel", + "reg imen", + "itab ine▁", + "ivid ual", + "I RB", + "v is", + "▁the▁ event", + "iz ed▁", + "o h", + "e▁ a", + "c isplatin", + "f ic", + "▁p .▁", + "as sess", + "enc e▁in", + "-rel ated▁", + "▁I V", + "ous ly▁", + "mCl one▁", + "alysis▁S et", + "c aus", + "ol ic", + "▁toxic ity▁", + "p articip", + "▁ Q", + "▁t wo", + "ev id", + "ance▁ with", + "CT -", + "▁ass ign", + "sign ificant", + "ing ▁and▁", + "mit te", + "▁for ▁the▁", + "D MC", + "▁p os", + "he a", + "require d▁", + ") ▁(", + ".▁ O", + "ed ▁that", + "em on", + "▁On col", + "ubject s▁", + "receiv ing", + "norm al", + "B C", + "k g", + "v en", + "er v", + "al y", + "st ra", + "osp ital", + "1 12", + "ys ician", + "▁ KRAS", + "at e", + "▁c linical▁", + "up port", + "car boplatin", + ") ▁will▁be▁", + "6 18", + "y n", + "\n\n O", + "▁b etween", + "▁I MC-", + "af ter", + "question na", + "b ra", + "s .▁The▁", + "▁C h", + "\n\nE ▁R▁O▁F▁E▁B", + "▁p ain", + "ation ▁of▁the▁", + "FI RI", + "OL FIRI", + "U S", + "ate▁ the▁", + "▁analysis▁ of", + "▁17 :", + "ex pect", + "): ▁p.▁", + "▁requ ire", + "/ m", + "os ph", + "ycl e▁", + "e▁S ection", + "T A", + "i ent", + "\n\n 9", + "study ▁treatment", + "ary▁ 200", + "▁Sub st", + "ing ▁s", + "abil ity", + "▁lung ▁cancer", + "- S", + "s .", + "t t", + "x aliplatin", + "▁A \n\nF▁O", + "ch emotherapy▁", + "▁re ceptor", + "▁Ad verse▁Event", + "emon str", + "y▁ or", + "▁S AE", + "rati o", + "V ersion", + "▁m m", + "is▁ not", + "ec a", + ") ▁Clinical▁", + "▁b one▁", + "o ber", + "u al▁", + "▁res earch", + "Z en", + "▁of ▁a", + "um our", + ".\n\n T", + "▁1 5", + "▁con firm", + "\n\nD ▁E▁T▁N▁I▁R▁P", + "▁Drug ▁Subst", + "stra Zen", + "straZen eca", + "S AE", + "ou g", + "▁with draw", + "\n\nS ▁T▁I", + "pec ifi", + "▁the▁ b", + ",▁ in", + "▁h ealth", + "cent ration", + ")▁Clinical▁ Protocol", + "at ▁least", + "▁c l", + "▁s urvival▁", + "▁O F", + "\n\nC linical▁", + "amin ation", + "▁Study▁ Code▁", + "e ither", + "▁ag re", + "n ew", + "ct ober", + "pl an", + "per son", + "\n\nS tudy▁", + "andom is", + "(cid:120 )", + "F 8", + "d ing", + "i qu", + "th es", + "▁P h", + "pprov ed▁", + "rit ten", + "8 6", + "▁b as", + "el ow", + "▁A 618", + "ter im", + "1 ,▁", + "I G", + "r al", + "u rop", + "▁ <", + "▁the▁ c", + "as cular", + "eg ,▁", + "f i", + "es s▁of", + "r of", + "ed iranib", + "im aging", + "▁h av", + "pect iv", + "r y", + "is m", + "▁T reatment", + "\n\nY ▁T▁I▁D▁I▁L▁A▁V", + "▁m easurement", + "3 5", + "at t", + "▁the▁ end▁of", + "es▁ not", + "11 F8", + "state▁ cancer", + "▁a uthor", + "▁1 8", + "ch emotherapy", + "aly z", + "H R", + "a d▁", + "st or", + "▁in ▁combination▁with", + "act er", + "\n\nAd d▁", + "z ard▁", + "at es", + "\n\n the▁", + "▁and▁ s", + "▁O ctober", + "riteria ▁for", + "r ate▁", + "ar acter", + "om e▁", + "\n\nC ▁I▁N▁O▁R▁T▁C▁E▁L▁E", + "xim um", + "9 01", + "p ens", + "er al▁", + "on ly▁", + "us ing▁the▁", + "con firm", + "▁l ong", + "\n\nE ▁S▁A▁E▁L▁P", + "kin etic", + "▁ob serv", + "arr hea", + ") ▁or", + "ci um", + "armac o", + "t urn", + ",▁ R", + "▁s p", + "▁s afety▁", + "▁w ere▁", + "pl orator", + "olog y", + "9 9", + "L LC", + "e 18", + "▁2 0", + "ex cept", + "du e▁to", + "On :", + "pproved \\A", + "fl uorouracil", + "▁over all", + "▁AB I-007", + "\\A pproved\\A", + "77 e18", + "oug h", + "pproved▁ On:", + "901 77e18", + "\\Approved\\A pproved▁On:", + "8 1", + "ag e:", + "other apy▁", + "▁ph ase▁", + "mer ic", + "m ost", + "▁c as", + "eri ous▁", + "▁5 -", + "▁ac id▁", + "armaco kinetic", + "al ▁of", + "ep h", + "▁subject s▁with", + "▁sign ificant", + ".,▁ et▁al", + "▁reg imen", + "re fer", + "ug ust", + "▁is▁ not", + "H O", + "per t", + "med ian", + "b lood▁", + "er al", + "y▁ s", + "an alys", + "▁c or", + "▁s ymptom", + "\n\nP rotocol", + "dur ing", + "mClone▁ LLC", + ", ▁as▁", + "T reatment", + "reast ▁cancer", + "ur pos", + "ys ical▁", + "pres s", + "EGF R", + "On c", + "................................................ ........", + "▁d ocetaxel", + "▁A ND", + "ens itiv", + "EC OG", + "inc ip", + "growth ▁factor", + "1 00", + "l ast", + "▁th es", + "ob jectiv", + "................................................................................................ ........", + "▁advanc ed▁", + "Clinical▁Study▁Protocol ▁Drug▁Subst", + "f ection", + "ic s▁", + "ol on", + "study▁ drug", + "respons ible▁for", + "▁Study▁Code▁ D", + ") ;", + "l ess", + "it ive▁", + "cal cul", + "otent ial", + "\n\nx \n\nx", + "E x", + ",▁ W", + "ut il", + "ist ing", + "cont act", + "\n\n1 3", + "▁wh en", + ",▁ which", + "▁p rior▁to", + "▁to ler", + "ate▁ th", + "e .▁", + "r ation▁of", + "es ▁to", + "▁s erum", + "▁A ugust", + "op p", + "ed▁to ▁be▁", + "▁med ical▁", + "stru ction", + "cl ear", + "▁mg/ kg", + "efin ition", + "- bas", + ": \n\n", + "at eri", + ".\n\n 6", + "▁E GF", + "5- FU", + "R ECIST", + "▁with out", + "\n\n1 0", + "gress ive▁", + "p rimary▁", + "it i", + "\n\nS ection:", + "\n\nS▁I \n\nS▁I▁H▁T", + "ild -t", + "d ependent", + "p e", + "e▁ from", + "ur ing", + "▁con tain", + "▁Clin ▁Oncol", + "2 6", + "▁C A", + ".▁A d", + "po thes", + "stit ut", + "Cons ent", + "2 )", + "C 00", + "P ro", + "S I", + "p rior", + "▁the▁ following", + "▁p emetrex", + "res pon", + "▁P D", + "us ed▁for", + "anc e▁of", + "7 0", + ",▁ if", + "cont ain", + "lo od", + "en ia", + "re duction", + "▁an ▁", + "ing ▁", + "at ure", + ".▁ L", + "ar b", + "▁p rior", + "▁or ▁", + "▁con dition", + "bo v", + "defin ed▁as", + "nd point", + ".,▁et▁al .,▁", + "▁p res", + "▁s ystem", + "▁C on", + "iz er", + "▁O NC", + "e▁to ▁be▁", + "▁tim e▁to", + "▁ONC .000−", + "re d", + "▁s unitinib", + "e▁s ubject", + "▁G rade▁", + "report ▁form", + "▁cons ent", + "▁peri od▁", + "▁ter m", + "with draw", + "evalu ation", + "▁mod el", + "2 9", + "\n\n t", + "ct or", + "\n\nA mended▁", + ".3 .1", + "▁week s▁", + "e /", + "e plac", + "er ▁than", + "as on", + "▁the y▁", + "h er", + "▁1 ▁1", + "es▁ or", + "ec aus", + "rel ation", + "agn os", + "5 01", + "P D", + "s ummar", + "it ial", + "▁patients▁ who", + "po st", + "cre tion", + "▁Th er", + "▁AB X-EGF", + "R P", + "m or", + "re commend", + "y▁ (", + ",▁ T", + "us e▁of", + "▁ac cept", + "▁the▁d ate▁of", + "hy d", + "-5 D", + "2 -", + "5 )", + "of f", + "ed▁ (", + "▁p ar", + "▁P atients▁", + "our c", + "bra x", + "Q -5D", + "ed ▁treatment", + "▁b enefit", + "▁1 1", + "oul d", + "cent ral▁", + "▁appro priate▁", + "urg er", + "A N", + "S ci", + "f izer", + "▁a cid", + "▁c aus", + "▁C P", + "il ar", + "▁2 1", + "\n\n0 90177e18", + "4 6", + "a w", + "i ev", + "\n\n th", + "em b", + "▁2 7", + "ut rop", + "ph osph", + "oun d", + "ech n", + "\n\n .▁T▁N▁E▁M▁U▁C▁O▁D", + ",▁ K", + "im um", + "▁h uman", + "e▁th an", + "▁e ither", + "mon itor", + "reas on", + "- C", + "b evacizumab", + "d o", + "e▁ f", + "ur rent", + "cl os", + "▁st art", + "loc k", + "onitor ing", + "Y ou", + "i er", + "m easure", + "ation al", "▁re cord", - "▁rec ord", - "▁ record", - "ta in", - "t ain", - "le m", - "l em", - "it al", - "ita l", - "i tal", - "▁i mp", - "▁im p", - "▁ imp", - "eg o", - "e go", - "▁o d", - "▁ od", - "▁re ce", - "▁rec e", - "▁ rece", - "mi t", - "m it", + "ject ion", + "at ed▁in", + "el ay", + "fficacy▁ An", + "▁April ▁2008", + "4 01", + "E D", + "h av", + "em c", + "pare d▁to", + "▁d at", + ".\n\n E", + "▁f ail", + "av ail", + "fident ial▁", + "▁August ▁2007", + "l aboratory", + ",▁ 199", + "con d▁", + "▁N o", + "▁3 ▁D", + "Trial▁Protocol :", + "▁Edition▁Number ▁3▁D", + "Clinical▁Study▁Protocol▁Drug▁Subst ance▁", + "- fre", + "o int", + "− Jul", + "▁ :", + "▁th ose▁", + "is ▁a", + "−201 4", + "▁Panitumumab▁Protocol▁Number:▁200 50", + "▁Feb ru", + "−Jul −2014", + "o id", + "is ed▁", + "reg ard", + "reg ulator", + "formed▁ Consent", + "▁ant ic", + "▁it s▁", + "enroll ment", + "A TION", + "\n\n in", + "▁m etastas", + "cid ence▁of", + "ens or", + "vestigation al▁", + "abil ity▁", + "c ycl", + "− 6", + ".▁ 1", + "incip al▁", + ") .", + "e .▁The▁", + "n ess", + "w eight", + "\n\n m", + "Th is▁", + "c over", + "l imit", + ",▁ d", + ".\n\n 5", + "im ilar", + "▁f urther", + "\n\nA ll", + "▁X ▁X", + "A mgen", + "b eing", + "▁a m", + "▁h igh", + "ver all", + "▁n orm", + "▁M ed", + "io Sci", + "M ENT", + "l aboratory▁", + "v ant", + ".▁ G", + "ag ement", + "iz e▁", + "A ssessment", + "L Y231514", + "U C", + "▁m eet", + "▁A ssessment", + "▁1 00", + "ap ec", + "▁pro cedure", + "ak en", + "▁toxic ity", + "▁of▁12 6", + "w er", + "ase▁ report▁form", + "▁patient s", + "occur r", + "hem at", + "▁days ▁after", + "eplac e:", + "al ate▁", + "et t", + "op s", + "s▁in ▁the▁", + "▁treat ed▁with", + "▁b iomarker", + ".\n\n D", + "▁dur ing▁the▁", + "ol ed", + "▁re action", + "▁as ▁a", + "ult i", + "eg in", + "▁have▁ been", + "MC L", + "pos sibl", "ff ic", - "f fic", - "stack overflow", - "ie ve", - "iev e", - "▁ З", - "▁n ov", - "▁no v", - "▁ nov", - "ц е", - "▁In tern", - "▁Int ern", - "▁Inter n", - "▁ Intern", - "b u", - "▁s ugg", - "▁su gg", - "▁sug g", - "▁l oop", - "▁lo op", - "▁ loop", - "ri de", - "rid e", - "r ide", - "▁$ (", - "▁ $(", - "▁s uper", - "▁su per", - "▁sup er", - "▁ super", - "ri d", - "r id", - "ны х", - "н ых", - "▁P er", - "▁Pe r", - "▁ Per", - "▁d om", - "▁do m", - "▁ dom", - "= '", - "ut sch", - "uts ch", - "le n", - "l en", - "▁w rite", - "▁writ e", - "▁wr ite", - "▁ write", - "▁in v", - "▁ inv", - "ou th", - "out h", - "o uth", - "▁H er", - "▁He r", - "▁ Her", - "▁y ears", - "▁year s", - "▁ye ars", - "▁or iginal", - "▁orig inal", - "▁origin al", - "▁ original", - "eg a", - "e ga", - "▁S te", - "▁St e", - "▁ Ste", - "▁se ems", - "▁see ms", - "▁seem s", - "é g", - "▁n ext", - "▁ne xt", - "▁ next", - "ed er", - "ede r", - "e der", - "▁N e", - "▁ Ne", - "av as", - "ava s", - "a vas", - "ific ation", - "ifi cation", - "ifica tion", - "Ex ception", - "▁D er", - "▁De r", - "▁ Der", - "▁v e", - "▁ ve", - "at ic", - "ati c", - "ha t", - "h at", - "br ary", - "bra ry", - "re turn", - "ret urn", - "ur ch", + "▁tot al", + "represent ativ", + "plorator y▁", + "b )", + "r ac", + "at ure▁", + "an u", + "pro duct", + "▁l ast", + "ate▁ in", + "ost ic", + "FA CT-", + "R S", + ",▁ F", + "et in", + "ev ant", + "ed▁in ▁Section", + "ide▁ effect", + "4 2", + "P R", + "▁a mendment", + "el f", + "▁con centration", + "port ant", + "ateri al", + "e▁ with", + "\n\n a", + "ra ven", + "number ▁of", + "▁201 0", + "L N", + "\n\n .▁E▁S▁U", + "▁w ould▁", + "▁treatment ▁group", + "ed▁to ▁the▁", + "pared▁ with", + "C00 01", + "l if", + "or ig", + "s▁ must▁be▁", + ".\n\n In", + "▁I MCL", + "hib itor", + "( f", + "F or", + "e y", + "▁P hase▁", + "olog ical", + "CR C", + "s mall", + "u e▁to", + "ation ,▁", + "▁( se", + "- label", + "s ymptom", + "▁ ens", + "▁d enosumab", + "ad verse▁event", + "ance▁ stat", + "vestigation al", + "▁ob tain", + "▁sub sequent", + "comitant ▁medication", + "c us", + "p or", + "ol um", + "ific ance▁", + "ser um", + "▁car cinoma", + "▁the▁tim e▁of", + "ype▁ KRAS", + "zard▁ ratio", + "▁IMCL ▁CP", + "▁ e▁", + "re action", + "al ign", + "▁with ▁the▁", + "meric an", + "utrop enia", + "as k", + "▁2 8", + "▁com pl", + "▁dose▁ level", + ".▁H owever", + "oled ronic", + "3 )", + "s s", + "re m", + "ing ,▁", + "▁are▁ not", + "eth od▁", + "▁have▁ a", + "▁evalu ation", + "e ;", + "l ess▁", + "▁C riteria", + "▁( C", + "ir e▁", + "qu am", + "g an", + "g est", + "n el", + "▁ er", + "▁R eport", + ".▁In ▁addition", + "e e▁", + "g l", + "n ecess", + "on ly", + "is on", "is ion", - "isi on", - "m i", - "oi nt", - "oin t", - "o int", - "▁d ay", - "▁da y", - "▁ day", - "ic tion", - "ict ion", - "i ction", - "á l", - "▁é s", - "▁ és", - "▁th ough", - "▁thou gh", - "▁ though", - "ac tion", - "act ion", - "a ction", - "í t", - "un gen", - "ung en", - "unge n", - "ou rs", - "our s", - "o urs", - "▁s cript", - "▁scr ipt", - "▁scri pt", - "▁ script", - "▁in formation", - "▁inform ation", - "▁ information", - "▁mult i", - "▁mul ti", - "▁ multi", - "▁\\ \\", - "▁ \\\\", - "st er", - "ste r", - "s ter", - "к е", - "A C", - "ci es", - "cie s", - "c ies", - "▁dis play", - "▁disp lay", - "▁ display", - "om an", - "oma n", - "o man", - "Tim e", - "T ime", - "iu s", - "i us", - ")) ;", - ") );", - "tr e", - "t re", - "▁l im", - "▁li m", - "▁ lim", - "at ely", - "ate ly", - "atel y", - "é d", - "is te", - "ist e", - "i ste", - "▁с а", - "▁ са", - "pos t", - "po st", - "p ost", - "ue l", - "u el", - "im g", - "▁ ч", - "ск а", - "с ка", - "el d", - "e ld", - "pp er", - "ppe r", - "p per", - "ul a", - "u la", - "▁gener al", - "▁gen eral", - "▁gene ral", - "▁ general", - "A l", - "For m", - "F orm", - "▁u pon", - "▁up on", - "z o", - "am ente", - "ament e", - "amen te", - "a mente", - "▁p rom", - "▁pro m", - "▁pr om", - "▁ prom", - "▁ ü", - "le x", - "l ex", - "▁t urn", - "▁tu rn", - "▁tur n", - "▁ turn", - "▁м е", - "▁ ме", - "en tion", - "ent ion", - "enti on", - "ле н", - "л ен", - "▁a f", - "▁ af", - "ic le", - "i cle", - "ст в", - "с тв", - "▁F il", - "▁ Fil", - "▁ Ф", - "ava script", - "avas cript", - "Ma n", - "M an", - "ar a", - "a ra", - "wa re", - "war e", - "w are", - "al ign", - "ali gn", - "an gle", - "ang le", - "▁S c", - "▁ Sc", - "un ic", - "uni c", - "u nic", - "▁f ran", - "▁fr an", - "▁fra n", - "▁ fran", - "U n", - "z i", - "me t", - "m et", - "Ad d", - "A dd", - "▁p ub", - "▁pu b", - "▁ pub", - "ко в", - "к ов", - "▁g en", - "▁ge n", - "▁ gen", - "▁p od", - "▁po d", - "▁ pod", - "▁s um", - "▁su m", - "▁ sum", - "▁h aving", - "▁ha ving", - "▁hav ing", - "▁a vec", - "▁av ec", - "▁ave c", - "s l", - "▁f ig", - "▁fi g", - "▁ fig", - "▁R es", - "▁Re s", - "▁ Res", - "Dat e", - "Da te", - "D ate", - "ul es", - "ule s", - "u les", - "wi th", - "w ith", - "ски й", - "с кий", - "g u", - "E T", - "▁b ro", - "▁br o", - "▁ bro", - "ri e", - "r ie", - "ap s", - "a ps", - "en ding", - "end ing", - "endi ng", - "ma il", - "mai l", - "m ail", - "oo k", - "o ok", - "▁su ccess", - "▁succ ess", - "▁suc cess", - "▁ success", - "ber g", - "be rg", - "b erg", - "▁d eb", - "▁de b", - "▁ deb", - "el ta", - "elt a", - "() `", - "( )`", - "ent ial", - "enti al", - "fr ame", - "fra me", - "fram e", - "f rame", - "Ke y", - "K ey", - "in n", - "i nn", - "▁sim ple", - "▁simp le", - "▁simpl e", - "▁ simple", - "iv al", - "iva l", - "i val", - "▁c are", - "▁car e", - "▁ca re", - "▁ care", - "▁W eb", - "▁We b", - "▁ Web", - "\") .", - "\" ).", - ">< /", - "> ", - "▁ />", - "k o", - "▁ex per", - "▁exp er", - "▁se par", - "▁sep ar", - "▁ separ", - "y l", - "ou rn", - "our n", - "o urn", - "▁d ev", - "▁de v", - "▁ dev", - "▁a uch", - "▁au ch", - "▁auc h", - "▁ auch", - "▁b lock", - "▁bl ock", - "▁blo ck", - "▁ block", - "bo ok", - "b ook", - "▁m ap", - "▁ma p", - "▁ map", - "il la", - "ill a", - "i lla", - "▁com put", - "▁comp ut", - "▁ comput", - "▁s pace", - "▁sp ace", - "▁spac e", - "▁ space", - "res ult", - ") }", - "▁e cho", - "▁ec ho", - "▁ echo", - "con fig", - "conf ig", - "h i", - "▁lar ge", - "▁larg e", - "▁ large", - "▁w idth", - "▁wid th", - "▁ width", - "▁G o", - "▁ Go", - "ma t", - "m at", - "▁d iff", - "▁di ff", - "▁dif f", - "▁ diff", - "▁k ind", - "▁ki nd", - "▁kin d", - "▁ kind", - "an ces", - "ance s", - "anc es", - "yn am", - "yna m", - "y nam", - "▁col or", - "▁co lor", - "▁ color", - "In t", - "I nt", - "so l", - "s ol", - "▁p i", - "▁ pi", - "▁char acter", - "▁charact er", - "▁ character", - "om ent", - "ome nt", - "omen t", - "o ment", - "▁res ponse", - "▁respons e", - "▁ response", - "ig ma", - "ward s", - "war ds", - "w ards", - "ar row", - "arr ow", - "с у", - "ti es", - "t ies", - "▁ü ber", - "▁ über", - "Im age", - "y d", - "▁п ере", - "▁пер е", - "▁пе ре", - "▁ пере", - "▁n ode", - "▁no de", - "▁nod e", - "▁ node", - "▁it em", - "▁i tem", - "▁ item", - "ach ine", - "achi ne", - "im a", - "i ma", - "▁v a", - "▁ va", - "▁appro ach", - "▁w er", - "▁we r", - "▁ wer", - "▁ч е", - "▁ че", - "O n", - "ol low", - "oll ow", - "он а", - "о на", - "ct ed", - "c ted", - "ur ed", - "ure d", - "u red", - "Cont roller", - "Control ler", - "li ed", - "lie d", - "l ied", - "▁j o", - "▁ jo", - "▁d al", - "▁da l", - "▁ dal", - "un k", - "▁ î", - "st art", - "sta rt", - "star t", - "ol a", - "o la", - "▁com pon", - "▁comp on", - "I C", - "bi t", - "b it", - "▁b ase", - "▁bas e", - "▁ba se", - "▁ base", - "п у", - "▁id ea", - "▁ide a", - "▁ idea", - "▁d ire", - "▁di re", - "▁dir e", - "▁ dire", - "▁r ad", - "▁ra d", - "▁ rad", - "gr oup", - "gro up", - "▁W ith", - "▁Wi th", - "▁Wit h", - "▁ With", - "ser ver", - "serv er", - "serve r", - "si de", - "s ide", - "si ng", - "sin g", - "s ing", - "▁d ies", - "▁di es", - "▁die s", - "▁n ear", - "▁ne ar", - "▁ near", - "▁v oor", - "▁vo or", - "▁ voor", - "▁arg ument", - "▁ argument", - "▁} ,", - "▁ },", - "▁l and", - "▁la nd", - "▁lan d", - "▁ land", - "▁n ames", - "▁name s", - "▁na mes", - "▁nam es", - "▁ names", - "▁o ption", - "▁op tion", - "▁opt ion", - "▁ option", - "ith ub", - "pp ed", - "ppe d", - "p ped", - "au g", - "a ug", - "▁l inks", - "▁link s", - "▁lin ks", - "▁ links", - "▁f ull", - "▁fu ll", - "▁ful l", - "▁ full", - "▁s itu", - "▁si tu", - "▁sit u", - "▁con sole", - "▁cons ole", - "▁ console", - "▁e tc", - "▁et c", - "▁ etc", - "au x", - "a ux", - "▁C or", - "▁Co r", - "▁ Cor", - "icro soft", - "▁c ame", - "▁cam e", - "▁ca me", - "lo cal", - "loc al", - "l ocal", - "▁k nown", - "▁kn own", - "▁know n", - "▁ known", - "▁multi ple", - "▁multip le", - "▁ multiple", - "angu age", - "▁t otal", - "▁to tal", - "▁tot al", - "▁ total", - "ol ogy", - "olog y", - "olo gy", - "ä t", - "▁ Х", - "▁f re", - "▁fr e", - "▁ fre", - "▁t en", - "▁te n", - "▁ ten", - "ide o", - "▁b es", - "▁be s", - "▁ bes", - "tr ue", - "Qu ery", - "Que ry", - "om m", - "o mm", - "▁A rt", - "▁Ar t", - "▁ Art", - "▁ke ep", - "▁ keep", - "▁Un iversity", - "▁Univers ity", - "re ate", - "rea te", - "pp ort", - "ppo rt", - "p port", - "▁p ython", - "▁ python", - "tr a", - "t ra", - "ect or", - "ec tor", - "e ctor", - "р і", - "op h", - "o ph", - "▁c onc", - "▁con c", - "▁co nc", - "▁f our", - "▁fo ur", - "▁fou r", - "▁ four", - "vi ron", - "vir on", - "▁v ia", - "▁vi a", - "▁ via", - "? \"", - "im age", - "ima ge", - "ol l", - "o ll", - "ны е", - "н ые", - "▁con text", - "▁cont ext", - "▁conte xt", - "▁ context", - "▁s em", - "▁se m", - "▁ sem", - ". _", - "▁e ng", - "▁en g", - "▁ eng", - "ma r", - "m ar", - "A D", - "▁m or", - "▁mo r", - "▁ mor", - "▁C al", - "▁Ca l", - "▁ Cal", - "▁c ell", - "▁ce ll", - "▁cel l", - "▁ cell", - "im al", - "ima l", - "i mal", - "AT E", - "A TE", - "▁in f", - "▁ inf", - "ö n", - "uf fer", - "uff er", - "s q", - ".. ..", - "... .", - ". ...", - "▁z ur", - "▁zu r", - "W ith", - "ра н", - "р ан", - "ch n", - "c hn", - "▁d oor", - "▁do or", - "▁ door", - "cont ent", - "▁m iss", - "▁mi ss", - "▁mis s", - "▁ miss", - "▁s imp", - "▁sim p", - "▁si mp", - "▁ simp", - "á r", - "ir a", - "i ra", - "▁h at", - "▁ha t", - "▁ hat", - "Te st", - "T est", - "▁c ertain", - "▁cert ain", - "▁cer tain", - "▁ certain", - "N S", - "▁c ho", - "▁ch o", - "▁ cho", - "▁ad v", - "▁ adv", - "wh ere", - "w here", - "▁lo oking", - "▁look ing", - "▁ looking", - "▁t imes", - "▁time s", - "▁tim es", - "▁ti mes", - "▁ times", - "ни х", - "н их", - "ut o", - "u to", - "▁ É", - "ca n", - "c an", - "ho st", - "hos t", - "h ost", - "▁( *", - "▁ (*", - "lo at", - "▁n icht", - "▁ni cht", - "▁nic ht", - "▁nich t", - "Fi eld", - "F ield", - "bu rg", - "bur g", - "b urg", - "con st", - "cons t", - "ad es", - "ade s", - "a des", - "▁M us", - "▁Mu s", - "▁ Mus", - "▁n othing", - "▁not hing", - "▁no thing", - "▁ nothing", - "▁in cre", - "▁inc re", - "▁M in", - "▁Mi n", - "▁ Min", + "mis sion", + "such ▁as▁", + "% ▁of", + "E ndpoint", + "▁a re", + "ed▁ m", + ".▁ 199", + "ist ent", + ".4 .1", + "\n\nI mClone▁LLC", + "▁avail able▁", + "▁t arget▁lesion", + "st andard▁", + "ro gen", + "ol id", + "wh ether", + "▁on ly", + "▁v alu", + "▁ex pression", + "▁is ▁a", + "has▁ been", + "▁IMC- 11F8", + "o per", + "\n\nP ro", + "enc y▁", + "our s", + "ph ase▁", + "▁0▁0 ▁2", + "▁addition al", + "e. g", + "3 \n\nA", + "g n", + "▁ ≥", + "▁t el", + "on e▁s", + "▁a ▁patient", + "▁p opulation", + ".\n\n 3", + "res pectiv", + "\n\nS unitinib", + "▁the▁s ponsor", + "p an", + "or s", + "if y▁", + "▁of▁ each", + "▁through out", + "dendum ▁13", + "dic t", + "ospital ization", + "p ir", + "ar ch", + "▁b reast▁cancer", + "▁1 ▁0", + "ut ant", + "ex amination", + "ital ▁sign", + "▁CT CAE", + "06 9", + "evid ence▁of", + "ent ral▁", + "it is▁", + "▁Arm ▁A", + "brax is▁", + "e▁ P", + "for t", + "▁D enosumab", + "ap p", + "ed▁in to", + "str ati", + "ibil ity", + "ograph ic", + "84 80", + "(f )▁Clinical▁Protocol", + "% )", + "b ut", + "d evelop", + "r en", + "▁ studies▁", + "▁ .▁1", + "▁t em", + "▁treatment ▁arm", + "rib ut", + "require ment", + "regnanc y", + "E T", + "▁ d▁e▁v▁o▁r▁p▁p▁A", + "▁c isplatin", + "▁S ubject", + "ep ar", + "▁the▁p rimary▁", + "6 5", + "ed ing", + "ur ing▁the▁", + "e▁t umor", + "▁200 0", + "▁200 5", + ".0 ▁Approved▁by", + "25 8", + "▁.▁1 ▁\\", + "3 -", + "▁A ll", + "ulti pl", + "j u", + "at es▁", + "at ely", + "▁1 ▁6", + "▁C onfidential", + "con dition", + "▁h as", + "▁inter im", + "e ,▁and▁", + "▁ versus▁", + ".\n\n 7", + "op t", + "▁con duct", + "▁5 0", + "ail y▁", + "med ical▁", + "▁per son", + "▁April▁2008 \n\nPage▁", + "6 0", + "P h", + "s ;", + "\n\n V", + "st atist", + "▁the▁ f", + "ed▁ Version", + "es ign", + "appro priate▁", + "-lin e▁treatment", + "▁\\ ▁d▁e▁v▁o▁r▁p▁p▁A", + "▁0▁0▁2 ▁-", + "A T", + "▁t rial▁", + "ion ▁of▁the▁", + "it ed▁", + "▁p ractic", + "▁b i", + "ol ec", + "▁I f", + "▁0 ▁1▁0", + "▁ther ap", + "CT CAE", + "▁0▁0 ▁0▁0", + "otent ial▁", + "Ad verse▁Event", + ")\n\nGEL▁Version▁ID: ▁ONC.000−", + "▁0▁0▁0▁0 ▁0▁1▁0", + "i .", + "▁a pp", + "ed act", "▁p ower", - "▁po wer", - "▁pow er", - "▁ power", - "▁Amer ican", - "▁America n", - "▁ American", - "l n", - "val id", - "un gs", - "ung s", - "▁N ational", - "▁Nat ional", - "▁Nation al", - "▁ National", - "▁S an", - "▁Sa n", - "▁ San", - "▁Y ork", - "Re quest", - "ch ar", - "cha r", - "c har", - "▁Z e", - "▁ Ze", - "but ton", - "b utton", - "▁a lg", - "▁al g", - "▁ alg", - "SO N", - "S ON", - "▁a p", - "▁ ap", - "uf f", - "u ff", - "ab ility", - "abil ity", - "е м", - "▁any thing", - "el a", - "e la", - "() )", - "( ))", - "б а", - "amp ion", - "ampio n", - "▁p ot", - "▁po t", - "▁ pot", - "▁f ut", - "▁fu t", - "ail able", - "▁p rop", - "▁pro p", - "▁pr op", - "▁ prop", - "\" ]", - "▁l ess", - "▁le ss", - "▁les s", - "▁ less", - "la g", - "l ag", - "▁A ugust", - "▁Aug ust", - "▁ August", - "I t", - "▁p lease", - "▁ple ase", - "▁st yle", - "▁sty le", - "▁ style", - "▁Al so", - "▁Als o", - "▁ Also", - "b t", - "▁pro bably", - "▁prob ably", - "▁O ne", - "▁On e", - "▁ One", - "▁p oss", - "▁po ss", - "▁pos s", - "▁ poss", - "U I", - "ui t", - "u it", - "▁W est", - "▁We st", - "▁Wes t", - "▁ West", - "h n", - "+ \\", - "But ton", - "Butt on", - "B utton", - "js on", - "j son", - "er r", - "e rr", - "ra me", - "ram e", - "r ame", - "do m", - "d om", - "il on", - "ilo n", - "i lon", - "al f", - "▁c lient", - "▁cl ient", - "▁cli ent", - "▁ client", - "▁cont inu", - "▁contin u", - "▁ continu", - "x ml", - "pe c", - "p ec", - "ad or", - "ado r", - "a dor", - "l s", - "▁how ever", - "▁A ny", - "▁An y", - "▁ Any", - "än d", - "ä nd", - "math rm", - "▁u rl", - "▁ur l", - "▁ url", - "▁b ook", - "▁bo ok", - "▁ book", - "▁g l", - "▁ gl", - "iv es", - "ive s", - "i ves", - "g i", - "▁t ro", - "▁tr o", - "▁U S", - "▁ US", - "po int", - "p oint", - "op en", - "ope n", - "o pen", - "▁c ur", - "▁cu r", - "▁ cur", - "▁e ra", - "▁er a", - "▁ era", - "▁part icular", - "▁partic ular", - "▁particul ar", - "▁parti cular", - "▁H T", - "▁ HT", - "oo t", - "o ot", - "el lo", - "ell o", - "lo bal", - "lob al", - "▁a ction", - "▁act ion", - "▁ac tion", - "▁ action", - "▁I nt", - "▁In t", - "▁ Int", - "▁in clude", - "▁incl ude", - "▁includ e", - "▁inclu de", - "▁ include", - "▁el ements", - "▁element s", - "▁ele ments", - "▁elem ents", - "▁ elements", - "на я", - "ar ds", - "ard s", - "▁B l", - "▁ Bl", - "▁h um", - "▁hu m", - "▁ hum", - "fr om", - "f rom", - "ch ange", - "chan ge", - "▁function s", - "▁fun ctions", - "▁ functions", - "he n", - "h en", - "Ser vice", - "Serv ice", - "▁he ight", - "▁ height", - "▁L and", - "▁La nd", - "▁Lan d", - "▁ Land", - "ia s", - "i as", - "g s", - "ió n", - "i ón", - "ло в", - "л ов", - "no de", - "n ode", - ". ”", - "ha nd", - "han d", - "h and", - "▁б у", - "▁ бу", - "▁a mb", - "▁am b", - "▁ amb", - "▁L u", - "▁ Lu", - "▁th row", - "▁thr ow", - "▁thro w", - "▁ throw", - "▁m ot", - "▁mo t", - "▁ mot", - "▁A ct", - "▁Ac t", - "▁ Act", - "▁w orld", - "▁wor ld", - "▁ world", - "_ \\", - "ba se", - "bas e", - "b ase", - "▁C o", - "▁ Co", - "▁ar ch", - "▁arc h", - "▁ arch", - "▁## ##", - "▁### #", - "▁ ####", - "ge d", - "g ed", - "pr il", - "p ril", - "ol der", - "old er", - "o lder", - "Mod el", - "Mode l", - "Mo del", - "M odel", - "▁sever al", - "li e", - "l ie", - "che ck", - "c heck", - "] {", - "con s", - "co ns", - "c ons", - "▁T ra", - "▁Tr a", - "▁ Tra", - "he ck", - "▁l east", - "▁le ast", - "do wn", - "d own", - "eb ru", - "e bru", - "De f", - "D ef", - "par am", - "pa ram", - "para m", - "p aram", - "is cher", - "isch er", - "ische r", - "isc her", - "i scher", - "▁c as", - "▁ca s", - "▁ cas", - "C H", - "▁add ress", - "▁addr ess", - "▁ address", - "▁ра з", - "▁ раз", - "uf en", - "ufe n", - "u fen", - "ur ope", - "uro pe", - "urop e", - "е й", - "▁b ound", - "▁bo und", - "▁bou nd", - "▁ bound", - "C O", - "▁A ng", - "▁An g", - "▁ Ang", - "▁M a", - "▁ Ma", - "In dex", - "Ind ex", - "co re", - "cor e", - "c ore", - "ou ch", - "ouc h", - "o uch", - "at abase", - "ata base", - "rib ution", - "ribu tion", - "doc ument", - "d ocument", - "L e", - "}_ {", - "} _{", - "ve rn", - "ver n", - "v ern", - "▁stat ement", - "▁state ment", - "▁ statement", - "▁B rit", - "▁Br it", - "on o", - "o no", - "ps ilon", - "psi lon", - "▁le vel", - "▁lev el", - "▁ level", + "▁s chedul", + "oc yt", + "us ed▁in", + "op y▁of", + "▁cons ider", + "edact ed▁Version", + "3 2", + "6 258", + "c as", + "or d", + "................................ ........", + "pro tein", + "▁E n", "▁pro duct", - "▁produ ct", - "▁prod uct", - "▁ product", - "I S", - "▁c ourse", - "▁cour se", - "▁cours e", - "▁ course", - "▁M r", - "▁ Mr", - "> \r", - "▁back ground", - "▁ background", - "▁re t", - "▁r et", - "▁ ret", - "er ing", - "eri ng", - "e ring", - "mo st", - "mos t", - "m ost", - "сь ко", - "ськ о", - "▁th read", - "▁thr ead", - "▁thre ad", - "▁ thread", - "it ional", - "ition al", - "iti onal", - "it es", - "ite s", - "i tes", + "▁M RI", + "MG EN", + "▁randomiz ed▁", + "▁Edition▁Number▁3▁D ate▁", + "/ d", + "U N", + "s it", + "y ear", + "▁t umour", + "ing ▁on", + "un e▁", + ".▁I t", + "o od▁", + "at ch", + "ed ,", + "▁c olon", + "▁s kin", + "ou bl", + "▁con f", + "oun d▁", + "▁can ▁be▁", + "▁A\n\nF▁O \n\nY▁P▁O▁C", "P l", - "▁d os", - "▁do s", - "g a", - "da y", - "d ay", - "▁G ener", - "▁Ge ner", - "▁Gen er", - "▁Gene r", - "▁ Gener", - "▁t w", - "▁ tw", - "A d", - "\"> <", - "\" ><", - "▁( $", - "▁ ($", - "▁m oment", - "▁mo ment", - "▁mom ent", - "tit le", - "t itle", - "cre ate", - "c reate", - "vers ion", - "v ersion", - "Man ager", - "▁f ur", - "▁fu r", - "▁ fur", - "pp ing", - "ppi ng", - "p ping", - "ij n", - "о с", - "▁r ather", - "▁ra ther", - "▁rat her", - "pt ember", - "O S", - "▁s ite", - "▁si te", - "▁sit e", - "▁ site", - "▁c aus", - "▁ca us", - "an i", - "a ni", - "▁h ome", - "▁hom e", - "▁ho me", - "▁ home", - "м і", - "▁sh ort", - "▁sho rt", - "▁ short", - "p a", - "▁l ead", - "▁le ad", - "is hed", - "ish ed", - "ci ng", - "cin g", - "c ing", - "or ding", - "ord ing", - "ordin g", - "▁p rote", - "▁pro te", - "▁pr ote", - "▁prot e", - "▁ prote", - "с ле", - "LE CT", - "L ECT", - "▁di dn", - "▁did n", - "pos ition", - "p osition", - "\", \"", - "\" ,\"", - "() ,", - "( ),", - "tr ans", - "tra ns", - "▁l ot", - "▁lo t", - "▁ lot", - "▁о д", - "▁ од", - "A S", - "▁s at", - "▁sa t", - "▁po ints", - "▁point s", - "▁ points", - "g ithub", - "st yle", - "sty le", - "▁го ду", - "▁год у", - "▁D is", - "▁Di s", - "▁ Dis", - "pon ent", - "om et", - "ome t", - "o met", - "ze r", - "z er", - "UL L", - "U LL", - "▁p a", - "▁ pa", - "A P", - "ac es", - "ace s", - "a ces", - "▁Un ited", - "▁Unit ed", - "am a", - "a ma", - "et y", - "e ty", - "Col or", - "Co lor", - "▁en ough", - "U S", - "▁l ength", - "▁leng th", - "▁ length", - "() );", - "()) ;", - "( ));", - "^{ \\", - "^ {\\", - "ft y", - "f ty", - "Bo x", - "B ox", - "ap ter", - "apt er", - "▁comp let", - "▁comple t", - "▁compl et", - "ни к", - "ma x", - "m ax", - "ob ject", - "obj ect", - "o bject", - "( {", - "img ur", - "it ive", - "iti ve", - "un ch", - "unc h", - "▁S ub", - "▁Su b", - "▁ Sub", - "en de", - "end e", - "e nde", - "г у", - "ateg ory", - "ategor y", - "т ы", - "ia no", - "ian o", - "i ano", - "▁u pd", - "▁up d", - "▁A ust", - "▁Aus t", - "▁Au st", - "}{ \\", - "} {\\", - "to p", - "t op", - "la s", - "l as", - "pi s", - "p is", - "in ess", - "ine ss", - "ines s", - "i ness", - "▁{ \r", - "▁ {\r", - "▁ Е", - "G r", - "▁A S", - "▁ AS", - "▁в е", - "▁ ве", - "th ers", - "ther s", - "the rs", - "▁d efined", - "▁def ined", - "▁define d", - "▁defin ed", - "▁ defined", - "az ione", - "azi one", - "a zione", - "▁o ffic", - "▁of fic", - "▁off ic", - "▁au tom", - "▁aut om", - "▁auto m", - "▁ autom", - "ü n", - "▁b row", - "▁br ow", - "▁bro w", - "▁ brow", - "▁s erv", - "▁se rv", - "▁ser v", - "▁ serv", - "▁re move", - "▁rem ove", - "▁remov e", - "▁ remove", - "ir o", - "i ro", - "▁B ibli", - "▁Bib li", - "E D", - "▁w hole", - "▁wh ole", - "▁who le", - "▁ ш", - "▁J ava", - "▁Ja va", - "▁ Java", - "▁z um", - "▁zu m", - "u a", - "p m", - "de v", - "d ev", - "к ра", - "ol ds", - "old s", - "▁W ar", - "▁Wa r", - "ä n", - "pa ss", - "pas s", - "p ass", - "u z", - "[ \"", - "▁t ri", - "▁tr i", - "▁ tri", - "is ed", - "ise d", - "i sed", - "х а", - "▁mem ory", - "▁memor y", - "▁ memory", - "▁P ort", - "▁Po rt", - "▁Por t", - "▁ Port", - "op er", - "ope r", - "o per", - "U p", - "▁Th ank", - "▁ Thank", - "▁M ich", - "▁Mi ch", - "▁Mic h", - "▁ Mich", - "yc h", - "y ch", - "bo ard", - "boa rd", - "б у", - "In st", - "▁b egin", - "▁be gin", - "▁beg in", - "▁ begin", - "in ation", - "ina tion", - "▁M od", - "▁Mo d", - "▁ Mod", - "_ ,", - "▁D en", - "▁De n", - "▁ Den", - "op tion", - "opt ion", - "o ption", - "▁con struct", - "▁const ruct", - "▁constru ct", - "▁ construct", - "▁J ust", - "▁Ju st", - "▁ Just", - "Ma p", - "M ap", - "ru n", - "r un", - "▁re spect", - "▁res pect", - "▁resp ect", - "ha m", - "h am", - "ма н", - "м ан", - "im edia", - "ime dia", - "i media", - "▁a pply", - "▁app ly", - "▁ap ply", - "▁ apply", - "cri ption", - "cript ion", - "ma in", - "mai n", - "m ain", - "▁К а", - "▁ Ка", - "oi d", - "o id", - "Co de", - "C ode", - "} ;", - "In fo", - "Inf o", - "▁for mat", - "▁form at", - "▁forma t", - "▁ format", - "Lo g", - "L og", - "▁с у", - "▁ су", - "▁l at", - "▁la t", - "▁ lat", - "ut or", - "uto r", - "u tor", - "▁re ference", - "▁refer ence", - "▁ reference", - "▁cal cul", - "▁calc ul", - "▁ calcul", - "on n", - "o nn", - "L o", - "in fty", - "inf ty", - "▁a long", - "▁al ong", - "▁ č", - "▁t ask", - "▁ta sk", - "▁ task", - "▁e v", - "▁ ev", - "th eta", - "the ta", - "ra s", - "r as", - "jo r", "j or", - "▁б о", - "▁ бо", - "▁princi p", - "▁prin cip", - "M y", - "▁e iner", - "▁ein er", - "▁eine r", - "▁E s", - "▁ Es", - "om b", - "o mb", - "qu ad", - "qua d", - "^{ -", - "^ {-", - "um p", - "u mp", - "▁t ill", - "▁til l", - "▁ti ll", - "д і", - "▁lo oks", - "▁look s", - "▁o k", - "▁ ok", - "ц а", - "n u", - "Fi l", - "F il", - "▁s ont", - "▁so nt", - "▁son t", - "▁M ed", - "▁Me d", - "▁ Med", - "ag ue", - "agu e", - "a gue", - "▁c ost", - "▁co st", - "▁cos t", - "▁ cost", - "▁S im", - "▁Si m", - "▁ Sim", - "▁com ment", - "▁comm ent", - "▁comme nt", - "▁ comment", - "▁( \\", - "▁ (\\", - "eg en", - "ege n", - "e gen", - "▁para meter", - "▁param eter", - "▁paramet er", - "▁ parameter", - "▁F rance", - "▁Fran ce", - "▁Fr ance", - "▁Franc e", - "▁ France", - "re p", - "r ep", - "▁T H", - "▁ TH", - "▁y et", - "▁ye t", - "▁a way", - "▁aw ay", - "▁ away", - "▁c irc", - "▁ci rc", - "▁cir c", - "▁ circ", - "▁A PI", - "▁AP I", - "▁ API", - "em p", - "e mp", - "в і", - "L ayout", - "▁l ines", - "▁li nes", - "▁line s", - "▁lin es", - "▁ lines", - "▁P art", - "▁Par t", - "▁Pa rt", - "▁ Part", - "em pt", - "emp t", - "▁B i", - "▁ Bi", - "▁m ind", - "▁min d", - "▁mi nd", - "▁ mind", - "k y", - "gi ng", - "gin g", - "g ing", - "▁re port", - "▁rep ort", - "▁repo rt", - "▁ report", - "▁A dd", - "▁Ad d", - "▁ Add", - "ро д", - "р од", - "▁r ange", - "▁ran ge", - "▁rang e", - "▁ range", - "ci as", - "cia s", - "c ias", - "li p", - "l ip", - "▁K ar", - "▁Ka r", - "▁ Kar", - "▁Comm ons", - "▁Common s", - "ger ufen", - "af f", - "a ff", - "se c", - "s ec", - "▁h tml", - "▁ html", - "li g", - "l ig", - "▁w indow", - "▁wind ow", - "▁ window", - "in ition", - "ini tion", - "init ion", - "ci s", - "c is", - "▁u t", - "▁ ut", - "el n", - "e ln", - "▁a ux", - "▁au x", - "▁ aux", - "▁n eg", - "▁ne g", - "▁ neg", - "Ha nd", - "H and", - "▁) ;", - "▁ );", - "▁a nal", - "▁an al", - "▁ anal", - "▁f ri", - "▁fr i", - "▁ fri", - "▁с и", - "▁ си", - "et ch", - "etc h", - "m d", - "pa ge", - "pag e", - "p age", - "▁l ibrary", - "▁li brary", - "▁ library", - "▁: =", - "▁ :=", - "RO M", - "R OM", - "Y ou", - "sp ace", - "s pace", - "▁d urch", - "▁dur ch", - "▁h ost", - "▁ho st", - "▁hos t", - "▁ host", - "av en", - "ave n", - "a ven", - "▁F ile", - "▁Fil e", - "▁ File", - "al le", - "all e", - "a lle", - "ти в", - "▁p ap", - "▁pa p", - "ст во", - "ств о", - "с тво", - "mar k", - "m ark", - "▁m ais", - "▁ma is", - "▁mai s", - "er man", - "erm an", - "Si ze", - "S ize", - "е к", - "▁М а", - "▁ Ма", - "▁is n", - "▁i sn", - "▁c opy", - "▁co py", - "▁cop y", - "▁ copy", - "st en", - "ste n", - "s ten", - "ri ver", - "riv er", - "rive r", - "r iver", - "▁w ent", - "▁we nt", - "▁wen t", - "▁j avascript", - "▁java script", - "▁ javascript", - "▁s am", - "▁sa m", - "▁ sam", - "▁f rame", - "▁fr ame", - "▁fra me", - "▁fram e", - "▁ frame", - "▁v i", - "▁ vi", - "▁pre vious", - "▁prev ious", - "▁ previous", - "ro du", - "rod u", - "r odu", - "▁method s", - "▁ methods", - "▁ne cess", - "▁neces s", - "▁ necess", - "N A", - "ck et", - "cke t", - "c ket", - "▁o pt", - "▁op t", - "▁ opt", - "Lo c", - "L oc", - "ho w", - "h ow", - "▁î n", - "▁ în", - "sh ip", - "s hip", - "▁it self", - "▁its elf", - "▁P lease", - "▁Ple ase", - "▁ Please", - "ie ne", - "ien e", - "i ene", - "ве р", - "в ер", - "▁< <", - "▁ <<", - "▁m ill", - "▁mil l", - "▁mi ll", - "▁ mill", - "▁t rad", - "▁tr ad", - "▁tra d", - "▁ trad", - "pa ce", - "p ace", - "▁H ar", - "▁Ha r", - "▁ Har", - "it en", - "ite n", - "i ten", - "wi se", - "w ise", - "writ e", - "wr ite", - "w rite", - "ци и", - "р ы", - "Lin e", - "Li ne", - "L ine", - "ol o", - "o lo", - "▁ac cept", - "▁ accept", - "he ight", - "▁e lect", - "▁el ect", - "▁ele ct", - "▁ elect", - "el la", - "ell a", - "e lla", - "▁p å", - "Se lect", - "S elect", - "▁ ли", - "▁\\ <", - "▁ \\<", - "( (", - "▁I D", - "▁ ID", - "op s", - "o ps", - "ва н", - "в ан", - "i ó", - "T P", - "» ,", - "ne ction", - "nect ion", - "n ection", - "par ent", - "pa rent", - "▁M ag", - "▁Ma g", - "▁ Mag", - "Tab le", - "T able", - "O ver", - "▁n etwork", - "▁net work", - "▁ network", - "с по", - "▁as sign", - "▁ass ign", - "▁ assign", - "ig ger", - "igg er", - "ir m", - "i rm", - ") `", - "ot tom", - "ott om", - "otto m", - "be ta", - "bet a", - "b eta", - "▁d ell", - "▁de ll", - "▁del l", - "▁b ody", - "▁bo dy", - "▁bod y", - "▁ body", - "▁д а", - "▁ да", - "▁Y our", - "▁You r", - "▁ Your", - "▁f ue", - "▁fu e", - "▁p ackage", - "▁pack age", - "▁ package", - "▁l ight", - "▁lig ht", - "▁ light", - "▁* *", - "▁ **", - "M P", - "▁c ou", - "▁co u", - "▁ cou", - "ye s", - "y es", - ": \\", - "▁ Ч", - "▁m ention", - "▁men tion", - "▁ment ion", - "en sch", - "ens ch", - "▁d eg", - "▁de g", - "▁ deg", - "▁con vert", - "▁conver t", - "▁conv ert", - "▁ convert", - "▁D av", - "▁Da v", - "ad t", - "a dt", - "Res ult", - "th ough", - "▁b us", - "▁bu s", - "▁ bus", - "x y", - "▁s een", - "▁se en", - "▁see n", - "▁ seen", - "Al l", - "A ll", - "pu blic", - "pub lic", - "p ublic", - "iv ely", - "ive ly", - "ivel y", - "▁R ec", - "▁Re c", - "▁ Rec", - "▁H is", - "▁Hi s", - "si m", - "s im", - "▁f ör", - "▁fö r", - "▁ för", - "▁h istor", - "▁his tor", - "▁hi stor", - "▁hist or", - "▁ histor", - "▁s ett", - "▁se tt", - "▁set t", - "▁ sett", - "ra t", - "r at", - "ab led", - "able d", - "abl ed", - "a bled", - "▁» ,", - "▁ »,", - "go ogle", - "We b", - "W eb", - "é l", - "▁t itle", - "▁tit le", - "▁ title", + ",▁ m", + ",▁ you", + "ing ▁to▁the▁", + "▁E x", + "ther apy▁", + "▁F OLFOX", + "RP 6258", + "3 4", + "in f", + "\n\n \\", + "▁in formed▁consent", + "up ▁to", + "▁r isk", + "pr of", + "efficac y", + "ox aliplatin", + "open -label", + "▁\\▁d▁e▁v▁o▁r▁p▁p▁A \n\n\\", + "er n", + ",▁ N", + "ing ▁of▁the▁", + "as od", + "▁w as", + "▁E fficacy▁An", + "ad i", + ".3 .2", + "te b", + "ind ing", + "▁accord ance▁with", + "M R", + "n on", + "▁l if", + "other ▁than", + "e▁s ampl", + ".0▁Approved▁by \n\nApproved\n\nDate▁Printed:", + ") ▁in", + "H 3E-MC-JM", + "Z ER", + "e y▁", + "f a", + "v ariabl", + "▁ ", + "on ▁the▁", + "of ▁the▁", + "ol er", + "▁2 5", + "▁on ly▁", + "▁the▁d ata", + "▁appro pri", + "FI ZER", + "le ucovorin", + "discontinu ation", + "▁CONFIDENTIAL ▁Page▁", + "FIZER ▁CONFIDENTIAL▁Page▁", + "I EC", + "p ain", + "ro un", + "et ail", + "▁C V", + "▁P RO", + "ex perienc", + "ep o", + "aus ea", + "\n\nH 3E-MC-JM", + "asod ex", + "v itamin▁D", + "at ur", + "iv al", + "▁P R", + "▁ind ic", + "▁do ctor", + "evi ew", + "ificance▁ level", + ",▁ with", + "▁the▁t rial", + "▁med ical", + "1 B", + "r in", + "▁m arker", + "our n", + "▁G rade▁3", + "RI O", + "▁Nov ember", + "2 ▁(", + ": 5", + "▁ ident", + "it ▁is▁", + "▁3 .0", + "With :", + "▁perform ance▁stat", + "epo etin", + "8 7", + "H D", + "r ang", + "s ,▁and", + "e▁ will▁be▁", + "in -", + "s▁ were▁", + "ar boplatin", + "▁b ut", + "ec om", + "op y▁", + "cont roll", + "IT T", + "▁clinical ▁trial", + ".▁J ▁Clin▁Oncol", + "li k", + "\n\n090177e18 069", + "ju vant", + "t arget▁lesion", + "\n\n d", + "ed▁ using", + "▁c ut", + "▁S afety▁", + "▁200 4", + "▁M ay▁", + "▁v itamin▁D", + "▁pro state▁cancer", + "mon g", + ") .▁The▁", + "- D", + "- day▁", + "3 7", + "B I-007", + "U D", + "z oledronic", + "for ▁the▁", + ".\n\n B", + "em ist", + "us ed▁", + "com bin", + "ach ment", + ",▁b ut", + "-m onth", + "▁Denosumab ▁Protocol▁Number:▁200", + "A R", + "▁a ▁p", + "om it", + "00 ▁mg/m2", + "▁al fa", + "A ppendix", + "C C", + "e ,▁the▁", + "o k", + "s▁ may▁be▁", + "an alyz", + "minist ration", "▁J anu", - "▁Jan u", - "▁Ja nu", - "ј а", - "▁t ook", - "▁to ok", - "▁too k", - "id en", - "ide n", - "i den", - "s z", - "▁G et", - "▁Ge t", - "▁ Get", - "▁object s", - "▁ objects", - "▁com mon", - "▁comm on", - "▁ common", - "▁ch anges", - "▁change s", - "▁chang es", - "▁ changes", - "▁L ond", - "▁Lo nd", - "▁ Lond", - "▁ex tern", - "▁ext ern", - "▁j u", - "▁ ju", - "I s", - "▁av ailable", - "▁avail able", - "▁ available", - "tr i", - "t ri", - "▁m ás", - "▁má s", - "os a", - "o sa", - "B e", - "▁D ata", - "▁Da ta", - "▁Dat a", - "▁ Data", - "ur al", - "ura l", - "u ral", - "▁h om", - "▁ho m", - "▁ hom", - "▁acc ount", - "▁ac count", - "▁ account", - "o o", - "▁p erm", - "▁per m", - "▁pe rm", - "▁ perm", - "res pond", - "resp ond", - "y t", - "▁s end", - "▁se nd", - "▁sen d", - "▁ send", - "▁return s", - "▁ returns", - "iv id", - "ivi d", - "i vid", - "▁ex pla", - "▁exp la", - "▁expl a", - "í n", - "▁n or", - "▁no r", - "▁ nor", - "I f", - "▁F rom", - "▁Fr om", - "▁Fro m", - "▁ From", - "▁t arget", - "▁tar get", - "▁ target", - "fe ct", - "f ect", - "ен т", - "▁u it", - "▁ui t", - "▁ uit", - "▁J o", - "▁ Jo", - "▁vari ables", - "▁variable s", - "▁ variables", - "▁s eries", - "▁se ries", - "▁ser ies", - "▁serie s", - "▁ series", - "▁f unc", - "▁fun c", - "▁fu nc", - "▁ func", - "▁him self", - "▁ч а", - "▁ ча", - "an ti", - "ant i", - "▁a ch", - "▁ac h", - "▁ ach", - "ia log", - "ial og", - "i alog", - "▁s td", - "▁st d", - "▁ std", - "a e", - "▁f oot", - "▁fo ot", - "▁foo t", - "▁ foot", - "▁un ter", - "▁ unter", - "gr ess", - "gres s", - "gre ss", - "g ress", - "No t", - "N ot", - "ra d", - "r ad", - "f ér", - "▁u til", - "▁ut il", - "▁ util", - "or em", - "ore m", - "o rem", - "▁s ou", - "▁so u", - "op t", - "o pt", - "▁o g", - "▁ og", - "▁u ma", - "▁um a", - "▁ uma", - "it ar", - "ita r", - "i tar", - "▁O k", - "▁ Ok", - "ü ck", - "sq rt", - "▁a nt", - "▁an t", - "▁ ant", - "▁wer den", - "▁werd en", - "å r", - "}) ;", - "} );", - "▁P aris", - "▁Par is", - "▁Pa ris", - "▁ex ception", - "▁except ion", - "▁ exception", - "▁de term", - "▁det erm", - "▁V ol", - "▁Vo l", - "▁ Vol", - "▁S am", - "▁Sa m", - "▁ Sam", - "▁e ss", - "▁es s", - "▁ ess", - "li es", - "lie s", - "l ies", - "ion i", - "io ni", - "i oni", - "od ing", - "odi ng", - "o ding", - "id get", - "idge t", - "▁p ri", - "▁pr i", + "▁su ch", + "tt achment", + "2 17", + "m et", + "p revi", + "▁m an", + "ch est", + "▁pro tein", + "and ard", + "▁Protocol▁Number:▁200 401", + "NC I", + "▁im prov", + "▁AMG▁162 ▁Protocol▁Number:▁200401", + "cri ption", + "1 30", + "F OLFOX", + "T -", + "c ensor", + "e ut", + "j ud", + "r or", + ".. .▁", + "▁( S", + "▁( or", + "▁2 6", + "\n\nA MGEN", + "op os", + "▁treatment ▁with", + ".1 .2", + ".0 \n\nApproved\n\nDate▁Printed:", + "radi ation", + "consider ed▁", + "upport ive▁", + "arb epoetin", + "G rade▁", + "h igh", + "i e,▁", + "p opulation", + "▁t yp", + "at e\n\n", + "▁d ue▁to", + "▁or der", + "ast in", + "▁car boplatin", + "▁includ e▁", + "perform ed", + "▁det ail", + "▁previ ous▁", + ")▁( cid:", + "112 1B", + "t reat", + "ing ▁p", + "▁m ic", + "ac cept", + "Th er", + "▁al on", + "▁com pli", + "▁g iven", + "ider m", + "ifi ed▁", + "▁subjects▁ who", + "▁loc al", + "ibil ity▁", + ", ▁all", + "re d▁", + "al g", + "ion ▁of", + ".\n\n d▁e▁v▁o▁r▁p▁p▁A\n\nProduct:", + "com par", + "ain tain", + "gen etic", + "clin ically▁", + "▁Res ponse▁", + "relation ship", + "ffic ient", + "o -", + "▁ >", + "▁a ▁l", + ",▁ E", + "ig u", + "▁o xaliplatin", + "▁the▁d is", + "b aseline▁", + "g uidelin", + "s kin", + "re main", + "▁s upplement", + "main tain", + "▁coll ect", + "fic ial▁", + "( b)", + "9 8", + "in creas", + "is▁ of", + "res olv", + "▁C ycle▁", + "e▁s hould▁be▁", + "ph armac", + "s▁in clud", + "▁af f", "▁wh ether", - "▁whe ther", - "▁п од", - "▁по д", - "▁num bers", - "▁number s", - "▁ numbers", - "▁ ~", - "ev ent", - "even t", - "e vent", - "▁sh ows", - "▁show s", - "▁sho ws", - "at ures", - "atur es", - "ature s", - "atu res", - "▁h ouse", - "▁ho use", - "▁hous e", - "▁ house", - "▁f ace", - "▁fa ce", - "▁fac e", - "▁ face", - "▁s ię", - "▁si ę", - "viron ment", - "va n", - "v an", - "▁in cluding", - "▁includ ing", - "▁inclu ding", - "▁ including", - "▁< -", - "▁ <-", - "ti mes", - "time s", - "tim es", - "t imes", - "no w", - "n ow", - "▁p ur", - "▁pu r", - "▁ pur", - "if ier", - "ifi er", - "ifie r", - "▁e mp", - "▁em p", - "▁ emp", - "▁c la", - "▁cl a", - "▁ cla", - "mo n", - "m on", - "▁D as", - "▁Da s", - "ad y", - "a dy", - "▁в ід", - "▁ві д", - "▁ від", - "▁ ц", - "ab or", - "a bor", - "OS T", - "O ST", - "▁b and", - "���ban d", - "▁ba nd", - "▁ band", - "▁ ú", - "▁ex actly", - "▁exact ly", - "ie rt", - "ier t", - "i ert", - "av ig", - "avi g", - "▁re du", - "▁r edu", - "▁red u", - "▁ redu", - "▁S E", - "▁ SE", - "lish ed", - "lis hed", - "l ished", - "B u", - "Mess age", - "M essage", - "ce ll", - "cel l", - "c ell", - "ful ly", - "full y", - "▁s v", - "▁ sv", - "▁m akes", - "▁ma kes", - "▁make s", - "▁mak es", - "po l", - "p ol", - "▁re quired", - "▁require d", - "▁requ ired", - "▁ required", - "fer rer", - "▁p ers", - "▁per s", - "▁pe rs", - "▁ pers", - "▁m i", - "▁ mi", - "F I", - "▁Pa ul", - "▁ Paul", - "▁U I", - "▁ UI", - "▁B el", - "▁Be l", - "▁ Bel", - "in c", - "i nc", - "▁cont ains", - "▁contain s", - "▁ contains", - "O ut", - "as ure", - "p u", - "ot o", - "o to", - "▁g ame", - "▁ga me", - "▁gam e", - "▁ game", - "z n", - "▁W hy", - "▁Wh y", - "▁ Why", - "or ith", - "ori th", - "bi g", - "b ig", - "ки й", - "sig ma", - "s igma", - "▁qu ite", - "▁qui te", - "▁quit e", - "▁j ed", - "▁je d", - "▁ jed", - "re c", - "r ec", - "▁S QL", - "▁ SQL", - "б е", - "▁M art", - "▁Mar t", - "▁Ma rt", - "▁ Mart", - "y a", - "▁sch ool", - "▁ school", - "▁sim ply", - "▁simp ly", - "▁simpl y", - "▁v or", - "▁vo r", - "▁ vor", - "▁d ouble", - "▁dou ble", - "▁doub le", - "▁ double", - "ра в", - "▁S tr", - "▁St r", - "▁ Str", - "ie m", - "i em", - "▁al bum", - "▁alb um", - "▁ album", - "▁re sol", - "▁res ol", - "▁ resol", - "▁d ei", - "▁de i", - "▁W ik", - "▁Wi k", - "▁ Wik", - "▁a w", - "▁ aw", - "um b", - "u mb", - "ol s", - "o ls", - "▁* /", - "▁ */", - "▁z e", - "▁ ze", - "▁a nim", - "▁an im", - "▁ani m", - "▁ anim", - "/ >", - "ri s", - "r is", - "re sh", - "res h", - "r esh", - "N o", - "ique s", - "iqu es", - "i ques", - "cur rent", - "curr ent", - "c urrent", - "▁per iod", - "▁peri od", - "▁ period", - "▁A pril", - "▁Ap ril", - "▁st ore", - "▁stor e", - "▁sto re", - "▁ store", - "', '", - "' ,'", - "▁S et", - "▁Se t", - "▁ Set", - "= {", - "ach ed", - "ac hed", - "ache d", - "a ched", - "▁M al", - "▁Ma l", - "▁ Mal", - "▁P al", - "▁Pa l", - "▁ Pal", - "an tes", - "ant es", - "ante s", - "ate rial", - "ater ial", - "▁work ed", - "▁wor ked", - "le q", - "l eq", - "ore ferrer", - "▁h appen", - "▁ha ppen", - "▁happ en", - "▁b ox", - "▁bo x", - "▁ box", - "ne y", - "n ey", - "▁c lose", - "▁cl ose", - "▁clos e", - "▁clo se", - "▁ close", - "▁g ran", - "▁gr an", - "▁gra n", - "▁l ie", - "▁li e", - "▁ lie", - "▁i r", - "▁ ir", - "▁ex pected", - "▁exp ected", - "▁expect ed", - "▁ expected", - "▁д ля", - "cl ick", - "cli ck", - "clic k", - "c lick", - "ș i", - "▁p arte", - "▁par te", - "▁part e", - "og n", - "o gn", - "▁F orm", - "▁For m", - "▁Fo rm", - "▁ Form", - "▁m emb", - "▁me mb", - "▁mem b", - "▁p lan", - "▁pl an", - "▁pla n", - "▁ plan", - "▁te am", - "▁tea m", - "▁ team", - "] [", - "▁c ommun", - "▁com mun", - "▁comm un", - "or ry", - "orr y", - "en cy", - "enc y", - "g l", - "in ary", - "ina ry", - "inar y", - "cd ot", - "c dot", - "^ \\", - "▁F irst", - "▁Fir st", - "▁ First", - "an der", - "and er", - "ande r", - "a nder", - "▁D ec", - "▁De c", - "▁ Dec", - "re quest", - "req uest", - "ст ва", - "ств а", - "с тва", - "▁str ucture", - "▁struct ure", - "▁ structure", - "▁| |", - "▁ ||", - "▁C omp", - "▁Com p", - "▁Co mp", - "▁ Comp", - "act ory", - "actor y", - "▁M il", - "▁Mi l", - "▁ Mil", - "▁S ome", - "▁So me", - "▁Som e", - "▁ Some", - "St ream", - "▁as sum", - "▁ass um", - "ue n", - "u en", - "▁w ords", - "▁word s", - "▁wor ds", - "▁ words", - "▁Se ptember", - "▁Sept ember", - "▁К о", - "▁ Ко", - "▁d ays", - "▁da ys", - "▁day s", - "▁ days", - "or ies", - "ori es", - "orie s", - "o ries", - "ста в", - "s m", - "vi n", - "v in", - "part ial", - "▁par ent", - "▁pa rent", - "▁pare nt", - "▁ parent", - "o j", - "ни и", - "! \"", - "ug in", - "u gin", - "▁W indows", - "▁Wind ows", - "▁Window s", - "▁ Windows", - "E d", - ": }", - "▁ q", - "▁b en", - "▁be n", - "▁ ben", - "ia na", - "ian a", - "i ana", - "▁l abel", - "▁la bel", - "▁lab el", - "▁ label", - "st ate", - "sta te", - "stat e", - "ut ed", - "ute d", - "u ted", - "▁( )", - "▁ ()", - "▁с во", - "▁e dit", - "▁ed it", - "▁ edit", - "ur ing", - "uri ng", - "u ring", - "▁N S", - "▁ NS", - "▁J ahr", - "▁Jah r", - "▁Ja hr", - "▁prov ide", - "H e", - "▁Y es", - "▁Ye s", - "▁ Yes", - "an el", - "ane l", - "a nel", - "en ame", - "ena me", - "e name", - "▁D on", - "▁Do n", - "▁ Don", - "is k", - "i sk", - "gr a", - "g ra", - "el ij", - "eli j", - "e lij", - "▁r oot", - "▁ro ot", - "▁ root", - "* /", - "▁F re", - "▁Fr e", - "▁ Fre", - "▁M or", - "▁Mo r", - "▁ Mor", - "us ed", - "use d", - "u sed", - "ran ge", - "r ange", - "▁t amb", - "▁ta mb", - "▁tam b", - "▁mod ule", - "▁ module", - "▁d irectory", - "▁direct ory", - "▁director y", - "▁ directory", - "ound s", - "oun ds", - "Act ivity", - "Activ ity", - "▁m u", - "▁ mu", - "in fo", - "inf o", - "▁f ree", - "▁fr ee", - "▁fre e", - "▁ free", - "or ge", - "org e", - "ta b", - "t ab", - ") =", - "la ng", - "lan g", - "l ang", - "▁о с", - "▁ ос", - "▁F ROM", - "▁FR OM", - "▁ FROM", - "▁en ter", - "▁ent er", - "▁ enter", - "▁bec ame", - "id ae", - "ida e", - "х и", - "▁St ates", - "▁State s", - "▁Stat es", - "▁Sta tes", - "ver se", - "vers e", - "▁ex pl", - "▁exp l", - "▁ expl", - "yn t", - "y nt", - "U N", - "e e", - "en dent", - "end ent", - "enden t", - "ende nt", - "▁m aking", - "▁ma king", - "▁mak ing", - "▁ making", - "▁\" $", - "un i", - "u ni", - "qu ence", - "▁l ui", - "▁lu i", - "H T", - "▁us es", - "▁use s", - "▁ uses", - "zi e", - "z ie", - "ni a", - "n ia", - "Cont ent", - "▁C ount", - "▁Co unt", - "▁Coun t", - "▁Cou nt", - "▁ Count", - "▁stand ard", - "▁ standard", - "EN T", - "E NT", - "▁ко н", - "▁к он", - "▁ кон", - "fo rt", - "for t", - "f ort", - "ad as", - "ada s", - "a das", - "з у", - "S ystem", - "▁S w", - "▁ Sw", - "▁e ver", - "▁ev er", - "▁ ever", - "L O", - "▁cor respond", - "▁P o", - "▁ Po", - "ar gin", - "arg in", - "к т", - "і й", - "▁re main", - "▁rem ain", - "ci o", - "c io", - "▁act ual", - "▁actu al", - "▁ actual", - "ст у", - "с ту", - "▁s ind", - "▁si nd", - "▁sin d", - "▁P e", - "▁ Pe", - "▁ch anged", - "▁change d", - "▁chang ed", - "▁ changed", - "▁N ote", - "▁No te", - "▁Not e", - "▁ Note", - "sk ie", - "ski e", - "s kie", - "▁famil y", - "▁fam ily", - "▁ family", - "it à", - "co s", - "c os", - "tx t", - "t xt", - "ke r", - "k er", - "ce ed", - "c eed", - "▁a rr", - "▁ar r", - "▁ arr", - "▁c am", - "▁ca m", - "▁ cam", - "iz er", - "ize r", - "i zer", - "▁D an", - "▁Da n", - "▁ Dan", - "he l", - "h el", - "ic ult", - "icul t", - "H P", - "il er", - "ile r", - "i ler", - "▁S al", - "▁Sa l", - "▁ Sal", - "▁con nection", - "▁conne ction", - "▁connect ion", - "▁conn ection", - "▁ connection", - "us ion", - "k n", - "R I", - "▁v om", - "▁vo m", - "List ener", - "▁ ö", - "▁d im", - "▁di m", - "▁ dim", - "▁p ress", - "▁pr ess", - "▁pre ss", - "▁pres s", - "▁ press", - "▁e sc", - "▁es c", - "▁ esc", - "▁T ry", - "▁Tr y", - "▁ Try", - "at alog", - "ata log", - "atal og", - "▁th anks", - "▁than ks", - "▁thank s", - "D O", - "▁w ritten", - "▁writ ten", - "▁wr itten", - "▁ written", - "di r", - "d ir", - "re w", - "r ew", - "▁f ire", - "▁fi re", - "▁fir e", - "▁ fire", - "▁N ach", - "▁Na ch", - "▁ á", - "en c", - "e nc", - "▁or igin", - "▁orig in", - "▁ origin", - "▁Nov ember", - "▁} ;", - "▁ };", - "Co unt", - "C ount", - "▁З а", - "▁ За", - "▁g raph", - "▁gr aph", - "▁gra ph", - "▁ graph", - "▁m is", - "▁mi s", - "▁ mis", - "▁Ex ternal", - "▁Ext ernal", - "▁Extern al", - "▁Externa l", - "▁ External", - "▁o ptions", - "▁option s", - "▁opt ions", - "▁ options", - "▁U RL", - "▁ URL", - "▁p hp", - "▁ph p", - "▁ php", - "▁in tegr", - "▁int egr", - "▁inte gr", - "▁ integr", - "Con fig", - "Conf ig", - "▁T ext", - "▁Te xt", - "▁Tex t", - "▁ Text", - "in ner", - "inn er", - "▁c rit", - "▁cr it", - "▁cri t", - "▁ crit", - ", ”", - "▁t og", - "▁to g", - "$ $", - "no f", - "n of", - "▁s es", - "▁se s", - "üh r", - "ü hr", - "▁S ince", - "▁Sin ce", - "▁ Since", - "De s", - "D es", - "ub e", - "u be", - "▁s ection", - "▁se ction", - "▁sec tion", - "▁sect ion", - "▁ section", - "▁g i", - "▁ gi", - "fo rd", - "for d", - "f ord", - "▁A ss", - "▁As s", - "▁ Ass", - "ain er", - "ai ner", - "aine r", - "a iner", - "tt p", - "t tp", - "▁be hav", - "▁beh av", - "port s", - "por ts", - "dr aw", - "dra w", - "d raw", - "Th is", - "T his", - "ran ch", - "r anch", - "in ding", - "ind ing", - "indi ng", - "▁e stab", - "▁est ab", - "▁es tab", - "▁esta b", - "▁ob tain", - "▁obt ain", - "ri ch", - "ric h", - "r ich", - "li cit", - "lic it", - "е в", - "▁qu al", - "▁q ual", - "▁ qual", - "▁z a", - "▁ za", - "▁h ar", - "▁ha r", - "▁ har", - "▁f ac", - "▁fa c", - "▁ fac", - "aa r", - "a ar", - "je t", - "j et", - "ic les", - "icle s", - "i cles", - "▁A us", - "▁Au s", - "▁ Aus", - "▁h or", - "▁ho r", - "▁ hor", - "▁re mov", - "▁rem ov", - "▁w ie", - "▁ wie", - "Cl ient", - "C lient", - "▁n atur", - "▁nat ur", - "hi p", - "h ip", - "Su b", - "S ub", - "▁r andom", - "▁ran dom", - "▁rand om", - "▁ random", - "D F", - "▁a rea", - "▁are a", - "▁ar ea", - "▁ area", - "ta g", - "t ag", - "P r", - "▁I tal", - "▁It al", - "▁ Ital", - "▁r oku", - "▁ro ku", - "▁rok u", - "no follow", - "nof ollow", - "* }", - "▁o thers", - "▁other s", + "\n\n2 \n\n3", + "▁minut es", + "▁applic abl", + "-bas ed▁", + "O ak", + "a plan", + "c ru", + "e ier", + "n er", + "r up", + "re pe", + "im medi", + "ur e▁that", + "▁P SA", + "wh ere▁", + "eth yl", + "ous and▁", + "rib ution", + "17 :", + "▁ob jective▁", + "indic ated", + "at ▁the▁", + "lind ed▁", + "▁do es▁not", + "▁October ▁2006", + "A ug", + "F ollow", + ".▁ W", + ".\n\n 2", + "pro cedures", + "▁f l", + "imen sion", + "ZD 217", + "▁mor e▁than", + "oxic ity▁", + "arbepoetin ▁alfa", + "8 \n\nPage▁", + "P roduct", + "p ut", + "w is", + "in fusion", + "it s▁", + "ing ▁in", + "es▁ will", + "▁S ep", + "▁D ose▁", + "▁on e▁", + "▁ab normal", + "elig ibl", + "UD Y", + "2 :", + "9 4", + "S ponsor", + "f unction", + "s afety▁", + "as ma", + "▁d ay▁", "▁l imit", - "▁li mit", - "▁lim it", - "▁ limit", - "▁s il", - "▁si l", - "▁ sil", - "▁s av", - "▁sa v", - "▁o ften", - "▁of ten", - "▁oft en", - "▁re nder", - "▁r ender", - "▁ren der", - "▁rend er", - "▁rende r", - "▁ render", - "D B", - "▁M c", - "▁ Mc", - "▁z ijn", - "▁zij n", - "же н", - "ж ен", - "▁t ag", - "▁ta g", - "▁ tag", - "min g", - "mi ng", - "m ing", - "li chen", - "lic hen", - "lich en", - "liche n", - "l ichen", - "pa ck", - "p ack", - "▁A g", - "▁ Ag", - "▁s ense", - "▁sens e", - "▁sen se", - "p g", - "Met hod", - "M ethod", - "ag ed", - "age d", - "a ged", - "á g", - "ł a", - "▁inter est", - "▁inte rest", - "▁as soci", - "▁ass oci", - "▁ associ", - "vol ution", - "▁em pty", - "▁emp ty", - "▁ empty", - "ic he", - "ich e", - "i che", - "▁g ro", - "▁gr o", - "▁ gro", - "▁t ypes", - "▁type s", - "▁typ es", - "▁ty pes", - "▁ types", - "▁S ie", - "▁Si e", - "In ter", - "Int er", - "▁n oreferrer", - "▁ noreferrer", - "▁g ives", - "▁giv es", - "▁give s", - "▁gi ves", - "ha l", - "h al", - "▁s ave", - "▁sa ve", - "▁sav e", - "▁ save", - "▁f ont", - "▁fo nt", - "▁fon t", - "▁ font", - "ru ction", - "ruct ion", - "S cript", - "▁a lla", - "▁al la", - "▁all a", - "▁ alla", - "▁s ays", - "▁sa ys", - "▁say s", - "▁f u", - "▁ fu", - "ap e", - "a pe", - "▁l anguage", - "▁ language", - "ig er", - "ige r", - "i ger", - "▁K ing", - "▁Ki ng", - "▁Kin g", - "bo r", - "b or", - "u v", - "▁s hall", - "▁sh all", - "▁E urope", - "▁Europ e", - "▁Euro pe", - "▁Eur ope", - "▁ Europe", - "▁ein em", - "▁eine m", - "▁w ater", - "▁wa ter", - "▁wat er", - "▁ water", - "▁g overn", - "▁go vern", - "▁gover n", - "an z", - "at ors", - "ator s", - "ato rs", - "▁mon th", - "▁mo nth", - "▁mont h", - "▁ month", - "y e", - "▁import ant", - "▁ important", - "at z", - "a tz", - "fir st", - "f irst", - "▁Tr ans", - "▁Tra ns", - "▁ Trans", - "▁M ad", - "▁Ma d", - "▁ Mad", - "▁b ra", - "▁br a", - "▁ bra", - "ik a", - "i ka", - "▁S aint", - "▁Sa int", - "▁Sain t", - "▁ Saint", - "or ia", - "ori a", - "o ria", - "kr e", - "k re", - "em ents", - "ement s", - "emen ts", - "e ments", - "▁B en", - "▁Be n", - "▁ Ben", - "la v", - "l av", - "▁ad min", - "▁adm in", - "▁ admin", - "▁H en", - "▁He n", - "▁ Hen", - "ri l", - "r il", - "▁S m", - "▁ Sm", - "ca t", - "c at", - "▁Re fer", - "▁Ref er", - "▁ Ш", - "▁p ract", - "▁pr act", - "▁pra ct", - "▁prac t", - "▁P at", - "▁Pa t", - "▁ Pat", - "▁G re", - "▁Gr e", - "▁ Gre", - "▁you ng", - "▁yo ung", - "▁In ter", - "▁Int er", - "▁ Inter", - "om a", - "o ma", - "te ger", - "ib ility", - "ibil ity", - "▁param eters", - "▁parameter s", - "▁paramet ers", - "▁ parameters", - "▁every thing", - "da t", - "d at", - "ur op", - "uro p", - "u rop", - "ole an", - "o lean", - "▁return ed", - "▁C lass", - "▁Cl ass", - "▁Cla ss", - "▁ Class", - "ac y", - "a cy", - "## ##", - "▁p ř", - "▁f older", - "▁fol der", - "▁fo lder", - "▁ folder", - "▁k on", - "▁ko n", - "▁ kon", - "▁gu ess", - "g t", - "je n", - "j en", - "an nel", - "ann el", - "anne l", - "ic on", - "ico n", - "i con", - "▁c omb", - "▁com b", - "▁co mb", - "▁ comb", - "ri ct", - "ric t", - "r ict", - "▁h ij", - "▁hi j", - "▁aut hor", - "▁auth or", - "▁ author", - "se e", - "s ee", - "he re", - "her e", - "h ere", - "st ra", - "str a", - "s tra", - "▁ent ire", - "▁direct ly", - "ra ft", - "raf t", - "r aft", - "he et", - "es ter", - "est er", - "este r", - "e ster", - "▁м и", - "▁ ми", - "▁m ass", - "▁ma ss", - "▁mas s", - "▁ mass", - "un tu", - "unt u", - "▁u sers", - "▁us ers", - "▁use rs", - "▁user s", - "▁ users", - "ch i", - "c hi", - "P E", - "▁com ponent", - "▁compon ent", - "▁ component", - "Cl ick", - "C lick", - "At t", - "A tt", - "▁s obre", - "▁so bre", - "▁sob re", - "an ds", - "and s", - "▁H ol", - "▁Ho l", - "▁ Hol", - "▁S ant", - "▁San t", - "▁Sa nt", - "or i", - "o ri", - "▁s ua", - "▁su a", - "st d", - "s td", - "ent ic", - "enti c", - "C C", - "▁fil ter", - "▁ filter", - "S QL", - "▁G od", - "▁Go d", - "A t", - "▁м у", - "▁ му", - "▁per formance", - "▁perform ance", - "del ta", - "d elta", - "an de", - "and e", - "a nde", - "am er", - "ame r", - "a mer", - "д ы", - "▁c ult", - "▁cu lt", - "▁cul t", - "▁N or", - "▁No r", - "bu t", - "b ut", - "▁l ik", - "▁li k", - "▁ lik", - "**** ****", - "ст вен", - "ств ен", - "стве н", - "▁com me", - "▁comm e", - "▁d r", - "▁ dr", - "im er", - "ime r", - "i mer", - "or din", - "ord in", - "▁cond ition", - "▁ condition", - "es te", - "est e", - "e ste", - "( [", - "F F", - "ть ся", - "im o", - "i mo", - "ra b", - "r ab", - "і ль", - "▁h alf", - "▁hal f", - "▁ half", - "ea ch", - "e ach", - "Di s", - "D is", - "▁r ows", - "▁ro ws", - "▁row s", - "▁ rows", - "▁h on", - "▁ho n", - "▁ hon", - "▁t ogether", - "▁tog ether", - "▁ și", - "me di", - "med i", - "m edi", - "ag n", - "a gn", - "al led", - "all ed", - "alle d", - "▁v ill", - "▁vi ll", - "▁vil l", - "IN G", - "I NG", - "id den", - "idd en", - "▁d raw", - "▁dr aw", - "▁dra w", - "▁ draw", - "yn tax", - "ynt ax", - "▁att empt", - "UR L", - "U RL", - "pos e", - "po se", - "p ose", - "▁in dic", - "▁ind ic", - "ни ка", - "ник а", - "▁Eng lish", - "▁ English", - "▁d éc", - "▁dé c", - "▁ne eds", - "▁need s", - "▁n ormal", - "▁nor mal", - "▁norm al", - "▁ normal", - "ur t", - "u rt", - "▁н о", - "▁ но", - "}} \\", - "} }\\", - "la st", - "las t", - "l ast", - "▁F in", - "▁ Fin", - "▁F ebru", - "▁Fe bru", - "▁Feb ru", - "il a", - "i la", - "▁c ountry", - "▁count ry", - "▁coun try", - "▁ country", - "▁field s", - "▁fiel ds", - "▁ fields", - "▁m ax", - "▁ma x", - "▁ max", - "lé s", - "l és", - "ow ie", - "owi e", - "o wie", - "▁de ux", - "▁bu ilt", - "▁ built", - "▁M ain", - "▁Ma in", - "▁Mai n", - "▁ Main", - "▁c amp", - "▁cam p", - "▁ca mp", - "▁ camp", - "iv o", - "i vo", - "iv a", - "i va", - "ic y", - "i cy", - "zi one", - "z ione", - "No de", - "N ode", - "▁: )", - "▁ :)", - "▁am ong", - "▁O b", - "▁ Ob", - "▁c ases", - "▁case s", - "▁cas es", - "▁ cases", - "ha ps", - "h aps", - "se rs", - "ser s", - "s ers", - "ar ter", - "art er", - "arte r", - "śc i", - "ś ci", - "▁it er", - "▁i ter", - "▁ iter", - "▁n amed", - "▁name d", - "▁na med", - "▁nam ed", - "▁ named", - "ex ec", - "exe c", - "▁se ason", - "▁sea son", - "▁ season", - "to t", - "t ot", - "= >", - "gr aph", - "gra ph", - "g raph", - "▁n il", - "▁ni l", - "▁ nil", - "ac ional", - "acion al", - "aci onal", - "▁N ULL", - "▁ NULL", - "▁spe cial", - "▁spec ial", - "▁ special", - "ст е", - "с те", - "cs s", - "c ss", - "▁\\ (", - "v s", - "ae l", - "a el", - "▁c ity", - "▁ci ty", - "▁cit y", - "▁ city", - "ov a", - "o va", - "▁art icle", - "▁ article", - "▁S outh", - "▁So uth", - "▁Sou th", - "Act ion", - "Ac tion", - "A ction", - "ç a", - "sp ring", - "spr ing", - "s pring", - "it ude", - "itu de", - "itud e", - "▁com plex", - "▁comp lex", - "▁comple x", - "▁compl ex", - "▁ complex", - "▁ч то", - "bu ild", - "g amma", - "▁E nt", - "▁En t", - "▁ Ent", - "ie rs", - "ier s", - "i ers", - "' .", - "ca r", - "c ar", - "ap ache", - "apa che", - "in gen", - "ing en", - "inge n", - "In put", - ":  ", - "▁d ynam", - "▁dy nam", - "al ls", - "all s", - "sh ow", - "s how", - "| \\", - "▁w ird", - "▁wir d", - "B ar", - "al th", - "alt h", - "mod el", - "mo del", - "mode l", - "m odel", - "Tr ans", - "Tra ns", - "Ro w", - "R ow", - "ab e", - "a be", - "▁l ib", - "▁li b", - "▁ lib", - "nu ll", - "n ull", - "ra gment", - "rag ment", - "▁St ate", - "▁Stat e", - "▁Sta te", - "▁ State", - "▁l aw", - "▁la w", - "▁ law", - "Fr ame", - "F rame", - "▁L o", - "▁ Lo", - "ge b", - "g eb", - "}$ .", - "} $.", - "▁ne eded", - "▁need ed", - "▁con tr", - "▁cont r", - "▁ contr", - "ar ies", - "ari es", - "arie s", - "a ries", - "▁s creen", - "▁sc reen", - "▁scr een", - "▁ screen", - "y r", - "m m", - "▁sh own", - "▁show n", - "▁sho wn", - "▁b ad", - "▁ba d", - "▁ bad", - "▁c ast", - "▁cas t", - "▁ca st", - "▁ cast", - "▁T est", - "▁Te st", - "▁ Test", - "▁A uf", - "▁Au f", - "▁qu ant", - "▁quan t", - "▁ quant", - "ig a", - "i ga", - "▁re n", - "▁r en", - "▁ ren", - "▁M ac", - "▁Ma c", - "▁ Mac", - "▁trans form", - "▁ transform", - "▁d ifference", - "▁dif ference", - "▁differ ence", - "▁t it", - "▁ti t", - "▁ tit", - "T E", - "▁st ep", - "▁ste p", - "▁ step", - "▁c apt", - "▁cap t", - "▁ca pt", - "▁ capt", - "▁col lection", - "▁coll ection", - "▁collect ion", - "▁colle ction", - "▁ collection", - "iction ary", - "▁T om", - "▁To m", - "▁ Tom", - "ri er", - "rie r", - "r ier", - "▁m ove", - "▁mov e", - "▁mo ve", - "▁ move", - "co pe", - "cop e", - "c ope", - "or ds", - "ord s", - "▁fur ther", - "▁column s", - "▁ columns", - "▁L in", - "▁Li n", - "▁ Lin", - "▁f ixed", - "▁fix ed", - "▁ fixed", - "▁child ren", - "▁ children", - "M S", - "m o", - "un a", - "u na", - "▁ind ivid", - "tt y", - "t ty", - "as te", - "ast e", - "a ste", - "sr c", - "s rc", - "mat ch", - "m atch", - "w i", - "▁ х", - "▁д и", - "▁ ди", - "▁o rd", - "▁or d", - "▁ ord", - "iv ing", - "ivi ng", - "i ving", - "▁B ro", - "▁Br o", - "▁ Bro", - "▁al most", - "▁P res", - "▁Pr es", - "▁Pre s", - "▁ Pres", - "re ci", - "rec i", - "ar ing", - "ari ng", - "arin g", - "a ring", - "▁/ //", - "▁// /", - "▁ ///", - "ет ся", - "е тся", - "▁s ig", - "▁si g", - "▁ sig", - "lig ht", - "l ight", - "▁R ed", - "▁Re d", - "▁ Red", - "▁sugg est", - "▁sug gest", - "ol f", - "▁é té", - "▁ét é", - "▁ été", - "is ation", - "isa tion", - "isat ion", - "з на", - "Ne w", - "N ew", - "ст ан", - "ста н", - "с тан", - "L A", - "un icip", - "unic ip", - "uni cip", - "▁fig ure", - "▁figur e", - "▁ figure", - "m t", - "ia le", - "ial e", - "i ale", - "▁c atch", - "▁cat ch", - "▁ catch", - "de fault", - "def ault", - "▁t ele", - "▁te le", - "▁tel e", - "▁ tele", - "▁m atter", - "▁mat ter", - "ca st", - "cas t", - "c ast", - "▁R ich", - "▁Ric h", - "▁Ri ch", - "▁ Rich", - "▁hand le", - "▁ handle", - "val u", - "va lu", - "v alu", - "$ -", - "о б", - "▁j son", - "▁js on", - "▁ json", - "Cre ate", - "C reate", - "▁ex am", - "ал ь", - "а ль", - "ю т", - "or ed", - "ore d", - "o red", - "id os", - "ido s", - "ap pend", - "app end", - "appen d", - "appe nd", - "▁Ar ray", - "▁Arr ay", - "▁ Array", - "к с", - "} [", - "ri ve", - "riv e", - "r ive", - "▁c lub", - "▁cl ub", - "▁ club", - "ma nn", - "man n", - "m ann", - "▁e ste", - "▁est e", - "▁es te", - "▁ este", - "es ta", - "est a", - "e sta", - "▁G i", - "▁ Gi", - "▁J ap", - "▁Ja p", - "▁N ame", - "▁Na me", - "▁Nam e", - "▁ Name", - "Col umn", - "ou ps", - "oup s", - "o ups", - "is mo", - "ism o", - "▁C ity", - "▁Ci ty", - "▁Cit y", - "▁ City", - "▁class es", - "▁classe s", - "▁ classes", - "▁in fl", - "▁inf l", - "▁ infl", - "h l", - "ро м", - "р ом", - "▁ad ding", - "▁add ing", - "▁ adding", - "▁f ail", - "▁fa il", - "▁ fail", - "x x", - "õ es", - "S c", - "ut il", - "uti l", - "u til", - "▁l ocation", - "▁lo cation", - "▁loc ation", - "▁ location", - "le ge", - "leg e", - "l ege", - "ag o", - "a go", - "▁pro perties", - "▁proper ties", - "▁ properties", - "ab il", - "abi l", - "a bil", - "va s", - "v as", - "}$ ,", - "} $,", - "it ted", - "itt ed", - "itte d", - "ó d", - "▁D em", - "▁De m", - "▁as ked", - "▁ask ed", - "▁t ab", - "▁ta b", - "▁ tab", - "S ource", - "▁error s", - "▁err ors", - "▁ errors", - "ograph ie", - "▁ж и", - "▁ жи", - "▁m al", - "▁ma l", - "▁ mal", - "st ract", - "str act", - "stra ct", - "▁d ro", - "▁dr o", - "▁ dro", - "ra k", - "r ak", - "▁n ote", - "▁not e", - "▁no te", - "▁ note", - "▁set ting", - "▁sett ing", - "▁ setting", - "▁f em", - "▁fe m", - "▁s aw", - "▁sa w", - "ia r", - "i ar", - "HE R", - "H ER", - "е с", - "▁p red", - "▁pr ed", - "▁pre d", - "▁ pred", - "▁O ut", - "▁ Out", - "▁it ems", - "▁item s", - "▁ items", - "ла н", - "л ан", - "▁w erd", - "▁we rd", - "▁wer d", - "ers ion", - "li a", - "l ia", - "▁s in", - "▁si n", - "▁ sin", - "ich te", - "icht e", - "i chte", - "▁fe el", - "▁fee l", - "▁п ра", - "▁пр а", - "▁ пра", - "▁o der", - "▁od er", - "▁ oder", - "U E", - "oc ument", - "▁m ode", - "▁mod e", - "▁mo de", - "▁ mode", - "▁N a", - "▁ Na", - "де н", - "д ен", - "me s", - "m es", - "frame work", - "▁a uto", - "▁au to", - "▁aut o", - "▁ auto", - "ны м", - "н ым", - "ub y", - "u by", - "▁tem plate", - "▁temp late", - "▁ template", - "▁m ess", - "▁me ss", - "▁mes s", - "▁ mess", - "ie der", - "ied er", - "i eder", - "▁rel ated", - "▁rela ted", - "▁relate d", - "▁ related", - "ok en", - "oke n", - "o ken", - "▁follow s", - "se arch", - "s earch", - "am i", - "a mi", - "▁w ait", - "▁wa it", - "▁ wait", - "ig r", - "i gr", - "▁l ow", - "▁lo w", - "▁ low", - "ски х", - "ск их", - "с ких", - "ска я", - "с кая", - "▁M ark", - "▁Mar k", - "▁ Mark", - "▁i ll", - "▁il l", - "▁ ill", - "am ento", - "ament o", - "amen to", - "\\ <", - "▁d f", - "▁ df", - "os ition", - "osi tion", - "▁В и", - "is f", - "i sf", - "▁De utsch", - "ah l", - "a hl", - "wa r", - "w ar", - "it ect", - "ite ct", - "▁s al", - "▁sa l", - "▁ sal", - "el en", - "ele n", - "e len", - "By Id", - "▁g ru", - "▁gr u", - "▁ gru", - "s v", - "▁pass ed", - "▁pas sed", - "▁passe d", - "▁a ñ", - "▁ añ", - "Sc h", - "S ch", - "▁sol ve", - "we ise", - "weis e", - "wei se", - "at os", - "ato s", - "▁m eg", - "▁me g", - "▁m ember", - "▁mem ber", - "▁memb er", - "▁ member", - "er name", - "ern ame", - "erna me", - "▁con nect", - "▁conne ct", - "▁conn ect", - "▁ connect", - "ip s", - "i ps", - "▁r ound", - "▁ro und", - "▁rou nd", - "▁ round", - "▁ ]", - "ne s", - "n es", - "▁d ir", - "▁di r", - "▁ dir", - "▁Lond on", - "d y", - "F A", - "▁rece ived", - "▁receive d", - "re et", - "ree t", - "▁L og", - "▁Lo g", - "▁ Log", - "▁Sch ool", - "an go", - "ang o", - "▁The se", - "▁Th ese", - "▁M ont", - "▁Mon t", - "▁Mo nt", - "▁ Mont", - "▁e ner", - "▁en er", - "▁ ener", - "la d", - "l ad", - "▁def ine", - "▁defin e", - "▁ define", - "si gn", - "sig n", - "s ign", - "▁c le", - "▁cl e", - "▁ cle", - "fig ure", - "▁V iew", - "▁Vi ew", - "▁Vie w", - "▁ View", - "text bf", - "$ \\", - "з ы", - "num ber", - "n umber", - "▁d in", - "▁di n", - "▁ din", - "el ler", - "ell er", - "elle r", - "orith m", - "ori thm", - "fal se", - "f alse", - "fo l", - "f ol", - "ffic ient", - "▁HT ML", - "▁ HTML", - "li che", - "lic he", - "lich e", - "l iche", - "▁M o", - "▁ Mo", - "▁int rodu", - "▁intr odu", - "▁intro du", - "ex p", - "e xp", - "▁st rong", - "▁str ong", - "▁stro ng", - "▁ strong", - "▁t hus", - "▁th us", - "/ )", - "▁e le", - "▁el e", - "▁ ele", - "▁та к", - "▁ так", - "▁п а", - "▁ па", - "▁d ont", - "▁do nt", - "▁don t", - "▁c ause", - "▁caus e", - "▁ca use", - "Num ber", - "N umber", - "▁im ages", - "▁image s", - "▁imag es", - "▁ images", - "▁s ample", - "▁sam ple", - "▁ sample", - "▁s ci", - "▁sc i", - "▁ sci", - "li ke", - "lik e", - "l ike", - "▁L ou", - "▁Lo u", - "▁ Lou", - "di v", - "d iv", - "an c", - "a nc", - "▁f ront", - "▁fr ont", - "▁fro nt", - "▁ front", - "ne n", - "n en", - "▁miss ing", - "▁mis sing", - "▁ missing", - "ar ia", - "ari a", - "a ria", - "pr es", - "pre s", - "p res", - "▁п ред", - "▁пре д", - "D I", - "fil ter", - "▁M it", - "▁Mi t", - "U R", - "▁o pp", - "▁op p", - "▁ opp", - "▁s ql", - "▁sq l", - "▁ sql", - "▁ро ку", - "er en", - "ere n", - "e ren", - "em at", - "ema t", - "e mat", - "í s", - "▁Je an", - "▁ Jean", - "é c", - "▁c i", - "▁ ci", - "en ne", - "enn e", - "at form", - "▁t aken", + "op tion", + "alys is", + "01 2", + "▁ex perienc", + "ousand▁ Oak", + ", ▁an", + "a ir", + "d ec", + "e ad", + "er min", + "st aff", + "▁b efore▁", + "ad dition", + "ad just", + "ne ed", + "agn es", + "▁ind ividual", "▁tak en", - "▁take n", - "▁ta ken", - "▁O f", - "▁ Of", - "▁на се", - "▁e rr", - "▁er r", - "▁ err", - "O P", - "Fr om", - "F rom", - "De fault", - "Def ault", - "▁Gener al", - "▁Gen eral", - "▁Gene ral", - "▁ General", - "wik i", - "wi ki", - "w iki", - "▁g rand", - "▁gr and", - "▁gra nd", - "▁gran d", - "▁ grand", - "▁e inen", - "▁ein en", - "▁eine n", - "Re g", - "R eg", - "Hand ler", - "Handle r", - "con om", - "co nom", - "cono m", - "c onom", - "an ger", - "ang er", - "ange r", - "▁бы л", - "▁L os", - "▁Lo s", - "▁ Los", - "▁ex pression", - "▁exp ression", - "▁express ion", - "▁expr ession", - "▁ expression", - "ш а", - "ya l", - "y al", - "▁$ ('", - "▁$( '", - "▁sw itch", - "▁ switch", - "▁v ector", - "▁ve ctor", - "▁vec tor", - "▁ vector", - "▁T hom", - "▁Th om", - "▁v irt", - "▁vi rt", - "▁vir t", - "▁ virt", - "le ased", - "lease d", - "lea sed", - "▁c over", - "▁co ver", - "▁cov er", - "▁ cover", - "▁re sp", - "▁r esp", - "▁res p", - "▁ resp", - "ak o", - "a ko", - "ren ch", - "ot a", - "o ta", - "C ell", - "an ged", - "ang ed", - "ange d", - "▁+ =", - "▁ +=", - "la c", - "l ac", - "sk a", - "s ka", - "ne xt", - "nex t", - "n ext", - "▁Intern ational", - "▁W il", - "▁Wi l", - "▁ Wil", - "▁o nt", - "▁on t", - "▁ ont", - "ib r", - "i br", - "us tr", - "ust r", - "u str", - "▁b lack", - "▁bl ack", - "▁bla ck", - "▁ black", - "▁select ed", - "▁sel ected", - "▁sele cted", - "▁ selected", - "ch er", - "che r", - "c her", - "▁l iter", - "▁li ter", - "▁lit er", - "▁ liter", - "ro ot", - "r oot", - "л ся", - "▁L ife", - "▁Li fe", - "▁ Life", - "▁in sert", - "▁ins ert", - "▁inser t", - "▁inse rt", - "▁ insert", - "▁mat rix", - "▁ matrix", - "is es", - "ise s", - ") ]", - "▁p el", - "▁pe l", - "▁ pel", - "Over ride", - "ry pt", - "▁for mer", - "▁form er", - "▁forme r", - "▁ former", - "▁Fil m", - "▁N orth", - "▁Nor th", - "cl ient", - "cli ent", - "c lient", - "▁n ight", - "▁ night", - "хо ди", - "ход и", - "▁A ustral", - "▁Aust ral", - "▁ Austral", - "▁R et", - "▁Re t", - "▁ Ret", - "rh o", - "r ho", - "▁п ер", - "▁пе р", - "▁ пер", - "ip edia", - "ipe dia", - "▁ex press", - "▁exp ress", - "▁expr ess", - "▁expres s", - "▁ express", - "▁th ird", - "▁ third", - "▁ma jor", - "▁maj or", - "▁ major", - "▁g rad", - "▁gr ad", - "▁gra d", - "▁ grad", - "ow e", - "o we", - "▁bel ieve", - "our nal", - "ourn al", - "▁st atus", - "▁stat us", - "▁ status", - "un c", - "u nc", - "▁d ou", - "▁do u", - "▁J SON", - "▁JS ON", - "▁ JSON", - "ui s", - "u is", - "▁pop ulation", - "▁popula tion", - "▁popul ation", - "en z", - "▁Will iam", - "s f", - "▁O bject", - "▁Ob ject", - "▁ Object", - "▁c in", - "▁ci n", - "▁ cin", - "▁D i", - "▁ Di", - "cur ity", - "c urity", - "▁O pen", - "▁Op en", - "▁ Open", - "▁ ле", - "la r", - "l ar", - "ad ding", - "add ing", - "▁k om", - "▁ko m", - "▁ kom", - "}( \\", - "} (\\", - "▁k il", - "▁ki l", - "▁ kil", - "um er", - "ume r", - "u mer", - "\"/ >", - "\" />", - "▁fe ature", - "▁ feature", - "▁A re", - "▁Ar e", - "▁ Are", - "ck s", - "c ks", - "▁Intern et", - "▁Inter net", - "▁ Internet", - "▁i h", - "▁ ih", - "▁start ed", - "▁star ted", - "▁ear ly", - "▁be gan", - "▁beg an", - "T H", - "p ython", - "as p", - "a sp", - "▁F r", - "▁ Fr", - "▁c los", - "▁cl os", - "▁clo s", - "▁ clos", + "▁loc al▁", + "/ T", + "3 1", + ",▁ c", + "ro ch", + "▁b od", + "se cond", + "27 2", + "ysical▁ examination", + "iderm al▁", + "- ra", + "E valu", + "M ed", + "m etastas", + "m easurable▁", + "es ▁that", + "es▁ from", "ist ic", - "isti c", - "▁mus ic", - "▁ music", - "▁d ig", - "▁di g", - "▁ dig", - "▁it al", - "▁i tal", - "▁ ital", - "▁D avid", - "▁Dav id", - "▁Da vid", - "▁ David", - "▁web site", - "▁ website", - "▁cont roller", - "▁control ler", - "▁ controller", - "▁M er", - "▁Me r", - "▁ Mer", - "con text", - "cont ext", - "pro duct", - "produ ct", - "prod uct", - "os p", - "o sp", - "▁j un", - "▁ju n", - "ro wn", - "row n", - "r own", - "▁A z", - "▁ Az", - "\": \"", - "\" :\"", - "▁a an", - "▁aa n", - "▁D ate", - "▁Da te", - "▁Dat e", - "▁ Date", - "mu lt", - "mul t", - "m ult", - "▁b rowser", - "▁brow ser", - "▁ browser", - "ре д", - "wh ich", - "R A", - "qu are", - "qua re", - "▁R uss", - "▁Ru ss", - "▁Rus s", - "▁ Russ", - "▁s oon", - "▁so on", - "▁P re", - "▁Pr e", - "▁ Pre", - "ta u", - "t au", - "▁we ek", - "▁ week", - "▁б а", - "▁ ба", - "▁o ct", - "▁oc t", - "▁ oct", - "▁t own", - "▁to wn", - "▁ town", - "ro y", - "r oy", - "▁e ls", - "▁el s", - "▁ els", - "bl ic", - "b lic", - "und le", - "▁H istor", - "▁His tor", - "▁Hi stor", - "▁Hist or", - "▁f oi", - "▁fo i", - "▁mod els", - "▁model s", - "▁mode ls", - "▁ models", - "з о", - "on ym", - "ony m", - "o nym", - "Par am", - "Pa ram", - "P aram", - "▁M et", - "▁Me t", - "▁ Met", - "ge ner", - "gen er", - "g ener", - "j ą", - "▁e spe", - "▁es pe", - "▁esp e", - "C E", - "▁de vice", - "▁dev ice", - "▁devi ce", - "▁ device", - "el low", - "ell ow", - "ello w", - "▁de bug", - "▁deb ug", - "▁ debug", - "ér ie", - "éri e", - "é rie", - "us ing", - "u sing", - "ан г", - "а нг", - "▁* )", - "▁ *)", - "ud i", - "u di", - "▁M iss", - "▁Mi ss", - "▁Mis s", - "▁ Miss", - "ко м", - "к ом", - "pos ed", - "po sed", - "pose d", - "p osed", - "▁z we", - "▁zw e", - "і н", - "▁Ro bert", - "▁Rob ert", - "▁O ct", - "▁ Oct", - "lo p", - "l op", - "ja r", - "j ar", - "▁a ver", - "▁av er", - "▁ave r", - "▁ aver", - "▁ha bit", - "▁hab it", - "▁: :", - "▁ ::", - "än g", - "ä ng", - "St art", - "Star t", - "▁p ow", - "▁po w", - "▁ pow", - "▁s rc", - "▁sr c", - "▁ src", - "▁pat tern", - "▁ pattern", - "▁ Э", - "▁b i", - "▁ bi", - "ot es", - "ote s", - "o tes", - "▁_ _", - "▁ __", - "▁s ens", - "▁se ns", - "▁sen s", - "▁ sens", - "▁a void", - "▁av oid", - "▁avo id", - "ex ample", - "ut t", - "u tt", - "La bel", - "Lab el", - "L abel", - "te x", - "t ex", - "bo ot", - "b oot", - "es to", - "est o", - "e sto", + "▁of▁ 6", + "D A", + "G roup", + "− Aug", + "▁ “", + "▁f unction", + "od ium", + "eri or", + "cur r", + "▁2007 ▁17:", + "▁13 −Aug", + "36 .4", + "cess ▁to", + "mod el", + "▁differ ent", + "\n\n13 ▁Sep", + "−6 36.4", + "17: 03", + "272 −636.4", + "▁2007▁17: 17:03", + "▁13−Aug −201", + "\n\n13▁Sep ▁2007▁17:17:03", + "9 0", + "9 5%", + "d irect", + "h el", + "ro ph", + "▁c ediranib", + "▁b een", + "▁s creening", + "pl us▁", + "em erg", + "ag raph", + "▁ph ysician", + "................................................................................................ ................", + "▁tak e▁", + "\n\nConfidential \n\nAMGEN", + "apec itabine▁", + "▁May▁ 200", + "f ter", + "s ol", + "▁t arget", + ",▁ J", + "▁T o", + "▁g rade▁", + "olog ical▁", + "▁J une▁", + "▁day s▁", + "St at", + "▁et▁al .▁200", + "elect ronic", + "▁tel eph", + "▁Janu ary▁200", + "E Q-5D", + "it is", + "ro ut", + "ation s▁", + "▁d emonstr", + "oc k", + "ul a", + "▁T able▁", + "other apy", + "og lo", + "e▁th e▁s", + "▁any▁ other", + "CT G", + "▁det ect", + "person nel", + "quam ous▁", + "I M", + "c um", + "d e", + "l or", + "l ist", + "p rimary", + "s ▁a", + "ed .▁The▁", + "ev en", + "ra in", + "ot ic", + "\n\nN o", + "he alth", + "24 9", + "▁up ▁to", + "l at", + "s /", + "▁ known", + "ed )", + "ation ▁in", + "ol d", + "ur in", + "\n\nA mgen", + "all ow", + "▁ar e▁s", + "▁F or", + "tud y", + "▁4 ▁week", + "ed▁by ▁the▁investigator", + "▁ag ain", + "e in", + ".\n\n N", + "ment ▁of", + "ev ised▁", + "ug gest", + "▁the▁s afety▁", + "▁on c", + "▁ch est", + "▁6 ▁month", + "equ ate▁", + "▁Dec ember", + "H A", + "l ow", + "▁ u", + "▁ en", + "re ad", + "re duc", + "▁m y▁", + "▁P atient", + "il y▁", + "ag e", + "▁N C", + "▁day s▁prior▁to", + "car e▁", + "inter im", + "norm al▁", + "stitution al▁", + "\n\nD▁E▁T▁N▁I▁R▁P \n\nA", + "echn iqu", + "1 01", + "l ig", + "s k", + "▁p aclitaxel", + "report ed▁", + "evalu ated▁", + "▁10 9", + "\n\nT able▁", + "abil ity▁of", + "▁min imum", + "43 20", + "summar iz", + "vestigational▁ Product", + "one▁s can", + "▁tem per", + "▁Efficacy▁An alysis▁Set", + "ival ent", + "on al", + "▁( P", + "▁re duc", + "▁N SCLC", + "cont rol", + ".▁A t", + "rel evant", + "▁di ameter", + "▁the▁treatment ▁of", + "ours e▁of", + "O b", + "R eport", + "T umor", + "r incipal▁", + "u ro", + ",�� h", + "▁and▁ D", + "▁( m", + "▁al one▁", + "requ ir", + "▁analysis▁ will▁be▁", + "efor e▁the▁", + "bl em", + "\n\nS▁T▁I \n\nK▁C▁E▁H▁C", + "emc itabine▁", + "oglo bin", + "d :", + "s cal", + "u ally▁", + "v astin", + "at e,▁", + "ed▁ until", + ".▁ 5", + "\n\nC om", + "s▁s hould▁", + "▁discontinu ation", + "E F", + "s ent", + ".▁ Wh", + "▁D NA", + "40 249", + "▁mor e▁", + "▁ter min", + "ild-t ype▁KRAS", + "N SCLC", + "a ximum", + "i res", + "s hould▁", + "es ▁are▁", + "id ence▁in", + "reat ening", + "ter val", + "▁r andomis", + "ity ▁to", + "ult ic", + "▁from ▁the▁", + "peri od", + "▁im medi", + "emetrexed▁ H3E-MC-JM", + "3\n\nA pproved▁by", + "▁13−Aug−201 3\n\nApproved▁by", + ") ,", + ".▁ On", + "▁pro cedures", + "ear ly▁", + "▁F OLFIRI", + "01 47", + "eg a", + "-fre e▁s", + "( S", + "c riteria", + "n ing", + "es ▁the▁", + "im portant", + "(cid: 13", + "can ▁be▁", + "le ad", + "▁Th ousand▁Oak", + "▁cell ▁lung▁cancer", + "▁dec reas", + "h istor", + "s ing", + "or der", + ".▁ V", + "ed ▁according▁to", + "▁m on", + "▁m ethod", + "med ical", + "▁addition al▁", + "erious▁ Adverse▁Event", + "m etastatic", + "re turn", + "ef er", + "▁of▁ 0", + "act iv", + "▁g uidelin", + "▁st andard▁", + "iffer ent", + "▁provid e▁", + "ubl ication", + "utant ▁KRAS", + "8480 C0001", + "▁13−Aug−2013\n\nApproved▁by \n\n13▁Sep▁2007▁17:17:03", + ") ,▁and▁", + "▁ k", + "\n\n W", + "as ed▁on", + "with out", + "com mon", + "▁6 0", + "Protocol ▁A618", + "▁particip ate▁in", + "▁determin e▁", + "\n\nProtocol ▁Amendment", + ") ▁for", + "- study▁", + "/ IRB", + "B ioSci", + "i k", + "s .▁A", + "s chedul", + "▁ studies", + "▁p ost", + "▁c urrent", + "▁w omen", + "▁and▁ d", + "ced ure▁", + "subject s▁", + "▁30 −Jul−2014", + "▁applic able▁", + "measure d▁", + "braxis▁ BioSci", + "▁CV .000−", + "alg es", + "(b) ▁Confidential", + ", 000", + "S chedul", + "U p", + "▁ questionna", + "\n\n b", + "\n\n (cid:120)", + "▁C o", + "▁P er", + "ex am", + "▁U LN", + "▁X RP6258", + "risk ▁of", + "▁CR F", + "▁pos sibl", + "272−636.4 .0\n\nApproved\n\nDate▁Printed:", + "8 9", + ",▁ O", + ".\n\n R", + "▁in volv", + "▁C asodex", + "ection ▁of", + "bo th", + "▁ex pos", + "hem ist", + "itab in", + "-200 7", + "ZD4054 ▁Study▁Code▁D", + "Clinical▁Study▁Protocol▁Drug▁Substance▁ ZD4054▁Study▁Code▁D", + "gn ostic", + "teb ral▁", + "eut ic", + "evised▁ Clinical▁Study▁Protocol▁Drug▁Substance▁ZD4054▁Study▁Code▁D", + "▁Thousand▁Oak s", + "evised▁Clinical▁Study▁Protocol▁Drug▁Substance▁ZD4054▁Study▁Code▁D 4320", + "E P", + "ent ly▁", + "▁c reatinine▁", + "ing ▁or", + "▁and▁ in", + "est abl", + "▁cycl e▁", + "formed▁consent ▁form", + "▁the▁subject ’s▁", + "calcul ated▁", + "- 2", + "L D", + "M od", + "re ct", + "ur ine▁", + "os is", + "▁re main", + "▁l eg", + "ex tension", + "e,▁ or", + "▁will ▁not▁be▁", + "e▁d ata", + "▁e qu", + "▁9 54", + "MG ▁954", + "regn ant", + "8480C0001 3", + "establ ish", + "7 ▁August▁2007", + ".\n\n 9", + ".\n\n If", + "ut com", + "ther apy", + "per tension", + "\n\nS t", + "▁ex ampl", + "EC G", + "▁med ian", + "20 3", + "\n\nR eplace:", + "cri pt", + ")\n\nGEL▁Version▁ID: ▁CV.000−", + "▁assign ment", + "▁long er", + "c ut", + "g /m", + "w ork", + "w ritten", + "\n\n If", + "et ter", + "est ▁diameter", + "and l", + "\n\n1 \n\n2\n\n3", + "▁of▁1 0", + "CT ▁scan", + "artic ular", + "▁stat us", + "▁again st", + "ultic enter", + "b um", + "e cond▁", + "l og", + "▁d ate▁", + ".\n\n 8", + "ot al▁", + "▁E C", + "▁3 1", + ".▁Th ese▁", + "pect ive▁", + "▁ab d", + "peri ence▁", + "ass ign", + "ha zard▁ratio", + "C P", + "b est", + "v al▁", + "▁a ▁subject", + "▁th rom", + "▁the▁ protocol", + "ex clud", + "▁M alate▁", + "▁g rowth", + "▁L esion", + "xic ity▁", + "▁J M", + "clin ic", + ".▁C on", + "▁sign ificance▁level", + "ran k", + "▁Study▁ D", + "▁accord ing▁to▁the▁", + "▁(A MG▁954", + "▁approv al", + "▁avail abl", + "\n\nE▁R▁O▁F▁E▁B \n\nY▁T▁I▁D▁I▁L▁A▁V", + "growth▁factor ▁receptor", + "▁the▁dis cretion", + "272−636.4.0\n\nApproved\n\nDate▁Printed: ▁13−Aug−2013\n\nApproved▁by\n\n13▁Sep▁2007▁17:17:03", + "R eview", + "t est", + "or l", + ",▁ patients▁", + "th ics▁", + ".\n\n 10", + "▁P AN", + "em a", + "\n\nA BI-007", + "enc e,▁", + "▁with ▁a", + "▁the▁in vestigational▁product", + "s.▁ In", + "ous ly", + "ER S", + "rans fer", + "appro ximately▁", + "IT UM", + "AB ▁(AMG▁954", + "UM AB▁(AMG▁954", + "501 81", + "▁PAN ITUM", + ") ▁Protocol▁Number:▁200", + ",▁ w", + "▁p rof", + "ot al", + "\n\nS ubject", + "▁the▁p rimary", + "▁Date:▁0 7▁August▁2007", + "▁January▁200 9", + "40249 ▁Date:▁07▁August▁2007", + "▁30−Jul−2014 \n\nS", + "UMAB▁(AMG▁954 )▁Protocol▁Number:▁200", + "▁PANITUM UMAB▁(AMG▁954)▁Protocol▁Number:▁200", + "▁PANITUMUMAB▁(AMG▁954)▁Protocol▁Number:▁200 40249▁Date:▁07▁August▁2007", + "- in", + "6 ▁month", + "L IN", + "O T", + "e after", + "l ess▁of", + "s pecific", + "▁s olution", + "ub in", + "▁f ull", + "pon ent", + "▁metastatic ▁colorectal▁cancer", + "▁the▁last ▁dose▁of", + "▁the▁sam e▁", + "▁ irinotecan", + "al t", + "is ▁to", + "ist ribution", + "s,▁ or", + "out lin", + "ase▁ (", + "▁In c", + "▁ass ess▁", + "pers ensitiv", + "respectiv ely", + "strati fi", + "i ally▁", + "▁t abl", + "ed▁ if", + "▁of ficial▁", + "▁S D", + "▁L ill", + "▁ch aracter", + "olog y,▁", + "e▁d ocument", + ".▁P atient", + "se e▁", + "▁cont rol", + ".▁N o", + "ric t", + "E X", + "M RI", + "m ean", + "t ic", + "▁ ZD4054", + ".... .▁", + "es :", + "▁in ▁patients▁with", + "ub sequent", + "▁or ▁4", + "ex isting", + ".▁T o", + "▁tak ing", + "umm ary▁", + "▁blood▁ sampl", + "▁Date:▁0 4", + "▁Panitumumab▁Protocol▁Number:▁200 50181", + "A C", + "X OL", + "f requ", + "n d▁of", + "n eck", + "ing ▁for", + "▁s ection", + "em or", + "ul mon", + "ast ro", + "200 4", + "▁the▁s ampl", + "▁pl at", + "sub mitt", + "\n\nC▁I▁N▁O▁R▁T▁C▁E▁L▁E \n\nN", + "▁Ther apy▁", + "orig inal", + "▁app ear", + ", ▁the▁investigator", + "4 ▁week", + "I MC-", + "s ▁as▁", + "st opp", + "an e", + "ed .", + "\n\nP h", + "▁ad verse▁", + "▁R ec", + "wh ile▁", + "e▁b lood▁", + "▁Febru ary▁200", + "▁norm al", + "\n\nConfidential\n\nAMGEN \n\nProduct:", + "c ulation", + "g ram", + "l id", + "m ph", + "t aken", + "u s▁(", + "▁ qual", + "▁an ▁in", + "▁p emetrexed▁", + "▁w ors", + "ol d▁", + "▁com pared▁to", + "▁on ▁the▁", + "▁6 ▁0▁0▁0▁0▁0▁1▁0", + "plat elet", + ".4 .2", + "vi a", + "▁Date: ▁21", + "▁complet e▁", + "ogen ic", + "▁any ▁tim", + "IV RS", + "ed▁a bov", + "________ ________", + "ed▁c opy▁", + "is▁not ▁official▁", + "▁Panitumumab▁Protocol▁Number:▁20050 203", + "▁Date:▁21 ▁January▁2009", + "ed▁copy▁ is▁not▁official▁", + "▁Panitumumab▁Protocol▁Number:▁20050203 ▁Date:▁21▁January▁2009", + "ed▁copy▁is▁not▁official▁ record", + "L /", + "▁ ........................................................................................", + "▁p ath", + "▁C I", + "▁( cid:", + "ed▁in ▁a", + "ardi ov", + "▁bas ed▁on", + "braxis▁BioSci ence▁", + "p any▁", + "s p", + "▁ end", + "▁th ir", + "pro cedure", + "▁( R", + "▁n on", + "▁the▁s it", + "ob jective▁", + "▁pl ann", + "requ est", + "▁pre -", + "regnancy ▁test", + ".0▁Approved▁by\n\nApproved\n\nDate▁Printed: ▁30−Jul−2014\n\nS", + "jud g", + "▁teleph one▁", + "alges ic", + "7 5", + "P hase▁", + "b enefit", + "g reat", + "r h", + "s ▁the▁", + "▁ ≤", + "▁a mong", + "er iv", + "re -", + "st im", + ".▁ You", + "▁A straZeneca", + "▁n ecess", + "▁ad d", + "ov ari", + "result s▁of", + "▁di agnos", + "randomiz ed▁to", + "mod ification", + "-s id", + "sol ut", + "I S", + "o od", + "s ▁ar", + ",▁ including", + ".▁ (", + "▁re present", + "with ▁the▁", + "ap s", + "▁or ▁MRI", + "ter m", + "ator y▁", + "▁and ▁a", "▁M arch", - "▁Mar ch", - "▁Marc h", - "▁e asy", - "▁eas y", - "ict ure", - "Gr oup", - "▁f ather", - "▁fa ther", - "▁fat her", - "▁ father", - "▁up dated", - "▁update d", - "▁upd ated", - "▁ updated", - "▁V o", - "▁I II", - "▁II I", - "▁ III", + "\n\nC ONFIDENTIAL", + "ay s▁", + "▁In vestigator", + ".▁E x", + ".▁C ancer", + "urvival▁ (", + "▁accept able▁", + "▁PANITUMUMAB▁(AMG▁954)▁Protocol▁Number:▁20040249▁Date:▁07▁August▁2007 \n\nPage▁", + "S F", + "l eas", + "r Cl", + "▁ efficacy▁", + "▁m en", + "▁m ay", + "im pl", + "▁n od", + "gen er", + "\n\nE x", + "atist ical▁", + "go ing", + "ingl e▁", + ", ▁then", + "g rad", + "w w", + "er t", + "al ity", + "ed ▁the▁", + "▁( T", + "▁re duction", + "▁of▁ your", + "▁of▁the▁ study", + "▁F ollow", + ".▁The▁ investigator", + "xic ity", + ",▁and ▁the▁", + "peri or", + "require d", + "▁clin ically▁", + "▁Clinical▁ Trial▁Protocol:", + "▁Res earch", + "▁ver sion", + "PA ND", + "\n\nSunitinib ▁Malate▁", + "▁conf idence▁in", + "roph il", + "▁Clinical▁Trial▁Protocol: ▁CA", + ": ▁1", + "U R", + "e .▁If", + "l os", + "n ext", + "o y", + "at as", + "en g", + "ation ▁or", + "▁m et", + ".\n\n Wh", + "▁will▁be▁ administer", + "▁v s▁", + "ens ive▁", + "▁us ing", + "▁the▁patient ’s▁", + "hy pothes", + "oth el", + "-lin e▁", + "avail able▁", + "- week", + "2 ▁week", + "4 4", + "T UDY", + "d n", + "d elay", + "f at", + "r ight", + "\n\n to", + "▁an other", + "▁m align", + "▁and▁ other", + "im in", + "▁I N", + "up on", + "e▁s iz", + "lo b", + "rel ated▁", + "ly mph", + "▁cont act", + "▁reg ard", + "Onc ology▁", + "contain ing", + "omit ing", + "7 2", + "8 8", + "9 1", + "C H", + "P RO", + "l ot", + "n ausea", + "s ite▁", + "v ial", + "\n\n U", + "al ine▁", + "al▁ or", + "▁D ata", + "ex pos", + "In c", + "▁analys es", + ".5 .1", + "▁ex t", + "▁assessment ▁of", + "he art", + "\n\nT o", + "▁particip ant", + "▁Date:▁04 ▁April▁2008\n\nPage▁", + "▁Panitumumab▁Protocol▁Number:▁20050203▁Date:▁21▁January▁2009 \n\nPage▁", + "- 1", + "D ata", + "X PAND", + "c etuximab", + "o ag", + "s id", + "s ),▁", + "w as", + "st anc", + "▁s urger", + ".\n\n Y", + "ul y▁", + "con fidential▁", + "\n\nA braxis▁BioScience▁", + "dos e▁of", + "▁of▁12 7", + "disease▁ progression", + "ma ximum", + "(b)▁Confidential \n\nProtocol▁Amendment", + "7 4", + "J EC", + "o pl", + "s ence▁of", + "is /", + "▁w ritten", + "▁2 .0", + "us ed", + "▁h a", + "ver t", + "▁v s.▁", + ".▁S ubject", + "10 6", + "▁reg ulator", + "equ ire", + "-M eier", + "aplan -Meier", + "ardiov ascular", + "1 .5", + "u ch", + "▁ question", + "s▁ may▁", + "ed ▁tumor", + "▁in fection", + "il ir", + "ch iev", + "▁com mon", + "▁F inal▁", + "follow ed▁for", + "▁dos ing", + "▁radi ation", + "ardi ac", + "olec ular", + "▁order ▁to", + "▁aff ect", + "▁109 /L", + "▁6▁0▁0▁0▁0▁0▁1▁0 \n\nSunitinib▁Malate▁", + "ilir ubin", + "' s▁", + "c are", + "f urther", + "s )\n\n", + "ic e▁", + "▁A c", + "em al", + "ag e▁of", + "\n\nP age:", + ".1 0", + "ak ing", + "▁of▁1 33", + "cal cium", + "▁you ▁are▁", + "onfidential \n\nPage▁", + "▁5- FU", + "ask ed▁to", + "prof il", + "thics▁ Com", + "7 )", + "B JEC", + "s ever", + "s ,▁the▁", + "▁ endpoint", + "s▁ have▁", + "et c", + "▁s erious▁adverse▁event", "om ega", - "ome ga", - "▁a lle", - "▁al le", - "▁all e", - "▁ alle", - "Re c", - "R ec", - "y g", - "з е", - "▁D im", - "▁Di m", - "▁ Dim", - "ne ct", - "n ect", - "▁T or", - "▁To r", - "▁de utsch", - "▁ deutsch", - "▁wh ite", - "▁ white", - "▁n ational", - "▁nation al", - "▁nat ional", - "pp e", - "p pe", - "▁a ir", - "▁ai r", - "▁ air", - "▁pass word", - "▁ password", - "de t", - "d et", - "▁b ig", - "▁bi g", - "▁ big", - "▁U se", - "▁Us e", - "▁ Use", - "cal l", - "ca ll", - "c all", - "▁ex tra", - "▁ext ra", - "▁extr a", - "▁ extra", - "W e", - "an ia", - "ani a", - "a nia", - "▁h old", - "▁ho ld", - "▁hol d", - "▁ hold", - "Cont rol", - "▁C O", - "▁ CO", - "▁м і", - "▁ мі", - "it i", - "i ti", - "▁K e", - "▁ Ke", - "en u", - "e nu", - "▁P ark", - "▁Par k", - "то м", - "т ом", - "▁a uth", - "▁au th", - "▁aut h", - "▁ auth", - "▁c enter", - "▁cent er", - "▁ center", - "P h", - "то в", - "т ов", - "id ing", - "idi ng", - "i ding", - "▁a cross", - "▁ac ross", - "▁s ong", - "▁so ng", - "▁son g", - "▁ song", - "▁ph ys", - "▁ phys", - "▁n umer", - "▁num er", - "▁nu mer", - "▁ numer", - "щ а", - "▁A lex", - "▁Al ex", - "▁Ale x", - "▁ Alex", - "▁problem s", - "▁proble ms", - "▁probl ems", - "▁E rror", - "▁Er ror", - "▁Err or", - "▁ Error", - "form at", - "for mat", - "▁A cc", - "▁Ac c", - "▁ Acc", - "▁s ix", - "▁si x", - "▁ six", - "▁d b", - "▁ db", - "▁C ast", - "▁Cas t", - "▁Ca st", - "▁ Cast", - "om s", - "o ms", - "pro ject", - "proj ect", - "▁v ert", - "▁ver t", - "▁ve rt", - "▁ vert", - "cre t", - "cr et", - "c ret", - "▁he ader", - "▁head er", - "▁ header", - "▁st ream", - "▁stre am", - "▁ stream", - "id s", - "i ds", - "▁t or", - "▁to r", - "▁ tor", - "▁se pt", - "▁sep t", - "▁est im", - "▁es tim", - "▁de cl", - "▁dec l", - "▁ decl", - "▁g ave", - "▁ga ve", - "▁p layer", - "▁pl ayer", - "▁play er", - "▁pla yer", - "▁ player", - "ys is", - "▁д ру", - "▁др у", + "▁1 ,▁", + "▁l aboratory", + "ut ure▁", + "ist ant", + "per cent", + "ep idermal▁", + "▁st atist", + "\n\nF or", + "5- fluorouracil", + "rint ed▁copy▁is▁not▁official▁record", + "▁requ ir", + "▁stat us▁", + "Res ponse▁", + "\n\nABI-007 ▁Clinical▁Trial▁Protocol:▁CA", + ". 00", + "N P", + "e al", + "▁s pecific", + "ol /L", + "us pect", + "ot t", + "▁D os", "am m", - "a mm", - "щ о", - "▁( \"", - "▁ (\"", - "▁a x", - "▁ ax", - "Pro perty", - "us r", - "u sr", - "▁some one", - "▁im pro", - "▁imp ro", - "▁impr o", - "ad en", - "ade n", - "a den", - "ro te", - "rot e", - "r ote", - "▁М и", - "i h", - "++ )", - "+ +)", - "▁v ideo", - "▁vide o", - "▁ video", - "▁ex ists", - "▁exist s", - "▁ exists", - "к ла", - "▁comp lete", - "▁comple te", - "▁complet e", - "▁compl ete", - "▁ complete", - "▁s ession", - "▁sess ion", - "▁ session", - "▁const ant", - "▁ constant", - "ic os", - "ico s", - "i cos", - "▁p ack", - "▁pa ck", - "▁pac k", - "▁ pack", - "ro me", - "rom e", - "r ome", - "eg r", - "e gr", - "App lication", - "▁y es", - "▁ye s", - "▁ yes", - "▁e lle", - "▁el le", - "▁ell e", - "▁ elle", - "▁e mail", - "▁em ail", - "▁ email", - "or f", - "o rf", - "ca se", - "cas e", - "c ase", - "▁po inter", - "▁point er", - "▁ pointer", - "▁reg ard", - "se n", - "s en", - "st atus", - "stat us", - "▁m es", - "▁me s", - "▁ mes", - "▁d elle", - "▁de lle", - "▁del le", - "▁dell e", - "ing ton", - "ingt on", - "▁B as", - "▁Ba s", - "▁ Bas", - ") ^", - "de velop", - "▁for ce", - "▁ force", - "▁char acters", - "▁charact ers", - "▁character s", - "▁c ross", - "▁cr oss", - "▁cro ss", - "▁ cross", - "▁de ath", - "▁t akes", - "▁tak es", - "▁take s", - "▁ta kes", - "ér i", - "é ri", - "ig ne", - "ign e", - "че н", - "ч ен", - "U P", - ". :", - "Th read", - "j u", - "in y", - "i ny", - "▁det ails", - "▁detail s", - "▁ details", - "▁x ml", - "▁ xml", - "ta it", - "t ait", - "out put", - "mess age", - "m essage", - "' '", - "▁Brit ish", - "vi lle", - "vil le", - "v ille", - "▁D iv", - "▁Di v", - "▁ Div", - "▁U ser", - "▁Use r", - "▁Us er", - "▁ User", - "c m", - "ч но", - "col umn", - "eq ref", - "ó r", - "on om", - "ono m", - "o nom", - "▁P ost", - "▁Po st", - "▁Pos t", - "▁ Post", - "el len", - "ell en", - "elle n", - "A b", - "ul té", - "ult é", - "▁per fect", - "▁perf ect", - "() {", - "( ){", - "vis ion", - "v ision", - "act ive", - "activ e", - "li er", - "lie r", - "l ier", - "ri j", - "r ij", - "s d", - "▁k ö", - "▁ kö", - "▁n ie", - "▁ni e", - "▁ nie", - "▁re lig", - "▁rel ig", - "▁reli g", - "▁o t", - "▁ ot", - "▁m achine", - "▁mach ine", - "▁ machine", - "▁h eld", - "▁he ld", - "▁hel d", - ")$ .", - ") $.", - "==== ====", - "ck er", - "cke r", - "c ker", - "в ы", - "bo rn", - "bor n", - "b orn", - "▁p ast", - "▁pas t", - "▁pa st", - "ри я", - "▁D r", - "▁ Dr", - "▁reg ular", - "▁regul ar", - "▁ regular", - "▁prov ided", - "▁provide d", - "TE R", - "T ER", - "▁un ivers", - "▁ univers", - "▁g ets", - "▁get s", - "▁ge ts", - "▁ gets", - "▁n u", - "▁ nu", - "▁/ *", - "▁ /*", - "ob er", - "obe r", - "o ber", - "fi n", - "f in", - "▁n ella", - "▁ne lla", - "▁nel la", - "▁nell a", - "▁be come", - "▁bec ome", - "▁becom e", - "▁` `", - "▁ ``", - "▁h istory", - "▁histor y", - "▁hi story", - "▁hist ory", - "▁ history", - "▁S ol", - "▁So l", - "▁ Sol", - "▁R ad", - "▁Ra d", - "▁ Rad", - "▁term s", - "▁ter ms", - "▁even ts", - "▁event s", - "▁ev ents", - "▁ events", - "ly mp", - ")) )", - ") ))", - "ро ва", - "ров а", - "р ова", - "▁ab sol", - "▁abs ol", - "▁so ft", - "▁ soft", - "lin ks", - "link s", - "l inks", - "▁h ope", - "▁ho pe", - "▁hop e", - "▁su bject", - "▁sub ject", - "▁ subject", - "\") ,", - "\" ),", - "▁cre ating", - "▁} \r", - "▁ }\r", - "▁S k", - "▁ Sk", - "▁f low", - "▁fl ow", - "▁flo w", - "▁ flow", - "▁Р а", - "▁as sert", - "▁ass ert", - "▁asse rt", - "▁ assert", - "ze t", - "z et", - "▁F rank", - "▁Fran k", - "▁Fr ank", - "s a", - "▁dist ribution", - "▁distribu tion", - "▁distrib ution", - "▁ distribution", - "c u", - "ba nd", - "ban d", - "b and", - "iz z", - "i zz", - "▁j ob", - "▁jo b", - "▁ job", - "in er", - "ine r", - "i ner", - "st ruct", - "str uct", + "\n\nP atients▁", + "▁that ▁is▁", + "▁5 0%", + "40 8", + "▁administ ration▁of", + "\n\nR evised▁Clinical▁Study▁Protocol▁Drug▁Substance▁ZD4054▁Study▁Code▁D4320", + "performed▁ at", + "▁dur ing", + "ingl e-", + "analysis▁ of", + "( d", + "a jor", + "® \n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:", + "oc h", + "pl ain", + "▁re turn", + "▁l ess", + "ver y▁", + "port ion", + "▁this▁ protocol", + "s.▁ S", + "ed▁by ▁a", + "▁us e▁", + "▁Arm ▁B", + "clusion ▁Criteria", + "tern ational▁", + "fract ure▁", + "gressive▁ disease▁", + "▁system ic", + "small ▁cell▁lung▁cancer", + "- rank", + "G rade▁3", + "c ase▁report▁form", + "h uman", + ",▁ un", + "ic k", + "et opos", + "ou th", + "▁P eri", + "ut am", + "ex pression", + "com bination", + "12 -0", + "▁will ▁also▁be▁", + "reg ulation", + "11 -0", + "20 408", + "patients▁ with", + "kn ow", + "\n\nConfidential \n\nPage▁", + "urop ath", + "regard less▁of", + "L T", + "f ication", + "▁ estim", + "e▁ is▁", + "ro k", + "um b", + ".\n\n LY231514", + "is▁ or", + "▁h ospitalization", + "act ive▁", + "12 2", + "▁ch ild", + "▁ac count", + "ed▁as ▁a", + "▁activ ity▁", + "ogen es", + "ech an", + "pert y▁of", + "lot inib", + "B P", + "h our", + "e▁ C", + "▁t echniqu", + "\n\n of", + "al so", + "ic in", + "ation s", + "▁w ork", + ".\n\n 4", + "op in", + "▁com pared▁with", + ".3 .3", + "\n\nC on", + "e▁in ▁the▁", + ".▁Th es", + "ser t", + "ne ut", + "................................................................................................ ..", + "sub sequent", + "▁time▁ point", + "mad e▁", + "ubjects▁ who", + "▁Study▁Code▁D 8480C00013", + "necess ary", + "L ill", + "h ip", + "m easurement", + "s ponsor", + "u s▁of", + "y ▁to", + "in ▁patients▁with", + "\n\n 12", + "er oid", + "s▁ A", + "an k", + "ar cinoma", + "▁in ▁a", + "▁S C", + "▁l in", + "ap an", + "▁ad juvant", + "▁0 ▁.▁1▁\\", + "▁g reat", + "▁this▁ research", + "▁st rati", + "es▁of ▁the▁", + "▁test ing", + "ed▁with in", + "peri od▁", + "30 -day▁", + "ity▁of ▁lif", + "-0 52", + "s▁b efore▁", + "48 -052", + "regulator y▁", + "app ear", + "▁the▁discretion ▁of▁the▁", + "( 1", + "- 6", + "b iomarker", + "▁ ................................................................................", + "e▁ and", + "▁or ▁placebo", + "e▁t est", + "▁ch emist", + "▁ass um", + "▁the y", + "every▁ 3", + "uc os", + "Clinical▁ Trial▁Protocol", + "using ▁a", + "▁CT ▁scan", + "response▁ (", + "▁gen etic", + "ethod s▁of", + "Cons ider", + "▁equ ivalent", + "▁Final▁ Protocol", + "3 9", + "O utcom", + "b efore▁", + "e .▁A", + "e CRF", + "w ard", + "it umor", + "es oph", + "▁d efin", + "▁T umor", + "▁is▁ responsible▁for", + "s,▁ including", + "cons istent", + ".▁Th er", + "▁Com mitte", + "▁do ▁not", + "oh ort", + "▁2000 48-052", + "▁colon ▁cancer", + "MR ▁200048-052", + "IEC /IRB", + "5 6", + "d ate▁", + "y nd", + "\n\n be▁", + "▁l aboratory▁", + "follow s:", + "▁6 .0", + "ies▁ of", + "mon ▁T", + "▁W ith", + "▁antibod ies", + "regnanc y▁", + "▁EGF r", + "\n\n1\n\n2\n\n3 \n\n4", + ") ▁is▁", + "6 06", + "S RE", + "f ul", + "g rade▁", + "▁ enroll", + "▁ evidence▁of", + "e▁ on", + "s▁ is▁", + ",▁ V", + "▁b eing", + "es )", + "pro pos", + "▁v ial", + "e▁d os", + ".▁P ro", + "pec imen", + "▁analysis▁ set", + "alysis▁ of", + "▁inter val", "stru ct", - "á k", - "T O", - "au f", - "a uf", - "▁ext ends", - "▁extend s", - "▁G ra", - "▁Gr a", - "dis play", - "▁sign ific", - "on ey", - "one y", - "o ney", - "s ource", - "m icrosoft", - "in der", - "ind er", - "inde r", - "i nder", - "▁qu ick", - "▁qui ck", - "▁ quick", - "▁w onder", - "▁won der", - "▁wo nder", - "Inst ance", - "el les", - "ell es", - "elle s", - "e lles", - "è me", - "▁comp any", - "▁compan y", - "▁ company", - "u ß", - ". }", - "▁separ ate", - "U M", - "HER E", - "HE RE", - "H ERE", - "▁writ ing", - "▁wr iting", - "▁ writing", - "it ution", - "itu tion", - "itut ion", - "▁G esch", - "▁Ge sch", - "▁Ges ch", - "м я", - "▁J ames", - "▁Ja mes", - "▁Jam es", - "▁ James", - "▁D E", - "▁ DE", - "▁S pe", - "▁Sp e", - "▁ Spe", - "pro cess", - "proc ess", - "St r", - "S tr", - "▁s ym", - "▁sy m", - "▁ sym", - "▁a o", - "▁ ao", - "▁w y", - "��� wy", - "▁any one", - "▁U p", - "▁ Up", - "use um", - "ar on", - "aro n", - "a ron", - "▁def inition", - "▁defin ition", - "▁definit ion", - "▁ definition", - "▁` $", - "▁f av", - "▁fa v", - "rib utes", - "ribute s", - "ribu tes", - "▁R é", - "ograf ia", - "ografi a", - "el ement", - "ele ment", - "elem ent", - "e lement", - "ca p", - "c ap", - "pa t", - "p at", - "▁B ra", - "▁Br a", - "▁ Bra", - ") (", - "▁acc ording", - "▁accord ing", - "г е", - "▁p ie", - "▁pi e", - "▁ pie", - "el i", - "e li", - "} \"", - "▁act iv", - "▁ activ", - "▁s top", - "▁st op", - "▁sto p", - "▁ stop", - "pat ch", - "p atch", - "т і", - "▁J ose", - "▁Jo se", - "▁Jos e", - "▁ Jose", - "En d", - "E nd", - "▁p rze", - "▁pr ze", - "▁prz e", - "▁a ge", - "▁ag e", - "▁ age", - "it ory", - "ito ry", - "itor y", - "▁P HP", - "▁ PHP", - "ag ement", - "age ment", - "agem ent", - "▁` .", - "▁ `.", - "▁pre tty", - "▁pret ty", - "▁re comm", - "▁rec omm", - "▁recom m", - "▁s ud", - "▁su d", - "▁re qu", - "▁r equ", - "▁req u", - "▁об ла", - "at ives", - "ative s", - "ativ es", - "ati ves", - "▁H igh", - "▁Hi gh", - "▁ High", - "á z", - "ou l", - "o ul", - "re st", - "res t", - "r est", - "▁T er", - "▁Te r", - "un der", - "und er", - "unde r", - "u nder", - "th ern", - "ther n", - "the rn", - "cent er", - "cen ter", - "cente r", - "c enter", - "▁u r", - "▁ ur", - "la t", - "l at", - "▁inter face", - "▁ interface", - "▁и н", - "▁ ин", - "▁wh ose", - "▁who se", - "ic as", - "ica s", - "i cas", - "am en", - "ame n", - "a men", - "Fil ter", - "▁st ation", - "▁stat ion", - "▁sta tion", - "▁stati on", - "▁ station", - "Pa ge", - "P age", - "▁a rm", - "▁ar m", - "▁ arm", - "▁e yes", - "▁eye s", - "▁ра й", - "▁s eu", - "▁se u", - "ol i", - "o li", - "wi n", - "w in", - "li k", - "l ik", - "ge x", - "g ex", - "ch an", - "cha n", - "c han", - "id ence", - "iden ce", - "ar gs", - "arg s", - "ak ing", - "aki ng", - "a king", - "▁Go ogle", - "▁ Google", - "▁St ud", - "▁Stu d", - "▁h o", - "▁ ho", - "то ры", - "тор ы", - "S u", - "▁autom at", - "▁auto mat", - "êm e", - "ê me", - "▁c y", - "▁ cy", - "lo r", - "l or", - "▁st ack", - "▁sta ck", - "▁ stack", - "▁SE LECT", - "▁ SELECT", - "A F", - "▁> >", - "▁ >>", - "▁com pet", - "▁comp et", - "▁p air", - "▁pa ir", - "▁ pair", - "▁ing lés", - "Res ponse", - "▁F ig", - "▁ Fig", - "gr ad", - "gra d", - "g rad", - "▁document ation", - "▁ documentation", - "▁c ant", - "▁can t", - "▁ca nt", - "▁app reci", - "å n", - "▁le arn", - "▁lear n", - "▁ learn", - "▁in dep", - "▁ind ep", - "▁inde p", - "▁p al", - "▁pa l", - "▁ pal", - "pack age", - "p ackage", - "ar es", - "are s", - "a res", - "▁Ber lin", - "▁Berl in", - "б ли", - "re ich", - "rei ch", - "ё н", - "▁s atisf", - "▁sat isf", - "▁reg ion", - "▁ region", - "▁fri end", - "▁ friend", - "▁Ge orge", - "▁Georg e", - "▁В о", - "▁ Во", - "▁\" \"", - "▁ \"\"", - "▁des de", - "Fact ory", - "F actory", - "▁Count y", - "▁Coun ty", - "ou v", - "o uv", - "▁ ‘", - "▁inst alled", - "▁install ed", - "▁instal led", - "▁ installed", - "▁w anted", - "▁want ed", - "▁P ython", - "▁ Python", - "▁inter pre", - "▁in cluded", - "▁includ ed", - "▁include d", - "▁inclu ded", - "▁( (", - "▁ ((", - "▁al tern", - "▁alt ern", - "▁alter n", - "▁alte rn", - "▁ altern", - "is to", - "ist o", - "i sto", - "g n", - "▁b order", - "▁bor der", - "▁bord er", - "▁ border", - "pd f", - "p df", - "▁d up", - "▁du p", - "▁ dup", - "▁down load", - "▁ download", - "ju st", - "jus t", - "j ust", - "▁m embers", - "▁mem bers", - "▁memb ers", - "▁member s", - "▁ members", - "ch ild", - "chi ld", - "▁p ay", - "▁pa y", - "▁ pay", - "▁c er", - "▁ce r", - "▁ cer", - "▁lo oked", - "▁look ed", - "▁correct ly", - "au th", - "aut h", - "a uth", - "▁с тан", - "▁ст ан", - "▁ста н", - "▁ стан", - "▁e sp", - "▁es p", - "▁ esp", - "▁d esc", - "▁de sc", - "▁des c", - "▁ desc", - "eb en", - "e ben", - "▁qu estions", - "▁question s", - "▁quest ions", - "▁questi ons", - "▁ questions", - "ma l", - "m al", - "▁ab gerufen", - "▁ abgerufen", - "▁B and", - "▁Ba nd", - "▁Ban d", - "▁[ ]", - "▁ []", - "Bas e", - "B ase", - "▁r is", - "▁ri s", - "▁ ris", - "▁f ort", - "▁for t", - "▁fo rt", - "▁ fort", - "▁I d", - "▁ Id", - "▁var ious", - "▁vari ous", - "▁Le ague", - "▁H and", - "▁Ha nd", - "▁Han d", - "▁ Hand", - "▁T ype", - "▁Ty pe", - "▁Typ e", - "▁ Type", - "ir l", - "i rl", - "▁F e", - "▁ Fe", - "i én", - "it ter", - "itt er", - "itte r", - "▁f ast", - "▁fa st", - "▁fas t", - "▁ fast", - "st a", - "s ta", - "▁ex cept", - "▁ except", - "ic z", - "i cz", - "▁F rench", - "▁en vironment", - "▁environ ment", - "▁ environment", - "▁con se", - "▁cons e", - "у р", - "о го", - "▁necess ary", - "tar get", - "t arget", - "▁re ading", - "▁read ing", - "▁ reading", - "ho me", - "hom e", - "h ome", - "ze ich", - "▁e qual", - "▁equ al", - "▁eq ual", - "▁ equal", - "▁pi ù", - "▁p rem", - "▁pr em", - "▁pre m", - "▁diff icult", - "▁u nit", - "▁un it", - "▁ unit", - "▁re place", - "▁rep lace", - "▁repla ce", - "▁ replace", - "▁he art", - "▁hear t", - "▁ heart", - "▁t alk", - "▁tal k", - "A M", - "▁R E", - "▁ RE", - "▁P erson", - "▁Per son", - "▁Pers on", - "▁ Person", - "end ency", - "enden cy", - "▁i mm", - "▁im m", - "▁ imm", - "▁h uman", - "▁hum an", - "▁hu man", - "▁ human", - "d n", - "▁K ir", - "▁Ki r", - "▁A ut", - "▁Au t", - "▁ Aut", - "kn own", - "know n", - "k nown", - "▁fr equ", - "▁fre qu", - "sys tem", - "s ystem", - "ла в", - "▁S z", - "▁G al", - "▁Ga l", - "но е", - "sel ves", - "right arrow", - "r ightarrow", - "▁С а", - "▁ Са", - "=\" @", - "▁build ing", - "▁ building", - "im port", - "imp ort", - "▁f am", - "▁fa m", - "▁de lete", - "▁del ete", - "▁delet e", - "▁ delete", - "air e", - "ai re", - "a ire", - "ma ry", - "mar y", - "m ary", - "▁f und", - "▁fun d", - "▁fu nd", - "▁ fund", - "▁part icip", - "▁partic ip", - "▁parti cip", - "▁partici p", - "▁s yn", - "▁sy n", - "▁ syn", - "si n", - "s in", - "▁l ower", - "▁lo wer", - "▁low er", - "▁ lower", - "▁z ero", - "▁ze ro", - "▁ zero", - "▁s ec", - "▁se c", - "▁ sec", - "▁f ra", - "▁fr a", - "▁ fra", - "Po int", - "P oint", - "▁fa iled", - "▁fail ed", - "▁ failed", - "ien to", - "ient o", - "i ento", - "cu p", - "c up", - "▁s low", - "▁sl ow", - "▁slo w", - "▁ slow", - "▁n ation", - "▁na tion", - "▁nat ion", - "äh r", - "ä hr", - "▁in fo", - "▁inf o", - "▁ info", - "▁P ublic", - "▁Pub lic", - "▁Pu blic", - "▁ Public", - "▁de cla", - "▁dec la", - "▁decl a", - "▁Т а", - "▁s old", - "▁so ld", - "▁sol d", - "▁R em", - "▁Re m", - "▁ Rem", - "▁Ph il", - "ст ра", - "стр а", - "с тра", - "▁me hr", - "▁W ork", - "▁Wor k", - "▁ Work", - "▁N ord", - "▁No rd", - "▁Nor d", - "▁f ait", - "▁fa it", - "▁g ew", - "▁ge w", - "▁ gew", - "print ln", - "ob ile", - "obil e", - "obi le", - "▁K on", - "▁Ko n", - "▁ass ume", - "▁assum e", - "land s", - "lan ds", - "l ands", - "▁a mount", - "▁am ount", - "▁ amount", - "▁P ress", - "▁Pr ess", - "▁Pres s", - "▁Pre ss", - "▁ Press", - "ý ch", - "▁ma xim", - "▁max im", - "▁ maxim", - "▁Ch ampion", - "▁Champ ion", - "li brary", - "l ibrary", - "a ñ", - "▁W al", - "▁Wa l", - "Com m", - "Co mm", - "C omm", - "] ]", - "▁z w", - "▁ zw", - "▁so cial", - "▁soci al", - "▁soc ial", - "▁ social", - "L I", - "▁Un ter", - "vo r", - "v or", - "Del ta", - "D elta", - "em ail", - "ema il", - "e mail", - "ra int", - "rain t", - "rai nt", - "r aint", - "on i", - "o ni", - "▁a lt", - "▁al t", - "▁ alt", - "▁n é", - "▁ né", - "ци я", - "ograph y", - "▁mention ed", - "▁ment ioned", - "▁< =", - "▁ <=", - "▁c ette", - "▁ce tte", - "▁cet te", - "▁current ly", - "▁curr ently", - "va re", - "var e", - "v are", - "iz ing", - "izi ng", - "izin g", - "i zing", - "▁D ef", - "▁De f", - "▁ Def", - "ic ol", - "ico l", - "i col", - "ün d", - "ü nd", - "▁config uration", - "▁configur ation", - "▁ configuration", - "est ig", - "esti g", - "II I", - "I II", - "la m", - "l am", - "i ère", - "▁E ar", - "▁t u", - "▁ tu", - "En t", - "E nt", - "▁U sing", - "▁Us ing", - "▁ Using", - "▁ко м", - "▁к ом", - "▁ ком", - "ci e", - "c ie", - "▁pro of", - "▁ proof", - "▁in vol", - "▁inv ol", - "▁H istory", - "▁Histor y", - "▁Hi story", - "▁Hist ory", - "▁ History", - "> <", - "▁A ND", - "▁AN D", - "▁ AND", - "av y", - "a vy", - "▁rel ations", - "▁relation s", - "$ {", - "▁com es", - "▁co mes", - "▁come s", - "▁ comes", - "▁d irection", - "▁direct ion", - "▁dire ction", - "▁dir ection", - "▁ direction", - "▁J une", - "▁Ju ne", - "▁Jun e", - "▁W ay", - "▁Wa y", - "Com ponent", - "ec h", - "e ch", - "▁P eter", - "▁Pe ter", - "▁Pet er", - "▁ Peter", - "s g", - "▁s tra", - "▁st ra", - "▁str a", - "▁ stra", - "uc t", - "u ct", - "▁im plementation", - "▁implement ation", - "▁ implementation", - "att le", - "▁c z", - "▁ cz", - "pl ot", - "p lot", - "▁play ed", - "▁pla yed", - "\"> < /", - "\" > (", - "▁g round", - "▁gr ound", - "▁gro und", - "▁ ground", - "un n", - "u nn", - "ro d", - "r od", - "sp e", - "s pe", - "urs or", - "▁le ave", - "er k", - "▁t al", - "▁ta l", - "▁ tal", - "▁b ottom", - "▁bot tom", - "▁bott om", - "▁ bottom", - "I O", - "▁pop ular", - "▁popula r", - "▁popul ar", - "ig o", - "i go", - "▁T ime", - "▁Tim e", - "▁Ti me", - "▁ Time", - "val ues", - "value s", - "valu es", - "▁L oc", - "▁Lo c", - "▁ Loc", - "▁C lub", - "▁Cl ub", - "▁an che", - "▁anc he", - "▁anch e", - "▁ anche", - "ia ł", - "i ał", - "і ї", - "Om ega", - "▁loc ated", - "▁locate d", - "▁ located", - "U rl", - "▁E sp", - "▁Es p", - "▁ Esp", - "л ы", - "ц ь", - "ul ate", - "ula te", - "u late", - "▁j oin", - "▁jo in", - "▁ join", - "av es", - "ave s", - "a ves", - "ve t", - "v et", - "li o", - "l io", - "re move", - "rem ove", - "▁t oken", - "▁to ken", - "▁ token", - "▁op tim", - "▁opt im", - "▁ optim", - "▁c laim", - "▁cla im", - "olog ical", - "▁c ss", - "▁cs s", - "▁ css", - "▁al though", - "▁ although", - "▁p riv", - "▁pr iv", - "▁pri v", - "▁ priv", - "▁B a", - "ü l", - "entic ation", - "enti cation", - "▁v en", - "▁ve n", - "▁ ven", - "Ser ver", - "Serv er", - "▁C ong", - "▁Con g", - "▁Co ng", - "NE T", - "N ET", - "CO N", - "C ON", - "d t", - "per ties", - "pert ies", - "▁e pis", - "▁ep is", - "wik ipedia", - "▁eng ine", - "▁ engine", - "▁f er", - "▁fe r", - "▁ fer", - "get Element", - "▁C la", - "▁Cl a", - "▁ Cla", - "ř í", - "▁r om", - "▁ro m", - "▁ rom", - "var epsilon", - "vare psilon", - "▁pr ime", - "▁prim e", - "▁pri me", - "▁ prime", - "is try", - "ist ry", - "istr y", - "pe cted", - "pect ed", - "pec ted", - "p ected", - "or age", - "ora ge", - "o rage", - "▁t ouch", - "▁to uch", - "▁tou ch", - "▁ touch", - "▁[ '", - "▁ ['", - "▁d an", - "▁da n", - "▁ dan", - "E m", - "ac iones", - "acion es", - "aci ones", - "a ciones", - "Ca n", - "C an", - "▁w hom", - "▁wh om", - "▁who m", - "▁be havior", - "▁behav ior", - "▁str ings", - "▁string s", - "▁ strings", - "▁E urop", - "▁Euro p", - "▁Eu rop", - "▁Eur op", - "▁R om", - "▁Ro m", - "ci rc", - "cir c", - "c irc", - "▁p un", - "▁pu n", - "▁reg ister", - "▁ register", - "b untu", - "ra in", - "rai n", - "r ain", - "O b", - "T A", - "▁s ometimes", - "▁some times", - "▁somet imes", - "▁m ent", - "▁me nt", - "▁men t", - "▁ ment", - "▁in teger", - "▁inte ger", - "▁ integer", - "▁J ac", - "▁Ja c", - "▁ Jac", - "le gate", - "leg ate", - "ot hing", - "oth ing", - "o thing", - "▁s ound", - "▁so und", - "▁sou nd", - "▁ sound", - "la ces", - "lace s", - "lac es", - "l aces", - "▁Б а", - "r b", - "d i", - "ле ния", - "▁them selves", - "▁B lack", - "▁Bl ack", - "▁Bla ck", - "▁ Black", - "▁s ettings", - "▁sett ings", - "▁setting s", - "▁ settings", - "▁n orm", - "▁no rm", - "▁nor m", - "▁ norm", - "▁r uns", - "▁run s", - "▁ru ns", - "▁N OT", - "▁NO T", - "▁ NOT", - "K E", - "▁per haps", - "▁ Я", - "▁m ol", - "▁mo l", - "▁a ns", - "▁an s", - "▁ ans", - "at re", - "atr e", - "a tre", - "▁D ies", - "▁Die s", - "▁Di es", - "To ken", - "T oken", - "an ie", - "ani e", - "a nie", - "▁all owed", - "▁allow ed", - "▁allo wed", - "▁ allowed", - "R ange", - "▁G ro", - "▁Gr o", - "vi a", - "v ia", - "ut orial", - "uto rial", - "utor ial", - "ens or", - "enso r", - "est ival", - "esti val", - "); \r", - ") ;\r", - "кра ї", - "▁turn ed", - "▁tur ned", - "sc ope", - "scop e", - "s cope", - "▁b ien", - "▁bi en", - "= $", - "▁ext ension", - "▁extens ion", - "▁ extension", - "at ore", - "ator e", - "ato re", - "▁Р о", - "▁spec ify", - "ed u", - "e du", - "Dat os", - "D atos", - "▁st ored", - "▁stor ed", - "▁store d", - "▁sto red", - "▁p arse", - "▁par se", - "▁ parse", - "▁an swers", - "▁answer s", - "▁ans wers", - "il ls", - "ill s", - "▁he ard", - "▁hear d", - "l u", - "▁T HE", - "▁TH E", - "▁ THE", - "▁g én", - "▁gé n", - "▁f ul", - "▁fu l", - "▁ ful", - "e z", - "▁P rem", - "▁Pr em", - "▁Pre m", - "th en", - "the n", - "t hen", - "d p", - "сь кого", - "сько го", - "ськ ого", - "▁S i", - "▁ Si", - "ç o", - "Ed it", - "E dit", - "кі в", - "к ів", - "▁Л и", - "▁S ing", - "▁Si ng", - "▁Sin g", - "▁ Sing", - "▁c ateg", - "▁cat eg", - "Eq u", - "E qu", - "▁g uer", - "▁gu er", - "▁ guer", - "W idth", - "▁Christ ian", - "st at", - "sta t", - "s tat", - "W rite", - "▁w oman", - "▁wo man", - "wo od", - "w ood", - "V is", - "ра з", - "▁$ $\\", - "▁$$ \\", - "ode r", - "od er", - "o der", - "▁b ool", - "▁bo ol", - "▁ bool", - "▁intern ational", - "но сть", - "ност ь", - "нос ть", - "▁Rich ard", - "▁Ric hard", - "▁add ition", - "▁Mus ic", - "▁ Music", - "▁a ber", - "▁ab er", - "t ó", - "▁h ier", - "▁hi er", - "ug h", - "u gh", - "▁p ob", - "▁po b", - "▁t ables", - "▁table s", - "▁tab les", - "▁ta bles", - "▁ tables", - "D o", + "is one▁", + "▁s upportive▁", + "▁m aterial", + ".\n\n H", + "ol ism", + "con fidential", + "con comitant▁medication", + "▁f atty", + "\n\nP FIZER▁CONFIDENTIAL▁Page▁", + "▁res pect", + "▁patients▁ (", + "str ic", + "▁Date: ▁14", + "▁x ▁109/L", + "ed▁at ▁the▁", + "ron ch", + "oci et", + "▁Com pany▁", + "▁determin e▁the▁", + "overall ▁survival", + "▁antibod y▁", + "▁par ameter", + "ett ing", + "▁appropri at", + "previ ously▁", + "stitutional▁ Review", + "/122\n\nEMD▁271786▁EMR▁200048-052 \n\nEXPAND", + "3E-US-S130(d )▁Clinical▁Protocol", + "▁Date:▁14 ▁November▁2006", + "1 ;", + "5 5", + "A CT-", + "h ow", + "o L", + "s pecifi", + "e▁ c", + "in stitution", + "▁a ▁f", + "or y▁", + ".▁ K", + "ed .▁If", + "ou s▁in", + "ur e▁to", + "em pt", + "▁S ign", + "▁will▁be▁ provid", + "▁com mer", + "\n\nC T", + "s.▁ Th", + "ard ial▁", + "▁Date: ▁30", + "ed▁at ▁least", + "ym ph", + "▁cycl es", + "id▁ not", + "▁includ ing", + "discontinu ed▁from", + "start ing", + "ubl ish", + "▁medical▁ record", + "▁Denosumab▁Protocol▁Number:▁200 50136", + "neut rophil", + "gre ement", + "-cell ▁lung▁cancer", + "▁ABX-EGF▁Protocol▁Number:▁20020408▁Amendment▁4▁Date:▁26▁April▁2005 \n\nPage▁", + "ational▁Cancer ▁Institut", + "▁Denosumab▁Protocol▁Number:▁20050136 ▁Date:▁30", + ". [", + "2 ▁Amendment", + "F L", + "e art", + "l ab", + "e▁ at", + "on c", + "or ▁other", + "re ction", + "ed d", + "▁A t", + "▁1 ▁week", + "os is▁", + "▁( N", + "▁2 ▁week", + "ra ction", + "▁h is/her", + "▁R ECIST", + "▁B 12", + "▁5 ▁0", + "▁G roup", + "pos ition", + "he et", + "▁Ad dendum", + "administ ration▁of", + "Investigator ’s▁", + "administer ed▁", + "mitt ee", + "open ia", + "▁bone▁ metastas", + "▁man agement", + "▁EC OG", + "▁31 −Jul−2014", + "kaline▁ phosph", + "▁TA XOL", + "▁of▁121\n\nClinical▁Trial▁Protocol▁IMCL▁CP11-0806▁IMC-11F8 \n\nImClone▁LLC▁Version▁6.0", + "0 9", + "A ll", + "A mended▁", + "A straZeneca", + "C ED", + "F orm", + "a \\Approved\\Approved▁On:", + "a 3a", + "d one▁", + "e ),▁", + "v ascular", + "er m", + "st age▁", + "ed .▁A", + "▁p rimary▁", + "▁m ean", + "▁m onitor", + "▁m onitoring", + "▁and▁ m", + "▁in itial", + "▁P l", + "▁P fizer", + "\n\nP rimary▁", + "▁pro t", + "ep -2007▁0", + "▁st rat", + "\n\n1 5", + "▁of▁1 01", + "lood▁ sampl", + "▁ab l", + "▁therapy ,▁", + "▁car ry▁", + "\n\nH 3E-US-S130(d)▁Clinical▁Protocol", + "▁– ▁Company▁", + "28 ▁August▁2007", + "reatinine▁ clear", + "112 2▁Amendment", + "yn ops", + "-S ep-2007▁0", + "▁27 -Sep-2007▁0", + "2: 42", + "Protocol▁A618 1122▁Amendment", + "▁leg ally", + ".\n\nWh at", + "▁1,▁ 28▁August▁2007", + "\n\nProduct:▁AMG▁162▁Protocol▁Number:▁20040138▁Date:▁19▁February▁200 8\n\nPage▁", + "®\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁Panitumumab▁Protocol▁Number:▁20050251▁Date:▁10▁October▁2006 \n\nPage▁", + "Confidential▁ Page▁", + "Amended▁ Protocol▁A6181122▁Amendment", + "a\\Approved\\Approved▁On: ▁27-Sep-2007▁0", + "a3a a\\Approved\\Approved▁On:▁27-Sep-2007▁0", + "▁–▁Company▁ Confidential▁Page▁", + "Amended▁Protocol▁A6181122▁Amendment ▁1,▁28▁August▁2007", + "a3aa\\Approved\\Approved▁On:▁27-Sep-2007▁0 2:42", + "( m", + ": 45", + "k ept", + "l ic", + "p act", + "s afety", + "in vestig", + "es ,▁and▁", + "▁s afety", + "▁and▁ p", + "▁and▁ for", + "▁A UC", + "▁h ad", + "▁M an", + "▁F actor", + "▁H ealth", + "▁patients▁ receiving", + "▁G en", + "▁pl asma", + ".▁P hase▁", + "ne utropenia", + "▁it ▁is▁", + "▁therapy▁ for", + "........................................................................................ ..", + "AB I-007", + "elig ibility", + "▁su fficient", + "▁part ial▁", + "emb edd", + "▁norm al▁", + "rac ept", + "/d L", + "variabl es", + "\n\nH3E-MC-JM IG(f)▁Clinical▁Protocol", + "genetic ▁research", + "orl d", + "solut e▁", + "Oncology▁ Group", + "olorectal▁ Cancer", + "stitutional▁Review ▁Bo", + "1 st", + "6 9", + "N on-", + "R el", + "U 01", + "e .▁S", + "s pect", + "t on", + "u cl", + "v ir", + "y \n\n", + "in vestigational▁product", + "▁t ub", + "ed▁ dos", + "▁p rimary", + "▁b ilirubin", + "▁of ▁an", + "▁m easurable▁", + "ill ness", + "pl eas", + "▁( B", + "ag e,▁", + "▁E valu", + "up per", + "ort ic", + "▁patients▁ in", + "e▁d uring▁the▁", + "s\n\n The▁", + "includ ed▁in", + "ary n", + "emet ic", + "first -line▁treatment", + "pre t", + "ind ependent", + "▁report ed▁", + ",▁200 8", + "ha zard", + "........................................................................................ ....", + "▁201 1", + "▁IMC- 1121B", + "101 45", + "uro Q", + "emetrexed▁H3E-MC-JM HO", + "▁confidence▁in terval", + "thics▁Com mitte", + "/ placebo", + "5 22", + "N ov", + "b aselin", + "b egin", + "e ,▁and", + "i as", + "s erious▁adverse▁event", + "re ceive▁", + "▁d ate▁of", + ".\n\n For", + "im ens", + "▁1 ▁.▁1▁\\", + "un less▁", + "ri es▁", + "▁f requ", + "▁M ed▁", + "▁g rade▁3", + "▁res pon", + "e▁in hibitor", + "▁6 ▁8", + "cre ase▁", + "ed▁for ▁each", + "▁month s▁after", + "includ ing▁the▁", + "▁analysis▁ will", + "▁toxic ities", + "require d▁to", + "▁it em", + "itamin ▁B12", + "appro v", + "inc e▁", + "▁des crib", + "\n\n8 ▁2", + "represent ative▁", + "▁hy pothes", + "▁cal culation", + "evid enc", + "ate▁th at", "▁high er", - "ps i", - "p si", - "r á", - "▁act ive", - "▁activ e", - "▁ active", - "▁T able", - "▁Ta ble", - "▁Tab le", - "▁ Table", - "њ е", - "▁de scription", - "▁des cription", - "▁descri ption", - "▁descript ion", - "▁ description", - "▁se emed", - "▁see med", - "▁seem ed", - "ís t", - "í st", - "▁my self", - "▁m enu", - "▁me nu", - "▁men u", - "▁ menu", - "de l", - "d el", - "▁ ž", - "el e", - "e le", - "A ut", - "▁г ру", - "mu t", - "m ut", - "oo n", - "o on", - "as c", - "a sc", - "bu g", - "b ug", - "▁m oved", - "▁mov ed", - "▁mo ved", - "▁move d", - "C L", - "▁data s", - "▁dat as", - "▁ datas", - "S O", - "о ло", - "▁Ge org", - "▁re ach", - "▁r each", - ": \"", - "▁e valu", - "▁ev alu", - "▁eval u", - "▁ evalu", - "▁H el", - "▁He l", - "▁ Hel", - "▁R iver", - "▁Riv er", - "▁Ri ver", - "▁А р", - "▁ Ар", - "// //", - "/// /", - "/ ///", - "▁s ets", - "▁se ts", - "▁set s", - "▁ sets", - "▁O lymp", - "Ad apter", - ". '", - "ov ern", - "over n", - "ove rn", - "o vern", - "▁L ord", - "▁Lo rd", - "▁Lor d", - "! --", - "jp g", - "j pg", - "im ento", - "iment o", - "imen to", - "▁Pro f", - "▁Pr of", - "▁ach ieve", - "▁achiev e", - "} :", - "▁in cor", - "▁inc or", - "▁o nder", - "▁on der", - "▁onde r", - "▁ onder", - "en gl", - "eng l", - "AB LE", - "▁M ary", - "▁Mar y", - "▁Ma ry", - "▁w aren", - "▁war en", - "▁wa ren", - "la ge", - "lag e", - "l age", - "De c", - "D ec", - "анг л", - "en cias", - "enc ias", - "encia s", - "enci as", - "ле й", - "л ей", - "▁M achine", - "▁Mach ine", - "▁ Machine", - "▁А н", - "ud a", - "u da", - "▁ ś", - "▁X X", - "▁ XX", - "on ly", - "ле ние", - "▁tamb ién", - "ne j", - "n ej", - "▁rel ative", - "▁relativ e", - "▁ relative", - "▁h ours", - "▁ho urs", - "▁hour s", - "▁ind eed", - "▁inde ed", - "un do", - "und o", - "in gu", - "ing u", - "ar ea", - "are a", - "a rea", - "▁C reate", - "▁Cre ate", - "▁ Create", - "be it", - "bei t", - "▁rem oved", - "▁remove d", - "▁remov ed", - "ma ster", - "mas ter", - "maste r", - "m aster", - "ha us", - "h aus", - "▁B ern", - "▁Be rn", - "▁Ber n", - "▁sp eed", - "▁spe ed", - "▁ speed", - "▁B ay", - "▁Ba y", - "▁A tt", - "▁At t", - "▁ Att", - "▁N one", - "▁No ne", - "▁Non e", - "▁ None", - "app lication", - "ü d", - "▁f it", - "▁fi t", - "▁ fit", - "▁M aria", - "▁Mar ia", - "▁Ma ria", - "▁Mari a", - "▁n ord", - "▁no rd", - "▁nor d", - "▁s plit", - "▁sp lit", - "▁spl it", - "▁ split", - "▁st ru", - "▁str u", - "▁ stru", - "▁o fficial", - "▁off icial", - "▁offic ial", - "▁offici al", - "▁exec ute", - "▁execut e", - "▁ execute", - "ou ve", - "ouv e", - "o uve", - "{ {", - "▁A p", - "▁ Ap", - "▁к у", - "▁ ку", - "I L", - "▁ ^", - "di m", - "d im", - "▁set up", - "▁ setup", - "с к", - "▁sh are", - "▁ share", - "▁min utes", - "▁minute s", - "gl e", - "g le", - "oc o", - "o co", - "st ell", - "ste ll", - "▁C oun", - "▁Co un", - "▁Cou n", - "▁tem per", - "▁temp er", - "▁ temper", - "ke it", - "сь кий", - "a o", - "▁L ong", - "▁Lo ng", - "▁ Long", - "( &", - "ка н", - "к ан", - "▁d ens", - "▁de ns", - "▁den s", - "▁ dens", - "Bu t", - "B ut", - "X X", - "DA TE", - "DAT E", - "D ATE", - "ga n", - "g an", - ".) .", - ". ).", - "▁en try", - "▁ent ry", - "▁entr y", - "▁ entry", - "inst all", - "▁з на", - "▁ зна", - "▁S om", - "▁So m", - "Comm and", - "ße n", - "ß en", - "▁start ing", - "▁star ting", - "▁s to", - "▁st o", - "▁ sto", - "I G", - "▁min im", - "▁mi nim", - "▁mini m", - "▁exp licit", - "▁explic it", - "▁by tes", - "▁byte s", - "▁ bytes", - "▁par ty", - "▁part y", - "▁ party", - "to ber", - "t ober", - "▁G rand", - "▁Gr and", - "▁Gra nd", - "▁Gran d", - "▁V or", - "▁Vo r", - "▁ Vor", - "▁l eur", - "▁le ur", - "▁ leur", - "Doc ument", - "D ocument", - "er c", - "e rc", - "ens ive", - "C P", - "en v", - "▁arg uments", - "▁argument s", - "▁ arguments", - "▁G ran", - "▁Gr an", - "▁Gra n", - "ar ily", - "ari ly", - "▁l in", - "▁li n", - "▁ lin", - "t n", - "( -", - "ge q", - "g eq", - "▁F amil", - "▁Fa mil", - "▁Fam il", - "▁ Famil", - "▁Б о", - "▁t our", - "▁to ur", - "▁tou r", - "▁n av", - "▁na v", - "▁ nav", - "▁proper ly", - "▁M rs", - "▁Mr s", - "▁M el", - "▁Me l", - "▁sc ale", - "▁scal e", - "▁ scale", - "ast ic", - "d s", - "▁S ir", - "▁Si r", - "▁Ch urch", - "}^ {\\", - "}^{ \\", - "} ^{\\", - "yo u", - "y ou", - "/ .", - "S o", - "▁br ought", - "▁r ole", - "▁ro le", - "▁rol e", - "▁ role", - "▁S ur", - "▁Su r", - "▁ Sur", - "▁f ond", - "▁fo nd", - "▁fon d", - "▁g es", - "▁ge s", - "▁ ges", - "ż e", - "et en", - "ete n", - "e ten", - "▁é tait", - "▁ét ait", - "▁ était", - "SE R", - "S ER", - "▁ко торы", - "▁кото ры", - "▁equ ation", - "▁ equation", - "as px", - "asp x", - "▁A fr", - "▁Af r", - "▁d it", - "▁di t", - "▁ dit", - "em pty", - "emp ty", - "empt y", - "al ement", - "ale ment", - "alem ent", - "a lement", - "wr ap", - "w rap", - "▁B et", - "▁Be t", - "▁col lect", - "▁coll ect", - "▁colle ct", - "▁ collect", - "▁g it", - "▁gi t", - "▁ git", - "▁v ie", - "▁vi e", - "▁ vie", - "▁. .", - "▁ ..", - "ро й", - "▁< ?", - "▁ ", - "▁В а", - "no st", - "nos t", - "n ost", - "▁n em", - "▁ne m", - "▁ nem", - "▁p en", - "▁pe n", - "▁ pen", - "Op en", - "O pen", - "▁ch urch", - "ко н", - "к он", - "▁a verage", - "▁aver age", - "▁ave rage", - "▁com ments", - "▁comm ents", - "▁comment s", - "▁ comments", - "▁correspond ing", - "lev ant", - "▁b ed", - "▁be d", - "▁ bed", - "▁mean ing", - "V ersion", - "Lin k", - "L ink", - "be l", - "b el", - "▁ext ract", - "▁extra ct", - "▁extr act", - "▁ extract", - "ś ć", - "▁I V", - "▁ IV", - "▁I r", - "▁comp uter", - "▁comput er", - "▁compute r", - "▁a ffect", - "▁af fect", - "▁aff ect", - "▁С та", - "▁Ст а", - "A X", - "so rt", - "s ort", - "▁s pecies", - "▁spe cies", - "▁spec ies", - "▁specie s", - "▁ species", - "▁O per", - "▁Op er", - "▁ Oper", - "▁h ash", - "▁ha sh", - "▁has h", - "▁ hash", - "ch es", - "che s", - "c hes", - "▁Einz eln", - "▁Einzel n", - "▁ke ys", - "▁key s", - "▁ keys", - "▁mar zo", - "▁inter pret", - "▁interpre t", - "ho od", - "h ood", - "▁co ordin", - "▁coord in", - "ö s", - "ra ge", - "rag e", - "r age", - "et z", - "e tz", - "iz a", - "i za", - "де р", - "д ер", - "ü t", - "^ *", - "▁mod ify", - "▁term in", - "▁ter min", - "▁ termin", - "▁c red", - "▁cre d", - "▁cr ed", - "▁ cred", - "zo n", - "z on", - "ну ю", - "н ую", - "▁m ie", - "▁mi e", - "▁' '", - "▁ ''", - "▁M os", - "▁Mo s", - "▁conne cted", - "▁connect ed", - "▁conn ected", - "▁ connected", - "N O", - "▁comp ile", - "▁ compile", - "▁\" \\", - "▁ \"\\", - "▁c at", - "▁ca t", - "▁ cat", - "f iddle", - "ut a", - "u ta", - "Acc ess", - "Ac cess", - "A ccess", - "▁S to", - "▁St o", - "▁ Sto", - "▁B ur", - "▁Bu r", - "▁n orth", - "▁nor th", - "G amma", - "▁al loc", - "▁all oc", - "▁allo c", - "▁ alloc", - "In it", - "I nit", - "▁L ink", - "▁Lin k", - "▁ Link", - "ial ize", - "iali ze", - "Im pl", - "Imp l", - "ou pe", - "oup e", - "rop ri", - "▁G old", - "▁Go ld", - "▁Gol d", - "▁s olo", - "▁so lo", - "▁sol o", - "▁D ist", - "▁Dis t", - "▁Di st", - "▁ Dist", - ", -", - "na v", - "n av", - "▁al ert", - "▁ale rt", - "▁ alert", - "es is", - "esi s", - "▁O s", - "▁ Os", - "// /", - "/ //", - "▁f eb", - "▁fe b", - "▁- ->", - "▁-- >", - "▁ -->", - "fo ot", - "foo t", - "f oot", - "▁F ried", - "▁Fr ied", - "▁Fri ed", - "▁Einzeln ach", - "▁Einzel nach", - "▁re v", - "▁r ev", - "▁ rev", - "ze it", - "▁S tat", - "▁St at", - "▁Sta t", - "▁ Stat", - "▁S eg", - "▁Se g", - "▁ Seg", - "▁b lo", - "▁bl o", - "▁ blo", - "wi ck", - "w ick", - "E L", - "ca ption", - "cap tion", - "capt ion", - "he ader", - "head er", - "▁pres ident", - "▁presiden t", - "▁mult ip", - "▁multi p", - "▁mul tip", - "▁ multip", - "▁Einzelnach weise", - "▁se ine", - "▁sein e", - "▁sei ne", - "? ”", - "Func tion", - "Fun ction", - "F unction", - "▁St and", - "▁Sta nd", - "▁Stan d", - "▁ Stand", - "▁F unction", - "▁Fun ction", - "▁ Function", - "▁? >", - "▁ ?>", - "▁B ill", - "▁Bi ll", - "▁Bil l", - "▁s pect", - "▁sp ect", - "▁spe ct", - "▁spec t", - "▁ spect", - "▁re direct", - "▁red irect", - "▁ redirect", - "ru pt", - "rup t", - "r upt", - "▁w alk", - "▁wal k", - "▁ walk", - "в ши", - "spring framework", - "pl ace", - "pla ce", - "p lace", - "é ho", - "Ent ity", - "▁Ser vice", - "▁Serv ice", - "▁ Service", - "in te", - "int e", - "▁tr aining", - "▁tra ining", - "▁train ing", - "▁ training", - "▁( `", - "▁ (`", - "фо р", - "ф ор", - "▁к ра", - "▁ кра", - "au r", - "a ur", - "▁f etch", - "▁fet ch", - "▁ fetch", - "▁ †", - "▁m ême", - "▁ même", - "▁( '", - "▁ ('", - "at ively", - "ative ly", - "ativ ely", - "▁exec ut", - "ä ch", - "▁Catalog ue", - "ba sed", - "base d", - "bas ed", - "b ased", - "Att ribute", - "▁s pring", - "▁sp ring", - "▁spr ing", - "▁ spring", - "ph one", - "phon e", - "т ра", - "▁п и", - "▁ пи", - "те ра", - "тер а", - "т ера", - "▁` \\", - "▁O d", - "On e", - "O ne", - "se nd", - "sen d", - "s end", - "bo n", - "b on", - "▁ °", - "M O", - "▁as king", - "▁ask ing", - "▁o ù", - "▁ing år", - "▁test ing", - "▁ testing", - "▁ф а", - "▁ фа", - "▁B ook", - "▁Bo ok", - "▁ Book", - "im m", - "i mm", - "▁pro gress", - "▁ progress", - "br o", - "b ro", - "F irst", - "▁p hot", - "▁ph ot", - "▁O N", - "▁ ON", - "Tem plate", - "Temp late", - "develop er", - "an not", - "ann ot", - "anno t", - "▁> =", - "▁ >=", - "miss ion", - "m ission", - "▁k tó", - "▁ któ", - "p c", - "ba ch", - "b ach", - "ze nt", - "zen t", - "z ent", - "ue d", - "u ed", - "▁o nes", - "▁on es", - "▁one s", - "▁ ones", - "ј и", - "▁r out", - "▁ro ut", - "▁rou t", - "▁ rout", - "▁К и", - "Pos t", - "Po st", - "P ost", - "ці ї", - "ц ії", - "▁V ir", - "▁Vi r", - "ne k", - "n ek", - "ag ing", - "agi ng", - "agin g", - "a ging", - "▁о к", - "▁ ок", - "iz ont", - "izo nt", - "izon t", - "▁ag osto", - "▁ago sto", - "▁cho ose", - "▁ choose", - "▁ \r", - "▁system s", - "▁syst ems", - "lo ss", - "los s", - "l oss", - "ien te", - "ient e", - "i ente", - "▁C re", - "▁Cr e", - "▁ Cre", - "▁con tra", - "▁cont ra", - "▁contr a", - "▁ contra", - "um s", - "u ms", - "▁begin ning", - "em y", - "e my", - "ist ics", - "istic s", - "isti cs", - "▁s erved", - "▁ser ved", - "▁serv ed", - "▁serve d", - "Do wn", - "D own", - "option s", - "opt ions", - "o ptions", - "▁G overn", - "▁Go vern", - "▁B Y", - "▁ BY", - "▁j est", - "▁je st", - "▁ jest", - "t é", - "▁cont inue", - "▁contin ue", - "▁continu e", - "▁ continue", - "pe rs", - "per s", - "p ers", - "▁eas ier", - "▁c os", - "▁co s", - "▁ cos", - "es so", - "ess o", - "> >", - "Ne t", - "N et", - "▁B or", - "▁Bo r", - "▁C r", - "▁ Cr", - "▁trans fer", - "▁C SS", - "▁CS S", - "▁ CSS", - "▁fin ns", - "▁х о", - "▁ хо", - "us ername", - "user name", - "▁con stru", - "▁const ru", - "▁p ain", - "▁pa in", - "▁T em", - "▁Te m", - "▁ Tem", - "▁spec ified", - "▁b rit", - "▁br it", - "▁ brit", - "ски е", - "с кие", - "ir k", - "ra pper", - "rap per", - "r apper", - "▁c ounter", - "▁co unter", - "▁count er", - "▁coun ter", - "▁ counter", - "▁[ \"", - "▁ [\"", - "ode d", - "od ed", - "o ded", - "да н", - "д ан", - "pro perty", - "ha rd", - "har d", - "h ard", - "ist rict", - "istr ict", - ") /", - "▁P our", - "▁Po ur", - "▁W here", - "▁Wh ere", - "▁Whe re", - "▁ Where", - "▁= ==", - "▁== =", - "▁ ===", - "▁s owie", - "▁so wie", - "▁sow ie", - "▁П ро", - "▁d ess", - "▁de ss", - "▁des s", - "▁ dess", - "▁t ras", - "▁tr as", - "▁tra s", - "▁ tras", - "▁у ча", - "▁O ver", - "▁ Over", - "no te", - "not e", - "n ote", - "▁Amer ica", - "▁ America", - "c p", - "▁gr ande", - "▁gra nde", - "▁gran de", - "▁grand e", - "M e", - ") -", - "Mod e", - "Mo de", - "M ode", - "▁pass ing", - "▁pas sing", - "▁g iving", - "▁giv ing", - "▁gi ving", - "C l", - "} /", - "Me nu", - "Men u", - "M enu", - "! !", - "ang ular", - "angu lar", - "▁la unch", - "▁ launch", - "var phi", - "▁Joh ann", - "▁Johan n", - "▁for each", - "▁fore ach", - "▁ foreach", - "r ó", - "se qu", - "seq u", - "s equ", - "if i", - "i fi", - "A m", - "ar p", - "a rp", - "▁b uffer", - "▁buf fer", - "▁buff er", - "▁ buffer", - "▁n i", - "▁ ni", - "▁m ix", - "▁mi x", - "▁ mix", - "▁M useum", - "▁Muse um", - "▁me ant", - "▁mean t", - "as i", - "a si", - "▁k an", - "▁ka n", - "▁ kan", - "пра в", - "п рав", - "Com p", - "Co mp", - "C omp", - "is toire", - "ist oire", - "isto ire", - "if ul", - "i ful", - "je r", - "j er", - "iss ions", - "ission s", - "Re source", - "Res ource", - "▁в оз", - "▁во з", - "▁S T", - "▁ ST", - "▁sol utions", - "▁solution s", - "▁be long", - "▁bel ong", - "▁As soci", - "▁Ass oci", - "▁ Associ", - "c f", - "▁M är", - "▁g rid", - "▁gr id", - "▁ grid", - "M ult", - "▁require s", - "▁requ ires", - "k k", - "▁t each", - "▁te ach", - "▁tea ch", - "eme inde", - "emein de", - "▁s quare", - "▁squ are", - "▁ square", - "▁ко ман", - "▁ком ан", - "▁E vent", - "▁Ev ent", - "▁Even t", - "▁ Event", - "▁r ules", - "▁rule s", - "▁ru les", - "▁ rules", - "▁b ur", - "▁bu r", - "▁ bur", - "▁e ing", - "▁ein g", - "▁ eing", - "▁M ai", - "▁Ma i", - "▁n am", - "▁na m", - "▁ nam", - "▁s lä", - "▁sl ä", - "hö r", - "h ör", - "▁t ip", - "▁ti p", - "▁ tip", - "▁Liter atur", - "▁s cope", - "▁sc ope", - "▁scop e", - "▁ scope", - "over line", - "▁ex it", - "▁ exit", - ") ?", - "be t", - "b et", - "▁v ict", - "▁vi ct", - "▁vic t", - "Of f", - "O ff", - "▁appro xim", - "▁G eb", - "▁Ge b", - "kt op", - "k top", - "he it", - "▁ Ю", - "tem plate", - "temp late", - "ро н", - "р он", - "▁u no", - "▁un o", - "▁ uno", - "Ser v", - "Se rv", - "S erv", - "▁frame work", - "▁ framework", - "oper ator", - "opera tor", - "▁gener ally", - "▁general ly", - "▁h undred", - "▁d ivers", - "▁di vers", - "▁div ers", - "▁diver s", - "ov i", - "o vi", - "▁r és", - "▁ré s", - "▁ rés", - "ab s", - "a bs", - "▁g al", - "▁ga l", - "▁ gal", - "ça is", - "ç ais", - "▁fe et", - "▁fee t", - "▁v irtual", - "▁virt ual", - "▁ virtual", - "cz y", - "c zy", - "ск у", - "с ку", - ". /", - "h u", - "an cy", - "anc y", - "▁recomm end", - "▁п ід", - "▁пі д", - "▁m oney", - "▁mon ey", - "▁mo ney", - "▁vers ions", - "▁version s", - "▁ versions", - "▁hel ps", - "▁help s", - "▁H or", - "▁Ho r", - "▁ Hor", - "Item s", - "It ems", - "lo ok", - "l ook", - "con nect", - "conne ct", - "conn ect", - "an ges", - "ang es", - "ange s", - "View Controller", - "el ijk", - "elij k", - "eli jk", - "e lijk", - "▁occ up", - "▁oc cup", - "▁ occup", - "▁ed itor", - "▁edit or", - "▁ editor", - "au to", - "aut o", - "a uto", - "ö g", - "▁second s", - "▁sec onds", - "▁ seconds", - "▁ob vious", - "v m", - "ak es", - "ake s", - "a kes", - "▁g egen", - "▁ge gen", - "▁geg en", - "▁t il", - "▁ti l", - "▁ til", - "ject ion", - "je ction", - "j ection", - "ле ння", - "лен ня", - "▁oper ations", - "▁operation s", - "▁E ast", - "og y", - "o gy", - "▁P olit", - "▁Pol it", - "▁Po lit", - "ut en", - "ute n", - "u ten", - "▁Jose ph", - "\" `", - "▁Comp any", - "▁ Company", - "▁call back", - "▁ callback", - "▁s en", - "▁se n", - "▁ sen", - "cc ión", - "cció n", - "c ción", - "▁associ ated", - "▁associate d", - "▁cont aining", - "▁contain ing", - "▁pract ice", - "elij ke", - "elijk e", - "e lijke", - "ok e", - "o ke", - "ér a", - "é ra", - "un s", - "u ns", - "an ta", - "ant a", - "ve y", - "v ey", - "z u", - "▁B es", - "▁Be s", - "▁F lor", - "▁Fl or", - "▁Flo r", - "me m", - "m em", - "yc z", - "y cz", - "▁arch itect", - "▁an ni", - "▁ann i", - "▁ anni", - "▁cont act", - "▁ contact", - "Y PE", - "▁C as", - "▁Ca s", - "▁по лу", - "▁пол у", - "ov o", - "o vo", - "▁b ring", - "▁br ing", - "▁con cept", - "▁conce pt", - "▁j s", - "▁ js", - "▁Refer encias", - "em ble", - "emb le", - "embl e", - "▁ н", - "▁supp orted", - "▁support ed", - "▁ supported", - "Bi g", - "B ig", - "▁H ans", - "▁Ha ns", - "▁Han s", - "er v", - "e rv", - "▁M aj", - "▁Ma j", - "▁ar riv", - "▁arr iv", - "▁H ave", - "▁Ha ve", - "▁Hav e", - "▁ Have", - "▁prob ability", - "▁probabil ity", - "▁P op", - "▁Po p", - "▁ Pop", - "▁P ass", - "▁Pa ss", - "▁Pas s", - "▁ Pass", - "to ken", - "tok en", - "t oken", - "Pro vider", - "▁R a", - "Re ader", - "Read er", - "oot h", - "oo th", - "o oth", - "la p", - "l ap", - "▁ass ist", - "ad ow", - "ado w", - "▁t ests", - "▁test s", - "▁ tests", - "сс и", - "с си", - "▁k ing", - "▁ki ng", - "▁kin g", - "▁ king", - "lang le", - "lan gle", - "l angle", - "▁S um", - "▁Su m", - "▁ Sum", - "O IN", - "▁se curity", - "▁sec urity", - "▁ security", - "ni s", - "n is", - ".. /", - ". ./", - "▁bas ic", - "▁ basic", - "un ity", - "uni ty", - "unit y", - "` :", - "▁ко то", - "ko w", - "k ow", - "▁Bibli othèque", - "as ion", - "asi on", - "al o", - "a lo", - "if est", - "ife st", - "i fest", - "▁nov embre", - "▁p eu", - "▁pe u", - "▁ Ж", - "en schaft", - "ensch aft", - "cl us", - "c lus", - "ј у", - "He ight", - "ú n", - "▁t ur", - "▁tu r", - "▁ide as", - "▁idea s", - "▁c es", - "▁ce s", - "▁ ces", - "fr ak", - "fra k", - "f rak", - "▁pre mier", - "▁prem ier", - "▁premi er", - "it ation", - "ita tion", - "itat ion", - "▁s é", - "HT ML", - "▁Ro yal", - "▁Roy al", - "сь кої", - "сько ї", - "▁by te", - "▁ byte", - "P S", - "▁s egu", - "▁se gu", - "▁seg u", - "▁ segu", - "in en", - "ine n", - "i nen", - "▁Gre at", - "▁К у", - "▁ex ternal", - "▁ext ernal", - "▁extern al", - "▁ external", - "T itle", - "To p", - "T op", - "Pro cess", - "Proc ess", - "it ät", - "itä t", - "▁` /", - "▁se cret", - "▁sec ret", - "▁secre t", - "▁ secret", - "pos itory", - "▁pot ential", - "▁B ud", - "▁Bu d", - "name s", - "na mes", - "nam es", - "n ames", - "as ons", - "ason s", - "aso ns", - "stack exchange", - "back ground", - "пе р", - "п ер", - "со в", - "с ов", - "aft er", - "af ter", - "a fter", - "▁p ero", - "▁per o", - "▁pe ro", - "▁so ftware", - "▁soft ware", - "▁ software", - "▁s ed", - "▁se d", - "▁ sed", - "▁array s", - "▁arr ays", - "tm p", - "t mp", - "▁a sp", - "▁as p", - "▁ asp", - "sc ale", - "scal e", - "▁L at", - "▁La t", - "▁ Lat", - "an al", - "ana l", - "a nal", - "▁g em", - "▁ge m", - "▁ gem", - "P U", - "▁Al tri", - "▁Alt ri", - "Th at", - "T hat", - "▁Н и", - "if act", - "ifa ct", - "i fact", - "Add ress", - "▁s outh", - "▁so uth", - "▁sou th", - "▁sout h", - "▁form ula", - "▁Col leg", - "▁Coll eg", - "▁і н", - "▁ ін", - "kt ion", - "k tion", - "▁s ac", - "▁sa c", - "S H", - "aj o", - "a jo", - "et c", - "e tc", - "v c", - "` ](", - "▁D ur", - "▁Du r", - "▁М е", - "▁Sm ith", - "▁ Smith", - "it ems", - "ite ms", - "item s", - "C K", - "el o", - "e lo", - "▁pl ugin", - "▁plug in", - "▁ plugin", - "▁s erie", - "▁se rie", - "▁ser ie", - "▁ serie", - "ien ne", - "ienn e", - "i enne", - "▁и ли", - "Ma r", - "M ar", - "▁Im age", - "▁ Image", - "go t", - "g ot", - "an das", - "and as", - "anda s", - "▁mat ches", - "▁match es", - "▁ matches", - "▁w orth", - "▁wor th", - "▁ worth", - "▁D eb", - "▁De b", - "▁ Deb", - "▁c ache", - "▁ca che", - "▁ cache", - "▁f elt", - "▁fe lt", - "▁fel t", - "er sch", - "ers ch", - "iz es", - "ize s", - "i zes", - "Op er", - "O per", - "▁Jah re", - "▁Jahr e", - "▁Ja hre", - "▁comm une", - "▁commun e", - "th read", - "▁n y", - "▁ ny", - "de c", - "d ec", - "ou w", - "o uw", - "▁sur face", - "▁P or", - "▁Po r", - "▁St reet", - "▁Stre et", - "пр и", - "п ри", - "▁c andid", - "▁can did", - "▁cand id", - "▁Re turn", - "▁Ret urn", - "▁ Return", - "▁K om", - "▁Ko m", - "gr u", - "g ru", - "▁т и", - "▁ ти", - "[ \\", - "▁dep ends", - "▁depend s", - "▁in flu", - "▁inf lu", - "▁infl u", - "▁to wards", - "▁toward s", - "ain ed", - "ai ned", - "aine d", - "a ined", - "▁r ank", - "▁ran k", - "▁ rank", - "▁Janu ar", - "▁com ponents", - "▁compon ents", - "▁component s", - "▁ components", - "ge st", - "ges t", - "g est", - "getElement ById", - "▁check ed", - "▁ checked", - "air s", - "ai rs", - "a irs", - "jo in", - "j oin", - "▁d ead", - "▁de ad", - "▁h it", - "▁hi t", - "▁ hit", - "én y", - "é ny", - "▁equ ivalent", - "▁equival ent", - "▁П ре", - "▁app ropri", - "Pa ss", - "P ass", - "▁pr imer", - "▁prim er", - "▁pri mer", - "▁prime r", - "engl isch", - "▁app ar", - "▁ap par", - "▁D uring", - "▁Du ring", - "▁Dur ing", - "▁know ledge", - "▁tr igger", - "▁trig ger", - "▁ trigger", - "▁c ore", - "▁cor e", - "▁co re", - "▁ core", - "▁O l", - "▁P rodu", - "▁Pro du", - "▁Pr odu", - "▁ Produ", - "▁F ern", - "▁Fe rn", - "▁Fer n", - "▁ Fern", - "▁на ча", - "▁ нача", - "T e", - "▁M ot", - "▁Mo t", - "er ve", - "erv e", - "тв о", - "т во", - "▁m id", - "▁mi d", - "▁ mid", - "▁fin ally", - "▁final ly", - "air es", - "ai res", - "aire s", - "a ires", - "▁es pecially", - "▁espe cially", - "▁especial ly", - "▁t ut", - "▁tu t", - "▁rece ive", - "ad re", - "adr e", - "▁ne igh", - "▁nei gh", - "kt et", - "kte t", - "il de", - "ild e", - "▁rad io", - "▁radi o", - "▁ radio", - "▁d river", - "▁dr iver", - "▁drive r", - "▁dri ver", - "▁driv er", - "▁ driver", - "ли сь", - "end encies", - "enden cies", - "▁I E", - "▁ IE", - "▁s aved", - "▁sa ved", - "▁sav ed", - "▁save d", - "▁ saved", - "ff ect", - "ffe ct", - "f fect", - "▁Way back", - "ia t", - "i at", - "▁p adding", - "▁pad ding", - "▁ padding", - "wind ow", - "w indow", - "ти че", - "▁m ur", - "▁mu r", - "ac tor", - "act or", - "a ctor", - "▁H an", - "▁Ha n", - "он аль", - "она ль", - "о наль", - "▁g ar", - "▁ga r", - "▁ gar", - "▁famil jen", - "ó s", - "▁n ationale", - "▁national e", - "▁nation ale", - "▁nat ionale", - "▁p ré", - "▁pr é", - "de d", - "d ed", - "on al", - "ona l", - "o nal", - "▁Pres ident", - "▁\\ ,", - "▁ \\,", - "▁place d", - "▁pla ced", - "er ni", - "ern i", - "▁sign al", - "▁sig nal", - "▁ signal", - "na b", - "n ab", - "h m", - "Mo n", - "M on", - "▁v s", - "▁ vs", - "S C", - "▁proget ti", - "▁ Ü", - "▁for ms", - "▁form s", - "▁ forms", - "▁message s", - "▁mess ages", - "▁ messages", - "in f", - "us ers", - "use rs", - "user s", - "u sers", - "GE T", - "G ET", - "▁d els", - "▁de ls", - "▁del s", - "Col lection", - "Coll ection", - "Collect ion", - "▁G ood", - "▁Go od", - "▁ Good", - "▁May be", - "▁ Maybe", - "▁com pr", - "▁comp r", - "▁lar ger", - "▁large r", - "▁larg er", - "gr es", - "gre s", - "g res", - "ap er", - "ape r", - "a per", - "▁П ри", - "un des", - "und es", - "unde s", - "▁s ea", - "▁se a", - "▁S pring", - "▁Sp ring", - "▁Spr ing", - "▁ Spring", - "ul o", - "u lo", - "▁me chan", - "▁s ans", - "▁sa ns", - "▁san s", - "G B", - "Val id", - "▁comm unic", - "▁commun ic", - "▁ communic", - "▁p ra", - "▁pr a", - "vi er", - "vie r", - "v ier", - "▁С е", - "▁a in", - "▁ai n", - "▁ ain", - "ту ра", - "тур а", - "ko m", - "k om", - "sk iego", - "ski ego", - "skie go", - "ко во", - "ков о", - "к ово", - "ad ata", - "ada ta", - "a data", - "▁Р е", - "▁bo olean", - "▁ boolean", - "se ts", - "set s", - "s ets", - "▁eff ort", - ". [", - "▁z ostał", - "P A", - "▁V ict", - "▁Vi ct", - "▁Vic t", - "S D", - "ow ał", - "owa ł", - "▁e mb", - "▁em b", - "▁ emb", - "▁pr ima", - "▁prim a", - "▁pri ma", - "▁h our", - "▁ho ur", - "▁ hour", - "sub section", - "▁F ort", - "▁For t", - "▁Fo rt", - "math frak", - "ig in", - "igi n", - "i gin", - "G L", - ") +", - "f i", - "▁an ci", - "▁anc i", - "▁ anci", - "▁p an", - "▁pa n", - "▁ pan", - "\\ )", - "▁l ug", - "▁lu g", - "▁dep loy", - "▁ deploy", - "do main", - "dom ain", - "▁s light", - "▁sl ight", - "JS ON", - "J SON", - "▁mor ning", - "▁h i", - "▁ hi", - "▁comp are", - "▁compar e", - "▁ compare", - "ij e", - "i je", - "▁bl ue", - "▁ blue", - "▁A c", - "▁ Ac", - "▁m iddle", - "▁ middle", - "an den", - "and en", - "ande n", - "▁sh ared", - "▁share d", - "▁ shared", - "▁C amp", - "▁Cam p", - "▁Ca mp", - "▁ Á", - "ound ed", - "oun ded", - "u w", - "ier ung", - "St ack", - "▁e ines", - "▁ein es", - "▁eine s", - "▁D a", - "▁ Da", - "li j", - "l ij", - "en ti", - "ent i", - "▁ й", - "U til", - "▁exper ience", - "▁experien ce", - "▁a wait", - "▁aw ait", - "▁ await", - "ul s", - "u ls", - "▁request s", - "▁requ ests", - "▁ requests", - "▁im pos", - "▁imp os", - "▁const raint", - "▁ constraint", - "Ch ange", - "em ph", - "emp h", - "бе р", - "б ер", - "▁An other", - "C ustom", - "▁signific ant", - "▁significa nt", - "c r", - "▁mill ion", - "re ek", - "ree k", - "▁d alla", - "▁da lla", - "▁dal la", - "▁dall a", - "▁G erm", - "▁Ge rm", - "▁Ger m", - "ot al", - "ota l", - "o tal", - "at eur", - "ate ur", - "bt n", - "b tn", - "▁th inking", - "▁think ing", - "▁thin king", - "▁inter val", - "▁ interval", - "on ne", - "onn e", - "▁l iv", - "▁li v", - "▁ liv", - "() :", - "( ):", - "▁В е", - "o e", - "▁E v", - "me ta", - "met a", - "m eta", - "▁b road", - "▁bro ad", - "Re m", - "R em", - "ap ply", - "app ly", - "a pply", - "▁cou ple", - "▁coup le", - "▁te chni", - "▁techn i", - "id ades", - "ida des", - "idad es", - "idade s", - "▁go al", - "▁ goal", - "▁C D", - "▁ CD", - "ha b", - "h ab", - "▁ex plan", - "▁exp lan", - "▁expla n", - "▁expl an", - "an ner", - "ann er", - "anne r", - "▁B ecause", - "bl og", - "blo g", - "b log", - "include graphics", - "▁vo ice", - "▁ voice", - "▁M ap", - "▁Ma p", - "▁ Map", - "vent ion", - "ven tion", - "v ention", - "S ession", - "▁L iens", - "▁Li ens", - "▁Lie ns", - "▁s or", - "▁so r", - "c ategory", - "ash ington", - "▁Mär z", - "po p", - "p op", - "il let", - "ill et", - "ille t", - "▁z wei", - "▁zwe i", - "▁zw ei", - "▁L ie", - "▁Li e", - "N ull", - "add ress", - "addr ess", - "▁f actor", - "▁fact or", - "▁fa ctor", - "▁fac tor", - "▁ factor", - "▁l igne", - "▁lig ne", - "▁HT TP", - "▁ HTTP", - "▁s uf", - "▁su f", - "▁person al", - "▁pers onal", - "▁persona l", - "ci p", - "c ip", - "▁D ar", - "▁Da r", - "▁a dm", - "▁ad m", - "ко й", - "▁E xt", - "▁Ex t", - "▁ Ext", - "▁g od", - "▁go d", - "▁ god", - "a a", - "R ight", - "ét é", - "é té", - "▁d ynamic", - "▁dynam ic", - "▁ dynamic", - "▁main tain", - "to r", - "t or", - "#### ####", - "▁F ra", - "▁Fr a", - "▁cho ice", - "▁ choice", - "▁с то", - "▁ст о", - "▁ сто", - "С Р", - "▁F eder", - "▁Fe der", - "▁Fed er", - "st on", - "sto n", - "s ton", - "▁f lag", - "▁fl ag", - "▁fla g", - "▁ flag", - "ki t", - "k it", - "Mod ule", - "▁с по", - "▁сп о", - "▁ спо", - "▁S tra", - "▁St ra", - "▁Str a", - "ic ks", - "ick s", - "i cks", - "▁h aven", - "▁ha ven", - "▁have n", - "▁hav en", - "▁M ass", - "▁Ma ss", - "▁Mas s", - "▁E mp", - "▁Em p", - "▁ Emp", - "▁P i", - "▁ Pi", - "▁P en", - "▁Pe n", - "Re ct", - "Rec t", - "R ect", - "▁K r", - "it at", - "ita t", - "i tat", - "el er", - "ele r", - "e ler", - "я бря", - "it et", - "ite t", - "▁St art", - "▁Sta rt", - "▁Star t", - "▁ Start", - "▁produ ced", - "▁produce d", - "▁по л", - "▁ пол", - "( _", - "▁de let", - "▁del et", - "▁h ot", - "▁ho t", - "▁ hot", - "▁Gesch ichte", - "~ ~", - "▁month s", - "▁mont hs", - "▁t od", - "▁to d", - "▁ tod", - "▁н и", - "▁ ни", - "ú s", - "te mp", - "tem p", - "t emp", - "▁D ez", - "▁De z", - "ype s", - "yp es", - "y pes", - "▁c ui", - "▁cu i", - "om mun", - "omm un", - "act ions", - "action s", - "a ctions", - "▁e igen", - "▁eig en", - "▁immedi ately", - "▁immediate ly", - "P L", - "▁Г о", - "▁B al", - "▁Ba l", - "▁ Bal", - "љ е", - "ul ui", - "ulu i", - "▁on line", - "▁ online", - "▁a ños", - "▁añ os", - "▁año s", - "▁name space", - "▁names pace", - "▁ namespace", - "▁m ond", - "▁mon d", - "▁mo nd", - "▁ mond", - "▁B ase", - "▁Bas e", - "▁Ba se", - "▁ Base", - "▁Can ada", - "▁Canad a", - "et zt", - "etz t", - "} -", - "▁de fin", - "▁def in", - "▁ defin", - "▁dou bt", - "▁doub t", - "▁inv estig", - "▁invest ig", - "view s", - "vie ws", - "▁L ine", - "▁Li ne", - "▁Lin e", - "▁ Line", - "▁st age", - "▁sta ge", - "▁stag e", - "▁ stage", - "ett ings", - "ub re", - "u bre", - "f loat", - "▁P lay", - "▁Pl ay", - "▁Pla y", - "▁ Play", - "▁L as", - "▁La s", - "pt r", - "p tr", - "▁be comes", - "▁become s", - "▁becom es", - "est amp", - "esta mp", - "▁in dependent", - "▁indep endent", - "▁independ ent", - "▁anal ysis", - "▁ analysis", - "▁L ook", - "▁Lo ok", - "▁ Look", - "la in", - "l ain", - "▁ра с", - "Re ference", - "▁s orry", - "▁sor ry", - "▁supp osed", - "▁suppose d", - "▁sup posed", - "û t", - "▁deg ree", - "ut z", - "u tz", - "M M", - "▁des ired", - "▁desire d", - "ł y", - "▁l en", - "▁le n", - "▁ len", - "▁al one", - "▁ alone", - "sign ed", - "sig ned", - "s igned", - "▁S ta", - "▁St a", - "Per son", - "Pers on", - "P erson", - "▁app lied", - "▁B ack", - "▁Ba ck", - "▁Bac k", - "▁ Back", - "▁m ars", - "▁ma rs", - "▁mar s", - "Par t", - "Pa rt", - "P art", - "▁D id", - "▁Di d", - "▁ Did", - "▁extern es", - "▁externe s", - "▁n p", - "▁ np", - "on go", + "▁require ment", + "respon d", + "ational e▁for", + "▁throughout ▁the▁study", + "▁1▁6 ▁6▁8", + "▁March ▁2007", + "empl oy", + "▁5▁0 ▁7▁0▁0▁2▁-", + "▁1▁.▁1▁\\ \n\n8▁2", + "▁g▁u ▁A▁-▁1▁3", + "▁4▁: ▁5▁0▁7▁0▁0▁2▁-", + "▁1▁.▁1▁\\\n\n8▁2 ▁1▁6▁6▁8", + "▁4▁:▁5▁0▁7▁0▁0▁2▁- ▁g▁u▁A▁-▁1▁3", + "2 ;", + "T rial", + "p en", + "p ne", + "z ym", + "on e-", + "\n\n Wh", + "s▁ [", + "al ▁s", + "▁an alyz", + "▁s et", + "▁of ▁all", + ".\n\n I", + "pro state▁cancer", + "▁( eg,▁", + "▁h er", + "study▁ will", + "▁com ponent", + "▁B aseline▁", + "▁B ioSci", + "▁st or", + "▁will ▁receive▁", + "follow ▁up", + ".▁S tudy▁", + "▁clin ic", + "▁evalu ate▁", + "▁non- target▁lesion", + "urop ean", + "util ity▁", + "▁Patients▁ with", + "emc itabin", + "merican ▁BioSci", + "measurable▁ lesion", + "MUNEX \n\nConfidential\n\nAMGEN\n\nProduct:", + "\n\nAmended▁Clinical▁Trial▁Protocol▁5▁XRP6258/EFC6193 \n\n2", + "CED URES", + "/ min", + "T C", + "d ate▁of", + "f actor", + "t inu", + "▁ i", + "▁a bov", + "al id", + "an ad", + "▁an algesic", + "ed ▁according▁to▁the▁", + "▁c olorectal", + "▁b elow", + "es sion", + "for ▁exampl", + "▁m ajor", + "▁in cidence▁of", + "▁C ycl", + "▁S TUDY", + "am il", + "all i", + "e▁th eir", + "cor rect", + "▁res olution", + "xic ities", + "ost e", + "▁X IV", + ".\n\nP age:", + ",▁S t", + "randomiz ed,▁", + "s▁b y▁", + "observ ed▁", + "ext ent", + "\n\nAmended▁ Clinical▁Study▁Protocol▁Drug▁Substance▁Cediranib▁(RECENTIN,▁AZD2171)▁Study▁Code▁D8480C00013", + "▁would▁ be▁", + "necess ary▁", + "clinically▁ indicated", + "ence,▁ Inc", + "perty▁of▁the▁sanofi-aventis▁group▁-▁strictly▁confidential▁WW-CLIN-PR007-SD-03▁VERSION▁n°02▁(19-DEC-200 5)", + "mon▁Terminology▁Criteria▁for ▁Adverse▁Event", + "\n\nAmended▁Clinical▁Trial▁Protocol▁5▁XRP6258/EFC6193\n\n2 1-Jul-2008▁Version▁number:▁1▁(electronic▁2.0", + "( 2", + "3 ,▁", + "5 ;", + "; ▁•", + "Y our", + "h ad", + "r ash", + "− 30", + "▁ s▁", + "▁ d▁", + "▁t w", + "s▁ during▁the▁", + "ed▁ Outcom", + "▁S ociet", + "▁or ▁without", + "▁M A", + "▁3 ▁week", + "▁o il", + "▁g rad", + "▁v ariabl", + "▁v olum", + "▁study▁ medication", + "GF R", + "▁dos es▁of", + "15 ▁February▁2011", + "\n\n2 1", + "e, ▁a", + "▁mod er", + "▁Pro cedure", + "▁Feb ▁2011", + "▁phas e▁of", + "▁18 ▁Feb▁2011", + "▁11 :38", + "do ▁not", + "▁fail ure", + "▁fail ure▁", + "▁ens ure▁that", + ":5 5", + "rincipal▁ investigator", + "appear ance▁of", + "C000 33", + "▁Denosumab▁Protocol▁Number:▁20050244▁Date:▁05▁May▁200 8\n\nPage▁", + "522 −30", + "▁4▁:▁5▁0▁7▁0▁0▁2▁-▁g▁u▁A▁-▁1▁3 ▁\\▁d▁e▁v▁o▁r▁p▁p▁A\n\n\\", + "merican▁BioSci ence,▁Inc", + "▁18▁Feb▁2011 ▁11:38", + "522−30 6.7", + "▁18▁Feb▁2011▁11:38 :55", + "6 4", + "M utant▁KRAS", + "R ec", + "d el", + "l ower", + "▁ ent", + "of t", + "ed▁ M", + "▁c opy▁of", + "es ▁and", + "ation ▁(", + "▁s urg", + "▁of ▁Cancer", + "om in", + "▁1 .0", + "▁P rimary▁", + "▁h el", + "▁or gan", + "form ance▁", + "ef ic", + "▁analys es▁of", + "▁st opp", + "▁study▁ visit", + "▁7 0", + ".6 .2", + "ated ▁that", + "efficac y▁and▁", + "▁An alys", + "................................................ ......", + "qual ity▁of▁lif", + "do es▁not", + "▁antic ip", + "▁Edition▁Number▁3▁Date▁ 15▁February▁2011", + "ourn al▁of", + "\n\n090177e18069 a3aa\\Approved\\Approved▁On:▁27-Sep-2007▁02:42", + "▁cut -off", + "Follow -up", + "(106 )\n\nGEL▁Version▁ID:▁ONC.000−272−636.4.0\n\nApproved\n\nDate▁Printed:▁13−Aug−2013\n\nApproved▁by\n\n13▁Sep▁2007▁17:17:03", + "C00033 ▁Edition▁Number▁3▁Date▁15▁February▁2011", + "▁4▁:▁5▁0▁7▁0▁0▁2▁-▁g▁u▁A▁-▁1▁3▁\\▁d▁e▁v▁o▁r▁p▁p▁A\n\n\\ ▁1▁.▁1▁\\\n\n8▁2▁1▁6▁6▁8", + "% ▁(", + "( C", + "6 2", + "A MG▁162", + "L aboratory▁", + "T T", + "b ear", + "▁ q", + "▁th em", + "um ▁of▁the▁", + "▁m is", + "pl or", + "▁S tudy", + "ot ransfer", + "▁l ow", + "▁f eel", + "du ced", + "▁of▁ 98", + "e▁s it", + "▁con fidential", + "12 48", + "\n\nC R", + "\n\nC h", + "e▁in clud", + "ell a", + "report ed▁to", + ".▁P h", + "▁tumor ▁tissu", + "effect ive▁", + "pre dict", + "▁X -ra", + "arget ▁Lesion", + "▁W eek", + ".\n\nA n", + "An alysis▁", + "outcom e▁variabl", + "▁CR C", + "▁author ized▁", + "fizer ▁–▁Company▁Confidential▁Page▁", + "lik ely", + "▁improv ement", + "94 )\n\nGEL▁Version▁ID:▁CV.000−", + "▁Lung ▁Cancer", + "perty▁of▁the▁sanofi-aventis▁group▁-▁strictly▁confidential▁WW-CLIN-PR007-SD-03▁VERSION▁n°02▁(19-DEC-2005) \n\nPage▁", + "94)\n\nGEL▁Version▁ID:▁CV.000− 522−306.7", + ") .▁In", + "T H", + "d ifferent", + "f ound▁", + "m pt", + "▁t ▁c", + ",▁ will▁be▁", + ".▁ 19", + "ing ▁from", + "▁of ▁panitumumab", + "00 ▁mg", + "▁I U", + "study▁ medication", + "▁ad equate▁", + "av or", + "ph en", + "▁this▁ document", + "ical utam", + "minist er", + "▁the▁in ter", + "rit er", + "▁tumor ▁assessment", + "17 4", + "NC CTG", + "▁inter est", + ".▁200 0", + "ed▁from ▁the▁", + "agn ostic", + "▁discontinu ation▁of", + "▁treat ed▁", + ".9 %", + "▁respons e▁to", + "▁dec ision", + "\n\nG rade▁", + "▁reason able▁", + "ord in", + "\n\nAmgen ▁Thousand▁Oaks", + "hemist ry▁", + "▁the▁discretion▁of▁the▁ investigator", + "U01 1248", + "MUNEX\n\nConfidential\n\nAMGEN\n\nProduct: ▁ABX-EGF▁Protocol▁Number:▁20020408▁Amendment▁4▁Date:▁26▁April▁2005\n\nPage▁", + "H )", + "P C", + "R eg", + "T able▁", + "c a", + "e ucovorin", + "r ing", + "e▁ an", + "e▁ as", + "in volv", + "▁A ss", + "▁( 80", + "▁S erum", + "▁S erious▁Adverse▁Event", + "▁re fer", + "study▁ will▁be▁", + "▁pro cess", + "e\n\n C", + "ad d", + "▁as▁ describ", + "▁st andard", + "▁will ▁be\n\n", + "▁ant itumor", + "pos itive▁", + "ifi ed▁as▁", + "progression -free▁s", + ".▁D ata", + "pr incipal▁", + "patients▁ who", + "unction al▁", + "clusion ▁criteria", + "▁int ak", + "▁a▁c opy▁of", + "▁pos itive▁", + "▁overall ▁survival", + "gressive▁ diseas", + "ey on", + "olid ▁tumor", + "accept able▁to", + "ummary▁ of", + "sp ection", + "▁July▁ 2004", + "▁of▁101 \n\n090177e18069a3aa\\Approved\\Approved▁On:▁27-Sep-2007▁02:42", + "▁abl e▁to", + "▁hel p", + "riter ion", + ", 6", + "- Up", + "2 25", + "6 8", + "F DA", + "S alt", + "Y P", + "a )", + "h es", + "r inotecan", + "▁ ........................................................................................................", + "\n\n p", + "\n\n treatment", + "re st", + "ro om", + "ar ily▁", + "▁P K", + "▁h owever", + "ys ical", + "abl e▁of", + "min imum", + "ant ic", + "▁will▁be▁ collect", + "▁as▁ possibl", + "▁on e▁of▁the▁", + "ific ation▁of", + "▁ch eck", + "▁ex perience▁", + "▁the▁t wo", + "cre en", + "▁each ▁patient", + "ci ent", + "complet ed", + "▁response▁ rate▁", + "▁On c", + "▁agre ement", + "35 ▁Date:▁14▁November▁2006", + "▁therap eutic", + "▁December ▁2010", + "▁temper ature▁", + "▁Cooperative▁ Oncology▁Group", + ") \n\nS", + "O P", + "O ther", + "r id", + "▁ know", + "in ▁a", + "st andard", + "▁w er", + "el vis", + "ol y", + "▁2 2", + "▁f uture▁", + "end er", + "▁and ▁all", + "▁pro gram", + "e\n\n S", + "▁0 8", + "▁3 .3", + "12 7", + "s.▁ P", + "▁wh ile▁", + ".6 .1", + "▁assessment s▁", + ".▁C h", "ong o", - "▁e sta", - "▁est a", - "▁es ta", - "▁ esta", - "Bl ock", - "B lock", - "▁p ou", - "▁po u", - "ad ores", - "ado res", - "ador es", - "▁St udio", - "▁Stud io", - "▁ Studio", - ". $", - "▁re ached", - "▁reach ed", - "bo t", - "b ot", - "▁J uni", - "▁Ju ni", - "▁Jun i", - "to ns", - "ton s", - "t ons", - "it el", - "ite l", - "i tel", - "▁G ar", - "▁Ga r", - "▁art icles", - "▁article s", - "▁ articles", - "▁D istrict", - "▁Dist rict", - "▁tr ouble", - "▁trou ble", - "li de", - "l ide", - "▁F ound", - "▁Fou nd", - "▁Fo und", - "▁ Found", - "á d", - "▁e quip", - "▁equ ip", - "▁in ternal", - "▁int ernal", - "▁inter nal", - "▁intern al", - "▁ internal", - "'] ,", - "' ],", - "▁a sync", - "▁as ync", - "▁ async", - "U B", - "ge l", - "g el", - "▁a i", - "▁ ai", - "ens ure", - "▁app eared", - "▁appear ed", - "▁appe ared", - "▁$ _", - "▁ $_", - "▁max imum", - "▁maxim um", - "▁С и", - "р ь", - "▁ann oun", - "▁anno un", - "ла сь", - "▁c m", - "▁ cm", - "га н", - "г ан", - "au pt", - "a upt", - "▁l atter", - "▁lat ter", - "▁pl atform", - "▁plat form", - "▁ platform", - "▁d ra", - "▁dr a", - "▁ dra", - "▁cap ital", - "▁capit al", - "▁sol ved", - "▁solve d", - "ri z", - "r iz", - "ed ic", - "edi c", - "e dic", - "▁M ur", - "▁Mu r", - "▁T op", - "▁To p", - "▁ Top", - "т ся", - "Pa nel", - "Pane l", - "Pan el", - "P anel", - "ru le", - "r ule", - "et ic", - "eti c", - "▁R en", - "▁Re n", - "▁Wik imedia", - "▁ Wikimedia", - "▁T O", - "▁ TO", - "se cond", - "sec ond", - "is l", - "i sl", - "▁h y", - "▁ hy", - "▁n iet", - "▁nie t", - "▁ni et", - "▁lo aded", - "▁load ed", - "▁ loaded", - "di g", - "d ig", - "▁ma yo", - "▁may o", - "[ :", - "Ac c", - "A cc", - "▁b ek", - "▁be k", - "▁ bek", - "ни ю", - "lo gin", - "log in", - "t x", - "▁F ur", - "▁Fu r", - "▁S anta", - "▁San ta", - "▁Sant a", - "az z", - "a zz", - "▁con duct", - "▁cond uct", - "▁condu ct", - "▁In dia", - "▁Ind ia", - "Or der", - "Ord er", - "ir th", - "irt h", - "t w", - "} +", - "▁w ieder", - "▁wie der", - "▁E du", - "▁Ed u", - "A V", - "▁` ``", - "▁`` `", - "▁ ```", - "▁man ually", - "▁manual ly", - "���R ead", - "▁Re ad", - "▁ Read", - "fortun ately", - "▁R un", - "▁Ru n", - "▁ Run", - "▁A ward", - "▁Aw ard", - "▁F oot", - "▁Foo t", - "▁Fo ot", - "▁ Foot", - "* )", - "par ams", - "param s", - "pa rams", - "para ms", - "п і", - "▁n ative", - "▁nat ive", - "▁ native", - "ri ft", - "rif t", - "r ift", - "▁ ä", - "AT H", - "A TH", - "▁your self", - "▁yours elf", - "▁p rior", - "▁pr ior", - "▁pri or", - "▁c it", - "▁ci t", - "▁ cit", - "ä h", - "▁tre at", - "▁me as", - "rib uted", - "ribute d", - "ribu ted", - "▁c lar", - "▁cl ar", - "▁cla r", - "▁ clar", - "ca rd", - "car d", - "c ard", - "RO R", - "R OR", - "il les", - "ill es", - "ille s", - "i lles", - "▁l ayer", - "▁la yer", - "▁lay er", - "▁ layer", - "au er", - "a uer", - "▁r at", - "▁ra t", - "▁ rat", - "bern ate", - "▁st ato", - "▁stat o", - "▁sta to", - "▁Ch ina", - "▁Chi na", - "▁$ ('#", - "▁$(' #", - "▁n aar", - "▁na ar", - "zi p", - "z ip", - "▁$ {\\", - "▁${ \\", - "▁appreci ated", - "▁appreciate d", - "▁и ме", - "▁им е", - "ż y", - "▁prze z", - "▁prz ez", - "▁Ind ian", - "▁India n", - "▁T od", - "▁To d", - "▁S ource", - "▁ Source", - "▁дру ги", - "in ternal", - "int ernal", - "inter nal", - "intern al", - "ion ale", - "ional e", - "iona le", - "Pro duct", - "Produ ct", - "▁M en", - "▁Me n", - "▁ Men", - "▁u pper", - "▁up per", - "▁upp er", - "▁ upper", - "▁E very", - "▁Ev ery", - "▁Ever y", - "▁ Every", - "}, \\", - "} ,\\", - "▁print f", - "▁prin tf", - "▁ printf", - "▁contin ued", - "▁continu ed", - "▁continue d", - "▁n odes", - "▁no des", - "▁node s", - "▁nod es", - "▁ nodes", - "л ки", - "▁n ice", - "▁ni ce", - "▁nic e", - "▁ nice", - "mod ules", - "module s", - "ei gn", - "e ign", - "▁M ex", - "▁Me x", - "▁Acc ording", - "▁un defined", - "▁und efined", - "▁ undefined", - "▁b inary", - "▁bin ary", - "▁ binary", - "cu t", - "c ut", - "Cur rent", - "C urrent", - "ed y", - "e dy", - "}} {", - "} }{", - "ble s", - "bl es", - "b les", - "▁во й", - "▁ вой", - "sc ri", - "scr i", - "s cri", - "eq n", - "Ch anged", - "Change d", - "▁kö z", - "▁rem ote", - "▁ remote", - "в ля", - "▁qu el", - "▁que l", - "▁q uel", - "▁ quel", - "▁al ign", - "▁ali gn", - "▁ align", - "▁п ар", - "▁па р", - "▁ пар", - "S V", - "ye r", - "y er", - "▁Cal iforn", - "▁p laces", - "▁pl aces", - "▁place s", - "▁pla ces", - "▁prim ary", - "▁pri mary", - "▁prima ry", - "▁ primary", - "▁con v", - "▁ conv", - "▁J uli", - "▁Jul i", - "▁Ju li", - "▁vis ual", - "▁ visual", - "▁S elect", - "▁Se lect", - "▁Sel ect", - "▁Sele ct", - "▁ Select", - "at ory", - "ator y", - "ato ry", - "= (", - "is er", - "ise r", - "i ser", - "▁int ent", - "▁inte nt", - "▁inten t", - "▁ intent", - "su r", - "s ur", - "cont ainer", - "ic ed", - "ice d", - "i ced", - "▁bo ard", - "▁ board", - "as tr", - "ast r", - "a str", - "om ial", - "omi al", - "ве т", - "в ет", - "з ва", - "▁c ru", - "▁cr u", - "▁Ok tober", - "sa ve", - "s ave", - "▁gre ater", - "▁great er", - "▁in n", - "▁i nn", - "▁ inn", - "▁p icture", - "▁ picture", - "▁Т о", - "▁obtain ed", - "▁obt ained", - "Wik imedia", - "ú blic", - "▁l ors", - "▁lo rs", - "▁m ont", - "▁mon t", - "▁mo nt", - "▁ mont", - "ob re", - "o bre", - "▁c ivil", - "▁ci vil", - "▁civ il", - "▁const ruction", - "▁construct ion", - "▁constru ction", - "▁W elt", - "▁We lt", - "▁Wel t", - "▁U nder", - "▁Un der", - "▁Und er", - "▁ Under", - "und ert", - "under t", - "unde rt", - "▁ed ge", - "▁ edge", - "▁L iste", - "▁List e", - "▁Li ste", - "▁Lis te", - "cs v", - "c sv", - "▁ex periment", - "▁exper iment", - "local host", - "▁E dit", - "▁Ed it", - "▁ Edit", - "gr eg", - "gre g", - "g reg", - "ov á", - "o vá", - "љ а", - "ms g", - "m sg", - "▁G reen", - "▁Gr een", - "▁Gre en", - "▁Gree n", - "▁ Green", - "Di alog", - "D ialog", - "Id ent", - "I dent", - "▁J S", - "▁ JS", - "^{ (", - "^ {(", - "▁slä ktet", - "__ __", - "___ _", - "_ ___", - "Pro ject", - "▁bes kre", - "▁b er", - "▁be r", - "▁ ber", - "▁would n", - "▁re act", - "▁ react", - "He l", - "H el", - "z w", - "▁W ashington", - "or ie", - "ori e", - "o rie", - "ta sk", - "t ask", - "▁c ategory", - "▁categ ory", - "▁categor y", - "▁ category", - "▁art ist", - "an no", - "ann o", - "▁o ok", - "▁ ook", - "am men", - "amm en", - "▁Min ister", - "▁de clar", - "▁dec lar", - "▁decl ar", - "▁decla r", - "▁K ey", - "▁Ke y", - "▁ Key", - ", .", - "▁m ach", - "▁ma ch", - "▁mac h", - "▁w w", - "▁ ww", - "is en", - "ise n", - "i sen", - "Fr an", - "F ran", - "▁Ро сси", - "▁Рос си", - "бо р", - "б ор", - "т ри", - "▁r ock", - "▁ro ck", - "▁ rock", - "qu is", - "qui s", - "q uis", - "mo s", - "m os", - "пе ра", - "пер а", - "п ера", - "▁est erni", - "▁g old", - "▁go ld", - "▁gol d", - "Window s", - "W indows", - "% %", - "▁part ial", - "▁parti al", - "▁ partial", - "▁we ight", - "▁ weight", - "▁s pr", - "▁sp r", - "▁ spr", - "}) .", - "} ).", - "▁fran çais", - "fu n", - "f un", - "▁th ous", - "▁thou s", - "ho lder", - "hol der", - "hold er", - "h older", - "▁g one", - "▁go ne", - "▁ Č", - "▁re nd", - "▁r end", - "▁ren d", - "▁ rend", - "D A", - "▁answer ed", - "▁F alse", - "▁Fal se", - "▁ False", - "B uffer", - "▁d augh", - "▁da ugh", - ".- -", - ". --", - "▁S how", - "▁Sh ow", - "▁Sho w", - "▁ Show", - "▁re ct", - "▁r ect", - "▁rec t", - "▁ rect", - "▁K re", - "▁Kr e", - "d r", - "os oph", - "oso ph", - "▁y ield", - "ur ity", - "uri ty", - "to String", - "av al", - "ava l", - "a val", - "Po l", - "P ol", - "▁l ock", - "▁lo ck", - "▁loc k", - "▁ lock", - "im ation", - "ima tion", - "imat ion", - "ant ic", - "anti c", - "Lo cal", - "Loc al", - "L ocal", - "▁beskre vs", - "it és", - "ité s", - "gr id", - "g rid", - "у т", - "▁_ {", - "▁ _{", - "с і", - "FI LE", - "▁к м", - "▁spe ak", - "sum mary", - "pr op", - "pro p", - "p rop", - "java script", - "j avascript", - "z k", - "izont al", - "izon tal", - "▁tr ois", - "▁tro is", - "▁R od", - "▁Ro d", - "pr ise", - "ро во", - "ров о", - "р ово", - "▁o dd", - "▁od d", - "▁ odd", - "▁g est", - "▁ge st", - "▁ges t", - "▁ gest", - "▁produ ce", - "▁prod uce", - "▁w aar", - "▁wa ar", - "▁A v", - "▁ Av", - "ri bu", - "rib u", - "ва ння", - "ван ня", - "▁fin ished", - "▁finish ed", - "▁ad apt", - "▁S ar", - "▁Sa r", - "text it", - "tex tit", - "▁C e", - "▁F a", - "▁ Fa", - "os en", - "ose n", - "o sen", - "▁de riv", - "▁der iv", - "▁s hip", - "▁sh ip", - "▁ ship", - "▁o pin", - "▁op in", - "▁E ven", - "▁Ev en", - "ge sch", - "ges ch", - "g esch", - "▁supp ose", - "▁sup pose", - "▁F er", - "▁Fe r", - "ско е", - "▁w orden", - "▁word en", - "▁wor den", - "se y", - "s ey", - "hl ine", - "h line", - "▁Un ion", - "▁ Union", - "▁/ **", - "▁/* *", - "▁ /**", - "▁v ez", - "▁ve z", - "▁ vez", - "▁Colleg amenti", - "▁Soci ety", - "▁Soc iety", - "▁e conom", - "▁econ om", - "▁ec onom", - "š í", - "o i", - "▁or ient", - "▁ orient", - "▁T eil", - "▁Te il", - "re nt", - "ren t", - "r ent", - "ле кс", - "лек с", - "▁s olid", - "▁sol id", - "▁c art", - "▁car t", - "▁ca rt", - "▁ cart", - "******** ********", - "▁c ab", - "▁ca b", - "▁M essage", - "▁Mess age", - "▁ Message", - "do ts", - "dot s", - "d ots", - "▁é g", - "▁ ég", - "▁t we", - "▁tw e", - "ag a", - "a ga", - "▁n az", - "▁na z", - "▁M icrosoft", - "▁Micro soft", - "▁ Microsoft", - "▁under arter", - "pp en", - "ppe n", - "p pen", - "▁re cent", - "▁rec ent", - "▁rece nt", - "▁n et", - "▁ne t", - "▁ net", - "▁res ources", - "▁resource s", - "▁ resources", - "St e", - "S te", - ". \\", - "▁S O", - "▁ SO", - "ло м", - "л ом", - "▁c ele", - "▁ce le", - "▁cel e", - "▁l ic", - "▁li c", - "▁ lic", - "▁ben ef", - "▁bene f", - "ld ots", - "l dots", - "▁se rial", - "▁ser ial", - "▁seria l", - "▁ serial", - "In teger", - "cl es", - "cle s", - "c les", - "▁m iles", - "▁mil es", - "▁mi les", - "▁mile s", - "▁A le", - "▁Al e", - "▁en tered", - "▁ent ered", - "▁enter ed", - "▁T wo", - "▁Tw o", - "▁ Two", - "wi e", - "w ie", - "▁in cludes", - "▁incl udes", - "▁includ es", - "▁include s", - "▁inclu des", - "▁ includes", - "▁E ach", - "▁ Each", - "el ling", - "ell ing", - "elli ng", - "qu er", - "que r", - "q uer", - "▁D om", - "▁Do m", - "▁ Dom", - "p f", - "W S", - "▁stra ight", - "▁S tan", - "▁St an", - "▁Sta n", - "▁n os", - "▁no s", - "▁ nos", - "í cul", - "at ro", - "atr o", - "▁C enter", - "▁Cent er", - "▁ Center", - "F T", - "▁In ga", - "▁Ing a", - "il o", - "i lo", - "▁w ww", - "▁ww w", - "▁ www", - "js fiddle", - "ni c", - "n ic", - "▁Europe an", - "▁com mer", - "▁comm er", - "▁comme r", - "▁g irl", - "▁gi rl", - "▁gir l", - "to tal", - "tot al", - "t otal", - "▁S tar", - "▁St ar", - "▁Sta r", - "▁ Star", - "▁sugg ested", - "▁suggest ed", - "pa l", - "p al", - "▁zw ischen", - "пи са", - "пис а", - "I M", - "▁hand ler", - "▁handle r", - "▁ handler", - "▁Pro gram", - "▁Pr ogram", - "▁ Program", - "xs l", - "x sl", - "ál y", - "á ly", - "B U", - ",- -", - ", --", - "▁v id", - "▁vi d", - "▁ vid", - "▁estab lished", - "▁establish ed", - "▁S piel", - "▁Sp iel", - "om etry", - "ome try", - "omet ry", - "un es", - "une s", - "u nes", - "▁s it", - "▁si t", - "▁in her", - "▁p uis", - "▁pu is", - "▁ puis", - "▁ être", - "▁M ost", - "▁Mo st", - "▁Mos t", - "He ader", - "Head er", - "in sert", - "ins ert", - "▁s ist", - "▁si st", - "▁f avor", - "▁fa vor", - "▁fav or", - "de st", - "des t", - "d est", - "▁ent ity", - "▁ entity", - "Ca l", - "C al", - "▁There fore", - "D D", - "; ;", - "▁Dez ember", - "▁R h", - "im ents", - "iment s", - "imen ts", - "i ments", - "▁return ing", - "st o", - "s to", - "▁Val ue", - "▁ Value", - "▁l iber", - "▁li ber", - "▁lib er", - "▁Res ult", - "▁ Result", - "▁b ind", - "▁bi nd", - "▁bin d", - "▁ bind", - "vo ir", - "v oir", - "▁T im", - "▁Ti m", - "▁ Tim", - "▁M ovie", - "▁Mo vie", - "▁Mov ie", - "▁ Movie", - "we g", - "w eg", - "ke t", - "k et", - "▁и сто", - "▁ис то", - "▁fri ends", - "▁friend s", - "▁f n", - "▁ fn", - "▁é l", - "▁ él", - "▁& =", - "▁ &=", - "ar den", - "ard en", - "arde n", - "ff icial", - "ffic ial", - "▁comm unity", - "▁commun ity", - "▁ community", - "▁a pi", - "▁ap i", - "▁ api", - "Ar gs", - "Arg s", - "ie ren", - "ier en", - "iere n", - "i eren", - "▁d ann", - "▁da nn", - "▁dan n", - "om orph", - "ad r", - "a dr", - "lo op", - "l oop", - "um an", - "uma n", - "u man", - "▁v ous", - "▁vo us", - "▁vou s", - "▁ vous", - "bs t", - "b st", - "sub mit", - "\\ |", - "ти н", - "т ин", - "Cont ainer", - "as ket", - "ask et", - "? )", - "Se c", - "S ec", - "▁d rive", - "▁dr ive", - "▁dri ve", - "▁driv e", - "▁ drive", - "As s", - "A ss", - "▁s we", - "▁sw e", - "▁a mer", - "▁am er", - "▁ amer", - "▁m ine", - "▁min e", - "▁mi ne", - "▁ mine", - "▁H am", - "▁Ha m", - "▁av ait", - "▁ avait", - "▁H on", - "▁Ho n", - "▁a près", - "▁ap rès", - "▁apr ès", - "▁ après", - "▁M ann", - "▁Man n", - "▁Ma nn", - "сь ка", - "ськ а", - "▁incre ase", - "▁t y", - "▁ ty", - "sk y", - "s ky", - "▁acc ur", - "▁ac cur", - "art icle", - "we ight", - "weig ht", - "▁s ex", - "▁se x", - "▁ sex", - "▁list ade", - "▁lista de", - "/* *", - "/ **", - "▁est á", - "}} $", - "} }$", - "ar go", - "arg o", - "def ine", - "defin e", - "▁со став", - "▁соста в", - "s ession", - "ad s", - "a ds", - "ст ви", - "ств и", - "▁L aw", - "▁La w", - "▁d ialog", - "▁di alog", - "▁dia log", - "▁ dialog", - "▁dup licate", - "▁é p", - "▁ ép", - "▁v oc", - "▁vo c", - "fr i", - "f ri", - "▁g reen", - "▁gr een", - "▁gre en", - "▁ green", - "▁h idden", - "▁hid den", - "▁ hidden", - "▁Is land", - "▁di ag", - "▁dia g", - "ow ej", - "owe j", - "my sql", - "mys ql", - "mysq l", - "te il", - "tei l", - "t eil", - "r ä", - "ik an", - "ika n", - "i kan", - "▁Jos é", - "al ed", - "ale d", - "a led", - "Run time", - "R untime", - "▁t rain", - "▁tr ain", - "▁tra in", - "▁ train", - "▁Di vision", - "▁Div ision", - "ни ц", - "▁S pan", - "▁Sp an", - "▁ Span", - "ни ма", - "ним а", - ")= \\", - ") =\\", - "та н", - "т ан", - "▁st ay", - "▁sta y", - "▁f oo", - "▁fo o", - "▁ foo", - "▁acc om", - "▁ac com", - "▁h ers", - "▁he rs", - "▁her s", - "▁на у", - "▁M ün", - "ide os", - "ideo s", - "st atic", - "stat ic", - "▁re ady", - "▁read y", - "▁ ready", - "] `", - "▁vis ible", - "▁vi sible", - "▁ visible", - "▁H ope", - "▁Ho pe", - "▁Hop e", - "ul ated", - "ula ted", - "ulate d", - "▁C ult", - "▁Cu lt", - "ст ро", - "стр о", - "с тро", - "C o", - "▁sm aller", - "▁small er", - "at ura", - "atur a", - "atu ra", - "▁perfect ly", - "re q", - "r eq", - "▁pro posed", - "▁prop osed", - "▁propos ed", - "▁propose d", - "▁deg li", - "Se arch", - "S earch", - "▁i ch", - "▁ic h", - "▁ ich", - "Ma x", - "M ax", - "▁vol ume", - "▁ volume", - "exec ute", - "gr e", - "g re", - "▁s port", - "▁sp ort", - "▁spo rt", - "ud ad", - "uda d", - "P T", - "▁Rec ords", - "▁Record s", - "▁c ook", - "▁co ok", - "▁ cook", - "▁exp and", - "▁ expand", - "б і", - "▁al tri", - "▁alt ri", - "pp et", - "ppe t", - "p pet", - "ar se", - "ars e", - "▁w et", - "▁we t", - "▁B ob", - "▁Bo b", - "▁ Bob", - "▁F C", - "▁ FC", - "▁Associ ation", - "uj e", - "u je", - "▁f el", - "▁fe l", - "▁ fel", - "▁с лу", - "▁ слу", - "▁B ig", - "▁Bi g", - "▁ Big", - "/ \\", - "G e", - "wh ile", - "{ (", - "▁su fficient", - "Pos ition", - "P osition", - "▁under standing", - "▁understand ing", - "▁n ue", - "▁nu e", - "▁r az", - "▁ra z", - "▁ raz", - "▁y e", - "▁ ye", - "he m", - "h em", - "N um", - "▁Pro ject", - "▁ Project", - "▁I ts", - "▁It s", - "▁h asta", - "▁ha sta", - "▁has ta", - "▁hast a", - "en so", - "ens o", - "▁w ire", - "▁wir e", - "▁ wire", - "Re t", - "R et", - "u j", - "pro of", - "▁re levant", - "▁relev ant", - "▁part ir", - "▁parti r", - "▁a go", - "▁ag o", - "▁ ago", - "if icate", - "ific ate", - "ifica te", - "▁d omin", - "▁do min", - "▁dom in", - "▁ domin", - "▁b oy", - "▁bo y", - "▁ boy", - "▁p lant", - "▁pl ant", - "▁pla nt", - "▁plan t", - "▁ plant", - "▁enc oding", - "▁ encoding", - "▁th rows", - "▁thr ows", - "▁throw s", - "▁thro ws", - "▁R ock", - "▁Ro ck", - "▁Roc k", - "zo ne", - "zon e", - "z one", - "ga ng", - "gan g", - "g ang", - "wid get", - "w idget", - "▁interest ing", - "DE R", - "D ER", - "▁d emon", - "▁de mon", - "▁dem on", - "▁demo n", - "▁off ice", - "▁offic e", - "▁ office", - "am t", - "a mt", - "ät er", - "ä ter", - "▁Wh ite", - "▁Whit e", - "▁ White", - "▁v ersch", - "▁ver sch", - "▁vers ch", - "▁die ser", - "▁dies er", - "▁diese r", - "▁M ount", - "▁Mo unt", - "▁Mou nt", - "▁ Mount", - "▁stud ents", - "▁student s", - "▁P ub", - "▁Pu b", - "▁ Pub", - "▁Д е", - "ij a", - "i ja", - "▁C y", - "▁ Cy", - "▁Californ ia", - "▁ab ril", - "äl l", - "ä ll", - "▁ч ем", - "▁че м", - "T V", - "▁m és", - "▁mé s", - "▁decl ared", - "▁decla red", - "▁declar ed", - "▁declare d", - "▁ ю", - "ő l", - "ap pa", - "app a", - "a ppa", - "▁Б е", - "ec ho", - "ech o", - "e cho", - "num er", - "nu mer", - "n umer", - "▁po sted", - "▁pos ted", - "▁post ed", - "▁poste d", - "▁в ер", - "▁ве р", - "▁ вер", - "▁годи не", - "▁we ak", - "▁ weak", - "▁Re public", - "▁Rep ublic", - "▁Repub lic", - "▁ch ampion", - "▁champ ion", - "ensure math", - "you r", - "yo ur", - "y our", - "▁O ber", - "▁Ob er", - "▁Cent ral", - "is a", - "i sa", - "ан д", - "а нд", - "y y", - "▁full y", - "▁ful ly", - "▁ fully", - "▁S D", - "▁ SD", - "▁Lin ux", - "▁ Linux", - "▁Sc ott", - "▁Scot t", - "part ment", - "ko n", - "k on", - "▁cont ract", - "▁contr act", - "▁contra ct", - "▁O F", - "▁ OF", - "▁a le", - "▁al e", - "▁ ale", - "▁A nn", - "▁An n", - "▁на д", - "▁ над", - "la h", - "l ah", - "▁N ext", - "▁Ne xt", - "▁ Next", - "or en", - "ore n", - "o ren", - "▁d isk", - "▁di sk", - "▁dis k", - "▁ disk", - "▁e g", - "▁ eg", - "at u", - "a tu", - "ло ги", - "лог и", - "▁g ames", - "▁game s", - "▁ga mes", - "▁gam es", - "Le ft", - "L eft", - "▁l u", - "▁ lu", - "▁fin ite", - "▁finit e", - "▁ finite", - "▁к и", - "▁ ки", - "▁cr ash", - "▁cra sh", - "ph er", - "phe r", - "p her", - "ex e", - "e xe", - "AT ION", - "▁br other", - "▁bro ther", - "En g", - "E ng", - "ta t", - "t at", - "▁In teger", - "▁ Integer", - "но му", - "ном у", - "н ому", - "▁col on", - "▁co lon", - "▁ colon", - "i qu", - ")) .", - ") ).", - "iv i", - "i vi", - "▁M ethod", - "▁Met hod", - "▁ Method", - "ar ten", - "art en", - "arte n", - "Un i", - "U ni", - "ve ctor", - "vec tor", - "v ector", - "▁w ood", - "▁wo od", - "▁ wood", - "р т", - "▁Л е", - "▁siè cle", - "▁g ent", - "▁ge nt", - "▁gen t", - "▁ gent", - "} \r", - "▁cont ents", - "▁content s", - "▁conten ts", - "▁ contents", - "▁com pan", - "▁comp an", - "G o", - "▁j ou", - "▁jo u", - "▁ jou", - "ue nt", - "uen t", - "u ent", - "As ync", - "A sync", - "print f", - "▁M odel", - "▁Mod el", - "▁Mo del", - "▁Mode l", - "▁ Model", - "▁ke pt", - "AS E", - "A SE", - "▁prov ides", - "▁provide s", - "▁Ab gerufen", - "▁G all", - "▁Gal l", - "▁Ga ll", - "▁Al f", - "S A", - "▁M em", - "▁Me m", - "▁ Mem", - "▁k ter", - "▁ kter", - "▁B ru", - "▁Br u", - "And roid", - "( :", - "▁У краї", - "▁Укра ї", - "N e", - "M in", - "at r", - "a tr", - "▁H al", - "▁Ha l", - "de lete", - "del ete", - "od o", - "o do", - "▁n ão", - "èn e", - "è ne", - "▁calcul ate", - "▁calc ulate", - "Js on", - "J son", - "ke ys", - "key s", - "не й", - "н ей", - "▁h ence", - "▁hen ce", - "▁o w", - "▁ ow", - "▁L ib", - "▁Li b", - "▁ Lib", - "en o", - "e no", - "▁L ove", - "▁Lo ve", - "▁Lov e", - "os i", - "o si", - "wi de", - "wid e", - "w ide", - "▁s core", - "▁sc ore", - "▁ score", - "ful l", - "fu ll", - "f ull", - "во д", - "в од", - "▁determ ine", - "▁determin e", - "▁s paces", - "▁sp aces", - "▁space s", - "▁spac es", - "▁ spaces", - "ло ва", - "лов а", - "л ова", - "▁pe ut", - "▁peu t", - "ér al", - "éra l", - "é ral", - "ó ł", - "▁app oint", - "▁ap point", - "▁T w", - "▁ Tw", - "< ?", - "▁Or der", - "▁Ord er", - "▁ Order", - "▁h op", - "▁ho p", - "ran dom", - "rand om", - "r andom", - "ca che", - "c ache", - "▁dest roy", - "▁ destroy", - "▁r ace", - "▁ra ce", - "▁rac e", - "▁ race", - "T ag", - "▁r id", - "▁ri d", - "▁ rid", - "▁neg ative", - "▁ negative", - "Ca r", - "C ar", - "ens ional", - "ension al", - "d k", - "▁c ro", - "▁cr o", - "▁ cro", - "▁TH EN", - "▁THE N", - "▁$ .", - "▁ $.", - "en sk", - "ens k", - "N E", - "H O", - "▁k le", - "▁kl e", - "osp ital", - "kt e", - "k te", - "fér ences", - "férence s", - "ud es", - "ude s", - "u des", - "I R", - "ot ion", - "oti on", - "o tion", - "▁Re al", - "▁ Real", - "▁Febru ar", - "и н", - "▁O ld", - "▁Ol d", - "▁ Old", - "ко го", - "к ого", - "le ich", - "lei ch", - "▁ р", - "ía n", - "í an", - "▁г а", - "▁ га", - "ci de", - "cid e", - "c ide", - "la b", - "l ab", - "▁p ull", - "▁pu ll", - "▁pul l", - "▁ pull", - "▁' /", - "Lo ng", - "L ong", - ", $", - "▁appropri ate", - "▁бы ла", - "▁был а", - "f ühr", - "▁M edia", - "▁Me dia", - "▁Med ia", - "▁Medi a", - "▁ Media", - "▁m anner", - "▁man ner", - "▁Г е", - "de scription", - "des cription", - "Be an", - "▁L ar", - "▁La r", - "▁ Lar", - "'] ;", - "' ];", - "▁re lation", - "▁rel ation", - "▁rela tion", - "▁ relation", - "▁S orry", - "▁Sor ry", - "ha r", - "h ar", - "cp p", - "c pp", - "▁K o", - "▁exec ution", - "▁execut ion", - "▁ execution", - "in os", - "ino s", - "i nos", - "▁b ul", - "▁bu l", - "▁ bul", - "gr ade", - "gra de", - "grad e", - "g rade", - "▁M u", - "▁p il", - "▁pi l", - "wr it", - "w rit", - "ific ations", - "ification s", - "in ese", - "ine se", - "ines e", - "▁Ph ili", - "▁Phil i", - "d x", - "▁le ading", - "▁lead ing", - "▁ leading", - "▁J ournal", - "ov ed", - "ove d", - "o ved", - "▁cont ro", - "▁contr o", - "но ва", - "нов а", - "н ова", - "Y es", - "▁ch annel", - "▁ channel", - ")) ,", - ") ),", - "is ten", - "ist en", - "iste n", - "i sten", - "ak a", - "a ka", - "To String", - "ma s", - "m as", - "▁e tt", - "▁et t", - "▁ ett", - "▁for ces", - "▁force s", - "ul ations", - "ulation s", - "▁C all", - "▁Cal l", - "▁Ca ll", - "▁ Call", - "▁explan ation", - "or ing", - "ori ng", - "o ring", - "AT A", - "A TA", - "ch ter", - "cht er", - "chte r", - "wh en", - "w hen", - "V C", - "▁Jah rh", - "▁Jahr h", - "Ca se", - "C ase", - "▁comm ands", - "▁command s", - "▁ commands", - "▁r ich", - "▁ric h", - "▁ri ch", - "▁ rich", - "bu s", - "b us", - "F e", - "mb ox", - "m box", - "▁re con", - "▁rec on", - "ñ o", - "▁s hape", - "▁sh ape", - "▁ shape", - "ow y", - "o wy", - "en try", - "ent ry", - "entr y", - "it able", - "ita ble", - "i table", - "▁e lection", - "▁el ection", - "▁elect ion", - "▁ele ction", - "є ться", - "▁p rep", - "▁pr ep", - "▁pre p", - "▁ prep", - "v á", - "▁in fin", - "▁inf in", - "lo t", - "l ot", - "▁bo oks", - "▁book s", - "▁ books", - "▁U SA", - "▁US A", - "▁ USA", - "ли н", - "л ин", - "▁p om", - "▁po m", - "▁ pom", - "▁n as", - "▁na s", - "▁ nas", - "▁t ags", - "▁tag s", - "▁ta gs", - "▁ tags", - "▁exec uted", - "▁execute d", - "▁execut ed", - "ail le", - "ai lle", - "a ille", - "lu ng", - "l ung", - "▁Java Script", - "▁ JavaScript", - "▁b all", - "▁bal l", - "▁ba ll", - "▁ ball", - "▁ain si", - "▁P ri", - "▁Pr i", - "{ $", - "▁U N", - "▁ UN", - "▁R am", - "▁Ra m", - "▁h ear", - "▁he ar", - "▁U buntu", - ">( );", - ">() ;", - "> ();", - "▁p ure", - "▁pu re", - "▁pur e", - "▁em bed", - "▁emb ed", - "▁ embed", - "a ção", - "cont roller", - "control ler", - "▁mar ried", - "▁F ol", - "▁Fo l", - "fa mil", - "f amil", - "▁p rec", - "▁pr ec", - "▁pre c", - "▁ prec", - "▁rec urs", - "pa d", - "p ad", - "istr ation", - "istra tion", - "▁respect ively", - "▁respective ly", - "[ $", - "au tor", - "aut or", - "auto r", - "a utor", - "▁g rav", - "▁gr av", - "▁gra v", - "ie ra", - "ier a", - "i era", - "az ioni", - "azi oni", - "a zioni", - "▁B ul", - "▁Bu l", - "▁Austral ia", - "mon d", - "mo nd", - "m ond", - "▁T ro", - "▁Tr o", - "▁E le", - "▁El e", - "pack ages", - "package s", - "ms dn", - "▁A ls", - "▁Al s", - "▁pr zy", - "▁prz y", - "AR T", - "A RT", - "▁char ge", - "▁charg e", - "▁ charge", - "▁app lications", - "▁application s", - "▁applic ations", - "Un it", - "Uni t", - "U nit", - "ar en", - "are n", - "a ren", - "▁sud den", - "om eter", - "ome ter", - "omet er", - "o meter", - "▁d ot", - "▁do t", - "▁ dot", - "ac ji", - "a cji", - "кт ор", - "кто р", - "к тор", - "im in", - "imi n", - "i min", - "en ing", - "eni ng", - "e ning", - "▁d onde", - "▁do nde", - "▁don de", - "▁H o", - "tr ee", - "tre e", - "t ree", - "m b", - "▁d rag", - "▁dr ag", - "▁dra g", - "▁ drag", - "aj e", - "a je", - "▁in valid", - "▁ invalid", - "▁fin ish", - "la im", - "▁f eed", - "▁fe ed", - "▁fee d", - "▁ feed", - "▁N ap", - "▁Na p", - "ro om", - "r oom", - "im ages", - "ima ges", - "image s", - "▁са й", - "▁su cc", - "▁suc c", - "if fer", - "iff er", - "iffe r", - "▁a ño", - "▁añ o", - "▁c ual", - "▁cu al", - "ме ри", - "мер и", - "D R", - "▁B ilder", - "▁Bi lder", - "▁Bild er", - "▁Bil der", - "б ра", - "ra it", - "rai t", - "r ait", - "pa n", - "p an", - "ен ь", - "е нь", - "▁dist inct", - "▁K n", - "ön ig", - "ö nig", - "an ced", - "ance d", - "anc ed", - "▁lo ading", - "▁load ing", - "▁ loading", - "▁Te chn", - "▁S el", - "▁Se l", - "mu s", - "m us", - "▁r ail", - "▁ra il", - "▁st udent", - "▁stud ent", - "▁ student", - "▁not ice", - "▁s la", - "▁sl a", - "▁Д а", - "▁gu ard", - "▁ guard", - "▁D ay", - "▁Da y", - "▁ Day", - "ва ли", - "вал и", - "в али", - "Op tion", - "Opt ion", - "O ption", - "ais on", - "ai son", - "a ison", - "ip p", - "i pp", - "▁J un", - "▁Ju n", - "▁f ell", - "▁fe ll", - "▁fel l", - "▁ab solute", - "▁absol ute", - "▁ absolute", - "ов е", - "о ве", - "de bug", - "deb ug", - "▁S ud", - "▁Su d", - "п ы", - "ug ins", - "ugin s", - "▁view s", - "▁vie ws", - "▁ views", - "la y", - "l ay", - "▁s urr", - "▁su rr", - "▁sur r", - "▁st ood", - "▁sto od", - "▁ stood", - "▁в і", - "▁ ві", - "select ed", - "sel ected", - "г і", - "▁att ributes", - "▁attribute s", - "▁ attributes", - "fin al", - "fi nal", - "f inal", - "en da", - "end a", - "▁B on", - "▁Bo n", - "ne rs", - "ner s", - "n ers", - "▁W er", - "▁We r", - "bu r", - "b ur", - "it tel", - "itt el", - "itte l", - "▁m oving", - "▁mov ing", - "▁mo ving", - "▁P lan", - "▁Pl an", - "▁Pla n", - "▁ Plan", - "is ches", - "isch es", - "ische s", - "isc hes", - "J ava", - "▁b asis", - "▁bas is", - "▁B us", - "▁Bu s", - "▁ Bus", - "▁A u", - "▁I ll", - "▁Il l", - "▁ Ill", - "▁вре мя", - "▁ц ент", - "▁ цент", - "hand le", - "сту п", - "▁F ar", - "▁Fa r", - "▁o raz", - "▁or az", - "▁ora z", - "oc r", - "o cr", - "▁se it", - "▁sei t", - "on der", - "ond er", - "onde r", - "o nder", - "до м", - "д ом", - ": /", - "ch or", - "cho r", - "c hor", - "▁T own", - "▁To wn", - "▁Tow n", - "▁def init", - "▁defin it", - "re act", - "rea ct", - "▁pie ce", - "▁Kar l", - "▁Ka rl", - "C I", - "▁App lication", - "▁ Application", - "un ter", - "unt er", - "unte r", - "▁for med", - "▁form ed", - "▁forme d", - "▁ formed", - "▁п у", - "▁ пу", - "B o", - "▁Dan iel", - "▁ Daniel", - "▁п ла", - "▁ пла", - "Bo dy", - "B ody", - "}) $", - "} )$", - "▁бы ли", - "▁был и", - "▁e arth", - "▁ear th", - "г ла", - "Th ere", - "The re", - "T here", - "▁с тра", - "▁ст ра", - "▁ стра", - "▁v ille", - "▁vi lle", - "▁vill e", - "▁vil le", - "▁ ville", - "▁c entre", - "▁cent re", - ") \r", - "▁help ful", - "▁+ +", - "▁ ++", - "▁C G", - "▁ CG", - "iz ione", - "izi one", - "izio ne", - "i zione", - "▁G ame", - "▁Ga me", - "▁Gam e", - "▁ Game", - "▁Wh ich", - "▁p ip", - "▁pi p", - "▁ pip", - "▁Port ug", + "chedul e▁of", + "▁An alysis", + "stat us", + "▁should▁ not", + "econd ary", + "IN G", + "▁activ ity", + "▁the▁c riteria▁for", + "ecaus e▁of", + "suppl i", + "principal▁ investigator", + "6 ;", "D S", - "▁de scribe", - "▁des cribe", - "▁descri be", - "▁check ing", - "▁man ager", - "▁manage r", - "▁ manager", - "B O", - "▁B undes", - "▁Bund es", - "▁Bun des", - "bu ch", - "b uch", - "▁dec ided", - "▁decide d", - "▁decid ed", - "▁Jahrh undert", - "▁f if", - "▁fi f", - "▁ fif", - "e fficient", - "an ci", - "anc i", - "br aries", - "bra ries", - "▁f ails", - "▁fa ils", - "▁fail s", - "▁k ernel", - "▁ker nel", - "▁ kernel", - "▁G l", - "▁N acional", - "▁pro ceed", - "▁proc eed", - "▁f uer", - "▁fue r", - "▁fu er", - "▁l iving", - "▁li ving", - "▁liv ing", - "▁success fully", - "▁successful ly", - "▁f aster", - "▁fa ster", - "▁fast er", - "▁fas ter", - "▁con tre", - "▁cont re", - "▁contr e", - "▁ contre", - "▁pr ison", - "▁pri son", - "▁pris on", - "OR T", - "O RT", - "he lp", - "hel p", - "▁a utor", - "▁au tor", - "▁aut or", - "▁auto r", - "▁ autor", - "ła w", - "ł aw", - "aj ą", - "a ją", - "▁A rm", - "▁Ar m", - "▁ Arm", - "▁pro vin", - "▁prov in", - "▁na am", - "/ #", - "se d", - "s ed", - "▁g esch", - "▁ge sch", - "▁ges ch", - "▁ gesch", - "▁м ар", - "▁ма р", - "▁ мар", - "es k", - "e sk", - "ter m", - "te rm", - "t erm", - "▁T ex", - "▁Te x", - "▁ Tex", - "ir ing", - "iri ng", - "i ring", - "▁t ools", - "▁to ols", - "▁too ls", - "▁tool s", - "▁ tools", - "PD F", - "P DF", - "▁u lt", - "▁ul t", - "▁ ult", - "iss enschaft", - "issen schaft", - "▁could n", - "di ng", - "din g", - "d ing", - "De p", - "D ep", - "{ -", - "▁pre dict", - "▁pred ict", - "▁ predict", - "ant age", - "anta ge", - "▁L ike", - "▁Li ke", - "▁ Like", - "▁Б и", - "to ols", - "tool s", - "t ools", - "es tra", - "est ra", - "estr a", - "e stra", - "▁k i", - "▁ ki", - "▁J im", - "▁Ji m", - "st ar", - "sta r", - "s tar", - "▁re mark", - "▁r emark", - "▁rem ark", - "▁ remark", - "ó g", - "na bla", - "nab la", - "▁Al though", - "mod e", - "mo de", - "m ode", - "H ost", - "▁st range", - "▁str ange", - "▁stran ge", - "No ne", - "Non e", - "N one", - "bl ack", - "bla ck", - "b lack", - "▁F estival", - "▁Fest ival", - "▁I S", - "▁ IS", - "an za", - "anz a", - "▁( -", - "▁ (-", - "ic ket", - "ick et", - "i cket", - "ко ла", - "кол а", - "▁J es", - "▁Je s", - "▁f lex", - "▁fl ex", - "▁fle x", - "▁ flex", - "▁ À", - "▁N etwork", - "▁Net work", - "▁ Network", - "▁E X", - "▁ EX", - "▁e nero", - "▁en ero", - "▁ener o", - "! ”", - "▁O rt", - "▁Or t", - "▁al ors", - "▁Or iginal", - "▁Origin al", - "▁Orig inal", - "▁ Original", - "▁z o", - "▁ zo", - "ны ми", - "ным и", - "▁s pl", - "▁sp l", - "▁ spl", - "Dra w", - "Dr aw", - "D raw", - "yo nd", - "y ond", - "─ ─", - "▁O t", - "▁d ram", - "▁dr am", - "▁dra m", - "▁di vision", - "▁div ision", - "▁divis ion", - "▁e fficient", - "▁effic ient", - "▁ efficient", - "▁Г а", - "▁v ier", - "▁vi er", - "▁vie r", - "▁ vier", - "na k", - "n ak", - "L S", - "▁sp irit", - "▁spir it", - "zeich net", - "▁d ici", - "▁di ci", - "▁dic i", - "cl ear", - "cle ar", - "c lear", - "co py", - "cop y", - "c opy", - "ya r", - "y ar", - "▁ро ці", - "us qu", - "u squ", - "▁n ous", - "▁no us", - "▁nou s", - "▁b lev", - "▁bl ev", - "▁ble v", - "ж де", - "Ar g", - "A rg", - "▁per formed", - "▁perform ed", - "▁M ake", - "▁Ma ke", - "▁Mak e", - "▁ Make", - "▁Car ol", - "▁Ca rol", - "et to", - "ett o", - "e tto", - "▁S and", - "▁San d", - "▁Sa nd", - "▁D isc", - "▁Dis c", - "▁Di sc", - "En c", - "E nc", - "re ro", - "rer o", - "r ero", - "ha sh", - "has h", - "h ash", - "▁f ocus", - "▁fo cus", - "▁foc us", - "▁ focus", - "▁att ention", - "▁a gre", - "▁ag re", - "▁agr e", - "▁di vis", - "▁div is", - "▁бы ло", - "▁был о", - "▁e j", - "▁ ej", - "▁m arch", - "▁mar ch", - "▁marc h", - "▁ph ase", - "▁ phase", - "ía s", - "í as", - "▁ph il", - "▁P ap", - "▁Pa p", - "▁r iver", - "▁riv er", - "▁ri ver", - "▁ river", - "▁c aused", - "▁caus ed", - "▁cause d", - "▁ca used", - "pl ugin", - "▁Te am", - "▁ Team", - "ul er", - "ule r", - "u ler", - "▁$ (\"#", - "▁$(\" #", - "ie j", - "i ej", - "I SBN", - "na m", - "n am", - "▁f ight", - "▁fig ht", - "vi d", - "v id", - "▁L ud", - "▁Lu d", - "Select ed", - ":@ \"", - ": @\"", - "▁P od", - "▁Po d", - "▁ Pod", - "▁ann ées", - "▁année s", - "ar ios", - "ari os", - "ario s", - "a rios", - "▁deutsch er", - "▁deutsche r", - "▁N A", - "▁ NA", - "▁и ю", - "▁d ictionary", - "▁diction ary", - "▁ dictionary", - "▁Л а", - "▁T ri", - "▁Tr i", - "▁ Tri", - "è n", - "▁polit ical", - "rid ge", - "r idge", - "at ten", - "att en", - "atte n", - "▁circ le", - "▁cir cle", - "▁ circle", - "▁trans port", - "▁ transport", - "em as", - "ema s", - "e mas", - "F C", - "▁replace d", - "▁repla ced", - "▁A ud", - "▁Au d", - "is ka", - "isk a", - "i ska", - "Config uration", - "▁so ort", - "▁Н е", - "▁s equ", - "▁se qu", - "▁seq u", - "▁ sequ", - "PR O", - "P RO", - "▁b ud", - "▁bu d", - "▁ bud", - "▁{ {", - "▁ {{", - "lie ß", - "l ieß", - "▁M as", - "▁Ma s", - "de rs", - "der s", - "d ers", - "us ammen", - "es a", - "e sa", - "▁L y", - "в ро", - "ma c", - "m ac", - "▁и спо", - "▁ис по", - "▁s uc", - "▁su c", - "u y", - "▁ill ustr", - "▁prim era", - "▁prime ra", - "▁primer a", - "il ation", - "ila tion", - "i lation", - "▁st orage", - "▁stor age", - "▁sto rage", - "▁ storage", - "▁par ams", - "▁para ms", - "▁param s", - "▁pa rams", - "▁ params", - "ka z", - "k az", - "▁term inal", - "▁termin al", - "ра ль", - "рал ь", - "р аль", - "▁h olds", - "▁hold s", - "▁hol ds", - "▁ holds", - "ло сь", - "▁n ad", - "▁na d", - "▁ nad", - "” .", - "▁oct ubre", - "bu l", - "b ul", - "▁h us", - "▁hu s", - "▁ hus", - "UL T", - "U LT", - "▁ég alement", - "▁M ill", - "▁Mil l", - "▁Mi ll", - "▁ Mill", - "ła d", - "ł ad", - "▁cont iene", - "\" ?", - "▁> >>", - "▁>> >", - "Qu e", - "Q ue", - "   ", - "▁p lain", - "▁pl ain", - "▁pla in", - "▁ plain", - "at iva", - "ativ a", - "ati va", - "oc ker", - "ock er", - "o cker", - "Name s", - "Na mes", - "N ames", - "▁J ud", - "▁Ju d", - "▁ag ree", - "▁agre e", - "▁agr ee", - "▁G emeinde", - "▁Geme inde", - "la re", - "lar e", - "l are", - "ка за", - "каз а", - "▁st arts", - "▁start s", - "▁star ts", - "▁ starts", - "▁p rice", - "▁pr ice", - "▁pri ce", - "▁ price", - "T arget", - "cu s", - "c us", - "▁Inst ead", - ". ;", - "▁altern ative", - "▁alter native", - "▁в ла", - "I E", - "▁organ iz", - "in u", - "i nu", - "▁comp leted", - "▁comple ted", - "▁complet ed", - "▁complete d", - "▁car ry", - "at om", - "ato m", - "a tom", - "▁dep ending", - "▁depend ing", - "▁O ur", - "▁in sp", - "▁ins p", - "▁& \\", - "▁ &\\", - "ail y", - "ai ly", - "a ily", - "ir ection", - "ire ction", - "irect ion", - "ф а", - "▁d efe", - "▁de fe", - "▁def e", - "TA C", - "T AC", - "▁de signed", - "▁des igned", - "▁design ed", - "▁v oir", - "▁vo ir", - "▁ voir", - "bre ak", - "▁part ie", - "▁parti e", - "▁J ahren", - "▁Jah ren", - "▁Jahr en", - "▁Jahre n", - "▁Ja hren", - "▁st udio", - "▁stud io", - "▁studi o", - "▁ studio", - "▁j our", - "▁jo ur", - "▁jou r", - "▁N otes", - "▁No tes", - "▁Not es", - "▁Note s", - "fi re", - "fir e", - "f ire", - "ho use", - "hou se", - "h ouse", - "su ccess", - "▁J uan", - "▁Ju an", - "J S", - "▁C ustom", - "▁ Custom", - "▁b esch", - "▁be sch", - "▁bes ch", - "▁st ated", - "▁stat ed", - "▁state d", - "▁sta ted", - "boot strap", - "öt t", - "ö tt", - "oz zá", - "▁C ON", - "▁CO N", - "▁ CON", - "ha v", - "h av", - "▁s leep", - "▁sle ep", - "▁ sleep", - "ed a", - "e da", - "ho t", - "h ot", - "án d", - "á nd", - "▁S y", - "▁tem ps", - "▁temp s", - "▁ temps", - "am ar", - "ama r", - "a mar", + "N ew", + "O ct", + "T E", + "c all", + "r ative▁", + "\n\n panitumumab", + "st and", + ",▁ I", + "▁b linded▁", + "is▁ (", + "ur ia", + "ot ass", + "ow el", + "▁h r", + "▁l iver", + "▁or ▁other", + "ay▁ of", + "▁R adi", + "▁will▁be▁ performed▁", + "▁3 6", + "▁on ▁Day▁1", + "▁In formation", + "first ▁dose▁of", + "evelop ment", + "▁An y▁", + "randomiz ed▁", + "dis cus", + "▁gen er", + "required▁ for", + "\n\nx\n\nx \n\nx\n\nx", + "▁Med ication", + "ourn al", + "▁June▁ 2009", + "▁NC CTG", + "IMC- 1121B", + "▁6▁0▁0▁0▁0▁0▁1▁0\n\nSunitinib▁Malate▁ Amended▁Protocol▁A6181122▁Amendment▁1,▁28▁August▁2007", + "uestion na", + "otass ium", + ") ▁at", + "1 /", + "E A", + "P ractic", + "b e\n\n", + "f ail", + "i ol", + "l ect", + "s cor", + "v ari", + "▁ early▁", + "er il", + ",▁ for", + "▁b o", + "▁to ▁a", + "▁d ep", + ".\n\n .▁E▁S▁U", + "ol id▁", + "res pir", + "ra st", + "▁E V", + "ain tenance▁", + "eri ou", + "ever y", + "▁the▁p urpose▁of", + ".▁Th e\n\n", + "su fficient", + "ed▁with ▁the▁", + "▁W h", + "draw n", + ",▁C h", + "▁(A rm", + "vail able▁", + "chang e▁in", + "\n\nAn y▁", + "▁differ ence▁in", + "aff in-", + "▁cas e▁of", + "▁patients ▁treated▁with", + "▁design e", + ".0▁Approved▁by\n\nApproved\n\nDate▁Printed:▁30−Jul−2014\n\nS ▁18▁Feb▁2011▁11:38:55", + "▁they ▁are▁", + "astern ▁Cooperative▁Oncology▁Group", + "formance▁ Stat", + ", 9", + "1 120", + "4 ;", + "e opl", + "l eg", + "l aw", + "m ▁J", + "▁ identifi", + "e▁ G", + "ed g", + "ing ▁any▁", "▁s cal", - "▁sc al", - "▁ scal", - "▁a st", - "▁as t", - "▁ ast", - "▁op ening", - "▁open ing", - "cli pse", - "clip se", - "c lipse", - "▁program ming", - "▁ programming", - "▁let ters", - "▁letter s", - "▁lett ers", - "▁pro file", - "▁prof ile", - "▁profil e", - "▁ profile", - "na h", - "n ah", - "▁be yond", - "▁Fur ther", - "face s", - "fa ces", - "fac es", - "f aces", - "▁c hart", - "▁ch art", - "▁char t", - "▁cha rt", - "▁ chart", - "зд а", - "з да", - "ai gn", - "a ign", - "ні й", - "н ій", - "▁R ol", - "▁Ro l", - "ова но", - "ован о", - "ter ior", - "te rior", - "we d", - "w ed", - "▁her self", - "▁hers elf", - "▁n g", - "▁ ng", - "angu ages", - "anguage s", - "}= \\", - "} =\\", - "ynam ic", - "yna mic", - "▁j ug", - "▁ju g", - "▁Ex ample", - "▁ Example", - "▁( †", - "▁play ing", - "▁pla ying", - "▁us age", - "▁ usage", - "▁man aged", - "▁manage d", - "▁ managed", - "▁N atur", - "▁Nat ur", - "те ри", - "тер и", - "▁E t", - "er ia", - "eri a", - "e ria", - "▁daugh ter", - "ни ем", - "ние м", - "F ragment", - "▁h ol", - "▁ho l", - "▁ hol", - "F l", - "огра фи", - "ограф и", - "о графи", - "▁i hn", - "▁ih n", - "ü h", - "inst ance", - "▁com un", - "▁co mun", - "▁tr uth", - "▁са мо", - "▁сам о", - "▁implement ed", - "▁any way", - "▁C ro", - "▁Cr o", - "ф е", - "G C", - "ub untu", - "u buntu", - "ty pes", - "type s", - "typ es", - "t ypes", - "ê s", - ".~ \\", - ". ~\\", - "fo ld", - "fol d", - "f old", - "▁jo ined", - "▁join ed", - "? ?", - "▁m é", - "▁ mé", - "▁w ild", - "▁wil d", - "к лю", - "row ser", - "rows er", - "▁H ome", - "▁Ho me", - "▁Hom e", - "▁ Home", - "sk iej", - "ski ej", - "skie j", - "s kiej", - "▁J OIN", - "▁ju in", - "ho f", - "h of", - "▁data set", - "▁dat aset", - "▁datas et", - "▁ dataset", - "ж ду", - "') )", - "' ))", - "▁mie js", - "AP I", - "A PI", - "▁ed ited", - "▁edit ed", - "ool s", - "oo ls", - "o ols", - "▁se eing", - "▁see ing", - "ij d", - "i jd", - "▁pro cedure", - "▁proced ure", - "▁B ras", - "▁Br as", - "▁Bra s", - "▁s igned", - "▁sign ed", - "▁sig ned", - "▁ signed", - "▁extern os", - "▁dis app", - "▁D irect", - "▁Di rect", - "▁Dire ct", - "▁Dir ect", - "▁ Direct", - "cy c", - "c yc", - "▁cons ult", - "ör d", - "ö rd", - "W idget", - "ci ous", - "cio us", - "c ious", - "se ct", - "sec t", - "s ect", - "▁Д и", - "▁w ind", - "▁win d", - "▁ wind", - "▁Archiv ado", - "am l", - "a ml", - "с с", - "W h", - "kb d", - "k bd", - "▁Ar my", - "▁Arm y", - "▁s uffer", - "▁suf fer", - "▁suff er", - "art ifact", - "▁resol ve", - "▁ resolve", - "▁S port", - "▁Sp ort", - "▁Spo rt", - "▁ц е", - "▁ це", - "id as", - "ida s", - "i das", - "▁t ax", - "▁ta x", - "▁ tax", - "id i", - "i di", - "▁a ctions", - "▁act ions", - "▁action s", - "▁ actions", - "пр а", - "п ра", - "pu és", - "p ués", - "▁n aj", - "▁na j", - "F alse", - "▁ch ance", - "▁та ко", - "▁так о", - "ä d", - "▁d ol", - "▁do l", - "▁en v", - "▁ env", - "▁bas ically", - "▁basic ally", - "▁Coun cil", - "zt e", - "z te", - "▁display ed", - "ni l", - "n il", - "comp lete", - "comple te", - "▁L em", - "▁Le m", - "ian ce", - "i ance", - "▁ос нов", - "▁de pend", - "▁dep end", - "pl om", - "ens us", - "ut s", - "u ts", - "▁H ot", - "▁Ho t", - "▁ Hot", - "bit r", - "bi tr", - "▁valid ation", - "▁ validation", - "ab b", - "a bb", - "▁т ре", - "▁ тре", - "k m", - "z d", - "ö ff", - "W E", - "▁inter ested", - "▁interest ed", - "▁{ \"", - "▁ {\"", - "ar o", - "a ro", - "▁cor rel", - "▁corre l", - "▁corr el", - "▁d edic", - "▁de dic", - "▁ded ic", - "▁l ists", - "▁list s", - "▁ lists", - "▁Bibli ografia", - "▁ear lier", - "pr ogram", - "pro gram", - "prog ram", - "▁prem ière", - "▁premi ère", - "fr ont", - "f ront", - "T ab", - "ст ву", - "ств у", - "dr op", - "dro p", - "d rop", - "▁f ear", - "▁fe ar", - "▁En laces", - "▁C apt", - "▁Cap t", - "▁Ca pt", - "▁ Capt", - "▁real iz", - "▁h al", - "▁ha l", - "▁ hal", - "▁inst ances", - "▁instance s", - "▁su sp", - "▁sus p", - "il ling", - "ill ing", - "illi ng", - "% ;", - "{ }", - "| |", - "▁part ition", - "▁parti tion", - "▁ partition", - "▁Bu ild", - "▁ Build", - "▁w o", - "▁ wo", - "▁П ер", - "▁Пе р", - "▁direct or", - "▁dire ctor", - "▁dir ector", - "▁S in", - "▁Si n", - "ти я", - "rs g", - "r sg", - "ou ver", - "ouv er", - "ouve r", - "▁near ly", - "od a", - "o da", - "кти в", - "к тив", - "▁s ir", - "▁si r", - "IM E", - "I ME", - "▁jan vier", - "▁W in", - "▁Wi n", - "▁ Win", - "Bu ild", - "ie urs", - "ieu rs", - "ieur s", - "i eurs", - "IN E", - "I NE", - "d ouble", - "La st", - "L ast", - "▁pol icy", - "▁polic y", - "▁ policy", - "st ore", - "sto re", - "stor e", - "▁obser ved", - "▁observ ed", - "▁observe d", - "▁obs erved", - "▁famil ie", - "ni ca", - "nic a", - "n ica", - "re y", - "r ey", - "з ь", - "▁Y ear", - "▁Ye ar", - "▁ Year", - "▁develop ed", - "▁deve loped", - "▁Inst itute", - "▁Instit ute", - "▁Institut e", - "▁re ply", - "▁rep ly", - "Com ple", - "Comp le", - "ic ian", - "ici an", - "icia n", - "i cian", - "▁G uer", - "▁Gu er", - "▁d all", - "▁da ll", - "▁dal l", - "▁d esp", - "▁de sp", - "▁des p", - "▁Foot ball", - "Em pty", - "Emp ty", - "ck en", - "cke n", - "c ken", - "un da", - "und a", - "▁U r", - "▁i g", - "▁ ig", - "▁A tl", - "▁At l", - "aut hor", - "auth or", - "▁B ol", - "▁Bo l", - "zi g", - "z ig", - "na t", - "n at", - "š t", - "se curity", - "sec urity", - "on ic", - "oni c", - "o nic", - "▁p es", - "▁pe s", - "▁ pes", - "it an", - "ita n", - "i tan", - "▁Ex tern", - "▁Ext ern", - "ja n", - "j an", - "VA L", - "V AL", - "▁и м", - "▁ им", - "bo ld", - "bol d", - "b old", - "▁в а", - "▁ ва", - "▁М о", - "▁dis put", - "▁disp ut", - "▁t rick", - "▁tr ick", - "▁tri ck", - "▁p ed", - "▁pe d", - "▁ ped", - ")^ {", - ") ^{", - "in to", - "int o", - "Si m", - "S im", - "▁par allel", - "▁ parallel", - "fo x", - "f ox", - "norm al", - "nor mal", - "n ormal", - "in ent", - "ine nt", - "inen t", - "пе ди", - "п еди", - "ho ld", - "hol d", - "h old", - "O K", - "▁c hem", - "▁ch em", - "▁che m", - "▁ chem", - "▁tw ice", - "▁us ername", - "▁user name", - "▁ username", - "i č", - "▁re presentation", - "▁represent ation", - "▁repres entation", - "▁j ournal", - "▁jour nal", - "▁journ al", - "▁: -", - "▁ :-", - "▁b att", - "▁ba tt", - "▁bat t", - "\\ %", - "▁certain ly", - "▁Ex ception", - "▁ Exception", - "ep s", - "e ps", - "sh ot", - "s hot", - "at egy", - "ate gy", - "ateg y", - "Sh ow", - "S how", - "▁Car l", - "▁Ca rl", - "ri g", - "r ig", - "▁rep orted", - "▁report ed", - "bot tom", - "b ottom", - "T F", - "▁Francis co", - "na p", - "n ap", - "▁Champion ship", - "▁Champions hip", - "▁c ourt", - "▁co urt", - "▁cour t", - "▁cou rt", - "▁ court", - "▁s ources", - "▁source s", - "io ur", - "i our", - "▁con serv", - "▁cons erv", - "▁conse rv", - "▁conser v", - "di ct", - "dic t", - "d ict", - "▁Р у", - "I B", - "▁V e", - "▁ №", - "▁E R", - "▁ ER", - "\") );", - "\")) ;", - "\" ));", - "▁P oint", - "▁Po int", - "▁ Point", - "az ine", - "azi ne", - "▁inter net", - "▁intern et", - "д на", - "▁car ried", - "▁carri ed", - "▁F ield", - "▁ Field", - "ax is", - "axi s", - "a xis", - "▁S un", - "▁Su n", - "▁a ve", - "▁av e", - "▁ ave", - "пи с", - "п ис", - "я н", - "as y", - "▁ju lio", - "▁jul io", - "▁juli o", - "▁de puis", - "▁dep uis", - "▁sugg estion", - "▁suggest ion", - "[ [", - "▁Arch ive", - "▁Archiv e", - "ę p", - "▁P ra", - "▁Pr a", - "re h", - "r eh", - "▁demon str", - "ф і", - "cm d", - "c md", - "▁was n", - "▁wa sn", - "▁ph one", - "▁ phone", - "up load", - "ay a", - "a ya", - "то ра", - "тор а", - "li nes", - "line s", - "lin es", - "l ines", - "▁in du", - "▁ind u", - "▁ indu", - "▁v ot", - "▁vo t", - "▁es pa", - "▁esp a", - "▁b in", - "▁bi n", - "▁ bin", - "▁по сле", - "▁пос ле", - "pl an", - "pla n", - "p lan", - "▁ju nio", - "▁jun io", - "▁juni o", - "or ial", - "oria l", - "ori al", - "o rial", - "fr ee", - "fre e", - "f ree", - "ster reich", - "▁д у", - "▁ ду", - "▁link ed", - "▁lin ked", - "▁en able", - "▁ enable", - "P C", - "▁dens ity", - "▁E gy", - "▁Eg y", - "y o", - "end re", - "▁с ъ", - "▁ital iano", - "▁A R", - "▁ AR", - "▁P ers", - "▁Per s", - "▁Pe rs", - "▁ Pers", - "fér és", - "▁с кла", - "V ar", - "▁On ce", - "▁ Once", - "Re d", - "R ed", - "buf fer", - "buff er", - "b uffer", - "▁En ter", - "▁Ent er", - "▁ Enter", - "▁ Š", - "im iento", - "imi ento", - "St ore", - "Sto re", - "▁he alth", - "va t", - "v at", - "IS T", - "I ST", - "O h", - "▁k w", - "▁ kw", - "▁r iv", - "▁ri v", - "▁ riv", - "▁some where", - "ograf ie", - "ografi e", - "priv ate", - "p rivate", - "кт и", - "к ти", - "▁de lay", - "▁del ay", - "▁ delay", - "▁H ttp", - "▁ Http", - "jo b", - "j ob", - "ra el", - "r ael", - "em por", - "emp or", - "▁dici embre", - "▁dic iembre", - "êt e", - "ê te", - "ц у", - "▁com mit", - "▁comm it", - "▁ commit", - "os o", - "o so", - "Val ues", - "Value s", - "▁he aders", - "▁head ers", - "▁header s", - "▁ headers", - "trans form", - "▁process ing", - "▁proces sing", - "▁ processing", - "r å", - "▁A h", - "▁ Ah", - "▁N ode", - "▁No de", - "▁ Node", - "-- ----------", - "---- --------", - "-------- ----", - "------ ------", - "----- -------", - "------- -----", - "---------- --", - "▁f aire", - "▁fa ire", - "▁fair e", - "▁h un", - "▁hu n", - "Pl ayer", - "Play er", - "P layer", - "▁re view", - "▁rev iew", - "▁ review", - "г да", - "▁lim ited", - "▁limit ed", - "▁ limited", - "▁Pro perty", - "▁ Property", - "▁s erve", - "▁ser ve", - "▁serv e", - "▁ serve", - "ri age", - "ria ge", - "▁M aster", - "▁Ma ster", - "▁Mas ter", - "▁ Master", - "▁k ann", - "▁kan n", - "▁ka nn", - "cre te", - "cret e", - "cr ete", - "ph ere", - "pher e", - "phe re", - "p here", - "ё р", - "▁ch ief", - "▁chi ef", - "▁sc ene", - "▁scen e", - "▁ scene", - "ki n", - "k in", - "▁un iform", - "▁ uniform", - "▁feb rero", - "\" }", - "il lo", - "ill o", - "IT E", - "I TE", - "ou vel", - "ouv el", - "ouve l", - "use package", - "en th", - "ent h", - "e nth", - "▁quick ly", - "L ambda", - "xe s", - "x es", - "▁c ells", - "▁cell s", - "▁cel ls", - "ro g", - "r og", - "am in", - "ami n", - "a min", - "▁М ар", - "▁Ма р", - "▁may or", - "▁mayo r", - "pl ayer", - "play er", - "pla yer", - "p layer", - "++ ;", - "▁На се", - "▁sa fe", - "▁saf e", - "▁ safe", - "▁ve loc", - "▁vel oc", - "▁о бра", - "▁об ра", - "▁ обра", - "Data base", - "Dat abase", - "D atabase", - "ne h", - "n eh", - "Ver t", - "V ert", - "▁f le", - "▁fl e", - "▁ф ор", - "▁фо р", - "▁ фор", - "▁f oreign", - "▁for eign", - "▁fore ign", - "Ab stract", - "▁m agn", - "▁ma gn", - "▁mag n", - "▁mod ified", - "▁milit ary", - "▁militar y", - "▁m onde", - "▁mon de", - "▁mo nde", - "▁mond e", - "▁A ction", - "▁Act ion", - "▁Ac tion", - "▁ Action", - "▁b ank", - "▁ban k", - "▁ bank", - "Ser ial", - "Se rial", - "▁contin uous", - "▁continu ous", - "▁g el", - "▁ge l", - "▁ gel", - "▁phys ical", - "▁introdu ced", - "▁introduce d", - "ut ure", - "ri ck", - "ric k", - "r ick", - "▁present ed", - "▁pres ented", - "▁presente d", - "▁P rov", - "▁Pro v", - "▁Pr ov", - "▁B oth", - "▁Bo th", - "▁Bot h", - "Po s", - "P os", - "su per", - "sup er", - "s uper", - "& #", - "▁f inding", - "▁find ing", - "▁fin ding", - "ne l", - "n el", - "un de", - "und e", - "u nde", - "▁fr ån", - "sk im", - "ski m", - "s kim", - "▁H ill", - "▁Hi ll", - "▁Hil l", - "f n", - "▁Can ad", - "▁Ca nad", - "▁int ended", - "▁inten ded", - "▁intend ed", - "ozzá férés", - "▁ju illet", - "▁W ars", - "▁War s", - "▁Wa rs", - "▁success ful", - "▁ch arg", - "▁char g", - "▁cha rg", - "▁ charg", - "ie le", - "iel e", - "i ele", - "om ething", - "ome thing", - "omet hing", - "ok u", - "o ku", - "f etch", - "▁} }", - "▁ }}", - "ban k", - "b ank", - "operator name", - "▁Col or", - "▁Co lor", - "▁ Color", - "▁C ard", - "▁Car d", - "▁Ca rd", - "▁ Card", - "t u", - "▁\" ,", - "▁ \",", - "wi d", - "w id", - "▁g ep", - "▁ge p", - "X ML", - "======== ========", - "▁Vir gin", - "ähr end", - "äh rend", - "lic ated", - "licate d", - "lica ted", - "Di r", - "D ir", - "ze ro", - "zer o", - "z ero", - "▁K al", - "▁Ka l", - "▁Par ty", - "▁Part y", - "▁ å", - "pr ice", - "p rice", - "do n", - "d on", - "▁w arning", - "▁war ning", - "▁warn ing", - "▁ warning", - "▁B ad", - "▁Ba d", - "▁ Bad", - "▁S upp", - "▁Su pp", - "▁Sup p", - "▁ Supp", - "▁L iga", - "▁Li ga", - "▁Lig a", - "▁P ierre", - "▁Pier re", - "▁ Pierre", - "Re cord", - "Rec ord", - "ul ator", - "ula tor", - "▁R ome", - "▁Ro me", - "▁Rom e", - "▁the orem", - "▁ theorem", - "▁entire ly", - "ски м", - "ск им", - "с ким", - "he t", - "h et", - "▁d opo", - "▁do po", - "▁dop o", - "Ne xt", - "N ext", - "ml ung", - "m lung", - "wi g", - "w ig", - "▁A th", - "▁At h", - "▁S ou", - "▁So u", - "li cher", - "lic her", - "lich er", - "liche r", - "l icher", - "▁s udo", - "▁su do", - "▁sud o", - "▁ sudo", - "es ts", - "est s", - "хі в", - "х ів", - "▁sept iembre", - "▁m icro", - "▁mi cro", - "▁mic ro", - "▁t rop", - "▁tr op", - "▁tro p", - "fi t", - "f it", - "Co re", - "Cor e", - "C ore", - "▁Rad io", - "▁ Radio", - "▁Or gan", - "▁ Organ", - "▁P ower", - "▁Po wer", - "▁Pow er", - "▁ Power", - "C F", - "▁L ast", - "▁La st", - "▁Las t", - "▁ Last", - "▁op pos", - "▁opp os", - "▁off set", - "▁ offset", - "▁re gia", - "▁reg ia", - "▁min imum", - "▁minim um", - "▁hel ped", - "▁help ed", - "an don", - "and on", - "ando n", - "if ying", - "ify ing", - "ru it", - "r uit", - "ensch app", - "▁b ere", - "▁be re", - "▁ber e", - "▁ bere", - "V M", - "▁A wards", - "▁Award s", - "▁Aw ards", - "▁a gr", - "▁ag r", - "▁ agr", - "yn omial", - "en ced", - "ence d", - "enc ed", - "▁dev ices", - "▁device s", - "▁devi ces", - "▁b ot", - "▁bo t", - "▁ bot", - "▁f irm", - "▁fi rm", - "▁fir m", - "▁w riter", - "▁writ er", - "▁wr iter", - "▁write r", - "▁ writer", - "▁r ing", - "▁ri ng", - "▁rin g", - "▁ ring", - ". -", - "is tes", - "ist es", - "iste s", - "l ä", - "▁m el", - "▁me l", - "▁ mel", - "ent ation", - "enta tion", - "▁Sch w", - "▁Sc hw", - "▁n ome", - "▁no me", - "▁nom e", - "▁ nome", - "▁po bla", - "▁pob la", - "▁w oj", - "▁wo j", - "▁u l", - "▁ ul", - "en to", - "ent o", - "ы х", - "▁res ist", - "▁rem ains", - "▁remain s", - "▁C a", - "▁ Ca", - "añ a", - "a ña", - "▁C ourt", - "▁Co urt", - "▁Cour t", - "▁Cou rt", - "ut able", - "uta ble", - "u table", - "ential ly", - "enti ally", - "▁t rat", - "▁tr at", - "▁tra t", - "▁ trat", - "▁Vis ual", - "▁ Visual", - "▁rest rict", - "▁pre viously", - "▁previous ly", - "▁prev iously", - "ca tion", - "cat ion", - "c ation", - "▁о со", - "▁ос о", - "▁My SQL", - "f ör", - "cal a", - "ca la", - "c ala", - "▁c ulture", - "▁cult ure", - "li ve", - "liv e", - "l ive", - "▁accept ed", - "Di d", - "D id", - "▁h ous", - "▁ho us", - "▁se lection", - "▁select ion", - "▁sel ection", - "▁sele ction", - "▁ selection", - "▁de cre", - "▁dec re", - "mar gin", - "m argin", - "ur b", - "u rb", - "▁I nc", - "▁In c", - "▁M any", - "▁Man y", - "▁Ma ny", - "▁ Many", - "ib t", - "i bt", - "▁succ eed", - "▁suc ceed", - "Bind ing", - "B inding", - "c í", - "▁R og", - "▁Ro g", - "▁should n", - "cl oud", - "clo ud", - "clou d", - "▁d z", - "▁ dz", - "ва в", - "▁p ix", - "▁pi x", - "sm all", - "▁project s", - "▁ projects", - "▁O K", - "▁ OK", - "▁la test", - "▁lat est", - "▁late st", - "▁ latest", - "▁re ferences", - "▁refer ences", - "▁reference s", - "Pro gram", - "Pr ogram", - "▁er st", - "▁ers t", - "▁ erst", - "▁я к", - "▁k am", - "▁ka m", - "▁C amb", - "▁Cam b", - "▁Ca mb", - "el lt", - "ell t", - "ö d", - "no ne", - "non e", - "n one", - "▁j usqu", - "▁ju squ", - "ki ng", - "kin g", - "k ing", - "▁P ed", - "▁Pe d", - "as sert", - "ass ert", - "asse rt", - "asser t", - "C S", - "ri to", - "rit o", - "r ito", - "es sa", - "ess a", - "ль ко", - "▁V on", - "▁Vo n", - "▁Ed ward", - "▁im possible", - "▁impos sible", - "n p", - "word s", - "wor ds", - "w ords", - "ie lt", - "iel t", - "i elt", - "▁P age", - "▁Pa ge", - "▁ Page", - "le rs", - "ler s", - "l ers", - "▁p ier", - "▁pi er", - "▁pie r", - "▁обла сти", - "itt ee", - "itte e", - "▁( [", - "▁ ([", - "▁t rust", - "▁tr ust", - "N G", - "re du", - "red u", - "r edu", - "< <", - "ri al", - "ria l", - "r ial", - "▁product s", - "▁ products", - "▁E rn", - "▁Er n", - "ri ère", - "r ière", - "го в", - "г ов", - "▁Re ich", - "▁Ro ad", - "▁n ested", - "▁ne sted", - "▁nest ed", - "▁ nested", - "Dis play", - "▁str ength", - "ograf ía", - "▁ann ounced", - "▁announ ced", - "▁S cience", - "▁Sc ience", - "▁Sci ence", - "▁рай о", - "Param eter", - "▁T ask", - "▁Ta sk", - "▁Tas k", - "▁ Task", - "um ents", - "ument s", - "umen ts", - "u ments", - "▁ad opt", - "▁On ly", - "▁ Only", - "ют ь", - "ю ть", - "▁c li", - "▁cl i", - "▁ cli", - "▁l em", - "▁le m", - "▁ lem", - "st ood", - "sto od", - "▁F I", - "▁ FI", - "ên cias", - "ência s", - "pon ents", - "ponent s", - "] $", - "com ment", - "comm ent", - "▁y a", - "▁ ya", - "sh ould", - "ik e", - "i ke", - "ti m", - "t im", - "el lig", - "ell ig", - "elli g", - "▁s ending", - "▁send ing", - "▁sen ding", - "▁a jax", - "▁aj ax", - "▁ ajax", - "▁nov iembre", - "um es", - "ume s", - "u mes", - "▁we iter", - "▁weit er", - "▁D ans", - "▁Dan s", - "▁Da ns", - "op p", - "o pp", - "▁sept embre", - "▁sep tembre", - "ot imes", - "oti mes", - "o times", - "z ő", - "▁e p", - "▁ ep", - "ve re", - "ver e", - "v ere", - "▁o h", - "▁ oh", - ": =", - "▁S ong", - "▁So ng", - "▁Son g", - "” ,", - "▁v iv", - "▁vi v", - "▁ viv", - "▁qu eries", - "▁que ries", - "▁quer ies", - "▁v á", - "▁ vá", - "▁déc embre", - "▁un able", - "▁una ble", - "▁e rh", - "▁er h", - "▁` -", - "▁ `-", - "▁L ee", - "▁Le e", - "▁er sten", - "▁erst en", - "▁erste n", - "▁ers ten", - "ô t", - "ст ве", - "ств е", - "T S", - "▁f ragment", - "▁fra gment", - "▁frag ment", - "▁ fragment", - "▁w ide", - "▁wid e", - "▁ wide", - "▁s uff", - "▁su ff", - "▁suf f", - "▁d ut", - "▁du t", - "▁V ere", - "▁Ver e", - "▁Ve re", - "і с", - "ad ing", - "adi ng", - "adin g", - "a ding", - "ie go", - "ieg o", - "i ego", - "ic ago", - "ica go", - "▁Ar gent", - "▁Arg ent", - "or er", - "ore r", - "o rer", - "en nes", - "enn es", - "enne s", - "▁L eb", - "▁Le b", - "lin ux", - "ac ing", - "aci ng", - "a cing", - "▁br oken", - "▁bro ken", - "▁broke n", - "t p", - "í o", - "ab eth", - "abe th", - "abet h", - "ist as", - "ista s", - "ge w", - "g ew", - "i ème", - "ca s", - "c as", - "▁pre ced", - "▁prec ed", - "▁D al", - "▁Da l", - "▁comp ared", - "▁compar ed", - "▁compare d", - "equ iv", - "il ly", - "ill y", - "te en", - "t een", - "▁Con sole", - "▁Cons ole", - "▁ Console", - "▁st rict", - "▁str ict", - "▁stri ct", - "it aire", - "ita ire", - "i taire", - "▁E D", - "▁ ED", - "ential s", - "enti als", - "▁p erman", - "▁per man", - "▁perm an", - "▁t ous", - "▁to us", - "▁tou s", - "▁g eme", - "▁ge me", - "▁gem e", - "▁ geme", - "▁ext rem", - "▁extr em", - "▁ок ру", - "k g", - "▁he avy", - "▁heav y", - "▁av ril", - "▁an ti", - "▁ant i", - "▁ anti", - "▁oct obre", - "ut f", - "u tf", - "he lm", - "hel m", - "h elm", - "am ples", - "ample s", - "amp les", - "▁( _", - "▁ (_", - "ak en", - "ake n", - "a ken", - "▁d ear", - "▁de ar", - "▁opin ion", - "▁f ish", - "▁fi sh", - "▁fis h", - "▁ fish", - "▁Alex ander", - "▁Alexand er", - "i w", - "и м", - "ca dem", - "cade m", - "c adem", - "▁ref lect", - "▁ reflect", - "▁д р", - "▁t rib", - "▁tr ib", - "▁tri b", - "com mon", - "comm on", - "▁clear ly", - "▁s af", - "▁sa f", - "=\"@ +", - "▁М ос", - "▁Мо с", - "си те", - "eqn array", - "nu ng", - "n ung", - "▁relations hip", - "▁relation ship", - "▁S em", - "▁Se m", - "▁ Sem", - "▁k illed", - "▁kil led", - "▁kill ed", - "te d", - "t ed", - "un o", - "u no", - "▁ лі", - "▁w id", - "▁ wid", - "an ning", - "ann ing", - "anni ng", - "▁p anel", - "▁pa nel", - "▁pan el", - "▁ panel", - "▁L eben", - "▁Le ben", - "▁Leb en", - "▁r uby", - "▁ru by", - "▁rub y", - "▁ ruby", - "ans ion", - "▁a ren", - "▁are n", - "▁ar en", - "▁ aren", - "tab ular", - "al et", - "ale t", - "a let", - "}$ $", - "} $$", - "▁L ake", - "▁La ke", - "▁Lak e", - "▁su ite", - "▁suit e", - "▁ suite", - "▁min or", - "▁mi nor", - "H ozzáférés", - "▁xml ns", - "▁ xmlns", - "DI R", - "D IR", - "dr iver", - "drive r", - "dri ver", - "d river", - "in ts", - "int s", - "▁v ic", - "▁vi c", - "▁ vic", - "AN D", - "A ND", - "pr im", - "p rim", - "сы лки", - "▁O x", - "T C", - "riv ial", - "at ie", - "ati e", - "▁e ight", - "▁eig ht", - "▁eigh t", - "▁conf lic", - "▁confl ic", - "an gel", - "ang el", - "ange l", - "▁B egr", - "▁Be gr", - "▁Beg r", - "▁explicit ly", - "ют ся", - "ю тся", - "▁D ev", - "▁De v", - "▁ Dev", - "re nder", - "ren der", - "rend er", - "r ender", - "▁re produ", - "▁rep rodu", - "▁repr odu", - "▁repro du", - "▁c ré", - "▁cr é", - "G u", - "M B", - "▁k ön", - "▁kö n", - "▁rem ained", - "▁remain ed", - "▁k l", - "▁ kl", - "хо в", - "х ов", - "▁b yl", - "▁by l", - "Ph i", - "P hi", - "▁de tail", - "▁det ail", - "▁ detail", - "ja v", - "j av", - "▁m ouse", - "▁mo use", - "▁mou se", - "▁ mouse", - "B as", - "i ę", - "as ser", - "ass er", - "asse r", - "h s", - "▁sh ift", - "▁ shift", - "▁ú lt", - "▁ últ", - "ra nd", - "ran d", - "r and", - "▁b tn", - "▁ btn", - "ra z", - "r az", - "▁p ul", - "▁pu l", - "▁stat ements", - "▁state ments", - "▁statement s", - "file name", - "fil ename", - "▁prom pt", - "él é", - "é lé", - "ik z", - "▁S us", - "▁Su s", - "▁de but", - "▁deb ut", - "St at", - "S tat", - "form s", - "for ms", - "▁H ein", - "▁He in", - "st adt", - "sta dt", - "stad t", - "en nis", - "enn is", - "по л", - "ar ante", - "aran te", - "ці й", - "ц ій", - "▁que ue", - "▁ queue", - "▁re ci", - "▁rec i", - "▁ reci", - "▁s ta", - "▁st a", - "▁ sta", - "yn chron", - "cent ering", - "center ing", - "cente ring", - "So me", - "S ome", - "Gr aph", - "G raph", - "▁t ested", - "▁te sted", - "▁test ed", - "▁K unst", - "▁Kun st", - "о м", - "▁N othing", - "▁No thing", - "▁Not hing", - "▁ Nothing", - "ie u", - "i eu", - "“ .", - "B undle", - "▁of icial", - "▁ofic ial", - "al low", - "all ow", - "allo w", - "▁Re act", - "▁L ibrary", - "▁Li brary", - "▁ Library", - "bl ue", - "▁ver w", - "▁ve rw", - "▁p are", - "▁par e", - "▁pa re", - "▁Fried rich", - "▁a ware", - "▁aw are", - "▁ aware", - "Ex p", - "E xp", - "▁effect s", - "▁го ро", - "▁гор о", - "lop edia", - "loped ia", - "▁V en", - "▁Ve n", - "ra le", - "ral e", - "r ale", - "▁F inal", - "▁Fin al", - "▁ Final", - "▁pro pos", - "▁prop os", - "la cement", - "lace ment", - "lac ement", - "kt en", - "kte n", - "k ten", - "▁no vel", - "▁nov el", - "or ter", - "ort er", - "orte r", - "▁German y", - "▁Ger many", - "▁Germ any", - "▁d jango", - "▁ django", - "▁trans ition", - "▁ transition", - "▁happ ened", - "▁happen ed", - "▁beaut iful", - "▁ne ither", - "▁nei ther", - "▁li braries", - "▁h ide", - "▁hi de", - "▁hid e", - "▁ hide", - "al g", - "a lg", - "▁a spect", - "▁as pect", - "▁asp ect", - "▁for get", - "▁forg et", - "cade my", - "cadem y", - "on te", - "ont e", - "re fix", - "ref ix", - "▁cl oud", - "▁clo ud", - "▁ cloud", - "ne d", - "n ed", - "cd ots", - "cdot s", - "c dots", - "reg ister", - "ny m", - "n ym", - ".) :", - ". ):", - "▁J ew", - "▁Je w", - "▁t rès", - "▁tr ès", - "ни че", - "▁D or", - "▁Do r", - "▁p roc", - "▁pro c", - "▁pr oc", - "▁ proc", - "▁g an", - "��ga n", - "▁ gan", - "▁ є", - "▁S av", - "▁Sa v", - "v í", - "Setting s", - "S ettings", - "▁V ari", - "▁Var i", - "▁Va ri", - "▁ Vari", - "▁c ours", - "▁co urs", - "▁cour s", - "▁cou rs", - "R o", - "▁con j", - "▁re asons", - "▁reason s", - "▁re ader", - "▁read er", - "▁ reader", - "лекс анд", - "ic ate", - "ica te", - "}) ,", - "} ),", - "▁task s", - "▁ tasks", - "▁R ay", - "▁Ra y", - "▁r ic", - "▁ri c", - "▁ ric", - "K e", - "on ie", - "oni e", - "o nie", - "r f", - ") [", - "▁sub sequ", - "▁subs equ", - "▁T urn", - "▁Tur n", - "▁Tu rn", - "▁ Turn", - "▁VI AF", - "math sf", + "▁d ay▁1", + "th at", + "▁in ▁this▁study", + "ur ance▁", + "▁( 2", + "▁( 94)\n\nGEL▁Version▁ID:▁CV.000−522−306.7", + "▁I C", + "▁l ymph", + "▁or ▁not", + "iz e▁the▁", + "▁pro long", + "com pan", + "and id", + "▁R e", + "▁0 .8", + "▁com bin", + "able▁ for", + "out sid", + "▁will ▁continu", + "s▁( including", + "\n\n1 ▁4▁:▁5▁0▁7▁0▁0▁2▁-▁g▁u▁A▁-▁1▁3▁\\▁d▁e▁v▁o▁r▁p▁p▁A\n\n\\▁1▁.▁1▁\\\n\n8▁2▁1▁6▁6▁8", + "▁any▁ caus", + "ed▁for ▁all", + "▁7 2", + "▁month s▁for", + ".▁C om", + "▁le ad", + "▁16 ▁July▁2004", + "\n\nR es", + "▁sampl e▁", + "▁sampl es▁", + "inc e▁th", + "plic able▁", + "ish ▁oil", + "week ly▁", + "TION S", + "03 1", + "\n\nL Y231514", + "▁every▁ 3", + "▁compar ison", + "/m m", + "▁hav e▁s", + "▁Grade▁ 4", + "-C SF", + "▁PRO CEDURES", + "▁AMG▁162▁Protocol▁Number:▁200401 35▁Date:▁14▁November▁2006", + "even ▁if", + "read y▁", + "cut ane", + "log -rank▁test", + "▁Study▁D esign", + "- 8", + "4 33", + "6 1", + "6 7", + "9 6", + "D isease▁", "H E", - "▁dec lare", - "▁decl are", - "▁decla re", - "▁declar e", - "▁pro tocol", - "▁proto col", - "▁ protocol", - "▁P C", - "▁ PC", - "ци он", - "View ById", - "▁an imation", - "▁anim ation", - "▁ animation", - "▁conf used", - "ви ч", - "▁en abled", - "▁enable d", - "▁ enabled", - "ow o", - "o wo", - "ás t", - "á st", - "ö t", - "▁m and", - "▁ma nd", - "▁man d", - "▁R ail", - "▁Ra il", - "field s", - "▁K ap", - "▁Ka p", - "▁al gebra", - "▁ algebra", - "▁С у", - "fér ence", - "▁C urrent", - "▁Cur rent", - "▁ Current", - "с но", - "▁L im", - "▁Li m", - "Par ams", - "Param s", - "Pa rams", - "▁Ant onio", - "▁Anton io", - "▁Anto nio", - "▁t v", - "▁ tv", - "la te", - "lat e", - "l ate", - "if er", - "ife r", - "i fer", - "En try", - "Ent ry", - "▁S erv", - "▁Se rv", - "▁Ser v", - "▁ Serv", - "▁mus ical", - "▁music al", - "▁musica l", - "▁t race", - "▁tr ace", - "▁tra ce", - "▁trac e", - "▁ trace", - "▁s cient", - "▁sc ient", - "▁sci ent", - "fi c", - "f ic", - "▁for got", - "▁forg ot", - "v ideo", - "▁o lder", - "▁old er", - "▁ol der", - "▁ older", - "Tr ee", - "T ree", - "▁u ns", - "▁un s", - "▁ uns", - "ни ки", - "ник и", - "▁E uropa", - "▁Europ a", - "▁Euro pa", - "▁Z we", - "▁Zw e", - "▁б е", - "▁ бе", - "▁v ec", - "▁ve c", - "▁ vec", - "ж у", - "Mat ch", - "M atch", - "sp an", - "s pan", - "▁bl ank", - "▁blan k", - "▁ blank", - "▁sp äter", - "▁T y", - "▁ Ty", - "▁d ict", - "▁di ct", - "▁dic t", - "▁ dict", - "ñ a", - "▁conf irm", - "▁confir m", - "▁ confirm", - "▁v ý", - "за н", - "з ан", - "Re l", - "R el", - "fil m", - "fi lm", - "▁R ot", - "▁Ro t", - "▁ Rot", - "▁H y", - "▁ Hy", - "ка х", - "▁dem and", - "▁min ist", - "▁mini st", - "▁Mad rid", - "▁us ual", - "sp iel", - "s piel", - "er os", - "ero s", - "e ros", - "▁t utorial", - "▁tut orial", - "▁ tutorial", - "▁С ��ылки", - "s ys", - "ци аль", - "▁sp read", - "▁spr ead", - "▁spre ad", - "▁con vers", - "▁conver s", - "▁conv ers", - "▁r oll", - "▁ro ll", - "▁rol l", - "▁ roll", - "artifact Id", - "▁N umber", - "▁Num ber", - "▁ Number", - "▁sym met", - "▁M ult", - "▁Mu lt", - "▁Mul t", - "▁ Mult", - "ex pected", - "exp ected", - "expect ed", - "▁a xis", - "▁ax is", - "▁ axis", - "▁match ing", - "▁f ood", - "▁fo od", - "▁foo d", - "group Id", - "Map p", - "Ma pp", - "M app", - "▁с вя", - "▁v end", - "▁ve nd", - "▁ven d", - "F ound", - "ot to", - "ott o", - "o tto", - "Ca t", - "C at", - "cri t", - "cr it", - "c rit", - "ist ent", - "iste nt", - "isten t", - "▁d rei", - "▁dr ei", - "▁dre i", - "▁en ded", - "▁end ed", - "▁ende d", - "▁ ended", - "▁T ele", - "▁Te le", - "▁Tel e", - "com ponent", - "▁invol ved", - "▁involve d", - "▁Est ados", - "▁Estado s", - "▁Estad os", - "▁d anger", - "▁dan ger", - "▁ch ain", - "▁cha in", - "▁ chain", - "▁P rom", - "▁Pro m", - "▁Pr om", - "▁ Prom", - "ho m", - "h om", - "▁pol ít", - "co p", - "c op", - "▁n ap", - "▁na p", - "▁ nap", - "ri f", - "r if", - "ple ments", - "pl ements", - "plement s", - "▁v ent", - "▁ve nt", - "▁ven t", - "▁ vent", - "an na", - "ann a", - "an ted", - "ant ed", - "ante d", - "date d", - "da ted", - "dat ed", - "d ated", - "an th", - "ant h", - "a nth", - "▁thread s", - "▁thre ads", - "▁ threads", - "зо ва", - "зов а", - "з ова", - "▁ста нов", - "▁стан ов", - "▁ станов", - "▁e erst", - "▁eer st", - "bu f", - "b uf", - "he id", - "▁R u", - "▁P rim", - "▁Pr im", - "▁Pri m", - "▁ Prim", - "▁m igr", - "▁mi gr", - "▁mig r", - "▁ migr", - "▁Un idos", - "▁ar bitr", - "▁r oman", - "▁ro man", - "▁rom an", - "ount ry", - "oun try", - "ult ur", - "▁K önig", - "▁Kö nig", - "▁an not", - "▁ann ot", - "▁anno t", - "▁ annot", - "ach ing", - "ac hing", - "achi ng", - "▁H aupt", - "▁Ha upt", - "um in", - "umi n", - "u min", - "▁h em", - "▁he m", - "▁ hem", - "ck ets", - "cket s", - "cke ts", - "ba u", - "b au", - "ect ion", - "ec tion", - "e ction", - "ef t", - "e ft", - "▁package s", - "▁pack ages", - "▁ packages", - "▁K ur", - "▁Ku r", - "th ur", - "▁p ays", - "▁pa ys", - "▁pay s", - "li ament", - "lia ment", - "▁Б у", - "▁c ada", - "▁ca da", - "▁cad a", - "po ints", - "point s", - "oc ket", - "ock et", - "o cket", - "▁v erb", - "▁ver b", - "▁ve rb", - "▁ verb", - "ле е", - "▁sub mit", - "▁subm it", - "▁ submit", - "▁s an", - "▁sa n", - "▁ san", - "ru by", - "r uby", - "▁e ast", - "▁eas t", - "▁ east", - "ko v", - "k ov", - "▁Ver lag", - "▁Verl ag", - "▁ Verlag", - "▁s pot", - "▁sp ot", - "▁spo t", - "▁ spot", - "pp o", - "p po", - "E ach", - "je kt", - "▁Bi ographie", - "▁ne ws", - "▁new s", - "▁ news", - "▁pa ís", - "uf act", - "u fact", - "▁d ia", - "▁di a", - "▁ dia", - "ко ва", - "ков а", - "к ова", - "▁accom pl", - "▁accomp l", - "▁É t", - "▁ Ét", - "il ities", - "ili ties", - "▁i hm", - "▁ih m", - "in voke", - "inv oke", - "▁app end", - "▁ap pend", - "▁appe nd", - "▁ append", - ".) ,", - ". ),", - "▁l ab", - "▁la b", - "▁ lab", - "an ging", - "ang ing", - "is tan", - "ist an", - "ista n", - "i stan", - "re sol", - "res ol", - "reso l", - "▁S ection", - "▁Se ction", - "▁Sec tion", - "▁ Section", - "Par ent", - "Pa rent", - "mo z", - "m oz", - "Ma t", - "M at", - "st yles", - "style s", - "sty les", - "un den", - "und en", - "unde n", - "“ ,", - "irt schaft", - "ки м", - "к им", - "▁Fin ally", - "▁Final ly", - "ph en", - "phe n", - "p hen", - "▁P ac", - "▁Pa c", - "▁Array List", - "▁ ArrayList", - "▁re cover", - "▁rec over", - "▁e ducation", - "▁educ ation", - "mod els", - "model s", - "mode ls", - "pe d", - "p ed", - "▁h appy", - "▁ha ppy", - "▁happ y", - "ч у", - "▁guer ra", - "me dia", - "med ia", - "medi a", - "m edia", - "O F", - "▁ens ure", - "▁ ensure", - "Mar k", - "M ark", - "data base", - "dat abase", - "datab ase", - "d atabase", - "og gle", - "▁pub lish", - "▁publi sh", - "▁ publish", - "O W", - "▁B au", - "▁Ba u", - "? .", - "▁ча сти", - "▁час ти", - "▁част и", - "▁re pository", - "▁repos itory", - "▁ repository", - "▁M att", - "▁Ma tt", - "▁Mat t", - "hi gh", - "h igh", - "ov en", - "ove n", - "o ven", - "▁g er", - "▁ge r", - "▁ ger", - "▁un known", - "▁ unknown", - "Am er", - "A mer", - "▁B rown", - "▁Br own", - "▁Bro wn", - "▁Brow n", - "AL L", - "A LL", - "▁result ing", - "▁b or", - "▁bo r", - "▁ bor", - "▁po et", - "ни ми", - "ним и", - "Em ail", - "E mail", - "F ont", + "P SA", + "a i", + "c it", + "f inding", + "s ▁to▁the▁", + "s creening", + "s ▁about", + "v as", + "e▁ as▁", + "▁t r", + "at igu", + "it e▁blood▁", + "ro x", + "ed -", + "▁of ▁patients▁with", + ".\n\n 12", + "▁in iti", + "stud i", + "est ru", + "▁f ever", + "ver tebral▁", + "e▁t rial", + "iz ing", + "▁O \n\nY▁P▁O▁C", + "▁g o", + "▁L -M", + "from ▁the▁", + ".5 .2", + "ens ity▁", + "rel ated", + "ang u", + "▁Date: ▁16▁July▁2004", + "▁le ucovorin", + "▁Protocol▁Number:▁200 10145", + "OR D", + "▁gen eral", + "▁chemotherapy▁ regimen", + "▁there▁ are▁", + "ma jor", + "▁a▁m aximum", + "DMC ▁will", + "▁require d", + "▁safety▁ data", + "y▁s ystem", + "\n\nCom plet", + "▁prof il", + "▁strati fi", + "s▁before▁ randomization", + "▁September ▁2007", + "▁Protocol▁Amendment ▁6", + "▁Denosumab▁Protocol▁Number:▁20050136▁Date:▁30 ▁April▁2008\n\nPage▁", + "estru ction", + "- 2010", + "f ac", + "m ethod", + "u ally", + "w ar", + "\n\n for", + "re tain", + "it al▁", + "▁an ▁ex", + "▁c m", + "▁c od", + "▁c apecitabine▁", + "▁b est", + "▁to ▁have▁", + "▁w eight", + "el :", + "ac cess▁to", + "▁( including", + "▁2 ▁1", + "us h", "▁h ist", - "▁his t", - "▁hi st", - "▁to day", - "▁tod ay", - "▁toda y", - "▁ today", - "▁B erg", - "▁Be rg", - "▁Ber g", - "▁but tons", - "▁button s", - "та л", - "т ал", - "▁s ni", - "▁sn i", - "▁че лов", - "Cr e", - "C re", - "▁un ion", - "▁ union", - "▁z ich", - "ish op", - "i shop", - "▁qu ando", - "▁quand o", - "▁quan do", - "P o", - "CT ION", - "▁C ost", - "▁Co st", - "▁Cos t", - "▁ Cost", - "су дар", - "er ved", - "erv ed", - "erve d", - "Not e", - "No te", - "N ote", - "Equ al", - "Eq ual", - "E qual", - "ли я", - "бу р", - "б ур", - "▁ab stract", - "▁abstra ct", - "▁ abstract", - "st op", - "sto p", - "s top", - "▁ad vice", - "▁adv ice", - "▁i con", - "▁ic on", - "▁ icon", - "▁tr avel", - "▁tra vel", - "▁trav el", - "B S", - "ve ns", - "ven s", - "v ens", - "▁b atch", - "▁bat ch", - "▁ batch", - "li que", - "liqu e", - "l ique", - "she et", - "s heet", - "▁i hre", - "▁ih re", - "▁ihr e", - "em on", - "emo n", - "e mon", - "ber to", - "bert o", - "▁as signed", - "▁ass igned", - "▁assign ed", - "ь ю", - "Ph one", - "▁a ward", - "▁aw ard", - "▁function ality", - "▁functional ity", - "al la", - "all a", - "a lla", - "▁D am", - "▁Da m", - "▁ci udad", - "▁cl uster", - "▁clust er", - "▁ cluster", - "De scription", - "Des cription", - "▁s heet", - "▁she et", - "▁ sheet", - "▁Austral ian", - "▁Australia n", - "▁» .", - "▁ ».", - "▁\" <", - "▁wonder ing", - "ain e", - "ai ne", - "a ine", - "▁represent ed", - "▁repres ented", - "ka ppa", - "kap pa", - "k appa", - "n b", - "▁s y", - "▁K ö", - "=\" #", - "▁s even", - "▁se ven", - "Direct ory", - "D irectory", - "▁s ister", - "▁si ster", - "▁sist er", - "pl ates", - "plate s", - "pla tes", - "▁l uck", - "▁lu ck", - "▁luc k", - "▁rem aining", - "▁remain ing", - "▁V ill", - "▁Vi ll", - "▁Vil l", - "wer k", - "w erk", - "an ni", - "ann i", - "et ti", - "ett i", - "fun c", - "fu nc", - "f unc", - "▁b an", - "▁ba n", - "▁ ban", - "im s", - "i ms", - "mi ss", - "mis s", - "m iss", - "ag raph", - "agr aph", - "a graph", - "ек си", - "е кси", - "▁R ef", - "▁Re f", - "▁ Ref", - "ni tt", - "nit t", - "n itt", - "▁G ab", - "▁Ga b", - "▁and ere", - "▁jed och", - "result s", - "! \\", - "▁l isted", - "▁li sted", - "▁list ed", - "▁liste d", - "▁l oro", - "▁lo ro", - "▁kn ows", - "▁know s", - "ж но", - "R ad", - "▁s ocket", - "▁so cket", - "▁soc ket", - "▁ socket", - "mult i", - "mul ti", - "▁р і", - "▁ рі", - "ra ils", - "rai ls", - "r ails", - "▁t ar", - "▁ta r", - "▁ tar", - "▁gent le", - "se tt", - "set t", - "s ett", - "serv ices", - "service s", - "bo und", - "b ound", - "ig keit", - "aj a", - "a ja", - "▁c md", - "▁cm d", - "▁ cmd", - "ag ger", - "agg er", - "▁b a", - "▁ ba", - "▁Be lg", - "▁Bel g", - "▁K le", - "▁Kl e", - "▁word t", - "▁wor dt", - "▁f ost", - "▁fo st", - "▁fos t", - "▁dim ension", - "An g", - "A ng", - "um ing", - "umin g", - "umi ng", - "u ming", - "Ob j", - "не н", - "н ен", - "▁M arie", - "▁Mar ie", - "▁Ma rie", - "▁Mari e", - "▁ Marie", - "ex ists", - "exist s", - "т ро", - "▁бо ль", - "▁ боль", - "em ente", - "ement e", - "emen te", - "e mente", - "▁J on", - "▁Jo n", - "SE RT", - "SER T", - "S ERT", - "▁high est", - "ak i", - "a ki", - "▁t res", - "▁tr es", - "▁tre s", - "▁ tres", - "▁circ um", - "▁D own", - "▁Do wn", - "▁Dow n", - "▁ Down", - "om men", - "omm en", - "ur er", - "ure r", - "u rer", - "▁caus es", - "▁cause s", - "▁ca uses", - "ven ue", - "iss ance", - "▁influ ence", - "▁influen ce", - "▁f at", - "▁fa t", - "ре ди", - "ред и", - "р еди", - "}\\ \\", - "} \\\\", - "▁en tr", - "▁ent r", - "▁ entr", - "▁S ign", - "▁Si gn", - "▁Sig n", - "▁ Sign", - "▁к ла", - "▁ кла", - "▁b inding", - "▁bind ing", - "▁bin ding", - "▁ binding", - "es sen", - "ess en", - "esse n", - "▁Ф ран", - "▁L ocal", - "▁Lo cal", - "▁Loc al", - "▁ Local", - "▁я вля", - "ap pro", - "app ro", - "▁dep endencies", - "▁depend encies", - "▁ dependencies", - "▁talk ing", - "▁tal king", - "▁zur ück", - "con nection", - "connect ion", - "conne ction", - "conn ection", - "Act ive", - "Activ e", - "bb e", - "b be", - "ir ls", - "irl s", - "▁In f", - "▁ Inf", - "w d", - "▁и с", - "▁ ис", - "ro ad", - "▁con ven", - "▁conv en", - "ě t", - "ве з", - "в ез", - "▁ent ries", - "▁entr ies", - "▁ entries", - "es c", - "e sc", - "▁b its", - "▁bit s", - "▁bi ts", - "▁ bits", - "as so", - "ass o", - "W R", - "sh ips", - "ship s", - "s hips", - "▁d és", - "▁dé s", - "es p", - "e sp", - "Ma ke", - "M ake", - "▁famil iar", - "▁familia r", - "Ar t", - "A rt", - "▁ar my", - "▁arm y", - "ct r", - "c tr", - "ér ic", - "éri c", - "é ric", - "que ue", - "▁\\ {", - "▁ \\{", - "ue la", - "uel a", - "u ela", - "am iento", - "ami ento", - "ши х", - "ш их", - "▁\" \"\"", - "▁\"\" \"", - "con tr", - "cont r", - "лл е", - "л ле", - "F S", - "▁mar ket", - "▁mark et", - "▁ market", - "ån g", - "å ng", - "cite p", - "cit ep", - "Il l", - "I ll", - "ran k", - "r ank", - "▁s ender", - "▁se nder", - "▁send er", - "▁sen der", - "▁ sender", - "▁be im", - "▁bei m", - "ра к", - "▁com pat", - "▁comp at", - "▁ compat", - "▁occ urs", - "▁occur s", - "▁d iese", - "▁di ese", - "▁die se", - "▁dies e", - "сти ту", - "aw a", - "a wa", - "▁i OS", - "▁Ch inese", - "▁Chine se", - "▁T R", - "▁ TR", - "▁K en", - "▁Ke n", - "▁U ne", - "▁Un e", - "▁cre ates", - "▁create s", - "▁sh owed", - "▁show ed", - "▁sho wed", - "▁é v", - "▁ év", - "olog ia", - "olo gia", - "▁pro test", - "▁prote st", - "▁prot est", - "▁P f", - "▁s quad", - "▁squ ad", - "++ ,", - "á v", - "▁ess ere", - "з я", - "ko l", - "k ol", - "▁slight ly", - "ad dr", - "add r", - "â n", - "▁red uce", - "▁redu ce", - "▁ reduce", - "▁\\ (\\", - "▁\\( \\", - "▁D ep", - "▁De p", - "▁ Dep", - "▁gener ic", - "▁gene ric", - "▁ generic", - "Lo ader", - "Load er", - "ț i", - "▁п ос", - "▁по с", - "▁occ asion", - "▁occas ion", - "▁L ady", - "▁La dy", - "▁Lad y", - "ent ity", - "enti ty", - "▁av ant", - "▁ avant", - "▁P as", - "▁Pa s", - "ag gio", - "aggi o", - "agg io", - "\\ {", - "па д", - "athol ic", - "Pass word", - "▁res pond", - "▁resp ond", - "▁ respond", - "▁N on", - "▁No n", - "▁ Non", - "A G", - "ne g", - "n eg", - "▁у с", - "▁ ус", - "bl ob", - "blo b", - "b lob", - "ck e", - "c ke", - "▁Cons ider", - "▁C are", - "▁Car e", - "▁Ca re", - "ik i", - "i ki", - "▁Ch icago", - "in den", - "ind en", - "inde n", - "▁C op", - "▁Co p", - "] +", - "ö m", - "év rier", - "к ло", - "al en", - "ale n", - "a len", - "▁m aj", - "▁ma j", - "ra cy", - "rac y", - "r acy", - "or te", - "ort e", - "ien ts", - "ient s", - "i ents", - "el ls", - "ell s", - "act ivity", - "activ ity", - "▁r untime", - "▁run time", - "▁runt ime", - "▁ runtime", - "NU LL", - "N ULL", - "▁poss ibly", - "▁possib ly", - "▁s tri", - "▁st ri", - "▁str i", - "iz i", - "i zi", - "▁m ir", - "▁mi r", - "▁ mir", - "▁V ersion", - "▁Vers ion", - "▁ Version", - "pr ime", - "prim e", - "▁tw enty", - "▁M ah", - "▁Ma h", - "▁s ounds", - "▁sound s", - "ше н", - "ш ен", - "cl usion", - "clus ion", - "ac z", - "a cz", - "▁determ ined", - "▁determine d", - "▁determin ed", - "▁R ep", - "▁Re p", - "▁ Rep", - "▁Land es", - "▁Lan des", - "▁w all", - "▁wa ll", - "▁wal l", - "▁ wall", - "ig i", - "i gi", - "▁re set", - "▁res et", - "▁ reset", - "ш о", - "ya n", - "y an", - "Me t", - "M et", - "e i", - "▁app earance", - "▁appear ance", - "▁f ois", - "▁fo is", - "▁foi s", - "▁ fois", - "▁n ell", - "▁ne ll", - "▁nel l", - "▁ nell", - "es i", - "e si", - "ё т", - "lo or", - "l oor", - "▁U l", - "▁resol ution", - "▁f ot", - "▁fo t", - "▁through out", - "▁r i", - "▁ ri", - "Le vel", - "po ol", - "p ool", - "▁id entity", - "▁ident ity", - "▁ identity", - "▁j anu", - "▁jan u", - "▁ja nu", - "▁im per", - "▁imp er", - "▁ imper", - "▁ö ver", - "} `", - "▁in fer", - "▁inf er", - "▁d ates", - "▁da tes", - "▁dat es", - "▁date s", - "▁ dates", - "▁Stand ard", - "▁ Standard", - "for ce", - "oc key", - "ock ey", - "ter a", - "te ra", - "t era", - "▁dist ingu", - "▁pres ence", - "li ca", - "lic a", - "l ica", - "▁le aving", - "it ung", - "itu ng", - "é b", - "▁estab lish", - "▁m aar", - "▁ma ar", - "ad i", - "a di", - "▁New s", - "▁Ne ws", - "▁ News", - "az on", - "a zon", - "fo lg", - "fol g", - "f olg", - "▁H ence", - "▁Hen ce", - "▁Y e", - "▁f ab", - "▁fa b", - "▁ fab", - "▁f ühr", - "▁ führ", - "it map", - "▁V ers", - "▁Ver s", - "▁Ve rs", - "ro v", - "r ov", - "Si gn", - "S ign", - "de vice", - "dev ice", - "S igma", - "▁wet enschapp", - "▁P s", - "PA TH", - "P ATH", - "▁t orn", - "▁to rn", - "▁tor n", - "ve st", - "ves t", - "v est", - "ст ов", - "сто в", - "с тов", - "ac count", - "acc ount", - "acco unt", - "▁lar gest", - "▁large st", - "▁larg est", - "▁per cent", - "▁perce nt", - "▁ percent", - "▁W omen", - "▁Wo men", - "▁im g", - "▁ img", - "to ol", - "t ool", - "▁r oce", - "▁ro ce", - "▁a y", - "▁ ay", - "in et", - "ine t", - "i net", - "▁ao ût", - "▁pol ynomial", - "▁integr al", - "▁integra l", - "▁a reas", - "▁are as", - "▁area s", - "} '", - "▁h yp", - "▁hy p", - "loy ee", - "та ль", - "тал ь", - "т аль", - "▁pro xy", - "▁ proxy", - "▁W y", - "▁М екси", - "▁Ме кси", - "▁es cape", - "▁esc ape", - "▁ escape", - "ol ar", - "ola r", - "o lar", - "▁mis take", - "▁mist ake", - ")} {", - ") }{", - "▁P ot", - "▁Po t", - "▁process es", - "▁proc esses", - "\"> \r", - "\" >\r", - "hal ten", - "halt en", - "zz a", - "z za", - "am o", - "a mo", - "к ре", - "▁W ood", - "▁Wo od", - "ø r", - "▁с ер", - "▁се р", - "▁ сер", - "oc ia", - "oci a", - "o cia", - "tw o", - "t wo", - "pro file", - "prof ile", - "▁A st", - "▁As t", - "em bro", - "emb ro", - "▁ar ms", - "▁arm s", - "in as", - "ina s", - "i nas", - "in nen", - "inn en", - "▁m sg", - "▁ms g", - "▁ msg", - "IN T", - "I NT", - "▁b atter", - "▁batt er", - "▁bat ter", - "ign ment", - "▁v y", - "▁ vy", - "H rsg", - "▁G rund", - "▁Gr und", - "▁Gru nd", - "ro c", - "r oc", - "se g", - "s eg", - "▁de cor", - "▁dec or", - "▁ decor", - "▁event ually", - "> ,", - "▁p ag", - "▁pa g", - "▁ pag", - "an ten", - "ant en", - "ante n", - "a nten", - "▁str ugg", - "▁stru gg", - "}^ \\", - "} ^\\", - "date n", - "da ten", - "dat en", - "d aten", - "▁re la", - "▁r ela", - "▁rel a", - "по в", - "п ов", - "▁ко ро", - "▁кор о", - "▁B os", - "▁Bo s", - "▁l abor", - "▁la bor", - "▁lab or", - "▁Se cret", - "▁Sec ret", - "▁ Secret", - "ug en", - "uge n", - "u gen", - "▁j ap", - "▁ja p", - "▁hus band", - "▁Al bum", - "▁Alb um", - "▁et wa", - "▁про из", - "ri cht", - "ric ht", - "rich t", - "r icht", - "ra ch", - "rac h", - "r ach", - "ba t", - "b at", - "▁pre par", - "▁prep ar", - "▁St ock", - "▁Sto ck", - "▁l ack", - "▁la ck", - "▁lac k", - "▁ lack", - "хі д", - "х ід", - "▁h ogy", - "▁ho gy", - "▁Ch rome", - "▁Chr ome", - "▁Ad min", - "▁ Admin", - "▁com parison", - "▁compar ison", - "▁incre asing", - "н г", - "im i", - "i mi", - "D b", - "▁g ef", - "▁ge f", - "▁ gef", - "uch t", - "uc ht", - "u cht", - "és e", - "é se", - "gen ce", - "g ence", - "▁C ore", - "▁Cor e", - "▁Co re", - "▁ Core", - "▁in correct", - "▁incor rect", - "▁ass uming", - "▁assum ing", - "our se", - "ours e", - "ie ron", - "ier on", - "iero n", - "▁The orem", - "▁ Theorem", - "▁c asa", - "▁cas a", - "▁ca sa", - "je s", - "j es", - "▁д ере", - "▁де ре", - "▁` \"", - "L D", - "ä ß", - "De b", - "D eb", - "▁su iv", - "▁B ank", - "▁Ban k", - "li bs", - "lib s", - "▁Le on", - "▁Leo n", - "▁qu art", - "▁quar t", - "▁prof essional", - "▁profession al", - "▁profess ional", - "▁t iene", - "▁ti ene", - "▁tie ne", - "▁acc omp", - "▁ac comp", - "▁accom p", - "ст ер", - "сте р", - "с тер", - "▁U K", - "▁ UK", - "N N", - "▁l í", - "ц я", - "ke l", - "k el", - "▁ •", - "▁d ise", - "▁di se", - "▁dis e", - "on to", - "ont o", - "▁m á", - "if s", - "i fs", - "bi ld", - "bil d", - "b ild", - "▁comp ute", - "▁comput e", - "▁ compute", - "▁é d", - "▁ éd", - "j ę", - "▁M é", - "▁l anguages", - "▁language s", - "▁T imes", - "▁Time s", - "▁Tim es", - "▁Ti mes", - "▁ Times", - "ce n", - "c en", - "▁ав то", - "ý m", - "en ez", - "ene z", - "e nez", - "▁u pp", - "▁up p", - "▁ upp", - "▁m éd", - "▁mé d", - "▁cu ando", - "о д", - "Int ent", - "ee rd", - "e erd", - "▁T al", - "▁Ta l", - "off set", - "offs et", - "▁h aben", - "▁ha ben", - "▁hab en", - "▁habe n", - "re me", - "rem e", - "r eme", - "▁St ack", - "▁Sta ck", - "▁ Stack", - "▁d ri", - "▁dr i", - "▁ dri", - "▁sein em", - "▁seine m", - "▁sei nem", - "▁f évrier", - "▁comb ination", - "▁combin ation", - "▁s oll", - "▁so ll", - "▁sol l", - "▁mov ement", - "▁mo vement", - "▁move ment", - "Sp ec", - "Spe c", - "S pec", - "к ры", - "ret ch", - "r etch", - "Off set", - "Ro ot", - "R oot", - "А р", - "wa rt", - "war t", - "w art", - "▁F ollow", - "▁Fol low", - "▁So cial", - "▁Soci al", - "▁Soc ial", - "ни ков", - "ник ов", - "▁ →", - "Do n", - "D on", - "▁h arm", - "▁ha rm", - "▁har m", - "▁ harm", - "ag r", - "a gr", - "ne go", - "neg o", - "n ego", - "re source", - "res ource", - "▁L uc", - "▁Lu c", - "▁se inen", - "▁sein en", - "▁seine n", - "▁sei nen", - "▁De partment", - "▁Depart ment", - "▁Up date", - "▁ Update", - "▁Tex as", - "▁re ve", - "▁rev e", - "▁P os", - "▁Po s", - "▁ Pos", - "▁s hot", - "▁sh ot", - "▁sho t", - "▁ shot", - "ot he", - "oth e", - "o the", - "▁repe ated", - "▁repeat ed", - "▁rec ently", - "▁recent ly", - "áb an", - "á ban", - "ak s", - "a ks", - "па н", - "п ан", - "▁c ha", - "▁ch a", - "▁ cha", - "oh l", - "o hl", - "▁t end", - "▁te nd", - "▁ten d", - "▁д во", - "ch ts", - "cht s", - "ça ise", - "çais e", - "pl ing", - "p ling", - "al bum", - "e j", - "▁` [", - "ma ps", - "map s", - "m aps", - "▁un its", - "▁unit s", - "▁< !--", - "▁", - "St and", - "▁techn ique", - "▁techni que", - "▁E ss", - "▁Es s", - "▁Ox ford", - "▁ ла", - "t ikz", - "ли й", - "Log in", - "Lo gin", - "▁min ister", - "▁minist er", - "▁mini ster", - "▁ minister", - "▁c url", - "▁cu rl", - "▁cur l", - "▁ curl", - "ka n", - "k an", - "▁m aps", - "▁ma ps", - "▁map s", - "▁ maps", - "in da", - "ind a", - "ri eb", - "rie b", - "r ieb", - "▁E ND", - "▁EN D", - "▁ END", - "if ies", - "ifi es", - "ifie s", - "con sole", - "cons ole", - "bu ry", - "bur y", - "b ury", - "▁L E", - "▁ LE", - "▁indep end", - "▁inde pend", - "▁t a", - "▁ ta", - "▁ Ś", - "on el", - "one l", - "o nel", - "és z", - "é sz", - "▁I st", - "▁Is t", - "ut ive", - "uti ve", - "ё л", - "▁Reg ion", - "▁ Region", - "▁( =", - "▁comp act", - "ço is", - "ç ois", - "▁label s", - "▁lab els", - "▁ labels", - "autor ité", - "▁s tan", - "▁st an", - "▁sta n", - "▁ stan", - "▁fran çaise", - "▁français e", - "▁rem oving", - "▁remov ing", - "y c", - "} |", - "▁Ex ec", - "▁ Exec", - "($ _", - "( $_", - "ma g", - "m ag", - "be fore", - "▁stop ped", - "▁sto pped", - "ми и", - "▁ref resh", - "▁ refresh", - "un kt", - "unk t", - "ic io", - "ici o", - "i cio", - "X ml", - "▁T ab", - "▁Ta b", - "▁ Tab", - "▁f ounded", - "▁found ed", - "▁f al", - "▁fa l", - "▁ fal", - "f x", - "▁Histor ia", - "▁Hist oria", - "▁Ear ly", - "▁Earl y", - "Do m", - "D om", - "▁de cide", - "▁dec ide", - "▁decid e", - "▁under stood", - "▁j ur", - "▁ju r", - "▁N r", - "▁cap ac", - "wa s", - "w as", - "▁en emy", - "▁enem y", - "▁program s", - "▁m ask", - "▁ma sk", - "▁mas k", - "▁ mask", - "ск е", - "с ке", - "▁gr oupe", - "▁group e", - "ca m", - "c am", - "▁w idget", - "▁wid get", - "▁ widget", - "RE ATE", - "▁se va", - "▁Bar cel", - "▁p erd", - "▁per d", - "▁pe rd", - "▁М у", - "ran ce", - "r ance", - "TY PE", - "T YPE", - "▁{ '", - "▁ {'", - "▁b ill", - "▁bi ll", - "▁bil l", - "▁\" _", - "' `", - "ba hn", - "bah n", - "b ahn", - "▁cont ained", - "▁contain ed", - "Cl ose", - "C lose", - "ru g", - "r ug", - "eg y", - "e gy", - "▁s ight", - "▁sig ht", - "▁Pro vin", - "▁Prov in", - "н ю", - "ar z", - "a rz", - "ще н", - "щ ен", - "▁J oe", - "▁Jo e", - "▁de leted", - "▁delete d", - "▁delet ed", - "▁A uto", - "▁Aut o", - "▁Au to", - "▁ Auto", - "▁m eter", - "▁me ter", - "▁met er", - "▁ meter", - "C G", - "ъ л", - "▁p ent", - "▁pe nt", - "▁pen t", - "▁ pent", - "▁be zeichnet", - "Su m", - "S um", - "db c", - "d bc", - "▁Pl atz", - "▁Pla tz", - "▁Plat z", - "ect ors", - "ector s", - "e ctors", - "▁L ittle", - "QU E", - "Q UE", - "ці я", - "ц ія", - "те ля", - "тел я", - "nig ht", - "n ight", - "▁l l", - "▁ ll", - "▁most ly", - "UI D", - "U ID", - "▁b ez", - "▁be z", - "▁ bez", - "do b", - "d ob", - "кс и", - "к си", - "ter ne", - "tern e", - "t erne", - "▁cor ner", - "▁corn er", - "at y", - "a ty", - "▁impro ve", - "▁improv e", - "▁impr ove", - "▁in tr", - "▁int r", - "▁` @", - "ar od", - "aro d", - "a rod", - "▁install ation", - "▁instal lation", - "▁Refer ências", - "ig an", - "iga n", - "i gan", - "▁crit ic", - "ad el", - "ade l", - "a del", - "▁се ло", - ", \r", - "at ori", - "ator i", - "ato ri", - "▁F ri", - "▁Fr i", - "▁ Fri", - "▁ré férences", - "▁Int ent", - "▁ Intent", - "▁t ant", - "▁tan t", - "▁ta nt", - "un ci", - "unc i", - "▁level s", - "▁lev els", - "er es", - "ere s", - "e res", - "▁e mer", - "▁em er", - "▁ emer", - "sa fe", - "t k", - "▁c ham", - "▁ch am", - "▁cha m", - "▁great ly", - "▁we it", - "▁ weit", - "▁co ach", - "▁to ward", - "Hom e", - "H ome", - "▁Bo olean", - "▁ Boolean", - "те л", - "т ел", - "▁m ock", - "▁mo ck", - "▁ mock", - "▁appreci ate", - "▁C ross", - "▁Cr oss", - "▁Cro ss", - "▁T ake", - "▁Ta ke", - "▁Tak e", - "▁ Take", - "D P", - "▁s ides", - "▁si des", - "▁side s", - "▁sid es", - "▁Norm daten", - "де й", - "д ей", - "st al", - "sta l", - "s tal", - "▁c out", - "▁co ut", - "▁cou t", - "▁ cout", - "b n", - "▁V ert", - "▁Ver t", - "▁Ve rt", - "▁ Vert", - "▁b ird", - "▁bi rd", - "▁bir d", - "▁ bird", - "▁dynam ically", - "▁dynamic ally", - "▁D ol", - "▁Do l", - "▁B urg", - "▁Bu rg", - "▁Bur g", - "▁d og", - "▁do g", - "▁ dog", - "ät t", - "ä tt", - "▁n uc", - "▁nu c", - "E C", - "By tes", - "Byte s", - "▁a k", - "▁ ak", - "re land", - "rel and", - "r eland", - "▁gu itar", - "▁reg arding", - "▁regard ing", - "▁F uß", - "▁Fu ß", - "▁до л", - "▁ дол", - "au ss", - "aus s", - "a uss", - "▁j ej", - "▁je j", - "ac o", - "a co", - "▁up dates", - "▁update s", - "▁upd ates", - "ру к", - "р ук", - "(' /", - "▁c old", - "▁col d", - "▁co ld", - "▁G iven", - "▁Gi ven", - "▁Give n", - "hi n", - "h in", - "▁fe eling", - "▁feel ing", - "▁fee ling", - "ig li", - "fa h", - "f ah", - "ст ре", - "стр е", - "с тре", - "bo ol", - "b ool", - "init ial", - "▁станов ника", - "▁An na", - "▁Ann a", - "▁h ors", - "▁hor s", - "▁ho rs", - "▁d oll", - "▁do ll", - "▁dol l", - "▁con sum", - "▁cons um", - "▁ consum", - "ub er", - "ube r", - "u ber", - "stand ing", - "stan ding", - "act iv", - "з і", - "check ed", - "▁perm issions", - "▁permission s", - "▁M onte", - "▁Mon te", - "▁Mont e", - "Write Line", - "pl us", - "p lus", - "▁E qu", - "▁Eq u", - "▁ Equ", - "▁и х", - "▁ их", - "ч ки", - "un que", - "▁L O", - "▁ LO", - "e a", - "sam ple", - "s ample", - "ie sz", - "ies z", - "i esz", - "or al", - "ora l", - "o ral", - "▁И н", - "os ton", - "ost on", - "osto n", - "o ston", - "▁S imon", - "▁Sim on", - "▁Si mon", - "fa st", - "fas t", - "f ast", - "m k", - "as sen", - "ass en", - "asse n", - "▁arch itecture", - "▁architect ure", - "▁ architecture", - "ens es", - "ense s", - "▁ Å", - "▁to pic", - "▁top ic", - "▁ topic", - "▁dis able", - "▁ disable", - "▁C ru", - "▁Cr u", - "▁Cont rol", - "▁ Control", - "▁cre ation", - "▁hy per", - "▁hyp er", - "▁ hyper", - "it ud", - "itu d", - "же ния", - "ar am", - "ara m", - "a ram", - "▁г де", - "ien st", - "iens t", - "i enst", - "ed ule", - "edu le", - "▁B ot", - "▁Bo t", - "▁О с", - "▁The ir", - "an ne", - "ann e", - "M icrosoft", - "▁P M", - "▁ PM", - "yd ro", - "y dro", - "ent lich", - "▁E ine", - "▁Ein e", - "CH AR", - ": '", - "We ll", - "Wel l", - "W ell", - "le ton", - "let on", - "l eton", - "▁support s", - "▁sup ports", - "'] )", - "' ])", - "man ual", - "▁v ice", - "▁vi ce", - "▁vic e", - "▁ vice", - "as a", - "a sa", - "cl os", - "clo s", - "c los", - "vi sed", - "vis ed", - "v ised", - "▁p ok", - "▁po k", - "tr ack", - "tra ck", - "t rack", - "но ст", - "нос т", - "... .....", - ".... ....", - "..... ...", - "▁' \\", - "▁ '\\", - "² .", - "▁or ders", - "▁order s", - "▁ord ers", - "▁ orders", - "et ta", - "ett a", - "e tta", - "▁con version", - "▁conv ersion", - "▁convers ion", - "▁t rade", - "▁tr ade", - "▁tra de", - "▁trad e", - "cl i", - "c li", - "▁И сто", - "▁Ис то", - "▁a kt", - "▁ak t", - "▁ akt", - "▁sub set", - "▁subs et", - "▁ subset", - "▁a ug", - "▁au g", - "▁ aug", - "▁le aves", - "▁leave s", - "Mat h", - "Ma th", - "M ath", - "an ned", - "ann ed", - "anne d", - "ka l", - "k al", - "▁Ве ли", - "▁n og", - "▁no g", - "▁ nog", - "▁e th", - "▁et h", - "▁ eth", - "▁h air", - "▁ha ir", - "ar ound", - "aro und", - "a round", - "▁java x", - "▁jav ax", - "▁ javax", - "во й", - "▁C entre", - "▁Cent re", - "ö ß", - "ut i", - "u ti", - "▁n avigation", - "▁navig ation", - "▁ navigation", - "▁P S", - "▁ PS", - "▁w a", - "▁ wa", - "▁Ро ссии", - "▁Рос сии", - "▁Росси и", - "us a", - "u sa", - "ze ta", - "zet a", - "z eta", - "▁P DF", - "▁ PDF", - "▁m ismo", - "▁mis mo", - "▁mism o", - "pro perties", - "me ister", - "ль та", - "for ward", - "▁O st", - "▁Os t", - "ki ns", - "kin s", - "k ins", - "▁s ido", - "▁si do", - "▁sid o", - "зо в", - "з ов", - "ta gs", - "tag s", - "t ags", - "▁a ctor", - "▁act or", - "▁ac tor", - "▁ actor", - "▁f ly", - "▁fl y", - "▁ fly", - "C R", - "ag ini", - "agi ni", - "agin i", - "▁l ett", - "▁le tt", - "▁let t", - "▁ lett", - "en i", - "e ni", - "te ch", - "t ech", - "▁E nc", - "▁En c", - "▁ Enc", - "or acle", - "ora cle", - "o racle", - "amil ton", - "ze j", - "z ej", - "fe n", - "f en", - "ume rate", - "umer ate", - "▁qu esto", - "▁que sto", - "▁q uesto", - "▁quest o", - "da rt", - "dar t", - "d art", - "▁K ore", - "▁Ko re", - "▁Kor e", - "ap is", - "api s", - "a pis", - "ep er", - "e per", - "Sc reen", - "S creen", - "wa ll", - "wal l", - "w all", - "▁is land", - "sh e", - "s he", - "▁l igger", - "▁lig ger", - "в ся", - "fa ng", - "fan g", - "f ang", - "▁t ard", - "▁tar d", - "▁ta rd", - "▁pla ats", - "▁п ло", - "▁ пло", - "▁Off ice", - "▁Offic e", - "▁ Office", - "▁S ET", - "▁SE T", - "▁ SET", - "▁circ uit", - "je d", - "j ed", - "Sa ve", - "S ave", - "ль но", - "So cket", - "S ocket", - "▁In dex", - "▁Ind ex", - "▁ Index", - "AC K", - "A CK", - "id ers", - "ide rs", - "ider s", - "i ders", - "er er", - "ere r", - "e rer", - "▁С ША", - "▁l ady", - "▁la dy", - "▁lad y", - "▁sch eme", - "▁sche me", - "ie lle", - "iel le", - "i elle", - "▁ex erc", - "▁exer c", - ")} \\", - ") }\\", - "Date Time", - "at han", - "ath an", - "a than", - "▁Prof essor", - "▁mo ins", - "▁moi ns", - "▁Ex cel", - "▁ Excel", - "▁H ay", - "▁Ha y", - "▁Mus ik", - "▁ ї", - "ę d", - "▁\" .", - "▁ \".", - "▁бу в", - "▁inst rument", - "▁instru ment", - "па р", - "п ар", - "▁б ере", - "▁бе ре", - "▁ бере", - "▁polit ique", - "▁trad ition", - "▁V M", - "▁ VM", - "▁Ar ts", - "▁Art s", - "▁C i", - "Us e", - "U se", - "▁a ggreg", - "▁ag greg", - "▁ aggreg", - "▁we eks", - "▁week s", - "▁o pport", - "▁op port", - "▁opp ort", - "it ing", - "iti ng", - "i ting", - "▁vert ical", - "▁ vertical", - "▁N az", - "▁Na z", - ".. .)", - "... )", - "iz o", - "i zo", - "▁c ycle", - "▁cy cle", - "▁cycl e", - "▁ cycle", - "▁tem po", - "▁temp o", - "т ре", - "▁hand ling", - "ist ence", - "isten ce", - "▁p aste", - "▁pas te", - "▁pa ste", - "▁past e", - "▁ paste", - "▁en jo", - "RO UP", - "▁o uter", - "▁out er", - "▁ou ter", - "▁ outer", - "▁su pply", - "▁supp ly", - "▁sup ply", - "em an", - "ema n", - "e man", - "▁acc ident", - "▁\\ ]", - "▁ \\]", - "▁те х", - "▁ тех", - "Po ol", - "P ool", - "ot ing", - "oti ng", - "o ting", - "onym ous", - "▁Gi ov", - "▁u d", - "▁ ud", - "▁. /", - "▁ ./", - "ER ROR", - "ERR OR", - "con struct", - "const ruct", - "text width", - "qu ipe", - "qui pe", - "quip e", - "case s", - "cas es", - "c ases", - "▁а д", - "▁R ow", - "▁Ro w", - "▁ Row", - "Hol der", - "Hold er", - "H older", - "wa n", - "w an", - "ar na", - "arn a", - "Me m", - "M em", - "▁Canad ian", - "▁Com mission", - "▁Comm ission", - "su n", - "s un", - "▁app s", - "▁ap ps", - "▁ apps", - "▁B lo", - "▁Bl o", - "▁i hrer", - "▁ih rer", - "▁ihr er", - "▁ihre r", - "▁famil le", - "▁fam ille", - "▁m ě", - "▁p y", - "▁ py", - "и с", - "▁т ого", - "▁то го", - "▁ того", - "▁Ag ain", - "▁ign ore", - "▁ignor e", - "▁ ignore", - "▁tele vision", - "▁televis ion", - "Pa t", - "P at", - "hi de", - "h ide", - "▁R ev", - "▁Re v", - "▁b ear", - "▁be ar", - "ph y", - "p hy", - "▁no ise", - "▁w ra", - "▁wr a", - "at ionale", - "ation ale", - "ational e", - "▁coll abor", - "bor der", - "b order", - "▁el ected", - "▁elect ed", - "▁ele cted", - "▁sur pr", - "▁a voir", - "▁av oir", - "▁avo ir", - "▁ avoir", - "▁ass embly", - "▁assemb ly", - "▁ assembly", - "▁об ще", - "▁arbitr ary", - "▁br ief", - "▁- --", - "▁-- -", - "▁ ---", - "▁M aur", - "▁Ma ur", - "▁Mau r", - "gr ession", - "gress ion", - "g ression", - "ic ia", - "ici a", - "i cia", - "▁lie gt", - "▁Fig ure", - "▁on to", - "▁ont o", - "▁ onto", - "Re pository", - "Repos itory", - "▁dé f", - "▁f orth", - "▁for th", - "▁fort h", - "▁cl icked", - "▁click ed", - "se ite", - "▁n otes", - "▁not es", - "▁no tes", - "▁note s", - "▁ notes", - "nat ive", - "n ative", - "▁ED IT", - "▁ EDIT", - "ы е", - "M T", - "am ental", - "ament al", - "amen tal", - "▁r ose", - "▁ro se", - "▁ros e", - "▁ rose", - "▁pu ede", - "▁pue de", - "De legate", - "Deleg ate", - "ub a", - "u ba", - "ne o", - "xi s", - "x is", - "▁Ar thur", - "UR E", - "U RE", - "am ing", - "ami ng", - "amin g", - "a ming", - "De vice", - "Dev ice", - "▁d iam", - "▁di am", - "▁dia m", - "st änd", - "▁p ron", - "▁pro n", - "▁pr on", - "oi s", - "o is", - "com ing", - "co ming", - "c oming", - "Param eters", - "Parameter s", - "uv ud", - "▁ab ility", - "▁ ability", - "▁m ét", - "▁mé t", - "▁Un fortunately", - "f d", - "D ictionary", - "so cket", - "sock et", - "s ocket", - "▁con oc", - "▁co noc", - "cont ains", - "es sed", - "ess ed", - "esse d", - "▁gel dig", - "▁geld ig", - "ни ца", - "ниц а", - "▁point ed", - "es ti", - "est i", - "no m", - "n om", - "ографи я", - "▁represent s", - "▁repres ents", - "▁man ip", - "wor ld", - "w orld", - "▁resol ved", - "▁resolve d", - "te gr", - "t egr", - "▁d ort", - "▁do rt", - "▁dor t", - "as tern", - "ast ern", - "aster n", - "aste rn", - "▁camp aign", - "▁pr imo", - "▁prim o", - "▁pri mo", - "▁; ;", - "▁ ;;", - "▁sni ppet", - "▁N ik", - "▁Ni k", - "To tal", - "T otal", - "iss ement", - "isse ment", - "AC E", - "A CE", - "▁ver ify", - "▁ verify", - "if fe", - "iff e", - "i ffe", - "la gen", - "lag en", - "lage n", - "l agen", - "ie ur", - "ieu r", - "i eur", - "▁convert ed", - "▁conver ted", - "▁Mil it", - "▁Mi lit", - "▁A lg", - "▁Al g", - "▁ Alg", - "▁R on", - "▁Ro n", - "▁k onn", - "▁kon n", - "▁ko nn", - "ap ple", - "app le", - "▁dis pos", - "▁disp os", - "stell ung", - "▁re tain", - "▁ret ain", - "▁m entre", - "▁men tre", - "▁ment re", - "▁ne ut", - "▁neu t", - "▁ neut", - "▁N ight", - "ch é", - "c hé", - "at ti", - "att i", - "▁o bra", - "▁ob ra", - "▁super ior", - "▁Con gress", - "▁Cong ress", - "ё м", - "▁c odes", - "▁code s", - "▁co des", - "▁cod es", - "▁ codes", - "▁A ma", - "▁Am a", - "▁E arth", - "▁Ear th", - "▁oppos ite", - "▁p ool", - "▁po ol", - "▁ pool", - "▁D un", - "▁Du n", - "же ние", - "▁\" ${", - "▁\"$ {", - "in v", - "▁у ни", - "▁And rew", - "▁Andre w", - "те лей", - "тел ей", - "▁by ł", - "Un ivers", - "Uni vers", - "▁Ang ular", - "an im", - "ani m", - "a nim", - "до ва", - "дов а", - "д ова", - "BU G", - "B UG", - "ut ely", - "ute ly", - "▁draw ing", - "▁dra wing", - "▁g ain", - "▁ga in", - "▁four th", - "▁Pro blem", - "▁ Problem", - "▁sudden ly", - "▁ Ä", - "on na", - "onn a", - "▁K ont", - "▁Kon t", - "▁Ko nt", - "▁Bilder n", - "▁Bild ern", - "▁Bil dern", - "▁konn te", - "ž e", - "Tr ace", - "Tra ce", - "T race", - "▁sec ure", - "▁ secure", - "▁któ ry", - "▁e q", - "▁ eq", - "▁f ormal", - "▁for mal", - "▁form al", - "▁forma l", - "amer ikan", - "▁A nal", - "▁An al", - "▁Ana l", - "▁ Anal", - "▁R ewrite", - "▁Re write", - "▁D ouble", - "▁Dou ble", - "▁ Double", - "cre ated", - "create d", - "N U", - "MD b", - "M Db", - "ap es", - "ape s", - "a pes", - "Un is", - "Uni s", - "U nis", - "▁e special", - "▁espe cial", - "▁espec ial", - "}) \\", - "} )\\", - "ed om", - "edo m", - "e dom", - "▁c ategor", - "▁categ or", - "Re turn", - "Ret urn", - "▁H amb", - "▁Ha mb", - "▁Ham b", - "▁R io", - "▁Ri o", - "▁M ir", - "▁Mi r", - "▁G eme", - "▁Ge me", - "▁Gem e", - "ab ilities", - "abil ities", - "tr z", - "t rz", - "us et", - "use t", - "u set", - "ier ra", - "net work", - "n etwork", - "▁do ctor", - "▁doc tor", - "eur s", - "eu rs", - "e urs", - "▁l isten", - "▁li sten", - "▁list en", - "▁liste n", - "▁ listen", - "д ж", - "▁H ö", - "▁cons ists", - "▁consist s", - "as m", - "a sm", - "Ch r", - "C hr", - "al and", - "ala nd", - "a land", - "▁испо ль", - "▁ис поль", - "▁испол ь", - "▁lug ar", - "▁lu gar", - "▁def initely", - "▁definit ely", - "▁definite ly", - "mo ve", - "mov e", - "m ove", - "úblic a", - "ú blica", - "▁l än", - "▁lä n", - "is mus", - "ism us", - "▁др жа", - "▁d t", - "▁ dt", - "▁Per haps", - "▁Bra sil", - "▁Bras il", - "Jo hn", - "J ohn", - "▁prom ise", - "ł u", - "re ens", - "ree ns", - "reen s", - "▁ps ych", - "▁W ho", - "▁Wh o", - "▁ Who", - "ря д", - "▁IN TO", - "▁INT O", - "▁Pe ople", - "▁Will iams", - "▁William s", - "▁M arg", - "▁Mar g", - "▁Ma rg", - "▁д ан", - "▁да н", - "▁ дан", - "re cord", - "rec ord", - "▁E uro", - "▁Eu ro", - "▁Eur o", - "▁Virgin ia", - "▁R est", - "▁Re st", - "▁Res t", - "▁ Rest", - "▁C orn", - "▁Cor n", - "▁Co rn", - "}} ,", - "} },", - "▁G rid", - "▁Gr id", - "▁ Grid", - "▁in ject", - "▁inj ect", - "▁ inject", - "на н", - "н ан", - "▁c row", - "▁cr ow", - "▁cro w", - "▁Ph ys", - "▁ Phys", - "▁D O", - "▁ DO", - "▁\" -", - "▁incre ased", - "▁increase d", - "ach er", - "ac her", - "ache r", - "a cher", - "pe at", - "Li n", - "L in", - "▁D ub", - "▁Du b", - "ri ces", - "ric es", - "rice s", - "r ices", - "ag nost", - "agn ost", - "d l", - "▁cur ve", - "▁curv e", - "ü g", - "ri ce", - "ric e", - "r ice", - "l anguage", - "Click Listener", - "▁municip al", - "▁O ri", - "▁Or i", - "▁ Ori", - "▁B ild", - "▁Bi ld", - "▁Bil d", - "▁C ab", - "▁Ca b", - "▁V ar", - "▁Va r", - "▁ Var", - "▁n oted", - "▁not ed", - "▁no ted", - "▁note d", - "▁ Î", - "▁s ubs", - "▁su bs", - "▁sub s", - "ia tion", - "iat ion", - "i ation", - "W OR", - "in gly", - "ing ly", - "▁R us", - "▁Ru s", - "ie ns", - "ien s", - "i ens", - "IN FO", - "INF O", - "к ва", - "at ivo", - "ativ o", - "ati vo", - "ge nde", - "gen de", - "g ende", - "▁Fran z", - "▁Fr anz", - "▁is ol", - "▁i sol", - "ed es", - "ede s", - "e des", - "ni er", - "nie r", - "n ier", - "▁N O", - "▁ NO", - "▁H as", - "▁Ha s", - "▁ Has", - "be ans", - "bean s", - "▁p andas", - "▁pan das", - "▁ pandas", - "(\" %", - "ві т", - "ут бо", - "▁g ather", - "▁ga ther", - "▁gat her", - "▁le gal", - "▁leg al", - "▁ legal", - "in clud", - "▁circum st", - "cript or", - "ri ble", - "rib le", - "r ible", - "▁S üd", - "▁Sü d", - "▁a pro", - "▁ap ro", - "▁apr o", - "Ap i", - "A pi", - "▁на й", - "▁Afr ican", - "▁Africa n", - "ow ski", - "ows ki", - "▁John son", - "ie k", - "i ek", - "▁v ote", - "▁vo te", - "▁vot e", - "▁ vote", - "▁K an", - "▁Ka n", - "▁b ibli", - "▁bib li", - "▁ bibli", - "▁h aar", - "▁ha ar", - "▁v r", - "▁ vr", - "]) ,", - "] ),", - "subset eq", - "Par ser", - "Parse r", - "ia ni", - "ian i", - "i ani", - "is é", - "id ea", - "ide a", - "On ly", - "▁á l", - "▁ ál", - "▁C atal", - "▁Ca tal", - "▁Cat al", - "▁C ase", - "▁Cas e", - "▁Ca se", - "▁ Case", - "se h", - "s eh", - "▁en counter", - "▁enc ounter", - "▁re form", - "▁ref orm", - "ми ни", - "мин и", - "▁S tre", - "▁St re", - "▁Str e", - "ex ception", - "except ion", - "▁T ar", - "▁Ta r", - "та р", - "т ар", - "tr l", - "t rl", - "▁А лександ", - "ле кт", - "лек т", - "equ al", - "eq ual", - "e qual", - "O p", - "▁l if", - "▁li f", - "▁й ого", - "▁volt age", - "▁volta ge", - "sh ire", - "s hire", - "▁Gro ß", - "в ня", - "ning s", - "n ings", - "н ци", - "▁l ag", - "▁la g", - "▁ lag", - "▁and eren", - "▁andere n", - "▁v ac", - "▁va c", - "▁ma cro", - "▁mac ro", - "▁ macro", - "= [", - "Th en", - "The n", - "T hen", - "▁control s", - "▁contr ols", - "▁contro ls", - "▁ controls", - "se q", - "s eq", - "olog ies", - "ologie s", - "▁select or", - "▁sel ector", - "▁sele ctor", - "▁ selector", - "▁Украї ни", - "хів овано", - "ы й", - "allen ge", - "alleng e", - "▁I MDb", - "▁IM Db", - "um my", - "umm y", - "ye n", - "y en", - "▁b este", - "▁be ste", - "▁best e", - "▁bes te", - "▁B ox", - "▁Bo x", - "▁ Box", - "▁ch air", - "▁cha ir", - "▁S ab", - "▁Sa b", - "er de", - "erd e", - "▁n ast", - "▁na st", - "▁nas t", - "iv amente", - "iva mente", - "▁об ъ", - "▁require ments", - "▁requirement s", - "▁me eting", - "▁meet ing", - "▁fin an", - "���fi nan", - "▁A dam", - "▁Ad am", - "▁Ada m", - "▁tele vis", - "▁b right", - "▁br ight", - "▁brig ht", - "▁G it", - "▁Gi t", - "▁ Git", - "E G", - "▁G il", - "▁Gi l", - "r ès", - "▁C ond", - "▁Con d", - "▁Co nd", - "▁ Cond", - "▁f t", - "▁ ft", - "▁бу ло", - "- +", + "ap eutic", + "▁or \n\n", + "▁pro gress", + "▁ad enocarcinoma", + "e▁to ▁the▁", + "ed▁b efore▁", + "▁of▁ 81", + "▁3 7", + "▁con comitant", + "olog y▁and▁", + "ail y", + "s.▁ J", + "ens ity", + "▁G uidelin", + "s.\n\n S", + "▁has▁ not", + "ymptom atic", + "▁must▁be▁ obtain", + "ros pective▁", + "-200 6", + "related▁to ▁the▁", + "ify ▁the▁", + "▁October ▁2010", + "▁par agraph", + "imilar ▁to", + "C0001 5", + "▁Report ing", + "statist ical", + "▁power ▁to▁detect", + "aps ul", + "▁regulator y", + "▁discus sion", + "withdrawn ▁from", + "cient ific", + "W ild-type▁KRAS", + "a -", + "l ational▁", + "r ate▁of", + "v ital▁sign", + "y oc", + "s▁ who", + ",▁ con", + "ed ;", + "ed ,▁and▁", + "▁of ▁C", + "▁m ight", + "▁and▁ bevacizumab", + "ur e▁in", + "▁( E", + "▁I RB", + "un able▁to", + "▁O r", + "eas ure▁", + "▁treatment ▁for", + "▁v ia", + "follow ing▁the▁", + "▁any▁ reason", + "\n\nD ose▁", + "s▁and▁ symptom", + "▁J apan", "EN D", - "E ND", - "er ne", - "ern e", - "▁Com put", - "▁Comp ut", - "▁ Comput", - "▁i ls", - "▁il s", - "▁ ils", - "▁g all", - "▁gal l", - "▁ga ll", - "▁c sv", - "▁cs v", - "▁ csv", - "łu g", - "ł ug", - "▁sum mer", - "▁summ er", - "ga me", - "g ame", - "▁pos ts", - "▁post s", - "▁ posts", - "Ар хівовано", - "▁z ij", - "▁de termin", - "▁determ in", - "▁ab andon", - "co unter", - "count er", - "c ounter", - "▁require ment", - "▁requ irement", - "▁T it", - "▁Ti t", - "irt ual", - "▁V ideos", - "▁Video s", - "▁qu iet", - "▁qui et", - "▁T erm", - "▁Te rm", - "▁Ter m", - "▁ Term", - "▁time out", - "▁ timeout", - "Pr int", - "▁in vent", - "▁inv ent", - "▁inve nt", - "la is", - "l ais", - "▁mon itor", - "ha lb", - "hal b", - "▁W ild", - "▁Wil d", - "▁Wi ld", - "▁le ader", - "▁lead er", - "▁с ель", - "▁се ль", - "▁util iz", - "▁par ents", - "▁parent s", - "▁for ced", - "▁force d", - "▁pro ved", - "▁pr oved", - "▁prov ed", - "▁prove d", - "▁effect ive", - "▁l lam", - "▁ll am", - "▁С по", - "or b", - "o rb", - "gg i", - "g gi", - "▁ass umption", - "▁assum ption", - "▁su bm", - "▁sub m", - "▁в ій", - "▁ві й", - "il ia", - "ili a", - "i lia", - "▁re verse", - "▁revers e", - "▁rever se", - "▁ reverse", - "' \"", - "▁qu otes", - "▁quot es", - "▁quote s", - "▁s ites", - "▁si tes", - "▁site s", - "▁sit es", - "▁ sites", - "ig ung", - "igu ng", - "▁A rg", - "▁Ar g", - "▁ Arg", - "D ouble", - "▁s creens", - "▁sc reens", - "▁screen s", - "▁cl ause", - "▁cla use", - "▁b undle", - "▁bund le", - "▁ bundle", - "▁phil osoph", - "▁N um", - "▁Nu m", - "▁ Num", - "▁g leich", - "▁gle ich", - "▁ gleich", - "ul y", - "u ly", - "dir ect", - "di rect", - "dire ct", - "d irect", - "asket ball", - "ow any", - "owa ny", - "owan y", - "\\} $", - "\\ }$", - "▁rad ius", - "▁radi us", - "▁ radius", - "▁S earch", - "▁Se arch", - "▁ Search", - "Pro perties", - "▁e lev", - "▁el ev", - "▁ele v", - "▁p rod", - "▁pro d", - "▁pr od", - "▁ prod", - "▁\" %", - "is ión", - "isi ón", - "De bug", - "Deb ug", - "Se cond", - "Sec ond", - "( !", - "▁C atholic", - "ро ван", - "ров ан", - "рова н", - "р ован", - "le z", - "l ez", - "P a", - "ps on", - "p son", - "▁er ste", - "▁erst e", - "▁ers te", - "▁F u", - "▁l it", - "▁li t", - "▁ lit", - "▁S aison", - "▁Sa ison", - "▁H ash", - "▁Ha sh", - "▁Has h", - "▁ Hash", - "▁ex em", - "▁пред став", - ") *", - "▁e u", - "▁ eu", - "▁ │", - "▁g ab", - "▁ga b", - "eta iled", - "Co py", - "C opy", - "▁д ва", - "ev en", - "e ven", - "K ind", - "▁Jack son", - "а л", - "▁con sec", - "▁cons ec", - "▁conse c", - "US ER", - "USE R", - "U SER", - "▁T ok", - "▁To k", - "( .", - "▁$ |", - "▁T amb", - "▁Ta mb", - "▁Tam b", - "▁Lem ma", - "ha ng", - "han g", - "h ang", - "▁cont ribution", - "▁contrib ution", - "▁contribu tion", - "roll ers", - "rol lers", - "roller s", - "rolle rs", - "▁stud ies", - "▁studi es", - "▁p oi", - "▁po i", - "ge ms", - "gem s", - "g ems", - "▁U P", - "▁ UP", - "▁W ol", - "▁Wo l", - "> \"", - "▁f loor", - "▁fl oor", - "▁flo or", - "▁ floor", - "▁init ialize", - "▁initial ize", - "▁ initialize", - "▁L ew", - "▁Le w", - "ze k", - "z ek", - "ar te", - "art e", - "▁pos itions", - "▁position s", - "▁posit ions", - "▁por tion", - "▁port ion", - "co ver", - "cov er", - "c over", - "w p", - "ов ого", - "ово го", - "о вого", - "▁p iano", - "▁pi ano", - "▁pian o", - "▁pia no", - "▁m etal", - "▁me tal", - "▁met al", - "▁meta l", - "▁s amples", - "▁sam ples", - "▁sample s", - "▁ samples", - "▁С ан", - "▁Са н", - "vari able", - "▁ста ть", - "▁inte gers", - "▁integer s", - "Wh ere", - "W here", - "famil y", - "▁n un", - "▁nu n", - "▁in crement", - "▁incre ment", - "▁ increment", - "ix ed", - "▁he eft", - "ft e", - "f te", - "▁v il", - "▁vi l", - "▁ vil", - "▁ot ros", - "▁otro s", - "Mult imedia", - "Multi media", - "▁Hen ri", - "ad ed", - "ade d", - "a ded", - "ге н", - "г ен", - "▁cap it", - "▁ca pit", - "▁други х", - "is p", - "i sp", - "IT Y", - "I TY", - "▁constraint s", - "▁K irche", - "▁Kir che", - "▁Kirch e", - "fo und", - "f ound", - "ши й", - "▁p ic", - "▁pi c", - "▁ pic", - "▁t ou", - "▁to u", - "cre d", - "cr ed", - "c red", - "ро б", - "р об", - "▁M ess", - "▁Me ss", - "▁Mes s", - "▁ Mess", - "Jo b", - "J ob", - "▁M ais", - "▁Ma is", - "▁Mai s", - "▁st yles", - "▁style s", - "▁sty les", - "▁ styles", - "fa ll", - "fal l", - "f all", - "▁U k", - "▁st reet", - "▁stre et", - "▁ street", - "oc cer", - "occ er", - "es en", - "ese n", - "e sen", - "▁col ors", - "▁color s", - "▁ colors", - "ce an", - "ю ще", - "con ne", - "conn e", - "c onne", - "▁r atio", - "▁rat io", - "an ton", - "ant on", - "anto n", - "▁F el", - "▁Fe l", - "▁custom er", - "▁cust omer", - "▁ customer", - "▁P rix", - "▁Pr ix", - "▁Pri x", - "rá s", - "r ás", - "pr ed", - "pre d", - "p red", - "▁elect ron", - "▁electro n", - "s ym", - "▁ве ли", - "▁ вели", - "▁over flow", - "▁ overflow", - "▁$ [", - "▁P OST", - "▁PO ST", - "▁ POST", - "▁C in", - "▁Ci n", - "sc heid", - "sche id", - "(\" /", - "( \"/", - "▁search ing", - "▁pur poses", - "▁purpose s", - "▁arr ived", - "▁arriv ed", - "▁arrive d", - "▁p unt", - "▁pu nt", - "▁pun t", - "▁l ad", - "▁la d", - "▁ lad", - "P ython", - "▁le ads", - "▁lead s", - "▁s and", - "▁sa nd", - "▁san d", - "па да", - "пад а", - "▁comm unes", - "▁commun es", - "▁commune s", - "▁CH AP", - "▁c aso", - "▁cas o", - "▁ca so", - "r z", - "▁d w", - "▁ dw", - "ac a", - "a ca", - "▁Col umb", - "child ren", - "ê t", - "sch emas", - "sche mas", - "schema s", - "▁instru ctions", - "▁instruction s", - "▁instruct ions", - "▁- \\", - "▁ -\\", - "▁Is rael", - "▁Isra el", - "no ści", - "▁об раз", - "▁обра з", - "▁ образ", - "▁со вет", - "▁сов ет", - "▁imm agini", - "▁F red", - "▁Fre d", - "▁Fr ed", - "▁G lobal", - "▁Glo bal", - "▁ Global", - "▁th ick", - "▁ thick", - "▁fue ron", - "▁fuer on", - "▁th rown", - "▁thr own", - "▁throw n", - "▁thro wn", - "▁c lock", - "▁cl ock", - "▁clo ck", - "▁ clock", - "en able", - "ena ble", - "'' '", - "' ''", - "▁S und", - "▁Su nd", - "▁Sun d", - "▁cont empor", - "an swer", - "ans wer", - "▁man ufact", - "▁i o", - "▁ io", - "q quad", - "OU T", - "O UT", - "▁L ab", - "▁La b", - "▁ Lab", - "▁Z w", - "le gal", - "leg al", - "▁V el", - "▁Ve l", - "▁ra ise", - "▁ raise", - "▁de liver", - "▁del iver", - "▁deli ver", - "▁V oir", - "▁Vo ir", - "▁ass umed", - "▁assum ed", - "▁assume d", - "Le t", - "L et", - "ier ten", - "iert en", - "ierte n", - "i erten", - "▁K ong", - "▁Kon g", - "▁Ko ng", - "▁E xp", - "▁Ex p", - "▁ Exp", - "▁J ug", - "▁Ju g", - "▁dec laration", - "▁declar ation", - "▁F ish", - "m é", - "▁spe ech", - "▁t ent", - "▁te nt", - "▁ten t", - "▁R oute", - "▁Ro ute", - "▁Rou te", - "▁Rout e", - "▁ Route", - "__ (", - "_ _(", - "▁ré alis", - "▁réal is", - "▁De sign", - "▁Des ign", - "set Text", - "▁St ation", - "▁Stat ion", - "▁Sta tion", - "▁Stati on", - "▁ Station", - "ar chy", - "arch y", - "arc hy", - "▁ка то", - "▁d ent", - "▁de nt", - "▁den t", - "▁ dent", - "▁K l", - "i ß", - "▁r isk", - "▁ris k", - "▁ri sk", - "▁B road", - "▁Bro ad", - "▁v ectors", - "▁ve ctors", - "▁vector s", - "▁S pec", - "▁Sp ec", - "▁Spe c", - "▁ Spec", - "▁ro utes", - "▁route s", - "▁rout es", - "▁rou tes", - "▁ routes", - "ym n", - "y mn", - "▁G reg", - "▁Gr eg", - "▁Gre g", - "▁полу чи", - "gi e", - "g ie", - "OR M", - "ве де", - "вед е", - "в еде", - "wa lt", - "wal t", - "w alt", - "▁e fter", - "P tr", - "▁su bt", - "▁sub t", - "▁b irth", - "▁bir th", - "▁dr awn", - "▁draw n", - "▁dra wn", - "me ss", - "mes s", - "m ess", - "мери кан", - "V E", - "▁P ut", - "▁Pu t", - "▁ Put", - "▁a sc", - "▁as c", - "▁ asc", - "▁f eder", - "▁fe der", - "▁fed er", - "с ли", - "▁P rin", - "▁Pr in", - "▁Pri n", - "▁s tick", - "▁st ick", - "re set", - "res et", - "y k", - "st udio", - "stud io", - "▁St ill", - "Con st", - "Cons t", - "ac ió", - "aci ó", - "a ció", - "▁Portug al", - "▁script s", - "▁scri pts", - "▁ scripts", - "und ial", - "▁l ives", - "▁li ves", - "▁live s", - "▁liv es", - "▁s zer", - "▁sz er", - "▁sze r", - "▁est ado", - "▁esta do", - "▁estad o", - "fo lder", - "fol der", - "fold er", - "f older", - "▁communic ation", - "Ro ute", - "Rout e", - "R oute", - "▁sw ift", - "▁ swift", - "те н", - "т ен", - "▁k ill", - "▁kil l", - "▁ki ll", - "▁ kill", - "▁P R", - "▁ PR", - "jo int", - "join t", - "j oint", - "▁ob jective", - "▁object ive", - "▁comp licated", - "▁Ü ber", - "es h", - "e sh", - "p icture", - "ra ine", - "rain e", - "rai ne", - "r aine", - "com put", - "comp ut", - "▁pro port", - "▁pr oport", - "▁prop ort", - "▁propor t", - "og s", - "o gs", - "ül t", - "ü lt", - "▁quant um", - "к ри", - "▁s op", - "▁so p", - "▁lo ops", - "▁loop s", - "▁Re ference", - "▁Refer ence", - "▁ Reference", - "▁n ei", - "▁ne i", - "IC E", - "I CE", - "▁v erm", - "▁ver m", - "▁ve rm", - "▁a dj", - "▁ad j", - "▁ adj", - "▁per ò", - "▁t rou", - "▁tr ou", - "▁tro u", - "is ions", - "ision s", - "isi ons", - "▁App le", - "▁Ap ple", - "serv able", - "▁B oston", - "▁Bo ston", - "▁Bos ton", - "or et", - "ore t", - "o ret", - "ok s", - "o ks", - "▁k g", - "▁ kg", - "def ined", - "define d", - "defin ed", - "d efined", - "pl atform", - "cl er", - "cle r", - "c ler", - "ograph ic", - "ri tt", - "rit t", - "r itt", - "▁d ic", - "▁di c", - "▁ dic", - "▁M ond", - "▁Mon d", - "▁Mo nd", - "▁I reland", - "▁Ir eland", - "▁U na", - "▁Un a", - "▁commer cial", - "▁P u", - "D i", - "▁е ё", - "▁pre cis", - "▁prec is", - "на род", - "нар од", - "▁qu atre", - "ust ral", - "ustr al", - "▁d ag", - "▁da g", - "▁ dag", - "ig ue", - "igu e", - "i gue", - "▁b urn", - "▁bu rn", - "▁bur n", - "▁ burn", - "▁offic er", - "▁office r", - "▁А в", - "▁high light", - "▁ highlight", - "▁Supp ose", - "▁Sup pose", - "od i", - "o di", - "serv let", - "▁En cyc", - "▁Enc yc", - "▁R ange", - "▁Ran ge", - "▁Rang e", - "▁ Range", - "ти й", - "P lease", - "▁ро ків", - "qu ant", - "qua nt", - "▁f lat", - "▁fl at", - "▁fla t", - "▁ flat", - "▁Ré férence", - "сле дова", - "след ова", - "ro le", - "rol e", - "r ole", - "▁d iesen", - "▁di esen", - "▁die sen", - "▁dies en", - "▁diese n", - "}} (", - "} }(", - "▁Ind ust", - "▁nú mer", - "▁\" ;", - "▁ \";", - "lu s", - "l us", - "ô le", - "▁z m", - "▁ zm", - "de g", - "d eg", - "▁r ough", - "▁ro ugh", - "▁rou gh", - "▁ rough", - "In v", - "▁h ur", - "▁hu r", - "▁R ess", - "▁Re ss", - "▁Res s", - "ch s", - "c hs", - "▁turn s", - "▁tur ns", - "ne ro", - "ner o", - "n ero", - "function s", - "fun ctions", - "ал и", - "а ли", - "▁hab itants", - "▁habit ants", - "а т", - "iss ues", - "issue s", - "▁h uge", - "▁hu ge", - "Util s", - "▁S at", - "▁Sa t", - "▁го судар", - "▁co ast", - "sh ape", - "sha pe", - "s hape", - "L C", - "▁log ging", - "▁ logging", - "en dor", - "end or", - "endo r", - "▁l ies", - "▁li es", - "▁lie s", - "▁ lies", - "▁d ifer", - "▁di fer", - "▁dif er", - "▁crit ical", - "▁critic al", - "X T", - "ми на", - "мин а", - "an sk", - "ans k", - "Result s", - "k c", - "ivers e", - "iver se", - "i verse", - "EX T", - "E XT", - "AL SE", - "▁v ál", - "▁vá l", - "P i", - "comp ile", - "hel lo", - "hell o", - "h ello", - "▁чем пи", - "▁It alia", - "▁Ital ia", - "▁ Italia", - "ко ло", - "кол о", - "к оло", - "▁ed ition", - "▁edit ion", - "gr und", - "gru nd", - "g rund", - "▁data frame", - "▁Follow ing", - "re ib", - "rei b", - "▁J eff", - "▁Je ff", - "▁citt à", - "IT able", - "I Table", - "▁$ (\\", - "▁$( \\", - "▁redu ced", - "▁reduce d", - "ob il", - "obi l", - "o bil", - "▁any where", - "' (", - "▁p hr", - "▁ph r", - "▁ phr", - "▁K h", - "▁F rame", - "▁Fr ame", - "▁Fra me", - "▁ Frame", - "▁man ual", - "▁ manual", - "▁c ra", - "▁cr a", - "▁ cra", - "▁V S", - "▁ VS", - "% =", - "Instance State", - "▁б ра", - "▁ бра", - "▁D rag", - "▁Dr ag", - "▁Dra g", - "▁ Drag", - "▁H err", - "▁He rr", - "▁Her r", - "▁г у", - "▁ гу", - "▁m ús", - "To ol", - "T ool", - "▁P rivate", - "▁Priv ate", - "▁ Private", - "▁s ynchron", - "▁syn chron", - "ir ation", - "ira tion", - "irat ion", - "▁о бо", - "▁об о", - "▁typ ically", - "▁typical ly", - "▁imp licit", - "or ient", - "ori ent", - "orie nt", - "▁t imer", - "▁time r", - "▁tim er", - "▁ti mer", - "▁ timer", - "▁kön nen", - "ie st", - "ies t", - "i est", - "ra id", - "rai d", - "▁expression s", - "▁express ions", - "▁expr essions", - "▁a im", - "▁ai m", - "▁s tre", - "▁st re", - "▁str e", - "▁ stre", - "▁w rap", - "▁wr ap", - "▁wra p", - "▁ wrap", - "▁B art", - "▁Bar t", - "▁Ba rt", - "▁b ron", - "▁br on", - "▁bro n", - "▁key board", - "po w", - "p ow", - "▁gru po", - "▁grup o", - "▁ре зу", - "▁prof essor", - "▁profess or", - "▁H ead", - "▁He ad", - "▁ Head", - "но ю", - "min us", - "m inus", - "▁Mich el", - "▁Mic hel", - "NO T", - "N OT", - "mo r", - "m or", - "] }", - "wide hat", - "ar is", - "ari s", - "a ris", - "тера тура", - "de fn", - "def n", - "is trz", - "ist rz", - "istr z", - "▁t anto", - "▁tan to", - "▁tant o", - "▁P ow", - "▁Po w", - "▁ind icate", - "▁indic ate", - "▁W inter", - "▁Win ter", - "res hold", - "resh old", - "рі в", - "р ів", - "▁` (", - "▁o wner", - "▁own er", - "▁ow ner", - "▁ owner", - "▁d isp", - "▁di sp", - "▁dis p", - "▁к ри", - "▁ кри", - "ме т", - "м ет", - "мен т", - "м ент", - "re port", - "rep ort", - "repo rt", - "re quire", - "▁v oy", - "▁vo y", - "▁ voy", - "▁A P", - "▁ AP", - "▁Esp aña", - "▁Españ a", - "▁S ão", - "j är", - "No n", - "N on", - "Li brary", - "L ibrary", - "ich ten", - "icht en", - "ichte n", - "i chten", - "▁struct ures", - "▁structure s", - "▁m uy", - "▁mu y", - "ár io", - "á rio", - "▁cert ificate", - "▁certific ate", - "чно го", - "ч ного", - "▁prov ince", - "▁provin ce", - "pa ges", - "page s", - "pag es", - "p ages", - "da l", - "d al", - "▁Fre der", - "▁Fr eder", - "▁Fred er", - "ь е", - "Exec ute", - "▁an cient", - "▁anci ent", - "▁anc ient", - "▁ancien t", - "▁fil ms", - "▁film s", - "▁Al fred", - "▁Alf red", - "Aut o", - "A uto", - "▁a tom", - "▁at om", - "▁ atom", - "▁e ll", - "▁el l", - "▁ ell", - "▁H arr", - "▁Har r", - "▁Ha rr", - "й н", - "▁\" #", - "▁n acional", - "▁nac ional", - "▁neigh bor", - "▁neighb or", - "сту па", - "ступ а", - "▁w it", - "Po p", - "P op", - "▁G reek", - "▁Gre ek", - "▁Gree k", - "▁re peat", - "▁repe at", - "▁ repeat", - "ba d", - "b ad", - "▁S C", - "▁ SC", - "▁Date Time", - "▁ DateTime", - "ш ти", - "▁W H", - "▁ WH", - "▁пра ви", - "▁прав и", - "▁ прави", - "▁Т и", - "▁s aison", - "▁sa ison", - "▁H art", - "▁Har t", - "▁Ha rt", - "direct ory", - "d irectory", - "ua n", - "u an", - "no rm", - "nor m", - "n orm", - "▁Phil ipp", - "▁Phili pp", - "▁Philip p", - "▁su spect", - "▁sus pect", - "▁susp ect", - "▁an no", - "▁ann o", - "▁ anno", - "b c", - "с ла", - "$ (", - "▁be find", - "▁bef ind", - "oc s", - "o cs", - "la test", - "lat est", - "late st", - ";\" >", - "; \">", - "▁after wards", - "PU T", - "P UT", - "▁j a", - "▁ ja", - "▁H il", - "▁Hi l", - "y z", - "▁B our", - "▁Bo ur", - "▁Bou r", - "▁la id", - "▁Д же", - "▁Дж е", - "pi e", - "p ie", - "w atch", - "▁E q", - "▁ Eq", - "cont act", - "ib er", - "ibe r", - "i ber", - "check box", - "▁esp añ", - "▁espa ñ", - "an se", - "ans e", - "▁ш ко", - "▁ шко", - "ef f", - "e ff", - "xx x", - "x xx", - "▁G ET", - "▁ GET", - "▁l ov", - "▁lo v", - "▁ lov", - "it ute", - "itu te", - "itut e", - "ze ch", - "zec h", - "z ech", - "ter e", - "te re", - "t ere", - "▁p urs", - "▁pu rs", - "▁pur s", - "ke ns", - "ken s", - "k ens", - "ian te", - "i ante", - "▁F ree", - "▁Fre e", - "▁Fr ee", - "▁ Free", - "▁ор гани", - "▁орган и", - "kre is", - "▁{ :", - "▁ {:", - "sh ared", - "share d", - "sha red", - "▁G raph", - "▁Gr aph", - "▁Gra ph", - "▁ Graph", - "▁conne ctions", - "▁connection s", - "▁connect ions", - "▁D OM", - "▁DO M", - "▁ DOM", - "▁C art", - "▁Car t", - "▁Ca rt", - "▁ Cart", - "ss on", - "s son", - "▁H amilton", - "те ли", - "тел и", - "▁r estaur", - "▁rest aur", - "▁resta ur", - "Re sol", - "Res ol", - "Dr iver", - "D river", - "▁en f", - "▁ enf", - "ED IT", - "▁p rev", - "▁pr ev", - "▁pre v", - "▁ prev", - "▁i k", - "▁ ik", - "▁s ă", - "j ö", - "▁С ССР", - "▁col our", - "ch ten", - "cht en", - "chte n", - "▁e stad", - "▁est ad", - "▁esta d", - "in ois", - "ino is", - "▁con fir", - "▁conf ir", - "▁v é", - "▁ vé", - "▁C es", - "▁Ce s", - "▁N ever", - "▁Ne ver", - "▁Nev er", - "om er", - "ome r", - "o mer", - "ж да", - "с лу", - "че ния", - "dl l", - "d ll", - "▁y outh", - "▁you th", - "▁yo uth", - "em en", - "eme n", - "e men", - "▁stud ied", - "▁studi ed", - "▁K il", - "▁Ki l", - "ci on", - "cio n", - "c ion", - "▁n avig", - "▁nav ig", - "re quired", - "require d", - "orith ms", - "orithm s", - "il or", - "ilo r", - "i lor", - "▁Deutsch en", - "▁Deutsche n", - "▁person s", - "▁pers ons", - "▁Barcel ona", - "▁form ation", - "▁format ion", - "▁forma tion", - "▁ formation", - "ab ei", - "abe i", - "a bei", - "▁про тив", - "▁проти в", - "Eng ine", - "ON E", - "O NE", - "og rá", - "Ca p", - "C ap", - "ri r", - "r ir", - "▁g ate", - "▁ga te", - "▁gat e", - "▁ gate", - "or ation", - "ora tion", - "ma ven", - "m aven", - "▁comb ined", - "▁combin ed", - "▁combine d", - "▁at tr", - "▁att r", - "▁ attr", - "▁h ook", - "▁ho ok", - "▁ hook", - "▁которы й", - "▁ser vers", - "▁server s", - "▁serv ers", - "▁serve rs", - "uct ure", - "же ння", - "жен ня", - "t v", - "▁re q", - "▁r eq", - "▁ req", - "ja l", - "j al", - "▁loc ally", - "▁local ly", - "}} {\\", - "}}{ \\", - "} }{\\", - "B r", - "▁H ier", - "▁Hi er", - "мо р", - "м ор", - "▁a part", - "▁ap art", - "▁apar t", - "\"] ,", - "\" ],", - "▁%> %", - "▁z usammen", - "▁zus ammen", - "▁ident ify", - "▁Al tern", - "▁Alt ern", - "▁Alter n", - "▁б ро", - "▁ бро", - "▁ц и", - "▁ ци", - "g h", - "▁T en", - "▁Te n", - "R S", - "фор ма", - "▁n elle", - "▁ne lle", - "▁nel le", - "▁nell e", - "▁ nelle", - "▁H in", - "▁Hi n", - "ound ing", - "oun ding", - "▁re prés", - "▁rep rés", - "▁repr és", - "ap h", - "a ph", - "▁[ \\", - "▁ [\\", - "▁S ports", - "▁Sport s", - "ра л", - "р ал", - "▁t hre", - "▁th re", - "▁thr e", - "▁p rin", - "▁pr in", - "▁pri n", - "▁El iz", - "▁Eli z", - "▁F our", - "▁Fou r", - "▁Fo ur", - "▁soci ety", - "▁soc iety", - "Trans action", - "▁v eg", - "▁ve g", - "▁ veg", - "▁sch ools", - "▁school s", - "▁over all", - "▁t ail", - "▁ta il", - "▁ tail", - "üb er", - "ü ber", - "▁S ov", - "▁So v", - "▁С ер", - "▁Се р", - "▁r app", - "▁ra pp", - "▁rap p", - "▁tra ffic", - "qu estion", - "quest ion", - "ques tion", - "▁en viron", - "▁envi ron", - "▁ environ", - "ate ien", - "ic us", - "i cus", - "▁n arrow", - "▁narr ow", - "▁nar row", - "▁p ray", - "▁pr ay", - "▁pra y", - "▁B ou", - "▁Bo u", - "▁C lient", - "▁Cl ient", - "▁ Client", - "ab l", - "a bl", - "▁Aud iod", - "▁Audio d", - "▁n pm", - "▁np m", - "▁ npm", - "▁Col umn", - "▁ Column", - "▁G ames", - "▁Game s", - "▁Ga mes", - "▁Gam es", - "av er", - "ave r", - "a ver", - "ony mes", - "onym es", - "onyme s", - "▁По сле", - "n ą", - "▁N u", - "▁D ick", - "▁Di ck", - "▁Dic k", - "▁t ensor", - "▁tens or", - "▁ tensor", - "▁@ \"", - "▁ @\"", - "v é", - "I con", - "▁по да", - "▁под а", - "▁ пода", - "▁G on", - "▁Go n", - "/) .", - "/ ).", - "is tra", - "ist ra", - "istr a", - "i stra", - "▁Audiod ateien", - "De lete", - "Del ete", - "}} }", - "} }}", - "▁j ump", - "▁ju mp", - "▁О б", - "▁princi ple", - "▁princip le", - "▁Ét ats", - "ok ed", - "oke d", - "o ked", - "▁В ла", - "Inter val", - "▁s au", - "▁sa u", - "en code", - "enc ode", - "▁p on", - "▁po n", - "▁ pon", - "cat ch", - "c atch", - "▁t iem", - "▁ti em", - "▁tie m", - "▁G ust", - "▁Gu st", - "M C", - "lim its", - "limit s", - "▁ke eping", - "▁keep ing", - "▁s ongs", - "▁son gs", - "▁song s", - "▁ав гу", - "▁рай он", - "▁райо н", - "▁not ification", - "▁ notification", - "▁off ered", - "▁offer ed", - "Co r", - "C or", - "▁sh ut", - "error s", - "err ors", - "▁E N", - "▁ EN", - "▁lat ach", - "▁sel bst", - "▁check box", - "▁ checkbox", - "▁c ool", - "▁co ol", - "▁f actory", - "▁fact ory", - "▁factor y", - "▁ factory", - "▁pa id", - "dim ensional", - "ni ej", - "nie j", - "n iej", - "pt on", - "pto n", - "p ton", - "▁p in", - "▁pi n", - "▁ pin", - "ak ed", - "ake d", - "a ked", - "▁re li", - "▁r eli", - "▁rel i", - "▁T aylor", - "▁S omething", - "▁Some thing", - "▁Som ething", - "▁ Something", - "im um", - "▁V in", - "▁Vi n", - "▁iter ation", - "Fin d", - "Fi nd", - "F ind", - "ко ви", - "ков и", - "к ови", - "▁bo ys", - "▁boy s", - "▁Sim ple", - "▁ Simple", - "▁C rist", - "▁Cr ist", - "▁Cris t", - "▁W as", - "▁Wa s", - "ân d", - "â nd", - "▁V a", - "▁т ра", - "▁ тра", - "▁dest ination", - "▁destin ation", - "▁ destination", - "li mp", - "lim p", - "l imp", - "▁K at", - "▁Ka t", - "wor th", - "wort h", - "w orth", - "▁K or", - "▁Ko r", - "i ção", - "= `", - "▁fair ly", - "fall s", - "fal ls", - "f alls", - "▁re ject", - "▁d ream", - "▁dre am", - "be ll", - "bel l", - "b ell", - "▁t oute", - "▁to ute", - "▁tout e", - "▁tou te", - "▁$ \\{", - "▁$\\ {", - "▁st one", - "▁sto ne", - "▁ stone", - "▁prote ct", - "▁prot ect", - "▁ex cell", - "▁exc ell", - "▁excel l", - "▁Me xico", - "▁Mex ico", - "▁d ash", - "▁da sh", - "▁das h", - "▁ dash", - "▁f ault", - "▁fa ult", - "▁ fault", - "p matrix", - "al ler", - "all er", - "alle r", - "▁guer re", - "or igin", - "ori gin", - "orig in", - "hi bernate", - "í lia", - "▁Reg ister", - "▁ Register", - "un to", - "unt o", - "▁B at", - "▁Ba t", - "▁b ow", - "▁bo w", - "▁ bow", - "сь ких", - "ськ их", - "et à", - "▁L uis", - "▁Lu is", - "▁f ou", - "▁fo u", - "▁Cam bridge", - "▁Camb ridge", - "▁o tt", - "▁ot t", - "▁ ott", - "su p", - "s up", - "re as", - "rea s", - "▁point ers", - "▁pointer s", - "▁Bo ard", - "▁ Board", - "▁р и", - "▁ ри", - "▁d riv", - "▁dr iv", - "▁dri v", - "ни н", - "н ин", - "▁C irc", - "▁Ci rc", - "▁Cir c", - "▁ Circ", - "▁t hou", - "▁th ou", - "Di v", - "D iv", - "sp ark", - "s park", - "la ment", - "lam ent", - "l ament", - "▁V AL", - "▁ VAL", - "Se nd", - "S end", - "▁Ir ish", - "o y", - "▁T u", - "▁ Tu", - "▁t rivial", - "Form s", - "For ms", - "▁as í", - "▁Im per", - "▁Imp er", - "▁sign ature", - "un os", - "uno s", - "u nos", - "▁N eg", - "▁Ne g", - "▁can cel", - "▁ cancel", - "▁Hein rich", - "ee d", - "e ed", - "Ill ustration", - "▁s ulla", - "▁su lla", - "▁sul la", - "▁sull a", - "▁qu arter", - "▁quart er", - "▁quar ter", - "as z", - "a sz", - "▁b log", - "▁bl og", - "▁blo g", - "▁ blog", - "fi ca", - "fic a", - "f ica", - "wo n", - "w on", - "qu et", - "que t", - "q uet", - "]) )", - "] ))", - "▁gener ation", - "▁c aught", - "▁ caught", - "▁l ands", - "▁land s", - "▁lan ds", - "▁ lands", - "▁King dom", - "schaft en", - "ro ns", - "ron s", - "r ons", - "ann els", - "annel s", - "anne ls", - "▁Spe cial", - "▁Spec ial", - "▁ Special", - "t utorial", - "ti p", - "t ip", - "▁\" \",", - "▁\"\" ,", - "▁Az ure", - "▁ Azure", - "▁b ounded", - "▁bound ed", - "▁ bounded", - "S m", - "ta r", - "t ar", - "ве н", - "в ен", - "▁з ем", - "▁зе м", - "▁ зем", - "▁not ation", - "▁ notation", - "▁ap ache", - "▁ apache", - "▁g az", - "▁ga z", - "ier no", - "i erno", - "an gen", - "ang en", - "ange n", - "pect ive", - "▁elect ric", - "▁s emi", - "▁se mi", - "▁sem i", - "MA X", - "M AX", - "ed erb", - "eder b", - "ede rb", - "object s", - "▁dif ferences", - "▁differ ences", - "▁difference s", - "is ted", - "ist ed", - "iste d", - "i sted", - "hr ef", - "hre f", - "h ref", - "ic ip", - "ici p", - "i cip", - "▁num py", - "▁ numpy", - "▁ф утбо", - "lo ader", - "load er", - "▁d ich", - "▁di ch", - "▁dic h", - "љ у", - "▁D é", - "H z", - "▁P aram", - "▁Par am", - "▁Pa ram", - "▁Para m", - "▁ Param", - "document ation", - "ir craft", - "irc raft", - "E M", - "▁inst itution", - "▁instit ution", - "com pat", - "comp at", - "▁а ль", - "▁ал ь", - "▁ аль", - "сла в", - "с лав", - "▁N et", - "▁Ne t", - "▁ Net", - "ци ональ", - "цион аль", - "циона ль", - "▁broad cast", - "date time", - "dat etime", - "as ync", - "asy nc", - "a sync", - "vr e", - "v re", - "me an", - "▁C hem", - "▁Ch em", - "▁Che m", - "▁est imate", - "▁estim ate", - "ic ana", - "ica na", - "ican a", - "▁g rep", - "▁gr ep", - "▁gre p", - "▁ grep", - "te k", - "t ek", - "ä m", - "or ig", - "ori g", - "o rig", - "▁Vict or", - "▁Vi ctor", - "▁Vic tor", - "ut enant", - "ute nant", - "uten ant", - "an ga", - "ang a", - "pi n", - "p in", - "▁ver tex", - "▁vert ex", - "▁verte x", - "▁CHAP TER", - "ci ty", - "cit y", - "c ity", - "ug by", - "gr een", - "gre en", - "g reen", - "▁K er", - "▁Ke r", - "▁dif fér", - "▁diff ér", - "▁necess arily", - "D C", - "Line ar", - "Lin ear", - "Li near", - "al em", - "ale m", - "a lem", - "▁L ater", - "▁La ter", - "▁Lat er", - "▁Late r", - "▁m eta", - "▁me ta", - "▁met a", - "▁ meta", - "je m", - "j em", - "ra gen", - "rag en", - "rage n", - "r agen", - "Ma y", - "M ay", - "▁Mitg lied", - "▁s orted", - "▁sort ed", - "▁sor ted", - "▁sorte d", - "▁ sorted", - "us sen", - "uss en", - "▁sp oke", - "▁spo ke", - "▁dis abled", - "▁disable d", - "▁ disabled", - "▁accompl ish", - "▁accomp lish", - "▁Russ ia", - "th ere", - "ther e", - "the re", - "t here", - "ee s", - "e es", - "▁h all", - "▁ha ll", - "▁hal l", - "▁ hall", - "▁met ric", - "▁ metric", - "att ribute", - "то го", - "т ого", - "ab out", - "▁L am", - "▁La m", - "ch annel", - "chan nel", - "▁e pisode", - "▁epis ode", - "▁$ ('.", - "▁$( '.", - "▁$(' .", - "▁ ought", - "▁E ste", - "▁Est e", - "▁Es te", - "Object s", - "▁valid ate", - "▁ validate", - "▁r im", - "▁ri m", - "▁ rim", - "▁numer ous", - "▁numero us", - "▁J avascript", - "▁Java script", - "▁G L", - "▁ GL", - "▁It aly", - "▁Ital y", - "ederb örd", - "on ato", - "ona to", - "bo oks", - "book s", - "st one", - "ston e", - "sto ne", - "х у", - "▁j el", - "▁je l", - "▁ jel", - "ir i", - "i ri", - "▁A SP", - "▁AS P", - "G A", - "▁st ata", - "▁stat a", - "▁sta ta", - "▁b az", - "▁ba z", - "▁ baz", - "Da y", - "D ay", - "th m", - "t hm", - "d h", - "▁F iles", - "▁Fil es", - "▁File s", - "▁ Files", - "Android Runtime", - "▁che cks", - "▁check s", - "k r", - "▁v enne", - "▁ven ne", - "S L", - "av ia", - "avi a", - "a via", - "ka zy", - "kaz y", - "k azy", - "▁Th ree", - "▁ Three", - "Ad min", - "▁col lege", - "▁coll ege", - "▁colleg e", - "▁colle ge", - "G lobal", - "ti on", - "t ion", - "▁cur ious", - "sh ort", - "▁b ass", - "▁bas s", - "▁ba ss", - "де ла", - "▁де я", - "Sch ema", - "' \\", - "di ff", - "d iff", - "▁C A", - "▁ CA", - "▁Cor por", - "▁oper ators", - "▁operator s", - "om rå", - "▁ed ges", - "▁edge s", - "); `", - ") ;`", - "in ds", - "ind s", - "▁g ing", - "▁gi ng", - "▁ ging", - "& &", - "}- \\", - "} -\\", - "ra no", - "ran o", - "r ano", - "▁s ão", - "▁ad ds", - "▁add s", - "el or", - "elo r", - "e lor", - "▁un signed", - "▁uns igned", - "▁ unsigned", - "▁п р", - "▁ пр", - "▁Con fig", - "▁Conf ig", - "▁ Config", - "▁E sc", - "▁Es c", - "▁ch ose", - "▁cho se", - "▁pie ces", - "▁piece s", - "▁reg ions", - "▁region s", - "Es t", - "E st", - "▁B attle", - "▁Batt le", - "▁f oc", - "▁fo c", - "▁L ight", - "▁Lig ht", - "▁ Light", - "pad ding", - "p adding", - "ab en", - "abe n", - "a ben", - "▁e urop", - "▁eu rop", - "▁euro p", - "il lon", - "ill on", - "illo n", - "▁е сть", - "▁b ord", - "▁bo rd", - "▁bor d", - "▁о тно", - "▁от но", - "▁H ong", - "▁Hon g", - "▁Ho ng", - "▁v ul", - "▁vu l", - "pl ugins", - "plugin s", - "▁' <", - "▁k ur", - "▁ kur", - "reg ion", - "▁Re pub", - "▁Rep ub", - "ic her", - "ich er", - "iche r", - "i cher", - "}_ \\", - "} _\\", - "▁me dal", - "▁med al", - "▁More over", - "B I", - "A v", - "ut er", - "ute r", - "u ter", - "▁s can", - "▁sc an", - "▁ scan", - "▁M unicip", - "▁Mun icip", - "▁contr ast", - "▁contra st", - "▁I g", - "▁ Ig", - "▁го род", - "▁горо д", - "▁гор од", - "▁ город", - "rel ated", - "al ing", - "ali ng", - "alin g", - "a ling", - "▁м ат", - "▁ма т", - "▁ мат", - "ün st", - "▁Ch ris", - "▁Chr is", - "w y", - "▁Act ually", - "▁Univers idad", - "Event Listener", - "▁tempor ada", - "▁ass ignment", - "▁assign ment", - "▁M ike", - "▁Mi ke", - "▁Mik e", - "▁w ährend", - "▁ś wi", - "▁św i", - "▁с ред", - "▁сре д", - "ка де", - "▁calcul ated", - "▁calculate d", - "▁calc ulated", - "▁el ler", - "▁elle r", - "▁ell er", - "▁ eller", - "▁A sh", - "▁As h", - "ri el", - "rie l", - "r iel", - "▁hard ware", - "▁int ens", - "▁inte ns", - "▁inten s", - "(' .", - "( '.", - "il li", - "ill i", - "ag on", - "ago n", - "a gon", - "▁G y", - "▁he ute", - "▁heut e", - "▁s le", - "▁sl e", - "▁liter ature", - "se m", - "s em", - "man ager", - "mana ger", - "▁Gr ande", - "▁Gra nde", - "▁Grand e", - "▁Gran de", - "▁m ixed", - "▁mix ed", - "▁В ер", - "▁Ве р", - "í cí", - "▁s oit", - "▁so it", - "▁wel come", - "че ние", - "▁Univers ität", - "▁bu ilder", - "▁build er", - "▁ builder", - "sim ple", - "simp le", - "ic ode", - "ico de", - "i code", - "ř e", - "in dent", - "ind ent", - "inden t", - "inde nt", - "op o", - "o po", - "▁ad vanced", - "▁adv anced", - "▁advance d", - "tem per", - "temp er", - "ed ge", - "▁dat etime", - "▁date time", - "▁ datetime", - "▁d onc", - "▁do nc", - "▁don c", - "ла ння", - "лан ня", - "▁v erd", - "▁ver d", - "▁ve rd", - "д но", - "it os", - "ito s", - "▁he at", - "vi sible", - "vis ible", - "me l", - "m el", - "▁Giov anni", - "▁var iety", - "▁vari ety", - "▁r outer", - "▁ro uter", - "▁route r", - "▁rout er", - "▁rou ter", - "▁ router", - "Vec tor", - "V ector", - "▁W alk", - "▁Wal k", - "▁ob viously", - "▁obvious ly", - "he in", - "h ein", - "Fi n", - "F in", - "ITable View", - "Y ear", - "▁E conom", - "▁vel ocity", - "▁veloc ity", - "▁C ivil", - "▁Ci vil", - "▁ ј", - "al ert", - "ale rt", - "aler t", - "Ident ifier", - "èn cia", - "▁normal ly", - "▁norm ally", - "▁E gypt", - "▁Egy pt", - "▁c tx", - "▁ ctx", - "▁Ver ein", - "▁Vere in", - "▁H u", - "ult ure", - "ultur e", - "ни те", - "l é", - "▁W ien", - "▁Wi en", - "▁Wie n", - "▁P rz", - "▁Pr z", - "By te", - "▁n ah", - "▁na h", - "▁ nah", - "is ms", - "ism s", - "▁Pub lish", - "▁He rz", - "▁Her z", - "ic ul", - "i cul", - "pis ode", - "ч і", - "▁die sem", - "▁dies em", - "▁diese m", - "k ö", - "Vis ible", - "▁r ig", - "▁ri g", - "▁ rig", - "`) .", - "` ).", - "Par se", - "P arse", - "▁Jac ques", - "N I", - "▁g lass", - "▁gl ass", - "▁gla ss", - "▁ glass", - "-- -+", - "--- +", - "- --+", - "▁initial ly", - "▁initi ally", - "▁k r", - "▁ kr", - "CC N", - "C CN", - "pl ays", - "play s", - "pla ys", - "▁s igu", - "▁si gu", - "▁sig u", - "F older", - "st orage", - "sto rage", - "stor age", - "▁\\ |", - "▁ \\|", - "iv os", - "ivo s", - "i vos", - "ск ую", - "ску ю", - "▁M oh", - "▁Mo h", - "▁Comm ittee", - "▁K im", - "▁Ki m", - "e u", - "те м", - "т ем", - "▁orig inale", - "▁original e", - "▁origin ale", - "ir s", - "i rs", - "▁R eb", - "▁Re b", - "it ut", - "itu t", - "n l", - "▁P ier", - "▁Pi er", - "▁Pie r", - "▁] ;", - "▁ ];", - "▁F al", - "▁Fa l", - "▁\" \";", - "▁\"\" ;", - "mv c", - "m vc", - "▁fe male", - "▁fem ale", - "▁b ridge", - "▁br idge", - "▁brid ge", - "▁ bridge", - "▁t ít", - "kt r", - "k tr", - "> )", - "▁se at", - "▁sea t", - "▁v ess", - "▁ve ss", - "▁ves s", - "▁U SB", - "▁US B", - "▁Art icles", - "▁Article s", - "▁De scription", - "▁Des cription", - "▁Descri ption", - "▁ Description", - "▁o c", - "▁ oc", - "▁h ouses", - "▁house s", - "▁ho uses", - "▁hous es", - "▁П ет", - "▁Пе т", - "lo n", - "l on", - "Not ification", - "▁press ure", - "▁ку ль", - "▁ куль", - "ig ned", - "ign ed", - "igne d", - "▁relig ious", - "fa n", - "f an", - "ig lia", - "igli a", - "▁class ification", - "▁classific ation", - "og ether", - "oge ther", - "▁S DK", - "▁SD K", - "▁ SDK", - "▁H uman", - "▁Hu man", - "▁Hum an", - "▁com mission", - "▁comm ission", - "▁О р", - "▁an tes", - "▁ant es", - "▁ante s", - "▁ antes", - "D T", - "èt e", - "è te", - "pr és", - "p rés", - "/ \"", - "▁( «", - "▁h ö", - "▁ hö", - "▁ча с", - "▁ час", - "▁j ak", - "▁ja k", - "▁ jak", - "ie nen", - "ien en", - "iene n", - "i enen", - "ug g", - "u gg", - "W A", - "▁place holder", - "▁ placeholder", - "Wil l", - "W ill", - ", ,", - "▁K am", - "▁Ka m", - "▁w en", - "▁we n", - "▁ wen", - "▁Sch ul", - "ți e", - "ț ie", - "▁a ud", - "▁au d", - "▁ aud", - "▁s ue", - "▁su e", - "▁re ferred", - "▁refer red", - "ва т", - "в ат", - "▁P ara", - "▁Par a", - "▁Pa ra", - "▁b la", - "▁bl a", - "▁ bla", - "UE S", - "U ES", - "▁stat ist", - "▁stati st", - "▁т у", - "▁ ту", - "▁Wars za", - "gu e", - "g ue", - "▁I de", - "▁Id e", - "math scr", - "▁l ieu", - "▁li eu", - "▁lie u", - "▁b od", - "▁bo d", - "▁r us", - "▁ru s", - "▁ rus", - "▁bo at", - "xs pace", - "x space", - "▁mod al", - "▁mo dal", - "▁ modal", - "ле к", - "л ек", - "to pic", - "top ic", - "ma ny", - "man y", - "m any", - "sk ý", - "▁organ ization", - "▁organiz ation", - "▁г ене", - "▁ге не", - "▁Wil son", - "▁com fort", - "ib il", - "i bil", - ": -", - "▁an imal", - "▁anim al", - "▁ani mal", - "Re port", - "Rep ort", - "ка ми", - "кам и", - "jo n", - "j on", - "▁k er", - "▁ke r", - "▁ ker", - "▁к ни", - "moz illa", - "Pr ice", - "P rice", - "ant in", - "anti n", - "em ento", - "ement o", - "emen to", - "ma y", - "m ay", - "▁l ung", - "▁lu ng", - "▁lun g", - "▁ lung", - "▁b low", - "▁bl ow", - "▁blo w", - "ede ut", - "▁type d", - "▁typ ed", - "▁ty ped", - "▁dec ember", - "▁. ...", - "▁... .", - "▁.. ..", - "▁ ....", - "li ance", - "l iance", - "▁v iel", - "▁vi el", - "▁vie l", - "▁Ф и", - "pr esa", - "pre sa", - "pres a", - "▁ос іб", - "▁N am", - "▁Na m", - "▁G ren", - "▁Gr en", - "▁Gre n", - "си лання", - "VI D", - "V ID", - "st re", - "str e", - "s tre", - "we is", - "wei s", - "▁prote ction", - "▁protect ion", - "▁prot ection", - "ta ient", - "t aient", - "▁offic ers", - "▁office rs", - "▁officer s", - "т но", - "▁B rig", - "▁Br ig", - "▁int ellig", - "▁intel lig", - "я х", - "IT H", - "I TH", - "▁separ ated", - "▁separate d", - "▁L CCN", - "ní m", - "n ím", - "cl ock", - "clo ck", - "c lock", - "▁ap are", - "▁apar e", - "яв и", - "я ви", - "▁Eliz abeth", - "▁W ater", - "▁Wat er", - "▁Wa ter", - "geb iet", - "▁con vent", - "▁conv ent", - "▁conven t", - "fu rt", - "fur t", - "f urt", - "▁be iden", - "▁bei den", - "▁beide n", - "ba sh", - "bas h", - "b ash", - "▁че рез", - "▁чер ез", - "▁u b", - "▁ ub", - "▁Stat ist", - "▁Stati st", - "▁lim its", - "▁limit s", - "▁ limits", - "V ol", - "ct x", - "c tx", - "▁но в", - "▁н ов", - "▁ нов", - "gu ide", - "gui de", - "mi c", - "m ic", - "ie sa", - "ies a", - "i esa", - "▁h uvud", - "R T", - "Fi g", - "F ig", - "▁l ect", - "▁le ct", - "▁ lect", - "con n", - "co nn", - "c onn", - "im it", - "imi t", - "i mit", - "га р", - "г ар", - "▁b ajo", - "▁ba jo", - "scri be", - "scr ibe", - "s cribe", - "re gex", - "reg ex", - "▁C ass", - "▁Cas s", - "▁Ca ss", - "▁pro pag", - "▁prop ag", - "' $", - "▁prof es", - "un ique", - "uni que", - "▁S ql", - "▁ Sql", - "un ion", - "uni on", - "ri os", - "rio s", - "r ios", - "pi p", - "p ip", - "-- +", - "- -+", - "ka dem", - "k adem", - "column s", - "▁v ary", - "▁var y", - "▁va ry", - "▁bere its", - "▁d oi", - "▁do i", - "▁Com mon", - "▁Comm on", - "▁ Common", - "▁Ro bin", - "▁Rob in", - "▁ ×", - "▁s ei", - "▁se i", - "▁s yst", - "▁sy st", - "▁sys t", - "▁v ä", - "▁ vä", - "▁De fault", - "▁Def ault", - "▁ Default", - "▁t ym", - "▁ty m", - "pe l", - "p el", - "▁bel ieved", - "▁believe d", - "▁pro vider", - "▁prov ider", - "▁provide r", - "▁ provider", - "▁min imal", - "▁minim al", - "▁mini mal", - "та ли", - "тал и", - "т али", - "ain es", - "ai nes", - "aine s", - "a ines", - "K it", - "iz io", - "izi o", - "is sen", - "iss en", - "isse n", - "pr essed", - "press ed", - "pres sed", - "▁s tag", - "▁st ag", - "▁sta g", - "▁ stag", - "▁u int", - "▁ui nt", - "▁ uint", - "ko r", - "k or", - "▁ра спо", - "▁рас по", - "▁in herit", - "▁inher it", - "▁comp iled", - "▁compile d", - "▁f ebru", - "▁fe bru", - "▁feb ru", - "▁t mp", - "▁tm p", - "▁ tmp", - "work s", - "wor ks", - "ч на", - "draw able", - "▁N av", - "▁Na v", - "▁ Nav", - "▁though ts", - "▁thought s", - "ro ute", - "rout e", - "rou te", - "r oute", - "▁con cert", - "▁conc ert", - "▁conce rt", - "▁option al", - "▁opt ional", - "▁ optional", - "▁b ras", - "▁br as", - "▁bra s", - "▁ bras", - "▁prov iding", - "со м", - "с ом", - "id x", - "i dx", - "emp lo", - "empl o", - "▁ко ли", - "▁ коли", - "▁B ere", - "▁Be re", - "▁Ber e", - "▁E ls", - "▁El s", - "ре мен", - "рем ен", - "▁де ка", - "co ut", - "cou t", - "c out", - "la yer", - "lay er", - "l ayer", - "▁g lob", - "▁gl ob", - "▁glo b", - "▁ glob", - "fore ach", - "for each", - "▁E ducation", - "▁Edu cation", - "P O", - "▁im prov", - "▁imp rov", - "▁impro v", - "▁impr ov", - "▁cl ients", - "▁client s", - "▁cli ents", - "gr oups", - "group s", - "gro ups", - "▁k ont", - "▁kon t", - "▁ko nt", - "De l", - "D el", - "re tt", - "ret t", - "r ett", - "▁s up", - "▁su p", - "▁ sup", - "▁m og", - "▁mo g", - "ta n", - "t an", - "▁com pl", - "▁comp l", - "ir ty", - "irt y", - "▁nouve au", - "os z", - "o sz", - "▁N avy", - "▁Na vy", - "▁Nav y", - "ber e", - "be re", - "b ere", - "ma sk", - "mas k", - "m ask", - "ov é", - "o vé", - "zi l", - "z il", - "PE R", - "P ER", - "▁pobla ción", - "▁població n", - "▁d etailed", - "▁detail ed", - "ле т", - "л ет", - "▁famil ies", - "▁familie s", - "ab et", - "abe t", - "a bet", - "е вич", - "änd er", - "än der", - "ände r", - "ä nder", - "▁å r", - "▁ år", - "▁p endant", - "▁b il", - "▁bi l", - "▁ bil", - "▁h int", - "▁hi nt", - "▁hin t", - "ode n", - "od en", - "o den", - "▁exp ansion", - "▁p ont", - "▁po nt", - "▁pon t", - "▁ pont", - "as ant", - "asa nt", - "▁K ind", - "▁Ki nd", - "▁Kin d", - "▁ Kind", - "ij i", - "i ji", - "▁A uth", - "▁Aut h", - "▁Au th", - "▁ Auth", - "laim ed", - "ref lect", - "] =", - "by tes", - "byte s", - "ho ver", - "hov er", - "h over", - "▁ц ер", - "▁це р", - "▁ цер", - "grad le", - "Ar ch", - "ap est", - "ape st", - "apes t", - "ás a", - "á sa", - "Car d", - "Ca rd", - "C ard", - "▁tempor ary", - "▁départ ement", - "class es", - "жи ва", - "▁х удо", - "▁m ole", - "▁mo le", - "▁mol e", - "R Y", - "L P", - "▁p ec", - "▁pe c", - "▁ pec", - "rodu ction", - "▁Gu ard", - "▁Par liament", - "▁inst anti", - "▁instant i", - "▁not amment", - "▁D oug", - "▁Do ug", - "▁Dou g", - "▁Mar sh", - "▁Mars h", - ". ~", - "▁\\ \"", - "▁ \\\"", - "▁t hé", - "▁th é", - "▁li bre", - "▁lib re", - "do es", - "▁dé but", - "▁U nit", - "▁Un it", - "▁ Unit", - "▁с ту", - "▁ст у", - "▁ сту", - "▁le ague", - "▁qu ale", - "▁q uale", - "▁qual e", - "▁состав ля", - "▁соста вля", - "Se curity", - "Sec urity", - "▁appar ently", - "▁apparent ly", - "▁tro ops", - "ic ano", - "ica no", - "ican o", - "i cano", - "▁M B", - "▁ MB", - "en ze", - "enz e", - "lo ading", - "load ing", - "▁dist ributed", - "▁distribu ted", - "▁distrib uted", - "write r", - "writ er", - "wr iter", - "w riter", - "res ources", - "resource s", - "h ö", - "ut ils", - "util s", - "uti ls", - "▁prep ared", - "▁prepar ed", - "▁prepare d", - "ci er", - "cie r", - "c ier", - "op ol", - "opo l", - "o pol", - "▁län kar", - "he s", - "h es", - "н ва", - "▁op ens", - "▁open s", - "▁ opens", - "ag og", - "ago g", - "inter face", - "▁F und", - "▁Fu nd", - "▁Fun d", - "▁pent ru", - "ní ch", - "n ích", - "▁config ured", - "▁configure d", - "▁configur ed", - "▁Web site", - "▁list ener", - "▁listen er", - "▁liste ner", - "▁ listener", - "iv el", - "ive l", - "i vel", - "n ę", - "min a", - "mi na", - "m ina", - "▁in vest", - "▁inv est", - "▁inve st", - "▁м іс", - "▁мі с", - "▁d av", - "▁da v", - "▁p atch", - "▁pat ch", - "▁ patch", - "pi eler", - "piel er", - "pie ler", - "▁Ext erna", - "▁Extern a", - "t f", - "▁e red", - "▁er ed", - "▁ere d", - "▁ ered", - "▁Ass embly", - "▁ Assembly", - "▁s out", - "▁so ut", - "▁sou t", - "▁v erk", - "▁ver k", - "▁ verk", - "me rs", - "mer s", - "m ers", - "t oggle", - "▁up dating", - "▁upd ating", - "▁K ent", - "▁Ke nt", - "▁Ken t", - "ec a", - "e ca", - "FA ULT", - "▁tit re", - "▁ti tre", - "▁K enn", - "▁Ke nn", - "▁Ken n", - "▁Ми ха", - "ст ор", - "сто р", - "с тор", - "▁p ode", - "▁po de", - "▁pod e", - "▁S eb", - "▁Se b", - "це в", - "ц ев", - "E Y", - "▁sil ver", - "▁cap acity", - "▁capac ity", - "▁comple tion", - "▁complet ion", - "▁Pe dro", - "▁Ped ro", - "fe l", - "f el", - "va no", - "van o", - "v ano", - "ze ug", - "▁in terior", - "▁inter ior", - "▁inte rior", - "▁Res ponse", - "▁ Response", - "éd ia", - "é dia", - "▁World Cat", - "▁c ă", - "qu el", - "que l", - "q uel", - "So l", - "S ol", - "іс ля", - "▁D omin", - "▁Do min", - "▁Dom in", - "▁c um", - "▁cu m", - "ce p", - "c ep", - "▁M use", - "▁Mus e", - "▁Mu se", - "▁M aría", - "▁Mar ía", - "▁Ma ría", - "▁function al", - "▁ad apter", - "▁adapt er", - "▁ adapter", - "config uration", - "▁t ipo", - "▁tip o", - "▁ti po", - "▁B ry", - "▁Br y", - "v y", - "U L", - "▁tra vers", - "▁trav ers", - "! (", - "▁absol utely", - "▁absolute ly", - "л та", - "тт я", - "т тя", - "▁I T", - "▁ IT", - "▁во ен", - "yc le", - "y cle", - "be st", - "bes t", - "b est", - "▁construct ed", - "▁constru cted", - "▁фи ль", - "▁ филь", - "ci do", - "cid o", - "c ido", - "ex it", - "ga rt", - "gar t", - "g art", - "▁provin cia", - "ve z", - "v ez", - "ci pl", - "cip l", - "▁Face book", - "▁Fac ebook", - "▁y ellow", - "▁ yellow", - "▁Sum mer", - "▁point ing", - "▁poss ibility", - "▁possib ility", - "▁possibil ity", - "▁leg isl", - "▁мо ж", - "▁ мож", - "de rn", - "der n", - "d ern", - "ко но", - "кон о", - "▁mechan ism", - "▁Bern ard", - "ex pr", - "exp r", - "ло ви", - "лов и", - "л ови", - "▁dig its", - "▁digit s", - "▁de legate", - "▁deleg ate", - "▁ delegate", - "og ram", - "o gram", - "▁D ictionary", - "▁ Dictionary", - "is y", - "▁s po", - "▁sp o", - "/ $", - "clude d", - "clud ed", - "▁M VC", - "▁t ém", - "▁té m", - "▁print ed", - "▁prin ted", - "▁G ott", - "▁Go tt", - "▁Got t", - "▁O m", - "▁ Om", - "ans as", - "▁D urch", - "▁Dur ch", - "▁I dent", - "▁Id ent", - "▁Ide nt", - "▁ Ident", - "Q U", - "ht m", - "h tm", - "▁S ul", - "▁Su l", - "'] .", - "' ].", - "▁du ty", - "▁dut y", - "▁Aut hor", - "▁Auth or", - "▁ Author", - "▁n ě", - "▁ ně", - "ow ego", - "owe go", - "pu s", - "p us", - "em bl", - "emb l", - "Exec utor", - "B L", - "▁M ens", - "▁Me ns", - "▁Men s", - "dis patch", - "▁M id", - "▁Mi d", - "ap ps", - "app s", - "Trans form", - "▁D at", - "▁Da t", - "▁ Dat", - "▁im pl", - "▁imp l", - "▁ impl", - "ou x", - "o ux", - "ho lm", - "hol m", - "▁I ns", - "▁In s", - "▁Emp ire", - "ру п", - "▁Ap ache", - "SI ON", - "S ION", - "▁pass age", - "######## ########", - "▁ex pressed", - "▁express ed", - "▁expr essed", - "▁expres sed", - "на д", - "▁o l", - "▁ ol", - "▁h avia", - "▁ha via", - "▁hav ia", - "▁бо лее", - "▁enjo y", - "form ance", - "▁dim ensions", - "▁dimension s", - "▁ч ер", - "▁че р", - "▁ чер", - "Se e", - "S ee", - "▁m outh", - "▁mo uth", - "▁mou th", - "▁ mouth", - "▁g au", - "▁ga u", - "ien cy", - "i ency", - "▁Carol ina", - "Dis t", - "Di st", - "D ist", - "rad io", - "li mit", - "lim it", - "l imit", - "/ ?", - "▁B all", - "▁Ba ll", - "▁Bal l", - "ні сть", - "Mem ber", - "M ember", - "wa ter", - "w ater", - "▁mur der", - "▁stand ing", - "▁stan ding", - "▁ standing", - "▁V II", - "▁VI I", - "Cent er", - "C enter", - "pp a", - "p pa", - "ur eau", - "ure au", - "▁Le ip", - "▁ob jet", - "▁obj et", - "▁Act ivity", - "▁Activ ity", - "▁ Activity", - "em bers", - "ember s", - "emb ers", - "v r", - "▁con du", - "▁cond u", - "Cell s", - "C ells", - "in us", - "inu s", - "▁' ,", - "▁ ',", - "▁af raid", - "▁х а", - "▁ ха", - "▁V ic", - "▁Vi c", - "test ing", - "tes ting", - "Tu be", - "T ube", - "▁v ast", - "▁va st", - "▁vas t", - "P M", - "ni h", - "n ih", - "SS N", - "S SN", - "▁Ch ile", - "▁Chi le", - "yl van", - "▁B ow", - "▁Bo w", - "▁relig ion", - "op her", - "oph er", - "ophe r", - "o pher", - "▁C oll", - "▁Col l", - "▁Co ll", - "▁ Coll", - "▁dig ital", - "▁digit al", - "zi oni", - "z ioni", - "Se ction", - "Sec tion", - "S ection", - "▁резу льта", - "Foo t", - "F oot", - "con vert", - "conv ert", - "▁rece iving", - "Cont act", - "▁h ero", - "▁he ro", - "▁her o", - "sa m", - "s am", - "▁pos terior", - "▁poster ior", - "▁poste rior", - "ow i", - "o wi", - "An t", - "A nt", - "▁fl ags", - "▁flag s", - "▁fla gs", - "▁ flags", - "▁Ze aland", - "▁b ounds", - "▁bound s", - "▁ bounds", - "▁where as", - "▁whe reas", - "in fl", - "inf l", - "Pl ay", - "P lay", - "▁d emo", - "▁de mo", - "▁dem o", - "▁ demo", - "▁g ibt", - "▁gi bt", - "▁h ospital", - "▁hosp ital", - "▁v olta", - "▁vol ta", - "▁volt a", - "л ё", - "▁f ashion", - "▁ex ceed", - "▁exc eed", - "el enium", - "elen ium", - "It er", - "I ter", - "kr ie", - "k rie", - "▁integr ation", - "▁integra tion", - "▁ integration", - "▁Other wise", - "ad u", - "a du", - "Sh e", - "S he", - "on de", - "ond e", - "o nde", - "ui nt", - "u int", - "rad ius", - "▁r am", - "▁ra m", - "▁ ram", - "▁ál bum", - "▁т ур", - "▁ту р", - "▁ тур", - "▁d y", - "▁ dy", - "▁O tt", - "▁Ot t", - "▁пер и", - "▁пе ри", - "re v", - "r ev", - "ri or", - "rio r", - "r ior", - "í d", - "ir at", - "ira t", - "i rat", - "▁в клю", - "▁import ante", - "▁important e", - "▁Du ke", - "▁caus a", - "▁ca usa", - "▁Math emat", - "▁di plom", - "▁N icol", - "▁Nic ol", - "▁Ni col", - "▁ex clus", - "▁exc lus", - "▁debug ging", - "▁G h", - "or iginal", - "origin al", - "orig inal", - "ly n", - "l yn", - "▁P la", - "▁Pl a", - "su ite", - "suit e", - "ch at", - "cha t", - "c hat", - "▁e stud", - "▁est ud", - "ue lle", - "uel le", - "u elle", - "▁p ert", - "▁per t", - "▁pe rt", - "▁ pert", - "▁import ance", - "▁appro aches", - "▁approach es", - "▁d la", - "▁про ф", - "Pr es", - "Pre s", - "P res", - "< \\", - "pre fix", - "p refix", - "SS ION", - "S SION", - "ро ди", - "род и", - "count ry", - "c ountry", - "it zer", - "itz er", - "▁ко р", - "▁к ор", - "▁ кор", - "▁sing ular", - "go v", - "g ov", - "ри н", - "р ин", - "▁F A", - "▁ FA", - "▁mat rices", - "ol are", - "ola re", - "olar e", - "o lare", - "ni ka", - "nik a", - "n ika", - "po wer", - "pow er", - "p ower", - "ll a", - "l la", - "▁des ire", - "▁famil ia", - "▁fam ilia", - "до р", - "д ор", - "▁f an", - "▁fa n", - "▁ fan", - "gener ated", - "generate d", - "▁C os", - "▁Co s", - "▁ż e", - "▁ że", - "▁D iese", - "▁Die se", - "▁Di ese", - "▁Dies e", - "mo v", + "amin otransfer", + "18 65", + "40 .5", + "ass ociated▁with", + "\n\nY ou", + "OR TC", + "▁days )", + "▁rel ated▁to", + "ivid ual▁", + "▁PFS ▁event", + "▁document ed▁", + ".\n\nC onfidential\n\nPage▁", + "▁17: 07", + "▁A618 1120", + "rof t", + "\\Approved\\Approved▁On: ▁25-", + "laboratory ▁test", + "alate▁ Salt", + "▁compl y▁with", + "curr ence▁", + "return ed▁to", + "▁wors ening", + "▁ha zard▁ratio", + "esoph ag", + "corpor ating", + "ouble- blind", + "gi ogenes", + ",▁25 ▁October▁2010", + "174 1865", + "Oct -2010", + "affin- embedd", + "▁L-M alate▁Salt", + "▁Protocol▁Amendment▁6 ,▁25▁October▁2010", + "▁A6181120 ▁Protocol▁Amendment▁6,▁25▁October▁2010", + "\\Approved\\Approved▁On:▁25- Oct-2010", + "1741865 \\Approved\\Approved▁On:▁25-Oct-2010", + "1741865\\Approved\\Approved▁On:▁25-Oct-2010 ▁17:07", + "6 3", + "b stract", + "c op", + "m ail", + "m eet", + "o or", + "s unitinib", + "s ▁and▁the▁", + "s ▁associated▁with", + "on e", + "▁a ▁2", + "er ror", + "▁th os", + "▁p otential", + "▁c are", + "▁b one▁scan", + "ation ▁for", + "▁of ▁treatment", + "▁and▁ S", + ".\n\n 13", + "em ographic", + "▁S econdary▁", + "am ily▁", + "od y▁", + "ate▁ a", + "▁pro gnostic", + "op port", + "su perior", + "50 %", + "are a", + "s.\n\n The▁", + "................................................................................ ..", + "pare d", + "which ever", + "▁sit u", + "collect ed▁", + "ros s", + "statist ic", + "▁cut off", + "sk i", + "emetrexed▁H3E-MC-JM HR", + "lead ing▁to", + "eng th", + "▁(94)\n\nGEL▁Version▁ID:▁CV.000−522−306.7 .0▁Approved▁by\n\nApproved\n\nDate▁Printed:▁30−Jul−2014\n\nS▁18▁Feb▁2011▁11:38:55", + ". V", + "1 \n\n7", + "7 ▁December▁2010", + "d estroy", + "i arrhea", + "m aging", + "p air", + "re plac", + "al ing", + "▁c entral▁", + "as m", + "▁d imension", + "▁and▁ f", + "▁and▁ will", + "▁in ▁S", + "▁in vestigational", + "oc al▁", + "oc hem", + "▁C ell", + "il i", + "▁( d", + "ot oxic", + "▁l ist", + "eas ures", + "ad ir", + "e▁s ize▁", + "▁0 6", + "ph yl", + "\n\n1 1", + ".▁S ampl", + "s▁will▁be▁ performed▁", + "▁pl eur", + "▁per formed▁", + "pec ial", + "▁10 :", + "cept ion", + "cent er", + "e.\n\n The▁", + "pre -", + "▁The▁ investigator", + "▁mg/m L", + "evelop ment▁of", + "Clinical▁ Practic", + "▁Th ere▁", + "non- target▁lesion", + "ulator y▁", + "06 :45", + "▁antibod y", + "ardi ogram", + "▁sever e▁", + "▁Dec ▁2010", + "▁17: 06:45", + "confirm ed▁", + "most ▁common", + "▁Ther apy", + "−6 40.5", + "controll ed▁", + "put er", + "▁days▁prior▁to ▁randomization", + "cript ive▁", + "emor rh", + "▁malign anc", + "▁mg/d L", + "ous▁in fusion", + "09 ▁June▁2009", + "ucl e", + "(106)\n\nGEL▁Version▁ID:▁ONC.000−272−636.4.0\n\nApproved\n\nDate▁Printed:▁13−Aug−2013\n\nApproved▁by\n\n13▁Sep▁2007▁17:17:03 \n\nAmended▁Clinical▁Study▁Protocol▁Drug▁Substance▁Cediranib▁(RECENTIN,▁AZD2171)▁Study▁Code▁D8480C00013", + "icalutam ide▁", + "U011248 ▁L-Malate▁Salt", + "▁08 ▁Dec▁2010", + "433 −640.5", + "ite▁blood▁ cell", + "▁Date:▁16▁July▁2004 \n\nPage▁", + "▁08▁Dec▁2010 ▁17:06:45", + ") ▁with", + "- Nov", + ": 14", + "M an", "m ov", - "▁de note", - "▁den ote", - "\") ]", - "\" )]", - "ou vern", - "ouv ern", - "ouve rn", - "ouver n", - "am an", - "ama n", - "a man", - "▁in ser", - "▁ins er", - "▁inse r", - "ij k", - "i jk", - "ot ta", - "ott a", - "o tta", - "er al", - "era l", - "e ral", - "де ль", - "д ель", - "() ->", - "( )->", - "▁p oder", - "▁po der", - "▁pod er", - "▁pode r", - "ig es", - "ige s", - "i ges", - "▁On line", - "▁we ird", - "ia c", - "i ac", - "▁quel ques", - "▁quelque s", - "ère nt", - "è rent", - "▁t el", - "▁te l", - "▁ tel", - "▁L atin", - "▁Lat in", - "ver ter", - "vert er", - "verte r", - "ля р", - "ро и", - "▁p df", - "▁pd f", - "▁ pdf", - "▁key word", - "▁ keyword", - "Hand le", - "A fter", - "re ce", - "rec e", - "▁ident ical", - "style sheet", - "styles heet", - "▁стан ови", - "▁станов и", - "▁k a", - "▁ ka", - "ce ment", - "cem ent", - "c ement", - "те т", - "т ет", - "▁c hat", - "▁ch at", - "▁cha t", - "▁ chat", - "▁M un", - "▁Mu n", - "ał a", - "a ła", - "AN T", - "A NT", - "ol óg", - "▁f ant", - "▁fa nt", - "▁fan t", - "▁for est", - "▁fo rest", - "▁fore st", - "▁ви ко", - "cu ss", - "cus s", - "c uss", - "▁se hr", - "pa g", - "p ag", - "ot ic", - "oti c", - "▁á ll", - "▁ál l", - "▁ áll", - "ма ти", - "мат и", - "▁\" '", - "+ \"", - "An imation", - "Anim ation", - "ходи т", - "ход ит", - "az u", - "a zu", - "▁pl ays", - "▁play s", - "▁pla ys", - "▁ plays", - "iz ioni", - "izi oni", - "izio ni", - "i zioni", - "ми че", - "▁b omb", - "▁bo mb", - "▁bom b", - "▁mer ely", - "▁mere ly", - "▁hold ing", - "▁hol ding", - "▁w enn", - "▁we nn", - "▁wen n", - "▁m edic", - "▁me dic", - "▁med ic", - "▁medi c", - "▁spe aking", - "▁speak ing", - "ong odb", - "ongo db", - "▁Cam pe", - "▁Camp e", - "in ity", - "ini ty", - "init y", - "▁я нва", - "() `.", - "()` .", - "( )`.", - "lu ss", - "lus s", - "l uss", - "▁H istoire", - "▁His toire", - "▁Hist oire", - "▁oper ating", - "▁opera ting", - "Ch annel", - "▁accur acy", - "▁b os", - "▁bo s", - "▁ bos", - "▁ev ident", - "ци ю", - "event s", - "ev ents", - "even ts", - "text rm", - "or eign", - "ore ign", - "▁i i", - "▁ ii", - "hr en", - "hre n", - "h ren", - "lo wer", - "low er", - "l ower", - "▁т ом", - "▁то м", - "▁ том", - "▁Ab out", - "▁ About", - "▁a j", - "▁ aj", - "er i", - "e ri", - "сту пи", - "ступ и", - "▁di git", - "▁dig it", - "▁ digit", - "▁Sp ain", - "▁D aten", - "▁Date n", - "▁Da ten", - "▁Dat en", - "▁for me", - "▁form e", - "▁ш та", - "▁ шта", - "▁B ach", - "▁Ba ch", - "▁Bac h", - "no number", - "non umber", - "▁recomm ended", - "▁recommend ed", - "▁re ads", - "▁read s", - "his toire", - "h istoire", - "▁s ang", - "▁sa ng", - "▁san g", - "▁? ?", - "▁ ??", - "▁с тал", - "▁ст ал", - "▁ста л", - "sc ore", - "s core", - "fa s", - "f as", - "▁c ub", - "▁cu b", - "▁g rew", - "▁gr ew", - "▁gre w", - "▁cent ro", - "▁bek annt", - "Event s", - "BE R", - "B ER", - "he w", - "h ew", - "сс а", - "с са", - "▁major ity", - "ît re", - "î tre", - "en ci", - "enc i", - "▁Qu ery", - "▁Que ry", - "▁ Query", - "▁któ re", - "i ć", - "▁complex ity", - "▁Fran çois", - "const raint", - "ур на", - "═ ═", - "▁iter ate", - "le tt", - "let t", - "l ett", - "pe ror", - "per or", - "▁Neder land", - "sh are", - "sha re", - "▁incl u", - "▁inc lu", - "än ger", - "äng er", - "änge r", - "▁N ic", - "▁Ni c", - "ч о", - "F ull", - "▁ra pport", - "▁rapp ort", - "▁rap port", - "ec lipse", - "e clipse", - "▁indust ry", - "he aders", - "head ers", - "header s", - "▁Р и", - "ch sel", - "chs el", - "▁po lic", - "▁pol ic", - "sch ied", - "% ,", - "O D", - "▁J ak", - "▁Ja k", - "({ \\", - "( {\\", - "al igned", - "align ed", - "▁frequ ently", - "▁frequent ly", - "▁su oi", - "▁suo i", - "▁ess entially", - "▁essential ly", - "▁R ic", - "▁Ri c", - "▁re ports", - "▁report s", - "▁dec imal", - "ra r", - "r ar", - "▁F oo", - "▁Fo o", - "▁ Foo", - "▁K a", - "▁D C", - "▁ DC", - "▁sim pler", - "▁simple r", - "▁simp ler", - "▁simpl er", - "Pa ne", - "Pan e", - "P ane", - "? }", - "So rt", - "S ort", - "▁pos it", - "cd n", - "c dn", - "kt ur", - "▁aw k", - "▁ awk", - "зе р", - "з ер", - "P F", - "u ur", - "▁R oss", - "▁Ro ss", - "▁Ros s", - "▁m ant", - "▁ma nt", - "▁man t", - "N a", - "Con s", - "Co ns", - "C ons", - ")) ))", - "))) )", - ") )))", - "▁techn iques", - "▁techni ques", - "▁technique s", - "im pl", - "imp l", - "▁dro pped", - "▁drop ped", - "▁L ista", - "▁List a", - "▁Li sta", - "▁Lis ta", - "▁Bas ically", - "▁Basic ally", - "en tal", - "ent al", - "enta l", - "▁cel ui", - "▁str ategy", - "▁strateg y", - "▁strat egy", - "▁W ales", - "▁Wal es", - "▁Wa les", - "na n", - "n an", - "▁g min", - "▁gr öß", - "▁eer ste", - "▁eerst e", - "T im", - "nt en", - "n ten", - "re sp", - "res p", - "r esp", - "▁s table", - "▁st able", - "▁sta ble", - "▁ stable", - "no v", - "n ov", - "ro b", - "r ob", - "но ј", - "▁mar riage", - "get String", - "Aut hor", - "Auth or", - "▁G raf", - "▁Gr af", - "▁Gra f", - "▁di agram", - "▁diag ram", - "▁dia gram", - "gi a", - "g ia", - "Net work", - "N etwork", - "▁com posed", - "▁comp osed", - "▁compos ed", - "▁compose d", - "▁miss ed", - "▁mis sed", - "▁M eg", - "▁Me g", - "▁пра во", - "▁прав о", - "▁hom onymes", - "▁Bo oks", - "▁Book s", - "▁en cou", - "▁enc ou", - "port e", - "por te", - "p orte", - "▁rot ation", - "▁f ir", - "▁fi r", - "▁ fir", - "те льно", - "тель но", - "▁g un", - "▁gu n", - "▁ gun", - "▁A ff", - "▁Af f", - "▁ Aff", - "но к", - "н ок", - "▁Fuß ball", - "▁St ory", - "▁Sto ry", - "▁ Story", - "▁Ch ap", - "▁Cha p", - "▁) .", - "▁ ).", - "▁Se it", - "мо н", - "м он", - "▁t élé", - "▁té lé", - "▁cop ied", - "▁cons istent", - "▁consist ent", - "▁dr ink", - "▁C ham", - "▁Ch am", - "▁Cha m", - "▁mat ters", - "▁matter s", - "▁render ed", - "▁rend ered", - "▁rende red", - "▁hyp oth", - "œ uv", - "▁me er", - "▁par sing", - "▁P RO", - "▁PR O", - "▁ PRO", - "se ries", - "ser ies", - "serie s", - "s eries", - "▁z á", - "▁ zá", - "stra ße", - "▁B oot", - "▁Bo ot", - "▁ Boot", - "▁re po", - "▁rep o", - "▁ repo", - "wo r", - "w or", - "▁St ream", - "▁Stre am", - "▁ Stream", - "▁A N", - "▁ AN", - "▁п ів", - "▁пі в", - "▁S M", - "▁ SM", - "▁A rn", - "▁Ar n", - "▁ Ž", - "▁[ ];", - "▁[] ;", - "Res ources", - "Resource s", - "▁el abor", - "▁ela bor", - "▁E th", - "▁Et h", - "▁l iste", - "▁li ste", - "▁list e", - "▁rel atively", - "▁relative ly", - "▁relativ ely", - "ch ant", - "chan t", - "cha nt", - "=\" \"", - "= \"\"", - "▁l ift", - "▁li ft", - "▁lif t", - "C N", - "Service s", - "Serv ices", - "ME NT", - "M ENT", - "▁и гра", - "▁иг ра", - "▁ игра", - "б ре", - "▁J ord", - "▁Jo rd", - "▁t ec", - "▁te c", - "ш ка", - "▁S up", - "▁Su p", - "▁infl uen", - "▁influ en", - "on ds", - "ond s", - "hand ler", - "handle r", - "▁b anda", - "▁band a", - "▁ban da", - "▁vert ices", - "▁z ap", - "▁za p", - "▁c ord", - "▁cor d", - "▁co rd", - "▁ cord", - "al ter", - "alt er", - "ze nia", - "zen ia", - "z enia", - "ât eau", - "âte au", - "▁know ing", - "▁Argent ina", - "Ar ea", - "Are a", - "A rea", - "ан е", - "а не", - "f c", - "=\" /", - "= \"/", - "▁M ik", - "▁Mi k", - "at ă", - "ie ux", - "ieu x", - "▁deutsch en", - "▁deutsche n", - "▁trad itional", - "▁tradition al", - "de code", - "dec ode", - "ve x", - "v ex", - "▁size of", - "▁ sizeof", - "▁F un", - "▁Fu n", - "▁ Fun", - "▁par ser", - "▁parse r", - "▁ parser", - "▁Flor ida", - "▁build ings", - "▁building s", - "▁Man uel", - "ri le", - "ril e", - "r ile", - "▁log ged", - "▁strong ly", - "▁re vol", - "▁rev ol", - "не е", - "xi co", - "xic o", - "x ico", - "▁F air", - "▁Fa ir", - "ca rt", - "car t", - "c art", - "▁W ort", - "▁Wo rt", - "▁Wor t", - "▁Jes us", - "em es", - "eme s", - "e mes", - "sch rift", - "Input Stream", - "wa d", - "w ad", - "▁gran des", - "▁grand es", - "▁grande s", - "▁númer o", - "▁O tto", - "▁Ot to", - "▁Ott o", - "ien tes", - "ient es", - "iente s", - "i entes", - "▁fam ous", - "ol ogne", - "olog ne", - "J e", - "ни ш", - "▁Guer ra", - "bar a", - "ba ra", - "b ara", - "▁c ad", - "▁ca d", - "el ve", - "br ace", - "bra ce", - "b race", - "▁J r", - "st able", - "sta ble", - "stab le", - "s table", - "EC T", - "E CT", - "lem ma", - "med iate", - "medi ate", - "media te", - "▁v in", - "▁vi n", - "▁ vin", - "▁mon ument", - "▁c v", - "▁ cv", - "▁w inter", - "▁win ter", - "▁trans formation", - "▁transform ation", - "▁N ick", - "▁Nic k", - "▁Ni ck", - "str onom", - "▁f rag", - "▁fr ag", - "▁fra g", - "▁in tel", - "▁int el", - "▁inte l", - "ra ction", - "rac tion", - "ract ion", - "r action", - "▁consider ing", - "▁consid ering", - "▁F le", - "▁Fl e", - "▁ ло", - "▁A près", - "▁Ap rès", - "▁A M", - "▁ AM", - "▁H um", - "▁Hu m", - "▁m undo", - "NE R", - "N ER", - "▁Be low", - "▁Bel ow", - "▁го рода", - "▁горо да", - "▁город а", - "ar ters", - "art ers", - "arter s", - "arte rs", - "-- \"", - "▁П е", - "▁ Пе", - "î t", - "▁t xt", - "▁tx t", - "▁ txt", - "an gers", - "ang ers", - "ange rs", - "anger s", - "▁t hy", - "▁th y", - "▁ thy", - "CL A", - "C LA", - "ib les", - "ible s", - "i bles", - "▁request ed", - "▁requ ested", - "▁Alex and", - "▁fact ors", - "▁fa ctors", - "▁factor s", - "▁produ ces", - "▁produce s", - "ning en", - "n ingen", - "▁со стоя", - "▁optim ization", - "ch od", - "cho d", - "c hod", - "> `", - "▁Wik ip", - "nost i", - "nos ti", - "n osti", - "▁compet ition", - "▁H ann", - "▁Ha nn", - "▁Han n", - "▁z ona", - "▁zo na", - "d c", - "de sign", - "des ign", - "▁Z u", - "▁e spec", - "▁es pec", - "▁espe c", - "▁esp ec", - "equ ality", - "equal ity", - "e quality", - "▁A bb", - "▁Ab b", - "▁develop er", - "▁ developer", - "▁\" ^", - "▁Sh ort", - "▁Sho rt", - "▁ Short", - "▁pl ans", - "▁pla ns", - "▁plan s", + "m aterial", + "s ?", + "\n\n With:", + "it em", + ",▁ ch", + ",▁ 19", + "▁to \n\n", + "▁and▁ PFS", + ".\n\n L", + "ur ation▁of", + "pl ication", + "▁1 .2", + "▁( ie,▁", + "▁h ttp://", + "▁pro cedure▁", + "op aus", + "▁ar e▁the▁", + "e\n\n D", + "ed▁in ▁accordance▁with", + ".2 2", + "▁of▁ 5", + "cor responding", + "ce ipt", + "▁st able▁", + "▁4 0", + "▁4 5", + "▁wh at", + "10 99", + "▁un blind", + "▁Protocol ▁A618", + "▁tumor ▁cell", + "ement ▁of", + "cent r", + "so on", + "s.\n\n P", + "every▁ 6▁week", + "▁im ag", + "▁the▁patient ▁is▁", + "no ▁longer", + "complet ed▁", + "▁the▁study▁ drug", + "▁Com bination", + "dis cretion", + "▁sh ould", + "clinical▁ study▁", + "▁start ing", + "▁Edition▁Number▁3▁Date▁ 7▁December▁2010", + "dec reas", + "adjust ed▁", + "▁bod y▁", + "quamous▁ cell", + "rincipal▁ Investigator", + "great er▁than", + "\n\nABI-007▁Clinical▁Trial▁Protocol:▁CA 031", + "▁orig inal", + "▁Monitoring ▁Committe", + "▁survival▁( OS", + "bear ing▁p", + "C00015 ▁Edition▁Number▁3▁Date▁7▁December▁2010", + "opport un", + "I B", + "l iver", + "s \n\nS", + "in a", + ",▁ 1", + "ic ro", + "▁m ost", + "▁m utation", + ".\n\n .▁T▁N▁E▁M▁U▁C▁O���D", + "el v", + "el iev", + "pl asma", + "if ▁the▁", + "op or", + "ed▁in ▁Appendix", + "ad equate▁", + "▁al ong", + "▁will▁be▁ assess", + "▁3 ▁:", "▁v it", - "▁vi t", - "iz able", - "iza ble", - "burg h", - "bur gh", - "ag em", - "age m", - "a gem", - "▁Pr int", - "▁Pri nt", - "▁Prin t", - "▁ Print", - "í v", - "▁su itable", - "▁suit able", - "pi cker", - "pic ker", - "pick er", - "p icker", - "Pro file", - "an dy", - "and y", - "▁qu ot", - "▁ quot", - "▁Dur ante", - "▁Durant e", - "▁Fran cia", - "▁Fr ancia", - "▁Franc ia", - "▁t art", - "▁tar t", - "▁ta rt", - "▁V enez", - "▁Ve nez", - "▁Ven ez", - "▁dis patch", - "▁disp atch", - "▁ dispatch", - "▁observ ations", - "▁observation s", - "▁ ż", - "In valid", - "▁occ urr", - "▁occur r", - "▁oc curr", - "т ки", - "Mem ento", - "M emento", - "▁S yd", - "▁Sy d", - "▁tiem po", + "▁st op", + "▁week ly▁", + "ed▁for ▁the▁", + "par agraph", + ",▁or ▁other", + ".▁If ▁you", + "................................................................................ ....", + ".\n\nP FIZER▁CONFIDENTIAL▁Page▁", + "▁year s▁of", + "▁disease▁progression ▁or", + "▁dis order", + "▁Amgen ▁Inc", + "di agnos", + "▁withdraw al", + "▁cl ass", + "▁advanced▁ non-", + "ops y▁", + ".▁It ▁is▁", + "zoledronic ▁acid", + "▁temper ature", + "persensitivity▁ reaction", + "▁06 ▁October▁2006", + "▁3▁: ▁2▁1", + "( 34", + "5 1", + "A ST", + "D is", + "c ial", + "e ep", + "l edg", + "n ual▁", + "p otential▁", + "e▁ all", + "\n\n [", + "st ant", + ",▁ st", + ",▁ in▁the▁", + "▁p ort", + "um ption", + "▁d ate:", + "al▁ relationship", + "ab ase▁", + "pro gress", + "ra p", + "anc reat", + "ex press", + "\n\nA t", + "▁T im", + "▁ad vers", + "▁treatment ▁assignment", + "ain t", + "▁is▁ defined▁as", + "e▁th e▁subject", + "▁of▁the▁ study▁", + "200 7", + "ated▁ for", + "rel imin", + "\n\nX ▁X▁X", + "EN C", + "▁ass ociated▁", + "18 cc", + "▁16 -Nov", + ").\n\n The▁", + "▁form ula", + ".\n\nP ro", + "▁report ing", + "vanc ed▁", + "comitant ▁Medication", + "▁can not▁be▁", + "-s pecifi", + "ship p", + "ENT S", + "(cid:120 )\n\n", + "▁x▁x ▁x▁x", + "▁baselin e▁to", + "oph il", + "▁sever ity", + "\n\nO verall", + "▁18 :5", + "\\Approved\\Approved▁On: ▁16-Nov", + "ild-t yp", + "MENT S", + "▁(se e▁", + "\n\nSunitinib ▁A6181120▁Protocol▁Amendment▁6,▁25▁October▁2010", + "olec ul", + "ood▁ Clinical▁Practic", + "atur e▁of", + "▁previous▁ dos", + "▁onc e▁", + ")\n\nGEL▁Version▁ID:▁CV.000− 433−640.5", + "stim ulating", + "earli er", + "▁endothel ial▁", + "-2006 ▁18:5", + "1741865\\Approved\\Approved▁On:▁25-Oct-2010▁17:07 \n\nSunitinib▁A6181120▁Protocol▁Amendment▁6,▁25▁October▁2010", + "U011248▁L-Malate▁Salt ▁Protocol▁A618", + "18cc \\Approved\\Approved▁On:▁16-Nov", + "U011248▁L-Malate▁Salt▁Protocol▁A618 1099", + "18cc\\Approved\\Approved▁On:▁16-Nov -2006▁18:5", + "C A", + "E fficacy▁", + "M ethod", + "P E", + "e \n\nP", + "h andl", + "n d▁", + "n ess▁of", + "p ath", + "at is", + "s▁ other▁than", + "re d▁to", + "st ip", + ",▁ 12", + "ar ction", + "▁b leeding", + "▁in ▁this▁", + "res ect", + "id ine▁", + "pro duc", + "un known", + "with hel", + "ap ac", + "am id", + "ch emist", + "▁treatment ▁effect", + "\n\nS afety▁", + "▁of▁ outcome▁variabl", + "................................................................ ....", + "▁o ste", + "▁com pens", + "▁the▁p revious▁", + "▁the▁in fusion", + "▁the▁t umor", + "▁the▁d rug", + "report ed▁as▁", + "ed▁at ▁baselin", + "................................................................................ ......", + "▁your ▁doctor", + "▁reg ion", + ".\n\nP age▁", + "provid ed▁to", + "number ▁of▁", + "▁result ▁in", + "▁Pro gression", + "s▁on ▁the▁", + "\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct: ▁AMG▁162▁Protocol▁Number:▁20040135▁Date:▁14▁November▁2006", + "\n\nO ther", + "▁pres erv", + "mor e▁", + "apec itabin", + "Ther apy▁", + "de em", + "▁decreas e▁in", + "platelet ▁count", + "oag ulation", + "\n\nAbraxis▁BioScience▁ 09▁June▁2009", + "\n\nRevised▁Clinical▁Study▁Protocol▁Drug▁Substance▁ZD4054▁Study▁Code▁D4320 C00033▁Edition▁Number▁3▁Date▁15▁February▁2011", + "etopos id", + "\n\nAb breviation", + "opy rim", + "▁Engl ▁J", + "accord ing▁to", + "▁of▁101\n\n090177e18069a3aa\\Approved\\Approved▁On:▁27-Sep-2007▁02:42 \n\n1▁4▁:▁5▁0▁7▁0▁0▁2▁-▁g▁u▁A▁-▁1▁3▁\\▁d▁e▁v▁o▁r▁p▁p▁A\n\n\\▁1▁.▁1▁\\\n\n8▁2▁1▁6▁6▁8", + "discus s", + ") .▁S", + ", ▁this▁", + "- of", + "- hour", + ": \n\n1", + "A ss", + "B X-EGF", + "P I", + "U L", + "U BJEC", + "d ated▁", + "f e", + "n ess▁", + "y ros", + "▁ efficacy", + "▁ eligibility▁", + "in cidence▁of", + "\n\n or", + "er c", + "y▁ in", + ",▁ will", + ",▁ subject", + ",▁ it▁is▁", + ".▁ With", + "ct iv", + "▁p articular", + "▁c ould▁", + "es cription", + "▁to ▁re", + "▁s elect", + "▁d elay", + "▁and▁ neck", + "▁1 :1", + "▁C O", + "▁( 1)", + "▁S RE", + "▁re st", + "▁D is", + "▁h yp", + "ter val▁", + "ex amin", + "end ar", + "per man", + "\n\nA ▁", + "ate▁ (", + "▁as pect", + "▁T axol", + "▁N utr", + "og n", + "\n\nS D", + "▁200 3", + "▁M ethods▁of", + "▁L D", + "▁H ar", + "s▁( eg,▁", + "▁study▁ ent", + "s.▁ H", + "ax an", + ".▁C lin", + "occur red▁", + "par ameter", + "▁data ▁from", + "\n\n3 ▁4", + "sh own", + "▁follow ing", + "▁follow ed▁by▁", + "agn etic", + "▁continu ous▁", + "▁should▁ not▁be▁", + "▁activ ities", + "▁number ▁of", + "given ▁to", + "RE AT", + "▁there▁ is▁a", + "........................................................................ ....", + "▁trans fusion", + "▁require d▁", + "▁thes e▁s", + "small -cell▁lung▁cancer", + "s▁includ ing", + "▁day▁ of", + "Ga ult", + "ackage▁ insert", + "▁respect ▁to", + "umbar▁sp ine▁", + "olid▁ Tumor", + "7 8", + "M A", + "h orm", + "l ack", + "r y,▁", + "s \n\nP", + "y /", + "y es", + "y ch", + "▁ qu", + "in vestigation", + "▁a ▁M", + "ic ▁acid▁", + "▁p regnancy▁test", + "▁c urv", + "▁s equ", + "ab as", + "anc e", + "anc e:", + "ag er", + "▁D isease▁", + "abl e\n\n", + "▁O ▁-", + "▁ad her", + "ib i", + "e\n\n The▁", + "ed▁b ased▁on", + "e▁s ystem", + ".▁A l", + "▁g l", + "▁at ▁baseline▁", + "▁ac cess▁to", + "▁In vestigational▁Product", + "▁is \n\n", + "▁tumor ▁response▁", + "▁ph armacokinetic", + ".\n\nA mgen", + "inal ization", + "▁evalu ate▁th", + "\n\n6 ▁0▁0▁2▁-", + "▁the▁tim e▁", + "-rel ated", + "uor opyrim", + "▁E▁T▁N▁I▁R▁P \n\nA", + "emat ology▁", + "particip ant", + "▁OF ▁T", + "▁the▁f inal", + "leas e▁", + "▁Final▁Protocol ▁06▁October▁2006", + "consistent ▁with", + "▁Require ment", + "▁t▁c ▁O▁-", + "▁of▁81 \n\nABI-007▁Clinical▁Trial▁Protocol:▁CA031", + "1\n\n7 ▁3▁:▁2▁1", + "U011248▁L-Malate▁Salt▁Protocol▁A6181099 ▁Final▁Protocol▁06▁October▁2006", + "18cc\\Approved\\Approved▁On:▁16-Nov-2006▁18:5 1\n\n7▁3▁:▁2▁1", + "yros ine▁", + "\n\n6▁0▁0▁2▁- ▁t▁c▁O▁-", + "\n\n6▁0▁0▁2▁-▁t▁c▁O▁- ▁1▁1", + "0 46", + "9 5", + "B L", + "K aplan-Meier", + "V EGFR", + "▁ el", + "\n\n ®\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁Panitumumab▁Protocol▁Number:▁20050251▁Date:▁10▁October▁2006\n\nPage▁", + "▁a ction", + "er y▁", + "s▁ such▁as▁", + "al \n\n", + "it l", + "▁the▁ m", + ",▁ etc", + "ed u", + "ed ▁through", + "▁c ase▁report▁form", + "▁b isphosphon", + "▁s lid", + "as one▁", + "▁and▁ c", + "▁C isplatin", + "pro blem", + "reat h", + "▁re cover", + "▁l ine▁", + "ec ome▁", + "ons et", + "▁and ▁to", + "op ath", + "ed▁in ▁this▁study", + "enc y▁of", + "In corporating", + "▁200 1,▁", + "▁of▁ 91", + "▁al tern", + "▁al pha", + "▁will▁be▁ perform", + "▁3 ▁–", + "▁v alid", + "▁6 ▁1▁1", + "dition al▁", + "▁the▁in formation", + "cons ist", + "▁V EGF", + "\n\nD iscontinu", + "19 ▁2001,▁", + "▁dos es▁", + "mon otherapy▁", + "includ ed▁in▁the▁", + "occur red", + "radi ograph", + "\n\nN ▁A", + "pre dn", + ").\n\n S", + "▁cycl es▁", + "e▁b y", + "rough out", + "fficac y", + "▁sh all", + ".▁N ▁Engl▁J", + "▁tissu e▁", + ".\n\nC ▁I▁N▁O▁R▁T▁C▁E▁L▁E", + ".▁Patients▁ with", + "▁increas ed▁", + "▁St at", + "oh ist", + "▁Ch ang", + "▁the▁end▁of ▁the▁", + ",▁as▁ well", + "........................................................ ....", + ".\n\nE ▁S▁A▁E▁L▁P", + "▁1▁6 ▁0▁0▁0▁0▁0▁1▁0", + "inf erior", + "▁compli ance▁with", + "emerg ent", + "▁June▁ 19▁2001,▁", + "sent ▁to", + "efer ▁to", + "\n\nC▁I▁N▁O▁R▁T▁C▁E▁L▁E\n\nN ▁A\n\nF▁O\n\nY▁P▁O▁C", + "impl ement", + "fication ▁factor", + "30-day▁ postdiscontinuation", + "exameth asone▁", + "▁dated▁ 23", + "uroQ ol", + "▁(80 )\n\nGEL▁Version▁ID:▁CV.000−433−640.5", + "unctional▁ Assessment", + "yoc ardial▁", + "▁date: ▁June▁19▁2001,▁", + "\n\n3▁4 ▁6▁1▁1", + "inalization ▁date:▁June▁19▁2001,▁", + "▁3▁– ▁dated▁23", + "\n\n3▁4▁6▁1▁1 ▁1▁6▁0▁0▁0▁0▁0▁1▁0", + "inalization▁date:▁June▁19▁2001,▁ Incorporating", + "- dose▁", + "4 W", + "8 2", + "A greement", + "d en", + "s urvival", + "e▁ J", + "on ist", + ",▁ Y", + ",▁ at", + "▁s o", + "▁s odium", + ".\n\n Th", + "ol ym", + "ac cur", + "▁P A", + "▁P emetrexed▁", + "con firmed", + "▁re con", + "▁re cruit", + "▁l og", + "▁or ▁n", + "ys pne", + "▁pro s", + "In vestigational▁Product", "▁st aff", - "▁sta ff", - "▁se ctions", - "▁section s", - "▁sect ions", - "▁ sections", - "▁s sh", - "▁ss h", - "▁ ssh", - "▁N GC", - "ë l", - "▁er re", - "▁err e", - "▁div ided", - "▁divide d", - "▁divid ed", - "▁With out", - "▁du rant", - "▁dur ant", - "▁j aar", - "▁ja ar", - "▁ −", - "▁sold iers", - "▁soldier s", - "ун к", - "la pse", - "lap se", - "laps e", - "▁Val ley", - "▁Vall ey", - "▁Valle y", - "▁( :", - "▁ (:", - "re ra", - "rer a", - "r era", - "▁d ével", - "▁dé vel", - "▁p éri", - "▁pé ri", - "▁calcul ation", - "▁calc ulation", - "▁ke ine", - "▁kein e", + "follow ed▁until", + "▁5 %", + "▁patients▁ will▁be▁", + "▁the▁in vestigational", + "▁ex pect", + "▁U S", + "str ong", + "\n\nN on-", + "s▁are▁ not", + "\n\nx ▁x", + "man agement", + "ibil ity▁of", + "part ▁of▁the▁", + "state▁ Cancer", + "........................................................................ ......", + "ype▁ I", + "ify ing", + "ecaus e▁", + "e▁f il", + "phase▁ II", + "▁November ▁2008", + "Grade▁ 4", + "▁NC I", + "g/m L", + "▁telephone▁ contact", + "ww w", + "ingle- agent", + "▁great er", + "cr ual", + "▁Methods▁of ▁assessment", + "\n\n6▁0▁0▁2▁-▁t▁c▁O▁-▁1▁1 ▁\\▁d▁e▁v▁o▁r▁p▁p▁A\n\n\\▁0▁.▁1▁\\", + "yspne a", + "8 ▁week", + "D esign", + "E ▁EV", + "G uid", + "V D", + "b lood", + "c roft", + "f ound", + "g emcitabine▁", + "l arg", + "m ograph", + "t ▁is▁", + "t raven", + "y ro", + "▁ µ", + "en og", + "s▁ per", + "▁the▁ 2", + "an op", + "ro po", + "▁p ublication", + "▁d eriv", + "▁m easur", + "om at", + "om agnes", + "▁C ox", + "▁C olorectal▁Cancer", + "ra w", + "▁I \n\nS▁I▁H▁T", + "▁f inding", + "am ic", + "▁or ▁2", + "\n\nP D", + "per cal", + "▁as ▁an", + "ef t", + "ast ic", + "age▁ and▁", + "not ification", + "▁subject s▁will▁be▁", + "s▁( ±", + "\n\n1 4", + "lo st", + "e▁d uring", + "▁is ▁to▁be▁", + "▁- ▁5", + "ci pl", + "appro pri", + "document ed▁", + "▁mod ification", + "▁any ▁time▁", + "▁diseas e", + "econdary▁ endpoint", + "........................................................ ......", + "70 54I", + "es▁or ▁No", + "▁meet ing", + "phase▁ III", + "ibility ▁that", + "ZD217 1", + "option al", + "95% ▁CI", + "ock croft", + "exclud ing", + "oag ul", + "opin ion", + "emetrexed▁H3E-MC-JMHO (b)▁Confidential\n\nProtocol▁Amendment\n\nPage▁", + "ongo ing", + "ancreat ic", + "enog raft", + "anop articl", + ", 5", + ", ▁a▁s", + "- 4", + ". 01", + "7 )▁(cid:", + "8 5", + "A 4", + "C riteria", + "C isplatin", + "C arboplatin", + "D ay▁1", + "I HC", + "K L", + "Q oL", + "c ard", + "e h", + "h ould", + "r un", + "s erious", + "s ▁thereafter", + "▁ d▁e▁v▁o▁r▁p▁p▁A\n\nProduct:", + "▁ urine▁", + "▁a mended▁", + "re com", + ",▁ respectively", + "ed▁ when", + "▁b lind", + "ation ship", + "as e▁of", + "al▁ CT▁scan", + "el an", + "▁A m", + "▁A im", + "ev ic", + "id em", + "▁( H", + "▁( L", + "us ual", + "▁O xaliplatin", + "enc e▁to", + "e▁s cor", + "▁of▁the▁ t", + "▁as▁ referenc", + "▁all ▁other", + "12 ▁November▁2008", + "ult i-", + "__ _", + "▁appro xim", + "articip ant", + "car ri", + "An alys", + "outcom es", + "IT Y", + "observ ation", + "▁rel ated▁", + ".\n\nThe▁ investigator", + "▁compar e▁", + "▁mL /min", + "▁Dec ▁2004", + "expect ed▁to", + "▁sp ir", + "ensitiv ity", + "util ity", + "▁serum ▁creatinine▁", + "▁contain ing", + "monitor ing", + "▁therap ies", + "rup t", + "▁of▁6 9", + "▁December ▁2004", + "▁participate▁in ▁this▁study", + "▁tabl et", + "▁necess ary", + "right ▁to", + "is▁or ▁her", + "Evaluation ▁Criteria", + "▁fatty ▁acid", + "kaline▁phosph atas", + "▁legally ▁acceptable▁", + "\n\n21 ▁Dec▁2004", + "efic i", + "127 −", + "relimin ary▁", + "www .", + "\n\n21▁Dec▁2004 ▁10:", + ") ,▁the▁", + ", ▁the▁patient", + ", ▁abdomen", + "7 1", + "A UC", + "d et", + "l em", + "s een", + "▁ own", + "▁ routine▁", + "er b", + "ed▁ out", + "ic kn", + "▁c ardiac", + "▁and▁ 3", + "▁and▁ OS", + ".\n\n [", + ".\n\n With:", + "res istant", + "ul ation▁of", + "▁E urop", + "ex ploratory▁", + "▁treatment ▁is▁", + ".1 2", + "ort ality", + "ant i-", + "\n\nS ection", + "▁that ▁may▁", + "▁of▁ 74", + "wh at", + "▁the▁s ign", + "bo emb", + "▁6 .4", + "▁study▁ (", + "▁the▁d os", + "▁pl an", + "CT C", + "▁study ▁therapy", + "pre h", + "to -", + "................................................................................................ ......", + "▁car e▁", + "collect ed▁for", + "▁loc ally", + "▁rel evant", + "man u", + "\n\nM ed", + "elig ible▁for", + "▁study▁drug ▁administration", + "▁part ner", + "▁Ch emotherapy▁", + "recommend ed▁that", + "Ph armac", + "▁therap ies▁", + "▁Grade▁3 ▁or▁4", + "▁Dose▁ Modification", + "▁limit ▁of", + "dec ision", + "curr enc", + "Report ▁Form", + "Protocol▁A618 10", + ".0▁Approved▁by\n\nApproved\n\nDate▁Printed:▁30−Jul−2014\n\nS ▁08▁Dec▁2010▁17:06:45", + "▁malign ant", + "lymph ▁nod", + "site▁ personnel", + "\n\nAbraxis▁BioScience▁ 12▁November▁2008", + "▁XIV ▁Page▁", + "\n\nAmended▁Clinical▁Trial▁Protocol▁5▁XRP6258/EFC6193\n\n21-Jul-2008▁Version▁number:▁1▁(electronic▁2.0 )\n\n", + "\n\n6▁0▁0▁2▁-▁t▁c▁O▁-▁1▁1▁\\▁d▁e▁v▁o▁r▁p▁p▁A\n\n\\▁0▁.▁1▁\\ \n\n3▁4▁6▁1▁1▁1▁6▁0▁0▁0▁0▁0▁1▁0", + "percal cemia", + "▁of▁69 ▁Addendum▁13", + ") ▁of", + "/ 00", + "/ carboplatin", + "> >", + "P CR", + "d ex", + "d ilut", + "r d▁", + "s am", + "\n\n n", + "or ac", + ",▁ Z", + "ro c", + ".▁ Onc", + "ed )\n\n", + "▁c apsul", + "es ,", + "ation ▁is▁", + "as ed▁on▁the▁", + "▁d istribution", + "▁d id▁not", + "▁m atch", + "im ag", + "▁( eg", + "us e▁", + "con cern", + "if fic", + "▁l ight", + "ep at", + "\n\nS U011248▁L-Malate▁Salt▁Protocol▁A6181099▁Final▁Protocol▁06▁October▁2006", + "▁r en", + ".▁A m▁J", + "▁on e▁or", + "▁B icalutamide▁", + "s,▁ which", + "12 ▁week", + "▁the▁p re", + "▁ex ploratory▁", + "\n\nX ▁X", + "▁tim e▁of", + "effect ▁of▁", + "NC I-", + "▁im portant", + "▁cons ecutive▁", + "e▁b y▁", + "▁visit ▁or", + "80 %", + "response▁ rat", + "-t reatment", + "........................................................................ ..", + "\n\nAn y", + "cer tain", + "▁hy pertension", + "▁confirm ed▁", + "ysical▁ Ex", + "withdraw al", + "▁the▁date▁of ▁randomization", + "clos ure▁", + "regard ing", + ")\n\nGEL▁Version▁ID:▁ONC.000− 127−", + "guidelin es", + "▁supplement ation", + "▁immedi ately▁", + "AC K", + "ovari ates", + "▁Ac count", + "BJEC TIV", + ".\n\nLY231514 \n\nPage▁", + "Lill y▁", + "▁histor y▁of", + "e▁sh own", + "Bri en", + "wor st", + "reatinine▁clear ance▁", + "(34 )\n\nGEL▁Version▁ID:▁ONC.000−127−", + "\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁AMG▁162▁Protocol▁Number:▁20040135▁Date:▁14▁November▁2006 \n\nPage▁", + "ibi otic", + "iffic ult", + "▁Bicalutamide▁ Study▁", + "BJECTIV ES", + "3 ▁F", + "M T", + "d ▁and▁", + "h o", + "i el", + "p urpos", + "s urger", + "t i-", + "t opos", + "v omiting", + "w it", + "▁ ", + "e▁ B", + "at ▁the▁end▁of", + "on ance▁", + "re vers", + "▁and▁ N", + "ur fac", + "pro b", + "pro cedure▁", + "con comitant", + "▁S unitinib", + "▁D IS", + "▁l ik", + "▁E ▁S▁A▁E▁L▁P", + "ch em", + "lin e▁", + "ep atic", + "................................................................ ..", + "e▁th e▁in", + "cor d▁", + ".▁A fter", + "▁4 6", + "▁ex ce", + "report ed▁in", + "▁pre dn", + "sh ow", + "dur ation▁of▁", + "▁reg ular", + ".▁F ollow", + "\n\nI ▁am", + ",▁S h", + "hy pertension", + "ox y", + "▁ap opt", + "▁particip ate▁", + "mod ified▁", + "s▁b etween", + "\n\n7 5%", + "arr is▁", + "1- day▁", + "▁activ ity▁of", + "Ad ministration", + "▁– ▁Amendment▁2", + "during▁the▁ study", + "Con ference▁", + "chemotherapy▁ regimen", + "y▁or ▁its▁design", + "▁AND ▁D", + "ATION AL", + "e.g .▁", + "ocyt openia", + ",▁h owever", + "kelet al▁", + "▁decid e▁to", + "▁the▁pres ence▁of", + "yrosine▁ kin", + "unctional▁Assessment ▁of▁Cancer", + "( eg,▁", + "/ leucovorin", + "8 ;", + "A TA", + "E FI", + "F R", + "G CP", + "I L", + "Q u", + "U G", + "c ogn", + "s ,\n\n", + "▁ Z", + "▁ iv", + "▁ ........................................", + "in itial", + "at e▁to", + "on t", + "s▁ occurring", + "al in", + "al og", + "ic ally", + "▁s ponsor", + "▁s upport", + "▁of ▁these▁", + "ou rag", + ".\n\n W", + "ol us▁", + "▁S ynops", + "▁D efinition", + "▁D eriv", + "ap er", + "▁E p", + "am p", + "e▁t rans", + "\n\nP R", + "▁O b", + "com p", + "▁treatment ▁phas", + "................................................................ ......", + "▁0 .5", + "▁3 .4", + "▁of▁the▁ following", + "▁L aboratory▁", + "▁at ▁any▁tim", + "\n\n1 ▁8", + "s▁in volv", + "▁of▁1 6", + "▁In formed▁Consent", + "vent or", + "▁is ▁to", + "▁month s,▁", + "▁ag ed▁", + "ace ut", + "arm aceut", + "▁cycl e▁of", + "sh ould", + "▁addition ▁to", + ".▁D ose▁", + "▁includ es", + "▁discontinu e▁", + "hase▁ III", + "dose▁ reduction", + "▁new ▁lesion", + "▁previ ously", + "▁protocol ▁amendment", + "questionna ire", + "▁AND ▁R", + "less ▁than", + "▁pemetrex ed▁and▁", + "▁Con t", + "lif e-threatening", + "▁vari able▁", + "inf arction", + "▁mic ro", + "lat elet", + "▁mon oclonal", + "▁Per formance▁Stat", + "ation▁or ▁calculation", + "\n\nRevised▁Clinical▁Study▁Protocol▁Drug▁Substance▁ZD4054▁Study▁Code��D4320 C00015▁Edition▁Number▁3▁Date▁7▁December▁2010", + "TIC AL", + "pheral▁ neuropath", + "solute▁ neutrophil", + "▁of▁101\n\n090177e18069a3aa\\Approved\\Approved▁On:▁27-Sep-2007▁02:42\n\n1▁4▁:▁5▁0▁7▁0▁0▁2▁-▁g▁u▁A▁-▁1▁3▁\\▁d▁e▁v▁o▁r▁p▁p▁A\n\n\\▁1▁.▁1▁\\\n\n8▁2▁1▁6▁6▁8 ▁6▁0▁0▁0▁0▁0▁1▁0\n\nSunitinib▁Malate▁Amended▁Protocol▁A6181122▁Amendment▁1,▁28▁August▁2007", + "▁of▁81\n\nABI-007▁Clinical▁Trial▁Protocol:▁CA031 \n\nAbraxis▁BioScience▁09▁June▁2009", + "18cc\\Approved\\Approved▁On:▁16-Nov-2006▁18:51\n\n7▁3▁:▁2▁1 \n\n6▁0▁0▁2▁-▁t▁c▁O▁-▁1▁1▁\\▁d▁e▁v▁o▁r▁p▁p▁A\n\n\\▁0▁.▁1▁\\\n\n3▁4▁6▁1▁1▁1▁6▁0▁0▁0▁0▁0▁1▁0", + "Conference▁ on", + "▁Deriv ation▁or▁calculation", + "( 6", + "C od", + "H y", + "L Q", + "N I", + "Y ▁T▁I▁D▁I▁L▁A▁V", + "g ent", + "g ether", + "i ▁S", + "m ark", + "r d", + "▁ end▁of", + "or th", + "al ▁cell", + "ed▁ upon", + "▁p ulmonary▁", + "▁b ox", + "▁to ▁receive▁", + "▁to ▁follow-up", + "is ition", + "▁s om", + "▁of ▁subject", + "pl ay", + "▁C etuximab", + "▁S A", + "▁h is▁or▁her", + "enc es", + ".1 1", + ".2 .5", + "In ternational▁", + "▁is▁ in", + "▁al ter", + "▁con comitant▁medication", + "▁g uid", + "▁B :", + "▁all ergic", + "tud ies▁", + "▁H y", + ")\n\n (cid:", + "\n\n1 00", + "▁patient s,▁", + "▁have▁ no", + "▁un iqu", + "ated ▁and▁", + "ed▁at ▁a", + "ran ul", + ".7 .1", + "bas is▁of", + "ff ect", + "\n\n3 \n\n3", + "ci ally", + "\n\nAd verse▁Event", + "▁30 ▁days▁after", + "ox ant", + "▁particip ation▁in", + "s▁will ▁also▁be▁", + "s▁after ▁the▁last▁dose▁of", + "GEL▁Version▁ID: ▁ONC.000−", + "▁antibod ies▁", + "▁Appendix ▁D", + "meric a", + "\n\nSection: ▁10", + "e▁from ▁baseline▁", + "\n\n090177e18 1741865\\Approved\\Approved▁On:▁25-Oct-2010▁17:07\n\nSunitinib▁A6181120▁Protocol▁Amendment▁6,▁25▁October▁2010", + "align anc", + "ify▁ for", + "▁appropri ate", + "previ ous▁", + "▁mon otherapy▁", + ",▁w e▁will", + "while▁ on", + "▁plann ed▁", + "▁or▁MRI ▁scan", + "e▁dos e▁of", + "▁darbepoetin▁alfa ▁Protocol▁Number:▁20010145", + "otherwis e▁", + "urvival▁(PFS )", + "ortic ost", + "alli ative▁", + "▁Har mon", + "olym orph", + "▁darbepoetin▁alfa▁Protocol▁Number:▁20010145 ▁–▁Amendment▁2", + "W BC", + "] )", + "l aborator", + "l /00", + "r ile▁", + "▁ ±", + "e▁ A", + "in k", + "er s▁", + "ar -2007", + "▁b egin", + "▁b ronch", + "for ▁each", + "▁w rit", + "om er", + ".\n\n 1", + "ol in", + "▁A NC", + "▁in hibition", + "▁1 20", + "ra y▁", + "▁S chedul", + "▁re f", + "▁re current", + "▁E vent", + "ch osen", + "▁or al", + "\n\nA rm", + "▁T oxicity▁", + "▁will▁be▁ asked▁to", + "▁will▁be▁ censored▁at", + "e▁s hould▁", + "wh il", + "▁wh er", + "e▁d etail", + "▁is ▁an", + "▁7 5%", + "▁ab normal▁", + "▁ob jectiv", + "defin ed▁in▁Section", + "▁therapy▁ or", + "ru e▁", + "perform ed▁as▁", + "▁complet ion", + "▁Com pli", + "▁approximately▁ 30", + "hem oglobin", + "▁their ▁last", + "ild -T", + "s▁will ▁not▁be▁", + "▁rel ated", + "review ▁bo", + "yn amic", + "▁observ ed▁in", + "▁Report ed▁Outcom", + "▁only▁ be▁", + "▁take▁ part", + "evaluated▁ for", + "\n\nABI-007▁Clinical▁Trial▁Protocol:▁CA 046", + "portion al▁", + "etopos ide▁", + "opin ion▁of▁the▁", + "▁del iver", + "▁(80)\n\nGEL▁Version▁ID:▁CV.000−433−640.5 .0▁Approved▁by\n\nApproved\n\nDate▁Printed:▁30−Jul−2014\n\nS▁08▁Dec▁2010▁17:06:45", + "yocardial▁ infarction", + "7054I l/00", + "- being", + "; ▁", + "D ay▁", + "E ▁S▁A▁E▁L▁P", + "R eplace:", + "V ES", + "V ERS", + "d etail", + "n ull", + "o z", + "\n\n d▁e▁v▁o▁r▁p▁p▁A", + "▁a ▁minimum", + "er s", + ",▁ randomized,▁", + "ed▁ visit", + "ed ,▁the▁", + "▁b reast", + "es s▁or", + "▁s etting", + "▁of ▁2", + "▁and▁ will▁be▁", + "▁( 0", + "▁2 .3", + "con current", + "anc e▁to", + "▁S oc", + "▁l ower", + "ap able▁of", + "ex perience▁", + "ex periment", + "abl e,▁", + "▁will▁be▁ record", + "event s▁", + "▁com p", + "200 0", + "int raven", + "int oler", + "e▁in dic", + "platin um", + "gen eral", + "ens iv", + "▁V isit", + "reg ular", + "e▁d aily▁", + "TI G", + "▁un it", + "▁from ▁study▁treatment", + "▁month s▁(", + "e- to-", + ",▁and /or", + "▁le ad▁", + "St atistical▁", + "▁the▁tim e▁of▁the▁", + "s▁b efor", + "arr ho", + ".2.1 .1", + "▁metastatic ▁breast▁cancer", + ".▁N ew", + "▁chemotherapy▁ (", + "▁chang e▁in", + "oph or", + "\n\nG en", + "▁ver tebral▁", + "▁in▁combination▁with ▁docetaxel", + "\n\nAdd▁ 3", + "util iz", + ",▁which ever", + "-bas ed", + "do ctor", + "rac ycl", + "\n\n.▁E▁S▁U \n\nE▁R▁O▁F▁E▁B\n\nY▁T▁I▁D▁I▁L▁A▁V", + "▁compl aint", + "standard▁ of", + "▁practic e▁", + ".0▁Approved▁by\n\nApproved\n\nDate▁Printed: ▁31−Jul−2014", + "combin ation▁of", + "▁of▁6 3▁F", + "▁randomis ation", + "▁adverse▁ effect", + "▁thre e▁", + "▁on-study▁ SRE", + "▁regression ▁model", + "men opaus", + "▁Procedure s▁for", + "YP 3", + "▁in▁S olid▁Tumor", + "oagul ant", + "manu fact", + "VES TIG", + "▁of▁63▁F inalization▁date:▁June▁19▁2001,▁Incorporating", + ") .▁", + "2 f", + "6 -", + "7 3", + "9 2", + "S TICAL", + "m ol/L", + "o ice▁", + "p ed", + "p ublish", + "v s.▁", + "w ay▁", + "’ Brien", + "in formed▁consent", + "in fection", + "on ▁a", + "on e▁in", + "▁a \n\n", + "al yt", + "ic ▁acid", + "ed uc", + "is s", + "um on", + "th racycl", + "▁w ild-type▁KRAS", + ".\n\n ST", + "ill er", + "▁A merica", + "ith m", + "▁C ons", + "est hes", + "es▁ should▁be▁", + "pro gressive▁disease▁", + "▁2 ▁:", + "▁S uppl", + "▁h emoglobin", + "▁E D", + "▁or ▁PR", + "▁and ▁an", + "ant ibod", + "▁of▁the▁ protocol", + "▁on going", + "▁at ▁the▁time▁of", + ".5 ▁mg", + ".▁S afety▁", + ".▁S unitinib", + "TI STICAL", + "▁U p", + "e▁the▁ following", + ".▁P re", + "record ed▁as", + "radi otherapy▁", + "25 %", + "▁16 :14", + "▁a▁s ingle▁", + "\n\nF ollow", + "ER ENC", + "ack ag", + "\n\n0 \n\n1\n\n2\n\n3\n\n4", + "▁19 -M", + ".\n\nC ONFIDENTIAL", + "design ed▁to", + "▁14 ▁March▁2007", + "Res pons", + "▁under ▁the▁", + ".\n\nT able▁", + "86 \\Approved\\Approved▁On:", + "\n\nAdd▁ 6", + "blood▁ sampl", + "dependent ▁E", + "recommend ation", + ".\n\nE ▁R▁O▁F▁E▁B", + "orig inal▁", + "Pl acebo", + "87 ▁Final▁Protocol", + "accept able▁", + "012 -0", + "emerg ency▁", + "▁immedi ate▁", + "orl d▁", + "judg ment", + "▁version ▁3.0", + ".\n\nY ▁T▁I▁D▁I▁L▁A▁V", + "▁50% ▁of", + "▁Peri od", + "▁child bearing▁p", + "▁work ing", + "PP END", + "abov e▁", + "\n\nH3E-MC-JMHD(f)▁Clinical▁Protocol \n\nPage▁", + "▁95% ▁CI", + "volum e▁of", + "▁As sign", + "emetrexed▁H3E-MC-JMHR (b)▁Confidential\n\nProtocol▁Amendment\n\nPage▁", + "lem ing", + "Protocol▁A61810 87▁Final▁Protocol", + "▁Derivation▁or▁calculation ▁of▁outcome▁variabl", + "▁darbepoetin▁alfa▁Protocol▁Number:▁20010145▁–▁Amendment▁2 ▁Date:▁16▁July▁2004\n\nPage▁", + "ar-2007 ▁16:14", + "VERS E▁EV", + "2f 86\\Approved\\Approved▁On:", + "▁2▁: ▁1▁1", + "▁19-M ar-2007▁16:14", + "Protocol▁A6181087▁Final▁Protocol ▁14▁March▁2007", + "2f86\\Approved\\Approved▁On: ▁19-Mar-2007▁16:14", + "- \n\n", + "A merican", + "D R", + "E G", + "P eri", + "f ill", + "m enc", + "p ur", + "p emetrexed▁", + "r ine▁", + "s \n\nAll", + "w id", + "in formed▁consent▁form", + "er lotinib", + "re cent", + "re cover", + "▁th ough", + "ed /", + "▁b irth", + "▁m ethyl", + "ol der", + "iv ing", + "ow ard▁", + "▁f inal", + "end or", + "oll ection", + "will▁be▁ assess", + "▁ar ch", + "ph ysical▁examination", + "▁F ACT-", + "▁all oc", + "▁6 ▁week", + "▁at ▁each", + "▁wh om", + "ept or", + "▁have▁ an", + "includ e▁", + "▁analysis▁ for", + "ed▁with ▁a", + "▁x -ra", + "▁disease▁ (", + "▁9 0", + "▁8 0%", + "etermin ation▁of", + "\n\nT ime▁to", + "▁follow ▁up", + "▁inter fer", + ".\n\nP atients▁", + "dos ing", + "outcom es▁", + "▁mod ified▁", + "▁rel ationship", + "IST ▁OF", + "▁respons e▁of", + "▁ne ed▁to", + "such ▁as", + "▁cl os", + "▁phase▁ III", + "primary▁ endpoint", + "central▁ imaging", + "i. e.▁", + "remain ing", + "lat er", + "▁determine▁ if", + "▁possibl e▁", + "bum in-", + "▁character istic", + "IMC- 11F8", + "fat igu", + "apt ure", + "astrointest inal▁", + "▁strat um", + "for▁exampl e,▁", + "antic ip", + "ORD ERS", + "30-day▁postdiscontinuation ▁follow-up", + "▁DIS ORDERS", + "Conference▁on ▁Harmon", + "orticost eroid", + "YP3 A4", + "- B", + "- valu", + ". g", + "8 )", + "9 )", + "S U", + "S ystem", + "b elow", + "e (s)", + "h old▁", + "i h", + "▁ ↓", + "at l", + "\n\n will▁be▁", + "en d▁", + "er yth", + "al vert", + "ent ly", + "▁the▁ use▁of", + ",▁ except", + "ing ▁of▁", + "ing ▁information", + "▁b rain", + "▁to ▁1", + "▁s oft", + "▁m olecul", + ".\n\n 11", + "al▁ CT", + "ol unt", + "ab out", + "pro gnostic", + "▁2 .5", + "▁I EC", + "▁D ays▁", + "▁f our", + "ate▁ and▁", + "▁pro stat", + "▁for ▁each", + "ed▁in formed▁consent▁form", + "▁treatment ▁cycl", + "s▁of ▁a", + "▁r ▁a▁M", + "▁3 ▁1▁6", + "▁con vention", + "▁the▁s econd▁", + "will ▁receive▁", + "▁4 8", + "▁ac ut", + "one▁ or", + "s.▁ This▁", + "▁pl ac", + ".▁P anitumumab", + "may▁ occur", + "▁adverse▁event s▁(", + "▁per for", + ".▁In ▁the▁event", + "RI AL", + "▁9 .1", + "pre vention", + ").\n\n P", + "ification ▁number", + "defin ition", + "ack aging", + "▁An alysis▁", + "pecific ▁Aim", + "▁et▁al ,▁199", + "\n\n7 ▁0▁0▁2▁-", + "▁sh ip", + "▁gen e▁", + "s▁from ▁the▁", + "long er", + "describ ed▁in▁the▁", + "describ ed▁in▁Section", + "▁first -line▁treatment", + "▁Grade▁ 1", + "▁period▁ of", + "hav ing", + "▁dat e.\n\n", + "▁compl ication", + "▁determine▁ whether", + "▁may ▁also", + "▁statist ical", + "TIV E", + "United▁ St", + "-term ▁follow-up", + "-to -treat", + "stric t", + "▁prot ect", + "vir on", + "▁endothelial▁ growth▁factor", + "▁-▁5 ▁1", + "\n\n1▁8 ▁3▁1▁6", + "solute▁neutrophil ▁count", + "18cc\\Approved\\Approved▁On:▁16-Nov-2006▁18:51\n\n7▁3▁:▁2▁1\n\n6▁0▁0▁2▁-▁t▁c▁O▁-▁1▁1▁\\▁d▁e▁v▁o▁r▁p▁p▁A\n\n\\▁0▁.▁1▁\\\n\n3▁4▁6▁1▁1▁1▁6▁0▁0▁0▁0▁0▁1▁0 \n\nSU011248▁L-Malate▁Salt▁Protocol▁A6181099▁Final▁Protocol▁06▁October▁2006", + "▁2▁:▁1▁1 \n\n7▁0▁0▁2▁-", + "▁r▁a▁M ▁-▁5▁1", + "\n\n1▁8▁3▁1▁6 ▁4", + "▁2▁:▁1▁1\n\n7▁0▁0▁2▁- ▁r▁a▁M▁-▁5▁1", + "( 5", + "3 :", + "9 0%", + ": ▁a", + ": \n\n\n\n", + "; ▁(", + "D E", + "b reast", + "c ould▁", + "d ay", + "m arker", + "p ower", + "r b", + "v s▁", + "ent ial▁", + "▁an swer", + "▁c all", + "▁d ef", + "▁m l", + "▁and▁ P", + ".\n\n 15", + "▁C arboplatin", + "es▁ may▁be▁", + "con centration", + "un treat", + "cl ar", + "am ount", + "ons quamous▁", + "▁R andomization", + "ed▁in ▁Table▁", + "▁treatment ▁and▁", + "enc e\n\n", + "In t", + "▁that ▁are▁", + "▁al bumin", + "▁will▁be▁ summariz", + "▁3 8", + "▁g emcitabine▁", + ".3 .4", + "▁B lood▁", + "▁6 .1", + "ase▁ Report▁Form", + "ept id", + "ced iranib", + "▁W C", + "▁day s▁before▁randomization", + "enter ed▁into", + "JM IG", + "hem or", + "loc al", + "▁requ ire▁", + "e▁m ust", + "well ▁toler", + "▁Y ou", + "��anti- cancer", + "▁CA 012-0", + "hyd rox", + "reason ▁for", + "aintain ▁dose▁level", + "adjust ment", + "sk y▁", + ".▁Wh en", + "▁termin ation", + "▁questionna ire", + "hemist ry", + "▁taking ▁as▁referenc", + "▁Pain ▁In", + "course▁of ▁the▁study", + "class ified▁as▁", + "▁Randomiz ed,▁", + "ohn son", + "▁reasonable▁ poss", + "opportun ity▁to", + "agnetic ▁res", + ".\n\nAmgen ▁Thousand▁Oaks", + "preh ensive▁", + "onance▁ imaging", + "olymorph ism", + "2f86\\Approved\\Approved▁On:▁19-Mar-2007▁16:14 \n\n0", + ". S", + "1 ]", + "5 ,▁", + "D C", + "D ocument", + "E uropean", + "M IN", + "b od", + "b efore▁the▁", + "h yp", + "i agnos", + "m outh", + "p emetrex", + "t d", + "u s▁will▁be▁", + "w e▁", + "▁ ep", + "▁ our", + "▁ .▁T▁N▁E▁M▁U▁C▁O▁D", + "▁t eam", + "at ▁the▁time▁of", + "\n\n g", + "\n\n an", + "\n\n GEL▁Version▁ID:▁ONC.000−", + "s▁ when", + "re ach", + "al cul", + "st ain", + ".▁ Your", + "ing ▁that", + "es .", + "es .▁The▁", + "▁to ▁determine▁the▁", + "as e-", + "el y,▁", + "ur r", + "▁re tain", + "▁re mov", + "▁or ▁e", + "ir cul", + "ator y", + "▁T rial", + "ast er", + "and ▁the▁", + "rom atas", + "▁treatment ▁of", + "enc ourag", + "In formed▁Consent▁Form", + "e▁s um", + "e▁th ickn", + ".▁A vailable▁", + "▁will ▁provid", + "s▁( or", + "▁any▁ un", + "s▁and▁ other", + ".▁S ubjects▁", + "ang i", + "▁G CP", + "▁un able▁to", + "▁is ▁administer", + "▁adverse▁event s,▁", + "50 ▁mg/m2", + "te er", + "▁9 9", + "every▁ 2▁week", + "ard▁ (", + "ind ow", + "▁a▁s eparate▁", + "▁min im", + "199 9", + ".▁R ec", + "▁complet e▁the▁", + "otent ially▁", + "dis pens", + "e▁S ize▁", + "blind ed▁", + "go al", + "PA RC", + "Version ▁3.0", + "▁mm ol/L", + "▁phase▁ II", + "▁symptom atic", + "........................................................................................................ ..", + "central▁ laboratory", + "ness ▁to", + "▁ens ure▁", + "%▁of ▁previous▁dos", + "ribut ed▁to", + "▁compli anc", + "-based▁ chemotherapy", + "▁objective▁ progression", + "IM P", + "(S D", + "▁the▁primary ▁analysis▁", + "▁qual ify▁for", + "▁6▁0▁0▁0▁0▁0▁1▁0\n\nSunitinib▁Malate▁ Protocol▁A6181087▁Final▁Protocol▁14▁March▁2007", + "▁direct ly▁", + "head ach", + "▁any▁of ▁the▁following", + "lic e▁thickn", + "Rel ated▁", + "▁Or gan", + "e▁fil ter", + "arrho ea", + "ERENC ES", + "▁Assign ment", + "viron ment", + "\n\n1▁8▁3▁1▁6▁4 ▁6▁0▁0▁0▁0▁0▁1▁0\n\nSunitinib▁Malate▁Protocol▁A6181087▁Final▁Protocol▁14▁March▁2007", + "▁2▁:▁1▁1\n\n7▁0▁0▁2▁-▁r▁a▁M▁-▁5▁1 ▁\\▁d▁e▁v▁o▁r▁p▁p▁A\n\n\\▁0▁.▁1▁\\", + "agnetic▁res onance▁imaging", + "- lif", + "N e", + "S 130", + "U LN", + "b al", + "d iffer", + "d ay▁1", + "h old", + "h alf", + "p a", + "r iv", + "in or", + "at ▁any▁tim", "er tain", - "ert ain", - "erta in", - "▁те ле", - "ру д", - "▁c ul", - "▁cu l", - "▁ cul", - "▁cl oth", - "▁clo th", - "; }", - "▁pr zed", - "▁prze d", - "▁prz ed", - "Mon th", - "Mo nth", - "Mont h", - "Pi cker", - "P icker", - "▁S V", - "▁ SV", - "ar ian", - "ari an", - "aria n", - "a rian", - "▁Re view", - "▁Rev iew", - "▁h ang", - "▁ha ng", - "▁han g", - "▁ hang", - "▁о кт", - "▁ок т", - "▁F ront", - "▁Fr ont", - "▁Fro nt", - "▁ Front", - "ot lin", - "▁trans lation", - "▁transl ation", - "▁m odo", - "▁mod o", - "▁mo do", - "▁stat istics", - "▁statist ics", - "▁N ue", - "▁Nu e", - "▁Ни кола", - "NU M", - "N UM", - "▁s hips", - "▁sh ips", - "▁ship s", - "▁ ships", - "▁Re port", - "▁Rep ort", - "▁ Report", - "{ [", - "E ffect", - "ie ri", - "ier i", - "i eri", - "▁par ties", - "▁part ies", - "▁partie s", - "▁parti es", - "pl a", - "p la", - "r w", - "▁Work s", - "▁Wor ks", - "▁i ron", - "▁ir on", - "▁att ract", - "▁attr act", - "▁attra ct", - "▁c ort", - "▁cor t", - "▁co rt", - "n á", - "▁Ste ve", - "▁b ene", - "▁be ne", - "▁ben e", - "то н", - "т он", - "ícul a", - "Tw o", - "T wo", - "▁г лав", - "▁гла в", - "▁V ideo", - "▁ Video", - "▁power ful", - "au ch", - "auc h", - "a uch", - "ma nde", - "man de", - "m ande", - "äch st", - "ächs t", - "La t", - "L at", - "▁z na", - "▁zn a", - "▁ zna", - "▁fig ures", - "▁figure s", - "▁figur es", - "▁a lias", - "▁al ias", - "▁ali as", - "▁ alias", - "ne x", - "n ex", - "▁c ategories", - "▁categ ories", - "▁categor ies", - "▁categorie s", - "▁ categories", - "cal led", - "call ed", - "c alled", - "▁Sim ilar", - "▁g irls", - "▁girl s", - "▁gir ls", - "pe z", - "p ez", - "▁j oint", - "▁jo int", - "▁join t", - "▁ joint", - "ро го", - "р ого", - "ik en", - "ike n", - "i ken", - "чи на", - "чин а", - "an cia", - "anc ia", - "anci a", - "▁t ijd", - "▁ti jd", - "▁R ose", - "▁Ro se", - "▁Ros e", - "▁alg orithms", - "▁algorithm s", - "▁print ing", - "▁prin ting", - "ne a", - "n ea", - "▁exec uting", - "▁execut ing", - "▁l ambda", - "▁ lambda", - "▁reg ional", - "▁region al", - "▁Co pa", - "▁Cop a", - "F oo", - "ph ys", - "phy s", - "z m", - "▁L aur", - "▁La ur", - "▁Lau r", - "▁candid ate", - "▁J a", - "zy m", - "z ym", - "Ex ample", - "▁s piel", - "▁sp iel", - "▁ spiel", - "▁д ей", - "▁де й", - "▁ дей", - "ne hmen", - "neh men", - "nehm en", - "ke iten", - "keit en", - "▁с ент", + "or ithm", + "s▁ if", + "re fract", + "ar ly▁", + "ing ▁an", + "om ain", + ".\n\n K▁C▁E▁H▁C", + "is▁ in", + "is▁ defined▁as", + "00 ▁IU", + "us ed▁as▁", + "▁S ubjects▁", + "▁re pe", + "with ▁a", + "▁E ach", + "▁f acil", + "ch ema", + "▁or ▁1", + "\n\nP rinted▁copy▁is▁not▁official▁record.\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁Panitumumab▁Protocol▁Number:▁20050203▁Date:▁21▁January▁2009\n\nPage▁", + "study▁ is▁", + "▁and ▁toler", + "▁T oxicity", + "▁for ▁all", + "ib ly▁", + "ad verse▁", + "▁g /dL", + "cur v", + "▁the▁p rior", + ")\n\n 4", + "▁study▁ completion", + "\n\n1 \n\n1", + "ly ing", + "▁the▁d ose▁", + "\n\nE nd▁of", + ".▁Th e▁t", + ".▁C linical▁", + "ed▁with out", + "have▁ a", + "al▁pro tein", + "s▁with in", + "\n\n2 \n\n2", + "▁should▁be▁ performed▁", + "ind ividual", + "▁a▁s erious▁adverse▁event", + "dur ation▁of", + "data ▁from", + ".\n\nS ection:", + ".\n\nS ▁I▁H▁T", + ".\n\nS ▁T▁I\n\nK▁C▁E▁H▁C", + "e▁treatment ▁effect", + "appro val", + "fficac y▁of", + "dis play", + "▁dis pens", + "your ▁doctor", + "▁2006 ;", + "▁det erior", + "▁a▁c entral▁", + "just ment", + "▁baselin e,▁", + "emat ology", + "vis ion", + "▁IV ▁infusion", + "▁Q ual", + "▁Adverse▁Event s▁", + "refer ▁to", + "........................................................ ..", + "▁Med ical▁", + "▁En d▁of", + "▁wors en", + "Lill y", + "▁great er▁than", + "▁chemist ry▁", + "regulatory ▁author", + "▁as▁well ▁as▁", + "ECOG▁performance▁stat us", + "TIN G", + "▁commer cial", + "\n\nH3E-US-S130(d)▁Clinical▁Protocol \n\nPage▁", + "▁surg ical", + "mpt ly▁", + "stimulating ▁factor", + "found ▁to▁be▁", + "recom mended▁", + "hemor rh", + "ircul ating", + "( 4", + ", 10", + "1 :", + ": ▁0", + ": ▁http://", + "P rincipal▁Investigator", + "S D", + "S H", + "e z", + "l etter", + "p ublication", + "r ul", + "s ▁as", + "t m", + "w e", + "▁ studi", + "\n\n (cid:13", + "or n", + "al p", + "it ative▁", + ",▁ no", + "▁an ▁un", + "▁p eopl", + "▁c ohort", + "ing ▁this▁", + "▁of ���thes", + "▁of ▁denosumab", + "▁d efinition", + ".\n\n b", + "ill ett", + "ab ul", + "▁in stitution", + "▁in struction", + "es▁ in▁the▁", + "us cular", + "▁h om", + "▁l arg", + "\n\nP re", + "ate▁ you", + "lin ical", + "abl e", + "abl y▁", + "abl e▁s", + "▁pro gressive▁disease▁", + "ed▁in formation", + "▁of▁ study▁drug", + "e▁s ub", + "art ment", + "cont racept", + "▁the▁s ub", + "ay o", + "eg re", + "▁ex amin", + "▁after ▁the▁", + "10 ▁September▁2007", + "report ed", + "▁may▁ have▁been", + "▁7 5▁mg/m2", + "ost -", + "▁ass ay", + "▁10 .6", + "can not▁be▁", + "▁assessment s▁will▁be▁", + "ed▁at ▁baseline▁", + "▁us ing▁the▁", + "24 -month", + "▁inter n", + ")▁ •", + "rowth ▁Factor", + "mall ▁Cell", + ".▁An alysis▁of", + "conduct ed▁in", + "clinical▁ study", + "osp asm", + "diseas e,▁", + "▁of▁a ction", + "new ▁lesion", + "\n\nAmended▁ Clinical▁Study▁Protocol", + "central▁ laboratory▁", + "▁procedure s▁", + "\n\n.▁E▁S▁U \n\nE▁R▁O▁F▁E▁B", + "▁Phase▁ 3", + "▁reason s▁other▁than", + "e▁P aclitaxel", + "▁Edition▁Number▁3▁Date▁ 10▁September▁2007", + "met ab", + "▁growth ▁factor", + "\n\nCONFIDENTIAL \n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁PANITUMUMAB▁(AMG▁954)▁Protocol▁Number:▁20040249▁Date:▁07▁August▁2007\n\nPage▁", + "▁requir ing", + "BP I-", + "▁this▁research ▁study", + "astrointest inal", + "prefer red", + "pressure ,▁", + "Broch ure▁", + "aminotransfer ase▁(", + "▁advers e\n\n", + "edu ction", + "anoparticl e▁Paclitaxel", + "Evaluation▁Criteria ▁in▁Solid▁Tumor", + "\n\nABI-007▁Clinical▁Trial▁Protocol:▁CA046 \n\nAbraxis▁BioScience▁12▁November▁2008", + ". )", + "3 .0", + "9 3", + "A P", + "D os", + "L AN", + "M B", + "S ampl", + "c olor", + "d enosumab", + "h ospital", + "i form", + "l acebo", + "m ethyl", + "n erv", + "s ,▁a", + "t r", + "w e▁will", + "’ s\n\n", + "▁ #", + "e▁ patient", + "at tern", + "on ▁Day▁1", + "▁a ▁t", + "re cruit", + "al cium", + "it u", + "ed▁ patient", + "ing ▁with", + "▁b reath", + "et ric", + "▁to ▁s", + "▁to ▁obtain", + "▁to ▁prevent", + "▁d ate", + "▁m easure", + "▁and▁ M", + "▁and▁ T", + "im pact", + "ur er", + "ur ation", + "pl ement", + "il at", + "▁( I", + "▁2 5%", + "ot er", + "▁D iscontinu", + "▁l o", + "e▁t wo", + "\n\nA MG▁162", + "▁pro c", + "com mitte", + "▁treatment ▁regimen", + "▁is▁ given", + "▁will▁be▁ stratifi", + "e▁s urvival", + "e▁th e▁d", + "▁M J", + "▁r ang", + "▁r ate▁of", + "▁con cern", "int ent", - "inte nt", - ". (", - "▁пер вы", - "pr om", - "pro m", - "p rom", - "▁n at", - "▁na t", - "▁ nat", - "▁im agine", - "▁imag ine", - "call back", - "com ponents", - "component s", - "with out", - "▁a quest", - "▁aqu est", - "Su pport", - "Supp ort", - "▁respons ible", - "▁j ego", - "▁je go", - "l j", - "wi ll", - "w ill", - "le an", - "lea n", - "el and", - "ela nd", - "e land", - "olog ía", - "m c", - "Pro xy", - "▁o cup", - "▁oc up", - "▁на ходи", - "▁r ub", - "▁ru b", - "ні в", - "н ів", - "▁F all", - "▁Fa ll", - "▁Fal l", - "am os", - "amo s", - "a mos", - "▁E p", - "en tre", - "ent re", - "entr e", - "fa il", - "f ail", - "W orld", - "▁Ed itor", - "▁Edit or", - "▁ Editor", - "▁ex pos", - "▁exp os", - "▁f inds", - "▁find s", - "▁fin ds", - "▁C ulture", - "▁Cult ure", - "▁ Culture", - "LE ASE", - "▁m ovie", - "▁mov ie", - "▁mo vie", - "▁ movie", - "< =", - "omet ric", - "o metric", - "el ing", - "eli ng", - "elin g", - "e ling", - "numer able", - "ou rd", - "our d", - "o urd", - "▁S ea", - "▁Se a", - "▁b ild", - "▁bi ld", - "▁bil d", - "▁ bild", - "▁о ста", - "▁ос та", - "▁ост а", - "bl o", - "b lo", - "▁l ose", - "▁lo se", - "▁los e", - "▁ lose", - "at eurs", - "ate urs", - "ateur s", - "ou red", - "our ed", - "oure d", - "o ured", - "▁B att", - "▁Ba tt", - "▁Bat t", - "() ;\r", - "(); \r", - "( );\r", - "▁p oz", - "▁po z", - "pos ts", - "post s", - "pe nd", - "pen d", - "p end", - "cer tain", - "cert ain", - "c ertain", - "ни ком", - "ник ом", - "J ust", - "web kit", - "dem ás", - "~~ ~~", - "▁indic ates", - "▁indicate s", - "▁p ark", - "▁par k", - "▁ park", - "ri que", - "r ique", - "vo d", - "v od", - "▁Ch amp", - "▁Cham p", - "▁Cha mp", - "ft ware", - "OP T", - "O PT", - "dj ango", - "d jango", - "re lease", - "▁ È", - "S R", - "▁polit ician", - "▁r oi", - "▁ro i", - "at uren", - "atur en", - "ature n", - "atu ren", - "▁Deutsch e", - "ta gon", - "tag on", - "t agon", - "▁M ov", - "▁Mo v", - "ob ierno", - "obi erno", - "▁da ß", - "ut her", - "uth er", - "u ther", - "in di", - "ind i", - "▁Wik ipedia", - "▁Wikip edia", - "▁Wikiped ia", - "▁a nos", - "▁an os", - "▁ano s", - "▁ anos", - "▁ob serve", - "▁obser ve", - "▁observ e", - "▁obs erve", - "el ly", - "ell y", - "▁rail way", - "at on", - "ato n", - "a ton", - "▁e num", - "▁en um", - "▁ enum", - "hu s", - "h us", - "▁in hab", - "P si", - "oir e", - "oi re", - "o ire", - "▁Х о", - "▁S pace", - "▁Sp ace", - "▁ Space", - "▁Ар хи", - "▁an terior", - "▁ante rior", - "▁ Ł", - "is ons", - "ison s", - "iso ns", - "I l", - "▁am éric", - "la ps", - "lap s", - "l aps", - "▁B BC", - "▁BB C", - "QUE ST", - "Con stra", - "Const ra", - "Cons tra", - "mon t", - "mo nt", - "m ont", - "ä ft", - "▁ä ven", - "ub ern", - "ube rn", - "uber n", - "u bern", - "< !--", - "▁c oding", - "▁co ding", - "▁cod ing", - "the ory", - "at hed", - "ath ed", - "▁Ar be", - "▁ш и", - "▁ ши", - "for Each", - "om orphism", - "omorph ism", - "det ails", - "detail s", - "ach sen", - "in tegr", - "int egr", - "inte gr", - "V or", - "Un known", - "ace ae", - "a ceae", - "in ue", - "inu e", - "es ome", - "eso me", - "e some", - "▁F ir", - "ch ain", - "cha in", - "▁extrem ely", - "▁extreme ly", - "mult icol", - "multi col", - "▁Sw ift", - "▁address es", - "▁addr esses", - "hs pace", - "h space", - "▁Ro ger", - "▁Rog er", - "▁d essen", - "▁des sen", - "▁dess en", - "▁con sequ", - "▁cons equ", - "▁conse qu", - "ual mente", - "▁Pre mier", - "▁Prem ier", - "▁Re cord", - "▁Rec ord", - "▁ Record", - "▁B ron", - "▁Br on", - "▁Bro n", - "ki r", - "k ir", - "se x", - "s ex", - "in tern", - "int ern", - "inter n", - "inte rn", - "▁benef it", - "▁bene fit", - "um en", - "ume n", - "u men", - "▁be coming", - "▁bec oming", - "▁becom ing", - "▁l ig", - "▁li g", - "▁ lig", - "▁pop ula", - "▁popul a", - "os c", - "o sc", - "▁c iv", - "▁ci v", - "▁great est", - "▁pro ces", - "▁proc es", - "] *", - "▁ме сто", - "▁мест о", - "▁' $", - "▁ '$", - "he ll", - "hel l", - "h ell", - "(\" \\", - "( \"\\", - "▁n ine", - "▁ni ne", - "▁nin e", - "▁F ac", - "▁Fa c", - "ul pt", - "ulp t", - "jo urs", - "jou rs", - "j ours", - "▁C opy", - "▁Co py", - "▁Cop y", - "▁ Copy", - "▁activ ities", - "▁Dem ocr", - "▁Demo cr", - "E s", - "Su ccess", - "▁E sta", - "▁Est a", - "▁Es ta", - "it ul", - "itu l", - "is ti", - "ist i", - "▁B ed", - "▁Be d", - "ja s", - "j as", - "▁т ем", - "▁те м", - "▁ тем", - "▁H ung", - "▁Hu ng", - "▁Hun g", - "G ame", - "▁he av", - "onn ées", - "▁branch es", - "▁bran ches", - "bo rg", - "bor g", - "b org", - "▁v l", - "▁ vl", - "▁slow ly", - "F a", - "Go ogle", - "em i", - "e mi", - "▁circumst ances", - "▁' %", - "▁U nd", - "▁Un d", - "▁ Und", - "▁Vict oria", - "▁Victor ia", - "▁T yp", - "▁Ty p", - "▁ Typ", - "rupt ed", - "rup ted", - "▁rel ativ", - "▁s lo", - "▁sl o", - "▁p adre", - "▁pad re", - "▁d aily", - "▁da ily", - "▁dai ly", - "▁or th", - "▁ort h", - "▁ orth", - "чни й", - "ч ний", - "▁fran zös", - "▁t eil", - "▁te il", - "▁ teil", - "▁Se curity", - "▁Sec urity", - "▁ Security", - "or don", - "ord on", - "ordo n", - "▁s weet", - "▁swe et", - "SI ZE", - "▁C el", - "▁Ce l", - "èt res", - "è tres", - "om mes", - "omm es", - "▁с і", - "▁ сі", - "▁effort s", - "ą z", - "▁oh ne", - "▁South ern", - "▁Sou thern", - "▁approxim ately", - "▁approximate ly", - "це н", - "ц ен", - "(' #", - "▁s aving", - "▁sa ving", - "▁sav ing", - "nb sp", - "▁trans late", - "▁transl ate", - "▁ translate", - "▁Î n", - "mem ber", - "m ember", - "▁l aws", - "▁la ws", - "▁law s", - "▁ж ен", - "▁же н", - "▁ жен", - "▁си сте", - "t c", - "> \\", - "el te", - "elt e", - "▁e hem", - "▁con trad", - "▁cont rad", - "▁contr ad", - "▁contra d", - "▁ру с", - "▁р ус", - "▁ рус", - "ь я", - "▁M iddle", - "▁ Middle", - "qu ip", - "qui p", - "▁c hez", - "▁ch ez", - "▁che z", - "▁ chez", - "Field s", + "▁B evacizumab", + "tud ies", + "will ▁be\n\n", + "▁6 .2", + "▁H R", + "s.▁ C", + "rel eas", + "afet y,▁", + "xic ities▁", + "10 ▁mg", + "▁tim e▁and▁", + ".,▁ L", + "\n\nN ▁A\n\nF▁O\n\nY▁P▁O▁C", + "▁cons ult", + "fl ect", + "▁death ▁or", + "▁sampl es▁will▁be▁", + "▁discontinu ation▁of▁", + "inc e▁the▁", + "e▁or ▁sh", + "IC H", + "TA XOL", + "▁mm ▁with", + "▁Ph armac", + "▁observ ation", + "plorator y", + "\n\nProtocol ▁Attachment▁JM", + "objectiv es", + "▁weeks▁ until", + "post -", + "avail able▁to", + "▁total ▁of▁", + "FACT- P", + "▁typ e▁of", + "addition al", + "plus▁ carboplatin", + "▁post -", + "extension ▁lead▁", + "great er", + "United▁ Stat", + "rig er", + "ca ution", + "▁IC ON", + "/mm 3", + "omagnes emia", + "ild-T ype▁KRAS", + "2f86\\Approved\\Approved▁On:▁19-Mar-2007▁16:14\n\n0 ▁2▁:▁1▁1\n\n7▁0▁0▁2▁-▁r▁a▁M▁-▁5▁1▁\\▁d▁e▁v▁o▁r▁p▁p▁A\n\n\\▁0▁.▁1▁\\", + ") \n\nA", + ". D", + "/ MRI", + "4 -", + "; ▁or", + "A b", + "D RA", + "P K", + "b irth", + "c cess", + "h tm", + "j unction", + "m onth", + "p regnancy▁test", + "t arget", + "y vitamin▁D", + "in struct", + "at ▁each", + "▁a ▁significant", + "s▁ due▁to", + "st ick", + "ed▁ over", + "▁an ▁adverse▁event", + "▁an thracycl", + "ed ,▁or", + "▁p urpos", + "ing er", + "▁b efore▁the▁", + "is ▁that", + "▁s pecifi", + "▁s ource▁document", + "▁w ish", + "▁m aximum", + "▁A N", + "▁in ▁Combination", + "id ne", + "▁( n", + "ul s", + "▁re -", + "▁re ceipt", + "▁f at", + "▁n egative▁", + "od ynamic", + "ate▁ for", + "In formation", + "ph ysical", + "▁F OR", + "▁B aselin", + "ach iev", + "▁5 .5", + "▁patients▁ enroll", + "▁4 2", + "▁ac cess", + "▁ac cru", + "po on", + "▁ex plor", + "ed▁on ly▁", + "▁the▁d evelopment▁of", + "▁ant igen", + "▁ant ibiotic", + "▁Protocol ▁CA012-0", + "▁7 5", + ",▁the▁ following", + "▁ass ay▁", + "radi otherapy", + "every▁ 6▁month", + "▁trial ▁of", + "▁Ad verse▁event", + ",▁S ch", + "result ▁in", + "e▁treatment ▁start", + "provid ed", + "▁sub scal", + "36 -month", + "rol e▁of", + "▁occur s▁", + "▁Cancer ▁In", + "▁event s▁", + "▁(A NC", + "urg ical▁", + "Ad justment", + "▁there▁ is", + "▁ne ed", + "\n\nAn alysis▁Set", + "open ▁label", + "Con t", + "▁clinical▁ studies▁", + "ation▁of▁the▁ study", + "expect ed▁", + "press ure▁", + "▁pemetrex ed", + "mor e▁than", + ".▁G en", + "rem ophor", + "\n\nPro gression", + "▁the▁primary▁ endpoint", + "experienc ing", + "▁abnormal ities▁", + "▁limit ed▁to", + "▁Lill y▁or▁its▁design", + "Broch ure", + "▁(N anoparticle▁Paclitaxel", + "▁carry▁ out", + "cutane ous▁", + "vas ive▁", + "▁(94)\n\nGEL▁Version▁ID:▁CV.000−522−306.7.0▁Approved▁by\n\nApproved\n\nDate▁Printed:▁30−Jul−2014\n\nS▁18▁Feb▁2011▁11:38:55 \n\nRevised▁Clinical▁Study▁Protocol▁Drug▁Substance▁ZD4054▁Study▁Code▁D4320C00033▁Edition▁Number▁3▁Date▁15▁February▁2011", + "s.▁H owever", + "uoropyrim idin", + "ysical▁Ex amination", + "EFI NI", + "null ▁hypothes", + "C ▁I▁N▁O▁R▁T▁C▁E▁L▁E", + "R eduction", + "U ND", + "f ax", + "m at", + "y es▁", + "▁ eth", + "e▁ n", + "in anc", + "in vestigational", + "▁a udit", + "or ption", + "d▁ or", + "re am", + "▁the▁ IVRS", + ",▁ 24", + "ed ▁about", + "▁of ▁the\n\n", + "▁m ad", + ".\n\n G", + "▁A \n\nS▁I\n\nS▁I▁H▁T", + "▁in vestigation", + "▁in clusion", + "▁C entral▁", + "es▁ on", + "▁P C", + "us ually▁", + "▁re t", + "ap plicable▁", + "▁pro gressive▁diseas", + "▁N atl", + "▁ar ter", + "and /or", + "ad juvant", + "▁will▁be▁ present", + "art il", + "act ic", + "cont ent", + "ity▁ in", + "ated▁ with", + "▁v is", + "▁B ackgroun", + "▁all ▁randomized▁", + "ip stick", + "e▁in formation", + "▁4 00▁mg/m2", + "▁the▁p rincipal▁investigator", + "▁ac crual", + "▁study▁ in", + "▁any▁ s", + "ed▁by ▁an", + "▁may▁ continu", + "▁10 %", + "ix ed▁", + ".▁C etuximab", + "\n\nX\n\nX \n\nX", + "▁the▁l esion", + "▁inter vention", + ".▁F urther", + "data ▁will▁be▁", + ")▁ ≤", + "level s▁of", + "▁Com mon▁Terminology▁Criteria▁for▁Adverse▁Event", + "▁report ed▁in", + "▁clinical ▁progression", + "observ ed", + "▁rel ative▁to", + "▁stat us▁of", + "........................................................................................ ......", + "RB C", + "▁approv ed▁", + "▁Y ork", + "ed▁c olorectal▁cancer", + "-m g", + "analysis▁ will▁be▁", + "▁Q uestionna", + "questionna ir", + "stor age▁", + "▁contain s▁", + "▁prior ▁to▁the▁", + "▁ens uring", + ".▁However ,▁", + "95% ▁confidence▁interval", + "uro to", + "Phase▁ 3", + "▁represent ative▁", + "Consider ations▁", + "-related▁to xicities", + "▁Reg imen", + "▁at▁a ▁dose▁of", + "▁total▁ hip", + "yel oma", + "confidential ity▁of", + "▁recruit ment", + "armaceut ical", + "ranul ocyt", + "▁reasonable▁poss ibility▁that", + ") \n\nCONFIDENTIAL", + ": 50", + "; ▁and▁", + "B SC", + "D H", + "E n", + "L ES", + "M E", + "N ational▁Cancer▁Institut", + "f emal", + "h ospitalization", + "l e▁", + "s ▁and/or", + "v oid▁", + "\n\n Investigator", + "s▁ •", + "s▁ not", + "re ase▁", + "an ine▁", + "ct ive▁", + "ar a", + "▁c ur", + "es s▁s", + "▁to ▁Amgen", + "▁s yndrom", + "▁d eviation", + ".\n\n O", + "▁A merican", + "▁in ▁terms▁of", + "res ection", + "res olution", + "▁C l", + "▁P LAN", + "▁( F", + "▁S NP", + "▁h ospital", + "▁E ▁R▁O▁F▁E▁B", + "ex plain", + "study▁ for", + "study▁ sit", + "▁and ▁the▁investigator", + "▁T ime▁to", + "ef ▁Pain▁In", + "com ment", + "\n\nS erum", + "▁will▁be▁ the▁", + "▁will▁be▁ given", + "e▁s ign", + "e▁s ever", + "▁r at", + "▁3 .1", + "cor rection", + "200 8", + "▁v ascular", + "▁v ital▁sign", + "▁ch art", + "▁ch ronic", + "e▁in ter", + ".4 .3", + "gen ital", + "10 3", + "▁the▁d efinition", + "evalu ation▁of", + "▁month s▁of", + "revi ously▁", "▁per mit", - "▁perm it", - "ik el", - "ike l", - "i kel", - "▁w ir", - "▁t rial", - "▁tr ial", - "▁tri al", - "▁ver schied", - "▁versch ied", - "▁ф ев", - "▁фе в", - "▁m ale", - "▁ma le", - "▁mal e", - "▁ male", - "▁я зы", - "▁ny el", - "ak ter", - "akt er", - "akte r", - "a kter", - "▁den omin", - "cept or", - "cep tor", - "▁W at", - "▁Wa t", - "▁f ino", - "▁fin o", - "▁fi no", - "▁XV III", - "▁XVI II", - "▁XVII I", - "ry ption", - "rypt ion", - "de sc", - "des c", - "d esc", - "ap a", - "a pa", - "ле на", - "лен а", - "л ена", - "▁k ol", - "▁ko l", - "▁ kol", - "▁ Є", - "▁dep endent", - "▁depend ent", - "▁ dependent", - "▁C ra", - "▁Cr a", - "▁st orm", - "▁stor m", - "▁sto rm", - "▁Г ер", - "▁Ге р", - "▁p ipe", - "▁pi pe", - "▁pip e", - "▁ pipe", - "▁att ended", - "▁attend ed", - "▁v ita", - "▁vi ta", - "▁vit a", - "uz ione", - "u zione", - "cz as", - "cza s", - "c zas", - "on da", - "ond a", - "▁b old", - "▁bo ld", - "▁bol d", - "▁ bold", - "Column s", - "ic ió", - "ici ó", - "i ció", - "▁c zę", - "▁cz ę", - "▁из вест", - "▁Cl oud", - "▁Clo ud", - "▁ Cloud", - "▁w arm", - "▁war m", - "▁wa rm", - "▁с ы", - "▁ сы", - "▁с те", - "▁ст е", - "▁ сте", - "▁produ cer", - "▁produce r", - "▁Lud wig", - "▁Nor thern", - "▁North ern", - "ł ą", - "NS String", - "▁H ad", - "▁Ha d", - "▁И ван", - "▁E g", - "▁I mp", - "▁Im p", - "▁ Imp", - "ш і", - "▁A uch", - "▁Au ch", - "то к", - "т ок", - "▁H it", - "▁Hi t", - "▁qu ien", - "▁qui en", - "▁de partment", - "▁depart ment", - "▁erh ielt", - "▁u i", - "▁ ui", - "▁S pr", - "▁Sp r", - "се р", - "с ер", - "ou rt", - "our t", - "o urt", - "▁Ste phen", - "▁Step hen", - "▁Steph en", - "te am", - "▁z ip", - "▁ zip", - "▁B ang", - "▁Ba ng", - "▁Ban g", - "▁grow th", - "▁j am", - "▁ja m", - "▁K ais", - "▁Ka is", - "b matrix", - "▁As ia", - "▁rég ion", - "= /", - "▁Pac ific", - "▁author ity", - "▁# [", - "та ми", - "там и", - "▁every one", - "▁att end", - "▁atte nd", - "▁ attend", - "▁tim estamp", - "▁ timestamp", - "▁t ries", - "▁tr ies", - "▁tri es", - "▁f f", - "▁ ff", - "ше й", - "ш ей", - "▁develop ing", - "ol t", - "o lt", - "up s", - "u ps", - "▁moment o", - "▁mom ento", - "▁S ain", - "▁Sa in", - "Te rm", - "T erm", - "▁c elle", - "▁ce lle", - "▁cell e", - "▁cel le", - "G R", - "Mo use", - "M ouse", - "▁челов ек", - "▁челове к", - "▁Col lection", - "▁Coll ection", - "▁Collect ion", - "▁ Collection", - "ât re", - "â tre", - "▁W rite", - "▁Writ e", - "▁ Write", - "▁P om", - "▁Po m", - "[ -", - "Ca m", - "C am", - "▁loc ations", - "▁location s", - "▁J son", - "▁ Json", - "el led", - "ell ed", - "elle d", - "select or", - "sel ector", - "re peat", - "ct ors", - "ctor s", - "ot te", - "ott e", - "o tte", - "ви зи", - "änd e", - "än de", - "ä nde", - "▁ach ieved", - "▁achieve d", - "▁achiev ed", - "▁main ly", - "____ ____", - "! )", - "▁явля ется", - "▁c ities", - "▁ci ties", - "▁cit ies", - "sing le", - "sin gle", - "г ре", - "▁P ak", - "▁Pa k", - "▁allow ing", - "▁allo wing", - "fer red", - "▁а пре", - "хо дя", - "ход я", - "▁brow sers", - "▁browser s", - "▁es crit", - "▁esc rit", - "▁escri t", - "▁mount ain", - "▁network s", - "▁net works", - "ki nd", - "kin d", - "k ind", - "li ver", - "live r", - "liv er", - "l iver", - "▁cl osing", - "▁clos ing", - "▁clo sing", - "▁sk ip", - "▁ski p", - "▁ skip", - "ú t", - "▁d uration", - "▁dur ation", - "▁ duration", - "ét ait", - "éta it", - "é tait", - "▁s cr", - "▁sc r", - "▁ scr", - "B B", - "ór ia", - "ó ria", - "▁K ultur", - "▁Kult ur", - "▁output s", - "multi column", - "multicol umn", - "▁bel ongs", - "▁belong s", - "fe ature", - "uc ky", - "uck y", - "▁j uli", - "▁ju li", - "▁jul i", - "▁рай она", - "▁райо на", - "▁район а", - "з во", - "fact ory", - "factor y", - "f actory", - "Fun c", - "F unc", - "▁ut ter", - "▁ utter", - "▁TO DO", - "▁o bt", - "▁ob t", - "ateg ories", - "ategor ies", - "▁com bine", - "▁comb ine", - "▁combin e", - "▁W all", - "▁Wal l", - "▁Wa ll", - "▁under lying", - "ar ono", - "aron o", - "aro no", - "▁P rote", - "▁Pro te", - "▁Pr ote", - "c ów", - "st an", - "sta n", - "s tan", - "▁G ew", - "▁Ge w", - "▁opt imal", - "▁optim al", - "▁Archiv link", - "▁S cript", - "▁ Script", - "▁destroy ed", - "х е", - "▁Fire fox", - "▁s ole", - "▁so le", - "▁sol e", - "▁ sole", - "La yer", - "L ayer", - "т ку", - "▁st ores", - "▁stor es", - "▁store s", - "▁sto res", - "▁dis plays", - "▁display s", - "is hing", - "ish ing", - "ishi ng", - "▁о ст", - "▁ос т", - "▁inst ant", - "▁el ő", - "▁habit antes", - "▁Ein wo", - "▁a li", - "▁al i", - "▁ ali", - "▁ER ROR", - "▁ERR OR", - "▁ ERROR", - "▁a head", - "▁ah ead", - "▁go als", - "▁goal s", - "▁m ár", - "▁má r", - "▁s ą", - "▁m art", - "▁ma rt", - "▁mar t", - "▁ mart", - "мини стра", - "F r", - "▁V illa", - "▁Vill a", - "▁Vi lla", - "▁Vil la", - "▁M arc", - "▁Mar c", - "▁Ma rc", - "ro py", - "rop y", - "r opy", - "ag ram", - "agr am", - "a gram", - "ha pe", - "h ape", - "ме й", - "м ей", - "▁A L", - "▁ AL", - "▁conne xes", - "▁En tre", - "▁Ent re", - "St ep", - "Ste p", - "лі в", - "л ів", - "▁De ath", - "▁r ise", - "▁ris e", - "▁ri se", - "▁f os", - "▁fo s", - "▁l ev", - "▁le v", - "▁ lev", - "ga be", - "g abe", - "▁b roke", - "▁br oke", - "▁bro ke", - "product s", - "▁m edi", - "▁me di", - "▁med i", - "▁ medi", - "▁dis pon", - "▁disp on", - "Pack age", - "P ackage", - "Image View", - "▁N ag", - "▁Na g", - "uj ą", - "u ją", - "W ord", - "▁k ole", - "▁ko le", - "▁kol e", - "ße r", - "ß er", - ")` .", - ") `.", - "▁r ol", - "▁ro l", - "▁ rol", - "▁ í", - "те й", - "т ей", - "Pro gress", - "be an", - "▁s empre", - "▁sem pre", - "State ment", - "Stat ement", - "UP DATE", - "▁mond iale", - "▁w rapper", - "▁wr apper", - "▁wra pper", - "▁wrap per", - "▁ wrapper", - "▁C hart", - "▁Ch art", - "▁Char t", - "▁Cha rt", - "▁ Chart", - "▁on Click", - "че ння", - "чен ня", - "LO G", - "some thing", - "som ething", - "s omething", - "▁IN SERT", - "▁ INSERT", - "ще ния", - "ue t", - "u et", - "wer p", - "we rp", - "ro und", - "rou nd", - "r ound", - "ic hen", - "ich en", - "iche n", - "i chen", - "▁X VI", - "▁XV I", - "з ни", - "▁ave va", - "▁St ore", - "▁Sto re", - "▁ Store", - "▁x s", - "▁ xs", - "ra cht", - "rac ht", - "rach t", - "r acht", - "sc ar", - "s car", - "▁op era", - "▁oper a", - "▁ opera", - "▁deg rees", - "▁degree s", - "▁cit iz", - "äs ident", - "▁class ical", - "▁classic al", - "▁Jer sey", - "▁er sch", - "▁ers ch", - "▁ ersch", - "▁treat ment", - "▁насе ље", - "н ня", - "▁bo ost", - "▁ boost", - "am ount", - "amo unt", - "a mount", - "▁со зда", - "ér ieur", - "érie ur", - "éri eur", - "▁t elling", - "▁tell ing", - "▁tel ling", - "Ha s", - "H as", - "▁in iti", - "▁init i", - "▁П и", - "ev al", - "e val", - "▁M atch", - "▁Mat ch", - "▁ Match", - "▁cor re", - "▁corr e", - "Point er", - "Po inter", - "▁pass es", - "▁passe s", - "comp any", - "▁а н", - "▁ ан", - "ach es", - "ac hes", - "ache s", - "a ches", - "▁sig lo", - "не м", - "н ем", - "▁ex change", - "▁ exchange", - "ci to", - "cit o", - "c ito", - "▁B ab", - "▁Ba b", - "Do c", - "D oc", - "ze ś", - "▁на род", - "▁ народ", - "▁conf lict", - "▁conflic t", - "▁confl ict", - "▁nov ember", - "ea u", - "e au", - "ö v", - "▁H ub", - "▁Hu b", - "▁ Hub", - "▁p oco", - "▁po co", - "▁poc o", - "en sa", - "ens a", - "sch ließ", - "lass e", - "las se", - "l asse", - "data s", - "dat as", - "▁с ти", - "▁ст и", - "▁ сти", - "un ivers", - "uni vers", - "ek s", - "e ks", - "▁C ho", - "▁Ch o", - "▁ Cho", - "▁c ô", - "▁( .", - "▁ (.", - "ew nę", - "▁Ch ief", - "▁Chi ef", - "▁ch ef", - "▁che f", - "▁у прав", - "ul i", - "u li", - "▁' ''", - "▁'' '", - "▁ '''", - "nap shot", - "▁re lac", - "▁rel ac", - "▁rela c", - "ég e", - "é ge", - "w t", - "we nd", - "wen d", - "w end", - "os ing", - "osi ng", - "o sing", - "▁ha cer", - "▁hace r", - "▁ф ран", - "au tres", - "aut res", - "autre s", - "▁f ils", - "▁fil s", - "▁fi ls", - "er ed", - "ere d", - "e red", - "▁По силання", - "▁th erm", - "▁the rm", - "▁ther m", - "ер жа", - "su ch", - "s uch", - "▁i hren", - "▁ih ren", - "▁ihr en", - "▁ihre n", - "▁en contr", - "▁l ots", - "▁lo ts", - "▁lot s", - "lo go", - "log o", - "l ogo", - "▁W i", - "/ (", - "ш ње", - "DA TA", - "DAT A", - "D ATA", - "▁P layer", - "▁Pl ayer", - "▁Play er", - "▁Pla yer", - "▁ Player", - "▁Leip zig", - "▁rel atives", - "▁relative s", - "▁relativ es", - "ре в", - "р ев", - "▁new sp", - "▁news p", - "? ,", - "▁St utt", - "▁Stu tt", - "▁d ual", - "▁du al", - "▁compan ies", - "▁z am", - "▁za m", - "put ation", - "▁in equality", - "▁t rem", - "▁tr em", - "▁tre m", - "hi ps", - "hip s", - "h ips", - "an ch", - "anc h", - "▁ Ż", - "бур г", - "▁cop ies", - "da sh", - "das h", - "d ash", - "во р", - "в ор", - "spiel er", - "s pieler", - "▁Re volution", - "▁Revol ution", - "es ty", - "est y", - "e sty", - "▁j unto", - "▁jun to", - "▁junt o", - "▁Ind eed", - "ok al", - "oka l", - "o kal", - "ctr ine", - "▁F ord", - "▁For d", - "▁Fo rd", - "▁C REATE", - "▁ CREATE", - "▁w alls", - "▁wall s", - "▁wal ls", - "▁a ute", - "▁au te", - "▁aut e", - "S U", - "wh y", - "w hy", - "plement ation", - "ro ut", - "rou t", - "r out", - "Mat rix", - "▁s ad", - "▁sa d", - "ан а", - "а на", - "▁P ic", - "▁Pi c", - ". “", - "▁A C", - "▁ AC", - "▁F est", - "▁Fe st", - "▁des ktop", - "▁ desktop", - "▁P ay", - "▁Pa y", - "▁ Pay", - "ome times", - "omet imes", - "▁T ak", - "▁Ta k", - "ра б", - "▁S ever", - "▁Se ver", - "▁nor thern", - "▁north ern", - "an ter", - "ant er", - "ante r", - "▁Mod ern", - "▁Mo dern", - "▁Mode rn", - "wa l", - "w al", - "{ \r", - "on line", - "ö k", - "▁brit ann", - "$ _", - "▁j ar", - "▁ja r", - "▁ jar", - "T L", - "xx xx", - "xxx x", - "x xxx", - "mer ge", - "▁N amen", - "▁Name n", - "▁Na men", - "▁Nam en", - "▁K EY", - "▁ KEY", - "▁re fers", - "▁ref ers", - "▁refer s", - "▁h in", - "▁hi n", - "▁ hin", - "▁Vol ks", - "▁Volk s", - "st eller", - "stell er", - "stelle r", - "vi ation", - "via tion", - "v iation", - "on io", - "oni o", - "o nio", - "ight er", - "igh ter", - "Com pat", - "Comp at", - "▁C E", - "▁ CE", - "▁p ró", - "▁pr ó", - "▁encuent ra", - "the orem", - "▁pub li", - "▁Develop ment", - "н д", - "▁r os", - "▁ro s", - "▁ ros", - "▁s hr", - "▁sh r", - "se au", - "s eau", - "▁gener ating", - "▁gene rating", - "▁difficult y", - "▁Ex press", - "▁Exp ress", - "▁ Express", - "Al ignment", - "de utsch", - "▁Вла ди", - "▁sugg ests", - "▁suggest s", - "▁Famil y", - "▁Fam ily", - "▁ Family", - "bb i", - "b bi", - "]) .", - "] ).", - "st aw", - "sta w", - "▁pres idente", - "▁president e", - "▁presiden te", - "▁st esso", - "in x", - "i nx", - "set up", - "▁con form", - "▁conf orm", - "▁f ro", - "▁fr o", - "=\\ \"", - "= \\\"", - "▁d å", - "ic iones", - "ici ones", - "icio nes", - "icion es", - "i ciones", - "▁e volution", - "▁evol ution", - "pr ote", - "pro te", - "p rote", - "▁pr ints", - "▁print s", - "▁prin ts", - "▁P ont", - "▁Po nt", - "▁Pon t", - "▁conf usion", - "▁ Й", - "▁d ello", - "▁del lo", - "▁dell o", - "▁man if", - "Def inition", - "ár a", - "á ra", - "ma ls", - "mal s", - "m als", - "▁s ale", - "▁sa le", - "▁sal e", - "▁drop down", - "▁ dropdown", - "Ch ain", - "Amer ican", - "America n", - "▁m k", - "▁ mk", - "▁B ez", - "▁Be z", - "▁F ue", - "▁Fu e", - "▁N E", - "▁ NE", - "гра фи", - "граф и", - "doc ker", - "do cker", - "d ocker", - "▁^ {", - "▁ ^{", - "As sert", - "Ass ert", - "▁hor izontal", - "▁horizon tal", - "▁ horizontal", - "(@ \"", - "( @\"", - "▁д ву", - "pro xy", - "U ri", - "gen cy", - "g ency", - "▁\" [", - "▁Q t", - "▁ Qt", - "▁N ames", - "▁Name s", - "▁Na mes", - "▁Nam es", - "▁ Names", - "▁evalu ate", - "▁eval uate", - "! /", - "▁ein ges", - "▁eing es", - "▁syn th", - "▁sy nth", - "▁You Tube", - "▁turn ing", - "▁tur ning", - "▁E ric", - "▁Er ic", - "▁б ли", - "▁ бли", - "▁k lub", - "▁kl ub", - "pl orer", - "▁s ports", - "▁sport s", - "▁s ia", - "▁si a", - "о ш", - "▁d ai", - "▁da i", - "▁e urope", - "▁europ e", - "▁euro pe", - "ic ians", - "ici ans", - "ician s", - "icia ns", - "ings områ", - "▁d re", - "▁dr e", - "▁work around", - "▁s uit", - "▁su it", - "▁ suit", - "amb igu", - "▁quant ity", - "▁ quantity", - "▁seg undo", - "Sym bol", - "S ymbol", - "▁m oral", - "▁mo ral", - "▁mor al", - "Ch art", - "Char t", - "C hart", - "▁da mit", - "▁dam it", - "▁attempt s", - "▁d onn", - "▁do nn", - "▁don n", - "jo s", - "j os", - "▁e re", - "▁er e", - "▁ ere", - "▁hom me", - "▁ homme", - "si mp", - "sim p", - "s imp", - "rypt ed", - "▁act s", - "▁ac ts", - "inner HTML", - "▁tourn ament", - "▁s ky", - "▁sk y", - "▁ sky", - "Time r", - "Tim er", - "T imer", - "▁mill ions", - "▁million s", - "^ +", - "ag ent", - "age nt", - "agen t", - "a gent", - "') );", - "')) ;", - "' ));", - "▁o st", - "▁os t", - "▁ ost", - "▁g la", - "▁gl a", - "▁по мо", - "▁f ün", - "ст вом", - "ств ом", - "ство м", - "ewnę trz", - "▁Mé xico", - "▁l ub", - "▁lu b", - "▁ lub", - "▁É d", - "if ik", - "ifi k", - "i fik", - "че ский", - "▁im mer", - "▁imm er", - "▁ immer", - "en sen", - "ens en", - "ense n", - "an ny", - "ann y", - "in line", - "▁g over", - "▁go ver", - "au c", - "a uc", - "▁re pre", - "▁rep re", - "▁repr e", - "▁histor ia", - "▁hist oria", - "A g", - "▁p lt", - "▁pl t", - "▁Pr inci", - "▁Prin ci", - "im eter", - "ime ter", - "imet er", - "i meter", - "ő s", - "š e", - "▁U E", - "▁ UE", - "Equ als", - "Equal s", - "Eq uals", - "Dis patch", - "le gen", - "leg en", - "lege n", - "l egen", - "ла зи", - "чно й", - "ч ной", - "▁st ell", - "▁ste ll", - "▁ stell", - "ń st", - "▁c ri", - "▁cr i", - "▁ cri", - "▁In dep", - "▁Ind ep", - "è de", - "}\\ )", - "} \\)", - "▁w yst", - "▁wy st", - "▁wys t", - "▁fig ured", - "▁figure d", - "▁figur ed", - "AT CH", - "éb en", - "é ben", - "la cht", - "lac ht", - "lach t", - "l acht", - "▁succeed ed", - "gr y", - "g ry", - "▁p ret", - "▁pr et", - "▁pre t", - "▁ pret", - "▁S af", - "▁Sa f", - "▁\" );", - "▁\") ;", - "▁ \");", - "e h", - "▁offic iel", - "▁offici el", - "краї н", - "wi nd", - "win d", - "w ind", - "▁sc atter", - "▁F ox", - "▁Fo x", - "ic ious", - "ici ous", - "icio us", - "i cious", - "Man y", - "Ma ny", - "M any", - "up er", - "u per", - "▁Con vert", - "▁ Convert", - "st erd", - "ste rd", - "ster d", - "▁St ein", - "▁Ste in", - "▁О т", - "}^ {(", - "}^{ (", - "} ^{(", - "bet ween", - "hi re", - "h ire", - "▁on Create", - "▁ onCreate", - "; ", - "- ->", - "▁p ří", - "▁př í", - "pan das", - "p andas", - "▁P lus", - "▁Pl us", - "▁ Plus", - "yl l", - "y ll", - "▁t error", - "▁te rror", - "▁ter ror", - "▁c rim", - "▁cr im", - "▁cri m", - "▁z ak", - "▁za k", - "▁ zak", - "iss ue", - "pa nel", - "pan el", - "p anel", - "sv g", - "▁re b", - "▁r eb", - "▁ reb", - "Custom er", - "sw itch", - "об ра", - "о бра", - "▁Champion ships", - "▁Championship s", - "▁Champions hips", - "cl o", - "c lo", - "at te", - "att e", - "a tte", - "▁any more", - "▁excell ent", - "▁opport unity", - "▁opportun ity", - "▁B ahn", - "▁Ba hn", - "▁Bah n", - "чи н", - "ч ин", - "et ing", - "eti ng", - "e ting", - "▁inc ident", - "to m", - "t om", - "Per s", - "Pe rs", - "P ers", - "bb en", - "bbe n", - "b ben", - "ствен ной", - "ственно й", - "и х", - "ro uter", - "route r", - "rout er", - "rou ter", - "r outer", - "▁new ly", - "▁sil ence", - "▁G NU", - "▁R ails", - "▁Ra ils", - "▁Rail s", - "▁A mb", - "▁Am b", - "▁Q ual", - "▁Qu al", - "▁ Qual", - "▁Sch aus", - "▁Sc haus", - "▁S ohn", - "▁So hn", - "▁A LL", - "▁AL L", - "▁ ALL", - "▁ro yal", - "▁roy al", - "▁ £", - "wi ę", - "w ię", - "▁ent fer", - "▁Re move", - "▁Rem ove", - "▁ Remove", - "▁hard ly", - "Us ing", - "U sing", - "ло г", - "▁I ch", - "▁d erni", - "▁der ni", - "▁Con nection", - "▁Connect ion", - "▁ Connection", - "fi sh", - "f ish", - "▁In form", - "▁Inf orm", - "▁Info rm", - "▁E ner", - "▁En er", - "ro it", - "r oit", - "B bb", - "View Model", - "V ideo", - "il ey", - "ile y", - "i ley", - "▁м ного", - "▁мно го", - "▁G em", - "▁Ge m", - "▁comp reh", - "▁compr eh", - "en umerate", - "ul as", - "ula s", - "u las", - "▁B ah", - "▁Ba h", - "▁Y et", - "▁Ye t", - "B R", - "х ра", - "▁count y", - "▁coun ty", - "▁H ist", - "▁His t", - "▁Hi st", - "▁Г у", - "▁ Ј", - "▁m ari", - "▁ma ri", - "▁mar i", - "▁C lar", - "▁Cl ar", - "▁Cla r", - "Bit map", - "B itmap", - "▁C z", - "▁m ån", - "▁må n", - "▁m ere", - "▁me re", - "▁mer e", - "▁mus ique", - "al so", - "als o", - "date s", - "da tes", - "dat es", - "d ates", - "▁D VD", - "▁g ol", - "▁go l", - "fo ny", - "fon y", - "f ony", - "▁Cast le", - "▁фа ми", - "▁arr ang", - "▁Bus iness", - "▁K az", - "▁Ka z", - "▁o sc", - "▁os c", - "▁ osc", - "▁se colo", - "▁sec olo", - "▁aff ected", - "▁affect ed", - "▁He alth", - "re b", - "r eb", - "ed itor", - "edit or", - "edi tor", - "▁own ed", - "▁ow ned", - "▁ owned", - "t l", - "▁v í", - "▁ ví", - "чни х", - "ч них", - "к ви", - "▁dev ient", - "▁devi ent", - "M utable", - "▁t egen", - "▁te gen", - "Reg ister", - "є ю", - "▁car acter", - "лл и", - "л ли", - "▁n ouvelle", - "▁nouve lle", - "ok o", - "o ko", - "icht et", - "ichte t", - "▁e vol", - "▁ev ol", - "▁H ab", - "▁Ha b", - "▁mil itar", - "▁milit ar", - "▁p uts", - "▁put s", - "▁pu ts", - "end if", - "endi f", - "▁Dav is", - "▁Da vis", - "▁Scot land", - "reg ular", - "▁Con text", - "▁Cont ext", - "▁ Context", - "is piel", - "isp iel", - "i spiel", - "▁G allery", - "▁Gall ery", - "\", \r", - "\" ,\r", - "▁a rc", - "▁ar c", - "▁ arc", - "▁IN FO", - "▁ INFO", - "▁c od", - "▁co d", - "▁ cod", - "ді в", - "д ів", - "▁v archar", - "▁var char", - "▁ varchar", - "▁tou jours", - "at ial", - "ati al", - "atia l", - "▁h anno", - "▁han no", - "▁проф ес", - "▁launch ed", - "▁насе лення", - "▁t on", - "▁to n", - "▁ ton", - "au sed", - "ause d", - "aus ed", - "a used", - "▁і з", - "▁t ö", - "▁P ur", - "▁Pu r", - "▁o lymp", - "AR N", - "ó m", - "▁a ugust", - "▁aug ust", - "▁f urn", - "▁fur n", - "▁fu rn", - "▁Col omb", - "▁Sta ats", - "▁Staat s", - "ho ra", - "hor a", - "h ora", - "▁м ор", - "▁мо р", - "▁ мор", - "can vas", - "▁gr ave", - "▁gra ve", - "▁grav e", - "▁com position", - "▁comp osition", - "▁compos ition", - "ac ja", - "▁которы е", - "▁ч о", - "▁ чо", - "Gener al", - "Gen eral", - "ан і", - "а ні", - "▁Joh annes", - "▁Johann es", - "▁Johan nes", - "ка р", - "к ар", - "▁ча ст", - "▁час т", - "▁Ва си", - "ss h", - "s sh", - "▁repla cing", - "▁< >", - "▁ <>", - "ці в", - "ц ів", - "la us", - "lau s", - "l aus", - "en y", - "e ny", - "äh l", - "ä hl", - "▁m arg", - "▁ma rg", - "▁mar g", - "ci ence", - "c ience", - "▁inst ruction", - "▁instru ction", - "▁instruct ion", - "▁ко ји", - "Ed itor", - "Edit or", - "▁fund amental", - "mu nd", - "mun d", - "m und", - "▁exception s", - "▁except ions", - "▁p late", - "▁pl ate", - "▁pla te", - "▁plat e", - "▁ plate", - "▁L is", - "▁Li s", - "▁d eren", - "▁de ren", - "▁der en", - "▁dere n", - "pr ep", - "pre p", - "p rep", - "▁janu ari", - "Sc ope", - "S cope", - "yn ast", - "yna st", - "r v", - "or sz", - "ors z", - "▁T ony", - "▁To ny", - "▁Ton y", - "▁д і", - "▁ ді", - "▁о дна", - "▁од на", - "▁s ab", - "▁sa b", - "ot i", - "o ti", - "je l", - "j el", - "▁gener ator", - "▁ generator", - "▁' .", - "▁ '.", - "▁sh arp", - "▁ sharp", - "▁то лько", - "▁account s", - "▁ž e", - "▁ že", - "▁for am", - "▁fo ram", - "▁g ouvern", - "TI ME", - "T IME", - "▁Sov iet", - "▁G é", - "▁ex ped", - "▁exp ed", - "▁ord inary", - "▁ordin ary", - "▁ ordinary", - "▁Con serv", - "▁Cons erv", - "▁Conse rv", - "▁com pla", - "▁comp la", - "▁compl a", - "te i", - "t ei", - "▁cap tain", - "▁capt ain", - "▁Sam uel", - "▁D ark", - "▁Dar k", - "▁в ін", - "▁ві н", - "▁de light", - "▁del ight", - "re cht", - "rec ht", - "di a", - "d ia", - "ess es", - "esse s", - "ul p", - "u lp", - "ш ки", - "be z", - "b ez", - "▁det ection", - "▁detect ion", - "▁cook ie", - "▁ cookie", - "an try", - "ant ry", - "Mult i", - "ob a", - "o ba", - "▁j oy", - "▁jo y", - "▁safe ty", - "▁saf ety", - "| ^", - "po d", - "p od", - "ad ém", - "▁Ch ron", - "▁Chr on", - "▁D jango", - "▁Dj ango", - "▁ehem al", - "k h", - "è le", - "▁p oc", - "▁po c", - "B ottom", - "la unch", - "ne m", - "n em", - "▁G ROUP", - "▁ GROUP", - "ní ho", - "▁G ib", - "▁Gi b", - "sd k", - "s dk", - "B E", - "▁G ene", - "▁Ge ne", - "▁Gen e", - "▁St aff", - "▁Sta ff", - "▁subsequ ent", - "ic ion", - "ici on", - "icio n", - "i cion", - "▁vict ory", - "▁c anon", - "▁can on", - "▁ca non", - "iz ar", - "iza r", - "i zar", - "iz ia", - "izi a", - "i zia", - "▁m ate", - "▁ma te", - "▁mat e", - "▁ mate", - "▁lay ers", - "▁layer s", - "▁ layers", - "su do", - "s udo", - "sch ule", - "per iment", - "ül et", - "ü let", - "AR CHAR", - "▁тер рито", - "▁me asures", - "▁measure s", - "▁meas ures", - "▁z ou", - "▁zo u", - "ops is", - "на ми", - "tb ody", - "t body", - "▁e se", - "▁es e", - "▁ ese", - "ster dam", - "sterd am", - "▁ph oto", - "▁phot o", - "▁ photo", - "ynchron ous", - "set minus", - "▁lo ads", - "▁load s", - "▁ loads", - "▁ple asure", - "▁me ille", - "}\\ ,", - "} \\,", - "qu al", - "qua l", - "q ual", - "▁fav our", - "▁r od", - "▁ro d", - "▁ rod", - "De r", - "D er", - "ра бо", - "раб о", - "▁pr essed", - "▁pres sed", - "▁press ed", - "▁ pressed", - "r ę", - "ie ving", - "iev ing", - "mate rial", - "m aterial", - "vi rt", - "vir t", - "v irt", - "▁cap able", - "с ло", - "us hed", - "ush ed", - "▁по бе", - "uset ts", - "un signed", - "uns igned", - "k ów", - "▁o v", - "▁ ov", - "eg eben", - "ege ben", - "e geben", - "▁app lying", - "▁apply ing", - "▁gal ax", - "▁ga lax", - "▁O racle", - "▁Or acle", - "▁Stutt gart", - "In fl", - "Inf l", - "ach usetts", - "▁de el", - "li re", - "l ire", - "▁stat unit", - "▁Polit iker", - "▁Politik er", - "▁beaut y", - ") >", - "▁Columb ia", - "▁zewnętrz ne", - "▁про гра", - "▁пр огра", - "▁d x", - "▁ dx", - "ck now", - "c know", - "▁d ub", - "▁du b", - "un ächst", - "find ViewById", - "▁M and", - "▁Man d", - "▁Ma nd", - "ál l", - "á ll", - "na ire", - "n aire", - "▁dest in", - "is ting", - "ist ing", - "isti ng", - "ag gi", - "agg i", - "a ggi", - "ch art", - "char t", - "cha rt", - "c hart", - "▁just ice", - "Sim ple", - "▁un fortunately", - "і р", - "▁qu esta", - "▁que sta", - "▁quest a", - "▁ questa", - "▁Govern or", - "я в", - "▁mús ica", - "▁equ ipo", - "▁equip o", - "▁D est", - "▁De st", - "▁Des t", - "▁ Dest", - "el ect", - "ele ct", - "e lect", - "Stack Trace", - "зо м", - "з ом", - "pr oc", - "pro c", - "p roc", - "ent in", - "enti n", - "ad ora", - "ado ra", - "ador a", - "▁Л ю", - "▁register ed", - "H L", - "face book", - "fac ebook", - "▁st oring", - "▁stor ing", - "▁sto ring", - "▁Current ly", - "▁qu adr", - "▁quad r", - "Stand ard", - "tr im", - "tri m", - "t rim", - "ear s", - "ea rs", - "e ars", - "se nder", - "sen der", - "send er", - "s ender", - "▁V as", - "▁Va s", - "▁ed ific", - "▁B ür", - "▁Bü r", - "▁C ountry", - "▁Count ry", - "▁Coun try", - "▁ Country", - "th a", - "t ha", - "; \"", - "no r", - "n or", - "▁Do ctor", - "▁Doc tor", - "ru ment", - "rum ent", - "r ument", - "Ge n", - "G en", - "▁B uen", - "▁Bu en", - "ra de", - "rad e", - "r ade", - "▁k un", - "n avigation", - "Pa y", - "P ay", - "▁capt ured", - "▁capture d", - "▁st ruck", - "▁str uck", - "▁stru ck", - "ven ir", - "ém ent", - "é ment", - "▁T ree", - "▁Tr ee", - "▁Tre e", - "▁ Tree", - "▁x x", - "▁ xx", - "▁n arr", - "▁na rr", - "▁nar r", - "ль ного", - "льно го", - "▁inst alling", - "▁install ing", - "▁instal ling", - "▁associ ation", - "▁insert ed", - "▁inser ted", - "er ner", - "ern er", - "erne r", - "valid ate", - "▁l ut", - "▁lu t", - "▁g lo", - "▁gl o", - "▁techn ology", - "▁P lace", - "▁Pl ace", - "▁Pla ce", - "▁ Place", - "$ ?", - "▁z v", - "с лі", - "E P", - "▁at mos", - "ug o", - "u go", - "ér t", - "é rt", - "▁W erk", - "▁Wer k", - "▁% }", - "te le", - "tel e", - "t ele", - "Sp an", - "S pan", - "▁R aj", - "▁Ra j", - "▁Person en", - "▁Pers onen", - "▁C ant", - "▁Can t", - "▁Ca nt", - "▁com bat", - "▁comb at", - "▁observ ation", - "▁obs ervation", - "param eter", - "para meter", - "▁agre ed", - "▁agree d", - "▁agr eed", - "pu r", - "p ur", - "▁sh adow", - "▁ shadow", - "▁g ł", - "Key s", - "Ke ys", - "Cre d", - "Cr ed", - "C red", - "ou ri", - "our i", - "o uri", - "▁p ale", - "▁pa le", - "▁pal e", - "ic ké", - "ick é", - "▁We ek", - "▁ Week", - "▁Pr ime", - "▁Pri me", - "▁Prim e", - "> .", - "Init ial", - "▁о дин", - "▁од ин", - "▁' ',", - "▁'' ,", - "▁у чи", - "▁In v", - "▁ Inv", - "col a", - "co la", - "c ola", - "ci ble", - "c ible", - "▁The atre", - "▁b em", - "▁be m", - "▁satisf y", - "x l", - "▁ра зви", - "▁раз ви", - "▁p ixel", - "▁pix el", - "lá n", - "l án", - "▁tw ee", - "▁twe e", - "ço n", - "ç on", - "не ния", - "▁A T", - "▁ AT", - "èg e", - "è ge", - "▁M ort", - "▁Mor t", - "▁Mo rt", - "▁my sq", - "▁ mysq", - "ft en", - "fte n", - "f ten", - "▁п ес", - "▁пе с", - "ém a", - "é ma", - "▁Service s", - "▁Serv ices", - "▁ Services", - "custom er", - "▁A WS", - "ъ т", - "▁A ch", - "▁Ac h", - "% .", - "▁clar ify", - "▁уни версите", - "xt ure", - "um i", - "u mi", - "▁s å", - "▁P el", - "▁Pe l", - "se rial", - "ser ial", - "UR I", - "U RI", - "▁r g", - "▁ rg", - "▁со ста", - "ch estra", - "che stra", - "ches tra", - "]. [", - "] .[", - "we n", - "w en", - "▁Lond res", - "▁an ys", - "▁any s", - "Data Source", - "▁рай оне", - "▁райо не", - "▁район е", - "▁re in", - "▁r ein", - "▁rei n", - "▁met adata", - "▁meta data", - "▁ metadata", - "um ble", - "umb le", - "ar beit", - "arbe it", - "hn er", - "h ner", - "ci ent", - "cie nt", - "c ient", - "▁n orte", - "▁nor te", - "▁о на", - "▁он а", - "▁ она", - "▁sc ored", - "▁score d", - "▁r ay", - "▁ra y", - "▁ ray", - "▁фев ра", - "▁фе вра", - "▁pro tagon", - "▁prot agon", - "▁S ac", - "▁Sa c", - "▁comm only", - "▁common ly", - "Linear Layout", - "▁app lic", - "▁ма я", - "З а", - "▁access ible", - "ie wer", - "iew er", - "fl ag", - "f lag", - "▁R ück", - "ä u", - "▁e rano", - "▁er ano", - "▁era no", - "▁eran o", - "▁auth entic", - "▁ authentic", - "▁R y", - "▁не ско", - "▁emb argo", - "▁embar go", - "▁d ry", - "▁dr y", - "▁reason able", - "▁Mod ule", - "▁ Module", - "▁acc eler", - "▁inter view", - "▁C reek", - "▁Cre ek", - "▁al pha", - "▁ alpha", - "se rie", - "ser ie", - "s erie", - "Th ey", - "The y", - "ю чи", - "▁H of", - "▁Ho f", - "▁C R", - "▁ CR", - "mod al", - "mo dal", - "▁sequence s", - "▁sequ ences", - "cl osed", - "close d", - "clos ed", - "clo sed", - ")} $", - ") }$", - "▁Ч ер", - "▁Че р", - "▁OR DER", - "▁ ORDER", - "Right arrow", - "R ightarrow", - "haus en", - "}} _", - "} }_", - "▁tamb é", - "▁magn etic", - "▁magnet ic", - "▁Mc C", - "▁win ning", - "under line", - "▁Bill board", - "na io", - "▁l iqu", - "▁li qu", - "▁ liqu", - "display style", - "time out", - "▁consider able", - "▁e ben", - "▁eb en", - "▁ eben", - "iffer ent", - "iffe rent", - "an u", - "a nu", - "▁С ов", - "▁Со в", - "[ (", - "▁: -)", - "▁:- )", - "le itung", - "form ed", - "for med", - "▁Man ager", - "▁ Manager", - "▁on click", - "T Y", - "та х", - "C V", - "run time", - "r untime", - "po que", - "▁Л о", - "Tem p", - "Te mp", - "T emp", - "lo aded", - "load ed", - "▁! ==", - "▁!= =", - "▁s inger", - "▁sing er", - "▁sin ger", - "fa r", - "f ar", - "▁Com ple", - "▁Comp le", - "▁ Comple", - "▁Ö sterreich", - "Pol icy", - "▁work er", - "▁wor ker", - "▁ worker", - "W rapper", - "ob i", - "o bi", - "▁discuss ed", - "▁b uy", - "▁bu y", - "▁янва ря", - "▁D in", - "▁Di n", - "▁g ed", - "▁ge d", - "▁ ged", - "ско ј", - "E urope", - "▁t all", - "▁tal l", - "▁ta ll", - "ho s", - "h os", - "ла го", - "▁B lock", - "▁Bl ock", - "▁Blo ck", - "▁ Block", - "▁ident ified", - "List View", - "▁attempt ing", - "▁typ ical", - "ps um", - "p sum", - "os ter", + "▁c ategor", + "▁s pecimen", + ".\n\n Study▁", + "al▁ for", + "▁C BC", + "es▁ were▁", + "es▁ only", + "il ution", + "▁2 9", + "anc e,▁", + "▁l umbar▁spine▁", + "▁E L", + "▁n ext", + "\n\nA pproved▁by", + "com mer", + "av ir", + "\n\nS ampl", + "▁M easurement", + "▁com mitte", + "port ion▁of", + "▁the▁s um▁of▁the▁", + "int end", + "s,▁ s", + "▁all ▁subjects▁", + "▁will ▁have▁", + "▁H A", + "▁subject s▁(", + "▁patients▁ on", + "▁study▁ is▁", + "▁pl ot", + "over ▁the▁", + "▁sign s▁and▁symptom", + "▁cont rast", + ".▁T umor", + "first -line▁", + "e▁for ▁the▁", + ".7 .2", + "\n\nR ec", + "▁pre par", + "▁pre medication", + "ity▁of ▁the▁", + "e, ▁then", + "▁reg ulation", + ".\n\nP hase▁III", + "\n\nI V", + "equ iv", + "▁30 %", + "▁progression -free▁s", + "▁cell s", + "ssessment ▁of", + "dis clos", + "▁response▁ will▁be▁", + ".▁An n", + "AB LES", + "▁PFS ▁in▁the▁", + "urn over", + "\n\nConfidential \n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁AMG▁162▁Protocol▁Number:▁20040135▁Date:▁14▁November▁2006\n\nPage▁", + "eet ing", + "mis sing", + "▁count ries▁", + "treatment ▁phas", + "olic ▁acid", + "▁in▁combination▁with ▁FOLFOX", + "confirm ed▁by▁", + "blood▁ cell", + "last ▁dose▁of", + "objectiv e▁tumor", + ",▁W illett", + "Pro cedures", + "▁ens ur", + "▁er lotinib", + "▁er yth", + "roun d", + "\n\n090177e18069 2f86\\Approved\\Approved▁On:▁19-Mar-2007▁16:14\n\n0▁2▁:▁1▁1\n\n7▁0▁0▁2▁-▁r▁a▁M▁-▁5▁1▁\\▁d▁e▁v▁o▁r▁p▁p▁A\n\n\\▁0▁.▁1▁\\\n\n1▁8▁3▁1▁6▁4▁6▁0▁0▁0▁0▁0▁1▁0\n\nSunitinib▁Malate▁Protocol▁A6181087▁Final▁Protocol▁14▁March▁2007", + "NCI ▁CTCAE", + "▁fl uorouracil", + "allow ed▁to", + "▁creatinine▁ clear", + "▁EC G", + "▁add ress", + "every▁3 ▁week", + "response▁( CR", + "Consider ation", + "▁there▁is▁ no", + "recon struction", + "recon stitut", + "▁becom es▁", + "(m g", + "▁MA NAGEMENT", + "omin ant", + "▁vit ro", + "perman ently▁", + "portional▁ hazard", + "▁antag onist", + "( ORR", + "/ f", + "1 50", + "1 )▁", + "2 ]", + "4 ]", + "5 ]", + "6 ]", + ": ▁(", + "D UCT", + "H ER", + "N S", + "O ral▁", + "O X-", + "P er", + "R ectal▁", + "V isit", + "b rid", + "d istribution", + "g ency▁", + "m anner", + "o ot", + "r ath", + "r y▁and▁", + "s upplement", + "t ra", + "u rolog", + "w ors", + "▁ establish", + "s▁ m", + "re current", + "it er", + "▁an emia", + "ic arbon", + ".▁ Un", + "▁p o", + "▁p otential▁", + "▁c ode▁", + "es \n\n", + "▁to ▁confirm", + "is ▁allow", + "▁s een", + "▁s econd▁", + "▁w aking▁hour", + "▁1 000", + "▁P J", + "▁P emetrex", + "il y", + "▁( ECOG", + "▁2 -sided▁", + "un d", + "▁D R", + "▁D MC", + "▁or ▁a", + "▁or ▁mor", + "▁or ▁its▁design", + "ther e▁", + "up d", + "ed▁in ▁an", + "ed▁in ▁combination▁with", + "enc ies▁", + "e▁th ese▁", + "▁0 .00", + "▁0 .01", + "ear n", + "▁g ive▁", + ".3 3", + "▁all ▁s", + "ure a", + "▁analys es▁for", + "▁4 .3", + "s▁( S", + "\n\n1 .1", + "▁the▁t rial▁", + "▁wh ere▁", + "ly ,▁", + "\n\nE ach", + "se e▁section", + "▁from ▁the▁study", + "s\n\n (", + "▁tumor ▁progression", + "▁dos e-", "ost er", - "o ster", - "▁ж урна", - "P e", - "mer ce", - "▁un expected", - "hu i", - "h ui", - "let ter", - "lett er", - "lette r", - "l etter", - "▁nue vo", - "▁а бо", - "▁VAL UES", - "▁I z", - "Fl ags", - "Flag s", - "▁TR UE", - "▁ TRUE", - "iz ación", - "iza ción", - "▁gro wing", - "▁grow ing", - "es tre", - "est re", - "estr e", - "e stre", - "▁p oly", - "▁po ly", - "▁pol y", - "▁ poly", - "▁St one", - "▁Sto ne", - "▁V III", - "▁VI II", - "▁VII I", - "▁local host", - "▁ localhost", - "äh lt", - "ähl t", - "▁embed ded", - "jd bc", - "j dbc", - "▁con vention", - "▁conv ention", - "▁conven tion", - "▁convent ion", - "▁s cala", - "▁sc ala", - "▁scal a", - "▁ scala", - "со к", - "с ок", - "▁an alog", - "▁anal og", - "▁\" +", - "▁ \"+", - "ц ю", - "oc c", - "o cc", - "▁l itt", - "▁li tt", - "▁lit t", - "P N", - "▁а ктив", - "▁ак тив", - "att ributes", - "attribute s", - "▁F erd", - "▁Fe rd", - "▁Fer d", - "▁az ure", - "▁ azure", - "ș ti", - "ño s", - "ñ os", - "pi ng", - "pin g", - "p ing", - "▁te acher", - "▁teach er", - "▁tea cher", - "} &", - "ip e", - "i pe", - "▁N ob", - "▁No b", - "▁и ма", - "▁им а", - "Bi nd", - "B ind", - "▁mag ic", - "▁Trans port", - "▁ Transport", - "ix el", - "▁comp uted", - "▁comput ed", - "▁compute d", - "ag na", - "agn a", - "er st", - "ers t", - "H A", - "W ait", - "▁author s", - "▁auth ors", - "▁; )", - "cl am", - "cla m", - "c lam", - "▁Pen nsylvan", - "▁d rug", - "▁dr ug", - "▁dru g", - "▁v ain", - "▁va in", - "▁employ ed", - "▁individ uals", - "▁individual s", - "▁an ge", - "▁ang e", - "▁ ange", - "ut at", - "uta t", - "u tat", - "▁$ -", - "▁ $-", - "cor rect", - "corr ect", - "▁exper iments", - "▁experiment s", - "Arg ument", - "▁I B", - "▁ IB", - "▁p ère", - "▁B rian", - "▁Br ian", - "ber ger", - "berg er", - "Ma c", - "M ac", - "ia st", - "ias t", - "i ast", - "Per m", - "Pe rm", - "P erm", - "Ca st", - "C ast", - "▁{ };", - "▁{} ;", - "▁St udent", - "▁Stud ent", - "▁Stu dent", - "▁ Student", - "▁st att", - "▁stat t", - "▁sta tt", - "al gebra", - "▁equ als", - "▁equal s", - "▁eq uals", - "▁ equals", - "▁pro jet", - "▁prés ident", - "Activity Thread", - "▁ein z", - "en ia", - "eni a", - "e nia", - "re z", - "r ez", - "ess ional", - "ession al", - "▁авгу ста", - "over ride", - "ne ws", - "new s", - "▁pla net", - "▁plan et", - "▁plane t", - "n n", - "▁W is", - "▁Wi s", - "тв ер", - "т вер", - "▁Val id", - "▁ Valid", - "▁G ef", - "▁Ge f", - "гра д", - "▁e ig", - "an tom", - "ant om", - "anto m", - "▁Me ister", - "fl ags", - "flag s", - "ffic iale", - "fficial e", - "ша я", - "- ,", - "at ionen", - "ation en", - "ati onen", - "atio nen", - "mo use", - "m ouse", - "stand ard", - "Sing le", - "▁b ol", - "▁bo l", - "▁ bol", - "is is", - "isi s", - "▁f ruit", - "▁fr uit", - "c ourse", - "it ants", - "itan ts", - "▁é taient", - "▁ét aient", - "Text Field", - "▁ф он", - "▁фо н", - "▁a ircraft", - "▁air craft", - "▁I SSN", - "▁IS SN", - "▁west ern", - "▁ western", - "▁represent ing", - "Es p", - "E sp", - "▁El se", - "▁Els e", - "▁ Else", - "▁s izes", - "▁si zes", - "▁size s", - "▁satisf ied", - "ot os", - "oto s", - "U D", - "Fin al", - "Fi nal", - "F inal", - "ó j", - "è ve", - "▁R oy", - "▁Ro y", - "ff en", - "ffe n", - "f fen", - "▁s alt", - "▁sa lt", - "▁sal t", - "▁L abel", - "▁La bel", - "▁Lab el", - "▁ Label", - "S k", - "▁к ре", - "▁ кре", - "▁Ли тература", - "▁с м", - "Att ributes", - "Attribute s", - "ay e", - "a ye", - "сь к", - "▁вы со", - "- )", - "os es", - "ose s", - "cal cul", - "calc ul", - "▁C annot", - "▁Can not", - "▁ Cannot", - "Gener ic", - "em o", - "e mo", - "▁A utor", - "▁Aut or", - "▁Au tor", - "▁Auto r", - "лё н", - "л ён", - "ла га", - "vo te", - "v ote", - "lic ates", - "licate s", - "lica tes", - "ru s", - "r us", - "él i", - "é li", - "op f", - "o pf", - "at ique", - "ati que", - "sc ala", - "scal a", - "s cala", - "▁Oh io", - "▁Brit ann", - "▁b ef", - "▁be f", - "▁Е вро", - "▁Ев ро", - "▁Care er", - "is ée", - "isé e", - "ó t", - "bo se", - "bos e", - "b ose", - "▁Б ер", - "▁Бе р", - "▁Cont roller", - "▁Control ler", - "▁ Controller", - "po le", - "pol e", - "p ole", - "▁al len", - "▁all en", - "▁alle n", - "▁ allen", - "▁h ack", - "▁ha ck", - "▁ext ent", - "▁cal ci", - "▁calc i", - "Me r", - "M er", - "▁sum mary", - "▁summar y", - "▁summ ary", - "▁ summary", - "Mar t", - "Ma rt", - "M art", - "▁histor ical", - "▁historic al", - "im at", - "ima t", - "i mat", - "bu d", - "b ud", - "▁F OR", - "▁FO R", - "▁ FOR", - "ex port", - "exp ort", - "ed i", - "e di", - "Map ping", - "Mapp ing", - "Ma pping", - "M apping", - "▁A y", - "▁R uby", - "▁Ru by", - "▁Rub y", - "▁definition s", - "▁defin itions", - "▁definit ions", - "▁{ $", - "▁ {$", - "▁y ours", - "▁you rs", - "▁your s", - "▁yo urs", - "ri as", - "ria s", - "r ias", - "To uch", - "T ouch", - "▁G az", - "▁Ga z", - "▁Aut om", - "▁Au tom", - "▁Auto m", - "▁ Autom", - "▁и стори", - "▁исто ри", - "▁ис тори", - "▁d elen", - "▁de len", - "▁del en", - "▁K inder", - "▁Kind er", - "▁Ki nder", - "▁Kin der", - "}} %", - "} }%", - "▁perform ing", - "F R", - "▁S ig", - "▁Si g", - "▁B rad", - "▁Br ad", - "▁Bra d", - "br as", - "bra s", - "b ras", - "▁J ar", - "▁Ja r", - "pk g", - "p kg", - "w r", - "▁P ays", - "▁Pa ys", - "▁Pay s", - "N C", - "▁op posed", - "▁opp osed", - "▁oppos ed", - "Tr y", - "T ry", - "▁ве зе", - "▁B og", - "▁Bo g", - "▁writ es", - "▁wr ites", - "▁write s", - "▁st ories", - "▁stor ies", - "▁sto ries", - "▁m ater", - "▁ma ter", - "▁mat er", - "▁mate r", - "▁stag ione", - "▁s ty", - "▁st y", - "▁ sty", - "▁compat ible", - "▁ compatible", - "he ast", - "h east", - "▁G uy", - "▁Gu y", - "egr ünd", - "▁ident ifier", - "▁ identifier", - "▁he ads", - "▁head s", - "по зи", - "▁st up", - "▁t f", - "▁ tf", - "▁ј ош", - "▁H ugh", - "▁Hu gh", - "▁c ards", - "▁car ds", - "▁card s", - "▁ cards", - "ov y", - "o vy", - "▁To ast", - "al las", - "all as", - "alla s", - "▁p úblic", - "▁ass umes", - "▁assum es", - "▁assume s", - "▁чемпи она", - "yc ler", - "ycle r", - "y cler", - "▁Juni or", - "▁Jun ior", - "▁F ich", - "▁estim ated", - "▁estimate d", - "ze rw", - "zer w", - "di alog", - "dia log", - "d ialog", - "ши н", - "ш ин", - "sh ell", - "she ll", - "s hell", - "▁н их", - "▁ни х", - "▁ них", - "▁p itch", - "▁pit ch", - "до л", - "out ube", - "▁S anti", - "▁San ti", - "▁Sant i", - "On ClickListener", - "▁M agyar", - "▁Mag yar", - "▁v ue", - "▁vu e", - "▁ vue", - "i ão", - "▁` #", - "col lect", - "coll ect", - "▁R ou", - "▁Ro u", - "anal ysis", - "istrz ost", - "▁Dig ital", - "▁ Digital", - "▁c rist", - "▁cr ist", - "▁cri st", - "ri ere", - "rie re", - "rier e", - "r iere", - "▁cam po", - "▁camp o", + "effect ▁of", + "bin ding", + "▁per man", + "record ed▁in", + "record ed▁on", + ".▁T wo", + "ark et", + "▁your ▁last", + "▁the\n\n investigator", + "▁a▁s ubsequent", + "hy dra", + "result s▁in", + "performed▁ within", + "equ ivalent", + "▁subjects▁ receiving", + "inter action", + "▁complet ion▁of▁the▁", + "▁sub mission", + "hase▁ 3", + ".8 .1", + "▁should▁ contact", + "1) (cid:", + "part ate▁", + ",▁A ST", + "lesion s▁", + "▁radi otherapy", + "by ▁the▁investigator", + "▁Pro cedures", + "cri be▁", + "describ ed▁in", + "IC AL", + "yn th", + "US P", + "only▁ be▁", + "refer ence▁", + "pert ensive▁", + "▁cor respond", + "▁No ▁No", + "egin ning", + "pan el:", + "▁conduct ed", + "▁lif e-threatening", + "▁mic ron", + "relationship ▁between", + ".▁V itamin▁D", + "subjects▁ who", + "Schedul e▁(", + "clinic ▁visit▁or", + "\n\nPh ysical▁examination", + "▁men ▁with", + ".\n\nY ▁P▁O▁C", + ".▁Ther efore,▁", + "flamm atory▁", + "▁(1 ),▁", + "▁analyses▁will▁be▁ conduct", + "▁Man agement", + "aryn x", + "likely ▁to", + "▁72 ▁hour", + "imilar▁to ▁that", + "\n\nC▁I▁N▁O▁R▁T▁C▁E▁L▁E\n\nN▁A\n\nF▁O\n\nY▁P▁O▁C \n\nD▁E▁T▁N▁I▁R▁P\n\nA\n\nS▁I\n\nS▁I▁H▁T", + "lost ▁to▁follow-up", + "▁amended▁ protocol", + "arris▁ WS", + "Cod e:", + "VERSE▁EV ENT", + "inor el", + "▁in▁Combination ▁with", + "& N", + ", ▁they▁", + "/ -", + ": risk", + "A l", + "L S", + "M O", + "P atient", + "T P", + "W ild-Type▁KRAS", + "d aily▁", + "d epending▁on", + "f inal▁", + "h owever", + "n ic", + "n egative▁", + "s urance▁", + "▁ .▁E▁S▁U", + "▁ ..................................................................................................", + "\n\n KRAS", + "\n\n product", + "er ▁R", + "or gan", + "d▁ (", + "al ▁p", + "y▁ Guid", + "ent ire▁", + "an el", + "ar ian", + "ed ▁against", + "es pec", + "es ▁to▁the▁", + "▁to ▁the▁patient", + "▁s erv", + "▁d rop", + "th ical▁", + "▁and▁ F", + "▁and▁ 10", + "▁A SCO", + "im e▁", + "im al▁", + "res um", + "ra y", + "▁I .V", + "▁h ematologic", + "▁l ig", + "ap ies", + "ver age▁", + "▁or ▁in", + "▁or ▁designe", + "e▁t urnover", + "ist er", + "▁T issu", + "ess ential", + "ep artment", + "study -specific", + "ed▁b etween", + "▁will▁be▁ analyz", + "▁will▁be▁ test", + "e▁th is▁", + "▁M od", + "▁of▁the▁ patient", + "▁are▁ met", + "▁on e▁of", + "▁B iomarker", + "ce eding", + "▁the▁in dividual", + "s▁in ▁case▁of", + "gen e▁", + "\n\nD os", + "ob lig", + "▁patient s.▁", + "▁G ood▁Clinical▁Practic", + "▁un less▁", + "AE s▁", + "▁from ▁baseline▁to", + "pres erv", + "▁per mitt", + "are d", + ",▁and ▁all", + "have▁ not", + "▁8 .1", + "\n\nThe▁ investigator", + "le ad▁", + "main tenance▁", + "▁di et", + "Cl ear", + "reas ons", + ".▁M ed", + "elect ive▁", + "▁up on", + "\n\nIn formed▁Consent", + "▁number ▁of▁", + ".▁J ournal▁of", + "ed▁or ▁chair", + "tern al", + "tern al▁", + "tern ative▁", + "▁within ▁30", + "▁the▁sam e▁d", + "IC ES", + "reatinine▁ Clear", + "▁24 -hour", + "olic y", + "terim ▁Analysis", + "▁hav e▁the▁", + "except ion▁of", + "objectiv e▁of", + "▁Con comitant▁medication", + "limit ing", + "possibl e▁", + "symptom atic", + "▁denosumab ▁is▁", + "ultipl e▁", + "▁consider ed▁", + "▁risk ▁of", + "▁medical ▁condition", + "jud ic", + "rout in", + "IM MUNEX\n\nConfidential\n\nAMGEN\n\nProduct:▁ABX-EGF▁Protocol▁Number:▁20020408▁Amendment▁4▁Date:▁26▁April▁2005\n\nPage▁", + "▁immedi ately", + "s.▁In ▁addition", + "see▁ Appendix", + "▁Data ▁Monitoring▁Committe", + "▁regulator y▁", + "afety▁and▁ efficacy▁", + "▁multipl e▁", + "head ▁and▁neck", + "otyp ing", + "▁phase▁of ▁the▁study", + "▁ent ry▁", + "phen hydra", + "ital▁ Sign", + "▁cutoff ▁date▁", + "ochem ical", + "det ect", + "effect▁of▁ ZD4054", + "▁exce ed▁", + "alog u", + "i▁S ankyo", + "International▁ Conference▁on▁Harmon", + "review▁bo ard", + "ped ited▁", + "PPEND ICES", + "hydrox yvitamin▁D", + "▁may▁have▁been ▁caus", + "instruct ed▁to", + "▁wish ▁to", + "ustral ia", + "aiich i▁Sankyo", + "phenhydra min", + ") .▁This▁", + "+ DHA", + ", ▁as", + "- emergent", + "5 00", + "8 -", + "9 ]", + "B UN", + "C onfidential\n\nPage▁", + "E fficacy▁of", + "H istor", + "P S", + "R andomization", "U s", - "▁circ a", - "▁cir ca", - "▁Com ponent", - "▁ Component", - "▁NS String", - "▁ NSString", - "p d", - "▁pr ince", - "▁prin ce", - "▁in voke", - "▁inv oke", - "▁ invoke", - "▁Mar ine", - "▁Mari ne", - "Al low", - "All ow", - "est ic", - "esti c", - "ри сти", - "рис ти", - "рист и", - "bo ne", - "bon e", - "b one", - "ту ры", - "тур ы", - "▁pass ion", - "ác ió", - "á ció", - "▁o rn", - "▁or n", - "▁ orn", - "ве д", - "▁in vari", - "▁inv ari", - "▁н і", - "▁ ні", - "Re move", - "Rem ove", - "en cies", - "enc ies", - "enci es", - "il ib", - "ili b", - "i lib", - "▁Direct or", - "▁Dire ctor", - "▁Dir ector", - "\" \"", - "▁Con se", - "▁Cons e", - "google apis", - "ó k", - "▁У кра", - "▁H aving", - "▁Ha ving", - "▁Hav ing", - "Do main", - "Dom ain", - "ie rz", - "ier z", - "но логи", - "н ологи", - "Ch o", - "C ho", - "un defined", - "und efined", - "al loc", - "all oc", - "allo c", - "▁p ied", - "▁pi ed", - "▁pie d", + "V I", + "a EC", + "c ip", + "e .▁D", + "e hydration", + "g u", + "g res", + "g raph", + "h am", + "i or", + "p articular", + "p ending", + "▁t yrosine▁kin", + "\n\n K", + "\n\n with", + "\n\n (cid:", + "st eril", + "ro ly", + "ed▁ not", + ".▁ 2", + "ed .▁In", + "▁p regnancy▁", + "ation s▁of", + "is ▁an", + "is sion", + "om as", + ".\n\n RE", + ".\n\n You", + "al▁ expos", + "iv e\n\n", + "res orption", + "oc last", + "▁1 50▁mg", + "est er", + "ra re", + "▁I mmun", + "▁re currence▁", + "▁l ab", + "▁E Q-5D", + "▁f emal", + "e▁t umour", + "\n\nP fizer▁–▁Company▁Confidential▁Page▁", + "study -related▁", + "ed▁b ut", + "age▁ IV", + "▁is▁ s", + "▁of▁ study▁", + "▁will▁be▁ consider", + "▁0 .7", + "▁of▁the▁ event", + "▁com mun", + "not ifi", + "▁B one▁", + "▁analys es▁will", + "▁the▁in itial▁", + "ly ▁to", + "Protocol ▁Attachment▁JM", + "▁un less", + "s▁for ▁each", + "pres crib", + "▁study ▁arm", + "▁test s▁", + "are d▁", + "pre pared▁", + "subject s▁with", + "▁- ▁-", + "▁the\n\n subject", + "▁Study▁ of", + "................................................................................................ .......▁", + "▁im plement", + "s▁that ▁you", + "hy th", + "▁therapy▁ with", + "result s▁will▁be▁", + "performed▁ for", + "you ▁are▁", + "enroll ed▁in", + "▁ap art", + "duc ed▁", + "▁should▁ continu", + "▁requ ires", + "Wh en", + "clinical ▁data", + "▁chang e\n\n", + "under lying", + "must ▁have▁", + "▁OS ▁event", + "▁OS ▁and▁PFS", + "start ▁of", + "▁randomiz ed▁trial", + "indic ated▁", + "PA +DHA", + "significant ly▁", + "▁Ph armacokinetic", + "▁bas is", + "stor ed▁at", + "▁observ ed▁", + "most ▁recent", + "al▁of ▁consent", + "objectiv es▁", + "opp ing", + "ild-t ype▁", + "▁Edition▁Number▁3▁D ate\n\n", + "▁carcinoma ▁of▁the▁", + "plann ed▁", + "▁schedul e▁", + ".▁It ▁is", + "▁PRO DUCT", + "lik e▁", + ",▁c reatinin", + "▁en zym", + "\n\nS▁T▁I\n\nK▁C▁E▁H▁C \n\nE▁S▁A▁E▁L▁P", + "should▁ not▁be▁", + "▁Co .,▁Ltd", + "us▁( 0", + "▁among ▁subjects▁with", + "gener ally▁", + "thics▁Com mittee", + "▁statist ically▁significant", + "(1 ):▁p.▁", + "participation ▁in▁the▁", + "▁horm one▁", + "▁appl ication", + "omega-3 ▁fatty▁acid", + "lorid e,▁", + "exameth ason", + "yel os", + "effort ▁should▁be▁made▁to", + "▁improvement ▁in", + "avor able▁", + ".▁2000 ;", + "phyl ax", + "opor osis", + "ness▁of ▁breath", + "▁compens ate▁you", + "▁aspect s▁of", + "▁study▁ent ry", + "BL IG", + "▁limit▁of ▁normal▁", + "urfac e▁", + "▁Soc ▁Clin▁Oncol", + "▁perfor ation", + "idne y▁", + "▁Natl ▁Cancer▁Inst", + "eturn ▁of", + ",▁potassium ,▁ch", + ",▁Willett ▁WC", + "roly t", + ") ▁that", + ") ▁should▁be▁", + ") ,▁a", + ", ▁t", + "/ Placebo", + "7 5%", + "; \n\n", + "C ox", + "E ▁R▁O▁F▁E▁B", + "F igure▁", + "O verall", + "] ▁and▁", + "g ender", + "h enia", + "m uch", + "n ature▁of", + "p ose▁", + "t ransfer", + "▁ ‘", + "▁ eligibl", + "at ent", + "▁a im", + "s▁ regarding", + "re e▁", + "it rogen", + "ed▁ f", + "ed▁ due▁to", + "ed▁ during", + "▁p regnancy", + "▁to ▁moder", + "▁s ummar", + "▁of ▁blood▁", + "▁m easure▁", + "el t", + "▁in ▁this▁study▁", + "ur s", + "os in", + "est ern", + "▁( p", + "em in", + "▁I mClone▁LLC", + "ag es▁", + "▁D evelopment", + "ap hy", + "▁E fficacy▁", + "▁E fficacy", + "am ine▁", + "▁or ▁m", + "e▁t reat", + "ex ist", + "qu isition", + "lin d▁", + "lin ear", + "▁ad vant", + "▁N ew", + "ess el", + "com mun", + "ive▁ heart", + ".2 \n\nR", + "e▁to xicity▁", + "▁al w", + "▁al ready▁", + "▁will▁be▁ obtain", + "▁will▁be▁ responsible▁for", + "▁con current", + "▁of▁the▁ subject", + "ity▁ (", + "▁as▁ defin", + "200 6", + "ever e▁", + "▁B i", + "▁y et", + "▁will ▁have▁a", + "▁5 5", + "▁5 .2", + "▁5 .3", + "will ▁not", + "ult iv", + ")\n\n D", + "s▁( RECIST", + "eg r", + "rel i", + "▁the▁t reat", + "▁the▁t otal▁", + "reg imens", + "Protocol :", + "10 7", + "evalu ating", + "▁tumor ▁measurement", + "e▁v isit", + ".▁In vestigator", + "record ed", + "▁cont roll", + "Study▁ T", + "▁Ad vanced▁", + "dos es▁of", + "▁includ es▁", + ".▁200 5", + "inter n", + "▁Com plet", + ",▁200 0", + "▁must ▁not▁be▁", + "TION ▁OF", + "IV ▁infusion", + "▁document ation▁of", + "▁des cription", + "blind ed▁treatment", + "▁approv al▁of", + "▁within ▁1", + "\n\nF▁O \n\nY▁P▁O▁C", + "▁who ▁conducted", + "ubl ic", + "ash ion", + "imaging ▁techniqu", + "▁medical▁ event", + "▁or▁ “", + "summar is", + "▁patients▁who ▁have▁", + "\n\nin vestigational▁product", + "▁Phase▁ 2", + "ss um", + "ET ▁scan", + "ord ing▁of", + "▁CV D", + "addition ▁of", + "direct ly▁", + "histor y▁of", + ",▁w e▁", + "persensitiv ity", + "▁Rec eptor", + "\n\nConfidential\n\nAMGEN\n\nProduct: ▁darbepoetin▁alfa▁Protocol▁Number:▁20010145▁–▁Amendment▁2▁Date:▁16▁July▁2004\n\nPage▁", + "\n\nEx ploratory▁", + "▁assum ption", + "Objectiv es", + "e▁tim e▁", + "itt l", + "▁CON T", + "▁carry▁ on", + "ession al", + "appearance▁of ▁all", + ".▁Ph armac", + "▁a▁copy▁of ▁the▁", + "s.▁P atients▁", + "▁Re action", + "ince▁th e▁treatment▁start", + "Wild-type▁KRAS ▁Efficacy▁Analysis▁Set", + "ulatory▁ A", + "▁body▁ weight", + "▁along ▁with", + ".▁N▁Engl▁J ▁Med▁", + "efer▁to ▁Section", + "▁or▁n ail", + "▁approxim ately", + "carri ed▁out", + ".▁Am▁J ▁Clin▁Nutr", + "menopaus al", + "oward▁ medical▁occurr", + ":▁http:// www.", + "extension▁lead▁ period", + "(O H)", + "\n\nIM MUNEX\n\nConfidential\n\nAMGEN\n\nProduct:▁ABX-EGF▁Protocol▁Number:▁20020408▁Amendment▁4▁Date:▁26▁April▁2005\n\nPage▁", + "ebrile▁ neutropenia", + ".\n\nPhase▁III ▁Protocol▁CA012-0▁ABI-007▁(Nanoparticle▁Paclitaxel)\n\nCONFIDENTIAL", + "Oral▁ Rectal▁", + ", 3", + "- SCLC", + "5 00▁mg/m2", + "7 45", + "F atigu", + "S cal", + "c olorectal▁cancer", + "d r", + "l angu", + "m utant▁KRAS", + "m ulticenter", + "r andom", + "s uggest", + "” ▁or▁“", + "▁ &", + "e▁ D", + "\n\n 30", + "or ter", + "or ▁cyt", + "s▁ model", + "al k", + "al pha", + ",▁ placebo", + "ed▁ log-rank▁test", + "es ▁an", + "es e▁sit", + "is ol", + "▁d am", + "▁w oman", + "▁m ortality", + "▁and▁ must", + "▁and▁ carboplatin", + "▁and▁ Treatment", + "is▁ no", + "▁A b", + "▁A ci", + "▁in ▁writ", + "oc rit", + "▁C or", + "▁P rior", + "▁P ath", + "pro long", + "▁2 .1", + "▁S U", + "ot ograph", + "ag e▁to", + "▁h eart", + "▁or ▁the▁", + "e▁t echniqu", + "ut om", + "\n\nP RO", + "▁n ec", + "▁n ovel", + "\n\nA ttachment", + "ate▁ s", + "study▁ of", + "▁O BLIG", + "com ponent", + "com menc", + "▁ar th", + "and rogen", + "▁R EP", + "age▁ (", + "▁of▁ M", + "▁will▁be▁ calculated▁", + "▁0 .0", + "▁as▁ per", + "▁on ▁day▁1", + "▁v endor", + "▁B SA", + "▁res erv", + "▁st eril", + "▁5 00", + "▁ex press", + "\n\nD ata", + "s▁and▁ in", + "▁patient s▁to", + "▁from ▁a", + "ed▁by▁ Lilly", + "▁study -related▁", + "▁to▁the▁ first", + ".▁C arboplatin", + "▁sign aling", + "▁cont ribut", + "▁9 .3", + "▁us e▁in", + "al▁pro cedures", + "▁other ▁than", + "ER B", + ".▁D uring▁the▁", + "▁inter val▁", + "oth elin", + "fl ow", + "performed▁ on", + ".▁R andomiz", + "until ▁the▁", + ".▁200 4", + "▁complet ed▁", + "ES S", + "randomiz ed", + "stat us▁", + "dis cover", + "................................................ ....", + ",▁200 7", + "▁dur ation▁of", + "sub set", + "▁level s▁of", + "man ag", + "▁activ ities▁", + "s▁after ▁the▁", + "reast ▁Cancer", + "▁Section :", + "▁then ▁be▁", + "▁K aplan-Meier", + "\n\nL IST▁OF", + "iver s", + "are▁ no", + "▁no ▁longer", + "▁Day▁1 ▁of", + "▁IV RS", + "\n\nO b", + "expect ed", + "▁the▁b est", + "▁the▁b aseline▁", + "\n\nClinical▁ Study▁", + "ral izing", + "▁measurement s▁and▁", + "except ion", + "▁period▁ (", + "summar ized▁", + "emb olism", + "e▁f requ", + "lif er", + ".▁However ,▁if", + "▁evaluation ▁period", + "▁are \n\n", + "▁only )", + "ET HO", + "▁50 ▁mg", + "▁ident ify", + "roch ure", + "plus▁ cisplatin", + ",▁J ohnson", + "▁up▁to ▁2▁year", + "▁the▁safety▁ follow▁up", + "ogenic ity", + "L/ 00", + "▁regard ing", + "rok en", + ".▁Pro c", + "▁fract ure", + "character iz", + "followed▁ up", + "stric tion", + "▁had ▁a", + "orld wid", + "▁primary ▁tumor", + "eyon d", + "acceptable▁to xicity", + "▁years▁of ▁ag", + "erc k", + "▁pros pective▁", + "▁legally▁acceptable▁ representative▁", + "e▁trans amin", + "gether ▁with", + ".\n\nST UDY", + "▁prostat ectom", + "DE RA", + "comment ]", + "radical ▁prostatectom", + "% ▁power▁to▁detect", + ") ▁and▁the▁", + ", ▁that", + "- lead▁", + ". A", + "3 ]", + "3 .1", + "4 50", + "; ▁3", + "B aseline▁", + "C I", + "C rCl", + "E thics▁Committe", + "G I", + "R e", + "S tudy", + "W eek", + "b on", + "c ardiovascular", + "c ohort", + "e .▁M", + "g uid", + "m g", + "n own", + "o prot", + "p ite▁", + "r one▁", + "v itamin", + "▁ em", + "▁ every", + "e▁ L", + "in ess", + "re e▁S", + "st ability▁", + "st ein", + "▁the▁ result", + "▁b eliev", + "▁to ▁6", + "is e▁", + "▁and▁ H", + "al▁ function", + "el -", + "el ine▁", + "▁C L", + "es▁ B", + "▁( D", + "▁( for", + "▁( e.g.,▁", + "us ,▁", + "us cl", + "ul in", + "if ▁they▁", + "▁S ▁T▁I\n\nK▁C▁E▁H▁C", + "▁I FL", + "▁re ad", + "ot ion", + "▁D ay▁", "▁f raction", - "▁fr action", - "▁fra ction", - "bi a", - "b ia", - "▁п оло", - "▁по ло", - "▁пол о", - "▁ поло", - "ug no", - "min ister", - "▁princip ale", - "▁principal e", - "▁ref used", - "▁refuse d", - "brow ser", - "b rowser", - "* ,", - "▁H ospital", - "▁univers al", - "▁Ern st", - "wh o", - "w ho", - "▁G ard", - "▁Gar d", - "▁Ga rd", - "' _", - "con de", - "co nde", - "cond e", - "c onde", - "▁[ {", - "▁ [{", - "so b", - "s ob", - "▁C rit", - "▁Cr it", - "▁дека бря", - "▁p unto", - "▁pun to", - "▁punt o", - "▁einges etzt", - "▁t ör", - "▁tö r", - "▁N i", - "▁w orry", - "▁wor ry", - "▁leg end", - "▁ legend", - "▁бу ли", - "▁k omm", - "▁kom m", - "▁ko mm", - "ri jk", - "rij k", - "r ijk", - "ef fect", - "eff ect", - "e ffect", - "Or i", - "O ri", - "RE S", - "R ES", - "▁P eters", - "▁Pe ters", - "▁Peter s", - "▁Pet ers", - "▁B aron", - "▁Bar on", - "▁Ba ron", - "▁G ot", - "▁Go t", - "▁hon est", - "▁ho nest", - "är e", - "ä re", - "ás z", - "á sz", - "▁no ble", - "▁nob le", - "▁con clusion", - "▁conclus ion", - "▁concl usion", - "▁form atting", - "▁format ting", - "▁formatt ing", - "▁o tto", - "▁ot to", - "▁ott o", - "▁ otto", - "▁de leg", - "▁del eg", - "м б", - "pt op", - "pto p", - "p top", - "▁s ends", - "▁send s", - "▁sen ds", - "ur name", - "urn ame", - "▁f estival", - "▁fest ival", - "▁festiv al", - ", ‎", - "ру с", - "р ус", - "▁d och", - "▁do ch", - "▁doc h", - "sub ject", - "su bject", - "▁care ful", - "qu ent", - "que nt", - "q uent", - "▁Lo ad", - "▁ Load", - "temper aturen", - "▁r ue", - "▁ru e", - "Mem ory", - "ț a", - "ion a", - "io na", - "i ona", - "▁dent ro", - "▁beg ann", - "▁began n", - "▁A qu", - "▁scient ific", - "ka ń", - "ло к", - "л ок", - "el de", - "eld e", - "▁Th ose", - "qu ier", - "qui er", - "act ér", - "▁Auf lage", - ") '", - "▁grad ient", - "▁ gradient", - "in teger", - "inte ger", - "▁Im port", - "▁Imp ort", - "▁ Import", - "S K", - "▁St atus", - "▁Stat us", - "▁ Status", - "▁exp lo", - "▁expl o", - "A E", - "Sh ell", - "She ll", - "S hell", - "▁Pa ulo", - "▁Paul o", - ". »", - "} '", - "hav ior", - "le i", - "l ei", - "ul f", - "▁ge ometry", - "▁geom etry", - "▁geomet ry", - "▁ geometry", - "pr ev", - "pre v", - "p rev", - "em pl", - "emp l", - "▁L é", - "an son", - "ans on", - "▁A lice", - "▁Al ice", - "▁Ali ce", - "pro totype", - "proto type", - "RE AD", + "t ak", + "x -ra", + "y cardia", + "▁ eligibility", + "▁ employ", + " ", + "on e,▁", + "\n\n iv", + "en vironment", + "or pt", + "s▁ P", + "s▁ occur", + "s▁ which", + "s▁ identifi", + "s▁ using▁a", + "s▁ do▁not", + "al /", + "al ready▁", + "st op", + ",▁ data", + "▁an ▁event", + "ar rier", + "ed ▁tissu", + "es s▁in", + "for ward", + "is ▁to▁be▁", + "▁s erious▁", + "▁s ingle▁", + "▁s pecial", + "th ▁December▁2004", + "▁w or", + "▁and▁ oxaliplatin", + "▁and▁ valid", + ".\n\n 14", + "ab normal", + "iv e▁of", + "▁in ▁Section", + "▁in ▁accordance▁with", + "▁in ▁order▁to", + "im m", + "im ulating", + "ur ic▁acid", + "oc ial", + "pro portion", + "▁( 5", + "▁( J", + "▁( and▁", + "▁( i.e.,▁", + "▁S W", + "▁I II", + "▁I ND", + "▁re pair", + "cl us", + "ri st", + "▁h andl", + "e▁t yp", + "ir radi", + "\n\nA straZeneca", + "lin k", + "▁T est", + "▁T oxic", + "▁ad equ", + "com pr", + "ed▁in fusion", + "In jection", + "ad equ", + "▁of▁ study▁treatment", + "▁of▁ 32", + "e▁th reatening", + "▁M ETHO", + "▁r ight", + "▁0 .9", + "ph ysical▁", + "▁on e▁dose▁of", + "▁v ivo", + "▁L B", + "able▁ and▁", + "s,▁ such▁as▁", + "▁ther efore▁", + "▁ch arter", + "▁5 ▁mm", + "▁5 ▁20", + "will ing▁to", + ")\n\n X", + "s▁( ≤", + "eg ativ", + "continu ous▁", + "▁any▁ of▁the▁", + "formed▁ of", + "▁G -CSF", + "▁In formed▁Consent▁Form", + "on- study▁", + "▁tumor ▁growth", + "ous▁ system", + "▁ass ist", + ".▁E nd▁of", + "▁assessment ▁of▁", + "e.\n\n 8", + "▁us ed", + "pre par", + "pre paration", + "▁im pact", + "▁follow ing▁the▁", + ".▁D rug", + "▁the▁l ocal▁", + "▁inter ruption", + "complet e▁or", + "ed▁as ▁the▁", + "ed▁in▁the▁ protocol", + "▁day s▁befor", + "▁cons equ", + "hy persensitivity▁reaction", + "hy percalcemia", + "▁therapy▁ will▁be▁", + "es,▁ including", + "▁act ual", + "▁the▁study▁ is▁", + "▁approximately▁ 1", + "▁approximately▁ 2", + "number ▁and▁", + "▁dis clos", + "sub study", + "▁metastatic ▁disease▁", + "▁Res ult", + "sampl es▁will▁be▁", + "ric ular", + "▁baseline▁ and▁", + "▁this \n\n", + "▁chang e▁of", + "▁ne ut", + "▁plus▁ FOLFIRI", + "assessment ▁of", + "▁St aging", + "▁part ▁of▁the▁", + "easurable▁ lesion", + "▁sever ity▁", + "-related▁ quality▁of▁lif", + "▁Q 4W", + "required▁ by", + "▁analysis▁of ▁the▁", + "▁require d▁for", + "▁bone▁ lesion", + "▁withdraw al▁from", + "median ▁survival", + "▁cor relation", + "ateri al▁", + ".▁L ancet", + "ecaus e▁the▁", + "ourc e▁", + "\n\nm onth", + "▁e▁ n", + "▁ident ify▁", + "T- 11", + "▁a▁l arg", + "................................................................................................................ ..", + ".\n\nN ▁A\n\nF▁O\n\nY▁P▁O▁C", + "▁applicable▁ law", + "▁tabl es", + "▁met ab", + "followed▁for ▁survival▁", + ",▁un less▁", + "(1 ):", + "stable▁ disease▁", + "ologically▁ or▁cyt", + "unt oward▁medical▁occurr", + ",▁al kaline▁phosphatas", + "▁Wh en", + "whichever ▁is▁", + "▁pleur al▁effusion", + "▁sodium ▁chlorid", + "ockcroft ▁and▁Gault", + "revers ibl", + "▁Synops is", + "(6 ):", + "olin ic▁acid▁", + "▁vertebral▁ fracture▁", + "VESTIG ATIONAL", + "angi ogenic", + "ohistoc hemistry▁", + "clinic▁visit▁or ▁telephone▁contact", + "(OH) D", + "▁REPOR TING", + "fined▁to▁b ed▁or▁chair", + ") .▁If", + ", 11", + "/ N", + "/ t", + "/ day▁", + "0 .00", + "3 rd", + "6 0%", + "7 ]", + ": ▁", + ": \n\nC", + "C D", + "N am", + "N umber", + "T arget", + "c int", + "d oubl", + "e u", + "e .▁T", + "i ▁R", + "i as▁", + "k eep", + "n adir", + "o is", + "p ractic", + "r ch", + "s ia", + "s imilar", + "s ide▁effect", + "s upportive▁", + "t otal", + "y ▁and", + "z en", + "▁ μ", + "▁ ", + "▁ ................................................", + "▁ etoposid", + "e▁ any▁", + "at ed▁by", + "at ern", + "\n\n ≤", + "\n\n lesion", + "\n\n randomization", + "s▁ -", + "s▁ B", + "s▁ based▁on", + "s▁ used▁in", + "st abl", + ",▁ hemat", + "ed▁ will▁be▁", + "ed▁ dose▁", + "ar ies", + "▁p aper", + "▁c ertain", + "es ;", + "for d▁", + "et it", + "is en", + "is ▁the▁", + "▁s econdary▁", + "▁d on", + "▁d ig", + "▁d aily", + "th ir", + "▁w k", + "▁m aintenance▁", + "▁and▁ 4", + "▁and▁ 5-FU", + ".\n\n Protocol", + "el s", + "▁A p", + "▁in spect", + "ig raph", + "▁1 ▁and▁", + "▁1 .4", + "▁1 ▁dose▁level", + "es▁ [", + "em por", + "▁2 0%", + "▁S ▁I▁H▁T", + "▁I ▁am", + "▁f ive▁", + "▁or ▁D", + "▁or ▁IEC", + "e▁t aken", + "▁for ▁the▁treatment▁of", + "▁R es▁", + "▁R eplace:", + ".2 7", + "ed▁b efor", + "▁of▁ VEGF", + "▁will▁be▁ performed", + "e▁s kin", + "▁0 5", + "▁3 ▁year", + "▁3 rd▁", + "act ual", + "cor d▁of", + "wh ol", + "wh ose▁", + "cont ribut", + "200 3", + "200 5", + "200 .3", + "▁the▁s afety", + ",▁and▁ p", + "▁5 .0", + "ity ,▁", + "▁6 .9", + "s▁in ▁patients▁with", + "▁V A", + "ell ular", + "e▁d rug", + "▁patient ▁is▁", + "▁the▁d at", + "▁the▁d esign", + "▁G rad", + "▁tim e▁(", + "▁from ▁the▁study▁", + "▁dos e\n\n", + "e▁v alu", + "includ es", + "over ▁30", + "AL Y", + "▁ab il", + "ed▁at ▁the▁time▁of", + "................................................................................ .......▁", + "ative▁ sit", + "▁pre treatment", + "ence▁ and▁", + "▁a▁s ec", + "▁the▁l evel", + "▁the▁l ong", + "199 .3", + "An alysis", + "SA )", + "▁subjects▁ have▁", + "crib ed▁", + "36 :54", + "umm ary", + "risk s▁of", + "▁which ▁the▁", + "part ner", + "elet e:", + ".\n\nC onfidential\n\nProduct:▁AMG▁162▁Protocol▁Number:▁20040138▁Date:▁19▁February▁2008\n\nPage▁", + "by -", + "▁diseas e.\n\n", + "▁Pro state▁Cancer", + "start ▁of▁the▁", + "s▁and ▁treatment", + "▁every▁ 4▁week", + "▁ver ification", + "▁the▁sam e▁dose▁", + "▁clinical▁ outcom", + "▁between ▁the▁2", + "▁analysis▁of ▁PFS", + "▁15 ▁minutes", + "▁confirm ation▁of▁", + "\n\nY▁T▁I▁D▁I▁L▁A▁V \n\nS▁T▁I", + "\n\nAdd▁ 5", + "▁20 th▁December▁2004", + "100 %", + "egin n", + "number▁of ▁patients▁", + "▁Phase▁ III", + "align ant", + "▁vari ation", + ",▁with out", + "Grade▁ 1", + "................................................................................................................ ........", + "▁chest ▁CT", + "extension ▁period▁", + "written ▁informed▁consent", + ".▁Con comitant", + "▁solution ▁for", + "▁clinically▁ significant", + "profil e▁of", + "▁account ability▁", + "PT V", + "ackgroun d▁", + ".▁U pon", + "\n\nl \n\na", + "▁recommend ation", + "early ▁termination", + "character istic", + "▁att ack", + "\n\nCT CAE", + "▁the▁informed▁consent ▁discussion", + "omin ated▁", + ".\n\nAn y▁", + "room ▁temperature▁", + "eriou s,▁", + "▁(Arm ▁A", + "\n\nLY231514 \n\nPage▁", + "▁has▁not ▁been", + "\n\nAbbreviation s:", + ",▁as▁well ▁as▁", + "Analys es", + "\n\n21▁Dec▁2004▁10: 21:", + "\n\n21▁Dec▁2004▁10: 36:54", + "▁allergic ▁reaction", + "e▁from▁baseline▁ in", + "Peri od", + "▁arch iv", + "▁ship ment", + "refract ory▁", + "ropoi etin", + "fib ros", + "emov al▁of", + "inal▁cor d▁", + "blinded▁treatment ▁phas", + ",▁placebo -", + "cint igraph", + "\n\n21▁Dec▁2004▁10:21: 22", + "% ),▁", + "( 7", + "( D", + ") ▁on", + ", 12", + "- R", + "- associated▁", + "- ▁or▁nail", + "/ A", + "2 14", + "6 th", + "8 ▁weeks▁", + ": ▁the▁", + "A ttachment", + "C N", + "C ycle▁", + "F F", + "G PT", + "M )", + "Q uestionna", + "V )", + "V F", + "Z ometa", + "a it", + "a uthor", + "b one▁scan", + "f our", + "h n", + "k ey", + "l u", + "s om", + "s af", + "s olution", + "t yp", + "v essel", + "w indow", + "z el", + "▁ onset", + "▁t eas", + "▁t axan", + "at al", + "\n\n GF", + "\n\n analysis▁", + "or ▁to", + "s▁ R", + "s▁ S", + "s▁ containing", + "s▁ may", + "al iv", + "it z", + "an in", + ",▁ investigator", + "ed▁ via", + "▁an ▁AE", "ic ular", - "icul ar", - "i cular", - "▁б і", - "▁ бі", - "▁deutsch e", - "▁Re present", - "si tes", - "site s", - "s ites", - "▁Me an", - "▁d iss", - "▁di ss", - "▁dis s", - "▁Z ur", - "▁Zu r", - "▁п рез", - "▁пре з", - "▁пр ез", - "PA R", - "P AR", - "▁' #", - "▁D ra", - "▁Dr a", - "▁ Dra", - "со н", - "с он", - "▁ste ht", - "mar kt", - "mark t", - "▁e ase", - "▁eas e", - "Draw ing", - "Dra wing", - "= %", - "St op", - "Sto p", - "S top", - "▁s erving", - "▁ser ving", - "▁serv ing", - "▁servi ng", - "▁tak że", - "▁D NS", - "▁liter al", - "▁lit eral", - "Di e", - "D ie", - "▁в ос", - "▁во с", - "▁sen ior", - "ac ion", - "aci on", - "a cion", - "▁u buntu", - "▁ub untu", - "▁ ubuntu", - "▁Frank furt", - "▁Sun day", - "▁Sund ay", - "á b", - "▁jour ney", - "▁journ ey", - "is sa", - "iss a", - "ber ry", - "▁s ep", - "▁se p", - "▁ sep", - "▁i on", - "▁io n", - "▁ ion", - "wer t", - "we rt", - "w ert", - "or szág", - "orsz ág", - "ser ve", - "serv e", - "s erve", - "▁Mil ano", - "▁Milan o", - "▁ве ка", - "ра х", - "▁ию ля", - "▁man era", - "▁st ations", - "▁stat ions", - "▁station s", - "▁stati ons", - "▁adopt ed", - "▁any body", - "VER SION", - "F E", - "do rf", - "dor f", - "d orf", - ".. .,", - "... ,", - "▁обра зова", - "▁образ ова", - "Log ger", - "фи циаль", - "фици аль", - "WR ITE", - "▁h am", - "▁ha m", - "▁ ham", - "▁F uture", - "▁Fut ure", - "▁ Future", - "ot en", - "ote n", - "o ten", - "▁A G", - "▁ AG", - "▁t rained", - "▁tr ained", - "▁tra ined", - "▁train ed", - "▁N ich", - "▁Nic h", - "▁Ni ch", - "▁un iversity", - "▁univers ity", - "▁Olymp ics", - "▁Olympic s", - "▁d oit", - "▁do it", - "▁doi t", - "▁cult ural", - "▁cultura l", - "Con f", - "▁Con ference", - "or no", - "orn o", - "▁M P", - "▁ MP", - "▁b ou", - "▁bo u", - "ci n", - "c in", - "Hi gh", - "H igh", - "ann te", - "annt e", - "▁display ing", - "▁ch apter", - "▁chap ter", - "▁ chapter", - "▁Fra uen", - "▁Frau en", - "▁real ized", - "▁realiz ed", - "▁realize d", - "▁attempt ed", - "▁pre ferred", - "▁prefer red", - "Da t", - "D at", - "▁tr ouve", - "▁tro uve", - "▁trou ve", - "▁trouv e", - "▁int ention", - "▁intent ion", - "▁inten tion", - "▁Not ice", - "tim estamp", - "* (", - "▁Ш а", - "an as", - "ana s", - "a nas", - "cl a", - "c la", - "is z", - "i sz", - "tb l", - "t bl", - "Ar r", - "A rr", - "▁in verse", - "▁ter rible", - "▁occup ied", - "J AX", - "< -", - "▁Phil osoph", - "▁Cor ps", - "bu ilder", - "build er", - "▁beg ins", - "▁begin s", - "▁c ensus", - "▁cens us", - ". ’", - "▁pro ven", - "▁pr oven", - "▁prov en", - "▁prove n", - "met ric", - "▁incre ases", - "▁increase s", - "wi ch", - "w ich", - "▁A BC", - "▁AB C", - "▁ ABC", - "project s", - "▁T hor", - "▁Th or", - "▁conf idence", - "▁u fficiale", - "el m", - "e lm", - "▁g arden", - "▁gar den", - "▁gard en", - "▁rob ust", - "▁cos ì", - "ie dz", - "ied z", - "▁Is lam", - "▁Add ress", - "▁ Address", - "▁div ide", - "▁divid e", - "▁E u", - "ca tal", - "cat al", - "c atal", - "de tail", - "det ail", - "ep endant", - "f g", - "▁b ew", - "▁be w", - "▁ bew", - "▁f is", - "▁fi s", - "▁B O", - "▁ BO", - "▁w sp", - "▁ws p", - "▁p ipeline", - "▁pip eline", - "▁pipe line", - "h d", - "▁S ession", - "▁ Session", - "lä nd", - "l änd", - "iv eau", - "ive au", - "es tr", - "est r", - "e str", - "▁p article", - "▁part icle", - "▁partic le", - "▁parti cle", - "▁lar avel", - "▁ laravel", - "pi c", + "ic ron", + "▁p oly", + "▁p oor", + "ing ▁placebo", + "ing ness▁to", + "▁b al", + "es ,▁and", + "es ▁to▁", + "▁s econd", + "▁d epend", + "▁m ethod▁", + "▁m echanism", + "om ach", + ".\n\n 16", + ".\n\n 0\n\n1\n\n2\n\n3\n\n4", + "al▁ D", + "el ay▁", + "▁in crease▁", + "es▁ must▁be▁", + "es▁ have▁been", + "▁P res", + "▁( 5-FU", + "▁( IVRS", + "▁2 1-day▁cycl", + "us ed▁on", + "▁re cord▁", + "ow ski", + "▁D uring▁the▁", + "▁E ND", + "▁or ▁l", + "▁or ally▁", + "▁or ▁his/her", + "\n\nP rior", + "qu artil", + "od a", + "\n\nA BX-EGF", + "▁and ▁any▁", + "▁O ver", + "▁pro duc", + "▁N am", + "▁R ES", + "ed▁in traven", + "▁treatment ▁in", + ".2 3", + "▁is▁ discontinu", + "▁al gorithm", + "▁al opecia", + "e▁s pecific", + "▁r un", + "▁0 90177e18", + "▁3 .2", + "▁con junction", + ".▁A ccess", + "▁the▁s urvival▁", + "ave▁ you", + "out patient", + "▁st eroid", + "ing▁the▁ study", + "▁6 2", + "▁6 .3", + "▁4 .0", + "▁the▁p anitumumab", + "dition al", + "s▁( CTCAE", + ".4 9", + "emother apeutic", + "ly ▁available▁", + "10 4", + "▁tim es", + "▁tim e▁for", + "ies ▁to", + "▁may▁ request", + "effect iv", + "so ▁that", + "s.\n\n 6", + "▁Date: ▁20th▁December▁2004", + "aborator ies▁", + "▁Number: ▁05", + "CR O", + "25 ▁Edition▁Number", + "first ▁met", + "\n\nN ▁A\n\nF▁O", + "he al", + "pre vent", + "every▁ 2", + "\n\n2 .1", + "\n\nR est", + "ass umption", + "\n\nF ACT-", + "\n\n3 .3", + "dur ation", + "respons ibility▁of", + "no ▁less▁than", + "▁dose▁ (", + "ed▁as ▁target▁lesion", + "\n\n4 .1", + "data ▁for", + "\n\nI ▁have▁", + "result ing▁in", + "▁min or", + "perform ed▁in", + "▁sit es", + "consider ed", + "consider ation", + "▁if ▁you", + "▁mod ifi", + "ed\n\n to", + "ed▁s ampl", + "val ence▁of", + "fficac y▁and▁", + "▁Cancer ▁Societ", + ",▁200 3", + "▁clinical ▁trial▁", + "▁must ▁not", + "review ▁of", + ".▁N ot", + "▁chemotherapy▁ is▁", + "▁12 .2", + "▁both ▁arm", + "▁K Ga", + "▁this▁study▁ is▁to", + "▁Edition ▁Number:▁05", + "\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct: ▁Denosumab▁Protocol▁Number:▁20050244▁Date:▁05▁May▁2008\n\nPage▁", + "▁St age▁III", + "▁by ▁an", + "▁every▁ 2▁week", + "Com plet", + "▁a▁m ulticenter", + "▁first -line▁", + "▁hy per", + "▁hy persensitivity▁reaction", + "Code▁ 7054Il/00", + "fic e▁", + "olic y▁", + ".▁O f", + "yn omol", + "stor ed▁for", + "most ▁frequ", + "median ▁PFS", + "Clinical▁Study▁Protocol▁Drug▁Subst ance:", + "); ▁•", + "▁medical▁ histor", + "SI DERA", + "▁Con comitant", + "▁patients▁who ▁are▁", + "hyd rogen", + "2- week", + "▁par affin-embedd", + "\n\nth e▁in", + "avail abl", + "▁further ▁detail", + "s▁in▁the▁ ITT", + "anu fact", + ".\n\nIn ▁addition", + "ee▁ Appendix", + "plann ed", + "whether ▁or▁not", + "one▁s cintigraph", + "▁Subject s▁with", + "▁2005 ;", + "▁vitamin▁D 3", + ".\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct: ▁Panitumumab▁Protocol▁Number:▁20050181▁Date:▁04▁April▁2008\n\nPage▁", + "▁fl uoropyrimidin", + "▁(m CRC", + "▁expos ure", + "exclud ed▁from", + "OT ENTIAL", + "alt z", + "▁adverse▁ drug", + "▁........................................................................................ ....", + "▁path ologic", + "Phase▁ III", + "randomized▁to ▁receive▁", + "och ran", + "-related▁to xicities▁", + "poss ibly▁", + "Not e:", + "az ol", + "y- stimulating▁factor", + "▁CON SIDERA", + "▁bon e\n\n", + "▁suppl ies", + "▁Randomiz ed▁", + "54I L/0024", + ".▁Res ult", + ".\n\nH ow", + "▁fatty ▁acid▁", + "▁analgesic ▁us", + "▁70 54IL/0024", + "▁adenocarcinoma ▁of▁the▁", + "(34)\n\nGEL▁Version▁ID:▁ONC.000−127− 200.3", + "(34)\n\nGEL▁Version▁ID:▁ONC.000−127− 199.3", + "▁Bicalutamide▁Study▁ Code:", + "▁Bicalutamide▁Study▁ Code▁7054Il/00", + "▁AND▁D EFINI", + "▁bronch ospasm", + "manufact urer", + "▁ED -SCLC", + "TISTICAL ▁METHO", + "▁Derivation▁or▁calculation▁of▁outcome▁variabl e", + "▁though t", + "▁Organ ization", + "▁repe at", + "▁occurs▁ first", + "RAN KL", + "▁reasonable▁possibility▁that▁the▁event ▁may▁have▁been▁caus", + "equiv oc", + "yelos uppression", + "utom atic", + "erck ▁KGa", + "inancial▁ Dis", + "▁or▁significant ▁dis", + "▁5▁20 ▁December▁2004", + "25▁Edition▁Number ▁5▁20▁December▁2004", + "▁Edition▁Number:▁05 ▁Date:▁20th▁December▁2004", + "ynomol g", + "Clinical▁Study▁Protocol▁Drug▁Substance: ▁Bicalutamide▁Study▁Code:", + "▁7054IL/0024 ▁Edition▁Number:▁05▁Date:▁20th▁December▁2004", + "▁Bicalutamide▁Study▁Code▁7054Il/00 25▁Edition▁Number▁5▁20▁December▁2004", + "TISTICAL▁METHO DS", + "erck▁KGa A", + "Clinical▁Study▁Protocol▁Drug▁Substance:▁Bicalutamide▁Study▁Code: ▁7054IL/0024▁Edition▁Number:▁05▁Date:▁20th▁December▁2004", + "( 10", + ") ▁was▁", + "2 ▁Feb", + "6 00", + "A ustralia", + "D 1", + "I mmun", + "O xaliplatin", + "P O", + "T reat", + "a ution", + "d imension", + "g astric▁cancer", + "i ▁M", + "i ous▁", + "k er", + "m arrow", "p ic", - "▁n au", - "▁na u", - "▁f ins", - "▁fin s", - "▁fi ns", - "▁V il", - "▁Vi l", - "▁f us", - "▁fu s", - "▁qu asi", - "oper ation", - "opera tion", - "▁al ler", - "▁all er", - "▁alle r", - "▁ aller", - "▁an aly", - "▁anal y", - "▁ analy", - "▁О н", - "▁M es", - "▁Me s", - "▁о пера", - "▁оп ера", - "▁hand led", - "▁handle d", - "▁de prec", - "▁dep rec", - "tt o", - "t to", - "▁E k", - "▁st ran", - "▁str an", - "▁stra n", - "▁ang lais", - "ju re", - "j ure", - "▁Sil ver", - "▁close ly", - "▁clos ely", - "en kins", - "enk ins", - "an os", - "ano s", - "a nos", - "st ed", - "ste d", - "s ted", - "▁сент ября", - "br and", - "bra nd", - "b rand", - "нь о", - "▁prés ent", - "▁pré sent", - "ro k", - "r ok", - "mo unt", - "m ount", - "▁Anth ony", - "▁Further more", - "in ha", - "▁ар хи", - "▁раз ли", - "▁окт ября", - "▁p int", - "▁pi nt", - "▁pin t", - "n ý", - "pt s", - "p ts", - "▁ital ien", - "▁ре ги", - "ле з", - "л ез", - "ди на", - "дин а", - "ather ine", - "In ternal", - "Int ernal", - "Inter nal", - "Intern al", - "Qu estion", - "▁sett lement", - "▁В се", - "▁fol ders", - "▁folder s", - "д ри", - "▁val or", - "▁va lor", - "▁M iller", - "▁Mil ler", - "▁Mill er", - "▁As sert", - "▁Ass ert", - "▁ Assert", - "▁pat ient", - "▁N ieder", - "▁Ni eder", - "▁Nie der", - "▁Nied er", - "▁E P", - "▁ EP", - "▁A gr", - "▁Ag r", - "▁o nde", - "▁on de", - "▁ onde", - "▁s cop", - "▁sc op", - "▁ scop", - "se quence", - "sequ ence", - "▁P L", - "▁ PL", - "▁se ek", - "▁see k", - "java se", - "jav ase", - "▁V ector", - "▁Ve ctor", - "▁Vec tor", - "▁ Vector", - "▁n á", - "▁ ná", - "▁categor ía", - "cl one", - "clo ne", - "N R", - "av ailable", - "▁B esch", - "▁Be sch", - "▁Bes ch", - "▁e clipse", - "▁ec lipse", - "▁ eclipse", - "wick lung", - "dep loy", - "en ie", - "eni e", - "e nie", - "▁\" )", - "▁ \")", - "äs t", - "ä st", - "▁s ync", - "▁syn c", - "▁sy nc", - "▁ sync", - "CO DE", - "▁Ч е", - "▁flo ating", - "▁float ing", - "/ `", - "▁ret ired", - "▁retir ed", - "de b", - "d eb", - "▁part icul", - "▁partic ul", - "▁parti cul", - "▁coll ected", - "▁collect ed", - "▁colle cted", - "▁down loaded", - "▁download ed", - "ni ce", - "nic e", - "n ice", - "▁B uffer", - "▁Buff er", - "▁ Buffer", - "▁Acc ount", - "▁Ac count", - "▁ Account", - "▁m aggio", - "▁mag gio", - "▁ре да", - "▁ред а", - "▁s ales", - "▁sa les", - "▁sal es", - "▁sale s", - "▁statunit ense", - "▁K i", - "▁F err", - "▁Fe rr", - "▁Fer r", - "Lo ck", - "Loc k", - "L ock", - "▁Is abel", - "▁Isa bel", - "cl ar", - "cla r", - "c lar", - "▁p ov", - "▁po v", - "at ra", - "atr a", - "a tra", - "▁Fr au", - "▁Fra u", - "▁sort ing", - "▁sor ting", - "▁sorti ng", - "▁phr ase", - "▁апре ля", - "▁дея тель", - "▁And ré", - "def inition", - "defin ition", - "writ ing", - "wr iting", - "ér é", - "é ré", - "щ у", - "▁O rd", - "▁Or d", - "▁ Ord", - "▁r um", - "▁ru m", - "▁ rum", - "▁T urk", - "▁Tur k", - "▁I van", - "th eless", - "the less", - "▁г и", - "▁ ги", - "▁s ake", - "▁sa ke", - "▁B ased", - "▁Bas ed", - "▁Ba sed", - "▁Base d", - "de ck", - "dec k", - "or us", - "oru s", - "o rus", - "▁tut ti", - "▁b lan", - "▁bl an", - "▁bla n", - "▁П у", - "De tail", - "Det ail", - "▁Н о", - "▁S ky", - "▁Sk y", - "▁p rès", - "▁pr ès", - "▁ près", - "мо й", - "col n", - "co ln", - "че ской", - "et i", - "e ti", - "▁ar row", - "▁arr ow", - "▁ arrow", - "▁C ha", - "▁Ch a", - "ch mark", - "œ ur", - "fa b", - "f ab", - "ку ль", - "Grid View", - "▁Back ground", - "▁ Background", - "s n", - "▁segu ito", - "▁n ic", - "▁ni c", - "▁ nic", - "co u", - "c ou", - "ті в", - "т ів", - "▁b zw", - "add EventListener", - "syn c", - "s ync", - "az zo", - "azz o", - "ab stract", - "as sets", - "ass ets", - "asse ts", - "asset s", - "▁D ru", - "▁Dr u", - "з д", - "ord net", - "▁b igger", - "▁big ger", - "▁initial ized", - "▁initialize d", - "ка з", - "og ene", - "ogen e", - "oge ne", - "vi ously", - "vious ly", - "v iously", - "▁g uid", - "▁gu id", - "scheid ung", - "▁Z ent", - "▁Ze nt", - "▁fr ames", - "▁frame s", - "▁fra mes", - "▁fram es", - "▁ frames", - "ri eben", - "rie ben", - "rieb en", - "r ieben", - "▁iss ued", - "▁issue d", - "▁issu ed", - "▁d ow", - "▁do w", - "▁descri bes", - "▁describe s", - "il st", - "ils t", - "i lst", - "▁c riteria", - "▁crit eria", - "▁criter ia", - "▁gentle man", - "Bas ic", - "ne z", - "n ez", - "De v", - "D ev", - "Mo ve", - "M ove", - "▁est aba", - "▁estab a", - "▁esta ba", - "▁set tembre", - "▁sett embre", - "circ le", - "cir cle", - "▁f ais", - "▁fa is", - "▁m yst", - "▁my st", - "▁arch iv", - "▁ archiv", - "d ynamic", - "j à", - "it as", - "ita s", - "▁я кий", - "▁d or", - "▁do r", - "▁ dor", - "▁Am azon", - "▁Ama zon", - "▁ne ces", - "▁Mar cel", - "▁Marc el", - "▁e lla", - "▁el la", - "▁ell a", - "▁ ella", - "ро к", - "р ок", - "▁Pennsylvan ia", - "cul ar", - "cu lar", - "c ular", - "Pa ck", - "P ack", - "it age", - "ita ge", - "▁B urn", - "▁Bu rn", - "▁Bur n", - "▁R O", - "▁ RO", - "▁о ни", - "▁он и", - "▁ они", - "~ $", - "Te X", - "as sign", - "ass ign", - "▁be at", - "id ense", - "iden se", - "ac ent", - "ace nt", - "a cent", - "Al ert", - "▁str ateg", - "▁strat eg", - "▁mån aden", - "LO C", - "L OC", - "▁c atalog", - "▁cat alog", - "▁catal og", - "▁ catalog", - "print StackTrace", - "() ).", - "()) .", - "( )).", - "us ted", - "ust ed", - "u sted", - "▁Frame work", - "▁ Framework", - "EC K", - "E CK", - "▁a té", - "▁at é", - "Frame work", - "▁att acks", - "▁attack s", - "▁B ert", - "▁Be rt", - "▁Ber t", - "▁т ран", - "▁тра н", - ": %", - "ar si", - "ars i", - "not ation", - "▁log ical", - "▁logic al", - "we et", - "▁vis ited", - "▁visit ed", - "br u", - "b ru", - "▁sur prise", - "▁surpr ise", - "^ ^", - "in ale", - "inal e", - "ina le", - "rem ote", - "'} ,", - "' },", - "Syn tax", - "S yntax", - "ia ne", - "ian e", - "i ane", - "on nen", - "onn en", - "onne n", - "▁bre aking", - "▁break ing", - "par ser", - "parse r", - "ap k", - "a pk", - "▁Mig uel", - "▁ §", - "▁act ing", - "▁ac ting", - "▁g ebru", - "▁ge bru", - "▁geb ru", - "At Index", - "ють ся", - "ю ться", - "▁of fers", - "▁off ers", - "▁offer s", - "▁p rac", - "▁pr ac", - "▁pra c", - "▁g rant", - "▁gr ant", - "▁gra nt", - "▁gran t", - "tern oon", - "▁ac quired", - "▁acqu ired", - "▁N y", - "▁com ma", - "▁comm a", - "ní k", - "n ík", - "▁St ep", - "▁Ste p", - "▁ Step", - "in ners", - "inn ers", - "inner s", - "▁S A", - "▁ SA", - "▁w at", - "▁wa t", - "da ys", - "day s", - "d ays", - "▁rect angle", - "da r", - "d ar", - "▁t rac", - "▁tr ac", - "▁tra c", - "▁Ind ones", - "▁feed back", - "▁bre aks", - "▁break s", - "part ition", - "ic ans", - "ica ns", - "ican s", - "▁Not ices", - "▁Notice s", - "▁impro ved", - "▁improve d", - "▁improv ed", - "▁impr oved", - "ph an", - "pha n", - "p han", - "▁differ ential", - "▁different ial", - "▁differenti al", - "script s", - "scri pts", - "▁X III", - "▁XII I", - "▁XI II", - "▁L abor", - "▁La bor", - "▁Lab or", - "▁prec ision", - "▁precis ion", - "▁s eed", - "▁se ed", - "▁see d", - "▁ seed", - "bund le", - "b undle", - "id ents", - "ident s", - "iden ts", - "hr e", - "h re", - "▁Doug las", - "ul d", - "u ld", - "▁second ary", - "▁seconda ry", - "▁b rig", - "▁br ig", - "▁confirm ed", - "▁confir med", - "▁cla ims", - "▁claim s", - "Ro le", - "R ole", - "▁Jew ish", - "▁p řed", - "▁př ed", - "▁ho tel", - "▁hot el", - "▁comp te", - "▁compt e", - "▁rec ursive", - "▁recurs ive", - "](# )", - "▁rot ate", - "▁ rotate", - "▁ch rome", - "▁chr ome", - "▁chrom e", - "▁ chrome", - "in ea", - "ine a", - "i nea", - "%; \r", - "% ;\r", - "▁En vironment", - "▁ Environment", - "pl atz", - "pla tz", - "▁Sing le", - "▁Sin gle", - "▁ Single", - "▁s event", - "▁se vent", - "▁seven t", - "▁pos ting", - "▁post ing", - "▁de aling", - "▁deal ing", - "param eters", - "parameter s", - "гра ф", - "Auth entication", - "to uch", - "t ouch", - "A z", - "▁g ray", - "▁gr ay", - "▁gra y", - "▁ gray", - "en cing", - "enc ing", - "enci ng", - "bold math", - "▁сай те", - "▁сайт е", - "▁Z a", - "an je", - "▁p olar", - "▁po lar", - "▁pol ar", - "▁у ли", - "ki l", - "k il", - "▁h over", - "▁ho ver", - "▁ hover", - "▁RE ST", - "▁C ome", - "▁Com e", - "▁Co me", - "▁ Come", - "j b", - "▁Georg ia", - "▁Est ado", - "▁Esta do", - "▁Estad o", - "Output Stream", - "ћ и", - "▁d ump", - "▁du mp", - "▁ dump", - "▁A ge", - "▁Ag e", - "▁ Age", - "▁s wo", - "▁sw o", - "m obile", - "oc cup", - "occ up", - "ше го", - "ш его", - "▁const itution", - "▁constitu tion", - "▁constit ution", - "go od", - "g ood", - "ak u", - "a ku", - "▁а нг", - "▁ан г", - "▁ анг", - "ie ck", - "iec k", - "▁Ps ych", - "▁ro ots", - "▁root s", - "▁v est", - "▁ve st", - "▁ves t", - "▁ vest", - "▁го дах", - "▁года х", - "▁Rep ública", - "▁p ian", - "▁pi an", - "▁pia n", - "igr ation", - "▁pr éc", - "▁pré c", - "▁gener ates", - "▁generate s", - "L Y", - "( `", - "▁= ~", - "ше ния", - "▁R ah", - "▁Ra h", - "▁connect ing", - "ž í", - "▁f ő", - "▁a ppel", - "▁app el", - "▁ap pel", - "▁appe l", - "▁Rail way", - "г ли", - "▁dével opp", - "▁a po", - "▁ap o", - "fr an", - "fra n", - "f ran", - "▁im mediate", - "▁immedi ate", - "во го", - "в ого", - "Run ner", - "ä g", - "Some thing", - "S omething", - "▁gén éra", - "Event Args", - "in ction", - "inc tion", - "inct ion", - "gl y", - "g ly", - "▁D ue", - "▁Du e", - "▁p rost", - "▁pro st", - "▁pr ost", - "▁pros t", - "▁refer ring", - "▁j og", - "▁jo g", - "▁exec utable", - "▁execut able", - "▁D ream", - "▁Dre am", - "ac s", - "a cs", - "▁C ole", - "▁Col e", - "▁Co le", - "am pf", - "amp f", - "▁B is", - "▁Bi s", - "▁ию ня", - "li eder", - "lied er", - "lie der", - "l ieder", - "те к", - "т ек", - "▁v b", - "▁ vb", - "▁m om", - "▁mo m", - "▁: (", - "▁ :(", - "▁der nier", - "▁derni er", - "' =>", - "▁э того", - "▁это го", - "▁ne ue", - "▁neu e", - "▁Ч а", - "▁weiter e", - "▁weit ere", - "▁al leg", - "▁all eg", - "▁alle g", - "▁re ality", - "▁real ity", - "▁jud ge", - "▁B alt", - "▁Ba lt", - "▁Bal t", - "▁t hin", - "▁th in", - "▁G ed", - "▁Ge d", - "ie val", - "iev al", - "i eval", - "m x", - "ці ональ", - "▁вы пу", - "▁I X", - "▁ IX", - "▁bl ind", - "▁Mo tor", - "▁Mot or", - "▁ш а", - "▁ ша", - "▁approxim ation", - "da m", - "d am", - "▁f og", - "▁fo g", - "▁ fog", - "ко р", - "к ор", - "▁W rit", - "▁l ing", - "▁li ng", - "▁lin g", - "▁ ling", - "▁пи са", - "▁ писа", - "▁M ars", - "▁Mar s", - "▁Ma rs", - "ot ti", - "ott i", - "En um", - "E num", - "▁T rib", - "▁Tr ib", - "▁Tri b", - "▁m erc", - "▁me rc", - "▁mer c", - "zu ng", - "z ung", - "van ced", - "v anced", - "cf g", - "c fg", - "на х", - "sch en", - "sc hen", - "sche n", - "s chen", - "\"] .", - "\" ].", - "be k", - "b ek", - "▁s ter", - "▁st er", - "▁ste r", - "▁ ster", - "j p", - "▁R ap", - "▁Ra p", - "▁rec ording", - "▁record ing", - "▁pe int", - "▁l ets", - "▁le ts", - "▁let s", - "▁ lets", - "än ge", - "äng e", - ">\" ;", - "> \";", - "▁міс це", - "▁c aval", - "▁ca val", - "▁cav al", - "▁C SV", - "▁CS V", - "▁ent stand", - "▁hel per", - "▁help er", - "▁ helper", - "en det", - "end et", - "ende t", - "▁G ram", - "▁Gr am", - "▁Gra m", - "▁D iego", - "▁Die go", - "▁Di ego", - "▁B ishop", - "▁Bi shop", - "TA G", - "T AG", - "▁e cc", - "▁ec c", - "▁E en", - "▁A V", - "▁ AV", - "C ity", - "▁Gu ide", - "hi nd", - "hin d", - "h ind", - "ri cal", - "ric al", - "rica l", - "r ical", - "▁Ос нов", - "Bu s", - "B us", - "▁z unächst", - "▁t ick", - "▁ti ck", - "▁ tick", - "▁Col onel", - "Th anks", - "Thank s", - "▁f erm", - "▁fe rm", - "▁fer m", - "▁gr anted", - "▁gran ted", - "▁grant ed", - "▁th reshold", - "omorph ic", - "▁H un", - "▁Hu n", - "en is", - "eni s", - "e nis", - "▁п рав", - "▁пра в", - "▁ прав", - "▁я кі", - "▁як і", + "p rim", + "p oly", + "u per", + "▁ y▁", + "▁ ....................................................................................................", + "\n\n from", + "\n\n record", + "\n\n 20", + "\n\n 25", + "\n\n information", + "▁a mend", + "er o", + "s▁ until", + "re et", + "re start", + "▁th oracic", + "it ch", + "▁the▁ appropriate▁", + ",▁ di", + ",▁ phosphor", + "ed▁ during▁the▁", + "▁an imal", + ".▁ 3", + "ing ,▁and▁", + "ation ▁with▁the▁", + "▁to ▁continu", + "▁to ▁participate▁in", + "is ▁and▁", + "is ▁an▁", + "um er", + "▁d evic", + "▁and▁ 7", + "▁in ▁the▁s", + "▁in hibit", + "ur it", + "▁1 :", + "▁1 ▁(", + "pro per", + "▁( SAE", + "us ed▁at", + "ub mitt", + "am ide▁", + "form ing", + "ther apeutic", + "ter o", + "\n\nP RI", + "▁n g/mL", + "\n\nA l", + "▁T O", + "▁T HE", + "▁ad vis", + "▁ad mission", + "▁R S", + "▁R AN", + "▁treatment .", + ".1 3", + "min or", + "▁200 401", + "▁will▁be▁ ask", + "▁will▁be▁ assign", + "e▁s ymptom", + "e▁s ide▁effect", + "▁3 9", + "▁com pan", + ".▁A ▁copy▁of", + "ity▁ for", + "▁as▁ need", + "as▁ follows:", + "▁the▁s ubsequent", + "ly▁ s", + "s,▁ with", + "▁st ain", + "will ▁have▁", + "▁4 9", + "▁the▁p urpos", + "▁ac ne", + "\n\n1 7", + ".5 .3", + "med ic", + "s▁and▁ SAE", + "▁patient s▁and▁", + "10 9", + "▁the▁d ay▁", + "▁G I", + "▁U s", + "\n\nE GF", + "requ ire▁", + "s\n\n 7", + "roduct ion", + "CT SU", + "▁10 ▁mg", + ".▁In ▁the▁", + "s.\n\n 8", + "par affin-embedd", + "progression ▁of", + "▁in▁the▁ absence▁of", + "s▁s uggest", + "he um", + ").\n\n A", + ".▁If ▁a", + "▁Ad minister", + "▁pre -specifi", + "▁Study▁ Treatment", + "▁a▁s econd▁", + "▁the▁l ung", + "▁dose▁ escal", + "▁reg imens", + "e▁b evacizumab", + "▁Clinical▁ Oncology▁", + ".\n\nS ▁I\n\nS▁I▁H▁T", + "ox id", + "consider ed▁as▁", + "discontinu e▁", + "St imulating", + "▁do ▁so", + "▁occur s,▁", + "dis comfort", + "yt ic", + ".▁N on-", + "ext ract", + "▁receiv ed▁at▁least", + "clinical ▁trial▁", + "▁the▁treatment ▁group", + "rat e,▁", + "under going", + ".▁For ▁exampl", + "▁dec ide▁", + "▁2008 ;", + "▁a▁c linical▁", + ",▁et▁al .▁A", + "identifi er", + "▁compar e▁treatment", + "▁Appendix ▁Edition▁Number", + "▁hy d", + "21 ▁days", + "▁Ch aracter", + "\n\n9 .1", + "▁Drug▁Subst ance▁", + "at▁least ▁1", + "........................................................ .....▁", + ":\n\n (cid:120)", + "\n\nth e▁s", + "echn ical▁", + "fficacy▁An alysis▁Set", + ".\n\nD ▁E▁T▁N▁I▁R▁P", + "▁during▁the▁ study", + "pan el", + "\n\nV isit", + "▁skin ▁cancer", + ",▁N o", + "ecom mend", + "ITT ▁population", + "▁such ▁as▁", + "FOLFOX 6", + "censor ed▁on", + "Grade▁ 2", + ".▁W e▁", + "lig ibility▁", + ".▁Wh at", + "(cid:13 1)▁", + "measured▁ by▁", + "Schedul e▁of", + "▁Panitumumab▁Protocol▁Number:▁20050181 ▁Amendment▁2", + "frequ ency▁", + "\n\nC▁I▁N▁O▁R▁T▁C▁E▁L▁E\n\nN ▁A\n\nF▁O", + "\n\nPh armacokinetic", + "▁........................................................................................ ......", + "ed▁in▁a ▁1:1▁ratio", + "▁telephone▁ number", + "Phase▁ 2", + "leas on", + "available▁ for", + "plain t", + "active▁ v", + "measurement s▁and▁", + "Consider ations", + "▁With draw", + "▁intraven ous", + "\n\nx▁x▁x ▁x", + "IRB/ aEC", + "▁cent re", + "▁to▁ens ure▁", + "erm at", + "▁prot ection", + "▁should▁not ify▁the▁", + "▁Radi ation", + "phyl actic", + "▁advanced▁non- small▁cell▁lung▁cancer", + "red▁to ▁as▁", + "withhel d▁", + "seen ▁in", + "▁Europ e,▁", + "\n\nMed ical▁", + "NCI- CTCAE", + "▁predn isone▁", + "s▁involv ed▁in", + "▁Cont act", + "▁Appendix▁D ate▁", + "▁under▁the▁ curv", + "one▁or ▁mor", + "encourag ed▁to", + "▁anthracycl in", + "▁Lilly▁or▁its▁design ee▁", + "▁ret rospective▁", + "ordinating ▁investigator", + "▁Antibod ies", + ".▁Available▁at :▁http://www.", + "Fl uorouracil", + "itoxant rone▁", + "▁lumbar▁spine▁ BMD", + "rare ly▁", + "osin ophil", + "▁CONT ENTS", + "▁Day▁1▁of ▁Cycle▁1", + "irrespectiv e▁of", + "▁is▁responsible▁for▁ensuring ▁that", + ".\n\nAppendix ▁XIV▁Page▁", + "▁CONSIDERA TIONS", + "▁Panitumumab▁Protocol▁Number:▁20050181▁Amendment▁2 ▁Date:▁04▁April▁2008\n\nPage▁", + ", ▁there▁", + "- 15", + "- derived▁", + ". org", + "/ S", + "1 ),▁", + "2 )▁and▁", + ": ▁In", + "; ▁p", + "B i", + "B est", + "C ell", + "D UC", + "E MENT", + "F )", + "N ▁A\n\nF▁O\n\nY▁P▁O▁C", + "S ubject", + "T im", + "b lock", + "e k", + "f ashion", + "m ak", + "m ethod▁", + "m ega", + "n ess▁or", + "u ish", + "v it", + "w ild-type▁KRAS", + "w ild-typ", + "y )", + "y ,▁or", + "− 77", + "▁ ................................", + " ▁", + "\n\n h", + "\n\n Un", + "▁a ▁re", + "en sion", + "s▁ was▁", + "re cogn", + "st ep", + "st ea", + "y▁ S", + "y▁ for", + ",▁ on", + ",▁ who", + ",▁ until", + ",▁ weight", + ",▁ oxaliplatin", + ",▁ where▁", + ",▁ nausea", + "ro zen", + "▁an ▁increase▁in", + ".▁ 16", + ".▁ Up", + "ar cin", + "ed ▁therapy", + "es ,▁or", + "es ,\n\n", + "es s▁of▁the▁", + "et y▁of", + "▁s erious", + "▁s uspect", + "as e▁inhibitor", + "▁w id", + "▁and▁ if", + "om ening", + "al▁ in", + "el ▁J", + "▁in itial▁", + "▁1 %", + "▁C EA", + "▁C YP3A4", + "▁P T", + "▁P art", + "pro portion▁of", + "▁( K", + "▁( 2)", + "▁( 32", + "con f", + "if e▁", + "▁S kin", + "▁S CCHN", + "▁re d▁", + "ot ype▁", + "ot ension", + "un expect", + "▁D r", + "cl -2", + "▁or ▁SAE", + "\n\nP emetrexed▁H3E-MC-JMHO(b)▁Confidential\n\nProtocol▁Amendment\n\nPage▁", + "per ▁local", + "ate▁ or", + "▁and ▁about", + "▁as ▁to", + "ep .", + "ef ul", + "▁for th", + "▁treatment ▁failure▁", + "s▁of ▁your", + "\n\nS TUDY", + "▁of▁ 5%", + "e▁s etting", + "cor relation", + "▁as▁ follows:", + "▁this▁ h", + "clud e▁", + "▁will ▁occur", + "▁5 ▁x▁ULN", + "▁6 5", + "from ▁the▁date▁of▁randomization", + "▁subject s▁to", + "▁patients▁ have▁", + ")\n\n If", + "eg er", + "continu ed)\n\n", + "\n\n1 8", + "ept omening", + "fer ▁MJ", + "ation▁of ▁Addendum", + "e▁d aily", + "ath eter", + "ob il", + "▁patient s\n\n", + "▁patient s)", + "10 2", + "▁tim e\n\n", + "▁tim epoint", + "▁In ▁addition", + "▁from ▁all", + "vent ory▁", + "▁is ▁any▁", + "(cid: 14", + "▁10 .1", + "▁10 ▁minutes", + "te bra", + "▁x ▁109", + "CR PC", + "▁us ed▁in", + "▁us ed▁for", + "▁us ually▁", + "\n\nProduct: ▁Denosumab▁Protocol▁Number:▁20050136▁Date:▁30▁April▁2008\n\nPage▁", + "al▁pro gression", + "every▁ 4▁week", + "▁trial s▁", + "e, ▁the▁investigator", + "sh ortness▁of▁breath", + "▁day s▁(", + "ically▁ documented▁", + "e▁b efore▁", + "fl uor", + "▁act ual▁", + "in▁the▁ absence▁of", + "sign ificance▁level", + "▁sampl e▁siz", + ".▁R e", + "ann a", + "ann ed▁M", + ".▁200 6", + "\n\nH a", + "St age▁III", + "St opping", + "▁sub -", + "▁ind ividual▁", + "\n\n6 .3", + "▁provid es", + "▁response▁ assessment", + "RO DUC", + "efit inib", + "urg ical", + "ext end", + "\n\nB evacizumab", + "▁follow-up ▁visit", + "▁to▁ estim", + "ry▁ skin", + "▁document ation▁of▁", + ".▁E▁S▁U \n\nE▁R▁O▁F▁E▁B", + "▁Clin ical", + "▁chang es", + "▁2006 ▁15", + "▁su it", + "FA CT", + "▁increas ing", + "design e", + "▁minut es,▁", + ",▁p elvis", + "▁sever al", + ".▁O verall", + "▁require s▁", + "\n\n9 .2", + "▁agre es▁to", + "▁bas ed▁on▁the▁", + "▁the▁c ourse▁of", + "\n\nAdd▁ 9", + "▁cor rect", + "▁symptom s▁of", + "100 )", + "isting uish", + "used▁for ▁the▁", + ".\n\nD ▁E▁T▁N▁I▁R▁P\n\nA", + "▁(se e▁section", + "collection ▁of", + "▁are :", + "\n\nPro cedures▁in▁case▁of", + "8480 C0000", + "-line▁treatment ▁of", + "cas e▁of", + "other▁than ▁the▁", + ",▁with ▁the▁", + ".0\n\nApproved\n\nDate▁Printed: ▁31−Jul−2014", + "compar ator", + ".▁W e▁will", + "ermin ation", + "es▁from ▁the▁", + "control ▁arm", + "▁procedures ▁are▁", + "▁questionna ire▁", + "▁questionna ires", + "▁leg al▁", + ",▁patients▁ will▁be▁", + "▁Lill y▁and▁Com", + "ovari ates▁", + "gener ic", + "expos ed▁to", + "▁compared▁with ▁placebo", + "▁Study▁Code▁D8480C00013 ▁Appendix▁Edition▁Number", + "period▁ of", + ":38 :50", + "dat abas", + "kelet al", + "▁of▁128 \n\n", + "▁be half", + "▁Sampl e▁Size▁", + "wher e▁the▁", + "participating ▁in▁the▁", + "pharmacokinetic s▁of", + "SS ESS", + "▁supportive▁ care▁", + "osis▁ in", + "kaline▁phosph at", + "flu enc", + "▁q 21", + "ella ▁D", + "outsid e▁the▁", + "▁initi ation▁of", + "icro RNA", + "▁sponsor -", + "amp fer▁MJ", + "▁ref riger", + "ensiv e-", + ".0▁Approved▁by\n\nApproved\n\nDate▁Printed:▁31−Jul−2014 \n\n21▁Dec▁2004▁10:36:54", + "▁Cons ent", + "dependent▁E thics▁Committe", + "bumin- adjusted▁", + "▁albumin ,", + "(4 ):▁p.▁", + "contracept ion", + "egre e▁of", + "▁this▁research▁study ?", + "▁AN ALY", + "ef▁Pain▁In ventor", + "▁become▁ pregnant", + "MINISTRA TIVE", + "▁congenital ▁anom", + "\n\nApproved▁by \n\n21▁Dec▁2004▁10:21:22", + "permanently▁ discontinu", + "hyth m", + "▁who▁conducted ▁the▁informed▁consent▁discussion", + "▁comes▁ first", + ",▁potassium,▁chloride,▁ bicarbon", + "AZD2171 ▁Study▁Code▁D8480C00013▁Appendix▁Edition▁Number", + "inal▁cord▁ compression", + "214 −77", + "2▁Feb ▁2006▁15", + "▁Drug▁Substance▁ AZD2171▁Study▁Code▁D8480C00013▁Appendix▁Edition▁Number", + "anned▁M ethods▁of", + "214−77 1.5", + "2▁Feb▁2006▁15 :38:50", + "% ▁in", + "% ▁in▁the▁", + "( s)\n\n", + ") ,▁and", + ", ▁are▁", + ", 13", + ", ▁these▁", + ". L", + "0 .0", + "1 ▁(", + ": 3", + "C alvert", + "F ▁O\n\nY▁P▁O▁C", + "H ugh", + "J ,▁B", + "O ffic", + "T O", + "V itamin▁D", + "W ild-typ", + "] ,[", + "c reatinine▁", + "f ew", + "g reg", + "i ▁C", + "r lotinib", + "s ▁treat", + "t ane", + "u clear", + "v olunt", + "y ,▁and▁", + "▁ ", + "▁ ........................", + "▁ versus", + "in e,▁", + "in ▁which", + "at es▁and▁", + "on e▁of", + "\n\n GE", + "re f", + "al ▁power", + "st er", + ",▁ 6", + ",▁ 9", + ",▁ 15", + ",▁ 5-FU", + ",▁ USP", + "ed▁ graph", + ".▁ b", + "ct ep.", + "ar agraph", + "▁p attern", + "ing ,▁s", + "▁b ag", + "is ▁also", + "▁s imilar", + "▁s ingle-agent", + "▁s alin", + "▁s lice▁thickn", + "▁of ▁A", + "▁d ail", + "▁d ilution", + "▁and▁ vomiting", + "om e-", + "iv ely▁", + "▁in ▁subjects▁with", + "▁P S", + "▁P articipant", + "▁P reviously▁", + "pro gressive▁diseas", + "Th ere▁", + "us ed▁and▁", + "if t", + "▁S ponsor", + "▁I rinotecan", + "un used▁", + "▁D i", + "▁l ittl", + "▁E ndpoint", + "am e▁", + "ver tebral", + "▁or ▁p", + "▁or ▁at", + "qu arter", + "▁pro lifer", + "all eng", + "▁T RIO", + "op ard", + "will▁be▁ collect", + "will▁be▁ used▁to", + "and ler", + "▁R ev", + "▁R ational", + "▁treatment ▁(", + "▁treatment ▁period", + "ed▁to ▁have▁", + "ed▁to ▁receive▁", + ".2 9", + "s▁of ▁all", + "▁that ▁occur", + "e▁th e▁infusion", + "▁M F", + "▁0 .05", + "▁com prehensive▁", + "▁F irst", + ".▁The▁ sponsor", + "not ▁to", + "int il", + "ing▁the▁ study▁", + "▁5 .1", + "bo ok", + "ity ▁and▁", + "▁6 .5", + ")\n\n R", + "ampl es▁of", + "s▁( SAE", + "▁study▁ doctor", + "▁cancer ▁treatment", + "ire d", + "▁the▁t oxicity▁", + "ell ect", + "ept ic", + "▁after ▁failure▁of", + "cre panc", + "ly \n\n", + ".▁P rior", + "\n\nE Q-5D", + "▁In t", + ".▁Th ey▁", + "et▁al .▁200", + "▁tumor ▁typ", + "ced ur", + "▁may▁ have▁", + "bin d", + "e- fre", + "▁analysis▁ (", + ".▁In ▁this▁", + "18 0", + "▁ph ysical", + "record s▁", + "▁cont iguous▁", + "▁med i", + "radi ologist", + "▁le uk", + "▁9 .2", + "▁8 .2.1", + "al▁pro tocol", + "30 ▁days▁", + "\n\nR andomization", + "Study▁ D", + "▁Ad d:", + "ass ociation", + "▁the▁study ▁treatment", + "serv ation", + "respons e\n\n", + ".▁D es", + "no ▁more▁than", + "▁dose▁ is▁", + "▁inter stit", + ".\n\nA \n\nS▁I", + ".\n\nP roduct:▁Denosumab▁Protocol▁Number:▁20050136▁Date:▁30▁April▁2008\n\nPage▁", + "23 ▁Edition▁Number", + "hy pertensive▁", + "in▁the▁ event", + ")▁ versus▁", + "creas ed▁", + "main ▁study", + "▁Th ese▁", + "dos e-", + "e▁and▁ other", + "▁di phenhydramin", + "▁peri pheral▁neuropath", + "consider ed▁s", + "question s▁about", + "pon tane", + "▁complet ing", + "▁discontinu e▁from", + "document ed▁in", + "iom etric", + "dis abl", + "loc ally", + "▁dis position", + "▁mor e▁detail", + "▁rel i", + "urg ent", + "\n\nIn vestigational▁Product", + ".▁N either", + "........................................................................................ .▁", + "\n\nB lood▁", + "clinical▁ research", + "your ▁last", + "osp ital▁", + "\n\n8 .3", + "▁CR ▁or▁PR", + "li ▁Lilly▁and▁Com", + "▁within ▁24▁hour", + "▁Pro c", + "▁count ,▁", + "▁chemotherapy ▁alon", + "oph ag", + "▁St reet", + "determin ed▁by▁", + "▁review ▁of", + "▁every▁ 6▁month", + "\n\nG S", + "▁ver y▁", + "cer t", + ".▁O b", + "att ribut", + "▁were▁ not", + "99 .9", + "▁thes e▁data", + "Ex tension", + "\n\nSection: ▁Appendix", + "contain er", + "ed▁treatment ▁with", + "ED TA", + "possibl e▁that", + "FACT- L/N", + "s▁must▁be▁ complet", + "▁e▁ r", + "▁design ee▁", + "\n\nV ery▁", + "▁schedul ed▁", + "▁randomized▁ subject", + "open-label ▁treatment▁phas", + "▁ident ification", + "eut rophil", + "▁> 99.9", + "▁applicabl e)", + "eligibl e▁", + "itis /", + "medical ▁condition", + "▁median ▁PFS", + "frequ ently▁", + "▁efficacy▁ endpoint", + "▁Follow -Up", + "▁of▁133 \n\n", + ",▁un less", + "expression ▁of", + "know ledg", + "▁................................................................................ ......", + "▁fre e▁survival", + "▁appl y", + "IRB/ EC", + "Arm ▁A", + "WB DC", + "be▁t reat", + "men d▁", + "stitutional▁Review▁Bo ard▁(", + "ince▁ your▁last", + "▁tw ice▁", + "▁authorized▁ representativ", + "▁the▁inter pret", + "▁while▁ on", + "TE RI", + "eriou s▁and▁", + "e▁G uidelin", + "compan y", + "unable▁to ▁toler", + "returned▁to ▁baselin", + "clinical▁study▁ report", + "▁(see▁ Appendix", + "stip ation", + "amid ron", + "chemist ry▁", + "\n\nA▁ ®", + ".▁Al though", + "▁Requirement s", + "▁urine▁ collection", + "efici ency▁", + "epat itis▁", + "ATIONAL E", + "pur pose▁", + "prevention ▁of", + "▁and▁toler ability▁of", + "adverse▁ effect", + "alp able▁", + "\n\nAmended▁Clinical▁Study▁Protocol ▁Bicalutamide▁Study▁Code▁7054Il/0025▁Edition▁Number▁5▁20▁December▁2004", + "birth ▁defect", + "ART ▁B:", + "FOR M", + "mok ing", + "▁prefer red", + "mallest ▁s", + "\n\nClinical▁Study▁ Protocol:", + "omere▁ length", + ".▁Schedule▁of ▁Assessment", + "je opard", + "(34)\n\nGEL▁Version▁ID:▁ONC.000−127−200.3 .0\n\nApproved\n\nDate▁Printed:▁31−Jul−2014", + "(34)\n\nGEL▁Version▁ID:▁ONC.000−127−199.3 .0▁Approved▁by\n\nApproved\n\nDate▁Printed:▁31−Jul−2014\n\n21▁Dec▁2004▁10:36:54", + "heum at", + "214−771.5 .0▁Approved▁by\n\nApproved\n\nDate▁Printed:▁31−Jul−2014", + "23▁Edition▁Number ▁7", + "( M", + "( 11", + ") ▁scan", + ", ▁the\n\n", + ", ▁total▁bilirubin", + "- Report", + ". J", + "/ birth▁defect", + "3 .", + "4 )(cid:", + "6 :", + ": ▁W", + "; ▁and", + "A X", + "A ppro", + "D I", + "E U", + "M L", "P G", - "▁w s", - "▁ ws", - "▁techn ical", - "▁techni cal", - "est ro", - "estr o", - "kl är", - "k lär", - "va rs", - "var s", - "v ars", - "oc rat", - "ocr at", - "▁оп шти", - "on so", - "ons o", - "ib a", - "i ba", - "▁S ave", - "▁Sa ve", - "▁Sav e", - "▁ Save", - "▁program a", - "▁в ъ", - "▁inv ån", - ">( )", - "> ()", - "▁me jor", - "▁с лова", - "▁сло ва", - "▁rep lacement", - "▁replace ment", - "▁repla cement", - "▁im pr", - "▁imp r", - "▁Frances co", - "▁Ho tel", - "▁Hot el", - "▁UP DATE", - "▁ UPDATE", - "▁му зы", - "ug s", - "u gs", - "va rd", - "var d", - "v ard", - "▁f az", - "▁fa z", - "in ton", - "int on", - "into n", - "▁ar ts", - "▁art s", - "▁ arts", - "▁K y", - "▁I ls", - "▁Il s", - "▁s era", - "▁se ra", - "▁ser a", - "▁Vol ume", - "▁ Volume", - "▁gi ugno", - "▁a sym", - "▁as ym", - "▁P ir", - "▁Pi r", - "▁N AS", - "▁NA S", - "▁T am", - "▁Ta m", - "ě l", - "Se qu", - "Seq u", - "S equ", - "km al", - "k mal", - "▁E ins", - "▁Ein s", - "▁ком па", - "▁комп а", - "ob e", - "o be", - "oo r", - "o or", - "▁he ap", - "ct l", - "c tl", - "▁separ ately", - "▁separate ly", - "re ader", - "read er", - "rea der", - "▁signific antly", - "▁significant ly", - "▁L ag", - "▁La g", - "no tes", - "not es", - "note s", - "n otes", - "▁s ele", - "▁se le", - "▁sel e", - "▁dedic ated", - "▁H ost", - "▁Ho st", - "▁ Host", - "cho ice", - "wi ng", - "win g", - "w ing", - "▁T itel", - "▁Tit el", - "▁Ti tel", - "▁befind et", - "lar ge", - "larg e", - "▁con ten", - "▁cont en", - "▁co nten", - "▁conte n", - "Java Script", - "▁de ser", - "▁des er", - "▁G ordon", - "▁Gor don", - "с пе", - "▁p atri", - "▁pat ri", - "▁pa tri", - "▁patr i", - "▁R andom", - "▁Rand om", - "▁Ran dom", - "▁ Random", - "▁Return s", - "ы м", - "ро ма", - "ром а", - "▁Stud ies", - "S l", - "▁fr ü", - "TE XT", - "T EXT", - "in ate", - "ina te", - "▁T ol", - "▁To l", - "▁every where", - "ar ta", - "art a", - "▁or bit", - "▁orb it", - "▁A ires", - "▁Air es", - "▁I ss", - "▁Is s", - "▁te ż", - "▁d iverse", - "▁di verse", - "▁divers e", - "▁diver se", - "▁n umeric", - "▁numer ic", - "▁ numeric", - "ma z", - "m az", - "▁m ise", - "▁mi se", - "▁mis e", - "▁batt ery", - "▁batter y", - "▁bat tery", - "▁A kadem", - "▁Ak adem", - "не ние", - "▁simult ane", - "▁D ead", - "▁De ad", - "▁cl ust", - "▁ot ro", - "▁c erca", - "▁cer ca", - "() `,", - "()` ,", - "( )`,", - "ro z", - "r oz", - "ă t", - "▁M O", - "▁ MO", - "ri ften", - "rift en", - "rif ten", - "import ant", - "▁je ho", - "▁find ViewById", - "▁ findViewById", - "▁con sequence", - "▁conse quence", - "▁consequ ence", - "▁measure d", - "▁meas ured", - "is hes", - "ish es", - "▁s ze", - "▁sz e", - "ien do", - "i endo", - "▁W ahl", - "▁Wa hl", - "st rip", - "str ip", - "AR D", - "▁op acity", - "▁ opacity", - "WOR D", - "W ORD", - "▁В і", - "▁L ocation", - "▁Lo cation", - "▁Loc ation", - "▁ Location", - "ra i", - "r ai", - "пе н", - "п ен", - "▁r if", - "▁ri f", - "▁ rif", - "auss ian", - "File Name", - "▁dis co", - "▁disc o", - "il en", - "ile n", - "i len", - "▁v agy", - "▁va gy", - "li city", - "lic ity", - "licit y", - "l icity", - "B order", - "▁T rack", - "▁Tr ack", - "▁Tra ck", - "▁ Track", - "бо м", - "б ом", - "fa ct", - "fac t", - "f act", - "ok a", - "o ka", - "▁g ior", - "▁gi or", - "▁ gior", - "▁XV II", - "▁XVI I", - "▁d är", - "Si te", - "S ite", - "ał o", - "a ło", - "sk á", - "s ká", - "▁pix els", - "▁pixel s", - "vi ty", - "v ity", - "j Query", - "▁sc ulpt", - "▁c argo", - "▁car go", - "▁direct ive", - "▁w al", - "▁wa l", - "▁ wal", - "▁c onna", - "▁con na", - "▁conn a", - "▁Th rough", - "▁э том", - "▁это м", - "St atic", - "Stat ic", - "oms nitt", - "▁r und", - "▁run d", - "▁ru nd", - "▁ rund", - "▁c laimed", - "▁claim ed", - "з ня", - "sh a", - "s ha", - "▁r ag", - "▁ra g", - "▁ rag", - "cre ment", - "cr ement", - "▁fün f", - "▁r ival", - "▁riv al", - "▁ri val", - "▁ rival", - "ri n", - "r in", - "sl ash", - "▁th irty", - "s leep", - "оло ги", - "о логи", - "S M", - "ga te", - "gat e", - "g ate", - "iz ations", - "ization s", - "vi k", - "v ik", - "▁b less", - "▁bl ess", - "▁ble ss", - "▁Ill inois", - "▁T E", - "▁ TE", - "ut ing", - "uti ng", - "u ting", - "▁sol ving", - "GE R", - "G ER", - "▁X IV", - "▁XI V", - "▁Ind ians", - "▁India ns", - "▁Indian s", - "ex press", - "exp ress", - "expr ess", - "▁H eil", - "▁He il", - "▁mu jer", - "▁invån are", - "'] );", - "']) ;", - "' ]);", - "▁a ur", - "▁au r", - "▁ aur", - "bo ost", - "G O", - "▁n in", - "▁ni n", - "to k", - "t ok", - "go d", - "g od", - "ot er", - "ote r", - "o ter", - ")$ $", - ") $$", - "▁desc end", - "р ю", - "▁L anguage", - "▁ Language", - "▁d iver", - "▁di ver", - "▁div er", - "▁Ass uming", - "▁fre quent", - "▁frequ ent", - "ч ні", - "▁Bi ography", - ", [", - "ur m", - "u rm", - "▁walk ed", - "▁wal ked", - "▁feder al", - "▁fed eral", - "▁Mich igan", - "▁fact s", - "▁fac ts", - "▁In tegr", - "▁Int egr", - "▁ Integr", - "LE S", - "L ES", - "▁A lan", - "▁Al an", - "▁c oup", - "▁co up", - "▁cou p", - "Be r", - "B er", - "▁p articles", - "▁part icles", - "▁partic les", - "▁particle s", - "▁parti cles", - "ћ е", - "Infl ater", - "+ (", - "Bo und", - "B ound", - "▁S ü", - "A udio", - "cite t", - "cit et", - "c itet", - "ye ct", - "y ect", - "▁n r", - "▁ nr", - "x e", - "▁B run", - "▁Br un", - "▁Bru n", - "▁_ ,", - "▁ _,", - "av or", - "avo r", - "a vor", - "▁dis cipl", - "al m", - "a lm", - "▁но ября", - "▁S SL", - "▁SS L", - "▁ SSL", - "▁Ka iser", - "▁Kais er", - "▁re cher", - "▁rec her", - "yg on", - "y gon", - "▁regard less", - "▁config ur", - "▁un necess", - "▁Cl ark", - "▁Clar k", - "PH P", - "P HP", - "▁F ALSE", - "▁ FALSE", - "▁p ad", - "▁pa d", - "▁ pad", - "$ }", - "▁v alu", - "▁val u", - "▁va lu", - "▁ valu", - "▁dise ase", - "▁ma ior", - "▁mai or", - "▁h ommes", - "▁hom mes", - "▁homme s", - "▁Ed ition", - "▁Edit ion", - "sl ant", - "s lant", - "▁en ding", - "▁end ing", - "▁ ending", - "▁sett led", - "ur us", - "uru s", - "u rus", - "he d", - "h ed", - "Pat tern", - "▁го дина", - "▁годи на", - "▁Phil adel", - "tikz picture", - "▁co al", - "▁s ede", - "▁se de", - "▁sed e", - "▁satisf ies", - "▁t rim", - "▁tr im", - "▁tri m", - "▁ trim", - "▁b at", - "▁ba t", - "▁ bat", - "▁améric ain", - "▁lug lio", - "▁по ча", - "▁поч а", - "ff ff", - "fff f", - "f fff", - "▁T arget", - "▁Tar get", - "▁ Target", - "gener ate", - "▁Z ie", - "ți a", - "ț ia", - "▁g ard", - "▁gar d", - "▁ga rd", - "▁work ers", - "▁worker s", - "▁J ob", - "▁Jo b", - "▁ Job", - "▁ur ban", - "▁urb an", - "▁ urban", - "ah len", - "ahl en", - "a hlen", - "▁Build ing", - "▁n eu", - "▁ne u", - "▁ch ron", - "▁chr on", - "▁ chron", - "▁Ear l", - "gr o", - "g ro", - "US E", - "U SE", - "▁X II", - "▁XI I", - "▁we alth", - "▁ wealth", - "in ae", - "ina e", - "▁Б ра", - "▁li bert", - "▁lib ert", - "▁liber t", - "ir os", - "iro s", - "i ros", - ": $", - "le e", - "l ee", - "ie ves", - "ieve s", - "iev es", - "▁Just ice", - "▁o il", - "▁Ath let", - "▁c lo", - "▁cl o", - "▁ clo", - "Sc ale", - "Scal e", - "▁l ips", - "▁li ps", - "▁lip s", - "▁a pril", - "▁ap ril", - "▁apr il", - "▁im pression", - "▁imp ression", - "▁impr ession", - "▁impress ion", - "▁per ce", - "▁уча сти", - "▁участ и", - "vi l", - "v il", - "éc h", - "é ch", - "▁e quality", - "▁equ ality", - "▁equal ity", - "▁ equality", - "▁м ет", - "▁ме т", - "▁ мет", - "▁an notation", - "▁annot ation", - "▁ annotation", - "er nal", - "ern al", - "erna l", - "▁M ach", - "▁Ma ch", - "▁Mac h", - "▁int itul", - "pro blem", - "prob lem", - "ющи х", - "ю щих", - "op lus", - "o plus", - "▁thous ands", - "▁thousand s", - "▁calcul ations", - "▁calculation s", - "▁calc ulations", - "um ps", - "ump s", - "▁tri angle", - "▁ triangle", - "ph al", - "pha l", - "p hal", - "▁D orf", - "▁Do rf", - "▁Dor f", - "▁doll ars", - "▁d enen", - "▁de nen", - "▁den en", - "l ès", - "ol id", - "oli d", - "▁Result s", - "▁ Results", - "▁Stad ium", - "▁D esp", - "▁De sp", - "▁Des p", - "▁E isen", - "im ir", - "imi r", - "i mir", - "▁s otto", - "▁so tto", - "▁sott o", - "▁č i", - "▁ či", - "at able", - "ata ble", - "a table", - "or um", - "oru m", - "o rum", - "▁conver gence", - "▁je une", - "▁jeu ne", - "ok ing", - "oki ng", - "o king", - "▁жи во", - "ain ing", - "ai ning", - "a ining", - "po inter", - "point er", - "cul o", - "cu lo", - "c ulo", - "▁js ou", - "▁g rab", - "▁gr ab", - "▁gra b", - "ak te", - "akt e", - "a kte", - "▁ho ping", - "▁hop ing", - "▁M ak", - "▁Ma k", - "▁s ag", - "▁sa g", - "origin e", - "orig ine", - "▁по след", - "▁после д", - "▁V eg", - "▁Ve g", - "▁the oret", - "▁T ru", - "▁Tr u", - "ne ment", - "nem ent", - "n ement", - "▁f aces", - "▁fa ces", - "▁face s", - "▁fac es", - "▁ faces", - "H or", - "Jo in", - "J oin", - "ar el", - "are l", - "a rel", - "▁о коло", - "▁ок оло", - "How ever", - "▁c atal", - "▁ca tal", - "▁cat al", - "▁ catal", - "bo urg", - "bour g", - "b ourg", - "▁mysql i", - "▁mysq li", - "▁ mysqli", - "ac ions", - "acion s", - "aci ons", - "▁Init ial", - "▁ Initial", - "▁r ain", - "▁ra in", - "▁ rain", - "it ure", - "itu re", - "▁Sci ences", - "▁Science s", - "▁Kre is", - "._ _", - ". __", - "▁cin q", - "▁A uß", - "▁Au ß", - "ith met", - "it ors", - "ito rs", - "itor s", - "am azon", - "ama zon", - "▁g ap", - "▁ga p", - "▁ign ored", - "▁ignore d", - "▁ignor ed", - "ad v", - "ко ї", - "▁ча сть", - "▁час ть", - "▁част ь", - "▁cor por", - "▁corpo r", - "це р", - "ц ер", - "▁cr ime", - "▁cri me", - "▁crim e", - "uo us", - "u ous", - "▁на лази", - "Data Frame", - "во ди", - "вод и", - "Ig n", - "I gn", - "▁Lin coln", - "▁me nos", - "▁men os", - "▁Lu ft", - "▁L ind", - "▁Li nd", - "▁Lin d", - "▁C ook", - "▁Co ok", - "▁ Cook", - "▁material s", - "ap ped", - "app ed", - "appe d", - "a pped", - "ign ore", - "▁от кры", - "fr ied", - "fri ed", - "f ried", - "▁gouvern ement", - "▁f ired", - "▁fire d", - "▁fi red", - "▁fir ed", - "▁screen shot", - "▁screens hot", - "се н", - "с ен", - "▁[ (", - "▁ [(", - "▁органи за", - "Graph ics", - "▁про ти", - "▁p hen", + "S tudies", + "T RIO", + "U T", + "V ital▁sign", + "V EF", + "a ▁A", + "b ine▁", + "b orn", + "d om", + "d id▁not", + "e ’", + "e ’s▁", + "e .▁At", + "f ever", + "f ound▁to", + "g el", + "i ▁P", + "l and", + "n rollment", + "o i", + "p y", + "p ackag", + "s on-", + "s erious▁", + "s ▁are▁s", + "t im", + "– ▁Arm▁A", + "▁ illness", + "e▁ must▁be▁", + "e▁ after", + "▁t en", + "▁t ract", + "on azol", + "\n\n chemotherapy▁", + "\n\n 5-FU", + "▁a ▁n", + "s▁ D", + "re gression", + "re currenc", + "al ▁partner", + "al ternative▁", + "st ability", + "ent ricular", + "▁the▁ results▁of", + "an swer", + ",▁ 4", + ",▁ 7", + "ar ia", + "ed ▁assessment", + "ed .▁This▁", + "▁p ag", + "▁p ublish", + "▁p alliative▁", + "▁c apecitabin", + "▁c orticosteroid", + "et a-", + "▁to ▁this▁", + "th e▁s", + "▁and▁ of", + "▁and▁ EQ-5D", + ".\n\n 19", + ".\n\n Other", + "ill ary▁", + "al▁ visit", + "el op", + "▁in ▁Table▁", + "▁in ▁situ", + "ur ation▁of▁", + "res id", + "oc ock", + "il t", + "▁( as▁", + "anc e▁in", + "▁S ever", + "▁S cal", + "▁re com", + "▁re ach", + "ag re", + "ap plic", + "▁f inal▁", + "▁f amil", + "▁f olic▁acid▁", + "\n\nP emetrexed▁H3E-MC-JMHR(b)▁Confidential\n\nProtocol▁Amendment\n\nPage▁", + "\n\nA \n\n®\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁Panitumumab▁Protocol▁Number:▁20050251▁Date:▁10▁October▁2006\n\nPage▁", + "ate▁ with", + "study▁ design", + "▁and rogen", + "eas ibl", + "▁N ▁A\n\nF▁O\n\nY▁P▁O▁C", + "▁for ▁D", + "▁R evised▁Clinical▁Study▁Protocol▁Drug▁Substance▁ZD4054▁Study▁Code▁D4320", + ".2 1", + "age▁ Adjustment", + "e▁s uggest", + "▁of▁the▁ original", + "e,▁ m", + "▁as▁ soon▁as▁possibl", + "▁are▁ being", + "ated▁ at", + "▁v en", + "▁B ased▁on", + "▁5 3", + "▁6 -month", + "▁patients▁ per", + "▁patients▁ have▁been", + "minist rative▁", + "s▁( eg", + "▁ac cum", + ".4 8", + "\n\n1 9", + "rel ative▁to", + "▁ex tension", + "\n\nD enosumab", + "ed▁by ▁treatment▁group", + "ation▁of ▁a", + "EC TION", + ".▁S ubjects▁who", + "s▁will▁be▁ present", + "s▁will▁be▁ randomiz", + "▁U tero", + "▁tim ely▁", + "▁tim es▁the▁", + "s\n\n In", + "ed▁by▁ M", + "▁is su", + "▁is ▁also", + "▁is ▁associated▁with", + "▁may▁ not", + "▁may▁ develop", + "▁may▁ experienc", + "▁7 7", + "▁7 .3", + ",▁the▁ Investigator", + "▁ass ess▁s", + "pec ial▁", + ".6 7", + "▁to▁the▁ clinic", "▁ph en", - "▁ phen", - "cr aft", - "cra ft", - "c raft", - "▁b rain", - "▁br ain", - "▁bra in", - "▁C omo", - "▁Com o", - "▁Co mo", - "▁Every thing", - "an es", - "ane s", - "a nes", - "IG N", - "I GN", - "▁n ederbörd", - "▁ nederbörd", - "▁For est", - "▁Fore st", - "▁Fo rest", - "za hl", - "z ahl", - "▁Am ong", - "Q t", - "▁to gg", - "▁tog g", - "▁vari ant", - "▁ variant", - "▁h ill", - "▁hi ll", - "▁ hill", - "пи си", - "пис и", - "col on", - "co lon", - "colo n", - "▁dic embre", - "го р", - "г ор", - "▁W ind", - "▁Win d", - "▁Wi nd", - "ünst ler", - "▁= \\", - "▁ =\\", - "sa ved", - "save d", - "s aved", - "▁n ej", - "▁ne j", - "▁ nej", - "un te", - "unt e", - "ut to", - "utt o", - "u tto", - "▁rec ens", - "▁rece ns", - "▁s ick", - "▁si ck", - "▁sic k", - "▁d esen", - "▁de sen", - "▁des en", - "US T", - "U ST", - "▁wor st", - "▁An gel", - "▁Ang el", - "od ox", - "odo x", - "▁Prov ince", - "▁Provin ce", - "▁M az", - "▁Ma z", - "▁agre ement", - "▁agree ment", - "▁B ass", - "▁Bas s", - "▁Ba ss", - "▁seg unda", - "on ces", - "once s", - "onc es", - "▁Lin ki", - "▁Link i", - "▁C L", - "▁ CL", - "▁j á", - "it ement", - "ite ment", - "item ent", - "▁á rea", - "▁ár ea", - "▁scal ar", - "▁scala r", - "▁Р ес", - "▁Ре с", - "aw t", - "a wt", - "si eme", - "▁j uni", - "▁ju ni", - "▁jun i", - "▁худо ж", - "ik us", - "iku s", - "▁l id", - "▁li d", - "pp el", - "ppe l", - "p pel", - "av i", - "a vi", - "▁bal ance", - "ip ping", - "ipp ing", - "ippi ng", - "i pping", - "cuss ion", - "че ских", - "(\" .", - "( \".", - "Al so", - "▁w his", - "▁wh is", - "HO ME", - "▁b rown", - "▁br own", - "▁bro wn", - "▁brow n", - "▁d ía", - "▁dí a", - "▁pu ò", - "plot lib", - "▁Jahrhundert s", - "D K", - "▁an chor", - "▁anc hor", - "▁anch or", - "▁ anchor", - ".. .]", - "... ]", - "▁Aust ria", - "▁m arca", - "▁mar ca", - "▁marc a", - "▁g ez", - "▁ge z", - "ious ly", - "i ously", - "▁l azy", - "▁la zy", - "x a", - "▁Ch annel", - "▁Chan nel", - "▁ Channel", - "▁ne uen", - "▁neue n", - "▁neu en", - "da s", - "d as", - "▁search ed", - "▁sta at", - "▁ staat", - "▁Та к", - "▁Jo sef", - "▁Jose f", - "▁Jos ef", - "▁S her", - "▁Sh er", - "▁She r", - "po is", - "p ois", - "▁e nem", - "▁en em", - "▁access ing", - "▁не ко", - "▁fur ono", - "▁pse udo", - "▁pseud o", - "? >", - "▁estado un", - "▁estad oun", - "▁Ви ди", - "▁mot iv", - "▁re call", - "▁rec all", - "is son", - "iss on", - "i sson", - "ó b", - ")- -", - ") --", - "▁E rz", - "▁Er z", - "▁са вез", - "Dir ect", - "Di rect", - "D irect", - "со б", - "с об", - "▁s ho", - "▁sh o", - "v ölker", - "A p", - "ge ns", - "gen s", - "g ens", - "ниш тво", - "▁Am sterdam", - "us k", - "u sk", - "п ло", - "▁sim ulation", - "▁B C", - "▁ BC", - "▁W oj", - "▁Wo j", - "au tom", - "aut om", - "auto m", - "Al ex", - "A lex", - "▁econom ic", - "▁econ omic", - "го м", - "г ом", - "ik ai", - "ika i", - "▁a ltre", - "▁al tre", - "▁alt re", - "▁' -", - "▁ '-", - "▁W eg", - "▁We g", - "Not Found", - "й ской", - "▁convert ing", - "▁conver ting", - "ph abet", - "pha bet", - "at rice", - "atr ice", - "atri ce", - "bour ne", - "al om", - "alo m", - "▁comp aring", + ".▁C ons", + "patient ▁population", + "e▁( GCP", + "s▁s chedul", + "\n\nN umber", + ").\n\n 2", + "\n\n2 3", + "▁Ad d▁", + "ity▁of ▁investigational▁product", + "▁also ▁been", + "des cription", + "▁a▁s afety▁", + "respons e▁system", + ".▁D ATA", + ".▁D o▁not", + "id▁ in", + "\n\nI MC-", + "hy po", + ".\n\nS ▁T▁I", + "ack ▁of", + "▁the▁study▁ (", + "▁infusion ▁of", + "▁13 .4", + "\n\n0 2▁Feb▁2006▁15:38:50", + "▁subjects▁ will", + "▁CT ▁or▁MRI▁scan", + "plic ate▁", + ".▁B ased▁on", + "▁analysis .▁The▁", + ".8 .2", + "ed▁s olution", + "rol e▁in", + "▁occur ring", + "▁should▁ have▁", + "ros cribed▁", + "▁sh ort", + "▁clinical ▁data", + "▁rel aps", + "sampl e▁size▁", + "es▁for ▁the▁", + "▁stat us▁will▁be▁", + "▁chemotherapy▁ for", + "▁placebo ▁(", + "chang es▁", + "▁any \n\n", + ".▁E▁S▁U \n\nE▁R▁O▁F▁E▁B\n\nY▁T▁I▁D▁I▁L▁A▁V", + "▁12 ▁month", + "▁determin ing", + "rat es▁of", + ".\n\nC om", + "▁chang es▁", + "▁criteria ▁are▁met", + "qual ity", + "▁Y our", + "▁Y es▁or▁No", + "▁differ ence▁", + "are▁ first▁met", "▁compar ing", - "▁Z o", - "▁f la", - "▁fl a", - "ва я", - "▁en tra", - "▁ent ra", - "▁entr a", - "▁char set", - "▁chars et", - "develop ers", - "developer s", - "íst ica", - "} >", - "▁J azz", - "▁Ja zz", - "▁How ard", - "▁Ho ward", - "ш та", - "▁cl one", - "▁clo ne", - "▁ clone", - "do or", - "d oor", - "▁P in", - "▁Pi n", - "** *", - "* **", - "▁sil ent", - "ec ycle", - "e cycle", - "is ce", - "isc e", - "i sce", - "▁m ud", - "▁mu d", - "▁Dis play", - "▁ Display", - "▁l ip", - "▁li p", - "▁ lip", - "▁исполь зова", - "▁character istic", - "▁s b", - "▁ sb", - "fire base", - "▁B ew", - "▁Be w", - "Cal endar", - "▁u so", - "▁us o", - "▁ uso", - "ès e", - "è se", - "▁R at", - "▁Ra t", - "▁es per", - "▁espe r", - "▁esp er", - "▁ esper", - "▁throw ing", - "▁thro wing", - "▁ro dz", - "▁rod z", - "▁y ards", - "▁yard s", - "▁g rass", - "▁gr ass", - "▁gra ss", - "▁mar ker", - "▁mark er", - "▁ marker", - "▁K os", - "▁Ko s", - "Th eta", - "The ta", - "▁organ is", - "ker nel", - "kern el", - "k ernel", - "▁person as", - "▁pers onas", - "▁persona s", - "ke ep", - "kee p", - "▁exc laimed", - "os lav", - "▁Ent ertain", - "▁Enter tain", - "не р", - "н ер", - "▁in won", - "▁R and", - "▁Ra nd", - "▁Ran d", - "red uce", - "redu ce", - "fa c", - "f ac", - "ex pression", - "exp ression", - "expr ession", - "express ion", - "y j", - "▁differ enti", - "▁different i", - "ag lia", - "agli a", - "▁tem plates", - "▁template s", - "▁ templates", - "▁m ű", - "▁p rv", - "▁pr v", - "▁m ois", - "▁mo is", - "▁moi s", - "▁gew ann", - "▁бу ла", - "bib li", - "b ibli", - "de mo", - "dem o", - "d emo", - "▁And erson", - "▁Anders on", - "▁ре д", - "▁ ред", - "▁por que", - "▁P ologne", - "▁Pol ogne", - "▁t rip", - "▁tr ip", - "▁tri p", - "▁exem ple", - "▁exempl e", - "▁Intern acional", - "▁ка о", - "In sert", - "gen eral", - "gener al", - "SE SSION", - "ber ga", - "berg a", - "hä lt", - "h ält", - "un as", - "una s", - "u nas", - "ми ра", - "мир а", - "▁yield s", - "map sto", - "maps to", - "sp ot", - "s pot", - "▁+ \\", - "▁ +\\", - "лл а", - "л ла", - "▁precis ely", - "▁precise ly", - "▁ч лен", - "sh adow", - "Ar e", - "A re", - "un al", - "una l", - "u nal", - "▁dis par", - "▁disp ar", - "▁tít ulo", - "ne st", - "nes t", - "n est", - "▁L ow", - "▁Lo w", - "▁p rot", - "▁pro t", - "▁pr ot", - "▁C osta", - "▁Co sta", - "▁Cost a", - "▁Cos ta", - "name d", - "na med", - "nam ed", - "n amed", - "▁g ained", - "▁ga ined", - "▁gain ed", - "les ia", - "l esia", - "▁admin istration", - "▁administr ation", - "Im port", - "Imp ort", - "br anch", - "b ranch", - "▁sym path", - "vo j", - "v oj", - "▁E C", - "▁ EC", - "▁municip io", - "▁anim ated", - "▁animate d", - "▁direct ories", - "▁director ies", - "▁ro of", - "zą d", - "z ąd", - "im et", - "ime t", - "i met", - "pr oto", - "pro to", - "bl a", - "b la", - ": ]", - "ha ve", - "hav e", - "h ave", - "at em", - "ate m", - "a tem", - "▁n s", - "▁ ns", - "▁s ector", - "▁se ctor", - "▁sec tor", - "▁sect or", - "th ree", - "ow ane", - "owa ne", - "owan e", - "wer s", - "we rs", - "w ers", - "ов их", - "ови х", - "ren ce", - "r ence", - "▁ex tr", - "▁ext r", - "ig ten", - "igt en", - "igte n", - "▁occ ident", - "ț ă", - "▁e at", - "▁h ydro", - "▁hy dro", - "▁hyd ro", - "ubern etes", - "[ @", - "▁M oon", - "▁Mo on", - "▁S ho", - "▁Sh o", - "▁else where", - "ül ler", - "üll er", - "Up load", - "ла нд", - "лан д", - "л анд", - "▁F ör", - "w issenschaft", - "K S", - "▁phys ics", - "▁ physics", - "t z", - "▁се ред", - "▁Ar beit", - "▁Arbe it", - "▁ме ст", - "▁ мест", - "▁Geb iet", - "▁in sect", - "▁ins ect", - "▁inse ct", - "A h", - "iz ado", - "iza do", - "▁tem ple", - "▁temp le", - "▁ann ual", - "st ad", - "sta d", - "▁hab itat", - "▁habit at", - "▁A B", - "▁ AB", - "wo rt", - "wor t", - "w ort", - "▁re pos", - "▁rep os", - "▁repo s", - "▁N eu", - "▁Ne u", - "▁$ (\".", - "▁$( \".", - "▁$(\" .", - "Vor lage", - "▁repre zent", - "est anden", - "In tern", - "Int ern", - "Inter n", - ". `", - "▁fa iling", - "▁fail ing", - "▁M aterial", - "▁Mate rial", - "▁ Material", - "▁effect ively", - "▁effective ly", - "те лем", - "тел ем", - "▁г ла", - "▁ гла", - "▁na hm", - "▁nah m", - "▁ nahm", - "▁differ ently", - "▁different ly", - "ext ension", - "▁V erm", - "▁Ver m", - "▁Ve rm", - "en abled", - "ena bled", - "enable d", - "con figure", - "config ure", - "ni o", - "n io", - "ci ones", - "cio nes", - "cion es", - "c iones", - "▁B each", - "▁Be ach", - "со на", - "сон а", - "с она", - "▁copy ing", - "▁cop ying", - "▁у країн", - "▁при зна", - "▁приз на", - "z h", - "Des ktop", - "▁s ost", - "▁so st", - "▁sub sequently", - "▁subsequ ently", - "▁subsequent ly", - "▁Le hr", - "▁ ó", - "lä r", - "l är", - "od or", - "odo r", - "o dor", - "ph on", - "p hon", - "n c", - "iter ator", - "▁э ти", - "▁europ é", - "▁Tor onto", - "ód igo", - "▁p osto", - "▁po sto", - "▁pos to", - "▁post o", - "ff e", - "f fe", - "▁c rew", - "▁cre w", - "▁cr ew", - "▁Sch war", - "▁Schw ar", - "S a", - "squ are", - "s quare", - "▁be side", - "▁bes ide", - "▁М і", - "▁a th", - "▁at h", - "▁ ath", - "▁ad vent", - "▁adv ent", - "c ji", - "writ ten", - "wr itten", - "w ritten", - "▁r uss", - "▁ru ss", - "▁rus s", - "ro st", - "ros t", - "r ost", - "H I", - "▁d ice", - "▁di ce", - "▁dic e", - "cc a", - "c ca", - "▁d ép", - "▁dé p", - "pl y", - "p ly", - "big g", - "bi gg", - "b igg", - "zi ał", - "zia ł", - "z iał", - "üt t", - "ü tt", - "▁о дно", - "▁од но", - "J ECT", - "сь кому", - "сько му", - "ськ ому", - "no s", - "n os", - "mo ck", - "m ock", - "La unch", - "sa me", - "sam e", - "s ame", - "▁j obs", - "▁jo bs", - "▁job s", - "▁wide ly", - "▁wid ely", - "▁def ines", - "▁define s", - "▁defin es", - "▁P se", - "▁Ps e", - "▁neigh bour", - "▁neighb our", - "ющи е", - "▁cl oser", - "▁close r", - "▁clos er", - "▁clo ser", - "▁рас поло", - "▁распо ло", - "▁cl ubs", - "▁club s", - "fl y", - "f ly", - "ши м", - "ш им", - "▁suffer ed", - "▁suff ered", - "▁n ar", - "▁na r", - "▁ nar", - "▁l avor", - "▁la vor", - "▁lav or", - "Ext ension", - "ition ally", - "itional ly", - "▁g race", - "▁gr ace", - "▁gra ce", - "▁Campe onato", - "▁Christ mas", - "m iddle", - "oth ek", - "othe k", - "el ements", - "element s", - "ele ments", - "elem ents", - "▁son dern", - "▁t arde", - "▁tar de", - "▁tard e", + "ate 1", + "▁analysis▁of ▁OS", + "▁the▁b eginn", + "▁health ▁state▁", + "▁Study▁Code▁ 7054Il/00", + "▁Ph ysician", + "▁bas ed▁", + "▁and▁s hould▁", + "confirm ation", + "▁cor rel", + "▁AND ▁L", + "util ization", + "▁contain er", + "Pro state▁Cancer", + "▁or▁ urine▁", + ".3.1 .2", + "▁caus al▁relationship", + "utrop enic", + "clos ure", + "▁Med ic", + "▁e▁ e▁", + "arch iv", + "▁Arm▁A ▁and▁", + ")\n\nGEL▁Version▁ID:▁ONC.000− 214−771.5.0▁Approved▁by\n\nApproved\n\nDate▁Printed:▁31−Jul−2014", + "protein uria", + "▁skin ▁rash", + "▁indic ate▁that", + "▁doctor ▁will", + "▁a▁p articular", + "▁typ es▁of", + "increas ed▁", + "pharmac odynamic", + "▁aff ili", + "direct ed▁against", + "▁teleph on", + "sent ▁to▁the▁", + "▁approval ▁of▁the▁protocol", + "tic aria", + "procedure s▁", + "▁non compli", + ".▁The▁investigator ▁must", + "hypothes iz", + "lymph ocyt", + "dose▁of ▁panitumumab", + "ed▁tumor ▁tissu", + "Grade▁3 ▁or▁4", + "▁hospitalization ▁or", + "▁activity▁ in", + "▁chemist ry", + "▁you▁have▁ any▁", + "▁investig ate▁", + "▁25- hydroxyvitamin▁D", + "ECOG▁performance▁stat us▁(0", + "\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX \n\nX\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX", + "2,▁ 3", + "ALT ,▁AST", + "1▁and▁ 2", + "▁Pl us▁", + ",▁2008 ;", + "▁months▁after ▁the▁first", + "oste oclast", + "▁tumor▁tissu e▁sampl", + "▁lead ▁to", + "▁have▁s ome▁", + "▁go al", + "▁might ▁be▁", + "ody▁ weight", + "▁along ▁with▁the▁", + "paragraph \n\nReplace:", + "resect able▁", + "▁hyp ocalcemia", + "VEGFR -2", + ".▁N▁Engl▁J ▁Med", + ".\n\nE▁S▁A▁E▁L▁P \n\n.▁T▁N▁E▁M▁U▁C▁O▁D", + "▁PA TI", + "\n\nNon- PD", + "resistant ▁prostate▁cancer", + "▁Account ability", + "▁Ob jective▁", + "▁aged▁ ≥", + "▁micro RNA", + "’Brien -F", + "▁taking▁as▁referenc e▁the▁", + "teer ing", + "nerv ous▁system", + "▁will▁be▁stratifi ed▁by▁", + "▁discontinuation▁of▁ study▁treatment", + "▁vascular ▁endothelial▁growth▁factor", + "abd omen", + "▁persistent ▁or▁significant▁dis", + "emoral▁neck ▁BMD", + "PEC I", + "▁disease\n\n progression", + "▁Efficacy \n\nAnalysis▁Set", + "▁or▁equal ▁to", + "▁Heart ▁Ass", + "▁thromboembolic ▁event", + "VESTIGATIONAL ▁PRODUCT", + "▁RAN KL", + "RODUC TION", + "-Report ed▁Outcom", + "▁Study▁Code▁7054Il/00 23▁Edition▁Number▁7", + "( s),▁", + ") ▁in▁the▁", + "- minut", + "/ sh", + "3 )(cid:", + "3 )▁(cid:", + "4 )▁(cid:", + "5 W", + "8 :", + ": \n\nS", + ": ▁B", + "C entral▁", + "F ract", + "F irst", + "H &N", + "N R", + "P )", + "P ONS", + "R eturn▁of", + "X X", + "d f", + "d ys", + "d elet", + "d ifficult", + "e i", + "e ”", + "e Met", + "g one▁", + "g astrointestinal▁", + "k it", + "m easures", + "m oter", + "n egativ", + "p df", + "s upport", + "s ▁as▁a", + "u perior", + "v ul", + "v itamin▁B12", + "▁ ir", + "▁ kin", + "e▁ form", + "e▁ Com", + "in spect", + "at e.\n\n", + "at ed▁in▁the▁", + "at es,▁", + "\n\n Q", + "\n\n un", + "\n\n form", + "\n\n 50", + "or ▁equivalent", + "or rection", + "s▁ C", + "s▁ ................................................................................", + "s▁ defin", + "▁th ink", + "st ream", + ",▁ per", + ",▁ diarrhea", + "▁an n", + "ic ardial▁", + "▁c ost", + "ing ▁at", + "▁b ack", + "▁b owel", + "es ),▁", + "▁to ▁the\n\n", + "is od", + "▁s us", + "▁s ingl", + "▁s ourc", + "ou s▁(", + "▁d ys", + "▁w all", + "▁m ass", + "▁m ▁u", + "▁m aking", + "▁and▁ n", + ".\n\n 17", + "ol un", + "ol ys", + "ab or", + "is▁ is▁", + "▁A \n\nS▁I", + "ur den", + "ac erb", + "es▁ may▁", + "es▁ containing", + "▁( MRI", + "▁2 .2", + "con clud", + "con clusion", + "ra ys", + "▁S PARC", + "▁re striction", + "un ning", + "▁D arbepoetin▁alfa", + "ap ies▁", + "ap ular", + "ap pli", + "ch arg", + "▁or ▁after", + "▁n ▁o", + "▁n adir", + "\n\nA E", + "\n\nA \n\nS▁I", + "▁O ption", + "▁T RT", + "▁ad vert", + "ep ression", + "will▁be▁ summariz", + "will▁be▁ censored▁at", + "▁for ▁patients▁with", + "▁for ▁detail", + "▁for ward", + "▁R A", + "▁R edacted▁Version", + "▁treatment -emergent", + ".1 %", + ".1 4", + "In ter", + "ad ing", + "ad em", + "ant el-", + "▁is▁ required", + "▁of▁ 4", + "▁of▁ irinotecan", + "▁will▁be▁ based▁on", + "▁will▁be▁ suppli", + "▁M SI", + "▁r ath", + ",▁and▁ in", + "int egr", + "▁all ▁of▁the▁following", + "ary▁ n", + "▁res id", + "▁analys es,▁", + "ach er", + "▁6 6", + "▁H orm", + "▁subject s,▁", + "▁the▁p ast", + "▁the▁p otential▁", + "▁study▁ enrollment", + "ident ification▁number", + "s▁in dic", + "ens zel", + "▁any▁ fracture▁", + "▁V ITAL", + "▁ex amination", + "\n\nD ate1", + "eth ical▁", + ".▁S econdary▁", + ".▁S erious▁Adverse▁Event", + "s▁will▁be▁ summariz", + "ies▁ will▁be▁", + "report ed▁s", + "AE s▁will▁be▁", + ".▁P rimary▁", + "▁of▁1 9", + "\n\nE lect", + "ed▁by▁ clinic▁visit▁or▁telephone▁contact", + "pos ure▁in", + "▁7 .6", + "mon t", + "▁per ▁year", + ".▁In terim", + ".▁E ffect", + "▁ph ys", + "record ed▁as▁", + "s.\n\n 2", + ",▁and ▁any▁", + "▁sign al", + "▁ab ort", + "e.\n\n If", + "▁9 0%", + "▁each ▁of▁the▁", + "he aling", + "pre ced", + "ne ed▁for", + "\n\nR ationale▁for", + "▁you ▁decide▁to", + "▁a▁s ubset", + "e, ▁albumin,", + "\n\n3 .1", + "▁The▁ primary▁", + "▁dose▁ will▁be▁", + "▁W eight", + "▁W ork", + "I- H", + ".\n\nP fizer▁–▁Company▁Confidential▁Page▁", + "s▁that ▁do▁not", + "\n\nAd d", + "result ing▁from", + "performed▁ using", + ")▁ if", + "Event s▁", + "d▁e▁v▁o▁r▁p▁p▁A\n\nProduct: ▁Panitumumab▁Protocol▁Number:▁20050181▁Date:▁04▁April▁2008\n\nPage▁", + "sign ed▁and▁", + "▁di arrhoea", + "perform ance▁stat", + "▁dose▁of ▁panitumumab", + "▁dose▁of ▁study▁drug", + "▁ind ex", + ".▁B r", + "response▁ assessment", + "▁Panitumumab ▁Clinical▁", + "▁occur r", + "\n\n6 .4", + ".▁M or", + "loc ation", + "atist ic", + "s▁will ▁occur", + "week s▁", + "▁blood▁ pressure▁", + "▁result s▁from", + "sampl e▁", + "ation▁of▁ existing", + "e▁m ethod", + "▁administer ed", + "▁to▁ ver", + "▁to▁ zoledronic▁acid▁", + "clinical ▁practic", + "▁advanc ed▁or", + ",▁A l", + "-5 ▁Dimension", + "▁radi ological", + "overall ▁survival▁", + "▁effect s▁of", + ",▁B on", + "qual ity▁of", + "go od▁", + "▁who ▁have▁", + "-m ail", + "-m icron", + "determin ed▁to▁be▁", + "long est▁dimension", + "Res ult", + "▁assign ed▁", + "s.▁The▁ investigator", + "ation▁of▁the▁ study▁", + "▁bone▁ los", + "▁cl as", + "▁OF ▁S", + "▁OF ▁CONTENTS", + "▁the▁c ase▁report▁form", + "▁hav e▁their", + "rate▁ for", + "dependent ▁children", + "▁an▁ estimated▁", + "▁Con current", + "▁sunitinib /placebo", + "\n\nt est", + "\n\nt umor", + "\n\nAmended▁ Clinical▁Study▁Protocol▁Drug▁Substance:▁Bicalutamide▁Study▁Code:▁7054IL/0024▁Edition▁Number:▁05▁Date:▁20th▁December▁2004", + "emb ran", + "ensor y▁", + "▁high -", + "▁100 %", + "▁during▁the▁ course▁of▁the▁study", + "▁vari ety▁of", + "ren al", + "▁but ▁not", + "combin ed▁with", + "previ ously", + "▁(or ▁equivalent", + "compar ing", + "guidelin es▁", + "▁PSA ▁progression", + "▁fl u", + "▁abnormal ity", + "need ed▁to", + "▁local▁ regulation", + "95% ▁confidence▁interval▁", + "ed▁by▁the▁investigator ▁or", + "ed▁by▁the▁investigator ▁to▁be▁", + "▁chest ▁X-ra", + "\n\nTable▁ 1", + "Ob jective▁", + "▁and▁D rug", + "scal e▁scor", + "measured▁ in", + "hazard▁ratio ▁for", + "▁availabl e,▁", + "OT E:", + "▁character iz", + ".▁Cancer ▁Research", + "▁regard ▁to", + "▁surger y▁", + "ogenes is", + "s▁A ▁and▁D", + "▁................................................................................ ....", + "every▁3 ▁month", + "improv ement", + "followed▁by▁ 5-FU", + "▁Pre medication", + "▁95% ▁confidence▁interval", + "flamm ation", + "▁side▁effect s▁of", + "▁have▁not ▁progress", + "administration ▁of▁the▁", + "▁pharmac ogenetic", + "▁2007; ▁8", + "-treat ed▁", + "Qual ity▁of▁Lif", + "-F ree▁S", + ".▁Res ponse▁", + "discontinued▁from ▁study▁treatment", + ".[ see▁comment]", + "lab ell", + "▁At ▁least", + "\n\nWh en", + "▁stor age▁", + "▁Analys es▁", + ".9% ▁Sodium", + "▁refer enc", + "progression-free▁s urvival", + "▁dep ress", + "▁regulatory ▁ag", + "▁vit a", + "▁class ification", + "▁advanced▁non- small-cell▁lung▁cancer", + "\n\nX▁X▁X ▁X▁X", + "▁oste oporosis", + "horm one▁", + "▁OF▁T HE", + "management ▁of", + "ockcroft -Gault", + "▁the▁dos e▁of", + "▁AND▁R ATIONALE", + "Hy pothes", + "▁pulmonary▁ fibros", + "▁30▁days▁after ▁the▁last▁dose▁of", + "▁Compli ance▁", + "▁methyl ation", + "Evaluation▁Criteria▁in▁Solid▁Tumor s▁(RECIST", + "intent -to-treat", + "▁cur ative▁", + "fiel d▁", + "▁progression-free▁s urvival", + "▁cells /L", "▁perman ent", - "▁con clude", - "▁concl ude", - "Se g", - "S eg", - "▁а каде", - "}\" ,", - "} \",", - "▁февра ля", - "ře d", - "ř ed", - "▁I L", - "▁ IL", - "ju d", - "j ud", - "▁U SS", - "▁US S", - "▁N ature", - "▁Natur e", - "▁Nat ure", - "if ference", - "iffer ence", - "iffe rence", - "Serial izer", - "▁tw elve", - "ti d", - "t id", - "ми я", - "че ского", - "▁cal endar", - "▁ calendar", - "con cat", - "▁inter section", - "▁intersect ion", - "▁P A", - "▁ PA", - "az ure", - "azu re", - "▁situ ée", - "▁situé e", - "▁k inds", - "▁kind s", - "▁kin ds", - "▁aus ge", - "▁r ural", - "▁ru ral", - "Th eme", - "The me", - "▁t ale", - "▁tal e", - "▁ta le", - "no indent", - "go ing", - "r x", - "ag i", - "a gi", - "wrap per", - "wr apper", - "w rapper", - "▁Co ast", - "mb H", - "▁пере д", - "▁пе ред", - "sp re", - "spr e", - "s pre", - "▁} \\", - "▁ }\\", - "▁L I", - "▁ LI", - "zn am", - "zna m", - "z nam", - "it led", - "itle d", - "Sam ple", - "S ample", - "ul iar", - "uli ar", - "* \\", - "▁res istance", - "▁resist ance", - "st ock", - "sto ck", - "ke d", - "k ed", - "▁H E", - "▁ HE", - "▁pos session", - "▁poss ession", - "▁possess ion", - "▁R ing", - "▁Ri ng", - "▁m agyar", - "▁mag yar", - "ou ts", - "out s", - "o uts", - "▁Secret ary", - "nd e", - "n de", - "▁W ald", - "▁Wal d", - "▁Wa ld", - "- (", - "▁I SO", - "▁IS O", - "▁ ISO", - "▁af ternoon", - "ion en", - "io nen", - "ione n", - "i onen", - "▁st ops", - "▁stop s", - "▁sto ps", - "▁const ants", - "▁constant s", - "gu ard", - "bo w", - "b ow", - "▁e rs", - "▁er s", - "▁ ers", - "▁Fire base", - "▁C lear", - "▁Cl ear", - "▁Cle ar", - "▁ Clear", - "▁H oly", - "▁Hol y", - "▁Ho ly", - "W in", - "▁title s", - "▁tit les", - "▁т рав", - "▁тра в", - "▁cont rib", - "▁contr ib", - "▁ contrib", - "hä ng", - "h äng", - "▁phot ograph", - "▁photo graph", - "▁Dist ribution", - "if ts", - "ift s", - "▁a unque", - "com b", - "co mb", - "c omb", - "AD D", - "A DD", - "▁public ation", - "▁pub lication", - "▁publi cation", - "▁слу ж", - "▁к ня", - "▁ay ant", - "▁re store", - "▁r estore", - "▁rest ore", - "▁resto re", - "▁bel ief", - "▁v ég", - "▁vé g", - "▁ext ensions", - "▁extension s", - "▁extens ions", - "▁ extensions", - "▁de com", - "▁dec om", - "вши й", - "в ший", - "W T", - "▁par ti", - "▁part i", - "▁gi oc", - "▁ми ра", - "▁ мира", - "▁is su", - "▁iss u", - "pi pe", - "pip e", - "p ipe", - "▁pro ps", - "▁pr ops", - "▁prop s", - "▁ props", - "▁w illing", - "▁will ing", - "▁wil ling", - "▁n est", - "▁ne st", - "▁ nest", - "as o", - "a so", - "po t", - "p ot", - "▁hand les", - "▁handle s", - "▁ф о", - "▁ фо", - "▁m oder", - "▁mod er", - "▁mo der", - "▁mode r", - "▁eben falls", - "▁fight ing", - "um bn", - "umb n", - "▁trans parent", - "▁K rist", - "▁Kr ist", - "▁home s", - "▁hom es", - "▁ho mes", - "▁voy age", - "Fa iled", - "Fail ed", - "▁B ird", - "▁Bi rd", - "▁Bir d", - "▁He art", - "Count er", - "Co unter", - "C ounter", - "▁Scott ish", - "át ica", - "▁ar beit", - "▁ arbeit", - "^{ -\\", - "^{- \\", - "▁S or", - "▁So r", - "▁eng aged", - "▁engag ed", - "▁a side", - "▁as ide", - "▁asi de", - "▁F ou", - "▁Fo u", - "▁w iel", - "▁wie l", - "▁re const", - "▁recon st", - "ou sin", - "ous in", - "▁host ed", - "▁ho sted", - "▁hos ted", - "▁c lasse", - "▁class e", - "▁cl asse", - "▁clas se", - "▁con test", - "▁cont est", - "▁conte st", - ".. .\"", - "... \"", - "мо м", - "м ом", - "▁be an", - "▁ bean", - "ge m", - "g em", - "▁consult ato", - "▁b io", - "▁bi o", - "▁ bio", - "▁subject s", - "bo Box", - "▁Sch rift", - "▁d inner", - "▁din ner", - "ă r", - "▁r ówn", - "▁% %", - "▁ %%", - "ba ge", - "bag e", - "b age", - "▁ver öff", - "▁det ected", - "▁detect ed", - "ie nn", - "ien n", - "i enn", - "ro se", - "ros e", - "r ose", - "▁T on", - "▁To n", - "Comp lete", - "Comple te", - "▁pro to", - "▁pr oto", - "▁prot o", - "▁ proto", - "ich ts", - "icht s", - "i chts", - "ST AT", - "Check ed", - "▁in ten", - "▁i nten", - "▁int en", - "▁inte n", - "▁s mile", - "▁sm ile", - "▁st rip", - "▁str ip", - "▁stri p", - "▁ strip", - "ne ut", - "') ;\r", - "'); \r", - "' );\r", - "fo ur", - "f our", - "▁to das", - "▁tod as", - "▁toda s", - "Control s", - "▁thor ough", - "ru p", - "r up", - "▁држа ви", - "it ă", - "Pro tocol", - "К а", - "▁expand ed", - "ex tra", - "ext ra", - "op ort", - "opo rt", - "o port", - "▁Ста нов", - "le ases", - "lease s", - "▁n otion", - "▁not ion", - "▁no tion", - "▁g uest", - "▁gu est", - "▁Is lands", - "▁Island s", - "ic ked", - "ick ed", - "▁D ave", - "▁Dav e", - "▁Da ve", - "▁ref lection", - "▁reflect ion", - "li v", - "l iv", - "ál ní", - "▁reve aled", - "▁s og", - "▁so g", - "▁T ax", - "▁Ta x", - "▁period o", - "▁peri odo", - "▁Welt krie", - "catal ina", - "qu é", - "q ué", - "▁F ather", - "▁Fa ther", - "▁B ir", - "▁Bi r", - "ex pect", - "exp ect", - "▁re gression", - "▁reg ression", - "in é", - "i né", - "▁d abei", - "▁da bei", - "pe rm", - "per m", - "p erm", - "ме не", - "мен е", - "м ене", - "▁A bd", - "▁Ab d", - "▁C F", - "▁ CF", - "ar ks", - "ark s", - "resol ve", - "wed ge", - "w edge", - "▁initial ization", - "▁Vé ase", - "▁при ня", - "st mt", - "▁in come", - "▁inc ome", - "M Y", - "▁od kazy", - "▁Sie he", - "▁bod ies", - "▁s oc", - "▁so c", - "R andom", - "▁s enza", - "▁sen za", - "ab lo", - "abl o", - "a blo", - "▁reg arded", - "▁regard ed", - "on Create", - "▁Mag azine", - "▁R af", - "▁Ra f", - "▁Buen os", - "и л", - ")) );", - "))) ;", - ") ));", - "ca pt", - "cap t", - "c apt", - "re direct", - "red irect", - "▁pe tit", - "▁pet it", - "▁f arm", - "▁far m", - "▁fa rm", - "▁r ôle", - "▁стать и", - "     ", - "sub figure", - "èce s", - "è ces", - "zi el", - "zie l", - "z iel", - "▁о кон", - "▁ок он", - "E E", - "me e", - "m ee", - "▁p erten", - "▁per ten", - "▁pert en", - "▁représ ent", - "▁L A", - "▁ LA", - "? '", - "▁т ру", - "▁r ational", - "▁rat ional", - "▁ratio nal", - "os of", - "oso f", - "▁k ne", - "▁kn e", - "▁art ists", - "▁artist s", - "Fl ow", - "F low", - "▁А ль", - "▁Ал ь", - "iz ard", - "iza rd", - "izar d", - "▁num ero", - "▁numer o", - "act ic", - "a ctic", - "▁de struct", - "▁dest ruct", - "▁destru ct", - "▁П ра", - "ons ieur", - "q t", - "ab estanden", - "no ść", - "Con nect", - "Conne ct", - "▁o racle", - "▁or acle", - "▁ora cle", - "▁ oracle", - "▁Stock holm", - "size of", - "▁gem äß", - "AC T", - "A CT", - "▁ex pert", - "▁exp ert", - "▁exper t", - "ut ions", - "ution s", - "uti ons", - "▁h acia", - "▁ha cia", - "▁log ger", - "▁ logger", - "▁f ool", - "▁fo ol", - "▁foo l", - "ry pto", - "rypt o", - "æ r", - "▁c idade", - "▁ci dade", - "▁состав е", - "▁соста ве", - "ok er", - "oke r", - "o ker", - "▁Trans fer", - "▁den ied", - "Tr ack", - "Tra ck", - "T rack", - "▁r adi", - "▁ra di", - "▁rad i", - "ze c", - "z ec", - "▁Histor ic", - "▁Einwo hner", - "ко ю", - "▁х ра", - "▁ хра", - "▁C ategory", - "▁ Category", - "▁Dis ney", - "▁sw ap", - "▁ swap", - "Be gin", - "B egin", - "▁m ientras", - "▁d ance", - "▁dan ce", - "▁t ête", - "▁d roit", - "▁dr oit", - "▁dro it", - "er ta", - "ert a", - "▁bird s", - "▁bir ds", - "▁con vin", - "▁conv in", - "par ator", - "para tor", - "д ра", - "▁E S", - "▁ ES", - "▁Ress ources", - "▁Ressource s", - "EG IN", - "ück e", - "ü cke", - "▁Cr uz", - "▁Cru z", - "ab ling", - "abl ing", - "a bling", - "▁\" @", - "▁me tres", - "▁met res", - "▁B eg", - "▁Be g", - "▁Gr ünd", - "▁B oh", - "▁Bo h", - "▁m ile", - "▁mil e", - "▁mi le", - "▁ mile", - "▁Techn ology", - "\" +", - "ac co", - "acc o", - "a cco", - "▁s s", - "▁ ss", - "▁F ed", - "▁Fe d", - "▁H end", - "▁He nd", - "▁Hen d", - "us ch", - "usc h", - "u sch", - "it ä", - "fol k", - "f olk", - "▁abs or", - "an tal", - "ant al", - "anta l", - "od ge", - "▁WH EN", - "▁Extern í", - "▁Reg iment", - "▁evalu ation", - "▁T ai", - "▁Ta i", - "▁voc als", - "▁vocal s", - "▁ex perimental", - "▁experiment al", - "em bed", - "emb ed", - "▁M inn", - "▁Min n", - "▁Mi nn", - "▁в ме", - "pr ec", - "pre c", - "p rec", - "ever y", - "ev ery", - "e very", - "▁ho of", - "▁Fern ando", - "▁Bibli ographie", - "▁n ag", - "▁na g", - "amerikan ischer", - "▁m arks", - "▁mar ks", - "▁mark s", - "▁ marks", - "▁U TC", - "▁ UTC", - "▁un certain", - "ди я", - "ol ia", - "oli a", - "o lia", - "▁c up", - "▁cu p", - "▁ cup", - "▁f ille", - "▁fil le", - "▁fill e", - "▁fi lle", - "▁d ok", - "▁do k", - "use ppe", - "est erd", - "ester d", - "este rd", - "e sterd", - "▁B rand", - "▁Br and", - "▁Bra nd", - "▁Bran d", - "▁Th ird", - "P P", - "no des", - "node s", - "n odes", - "▁P ad", - "▁Pa d", - "▁ Pad", - "▁l oved", - "▁lo ved", - "▁love d", - "▁lov ed", - "sw ing", - "s wing", - "▁surpr ised", - "▁surprise d", - "ar di", - "ard i", - "▁G R", - "▁ GR", - "] \"", - "▁equ ally", - "▁equal ly", - "▁eq ually", - "ih e", - "i he", - "ca re", - "car e", - "c are", - "пи сок", - "пис ок", - "li jk", - "lij k", - "l ijk", - "ri nn", - "rin n", - "r inn", - "▁\\ [\\", - "▁\\[ \\", - "▁s ons", - "▁so ns", - "▁son s", - "▁t ät", - "ic amente", - "ica mente", - "▁l isting", - "▁list ing", - "iel lement", - "ielle ment", - "▁nyel ven", - "▁d s", - "▁ ds", - "▁agr icult", - "▁H ermann", - "▁Her mann", - "▁Herm ann", - "▁bes ides", - "▁beside s", - "pro gress", - "prog ress", - "▁pec uliar", - "fo cus", - "f ocus", - "c n", - "- $", - "ствен ный", - "ou rg", - "our g", - "o urg", - "▁w yn", - "▁wy n", - "▁conduct ed", - "▁condu cted", - "▁Станов ништво", - "connect ed", - "conne cted", - "conn ected", - "▁b ott", - "▁bo tt", - "▁bot t", - "▁с мер", - "▁см ер", - "▁P oz", - "▁Po z", - "un ct", - "unc t", - "con da", - "cond a", - "c onda", - "▁савез ној", - "▁ha vet", - "▁have t", - "▁hav et", - "li gt", - "lig t", - "l igt", - "or ted", - "ort ed", - "orte d", - "▁ent ering", - "▁enter ing", - "mult ip", - "multi p", - "mul tip", - "▁Tem ple", - "▁Temp le", - "▁P lant", - "▁Pl ant", - "▁Plan t", - "▁Pla nt", - "type of", - "▁V lad", - "▁qu ed", - "▁que d", - "▁q ued", - "▁re ste", - "▁r este", - "▁res te", - "▁rest e", - "▁ма й", - "▁ май", - "▁V ery", - "▁Ver y", - "▁Ve ry", - "ambigu ation", - "▁ch alleng", - "▁res pective", - "▁respect ive", - "▁т ор", - "▁то р", - "▁ тор", - "C trl", - "▁abs ence", - "ar u", - "a ru", - "во е", - "▁för st", - "▁s q", - "▁ sq", - "▁Em peror", - "▁I gn", - "▁Ig n", - "▁ Ign", - "▁т ова", - "▁то ва", - "▁ това", - ": `", - "ad oop", - "ado op", - "▁Mad ame", - "▁gru ppo", - "▁grup po", - "st ud", - "▁extern as", - "▁Александ р", - "▁d ign", - "▁di gn", - "▁dig n", - "▁жи ве", - "Am ount", - "A mount", - "▁correl ate", - "▁corre late", - "▁F ant", - "▁Fa nt", - "▁r ails", - "▁ra ils", - "▁rail s", - "▁ rails", - "f p", - "министра тив", - "▁b ought", - "▁fil ters", - "▁filter s", - "▁ filters", - "▁anc ora", - "▁part ner", - "▁qu and", - "▁quan d", - "sym bol", - "s ymbol", - "ul ating", - "ula ting", - "▁z d", - "▁ zd", - "aw n", - "a wn", - "▁G rant", - "▁Gr ant", - "▁Gra nt", - "▁Gran t", - "bec ause", - "b ecause", - "ra ble", - "rab le", - "r able", - "\\ }", - "íst icas", - "ística s", - "▁у че", - "▁péri ode", - "▁s ke", - "▁sk e", - "▁ ske", - "▁Any way", - "▁index es", - "▁inde xes", - "▁direct ions", - "▁dire ctions", - "▁direction s", - "▁R AM", - "▁RA M", - "▁ RAM", - "ch rome", - "chr ome", - "chrom e", - "▁a post", - "▁ap ost", - "▁apo st", - "▁war nings", - "▁warning s", - "▁warn ings", - "▁Air port", - "V I", - "ab ile", - "abil e", - "abi le", - "▁l ord", - "▁lo rd", - "pro vider", - "prov ider", - "▁J i", - "ost ream", - "o stream", - "▁geme ente", - "table View", - "Ex tra", - "Ext ra", - "c ursor", - "eg round", - "egr ound", - "e ground", - "▁M oz", - "▁Mo z", - "▁r ib", - "▁ri b", - "▁ rib", - "▁m orph", - "▁mor ph", - "lo ads", - "load s", - "el sk", - "els k", - "▁M AX", - "▁MA X", - "▁ MAX", - "▁Santi ago", - "▁H im", - "▁Hi m", - "code s", - "co des", - "cod es", - "c odes", - "▁l anz", - "▁lan z", - "▁count s", - "▁coun ts", - "rinn ingsområ", - "щ ё", - "▁sp é", - "▁pier ws", - "▁pierw s", - "▁S ver", - "▁Sv er", - "▁a cknow", - "▁ac know", - "Bo olean", - "▁фами ли", - "▁Sen ate", - "шо в", - "ш ов", - "ag ers", - "age rs", - "ager s", - "a gers", - "▁Nue va", - "bi l", - "b il", - "ki em", - "kie m", - "k iem", - "▁M ey", - "▁Me y", - "wi j", - "w ij", - "▁G mbH", - "valid ation", - "▁en suite", - "in king", - "ink ing", - "▁c ampion", - "▁camp ion", - "▁finan cial", - "▁financi al", - "iz on", - "izo n", - "i zon", - "He aders", - "Head ers", - "Header s", - "▁deprec ated", - "▁fon ction", - "RE G", - "R EG", - "▁vol umes", - "▁volume s", - "▁C hi", - "▁Ch i", - "▁encounter ed", - "la k", - "l ak", - "ра я", - "▁contin ues", - "▁continu es", - "▁continue s", - "▁~ [", - "uer te", - "u erte", - "▁\\ ;", - "▁ \\;", - "▁D ok", - "▁Do k", - "▁we ights", - "▁weight s", - "▁r h", - "▁ rh", - "▁Na pole", - "▁Nap ole", - "▁natur ally", - "▁natural ly", - "sk u", - "s ku", - "pa s", - "p as", - "▁g egründ", - "et r", - "e tr", - "▁K u", - "ic ted", - "ict ed", - "i cted", - "▁fab ric", - "▁A SC", - "▁AS C", - "▁ ASC", - "▁Entertain ment", - "▁en erg", - "▁ener g", - "кла д", - "к лад", - "om on", - "omo n", - "o mon", - "th eme", - "the me", - "▁ха рак", - "▁d raft", - "▁dr aft", - "▁dra ft", - "▁ch annels", - "▁channel s", - "▁de sert", - "▁des ert", - "▁deser t", - "▁tra vés", - "▁trav és", - "▁L ock", - "▁Lo ck", - "▁Loc k", - "▁ Lock", - "▁s iendo", - "▁si endo", - "фе к", - "ф ек", - "m ême", - "▁pa cket", - "▁pack et", - "▁pac ket", - "▁Mount ain", - "▁F ahr", - "▁Fa hr", - "bra io", - "пе ре", - "пер е", - "п ере", - "▁gen annt", - "▁dep loyment", - "▁deploy ment", - "Pa l", - "P al", - "но г", - "ст ру", - "стр у", - "Pr im", - "P rim", - "f ür", - "▁danger ous", - "▁sz ám", - "re ck", - "rec k", - "▁pop up", - "ic ky", - "ick y", - "in ar", - "ina r", - "i nar", - "co wo", - "cow o", - "c owo", - "нци кло", - "ít ás", - "▁pl ugins", - "▁plugin s", - "▁plug ins", - "▁ plugins", - "▁dr iven", - "▁drive n", - "▁dri ven", - "▁driv en", - "ле в", - "л ев", - "▁\" (", - "tt a", - "t ta", - "▁ Ú", - "▁e b", - "▁ eb", - "▁' ';", - "▁'' ;", - "▁kn ock", - "▁ос нова", - "▁основ а", - "▁m aison", - "▁ma ison", - "▁mais on", - "▁mai son", - "г ля", - "▁Hon or", - "▁Ho nor", - "ta il", - "t ail", - "ri tz", - "rit z", - "r itz", - "▁gu ys", - "▁combin ations", - "▁combination s", - "ond ere", - "onder e", - "onde re", - "▁A ld", - "▁Al d", - "▁f iddle", - "▁ fiddle", - "да в", - "ur d", - "u rd", - "▁pro jection", - "▁project ion", - "▁Tamb ién", - "ve rb", - "ver b", - "v erb", - "▁ter re", - "▁ terre", - "ru gu", - "rug u", - "▁se ptember", - "▁sept ember", - "▁< !", - "co st", - "cos t", + "thics▁Committee /In", + "▁alw ays▁", + "▁nec itumumab", + "ate▁s ynth", + "rosatell it", + "▁Japanese▁sit es▁only", + "▁conventional ▁techniqu", + "ABLE ▁OF▁CONTENTS", + "underst ood", + "physical▁ exam", + "ologically▁or▁cyt ologically▁", + "atern al▁expos", + "▁conjunction ▁with", + "▁Derivation▁or▁calculation▁of▁outcome▁variable ......................................................", + "ynomolg us▁", + "▁the▁purpos es▁of", + "▁(32 )\n\nGEL▁Version▁ID:▁ONC.000−214−771.5.0▁Approved▁by\n\nApproved\n\nDate▁Printed:▁31−Jul−2014", + "intil es▁", + ",▁2008; ▁Page▁", + "unning ham", + "e,▁albumin, ▁total▁protein", + "& E", + "( G", + ") -", + ") .▁All", + ", ▁any▁", + "0 ;", + "0 .22", + "2 nd▁", + "4 00", + ": ▁P", + "A *", + "A FETY", + "B lind", + "E AS", + "O W", + "P LS", + "S E", + "S ection", + "U RA", + "a ▁M", + "a ▁H", + "b lind▁", + "b roken", + "e ak", + "e utropenia", + "f ood▁", + "i e,", + "m al", + "m as", + "p ing", + "s ec", + "s .▁An", + "x y", + "▁ op", + "▁ zoledronic▁acid", + "▁ ......................................................................................................", + "in d▁", + "in ▁subjects▁with", + "at in", + "at eness▁of", + "en u", + "en z", + "er r", + "or ▁un", + "s▁ 3", + "s▁ J", + "re cord▁", + "re strict", + "al ian", + "▁the▁ C", + "▁the▁ appearance▁of", + "ic ient", + "▁p ill", + "▁c over", + "ing ful", + "▁b ottl", + "▁to ▁d", + "▁to ▁8", + "is ch", + "▁s or", + "▁s urviv", + "▁m ut", + "▁m anner", + "▁and▁ 6", + "▁and▁ patient", + "om as▁", + "al▁ event", + "al▁ 5-FU", + "el a", + "el eg", + "ol it", + "▁A ST", + "▁A mended▁", + "iv ely", + "▁in ▁your", + "▁in spection", + "ur e▁d", + "oc ardiogram", + "ac cess", + "ac count", + "▁P age:", + "▁P latelet", + "���( V", + "▁( per", + "▁( AE", + "▁( HR", + "▁( ITT)", + "us ed,▁", + "ra mont", + "▁S J", + "▁S cor", + "▁S ▁T▁I", + "▁S chema", + "▁D ays", + "with ▁placebo", + "▁or ▁your", + "▁or ▁discomfort", + "e▁t arget", + "ut ure", + "end el", + "▁n ode▁", + "per ▁protocol", + "oll ection▁of", + "▁as pir", + "▁pro portional▁hazard", + "▁ad dendum", + "eas on", + "▁N orth", + "will▁be▁ administer", + "com pared", + "▁R E", + "▁treatment \n\n", + "study \n\n", + ".1 9", + "av oid", + "▁200 9", + "▁is▁ provid", + "▁of▁ un", + "▁of▁ every▁", + "▁will▁be▁ defined▁as", + "e▁s can", + "e▁th rough", + "▁M 0", + "cont ra", + "e,▁ which", + ".▁A s▁", + ".▁A pproximately▁", + "▁the▁s pecific", + "▁the▁s econd", + "ly▁ for", + ".3 1", + "▁B ID", + "▁all ▁subsequent", + "ary▁ for", + "▁st age▁", + "▁st erile▁", + "▁will \n\n", + "▁will ▁sign", + "▁will ▁compensate▁you", + "ing▁the▁ following", + "▁4 .2", + ")\n\n \n\n", + "continu e▁to", + "ident ify▁", + "ire ction", + "ens it", + "cons ecutive▁", + "▁ex isting", + "▁ex amine▁", + "▁wh ol", + "med ically▁", + "e▁d imension", + ".▁S ubsequent", + ".▁S ee▁Section", + "ob last", + "10 5", + "▁the▁d ate▁", + "ang ina", + "▁have▁ access▁to", + "AE s)", + ".▁P lease▁", + "\n\nE valu", + "▁In dependent", + "▁In clusion▁Criteria", + "evalu ated▁in", + "▁is ▁available▁", + ",▁the▁ study▁", + "▁adverse▁event s▁and▁", + "s) ▁with", + "▁10 .2", + "▁10 .2.1", + "▁to▁the▁ study", + ".▁E lig", + "▁assessment ▁of▁the▁", + "▁ph otograph", + "RA F", + "RI ABLES", + "▁ab solut", + "patient ’s▁", + "s▁s h", + "cal culation", + ").\n\n 6", + "▁lesion s,▁", + "ass um", + "des cript", + "▁the▁study .▁The▁", + "▁cycl e▁(", + "e, ▁as▁", + "................................................................................................ ...▁", + "sh all", + "\n\nY es", + ".▁D is", + ".▁D iscontinu", + "complet ely▁", + "\n\nThe▁ subject", + "\n\n4 .7", + "▁cons istent", + "uc ci", + ".\n\nP emetrexed▁H3E-MC-JMHO(b)▁Confidential\n\nProtocol▁Amendment\n\nPage▁", + "s▁that ▁occur", + "s▁that ▁are▁not", + "result s▁", + "▁Clinical▁ Trial", + "fl ush", + "equ al", + "level ▁of", + "using ▁an", + "▁the▁study▁ sit", + "▁over dose▁", + "SA ID", + "until ▁toxicity▁", + ".▁200 1;", + "enroll ed▁into", + "ed.\n\n 7", + ",▁P h", + "▁sub mitt", + "▁CT /MRI", + "▁if ▁I", + ".▁B linded▁", + "ed▁s ince▁the▁treatment▁start", + "▁provid ed▁", + "▁response▁ are▁first▁met", + "▁the▁tim e▁to", + "atist ical", + "s▁b efore▁the▁", + ",▁M or", + "▁dis cover", + "▁sh rink", + ".▁H ealth", + "▁study▁treatment ▁or", + "▁study▁treatment ▁visit", + "▁study▁treatment ▁administration", + "▁must ▁have▁a", + "ed▁on▁the▁ CRF", + "ext rem", + "clinical▁ outcom", + ".\n\nThe▁ following", + "obtain ed▁from", + "▁ne uroto", + "▁effect ive▁", + "ed▁by▁the▁ Investigator", + "▁tot al▁of", + "▁this▁study▁ is▁", + "Com mitte", + "\n\n5 \n\n6", + "▁no ▁more▁than", + "\n\nAppendix ▁A", + "▁the▁sam e▁techniqu", + "IC S", + "\n\nK▁C▁E▁H▁C \n\nE▁S▁A▁E▁L▁P", + "Cancer ▁Research", + "growth ▁of", + "▁coll ection▁of", + "fic ial", + "▁two ▁week", + "questionna ires", + "ability /", + "ability ,▁", + "▁bone▁ resorption", + "at▁least ▁one▁", + "▁cl ar", + "1,▁ 2", + "▁hav ing", + "pectiv ely", + "▁and▁s urvival", + "▁phase▁ 2", + "▁cor responding", + "▁the▁following :", + "aw son-", + "\n\nth at", + "monitor ed▁", + "e▁f acil", + "▁dat abase▁", + ",▁199 9", + "▁those▁ who", + "ability▁ for", + "ee▁ J", + "▁valu e▁", + "\n\nPro perty▁of▁the▁sanofi-aventis▁group▁-▁strictly▁confidential▁WW-CLIN-PR007-SD-03▁VERSION▁n°02▁(19-DEC-2005)\n\nPage▁", + "e.g .", + "app en", + "8480 C000", + "Ph armacokinetic", + "▁app etit", + "▁conf id", + "▁25 (OH)D", + "▁ident ification▁number", + "s▁were▁ not", + "ecom mended▁", + "AR Y", + "▁protein uria", + "performed ▁after", + "treat ed▁", + "▁experienc ed▁", + "addition ▁of▁panitumumab", + "need l", + "▁different ial", + "▁different ial▁", + "de hydrogen", + "▁onc e▁daily▁", + ".▁On ly▁", + "▁guidelin es▁(", + "▁involv ement", + "\n\nSt atistical▁", + ".▁Con tinu", + "-in duced▁", + "outlin ed▁in▁Section", + "▁SD ▁PD", + "▁qual ity▁of▁lif", + "benefit s▁of", + "▁necess arily▁", + "ood ▁and▁Drug", + "▁version ▁of▁the▁", + "confidential▁ information", + "▁AD T", + "▁present ation", + "▁del ay▁", + "▁predict or", + "▁ask ed▁to", + "agnesium ,▁creatinin", + "remov ed▁from▁the▁", + "ergic ▁reaction", + "▁error s▁(", + "ret rospective▁", + "ominal ▁significance▁level", + "initi ation", + "e▁dis order", + "local▁ regulation", + "e▁to▁receive▁ the▁", + "response▁rate▁ (ORR", + "kept ▁in", + "▁partial▁ respons", + ",▁St ampfer▁MJ", + "Rec ord", + "um▁of▁the▁ longest▁diameter", + "▁as▁describ ed▁in▁Section", + "▁program m", + "respir atory▁", + "\n\nRes ult", + "ochem ical▁", + "Man ager", + "▁stable▁ disease▁", + "\n\nA▁ ®\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:", + "itl e:", + "uroQol -5▁Dimension", + "traven ous▁", + "▁legally▁acceptable▁ representativ", + ",▁however ,▁", + "▁monoclonal ▁antibody▁", + "\n\n100 %", + "standard▁of ▁car", + ".\n\nCONFIDENTIAL \n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁PANITUMUMAB▁(AMG▁954)▁Protocol▁Number:▁20040249▁Date:▁07▁August▁2007\n\nPage▁", + "Document ation", + "display ed▁graph", + "▁rang e▁of", + ",▁24 ,▁", + "anine▁ aminotransferase▁(", + "▁the▁subset ▁of▁subject", + "ATOR Y", + "▁abdominal ▁pain", + "wallow ing", + "amend ment", + "Ha enszel", + "partate▁ aminotransferase▁(", + "inorel bine▁", + "e▁turnover ▁marker", + "ultiv ari", + "flow ▁chart", + "▁the▁dur ation▁of▁the▁study", + "neopl astic", + "asse▁et▁al .▁2000", + "\n\nPRI NT", + "(cid:131)▁ You", + "eptomening eal", + "ically▁documented▁ PD", + "▁ANALY SIS", + "▁congenital▁anom aly", + "WBDC ▁system", + "(34)\n\nGEL▁Version▁ID:▁ONC.000−127−200.3.0\n\nApproved\n\nDate▁Printed:▁31−Jul−2014 \n\nApproved▁by\n\n21▁Dec▁2004▁10:21:22", + "’Brien-F leming", + "▁Heart▁Ass ociation", + "icardial▁ effusion", + "olun teer", + "antel- Haenszel", + "\n\nDate1 \n\nPRINT", + "awson- Hugh", + "addition▁of▁panitumumab ▁to", + ", ▁the▁subject", + "- 17", + ". C", + "1 .2", + "2 /", + "6 )▁(cid:", + "7 0%", + "8 ]", + "C linical", + "G T", + "G loss", + "I )", + "R isk", + "U .S", + "V oice▁", + "Z oledronic", + "b reast▁cancer", "c ost", - "▁n ut", - "▁nu t", - "▁ nut", - "{ %", - "▁ub ic", - "am arin", - "ama rin", - "amar in", - "ти и", - "▁pat ron", - "▁patr on", - "▁am ely", - "▁e sto", - "▁est o", - "▁es to", - "▁ esto", - "▁li stop", - "▁list op", - "fa l", - "f al", - "▁P rop", - "▁Pro p", - "▁Pr op", - "▁ Prop", - "▁O nt", - "▁On t", - "▁M ade", - "▁Ma de", - "▁Mad e", - "TE ST", - "▁N em", - "▁Ne m", - "▁N ations", - "▁Nat ions", - "▁Nation s", - "▁в у", - "▁ ву", - "in cluding", - "includ ing", - "▁spect rum", - "▁L an", - "▁La n", - "▁E ver", - "▁Ev er", - "Pa ul", - "t m", - "App end", - "Ap pend", - "Rel ative", - "dis abled", - "disable d", - "return s", - "▁flow ers", - "▁flo wers", - "▁flower s", - "ik u", - "i ku", - "▁| \\", - "▁ |\\", - "▁Jord an", - "▁Sm all", - "▁c ic", - "▁ci c", - "▁sex ual", - "au tre", - "aut re", - "ва л", - "в ал", - "▁r ip", - "▁ri p", - "▁ rip", - "ou st", - "ous t", - "o ust", - "▁Philadel phia", - "▁u k", - "▁ uk", - "▁M ongo", - "▁Mon go", - "▁Mong o", - "xml ns", - "▁sh op", - "▁sho p", - "▁ shop", - "▁debug ger", - "▁z aj", - "▁za j", - "▁B illy", - "▁Bill y", - "▁Bil ly", - "▁n iem", - "▁nie m", - "▁ni em", - "ol is", - "oli s", - "o lis", - "▁ро ссий", - "ag ner", - "agn er", - "agne r", - "▁m aven", - "▁ma ven", - "▁ maven", - "▁Gu stav", - "▁Gust av", - "A us", - "comp are", - "▁j eu", - "▁je u", - "ud er", - "ude r", - "u der", - "ish ment", - "▁ди визи", - "▁Fin land", - "ну т", - "н ут", - "z és", - "▁Liga ções", - "▁Lig ações", - "▁qu ello", - "▁quel lo", - "an notation", - "annot ation", - "▁th rew", - "▁thr ew", - "▁thre w", - "▁Pro of", - "▁ Proof", - "▁A rea", - "▁Ar ea", - "▁Are a", - "▁ Area", - "as hi", - "ash i", - "▁F O", - "▁ FO", - "ja min", - "j amin", - "ден т", - "д ент", - "▁un us", - "fri end", - ".\" );", - ".\") ;", - ". \");", - "▁tra kten", - "document class", - "an ka", - "ank a", - "▁ar rive", - "▁arr ive", - "▁arriv e", - "▁d onne", - "▁don ne", - "▁donn e", - "ol y", - "o ly", - "▁R ein", - "▁Re in", - "▁face book", - "▁fac ebook", - "▁ facebook", - "ic ina", - "ici na", - "sl ice", - "s lice", - "▁n agy", - "▁na gy", - "▁nag y", - "▁he bben", - "▁I C", - "▁ IC", - "▁B ag", - "▁Ba g", - "▁ Bag", - "▁circ ul", - "▁cir cul", - "ác t", - "á ct", - "mit t", - "mi tt", - "m itt", - "▁g rey", - "▁gr ey", - "▁gre y", - "▁c av", - "▁ca v", - "▁осо би", - "▁sym metric", - "▁symmet ric", - "▁S ic", - "▁Si c", - "▁med ium", - "▁medi um", - "▁ medium", - "▁U TF", - "▁ UTF", - "▁D opo", - "▁Do po", - "í ch", - "bar e", - "ba re", - "b are", - "dz ie", - "d zie", - "▁he aven", - "▁heav en", - "▁cam pe", - "▁camp e", - "ester day", - "esterd ay", - "▁W issenschaft", - "по ль", - "пол ь", - "di d", - "d id", - "al er", - "ale r", - "a ler", - "▁citiz ens", - "▁Marg aret", - "▁s ought", - "ch arts", - "char ts", - "chart s", - "CL C", - "C LC", - "ol ly", - "oll y", - "ys z", - "y sz", - "wa ld", - "wal d", - "w ald", - "▁f en", - "▁fe n", - "▁ fen", - "▁S ix", - "▁Si x", - "▁U rs", - "▁Ur s", - "▁ор ган", - "▁T rad", - "▁Tr ad", - "▁Tra d", - "cu e", - "c ue", - "sch utz", - "▁prec ise", - "▁precis e", - "▁W indow", - "▁Wind ow", - "▁ Window", - "ти е", - "ло ві", - "лов і", - "it ori", - "ito ri", - "itor i", - "dis ambiguation", - "▁х и", - "▁ хи", - "▁N atural", - "▁Natur al", - "▁Nat ural", - "da n", - "d an", - "▁con crete", - "ци ја", - "▁s pel", - "▁sp el", - "▁spe l", - "▁Fa iled", - "▁Fail ed", - "▁ Failed", - "ści e", - "śc ie", - "ś cie", - "▁b uf", - "▁bu f", - "▁ buf", - "uc a", - "u ca", - "ic ional", - "ici onal", - "icio nal", - "icion al", - "▁ott obre", - "▁otto bre", - "▁ф і", - "▁ фі", - "▁submit ted", - "▁subm itted", - "la ve", - "lav e", - "l ave", - "▁P lot", - "▁Pl ot", - "▁ Plot", - "▁col leg", - "▁coll eg", - "▁colle g", - "ad em", - "ade m", - "a dem", - "▁ch aque", - "▁cha que", - "▁neighbor hood", - "▁calci atore", - "Lo op", - "L oop", - "▁G ast", - "▁Ga st", - "▁Gas t", - "▁ко гда", - "▁indust rial", - "▁industri al", - "▁f atal", - "▁fa tal", - "▁fat al", - "▁C ert", - "▁Ce rt", - "▁Cer t", - "▁ Cert", - "la tion", - "lat ion", - "l ation", - "▁О дна", - "▁Од на", - "▁jam ais", - "▁acc um", - "Id entity", - "Ident ity", - "▁Me dal", - "▁Med al", - "Met adata", - "Meta data", - "▁лю дя", - "br idge", - "brid ge", - "b ridge", - "Go od", - "G ood", - "▁что бы", - "▁comp oser", - "▁compos er", - "▁compose r", - "▁b read", - "▁br ead", - "▁bre ad", - "▁clos ure", - "▁ closure", - "▁large ly", - "▁larg ely", - "F B", - "▁обла сть", - "▁autom atic", - "▁automat ic", - "ar ía", - "a ría", - "▁sufficient ly", - "▁ital iana", - "▁ка че", - "▁J ó", - "hi story", - "histor y", - "h istory", - "▁H D", - "▁ HD", - "▁sigu iente", - "ne ll", - "nel l", - "n ell", - "▁G ree", - "▁Gr ee", - "▁Gre e", - "▁T i", - "▁trans ferred", - "▁transfer red", - "équ ipe", - "é quipe", - "▁Phili ppe", - "▁Philipp e", - "▁Philip pe", - "▁encou rag", - "▁V ietnam", - "▁graph s", - "▁symmet ry", - "fr ed", - "fre d", - "f red", - "we ek", - "▁bron ze", - "ry s", - "r ys", - "▁name ly", - "▁nam ely", - "on ders", - "ond ers", - "onder s", - "onde rs", - "lem agne", - "X Y", - "Con vert", - "}] (", - "} ](", - "Reg ion", - "pe cies", - "pec ies", - "▁te xture", - "▁text ure", - "▁c hr", - "▁ch r", - "▁ chr", - "не го", - "н его", - "▁some body", - "a qu", - "er as", - "era s", - "e ras", - "▁Н ово", - "▁Но во", - "▁Нов о", - "▁d ez", - "▁de z", - "an iu", - "ani u", - "a niu", - "ok rat", - "▁co vers", - "▁cover s", - "▁cov ers", - "▁sign als", - "▁signal s", - "ђ е", - "▁H eb", - "▁He b", - "▁An ti", - "▁Ant i", - "IV E", - "I VE", - "▁re ss", - "▁r ess", - "▁res s", - "▁ ress", - "LE TE", - "yn a", - "y na", - "п ла", - "жде ния", - "ж дения", - "▁ch amp", - "▁cha mp", - "▁cham p", - "▁vill ages", - "▁village s", - "▁villa ges", - "Z one", - "▁i Phone", - "▁sou vent", - "сь кі", - "ськ і", - "▁feb braio", - "ér cito", - "▁X I", - "ok at", - "oka t", - "▁mem bres", - "▁memb res", - "▁membre s", - "ju nit", - "j unit", - "▁D raw", - "▁Dr aw", - "▁Dra w", - "▁ Draw", - "▁п рово", - "▁про во", - "▁пров о", - "▁пр ово", - "aud io", - "audi o", - "a udio", - "en dl", - "end l", - "▁N ad", - "▁Na d", - "▁magn itude", - "Su r", - "S ur", - "ic ing", - "ici ng", - "i cing", - "▁un w", - "▁о три", - "▁от ри", - "▁B ey", - "▁Be y", - "▁V ik", - "▁Vi k", - "▁polít ica", - "port er", - "por ter", - "porte r", - "p orter", - "▁Bar bara", - "▁Barb ara", - "ál t", - "á lt", - "bi b", - "b ib", - "▁accom pan", - "▁accomp an", - "V P", - "▁en coded", - "▁enc oded", - "▁encode d", - "▁ encoded", - "▁S ometimes", - "▁Some times", - "bi rd", - "bir d", - "b ird", - "▁U lt", - "▁Ul t", - "▁t un", - "▁tu n", - "get Text", - "▁ar rival", - "▁arr ival", - "▁arriv al", - "script style", - "{ `", - "▁pers pective", - "LI NE", - "LIN E", - "L INE", - "Form atter", - "Format ter", - "▁b om", - "▁bo m", - "в ра", - "DE BUG", - "Bound s", - "B ounds", - "▁T itle", - "▁Tit le", - "▁ Title", - "l ó", - "Da n", - "D an", - "▁g ene", - "▁ge ne", - "▁gen e", - "▁B it", - "▁Bi t", - "▁ Bit", - "▁reprodu ce", - "▁graph ics", - "▁ graphics", - "▁с ем", - "▁се м", - "р ё", - "▁ре ки", - "us alem", - "usa lem", - "ро ж", - "▁D ES", - "▁DE S", - "▁So ftware", - "ur ance", - "u rance", - "ithmet ic", - "en ess", - "ene ss", - "enes s", - "e ness", - "ic hi", - "ich i", - "i chi", - "Con verter", - "Convert er", - "▁g ithub", - "▁ github", - "erd ings", - "gl ise", - "ác h", - "á ch", - "▁bu ried", - "▁bur ied", - "▁v ision", - "▁vis ion", - "▁ vision", - "M iss", - "▁s ees", - "▁se es", - "▁see s", - "▁person nes", - "▁pers onnes", - "▁personn es", - "▁personne s", - "▁In tel", - "▁Int el", - "el ia", - "eli a", - "e lia", - "▁č lán", - "▁c hi", - "▁ch i", - "▁ chi", - "▁k las", - "▁kl as", - "au té", - "aut é", - "▁st ark", - "▁star k", - "cz e", - "c ze", - "▁dr ivers", - "▁driver s", - "▁drive rs", - "▁dri vers", - "▁driv ers", - "v n", - "! ,", - "▁го ды", - "▁год ы", - "H i", - "▁expla ins", - "▁expl ains", - "▁explain s", - "art icles", - "article s", - "▁z ug", - "▁zu g", - "▁ zug", - "Pro m", - "Pr om", - "P rom", - "> =", - "▁Be at", - "▁S ax", - "▁Sa x", - "vert ical", - "кт о", - "к то", - "▁pl ants", - "▁plan ts", - "▁plant s", - "▁Ré férences", - "▁Référence s", - "▁og ni", - "▁c urs", - "▁cu rs", - "▁cur s", - "▁S K", - "▁ SK", - "он и", - "о ни", - "▁des tac", - "▁dest ac", - "\") ;\r", - "\"); \r", - "\" );\r", - "▁S ure", - "▁Su re", - "▁Sur e", - "▁part ido", - "▁parti do", - "▁Fol ge", - "▁Mo ore", - "▁w z", - "ск ус", - "ску с", - "lt re", - "l tre", - "on do", - "ond o", - "▁p ose", - "▁po se", - "▁pos e", - "▁ pose", - "im os", - "imo s", - "i mos", - "бо й", - "ци па", - "ju s", - "j us", - ".. ...", - "... ..", - ".... .", - ". ....", - "▁ép oca", - "▁qu anto", - "▁quant o", - "▁quan to", - "▁Su pport", - "▁Supp ort", - "▁Sup port", - "▁ Support", - "gesch ichte", - "SER VER", - "▁George s", - "▁Georg es", - "en um", - "enu m", - "e num", - "▁h erm", - "▁he rm", - "▁her m", - "▁ne bo", - "▁C hr", - "▁Ch r", - "▁ Chr", - "char acter", - "▁* **", - "▁** *", - "▁ ***", - "▁For sch", - "ia mi", - "iam i", - "i ami", - "▁ ¿", - "cy ch", - "cyc h", - "c ych", - "▁fif th", - "se nt", - "sen t", - "s ent", - "▁and erem", - "▁andere m", - "▁proport ion", - "▁propor tion", - "▁p rest", - "▁pr est", - "▁pre st", - "▁pres t", - "▁G irl", - "▁Gi rl", - "▁Gir l", - "▁d rama", - "▁dr ama", - "▁dra ma", - "▁dram a", - "wa nd", - "wan d", - "w and", - "▁M ail", - "▁Ma il", - "▁Mai l", - "▁ Mail", - "▁L ux", - "▁Lu x", - "▁kter ý", - "▁Ges ellschaft", - "▁Hin weis", - "nis se", - "n isse", - "▁m ondo", - "▁mon do", - "▁mond o", - "E q", - "▁per í", - "▁pe rí", - "▁e astern", - "▁eas tern", - "▁east ern", - "▁UE FA", - "ual e", - "ua le", - "u ale", - "▁con vex", - "▁conv ex", - "▁по ль", - "▁пол ь", - "▁ поль", - "▁H ey", - "▁He y", - "ze nie", - "zen ie", - "z enie", - "init ely", - "▁Z usammen", - "SS L", - "S SL", - "oc al", - "oca l", - "o cal", - "▁c anal", - "▁can al", - "▁ca nal", - "vo y", - "v oy", - "▁К ри", - "▁köz ött", - "▁c ars", - "▁car s", - "▁ca rs", - "▁vers ión", - "En vironment", - "He r", - "H er", - "▁se ñ", - "▁sp atial", - "ym i", - "y mi", - "Fi re", - "F ire", - "▁ve get", - "▁veg et", - "▁W ie", - "▁Wi e", - "▁zn aj", - "▁zna j", - "▁dam age", - "▁en dl", - "▁end l", - "▁ endl", - "gi f", - "g if", - "▁qu ali", - "▁qual i", - "▁которы х", - "el lan", - "ell an", - "ella n", - "▁m ens", - "▁me ns", - "▁men s", - "▁pl ug", - "▁a bund", - "▁ab und", - "FI G", - "F IG", - "▁s f", - "▁ sf", - "▁con fl", - "▁conf l", - "▁насе ления", - "▁princi ples", - "▁princip les", - "▁principle s", - "▁Gab riel", - "ib e", - "i be", - "▁{ %", - "▁ {%", - "▁pobla ció", - "ні ципа", - "▁ext reme", - "▁extrem e", - "▁extr eme", - "▁as se", - "▁ass e", - "▁ asse", - "▁v u", - "▁ vu", - "Mo ck", - "M ock", - "▁spiel te", - "▁A er", - "▁d atos", - "▁dat os", - "en des", - "end es", - "ende s", - "▁G el", - "▁Ge l", - "▁G or", - "▁Go r", - "Ch rist", - "Chr ist", - "ch os", - "cho s", - "c hos", - "Process or", - "Proc essor", - "▁in struct", - "▁inst ruct", - "▁instru ct", - "▁p icked", - "▁pick ed", - "▁pic ked", - "nah me", - "nahm e", - "fa hr", - "fah r", - "f ahr", - "▁indic ated", - "▁indicate d", - "▁% .", - "▁ %.", - "▁t s", - "▁ ts", - "▁not able", - "▁no table", - "▁qual ified", - "▁А л", - "Bl ack", - "B lack", - "▁coun cil", - "▁over head", - "ac i", - "a ci", - "an née", - "ann ée", - "▁init With", - "bi ó", - "b ió", - "▁int roduction", - "▁introdu ction", - "▁compan ion", - "▁ex pon", - "▁exp on", - "▁k ör", - "▁kö r", - "ob y", - "o by", - "bu rn", - "bur n", - "b urn", - "gn u", - "g nu", - "virt ual", - "v irtual", - "▁intel lect", - "▁д ержа", - "▁ держа", - "' +", - "б ле", - "▁strict ly", - "▁recogn ize", - "ho ur", - "hou r", - "h our", - "▁W rest", - "en nen", - "enn en", - "enne n", - "$) .", - "$ ).", - "ff f", - "f ff", - "▁Cent ro", - "▁P itt", - "▁Pi tt", - "▁Pit t", - "▁d ział", - "▁dz iał", - "▁ dział", - "▁c ela", - "▁ce la", - "▁cel a", - "▁frances e", - "▁franc ese", - "ра ми", - "spe cial", - "spec ial", - "▁D up", - "▁Du p", - "to ire", - "t oire", - "ка ль", - "кал ь", - "к аль", - "CO UNT", - "▁Br ook", - "▁Bro ok", - "▁ру ково", - "pub lique", - "▁se conda", - "▁second a", - "▁sec onda", - "▁com pt", - "▁comp t", - "▁b land", - "▁bl and", - "▁bla nd", - "▁blan d", - "Be fore", - "▁P ack", - "▁Pa ck", - "▁Pac k", - "▁ Pack", - "al ty", - "alt y", - "öd er", - "ö der", - "▁interval s", - "▁Daten bank", - "Mo vie", - "M ovie", - "▁trans m", - "▁tran sm", - "▁t ap", - "▁ta p", - "▁по ч", - "fo n", - "f on", - "ia i", - "i ai", - "▁f ib", - "▁fi b", - "▁w yd", - "▁wy d", - "▁h ung", - "▁hun g", - "▁hu ng", - "▁ hung", - "▁a live", - "▁al ive", - "▁ali ve", - "Cl ear", - "C lear", - "▁p ushed", - "▁push ed", - "▁tu ple", - "▁ tuple", - "ach en", - "ac hen", - "ache n", - "a chen", - "го во", - "гов о", - "г ово", - "▁re vers", - "▁rev ers", - "▁reve rs", - "▁rever s", - "▁au gment", - "▁aug ment", - "▁ch allenge", - "▁challeng e", - "lo st", - "los t", - "l ost", - "▁deux ième", - "struct or", - "stru ctor", - "▁mehr erer", - "▁mehrere r", - "at ural", - "atur al", - "atura l", - "atu ral", - "Sp lit", - "S plit", - "ст ем", - "сте м", - "с тем", - "ш ла", - ")\\ \\", - ") \\\\", - "▁D og", - "▁Do g", - "▁develop ers", - "▁developer s", - "▁ developers", - "▁n od", - "▁no d", - "▁сто ро", - "▁Na N", - "▁ NaN", - "▁pr iest", - "▁pri est", - "▁ex ha", - "UN D", - "U ND", - "pa ir", - "p air", - "al one", - "alo ne", - "▁m oon", - "▁mo on", - "▁# !/", - "▁g uns", - "▁gu ns", - "▁gun s", - "ro la", - "rol a", - "r ola", - "чи та", - "▁Encyc lopedia", - "▁Encyclop edia", - "at is", - "ati s", - "a tis", - "▁' \"", - "▁ '\"", - "zy ch", - "z ych", - "▁super fic", - "▁э к", - "еде ра", - "fe ed", - "f eed", - "LA Y", - "F i", - "un ks", - "unk s", - "ise cond", - "i second", - "▁' @", - "▁Ad ding", - "▁Add ing", - "ро е", - "▁t ang", - "▁tan g", - "▁ta ng", - "ц о", - "hu ng", - "h ung", - "bi s", - "b is", - "sk ého", - "ské ho", - "▁ad vert", - "▁adv ert", - "▁за нима", - "uz z", - "u zz", - "ág ina", - "▁T el", - "▁Te l", - "si g", - "s ig", - "▁E z", - "▁guarante e", - "▁te aching", - "▁teach ing", - "ot y", - "o ty", + "d ensity", + "e .▁E", + "e uk", + "e osinophil", + "f arin", + "g ly", + "i ov", + "n ight", + "n ominated▁", + "o es▁not", + "p ast", + "r hythm", + "s un", + "s .▁All", + "s ome▁", + "s heet", + "u er", + "w ays", + "▁ ", + "▁ ed", + "▁ etoposide▁", + "e▁ versus▁", + "e▁ pain", + "in ct", + "in clusion", + "at es▁of", + "at ures", + "at ▁the▁discretion▁of▁the▁investigator", + "\n\n ECOG", + "▁a ▁r", + "or ex", + "s▁ L", + "s▁ receiv", + "s▁ develop", + "st henia", + "y▁ K", + ",▁ g", + ",▁ of", + ",▁ when", + ",▁ platelet▁count", + "ed▁ while▁on", + ".▁ 18", + "ed ,▁a", + "▁p en", + "▁p ancreatic▁cancer", + "▁c irculating", + "▁c astration", + "ing ▁all", + "▁s ent", + "▁s elf-", + "▁of ▁D", + "um ulative▁", + "▁d one▁", + "▁w e▁", + "▁m agnetic▁resonance▁imaging", + "▁m arket", + "▁and▁ cisplatin", + "▁and▁ secondary▁", + "om ission", + ".\n\n 23", + "al▁ A", + "ab et", + "▁A merican▁BioScience,▁Inc", + "▁in stitutional▁", + "▁in ▁Patients▁with", + "im port", + "ur ▁J▁Cancer", + "oc cas", + "▁C RI", + "▁( the▁", + "us eful", + "▁S G", + "▁re flect", + "un ding", + "un equivoc", + "▁D H", + "▁D M", + "▁D ocument", + "▁D 5W", + "cl ot", + "ri ef", + "▁h eight", + "▁l at", + "▁l ess▁", + "e▁of ▁administration", + "▁E PA+DHA", + "▁f e", + "ch ain", + "▁or ▁carboplatin", + "\n\nP l", + "\n\nP ain", + "od d", + "\n\nA fter", + "▁and ▁their", + "▁pro gressive▁", + "▁pro phylax", + "▁for ▁their", + "▁treatment ▁or", + "▁treatment -related▁", + "enc ies", + ".2 4", + "av is▁", + "ad ic", + "▁of▁ vitamin▁D", + "▁r ▁", + "▁r ac", + "▁r ating", + "▁3 2", + "▁3 4", + "▁3 .4.1", + "▁of▁the▁ data", + "e,▁ with", + ".▁The▁ first", + ".▁The▁ subject", + ".▁The▁ median", + "▁on e-", + ",▁and▁ 3", + "ee z", + "▁v ir", + "ly▁ with", + ".3 6", + "▁B linded▁", + "▁res ist", + "▁res ection", + "▁will ▁allow", + "e▁in ▁patients▁with", + "e▁in dividual", + "olog y▁of", + "▁5 6", + "▁5 .6", + "▁6 .6", + "▁6 0%", + "and▁ cisplatin", + "▁4 1", + "▁4 7", + "▁4 .4", + "▁the▁p otential", + "s▁( e.g.,▁", + "▁the▁in vestig", + ".4 5", + "▁study▁ procedures", + "▁study▁ participant", + ".5 2", + "▁ex act", + "▁the▁t rue▁", + "\n\nD ay▁1", + "eth ical", + "eth nic", + "e▁d efinition", + ".▁S it", + "ob struction", + "10 )", + "ies▁ must▁be▁", + "▁G 4PFS", + "ely▁ disabl", + "▁J E", + "s\n\n (cid:120)", + "▁7 .2", + "▁dos e,▁", + "e- related▁", + "▁ass ays", + "afety▁ data", + ".6 .6", + "s.\n\n 9", + "s.\n\n In", + "s.\n\n With:", + ",▁and ▁a", + "▁ab s", + ".▁T RIAL", + "e.\n\n 9", + "patient ▁is▁", + ".,▁ S", + "\n\nN am", + "pre caution", + "30 %", + "▁X P", + "\n\nR adi", + "NC E", + "▁Ad ditional▁", + "▁pre m", + "ence▁ or", + "▁a▁s imilar", + "ating ▁to", + "ification s▁for", + ".\n\nA \n\n®\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁Panitumumab▁Protocol▁Number:▁20050251▁Date:▁10▁October▁2006\n\nPage▁", + "\n\n4 .2", + "\n\n4 .2.1", + "le ep", + "\n\nI t", + ")▁ ", + "▁infusion ▁reaction", + "firm ation", + ".▁R adi", + "you ▁have▁", + "receiv ed", + "ann ucci", + ".▁200 8", + "JM HR", + "\n\nH ealth", + "▁discontinu es▁", + ",▁P er", + "randomiz ed▁trial", + "St andard", + "stat ement", + "▁sub set", + "outcom es▁(PRO", + "cancer .gov/", + "ild -", + ",\n\n and▁", + ".8 5", + "collect ed▁from", + "16 )(cid:", + "s▁b ut", + "elect rolyt", + "▁drug ▁delivery▁system", + "▁through ▁the▁", + "▁must ▁have▁", + ",▁C A", + "▁rel ation▁to", + "▁blood▁ collection", + "▁result ▁from", + ",▁b evacizumab", + "IN R", + "ext ros", + "▁activ e,", + "risk ▁factor", + "▁chemotherapy▁ cycl", + "\n\nM onth", + "▁can ▁occur", + "▁respons e\n\n", + "▁randomization ▁to", + "clinical▁ studies▁", + "your ▁own", + "▁Arm ▁D", + "▁12 .1", + "under taken", + "▁CR ,▁PR", + "▁increas e▁of", + "aff ect", + "▁anti- EGFr", + "���St atistical▁", + "▁trans lational▁", + "easurable▁ Lesion", + "▁every▁ 12▁week", + "identifi ed▁as▁", + "placebo ▁group", + "IC D", + "diseas e\n\n", + "assess ed▁by▁", + "▁two -", + ")▁will▁be▁ used▁to", + "ing▁s cal", + "ates ▁that", + "▁toler ated", + "▁toler ability", + "gressive▁ Disease▁", + "▁pemetrex ed,▁", + "▁Patients▁ who", + "emb ry", + "▁dat abas", + "regard ing▁the▁", + "▁Assessment ▁of", + "▁concentration s▁of", + "lif e▁threatening", + "quam ation", + "▁CTCAE ▁=", + "evidence▁of ▁disease▁progression", + "▁the▁primary▁ prevention▁of", + "condition al▁", + "▁bi ops", + "CTCAE ▁version▁3.0", + ",▁you ▁will", + "prof ile▁", + "roun d▁", + ",▁but ▁not", + "high est", + "guidelin es▁for", + "▁Cycle▁ 2", + "▁fl uid", + "safety▁ of", + "▁local▁ requirement", + "measurable▁ disease▁", + "istic ▁regression▁model", + "curr ence▁of", + "list ed▁abov", + "urin alysis▁", + "idence▁in terval", + "▁metastatic▁colorectal▁cancer ▁(mCRC", + "▁adverse▁ reaction", + "e▁blood▁ count", + "▁nod ul", + "▁laboratory ▁abnormalities▁", + "epidermal▁ growth▁factor", + "\n\nCon comitant", + "subsequent ly▁", + "hip ment", + ".▁Addition al▁", + "Sign ific", + ".▁The▁patient ▁has▁", + "region al", + "▁fil ter", + "▁immun od", + "ret ention", + "rag m", + ".▁U s", + "ible▁ person", + "▁received▁ panitumumab", + "\n\nTh ere▁", + "▁siz e▁(", + "▁sites▁of ▁diseas", + "system ic", + "Bri ef▁Pain▁Inventor", + "▁mean s▁that", + "▁and▁p elvis", + "first-line▁treatment ▁of", + "▁respon ding", + "▁clinic ▁visit", + "▁clinic ally", + "▁incidence▁of ▁new", + "effective▁ in", + "TH ICS", + "found▁ in▁the▁", + "▁........................................................................................................ ..", + "\n\nx\n\nx\n\nx\n\nx \n\nx\n\nx\n\nx\n\nx", + "e▁G ramont", + "▁Guidelin es", + "▁performed▁ at", + "nual▁ M", + "stant ial", + "UL ATORY", + "▁could▁ be▁", + "horm onal", + "▁qu eri", + "▁Methods▁of▁assessment ▁..........................................................................................", + "run -in", + "sam e▁m", + "MT D", + "topos ide▁", + "wit ch", + ".\n\nW ill", + "▁inhibition ▁of", + "▁120 ▁mg", + "Statistical▁ Analysis▁Plan", + "▁a▁single▁ agent", + "emergency▁ room", + "EG AL", + "preferred ▁term", + "Brochure▁ for", + "ilat eral▁", + "esophage al", + "▁head ▁and▁neck", + "malignanc y▁", + "▁mov ement", + ".htm l", + "hort ▁Form", + ":risk ▁profile▁", + "▁among▁subjects▁with ▁wild-type▁KRAS▁tumor", + "▁no▁longer ▁be▁", + ".▁Proc ▁Am▁Soc▁Clin▁Oncol", + "oprot eger", + "▁Performance▁Status▁ Scal", + "▁type▁I ▁error", + "▁platelet ▁count", + "Growth▁Factor ▁Receptor", + "radiology▁ review", + "emcitabine- cisplatin", + "▁Schedule▁ 4/", + "▁applicable▁to ▁amended▁protocol", + "▁(cid:120 )", + "▁tables poon", + "8▁weeks▁ ±▁1▁week", + "ed▁intraven ously▁", + "TERI A", + ".9%▁Sodium ▁Ch", + "▁(32)\n\nGEL▁Version▁ID:▁ONC.000−214−771.5.0▁Approved▁by\n\nApproved\n\nDate▁Printed:▁31−Jul−2014 \n\n02▁Feb▁2006▁15:38:50", + "ood▁and▁Drug ▁Administration", + "iov annucci", + "orex ia", + "▁CRI TERIA", + "% ▁to", + ") ▁of▁the▁", + ") .▁For", + ", ▁administer", + "- ▁and▁", + "- ▁up", + ". ”", + "/ G", + "/ M", + "/ withdraw", + "0 .5", + "1 000", + "2 .▁C", + "8 00", + ": ▁S", + "< 0.00", + "A MA", + "B iomarker", + "I FL", + "P rimary▁", + "S can", + "V AL", + "V AS", + "a emia", + "b ound", + "b owel", + "e ):", + "f fer", + "g er", + "h om", + "i ally", + "l ip", + "m ight", + "m easur", + "m echanism", + "n =", + "o ol", + "p atent", + "s urvival▁", + "x ia", + "▁ ........................................................", + "▁ older", + "e▁ R", + "e▁ may▁be▁", + "in ▁accordance▁with", + "▁t end", + "▁t ell", + "at e)", + "at ely,▁", + "\n\n medication", + "\n\n administration", + "en o", + "en hanc", + "er ▁B", + "er son", + "s▁ &", + "s▁ ................................................", + "s▁ Ad", + "s▁ using▁the▁", + "re mit", + "re duced", + "re flect", + "▁th us▁", + "al opath", + "st rok", + "▁the▁ opportunity▁to", + "an ol", + ",▁ is▁", + ",▁ 18", + ",▁ median", + "ed▁ protocol", + "ed▁ data", + "ed▁ placebo", + ".▁ 7", + "ed .▁C", + "▁p y", + "▁p age▁", + "▁p regnant", + "for ▁all", + "et ing", + "et ab", + "▁to ▁provide▁", + "▁s end", + "▁s ensitivity", + "um a", + "▁d ifficult", + "th ▁paragraph", + "▁w ash", + "▁w ater", + "▁and▁ document", + "▁and▁ non-", + "▁and▁ 48", + "▁and▁ without", + ".\n\n V", + ".\n\n 20", + "ill ion", + "ill s,▁", + "ill ness▁", + "el aps", + "is▁ N", + "▁A ctiv", + "▁in ▁an", + "ur ticaria", + "ith el", + "id i", + "id yl", + "ac et", + "pro perty▁of", + "pro mptly▁", + "▁( v", + "▁2 50", + "us ed▁in▁the▁", + "ul se", + "ul ated", + "con vention", + "if ▁you", + "▁re cogn", + "ot ide▁", + "▁D I", + "▁D elay", + "e▁of ▁your", + "e▁of ▁death", + "ver ag", + "ch ronic", + "▁or ▁CR", "ter min", - "term in", - "▁distribution s", - "▁distrib utions", - "FL A", - "F LA", - "▁Gi useppe", - "query Selector", - "▁/ \\", - "▁ /\\", - "▁S quad", - "g z", - "de lay", - "del ay", - "▁surr ounding", - "▁m anus", - "▁man us", - "▁H ou", - "▁Ho u", - "² ,", - "▁cult iv", - "▁trouble s", - "▁trou bles", - "▁r aison", - "▁ra ison", - "exp and", - "▁c ov", - "▁co v", - "▁ cov", - "nung en", - "n ungen", - ")) {", - ") ){", - "▁g een", - "▁ge en", - "▁au ßer", - "▁Л і", - "ř i", - "▁situ ations", - "▁situation s", - "▁tele p", - "▁tel ep", - "▁J ed", - "▁Je d", - "▁trav ail", - "▁trava il", - "li as", - "lia s", - "l ias", - "bul let", - "▁select ing", - "av ier", - "avi er", - "a vier", - "▁ess ential", - "( /", - "yy yy", - "št ě", - "ul ty", - "ult y", - "▁k ra", - "▁kr a", - "▁t abs", - "▁tab s", - "▁ta bs", - "▁ tabs", - "▁experience d", - "▁experien ced", - "az i", - "a zi", - "▁D irectory", - "▁Direct ory", - "▁Director y", - "▁ Directory", - "▁c ron", - "▁cr on", - "▁cro n", - "▁s pend", - "▁sp end", - "▁spe nd", - "▁R A", - "▁ RA", - "▁s elenium", - "▁sel enium", - "▁ selenium", - "▁T hé", - "▁Th é", - "Element s", - "El ements", - "ci i", - "c ii", - "▁p lat", - "▁pl at", - "▁pla t", - "▁arch ive", - "▁archiv e", - "▁ archive", - "▁ass istance", - "▁assist ance", - "▁ne ck", - "▁A venue", - "▁Aven ue", - "▁w heel", - "▁whe el", - "▁h ade", - "▁ha de", - "▁had e", - "Com mon", - "Comm on", - "▁D ialog", - "▁Di alog", - "▁Dia log", - "▁ Dialog", - "▁f org", - "▁for g", - "▁fo rg", - "▁sur ely", - "▁sure ly", - "▁h ockey", - "kt ó", - "k tó", - "▁t k", - "▁ tk", - "▁Br uce", - "▁Bru ce", - "▁e norm", - "▁en orm", - ", ’", - "▁Christ opher", - "▁Christoph er", - "je v", - "j ev", - "▁qu ad", - "▁ quad", - "▁A JAX", - "▁rel ief", - "▁reli ef", - "▁m odes", - "▁mod es", - "▁mo des", - "▁mode s", - "sk lär", - "s klär", - "▁V id", - "▁Vi d", - "▁Se rial", - "▁Ser ial", - "▁ Serial", - "▁to kens", - "▁token s", - "▁Pol and", - "▁Po land", - "\\ ]", - "▁v ide", - "▁vi de", - "▁vid e", - "ro oms", - "room s", - "om as", - "oma s", - "o mas", - "▁B ureau", - "▁Bur eau", - "c x", - "ность ю", - "ност ью", - "▁sign s", - "▁sig ns", - "ше ние", - "los sen", - "loss en", - "l ossen", - "▁Que ens", - "▁Queen s", - "▁m embre", - "▁mem bre", - "▁memb re", - "▁m ez", - "▁me z", - "▁ mez", - "▁B ool", - "▁Bo ol", - "▁ Bool", - "▁N aj", - "▁Na j", - "▁Mem ory", - "▁ Memory", - "▁K han", - "▁Kh an", - "▁l à", - "▁ là", - "▁H ud", - "▁Hu d", - "▁d ismiss", - "▁dis miss", - "ight h", - "igh th", - "▁f s", - "▁ fs", - "pr event", - "pre vent", - "prev ent", - "▁ме да", - "▁Pol ice", - "▁Po lice", - "▁с ко", - "▁ ско", - "fin ite", - "▁a mi", - "▁am i", - "▁ ami", - "▁M uch", - "▁Mu ch", - "ow ania", - "owa nia", - "owan ia", - "OR Y", - "O RY", - "io rs", - "ior s", - "i ors", - "▁Prem io", - "▁text box", - "d m", - "▁a fin", - "▁af in", - "▁Don ald", - "▁ Donald", - "▁P riv", - "▁Pr iv", - "▁Pri v", - "▁de cid", - "▁dec id", - "▁Maur ice", - "▁Mau rice", - "ag an", - "aga n", - "a gan", - "▁Britann ica", - "▁o ft", - "▁of t", - "▁consec utive", - "\"? >", - "\" ?>", - "ови й", - "st udent", - "stud ent", - "▁pe que", - "▁di eses", - "▁dies es", - "▁diese s", - "▁ret our", - "ét r", - "é tr", - "▁с ез", - "▁се з", - "▁k re", - "▁kr e", - "▁ kre", - "▁v otes", - "▁vo tes", - "▁vot es", - "▁vote s", - "ru ption", - "rupt ion", - "rup tion", - "iz ada", - "iza da", - "▁W iel", - "▁Wi el", - "▁Wie l", - "▁G ray", - "▁Gr ay", - "▁Gra y", - "▁Le op", - "▁Leo p", - "teil ung", - "tei lung", - "([ '", - "( ['", - "▁wh ites", - "▁white s", - "fr ica", - "fri ca", - "f rica", - "an imation", - "anim ation", - "cur l", - "cu rl", - "c url", - "ling s", - "lin gs", - "l ings", - "=\" $", - "lo yd", - "loy d", - "text sc", - "ор у", - "о ру", - "▁се ла", - "es ian", - "esi an", - "esia n", - "▁M ission", - "▁Miss ion", - "▁не за", - "▁ult imately", - "бо в", - "б ов", - "ol en", - "ole n", - "o len", - "ско му", - "ском у", - "ск ому", - "с кому", - "ne te", - "net e", - "n ete", - "▁D it", - "▁Di t", - "▁co stru", - "▁cost ru", - "dep endent", - "▁Re source", - "▁Res ource", - "▁ Resource", - "▁host s", - "▁hos ts", - "▁ hosts", - "▁re ar", - "▁r ear", - "D uration", - "ни ків", - "ник ів", - "М а", - "▁pl anning", - "▁plan ning", - "▁pre diction", - "▁pred iction", - "▁predict ion", - "▁L yn", - "▁Ly n", - "▁k ir", - "▁ki r", - "▁ kir", - "▁Leg isl", - "ма т", - "м ат", - "▁S occer", - "▁Soc cer", - "▁sur vey", - "▁surv ey", - "▁surve y", - "▁estadoun idense", - "or gen", - "org en", - "orge n", - "jo urd", - "jou rd", - "j ourd", - "▁ap rile", - "▁april e", - "▁apr ile", - "▁i ds", - "▁id s", - "▁ ids", - "сь ке", - "ськ е", - "▁emp loyee", - "▁employ ee", - "▁ employee", - "▁Schaus pieler", - "р ъ", - "▁mult imedia", - "▁multi media", - "▁сво ю", - "▁w ine", - "▁win e", - "▁E U", - "ic ă", - "▁R hein", - "▁Rh ein", - "▁Pal mar", - "ot eca", - "ote ca", - "▁prep are", - "▁prepar e", - "▁ prepare", - "▁T ot", - "▁To t", - "▁N ull", - "▁Nu ll", - "▁ Null", - "▁k in", - "▁ki n", - "▁ kin", - "in als", - "inal s", - "ina ls", - "▁New ton", - "▁t bl", - "▁ tbl", - "▁S old", - "▁So ld", - "▁Sol d", - "▁ver f", - "▁ve rf", - "at uring", - "atur ing", - "atu ring", - "▁la ptop", - "▁lap top", - "▁Со вет", - "▁Сов ет", - "▁Сове т", - "se cret", - "sec ret", - "▁Olymp ic", - "▁football er", - "▁Rud olf", - "▁con he", - "zy sk", - "▁evalu ated", - "▁evaluate d", - "» )", - "sh op", - "re pository", - "▁z ach", - "▁za ch", - "▁l osing", - "▁lo sing", - "▁los ing", - "et ter", - "ett er", - "ette r", - "▁W irtschaft", - "та к", - "▁unnecess ary", - "▁P hot", - "▁Ph ot", - "▁Pho t", - "an ska", - "ans ka", - "ansk a", - "▁N ative", - "▁Nat ive", - "▁ Native", - "CC E", - "C CE", - "▁fi fty", - "▁fif ty", - "▁e rw", - "▁er w", - "r h", - "is sent", - "iss ent", - "isse nt", - "issen t", - "}{ (", - "} {(", - "▁lan ç", - "▁X code", - "го род", - "гор од", - "ci r", + "\n\nP SA", + "\n\nP latelet", + "▁n mol/L", + "▁n itrogen", + "ist ▁of", + "▁and ▁any▁other", + "abl e)", + "▁O N", + "ess ential▁", + "ep eat", + "com puter", + "▁ar e▁th", + "enc eph", + ".2 6", + "e▁to ▁withdraw", + "ed▁b lood▁", + "s▁of ▁disease▁progression", + "In formed▁Consent", + "our se", + "ad vert", + "\n\nS ubjects▁", + "▁al though", + "e▁s een", + "e▁th roughout", + "▁r are▁", + "▁3 ▁hour", + "▁of▁the▁ investigator", + "cont rast", + "e,▁ in", + "▁o ▁n", + "▁com pared", + "▁the▁s ever", + "▁v 3.0", + "▁B SC", + "▁this▁ event", + "▁res um", + "ure d▁", + "ach ycardia", + "\n\nC isplatin", + "\n\nC arboplatin", + "▁will ▁take▁", + "▁will ▁only▁be▁", + "▁H uman", + "▁4 3", + "minist ration▁of", + "▁the▁in stitution", + "▁the▁in itiation▁of", + "one▁ (", + "eg old▁", + "pprov al", + "gen eral▁", + "▁the▁t otal", + "ed▁by ▁the▁subject", + "▁after ▁start▁of", + "e▁d iscontinu", + ".▁S uch", + "ies▁ (", + "▁G uid", + "ous ,▁and▁", + "▁J r", + "▁J ournal▁of", + "▁tim es▁", + "requ ires", + ".▁Th us", + "▁may▁ experience▁", + "mon oclonal", + "s.\n\n 10", + "▁ab us", + "ym idyl", + "e.\n\n 6", + "25 -", + "s▁s how", + "▁each ▁arm", + ").\n\n In", + ".7 0", + "▁form al", + "bas ed▁upon", + "▁should▁be▁ not", + "\n\nR efer", + "etermin ation", + "▁to▁be▁ performed▁", + "▁pre judic", + "des ir", + "▁a▁s ampl", + "\n\nF ull", + "e, ▁all", + ".▁D os", + "complet ion▁of▁the▁", + "ed▁as ▁a▁c", + "KRAS ▁status▁", + "▁day s▁from", + "s▁that ▁may▁", + "▁therapy▁ of", + "ru ct", + "perform ed▁by▁", + ".▁R EFERENCES", + "SA TION", + "formed▁consent ▁document", + "▁year s▁", + "▁approximately▁ 3", + "randomiz ed▁into", + "\n\n6 .2", + "▁should▁ be\n\n", + "\n\n7 .1", + "\n\n7 .6", + "s▁will ▁receive▁", + "administer ed▁at", + "sampl e▁siz", + "risk ▁for", + "risk s▁and▁", + "▁chemotherapy▁ or", + "\n\nM aintain▁dose▁level", + "conduct ed▁at", + "▁information ▁about", + "ull et", + "RE VI", + "-s cor", + "▁12 .5", + "\n\n8 .4", + "under ▁the▁", + "Clinical▁Study▁ Agreement", + "▁plus▁ placebo", + "▁plus▁ cisplatin", + ".▁I rinotecan", + "fre e▁", + "▁increas e▁to", + "▁investigational▁product ▁is▁", + "oph arynx", + "▁anti- denosumab", + "are▁ not", + "\n\n5 .1", + "\n\ns chedul", + "\n\ns erious▁adverse▁event", + "-M antel-Haenszel", + "▁randomiz ed,▁", + "▁Form ula", + "▁develop ing", + "econdary▁ Endpoint", + "▁sever e▁d", + "IRB )", + "▁the▁event ▁is▁", + "required▁ by▁", + "ing▁s creening", + "s. [", + "▁research er", + "▁health ▁status▁", + "▁cl early▁", + "▁Ph ysical▁examination", + "▁Ph one:", + "stor ed▁in", + "▁20 ▁mm", + ",▁which ▁is▁", + "▁mg/kg ▁given", + "▁CA 19-9", + ".,▁et▁al.,▁ A", + "▁system atic", + "e/ cisplatin", + "▁patients▁who ▁receive▁", + "▁Patients▁ will▁be▁", + "possibl e▁to", + "▁total ▁cancer", + "product ▁complaint", + "e▁with ▁the▁", + "lif e▁", + "▁vari ous▁", + ".▁199 5;", + "▁valu es", + "ed▁into ▁the▁", + "▁studies▁ of", + "medical▁ histor", + "▁indic ate▁", + "considered▁ related▁to", + "Ther apy", + "relationship ▁to", + ",▁E isen", + "skin ▁rash", + "▁applicabl e\n\n", + "repe ated", + "immedi ate▁", + ",▁c etuximab", + "Med icin", + "ological▁ imaging", + "\n\nNo \n\nUE", + "urin ary▁", + "▁the▁safety▁ follow-up▁visit", + "▁chest ▁CT▁scan", + "▁(m L/min", + "▁alone▁ (", + "s▁should▁ not▁be▁", + "activ ity▁", + "▁post menopausal", + "subjects▁ have▁", + "tic ancer", + "▁(T TP", + "▁you▁are▁ a", + "▁laboratory ▁test", + "▁account ability", + "e▁C ollection", + "neut ralizing", + "every▁3 ▁months▁", + "propos ed▁m", + "▁accur ac", + "recorded▁on▁the▁ appropriate▁", + "▁Pre clinical▁", + "class ifi", + "Ch ang", + "▁mak e▁", + "▁1.5 ▁x▁109/L", + "=0 .00", + "NT X", + "NT x", + "▁Coll ection▁of", + "▁shown ▁to", + "institution al▁practic", + "s.▁Th es", + "▁Pl acebo", + "lood▁sampl es▁for", + "▁grade▁3 ▁or▁4", + "▁respon der", + "pen -label", + "▁variabl es", + "▁confidential ity▁", + "▁22 ▁March▁2007", + "vari ous▁", + "/mm 3)", + "Man agement", + "every▁6▁week s▁(±", + "express ing", + "▁altern ative▁", + "▁shall ▁be▁", + "▁sodium ,▁potassium,▁chloride,▁bicarbon", + "▁recon stitut", + "\n\nPD \n\nAny", + "▁of▁the▁t otal▁", + "NCI- CTC", + "▁lik ely", + "▁decide▁to ▁withdraw", + "IL ITY", + "\n\nGen etic", + "oice▁ response▁system", + "▁hemoglobin ▁concentration", + "well▁toler ated", + "headach e,▁", + "open▁label ▁ZD4054", + "▁arter ial", + "storage▁ condition", + "redn isone▁", + "emper ature▁", + "▁Clinical▁Onc ology,▁", + "ACKGROUND ▁AND▁RATIONALE", + "▁str ata", + "▁(NSCLC )", + "aryng eal", + "▁ICH ▁GCP", + "panel: ▁sodium,▁potassium,▁chloride,▁bicarbon", + "▁serv e▁as", + "▁is▁s uspect", + "Protocol▁Attachment▁JM HO", + "▁Fax :", + "iat ric", + "compos ite▁", + "▁the▁day ▁after", + "▁VA RIABLES", + "ochran -Mantel-Haenszel", + "utomatic ally▁", + "active▁v oice▁response▁system", + "▁x▁109 ▁cells/L", + "alpable▁ lymph▁nod", + "(34)\n\nGEL▁Version▁ID:▁ONC.000−127−199.3.0▁Approved▁by\n\nApproved\n\nDate▁Printed:▁31−Jul−2014\n\n21▁Dec▁2004▁10:36:54 \n\nAmended▁Clinical▁Study▁Protocol▁Drug▁Substance:▁Bicalutamide▁Study▁Code:▁7054IL/0024▁Edition▁Number:▁05▁Date:▁20th▁December▁2004", + "posure▁in ▁Utero", + "ynomolgus▁ mon", + "e,▁albumin,▁total▁protein ,▁total▁bilirubin", + "awson-Hugh es▁B", + "occas ion", + "enceph alopath", + "ymidyl ate▁synth", + "( X", + "( 16", + "- G", + "- f", + "- ▁or", + ". R", + ". ▁and▁", + "/ ND", + "1 .0", + "5 )▁(cid:", + "7 )\n\n(cid:13", + ": ▁All", + "A A", + "B REVI", + "C enter", + "C ase▁Report▁Form", + "H els", + "I ND", + "I RC", + "I DMC▁will", + "R est", + "T OR", + "T oxicity", + "b eliev", + "c ardiac", + "c reatinin", + "f it", + "g ain", + "h and", + "l ide▁", + "l tr", + "m ultipl", + "m elanoma", + "s ▁an", + "s afety▁and▁", + "v eal", + "w ater", + "z em", + "▁ %", + "in ess▁", + "in ▁order▁to", + "in cidence▁", + "▁t echn", + "at ter", + "at ▁any▁", + "on ych", + "▁a ▁drug", + "▁a ▁30%", + "er tebral▁", + "or ▁non-", + "s▁ un", + "re en", + "re ceipt", + "re produc", + "▁the▁ overall", + "▁the▁ modified▁RECIST▁criteria", + "an y", + ",▁ 3", + ",▁ Q", + ",▁ Th", + ",▁ 201", + ",▁ carboplatin", + ",▁ leucovorin", + ",▁ both", + "ro g", + "ed▁ study▁", + "▁an nual▁", + ".▁ 4", + "▁c ross", + "ing ton", + "▁b it", + "▁to ▁10", + "is ,▁", + "▁s aline▁", + "▁s ingle-", + "▁s econdary▁endpoint", + "as ▁a", + "▁of ▁N", + "▁of ▁bevacizumab", + "▁d istant", + "▁m ail", + "▁and▁ at", + "om inal▁", + "ud den", + "ect or", + ".\n\n J", + ".\n\n This▁", + "ill y▁or", + "▁A L", + "▁A S", + "▁A braxis▁", + "▁A pproximately▁", + "▁A ctive▁", + "▁in s", + "▁in -line▁filter", + "res h", + "▁1 )", + "▁C ut", + "▁C ount", + "os c", + "est ▁response▁of", + "▁S heet", + "▁S pecific▁Aim", + "▁I I", + "▁l earn", + "▁E XPAND", + "▁f avor", + "ch art", + "▁n onsquamous▁", + "ist ula", + "▁T reat", + "▁N ational▁Cancer▁Institut", + "com pl", + "com pens", + "▁R R", + "ed▁in ▁this▁", + "▁treatment ▁failure", + "enc es▁of▁the▁", + "ed▁to ▁occur", + "ed▁b reast▁cancer", + "ed▁b ased▁on▁the▁", + "min im", + "s▁of ▁Addendum", + "ign ificant", + "\n\nS erious▁Adverse▁Event", + "\n\nS ubjects▁who", + "▁that ▁the▁investigator", + "e▁th e▁treatment▁effect", + "act ual▁", + "wh ite▁blood▁cell", + "e,▁ will▁be▁", + "e,▁ but", + "ear ing", + "▁F igure▁", + ".▁A D", + ".▁A bstract", + ".▁The▁ primary", + "ity▁ or", + "▁as▁ clinically▁indicated", + "▁the▁s econdary▁endpoint", + "able▁ Disease▁", + "int ention", + "int ensity", + "▁all erg", + "▁res pir", + "12 -lead▁ECG", + "out ine▁", + "\n\nC ons", + "from ▁a", + "▁H 3E-MC-JM", + "▁H andl", + "▁subject s▁that", + "▁patients▁ were▁", + ")\n\n E", + "▁at ▁which", + "s▁( as▁", + ".4 0", + "s▁in ▁this▁", + ".5 6", + ".5 7", + "▁week s▁of", + "▁ex ception", + "▁wh os", + "\n\nD ay▁", + "\n\nD uring▁the▁", + "ed▁for ▁the▁study", + ".▁S ever", + ".▁S imilar", + ".▁S hould", + "▁patient ’s▁", + "▁patient ▁has▁", + "s▁will▁be▁ assess", + "s▁will▁be▁ calcul", + "▁e CRF", + "\n\nE th", + "\n\nE very▁", + "der mat", + "s\n\n 9", + "ax oter", + "ration al", + "▁may▁ hav", + "▁ass oci", + "includ e:", + ".6 2", + "50 7)", + "18 7", + "▁mg/ day▁", + "record s▁of", + "s.\n\n If", + ".▁C l", + "▁ab solute▁neutrophil▁count", + ",▁or ▁until", + "▁in▁the▁ study▁", + "FI SH", + "▁disease▁ will▁be▁", + "\n\nN ew", + "▁each ▁visit", + "▁data ▁on", + "▁other wis", + "ne ed▁to", + "NC CN", + "▁the\n\n treatment", + "▁the▁patient ▁to", + "ed,▁ but", + "ER MS", + "\n\nY ear", + ".▁D ue▁to", + "pr incip", + "uc k", + "iven ess", + "s▁or ▁other", + "\n\nAd minister", + "▁accord ing", + "ally ▁acceptable▁", + "provid ed▁that", + "ativ e\n\n", + "consider ed▁a", + "\n\n0 \n\n1", + "▁ap pli", + "▁AB BREVI", + ",▁P fizer", + "document ed", + "36 0", + "▁continu ing", + "▁continu e▁to", + "▁continu e▁to▁be▁", + "collect ed▁at", + "▁provid ing", + "dose▁ and▁", + "16 )", + ",▁s kin", + "ha emorrh", + "▁up d", + "administer ed▁as▁", + "▁blood▁ pressure", + "yt otoxic", + "▁chemotherapy▁ regimens", + "▁administer ed▁to", + "conduct ed▁to", + "▁receiv e\n\n", + "▁des cribe▁", + "estim ated", + ".▁J AMA", + "\n\n8 .2", + "ed▁or ally▁", + "information ▁on", + "▁criteria :", + "\n\nAn alysis▁of", + "▁agent s▁", + "________ ____", + "li qu", + "▁K ey▁", + "▁Y es", + "▁within ▁7", + "▁Sub sequent", + "/L V", + "▁allow ▁for", + "▁part ▁of▁the▁study", + "irect ▁access▁to", + "▁protocol ▁deviation", + "\n\nAppendix ▁D", + "▁hy brid", + "▁clinical▁ study▁report", + "chemotherapy▁ for", + "pecifi ed▁", + "▁health ▁stat", + "IG N", + "▁cas es", + "blood▁ pressure", + ",▁as▁ follow", + "▁advanced▁ cancer", + "ics▁ committe", + "ature ,▁", + "▁Con comitant▁Medication", + "▁11 .1", + "aw a", + "aw ar", + "▁dat e▁to", + "laboratory▁ result", + ".▁G rade▁3", + "hemat ology▁", + "product ive▁", + "e▁with out", + "▁Phase▁ II", + "▁Report ing▁of", + "ed▁m etastatic", + ".▁199 8;", + "phase▁ 2", + "▁throughout ▁the▁", + "epar ately", + "▁versus▁ placebo", + "opt ys", + "▁person ally▁", + "open-label ,▁", + "▁only▁ limit", + "rang ing▁from", + "ed▁using ▁a", + "combin ant", + "omit t", + "chest ▁X-ra", + "ing▁p ath", + "-based▁ chemotherapy▁regimen", + "function al▁well", + "addition al▁", + "Med DRA", + "▁screening ▁procedure", + "▁6▁month s▁", + "▁6▁month s▁after", + "normal▁ rang", + "▁analysis▁will▁be▁ performed▁", + ".▁Wh ere▁", + "▁mon otherapy", + "activ ity▁of", + "▁women ▁of", + "Schedul e▁", + "▁the▁primary ▁analysis", + "LIN G", + "stratifi ed▁by▁", + "▁character ize▁the▁", + "existing ▁condition", + "▁appear ▁to▁be▁", + "▁path way▁", + "▁pre- randomization", + "▁(T able▁", + "active▁ Voice▁", + "\n\nCon tinu", + "made▁ available▁to", + "▁SC ▁injection", + ".▁Addition ally,▁", + "-related▁to xicity▁", + "demonstr ated▁that", + "▁multipl e▁myeloma", + "▁........................................................................ ....", + "region al▁", + "▁small ▁cell▁lung▁cancer", + "▁and▁B evacizumab", + "colon y-stimulating▁factor", + "▁have▁not ▁been", + "compared▁ between", + ".▁Other wis", + "▁mg/d ay", + "deriv ed▁from", + "▁................................................................ ..", + "participating ▁in▁this▁study", + "\n\nRedacted▁Version \n\n", + "▁calcul ated▁", + "▁Sign ature", + "age,▁ Administration", + "necessary▁ for", + "(2 ):▁p.▁", + "had ▁a", + "▁variabl es▁", + "oft w", + ".9% ▁sodium▁chlorid", + "leg al▁", + "▁prolong ation▁of▁existing", + "compan i", + "▁will▁continu e▁to", + "▁a▁2 0%", + "▁imag in", + "rap id", + "rap id▁", + "Method s:", + "path way", + "▁preserv ativ", + "Therapy▁ During", + "▁eligibility▁ criteria", + "▁el imin", + ",▁etc .", + ",▁as▁well ▁as", + "▁NCI ▁CTCAE", + "t▁is▁ important", + "usual ▁activities", + "wit z", + "unctional▁Assessment▁of▁Cancer ▁Therapy", + "▁Cont ent", + "▁uniqu e▁", + "▁comp ound", + "▁ED TA", + "dependent▁E thics▁Committee/In", + "Peri od▁", + "central▁imaging ▁vendor", + "rb itu", + "▁the▁primary▁analysis▁ data▁cut-off", + "riv ation", + "▁deterior ation", + "\n\nAmended▁Clinical▁Study▁Protocol ▁Study▁Code▁7054Il/0023▁Edition▁Number▁7", + "▁post- baseline▁", + "▁accru al▁", + "7)▁(cid:13 7)▁(cid:13", + "▁satis f", + "ley▁ J", + "(PD ):", + "▁Non hematologic", + "rath er▁than", + "▁or▁designe e▁will", + "▁limit▁of▁normal▁ (", + "ild▁to▁moder ate▁", + "sett ing", + "capable▁of ▁all▁s", + "romos om", + "▁Head ▁and▁Neck", + "▁the▁dat abase▁", + "▁abil ity▁to", + "▁the▁same▁dose▁ level", + "▁END PO", + ",▁phosphor ous,▁and▁", + "▁q21 d", + "Calvert ▁formula", + "greg ate▁", + "\n\nClinical▁Study▁Protocol: ▁Appendix", + "▁tract ▁infection", + "▁for▁D estruction", + "vul sion", + "▁advanced▁or ▁metastatic", + "▁flu id▁", + "intiles▁ L", + "ability/ inc", + "quamation *", + "Hels ink", + "ltr as", + "▁ABBREVI ATIONS", + "rbitu x", + "( including", + "- 7", + "- A", + "/ omega-3", + "1 b", + "2 ),▁", + "7 .5", + ": ▁(1)", + "? \n\n1\n\n2\n\n3", + "A M", + "A braxis▁", + "C F", + "C G", + "D x", + "D efinition", + "E M", + "E d", + "F T", + "P rior", + "P ath", + "T 3", + "U ATION", + "W ild-type▁", + "a im", + "b ack", + "c m", + "c ess▁of", + "c ili", + "e ine▁", + "e clar", + "f ol", + "g G", + "k ▁MF", + "m ac", + "m ence▁", + "m atch", + "n or", + "o ▁G", + "p ulmonary▁", + "r anc", + "s um", + "s ur", + "t rial▁", + "u ation", + "v ary▁", + "x iet", + "β -", + "▁ j", + "▁ ", + "▁ omega-3▁fatty▁acid", + "e▁ [", + "e▁ r", + "in eopl", + "▁t able▁", + "▁t ru", + "at e-", + "\n\n y▁", + "\n\n should▁be▁", + "▁a ▁new", + "▁a romatase▁inhibitor", + "en ed", + "or ▁b", + "or ▁depress", + "s▁ contain", + "s▁ list", + "re -s", + "re currence▁", + "ent ir", + "▁the▁ number▁of", + "of sky▁", + "an o", + ",▁ “", + ",▁ defined▁as", + "▁an ▁overall", + "▁an ▁SRE", + "ic ▁lesion", + "ic tion", + ".▁ 0", + ".▁ 13", + ".▁ Qual", + "ed ent", + "▁p ur", + "▁p olymorphism", + "▁p neumon", + "▁b le", + "▁b atch", + "es ▁and/or", + "▁to ▁Pfizer", + "▁s ol", + "▁of ▁patient", + "▁of ▁this", + "▁of ▁AMG▁162", + "▁d u", + "▁d iverticul", + "th rom", + "▁m utant", + "▁and▁ non", + "▁and▁ will▁not▁be▁", + "el ev", + "el oda", + "▁A pproved\n\nDate▁Printed:", + "▁A ZD2171", + "▁in vasive▁", + "▁C enter", + "▁C FR", + "ac ent", + "es▁ A", + "▁P ar", + "pro cedur", + "▁( IMC-1121B", + "ra v", + "if en", + "▁I maging", + "▁re d", + "▁re currenc", + "ag en", + "un s", + "un iqu", + "▁E OS", + "▁f ul", + "▁f ood▁", + "ch ocardiogram", + "▁or ▁for", + "e▁t issu", + "ut opsy▁", + "ther ton", + "ex erc", + "end othel", + "\n\nA NC", + "▁and ▁the▁study▁", + "abl et", + "▁T arget▁Lesion", + "▁T REATMENT", + "▁N O", + "op oi", + "toc h", + "will▁be▁ taken", + "com plication", + "▁treatment ,▁", + ".2 8", + "ant itative▁", + "▁that ▁would▁", + "▁of▁ 3", + "▁will▁be▁ analys", + "▁will▁be▁ used▁in", + "e▁s urvival▁", + "▁M ay", + "▁r andom", + "▁3 .5", + "▁3 ▁weeks▁", + "cor rel", + "▁com ment", + "▁F U", + ".▁A straZeneca", + ".▁A ssum", + ".▁The▁ s", + ".▁The▁ study▁", + "▁g ain", + "▁the▁s ource▁document", + "▁v ial▁", + "▁v itamin", + ".3 0", + ".3 8", + "clud ing", + "▁ther efore,▁", + "ach /", + "▁will ▁continue▁", + "e▁in iti", + "follow ed▁as▁", + "▁patients▁ from", + "▁4 .8", + "ew ork", + ".4 %", + ".4 3", + "▁study▁ design", + "▁study▁ participation", + "continu e▁to▁be▁", + "\n\n1 st", + "po or", + "s▁in ▁a", + ".5 4", + "s.▁ Ther", + "s.▁ To", + "ance▁ for", + "\n\nD is", + "ed▁for ▁this▁study", + "s▁and▁ will▁be▁", + "▁the▁d iagnos", + "s▁will▁be▁ complet", + "s▁will▁be▁ made▁to", + "ies▁ in", + "▁J L", + "▁pl us", + "ov arian", + "▁In travenous▁", + "ced ing", + "su per", + "▁dos es", + ".▁E ur▁J▁Cancer", + "▁assessment ▁(", + "▁test ▁for", + "RI N", + "▁9 .1.2", + "\n\nX\n\nX ▁X▁X", + "\n\nN O", + "▁each ▁treatment▁arm", + "he /sh", + "s▁with ▁respect▁to", + "▁data ▁protection", + ").\n\n 4", + "ne ed▁to▁be▁", + "\n\nR educ", + "▁the\n\n study", + "24 ▁hour", + "▁you ▁to", + "▁a▁s ub", + "▁cycl e,▁", + "respons e,▁", + "etastatic ▁Colorectal▁Cancer", + "\n\nThe▁ principal▁investigator", + "ically▁ steril", + "data ▁cutoff▁date▁", + "5- Fluorouracil", + "defin ed▁in", + "s▁or ▁symptom", + "ung ▁Cancer", + "▁death ▁(", + ".\n\nS ubjects▁who", + "patients▁ (", + "▁An y", + "▁peri pheral", + "ox ifen", + ".▁R ationale▁for", + "until ▁disease▁progression", + ".▁200 2", + "\n\n0 \n\n0", + "ed.\n\n 6", + "ed.\n\n 10", + "▁discontinu ed▁", + "\n\n\n\n In", + "es▁in volv", + "\n\n6 0", + "\n\n7 .2", + "\n\n7 .3", + "\n\n7 .4", + ",▁200 6", + "elect rocardiogram", + "abel ing", + "▁non- small-cell▁lung▁cancer", + "1- 2", + "1- year", + "▁level s▁", + "▁level ▁of", + "▁blood▁ pressure,▁", + "TION AL", + "ation▁of▁ Helsink", + "yt im", + ".▁An alys", + "s, ▁are▁", + "e▁m easurement", + "▁On e▁", + "\n\nM 0", + "\n\nM ethod▁of", + "ologic ally", + "▁receiv es▁", + "plac e▁", + "pproved▁by ▁the▁", + "▁chang e▁from▁baseline▁in", + "under stand", + "well ing", + "▁int ramuscular", + "▁diseas e,", + "qual ity▁", + "\n\nConfidential \n\nProduct:▁AMG▁162▁Protocol▁Number:▁20040138▁Date:▁19▁February▁2008\n\nPage▁", + "assessment ▁date.\n\n", + "s▁and \n\n", + "\n\n( X", + ".1.1 .1", + "▁trans amin", + "▁review ▁and▁", + "identifi ed▁by▁", + "▁according▁to ▁RECIST", + "Con duct", + "Con tinu", + "▁perform ing", + "▁at▁least ▁2", + "emat ology▁and▁", + "\n\nAppendix ▁F", + "olic k▁MF", + "▁pain ▁progression", + "expect ed▁to▁be▁", + "ability ▁to", + ".\n\nT reatment", + ",▁in ▁accordance▁with", + "▁health ▁status", + "imaging ▁mod", + "▁Treatment ▁Assignment", + "att ributed▁to", + "\n\nSection: ▁Protocol", + ".▁L eucovorin", + "▁consent ▁of", + "▁period▁ or", + ",▁T able▁", + "monitor ing▁of", + "clos ely▁", + ",▁199 6", + ",▁d ifferential", + "ed▁to▁the▁ extent", + "▁Phase▁ I", + "gl ish", + "▁design ee", + "pir al▁CT", + "▁the▁primary▁ PFS", + "condition al▁power", + "▁has ▁already▁", + "opt imal▁", + "▁person al", + "Ph ysician", + "\n\nV ital▁sign", + "▁app ar", + "▁power ▁for", + "▁FOLFOX 4", + "▁informed▁consent ▁form", + "up▁to ▁a▁maximum", + "oler ability▁of", + "experienc ed▁", + "rin alysis", + "considered▁ non-", + "treat ed▁with", + "o- )", + "e▁should▁be▁ used▁to", + "pharmac ist", + "▁aff in", + "Sponsor ▁will", + "dec id", + "▁before▁ any▁", + "▁demonstr ated▁", + "cum ulative▁", + "s▁a ▁result", + "health ▁stat", + "▁k eep", + "▁involv ed▁in", + "best ▁overall", + "▁the▁protocol ,▁", + "▁Lesion s\n\n", + ".▁To ▁date,▁", + "▁taking ▁part", + "s▁as▁ well", + "▁pemetrexed▁ plus▁carboplatin", + "▁diagnos is▁", + "-sid ed", + "▁may ▁also▁be▁", + "hypothes is", + "related▁ event", + "PRO ▁assessment", + "heart ▁rate,▁", + ".\n\nY our", + "▁common ly▁", + "omega -6", + "och berg", + "▁return ▁to▁the▁clinic", + "very▁ effort▁should▁be▁made▁to", + "s▁A ▁and▁B", + "▁strati fication", + "demonstr ated▁", + "▁fre ez", + "▁anti hist", + "hist ology▁", + "▁Reg ulatory▁A", + "▁member s▁", + "▁horm onal", + "▁pers ons", + "valid ation", + "prior▁to▁the▁ start", + "at▁a ▁significance▁level", + "bone▁ metastas", + "compli ance▁with", + ".▁Patients▁who ▁have▁not", + "▁de clin", + "Ch emotherapy▁", + "▁to▁ens ur", + "accord ing▁to▁the▁", + "▁Un ion", + "ABX-EGF ▁infusion", + "omet ric", + "▁Non- PD", + "▁appropriat e▁to", + "▁a▁f ew", + "▁IMC-1121B ▁or▁placebo", + "▁volum e▁of", + "▁surg ical▁", + "▁anticip ated", + "▁able▁to ▁carry▁out", + "able▁of ▁Content", + "▁the▁two ▁treatment▁arm", + "▁the▁criteria▁for ▁response▁are▁first▁met", + "▁36 \n\nSection:▁2.3", + "▁gener ally▁", + "1/ 2", + "▁Re con", + "vertebral▁ fracture", + "▁of▁C enter", + "▁prognostic ▁factor", + "pair ment", + "centr e▁", + "▁starting ▁study▁treatment", + "plasma ▁and▁", + "stip ation,▁", + "▁Dis position", + "▁hyp omagnesemia", + "accur ately▁", + "\n\nx▁x \n\nx▁x", + "omat itis", + "▁the▁sign ed▁", + "e▁shown ▁that", + "ti- Panitumumab", + "▁Synops is▁", + "comp ati", + "▁Performance▁Stat us", + "▁have▁no ▁problem", + "\n\n3\n\n3 \n\n3\n\n3", + "laborator ies", + "▁objectiv e▁tumor", + "TISTICAL ▁CONSIDERATIONS", + "▁childbearing▁p otential▁", + "central▁imaging ▁center", + "eptid e▁(", + "(SD ):", + "▁IV▁infusion ▁in", + "▁to▁prevent ▁one▁of▁the▁", + "ilat eral", + "36-month ▁evaluation▁period", + "Cont rol", + "▁Questionna ire", + "En glish", + "esophage al▁", + "arc otic", + "▁str ong", + "▁signific ance▁of", + "e▁Siz e▁and▁", + "documented▁in▁the▁ CRF", + "▁Society▁of ▁Clinical▁Oncology▁", + "▁one▁or▁more▁ new▁lesion", + "sych iatric", + "▁anx ious▁", + "urolog ic", + "urea ▁nitrogen", + "▁lig and", + ".▁Med ian", + "cip ient", + "▁within▁1 ▁working", + "▁dam age▁", + "▁steril e,▁", + "Response▁( CR", + "▁of▁63▁Finalization▁date:▁June▁19▁2001,▁Incorporating▁Amendment▁3▁–▁dated▁23▁May▁200 3\n\nAmerican▁BioScience,▁Inc.\n\nPhase▁III▁Protocol▁CA012-0▁ABI-007▁(Nanoparticle▁Paclitaxel)\n\nCONFIDENTIAL", + "ayo▁Clin ic", + "hol ding", + "izz iness", + "offer ed▁", + "suit able▁for", + "arn ofsky▁", + "▁meets ▁the▁criteria▁for", + ",▁strok e,▁", + ",▁hemat ocrit", + "▁the▁long est▁diameter", + "emoval▁of ▁Subject", + "▁090177e18 069", + "possibly▁ related▁to", + "is▁an▁ open-label", + "oxid ant", + "mega -3", + "▁red▁ blood▁cell", + "ctep. cancer.gov/", + "iometric s▁", + "eficiency▁ vir", + "Appro ach/", + "▁have▁some▁ problem", + "\n\n5\n\n6 \n\n7", + "\n\nA▁®\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct: ▁PANITUMUMAB▁(AMG▁954)▁Protocol▁Number:▁20040249▁Date:▁07▁August▁2007\n\nPage▁", + "anine▁aminotransferase▁( ALT", + "partate▁aminotransferase▁( AST", + "▁congenital▁anomaly /birth▁defect", + "Gloss ary", + "\n\nMonth \n\nYear", + "oproteger in", + "▁prejudic e▁to", + "proposed▁m echanism▁of▁action", + ",▁as▁follow s▁(≤", + "eclar ation▁of▁Helsink", + "ineopl astic", + "opoi etic", + "▁anxious▁ or▁depress", + ") .▁Subject", + ", ▁the▁s", + "- d", + "- ▁", + "- 10", + "- 50", + "- feeding", + "1 .", + "1 ▁error", + "3 rd▁", + "7 )(cid:", + "< <", + "A GE", + "A vastin", + "B evacizumab", + "C anada", + "D iseas", + "G rad", + "M onth", + "N OP", + "S pecific", + "S tudies▁", + "T axol", + "Z E", + "] ▁H", + "a udit", "c ir", - "▁pel ícula", - "▁O scar", - "▁Os car", - "▁sh ore", - "▁sho re", - "▁supp lied", - "ex amples", - "example s", - "Me ss", - "M ess", - "VI CE", - "V ICE", - "▁ex clude", - "▁h en", - "▁he n", - "▁ hen", - "▁гу бер", - "▁F ragment", - "▁Fra gment", - "▁ Fragment", - "▁B itte", - "▁Bi tte", - "▁Bit te", - "▁Bes ides", - "▁h es", - "▁he s", - "▁ hes", - "▁ih rem", - "▁ihr em", - "▁ihre m", - "▁Ser ge", - "▁art ific", - "=\" ${", - "=\"$ {", - "ло во", - "лов о", - "л ово", - "ut eur", - "ute ur", - "ta ire", - "t aire", - "па с", - "▁eas iest", - "▁fam iglia", - "N ormal", - "▁d alle", - "▁da lle", - "▁dal le", - "▁dall e", - "▁n ations", - "▁nation s", - "▁nat ions", - "r p", - "th ead", - "the ad", - "t head", - "▁обла сті", - "▁Democr atic", - "▁челов е", - "мо ж", - "▁г ер", - "▁ге р", - "▁ гер", - "▁small est", - "▁Publish ing", - "▁T s", - "▁laugh ed", - "ll e", - "l le", - "▁A mt", - "▁Am t", - "▁I IS", - "▁II S", - "FOR M", - "F ORM", - "Ma g", - "M ag", - "до н", - "д он", - "▁st oria", - "▁stor ia", - "▁sto ria", - "▁organ ized", - "▁organiz ed", - "č ní", - "▁o x", - "▁ ox", - "ling en", - "lin gen", - "l ingen", - "▁lu ego", - "cc ió", - "c ció", - "▁re ly", - "▁r ely", - "▁rel y", - "▁t ussen", - "er ten", - "ert en", - "erte n", - "▁hon our", - "▁Cla ude", - "▁Claud e", - "▁Ko rea", - "▁Kore a", - "▁Kor ea", - "▁Met ropol", - "▁Metro pol", - "Su per", - "S uper", - "ri en", - "rie n", - "r ien", - "ér ature", - "att ro", - "attr o", - "▁б іль", - "▁бі ль", - "▁ біль", - "▁Her bert", - "▁aut eurs", - "▁aute urs", - "▁dar auf", - "▁m ental", - "▁men tal", - "▁ment al", - "▁r ang", - "▁ra ng", - "▁ran g", - "▁s ón", - "▁só n", - "▁S oph", - "▁So ph", - ")\" ,", - ") \",", - "Des criptor", - "prep are", - "▁Land kreis", - "H C", - "cr oss", - "cro ss", - "c ross", - "ли за", - "▁Lo gin", - "▁Log in", - "▁ Login", - "on en", - "one n", - "o nen", - "Fe ature", - "▁m useum", - "▁muse um", - "▁ museum", - "ve k", - "v ek", - "▁Nel son", - "▁re jo", - "▁коман ди", - "▁sum mar", - "▁summ ar", - "▁сле ду", - "▁след у", - "äm p", - "ä mp", - "▁G as", - "▁Ga s", - "во м", - "в ом", - "VAL UE", - "in ge", - "ing e", - "per iod", - "lass en", - "las sen", - "lasse n", - "l assen", - "áv al", - "á val", - "▁alt ogether", - "um ph", - "ump h", - "ist ro", - "istr o", - "ą ż", - "▁Ke ep", - "▁Mar co", - "▁Marc o", - "▁ét ant", - "▁D re", - "▁Dr e", - "ge ometry", - "▁K as", - "▁Ka s", - "message s", - "mess ages", - "Co ok", - "C ook", - "▁S ide", - "▁Si de", - "▁Sid e", - "▁ Side", - "▁ко ми", - "▁ком и", - "ст ри", - "стр и", - "с три", - "▁ex cess", - "▁exc ess", - "▁Bi ografia", - "XX XX", - "XXX X", - "X XXX", - "▁N ie", - "▁Ni e", - "ven dor", - "v endor", - "xs d", - "x sd", - "Mil l", - "M ill", - "process ing", - "▁Miss ouri", - "▁perm ett", - "▁permet t", - "▁a par", - "▁ap ar", - "▁cro wd", - "▁crow d", - "fer t", - "fe rt", - "f ert", - "▁D ou", - "▁Do u", - "r í", - "▁C C", - "▁ CC", - "▁pay ment", - "▁ payment", - "▁Hol lywood", - "▁V irtual", - "▁ Virtual", - "▁sp oken", - "▁spoke n", - "▁spo ken", - "▁t ram", - "▁tr am", - "▁tra m", - "▁Comm unity", - "▁Commun ity", - "▁administr ative", - "▁в оло", - "▁во ло", - "gi or", - "gio r", - "g ior", - "vis or", - "▁Укра и", - "st age", - "sta ge", - "stag e", - "▁For mat", - "▁Form at", - "▁ Format", - "▁conven ient", - "Н а", - "▁med ian", - "▁media n", - "▁medi an", - "▁в ра", - "▁ вра", - "▁Пре ма", - "en ig", - "eni g", - "e nig", - "▁Op era", - "▁Oper a", - "ré s", - "r és", - "▁f mt", - "▁ fmt", - "▁effic iency", - "ma le", - "mal e", - "m ale", - "Ma ster", + "c eas", + "f atty", + "f uture", + "g e▁", + "g ia", + "h an", + "h ragm", + "m ulti-", + "o am", + "p et", + "p ulmon", + "p olymorphism", + "r as", + "s ▁taking", + "s election", + "w ard▁", + "y ▁active,", + "≥ ▁3", + "▁ )", + "▁ e\n\n", + "▁ just", + "e▁ if", + "at ▁any▁time▁", + "on e)", + "\n\n 200", + "\n\n \n\nD", + "\n\n endpoint", + "\n\n approximately▁", + "\n\n disease▁progression", + "▁a ▁person", + "▁a ▁previous▁", + "▁a ▁median", + "en ess", + "en ▁J", + "or ▁serum", + "s▁ ........................................................................", + "st hes", + "it ol", + "▁the▁ adverse▁event", + "an not", + "an agement", + "an -D", + ",▁ 10", + ",▁ either", + ",▁ NCI", + ",▁ while▁", + "ro b", + "ro vascular", + "ed▁ ABI-007", + "▁an ▁investigator", + "▁an alogu", + "ic t", + "ar ily", + "ed ▁adverse▁event", + "ed ▁therapy▁", + "ed eral▁", + "▁p ack", + "▁p otent", + "▁p rincipal▁investigator", + "▁c yto", + "es c", + "ation ▁with", + "▁to ▁the▁subject", + "▁to ▁evaluate▁th", + "▁s afety▁and▁", + "▁of ▁23", + "▁w ant", + "▁w e▁will", + "▁m es", + "▁m utant▁KRAS", + "▁m illion", + "▁and▁ 5", + "▁and▁ MRI", + "▁and▁ women", + ".\n\n (", + "el ih", + "ol ytic", + "▁A :", + "▁A braxis", + "▁in ▁which", + "ur t", + "ur sing", + "ur rog", + "res ent", + "res pect", + "▁1 ▁year", + "▁C H", + "▁C remophor", + "ac ut", + "▁P regnancy▁", + "▁P ET▁scan", + "pro state▁", + "▁( with", + "▁( a)", + "us ually", + "if ▁applicabl", + "▁S upportive▁", + "ub icin", + "▁I mClone▁", + "▁re ference▁", + "ag e.\n\n", + "ow der", + "▁D ES", + "▁D HA", + "▁h e/", + "▁h e▁or▁sh", + "▁l aborator", + "ap hragm", + "▁E NR", + "▁f ax", + "e▁t otal", + "\n\nP lacebo", + "ex ternal", + "ex ▁Cor", + "\n\nA m", + "\n\nA \n\nS▁I\n\nS▁I▁H▁T", + "\n\nA LT", + "\n\nA ▁Randomized,▁", + "▁O utcom", + "▁pro pos", + "▁T R", + "up press", + "▁N ▁A", + "ep s", + "▁for ▁treatment", + "▁R ationale▁for", + "e\n\n E", + "ed▁in fection", + "▁treatment ▁until", + "ed▁to ▁Amgen", + "ed▁to ▁have▁a", + "ort on", + "og -rank▁test", + "ant i", + "\n\nS AE", + "▁that ▁your", + "▁is▁ defined▁as▁", + "▁of▁ other", + "e▁s afety▁", + "e▁s uch", + "▁M on", + "▁of▁the▁ trial", + "e,▁ ALT,▁AST", + "▁F ail", + ".▁A ppro", + ".▁The▁ hazard▁ratio", + "▁the▁s econdary▁", + "ated▁ (", + "int ens", + "▁B oth", + "▁B reast▁Cancer", + "▁all ▁of▁the▁", + "ip ment", + "▁will ▁include▁", + "eff icient", + "will ▁remain", + "▁6 9", + "▁H ER", + "▁4 00▁IU", + "▁the▁in formed▁consent▁form", + "▁ac ross", + "continu ed)", + "ident ify", + "vi al▁", + "s.▁ E", + "s.▁ M", + "s.▁ W", + "cons ult", + "med icin", + "ally▁ con", + "e▁d es", + "▁patient ▁will▁be▁", + "▁patient s▁are▁", + "10 8", + "s▁will▁be▁ performed▁at", + "ies▁ of▁the▁", + "report ed▁in▁the▁", + "▁J oint", + "GF -", + "▁In ternational▁", + "ed▁by▁ C", + "▁may▁ lead▁to", + "▁month s▁for▁the▁", + "pres ence▁of", + "CT ▁or▁MRI", + "(cid: 12", + "(cid: 100)", + "▁adverse▁event s\n\n", + "▁per mission", + "e▁v ial", + "includ ed▁", + "▁10 .4", + "so hn", + "arg in", + "record s,▁", + "over ▁tim", + "▁cont ribution", + "▁ab stract", + "20 ▁mg", + "investigator ▁should▁", + "▁8 .5", + "▁8 ▁hour", + "ppend ic", + "every▁ 6", + ".▁If ▁a▁subject", + "\n\n2 .2", + "▁form s▁will▁be▁", + "▁lesion s▁", + "\n\nR ational", + "▁Study▁ Endpoint", + "present ed▁in", + "present ▁at", + "\n\nT ABLE▁OF▁CONTENTS", + "On ly▁", + "▁the▁patient ▁has▁", + "ER C", + "\n\nY our", + "\n\nY ES", + "KRAS ▁Efficacy▁Analysis▁Set", + ".\n\nA t", + "e) ▁and▁", + ".▁F OLFIRI", + "▁day s▁(±", + "le ast", + ".\n\nP anitumumab", + "e▁b reak", + "hy per", + "▁therapy▁ in", + "including ▁a", + "e▁treatment ▁with", + "199 8", + "etw ork", + "An ti-", + "▁evalu ated▁in", + "provid ed▁in▁the▁", + "ack ▁of▁", + "▁the▁study▁ is▁to", + "▁sampl e▁for", + "▁sampl e▁will▁be▁", + "▁the▁subject ▁or", + "▁dose▁of ▁investigational▁product", + "appro ach", + "ed.\n\n D", + "ed.\n\n In", + "▁et▁al ▁19", + "▁if ▁the▁", + "▁if ▁it", + "▁if ▁this▁h", + ".▁B reak", + "eb rovascular", + "dis s", + ",▁s uppl", + "ha uer", + "s▁will ▁includ", + "week ly", + "▁survival ▁and▁", + "▁hour s▁after", + "administer ed", + "sub group", + "\n\nIn clusion▁Criteria", + "▁activ e▁treatment", + "\n\nB aselin", + "conduct ▁of", + "part ial", + "uthor ship", + "▁until ▁PD", + "OS E", + "▁there▁ a", + "▁document ation", + "22 :", + "estim ate▁of", + "estim ated▁that", + "follow-up ▁information", + "under gone▁", + ",▁B l", + "▁dec rease▁", + "▁approv al▁from", + "▁antibod y▁(", + ".▁I maging", + "s▁should▁be▁ performed▁", + "▁bevacizumab ▁and▁", + "▁chemotherapy ▁and▁", + "research ▁study▁", + "oph osph", + "▁St age▁IV", + "istor y▁of", + "determin ation▁of", + "▁trans cription", + "▁part ▁of", + "describ ed▁abov", + "\n\ns ymptom", + "▁Day▁1 ▁of▁each▁cycl", + "cer al", + "\n\nAppendix ▁C", + "s,▁and▁ other", + "▁Q u", + "erv ic", + "expect anc", + "ycle▁ 1", + "\n\n9 .3", + "▁15 ▁mg/kg", + "fi ed▁with", + "▁measurement s▁", + "chemotherapy ▁and▁bevacizumab", + "HR QoL", + "Ex ploratory▁", + ".,▁et▁al.,▁ M", + "evaluation ▁or", + "\n\nt ime▁to", + "recommend ed▁for", + "ourc e:", + "central▁ review", + "central▁ radiology▁review", + "46 2", + "measure d", + ".\n\nE X", + "MENT AL", + "Assessment s▁", + "▁100 ▁x▁109/L", + "FACT- Fatigu", + "por ation", + "olum e▁of", + "▁valu e▁of", + "▁tel omere▁length", + "epar ately▁", + "▁2000 ;", + "opt otic", + "medical▁ institution", + "statist ically▁significant", + "▁bi ologic", + "Pl eas", + "▁Ex tension", + "▁was \n\n", + "▁Efficacy▁An alysis", + ")▁in ▁patients▁with", + "▁PRO TOCOL", + "▁indic ator", + "ITT ▁Efficacy▁Analysis▁Set", + "▁2004 ;", + "met a-", + "chest ▁CT▁scan", + "▁due▁to ▁any▁caus", + "▁alon e.\n\n", + ".\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct: ▁Denosumab▁Protocol▁Number:▁20050244▁Date:▁05▁May▁2008\n\nPage▁", + "▁et▁al.▁200 5)", + "▁demonstr ating", + "▁demonstr ate▁a", + "▁4▁week s▁of", + ".\n\nN ot", + ".\n\nN ▁A\n\nF▁O", + "▁en hanc", + "▁alone▁ as", + "risk▁of ▁death", + "▁Study▁D rug", + "▁availabl e)", + "rict ed▁in", + "▁Therapy▁ for", + "stopp ed▁", + "▁compared▁to ▁placebo", + "▁path way", + "▁add res", + ".▁( for", + ".\n\nWh o", + "expos ure▁to", + "▁ext ent", + "Data ▁Collection", + "▁ha zard▁", + "sever ity", + "etc .", + "Response▁ System", + "▁return ed▁to", + "▁systemic ▁anticancer▁therapy", + "measurement ▁of", + "us▁of ▁0", + "▁this▁research ▁study▁", + "▁they ▁are▁s", + ",▁V an", + "ethod▁of ▁assessment", + "▁the▁interim ▁analysis", + "RT K", + "dat es▁of", + "participation ▁in▁the▁study", + "cr as", + "▁intraven ous▁infusion", + "fil ter", + "▁as▁well ▁as", + "▁receiving ▁panitumumab", + "-L ine▁", + "▁small -cell▁lung▁cancer", + "light ly▁", + ",▁v omiting", + "▁cent r", + "▁1.5 ▁x▁ULN", + "▁pharmac ist", + "fin anc", + "eam ▁Physician", + "▁will▁be▁used▁to ▁compare▁treatment", + "▁calcul ate▁the▁", + ",▁al though", + "omet im", + "quant itative▁", + "▁commer cially▁available▁", + "Investigator’s▁ Brochure", + "Form ulation", + "▁AUC ▁6", + "▁sufficient ▁shrink", + "▁Evalu ation", + "approv ed▁", + "▁platinum -based▁", + "MP LE", + "▁Cycl es▁", + "efficacy▁and▁ safety", + "▁the▁inter action", + "\n\nAmgen▁Thousand▁Oaks \n\nConfidential\n\nAMGEN\n\nProduct:▁darbepoetin▁alfa▁Protocol▁Number:▁20010145▁–▁Amendment▁2▁Date:▁16▁July▁2004\n\nPage▁", + "acceptable▁to xicity▁", + "▁should▁not ify▁", + "▁blinded▁ study▁medication", + "▁(Arm ▁B", + ",9 ,10", + "▁will▁continu e▁to▁be▁", + ".▁Com par", + "▁profil e▁of", + "el: ▁+", + "s▁and▁the▁ proposed▁mechanism▁of▁action", + "▁x▁x▁x▁x ▁x▁x▁x▁x", + "discuss ed▁with", + "UBJEC TS", + ".▁Clin ▁Cancer", + "▁will▁be▁perform ed▁to", + "followed▁until ▁resolution", + "▁Dose▁Modification s▁for", + "d▁and▁ Signific", + "s▁occurring ▁at▁the▁sit", + "▁Ep idemi", + "E▁S▁A▁E▁L▁P \n\n.▁T▁N▁E▁M▁U▁C▁O▁D", + "apable▁of ▁only▁limit", + "intraven ous▁infusion", + "e▁indic ate▁", + ".▁New ▁York", + "VESTIG ATOR", + "recommendation s▁for", + ".\n\nE▁R▁O▁F▁E▁B \n\nY▁T▁I▁D▁I▁L▁A▁V", + "orld▁ Health", + "▁x-ra y▁", + "▁interfer e▁with", + "▁acut e▁", + "bal anc", + "▁larg e▁", + "▁lo ok", + "▁mm▁with ▁spiral▁CT▁scan", + "every▁6▁month s▁for", + ".▁Further mor", + "▁total▁hip ▁BMD", + "ranulocyt e▁", + "▁Clinical▁Onc ology", + "▁missing ▁data", + ",▁An ti-Panitumumab", + "cho os", + ".▁Ann ▁Oncol", + "▁creatinine▁clear anc", + "gene▁ expression", + "▁diet ary▁", + ".▁Journal▁of ▁Clinical▁Oncology,▁", + "objective▁of ▁this▁study▁is▁to", + "effect▁of▁ZD4054 ▁in▁combination▁with▁docetaxel▁on", + "Histor y", + "particular ly▁", + "idney▁ ston", + "▁the▁treat ing▁physician", + "\n\nPRO TOCOL", + "▁arth rit", + "mg/m2 ▁IV", + "±▁3 ▁days", + "capture d▁", + "pG ▁is", + "▁medicin al▁product", + "gestive▁heart ▁failure", + "stimated▁ Study▁D", + "▁sensitiv ity▁to", + "ity▁Ass urance▁", + "e-bas ed▁", + "origin al▁protocol", + "ois otop", + "▁teas poon", + "▁taxan e▁", + "prim arily▁", + "Stimulating ▁Factor", + "ecommend ation", + ".▁Up ▁and▁about", + "conf idence▁interval", + "SSESS MENTS", + "▁sponsor- nominated▁", + "ref riger", + "jeopard iz", + "▁causal▁relationship ▁with", + "▁e▁e▁ k", + "▁Arm▁A▁and▁ Arm▁B", + "▁PATI ENTS", + "3)▁(cid: 4)▁(cid:", + "dys cras", + "▁phys ically▁", + "▁to▁zoledronic▁acid▁ with", + "rosatellit e▁in", + "EAS URE", + "endel sohn", + "(34)\n\nGEL▁Version▁ID:▁ONC.000−127−200.3.0\n\nApproved\n\nDate▁Printed:▁31−Jul−2014\n\nApproved▁by\n\n21▁Dec▁2004▁10:21:22 \n\nAmended▁Clinical▁Study▁Protocol▁Bicalutamide▁Study▁Code▁7054Il/0025▁Edition▁Number▁5▁20▁December▁2004", + "▁lat er▁than", + ".6.6 ,▁Anti-Panitumumab", + "desir able▁", + "5)▁(cid: 6)▁(cid:", + "melanoma ▁skin▁cancer", + "axoter e", + "▁limit▁of▁normal▁( ULN", + "intiles▁L aboratories▁", + "throm bin", + "▁36\n\nSection:▁2.3 .6.6,▁Anti-Panitumumab", + "eclaration▁of▁Helsink i", + "NOP SIS", + "▁DES IGN", + "▁ENR OLL", + "apable▁of▁only▁limit ed▁s", + "stimated▁Study▁D uration", + "▁36\n\nSection:▁2.3.6.6,▁Anti-Panitumumab ▁Antibodies", + "% ▁of▁the▁", + "% ,▁respectively", + "( B", + "( 12", + ") ▁may▁be▁", + "+ /-", + "- lik", + "1 40", + "6 ,▁12", + ": 15", + "A Z", + "B SA", + "C ONFIDENTIAL", + "C reatinine▁Clear", + "D ouble-", + "E TIC", + "G emcitabine▁", + "G leason", + "J ,▁G", + "J ,▁K", + "L A", "M aster", - "Ser ies", - "Se ries", - "S eries", - "▁s yd", - "▁sy d", - "gener ic", - "inter val", - "▁e fect", - "▁inwon ers", - "лим пи", - "ir ement", - "ire ment", - "Er r", - "E rr", - "ö h", - "▁l ying", - "▁ly ing", - "▁ lying", - "▁S ettings", - "▁Setting s", - "▁ Settings", - "! =", - "em atic", - "emat ic", - "arg v", - "▁Bas ic", - "▁ Basic", - "▁consider ation", - "▁h abe", - "▁ha be", - "▁hab e", - "- %", - "▁mount ains", - "▁mountain s", - "▁pe ak", - "▁f allen", - "▁fall en", - "▁fal len", - "ed ed", - "ede d", - "e ded", - "log ic", - "▁mat ched", - "▁match ed", - "▁typ ing", - "▁ty ping", - ")} ,", - ") },", - "▁f ancy", - "▁fan cy", - "▁eleg ant", - "ا ل", - "▁уча ст", - "▁Sa rah", - "▁Sar ah", - "▁V erd", - "▁Ver d", - "▁Ve rd", - "▁t ego", - "▁te go", - "ru les", - "rule s", - "r ules", - "▁mo unted", - "▁mount ed", - "▁і м", - "ер у", - "е ру", - "st off", - "sto ff", - "fa hren", - "fah ren", - "fahr en", - "f ahren", - "dist ance", - "d istance", - "▁Lic ense", - "▁LE FT", - "▁ LEFT", - "▁w p", - "▁ wp", - "/ {", - "▁am azon", - "▁amaz on", - "▁ amazon", - "> &", - "▁els ő", - "qu arters", - "▁sh ock", - "▁sho ck", - "ni ck", - "nic k", - "n ick", - "▁Arch ite", - "▁S quare", - "▁r ates", - "▁ra tes", - "▁rate s", - "▁rat es", - "io re", - "ior e", - "i ore", - "▁N at", - "▁Na t", - "▁Char lot", - "re ichen", - "reich en", - "rei chen", - "reiche n", - "▁var iation", - "▁vari ation", - "os is", - "osi s", - "li fe", - "l ife", - "sl ide", - "s lide", - "ab i", - "a bi", - "uk i", - "u ki", - "my sq", - "mys q", - "▁prim itive", - "▁primit ive", - "▁univers itaire", - "LE NG", - "ale ż", - "eb ook", - "e book", - "s yn", - "▁G egen", - "▁Ge gen", - "▁Geg en", - "▁K ü", - "▁а ле", - "▁ал е", - "▁L ub", - "▁Lu b", - "con current", - "izz ato", - "izza to", - "▁st ub", - "▁i e", - "▁ ie", - "▁' ./", - "▁'. /", - "co d", - "c od", - "▁intern acional", - "▁G las", - "▁Gl as", - "▁Gla s", - "▁m are", - "▁ma re", - "▁mar e", - "▁N eb", - "▁Ne b", - "▁G B", - "▁ GB", - "kw args", - "▁a ument", - "▁au ment", - "WI D", - "W ID", - "▁ро д", - "▁р од", - "▁ род", - "p unkt", - "▁G rad", - "▁Gr ad", - "▁Gra d", - "▁ Grad", - "S N", - "AM P", - "A MP", - "▁B orn", - "▁Bo rn", - "▁Bor n", - "▁Guer re", - "го тов", - "▁med io", - "▁medi o", - "Me d", - "M ed", - "su pp", - "sup p", - "s upp", - "act ual", - "drop down", - "▁ok tober", - "▁ ř", - "▁circ ular", - "▁cir cular", - "▁circul ar", - "▁s kin", - "▁sk in", - "▁ski n", - "▁em phas", - "▁emp has", - "▁го лов", - "▁голо в", - "▁p ue", - "▁pu e", - "▁inform ations", - "▁information s", - "▁Wolf gang", - "▁us eless", - "▁use less", - "и т", - "▁Jo an", - "▁б ор", - "▁бо р", - "▁ бор", - "▁G lad", - "▁Gl ad", - "▁Gla d", - "▁K now", - "▁Kn ow", - "▁Kno w", - "ké nt", - "k ént", - "sp eed", - "spe ed", - "▁Ke vin", - "un ft", - "▁ar qu", - "▁ arqu", - "▁C asa", - "▁Cas a", - "▁Ca sa", - "(. ..", - "( ...", - "▁rapid ly", - "▁pro ble", - "▁prob le", - "▁probl e", - "▁Ви кипеди", - "že n", - "ž en", - "▁N eben", - "▁Ne ben", - "▁Neb en", - "▁M eter", - "▁Me ter", - "▁Met er", - "Child ren", - "ce m", - "c em", - "ig os", - "igo s", - "aj u", - "a ju", - "▁Ret rie", - "▁H ell", - "▁He ll", - "▁Hel l", - "▁g ig", - "▁gi g", - "▁contro vers", - "▁z oom", - "▁zo om", - "▁zoo m", - "▁c ens", - "▁ce ns", - "▁alc uni", - "▁He ader", - "▁Head er", - "▁ Header", - "Me ta", - "Met a", - "M eta", - "Re quired", - "▁ин ститу", - "▁s kup", - "▁sk up", - "▁ing les", - "ég l", - "é gl", - "bi j", - "b ij", - "▁t ér", - "▁té r", - "▁com pag", - "▁comp ag", - "▁comm itted", - "▁commit ted", - "▁process ed", - "▁proc essed", - "▁proces sed", - "Lo wer", - "L ower", - "▁F oreign", - "▁For eign", - "▁Fore ign", - "▁ Foreign", - "▁s eq", - "▁se q", - "▁ seq", - "sheet s", - "she ets", - "▁F em", - "▁Fe m", - "ho z", - "h oz", - "in ks", - "ink s", - "▁k all", - "▁ka ll", - "▁kal l", - "vari ant", - "▁li bro", - "▁lib ro", - "▁cl icks", - "▁click s", - "▁cli cks", - "▁g obierno", - "ie gel", - "ieg el", - "мо го", - "м ого", - "ge me", - "gem e", - "g eme", - "▁t ower", - "▁to wer", - "▁par ish", - "▁T CP", - "▁l s", - "▁ ls", - "▁n ginx", - "▁ng inx", - "▁ nginx", - "Na N", - "▁D ir", - "▁Di r", - "▁ Dir", - "▁Begr iffe", - "▁Begriff e", - "ar ie", - "ari e", - "a rie", - "ím p", - "í mp", - "ic ios", - "ici os", - "icio s", - "i cios", - "▁sh aring", - "▁cin éma", - "be c", - "b ec", - "RE D", - "R ED", - "▁K ra", - "▁Kr a", - "ab ol", - "a bol", - "▁fl ux", - "▁flu x", - "▁exp ensive", - "▁су ще", - "▁` _", - "oc z", - "o cz", - "ли ст", - "▁acqu aint", - "▁w ise", - "▁wis e", - "▁ wise", - "▁pou voir", - "▁pouv oir", - "▁dev ant", - "▁moment um", - "im mer", - "imm er", - "▁C oupe", - "▁Cou pe", - "index Of", - "▁does nt", - "▁doesn t", - "▁за в", - "▁lic ense", - "▁ â", - "CS S", - "C SS", - "▁r ice", - "▁ric e", - "▁ri ce", - "▁ rice", - "Te am", - "▁a no", - "▁an o", - "▁ ano", - "li t", - "l it", - "▁mer ged", - "▁merge d", - "▁C ell", - "▁Ce ll", - "▁Cel l", - "▁ Cell", - "л л", - "bo y", - "b oy", - "as ts", - "ast s", - "▁s ell", - "▁se ll", - "▁sel l", - "▁gro ße", - "▁groß e", - "▁virt uel", - "▁virtue l", - "Can cel", - "▁s j", - "g ment", - ". <", - "ча й", - "i ë", - "ak h", - "a kh", - "iz ers", - "ize rs", - "izer s", - "pr it", - "p rit", - "▁T ib", - "▁Ti b", - "▁elabor ate", - "▁f é", - "▁м еди", - "▁ме ди", - "LENG TH", - "▁prim arily", - "▁sc ores", - "▁score s", - "▁carry ing", - "▁l ake", - "▁la ke", - "▁lak e", - "com pose", - "comp ose", - "compos e", - "▁Town ship", - "un ge", - "ung e", - "▁al berga", - "an ych", - "any ch", - "a nych", - "qu elle", - "que lle", - "quel le", - "q uelle", - "▁Ar k", - "▁p ris", - "▁pr is", - "▁pri s", - "▁v oll", - "▁vo ll", - "▁vol l", - "ш ли", - "Valid ation", - "▁ce ux", - "▁pop ulate", - "▁popula te", - "▁popul ate", - "\" \r", - "▁fem mes", - "▁femme s", - "AN G", - "A NG", - "▁Desp ite", - "вы е", - "в ые", - "is ke", - "isk e", - "i ske", - "zu g", - "z ug", - "на ча", - "▁h atten", - "▁hat ten", - "▁hatte n", - "IN SERT", - "Emp loyee", - "▁mo ments", - "▁moment s", - "▁mom ents", - "▁últ ima", - "▁h older", - "▁hold er", - "▁ho lder", - "▁hol der", - "▁ holder", - "bl ank", - "Col lections", - "Collection s", - "Collect ions", - "ath ers", - "ather s", - "a thers", - "▁g rade", - "▁gr ade", - "▁gra de", - "▁grad e", - "▁ grade", - "▁aff airs", - "▁affair s", - ".$ $", - ". $$", - "▁d elta", - "▁del ta", - "▁ delta", - "▁Jug end", - "▁españ ol", - "▁O UT", - "▁ OUT", - "▁mathemat ical", - "▁m ongo", - "▁mon go", - "▁Ф е", - "ul ing", - "uli ng", - "u ling", - "▁re volution", - "▁revol ution", - "▁c oin", - "▁co in", - "▁sub class", - "\" =>", - "äch e", - "ä che", - "▁p yg", - "▁py g", - "ща я", - "ill ery", - "ille ry", - "iller y", - "▁com enz", - "dep th", - "▁c él", - "▁re size", - "▁res ize", - "▁ resize", - "▁S ame", - "▁Sam e", - "▁Sa me", - "▁st rik", - "▁str ik", - "▁stri k", - "▁t ir", - "▁ti r", - "▁sc arc", - "▁scar c", - "▁M ember", - "▁Mem ber", - "▁ Member", - "sub scribe", - "ó ż", - "út bol", - "ex cept", - "▁dr iving", - "▁dri ving", - "▁driv ing", - "ki e", - "k ie", - "zo ny", - "zon y", - "z ony", - "ème s", - "è mes", - "Da vid", - "D avid", - "iss ant", - "issa nt", - "▁т ы", - "▁ ты", - "▁é lect", - "▁él ect", - "▁re name", - "▁r ename", - "▁ren ame", - "▁R unning", - "▁Run ning", - "▁ Running", - "▁inter faces", - "▁interface s", - "//////// ////////", - "▁Wal ker", - "▁Walk er", - "▁soci été", - "▁as ks", - "▁ask s", - "br id", - "b rid", - "▁je we", - "▁se ines", - "▁sein es", - "▁seine s", - "▁sei nes", - "▁ag ents", - "▁agent s", - "▁M Y", - "▁ MY", - "▁Law rence", - "de ss", - "des s", - "d ess", - "ie sen", - "ies en", - "iese n", - "i esen", - "▁людя х", - "прав и", - "пра ви", - "▁anc est", - "▁wel che", - "ra um", - "r aum", - "▁o rb", - "▁or b", - "▁ orb", - "sc al", - "s cal", - "▁L ear", - "▁Le ar", - "▁w ear", - "▁we ar", - "▁s lave", - "▁sl ave", - "▁sla ve", - "▁re named", - "▁ren amed", - "▁rename d", - "če n", - "č en", - "ma ste", - "mas te", - "m aste", - "ang les", - "angle s", - "▁Am érica", - "▁t i", - "▁ ti", - "▁dem sel", - "▁bene ath", - "bin ary", - "b inary", - "▁ed ición", - "▁kil omet", - "▁kilom et", - "ui ts", - "uit s", - "u its", - "▁cu atro", - "▁ent rance", - "▁entr ance", - "ond issement", - "▁b ag", - "▁ba g", - "▁ bag", - "▁Ar men", - "▁Arm en", - "ij o", - "i jo", - "▁L ors", - "▁Lo rs", - "▁Lor s", - "▁demsel ben", - "ê m", - "▁dis crete", - "▁prom inent", - "▁J ay", - "▁Ja y", - "de cor", - "dec or", - "D L", - "▁d í", - "St ruct", - "Str uct", - "▁P roduction", - "▁Produ ction", - "▁Product ion", - "th ey", - "the y", - "ar ius", - "ari us", - "sch nitt", - "▁C ou", - "▁Co u", - "▁l ex", - "▁le x", - "▁ lex", - "y outube", - "▁рабо та", - "st ation", - "sta tion", - "stat ion", - "se p", - "s ep", - "▁mi rror", - "▁mir ror", - "▁h its", - "▁hit s", - "▁hi ts", - "▁Be ck", - "at ically", - "atic ally", - "▁L az", - "▁La z", - "▁w inner", - "▁win ner", - "DE X", - "D EX", - "▁I NT", - "▁IN T", - "▁ INT", - "}^ {-", - "}^{ -", - "} ^{-", - "▁w egen", - "▁we gen", - "▁weg en", - "ma d", - "m ad", - "An gle", - "Ang le", - "zi ng", - "zin g", - "z ing", - "▁Bay ern", - "▁Bayer n", - "sa l", - "s al", - "äg er", - "ä ger", - "▁bus y", - "▁st ör", - "▁f olk", - "▁fol k", - "▁ folk", - "▁p rix", - "▁pr ix", - "▁pri x", - "▁al located", - "▁alloc ated", - "▁allocate d", - "▁p t", - "▁ pt", - "af fen", - "aff en", - "a ffen", - "cl uster", - "clus ter", - "▁com plement", - "▁comp lement", - "▁comple ment", - "▁compl ement", - "ár s", - "á rs", - "▁Amer ika", - "рі й", - "р ій", - "▁val ley", - "▁vall ey", - "▁valle y", - "▁ro oms", - "▁room s", - "▁ rooms", - "▁m oi", - "▁mo i", - ".\" ,", - ". \",", - ";; ;;", - "▁lo west", - "▁low est", - "no g", - "n og", - "▁land et", - "▁lan det", - "▁program me", - "ch io", - "chi o", - "▁W ährend", - "ánd ez", - "▁дол ж", - "▁o uv", - "▁ou v", - "▁ ouv", - "om ány", - "▁Википеди и", - "▁s ó", - "▁ele ktr", - "De sc", - "Des c", - "D esc", - "▁Be aut", - "▁Beau t", - "на р", - "н ар", - "▁мо же", - "▁мож е", - "P ierre", - "es ota", - "eso ta", - "▁oper ated", - "▁opera ted", - "▁operate d", - "▁f orte", - "▁for te", - "▁fort e", - "ри с", - "р ис", - "▁op position", - "▁opp osition", - "▁oppos ition", - "al ia", - "ali a", - "a lia", - "▁S yl", - "▁Sy l", - "get Name", - "ве ли", - "fi k", - "f ik", - "▁com prom", - "▁comp rom", - "▁compr om", - "▁Text View", - "▁ TextView", - "Sp ring", - "S pring", - "met adata", - "meta data", - "en gu", - "eng u", - "/ ,", - "▁car ri", - "is tol", - "ist ol", - "isto l", - "▁diag onal", - "li sta", - "list a", - "lis ta", - "l ista", - "iz en", - "ize n", - "i zen", - "▁re nde", - "▁r ende", - "▁ren de", - "▁rend e", - "gc c", - "g cc", - "be ck", - "bec k", - "li us", - "l ius", - "ir al", - "ira l", - "i ral", - "Resol ver", - "▁percent age", - "▁at tra", - "▁att ra", - "▁attr a", - "str ings", - "string s", - "wi ąz", - "od s", - "o ds", - "во лю", - "ę ż", - "▁news paper", - "▁newsp aper", - "im iter", - "imi ter", - "imit er", - "AB C", - "A BC", - "▁Man chester", - "[ {", - "Ag ent", - "Age nt", - "A gent", - "▁W or", - "▁Wo r", - "▁K ath", - "▁Kat h", - "▁Ka th", - "▁по ві", - "▁пов і", - "▁ent onces", - "▁n iveau", - "at ted", - "att ed", - "atte d", - "le arn", - "lear n", - "lea rn", - "at iques", - "ati ques", - "atique s", - "▁у би", - "▁qu indi", - "bin ding", - "bind ing", - "b inding", - "▁import ed", - "▁imp orted", - "▁H orn", - "▁Hor n", - "▁Ho rn", - "em berg", - "ember g", - "emb erg", - "com plex", - "comp lex", - "comple x", - "▁ne ural", - "▁neu ral", - "▁neur al", - "in formation", - "▁recogn ition", - "in gt", - "ing t", - "▁inhab itants", - "vu e", - "v ue", - "▁Be völker", - "▁cur ves", - "▁curve s", - "▁curv es", - "▁l eb", - "▁le b", - "▁ leb", - "ді й", - "д ій", - "▁s ow", - "▁so w", - "▁sent iment", - "P H", - "ra che", - "rac he", - "rach e", - "r ache", - "▁- (", - "▁ -(", - "▁e stable", - "▁est able", - "▁es table", - "▁estab le", - "▁esta ble", - "▁Ferd inand", - "▁é crit", - "▁éc rit", - "▁prime iro", - "▁t ex", - "▁te x", - "▁ tex", - "▁inter mediate", - "ve rage", - "ver age", - "vera ge", - "ib us", - "i bus", - "▁s erves", - "▁ser ves", - "▁serv es", - "▁serve s", - "iv as", - "iva s", - "i vas", - "▁b ru", - "▁br u", - "▁ bru", - "▁l um", - "▁lu m", - "att ice", - "atti ce", - "ч ный", - "▁D res", - "▁Dr es", - "▁Dre s", - "▁v ideos", - "▁video s", - "▁vide os", - "d uration", - "▁a bit", - "▁ab it", - "▁e gg", - "▁eg g", - "ograph ical", - "ographic al", - "al ph", - "ST ATE", - "STAT E", - "▁па ра", - "▁пар а", - "▁ пара", - "re ading", - "read ing", - "rea ding", - "▁veh icle", - "▁fort une", - "ult ats", - "▁St oria", - "▁Sto ria", - "mi dt", - "mid t", - "łą cz", - "▁Mem orial", - "▁v as", - "▁va s", - "▁ vas", - "▁з ан", - "▁за н", - "▁ зан", - "▁ut ility", - "▁util ity", - "▁ob sc", - "▁obs c", - "▁rel acion", - "▁rela cion", - "▁relac ion", - "▁run at", - "▁ru nat", - "Re lease", - "ta ke", - "t ake", - "▁O liver", - "▁Ol iver", - "▁Oliv er", - "▁S id", - "▁Si d", - "ul os", - "ulo s", - "u los", - "▁G arc", - "▁Gar c", - "▁Ga rc", - "▁роз та", - "▁S ak", - "▁Sa k", - "P y", - "führ t", - "f ührt", - "▁tra bal", - "▁trab al", - "* {", - "▁z es", - "▁ze s", - "▁ zes", - "▁sz ere", - "▁szer e", - "▁sze re", - "▁v arios", - "▁var ios", - "▁vari os", - "▁va rios", - "▁o tra", - "▁ot ra", - "▁e val", - "▁ev al", - "▁ eval", - "▁situ é", - "▁sit ué", - "▁w ounded", - "▁Vin cent", - "▁вико ри", - "▁en code", - "▁enc ode", - "▁ encode", - "Mod al", - "Mo dal", - "▁f orb", - "▁for b", - "▁fo rb", - "▁dynam ics", - "▁dynamic s", - "▁de pos", - "▁dep os", - "ar de", - "ard e", - "▁street s", - "▁stre ets", - "▁K omm", - "▁Kom m", - "▁Ko mm", - "=$ (", - "= $(", - "▁по вер", - "▁пов ер", - "▁пове р", - "▁d ois", - "▁do is", - "▁doi s", - "▁v itt", - "▁vi tt", - "▁vit t", - "▁automat isch", - "▁re load", - "▁ reload", - "▁Ver walt", - "ber o", - "be ro", - "b ero", - "▁h ub", - "▁hu b", - "▁m os", - "▁mo s", - "▁ mos", - "▁t utto", - "▁tu tto", - "▁tut to", - "▁Freder ick", - "ło w", - "ł ow", - "ant ages", - "anta ges", - "antage s", - "aqu e", - "a que", - "pa per", - "p aper", - "▁ein ige", - "`) ,", - "` ),", - "d j", - "▁P le", - "▁Pl e", - "▁% ,", - "▁ %,", - "▁B itmap", - "▁Bit map", - "▁ Bitmap", - "▁friend ly", - "▁tr uly", - "▁st roke", - "▁str oke", - "▁stro ke", - "▁ stroke", - "ro ph", - "rop h", - "r oph", - "▁en gl", - "▁eng l", - "▁ engl", - "▁c off", - "▁co ff", - "▁d ust", - "▁du st", - "▁dus t", - "▁Jah res", - "▁Jahr es", - "▁Jahre s", - "pp i", - "p pi", - "▁w ys", - "▁wy s", - "fa ctor", - "fact or", - "fac tor", - "f actor", - "sch luss", - "▁дере вня", - "▁дерев ня", - "▁P ast", - "▁Pa st", - "▁Pas t", - "▁до ма", - "CO M", - "C OM", - "▁pu eden", - "▁puede n", - "▁pue den", - "▁g ift", - "▁gi ft", - "▁G la", - "▁Gl a", - "▁trigger ed", - "él y", - "é ly", - "ül és", - "ü lés", - "▁O liv", - "▁Ol iv", - "▁ver so", - "▁vers o", - "▁ verso", - "▁l le", - "▁ll e", - "▁ lle", - "▁G li", - "▁Gl i", - "▁L td", - "o a", - "▁territ orio", - "ord re", - "▁de ck", - "▁dec k", - "▁ deck", - "dr a", - "d ra", - "as zt", - "asz t", - "▁concern ing", - "▁Add itionally", - "▁kter é", - "▁g rund", - "▁gr und", - "▁gru nd", - "▁ grund", - "▁G est", - "▁Ge st", - "▁Ges t", - "▁ Gest", - "▁mis under", - "pr et", - "pre t", - "p ret", - "── ──", - "▁re putation", - "zi a", - "z ia", - "▁у спе", - "▁ус пе", - "▁esc aped", - "▁escape d", - "▁P rag", - "▁Pr ag", - "▁Pra g", - "per form", - "▁a ustral", - "▁aust ral", - "▁V ater", - "▁Va ter", - "ча с", - "▁r aces", - "▁ra ces", - "▁race s", - "▁rac es", - "▁By te", - "▁ Byte", - "Ma sk", - "M ask", - "▁Ter rit", - "▁Terr it", - "ст ю", - "▁V oci", - "▁Vo ci", - "▁Fich ier", - "▁Насе лення", - "▁Unter scheidung", - "te enth", - "teen th", - "▁pi lot", - "▁pil ot", - "▁j i", - "▁ ji", - "▁дву х", - "▁orient ation", - "▁ orientation", - "ind re", - "▁D ort", - "▁Do rt", - "▁Dor t", - "ça s", - "ç as", - "п ли", - "▁re action", - "▁react ion", - "▁cons isting", - "▁consist ing", - "▁fer ro", - "ти сти", - "ya rd", - "yar d", - "y ard", - "▁с ві", - "▁interpret ation", - "i ą", - "ra h", - "r ah", - "▁f and", - "▁fa nd", - "▁fan d", - "Pub lic", - "P ublic", - "▁un iverse", - "▁univers e", - "▁ret ir", - "▁cons cious", - "ar qu", - "▁w aste", - "▁was te", - "▁wa ste", - "▁B ib", - "▁Bi b", - "ycler View", - "▁list ening", - "▁listen ing", - "▁liste ning", - "gle ich", - "g leich", - "nie js", - "niej s", - "▁cor relation", - "▁correl ation", - "▁corre lation", - "▁rece iver", - "▁receive r", - "▁у да", - "▁cour age", - "▁cou rage", - "uch s", - "uc hs", - "u chs", - "fa ss", - "fas s", - "f ass", - "▁ch unk", - "▁ chunk", - "▁An fang", - "▁gro ßen", - "▁große n", - "▁groß en", - "cont inue", - "continu e", - "▁Warsza wa", - "h é", - "i y", - "iv ement", - "ive ment", - "i vement", - "▁ α", - "▁ex posed", - "▁exp osed", - "▁expos ed", - "▁expose d", - "▁z ahl", - "▁za hl", - "▁ zahl", - "▁sa cr", - "▁sac r", - "▁Lo oks", - "▁Look s", - "▁e ager", - "en ten", - "ent en", - "ente n", - "e nten", - "C ursor", - "/ _", - "ix a", - "i xa", - "ре ла", - "зна ча", - "з нача", - "▁фамили ей", - "▁ar gent", - "▁arg ent", - "▁ argent", - "▁An ders", - "▁And ers", - "œuv re", - "▁I sa", - "▁Is a", - "мен та", - "мент а", - "▁ad vers", - "▁adv ers", - "ri ction", - "ric tion", - "rict ion", - "r iction", - "G P", - "▁п ісля", - "▁pre serve", - "▁pres erve", - "▁G arden", - "▁Gar den", - "▁Gard en", - "R ate", - "ap rès", - "a près", - "▁read able", - "in du", - "ind u", - "▁s kill", - "▁sk ill", - "▁ski ll", - "▁hel ping", - "▁help ing", - "ograph ique", - "cl ing", - "cli ng", - "c ling", - "olog ist", - "▁Fil ter", - "▁ Filter", - "▁f inger", - "▁fin ger", - "▁V all", - "▁Val l", - "▁Va ll", - "▁Pol ish", - "▁Po lish", - "l g", - "▁Famil ien", - "▁Familie n", - "▁w aters", - "▁water s", - "▁wa ters", - "▁wat ers", - "▁pse ud", - "az a", - "a za", - "_ )", - "AR Y", - "A RY", - "▁с реди", - "▁сред и", - "▁сре ди", - "▁M ust", - "▁Mus t", - "▁Mu st", - "▁B od", - "▁Bo d", - "an on", - "ano n", - "a non", - "▁l ado", - "▁la do", - "▁lad o", - "▁t ight", - "im en", - "ime n", - "i men", - "ap pen", - "app en", - "appe n", - "a ppen", - "fr ames", - "frame s", - "fra mes", - "fram es", - "in gers", - "ing ers", - "inger s", - "inge rs", - "▁CO VID", - "▁з і", - "▁ зі", - "▁с ве", - "▁ц ь", - "▁ ць", - "▁L eft", - "▁Le ft", - "▁ Left", - "]] ;", - "] ];", - "ч ь", - "фи ка", - "▁с ло", - "▁ сло", - "▁п і", - "▁ пі", - "▁ex iste", - "▁exist e", - "▁Atl antic", - "▁maintain ed", - "▁ir re", - "▁an née", - "▁ann ée", - "▁ année", - "▁comm ented", - "▁comment ed", - "ве ро", - "вер о", - "ber ta", - "bert a", - "b erta", - "▁L ad", - "▁La d", - "▁U pon", - "▁Up on", - "▁p ause", - "▁pa use", - "▁pau se", - "mi ll", - "mil l", - "m ill", - "op ter", - "opt er", - "U K", - "ре с", - "р ес", - "нцикло педи", - "▁along side", - "▁ro bot", - "▁rob ot", - "▁f ert", - "▁fe rt", - "▁fer t", - "▁ fert", - "▁m oy", - "▁mo y", - "▁a de", - "▁ad e", - "▁ ade", - "Map per", - "Mapp er", - "Ma pper", - "M apper", - ")- >", - ") ->", - "ig ua", - "igu a", - "ét ique", - "т ка", - "al ias", - "ali as", - "alia s", - "a lias", - "▁о ри", - "▁ор и", - "▁M agn", - "▁Ma gn", - "▁Mag n", - "▁gehör te", - "▁gehört e", - "im b", - "i mb", - ")} {\\", - ")}{ \\", - ") }{\\", - "▁Wikip édia", - "▁u rs", - "▁ur s", - "▁ urs", - "▁e nde", - "▁en de", - "▁end e", - "▁ ende", - "le b", - "l eb", - "▁G C", - "▁ GC", - "H ol", - "an cing", - "anc ing", - "anci ng", - "Un ion", - "Uni on", - "▁ten ía", - "T T", - "▁e state", - "▁est ate", - "▁esta te", - "▁estat e", - "h á", - "▁по лі", - "▁пол і", - "ul tan", - "ult an", - "▁H ockey", - "ul se", - "uls e", - "▁cho ices", - "▁choice s", - "sch er", - "sc her", - "sche r", - "s cher", - "▁[ ],", - "▁[] ,", - "▁pot entially", - "▁potential ly", - "▁Ü bers", - "▁Über s", - "▁ad mit", - "▁adm it", - "Com ment", - "Comm ent", - "ст я", - "с тя", - "▁V ien", - "▁Vi en", - "▁Vie n", - "▁ц і", - "▁ ці", - "▁per mut", - "▁perm ut", - "c gi", - "▁cr ít", - "Con sole", - "Cons ole", - "ct ic", - "▁ok res", - "aw k", - "foot ball", - "ou est", - "o uest", - "CT YPE", - "C TYPE", - "olog ique", - "▁const it", - "▁cons tit", - "▁inter ests", - "▁interest s", - "▁Pro gress", - "▁ Progress", - "▁M enu", - "▁Me nu", - "▁Men u", - "▁ Menu", - "▁tak é", - "▁ta ké", - "▁As ian", - "▁Asia n", - "▁за щи", - "▁young er", - "▁w ished", - "▁wish ed", - "▁wis hed", - "▁S ort", - "▁So rt", - "▁Sor t", - "▁ Sort", - "▁aud ience", - "▁audi ence", - "am ba", - "amb a", - "▁gehör t", - "▁K ansas", - "ya ume", - "▁Prof essional", - "â ce", - "▁f atto", - "▁fa tto", - "▁fat to", - "to d", - "t od", - "▁data sets", - "▁datas ets", - "▁dataset s", - "▁f are", - "▁far e", - "▁fa re", - "▁ fare", - "▁w aves", - "▁wave s", - "▁wa ves", - "~ /", - "▁measure ment", - "▁w ol", - "▁wo l", - "▁ wol", - "ind ust", - "indu st", - "▁strugg ling", - "▁pull ed", - "▁pul led", - "▁car atter", - "▁Ex terne", - "▁Ext erne", - "▁Extern e", - "▁дей стви", - "cn t", - "c nt", - "li ches", - "lic hes", - "lich es", - "liche s", - "▁Pos sible", - "▁Poss ible", - "▁fa ced", - "▁face d", - "▁fac ed", - "▁hypoth esis", - "▁kil om", - "▁n är", - "▁nä r", - "bo olean", - "P Y", - "am pa", - "amp a", - "▁k iss", - "▁ki ss", - "▁kis s", - "▁as tero", - "▁ast ero", - "▁neg li", - "am ents", - "ament s", - "amen ts", - "a ments", - "▁S tu", - "▁St u", - "at ó", - "a tó", - "▁Const itution", - "▁inter pol", - "▁Un able", - "▁Una ble", - "▁p is", - "▁pi s", - "▁ pis", - "▁p arc", - "▁par c", - "▁pa rc", - "\"] )", - "\" ])", - "ple r", - "pl er", - "p ler", - "▁aut ory", - "▁auto ry", - "▁autor y", - "▁alg unos", - "yw na", - "}) )", - "} ))", - "▁f alls", - "▁fall s", - "▁fal ls", - "▁ falls", - "▁é quip", - "▁e mit", - "▁em it", - "▁ emit", - "▁pro fil", - "▁prof il", - "ge ts", - "get s", - "g ets", - "ф о", - "▁Milit ary", - "▁nombre ux", - "oc t", - "o ct", - "Re place", - "Rep lace", - "▁se asons", - "▁season s", - "▁ch âteau", - "▁type of", - "▁ typeof", - "po lit", - "pol it", - "p olit", - "▁r and", - "▁ra nd", - "▁ran d", - "▁ rand", - "▁qu ar", - "▁erst mals", - "си ни", - "▁pay load", - "▁ payload", - "П о", - "кі н", - "к ін", - "re po", - "rep o", - "▁P av", - "▁Pa v", - "Sc ore", - "S core", - "er ves", - "erv es", - "erve s", - "▁soll te", - "▁мі ж", - "éb ec", - "é bec", - "▁c lip", - "▁cl ip", - "▁cli p", - "▁ clip", - "▁N ice", - "▁Nic e", - "▁Ni ce", - "▁n eben", - "▁ne ben", - "▁ass ass", - "it ories", - "ito ries", - "itor ies", - "itori es", - "▁un ity", - "▁unit y", - "▁ unity", - "▁е н", - "▁ ен", - "▁Inst itut", - "▁Instit ut", - "▁ Institut", - "▁intern ationale", - "▁international e", - "▁на ук", - "▁нау к", - "▁com and", - "▁kle ine", - "▁klein e", - "▁adj acent", - "▁deliver ed", - "▁ш е", - "▁ ше", - "зе м", - "з ем", - "▁c ot", - "▁co t", - "▁ cot", - "vis ual", - "ва ет", - "▁C ensus", - "\\ _", - "▁territ ory", - "чи л", - "ч ил", - "ч ные", - "fl utter", - "Did Load", - "Document s", - "Doc uments", - "▁d ob", - "▁do b", - "▁ dob", - "Br e", - "B re", - "an imate", - "ani mate", - "anim ate", - "▁b iz", - "▁bi z", - "▁b ata", - "▁ba ta", - "▁bat a", - "▁S U", - "▁ SU", - "es o", - "e so", - "▁p riority", - "▁prior ity", - "vá n", - "v án", - "ir as", - "ira s", - "i ras", - "▁char ged", - "▁charge d", - "▁charg ed", - "▁M icro", - "▁Mi cro", - "▁Mic ro", - "at oire", - "ato ire", - "a toire", - "че р", - "ч ер", - "ab ad", - "aba d", - "a bad", - "ur u", - "u ru", - "▁v š", - "dir e", - "di re", - "d ire", - "▁Tw itter", - "▁м ето", - "▁ме то", - "▁мет о", - "). .", - ") ..", - "▁Ц ент", - "▁ent wick", - "▁M ind", - "▁Min d", - "▁Mi nd", - "▁ф унк", - "F uture", - "ls t", - "l st", - "ło ż", - "fl i", - "f li", - "t ensor", - "▁top ology", - "▁ar te", - "▁art e", - "▁ arte", - "ER T", - "E RT", - "▁var iance", - "▁vari ance", - "Im ages", - "Image s", - "▁( @", - "▁ (@", - "Array List", - "O C", - "▁Де мо", - "auc oup", - "▁de notes", - "▁den otes", - "▁denote s", + "O ver", + "O ST", + "P T-11", + "S erious▁Adverse▁Event", + "T ime▁to", + "V C", + "V ER", + "W ,▁S", + "Y es▁or▁No", + "a ▁D", + "a ▁bit", + "b e", + "b u", + "c ovariates", + "e ous▁", + "f oc", + "f all", + "f ix", + "f acil", + "f uture▁", + "f unding", + "g a", + "h in", + "j acent", + "k eys", + "l ev", + "p otentially▁", + "r ace", + "r are▁", + "s a", + "s qu", + "s ▁through", + "t ime▁to", + "y toch", + "▁ −", + "▁ eas", + "▁ ever", + "▁ outlin", + "▁ esophag", + "e▁ p", + "in avir", + "▁t ast", + "at es▁(", + "at ▁screening", + "at e▁transamin", + "on ic", + "on e▁of▁the▁", + "\n\n and", + "\n\n OS", + "\n\n analysis", + "▁a ▁1", + "▁a ▁non-", + "▁a void▁", + "or \n\n", + "or d▁", + "s▁ –", + "s▁ using", + "re e-", + "▁th or", + "▁th us", + "▁th yroid▁", + "st age▁III", + "it ate▁", + "it al▁or", + "▁the▁ other", + "▁the▁ right▁to", + "of ▁Consent", + "an alyt", + ",▁ follow-up", + ",▁ based▁on", + "ro ad", + "ed▁ up", + ".▁ Protocol", + "ar ine▁", + "▁p otentially▁", + "▁c av", + "▁c ourse", + "▁b lack", + "es ▁as▁", + "es ,▁a", + "ation ,▁or", + "▁to ▁evaluate▁the▁", + "▁to mograph", + "as ons", + "▁of ▁approximately▁", + "▁of ▁paclitaxel", + "▁of ▁cycles▁", + "um ▁LD", + "▁d ipstick", + "▁w ound▁", + "▁and▁ not", + "▁and▁ your", + "▁and▁ weight", + "▁and▁ post-", + "ect ib", + ".\n\n d▁e▁v▁o▁r▁p▁p▁A", + "is▁ F", + "▁A cid", + "▁A LT", + "▁in ▁10", + "▁in ▁the\n\n", + "................................ ....", + "................................ ......", + "ur witz", + "ev ident", + "oc rin", + "pl ant", + "▁C 1", + "▁C arcinoma", + "es▁ it", + "▁P olicy", + "▁P ART▁B:", + "pro gn", + "▁( ±", + "▁( not", + "▁( to", + "▁( LD", + "▁( longest▁diameter", + "▁( Version▁3.0", + "▁S ci", + "▁S ummary▁of", + "▁S ▁I\n\nS▁I▁H▁T", + "▁re productive▁", + "▁re asons", + "ot ally▁con", + "un n", + "▁D FS", + "▁D eath", + "cl ose▁", + "ap pe", + "▁E B", + "▁E nd", + "▁f ib", + "▁or ▁T", + "▁or ▁greater", + "e▁t ub", + "▁n ail", + "od ay", + "\n\nA ST", + "▁T arget", + "▁ad ding", + "▁N OT", + "op oul", + "will▁be▁ analyz", + "▁ar rest", + "▁for ▁genetic▁research", + "▁R PLS", + "enc od", + "ed▁to ▁your", + ".1 6", + ".1 7", + ".1 .4", + ".2 \n\nStudy▁", + "▁with hold", + "▁with ▁zoledronic▁acid▁", + "ed▁b oth", + "s▁of ▁blood▁", + "s▁of ▁22▁March▁2007", + "▁that ▁tim", + "▁that ▁may▁be▁", + "▁200 3;", + "▁will▁be▁ used▁for", + "▁M C", + "▁3 -week", + "▁con stitut", + "cor related▁", + "event ▁that", + "▁of▁the▁ first", + "▁o ▁t", + ".▁The▁ Investigator", + "▁as▁ direct", + "▁as▁ specifi", + "▁g iv", + "▁on ▁all", + ",▁and▁ 1", + ",▁and▁ at", + ",▁and▁ bevacizumab", + "ine▁ needl", + "▁L Y231514", + "▁this▁ is▁", + "s,▁ bas", + "s,▁ CA", + "▁all el", + "▁all ▁pre-", + "\n\nC etuximab", + "▁ch arg", + "ing▁the▁ protocol", + "▁5 4", + "▁6 ▁mg/kg", + ")\n\n M", + "▁the▁in vestigational▁", + ".4 1", + ".4 2", + ".4 6", + "continu e▁", + "continu ous", + "ident ification", + ".5 %", + "s.▁ Ex", + "▁any▁ in", + "▁any▁ subject", + "▁V itamin▁B12", + "▁the▁t arget▁lesion", + "\n\nD elete:", + ".▁S erum", + "▁the▁d eath", + "▁G A", + ".▁P FS", + ".▁P leas", + "▁is ▁allow", + "ial▁ lung", + "mon ocyt", + "str enu", + "s) ▁will▁be▁", + ".6 .3", + "▁to▁the▁ efficacy▁of", + "▁assessment s▁(", + "▁ag onist", + "▁ph osph", + "record ing", + "s.\n\n 3", + "te omic", + ".▁T otally▁con", + ",▁or ▁death", + ".,▁ M", + "▁8 8", + "e▁( IEC", + "15 00", + "every▁ 4", + ".7 2", + "▁form ▁used", + "ular ▁fil", + "Study▁ Medication", + "▁has▁ returned▁to▁baselin", + "▁a▁s chedul", + "▁cycl e\n\n", + "e, ▁the▁patient", + "dur ing▁screening", + "ER MI", + "▁the▁l ow", + "▁inter pret", + "▁reg istration/", + ".\n\nA D", + "▁day s▁or", + "▁day s▁before▁", + "uc oc", + "data ▁on", + "e▁b etween", + "pri ateness▁of", + "▁panitumumab ▁in▁combination▁with", + "s▁or ▁to", + "▁Clinical▁ Research", + "▁death ,▁", + "d▁e▁v▁o▁r▁p▁p▁A\n\nProduct: ▁Denosumab▁Protocol▁Number:▁20050244▁Date:▁05▁May▁2008\n\nPage▁", + "▁evalu ating", + "enter al", + "ed▁from ▁Amgen", + "▁cell ▁lin", + "JM HO", + "appro val▁", + ",▁P a", + "randomiz ed▁in▁a▁1:1▁ratio", + "y▁and▁ capable▁of▁all▁s", + "▁CT ▁or▁MRI", + "e▁that ▁is▁", + ".▁B i", + ".▁B y▁", + "response▁ and▁", + "number ,▁", + "ed▁s lid", + "▁Page▁ 1", + "................................................ ...▁", + "▁disease▁progression ▁is▁", + "ros ome▁", + "-t elop", + "▁dis cretion", + "▁dis crepanc", + "▁drug s▁", + "▁dur ation▁of▁", + "▁dur ing▁or", + "▁loc ation", + "administer ed▁in", + "man ual", + "man uscript", + ".▁An y", + "\n\nIn ternational▁", + "▁respons ible▁person", + "part ▁of", + "▁until ▁the▁", + "ogen ous▁", + "RE G", + ")(cid: 10", + "obtain ed▁", + "\n\n8 \n\n9", + "▁Amgen ’s▁", + "by ▁a", + "s▁should▁be▁ select", + ".▁Patients▁ will", + "▁increas e▁the▁", + "▁count ri", + "\n\n( continued)\n\n", + "▁who ▁are▁", + "▁baselin e▁of", + "determin ed▁", + "▁a▁m ean", + "Con comitant▁Medication", + "▁protocol ▁procedure", + "▁mL ▁of", + "▁develop ed▁", + "▁the▁first ▁day▁of", + "▁the▁sam e▁tim", + "▁+ /-", + "▁phas e,▁", + "particip ation▁in", + "▁Q Tc", + ".\n\nT umor", + "▁15 72", + "▁confirm ation▁of", + "▁withdraw n", + "▁withdraw al▁of▁consent", + "andomis ation", + "ral gia", + "▁hav e\n\n", + "▁18 ▁years▁of▁ag", + "pens ation", + "▁long -term", + "▁safety▁ concern", + "median ▁OS", + "analys es", + "Treatment ▁of▁", + "study▁drug ▁administration", + ",▁W ang", + "ate▁th at▁the▁", + "\n\n10 .1", + "reduction ▁in", + "▁time▁to ▁clinical▁progression", + "▁period▁ for", + "▁accept able▁to", + "▁accept able\n\n", + "2- hour", + "▁caus ality", + "\n\nth e▁subject", + "▁its▁ representativ", + "\n\nin fusion", + "▁am bulator", + "▁meet ▁the▁", + "▁days▁after ▁the▁last", + "rac ellular", + "▁amendment s,▁", + "▁amendment ▁3▁–▁dated▁23", + "gl ucos", + "ison ▁of", + "▁vari ous", + "▁valu es▁", + "respectiv ely▁", + "epar in", + "▁conduct ▁of▁the▁", + "statist ical▁", + "▁consider ation", + "▁Ex clusion▁Criteria", + "\n\nd eath", + "omit ing,▁", + "▁treatment▁with ▁panitumumab", + "ing▁p uls", + "▁> ▁2", + "remain s▁", + "▁whether ▁or▁not", + "staff ▁will", + "Stat ement", + "e▁the▁s afety▁", + "\n\nAmgen ▁Inc", + "▁chest ,▁abdomen", + "▁Patient ▁Reported▁Outcom", + "stitutional▁ review▁board", + "\n\nTable▁ 3", + "▁the▁treatment▁of ▁patients▁with", + "should▁ not", + "measured▁ from▁the▁date▁of▁randomization", + "\n\nSt op", + "LIN ICAL", + ".▁Patient ▁has▁", + "▁blood▁sampl e▁will▁be▁", + "emor adi", + "▁appear s▁to▁be▁", + "▁(cid: 13", + "▁add ed▁to", + "▁of▁your ▁cancer", + "required ▁to▁be▁", + "lymph ▁node▁", + "▁regard ing▁the▁", + "▁written ▁informed▁consent", + "sever ity▁of", + "▁Dos age,▁Administration", + "▁administration▁of ▁investigational▁product", + "▁estim ate▁the▁", + ".▁Thes e▁data", + "▁lin e▁treatment", + "▁strati fication▁factor", + "▁the▁discretion▁of▁the▁ Investigator", + "▁................................................................................ ..", + "e▁test ing", + "ful fill", + "grade▁ 4", + ".▁Pro ceeding", + "stable▁ angina", + "▁AD VERSE▁EVENT", + "Modification s▁for", + "Not ification", + "’s ▁treatment▁assignment", + "▁........................................................................ ......", + "▁on-study▁ chemotherapy", + "version ▁of▁the▁", + "ID MS", + "\n\nNot ▁applicable▁to▁amended▁protocol", + "▁or▁s edent", + "ass▁ vial", + "▁Respons e", + "▁cent ral", + "participating ▁in", + "-to -", + "quant ity▁of", + "▁att empt", + "▁appropriat e.\n\n", + "neutrophil s,▁", + "onc e▁", + "▁Man ual", + ".▁Phase▁ III", + "▁measurable▁ lesion", + "▁respon d", + "▁months▁after ▁the▁last", + "evidenc e▁that", + "pne umon", + "al▁s urv", + "\n\nAmended▁Clinical▁Trial▁Protocol▁5▁XRP6258/EFC6193\n\n21-Jul-2008▁Version▁number:▁1▁(electronic▁2.0 )", + "▁anticip ated▁that", + "reported▁to ▁Amgen", + "▁discontinuation▁of ▁treatment", + ".▁Ch emotherapy▁", + "weekly▁ for", + "▁tr end", + "war e▁of", + "whichever ▁occurs▁first", + "▁There▁ is▁a", + "▁starting ▁dose▁of", + ",▁in▁the▁ opinion▁of▁the▁investigator", + "y/ illness", + "▁gl utam", + "▁at▁baseline▁ and▁", + "▁OF▁T ERMS", + "▁recon stitution", + "erb st", + "▁limit▁of ▁normal", + "dilut ed▁solution", + "▁light ▁or▁sedent", + "at▁the▁end▁of ▁treatment", + "▁predn ison", + "▁apopt otic", + "▁discontinue▁ study▁treatment", + "▁of▁101\n\n090177e18069a3aa\\Approved\\Approved▁On:▁27-Sep-2007▁02:42\n\n1▁4▁:▁5▁0▁7▁0▁0▁2▁-▁g▁u▁A▁-▁1▁3▁\\▁d▁e▁v▁o▁r▁p▁p▁A\n\n\\▁1▁.▁1▁\\\n\n8▁2▁1▁6▁6▁8▁6▁0▁0▁0▁0▁0▁1▁0\n\nSunitinib▁Malate▁Amended▁Protocol▁A6181122▁Amendment▁1,▁28▁August▁2007 \n\nPfizer▁–▁Company▁Confidential▁Page▁", + "ed▁at▁a ▁dose▁of", + "▁will▁be▁censored▁at ▁the▁date▁of▁the▁last", + "▁practice▁ guidelines", + "▁of▁63▁Finalization▁date:▁June▁19▁2001,▁Incorporating ▁amendment▁3▁–▁dated▁23", + "▁relationship ▁to", + "fatigu e,▁", + "▁DISORDERS ▁-", + "▁IEC /IRB", + "refract or", + "arly▁ Stopping", + "▁commercial ▁pharmaceutical▁product", + "impact ▁of", + "ICH ▁GCP", + "▁mm▁with ▁conventional▁techniqu", + "\n\nProgression -free▁s", + "mat ter", + "End▁of ▁Study▁", + "▁<< of▁Consent", + "▁angiogenes is", + "e-specific ▁antigen", + "revis ed▁", + "▁ascit es,▁", + "▁cho ose▁", + "bulator y▁and▁capable▁of▁all▁s", + "objective▁tumor ▁respons", + "oot not", + "es▁to▁the▁ protocol", + "▁from▁baseline▁to ▁month", + "▁number▁of▁ event", + "▁the▁same▁d ay", + "routin ely▁", + "quisition ▁of", + "reli able▁", + ".▁Pharmac y▁Guid", + "▁Kaplan-Meier ▁method", + "Re action", + "\n\nDescription ▁of", + "▁Rece ipt", + "▁white▁blood▁cell ▁count", + "progression-free▁survival▁(PFS) ▁compared▁to", + "\n\nComplete▁ Response▁(CR", + "dominant ly▁s", + "s.▁I t", + "representative▁of ▁all", + "orpt ive▁", + "on-study▁ SRE", + "VF 2", + ".▁Access ed▁", + "forming ▁growth▁factor", + "volunt ary", + "s▁(SAE s)", + ".▁Neither ▁Amgen", + "▁preferred ▁term", + "ML H", + "▁or▁urine▁ pregnancy▁test", + "rate▁for ▁solution▁for", + "eleg ation▁of", + "▁aspir in", + "▁will▁compensate▁you ▁if▁this▁h", + "agnesium,▁creatinin e,▁albumin,▁total▁protein,▁total▁bilirubin", + "eosinophil s,▁bas", + "ely▁disabl ed.▁C", + "▁CTCAE▁= ▁Common▁Terminology▁Criteria▁for▁Adverse▁Event", + "▁immunod eficiency▁vir", + "nual▁M eeting", + "▁(32)\n\nGEL▁Version▁ID:▁ONC.000−214−771.5.0▁Approved▁by\n\nApproved\n\nDate▁Printed:▁31−Jul−2014\n\n02▁Feb▁2006▁15:38:50 \n\nAmended▁Clinical▁Study▁Protocol▁Study▁Code▁7054Il/0023▁Edition▁Number▁7", + "/withdraw al▁visit", + "egold▁ C", + "▁mg/kg▁given ▁once▁", + ",▁Eisen hauer", + ",▁phosphorous,▁and▁ uric▁acid", + "▁ABBREVIATIONS ▁AND▁DEFINI", + "cili ation", + "ricted▁in ▁physically▁", + "▁ENROLL MENT", + "ytoch rom", + "ectib ix", + "appe ared", + "strenu ous", + "▁form▁used >>", + "ular▁fil tration", + "ERMI NA", + "▁ambulator y▁and", + "ing▁puls e,▁", + "▁of▁63▁Finalization▁date:▁June▁19▁2001,▁Incorporating▁amendment▁3▁–▁dated▁23 ▁May", + "▁<>", + "eosinophils,▁bas ophil", + "ely▁disabled.▁C annot", + "ricted▁in▁physically▁ strenuous", + "% ▁versus▁", + "' s▁s", + "- E", + "- 28", + "- Related▁", + "1 ▁level", + "1 :1", + "2 16", + ": ▁T", + ": ▁M", + "; ▁it", + "C M", + "D epartment", + "F ERENCES", + "G uidelin", + "I maging", + "J ,▁M", + "L )", + "L AC", + "N F", + "P ost", + "Q U", + "R ad", + "S uppl", + "T M", + "V A", + "W HO", + "X AL", + "[ plasma▁and▁", + "] ,▁and▁", + "] .▁In", + "a xim", + "a verage▁", + "b ag", + "c orticosteroid", + "d on", + "d re", + "d ipstick", + "e er", + "e .▁All", + "g ive▁", + "h arm", + "h ttp://", + "i j", + "i ation", + "j un", + "n ever", + "n ell", + "n onsquamous▁", + "o al", + "o ok", + "s em", + "s urg", + "s ingle▁", + "w ide▁", + "w arrant", + "y alg", + "° F", + "± ▁15▁minutes", + "▁ 00", + "▁ effort", + "e▁ 1", + "e▁ has▁been", + "in ic", + "in crease▁", + "in formed▁of", + "▁t rough", + "▁t roponin", + "at inib", + "at zem", + "\n\n ac", + "\n\n event", + "\n\n Version", + "\n\n Qu", + "▁a pproved", + "en al▁", + "en rolment", + "s▁ report", + "s▁ consent", + "s▁ relevant", + "y▁ A", + "y▁ b", + "y▁ stimulating▁factor", + "ent an", + "it ing", + "▁the▁ AE", + ",▁ sign", + ",▁ non-", + "▁an ▁SAE", + "▁an ▁objective▁", + "▁an ▁ongoing", + "ic ▁attack", + ".▁ 10", + ".▁ 11", + "▁c erv", + "ing ▁about", + "for ▁at▁least", + "et ]", + "et ary▁", + "et ention", + "▁to ▁assess", + "is sing", + "▁of ten", + "um atic", + "▁d er", + "▁d evi", + "▁d examethasone▁", + "▁d raw", + "▁w alk", + "▁w ait", + "▁m ix", + "▁m outh", + "▁m aterial▁", + "▁and▁ 1", + ".\n\n U", + ".\n\n d", + ".\n\n Investigator", + ".\n\n 33", + "ol us", + "ab stract", + "▁in \n\n", + "▁in cid", "im on", - "imo n", - "i mon", - "њ и", - "▁Prz yp", - "▁Z ag", - "▁Za g", - "▁ди ре", - "▁Similar ly", - "б ро", - "▁mil itaire", - "▁milit aire", - "▁т ому", - "▁то му", - "▁том у", - "▁ тому", - "▁John ny", - "▁Мекси ку", - "ћ а", - "Su pp", - "S upp", - "▁jun ior", - "▁junio r", - "▁juni or", - "ol tre", - "olt re", - "o ltre", - "▁Мо ск", - "▁Мос к", - "▁adm itted", - "▁admit ted", - "▁relig ios", - "зя й", - "е го", - "▁t ears", - "▁te ars", - "▁tea rs", - "in go", - "ing o", - "od u", - "o du", - "iv eness", - "ive ness", - "iven ess", - "▁l ogo", - "▁lo go", - "▁log o", - "▁ logo", - "▁últ imo", - "▁al iment", - "▁ali ment", - "▁U ITableView", - "▁ UITableView", - ") !", - "▁n j", - "le tte", - "let te", - "lett e", - "l ette", - "▁res ident", - "▁resid ent", - "▁term ine", - "▁ter mine", - "▁termin e", - "▁у же", - "▁С те", - "▁Ст е", - "off ice", - "▁c arte", - "▁car te", - "▁cart e", - "▁li vre", - "▁liv re", - "▁Мо сков", - "▁Мос ков", - "▁Моск ов", - "▁e lections", - "▁elect ions", - "▁ele ctions", - "▁election s", - "зи ден", - "Tr igger", - "▁Ben jamin", - "add Class", - "ско г", - "▁Ob servable", - "▁Observ able", - "▁ Observable", - "Cl a", - "C la", - "gem ein", - "geme in", - "g emein", - "▁con sent", - "▁cons ent", - "▁conse nt", - "в ри", - "▁un fold", - "▁unf old", - "▁govern or", - "▁gover nor", - "▁governo r", - "на л", - "н ал", - "▁t oda", - "▁to da", - "▁tod a", - "Rem ote", - "ar ias", - "ari as", - "aria s", - "a rias", - "▁in stal", - "▁inst al", - "▁ins tal", - "fix ed", - "f ixed", - "▁dec ay", - "▁де рев", - "▁дере в", - "xy z", - "x yz", - "▁D ATE", - "▁DA TE", - "▁DAT E", - "▁ DATE", - "im ar", - "ima r", - "i mar", - "nt il", - "n til", - "▁start up", - "al ion", - "ali on", - "▁ko lej", - "▁kol ej", - "▁kole j", - "ci os", - "cio s", - "c ios", - "▁r anges", - "▁range s", - "▁ran ges", - "▁rang es", - "▁stup id", - "▁implement ations", - "▁implementation s", - "▁r m", - "▁ rm", - "én ek", - "é nek", - "▁g cc", - "▁ gcc", - "▁sc ène", - "N avigation", - "▁  ", - "▁к ан", - "▁ка н", - "▁ кан", - "▁town s", - "User name", - "Us ername", - "▁ф е", - "▁ фе", - "▁le aders", - "▁lead ers", - "▁leader s", - "oi t", - "o it", - "w är", - "▁d ummy", - "▁ass istant", - "▁assist ant", - "{$ \\", - "{ $\\", - "бі р", - "б ір", - "▁r oy", - "▁ro y", - "▁ roy", - "▁L ayout", - "▁ Layout", - "▁J ung", - "▁Ju ng", - "▁Jun g", - "Line s", - "Lin es", - "Li nes", - "L ines", - "▁Hol land", - "по р", - "п ор", - "▁Г ри", - "▁B ened", - "▁Be ned", - "▁Ben ed", - "▁П од", - "▁По д", - "xl s", - "x ls", - "▁G ol", - "▁Go l", - "▁Al eks", - "▁Ale ks", - "▁ej emplo", - "▁se zon", - "ar ding", - "ard ing", - "ardi ng", - "ardin g", - "foot note", - "▁Cong rès", - "re fer", - "ref er", - "ска та", - "с ката", - "Iter ator", - "▁our selves", - "▁M ic", - "▁Mi c", - "▁c ódigo", - "▁пло ща", - "▁\\ $", - "▁Char lie", - "No des", - "Node s", - "N odes", - "▁p uzz", - "▁pu zz", - "▁Ident ifier", - "▁ Identifier", - "▁fl utter", - "▁ flutter", - "▁pr ü", - "▁ prü", - "▁o rt", - "▁or t", - "▁ ort", - "▁C ort", - "▁Cor t", - "▁Co rt", - "astic search", - "▁С вя", - "▁B ull", - "▁Bu ll", - "▁Bul l", - "ud em", - "ude m", - "u dem", - "▁ap parent", + "im et", + "im ult", + "................................ ..", + "pl us", + "pl eur", + "▁1 /", + "es▁ is▁", + "▁P FIZER▁CONFIDENTIAL▁Page▁", + "▁P revious▁", + "pro ject", + "▁( within", + "▁( EGFR", + "▁( serum", + "▁2 .4", + "▁S tud", + "ot id", + "ot rex", + "▁l etter", + "▁f ew", + "▁f elt", + "▁f ebrile▁neutropenia", + "e▁t otal▁", + "▁n ow", + "▁n atur", + "\n\nA pproved", + "\n\nA ssessment▁of", + "▁O RR", + "▁O XAL", + "▁pro b", + "▁ad apt", + "▁ar rang", + "other ▁treatment", + "▁for ▁this▁", + "▁for ▁colorectal▁cancer", + "▁for ▁metastatic▁colorectal▁cancer", + "and ers▁", + "e\n\n (", + "enc es▁of", + "enc y,▁", + "s▁of f", + "ad vanced▁", + "\n\nS urvival▁", + "\n\nS afety", + "▁that ▁of", + "▁of▁ existing", + "▁will▁be▁ estimated▁", + "e▁s elect", + "▁M aintain▁dose▁level", + "▁3 1,▁", + "▁3 ▁x▁ULN", + "▁of▁the▁ investigational▁product", + "wh eez", + ".▁The▁ overall", + ".▁The▁ incidence▁of", + "ity▁ Form", + "▁the▁s erum", + "▁on ▁study", + "ated▁ lung", + "ated▁ fatty", + "ine▁ and▁", + "int ensity▁", + "s,▁ S", + "s,▁ respectively", + "12 3", + "ip s", + "▁st ill", + "▁st abiliz", + "▁ch emotherapeutic", + "▁will ▁include▁a", + "e▁in volv", + "▁5 00▁mg/m2", + "▁5 ▁years▁of", + "▁6 ▁1", + "▁6 .3.1", + "cur ric", + "▁subject s▁treated▁with", + "▁4 %", + "▁the▁p emetrex", + "▁ac cident", + "eg o", + "eg e▁of", + ".4 4", + "continu ed▁until", + ".5 1", + ".5 8", + "s.▁ You", + "▁week s)", + "rit ical", + "▁any▁ purpose▁", + "▁ex clud", + "ell ow", + "ell et]", + "ance▁ and▁", + "▁wh il", + "ed▁by ▁the▁patient", + "eth otrex", + "ally▁ related▁to", + "ed▁for ▁a", + "s▁and▁ Study▁T", + "e▁d ail", + "▁patient s,", + "ang itis▁", + "▁G ▁M", + "▁un used▁", + "ous ework", + "▁U PCR", + "e▁the▁ right▁to", + "pt s)▁with", + ".▁P ower", + "s\n\n For", + "ed▁by▁ each", + "evalu ating▁the▁", + "▁tumor ▁lesion", + "▁tumor ▁imaging", + "effect ▁on", + "▁study \n\n", + "▁study ▁therapy▁", + "artic ulate▁", + "s) .", + "pp ear", + "record ed▁and▁", + "record ing▁of", + "s.\n\n 5", + "s.\n\n D", + ",▁and ▁that", + "▁sign ▁this▁", + "RI MENTAL", + ".▁T able▁", + ",▁or ▁if", + "▁9 .1.1", + "pre treatment", + ").\n\n 5", + "\n\n2 2", + "y▁of ▁the▁following", + "▁should▁be▁ discontinu", + "▁Ad EERS", + "▁Study▁ Manager", + "ass e▁P", + "\n\nF irst", + "▁the▁patient 's▁", + "respons e", + "respons ibility▁", + "▁The▁ Investigator", + "s▁are▁ responsible▁for", + "▁W T", + "KRAS ▁testing", + "KRAS ▁mutation", + "▁ob lig", + "▁day s▁of▁the▁", + "\n\nI ▁feel", + "i- squ", + "▁panitumumab ▁administration", + "▁therapy▁ is▁", + "result s▁of▁the▁", + "dos age▁", + "▁progression ▁event", + "▁peri pheral▁", + "▁over ▁30", + "receiv ed▁treatment▁with", + "consider ed▁in", + "consider ed▁for", + "▁subjects▁ randomized▁to", + "▁approximately▁ every▁6▁months▁for", + "▁their ▁sp", + "▁et▁al .▁199", + "disease▁ or", + "es▁will▁be▁ test", + "ish er", + "iom et", + "▁provid es▁", + "▁response▁ is▁", + "dose▁ until▁toxicity▁", + "▁the▁tim e▁that", + "▁these▁ studies▁", + "s▁b elow", + ",▁M ur", + "\n\n7 .5", + ",▁200 9", + "elect ed▁", + "s▁will ▁only▁be▁", + "▁non- measurable▁lesion", + "▁must ▁be\n\n", + "sub investigator", + "▁level ▁is▁", + "▁metastatic ▁sit", + "▁blood▁ [plasma▁and▁", + "▁result s▁of", + "arget▁lesion s▁should▁be▁select", + "IN TS", + "IN VESTIGATIONAL▁PRODUCT", + ".▁N on", + "\n\nB aseline▁", + "\n\nB iomarker", + "given ▁at", + "part ate▁transamin", + "uthor ization", + "rati fication", + "▁tissu e▁block", + "chang es", + "chang es▁to", + "ry▁ (", + ")(cid: 3)(cid:", + ",▁H ean", + ".▁J ournal", + "di ent", + "▁ne uropath", + "ed▁or gan", + "▁both ▁treatment▁arm", + "▁int ens", + "▁int ellect", + "ed▁by▁the▁ following", + "▁approv ed▁informed▁consent▁form", + "known ▁as▁", + "▁a▁c or", + "ed▁c ycl", + ",▁D ay▁1", + "▁previ ous", + "▁every▁ 21▁days", + "Un der", + ",▁L ang", + "▁develop ment▁of", + "\n\nAppendix ▁B", + ",▁p ower", + "▁cetuximab ▁infusion", + "▁period ic", + "caus al▁relationship", + "▁two -sided▁", + "▁KRAS ▁status▁", + "study▁treatment ▁period▁or", + "chemotherapy▁ (", + "▁research ▁study", + "▁of▁a ▁light▁or▁sedent", + "▁health y▁", + "▁health care▁", + "▁health ▁care▁", + "▁health -related▁quality▁of▁lif", + "IG IB", + "▁author ization", + "▁and▁s cientific", + "▁20 ▁mg", + "erious▁ or", + "eph er", + "during ▁follow-up", + ",▁W ol", + "▁prior▁to ▁randomization", + "e.▁ W", + "respon d▁to", + "used▁for ▁any▁purpose▁", + "eplac ement▁of", + "er▁than ▁the▁", + "▁11 .2", + "\n\nth is▁", + ",▁d yspnea", + "ize▁ each", + "▁patients ▁treat", + "hemat ology", + "▁28 ▁days", + "▁28 ▁days▁", + "quam ous", + "%▁of ▁patients▁", + "strati fication", + "develop ed▁", + "▁bi as", + "........................................ .▁", + "▁risk ▁factor", + "prof essional", + "open-label ▁denosumab", + "▁25 ▁mg", + "atur ated▁fatty", + "▁PR ▁PR", + "-D ay▁", + "combin ed▁", + "AR M", + "▁man age▁", + "▁detail ed▁", + "ing▁p urpos", + "▁alon e,▁", + "▁alon e)", + "compar ative▁", + "▁oxaliplatin ▁dose▁level", + "resolv ed▁", + "s▁includ e▁", + "where▁ appropri", + "▁individual s▁", + "roch ure▁", + "▁bod y▁system", + "es▁from ▁baseline▁", + ",▁h yp", + "▁analysis▁will▁be▁ conduct", + ".▁Wh ile▁", + "period ically▁", + ".▁On col", + "▁current ly▁available▁", + "▁involv ed▁organ", + "\n\nSt or", + "CT▁scan ▁or▁MRI", + "assign ed▁a", + ".▁Con comitant▁Medication", + "▁prof essional", + "otal ▁bilirubin", + "stratifi ed▁log-rank▁test", + "stopp ed▁for", + "▁Rec ord", + "ogenic ity▁", + ".▁The▁investigator ▁should▁notify▁the▁", + "delay ed▁for", + "▁IN FORM", + "▁ext raction", + "\n\nPage: ▁36\n\nSection:▁2.3.6.6,▁Anti-Panitumumab▁Antibodies", + "▁statist ic", + "▁specific ally▁", + "▁Dos age▁Adjustment", + "\n\nPatients▁ who", + "▁this▁research .▁Neither▁Amgen", + "▁chemist ry,▁", + "▁EGFr ▁expression", + "e▁on ▁a", + "▁well -being", + "recorded▁on▁the▁ case▁report▁form", + "▁predict ive▁", + "s▁must ▁not▁be▁", + "▁assess▁the▁ effects▁of", + "prior▁to▁the▁ first", + "version ▁3.0", + "▁rate▁ (", + "\n\nNot e:", + ".▁Patients▁who ▁are▁", + "▁5-fluorouracil /", + "igen etic", + "=0 .0", + "hibition ▁of", + "e▁dis comfort", + "EL L", + "▁consist s▁of", + "▁and▁E arly▁Stopping", + "▁calcul ate▁", + "▁thromb osis", + "starting ▁dose▁of", + "lood▁sampl es▁will▁be▁", + "lic ens", + "▁plasma ▁concentration", + ".▁Phase▁ II", + "▁sufficient ▁increase▁to", + "box ▁number", + "flu id▁", + "\n\nWh at", + "▁grad ing", + "▁mis s", + "e▁as pir", + "▁experience▁ any▁", + "▁3.3 .4", + "fail ure", + "▁fever ▁or", + "▁stratifi ed▁by▁the▁randomization", + "ed▁before▁ any▁", + "statistical ▁analysis▁plan", + "▁investigational \n\nproduct", + "ed▁in▁accordance▁with ▁the▁", + "adjusted▁ HR", + ".▁It▁is▁ recommended▁that", + "PE RIMENTAL", + "withhel d▁for", + "▁select ed▁", + "▁activities .▁Up▁and▁about", + "▁Investigational▁Product ▁for▁Destruction", + "▁and▁c ardiovascular", + ".\n\nTh ere▁", + "s▁per ▁organ", + "omat itis▁", + ",5 ,6", + "▁ren al▁cell▁carcinoma", + "▁apopt osis", + "▁aged▁ >", + "should ▁also▁be▁", + "▁previously ▁treat", + "▁previously ▁treated▁", + "(6 ):▁p.▁", + "omer ular▁filtration", + "performed▁as▁ clinically▁indicated", + "recent ly▁", + "▁arch ival", + "hold▁ dose▁until▁toxicity▁", + "United▁St ates▁", + "(5 ):▁p.▁", + "▁ml /min", + "amount ▁of", + "entered▁into ▁the▁study", + "European ▁Union", + "▁unable▁to ▁carry▁out", + "blinded▁ study▁medication", + "goal ▁of▁the▁", + "▁qualify▁for ▁PD", + "pa id▁", + "▁the▁prior ▁written", + "we ak", + "▁Discontinu ation▁of", + "▁proc es", + "▁Lilly▁or▁its▁design e", + "▁all▁randomized▁ subject", + "reported▁as ▁adverse▁event", + "Ac adem", + "▁radiograph ically▁documented▁PD", + "▁Metastatic ▁Colorectal▁Cancer", + "double-blind ,▁placebo-", + "▁tra il", + ",▁pleas e▁", + "▁1999 ;", + "has▁not ▁been", + "loride▁ Injection", + "\n\nS▁T▁I\n\nK▁C▁E▁H▁C\n\nE▁S▁A▁E▁L▁P\n\n.▁T▁N▁E▁M▁U▁C▁O▁D \n\nC▁I▁N▁O▁R▁T▁C▁E▁L▁E\n\nN▁A\n\nF▁O\n\nY▁P▁O▁C\n\nD▁E▁T▁N▁I▁R▁P\n\nA\n\nS▁I\n\nS▁I▁H▁T", + "▁EL IGIB", + "reconstruction ▁interval▁", + "thical▁ Review", + "▁24-hour ▁urine▁collection", + "terim▁Analysis ▁and▁Early▁Stopping", + ".\n\nRE FERENCES", + "ed▁but ▁not", + "▁controll ed▁", + "▁and▁Treatment ▁Schema", + "age▁to ▁qualify▁for", + "▁prescrib ing▁information", + ".▁1999 ;", + "▁fully▁ human", + "moder ate▁", + "objectives▁of ▁the▁study", + "categor iz", + "ossibl e▁", + "▁the▁differ ence▁in", + "ed▁onc e▁", + "PACCE ▁protocol", + "▁compliance▁ is▁", + "respiration ▁rate", + "▁progn osis", + "▁Roch ester", + "s▁- ▁Other", + "▁dig it", + "thir d▁", + "▁3rd▁ quarter", + "▁a▁sec ure▁", + "▁between▁the▁2 ▁treatment▁arm", + "▁run -in", + "fice▁ work", + "most▁frequ ently▁", + "▁adverse▁drug ▁reaction", + "inancial▁Dis closure▁", + "red▁to▁as▁ “", + "one▁or▁mor e▁of▁the▁following", + "Wild-typ e▁and▁", + "ome- ▁what", + "▁littl e▁b", + "▁diphenhydramin e▁", + ".▁Ob jectiv", + "attribut able▁to", + "the▁s am", + "▁persistent▁or▁significant▁dis ability/inc", + "ethical▁ review▁board", + "▁abort ion", + "ensory▁ neuropath", + "with▁placebo ▁in▁terms▁of", + "ability▁for ▁accurate▁", + "▁result▁from ▁this▁research.▁Neither▁Amgen", + "\n\nFull y▁active,", + "risks▁and▁ benefits▁of", + "Medicin e,▁", + "active▁Voice▁ Response▁System", + "▁SC▁injection ▁of▁denosumab", + "Therapy▁During ▁Study▁", + "uns aturated▁fatty", "▁appar ent", - ":- -", - ": --", - "▁Х ар", - "▁Ха р", - "▁L ap", - "▁La p", - "▁com port", - "▁comp ort", - "mat ically", - "m atically", - "▁cu rios", - "▁cur ios", - "▁мо жет", - "▁мож ет", - "▁може т", - "▁B h", - "ap ping", - "app ing", - "a pping", - "▁b asketball", - "▁basket ball", - "ze tek", - "zet ek", - "▁r unt", - "▁run t", - "▁ru nt", - "▁Mil an", - "▁Mi lan", - "fe ction", - "fect ion", - "f ection", - "rí a", - "r ía", - "▁K in", - "▁Ki n", - "▁s lower", - "▁sl ower", - "▁slow er", - "▁slo wer", - "bo th", - "bot h", - "b oth", - "▁Inst ituto", - "▁Instit uto", - "▁Institut o", - "▁Histor ical", - "▁Historic al", - "▁równ ież", - "mat ches", - "match es", - "yc i", - "y ci", - "▁esp èce", - "▁Schwe izer", - "▁Schweiz er", - "N T", - "S F", - "ac ia", - "aci a", - "a cia", - "for ge", - "f orge", - "Point s", - "Po ints", - "num bers", - "number s", - "▁f alling", - "▁fall ing", - "▁fal ling", - "▁inherit ance", - "▁Er st", - "▁custom ers", - "▁customer s", - "▁a ctu", - "▁act u", - "▁ac tu", - "▁m igration", - "▁migr ation", - "\\ '", - "Pl an", - "P lan", - "M r", - "ot hy", - "oth y", - "o thy", - "▁up grad", - "би ра", - "▁O ffic", - "▁Of fic", - "▁Off ic", - "▁W ait", - "▁Wa it", - "▁ Wait", - "▁to ler", - "ar don", - "ard on", - "ardo n", - "▁s lide", - "▁sl ide", - "▁sli de", - "▁ slide", - ") _", - "▁ста в", - "▁ став", - "▁nu clear", - "▁nuc lear", - "▁nucle ar", - "▁B il", - "▁Bi l", - "ow ner", - "own er", - "o wner", - "▁Har ris", - "▁Harr is", - "In formation", - "▁p ó", - "▁вклю ча", - "▁nu ovo", - "▁C av", - "▁Ca v", - "▁De scri", - "▁Des cri", - "▁а к", - "ód zt", - "▁react js", - "▁Ad ams", - "▁Adam s", - "▁Ada ms", - "▁Altern atively", - "ст рук", - "стру к", - "стр ук", - ")` ,", - ") `,", - "sub string", - "subst ring", - "substr ing", - "▁mass ive", - "▁heav ily", - "▁се зо", - "▁сез о", - "▁A na", - "▁An a", - "▁v ale", - "▁val e", - "▁va le", - "Pa d", - "P ad", - "▁E ither", - "▁r s", - "▁ rs", - "an che", - "anc he", - "anch e", - "▁up loaded", - "▁upload ed", - "▁( /", - "▁ (/", - "▁с пор", - "▁спо р", - "▁сп ор", - "▁redu ction", - "▁Tok yo", - "gr en", - "gre n", - "g ren", - "▁m igli", - "▁mig li", - "▁iter ator", - "▁ iterator", - "st av", - "sta v", - "▁support ing", - "▁ö sterreich", - "▁NS Log", - "ist iques", - "isti ques", - "istique s", - "ri min", - "rim in", - "r imin", - "MO DE", - "}} }\\", - "}}} \\", - "} }}\\", - "▁exp los", - "▁expl os", - "▁explo s", - "от е", - "о те", - "▁( „", - "Sa l", - "S al", - "▁simple st", - "▁simpl est", - "▁gi à", - "▁та н", - "▁т ан", - "▁ тан", - "▁c yl", - "▁cy l", - "bi r", - "b ir", - "▁measure ments", - "▁measurement s", - "Create d", - "Cre ated", - "er ek", - "ere k", - "e rek", - "look up", - "w irtschaft", - "▁В оло", - "▁Во ло", - "▁Вол о", - "ti mer", - "time r", - "tim er", - "t imer", - "de rr", - "der r", - "d err", - "▁ст ала", - "▁ста ла", - "▁стал а", - "▁sc enes", - "▁scen es", - "▁scene s", - "▁per su", - "▁pers u", - "li est", - "lie st", - "lies t", - "l iest", - "▁sch edule", - "▁sched ule", - "ta l", - "t al", - "ле но", - "лен о", - "▁pain ting", - "▁paint ing", - "▁impro vement", - "▁improve ment", - "▁improv ement", - "so ftware", - "soft ware", - "▁govern o", - "▁gover no", - "▁H ir", - "▁Hi r", - "Exec ution", - "▁Ok ay", - "Pro p", - "Pr op", - "P rop", - "lo ster", - "los ter", - "lost er", - "l oster", - "ніципа лі", - "▁peu vent", - "ol u", - "o lu", - "▁Ф а", - "roll o", - "rol lo", - "▁ко ло", - "▁к оло", - "▁ коло", - "▁car rière", - "▁carri ère", - "▁t oggle", - "▁tog gle", - "▁togg le", - "▁ toggle", - "▁( $\\", - "▁($ \\", - "▁aggreg ate", - "▁Б і", - "text area", - "O k", - "it to", - "itt o", - "i tto", - "▁s tim", - "▁st im", - "▁recurs ion", - "▁Feder ation", - ")_ {", - ") _{", - "ate gor", - "ateg or", - "▁dist ribu", - "▁distrib u", - "Cl oud", - "▁m adre", - "▁mad re", - "▁i v", - "▁ iv", - "▁Lie utenant", - "▁subst ant", - "▁le af", - "▁ leaf", - "▁Kont rola", - "V A", - "▁t omb", - "▁to mb", - "▁tom b", - "э н", - "ato es", - "▁god ine", - "▁# >", - "C ert", - "▁em presa", - "▁empres a", - "Pro ps", - "Pr ops", - "Prop s", - "▁pl anned", - "▁plan ned", - "▁random ly", - "j ähr", - "el em", - "ele m", - "e lem", - "▁Oper ation", - "▁Opera tion", - "▁ Operation", - "* `", - "pro tocol", - "proto col", - "() ));", - "()) );", - "())) ;", - "( )));", - "we l", - "w el", - "▁p raw", - "▁pr aw", - "▁pra w", - "▁с им", - "▁си м", - "▁w ob", - "▁wo b", - "▁h ace", - "▁ha ce", - "▁near est", - "dis able", - "▁C ommun", - "▁Com mun", - "▁Comm un", - "▁re vel", - "▁rev el", - "▁reve l", - "Fr ee", - "Fre e", - "F ree", - "▁bra ckets", - "IO Exception", - "▁al to", - "▁alt o", - "▁mar ry", - "▁a uc", - "▁au c", - "▁ auc", - "), \\", - ") ,\\", - "▁typ o", - "▁ty po", - "ed ad", - "eda d", - "ar á", - "a rá", - "ic ator", - "ica tor", - "tat ywna", - "▁b uff", - "▁bu ff", - "▁buf f", - "▁ buff", - "or ders", - "ord ers", - "order s", - "orde rs", - "▁as ynchronous", - "▁e con", - "▁ec on", - "▁f eu", - "▁fe u", - "▁I ron", - "▁Ir on", - "▁r ising", - "▁ris ing", - "▁ri sing", - "Rad ius", - "cl k", - "▁zwe iten", - "▁zwei ten", - "▁zweite n", - "` '", - "▁un iqu", - "▁F M", - "▁ FM", - "▁B ran", - "▁Br an", - "▁Bra n", - "▁f lu", - "▁fl u", - "▁ flu", - "▁sens itive", - "ur re", - "urr e", - "▁I ter", - "▁It er", - "▁ Iter", - "▁S ein", - "▁Se in", - "▁difer entes", - "▁diferen tes", - "▁не го", - "▁н его", - "▁ него", - "ch ia", - "chi a", - "▁An leitung", - "atur day", - "▁sh orter", - "▁short er", - "▁transl ated", - "▁translate d", - "▁R és", - "▁Ré s", - "▁r ode", - "▁ro de", - "▁rod e", - "dr ag", - "dra g", - "d rag", - "▁l ange", - "▁lang e", - "▁lan ge", - "B i", - "ü b", - "le ur", - "l eur", - "▁order ing", - "▁ord ering", - "al ous", - "alo us", - "▁К ор", - "▁Ко р", - "ar char", - "arch ar", - "arc har", - "dest roy", - "erv ation", - "erva tion", - "]] ,", - "] ],", - "Accessor Impl", - "▁autory tatywna", - "Se quence", - "Sequ ence", - "▁pro yect", - "▁b ran", - "▁br an", - "▁bra n", - "▁( +", - "▁K ab", - "▁Ka b", - "▁z em", - "▁ze m", - "▁ zem", - "▁Cal cul", - "▁ Calcul", - "▁se ul", - "▁seu l", - "▁N iger", - "▁Ni ger", - "▁ch iam", - "▁chi am", - "th row", - "▁Plan et", - "▁Pla net", - "bild ung", - "▁z ones", - "▁zo nes", - "▁zone s", - "trans ition", - "ле ний", - "▁m apped", - "▁ma pped", - "▁map ped", - "on aut", - "ona ut", - "Pa ir", - "P air", - "il ian", - "ili an", - "ilia n", - "▁M organ", - "▁Mor gan", - "▁un to", - "▁ unto", - "jo u", - "j ou", - "▁h id", - "▁hi d", - "▁M eta", - "▁Me ta", - "▁Met a", - "▁ Meta", - "▁e lles", - "▁el les", - "▁elle s", - "▁ell es", - "▁ elles", - "Lo u", - "L ou", - "ra ma", - "ram a", - "r ama", - "ge ordnet", - "▁scarc ely", - "▁m int", - "▁min t", - "▁mi nt", - "F ocus", - "▁Al ter", - "▁Alt er", - "▁d io", - "▁di o", - "▁am pl", - "▁amp l", - "ière ment", - "▁ис следова", - "LE D", - "L ED", - "alg orithm", - "▁сай ті", - "▁сайт і", - "▁\" \")", - "▁\"\" )", - "Hi story", - "H istory", - "p k", - "▁W hit", - "▁Wh it", - "▁си стем", - "▁систе м", - "▁Kir chen", - "▁Kirche n", - "▁Kirch en", - "r à", - "AP P", - "A PP", - "▁< %", - "ant ine", - "anti ne", - "antin e", - "▁D isk", - "▁Dis k", - "▁Di sk", - "con v", - "we lt", - "wel t", - "w elt", - "▁F ut", - "▁Fu t", - "▁N om", - "▁No m", - "or do", - "ord o", - "el lij", - "ell ij", - "elli j", - "▁rece ives", - "▁receive s", - "co w", - "c ow", - "yt u", - "y tu", - "▁o bras", - "▁ob ras", - "▁obra s", - "▁p urchase", - "▁purch ase", - "▁ear ned", - "▁acc essed", - "▁access ed", - "ax i", - "a xi", - "▁M ans", - "▁Man s", - "▁Ma ns", - "iv an", - "iva n", - "i van", - "▁t uvo", - "▁tu vo", - "▁T race", - "▁Tr ace", - "▁Tra ce", - "▁ Trace", - "rim onio", - "▁desen vol", - "ér ique", - "éri que", - "é rique", - "▁result ed", - "▁comp uting", - "▁comput ing", - "▁insp ired", - "▁inspir ed", - "▁Pr ize", - "▁Pri ze", - "* \"", - "Com put", - "Comp ut", - "▁ext ensive", - "▁extens ive", - "è g", - "▁Port ály", - "▁cast le", - "▁ castle", - "▁* .", - "▁ *.", - "▁ph otos", - "▁phot os", - "▁photo s", - "▁vo et", - "ON G", - "O NG", - "▁A lle", - "▁Al le", - "▁All e", - "▁thre aten", - "▁threat en", - "st üt", - "▁album s", - "▁alb ums", - "▁d ense", - "▁den se", - "▁dens e", - "fl at", - "f lat", - "cont inu", - "Sub ject", - "Su bject", - "▁read only", - "Op t", - "O pt", - "пи ско", - "пис ко", - "▁A ber", - "▁Ab er", - "▁P osition", - "▁Pos ition", - "▁ Position", - "▁To day", - "▁Tod ay", - "▁m ini", - "▁min i", - "▁mi ni", - "▁B ef", - "▁Be f", - "li sten", - "list en", - "lis ten", - "l isten", - "ствен ного", - "ственно го", - "SU B", - "S UB", - "os sa", - "oss a", - "▁P ope", - "▁Po pe", - "▁Pop e", - "▁Jim my", - "▁Д ру", - "ungs seite", - "▁t ren", - "▁tr en", - "▁tre n", - "op tim", - "opt im", - "it sch", - "its ch", - "▁s amt", - "▁sa mt", - "▁sam t", - "▁испо л", - "▁ис пол", - "& =", - "▁Przyp isy", - "▁про дол", - "C r", - "er mann", - "erm ann", - "erman n", - "▁ма тери", - "▁мате ри", - "▁H ugo", - "▁Hu go", - "▁De ze", - "▁Dez e", - "TR UE", - "▁defe at", - "▁watch ed", - "▁wat ched", - "▁G ent", - "▁Ge nt", - "▁Gen t", - "AU T", - "A UT", - "or ous", - "oro us", - "▁о преде", - "ori entation", - "orient ation", - "▁distingu ished", - "▁distinguish ed", - "▁mes mo", - "▁s li", - "▁sl i", - "ме на", - "мен а", - "м ена", - "mit tel", - "mitt el", - "m ittel", - "ge richt", - "ger icht", + "at▁a▁significance▁level ▁of▁5%", + "or▁serum ▁pregnancy▁test", + "ometim es▁", + "▁sufficient▁shrink age▁to▁qualify▁for", + "d▁and▁Signific ance:", + "3)▁(cid:4)▁(cid: 5)▁(cid:6)▁(cid:", + "ine▁needl e▁aspir", + "▁all▁pre- disease▁", + "▁registration/ randomization", + "priateness▁of ▁Measurement", + "representative▁of▁all ▁involved▁organ", + "elegation▁of ▁Author", + "atzem eier", + "imult ane", + "s▁and▁Study▁T ermination", + "▁their▁sp ous", + "▁blood▁[plasma▁and▁ cell", + ",▁Hean ey▁", + "▁of▁a▁light▁or▁sedent ary▁n", + "▁assess▁the▁effects▁of ▁ZD4054", + "PERIMENTAL ▁PLAN", + "hold▁dose▁until▁toxicity▁ is▁", + "▁ELIGIB ILITY", + "% ,▁", + "( if", + "( neutrophils,▁", + ") \n\nC", + ") .▁P", + ", ▁third▁", + "- P", + "- 18", + "- 23", + "- paclitaxel", + "- and-", + "/ in", + "/ benefit", + "0 )", + "1 .3", + "8 .0", + ": 4", + ": 6", + ": \n\nThe▁", + ": 26", + ": 29", + ": ▁If", + "C VD", + "D G", + "E ING", + "H andl", + "I X", + "I .V", + "K S", + "M ulticenter", + "N O", + "N ▁A", + "O D", + "S cor", + "W eight", + "b ecause▁of", + "b ecause▁", + "c u", + "c ial▁", + "c oh", + "c ritical▁", + "e e▁the▁", + "f eet", + "f eel", + "i ro", + "l et", + "l act", + "m ab", + "m ethods▁of", + "m ethod▁of", + "m easure▁", + "n ucle", + "o .", + "p owder", + "r ich", + "s ch", + "t rans", + "v ein", + "– ▁S", + "” ▁and▁", + "≤ 1", + "▁ kg", + "▁ emergent", + "▁ radical▁prostatectom", + "e▁ In", + "in ,▁", + "in stitut", + "in flammatory▁", + "in fluenc", + "▁t urn", + "▁t rain", + "▁t ired", + "on ▁P", + "\n\n ", + "\n\n is▁", + "\n\n 40", + "\n\n adverse▁event", + "\n\n 50%", + "▁a x", + "▁a ▁study▁", + "er ▁A", + "s▁ 6", + "s▁ can", + "al ▁cancer", + "st ead", + "y▁ M", + "ent ries▁", + "it ron", + "▁the▁ DMC", + ",▁ 8", + ",▁ must▁be▁", + ",▁ week", + ",▁ Wh", + ",▁ lung", + ",▁ even▁if", + "ro v", + "ro at", + "ro ok", + "ed▁ health", + "▁an ▁interim", + "▁an ytim", + "ic l", + "ic ▁or", + "ic ens", + ".▁ or", + ".▁ 15", + "ar e▁m", + "ed ▁and/or", + "ed .▁For", + "▁p regnanc", + "▁c ardi", + "ing ▁in▁the▁", + "ing ▁this▁document", + "▁b l", + "for ▁a", + "for ▁any▁reason", + "et a", + "et oc", + "▁to p", + "▁to ▁an", + "▁to ▁maintain", + "is ation▁(", + "▁s pec", + "▁of ▁original", + "▁d emographic", + "▁m M", + "▁m ult", + "▁m ulticenter", + "▁and▁ 15", + "▁and▁ fluorouracil", + "▁and▁ Amgen", + "▁and▁ platelet", + "▁and▁ 5-fluorouracil", + ".\n\n 25", + ".\n\n 24", + ".\n\n 27", + ".\n\n (cid:120)", + ".\n\n IMMUNEX\n\nConfidential\n\nAMGEN\n\nProduct:▁ABX-EGF▁Protocol▁Number:▁20020408▁Amendment▁4▁Date:▁26▁April▁2005\n\nPage▁", + "ment al", + "al▁ outcom", + "ol ubl", + "is▁ will▁be▁", + "▁A gent", + "▁in duc", + "▁in corpor", + "ur b", + "ig m", + "▁C urrent", + "▁C alculated▁", + "es▁ between", + "▁P roduct", + "▁P ractic", + "▁P re-", + "il ogram", + "▁( O", + "▁( Z", + "▁( c", + "▁( CRF", + "▁( CRC", + "▁( WBC", + "▁( that▁is", + "▁2 ▁cm", + "if est", + "▁S I", + "▁S h", + "▁S keletal▁", + "▁S tudies", + "ag es", + "▁D ate\n\n", + "▁h and", + "with in▁the▁", + "▁l -L", + "ap pens", + "▁E thics▁Committe", + "▁E ligibility▁", + "▁f ill", + "▁f ound", + "▁f ind▁", + "am etric", + "am isol", + "ir culation", + "ut er", + "form ula", + "ther apies", + "\n\nP re-", + "ex act", + "ex clusion", + "ex pens", + "ex ploratory", + "per icardial▁effusion", + "\n\nA ssessment", + "\n\nA ▁little▁b", + "▁and ▁tumor", + "▁and ▁the▁same▁techniqu", + "▁as ▁a▁single▁agent", + "▁pro ject", + "▁pro mptly▁", + "▁T 2", + "▁T NM", + "up dated▁", + "▁for ▁the▁purpose▁of", + "and ▁a", + "e\n\n 4", + "e\n\n 6", + "rom ol/L", + ".2 .6", + "av our", + "ad vanc", + "ad vis", + "ant itumor", + "\n\nS ome-▁what", + "▁that ▁has▁", + "▁200 2", + "▁is▁ oblig", + "▁of▁ 9", + "▁of▁ W", + "▁of▁ zoledronic▁acid▁", + "▁of▁ XRP6258", + "▁al kaline▁phosphat", + "e▁s cal", + "e▁s erum", + "e▁s imilar", + "e▁s ubjects▁who", + "e▁th em", + "▁M ED", + "▁r ank", + "▁3 5%", + "▁of▁the▁ sampl", + "e,▁ s", + "e,▁ including", + "▁com promis", + ".▁The▁ following", + "▁as▁ long", + "▁as▁ part▁of▁the▁", + "200 401", + "▁the▁s hipment", + "▁are▁ also", + ",▁and▁ d", + ",▁and▁ other", + "ition er", + "▁L S", + ".3 4", + ".3 7", + "▁B NP", + "▁B PI", + "▁this▁ section", + "▁all ▁study▁", + "ure tic", + "ip p", + "▁st aging", + "▁will ing▁to", + "▁will ▁remain", + "▁will \n\nbe▁", + "ing▁the▁ first▁dose▁of", + "ity -of", + "▁6 3", + "▁6 .2.1", + "▁H yp", + "▁4 0%", + "▁the▁p oss", + "ampl ification", + "\n\nPage▁ 1", + "s▁( a", + "▁the▁in jection", + "▁ac c", + "▁ac ross▁", + "one▁ number", + "eg ion", + "eg ally▁acceptable▁", + ".4 7", + ".4 .4", + "▁study▁ screening", + "s▁in ▁this▁study", + "s▁in ▁human", + "▁week s,▁", + "▁any▁ study▁", + "▁ex cess", + "reg ister", + "▁wh ose▁", + "s▁and▁ Definition", + "ed▁on ▁Day▁1", + "e▁d eath", + "ath yroid▁", + ".▁S ub", + ".▁S TUDY", + "s▁will▁be▁ maintain", + "▁G lobal▁", + "der ly▁", + "orm al", + "),▁ with", + "),▁ including", + "s\n\n M", + "rim idine▁", + "▁not ify▁", + "eter son", + "▁7 4", + "▁7 ▁days", + "▁adverse▁event ▁report", + ".6 0", + ".6 3", + ".▁In ternational▁", + "over n", + "s.\n\n 4", + "s.\n\n All", + ".▁C opies▁of", + ".▁C irculation", + "AL ITY", + "par ent", + ",▁or \n\n", + "CR ▁or▁PR", + "ract itioner", + "radi ological", + "patient ▁hospitalization▁or", + "▁disease▁ and▁", + "s▁s hould", + "s▁s ubmitt", + "▁us ual", + "▁each ▁subject", + "pre ad", + "30 ▁mg", + "▁data ▁collect", + "▁data ▁monitoring", + "▁your ▁body", + "▁your ▁study▁doctor", + "▁to▁be▁ us", + "▁a▁s pecific", + "▁cycl es▁(", + "\n\nT oxicity▁", + ".▁D etermination▁of", + "▁the▁l ocal", + "▁reg istration", + "complet ed.\n\n", + "▁W ELL", + "e) .", + "\n\nThe▁ secondary▁", + "\n\n4 .3", + "e▁b lood", + "e▁b arrier", + "\n\nI EC", + "\n\nI RB", + "▁visit ▁the▁", + "defin ed▁by▁", + "yst ic▁lesion", + "s▁or ▁worsen", + "▁was▁ removed▁from▁the▁", + "result s▁from", + "fl uoropyrimidin", + "equ ence▁", + "cond om", + "dos es▁", + "An t", + "provid ed▁in▁Appendix", + "prior▁to ▁each", + "ed▁and▁ document", + "ed▁and▁ dated▁", + "▁over dos", + "▁13 .1", + "perform ance▁of", + ".▁200 4;", + "consider ed▁an", + "▁complet e▁a", + "discontinu ation▁of", + "▁approximately▁ 12", + ",▁P AX", + "▁sub typ", + "▁their ▁size▁(", + "▁ind ication", + "ed\n\n in", + "▁occur red", + "▁response▁ (", + ",▁s hould▁be▁", + ",▁s unitinib", + "arr ativ", + "▁drug ▁product", + "▁dur ing▁a", + "▁non- mut", + ",▁C old", + "▁loc al▁procedures", + "observ ed▁to", + "1- 6", + "▁(A MG▁162", + "1) ▁(cid:", + "s, ▁an", + "e▁m onth", + "\n\nB y▁", + "\n\nB efore▁", + "mer gency▁", + "▁information ▁sheet", + "▁receiv e▁treatment", + "end▁of ▁study", + "▁to▁ establish", + "IV )", + "▁this ▁test", + ".\n\nThe▁ patient", + ",▁A rb", + "was▁ not", + "▁the▁treatment ▁of▁", + "▁the▁treatment ▁arm", + "▁the▁treatment ▁assignment", + "obtain ed▁prior▁to", + "▁determin ation▁of", + "22 )(cid:", + ",▁H u", + ",▁H arris▁WS", + "rat es", + "osp ital▁or", + "▁radi ologic", + "di hyd", + "di agnostic", + "information ▁about", + "ship ment", + "\n\nAn ▁adverse▁event", + "▁avail able▁to", + "▁plus▁ BSC", + "ite▁ a▁bit", + "▁within ▁3", + "ed▁c aus", + "▁assess ing", + "oph en", + ",▁D awson-Hughes▁B", + "used▁to ▁assess▁", + "s▁at ▁any▁time▁", + "▁by ▁a", + "▁every▁ other", + ".2.2 .2", + "\n\nX\n\nX\n\nX\n\nX \n\nX", + "▁randomiz ed▁to", + "alysis▁S ubset", + "\n\nAppendix ▁X", + "analysis▁ of▁the▁", + "▁hy po", + "▁hy percalcemia", + "fract ur", + "dic tion", + "indic ator", + "▁+ 1", + "ing▁and▁ Data▁Collection", + "DMC ▁member", + ".▁O xaliplatin", + "ing▁s ystem", + "▁the▁b lood", + "▁Ph ysical▁Examination", + "rof il", + "▁and▁s afety▁", + ",▁R os", + "▁overall ▁survival▁(OS", + "▁docetaxel -based▁chemotherapy▁regimen", + "\n\n13 .1", + "▁prior▁to ▁disease▁progression", + "Pro of▁of", + ".,▁et▁al.,▁ C", + "▁they▁ have▁", + "ecaus e▁th", + "PD GFR", + "RP C", + "mor e▁frequ", + "measure d▁and▁", + "▁Med DRA", + "wer e▁d", + "▁days▁after ▁the▁last▁dose▁of", + "ulti plic", + "representativ es▁from", + "FACT- B", + "serum ▁calcium", + "▁are▁not ▁limited▁to", + "pers ons", + "ed▁m ethod", + "e▁P anitumumab", + "▁cisplatin ▁plus▁", + "AT E", + "atch ful", + "▁conf in", + "▁risk ▁reduction", + ",▁N ew", + "▁ ▁", + "on▁the▁ CRF", + "▁marker s▁of", + "▁performance▁stat us▁", + "▁man ual", + "censor ed▁using▁the▁", + "▁carboplatin ▁infusion", + "▁subjects▁who ▁have▁", + "resolv ed▁to", + "pharmac y▁", + "▁applicabl e▁sit", + ".\n\n2 .3", + "procedures ▁and▁", + "procedures ▁are▁", + "option al▁", + "second ary", + "Evalu ations", + "272−636.4 .0", + "hel d▁for", + "▁To ▁be▁", + "▁any▁other ▁reason", + "▁reduc ed▁", + "▁alone▁ or", + "ate,▁ BUN", + "▁discontinuation ▁from▁study▁treatment", + "▁termin ate▁the▁", + "ed▁according▁to ▁treatment", + "\n\nW BC", + "schedul e▁of", + "▁Per form", + ",▁O '", + "EP LAC", + "rect um", + "work ▁activities.▁Up▁and▁about", + "assign ment", + "see▁ Table▁", + "▁pemetrexed▁ plus▁cisplatin", + "objective▁ progression", + "judg ed▁to▁be▁", + "▁March ▁2006", + ".▁Ex clusion▁Criteria", + "▁Follow ed▁by▁M", + "delay ed▁until", + "▁contact ▁with", + "used ▁throughout▁the▁study", + "▁Ac cess", + "▁you▁are▁ pregnant", + "▁use▁ an", + "▁work ▁of▁a▁light▁or▁sedentary▁n", + "▁Tumor ▁Response▁", + "▁Committe e▁on", + "mon▁T oxicity▁", + "▁antibodies ▁to", + "▁evidence▁of ▁disease▁progression", + "PT H", + "hist ology", + "kelet al▁surv", + "e▁sh ould", + "at▁a ▁minimum", + "received▁ prior", + "omega-3 ▁fatty▁acid▁", + "▁diarrhea ▁(", + "randomis ation", + "▁Sampl ing", + "bi ops", + "bi ological", + "light ▁h", + "select ed▁", + ".\n\nAd verse▁event", + "▁mak e▁s", + "▁administered▁ over", + "▁will▁not ▁be\n\n", + "▁Overall ▁Response▁", + "▁participating ▁in", + "second▁ interim", + "Gen eral", + "▁co incid", + "ABX-EGF ▁arm", + "iet ary▁", + "▁att ribut", + ".▁Each ▁vial", + ".▁Res pon", + "▁endothel ial▁cell", + ".▁K aplan-Meier", + "vascular ization", + "Non- Small▁Cell▁Lung▁Cancer", + "▁measurable▁ lesions▁", + "▁the▁informed▁consent ▁document", + "al▁s ourc", + ".\n\nI t", + "▁d▁ o", + "▁Procedure s▁", + "lower ▁than", + "ed▁M arch", + "▁organ ▁clas", + "▁confidential ity", + "e▁includ e▁", + "ella ▁F", + ".▁Ph armacokinetic", + "hemistry▁ panel:▁sodium,▁potassium,▁chloride,▁bicarbon", + "▁positive▁ benefit", + "▁one▁of▁the▁ following", + "OP G", + ".\n\n.▁E▁S▁U \n\nE▁R▁O▁F▁E▁B\n\nY▁T▁I▁D▁I▁L▁A▁V", + "▁0.8 5", + "ince▁th is▁", + "withdrawn▁from ▁the▁study▁", + "superior ▁to", + "▁stable▁ diseas", + "▁tumor▁cell s▁and▁the▁proposed▁mechanism▁of▁action", + "2007 ;", + "number▁of▁ event", + "uoropyrim idine▁", + "ematology▁ panel:", + "▁log -rank▁test", + "yro id", + "▁Cox ▁model", + "▁Cox ▁regression▁model", + "▁locally ▁advanced▁", + "prob abl", + "duration▁of▁ response▁(", + "▁Definition s", + "▁AND▁R EPLAC", + "▁SA MPLE", + ",▁we▁will ▁have▁", + "▁take▁part ▁in", + "\n\nFollow -up", + "(5 ):", + "Ne utropenia", + "▁and▁toler ability▁", + "▁a▁central▁ laboratory", + "▁End▁of ▁Study▁", + "able▁s afety▁", + "▁reasons▁other▁than ▁PD", + "▁and▁T im", + "\n\nProtocol▁Attachment▁JM HO", + "▁(ANC ▁<", + "ed▁about ▁the▁", + "ef▁Pain▁In ventory▁", + "▁super ficial", + "(9 ):", + "▁bound ary▁", + "Monitor ing▁and▁Data▁Collection", + "dist ribut", + "▁HA HA", + "\n\nIV RS", + "▁correspond s▁to", + "MO VAL", + "▁exceed▁ 10", + "pedited▁ reporting", + "▁tyrosine▁kin ase▁inhibitor", + "commun ic", + "Study▁T eam▁Physician", + "random ly", + "cardiovascular ▁mortality", + "▁concent ration▁of", + "▁contracept ion", + "\n\nFigure▁ 1", + "reported▁as▁an ▁AE", + "▁association ▁with", + "\n\nStudy▁Design \n\nThis▁", + "▁hemorrh age▁", + "loss▁of ▁appetit", + "▁syn erg", + "▁half -lif", + "▁deem ed▁", + "pen-Label ▁Treatment", + "▁in▁Section ▁4.7.1.1", + "imm ▁EB", + "irradi ated▁", + "compr is", + "itz ▁GA", + "anin e▁transamin", + "quartil es,▁and▁", + "\n\nRest ricted▁in▁physically▁strenuous", + "\n\nthe▁in vestigator", + "▁reasonable▁possibility▁that▁the▁event▁may▁have▁been▁caus ed▁by", + "▁stain ing", + "EMENT ▁OF▁S", + "stea d▁of", + "participating▁in▁the▁ PACCE▁protocol", + "MINISTRATIVE ▁AND▁L", + "▁prolifer ation", + "▁Rational e▁", + "▁interstit ial▁lung", + "li▁Lilly▁and▁Com pany▁", + "cert ification", + "\n\nVery▁ much", + "heumat oid", + "(11 ):", + "▁a▁safety▁ follow-up▁visit", + "PONS OR", + "▁dys function", + "▁Work sheet", + "▁to▁ver ify", + "embran e▁", + "-Free▁S urvival", + "▁always▁ be▁", + "ultivari ate▁", + "addition▁of▁panitumumab▁to ▁chemotherapy▁(", + "rhythm ia", + "gressive▁Disease▁ (PD):", + "EGAL ▁OBLIGATIONS", + ".9%▁Sodium▁Ch loride▁Injection", + "idi arr", + "essential▁ for", + "onych ia", + ".▁Qual ifications▁for", + "RIN G", + "accurately▁ measured▁in", + "rob ust", + "▁he/ sh", + "EASURE MENTS", + "correlated▁ with", + "Notification ▁Worksheet", + "\n\nComplete▁Response▁(CR ):", + "rate▁for▁solution▁for ▁infusion", + "ERMINA TION▁OF", + "▁of▁63▁Finalization▁date:▁June▁19▁2001,▁Incorporating▁amendment▁3▁–▁dated▁23▁May ,▁200", + "\n\nQu ite▁a▁bit", + "articulate▁ matter", + "arget▁lesions▁should▁be▁select ed▁on▁the▁basis▁of", + "epher d▁", + "elegation▁of▁Author ity▁Form", + "etoc onazol", + "\n\nA▁little▁b it", + "▁the▁poss ibility▁of", + "▁was▁removed▁from▁the▁ regimen", + ",▁Cold itz▁GA", + ",▁Arb uck", + "Proof▁of ▁Receipt", + "atchful ▁wait", + "censored▁using▁the▁ last", + "▁Followed▁by▁M aintenance▁", + "▁measurable▁lesions▁ up▁to▁a▁maximum", + "▁AND▁REPLAC EMENT▁OF▁S", + "MOVAL ▁AND▁REPLACEMENT▁OF▁S", + "MINISTRATIVE▁AND▁L EGAL▁OBLIGATIONS", + "MOVAL▁AND▁REPLACEMENT▁OF▁S UBJECTS", + "% \n\n0", + "( except", + ") ▁after", + ") ,\n\n", + ") ▁within", + ") ,▁and▁the▁", + ", 4", + ", 8", + ", ▁any", + "- 16", + "- 65", + "/ kg", + "2 -sided▁", + "3 ▁d", + "4 .", + "4 .0", + "6 ▁cycles▁of", + "7 .1", + ": ▁•", + "; ▁", + "; ▁if", + "A CR", + "A gent", + "C 225", + "C ockcroft▁and▁Gault", + "D B", + "D M", + "E K", + "E ,▁S", + "E RIO", + "E astern▁Cooperative▁Oncology▁Group", + "E ORTC▁QLQ-C30", + "F unctional▁Assessment▁of▁Cancer▁Therapy▁", + "F unctional▁Assessment▁of▁Cancer▁Therapy", + "G ill", + "H NC", + "I mClone▁", + "I ▁am", + "K M", + "L ong", + "N ▁A\n\nF▁O", + "P ower", + "T R", + "V ITAL", + "Y Y", + "a uc", + "b ronch", + "c ode▁", + "c ovari", + "c apecitabin", + "c ounter", + "d ated▁in", + "d arbepoetin▁alfa", + "d ays▁", + "e av", + "f ast", + "f avorable▁", + "g et", + "m ount", + "n y▁", + "n atur", + "o oxygen", + "p alliative▁", + "p ase-", + "p ublic", + "r urit", + "s pecimen", + "u it", + "u fficient", + "v oid", + "w t", + "w y", + "w eb", + "w ash", + "w ould", + "y ;", + "y g", + "y ▁are▁", + "“ other", + "▁ ................", + "▁ et", + "▁ e▁v", + "▁ ®\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁Panitumumab▁Protocol▁Number:▁20050251▁Date:▁10▁October▁2006\n\nPage▁", + "▁ outsid", + "e▁ cell", + "in ski", + "▁t ype▁", + "at ed▁based▁on", + "\n\n cancer", + "\n\n review", + "\n\n analys", + "\n\n subjects▁", + "en berg", + "er ated▁lung", + "or ▁leg", + "or adic", + "s▁ 5", + "s▁ is", + "s▁ you", + "re ed", + "y▁ with▁the▁", + "ion ucl", + "it ▁is", + "it ating", + "▁the▁ Sponsor", + "▁the▁ original", + "▁the▁ IEC/IRB", + "an -", + ",▁ first", + ",▁ provid", + ",▁ may▁be▁", + ",▁ Ad", + ",▁ standard▁", + ",▁ platelet", + "▁an ▁individual", + "▁an ▁abnormal▁", + ".▁ Y", + ".▁ 14", + ".▁ ECOG", + "ar -", + "ed ▁tumour", + "▁p rim", + "▁p anel", + "▁p ump", + "▁p ellet]", + "▁c op", + "▁c ert", + "▁c ynomolgus▁mon", + "▁b e:", + "es id", + "es cent", "et on", - "eto n", - "e ton", - "-> {", - "- >{", - "▁w ont", - "▁won t", - "▁wo nt", - "▁w eg", - "▁we g", - "▁ weg", - "▁class ific", - "il us", - "i lus", + "et ▁forth", + "▁to ▁another", + "▁to gether▁with", + "is ▁a▁m", + "is olon", + "▁s ex", + "▁s econdary", + "▁s cientific", + "▁s afety,▁", + "as ed▁", + "as ian", + "▁of fic", + "▁of ▁two", + "▁of ▁previous▁dos", + "ou ill", + "▁w arrant", + "▁m and", + "▁m ild", + "▁m CRPC", + "▁and▁ A", + "▁and▁ clinical▁", + "▁and▁ has▁been", + "▁and▁ final", + "ect ed▁", + ".\n\n 18", + ".\n\n 28", + "ill i", + "is▁ responsible▁for", + "▁A T", + "iv e,▁", + "oc rine▁", + "▁1 ▁month", + "▁C al", + "▁C olon", + "os cl", + "os is▁or", + "est ▁X-ra", + "es▁ must", + "▁P ublication", + "pro xim", + "pro gres", + "▁( 7", + "▁( excluding", + "em an", + "▁2 nd▁", + "if f", + "▁I HC", + "ot o", + "ag u", + "ag ic", + "▁D J", + "▁D ATA", + "▁l ot", + "▁l ost", + "▁l oper", + "▁E R", + "▁f all", + "▁f ield", + "am pt", + "am ong", + "ver ifi", + "ch alleng", + "▁or ▁breast", + "▁or ▁rect", + "▁or ▁drug▁delivery▁system", + "e▁t ermin", + "ys elf", + "form ation▁of", + "\n\nP rinted▁copy▁is▁not▁official▁record", + "iz ed▁s", + "ex ternal▁", + "ec ret", + "ist ribut", + "per -", + "▁and ▁abdomen", + "▁as certain", + "▁as ▁appropriate", + "▁pro gres", + "all ing", + "▁T ranslational▁Research", + "▁ad v", + "▁ar is", + "▁R el", + "▁R NA", + "▁R efer", + "ed▁in ▁this▁document", + "min eral", + "In d", + "In dependent", + "\n\nS election", + "▁that ▁particular", + "▁al coh", + "e▁s afety", + "e▁s ee▁Section", + "e▁th e▁sampl", + "▁0 .2", + "▁3 ▁days)", + "▁con ven", + "▁of▁the▁ drug", + "cont ext", + "▁F WB", + ".▁A c", + ".▁A s", + ".▁A ▁subject", + ".▁The▁ purpose▁of", + "▁as▁ it", + "▁g u", + "▁g lobal", + "hould▁ not", + "200 5;", + "▁on ▁Days▁", + "▁v entricular", + "▁v olunteer", + "▁L ead▁", + ".3 5", + "s,▁ but", + "▁ther efor", + "▁st abil", + "▁ch osen", + "▁ch emoradi", + "▁will ingness▁to", + "follow ed▁by▁a", + "ing▁the▁ t", + "▁5 9", + "▁5 .7", + "will ▁occur", + "from ▁the▁study▁", + "▁H NC", + "▁H &E", + "and▁ m", + "▁subject ▁with", + "▁the▁p ost", + "▁the▁p aclitaxel", + "▁the▁p regnancy▁", + "▁the▁p ackage▁insert", + ")\n\n 2", + ")\n\n [", + "▁at \n\n", + "▁at ▁the▁tim", + "▁at ▁the▁first", + "▁at ▁the▁time▁of▁the▁", + "s▁( longest▁diameter", + "▁study▁ will▁be▁", + "ident ical", + "s▁in ter", + "s.▁ F", + "s.▁ R", + "s.▁ T", + "▁week s▁and▁", + "cons isting", + "ell ing", + "ation▁of ▁data", + "▁patient s▁that", + "▁the▁d et", + "report ed▁by▁", + "report ing▁of", + "e▁the▁ Efficacy▁of", + ".▁P ostdiscontinuation", + "\n\nE fficacy▁Analysis▁Set", + "▁In terim", + "▁In dividual▁", + "s\n\n H", + "s\n\n of", + ".▁Th e▁tim", + "on- study", + "▁may▁ requir", + "▁dos e.\n\n", + "pres s▁", + "(cid: 11", + "may▁ not", + "e▁v itamin▁D", + "ser tion", + "▁analysis▁ data▁cut-off", + ".▁In ▁the▁case▁of", + ".▁E stim", + ".▁E rlotinib", + "record ed.\n\n", + ",▁and ▁to", + "11 3", + "AL U", + ".▁T issu", + "ed▁with in▁the▁", + "’s▁ b", + "▁x ▁upper", + "20 5-", + ",▁or ▁m", + "▁disease▁ assessment", + "investigator ▁will", + "▁9 2", + "▁9 .4.1", + "▁8 5", + "▁8 5▁mg/m2", + "e▁( or", + "first -lin", + "\n\nProduct: ▁darbepoetin▁alfa▁Protocol▁Number:▁20010145▁–▁Amendment▁2▁Date:▁16▁July▁2004\n\nPage▁", + "\n\nN A*", + "pre medic", + "every▁ 12▁week", + ").\n\n 10", + "................................................................................ ...▁", + "▁form ulation", + "bas is▁for", + "▁the\n\n IEC/IRB", + "▁pre dominantly▁s", + "ed▁as▁ follows:", + "ass ification", + "des pite▁", + "▁a▁s creening", + "14 -", + "\n\nT able▁of▁Content", + "▁the▁patient ▁must▁be▁", + "respons es▁", + "respons ibilities▁", + ".▁D isease▁", + "complet ed▁at", + "▁W IT", + "\n\n4 .9", + ".▁F orm", + "▁cons umption", + "data ,▁", + "I- L", + ".\n\nP lease▁", + "e▁b ecom", + "13 ]", + "\n\nI mmun", + ",▁S afety▁", + "▁panitumumab ▁or", + "yst olic", + "lind ing", + "LC SS", + "s▁or ▁s", + "performed▁ using▁the▁", + "equ ential", + "▁death s▁", + "ures ,▁", + "▁30 ▁mg", + "▁evalu ation▁of", + "▁sampl e,▁", + "ativ e▁treatment", + ".▁R eg", + ".▁R efer▁to▁Section", + "you ▁will▁be▁asked▁to", + "▁cell s▁in", + "▁complet ion▁of", + "\n\nH emoglobin", + "NA **", + "ed.\n\n 5", + "ed.\n\n 9", + ",▁P at", + "St andard▁", + "\n\n\n\n If", + "▁CT X", + "disease▁ (", + "▁mod ul", + "ed\n\n for", + "▁analysis ▁and▁", + "▁continu ous▁infusion", + "▁occur s▁prior▁to", + "dis position", + "................................................ ..", + "16 9", + ".▁H y", + ".▁H ar", + ".2.1 .2", + "▁must ▁ensure▁that", + "observ ed▁at", + "▁rel eas", + "1- 3", + "▁(A UC", + "\n\nIn t", + ",▁b reast", + "risk s▁associated▁with", + "\n\nB one▁", + "\n\nB efor", + "▁this ▁tim", + "when ▁the▁", + "▁advanc ed,▁", + "▁advanc ed▁s", + "▁advanc ed▁breast▁cancer", + "blind ing", + "▁chang e▁", + ".▁J ▁Natl▁Cancer▁Inst", + "▁effect ▁of", + "........................................................................ .......▁", + "well -being", + "▁int ensity▁", + "must ▁sign", + "▁a▁c aus", + "▁K :", + ".▁I m", + "ram p", + "start ▁of▁treatment", + "▁investigational▁product ▁will▁be▁", + "▁has▁been ▁reported▁in", + "\n\nL ong", + "\n\nL aboratory", + ",▁et▁al .▁Cetuximab", + "ea u", + "determin ed▁from", + "determin ed▁that", + "▁trans port", + "s▁at ▁least", + "mCl one", + "identifi ed▁as▁target▁lesion", + "Com pli", + "\n\n5 .3", + "count ry", + "\n\ns urvival", + "▁14 ▁days▁prior▁to▁randomization", + "prov en", + "▁ver ify", + "43 1", + ",▁L ee▁J", + "\n\nAppendix ▁E", + "\n\nAppendix ▁G", + "\n\nAppendix ▁XIV▁Page▁", + "▁under going", + "▁the▁event ▁of", + "caus ality", + "▁Q oL", + "▁assign ed▁treatment", + "▁KRAS ▁mutation", + "\n\nO xaliplatin", + "▁between ▁1▁and▁", + "▁pain ▁control", + "TA ▁visit", + "▁Adverse▁Event s", + "▁Treatment ▁Group", + "att ach", + "▁long -term▁follow-up", + "▁observ ed", + "▁sp oradic", + "ECOG ▁PS", + "▁advanced▁ gastric▁cancer", + "▁when ▁the▁", + "▁pemetrex ed▁infusion", + "70 ▁and▁", + ".▁L aboratory▁", + "withdraw ▁from", + "mor e▁sever", + "recommend ed", + "▁accept abl", + "ed▁( eg,▁", + "urger y▁", + "aw el▁J", + "monitor ed▁for", + ",▁199 8", + "▁No .▁", + "▁meet ing▁the▁", + "▁of▁126 \n\n", + "▁during▁the▁ treatment▁phas", + "▁subsequent ly▁", + "serum ▁creatinine▁", + "mission ▁Form", + "ed▁m easurable▁", + ".▁199 7;", + "has▁been ▁observed▁in", + "oper able▁", + "%) ▁patient", + "▁Subject ▁incidence▁of", + "e▁tumor ▁assessment", + "opt im", + "▁person al▁", + "\n\nV EGF", + "▁the▁f ull", + "cas es▁", + "........................................ ..", + "protein ▁expression", + "▁En rollment", + "ed, ▁all", + "inf us", + "oler ated▁", + "▁only▁ if", + "▁Janu ary▁", + "▁typ ically▁", + "red▁ blood▁cell", + "compar e▁", + "remain der", + "▁objective▁ response▁rat", + "▁does▁not ▁meet", + "▁individual ▁patient", + "▁cediranib ▁in▁combination▁with▁FOLFOX", + "e▁the▁s am", + "de hydration", + "lat ter", + "▁4▁week s,▁", + "▁en vironment", + "▁NC I-", + "reported▁ lesion", + "control ▁group", + "requir ing▁", + "ually▁ for", + "ed▁according▁to ▁local", + "▁provide▁ an", + "▁k ey▁", + "measured▁ by▁the▁", + "▁the▁subject’s▁ clinical▁", + "calculated▁ from", + "LD ▁of▁target▁lesion", + "g/m l", + "▁the▁primary ▁analysis▁of", + "s,▁or ▁other", + "outlin ed▁in", + "mean ingful", + "▁qual ify", + "ert iary▁", + "▁Follow ing", + ".▁Subject s▁with", + "▁serious▁adverse▁event ▁information", + "ed▁by▁a erated▁lung", + "combination ▁with", + ".▁Ther eafter", + "yndrom e▁(", + "▁discus s", + "\n\ni \n\n", + "........................ ....", + "▁minutes▁ on▁Day▁1", + "escal ated▁to", + "’s ▁assessment", + "▁of▁119 \n\n", + "valid ated▁", + "Test ing", + "▁investig ative▁sit", + "▁ask ▁question", + "\n\nx▁x▁x \n\nx▁x▁x", + "▁Monitoring ▁Committee", + "ackgroun d", + "compli ant", + "randomis ed▁to", + "volum e▁", + ",▁v on▁P", + "dent ification", + "earli est", + "▁bon e▁turnover▁marker", + "co ordinating▁investigator", + "▁................................................................ ......", + "Gen eral▁", + "astric ▁Cancer", + "e▁dose▁ by▁", + "▁patients▁( pts)▁with", + "s.▁Th ese▁", + "▁Denosumab▁Protocol▁Number:▁20050136▁Date:▁30 ▁April▁2008", + "Investigator’s▁ Agreement", + "vascular ▁endothelial▁growth▁factor", + "▁Pl anned▁Methods▁of", + "\n\nPrimary▁ Objectiv", + "▁Health care▁", + "▁normal▁ limit", + "stitutional▁Review▁Bo ard▁", + "e▁during▁the▁ study", + "s.▁If ▁the▁", + "ohn ’s▁", + "▁of▁98 \n\n", + "likely ▁to▁be▁", + "▁the▁inter vention", + "ordin ator", + "\n\nAmgen▁Thousand▁Oaks \n\nConfidential\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁AMG▁162▁Protocol▁Number:▁20040135▁Date:▁14▁November▁2006\n\nPage▁", + "▁liver ▁metastases▁", + "vari able▁", + "▁to▁a void▁", + "sufficient ly▁", + "drawn ▁from", + "▁lymph ocyt", + "\n\nComplet ely▁disabled.▁Cannot", + "▁(d epending▁on", + "▁malignanc y▁", + "Man ual", + ",▁ch ills,▁", + "▁Monitoring▁Committe e▁(DMC", + "icro ar", + "elv ic", + "elv is▁", + "resect able,▁", + "▁decrease▁in ▁the▁sum▁of▁the▁", + "Ass ociation", + ".▁With in", + "▁continuous▁ daily▁", + "▁these▁s ide▁effect", + "▁the▁information ▁provid", + "\n\nDiscontinu ation▁of", + "▁expect ed▁to", + "elan i", + "Analys es▁", + "boemb olism", + "▁regular ▁interval", + "\n\n75% \n\n75%", + "▁micro ar", + "▁ref us", + "standard▁of ▁care", + "▁three▁ week", + "▁Procedures▁for ▁All", + "▁95%▁CI :▁0", + "▁birth ▁control", + "▁x-ra y", + "anticip ated▁", + "end▁ date▁", + "olunt ary▁", + "▁2.5 ▁mg/kg", + "ackaging ▁and▁", + ";▁( 3)", + "could▁ be▁", + "bod y▁system", + "s▁(or ▁sites▁of▁diseas", + "▁minim ize▁the▁", + "\n\n2\n\n2 \n\n2\n\n2", + "\n\n(cid:13 1)", + "e▁sub scale▁scor", + "contracept ive▁", + "▁intern al", + "color ation", + "▁explor e▁", + "▁explor e▁the▁", + ".▁Gen eral▁", + "▁Backgroun d▁and▁Significance:", + "ixed▁ effect", + "e▁sign ificant", + "e▁inter vention", + "emper ature", + "oss ella▁F", + "▁cho ic", + "ated▁b enefit", + "],▁ [", + "▁CBC ,▁differential", + "intend ed▁to", + "over▁the▁ 36-month▁evaluation▁period", + "\n\nRec ording▁of", + "round ed▁by▁aerated▁lung", + "▁2-sided▁ 95%▁confidence▁interval", + "Schedule▁( Attachment", + "▁Biomarker ▁Development", + "▁commun ication", + "▁carry▁on ▁any▁s", + "Oral▁Rectal▁ Oral▁Rectal▁", + "▁Aci d▁", + "▁express ing", + "ed▁by▁Lilly :", + "▁experiment al", + ".▁Specific ally,▁", + "▁contracept ive▁", + ",▁et▁al.▁Phase▁ II", + "▁hormone- resistant▁prostate▁cancer", + "left ▁to", + ",▁blood▁ pressure,▁", + "▁the▁baselin e▁sum", + "▁(W estern", + "Journal ▁of▁", + "▁SY NOPSIS", + "s▁that▁can▁be▁ accurately▁measured▁in", + ".\n\nSUBJECT ▁ENROLLMENT", + "strongly▁ encouraged▁to", + "e▁disease▁ assessment", + ",▁Man egold▁C", + "▁time▁from ▁randomization", + "▁ruler ▁to▁estim", + "scan n", + "▁adequ ately", + "complete▁or ▁partial▁response▁", + "▁actual ▁body▁weight", + "followed▁for▁survival▁ for", + "doubl et", + "▁μ g", + "empor ary▁", + "▁every▁4▁week s▁schedul", + "no▁less▁than ▁4▁weeks▁after", + "▁Stage▁III B", + "altz ▁LB", + "uper ficial▁", + "\n\nEGF r", + "measurements▁and▁ variables", + "▁Lilly▁or▁its▁designee▁ via", + ",▁who ▁will", + "obil ity", + "other▁than▁the▁ evaluation▁or", + "▁Previously▁ Un", + "EDTA ▁blood▁[plasma▁and▁cell", + "▁>99.9 ▁>99.9", + "stitutional▁Review▁Board▁( IRB)", + "▁patients▁per ▁arm", + "orrection s▁to", + "▁sourc e▁data", + "▁Darbepoetin▁alfa ▁Protocol▁Number:▁20010145", + "▁advert ising", + "▁resid ual", + "▁curative▁ intent", + "unningham ▁D", + "▁proportional▁hazard s▁model", + "\n\nResult s▁in", + "▁SG ,▁Eisenhauer", + "▁prem atur", + "embry onic", + "▁120▁mg ▁SC", + "▁head▁and▁neck ▁cancer", + "s▁Ad minister", + "▁you▁are▁a ▁woman", + "able▁Disease▁ (SD):", + "▁hybrid ization", + "▁imagin able▁", + "re-s creen", + "▁Recon ciliation", + "\n\n5\n\n6\n\n7 \n\n8\n\n9", + "e,▁ALT,▁AST ,▁calcium", + "including▁a ▁ruler▁to▁estim", + ".\n\nEX PERIMENTAL▁PLAN", + "financ ial", + "▁has▁returned▁to▁baselin e,▁then", + "▁conduct▁of▁the▁ clinical▁investigation", + "▁mm▁with▁conventional▁techniqu es▁or", + "▁will▁compensate▁you▁if▁this▁h appens", + "▁ambulatory▁and ▁able▁to▁carry▁out", + "▁6▁1 ▁G▁M", + "asse▁P ,▁Arbuck", + "▁INFORM ATION", + "atzemeier ▁U", + "-and- subsequent", + "▁and▁the▁same▁techniqu e▁should▁be▁used▁to", + ",▁PAX gen", + "▁work▁of▁a▁light▁or▁sedentary▁n ature,▁", + "heumatoid ▁arthrit", + "censored▁using▁the▁last ▁available▁", + "auc asian", + "or▁leg al▁partner", + ",▁von▁P awel▁J", + "▁SG,▁Eisenhauer ▁EA", + "including▁a▁ruler▁to▁estim ate▁th", + "▁6▁1▁G▁M ▁A", + "asse▁P,▁Arbuck ▁SG,▁Eisenhauer▁EA", + "( as▁", + "( IHC", + ") /", + ") ▁In", + ") ▁-", + ") ▁was", + ", ▁the▁sponsor", + ", ▁treatment▁with", + "- re", + "- 99", + "- by-", + ". E", + "/ 0", + "/ PR", + "/ vomiting", + "/ exclusion▁criteria", + "0 .9", + "1 ▁year", + "3 00", + "8 5-", + "8 5%", + "8 2)", + ": ▁An", + "; ▁s", + "> 2", + "A mendment", + "C o", + "C hemistry▁", + "C ollection", + "D iscontinu", + "E I", + "E TA", + "E pidermal▁", + "H ochberg", + "H ARM", + "I m", + "L ,▁C", + "M ,▁C", + "N -", + "O bl", + "R ational", + "T X", + "a ud", + "b ound▁", + "b etter", + "d evi", + "e \n\nAn", + "e agu", + "f ram", + "f oot", + "g ulin", + "i ou", + "i oc", + "i eth", + "k ▁r", + "l though", + "l iving", + "l earn", + "m l", + "m y▁", + "n es", + "n ect", + "n ▁=", + "p eptid", + "s ”", + "s ▁according▁to", + "s creen", + "s urgical▁", + "s ophag", + "u z", + "v inc", + "v endor", + "w k", + "w orldwid", + "y ing", + "” ▁(", + "▁ \"", + "▁ ×", + "▁ formation", + "▁ open-label▁Casodex", + "e▁ you", + "e▁ into", + "e▁ would▁", + "in e,", + "▁t ▁s▁", + "on d", + "on al▁", + "on ▁D", + "\n\n >", + "\n\n at", + "\n\n as", + "\n\n blood▁", + "\n\n bevacizumab", + "\n\n yes▁", + "▁a ▁trial", + "er a", + "er ▁S", + "or st", + "or ubicin", + "s▁ /", + "s▁ following", + "s▁ versus▁", + "s▁ such", + "s▁ resulting▁from", + "re vascularization", + "al ive▁", + "ent r", + "it e\n\n", + ",▁ may▁", + ",▁ dos", + ",▁ only▁", + ",▁ followed▁by▁", + ",▁ including▁the▁", + "ed▁ “", + "ed▁ following", + "▁an ▁appropriate▁", + "▁an ▁additional", + ".▁ [", + ".▁ c", + ".▁ 12", + ".▁ 25", + ".▁ 30", + ".▁ 22", + "ed ?", + "ed ,\n\n", + "ed ▁appropriate▁", + "▁p ast", + "▁p olicy▁", + "▁c o-", + "▁c apt", + "▁c apture", + "ing ▁treatment", + "es .▁C", + "for d", + "▁to ▁collect", + "▁to ▁participate▁in▁the▁", + "is ,▁and▁", + "is ▁associated▁with", + "▁of ▁cycle▁", + "▁d estroy", + "▁w eb", + "▁w ould", + "▁m anufact", + "▁and▁ h", + "▁and▁ study▁", + "▁and▁ irinotecan", + "▁and▁ last", + "▁and▁ results▁of", + "▁and▁ check", + "▁and▁ platelet▁count", + ".\n\n c", + ".\n\n (cid:", + ".\n\n Un", + ".\n\n 26", + "al▁ (", + "al▁ S", + "al▁ f", + "al▁ vitamin▁D", + "al▁ 5-fluorouracil", + "el and▁", + "el son", + "▁A G", + "▁A MGEN", + "▁A fter", + "im put", + "ig ment", + "id d", + "id imension", + "▁1 5-", + "▁1 80", + "▁1 ▁or▁2", + "▁C K", + "▁C ur", + "▁C riterion", + "ac etic", + "pro mpt", + "pro portional▁hazard", + "▁( <", + "▁( JM", + "▁( EGFr", + "▁( VEGF", + "▁( Visit", + "▁( includes", + "▁( wt", + "em otion", + "us iness▁", + "ul ated▁", + "con ven", + "con omic", + "con stant", + "▁S TA", + "▁S 130", + "▁S teering", + "▁I ▁have▁", + "▁re combinant", + "ag ain", + "▁D ate▁of", + "▁D uration▁of", + "▁D ▁E▁T▁N▁I▁R▁P\n\nA", + "▁D elegation▁of▁Authority▁Form", + "cl -", + "ri x", + "▁h is▁", + "▁h eparin", + "▁E astern▁Cooperative▁Oncology▁Group▁(ECOG)", + "ject ▁the▁", + "▁or ▁SD", + "▁or ▁less", + "e▁t oday", + "\n\nP ost", + "\n\nP AGE", + "ec ision", + "\n\nA pproximately▁", + "study▁ duration", + "▁pro ce", + "▁pro pert", + "▁ad jacent", + "ast inal", + "▁for ▁other", + "▁for ▁Arm▁A", + "▁for ▁injection", + "▁R ,▁B", + "e\n\n of", + "rom et", + "▁treatment ▁should▁be▁", + "enc ounter", + ".1 5", + ".1 8", + "▁with ▁treatment▁group", + "▁with holding", + "ed▁b one▁", + "s▁of ▁the▁data", + "In f", + "▁that ▁it", + "▁200 20408▁Amendment▁4", + "▁is▁ obtain", + "▁of▁ study-related▁", + "▁al ert", + "e▁s election", "▁M D", - "▁ MD", - "task s", - "▁c him", - "▁ch im", - "▁chi m", - "aw ait", - "awa it", - "a wait", - "▁g ang", - "▁gan g", - "▁ga ng", - "▁ gang", - "▁w ię", - "▁ wię", - "th rough", - "▁Russ ell", - "▁guess ing", - "▁а кт", - "▁ак т", - "б лі", - "c ategories", - "су т", - "с ут", - "▁F en", - "▁Fe n", - "▁му ж", - "▁ne wer", - "▁new er", - "▁A sync", - "▁As ync", - "▁ Async", - "▁t erme", - "▁term e", - "▁ter me", - "> /", - "па ра", - "пар а", - "▁T rust", - "▁Tr ust", - "▁Tru st", - "▁O pt", - "▁Op t", - "▁ Opt", - "▁d ah", - "▁da h", - "▁wonder ful", - "adrat kil", - "▁Г ра", - "ma pping", - "map ping", - "m apping", - "▁disc overy", - "▁discover y", - "▁disco very", - "▁B E", - "▁ BE", - "En able", - "▁Fri end", - "с ня", - "▁cont rolled", - "▁control led", - "чно ї", - "ч ної", - "▁contribution s", - "▁contrib utions", - "j ší", - "▁L ev", - "▁Le v", - "▁franc és", - "▁m ic", - "▁mi c", - "▁ mic", - "zi k", - "z ik", - "▁a lem", - "▁al em", - "▁ale m", - "▁ alem", - "can cel", - "! '", - "▁g rat", - "▁gr at", - "▁gra t", - "▁Begriff sklär", - "Cam era", - "if icación", - "ific ación", - "ifica ción", - "ró d", - "r ód", - "▁Arn old", - "▁bezeichnet er", - "▁f ought", - "▁de put", - "▁dep ut", - "▁D rop", - "▁Dr op", - "▁Dro p", - "▁ Drop", - "ta x", - "t ax", - "d g", - "▁H op", - "▁Ho p", - "G N", - "▁Kir ch", - "▁Б ар", - "▁Ба р", - "In voke", - "Inv oke", - "▁er halten", - "▁ve el", - "▁word press", - "▁ wordpress", - "▁IN NER", - "trans action", - "▁dé jà", - "Fa ct", - "F act", - "▁над мор", - "▁angular js", - "▁á t", - "▁ át", - "▁a lap", - "▁al ap", - "▁P rice", - "▁Pr ice", - "▁Pri ce", - "▁ Price", - "▁eff et", - "▁s phere", - "▁sp here", - "▁spher e", - "Class Loader", - "▁r ugby", - "▁rug by", - "▁king dom", - "▁M ut", - "▁Mu t", - "▁ки но", - "▁re ward", - "ci t", - "c it", - "▁present e", - "▁pres ente", - "St o", - "S to", - "Char acter", - "lo gs", - "log s", - "l ogs", - "▁cent rale", - "▁central e", - "▁m ouv", - "▁mo uv", - "▁mou v", - "▁ok ay", - "▁ap lic", - "Mo re", - "Mor e", - "M ore", - "ény ek", - "▁Kö ln", - "ne tt", - "net t", - "n ett", - "▁исто рии", - "▁истори и", - "▁descri bing", - "▁sold ier", - "▁N eed", - "▁Ne ed", - "L ight", - "▁\" \\<", - "▁\"\\ <", - "▁h av", - "▁ha v", - "▁ hav", - "er mo", - "erm o", - "▁infer ior", - "le a", - "l ea", - "▁g g", - "▁ gg", - "▁кон це", - "fra gment", - "f ragment", - "s b", - "Count ry", - "C ountry", - "▁v ě", - "▁ vě", - "▁B eng", - "▁Be ng", - "▁Ben g", - "▁Э то", - "▁во до", - "ма р", - "м ар", - "STR ING", - "▁ú j", - "multi ple", - "multip le", - "state ment", - "stat ement", - "▁invol ves", - "▁involve s", - "▁te cn", - "▁tec n", - "St udent", - "gr é", - "g ré", - "▁le an", - "▁ lean", - "▁bring ing", - "▁Med ical", - "▁Medic al", - "▁Medi cal", - "▁програ м", - "▁V og", - "▁Vo g", - "▁ж ов", - "▁Sp irit", - "nt h", - "n th", - "▁stand ards", - "▁standard s", - "▁Pro file", - "▁Prof ile", - "▁Profil e", - "▁ Profile", - "▁e z", - "▁ ez", - "▁террито рии", - "▁s tem", - "▁st em", - "▁ste m", - "ui l", - "u il", - "▁O g", - "B tn", - "na l", - "n al", - "▁near by", - "▁produ cing", - "cri v", - "cr iv", - "c riv", - "▁assum ptions", - "▁assumption s", - "▁S park", - "▁Sp ark", - "▁L ot", - "▁Lo t", - "it udes", - "itu des", - "itude s", - "itud es", - "af ka", - "fi ve", - "f ive", - "at io", - "ati o", - "▁distingu ish", - "ro ck", - "roc k", - "r ock", - "égl ise", - "é glise", - "▁rapp res", - "▁rap pres", - ">\\ <", - "> \\<", - "лі й", - "л ій", - "▁ми ни", - "▁ мини", - "▁intitul é", - "}} (\\", - "}}( \\", - "} }(\\", - "▁R out", - "▁Ro ut", - "▁Rou t", - "▁ Rout", - "▁B order", - "▁Bor der", - "▁ Border", - "▁over rid", - "HO ST", - "H OST", - "rit ten", - "ritt en", - "r itten", - "sa y", - "s ay", - "▁Ч и", - "icht ung", - "▁straight forward", - "ob b", - "o bb", - "▁Ter ra", - "▁Terr a", - "▁[ :", - "▁ [:", - "Be n", - "B en", - "▁compos ite", - ")+ \\", - ") +\\", - "▁c rown", - "▁cr own", - "▁cro wn", - "▁crow n", - "dir ection", - "direct ion", - "dire ction", - "d irection", - "▁неско лько", - "▁av ail", - "▁purch ased", - "▁purchase d", - "ho ok", - "h ook", - "et ies", - "eti es", - "e ties", - "▁f ase", - "▁fa se", - "▁fas e", - "▁R um", - "▁Ru m", - "▁ge nom", - "▁gen om", - "▁d ét", - "▁dé t", - "ow ą", - "mp eg", - "▁І н", - "des ktop", - "▁in jection", - "▁inj ection", - "▁inject ion", - "ag le", - "a gle", - "▁E dd", - "▁Ed d", - "_{ (", - "_ {(", - "▁H em", - "▁He m", - "ut os", - "uto s", - "pr oj", - "pro j", - "▁superfic ie", - "Pl ot", - "P lot", - "▁D ocker", - "▁Do cker", - "▁Doc ker", - "ät z", - "ä tz", - "kre ich", - "k reich", - "▁un clear", - "▁uncle ar", - "▁Un ity", - "▁Unit y", - "▁stream s", - "▁stre ams", - "ви д", - "▁simpl ified", - "Fil l", - "Fi ll", - "F ill", - "▁s ant", - "▁sa nt", - "▁san t", - "▁K ommun", - "▁Kom mun", - "▁Komm un", - "▁d uc", - "▁du c", - "▁д ве", - "▁o bs", - "▁ob s", - "▁ obs", - "ž it", - "▁Jane iro", - "б я", - "▁pr esso", - "▁pres so", - "▁press o", - "▁Min istry", - "▁b urst", - "▁bur st", - "▁re aching", - "▁reach ing", - "li ter", - "lit er", - "l iter", - "▁response s", - "▁respons es", - "▁E ug", - "▁Eu g", - "▁s od", - "▁so d", - "▁C ord", - "▁Cor d", - "▁Co rd", - "▁P erm", - "▁Per m", - "▁Pe rm", - "▁ Perm", - "par ts", - "part s", - "p arts", - "ци ма", - "vari ables", - "variable s", - "▁forgot ten", - "Fe rn", - "F ern", - "ost ęp", - "v l", - "▁С м", - "ki m", - "k im", - "aj ąc", - "ają c", - "a jąc", - "на ль", - "нал ь", - "н аль", - "г ле", - "hel per", - "help er", - "du p", - "d up", - "eu w", - "e uw", - "fr a", - "f ra", - "ell ite", - "elli te", - "an ya", - "any a", - "▁re ign", - "▁r eign", - "▁rei gn", - "ges amt", - "се да", - "▁R yan", - "▁Ry an", - "▁form atted", - "▁format ted", - "▁formatt ed", - "▁B org", - "▁Bo rg", - "▁Bor g", - "wal k", - "w alk", - "▁а л", - "▁ ал", - "agnost ics", - "agnostic s", - "▁C ape", - "▁Cap e", - "▁Ca pe", - "▁Fran co", - "▁Franc o", - "▁f ug", - "▁fu g", - ": )", - "ю з", - "F etch", - "▁rough ly", - "▁M is", - "▁Mi s", - "uet ooth", - "▁Venez uela", - "▁a stronom", - "▁astr onom", - "\") `", - "\" )`", - "om bres", - "omb res", - "▁кото рой", - "ó p", - "ow ed", - "owe d", - "o wed", - "H R", - "▁C amer", - "▁Cam er", - "▁Ca mer", - "ки е", - "par ison", - "▁B ij", - "▁Bi j", - "tem plates", - "template s", - "en vironment", - "environ ment", - "iz ação", - "iza ção", - "▁é r", - "▁ ér", - "▁pl enty", - "▁Type Error", - "▁for ty", - "▁fort y", - "ко ном", - "кон ом", - "коно м", - "▁S ed", - "▁Se d", - "▁th ats", - "▁that s", - "▁gra vity", - "▁grav ity", - "▁gravit y", - "▁ gravity", - "▁spirit ual", - "▁dup licates", - "▁duplicate s", - "▁enc ryption", - "▁encrypt ion", - "▁re ven", - "▁r even", - "▁rev en", - "▁reve n", - "▁ reven", - "get Instance", - "äl lor", - "äll or", - "dis k", - "di sk", - "d isk", - "▁th ro", - "▁thr o", - "▁N ak", - "▁Na k", - "▁p oł", - "▁po ł", - "▁her aus", - "in valid", - "s By", - "Bo ot", - "B oot", - "▁bu cket", - "▁ bucket", - "▁P arse", - "▁Par se", - "▁ Parse", - "he x", - "h ex", - "Con ne", - "C onne", - "▁Comp uter", - "▁Comput er", - "zy k", - "z yk", - "▁indu ced", - "▁Br uno", - "▁Bru no", - "▁Brun o", - "▁address ed", - "▁addr essed", - "ma nia", - "man ia", - "m ania", - "▁in clus", - "▁incl us", - "▁inc lus", - "▁inclu s", - "oun ced", - "ounce d", - "script size", - "scripts ize", - "▁E pis", - "▁Ep is", - "▁v ocal", - "▁vo cal", - "▁voc al", - "▁Jon athan", - "у м", - "st aden", - "sta den", - "stad en", - "▁Child ren", - "▁ Children", - "пе й", - "п ей", - "It alia", - "Ital ia", - "reib ung", - "▁n ost", - "▁no st", - "▁nos t", - "▁ nost", - "▁е щё", - "▁Wer ke", - "▁Werk e", - "▁act ress", - "▁Minn esota", - "ri ke", - "rik e", - "r ike", - "▁t ek", - "▁te k", - "▁ tek", - "▁prime ira", - "▁f rat", - "▁fr at", - "▁fra t", - "▁Config uration", - "▁ Configuration", - "▁b id", - "▁bi d", - "▁ bid", - "tr igger", - "Cont ents", - "Content s", - "▁const antly", - "▁constant ly", - "!! !", - "! !!", - "▁d read", - "▁dr ead", - "▁dre ad", - "▁hundred s", - "ist ische", - "isti sche", - "▁card inal", - "T ABLE", - "▁est os", - "▁esto s", - "ass oc", - "asso c", - "gr ay", - "gra y", - "g ray", - "▁Sch loss", - "▁Schl oss", - "▁s che", - "▁sc he", - "▁sch e", - "▁ sche", - "con g", - "co ng", - "c ong", - "▁ko ji", - "ète s", - "èt es", - "è tes", - "▁E ra", - "▁Er a", - "om i", - "o mi", - "▁S R", - "▁ SR", - "▁wr apped", - "▁wra pped", - "▁wrap ped", - "▁tr unc", - "▁a h", - "▁ ah", - "eg os", - "ego s", - "ok i", - "o ki", - "mo uth", - "m outh", - "log ging", - "▁f asc", - "▁fa sc", - "▁fas c", - "▁S ample", - "▁Sam ple", - "▁ Sample", - "▁c onte", - "▁con te", - "▁cont e", - "▁v illa", - "▁vi lla", - "▁vill a", - "▁vil la", - "▁ villa", - "com ments", - "comm ents", - "comment s", - "▁b atal", - "▁ba tal", - "▁bat al", - "▁bata l", - "▁Garc ía", - "▁N orte", - "▁Nor te", - "▁we chsel", - "▁Muse o", - "▁enf ants", - "▁whis per", - "na ke", - "nak e", - "n ake", - "▁jed nak", - "l ês", - "en ders", - "end ers", - "ender s", - "ende rs", - "▁ä l", - "▁ äl", - "▁V B", - "▁ VB", - "▁cook ies", - "▁cookie s", - "ze ti", - "zet i", - "z eti", - "at um", - "atu m", - "▁d edu", - "▁de du", - "▁ded u", - "▁arr anged", - "▁arrang ed", - "la z", - "l az", - "▁cu enta", - "ym l", - "y ml", - "▁f lav", - "▁fl av", - "▁fla v", - "M R", - "em et", - "eme t", - "e met", - "бі ль", - "б іль", - "cm p", - "c mp", - "it uto", - "itu to", - "itut o", - "ze tt", - "zet t", - "z ett", - "▁en vi", - "▁env i", - "▁k ot", - "▁ko t", - "$ :", - "up per", - "upp er", - "u pper", - "▁Al berto", - "▁Albert o", - "k b", - "An al", - "A nal", - "ör t", - "ö rt", - "▁[ -", - "▁ [-", - "▁führ te", - "▁führt e", - "ia h", - "i ah", - "▁T un", - "▁Tu n", - "▁и скус", - "uw e", - "u we", - "is pecies", - "i species", - "P ub", - "Syn c", - "S ync", - "▁Colomb ia", - "ak ers", - "ake rs", - "aker s", - "▁Imper ial", - "ov ing", - "ovi ng", - "o ving", - "▁int elligence", - "▁intellig ence", - "▁equip ment", - "ei n", - "e in", - "dag ger", - "d agger", - "▁Ed ge", - "▁ Edge", - "▁Рес публи", - "adratkil ometer", - "▁An to", - "▁Ant o", - "▁char ges", - "▁charge s", - "▁charg es", - "▁O cean", - "▁simpl ify", - "▁m iesz", - "▁mi esz", - "▁mie sz", - "run ning", - "r unning", - "▁L ac", - "▁La c", - "gen ommen", - "▁represent ative", - "= .", - "▁P red", - "▁Pr ed", - "▁Pre d", - "▁ Pred", - "▁sp ite", - "ci ale", - "cial e", - "cia le", - "c iale", - "▁n ave", - "▁na ve", - "▁nav e", - "▁ext ens", - "▁neut ral", - "▁кото рая", - ".< /", - ". : :", - "> ::", - "ш ёл", - "▁princip ales", - "▁principal es", - "▁principale s", - "▁ц ар", - "▁t ied", - "▁ti ed", - "▁tie d", - "▁al ta", - "▁alt a", - "▁C it", - "▁Ci t", - "li ned", - "line d", - "lin ed", - "l ined", - "ma jor", - "▁p unk", - "▁pun k", - "▁cin co", - "ick ý", - "▁r aggi", - "▁ra ggi", - "▁rag gi", - "ty pen", - "type n", - "typ en", - "тель ство", - "▁con ference", - "▁confer ence", - "▁с іль", - "▁сі ль", - "▁he ut", - "i š", - "ет а", - "е та", - "vel ope", - "velop e", - "h box", - "no wn", - "now n", - "n own", - "▁z ar", - "▁za r", - "▁ zar", - "kt iv", - "ie ß", - "▁с тре", - "▁ст ре", - "▁ стре", - "▁Event Args", - "▁ EventArgs", - "▁I ra", - "▁Ir a", - "▁V BA", - "▁VB A", - "▁S anto", - "▁San to", - "▁Sant o", - "▁F ach", - "▁Fa ch", - "▁Fac h", + "▁M I", + "▁M aster", + "▁0 .25", + "event -", + "event ▁analysis", + "▁of▁the▁ treatment", + "wh os", + "▁com menc", + "▁F A", "▁F F", - "▁ FF", - "▁Ray mond", - "ме ц", - "im plementation", - "▁bro thers", - "▁brother s", - "▁cô té", - "▁cont rollers", - "▁control lers", - "▁controller s", - "▁C le", - "▁Cl e", - "▁c able", - "▁ca ble", - "▁cab le", - "▁con fer", - "▁conf er", - "▁{ -", - "▁ {-", - "▁cz ł", - "▁Fil ip", - "at orio", - "ator io", - "ato rio", - "atori o", - "▁w icht", - "▁be aucoup", - "▁L it", - "▁Li t", - "▁s essions", - "▁session s", - "▁sess ions", - "▁Su ccess", - "▁ Success", - "▁ro uting", - "▁rout ing", - "▁rou ting", - "ni u", - "n iu", - "▁V ice", - "▁Vi ce", - "▁Vic e", - "▁k rit", - "▁kr it", - "up dated", - "update d", - "▁In valid", - "▁ Invalid", - "▁Mann schaft", - "▁a os", - "▁ao s", - "▁t udi", - "▁tu di", - "▁tud i", - "▁des prés", - "▁desp rés", - "qu a", - "q ua", - "Cont ains", - "Comp any", - "▁person a", - "▁pers ona", - "ad apter", - "с ни", - "▁v oj", - "▁vo j", - "▁ voj", - "▁e scri", - "▁es cri", - "▁esc ri", - "ag t", - "a gt", - "▁с тво", - "▁ст во", - "▁ ство", - "▁dist rito", - "ap an", - "apa n", - "a pan", - "▁aspect s", - "▁z al", - "▁za l", - ")^ {\\", - ")^{ \\", - ") ^{\\", - "▁syst ème", - "▁а на", - "▁ан а", - "▁ ана", - "ium s", - "iu ms", - "i ums", - "▁prem iers", - "▁premi ers", - "▁premier s", - "▁по э", - "▁m ère", - "▁G un", - "▁Gu n", - "ap ing", - "api ng", - "a ping", - "▁R ain", - "▁Ra in", - "▁ig ual", - "▁process or", - "▁proc essor", - "▁ processor", - "') `", - "' )`", - "bl ing", - "b ling", - "▁m ism", - "▁mi sm", - "▁mis m", - "br áz", - "▁close st", - "▁clos est", - "▁Re ading", - "▁Read ing", - "▁по пу", - "con o", - "co no", - "c ono", - "▁k ult", - "▁! !", - "▁ !!", - "▁Ex pression", - "▁Exp ression", - "▁Express ion", - "▁ Expression", - "▁indu ction", - "▁induct ion", - "ah ren", - "ahr en", - "a hren", - "▁c p", - "▁ cp", - "▁viol ence", - "ient í", - "cent e", - "cen te", - "c ente", - "▁D ob", - "▁Do b", - "ja ck", - "j ack", - "so ng", - "son g", - "s ong", - "bu cket", - "▁de port", - "▁dep ort", - "ки ми", - "ким и", - "l m", - "▁in noc", - "▁inn oc", - "Ch anges", - "Change s", - "▁pro hib", - "ang ol", - "ango l", - "isecond s", - "i seconds", - "▁п ор", - "▁по р", - "▁ пор", - "▁h ip", - "▁hi p", - "▁ hip", - "▁p ů", - "en dorf", - "end orf", - "endo rf", - "endor f", - "▁sch eduled", - "▁schedule d", - "▁Fl ug", - "ac yj", - "acy j", - "▁Fil ms", - "▁Film s", - "athed ral", - "Po wer", - "P ower", - "ar din", - "ard in", - "ardi n", - "ka p", - "k ap", - "ic ken", - "ick en", - "i cken", - "re size", - "res ize", - "eu s", - "e us", - "r r", - "ля н", - "л ян", - "▁H av", - "▁Ha v", - "▁o ra", - "▁or a", - "▁ ora", - "FR OM", - "F ROM", - "ло ся", - "▁te rug", - "▁ter ug", - "▁W idth", - "▁ Width", - "▁accept s", - "бе н", - "б ен", - "▁m ich", - "▁mi ch", - "▁mic h", - "▁C zech", - "▁Cz ech", - "▁B edeut", - "▁ви д", - "▁ вид", - "ô me", - "▁L oop", - "▁Lo op", - "▁ Loop", - "sp ect", - "spe ct", - "spec t", - "s pect", - "ü k", - "es ton", - "est on", - "esto n", - "e ston", - "▁s lot", - "▁sl ot", - "▁slo t", - "▁został a", - "▁Charlot te", - "▁состав ляет", - "▁составля ет", - "▁Prom ise", - "▁e po", - "▁ep o", - "▁d iction", - "▁di ction", - "▁dict ion", - "▁dic tion", - "▁ diction", - "▁Frank lin", - "▁R iv", - "▁Ri v", - "ру г", - "ci da", - "cid a", - "c ida", - "▁Ex plorer", - "cook ie", - "▁former ly", - "▁municip ality", - "▁municipal ity", - "▁Ste fan", - "▁Stef an", - "list s", - "lis ts", - "l ists", - "CO MP", - "COM P", - "Le n", - "L en", - "▁Sta at", - "▁N BA", - "de ns", - "den s", - "d ens", - "▁osc ill", - "! .", - "▁P O", - "▁ PO", - "ô ne", - "es es", - "ese s", - "▁на циональ", - "vo or", - "v oor", - "▁ко пи", - "▁по зи", - "▁ пози", - "ul u", - "u lu", - "Const raint", - "Constra int", - "▁сво ей", - "▁algebra ic", - "ч ня", - "Di ct", - "D ict", - "▁appear ing", - "▁appe aring", - "▁p rav", - "▁pr av", - "▁pra v", - "▁Univers al", - "B rowser", - "▁Sing ap", - "ennes see", - "] _", - "▁S of", - "▁So f", - "▁C ad", - "▁Ca d", - "oun ce", - "▁cost s", - "▁cos ts", - "]{ \\", - "] {\\", - "../ ../", - "ськ ій", - "ські й", - "üh l", - "ü hl", - "ie ty", - "iet y", - "i ety", - "п р", - "▁interpre ted", - "▁interpret ed", - "aj n", - "col og", - "co log", - "colo g", - "c olog", - "Y S", - "ma ns", - "man s", - "m ans", - "▁met rics", - "▁metric s", - "▁reg istr", - "▁ registr", - "ist ance", - "istan ce", - "▁По ль", - "▁an onymous", - "▁ anonymous", - "▁institution s", - "▁instit utions", - "▁z dob", - "▁zd ob", - "pr üng", - "prü ng", - "▁ар ти", - "▁e stat", - "▁est at", - "▁es tat", - "▁esta t", - "ac ci", - "acc i", - "▁academ ic", - "▁ch iesa", - "▁chi esa", - "▁G ian", - "▁Gi an", - "▁Gia n", - "cont rib", - "contr ib", - "um ed", - "ume d", - "u med", - "▁G ir", - "▁Gi r", - "▁base ball", - "numer ic", - "n umeric", - "Gener ator", - "G M", - "▁t iny", - "▁ti ny", - "▁tin y", - "▁ tiny", - "▁dist inction", - "▁distinct ion", - "ге р", - "г ер", - "▁r ust", - "▁ru st", - "▁rus t", - "▁ rust", - "▁FI FA", - "▁Pro perties", - "▁ Properties", - "^ -", - "▁э кс", - "▁эк с", - "▁Sta nis", - "▁Stan is", - "▁A jax", - "es cape", - "esc ape", - "▁con sp", - "▁cons p", - "▁C hen", - "▁Ch en", - "▁Che n", - "▁N aval", - "▁Na val", - "▁Nav al", - "Bi t", - "B it", - "▁b ât", - "ски ми", - "ским и", - "с кими", - "dr ive", - "dri ve", - "d rive", - "▁R ound", - "▁Ro und", - "▁Rou nd", - "ph oto", - "▁Le vel", - "▁Lev el", - "▁ Level", - "▁g eg", - "▁ge g", - "▁ geg", - "To m", - "T om", - "▁M obile", - "▁ Mobile", - "▁T rop", - "▁Tr op", - "▁Tro p", - "Dir ection", - "Direct ion", - "D irection", - "is an", - "isa n", - "i san", - ")^ {-", - ")^{ -", - ") ^{-", - "▁Set ting", - "▁ Setting", - "▁Pro bably", - "ль я", - "л ья", - "▁as sets", - "▁ass ets", - "▁asse ts", - "▁asset s", - "▁ assets", - "▁a tte", - "▁at te", - "▁att e", - "▁ atte", - "▁b ulk", - "▁bul k", - "és t", - "é st", - "▁w ing", - "▁win g", - "▁ wing", - "ni us", - "niu s", - "n ius", - "▁w ins", - "▁win s", - "▁l ud", - "▁lu d", - "us hing", - "ush ing", - "▁d even", - "▁de ven", - "▁dev en", - "▁deve n", - "огра ф", - "о граф", - "burg er", - "bur ger", - "b urger", - "▁em bar", - "▁emb ar", - "Filter Chain", - "▁t um", - "▁tu m", - "▁ö ss", - "▁nom mé", - "▁p ir", - "▁pi r", - "▁l uc", - "▁lu c", - "db o", - "d bo", - "ag ues", - "ague s", - "agu es", - "▁al can", - "▁alc an", - "ou wen", - "ouw en", - "▁Stan ley", - "ци али", - "▁g rown", - "▁gr own", - "▁gro wn", - "▁grow n", - "▁pres erved", - "▁preserve d", - "▁s olar", - "▁so lar", - "▁sol ar", - "▁Насе ление", - "▁perform ances", - "▁performance s", - "▁C ow", - "▁Co w", - "▁engine ering", - "▁engineer ing", - "▁sc aling", - "▁scal ing", - "at omic", - "ato mic", - "atom ic", - "end ance", - "▁a ce", - "▁ac e", - "▁ ace", - "än gen", - "äng en", - "änge n", - "An im", - "A nim", - "ph ase", - "pha se", - "phas e", - "z burg", - "O ld", - "▁serv ant", - "▁geme ins", - "▁Ob serv", - "trans late", - "▁cover ing", - "▁cov ering", - "▁est án", - "▁está n", - "▁problem a", - "▁proble ma", - "▁probl ema", - "▁у станов", - "▁l lev", - "▁ll ev", - "▁lle v", - "▁c zerw", - "é al", - "me z", - "m ez", - "RE E", - "R EE", - "ER R", - "ту ри", - "тур и", - "se gu", - "seg u", - "s egu", - "▁pro fit", - "▁prof it", - "▁multip lication", - "kom men", - "k ommen", - "▁f aut", - "▁fa ut", - "▁candid ates", - "▁candidate s", - "▁U ri", - "▁Ur i", - "▁ Uri", - "▁La ura", - "▁Laur a", - "▁Lau ra", - "▁s ap", - "▁sa p", - "▁ви сини", - "▁Bet ween", - "fa de", - "f ade", - "▁res erved", - "▁reserve d", - "▁invol ving", - "▁M are", - "▁Mar e", - "▁Ma re", - "▁Cont ainer", - "▁ Container", - "▁на зна", - "▁DE BUG", - "▁ DEBUG", - "▁h urt", - "▁hur t", - "▁hu rt", - "▁Pol ski", - "▁l ux", - "▁lu x", - "C B", - "wa ch", - "w ach", - "▁пери од", - "▁перио д", - "▁C atherine", - "▁g anz", - "▁gan z", - "uch te", - "ucht e", - "u chte", - "▁cons umer", - "▁consum er", - "▁consume r", - "▁cross ed", - "ord ered", - "order ed", - "orde red", - "aw ay", - "awa y", - "a way", - "te chn", - "tech n", - "▁sub scri", - "▁subs cri", - "▁short cut", - "▁произ вод", - "▁simultane ously", - "▁r ating", - "▁ra ting", - "▁rat ing", - "▁ rating", - "▁K ings", - "▁King s", - "▁Kin gs", - "▁relations hips", - "▁relation ships", - "▁relationship s", - "▁S ex", - "▁Se x", - "▁T ool", - "▁To ol", - "▁ Tool", - "ag h", - "a gh", - "ac ters", - "act ers", - "acter s", - "log ger", - "hom me", - "en gers", - "eng ers", - "enger s", - "▁R i", - "ear ance", - "ea rance", - "▁appear ances", - "▁appearance s", - "Re al", - "▁p asse", - "▁pass e", - "▁pas se", - "ic lopedia", - "ч ко", - "ter re", - "▁Ont ario", - "▁пере да", - "▁перед а", - "fo oter", - "foo ter", - "foot er", - "arch ivi", - "archiv i", - "if iz", - "ifi z", - "▁Pro test", - "▁Prote st", - "▁L IN", - "▁LI N", - "▁ LIN", - "unn able", - "▁cent uries", - "▁B ayer", - "▁Ba yer", - "▁Bay er", - "ці ю", - "ов ин", - "ови н", - "о вин", - "▁And rea", - "▁Andre a", - "se lection", - "select ion", - "sel ection", - "▁c alm", - "▁cal m", - "▁ca lm", - "▁mod ification", - "▁modific ation", - "▁short ly", - "in aire", - "ina ire", - "i naire", - "▁f usion", - "▁fus ion", - "▁feel ings", - "▁feeling s", - "▁fee lings", - "P K", - "▁Ro berto", - "▁Robert o", - "г не", - "Sh ared", - "▁mehr ere", - "▁N iem", - "▁Ni em", - "▁Nie m", - "om p", - "o mp", - "En v", - "▁Art icle", - "▁P ok", - "▁Po k", - "▁V ARCHAR", - "▁d il", - "▁di l", - "▁af ford", - "▁aff ord", - "▁con front", - "▁conf ront", - "ow anie", - "owa nie", - "owan ie", - "▁min istre", - "▁minist re", - "▁mini stre", - "ad esh", - "ade sh", - "ades h", - "▁P oly", - "▁Pol y", - "▁Po ly", - "▁Ра спо", - "▁Рас по", - "▁Gru ppe", - "▁H elen", - "▁He len", - "▁Hel en", - "▁c c", - "▁ cc", - "▁port rait", - "be w", - "b ew", - "▁b eta", - "▁be ta", - "▁bet a", - "▁ beta", - "▁W ir", - "▁Wi r", - "▁A udio", - "▁Aud io", - "▁ Audio", - "▁( \\<", - "▁(\\ <", - "rior ity", - "▁n it", - "▁ni t", - "▁ nit", - "▁пред стави", - "▁представ и", - "▁V ie", - "▁Vi e", - "▁w ür", - "▁ wür", - "▁H old", - "▁Hol d", - "▁Ho ld", - "▁ Hold", - "▁S ad", - "▁Sa d", - "▁To chter", - "▁o ltre", - "▁ol tre", - "▁ oltre", - "▁Act iv", - "▁ Activ", - "▁J ason", - "▁Ja son", - "▁Jas on", - "▁wie ku", - "▁reg ards", - "▁regard s", - "▁t aste", - "▁ta ste", - "agnost ic", - "ла ся", - "▁S elf", - "▁Sel f", - "▁ Self", - "▁a pr", - "▁ap r", - "▁De ep", - "sc op", - "s cop", - "Act iv", - "▁type def", - "▁typed ef", - "Content View", - "comp iler", - "compile r", - "▁R oth", - "▁Ro th", - "▁Rot h", - "x c", - "зи к", - "▁l argo", - "▁lar go", - "▁larg o", - "▁R ena", - "▁Re na", - "▁Ren a", - "he iten", - "heit en", - "▁platform s", - "▁plat forms", - "ul la", - "ull a", - "u lla", - "▁gl ance", - "▁mas cul", - "▁m ex", - "▁me x", - "▁J orge", - "▁fun cion", - "▁func ion", - "cho ose", - "▁re views", - "▁review s", - "▁Al ban", - "▁Alb an", - "▁G lo", - "▁Gl o", - "▁S pecies", - "▁Spe cies", - "▁Spec ies", - "▁F ame", - "▁Fa me", - "▁Fam e", - "▁R oll", - "▁Ro ll", - "▁Rol l", - "▁P uerto", - "▁\\ )", - "▁ \\)", - "ym nas", - "ymn as", - "en viron", - "▁i phone", - "▁Wrest ling", - "ał y", - "a ły", - "▁Ind iana", - "▁India na", - "▁Indian a", - "Rad io", - "V S", - "▁independ ence", - "та й", - "▁de code", - "▁dec ode", - "▁ decode", - "Wh ite", - "▁j ourn", - "▁jo urn", - "▁jou rn", - "▁jour n", - "ícul o", - "í culo", - "▁Bar b", - "▁Ba rb", - "▁Ev angel", - "▁An dy", - "▁And y", - "▁Wel come", - "▁De vice", - "▁Dev ice", - "▁ Device", - "ge f", - "g ef", - "▁remember ed", - "▁vari ations", - "▁variation s", - "▁Ad olf", - "it aine", - "ita ine", - "▁надмор ској", - "▁s team", - "▁ste am", - "▁concern s", - "▁` |", - "▁би о", - "тель ства", - "▁qu attro", - "ext end", - "▁trab ajo", - "▁trabaj o", - "en berg", - "▁scen arios", - "▁scenario s", - "ân t", - "â nt", - "▁kom mt", - "▁komm t", - "▁dom estic", - "▁B asketball", - "▁Co oper", - "so ck", - "s ock", - "дер жа", - "д ержа", - "={ \\", - "= {\\", - "▁in ici", - "▁P hill", - "▁Ph ill", - "▁Phil l", - "▁гене рал", - "archivi ato", - "ъ н", - "Ro b", - "R ob", - "▁t ong", - "▁to ng", - "▁ton g", - "▁character istics", - "▁characteristic s", - "▁a maz", - "▁am az", - "▁M ode", - "▁Mod e", - "▁Mo de", - "▁ Mode", - "▁inaug ur", - "we hr", - "ra nt", - "ran t", - "r ant", - "ion ali", - "ional i", - "iona li", - "▁M other", - "▁Mo ther", - "▁Mot her", - "M a", - "é qu", - "▁K elly", - "▁Kel ly", - "ci le", - "cil e", - "c ile", - "▁beste ht", - "▁estim ates", - "▁estimate s", - "rugu ay", - "▁A ns", - "▁An s", - "Ma d", - "M ad", - "▁на в", - "▁d onnées", - "▁donn ées", - "▁donné es", - "▁ données", - "▁trop ical", - "▁Sever al", - "el ter", - "elt er", - "elte r", - "▁P ho", - "▁Ph o", - "ke m", - "k em", - "▁Custom er", - "▁ Customer", - "▁скла ді", - "▁c ourses", - "▁course s", - "▁cours es", - "Pl atform", - "nav bar", - "le arning", - "lear ning", - "learn ing", - "▁Sw edish", - "▁z ast", - "▁za st", - "▁zas t", - "▁L ig", - "▁Li g", - "man agement", - "▁l od", - "▁lo d", - "uff le", - "Text ure", - "Te xture", - "ar ga", - "arg a", - "át um", - "▁D DR", - "ні ї", - "н ії", - "▁Soci été", - "▁dom ains", - "▁domain s", - "▁perm itted", - "▁permit ted", - "▁ex terne", - "▁ext erne", - "▁extern e", - "▁quel que", - "v t", - "ym an", - "y man", - "▁W ard", - "▁War d", - "▁Wa rd", - "▁ag li", - "▁ agli", - "▁and ra", - "▁an dra", - "▁ andra", - "S napshot", - "▁m å", - "▁ye ah", - "де на", - "ден а", - "д ена", - "ęp u", - "ę pu", - "ask ell", - "▁Ré publique", - "in ject", - "▁' ;", - "▁ ';", - "än n", - "ä nn", - "▁z elf", - "▁Ent wicklung", - "ár ia", - "á ria", - "on omy", - "ono my", - "onom y", - "▁s vil", - "▁sv il", - "ie se", - "ies e", - "i ese", - "▁con ser", - "▁cons er", - "▁conse r", - "▁n im", - "▁ni m", - "▁ nim", - "▁r ész", - "▁ré sz", - "▁rés z", - "▁И тали", - "▁part ici", - "▁partic i", - "▁parti ci", - "▁L ion", - "▁Li on", - "s r", - "al ways", - "▁Влади мир", - "че ские", - "[ ,", - "▁Def inition", - "▁ Definition", - "na nt", - "nan t", - "n ant", - "oe m", - "o em", - "Id s", - "I ds", - "▁в не", - "▁[ ...]", - "▁на прав", - "▁нап рав", - "▁G O", - "▁ GO", - "▁å rs", - "▁år s", - "▁ut án", - "▁out ros", - "▁reg ión", - "▁M ong", - "▁Mon g", - "▁Mo ng", - "▁fil me", - "▁film e", - "▁tri ple", - "▁trip le", - "▁sp ons", - "▁spo ns", - "De velop", - "▁out come", - "▁B ible", - "▁Bi ble", - "▁Bib le", - "▁и мени", - "▁име ни", - "▁имен и", - "Can vas", - "пу та", - "cur r", - "cu rr", - "c urr", - "ás ok", - "){ \\", - ") {\\", - "ning ar", - "` ;", - "▁Fl ash", - ": #", - "mu st", - "mus t", - "m ust", - "cp u", - "c pu", - "▁form ats", - "▁format s", - "▁forma ts", - "Ha r", - "H ar", - "▁epis odio", - "▁R osa", - "▁Ro sa", - "▁Ros a", - "▁d ès", - "em it", - "emi t", - "e mit", - "rit eria", - "rite ria", - "riter ia", - "An notation", - "Fl ag", - "F lag", - "g mail", - "▁N ormal", - "▁Nor mal", - "▁Norm al", - "▁ Normal", - "oll ary", - "ollar y", - "▁f oss", - "▁fo ss", - "▁fos s", - "▁con current", - "▁conc urrent", - "▁ concurrent", - "▁crash es", - "▁ви де", - "▁вид е", - "▁Min or", - "▁Mi nor", - "▁S it", - "▁Si t", - "▁S N", - "▁ SN", - "▁s car", - "▁sc ar", - "▁ scar", - "▁fe min", - "▁fem in", - "▁spec ification", - "▁specific ation", - "so ap", - "▁o perate", - "▁oper ate", - "▁opera te", - "▁principal mente", - "▁a ust", - "▁au st", - "▁aus t", - "ib ile", - "ibil e", - "it ime", - "iti me", - "i time", - "ле жа", - "if rame", - "i frame", - "▁concept s", - "▁conce pts", - "▁t ack", - "▁ta ck", - "▁v iss", - "▁vis s", - "▁vi ss", - "▁car bon", - "ter y", - "te ry", - "t ery", - "▁n aming", - "▁na ming", - "▁nam ing", - "▁Or ts", - "▁Ort s", - "id ente", - "ident e", - "iden te", - "▁Cap it", - "▁Ca pit", - "▁ex pr", - "▁exp r", - "▁ expr", - "▁насе љу", - "▁Select ed", - "▁Sel ected", - "▁Sele cted", - "▁ Selected", - "▁h inter", - "▁hint er", - "▁hin ter", - "▁i frame", - "▁if rame", - "▁ iframe", - "▁z b", - "index Path", - "col l", - "co ll", - "c oll", - "▁wr ześ", - "▁a cht", - "▁ac ht", - "▁ach t", - "▁ acht", - "▁grad ually", - "▁gradu ally", - "▁ч у", - "▁ чу", - "зе й", - "з ей", - "ha ft", - "h aft", - "▁t ran", - "▁tr an", - "▁tra n", - "▁la quelle", - "yt ics", - "ID E", - "I DE", - "▁py game", - "▁pyg ame", - "▁P ackage", - "▁Pack age", - "▁ Package", - "▁class Name", - "▁ className", - "B al", - "pe rl", - "per l", - "ти на", - "тин а", - "O cc", - "▁in frastr", - "▁Champion s", - "▁Champ ions", - "▁class ic", - "▁R aw", - "▁Ra w", - "▁ Raw", - "▁partial ly", - "▁parti ally", - "▁T ed", - "▁Te d", - "▁sto let", - "ra ined", - "rain ed", - "raine d", - "rai ned", - "r ained", - "WH ERE", - "W HERE", - "▁v all", - "▁val l", - "▁va ll", - "▁Jul ia", - "▁Ju lia", - "▁Juli a", - "za t", - "z at", - "▁surr ounded", - "SE E", - "S EE", - "▁walk ing", - "▁wal king", - "B ad", - "FO R", - "F OR", - "con tre", - "cont re", - "contr e", - "▁Pal est", - "▁Pale st", - "át ico", - "▁engine er", - "▁part ners", - "▁partner s", - "▁Je ws", - "▁Jew s", - "il ers", - "ile rs", - "iler s", - "i lers", - "▁c erem", - "▁ce rem", - "▁cer em", - "▁inter actions", - "▁interaction s", - "▁interact ions", - "ac u", - "a cu", - "st y", - "s ty", - "▁Prince ss", - "▁Prin cess", - "sh arp", - "sha rp", - "▁Sing les", - "▁Single s", - "▁ї х", - "ch ez", - "che z", - "c hez", - "Rece iver", - "Receive r", - "▁pat ients", - "▁patient s", - "string ify", - "▁compet ed", - "be y", - "b ey", - "$ ;", - "▁B d", - "had oop", - "h adoop", - "▁Div isión", - "öl d", - "ö ld", - "▁restrict ed", - "▁comm ander", - "▁command er", - "▁comma nder", - "▁High way", - "▁Č esk", - "▁m yth", - "▁my th", - "ча н", - "ч ан", - "ra ham", - "rah am", - "▁en qu", - "▁p og", - "▁po g", - "▁com una", - "▁comun a", - "▁print ln", - "▁ println", - "▁к руп", - "▁de pois", - "▁dep ois", - "▁se ats", - "▁sea ts", - "▁seat s", - "▁neigh b", - "ци она", - "цион а", - "ag ine", - "agi ne", - "agin e", - "▁cloth es", - "▁clo thes", - "▁P rior", - "▁Pr ior", - "▁Pri or", - "Br ain", - "Bra in", - "B rain", - "FF FF", - "': '", - "' :'", - "fe atures", - "feature s", - "▁file system", - "▁files ystem", - "▁sing les", - "▁single s", - "▁Mel bourne", - "▁dest ruction", - "▁destruct ion", - "▁destru ction", - "▁Ly on", - "▁In sel", - "▁Ins el", - "Na v", - "N av", - "▁Re place", - "▁Rep lace", - "▁ Replace", - "▁l é", - "▁ lé", - "Wh o", - "W ho", - "▁E stad", - "▁Est ad", - "▁Esta d", - "▁dim ensional", - "▁dimension al", - "▁ dimensional", - "▁ö ff", - "▁ öff", - "▁gr ands", - "▁gran ds", - "▁grand s", - "дж а", - "д жа", - "pl ane", - "plan e", - "pla ne", - "p lane", - "но сті", - "ност і", - "нос ті", - "▁Or igin", - "▁Ori gin", - "▁Orig in", - "▁ Origin", - "W I", - "än ner", - "änn er", - "▁C ry", - "▁Cr y", - "IT ION", - "▁fö dd", - "▁cult ura", - "▁R ank", - "▁Ran k", - "▁v uel", - "▁vue l", - "▁vu el", - "▁z ag", - "▁za g", - "▁Ma xim", - "▁Max im", - "он у", - "о ну", - "() ))", - "()) )", - "( )))", - "R aw", - "kir che", - "k irche", - "▁a demás", - "▁t ie", - "▁ti e", - "▁St yle", - "▁ Style", - "ско в", - "ск ов", - "с ков", - "ist ant", - "ista nt", - "istan t", - "ol ph", - "▁Z ür", - "▁In fo", - "▁Inf o", - "▁ Info", - "DO M", - "D OM", - "us c", - "u sc", - "na hm", - "nah m", - "▁Ф едера", - "▁F ot", - "▁Fo t", - "▁spec ifying", - "▁specify ing", - "▁tit olo", - "▁Bo ys", - "▁Boy s", - "ie ch", - "iec h", - "i ech", - "Pl ace", - "P lace", - "▁H off", - "▁Ho ff", - "▁Hof f", - "▁c ached", - "▁ca ched", - "▁cache d", - "ва ль", - "вал ь", - "в аль", - "is her", - "ish er", - "roll ing", - "rol ling", - "op ens", - "ope ns", - "open s", - "▁h r", - "▁ hr", - "-- ----", - "---- --", - "--- ---", - "----- -", - "- -----", - "▁mag gior", - "▁maggio r", - "▁trans actions", - "▁transaction s", - "▁c riminal", - "▁crim inal", - "▁re tre", - "▁ret re", - "▁retr e", - "▁Camp bell", - ")) :", - ") ):", - "▁n ed", - "▁ne d", - "▁ ned", - "Page r", - "Pa ger", - "P ager", - "▁H ero", - "▁He ro", - "▁Her o", - "(_ _", - "( __", - "▁un cle", - "▁re aches", - "▁reach es", - "ar to", - "art o", - "▁h ello", - "▁hel lo", - "▁hell o", - "▁ hello", - "Pre ferences", - "▁за тем", - "Name d", - "Na med", - "N amed", - "▁re aders", - "▁read ers", - "▁reader s", - "х і", - "ke rn", - "ker n", - "k ern", - "▁у по", - "ки н", - "к ин", - "▁l av", - "▁la v", - "▁ lav", - "▁n ob", - "▁no b", - "▁se cre", - "▁sec re", - "▁List View", - "▁ ListView", - "ва ния", - "▁May or", - "bo rough", - "bor ough", - "▁fil osof", - "не ння", - "нен ня", - "фр и", - "ф ри", - "▁p atr", - "▁pat r", - "▁pa tr", - "F M", - "▁a cid", - "▁ac id", - "▁Salv ador", - "▁a bb", - "▁ab b", - "▁ abb", - "▁G raham", - "▁Gra ham", - "pol icy", - "neg ative", - "ński ego", - "ń skiego", - "▁He imat", - "▁d azu", - "▁da zu", - "▁m ely", - "▁me ly", - "▁mel y", - "▁r ide", - "▁rid e", - "▁ri de", - "▁ ride", - "▁du ties", - "▁dut ies", - "ov ery", - "over y", - "ove ry", - "o very", - "▁Pro position", - "▁Prop osition", - "▁Pa olo", - "/ '", - "▁M au", - "▁Ma u", - "im enti", - "iment i", - "imen ti", - "Sa int", - "S aint", - "fa ther", - "f ather", - "▁equ ilib", - "ph ony", - "phon y", - "▁c las", - "▁cl as", - "▁cla s", - "▁от ли", - "▁Buffer ed", - "▁Buff ered", - "re k", - "r ek", - "▁m itt", - "▁mit t", - "▁mi tt", - "▁ mitt", - "▁H ur", - "▁Hu r", - "▁Har vard", - "▁demonstr ate", - "ua rio", - "u ario", - "▁do lor", - "▁dol or", - "▁reject ed", - "▁M üller", - "▁n ac", - "▁na c", - "▁B elle", - "▁Be lle", - "▁Bel le", - "▁Bell e", - "▁gather ed", - "n r", - "fr ika", - "fri ka", - "öl l", - "ö ll", - "▁chem ical", - "ni g", - "n ig", - "▁cal c", - "▁ calc", - "▁DE FAULT", - "▁ DEFAULT", - "▁philosoph y", - "▁Lar avel", - "▁al ignment", - "▁align ment", - "E V", - "e or", - "▁d zie", - "▁dz ie", - "▁ dzie", - "▁m est", - "▁me st", - "▁mes t", - "▁I o", - "CR E", - "C RE", - "з ви", - "▁M edic", - "▁Me dic", - "▁Med ic", - "▁Medi c", - "▁n ä", - "▁z ab", - "▁za b", - "▁S lov", - "▁Sl ov", - "▁Slo v", - "ut lich", - "▁am plit", - "▁ampl it", - "▁amp lit", - "▁Fran kreich", - "▁Frank reich", - "▁к іль", - "▁кі ль", - "IN D", - "I ND", - "exec ution", - "▁Kar riere", - "d ostęp", - "▁r éal", - "▁ré al", - "en go", - "eng o", - "▁se vere", - "▁sever e", - "зм а", - "з ма", - "▁тур ни", - "▁C arter", - "▁Car ter", - "▁Cart er", - "▁Rob inson", - "▁Robin son", - "getElement sBy", - "▁pro totype", - "▁proto type", - "▁ prototype", - "▁jap on", - "▁ja pon", - "führ ung", - "f ührung", - "▁con segu", - "▁cons egu", - "▁conse gu", - "▁st udi", - "▁stud i", - "▁l ire", - "▁li re", - "▁ lire", - "▁sch ließ", - "▁ schließ", - "▁B uff", - "▁Bu ff", - "▁red und", - "▁redu nd", - "▁e rn", - "▁er n", - "▁ ern", - "▁my ster", - "▁myst er", - "▁prop rio", - "▁propri o", - "ate ful", - "▁Par ent", - "▁Pa rent", - "▁ Parent", - "▁lad ies", - "ra ck", - "rac k", - "r ack", - "ти ка", - "тик а", - "en burg", - "▁каче стве", - "▁E F", - "▁ EF", - "▁st am", - "▁sta m", - "▁nue va", - "▁fil tered", - "▁filter ed", - "re ten", - "ret en", - "r eten", - "▁I an", - "▁Matt hew", - "▁Matth ew", - "ki h", - "k ih", - "▁ ő", - "▁ком пози", - "▁for ever", - "▁fore ver", - "oir es", - "oi res", - "oire s", - "o ires", - ":\\ \\", - ": \\\\", - "▁ét udes", - "▁s oup", - "▁so up", - "▁sou p", - "▁p leased", - "▁please d", - "▁ple ased", - ")} (", - ") }(", - "▁S top", - "▁St op", - "▁Sto p", - "▁ Stop", - "Set ter", - "S etter", - "▁He lp", - "▁Hel p", - "▁ Help", - "▁b ars", - "▁bar s", - "▁ba rs", - "▁ bars", - "▁ER R", - "▁ ERR", - "▁( ?", - "▁ (?", - "▁po etry", - "▁poet ry", - "▁U til", - "▁Ut il", - "▁ Util", - "A K", - "▁f ick", - "▁fi ck", - "▁fic k", - "▁I M", - "▁ IM", - "▁pro ud", - "▁pr oud", - "но си", - "нос и", - "▁m uerte", - "▁mu erte", - "▁Palmar ès", - "▁N as", - "▁Na s", - "щи х", - "щ их", - "▁qu er", - "▁que r", - "▁q uer", - "▁ quer", - "▁a penas", - "▁ap enas", - "][ '", - "] ['", - "▁Kon st", - "по н", - "п он", - "▁Sch iff", - "▁m p", - "▁ mp", - "▁б лаго", - "fr am", - "fra m", - "f ram", - "▁house hold", - "▁t ract", - "▁tr act", - "▁tra ct", - "▁trac t", - "enc oding", - "▁und ert", - "▁under t", - "▁ undert", - "▁A ug", - "▁Au g", - "ов ан", - "ова н", - "о ван", - "▁Ar ten", - "▁Art en", - "▁Arte n", - "▁inv oked", - "▁invoke d", - "▁d ynast", - "▁fle et", - "че ство", - "▁Mur ray", - "▁g ut", - "▁gu t", - "eli hood", - "▁S SH", - "▁SS H", - "от вет", - "▁person ally", - "▁personal ly", - "при я", - "п рия", - "▁fin anci", - "▁finan ci", - "▁Thom pson", - "al u", - "a lu", - "id entity", - "ident ity", - "▁G rab", - "▁Gr ab", - "▁Gra b", - "add le", - "É t", - "▁T ob", - "▁To b", - "▁ver lor", - "▁verl or", - "▁Saint e", - "▁Sa inte", - "▁Sain te", - "▁d op", - "▁do p", - "▁в ере", - "▁ве ре", - "▁вер е", - "__ _", - "_ __", - "▁prom otion", - "▁- =", - "▁от де", - "▁amb igu", - "▁ ambigu", - "OR DER", - "ORD ER", - "▁Comm unic", - "▁Commun ic", - "▁im ply", - "▁imp ly", - "▁impl y", - "on ed", - "one d", - "o ned", - "clud ing", - "▁coll ision", - "▁fragment s", - "▁frag ments", - "script ion", - "scri ption", - "s cription", - "▁' {", - "ля х", - "л ях", - "▁h ans", - "▁ha ns", - "▁han s", - "у с", - "wi re", - "w ire", - "name space", - "names pace", - "▁s word", - "▁sw ord", - "▁swo rd", - "ref resh", - "▁kw am", - "z s", - "comm ons", - "common s", - "▁c osa", - "▁co sa", - "▁cos a", - "▁reg ime", - "gr ep", - "gre p", - "g rep", - "▁di oc", - "▁dio c", - "▁Cont act", - "▁ Contact", - "▁est as", - "▁esta s", - "▁Ste wart", - "▁v iele", - "▁vi ele", - "▁vie le", - "▁viel e", - "то ва", - "тов а", - "т ова", - "▁R an", - "▁Ra n", - "an nes", - "ann es", - "anne s", - "id ay", - "ida y", - "i day", - "▁s napshot", - "▁snap shot", - "or row", - "orr ow", - "▁za č", - "▁участи е", - "▁prom ised", - "▁promise d", - "Ass embly", - "▁champion ship", - "▁champions hip", - "▁Def ine", - "▁e ren", - "▁er en", - "▁ere n", - "▁ eren", - "▁но во", - "▁н ово", - "▁нов о", - "▁ ново", - "▁th inks", - "▁think s", - "▁thin ks", - "Ag e", - "A ge", - "▁g ev", - "▁ge v", - "var char", - "v archar", - "iv ità", - "com pos", - "comp os", - "▁M utter", - "▁Mut ter", - "CO NT", - "CON T", - "arm ée", - "ag net", - "agn et", - "agne t", - "▁B row", - "▁Br ow", - "▁Bro w", - ". —", - "▁Tele vision", - "▁Д ля", - "▁v m", - "▁ vm", - "▁or din", - "▁ord in", - "▁ ordin", - "▁Миха й", - "▁apro xim", - "') ->", - "' )->", - "▁z oo", - "▁zo o", - "ip pi", - "ipp i", - "i ppi", - "▁s ino", - "▁si no", - "▁sin o", - "▁Qu ébec", - "ra ges", - "rag es", - "rage s", - "r ages", - "ä ck", - "ei ng", - "ein g", - "e ing", - "ar lo", - "pi os", - "pio s", - "p ios", - "▁C han", - "▁Ch an", - "▁Cha n", - "▁el li", - "▁ell i", - "▁ elli", - "▁in cons", - "▁inc ons", - "▁incon s", - "gest ellt", - "g estellt", - "pp ers", - "pper s", - "ppe rs", - "p pers", - "Je an", - "anst alt", - "▁D ance", - "▁Dan ce", - "▁to en", - "▁toe n", - "▁de cis", - "▁dec is", - "▁Ре зу", - "▁official ly", - "▁offici ally", - "ät ze", - "ätz e", - "▁до ро", - "▁e numer", - "▁en umer", - "▁enum er", - "▁trois ième", - "ty p", - "t yp", - "of fs", - "off s", - "бо ль", - "od n", - "o dn", - "▁Z ar", - "▁Za r", - "▁дру го", - "qu ia", - "qui a", - "▁Nicol as", - "▁Nic olas", - "▁Nicola s", - "пи су", - "пис у", - "▁m ob", - "▁mo b", - "pa ces", - "pace s", - "p aces", - "нь ого", - "ньо го", - "Al g", - "A lg", - "éro ï", - "Error s", - "Err ors", - "▁г ре", - "▁ гре", - "▁жен щи", - "in ch", - "inc h", - "▁Kore an", - "▁Korea n", - "▁A post", - "▁Ap ost", - "▁L iver", - "▁Li ver", - "▁Live r", - "▁Liv er", - "▁element ary", - "▁D I", - "▁ DI", - "ви си", - "▁so il", - "▁D LL", - "▁r isp", - "▁ris p", - "▁ri sp", - "▁Sh akespe", - "▁G aussian", - "▁K urt", - "▁Kur t", - "▁Ku rt", - "Ver tex", - "Vert ex", - "eb ol", - "e bol", - "organ isation", - "är en", - "äre n", - "ä ren", - "▁Y ES", - "▁ YES", - "C UR", - "▁нача ль", - "▁по стро", - "▁пос тро", - "▁Lu igi", - "▁c aching", - "prevent Default", - "am d", - "a md", - "▁V it", - "▁Vi t", - "sub st", - "su bst", - "▁ст рои", - "▁C ampion", - "▁Camp ion", - "ch r", - "c hr", - "фе ре", - "фер е", - "ф ере", - "▁С писок", - "N F", - "▁c ím", - "▁cí m", - "▁h é", - "▁ hé", - "re bbe", - "reb be", - "oc y", - "o cy", - "be low", - "bel ow", - "▁by lo", - "▁byl o", - "▁У и", - "▁\\ ({\\", - "▁\\( {\\", - "▁` :", - "▁ `:", - "gi ore", - "gio re", - "gior e", - "g iore", - "Sa n", - "S an", - "▁G ate", - "▁Ga te", - "▁в с", - "▁o limp", - "▁ol imp", - "▁Mat rix", - "▁ Matrix", - "▁he aring", - "▁hear ing", - "ri i", - "r ii", - "tf rac", - "t frac", - "▁allem and", - "▁V ue", - "л н", - "▁comp iling", - "▁E ns", - "▁En s", - "▁investig ation", - "▁A x", - "▁ch ars", - "▁char s", - "▁cha rs", - "▁target s", - "▁tar gets", - "▁l oud", - "▁lo ud", - "us ement", - "use ment", - "▁N ether", - "▁Ne ther", - "▁Net her", - "com merce", - "IG HT", - "oc oa", - "oco a", - "if ecycle", - "ife cycle", - "▁Le o", - "pr iv", - "p riv", - "▁go ods", - "▁good s", - "ad amente", - "ada mente", - "A ustral", - "▁re boot", - "▁reb oot", - "Ge st", - "G est", - "▁represent ations", - "▁representation s", - "ce u", - "c eu", - "▁do ctrine", - "ce rs", - "cer s", - "c ers", - "▁K rak", - "▁Kr ak", - "▁Kra k", - "▁adv oc", - "▁squad ra", - "▁arbeit ete", - "üs t", - "ü st", - "▁p ill", - "▁pi ll", - "▁pil l", - "An swer", - "▁к віт", - "▁W a", - "um ann", - "uman n", - "uma nn", - "u mann", - "▁D ynam", - "▁Dy nam", - "Fa mil", - "F amil", - "▁t ennis", - "▁ten nis", - "▁Engine ering", - "▁circ les", - "▁cir cles", - "▁circle s", - "▁Mary land", - "▁b esta", - "▁be sta", - "▁best a", - "▁bes ta", - "▁b ases", - "▁bas es", - "▁base s", - "▁znaj du", - "ктор а", - "кто ра", - "к тора", - "▁ar rest", - "▁arr est", - "ле р", - "л ер", - "▁G ia", - "▁Gi a", - "▁remark able", - "▁мо гу", - "▁Sup reme", - "▁` %", - "do r", - "d or", - "▁au jourd", - "▁w is", - "WID TH", - "▁mis ma", - "▁mism a", - "▁fl uid", - "▁flu id", - "▁pet ite", - "▁petit e", - "▁T ow", - "▁To w", - "Reg istry", - "em ed", - "eme d", - "e med", - "▁Wis consin", - "▁R acing", - "▁Ra cing", - "▁reg istration", - "▁registr ation", - "/ %", - "th ird", - "▁mon uments", - "▁monument s", - "че й", - "ч ей", - "▁j et", - "▁je t", - "▁ jet", - "▁Ur ban", - "ál va", - "▁mil ieu", - "▁poss ess", - "▁g erm", - "▁ge rm", - "▁ger m", - "dep endencies", - "▁enem ies", - "▁s amen", - "▁sa men", - "▁same n", - "▁sam en", - "▁W erner", - "▁Wer ner", - "▁h izo", - "▁hi zo", - "▁t d", - "▁ td", - "▁y esterday", - "▁А д", - "▁ha sn", - "▁has n", - "cel lation", - "cell ation", - "ov ání", - "ová ní", - "li ka", - "lik a", - "l ika", - "We ek", - "▁I ng", - "▁In g", - "▁E mail", - "▁Em ail", - "▁ Email", - "▁m ètres", - "▁O CLC", - "▁among st", - "▁spl end", - "fu r", - "f ur", - "ant ics", - "anti cs", - "antic s", - "▁X XX", - "▁XX X", - "▁ XXX", - "▁груп пы", - "la ch", - "lac h", - "l ach", - "▁c ousin", - "▁cou sin", - "▁in variant", - "▁invari ant", - "ђ у", - "▁Be ispiel", - "▁Bei spiel", - "▁hard er", - "▁har der", - "▁b ell", - "▁be ll", - "▁bel l", - "▁ bell", - "▁or ch", - "▁ orch", - "t b", - "Foot note", - "re gon", - "reg on", - "Mart in", - "▁in con", - "▁inc on", - "▁attack ed", - "_{ -", - "_ {-", - "▁T ras", - "▁Tr as", - "▁Tra s", - "par ty", - "part y", - "ite it", - "▁s aint", - "▁sa int", - "▁sain t", - "rás ok", - "r ások", - "▁contain ers", - "▁container s", - "M o", - "▁S n", - "quant ity", - "▁r as", - "▁ra s", - "▁ ras", - "▁C anal", - "▁Can al", - "▁Ca nal", - "cc ion", - "c cion", - "uv o", - "u vo", - "▁i dx", - "▁id x", - "▁ idx", - "type name", - "typen ame", - "typ ename", - "▁R ugby", - "▁Se ems", - "▁See ms", - "▁trans mit", - "▁transm it", - "▁Pr äsident", - "з не", - "▁B aker", - "▁Ba ker", - "▁Bak er", - "in th", - "int h", - "i nth", - "▁tö bb", - "ver ein", - "vere in", - "▁espe cie", - "▁espec ie", - ", (", - "▁t éc", - "▁té c", - "▁W ITH", - "▁u nos", - "▁un os", - "▁uno s", - "▁ unos", - "▁polit ics", - "create Element", - "▁st ats", - "▁stat s", - "▁sta ts", - "▁ stats", - "▁T ennessee", - "▁Bedeut ung", - "▁S creen", - "▁Sc reen", - "▁ Screen", - "▁Stra ße", - "an ze", - "anz e", - "▁part ly", - "man uel", - "ol ation", - "ola tion", - "o lation", - "hor izontal", - "érie ure", - "érieur e", - "am pio", - "amp io", - "▁ст рук", - "▁ струк", - "We ight", - "La nd", - "L and", - "po ly", - "pol y", - "p oly", - "▁D ak", - "▁Da k", - "▁Ass ume", - "\". $", - "\" .$", - "▁c asi", - "▁cas i", - "▁ca si", - "▁g ross", - "▁gr oss", - "▁gro ss", - "▁gros s", - "▁ent ertain", - "▁enter tain", - "▁déc ada", - "'. $", - "' .$", - "en cer", - "ence r", - "enc er", - "▁guarante ed", - "▁guarantee d", - "]$ .", - "] $.", - "ли ся", - "▁accept able", - "ra ise", - "rai se", - "rais e", - "ir us", - "i rus", - "we it", - "wei t", - "▁А на", - "▁Ан а", - "▁h ills", - "▁hill s", - "ip age", - "i page", - "BI T", - "B IT", - "▁nu cle", - "▁nuc le", - "▁ut ilis", - "▁util is", - "CA A", - "C AA", - "ène s", - "èn es", - "è nes", - "▁Schwe iz", - "▁A A", - "▁ AA", - "ning er", - "n inger", - "▁b ands", - "▁band s", - "▁ban ds", - "▁t ender", - "▁te nder", - "▁ten der", - "▁tend er", - "so m", - "s om", - "W arning", - "▁B ischof", - "▁A rc", - "▁Ar c", - "▁W oman", - "▁Wo man", - "▁trans mission", - "▁transm ission", - "ч ни", - "is tre", - "ist re", - "istr e", - "i stre", - "B Y", - "▁S I", - "▁ SI", - "▁П ар", - "▁Па р", - "▁} ).", - "▁}) .", - "▁ }).", - "▁present a", - "▁pres enta", - "▁Re né", - "▁Ren é", - "▁happ iness", - "▁P unk", - "col s", - "co ls", - "c ols", - "▁Des de", - "рё х", - "▁м она", - "▁мо на", - "▁scr atch", - "▁t cp", - "▁ tcp", - "ête s", - "êt es", - "ê tes", - "it ated", - "ita ted", - "itat ed", - "itate d", - "▁dif eren", - "▁difer en", - "ge h", - "g eh", - "na hmen", - "nah men", - "nahme n", - "nahm en", - "П е", - "ck i", - "c ki", - "▁Te atro", - "▁Re member", - "▁Rem ember", - "▁f right", - "▁fr ight", - "▁Y am", - "▁Ya m", - "west ern", - "le ted", - "let ed", - "lete d", - "▁в стре", - "▁вс тре", - "▁telep ülés", - "зи н", - "з ин", - "▁Qu ant", - "▁ Quant", - "▁su pre", - "▁sup re", - "áj a", - "á ja", - "ді я", - "д ія", - "▁car rera", - "▁carre ra", - "kre t", - "kr et", - "k ret", - "par a", - "pa ra", - "p ara", - "▁S UM", - "▁SU M", - "▁ SUM", - "▁p it", - "▁pi t", - "▁ pit", - "ź dz", - "é o", - "ре ння", - "рен ня", - "▁C hor", - "▁Ch or", - "▁Cho r", - "▁vo ix", - "▁exec utive", - "▁execut ive", - "▁all erdings", - "May be", - "▁д ень", - "▁де нь", - "▁f lying", - "▁fl ying", - "▁fly ing", - "▁par liament", - "жда н", - "ж дан", - "▁f ram", - "▁fr am", - "▁fra m", - "▁ fram", - "▁жов т", - "▁u gly", - "▁бу ду", - "ig ny", - "ign y", - "\\| _{", - "\\ |_{", - "▁b itter", - "▁bit ter", - "sc e", - "s ce", - "▁p ole", - "▁po le", - "▁pol e", - "▁ pole", - "Ver lag", - "▁total ité", - "▁found ation", - "j t", - "▁s lice", - "▁sl ice", - "▁sli ce", - "▁ slice", - "if ique", - "ifi que", - "▁integr ate", - "▁integra te", - "st rij", - "str ij", - "▁asym pt", - "▁е му", - "▁pert urb", - "▁F low", - "▁Fl ow", - "▁Flo w", - "▁ Flow", - "jb oss", - "RI G", - "R IG", - "▁A less", - "▁Al ess", - "▁Ale ss", - "XX X", - "X XX", - "▁s umm", - "▁su mm", - "▁sum m", - "sql ite", - "▁che er", - "pr ob", - "pro b", - "p rob", - "▁G PU", - "▁GP U", - "zi ł", - "z ił", - "(* )", - "( *)", - "▁in duct", - "▁ind uct", - "▁indu ct", - "RA Y", - "bl att", - "bla tt", - "qu esta", - "que sta", - "quest a", - "ques ta", - "or u", - "o ru", - "▁In side", - "▁Ins ide", - "▁Mc G", - "▁N ep", - "▁Ne p", - "м п", - "▁in ve", - "▁inv e", - "▁An imal", - "▁Anim al", - "▁s ob", - "▁so b", - "▁ sob", - "ít ott", - "loy ment", - "▁b und", - "▁bu nd", - "▁ bund", - "St ation", - "Stat ion", - "▁B EGIN", - "▁part iellement", - "ig g", - "i gg", - "est ore", - "esto re", - "e store", - "▁co inc", - "▁coin c", - "▁Som mer", - "▁m d", - "▁ md", - "▁loc ked", - "▁lock ed", - "▁ locked", - "math char", - "ar ma", - "arm a", - "pe nt", - "pen t", - "p ent", - "ar ium", - "ari um", - "a rium", - "▁e ars", - "▁ear s", - "▁ ears", - "▁S ongs", - "▁Son gs", - "▁Song s", - "▁similar ly", - "▁liter ally", - "▁literal ly", - "▁in ches", - "▁inc hes", - "▁af fection", - "▁aff ection", - "▁affect ion", - "l p", - "▁con cluded", - "▁conclude d", - "▁му ніципалі", - "▁па мя", - "est aur", - "esta ur", - "▁J osh", - "▁Jo sh", - "▁Jos h", - "▁F ritz", - "▁Fr itz", - "▁Fri tz", - "DB C", - "D BC", - "д ён", - "pos a", - "po sa", - "p osa", - "▁gold en", - "▁gol den", - "▁p c", - "▁ pc", - "▁com te", - "▁Z iel", - "▁Zie l", - "▁prés ente", - "▁présent e", - "mar ks", - "mark s", - "m arks", - "ig neur", - "ign eur", - "igne ur", - "▁D rive", - "▁Dr ive", - "▁neg lect", - "▁roz p", - "▁F ive", - "sp aces", - "space s", - "s paces", - "▁M edi", - "▁Me di", - "▁Med i", - "▁ex isted", - "▁exist ed", - "▁existe d", - "▁by ła", - "▁był a", - "дж и", - "д жи", - "▁fr ente", - "т ник", - "od d", - "o dd", - "▁answer ing", - "bi an", - "bia n", - "b ian", - "▁E ugen", - "▁Eu gen", - "▁Eug en", - "▁Public ations", - "▁Pub lications", - "▁D ia", - "▁Di a", - "l á", - "▁' _", - "▁ '_", - "▁rec uper", - "ом у", - "о му", - "▁App end", - "▁Ap pend", - "▁ Append", - "ob ar", - "oba r", - "o bar", - "▁employ ees", - "▁employee s", - "▁comp ens", - "eme tery", - "emet ery", - "▁э лект", - "MO N", - "M ON", - "ol in", - "oli n", - "o lin", - "▁histor ic", - "hi s", - "h is", - "ą d", - "n m", - "▁G oth", - "▁Go th", - "▁Got h", - "▁st ress", - "▁str ess", - "▁stre ss", - "▁parte cip", - "▁A w", - "▁s ar", - "▁sa r", - "▁h u", - "▁ hu", - "▁mat plotlib", - "▁M yst", - "▁My st", - "▁Mys t", - "() ;`", - "(); `", - "( );`", - "sch ein", - "sc hein", - "sche in", - "Long rightarrow", - "▁р я", - "▁ ря", - "▁Is ra", - "[ ^", - "no u", - "n ou", - "▁syn d", - "▁sy nd", - "work ing", - "wor king", - "▁N ation", - "▁Na tion", - "▁Nat ion", - "▁P ent", - "▁Pe nt", - "▁Pen t", - "▁k lass", - "▁kl ass", - "▁klas s", - "▁applic able", - "▁D iam", - "▁Di am", - "▁Dia m", - "▁bras ile", - "▁p ac", - "▁pa c", - "▁He ight", - "▁ Height", - "P ut", - "▁int ro", - "▁intr o", - "▁ intro", - "▁unus ual", - "na s", - "n as", - "▁Geb äude", - "▁be am", - "▁R ect", - "▁Re ct", - "▁Rec t", - "▁ Rect", - "▁Prim era", - "▁Prime ra", - "▁h aut", - "▁ha ut", - "▁t rait", - "▁tr ait", - "▁tra it", - "prü ft", - "in ación", - "ina ción", - "▁configuration s", - "▁configur ations", - "▁g ilt", - "▁gi lt", - "▁territ oire", - "he z", - "h ez", - "▁al te", - "▁alt e", - "rel ative", - "Ex cel", - "▁W right", - "G V", - "по ли", - "пол и", - "Qu ant", - "▁ga uge", - "▁gau ge", - "▁multi ply", - "▁multip ly", - "AS S", - "A SS", - "ствен но", - "ан у", - "а ну", - "▁j eden", - "▁je den", - "▁jed en", - "▁liter ary", - "▁D ro", - "▁Dr o", - "▁adv ise", - "▁advis e", - "it zen", - "itz en", - "▁dis ag", - "web site", - "▁д ія", - "▁ді я", - "▁ дія", - "▁ob server", - "▁obser ver", - "▁observ er", - "▁observe r", - "▁janu ár", - "v ě", - "ku p", - "k up", - "▁S es", - "▁Se s", - "▁woj ew", - "▁st ages", - "▁stage s", - "▁sta ges", - "▁stag es", - "▁вре мени", - "▁време ни", - "łu ż", - "но с", - "н ос", - "Down load", - "ip o", - "i po", - "▁g raf", - "▁gr af", - "▁gra f", - "▁ро бо", - "▁Nik ol", - "▁Ni kol", - "▁f ic", - "▁fi c", - "▁ fic", - "▁jo ining", - "▁join ing", - "▁divers os", - "▁LI KE", - "▁F itz", - "▁d imin", - "▁di min", - "▁dim in", - "▁dist rib", - "Sa m", - "S am", - "ko z", - "k oz", - "▁al phabet", - "▁alpha bet", - "os er", - "ose r", - "o ser", - "OU R", - "O UR", - "uk a", - "u ka", - "ка я", - "▁ste el", - "▁` --", - "▁`- -", - "▁t ener", - "▁te ner", - "▁ten er", - "mar ker", - "mark er", - "▁He aven", - "new command", - "▁prison ers", - "▁prisoner s", - "▁K night", - "▁Kn ight", - "▁present s", - "▁pres ents", - "▁qu esti", - "▁quest i", - "▁tr ains", - "▁tra ins", - "▁train s", - "op era", - "ope ra", - "oper a", - "▁Li near", - "▁Lin ear", - "▁Line ar", - "▁ Linear", - "▁M E", - "▁ ME", - "▁B uc", - "▁Bu c", - "Le g", - "L eg", - "▁ag ua", - "▁ agua", - "▁Gr iff", - "ol g", - "o lg", - "ds t", - "d st", - ". \r", - "▁person es", - "▁pers ones", - "▁persone s", - "Ma l", - "M al", - "бе ре", - "бер е", - "б ере", - "fol ge", - "folg e", - "▁ac ab", - "ct u", - "c tu", - "pt ic", - "▁N avigation", - "▁ Navigation", - "R uss", - "га ль", - "г аль", - "▁F ul", - "▁Fu l", - "▁ма є", - "чна я", - "ч ная", - "wn er", - "w ner", - "con tra", - "cont ra", - "contr a", - "▁jou eur", - "▁joue ur", - "▁J ess", - "▁Je ss", - "▁Jes s", - "▁re new", - "▁ren ew", - "▁l ap", - "▁la p", - "▁ lap", - "▁cas ting", - "▁cast ing", - "ga l", - "g al", - "▁tém atu", - "▁на зыва", - "за х", - "ч не", - ")- \\", - ") -\\", - "▁ча сто", - "▁час то", - "▁част о", - "}$ -", - "} $-", - "▁l icz", - "▁li cz", - "▁lic z", - "▁e mot", - "▁em ot", - "ha rm", - "har m", - "h arm", - "▁occasion ally", - "▁hor ror", - "▁ho rror", - "ea st", - "e ast", - "▁pr inter", - "▁print er", - "▁prin ter", - "ar an", - "ara n", - "a ran", - "▁Miss iss", - "fol low", - "f ollow", - "▁Bar ry", - "▁investig ate", - "go w", - "g ow", - "▁Amer icans", - "▁American s", - "▁America ns", - "S ince", - "▁від о", - "▁ві до", - "▁re un", - "os ci", - "osc i", - "o sci", - "▁Ch apter", - "▁Chap ter", - "▁b ay", - "▁ba y", - "▁ bay", - "ро ме", - "ром е", - "et he", - "eth e", - "e the", - "éd ie", - "é die", - "com ot", - "co mot", - "como t", - "▁miejs cowo", - "▁stud ierte", - "▁studi erte", - "ou vert", - "ouv ert", - "ouve rt", - "ouver t", - "▁к ур", - "▁ку р", - "▁ кур", - "▁DE SC", - "▁DES C", - "▁touch ed", - "▁tou ched", - "▁Jer ry", - "ue se", - "ues e", - "u ese", - "ли ще", - "auth entication", - "authentic ation", - "▁col le", - "▁co lle", - "▁coll e", - "he art", - "▁reg iment", - "▁regime nt", - "cri bed", - "cribe d", - "▁Бо ль", - "▁про ис", - "ce ae", - "▁mass es", - "▁sc rolling", - "▁scroll ing", - "us to", - "ust o", - "u sto", - "S W", - "ov at", - "ova t", - "o vat", - "▁gr âce", - "▁Архи в", - "▁Се вер", - "av ait", - "ava it", - "▁Marsh all", - "▁Mars hall", - "▁Hash Map", - "▁ HashMap", - "ac on", - "aco n", - "a con", - "ück en", - "ücke n", - "ü cken", - "[] )", - "[ ])", - "▁ev angel", - "et zung", - "etz ung", - "tt emberg", - "st ers", - "ste rs", - "ster s", - "s ters", - "T M", - "▁ли тера", - "qu ot", - "Pr ed", - "Pre d", - "P red", - "▁w erk", - "▁wer k", - "▁ werk", - "▁ha ber", - "▁hab er", - "▁habe r", - "la va", - "lav a", - "l ava", - "vo us", - "v ous", - "▁L ate", - "▁La te", - "▁Lat e", - "cy cle", - "cyc le", - "c ycle", - "ти рова", - "▁про ду", - "▁прод у", - "▁pop ulations", - "▁population s", - "▁popul ations", - "▁Y an", - "▁Ya n", - "Pre fix", - "P refix", - "actér istiques", - "+ '", - "() `](", - "()` ](", - "▁Л ь", - "фи ль", - "▁жи зни", - "ft p", - "f tp", - "▁все х", - "▁g dzie", - "▁v idea", - "▁vid ea", - "▁vide a", - "oa uth", - "o auth", - "▁p id", - "▁pi d", - "▁ pid", - "ů m", - "▁p esso", - "▁pes so", - "▁track ing", - "▁trac king", - "iz in", - "izi n", - "i zin", - "▁Mor ris", - "щи й", - "▁Provin z", - "▁M itte", - "▁Mit te", - "▁Mi tte", - "▁Mitt e", - "▁artific ial", - "bráz ky", - "▁до сти", - "▁rest ored", - "▁restore d", - "▁resto red", - "▁commun icate", - "▁communic ate", - "ag it", - "agi t", - "a git", - "Rec ogn", - "▁l on", - "▁lo n", - "▁ lon", - "▁за ня", - "▁зан я", - "▁Arg ument", - "▁ Argument", - "fl ush", - "flu sh", - "ма на", - "ман а", - "м ана", - "sec onds", - "second s", - "U C", - "▁R uth", - "▁Ru th", - "▁t ub", - "▁tu b", - "▁B ret", - "▁Br et", - "▁Bre t", - "▁P ere", - "▁Per e", - "▁Pe re", - "▁respons ibility", - "ńcz y", - "ń czy", - "▁environment s", - "▁environ ments", - "ke e", - "k ee", - "▁g root", - "▁gr oot", - "▁gro ot", - "▁pain ted", - "▁paint ed", - "▁Éd itions", - "cp y", - "c py", - "ár t", - "á rt", - "lich keit", - "ar da", - "ard a", - "B atch", - "▁Leop old", - "re ason", - "rea son", - "reas on", - "n oreferrer", - "se ns", - "sen s", - "s ens", - "▁ro cks", - "▁rock s", - "▁Hit ler", - "ла т", - "л ат", - "▁qu oted", - "▁quot ed", - "▁quote d", - "▁ко лле", - "▁у ров", - "ba g", - "b ag", - ".\" )", - ". \")", - "▁M L", - "▁ ML", - "▁kom t", - "▁ko mt", - "▁[ _", - "▁ [_", - "▁spect ral", - "ed o", - "e do", - "▁in sieme", - "▁suffer ing", - "▁suff ering", - "sl ider", - "slide r", - "▁Kenn edy", - "ol ate", - "ola te", - "o late", - "▁P atri", - "▁Pa tri", - "▁Pat ri", - "зи и", - "O H", - "▁те а", - "▁пра ва", - "▁прав а", - "ма х", - "re write", - "rew rite", - "r ewrite", - "▁Eins atz", - "ex ternal", - "ext ernal", - "hol ds", - "hold s", - "h olds", - "▁P laces", - "▁Pl aces", - "▁Pla ces", - "▁Place s", - "at ype", - "aty pe", - "a type", - "▁vul ner", - "▁abandon ed", - "Or igin", - "Ori gin", - "▁max imal", - "▁maxim al", - "AA AA", - "▁Base ball", - "▁C lose", - "▁Cl ose", - "▁Clo se", - "▁ Close", - "▁pa inter", - "▁pain ter", - "▁paint er", - "▁assign ing", - "N B", - "bl ast", - "bla st", - "b last", - "▁K ünstler", - ")] (", - ") ](", - "fa ch", - "fac h", - "f ach", - "▁Const antin", - "▁Constant in", - "ok es", - "oke s", - "o kes", - "▁no body", - "▁nob ody", - "▁subt ract", - "▁fos se", - "▁foss e", - "▁cert ific", - "▁m use", - "▁mus e", - "▁mu se", - "/) ,", - "/ ),", - "▁Pro fil", - "▁Prof il", - "▁pro xim", - "▁Jer usalem", - "▁simp licity", - "▁simpl icity", - "▁w sz", - "▁ws z", - "NUM BER", - "utt avia", - "U ITableView", - "ich ter", - "icht er", - "ichte r", - "i chter", - "жа н", - "ж ан", - "▁L av", - "▁La v", - "it chen", - "itch en", - "▁Ч ем", - "▁Че м", - "T u", - "▁ge om", - "▁zv uky", - "▁Sur vey", - "AN CE", - "▁enc rypted", - "▁encrypt ed", - "pr of", - "pro f", - "▁d are", - "▁da re", - "▁dar e", - "▁L oren", - "▁Lo ren", - "▁Lor en", - "т в", - "▁А лек", - "▁Ал ек", - "▁comput ers", - "▁computer s", - "▁compute rs", - "▁expect ation", - "▁substant ial", - "▁Д ми", - "▁` {", - "▁д ра", - "▁др а", - "▁ дра", - "ub ble", - "▁per forms", - "▁perform s", - "▁Kr ieg", - "▁Krie g", - "▁in coming", - "▁inc oming", - "▁Class ification", - "Web View", - "▁epis odes", - "▁episode s", - "ap per", - "app er", - "appe r", - "a pper", - "äu fig", - "▁gi ov", - "▁De part", - "▁Dep art", - "бо ра", - "бор а", - "ed ly", - "os pod", - "osp od", - "▁p tr", - "▁pt r", - "▁ ptr", - "▁d átum", - "▁est imation", - "▁estim ation", - "ic ole", - "ico le", - "icol e", - "i cole", - "▁- ---", - "▁-- --", - "▁--- -", - "▁ ----", - "▁prin ces", - "▁prince s", - "HE AD", - "▁diff usion", - "▁diffus ion", - "▁d rie", - "▁dr ie", - "▁dri e", - "▁A da", - "▁Ad a", - "ни це", - "ниц е", - "ng inx", - "n ginx", - "sh al", - "sha l", - "s hal", - "▁febru ari", - "▁T at", - "▁Ta t", - "lo oking", - "look ing", - "ku nd", - "k und", - "▁De an", - "m ongodb", - "вши х", - "в ших", - "▁A ur", - "▁Au r", - "▁Fl ora", - "▁Flor a", - "▁Flo ra", - "▁Stud ios", - "▁Studio s", - "��и је", - "ei l", - "e il", - "Inst all", - "▁f ranch", - "▁fr anch", - "▁fran ch", - "▁franc h", - "▁H MS", - "▁pract ices", - "▁practice s", - "le j", - "l ej", - "da le", - "dal e", - "d ale", - "▁po ste", - "▁pos te", - "▁post e", - "▁H els", - "▁He ls", - "▁Hel s", - "▁reli able", - "źdz ier", - "▁ver se", - "▁vers e", - "▁ verse", - "er meister", - "erme ister", - "▁qu it", - "▁qui t", - "▁q uit", - "▁ quit", - "ét ico", - "il is", - "ili s", - "i lis", - "ed or", - "edo r", - "e dor", - "▁Cult ural", - "▁Cultura l", - "дж е", - "д же", - "▁li ked", - "▁like d", - "▁lik ed", - "▁m ongodb", - "▁mongo db", - "▁ mongodb", - "▁Broad way", - "▁I R", - "▁ IR", - "es zt", - "esz t", - "ho v", - "h ov", - "▁m íst", - "▁mí st", - "re iche", - "reich e", - "rei che", - "▁k B", - "ст ом", - "сто м", - "с том", - "▁SQL ite", - "▁tor neo", - "\\ .", - "Or d", - "O rd", - "▁Admin istration", - "▁Administr ation", - "▁з да", - "▁ зда", - "▁H inter", - "▁Hin ter", - "▁V ia", - "▁Vi a", - "Dec imal", - "or ious", - "ori ous", - "orio us", - "▁nécess aire", - "w x", - "▁t ej", - "▁te j", - "▁t ema", - "▁te ma", - "▁tem a", - "O brázky", - "ри те", - "рит е", - "▁build s", - "▁l aten", - "▁la ten", - "▁lat en", - "▁late n", - "▁г г", - "Vis ibility", - "lä u", - "l äu", - "▁se chs", - "▁sec hs", - "▁лу ч", - "ce ra", - "cer a", - "c era", - "Co uld", - "C ould", - "▁tra ject", - "}} ^{", - "}}^ {", - "} }^{", - "▁Jap on", - "▁Ja pon", - "an other", - "ano ther", - "I K", - "▁belong ing", - "▁fac ilities", - "▁facil ities", - "▁D aily", - "▁Da ily", - "▁de ce", - "▁dec e", - "int ro", - "▁слу ча", - "Name space", - "Names pace", - "▁B ak", - "▁Ba k", - "loc ale", - "local e", - "U G", - "=$ {", - "= ${", - "▁comp añ", - "ją c", - "j ąc", - "▁ar ithmetic", - "fo rum", - "for um", - "f orum", - "▁por ta", - "▁port a", - "on k", - "▁g ender", - "▁ge nder", - "▁gen der", - "▁ gender", - "▁expect s", - "б ка", - "▁n ak", - "▁na k", - "▁ nak", - "▁G race", - "▁Gr ace", - "▁Gra ce", - "▁st ro", - "▁str o", - "ivid ual", - "▁C OM", - "▁CO M", - "▁ COM", - "▁F arm", - "▁Fa rm", - "▁Far m", - "▁c anton", - "▁can ton", - "▁cant on", - "то му", - "том у", - "т ому", - "java x", - "jav ax", - "се й", - "с ей", - "▁brief ly", - "Fa ce", - "F ace", - "rot ate", - "const ant", - "▁g allery", - "▁gall ery", - "ast ro", - "astr o", - "all ery", - "alle ry", - "aller y", - "▁D J", - "char ge", - "charg e", - "ходи ть", - "ходит ь", - "C ent", - "\\\" ,", - "\\ \",", - "▁d onna", - "▁don na", - "▁donn a", - "ar ca", - "arc a", - "la de", - "lad e", - "l ade", - "zi n", - "z in", - "▁N ed", - "▁Ne d", - "▁host ing", - "▁hos ting", - "id or", - "ido r", - "i dor", - "it ative", - "itat ive", - "ig s", - "i gs", - "▁п ря", - "▁пр я", - "▁t icket", - "▁tick et", - "▁ti cket", - "▁stud ying", - "▁study ing", - "▁des igner", - "▁design er", - "lap sed", - "lapse d", - "laps ed", - "l apsed", - "▁la at", - "▁d ix", - "▁di x", - "▁integr ated", - "▁integrate d", - "▁integra ted", - "▁in formed", - "▁inform ed", - "▁be have", - "▁beh ave", - "▁behav e", - "▁la bour", - "▁lab our", - "est ellt", - "cal endar", - "▁k illing", - "▁kil ling", - "▁kill ing", - "▁tw itter", - "▁ twitter", - "ia e", - "i ae", - "▁histor ique", - "DE FAULT", - "ia ła", - "iał a", - "i ała", - "▁theoret ical", - "▁un ders", - "▁und ers", - "▁under s", - "ля ет", - "at an", - "ata n", - "a tan", - "▁s urname", - "▁sur name", - "▁inter cept", - "гла сно", - "▁општи ни", - "▁t ired", - "▁tir ed", - "▁ti red", - "▁B eth", - "▁Be th", - "▁Bet h", - "▁ад министратив", - "L i", - "▁Т ур", - "▁Ту р", - "▁Sc anner", - "▁S tern", - "▁St ern", - "▁Ste rn", - "▁Ster n", - "▁вме сте", - "▁report ing", - "▁s ull", - "▁su ll", - "▁sul l", - "ци ей", - "ber ts", - "bert s", - "og onal", - "ogo nal", - "ő k", - "▁i psum", - "▁ip sum", - "▁seu lement", - "▁seul ement", - "▁seule ment", - "▁Se iten", - "▁Seit en", - "▁Seite n", - "word press", - "▁fe aturing", - "ist ischen", - "isti schen", - "istische n", - "ju b", - "j ub", - "▁é tr", - "▁ét r", - "▁ étr", - "▁t ea", - "▁te a", - "▁adapt ed", - "▁sc ales", - "▁scale s", - "▁scal es", - "▁n an", - "▁na n", - "▁ nan", - "get Value", - "▁Bl ues", - "▁Blue s", - "ac les", - "acle s", - "a cles", - "▁st ati", - "▁stat i", - "▁sta ti", - "▁ent itled", - "▁R alph", - "gra vity", - "▁entre pr", - "któ ber", - "li mat", - "lim at", - "l imat", - "li s", - "l is", - "De mo", - "D emo", - "re lation", - "rel ation", - "▁n ep", - "▁ne p", - "pro wad", - "it is", - "iti s", - "i tis", - "▁p up", - "▁pu p", - "neh mer", - "nehm er", - "▁disapp oint", - "▁et was", - "▁etwa s", - "an non", - "ann on", - "anno n", - "▁appro ved", - "▁cl ever", - "▁cle ver", - "Lo ading", - "Load ing", - "▁ver z", - "▁ve rz", - "res se", - "ress e", - "r esse", - "▁insp ir", - "▁sam pling", - "▁B ek", - "▁Be k", - "}) $.", - "})$ .", - "} )$.", - "▁г рома", - "▁spe cie", - "▁spec ie", - "▁re pub", - "▁rep ub", - "▁lo ader", - "▁load er", - "▁ loader", - "▁e rf", - "▁er f", - "▁should er", - "ra is", - "rai s", - "r ais", - "▁ма те", - "▁мат е", - "▁Mon th", - "▁Mont h", - "▁Mo nth", - "▁ Month", - "Sc ene", - "▁block ing", - "▁o cean", - "ge ben", - "geb en", - "g eben", - "▁Kil ometer", - "▁b edeut", - "▁M ix", - "▁Mi x", - "fm t", - "f mt", - "▁Nor weg", - "▁ID s", - "par allel", - "▁ant icip", - "▁anti cip", + ".▁A b", + "▁as▁ ≥", + "▁g astrointestinal", + "▁g efitinib", + "▁on ward", + ",▁and▁ S", + "rad ionucl", + "▁L etter", + "ly▁ diagnos", + ".3 9", + "▁this▁ substudy", + "▁st ay▁", + "\n\nC apable▁of▁only▁limited▁s", + "▁will ▁help", + "e▁in terim", + "e▁in fection", + "e▁in terval", + "▁5 8", + "▁5 25", + "▁5 .5.1", + "will ▁also", + "will ing▁or", + "▁6 -week", + "▁H RPC", + "▁patients▁ in▁the▁", + ")\n\n and▁", + "▁at ▁any▁", + "▁at ▁the▁end▁of", + "s▁( such▁as▁", + "▁the▁in struction", + "▁ac com", + "▁ac company", + "▁study▁ conduct", + "\n\n1 .2", + "▁mg ▁AMG▁162", + "ire gulin", + "ens ure▁that", + "▁the▁t yp", + "▁after ▁2", + "ed▁on ▁a", + "19 89", + "EC ORD", + ".▁S h", + ".▁S ome▁", + ".0 ▁mL", + ".0 ▁g/dL", + "▁patient ▁population", + "▁un stain", + "▁e qual", + "▁J ournal", + "▁tim e-to-event", + "▁from ▁baseline▁", + "▁from ▁the▁treatment", + "s\n\n must▁be▁", + "ed▁by▁ subject", + "ax is", + "▁Protocol ▁Number", + ".▁Th e", + "et▁al ,▁200", + "▁tumor ▁for", + "ON E", + "▁dos age▁", + "roduct ion▁of", + "ost on", + "CT /MRI", + "es▁of ▁America", + "may▁ have▁", + "▁adverse▁event s▁will▁be▁", + "mon otherapy", + "pect romet", + "▁10 .5", + ".6 8", + ".▁In t", + "▁assessment ▁and▁", + "▁assessment ▁is▁", + "▁sign ificance▁", + "▁sign s▁the▁", + "peri pheral", + "20 ]", + ",▁or ▁an", + "progression ▁fre", + "patient s▁are▁", + "▁9 8", + "▁9 .4", + "e▁( NCI", + "s▁s elect", + "s▁s pecifi", + "▁each ▁treatment▁group", + "pre pared", + "every▁ effort▁should▁be▁made▁to", + "every▁ 8▁weeks▁±▁1▁week", + ".7 7", + "\n\n2 6th", + "y▁of ▁the▁", + "▁should▁be▁ follow", + "▁should▁be▁ exerc", + "roll ed▁", + "▁the▁investigator (s)", + "▁the▁investigator 's▁", + "▁the\n\n primary▁", + "ed▁as▁ part▁of▁the▁", + "easure s▁", + "protocol -specifi", + "ating ▁that", + "ron ically▁", + "ed,▁ with", + "respons ibility", + "respons ible▁", + "\n\nY es▁or▁No", + "▁addition ▁to▁the▁", + "▁The▁ following", + "▁the▁l ower", + "▁dose▁ and▁", + "▁dose▁ adjustment", + "coll eagu", + "KRAS ▁status", + ".\n\nP emetrexed▁H3E-MC-JMHR(b)▁Confidential\n\nProtocol▁Amendment\n\nPage▁", + ".\n\nP OTENTIAL", + "e▁b enefit", + "s▁to ▁follow-up", + "13 )(cid:", + "▁panitumumab ▁in", + "oth enberg", + "s▁or ▁term", + "▁was▁ observed▁in", + "▁Clinical▁ Study▁", + "▁Version ▁4.0", + "ung al", + "▁death s▁have▁occurred", + "▁30 -day▁", + "▁evalu ate▁t", + "provid er", + "provid ed▁with", + "sign ing▁this▁", + "using ▁the▁same▁", + "▁sampl ing", + "ox orubicin", + "until ▁disease▁progression▁or", + "▁mg/m2 /day▁", + "▁the▁subject ’s\n\n", + "inter est", + "▁complet ely▁", + "▁approximately▁ 10", + "▁approximately▁ 745", + "▁particip ate", + "▁discontinu ation▁of▁the▁", + ",▁P FS", + ",▁P lacebo", + "valu es▁", + "\n\n\n\n \n\n", + "▁et▁al ▁200", + "▁et▁al ▁2007", + "▁et▁al .▁19", + "▁analysis ,▁", + "▁continu e▁in", + "▁continu e▁to▁receive▁", + "ed▁s urvival", + "collect ed▁to", + "▁= ▁area", + "▁response▁ rate▁of", + "dose▁ (", + "16 0", + "▁should▁ only▁be▁", + "▁these▁ studies", + "▁these▁ agent", + ",▁M at", + ",▁M oor", + "RO QOL", + ".▁H arris▁WS", + "▁must ▁submit", + ",▁C D", + "observ ed▁in▁the▁", + "▁(A BI-007", + "▁result ed▁in", + "ation▁of▁ study▁drug", + "man ager", + "review ▁of▁the▁", + "s, ▁as▁", + "s, ▁tumor▁cells▁and▁the▁proposed▁mechanism▁of▁action", + "▁19 76", + "e▁m easure", + "▁chemotherapy▁ with", + "able▁to ▁Evalu", + ".▁This▁ will▁be▁", + "clinical ▁benefit", + "ull er", + "hib its▁", + "rati os", + "▁this ▁amended▁protocol", + "▁PFS ▁in", + "ed▁a mong", + "▁Arm ▁G", + "▁12 ▁week", + "studies▁ have▁", + "rat um", + ".\n\nC h", + "clusion ▁Criterion", + "ech t", + "OLF OX-", + "must ▁not▁be▁", + ".▁For ▁the▁", + "Clinical▁Study▁ Report", + "▁agent s,▁", + "▁agent (s)", + "▁• ▁S", + "FA S", + "▁increas ed▁in", + "▁this▁study▁ protocol", + "s▁on ly", + "▁AE s▁and▁SAE", + ",▁et▁al :", + ",▁et▁al .▁S", + "io ▁n", + "s▁and ▁their", + "▁anti- AMG▁162", + "\n\n5 .\n\nSUBJECT▁ENROLLMENT", + "Con comitant▁medication", + "▁ver tebra", + "cer ning", + "▁the▁sam e▁m", + "IC H)", + "indic ate▁that", + "21 ]", + "▁Dec reas", + "IRB ▁or▁IEC", + "▁toxicity▁ grade▁", + "evid ence▁", + "▁for▁the▁ following", + "\n\n9 .4", + "▁of▁a ▁new", + ",▁in ▁which", + "▁agre e▁that", + "person ally▁", + "only▁ for", + "▁overall ▁survival▁", + "Treatment ▁of", + "EGFR -", + "100 ▁mg/m2", + "▁medical▁ emerg", + "▁an▁ option", + ".▁L ong", + "e/ Cisplatin", + "her ein", + "y▁( CT", + "2- 7", + "\n\nth roughout", + "▁record ed▁", + "-fre e▁disease▁assessment", + ",▁d epending▁on", + "▁Med icin", + "▁100 )", + "▁procedure s▁for", + "▁have▁been ▁report", + "FACT- L", + "vestigational ▁drug", + "▁are▁not ▁confirmed", + "pers ed", + "▁design ed▁to", + "▁≥ 2", + ".\n\n3 .1", + "e▁P 450", + "ren al▁function", + "3- year", + "Ph arm", + "▁If ▁you", + "used▁in vestigational▁product", + "cas es,▁", + "/d ay", + "▁skin ▁reaction", + "▁Ex t", + "non e)", + "▁appropri ate,▁", + "▁PR ▁or▁CR", + "▁the▁trial ▁are▁", + "ourn al▁", + "▁ident ical", + "it▁is▁ estimated▁that", + "controll ed▁trial", + "lik ely▁", + "\n\nd enosumab", + ".\n\nB evacizumab", + "chest ▁CT", + "FOLFOX 4", + "▁(S GOT", + "▁alon e", + ",▁all ▁subjects▁", + "▁a▁l egally▁acceptable▁", + "increas e▁the▁", + "linded▁ Treatment", + "▁experienc es▁a", + "▁before▁ study▁", + "▁before▁ randomization", + "▁local▁ institutional▁practic", + "measurable▁ diseas", + "es▁that ▁are▁", + "▁grade▁ 2", + "▁days▁ following", + "s▁a mong", + "\n\nNo \n\nPR", + "health ▁status", + "▁known ▁to▁have▁", + "old berg", + "▁For ▁all", + "▁(P SA)", + ".▁5 8", + ".▁5 .7", + "medical ▁car", + "▁of▁0 .025", + "\n\nW eek", + "establish ed▁tumor", + ".\n\n8 .2", + ".\n\n8 .3", + "assign ed▁to", + "▁availabl e.\n\n", + "-in duced", + "▁full ▁consent", + "persensitiv ity▁to", + "ummary▁ statistic", + "astro enter", + "▁(cid: 116)", + "with▁the▁ exception▁of", + "atory▁ Obl", + ".▁Ex pos", + "delay ed▁", + "expos ure▁", + "was ▁also", + "▁of▁127 \n\n", + "1.5 ▁x▁ULN", + "s▁may▁ occur", + "▁use▁ adequate▁", + "LT ▁<", + "▁activity▁ but", + "e▁C asodex", + "▁compared▁with ▁docetaxel", + "\n\nCon t", + "before▁ each", + "consistent ▁with▁the▁", + "▁do▁not ▁have▁", + ".▁Addition ally", + "▁los s,▁", + "-related▁to xicity", + "Safety▁ Follow-Up", + "▁agree▁to ▁ensure▁that", + "Objectiv es:", + "▁anti androgen", + "may ▁also▁be▁", + "▁minutes▁ prior▁to", + "escal ation", + "▁anticancer ▁therapy▁", + "▁2▁year s▁after", + "prior▁to▁the▁ first▁dose▁of", + "▁fract ures", + "\n\nNot ▁at▁all", + "▁or▁s ponsor", + "▁small ▁lesion", + "▁center s:", + "TIN AL", + "colon y▁stimulating▁factor", + "colon ▁or▁rect", + "▁5-fluorouracil /leucovorin", + ".▁St at", + "▁Ant i-", + "complete▁ respons", + "complete▁ response▁", + "Ch aracter", + "s.▁B iometrics▁", + "dent ity▁of▁investigational▁product", + "▁participating ▁in▁the▁study", + "▁Engl and▁", + "initi ally▁", + "local▁ regulatory▁requirement", + "°C ▁(", + "▁Non- metastatic", + "▁a▁b est▁response▁of", + "how ▁good▁", + "▁Sign ature▁", + "▁Sign atory▁Obl", + "Investigator’s▁ Brochure▁", + "\n\nPrimary▁ Endpoint", + "▁measurable▁ disease▁", + "begin ning", + "al▁s equence▁", + "▁component s▁of", + "▁abov e▁", + "▁major ▁body▁system", + "ed▁M etastatic▁Colorectal▁Cancer", + "▁Primary▁ Endpoint", + "▁Study ▁to", + "predict ive▁", + "Reg ulatory▁A", + "▁Serious▁Adverse▁Event ▁Reporting", + "e\n\nC onfidential\n\nPage▁", + "▁able▁to ▁carry▁on", + "leg ibl", + "▁tr uly▁", + "vertebral▁ fracture▁", + "angu age", + ",▁con fined▁to▁bed▁or▁chair", + "following▁the▁ last▁dose▁of", + "▁documented▁ disease▁progression", + "▁mg/dL ;", + "every▁6▁week s,▁", + "▁original ▁source▁document", + "▁treatment▁effect ▁on", + "examin ing", + "ate▁( or", + "occurred▁ in", + "▁curv es▁will▁be▁", + "▁sequ ential", + "▁bisphosphon ates", + "▁alpha ▁level", + "predn ison", + "uroQol ▁Group", + "▁recon struction", + "▁pros pectively▁", + "▁deriv ative▁", + ",5 00", + "idem iol", + "decision ▁to", + "▁match ing▁placebo", + "use▁ only", + "▁important ▁medical▁event", + "purpos es", + "keletal▁ related▁event", + "▁Ep idemiol", + "▁pemetrexed▁and▁ cisplatin", + "▁objectiv es▁and▁", + "▁related ness▁to", + "ers us▁", + "▁unit ▁errors▁(", + ".2.1.1 .6", + "utiliz ed▁for", + ".\n\nST A", + "iller ▁J", + "▁Cons ider", + "antibod ies", + ".\n\nY▁T▁I▁D▁I▁L▁A▁V \n\nS▁T▁I", + "30-day▁postdiscontinuation▁follow-up ▁visit", + "eryth ema", + "may▁occur ▁between▁1▁and▁", + "described▁in▁the▁ protocol", + ";▁( 2)", + "vs▁ no", + "-based▁chemotherapy ▁and▁bevacizumab", + "▁objective▁progression -free▁disease▁assessment", + "Ne uropath", + "differ enc", + ".\n\nS▁T▁I\n\nK▁C▁E▁H▁C \n\nE▁S▁A▁E▁L▁P", + "▁dispens ing", + "▁chemistry▁ panel", + "regulatory▁author ities", + "hemorrh age▁", + "publication ▁or", + "▁peopl e▁", + "▁the▁sub group", + "ost- Study▁", + "▁10.6 .2.1", + "metab ol", + "color ▁photograph", + "▁consult ation▁with▁the▁", + "\n\nProtocol▁Attachment▁JM HD", + "United▁Stat es▁of▁America", + "▁anthracycl ine▁", + "Reduction s▁for", + "▁vis ual", + "▁Backgroun d▁", + "▁York ▁Heart▁Association", + "▁carcin omas", + "▁at▁least▁on e▁dimension", + "▁head ach", + "height ▁(", + "▁mucos itis", + "▁Investigator’s▁ Brochure", + "(8 ):▁p.▁", + "ed▁in▁the▁Study▁ Plan", + "▁participation ▁in▁the▁study", + "e▁size▁of ▁the▁lesion", + "▁circumstanc es▁", + "commer cial", + "(mg /dL", + "upd ates", + ".\n\nY▁P▁O▁C \n\nD▁E▁T▁N▁I▁R▁P", + "inorel bin", + "▁150▁mg ▁once▁daily▁", + "▁carcinoma▁of▁the▁ head▁and▁neck", + "participation▁in▁the▁ clinical▁study", + "Figure▁ S130", + "appearance▁of▁all ▁target▁lesion", + "langu age▁", + "othelin ▁receptor", + "▁measurements▁and▁ variables", + "stability▁ limit", + "▁Oncology▁ Group", + "▁viol ation", + "▁other▁lesion s▁(or▁sites▁of▁diseas", + "Experienc e", + "cagliotti ▁G", + ".\n\nSUBJECT ▁ELIGIBILITY", + ".▁Refer ences", + "▁tempor al▁sequence▁", + "▁signature▁ p", + "index ▁scor", + "▁previously▁untreat ed▁", + "anadian ▁Cancer▁Societ", + "▁a▁larg e▁", + "▁inspect ing▁the▁", + "-▁or▁nail -related▁toxicities", + "▁thought ▁to▁be▁", + "▁200401 35", + "s▁suggest ive▁of", + "▁Character istic", + "echnical▁ Standard", + "▁is▁any▁ untoward▁medical▁occurr", + "ensive- stage▁", + "dependent▁Ethics▁Committe e▁(IEC", + "s▁treat ed▁at▁the▁", + "unable▁to▁toler ate▁", + "epatitis▁ B", + "▁timely▁ manner", + "▁phen otyp", + "\n\nNumber ▁of", + "Fract ure▁", + "ed▁by▁clinic▁visit▁or▁telephone▁contact ▁approximately▁every▁6▁months▁for", + ".▁Effect s▁of", + ",▁Bon om", + "aternal▁expos ure", + "▁to▁d istinguish", + "▁surviv al▁pro", + "▁(AE )", + "▁or▁your ▁legally▁acceptable▁representative▁", + "▁must▁have▁a ▁negative▁", + "▁differential▁ (neutrophils,▁", + "▁ g", + "ence▁or ▁absence▁of", + "▁translational▁ research", + "▁metastatic▁colorectal▁cancer▁(mCRC )", + "ULATORY ▁OBLIGATIONS", + "hort▁Form ▁(", + "remit ies", + "ological▁imaging ▁of▁the▁", + "▁postmenopausal ▁women", + "s▁will▁be▁calcul ated▁and▁", + "▁health▁stat e▁today", + "oftw are", + "▁prolongation▁of▁existing ▁hospitalization", + "▁a▁20% ▁increase▁in", + "▁satisf action", + "▁ENDPO INTS", + "s▁with▁respect▁to ▁both", + "▁transamin as", + "▁has▁already▁ been", + "compati bl", + "▁mutant▁KRAS ▁tumor", + "▁Supportive▁ C", + "\n\nAm bulatory▁and▁capable▁of▁all▁s", + "▁contribution s▁to", + "ebrovascular ▁accident", + ".▁(for ▁Japanese▁sites▁only", + "rosatellite▁in stability", + "Double- Blind", + "Gleason ▁scor", + "▁thor ough", + "▁(longest▁diameter ▁to▁be▁", + ".▁Totally▁con fined▁to▁bed▁or▁chair", + "lymph▁node▁ is▁N", + "▁Dosage,▁Administration ,▁and▁", + ".▁Proceeding s▁of▁the▁", + "at▁the▁end▁of▁treatment /withdrawal▁visit", + "ytochrom e▁P450", + "dre w", + "▁of▁existing ▁non-target▁lesion", + "s,▁S ubset", + "▁stratified▁by▁the▁randomization ▁factor", + "▁and▁cardiovascular ▁disease▁", + "▁unable▁to▁carry▁out ▁any▁", + "▁persistent▁or▁significant▁disability/inc apacity", + "”▁and▁ “", + "▁SI ZE", + "▁BPI ▁scor", + "▁Committee▁on ▁Cancer", + "▁and▁Tim ing▁of", + "ef▁Pain▁Inventory▁ –▁S", + "arget▁lesions▁should▁be▁selected▁on▁the▁basis▁of ▁their▁size▁(", + "Proof▁of▁Receipt ▁Form", + "▁alcoh ol", + "ALU ATIONS", + "▁time▁from▁randomization ▁date▁to", + "other▁than▁the▁evaluation▁or ▁conduct▁of▁the▁clinical▁investigation", + "▁Darbepoetin▁alfa▁Protocol▁Number:▁20010145 ▁Date:▁16▁July▁2004\n\nPage▁", + "including▁a▁ruler▁to▁estimate▁th e▁size▁of▁the▁lesion", + "HARM AC", + "willing▁or ▁unable▁to", + "\n\n26th ▁April▁2005", + "clusion▁Criterion ▁[", + "colon▁or▁rect um", + "how▁good▁ or▁b", + "▁Signatory▁Obl ig", + "may▁occur▁between▁1▁and▁ 9", + "▁temporal▁sequence▁ from", + "( 18", + "( 2)", + ") ▁as▁", + ") ▁and/or", + ") ▁plus▁", + ") ▁have▁been", + ", ▁temperature", + "- th", + "- drug", + "- 25", + "- na", + "- approv", + "/ no", + "/ 100", + "/ infusion", + "0 -", + "1 a", + "1 50▁mg", + "2 .", + "2 ▁and▁", + "3 )\n\n", + "7 ▁September▁2007", + ": 13", + "; ▁in", + "A D", + "A p", + "C hemistry", + "C onfidential\n\nProduct:▁AMG▁162▁Protocol▁Number:▁20040138▁Date:▁19▁February▁2008\n\nPage▁", + "E uroQ", + "H ▁agonist", + "I mClone▁LLC", + "K ing", + "K ,▁L", + "K aplan", + "L ab", + "L ast", + "L an-D", + "M ARY", + "N tx", + "P Y", + "T oxic", + "T umour", + "W omen", + "[ RNA", + "a ,▁", + "a ult", + "a eno", + "b ecom", + "b isphosphon", + "c ision", + "c ross", + "c irculating", + "d ep", + "d ail", + "d evic", + "d efici", + "f el", + "f fusion", + "h ospital▁or", + "i )", + "i ec", + "i ary", + "k ey▁", + "l cer", + "l isting", + "m L", + "m any▁", + "m olecular", + "m echanism▁of▁action", + "n ia", + "n ing▁of▁the▁", + "o y▁", + "o ▁S", + "o ▁R", + "o encephalopath", + "o embryonic", + "p end", + "r ising", + "s \n\nD", + "s cientific", + "s pecial", + "s ▁approximately▁30", + "t inent", + "v in", + "w ent", + "y .", + "y rimidine▁", + "≤ ▁5▁x▁ULN", + "▁ ................................................................................................", + "▁ util", + "▁ opinion", + "▁ judgment", + "▁ room▁temperature▁", + "in h", + "in hibitor", + "▁t ext", + "▁t rue▁", + "at o", + "at es▁in", + "at ▁baseline▁", + "at ▁Week", + "on ▁subject", + "on ▁day▁1", + "\n\n <", + "\n\n investigator", + "\n\n was▁", + "\n\n visit", + "\n\n without", + "en ough", + "er lin", + "er cent", + "s▁ it", + "s▁ ................................................................", + "re ad▁", + "re dient", + "al ic", + "al ter", + "st age▁of", + "st abiliz", + "st omach", + "y▁ [", + "ent ry", + "it ud", + "▁the▁ physician", + ",▁ us", + ",▁ not", + ",▁ so", + ",▁ 14", + ",▁ cer", + ",▁ based▁on▁the▁", + ",▁ changes▁in", + "ed▁ drug", + "ed▁ product", + "▁an ▁additional▁", + ".▁ ", + ".▁ 35", + "ed ▁the▁study", + "ed ▁throughout", + "▁p -valu", + "▁p amidron", + "▁p articulate▁matter", + "▁c ap", + "▁c ourse▁of", + "▁c ovari", + "ing ▁Group", + "ing redient", + "▁b urden", + "▁b ullet", + "es k", + "es ,▁the▁", + "es ▁to▁be▁", + "es .▁B", + "ation s,▁", + "▁to ▁other", + "▁to ▁be\n\n", + "▁to ▁the▁date▁of", + "▁to ▁assess▁the▁", + "▁to ▁the▁date▁of▁death", + "is ul", + "▁s quamous▁", + "▁s impl", + "▁s ummary▁of", + "▁s afety▁and▁efficacy▁", + "▁s witch", + "▁of ▁previous▁", + "▁d egree▁of", + "▁w ar", + "▁w orld", + "▁m it", + "▁m ain", + "▁m amm", + "▁m easures", + "▁m ortality▁", + "▁m itoxantrone▁", + "▁m sec", + "▁and▁ g", + "▁and▁ subject", + "▁and▁ must▁be▁", + "▁and▁ may▁be▁", + "▁and▁ dis", + "▁and▁ design", + "▁and▁ blood▁sampl", + "▁and▁ vitamin▁B12", + ".\n\n 21", + ".\n\n (cid:131)▁You", + "ment ion", + "ab solut", + "▁A bstract", + "▁A fric", + "▁in ▁study▁", + "▁in ducer", + "res ist", + "ig and▁", + "▁C IMP", + "▁C anada", + "▁C XR", + "ac ular", + "ac cru", + "es▁ P", + "es▁ contain", + "▁P CR", + "pro duced", + "▁( in", + "▁( 17", + "em bl", + "▁2 :", + "▁2 84", + "us e▁vial", + "ul um", + "ul sky▁", + "if ies", + "▁S ymptom", + "▁S tudies▁", + "▁re cur", + "▁re plac", + "▁re fract", "▁re vis", - "▁rev is", - "ха н", - "х ан", - "▁с вет", - "▁све т", - "CA SE", - "C ASE", - "▁f ührt", - "▁führ t", - "▁ führt", - "▁at omic", - "▁atom ic", - "▁ atomic", - "▁dark ness", - "▁Fußball spieler", - "▁Ж и", - "quis ition", - "▁S ieg", - "▁Sie g", - "▁Si eg", - "C irc", - "▁c ientí", - "ne lle", - "nel le", - "nell e", - "n elle", - "SH A", - "S HA", - "▁u rb", - "▁ur b", - "▁ urb", - "▁k si", - "leq slant", - "▁ф рон", - "▁de fect", - "▁def ect", - "▁defe ct", - "▁r á", - "▁ rá", - "▁strong er", - "▁p ł", - "▁commun ities", - "ни на", - "нин а", - "en as", - "ena s", - "e nas", - "ienne nt", - "ienn ent", - "▁safe ly", - "▁saf ely", - "▁т я", - "▁ тя", - "▁ben chmark", - "▁Bra un", - "method s", - "arg ument", - "vo s", - "v os", - "ob ox", - "o box", - "ро ви", - "ров и", - "р ови", - "▁recher che", - "m n", - "▁br ings", - "▁bring s", - "m achine", - "CE SS", - "CES S", - "host s", - "hos ts", - "▁N Y", - "Aut ow", - "Auto w", - "▁сов ремен", - "▁G ary", - "▁Gar y", - "▁Ga ry", - "▁s ensor", - "▁sens or", - "▁document ed", - "▁pr endre", - "▁prend re", - "▁pe er", - "en ix", - "eni x", - "ha i", - "h ai", - "ar be", - "цен т", - "ц ент", - "_ (", - "▁U RI", - "▁ URI", - "ев а", - "е ва", - "▁Re gie", - "▁Reg ie", - "▁Mon ument", - "▁onder werp", - "B ag", - "ti t", - "t it", - "▁st ir", - "▁n erv", - "▁ne rv", - "▁ner v", - "стор ія", - "▁s ov", - "▁so v", - "▁writ ers", - "▁write rs", - "▁writer s", - "▁sort s", - "▁sor ts", - "ab solute", - "▁difficult ies", - "▁par lament", - "▁parl ament", - "▁IE numerable", - "▁dis sol", - "▁diss ol", - "▁CH ECK", - "ar ina", - "ari na", - "arin a", - "in burgh", - "D M", - "▁e ind", - "▁ein d", - "▁bud get", - "▁cert ains", - "▁certain s", - "▁för sta", - "▁först a", - "an ja", - "a nja", - "▁го дов", - "▁год ов", - "▁т ек", - "▁те к", - "▁ тек", - "▁D uch", - "▁Du ch", - "▁Duc h", - "gu i", - "g ui", - "▁Te ams", - "▁Team s", - "▁мно ги", - "Mar ie", - "Ma rie", - "M arie", - "In tegr", - "Int egr", - "Thread Pool", - "ru st", - "rus t", - "r ust", - "í k", - "% \"", - "en f", - "sp l", - "s pl", - "▁be gun", - "▁beg un", - "lo u", - "l ou", - "▁Rewrite Rule", - "tu ple", - "ane ous", - "▁mar ine", - "▁mari ne", - "▁ marine", - "at tan", - "att an", - "atta n", - "ik al", - "ika l", - "i kal", - "▁gradu ated", - "il lé", - "ill é", - "▁про ве", - "▁пров е", - "▁пр ове", - "▁Р оз", - "▁Ро з", - "', \r", - "' ,\r", - "▁Pf arr", - "▁n ivel", - "▁ni vel", - "▁пра цю", - "mus ic", - "▁set Timeout", - "ER S", - "E RS", - "▁E rik", - "▁Er ik", - "pi t", - "p it", - "▁Х ро", - "▁p ił", - "▁pi ł", - "▁p eri", - "▁per i", - "▁pe ri", - "до к", - "д ок", - "us zt", - "usz t", - "▁B ear", - "▁Be ar", - "Class Name", - "▁Par lament", - "▁a ix", - "▁ai x", - "▁inv ited", - "▁P ATH", - "▁PA TH", - "▁ PATH", - "xt er", - "x ter", - "▁R ace", - "▁Ra ce", - "▁h echo", - "▁he cho", - "▁T ower", - "▁To wer", - "▁Tow er", - "▁u tf", - "▁ut f", - "▁ utf", - "act ly", - "▁бу де", - "▁ang les", - "▁angle s", - "▁ angles", - "ня я", - "ouv elles", - "ouve lles", - "ouvel les", - "ouvelle s", - "▁cl imate", - "▁cli mate", - "▁clim ate", - "▁sing ing", - "▁sin ging", - "▁navig ate", - ">' ;", - "> ';", - "ad ows", - "ado ws", - "adow s", - "▁l eta", - "▁le ta", - "▁let a", - "▁S itz", - "▁Si tz", - "▁Sit z", - "▁part itions", - "▁partition s", - "▁d ock", - "▁do ck", - "▁doc k", - "▁ż y", - "▁ ży", - "▁alloc ate", - "▁benef its", - "▁benefit s", - "▁n ieder", - "▁nie der", - "▁ni eder", - "xp ath", - "x path", - "me ck", - "äl le", - "äll e", - "ä lle", - "▁cou pling", - "▁coup ling", - "жи л", - "ж ил", - "For Key", - "ar gent", - "arg ent", - "cl ou", - "clo u", - "c lou", - "▁instru ments", - "▁instrument s", - "▁ent hus", - "▁m ég", - "▁mé g", - "▁Па в", - "▁R ach", - "▁Ra ch", - "-- ---", - "---- -", - "--- --", - "- ----", - "▁API s", - "▁AP Is", - "▁V ier", - "▁Vi er", - "▁Vie r", - "C md", - "it ore", - "ito re", - "itor e", - "▁C uba", - "▁Cu ba", - "▁Cub a", - "▁dátum mal", - "▁embed ding", - "std io", - "▁Gil bert", - "▁ge prüft", - "▁st ating", - "▁stat ing", - "▁sta ting", - "▁stati ng", - "▁trigger s", - "▁trig gers", - "+ =", - "▁spé cial", - "▁del iber", - "▁deli ber", - "ми н", - "м ин", - "Pro du", - "Pr odu", - "P rodu", - "▁St ati", - "▁Stat i", - "▁Sta ti", - "▁z us", - "▁zu s", - "kt ionen", - "ktion en", - "Dispatch er", - "id al", - "ida l", - "i dal", - "▁L P", - "▁ LP", - "op tera", - "opt era", - "opter a", - "▁e star", - "▁est ar", - "▁es tar", - "▁esta r", - "▁зна чи", - "с мо", - "ous es", - "ouse s", - "o uses", - "eng ono", - "engo no", - "▁W PF", - "pub lish", - "▁t eor", - "▁te or", - "el if", - "eli f", - "▁e rg", - "▁er g", - "▁ erg", - "▁separ ation", - "Pa n", - "P an", - "▁Or chestra", - "Pe ter", - "P eter", - "bound s", - "b ounds", - "▁Shakespe are", - "▁cant ante", - "▁d emi", - "▁de mi", - "▁dem i", - "▁Pop ular", - "ф р", - "ar ring", - "arr ing", - "ци н", - "ц ин", - "▁И с", - "vo n", - "v on", - "▁subst itution", - "▁lí nea", - "\\}$ .", - "\\} $.", - "\\ }$.", - "com o", - "co mo", - "c omo", - "▁ва ж", - "wa gen", - "w agen", - "▁rare ly", - "▁period s", - "▁peri ods", - "gl ob", + "un likely▁to", + "▁D ocetaxel", + "▁D emographic", + "ri ev", + "▁h epatic", + "▁E M", + "▁E astern▁Cooperative▁Oncology▁Group", + "▁f ood", + "▁f atigu", + "▁f olic▁acid", + "ver ifying", + "ch anc", + "▁or ▁non-", + "e▁t rial▁", + "e▁t ime▁to", + "ir reversibl", + "qu ire▁", + "ec ros", + "end -of-", + "▁n g/ml", + "\n\nA s▁of▁22▁March▁2007", + "study▁ protocol", + "▁and ▁treatment", + "▁and ▁these▁", + "▁O c", + "▁O per", + "▁as ▁they▁", + "▁as eptic", + "up tion", + "▁N e", + "ef ram", + "will▁be▁ based▁on", + "com mittee", + "▁for ▁vitamin▁D", + "and ara", + "▁R H", + "▁R et", + "e\n\n M", + "e\n\n randomization", + "rom ycin", + "ed▁in vestigational▁product", + "ed▁in ▁your▁medical▁record", + "enc y▁and▁", + "enc y▁s", + "ed▁b as", + "ed▁b lock", + "In terim", + "In stitut", + "\n\nS econdary", + "▁that ▁will▁be▁", + "▁is▁ unable▁to", + "▁is▁ no▁longer", + "▁will▁be▁ extract", + "e▁s om", + "art o", + "art on", + "art ing", + "▁M iss", + "▁r ates▁", + "▁3 00", + "▁3 6▁month", + "▁3 -year", + "▁of▁the▁ National▁Cancer▁Institut", + "▁o ▁B", + "▁F ederal▁", + ".▁The▁ maximum", + "▁as▁ first-line▁treatment", + "▁as▁ first-line▁", + "200 ▁mg", + "200 3;", + "▁the▁s ymptom", + ",▁and▁ oxaliplatin", + "ection ▁of▁the▁", + "▁B lood", + "▁this▁ clinical▁study", + "verse▁ Drug", + "▁will ▁record", + "▁will ▁include▁all", + "follow -▁up", + "▁5 .4", + "▁6 .8", + "▁6 .1.1", + "▁subject s", + "▁4 80", + "ail ▁b", + "s▁( B", + "s▁( the▁", + "s▁( either", + "s▁( ie,▁", + ".4 ▁month", + "▁study▁ or", + "▁study▁ personnel", + "▁study▁ specific", + "▁study▁ day▁1", + "continu ation", + "s▁in -", + ".5 3", + ".5 ▁month", + "s.▁ Pro", + "cons equ", + "▁any▁ AE", + "▁ex cept", + "reg istration", + "\n\nD ead", + "fer ential", + "ally▁ measurable▁lesion", + ".▁S creening", + ".▁S afety", + "▁patient s.▁The▁", + "report ed\n\n", + "ard t", + "ard ian", + "▁U /L", + "▁J D", + "▁J ,▁S", + "▁J ,▁H", + "▁tim ing▁of", + "\n\nE fficacy▁", + "asel ga", + "▁In struction", + "▁In dex", + "oun c", + "s\n\n 3", + "s\n\n 6", + "s\n\n and▁", + "s\n\n Replace:", + "evalu able▁for", + "▁tumor ▁or", + "▁tumor s,▁", + "ON TIN", + "▁month s", + "effect ▁of▁treatment", + "(cid: 116)", + "may▁ includ", + "▁adverse▁event s▁of", + "amin ophen", + "▁per tinent", + "pec ify", + "pec imens", + "s) ,", + "▁10 .2.3", + ".6 1", + "▁to▁the▁ Efficacy▁of", + "▁analysis▁ in", + ".▁In itial", + ".▁In formed▁Consent", + ".▁E valu", + ".▁E Q-5D", + "▁test s,▁", + "▁test oster", + "18 ]", + "are sthes", + ",▁and ▁all▁other", + "11 1", + "▁sign s", + "▁sign ature", + "40 %", + "par ametric", + ",▁or ▁a", + "▁in▁the▁ D", + "radi o", + "e.\n\n 3", + "e.\n\n 10", + "patient -reported▁", + "25 ▁mg/m2", + "▁9 .2.1", + "e▁( 1)", + "s▁s et▁forth", + "▁us e▁a", + "\n\nN C", + "▁data ▁cut-off", + "▁trial ▁supplies", + "y▁of ▁Sci", + "bas is", + "▁should▁be▁ administer", + "▁should▁be▁ retain", + "▁lesion s▁per▁organ", + "\n\nR eport", + "17 9", + "NC Y", + "▁the\n\n following", + "▁pre val", + "\n\nF OLFIRI", + "On ly", + ".▁D ocument", + "s▁are▁ identifi", + "▁dose▁ in", + "complet ed▁in", + ".\n\nA MG▁162", + "e) ;", + "efficac y,▁", + "▁toxic ▁factor", + "\n\n4 .4", + "le uk", + "e▁b elow", + "5- 9", + "▁mg/m ▁2", + ",▁S tein", + "isk s▁of▁a", + "▁patients▁with ▁a", + "result s▁will▁not▁be▁", + "equ ential▁", + "equ ipment", + ".\n\nS econdary▁", + ".\n\nS AFETY", + "creas e▁in", + "e▁treatment ▁in", + "SC ONTIN", + "▁evalu at", + "ed▁and▁ reported▁lesion", + "▁An algesic", + "▁includ ed▁in▁the▁", + "▁over ▁120", + "iffer enc", + "▁factor ial", + "perform ed:", + "perform ance▁with", + "until ▁death", + "until ▁resolution", + "receiv ed▁at▁least", + "formed▁consent ▁must▁be▁obtain", + "▁cell ▁death", + "consider ed▁to", + "▁the▁subject ▁has▁", + "▁this▁study ▁are▁", + "NA NCY", + "discontinu ed▁for", + "▁treat ing", + "▁et▁al .,▁", + "▁if ▁a", + "▁if ▁they▁", + ".8 %", + "iom a", + "\n\n6 .5", + "\n\n6 .6", + ".▁M ayo▁Clin", + "▁provid e▁the▁", + "▁response▁ or", + "▁disease▁progression ▁should▁be▁", + ",▁s urger", + "mod ality▁", + "▁dis pos", + ".▁H ave▁you", + "▁drug ?", + "s▁will ▁include▁", + "current ▁version▁of▁the▁", + ",▁C ar", + "sub -", + "sub mission", + "▁level s▁will▁be▁", + "▁level ▁in▁the▁", + "▁metastatic ▁CRC", + "\n\nIn ▁addition", + ",▁b y", + "s, ▁the▁investigator", + "col d", + "▁activ ation", + "Ad d▁", + "e▁m aterial", + "\n\nB est", + "▁can not", + "▁administer ed▁a", + "▁respons e", + ".▁This▁ number", + ".▁This▁ information", + "clinical ▁progression", + "hib ited▁", + "▁this ▁treatment", + "▁this ▁time▁point", + ".▁T▁N▁E▁M▁U▁C▁O▁D \n\nC▁I▁N▁O▁R▁T▁C▁E▁L▁E", + ",▁A r", + "▁des criptive▁", + "K▁C▁E▁H▁C \n\nE▁S▁A▁E▁L▁P", + "▁12 .4", + ")(cid: 5", + ")(cid: 4)(cid:", + "estim ation", + "each ▁patient", + "▁Amgen ▁for", + "▁both ▁agent", + "▁avail ability", + "▁plus▁ sunitinib", + "known ▁to▁be▁", + ".▁Patients▁ should▁be▁", + "▁bevacizumab ▁until", + "ed▁c ardiac", + "treatment ▁phase▁", + "▁baselin e\n\n", + "▁allow ed", + "long -term▁follow-up", + "▁every▁ 6", + "within ▁7", + "Com prehensive▁", + "▁a▁m ember", + "45 ▁mL/min", + "▁Appendix ▁XIV▁Page▁", + "▁Day▁1 ▁of▁the▁", + "▁randomiz ed▁treatment", + "\n\nAppendix ▁1", + "related▁to ▁study▁drug", + "▁hy persensitivity", + "▁24 ▁week", + "indic ated▁for", + "oh en", + "assess ed", + "assess ed▁for", + "caus ing", + "caus e▁a", + "caus e▁of▁death", + "DMC ▁charter", + "hea d▁of▁the▁", + "receiving ▁panitumumab", + "yn thes", + "US )", + "chemotherapy▁ or", + "▁of▁a ▁pre-existing", + "plan ation", + "person al", + "person ▁who▁conducted▁the▁informed▁consent▁discussion", + "1,▁ 8", + "IG NA", + "▁the▁c as", + "confirm ed▁by", + "▁sp ending", + "▁sp inal▁cord▁compression", + "▁ABI-007 ▁and▁", + "▁phase▁ I", + "▁cas es,▁", + "y▁s upplement", + "▁cor onary▁", + "▁symptom s▁", + "contact ▁nam", + "▁medical▁ intervention", + "\n\n10 .6", + "\n\nt im", + "es▁or ▁no", + "y▁( BP", + "▁caus es▁", + "echn ology▁", + ".\n\n5 .5", + "▁further ▁treatment", + "▁Assessment s", + "ature▁ and▁", + "ide▁effect s▁of", + "▁e▁ d▁", + ".▁However ,▁the▁", + ".▁However ,▁in", + "▁er uption", + ".▁In▁addition ,▁the▁", + "only ▁to", + "▁investigator s▁and▁", + "▁available▁ for", + "▁target▁lesion s▁will▁be▁calculated▁and▁", + "standard▁ error", + "rogen -free▁", + "▁a▁patient ’s▁", + ".\n\n3 .3", + "respectiv ely,▁", + "ors ening", + "develop ment▁of", + "▁Subject ▁Information", + "3- 8", + "▁has ▁taken", + "▁conduct ▁of▁the▁study", + "▁person ▁who", + "s; ▁and▁", + "s; ▁however", + "▁bi as▁", + "▁randomized▁ patient", + "/d ocetaxel", + "▁informed▁consent ▁document", + "open-label ,▁Phase▁3", + "e▁sampl es▁will▁be▁", + "pain ▁severity", + "pain ▁interfer", + "vitamin▁D ▁supplement", + "▁PR ▁nor", + "rin alysis▁", + "▁marker s▁", + "s,▁and ▁the▁", + "s,▁and /or", + "▁clinical▁trial s,▁", + "\n\nd emonstr", + "▁subjects▁who ▁develop", + "skin ▁toxicity", + "pharmac ological", + "s▁includ ed▁", + "▁minutes ▁apart", + "es▁will ▁not▁be▁", + "eligibl e▁subject", + "▁experienc es▁", + "direct ly", + "▁grade▁ 1", + "▁et▁al.▁200 8", + "ula ▁vita", + "IM S", + "list ed▁in▁Section", + "s/ SAE", + ".\n\nN o", + "▁onc ology▁", + "▁days▁prior▁to ▁C1", + "care▁ physician", + "lig and", + "▁(m ultiple▁", + "▁procedures ▁and▁", + "es▁the▁ risk▁of", + "▁standard▁ of", + "▁remain s▁", + ".\n\nIf ▁you", + "g/m 2)", + "▁JM IG", + "▁availabl e", + "▁full -dose▁", + "▁the▁last▁dose▁of ▁study▁treatment", + "▁character ize▁each", + "mean ▁QTc", + "frequ ently", + "astro esophageal▁", + "\n\nPh armac", + "\n\nPh ysical▁Examination", + "▁qual ity", + "▁based▁on ▁assessment▁of", + ".▁( or▁equivalent", + "with▁the▁ exception", + ".▁Ex pression", + "gener ated", + "\n\nEx clusion▁Criteria", + "▁clinically▁ relevant", + ".\n\nWh en", + "PRO ▁endpoint", + "▁ext ensive▁", + "▁surger y,▁", + "▁radiation ▁therapy", + "emal e▁", + "s.▁S ubject", + "outh ▁America", + "ogenes is▁", + "also ▁been", + "\n\n12 .1", + "▁chemist ry▁and▁", + "propos ed", + "79 6", + "▁AD MINISTRA", + "ouble- blind▁", + "▁discus s▁with", + "Objectiv es▁", + "into ▁the▁study", + "▁intraven ously▁", + "▁........................................................................ ..", + "▁........................................................................ .......▁", + "s▁have▁been ▁observ", + "▁2▁year s▁after▁the▁last▁dose▁of", + "secondary▁ endpoint", + "▁immun e▁", + "ECOG▁performance▁stat us▁", + ".▁There▁ are▁no", + "randomis ed▁", + "flamm ation▁of▁the▁", + ")▁will ▁review", + "OC BP", + "consent▁form ,▁you", + "▁de hydration", + ".\n\nAd ditional▁", + "breviation s:", + "▁by▁the▁ Investigator", + ":▁The▁ addition▁of▁panitumumab▁to▁chemotherapy▁(", + "▁................................................................ ....", + "EL OX", + "▁consist ing▁of", + "1▁and▁ 8", + "SS URA", + "previously▁ untreat", + "ynops is", + "▁AUC ▁=▁area", + "begin s▁on", + "pen sion", + "▁abov e▁or", + "▁3▁week s▁after▁the▁last▁dose▁of", + "▁future▁ research", + "▁3.3 .5", + "▁while▁ receiving", + ".▁Ch ang", + "▁early▁ stopp", + "compan y,▁", + "▁lead ing▁to", + "▁go al▁", + "▁hist ology▁", + "statistical ▁analysis▁of", + "▁IRB ▁or▁IEC", + "s.\n\nThe▁ investigator", + "▁days▁prior▁to▁randomization ):", + "▁of▁5 ▁lesions▁per▁organ", + "centr ally▁", + ".\n\n.▁T▁N▁E▁M▁U▁C▁O▁D \n\nC▁I▁N▁O▁R▁T▁C▁E▁L▁E", + "▁disorder ▁that", + "express ed▁in", + "\n\nAt ▁least", + "shipp ing", + "resect ed▁", + "▁compens ation", + "\n\nAbbreviation s▁and▁Definition", + "perman ent", + "ate▁( UE", + "▁continuous▁ regimen", + "▁sequ ela", + "-related ▁activities", + "consist ing▁of", + "included▁in▁the▁ analysis▁of", + "▁Stat us", + "▁Stat us▁", + "▁expect ed▁", + "ropo ies", + "▁deriv ed▁from", + "omat ous▁", + "▁participate▁in▁this▁study ,▁you", + "▁the▁sign ificance▁level", + "sam e▁", + "worst ▁pain", + "chem ic▁attack", + "▁apopt osis▁in", + "▁includes ▁all", + "▁pemetrexed▁and▁ carboplatin", + "pheral▁neuropath y", + "Hy d", + "▁end▁of ▁study▁treatment▁visit", + "orth ▁America", + "WBC ▁differential▁(neutrophils,▁", + "\n\nArm ▁A", + "▁their▁last ▁evaluable▁", + "▁Reported▁Outcom es▁", + "▁comp eting", + ".▁New ▁guidelin", + "▁vertebral▁ fracture", + "-based ▁therapy", + "one▁in ▁Patients▁with", + "iss ure", + "e▁the▁following :", + "recorded▁as ▁adverse▁event", + "▁immediate▁ risk▁of▁death", + "PPEND IX", + "▁alloc ation", + "▁relationship ▁between", + "-B EING", + "▁gene▁ expression", + "es▁may▁be▁ collected▁", + "concentration ▁in", + ".\n\nAmgen▁Thousand▁Oaks \n\nConfidential\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁AMG▁162▁Protocol▁Number:▁20040135▁Date:▁14▁November▁2006\n\nPage▁", + "s▁when ▁the▁", + "1999 ;", + "half -lif", + "refer▁to ▁Section", + "metab olism", + "▁proc ess▁", + "\n\nProtocol▁Attachment▁JM HR", + "▁Baselin e:", + "▁eth ics▁committe", + "▁may▁continu e▁to▁receive▁", + "ranulocyt e-", + "▁time▁to▁progression ▁(TTP", + "ordinating ▁Investigator", + "INT RODUCTION", + "National▁ Academ", + "▁molecular ▁biomarker", + "▁inf used▁", + "▁xenograft ▁model", + "itis▁or ▁pulmonary▁fibros", + "▁General▁ Approach/", + "▁Society▁of ▁Clinical▁Oncology", + "▁incidence▁ rates▁of", + "disclos ed▁to", + "▁creatinine▁clear ance▁", + "VERSE▁EVENT ▁REPORTING", + "organ ▁function", + "al▁p olicy", + "thical▁ Conduct", + "AEs▁ leading▁to", + "▁denosumab▁is▁ determin", + "ission ▁tomograph", + "participation▁in▁the▁ clinical▁trial", + "▁will▁be▁responsible▁for ▁obtain", + "intern ational▁", + "dr iven", + "▁in▁writ ing", + "\n\nLIST▁OF ▁ABBREVIATIONS▁AND▁DEFINI", + ".\n\nSTUDY ▁PROCEDURES", + "▁em ission▁tomograph", + "tabul ated", + "ysesthes ias", + "chest,▁abdomen ,▁and▁p", + "▁Compar e▁the▁Efficacy▁of", + ",▁whichever▁is▁ earlier", + "pros pective▁", + ".▁Ant iemetic", + "baseline▁sum ▁LD", + "▁knowledg e▁of", + "EOS ▁visit", + "▁MS I-H", + ".▁Therefor e,", + ".▁Randomized▁ phase▁III", + "al/ pericardial▁effusion", + "ocial /f", + "▁(J une▁", + "clus ive▁", + "adequ ately▁", + "▁approximately▁2 ▁minutes▁apart", + "▁neut rophil", + ",▁alkaline▁phosphatas e,", + "rch iv", + "▁Ap plicable▁", + ".▁Not e▁that", + "Complet ion", + "▁Concomitant ▁Therapy▁", + "▁acne iform", + "▁intravenous ;", + "▁Europe,▁ Australia", + "recogn iz", + "e▁daily ;", + "(cid:14 9)", + "bumin-adjusted▁ serum▁calcium", + "▁slice▁thickn ess", + "clinical▁research ▁physician", + "▁count,▁ hemoglobin", + "Extension ▁Period▁", + "knowledg e▁of", + "▁recom mend▁", + "▁Revised▁Clinical▁Study▁Protocol▁Drug▁Substance▁ZD4054▁Study▁Code▁D4320 C00033▁Edition▁Number▁3▁Date▁15▁February▁2011", + "▁ven ous", + "\n\nIMC- 11F8", + "▁Medic ine▁", + "directed▁against ▁the▁", + "olys orb", + "▁2007;▁8 5:", + "0.22 -micron", + "eason s▁for", + "equal ▁to", + ",▁platelet▁count ,▁and▁", + "▁rac em", + "electrolyt e▁", + "▁CR,▁PR ,▁or", + "▁DI SCONTIN", + "▁Journal▁of ▁Cancer", + "composite▁ endpoint", + "posure▁in▁Utero ▁Form", + "ences▁of▁the▁ United▁States▁of▁America", + "\n\nEth ical", + "rational e▁for", + "▁Key▁ Study▁", + ".9%▁sodium▁chlorid e▁solution", + ",▁in▁accordance▁with ▁local▁procedures", + "]▁H ave▁", + "cir cl", + "e▁des crib", + "▁Joint ▁Committee▁on▁Cancer", + "expectanc y▁", + "s▁occurring▁at▁the▁sit e▁and▁other", + "desirable▁ medical▁condition", + "axotere ®", + "Master ▁Informed▁Consent▁Form", + "▁reproductive▁ potential", + "REG NANCY", + "Treatment▁of▁ Bone▁", + "e▁the▁safety▁ of", + "ectibix ®", + "inic rop", + "▁cerv ical", + "▁der ive▁", + "ppear ance▁of", + ",▁power ▁would▁be▁", + "▁sufficient▁increase▁to ▁qualify▁for▁PD", + "▁the▁prior▁written ▁consent▁of", + "▁sufficient▁shrinkage▁to▁qualify▁for ▁PR▁nor", + "▁all▁pre-disease▁ performance▁with", + ",▁Heaney▁ RP", + "itron ▁emission▁tomograph", + "uter ine▁", + "▁is▁oblig ated▁to", + "▁of▁W orld", + "▁WELL -BEING", + "judged▁to▁be▁ due▁to", + "mon▁Toxicity▁ Criteria", + "▁SAMPLE ▁SIZE", + "\n\nRestricted▁in▁physically▁strenuous ▁activity▁but", + "▁of▁63▁Finalization▁date:▁June▁19▁2001,▁Incorporating▁amendment▁3▁–▁dated▁23▁May,▁200 3\n\nAmerican▁BioScience,▁Inc.\n\nPhase▁III▁Protocol▁CA012-0▁ABI-007▁(Nanoparticle▁Paclitaxel)\n\nCONFIDENTIAL", + "▁pellet] ,▁PAXgen", + "illi am", + "mineral ▁d", + "ackaging▁and▁ Formulation", + "▁accom mod", + "\n\nYes▁or▁No \n\nPD\n\nAny", + "able▁to▁Evalu ate▁(UE", + "personally▁ dat", + ",▁confined▁to▁bed▁or▁chair ▁more▁than▁50%▁of▁waking▁hour", + "▁unable▁to▁carry▁out▁any▁ work▁activities.▁Up▁and▁about", + "King dom", + "aeno ic▁acid▁", + "alic yl", + "verse▁Drug ▁Reaction", + "y▁of▁Sci ences▁of▁the▁United▁States▁of▁America", + ".▁Mayo▁Clin ▁Proc", + "rogen-free▁ 0", + "pain▁interfer enc", + "▁ADMINISTRA TION", + "National▁Academ y▁of▁Sciences▁of▁the▁United▁States▁of▁America", + "thical▁Conduct ▁of▁the▁", + "▁DISCONTIN UATION", + "▁all▁pre-disease▁performance▁with out", + "( NA", + "( FACT-G", + "( Arm▁A", + ") ]", + ") ▁from", + ") ▁x", + ") ▁prior▁to", + ") ▁of▁0", + ", ▁there▁is▁", + "- 30", + "- 43", + "- 21", + "- associ", + ". )\n\n", + "/ bevacizumab", + "/ INR", + "0 .8", + "3 50", + "7 :", + ": 18", + ": ▁result", + "> ▁6▁month", + "? ”", + "C oll", + "C IMP", + "D OR", + "D ouble-blind", + "E E", + "E ORTC", + "E fficacy", + "I F", + "M easures", + "O M", + "R ▁form", + "R ,▁G", + "S ):", + "S afety", + "T F", + "T W", + "U til", + "W RS", + "b id", + "b one▁scintigraph", + "b acher", + "e over", + "e >>", + "f amily▁", + "f elt", + "g /dL", + "h ▁P", + "i e▁", + "i en", + "i ologic", + "i agnostic", + "l av", + "l umbar▁spine▁", + "n e-", + "n ominal▁significance▁level", + "o s▁", + "p and", + "p -valu", + "r ar", + "r um", + "r is▁", + "s f", + "s ▁than", + "s \n\n13", + "s lid", + "s ▁throughout▁the▁study", + "s ▁apart", + "t wo", + "u ent", + "w art", + "y :", + "y et", + "≥ 2", + "▁ @", + "▁ ic", + "▁ rout", + "▁ etc", + "▁ early", + "▁ embedd", + "▁ room", + "▁ ..............................................................", + "in ▁L", + "in ally,▁", + "in strument", + "in cipl", + "in vasive▁", + "▁t ri", + "▁t ap", + "▁t achycardia", + "▁t -scor", + "at e▁treatment", + "on ▁first", + "\n\n dose▁", + "\n\n obtain", + "\n\n are▁", + "\n\n factor", + "\n\n ________________________________", + "▁a pproved▁by▁the▁", + "er ▁H", + "........ ..", + "s▁ ≥", + "s▁ such▁as", + "d▁ =", + "al ▁anti-", + "al bumin", + "st ance▁", + "st ated", + "y▁ J", + "▁the▁ maximum", + ",▁ 11", + ",▁ using", + ",▁ Cl", + ",▁ your", + ",▁ chest", + ",▁ intoler", + ",▁ functional▁well", + "ed▁ directly▁", + "▁an aphyl", + ".▁ CT", + ".▁ OS", + "ar ameter", + "ar sen", + "ed ▁the▁study▁", + "ed ▁the▁data", + "▁p ractitioner", + "▁c eas", + "▁c ensor", + "ing ▁agent", + "▁b ecause▁of", + "▁b eyond▁", + "es ▁and▁the▁", + "ation s▁in", + "▁to ▁which", + "▁to ▁determin", + "▁to ▁improv", + "▁to ▁60", + "▁to ▁the▁investigational▁product", + "▁to ▁take▁part", + "▁s un", + "▁s ix", + "▁s EGFR", + "▁s election", + "as c", + "as ia", + "▁of ▁rest", + "▁d yspnea", + "th e▁d", + "▁and▁ by", + "▁and▁ at▁the▁", + "▁and▁ paclitaxel", + "▁and▁ followed▁by▁", + ".\n\n 29", + ".\n\n Ther", + "ment al▁", + "el ays", + "ol e▁of", + "▁A PPENDICES", + "iv e▁treatment", + "▁in ▁cancer", + "▁1 -", + "▁C D", + "▁C NS", + "ac ul", + "es▁ including", + "es▁ such▁as▁", + "es▁ with▁the▁", + "▁P O", + "▁P rior▁to", + "▁P PI", + "▁( un", + "▁( 12", + "▁( no", + "▁( week", + "▁( 1-", + "▁( kg", + "em optys", + "▁2 ▁Appendix▁Date▁", + "us ed▁at▁baselin", + "if ▁clinically▁indicated", + "▁S LD", + "▁S ervic", + "ub rod", + "▁re -s", + "▁re cord▁of", + "un ct", + "cl ough", + "ri k", + "ri end", + "with ▁an", + "ap optotic", + "▁E uropean", + "▁E ORTC", + "▁E toposid", + "▁E -mail", + "▁f emoral▁neck▁BMD", + "am ma", + "▁or ▁an", + "▁or ▁H", + "▁or ▁un", + "▁or ▁TAXOL", + "▁or ▁intoler", + "▁or ▁vomiting", + "ir rit", + "ut ein", + "ther oscl", + "The▁ primary▁", + "\n\nP K", + "\n\nP hase▁", + "\n\nP emetrexed▁H3E-MC-JMHO", + "end ron", + "▁n ature", + "▁n arcotic", + "ist ence▁of", + "\n\nA c", + "ate▁ dehydrogen", + "▁T SH", + "▁N ▁A\n\nF▁O", + "op pos", + "op ulation▁of", + "toc oll", + "will▁be▁ a", + "ast henia", + "▁ar rhythmia", + "▁for ▁which", + "▁for ▁at▁least", + "▁for ▁the▁first", + "▁for ▁any▁reason", + "▁R M", + "e\n\n To", + "ed▁in ▁the▁study", + "▁treatment ▁discontinuation", + "enc e▁that", + "enc y▁or", + "ive▁ patients▁with", + "av ar", + "e▁to xic", + "ed▁b efore▁the▁", + "s▁of ▁vitamin▁D", + "ign ature", + "\n\nS kin", + "\n\nS ponsor", + "\n\nS erious▁adverse▁event", + "▁is▁ suppli", + "▁is▁ required▁for", + "▁of▁ B", + "▁al kaline▁phosphatas", + "▁will▁be▁ identifi", + "e▁s pecifi", + "e▁th e▁dose▁by▁", + "▁M ethod", + "▁con ception", + "cor onary▁", + "ust ain", + "cont igu", + "▁com pr", + "▁F ood▁", + "▁F ▁O\n\nY▁P▁O▁C", + "▁F ▁Drug▁Substance▁AZD2171▁Study▁Code▁D8480C00013▁Appendix▁Edition▁Number", + ".▁A s▁a▁result", + ".▁The▁ DMC▁will", + ".▁The▁ most▁common", + "ity▁ is▁", + "▁as▁ compared▁to", + "▁as▁ monotherapy▁", + "▁as▁ defined▁in▁Section", + "200 6;", + "▁the▁s unitinib", + "▁the▁s chedule▁of", + "▁are▁ currently▁", + "▁on ▁an", + "ated▁ or", + "ated▁ KRAS", + "ine▁ is▁", + "▁L evel", + "▁L ,▁B", + "▁L eucovorin", + "ever sibl", + "▁B C", + "▁this▁ form", + "s,▁ low", + "▁st ead", + "▁st rok", + "olog ies▁", + "▁5 1", + "▁6 1", + "▁6 .4.1", + "▁6 .3.2", + "from ▁normal", + "ult in", + "▁patients▁ had▁", + "▁patients▁ experiencing", + "▁4 00", + "▁4 ▁mg", + "▁the▁p ath", + "▁at ▁screening", + "ampl es▁", + "s▁( EQ-5D", + "▁the▁in clusion", + "▁study▁ closure", + "continu ed▁", + "\n\n1 .\n\nTo", + "po ol", + "s▁in ▁walk", + "xim ately", + "gen omic", + ".5 9", + "s.▁ N", + "rit ish", + "▁ex clusion", + "▁ex acerb", + "ak i", + "urv e", + "▁after ▁the▁last▁dose▁of", + "cre t", + "s▁and▁ regulation", + "s▁and▁ mutant▁KRAS", + "s▁and▁ feet", + "19 ]", + "e▁d evelop", + "▁patient ▁reported▁", + "▁the▁d ocetaxel", + "▁the▁d evelopment", + "s▁will▁be▁ given", + "s▁will▁be▁ based▁on▁the▁", + "s▁will▁be▁ evaluated▁for", + "ies▁ with", + "▁un resectable▁", + "▁pl ay", + "▁tim e▁that", + "ies ,▁except", + "orm an", + "evalu ate▁", + ".▁Th re", + "et▁al ,▁199", + "▁tumor \n\n", + "ia z", + "▁7 3", + "▁dos es▁and▁", + "effect ▁modification", + ",▁the▁ F", + "may▁ patent", + "pect ed▁", + ".6 4", + ".6 6", + "▁to▁the▁ study▁", + ".▁In ▁a", + ".▁In ter", + ".▁E uroQol", + "▁assessment s▁at", + "▁ag e,▁", + "▁test ed▁", + "▁test ing▁of", + "s.\n\n 7", + "s.\n\n 13", + "RA TOR", + "11 4", + "11 6", + "▁med ically▁", + "▁med ically", + ",▁or ▁2", + "radi ologic", + "▁9 3", + "▁8 3:", + "mit oxant", + "\n\nN e", + "\n\nN ational▁Cancer▁Institut", + "pre m", + "s▁with ▁performing", + ").\n\n 3", + ".7 4", + ".7 6", + "▁should▁be▁ given", + "▁other ▁sites▁of▁disease▁", + "▁your ▁willingness▁to", + "ten d▁", + "▁pre vention", + "ed▁as▁ per", + "▁Study▁ Group", + "\n\nF orm", + "\n\nF OLFOX", + "▁cycl e.\n\n", + "\n\nT est", + "\n\n3 6", + "\n\n3 .5", + "sh orter", + ".▁D irect", + "no ”", + "complet ed▁and▁", + "complet ion▁of", + "▁W J", + "pr incipl", + "e) ▁KRAS", + ".\n\nP atient", + "5- 7", + "s▁that ▁have▁been", + "\n\nI CH", + "i- dimension", + "iven ess▁of", + "result ed▁in", + ".\n\nS afety▁", + "ated▁to ▁be▁", + ")▁ ", + "patients▁ in", + "An alyt", + "sign s▁and▁symptom", + "▁An nual▁Meeting", + "▁over ▁1▁hour", + "ru ising", + "▁13 .2", + "▁13 .3", + "perform ed,▁", + "perform ed▁and▁", + ",▁a sthenia", + ".▁200 2;", + ".▁200 5;", + "▁year s,▁", + "▁the▁subject s’", + "Investigator 's▁", + "▁group ▁A", + "▁approximately▁ every▁", + "▁AB C", + "ed.\n\n 4", + "▁discontinu e▁the▁", + "\n\n\n\n is▁", + "document ation▁of", + "▁their ▁review", + "▁their ▁physician", + ".▁B aseline▁", + "▁analysis .", + "▁and/or ▁the▁", + "ed▁s urvival▁", + "collect ed▁prior▁to", + "▁occur s▁at", + "\n\n6 .7", + "▁days .▁The▁", + "dis odium", + "dis order", + "IT D", + "dose▁ adjustment", + "▁disease▁progression ▁on", + "▁should▁ receive▁", + ",▁s ever", + ",▁s well", + ",▁s ubsequent", + "▁these▁ event", + "▁these▁ patients▁", + "ros cop", + ",▁M .D", + "▁sh orter", + "▁clinical ▁practic", + "X- ray", + "▁must ▁personally▁", + "▁hour s,▁", + "1- 5", + "1- 7", + "1- Day▁", + "administer ed▁to", + "sub stitut", + "▁metastatic ▁diseas", + ".9 0", + ".9 .1", + "\n\nIn formed▁consent", + "\n\nIn terim", + "s, ▁then", + "▁19 98", + "▁by▁ imaging▁techniqu", + "▁– ▁ag", + "AB G", + "AB I", + "conduct ed▁", + "▁information ▁should▁be▁", + "ric tion", + "▁to▁ identify▁", + "part ▁of▁", + "▁administration ▁of▁study▁drug", + "▁any ▁adverse▁event", + "were▁ no", + "▁document s▁to", + "▁document ▁their▁review", + "inal▁ Investigational▁Product", + "▁des quamation*", + "was▁ no", + "blind ed▁to", + ",▁H art", + ",▁H olick▁MF", + "studies▁ of", + ".\n\nC on", + "▁chang e▁to", + "▁radi ological▁", + "ed▁or ▁volunteer", + "▁OS ▁in▁the▁", + "▁time▁ fram", + "38 -", + "▁plus▁ carboplatin", + "ardi ologist", + "▁Pro perty▁of▁the▁sanofi-aventis▁group▁-▁strictly▁confidential▁WW-CLIN-PR007-SD-03▁VERSION▁n°02▁(19-DEC-2005)\n\nPage▁", + "▁Pro ceeding", + ".▁Patients▁ must▁have▁", + "▁this▁study▁ will", + ",▁G ar", + ",▁G ray▁", + "▁AE s,▁", + "▁Feb rile▁", + "▁who ▁will", + "▁anti- angiogenic", + "▁St andard▁", + "determin ed▁by", + "s▁at ▁the▁time▁of", + "within ▁72▁hour", + "Com mon", + "describ ed▁", + "describ es▁the▁", + "mad e▁by", + "count ry▁", + "▁compar e▁the▁treatment▁effect", + "day▁ of", + "▁first ▁dos", + ",▁L DH", + "\n\nAppendix ▁H", + "ummar iz", + "analysis▁ data▁cutoff▁date▁", + "ify ▁the▁investigator", + "ubl ing", + "ash ington", + "diseas e.\n\n", + "vis ual", + "▁two ▁consecutive▁", + ".▁O ste", + "112 48", + "▁clinical▁ fracture▁", + "expect ed▁s", + ".\n\nT REATMENT", + "▁15 ▁minutes▁", + "oug ier", + "▁cl ass▁", + "▁OF ▁STUDY", + "ritten ▁informed▁consent", + "▁measurement ▁and▁", + "▁measurement s\n\n", + "▁author ship", + "\n\nAdd▁ 10", + "\n\nthe▁ study▁", + ",▁R ubin", + ",▁R imm▁EB", + "except ion▁of▁the▁", + "except ▁Japan", + "due▁to ▁a", + "▁cor rection", + "during ▁treatment", + ",▁as▁ follows:", + "\n\nx\n\nx ▁x", + ".\n\n6 .2", + ".▁L ung▁Cancer", + "▁condition ▁that", + ".,▁et▁al.,▁ The▁", + "▁period▁ is▁", + "▁Ther asse▁et▁al.▁2000", + "recommend ed▁but▁not", + "▁21 ▁CFR", + "\n\n.▁T▁N▁E▁M▁U▁C▁O▁D \n\nC▁I▁N▁O▁R▁T▁C▁E▁L▁E", + "e▁f urther", + "▁record ing", + ",▁199 5", + "\n\nm easurement", + "Amgen ▁Delegation▁of▁Authority▁Form", + "laboratory▁ parameter", + "LY231514 \n\nH3E-MC-JMHD(f)▁Clinical▁Protocol\n\nPage▁", + "wer e\n\n", + "rac e,▁", + "FACT- H&N", + ",▁F ish", + ".\n\nIn t", + "adverse▁event .▁If", + "▁e▁ p", + "▁28 ▁days▁of", + "▁28 ▁days▁prior▁to▁randomization", + "▁compl y▁with▁the▁", + "▁(C PT-11", + "49 ▁weeks▁and▁", + "▁vari ation▁in", + "%▁of ▁patients▁treated▁with", + ".▁199 6;", + "oper ating", + ".\n\n3 .2", + "▁of▁each ▁laboratory▁", + "ographic ▁region", + "develop ment", + "ren ew", + "ren bacher", + "▁has ▁to▁be▁", + "\n\nV ital▁Sign", + "\n\nV olume▁of", + "statist ician", + "▁trial▁ (", + "otential▁ Risk", + "▁product ▁is▁", + "▁conf oun", + ",▁m agnesium,▁creatinine,▁albumin,▁total▁protein,▁total▁bilirubin", + "therapy▁ in▁patients▁with", + "▁was ▁also", + "▁was ▁administer", + "▁was ▁administered▁", + "MR T", + "non target▁lesion", + "▁appropri ately▁", + "▁indic ated▁", + "▁medical ▁problem", + "▁marker s", + "▁ident ity▁", + "▁ident ifying", + "opy▁ number", + "-day▁ period▁", + "37 -", + "s▁may▁be▁ performed▁as▁clinically▁indicated", + "▁such ▁a", + "T- 1", + "▁mic romol/L", + "▁alon e▁in", + "baseline▁ valu", + "maintain ing", + "▁does▁not ▁wish▁to", + ".\n\n2 .2", + "ing▁in ▁a", + "es▁will ▁be\n\n", + "▁Dose▁ Level", + "safety▁ data", + "ousand▁Oak s,▁CA", + ",▁an alyz", + "air clough", + "▁local▁ laboratory", + ",▁c apecitabine▁", + "▁bod y▁surface▁area", + "es▁that ▁are▁not▁confirmed", + "hel d▁", + "▁physician ▁may▁", + "▁Table▁ JMIG", + "e▁the▁s mallest▁s", + "allow ed", + "▁en rolment", + "reduc ed▁to", + "▁days▁prior▁to ▁Day▁1▁of▁Cycle▁1", + "interim ▁analysis▁", + "evaluated▁ leading▁to", + "\n\nTable▁ 6", + "scal e▁", + ".▁Wh il", + "), ▁time▁to▁progression▁(TTP", + "(cid:13 3)", + "▁guidelin es▁", + "▁and▁d istribut", + "▁expos ed▁to", + "▁and▁in stitution", + "establish ed▁", + "therapy ,▁", + "best ▁supportive▁car", + ",▁patients▁ with", + "▁assess▁ disease▁", + "ed▁if ▁the▁", + "▁path ology▁", + ".▁You ▁will", + "s▁ar ising", + "grad ed▁according▁to▁the▁", + "▁Follow ing▁the▁", + "oy al▁", + "▁will▁be▁administer ed▁", + "othel ioma", + "▁regard less▁of", + "\n\nU pon", + "▁participant s▁in", + "▁surger y▁or", + "equire d▁", + "▁Ac cess▁to", + "calcium ▁and▁vitamin▁D", + "Response▁ R", + "performed▁at ▁screening", + "regardless▁of ▁whether", + "e▁and /or", + "every▁3 ▁months▁for", + "▁defin ed▁as", + "▁evidence▁of ▁progression", + "▁the▁interim ▁analysis▁", + "dat abase▁", + "full y", + "enoc arcin", + "improv es▁", + "improv ed▁to", + "........................ ..", + "▁Reg istration", + "▁calcium ▁and▁vitamin▁D", + "immun otherapy", + "immun ogenicity", + ".▁Treatment ▁Compliance▁", + "\n\nx▁x▁x ▁x▁x▁x▁x", + "bone▁ marrow", + "▁evaluate▁the▁ response▁to", + "secondary▁ efficacy▁endpoint", + "▁as▁well ▁as▁the▁", + "▁small ▁molecul", + "▁site▁ personnel", + "▁decid es▁", + "\n\nProduct:▁AMG▁162▁Protocol▁Number:▁20040138▁Date:▁19▁February▁200 8", + "▁Overall ▁Survival", + "▁the▁pres ent", + "e▁dis cover", + "▁of▁s ix", + "▁co um", + "followed▁ every▁", + "Drug ▁Administration", + ".▁K ris", + ".\n\nWhat ▁are▁the▁", + "▁had ▁any▁", + "▁Evalu ate▁", + "▁date▁of ▁death", + "unless▁ otherwise▁", + "▁frequ ency▁", + "ed▁for▁each ▁treatment▁group", + "employ ed▁to", + "▁evaluate▁ whether", + "for▁exampl e,", + "correct ▁CRF", + "extent ▁of▁your", + "▁d▁ n", + "Rec or", + "▁1.0 ▁Appendix▁Date▁", + "efficacy▁and▁ safety▁of", + "(C rCl", + "\n\nCR \n\nCR", + "different i", + "▁treated▁ subject", + "\n\nGrade▁ 2", + "▁intak e▁of", + "rest ing▁pulse,▁", + "▁dep end▁", + ",▁Ch en", + "▁identifi ed▁and▁reported▁lesion", + "▁Study▁Design ▁..............................................................................................", + "ed- RECIST", + ".\n\n12 .2", + "▁stratifi ed▁log-rank▁test", + "s.▁J ▁Natl▁Cancer▁Inst", + "▁paragraph \n\nReplace:", + "Wild-type▁KRAS ▁Efficacy\n\nAnalysis▁Set", + ",▁con stipation,▁", + "returned▁to ▁Amgen", + "▁worsening ▁of▁", + "superior ▁to▁zoledronic▁acid▁with", + "▁situ ations▁", + "▁central▁ nervous▁system", + "most▁common ly▁", + "▁malignanc y", + "e▁the▁subject ’s▁", + ",▁it▁is▁ recommended▁that", + "▁Taxol /carboplatin", + "REAT MENTS", + "▁Disease▁ Progression", + "Kaplan-Meier ▁method", + "▁action ▁taken", + "ed▁through ▁the▁IVRS", + "consist s▁of", + "omagnes aemia", + "eh renbacher", + "▁Oxaliplatin /", + "ulti- center", + "▁serum▁creatinine▁ concentration▁in", + ",▁the▁patient ▁will▁be▁", + "▁locally ▁advanced▁or▁metastatic", + "site▁personnel ▁must", + "▁match ed▁placebo", + "BJECTIVES ▁........................................................................................................", + "revers ible▁", + "prob ability▁of", + "duration▁of▁ respons", + "▁regular ly▁", + "▁box ▁number", + "while▁on ▁study", + "▁ANC ▁<", + "▁wher e▁the▁", + "portional▁ hazard▁", + "▁a▁minimum ▁of▁", + ",▁randomized,▁ multicenter", + "progressive▁disease▁ will▁be▁", + ".▁Pre valence▁of", + "VERSE▁EV ENTS", + "▁6▁week s▁after", + "▁modified▁ RECIST", + "▁phase▁III ▁trial", + "▁characteristic s▁of", + "System s▁", + "iagnos is▁of", + ".\n\nK▁C▁E▁H▁C \n\nE▁S▁A▁E▁L▁P", + ".\n\nK▁C▁E▁H▁C \n\nE▁S▁A▁E▁L▁P\n\n.▁T▁N▁E▁M▁U▁C▁O▁D", + "study▁is▁ designed▁to", + "adverse▁ effects▁of", + ".▁The▁t otal", + "have▁a ▁causal▁relationship▁with", + "▁deterior ation▁of", + "alp it", + "▁of▁denosumab ▁with▁zoledronic▁acid▁", + "BPI- sf", + "▁measure d▁", + "objectives ▁are▁to", + "▁specifi ed▁", + "uls e▁", + "ed▁only▁ if", + "▁Central▁ Tumor▁Response▁", + "applicable▁ law", + "analysis▁will▁be▁ censored▁using▁the▁last▁available▁", + "e▁sign ature", + "comparison ▁of", + "Sub cutaneous▁", + "▁responsible▁for ▁the▁", + ")▁is▁defined▁as ▁the▁time▁from", + "ropoi etic", + "(9 ):▁p.▁", + "member s▁of", + "▁satis fied▁with", + "▁transient ▁is", + "▁how ▁to", + "Target▁Lesion s▁", + "▁tra uma", + "status▁of ▁that▁particular", + "▁anx iet", + "▁becomes▁ pregnant", + "wors ening", + "▁or▁its▁design e", + "effect▁of ▁AMG▁162", + "▁I.V .▁(or▁equivalent", + "preserv ative▁", + "effect▁of▁ZD4054 ▁on", + "International▁Conference▁on▁Harmon ization", + "Us e▁of", + "most▁recent ▁chemotherapy▁regimen", + "examethason e,▁", + "]▁and▁ dependent▁children", + "appearance▁of▁all ▁non-target▁lesion", + "▁on▁day▁1 ▁of▁cycles▁", + "discover ies", + ".A .,▁et▁al.,▁", + "Study ▁to", + "eline▁ on", + "ramuscular ▁Intravenous▁", + "aterials▁and▁ Methods:", + "▁authoriz ed▁to", + ".▁Report ing", + "▁poss ibility▁that", + "eleph one:", + "\n\nPer cent", + "▁some▁cas es,▁", + "Is ▁there▁a", + "romb ocytopenia", + "estimated▁to ▁be▁", + " ", + "forward ed▁to", + "▁Toxic ities▁", + "ohistochemistry▁ (IHC", + "▁the▁level ▁of", + "\n\nAdd▁5 ,6", + "\n\nl\n\na ▁c", + "FF PE", + "s▁(CTCAE )", + "one▁scintigraph y▁", + "▁2008; ▁83:", + "ermat ology", + "/S kin", + "correlation ▁between", + "ation▁of▁Addendum ▁9", + "▁suit ability▁for▁accurate▁", + "▁supportive▁care▁ al", + "ella▁D F", + "▁Drug▁Substance▁AZD2171▁Study▁Code▁D8480C00013▁Appendix▁Edition▁Number ▁1.0▁Appendix▁Date▁", + "unused▁ portion", + "ince▁your▁last ▁visit", + "gel ▁capsul", + "resid ual▁", + ".\n\nCom mon", + "▁difference▁ between", + "▁taking▁as▁reference▁the▁ nadir", + "-minut e▁infusion", + "▁mass es▁that▁are▁not▁confirmed", + "▁the▁potential▁ for", + "signed▁and▁ personally▁dat", + "▁assigned▁ study▁treatment", + "\n\nEvalu ation▁of", + "respiratory▁ rat", + "displayed▁graph ically▁", + "odd s▁", + "e▁definition ▁in▁Section▁4.7.1.1", + "▁performed▁at ▁this▁time▁point", + "▁Activ ities", + "▁(mL/min )\n\n", + "▁Head▁and▁Neck ▁Cancer", + "/omega-3 ▁ratio", + "mac or", + "utopsy▁ report", + "therton ▁PM", + "omega-6 /omega-3▁ratio", + "▁to▁prevent▁one▁of▁the▁ outcomes▁", + "offered▁ open-label▁denosumab", + "elih ood", + "▁laborator y▁and▁", + "▁demonstrating ▁a▁significant", + "▁demonstrate▁a ▁statistically▁significant", + ".▁Compar ison▁of", + "orld▁Health ▁Organization", + "pG▁is land▁", + "CONFIDENTIAL \n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁PANITUMUMAB▁(AMG▁954)▁Protocol▁Number:▁20040249▁Date:▁07▁August▁2007\n\nPage▁", + "▁and▁post- study▁treatment", + "\n\n(continued)\n\n H3E-MC-JM", + "▁will▁be▁censored▁at▁the▁date▁of▁the▁last ▁objective▁progression-free▁disease▁assessment", + "-E therton▁PM", + "jun ctiv", + "▁31,▁ 2010", + ",▁Wol f", + "eplacement▁of ▁Subject", + ".▁The▁investigator▁should▁notify▁the▁ IEC/IRB", + "s▁-▁Other ▁(", + "\n\nFully▁active, ▁able▁to▁carry▁on", + "active▁Voice▁Response▁System ▁(IVRS", + "▁Practic e▁Guidelin", + "▁(Z ubrod", + "▁MED IC", + "▁rank ▁test", + "▁adverse▁event▁report s▁receiv", + "▁applicable▁sit es▁of", + "▁Access ed▁March", + "randomly ▁assigned▁to", + "ERIO US", + "▁lost ▁to▁follow-up", + ".▁Har v", + "\n\nCompletely▁disabled.▁Cannot ▁carry▁on▁any▁s", + "▁ambulatory▁and▁able▁to▁carry▁out ▁work▁of▁a▁light▁or▁sedentary▁nature,▁", + "▁and▁last s▁approximately▁30", + "▁20020408▁Amendment▁4 \n\nPage▁", + "▁FF PE", + "▁signs▁the▁ consent", + "▁evaluate▁t ime▁to", + "ROQOL ▁EQ-5D", + "▁local▁institutional▁practic e),▁", + "▁survival▁pro b", + "IGNA T", + "▁person▁who ▁signs▁the▁consent", + "▁of▁5▁lesions▁per▁organ ▁and▁10", + "chest,▁abdomen,▁and▁p elvis", + "▁Applicable▁ (NA", + "olysorb ate▁", + "▁unable▁to▁carry▁out▁any▁work▁activities.▁Up▁and▁about ▁more▁than▁50%▁of▁waking▁hour", + ".▁Mayo▁Clin▁Proc ▁2008;▁83:", + "▁2▁Appendix▁Date▁ 7▁September▁2007", + "e▁the▁dose▁by▁ 1▁level", + "▁F▁Drug▁Substance▁AZD2171▁Study▁Code▁D8480C00013▁Appendix▁Edition▁Number ▁2▁Appendix▁Date▁7▁September▁2007", + "s▁in▁walk ing▁about", + "RATOR Y", + "s▁with▁performing ▁my▁", + "▁must▁personally▁ enter", + "▁by▁imaging▁techniqu es▁or", + "▁document▁their▁review ▁of▁each▁laboratory▁", + "▁compare▁the▁treatment▁effect ▁of▁denosumab▁with▁zoledronic▁acid▁", + ".▁Kris -Etherton▁PM", + "status▁of▁that▁particular ▁tumor▁for", + "▁masses▁that▁are▁not▁confirmed ▁and▁followed▁by▁", + "▁document▁their▁review▁of▁each▁laboratory▁ report", + "▁compare▁the▁treatment▁effect▁of▁denosumab▁with▁zoledronic▁acid▁ on", + "( T", + ") .▁This", + ", ▁to▁the▁", + ", ▁approximately▁", + ", ▁through", + ", ▁according▁to", + ", ▁time▁to", + ", ▁the▁data", + ", ▁assum", + ", ▁thrombocytopenia", + "- resistant", + ". B", + "/ U", + "/ week", + "0 .05", + "1 18", + "1 )\n\nIf", + "3 1)", + ": ▁E", + ": ▁H", + ": 19", + ": 23", + ": ▁Th", + "; ▁the▁", + "A braxis", + "B AP", + "C ochran-Mantel-Haenszel", + "D etermination", + "E arly▁", + "G 4PFS", + "J ournal▁of", + "M easurement", + "M utant", + "M -CSF", + "N on", + "O c", + "O RING", + "Q 2-week", + "R L", + "S erum", + "S election", + "S ubling", + "T D", + "T otal▁", + "V -", + "] )▁and▁", + "a ▁N", + "a ▁R", + "b ad", + "b ilirubin", + "b ecome▁", + "c is", + "c ast", + "c ough", + "c andid", + "d am", + "e al▁", + "f ing", + "f raction", "g lob", - "▁F rid", - "▁Fr id", - "▁Fri d", - "▁T err", - "▁Te rr", - "▁Ter r", - "▁Re lease", - "▁ Release", - "Brain z", - "▁гра ф", - "▁ граф", - "DI S", - "D IS", - "compat ible", - "▁po č", - "LI N", - "L IN", - "▁K ällor", - "▁A rizona", - "pp y", - "p py", - "Se q", - "S eq", - "▁A in", - "▁T ourn", - "▁To urn", - "▁Tour n", - "br ow", - "bro w", - "b row", - "▁K ör", - "▁Kö r", - "▁a sh", - "▁as h", - "▁ ash", - "ogene ous", - "▁dia lect", - "▁насе ља", - "mysql i", - "mysq li", - "цо в", - "ц ов", - "▁f lor", - "▁fl or", - "▁flo r", - "▁ф ло", - "IA B", - "I AB", - "▁With in", - "▁Wit hin", - "^ (", - "▁b ois", - "▁bo is", - "▁t ank", - "▁tan k", - "▁aff ili", - "▁h ijo", - "▁hij o", - "▁hi jo", - "▁K ate", - "▁Kat e", - "▁Ka te", - "▁Ver l", - "▁Ve rl", - "▁M iami", - "▁Mi ami", - "▁type script", - "▁types cript", - "њ у", - "▁V ern", - "▁Ver n", - "▁Ve rn", - "▁ви со", - "ie mann", - "iem ann", - "i emann", - "▁co verage", - "▁cover age", - "br ie", - "b rie", - "▁Start ing", - "▁Star ting", - "num py", - "▁J enkins", - "▁Jen kins", - "▁k ét", - "▁ké t", - "▁g rup", - "▁gr up", - "▁gru p", - "▁S cient", - "▁Sc ient", - "▁Sci ent", - "▁inter rupt", - "▁b lob", - "▁bl ob", - "▁blo b", - "▁ blob", - "ug el", - "uge l", - "u gel", - "▁Or th", - "▁Ort h", - "ab ama", - "aba ma", - "▁B apt", - "▁Ba pt", - "ow nik", - "own ik", - "▁бы ть", - "▁Jul ius", - "▁Ju lius", - "▁Juli us", - "▁П рез", - "▁Пре з", - "▁subst itute", - "support ed", - "supp orted", - "ch y", - "c hy", - "egy zetek", - "▁Per formance", - "▁Perform ance", - "less ly", - "Con structor", - "▁ext ending", - "▁extend ing", - "▁Mus lim", - "Over flow", - "▁J enn", - "▁Je nn", - "▁Jen n", - "▁produ z", - "▁prod uz", - "мі ї", - "м ії", - "▁país es", - "▁e ux", - "▁eu x", - "▁f ate", - "▁fa te", - "▁fat e", - "ol oge", - "olog e", - "olo ge", - "у к", - "▁wo bei", - "▁wob ei", - "▁S achsen", - "▁Sach sen", - "▁са йт", - "▁сай т", - "Mod els", - "Model s", - "Mode ls", - "▁F ast", - "▁Fa st", - "bes ondere", - "▁F R", - "▁ FR", - "▁a con", - "▁ac on", - "▁ acon", - "▁Den kmal", - "▁an ch", - "▁anc h", - "▁ anch", - "▁públic o", - "▁T as", - "▁Ta s", - "▁c and", - "▁can d", - "▁ca nd", - "▁pa ździer", - "▁М он", - "▁Мо н", - "▁vers us", - "ru t", - "r ut", - "G T", - "▁insert ing", - "▁inser ting", - "▁can ad", - "▁ca nad", - "є м", - "▁M etro", - "▁Met ro", - "▁Herz og", - "Ign ore", - "▁decre ase", - "▁п ун", - "▁пу н", - "▁F ischer", - "▁M all", - "▁Ma ll", - "▁Mal l", - "▁n örd", - "io stream", - "i ostream", - "▁Lux emb", - "pay load", - "▁Ze itung", - "▁Zeit ung", - "▁mod ifying", - "▁modify ing", - "▁C her", - "▁Ch er", - "▁Che r", - "▁Lu ci", - "▁Luc i", - "n x", - "▁lo ose", - "▁top ics", - "▁topic s", - "▁var ied", - "▁vari ed", - "▁va ried", - "▁p g", - "▁ pg", - "aj es", - "aje s", - "a jes", - "um m", - "u mm", - "View s", - "▁B eau", - "▁Be au", - "MA P", - "M AP", - "ip eline", - "ipe line", - "▁Inter est", - "ar ith", - "ari th", - "▁seg ún", - "▁Geme ins", - "▁Att ribute", - "▁ Attribute", - "comm unity", - "▁цент р", - "▁kil ometer", - "▁kilomet er", - "▁kilom eter", - "▁é conom", - "▁éc onom", - "lar ation", - "▁к ъ", - "▁car riage", - "▁carri age", - "▁L ane", - "▁La ne", - "▁Lan e", - "▁не об", - "ku r", - "k ur", - "▁A F", - "▁ AF", - "IN TER", - "INT ER", - ")) $", - ") )$", - "▁be ide", - "▁bei de", - "dest ination", - "▁font s", - "▁fon ts", - "▁ fonts", - "append Child", - "▁M AR", - "▁MA R", - "▁g ay", - "▁ga y", - "mi l", - "m il", - "le sh", - "les h", - "l esh", - "è t", - "▁W ang", - "▁Wa ng", - "▁Y ears", - "▁Year s", - "▁Ye ars", - "▁S ymbol", - "▁Sym bol", - "▁ Symbol", - "Li ve", - "L ive", - "qu ency", - "▁U sers", - "▁Use rs", - "▁User s", - "▁Us ers", - "▁ Users", - "▁Un icode", - "▁S au", - "▁Sa u", - "▁t ons", - "▁to ns", - "▁ton s", - "▁ tons", - "▁Н і", - "▁кра ї", - "▁ краї", - "AX I", - "▁P ick", - "▁Pi ck", - "▁Pic k", - "A I", - "▁h ath", - "▁ha th", - "▁hat h", - "▁a inda", - "▁ain da", - "▁p apa", - "▁pa pa", - "▁pap a", - "▁C enso", - "▁B ald", - "▁Ba ld", - "▁Bal d", - "▁Насе ље", - "▁sim ulations", - "▁simulation s", - "▁j aren", - "▁ja ren", - "▁jar en", - "▁inher ited", - "▁inherit ed", - "▁то й", - "▁ той", - "▁fe els", - "▁feel s", - "▁fee ls", - "ress ion", - "r ession", - "▁o któber", - "bi d", - "b id", - "ás i", - "á si", - "▁m uss", - "▁mus s", - "▁mu ss", - "vent ory", - "▁me ist", - "▁b ore", - "▁bo re", - "▁bor e", - "▁sl ider", - "▁slide r", - "▁sli der", - "▁ slider", - "де ли", - "\\ ;", - "▁extra cted", - "▁extract ed", - "ку р", - "к ур", - "Ed ge", - "▁per f", - "▁pe rf", - "▁Brig ade", - "▁гра д", - "▁ град", - "ie nie", - "ien ie", - "i enie", - "▁N orden", - "▁Nor den", - "▁Nord en", - "▁c ancer", - "▁can cer", - "\" /", - "C ur", - "▁С ере", - "▁Се ре", - "▁Сер е", - "▁liqu id", - "str ucture", - "struct ure", - "▁cho osing", - "▁Per l", - "▁Pe rl", - "Si de", - "S ide", - "ü s", - "ри тор", - "рито р", - "рит ор", - "▁k ost", - "▁ko st", - "▁pa ckets", - "▁pack ets", - "▁packet s", - "▁кото рого", - "▁Com un", - "▁Co mun", - "▁f ingers", - "▁fin gers", - "▁finger s", - "ográ fica", - "> :", - "▁champion nat", - "▁bl ieb", - "▁S itu", - "▁Si tu", - "▁Sit u", - "▁su ic", - "an dis", - "and is", - "Fr e", - "F re", - "▁C onc", - "▁Con c", - "▁Co nc", - "▁re public", - "▁rep ublic", - "▁repub lic", - "▁ar med", - "▁arm ed", - "▁h ell", - "▁he ll", - "▁hel l", - "▁ hell", - "▁h ög", - "▁hö g", - "rag ma", - "▁en se", - "▁ens e", - "▁ ense", - "▁ac res", - "▁В ід", - "▁Ві д", - "▁Re form", - "▁Ref orm", - "Main Activity", - "ke eper", - "keep er", - "kee per", - "er b", - "e rb", - "▁mon aster", - "sub subsection", - "▁Ди в", - "▁cre ature", - "▁indic ating", - "▁url s", - "▁ur ls", - "▁ urls", - "▁k ein", - "▁ke in", - "об раз", - "обра з", - "pi ck", - "pic k", - "p ick", - "▁Ad mir", - "▁old est", - "▁ol dest", - "▁m uz", - "▁mu z", - "▁contra diction", - "▁contrad iction", - "▁contradict ion", - "▁prob abil", - "illi ant", - "▁p av", - "▁pa v", - "▁pa pel", - "▁pap el", - "ub s", - "u bs", - "▁ж ена", - "▁же на", - "▁жен а", - "▁ жена", - "AM L", - "A ML", - "▁re cip", - "▁rec ip", - "▁reci p", - "▁C OL", - "▁CO L", - "▁ COL", - "ad ded", - "add ed", - "▁cl ue", - "▁Uk raine", - "▁Ukrain e", - "▁jel ent", - "че нь", - "чен ь", - "ч ень", - "▁mathemat ics", - "Ac cept", - "▁с от", - "▁со т", - "▁се вер", - "▁isol ated", - "▁по я", - "w ür", - "Ro uter", - "Route r", - "Rout er", - "R outer", - "CA T", - "C AT", - "rg b", - "r gb", - "▁L ov", - "▁Lo v", - "mu table", - "mut able", - "m utable", - "▁W es", - "▁We s", - "▁Ital ien", - "Dra g", - "Dr ag", - "D rag", - "en ium", - "eni um", - "at ting", - "att ing", - "atti ng", - "tc p", - "t cp", - "▁erfolg te", - "▁Be it", - "▁Bei t", - "га то", - "▁System s", - "▁Syst ems", - "▁re serve", - "▁res erve", - "er ee", - "ere e", - "e ree", - "▁Па ри", - "▁Пар и", - "▁з али", - "▁за ли", - "▁re nt", - "▁r ent", - "▁ren t", - "▁ rent", - "▁s unt", - "▁su nt", - "▁sun t", - "▁G irls", - "▁Girl s", - "▁Gir ls", - "▁Er nest", - "▁Ern est", - "▁f its", - "▁fi ts", - "▁fit s", - "▁op pon", - "▁opp on", - "▁живе ло", - "▁av aient", - "▁Flor ence", - "▁Flo rence", - "▁чи сле", - "▁eng ines", - "▁engine s", - "D ynamic", - "▁stycz nia", - "▁b ias", - "▁bi as", - "▁Ex change", - "ди й", - "▁histor iques", - "▁historique s", - "▁H ä", - "ho d", - "h od", - "▁w ł", - "sch ap", - "▁l ac", - "▁la c", - "▁ lac", - "▁F oi", - "▁Fo i", - "▁d well", - "▁dw ell", - "▁Unter nehmen", - "UR N", - "▁kilomet res", - "▁Одна ко", - "к ли", - "▁S ri", - "▁Sr i", - "Gr oups", - "Group s", - "min d", - "mi nd", - "m ind", - "os lov", - "fer n", - "fe rn", - "f ern", - "eg u", - "e gu", - "abel ed", - "abe led", - "F iddle", - "▁Cent ury", - "/ -", - "▁J egyzetek", - "He n", - "H en", - "ens emble", - "▁G ut", - "▁Gu t", - "_{ {\\", - "_ {{\\", - "▁ran king", - "▁rank ing", - "+ $", - "ал а", - "а ла", - "▁# {", - "▁ #{", - "im ientos", - "imiento s", - "ach im", - "ac him", - "achi m", - "ri des", - "ride s", - "rid es", - "r ides", - "▁K laus", - "▁Kl aus", - "▁int end", - "▁inte nd", - "▁inten d", - "▁Kent ucky", - "ci pe", - "cip e", - "c ipe", - "▁D ienst", - "▁Di enst", - "▁situ ated", - "▁pó ź", - "▁s crit", - "▁sc rit", - "▁scr it", - "▁scri t", - "cl ip", - "cli p", - "c lip", - "не т", - "н ет", - "ta bles", - "table s", - "tab les", - "t ables", - "▁N ied", - "▁Ni ed", - "▁Nie d", - "▁Mc K", - "▁pow st", - "▁kun nen", - "▁Ev ans", - "▁Eva ns", - "ж ды", - "ва ть", - "ват ь", - "uch ar", - "uc har", - "ucha r", - "u char", - "▁res idents", - "▁resid ents", - "▁resident s", - "ia k", - "i ak", - "▁Re sol", - "▁Res ol", - "▁ Resol", - "▁ve ces", - "▁vec es", - "▁satisf ying", - "▁satisfy ing", - "IN F", - "I NF", - "▁с ин", - "▁си н", - "▁cross ing", - "ib en", - "ibe n", - "i ben", - "▁ши ро", - "pt o", - "p to", - "IL L", - "I LL", - "▁ро ль", - "▁a ktiv", - "▁akt iv", - "▁обра щения", - "Wik ispecies", - "▁Hö he", - "cr o", - "c ro", - "══ ══", - "al tra", - "alt ra", - "▁FI LE", - "▁ FILE", - "▁u ps", - "▁up s", - "▁ ups", - "▁al location", - "▁all ocation", - "▁alloc ation", - "▁allo cation", - "Mich ael", - "▁acknow led", - "Lin ux", - "▁met ros", - "▁ metros", - "tt e", - "t te", - "af en", - "a fen", - "▁x code", - "▁тра ди", - "spe cies", - "spec ies", - "s pecies", - "��inj ury", - "▁са мы", - "▁сам ы", - "▁l attice", - "M aterial", - "and enburg", - "anden burg", - "▁huvud staden", - "st ory", - "sto ry", - "stor y", - "▁var ying", - "▁vary ing", - "▁kö vet", - "▁Росси йской", - "ir se", - "irs e", - "▁d rum", - "▁dr um", - "▁dru m", - "Pr essed", - "Press ed", - "Pres sed", - "La r", - "L ar", - "▁A gu", - "▁Ag u", - "▁w eil", - "▁we il", - "▁comm ence", - "▁Seg ún", - "Gest ure", - "Sh ape", - "S hape", - "▁V ors", - "▁Vo rs", - "▁Vor s", - "▁succ ès", - "▁correct ed", - "▁corre cted", - "▁corr ected", - "K ar", - "▁cr uel", - "▁cru el", - "▁polit ico", - "▁Schrift steller", - "▁ris ult", - "et u", - "e tu", - "arch iv", - "▁gén ero", - "▁gé nero", - "▁L ü", - "▁tri umph", - "OR S", - "O RS", - "L u", - "▁person nel", - "▁personn el", - "▁personne l", - "▁H ills", - "▁Hill s", - "▁Hil ls", - "as set", - "ass et", - "asse t", - "do min", - "dom in", - "d omin", - "Rece ive", - "▁O ak", - "▁K no", - "▁Kn o", - "▁The ory", - "ir ie", - "iri e", - "i rie", - "ow an", - "owa n", - "o wan", - "▁est ava", - "▁esta va", - "▁exec utes", - "▁execute s", - "▁execut es", - "й т", - "óp ez", - "ó pez", - "по ло", - "пол о", - "п оло", - "ét ica", - "▁назва ние", - "▁conver ges", - "▁not re", - "▁no tre", - "▁pop ulated", - "▁popula ted", - "▁popul ated", - "▁populate d", - "▁mov ements", - "▁move ments", - "▁movement s", - "▁statist ical", - "▁Zwe iten", - "qu in", - "qui n", - "▁import antes", - "▁important es", - "▁importante s", - "▁k lein", - "▁kle in", - "▁kl ein", - "▁Seg unda", - "schließ end", - "Fail ure", - "na r", - "n ar", - "da g", - "d ag", - "▁ru olo", - "▁f iction", - "▁fi ction", - "▁fic tion", - "▁fict ion", - "▁исполь зу", - "▁cr isis", - "▁Get ting", - ", %", - "▁ар мии", - "▁cam pus", - "▁camp us", - "▁fo oter", - "▁foot er", - "▁foo ter", - "▁ footer", - "▁d ías", - "▁día s", - "▁dí as", - "ба н", - "б ан", - "▁liber ty", - "▁libert y", - "▁g h", - "▁ gh", - "▁cham ber", - "▁district s", - "▁exc ited", - "▁can ción", - "ter o", - "te ro", - "t ero", - "▁Work ing", - "▁Wor king", - "▁czę ści", - "ль ный", - "▁f orum", - "▁for um", - "▁fo rum", - "▁ forum", - "▁E he", - "▁ка та", - "▁ ката", - "it ations", - "itation s", - "itat ions", - "To ols", - "Tool s", - "T ools", - "ach iv", - "achi v", - "▁c res", - "▁cre s", - "▁cr es", - "as to", - "ast o", - "a sto", - "▁re ver", - "▁r ever", - "▁rev er", - "▁reve r", - "▁n azionale", - "▁naz ionale", - "▁do ors", - "▁door s", - "▁N ancy", - "▁Nan cy", - "▁is lands", - "▁island s", - "Im p", - "I mp", - "▁Ch air", - "▁Cha ir", - "▁v orm", - "▁vo rm", - "▁vor m", - "se in", - "s ein", - "▁до ку", - "er set", - "ers et", - "▁tät ig", - "▁K rit", - "▁Kr it", - "▁п я", - "▁cons ervation", - "▁conserv ation", - "▁Part ido", - "▁Parti do", - "min ipage", - "Valid ator", - "▁rec overy", - "▁recover y", - "▁NA SA", - "▁NAS A", - "▁br east", - "▁bre ast", - "il ty", - "ilt y", - "an aly", - "ana ly", - "anal y", - "el ines", - "eli nes", - "eline s", - "elin es", - "e lines", - "▁S aturday", - "em ark", - "e mark", - "ce j", - "c ej", - "Ze ro", - "Z ero", - "▁Tur ner", - "▁Turn er", - "sec ure", - "Ex ists", - "▁R ick", - "▁Ric k", - "▁Ri ck", - "ev alu", - "eval u", - "e valu", - "ct rl", - "ctr l", - "c trl", - "▁com pression", - "▁comp ression", - "▁compr ession", - "▁compress ion", - "▁C URL", - "text color", - ")\\ ,", - ") \\,", - "long rightarrow", - "▁Fern seh", - "▁ Fernseh", - "ic ha", - "ich a", - "i cha", - "▁l oi", - "▁lo i", - "▁О те", - "▁От е", - "▁c ave", - "▁ca ve", - "▁cav e", - "▁do zen", - "▁expla ining", - "▁expl aining", - "▁explain ing", - "▁in nov", - "▁inn ov", - "▁Nich olas", - "▁dia meter", - "▁diam eter", - "▁M arian", - "▁Mar ian", - "▁Ma rian", - "▁Maria n", - "▁Mari an", - "▁f ires", - "▁fire s", - "▁fi res", - "▁fir es", - "▁art ifact", - "▁ artifact", - "▁Par ker", - "▁Park er", - "▁B und", - "▁Bu nd", - "▁Bun d", - "▁v erte", - "▁ver te", - "▁vert e", - "▁ verte", - "▁tal ent", - "▁tale nt", - "▁Lu cas", - "▁Luc as", - "re verse", - "▁folg enden", - "▁S ah", - "▁Sa h", - "ject ions", - "je ctions", - "jection s", - "▁inve ce", - "▁cost itu", - "▁s sl", - "▁ss l", - "▁ ssl", - "}} ^", - "} }^", - "▁viol ent", - "▁s pos", - "▁sp os", - "▁spo s", - "Ro ut", - "R out", - "jd k", - "j dk", - "▁за ме", - "▁f urent", - "▁fur ent", - "▁fu rent", - "an dal", - "and al", - "anda l", - "H om", - "▁Sen ior", - "▁p ounds", - "▁Disc ogs", - "▁з е", - "▁ зе", - "'} [", - "' }[", - "▁Napole on", - "ordin ates", - "ordinate s", - "à n", - "▁k urz", - "▁kur z", - "▁v ere", - "▁ver e", - "▁ve re", - "▁ vere", - "▁re use", - "▁Г ен", - "▁Ге н", - "▁S yst", - "▁Sy st", - "▁disapp eared", - "▁disappear ed", - "▁W atch", - "▁Wat ch", - "▁ Watch", - "bibli othek", - "▁кор пу", - "▁C s", - "▁} `", - "▁ }`", - "▁r ör", - "▁де ла", - "▁ дела", - "V B", - "▁calcul us", - "▁calc ulus", - "ро да", - "род а", - "▁jud gment", - "at ile", - "ati le", - "▁long ue", - "▁lon gue", - "▁H us", - "▁Hu s", - "J ac", - "}} )", - "} })", - "RI PT", - "IAB ot", - "▁ap ós", - "▁a ston", - "▁as ton", - "▁ast on", - "Web achiv", - "▁URL s", - "▁co at", - "▁э коно", - "▁l ear", - "▁le ar", - "▁ lear", - "ext ensions", - "extension s", - "▁Class ic", - "T I", - "▁T age", - "▁Tag e", - "▁Ta ge", - "▁l á", - "▁ lá", - "▁s emb", - "▁se mb", - "▁sem b", - "▁développ ement", - "IS TS", - "IST S", - "▁sol ves", - "▁solve s", - ",\\ ,", - ", \\,", - "▁чем пі", - "ord inary", - "ordin ary", - "▁B av", - "▁Ba v", - "▁much os", - "▁mu chos", - "▁mucho s", - "S elf", - "▁Ма й", - "▁D iet", - "▁Die t", - "▁Di et", - "▁necess ity", - "ві д", - "в ід", - "▁m ano", - "▁ma no", - "▁man o", - "▁С р", - "▁car re", - "▁Cam era", - "▁Camer a", - "▁ Camera", - "▁N arod", - "▁Na rod", - "▁Nar od", - "▁Ph one", - "▁Pho ne", - "▁ Phone", - "▁pol ym", - "▁poly m", - "im ore", - "imo re", - "i more", - "is Empty", - "▁Hou ston", - "▁Re ce", - "▁Rec e", - "▁ Rece", - "▁present ation", - "▁pres entation", - "▁presenta tion", - "▁ presentation", - "ни ципа", - "ници па", - "▁D b", - "▁ Db", - "▁conf ident", - "▁} {", - "▁ }{", - "▁bul let", - "▁ bullet", - "▁{ },", - "▁{} ,", - "AN GE", - "ANG E", - "▁No tre", - "▁Not re", - "ch in", - "chi n", - "c hin", - "▁Dr agon", - "▁Drag on", - "▁Dra gon", - "er ca", - "erc a", - "ia li", - "ial i", - "i ali", - "▁as set", - "▁ass et", - "▁asse t", - "▁ asset", - "▁mu ito", - "▁muit o", - "▁deep ly", - "▁rest riction", - "▁restrict ion", - "▁com merce", - "▁commer ce", - "▁ commerce", - "▁B omb", - "▁Bo mb", - "▁Bom b", - "c aught", - "q q", - "▁A rag", - "▁Ar ag", - "▁Ara g", - "▁не мец", - "▁Anal ysis", - "▁člán ku", - "▁b aby", - "▁ba by", - "▁e chter", - "▁о дного", - "▁од ного", - "▁одно го", - "же на", - "жен а", - "ж ена", - "▁white space", - "��whites pace", - "ç u", - "LI ST", - "L IST", - "fr ique", - "fri que", - "f rique", - "▁v arias", - "▁var ias", - "▁vari as", - "▁va rias", - "▁W it", - "▁Wi t", - "▁Lic encia", - "Ex it", - "▁sie rp", - "▁sier p", - "▁ass emb", - "▁asse mb", - "▁split ting", - "▁spl itting", - "▁pa lace", - "▁pal ace", - "▁b locked", - "▁block ed", - "▁bound aries", - "▁iter ations", - "▁iteration s", - "▁Rot ten", - "▁Ver kehr", - "▁we er", - "Test s", - "T ests", - "if ting", - "ift ing", - "▁reg ul", - "▁pers ist", - "▁Sol ution", - "p b", - "▁col lapse", - "▁ collapse", - "▁arr ested", - "▁arrest ed", - "▁pred icate", - "▁Z one", - "▁Zo ne", - "▁ Zone", - "▁in gen", - "▁ing en", - "▁ ingen", - "zá lez", - "▁b anks", - "▁bank s", - "▁ban ks", - "pl ant", - "plan t", - "pla nt", - "p lant", - "▁N ella", - "▁Ne lla", - "▁Nel la", - "▁Nell a", - "▁б ан", - "▁ба н", - "▁ бан", - "▁S now", - "▁Sn ow", - "▁Kre uz", - "í cio", - "▁en ters", - "▁ent ers", - "▁enter s", - "▁ex pose", - "▁exp ose", - "▁expos e", - "č i", - "ши е", - "Qu al", - "Q ual", - "▁lands cape", - "▁пода цима", - "ma i", - "m ai", - "st ag", - "sta g", - "s tag", - "ова ний", - "DE F", - "D EF", - "[] {", - "[ ]{", - "▁derni ère", - "ic ut", - "i cut", - "▁X ml", - "▁ Xml", - "▁sub group", - "▁Pol sce", - "▁W arning", - "▁War ning", - "▁ Warning", - "▁veh icles", - "▁vehicle s", - "io t", - "i ot", - "▁d ll", - "▁ dll", - "ro nt", - "ron t", - "r ont", - "▁Lou ise", - "▁Louis e", - "▁a ra", - "▁ar a", - "▁ ara", - "▁S cala", - "▁Sc ala", - "▁canon ical", - "▁pl acing", - "▁pla cing", - "ER Y", - "E RY", - "▁J ag", - "▁Ja g", - "▁v irus", - "▁vi rus", + "g emcitabin", + "h CG", + "j oint", + "l eptomeningeal", + "m CRC", + "m utant", + "o on", + "o eb", + "p plicable▁", + "p ackage▁insert", + "p aper", + "p attern", + "r ill", + "r incip", + "s per", + "s ▁also", + "s ▁act", + "s ide▁", + "s ............................................................................", + "s ▁are\n\n", + "u i", + "u al▁pro", + "u NTx", + "w ound▁", + "w orld", + "z ak", + "α =0", + "” ,▁“", + "≥ ▁2", + "▁ earli", + "▁ even▁if", + "▁ ............................................................", + "in struction", + "▁t ▁i", + "at ▁weeks▁", + "\n\n J", + "\n\n \n\nS", + "\n\n data", + "\n\n each", + "\n\n management", + "▁a verage▁", + "▁a void", + "en larg", + "er op", + "or ▁p", + "or ▁for", + "s▁ 1,▁", + "s▁ cannot▁be▁", + "re ject", + "re calculated▁", + "▁th roat", + "al s", + "al ▁and▁", + "st rom", + "st ated▁", + "st atic", + "it es▁", + "it arget", + "▁the▁ E", + "▁the▁ assessment", + "an ▁K", + ",▁ >", + ",▁ X", + ",▁ discontinu", + ",▁ cisplatin", + ",▁ using▁the▁", + ",▁ EGFR", + ",▁ reduc", + ",▁ second▁", + ",▁ ±▁3▁days", + "ro ad▁", + "ed▁ log", + "ed▁ vial", + "ed▁ Dos", + "ed it", + "ed ical▁", + "ed .▁F", + "ed ▁and▁the▁", + "ed ▁assessments▁will▁be▁", + "▁c apacity", + "▁c umulative▁", + "ing ▁m", + "ing ▁investigator", + "es ▁the▁s", + "for ▁any▁", + "▁to ▁3", + "▁to ▁perform", + "▁to ▁bone▁", + "▁to ▁help", + "▁to ▁check", + "▁to ▁whom", + "▁s id", + "▁s ec", + "▁s atur", + "▁s keletal", + "▁of ▁Casodex", + "th ose▁", + "▁m urine▁", + "▁and▁ 11", + "▁and▁ enter", + "▁and▁ cancer", + "▁and▁ follow-up", + "▁and▁ calcium", + ".\n\n With", + ".\n\n 22", + "el z", + "ab solute▁neutrophil▁count", + "▁A ppro", + "▁A UT", + "▁A SSESSMENTS", + "▁be▁ evaluated▁leading▁to", + "iv es,▁", + "▁in ▁NSCLC", + "▁in ▁the▁treatment▁of", + "▁in stanc", + "im pa", + "id e▁by", + "▁C J", + "ac crual", + "ac compani", + "es▁ at", + "es▁ without", + "▁P ost", + "▁P roduct:", + "▁P opulation", + "▁P roscribed▁", + "il k", + "▁( an", + "▁( 11", + "▁( SC", + "▁( by▁", + "▁( panitumumab", + "▁( except", + "▁( weight", + "▁( other▁than", + "▁( e.g.▁", + "▁( i.e.▁", + "▁2 +", + "ul ated▁in", + "ul in-", + "con cent", + "ra uterine▁", + "▁S P", + "▁S S", + "▁S ubjects▁who", + "▁re start", + "▁re veal", + "ot e▁", + "ag e/", + "▁D E", + "▁D one▁(", + "cl ine▁", + "ri ef▁Pain▁Inventory▁–▁S", + "▁h epat", + "▁h appen", + "▁l isting", + "▁l ater", + "▁l iter", + "e▁of ▁the▁patient", + "▁E ffect", + "▁f et", + "▁f ast", + "▁f easibl", + "ch i", + "▁or ▁PD", + "▁or ▁the▁sponsor", + "ir e▁(", + "ir regular", + "ys p", + "form al▁", + "\n\nP emetrexed▁", + "\n\nP artial▁", + "▁n utrient", + "per ▁treatment▁arm", + "study▁ visit", + "▁and ▁approximately▁", + "abl es", + "▁O ffic", + "▁O ’Brien-Fleming", + "▁pro m", + "▁pro per", + "▁pro mis", + "all el", + "▁T ri", + "ep ▁vein", + "will▁be▁ present", + "will▁be▁ responsible▁for", + "will▁be▁ followed▁for", + "com part", + "▁for ▁you", + "▁for ▁women", + "▁for ▁Lung▁Cancer", + "▁for ▁femal", + "▁for ▁evaluating", + "▁R BC", + "e\n\n th", + "e\n\n In", + "ed▁in dependent", + "▁treatment ▁by▁", + "ain dra", + "study ▁therapy", + "▁with \n\n", + "▁with ▁placebo", + "▁with ▁modification", + "e▁to ▁the▁individual", + "ed▁b rain", + "ad in", + "ad enocarcinoma", + "▁that ▁has▁been", + "▁that ▁is▁not", + "▁is▁ permitt", + "▁is▁ preferred", + "▁al ive▁", + "▁al anine▁transamin", + "▁will▁be▁ performed▁at", + "eri es▁of", + "▁M L", + "▁M ember", + "▁M ,▁P", + "▁M onitor", + "▁M ucos", + "▁M UGA", + "▁con clusion", + "▁of▁the▁ adverse▁event", + "▁of▁the▁ diluted▁solution", + "e,▁ pleas", + "▁o per", + ".▁The▁ study▁will", + "▁g emcitabin", + "▁g astric▁cancer", + "not ify▁", + "▁the▁s urvival", + "▁on -", + ",▁and▁ (", + ",▁and▁ by▁", + "▁v itamin▁B12", + "▁L A", + "▁L imit", + "▁L IST▁OF", + "▁B A", + "▁B E", + "▁B iom", + "s,▁ in", + "▁all ▁SAE", + "ure s▁", + "▁analys es▁(", + "▁analys es▁and▁", + "\n\nC ycl", + "\n\nC ycle▁", + "\n\nC ediranib", + "\n\nC linical", + "▁5 .4.1", + "▁6 .4.2", + "ult ras", + "▁H g", + "▁H ist", + "▁H emoglobin", + "▁patients▁ will", + "▁the▁p emetrexed▁", + "▁the▁p re-", + ")\n\n 7", + "▁at ▁his▁or▁her", + "ay lor", + "ay \n\nMonth\n\nYear", + "s▁( t", + "▁study▁ sit", + "continu e▁to▁receive▁the▁", + "gen otyp", + "gen otyping", + "gen otype▁", + "s.▁ L", + "s.▁ St", + "rel ev", + "▁any▁ SAE", + "▁any▁ symptom", + "▁any▁ problem", + "▁any▁ study-related▁", + "▁V EGFR", + "▁V ital▁Sign", + "▁ex ternal", + "▁ex ternal▁", + "onth ly▁", + "\n\nD uration▁of", + "s▁and▁ report", + "s▁and▁ risks▁of", + "19 )(cid:", + "e▁d ifferent", + "ly ▁associated▁with", + "ob es", + "▁patient s.\n\n", + "10 ]", + "▁the▁d iscontinu", + "▁the▁d estruction", + "▁the▁d uration▁of", + "▁the▁d etermination▁of", + "▁the▁d ate▁for", + "TI ES", + "s▁will▁be▁ used▁for", + "▁G oal", + "report ed▁for", + "▁U rine▁", + "▁e ight", + "▁tim es▁to", + "ies ▁and▁", + ".▁P regnancy▁", + "\n\nE thics▁", + "▁In tern", + "▁In jection", + "),▁ d", + "ed▁by▁ AstraZeneca", + "ed▁by▁ Pfizer", + "evalu ated▁by▁", + "▁is ▁assum", + "▁not ▁to", + "ON IT", + "▁may▁ caus", + "▁7 6", + "▁7 .8", + "▁7 ▁days▁after", + "su ant", + "▁month ly▁", + "▁month s▁and▁", + "▁dos ing,▁", + "clin ician", + "may▁ be\n\n", + "s) ▁or", + "▁10 ▁mL", + "▁10 .6.2", + ".6 5", + ".6 %)", + "▁analysis▁ may▁be▁", + ".▁In ▁order▁to", + ".▁E nd", + "▁assessment s▁are▁", + "▁test ▁the▁", + "▁test s▁or", + "record ed▁at▁baselin", + "RA D", + "RA Y", + ",▁and ▁the\n\n", + ".▁C A", + "▁cont ra", + ".▁T ime▁to", + "ed▁with ▁other", + "par affin", + ",▁or ▁the▁", + "▁in▁the▁ United▁States", + "e.\n\n 5", + "e.\n\n B", + "OL OG", + "▁9 4", + "▁9 6", + "EGF ▁receptor", + "e▁( IDMC", + "first ▁patient", + "s▁s upport", + "▁each ▁group", + "pre -specifi", + "pre existing▁condition", + "s▁with ▁the▁", + "▁data ▁for", + "▁data ▁from▁the▁", + "▁data ▁cutoff", + ").\n\n 8", + ".▁If ▁any▁", + "▁form al▁", + "bas is▁", + "ne ither", + "ne urolog", + "▁the▁investigator ▁believ", + "\n\nR eg", + "▁your ▁treatment", + "Study▁ 200", + "▁to▁be▁ obtain", + "▁has▁ no", + "ass AR", + "▁a▁s erum", + "▁the▁study .", + "▁the▁study .\n\nThe▁", + "\n\n3 1", + "▁the▁patient ▁population", + ".▁D ocetaxel", + ".▁D efinition", + "▁W BC", + ".\n\nA b", + "\n\nThe▁ overall", + "▁toxic ology▁", + "\n\n4 .2.2", + ".▁F uture▁", + "le eland▁", + "ically▁ for", + "uc cess", + "s▁that ▁the▁", + "s▁that ▁have▁", + "23 ]", + "\n\nI N", + "hy persensitivity", + "▁visit s▁", + "yst al", + "car cin", + "car e▁but", + "▁was▁ unable▁to", + "result s▁to", + "fl ict", + "performed▁ if", + "in▁the▁ form", + ".\n\nS erum", + ")▁ ", + "main ▁study▁", + "main ten", + "patients▁ may▁", + "e▁and▁ Events▁", + "provid e▁", + "urvival▁ Follow-up", + "▁An alysis▁Subset", + "▁the▁study▁ protocol", + "▁must▁be▁ completed", + "s: \n\n1", + "row n", + ".▁R ECIST", + "you ▁with", + ".▁200 1", + ".▁200 3;", + "question s▁regarding", + "▁the▁subject ▁is▁", + "▁the▁subject ’s", + "Investigator ▁B", + "▁complet ing▁the▁", + "▁complet e▁blood▁count", + "▁complet eness", + "▁this▁study .", + "▁this▁study ▁and▁", + "▁approximately▁ 462", + ",▁P SA", + "randomiz ed▁(", + "▁treat ing▁physician", + "document ▁contains▁", + "stat us▁will▁be▁", + "▁their ▁own", + "▁et▁al ▁2004", + "▁ind ivid", + "es▁will▁be▁ used▁to", + "ed\n\n on", + ".▁B oth", + ".▁B one▁scan", + "response▁ will▁be▁", + "▁Panitumumab ▁in▁Combination▁with", + "▁receive▁ panitumumab", + "▁= ▁creatinine▁clearanc", + "▁= ▁intravenous;", + "\n\n6 .4.1", + "dis pos", + "dis card", + ".▁M od", + ".▁M olecular", + "▁Cancer ▁J", + "▁event s▁are▁", + ",▁s elf-care", + "loc ally▁", + ",▁200 1", + ",▁200 1.▁", + "▁may▁be▁ given", + "▁may▁be▁ asked▁to", + "any▁ other", + ".▁H igh", + "▁mor e▁frequ", + ".2.1 0", + "▁non- melanoma▁skin▁cancer", + "▁survival ▁data", + "▁hour s▁of", + "▁loc k", + "▁rel ative▁", + "▁metastatic ▁colorectal▁carcinoma", + "▁result s▁are▁", + ",▁b linded▁", + ".▁N ature▁", + "ext ensive▁", + "Wh at", + "▁gen eral▁", + "▁gen e▁c", + "risk ▁of▁", + "e▁m etastas", + "▁follow-up ▁for", + "▁On ly▁", + "▁On ly", + "\n\nM onitoring", + "▁administer ed▁with", + "conduct ▁of▁the▁study", + "▁respons es", + "▁respons ibility▁", + ".▁This▁ is▁", + "▁to▁ irinotecan", + "▁to▁ elimin", + "▁baseline▁ assessment", + "uthor ities", + "▁placebo ▁relative▁to", + "▁until ▁disease▁progression▁or", + "ogen e", + "chang e▁in▁the▁", + "chang e▁from▁baseline▁", + "ry▁ mouth", + "▁this ▁time▁", + "plac ed▁on", + "▁document ▁the▁", + "▁the▁treatment ▁effect", + "obtain ed", + "lesion s,▁", + "▁Clin ic", + "by▁ which", + "di arrhoea", + "▁ne ither", + "▁ne utropenic", + "▁effect ▁in", + ".▁For ▁each", + "ZD4054 /placebo", + "ed▁by▁the▁ Sponsor", + "ype▁ 1▁error", + "▁approv ed▁for", + "▁plus▁ bevacizumab", + "Cons olidation", + ".▁I ▁am", + "(s) ▁or", + "▁within ▁4��week", + "▁Sub set", + "fre ez", + "start ▁of▁the▁study", + "/L illy▁or", + "▁this▁study▁ may▁be▁", + ",▁G atzemeier▁U", + "\n\nL esion", + "\n\nL DH", + ",▁et▁al .▁The▁", + "io id", + "research er", + "▁allow s▁for", + "▁trans forming▁growth▁factor", + "▁every▁ 6▁week", + "Com mon▁Terminology▁Criteria▁for▁Adverse▁Event", + "describ ed▁below", + "▁compar e▁Casodex", + "\n\nX\n\nX\n\nX\n\nX \n\nX\n\nX", + "\n\nX\n\nX\n\nX\n\nX \n\nX\n\nX\n\nX", + "\n\ns pecific", + "▁at▁least ▁25%", + "▁mL ▁of▁0", + "Un evaluable▁", + ",▁L i", + "▁the▁sam e\n\n", + "e▁will ▁not▁be▁", + "▁24 ▁month", + "▁24 ▁and▁48", + "indic ated▁in", + "▁IV ▁antibiotic", + "▁toxicity▁ attributed▁to", + "▁Q U", + "▁Q uestion", + "▁two -t", + "DMC ▁will▁be▁", + "required▁ for▁the▁", + "\n\nO mit", + "ate▁the▁ patient", + "ability ▁to▁determine▁the▁", + "is▁not ▁a", + "ual▁ Int", + "▁confirm ation", + "▁withdraw s▁consent", + "▁the▁b lood▁sampl", + "at▁least ▁one▁dose▁of", + "\n\nStudy▁ Glossary", + "ral at", + "ism atch", + ",▁R am", + "▁sp ine▁", + "▁cas es▁and▁", + "eph ro", + "HO RI", + "median ▁will▁be▁provid", + "analys es▁will▁be▁", + "▁symptom s,▁", + "▁symptom s▁or", + "100 ▁mg", + "100 ,000", + "▁prior▁to ▁each", + "▁serum ▁concentration", + "Pro cedure", + "▁an▁ emergency▁room", + "▁pres ence▁of", + "▁pres cription", + "▁Con centration", + "▁time▁to ▁event", + "e/ SD", + "post menopausal", + "use▁of ▁a", + "hyd roch", + "reason ably▁", + "fficacy▁An alys", + "is▁a mended▁", + "cycl e▁of", + ",▁d eath", + "▁further ▁information", + "▁X▁X ▁X▁X", + "Amgen ▁Thousand▁Oaks", + "▁am pl", + "▁high ly▁", + "▁procedure s▁should▁be▁", + "▁days▁after ▁receiving", + "representativ es▁of", + "anu ary▁", + "product ▁or▁for", + "▁last ▁dose▁of", + ",▁F ossella▁F", + "ey ▁are▁", + "▁Phase▁ 1", + "adverse▁event ▁CRF", + "cus sion", + "▁carcinoma ▁in▁situ", + "▁compl ex", + "ing,▁ stor", + "ethod▁ with", + "e; ▁•", + "▁Report ▁Form", + "gl utam", + "▁scor e,▁", + "▁reason s▁for", + "plann ed▁for", + "olid ▁tumour", + "▁throughout ▁the▁study▁", + "▁throughout ▁the▁treatment", + "▁CTCAE ▁Grade▁3", + "develop ing", + "3- 9", + "▁Confidential ity▁", + "▁interim ▁analyses", + "▁versus▁ yes", + "s; ▁•", + "▁the▁f inal▁", + "ited▁ data", + "▁colon ic", + ",▁you ▁should▁", + "therapy▁ (", + "prof it", + "open-label ▁treatment▁phase▁", + "ing▁of▁the▁ study", + "oler ability", + "rang e▁", + "ITT ▁Analysis▁Set", + "37 .5▁mg", + "▁a▁p otential", + "▁man ifest", + "▁protein s▁involved▁in", + "▁improv ed▁", + "▁(S GPT", + "▁local ized▁", + ",▁all ▁effort", + "▁Response▁ Evaluation▁Criteria▁in▁Solid▁Tumors▁(RECIST", + ",▁E urop", + "guidelin es▁in", + "guidelin es▁and▁", + "pharmac y,▁", + "function al", + "staff ▁member", + "Evalu able▁", + "▁demonstr ated", + "primary ▁analyses▁of", + "rain ing▁of▁", + "\n\nNo \n\nSD", + "▁known ▁as▁", + "HA )", + "▁en ough", + "read er", + "read ing", + "▁my▁ famil", + "reported▁ if", + "\n\nTable▁ JMIG", + ".▁At ▁the▁time▁of", + "▁and▁D NA", + "ires orptive▁", + "(cid:13 1)", + "s.▁A fter", + "(b)▁Confidential \n\nPage▁", + "Schedul e,▁", + ".\n\nR isks▁of▁a", + "-2 20", + "▁remain ing", + ".\n\n9 .1", + "▁exampl e,▁", + "▁median ▁survival", + "cut off", + "cut is/", + "\n\nIf ▁a▁patient", + "best ▁response▁", + "▁a▁subject ▁(or", + "▁approval ▁of▁the▁", + "▁approval ▁must▁be▁", + "EX T", + "▁blood▁sampl es▁for", + ",▁the▁investigator ▁or▁designee▁will", + "stopp ing", + "e▁blood▁ [RNA", + "▁complete▁ respons", + "▁complete▁ response▁", + "▁telephone▁ or", + "Phase▁ II", + "benefit ▁from", + ".▁You ▁will▁also▁be▁", + "▁necess ary▁", + "▁necess arily", + "\n\nEx planation", + "▁reduction ▁of", + ".▁The▁investigator ▁will", + "ation▁or ▁special", + "available▁ at", + "2▁week s▁off", + "lymph angitis▁", + "▁ext rem", + "Data ▁Monitoring▁Committee▁(DMC", + "was ▁a", + "was ▁associated▁with", + "▁written ▁information", + "▁written ▁agreement", + "1.5 ▁x▁109/L", + "followed▁for ▁survival", + "\n\nPage: ▁1", + "asked▁to ▁sign", + "percent ag", + "▁return ▁for", + "▁systemic ▁anti-tumor", + "Grade▁3 /4", + ".\n\nLY231514 \n\nH3E-MC-JMHD(f)▁Clinical▁Protocol\n\nPage▁", + "ed▁as▁a ▁sterile,▁", + ".▁Thes e▁includ", + ".▁Thes e▁signature", + "necessary ,▁", + "hip ping", + "measurement s▁(either", + "▁the▁discretion▁of▁the▁ treat", + ".▁Ther apy▁", + "MS S", + "Safety▁ follow-up", + "brevi ation▁or▁special", + "▁AD VERSE▁EVENTS", + "\n\ni ▁l", + "\n\ni \n\ns▁", + "▁request ▁or", + "▁anti oxidant", + "▁EGFR -", + "........................ ......", + "▁is▁the▁ responsibility▁of", + "s▁must ▁document▁their▁review▁of▁each▁laboratory▁report", + "▁direct ▁access▁to", + "▁appl y▁to", + ".▁The▁patient ▁has", + "▁anticancer ▁treatment", + "e▁sh ort", + "region ▁(Western", + ")▁and ▁their", + "class ification", + "▁independent ▁review", + "\n\nNot ▁applicable\n\n", + "-T erm", + "▁immun ogenicity", + "ed▁as▁an ▁AE", + "colon ▁cancer", + ".▁St atistical▁", + "▁Ant igen", + "▁Ant iemetic", + "s\n\nA ssessment▁of", + "es▁a ware▁of", + ",▁v omiting,▁", + "▁mak e▁a", + "▁et▁al,▁200 3)", + "has ▁a▁p", + "▁Engl ish", + "ectom y", + "▁As sess", + "e▁infusion ▁reaction", + "▁Denosumab▁Protocol▁Number:▁20050244▁Date:▁05▁May▁200 8", + "Qual ity▁Assurance▁", + "▁co oper", + "▁Cooperative▁ Group", + "Dose▁ Level", + "previously▁ received▁treatment▁with", + "empt y▁", + "▁Sign ificant", + "s.▁Th ere▁", + "e▁at ▁the▁same▁dose▁level", + "▁2▁week s▁of", + "▁his/her ▁signature", + "ynops is▁", + "▁Gen eral", + "▁partial▁ response▁(PR", + "upper ▁limit▁of▁normal", + "s\n\nThe▁ investigator", + "ias /d", + "▁(if ▁liver▁metastases▁", + "▁will▁receive▁ a", + "s▁during▁the▁ study▁treatment▁period▁or", + "del eg", + "▁ent itl", + "▁Primary▁ .......................................................................................................▁", + "▁anticip ated▁", + "Reg istration/", + "▁Serious▁Adverse▁Event s▁", + "▁refer s▁to", + "▁as▁describ ed▁below", + "▁antitumor ▁efficacy▁", + "positive▁ for", + "patients▁who ▁are▁", + "▁........................................................................................................ ....", + "▁response▁rate▁ (", + "▁response▁rate▁ (ORR", + "DS MB", + "New ▁England▁", + "IMC-1121B ▁or▁placebo", + "fail ure▁", + "ensity▁ (", + "access▁to ▁commercially▁available▁", + "▁hist ology", + "▁hist ologically▁or▁cytologically▁", + "▁Guidelin es▁", + "▁Reporting ▁Requirements", + "withdrawn▁from ▁study▁treatment", + "▁of▁C YP3A4", + "▁(E rbitux", + "\n\nDose▁ Level", + "▁Secondary▁ ..................................................................................................", + "▁unblind ing▁the▁study", + "s.\n\nP age:", + "paragraph \n\nAdd:", + "▁withdrawal ▁criteria▁are▁met", + "\n\nOverall ▁survival", + "path ologic", + "▁in▁this▁ substudy", + "chemist ry,▁", + "number▁of▁ vial", + "▁preserv e▁the▁", + ".▁Clin .▁Oncol", + "▁gl ass▁vial", + "▁the▁final ▁analysis", + "▁el ev", + "\n\nDiscontinu e▁bevacizumab", + ").\n\nS ubject", + "▁increased▁ risk▁of", + "▁Stat ement", + ".\n\nTh es", + "▁Pemetrexed▁ plus▁", + "▁5% ▁significance▁level", + "s▁are▁not ▁required", + "raw ford▁", + "eft ▁ventricular", + "▁d▁e▁v▁o▁r▁p▁p▁A\n\nProduct: ▁Panitumumab▁Protocol▁Number:▁20050203▁Date:▁21▁January▁2009\n\nPage▁", + "monitoring ▁visit", + ".▁Onc e▁", + ".▁Onc e▁the▁", + "▁the▁pre ceding", + "withdrawal ,▁or▁death", + "▁supplementation ▁reduc", + "e▁the▁in cidence▁of", + "s▁involv ing", + "▁of▁16 \n\nVersion", + "▁previously ▁treated▁with", + "\n\nAdverse▁Event s", + "laborator y▁and▁", + "▁Event ▁Goal", + "▁approximately▁30 ▁minutes", + "▁(0 )", + "intraven ous▁", + "general ized▁", + "▁unit s▁or▁term", + "utiliz ed▁to", + "▁Procedures▁for ▁discontinuation", + "publish ed,▁", + "▁Up date▁", + "radiotherapy▁ for", + "pemetrexed▁ 500▁mg/m2", + "recover ed▁from", + "▁modified▁ RECIST▁criteria", + "▁clos ely▁", + "30-day▁postdiscontinuation▁follow-up ▁period", + "eryth ropoietin", + "▁prostat e-specific▁antigen", + ".▁In▁the▁event ▁of", + "▁statistical ▁analysis", + "90% ▁power▁to▁detect", + "power ▁to▁detect", + "Int ent", + "▁anti-cancer ▁therapy", + "▁Randomized,▁ Multicenter", + "▁ep isod", + "urr ence▁of", + ".▁Rec ord", + "▁repe ated▁", + "(4 ):", + "24-month ▁treatment▁phas", + "astrointestinal ▁perforation", + "\n\nN▁A\n\nF▁O\n\nY▁P▁O▁C \n\nD▁E▁T▁N▁I▁R▁P\n\nA\n\nS▁I\n\nS▁I▁H▁T", + "▁purpos es", + "yes▁ vs▁no", + "investigational ▁drug", + "ream lin", + "applicable▁ regulatory▁requirement", + "▁Backgroun d", + "uroto xicity▁", + "BSC ▁arm", + "▁and▁the▁investigator ▁agree▁to", + "▁will▁be▁the▁ primary▁", + "interfer e▁with", + "therapy▁for ▁metastatic▁colorectal▁cancer", + "▁fracture▁ (", + "▁suggest ▁that", + "arc oid", + "reported▁on▁the▁ CRF", + ",▁panitumumab ▁was▁removed▁from▁the▁regimen", + "▁or▁d evic", + "▁FDA ▁1572", + "RAN K", + "▁its elf", + "-free▁ rates▁", + "▁biological ▁samples", + "\n\nUE /ND", + ",▁ther efore,▁", + "Japan ▁only", + "▁(FOLFOX )", + "ortality▁ in", + "▁abnormalities ,▁and▁", + "commer cially", + "▁plot s▁of", + "▁ensur e▁the▁", + "▁eryth ropoietin", + "(mg )▁=", + "wors en", + "imilar▁to▁that ▁of▁the▁", + "Wild-Type▁KRAS ▁Efficacy▁Analysis▁Set", + "▁within▁30 ▁days▁of", + "▁regulatory▁ report", + "International▁Conference▁on▁Harmon isation▁(", + "pending ▁function", + "clinical▁data ▁management", + "▁change\n\n No", + "Cox ▁model", + "▁advant age▁", + "commun ication", + "ultiv itamin", + "\n\nOb jectiv", + "\n\nOb jective▁", + ",▁Johnson ▁DH", + "▁primary▁tumor ▁is▁", + "e.▁M easurement", + "stein ▁L", + "▁concent rate▁for▁solution▁for▁infusion", + "▁antif olate▁", + "▁antif ungal", + "easurabl e:", + "Response▁( PR", + "deliver ed▁over", + "steroid al▁anti-", + "▁candid ates▁for", + "its elf", + "imer ic", + "ribonucle ic▁acid", + "▁non-metastatic ▁prostate▁cancer", + "▁as▁a▁result ▁of", + "down ▁of▁this", + "▁SY ST", + "▁Elect ronic", + "ed▁by▁Amgen ▁Inc", + "▁time▁to▁first ▁on-study▁SRE", + "experimental ▁arm", + "Each ▁person▁who▁signs▁the▁consent", + "▁se em", + "▁syn thes", + "▁Review ▁of", + "ryth ema", + "s▁identifi ed▁at▁baselin", + "proportion s▁of", + "▁change▁of ▁lumbar▁spine▁BMD", + "contribut e▁to", + "100% ▁dose▁level", + "\n\nanalysis▁ set", + "s▁may ▁also▁be▁", + "▁or▁l ess▁in", + "▁or▁his/her ▁designee▁", + "(10 ):▁p.▁", + "▁1▁( baselin", + "▁hyd ration", + ".org /", + ".▁In▁this▁ cas", + "▁authorized▁representativ es▁of", + "\n\nA▁® \n\nProduct:▁AMG▁162▁Protocol▁Number:▁20040138▁Date:▁19▁February▁2008\n\nPage▁", + "serious▁ AE", + ".▁DATA ▁ANALYSIS", + "▁the▁beginn ing▁of", + "ECOG▁performance▁status▁(0 ▁or▁1", + "PECI AL", + "PECI FIC", + "-Reported▁Outcom es▁(PRO", + "healing ▁complication", + ".▁Br ▁J", + "restrict ed▁to", + "▁Independent ▁Data▁Monitoring▁Committe", + ".▁Elig ibl", + "▁neuroto xicity", + "ability,▁ withdrawal,▁or▁death", + "▁the▁subset▁of▁subject s▁in▁the▁ITT", + "abet es,▁", + "unequivoc al▁progression", "▁vir us", - "em u", - "e mu", - "▁} );\r", - "▁}); \r", - "▁}) ;\r", - "▁м м", - "▁Tr ying", - "▁Try ing", - "▁Lex ikon", - "ab ord", - "abor d", - "▁exped ition", - "▁demand ed", - "▁demande d", - "Z yg", - "le in", - "lei n", - "l ein", - "▁verw endet", - "ри на", - "рин а", - "wo l", - "w ol", - "▁p ivot", - "▁одна ко", - "▁propri et", - "▁a wards", - "▁aw ards", - "▁award s", - "to ut", - "t out", - "▁as sim", - "▁ass im", - "▁St orm", - "▁Sto rm", - "Li mit", - "L imit", - "el in", - "eli n", - "e lin", - "we alth", - "ue z", - "u ez", - "▁rap present", - "▁rappres ent", - "▁re sta", - "▁r esta", - "▁res ta", - "▁rest a", - "▁gegründ et", - "▁journal ist", - "is ie", - "isi e", - "▁fac ility", - "▁facil ity", - "il led", - "ill ed", - "ille d", - "ul k", - "▁P K", - "▁ PK", - "An chor", - "▁_ )", - "▁ _)", - "V F", - "LA B", - "L AB", - "▁n å", - "od os", - "odo s", - "▁bill ion", - "vir ti", - "virt i", - "▁Je ux", - "юз а", - "ю за", - "tom cat", - "▁ch arts", - "▁char ts", - "▁chart s", - "▁ charts", - "▁B undle", - "▁Bund le", - "▁ Bundle", - "▁l st", - "▁ls t", - "▁ lst", - "▁ex er", - "▁fem ales", - "▁female s", - "▁oblig ed", - "▁a by", - "▁ab y", - "▁ aby", - "roll ed", - "rol led", - "rolle d", - "dr i", - "d ri", - "▁S che", - "▁Sch e", - "▁Sc he", - "▁vess els", - "▁vessel s", - "IMA RY", - "IM ARY", - "▁reason ing", - "▁про те", - "▁пр оте", - "FI LES", - "FILE S", - "ver k", - "v erk", - "os os", - "oso s", - "▁ком му", - "ді ї", - "д ії", - "▁d d", - "▁ dd", - "▁со ответ", - "▁IO Exception", - "▁ IOException", - "sk ých", - "ský ch", - "▁C LI", - "▁CL I", - "▁ CLI", - "▁ ње", - "C M", - "T D", - "▁possib ilities", - "▁possibil ities", - "▁Com pos", - "▁Comp os", - "hal f", - "h alf", - "▁web page", - "▁s wing", - "▁sw ing", - "▁ swing", - "▁z as", - "▁za s", - "▁ zas", - "▁cy cl", - "le id", - "lei d", - "ist ica", - "istic a", - "isti ca", - "▁In sert", - "▁Ins ert", - "▁ Insert", - "▁Sw eden", - "▁want ing", - "▁ ال", - "▁e euw", - "▁Admin istr", - "▁War ren", - "▁b s", - "▁ bs", - "▁p am", - "▁pa m", - "an us", - "anu s", - "Dr a", - "D ra", - "ex pl", - "exp l", - "▁K ant", - "▁Kan t", - "▁Ka nt", - "▁Aust in", - "▁c sak", - "▁cs ak", - "▁the atre", - "▁compat ibility", - "ма тиче", - "мати че", - "set State", - "б ю", - "}{ |", - "} {|", - "▁D y", - "▁Zw ischen", - "Al t", - "A lt", - "CLA RE", - "st eps", - "ste ps", - "step s", - "▁L age", - "▁La ge", - "▁Lag e", - "▁M itt", - "▁Mit t", - "▁Mi tt", - "▁Dub lin", - "▁рабо ты", - "de ep", - "▁fl ows", - "▁flow s", - "▁flo ws", - "▁Pa lace", - "▁Pal ace", - "▁Pala ce", - "un ix", - "uni x", - "re fs", - "ref s", - "um ar", - "uma r", - "u mar", - "as et", - "ase t", - "a set", - "co v", - "c ov", - "▁p ing", - "▁pi ng", - "▁pin g", - "▁ ping", - "▁Saf ari", - "fl ug", - "flu g", - "cre ens", - "creen s", - "c reens", - "{ #", - "▁ре а", - "ad ors", - "ado rs", - "ador s", - "▁a mor", - "▁am or", - "uc e", - "u ce", - "de mic", - "dem ic", - "▁Nether lands", - "▁cluster s", - "▁clust ers", - "▁en for", - "▁enf or", - "mar ine", - "▁b ugs", - "▁bu gs", - "▁bug s", - "izz ata", - "izza ta", - "▁s cra", - "▁sc ra", - "▁scr a", - "Le s", - "L es", - "qu ick", - "qui ck", - "▁turn o", - "▁tur no", - "_ *", - "ер а", - "е ра", - "Gener ated", - "> [", - "▁e stre", - "▁est re", - "▁es tre", - "▁ estre", - "or de", - "ord e", - "▁v erg", - "▁ver g", - "▁ve rg", - "ро з", - "р оз", - "▁p au", - "▁pa u", - "in cludes", - "include s", - "includ es", - "as sa", - "ass a", - "ad ers", - "ader s", - "ade rs", - "a ders", - "▁Гер ма", - "▁est aven", - "▁esta ven", - "▁ear liest", - "▁res ultado", - "▁result ado", - "mu n", - "m un", - "▁pl ots", - "▁plot s", - "▁ plots", - "di n", - "d in", - "sort ed", - "s orted", - "▁p reference", - "▁pre ference", - "▁prefer ence", - "ri ó", - "r ió", - "ту ре", - "тур е", - "▁L igue", - "▁Li gue", - "▁Lig ue", - "▁за вер", - "▁зав ер", - "ph r", - "p hr", - "▁p ocket", - "▁po cket", - "▁poc ket", - "▁par l", - "▁pa rl", - "▁l ak", - "▁la k", - "▁ lak", - "▁p owie", - "▁po wie", - "▁pow ie", - "▁al tres", - "▁alt res", - "▁altre s", - "$} ;", - "$ };", - "pl ain", - "pla in", - "p lain", - "▁C red", - "▁Cre d", - "▁Cr ed", - "▁ Cred", - "it za", - "itz a", - "pe rp", - "per p", - "Gr een", - "Gre en", - "G reen", - "▁dev oted", - "product ion", - "produ ction", - "p roduction", - "work er", - "wor ker", - "el sen", - "els en", - "else n", - "▁v ern", - "▁ver n", - "▁ve rn", - "▁ vern", - "▁már cius", - "▁Conf eder", - "▁Liver pool", - "▁му зи", - "▁em ails", - "▁email s", - "▁dist ances", - "▁distance s", - "▁seg ments", - "▁segment s", - "▁a nth", - "▁an th", - "▁ant h", - "▁ anth", - "▁w rest", - "▁wr est", - "▁ho og", - "▁cin ema", - "rr or", - "r ror", - "▁geb oren", - "▁é c", - "▁ éc", - "Mar ker", - "Mark er", - "▁Com pet", - "▁Comp et", - "▁ли сто", - "all owed", - "allow ed", - "allo wed", - "vol ume", - "Esp agne", - "Z e", - "▁fix es", - "▁fi xes", - "▁r ond", - "▁ro nd", - "▁arrang ement", - "/ ~", - ".] (", - ". ](", - "▁For rások", - "▁weiter en", - "▁weit eren", - "▁weitere n", - "ex cel", - "▁з мі", - "▁mod erne", - "▁modern e", - "▁moder ne", - "Eng lish", - "▁Transfer markt", - "▁be aring", - "▁bear ing", - "▁cl eared", - "▁clear ed", - "▁cle ared", - "▁са м", - "▁di vs", - "▁div s", - "ć i", - "▁э той", - "▁это й", - "▁Ге ор", - "sc ene", - "sce ne", - "▁a ges", - "▁ag es", - "▁age s", - "▁ ages", - "GE N", - "G EN", - "rä n", - "r än", - "▁T oul", - "▁To ul", - "▁A bs", - "▁Ab s", - "j át", - "▁med iante", - "▁medi ante", - "▁median te", - "▁em pres", - "▁emp res", - "▁Emp loyee", - "▁ Employee", - "▁polynomial s", - "▁optim ize", - "▁вы ступа", - "fa re", - "far e", - "f are", - "ве й", - "в ей", - "x f", - "qu ez", - "que z", - "q uez", - "▁bo tan", - "▁bot an", - "▁def end", - "▁defe nd", - "▁Qu art", - "Mon t", - "Mo nt", - "M ont", - "v b", - "ti ck", - "t ick", - "W D", - "min e", - "mi ne", - "m ine", - "▁mod ific", - "not ification", - "▁d enn", - "▁de nn", - "▁den n", - "▁al go", - "▁alg o", - "▁S po", - "▁Sp o", - "▁m istrzost", - "/ :", - "▁a present", - "▁apr esent", - "▁п род", - "▁про д", - "▁пр од", - "Vol ume", - "sk ą", - "s ką", - "prote cted", - "▁Turk ish", - "az y", - "a zy", - "▁p ouv", - "▁po uv", - "▁pou v", - "▁perí odo", - "sk og", - "sko g", - "▁ent ropy", - "▁entr opy", - "ze d", - "z ed", - "то ри", - "тор и", - "▁l ij", - "▁li j", - "▁ lij", - "bo ards", - "board s", - "▁ста ту", - "Bo ol", - "B ool", - "▁pol ity", - "▁polit y", - "@\" ,", - "@ \",", - "▁рі к", - "né e", - "n ée", - "▁Z ug", - "▁Zu g", - "▁Un iti", - "▁Unit i", - "ém et", - "é met", - "at ience", - "ati ence", - "di men", - "dim en", - "d imen", - "▁St even", - "▁Ste ven", - "▁Steve n", - "H a", - "ACT ION", - "A CTION", - "▁w and", - "▁wa nd", - "▁ wand", - "▁Na var", - "▁Nav ar", - "▁сі чня", - "W atch", - "▁Stu art", - "▁z de", - "▁zd e", - "▁кон тро", - "data set", - "dat aset", - "datas et", - "y ó", - "▁B ush", - "▁Bu sh", - "▁Bus h", - "▁се бя", - "▁wor thy", - "▁worth y", - "▁B le", - "▁Bl e", - "▁pro por", - "▁prop or", - "▁Vill age", - "▁Villa ge", - "▁Vil lage", - "▁r y", - "▁ ry", - "▁v oit", - "▁vo it", - "▁копи я", - "▁z p", - "▁c ura", - "▁cu ra", - "▁cur a", - "▁H tml", - "▁ Html", - "▁Die ser", - "▁Dies er", - "▁Diese r", - "▁D ays", - "▁Da ys", - "▁Day s", - "▁ Days", - "on nes", - "onn es", - "onne s", - "▁ant igu", - "▁anti gu", - "▁Sta aten", - "▁Staat en", - "▁f aint", - "▁fa int", - "on gs", - "ong s", - "▁ö st", - "▁ öst", - "Re direct", - "Red irect", - "ел ь", - "е ль", - "at orial", - "ator ial", - "ato rial", - "atori al", - "▁b other", - "▁bo ther", - "▁both er", - "▁bot her", - "Edit Text", - "▁Gi ul", - "▁за во", - "▁зав о", - "▁pue blo", - "▁Mississ ippi", - "ja k", - "j ak", - "▁w ings", - "▁win gs", - "▁wing s", - "on c", - "o nc", - "ív el", - "í vel", - "ien cia", - "i encia", - "ent licht", - "entlich t", - "▁B TW", - "or nal", - "orn al", - "▁Ко ро", - "▁Кор о", - "▁од ним", - "▁sa lv", - "▁sal v", - "▁f inden", - "▁find en", - "▁fin den", - "ge o", - "▁а виа", - "att ung", - "vi v", - "v iv", - "▁L uther", - "▁Lu ther", - "▁об щи", - "▁Ro lle", - "▁Rol le", - "▁Roll e", - "▁Ab raham", - "▁cent ered", - "▁center ed", - "▁sl ash", - "▁sla sh", - "▁ slash", - "is at", - "isa t", - "em ann", - "ema nn", - "eman n", - "e mann", - "O s", - "пар та", - "▁P ablo", - "▁Pa blo", - "▁collabor ation", - "path s", - "pat hs", - "éd ition", - "▁view ed", - "▁vie wed", - "▁cons isted", - "▁consist ed", - "▁recover ed", - "▁Mex ican", - "▁F ix", - "▁sp ell", - "▁spe ll", - "▁spel l", - "Spec ial", - "Spe cial", - "▁С т", - "ess eur", - "esse ur", - "▁Украи ны", - "form er", - "for mer", - "▁ś w", - "▁z eros", - "▁ze ros", - "▁zero s", - "▁Stra ßen", - "▁Straße n", - "▁organ isation", - "▁organis ation", - "▁ organisation", - "üss en", - "üs sen", - "▁S ierra", - "▁Se ason", - "▁Sea son", - "▁vol ont", - "Bean Factory", - "▁помо щ", - "▁pres sing", - "▁press ing", - "▁equival ence", - "▁c att", - "▁ca tt", - "▁cat t", - "ic ity", - "ici ty", - "i city", - "▁accompl ished", - "▁accomp lished", - "▁accomplish ed", - "▁y o", - "▁ yo", - "▁s ic", - "▁si c", - "▁im ports", - "▁import s", - "▁accom mod", - "▁Port o", - "▁Por to", - "▁я ка", - "▁як а", - "▁lo an", - "ти ки", - "тик и", - "▁check out", - "▁ass ess", - "▁asse ss", - "▁Pop ulation", - "ur ent", - "ure nt", - "uren t", - "u rent", - "clo jure", - "▁Sant os", - "▁Santo s", - "▁inform áció", - "PO S", - "P OS", - "▁g are", - "▁gar e", - "▁ga re", - "▁k ick", - "▁ki ck", - "▁rad ical", - "▁radi cal", - "▁Pe ace", - "▁stream ing", - "▁stre aming", - "ca mp", - "cam p", - "c amp", - "zą t", - "го вор", - "гов ор", - "гово р", - "▁Reg ierung", - "▁proceed ed", - "f m", - "ле ны", - "лен ы", - "▁ear nest", - "▁Par ad", - "▁Pa rad", - "▁Para d", - "request s", - "▁R aum", - "▁Ra um", - "š č", - "▁polic ies", - "▁T ig", - "▁Ti g", - "▁s itt", - "▁si tt", - "▁sit t", - "▁Ener gy", - "▁pur ely", - "▁pure ly", - "▁H aut", - "▁Ha ut", - "▁Sp eed", - "▁Spe ed", - "▁ Speed", - "bi o", - "b io", - "▁o range", - "▁or ange", - "▁big gest", - "▁britann ique", - "▁No table", - "▁Not able", - "v u", - "ле нии", - "би н", - "б ин", - "▁N ash", - "▁Na sh", - "▁Nas h", - "ще ние", - "▁c iel", - "▁ci el", - "adém ie", - "▁гру дня", - "▁jo ue", - "▁jou e", - "▁v oted", - "▁vo ted", - "▁vot ed", - "▁vote d", - "ri co", - "ric o", - "r ico", - "▁го р", - "▁г ор", - "▁ гор", - "▁коман ду", - "it ivity", - "iti vity", - "▁щ е", - "▁ ще", - "▁de finite", - "▁defin ite", - "▁definit e", - "uro pa", - "urop a", - "!\" );", - "! \");", - "Default s", - "▁неко торы", - "éd ération", - "▁s illy", - "▁sil ly", - "▁talk ed", - "▁tal ked", - "re u", - "r eu", - "▁L omb", - "▁Lo mb", - "▁stat ue", - "кт а", - "к та", - "ю р", - "um ably", - "▁горо де", - "▁город е", - "▁R untime", - "▁Run time", - "▁ Runtime", - "▁di agn", - "▁diag n", - "▁dia gn", - "▁r etro", - "▁ret ro", - "▁retr o", - "▁Sver ige", - "▁in icial", - "▁inici al", - "ien za", - "i enza", - "▁fig lio", - "▁z og", - "▁zo g", - "▁re y", - "▁r ey", - "▁ rey", - "▁R und", - "▁Run d", - "▁Ru nd", - "т ный", - "▁ce ased", - "er no", - "ern o", - "▁e sa", - "▁es a", - "▁ esa", - "▁tr ouv", - "▁tro uv", - "▁trou v", - "▁Gemeinde n", - "▁Geme inden", - "▁comer cial", - "sk ap", - "ska p", - "s kap", - "en ario", - "ena rio", - "▁ju ris", - "▁jur is", - "T B", - "на ла", - "нал а", - "н ала", - "▁v ij", - "▁vi j", - "V O", - "▁c lin", - "▁cl in", - "▁cli n", - "jö r", - "j ör", - "са н", - "с ан", - "ow ała", - "owa ła", - "ował a", - "rib ución", - "ribu ción", - "▁urs prüng", - "▁con dem", - "▁cond em", - "▁St age", - "▁Sta ge", - "▁ Stage", - "▁mix ing", - "▁рі з", - "▁f ans", - "▁fa ns", - "▁fan s", - "há z", - "h áz", - "so cial", - "soci al", - "za n", - "z an", - "▁с вой", - "▁сво й", - "Cook ie", - "▁Ro land", - "▁Rol and", - "az ionale", - "▁Sl oven", - "▁Slo ven", - "▁Slov en", - "▁F iche", - "▁Fich e", - "▁S é", - "h ä", - "▁official s", - "▁offici als", - "▁î nt", - "▁în t", - "Inter ceptor", - "Table s", - "Tab les", - "T ables", - "▁da von", - "▁dav on", - "init ialize", - "initial ize", - "]= \"", - "] =\"", - "▁B ody", - "▁Bo dy", - "▁Bod y", - "▁ Body", - "▁U pper", - "▁Up per", - "▁ Upper", - "▁Col lect", - "▁Coll ect", - "▁ Collect", - "▁Zür ich", - "Hor izontal", - "Ty p", - "T yp", - "▁polít ico", - "▁Rewrite Cond", - "▁h oped", - "▁hope d", - "▁ho ped", - "▁hop ed", - "▁anx ious", - "Li ter", - "L iter", - "ja hr", - "j ahr", - "▁ass emble", - "▁assemb le", - "▁c rypt", - "▁cry pt", - "lah oma", - "AS H", - "A SH", - "▁Б ри", - "▁C ic", - "▁Ci c", - "tw itter", - "hy per", - "▁T ell", - "▁Te ll", - "▁Tel l", - "іль ки", - "во бо", - "▁ba zie", - "▁baz ie", - "▁contempor ary", - "▁Param eter", - "▁Para meter", - "▁ Parameter", - "st wa", - "▁bek end", - "co ck", - "c ock", - "pre vious", - "prev ious", - "en ska", - "ens ka", - "ensk a", - "▁c aller", - "▁cal ler", - "▁call er", - "]] )", - "] ])", - "▁R az", - "▁Ra z", - "▁Se lon", - "▁Sel on", - "▁propos al", - "▁b ý", - "▁S ied", - "▁Sie d", - "▁Si ed", - "▁Arbe its", - "▁Arbeit s", - "▁p ride", - "▁pr ide", - "▁pri de", - "▁sl ope", - "▁slo pe", - "id é", - "grad ient", - "▁Дже рела", - "▁S H", - "▁ SH", - "▁раз рабо", - "ivers ity", - "спо дар", - "\\{ \\", - "\\ {\\", - "▁с тали", - "▁ст али", - "▁ста ли", - "▁стал и", - "▁Ein zel", - "▁Einz el", - "▁rg ba", - "▁A nim", - "▁An im", - "▁ Anim", - "▁a lles", - "▁al les", - "▁all es", - "▁alle s", - "▁ alles", - "ба р", - "б ар", - "er te", - "ert e", - "▁réalis é", - "▁réal isé", - "Inst itut", - "▁mar kup", - "▁mark up", - "▁v ars", - "▁var s", - "▁va rs", - "▁ vars", - "▁g am", - "▁ga m", - "▁Васи ль", - "iz za", - "izz a", - "i zza", - "▁C ob", - "▁Co b", - "▁M etal", - "▁Me tal", - "▁Met al", - "▁Meta l", - "▁le ak", - "▁L anc", - "▁La nc", - "▁Lan c", - "Sw itch", - "De lay", - "Del ay", - "at uur", - "atu ur", - "▁че ты", - "▁анг лий", - "▁leg acy", - "▁desar roll", - "▁top ological", - "▁jewe ils", - "▁Nederland se", - "▁atmos phere", - "ur ban", - "urb an", - "▁s lov", - "▁sl ov", - "▁slo v", - "▁law yer", - "pe cially", - "▁altern ate", - "▁para met", - "▁param et", - "▁establish ment", - "▁wood s", - "▁wo ods", - "P D", - "▁на и", - "▁m ang", - "▁ma ng", - "▁man g", - "▁wechsel te", - "сь ку", - "ськ у", - ". =", - "▁fif teen", - "SU M", - "S UM", - "▁F ro", - "▁Fr o", - "▁L ED", - "▁LE D", - "▁ LED", - "ow ano", - "owa no", - "owan o", - "стви е", - "▁D onnées", - "to l", - "t ol", - "ży n", - "ż yn", - "cre f", - "cr ef", - "c ref", - "стви и", - "ho rn", - "hor n", - "h orn", - "▁со об", - "▁обо ро", - "▁Comp lete", - "▁Comple te", - "▁ Complete", - "“ )", - "▁kind ly", - "▁Cham ber", - "s ég", + "identified▁as▁ non-target▁lesion", + "Brief▁Pain▁Inventor y▁(BP", + "same▁m ethod▁of▁assessment", + ".\n\nWill ▁I", + "▁are▁th ose▁", + "Rest ▁of▁World", + "▁post-baseline▁ PRO▁assessment", + "▁red act", + "▁review▁and▁ meta-", + "\n\nSection:▁Protocol ▁Synopsis", + "decid e▁to", + "▁antihist amin", + "pulmon is", + "▁mes othelioma", + "undergone▁ a", + "Pleas e▁", + "▁should▁notify▁ your▁doctor", + "▁Epidemi ology,▁", + "e▁indicate▁ how", + "funding ▁this▁clinical▁study", + "▁ever ▁comes▁first", + "y/illness ▁that▁is▁", + "erbst ▁RS", + "▁ascites,▁ pleur", + "single▁ agent", + "i-squ ar", + "used▁for▁any▁purpose▁ other▁than▁the▁evaluation▁or▁conduct▁of▁the▁clinical▁investigation", + "\n\nPage:▁36\n\nSection:▁2.3.6.6,▁Anti-Panitumumab▁Antibodies ,▁third▁", + "terim▁Analysis▁and▁Early▁Stopping ▁Guidelines", + "one▁or▁more▁of▁the▁following :", + "hold▁dose▁until▁toxicity▁is▁ grade▁", + ",▁week ▁13", + "▁l-L V)", + "patient▁hospitalization▁or ▁prolongation▁of▁existing▁hospitalization", + "▁data▁monitoring ▁committe", + "fractur e▁during▁the▁", + "▁synerg istic", + "epherd▁ FA", + "▁measurable▁lesions▁up▁to▁a▁maximum ▁of▁5▁lesions▁per▁organ▁and▁10", + "pase- 3", + "reed man", + "▁cynomolgus▁mon keys", + "ampt oth", + "per- protocol", + "consisting ▁of▁", + "▁Individual▁ Subject", + "205- 216", + "▁WIT H", + "mClone /Lilly▁or", + "dentification ▁Number", + "obility ,▁self-care", + "EDTA▁blood▁[plasma▁and▁cell ▁pellet],▁PAXgen", + "▁source▁data ▁verification", + "▁prematur e▁discontinu", + "▁imaginable▁ health▁stat", + "\n\n5\n\n6\n\n7\n\n8\n\n9 \n\n10", + ".▁Stat ▁Med▁", + "▁150▁mg▁once▁daily▁ with▁placebo▁in▁terms▁of", + "▁other▁lesions▁(or▁sites▁of▁diseas e)", + "▁20040135 \n\nPage▁", + "lymph▁node▁is▁N 0", + ".▁Proceedings▁of▁the▁ National▁Academy▁of▁Sciences▁of▁the▁United▁States▁of▁America", + "/infusion -related▁reaction", + "iec ew", + "oembryonic ▁antigen", + "▁Subject▁Information ▁Sheet", + "▁(multiple▁ event▁analysis", + "▁racem ate▁(or", + "▁Key▁Study▁ Endpoints", + "▁sufficient▁shrinkage▁to▁qualify▁for▁PR▁nor ▁sufficient▁increase▁to▁qualify▁for▁PD", + "wart z", + ",▁intoler ability,▁withdrawal,▁or▁death", + "s▁and▁mutant▁KRAS ▁tumor", + "1-Day▁ Cycl", + "inal▁Investigational▁Product ▁Reconciliation", + ".\n\nTREATMENT ▁PROCEDURES", + "recommended▁but▁not ▁required", + "ehrenbacher ▁L", + "portional▁hazard▁ model", + "ermatology /Skin", + "macor ®", + "▁(Zubrod )", + "▁must▁personally▁enter ▁the▁date▁for", + "▁by▁imaging▁techniques▁or ▁clinically", + "▁masses▁that▁are▁not▁confirmed▁and▁followed▁by▁ imaging▁techniqu", + "oeb el", + "erop ol", + "es▁the▁s mallest▁s", + "▁AUT HORI", + "▁Done▁( ND", + "aindra ult", + "ONIT ORING", + "assAR RAY", + "▁compare▁Casodex ▁150▁mg▁once▁daily▁with▁placebo▁in▁terms▁of", + "ual▁Int ramuscular▁Intravenous▁", + "product▁or▁for ▁up▁to▁2▁year", + ",▁all▁effort s▁will▁be▁made▁to", + "raining▁of▁ staff", + "cutis/ pulmonis", + "breviation▁or▁special ▁term", + "New▁England▁ Journal▁of▁", + "access▁to▁commercially▁available▁ product▁or▁for▁up▁to▁2▁year", + "▁of▁16\n\nVersion ▁Date:▁14▁November▁2006", + "down▁of▁this ▁analysis▁set", + "obility,▁self-care ,▁", + "▁must▁personally▁enter▁the▁date▁for ▁his/her▁signature", + ") ▁as", + ") ▁which", + ") ▁is▁a", + ") .▁If▁the▁", + ", ▁to▁be▁", + "- point", + "- 24", + "- 33", + "- 27", + "/ renew", + "0 .025", + "1 ).\n\n", + "1 ▁vs▁", + "2 _", + "3 54", + "3 80", + "4 ▁mg", + "7 ▁days", + "8 .3", + ": 10", + ": ▁p.▁", + ": ▁Patients▁", + ": ▁To", + "; ▁serum", + "@ may", + "A merican▁BioScience,▁Inc", + "B I", + "B U", + "C olon", + "D iction", + "E PA", + "E AR", + "E ffect", + "F WB", + "G -CSF", + "G ENC", + "H IV", + "H ,▁L", + "H ead", + "J ,▁C", + "L os", + "L EX", + "M easurable▁Lesion", + "N OT", + "N -telop", + "P IN", + "P ET", + "R )", + "S LD", + "S NP", + "T itle:", + "U BL", "W H", - "▁amb ient", - "к ро", - "▁ch eval", - "▁che val", - "▁на писа", - "fl u", - "f lu", - "▁Off iz", - "ma te", - "mat e", - "m ate", - "nat ural", - "n atural", - "se par", - "sep ar", - "em pre", - "emp re", - "View Holder", - "f w", - "▁le tech", - "▁let ech", - "▁tra iling", - "▁trail ing", - "at ri", - "atr i", - "a tri", - "▁G ó", - "▁B onn", - "▁Bo nn", - "▁Bon n", - "▁un likely", - "▁unlike ly", - "RA M", - "R AM", - "en st", - "ens t", - "St ats", - "Stat s", - "▁поли тиче", - ")- -(", - ")-- (", - "▁t rom", - "▁tr om", - "▁tro m", - "!. ..", - "! ...", - "▁Mean while", - "ст ана", - "ста на", - "стан а", - "▁Re ino", - "▁Rein o", - "▁A rist", - "▁Ar ist", - "▁Ari st", - "$} }%", - "$ }}%", - "▁so lem", - "▁sol em", - "▁sole m", - "clos ure", - "ign ation", - "ło d", - "ł od", - "▁di vor", - "▁div or", - "▁между народ", - "=\" ", + "199 6", + "dos ing▁schedul", + "e▁and▁ overall", + "provid ed▁by", + "rop yrimidine▁", + "ack ▁pain", + "▁di ary▁", + "▁the▁study▁ in", + "▁includ es▁a", + "▁must▁be▁ report", + "▁over ▁60", + "▁sampl es▁and▁", + "▁infusion s▁may▁be▁", + "▁infusion ▁pump", + ".▁R epeat", + "ND LING", + ",▁a \n\n", + "you ▁can", + "receiv ing▁the▁", + "▁sit e▁of", + "enroll ed▁in▁the▁", + "▁cell ular", + "consider ed▁measurable▁", + "▁subjects▁ have▁been", + "▁year s▁from", + "▁year s▁after▁the▁", + "▁the▁subject ▁agrees▁to", + "▁complet ed", + "▁complet e▁and▁", + "agn itud", + "▁this▁study ?", + "ES TINAL", + "\n\n\n\n if", + "outcom e▁", + "▁mod est", + ".▁B one▁", + ".▁B ecause▁the▁", + ",\n\n or", + "response▁ criteria", + "ed▁s ub", + "val id▁", + "▁occur ▁when", + "▁report s▁of", + "dose▁ reduc", + ",▁s ymptom", + ",▁s ymptomatic", + "▁these▁ other▁treatment", + "ros sover", + "-t ime▁", + "RO INT", + "s▁will ▁have▁", + "▁non- inferior", + "unction al", + "easur e▁of", + ",▁C ox", + "▁hour s▁prior▁to", + "observ ed▁with", + "1- 9", + "1- D", + "administer ed\n\n", + "sub cutaneous▁", + "▁level s▁in", + "e▁of▁the▁ person▁who▁conducted▁the▁informed▁consent▁discussion", + "1) .", + ".9 ▁mmol/L", + "▁blood▁ cell", + "▁blood▁ vessel", + "TION ▁OF▁TERMS", + "non- small-cell▁lung▁cancer", + "review ed▁for", + "\n\nIn dependent", + ",▁b y▁", + ",▁b ody▁weight", + "s, ▁as▁well▁as▁", + "▁gen otyping", + "e▁m or", + "tein uria", + "\n\nM od", + "▁administer ed▁intravenously▁", + "conduct ▁of▁the▁", + "▁respons e,▁", + "▁receiv ed\n\n", + "▁to▁ zoledronic▁acid", + "▁to▁ keep", + "mitt ed▁to", + "part y▁", + "clinical▁ examination", + "bl ank", + "ogen omic", + "▁any one▁", + "when ▁they▁are▁s", + "your ▁identity▁", + "▁document s,▁", + ",▁A ND", + "▁des pit", + "▁Arm ▁1", + "▁12 ▁months▁of", + ")(cid: 32", + "22 ]", + ",▁H oll", + "Print ed▁copy▁is▁not▁official▁record", + "-5 7", + "ean u", + "yl transfer", + "........................................................................ ...▁", + "under ▁applicable▁law", + "panitumumab ▁infusion", + "must ▁have▁been", + "s▁of▁the▁ protocol", + "ities▁ of", + "▁diseas e-fre", + "▁approv ed▁in", + "qual ified▁", + "ite▁ staff", + "ite▁ personnel", + "s▁should▁be▁ performed▁as▁", + "▁Pro gram", + "fre e▁of", + "▁bevacizumab ▁plus▁", + "▁bevacizumab ▁in▁combination▁with▁FOLFOX", + "/L eucovorin", + "▁Drug ▁Safety▁", + "(cid:120 )▁", + "▁AE s▁and▁", + "▁count ry", + "▁chemotherapy ▁are▁", + "s▁and ▁then", + "▁who ▁is▁not", + "▁who ▁received▁", + "within ▁a", + "▁according▁to ▁local▁", + "▁according▁to ▁standard▁", + "describ ed▁in▁Appendix", + "▁first ▁subject", + "prov ision", + "▁ver tebral", + "▁develop ▁a", + "▁develop s▁", + "analysis▁ set", + ",▁p rior", + "▁hy pertensive▁", + "▁hy persensitivity▁to", + "e▁will ▁also", + "e▁will ▁undergo", + "▁+ ▁5-FU", + "UM B", + "vis ual▁", + "assess ed▁", + "▁toxicity▁ recur", + "▁Q D", + "▁assign ing", + "normal ized▁", + "▁KRAS ▁WT", + "▁clinical▁ research", + "▁Ch RT", + "/m etastatic", + "study▁treatment ▁period", + "ing▁s kin", + "ing▁s erum", + "▁Adverse▁Event s▁(", + "▁bone▁ density", + "▁15 00", + "▁confirm ▁the▁", + "▁confirm ▁that", + "SAE R▁form", + "▁withdraw ▁from▁the▁study", + "▁the▁b eginning", + "at▁least ▁5", + "andomis ed,▁", + "iqu antitative▁", + "1,▁ 22", + "rof olate▁", + "▁Treatment ▁Arm", + "▁Treatment ▁Arm▁B", + "▁measurement s▁of", + "▁the▁end▁of ▁study", + "chemotherapy ▁and▁", + "stor ed▁in▁the▁", + "\n\nAdd▁ 12", + "▁20 ▁mg/mL", + "▁phase▁ 1", + "most \n\n", + "most ▁severe▁", + "▁is▁not ▁consider", + "y▁s can", + "........................................................ ...▁", + "▁AND ▁S", + "▁AND ▁PROCEDURES", + "▁thes e▁two", + "▁advanced▁ HNC", + "); ▁and▁", + "Ex perience▁", + "Ex clusion▁Criteria", + "▁mg/kg ▁to", + ".\n\n6 .3", + ".\n\n6 .4", + "dependent ▁on", + "▁contain s", + "▁CA SE", + ".▁Ad ministration", + "pothes is", + "Pro ject", + "▁PD ▁PD", + "ance▁of ▁approval▁must▁be▁", + "▁an▁ optional", + "▁an▁ outpatient", + "▁prior ▁bevacizumab", + "▁Con tinu", + "▁sunitinib ▁administer", + "▁Grade▁ ≤", + "withdraw al▁of▁consent", + "e/ carboplatin", + "mor ning", + "y▁( or", + "2- year", + "off -F", + "central▁ lab", + "▁caus e▁of", + "▁caus ality▁", + "▁human ▁tumor", + "▁human ▁immunodeficiency▁vir", + "reason able▁", + "reason s▁for", + "reason (s)", + "clos ure▁of", + "▁record ed▁since▁the▁treatment▁start", + "ated▁in to", + "hav e▁to", + "hav e▁to▁be▁", + "▁dat e.", + ".\n\nE ach", + ",▁199 0", + "ised▁ of", + "▁antic oagulation", + "vestigational▁ Plan", + "vestigational▁ New", + "\n\nm etastatic", + ",▁d ecreas", + "laboratory▁ finding", + "Assessment s:", + "▁Assessment s\n\n", + "rac er", + "FACT- C", + ",▁F ehrenbacher▁L", + "▁concentration ▁of▁the▁diluted▁solution", + "lif e-", + "ation,▁ it▁is▁", + "3) .▁The▁", + "▁(C ella", + "gl omerular▁filtration", + "only ▁the▁", + "▁scor es▁", + "▁Nov ▁2009", + "▁design ated▁", + "Endpoint s▁", + "ed▁m ethod▁of", + "standard▁ practic", + "dict ive▁", + "▁CTCAE ▁Grade▁3▁or▁4", + "e▁P oint", + "app a", + "develop ed▁a", + "▁treatment▁arm s:", + "ET ERMINATION▁OF", + "▁the▁primary▁ efficacy▁endpoint", + "▁has ▁also▁been", + "▁conduct ed▁", + "medical▁ information", + "appropriate▁ section", + "▁If ▁a▁patient", + "▁power ▁to", + "▁randomized▁ patients▁", + "▁randomized▁ clinical▁trial", + ",▁m ean", + "up▁to ▁2", + "ing▁of▁the▁ study▁for", + "▁was ▁amend", + "▁the▁data ▁from", + "▁medical \n\n", + "▁November ▁2005", + "▁ident ity", + "▁clinical▁trial s▁of", + "▁clinical▁trial s▁in", + "▁Safety▁ Analysis▁Set", + "37 .5", + "e,▁the▁ report▁accurately▁", + "accept abl", + "▁oxaliplatin ▁or▁irinotecan", + "▁the▁dis pens", + "procedures ▁and", + "need ed", + "second -line▁", + "es▁that ▁I", + "▁“ yes", + "▁function ,▁as▁follows▁(≤", + "direct ly▁to", + "hel d", + "................................................................................................................ ....", + "\n\nConfidential\n\nAMGEN \n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁AMG▁162▁Protocol▁Number:▁20040135▁Date:▁14▁November▁2006\n\nPage▁", + "▁et▁al.▁200 6", + "health ▁status▁", + "▁known ▁to▁be▁", + "urin ary", + "▁6▁month s▁prior▁to", + "▁minimum ▁of▁", + "▁(P RO", + ".▁5 3", + ".▁On e▁", + ".▁On ly", + "important ▁for", + "important ▁to▁the▁", + "important ▁medical▁event", + "histor y", + "metastatic ▁disease▁", + "metastatic ▁colorectal▁cancer", + "activ ities", + "▁guidelin es▁for", + "▁k ept", + "common ▁(", + "s.▁A bstract", + "schedul e▁", + "schedul ed▁visit", + "▁post discontinuation", + "Schedul e", + "\n\nb one▁", + "89 ;", + ",▁O ’", + "▁involv es▁", + "▁Casodex ▁150▁mg", + ".\n\n9 .2", + "cut -off", + "work ing", + "best ▁interest", + "best ▁currently▁available▁", + "▁significance▁level ▁of▁0.05", + "▁approval /renew", + "specific ally▁", + "outlin ed▁in▁section", + "▁character istics▁", + "frequ ent", + "▁the▁sampl e▁siz", + "original ▁sign", + ",▁the▁investigator ▁will", + "▁adverse▁ effects▁of", + "▁Rec urrent", + "\n\nConfidential\n\nAMGEN\n\nProduct: ▁Darbepoetin▁alfa▁Protocol▁Number:▁20010145▁Date:▁16▁July▁2004\n\nPage▁", + "▁pemetrexed▁ 500▁mg/m2", + "▁path ways", + "objective▁ response▁rat", + "judg ement", + "s▁ar e▁th", + ".▁Ex amples▁of", + "urvival▁( OS", + "impl ication", + "grad ed▁according▁to", + "▁reduction ▁in▁the▁", + "▁Research ▁B", + "next ▁cycle▁", + "hypothes is▁", + "hypothes is▁that", + "▁IN VESTIGATOR", + "upon ▁request", + "▁contact ▁the▁", + "▁ext ract", + "▁participant s▁who", + "▁vs.▁ 3.1", + "▁dosing ▁decision", + "▁affect ▁the▁", + "percent age▁", + "▁requir ing▁s", + "▁Dos e\n\n", + "▁this▁protocol ,▁the▁", + ",▁un acceptable▁toxicity", + "▁account ing▁for", + "ed▁as▁a ▁SAE", + "\n\nCon current", + "necessary ▁to", + "necessary ▁to▁elimin", + "▁CT▁scan ▁or▁MRI", + "date▁ and▁", + "▁EGFr ▁signaling", + "▁into ▁the▁study", + "▁blood ▁and", + "lung ▁cancer", + "▁adverse▁events▁ occurring", + "eligibility▁ criteria", + "▁EGFR ▁expression", + "into ▁the▁", + "▁direct ly", + "▁months▁ versus▁", + "permitt ed▁", + "\n\nx▁x▁x \n\nx\n\nx", + "ulmonary▁ embolism", + "had▁ been", + "▁had▁ been", + "TS \n\na.\n\nWhat", + "▁block ad", + "potential ▁biomarker▁development", + "itt ing", + "compli anc", + "defined▁as▁ 4▁week", + "y- Stimulating▁Factor", + "compared▁with ▁docetaxel", + "▁show ed▁", + "prefer abl", + "▁et▁al,▁200 4", + "▁suppl y", + "reporting /", + "▁2007; ▁99", + "e▁dis appearance▁of", + "unless ▁the▁", + "▁Un ited▁", + "▁some▁ circumstanc", + "▁and▁E PA+DHA", + "▁Al gorithm", + "response▁rate▁ was▁", + "▁Coll aborator", + "▁supportive▁ care", + "▁commer cial▁", + "\n\nCT ▁scan", + "▁legally ▁acceptable\n\n", + "▁and▁for ▁6▁month", + "Non- Target▁Lesion", + "▁of▁an ▁over", + "▁of▁an ▁Adverse▁Event", + "ortic oid", + "\n\nWh ere▁", + "▁set -up", + "oste opor", + "extent ▁of", + "▁doses▁of ▁panitumumab", + "▁Analys es▁of", + "TT PD", + "\n\nCR F", + "\n\nCR \n\nNo", + "\n\nCh emotherapy▁", + "▁authorized▁ under▁applicable▁law", + "TH ICAL", + "Reg imen", + "▁Ass oc", + "▁Ass oci", + "add itive▁", + "▁as▁describ ed▁abov", + "progression-free▁s urvival▁(PFS", + "patients▁who ▁have▁", + "antic oagulation", + "▁temperature▁ recording", + "▁liver ▁metastases", + "1/ 3", + "▁EV ALUATIONS", + "formance▁Stat us", + "ing▁any▁ record", + "▁IC D", + "outsid e▁of▁the▁", + "TIONS ▁OF", + "▁initi ally▁", + "method s▁", + "retain ed▁at", + "▁an▁ex tension", + "▁cm 3", + "ure▁in formation", + "e.\n\nThe▁ investigator", + "▁There▁ is▁no", + "▁class ified▁as▁", + "AST ROINT", + "▁endothelial▁ growth▁factor▁receptor", + "amid e,▁", + "ctiv ities▁", + ".▁Clin ical", + "given▁to ▁you", + "▁transfusion s,▁", + "y/ illness▁", + "▁qu arter", + "▁OF▁T RIAL", + "▁el derly▁", + ",▁etc .)", + "▁recover y", + ".\n\nC▁I▁N▁O▁R▁T▁C▁E▁L▁E \n\nN▁A", + "▁or▁n ear", + "Investigational▁Product ▁Accountability▁", + "▁US P", + "▁µ g/mL", + "Carboplatin ▁and▁Bevacizumab", + "serious ”", + "▁Europ e▁versus▁", + "▁malignant ▁pleur", + "ysical▁Ex am", + "Lilly▁ clinical▁research▁physician", + "iel d▁", + "procedure▁ for", + "▁AND▁D ETERMINATION▁OF", + "Qu intiles▁Laboratories▁", + "▁Ep idermal▁", + "▁Ob servation", + "▁months,▁ respectively", + ".▁Dose▁ reduction", + "▁variable▁ and▁", + "▁writ ing", + "▁75% ▁of▁previous▁", + "hemoglobin ▁concentration", + "▁lower ▁level", + "2000 ;", + "\n\n.▁E▁S▁U\n\nE▁R▁O▁F▁E▁B\n\nY▁T▁I▁D▁I▁L▁A▁V \n\nS▁T▁I\n\nK▁C▁E▁H▁C\n\nE▁S▁A▁E▁L▁P\n\n.▁T▁N▁E▁M▁U▁C▁O▁D\n\nC▁I▁N▁O▁R▁T▁C▁E▁L▁E\n\nN▁A\n\nF▁O\n\nY▁P▁O▁C\n\nD▁E▁T▁N▁I▁R▁P\n\nA\n\nS▁I\n\nS▁I▁H▁T", + "vs.▁ >▁6▁month", + "progressive▁disease▁ or", + "▁and▁an ▁IV▁infusion", + "recorded▁as ▁adverse▁events▁", + "▁immediate▁ hazard", + "recover y▁", + ".\n\nPatients▁ who", + "▁clos e▁to", + "30-day▁postdiscontinuation▁follow-up ▁period▁", + "below ▁the▁", + "solute▁neutrophil▁count ▁(ANC", + "▁taking▁as▁referenc es▁the▁smallest▁s", + ".\n\nAmgen▁Thousand▁Oaks \n\nConfidential\n\nAMGEN\n\nProduct:▁darbepoetin▁alfa▁Protocol▁Number:▁20010145▁–▁Amendment▁2▁Date:▁16▁July▁2004\n\nPage▁", + "hyp omagnesemia", + "▁ep ithel", + "\n\nan y", + "atory ▁tract▁infection", + "▁Trial ▁of", + "goal s▁for", + "▁symptomatic ▁progression", + "▁directly▁ or▁to", + "lice▁thickn ess", + "used▁as▁ referenc", + "found▁to▁be▁ abnormal", + "▁studi ed▁in", + "ed▁information ▁about", + "e▁sub mission", + "▁examin e▁the▁", + "▁Pharmac ogenetic", + "▁AN Y", + "▁(n =", + "▁Adverse▁event ▁evaluation", + "EFINI TION▁OF", + "inanc ial", + "▁all▁randomized▁ subjects▁have▁", + "▁400▁mg/m2 ▁IV", + "RBC ▁count,▁hemoglobin", + "confidentiality▁of ▁your▁medical▁record", + "▁Cl ar", + "▁PLAN ▁AND▁PROCEDURES", + "e▁inter action", + "redn ison", + "abd ominal", + "▁the▁subset ▁of", + "▁subject▁is▁ randomiz", + "e▁but ▁are▁not▁limited▁to", + "\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n", + "▁<< contact▁nam", + "\n\nAdd▁2 \n\nAdd▁2", + "ohistoc hemistry", + "▁injur y/illness▁", + "▁or▁IV ▁antifungal", + "▁radiotherapy▁ for", + "▁Investigator’s▁ Brochure▁for", + "itoxant ron", + "ed▁per ▁protocol", + "▁150 mg", + "▁by▁the▁investigator ▁or", + "▁incidence▁ and▁m", + "▁CrCl ▁group", + "e▁(DMC )▁will▁review", + "fiel d", + "loride▁ 50▁mg", + "disclos ure▁of", + "reconstruction ▁algorithm", + "/f avorable▁", + "Per ▁Protocol", + "distribution ▁of▁thes", + "▁your▁last ▁study▁treatment", + "▁should▁contact ▁<", - "▁== >", - "Ori entation", - "ci d", - "c id", - "Car t", - "Ca rt", - "C art", - "▁m urm", - "▁mu rm", - "▁mur m", - "▁ass ez", - "▁asse z", - "▁l inking", - "▁link ing", - "▁lin king", - "build ing", - "▁rec onna", - "▁recon na", - "▁s hook", - "▁sh ook", - "▁sho ok", - "man aged", - "mana ged", - "land a", - "lan da", - "l anda", - "▁Le ón", - "▁cré ation", - "до й", - "oc ity", - "oci ty", - "o city", - "▁w ij", - "▁ wij", - "▁wie ś", - "xt art", - "▁M ove", - "▁Mo ve", - "▁Mov e", - "▁ Move", - "lung en", - "l ungen", - "ству ет", - "or ney", - "orn ey", - "option al", - "opt ional", - "ma cro", - "mac ro", - "Cond ition", - "▁square s", - "▁squ ares", - "▁mist aken", - "▁mistake n", - "án t", - "á nt", - "▁R is", - "▁Ri s", - "▁sent ences", - "▁sentence s", - "er ea", - "ere a", - "e rea", - "▁m ij", - "▁mi j", - "Un d", - "U nd", - "▁nom br", - "z A", - "▁In dependent", - "▁Indep endent", - "▁Independ ent", - "▁p review", - "▁pre view", - "▁prev iew", - "▁ preview", - "im as", - "ima s", - "i mas", - "▁m ales", - "▁ma les", - "▁mal es", - "▁male s", - "in ental", - "inen tal", - "inent al", - "Th ank", - "▁p opol", - "▁po pol", - "▁pop ol", - "▁p over", - "▁po ver", - "▁pov er", - "▁gr asp", - "▁gra sp", - "▁im ped", - "▁imp ed", - "▁campion ato", - "▁W ei", - "▁We i", - "▁t itled", - "▁title d", - "▁tit led", - "▁A demás", - "▁Pass word", - "▁ Password", - "▁P am", - "▁Pa m", - "UI LD", - "▁ли пня", - "wer b", - "we rb", - "w erb", - "........ ........", - "▁R ío", - "▁te eth", - "b p", - "▁S W", - "▁ SW", - "ul aire", - "ula ire", - "▁se ized", - "▁sei zed", - "▁St ef", - "▁Ste f", - "ú l", - "▁v iz", - "▁vi z", - "ion y", - "io ny", - "i ony", - "▁j unt", - "▁ju nt", - "▁jun t", - "▁kter á", - "▁wrześ nia", - "< >", - "▁s urg", - "▁su rg", - "▁sur g", - "▁tu tte", - "▁tut te", - "▁H ob", - "▁Ho b", - "по від", - "пов ід", - "▁w ohl", - "▁wo hl", - "▁ wohl", - "▁t rag", - "▁tr ag", - "▁tra g", - "▁C rown", - "▁Cr own", - "▁Cro wn", - "▁Crow n", - "▁tr ova", - "▁tro va", - "▁trov a", - "сто ву", - "стов у", - "▁Vien na", - "ese hen", - "▁met ropol", - "▁reflect ed", - "те та", - "тет а", - "т ета", - "▁trad uc", - "▁tradu c", - "▁B ast", - "▁Bas t", - "▁Ba st", - "▁ersch ien", - "wo ord", - "() \"", - "( )\"", - "ta let", - "tal et", - "t alet", - "▁ro ads", - "▁road s", - "ве дения", - "веде ния", - "ühr ung", - "▁c ogn", - "▁co gn", - "▁V alle", - "▁Val le", - "▁Va lle", - "▁Vall e", - "▁land ing", - "▁lan ding", - "▁Re gex", - "▁Reg ex", - "▁I owa", - "▁Io wa", - "dz iał", - "d ział", - "▁erre ichte", - "au m", - "a um", - "▁found er", - "▁fo under", - "▁fou nder", - "ap olis", - "Comp iler", - "▁k op", - "▁ko p", - "▁ kop", - "▁m arc", - "▁ma rc", - "▁mar c", - "▁те ритор", - ")) `", - ") )`", - "▁l ei", - "▁le i", - "▁ lei", - "ge on", - "geo n", - "▁weap ons", - "▁weapon s", - "▁h orn", - "▁hor n", - "▁ho rn", - "▁ horn", - "▁el if", - "▁ elif", - "▁Cap ital", - "▁Capit al", - "ć e", - "▁for all", - "▁ forall", - "▁э та", - "pre view", - "prev iew", - "p review", - "▁D NA", - "▁s id", - "▁si d", - "or ch", - "▁R as", - "▁Ra s", - "▁a rab", - "▁ar ab", - "▁ara b", - "▁ arab", - "Be st", - "B est", - "▁с чита", - "▁L ópez", - "an ça", - "▁fun kc", - "▁t ienen", - "▁tiene n", - "▁ti enen", - "▁tie nen", - "; &", - "m useum", - "▁E rr", - "▁Er r", - "▁ Err", - "▁re sort", - "▁res ort", - "No v", - "N ov", - "▁k al", - "▁ka l", - "▁ kal", - "M W", - "ш ь", - "an chor", - "anc hor", - "anch or", - "▁ро ман", - "le ading", - "lea ding", - "▁m anten", - "▁ma nten", - "▁man ten", - "▁mant en", - "▁Sil va", - "da de", - "d ade", - "▁design ated", - "▁rev ista", - "▁revis ta", - "O ct", - "per cent", - "▁у ні", - "ident ifier", - "ma ss", - "mas s", - "m ass", - "@ @", - "uls ion", - "ger meister", - "g ermeister", - "▁pred icted", - "▁predict ed", - "▁с ви", - "жно й", - "ж ной", - "▁Er geb", - "▁c ust", - "▁cu st", - "▁remove s", - "▁remov es", - "ch arg", - "char g", - "cha rg", - "при мер", - "▁for ming", - "▁form ing", - "as ma", - "asm a", - "std out", - "F un", - "ym e", - "y me", - "ter ed", - "te red", - "tere d", - "t ered", - "urs ive", - "ig hed", - "igh ed", - "▁сле д", - "▁ след", - "ver band", - "verb and", - "▁LO G", - "▁ LOG", - "ra ms", - "ram s", - "r ams", - "éo n", - "é on", - "en dra", - "end ra", - "▁Be reich", - "▁Bere ich", - "▁tempor al", - "▁temp oral", - "▁tempo ral", - "▁lang ue", - "▁lan gue", - "▁I nn", - "▁In n", - "▁more over", - "▁tutorial s", - "M iddle", - "▁совет ский", - "▁mainten ance", - "as ures", - "asure s", - "▁vál to", - "BA SE", - "B ASE", - "▁disapp ear", - "ски я", - "▁conoc ido", - "▁На у", - "▁Li bert", - "▁Lib ert", - "▁Liber t", - "▁Har old", - "▁life time", - "▁lif etime", - "▁T ür", - "▁za wod", - "▁zaw od", - "om ic", - "omi c", - "o mic", - "▁Retrie ved", - "arch itecture", - "č ka", - "iform es", - "develop ment", - "ord nung", - "In f", - "le ben", - "leb en", - "l eben", - "▁St ars", - "▁Sta rs", - "▁Star s", + "▁T E", + "▁T eam", + "▁T ype▁I", + "up rac", + "▁N 0", + "▁N etwork", + "▁N UMB", + "du plicate▁", + "ep rivation", + "will▁be▁ the▁", + "com be▁", + "com pany▁", + "▁for ▁infusion", + "▁for ▁Arm▁B", + "e\n\n R", + "e\n\n report▁form", + "ed▁in terval", + "enc y▁(", + "enc ies▁of", + "ical▁ or", + "ed▁to ▁participate▁in", + "ed▁to ▁evaluate▁the▁", + "▁with ▁at▁least▁one▁", + "ed▁b evacizumab", + "s▁of ▁this▁", + "s▁of ▁these▁", + "s▁of ▁10▁mm", + "In fusion", + "ant ibiotic", + "\n\nS ub", + "▁that ▁was▁", + "▁that ▁no", + "▁that ▁can▁be▁", + "▁is▁ <", + "▁is▁ consider", + "▁is▁ met", + "▁is▁ expected▁to", + "▁is▁ well▁tolerated", + "▁of▁ Health", + "▁of▁ used▁and▁", + "▁will▁be▁ follow", + "▁will▁be▁ complet", + "▁will▁be▁ determin", + "▁will▁be▁ mad", + "▁will▁be▁ label", + "▁will▁be▁ summarized▁", + "e▁s yring", + "e▁s ee▁the▁", + "art ▁I", + "e▁th ey▁", + "▁M R", + "▁M ,▁B", + "▁M ,▁et▁al", + "▁3 .1.1", + "▁3 rd", + "▁con fidential▁", + "event h", + "event ▁goal", + "▁of▁the▁ study▁drug", + "▁of▁the▁ liver", + "e,▁ p", + "e,▁ BUN", + "ph ys", + "ph otograph", + "ph agia", + "▁com pared▁", + "▁com position", + "▁F R", + "▁F our", + ".▁A MG▁162", + ".▁A ssessment", + ".▁A merican", + ".▁The▁ randomization", + ".▁The▁ study▁drug", + "▁as▁ judg", + "not ed", + "not ▁pre", + "as▁ per", + "01 0", + "01 94", + "200 2.▁", + "▁are▁ given", + "▁are▁ as▁follows:", + "▁on ▁D", + "▁on ▁which", + ",▁and▁ 4", + ",▁and▁ will▁be▁", + ",▁and▁ will", + ",▁and▁ leucovorin", + ",▁and▁ maximum", + "▁v ▁3.0", + "ly▁ in", + "int roduction▁of", + "▁B MI", + "▁B lood▁sampl", + "▁this▁ determin", + "s,▁ concomitant▁medication", + "af e▁", + "▁res istant", + "▁res pectively", + "12 4", + "12 5", + "▁st omach", + "▁st reamlin", + "\n\nC lin", + "\n\nC ancer", + "\n\nC BC", + "\n\nC riteria▁for", + "\n\nC rCl", + "▁will ▁get", + "e▁in formed▁consent", + "follow ed▁by", + "▁5 00▁mg", + "will ▁include▁", + "▁6 .7", + "▁6 ▁cycles▁of", + "from ▁baseline▁of", + "▁subject s▁and▁", + "▁subject ▁number", + "▁patients▁ at", + "▁patients▁ not", + "▁patients▁ having", + "▁4 .3.1", + "▁4 .2.3", + "▁the▁p ossible▁", + ")\n\n o", + "dition ally", + "▁at test", + "▁at ▁hom", + "s▁( A", + "▁ac cess▁", + "▁study▁ week", + "continu ance▁of▁approval▁must▁be▁sent▁to", + "lo ok", + "s▁in ▁the▁primary▁prevention▁of", + "▁cancer ▁therapy", + ".5 ▁mg/dL", + "s.▁ G", + "s.▁ No", + "ens us", + "rel ate▁to", + "cons umption", + "▁the▁t oxic", + "ak o", + "ak ▁A", + "▁wh it", + "\n\nD ec", + "\n\nD ocument", + "\n\nD ate▁of", + "\n\nD etermination▁of", + "▁after ▁4▁weeks,▁", + "xic am", + "s▁and▁ for", + "s▁and▁ questions▁about", + "ed▁on ▁study▁", + "e▁d ocetaxel", + "e▁d eriv", + "\n\nX \n\n", + "ly ophil", + ".▁S TA", + ".▁S emin", + "ob arb", + "▁patient ▁survival", + "10 ▁mm▁with▁spiral▁CT▁scan", + "▁the▁d efin", + "▁the▁d ate▁and▁", + "TI T", + "s▁will▁be▁ compared▁", + "▁G rowth▁Factor", + "report ▁on", + "▁U rol", + "▁e y", + "▁J ,▁et▁al", + "▁In jur", + "▁In stitutional▁Review▁Board", + "▁In dependent▁Ethics▁Committee/In", + "),▁ WBC▁differential▁(neutrophils,▁", + "▁ant is", + "s\n\n \n\n", + "EN ETIC", + "s▁for ▁all", + "su ccess", + "▁dos ing▁schedul", + "formation ▁on", + "effect iveness▁of", + "CT ▁or▁MRI▁scan", + "may▁ not▁be▁", + "▁10 4", + "ibl e\n\n", + "▁analysis▁ population", + ".▁E vid", + ".▁E fficacy▁of", + ".▁E pidermal▁", + ".▁E nrollment", + "▁assessment s▁and▁", + "▁test ed▁in", + "record s▁to", + "over ▁2", + "over dos", + "RA L", + ".▁C oll", + "▁sign ing▁this▁document", + "▁ab str", + "▁ab solute▁", + ".▁T im", + "’s▁ disease,▁", + "’s▁ continuance▁of▁approval▁must▁be▁sent▁to", + "▁x ▁10", + "20 5", + "20 °C", + "drug ▁delivery▁system", + "CR P", + "ed▁at ▁any▁tim", + "radi ol", + "e.\n\n D", + "e.\n\n 13", + "e.\n\n C▁I▁N▁O▁R▁T▁C▁E▁L▁E", + "patient ▁hospital", + "▁disease▁ from▁normal", + "): S", + ".,▁ B", + "cal endar", + "pre dominant", + "▁data ▁and▁", + "▁data ,▁or", + "▁trial s▁for", + ").\n\n With:", + "................................................................................ .▁", + ".7 3", + "\n\n2 6", + "\n\n2 .3", + "\n\n2 \n\n2\n\n3", + "\n\n2 ▁6▁1▁G▁M▁A", + "▁should▁be▁ performed", + "ne o-)", + "\n\nR out", + "subject ▁number", + "etermin ation▁of▁", + "▁the\n\n protocol", + "▁has▁ shown", + "▁has▁ occurred", + "ass ification▁of", + "ence▁ between", + "▁a▁s impl", + "present ed▁as▁", + "14 )(cid:", + "\n\nT wo", + "\n\nT otal▁", + "\n\n3 .2", + "000 ▁IU", + "protocol ▁must▁be▁", + "protocol -specific", + "serv ed▁", + "▁the▁patient ▁or", + "▁the▁patient ▁should▁be▁", + "respons es", + "ER GENC", + "ST A", + "s▁are▁ present", + "▁dose▁ del", + "▁inter rupt", + "ed▁as ▁a▁m", + ".\n\nA BX-EGF", + "\n\nThe▁ primary", + "\n\nThe▁ Master▁Informed▁Consent▁Form", + "ed▁in▁the▁ Laboratory▁", + "\n\n4 .", + "\n\n4 9", + "uc ose▁", + "abil ization", + "e▁b i", + "e▁b aseline▁", + "e▁b eing", + "▁therapy .▁The▁", + "s▁that ▁cannot▁be▁", + "\n\nI rinotecan", + ",▁S e", + ",▁S ha", + "▁panitumumab ▁plus▁FOLFIRI", + "▁panitumumab ▁@", + "▁visit s▁to", + "defin ed▁by", + "olor less", + "▁it s\n\n", + "▁it s▁s", + "car ina", + "es,▁ but", + "result s▁s", + "performed▁ with", + "performed▁ at▁the▁", + "which ▁was▁not", + "Clinical▁ Trial▁", + "equ isition", + "▁death s▁are▁", + "▁death ,▁whichever", + "▁death ▁from▁any▁caus", + ".\n\nS h", + "▁30 ▁months▁after▁the▁last", + "rans amin", + "dos e)", + "ally ▁and▁", + "An y▁", + "An alysis▁of", + "e▁and▁ Method", + "e▁and▁ femal", + "provid ed▁in", + "provid ed▁to▁the▁", "sign al", - "sig nal", - "▁gram mar", - "▁cor so", - "▁cors o", - "▁W agner", - "▁ge ht", - "▁royal e", - "▁roy ale", - "wa rn", - "war n", - "w arn", - "um bled", - "umb led", - "umble d", - "▁inst it", - "▁ins tit", - "▁Ш и", - "h h", - "▁ref uge", - "▁favor ite", - "ier to", - "iert o", - "▁cond ado", - "▁T her", - "▁The r", - "▁Th er", - "▁человек а", - "▁челове ка", - "▁F ood", - "▁Foo d", - "▁Fo od", - "▁se izo", - "▁sei zo", - "▁Init ialize", - "▁Initial ize", - "▁con nu", - "▁conn u", - "▁over lap", - "▁E mil", - "▁Em il", - "▁Mart í", - "▁жовт ня", - "er va", - "erv a", - "▁bo ats", - "▁boat s", - "a ções", - "▁der rot", - "▁m alloc", - "▁mal loc", - "▁ malloc", - "▁con ject", - "▁conj ect", - "j k", - "▁s are", - "▁sa re", - "▁sar e", - "ле мен", - "лем ен", - "▁s ums", - "▁su ms", - "▁sum s", - "Author ization", - "▁K un", - "▁Ku n", - "]$ ,", - "] $,", - "geme inde", - "gemein de", - "g emeinde", - "od ot", - "odo t", - "o dot", - "de fin", - "def in", - "▁e mission", - "▁em ission", - "▁Кра с", - "▁app art", - "▁ap part", - "▁appar t", - "▁stop ping", - "▁sto pping", - "▁С ред", - "▁conj ug", - "▁ins ight", - "▁Broad cast", - "▁PM ID", - "▁adv antages", - "▁advantage s", - "en es", - "ene s", - "e nes", - "▁res idence", - "▁resid ence", - "lj en", - "l jen", - "iss eur", - "isse ur", - "▁pubblic ato", - "▁Git Hub", - "▁Per u", - "▁Pe ru", - "▁galax ies", - "▁annot ations", - "▁annotation s", - "ga s", - "g as", - "▁ré pond", - "▁rép ond", - "J s", - "▁independent ly", - "▁independ ently", - "N P", - "▁in qu", - "▁gr ounds", - "▁ground s", - "Com ponents", - "Component s", - "▁a nten", - "▁an ten", - "▁ant en", - "▁ante n", - "▁ anten", - "▁в з", - "▁h os", - "▁ho s", - "▁ hos", - "▁s int", - "▁si nt", - "▁sin t", - "▁h iding", - "▁hi ding", - "▁hid ing", - "▁wojew ództ", - "Message s", - "Mess ages", - "▁по каза", - "▁пока за", - "== =", - "= ==", - "▁Ab stract", - "▁ Abstract", - "▁l äng", - "▁län g", - "▁lä ng", - "▁Form ula", - "da wn", - "d awn", - "▁design s", - "Im g", - "▁Portug uese", - "▁incl uy", - "▁inclu y", - "avig ator", - "▁Bro thers", - "▁cont inent", - "▁contin ent", - "▁evident ly", - "ra ce", - "rac e", - "r ace", - "ць кого", - "▁re ck", - "▁rec k", - "▁ reck", - "▁сер пня", - "▁G rey", - "▁Gr ey", - "▁Gre y", - "▁appe al", - "▁un like", - "▁power shell", - "▁pow ershell", - "▁powers hell", - "▁r acc", - "▁ra cc", - "▁rac c", - "fer s", - "fe rs", - "f ers", - "▁bur ning", - "▁burn ing", - "fas st", - "fass t", - "inst alled", - "install ed", - "▁G ive", - "▁Gi ve", - "▁col onial", - "▁colon ial", - "▁ €", - "▁R ö", - "▁ch rist", - "▁chr ist", - "ne hm", - "neh m", - "та м", - "▁cor po", - "▁con virti", - "yt er", - "y ter", - "S ym", - "▁Gree ce", - "▁m oth", - "▁mo th", - "▁mot h", - "▁Joh an", - "▁Jo han", - "▁mon arch", - "▁Down load", - "▁ Download", - "▁c raft", - "▁cr aft", - "▁cra ft", - "▁ craft", - "u ž", - "▁Lu ke", - "▁suf fix", - "▁suff ix", - "\\ /", - "Ha ve", - "H ave", - "▁ка рь", - "▁кар ь", - "▁comfort able", - "▁t ips", - "▁tip s", - "▁ti ps", - "▁П ісля", - "▁бро ја", - "▁ин форма", - "M Q", - "бра н", - "б ран", - "▁t x", - "▁ tx", - "▁sl aves", - "▁sla ves", - "▁slave s", - "▁fire wall", - "▁For ces", - "▁Force s", - "at if", - "ati f", - "▁Qu ellen", - "▁thé âtre", - "ль ных", - "▁располо жен", - "▁Det ails", - "▁ Details", - "k ą", - "▁long itud", - "IN ST", - "▁n aval", - "▁na val", - "▁nav al", - "Fern seh", - "es sel", - "ess el", - "esse l", - "Gr ad", - "G rad", - "▁be lang", - "▁bel ang", - "▁a ggi", - "▁ag gi", - "▁ aggi", - "Zygote Init", - "ł ów", - "▁S ug", - "▁Su g", - "si l", - "s il", - "▁ex terior", - "щ і", - "OR D", - "en ser", - "ens er", - "ense r", - "▁rapid e", - "▁rap ide", - "▁тем пера", - "in cie", - "inci e", - "inc ie", - "S i", - "av am", - "ava m", - "ar ded", - "ard ed", - "arde d", - "▁Ad ded", - "▁Add ed", - "End point", - "hard t", - "har dt", - "ст ран", - "стра н", - "стр ан", - "▁est ilo", - "▁H az", - "▁Ha z", - "▁mus ste", - "▁muss te", - "u o", - "ii i", - "i ii", - "▁ř í", - "▁ ří", - "an zen", - "anz en", - "anze n", - "же ний", - "ah a", - "a ha", - "ARN ING", - "▁re nov", - "▁ren ov", - "▁div ine", - "▁convin ced", - "▁hum ans", - "▁human s", - "▁hu mans", - "▁depart ure", - "▁Med iter", - "▁Medi ter", - "q a", - "▁poss essed", - "▁possess ed", - "▁цер кви", - "gi v", - "g iv", - "▁сво ї", - "▁Ort ste", - "▁Orts te", - "R ich", - "pu is", - "p uis", - "in crement", - "▁Hann over", - "▁u cz", - "Do ne", - "Don e", - "D one", - "▁alg uns", - "FI X", - "F IX", - "▁Her itage", - "remove Class", - "фе р", - "ф ер", - "▁a bc", - "▁ab c", - "▁ abc", - "D r", - "▁се мей", - "▁сем ей", - "{ :", - "▁se ule", - "▁seu le", - "▁seul e", - "zeich nungen", - "zeichnung en", - "ad dy", - "add y", - "▁Par ís", - "üss eld", - "▁re ception", - "▁rece ption", - "fo lio", - "fol io", - "ti ny", - "t iny", - "▁recens ement", - "▁N ur", - "▁Nu r", - "▁k ier", - "▁ki er", - "▁g mina", - "▁gmin a", - "sta at", - "ánd ose", - "че ская", - "▁spe aker", - "▁speak er", - "▁expon ential", - "▁exponent ial", - "▁D ieu", - "▁Die u", - "▁Di eu", - "▁при з", - "▁пр из", - "▁Raf ael", - "▁gg plot", - "▁Tem plate", - "▁Temp late", - "▁ Template", - "ou re", - "our e", - "o ure", - "▁In ner", - "▁Inn er", - "▁ Inner", - "og ne", - "ogn e", - "ig are", - "iga re", - "▁Ar te", - "▁Art e", - "▁C ov", - "▁Co v", - "▁auf grund", - "▁Б ы", - "▁cerem ony", - "▁S part", - "▁Sp art", - "ject ive", - "y i", - "▁in izi", - "▁l atin", - "▁lat in", - "▁Never theless", - "▁D one", - "▁Do ne", - "▁Don e", - "▁ Done", - "т ря", - "▁A rr", - "▁Ar r", - "▁ Arr", - "se ason", - "▁скла ду", - "▁pod czas", - "▁Beaut iful", - "▁Weltkrie g", - "▁з о", - "▁ зо", - "▁over come", - "▁Pr aha", - "▁Pra ha", - "▁рай ону", - "▁райо ну", - "▁район у", - "▁sub scription", - "▁subs cription", - "▁subscri ption", - "ig ent", - "igen t", - "ige nt", - "i gent", - "▁по ка", - "la tex", - "lat ex", - "late x", - "▁b each", - "▁be ach", - "▁ро ках", - "ge g", - "g eg", - "▁pro bl", - "▁prob l", - "arg uments", - "argument s", - "▁organ izations", - "▁organiz ations", - "▁organization s", - "▁N an", - "▁Na n", - "▁st ones", - "▁sto nes", - "▁stone s", - "▁H unter", - "▁Hun ter", - "▁regular ly", - "шо го", - "ш ого", - "▁flex ible", - "op ts", - "opt s", - "o pts", - "á ř", - "wi tz", - "w itz", - "▁' )", - "▁ ')", - "PA SS", - "P ASS", - "▁k raj", - "▁kr aj", - "▁kra j", - "▁f ake", - "▁fa ke", - "he its", - "heit s", - "os ph", - "osp h", - "parse Int", - "F ALSE", - "▁prof ess", - "▁profes s", - "pe ople", - "▁pre cip", - "▁prec ip", - "dir name", - "▁per pet", - "▁Up dated", - "▁Update d", - "▁ Updated", - "ra yed", - "ray ed", - "▁prov oc", - "▁тра вня", - "▁трав ня", - "▁categ orie", - "▁categor ie", - "▁те о", - "с ну", - "ot r", - "o tr", - "▁Вер хов", - "▁comp ét", - "Co st", - "C ost", - "▁w ider", - "▁wide r", - "▁wid er", - "▁Ob viously", - "пи сан", - "писа н", - "пис ан", - "▁на стоя", - "▁see king", - "▁seek ing", - "() ),", - "()) ,", - "( )),", - "▁é quipe", - "▁équip e", - "▁ équipe", - "▁comm its", - "▁commit s", - "▁S vens", - "▁Sv ens", - "я бре", - "at ern", - "ate rn", - "ater n", - "a tern", - "▁h eter", - "▁he ter", - "▁het er", - "▁Boot strap", - "én é", - "é né", - "▁deriv atives", - "▁derivative s", - "▁Det roit", - "▁provin cial", - "▁provincia l", - "onom ie", - "E B", - "▁c uer", - "▁cu er", - "▁от носи", - "▁отно си", - "▁не й", - "▁н ей", - "▁ ней", - ") ».", - "▁Ci udad", - "IA L", - "I AL", - "zy st", - "z yst", - ")\" )", - ") \")", - "▁Al c", - "bl ogs", - "blog s", - "blo gs", - "b logs", - "▁par mi", - "▁Album s", - "▁Alb ums", - "▁Bo liv", - "▁Bol iv", - "▁c lés", - "▁cl és", - "Product s", - "uer do", - "▁ge lang", - "▁gel ang", - "zn ik", - "z nik", - "ha gen", - "h agen", - "an onymous", - "▁sv g", - "▁ svg", - "▁Cons eil", - "▁Conse il", - "▁A ri", - "▁Ar i", - "col i", - "co li", - "c oli", - "▁c zy", - "▁cz y", - "▁ czy", - "▁C V", - "▁ CV", - "▁f ord", - "▁for d", - "▁fo rd", - "▁ ford", - "▁Au ßer", - "▁Auß er", - "▁C I", - "▁ CI", - "▁t empt", - "▁tem pt", - "▁temp t", - "▁Organ isation", - "á š", - "▁cy cles", - "▁cycle s", - "▁cycl es", - "▁ges lacht", - "▁лю дей", - "ým i", - "ý mi", - "▁S pieler", - "▁Spiel er", - "ef e", - "e fe", - "▁Mar vel", - "▁por tal", - "▁port al", - "▁porta l", - "▁ portal", - "▁Сер г", - "▁g rado", - "▁gr ado", - "▁gra do", - "▁grad o", - "▁hand lers", - "▁handle rs", - "▁handler s", - "▁Inter face", - "▁ Interface", - "AM E", - "A ME", - "▁ser iously", - "▁serious ly", - "▁B inding", - "▁Bin ding", - "▁Bind ing", - "▁ Binding", - "▁R ang", - "▁Ra ng", - "▁Ran g", - "▁n ada", - "▁na da", - "▁nad a", - "oc e", - "o ce", - "▁inte gra", - "▁integr a", - "oc racy", - "ocr acy", - "▁аль бо", - "▁st ability", - "▁stabil ity", - "Un s", - "U ns", - "▁v eter", - "▁ve ter", - "-- ----+", - "---- --+", - "--- ---+", - "------ +", - "----- -+", - "▁se rait", - "▁ser ait", - "▁sera it", - "▁om itted", - "▁uncertain ty", - "on ian", - "oni an", - "onia n", - "▁re sto", - "▁r esto", - "▁res to", - "▁rest o", - "▁же лез", - "▁од ной", - "▁одно й", - "▁Bevölker ung", - "▁K raft", - "▁Kr aft", - "▁Kra ft", - "ст р", - "▁Mos cow", - "la ne", - "lan e", - "l ane", - "ar ab", - "ara b", - "a rab", - "▁s pole", - "▁sp ole", - "▁spo le", - "▁сво его", - "? :", - "ST ART", - "▁ин тер", - "▁инте р", - "▁sym pt", - "▁Loren zo", - "▁ej ec", - "▁pros per", - "DA T", - "D AT", - "лимпи й", - "▁sh apes", - "▁shape s", - "value Of", - "▁associ ate", - "▁Med ien", - "▁Medi en", - "EN V", - "▁с ре", - "▁држа ве", - "▁the ories", - "he b", - "h eb", - "▁Way ne", - "▁String Builder", - "iw ers", - "i wers", - "▁M aps", - "▁Ma ps", - "▁Map s", - "Ph ys", - "\\} \\", - "\\ }\\", - "▁P arte", - "▁Par te", - "▁Part e", - "▁Hud son", - "ло н", - "л он", - "L ng", - "▁р ы", - "▁ ры", - "ст ей", - "сте й", - "с тей", - "la u", - "l au", - "an cer", - "ance r", - "anc er", - "▁Co ppa", - "▁Cop pa", - "▁вій сь", - "▁u cc", - "▁Pat tern", - "▁ Pattern", - "▁gar bage", - "▁Gon zález", - "▁Encyc lop", - "et ten", - "ett en", - "ette n", - "Ex ternal", - "Ext ernal", - "RE F", - "R EF", - "> ;", - "lij ke", - "lijk e", - "▁inter sect", - "▁Un less", - "▁de eper", - "▁deep er", - "▁ж і", - "▁ жі", - "de nt", - "den t", - "d ent", - "le f", - "l ef", - "▁ch anson", - "▁diff us", - "▁pr imi", - "▁prim i", - "▁pri mi", - "▁W ieder", - "▁Wi eder", - "▁Wie der", - "▁a ws", - "▁aw s", - "▁ aws", - "ow ana", - "owa na", - "owan a", - "▁so ciale", - "▁social e", - "▁soci ale", - "▁soc iale", - "ik k", - "i kk", - "ль ной", - "льно й", - "▁div isions", - "▁division s", - "▁divis ions", - "ло со", - "▁Cl aud", - "▁Cla ud", - "▁Y a", - "▁v oce", - "▁vo ce", - "▁voc e", - "▁B ranch", - "▁Br anch", - "▁Bran ch", - "▁f itted", - "▁fit ted", - "or r", - "o rr", - "ôt el", - "ô tel", - "st roke", - "str oke", - "list ener", - "listen er", - "im an", - "ima n", - "i man", - "во сто", - "▁Sh ah", - "Int roduction", - "▁new line", - "▁t ile", - "▁til e", - "▁ti le", - "'] ))", - "']) )", - "' ]))", - "▁trav aux", - "▁trava ux", - "CON FIG", - "▁quadr atic", - "on neur", - "onn eur", - "onne ur", - "▁Gi org", - "▁ident ific", - "éric aine", - "érica ine", - "▁UI View", - "▁ UIView", - "▁Lib eral", - "▁Liber al", - "▁K och", - "▁Ko ch", - "▁Berlin er", - "▁Berl iner", - "▁not ifications", - "▁notification s", - "▁Su san", - "▁Sus an", - "▁c adre", - "▁cad re", - "▁K loster", - "▁Kl oster", - "▁exam ine", - "▁е дин", - "▁еди н", - "▁UN ION", - "▁al ten", - "▁alt en", - "▁alte n", - "▁f init", - "▁fin it", - "▁fi nit", - "▁pe dig", - "▁ped ig", - "cy k", - "c yk", - "▁mouv ement", - "▁mou vement", - "IO S", - "I OS", - "▁бри тан", - "▁b out", - "▁bo ut", - "▁bou t", - "▁ав тор", - "▁авто р", - "ниц тво", - "ет о", - "е то", - "le ra", - "ler a", - "l era", - "cl s", - "c ls", - "▁L ey", - "▁Le y", - "am y", - "a my", - "ag ens", - "age ns", - "agen s", - "a gens", - "as hed", - "ash ed", - "▁ok rę", - "г ро", - "el lett", - "ell ett", - "elle tt", - "▁F ellow", - "▁Fel low", - "▁manif old", - "$) ,", - "$ ),", - "ld er", - "l der", - "▁v oz", - "▁vo z", - "▁be gg", - "▁beg g", - "▁b aron", - "▁bar on", - "▁ba ron", - "▁f id", - "▁fi d", - "▁f iring", - "▁fi ring", - "▁fir ing", - "il da", - "ild a", - "de k", - "d ek", - "A U", - "it are", - "ita re", - "itar e", - "▁A ra", - "▁Ar a", - "▁Ex it", - "▁ Exit", - "▁cin emat", - "▁cinema t", - "▁int ros", - "▁intr os", - "▁intro s", - "▁contact s", - "пе ни", - "пен и", - "▁m öglich", - "▁Singap ore", - "str öm", - "▁H ern", - "▁He rn", - "▁Her n", - "▁six th", - "▁public ations", - "▁pub lications", - "▁publication s", - "vi e", - "v ie", - "▁H at", - "▁Ha t", - "▁accept ing", - "á c", - "st wo", - "s two", - "▁quiet ly", - "Ph oto", - "▁b asket", - "▁bas ket", - "▁eigen values", - "▁mé dec", - "▁méd ec", - "▁O limp", - "▁Ol imp", - "▁цер ков", - "al in", - "ali n", - "a lin", - "con sum", - "cons um", - "▁l assen", - "▁las sen", - "▁ lassen", - "▁ан ти", - "▁S eq", - "▁Se q", - "▁ Seq", - "\"; \r", - "\" ;\r", - "ra re", - "rar e", - "r are", - "▁$ |\\", - "▁$| \\", - "▁n ick", - "▁ni ck", - "▁nic k", - "▁ nick", - "df lare", - "V ec", - "bind ung", - "▁b g", - "▁ bg", - "ch anges", - "change s", - "chan ges", - "Day s", - "Da ys", - "D ays", - "▁M ouse", - "▁Mo use", - "▁Mou se", - "▁ Mouse", - "▁wait ed", - "▁wa ited", - "▁Tom atoes", - "▁f as", - "▁fa s", - "▁ fas", - "ver te", - "vert e", - "v erte", - "▁success ion", - "▁succ ession", - "со р", - "с ор", - "▁s ols", - "▁so ls", - "▁sol s", - "▁R ender", - "▁Re nder", - "▁Ren der", - "▁ Render", - "▁lead ership", - "▁leader ship", - "▁leaders hip", - "▁signific ance", - "▁ga uche", - "▁gau che", - "ca no", - "can o", - "c ano", - "▁P ie", - "▁Pi e", - "enso ort", - "▁cam bio", - "▁camb io", - "▁у з", - "▁ende av", - "Comp leted", - "Comple ted", - "Complete d", - "▁Архив ная", - "j d", - "ór ico", - "ó rico", - "▁church es", - "▁an imate", - "▁anim ate", - "▁ani mate", - "▁ animate", - "S G", - "comp ute", - "comput e", - "▁uniform ly", - "IN IT", - "ll es", - "lle s", - "l les", - "Http Request", - "К о", - "Di ff", - "D iff", - "▁s ah", - "▁sa h", - "air o", - "ai ro", - "a iro", - "may be", - "UT E", - "U TE", - "▁D ow", - "▁Do w", - "hu man", - "hum an", - "h uman", - "▁au rait", - "▁aur ait", - "dar k", - "d ark", - "▁re pair", - "▁rep air", - "▁n er", - "▁ne r", - "▁ ner", - "▁D abei", - "▁Da bei", - "▁Bo tan", - "▁Bot an", - "Or iginal", - "Origin al", - "az ă", - "▁N AT", - "▁NA T", - "im per", - "imp er", - "▁Y outh", - "▁You th", - "th es", - "the s", - "t hes", - "▁окру га", - "▁F lo", - "▁Fl o", - "▁break fast", - "ur ls", - "url s", - "▁über nahm", - "ár ios", - "ário s", - "á rios", - "▁O range", - "▁Or ange", - "▁Aff airs", - "sk e", - "s ke", - "▁not ify", - "▁ notify", - "imo ine", - "▁Ar ena", - "▁Are na", - "▁lib eral", - "▁liber al", - "▁o bec", - "▁ob ec", - "if a", - "i fa", - "gu ez", - "gue z", - "g uez", - "ion o", - "io no", - "i ono", - "пера тор", - "▁ret ained", - "▁retain ed", - "fa iled", - "fail ed", - "bin e", - "bi ne", - "b ine", - "т ных", - "▁CG Rect", - "cam era", - "ide note", - "iden ote", - "K B", - "▁l ights", - "▁light s", - "▁P ictures", - "▁Picture s", - "▁Squad ron", - "▁V olk", - "▁Vol k", - "▁b urg", - "▁bu rg", - "▁bur g", - "▁ burg", - ", ]", - "G i", - "ê que", - "make Text", - "▁every body", - "▁Hy per", - "▁Hyp er", - "▁De ux", - "▁gl ory", - "▁glo ry", - "pres entation", - "present ation", - "on ica", - "oni ca", - "onic a", - "o nica", - "▁fr ère", - "ag et", - "age t", - "a get", - "▁h ints", - "▁hint s", - "▁hin ts", - "▁t unnel", - "▁tun nel", - "▁E j", - "ál is", - "á lis", - "▁V iv", - "▁Vi v", - "ствен ных", - "▁c aps", - "▁cap s", - "▁ca ps", - "PA RT", - "PAR T", - "P ART", - "oc i", - "o ci", - "▁p rices", - "▁pr ices", - "▁pri ces", - "▁price s", - "curr ency", - "c urrency", - "▁a chter", - "▁ach ter", - "▁acht er", - "rom agnet", - "ge nder", - "gen der", - "gende r", - "g ender", - "▁s uis", - "▁su is", - "vers ions", - "version s", - "▁Tr aining", - "▁Tra ining", - "▁Train ing", - "in side", - "ins ide", - "eg e", - "e ge", - "▁tot ale", - "▁total e", - "▁D aar", - "▁Da ar", - "▁grud nia", - "▁I er", - "▁occasion s", - "▁occas ions", - "▁k de", - "▁tensor flow", - "▁ tensorflow", - "▁ó r", - "▁ ór", - "Method s", - "▁loop ing", - "▁direct eur", - "k ę", - "▁is omorphism", - "▁Jo ão", - "▁al igned", - "▁align ed", - "▁ aligned", - "он ов", - "о нов", - "ur ger", - "urg er", - "▁n ova", - "▁no va", - "▁nov a", - "mor row", - "m orrow", - "al tern", - "alt ern", - "alter n", - "H D", - "▁m arqu", - "▁mar qu", - "at ivas", - "ativ as", - "ati vas", - "ativa s", - "gg reg", - "g greg", - "▁anci en", - "▁anc ien", - "ni t", - "n it", - "▁sec ured", - "▁secure d", - "mi er", - "m ier", - "▁O le", - "▁Ol e", - "▁ин те", - "▁m inus", - "▁min us", - "▁ minus", - "▁clear er", - "▁n ello", - "▁nel lo", - "▁nell o", - "▁információ k", - "▁pro pre", - "▁prop re", - "{ .", - "il og", - "ilo g", - "i log", - "▁Qu ick", - "▁acc us", - "▁ac cus", - "emp loyee", - "▁з у", - "▁ зу", - "ць кий", - "фі цій", - "▁пу бли", - "▁ публи", - "▁b ent", - "▁be nt", - "▁ben t", - "▁по зво", - "▁П ор", - "▁По р", - "áz í", - "án ico", - "á nico", - "empty set", - "▁sur tout", - "re no", - "ren o", - "r eno", - "un ya", - "▁у ез", - "▁Mill ionen", - "▁listop ada", - "▁M aine", - "▁Ma ine", - "▁Main e", - "▁Mai ne", - "▁gru pos", - "▁grupo s", - "▁grup os", - "▁St orage", - "▁Sto rage", - "▁ Storage", - "▁app le", - "▁ap ple", - "▁ apple", - "▁L ö", - "ou sed", - "ous ed", - "ouse d", - "o used", - "д ро", - "sc i", - "s ci", - "▁hi bernate", - "▁ hibernate", - "do g", - "d og", - "▁во сто", - "▁вос то", - "▁ восто", - "▁intens ity", - "leg end", - "lege nd", - "legen d", - "▁W ille", - "▁Will e", - "▁Wil le", - "▁Wi lle", - "▁szer int", - "ges ellschaft", - "▁L iving", - "▁Li ving", - "▁Liv ing", - "al lo", - "all o", - "▁S plit", - "▁Sp lit", - "▁ Split", - "dr u", - "d ru", - "ne ed", - "n eed", - "▁Дж он", - "▁Sw iss", - "▁sp raw", - "▁spr aw", - "▁be ho", - "▁beh o", - "▁fot ograf", - "▁ren contre", - "▁k is", - "▁ki s", - "▁sign ing", - "▁sig ning", - "ak ult", - "aku lt", - "▁index ing", - "ap or", - "a por", - "▁con ception", - "▁concept ion", - "▁conce ption", - "ag greg", - "agg reg", - "a ggreg", - "▁Са вез", - "▁aff air", - "ě ní", - "A ugust", - "▁се кре", - "▁miesz kań", - "UI Image", - "▁b ishop", - "▁bi shop", - "▁ bishop", - "▁serv ants", - "▁servant s", - "▁tr ail", - "▁tra il", - "di git", - "dig it", - "▁jo ins", - "▁join s", - "▁N ear", - "▁Ne ar", - "öff entlich", - "> {", - "▁sk ład", - "ge führt", - "gef ührt", - "▁Hol z", - "▁Milit är", - "ach i", - "ac hi", - "a chi", - "Up per", - "U pper", - "pi ne", - "pin e", - "p ine", - "ut zt", - "utz t", - "▁nu ova", - "ibr ation", - "▁B ien", - "▁Bi en", - "▁пер вый", - "▁первы й", - "▁Cre ating", - "On ce", - "▁ein mal", - "▁ge ometric", - "▁geomet ric", - "st vo", - "▁k W", - "▁decom position", - "▁com edy", - "▁come dy", - "▁activ ation", - "▁an gry", - "▁ang ry", - "ill eurs", - "ille urs", - "▁inst antly", - "▁instant ly", - "▁suggest ing", - "▁C lay", - "▁Cl ay", - "▁Cla y", - "co t", - "c ot", - "▁G én", - "▁Gé n", - "($ (", - "( $(", - "un wrap", - "▁lif ted", - "▁lift ed", - "▁K it", - "▁Ki t", - "▁ Kit", - "▁l inea", - "▁li nea", - "▁line a", - "▁lin ea", - "о к", - "ha rt", - "har t", - "h art", - "-> _", - "▁n uit", - "▁nu it", - "▁Iss ue", - "ли и", - "▁r öm", - "Task s", - "▁S r", - "▁se is", - "▁sei s", - "as ia", - "asi a", - "}} $.", - "}}$ .", - "} }$.", - ": {", - "control s", - "contr ols", - "▁S tim", - "▁St im", - "▁Re cht", - "▁Rec ht", - "ocia ción", - "oci ación", - "▁N atal", - "▁Na tal", - "▁Nat al", - "▁Philipp ines", - "ul en", - "ule n", - "u len", - "F ixed", - "▁switch ed", - "Z ip", - "os pel", - "osp el", - "▁нача ле", - "▁B lan", - "▁Bl an", - "▁Bla n", - "ur st", - "urs t", - "▁aut our", - "▁auto ur", - "C a", - "▁lat itude", - "▁F rei", - "▁Fre i", - "▁Fr ei", - "▁Mus ée", - "▁K urz", - "▁Kur z", - "▁Ku rz", - "▁reg ião", - "sw ap", - "▁h ate", - "▁ha te", - "▁hat e", - "▁mod ifications", - "▁modification s", - "▁modific ations", - "▁К ом", - "▁Ко м", - "▁Anto ine", - "ug a", - "u ga", - "RE CT", - "R ECT", - "ét er", - "é ter", - "G ROUP", - "▁sacr ific", - "▁W he", - "▁Wh e", - "▁Ste vens", - "▁Steve ns", - "▁Steven s", - "olog ische", - "Sum mary", - "ob s", - "o bs", - "hn en", - "h nen", - "< %=", - "di enst", - "d ienst", - "re mark", - "rem ark", - "r emark", - "▁veröff entlicht", - "е л", - "▁M ock", - "▁Mo ck", - "▁ Mock", - "▁Ль в", - "▁tr ês", - "g b", - "▁celebr ated", - "▁E b", - "▁c osta", - "▁co sta", - "▁cost a", - "▁cos ta", - "▁Ge ographic", - "▁att achment", - "▁attach ment", - "mann schaft", - "▁depend ence", - "� �", - "▁att itude", - "et al", - "eta l", - "e tal", - "vi c", - "v ic", - "ba ut", - "bau t", - "b aut", - "▁д ов", - "▁до в", - "▁ дов", - "▁inter ven", - "▁G ü", - "ón ica", - "ó nica", - "▁P on", - "▁Po n", - "▁dispon ible", - "▁F eb", - "▁Fe b", - "▁wor ship", - "▁Specific ally", - "H y", - "ij u", - "i ju", - "▁c b", - "▁ cb", - "▁sp ac", - "lev eland", - "level and", - "▁local idad", - "▁prec eding", - "▁preced ing", - "▁H essen", - "x p", - "▁W ein", - "▁We in", - "▁Wei n", - "▁Rom â", - "▁gi orno", - "▁gior no", - "▁квіт ня", - "lla ços", - "▁Academ ia", - "▁k ül", - "▁Å rs", - "▁на ј", - "uc lide", - "Inter net", - "Intern et", - "or ton", - "ort on", - "▁c orn", - "▁cor n", - "▁co rn", - "я ми", - "▁\" *", - "▁Fel ix", - "ap at", - "apa t", - "a pat", - "▁сво и", - "MI T", - "M IT", - "ma de", - "mad e", - "m ade", - "▁lo comot", - "хо да", - "ход а", - "F P", - "▁p m", - "▁ pm", - ".* ;", - "▁H amm", - "▁Ha mm", - "▁Ham m", - "` }", - "Layout Inflater", - "== \"", - "= =\"", - "▁E ur", - "▁Eu r", - "▁d ogs", - "▁do gs", - "▁dog s", - "же нии", - "▁a zon", - "▁az on", - "▁ azon", - "▁em ulator", - "▁r icon", - "▁ric on", - "▁ri con", - "be eld", - "▁н у", - "▁ ну", - "▁approxim ate", - "L M", - "▁B ond", - "▁Bo nd", - "▁Bon d", - "▁en h", - "ęd z", - "ę dz", - "▁s olit", - "▁so lit", - "▁sol it", - "Relative Layout", - "et eor", - "ete or", - "ament os", - "amento s", - "▁in direct", + "using ▁a▁m", + "using ▁RECIST", + "urvival▁ status", + "ed▁and▁ may▁", + "ack et", + "201 3", + "▁includ e▁the▁", + "▁over -the-", + "▁sampl e▁of", + "▁sampl e▁size▁", + "▁13 .6", + "perform ed▁in▁accordance▁with", + ".▁R efer▁to", + "you ▁will▁be▁", + ".▁200 3", + "▁subjects▁ on", + "inter val▁", + "▁approximately▁ 50", + "▁AB I", + "▁discontinu e▁the▁patient", + ",▁P ro", + ",▁P ar", + ",▁P ark", + "▁treat ed▁in", + "St age▁IV", + "valu e▁of", + "\n\n\n\n a", + "document ed▁and▁", + "stat e,▁", + "cancer ▁risk", + "▁et▁al ▁2000", "▁ind irect", - "ib ől", - "▁g ros", - "▁gr os", - "▁gro s", - "▁Original s", - "▁Origin als", - "▁Orig inals", - "comm ands", - "command s", - "Ex port", - "Exp ort", - "▁A vec", - "▁Av ec", - "▁sole mn", - "▁solem n", - "▁correct ion", - "▁corre ction", - "▁corr ection", - "▁про води", - "▁прово ди", - "▁Mo sk", - "▁Mos k", - "▁по до", - "▁под о", - "▁geb ied", - "▁nast ęp", - "▁D river", - "▁Dr iver", - "▁Drive r", - "▁ Driver", - "▁O ok", - "▁V ec", - "▁Ve c", - "▁ Vec", - "▁lung o", - "▁lun go", - "fi cos", - "fic os", - "fico s", - "f icos", - "▁s vol", - "▁sv ol", - "▁svo l", - "▁k id", - "▁ki d", - "n ja", - "▁H r", - "▁под дер", - "▁vis ibility", - "▁ visibility", - "▁M éd", - "▁Mé d", - "▁c pu", - "▁cp u", - "▁ cpu", - "dis cussion", - "As set", - "Ass et", - "▁def ense", - "▁Any one", - "▁Just in", - "is zt", - "isz t", - "▁Coll ins", - "▁Val ent", - "▁P ale", - "▁Pa le", - "▁Pal e", - "▁f uel", - "▁fue l", - "▁fu el", - "▁n ose", - "▁no se", - "▁nos e", - "rí guez", - "▁Sch les", - "▁Schl es", - "▁Mal ays", - "▁com mut", - "▁comm ut", - "dr o", - "d ro", - "ui ng", - "u ing", - "▁R ico", - "▁Ric o", - "▁Ri co", - "▁Em ma", - "or p", - "o rp", - "▁K irk", - "▁Kir k", - "▁Qu ando", - "▁Ne ue", - "▁Neu e", - "▁de mande", - "▁dem ande", - "▁demand e", - "▁C over", - "▁Co ver", - "▁Cov er", - "▁res cue", - "▁gew ählt", - "▁Cal endar", - "▁ Calendar", - "▁Mad onna", - "W P", - "os hi", - "osh i", - "▁M aven", - "▁Ma ven", - "▁b elle", - "▁be lle", - "▁bel le", - "▁bell e", - "▁w x", - "▁ wx", - "▁su gar", - "▁sug ar", - "▁Bet rieb", - "▁equilib rium", - "E AR", - "▁text s", - "▁tex ts", - "сло в", - "с лов", - "▁czerw ca", - "▁D üsseld", - "▁EL SE", - "▁am ery", - "▁amer y", - "▁a ni", - "▁an i", - "▁ ani", - "▁o bey", - "▁ob ey", - "▁N ell", - "▁Ne ll", - "▁Nel l", - "▁in ne", - "▁inn e", - "▁т ро", - "▁ тро", - "F D", - "cc o", - "c co", - "▁Z ob", - "▁Zo b", - "al ette", - "ale tte", - "alet te", - "a lette", - "▁má jus", - "ect ed", - "ec ted", - "e cted", - "▁Tur key", - "▁Turk ey", - "▁Wh ether", - "▁Whe ther", - "q i", - "▁ш то", - "▁head quarters", - "en di", - "end i", - "ar us", - "aru s", - "a rus", - "op us", - "o pus", - "▁з оло", - "▁зо ло", - "▁de stru", - "▁dest ru", - "▁L ok", - "▁Lo k", - "▁satisf action", - "() \r", - "( )\r", - "▁Т ер", - "▁Те р", - "Jo se", - "J ose", - "▁con quer", - "▁conqu er", - "▁E ffect", - "▁ Effect", - "Layout Params", - "ie z", - "i ez", - "▁extern s", - "▁gegen über", - "▁E SP", - "▁ES P", - "ol ta", - "olt a", - "process or", - "proc essor", - "▁K ult", - "▁Ku lt", - "▁Atl anta", - "▁t ier", - "▁ti er", - "▁tie r", - "Oper ator", - "▁ди а", - "▁пи сь", - "▁gro ß", - "▁he arts", - "▁heart s", - "▁hear ts", - "▁mill imeter", - "al though", - "alth ough", - "al les", - "all es", - "alle s", - "a lles", - "▁Mag ic", - "tr aining", - "tra ining", - "train ing", - "ol ine", - "oli ne", - "olin e", - "o line", - "▁орган і", - ">\\< ^", - "> \\<^", - "ці аль", - "ex ports", - "export s", - "Work book", - "▁вере сня", - "▁t eles", - "▁te les", - "▁tele s", - "▁tel es", - "▁econom y", - "▁econ omy", - "▁ec onomy", - "▁t rap", - "▁tr ap", - "▁tra p", - "▁ref use", - "▁str anger", - "▁strange r", - "▁stran ger", - "▁inst inct", - "по да", - "ol an", - "ola n", - "o lan", - "▁n ing", - "▁ni ng", - "▁nin g", - "▁ ning", - "inf late", - "infl ate", - "itat ea", - "itate a", - "ack s", - "ac ks", - "a cks", - "▁J oy", - "▁Jo y", - "FL AG", - "FLA G", - "ail and", - "ai land", - "▁sort i", - "▁sor ti", - "▁в пер", - "▁p én", - "▁pé n", - "Not hing", - "No thing", - "N othing", - "▁sz áz", - "▁Á ng", - "▁A UT", - "▁ AUT", - "Act ions", - "Action s", - "A ctions", - "E very", - "▁чер вня", - "▁авто мо", - "▁rout ine", - "▁e struct", - "▁est ruct", - "▁G ang", - "▁Ga ng", - "▁Gan g", - "▁h oles", - "▁ho les", - "▁hol es", - "▁hole s", - "th esis", - "thes is", - "▁con cl", - "▁conc l", - "▁p é", - "ri ers", - "rie rs", - "rier s", - "r iers", - "ро вой", - "рово й", - "р овой", - "ad ic", - "adi c", - "a dic", - "Sp eed", - "Spe ed", - "▁command ed", - "▁N azionale", - "▁Naz ionale", - "Man aged", - "▁DE CLARE", - "▁se dan", - "▁sed an", - "String s", - "Str ings", - "▁sa cred", - "▁sac red", - "▁sacr ed", - "ter such", - "ters uch", - "▁abit anti", - "br it", - "b rit", - "▁N CAA", - "▁NC AA", - "▁С П", - "▁a ged", - "▁ag ed", - "▁age d", - "▁ aged", - "▁Ch iesa", - "▁Chi esa", - "▁re vision", - "▁rev ision", - "▁revis ion", - "op ro", - "o pro", - "▁over write", - "emb ros", - "embro s", - "▁sort ie", - "▁sorti e", - "▁ot ten", - "▁ott en", - "xi v", - "x iv", - "▁d eli", - "▁de li", - "▁del i", - "▁A sp", - "▁As p", - "▁b alls", - "▁bal ls", - "▁ball s", - "ka f", - "k af", - "▁br ave", - "▁bra ve", - "▁все го", - "▁вс его", - "eg n", - "e gn", - "jp eg", - "▁O sten", - "▁Os ten", - "▁Ost en", - "Const ants", - "▁Inf antry", - "▁N ev", - "▁Ne v", - "▁я ких", - "▁як их", - "▁му ниципа", - "ci ja", - "c ija", - "▁p oem", - "▁po em", - "▁ne gro", - "▁neg ro", - "ха р", - "х ар", - "▁A sk", - "▁As k", - "▁a vo", - "▁av o", - "▁ avo", - "▁Me yer", - "▁Mey er", - "▁W esten", - "▁We sten", - "▁West en", - "▁Wes ten", - "▁o ko", - "▁ok o", - "▁ oko", - "ag in", - "agi n", - "a gin", - "▁Süd en", - "▁Sü den", - "ent ries", - "entr ies", - "▁Rep ublik", - "▁Repub lik", - "Collection View", - "-- -----", - "---- ---", - "--- ----", - "------ -", - "----- --", - "- ------", - "▁fire fox", - "▁alc une", - "▁фо то", - "▁отри ма", - "~~~~ ~~~~", - "▁Ра з", - "▁Com plex", - "▁Comp lex", - "▁Comple x", - "▁p ia", - "▁pi a", - "▁public ada", - "we i", - "w ei", - "ced ure", - "occup ation", - "▁medic ine", - "▁dr ove", - "▁dro ve", - "Pro blem", - "▁beg inner", - "▁begin ner", - "▁thorough ly", - "ur ia", - "uri a", - "u ria", - "av ant", - "ava nt", - "avan t", - "uch a", - "uc ha", - "u cha", - "▁l ever", - "▁le ver", - "▁lev er", - "▁te atro", - "▁teat ro", - "AV A", - "A VA", - "sq u", - "s qu", - "tr at", - "tra t", - "t rat", - "iv atal", - "iva tal", - "▁d irty", - "▁dir ty", - "▁se conde", - "▁second e", - "▁sec onde", - "▁grav it", - "▁pro position", - "▁prop osition", - "▁propos ition", - "h bar", - "om ini", - "omin i", - "omi ni", - "▁ ”", - "▁C amil", - "▁Cam il", - "▁Ca mil", - "▁qu een", - "▁que en", - "mod ifier", - "J an", - "▁l yr", - "▁ly r", - "Com boBox", - "ion ic", - "io nic", - "ioni c", - "i onic", - "▁h oly", - "▁ho ly", - "▁hol y", - "▁Sebast ian", - "| _{", - "▁{ @", - "▁мо жно", - "▁мож но", - "▁Cre ative", - "▁inter ess", - "▁inte ress", - "▁C T", - "▁ CT", - "i ções", - "▁ch ant", - "▁cha nt", - "▁ chant", - "▁wsp ół", - "▁Мекси ка", - "▁ran ked", - "▁rank ed", - "▁paździer nika", - "▁b rut", - "▁br ut", - "▁bru t", - "▁far ther", - "▁V erb", - "▁Ver b", - "▁Ve rb", - "▁S even", - "▁Se ven", - "lb l", - "l bl", - "▁mention s", - "▁ment ions", - "▁F ight", - "▁Fig ht", - "if en", - "ife n", - "i fen", - "▁b og", - "▁bo g", - "▁re gres", - "▁reg res", - "▁sc oring", - "ic ane", - "ica ne", - "ican e", - "▁El li", - "▁Ell i", - "▁pie rw", - "▁pier w", - "me asure", - "ński ej", - "ń skiej", - "# {", - "▁де ся", - "▁var maste", - "▁Un ix", - "I Z", - "iti é", - "Prim ary", - "▁Spring er", - "▁Spr inger", - "ün g", - "ü ng", - "▁an v", - "▁vers ione", - "▁version e", - "▁should ers", - "▁shoulder s", - "▁бри га", - "▁j av", - "▁ja v", - "▁ jav", - "lt al", - "l tal", - "▁kall aste", - "▁Mitch ell", - "▁wire less", - "▁wir eless", - "▁Á l", - "resp ons", - "co uld", - "cou ld", - "c ould", - "▁re lax", - "▁rel ax", - "▁rela x", - "▁ relax", - "Lo nd", - "L ond", - "ń cz", - "ство вал", - "ствова л", - "▁pol ski", - "en ç", - "za r", + "plic it", + "plic ated▁", + "plic ated▁in", + "36 ▁month", + "response▁ is▁", + "olorectal ▁carcinoma", + "es▁in formed▁consent", + "ed▁s ol", + "▁receive▁ a", + "▁= ▁4", + "▁= ▁progressive▁diseas", + "▁occur ▁within", + ".▁M aterials▁and▁Suppl", + "▁provid ed▁that", + "▁response▁ is", + "IT E", + "dose▁ will▁be▁", + "dose▁ interruption", + "▁event ▁time▁and▁", + "▁should▁ remain", + ",▁s odium", + "▁these▁ criteria", + "ros is▁", + "mod ality", + "mod e▁of▁administration", + ",▁M D", + ",▁M ac", + ",▁M iller", + "erious ness", + "▁may▁be▁ difficult", + "sequent ial", + "any▁ study-specific", + "arr ative▁", + "▁clinical ▁and▁", + "▁drug s▁or", + "▁drug ▁effect", + "▁up dated▁", + "▁up tak", + "s▁will ▁not", + "▁non- hematologic", + "▁survival ▁time▁will▁be▁", + "observ ations", + "1- 10", + ".9 5", + "man age", + ".▁An ▁additional▁", + ".▁An ticancer", + "review ed▁and▁", + ",▁b efore▁", + "duction ▁of", + "▁gen es▁", + "Ad ditional▁", + "Ad ministrative▁", + "risk /benefit", + "\n\nB lood", + "▁follow-up ▁evaluation", + "▁– ▁Arm▁A", + "\n\nM RI", + "AB O", + "conduct ▁and▁results▁of", + "▁randomization ▁through", + ".▁This▁ will", + "▁receiv ed▁at", + "▁[ 3", + "end▁of ▁infusion", + "end▁of ▁study▁is▁", + "clinical ▁practice▁", + "▁baseline▁ characteristic", + "▁administration ▁of▁", + "▁administration ▁of▁the▁", + "▁any ▁additional", + "▁this ▁analysis", + "cell ent", + "III B", + ".\n\nThe▁ adverse▁event", + "▁advanc ed", + ",▁A straZeneca", + "▁des criptive▁statistic", + "lit er", + ")(cid: 22)(cid:", + ",▁H enne", + ".\n\nC onfidential", + "ma ▁RA", + "yl en", + "▁radi oisotop", + ".▁J ohn’s▁", + "di aphragm", + "▁effect s▁on", + "well ing▁and▁", + "must ▁be\n\n", + ",▁B UN", + "ed▁by▁the▁ applicable▁law", + "s▁of▁the▁ question", + "have▁been ▁answer", + "▁approv ed▁by▁Lilly", + "28 9]", + "▁antibod y,▁", + "efficacy▁ in", + "qual it", + "(s) ▁and▁", + "(s) ▁of▁the▁", + "assessment ▁of▁the▁", + "fre e▁to", + "fre ely▁", + "▁bevacizumab ▁in", + "▁increas es▁in", + "▁increas e▁in▁the▁", + ",▁G ord", + "irinotecan -containing", + "\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct: ▁Panitumumab▁Protocol▁Number:▁20050181▁Amendment▁2▁Date:▁04▁April▁2008\n\nPage▁", + "mis carri", + "design ee", + "ed▁c etuximab", + "ing▁a ▁patient", + "▁minut es▁of", + "▁baselin e", + "oph aryngeal", + "▁anti- epidermal▁growth▁factor▁receptor", + ".1.1 .2", + "during▁the▁ treatment", + "during▁the▁ course▁of", + "during▁the▁ course▁of▁the▁study", + "-m ethyl", + ",▁D avis▁", + "▁review ▁of▁the▁", + "▁review ed▁the▁data", + "Com par", + "\n\n5 .2", + "Jul y▁", + "\n\ns afety▁", + "▁14 ▁day", + "▁no ▁panitumumab", + "emat ological", + "▁first ▁clinical▁fracture▁", + "▁ver b", + "▁randomiz ed", + "Un til", + ",▁L e", + ",▁L ov", + "studies ,▁", + "studies ▁are▁", + "ummar ies▁of", + "▁the▁first ▁on-study▁SRE", + "▁under lying", + "▁coll abor", + "diseas e", + "diseas e▁setting", + "vis ually▁for", + "▁toxicity▁ (", + "ing▁and▁ handl", + "receiving ▁placebo", + "ate ,▁and▁", + "after ▁the▁", + "ing▁s chem", + "▁research ▁doctor", + "▁confirm ▁that▁you", + "at▁least ▁on", + "▁survival▁ in", + "▁bas is▁", + "▁< ▁1", + "▁< ▁0.00", + "▁the▁c ost", + "rof en", + "rof ile▁", + "stor ed▁in▁a", + "\n\nAdd▁ 11", + "\n\nAdd▁ 13", + "\n\nthe▁ study", + "only▁ with", + "confirm ing▁the▁", + "▁long -", + ",▁R iem", + "▁safety▁ report", + "▁20 ▁Nov▁2009", + "most ▁likely", + "pert inent", + "▁symptom s▁(", + "........................................................ .......▁", + "last ▁subject", + ",▁which ▁will▁be▁", + ",▁which ▁was▁", + ",▁which ▁means▁that", + "e.▁ Your", + "e.▁ When", + "clear ance▁", + "-bas ed\n\n", + "\n\n10 .2.1", + "Pro gnostic", + "▁pemetrex ed.\n\n", + "▁pemetrex ed-", + "used▁for ▁subsequent", + "▁sunitinib ▁in▁combination▁with", + "▁sunitinib ▁in▁patients▁with", + "▁consent ing", + "▁consent ▁form", + "▁term ▁follow-up", + "▁model s▁and▁", + "▁patients▁who ▁develop", + ",▁T aylor", + "▁caus ed", + "▁caus es", + "▁human ▁colon▁cancer", + "▁record ed▁on", + "ated▁in jur", + "hav ior", + "▁No :", + "▁its▁ receptor", + "▁metastas es▁(", + "▁metastas is▁(", + "limit ed▁", + ".\n\n5 .3", + "being ▁conduct", + "▁am b", + "▁am en", + "▁high -dose▁", + "▁high ▁affin", + ".▁G iovannucci", + "▁Assessment s▁", + "▁patients ;", + "occurr ing▁in", + "ett ing▁of", + ".\n\nD ocument", + "▁during▁the▁ past", + "▁as▁a ▁referenc", + "▁as▁a ▁22-hour", + "representativ e)", + "▁amendment s▁to", + "s▁must▁be▁ performed▁within", + "adverse▁event ▁has▁", + "▁obtain ed▁from", + "serum ▁pregnancy▁test", + "▁e▁ g", + "▁e▁ s▁", + "▁er as", + "collection ▁and▁", + "collection ▁for", + ".▁199 4", + "▁expression ▁in", + "\n\nPro cedures", + "▁≥ ▁9", + "▁tel omer", + "pan y", + "pir al▁CT▁scan", + "▁studies▁ in", + "e▁tumor ▁measurement", + "▁Confidential ity", + "▁Confidential \n\nPage▁", + "▁interim ▁analysis▁for", + "▁50 ▁mg/m2", + "medical▁ or", + "▁bi ost", + "........................................ ...▁", + "▁tumour ▁assessment", + "Pl us▁", + ",▁you ▁will▁be▁asked▁to", + "▁Ex amin", + "▁risk ▁for", + ",▁N ov", + ",▁N orman", + "MR ▁62", + "of▁the▁ combination", + "oler ated", + "it▁is▁ in", + "▁performance▁stat us▁of▁0", + "s▁were▁ identifi", + "for▁the▁ use▁of", + "combin ed▁with▁the▁", + "▁improv es▁", + "▁(or \n\n", + "▁(or ▁MRI", + "treat ed▁Metastatic▁Colorectal▁Cancer", + "▁compli ant", + "▁subjects▁who \n\n", + "clinically▁ indicated▁", + "skin ▁nodul", + "increas ing", + "resolv ed,▁", + "immedi ately,▁", + "where▁ applic", + "ethyl ation", + "▁does▁not ▁necessarily▁", + "▁fl ush", + "▁“ on-study", + "▁13−Aug−201 3", + "e▁the▁s ponsor", + "lat inum", + "▁are▁s uspect", + "▁4▁week s▁prior▁to", + "reduc ed▁by▁", + "▁my▁ medical▁information", + "\n\nTable▁ 2", + "\n\nTable▁ 4", + "▁(P K", + "▁(m al", + "ed▁until ▁disease▁progression", + "▁termin ology▁", + "), ▁then", + "(S ection", + "▁decreas ed▁", + ".▁V ol", + "activ ities▁", + "▁standard▁ deviation", + ")▁for ▁all", + "▁studies ▁that", + "▁post menopaus", + "▁current ly▁", + "▁and▁d estroy", + "alges ia", + "Schedul e\n\n", + "▁involv es", + "both ▁the▁", + "hemist ry,▁", + "ently▁ in", + "▁and▁in ▁combination▁with", + "▁cycle▁ is▁", + "calculated▁ for", + ".\n\n9 .3", + "best ▁of▁his▁or▁her", + "▁the▁protocol ▁or", + ".\n\n10 .6", + ".\n\n10 .6.2", + "-in duc", + "istribution ▁of", + "ology,▁ 199", + ".▁Patient s▁are▁", + ".▁No ▁other", + "4▁week s▁after", + "while▁ receiving", + "▁February▁200 8", + "▁an▁in vestigational▁", + "▁complete▁ response▁(CR", + "ed▁abov e)", + "objective▁ disease▁progression", + "re- start", + "grad ing▁scal", + "▁of▁your ▁concern", + "e.▁If ▁a", + "▁will▁be▁administer ed▁over", + "▁will▁be▁administer ed▁orally▁", + "▁the▁patient’s▁ medical▁record", + "CH N", + "CH ED", + ".5.1 .3", + "\n\nTo ▁be▁", + "used .▁C", + "▁ha zard", + "▁endpoint s▁will▁be▁", + "▁return ▁all", + "▁return s▁to", + "▁estim ated▁", + "▁estim ates▁and▁", + ".\n\nLY231514 \n\nH3E-US-S130(d)▁Clinical▁Protocol\n\nPage▁", + "▁child -", + "in▁patients▁with ▁metastatic", + "▁adjuvant ▁therapy", + "30-day▁ FU", + "e▁and ▁the▁", + "Outcom e▁In", + "Outcom e▁and▁Method", + "before▁ you", + "▁defin itive▁", + "SRE ▁(", + "▁enroll ▁approximately▁", + "▁enroll ed▁patient", + ",▁V er", + "MS H", + "▁well ▁being", + "▁/ ▁20▁Nov▁2009", + "▁present ▁at▁baseline▁", + "▁del ay▁of", + "Objectiv e(s)", + "DNA ▁methyl", + "pregnant ▁or▁breast", + "unblind ing", + "▁Bo ard", + "▁data▁will▁be▁ collect", + "’s ▁actual▁body▁weight", + "▁thre e▁month", + "immun e▁system", + "permitt ed▁for", + ".▁Treatment ▁with", + "▁Avastin ▁in▁combination▁with", + "\n\nAb breviation▁or▁special▁term", + "received▁ your▁own", + "ergic ▁bronchospasm", + "TS H", + "\n\nc olorectal▁cancer", + "ference▁ with", + "e▁M arin", + "ret ros", + ",▁f ever", + "s\n\nA t", + "s\n\nA ▁serious▁adverse▁event", + "y- state▁", + ",▁v ital▁sign", + "▁(1 40", + "pheral▁ Neuropath", + "▁the▁investigator’s▁ opinion", + "▁et▁al,▁200 5)", + "has ▁to▁be▁", + "has ▁also▁been", + "otherwis e▁indic", + "intervention ▁to▁prevent▁one▁of▁the▁outcomes▁", + "▁siz e▁of", + "▁suppl y▁", + "orph one▁", + "orph anol", + "second▁ line▁", + "prot ection▁of", + "▁differenc es▁will▁be▁", + "Gen etic", + "▁and▁E astern", + "▁Al though", + "▁4.7 .1", + "e▁dose▁ reduction", + ",▁al bumin", + "concomitant▁medication s▁or", + "ed▁at▁the▁ next", + "▁will▁be▁provid ed▁to", + "\n\nCT ▁or▁MRI▁scan", + "▁bone▁metastas es▁in", + "▁of▁121\n\nClinical▁Trial▁Protocol▁IMCL▁CP11-0806▁IMC-11F8\n\nImClone▁LLC▁Version▁6.0 \n\n", + "▁primary▁ cancer", + "▁Pl ann", + "\n\nH3E-US-S130(d)▁Clinical▁Protocol \n\nAttachment", + "investig ative▁", + "investig ating", + "independent ▁ethics▁committe", + "▁item ▁of▁the▁", + "▁hypothes is", + "▁platinum -containing", + "currently▁ undergoing", + "follow▁up ▁phas", + "▁moder ate▁to", + "▁copy▁of ▁this▁document", + "TT F", + "TH FR", + "phen yto", + "phen obarb", + "e▁an y", + "▁antitumor ▁activity", + ".▁Data ▁from", + "FDA ▁regulation", + "▁will▁be▁collect ed▁by▁clinic▁visit▁or▁telephone▁contact▁approximately▁every▁6▁months▁for", + "completed ▁their", + "call ed▁", + "▁blinded▁ IP", + "▁blinded▁ central▁radiology▁review", + "▁Radi otherapy▁", + "▁on▁Day▁1 ▁q21d", + "fail ed▁to", + "rast uz", + "aintenance▁ Therapy▁", + "▁have▁s erum", + "ed- stage▁", + "vertebral▁ fractures", + "angu age▁", + "▁stratifi ed▁by▁", + "war farin", + "▁cod e,▁", + "▁37 .5", + "▁concomitant \n\nmedication", + "s.\n\nS ection:", + "aminotransfer as", + "▁PFS▁event s▁are▁", + "▁documented▁ progression", + "▁worsening ▁of", + "▁hazard▁ratio ▁of▁0", + "▁central▁ review", + "▁and▁f ish▁oil", + "\n\n11 .1", + ".▁Sampl e▁Size▁and▁", + "▁malignanc ies", + "▁are▁the▁ best▁currently▁available▁", + "centr ifug", + "Dis comfort", + "▁is▁defined▁as ▁the▁time▁from", + "\n\nX▁X▁X ▁X", + "▁associated▁ symptom", + "ood▁Clinical▁Practic e▁(GCP", + "deem ed", + "▁efficacy ▁analysis", + ".▁With draw", + "▁these▁s ymptom", + "lack ▁of▁", + "▁qu artil", + "▁tumor▁response▁ assessment", + "▁recover y▁", + "▁valid ated▁", + "▁the▁information ▁collect", + "consist ency▁of", + "\n\nDiscontinu e▁Panitumumab", + "monotherapy▁ in", + "implement ation", + ",▁Y u", + "▁the▁investigational ▁team", + "▁US E", + "blood ;", + "age▁and▁ Administration", + "▁d▁e▁v▁o▁r▁p▁p▁A\n\nProduct: ▁Denosumab▁Protocol▁Number:▁20050244▁Date:▁05▁May▁2008\n\nPage▁", + "▁spir al▁CT", + "▁serum▁creatinine▁ (mg/dL", + "▁cardiac ▁failure", + "▁distribution ▁procedures", + "▁ren al▁function", + "surger y▁or", + "surger y▁to", + "▁46 ▁hour", + "show ed▁", + ".▁Follow -up", + "\n\n75% ▁of▁previous▁dos", + "▁AND▁D ISCO", + "▁Z oledronic", + "▁........................................ .......▁", + "▁of▁16 \n\nPage:", + "Y▁T▁I▁D▁I▁L▁A▁V \n\nS▁T▁I", + "mark ed▁", + "▁pulmonary▁ embolism", + "▁concomitant▁medication s▁and▁treatment", + "urvival▁(PFS) ▁compared▁to", + "whil e▁the▁patient", + "review▁bo ard▁(", + "oz yg", + "ers ma▁RA", + "▁will▁be▁record ed▁in▁the▁", + "platinum -based▁", + "ensiv e▁treatment▁in", + "Statistical▁ Method", + "\n\nGen eral▁", + "▁adverse▁effect s▁that▁you", + "informed▁consent ▁document", + "antibod y▁", + "antibod ies▁", + "Respons e\n\n", + "leming ▁TR", + "▁Derivation▁or▁calculation▁of▁outcome▁variabl e\n\n", + "▁FACT- Fatigu", + "▁disease▁( including", + "▁80% ▁power", + "▁modified▁ version▁of▁the▁", + "▁↓ ▁1▁dose▁level", + "▁soft gel▁capsul", + "ed▁in▁Table▁ 4", + "ence\n\n Replace:", + "▁anti-cancer ▁therapy▁", + "5,▁ 9", + "bod y", + "hyp ocalcemia", + "hyp otension", + "stain ing", + "▁retain ▁the▁right▁to", + "▁remov al▁from", + "▁phase▁II ▁study", + "agnetic▁resonance▁imaging ▁(MRI", + "differ ence▁in", + ".▁Clinical▁ Cancer▁Research", + "ECOG▁performance▁status ,▁body▁weight", + "hemorrh age,▁", + "letter ▁from▁the▁", + "▁institution al▁policy", + "▁75▁mg/m2 ▁on▁Day▁1", + "ed▁at▁baseline▁ and▁", + "24-month ▁evaluation▁period", + "TAXOL ▁package▁insert", + "United▁Stat es▁(", + "United▁Stat es▁and▁", + "achiev ed▁by▁", + "Cont rolled▁", + "null▁hypothes is▁", + "null▁hypothes is▁of", + "investigational ▁agent", + "▁at▁a▁dose▁of ▁120▁mg▁SC", + "resolution ▁of▁the▁event", + "▁subject▁is▁ randomized", + ".▁Adverse▁Event s▁", + "▁representativ e▁of", + "ACKGROUND ▁INFORMATION", + "▁................................................................................................................ ..", + "▁................................................................................................................ ......", + ",▁n ▁=", + "▁domain ▁of▁the▁", + "▁OR ▁P", + "▁signific anc", + "attempt ▁to", + "▁ill ust", + "▁1.1 ▁1.2", + "▁150 ▁mL", + "▁notification ▁to", + "▁notification ▁of▁the▁event", + "OLL OW", + "inal▁cor d", + "al▁well ▁being", + "▁to▁in hibit", + "▁CrCl ▁=▁creatinine▁clearanc", + "Withdraw al▁of", + "▁HA NDLING", + "▁cells /mm3", + "▁countries▁ except▁Japan", + "OX- 2", + "▁po ol", + "▁po ▁=", + "▁seen ▁in", + "▁seen ▁with", + "▁0.00 8", + "▁dose- limiting", + "▁perman ently▁", + "reference▁ by▁which", + "▁micron utrient", + "▁Mod ified▁", + "▁permitt ed▁by▁the▁applicable▁law", + "gu ardian", + ".\n\nRE MOVAL▁AND▁REPLACEMENT▁OF▁SUBJECTS", + "prepared▁ in", + "like▁ growth▁factor", + "▁the▁total▁ number▁of", + "addition▁of ▁cetuximab", + "▁Ab normal▁", + "▁Aci d▁(", + "▁reserv e▁the▁right▁to", + "s▁and▁in spection", + "▁up▁to▁2▁year s▁after▁the▁", + "characteriz ed▁by▁", + "%▁power▁to▁detect ▁a", + "Ethics▁Committe e▁(", + "▁and▁H uman", + "eline▁ for", + "▁200▁mg/m2 ▁racemate▁(or▁100▁mg/m2", + "▁Hematologic ▁Toxicity", + "that▁is ,▁", + "rif amp", + "▁alone▁as▁ first-line▁treatment", + "▁System ▁for▁Lung▁Cancer", + "▁as▁a▁result ▁of▁the▁", + "\n\nComplete▁ response▁(CR", + "▁cours es▁of", + "eleph one▁", + "pros pectively▁", + "radiation▁therapy ▁to▁bone▁", + "Laboratory▁Test s", + "▁knowledg e,▁the▁report▁accurately▁", + "▁portion▁of▁the▁ trial", + "\n\ndocument ation▁of", + ",▁Phase▁3 ▁Study▁of", + "▁Stor age▁and▁", + "▁the▁benefit :risk", + "utrition al▁", + "pen-Label ,▁Phase▁3▁Study▁of", + "▁IRB/ EC", + "▁single▁ agent", + "▁wor ry", + "irradi ated", + "▁impact ▁on", + "▁Staging ▁System▁for▁Lung▁Cancer", + "▁applicable▁law s,▁regulation", + "▁metab ol", + "thir d", + "▁maintenance▁ therapy▁", + "ence▁and▁ nature▁of", + "Questionna ire", + "▁poly unsaturated▁fatty", + "▁Over dose▁", + "▁a▁multicenter ,▁randomized,▁", + "most▁frequ ent", + "▁paraffin-embedd ed▁tumor", + "▁as▁need ed", + "▁dose▁escal ation", + "discontinue▁ therapy", + "▁received▁at▁least ▁one▁dose▁of", + "▁Withdraw al", + "▁wid es", + "▁(K M)", + "fluor esc", + "▁minutes,▁ followed▁by▁5-FU", + "▁procedures▁are▁ performed", + "▁legal▁ representativ", + ".▁Prior ▁treatment▁with", + ".▁Schedule▁of▁Assessment s▁(", + "–▁Arm▁A :", + "▁recom mended▁", + "▁Revised▁Clinical▁Study▁Protocol▁Drug▁Substance▁ZD4054▁Study▁Code▁D4320 C00015▁Edition▁Number▁3▁Date▁7▁December▁2010", + "▁patients▁have▁been ▁enroll", + "\n\nIMC- 1121B", + "▁the▁beginn ing▁of▁the▁", + "2,▁3 ,▁and▁4", + "Return▁of ▁Investigational▁Product▁for▁Destruction", + "▁ann ual", + "abor ative▁", + "ading ▁dose▁of", + "▁Horm one-", + "\n\nElect rocardiogram", + "▁occurr ence▁of", + "atistic s▁in", + "▁regulatory▁ag ency", + "ockcroft-Gault ▁formula", + "food▁ frequency▁", + "▁op ioid", + "▁(ITT) ▁population", + ".▁Elig ible▁", + "s▁sh all", + "▁neuroto xicity▁", + "▁confid ence▁", + "▁SD▁PD ▁PD▁PD", + "uroQol-5▁Dimension s▁(EQ-5D", + "▁the▁duration▁of▁the▁study .▁Copies▁of", + "Zoledronic ▁acid▁", + "euk emia", + "▁etoposide▁ plus▁carboplatin", + ",▁of fice▁work", + "\n\nPl anned▁Methods▁of", + "▁the▁investig ative▁sit", + ".▁Radi ographic", + "▁fluid ,▁or", + "Statistical▁Analysis▁Plan ▁(SAP", + "▁Performance▁Status▁Scal e\n\n", + "▁tablespoon s▁of▁blood▁", + "▁py rogen-free▁0", + "▁ON LY", + "free▁ liqu", + "▁Phone: ▁(507)", + "e▁Collection ▁and▁", + "ACKGROUND▁AND▁RATIONALE ........................................................................", + "-G oebel", + "-f old▁", + "▁a▁30% ▁decrease▁in▁the▁sum▁of▁the▁", + "intention -to-treat", + "▁have▁not▁been ▁met", + ".▁Otherwis e,▁", + "ltras ound", + "▁pur su", + "▁ful fil", + "will▁be▁taken ▁for", + "super ficial▁", + "\n\nNO \n\nYES", + "ed▁to▁the▁extent ▁permitted▁by▁the▁applicable▁law", + "s▁as▁well ▁as▁", + "▁red▁blood▁cell ▁count", + "Specific ▁Antigen", + "selection ��record", + "▁and▁MRI ▁are▁the▁best▁currently▁available▁", + "urrog ate▁", + "ex▁Cor poration", + "ed▁to▁have▁a ▁positive▁benefit:risk▁profile▁compared▁with", + "intens ity▁of", + "will▁remain ▁confidential", + ".▁Clin▁Cancer ▁Res▁", + "idney▁ston es,▁", + "\n\nPROTOCOL ▁SYNOPSIS", + "mg/m2▁IV ▁over▁2", + "▁sponsor-nominated▁ CRO", + "(12 ):▁p.▁", + "bu ffer", + "lev amisol", + "urwitz ▁H", + "respectively▁ (", + "-to- date▁", + "MLH 1", + "harm ful", + "nonsquamous▁ NSCLC", + "▁troponin ▁I", + "▁felt ▁to▁be▁", + "▁3▁x▁ULN ▁(if▁liver▁metastases▁", + "▁results▁of ▁the▁trial▁are▁", + "assigned▁a ▁status▁of", + "▁5-fluorouracil/ ▁leucovorin", + "3)▁(cid:4)▁(cid:5)▁(cid:6)▁(cid: 7)▁(cid:", + "KS ▁AND▁DISCO", + "iro xicam", + "▁Eligibility▁ Criteria", + "▁find▁ out", + "s▁will▁be▁maintain ed▁to▁the▁extent▁permitted▁by▁the▁applicable▁law", + "arrativ es▁of", + "observed▁to tal▁event", + "▁hypo th", + "persons ▁to▁whom", + "▁Rationale▁ ....................................................................................................", + "\n\nQuite▁a▁bit \n\nVery▁much", + "Cockcroft▁and▁Gault ▁formula", + ",▁provid ed▁the▁", + "▁cert ific", + "Ind ian", + "▁global ▁deterioration▁of", + "identical ▁to", + "▁x▁upper ▁limit▁of▁normal▁(ULN", + "▁personal▁ identifier", + "elani ▁CP", + "▁residual ▁disease▁from▁normal", + "-and-subsequent ▁on-study▁SRE", + "▁and▁the▁same▁technique▁should▁be▁used▁to ▁characterize▁each", + "\n\nyes▁ yes", + "▁recombinant ▁human", + "▁the▁typ e▁of", + "▁unstain ed▁slid", + "e▁(NCI )", + "s▁select ed▁for▁response▁assessment", + "▁Version▁4.0 ▁/▁20▁Nov▁2009", + "\n\nNot▁at▁all \n\nA▁little▁bit\n\nSome-▁what", + "▁derivative▁ material", + "▁to▁distinguish ▁residual▁disease▁from▁normal", + "compatibl e▁with", + "▁(longest▁diameter▁to▁be▁ recorded)", + "▁Signatory▁Oblig ations", + "fel d▁", + ",▁changes▁in ▁tumor▁measurement", + "▁EM ERGENC", + "Comprehensive▁ Cancer", + "head▁of▁the▁ medical▁institution", + "▁spending ▁function", + "astroesophageal▁ junction", + "with▁the▁exception ▁of▁", + "\n\nAbbreviations▁and▁Definition s▁(", + "▁competing ▁risk", + "▁denosumab▁is▁determin ed▁to▁have▁a▁positive▁benefit:risk▁profile▁compared▁with", + "\n\nLIST▁OF▁ABBREVIATIONS▁AND▁DEFINI TION▁OF▁TERMS", + "ocial/f amily▁", + "▁CR,▁PR,▁or ▁SD", + "▁the▁prior▁written▁consent▁of ▁Amgen▁Inc", + "lav icular", + "▁(1- sid", + "▁doses▁and▁ schedul", + "analysis▁data▁cutoff▁date▁ will▁be▁censored▁at", + "▁and▁distribut ed▁using", + "▁evaluate▁the▁response▁to ▁treatment▁in▁solid▁tumor", + "Drug▁Administration ▁case▁report▁form", + "preservative▁ free▁liqu", + "discoveries ,▁or", + "offered▁open-label▁denosumab ▁at▁a▁dose▁of▁120▁mg▁SC", + "ual▁pro pert", + "ide▁by ▁all", + "ulin- like▁growth▁factor", + "\n\nEthics▁ review", + "▁must▁be▁completed ▁and\n\n", + "Unevaluable▁ KRAS", + "Schedule,▁ Protocol", + "▁antioxidant ▁supplement", + "published,▁ your▁identity▁", + "\n\nUE/ND \n\nNo\n\nUE", + "▁or▁his/her▁designee▁ is▁responsible▁for", + "PECIFIC ▁A", + "▁are▁those▁ who", + "▁review▁and▁meta- analysis", + "i-squar e▁test", + "\n\nPage:▁36\n\nSection:▁2.3.6.6,▁Anti-Panitumumab▁Antibodies,▁third▁ paragraph\n\nReplace:", + "▁AUTHORI SATION", + "aindrault -Goebel", + "▁of▁16\n\nVersion▁Date:▁14▁November▁2006 \n\nd▁e▁v▁o▁r▁p▁p▁A", + "obility,▁self-care,▁ usual▁activities", + "Los s▁in", + "aortic ▁bif", + "entries ▁and/or", + "udra CT", + "e▁of▁the▁person▁who▁conducted▁the▁informed▁consent▁discussion \n\n1Each▁person▁who▁signs▁the▁consent▁must▁personally▁enter▁the▁date▁for▁his/her▁signature", + "necessary▁to▁elimin ate▁", + "▁authorized▁under▁applicable▁law ▁to▁consent", + "▁taking▁as▁references▁the▁smallest▁s um▁LD", + "confidentiality▁of▁your▁medical▁record s▁will▁be▁maintained▁to▁the▁extent▁permitted▁by▁the▁applicable▁law", + "▁Investigator’s▁Brochure▁for ▁further▁detail", + "▁Staging▁Manual ,▁S", + "▁clinical▁study▁report▁for▁this▁study ,▁", + "ctep.cancer.gov/reporting/ ctc", + "▁Master▁Subject▁Information▁Sheet ▁and▁Informed▁Consent▁Form", + ".▁New▁guidelines▁to ▁evaluate▁the▁response▁to▁treatment▁in▁solid▁tumor", + "▁I▁have▁an▁injury/illness▁related▁to ▁my▁", + ":▁systematic ▁review▁and▁meta-analysis", + "Handbook ▁for", + "arant e", + "olester ol", + "abbin avar", + "uprac lavicular", + "▁with▁at▁least▁one▁ un", + "s▁of▁10▁mm ▁or▁less▁in", + "▁this▁determin ation,▁it▁is▁", + "▁attest ▁that", + "▁after▁4▁weeks,▁ discontinue▁therapy", + "neo-) adjuvant", + "▁over-the- counter", + "▁may▁be▁difficult ▁to▁distinguish▁residual▁disease▁from▁normal", + "have▁been▁answer ed▁to▁your▁satisfaction", + "-methyl gu", + ",▁Riem ersma▁RA", + "MR▁62 20", + "▁“on-study ”", + "▁of▁your▁concern s▁and▁questions▁about", + "Outcome▁In dex", + "received▁your▁own ▁copy▁of▁this▁document", + "e▁Marin is▁F", + "rastuz umab", + "ensive▁treatment▁in ▁an▁emergency▁room", + "▁200▁mg/m2▁racemate▁(or▁100▁mg/m2 ▁l-LV)", + "▁results▁of▁the▁trial▁are▁ published,▁your▁identity▁", + "KS▁AND▁DISCO MFOR", + "▁EMERGENC Y", + "aortic▁bif urc", + "▁Master▁Subject▁Information▁Sheet▁and▁Informed▁Consent▁Form ▁Version▁4.0▁/▁20▁Nov▁2009", + "▁results▁of▁the▁trial▁are▁published,▁your▁identity▁ will▁remain▁confidential", + "( 19", + "( 15", + "( 17", + "( based▁on", + "( serum", + "( e.g.,▁", + "( ii", + ") \n\nPage▁", + ") ▁in▁combination▁with", + ", ▁th", + ", \n\nS", + ", ▁anti-", + ", ▁thes", + ", ▁there▁is", + ", ▁abdominal▁pain", + "- U", + "- 22", + "- log", + "- recurrent", + "- defined▁", + ". ;", + ". W", + "/ investigator", + "/ 13", + "/ NA**", + "0 -1", + "2 ,", + "2 W", + "2 1)(cid:", + "3 ▁(", + "3 46", + "4 %", + "5 .0", + "8 ,▁12", + "9 ;", + ": 2", + ": ▁D", + ": ▁N", + ": \n\nSubject", + ": ▁Amgen▁Inc", + "= 6", + "> 1", + "A bstract", + "B W", + "B aselin", + "B reast▁Cancer", + "C E", + "C L", + "C t", + "C riteria▁for", + "C ,▁W", + "C remophor", + "C XR", + "D CR", + "D ock", + "D 8480C0000", + "D OSE", + "E very▁", + "E MR▁6220", + "G ,▁S", + "H eart", + "H epatic", + "I H", + "I ▁have▁no▁problem", + "I ▁have▁some▁problem", + "I TIES", + "J ournal▁", + "L O", + "M MR", + "N ▁55", + "O AE", + "O MI", + "P M", + "P ark", + "P aclitaxel", + "P ET▁scan", + "P LEX", + "R Y", + "R andomisation", + "T 1", + "T erm", + "T echnical▁Standard", + "U SA", + "U TC", + "V alu", + "W ,▁G", + "[ 3", + "a ro", + "a ros", + "a ad▁", + "a ju", + "a esthes", + "b ,", + "b en", + "b ▁no", + "c k", + "c en", + "c oagulation", + "d ensit", + "e \n\nAd", + "f lo", + "f inger", + "f ebrile▁neutropenia", + "h l", + "h ▁C", + "i ar", + "i PLEX", + "j oy", + "l arynx", + "m ig", + "m icroRNA", + "m embrane▁", + "m ild▁to▁moderate▁in", + "p otent", + "p sych", + "p inal▁cord▁compression", + "s ]", + "s el", + "s alt", + "s atis", + "s ensitive▁", + "s lide▁", + "t y▁", + "u ard", + "v an", + "w ic", + "y es,▁", "z ar", - "▁d type", - "▁dt ype", - "ow ned", - "own ed", - "un known", - "unk nown", - "▁m utable", - "▁mu table", - "▁mut able", - "▁ mutable", - "▁si empre", - "▁Mont real", - "▁loc ate", - "▁tr aces", - "▁tra ces", - "▁trace s", - "▁trac es", - "▁ins gesamt", - "▁N il", - "▁Ni l", - "▁ Nil", - "▁п рода", - "▁про да", - "▁прод а", - "▁War ner", - "▁N au", - "▁Na u", - "tri angle", - "▁concentr ation", - "▁gentle men", - "äch t", - "ä cht", - "fil ters", - "filter s", - "inci pal", - "VAL ID", - "▁де пута", - "ad ó", - "▁kon st", - "gs å", - "ag as", - "aga s", - "a gas", - "▁meille ur", - "▁дан ным", - "є дна", - "en coded", - "enc oded", - "encode d", - "< '", - "▁she ets", - "▁sheet s", - "▁ sheets", - "cu ador", - "▁викори стову", - "▁De put", - "▁Dep ut", - "▁man ière", - "ą g", - "cs ol", - "c sol", - ")$ -", - ") $-", - "UI View", - "▁mill ones", - "▁E hren", - "▁Ehr en", - "Si l", - "S il", - "▁a tac", - "▁at ac", - "▁C old", - "▁Col d", - "▁Co ld", - "\" \\", - "▁appro ached", - "▁approach ed", - "▁Års med", - "W M", - "▁De port", - "▁Dep ort", - "mi s", - "m is", - "and box", - "ob serv", - "obs erv", - "set ting", - "sett ing", - "ha tó", - "hat ó", - "h ató", - "▁s trat", - "▁st rat", - "▁str at", - "▁stra t", - "▁s pre", - "▁sp re", - "▁spr e", - "▁ spre", - "▁person ne", - "▁pers onne", - "▁personn e", - "▁dir ige", - "▁dirig e", - "pu ll", - "p ull", - "da ting", - "dat ing", - "d ating", + "z ol", + "° ▁to", + "’ s▁of", + "“ audit▁trail", + "≥ 3", + "▁ rol", + "▁ encourag", + "▁ ulcer", + "e▁ patients▁with", + "in eligibl", + "at ▁baseline,▁", + "on ary", + "on atal", + "\n\n y", + "\n\n continu", + "\n\n no", + "\n\n week", + "\n\n must", + "\n\n 5-fluorouracil", + "\n\n chemotherapy▁regimen", + "\n\n ECOG▁performance▁status", + "▁a ▁P", + "▁a ▁pre", + "▁a ▁history▁of", + "▁a ▁change▁in", + "en opaus", + "er ic", + "or ▁g", + "s▁ G", + "s▁ T", + "s▁ used▁to", + "s▁ CH", + "al ,▁", + "al ▁con", + "al ,▁or", + "al arm", + "al ▁mesothelioma", + "st ag", + "st omatitis▁", + "y▁ D", + "y▁ signing▁this▁consent▁form,▁you", + "it ▁is▁not", + "▁the▁ complet", + "▁the▁ condition", + "▁the▁ option", + "▁the▁ attach", + "an ter", + "an ▁N", + ",▁ pro", + ",▁ over", + ",▁ OS", + ",▁ compared▁with", + ",▁ whil", + ",▁ hypo", + "ro duc", + "ed▁ death", + "ed▁ I▁am", + "▁an ▁investigational▁product", + "ic os", + ".▁ 24", + ".▁ (S", + "ar ic", + "ed .\n\nP", + "ed )▁and▁", + "ed .▁An", + "ed .▁All", + "▁p ay▁", + "▁p 53", + "▁p articl", + "▁p alpable▁lymph▁nod", + "▁c ou", + "▁c old", + "▁c ▁/", + "▁c arton", + "ing s▁", + "ing ▁and", + "ing ▁the▁subject", + "ing ▁for▁the▁", + "▁b other", + "es ch", + "es ▁all", + "es ▁the▁subject", + "for ▁the▁treatment▁of", + "et ime▁", + "et able▁and▁", + "et ▁No.▁", + "▁to ▁the▁investigator", + "▁to ▁you", + "▁to ▁either", + "▁to ▁FOLFOX", + "▁to ▁determine▁if", + "▁to ▁Informed▁Consent▁Form", + "is ▁approximately▁", + "▁s chem", + "▁s ensitive▁", + "▁s erious,▁", + "▁s ensory▁neuropath", + "▁s uccess", + "as p", + "▁of fer", + "▁of ▁Panitumumab", + "▁of ▁cetuximab", + "▁of ▁tumor▁cell", + "▁d ark", + "▁d ry▁", + "▁d ilut", + "▁d efici", + "▁d ouble-blind▁", + "th an", + "th is▁", + "th ree-", + "▁w arm", + "▁m ent", + "▁m ultiplic", + "▁m ismatch▁repair", + "▁and▁ I", + "▁and▁ ≤", + "▁and▁ be▁", + "▁and▁ blood▁", + "▁and▁ Consent", + "▁and▁ serum", + "▁and▁ genetic", + "▁and▁ metastas", + "▁and▁ overall▁survival", + "▁and▁ physical▁examination", + "▁and▁ FACT-P", + "▁and▁ Vitamin▁D", + "▁and▁ expression▁of", + "▁and▁ flow▁chart", + "▁and▁ Control", + "om ograph", + ".\n\n Q", + ".\n\n Response▁", + "ill a", + "ill ing", + "al▁ is▁", + "ol e▁", + "ol ▁M", + "ol escent", + "ab olic", + "is▁ no▁longer", + "is▁ BW", + "▁A ,▁T", + "▁in ▁any▁", + "▁in put", + "▁in ▁advanced▁colorectal▁cancer", + "▁in ▁some▁cas", + "▁in vit", + "▁in ▁making", + "res hold▁", + "oc inski", + "▁1 01", + "▁1 15", + "▁1 ▁day▁", + "▁C G", + "▁C ase▁Report▁Form", + "os cop", + "est ra", + "es▁ 3", + "es▁ by▁", + "▁P regnancy", + "pro tocoll", + "▁( study▁", + "▁( In", + "▁( irinotecan", + "▁( b)", + "▁( NCI", + "▁( ECG", + "▁( FDA", + "▁( i.e.", + "▁( measured▁by▁", + "▁2 .2.1", + "us ual▁", + "if ▁there▁are▁", + "▁S outh", + "▁I t▁is▁", + "▁re strict", + "ot oxicity▁", + "ow ell", + "un c", + "un ter", + "un common", + "un iform", + "un used▁investigational▁product", + "▁D C", + "▁D ur", + "▁D iet", + "cl ared▁", + "▁h eter", + "▁h old", + "with ▁ABI-007", + "e▁of ▁these▁", + "ap ent", + "ap parent", + "▁E stimated▁Study▁Duration", + "▁E T-1", + "▁f act", + "▁f ixed▁", + "▁f olinic▁acid▁", + "▁f avour", + "ver tebra", + "ch olesterol", + "▁or ▁to", + "▁or ▁as▁", + "▁or ▁in▁the▁", + "▁or ▁prior", + "▁or ▁local", + "▁or ▁FOLFIRI", + "▁or ▁equivalent", + "ther eafter", + "ther e▁is▁", + "\n\nP rior▁to", + "\n\nP ostdiscontinuation", + "\n\nP roscribed▁", + "iz es▁", + "ex cretion", + "ex acerb", + "ex plicit", + "▁n ons", + "▁n erv", + "▁n ▁d▁", + "▁n ominal▁significance▁level", + "ist inct", + "ist rar", + "od ilator", + "\n\nA UC", + "\n\nA ss", + "study▁ may▁be▁", + "▁and ▁after", + "▁and ▁administer", + "▁O ’Brien", + "▁O UTC", + "▁as ▁a▁s", + "▁as ymptomatic", + "▁as ▁a▁serious▁adverse▁event", + "▁pro ced", + "all point", + "all ▁Street", + "▁T umour", + "▁T otal▁", + "▁T el:", + "▁T itle:", + "▁T REATMENTS", + "ep ist", + "ep idemi", + "ep igenetic", + "op ies▁of▁the▁", + "ef ract", + "com /", + "com mence▁", + "▁for ▁PFS", + "▁for ▁both", + "▁for ▁review", + "▁R ul", + "▁R isk", + "▁R EG", + "▁R oyal▁", + "ib b", + "e\n\n 1", + "e\n\n subject", + "e\n\n treatment", + "rom boembolic", + "ed▁in dividual", + "▁treatment ▁and", + "▁treatment ▁on", + "▁treatment ▁option", + "▁treatment ▁of▁your▁cancer", + "enc es▁", + "ical▁ Plan", + "ed▁to ▁allow", + "ed▁to xicity", + ".2 %", + "▁with ▁panitumumab", + "▁with ▁95%▁CI", + "▁with drew", + "e▁to ▁protect", + "e▁to xicities▁", + "ed▁b i", + "ed▁b ack", + "s▁of ▁interest", + "s▁of ▁safety▁data", + "ber rant", + "In struction", + "In flammatory▁", + "our th", + "ad mission", + "ad igm", + "\n\nS C", + "▁that ▁all", + "▁that ▁patient", + "▁is▁ used▁to", + "▁is▁ identifi", + "▁is▁ further", + "▁is▁ necessary", + "▁is▁ required▁to", + "▁is▁ positiv", + "▁is▁ essential▁for", + "▁of▁ MI", + "▁of▁ established▁tumor", + "▁al iqu", + "▁al anine▁aminotransferase▁(ALT", + "▁will▁be▁ approximately▁", + "▁will▁be▁ made▁to", + "▁will▁be▁ followed▁until", + "▁will▁be▁ dilut", + "▁will▁be▁ manufact", + "▁will▁be▁ event-", + "▁M O", + "▁M al", + "▁M ,▁H", + "▁M eier", + "▁r ates", + "▁r ate\n\n", + "▁0 .22", + "▁3 ▁days▁", + "▁3 .4.2", + "▁con stant", + "act ▁of", + "cor e▁", + "event s", + "e,▁ M", + "e,▁ R", + "e,▁ irinotecan", + "vers e\n\n", + "▁com pany▁", + "▁F inancial▁Disclosure▁", + ".▁A SCO", + ".▁A greement", + "▁g /", + "▁g rant", + "▁g emcitabine-cisplatin", + "▁are▁ un", + "▁are▁ cons", + "▁are▁ responsible▁for", + "▁are▁ plann", + "▁are▁ available▁", + "▁are▁ clearly▁", + ",▁and▁ 5", + ",▁and▁ 15", + ",▁and▁ institution", + ",▁and▁ reproduc", + "ly▁ interval", + ".3 ).\n\n", + ".3 \n\nSampl", + "ever ▁possibl", + "▁B Y", + "▁B EN", + "▁B io", + "▁this▁ regimen", + "s,▁ even▁if", + "s,▁ 1999", + "af let", + "▁all ▁study▁medication", + "12 6", + "12 9", + "out ▁Panitumumab", + "▁analys es▁are▁", + "▁st ill▁be▁", + "▁st ate▁you", + "ial ▁pneumon", + "ach ine▁", + "\n\nC ollection", + "\n\nC ase▁Report▁Form", + "\n\nC ollection▁of", + "\n\nC hemistry▁panel:▁sodium,▁potassium,▁chloride,▁bicarbon", + "▁will ▁monitor", + "▁will ▁go", + "ing▁the▁ patient", + "ity ,▁an", + "▁6 4", + "▁6 00", + "▁6 ▁weeks▁", + "▁6 .10", + "▁H L", + "▁H owever", + "▁H ematology▁", + "and▁ subject", + "▁patients▁ enter", + "▁patients▁ only", + "▁4 .2.1", + ")\n\n L", + "▁at ▁any▁time▁", + "s▁( s", + "s▁( see▁Appendix", + "▁the▁in creas", + "▁the▁in dividual▁", + "eg al▁", + "eg uard", + "▁study▁ data", + "▁study▁ staff", + "▁study▁ withdrawal", + "continu ously", + "\n\n1 .\n\nO", + "lo per", + "vi ous▁", + "s▁in dex", + "▁cancer -related▁", + "gen es▁", + ".5 ▁mg/kg", + "s.▁ U", + "s.▁ Data", + "▁week ▁8", + "rel atively▁", + "cons erv", + "reg ulation▁of", + "ed▁by ▁the▁l", + "▁after ▁all", + "▁after ▁each", + "▁after ▁discussion", + "ally▁ for", + "ally▁ Ad", + "s▁and▁ subjects▁with", + "ed▁on ▁the▁l", + "e▁d iarrhea", + "e▁d irect▁access▁to", + ".▁S tudies▁", + ".▁S imopoul", + "▁the▁d iet", + "ang ▁et▁al,▁199", + "s▁will▁be▁ considered▁", + "s▁will▁be▁ performed", + "s▁will▁be▁ mail", + "s▁will▁be▁ sent▁to", + "s▁will▁be▁ collected▁and▁", + "▁G emcitabine▁", + "▁U SA", + "▁J S", + "▁pl astic", + "▁tim etable▁and▁", + "ies ▁that", + "ies .▁All", + "AE s),▁", + ".▁P SA", + ".▁P aclitaxel", + ".▁P reliminary▁", + "\n\nE stimated▁", + "orm onal", + "GF α", + "▁In complete▁response/SD", + "se e▁below", + "),▁ until", + "▁ant ineoplastic", + "▁from ▁Amgen", + "requ ency▁of", + "s\n\n will▁be▁", + "pos itron▁emission▁tomograph", + "evalu ation▁of▁", + "▁is ▁that", + "▁is ▁toler", + "▁Protocol ▁Amendment▁2", + ".▁Th us,▁", + "▁not ification▁of", + "▁tumor ▁biomarker", + "▁may▁ feel", + "▁7 8", + "su ffic", + "▁dos e,▁the▁", + "effect s▁on", + "pres cription", + "pres cribe▁", + ",▁the▁ DMC", + "▁study ▁therapy,▁", + "may▁ begin", + "▁adverse▁event s▁that", + "▁per ▁arm", + "▁per ▁day▁", + "▁per ▁lin", + "e▁v ari", + "pect rum", + "includ e▁the▁", + "includ e▁all", + "str ength", + "s) ,▁and▁", + "s) ▁should▁be▁", + "s) ▁until", + "▁to▁the▁ next", + "▁analysis▁ on", + ".▁In ▁this▁study", + ".▁In ▁case▁of", + "▁assessment s▁and", + "▁test s▁(", + "18 ▁year", + "ated ▁and▁destroy", + "record ed▁", + "over ▁time▁", + "s.\n\n .▁T▁N▁E▁M▁U▁C▁O▁D", + "s.\n\n Pro", + ",▁and ▁treatment", + ",▁and ▁the▁day▁after", + "AL ▁PRODUCT", + "▁ab sent", + "▁ab ide▁by▁all", + "peri pheral▁", + "’s▁ “audit▁trail", + "▁x ▁ic", + "20 )(cid:", + "ed▁at ▁screening", + "▁in▁the▁ model", + "▁in▁the▁ first-line▁treatment", + "▁in▁the▁ opinion▁of▁the▁investigator", + "▁in▁the▁ Treatment▁of▁Bone▁", + "e.\n\n 7", + "e.\n\n C", + "e.\n\n All", + "patient ▁who", + "): 5", + "▁8 .9", + "▁8 00▁IU", + "e▁( eg,▁", + "▁us e▁during▁the▁", + "mit age▁", + "\n\nProduct: ▁Denosumab▁Protocol▁Number:▁20050136▁Date:▁30▁April▁2008", + "\n\nN ▁H", + "\n\nN SCLC", + "▁each ▁assessment", + "▁each ▁dose▁of", + "▁each ▁radiological", + "▁X ▁D", + "▁X eloda", + ").\n\n 9", + ").\n\n If", + ".▁If ▁the▁true▁", + ".7 8", + "\n\n2 7", + "\n\n2 9", + "\n\n2 .\n\nTo", + "▁form at", + "bas aju", + "▁should▁be▁ destroy", + "ark ed▁", + "▁your ▁partner", + "ind ividual▁", + "▁Ad verse▁Drug▁Reaction", + "▁the\n\n study▁", + "▁pre clinical▁data", + "ed▁as▁ soon▁as▁possibl", + "▁Study▁ S", + "▁the▁study ▁team", + "▁cycl ooxygen", + "\n\nT im", + "e, ▁an", + "rial▁ fib", + "\n\n3 9", + "000 ▁g", + "sh ine▁", + "▁the▁patient ▁was▁", + "▁the▁patient ▁and▁the▁investigator▁agree▁to", + "dra ft", + "▁addition ally▁", + ".▁D o", + "no ▁additional", + "s▁are▁ administer", + "▁dose▁ interruption", + "▁W e▁", + "▁W il", + "▁than ▁in", + "pr urit", + "e) ▁is▁", + "ed▁in▁the▁ course▁of", + "\n\n4 .5", + "le b", + "data ,▁and▁", + "data .▁Direct", + "▁mg/m l", + ",▁S z", + ",▁S .,▁et▁al.,▁", + ",▁S omer", + "▁visit s,▁", + "defin ed▁and▁", + "lind ing▁and▁", + "s▁or ▁addition", + "▁was▁ reported▁in", + "in▁the▁ range▁of", + ")▁ –", + "main ly▁", + "e▁treatment ▁arm", + "▁progression ▁free▁survival", + "▁evalu ated▁", + "e▁and▁ disclosure▁of", + "sign ed▁by▁the▁investigator▁or", + "sign ,▁symptom", + "urvival▁ follow-up", + "ed▁and▁ un", + "ed▁and▁ dated▁in", + "▁di ary", + "▁the▁study▁ must▁be▁", + "▁the▁study▁ records▁to", + "may▁be▁ used▁for", + "s: \n\n\n\n", + "▁sampl es▁from", + "▁infusion -related▁reaction", + "row ley▁J", + "▁13 .5", + "▁13 5:", + ".▁R ational", + "SA BP", + "ND OMI", + ",▁a ▁regulatory▁author", + "ed▁from ▁a", + "▁sit e▁will▁be▁", + "▁sit es▁will", + "▁cell ▁lung", + "▁subjects▁ per", + "▁subjects▁ enroll", + "▁subjects▁ were▁", + "Investigator s▁", + "Investigator ▁should▁", + "\n\nH R", + "\n\nH &N", + "discontinu ed▁", + "discontinu ed▁if", + "▁Com pensation", + "▁approximately▁ 100", + "ed.\n\n If", + "▁discontinu e▁b", + "St ruct", + "valu e▁", + "valu es▁may▁be▁collected▁", + "\n\n\n\n is▁a", + "document ed▁in▁a", + "▁CT ▁Scan", + "▁et▁al ▁2003", + ",\n\n respectively", + "eb b", + "eb y▁", + "▁and/or ▁AstraZeneca", + "▁continu ation", + "▁Panitumumab ▁Preclinical▁", + "es▁in ▁relation▁to", + "ed▁s eparately", + "▁receive▁ any▁", + "collect ed▁using", + "▁occur s:", + "▁occur s▁after", + ")▁and▁ cisplatin", + "▁Page▁ 15", + "▁disease▁progression ▁is▁suspect", + "16 ]", + ",▁s om", + "▁these▁ analys", + "mod ified▁as▁", + "atist ical▁and▁", + "s▁b eing", + ",▁M .,▁et▁al.,▁", + ",▁M endelsohn", + "\n\n7 0", + "▁dis c", + "elect ronically▁", + "ha ematology▁and▁", + "any▁ caus", + ".▁H ospitalization", + "arr hyth", + "-rel ated▁injur", + "mall ▁cell▁lung▁cancer", + "▁drug ▁exposure▁", + "▁drug ▁abus", + "s▁will ▁remain", + "▁through ▁a", + "easur ability▁of", + "▁must ▁have▁been", + "▁loc ation,▁", + "1- 14", + "▁(A JCC", + "administer ed▁with", + "sub mit", + "1) .▁The▁", + "▁metastatic ▁prostate▁cancer", + ".9 9", + "ation▁of▁ “", + "norm ally▁", + "\n\nIn formation", + "\n\nIn vestigational▁product", + "▁stat us▁in", + "IN AL▁PRODUCT", + "▁gen es", + "Ad juvant", + "e▁m icroar", + "▁by▁ mouth", + "▁– ▁Arm▁B", + "▁– ▁general", + "\n\nM onitor", + "▁can ▁imag", + "▁administer ing", + "▁administer ed▁for", + "conduct ed▁as▁", + "▁information ▁and▁", + "▁number ▁per▁lin", + "given ▁over▁2▁to▁4", + "clinical▁ studies", + "clinical▁ judgment", + "▁tissu es", + "▁tissu e▁section", + "▁administration ,▁", + "OS ▁and▁PFS", + "▁ID MC", + "were▁ conduct", + "▁there▁ ar", + "▁there▁ have▁been", + "ities ;", + ".\n\nThe▁ principal▁investigator", + "▁des ired▁", + "K▁C▁E▁H▁C \n\nE▁S▁A▁E▁L▁P\n\n.▁T▁N▁E▁M▁U▁C▁O▁D", + "obtain ed▁for", + "obtain ▁approval▁from", + "ing▁of ▁biological▁samples", + "▁17 .1", + "lesion s▁will▁only▁be▁", + "studies▁ in", + "by▁ Amgen", + "-5 8", + "each ▁statement", + "▁radi ologist", + ".▁J .▁Clin.▁Oncol", + ".▁J ▁Urol", + "panitumumab ▁administration", + "information ,▁", + "▁CR ▁PR", + "urn bull", + "must ▁not", + ".▁For ▁patients▁who", + "\n\nAn t", + "ed▁by▁the▁ central▁laboratory", + "▁• ▁D", + "▁plus▁ prednisone▁", + "es▁and▁ monocyt", + "es▁and▁ Technical▁Standard", + "▁K ,▁S", + ".▁All ▁data", + ".▁All ▁other", + "▁Y es▁or▁no", + ".▁I MC-", + "\n\nConfidential ity▁", + "▁new ▁treatment", + "▁new ▁protocol▁amendment", + ",▁G re", + ",▁G rif", + ",▁G iovannucci", + "▁investigational▁product ▁administration", + "▁about ▁your", + "▁has▁been ▁for▁you", + "ed▁c ohort", + "ing▁a ▁comprehensive▁", + "s▁and ▁a", + "▁allow s▁", + "during▁the▁ first", + "▁St art", + "-m alate▁", + "▁trans mission", + "▁review ▁the▁subject’s▁", + "▁review ▁of▁the▁data", + "s▁at ▁baselin", + "s▁at ▁Baseline:", + "▁part y▁or", + "▁every▁ 4", + "within ▁30", + "within ▁the▁previous▁", + "Con nell", + "mad o", + "mad e▁by▁", + "▁protocol ▁violation", + "\n\nG l", + "\n\nG CP", + "\n\ns hould▁", + "\n\ns creening", + "▁14 ▁days▁before▁randomization", + "▁perform ▁a", + "MD AS", + "▁Appendix ▁A", + "▁ver ify▁the▁", + "Un iform", + "cer vix", + ",▁L eucovorin", + ",▁L itin", + "randomization ▁factor", + "studies ▁to", + "▁the▁first ▁PSA", + "related▁to ▁the▁study", + ",▁p emetrex", + "▁cetuximab ▁therapy▁", + "upplement ation", + "21 00", + "diseas e,", + "diseas e)", + "▁+ 44", + "label ed▁per", + "e▁a ▁t", + "ence▁in ▁a▁patient", + "▁IV ▁contrast", + "▁IV ▁infused▁", + "caus al", + "▁Q OL", + "▁assign ▁the▁study▁records▁to", + "ven ous▁", + "▁KRAS ▁status", + "▁clinical▁ study", + "618 10", + "ation▁of▁the▁ trial", + "expect ed▁that", + "osph or", + "▁the▁b evacizumab", + ",▁in creas", + "▁health ▁benefit", + "▁health ▁rating", + "at▁least ▁400▁IU", + "▁OF ▁EMERGENCY", + "▁agre es▁with▁the▁", + "new ▁responsible▁person", + "\n\nStudy▁ Treatment", + "\n\nStudy▁ flow▁chart", + "86 G", + "1,▁ 8,▁", + "IG H", + "▁hav e▁to", + "▁Treatment ▁Arm▁A", + "▁18 95", + "HR QOL", + "\n\nthe▁ event", + "▁and▁s end", + "▁October ▁2003", + "▁long er▁than", + "▁safety▁ review", + "▁safety▁ follow-up", + "▁safety▁ information", + "ology /", + "▁ABI-007 /carboplatin", + "▁phase▁ 3", + "▁subjects▁with out", + "refer red▁to▁as▁“", + "▁AND ▁QU", + "100 ▁x▁109/L", + "); ▁", + "▁serum ▁PSA", + ".\n\n6 .1", + "RECIST ▁Criteria", + "▁without ▁objective▁", + "primary▁ care▁physician", + ",▁if ▁b", + "contain ed▁in▁the▁", + "ing▁ evidence▁of", + ".▁L ill", + "▁or▁ early▁termination", + "▁condition al▁", + "bov e▁", + "▁Con f", + "red ness", + "evaluation ▁–▁general", + "\n\nt issu", + "2- 19", + "▁par affin", + "▁Patients▁ With", + "aw less", + ",▁K im", + "ier arch", + "measure s▁of", + "hav e▁shown▁that", + "avail ability▁of", + "ised▁ Registration/", + "cycl e,▁", + "\n\nm ▁c▁/", + ".\n\n5 .1", + ".\n\n5 .2", + "Amgen \n\n", + "▁Med ical", + ".▁G iven", + ".▁G rup", + "occurr ence▁and▁nature▁of", + "elf ▁care", + "▁would▁ indicate▁that", + ".\n\nIn ▁the▁", + "ey el", + "▁(se e▁definition▁in▁Section▁4.7.1.1", + "▁e▁ c", + "▁28 ,▁2008", + "▁28 ▁days▁before▁randomization", + "agent s▁inter", + "pers istent", + "▁scor e▁(", + "▁investigator ▁assessment", + "plann ed▁treatment", + "ed▁m ethod▁", + "ed▁m anner", + ".▁199 4;", + "▁only ),▁", + "\n\nPro gressive▁Disease▁(PD):", + "▁≥ ▁100▁x▁109/L", + "▁CTCAE ▁grad", + "▁CTCAE ▁Grade▁4", + "▁Arm▁A ▁(", + "%) ▁had▁", + "ren al▁", + "ren ch", + "requirement s▁for", + "▁the▁primary▁ OS", + "3- 4", + "ates▁ into", + ".\n\n7 .1", + "▁person ▁responsible▁for▁the▁", + "esign ▁and▁Control", + "AT ED", + "▁schedul ed▁visit", + "ocyt es", + "cas es▁of", + "▁MRI ▁scan", + "sit e▁of", + "ing▁on e▁(1)", + "atch ▁number", + "atch ing▁placebo", + "ed, ▁the▁investigator", + ",▁m ic", + "▁Ex clusion", + ")▁in ▁patients▁(pts)▁with", + "oler ability▁", + "▁25 ▁mg/m2", + "▁25 ,▁2008", + "▁the▁trial .▁The▁", + "▁medical ▁practitioner", + "▁Grade▁3 -4", + "s,▁and ▁agrees▁with▁the▁", + "▁but ton", + ".▁J▁Clin▁Oncol ▁23", + ".▁J▁Clin▁Oncol ▁22", + "▁Safety▁ Follow-Up", + "▁Safety▁ Officer", + ".\n\nB efore▁", + "CC 1", + "e,▁the▁ end▁of▁study▁is▁", + "analyz ed▁", + "chest ▁wall", + "NCI ]", + "▁improv e▁", + "▁(or ▁other", + ".1.2 ▁Rec", + "high ly▁", + "high -dose▁", + "▁mic rosatellite▁instability", + "▁mic roscop", + "Ther asse▁et▁al.▁2000", + "clinically▁ relevant", + "o- gastric▁cancer", + "▁a▁l og-rank▁test", + ",▁E l", + "baseline▁ BMD", + "skin ▁toxicity▁", + "▁supplement al▁sourc", + "resolv ed?", + "▁fl uoropyrimidine▁", + "infusion ▁reaction", + "▁Dose▁ Reduction", + "Sponsor ▁Contact", + "safety▁ information", + "safety▁ follow-up▁visit", + "▁experienc es", + "▁experienc es▁an", + "es▁that ▁have▁their", + "▁function al▁", + "▁function ▁test", + "plus▁ prednisone▁", + "................................................................................................................ ......", + "▁target ▁volum", + ",▁J ud", + ",▁J ack", + "▁To ▁evaluate▁", + "▁Table▁ 1", + "de clared▁", + "list ed▁in", + "ed▁by▁the▁investigator ▁as▁", + ".\n\nN ▁A", + "▁onc ology", + "▁chest ▁wall", + "HA SE", + "read ▁the▁attach", + "sk elet", + "▁paclitaxel ▁and▁carboplatin", + "evaluated▁ at▁each", + "\n\nTable▁ JMHD", + "ability▁of ▁all", + ".▁At ▁the▁", + "▁and▁D is", + "▁and▁D ay▁", + ".▁5 9", + "\n\nCom mon", + ".▁Wh er", + "▁randomis ation▁to", + "(S uppl", + ".▁V ial", + "activ ated▁", + "\n\nW eight", + "▁60 ▁mL/min", + "\n\nProtocol▁Amendment \n\nPage▁", + "s.▁A mgen", + "schedul ed▁", + "▁and▁d emographic", + ",000 /mm3)", + "\n\n(cid:120) ▁Percent", + "▁Per son", + "▁possibl e▁to", + ",▁O VER", + "EP O", + "▁and▁in itial", + "e,▁or ▁spinal▁cord▁compression", + "cut e▁", + "▁of▁10 ▁mM", + "▁date▁ for", + "▁throm boembolism", + ".▁Con firm", + ".▁Con current", + "▁significance▁level ▁of▁0.025", + ",▁patients▁ who", + ".\n\n10 .5", + "▁with▁a ▁black", + "▁the▁primary ▁tumor▁or", + "stratifi ed▁by▁the▁randomization", + ".▁No ▁significant", + "▁ZD4054 ▁or▁placebo", + "▁blood▁sampl e▁for", + "▁blood▁sampl ing▁and▁handl", + "▁Date:▁04 ▁April▁2008", + "▁Panitumumab▁Protocol▁Number:▁20050181 ▁Date:▁04▁April▁2008", + "▁the▁sampl e▁size▁", + "4▁week s▁prior▁to", + "▁normal ▁saline▁", + "▁qual ity▁", + "▁an▁in ability▁to▁determine▁the▁status▁of▁that▁particular▁tumor▁for", + "▁path ologist", + "procedure s▁or", + "objective▁ response▁rate▁", + "objective▁ response▁rate▁(ORR", + "▁plann ed▁interim", + "request ed▁to", + "▁add itive▁", + "IS H", + "s▁ar is", + "s▁ar e▁the▁", + ".▁Ex ception", + "▁men ▁and▁women", + "gener ated▁", + "▁(T O", + "▁Research ▁Addendum", + "▁Research ▁and▁Treatment", + "hypothes es", + "▁IN R", + "▁IN -T", + "▁IN ▁CASE", + "▁regard s▁to", + "88 8)", + "nausea ▁or▁vomiting", + "\n\nU LN", + "\n\nU rine▁", + "disease▁progression ▁or", + "maximum ▁tolerated▁", + "▁written ▁statement", + "▁vs.▁ 8", + "care \n\n", + "care fully▁", + "▁Ac et", + "▁5-FU /FA", + "sever ity▁", + "sever e▁(", + "▁endpoint s▁", + "▁statist ician", + "5-fluorouracil ▁dose▁level", + "uspect ed▁", + "▁50% ▁of▁the▁", + ",▁un stable▁angina", + ".▁Thes e\n\n", + "made▁ available▁for", + "made▁ only▁with", + "necessary ▁to▁provide▁", + "\n\n12 .4", + "es▁of▁the▁ company,▁", + "period▁ from", + "(1 ),▁", + "▁defin itiv", + "▁Tumor ▁Tissu", + "▁is▁responsible▁for ▁forward", + "s,▁including ▁small▁lesion", + "▁laboratory▁ certification", + "▁With in", + "es) .▁In", + ".▁Pro gression", + "▁well -t", + ".\n\nM EASUREMENTS", + "▁the▁interim ▁and▁final", + "▁you▁have▁ an", + "▁del ays", + "▁for▁a ▁duration▁of", + "full y▁in", + "\n\ni \n\nl\n\na", + "recorded▁on▁the▁ eCRF", + "hematologic ▁toxicities", + "improv ed", + "▁anti angiogenic", + "\n\nE▁S▁A▁E▁L▁P\n\n.▁T▁N▁E▁M▁U▁C▁O▁D \n\nC▁I▁N▁O▁R▁T▁C▁E▁L▁E\n\nN▁A\n\nF▁O\n\nY▁P▁O▁C\n\nD▁E���T▁N▁I▁R▁P\n\nA\n\nS▁I\n\nS▁I▁H▁T", + "cr ystal", + "may ▁also", + "▁is▁the▁ most▁common", + "▁minutes▁ at", + "HC G", + "hist ologic", + "▁histor y", + "▁........................................................................ ...▁", + "s▁must ▁also▁be▁", + "▁ask s▁about", + "\n\nAdd: ▁PART▁B:", + "ecut iv", + ")▁and ▁then", + "at▁a ▁starting▁dose▁of", + "censored▁at ▁the▁last", + "\n\nThis▁ is▁a", + "\n\nThis▁ study▁will▁be▁", + "▁rate▁ and▁", + "▁inform ing▁the▁", + "-T reat", + "▁recent ly▁", + "▁nam ed▁", + "consent▁form ▁should▁be▁provided▁to", + ".▁U sing", + "s.▁B r", + "compared▁to ▁docetaxel", + "▁resolv e▁", + "▁resolv e▁any▁", + "epidermal▁growth▁factor▁receptor ▁(EGFR", + "be▁t ermin", + "\n\nTh ese▁", + "orph ine▁", + "▁Require d▁", + "▁cycles▁of ▁treatment", + "▁2007; ▁9", + "changes▁in ▁laboratory▁valu", + "▁................................................................ .......▁", + "initi ated", + "\n\nsubject s▁with", + "character istics▁", + "▁Protocol▁Amendment s▁and▁Study▁Termination", + "▁less▁than ▁1", + "\n\nPatient ▁Reported▁Outcom", + "▁adjust ing▁for", + "immediately▁ life-threatening", + "▁third▁ dose▁reduction", + "wor ding", + "▁some▁ patients▁", + "perty▁of▁the▁sanofi-aventis▁group▁-▁strictly▁confidential▁WW-CLIN-PR007-SD-03▁VERSION▁n°02▁(19-DEC-200 5", + "ackage▁ Insert", + ",▁it ▁is", + "▁Non- Small▁Cell▁Lung▁Cancer", + "cidence▁ and▁", + "▁thromb osis▁", + "e.▁In vestigator", + "ating▁the▁ confidentiality▁of", + "overall▁survival ▁tend", + ".▁K M", + "starting ▁at", + "onc e▁daily▁", + "▁1▁week ▁or▁mor", + "administration▁of ▁panitumumab", + "done▁ at", + "▁primary▁ endpoint", + "▁Man uscript", + "▁Health ▁Study", + "▁Gen etic", + ".▁Phase▁ I", + "spect or", + "ed▁dos e,▁", + "pleas e▁", + "serious▁adverse▁event s▁", + "▁frequ ency", + "approv ed▁by▁the▁", + "flu ence▁", + "▁stor ed▁at", + "▁non-target▁lesion s▁identified▁at▁baselin", + "▁abov e▁the▁", + "▁analgesic s,▁", + "ession al▁", + "▁STUDY ▁P", + "▁STUDY ▁PROCEDURES", + "observed▁ RR", + "Rec ording▁of", + "▁ent ry", + "▁study▁visit ?", + "AMG▁162 ▁in▁the▁Treatment▁of▁Bone▁", + "bear ing", + "e▁includ ing", + "\n\nGrade▁ 1", + "Reg ulatory▁", + "add ress", + ".▁Data ▁Qual", + "rest ▁of", + "minimum ▁lesion", + "minimum ,▁and▁maximum", + "▁as▁possibl e▁", + "▁response▁rate▁ and▁", + "OP UL", + "in▁a ▁continuous▁regimen", + "▁wer e\n\n", + "▁and▁all ▁other▁sites▁of▁disease▁", + ".6.1 ▁General▁Approach/", + "suppli ed▁in", + "▁hr ▁after▁start▁of", + "▁on▁Day▁1 ▁of▁each▁cycl", + "▁Information ▁and▁Consent", + "▁gener ating", + "▁NCCTG ▁Addendum", + "EA ▁level", + "▁identifi er", + "▁IC F", + "▁prolong ed▁", + "▁combin ed▁", + ".▁Com plet", + "▁lead s▁to", + "▁tr ack", + "war eness▁of▁the▁", + "▁best ▁supportive▁car", + "▁concomitant ly▁with", + "▁must▁be▁obtain ed▁for▁all", + "▁might ▁affect", + "▁documented▁ PD", + "cop ies▁of", + "▁thos e▁that", + "area ▁under▁the▁curv", + "whichever ▁comes▁first", + "▁investigational ▁agent", + "confirmed▁ no▁less▁than▁4▁weeks▁after", + "controlled▁ Study▁to", + "ed▁in▁accordance▁with ▁institutional▁policy", + "▁should ▁also▁be▁", + "greater▁than ▁or▁equal▁to", + "opportun ity▁for", + ",▁1 ,▁or▁2", + "▁stop ▁the▁", + "diagnos is", + ",▁in▁the▁ case▁of", + "▁port ion▁of", + "▁of▁the▁study▁ staff", + "handl ing", + "▁of▁outcome▁variabl es▁in▁relation▁to", + "▁oste oclast", + "▁CO M", + "▁CO X-", + "▁study▁ent ry▁", + "yes /no", + "opath ological▁", + "▁valid ation", + "▁valid ated", + "▁VEGF ▁inhibitor", + "ohist ochemical▁", + "▁log istic▁regression▁model", + "▁staff )", + "▁the▁investigational ▁sit", + "s▁per ▁day", + "▁deriv ativ", + "notification s,���and▁agrees▁with▁the▁", + "▁d▁e▁v▁o▁r▁p▁p▁A\n\nProduct: ▁PANITUMUMAB▁(AMG▁954)▁Protocol▁Number:▁20040249▁Date:▁07▁August▁2007\n\nPage▁", + "▁d▁e▁v▁o▁r▁p▁p▁A\n\nProduct: ▁Panitumumab▁Protocol▁Number:▁20050181▁Date:▁04▁April▁2008\n\nPage▁", + "usual ▁activities▁", + "Pharmac y▁Guid", + "imag es▁", + "▁(eg ,▁a", + "▁the▁pre par", + "80% ▁dose▁level", + "purpos e▁of▁the▁", + "▁Sunitinib ▁Malate▁", + "show ed▁that", + "\n\nI▁am ▁able▁to", + "ATA ▁MANAGEMENT", + "▁........................................ ......", + "ont arget▁Lesion", + "▁to▁receive▁ either", + "▁is▁in advert", + "▁guid ance▁", + "\n\nSection:▁10 .5", + "▁recurrent ▁or", + "\n\nArm ▁B", + "▁a▁minimum ▁of▁two", + "regular ly▁", + "▁complaint ▁form", + "manufact uring", + "▁Suppl ):", + "\n\nAdd▁6 \n\nAdd▁6", + "recover ed▁to", + "▁FACT- L/N", + ".\n\nPatients▁ will▁be▁", + "dosing ▁regimen", + "▁determine▁if ▁denosumab▁is▁", + "bumin- bound▁", + "30-day▁postdiscontinuation▁follow-up ▁period▁(", + "-B ased▁", + "9) Toxicity▁", + "hold▁ panitumumab", + "▁↓ ▁One▁", + "▁brain ▁metastases", + "▁soft w", + "prognostic ▁factor", + "▁Days▁ 1-14", + ".▁In▁the▁event ▁that", + "definition s▁of", + "breast -feeding", + "clar ification", + "▁treatment▁and▁ follow-up", + "▁WC ,▁H", + "we▁ have▁", + ".▁Your ▁doctor▁will", + "▁objective▁progression ▁of", + "at▁any▁tim e▁and▁", + ")\n\n4 .2.1", + "▁should▁be▁performed▁ with", + "your▁doctor ▁will", + "▁2006; ▁8", + "▁Qual ity▁of▁Lif", + "▁Medical▁ Journal▁", + "we ating", + "\n\nPre treatment", + "▁the▁sub distribution", + "▁intern al▁", + "▁intern ational", + "▁reasons▁other▁than ▁disease▁progression", + "itu ation", + "▁and▁M eier", + "▁rate▁of ▁5%", + "▁HR QoL", + "▁consult ▁with", + "▁samples▁will▁be▁ destroy", + "▁observation ▁mad", + "extension▁lead▁ period▁", + ".D .,▁", + "at▁each ▁visit", + "▁need l", + "▁the▁primary▁endpoint ▁of", + "null▁hypothes is", + "ity▁in ▁accordance▁with", + "▁any▁s ide▁effect", + "ed▁by▁an ▁independent", + "▁Questionna ires", + "questionnair e▁and▁", + "▁contains▁ no", + "▁cur atively", + "▁deviation s▁from", + "▁Cl assification", + "▁rat es▁of", + "indication ▁to", + "▁confidence▁interval▁ for▁the▁", + "▁fracture▁ or", + "Radi otherapy▁", + "▁Supplement ),▁", + "e.\n\nP atients▁", + "partial▁ respons", + "partial▁ response▁(PR", + "\n\nAdd▁2 ,3", + "▁angiogenes is▁", + "▁mucos a", + "▁will▁be▁compared▁ at▁a▁significance▁level▁of▁5%", + "refer▁to▁the▁ current", + "▁questionnair e▁that", + "/In dependent▁Ethics▁Committee▁(IEC", + "▁mov e▁them", + "▁Survival▁ Follow-up", + "▁ascit es▁or", + "▁abdominal ▁masses▁that▁are▁not▁confirmed▁and▁followed▁by▁imaging▁techniqu", + "inform ation▁of", + "▁to▁in crease▁", + "estrogen ▁receptor", + "▁age▁ group", + "s▁taken ▁in▁combination▁with", + "▁all▁subjects▁ have▁", + "▁will▁have▁ access▁to", + "▁signs▁and▁symptom s▁of", + ".▁Ann al", + "▁address ▁and", + ".▁Un der", + "▁Pemetrex ed▁in", + "und red▁", + "▁or▁its▁design ated▁", + "arket ing", + "▁subjects▁receiving ▁AMG▁162", + ".▁Vitamin▁D ▁intak", + "Code: ▁D8480C00013", + "final▁ PFS", + "▁drop ▁in", + "▁ASCO ▁Annual▁Meeting▁Proceeding", + "symptomatic ▁deterioration", + "International▁Conference▁on▁Harmon isation", + "▁of▁study▁ population", + "notifi ed▁to", + "prescrib ed▁dos", + "ared▁ Res", + "enrolled▁in ▁the▁study", + "objectives▁ –", + "E▁R▁O▁F▁E▁B \n\nY▁T▁I▁D▁I▁L▁A▁V", + "egr ated▁", + "▁Advanced▁ Non-Small▁Cell▁Lung▁Cancer", + "▁Complet ed▁", + "▁description ▁of▁the▁", + ",▁we▁ have▁", + "Oral▁Rectal▁ Subcutaneous▁", + "▁SU 11248", + "▁reserv es▁the▁", + "▁study-related▁ record", + "▁interval▁ is▁", + "▁measurements▁and▁ co-", + "▁the▁safety▁follow��up ▁phas", + ".\n\nSTUDY ▁MANAGEMENT", + "oprot ection", + "vitamin ▁E", + "▁Day▁ 8", + "achin e▁typ", + "▁7▁days▁of ▁each▁radiological", + "▁199 3;", + "▁anti-panitumumab ▁antibody", + "procedures▁for ▁unblinding▁the▁study", + "▁regulatory▁author ities", + "▁regulatory▁author ities▁", + "nod ul", + "▁Approv ed▁by▁Lilly:", + "ysesthes ia", + "▁Fax :▁(", + "patient▁reported▁ outcomes▁(PRO", + "▁superior ity▁of", + "\n\nAppendix▁I ▁Page▁", + "\n\nStudy▁Design ▁and▁Treatment▁Schema", + "chest,▁abdomen ,▁pelvis", + "▁origin ▁in▁the▁D", + "ken s▁CH", + "▁principl es▁that▁have▁their", + "▁bolus▁ given▁over▁2▁to▁4", + "▁It alian", + "▁poss ibly▁", + "▁antibodies▁against ▁panitumumab", + "▁antibodies▁against ▁IMC-11F8", + "▁ECOG▁performance▁stat us", + "\n\nChang es▁to▁the▁protocol", + "▁exploratory▁biomarker ▁development", + ",▁whichever▁is▁ later", + "capture d", + "imb urg", + "\n\nPer form", + "▁a▁small ▁molecul", + ".▁Refer ▁to▁the▁", + "▁occurred▁ in", + "gestive▁heart ▁failure▁", + "regulatory▁ag ency▁", + "regulatory▁ag ency", + "ge ographic▁region", + "s▁during ▁treatment", + "▁Diseas e", + "▁RT K", + "romos ome▁", + "\n\nStudy ▁agreement", + "associ ation▁of", + "carcinoma ▁of▁the▁", + "hazard▁ ratios", + "▁the▁benefit :risk▁profile▁", + ",▁strok e,▁and▁", + "▁handl ing", + "compr ised▁of", + "▁LB ,▁Willett▁WC", + "▁consequ ences", + "▁change▁of ▁femoral▁neck▁BMD", + "ockcroft▁and▁Gault ▁1976", + "▁etoposid e/cisplatin", + "▁subjects▁have▁ access▁to▁commercially▁available▁product▁or▁for▁up▁to▁2▁year", + "ummary ▁tabl", + "▁confirmation▁of▁ eligibility", + ":▁the▁ effects▁of", + "▁bal ance▁of", + "▁second -line▁", + "▁Over view", + "▁modifi ed-RECIST", + "fficacy▁and▁ pharmacodynamic", + ".▁Of ▁the▁", + "stored▁for ▁up▁to", + "median▁PFS ▁for", + "▁AND▁DEFINI TIONS▁OF", + "inancial▁Dis closure", + "▁compan ies▁", + "▁pre-specifi ed▁", + "\n\nVisit \n\nVisit", + "Schedule▁of ▁Assessment", + "measurements▁and▁ variables▁", + "▁Radiation ▁Therapy▁", + "stea d▁of▁the▁", + "▁CYP3A4 ▁inhibitor", + "102 23", + "▁from▁all ▁supplemental▁sourc", + "anna ▁N", + "▁sub- population", + ".▁Overall ▁survival", + "TO I", + "▁slice▁thickn ess▁", + "▁or▁at ▁hom", + "▁First ▁Street", + "not▁to ▁participate▁in▁this▁study", + "bind ing▁of", + "▁leuk openia", + "▁peripheral▁neuropath y▁", + "▁discontinue▁from ▁study▁treatment", + "documented▁in ▁the▁subject’s▁", + "ince▁your▁last ▁study▁visit?", + "▁twice▁ per", + "▁the▁interpret ation▁of▁the▁study▁", + "chemistry▁ profil", + "epatitis▁ C", + "uration▁of▁ response▁(", + "ocock ▁SJ", + "ance▁in ▁Investigational▁Product", + "▁androgen ▁dep", + "▁health▁state▁ index▁scor", + "▁telephon e,▁and", + "\n\nNon-PD /NA**", + "inspect or", + "▁back ▁to", + "es),▁ surgery▁to", + "▁rath er▁than", + "▁a▁subset ▁of", + "95%▁confidence▁interval▁ for▁the▁", + "improvement ▁in", + "▁At▁least ▁a▁20%▁increase▁in", + "▁regulatory▁ag encies▁", + ",▁2008;▁Page▁ D", + "mas s▁index", + "▁the▁appearance▁of ▁one▁or▁more▁new▁lesion", + "▁Amended▁ Clinical▁Study▁Protocol", + "▁or▁discomfort ▁I▁have▁", + "e▁through ▁the▁", + "▁BID ▁=", + "▁the▁date▁ when", + ".▁Dis cussion", + "▁CT/MRI ▁scan", + ",▁Mor i", + "▁discover y▁or", + "at▁least▁one▁ on-study▁SRE", + "\n\nStatistical▁ evaluation▁–▁general", + ",▁Stampfer▁MJ ,▁Colditz▁GA", + ",▁24,▁ 36", + "ed▁while▁on ▁or▁after", + "▁of▁D esign▁and▁Control", + "useful ▁in", + "avis▁ CD", + "▁abs cess", + "▁pemetrexed,▁ carboplatin", + "lip id", + "erson al▁", + "▁sensitivity ▁analyses▁of", + "▁wash out", + "▁compared ▁to▁the▁", + "▁investigational▁product▁is▁ re", + "▁Formula ▁for", + "▁make▁ entries▁and/or", + "▁reconstitut ed▁ABI-007", + "▁VARIABLES ▁AND▁DEFINITIONS▁OF", + "7)\n\n(cid:13 7)\n\n(cid:13", + "7)\n\n(cid:13 7)▁(cid:137)▁(cid:13", + "at▁any▁ dos", + "compl ish", + "▁Figure▁ 1", + "▁H3E-MC-JM IG", + "▁throughout▁the▁ entir", + "▁(Table▁ 1)", + "regional▁ lymph▁node▁is▁N0", + "ltras ound▁", + "Dx S", + "Path ology▁", + "sur rounded▁by▁aerated▁lung", + "ened iamin", + "▁an▁SRE ▁by▁", + "endothel ial▁cell", + "s.▁Ther eafter", + "he/sh e▁must", + "\n\nM0 ▁M0", + "\n\nMethod▁of ▁assigning", + "▁intramuscular ▁injection", + "▁Non-PD ▁Non-PD", + "▁IV▁infusion▁in ▁500▁mL", + "arnofsky▁ Scor", + "▁anxious▁or▁depress ed▁I▁am", + "▁we▁will ▁have▁", + "uppress ive▁", + "medicin al▁product", + "FACT-Fatigu e▁subscale▁scor", + "▁alone▁as \n\n", + "▁will▁be▁used▁to▁compare▁treatment s▁with▁respect▁to▁both", + "J,▁K aplan", + "Over dose▁", + "facil ities", + "▁esophag itis▁", + "▁tast e▁in", + "unn ▁PA", + "ed▁both ▁individ", + "▁the▁investigational▁ study▁sit", + "rosome▁ amplification", + ")(cid:10 )(cid:", + "▁+/- ▁C225", + "reported▁to▁Amgen ▁within▁1▁working▁day▁of", + "▁glutam ic", + "\n\nProgression-free▁s urvival▁(PFS", + "\n\nDescription▁of ▁analysis▁set", + "informed▁of ▁all", + "e▁involv ement", + "▁intellect ual", + "Under going", + "where▁appropri ate", + "delayed▁for ▁up▁to", + "e▁on▁a ▁variable▁", + "▁fever▁or ▁infection", + "▁archival ▁tumour", + "Therapy▁During▁Study▁ Period", + "▁apparent ▁discrepanc", + "inflammatory▁ drug", + "▁tired ness", + "▁cardi oprotection", + "urb anc", + "▁Calculated▁ Creatinine▁Clear", + "▁Product ▁Characteristic", + "▁Sh ared▁Res", + "▁TNM ▁Staging▁System▁for▁Lung▁Cancer", + "advis ed▁to", + "athyroid▁ hormone▁", + ".▁Determination▁of ▁Sample▁Size▁", + "▁non-mut ated▁(", + "more▁frequ ent", + "▁risk▁reduction .▁For", + "procedures▁and▁ data.▁Direct", + "keletal▁surv eys", + "light▁h ousework", + ".▁Respon dent", + "ematology▁panel: ▁CBC", + "duration▁of▁response▁( DOR", + "▁corresponds▁to ▁ECOG", + "▁reasonable▁possibility▁that▁the▁event▁may▁have▁been▁caused▁by \n\ninvestigational▁product", + "▁always▁be▁ ask", + "idiarr heal", + "DM SC", + "covari ate▁", + "▁loper amide▁", + "’s▁b rochure", + ".▁Disease▁ progression", + ".▁Reg ulatory▁", + "▁occurs▁prior▁to ▁disease▁progression", + "70▁and▁ older", + "▁NCI- CTCAE", + "▁qualify ing▁for", + "▁Planned▁Methods▁of ▁Analysis▁", + "drawn▁from ▁each▁patient", + "emperature ,▁blood▁pressure,▁", + "▁adequately ▁treat", + "▁Previously▁Un treated▁Metastatic▁Colorectal▁Cancer", + "orrections▁to ▁electronic", + "/0 ,", + "surgical▁ resection", + "▁manufact urer", + "again st", + "▁must▁submit ▁and", + "echt ▁JR", + "▁an▁option ▁to", + "herein after", + "increase▁the▁ risk▁of", + "▁before▁study▁ initiation", + "▁known▁to▁have▁ di", + "every▁6▁weeks,▁ ±▁1▁week", + "examining ,▁analyz", + "publication▁or ▁presentation", + "ed▁in▁the▁Study▁Plan ,▁Table▁", + "hort▁Form▁( BPI-SF", + "oftware ’s▁“audit▁trail", + "▁time▁from▁randomization▁date▁to ▁date▁of", + "how▁good▁or▁b ad▁", + "dail y▁supplement", + "mechanism▁of▁action ▁of▁necitumumab", + "▁true▁ each▁statement", + "▁safety▁and▁efficacy▁ data", + "ulum ▁vita", + "▁should▁be▁retain ed▁in▁accordance▁with▁institutional▁policy", + "▁disease▁progression▁should▁be▁ evaluated▁for", + "▁level▁in▁the▁ blood;", + ",▁Ar mitage▁", + "▁coronary▁ heart", + "pain▁severity ▁and▁", + "vitamin▁D▁supplement s,▁", + "▁days▁prior▁to▁C1 D1", + "\n\nEthical ▁conduct▁of▁the▁study", + "circl ing▁one▁(1)", + "▁cervical ▁cancer", + ",▁Heaney▁RP ,▁Holick▁MF", + "▁is▁obligated▁to ▁inform", + "\n\nRestricted▁in▁physically▁strenuous▁activity▁but ▁ambulatory▁and▁able▁to▁carry▁out▁work▁of▁a▁light▁or▁sedentary▁nature,▁", + "aenoic▁acid▁ [", + "oppos ed▁to", + "▁Method s▁for", + "ine▁is▁ marked▁", + "ultin ational", + "\n\nTest ▁result", + "i-dimension ally▁measurable▁lesion", + "Analyt ical▁Plan", + "▁occurs▁at ▁or▁near", + "substitut ed▁for", + ",▁Gar land▁", + "▁Febrile▁ Neutropenia", + "describes▁the▁ conduct▁and▁results▁of", + "▁OF▁STUDY ▁VARIABLES▁AND▁DEFINITIONS▁OF", + ".\n\nInt roduction", + "\n\nVolume▁of ▁blood▁sampling▁and▁handl", + "▁medical▁problem s▁s", + "▁and▁institution ▁permit", + "best▁supportive▁car e▁(", + "▁Evaluate▁ AMG▁162▁in▁the▁Treatment▁of▁Bone▁", + "analysis▁will▁be▁censored▁using▁the▁last▁available▁ assessment▁date.\n\n", + "▁transient▁is chemic▁attack", + "residual▁ lesion", + "pG▁island▁ methyl", + "▁Practice▁Guidelin es▁and▁Technical▁Standard", + "▁MEDIC INAL▁PRODUCT", + "▁evaluate▁time▁to ▁response▁and▁", + "s▁with▁performing▁my▁ usual▁activities▁", + "▁earli er▁than", + "elz ack", + "rauterine▁ devic", + "e,▁pleas e▁indicate▁how", + "leeland▁ CS", + "▁gene▁c opy▁number", + "▁at▁least▁25% ▁for▁a▁duration▁of", + "▁mL▁of▁0 .9%▁Sodium▁Chloride▁Injection", + "Evaluable▁ Analysis▁Set", + ".▁These▁signature s▁will", + "▁fracture▁( vertebral▁", + "Response▁(PR ):", + "▁SYST EM", + "▁Epidemiology,▁ Biomarker", + "▁ever▁comes▁first .▁If", + "anton io", + "▁600▁mg/m2 ▁IV▁infusion▁in▁500▁mL", + "ultim ately▁", + ",▁Holl is▁BW", + "Printed▁copy▁is▁not▁official▁record .\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁Panitumumab▁Protocol▁Number:▁20050203▁Date:▁21▁January▁2009\n\nPage▁", + "ing▁any▁record s▁and▁report", + "▁and▁an▁IV▁infusion ▁of▁zoledronic▁acid▁", + "goals▁for ▁the▁target", + "▁400▁mg/m2▁IV ▁bolus▁given▁over▁2▁to▁4", + "/favorable▁ opinion", + "Committee▁of ▁Medical▁Journal▁", + "▁blood▁pressure,▁resting▁pulse,▁ respiration▁rate,▁and", + "recorded▁and▁measured▁ at▁baselin", + "s,▁Subsets,▁and▁ C", + "istence▁of▁one▁or▁more▁ non-target▁lesion", + "▁Biomedical▁ Journal", + "▁w▁±3▁d▁after ▁Day▁1", + "OME ▁VARIABLES", + "os▁A P", + "isl ation", + "▁wit ness", + "▁1.▁O BJECTIVES▁........................................................................................................", + "agaz in", + "\n\nAudit s▁and▁inspection", + "▁NUMB ER", + "▁confidential▁ information", + "eventh ▁Edition", + "▁on▁which ▁they▁are▁", + "\n\nDetermination▁of ▁sample▁siz", + "equisition ▁Form", + "ABO RATORY", + ",▁Henne kens▁CH", + "▁radioisotop es),▁surgery▁to", + "s▁of▁the▁question :", + "289] ,▁1997", + ",▁Gord on▁D", + "▁during▁the▁past ▁7▁days", + "best▁of▁his▁or▁her ▁knowledge,▁the▁report▁accurately▁", + "used.▁C orrections▁to▁electronic", + "▁child- bearing▁p", + "otherwise▁indic ated", + "▁item▁of▁the▁ Brief▁Pain▁Inventory▁(BP", + ".▁Sample▁Size▁and▁ Statistical▁Method", + "▁OR▁P REGNANCY", + "▁and▁Human ▁Servic", + "▁and▁MRI▁are▁the▁best▁currently▁available▁ and▁", + "▁global▁deterioration▁of ▁health▁status▁requiring", + "\n\nNot▁at▁all\n\nA▁little▁bit\n\nSome-▁what \n\nQuite▁a▁bit\n\nVery▁much", + "ensive▁treatment▁in▁an▁emergency▁room ▁or▁at▁hom", + "(serum ▁sample,▁", + "Dock et▁No.▁", + "DOSE ▁OR▁PREGNANCY", + "Randomisation ▁C", + "onatal ▁death", + "▁to▁Informed▁Consent▁Form ▁for", + "estra must", + "▁OUTC OME▁VARIABLES", + "all▁Street ▁Journal", + "efract ory▁", + "▁are▁cons uming", + ",▁and▁reproduc ing▁any▁records▁and▁report", + "▁BEN EFI", + "▁state▁you ▁can▁imag", + ".▁Simopoul os▁AP", + "▁timetable▁and▁ end▁of▁study", + "suffic i", + "rial▁fib rill", + "defined▁and▁ surrounded▁by▁aerated▁lung", + "linding▁and▁ procedures▁for▁unblinding▁the▁study", + "atistical▁and▁ Analytical▁Plan", + "arrhyth mic", + "▁number▁per▁lin e,▁please▁indicate▁how", + "lesions▁will▁only▁be▁ considered▁measurable▁when▁they▁are▁superficial▁", + "▁new▁protocol▁amendment ▁would▁be▁", + "▁has▁been▁for▁you ▁during▁the▁past▁7▁days", + "-malate▁ salt", + "▁review▁the▁subject’s▁ original", + "▁party▁or ▁move▁them", + "MDAS I-GI", + "Uniform ▁Requirement", + ",▁Litin ▁LB,▁Willett▁WC", + "▁OF▁EMERGENCY ,▁OVER", + "▁1895 ▁525", + "▁without▁objective▁ evidence▁of▁disease▁progression", + "▁or▁early▁termination ▁and▁send", + "ised▁Registration/ Randomisation▁C", + "\n\nm▁c▁/ ▁g", + ".▁Grup po", + "agents▁inter act", + "e,▁the▁end▁of▁study▁is▁ defined▁as▁4▁week", + ".1.2▁Rec ording▁of", + "baseline▁BMD ▁valu", + "read▁the▁attach ed▁protocol", + "▁Research▁Addendum ▁to▁Informed▁Consent▁Form▁for", + "▁Research▁and▁Treatment ▁of▁Cancer", + "▁IN-T EXT", + "▁IN▁CASE ▁OF▁EMERGENCY,▁OVER", + ".\n\nMEASUREMENTS ▁OF▁STUDY▁VARIABLES▁AND▁DEFINITIONS▁OF", + "▁asks▁about ▁your", + "ating▁the▁confidentiality▁of ▁the▁subject", + ".▁Data▁Qual ity▁Assur", + "▁of▁outcome▁variables▁in▁relation▁to ▁objectives▁and▁", + "notifications,▁and▁agrees▁with▁the▁ content", + "9)Toxicity▁ resolved?", + "▁↓▁One▁ 5-fluorouracil▁dose▁level", + "▁observation▁mad e▁on▁a▁variable▁", + "▁origin▁in▁the▁D eclaration▁of▁Helsinki", + "▁principles▁that▁have▁their ▁origin▁in▁the▁Declaration▁of▁Helsinki", + "▁from▁all▁supplemental▁sourc es▁combin", + "▁the▁interpretation▁of▁the▁study▁ result", + ".▁Discussion ▁of▁Design▁and▁Control", + "\n\nStatistical▁evaluation▁–▁general ▁aspect", + "oftware’s▁“audit▁trail ”", + "▁true▁each▁statement ▁has▁been▁for▁you▁during▁the▁past▁7▁days", + "circling▁one▁(1) ▁number▁per▁line,▁please▁indicate▁how", + "▁occurs▁at▁or▁near ▁the▁end▁of▁the▁", + "\n\nVolume▁of▁blood▁sampling▁and▁handl ing▁of▁biological▁samples", + "▁Evaluate▁AMG▁162▁in▁the▁Treatment▁of▁Bone▁ Loss▁in", + "▁at▁least▁25%▁for▁a▁duration▁of ▁1▁week▁or▁mor", + "Committee▁of▁Medical▁Journal▁ Editor", + "Docket▁No.▁ 86G", + "▁state▁you▁can▁imag ine▁is▁marked▁", + "▁IN▁CASE▁OF▁EMERGENCY,▁OVER DOSE▁OR▁PREGNANCY", + ".\n\nMEASUREMENTS▁OF▁STUDY▁VARIABLES▁AND▁DEFINITIONS▁OF ▁OUTCOME▁VARIABLES", + "circling▁one▁(1)▁number▁per▁line,▁please▁indicate▁how ▁true▁each▁statement▁has▁been▁for▁you▁during▁the▁past▁7▁days", + "% )\n\n", + "( 20", + "( 24", + "( 28", + "( including▁the▁", + "( a)", + ") \n\nP", + ") ▁N", + ") .▁E", + ") .▁C", + ") ▁visit", + ") ▁until", + ") ▁document", + ") .▁Patients▁", + ") ▁for▁the▁", + ") ▁were▁", + ") ▁is▁not", + ", ▁ag", + ", ▁the▁subject’s▁", + "- -", + "- J", + "- 54", + "- 13", + "- 80", + "- 70", + "- Ntx", + "- profit", + ". G", + ". pdf", + "/ 5", + "/ Ph", + "/ paclitaxel", + "/ vital▁sign", + "/ discomfort", + "/ ethnic", + "/ independent▁ethics▁committe", + "0 .", + "0 .1", + "1 19", + "2 1-Day▁Cycl", + "3 5%", + "3 ▁days)", + "5 ▁mg", + "6 -month", + "6 ▁plann", + "9 2:", + "9 00▁mg", + "9 ▁weeks▁until", + ": ▁R", + ": 12", + ": ▁J", + ": 28", + ": \n\n(", + ": ▁a▁m", + "; ▁S", + "; ▁M", + "; ▁L", + "; ▁NCI", + "= ▁0", + "> ▁1", + "B ▁receptor", + "B ased▁on", + "C or", + "C OG", + "C SI", + "D LT", + "D 8480C000", + "E scal", + "E toposid", + "E uroQol▁Group", + "F ig", + "F ax", + "F ood▁and▁Drug▁Administration", + "H u", + "H igh", + "I A", + "I gG", + "L ,▁L", + "M in", + "M easures▁", + "O r", + "O US", + "O MP", + "O ’Brien", + "O ’Brien-Fleming", + "P 3", + "Q LQ-C30", + "R ang", + "R efer", + "R atio", + "R etention", + "S /", + "S R", + "S h", + "S PARC", + "T issu", + "T ▁cell", + "T aken", + "U LE", + "V 5", + "Z ED", + "] ▁or", + "] ),▁", + "a um", + "a qu", + "a utomatically▁", + "a ive▁patients▁with", + "b le", + "c opy▁of", + "c ovariates▁", + "c osmetic", + "d res", + "d ominal", + "e .▁Th", + "e .▁In▁addition", + "f avor", + "f ish▁oil", + "f utility", + "g /", + "g astric", + "g iving", + "h ang", + "h olid", + "h is/her", + "h ospital▁", + "i R", + "i ere▁", + "i e▁C", + "j aw", + "k idney▁", + "k ilogram", + "l ed▁to", + "l uorouracil", + "l ess▁s", + "l ess▁of▁the▁", + "m e", + "m s", + "m agnesium", + "m alignant", + "m argin", + "o il", + "p in", + "p ag", + "p reliminary▁", + "r w", + "r end", + "s '", + "s eek", + "s ix", + "s pr", + "s ▁abnormal", + "s olid▁tumor", + "s pontane", + "s ▁available▁to", + "s ummary▁statistic", + "t een", + "t ry▁", + "u d▁", + "u ite▁", + "v ast", + "w est", + "w ish", + "w atchful▁wait", + "ï v", + "’ t", + "’ s▁a", + "” ▁on", + "≥ 1/", + "▁ escal", + "▁ effusion", + "▁ optional", + "▁ ..........................................................", + "▁ estrogen", + "▁ routin", + "▁ .▁0", + "e▁ collection", + "e▁ cetuximab", + "in ear", + "in ▁other", + "in jection", + "in eer", + "▁t ▁n", + "▁t rastuzumab", + "at im", + "at omic", + "on a", + "on ad", + "\n\n “", + "\n\n im", + "\n\n study", + "\n\n as▁", + "\n\n report", + "\n\n 54", + "\n\n 80", + "\n\n may▁be▁", + "\n\n inter", + "\n\n group", + "\n\n have▁been", + "\n\n US", + "\n\n contact", + "\n\n interval", + "▁a ▁clinical", + "▁a ▁local", + "▁a utomatically▁", + "▁a ▁docetaxel-based▁chemotherapy▁regimen", + "en ▁S", + "en ▁E", + "er l", + "er ▁C", + "er ▁J", + "er man", + "er cul", + "or ▁S", + "or ▁may▁not", + "........ ......", + "s▁ =", + "s▁ 10", + "s▁ observed▁in", + "s▁ ......................................................................................................", + "s▁ Sub", + "s▁ would▁be▁", + "re duct", + "re striction", + "al o", + "al one▁", + "al ities", + "st and▁", + "ion ▁of▁", + "ent al▁", + "it e", + "it ation", + "it one", + "it idine▁", + "▁the▁ n", + "▁the▁ ‘", + "▁the▁ consent", + "▁the▁ effects▁of", + "an ▁American", + ",▁ 5", + ",▁ Study▁", + ",▁ chemotherapy▁", + ",▁ has▁been", + ",▁ ie,▁", + ",▁ 5-fluorouracil", + ",▁ 56", + ",▁ see▁Section", + ",▁ consent▁form", + ",▁ on▁a", + ",▁ headache,▁", + ",▁ laboratories", + "ro vers", + "ro ubl", + "ed▁ during▁the▁study", + "ed▁ visually▁for", + "▁an g", + "▁an gi", + "▁an alyt", + "▁an ▁IVRS", + "ic c", + "ic z", + ".▁ 21", + ".▁ 29", + ".▁ 39", + "ll um", + "ar p", + "ar in-", + "ed ▁all", + "ed ing▁and▁", + "ed ▁time▁point", + "▁p ackaging", + "▁p ages▁", + "▁p mab", + "▁p igment", + "▁p iecew", + "▁c rit", + "▁c red", + "▁c oagulation", + "▁c atheter", + "▁b u", + "▁b eg", + "▁b ecause▁", + "▁b rief", + "es is", + "es .▁All", + "es ▁associated▁with", + "es ▁as▁an", + "for ▁the▁difference▁in", + "et o", + "et ect", + "et ium", + "ation ▁in▁the▁", + "▁to ol", + "▁to ▁com", + "▁to ▁disease▁progression", + "▁to ▁review", + "▁to gether", + "▁to ▁indicate▁", + "▁to ▁Lilly▁or▁its▁designee▁via", + "is pan", + "▁s af", + "▁s ett", + "▁s elf", + "▁s epar", + "▁s ince▁", + "▁s leep", + "as e,▁", + "as s▁s", + "as e;", + "▁of ▁E", + "▁of ▁their", + "▁of ▁Ch", + "▁of ▁cediranib", + "▁of ▁chest", + "▁of ▁DNA", + "▁of ▁childbearing▁potential▁", + "ou ch", + "▁d ate▁in", + "▁d epending▁on", + "th rough", + "▁w ild-typ", + "▁m ethod▁of", + "▁m ouse▁", + "▁m ild▁", + "▁m axim", + "▁and▁ one▁", + "▁and▁ 30", + "▁and▁ including", + "▁and▁ III", + "▁and▁ chemotherapy▁", + "▁and▁ stor", + "▁and▁ 49", + "▁and▁ maximum", + "▁and▁ does▁not", + "▁and▁ evaluate▁", + ".\n\n g", + ".\n\n 30", + ".\n\n 35", + ".\n\n Grade▁4", + "al▁ lymph▁nod", + "al▁ Anti-", + "el i", + "el ic", + "ab s", + "ab sent", + "▁A M", + "▁A P", + "▁A greement", + "▁A re▁", + "▁A SSURA", + "iv otal▁", + "▁in -", + "▁in ▁Cancer", + "▁in ▁both", + "▁in ▁bone▁", + "▁in ▁men▁with", + "▁in fluenc", + "................................ ...▁", + "ur a", + "ur se", + "ur ation▁for", + "ev ening", + "ev ice▁", + "ig uration", + "00 000", + "oc c", + "pl astin", + "▁1 ▁to", + "▁1 .2.3", + "▁C OLL", + "ac y", + "ac e▁", + "ac quisition▁of", + "es▁ specifi", + "es▁ should▁not▁be▁", + "▁P I", + "▁P ET", + "pro hibit", + "pro lifer", + "▁( 8", + "▁( X", + "▁( as", + "▁( radi", + "▁( 14", + "▁( SCLC", + "▁( such▁as▁", + "▁( defined▁as▁", + "▁( VEGFR", + "▁( CTC", + "▁( e.g.", + "▁( OPG", + "▁( x▁109/L", + "em zar", + "▁2 )", + "▁2 25", + "▁2 .2.5", + "ul ▁S", + "ul ates", + "ra ine▁", + "if ▁necessary", + "if ▁appropriate", + "▁S quamous▁", + "▁S ummary▁", + "▁S ymptomatic", + "▁S olid▁Tumor", + "▁S equential▁", + "▁I RC", + "▁re produc", + "ag gregate▁", + "un controll", + "un acceptable▁toxicity", + "▁D 1", + "▁D etail", + "▁D LT", + "▁D extros", + "cl ass▁", + "▁h ospital▁", + "▁h eav", + "e▁of ten", + "e▁of ▁Administration", + "▁E d", + "▁E ,▁B", + "▁E conomic", + "am ol", + "am oxifen", + "ch n", + "ch ron", + "ch air", + "ch emotherapeutic", + "▁or ▁v", + "▁or ally", + "▁or ▁lung", + "▁or ▁FOLFOX", + "▁or ▁EC", + "▁or ▁CT▁scan", + "▁or ▁pharmacist", + "e▁t axan", + "ir d▁", + "ut ophag", + "ut ies.▁All", + "form at", + "form ed", + "form ed▁to", + "form s/", + "\n\nP ublication", + "\n\nP lease▁", + "iz ation▁of", + "iz e▁discover", + "ex ual▁", + "qu ery▁", + "▁n M", + "▁n or▁other", + "▁n umer", + "od y▁surface▁area", + "ate▁ and", + "ate▁ with▁the▁", + "study▁ subject", + "study▁ data", + "study▁ population", + "study▁ participation", + "lin e▁or", + "▁and ▁time▁to", + "▁and ▁as▁needed", + "abl e,", + "▁pro xim", + "▁pro state▁", + "▁pro portion", + "▁pro mpt", + "▁T 1", + "▁T 3", + "▁T H", + "▁T S", + "▁T wo", + "▁T ype▁", + "▁T IS", + "▁T ABLES", + "▁T elephone:", + "▁ad en", + "▁ad olescent", + "▁N either", + "▁ar tic", + "▁for ▁additional", + "▁for ▁use▁in", + "▁for ▁collection▁of", + "▁for ▁Injection", + "▁for ▁Research▁and▁Treatment▁of▁Cancer", + "▁for -profit", + "▁R ep", + "▁R IS", + "e\n\n 3", + "e\n\n F", + "e\n\n If", + "e\n\n Study▁", + "e\n\n KRAS", + "rom at", + "▁treatment ▁due▁to", + "av ies▁", + "▁with ▁no", + "▁with ▁either", + "▁with ▁non-mutated▁(", + "e▁to ▁perform", + "e▁to ▁determine▁if", + "ed▁b est", + "s▁of ▁s", + "s▁of ▁the▁study▁", + "In ▁addition", + "be▁ maintained", + "ad e▁J", + "ant igen", + "\n\nS chedul", + "\n\nS evere▁", + "▁that ▁time▁point", + "▁that ▁you▁have▁", + "▁that ▁provides", + "▁is▁ complet", + "▁is▁ delay", + "▁is▁ less▁than", + "▁of▁ oxaliplatin", + "................................................................ .....▁", + "▁will▁be▁ repeated▁", + "▁will▁be▁ done▁", + "▁will▁be▁ included▁in", + "▁will▁be▁ sent▁to", + "▁will▁be▁ summaris", + "e▁s chedul", + "▁M E", + "▁M ,▁C", + "▁M ,▁G", + "▁M ,▁D", + "▁M ethod▁of", + "▁r ▁o", + "▁0 ▁to", + "▁0 \n\n1", + "▁3 ▁4", + "▁3 75", + "▁con struct", + "▁con stipation", + "▁con vulsion", + "▁con gestive▁heart▁failure", + "event -free▁rates▁", + "▁of▁the▁ correction", + "e,▁ S", + "▁o ▁i", + "▁com pos", "▁F act", - "▁Fa ct", - "▁Fac t", - "▁ Fact", - "▁manip ulate", - "▁M AC", - "▁MA C", - "▁d ej", - "▁de j", - "ult imo", - "F X", - "Li fe", - "L ife", - "▁c rack", - "▁cr ack", - "▁cra ck", - "▁m í", - "▁п ове", - "▁по ве", - "▁пов е", - "▁w ore", - "▁wor e", - "▁wo re", - "univers ité", - "▁form ulas", - "▁formula s", - "▁Elis abeth", - "pl ots", - "plot s", - "mi le", - "mil e", - "m ile", - "▁me nor", - "▁men or", - "ти л", - "т ил", - "key word", - "▁Balt imore", - "hr er", - "hre r", - "h rer", - "▁C lement", - "▁Cl ement", - "▁Cle ment", - "vi m", - "v im", - "ra ss", - "ras s", - "r ass", - "T ake", - "▁cím ű", - "▁Con vention", - "at ge", - "se ed", - "see d", - "s eed", - "▁D í", - "▁Sp ider", - "ah oo", - "aho o", - "▁име ет", - "ühr t", - "üh rt", - "▁по писа", - "▁C ot", - "▁Co t", - "▁no bles", - "▁noble s", - "▁nob les", - "RE SS", - "RES S", - "▁che min", - "▁chem in", - "▁gł ówn", - "G G", - "▁German ia", - "▁Ger mania", - "▁Germ ania", - "▁Alexand re", - "he ns", - "hen s", - "h ens", - "sw ift", - "oo p", - "o op", - "Sub view", - "▁requ iring", - "ęd zy", - "ędz y", - "▁f ict", - "▁fi ct", - "▁fic t", - "▁Кон стан", - "▁dé put", - "▁dép ut", - "▁surpr ising", - "▁de ix", - "▁dei x", - "▁unter schied", - "in son", - "ins on", - "▁Char acter", - "▁ Character", - "▁g estion", - "▁ges tion", - "▁gest ion", - "ch us", - "c hus", - "com es", - "co mes", - "come s", - "▁n eur", - "▁ne ur", - "▁neu r", - "▁ neur", - "▁ye ux", - "ol lar", - "oll ar", - "▁par ad", - "▁para d", - "▁pa rad", - "▁mag giore", - "▁maggio re", - "▁maggior e", - "TR AN", - "▁vo tre", - "▁vot re", - "▁des cent", - "▁desc ent", - "▁I con", - "▁ Icon", - "▁Jud ge", - "▁occup ation", - "▁ occupation", - "ep ing", - "e ping", - "▁ton gue", - "▁tong ue", - "▁En llaços", - "ru f", - "r uf", - "▁prote in", - "▁prot ein", - "▁vis itors", - "▁visit ors", - "▁visitor s", - "ax y", - "a xy", - "es ten", - "est en", - "este n", - "e sten", - "bl ica", - "blic a", - "b lica", - "h w", - "▁spir its", - "▁spirit s", - "▁redu ces", - "▁reduce s", - "▁м ен", - "▁ме н", - "▁ мен", - "▁L amb", - "▁La mb", - "▁Lam b", - "▁M ine", - "▁Min e", - "▁Mi ne", - "▁ver ified", - "▁B aby", - "▁Ba by", - "▁Bab y", - "▁pr ize", - "▁pri ze", - "в ър", - "▁rat ings", - "▁rating s", - "▁f ore", - "▁for e", - "▁fo re", - "▁ fore", - "as ha", - "ash a", - "a sha", - "ur rence", - "urr ence", - "▁int ér", - "▁Ol ímp", - "cr a", - "c ra", - "▁comput ational", - "▁computation al", - "ir che", - "irc he", - ".:  ", - "▁illustr ated", - "▁illustrate d", - "▁Sh are", - "▁house holds", - "▁household s", - "▁con volution", - "oe md", - "oem d", - "▁zd oby", - "▁zdob y", - "cc c", - "c cc", - "▁quant ities", - "Ch e", - "C he", - "Sh ould", - "▁ge nius", - "▁gen ius", - "ad j", - "a dj", - "х ва", - "Пе тер", - "EM A", - "E MA", - "▁R ights", - "▁Right s", - "▁E li", - "▁El i", - "VA R", - "V AR", - "ш ло", - "▁з бір", - "ift ung", - "▁cont ributed", - "▁contrib uted", - "▁contribu ted", - "▁contribute d", - "ze f", - "z ef", - "▁CH AR", - "▁ CHAR", - "▁S ib", - "▁Si b", - "▁M ant", - "▁Man t", - "▁Ma nt", - "▁свя зи", - "▁java fx", - "▁c ependant", - "▁in tu", - "▁int u", - "▁т вор", - "▁ Ó", - "gu er", - "gue r", - "g uer", - "ra do", - "rad o", - "r ado", - "▁Re vol", - "▁Rev ol", - "▁fé min", - "▁Or leans", - "▁p oj", - "▁po j", - "▁p rez", - "▁pr ez", - "▁pre z", - "Te x", - "T ex", - "ou wd", - "ouw d", - "? (", - "▁L IM", - "▁LI M", - "ist ique", - "isti que", - "es ar", - "esa r", - "▁he ures", - "ic ki", - "ick i", - "i cki", - "▁d bo", - "▁db o", - "▁ dbo", - "sk ih", - "ski h", - "s kih", - "conf irm", - "▁vil ág", - "▁ci utat", - "▁D R", - "▁ DR", - "▁Haw ai", - "ch ed", - "che d", - "c hed", - "▁s pher", - "��sp her", - "▁Art ikel", - "▁Multi ple", - "ci u", - "c iu", - "▁м ы", - "▁ мы", - "▁lip ca", - "]( /", - "] (/", - "Str ategy", - "▁Al abama", - "SD K", - "S DK", - "UT C", - "U TC", - "__ .", - "_ _.", - "Arg uments", - "Argument s", - "▁set ContentView", - "î le", - "By Val", - "▁J VM", - "юще го", - "▁Leon ard", - "▁just ify", - "це м", - "ц ем", - "▁n ab", - "▁na b", - "▁ nab", - "CCE SS", - "C CESS", - "▁hope s", - "▁ho pes", - "▁hop es", - ") &", - "se ro", - "ser o", - "s ero", - "▁за й", - "слі д", - "▁R ég", - "▁Ré g", - "▁S ang", - "▁San g", - "▁Sa ng", - "▁f ung", - "▁fun g", - "▁fu ng", - "ba ar", - "b aar", - "▁coff ee", - "ass embly", - "▁В ін", - "▁Ві н", - "э й", - "▁comp rend", - "▁compr end", - "fil led", - "fill ed", - "f illed", - "р д", - "od ia", - "odi a", - "o dia", - "▁g ens", - "▁ge ns", - "▁gen s", - "▁ gens", - "fl uss", - "flu ss", - "f luss", - "Draw able", - "▁sur ve", - "▁surv e", - "Set up", - "▁n ależ", - "▁conj unto", - "▁Е го", - "▁old al", - "▁ol dal", - "▁ver bose", - "▁verb ose", - "▁Elect ric", - "▁H arrison", - "▁Harr ison", - "▁Harris on", - "en gen", - "eng en", - "par agraph", - "para graph", - "▁n ouvelles", - "▁nouve lles", - "▁nouvelle s", - "▁вре ме", - "▁m emor", - "▁me mor", - "▁mem or", - "▁mayo ría", - "▁mayor ía", - "са д", - "▁bat aille", - "▁bata ille", - "▁therm al", - "▁ther mal", - "▁Хро нологи", - "▁B etter", - "▁Bet ter", - "by e", - "b ye", - "▁теа тра", - "ro e", - "r oe", - "▁se gle", - "▁seg le", - "ro tt", - "rot t", - "r ott", - "▁opin ions", - "▁opinion s", - ")} )", - ") })", - "üh le", - "ühl e", - "▁G ün", - "▁Gü n", - "▁ Щ", - "b ól", - "▁Lar ry", - "▁so lic", - "▁sol ic", - "▁z war", - "▁zw ar", - "▁Car oline", - "▁Carol ine", - "▁Reich s", - "Ext ensions", - "Extension s", - "mi gr", - "m igr", - ": @", - "▁en umerate", - "▁enumer ate", - "▁ enumerate", - "▁eigen en", - "▁eig enen", - "▁expl ore", - "▁explo re", - "ém u", - "é mu", - "▁g at", - "▁ga t", - "▁ gat", - "▁imper ial", - "▁Us ually", - "▁t ud", - "▁tu d", - "▁у кра", - "hi m", - "h im", - "▁cor ners", - "▁corner s", - "▁corn ers", - "▁S ER", - "▁SE R", - "▁ SER", - "▁interpre ter", - "▁interpret er", - "▁I ce", - "▁amount s", - "▁P ala", - "▁Pa la", - "▁Pal a", - "▁t inha", - "▁tin ha", - "vo le", - "vol e", - "v ole", - "▁g le", - "▁gl e", - "▁ gle", - "uc ci", - "▁sie he", - "Jac k", - "J ack", - "▁w oll", - "▁wo ll", - "▁wol l", - "▁e lder", - "▁el der", - "▁ко раб", - "▁eng ag", - "▁La urent", - "▁Laur ent", - "▁Lau rent", - "▁ach iev", - "ist ik", - "isti k", - "ar ct", - "arc t", - "тно го", - "т ного", - "▁g ir", - "▁gi r", - "▁Sing h", - "▁Sin gh", - "math op", - "US A", - "U SA", - "▁Pro jekt", - "▁de be", - "▁deb e", - "richt ung", - "r ichtung", - "▁T sch", - "▁Ts ch", - "um inate", - "umin ate", - "▁s zó", - "▁sz ó", - "ly ph", - "зи дент", - "зиден т", - "▁lim itations", - "▁limit ations", - "▁limitation s", - "юще й", - "▁b ila", - "▁bi la", - "▁bil a", - "P ush", - "▁off ering", - "▁offer ing", - "ien nes", - "ienne s", - "ienn es", - "i ennes", - "Fr i", - "F ri", - "▁post gresql", - "▁ postgresql", - "▁Tom my", - "▁partic olare", - "▁stolet í", - "▁ar rib", - "▁arr ib", - "▁E va", - "▁Ev a", - "sch ool", - "▁v endor", - "▁ven dor", - "▁vend or", - "▁ vendor", - "▁D allas", - "▁Dal las", - "▁pro long", - "CRE ATE", - "C REATE", - "▁suiv ante", - "STAT US", - "l à", - "k v", - "▁h äufig", - "▁Agr icult", - "▁h uit", - "▁hu it", - "▁in oltre", - "▁L loyd", - "▁францу з", - "▁вы пол", - "▁faith ful", - "▁В ар", - "▁Ва р", - "▁ver l", - "▁ve rl", - "▁ju ego", - "▁Резу лтати", - ", ...,", - "▁implicit ly", - "ir ks", - "irk s", - "Cal cul", - "▁m eses", - "▁mes es", - "om ed", - "ome d", - "o med", - "▁p ak", - "▁pa k", - "he rit", - "her it", - "▁opt ical", - "▁І сторія", - "ve is", - "▁capital e", - "▁capit ale", - "place holder", - "int rag", - "▁At las", - "▁Atl as", - "▁ Atlas", - ")] ;", - ") ];", - "ic ons", - "ico ns", - "icon s", - "i cons", - "▁B ent", - "▁Be nt", - "▁Ben t", - "▁W idget", - "▁ Widget", - "▁vol unt", - "av o", - "a vo", - "ég r", - "é gr", - "li ge", - "lig e", - "l ige", - "▁N AME", - "▁NA ME", - "▁ NAME", - "▁ab stra", - "▁abs tra", - "▁f ís", - "▁B rowser", - "▁Brow ser", - "▁ Browser", - "▁b ush", - "▁bu sh", - "▁bus h", - "ha ll", - "hal l", - "h all", - "▁cloud s", - "▁S UB", - "▁SU B", - "▁ SUB", - "▁t andis", - "▁tan dis", - "▁Common wealth", - "та я", - "▁exha ust", - "________ ________", - "▁Stat istics", - "▁Statist ics", - "▁Relig ion", - "▁Mu ham", - "ual s", - "ua ls", - "u als", - "go to", - "got o", - "g oto", - "Dig ital", - "Famil y", - "▁B un", - "▁Bu n", - "let in", - "Man agement", - "▁cap abilities", - "an nten", - "ann ten", - "annt en", - "annte n", - "▁се бе", - "▁st ays", - "▁stay s", - "▁sta ys", - "kt er", - "kte r", - "k ter", - "▁d ost", - "▁do st", - "▁dos t", - "▁Т ре", - "ло вич", - "лови ч", - "л ович", - "▁d ying", - "▁dy ing", - "se ctions", - "section s", - "sect ions", - "án os", - "á nos", - "▁app arten", - "▁appar ten", - "▁appart en", - "▁zo als", - "▁dr essed", - "▁dress ed", - "▁com press", - "▁comp ress", - "▁compr ess", - "ń ska", - "▁sierp nia", - "▁ти ту", - "diction ary", - "d ictionary", - "▁r abb", - "▁ra bb", - "▁vé rit", - "В о", - "▁sing leton", - "▁single ton", - "▁v ital", - "▁vi tal", - "▁vit al", - "▁vita l", - "Ref resh", - "ме ль", - "м ель", - "▁Z h", - "▁Af ghan", - "in kel", - "ink el", - "aa aa", - "▁particip ants", - "ar in", - "ari n", - "a rin", - "▁M old", - "▁Mo ld", - "▁Mol d", - "▁prim eros", - "▁prime ros", - "▁primer os", - "▁ра н", - "▁р ан", - "▁ ран", - "▁А мери", - "▁restaur ant", - "év el", - "é vel", - "▁S L", - "▁ SL", - "▁R ey", - "▁Re y", - "ch as", - "cha s", - "c has", - "▁elect rons", - "▁electron s", - "▁electro ns", - "▁Pitt s", - "▁Pit ts", - "▁J ules", - "▁Jul es", - "▁Ju les", - "ма й", - "en ant", - "ena nt", - "e nant", - "- }", - "ла д", - "▁Мос ква", - "▁Моск ва", - "go m", - "g om", - "▁Fern ández", - "fun d", - "fu nd", - "f und", - "int erno", - "inter no", - "intern o", - "▁M ari", - "▁Mar i", - "▁Ma ri", - "▁r ius", - "▁ri us", - "▁Pro zent", - "ст рі", - "стр і", - "▁в нут", - "ant erie", - "ante rie", - "anter ie", - "▁п рис", - "▁при с", - "▁пр ис", - "▁о бы", - "▁об ы", - "▁M arina", - "▁Mar ina", - "▁Mari na", - "▁occ urrence", - "▁occur rence", - "▁occurr ence", - "ri kt", - "rik t", - "r ikt", - "▁фи зи", - "▁sch wer", - "▁schw er", - "▁Г ре", - "Re set", - "Res et", - "▁much o", - "▁mu cho", - "an dr", - "and r", - "▁W ies", - "▁Wi es", - "▁Wie s", - "▁Ke ith", - "▁Jul ian", - "▁Juli an", - "▁Julia n", - "▁c ole", - "▁col e", - "▁co le", - "▁ cole", - "ci endo", - "c iendo", - "▁Cont empor", - "et ry", - "etr y", - "e try", - "el ian", - "eli an", - "elia n", - "ги и", - "▁го ло", - "▁г оло", - "▁d él", - "▁dé l", - "▁de cent", - "▁dec ent", - "▁dece nt", - "Р СР", - "▁sze ptember", - "ме ст", - "cast le", - "▁держа в", - "}\" )", - "} \")", - "▁ASC II", - "▁G len", - "▁Gl en", - "itzer land", - "T oggle", - "▁trad icional", - "▁P lat", - "▁Pl at", - "▁Pla t", - "ve e", - "v ee", - "ab gerufen", - "( |", - "CL I", - "C LI", - "}} $,", - "}}$ ,", - "} }$,", - "▁Bow l", - "▁M ale", - "▁Ma le", - "▁Mal e", - "▁B res", - "▁Br es", - "▁Bre s", - "▁п си", - "▁Ch allenge", - "z ó", - "▁pro jekt", - "▁neg oti", - "ab ove", - "a bove", - "▁пери о", - "▁long est", - "▁lon gest", - "auth entic", - "▁tr adu", - "▁tra du", - "▁trad u", - "▁mujer es", - "▁And re", - "▁ha dn", - "▁had n", - "▁Sch ule", - "▁Schul e", - "ode l", - "od el", - "o del", - "ble d", - "bl ed", - "b led", - "▁T rade", - "▁Tr ade", - "▁Tra de", - "▁Trad e", - "▁m obil", - "▁mo bil", - "▁mob il", - "▁alg unas", - "▁L ak", - "▁La k", - "▁Connect icut", - "▁al co", - "▁alc o", - "▁Sel bst", - "i ł", - "▁a lb", - "▁al b", - "ouver neur", - "ouvern eur", - "▁s r", - "▁ sr", - "▁v ba", - "▁vb a", - "lo ped", - "lop ed", - "l oped", - "▁Par tei", - "▁Part ei", - "▁Parte i", - "ua te", - "u ate", - "▁Auth entication", - "▁ Authentication", - "be i", - "b ei", - "}} .", - "} }.", - "▁kon nten", - "▁konn ten", - "▁konnte n", - "▁до по", - "▁h yd", - "▁hy d", - "Off ice", - "d onnées", - "▁C leveland", - "ri ta", - "rit a", - "r ita", - "ío s", - "í os", - "▁вы ше", - "▁Ro berts", - "▁Robert s", - "▁é lections", - "▁élect ions", - "▁' ')", - "▁'' )", - "▁publish ing", - "▁b apt", - "▁ba pt", - "<> ();", - "< >();", - "miss ing", - "mis sing", - "рова но", - "рован о", - "р овано", - "▁ho using", - "▁hous ing", - "▁in ference", - "▁infer ence", - "▁Rena issance", - "▁r èg", - "▁Ste ph", - "▁Step h", - "CE S", - "C ES", - "ER E", - "E RE", - "ке т", - "к ет", - "O U", - "▁group ing", - "ver kehr", - "ji h", - "j ih", - "ag li", - "▁mil k", - "la it", - "l ait", - "St age", - "▁by ly", - "▁byl y", - "▁wood en", - "▁wo oden", - "ke ley", - "kel ey", - "kele y", - "et ra", - "etr a", - "e tra", - "▁P eg", - "▁Pe g", - "▁don né", - "▁donn é", - "ad al", - "ada l", - "a dal", - "sequ ently", - "▁ins besondere", - "EL D", - "E LD", - "▁M am", - "▁Ma m", - "▁vol te", - "▁volt e", - "▁pro spect", - "▁pros pect", - "но ве", - "нов е", - "н ове", - "▁den oted", - "▁denote d", - "▁over lay", - "Per mission", - "Perm ission", - "ee n", - "e en", - "▁E M", - "▁ EM", - "▁u z", - "▁ uz", - "M c", - "ol it", - "oli t", - "o lit", - "▁ser vi", - "▁serv i", - "▁He idel", - "▁Wien er", - "▁Wi ener", - "▁Wie ner", - "▁il legal", - "▁predict ions", - "▁prediction s", - "▁go og", - "ho n", - "h on", - "▁Cin ema", - "▁ре волю", - "▁R ule", - "▁Ru le", - "▁ Rule", - "wo d", - "w od", - "▁rad iation", - "▁radi ation", - "o ł", - "ово ї", - "▁Per form", - "▁prison er", - "▁a met", - "▁am et", - "▁fig ura", - "▁figur a", - "▁Comm ander", - "▁Command er", - "▁о фициаль", - "▁t rov", - "▁tr ov", - "▁tro v", - "▁a cted", - "▁act ed", - "▁ac ted", - "▁work flow", - "▁Республи ки", - "▁guid ance", - "▁м ене", - "▁ме не", - "▁мен е", - "▁ мене", - "N ational", - "▁K el", - "▁Ke l", - "web pack", - "про стра", - "▁llam ado", - "al og", - "alo g", - "a log", - "ter ra", - "ix en", - "le graph", - "leg raph", - "ä ischen", - "▁teach ers", - "▁teacher s", - "ud en", - "ude n", - "u den", - "▁o gså", - "pos sible", - "poss ible", - "▁S oul", - "▁So ul", - "▁Sou l", - "▁Ge ography", - "▁за да", - "hi t", - "h it", - "▁an ger", - "▁ang er", - "▁ange r", - "▁ anger", - "▁rem porte", - "▁remp orte", - "Po d", - "P od", - "ч ке", - "▁a ria", - "▁ar ia", - "▁ aria", - "▁A stronom", - "ch apter", - "▁f ork", - "▁for k", - "▁Cu ando", - "men se", - "m ense", - "▁Christ ians", - "▁Christian s", - "g c", - "▁# (", - "Or gan", - "▁ste ady", - "▁stead y", - "ps e", - "p se", - "жи ть", - "ig nes", - "ign es", - "igne s", - "ater ra", - "a terra", - "mo vie", - "mov ie", - "m ovie", - "pos ta", - "po sta", - "post a", - "p osta", - "ra ste", - "ras te", - "r aste", - "▁Res source", - "▁Ress ource", - "▁Pa ís", - "▁( );", - "▁() ;", - "▁ ();", - "▁pen alty", - "т т", - "▁tras fer", - "cent ury", - "▁clean er", - "sel enium", - "s elenium", - "ort heast", - "orth east", - "xi c", - "x ic", - "лі ї", - "л ії", - "▁ingles e", - "▁T ang", - "▁Ta ng", - "▁Tan g", - "▁g ods", - "▁go ds", - "▁god s", - "fr ent", - "fre nt", - "f rent", - "ci ente", - "cient e", - "c iente", - "st arts", - "start s", - "star ts", - "▁mus ica", - "▁music a", - "ymnas ium", - "-- --+", - "---- +", - "--- -+", - "- ---+", - "▁ter rest", - "▁terre st", - "▁retr ieved", - "▁retrieve d", - "ia re", - "iar e", - "i are", - "un ning", - "unn ing", - "▁Mar cus", - "▁Marc us", - "▁prom ote", - "war ning", - "warn ing", - "w arning", - "ты й", - "т ый", - "}) $,", - "})$ ,", - "} )$,", - "Trans port", - "▁re son", - "▁res on", - "▁C lo", - "▁Cl o", - "▁e rm", - "▁er m", - "▁ erm", - "▁elimin ate", - "▁elim inate", - "he imer", - "heim er", - "▁s aves", - "▁sa ves", - "▁sav es", - "▁save s", - "▁pr ayer", - "▁pra yer", - "▁pray er", - "Class es", - "Ex press", - "Exp ress", - "Expr ess", - "▁Akadem ie", - "El se", - "Tu rn", - "T urn", - "▁ik ke", - "▁re i", - "▁r ei", - "▁ rei", - "▁di rett", - "▁dire tt", - "▁dir ett", - "▁R ost", - "▁Ro st", - "▁Ros t", - "▁P apa", - "▁Pa pa", - "▁Pap a", - "▁j sf", - "▁js f", - "ле нием", - "ление м", - "▁T ul", - "▁Tu l", - "▁Z ak", - "▁Za k", - "▁niem ieck", - "T w", - "am our", - "amo ur", - "ne sted", - "nes ted", - "nest ed", - "n ested", - "pp ets", - "ppe ts", - "ppet s", - "ш п", - "di t", - "d it", - "зе н", - "з ен", - "zy ma", - "zym a", - "hr te", - "Constra ints", - "Constraint s", - "▁own ership", - "▁owner ship", - "Ar m", - "A rm", - "▁cons umption", - "▁consum ption", - "▁f et", - "▁fe t", - "iv ari", - "iva ri", - "i vari", - "ch rom", - "chr om", - "set Attribute", - "▁com pose", - "▁comp ose", - "▁compos e", - "▁ compose", - "▁back ing", - "▁P az", - "▁Pa z", - "▁s cri", - "▁sc ri", - "▁scr i", - "▁ scri", - "▁Me chan", - "▁Nor way", - "▁J up", - "▁Ju p", - "▁m ér", - "▁mé r", - "▁administr ator", - "▁c abe", - "▁ca be", - "▁cab e", - "ival ent", - "▁thr one", - "▁thro ne", - "▁d ues", - "▁du es", - "▁due s", - "▁hum or", - "▁hu mor", - "▁A dri", - "▁Ad ri", - "▁ab ort", - "ña s", - "ñ as", - "▁Ки їв", - "j ící", - "▁zwe ite", - "▁zwei te", - "▁do ub", - "▁dou b", - "er shell", - "ers hell", - "шо й", - "▁F am", - "▁Fa m", - "å k", - "▁twe ede", - "▁twee de", - "▁R ib", - "▁Ri b", - "▁f ør", - "pc ión", - "p ción", - "in ned", - "inn ed", - "rv m", - "r vm", - "▁App ar", - "▁Ap par", - "▁D j", - "▁S hang", - "▁Sh ang", - "Dist ance", - "D istance", - "▁d awn", - "▁da wn", - "▁ dawn", - "▁Mat th", - "▁Matt h", - "▁err ichtet", - "ph antom", - "phan tom", - "▁re leases", - "▁release s", - "Recogn izer", - "▁K op", - "▁Ko p", - "▁P ul", - "▁Pu l", - "u é", - "na ts", - "nat s", - "n ats", - "re lax", - "rel ax", - "▁f led", - "▁fl ed", - "▁fle d", - "▁experience s", - "▁experien ces", - "ще е", - "ме ня", - "мен я", - "▁пер сона", - "▁Id entity", - "▁Ident ity", - "▁ Identity", - "re ts", - "ret s", - "r ets", - "k unft", - "la rg", - "lar g", - "l arg", - "List Item", - "v d", - "run ner", - "la nt", - "lan t", - "l ant", - "ip art", - "i part", - "ba y", - "b ay", - "ie i", - "i ei", - "▁length s", - "▁c attle", - "▁catt le", - "je ts", - "jet s", - "j ets", - "▁se hen", - "J ul", - "fa tt", - "f att", - "▁sur render", - "▁surr ender", - "▁Tr ump", - "▁Tru mp", - "дно го", - "д ного", - "▁Four ier", - "▁Fou rier", - "ie ben", - "ieb en", - "i eben", - "_ \"", - "▁frü her", - "▁gar ant", - "▁ga rant", - "uclide an", - "äg t", - "ä gt", - "▁пів ден", - "Page s", - "Pa ges", - "P ages", - "▁r ivers", - "▁river s", - "▁riv ers", - "▁ri vers", - "▁don ner", - "▁donn er", - "▁donne r", - "sv n", - "s vn", - "▁ ł", - "ov ě", - "o vě", - "▁Le ist", - "ar ial", - "ari al", - "aria l", - "a rial", - "ov ých", - "ový ch", - "▁f illing", - "▁fil ling", - "▁fill ing", - "▁mus icale", - "▁music ale", - "▁musical e", - "▁musica le", - "ma xim", - "max im", - "▁d ashed", - "▁das hed", - "▁dash ed", - "▁Н ов", - "▁Но в", - "Draw er", - "Dra wer", - "▁Medic ine", - "▁dok ument", - "ow el", - "owe l", - "o wel", - "vi ć", - "v ić", - "he ly", - "hel y", - "h ely", - "▁e let", - "▁el et", - "▁ele t", - "Sec onds", - "Second s", - "▁Gon z", - "ro u", - "r ou", - "▁fin ales", - "▁final es", - "▁finale s", - "r n", - "f ø", - "▁index ed", - "class Name", - "▁o ber", - "▁ob er", - "▁ ober", - "▁du as", - "▁optim ized", - "▁optimize d", - "▁k dy", - "vers ary", - "ener gy", - "▁цент ра", - "▁центр а", - "▁c urrency", - "▁curr ency", - "▁ currency", - "zy ż", - "Li ke", - "L ike", - "▁Г и", - "so no", - "son o", - "s ono", - "▁pa lab", - "▁pal ab", - "▁p ushing", - "▁push ing", - "ub lik", - "▁H ass", - "▁Ha ss", - "▁Has s", - "}\\ ,\\", - "}\\, \\", - "} \\,\\", - "un ker", - "unk er", - "▁F actory", - "▁Fact ory", - "▁ Factory", - "▁Res ources", - "▁Resource s", - "▁ Resources", - "date i", - "da tei", - "dat ei", - "▁T ools", - "▁To ols", - "▁Tool s", - "▁ Tools", - "▁ste hen", - "si me", - "sim e", - "s ime", - "▁Х у", - "▁h och", - "▁ho ch", - "▁Rod ríguez", - "zeit ig", - "▁Ter ry", - "▁Terr y", - "▁о бу", - "▁об у", - "Us age", - "urch ase", - "l ö", - "▁Int roduction", - "▁ Introduction", - "▁particip ation", - "ο ς", - "og li", - "ap y", - "a py", - "▁hope fully", - "pon der", - "po nder", - "pond er", - "p onder", - "▁Y ang", - "▁Yan g", - "▁Ya ng", - "▁prom ises", - "▁promise s", - "▁вер ну", - "▁о стров", - "▁ост ров", - "^{ +", - "▁most ra", - "▁mo stra", - "▁mos tra", - "▁CURL OPT", - "H H", - "▁std out", - "▁ stdout", - "▁br illiant", - "▁manus cript", - "▁de cir", - "▁dec ir", - "▁B olog", - "▁Bo log", - "▁Bol og", - "▁ме ста", - "▁мест а", - "▁in visible", - "▁C hal", - "▁Ch al", - "▁Cha l", - "▁analy ze", - "▁analyz e", - "pr ilis", - "pril is", - "att end", - "atten d", - "atte nd", - "M vc", - "th an", - "tha n", - "t han", - "ck o", - "c ko", - "▁Que bec", - "▁pl anta", - "▁plan ta", - "▁plant a", - "▁télé vis", - "▁un install", - "èn cies", - "▁gmin ie", - "▁P ref", - "▁Pr ef", - "▁Pre f", - "▁le quel", - "Inv ocation", - "▁ Í", - "▁trans formed", - "▁transform ed", - "MA N", - "M AN", - "ge baut", - "geb aut", - "▁со хра", - "▁вто рой", - "▁L ith", - "▁Li th", - "▁Lit h", - "wend ung", - "▁Polit ik", - "▁Sen ator", - "▁L L", - "▁ LL", - "жде ние", - "ш те", - "▁C és", - "▁b ande", - "▁band e", - "▁ban de", - "▁ba nde", - "▁histor ian", - "▁historia n", - "▁pass words", - "▁password s", - "mal loc", - "m alloc", - "▁sem if", - "▁semi f", - "▁r å", - "▁ rå", - "unic í", - "uni cí", - "Av ailable", - "Option al", - "Opt ional", - "▁T we", - "▁Tw e", - "▁k ró", - "▁kr ó", - "▁sub sets", - "▁subset s", - "▁subs ets", - "▁D AT", - "▁DA T", - "▁ DAT", - "▁double s", - "▁dou bles", - "▁doub les", - "ни ками", - "ника ми", - "▁з в", - "ge geben", - "geg eben", - "g egeben", - "▁По пис", - "▁jú lius", - "▁m eteor", - "▁met eor", - "Mo unt", - "M ount", - "iv ent", - "ive nt", - "iven t", - "i vent", - "▁N athan", - "▁Na than", - "▁Nat han", - "▁Sch utz", - "eg ov", - "ego v", - "e gov", - "▁d öd", - "▁me at", - "▁пун кт", - "▁m inds", - "▁min ds", - "▁mind s", - "eli very", - "▁T LS", - "ре м", - "р ем", - "cks å", - "▁stay ed", - "▁sta yed", - "▁B in", - "▁Bi n", - "▁P ia", - "▁Pi a", - "▁и мен", - "▁име н", - "▁им ен", - "▁Bob by", - "▁produ it", - "▁prod uit", - "em pio", - "emp io", - "▁redu cing", - "▁Y u", - "▁Gesch äft", - "▁per ché", - "▁c ors", - "▁cor s", - "▁co rs", - "▁i cons", - "▁icon s", - "▁ic ons", - "▁ icons", - "App Data", - "▁H og", - "▁Ho g", - "▁р ів", - "▁рі в", - "▁ рів", - "▁S ans", - "▁San s", - "▁Sa ns", - "▁si ège", - "▁siè ge", - "st ellen", - "stell en", - "stelle n", - "Br ush", - "OF F", - "O FF", - "▁vis itor", - "▁visit or", - "▁b ath", - "▁ba th", - "▁bat h", - "▁f ee", - "▁fe e", - "at isf", - "ati sf", - "atis f", - "▁cu rv", - "▁cur v", - "▁fol gender", - "▁folg ender", - "▁cons cience", - "▁Se attle", - "▁med ieval", - "▁medi eval", - "dist ribution", - "▁D M", - "▁ DM", - "▁м я", - "▁ мя", - "▁R UN", - "ak ov", - "ako v", - "a kov", - "ce il", - "c eil", - "▁let ting", - "▁lett ing", - "▁d ov", - "▁do v", - "▁о би", - "▁об и", - "ki ej", - "kie j", - "k iej", - "▁dire kt", - "▁t m", - "▁ tm", - "col ors", - "color s", - "colo rs", - "▁alt ro", - "▁tijd ens", - "]{ '", - "] {'", - "▁B om", - "▁Bo m", - "▁k unst", - "▁kun st", - "▁sh elter", - "▁r av", - "▁ra v", - "▁ rav", - "pre dict", - "pred ict", - "▁comenz ó", - "▁świ at", - "▁św iat", - "▁Du rant", - "▁Dur ant", - "▁sch emes", - "▁scheme s", - "▁sche mes", - "▁m esh", - "▁me sh", - "▁mes h", - "▁ind icator", - "▁indic ator", - "▁E mer", - "▁Em er", - "▁gu ilty", - "не ц", - "▁consequ ences", - "▁consequence s", - "cl udes", - "clude s", - "clud es", - "▁L ower", - "▁Lo wer", - "▁Low er", - "▁ Lower", - "▁по ме", - "▁p ace", - "▁pa ce", - "▁pac e", - "▁ pace", - "да го", - "▁am bos", - "▁amb os", - "l b", - "▁educ ated", - "ur ale", - "ura le", - "ural e", - "u rale", - "an h", - "es ség", - "ess ég", - "▁associ ations", - "▁association s", - "to wn", - "t own", - "▁t rif", - "▁tr if", - "▁tri f", - "sample s", - "sam ples", - "s amples", - "bo s", - "b os", - "▁S pect", - "▁Sp ect", - "▁Spe ct", - "▁Spec t", - "▁Ц е", - "alt ung", - "▁L ob", - "▁Lo b", - "▁curios ity", - "▁We iter", - "▁Wei ter", - "▁Weit er", - "est one", - "esto ne", - "eston e", - "e stone", - "▁dem ol", - "▁demo l", - "▁ap olog", - "▁apo log", - "▁D ynamic", - "▁Dynam ic", - "▁ Dynamic", - "In ner", - "es per", - "esp er", - "ec z", - "e cz", - "uel lement", - "uelle ment", - "▁Hamilton ian", - "At las", - "▁ar gue", - "▁arg ue", - "For eign", - "F oreign", - "col lapse", - "▁tér min", - "▁electron ic", - "▁electro nic", - "▁N R", - "▁ NR", - "▁c orr", - "▁cor r", - "▁co rr", - "▁ corr", - "tem ps", - "temp s", - "Index Path", - "я з", - "▁tal ál", - "to day", - "tod ay", - "wa ve", - "w ave", - "▁s ib", - "▁si b", - "▁с пи", - "▁сп и", - "▁con vey", - "▁conv ey", - "▁Gé ographie", - "▁Н ью", - "▁Hi bernate", - "▁t in", - "▁ti n", - "di c", - "d ic", - "pp ings", - "pping s", - "s weise", - "▁roll ing", - "▁rol ling", - "▁ rolling", - "▁select s", - ")\\ )", - ") \\)", - "▁po eta", - "▁poet a", - "▁сте пени", - "▁A br", - "▁Ab r", - "▁hö ch", - "▁s tern", - "▁st ern", - "▁ste rn", - "▁ster n", - "▁f jär", - "▁inst aller", - "▁install er", - "▁instal ler", - "de cl", - "dec l", - "▁m iser", - "▁mi ser", - "▁mis er", - "▁mise r", - "group by", - "sub str", - "subst r", - "▁phen omen", - "▁W ing", - "▁Win g", - "▁Wi ng", - "▁f ills", - "▁fil ls", - "▁fill s", - "▁ú nico", - "Run ning", - "R unning", - "Com e", - "Co me", - "C ome", - "ir able", - "ira ble", - "i rable", - "sim eq", - "sime q", - "▁re mp", - "▁r emp", - "▁rem p", - "ke le", - "kel e", - "k ele", - "li ers", - "lie rs", - "lier s", - "l iers", - "▁kwiet nia", - "▁inter rupted", - "▁interrupt ed", - "▁J et", - "▁Je t", - "=\\ {", - "= \\{", - "íd o", - "í do", - "▁Tai wan", - "▁воз ра", - "▁altern atives", - "▁alternative s", - "▁T ir", - "▁Ti r", - "▁Re serve", - "▁Res erve", - "▁К ур", - "▁Ку р", - "▁No bel", - "▁Nob el", - "▁рабо тал", - "▁работа л", - "▁a xes", - "▁ax es", - "▁C ependant", - "k á", - "▁er neut", - "▁D emo", - "▁De mo", - "▁Dem o", - "▁ Demo", - "comm unic", - "con structor", - "construct or", - "▁Mon day", - "▁Mond ay", - "N il", - "Hash Map", - "pay ment", - "▁fix ing", - "▁A DD", - "▁AD D", - "▁ ADD", - "re view", - "rev iew", - "▁poss ibil", - "▁possib il", - "▁g rote", - "▁gr ote", - "▁gro te", - "▁group ed", - "▁groupe d", - "▁L ima", - "▁Li ma", - "▁Lim a", - "▁A ugen", - "▁Au gen", - "▁Aug en", - "▁o ckså", - "on as", - "ona s", - "o nas", - "▁deb ate", - "▁In gl", - "▁Ing l", + "▁F ever", + "▁F atigu", + "▁F OLLOW", + ".▁A ▁hazard▁ratio", + ".▁A BX-EGF", + ".▁A PPENDICES", + ".▁The▁ number▁of", + "ity▁ will▁be▁", + "ity▁ Assessment", + "▁g raph", + "▁g ram", + "not ▁related▁to", + "▁the▁s olution", + "▁the▁s afety▁and▁", + ",▁and▁ subject", + ",▁and▁ 24", + ",▁and▁ vital▁sign", + "ated▁ plac", + "▁v eh", + "▁v 4.0", + "▁L ow", + "iseas e", + "▁B L", + "▁B efore▁", + "▁B one▁scan", + "▁this▁ with", + "s,▁ C", + "s,▁ it", + "s,▁ will▁be▁", + "s,▁ should▁be▁", + "s,▁ laboratory", + "s,▁ MRI", + "s,▁ etc", + "s,▁ so▁that", + "▁all ▁patient", + "▁all ▁patients", + "clud es▁", + "clud e▁the▁s", + "12 .3", + "ip unct", + "\n\nC entral▁", + "\n\nC oagulation", + "▁will ▁include:", + "▁will ▁serve▁as", + "▁will ▁the▁confidentiality▁of", + "e▁in vestigator", + "e▁in ▁combination▁with", + "e▁in struction", + "e▁in itial", + "ing▁the▁ articl", + "▁5 FU", + "▁5 ▁dimension", + "bo plastin", + "ity ▁and", + "will \n\nbe▁", + "will ▁be", + "▁6 7", + "▁6 8", + "▁6 :", + "from ▁randomisation", + "▁H ave▁you", + "and▁ survival", + "▁subject \n\n", + "▁subject s,", + "▁subject s’", + "▁patients▁ should▁be▁", + "▁4 .9", + ")\n\n (", + ")\n\n In", + ")\n\n Un", + ")\n\n For", + "gression ▁models▁and▁", + "▁at tain", + "▁at ▁start▁of", + "ail ed▁", + "s▁( for", + "s▁( CRF", + "s▁( e.g.▁", + "s▁( see▁section", + "eg en", + "▁study▁ guid", + "▁study▁ initiation", + "\n\n1 .", + "\n\n1 .3", + "\n\n1 .0", + "\n\n1 .\n\nB", + "\n\n1 .\n\n2", + "ase▁ 2", + "vi ously▁", + "gen es", + "s.▁ V", + "s.▁ Cancer", + "s.▁ Disease▁", + "▁week s▁(", + "▁week s▁for", + "ens on", + "rel ating▁to", + "▁any▁ form", + "▁any▁ subsequent", + "▁V alu", + "▁V entricular", + "▁V ersus▁", + "▁ex cess▁of", + "▁ex pedited▁reporting", + "ell er", + "ak e▁", + "\n\nD MC", + "\n\nD uring", + "\n\nD ay\n\nMonth\n\nYear", + "formed▁ decision", + "urv ey▁", + "▁after ▁the▁end▁of", + "▁after ▁paclitaxel", + "▁after ▁your▁last", + "eth ic", + "ed▁for ▁this▁", + "s▁and▁ preferred▁term", + "s▁and▁ p-valu", + "s▁and▁ investigative▁", + "ath ologic", + "ly ▁as▁possible▁", + ".▁S ci", + ".▁S ummary▁of", + ".▁S UBJECT", + "▁patient s.▁In", + "▁the▁d enosumab", + "s▁will▁be▁ includ", + "s▁will▁be▁ the▁", + "s▁will▁be▁ determin", + "s▁will▁be▁ taken", + "ies▁ or▁in", + "▁G D", + "▁G y▁", + "▁G y▁in", + "▁G astrointestinal▁", + "▁un scheduled▁visit", + "report ed▁according▁to▁the▁", + "▁e .g", + "▁J J", + "e▁the▁ error", + "▁tim e▁in", + ".▁P rospective▁", + "\n\nE vent", + "\n\nE nd", + "\n\nE ndpoint", + "\n\nE GFR", + "\n\nE nrollment", + "▁In itial", + "),▁ radiation▁therapy▁to▁bone▁", + "▁ant idiarrheal", + "s\n\n 2", + "s\n\n 5", + "s\n\n Y▁T▁I▁D▁I▁L▁A▁V", + "ed▁by▁ Consolidation", + "▁is ▁a▁c", + "▁is ▁a▁m", + "▁is ▁abnormal", + "▁is ▁able▁to", + "▁is ▁the▁purpose▁of", + ".▁Th e▁trial", + "▁not ic", + "▁not ation", + "▁not ▁be\n\n", + "▁not ▁associated▁with", + "EN SATION", + "▁may▁ result▁in", + "s▁for ▁the▁first", + "ial▁ TE", + "▁7 .2.1", + "▁7 ▁days▁before▁randomization", + "▁month s.\n\n", + "▁dos e", + "▁dos e.▁If", + "ich otom", + "effect s▁(", + "effect ▁was▁", + "ocument ation▁and▁", + "CT ▁of▁the▁", + "▁study ▁assessments▁", + "▁per ▁the▁modified▁RECIST▁criteria", + "str ont", + "s) .▁For", + ".6 9", + "50 ,000", + ".▁E l", + "▁assessment s", + "▁assessment s,▁", + "▁assessment ▁must▁be▁", + "▁ag e▁and▁", + "▁test s▁of", + "▁test ing▁and▁", + "are as", + "ated ▁according▁to", + "ated ▁tablet", + "▁ph one▁", + "s.\n\n Page▁", + ",▁and ▁then", + ",▁and ▁applicable▁", + "▁sign ed▁", + "▁sign ed▁and▁dated▁", + "RI OR", + "▁Date: ▁<>", + "who ▁in", + "▁ab st", + "te chn", + ".▁T el:▁+", + "ed▁with ▁the▁study", + "’s▁ discretion", + "20 ▁mm▁with▁conventional▁techniques▁or", + "ed▁at ▁the▁discretion▁of▁the▁investigator", + "radi ation,▁", + "25 ▁mg", + "ian o", + "kin e-", + "kin d▁of", + "▁9 .5", + "▁9 .7", + "▁9 13", + "emet ics▁", + "▁8 2", + "s▁s pecific", + "▁us e▁in▁the▁", + "ight Cycl", + "\n\nN 0", + "\n\nN CI", + "cal e▁(", + "cal cit", + "pre mix", + "▁data ▁will▁not▁be▁", + "every▁ 14", + "every▁ effort", + "▁trial s▁of", + ").\n\n [", + "▁should▁be▁ report", + "▁should▁be▁ performed▁in", + "____ ___", + "▁other ▁studies▁", + "ne o", + "ne utropenic", + "\n\nR ECIST", + "\n\nR eview", + "17 ]", + "subject ’s▁", + "▁your ▁future▁", + "▁your ▁rights▁as▁a", + "▁- 2", + "ed▁as▁ “", + "24 ▁and▁", + "24 -3", + "▁Study▁ Monitoring▁and▁Data▁Collection", + "▁Study▁ Code:▁D8480C00013", + "▁you ▁will", + "▁you ▁directly▁or▁to▁alter", + "▁a▁s light", + "▁the▁study \n\ns", + "\n\nF DA", + "▁cycl es,▁", + "present ing▁with", + "present ations,▁", + "\n\nT 2", + "\n\nT umour", + "\n\nT otal", + "\n\n3 4", + "\n\n3 .6", + "\n\n3 .8", + "000 ▁mg/m2", + "▁im port", + "▁im ▁=", + "On e▁", + "sh ared", + "▁the▁patient s’", + "ed,▁ label", + "dra in", + "▁The▁ first", + "▁the▁l at", + "no ▁further", + "▁dose▁ group", + "▁inter active▁voice▁response▁system", + "▁than ▁on▁placebo", + ".\n\nA PPENDICES", + "\n\n4 4", + "\n\n4 .8", + ".▁F rom", + ".▁F inally,▁", + "▁day s▁for", + "le av", + ".\n\nP rior▁to", + "e▁b eginning", + "s▁to ▁detect", + "s▁to ▁measur", + "s▁to ▁determine▁whether", + "s▁that ▁were▁", + "s▁that ▁result▁from▁this▁research.▁Neither▁Amgen", + "\n\nI NT", + "\n\nI t▁is▁", + "▁panitumumab \n\n", + "▁panitumumab -related▁", + "▁panitumumab ▁monotherapy▁", + "hy pert", + "defin ed▁to▁be▁", + "yst eine▁", + "▁patients▁with ▁ED-SCLC", + "car bam", + "/or al", + "▁was▁ shown", + "fl ak", + "fl uid", + "▁Version ▁No:", + "▁Version ▁Date:▁<>", + "▁min imal", + "▁min ▁after▁start▁of", + "▁death ▁due▁to", + ")▁ /", + "main ▁bronch", + "main ▁study▁is▁", + "must▁be▁ reported▁to", + "▁Th orac", + "uppl y▁and▁", + "199 4;", + "▁30 ▁days▁", + "An n", + "SC ▁injection", + "▁progression ▁is▁", + "▁progression ▁or▁death", + "▁evalu able▁for", + "e▁and▁ cisplatin", + "provid ed▁", + "prior▁to ▁dosing", + "sign ature", + "▁di hyd", + "▁the▁study▁ or", + "▁the▁study▁ design", + "▁includ ed▁", + "▁must▁be▁ submitted▁to▁the▁", + "▁sampl e▁d", + "ru v", + "ru it", + "▁infusion ▁(", + "ox in", + "perform ed.\n\n", + "ely :", + ",▁a ▁commercial▁pharmaceutical▁product", + ",▁a pplicable▁", + "you ▁will", + "until ▁study▁completion", + "receiv ed▁s", + "ann ock", + "ann itol", + "ed▁from ▁light", + "▁cell s▁", + "consider ing▁the▁", + "\n\nH epatic", + "discontinu ing", + "discontinu ed▁due▁to", + "ed.\n\n For", + "▁treat ed▁for", + "▁treat ▁based▁on", + "St age▁", + "▁sub cutane", + "▁sub cutaneous▁", + "▁et▁al ▁2005", + "OR E", + "duc ci", + "▁mod ify", + "es▁will▁be▁ assign", + ".▁B efore▁", + "eb rid", + "▁analysis \n\n", + "▁and/or ▁panitumumab", + "▁and/or ▁recurrent", + "▁Panitumumab ▁Investigator’s▁Brochure▁for▁further▁detail", + "ed▁s ince▁the▁", + "ed▁s hould▁not", + "collect ed▁in▁the▁", + "▁= ▁moder", + "▁= ▁mild", + "\n\n6 .", + "▁report ing▁s", + "▁provid es▁the▁", + "▁should▁ includ", + "▁should▁ call", + ",▁s hould▁", + ",▁s afety▁", + ",▁s urvival", + "▁these▁ patient", + "▁these▁ result", + "▁these▁ cas", + "▁these▁ monitoring▁visit", + "atist ician", + "s▁b eyond▁", + ",▁M onth", + ",▁M RI", + "\n\n7 .\n\nSTUDY▁MANAGEMENT", + "▁may▁be▁ develop", + ".▁H istory▁of", + "▁mor e▁f", + ".2.1 .3", + ".2.1 ▁Methods▁of▁assessment", + "▁clinical \n\n", + "▁drug -related▁", + "▁drug ▁depend", + "week ▁9", + "▁dur ing▁and▁", + "▁survival ▁benefit", + "▁must ▁remain", + ",▁C ont", + ",▁C rawford▁", + "observ ed▁for", + "▁blood▁ or", + "▁blood▁ draw", + "▁blood▁ product", + "▁result s▁", + "non- measurable▁lesion", + "ation▁of▁ study▁treatment", + "\n\nIn ▁the▁", + "\n\nIn duction", + ",▁b aseline▁", + "▁19 87", + "▁19 90", + "▁activ ely▁", + "▁gen es▁in", + "........................................................................................ ...▁", + "Ad dendum", + "e▁m ay", + "e▁m arker", + "\n\nB NP", + "thor ax", + "es▁( ie,▁", + "\n\nM or", + "\n\nM etastatic", + "\n\nM aximum", + "able▁to ▁receive▁", + "▁administer ed▁once▁", + "▁information ▁for", + "set ▁at", + "set ▁forth", + "▁receiv es", + "▁receiv ing▁the▁", + "▁receiv ing▁", + "▁[ 1]", + "end▁of ▁trial", + "▁to▁ enter", + "part ▁of▁your", + "ull ick", + "uthor ized▁s", + "e▁or ▁h", + "e▁or ▁all▁of▁the▁", + "e▁or ▁revis", + "urther mor", + "▁until ▁subjects▁have▁access▁to▁commercially▁available▁product▁or▁for▁up▁to▁2▁year", + "▁any ▁amendment", + "IV ▁investigational▁product", + "OX AL", + "▁document ing", + "▁Arm s▁A▁and▁D", + "was▁ observed▁in", + "was▁ chosen", + "obtain ▁the▁consent", + "▁AMG▁162 ▁in", + "▁AMG▁162 ▁level", + "▁17 5▁mg/m2", + ",▁H ol", + ",▁H ung", + "▁then ▁treat▁based▁on", + "OG -Ntx", + "by▁ either", + "▁chang e▁the▁", + "-5 5", + "stitution ,▁who▁will", + "overall ▁progression▁of", + "under ▁medical", + "▁criteria :\n\n", + "▁int ra-", + "ship ment▁of", + "must ▁also", + ".▁For ▁this▁", + "\n\nAn ▁observation▁made▁on▁a▁variable▁", + "by ▁the▁treating▁physician", + "▁OS ,▁the▁", + "s▁of▁the▁ abdomen", + "▁diseas e▁in", + "▁diseas e;", + "▁approv ed▁by▁", + "▁approv ed▁in▁the▁", + "known ▁to", + "▁a▁c ardiologist", + "▁K it", + "efficacy▁ variabl", + "▁Y ▁P▁O▁C", + "(s) ▁must", + "(s) ,▁and▁the▁", + "assessment s▁", + "s▁should▁be▁ representative▁of", + "vention al▁CT", + "vention s▁that▁result▁from▁this▁research.▁Neither▁Amgen", + "represent ing", + "▁new ▁cases▁of", + ",▁G rade▁", + "s▁on ▁Day▁1", + "versus▁ placebo", + ",▁et▁al .▁In", + ",▁et▁al .▁M", + ",▁et▁al .▁Irinotecan", + "▁count ries", + "ed▁c are", + "▁chemotherapy ▁administration", + "▁chemotherapy -na", + "▁x▁x ▁x", + "ing▁a ▁subject", + "ing▁a ▁high", + "ing▁a romatase▁inhibitor", + "s▁and ▁are▁", + "s▁and ▁those▁", + "s▁and ▁amendments▁to", + "research ▁using", + "-m L", + ",▁D ay▁", + "▁part ially▁", + "▁by \n\nthe▁investigator", + "▁every▁ 2", + "within ▁the▁past", + "identifi able▁", + "\n\n5 6", + "\n\n5 7", + "▁a▁m olecular", + "▁compar ator", + "▁14 ▁days", + "▁mL ▁vial", + "▁Appendix ▁C", + "▁first ▁line▁", + "-M elzack", + "\n\nAppendix ▁J", + "▁the▁first ▁documentation▁of▁", + ",▁p aclitaxel", + "IC F", + "▁under ▁a", + "indic ate▁", + "indic ating", + "21 ▁November▁2005", + "▁+ ▁FOLFIRI", + "PA RT", + "ized▁ fil", + "▁IV ▁bisphosphon", + "olic it", + "▁for▁the▁ final", + "▁pos ition", + ")▁( X", + "▁Oncol ▁2", + "normal ity", + "ate /", + "▁clinical▁ import", + "\n\nO c", + "▁between ▁the▁", + "/m onth", + "\n\n9 5%", + "\n\n9 .3.1", + "chemotherapy▁ in", + "▁SAE s▁and▁those▁", + "is▁not ▁positiv", + "▁research ▁companies▁", + "▁of▁a ▁treatment", + "▁of▁a ▁21-day▁cycl", + "▁confirm atory▁", + "▁withdraw al▁of", + "pecifi ed▁that", + ",▁in fection", + ",▁in formed▁consent▁form", + "▁cl ot", + "▁survival▁ rate▁", + "new ▁version", + "new ▁location", + "person ▁who▁conducted", + "ascular ▁endothelial▁growth▁factor", + "rof ich", + "▁hav e▁shown▁that", + "▁hav e▁the▁sampl", + "▁Treatment ▁of", + "att ention", + "▁the▁end▁of ▁study▁", + "▁the▁end▁of ▁study▁treatment", + "▁18 :", + "▁and▁s kin", + "▁and▁s unitinib", + "▁and▁s upport", + "pens ation▁for", + "▁observ ed▁or▁volunteer", + ",▁R e", + ",▁R ob", + "▁were▁ recorded,", + "except ▁where▁", + "due▁to ▁un", + "▁overall ▁survival▁(", + "▁significant ▁difference▁in", + "▁is▁not ▁yet", + "median ▁time▁to▁progression", + "blood▁ pressure,▁", + "y▁s hould▁", + "analys es▁", + "▁cor por", + "\n\nProtocol ▁Synopsis▁", + "Treatment ▁Arm▁A", + "Treatment ▁Cycl", + "ensitiv ity▁", + "ECOG ▁45", + "▁thes e▁drug", + "........................................................................................................ .....▁", + "▁advanced▁ esophag", + "calcul ated▁to", + "calcul ated▁based▁on", + "Ex pression", + "util izing", + "es▁to ▁have▁access▁to", + "▁serum ▁or▁urine▁pregnancy▁test", + "▁medical▁ emergency▁", + "▁EGF ▁receptor", + "RECIST ▁Criteria▁for", + "\n\nSection: ▁14", + "26 0", + "26 ]", + "Pro tein", + "▁PD ▁=▁progressive▁diseas", + "▁an▁ enrollment", + "▁an▁ electronic", + ".▁L esion", + "▁prior ▁chemotherapy▁regimen", + "▁condition s▁", + "▁consent ▁to▁the▁", + "▁patients▁who ▁received▁", + "post erior", + ",▁T ulsky▁", + "use▁of ▁radioisotopes),▁surgery▁to", + "▁the▁date▁of ▁withdrawal", + "2- 9", + "urger y", + "▁acid s▁and▁", + "echn etium", + ",▁K aplan-Meier", + "▁either ▁occur", + "▁either ▁“", + "▁record s▁will▁be▁", + "hav e▁shown", + ".\n\nE THICS", + "▁those▁ with", + "▁those▁ patients▁", + "\n\nin creas", + "ensor y", + "cycl e\n\n", + "cycl e)", + "weight ▁and▁", + "\n\nm etastas", + "cover ing", + ".\n\n5 .7", + "Amgen ▁Center", + "Assessment s\n\n", + "LY231514 \n\nH3E-US-S130(d)▁Clinical▁Protocol\n\nPage▁", + "▁procedure s▁will▁be▁", + "▁toxicity ▁that", + "wer e▁treat", + "hemat ological", + "ett ▁CL", + ".\n\nD enosumab", + "possibl e,▁", + "representativ es▁to▁have▁access▁to", + "product s▁develop", + "▁last ing", + "\n\na \n\nb", + "▁would▁ otherwise▁", + ".\n\nIn ▁some▁circumstanc", + ".\n\nIn ▁signing▁this▁document", + "ey es,▁", + "ation,▁ etc.", + "▁denosumab ▁concentration", + "adverse▁event ▁case▁report▁form", + "▁evaluation ▁by▁", + "▁(C ycle▁", + "▁(C 225", + "▁(C EA", + ".▁In▁addition ▁to", + "plann ed▁to", + "Endpoint s:", + "▁are :\n\n", + ".4.1 .2", + "▁is▁a ▁requirement", + ".\n\n3 2", + "▁the▁sponsor ’s▁", + "▁CTCAE ▁version▁3.0", + "▁CTCAE ▁v3.0", + "itis▁ (", + "app end", + "▁studies▁ with", + "3- week", + "▁All ▁other▁lesion", + "condition ▁of▁the▁drug", + ".\n\n7 .3", + "▁50 ▁ml/min", + "Ph osph", + "▁schedul e▁(", + "▁consider ed", + "▁En roll", + "/d epression", + "▁tumour ▁sampl", + "▁tumour ▁siz", + "ed, ▁then", + "▁colon ▁carcinoma", + ",▁m ulticenter", + "inf used▁", + ",▁N ak", + "▁accordance▁with ▁ICH▁GCP", + "non measurable▁lesion", + "non linear", + "other▁than ▁SAEs▁and▁those▁", + "e▁sampl es", + "▁the▁data ▁cutoff", + "▁appropri ately", + "leucovorin ,▁", + "experienc ed▁an", + "rang e▁from", + "controll ed▁by▁", + "▁Safety▁ Analysis", + "▁vitamin▁D ▁and▁", + ").▁The▁ original▁sign", + ".\n\nB oth", + "combin ed", + ",▁but ▁must", + "AR D", + "Appendix ▁B", + "radiation ▁treatment", + "high er▁than", + "▁detail s▁of", + "treat ed▁as▁", + "Ther apies", + "▁local ised▁", + ",▁all ▁subsequent", + "▁a▁l og", + "▁a▁l ist▁of", + ",▁E inh", + "skin ▁reaction", + "maintain ▁a▁list▁of", + "increas ed", + "▁PSA ▁valu", + "ethyl en", + "▁objective▁ disease▁progression", + "▁objective▁ response▁rate▁", + "Follow ▁Up", + ".\n\n2 .4", + "▁more▁than ▁on", + "▁Dose▁ reduction", + "▁one▁ year", + "adjust ed▁for", + "▁local▁ lab", + ",▁c ardiac", + ",▁c olorless", + "Evalu ation▁of", + "Evalu ations▁", + "Med ic", + "Med ian", + "▁function al", + "90 5", + "▁physician ,▁or▁other", + "▁take▁ plac", + "▁take▁ appropriate▁", + "sol vent", + "▁grade▁ 2▁or", + "▁et▁al.▁200 4", + "▁et▁al.▁200 2)", + "primary ▁tumor", + "primary ▁analysis▁of", + "rain ing", + "\n\nNo ▁change\n\n", + "\n\nAmgen ▁Protocol▁Number", + "▁en d▁", + "▁en able▁", + "read y", + "read ily", + "reduc ed▁", + "▁my▁ illness", + "▁my▁ records▁", + "reported▁ SAE", + "reported▁ immediately", + "evaluated▁ using", + "▁(P IN", + ".▁At ▁each", + "ate,▁ 5%", + ".▁5 7", + "s▁should▁ be▁taken", + "▁DNA ▁extraction", + "period ic", + "▁FOLFIRI ▁plus▁placebo", + "metastatic ▁breast▁cancer", + "activ ity▁in", + "▁standard▁ chemotherapy", + "▁60 ▁mg", + "▁studies ,▁the▁", + "▁current ▁practic", + ",000 ▁women", + "\n\nb efore▁", + "\n\nb aselin", + "▁possibl e,", + ",▁O z", + ".\n\nR andomization", + "▁expos ure▁of", + "urine▁ protein", + "ECG s▁may▁be▁performed▁as▁clinically▁indicated", + "best ▁possible▁", + "▁a▁subject ▁has▁", + ".▁Con comitant▁medication", + ".▁Con firmation", + "▁Study▁D ocumentation▁and▁", + "▁the▁discretion ▁of▁the\n\n", + ",▁w ould▁", + "▁the▁primary ▁and▁secondary▁", + "s,▁or ▁research▁companies▁", + "outlin ed▁below", + "outlin ed▁in▁Appendix", + "ase▁( AST", + "ology,▁ blood▁", + "tic ▁syndrom", + "▁the▁sampl e▁to▁be▁", + "submitt ed▁for", + "4▁week s▁on", + "ane ous▁", + "e▁blood▁ sampl", + "▁normal ization", + "us▁( ECOG", + "IVRS ▁vendor", + "▁(cid: 14", + "sp ection▁of", + "▁the▁sit uation", + "▁plann ing", + "▁pre- medication", + "judg ment▁of", + "▁necess ary▁for", + "results▁of ▁a", + "modification s▁for", + "IS S", + "term ▁“", + "\n\nCONFIDENTIAL \n\nA▁®\n\nd▁e▁v▁o▁r▁p▁p▁A\n\nProduct:▁PANITUMUMAB▁(AMG▁954)▁Protocol▁Number:▁20040249▁Date:▁07▁August▁2007\n\nPage▁", + ".▁Ex ploratory▁", + "\n\nEx ploratory", + ",▁then ▁the▁", + "ert iary", + "los s▁to▁follow-up", + "eng ineer", + "▁the▁patient’s▁ underlying", + "\n\nto ▁the▁", + "▁and▁other ▁researcher", + "▁ext end", + "sid ed▁", + "▁surger y▁(", + "confidential▁ information▁of", + "▁written ▁approval", + "▁question ▁is▁", + "s▁may▁ us", + "s▁may▁ prescribe▁", + "s)\n\n \n\n", + "s.▁S ever", + "▁systemic ▁therapy▁", + "▁estim ate▁th", + ".\n\n4 .2", + "\n\nCon comitant▁medication", + "▁lin ear", + "▁this▁research ▁will▁compensate▁you▁if▁this▁happens", + "es▁of▁the▁ medical", + "▁................................................................................ .....▁", + "before▁ any▁", + "e.▁A mgen", + "▁defin ed▁", + "▁Tumor ▁Lesion", + "▁With :", + ")▁is▁ defined▁as▁", + "FOLFIRI ▁arm", + "final ▁analysis▁for", + "stable▁ for", + "▁AD MINISTRATIVE", + "▁active▁ agent", + "▁active▁ infection", + "▁blood ▁test", + "▁blood ▁and/or", + "improv ed▁", + "unblind ing▁in", + "▁EGFR ▁inhibitor", + "cr is", + "poss ib", + "Not ▁Done▁(ND", + "Sign ificant", + "▁outcom es▁", + "▁outcom es▁of", + "▁........................................................................ .....▁", + "s▁must ▁be\n\n", + "▁appl ies", + "permitt ed", + ".▁The▁patient ▁has▁a", + ".▁Treatment s▁Administer", + "▁dose▁reduction s▁and▁", + "▁assess▁the▁ effect▁of▁ZD4054▁in▁combination▁with▁docetaxel▁on", + "az ep", + "\n\nTreatment ▁compli", + ".\n\nTo ▁investigate▁the▁", + "remov ed▁for", + "▁prevent ing", + "▁imaging ▁test", + "completion ▁or▁early▁termination▁and▁send", + "▁or▁s ell", + "▁or▁s uspect", + "\n\nc opy▁of", + "▁achiev e▁the▁", + "▁cyt ologic", + ".▁There▁ is▁", + "ret riev", + "▁nam es▁for", + "▁de cline▁", + ".▁This \n\n", + "kaline▁ Phosph", + "wher e▁the▁in", + "▁mCRC ▁among▁subjects▁with", + "▁the▁investigator’s▁ report", + "▁et▁al,▁200 4)", + "cod e▁break", + "otherwis e▁specifi", + "▁siz e;", + "▁4.6 .1.1", + "▁sites▁of ▁disease", + "MUNEX \n\nConfidential\n\nAMGEN", + "co protein", + "rig ger", + "▁Require d", + "▁participating ▁countries▁", + "estimated▁ using▁the▁", + "system ▁organ▁clas", + "ectom y,▁", + "ectom y/", + "▁will▁be▁used▁to ▁identify", + "local▁ laboratory▁", + "local▁ lab", + "EL IS", + "Qual ity", + "RR =", + "▁of▁s ingle-agent", + "▁enter ▁the▁", + "▁co /", + "▁co efficient", + "(106 )\n\nGEL▁Version▁ID:▁ONC.000−", + "ically▁significant ▁adverse▁events▁", + "▁Coll ege▁of", + "quant ities▁of", + "▁shown ▁to▁be▁", + "▁thromb otic", + "jur y▁", + ".\n\nH owever", + "concomitant▁medication s▁will▁be▁", + "ous▁in jection", + "▁2▁week s▁prior▁to", + "administered▁ over", + "\n\nPrimary▁ variabl", + "(m L/min", + "investig ated▁in", + "▁and▁p ackag", + "pleas e▁see▁Section", + "▁(B UN", + "included▁in ▁the▁shipment", + "begin ning▁of▁the▁", + "▁grade▁3 /4", + "▁respon d▁to", + "▁respon dent", + "▁analysis▁will ▁not", + "▁describ ed▁abov", + "representative▁ and▁", + "▁(if ▁applicable)", + "▁undergo ▁an▁", + ".▁Study▁ Population", + "CEDURES ▁IN▁CASE▁OF▁EMERGENCY,▁OVERDOSE▁OR▁PREGNANCY", + "▁resolution ▁to", + "3,▁ 6", + "had ▁the▁opportunity▁to", + "▁copy▁of ▁the▁", + "▁stopp ing▁the▁", + "Follow-up ▁Visit", + "effective▁ contraception", + "Analysis▁ Data", + ".▁19 82", + "▁of▁panitumumab ▁plus▁FOLFIRI", + "icalutam id", + "▁interest ▁in▁the▁", + "e▁an ▁objective▁", + "involv ement", + "▁as▁describ ed▁in▁Appendix", + "▁standard ized▁", + "acceptable▁to xicities", + "FDA ▁form", + "antic oagulant", + "▁experience▁ a", + "▁the▁two ▁treatment▁group", + "▁know ▁which", + "▁and▁all ▁amendment", + "▁while▁ you▁are▁", + "scor ed▁as▁", + "▁bo ard", + "▁dep artment", + "every ▁three▁week", + "▁(Arm ▁1", + "▁patients▁treated▁with ▁bevacizumab", + "▁prolong ation▁of", + "\n\nLY231514 \n\nH3E-US-S130(d)▁Clinical▁Protocol\n\nPage▁", + "▁comparison ▁of", + "PSA ▁values", + "s▁to▁the▁ appropriate▁", + "from▁the▁ IEC/IRB", + "related ness▁of", + "▁a▁maximum ▁of▁", + "▁progress ed▁after", + "ology▁and▁ Pharmacokinetic", + "ed; ▁however", + "▁any▁reason ,▁", + "aminotransfer ase\n\n", + "▁related▁to ▁that", + "cop e▁of", + "meet ing", + "▁thos e▁subject", + "ody▁ S", + "ili ary▁", + "▁(d arbepoetin▁alfa", + ".▁Sampl es▁will▁be▁", + "puter ized▁", + ",▁19 82)", + "▁procedure▁ (", + "▁unblind ing▁information", + "s.\n\nP artial▁", + "▁original ▁dose\n\n", + "diagnos ed▁with", + "shipp ed▁to", + "withhel d", + "▁compens ated▁for", + "▁result▁in ▁hospitalization", + "▁particular ▁clinical▁import", + "escription ▁of", + "▁delay s▁in", + "▁CO MP", + "perman ently", + "▁aspect s▁of▁the▁", + "shown ▁in▁Table▁", + "▁there▁is▁a ▁reasonable▁", + ".▁Al tern", + "reath ing", + "▁altern ative▁to", + "▁altern ative▁treatment", + "radiograph ically▁", + "roughout ▁the▁study", + "e▁J A", + "accur ate▁", + "▁5% ▁Dextros", + "▁telephone▁contact ▁with", + "▁µ mol/L", + "▁measur ing", + "notification ▁to▁Pfizer", + "▁subjects▁will▁be▁ followed▁for▁survival▁for", + "\n\n14 .▁REFERENCES", + "hould ▁a▁subject▁(or", + "s▁thereafter ▁until", + "▁urine▁ protein", + "▁(L awless", + ".\n\nThe▁investigator ▁will▁be▁responsible▁for▁obtaining▁an", + "rupt ▁until", + "▁cardiac ▁failure▁", + "anti- tumor", + "▁Chemotherapy▁ Al", + "▁Dose▁Modification ▁Algorithm", + "decision ▁by▁the▁investigator▁or", + "▁of▁69▁Addendum▁13 \n\n", + ".▁Onc ogen", + "▁ren al", + ".▁Am▁J ▁Clin▁Oncol", + "\n\nX▁X \n\nX▁X", + "\n\nAny \n\nYes", + "▁confirmed▁ CR▁or▁PR", + "▁immediately▁ if", + "e▁B lood▁", + "line▁ strok", + "\n\nI▁am ▁satisfied▁with", + "▁at▁any▁tim e▁by▁", + "▁protocol▁amendment s▁and▁", + "▁is▁in ▁effect", + "▁Hy per", + "▁Hy po", + "\n\n100 %▁of▁previous▁dose\n\n", + "▁oral ▁bisphosphon", + "▁will▁be▁censored▁at ▁the▁last", + "▁their▁last ▁observation", + "oz n", + "▁will▁be▁record ed", + "intraven ous", + "\n\nGen eral", + "\n\nAdd▁3 ,5,6", + "standard▁of ▁care▁", + "ped it", + "\n\nFollow ing▁the▁", + "acceptable▁ adverse▁event", + "▁alloc ation▁of", + "▁alloc ated▁to", + "▁at▁each ▁centr", + "▁90 ▁", + "SU E", + "▁the▁use▁of ▁your", + "▁soft ▁tissu", + "▁2.5 ▁x▁ULN", + "▁the▁second▁ interim▁analysis", + "may▁occur ▁in▁10", + ").\n\nP age:", + "▁Analysis▁ Population", + ";▁( 4)", + "local ▁practic", + "well▁toler ated▁in", + "▁ep idemi", + "\n\nGEL▁Version▁ID:▁ONC.000− 272−636.4.0", + ".▁Your ▁doctor", + "▁will▁provid e▁the▁", + "s▁(or ▁equivalent", + "▁any▁un expected▁s", + ".▁Rec ent", + "▁mmol/L ▁mmol/L", + "Related▁ Event", + "bal ance▁", + "hold ▁and▁check", + "▁facil it", + "data▁from ▁a", + "metab olic", + "recruit ed▁into", + "recruit ment▁of", + "▁(I FL", + "s.▁C lin", + "▁death▁or ▁hospitalization", + "▁Pharmac y▁Guid", + "target \n\nlesion", + "physical ▁well▁being", + "▁the▁development▁of ▁commercial▁pharmaceutical▁product", + "▁trial▁of ▁pemetrexed▁", + "Cont act", + "investigational \n\nproduct", + "▁inclusion ▁cutoff▁date▁", + "content s▁of", + "▁vis ceral", + "storage▁ period", + "▁will▁be▁the▁ primary", + "correction ▁fluid,▁or", + "▁the▁definition ▁of▁a", + "ranslational▁ research", + "s▁by ▁the▁", + "phosphor yl", + "ART ▁B", + "▁body ▁authorized▁under▁applicable▁law▁to▁consent", + "▁twic e▁daily;", + "2▁or ▁has▁returned▁to▁baseline,▁then", + "incid ence,▁", + "▁and▁pro pri", + "▁and▁pro mptly▁", + "partial▁ response▁", + "re▁ T", + ",▁U SA", + "ed,▁and ▁accurately▁", + "▁bound aries", + "▁Sodium ▁Acet", + "▁will▁be▁compared▁ between", + "▁80 5", + "▁understand ing▁of▁the▁", + "clearly▁ defined▁and▁surrounded▁by▁aerated▁lung", + "elf-care .▁Totally▁confined▁to▁bed▁or▁chair", + "/FA CT", + "▁ill ness▁or", + "revis ed▁to", + "▁molecular ▁weight", + "\n\nScreening ▁and▁demographic", + "cyt otoxic", + "mic id", + "▁urin ary▁", + "orb itol", + "▁the▁point ▁at▁which", + "▁your▁cancer ▁has▁", + "documentation ▁related▁to▁that", + "▁non-small▁cell▁lung▁cancer ▁(NSCLC)", + "▁Exploratory▁ ................................................................................................", + "\n\nS▁T▁I\n\nK▁C▁E▁H▁C\n\nE▁S▁A▁E▁L▁P\n\n.▁T▁N▁E▁M▁U▁C▁O▁D \n\nC▁I▁N▁O▁R▁T▁C▁E▁L▁E", + "’s▁in stitution,▁who▁will", + "ance,▁ other▁than▁SAEs▁and▁those▁", + "NS )", + "s▁m ight", + "▁second▁ line▁", + "recorded▁on ▁a▁Serious▁Adverse▁Event", + "▁No▁No ▁No▁No", + ",▁they▁ must", + "negative▁ or", + "▁I.V .▁", + "▁will▁be▁analyz ed▁using", + "▁Mod el", + "▁Good▁Clinical▁Practic e▁and", + "s.▁In▁addition ,▁the▁", + "pedited▁ report", + "instructed▁to ▁contact", + "▁wish▁to ▁assign▁the▁study▁records▁to", + "▁tyrosine▁kin as", + "▁will▁be▁consider ed▁a", + "s▁for▁each ▁endpoint", + "▁-▁- ▁-▁-", + "▁the\n\nsubject ▁or", + "▁OS▁event s▁are▁", + ",▁creatinin e,▁", + "▁summar iz", + ".2\n\nR andomization", + "prolong ed▁(", + "▁SU PP", + "▁heart beat", + ".▁During▁the▁ extension▁period", + "othelin -1", + "▁activities▁ of", + "summarized▁ descript", + "▁em ail", + "▁every ▁two▁week", + "▁Hematologic ▁Toxicity▁", + "\n\nDescription ▁of▁outcome▁variables▁in▁relation▁to▁objectives▁and▁", + "▁antif ol", + "\n\n4\n\n4\n\n4\n\n4 \n\n4\n\n4", + "unctional▁Assessment▁of▁Cancer▁Therapy▁ –", + "▁of▁63▁Finalization▁date:▁June▁19▁2001,▁Incorporating▁Amendment▁3▁–▁dated▁23▁May▁200 3", + "famil iar", + "ysesthes ias▁", + "▁nor ▁the▁principal▁investigator", + "▁Histor y", + "▁Histor y▁of", + "▁weekly ▁then▁treat▁based▁on", + "\n\nDisease▁ progression", + ".▁During ▁this▁", + "▁superior ity", + ".\n\nAdd▁ 6", + "protect ive▁", + "cagliotti ▁et▁al.▁200", + "creatinine▁clearance▁ (CrCl", + "▁evidenc e▁that", + "▁and▁placebo ▁group", + "▁Compar ison", + "▁third -", + "▁ECOG▁performance▁stat us▁", + "▁stopping ▁boundary▁", + "aries▁ for", + "▁squamous▁cell ▁carcinoma▁of▁the▁head▁and▁neck", + "▁of▁at▁least ▁2", + "▁the▁event▁that ▁bone▁scan", + "▁nonhematologic ▁toxicities", + "regulatory▁ag encies", + "(106)\n\nGEL▁Version▁ID:▁ONC.000−272−636.4.0\n\nApproved\n\nDate▁Printed:▁13−Aug−2013\n\nApproved▁by\n\n13▁Sep▁2007▁17:17:03\n\nAmended▁Clinical▁Study▁Protocol▁Drug▁Substance▁Cediranib▁(RECENTIN,▁AZD2171)▁Study▁Code▁D8480C00013▁Edition▁Number▁3▁Date\n\n .▁E▁S▁U", + "▁the▁time▁point s▁", + "▁efficacy▁and▁ safety", + "enn ett▁CL", + ",▁other ▁researcher", + "▁cess ation▁of▁", + "���rect al▁cancer", + "▁hemat ological", + "\n\nStudy ▁timetable▁and▁end▁of▁study", + "ured ▁and▁packag", + "▁stage▁III ▁colon▁cancer", + "▁data▁collection ▁for", + "▁Stor age▁", + "resolved▁or ▁stabiliz", + ".▁Therefor e,▁the▁", + "▁ruler ▁or▁c", + "▁withdrawal▁from ▁study▁treatment", + "▁metab olism", + "whichever▁is▁ later", + "Number :", + "doubl e▁barrier", + "s▁used▁in ▁this▁protocol,▁the▁", + "▁paper ▁forms▁will▁be▁", + "▁the▁design ated▁", + "over▁30 ▁minutes▁", + ".▁Concomitant ▁Therapy▁", + "PTV ▁receives▁", + "▁archiv ed▁tumor▁tissu", + "(7 ):▁p.▁", + "anin e-", + "▁bal anc", + "▁bal ance▁", + "randomized▁to▁receive▁ panitumumab", + ".\n\nHow ▁will▁the▁confidentiality▁of", + "▁Organization ▁for▁Research▁and▁Treatment▁of▁Cancer", + "▁reasonable▁possibility▁that▁the▁event▁may▁have▁been▁caus ed▁by▁", + "(10 ):", + "poly glutam", + "proper ly", + "amide▁ ribonucle", + "▁RS ,▁Rubin", + "▁dose▁escal ate▁to", + "\n\nx▁x▁x▁x \n\nx▁x▁x▁x", + "wild-typ e)▁KRAS", + ",▁on ▁behalf▁of▁a", + "▁PT V", + "▁Dr ive▁", + "per▁local ▁practic", + ".▁Re gression▁models▁and▁", + "▁behalf ▁of", + "▁pattern s▁of", + "andler ▁A", + "▁after▁failure▁of ▁a▁docetaxel-based▁chemotherapy▁regimen", + "▁physical ▁activity", + "pontane ously▁", + "▁reli ef", + "▁count,▁ RBC▁count,▁hemoglobin", + "▁these▁data ▁into▁the▁", + "\n\nSection:▁Appendix ▁K:▁Informed▁Consent", + "FACT-L/N tx", + "DI TIONS", + "TRIO ▁Safety▁Officer", + "born ▁bab", + "▁famil y,▁", + "▁are▁being ▁asked▁to", + "▁may▁experienc e▁include▁", + "▁CT▁or▁MRI▁scan ▁of▁your", + "▁correl ate▁with", + "▁Plus▁ D", + "Fract ure", + "First -line▁", + "ei ra", + "uperior ity▁of", + "▁ir rit", + "inspect ed▁visually▁for", + "s▁................................................................................ .....▁", + "▁sus pension", + "▁singl e▁dose▁", + "charg e▁s", + "integr ity▁of", + "\n\nRationale▁for ▁Chang", + "▁Panitumumab▁Clinical▁ Efficacy▁", + ".▁Mor eover", + "hazard▁ratio▁for ▁placebo▁relative▁to", + "Hypothes is", + "field▁ MR", + "account ability▁of▁all", + "▁Platelet ▁count", + "study\n\n drug", + "▁will▁sign ▁the▁final", + "consecutive▁ 12-lead▁ECG", + "▁overdose▁ with", + "▁SD▁PD ▁Any▁", + "▁legally▁acceptable▁representativ e)", + "unequivoc ally▁", + "ies▁must▁be▁ made▁available▁for", + "▁G4PFS ▁and▁PFS", + "▁discontinues▁ dos", + "risk▁factor s▁for", + "systemic ▁steroid", + "▁Schedule▁4/ 2▁(", + "/G OG-Ntx", + "hom e▁and▁", + "▁and▁document s▁to▁determine▁whether", + "acet amol", + "convention al", + "\n\nRefer ▁to▁the▁", + "every▁3▁months▁ ±", + "▁accurac y", + "▁the▁day▁after ▁the▁patient▁and▁the▁investigator▁agree▁to", + "▁a▁drug ▁or▁drug▁delivery▁system", + ",▁201 7", + "▁single- use▁vial", + "▁AL L", + "osc opy", + "\n\nSerious▁Adverse▁Event ▁Reporting", + "white▁blood▁cell ▁count", + "▁respir atory▁tract▁infection", + "dermat itis", + "s\n\n9 .1.1", + "\n\nAdminister ▁panitumumab▁@", + "▁administered▁to ▁the▁subject", + "____________ _", + "awa ▁Y", + "made▁available▁to ▁member", + "colony-stimulating▁factor ▁(G", + "ranc h", + "uniqu e▁to▁the▁individual", + "▁ful fill", + "ovarian ▁cancer", + "▁cycle,▁ hold▁and▁check", + "▁change▁from▁baseline▁in ▁lumbar▁spine▁BMD", + "▁disease, ▁ascites,▁pleur", + "quality▁ control", + "closely▁ monitor", + "ed▁to▁the▁extent ▁of▁the▁", + "▁persons ▁authorized▁to", + "ayo▁Clinic ▁Rochester", + "is▁an▁open-label ,▁randomized,▁multicenter", + "Month ▁24", + "pet itive▁", + "▁CH F", + "▁Pregnancy▁ Test", + "▁PET▁scan s▁or▁s", + "investigator▁should▁ maintain▁a▁list▁of", + "ERC OR", + "▁active▁treatment ▁than▁on▁placebo", + "jeopardiz e▁the▁subject", + "LA SA", + "▁(not ▁necessarily", + "\n\nAST ▁(SGOT", + "JMHO .1", + "▁Page▁1 ▁of▁1", + "\n\nInternational▁ Conference▁on▁Harmon", + "▁its▁representativ es", + "refractor y", + "refractor y▁to", + "reliable▁ data", + "▁Kaplan-Meier▁method s▁and▁", + "▁<> ▁Version▁Date:▁<>", + "http:// www.", + "surg ically▁steril", + "entan yl", + "anders▁ J,▁Kaplan", + "ips ilateral▁", + "curric ulum▁vita", + "e▁dail y▁(", + "iomet rik", + ",▁Mur ray▁", + ".▁Journal ▁of▁the▁National▁Cancer▁Institut", + "▁and▁scientific ▁judgment", + "comparative▁ analysis▁of", + "rochure▁ for", + "▁rate▁( GFR", + "paid▁ for", + "▁controlled▁ room▁temperature▁", + "Wild-type▁and▁ Mutant▁KRAS", + "▁assess▁the▁effects▁of▁ZD4054 ▁in▁combination▁with▁docetaxel▁on", + "icens ee", + ".▁or ▁sponsor-nominated▁CRO", + "ed▁and/or ▁compensated▁for", + "▁top ical", + "▁(WBC ▁count,▁RBC▁count,▁hemoglobin", + "antitumor ▁activity▁of", + "▁alkaline▁phosphat ase▁", + "ALITY ▁ASSURA", + "▁(AMG▁162 ▁or▁placebo", + "▁he/sh e▁", + "bronch ospasm", + ",▁standard▁ deviation,▁", + "esid e▁the▁error", + "▁to▁another ▁location,▁", + "▁offic er", + "ouill ard▁", + "agic ▁event", + "▁lot ▁number", + "ecret ed▁", + "▁on▁Days▁ 1▁and▁8", + "▁Lead▁ Period", + ")\n\n2 1-Jul-2008▁Version▁number:▁1▁(electronic▁2.0", + "▁the▁det erior", + "▁may▁requir e▁intervention", + "sertion ▁of▁the▁correction", + ",▁Safety▁ Evaluation", + ",▁Pat el", + "▁minutes▁on▁Day▁1 ▁of▁each▁cycl", + "General▁ (FACT-G", + "contraceptive▁ precaution", + "▁the▁baseline▁sum ▁longest▁diameter", + "85% ▁power", + "Epidermal▁ Growth▁Factor▁Receptor", + "vinc rist", + "ed▁appropriate▁ by▁the▁investigator", + "▁Steering ▁Committee", + "whos e▁tumor", + "▁from▁the▁treatment ▁portion▁of▁the▁trial", + "OLFOX- 4", + "EGFR- pathway", + ",▁all▁subjects▁ currently▁undergoing", + "▁a▁legally▁acceptable▁ representative)", + "Safety▁Follow-Up ▁visit", + "▁minutes▁prior▁to ▁paclitaxel", + "▁Non-metastatic ▁Prostate▁Cancer", + "30-day▁postdiscontinuation▁follow-up▁visit ▁occurs▁at▁or▁near▁the▁end▁of▁the▁", + "differenc es▁in", + "cagliotti▁G V", + ",▁Bonom i▁P", + "▁Supportive▁C are▁", + "willing▁or▁unable▁to ▁comply▁with", + "Kaplan ▁and▁Meier", + "Toxic ology▁and▁Pharmacokinetic", + "Women ’s▁", + "▁particulate▁matter ▁and▁dis", + "resist ance▁to", + "verifying ,▁and▁reproducing▁any▁records▁and▁report", + "end-of- study", + "s\n\n3 \n\nCapable▁of▁only▁limited▁s", + ".▁Initial ▁serious▁adverse▁event▁information", + "aresthes ias/d", + "results▁will▁not▁be▁ plac", + "▁response▁or ▁stable▁disease▁", + "modality▁ should▁be▁", + "▁dispos al", + "▁administered▁a ▁pharmaceutical▁product", + "▁a▁member ▁of▁the▁study▁staff", + "▁ABI-007▁and▁ TAXOL", + "g/m2) ▁100", + "\n\nPharmac ogenetic", + "▁chemistry▁and▁ hematology▁", + "▁2▁years▁after▁the▁last▁dose▁of ▁blinded▁IP", + "begins▁on ▁the▁day▁after▁the▁patient▁and▁the▁investigator▁agree▁to", + "statistical▁analysis▁of ▁the▁study▁is▁to", + "-related▁activities ▁and▁documents▁to▁determine▁whether", + "disclosed▁to ▁anyone▁", + "organ▁function ▁as▁defin", + "AEs▁leading▁to ▁discontinuation▁of▁the▁", + "able▁to▁Evaluate▁(UE ):", + "-associ ated", + "▁room ▁temperature", + "on▁first ▁demonstrating▁a▁significant", + "▁(week ▁5", + "ency▁or ▁drug▁abus", + "ritish ▁Journal▁of▁Cancer", + "may▁patent ▁or▁sell", + "▁days.▁The▁ 30-day▁postdiscontinuation▁follow-up▁visit▁occurs▁at▁or▁near▁the▁end▁of▁the▁", + ",▁magnesium,▁creatinine,▁albumin,▁total▁protein,▁total▁bilirubin ,▁alkaline▁phosphatas", + "▁participants▁in ▁this▁research▁will▁compensate▁you▁if▁this▁happens", + "▁identified▁and▁reported▁lesion ▁at▁baseline▁and▁", + "▁Oxaliplatin/ ▁5-fluorouracil/▁leucovorin", + "one▁scintigraphy▁ is▁not", + "▁taking▁as▁reference▁the▁nadir ▁SLD", + "▁demonstrate▁a▁statistically▁significant ▁effect▁in", + "\n\n(continued)\n\nH3E-MC-JM IG(f)▁Clinical▁Protocol", + "ERIOUS ▁ADVERSE▁EVENT", + "▁and▁lasts▁approximately▁30 ▁days.▁The▁30-day▁postdiscontinuation▁follow-up▁visit▁occurs▁at▁or▁near▁the▁end▁of▁the▁", + "▁survival▁prob ability▁", + "IGNAT URES", + "at▁weeks▁ 8,▁12", + "▁and▁enter ▁these▁data▁into▁the▁", + "chi ectom", + "▁promis ing", + "s▁(t emperature,▁blood▁pressure,▁", + "▁Intern ▁Med▁", + "▁your▁treatment ▁course", + "care▁but ▁unable▁to▁carry▁out▁any▁work▁activities.▁Up▁and▁about▁more▁than▁50%▁of▁waking▁hour", + "mainten anc", + "document▁contains▁ confidential▁information▁of", + "▁Cancer▁J ▁Clin", + "▁IV▁antibiotic ▁or▁IV▁antifungal", + "ephro tic▁syndrom", + ".▁You▁will▁also▁be▁ ask", + "lymphangitis▁ cutis/pulmonis", + ")▁and▁their ▁suitability▁for▁accurate▁", + "s▁during▁the▁study▁treatment▁period▁or ▁during▁the▁", + "▁prostate-specific▁antigen ▁(PSA)", + "▁will▁be▁the▁primary▁ population", + "-Reported▁Outcomes▁(PRO s)", + ".▁Eligibl e▁subject", + "identified▁as▁non-target▁lesion s▁and▁", + "▁measurable▁lesions▁up▁to▁a▁maximum▁of▁5▁lesions▁per▁organ▁and▁10 ▁lesions▁in", + "EDTA▁blood▁[plasma▁and▁cell▁pellet],▁PAXgen e▁blood▁[RNA", + "eropol ▁N", + "UBL IC", + "x2 ▁factorial", + "ineph rin", + "ing▁it ▁crit", + "▁business▁ day", + "▁reject ing▁the▁", + "▁li eu", + "▁the▁sum ▁of▁", + "s,▁ECG ▁and▁physical▁examination", + "▁acet aminophen", + ".\n\nPh armacokinetic", + "▁must▁be▁report ed▁in▁accordance▁with▁the▁", + "▁years▁after▁the▁ main▁study▁is▁", + "mitted▁to ▁Biomedical▁Journal", + "normalized▁ ratio", + "andomised,▁ Double-blind", + "rofolate▁ reduct", + "vestigational▁New ▁Drug", + "implication s▁for", + "▁requiring▁s ystemic", + "Investigational▁Product▁Accountability▁ Record", + "30-day▁postdiscontinuation▁follow-up▁period▁ begins▁on▁the▁day▁after▁the▁patient▁and▁the▁investigator▁agree▁to", + "▁all▁randomized▁subjects▁have▁ completed▁their", + "▁expected▁to▁benefit ▁you▁directly▁or▁to▁alter", + "▁Study▁to▁Compare▁the▁Efficacy▁of ▁Panitumumab▁in▁Combination▁with", + "Sublingual▁Intramuscular▁Intravenous▁ Oral▁Rectal▁Subcutaneous▁", + "▁was▁unable▁to▁be▁evaluated▁leading▁to ▁an▁inability▁to▁determine▁the▁status▁of▁that▁particular▁tumor▁for", + "▁Electronic▁Data ▁Record", + "cGill -Melzack", + "kal emia", + "▁of▁Health ▁and▁Human▁Servic", + "e▁see▁the▁ current▁version▁of▁the▁", + ".▁STA TISTICAL▁CONSIDERATIONS", + "▁death,▁whichever ▁occurs▁first", + "e.▁When ▁the▁evaluation▁of", + "▁my▁medical▁information ▁if▁I", + "re-start ed▁at▁the▁", + "CHED ULE", + ",▁Ver we", + "DNA▁methyl transfer", + "▁modified▁version▁of▁the▁ RECIST▁criteria", + "irradiated ▁area", + "▁(KM) ▁time▁to▁event", + "Return▁of▁Investigational▁Product▁for▁Destruction ▁Form", + "aborative▁ Group", + "▁the▁duration▁of▁the▁study.▁Copies▁of ▁the▁investigator’s▁report", + "mg/m2▁IV▁over▁2 ▁hr", + "▁3▁x▁ULN▁(if▁liver▁metastases▁ ≤▁5▁x▁ULN", + "Comprehensive▁Cancer ▁Network", + "preservative▁free▁liqu id▁in", + "discoveries,▁or ▁derivative▁material", + "▁Staging▁Manual,▁S eventh▁Edition", + "Handbook▁for ▁Investigator", + "abbinavar ▁F", + "neo-)adjuvant ▁(radi", + "have▁been▁answered▁to▁your▁satisfaction .\n\nIn▁signing▁this▁document", + "▁“on-study” ▁death", + "cen ario", + "iPLEX ▁G", + "icos apent", + "allpoint ▁pen", + "Inflammatory▁ Drug", + "▁will▁be▁manufact ured▁and▁packag", + "▁x▁ic ▁", + ",▁Somer field▁MR", + ",▁Grif fin", + "labeled▁per ▁site▁", + "▁AND▁QU ALITY▁ASSURA", + "s.▁Amgen ▁and▁other▁researcher", + "▁of▁10▁mM ▁Sodium▁Acet", + "made▁only▁with ▁the▁prior", + "▁named▁ representatives▁to▁have▁access▁to", + "consent▁form▁should▁be▁provided▁to ▁the▁subject▁or", + "perty▁of▁the▁sanofi-aventis▁group▁-▁strictly▁confidential▁WW-CLIN-PR007-SD-03▁VERSION▁n°02▁(19-DEC-2005 )\n\n21-Jul-2008▁Version▁number:▁1▁(electronic▁2.0", + "▁Manuscript s▁Sub", + "▁is▁inadvert ently▁", + "refer▁to▁the▁current ▁Panitumumab▁Investigator’s▁Brochure▁for▁further▁detail", + "▁will▁have▁access▁to ▁my▁medical▁information▁if▁I", + "▁study-related▁record s▁without", + "▁interval▁is▁ prolonged▁(", + "regulatory▁agency▁ inspector", + "regulatory▁agency (s),▁and▁the▁", + "▁the▁benefit:risk▁profile▁ is▁not▁positiv", + "▁First▁Street ▁SW", + "epatitis▁C ▁virus", + "ance▁in▁Investigational▁Product ▁Administration", + "ed▁while▁on▁or▁after ▁prior", + "▁make▁entries▁and/or ▁correction", + "he/she▁must ▁notify▁", + "unn▁PA ▁Jr", + "▁intellectual ▁content", + "▁must▁submit▁and ,▁where▁", + "residual▁lesion ▁be▁investig", + ".▁These▁signatures▁will ▁indicate▁that", + "▁ever▁comes▁first.▁If ▁the▁benefit:risk▁profile▁is▁not▁positiv", + "ensive▁treatment▁in▁an▁emergency▁room▁or▁at▁hom e▁for", + "▁party▁or▁move▁them ▁to▁another▁location,▁", + "read▁the▁attached▁protocol ▁entitl", + "6▁plann ed▁cycl", + "Hu EPO", + "kilogram s)", + "al▁Anti- Inflammatory▁Drug", + "uration▁for ▁Participant", + "▁COLL ECTION", + "acquisition▁of ▁informed▁consent", + "▁or▁EC HO", + "uties.▁All ▁persons▁authorized▁to", + "ize▁discover ies▁or▁in", + "▁nor▁other ▁participants▁in▁this▁research▁will▁compensate▁you▁if▁this▁happens", + "▁and▁as▁needed ▁thereafter", + "▁TIS SUE", + "▁RIS KS▁AND▁DISCOMFOR", + "event-free▁rates▁ at", + "clude▁the▁s election▁of", + "ing▁the▁articl e▁or▁revis", + "▁at▁start▁of ▁cycle,▁hold▁and▁check", + "▁study▁initiation ▁and▁as▁needed▁thereafter", + "s▁and▁p-valu es", + "s▁and▁investigative▁ staff", + "ly▁as▁possible▁ up▁to", + "reported▁according▁to▁the▁ protocol", + "stront ium", + "▁913 20", + "ightCycl er", + "▁Study▁Code:▁D8480C00013 ▁Version▁No:", + "▁im▁= ▁intramuscular", + ",▁a▁commercial▁pharmaceutical▁product ▁may▁be▁develop", + "es▁will▁be▁assign ed▁for▁each", + "ebrid ement", + "▁drug▁depend ency▁or▁drug▁abus", + "▁until▁subjects▁have▁access▁to▁commercially▁available▁product▁or▁for▁up▁to▁2▁year s,▁which", + "obtain▁the▁consent ▁of▁the▁subject", + "ventions▁that▁result▁from▁this▁research.▁Neither▁Amgen ▁nor▁other▁participants▁in▁this▁research▁will▁compensate▁you▁if▁this▁happens", + "pensation▁for ▁Injur", + "Treatment▁Cycl e-", + "ECOG▁45 99", + "▁advanced▁esophag o-gastric▁cancer", + "▁PD▁=▁progressive▁diseas e;", + ",▁Tulsky▁ DS", + "echnetium ▁99", + "Amgen▁Center ▁Drive▁", + "products▁develop ed▁from▁the▁sampl", + "condition▁of▁the▁drug ▁and▁enter▁these▁data▁into▁the▁", + ",▁Einh orn", + "▁my▁records▁ be▁maintained", + "s,▁or▁research▁companies▁ may▁patent▁or▁sell", + "included▁in▁the▁shipment ▁of▁used▁and▁", + "▁of▁panitumumab▁plus▁FOLFIRI ▁on", + "▁as▁described▁in▁Appendix ▁1", + "▁unblinding▁information .▁This▁", + "▁particular▁clinical▁import ance,▁other▁than▁SAEs▁and▁those▁", + "▁Dose▁Modification▁Algorithm ▁for", + "\n\nAny\n\nYes \n\nPD", + "▁the▁development▁of▁commercial▁pharmaceutical▁product s.▁Amgen▁and▁other▁researcher", + "ed,▁and▁accurately▁ reported▁according▁to▁the▁protocol", + "’s▁institution,▁who▁will ▁check", + "▁weekly▁then▁treat▁based▁on ▁interval", + ",▁other▁researcher s,▁or▁research▁companies▁may▁patent▁or▁sell", + "▁ruler▁or▁c ali", + "▁paper▁forms▁will▁be▁ made▁by", + ".\n\nHow▁will▁the▁confidentiality▁of ▁my▁records▁be▁maintained", + "▁RS,▁Rubin stein▁L", + "accountability▁of▁all ▁us", + "ies▁must▁be▁made▁available▁for ▁inspection", + "▁PET▁scans▁or▁s keletal▁surveys", + "anders▁J,▁Kaplan ▁RS,▁Rubinstein▁L", + "sertion▁of▁the▁correction ▁above▁or", + "aresthesias/d ysesthesias", + "document▁contains▁confidential▁information▁of ▁Amgen▁Inc", + "ing▁it▁crit ically▁for", + "▁expected▁to▁benefit▁you▁directly▁or▁to▁alter ▁your▁treatment▁course", + "▁will▁be▁manufactured▁and▁packag ed▁by▁Amgen▁Inc", + "▁AND▁QUALITY▁ASSURA NCE", + "▁of▁10▁mM▁Sodium▁Acet ate,▁5%", + "▁Manuscripts▁Sub mitted▁to▁Biomedical▁Journal", + "ize▁discoveries▁or▁in ventions▁that▁result▁from▁this▁research.▁Neither▁Amgen▁nor▁other▁participants▁in▁this▁research▁will▁compensate▁you▁if▁this▁happens", + "ing▁the▁article▁or▁revis ing▁it▁critically▁for", + "▁at▁start▁of▁cycle,▁hold▁and▁check ▁weekly▁then▁treat▁based▁on▁interval", + "▁Study▁Code:▁D8480C00013▁Version▁No: ▁<>▁Version▁Date:▁<>", + "▁particular▁clinical▁importance,▁other▁than▁SAEs▁and▁those▁ AEs▁leading▁to▁discontinuation▁of▁the▁", + "▁the▁development▁of▁commercial▁pharmaceutical▁products.▁Amgen▁and▁other▁researcher s▁may▁us", + "\" ▁of▁the▁study", + "\" sponsor", + "% ,▁and▁", + "' Inf", + "( 25", + "( to", + "( 14", + "( 13", + "( i.e.,▁", + "( essential", + "( EOS", + ") ▁of▁", + ") ▁M", + ") ,▁as▁", + ") .▁No", + ") \n\nAny▁", + ") ▁is▁an", + ") ,▁and▁all", + ") ▁provided▁that", + ", ▁ac", + ", ▁adverse▁event", + ", 16", + ", ▁an▁", + ", ▁the▁prior", + "- k", + "- 11", + "- arm", + "- 36", + "- 75", + "- 91", + "- enhanc", + ". H", + ". P", + ". ,▁and▁", + "/ D", + "/ s", + "/ d▁", + "/ fl", + "/ III", + "/ 5-FU", + "/ ALT", + "/ SD", + "/ Discomfort", + "0 .01", + "0 .75", + "1 ▁tablespoon", + "1 ▁oxaliplatin▁dose▁level", + "2 15", + "2 -0", + "2 1-day▁", + "3 ).\n\n", + "6 ▁mg/kg", + "6 -methylgu", + "7 90", + "7 ▁days▁prior▁to", + "9 00", + "9 -5", + ": ▁C", + ": ▁2", + ": 17", + ": \n\nH", + ": ▁intervention", + ": ▁N0147", + ": ▁Result", + ": ▁Proc", + "; 35", + "? \n\nA", + "? ▁J", + "? \n\nThis▁", + "A pprov", + "A VF2107", + "B ax", + "B rain", + "B ilirubin", + "B NP", + "C ent", + "C RA", + "C etuximab", + "C andid", + "C alcium", + "D P", "D a", - "SO UR", - "S OUR", - "ett be", - "▁Batt alion", - "▁F loat", - "▁Flo at", - "▁ Float", - "▁c one", - "▁con e", - "▁co ne", - "read sheet", - "co urt", - "cou rt", - "c ourt", - "li gen", - "lig en", - "lige n", - "l igen", - "▁Begin n", - "▁Beg inn", - "▁LI MIT", - "▁LIM IT", - "▁enjo yed", - "▁enjoy ed", - "▁Jak ob", - "▁t elt", - "▁te lt", - "▁tel t", - "back end", - "▁Gemeins ame", - "li nt", - "lin t", - "l int", - "al ling", - "all ing", - "▁b ör", - "gr and", - "gra nd", - "g rand", - "▁divers es", - "▁diverse s", - "▁z wiąz", - "▁Kom pon", - "▁inner halb", - "▁desar rollo", - "▁desarroll o", - "▁Ma sters", - "▁Mas ters", - "▁Master s", - "io so", - "ios o", - "i oso", - "]` .", - "] `.", - "▁frances a", - "▁franc esa", - "A ff", - "in ek", - "ine k", - "i nek", - "▁des sin", - "▁dess in", - "`. `", - "` .`", - "▁r anks", - "▁ran ks", - "▁rank s", - "бер г", - "▁s kal", - "▁sk al", - "▁S ultan", - "▁Sul tan", - "А Н", - "▁спо соб", - "▁contra dict", - "▁contrad ict", - "▁re com", - "▁rec om", - "▁Ok lahoma", - "▁Vlad imir", - "▁m eters", - "▁me ters", - "▁met ers", - "▁meter s", - "trans port", - "▁cons ulté", - "▁consult é", - "▁ consulté", - "▁A TP", - "▁AT P", - "eb b", - "e bb", - "▁vol unte", - "▁volunt e", - "▁out line", - "LI C", - "L IC", - "▁e uro", - "▁eu ro", - "Char Field", - "med ium", - "medi um", - "▁Belg ique", - "Pro c", - "Pr oc", - "P roc", - "ro utes", - "route s", - "rout es", - "rou tes", - "▁cont ribu", - "▁contrib u", - "! }", - "ší m", - "š ím", - "▁L ess", - "▁Le ss", - "▁Les s", - "▁K ost", - "▁Ko st", - "▁Kos t", - "▁eredet iből", - "re ven", - "rev en", - "r even", - "ver ify", - "▁S alt", - "▁Sal t", - "▁Sa lt", - "▁shoot ing", - "▁sho oting", - "▁dis pose", - "▁dispos e", - "▁disp ose", - "uj í", - "▁t ierra", - "▁tier ra", - "▁po ison", - "▁poi son", - "sa k", - "s ak", - "periment al", - "▁N é", - "▁K id", - "▁Ki d", - "ag yar", - "agy ar", - "▁archiv álva", - "be reich", - "bere ich", - "í z", - "▁R itter", - "▁Хронологи ја", - "ze um", - "да х", - "▁gr ünd", - "▁program mer", - "▁programme r", - "▁cons eil", - "▁conse il", - "▁enc rypt", - "integr ation", - "C ulture", - "▁Circ le", - "▁Cir cle", - "Ob servable", - "▁gen omsnitt", - "▁Se lection", - "▁Select ion", - "▁Sel ection", - "▁Sele ction", - "▁ Selection", - "▁ir regular", - "Aut res", - "Per cent", - "fa ult", - "f ault", - "▁virt ue", - "ą pi", - "▁s ess", - "▁se ss", - "▁ses s", - "▁Так же", - "Tim estamp", - "▁litt érature", - "▁mo ż", - "▁b orrow", - "▁bor row", - "▁con ced", - "▁conc ed", - "▁conce d", - "чни к", - "ч ник", - "▁L und", - "▁Lu nd", - "ION S", - "IO NS", - "yn ie", - "y nie", - "▁S hin", - "▁Sh in", - "▁o sob", - "▁os ob", - "b ě", - "▁int uit", - "▁intu it", - "▁на п", - "▁p roph", - "▁pro ph", - "▁pr oph", - "▁prop h", - "▁p itt", - "▁pi tt", - "▁pit t", - "▁IB M", - "▁T ill", - "▁Ti ll", - "▁h ina", - "▁hi na", - "▁hin a", - "it test", - "itt est", - "itte st", - "gener ator", - "▁N in", - "▁Ni n", - "▁K ot", - "▁Ko t", - "▁p asser", - "▁pass er", - "▁pas ser", - "▁passe r", - "▁dis position", - "▁dispos ition", - "▁disp osition", - "un ing", - "uni ng", - "u ning", - "▁f ame", - "▁fa me", - "▁fam e", - "▁t enia", - "▁te nia", - "▁ten ia", - "an cement", - "ance ment", - "anc ement", - "▁Su isse", - "` -", - "▁h ombres", - "▁hom bres", - "▁hombre s", - "▁inf inity", - "▁infin ity", - "▁окон ча", - "▁co sm", - "▁cos m", - "▁D ennis", - "▁Den nis", - "ba z", - "b az", - "ha upt", - "h aupt", - "▁might y", - "▁pr ede", - "▁pre de", - "▁pred e", - "us able", - "usa ble", - "▁ws zyst", - "▁wsz yst", - "▁l b", - "▁ lb", - "AB ASE", - "A BASE", - "j na", - "не в", - "н ев", - "▁as es", - "▁ ases", - "▁final mente", - "й м", - "pe ction", - "pect ion", - "pec tion", - "p ection", - "▁Stud ien", - "▁Norweg ian", - "ce go", - "c ego", - "IN DEX", - "IND EX", - "or ten", - "ort en", - "orte n", - "▁friend ship", - "▁friends hip", - "met ro", - "m etro", - "th ick", - "▁Z el", - "▁Ze l", - "LO W", - "L OW", - "▁there by", - "un ted", - "unt ed", - "unte d", - "▁sur faces", - "▁surface s", - "ющи м", - "%) .", - "% ).", - "▁W onder", - "▁Wo nder", - "▁redund ant", - "▁G ros", - "▁Gr os", - "▁Gro s", - "▁web sites", - "▁website s", - "▁v io", - "▁vi o", - "▁o cas", - "▁oc as", - "vé s", - "v és", - "▁G am", - "▁Ga m", - "d w", - "Ind icator", - "▁K ob", - "▁Ko b", - "▁j ack", - "▁ja ck", - "▁ jack", - "Hi nt", - "H int", - "▁A pol", - "▁Ap ol", - "▁други е", - "▁N UM", - "▁ NUM", - "▁o fic", - "▁of ic", - "yst ycz", - "▁were ld", - "▁wer eld", - "мо сти", - "LE FT", - "▁T ypes", - "▁Type s", - "▁Ty pes", - "▁Typ es", - "▁ Types", - "se en", - "see n", - "s een", - "un cia", - "unc ia", - "unci a", - "▁n arod", - "▁na rod", - "▁nar od", - "▁это т", - "Side note", - "S idenote", - "ue il", - "u eil", - "▁от ме", - "▁cour ts", - "▁court s", - "fi r", - "f ir", - "ur z", - "u rz", - "чен ко", - "Cred entials", - "▁imag ination", - "it ats", - "ita ts", - "itat s", - "bu ff", - "buf f", - "b uff", - "fl ash", - "▁bad ly", - "▁w orn", - "▁wor n", - "▁wo rn", - "▁окру гу", - "cat alog", - "catal og", - "c atalog", - "li me", - "lim e", - "l ime", - "▁G ill", - "▁Gi ll", - "▁Gil l", - "▁S ent", - "▁Se nt", - "▁Sen t", - "ie lla", - "iel la", - "i ella", - "▁Cra ig", - "▁S ele", - "▁Se le", - "▁Sel e", - "▁Indep end", - "▁prov incie", - "▁provin cie", - "os sen", - "oss en", - "▁за пад", - "▁запа д", - "▁inf ant", - "▁pr events", - "▁prevent s", - "▁prev ents", - "▁provin ces", - "▁province s", - "af é", - "be g", - "b eg", - "▁col ours", - "▁colour s", - "B F", - "ë n", - "▁Ме жду", - "î n", - "Ob server", - "for sch", - "í gen", - "um ption", - "ump tion", - "▁Ill ustr", - "ри ст", - "рис т", - "▁по лови", - "▁пол ови", - "▁поло ви", - "▁` &", - "▁o re", - "▁or e", - "▁ ore", - "▁supp lies", - "▁parent hes", - "Found ation", - "▁v ou", - "▁vo u", - "▁T out", - "▁To ut", - "Don ald", - "▁R ET", - "▁RE T", - "we ig", - "wei g", - "▁produ cción", - "mi x", - "m ix", - "▁ut wor", - "▁f öl", - "▁fö l", - "▁ent ão", - "▁S ister", - "▁Si ster", - "Tag s", - "T ags", - "▁Савез не", - "▁privile ges", - "▁na zw", - "▁naz w", - "▁R av", - "▁Ra v", - "▁re pro", - "▁rep ro", - "▁repr o", - "▁M ason", - "▁Ma son", - "▁Mas on", - "▁Pl atform", - "▁Plat form", - "▁ Platform", - "▁про бле", - "▁P érez", - "▁bl anc", - "▁bla nc", - "▁blan c", - "Be havior", - "фи ци", - "ek en", - "e ken", - "▁me ets", - "▁meet s", - "(. *", - "( .*", - "▁f å", - "ep en", - "e pen", - "ma ker", - "make r", - "m aker", - "▁lo yal", - "mem bers", - "member s", - "m embers", - "meister schaft", - "go al", - "ш лен", - "▁се веро", - "▁север о", - "ie nde", - "ien de", - "i ende", - "д ні", - "Pro of", - "▁exp lic", - "▁expl ic", - "▁elect ro", - "ie ls", - "iel s", - "i els", - "re load", - "▁el even", - "▁ele ven", - "▁elev en", - "▁part idos", - "▁partido s", - "în e", - "î ne", - "▁R egin", - "▁Re gin", - "▁Reg in", - "▁é x", - "▁Bu lg", - "▁Bul g", - "▁network ing", - "▁net working", - "▁se parator", - "▁separ ator", - "User Name", - "▁edific io", - "▁M ie", - "▁Mi e", - "▁id le", - "ye d", - "y ed", - "▁pass engers", - "▁passenger s", - "+ )", - "me no", - "men o", - "m eno", - "eg gi", - "e ggi", - "▁nice ly", - "▁nic ely", - "end encia", - "enden cia", - "чи й", - "ét és", - "été s", - "ight arrow", - "▁orth ogonal", - "▁H alf", - "▁Hal f", - "▁fe wer", - "▁few er", - "▁pro pi", - "▁prop i", - "▁pr imit", - "▁prim it", - "▁pri mit", - "▁primi t", - "ic ale", - "ical e", - "ica le", - "▁f lower", - "▁fl ower", - "▁flow er", - "▁flo wer", - "mer k", - "m erk", - "▁Оте че", - "▁pers istent", - "▁persist ent", - "▁V ille", - "▁Vill e", - "▁Vi lle", - "▁Vil le", - "Me n", - "M en", - "ga ben", - "gabe n", - "g aben", - "▁Isa ac", - "at ivity", - "ativ ity", - "ati vity", - "▁pół noc", - "▁r ok", - "▁ro k", - "▁ rok", - "car ds", - "card s", - "c ards", - "де ния", - "▁ю го", - "▁extra ordinary", - "▁k yr", - "(\" ,", - "( \",", - ")) ]", - ") )]", - "▁un ix", - "▁ unix", - "ко л", - "▁s ink", - "▁sin k", - "ap sed", - "aps ed", - "▁k ommen", - "▁kom men", - "▁komm en", - "▁ kommen", - "▁for cing", - "Ab out", - "▁H alle", - "▁Ha lle", - "▁Hall e", - "▁Hal le", - "▁Maj esty", - "▁Sw itch", - "▁ Switch", - "▁ab road", - "▁acceler ation", - "ur bed", - "urb ed", - "▁о стан", - "▁ос тан", - "▁оста н", - "▁ост ан", - "Re ady", - "Read y", - "▁пів ні", - "Br a", - "B ra", - "▁ць ого", - "▁pl ut", - "▁T rain", - "▁Tr ain", - "▁Tra in", - "▁á prilis", - "▁p uesto", - "▁pu esto", - "▁pue sto", - "▁t oss", - "▁to ss", - "▁irre levant", - "▁d ip", - "▁di p", - "se gment", - "seg ment", - "op acity", - "▁lors que", - "▁versch ill", - "ен а", - "е на", - "▁D oc", - "▁Do c", - "▁ Doc", - "%%%% %%%%", - "▁b orders", - "▁border s", - "▁bor ders", - "▁bord ers", - "ge bras", - "geb ras", - "gebra s", - "▁r ies", - "▁ri es", - "▁ ries", - "▁Olymp edia", - "▁Gener ation", - "met ros", - "metro s", - "▁hor izon", - "▁adapt ation", - "▁Z ahl", - "▁Za hl", - "▁na he", - "▁nah e", - "▁B ug", - "▁Bu g", - "P icture", - "љ и", - "R GB", - "O wner", - "ad in", - "adi n", - "a din", - "▁Catal unya", - "ný ch", - "n ých", - "▁cual quier", - "▁Inst itution", - "▁Instit ution", - "▁Institut ion", - "in sen", - "ins en", - "▁Bras ile", - "▁Brasil e", - "▁f itting", - "▁fit ting", - "De leg", - "Del eg", - "ic two", - "ict wo", - "▁Ex per", - "▁Exp er", - "och astic", - "▁d us", - "▁du s", - "▁по ра", - "▁пор а", - "▁sub string", - "▁subst ring", - "▁subs tring", - "▁substr ing", - "▁ substring", - "сси и", - "с сии", - "oi n", - "o in", - "▁ш кола", - "▁шко ла", - "▁c x", - "▁ cx", - "▁% )", - "▁ %)", - "▁Bud dh", - "▁p ending", - "▁pen ding", - "▁En try", - "▁Ent ry", - "▁ Entry", - "▁Be rl", - "▁Ber l", - "▁c ler", - "▁cl er", - "▁cle r", - "▁ cler", - "▁S oc", - "▁So c", - "▁r ounded", - "▁round ed", - "▁m v", - "▁ mv", - "ít ett", - "▁Di plom", - "▁französ ischen", - "▁G an", - "▁Ga n", - "▁Inv estig", - "▁index Path", - "▁ indexPath", - "▁mol ti", - "▁molt i", - "pers istence", - "▁XIX e", - "▁Elect ron", - "b ü", - "ge le", - "gel e", - "g ele", - "▁M aler", - "▁Ma ler", - "▁Mal er", - "▁Male r", - "▁proyect o", - "▁B ath", - "▁Ba th", - "▁Bat h", - "el lers", - "ell ers", - "elle rs", - "eller s", - "▁G P", - "▁ GP", - "on ing", - "oni ng", - "o ning", - "clou dflare", - "▁p ři", - "▁př i", - "▁d ed", - "▁de d", - "▁ ded", - "▁Od kazy", - "▁M sg", - "▁ Msg", - "▁B eing", - "▁Be ing", - "▁Bei ng", - "▁De puis", - "▁Dep uis", - "▁Pri mary", - "▁Prim ary", - "▁Prima ry", - "▁ Primary", - "▁App ro", - "▁Ap pro", - "▁form ally", - "▁formal ly", - "ступ ил", - "ступи л", - "▁fue ra", - "▁fu era", - "▁fuer a", - "▁R oot", - "▁Ro ot", - "▁ Root", - "▁aut onom", - "▁auto nom", - "▁secret ary", - "▁os ób", - "▁cu ales", - "▁cual es", - "▁Dep ending", - "▁a si", - "▁as i", - "▁ asi", - "ve ra", - "ver a", - "v era", - "▁rus se", - "▁russ e", - "▁pro ves", - "▁prov es", - "▁prove s", - "▁pres iden", - "R U", - "▁Wat son", - "▁web pack", - "▁ webpack", - "elli gence", - "ellig ence", - "ка м", - "▁Office r", - "▁Offic er", - "▁d elivery", - "▁deliver y", - "▁deli very", - "ж дён", - "▁им пе", - "▁w il", - "▁v esc", - "▁ve sc", - "▁ves c", - "uszt us", - "▁Ge off", - "() }", - "( )}", - "▁F ore", - "▁For e", - "▁Fo re", - "▁w enig", - "▁we nig", - "▁wen ig", - "▁A irl", - "▁Air l", - "▁E fter", - "▁Bre ak", - "▁St äd", - "is miss", - "ism iss", - "í p", - "▁avoid ed", - "▁avo ided", - "▁assert ion", - "D N", - "▁te at", - "▁tea t", - "ín a", - "í na", - "▁mechan ical", - "is u", - "i su", - "@ {", - "▁n ou", - "▁no u", - "▁ nou", - "Ital ie", - "source forge", - "▁s vo", - "▁sv o", - "▁kir ály", - "▁Re ferences", - "▁Refer ences", - "▁Reference s", - "si x", - "s ix", - "▁Arch ives", - "▁Archiv es", - "▁Archive s", - "▁fin ishing", - "▁finish ing", - "ac je", - "ét at", - "éta t", - "é tat", - "if fs", - "iff s", - "▁st ead", - "▁ste ad", - "▁fe as", - "aw are", - "awa re", - "a ware", - "la nde", - "land e", - "lan de", - "l ande", - "In ject", - "▁A gent", - "▁Ag ent", - "▁Age nt", - "▁ Agent", - "▁Norm datei", - "▁a men", - "▁am en", - "▁ amen", - "▁Arch itecture", - "az e", - "a ze", - "ș te", - "▁us ar", - "▁c ores", - "▁cor es", - "▁co res", - "▁core s", - "лі н", - "л ін", - "▁C astro", - "▁Cast ro", - "▁v æ", - ">\" ,", - "> \",", - "om ena", - "ome na", - "omen a", - "▁ge sam", - "▁ges am", - "▁Mart ín", - "▁Martí n", - "eg ung", - "egu ng", - "▁spole č", - "▁ampl itude", - "▁amplit ude", - "▁import ing", - "▁list view", - "TH E", - "T HE", - "zi ale", - "zial e", - "zia le", - "z iale", - "ce des", - "ced es", - "c edes", - "▁particul ier", - "▁Распо дела", - "▁кра й", - "▁d ivent", - "▁di vent", - "▁div ent", - "▁k é", - "▁ ké", - "qu it", - "qui t", - "q uit", - "то ром", - "тор ом", - "Check Box", - "▁Zob acz", - "ph e", - "p he", - "pt a", - "p ta", - "▁s jö", - "▁sj ö", - "▁розта ш", - "▁tedes co", - "▁s tal", - "▁st al", - "▁sta l", - "▁ stal", - "▁Be ruf", - "▁Ber uf", - "ова я", - "о вая", - "▁s vě", - "▁sv ě", - "▁fl ush", - "▁flu sh", - "▁ flush", - "▁від бу", - "▁rad ial", - "▁radi al", - "▁différ entes", - "ан та", - "▁Per ry", - "Col l", - "Co ll", - "C oll", - "li qu", - "l iqu", - "▁Option al", - "▁Opt ional", - "▁ Optional", - "▁Сан кт", - "▁LIN Q", - "▁Fran c", - "▁Fr anc", - "▁Fra nc", - "ci je", - "c ije", - "▁Gu illaume", - "kn ow", - "k now", - "▁Un its", - "▁Unit s", - "ol k", - "▁Syst ème", - "▁S ales", - "▁Sal es", - "▁Sa les", - "▁ehemal igen", - "ми рова", - "мир ова", - "x html", - "set opt", - "▁m ellan", - "▁mel lan", - "▁z ie", - "▁ zie", - "▁gi ant", - "Bo ard", - "▁C aval", - "▁Ca val", - "▁Cav al", - "▁def ence", - "-- --------", - "---- ------", - "-------- --", - "--- -------", - "------ ----", - "----- -----", - "------- ---", - "ps hire", - "p shire", - "ma rt", - "mar t", - "m art", - "▁Di oc", - "is kt", - "isk t", - "▁in se", - "▁ins e", - "▁é pisode", - "чи к", - "bar s", - "ba rs", - "b ars", - "Si to", - "S ito", - "▁integr ity", - "au ff", - "auf f", - "a uff", - "▁v är", - "▁vä r", - "Az ure", - "▁star b", - "▁sta rb", - "▁кон тра", - "▁Мекси чка", - "▁за па", - "▁Mount ains", - "▁Mountain s", - "}} =", - "} }=", - "▁pull ing", - "▁pul ling", - "▁sat ellite", - "▁at oms", - "▁atom s", - "▁profes or", - "▁repeated ly", - "▁repeat edly", - "▁inv asion", - "▁invas ion", - "program ming", - "├ ──", - "▁L ip", - "▁Li p", - "вши е", - "в шие", - "▁k een", - "▁ke en", - "▁crit ics", - "▁critic s", - "▁N icola", - "▁Nicol a", - "▁Nic ola", - "▁Ni cola", - "▁C and", - "▁Can d", - "▁Ca nd", - "▁dist int", - "▁he ading", - "▁head ing", - "p ragma", - "{ |", - "ym en", - "yme n", - "y men", - "▁ter rain", - "▁terra in", - "ied enis", - "▁bes onders", - "▁nomin ated", - "BO OL", - "▁K ay", - "▁Ka y", - "ci an", - "cia n", - "c ian", - "st elle", - "ste lle", - "stell e", - "▁disput e", - "▁disp ute", - "▁ щ", - "Data Set", - "no thing", - "not hing", - "n othing", - "Aut om", - "Auto m", - "hör en", - "hö ren", - "▁s hed", - "▁sh ed", - "▁she d", - "▁p aused", - "▁pa used", - "▁pause d", - "▁pau sed", - "sa n", - "s an", - "▁nun ca", - "!( \"", - "! (\"", - "▁po łoż", - "Se cret", - "Sec ret", - "▁Do main", - "▁Dom ain", - "▁ Domain", - "▁воз мож", - "X V", - "l v", - "ik h", - "i kh", - "▁S ony", - "▁So ny", - "▁Son y", - "m q", - "ot rop", - "otr op", - "▁Log ger", - "▁ Logger", - "▁thre at", - "as ted", - "ast ed", - "aste d", - "a sted", - "зь ко", - "▁fre ely", - "▁free ly", - "▁improve ments", - "▁improv ements", - "▁improvement s", - "ist ema", - "iste ma", - "▁illustr ate", - "▁t act", - "▁ta ct", - "▁fig ur", - "ué s", - "u és", - "rim inal", - "rimin al", - "od on", - "odo n", - "o don", - "int endo", - "▁influ enced", - "▁influence d", - "▁influen ced", - "FF ER", - "▁G host", - "▁Gh ost", - "▁со вер", - "▁сов ер", - "na d", - "n ad", - "ion ed", - "io ned", - "ione d", - "i oned", - "▁Event s", - "▁Ev ents", - "▁Even ts", - "▁ Events", - "▁wr apping", - "▁wra pping", - "▁wrap ping", - "-------- -+", - "--- ------+", - "------ ---+", - "----- ----+", - "------- --+", - "fi f", - "f if", - "▁( **", - "▁(* *", - "={ {", - "= {{", - "ма ль", - "м аль", - "▁loss es", - "▁Gal erie", - "te l", - "t el", - "▁лю того", - "▁K ru", - "▁Kr u", - "▁P olen", - "▁Pol en", - "▁Po len", - "ні м", - "ne ar", - "nea r", - "n ear", - "▁sh ame", - "▁moy enne", - "▁C P", - "▁ CP", - "pre is", - "▁pass enger", - "le k", - "l ek", - "ion ales", - "ional es", - "ionale s", - "iona les", - "kaf ka", - "k afka", - "▁partic ipe", - "▁particip e", - "▁parti cipe", - "▁partici pe", - "▁memb ership", - "▁member ship", - "▁members hip", - "[ _", - "land o", - "lan do", - "l ando", - "st elling", - "stell ing", - "Se m", - "S em", - "go n", - "g on", - "▁Cor rect", - "▁v alle", - "▁val le", - "▁va lle", - "▁vall e", - "▁read ily", - "▁Dok ument", - "hon neur", - "h onneur", - "▁test im", - "ul ative", - "do Filter", - "▁domin ant", - "am mer", - "amm er", - "▁ко ја", - "▁M onsieur", - "ze g", - "z eg", - "▁вій ни", - "▁F o", - "▁A my", - "▁Am y", - "▁ ¡", - "▁febru ár", - "▁down loading", - "▁download ing", - "▁l eng", - "▁le ng", - "▁len g", - "\\}$ ,", - "\\} $,", - "\\ }$,", - "▁ne at", - "▁C ache", - "▁Ca che", - "▁ Cache", - "IC ATION", - "▁de ve", - "▁dev e", - "▁s orrow", - "▁sor row", - "sl ow", - "s low", - "▁hin aus", - "▁hina us", - "▁recon oc", - "▁Lin ked", - "▁Link ed", - "▁Sh aw", - "mar ket", - "mark et", - "▁D ic", - "▁Di c", - "▁S ki", - "▁Sk i", - "▁del imiter", - "▁Main Activity", - "▁ MainActivity", - "▁Mus ical", - "▁Music al", - "▁Re yn", - "▁Rey n", - "Scroll View", - "▁convent ional", - "▁convention al", - "en ça", - "enç a", - "▁re factor", - "▁ref actor", - "' -", - "▁H ed", - "▁He d", - "spr ech", - "spre ch", - "▁ath let", - "▁e species", - "▁es pecies", - "▁espe cies", - "▁espec ies", - "▁especie s", - "▁Sch ön", - "▁kle inen", - "▁kleine n", - "▁klein en", - "ш ко", - "▁Й о", - "▁H appy", - "▁Ha ppy", - "multi row", - "▁august i", - "▁G and", - "▁Ga nd", - "▁Gan d", - "▁appoint ment", - "▁Medi abestanden", - "Th ree", - "▁Kenn eth", - "NE W", - "▁Not ification", - "▁ Notification", - "▁Mar x", - "▁Ma rx", - "▁in sc", - "▁ins c", - "Mo r", - "M or", - "вы й", - "в ый", - "vä st", - "v äst", - "vi dia", - "vid ia", - "v idia", - "▁demonstr ated", - "▁demonstrate d", - "font s", - "fon ts", - "▁k amen", - "▁kam en", - "▁ka men", - "▁S ter", - "▁St er", - "▁Ste r", - "▁mieszkań ców", - "▁K oh", - "▁Ko h", - "~$ \\", - "~ $\\", - "») .", - "» ).", - "re ne", - "ren e", - "r ene", - "ins ic", - "ic ká", - "ick á", - "xy gen", - "▁m n", - "▁ mn", - "▁s ched", - "▁sc hed", - "▁sch ed", - "▁sche d", - "AS C", - "A SC", - "I g", - "▁Const ant", - "▁opport un", - "▁My Class", - "se f", - "s ef", - "op ed", - "ope d", - "o ped", - "▁inj ured", - "VI S", - "V IS", - "▁P ero", - "▁Per o", - "▁Pe ro", - "▁U ntil", - "▁Un til", - "▁f lesh", - "▁fl esh", - "▁fle sh", - "orph ism", - "▁Port al", - "▁Por tal", - "▁gmin y", - "▁вла сти", - "▁N ä", - "кти че", - "к тиче", - "▁h rab", - "▁hr ab", - "▁C ub", - "▁Cu b", - "av oir", - "avo ir", - "a voir", - "▁L ars", - "▁La rs", - "▁Lar s", - "▁Бе ло", - "▁seizo en", - "▁Gen omsnitt", - "▁L il", - "▁Li l", - "▁P ool", - "▁Po ol", - "▁ Pool", - "▁D ios", - "▁Di os", - "T X", - "ae s", - "a es", - "aut ore", - "auto re", - "autor e", - "Al pha", - "st ates", - "state s", - "sta tes", - "stat es", - "La b", - "L ab", - "n ederbörd", - "er ton", - "ert on", - "▁b rid", - "▁br id", - "▁ brid", - "▁r icht", - "▁rich t", - "▁ric ht", - "▁ri cht", - "▁ richt", - "▁E la", - "▁El a", - "▁с ла", - "▁ сла", - "▁weap on", - "▁comb att", - "▁combat t", - "ag ar", - "aga r", - "a gar", - "▁reg nig", - "▁util isé", - "▁utilis é", - "▁ser vir", - "▁serv ir", - "▁servi r", - "▁b rick", - "▁br ick", - "▁gate way", - "▁tor raste", - "▁proced ures", - "▁procedure s", - "▁års nederbörd", - "▁Genomsnitt lig", - "чё т", - "ч ёт", - "▁om rå", - "▁ områ", - "▁regnig aste", - "▁че сть", - "▁a mid", - "▁am id", - "▁ami d", - "▁gr ateful", - "▁D IS", - "▁DI S", - "▁ DIS", - "DA Y", - "▁о ру", - "▁ор у", - "▁ ору", - "▁riv ière", - "he ure", - "▁Rich mond", - "▁Com par", - "▁Comp ar", - "▁Н ор", - "▁Но р", - "DO C", - "D OC", - "es ia", - "esi a", - "cal c", - "▁I U", - "▁v org", - "▁vo rg", - "▁vor g", - "▁hab ían", - "▁había n", - "ço it", - "ç oit", - "▁a rist", - "▁ar ist", - "▁к ли", - "▁ кли", - "▁S ue", - "▁Su e", - "▁T ouch", - "▁To uch", - "▁ Touch", - "▁Writ ing", - "ifi able", - "▁w c", - "▁with draw", - "за р", - "з ар", - "▁present ly", - "▁pres ently", - "▁F K", - "▁pr akt", - "▁pra kt", - "▁col ored", - "▁color ed", - "us b", - "u sb", - "▁Per ú", - "▁pl ata", - "▁pla ta", - "▁plat a", - "▁w ishes", - "▁wish es", - "▁wis hes", - "▁ка м", - "▁ кам", - "az ar", - "aza r", - "a zar", - "áv el", - "á vel", - "▁l amp", - "▁la mp", - "bi shop", - "b ishop", - "▁in clusion", - "▁incl usion", - "▁inclus ion", - "j q", - "ar th", - "art h", - "▁F lag", - "▁Fl ag", - "▁ Flag", - "▁но р", - "▁н ор", - "æ dia", - "UN CTION", - "▁Bahn hof", - "▁appro aching", - "▁approach ing", - "▁G ött", - "▁Gö tt", - "▁c ube", - "▁cu be", - "▁cub e", - "▁arg ued", - "▁argue d", - "▁Th ings", - "Gu i", - "G ui", - "до ви", - "дов и", - "д ови", - "▁re cre", - "▁rec re", - "▁ré seau", - "▁rés eau", - "▁sign ifica", - "▁signific a", - "Gi t", - "G it", - "geb racht", - "gebra cht", - "▁l iga", - "▁li ga", - "▁lig a", - "▁ liga", - "▁ass ured", - "al us", - "alu s", - "a lus", - "ри т", - "р ит", - "▁э нциклопеди", - "▁% ).", - "▁%) .", - "▁ %).", - "▁Prem ière", - "▁declar ations", - "▁declaration s", - "▁tr icky", - "▁trick y", - "▁pro files", - "▁prof iles", - "▁profile s", - "▁profil es", - "▁F on", - "▁Fo n", - "▁J as", - "▁Ja s", - "â r", - "ba bel", - "b abel", - "▁Fr iday", - "▁Fri day", - "▁Frid ay", - "▁jú nius", - "▁c ols", - "▁col s", - "▁co ls", - "▁ cols", - "▁EX ISTS", - "▁Ital iana", - "▁Italian a", - "▁Italia na", - "▁author ization", - "▁s ulle", - "▁su lle", - "▁sul le", - "▁sull e", - "▁E mb", - "▁Em b", - "▁Vari able", - "▁ Variable", - "tr ees", - "tre es", - "tree s", - "t rees", - "▁F ly", - "▁Fl y", - "ri ors", - "rio rs", - "rior s", - "r iors", - "▁da mals", - "▁dam als", - "▁find et", - "▁fin det", - "▁Se pt", - "▁Sep t", - "▁m undial", - "▁rem oval", - "▁remov al", - "▁long itude", - "▁longitud e", - "cl ic", - "cli c", - "c lic", - "▁f ade", - "▁fa de", - "▁ fade", - "▁grad le", - "▁ gradle", - "▁z ák", - "▁zá k", - "▁tim ing", - "▁ti ming", - "tr ightarrow", - "t rightarrow", - "at ia", - "ati a", - "- .", - "uch e", - "uc he", - "u che", - "▁ser ialize", - "▁serial ize", - "▁H mm", - "▁Represent atives", - "ba h", - "b ah", - "re nd", - "ren d", - "r end", - "ass ador", - "assa dor", - "▁sh ield", - "uc ion", - "u cion", - "▁am éricaine", - "▁améric aine", - "▁américain e", - "z ę", - "vi lla", - "vil la", - "v illa", - "▁hom bre", - "ás s", - "á ss", - "▁S F", - "▁ SF", - "▁repe ating", - "▁repeat ing", - "▁c riter", - "▁cr iter", - "▁crit er", - "▁cri ter", - "▁St ruct", - "▁Str uct", - "▁ Struct", - "?? ?", - "? ??", - "▁che ap", - "▁r ings", - "▁ring s", - "▁rin gs", - "ab häng", - "▁c orte", - "▁cor te", - "▁cort e", - "▁admin ist", - "ix on", - "gy pt", - "▁punt os", - "▁punto s", - "▁me zi", - "▁mez i", - "▁po chod", - "▁poc hod", - "is ko", - "isk o", - "i sko", - "ni ę", - "n ię", - "▁о су", - "▁ос у", - "▁á r", - "▁ ár", - "те льной", - "тель ной", - "тельно й", - "▁Metropol itan", - "ji n", - "j in", - "ze ss", - "zes s", - "z ess", - "▁ві ці", - "▁conflic ts", - "▁conflict s", - "ij st", - "▁Mar ket", - "▁Mark et", - "ст ров", - "стро в", - "стр ов", - "▁\" ,\"", - "▁\", \"", - "▁ \",\"", - "▁Sc roll", - "▁ Scroll", - "gu n", - "g un", - "та ра", - "тар а", - "▁am ateur", - "▁r óż", - "pos s", - "po ss", - "p oss", - "▁general ized", - "▁H arm", - "▁Har m", - "▁Ha rm", - "ci ta", - "cit a", - "c ita", - "▁Sw itzerland", - "ic ola", - "ico la", - "icol a", - "i cola", - "▁m uit", - "▁mu it", - "loc ated", - "▁c ó", - "▁a rose", - "▁ar ose", - "▁commun auté", - "}) ^", - "} )^", - "vis ibility", - "íd a", - "í da", - "▁F B", - "▁ FB", - "▁Fre und", - "ga t", - "g at", - "\": {\"", - "int ellij", - "if ie", - "ifi e", - "hm en", - "h men", - "▁éd ition", - "▁ édition", - "▁ко је", - "▁ін ших", - "om ing", - "omin g", - "omi ng", - "o ming", - "▁arqu itect", - "▁Pres idente", - "▁President e", - "▁П ід", - "▁ca bin", - "▁cab in", - "The orem", - "▁G ay", - "▁Ga y", - "if ice", - "ific e", - "ifi ce", - "▁h ect", - "▁he ct", - "l ą", - "irm ingham", - "▁sem antic", - "▁Louis iana", - "▁sac rifice", - "▁sacr ifice", - "▁sacrific e", - "▁Christ oph", - "▁Exec utive", - "_ +", - "j ák", - "▁s eria", - "▁se ria", - "▁ser ia", - "▁Over flow", - "▁ Overflow", - "▁Lu cy", - "▁Luc y", - "▁mel hor", - "▁vo ices", - "▁voice s", - "cz a", - "c za", - "▁ка пи", - "▁университе та", - "IN CT", - "▁col oc", - "▁co loc", - "▁pr ue", - "▁ge omet", - "▁geom et", - "▁di retto", - "▁dire tto", - "▁dir etto", - "▁dirett o", - "re so", - "res o", - "r eso", - "▁A kt", - "▁Ak t", - "▁un h", - "▁се ри", - "▁сер и", - "▁Al ert", - "▁Ale rt", - "▁ Alert", - "We l", - "W el", - "au di", - "aud i", - "a udi", - "äl er", - "ä ler", - "▁gu ests", - "▁guest s", - "▁и де", - "St udio", - "▁ка те", - "▁ex ponent", - "▁expon ent", - "rz e", - "r ze", - "pm od", - "p mod", - "ro lle", - "roll e", - "rol le", - "▁Lim ited", - "Al lemagne", - "▁p ity", - "▁pi ty", - "▁pit y", - "▁l ä", - "▁ lä", - "▁run ner", - "▁ runner", - "ke nde", - "ken de", - "k ende", - "E Q", - "▁M M", - "▁ MM", - "sz ág", - "по ді", - "▁reg ret", - "▁publi é", - "▁depart amento", - "▁acc used", - "▁accus ed", - "h p", - "▁P fl", - "▁Pf l", - "▁S int", - "▁Si nt", - "▁Sin t", - "▁ek onom", - "ra ctor", - "rac tor", - "ract or", - "r actor", - "▁П ів", - "▁aw ful", - "owa ć", - "] ->", - "▁F ine", - "▁Fin e", - "С а", - "ti s", - "t is", - "ét a", - "é ta", - "▁Ро ди", - "▁Düsseld orf", - "LO B", - "L OB", - "os as", - "osa s", - "wer ke", - "werk e", - "▁l ance", - "▁lan ce", - "▁листо пада", - "▁in complete", - "▁P icture", - "▁ Picture", - "(' \\", - "( '\\", - "es ters", - "est ers", - "ester s", - "este rs", - "e sters", - "▁belong ed", - "▁S ank", - "▁San k", - "am med", - "amm ed", - "▁repos itories", - "▁ad dr", - "▁add r", - "▁ addr", - "Col lect", - "Coll ect", - "H ot", - "▁t yl", - "▁ty l", - "▁instance of", - "▁bon us", - "ov ý", - "▁мо ря", - "▁мор я", - "▁inter active", - "▁interact ive", - "▁M ys", - "▁My s", - "▁Ed mund", - "file Name", - "em or", - "emo r", - "e mor", - "▁Т ри", - "▁R osen", - "▁Ro sen", - "▁Ros en", - "▁Rose n", - "▁Pr ima", - "▁Pri ma", - "▁Prim a", - "▁v oting", - "▁vo ting", - "▁vot ing", - "▁X P", - "▁Z ero", - "▁Ze ro", - "▁ Zero", - "▁L ed", - "▁Le d", - "ams ung", - "▁en ables", - "▁enable s", - "▁redirect s", - "AS T", - "A ST", - "Pa int", - "P aint", - "ack er", - "ac ker", - "a cker", - "le cht", - "▁chair man", - "▁A ven", - "▁Av en", - "▁S ach", - "▁Sa ch", - "▁Sac h", - "(\" <", - "ке р", - "к ер", - "▁mist akes", - "▁mistake s", - "▁We it", - "▁Wei t", - "▁pro wad", - "▁ prowad", - "▁did nt", - "▁didn t", - "én ario", - "un less", - "▁back wards", - "bo a", - "b oa", - "du ino", - "`` `", - "` ``", - "st or", - "sto r", - "s tor", - "Comple tion", - "pu esta", - "▁din ast", - "úl t", - "ú lt", - "▁S Y", - "▁ SY", - "if olia", - "œuv res", - "œuvre s", - "▁r acing", - "▁ra cing", - "▁rac ing", - "▁cab inet", - "▁cabin et", - "▁cut ting", - "▁th umb", - "▁Ка ра", - "▁Кар а", - "high light", - "ку п", - "▁s d", - "▁ sd", - "▁на ціональ", - "▁camp agne", - "▁register s", - "▁educ ational", - "▁education al", - "▁p esar", - "▁pes ar", - "üg e", - "ü ge", - "▁o ro", - "▁or o", - "▁ oro", - "burg o", - "bur go", - "▁Athlet ics", - "▁M TV", - "get Message", - "▁H yp", - "▁Hy p", - "▁vict im", - "▁vic tim", - ")) \\", - ") )\\", - "▁dr ums", - "▁dru ms", - "▁drum s", - "host name", - "ta ł", - "t ał", - "ma king", - "m aking", - "▁pow iat", - "ő d", - "thread s", - "▁absol v", - "▁лю ди", - "▁ste pped", - "▁step ped", - "ex ist", - "▁N K", - "▁v es", - "▁ve s", - "▁ ves", - "ist iche", - "istic he", - "isti che", - "% '", - "at ivos", - "ativ os", - "ati vos", - "ativo s", - "▁та кой", - "▁тако й", - "▁Mongo DB", - "▁U ng", - "▁Un g", - "▁Р ус", - "▁Ру с", - "▁e lim", - "▁el im", - "▁F if", - "ic ación", - "ica ción", - "▁T ennis", - "▁Ten nis", - "▁Jeff erson", - "j án", - "fo g", - "f og", - "an ha", - "anh a", - "zo r", - "z or", - "▁уні версите", - "ah u", - "a hu", - "ia da", - "i ada", - "S dk", - "Set ting", - "▁K ill", - "▁Kil l", - "▁Ki ll", - "▁W end", - "▁We nd", - "▁b ald", - "▁bal d", - "▁ba ld", - "▁K ub", - "▁Ku b", - "▁v isto", - "▁vis to", - "▁vi sto", - "▁je unes", - "▁jeune s", - "▁jeu nes", - "col lections", - "collection s", - "collect ions", - "ac í", - "a cí", - "вро пей", - "▁ar ise", - "он і", - "о ні", - "MA IN", - "до ступ", - "▁b erg", - "▁be rg", - "▁ber g", - "▁ berg", - "▁critic ism", - "▁Tor re", - "▁de script", - "▁des cript", - "▁descri pt", - "ière s", - "i ères", - "▁e studio", - "▁est udio", - "▁estud io", - "▁i li", - "▁il i", - "▁ ili", - "▁mil itare", - "▁milit are", - "▁militar e", - "▁Cl ara", - "▁Cla ra", - "▁Clar a", - "▁El len", - "▁Elle n", - "▁Ell en", - "lim ited", - "limit ed", - "л м", - "▁Esp añ", - "▁inf initely", - "▁infinite ly", - "Amer ica", - "ou c", - "o uc", - "gl ass", - "g lass", - "▁r ud", - "▁ru d", - "▁z at", - "▁za t", - "▁ zat", - "▁r in", - "▁ri n", - "▁ rin", - "▁Bibli ografía", - "▁mer chant", - "tensor flow", - "▁d ér", - "▁dé r", - "▁Active Record", - "IE S", - "I ES", - "▁link er", - "▁lin ker", - "▁estud ios", - "▁estudio s", - "cdn js", - "▁Го судар", - "án chez", - "ap pe", - "app e", - "a ppe", - "cl ub", - "c lub", - "▁dal ší", - "▁Alg orithm", - "df s", - "d fs", - "▁B ac", - "▁Ba c", - "▁ка фе", - "▁& =\\", - "▁&= \\", - "▁а т", - "▁ ат", - "▁Г лав", - "▁M ou", - "▁Mo u", - "M achine", - "(... )", - "( ...)", - "▁com part", - "▁comp art", - "▁compar t", - "▁aug usztus", - "av an", - "ava n", - "a van", - "▁roll ed", - "▁rol led", - "▁ rolled", - "▁е ди", - "▁ еди", - "Sc an", - "S can", - "▁ре гі", - "▁świ ata", - "▁świat a", - "▁m ines", - "▁min es", - "▁mi nes", - "▁mine s", - "}, {", - "▁T ier", - "▁Ti er", - "Can not", - "C annot", - "мі н", - "м ін", - "▁NE W", - "▁ NEW", - "▁Во л", - "▁M anh", - "▁Man h", - "▁Greg ory", - "▁princi pe", - "▁princip e", - "▁prin cipe", - "IS O", - "I SO", - "pr og", - "pro g", - "p rog", - "▁F ail", - "▁Fa il", - "▁ Fail", - "▁a a", - "▁ aa", - "▁fe cha", - "▁W CF", - "▁mag istr", - "▁Z ach", - "▁Za ch", - "▁un icode", - "▁con verter", - "▁convert er", - "▁conver ter", - "▁dis pers", - "▁disp ers", - "ks am", - "k sam", - "▁Un cle", - "Property Changed", - "▁l ider", - "▁li der", - "▁lid er", - "▁o pts", - "▁op ts", - "▁opt s", - "▁ opts", - "▁та м", - "▁ там", - "lock ed", - "loc ked", - "za k", - "z ak", - "▁co unted", - "▁count ed", - "▁coun ted", - "▁person e", - "▁pers one", - "▁hur ried", - "ät ter", - "ätt er", - "ätte r", - "▁out ras", - "▁ou tras", - "▁g enu", - "▁ge nu", - "▁gen u", - "B D", - "ve g", - "v eg", - "du e", - "d ue", - "▁P ract", - "▁Pr act", - "▁Pra ct", - "▁po sible", - "▁pos ible", - "▁cont ribute", - "▁contrib ute", - "▁contribu te", - "UM N", - "▁Bür ger", - "▁w ars", - "▁war s", - "▁wa rs", - "▁exhib ition", - "hi ll", - "h ill", - "▁a str", - "▁as tr", - "▁ast r", - "▁ astr", - "▁му зе", - "▁C ASE", - "▁CA SE", - "▁ CASE", - "man ifest", + "E ur", + "E MENTS", + "E fficacy▁Analys", + "F rom", + "F FIC", + "F ah", + "F DG", + "G B", + "G ,▁G", + "H L", + "H ▁test", + "H ospitalization", + "H ematology", + "H anna", + "I dentification▁Number", + "L L", + "L ung", + "L LN", + "M ay▁", + "M etastas", + "M AT", + "N L", + "O U", + "O ste", + "O ▁NOT", + "O pen-Label,▁Phase▁3▁Study▁of", + "P rofile▁", + "Q uestion", + "R ev", + "R och", + "S qu", + "T ype▁I", + "U LT", + "U rea", + "V itamin▁B12", + "W OG", + "W HS", + "[ 1]", + "] ▁+", + "a j", + "a ▁l", + "a ▁K", + "a ▁subject’s▁", + "b ain", + "b one", + "b olus▁", + "b ittl", + "c at", + "c app", + "c opy▁", + "c apacity", + "c ise▁", + "c Le", + "d -", + "d rogen", + "d estruction", + "d izziness", + "e em", + "e ign", + "e .▁Patients▁", + "e .▁These▁", + "e what", + "e oxy", + "f ive▁", + "f ixed▁", + "f rozen", + "f istula", + "f ine▁needle▁aspir", + "g ast", + "g rant", + "g astroesophageal▁junction", + "h u", + "h ▁t", + "h al", + "h ov", + "h epatic", + "h e▁or▁sh", + "h ives,▁", + "i aries", + "i ak▁A", + "i antonio", + "k ine▁", + "k -1", + "k dr", + "m -", + "m ild", + "m ometer", + "n R", + "n as", + "n utrient", + "o ▁per", + "o ▁Y", + "o ctor", + "p ine▁", + "p uscular", + "p ulse", + "p =0.00", + "r ur", + "r ive▁", + "r inc", + "s iz", + "s \n\nSubject", + "s ource▁document", + "s ..................................................................................", + "s erious,▁", + "s ▁the▁specific", + "s pecimens", + "t )", + "v es", + "v iven", + "v ital", + "v 3.", + "w rit", + "y i", + "y ers▁", "y ellow", - "F n", - "▁R C", - "▁ RC", - "▁s ott", - "▁so tt", - "▁su jet", - "▁S ocket", - "▁So cket", - "▁Soc ket", - "▁ Socket", - "▁Ch ine", - "▁Chi ne", - "▁frame works", - "▁framework s", - "Hol d", - "H old", - "êt s", - "ê ts", - "▁ф іль", - "▁фі ль", - "Lo aded", - "Load ed", - "op he", - "oph e", - "o phe", - "text e", - "tex te", - "▁ex pres", - "▁exp res", - "▁expr es", - "▁cons ume", - "▁consum e", - "▁R ichtung", - "ograf i", - "▁magn ific", - "à t", - "▁ind ul", - "▁indu l", - "ry ty", - "▁off ici", - "▁offic i", - "▁ass ault", - "ru nd", - "run d", - "r und", - "▁vari ants", - "▁variant s", - "▁сель сов", - "▁exc itement", - "Time s", - "Tim es", - "T imes", - "k otlin", - "▁g ering", - "▁ge ring", - "▁ger ing", - "▁En gel", - "▁Eng el", - "▁T imer", - "▁Time r", - "▁Tim er", - "▁Ti mer", - "▁ Timer", - "² ).", - "▁N g", - "äs st", - "sch au", - "SE rror", - "S Error", - "▁Ed wards", - "▁Edward s", - "▁Term inal", - "li ct", - "lic t", - "l ict", - "Un der", - "Und er", - "U nder", - "▁sp awn", - "ür gen", - "▁Außer dem", - "▁k itchen", - "fah rt", - "fahr t", - "▁Col ors", - "▁Color s", - "▁систе ма", - "▁систем а", - "▁termin ated", - "▁terminate d", - "▁La TeX", - "ig keiten", - "igkeit en", - "▁mes ure", - "▁Am ts", - "▁Amt s", - "▁emp ir", - "▁stri king", - "▁strik ing", - "▁exclus ive", - "те х", - "▁re z", - "▁r ez", - "▁ rez", - "▁qu an", - "▁q uan", - "▁Glas gow", - "▁lect ure", - "▁Test ament", - "▁fun ds", - "▁fund s", - "▁st essa", - "▁tri bes", - "▁trib es", - "▁tribe s", - "▁par fois", - "▁tre ball", - "ni tz", - "nit z", - "n itz", - "bo ve", - "b ove", - "▁за слу", - "▁ab sent", - "▁abs ent", - "▁L auf", - "▁La uf", - "▁Lau f", - "Sm ith", - "▁Никола й", - "▁europé enne", - "l r", - "▁program ma", - "▁mi dst", - "▁mid st", - "▁daugh ters", - "▁daughter s", - "S yn", - "ob en", - "obe n", - "o ben", - "ân ă", - "id an", - "ida n", - "i dan", - "▁t her", - "▁th er", - "▁the r", - "▁ ther", - "od ore", - "odo re", - "odor e", - "sd l", - "s dl", - "▁Q uint", - "▁Qu int", - "▁cas os", - "▁caso s", - "▁Z am", - "▁Za m", - "▁стра ны", - "▁sp rite", - "▁spr ite", - "ка л", - "к ал", - "▁n asc", - "▁na sc", - "▁nas c", - "▁сот руд", - "▁tr ava", - "▁tra va", - "▁trav a", - "▁хо зяй", - "▁U ruguay", - "▁s parse", - "▁sp arse", - "▁по ле", - "▁пол е", - "▁myst ery", - "▁myster y", - "▁M ang", - "▁Man g", - "▁Ma ng", - "reg istr", - "▁CG Float", - "▁sub mission", - "▁subm ission", - "ва на", - "ван а", - "в ана", - "▁\" :", - "▁ \":", - "▁Trace back", - "▁P it", - "▁Pi t", - "▁E hr", - "▁с ра", - "▁Graph ics", - "▁ Graphics", - "Up dated", - "Update d", - "▁sv ensk", - "▁sp acing", - "▁spac ing", - "tr itt", - "tri tt", - "t ritt", - "▁Gu inea", - "▁Fran ça", - "▁Fr ança", - "As soci", - "Ass oci", - "▁T ová", - "▁To vá", - "st ab", - "sta b", - "s tab", - "▁Le arning", - "▁Lear ning", - "▁B right", - "▁Br ight", - "▁Brig ht", - "ś c", - "▁id ő", - "}} _{\\", - "}}_{ \\", - "}}_ {\\", - "} }_{\\", - "▁dro ite", - "▁droit e", - "▁ra ising", - "get ting", - "yth m", - "yt hm", - "y thm", - "on yme", - "ony me", - "onym e", - "ż s", - "▁b lah", - "▁bl ah", - "▁bla h", - "▁ blah", - "Tag Name", - "Vert ical", - "▁a per", - "▁ap er", - "▁ aper", - "post gresql", - "▁Hand le", - "▁ Handle", - "ze w", - "z ew", - "▁sk ulle", - "▁op ere", - "▁oper e", - "lay ers", - "layer s", - "▁pos sono", - "▁poss ono", - "▁re late", - "▁rel ate", - "▁rela te", - "ą c", - "▁M ih", - "▁Mi h", - "â ge", - "▁Ś wi", - "iss es", - "isse s", - "▁serv let", - "▁ servlet", - "Lo s", - "L os", - "▁Ad vanced", - "▁Adv anced", - "at ica", - "ati ca", - "atic a", - "▁c ed", - "▁ce d", - "▁ ced", - "▁element os", - "ро на", - "рон а", - "р она", - "ik s", - "i ks", - "ar f", - "a rf", - "ar iat", - "ari at", - "aria t", - "M obile", - "ag ua", - "agu a", - "▁t imp", - "▁tim p", - "▁ti mp", - "▁Com ité", - "▁comb ining", - "▁combin ing", - "wo hl", - "w ohl", - "▁Stud y", - "▁Stu dy", - "co ordinate", - "▁recommend ation", - "▁transform ations", - "▁transformation s", - "un til", - "unt il", - "u ntil", - "bound ed", - "b ounded", - "▁и зу", - "▁из у", - "han ced", - "h anced", - "▁во про", - "▁P rés", - "▁Pr és", - "▁co ord", - "xt y", - "x ty", - "▁$ ,", - "▁ $,", - "▁champion s", - "▁champ ions", - "De n", - "D en", - "M il", - "(' ,", - "( ',", - "▁Pre is", - "▁e igh", - "▁eig h", - "▁mark ers", - "▁marker s", - "▁gew esen", - "ät ten", - "ätt en", - "ätte n", - "▁p ione", - "▁pi one", - "m v", - "▁ј у", - "▁ ју", - "zeich nis", - "ho ff", - "hof f", - "h off", - "New s", - "Ne ws", - "▁Stanis ław", - "▁Br andenburg", - "▁Brand enburg", - "▁Fe uer", - "= &", - "же т", - "ж ет", - "▁N eil", - "▁Ne il", - "▁w irk", - "▁wir k", - "▁soci età", - "▁sp are", - "▁civil e", - "▁civ ile", - "sp rach", - "spr ach", - "▁d isse", - "▁dis se", - "▁diss e", - "▁g ates", - "▁ga tes", - "▁gate s", - "▁gat es", - "▁a nom", - "▁an om", - "▁ano m", - "▁Федера ции", - "▁t ib", - "▁ti b", - "▁f útbol", - "▁Wikip ed", - "ia te", - "iat e", - "i ate", - "Fr ont", - "F ront", - "▁c raw", - "▁cr aw", - "▁cra w", - "▁R ak", - "▁Ra k", - "▁з ву", - "▁зв у", - "st reet", - "stre et", - "▁A gency", - "▁Ag ency", - "ва ло", - "вал о", - "▁Ра с", - "▁mk dir", - "ac ję", - "▁sh ares", - "▁share s", - "St ory", - "Sto ry", - "▁re marks", - "▁rem arks", - "▁remark s", - "▁key words", - "▁keyword s", - "Bo b", - "B ob", - "▁t oe", - "▁to e", - "▁V itt", - "▁Vi tt", - "▁Vit t", - "▁r hs", - "▁rh s", - "RO P", - "R OP", - "or is", - "ori s", - "o ris", - "/ @", - "си и", - "▁tra verse", - "▁travers e", - "▁refer encing", - "pr äsident", - "ro ng", - "ron g", - "r ong", - "') :", - "' ):", - "at ies", - "ati es", - "atie s", - "a ties", - "A W", - "Out let", - "▁é vol", - "▁év ol", - "ik es", - "ike s", - "i kes", - "▁environment al", - "ic um", - "▁L ied", - "▁Li ed", - "▁Lie d", - "▁w arn", - "▁war n", - "▁wa rn", - "▁ warn", - "▁But ler", - "▁% ),", - "▁%) ,", - "▁Zeit schrift", - "▁Mon tr", - "▁Mont r", - "в�� жа", - "▁Mer cur", - "je kte", - "jekt e", - "me ter", - "met er", - "m eter", - "du cation", - "▁att ributed", - "▁attribute d", - "* $", - "▁un f", - "▁Vert rag", - "zi en", - "zie n", - "z ien", - "▁Р об", - "▁Ро б", - "li ces", - "lic es", - "lice s", - "l ices", - "pp ly", - "p ply", - "an sen", - "ans en", - "anse n", - "▁ze it", - "▁ zeit", - "▁im mense", - "▁imm ense", - "▁lut ego", - "▁Bul gar", - "▁Bulg ar", - "▁mi embros", - "▁На циональ", - "▁Al low", - "▁All ow", - "▁ Allow", - "▁ang lès", - "д ви", - "▁T oy", - "▁To y", - "ту а", - "▁y ard", - "▁ya rd", - "▁ yard", - "( %", - "is ser", - "iss er", - "isse r", - "▁g olf", - "▁gol f", - "▁Uk rain", - "▁h osp", - "▁ho sp", - "▁hos p", - "In clude", - "▁L isa", - "▁Li sa", - "▁Lis a", - "▁c sal", - "▁cs al", - "▁M ira", - "▁Mi ra", - "▁Mir a", - "rec ogn", - "▁К е", - "▁h itting", - "▁hit ting", - "коно мі", - "коном і", - "▁Tourn ament", - "LO AD", - "▁Guard ian", - "▁da her", - "▁dah er", - "▁time zone", - "▁tom cat", - "▁ tomcat", - "▁success or", - "▁succ essor", - "▁successo r", - "▁V oid", - "▁Vo id", - "▁come ç", - "▁convert s", - "▁conver ts", - "äch s", - "ä chs", - "os ex", - "ose x", - "o sex", - "xe lles", - "x elles", - "as er", - "ase r", - "a ser", - "▁É s", - "▁m ou", - "▁mo u", - "▁u ng", - "▁un g", - "▁ ung", - "▁or igen", - "▁orig en", - "▁C row", - "▁Cr ow", - "▁Cro w", - "▁E rd", - "▁Er d", - "▁s ieben", - "▁si eben", - "▁sie ben", - "lu a", - "l ua", - "▁B B", - "▁ BB", - "RE NT", - "R ENT", - "▁pił kar", - "▁mar que", - "▁marqu e", - "▁La bour", - "▁Lab our", - "vi ders", - "vider s", - "vid ers", - "v iders", - "▁ex empl", - "▁exem pl", - "So und", - "S ound", - "▁W ass", - "▁Was s", - "▁Wa ss", - "arr ison", - "▁те чение", - "▁Of icina", - "▁D aw", - "▁Da w", - "▁K auf", - "▁Ka uf", - "én t", - "é nt", - "és ő", - "▁= \"", - "▁ =\"", - "▁k at", - "▁ka t", - "di ction", - "dict ion", - "dic tion", - "d iction", - "▁V oll", - "▁Vol l", - "▁Vo ll", - "▁high way", - "J ames", - "ze uge", - "zeug e", - "▁mod elo", - "▁model o", - "▁mode lo", - "Th row", - "▁F orum", - "▁For um", - "▁Fo rum", - "(\" @", - "▁en fer", - "▁enf er", - "▁спе циаль", - "Number s", - "Num bers", - "▁B inary", - "▁Bin ary", - "▁ Binary", - "▁Martí nez", - "▁Martín ez", - "▁St ato", - "▁Stat o", - "▁Sta to", - "▁fest iv", - "▁k atol", - "▁ka tol", - "▁kat ol", - "▁А б", - "▁lim itation", - "▁limit ation", - "▁S TR", - "▁ST R", - "▁ STR", - "▁О фициаль", - "ip es", - "ipe s", - "i pes", - "▁I sn", - "▁Is n", - "▁rule d", - "▁ru led", - "▁c í", - "▁ cí", - "ge ber", - "geb er", - "▁lavor o", - "▁lav oro", - "▁parenthes es", - "о з", - "▁équip es", - "▁équipe s", - "▁efficient ly", - "▁Per iod", - "▁ Period", - "▁Reg arding", - "le af", - "lea f", - "▁similar ity", - "▁gest ure", - "data b", - "da tab", - "dat ab", - "▁term inate", - "▁termin ate", - "▁sem antics", - "▁semantic s", - "▁A lo", - "▁Al o", - "▁c ig", - "▁ci g", - "▁Open GL", - "▁heut igen", - "xa ml", - "x aml", - "▁frequ encies", - ")} .", - ") }.", - "▁threaten ed", - "▁threat ened", - "ти к", - "▁cal cio", - "▁calci o", - "▁calc io", - "▁R iemann", - "▁Ri emann", - "sl ug", - "▁F inale", - "▁Fin ale", - "▁Final e", - "L R", - "▁Der by", - "▁о ще", - "▁de viation", - "▁dev iation", - "▁devi ation", - "äch en", - "äche n", - "ä chen", - "▁C ris", - "▁Cr is", - "но во", - "нов о", - "н ово", - "▁сто лі", - "▁re lev", + "z a▁n", + "’ ▁button", + "“ chronic", + "“ symptomatic▁deterioration", + "” )", + "” ▁if", + "▁ —", + "▁ ra", + "▁ elect", + "▁ e▁m", + "▁ ________", + "▁ eg,▁", + "▁ **", + "▁ optimal", + "▁ role▁in", + "▁ routinely▁", + "e▁ F", + "e▁ d▁", + "e▁ one▁", + "e▁ are▁", + "e▁ model", + "in us", + "in hibit", + "in flamm", + "in ▁our", + "in -line▁filter", + "in vit", + "in ▁nature", + "at ▁the\n\n", + "at ▁the▁tim", + "at abas", + "at ▁anytim", + "at al▁outcom", + "at ▁the▁discretion▁of▁the▁treat", + "on to", + "on ▁baseline▁", + "on avir", + "\n\n po", + "\n\n drug", + "\n\n arm", + "\n\n level", + "\n\n reaction", + "\n\n ________________", + "\n\n overall▁survival", + "\n\n ___", + "▁a ▁different", + "▁a ▁statistically▁significant", + "en al", + "en able▁", + "er on", + "or i", + "or s▁of", + "or ▁through", + "or ▁follow-up", + "or ▁within", + "or ▁preclinical▁data", + "s▁ 9", + "s▁ 11", + "s▁ is▁not", + "s▁ ..........................................................................................", + "s▁ ....................................................", + "s▁ deemed▁", + "s▁ gain", + "s▁ vary▁", + "re ll", + "re as▁", + "re ech", + "re cord▁of", + "re veal", + "▁th reatening", + "▁th ymidylate▁synth", + "al ang", + "al ong", + "st ay▁", + "st able", + "it re", + "it e▁for", + "▁the▁ current", + "▁the▁ follow-up", + "▁the▁ randomization", + "▁the▁ original▁", + "▁the▁ blinded▁treatment▁phas", + "an e▁", + "an ▁D", + "an ▁G", + "an y▁of", + "an alogu", + "an ▁immediate▁hazard", + "an algesia", + ",▁ study▁", + ",▁ In", + ",▁ 40", + ",▁ drug", + ",▁ NC", + ",▁ under", + ",▁ study▁treatment", + ",▁ due▁to", + ",▁ high", + ",▁ wher", + ",▁ what", + ",▁ erlotinib", + ",▁ such▁as", + ",▁ especially▁", + ",▁ glucos", + ",▁ fatigue,▁", + ",▁ representative▁of▁all▁involved▁organ", + ",▁ 2▁weeks▁off", + "ed▁ no", + "ed▁ disease▁", + "▁an ▁assessment▁of", + "▁an ▁important", + "▁an imal▁", + "ic o", + "................ ....", + ".▁ p", + ".▁ d▁", + ".▁ INTRODUCTION", + "ed -up", + "ed .\n\nS", + "ed ,▁as▁", + "ed .▁Patients▁with", + "▁p age", + "▁p alli", + "▁p ush", + "▁p ackag", + "▁c it", + "▁c ovariates", + "ing ▁M", + "ing ▁hormone▁", + "ing ▁cause▁of", + "▁b id", + "▁b i-", + "▁b icalutamide▁", + "▁b arrier", + "▁b olus", + "▁b eside▁the▁error", + "es .▁If", + "es \n\nThe▁", + "es e▁data", + "es \n\nof", + "ation ▁from", + "▁to ▁placebo", + "▁to ▁compar", + "▁to ▁withdraw", + "▁to ▁Treatment", + "▁to ▁the▁sponsor", + "▁to ▁conduct", + "▁to ▁50", + "▁to ▁take▁", + "▁to ▁reduc", + "▁to ▁determine▁", + "▁to ▁creatinine▁", + "▁to ▁control", + "▁to ▁evaluate▁", + "▁to ▁follow▁up", + "▁to ▁determine▁whether", + "▁to ▁measure▁", + "▁to ▁provide▁a", + "▁to ▁0.9", + "▁to ▁characterize▁the▁objective▁tumor▁respons", + "▁to ▁attest▁that", + "is -", + "is ▁assum", + "▁s ens", + "▁s low", + "▁s ince▁the▁treatment▁start", + "▁s era", + "as es▁of", + "as ed▁upon", + "▁of ▁ABX-EGF", + "▁of ▁protein", + "▁of ▁malignanc", + "▁of ▁chest,▁abdomen", + "▁d ress", + "▁d ella", + "▁d iction", + "▁d egrad", + "th ▁subject", + "th ey▁", + "▁m uch", + "▁m argin", + "▁m ioc", + "▁and▁ 2", + "▁and▁ 9", + "▁and▁ 12", + "▁and▁ report", + "▁and▁ 36", + "▁and▁ Appendix", + "▁and▁ maintain", + "▁and▁ zoledronic▁acid▁", + "▁and▁ fatigu", + "▁and▁ ANC", + "▁and▁ KRAS▁mutation", + "▁and▁ colleagu", + "▁and▁ 0.22-micron", + ".\n\n Z", + ".\n\n f", + ".\n\n h", + ".\n\n Clinical▁", + ".\n\n Withdrawal▁of", + "ill ip", + "al▁ infection", + "al▁ Therapy", + "el ��L", + "ol ar", + "ol ac", + "ab normal▁", + "ab solute▁", + "is▁ with", + "is▁ performed", + "is▁ restricted▁to", + "iv e▁t", + "iv e▁to", + "iv e-", + "iv ari", + "iv otal", + "▁in ▁W", + "▁in ▁clinical▁trial", + "▁in ▁any▁other", + "▁in ▁patients▁receiving", + "▁in ventor", + "▁in surance▁", + "im eter", + "im balanc", + "im onthly▁", + "ev olv", + "res s▁s", + "ig in", + "ig rad", + "00 9", + "id ence▁", + "oc abul", + "oc ally▁Ad", + "▁1 ,", + "▁1 12", + "▁1 -year", + "▁C ).\n\n", + "▁C ardi", + "▁C ediranib", + "▁C alcium", + "▁C LINICAL", + "os s▁of", + "es▁ C", + "es▁ during", + "▁P leas", + "▁P rednisone▁", + "▁P ost-Study▁", + "pro c", + "pro p", + "il uent", + "▁( “", + "▁( 200", + "▁( 16", + "▁( plac", + "▁( US", + "▁( 3)", + "▁( CTCAE", + "▁( test", + "▁( Grade▁3", + "▁( FOLFIRI", + "▁( include▁", + "▁( femal", + "▁( limited▁to", + "▁( ie,", + "em ic", + "em ur", + "em al▁A", + "▁2 .2.2", + "▁2 ▁x▁ULN", + "▁2 50▁mg/m2", + "us ed▁or", + "ul man", + "con vert", + "con struct", + "con nect", + "anc e▁that", + "if er", + "if ▁not", + "▁S L", + "▁S op", + "▁S pecific", + "▁S OC", + "▁S ee▁Section", + "▁I P", + "▁I gG", + "▁re test", + "▁re appear", + "ot or", + "ot ny▁", + "un controlled▁", + "un adjusted▁HR", + "un born▁bab", + "▁D ,▁B", + "▁h old▁", + "▁l ev", + "▁l iqu", + "▁l ength", + "e▁of ▁the▁s", + "e▁of ▁principal▁investigator", + "▁E th", + "▁E lig", + "▁E ffusion", + "▁f ile▁", + "▁f resh", + "ver y▁s", + "ch er", + "ch ill", + "▁or ▁G", + "▁or ▁may▁", + "▁or ▁consent", + "▁or ▁commercial", + "▁or ▁NO", + "▁or ▁matching▁placebo", + "e▁t ell", + "e▁t empor", + "ir radiation", + "ut ero", + "ut aneous▁", + "ys phagia", + "form yltransfer", + "\n\nP eri", + "\n\nP regnancy▁", + "\n\nP emetrexed▁H3E-MC-JMHR", + "iz ed,▁", + "iz ed▁c", + "iz ed▁tomograph", + "ex hibit", + "ex cipient", + "ex press▁", + "qu iv", + "ec itumumab", + "▁n utritional▁", + "▁n arratives▁of", + "per ▁the▁", + "\n\nA s", + "\n\nA ▁copy▁of", + "\n\nA ▁X▁D", + "ate▁ if", + "study▁ site▁", + "▁and ▁also", + "▁and ▁administration▁of", + "▁O ▁N", + "▁O ME", + "▁as ▁the▁independent", + "▁pro ven", + "▁pro phylactic", + "all ic", + "all el-", + "▁T 4", + "▁T echnetium▁99", + "up set", + "▁N 1", + "▁N A", + "▁N /A", + "▁N SAID", + "vestig ation▁of", + "op apular", + "will▁be▁ performed▁at", + "will▁be▁ kept", + "ast iere▁", + "▁for ▁patient", + "▁for ▁subjects▁with", + "▁for ▁specific", + "▁for ▁further▁detail", + "▁for ▁any▁other▁reason", + "and ▁after", + "and ▁then", + "▁R D", + "▁R ash", + "▁R equisition▁Form", + "e\n\n 2", + "▁treatment ▁given", + "▁treatment ▁rest", + "▁treatment ▁regimens", + "▁treatment -by-", + "▁treatment ▁administered▁for", + "study ,▁a", + "ed▁to xicity▁", + "ed▁to ▁ensure▁that", + ".1 .\n\nStudy▁", + "og astric", + ".2 .7", + "▁with ▁other", + "▁with ▁respect▁to", + "▁with ▁the▁longest▁diameter", + "ed▁b ecause▁of", + "min otransfer", + "s▁of ▁tumor", + "s▁of ▁CYP3A4", + "s▁of ▁the▁target▁lesion", + "s▁of ▁the▁dispens", + "be▁ readily", + "ant a", + "ant s▁of", + "\n\nS et", + "\n\nS urvival", + "\n\nS ummary▁of", + "▁that ▁persist", + "▁200 5)", + "▁is▁ conduct", + "▁is▁ stopp", + "▁is▁ expos", + "▁is▁ found▁to", + "▁is▁ hypothesiz", + "▁is▁ strongly▁encouraged▁to", + "▁is▁ unique▁to▁the▁individual", + "▁will▁be▁ considered▁", + "▁will▁be▁ allow", + "▁will▁be▁ used", + "▁will▁be▁ mail", + "▁will▁be▁ included▁in▁the▁", + "▁will▁be▁ censored▁on", + "▁will▁be▁ left▁to", + "e▁s unitinib", + "e▁s equ", + "e▁s ubsequent", + "eri ous▁infusion", + "art in", + "e▁th en", + "e▁th e▁treatment", + "▁M en", + "▁M etastas", + "▁M MR", + "▁M SS", + "▁r hin", + "▁0 .4", + "▁3 .3.2", + "▁3 2:", + "▁3 .3.3", + "▁con cerning", + "ust hov", + "e,▁ it", + "e,▁ patients▁", + "e,▁ platelet", + "e,▁ i.e.,▁", + "e,▁ incidence,▁", + "▁o xy", + "▁o ▁x▁ic▁", + "▁F IG", + "▁F emal", + "▁F leming", + ".▁A ▁recent", + ".▁A ▁second▁", + ".▁The▁ result", + ".▁The▁ analysis▁", + ".▁The▁ DMC", + ".▁The▁ use▁of", + ".▁The▁ monitor", + ".▁The▁ IEC/IRB", + "▁as▁ required", + "▁g ender", + "▁g lobal▁", + "not ▁consent", + "not ▁experienc", + "not ▁been", + "not ▁meeting", + "as▁ defined▁in▁Section", + "01 )", + "▁the▁s can", + "▁the▁s oftware’s▁“audit▁trail”", + "▁are▁ protein", + "▁are▁ described▁in▁Section", + "▁on ▁the▁s", + "▁on ▁active▁treatment▁than▁on▁placebo", + ",▁and▁ Amgen", + "rad ycardia", + "ated▁ study▁", + "ated▁ from", + "ated▁ with▁the▁", + "ition ▁of▁the▁", + "▁L ett", + "▁B iol", + "▁B ased▁on▁the▁", + "▁B AP", + "ific ance▁of", + "▁this▁ question", + "▁this▁ confidential▁information", + "s,▁ 200", + "s,▁ other▁than", + "s,▁ including▁the▁", + "s,▁ method", + "s,▁ lymphocyt", + "s,▁ laboratory▁and▁", + "▁y es▁", + "▁y ellow", + "▁all ▁data", + "▁all ▁study▁drug", + "▁all ▁patients▁who", + "▁all ▁samples▁", + "▁all ▁sites▁of▁disease▁", + "ary▁ lesion", + "12 -month", + "▁analys es▁in", + "▁st ruct", + "\n\nC LINICAL", + "▁ch emon", + "▁ch imeric", + "▁will ▁follow", + "▁will ▁comply▁with", + "▁will ▁employ", + "▁will ▁correct", + "e▁in ▁a", + "e▁in jection", + "e▁in strument", + "▁5 .2.1", + "▁5 .1.1", + "▁5 .2.2", + "▁6 ▁to", + "▁6 .1.3", + "from ▁other", + "▁H M", + "▁H igh", + "▁H ospitalization", + "▁subject ▁confidentiality▁", + "▁patients▁ for", + "▁4 47", + "▁4 .3.2", + "ew art", + ")\n\n 3", + ")\n\n T", + ")\n\n With", + ")\n\n (X", + "▁at ▁your", + "▁at ▁the▁investigator’s▁discretion", + "▁at ▁immediate▁risk▁of▁death", + "ay bittl", + "ampl e▁Siz", + "s▁( 2", + "s▁( C", + "s▁( G", + "▁ac knowledg", + "▁ac compani", + "▁ac ne-", + "eg ,▁p", + "▁study▁ document", + "▁study▁ requirement", + "▁study▁ observation", + "continu ed", + "continu e▁on", + "ident ity▁of▁investigational▁product", + "lo ia", + "s▁in ▁addition▁to", + "s▁in ▁women▁with", + ".5 5", + "s.▁ (", + "▁week ▁of▁rest", + "ens ure▁", + "ens e▁or", + "rit onavir", + "▁any▁ clinical", + "▁any▁ remaining", + "▁any▁ component", + "▁V ery▁", + "▁the▁t ransfer", + "▁the▁t ablet", + "ell 'Inf", + "▁wh ite▁", + "\n\nD ocetaxel", + "ed▁by \n\n", + "ed▁by ▁the\n\n", + "ed▁by ▁treatment▁arm", + "urv ey", + "▁after ▁pemetrex", + "▁after ▁carboplatin", + "▁after ▁discontinuation▁of▁treatment", + "ed▁for ▁consist", + "ed▁on ▁an", + "19 8", + "e▁d etermin", + "e▁d ate▁of", + "e▁d epend", + "e▁d esign", + "e▁d escription", + "e▁d o▁not", + "e▁d oes▁not", + ".▁S ch", + ".▁S urvival", + ".▁S ingle-", + ".0 ▁month", + "ob vious▁", + "▁patient s.▁S", + "s▁will▁be▁ collect", + "s▁will▁be▁ administer", + "s▁will▁be▁ conduct", + "▁have▁ caus", + "▁have▁ access", + "▁G emcitabin", + "▁un desirable▁medical▁condition", + "▁un willing▁or▁unable▁to▁comply▁with", + "ard ico", + "▁e jection", + "▁e -mail", + "▁J ,▁L", + "ov ind", + "▁tim ing,▁s", + "AE s,▁", + ".▁P oly", + ".▁P articipant", + ".▁P lacebo", + "\n\nE astern▁Cooperative▁Oncology▁Group", + "\n\nE stimated▁Study▁Duration", + "\n\nE fficacy▁and▁pharmacodynamic", + "),▁ will▁be▁", + "▁ant im", + "▁from ▁study▁", + "s\n\n R", + "s\n\n T", + "s\n\n [", + "s\n\n .▁T▁N▁E▁M▁U▁C▁O▁D", + "s\n\n New", + "s\n\n Y▁P▁O▁C", + "evalu ation▁of▁the▁study", + "▁is ▁a▁s", + "▁is ▁appropriate▁", + "▁not ▁indicated", + "▁tumor ▁model", + "▁may▁ withdraw", + "s▁for ▁verification", + "ement s▁should▁", + "▁7 )", + "▁7 .9", + "▁7 ▁days▁", + "su persed", + "▁month s▁from", + "▁month s▁in▁the▁", + "▁dos e,", + "▁dos es▁(", + "▁dos es▁are▁", + "▁dos es,", + "ction ▁to▁be▁", + "effect ▁is▁", + "CT D", + ",▁the▁ use▁of", + "e- adjusted▁", + "▁adverse▁event s", + "▁adverse▁event s▁were▁", + "vid ence▁", + "▁per ▁mL", + "e▁v alid", + "e▁v ocabul", + "str at", + "▁10 .5.1", + "▁10 .5.2", + "▁10 .▁STATISTICAL▁CONSIDERATIONS", + "ibl e▁method", + ".6 .4", + "can s▁were▁not▁performed▁at▁this▁time▁point", + ".▁In dividual", + ".▁E THICS", + ".▁E thical▁Review", + "▁assessment s▁for", + "record ed▁from", + "record s▁from", + "s.\n\n B", + "s.\n\n 11", + "s.\n\n C▁I▁N▁O▁R▁T▁C▁E▁L▁E", + "RA NCE", + ",▁and ▁their", + ",▁and ▁any▁other", + ".▁C ell", + ".▁C alcium", + ".▁C reatinine▁Clear", + "11 7", + "▁sign ▁of", + "▁sign alling", + "AL P", + "40 ▁–▁ag", + "peri pheral▁neuropath", + "par s", + "drug ?", + "drug ▁administration", + "drug ▁storage▁", + "drug ▁accountability", + "drug s▁taken▁in▁combination▁with", + ",▁or ▁both", + ",▁or ▁if▁you", + "CR \n\n", + "ed▁at ▁the▁end▁of", + "▁in▁the▁ event", + "▁in▁the▁ eCRF", + "ym pos", + "ym met", + "radi oisotop", + "e.\n\n 11", + "▁disease▁ fre", + "): ▁a", + "yp ed▁or", + "▁9 .0", + "\n\nX\n\nX \n\nX▁X", + ".,▁ K", + ".,▁ W", + "▁8 .5.1", + "▁8 .12", + "e▁( S", + "e▁( including", + "first ▁day▁of", + "▁us ed▁", + "▁us ed▁in▁this▁study", + "▁us ed▁in▁combination▁with", + "▁us e▁vocabul", + "\n\nProduct: ▁ABX-EGF▁Protocol▁Number:▁20020408▁Amendment▁4▁Date:▁26▁April▁2005\n\nPage▁", + "\n\nN 1", + "e▁for ▁completion", + "he it", + "ran ial▁", + "30 ▁and▁M", + "▁data ▁record", + "▁data ▁received▁at", + "▁data )▁provided▁that", + "every▁ other", + "every▁ week", + "every▁ 32", + "every▁ 21▁days", + "▁trial s▁in", + "▁trial ▁compar", + "▁trial ▁material", + "▁trial ▁comparing", + ".7 9", + "arm Dx", + "\n\n2 \n\nAmbulatory▁and▁capable▁of▁all▁s", + "▁should▁be▁ withheld▁", + "▁should▁be▁ signed▁and▁personally▁dat", + "▁should▁be▁ prepared▁in", + "earch ▁for", + "▁other s?", + "ne quiv", + "▁the▁investigator ▁will", + "▁the▁investigator ▁wish▁to▁assign▁the▁study▁records▁to", + "subject s▁will▁be▁", + "subject ▁who", + "subject s”", + "▁your ▁current", + "Study▁ Plan", + "ind ler", + "NC IC", + "▁- 20°C", + "▁to▁be▁ used▁at", + "▁pre clinical", + "▁pre cision", + "ed▁as▁ having", + "24 00", + "24 ▁week", + "24 -hour", + "▁has▁ demonstrated", + "▁Study▁ Endpoints", + "▁Study▁ Candid", + "des pit", + "▁a▁s econd", + "▁a▁s pecial", + "▁a▁s olit", + "\n\nF ax", + "▁cycl e.▁", + "present ▁at▁the▁", + "present ▁and▁no", + "14 ▁days", + "\n\nT 1", + "\n\nT arget", + "e, ▁their▁spous", + "\n\n3 3", + "\n\n3 5", + "\n\n3 .\n\nEXPERIMENTAL▁PLAN", + "000 ▁µg", + "▁im plication", + "▁im partial", + "protocol ▁signature▁p", + "▁the▁patient ’s", + "ed,▁ double-blind", + "▁The▁ primary", + "▁follow ▁a", + "▁follow ing▁", + "ification ▁of▁the▁", + ".▁D epending▁on", + ".▁D uration▁of", + "▁the▁l arg", + "▁the▁l aboratory", + "▁the▁l iver", + "▁the▁l umbar▁spine▁", + "▁the▁l og-rank▁test", + "ST S/", + "no ▁prior", + "s▁are▁ original", + "s▁are▁ no▁longer", + "▁dose▁ (mg)▁=", + "▁reg ister", + "y,▁ is▁", + "y,▁ including▁a▁ruler▁to▁estimate▁the▁size▁of▁the▁lesion", + "complet e,▁and▁", + "complet ed▁within", + "pr iv", + ".\n\nA c", + ".\n\nA ▁subject", + "▁ob es", + "▁ob viously▁", + "efficac i", + "\n\nThe▁ first", + "\n\nThe▁ study▁will", + "▁toxic ity▁of", + "\n\n4 .7.1", + ".▁F ever", + "ically▁ Significant", + "data ▁will▁not▁be▁", + "data ▁collection", + "e▁b owel", + "e▁b ody▁", + "5- 10", + "require s▁in-", + "unit ▁errors▁(", + "s▁that ▁may▁be▁", + "23 ▁2", + "23 .5", + "23 -3", + "\n\nI ▁worry", + ",▁S ug", + ",▁S imon", + ",▁S ien", + "▁panitumumab ▁infusion", + "defin ed▁in▁the▁", + "s▁or ▁inspection", + "s▁or ▁retest", + "ymptom s▁of", + "car e▁of▁the▁patient", + "es,▁ if", + "es,▁ it▁is▁", + "▁car ri", + "▁car bon", + "▁was▁ 10", + "▁was▁ given", + "▁was▁ freely▁", + "▁Clinical▁ Trial▁", + "in▁the▁ CRF", + "in▁the▁ case▁report▁form", + "▁death s▁occurring", + ".\n\nS IGNATURES", + ")▁ ×", + "e▁treatment ▁at", + "5% ▁significance▁level", + "must▁be▁ complet", + "must▁be▁ taken", + "must▁be▁ done▁", + "199 0;", + "dos e", + "dos e,▁", + "patients▁ must▁be▁", + "SC CHN", + "e▁and▁ blood▁", + "provid es▁", + "provid ed\n\n", + "urvival▁ in", + "rough t", + "ed▁and▁ be▁readily", + "▁di astolic", + "▁An ▁independent", + "▁An drogen", + "▁the▁study▁ will▁be▁", + "▁the▁study▁ will", + "▁the▁study▁ investigator", + "▁the▁study▁ may▁be▁", + "▁the▁study▁ site▁personnel", + "▁includ ing▁the▁", + "may▁be▁ judged▁to▁be▁due▁to", + "may▁be▁ asked▁to▁sign", + "▁must▁be▁ confirm", + "▁must▁be▁ reported▁to", + "s: ▁", + "▁infusion al▁5-fluorouracil", + "▁infusion ▁set-up", + "ox ▁model", + "enter ed", + "enter ed▁in", + ".▁R isk", + ".▁R EG", + "▁sit es▁(", + "▁sit e▁facil", + "▁sit e▁initi", + "enroll ed▁to", + "consider ed▁by▁the▁investigator▁to▁be▁", + "\n\n0 .8", + "\n\n0 \n\nFully▁active,▁able▁to▁carry▁on", + "▁year ly▁", + "▁year s▁after▁the▁last", + "▁the▁subject ▁signs", + "▁the▁subject ▁does▁not▁wish▁to", + "Investigator ▁must", + "▁complet e\n\n", + "▁complet e▁description", + "\n\nH uman", + "▁group ▁sequential", + "▁this▁study ▁and▁for", + "discontinu ing▁the▁", + "▁Com mission", + "▁approximately▁ 7", + "▁approximately▁ 16", + "▁particip ate,▁", + "▁discontinu es", + "ES P", + "ES ▁or▁NO", + "randomiz ed\n\n", + "randomiz ed▁to▁the▁", + "St atistical", + "St ratification", + "valu e▁in", + "document ed▁as▁", + "inc e▁treatment▁start", + "crib ing", + "▁ind welling", + "duc ed▁by▁", + "ed\n\n from", + "ed\n\n by", + ".▁B lood", + "ish ed▁", + "response▁ rate▁of", + "▁and/or ▁to", + "▁and/or ▁written▁statement", + ".8 .▁Treatment▁Compliance▁", + "ed▁s hould▁be▁", + "\n\nx \n\nPage▁", + "▁= ▁sever", + "▁= ▁No", + "▁= ▁absolute▁neutrophil▁count", + "\n\n6 1", + "\n\n6 5", + ".▁M ethod▁of", + ".▁M iller", + "▁provid ed▁by▁", + ")▁and▁ its▁", + ")▁and▁ progression-free▁survival▁(PFS)▁compared▁to", + "▁event s▁(", + "▁event s:", + "cess ive▁", + "▁disease▁progression ;", + "▁disease▁progression ▁(per", + "▁should▁ be▁taken", + ",▁s afety,▁", + ",▁s evere▁", + ",▁s pecify", + "loc ated▁and▁destroy", + "▁these▁ assessment", + "s▁b eyond", + ",▁M N▁55", + ",▁200 2", + "▁sh ock", + "elect as", + "▁may▁be▁ a", + "▁may▁be▁ found▁in▁the▁", + ".▁H ow", + "▁mor bid", + "s▁will ▁include▁a", + "cin amide▁ribonucle", + "▁must ▁also▁be▁", + "▁must ▁agree▁to", + "▁loc ally▁", + "medication ▁for", + "observ ed,", "▁rel ev", - "▁splend id", - "▁у чё", - "er ving", - "erv ing", - "ga ble", - "g able", - "▁général e", - "▁généra le", - "po m", - "p om", - "▁Che ers", - "▁impr ison", - "▁in dent", - "▁ind ent", - "▁inde nt", - "▁ indent", - "▁anal yz", - "▁analy z", - "▁re vert", - "▁rev ert", - "▁reve rt", - "▁rever t", - "ér er", - "ére r", - "é rer", - "▁ph ases", - "▁phase s", - "First Name", - "▁m ig", - "▁mi g", - "▁dist urb", - "▁mi xture", - "▁) {", - "▁ ){", - "int ure", - "▁T ried", - "▁Tr ied", - "▁Tri ed", - "▁soon er", - "▁p els", - "▁pe ls", - "▁pel s", - "▁ét abl", - "et ro", - "etr o", - "it ie", - "iti e", - "▁quart ier", - "▁го во", - "▁г ово", - "▁ гово", - "▁vá ros", - "uf e", - "u fe", - "he ten", - "het en", - "h eten", - "хо м", - "х ом", - "▁so ap", - "▁ soap", - "ut ors", - "uto rs", - "utor s", - "▁d uch", - "▁du ch", - "▁duc h", - "syn tax", - "s yntax", - "▁tr ibe", - "▁tri be", - "▁trib e", - "▁ch ante", - "▁chant e", - "Tr i", - "T ri", - "▁M ate", - "▁Ma te", - "▁Mat e", - "qu ality", - "qual ity", - "uo la", - "u ola", - "=\" .", - "= \".", - "ch k", - "▁в сі", - "▁вс і", - "▁prze ci", - "▁M eteor", - "▁Met eor", - "▁scatter ed", - "Pl us", - "P lus", - "tr ad", - "tra d", - "t rad", - "▁stack overflow", - "▁ stackoverflow", - "▁re tra", - "▁r etra", - "▁ret ra", - "▁retr a", - "▁éd itions", - "▁édition s", - "▁s ain", - "▁sa in", - "cri be", - "cr ibe", - "ig non", - "ign on", - "uc ker", - "uck er", - "u cker", - "▁ма ло", - "▁ten ir", - "▁ex ports", - "▁export s", - "▁ exports", - "▁aux ili", - "▁] ]", - "▁ ]]", - "▁C BS", - "un iform", - "uni form", - "▁period ic", - "ag rant", - "agr ant", - "▁em ple", - "▁emp le", - "W il", - "▁f res", - "▁fr es", - "▁fre s", - "▁str utt", - "▁stru tt", - "▁с віт", - "▁сві т", - "▁be tre", - "▁bet re", - "▁объ ек", - "ти ся", - "▁b isher", - "▁bis her", - "ba um", - "bau m", - "b aum", - "is hi", - "ish i", - "▁Gaz ette", - "background Color", - "j l", - "▁f iel", - "▁fi el", - "▁пре ма", - "▁protagon ista", - "▁Muham mad", - "▁sim ulate", - "▁H ook", - "▁Ho ok", - "fe st", - "f est", - "▁сво их", - "▁свои х", - "Se nder", - "Send er", - "S ender", - "▁list ened", - "▁listen ed", - "▁liste ned", - "ж і", - "je st", - "jes t", - "j est", - "ko rd", - "kor d", - "k ord", - "Cho ice", - "▁hoof d", - "redu cible", - "hp p", - "h pp", - "▁W u", - "š i", - "▁M arse", - "▁Mar se", - "▁Mars e", - "▁s oir", - "▁so ir", - "we sten", - "west en", - "w esten", - "em os", - "emo s", - "e mos", - "▁D uc", - "▁Du c", - "▁amer ik", - "| }{", - "▁G ul", - "▁Gu l", - "▁Sp rache", - "▁Spr ache", - "▁mis match", - "▁mism atch", - "Sc al", - "S cal", - "P ixel", - "E F", - "▁S ep", - "▁Se p", - "▁powie cie", - "ur k", - "▁Nap oli", - "▁neighbour hood", - "сто ян", - "стоя н", - "▁search es", - "yr us", - "y rus", - "пе т", - "п ет", - "He lp", - "Hel p", - "pon t", - "po nt", - "p ont", - "▁Or ient", - "▁Ori ent", - "▁Alf onso", - "▁monitor ing", - "ia o", - "i ao", - "éd é", - "▁Cés ar", - "ше е", - "Sh ift", - "su it", - "s uit", - "code d", - "co ded", - "cod ed", - "c oded", - "но то", - "▁Par ti", - "▁Part i", - "▁la sci", - "▁las ci", - "▁aw esome", - "us ta", - "ust a", - "u sta", - "▁С ове", - "▁Со ве", - "▁Сов е", - "▁F land", - "▁Fl and", - "oo m", - "o om", - "▁de vi", - "▁dev i", - "eng elsk", - "end um", - "▁Pa scal", - "▁Pas cal", - "▁B ind", - "▁Bi nd", - "▁Bin d", - "▁ Bind", - "▁sigu ientes", - "▁siguiente s", - "J B", - "▁Peters burg", - "▁incorrect ly", - "▁B ash", - "▁Bas h", - "▁Ba sh", - "▁pe los", - "▁pel os", - "▁pelo s", - "▁zes po", - "NS URL", - "▁př ek", - "▁Cr ime", - "na ch", - "n ach", - "▁th rust", - "▁thr ust", - "▁Cult ura", - "W F", - "▁S olo", - "▁So lo", - "▁Sol o", - "▁in vas", - "▁inv as", - "▁individ ually", - "▁individual ly", - "ib m", - "i bm", - "▁et apa", - "▁hand ed", - "▁han ded", - "▁where ver", - "▁interpol ation", - "▁mus ée", - "▁C NN", - "id ia", - "idi a", - "i dia", - "ńst w", - "▁pr zew", - "▁prze w", - "▁prz ew", - "ug hing", - "ugh ing", - "▁a ctors", - "▁act ors", - "▁actor s", - "▁Ori ental", - "▁Orient al", - "▁conven ience", - "▁mi asta", - "br ains", - "bra ins", - "▁ме ся", - "▁inf atti", - "▁All Movie", - "▁crit ique", - "▁success o", - "▁succ esso", - "anc ouver", - "▁f á", - "ъл гар", - "▁wis dom", - "▁Pho enix", - "ho le", - "hol e", - "h ole", - "▁inform ación", - "▁Air lines", - "▁Airl ines", - ". «", - "mo rt", - "mor t", - "m ort", - "user Id", - "▁*/ \r", - "▁C ongo", - "▁Con go", - "▁Cong o", - "▁\" `", - "▁ \"`", - "co rr", - "cor r", - "c orr", - "▁problem as", - "▁proble mas", - "▁problema s", - "▁probl emas", - "▁b ib", - "▁bi b", - "▁ bib", - "▁póź niej", - "▁file Name", - "▁ fileName", - "zo tt", - "z ott", - "ma cht", - "mac ht", - "m acht", - "▁Ul rich", - "C y", - "end point", - "▁she ep", - "▁i bn", - "Fe ed", - "F eed", - "▁sympath y", - "▁I b", - "▁territ orial", - "ra ting", - "rat ing", - "r ating", - "да ми", - "▁d st", - "▁ds t", - "▁ dst", - "у ю", - "ah o", - "a ho", - "▁s ug", - "▁su g", - "em ia", - "emi a", - "▁t ed", - "▁te d", - "▁ ted", - "▁A pi", - "▁Ap i", - "▁ Api", - "▁R ica", - "▁Ric a", - "▁Ri ca", - "▁M R", - "▁ MR", - "ński m", - "ń skim", - "▁V oor", - "▁Vo or", - "▁de vil", - "▁dev il", - "▁devi l", - "▁Ф о", - "▁N är", - "▁Nä r", - "▁... )", - "▁.. .)", - "▁ ...)", - "▁v ois", - "▁vo is", - "▁ab bre", - "▁abb re", - "▁M änner", - "xim o", - "xi mo", - "x imo", - "▁intellect ual", - "▁t ales", - "▁tal es", - "▁ta les", - "▁tale s", - "sim ilar", - "ne um", - "▁O rig", - "▁Or ig", - "▁Ori g", - "▁po stal", - "▁pos tal", - "▁post al", - "▁h vor", - "▁ident ification", - "▁identific ation", - "▁О д", - "ue sto", - "ues to", - "uest o", - "u esto", - "▁. ./", - "▁.. /", - "▁ ../", - "▁b ir", - "▁bi r", - "▁ bir", - "▁Л он", - "▁Ло н", - "▁es empio", - "▁E ing", - "▁Ein g", - "Exp and", - "▁PR IMARY", - "▁J in", - "▁Ji n", - "▁vš ak", - "ours es", - "ourse s", - "▁Be tty", - "▁Bet ty", - "▁W M", - "▁ WM", - "▁fl ask", - "▁fla sk", - "hl en", - "h len", - "▁A del", - "▁Ad el", - "lar avel", - "▁д ет", - "▁де т", - "сь кою", - "сько ю", - "▁M undo", - "▁Mun do", - "ic zn", - "icz n", - "ifi é", - "▁М ор", - "▁Мо р", - "▁д рев", - "▁др ев", - "Date Format", - "сь ким", - "ськ им", - "▁d ated", - "▁da ted", - "▁dat ed", - "▁date d", - "▁ dated", - "ко ли", - "кол и", - "▁результа те", - "\\) .", - "\\ ).", - "▁delay ed", - "so und", - "s ound", - "▁Ма к", - "▁\" ...", - "▁\". ..", - "▁b innen", - "▁bin nen", - "▁фа куль", - "▁pol ygon", - "▁poly gon", - "▁eg gs", - "▁egg s", - "At IndexPath", - "AtIndex Path", - "мен таль", - "мент аль", - "мента ль", - "▁in cred", - "▁incre d", - "▁inc red", - "ch unk", - "web driver", - "▁с вобо", - "▁сво бо", - "▁mi ędzy", - "Rece ived", - "Receive d", - "▁M onde", - "▁Mon de", - "▁Mo nde", - "▁Mond e", - "▁J Query", - "Bu tt", - "But t", - "B utt", - "▁P DO", - "▁for ec", - "▁fo rec", - "▁fore c", - "▁discipl ine", - "ch ev", - "che v", - "на т", - "н ат", - "▁re dis", - "▁red is", - "▁hun ting", - "▁al k", - "▁ alk", - "▁proof s", - "PR I", - "P RI", - "▁c hip", - "▁ch ip", - "▁chi p", - "és ie", - "▁H O", - "▁ HO", - "▁r ug", - "▁ru g", - "▁ rug", - "zo s", - "z os", - "▁s orte", - "▁sort e", - "▁sor te", - "▁ze igt", - "▁Phys ics", - "leg te", - "legt e", - "▁proport ional", - "▁proportion al", - "▁tool bar", - "ve ment", - "v ement", - "not in", - "▁prv ní", - "bl ah", - "bla h", - "b lah", - "▁prés ence", - "▁l loc", - "▁ll oc", - "▁lí der", - "▁Ac cept", - "▁ Accept", - "▁Al ways", - "▁\" {", - "▁divers i", - "▁diver si", - "ik or", - "iko r", - "i kor", - "Per iod", - "ж ён", - "▁Al liance", - "▁All iance", - "▁re lay", - "▁rel ay", - "▁rela y", - "Br o", - "B ro", - "jö n", - "j ön", - "▁B aud", - "▁Ba ud", - "▁Bau d", - "▁B ian", - "▁Bi an", - "') [", - "' )[", - "чи в", - "▁P oss", - "▁Po ss", - "▁Pos s", - "▁Mitg lieder", - "▁Mitglied er", - "▁n ev", - "▁ne v", - "Dan iel", - "▁t ends", - "▁ten ds", - "▁tend s", - "▁compag nie", - "▁liv res", - "▁livre s", - "lu b", - "l ub", - "▁ ▁", - "▁▁ ▁▁", - "▁▁▁ ▁", - "▁ ▁▁▁", - "▁▁ ▁▁▁▁▁▁", - "▁▁▁▁ ▁▁▁▁", - "▁▁▁▁▁ ▁▁▁", - "▁▁▁▁▁▁ ▁▁", - "▁▁▁ ▁▁▁▁▁", - "▁▁▁▁▁▁▁ ▁", - "▁ ▁▁▁▁▁▁▁", - "▁▁ ▁▁▁", - "▁▁▁▁ ▁", - "▁▁▁ ▁▁", - "▁ ▁▁▁▁", - "▁▁ ▁▁▁▁▁▁▁▁▁▁▁▁▁▁", - "▁▁▁▁ ▁▁▁▁▁▁▁▁▁▁▁▁", - "▁▁▁▁▁▁▁▁ ▁▁▁▁▁▁▁▁", - "▁▁▁▁▁ ▁▁▁▁▁▁▁▁▁▁▁", - "▁▁▁▁▁▁ ▁▁▁▁▁▁▁▁▁▁", - "▁▁▁▁▁▁▁▁▁▁▁▁ ▁▁▁▁", - "▁▁▁▁▁▁▁▁▁▁▁▁▁ ▁▁▁", - "▁▁▁▁▁▁▁▁▁▁ ▁▁▁▁▁▁", - "▁▁▁▁▁▁▁▁▁▁▁▁▁▁ ▁▁", - "▁▁▁ ▁▁▁▁▁▁▁▁▁▁▁▁▁", - "▁▁▁▁▁▁▁▁▁ ▁▁▁▁▁▁▁", - "▁▁▁▁▁▁▁ ▁▁▁▁▁▁▁▁▁", - "▁▁▁▁▁▁▁▁▁▁▁ ▁▁▁▁▁", - "▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁ ▁", - "▁ ▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁", - "▁▁ ▁▁▁▁", - "▁▁▁▁ ▁▁", - "▁▁▁▁▁ ▁", - "▁▁▁ ▁▁▁", - "▁ ▁▁▁▁▁", - "▁▁ ▁▁▁▁▁▁▁▁▁▁", - "▁▁▁▁ ▁▁▁▁▁▁▁▁", - "▁▁▁▁▁▁▁▁ ▁▁▁▁", - "▁▁▁▁▁ ▁▁▁▁▁▁▁", - "▁▁▁▁▁▁ ▁▁▁▁▁▁", - "▁▁▁▁▁▁▁▁▁▁ ▁▁", - "▁▁▁ ▁▁▁▁▁▁▁▁▁", - "▁▁▁▁▁▁▁▁▁ ▁▁▁", - "▁▁▁▁▁▁▁ ▁▁▁▁▁", - "▁▁▁▁▁▁▁▁▁▁▁ ▁", - "▁ ▁▁▁▁▁▁▁▁▁▁▁", - "▁▁ ▁▁▁▁▁▁▁▁▁▁▁", - "▁▁▁▁ ▁▁▁▁▁▁▁▁▁", - "▁▁▁▁▁▁▁▁ ▁▁▁▁▁", - "▁▁▁▁▁ ▁▁▁▁▁▁▁▁", - "▁▁▁▁▁▁ ▁▁▁▁▁▁▁", - "▁▁▁▁▁▁▁▁▁▁▁▁ ▁", - "▁▁▁▁▁▁▁▁▁▁ ▁▁▁", - "▁▁▁ ▁▁▁▁▁▁▁▁▁▁", - "▁▁▁▁▁▁▁▁▁ ▁▁▁▁", - "▁▁▁▁▁▁▁ ▁▁▁▁▁▁", - "▁▁▁▁▁▁▁▁▁▁▁ ▁▁", - "▁ ▁▁▁▁▁▁▁▁▁▁▁▁", - "▁▁ ▁▁▁▁▁▁▁▁", - "▁▁▁▁ ▁▁▁▁▁▁", - "▁▁▁▁▁▁▁▁ ▁▁", - "▁▁▁▁▁ ▁▁▁▁▁", - "▁▁▁▁▁▁ ▁▁▁▁", - "▁▁▁ ▁▁▁▁▁▁▁", - "▁▁▁▁▁▁▁▁▁ ▁", - "▁▁▁▁▁▁▁ ▁▁▁", - "▁ ▁▁▁▁▁▁▁▁▁", - "▁▁ ▁▁▁▁▁▁▁▁▁▁▁▁", - "▁▁▁▁ ▁▁▁▁▁▁▁▁▁▁", - "▁▁▁▁▁▁▁▁ ▁▁▁▁▁▁", - "▁▁▁▁▁ ▁▁▁▁▁▁▁▁▁", - "▁▁▁▁▁▁ ▁▁▁▁▁▁▁▁", - "▁▁▁▁▁▁▁▁▁▁▁▁ ▁▁", - "▁▁▁▁▁▁▁▁▁▁▁▁▁ ▁", - "▁▁▁▁▁▁▁▁▁▁ ▁▁▁▁", - "▁▁▁ ▁▁▁▁▁▁▁▁▁▁▁", - "▁▁▁▁▁▁▁▁▁ ▁▁▁▁▁", - "▁▁▁▁▁▁▁ ▁▁▁▁▁▁▁", - "▁▁▁▁▁▁▁▁▁▁▁ ▁▁▁", - "▁ ▁▁▁▁▁▁▁▁▁▁▁▁▁", - "▁▁ ▁", - "▁ ▁▁", - "▁▁ ▁▁▁▁▁▁▁", - "▁▁▁▁ ▁▁▁▁▁", - "▁▁▁▁▁▁▁▁ ▁", - "▁▁▁▁▁ ▁▁▁▁", - "▁▁▁▁▁▁ ▁▁▁", - "▁▁▁ ▁▁▁▁▁▁", - "▁▁▁▁▁▁▁ ▁▁", - "▁ ▁▁▁▁▁▁▁▁", - "▁▁ ▁▁▁▁▁", - "▁▁▁▁ ▁▁▁", - "▁▁▁▁▁ ▁▁", - "▁▁▁▁▁▁ ▁", - "▁▁▁ ▁▁▁▁", - "▁ ▁▁▁▁▁▁", - "▁▁ ▁▁▁▁▁▁▁▁▁", - "▁▁▁▁ ▁▁▁▁▁▁▁", - "▁▁▁▁▁▁▁▁ ▁▁▁", - "▁▁▁▁▁ ▁▁▁▁▁▁", - "▁▁▁▁▁▁ ▁▁▁▁▁", - "▁▁▁▁▁▁▁▁▁▁ ▁", - "▁▁▁ ▁▁▁▁▁▁▁▁", - "▁▁▁▁▁▁▁▁▁ ▁▁", - "▁▁▁▁▁▁▁ ▁▁▁▁", - "▁ ▁▁▁▁▁▁▁▁▁▁", - "▁▁ ▁▁▁▁▁▁▁▁▁▁▁▁▁", - "▁▁▁▁ ▁▁▁▁▁▁▁▁▁▁▁", - "▁▁▁▁▁▁▁▁ ▁▁▁▁▁▁▁", - "▁▁▁▁▁ ▁▁▁▁▁▁▁▁▁▁", - "▁▁▁▁▁▁ ▁▁▁▁▁▁▁▁▁", - "▁▁▁▁▁▁▁▁▁▁▁▁ ▁▁▁", - "▁▁▁▁▁▁▁▁▁▁▁▁▁ ▁▁", - "▁▁▁▁▁▁▁▁▁▁ ▁▁▁▁▁", - "▁▁▁▁▁▁▁▁▁▁▁▁▁▁ ▁", - "▁▁▁ ▁▁▁▁▁▁▁▁▁▁▁▁", - "▁▁▁▁▁▁▁▁▁ ▁▁▁▁▁▁", - "▁▁▁▁▁▁▁ ▁▁▁▁▁▁▁▁", - "▁▁▁▁▁▁▁▁▁▁▁ ▁▁▁▁", - "▁ ▁▁▁▁▁▁▁▁▁▁▁▁▁▁" + "▁(A l", + "administer ed▁s", + "sub stantial", + "▁level s▁and▁", + "▁metastatic ▁disease", + "▁metastatic ▁and/or▁recurrent", + "▁blood▁ count", + "▁blood▁ drawn", + "▁result ing▁from", + "ed▁on▁the▁ eCRF", + "ation▁of▁ overall", + ".▁An tic", + "review ed", + "review .▁The▁", + "review ▁of▁all", + "review ,▁subject", + "review ▁of▁study-related▁", + "\n\nIn ▁addition▁to", + "\n\nIn dependent▁Ethics▁Committee/In", + ",▁b one▁", + ",▁b ecause▁", + "es▁for ▁Standard▁", + "▁stat es:", + "s, ▁anticip", + "s, ▁abstract", + "s, ▁this▁study▁may▁be▁", + "▁19 97", + "▁19 96", + "▁19 95", + ".▁N ature", + "ext raction", + "risk ▁and▁", + "e▁m easurable▁lesion", + "\n\nB lood▁samples▁for", + "\n\nB linded▁Treatment", + "\n\nB linding▁and▁procedures▁for▁unblinding▁the▁study", + "▁by▁ representatives▁from", + "▁by▁ color▁photograph", + "▁– ▁S", + "es▁( e.g", + "es▁( leg", + "able▁to ▁continu", + "▁respons e,", + "▁respons ibilities▁", + "ograph ical▁", + "▁randomization ▁in▁the▁study", + "▁[ 11", + "end▁of ▁study▁visit", + "ull y▁", + "▁baseline▁ valu", + "▁baseline▁ weight", + "▁baseline▁ PSA", + "e▁or ▁the▁condition", + "urther ▁management", + "chang e▁", + "chang e▁must▁be▁", + "RE IM", + "when ▁clinically▁indicated", + "when ▁this▁event", + "▁ID ▁number", + "CAE PR", + "were▁ not", + "▁document s▁submitt", + "ed▁a pprov", + "ed▁a s▁of▁the▁data", + "▁12 ▁months▁(", + "▁12 -lead▁ECG", + "was▁ based▁on", + "▁the▁treatment ▁period", + "▁the▁treatment ▁phase▁of", + "eport ing", + "▁17 00", + "▁17 .0", + "blind ing▁at", + "▁Clin ically▁significant", + ",▁H arris▁", + ".000 5", + "▁chang e▁from", + "each ▁year", + "\n\n8 .7", + "▁Amgen 's▁", + "▁Amgen ▁and▁the▁investigator", + "di phenhydramin", + "di aries", + "di etary▁", + "▁ne ed▁for", + "▁ne urologic", + "ed▁or ▁reviewed▁the▁data", + "well ▁as▁", + "▁CR /PR", + "▁int end", + "▁int ention", + "\n\nAn ▁Investigational▁Product", + "▁OS ▁and/or", + "▁agent s▁that", + "▁diseas e.▁", + "▁diseas e,▁or", + "s▁from ▁the▁previous▁", + "▁time▁ is▁", + "have▁been ▁conduct", + "▁approv ed▁method▁of", + "▁plus▁ irinotecan", + "▁plus▁ cetuximab", + "▁plus▁ Carboplatin▁and▁Bevacizumab▁Followed▁by▁Maintenance▁", + "▁K D", + "▁K nown", + "▁K arnofsky▁Scor", + "▁study▁drug ▁or", + "efficacy▁ evaluation", + "▁Y ES▁or▁NO", + ".▁I mmun", + "assessment ▁of▁", + "\n\nApproved\n\nDate▁Printed: ▁13−Aug−2013", + "▁medication ▁you▁are▁", + "s▁should▁be▁ follow", + "▁within ▁42", + "▁Pro ject", + "▁Pro cedure▁", + ".▁Patients▁ should▁", + ".▁Patients▁ experiencing", + "▁new ly▁diagnos", + "just ifi", + "▁this▁study▁ with", + "▁this▁study▁ must▁be▁", + "medi ated", + ",▁G old", + ",▁G ood▁Clinical▁Practice▁(GCP", + "s▁on ly▁", + "s▁on ▁study", + "visit ing▁the▁investigator", + "versus▁ no", + "▁has▁been \n\n", + "▁has▁been ▁report", + ",▁et▁al .▁C", + "design ee▁", + "io edema", + "io ▁della", + "▁who \n\n", + "▁anti- EGFR", + "▁anti- hypertensive▁", + "▁allow s", + "▁allow ▁the▁", + "open ed▁vial", + ",▁D esch", + "determin ed▁on▁the▁", + "determin ed▁by▁the▁", + "determin ed▁to▁have▁", + "▁trans formation", + "▁review ▁process", + "▁review ▁will▁be▁performed▁", + "regnanc y▁(", + "within ▁24▁hour", + "within ▁4▁weeks▁of", + "\n\nY▁P▁O▁C \n\nD▁E▁T▁N▁I▁R▁P", + "Com pensation▁for▁Injur", + "\n\n5 3", + "\n\n5 .2.1", + "count ability", + "47 0", + "▁protocol ▁devi", + "\n\nG ood▁Clinical▁Practic", + "▁perform ing▁any▁", + "▁at▁least ▁28▁days▁after", + "▁first ▁study▁drug▁administration", + "Un ivers", + ",▁L im", + ",▁L illy▁or", + "\n\nAppendix ▁2", + "\n\nAppendix ▁K", + "ummar is", + "s,▁and▁ will▁be▁", + "▁the▁first ▁infusion", + "▁the▁first ▁analysis", + "▁the▁first ▁on-study▁", + "analysis▁ may", + ",▁p articular", + "▁cetuximab ▁treatment", + "▁cetuximab ▁in▁combination▁with", + "Cancer ▁Treatment▁Group", + "ify ing▁", + "▁sever ity▁to", + "based▁on ▁PFS", + "▁+ ▁FOLFOX", + "-3 rd", + "▁associated▁with ▁the▁use▁of", + "vis cer", + "vis ed▁informed▁consent", + "vis ceral", + "assess ed▁using", + "ence▁in ▁situ", + "▁IV ▁over", + "caus e▁", + "▁toxicity▁ or", + "▁toxicity▁ should▁", + "▁toxicity▁ criteria", + "▁toxicity▁ grad", + "▁toxicity▁ (G", + "ing▁and▁ visiting▁the▁investigator", + "required▁ in", + "required▁ study", + ".▁O ver", + "▁clinical▁ or▁preclinical▁data", + "carboplatin -paclitaxel", + ")▁will▁be▁ summariz", + "\n\nO utcom", + "\n\nO ste", + "▁between ▁the▁treatment▁arm", + "after ▁the▁last", + "▁pain ▁from", + "▁pain ▁severity", + "▁pain ▁severity▁", + "▁Adverse▁Event s\n\nAll", + "y▁or ▁radiotherapy", + "▁SAE s▁will▁be▁", + "▁mm ▁Hg", + "▁bone▁ pain", + "▁withdraw s▁from", + ",▁in fusion", + ",▁in spect", + ",▁in ▁the▁investigator’s▁opinion", + "at▁least ▁a", + "▁survival▁ follow-up", + "▁agre e▁to▁be▁", + "new ▁year", + "person al▁", + "\n\nStudy▁ Schedule,▁Protocol", + "▁the▁c ircumstanc", + "▁Treatment :", + "▁the▁end▁of ▁the▁trial", + "▁18 .0", + "ates ▁a▁significant", + "▁and▁s ponsor", + "confirm ation▁of", + "confirm ing▁that", + "▁safety▁ (", + "▁safety▁ evaluation", + "▁overall ▁5%▁significance▁level", + "▁phase▁ will▁be▁", + "▁5- year", + "▁acid▁ (", + "▁significant ▁medical▁", + "refer red▁", + "▁is▁not ▁required▁for", + "blood▁ collection", + "y▁s kin", + "analys es▁for", + "\n\nProtocol ▁amendment", + "EGFR ▁expression", + "EGFR ▁gene▁copy▁number", + "ensitiv ity▁of", + "▁thes e▁d", + "ics▁ committee", + "study▁drug ▁or", + "responsible▁for ▁the▁", + ",▁W eek", + ",▁W anders▁J,▁Kaplan▁RS,▁Rubinstein▁L", + ",▁which ▁is", + "▁prior▁to ▁administration", + "▁prior▁to ▁starting", + "es▁to ▁a", + ":\n\n o", + ":\n\n …", + ":\n\n If", + ":\n\n ▁", + "▁without ▁interruption", + "\n\n10 .5", + "26 )(cid:", + "Pro gram", + "SI B", + "▁the▁following :\n\n\n\n", + "▁the▁following ▁exception", + "used▁for ▁sensitivity▁analyses▁of", + ",▁if ▁applicable▁", + "▁an▁ opportunity▁to", + "ing▁ entries▁", + ".▁L ocal▁", + "▁prior ▁written▁agreement", + "▁or▁ enter", + "▁or▁ erythema", + "bov e▁the▁", + "e▁subject s▁in", + "▁Grade▁ 0", + "▁Grade▁ ≥2", + "▁consent ▁for", + "29 ]", + "29 ▁(week▁5", + "▁they▁ develop", + "summar ies▁", + "post -treatment", + "y▁( including", + "▁par enteral", + "▁par adigm", + "\n\nth an", + ",▁K aplan", + "monitor ▁to▁ensure▁that", + "bevacizumab ▁(", + "clos e▁to▁the▁", + "▁start ▁of▁other", + "▁dat es▁of", + "avail ability", + ",▁199 4", + "ised▁ representatives▁of", + "\n\nin fection", + "▁metastas es,▁", + "ability▁ or▁in", + "cycl es▁", + "cycl es▁of", + "cycl e▁(", + "e.▁The▁ investigator", + "\n\nm g", + "This▁ study▁will▁be▁", + ",▁d ocetaxel", + "being ▁studi", + "laboratory▁ for", + "▁meet ▁the▁criteria▁for", + "▁100 ▁mg", + "▁patients ▁achiev", + "hemat ological▁", + "▁treated▁with ▁no", + "▁biomarker s▁of", + "▁total ,▁representative▁of▁all▁involved▁organ", + "RS EMENTS", + ",▁F leming▁TR", + "▁amendment ▁3▁–▁dated▁23▁May▁200", + "elf care", + "\n\na )", + "ey er", + "ation,▁ suitable▁for", + "▁obtain ing", + "serum ▁glutamic", + "▁with▁the▁ Sponsor", + "▁with▁the▁ corresponding", + "▁with▁the▁ exception▁of▁the▁", + "▁28 ▁days▁befor", + "ing,▁ verifying,▁and▁reproducing▁any▁records▁and▁report", + "▁are▁not ▁known", + "▁are▁not ▁eligibl", + "e; \n\nDrug", + "▁(C NS)", + "▁Report ▁form", + "agent ▁is▁", + "plann ed▁interim", + "▁are as▁", + "ed▁m y▁", + "ed▁m ean", + "standard▁ operating", + "whether ▁the▁", + "phase▁ 1", + "▁≥ 1", + "e▁P ersonal▁", + "ren g", + "ren heit", + "▁Subject ’s▁", + "▁Subject s\n\nP", + "▁Subject ▁Confidentiality▁", + "e▁tumor ▁lesion", + ".0▁Approved▁by \n\nApproved", + "3- 7", + "3- only▁", + ".\n\n7 .4", + "60 ▁mg/m2", + "60 -minute▁infusion", + "▁the▁f ac", + "▁the▁f urther▁management", + "appropriate▁ care▁of▁the▁patient", + "▁trial▁ is▁", + "CTCAE v3.", + "▁consider ed▁to▁be▁", + "UN I", + "sit es,▁a", + "year ly▁", + "▁tumour ▁growth", + ".▁It ▁has", + "▁skin ▁lesion", + "▁skin -related▁toxicities▁", + "▁can▁be▁ assess", + ",▁you ▁should▁notify▁your▁doctor", + "therapy▁ in", + "up▁to ▁4", + "efficacy ▁analyses", + "efficacy ▁analyses▁will▁be▁", + "ing▁of▁the▁ wor", + "variabl es▁(", + "on▁the▁ basis▁of", + "on▁the▁ adverse▁event▁case▁report▁form", + "▁only▁ one▁", + "▁the▁data ▁analysis▁", + "▁the▁data ;▁and", + "experienc ed", + "experienc ing▁on", + "atur e▁of▁the▁", + "ourn igand▁", + "▁Grade▁3 /4", + "87 ;", + "rang e)", + "s,▁and ▁their▁spous", + "s▁were▁ observ", + "▁but ▁is▁", + "ITT ▁principl", + "\n\nd ay", + "▁Safety▁ Monitoring", + ".\n\nB ACKGROUND▁AND▁RATIONALE", + "used▁ consistent", + "AR TIC", + "AR FT", + "▁a▁p otent", + "▁a▁p -valu", + "00▁mg/m2 /day▁", + "ok es▁", + "▁such ▁a▁c", + "▁man ag", + "FOLFOX )▁will", + "censor ing", + "high light", + "Ther asse▁et▁al", + "▁subjects▁who ▁are▁", + "▁subjects▁who ▁have▁a", + ",▁all ▁original▁source▁document", + "▁Response▁ (", + ",▁E thical▁Review", + "▁supplement al▁vitamin▁D", + "maintain ed▁and▁be▁readily", + "increas e▁of", + "ing▁in to", + "▁Dose▁ Selection", + ",▁an other", + "dec rease▁", + "staff ▁are▁responsible▁for", + "▁before▁ progression", + "need ed▁for▁the▁", + "▁individual ▁box", + "▁local▁ laboratory▁", + "Med ical", + "es▁that ▁may▁be▁", + "curr ence,▁", + "▁different iation", + "direct ed▁in▁the▁Laboratory▁", + "plus▁ bevacizumab", + "emerg ency▁s", + "sol ubl", + "▁target ▁or▁non-", + "▁To ▁investigate▁potential▁biomarker▁development", + "▁demonstr ated▁in", + "ock roft", + "e▁the▁s afety", + "▁any▁other ▁systemic▁anti-tumor", + "list ed.\n\n", + "list ed▁below", + "health ▁care▁", + "health -related▁quality▁of▁lif", + "▁up▁to ▁3", + "▁known ▁response▁to", + "urin alysis", + "▁the▁safety▁ follow-up", + "▁chest ▁x-ray▁", + "▁my▁ friend", + "stitutional▁ review▁board▁(", + "sk a", + "\n\nTable▁ S130", + "▁temper atures", + "▁(P LT▁<", + "▁reduc ing", + "▁reduc e▁the▁dose▁by▁1▁level", + ".▁At ▁least", + "Ob servation", + ",▁h e▁or▁sh", + "▁alone▁ cannot▁be▁", + "ate,▁ complete,▁and▁", + "\n\nCom pensation", + "s▁should▁ be▁t", + "▁discontinuation ▁from▁the▁study▁", + "▁more▁ about", + "▁termin ology", + "▁randomis ed,▁double-blind", + "period ▁and▁for", + "lead er", + "ed▁according▁to ▁RECIST", + "▁k appa", + "▁current ▁and▁should▁", + "subjects▁ may▁", + "▁applicable▁ regulatory", + ",000 ▁men", + "\n\n(cid:120) ▁Subject▁incidence▁of", + ",▁O s", + ",▁O basaju", + "EP IC", + "rect om", + "▁remain ▁on", + "e▁data ▁are▁", + "ECG s▁should▁be▁", + "work ▁at▁hom", + "written ▁approval", + "written ▁approval▁of▁the▁protocol", + "\n\nIf ▁you", + "▁a▁subject ▁is▁", + "▁throm boplastin", + "▁Lesion s▁", + "▁Lesion s▁that▁can▁be▁accurately▁measured▁in", + "xicity▁ profil", + ".▁Con t", + "\n\nE▁R▁O▁F▁E▁B\n\nY▁T▁I▁D▁I▁L▁A▁V \n\nS▁T▁I", + "▁the▁discretion ▁of▁your", + "ase▁( G", + "ase▁( ALT", + "ase▁( LDH", + "▁assess▁ your", + ".▁Patient ▁has", + "▁control ▁for", + ".▁No ▁eras", + "mean ing▁of▁the▁wor", + "▁ZD4054 ▁studies", + "▁in▁patients▁with ▁cancer", + "▁blood▁sampl e▁(", + "AC S", + "AC Y", + "frequ ency", + "submitt ed,▁", + "▁appear ▁to", + ",▁the▁investigator ,▁or", + ",▁the▁investigator ▁is▁responsible▁for", + "▁February▁200 6", + "▁on▁the▁ CRF", + "▁complete▁ 6▁cycles▁of", + "ogenic ▁process", + "ardiov asc", + "▁based▁on ▁clinical▁or▁preclinical▁data", + "sp elling", + "▁the▁sit e", + "▁the▁sit e▁to", + "objective▁ is▁to", + "▁among ▁wild-type▁KRAS", + ".▁You ▁will▁be▁", + ".▁You ▁may▁", + "▁AstraZeneca ▁or", + "ood man", + "s▁ar e▁taken", + ".▁Cancer ▁Res", + ".▁Cancer ▁Epidemiology,▁Biomarker", + "\n\nEx tension", + "grad ed▁using", + "ert ip", + ".▁The▁investigator ▁is▁obligated▁to▁inform", + "atas et", + "right s▁to", + "right ▁now", + "al▁or ▁per", + "al▁or ▁life-threatening", + "▁ext remities", + "heart ▁rate", + "▁participant s▁will", + "sid iaries", + "was \n\n", + "maximum ▁concentration▁of▁the▁diluted▁solution", + "▁written ▁subject", + "▁5-FU /leucovorin", + "▁serious▁adverse▁event s,▁", + "▁laboratory ▁test▁result", + "percent ▁change▁from▁baseline▁in▁lumbar▁spine▁BMD", + "\n\nFor ▁the▁", + "▁requir e▁that", + "ott om", + "▁Dos ing", + "\n\nPatients▁ with", + "och ond", + "gressive▁disease▁ (PD", + "case▁report▁form ▁(CRF", + "▁Peri pheral▁neuropathy", + "▁Peri pheral▁Neuropath", + "regulation s/", + "regardless▁of ▁causality", + "rok e▁", + "ed▁as▁a ▁minimum", + ".\n\n4 1", + ".3.3 .3", + "\n\nCon firm", + "sponsor ▁will", + "(1 40▁–▁ag", + "▁they ▁are▁not", + "before▁ randomization", + "e.▁A fter", + "▁defin itely▁", + "▁Tumor ▁Assessment", + "▁is▁responsible▁for ▁informing▁the▁", + "▁Committe e▁(", + "MR▁200048-052 ▁Master▁Subject▁Information▁Sheet▁and▁Informed▁Consent▁Form▁Version▁4.0▁/▁20▁Nov▁2009", + "▁enroll ed▁", + "propos ed▁informed▁consent▁form", + "e▁dos es▁of", + "struct ▁patient", + "FOLFIRI )▁will", + "▁at▁the▁ next", + "corpor ates▁", + "paclitaxel ▁and▁carboplatin", + "▁active▁ in", + "unblind ing▁any▁", + "unblind ed▁when", + "unblind ed▁interim", + "▁adverse▁events▁ leading▁to", + "........................ .......▁", + "▁is▁the▁ \"sponsor", + "▁days▁of ▁the▁last", + "▁maintain ing", + "▁maintain ing▁a▁comprehensive▁", + "▁predict ▁disease▁progression", + "ource▁document s▁are▁original", + "Sign ature", + "▁appl ies▁to", + "United▁ Kingdom", + "fil es▁contain", + "immun ohistochemistry▁", + "▁label s▁with▁a", + "permitt ed▁to", + "az dur", + "▁Pre vention", + ".\n\nTo ▁collect", + "remov al▁from", + "▁had▁ previously▁", + "▁evaluate▁the▁ benefit", + "-L ung", + "▁fil es▁containing", + "efficacy▁of ▁the▁", + "▁site▁ staff", + "▁site▁ notification", + "\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX\n\nX \n\nX", + "repeated▁ every▁3▁week", + "umbar ▁vertebra", + "e▁M easures", + "e▁M anagement", + "TIN IB", + "▁decid es▁that", + "▁decid ing▁whether", + "udit ▁plan", + "rag ment", + ".▁This ▁approach", + "bi ochemical▁", + "select ed\n\nfor", + ",▁v an", + ",▁v itamin▁B12", + "▁daily▁ living", + "compared▁with ▁placebo", + "wher eas", + "-sided▁ log-rank▁test", + "▁resolv ed▁or", + "e▁the▁patient ▁has▁", + "▁the▁investigator’s▁ clinical▁judgment", + "▁et▁al,▁200 3", + "▁by▁the▁ Sponsor", + "cod one▁", + "dent al▁pro", + "intervention ▁indicated▁", + "▁siz e▁to", + "▁will▁not ▁compensate▁you", + "rig or", + "ed▁an ▁adverse▁event", + "election ▁and▁Timing▁of", + "early ▁as▁", + "▁the▁pres ence▁or▁absence▁of", + "deriv ing", + "▁continue▁ until", + "▁continue▁ receiving", + "▁continue▁ participation▁in▁the▁study", + "ater ▁for▁Injection", + "▁less▁than ▁or▁equal▁to", + "EL OX-", + "idin e,▁", + "ocal ca", + "▁differenc es▁between", + "immediately▁ notify▁", + "▁and▁E nd▁of", + "process ing", + "check ed▁for▁consist", + "ed▁using▁the▁ log-rank▁test", + ",▁al ong", + "insert ▁nam", + "▁use▁of ▁at▁least▁25%▁for▁a▁duration▁of▁1▁week▁or▁mor", + "Dose▁ Modification", + "e.▁In ▁the▁", + "still ▁on", + "▁becom es", + "▁material s▁", + "▁material ▁must▁be▁submitted▁to▁the▁", + "confidential ity▁is▁", + "▁respect ▁to▁the▁first", + "▁parameter s▁", + "▁a▁f ever", + "▁Group ▁B", + "▁primary▁ solid▁tumor", + "▁and▁m ember", + "\n\n15 .\n\nAPPENDICES", + "reatinine▁clear ance\n\n", + "kept ▁current▁and▁should▁", + "▁Man ager", + "▁Health ▁Status▁", + "ABI-007 /carboplatin", + "solute▁ Neutrophil", + "Rel ated▁to", + "e.▁S pecific", + "ton ▁D", + "▁tub ercul", + "ed▁dos e)", + "▁(B MI", + "▁(B SA)", + "▁(B ackground▁", + "e▁during▁the▁ study▁", + "▁analysis▁will ▁occur▁when", + "evidenc ed▁by▁", + "umbar▁sp ine,▁total▁hip", + "s.▁If ▁results▁of▁the▁trial▁are▁published,▁your▁identity▁will▁remain▁confidential", + "currently▁ with", + "currently▁ no", + "s▁[ CTCAE", + "▁of▁all ▁study-related▁", + "▁Baseline▁ and▁", + "utility▁ bound", + "▁major ▁CVD", + "▁Cycl es", + "oste oporosis", + "oste oblast", + "observed▁ during▁the▁study▁", + "▁3▁week s▁after", + "▁volum e▁infusion", + "▁volum e,▁platelet", + "do▁not ▁have▁", + "TT P", + "▁low ▁molecular▁weight", + "▁feel ing", + "▁improvement s▁in", + ").▁In ▁the▁event", + "TH ER", + "▁treated▁ patient", + "PC I", + "involv ing", + "involv ed▁with", + "e\n\nC ONFIDENTIAL", + "▁antitumor ▁activity▁", + "▁antitumor ▁activity▁of", + ",6 ,7", + "YP 2", + "arily▁ withdraw▁from", + "▁Onc ology", + "▁Onc ology,▁", + "▁temperature▁ alarm", + "in▁a ▁timely▁manner", + "▁future▁ medical▁car", + "▁and▁all ▁co/", + "s.▁P anitumumab", + ".▁Ch est", + ",▁I sh", + "▁liver ▁metastas", + "required▁for ▁a▁best▁response▁of", + "fail ed▁", + ",▁for ▁a", + "▁Wh ol", + "change▁in ▁hemoglobin", + "▁designe e▁will", + "that ▁are▁clearly▁", + "▁(2 1-day▁cycl", + "s▁(including ,▁if▁applicabl", + "ed▁for▁all ▁randomized▁patients▁", + "\n\nLY231514 \n\nH3E-MC-JMIG(f)▁Clinical▁Protocol\n\nPage▁", + "e▁trial s▁", + "\n\nComplet ion▁of", + "▁best ▁interest", + "ush ing", + "s.▁J ▁Clin▁Oncol", + "s.▁J ▁Nutr", + "▁Reporting ▁Procedures▁for▁All", + "▁discussion ▁(not▁necessarily", + "ed,▁and▁ stor", + "▁of▁C ertain", + "▁(E uroQol-5▁Dimension", + "▁IRB ▁approval▁of", + "▁via ▁the▁", + "▁PFS▁event s▁have▁occurred", + "▁worsening ▁of▁a▁pre-existing", + "esophag ectomy/", + "▁a▁2 5%", + "error s▁that▁occur", + "▁thos e▁subjects▁who", + "▁potential ▁side▁effect", + "pre- medication", + "pre- existing", + "▁antibody ▁assay", + "▁procedure▁ for", + "▁of▁5 .2", + "▁45 ▁mL/min", + "▁unblind ed▁", + "▁the▁patient▁is▁ lost▁to▁follow-up", + "▁should \n\nbe▁", + "elv e▁", + "nual▁ IEC/IRB", + "stant ially▁", + ",▁st abilization", + "progress ing", + "▁advers ely", + "ated▁for ▁2", + "▁associated▁ 95%▁confidence▁interval", + "▁oste opor", + "▁the▁previous▁ dose▁level", + "reported▁as▁ such", + "▁preserv e▁", + "▁of▁101\n\n090177e18069a3aa\\Approved\\Approved▁On:▁27-Sep-2007▁02:42\n\n1▁4▁:▁5▁0▁7▁0▁0▁2▁-▁g▁u▁A▁-▁1▁3▁\\▁d▁e▁v▁o▁r▁p▁p▁A\n\n\\▁1▁.▁1▁\\\n\n8▁2▁1▁6▁6▁8 ▁6▁0▁0▁0▁0▁0▁1▁0", + ",▁this▁ information", + "▁CO STS/", + "endar ▁Days", + "▁2003 0194", + "▁study▁ent ry▁and▁", + ".▁Al so", + "▁evaluate▁th e▁treatment▁effect", + "▁the▁final ▁analysis▁of", + "▁recover ed▁to", + "▁doses▁ ranging▁from", + "▁the▁end▁of▁the▁ blinded▁treatment▁phas", + "▁the▁end▁of▁the▁ storage▁period", + "30-day▁postdiscontinuation ▁visit", + "inalization▁date:▁June▁19▁2001,▁Incorporating ▁amendment▁3▁–▁dated▁23▁May▁200", + "accur ate,▁complete,▁and▁", + "▁PA CCE", + "▁the▁investigational ▁drug", + "larg e▁cell", + "age▁and▁ mode▁of▁administration", + "notification ▁to▁Amgen", + "appropri ate\n\n", + ",▁a▁s erum", + "Day▁1 ▁of", + "▁urine▁ or▁serum▁pregnancy▁test", + "▁blind ed▁investigational▁product", + "▁approxim ation", + "right▁to ▁discontinu", + "▁own ▁health▁state▁today", + "ed▁out ▁with▁a▁black", + "▁treatment▁is▁ discontinu", + "▁relevant ▁clinical", + "\n\nMed ian", + "eligible▁for ▁the▁study", + "Pharmac ology▁", + "roc ort", + "ation▁is▁ measured▁from▁the▁date▁of▁randomization", + "▁(eg ,▁s", + "▁important ▁intellectual▁content", + "e▁by▁ contact", + "withdrawal ▁criteria", + "withdrawal s▁due▁to", + "BJECTIVES \n\n1.1", + "surger y,▁", + "urfac e▁A", + "▁exce ed", + "▁regular ▁basis", + "initial ed▁and▁", + "comp ound", + ".▁Dose▁ escalation", + "▁monoclonal ▁antibod", + "▁monoclonal ▁antibody", + "LQ I", + "▁his▁or▁her ▁sit", + "International▁ Committee▁of▁Medical▁Journal▁Editor", + "▁allergic ▁bronchospasm", + "▁Hy pertension", + "▁uniqu e▁Personal▁", + "▁participation▁in ▁a", + "previous▁ SRE▁(", + "laborator y,▁", + "omer ase▁", + "olin ic▁acid", + "▁ANC ▁≥", + "\n\nArm ▁1:", + "e▁should▁ be\n\n", + "▁Compli ance", + "▁approximately▁30 ▁days▁after", + "combination▁of ▁cetuximab", + "▁Suppl ▁1:", + ".▁Sunitinib /Placebo", + ".▁Pre medication", + ".▁Pre paration", + "radiotherapy▁ or", + "▁a▁single▁ line▁strok", + "\n\nFollow ing", + ".\n\nCONFIDENTIAL ITY", + "\n\nAdd▁6 ,7", + ".\n\nY▁T▁I▁D▁I▁L▁A▁V \n\nS▁T▁I\n\nK▁C▁E▁H▁C", + "volume▁of ▁distribution", + "informed▁consent▁form ?", + "ed▁with▁a ▁unique▁Personal▁", + "primary▁endpoint ▁of", + "fatigu e▁(", + "▁↓ ▁1", + "▁four th", + "▁the▁second▁ infusion", + "▁48 ▁hours▁after", + "▁plac ement", + "▁call ed▁", + "European ▁Commission", + "bod y▁surface▁area", + "pemetrex ed▁and▁", + "\n\nan ▁investigator", + "▁will▁provid e▁the▁sponsor", + ".▁Subjects▁ not▁meeting", + "▁minim iz", + "▁minim ize▁", + ".▁Rec eptor", + "e▁Size▁ Determination", + "▁ensure▁ adequate▁", + "▁Assignment ▁to▁Treatment", + "00▁IU /", + "▁Subjects▁ Undergoing", + "▁facil ities▁", + "▁for▁all ▁target▁lesions▁will▁be▁calculated▁and▁", + "\n\n1\n\n1 \n\n1\n\n1", + "\n\n1\n\n1 \n\n2\n\n2\n\n3", + "\n\nEnd▁of ▁Study", + "ed▁without ▁prior▁written▁agreement", + "▁greater▁than ▁1", + "regulatory▁author ity", + "regulatory▁author ity▁in", + "rul ed▁out", + "▁intern ational▁", + "metab olit", + "▁a▁t axan", + "recruit ment", + "▁lo ▁Stud", + "committe e▁(", + "10▁mg ▁orally▁", + "▁time▁and▁ initial", + "birth ▁control", + "▁fat al", + "▁access ▁the▁IVRS", + "radiotherapy ,▁or", + "fax ed▁to", + "▁audit ▁by▁representatives▁from", + "▁Central▁ Cancer▁Treatment▁Group", + "▁will▁be▁present ed▁as▁a▁sterile,▁", + "ated▁with in▁the▁", + "uroto xicity", + "▁representative▁ and▁", + "▁at▁a▁dose▁of ▁6▁mg/kg", + "▁chronic ▁diseas", + "radiographic ▁studies", + "▁at▁least▁on e▁dose▁of", + "▁clear ance▁", + "▁twic e▁daily▁", + "(eg ,▁a", + "▁dist inct", + "▁dist al▁radi", + "▁Supplement ation", + "▁Not e:", + "▁Not ification▁of", + "▁subjects\n\n with", + "▁super ficial▁", + "▁super vision", + "istration/ Randomization", + ",▁U K", + "▁injur y▁", + "▁and▁then ▁every▁", + "▁the▁schedul ed▁", + "elf-care ,▁confined▁to▁bed▁or▁chair▁more▁than▁50%▁of▁waking▁hour", + "au er", + "promis ing", + "\n\nAmendment ▁2", + "▁10.3 ▁Sample▁Size▁", + "atively▁ resected▁", + "▁participation ▁in▁the▁", + "▁radiographic ▁scan", + "itis▁or ▁fib", + "Blood▁ Cell", + "mix ed▁with", + "al▁well -being", + ",▁An d", + "cho ic", + "\n\nDrug ▁Subst", + "documentation ▁(see▁Section", + "documentation ▁by▁color▁photograph", + "mith ▁T", + "▁eryth ema", + "allowed▁to ▁receive▁", + "reconstitut ed▁ABI-007", + "▁becomes▁ stabl", + "150 /100", + ":▁( may▁occur▁between▁1▁and▁9", + "rath er", + ".▁Un blinding▁at", + "▁PJ ,▁M", + "▁DR UG", + "▁or▁its▁design ee▁", + "upd ates▁", + "ed▁in▁combination▁with ▁cisplatin", + "▁0.01 103", + "▁analyses▁for ▁the▁", + "▁dose- related", + "recorded▁on ▁each", + "▁submission ▁to▁the▁", + "d▁( excluding", + "▁drop -in", + "▁hematologic ▁toxicities", + ",▁and▁all ▁drug-related▁", + "head▁and▁neck ▁cancer", + ").▁This▁ will", + "Histor y▁", + "cip itating", + ".\n\nRE G", + "▁recurrence▁ or", + "▁commun ity", + "notifi ed", + "prescrib ing▁information", + "▁tests▁ needed▁for▁the▁", + "▁implement ation▁of▁Addendum▁9", + "▁carcinoma▁of▁the▁ colon▁or▁rectum", + ",▁t achycardia", + "ed▁f rozen", + "▁of▁the▁subject .▁Unblinding▁at", + "▁as▁defin ed▁by▁the▁", + ")\n\nD iscontinu", + "▁description ▁of▁the▁event", + "Objectives \n\nReplace:", + ".▁Pharmac ogenetic", + "extension▁lead▁period ▁and▁", + "mutant▁KRAS ▁stratum", + "commenc ement▁of", + ",▁2007 .▁", + "▁the▁safety▁follow▁up ▁phase▁of▁the▁study", + "followed▁up ▁for", + "gether▁with ▁its", + "uscl e▁pain", + "▁experiment al▁", + ".▁Randomization ▁will▁be▁stratifi", + "▁has▁been▁shown ▁to", + "▁has▁been▁shown ▁to▁be▁", + ",▁et▁al.▁Phase▁ I", + "calculated ▁as", + "▁even ▁after▁discontinuation▁of▁treatment", + "steroid al▁Anti-Inflammatory▁Drug", + "of▁of ▁receipt", + "▁viol ating▁the▁confidentiality▁of▁the▁subject", + "reported▁as▁an ▁SAE", + "▁association ▁between", + "FIC ATION", + "\n\nHy pertension", + "▁during▁the▁study▁ period▁and▁for", + "maintained ▁temperature▁alarm", + "protect ed▁from▁light", + "▁third▁part ies,▁except", + ".M .,▁et▁al.,▁", + "▁evidenc e▁suggest", + "▁magnesium ▁level", + "ribonucle ic▁acid▁", + "non-inferior ity", + "▁break ing▁the▁", + "▁squamous▁cell ▁carcinoma", + "▁induction ▁therapy", + "explor ed.\n\n", + "▁will▁be▁us ed▁as", + "e▁subjects▁ may▁be▁", + "correspond ence\n\n", + "recorded▁in▁the▁ CRF", + "radiological▁ review", + "radiological▁ imag", + "▁data▁are▁ obtained", + "interpret ation▁of▁data", + "▁received ▁any▁", + "▁Phas e", + "▁cases▁ where▁", + "▁nonhematologic ▁toxicities▁", + "baseline▁sum ▁longest▁diameter", + "▁Accountability▁ Recor", + "mand ator", + ",▁other ▁written▁subject", + "▁and▁L eukemia", + "▁DS MB", + "s\n\n4 \n\nCompletely▁disabled.▁Cannot▁carry▁on▁any▁s", + "hair ▁los" ] } } \ No newline at end of file